

APPROVED DRUG PRODUCTS

WITH

THERAPEUTIC EQUIVALENCE EVALUATIONS

44th EDITION

THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2024

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2023.

44th EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2024

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations

CONTENTS

PAGE

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations

PREFACE TO FORTY FOURTH EDITION

The publication, *Approved Drug Products With Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). The main criterion for the inclusion of any product is that the product is the subject of an application with an approval that has not been withdrawn for safety or effectiveness reasons. Inclusion of products in the Orange Book is independent of any current regulatory action being taken administratively or judicially against a drug product. In addition, the Orange Book contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the FD&C Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state announcing FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The Orange Book was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the FD&C Act and FDA regulations at that time.

The therapeutic equivalence evaluations in the Orange Book reflect FDA's application of specific criteria to the multisource prescription drug products listed in the Orange Book and approved under Section 505 of the FD&C Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the codes appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication of the Orange Book in October 1980, concurrent with finalization of the rule, incorporated appropriate revisions. Each subsequent edition has included new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments amended the FD&C Act to establish, among other things, the 505(b)(2) and 505(j) approval pathways. The Hatch-Waxman Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Orange Book and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that have qualified under the FD&C Act for periods of exclusivity and provides patent information concerning the approved drug products in the Orange Book. The *Addendum* also provides additional information that may be helpful to those submitting an NDA under Section 505(b) of the FD&C Act or an ANDA under Section 505(j) of the FD&C Act to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Central Document Room, Attn: Director, Division of Orange Book Publication and Regulatory Assessment (DOBPRA), Office of Generic Drug Policy, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266. Comments received are publicly available to the extent allowable under the Freedom of Information Act and FDA regulations.

1.0 INTRODUCTION

1.1 Content and Exclusion

The Orange Book is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not subject to 505G; (3) drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn from sale for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or effectiveness reasons subsequent to being discontinued from marketing.[1] This publication also includes indices of prescription and OTC drug products by proprietary name (brand name or trade name) or, if no proprietary name exists, established name of the active ingredient and by applicant name, which have been abbreviated for this publication. Established names for active ingredients generally conform to compendial names or *United States Adopted Names* (USAN) as described in 21 CFR 299.4(e). A list of uniform terms is provided in Appendix C.

The *Addendum* contains patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research. The Hatch-Waxman Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and effectiveness and for which NDAs are required.

Under the FD&C Act, some drug products are given tentative approvals. The Agency will not include drug products with tentative approvals in the Orange Book because a drug product that is granted tentative approval is not an approved drug product. Tentative approval lists by month are available on FDA's website Drugs@FDA. When the tentative approval becomes a final approval through a subsequent action letter to the applicant, the Agency will list the drug product and the date of approval in the appropriate approved drug product list. In addition, we note that Section 505(x) of the FD&C Act affects the date of approval for certain drug products subject to scheduling under the Controlled Substances Act. For these drug products subject to scheduling, the Agency will list the drug product on FDA's website Drugs@FDA upon approval under Section 505(c) of the FD&C Act, and will list the drug product in the Orange Book upon the date of approval as determined under Section 505(x).

[1] Generally, newly approved products are added to the Active Section of the Orange Book (i.e., the Prescription Drug Product List or the Over-the-Counter Drug Product List), depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Division of Orange Book Publication and Regulatory Assessment is otherwise notified before publication. See Section 1.12.

The Orange Book identifies the application holder of a drug product and does not identify distributors or repackagers.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Pharmaceutical equivalents are drug products in identical dosage forms and route(s) of administration that contain identical amounts of the identical active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, or, in the case of modified-release dosage forms that require a reservoir or overage or such forms as prefilled syringes where the residual volume may vary, that deliver identical amounts of the active drug ingredient over the identical dosing period; do not necessarily contain the same inactive ingredients; and meet the identical compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.[2] They may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Pharmaceutical alternatives are drug products that contain the identical therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form, or the same salt or ester (e.g., tetracycline hydrochloride, 250 mg capsules vs. tetracycline phosphate complex, 250 mg capsules; quinidine sulfate, 200 mg tablets vs. quinidine sulfate, 200 mg capsules).[3] Each such drug product individually meets either the identical or its own respective compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.[4] Different dosage forms and strengths within a product line by a single manufacturer are pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Approved drug products are considered to be therapeutic equivalents if they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.[5]

FDA classifies as therapeutically equivalent those drug products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the identical active drug ingredient in the identical dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. The concept of therapeutic equivalence applies only to drug products containing the identical active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same

[2] 21 CFR 314.3(b).
[3] See 21 CFR 314.3(b).
[4] 21 CFR 314.3(b).
[5] 21 CFR 314.3(b).

condition (e.g., meperidine hydrochloride vs. morphine sulfate for the treatment of pain). Any drug product in the Orange Book repackaged and/or distributed by other than the applicant is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, certain aspects of labeling (e.g., the presence of specific pharmacokinetic information), and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a specific product be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product can be expected to have the same clinical effect and safety profile as the prescribed product when administered to patients under the conditions specified in the labeling.

Strength. Strength refers to the amount of drug substance contained in, delivered, or deliverable from a drug product, which includes: (1)(a) the total quantity of drug substance in mass or units of activity in a dosage unit or container closure (e.g., weight/unit dose, weight/volume or weight/weight in a container closure, or units/volume or units/weight in a container closure); and/or, as applicable, (b) the concentration of the drug substance in mass or units of activity per unit volume or mass (e.g., weight/ weight, weight/volume, or units/volume); or (2) such other criteria the Agency establishes for determining the amount of drug substance contained in, delivered, or deliverable from a drug product if the weights and measures described in clause (1)(a) do not apply (e.g., certain drug-device combination products for which the amount of drug substance is emitted per use or unit time).[6] Note that if the criteria the Agency establishes for determining and expressing the amount of drug substance in a product evolves over time, the Agency generally does not intend to revise the expressions of strength for drug products already included in the Orange Book, but rather intends to apply the criteria prospectively to drug products added to the Orange Book.

Although the strength of drug products in the Orange Book is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, it is sometimes expressed in terms of the amount of the active moiety.[7] For example, certain drug products included in the Orange Book include a designation of "EQ" next to their expression of strength. This "EQ" designation generally is used in connection with salt drug products to indicate that the strength of such drug product is being expressed in terms of the equivalent strength of the active moiety (e.g., "EQ 200 MG BASE"), rather than in terms of the strength of the active ingredient.

Bioavailability. Bioavailability is the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of drug action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed

[6] 21 CFR 314.3(b).
[7] Active moiety is the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt (including a salt with hydrogen or coordination bonds), or other noncovalent bonds (such as a complex, chelate, or clathrate) of the molecule, responsible for the physiological or pharmacological action of the drug substance. 21 CFR 314.3(b).

by scientifically valid measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action.[8]

Bioequivalence. Bioequivalence is the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.[9] Section 505(j)(8)(B) of the FD&C Act describes certain conditions under which a test drug and reference listed drug (RLD)(see Section 1.4) shall be considered bioequivalent:

> (i) the rate and extent of absorption of the [test] drug do not show a significant difference from the rate and extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or
>
> (ii) the extent of absorption of the [test] drug does not show a significant difference from the extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the [reference] listed drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other scientifically valid *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

For example, bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.[10]

1.3 Further Guidance on Bioequivalence

FDA's regulations and guidance documents provide additional information regarding bioequivalence and bioavailability, including methodologies and statistical criteria used to establish the bioequivalence of drug products.[11]

1.4 Reference Listed Drug and Reference Standard

---

[8] 21 CFR 314.3(b).
[9] 21 CFR 314.3(b).
[10] 21 CFR 320.24.
[11] We note that prior to the 36th edition of the Orange Book, the Preface to the Orange Book included a section entitled "Statistical Criteria for Bioequivalence." Please see FDA's regulations and guidance documents for additional information regarding bioequivalence and bioavailability. See generally 21 CFR part 320. See FDA Drugs guidance Web page at https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs and FDA Drugs guidance (Product-Specific Guidances for Generic Drug Development) Web page at https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development.

A reference listed drug is the listed drug[12] identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.[13] FDA's general practice is to designate as RLDs drug products that have been approved for safety and effectiveness under Section 505(c) of the FD&C Act. For an ANDA based on an approved suitability petition (a petitioned ANDA), the reference listed drug generally is the listed drug referenced in the approved suitability petition.[14]

A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an *in vivo* bioequivalence study required for approval.[15] FDA generally selects a single reference standard that ANDA applicants must use in *in vivo* bioequivalence testing. Ordinarily, FDA will select the reference listed drug as the reference standard. However, in some instances, the reference listed drug and the reference standard may be different. For example, where the reference listed drug has been withdrawn from sale for reasons other than safety or effectiveness, FDA may select an ANDA that is therapeutically equivalent to this reference listed drug as the reference standard.

FDA identifies reference listed drugs in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists. Listed drugs identified as reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate.

If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may submit a controlled correspondence to the Office of Generic Drugs to ask FDA to designate a reference listed drug for that drug product. Section 1.7, *Therapeutic Equivalence Evaluations Codes* (*products meeting necessary bioequivalence requirements*) explains the character coding system (e.g., **AB, AB1, AB2, AB3**...) for multisource prescription drug products listed under the same heading with two or more reference listed drugs.

FDA also identifies reference standards in the Prescription Drug Product and OTC Drug Product Lists. Listed drugs identified as reference standards represent FDA's best judgment at this time as to the appropriate comparator for purposes of conducting any *in vivo* bioequivalence studies required for approval.

A potential applicant should consult Agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that applications for generic drugs may be submitted and evaluated, e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale.

---

[12] A "listed drug" is a new drug product that has been approved under Section 505(c) of the FD&C Act for safety and effectiveness or under Section 505(j) of the FD&C Act, which has not been withdrawn or suspended under Section 505(e)(1) through (5) or Section 505(j)(6) of the FD&C Act, and which has not been withdrawn from sale for what FDA has determined are reasons of safety or effectiveness. Listed drug status is evidenced by the drug product's identification in the current edition of FDA's "Approved Drug Products With Therapeutic Equivalence Evaluations" (the list) as an approved drug. A drug product is deemed to be a listed drug on the date of approval for the NDA or ANDA for that drug product (21 CFR 314.3(b)).

[13] 21 CFR 314.3(b).

[14] 21 CFR 314.94(a)(3)(i).

[15] 21 CFR 314.3(b).

If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an *in vivo* bioequivalence study submit a controlled correspondence to the Office of Generic Drugs.

1.5 General Policies and Legal Status

The Orange Book contains public information and advice. It does not mandate the drug products that are purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the Orange Book sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners, and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the FD&C Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, e.g., reducing the cost of drugs to consumers. To the extent that the Orange Book identifies drug products approved under Section 505 of the FD&C Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the Orange Book does not necessarily mean that the drug product is in violation of Section 505 of the FD&C Act, that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion may be based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the Orange Book. Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling. However, these products may differ in other characteristics that are not required by statute or regulation to be the same, such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion, e.g., due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be patient-specific allergic reactions in rare cases due to a coloring or a preservative ingredient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the practitioner's prescribing of that product may be appropriate. Pharmacists must also be familiar with the different characteristics of therapeutically equivalent products, e.g., expiration dates/times and labeling directions for storage of the different products

(particularly for reconstituted products), so they can properly advise patients when one product is substituted for another.

Multisource and single-source drug products. In the Orange Book, FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the FD&C Act, which in most instances means those pharmaceutical equivalents available (i.e., not on the Discontinued Drug Product list) from more than one manufacturer. For such products, a therapeutic equivalence code generally is included and product information is highlighted in bold face and underlined. Those products with approved applications that are single source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included in the Orange Book, but no therapeutic equivalence code is included with such products. Any drug product in the Orange Book repackaged and/or distributed by the applicant or some other person authorized by the applicant (e.g., an authorized generic) is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book. The details of therapeutic equivalence codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products in the Orange Book are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. There are numerous entities other than the applicant that may be involved in the development, manufacturing, and/or marketing of a product. Products listed in the Orange Book are identified by the applicant's name (firm name on the Form FDA 356h in the application). Where the applicant's name does not appear on the label, a person wishing to relate a specific product to the applicant name in the Orange Book may refer to FDA's NDC Directory[16] and match its search terms to information on the label, such as the NDC Code if available.

Every product in the Orange Book is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the FD&C Act. In such circumstances, the Agency may commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product in the Orange Book. The main criterion for inclusion of a product is that it has an NDA or ANDA that has been approved and that has not been withdrawn for safety or effectiveness reasons. FDA believes that retention of a violative product in the Orange Book will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may, however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the Agency's assessment of whether a product meets the criteria for therapeutic equivalence.

1.7 Therapeutic Equivalence Evaluations Codes

Generally, prescription drug products that the Agency considers multisource have been assigned a therapeutic equivalence code. The coding system for therapeutic equivalence evaluations is designed to allow users to determine quickly whether the Agency has evaluated a particular approved

[16] https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory.

prescription drug product (e.g., a particular strength of an approved drug that is not on the Discontinued Drug Product list) as therapeutically equivalent to other pharmaceutically equivalent prescription drug products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With some exceptions (e.g., therapeutic equivalence evaluations for certain 505(b)(2) applications), the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter of the relevant therapeutic equivalence code as follows:

A Drug products that FDA considers to be <u>therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e., drug products for which:

(1) there are no known or suspected bioequivalence problems. These are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form; or

(2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC**, **BD**, **BE**, **BN**, **BP**, **BR**, **BS**, **BT**, **BX,** or **B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"**A**" products are those for which there are no known or suspected bioequivalence problems or for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an "**A**" code fall under one of two main policies:

(1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is either presumed and considered self-evident (based on other information in the application for some dosage forms (e.g., solutions)), or satisfied by a showing that an acceptable *in vitro* approach is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

(2) for those Drug Efficacy Study Implementation (DESI) drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional (e.g., pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution). FDA's determination that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in its labeling.

The Agency may use notes in this publication to point out special situations, such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Certain Special Situations*. For example, in certain instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note may be added to Section 1.8.

For example, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, generally the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts, esters or other noncovalent derivatives (such as a complex, chelate, or clathrate) of the same active moiety are regarded as different active ingredients. For the purpose of this publication, products containing such different active ingredients are considered pharmaceutical

alternatives and, thus, not therapeutically equivalent. Anhydrous and hydrated entities, as well as different polymorphs, are considered to be the same active ingredient and are expected to meet the same standards for identity to be considered pharmaceutical equivalents and therapeutic equivalents.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives and other inactive ingredients may differ among some therapeutically equivalent drug products. These differences do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Multisource drug products coded as **AA** contain active ingredients and are in dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Strength)* generally will be coded **AB** if data and information are submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three-character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes generally are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. If a study is submitted that demonstrates bioequivalence to a reference listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC and Procardia XL®, extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved. As a result, the generic drug products bioequivalent to Adalat® CC have been assigned a rating of **AB1** and those bioequivalent to Procardia XL® have been assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the Orange Book, they are considered therapeutically equivalent to the applicant’s drug product if the

applicant's drug product is rated either with an **AB** or three-character code or is single source in the Orange Book. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in general-use delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard and are otherwise determined to be therapeutically equivalent. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology. If bioequivalence needs to be demonstrated by *in vivo* methodology, then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, historically some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included in the Orange Book (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and FDA has not published

conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

Consistent with the definition of strength included in Section 1.2, *Therapeutic Equivalence-Related Terms,* the strength of parenteral drug products generally is identified by both the total drug content and the concentration of drug substance in a container approved by FDA.[17] In the past, the strength of liquid parenteral drug products in the Orange Book has not been fully displayed. Rather, the strength of liquid parenteral drug products in the Orange Book has been displayed in terms of concentration, expressed as x mg/mL. Generally, the amount of dry powder or lyophilized powder in a container is identified as the strength, expressed as x mg/vial.

However, FDA subsequently realized that the format of the Orange Book with respect to parenteral solutions should be changed to reflect that each strength of a drug is considered to be a separate listed drug. The Orange Book generally displays the strength of new approvals of parenteral solutions. Previously (i.e., prior to 2003), we would have displayed only the concentration of an approved parenteral solution, e.g., 1 mg/mL. For example, if this application had a 125 mL and 250 mL container approved, we would now display two product strengths, listing both total drug content and concentration of drug substance in the relevant approved container, e.g., 125 mg/125 mL (1 mg/mL) and 250 mg/250 mL (1 mg/mL).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted, or the application contains adequate scientific evidence establishing through an *in vitro* approach the bioequivalence of the product to a selected reference product, and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence and for which a waiver of *in vivo* bioequivalence has not been granted, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate *in vivo* bioequivalence data, and **BT** in the absence of such data.

"B" CODES

[17] The strengths of certain parenteral drug products, including contrast agents, may be expressed as a percentage.

Drug products that FDA, at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products.

"**B**" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "**B**" code fall under one of three main policies:

(1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

(2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or

(3) the drug products are under regulatory review.

The specific coding definitions and policies for the "**B**" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained drug substance available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because applicants developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been

submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard; such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate bioequivalence data are submitted, after which such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence; such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is

available, the products are coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Certain Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. The following are descriptions of certain examples of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

Gaviscon®. Gaviscon® is an OTC product that has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test that is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was

submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs that cite Gaviscon® tablets as the reference listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium.[18] Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two- or three-character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.[19]

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e., AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3, and therefore, Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3 MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3 MG	N021402	RLD	RS

[18] In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all 0.025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.
[19] The chart is current as of the date of publication of the annual edition. See the most current monthly cumulative supplement for updates to this information available at https://www.fda.gov/media/72973/download. Please consult the Active Section for information on other strengths.

AB3	LEVOXYL	KING PHARMS	0.2 MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3 MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM[20]	MYLAN	0.3 MG	A076187	–	RS

Patent Certification(s) and Reference Standard for ANDAs Duplicating a Drug Product Approved in a Petitioned ANDA. To submit an ANDA for a generic drug that is not the same as its reference listed drug because it has one different active ingredient in a fixed-combination drug product, or has a different route of administration, dosage form, or strength than that of the reference listed drug, an applicant first must obtain permission from FDA through what is known as a suitability petition pursuant to Section 505(j)(2)(C) of the FD&C Act. A petitioned ANDA relies on the reference listed drug described in the suitability petition. An ANDA seeking approval of a drug that is the same as a drug product approved in a petitioned ANDA should use as its reference listed drug, the reference listed drug that served as the basis for the approved suitability petition, and use the drug product approved in the petitioned ANDA as its reference standard for conducting an *in vivo* bioequivalence study required for approval. However, the reference listed drug for any such ANDA is generally the listed drug referenced in the approved suitability petition. The ANDA must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug that served as the basis for the approved suitability petition.[21] (This concept also generally applies to an ANDA applicant that utilizes a reference standard that is not a reference listed drug, as such an application must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug.)

Waived exclusivity. If an NDA submitted under Section 505(b) of the FD&C Act qualifies for exclusivity under the FD&C Act, the exclusivity is generally listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has qualified for this exclusivity, FDA will not accept for review and/or will not approve, as applicable, other applications blocked by the relevant exclusivity. If the listed drug is also protected by one or more patents, the approval date for an ANDA or 505(b)(2) application that relies on the listed drug will be determined based on an analysis of the applicant's patent certification(s) or statement(s) for each relevant patent and the effect of relevant exclusivity listed in the Orange Book. However, the

[20] Alvogen, Inc.'s tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

[21] If after approval of a suitability petition and before approval of an ANDA submitted pursuant to the approved petition, a drug product is approved in an NDA for the change described in the petition, the suitability petition and the listed drug identified in the petition can no longer be the basis of submission for such ANDA. Under these circumstances, an applicant seeking approval for a drug product with the change approved in the suitability petition must submit a new ANDA that identifies the drug product approved under such NDA as the RLD and comply with applicable regulatory requirements. See 21 CFR 314.93(f)(2).

holder of the NDA may waive its exclusivity as to any or all applications that might otherwise be blocked by such exclusivity. If an NDA holder waives its exclusivity, qualified applications may be accepted for review and/or approved, as applicable. An NDA for which the holder has waived its exclusivity as to all applications will be coded with a "W" in the Patent and Exclusivity Section of the Orange Book. The applicant whose product might otherwise be blocked by this exclusivity should indicate in the exclusivity statement in its application that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Category of Multisource Drug Products

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multisource drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of multisource drug products in the Orange Book (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific active ingredient and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying an actual or potential bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of multisource drug products as described above, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comments. Comments, along with scientific data, may be sent to the Director, Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Central Document Room, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submitted to support comments is generally an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. Comments including scientific data from an *in vivo* bioavailability/bioequivalence study should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and submission of comments based on such information is discouraged. However, when there is supporting published or unpublished scientific literature, copies should be submitted with comments.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The procedure described in Section 1.9 does not apply to a change in a single drug product code. For example, a change in a single drug product's

code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment in the Cumulative Supplement. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

We recognize that certain drug products approved in 505(b)(2) applications may not have therapeutic equivalence codes, and that FDA may undertake therapeutic equivalence evaluations with respect to such drug products. A person seeking to have a therapeutic equivalence rating for a drug product approved in a 505(b)(2) application may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and 21 CFR 10.30).[22]

1.11 Discontinued Section

Those drug products in the discontinued section of the Orange Book (Discontinued Drug Product List) for which a determination has been made that the products were not withdrawn for safety or effectiveness reasons have been annotated with a footnote following the product strength: "**Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**". The determinations listed in the Orange Book are only reflective of determinations made since 1995 and published in the Federal Register. The identification of these drug products in the Discontinued Drug Product List should avoid the submission of multiple citizen petitions requesting a determination for the same drug product.

Generally, approved products are added to the Discontinued Drug Product List when the applicant notifies the Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of the products' not-marketed status. Products may also be added to the Discontinued Drug Product List if annual reports or other submissions to the Agency indicate the product is not being marketed or as a result of other Agency administrative actions.[23] Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the FD&C Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicants are requested to inform DOBPRA of any changes or corrections, including any change in ownership or a product's marketing status that would result in the product being moved to the Discontinued Drug Product List. FDA notes that under Section 506I(a) of the FD&C Act, application holders must notify the Agency in writing 180 days prior to withdrawing a drug product from sale, or if 180 days is not practicable, not later than the date of withdrawal from sale. Furthermore, Section 506I(b) of

[22] Section 3222 of the Food and Drug Omnibus Reform Act of 2022 (enacted December 29, 2022) amended the FD&C Act by adding a new provision to Section 505(j)(7)(A). Section 505(j)(7)(A)(v)(I) sets forth certain conditions under which FDA considers therapeutic equivalence evaluation requests in an application for an eligible drug submitted or approved pursuant to Section 505(b)(2) of the FD&C Act.

[23] See, e.g., Section 506I(d) of the FD&C Act.

the FD&C Act requires that application holders notify the Agency in writing within 180 days of approval of a drug product if such drug product will not be available for sale within 180 days of approval. A request to include a newly approved product in the Discontinued Drug Product List, rather than parts 1 or 2 of the Orange Book (as discussed in Section 1.1), must be submitted to DOBPRA by the end of the month in which the product is approved to ensure that the product is not included in the Active Section of the next published Orange Book update. The Prescription Drug Product List and the Over-the-Counter (OTC) Drug Product List are collectively referred to as the "Active Section."

In addition, DOBPRA generally will act on requests to change a proprietary name for a listed drug only after approval of a supplement for the relevant change in proprietary name. To the extent that conventions for describing product identification information (i.e., active ingredients, dosage forms, routes of administration, product names, applicants, strengths) evolve over time, the Agency generally does not intend to revise such information for drug products already listed in the Orange Book, but rather intends to apply the change prospectively to drug products as they are added to the Orange Book.

You can contact DOBPRA by email at orangebook@fda.hhs.gov.

1.13 Availability of the Edition

The Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the Orange Book home page by clicking on Publications. An annual subscription of the PDF format may be obtained from the U.S. Government Publishing Office, https://www.gpo.gov/.

2.0 HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration* (see Section 2.2) and the *Therapeutic Equivalence Evaluations Illustration* (see Section 2.3) are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by “N” is a New Drug Application (NDA or commonly the innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Drug Product List, arranged alphabetically by active ingredient(s), contains product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "**A**" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and

compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Drug Product List.

Product Name Index *(Prescription and OTC Drug Product Lists)*. This is an index of drug products by trade name or established name of the active ingredient, if no trade name exists. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant *(Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT



*NOTE: REFERENCE LISTED DRUG AND REFERENCE STANDARD ARE DISCUSSED IN THE PREFACE SECTION 1.4

MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION



THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A"**) UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A")** AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH **"B"**) AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A **"B"**) ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION.*



NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

ABACAVIR SULFATE

SOLUTION;ORAL

ABACAVIR SULFATE

AA		AUROBINDO PHARMA LTD	**EQ 20MG BASE/ML**	**A077950**	**001**	Mar 14, 2018
AA		HETERO LABS LTD III	**EQ 20MG BASE/ML**	**A201107**	**001**	Sep 26, 2016

ZIAGEN

AA	**+!**	VIIV HLTHCARE	**EQ 20MG BASE/ML**	**N020978**	**001**	Dec 17, 1998

TABLET;ORAL

ABACAVIR SULFATE

AB		AUROBINDO PHARMA LTD	**EQ 300MG BASE**	**A077844**	**001**	Dec 17, 2012
AB		CIPLA	**EQ 300MG BASE**	**A078119**	**001**	Nov 21, 2017
AB	**!**	HETERO LABS LTD III	**EQ 300MG BASE**	**A091560**	**001**	Sep 13, 2013
AB		MYLAN PHARMS INC	**EQ 300MG BASE**	**A091294**	**001**	Jun 18, 2012
AB		STRIDES PHARMA	**EQ 300MG BASE**	**A091050**	**001**	Oct 28, 2016

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ

	+!	VIIV HLTHCARE	EQ 600MG BASE;EQ 50MG BASE;300MG	N205551	001	Aug 22, 2014

TABLET, FOR SUSPENSION;ORAL

TRIUMEQ PD

	+!	VIIV HLTHCARE	EQ 60MG BASE;EQ 5MG BASE;30MG	N215413	001	Mar 30, 2022

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB		AUROBINDO PHARMA LTD	**EQ 600MG BASE;300MG**	**A090159**	**001**	Nov 15, 2018
AB		CIPLA	**EQ 600MG BASE;300MG**	**A091144**	**001**	Mar 28, 2017
AB		LAURUS	**EQ 600MG BASE;300MG**	**A216332**	**001**	Jul 25, 2022
AB		LUPIN LTD	**EQ 600MG BASE;300MG**	**A204990**	**001**	Mar 28, 2017

EPZICOM

AB	**+!**	VIIV HLTHCARE	**EQ 600MG BASE;300MG**	**N021652**	**001**	Aug 02, 2004

TABLET, FOR SUSPENSION;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

	+!	MYLAN LABS LTD	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

	!	LUPIN LTD	EQ 300MG BASE;150MG;300MG	A202912	001	Dec 05, 2013

ABALOPARATIDE

SOLUTION;SUBCUTANEOUS

TYMLOS

	+!	RADIUS	3.12MG/1.56ML (2MG/ML)	N208743	001	Apr 28, 2017

ABEMACICLIB

TABLET;ORAL

VERZENIO

	+	ELI LILLY AND CO	50MG	N208716	001	Sep 28, 2017
	+		100MG	N208716	002	Sep 28, 2017
	+		150MG	N208716	003	Sep 28, 2017
	+!		200MG	N208716	004	Sep 28, 2017

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB	AMNEAL PHARMS	**250MG**	**A208327**	**001**	Jan 07, 2019
AB		**500MG**	**A208327**	**002**	Dec 23, 2020
AB	APOTEX	**250MG**	**A208453**	**001**	Oct 31, 2018
AB	DR REDDYS	**250MG**	**A208416**	**001**	May 18, 2020
AB		**500MG**	**A208416**	**002**	Sep 01, 2023
AB	FLORIDA	**500MG**	**A215086**	**001**	Mar 23, 2023
AB	GLENMARK PHARMS	**250MG**	**A209227**	**001**	Oct 16, 2019
AB		**500MG**	**A209227**	**002**	May 19, 2022
AB	HIKMA	**250MG**	**A208339**	**001**	Oct 31, 2018
AB	MSN	**250MG**	**A210686**	**001**	Jul 10, 2019
AB	MYLAN	**250MG**	**A208446**	**001**	Oct 31, 2018
AB		**500MG**	**A208446**	**002**	Dec 14, 2020
AB	NOVUGEN	**250MG**	**A215947**	**001**	Jan 05, 2022
AB		**500MG**	**A215947**	**002**	Jan 05, 2022
AB	QILU	**250MG**	**A212462**	**001**	Sep 27, 2019
AB		**500MG**	**A212462**	**002**	Jun 25, 2021

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB		RISING	**250MG**	**A208371**	**001**	Feb 25, 2019
AB		TEVA PHARMS USA	**250MG**	**A208432**	**001**	Oct 31, 2018
AB			**500MG**	**A210726**	**001**	Jan 26, 2023
AB		WOCKHARDT BIO AG	**250MG**	**A208380**	**001**	Feb 27, 2019

ZYTIGA

AB	**+**	JANSSEN BIOTECH	**250MG**	**N202379**	**001**	Apr 28, 2011
AB	**+!**		**500MG**	**N202379**	**002**	Apr 14, 2017

YONSA

	+!	SUN PHARM	125MG	N210308	001	May 22, 2018

ABIRATERONE ACETATE; NIRAPARIB TOSYLATE

TABLET;ORAL

AKEEGA

	+	JANSSEN BIOTECH	500MG;EQ 50MG BASE	N216793	001	Aug 11, 2023
	+!		500MG;EQ 100MG BASE	N216793	002	Aug 11, 2023

ABROCITINIB

TABLET;ORAL

CIBINQO

	+	PFIZER	50MG	N213871	001	Jan 14, 2022
	+		100MG	N213871	002	Jan 14, 2022
	+!		200MG	N213871	003	Jan 14, 2022

ACALABRUTINIB

CAPSULE;ORAL

CALQUENCE

	+!	ASTRAZENECA	100MG	N210259	001	Oct 31, 2017

ACALABRUTINIB MALEATE

TABLET;ORAL

CALQUENCE

	+!	ASTRAZENECA	EQ 100MG BASE	N216387	001	Aug 03, 2022

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB	**!**	GLENMARK GENERICS	**333MG**	**A202229**	**001**	Jul 16, 2013
AB		MYLAN	**333MG**	**A200142**	**001**	Mar 11, 2014
AB		ZYDUS PHARMS	**333MG**	**A205995**	**001**	May 26, 2017

ACARBOSE

TABLET;ORAL

ACARBOSE

AB		AVET LIFESCIENCES	**25MG**	**A202271**	**001**	Feb 07, 2012
AB			**50MG**	**A202271**	**002**	Feb 07, 2012
AB			**100MG**	**A202271**	**003**	Feb 07, 2012
AB		HIKMA	**25MG**	**A078470**	**001**	May 07, 2008
AB			**50MG**	**A078470**	**002**	May 07, 2008
AB			**100MG**	**A078470**	**003**	May 07, 2008
AB		IMPAX LABS	**25MG**	**A078441**	**001**	May 14, 2009
AB			**50MG**	**A078441**	**002**	May 14, 2009
AB			**100MG**	**A078441**	**003**	May 14, 2009
AB	**!**	STRIDES PHARMA	**25MG**	**A090912**	**001**	Jul 27, 2011
AB			**50MG**	**A090912**	**002**	Jul 27, 2011
AB			**100MG**	**A090912**	**003**	Jul 27, 2011
AB		VIRTUS PHARM	**25MG**	**A091343**	**001**	Oct 17, 2013
AB			**50MG**	**A091343**	**002**	Oct 17, 2013
AB			**100MG**	**A091343**	**003**	Oct 17, 2013
AB		WATSON LABS	**25MG**	**A077532**	**001**	May 07, 2008
AB			**50MG**	**A077532**	**002**	May 07, 2008
AB			**100MG**	**A077532**	**003**	May 07, 2008

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

AB	**!**	AMNEAL PHARM	**EQ 200MG BASE**	**A075047**	**001**	Dec 30, 1999
AB	**!**		**EQ 400MG BASE**	**A075047**	**002**	Dec 30, 1999
AB		ANI PHARMS	**EQ 200MG BASE**	**A074007**	**001**	Oct 18, 1995
AB			**EQ 400MG BASE**	**A074007**	**002**	Oct 18, 1995

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP		ASPIRO	**1GM/100ML (10MG/ML)**	**A216617**	**001**	Jul 27, 2022
AP		BAXTER HLTHCARE CORP	**1GM/100ML (10MG/ML)**	**A214331**	**001**	Sep 17, 2021
AP		EUGIA PHARMA	**1GM/100ML (10MG/ML)**	**A210969**	**001**	Oct 21, 2020
AP		HIKMA	**1GM/100ML (10MG/ML)**	**A202605**	**001**	Jun 13, 2016
AP		INFORLIFE	**1GM/100ML (10MG/ML)**	**A215403**	**001**	May 03, 2023
AP		MYLAN	**1GM/100ML (10MG/ML)**	**A213255**	**001**	Aug 07, 2020
AP	!	SANDOZ	**1GM/100ML (10MG/ML)**	**A204052**	**001**	Mar 22, 2016
AP		WOCKHARDT BIO AG	**1GM/100ML (10MG/ML)**	**A205746**	**001**	Apr 18, 2023
	+!	B BRAUN MEDICAL INC	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021
	+!		1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021
		FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767	001	Oct 28, 2015
	+!	HIKMA	1GM/100ML (10MG/ML)	N206968	001	Jun 03, 2022

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA	!	DR REDDYS LABS SA	**300MG;50MG**	**A207313**	**001**	Dec 27, 2017
AA		GRANULES	**300MG;50MG**	**A213115**	**001**	Nov 22, 2019

TABLET;ORAL

ALLZITAL

AA	!	LARKEN LABS INC	**325MG;25MG**	**A203484**	**001**	Dec 04, 2015

BUTALBITAL AND ACETAMINOPHEN

AA		LARKEN LABS INC	**325MG;50MG**	**A203484**	**002**	Dec 04, 2015
AA	!	LGM PHARMA	**300MG;50MG**	**A090956**	**001**	Aug 23, 2011
AA		MIKART	**300MG;50MG**	**A207386**	**001**	Nov 15, 2016
AA		NE RX PHARMA	**300MG;50MG**	**A214955**	**001**	Aug 16, 2022
AA		SENORES PHARMS	**300MG;50MG**	**A214088**	**001**	Apr 07, 2022
AA			**325MG;25MG**	**A214088**	**002**	Apr 07, 2022
AA			**325MG;50MG**	**A214088**	**003**	Apr 07, 2022

BUTAPAP

AA	!	MIKART	**325MG;50MG**	**A089987**	**001**	Oct 26, 1992

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		AUROLIFE PHARMA LLC	**325MG;50MG;40MG**	**A204733**	**001**	Sep 26, 2018
AA		DR REDDYS LABS SA	**300MG;50MG;40MG**	**A210817**	**001**	Dec 17, 2019
AA	!		**325MG;50MG;40MG**	**A089007**	**001**	Mar 17, 1986
AA		GRANULES	**300MG;50MG;40MG**	**A213321**	**001**	Apr 08, 2020
AA		LANNETT CO INC	**300MG;50MG;40MG**	**A212082**	**001**	Dec 17, 2019
AA			**325MG;50MG;40MG**	**A212083**	**001**	Dec 17, 2019
AA	!	LGM PHARMA	**300MG;50MG;40MG**	**A040885**	**001**	Nov 16, 2009
AA		NOVAST LABS	**300MG;50MG;40MG**	**A215047**	**001**	Nov 17, 2021
AA		NUVO PHARMS INC	**300MG;50MG;40MG**	**A207118**	**001**	Oct 28, 2016
AA		RISE PHARMA	**300MG;50MG;40MG**	**A214087**	**001**	Aug 13, 2021
AA			**325MG;50MG;40MG**	**A214087**	**002**	Aug 13, 2021
AA		TARO	**300MG;50MG;40MG**	**A213046**	**001**	Jul 01, 2020
AA		XSPIRE PHARMA	**300MG;50MG;40MG**	**A206615**	**001**	Aug 04, 2017

SOLUTION;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	!	MIKART	325MG/15ML;50MG/15ML;40MG/15ML	A040387	001	Jan 31, 2003

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		ABHAI LLC	**325MG;50MG;40MG**	**A211106**	**001**	Sep 26, 2018
AA	+	ACTAVIS LABS UT INC	**325MG;50MG;40MG**	**A088616**	**001**	Nov 09, 1984
AA		GRANULES	**325MG;50MG;40MG**	**A040864**	**001**	Dec 01, 2008
AA		LANNETT CO INC	**325MG;50MG;40MG**	**A200243**	**001**	Sep 13, 2012
AA		LGM PHARMA	**325MG;50MG;40MG**	**A209587**	**001**	Oct 31, 2018
AA		MIKART	**325MG;50MG;40MG**	**A089175**	**001**	Jan 21, 1987
AA	!	STRIDES PHARMA	**325MG;50MG;40MG**	**A040511**	**001**	Aug 27, 2003
AA			**325MG;50MG;40MG**	**A203647**	**001**	Sep 21, 2020

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB		HIKMA	**300MG;50MG;40MG;30MG**	**A215138**	**002**	Jan 26, 2022
AB			**325MG;50MG;40MG;30MG**	**A215138**	**001**	Jan 26, 2022
AB		LGM PHARMA	**300MG;50MG;40MG;30MG**	**A076560**	**002**	Jul 19, 2012
AB			**325MG;50MG;40MG;30MG**	**A076560**	**001**	Jun 10, 2004
AB		NOSTRUM LABS INC	**325MG;50MG;40MG;30MG**	**A075929**	**001**	Apr 22, 2002

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB		STRIDES PHARMA	**325MG;50MG;40MG;30MG**	**A204649**	**001**	Jul 08, 2020

FIORICET W/ CODEINE

AB	**+!**	ACTAVIS LABS UT INC	**325MG;50MG;40MG;30MG**	**N020232**	**001**	Jul 30, 1992

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

TREZIX

		XSPIRE PHARMA	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AKORN	**120MG/5ML;12MG/5ML**	**A040119**	**001**	Apr 26, 1996
AA		CHARTWELL	**120MG/5ML;12MG/5ML**	**A089450**	**001**	Oct 27, 1992
AA	**!**	GENUS LIFESCIENCES	**120MG/5ML;12MG/5ML**	**A087508**	**001**	

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AMNEAL PHARMS NY	**300MG;30MG**	**A040779**	**001**	May 29, 2008
AA		AUROLIFE PHARMA LLC	**300MG;15MG**	**A202800**	**001**	Apr 15, 2013
AA			**300MG;30MG**	**A202800**	**002**	Apr 15, 2013
AA			**300MG;60MG**	**A202800**	**003**	Apr 15, 2013
AA		ELITE LABS INC	**300MG;15MG**	**A212418**	**001**	Sep 10, 2019
AA			**300MG;30MG**	**A212418**	**002**	Sep 10, 2019
AA			**300MG;60MG**	**A212418**	**003**	Sep 10, 2019
AA	**!**	SPECGX LLC	**300MG;15MG**	**A040419**	**001**	May 31, 2001
AA	**!**		**300MG;30MG**	**A040419**	**002**	May 31, 2001
AA			**300MG;60MG**	**A040419**	**003**	May 31, 2001
AA		SUN PHARM INDS LTD	**300MG;30MG**	**A085868**	**001**	
AA			**300MG;60MG**	**A087083**	**001**	
AA		WES PHARMA INC	**300MG;15MG**	**A211610**	**001**	Jun 27, 2019
AA			**300MG;30MG**	**A211610**	**002**	Jun 27, 2019
AA			**300MG;60MG**	**A211610**	**003**	Jun 27, 2019

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	**!**	CHARTWELL	**325MG/15ML;7.5MG/15ML**	**A040482**	**001**	Sep 25, 2003
AA		GENUS	**325MG/15ML;7.5MG/15ML**	**A040894**	**001**	Jul 19, 2011
AA		PHARM ASSOC	**325MG/15ML;7.5MG/15ML**	**A040838**	**001**	May 10, 2013
AA		WES PHARMA INC	**325MG/15ML;7.5MG/15ML**	**A211023**	**001**	Mar 08, 2019
	!	MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010
	!	PHARM ASSOC	325MG/15ML;10MG/15ML	A040834	001	Apr 18, 2008

TABLET;ORAL

ANEXSIA 5/325

AA	**!**	SPECGX LLC	**325MG;5MG**	**A040409**	**001**	Oct 20, 2000

ANEXSIA 7.5/325

AA	**!**	SPECGX LLC	**325MG;7.5MG**	**A040405**	**001**	Sep 08, 2000

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		ABHAI LLC	**300MG;5MG**	**A209036**	**001**	Jun 21, 2017
AA			**300MG;7.5MG**	**A209036**	**002**	Jun 21, 2017
AA			**300MG;10MG**	**A209036**	**003**	Jun 21, 2017
AA			**325MG;5MG**	**A209037**	**001**	Jun 21, 2017
AA			**325MG;7.5MG**	**A209037**	**002**	Jun 21, 2017
AA			**325MG;10MG**	**A209037**	**003**	Jun 21, 2017
AA		AMNEAL PHARMS	**300MG;10MG**	**A207137**	**001**	Nov 29, 2016
AA		AMNEAL PHARMS NY	**300MG;5MG**	**A206869**	**001**	Jun 23, 2017
AA			**325MG;5MG**	**A040736**	**001**	Aug 25, 2006
AA			**325MG;7.5MG**	**A040746**	**002**	May 10, 2016
AA			**325MG;10MG**	**A040746**	**001**	Aug 25, 2006
AA		ASCENT PHARMS INC	**325MG;5MG**	**A211487**	**002**	Nov 07, 2018
AA			**325MG;7.5MG**	**A211487**	**003**	Nov 07, 2018
AA			**325MG;10MG**	**A211487**	**004**	Nov 07, 2018
AA		AUROLIFE PHARMA LLC	**300MG;5MG**	**A207709**	**001**	Sep 13, 2018
AA			**300MG;7.5MG**	**A207709**	**002**	Sep 13, 2018
AA			**300MG;10MG**	**A207709**	**003**	Sep 13, 2018
AA			**325MG;5MG**	**A201013**	**001**	Apr 11, 2012
AA			**325MG;7.5MG**	**A201013**	**002**	Apr 11, 2012
AA			**325MG;10MG**	**A201013**	**003**	Apr 11, 2012
AA	**!**	CHARTWELL	**300MG;5MG**	**A040658**	**001**	Jan 19, 2006
AA	**!**		**300MG;7.5MG**	**A040658**	**002**	Mar 24, 2006
AA	**!**		**300MG;10MG**	**A040658**	**003**	Jun 23, 2004

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA			**325MG;7.5MG**	**A040432**	**001**	Jan 22, 2003
AA		EPIC PHARMA LLC	**325MG;5MG**	**A203863**	**001**	Mar 30, 2018
AA			**325MG;7.5MG**	**A203863**	**002**	Mar 30, 2018
AA			**325MG;10MG**	**A203863**	**003**	Mar 30, 2018
AA		PRINSTON INC	**325MG;5MG**	**A214928**	**001**	Dec 30, 2021
AA			**325MG;7.5MG**	**A214928**	**002**	Dec 30, 2021
AA			**325MG;10MG**	**A214928**	**003**	Dec 30, 2021
AA		RHODES PHARMS	**300MG;5MG**	**A207808**	**001**	Mar 30, 2018
AA			**300MG;7.5MG**	**A207808**	**002**	Mar 30, 2018
AA			**300MG;10MG**	**A207808**	**003**	Mar 30, 2018
AA			**325MG;5MG**	**A202991**	**001**	Apr 12, 2016
AA			**325MG;7.5MG**	**A202991**	**002**	Apr 12, 2016
AA			**325MG;10MG**	**A202991**	**003**	Apr 12, 2016
AA		SPECGX LLC	**300MG;5MG**	**A206718**	**001**	Mar 31, 2017
AA			**300MG;7.5MG**	**A206718**	**002**	Mar 31, 2017
AA			**300MG;10MG**	**A206718**	**003**	Mar 31, 2017
AA	**!**		**325MG;10MG**	**A040400**	**001**	Jul 26, 2000
AA		STRIDES PHARMA	**325MG;5MG**	**A040655**	**001**	Jan 19, 2006
AA			**325MG;5MG**	**A202935**	**002**	Jun 15, 2016
AA			**325MG;7.5MG**	**A040656**	**001**	Jan 19, 2006
AA			**325MG;7.5MG**	**A202935**	**003**	Jun 15, 2016
AA			**325MG;10MG**	**A040355**	**001**	May 31, 2000
AA			**325MG;10MG**	**A202935**	**004**	Jun 15, 2016
AA		TRIS PHARMA INC	**300MG;5MG**	**A202214**	**004**	Mar 15, 2016
AA			**300MG;7.5MG**	**A202214**	**005**	Mar 15, 2016
AA			**300MG;10MG**	**A202214**	**006**	Mar 15, 2016
AA			**325MG;5MG**	**A202214**	**001**	Mar 27, 2013
AA			**325MG;7.5MG**	**A202214**	**002**	Mar 27, 2013
AA			**325MG;10MG**	**A202214**	**003**	Mar 27, 2013
AA		WES PHARMA INC	**300MG;5MG**	**A207509**	**001**	Oct 29, 2018
AA			**300MG;7.5MG**	**A207509**	**002**	Oct 29, 2018
AA			**300MG;10MG**	**A207509**	**003**	Oct 29, 2018
AA			**325MG;5MG**	**A210211**	**001**	Oct 30, 2017
AA			**325MG;7.5MG**	**A210211**	**002**	Oct 30, 2017
AA			**325MG;10MG**	**A210211**	**003**	Oct 30, 2017
	!	ASCENT PHARMS INC	325MG;2.5MG	A211487	001	Nov 07, 2018

ACETAMINOPHEN; IBUPROFEN SODIUM

SOLUTION;INTRAVENOUS

COMBOGESIC IV

	+!	HIKMA	1GM/100ML (10MG/ML);EQ 300MG BASE/100ML (EQ 3MG BASE/ML)	N215320	001	Oct 17, 2023

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

AA	**!**	ABHAI LLC	**325MG/5ML;5MG/5ML**	**A211499**	**001**	Dec 31, 2018
AA		NOSTRUM LABS INC	**325MG/5ML;5MG/5ML**	**A201448**	**001**	Aug 26, 2021
		MIKART	300MG/5ML;10MG/5ML	A202142	001	Nov 27, 2018

TABLET;ORAL

OXYCET

AA		SPECGX LLC	**325MG;5MG**	**A087463**	**001**	Dec 07, 1983

OXYCODONE AND ACETAMINOPHEN

AA		ABHAI LLC	**325MG;2.5MG**	**A210644**	**001**	Feb 09, 2018
AA			**325MG;5MG**	**A210644**	**002**	Feb 09, 2018
AA			**325MG;7.5MG**	**A210644**	**003**	Feb 09, 2018
AA			**325MG;10MG**	**A210644**	**004**	Feb 09, 2018
AA		ACTAVIS ELIZABETH	**325MG;2.5MG**	**A201447**	**001**	Apr 12, 2013
AA			**325MG;5MG**	**A201447**	**002**	Apr 12, 2013
AA			**325MG;7.5MG**	**A201447**	**003**	Apr 12, 2013
AA			**325MG;10MG**	**A201447**	**004**	Apr 12, 2013
AA		ALVOGEN	**325MG;5MG**	**A202677**	**003**	Mar 08, 2016
AA			**325MG;7.5MG**	**A202677**	**001**	Jul 26, 2012
AA			**325MG;10MG**	**A202677**	**002**	Jul 26, 2012
AA		AMNEAL PHARMS	**325MG;5MG**	**A040777**	**001**	Nov 27, 2007
AA		AMNEAL PHARMS NY	**325MG;7.5MG**	**A040778**	**002**	Jun 27, 2014
AA			**325MG;10MG**	**A040778**	**001**	Nov 27, 2007
AA		ASCENT PHARMS INC	**325MG;2.5MG**	**A207419**	**001**	Mar 22, 2017
AA			**325MG;5MG**	**A207419**	**002**	Mar 22, 2017
AA			**325MG;7.5MG**	**A207419**	**003**	Mar 22, 2017
AA			**325MG;10MG**	**A207419**	**004**	Mar 22, 2017

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA		AUROLIFE PHARMA LLC	**325MG;2.5MG**	**A201972**	**001**	Jul 15, 2013
AA			**325MG;5MG**	**A201972**	**002**	Jul 15, 2013
AA			**325MG;7.5MG**	**A201972**	**003**	Jul 15, 2013
AA			**325MG;10MG**	**A201972**	**004**	Jul 15, 2013
AA		CHARTWELL	**325MG;5MG**	**A207834**	**001**	Aug 15, 2019
AA			**325MG;7.5MG**	**A207834**	**002**	Aug 15, 2019
AA			**325MG;10MG**	**A207834**	**003**	Aug 15, 2019
AA		EPIC PHARMA LLC	**325MG;5MG**	**A203864**	**001**	Jul 02, 2018
AA			**325MG;7.5MG**	**A203864**	**002**	Jul 02, 2018
AA			**325MG;10MG**	**A203864**	**003**	Jul 02, 2018
AA		NOVEL LABS INC	**325MG;2.5MG**	**A204407**	**001**	Feb 24, 2017
AA			**325MG;5MG**	**A204407**	**002**	Feb 24, 2017
AA			**325MG;7.5MG**	**A204407**	**003**	Feb 24, 2017
AA			**325MG;10MG**	**A204407**	**004**	Feb 24, 2017
AA		RHODES PHARMS	**325MG;5MG**	**A201278**	**001**	Aug 28, 2014
AA			**325MG;7.5MG**	**A201278**	**002**	Aug 28, 2014
AA			**325MG;10MG**	**A201278**	**003**	Aug 28, 2014
AA		SPECGX LLC	**325MG;7.5MG**	**A040545**	**001**	Jun 30, 2004
AA			**325MG;10MG**	**A040545**	**002**	Jun 30, 2004
AA		WES PHARMA INC	**325MG;5MG**	**A207510**	**001**	Mar 21, 2018
AA			**325MG;7.5MG**	**A207510**	**002**	Mar 21, 2018
AA			**325MG;10MG**	**A207510**	**003**	Mar 21, 2018

PERCOCET

AA	**!**	VINTAGE PHARMS LLC	**325MG;2.5MG**	**A040330**	**001**	Jun 25, 1999
AA	**!**		**325MG;5MG**	**A040330**	**002**	Jun 25, 1999
AA	**!**		**325MG;7.5MG**	**A040330**	**003**	Nov 23, 2001
AA	**!**		**325MG;10MG**	**A040330**	**004**	Nov 23, 2001

OXYCODONE AND ACETAMINOPHEN

	!	MIKART	300MG;2.5MG	A040608	001	Dec 30, 2005
	!		300MG;5MG	A040608	002	Dec 30, 2005
	!		300MG;7.5MG	A040608	003	Dec 30, 2005
	!		300MG;10MG	A040608	004	Dec 30, 2005

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB		ALKEM LABS LTD	**325MG;37.5MG**	**A202076**	**001**	Mar 30, 2012
AB	**!**	AMNEAL PHARMS	**325MG;37.5MG**	**A090485**	**001**	Dec 09, 2009
AB		AUROBINDO PHARMA	**325MG;37.5MG**	**A207152**	**001**	Mar 22, 2017
AB		MICRO LABS LTD INDIA	**325MG;37.5MG**	**A201952**	**001**	Dec 14, 2012
AB		RISING	**325MG;37.5MG**	**A077858**	**001**	Sep 26, 2008
AB		SUN PHARM INDS INC	**325MG;37.5MG**	**A077184**	**001**	Dec 16, 2005
AB		ZYDUS PHARMS USA INC	**325MG;37.5MG**	**A090460**	**001**	Sep 06, 2012

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB		ACCORD HLTHCARE	**500MG**	**A207659**	**001**	Oct 18, 2018
AB		ALEMBIC	**500MG**	**A210423**	**001**	Feb 19, 2019
AB	**!**	CADILA	**500MG**	**A205301**	**001**	Jan 16, 2019
AB		HERITAGE PHARMA	**500MG**	**A040904**	**001**	Dec 10, 2008
AB		INDICUS PHARMA	**500MG**	**A090779**	**001**	Jul 14, 2011
AB		MICRO LABS LTD INDIA	**500MG**	**A207401**	**001**	Oct 01, 2020
AB		NOSTRUM LABS INC	**500MG**	**A204691**	**001**	Mar 29, 2016
AB		NOVAST LABS	**500MG**	**A203434**	**001**	Sep 30, 2016

TABLET;ORAL

ACETAZOLAMIDE

AB		AJANTA PHARMA LTD	**125MG**	**A211151**	**001**	Sep 11, 2023
AB			**250MG**	**A211151**	**002**	Sep 11, 2023
AB		APPCO	**125MG**	**A211372**	**001**	Feb 22, 2021
AB			**250MG**	**A211372**	**002**	Feb 22, 2021
AB		CHARTWELL MOLECULAR	**250MG**	**A084840**	**001**	
AB		EYWA PHARMA	**125MG**	**A211556**	**001**	Oct 18, 2019
AB			**250MG**	**A211556**	**002**	Oct 18, 2019
AB		HERITAGE PHARMA	**125MG**	**A205530**	**001**	Oct 27, 2016
AB			**250MG**	**A205530**	**002**	Oct 27, 2016
AB		MANKIND PHARMA	**125MG**	**A214282**	**001**	Oct 07, 2020
AB			**250MG**	**A214282**	**002**	Oct 07, 2020

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

AB		NE RX PHARMA	**125MG**	**A217197**	**001**	May 09, 2023
AB			**250MG**	**A217197**	**002**	May 09, 2023
AB		NOVITIUM PHARMA	**125MG**	**A210588**	**001**	Oct 17, 2019
AB			**250MG**	**A210588**	**002**	Oct 17, 2019
AB		RUBICON	**125MG**	**A215101**	**001**	Aug 19, 2021
AB			**250MG**	**A215101**	**002**	Aug 19, 2021
AB		STRIDES PHARMA	**125MG**	**A209734**	**001**	Nov 20, 2017
AB			**250MG**	**A209734**	**002**	Nov 20, 2017
AB		TARO	**125MG**	**A040195**	**001**	May 28, 1997
AB	!		**250MG**	**A040195**	**002**	May 28, 1997
AB		ZYDUS	**125MG**	**A211069**	**001**	Apr 04, 2023
AB			**250MG**	**A211069**	**002**	Apr 04, 2023

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP		AVET LIFESCIENCES	**EQ 500MG BASE/VIAL**	**A202693**	**001**	Dec 19, 2014
AP		HIKMA	**EQ 500MG BASE/VIAL**	**A040089**	**001**	Feb 28, 1995
AP		MYLAN ASI	**EQ 500MG BASE/VIAL**	**A200880**	**001**	May 09, 2012
AP	!	XGEN PHARMS	**EQ 500MG BASE/VIAL**	**A040784**	**001**	Dec 10, 2008
AP		ZYDUS PHARMS	**EQ 500MG BASE/VIAL**	**A206533**	**001**	Apr 15, 2019

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT		B BRAUN	**250MG/100ML**	**N018161**	**001**	
AT		BAXTER HLTHCARE	**250MG/100ML**	**N018523**	**001**	Feb 19, 1982
AT	**+!**	ICU MEDICAL INC	**250MG/100ML**	**N017656**	**001**	

SOLUTION/DROPS;OTIC

ACETIC ACID

AT		RISING	**2%**	**A207280**	**001**	Mar 09, 2018
AT		SAPTALIS PHARMS	**2%**	**A040607**	**001**	Feb 24, 2005
AT		TARO	**2%**	**A088638**	**001**	Sep 06, 1984

VOSOL

AT	!	HIKMA	**2%**	**N012179**	**001**	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

HYDROCORTISONE AND ACETIC ACID

AT		COSETTE	**2%;1%**	**A040609**	**001**	Feb 06, 2006
AT	**+!**	TARO	**2%;1%**	**A088759**	**001**	Mar 04, 1985

VOSOL HC

AT	**+!**	SAPTALIS PHARMS	**2%;1%**	**N012770**	**001**	

ACETOHYDROXAMIC ACID

TABLET;ORAL

LITHOSTAT

	+!	MISSION PHARMA	250MG	N018749	001	May 31, 1983

ACETYLCHOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC

MIOCHOL-E

	+!	BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETADOTE

AP	**+!**	CUMBERLAND PHARMS	**6GM/30ML (200MG/ML)**	**N021539**	**001**	Jan 23, 2004

ACETYLCYSTEINE

AP		ASPEN	**6GM/30ML (200MG/ML)**	**A213693**	**001**	Feb 03, 2022
AP		EUGIA PHARMA	**6GM/30ML (200MG/ML)**	**A207358**	**001**	Feb 29, 2016
AP		FRESENIUS KABI USA	**6GM/30ML (200MG/ML)**	**A200644**	**001**	Nov 07, 2012
AP		INDOCO	**6GM/30ML (200MG/ML)**	**A215620**	**001**	Feb 23, 2022
AP		RISING	**6GM/30ML (200MG/ML)**	**A203173**	**001**	Mar 24, 2015
AP		SAGENT PHARMS INC	**6GM/30ML (200MG/ML)**	**A091684**	**001**	Oct 31, 2017
AP		STERISCIENCE	**6GM/30ML (200MG/ML)**	**A217182**	**001**	Apr 19, 2023
AP		ZYDUS PHARMS	**6GM/30ML (200MG/ML)**	**A208166**	**001**	Jul 20, 2018

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

AN		ALVOGEN	**10%**	**A204674**	**001**	Feb 11, 2014
AN			**20%**	**A203853**	**001**	Jun 21, 2012
AN	!	AM REGENT	**10%**	**A072489**	**001**	Jul 28, 1995

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

AN	!		**20%**	**A072547**	**001**	Jul 28, 1995
AN		EXELA PHARMA	**20%**	**A205643**	**001**	Nov 01, 2023
AN		HOSPIRA	**10%**	**A073664**	**001**	Aug 30, 1994
AN			**20%**	**A074037**	**001**	Aug 30, 1994

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB		BARR LABS INC	**10MG**	**A091455**	**001**	Apr 04, 2013
AB			**25MG**	**A091455**	**002**	Apr 04, 2013
AB		IMPAX LABS INC	**10MG**	**A202552**	**001**	Dec 23, 2015
AB			**17.5MG**	**A202552**	**002**	Dec 23, 2015
AB			**22.5MG**	**A202552**	**003**	Dec 23, 2015
AB			**25MG**	**A202552**	**004**	Dec 23, 2015
AB		MYLAN	**10MG**	**A202148**	**001**	Sep 10, 2015
AB			**25MG**	**A202148**	**002**	Sep 10, 2015
AB		SIGMAPHARM LABS LLC	**10MG**	**A204633**	**001**	May 22, 2015
AB			**17.5MG**	**A204633**	**002**	May 22, 2015
AB			**22.5MG**	**A204633**	**003**	May 22, 2015
AB	!		**25MG**	**A204633**	**004**	May 22, 2015
AB		TEVA PHARMS USA	**17.5MG**	**A202897**	**001**	Apr 04, 2013
AB			**22.5MG**	**A202897**	**002**	Apr 04, 2013

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

	+!	COVIS	0.4MG/INH	N202450	001	Jul 23, 2012

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION

DUAKLIR PRESSAIR

	+!	COVIS	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB	!	APOTEX	**200MG**	**A075677**	**001**	Sep 28, 2005
AB		CADILA	**200MG**	**A204313**	**001**	Mar 25, 2016
AB		CADILA PHARMS LTD	**200MG**	**A201445**	**001**	Mar 06, 2014
AB		CARLSBAD TECHNOLOGY	**200MG**	**A206261**	**001**	Aug 16, 2017
AB		HERITAGE PHARMS	**200MG**	**A074889**	**001**	Oct 31, 1997
AB		INDOCO	**200MG**	**A075090**	**001**	Jan 26, 1999
AB		TEVA	**200MG**	**A074578**	**001**	Apr 22, 1997
AB		YILING	**200MG**	**A212173**	**001**	Sep 14, 2020

CREAM;TOPICAL

ACYCLOVIR

AB		ALEMBIC	**5%**	**A212361**	**001**	Nov 21, 2023
AB		AMNEAL	**5%**	**A208766**	**001**	Nov 09, 2020
AB	!	PADAGIS ISRAEL	**5%**	**A208702**	**001**	Feb 04, 2019
AB		ZYDUS LIFESCIENCES	**5%**	**A206770**	**001**	Feb 28, 2023

ZOVIRAX

AB	+	BAUSCH	**5%**	**N021478**	**001**	Dec 30, 2002

OINTMENT;TOPICAL

ACYCLOVIR

AB		ALEMBIC	**5%**	**A209000**	**001**	Apr 06, 2018
AB		AMNEAL PHARMS	**5%**	**A204605**	**001**	Jun 18, 2014
AB		APOTEX	**5%**	**A210774**	**001**	Sep 06, 2019
AB		CADILA	**5%**	**A205974**	**001**	Mar 15, 2019
AB		CHARTWELL RX	**5%**	**A212495**	**001**	Apr 07, 2020
AB		CIPLA	**5%**	**A211794**	**001**	Jan 18, 2019
AB		COSETTE	**5%**	**A205591**	**001**	Nov 13, 2017
AB		FOUGERA PHARMS INC	**5%**	**A206633**	**001**	May 11, 2016
AB		GLENMARK PHARMS SA	**5%**	**A205510**	**001**	Jul 31, 2017
AB		MACLEODS PHARMS LTD	**5%**	**A212444**	**001**	May 19, 2021
AB		MYLAN PHARMS INC	**5%**	**A202459**	**001**	Apr 03, 2013
AB		TARO	**5%**	**A205469**	**001**	Dec 21, 2016
AB		TORRENT	**5%**	**A209971**	**001**	Jan 11, 2019
AB		XIROMED	**5%**	**A201501**	**001**	Jan 29, 2020

ZOVIRAX

AB	+!	BAUSCH	**5%**	**N018604**	**001**	Mar 29, 1982

ACYCLOVIR

SUSPENSION;ORAL

ACYCLOVIR

AB		ACTAVIS MID ATLANTIC	**200MG/5ML**	**A074738**	**001**	Apr 28, 1997
AB		AUROBINDO PHARMA	**200MG/5ML**	**A216331**	**001**	Mar 31, 2022
AB		CHARTWELL RX	**200MG/5ML**	**A212718**	**001**	Apr 23, 2020
AB		HETERO LABS LTD III	**200MG/5ML**	**A215669**	**001**	Jul 01, 2022
AB		HIKMA	**200MG/5ML**	**A077026**	**001**	Jun 07, 2005
AB		MSN	**200MG/5ML**	**A217393**	**001**	Mar 09, 2023
AB	!	NOVITIUM PHARMA	**200MG/5ML**	**A212252**	**001**	Jul 10, 2020
AB		RUBICON	**200MG/5ML**	**A215724**	**001**	Aug 18, 2022

TABLET;BUCCAL

SITAVIG

	+!	LNHC	50MG	N203791	001	Apr 12, 2013

TABLET;ORAL

ACYCLOVIR

AB		APOTEX INC	**400MG**	**A077309**	**001**	Sep 29, 2005
AB			**800MG**	**A077309**	**002**	Sep 29, 2005
AB		CADILA PHARMS LTD	**400MG**	**A202168**	**001**	Nov 15, 2013
AB			**800MG**	**A202168**	**002**	Nov 15, 2013
AB		CARLSBAD	**400MG**	**A075382**	**001**	Apr 30, 1999
AB			**800MG**	**A075382**	**002**	Apr 30, 1999
AB		HERITAGE PHARMS	**400MG**	**A074891**	**001**	Oct 31, 1997
AB			**800MG**	**A074891**	**002**	Oct 31, 1997
AB		HETERO LABS LTD V	**400MG**	**A203834**	**001**	Oct 29, 2013
AB	!		**800MG**	**A203834**	**002**	Oct 29, 2013
AB		SQUARE PHARMS	**400MG**	**A209366**	**001**	Oct 07, 2019
AB			**800MG**	**A209366**	**002**	Oct 07, 2019
AB		STRIDES PHARMA	**400MG**	**A074946**	**001**	Nov 19, 1997
AB			**800MG**	**A074946**	**002**	Nov 19, 1997
AB		TEVA	**400MG**	**A074556**	**002**	Apr 22, 1997
AB			**800MG**	**A074556**	**003**	Apr 22, 1997
AB		YILING	**400MG**	**A210401**	**001**	Mar 07, 2018
AB			**800MG**	**A210401**	**002**	Mar 07, 2018
AB		ZYDUS PHARMS	**400MG**	**A204314**	**001**	Aug 19, 2014
AB			**800MG**	**A204314**	**002**	Aug 19, 2014

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

AP		EUGIA PHARMA	**EQ 50MG BASE/ML**	**A203701**	**001**	Oct 11, 2013
AP	!	FRESENIUS KABI USA	**EQ 50MG BASE/ML**	**A074930**	**001**	May 13, 1998
AP		HAINAN POLY	**EQ 50MG BASE/ML**	**A218111**	**001**	Jan 08, 2024
AP		ZYDUS PHARMS	**EQ 50MG BASE/ML**	**A206535**	**001**	Aug 31, 2018

ACYCLOVIR; HYDROCORTISONE

CREAM;TOPICAL

XERESE

	+!	BAUSCH	5%;1%	N022436	001	Jul 31, 2009

ADAGRASIB

TABLET;ORAL

KRAZATI

	+!	MIRATI THERAPS	200MG	N216340	001	Dec 12, 2022

ADAPALENE

CREAM;TOPICAL

ADAPALENE

AB		FOUGERA PHARMS	**0.1%**	**A090824**	**001**	Jun 30, 2010

DIFFERIN

AB	**+!**	GALDERMA LABS LP	**0.1%**	**N020748**	**001**	May 26, 2000

GEL;TOPICAL

ADAPALENE

AB		ACTAVIS MID ATLANTIC	**0.3%**	**A201000**	**001**	Oct 27, 2014
AB		ALEMBIC	**0.3%**	**A213508**	**001**	Jun 18, 2020
AB		ENCUBE ETHICALS	**0.3%**	**A200298**	**001**	Jun 14, 2012
AB		TARO	**0.3%**	**A208322**	**001**	Jun 23, 2016

DIFFERIN

AB	**+!**	GALDERMA LABS LP	**0.3%**	**N021753**	**001**	Jun 19, 2007

LOTION;TOPICAL

DIFFERIN

	+!	GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010

ADAPALENE

SOLUTION;TOPICAL

ADAPALENE

AB		CALL INC	**0.1%**	**A203981**	**001**	Sep 23, 2016
AB			**0.1%**	**A204593**	**001**	Jan 05, 2016

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB		ACTAVIS LABS UT INC	**0.3%;2.5%**	**A209641**	**001**	Jun 22, 2022
AB		ALEMBIC	**0.3%;2.5%**	**A214185**	**001**	Aug 04, 2022
AB		ENCUBE	**0.1%;2.5%**	**A206164**	**001**	May 23, 2018
AB		GLENMARK PHARMS LTD	**0.1%;2.5%**	**A208108**	**001**	Nov 08, 2019
AB		PADAGIS ISRAEL	**0.1%;2.5%**	**A205033**	**001**	Jan 23, 2018
AB			**0.3%;2.5%**	**A212464**	**001**	May 31, 2022
AB		TARO	**0.1%;2.5%**	**A206959**	**001**	Jan 24, 2018
AB			**0.3%;2.5%**	**A209148**	**001**	Oct 17, 2018
AB		ZYDUS PHARMS	**0.3%;2.5%**	**A214553**	**001**	Jun 03, 2022

EPIDUO

AB	**+!**	GALDERMA LABS LP	**0.1%;2.5%**	**N022320**	**001**	Dec 08, 2008

EPIDUO FORTE

AB	**+!**	GALDERMA LABS	**0.3%;2.5%**	**N207917**	**001**	Jul 15, 2015

ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CABTREO

	+!	BAUSCH	0.15%;3.1%;1.2%	N216632	001	Oct 20, 2023

ADEFOVIR DIPIVOXIL

TABLET;ORAL

ADEFOVIR DIPIVOXIL

AB		APOTEX	**10MG**	**A205459**	**001**	Jul 06, 2018
AB		SIGMAPHARM LABS LLC	**10MG**	**A202051**	**001**	Aug 29, 2013

HEPSERA

AB	**+!**	GILEAD	**10MG**	**N021449**	**001**	Sep 20, 2002

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

AP		FRESENIUS KABI USA	**3MG/ML**	**A077133**	**001**	Apr 27, 2005
AP			**3MG/ML**	**A205568**	**001**	Apr 16, 2018
AP		GLAND PHARMA LTD	**3MG/ML**	**A077283**	**001**	Jun 14, 2007
AP			**3MG/ML**	**A206778**	**001**	Feb 16, 2018
AP		HIKMA	**3MG/ML**	**A076404**	**001**	Jun 16, 2004
AP			**3MG/ML**	**A076500**	**001**	Jun 16, 2004
AP		MYLAN LABS LTD	**3MG/ML**	**A078686**	**001**	May 13, 2009
AP	**!**	RISING	**3MG/ML**	**A078076**	**001**	Oct 31, 2008

SOLUTION;INTRAVENOUS

ADENOSINE

AP		AVET LIFESCIENCES	**60MG/20ML (3MG/ML)**	**A202313**	**001**	Sep 15, 2014
AP			**90MG/30ML (3MG/ML)**	**A202313**	**002**	Sep 15, 2014
AP		EUGIA PHARMA	**60MG/20ML (3MG/ML)**	**A205331**	**001**	Nov 02, 2017
AP			**90MG/30ML (3MG/ML)**	**A205331**	**002**	Nov 02, 2017
AP		FRESENIUS KABI USA	**60MG/20ML (3MG/ML)**	**A077897**	**001**	Nov 27, 2017
AP			**90MG/30ML (3MG/ML)**	**A077897**	**002**	Nov 27, 2017
AP		HOSPIRA	**60MG/20ML (3MG/ML)**	**A203883**	**001**	Mar 24, 2014
AP			**90MG/30ML (3MG/ML)**	**A203883**	**002**	Mar 24, 2014
AP	**!**	MEITHEAL	**60MG/20ML (3MG/ML)**	**A077425**	**001**	Aug 29, 2013
AP	**!**		**90MG/30ML (3MG/ML)**	**A077425**	**002**	Aug 29, 2013
AP		MYLAN ASI	**60MG/20ML (3MG/ML)**	**A090212**	**001**	Mar 28, 2014
AP			**90MG/30ML (3MG/ML)**	**A090212**	**002**	Mar 28, 2014
AP		RISING	**60MG/20ML (3MG/ML)**	**A090450**	**001**	Oct 02, 2014
AP			**90MG/30ML (3MG/ML)**	**A090450**	**002**	Oct 02, 2014

AFAMELANOTIDE

IMPLANT;SUBCUTANEOUS

SCENESSE

	+!	CLIVUNEL INC	16MG	N210797	001	Oct 08, 2019

AFATINIB DIMALEATE

TABLET;ORAL

GILOTRIF

+	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292	001	Jul 12, 2013
+		EQ 30MG BASE	N201292	002	Jul 12, 2013
+!		EQ 40MG BASE	N201292	003	Jul 12, 2013

AIR POLYMER-TYPE A

FOAM;INTRAUTERINE

EXEM FOAM KIT

+!	GISKIT	10ML	N212279	001	Nov 07, 2019

ALBENDAZOLE

TABLET;ORAL

ALBENDAZOLE

AB		ACTAVIS ELIZABETH	**200MG**	**A208094**	**001**	May 20, 2019
AB	**!**	DR REDDYS	**200MG**	**A211034**	**001**	Jan 26, 2021
AB		EDENBRIDGE PHARMS	**200MG**	**A211117**	**001**	May 14, 2019
AB		MSN	**200MG**	**A213435**	**001**	Jan 21, 2021
AB		STRIDES PHARMA	**200MG**	**A210011**	**001**	Dec 07, 2018
AB		ZYDUS PHARMS	**200MG**	**A208979**	**001**	Dec 14, 2018

ALBUMIN HUMAN

INJECTABLE;INJECTION

OPTISON

+!	GE HEALTHCARE	10MG/ML	N020899	001	Dec 31, 1997

ALBUTEROL SULFATE

AEROSOL, METERED;INHALATION

ALBUTEROL SULFATE

AB1		CIPLA	**EQ 0.09MG BASE/INH**	**A209959**	**001**	Apr 08, 2020
AB1		SANDOZ	**EQ 0.09MG BASE/INH**	**A207085**	**001**	Jun 01, 2021

PROVENTIL-HFA

AB1	**+!**	KINDEVA	**EQ 0.09MG BASE/INH**	**N020503**	**001**	Aug 15, 1996

ALBUTEROL SULFATE

AB2		LUPIN	**EQ 0.09MG BASE/INH**	**A209954**	**001**	Aug 24, 2020

PROAIR HFA

AB2	**+!**	TEVA BRANDED PHARM	**EQ 0.09MG BASE/INH**	**N021457**	**001**	Oct 29, 2004

VENTOLIN HFA

BX	+!	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001

POWDER, METERED;INHALATION

PROAIR DIGIHALER

+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018

PROAIR RESPICLICK

+!	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015

SOLUTION;INHALATION

ALBUTEROL SULFATE

AN		LUOXIN AUROVITAS	**EQ 0.083% BASE**	**A206224**	**001**	Oct 17, 2017
AN		NEPHRON	**EQ 0.021% BASE**	**A076355**	**002**	Mar 31, 2010
AN	**!**		**EQ 0.042% BASE**	**A076355**	**001**	Jun 28, 2004
AN	**!**		**EQ 0.083% BASE**	**A074880**	**001**	Sep 17, 1997
AN	**!**		**EQ 0.5% BASE**	**A075664**	**001**	Jun 26, 2001
AN	**!**	RITEDOSE CORP	**EQ 0.021% BASE**	**A214531**	**001**	Dec 28, 2021
AN			**EQ 0.042% BASE**	**A214531**	**002**	Dec 28, 2021
AN			**EQ 0.083% BASE**	**A077839**	**001**	Dec 16, 2008
AN		SENTISS	**EQ 0.5% BASE**	**A074543**	**001**	Jan 15, 1998
AN		SUN PHARM	**EQ 0.083% BASE**	**A207857**	**001**	Jul 21, 2017
AN		WATSON LABS	**EQ 0.021% BASE**	**A077772**	**001**	Sep 25, 2007
AN			**EQ 0.042% BASE**	**A077772**	**002**	Sep 25, 2007

SYRUP;ORAL

ALBUTEROL SULFATE

AA		AMNEAL PHARMS	**EQ 2MG BASE/5ML**	**A079241**	**001**	May 12, 2010
AA		CHARTWELL MOLECULAR	**EQ 2MG BASE/5ML**	**A078105**	**001**	Dec 27, 2006
AA		CHARTWELL RX	**EQ 2MG BASE/5ML**	**A077788**	**001**	Jun 26, 2007
AA		COSETTE	**EQ 2MG BASE/5ML**	**A074454**	**001**	Sep 25, 1995
AA		HIKMA	**EQ 2MG BASE/5ML**	**A074749**	**001**	Jan 30, 1998
AA		QUAGEN	**EQ 2MG BASE/5ML**	**A212197**	**001**	Sep 06, 2019
AA	**!**	TEVA	**EQ 2MG BASE/5ML**	**A073419**	**001**	Mar 30, 1992

TABLET;ORAL

ALBUTEROL SULFATE

AB		AIZANT	**EQ 2MG BASE**	**A210948**	**001**	Mar 15, 2019
AB			**EQ 4MG BASE**	**A210948**	**002**	Mar 15, 2019
AB		AMNEAL PHARMS CO	**EQ 2MG BASE**	**A208804**	**001**	May 21, 2018
AB			**EQ 4MG BASE**	**A208804**	**002**	May 21, 2018

ALBUTEROL SULFATE

TABLET;ORAL

ALBUTEROL SULFATE

AB		DASH PHARMS NATCO	**EQ 2MG BASE**	**A072894**	**002**	Jan 17, 1991
AB	!		**EQ 4MG BASE**	**A072894**	**001**	Jan 17, 1991
AB		RISING	**EQ 2MG BASE**	**A207046**	**001**	Jun 29, 2018
AB			**EQ 4MG BASE**	**A207046**	**002**	Jun 29, 2018
AB		SUN PHARM INDUSTRIES	**EQ 2MG BASE**	**A072637**	**002**	Dec 05, 1989
AB			**EQ 4MG BASE**	**A072637**	**001**	Dec 05, 1989
AB		VIRTUS PHARM	**EQ 2MG BASE**	**A211397**	**001**	Oct 26, 2018
AB			**EQ 4MG BASE**	**A211397**	**002**	Oct 26, 2018
AB		ZYDUS PHARMS	**EQ 2MG BASE**	**A208884**	**001**	Oct 22, 2020
AB			**EQ 4MG BASE**	**A208884**	**002**	Oct 22, 2020

ALBUTEROL SULFATE; BUDESONIDE

AEROSOL, METERED;INHALATION

AIRSUPRA

	+!	ASTRAZENECA	EQ 90MCG BASE/INH;80MCG/INH	N214070	001	Jan 10, 2023

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN		CIPLA	**EQ 0.083% BASE;0.017%**	**A077559**	**001**	Dec 31, 2007
AN	!	NEPHRON	**EQ 0.083% BASE;0.017%**	**A076749**	**001**	Dec 31, 2007
AN		RITEDOSE CORP	**EQ 0.083% BASE;0.017%**	**A202496**	**001**	Oct 01, 2012
AN		SUN PHARM	**EQ 0.083% BASE;0.017%**	**A207875**	**001**	Aug 07, 2017

SPRAY, METERED;INHALATION

COMBIVENT RESPIMAT

	+!	BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH;0.02MG/INH	N021747	001	Oct 07, 2011

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	!	FOUGERA PHARMS	**0.05%**	**A076973**	**001**	Jul 12, 2005
AB		GLENMARK GENERICS	**0.05%**	**A079061**	**001**	Jun 23, 2009
AB		TARO	**0.05%**	**A076587**	**001**	Sep 15, 2005

OINTMENT;TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	!	FOUGERA PHARMS	**0.05%**	**A076884**	**001**	Jul 18, 2005
AB		GLENMARK GENERICS	**0.05%**	**A079227**	**001**	Jul 30, 2009
AB		TARO	**0.05%**	**A076730**	**001**	Jul 29, 2004

ALCOHOL

SOLUTION;INTRA-ARTERIAL

ABLYSINOL

	+	BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018
	+!		99% (5ML)	N207987	002	Jun 21, 2018

ALECTINIB HYDROCHLORIDE

CAPSULE;ORAL

ALECENSA

	+!	HOFFMANN-LA ROCHE	EQ 150MG BASE	N208434	001	Dec 11, 2015

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

AA	!	HIKMA	**EQ 70MG BASE/75ML**	**A090520**	**001**	Feb 25, 2013
AA		NOVITIUM PHARMA	**EQ 70MG BASE/75ML**	**A214512**	**001**	May 11, 2023

TABLET;ORAL

ALENDRONATE SODIUM

AB		APOTEX	**EQ 5MG BASE**	**A077982**	**001**	Aug 04, 2008
AB			**EQ 10MG BASE**	**A077982**	**002**	Aug 04, 2008
AB			**EQ 35MG BASE**	**A077982**	**003**	Aug 04, 2008
AB			**EQ 70MG BASE**	**A077982**	**004**	Aug 04, 2008
AB		AUROBINDO PHARMA	**EQ 10MG BASE**	**A090124**	**001**	Aug 04, 2008
AB			**EQ 35MG BASE**	**A090124**	**002**	Aug 04, 2008
AB			**EQ 70MG BASE**	**A090124**	**003**	Aug 04, 2008
AB		CIPLA	**EQ 5MG BASE**	**A076768**	**001**	Aug 04, 2008
AB			**EQ 10MG BASE**	**A076768**	**002**	Aug 04, 2008
AB			**EQ 35MG BASE**	**A076768**	**003**	Aug 04, 2008
AB			**EQ 40MG BASE**	**A076768**	**004**	Aug 04, 2008
AB			**EQ 70MG BASE**	**A076768**	**005**	Aug 04, 2008
AB		HANGZHOU BINJIANG	**EQ 5MG BASE**	**A090258**	**001**	Sep 24, 2009
AB			**EQ 10MG BASE**	**A090258**	**002**	Sep 24, 2009

ALENDRONATE SODIUM

TABLET;ORAL

ALENDRONATE SODIUM

AB			**EQ 35MG BASE**	**A090258**	**003**	Sep 24, 2009
AB			**EQ 70MG BASE**	**A090258**	**004**	Sep 24, 2009
AB		SUN PHARM	**EQ 5MG BASE**	**A090022**	**001**	Sep 10, 2008
AB			**EQ 10MG BASE**	**A090022**	**002**	Sep 10, 2008
AB			**EQ 35MG BASE**	**A090022**	**003**	Sep 10, 2008
AB			**EQ 70MG BASE**	**A090022**	**004**	Sep 10, 2008
AB		WATSON LABS	**EQ 35MG BASE**	**A076984**	**001**	Aug 04, 2008
AB			**EQ 40MG BASE**	**A076984**	**002**	Aug 04, 2008
AB			**EQ 70MG BASE**	**A076984**	**003**	Aug 04, 2008

FOSAMAX

AB	**+!**	ORGANON	**EQ 70MG BASE**	**N020560**	**005**	Oct 20, 2000

TABLET, EFFERVESCENT;ORAL

BINOSTO

	+!	RADIUS	EQ 70MG BASE	N202344	001	Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET;ORAL

FOSAMAX PLUS D

	+	ORGANON LLC	EQ 70MG BASE;2,800 IU	N021762	001	Apr 07, 2005
	+!		EQ 70MG BASE;5,600 IU	N021762	002	Apr 26, 2007

ALFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

ALFENTA

AP	**+!**	RISING	**EQ 0.5MG BASE/ML**	**N019353**	**001**	Dec 29, 1986

ALFENTANIL

AP		HOSPIRA	**EQ 0.5MG BASE/ML**	**A075221**	**001**	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

AB		APOTEX INC	**10MG**	**A079013**	**001**	Jul 18, 2011
AB		AUROBINDO PHARMA LTD	**10MG**	**A079060**	**001**	Aug 30, 2012
AB		INVAGEN PHARMS	**10MG**	**A090284**	**001**	Jan 17, 2012
AB		SUN PHARM	**10MG**	**A079057**	**001**	Jul 18, 2011
AB		UNICHEM	**10MG**	**A203192**	**001**	Jan 28, 2016

UROXATRAL

AB	**+!**	CONCORDIA	**10MG**	**N021287**	**001**	Jun 12, 2003

ALISKIREN HEMIFUMARATE

TABLET;ORAL

ALISKIREN HEMIFUMARATE

AB		ANCHEN PHARMS	**EQ 150MG BASE**	**A206665**	**001**	Mar 22, 2019
AB			**EQ 300MG BASE**	**A206665**	**002**	Mar 22, 2019

TEKTURNA

AB	**+**	NODEN PHARMA	**EQ 150MG BASE**	**N021985**	**001**	Mar 05, 2007
AB	**+!**		**EQ 300MG BASE**	**N021985**	**002**	Mar 05, 2007

ALITRETINOIN

GEL;TOPICAL

PANRETIN

	+!	CONCORDIA	EQ 0.1% BASE	N020886	001	Feb 02, 1999

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB		ACCORD HLTHCARE	**100MG**	**A203154**	**001**	May 06, 2013
AB			**300MG**	**A203154**	**002**	May 06, 2013
AB		CHARTWELL	**100MG**	**A077353**	**001**	Sep 08, 2005
AB			**300MG**	**A077353**	**002**	Sep 08, 2005
AB		HARMAN FINOCHEM	**100MG**	**A214443**	**001**	Mar 07, 2022
AB			**300MG**	**A214443**	**002**	Mar 07, 2022
AB		HETERO LABS LTD V	**100MG**	**A217748**	**001**	Aug 03, 2023
AB			**300MG**	**A217748**	**002**	Aug 03, 2023
AB		INDOCO	**100MG**	**A204467**	**001**	Jul 28, 2016
AB			**300MG**	**A204467**	**002**	Jul 28, 2016
AB		IPCA LABS LTD	**100MG**	**A090637**	**001**	Mar 16, 2011
AB			**300MG**	**A090637**	**002**	Mar 16, 2011
AB		LUPIN LTD	**100MG**	**A211807**	**001**	Dec 14, 2023
AB			**300MG**	**A211807**	**002**	Dec 14, 2023
AB		MYLAN	**100MG**	**A018659**	**001**	Oct 24, 1986
AB			**300MG**	**A018659**	**002**	Oct 24, 1986

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB		NORTHSTAR HLTHCARE	**100MG**	**A078253**	**001**	Sep 11, 2007
AB			**300MG**	**A078253**	**002**	Sep 11, 2007
AB		SUN PHARM INDUSTRIES	**100MG**	**A071450**	**002**	Jan 09, 1987
AB			**300MG**	**A071450**	**001**	Jan 09, 1987
AB		UNICHEM	**100MG**	**A211820**	**001**	Mar 12, 2019
AB	**!**		**300MG**	**A211820**	**002**	Mar 12, 2019
AB		VINTAGE PHARMS	**100MG**	**A075798**	**001**	Jun 27, 2003
AB			**300MG**	**A075798**	**002**	Jun 27, 2003
AB		WATSON LABS	**100MG**	**N018832**	**002**	Sep 28, 1984
AB			**300MG**	**N018877**	**001**	Sep 28, 1984
AB		ZYDUS PHARMS	**100MG**	**A210117**	**001**	Oct 12, 2017
AB			**300MG**	**A210117**	**002**	Oct 12, 2017

LOPURIN

AB		DR REDDYS LA	**100MG**	**A071586**	**001**	Apr 02, 1987
AB			**300MG**	**A071587**	**001**	Apr 02, 1987

ZYLOPRIM

AB	**+**	CASPER PHARMA LLC	**100MG**	**N016084**	**001**	
AB	**+**		**300MG**	**N016084**	**002**	
	+		200MG	N016084	003	Aug 04, 2022

ALLOPURINOL SODIUM

INJECTABLE;INJECTION

ALLOPURINOL SODIUM

AP		GLAND PHARMA LTD	**EQ 500MG BASE/VIAL**	**A212363**	**001**	Jan 26, 2022
AP		HIKMA	**EQ 500MG BASE/VIAL**	**A076870**	**001**	Aug 26, 2004

ALOPRIM

AP	**+!**	MYLAN	**EQ 500MG BASE/VIAL**	**N020298**	**001**	May 17, 1996

ALMOTRIPTAN MALATE

TABLET;ORAL

ALMOTRIPTAN MALATE

AB		AJANTA PHARMA LTD	**EQ 6.25MG BASE**	**A205523**	**001**	Mar 03, 2016
AB	**!**		**EQ 12.5MG BASE**	**A205523**	**002**	Mar 03, 2016
AB		MYLAN	**EQ 6.25MG BASE**	**A205171**	**001**	Nov 09, 2015
AB			**EQ 12.5MG BASE**	**A205171**	**002**	Nov 09, 2015
AB		TEVA PHARMS USA	**EQ 6.25MG BASE**	**A078027**	**001**	Jul 07, 2015
AB			**EQ 12.5MG BASE**	**A078027**	**002**	Jul 07, 2015

ALOGLIPTIN BENZOATE

TABLET;ORAL

NESINA

+	TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271	001	Jan 25, 2013
+		EQ 12.5MG BASE	N022271	002	Jan 25, 2013
+!		EQ 25MG BASE	N022271	003	Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

KAZANO

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;500MG	N203414	001	Jan 25, 2013
+!		EQ 12.5MG BASE;1GM	N203414	002	Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

OSENI

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 30MG BASE	N022426	005	Jan 25, 2013
+		EQ 25MG BASE;EQ 15MG BASE	N022426	001	Jan 25, 2013
+		EQ 25MG BASE;EQ 30MG BASE	N022426	002	Jan 25, 2013
+!		EQ 25MG BASE;EQ 45MG BASE	N022426	003	Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

AB		AMNEAL PHARMS	**EQ 0.5MG BASE**	**A206647**	**001**	Dec 22, 2016
AB			**EQ 1MG BASE**	**A206647**	**002**	Dec 22, 2016
AB		MANKIND PHARMA	**EQ 0.5MG BASE**	**A213614**	**001**	Sep 09, 2020
AB			**EQ 1MG BASE**	**A213614**	**002**	Sep 09, 2020
AB		RISING	**EQ 0.5MG BASE**	**A209180**	**001**	Jan 14, 2019
AB			**EQ 1MG BASE**	**A209180**	**002**	Jan 14, 2019

LOTRONEX

AB	**+**	SEBELA IRELAND LTD	**EQ 0.5MG BASE**	**N021107**	**002**	Dec 23, 2003
AB	**+!**		**EQ 1MG BASE**	**N021107**	**001**	Feb 09, 2000

ALPELISIB

TABLET;ORAL

PIQRAY

+	NOVARTIS	50MG	N212526	001	May 24, 2019
+		150MG	N212526	002	May 24, 2019
+!		200MG	N212526	003	May 24, 2019

VIJOICE

+	NOVARTIS	50MG	N215039	001	Apr 05, 2022
+		125MG	N215039	002	Apr 05, 2022
+!		200MG	N215039	003	Apr 05, 2022

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION;INTRAVENOUS

INFUVITE ADULT

+!	SANDOZ CANADA INC	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	N021163	001	May 18, 2000
+!		2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML	N021163	002	Jun 16, 2003

ALPRAZOLAM

CONCENTRATE;ORAL

ALPRAZOLAM

!	HIKMA	1MG/ML	A074312	001	Oct 31, 1993

TABLET;ORAL

ALPRAZOLAM

AB	ACTAVIS ELIZABETH	**0.25MG**	**A074342**	**001**	Oct 31, 1993
AB		**0.5MG**	**A074342**	**002**	Oct 31, 1993
AB		**1MG**	**A074342**	**003**	Oct 31, 1993
AB		**2MG**	**A074342**	**004**	Oct 31, 1993
AB	APOTEX INC	**0.25MG**	**A077741**	**001**	Jan 19, 2007
AB		**0.5MG**	**A077741**	**002**	Jan 19, 2007
AB		**1MG**	**A077741**	**003**	Jan 19, 2007
AB		**2MG**	**A077741**	**004**	Jan 19, 2007
AB	AUROBINDO PHARMA	**0.25MG**	**A203346**	**001**	Jul 31, 2015
AB		**0.5MG**	**A203346**	**002**	Jul 31, 2015
AB		**1MG**	**A203346**	**003**	Jul 31, 2015
AB		**2MG**	**A203346**	**004**	Jul 31, 2015
AB	BRECKENRIDGE	**0.25MG**	**A207507**	**001**	Jul 09, 2018
AB		**0.5MG**	**A207507**	**002**	Jul 09, 2018
AB		**1MG**	**A207507**	**003**	Jul 09, 2018
AB		**2MG**	**A207507**	**004**	Jul 09, 2018
AB	NATCO	**0.25MG**	**A200739**	**001**	Apr 15, 2015
AB		**0.5MG**	**A200739**	**002**	Apr 15, 2015
AB		**1MG**	**A200739**	**003**	Apr 15, 2015
AB		**2MG**	**A200739**	**004**	Apr 15, 2015
AB	NOVITIUM PHARMA	**0.25MG**	**A074174**	**001**	Oct 19, 1993
AB		**0.5MG**	**A074174**	**002**	Oct 19, 1993
AB		**1MG**	**A074174**	**003**	Oct 19, 1993
AB		**2MG**	**A074174**	**004**	Oct 19, 1993
AB	SANDOZ	**0.25MG**	**A074112**	**001**	Dec 29, 1995
AB		**0.5MG**	**A074112**	**002**	Dec 29, 1995
AB		**1MG**	**A074112**	**003**	Dec 29, 1995
AB		**2MG**	**A074909**	**001**	Mar 25, 1998
AB	STRIDES PHARMA	**0.25MG**	**A090248**	**001**	Sep 17, 2010
AB		**0.5MG**	**A090248**	**002**	Sep 17, 2010
AB		**1MG**	**A090248**	**003**	Sep 17, 2010
AB		**2MG**	**A090248**	**004**	Sep 17, 2010
AB	SUN PHARM	**0.25MG**	**A090082**	**001**	Jun 17, 2010
AB		**0.5MG**	**A090082**	**002**	Jun 17, 2010
AB		**1MG**	**A090082**	**003**	Jun 17, 2010
AB		**2MG**	**A090082**	**004**	Jun 17, 2010

XANAX

AB +	UPJOHN	**0.25MG**	**N018276**	**001**	
AB +		**0.5MG**	**N018276**	**002**	
AB +!		**1MG**	**N018276**	**003**	
AB +		**2MG**	**N018276**	**004**	Nov 27, 1985

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	**0.5MG**	**A078056**	**001**	Feb 13, 2007
AB			**1MG**	**A078056**	**002**	Feb 13, 2007
AB			**2MG**	**A078056**	**003**	Feb 13, 2007
AB			**3MG**	**A078056**	**004**	Feb 13, 2007
AB		AMNEAL PHARMS NY	**0.5MG**	**A078387**	**001**	May 30, 2008
AB			**1MG**	**A078387**	**002**	May 30, 2008
AB			**2MG**	**A078387**	**003**	May 30, 2008
AB			**3MG**	**A078387**	**004**	May 30, 2008
AB		ANCHEN PHARMS	**0.5MG**	**A078469**	**001**	Sep 29, 2011
AB			**1MG**	**A078469**	**002**	Sep 29, 2011
AB			**2MG**	**A078469**	**003**	Sep 29, 2011
AB			**3MG**	**A078469**	**004**	Sep 29, 2011
AB		APOTEX INC	**0.5MG**	**A078449**	**001**	Nov 12, 2008
AB			**1MG**	**A078449**	**004**	Dec 23, 2015
AB			**2MG**	**A078449**	**002**	Nov 12, 2008
AB			**3MG**	**A078449**	**003**	Nov 12, 2008
AB		AUROBINDO PHARMA	**0.5MG**	**A090871**	**001**	Jun 07, 2011
AB			**1MG**	**A090871**	**002**	Jun 07, 2011
AB			**2MG**	**A090871**	**003**	Jun 07, 2011
AB			**3MG**	**A090871**	**004**	Jun 07, 2011

XANAX XR

AB	**+**	UPJOHN	**0.5MG**	**N021434**	**001**	Jan 17, 2003
AB	**+**		**1MG**	**N021434**	**002**	Jan 17, 2003
AB	**+**		**2MG**	**N021434**	**003**	Jan 17, 2003
AB	**+!**		**3MG**	**N021434**	**004**	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	**0.25MG**	**A078561**	**001**	Mar 16, 2010
AB			**0.5MG**	**A078561**	**002**	Mar 16, 2010
AB			**1MG**	**A078561**	**003**	Mar 16, 2010
AB			**2MG**	**A078561**	**004**	Mar 16, 2010
AB		PAR PHARM	**0.25MG**	**A078088**	**001**	Jan 09, 2009
AB			**0.5MG**	**A078088**	**002**	Jan 09, 2009
AB	**!**		**1MG**	**A078088**	**003**	Jan 09, 2009
AB			**2MG**	**A078088**	**004**	Jan 09, 2009

ALPROSTADIL

INJECTABLE;INJECTION

ALPROSTADIL

AP		HIKMA	**0.5MG/ML**	**A074815**	**001**	Jan 20, 1998
AP		MEITHEAL	**0.5MG/ML**	**A075196**	**001**	Apr 30, 1999

CAVERJECT

AP	**+**	PFIZER	**0.01MG/VIAL**	**N020379**	**001**	Jul 06, 1995
AP	**+!**		**0.02MG/VIAL**	**N020379**	**002**	Jul 06, 1995
AP	**+!**		**0.04MG/VIAL**	**N020379**	**004**	May 19, 1997

EDEX

AP	**+**	AUXILIUM PHARMS LLC	**0.01MG/VIAL**	**N020649**	**002**	Jun 12, 1997
AP	**+**		**0.02MG/VIAL**	**N020649**	**003**	Jun 12, 1997
AP	**+!**		**0.04MG/VIAL**	**N020649**	**004**	Jun 12, 1997

PROSTIN VR PEDIATRIC

AP	**+!**	PFIZER	**0.5MG/ML**	**N018484**	**001**	

CAVERJECT IMPULSE

		PFIZER	0.01MG/VIAL	N021212	001	Jun 11, 2002
			0.02MG/VIAL	N021212	002	Jun 11, 2002

EDEX

	+!	AUXILIUM PHARMS LLC	0.01MG/VIAL	N020649	005	Jul 30, 1998
	+!		0.02MG/VIAL	N020649	006	Jul 30, 1998
	+!		0.04MG/VIAL	N020649	007	Jul 30, 1998

SUPPOSITORY;URETHRAL

MUSE

	+!	MYLAN SPECIALITY LP	0.25MG	N020700	002	Nov 19, 1996
	+!		0.5MG	N020700	003	Nov 19, 1996
	+!		1MG	N020700	004	Nov 19, 1996

ALVIMOPAN

CAPSULE;ORAL

ALVIMOPAN

AB		HIKMA	**12MG**	**A217753**	**001**	Aug 31, 2023
AB		PAR PHARM	**12MG**	**A216843**	**001**	Jan 24, 2023
AB	!	WATSON LABS TEVA	**12MG**	**A208295**	**001**	Dec 19, 2019

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB		ALEMBIC	**100MG**	**A208966**	**001**	Jun 21, 2017
AB	!	BIONPHARMA	**100MG**	**A078720**	**001**	May 29, 2008
AB		HERITAGE PHARMA	**100MG**	**A209171**	**001**	Jun 12, 2017
AB		HUMANWELL PURACAP	**100MG**	**A214580**	**001**	Dec 20, 2022
AB		RISING	**100MG**	**A210129**	**001**	Mar 02, 2020
AB		RUBICON	**100MG**	**A212044**	**001**	May 21, 2020
AB		SANDOZ	**100MG**	**A071293**	**001**	Feb 18, 1987
AB		STRIDES PHARMA	**100MG**	**A209047**	**001**	Jun 07, 2017
AB			**100MG**	**A211354**	**001**	Feb 18, 2022
AB		UPSHER SMITH LABS	**100MG**	**A070589**	**001**	Aug 05, 1986
AB		ZYDUS PHARMS	**100MG**	**A208278**	**001**	May 31, 2016

CAPSULE, EXTENDED RELEASE;ORAL

GOCOVRI

	+	ADAMAS OPERATIONS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017
	+!		EQ 137MG BASE	N208944	002	Aug 24, 2017

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

AA	!	AUROBINDO PHARMA USA	**50MG/5ML**	**A074170**	**001**	Oct 28, 1994
AA	!	CHARTWELL RX	**50MG/5ML**	**A074028**	**001**	Jun 28, 1993
AA	!	CMP PHARMA INC	**50MG/5ML**	**A075819**	**001**	Sep 11, 2002
AA		ELYSIUM	**50MG/5ML**	**A214178**	**001**	Aug 20, 2021
AA	!	PHARM ASSOC	**50MG/5ML**	**A074509**	**001**	Jul 17, 1995

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

AB		ALEMBIC	**100MG**	**A214284**	**001**	Oct 15, 2020
AB		ATHEM	**100MG**	**A210215**	**001**	Mar 10, 2020
AB		STRIDES PHARMA	**100MG**	**A209035**	**001**	Jun 09, 2017
AB	!	UPSHER SMITH LABS	**100MG**	**A076186**	**001**	Dec 16, 2002
AB		WATSON LABS INC	**100MG**	**A208096**	**001**	Dec 15, 2016

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

	+	ADAMAS OPERATIONS	EQ 129MG BASE	N209410	001	Feb 16, 2018
	+		EQ 193MG BASE	N209410	002	Feb 16, 2018

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

AB		APOTEX	**5MG**	**A210701**	**001**	May 19, 2022
AB			**10MG**	**A210701**	**002**	May 19, 2022
AB		AUROBINDO PHARMA	**5MG**	**A216531**	**001**	Jul 21, 2022
AB			**10MG**	**A216531**	**002**	Jul 21, 2022
AB		CIPLA	**5MG**	**A210715**	**001**	Apr 26, 2019
AB			**10MG**	**A210715**	**002**	Apr 26, 2019
AB		MYLAN	**5MG**	**A208441**	**001**	Mar 28, 2019
AB			**10MG**	**A208441**	**002**	Mar 28, 2019
AB		PAR PHARM INC	**5MG**	**A209509**	**001**	Apr 10, 2019
AB			**10MG**	**A209509**	**002**	Apr 10, 2019
AB		SIGMAPHARM LABS LLC	**5MG**	**A208354**	**001**	Apr 10, 2019
AB			**10MG**	**A208354**	**002**	Apr 10, 2019
AB		SUN PHARM	**5MG**	**A210784**	**001**	Mar 28, 2019
AB			**10MG**	**A210784**	**002**	Mar 28, 2019
AB		WATSON LABS INC	**5MG**	**A208252**	**001**	Mar 28, 2019
AB			**10MG**	**A208252**	**002**	Mar 28, 2019
AB		ZYDUS PHARMS	**5MG**	**A210058**	**001**	Mar 28, 2019
AB			**10MG**	**A210058**	**002**	Mar 28, 2019

LETAIRIS

AB	+	GILEAD	**5MG**	**N022081**	**001**	Jun 15, 2007
AB	+!		**10MG**	**N022081**	**002**	Jun 15, 2007

AMCINONIDE							
CREAM;TOPICAL							
AMCINONIDE							
AB	**!**	GENUS LIFESCIENCES	**0.1%**	**A076065**	**001**	May 15, 2003
AB		TARO PHARM INDS	**0.1%**	**A076229**	**001**	May 31, 2002
LOTION;TOPICAL							
AMCINONIDE							
	!	ANDA REPOSITORY	0.1%	A076329	001	Nov 06, 2002
OINTMENT;TOPICAL							
AMCINONIDE							
AB	**!**	ANDA REPOSITORY	**0.1%**	**A076096**	**001**	Nov 19, 2002
AB		TARO PHARM INDS	**0.1%**	**A076367**	**001**	Mar 19, 2003
AMIFAMPRIDINE PHOSPHATE							
TABLET;ORAL							
FIRDAPSE							
	+!	CATALYST PHARMS	EQ 10MG BASE	N208078	001	Nov 28, 2018
AMIFOSTINE							
INJECTABLE;INJECTION							
ETHYOL							
	+!	CLINIGEN	500MG/VIAL	N020221	001	Dec 08, 1995
AMIKACIN SULFATE							
INJECTABLE;INJECTION							
AMIKACIN SULFATE							
AP	**!**	AVET LIFESCIENCES	**EQ 250MG BASE/ML**	**A204040**	**001**	Dec 12, 2013
AP		FRESENIUS KABI USA	**EQ 250MG BASE/ML**	**A205604**	**001**	Dec 09, 2015
AP		HIKMA	**EQ 250MG BASE/ML**	**A063315**	**001**	Apr 11, 1994
AP		MEITHEAL	**EQ 250MG BASE/ML**	**A064045**	**002**	Sep 28, 1993
AP		SAGENT PHARMS INC	**EQ 250MG BASE/ML**	**A203323**	**001**	May 12, 2016
	!	HIKMA	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994
SUSPENSION, LIPOSOMAL;INHALATION							
ARIKAYCE KIT							
	+!	INSMED INC	EQ 590MG BASE/8.4ML	N207356	001	Sep 28, 2018
AMILORIDE HYDROCHLORIDE							
TABLET;ORAL							
AMILORIDE HYDROCHLORIDE							
AB	**!**	PAR PHARM	**5MG**	**A070346**	**001**	Jan 22, 1986
AB		SIGMAPHARM LABS LLC	**5MG**	**A079133**	**001**	Jan 30, 2009
MIDAMOR							
AB	**+**	PADAGIS US	**5MG**	**N018200**	**001**	
AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE							
TABLET;ORAL							
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
AB		BARR	**EQ 5MG ANHYDROUS;50MG**	**A071111**	**001**	May 10, 1988
AB	**!**	RISING	**EQ 5MG ANHYDROUS;50MG**	**A073209**	**001**	Oct 31, 1991
AMINO ACIDS							
INJECTABLE;INJECTION							
AMINO ACIDS							
		B BRAUN	15%(150GM/1000ML)	A091112	001	Apr 13, 2012
			15%(300GM/2000ML)	A091112	002	Apr 13, 2012
AMINOSYN II 10% IN PLASTIC CONTAINER							
		ICU MEDICAL INC	10% (10GM/100ML)	N020015	001	Dec 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER							
		ICU MEDICAL INC	15% (15GM/100ML)	N020041	001	Dec 19, 1991
AMINOSYN-PF 10%							
		ICU MEDICAL INC	10% (10GM/100ML)	N019492	002	Oct 17, 1986
AMINOSYN-PF 7%							
		ICU MEDICAL INC	7% (7GM/100ML)	N019398	001	Sep 06, 1985
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER							
		BAXTER HLTHCARE	15% (15GM/100ML)	A020512	001	Aug 30, 1996
PREMASOL 10% IN PLASTIC CONTAINER							
		BAXTER HLTHCARE	10% (10GM/100ML)	A075880	002	Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER							
		BAXTER HLTHCARE	6% (6GM/100ML)	A075880	001	Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER							
	+!	BAXTER HLTHCARE	20% (20GM/100ML)	N020849	001	Aug 26, 1998
TRAVASOL 10% IN PLASTIC CONTAINER							
		BAXTER HLTHCARE	10% (10MG/100ML)	N018931	003	Aug 23, 1984
TRAVASOL 5.5% IN PLASTIC CONTAINER							
		BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931	001	Aug 23, 1984

AMINO ACIDS

INJECTABLE;INJECTION

TRAVASOL 8.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931	002	Aug 23, 1984

TROPHAMINE

+!	B BRAUN	6% (6GM/100ML)	N019018	001	Jul 20, 1984

TROPHAMINE 10%

+!	B BRAUN	10% (10GM/100ML)	N019018	003	Sep 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;217MG/100ML;112MG/100ML	N020678	002	Mar 26, 1997

CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;217MG/100ML;112MG/100ML	N020678	005	Mar 26, 1997

CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;2 61MG/100ML;217MG/100ML;112MG/100ML	N020678	001	Mar 26, 1997

CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997

CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997

CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997

CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;2 61MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997

CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997

CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997

CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997

CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;INTRAVENOUS

KABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML ;147MG/100ML;3.9GM/100ML (1026ML)	N200656	004	Aug 25, 2014
+		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (1540ML)	N200656	005	Aug 25, 2014
+		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (2053ML)	N200656	006	Aug 25, 2014
+!		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (2566ML)	N200656	007	Aug 25, 2014

PERIKABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1440ML)	N200656	001	Aug 25, 2014
+		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1920ML)	N200656	002	Aug 25, 2014
+!		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML ;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	2.75%;10GM/100ML	N020734	002	Sep 29, 1997
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	2.75%;25GM/100ML	N020734	005	Sep 29, 1997
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	2.75%;5GM/100ML	N020734	001	Sep 29, 1997
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	4.25%;10GM/100ML	N020734	008	Sep 29, 1997
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	4.25%;20GM/100ML	N020734	010	Sep 29, 1997
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	4.25%;25GM/100ML	N020734	011	Sep 29, 1997
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	4.25%;5GM/100ML	N020734	007	Sep 29, 1997
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	5%;10GM/100ML	N020734	014	Sep 29, 1997
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	5%;15GM/100ML	N020734	015	Sep 29, 1997
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	5%;20GM/100ML	N020734	016	Sep 29, 1997
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	5%;25GM/100ML	N020734	017	Sep 29, 1997
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	5%;35GM/100ML	N020734	018	Sep 29, 1997

AMINOCAPROIC ACID

INJECTABLE;INJECTION

AMINOCAPROIC ACID						
AP	LUITPOLD	**250MG/ML**	**A071192**	**001**	Dec 01, 1987
AMINOCAPROIC ACID IN PLASTIC CONTAINER						
AP !	HOSPIRA	**250MG/ML**	**A070010**	**001**	Mar 09, 1987

SOLUTION;ORAL

AMICAR						
AA +!	HIKMA	**0.25GM/ML**	**N015230**	**002**		
AMINOCAPROIC ACID						
AA	AMNEAL	**0.25GM/ML**	**A212780**	**001**	Aug 23, 2019
AA	ANNORA PHARMA	**0.25GM/ML**	**A216464**	**001**	Nov 04, 2022
AA	AUROBINDO PHARMA	**0.25GM/ML**	**A216804**	**001**	Sep 26, 2022
AA	BELCHER	**0.25GM/ML**	**A213825**	**001**	Apr 08, 2021
AA	CARNEGIE	**0.25GM/ML**	**A214140**	**001**	Jan 26, 2021
AA	FLORIDA	**0.25GM/ML**	**A215510**	**001**	Mar 23, 2022
AA	SUNNY	**0.25GM/ML**	**A213213**	**001**	Dec 27, 2023
AA	TARO	**0.25GM/ML**	**A214458**	**001**	Mar 24, 2023
AA	TULEX PHARMS INC	**0.25GM/ML**	**A212494**	**001**	Aug 11, 2020

TABLET;ORAL

AMICAR						
AB +	HIKMA	**500MG**	**N015197**	**001**		
AB +		**1GM**	**N015197**	**002**	Jun 24, 2004
AMINOCAPROIC ACID						
AB	AMNEAL	**500MG**	**A212492**	**001**	Nov 26, 2019
AB	ANI PHARMS	**500MG**	**A211629**	**001**	Dec 14, 2020
AB	CARNEGIE	**500MG**	**A213928**	**001**	Feb 12, 2021
AB		**1GM**	**A213928**	**002**	Feb 12, 2021
AB	MSN	**500MG**	**A212938**	**001**	Nov 06, 2020
AB		**1GM**	**A212938**	**002**	Sep 13, 2023
AB	OPTIMUS	**500MG**	**A213944**	**001**	Sep 14, 2022
AB		**1GM**	**A213944**	**002**	Sep 14, 2022
AB	SUNNY	**500MG**	**A209060**	**001**	Nov 27, 2018
AB !		**1GM**	**A209060**	**002**	Nov 27, 2018

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION;ORAL

GLEOLAN					
+!	NXDC	1.5GM/VIAL	N208630	001	Jun 06, 2017

GEL;TOPICAL

AMELUZ					
+!	BIOFRONTERA	10%	N208081	001	May 10, 2016

SOLUTION;TOPICAL

LEVULAN					
+!	DUSA	20%	N020965	001	Dec 03, 1999

AMINOPHYLLINE
INJECTABLE;INJECTION
AMINOPHYLLINE
! HOSPIRA 25MG/ML A087242 001 Oct 26, 1983

AMINOSALICYLIC ACID
GRANULE, DELAYED RELEASE;ORAL
PASER
! EUROCEPT PHARMS 4GM/PACKET A074346 001 Jun 30, 1994

AMIODARONE HYDROCHLORIDE
INJECTABLE;INJECTION
AMIODARONE HYDROCHLORIDE

AP		ACELLA	**50MG/ML**	**A077610**	**001**	Oct 30, 2008
AP			**50MG/ML**	**A077834**	**001**	Oct 30, 2008
AP	**!**	FRESENIUS KABI USA	**50MG/ML**	**A075761**	**001**	Oct 15, 2002
AP	**!**	GLAND PHARMA LTD	**50MG/ML**	**A077161**	**001**	Apr 20, 2005
AP		HIKMA FARMACEUTICA	**50MG/ML**	**A077234**	**001**	Feb 25, 2008
AP		HOSPIRA	**50MG/ML**	**A203884**	**001**	Nov 25, 2013
AP	**!**	MYLAN INSTITUTIONAL	**50MG/ML**	**A076217**	**001**	Oct 15, 2002

NEXTERONE

	+!	BAXTER HLTHCARE	150MG/100ML (1.5MG/ML)	N022325	002	Nov 16, 2010
	+!		360MG/200ML (1.8MG/ML)	N022325	003	Nov 16, 2010

TABLET;ORAL
AMIODARONE HYDROCHLORIDE

AB		AURORBINDO PHARMA LTD	**200MG**	**A204742**	**001**	Jun 03, 2016
AB		CHARTWELL RX	**100MG**	**A077069**	**003**	Oct 04, 2016
AB			**200MG**	**A077069**	**001**	Apr 08, 2005
AB			**400MG**	**A077069**	**002**	Apr 08, 2005
AB		DR REDDYS LABS SA	**100MG**	**A075389**	**002**	Dec 28, 2017
AB			**200MG**	**A075389**	**001**	Jan 25, 2001
AB			**400MG**	**A075389**	**003**	Dec 28, 2017
AB		RUBICON	**100MG**	**A078578**	**002**	Feb 26, 2021
AB			**200MG**	**A078578**	**001**	Nov 06, 2008
AB			**400MG**	**A078578**	**003**	Feb 26, 2021
AB		TARO	**100MG**	**A075424**	**002**	Dec 18, 2002
AB	**!**		**200MG**	**A075424**	**001**	Mar 30, 2001
AB			**400MG**	**A076362**	**001**	Nov 29, 2002
AB		TEVA PHARMS	**200MG**	**A074739**	**001**	Nov 30, 1998
AB		UNICHEM	**200MG**	**A213446**	**001**	Jul 21, 2020
AB		ZYDUS PHARMS USA INC	**100MG**	**A079029**	**002**	Jan 06, 2023
AB			**200MG**	**A079029**	**001**	Sep 16, 2008
AB			**400MG**	**A079029**	**003**	Jan 06, 2023

PACERONE

AB		UPSHER SMITH LABS	**100MG**	**A075135**	**002**	Apr 12, 2005
AB			**200MG**	**A075135**	**001**	Apr 30, 1998
AB			**400MG**	**A075135**	**003**	Jul 02, 2020

AMIODARONE HYDROCHLORIDE

		TARO	300MG	A076362	002	Dec 02, 2003

AMISULPRIDE
SOLUTION;INTRAVENOUS
BARHEMSYS

	+!	ACACIA	5MG/2ML (2.5MG/ML)	N209510	001	Feb 26, 2020
	+!		10MG/4ML (2.5MG/ML)	N209510	002	Sep 01, 2020

AMITRIPTYLINE HYDROCHLORIDE
TABLET;ORAL
AMITRIPTYLINE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**10MG**	**A202446**	**001**	Jun 04, 2014
AB			**25MG**	**A202446**	**002**	Jun 04, 2014
AB			**50MG**	**A202446**	**003**	Jun 04, 2014
AB			**75MG**	**A202446**	**004**	Jun 04, 2014
AB			**100MG**	**A202446**	**005**	Jun 04, 2014
AB			**150MG**	**A202446**	**006**	Jun 04, 2014
AB		CHEMISTRY HLTH	**10MG**	**A216243**	**001**	Jun 06, 2022
AB			**25MG**	**A216243**	**002**	Jun 06, 2022
AB			**50MG**	**A216243**	**003**	Jun 06, 2022
AB			**75MG**	**A216243**	**004**	Jun 06, 2022
AB			**100MG**	**A216243**	**005**	Jun 06, 2022
AB			**150MG**	**A216243**	**006**	Jun 06, 2022
AB		MANKIND PHARMA	**10MG**	**A213999**	**001**	Feb 19, 2021
AB			**25MG**	**A213999**	**002**	Feb 19, 2021

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB			**50MG**	**A213999**	**003**	Feb 19, 2021
AB			**75MG**	**A213999**	**004**	Feb 19, 2021
AB			**100MG**	**A213999**	**005**	Feb 19, 2021
AB			**150MG**	**A213999**	**006**	Feb 19, 2021
AB		RISING	**10MG**	**A217411**	**001**	May 19, 2023
AB			**25MG**	**A217411**	**002**	May 19, 2023
AB			**50MG**	**A217411**	**003**	May 19, 2023
AB			**75MG**	**A217411**	**004**	May 19, 2023
AB			**100MG**	**A217411**	**005**	May 19, 2023
AB			**150MG**	**A217411**	**006**	May 19, 2023
AB		RUBICON	**10MG**	**A215376**	**001**	May 01, 2023
AB			**25MG**	**A215376**	**002**	May 01, 2023
AB			**50MG**	**A215376**	**003**	May 01, 2023
AB			**75MG**	**A215376**	**004**	May 01, 2023
AB			**100MG**	**A215376**	**005**	May 01, 2023
AB			**150MG**	**A215376**	**006**	May 01, 2023
AB	**+**	SANDOZ	**10MG**	**A085968**	**004**	
AB	**+!**		**25MG**	**A085968**	**002**	
AB	**+**		**50MG**	**A085968**	**001**	
AB	**+**		**75MG**	**A085968**	**006**	
AB	**+**		**100MG**	**A085968**	**003**	
AB	**+**		**150MG**	**A085968**	**005**	
AB		SUN PHARM INDS INC	**10MG**	**A089399**	**002**	Jul 14, 1987
AB			**25MG**	**A089399**	**001**	Jul 14, 1987
AB			**50MG**	**A089399**	**003**	Jul 14, 1987
AB			**75MG**	**A089399**	**004**	Jul 14, 1987
AB			**100MG**	**A089399**	**005**	Jul 14, 1987
AB			**150MG**	**A089399**	**006**	Jul 14, 1987
AB		UNICHEM	**10MG**	**A214548**	**001**	May 19, 2021
AB			**25MG**	**A214548**	**002**	May 19, 2021
AB			**50MG**	**A214548**	**003**	May 19, 2021
AB			**75MG**	**A214548**	**004**	May 19, 2021
AB			**100MG**	**A214548**	**005**	May 19, 2021
AB			**150MG**	**A214548**	**006**	May 19, 2021
AB		ZYDUS PHARMS	**10MG**	**A210086**	**001**	Oct 06, 2017
AB			**25MG**	**A210086**	**002**	Oct 06, 2017
AB			**50MG**	**A210086**	**003**	Oct 06, 2017
AB			**75MG**	**A210086**	**004**	Oct 06, 2017
AB			**100MG**	**A210086**	**005**	Oct 06, 2017
AB			**150MG**	**A210086**	**006**	Oct 06, 2017

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

AB		MICRO LABS	**EQ 12.5MG BASE;5MG**	**A211925**	**001**	Feb 02, 2022
AB			**EQ 25MG BASE;10MG**	**A211925**	**002**	Feb 02, 2022
AB		MYLAN PHARMS INC	**EQ 12.5MG BASE;5MG**	**A071297**	**002**	Dec 10, 1986
AB	**!**		**EQ 25MG BASE;10MG**	**A071297**	**001**	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

		MYLAN	10MG;2MG	A071443	002	Nov 10, 1988
			10MG;4MG	A071443	003	Nov 10, 1988
	!		25MG;2MG	A071443	004	Nov 10, 1988
	!		25MG;4MG	A071443	005	Nov 10, 1988
	!		50MG;4MG	A071443	001	Nov 10, 1988

AMLODIPINE BENZOATE

SUSPENSION;ORAL

KATERZIA

	+!	AZURITY	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019

AMLODIPINE BESYLATE

SOLUTION;ORAL

NORLIQVA

	+!	CMP DEV LLC	EQ 1MG BASE/ML	N214439	001	Feb 24, 2022

TABLET;ORAL

AMLODIPINE BESYLATE

AB		ACCORD HLTHCARE	**EQ 2.5MG BASE**	**A202553**	**001**	Apr 29, 2013
AB			**EQ 5MG BASE**	**A202553**	**002**	Apr 29, 2013

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB			**EQ 10MG BASE**	**A202553**	**003**	Apr 29, 2013
AB		ALKEM	**EQ 2.5MG BASE**	**A078925**	**001**	May 04, 2009
AB			**EQ 5MG BASE**	**A078925**	**002**	May 04, 2009
AB			**EQ 10MG BASE**	**A078925**	**003**	May 04, 2009
AB		AUROBINDO PHARMA	**EQ 2.5MG BASE**	**A078021**	**001**	Jul 17, 2007
AB			**EQ 5MG BASE**	**A078021**	**002**	Jul 17, 2007
AB			**EQ 10MG BASE**	**A078021**	**003**	Jul 17, 2007
AB		CHARTWELL RX	**EQ 2.5MG BASE**	**A076692**	**001**	Jul 20, 2007
AB			**EQ 5MG BASE**	**A076692**	**002**	Jul 20, 2007
AB			**EQ 10MG BASE**	**A076692**	**003**	Jul 20, 2007
AB		CHINA RESOURCES	**EQ 2.5MG BASE**	**A090752**	**003**	May 16, 2016
AB			**EQ 5MG BASE**	**A090752**	**001**	Apr 15, 2011
AB			**EQ 10MG BASE**	**A090752**	**002**	Apr 15, 2011
AB		CIPLA	**EQ 2.5MG BASE**	**A077073**	**001**	Sep 26, 2007
AB			**EQ 5MG BASE**	**A077073**	**002**	Sep 26, 2007
AB			**EQ 10MG BASE**	**A077073**	**003**	Sep 26, 2007
AB		COREPHARMA	**EQ 2.5MG BASE**	**A076719**	**001**	May 23, 2007
AB			**EQ 5MG BASE**	**A076719**	**002**	May 23, 2007
AB			**EQ 10MG BASE**	**A076719**	**003**	May 23, 2007
AB		EPIC PHARMA LLC	**EQ 2.5MG BASE**	**A078552**	**001**	Apr 08, 2009
AB			**EQ 5MG BASE**	**A078552**	**002**	Apr 08, 2009
AB			**EQ 10MG BASE**	**A078552**	**003**	Apr 08, 2009
AB		INVAGEN PHARMS	**EQ 2.5MG BASE**	**A077955**	**001**	Aug 28, 2007
AB			**EQ 2.5MG BASE**	**A206367**	**001**	Dec 10, 2015
AB			**EQ 5MG BASE**	**A077955**	**002**	Aug 28, 2007
AB			**EQ 5MG BASE**	**A206367**	**002**	Dec 10, 2015
AB			**EQ 10MG BASE**	**A077955**	**003**	Aug 28, 2007
AB			**EQ 10MG BASE**	**A206367**	**003**	Dec 10, 2015
AB		LUPIN	**EQ 2.5MG BASE**	**A078043**	**001**	Jul 12, 2007
AB			**EQ 5MG BASE**	**A078043**	**002**	Jul 12, 2007
AB			**EQ 10MG BASE**	**A078043**	**003**	Jul 12, 2007
AB		ORBION PHARMS	**EQ 2.5MG BASE**	**A078453**	**001**	Jul 02, 2009
AB			**EQ 5MG BASE**	**A078453**	**002**	Jul 02, 2009
AB			**EQ 10MG BASE**	**A078453**	**003**	Jul 02, 2009
AB		OXFORD PHARMS	**EQ 2.5MG BASE**	**A078414**	**001**	Apr 07, 2010
AB			**EQ 5MG BASE**	**A078414**	**002**	Apr 07, 2010
AB			**EQ 10MG BASE**	**A078414**	**003**	Apr 07, 2010
AB		POLYGEN PHARMS	**EQ 2.5MG BASE**	**A207821**	**001**	Jul 11, 2016
AB			**EQ 5MG BASE**	**A207821**	**002**	Jul 11, 2016
AB			**EQ 10MG BASE**	**A207821**	**003**	Jul 11, 2016
AB		STRIDES PHARMA	**EQ 2.5MG BASE**	**A077516**	**001**	Jul 11, 2007
AB			**EQ 5MG BASE**	**A077516**	**002**	Jul 11, 2007
AB			**EQ 10MG BASE**	**A077516**	**003**	Jul 11, 2007
AB		SUN PHARM INDS LTD	**EQ 2.5MG BASE**	**A077974**	**001**	Jul 09, 2007
AB			**EQ 5MG BASE**	**A077974**	**002**	Jul 09, 2007
AB			**EQ 10MG BASE**	**A077974**	**003**	Jul 09, 2007
AB		TEVA	**EQ 2.5MG BASE**	**A076846**	**001**	Jun 28, 2007
AB			**EQ 5MG BASE**	**A076846**	**002**	Jun 28, 2007
AB			**EQ 10MG BASE**	**A076846**	**003**	Jun 28, 2007
AB		UNICHEM	**EQ 2.5MG BASE**	**A203245**	**001**	Oct 21, 2013
AB			**EQ 5MG BASE**	**A203245**	**002**	Oct 21, 2013
AB			**EQ 10MG BASE**	**A203245**	**003**	Oct 21, 2013
AB		ZYDUS PHARMS USA	**EQ 2.5MG BASE**	**A078226**	**001**	Jul 09, 2007
AB			**EQ 5MG BASE**	**A078226**	**002**	Jul 09, 2007
AB			**EQ 10MG BASE**	**A078226**	**003**	Jul 09, 2007

NORVASC

AB	+	VIATRIS	**EQ 2.5MG BASE**	**N019787**	**001**	Jul 31, 1992
AB	+		**EQ 5MG BASE**	**N019787**	**002**	Jul 31, 1992
AB	+!		**EQ 10MG BASE**	**N019787**	**003**	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		APOTEX	**EQ 5MG BASE;EQ 10MG BASE**	**A205199**	**001**	Nov 18, 2019
AB			**EQ 5MG BASE;EQ 20MG BASE**	**A205199**	**002**	Nov 18, 2019
AB			**EQ 5MG BASE;EQ 40MG BASE**	**A205199**	**003**	Nov 18, 2019
AB			**EQ 5MG BASE;EQ 80MG BASE**	**A205199**	**004**	Nov 18, 2019
AB			**EQ 10MG BASE;EQ 10MG BASE**	**A205199**	**005**	Nov 18, 2019
AB			**EQ 10MG BASE;EQ 20MG BASE**	**A205199**	**006**	Nov 18, 2019
AB			**EQ 10MG BASE;EQ 40MG BASE**	**A205199**	**007**	Nov 18, 2019

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB			**EQ 10MG BASE;EQ 80MG BASE**	**A205199**	**008**	Nov 18, 2019
AB		DR REDDYS	**EQ 2.5MG BASE;EQ 10MG BASE**	**A203874**	**001**	Mar 07, 2014
AB			**EQ 2.5MG BASE;EQ 20MG BASE**	**A203874**	**002**	Mar 07, 2014
AB			**EQ 2.5MG BASE;EQ 40MG BASE**	**A203874**	**003**	Mar 07, 2014
AB			**EQ 5MG BASE;EQ 10MG BASE**	**A203874**	**004**	Mar 07, 2014
AB			**EQ 5MG BASE;EQ 20MG BASE**	**A203874**	**005**	Mar 07, 2014
AB			**EQ 5MG BASE;EQ 40MG BASE**	**A203874**	**006**	Mar 07, 2014
AB			**EQ 5MG BASE;EQ 80MG BASE**	**A203874**	**007**	Mar 07, 2014
AB			**EQ 10MG BASE;EQ 10MG BASE**	**A203874**	**008**	Mar 07, 2014
AB			**EQ 10MG BASE;EQ 20MG BASE**	**A203874**	**009**	Mar 07, 2014
AB			**EQ 10MG BASE;EQ 40MG BASE**	**A203874**	**010**	Mar 07, 2014
AB			**EQ 10MG BASE;EQ 80MG BASE**	**A203874**	**011**	Mar 07, 2014
AB		MYLAN	**EQ 5MG BASE;EQ 10MG BASE**	**A200465**	**004**	Nov 29, 2013
AB			**EQ 5MG BASE;EQ 20MG BASE**	**A200465**	**005**	Nov 29, 2013
AB			**EQ 5MG BASE;EQ 40MG BASE**	**A200465**	**006**	Nov 29, 2013
AB			**EQ 5MG BASE;EQ 80MG BASE**	**A200465**	**007**	Nov 29, 2013
AB			**EQ 10MG BASE;EQ 10MG BASE**	**A200465**	**008**	Nov 29, 2013
AB			**EQ 10MG BASE;EQ 20MG BASE**	**A200465**	**009**	Nov 29, 2013
AB			**EQ 10MG BASE;EQ 40MG BASE**	**A200465**	**010**	Nov 29, 2013
AB			**EQ 10MG BASE;EQ 80MG BASE**	**A200465**	**011**	Nov 29, 2013
AB		ZYDUS PHARMS	**EQ 2.5MG BASE;EQ 10MG BASE**	**A207762**	**001**	Jan 11, 2019
AB			**EQ 2.5MG BASE;EQ 20MG BASE**	**A207762**	**002**	Jan 11, 2019
AB			**EQ 2.5MG BASE;EQ 40MG BASE**	**A207762**	**003**	Jan 11, 2019
AB			**EQ 5MG BASE;EQ 10MG BASE**	**A207762**	**004**	Jan 11, 2019
AB			**EQ 5MG BASE;EQ 20MG BASE**	**A207762**	**005**	Jan 11, 2019
AB			**EQ 5MG BASE;EQ 40MG BASE**	**A207762**	**006**	Jan 11, 2019
AB			**EQ 5MG BASE;EQ 80MG BASE**	**A207762**	**007**	Jan 11, 2019
AB			**EQ 10MG BASE;EQ 10MG BASE**	**A207762**	**008**	Jan 11, 2019
AB			**EQ 10MG BASE;EQ 20MG BASE**	**A207762**	**009**	Jan 11, 2019
AB			**EQ 10MG BASE;EQ 40MG BASE**	**A207762**	**010**	Jan 11, 2019
AB			**EQ 10MG BASE;EQ 80MG BASE**	**A207762**	**011**	Jan 11, 2019
	CADUET					
AB	+	PHARMACIA	**EQ 2.5MG BASE;EQ 10MG BASE**	**N021540**	**009**	Jul 29, 2004
AB	+		**EQ 2.5MG BASE;EQ 20MG BASE**	**N021540**	**010**	Jul 29, 2004
AB	+		**EQ 2.5MG BASE;EQ 40MG BASE**	**N021540**	**011**	Jul 29, 2004
AB	+		**EQ 5MG BASE;EQ 10MG BASE**	**N021540**	**001**	Jan 30, 2004
AB	+		**EQ 5MG BASE;EQ 20MG BASE**	**N021540**	**002**	Jan 30, 2004
AB	+		**EQ 5MG BASE;EQ 40MG BASE**	**N021540**	**003**	Jan 30, 2004
AB	+		**EQ 5MG BASE;EQ 80MG BASE**	**N021540**	**004**	Jan 30, 2004
AB	+		**EQ 10MG BASE;EQ 10MG BASE**	**N021540**	**005**	Jan 30, 2004
AB	+		**EQ 10MG BASE;EQ 20MG BASE**	**N021540**	**006**	Jan 30, 2004
AB	+		**EQ 10MG BASE;EQ 40MG BASE**	**N021540**	**007**	Jan 30, 2004
AB	+!		**EQ 10MG BASE;EQ 80MG BASE**	**N021540**	**008**	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB		APOTEX	**EQ 2.5MG BASE;10MG**	**A091431**	**001**	Dec 30, 2013
AB			**EQ 5MG BASE;10MG**	**A091431**	**002**	Dec 30, 2013
AB			**EQ 5MG BASE;20MG**	**A091431**	**003**	Dec 30, 2013
AB			**EQ 5MG BASE;40MG**	**A091431**	**004**	Dec 30, 2013
AB			**EQ 10MG BASE;20MG**	**A091431**	**005**	Dec 30, 2013
AB			**EQ 10MG BASE;40MG**	**A091431**	**006**	Dec 30, 2013
AB		AUROBINDO PHARMA LTD	**EQ 2.5MG BASE;10MG**	**A202239**	**001**	Sep 05, 2012
AB			**EQ 5MG BASE;10MG**	**A202239**	**002**	Sep 05, 2012
AB			**EQ 5MG BASE;20MG**	**A202239**	**003**	Sep 05, 2012
AB			**EQ 5MG BASE;40MG**	**A202239**	**004**	Sep 05, 2012
AB			**EQ 10MG BASE;20MG**	**A202239**	**005**	Sep 05, 2012
AB			**EQ 10MG BASE;40MG**	**A202239**	**006**	Sep 05, 2012
AB		DR REDDYS LABS INC	**EQ 2.5MG BASE;10MG**	**A077183**	**001**	Apr 15, 2010
AB			**EQ 5MG BASE;10MG**	**A077183**	**002**	Apr 15, 2010
AB			**EQ 5MG BASE;20MG**	**A077183**	**003**	Apr 15, 2010
AB			**EQ 5MG BASE;40MG**	**A090149**	**001**	Jul 05, 2011
AB			**EQ 10MG BASE;20MG**	**A077183**	**004**	Apr 15, 2010
AB			**EQ 10MG BASE;40MG**	**A090149**	**002**	Jul 05, 2011
AB		LUPIN PHARMS	**EQ 2.5MG BASE;10MG**	**A078466**	**001**	Feb 05, 2010
AB			**EQ 5MG BASE;10MG**	**A078466**	**002**	Feb 05, 2010
AB			**EQ 5MG BASE;20MG**	**A078466**	**003**	Feb 05, 2010
AB			**EQ 5MG BASE;40MG**	**A078466**	**005**	Jul 05, 2011

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB			**EQ 10MG BASE;20MG**	**A078466**	**004**	Feb 05, 2010
AB			**EQ 10MG BASE;40MG**	**A078466**	**006**	Jul 05, 2011
AB		WATSON LABS	**EQ 2.5MG BASE;10MG**	**A077890**	**001**	Oct 14, 2010
AB			**EQ 5MG BASE;10MG**	**A077890**	**002**	Oct 14, 2010
AB			**EQ 5MG BASE;20MG**	**A077890**	**003**	Oct 14, 2010
AB			**EQ 10MG BASE;20MG**	**A077890**	**004**	Oct 14, 2010
AB		WATSON LABS INC	**EQ 5MG BASE;40MG**	**A090364**	**001**	Jul 05, 2011
AB			**EQ 10MG BASE;40MG**	**A090364**	**002**	Jul 05, 2011

LOTREL

AB	+	SANDOZ	**EQ 2.5MG BASE;10MG**	**N020364**	**002**	Mar 03, 1995
AB	+		**EQ 5MG BASE;10MG**	**N020364**	**003**	Mar 03, 1995
AB	+		**EQ 5MG BASE;20MG**	**N020364**	**004**	Mar 03, 1995
AB	+		**EQ 5MG BASE;40MG**	**N020364**	**007**	Apr 11, 2006
AB	+		**EQ 10MG BASE;20MG**	**N020364**	**005**	Jun 20, 2002
AB	+!		**EQ 10MG BASE;40MG**	**N020364**	**006**	Apr 11, 2006

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB		PAR PHARM INC	**EQ 5MG BASE;12.5MG;20MG**	**A206137**	**001**	Oct 26, 2016
AB			**EQ 5MG BASE;12.5MG;40MG**	**A206137**	**002**	Oct 26, 2016
AB			**EQ 5MG BASE;25MG;40MG**	**A206137**	**003**	Oct 26, 2016
AB			**EQ 10MG BASE;12.5MG;40MG**	**A206137**	**004**	Oct 26, 2016
AB			**EQ 10MG BASE;25MG;40MG**	**A206137**	**005**	Oct 26, 2016
AB		TEVA PHARMS USA	**EQ 5MG BASE;12.5MG;20MG**	**A202491**	**001**	Nov 03, 2016
AB			**EQ 5MG BASE;12.5MG;40MG**	**A202491**	**002**	Nov 03, 2016
AB			**EQ 5MG BASE;25MG;40MG**	**A202491**	**003**	Nov 03, 2016
AB			**EQ 10MG BASE;12.5MG;40MG**	**A202491**	**004**	Nov 03, 2016
AB			**EQ 10MG BASE;25MG;40MG**	**A202491**	**005**	Nov 03, 2016
AB		TORRENT	**EQ 5MG BASE;12.5MG;20MG**	**A203580**	**001**	Oct 26, 2016
AB			**EQ 5MG BASE;12.5MG;40MG**	**A203580**	**002**	Oct 26, 2016
AB			**EQ 5MG BASE;25MG;40MG**	**A203580**	**003**	Oct 26, 2016
AB			**EQ 10MG BASE;12.5MG;40MG**	**A203580**	**004**	Oct 26, 2016
AB			**EQ 10MG BASE;25MG;40MG**	**A203580**	**005**	Oct 26, 2016

TRIBENZOR

AB	+	COSETTE	**EQ 5MG BASE;12.5MG;20MG**	**N200175**	**001**	Jul 23, 2010
AB	+		**EQ 5MG BASE;12.5MG;40MG**	**N200175**	**002**	Jul 23, 2010
AB	+		**EQ 5MG BASE;25MG;40MG**	**N200175**	**003**	Jul 23, 2010
AB	+		**EQ 10MG BASE;12.5MG;40MG**	**N200175**	**004**	Jul 23, 2010
AB	+!		**EQ 10MG BASE;25MG;40MG**	**N200175**	**005**	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA	**EQ 5MG BASE;12.5MG;160MG**	**A206180**	**001**	Dec 19, 2017
AB			**EQ 5MG BASE;25MG;160MG**	**A206180**	**002**	Dec 19, 2017
AB			**EQ 10MG BASE;12.5MG;160MG**	**A206180**	**003**	Dec 19, 2017
AB			**EQ 10MG BASE;25MG;160MG**	**A206180**	**004**	Dec 19, 2017
AB			**EQ 10MG BASE;25MG;320MG**	**A206180**	**005**	Dec 19, 2017
AB		LUPIN LTD	**EQ 5MG BASE;12.5MG;160MG**	**A200797**	**001**	Jun 03, 2015
AB			**EQ 5MG BASE;25MG;160MG**	**A200797**	**002**	Jun 03, 2015
AB			**EQ 10MG BASE;12.5MG;160MG**	**A200797**	**003**	Jun 03, 2015
AB			**EQ 10MG BASE;25MG;160MG**	**A200797**	**004**	Jun 03, 2015
AB			**EQ 10MG BASE;25MG;320MG**	**A200797**	**005**	Jun 03, 2015
AB		STRIDES PHARMA	**EQ 5MG BASE;12.5MG;160MG**	**A201087**	**001**	Jun 01, 2015
AB			**EQ 5MG BASE;25MG;160MG**	**A201087**	**002**	Jun 01, 2015
AB			**EQ 10MG BASE;12.5MG;160MG**	**A201087**	**003**	Jun 01, 2015
AB			**EQ 10MG BASE;25MG;160MG**	**A201087**	**004**	Jun 01, 2015
AB			**EQ 10MG BASE;25MG;320MG**	**A201087**	**005**	Jun 01, 2015

EXFORGE HCT

AB	+	NOVARTIS	**EQ 5MG BASE;12.5MG;160MG**	**N022314**	**001**	Apr 30, 2009
AB	+		**EQ 5MG BASE;25MG;160MG**	**N022314**	**002**	Apr 30, 2009
AB	+		**EQ 10MG BASE;12.5MG;160MG**	**N022314**	**003**	Apr 30, 2009
AB	+		**EQ 10MG BASE;25MG;160MG**	**N022314**	**004**	Apr 30, 2009
AB	+!		**EQ 10MG BASE;25MG;320MG**	**N022314**	**005**	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB		AJANTA PHARMA LTD	**EQ 5MG BASE;20MG**	**A207216**	**001**	Oct 28, 2016
AB			**EQ 5MG BASE;40MG**	**A207216**	**002**	Oct 28, 2016
AB			**EQ 10MG BASE;20MG**	**A207216**	**003**	Oct 28, 2016
AB			**EQ 10MG BASE;40MG**	**A207216**	**004**	Oct 28, 2016
AB		ALEMBIC	**EQ 5MG BASE;20MG**	**A207073**	**001**	Jul 17, 2017
AB			**EQ 5MG BASE;40MG**	**A207073**	**002**	Jul 17, 2017
AB			**EQ 10MG BASE;20MG**	**A207073**	**003**	Jul 17, 2017
AB			**EQ 10MG BASE;40MG**	**A207073**	**004**	Jul 17, 2017
AB		ALKEM LABS LTD	**EQ 5MG BASE;20MG**	**A209042**	**001**	Aug 14, 2017
AB			**EQ 5MG BASE;40MG**	**A209042**	**002**	Aug 14, 2017
AB			**EQ 10MG BASE;20MG**	**A209042**	**003**	Aug 14, 2017
AB			**EQ 10MG BASE;40MG**	**A209042**	**004**	Aug 14, 2017
AB		AUROBINDO PHARMA	**EQ 5MG BASE;20MG**	**A206906**	**001**	May 15, 2017
AB			**EQ 5MG BASE;40MG**	**A206906**	**002**	May 15, 2017
AB			**EQ 10MG BASE;20MG**	**A206906**	**003**	May 15, 2017
AB			**EQ 10MG BASE;40MG**	**A206906**	**004**	May 15, 2017
AB		GLENMARK PHARMS LTD	**EQ 5MG BASE;20MG**	**A207807**	**001**	Jul 05, 2017
AB			**EQ 5MG BASE;40MG**	**A207807**	**002**	Jul 05, 2017
AB			**EQ 10MG BASE;20MG**	**A207807**	**003**	Jul 05, 2017
AB			**EQ 10MG BASE;40MG**	**A207807**	**004**	Jul 05, 2017
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE;20MG**	**A206884**	**001**	Oct 26, 2016
AB			**EQ 5MG BASE;40MG**	**A206884**	**003**	Oct 26, 2016
AB			**EQ 10MG BASE;20MG**	**A206884**	**002**	Oct 26, 2016
AB			**EQ 10MG BASE;40MG**	**A206884**	**004**	Oct 26, 2016
AB		MICRO LABS	**EQ 5MG BASE;20MG**	**A207435**	**001**	Nov 02, 2017
AB			**EQ 5MG BASE;40MG**	**A207435**	**002**	Nov 02, 2017
AB			**EQ 10MG BASE;20MG**	**A207435**	**003**	Nov 02, 2017
AB			**EQ 10MG BASE;40MG**	**A207435**	**004**	Nov 02, 2017
AB		ZYDUS PHARMS	**EQ 5MG BASE;20MG**	**A207771**	**001**	Sep 22, 2017
AB			**EQ 5MG BASE;40MG**	**A207771**	**002**	Sep 22, 2017
AB			**EQ 10MG BASE;20MG**	**A207771**	**003**	Sep 22, 2017
AB			**EQ 10MG BASE;40MG**	**A207771**	**004**	Sep 22, 2017

AZOR

AB	+	COSETTE	**EQ 5MG BASE;20MG**	**N022100**	**001**	Sep 26, 2007
AB	+		**EQ 5MG BASE;40MG**	**N022100**	**002**	Sep 26, 2007
AB	+		**EQ 10MG BASE;20MG**	**N022100**	**003**	Sep 26, 2007
AB	+!		**EQ 10MG BASE;40MG**	**N022100**	**004**	Sep 26, 2007

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

+	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015
+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015
+!		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

AB		LUPIN LTD	**EQ 5MG BASE;40MG**	**A201586**	**001**	Jan 08, 2014
AB			**EQ 5MG BASE;80MG**	**A201586**	**003**	Jan 08, 2014
AB			**EQ 10MG BASE;40MG**	**A201586**	**002**	Jan 08, 2014
AB			**EQ 10MG BASE;80MG**	**A201586**	**004**	Jan 08, 2014
AB		MYLAN	**EQ 5MG BASE;40MG**	**A202516**	**001**	Aug 26, 2014
AB			**EQ 5MG BASE;80MG**	**A202516**	**003**	Aug 26, 2014
AB			**EQ 10MG BASE;40MG**	**A202516**	**002**	Aug 26, 2014
AB	!		**EQ 10MG BASE;80MG**	**A202516**	**004**	Aug 26, 2014

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB		ALEMBIC	**EQ 5MG BASE;160MG**	**A202713**	**001**	Apr 03, 2015
AB			**EQ 5MG BASE;320MG**	**A202713**	**003**	Apr 03, 2015
AB			**EQ 10MG BASE;160MG**	**A202713**	**002**	Apr 03, 2015
AB			**EQ 10MG BASE;320MG**	**A202713**	**004**	Apr 03, 2015
AB		AUROBINDO PHARMA	**EQ 5MG BASE;160MG**	**A206512**	**001**	Apr 22, 2016
AB			**EQ 5MG BASE;320MG**	**A206512**	**002**	Apr 22, 2016
AB			**EQ 10MG BASE;160MG**	**A206512**	**003**	Apr 22, 2016
AB			**EQ 10MG BASE;320MG**	**A206512**	**004**	Apr 22, 2016
AB		HETERO LABS	**EQ 5MG BASE;160MG**	**A205137**	**001**	Sep 16, 2016
AB			**EQ 5MG BASE;320MG**	**A205137**	**003**	Sep 16, 2016
AB			**EQ 10MG BASE;160MG**	**A205137**	**002**	Sep 16, 2016

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB			**EQ 10MG BASE;320MG**	**A205137**	**004**	Sep 16, 2016
AB		LUPIN	**EQ 5MG BASE;160MG**	**A090245**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A090245**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A090245**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A090245**	**004**	Mar 30, 2015
AB		MYLAN	**EQ 5MG BASE;160MG**	**A090483**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A090483**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A090483**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A090483**	**004**	Mar 30, 2015
AB		NOVEL LABS INC	**EQ 5MG BASE;160MG**	**A202829**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A202829**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A202829**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A202829**	**004**	Mar 30, 2015
AB		STRIDES PHARMA	**EQ 5MG BASE;160MG**	**A090011**	**001**	Mar 28, 2013
AB			**EQ 5MG BASE;320MG**	**A090011**	**003**	Mar 28, 2013
AB			**EQ 10MG BASE;160MG**	**A090011**	**002**	Mar 28, 2013
AB			**EQ 10MG BASE;320MG**	**A090011**	**004**	Mar 28, 2013

EXFORGE

AB	**+**	NOVARTIS	**EQ 5MG BASE;160MG**	**N021990**	**002**	Jun 20, 2007
AB	**+**		**EQ 5MG BASE;320MG**	**N021990**	**004**	Jun 20, 2007
AB	**+!**		**EQ 10MG BASE;160MG**	**N021990**	**003**	Jun 20, 2007
AB	**+!**		**EQ 10MG BASE;320MG**	**N021990**	**005**	Jun 20, 2007

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP		3D IMAGING DRUG	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203779**	**001**	Oct 19, 2015
AP		BIOMEDCL RES FDN	**48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)**	**A204352**	**001**	May 01, 2015
AP		BRIGHAM WOMENS HOSP	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203783**	**001**	Oct 30, 2014
AP		CARDINAL HLTH 414	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203700**	**001**	Feb 25, 2013
AP		DECATUR	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204465**	**001**	Oct 23, 2014
AP	**+!**	FEINSTEIN	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**N022119**	**001**	Aug 23, 2007
AP		GEN HOSP	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A207025**	**001**	Feb 03, 2016
AP		IONETIX	**22.5mCi-225mCi/6ML (3.75-37.5mCi/ML)**	**A210524**	**001**	Dec 21, 2018
AP		JOHNS HOPKINS UNIV	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204514**	**001**	Aug 19, 2014
AP		KREITCHMAN PET CTR	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203938**	**001**	Dec 09, 2013
AP		MCPRF	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203321**	**001**	Feb 25, 2013
AP		METHODIST	**3.75mCi-260mCi/ML**	**A215083**	**001**	Jul 09, 2021
AP		MIDWEST MEDCL	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204457**	**001**	Nov 18, 2015
AP		MIPS CRF	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204535**	**001**	Nov 20, 2014
AP		NCM USA BRONX LLC	**3.75mCi-260mCi/ML**	**A204515**	**001**	Feb 04, 2015
AP		NUKEMED	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204455**	**001**	Apr 23, 2015
AP		PETNET	**30mCi-300mCi (3.75-37.5mCi/ML)**	**A204510**	**001**	Nov 02, 2015
AP		PRECISION NUCLEAR	**3.75mCi-260mCi/ML**	**A204547**	**001**	Aug 14, 2015
AP	**!**	SOFIE	**3.75mCi-260mCi/ML**	**A203543**	**001**	Dec 14, 2012
AP		UCLA BIOMEDICAL	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203812**	**001**	Jun 27, 2013
AP		UCSF RODIOPHARM	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204496**	**001**	Mar 28, 2014
AP		UNIV ALAHAMA BIRM	**15mCi-150mCi/4ML (3.75-37.5mCi/ML)**	**A211698**	**001**	Nov 03, 2022
AP		UNIV TX SW MEDCTR	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A209507**	**001**	Nov 01, 2019
AP		UNIV WISCONSIN	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A211740**	**001**	Sep 09, 2020
AP		WA UNIV SCH MED	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204506**	**001**	Feb 07, 2014

AMMONIUM CHLORIDE

INJECTABLE;INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

	!	HOSPIRA	5MEQ/ML	A088366	001	Jun 13, 1984

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB	**!**	PADAGIS ISRAEL	**EQ 12% BASE**	**A075774**	**001**	May 01, 2002
AB		TARO	**EQ 12% BASE**	**A075883**	**001**	Apr 10, 2003

LOTION;TOPICAL

AMMONIUM LACTATE

AB	**!**	PADAGIS ISRAEL	**EQ 12% BASE**	**A075570**	**001**	Jun 23, 2004
AB		TARO	**EQ 12% BASE**	**A076216**	**001**	May 28, 2004

AMOXAPINE

TABLET;ORAL

AMOXAPINE

	WATSON LABS	25MG	A072691	002	Aug 28, 1992
		50MG	A072691	003	Aug 28, 1992
		100MG	A072691	004	Aug 28, 1992
!		150MG	A072691	001	Aug 28, 1992

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB	AUROBINDO	**250MG**	**A065271**	**001**	Nov 09, 2005
AB		**500MG**	**A065271**	**002**	Nov 09, 2005
AB	CHARTWELL	**250MG**	**A062058**	**001**	
AB		**500MG**	**A062058**	**002**	
AB	HIKMA PHARMS	**250MG**	**A065291**	**001**	Feb 05, 2007
AB		**500MG**	**A065291**	**002**	Feb 05, 2007
AB	MICRO LABS	**250MG**	**A207471**	**001**	Jun 24, 2022
AB		**500MG**	**A207471**	**002**	Jun 24, 2022
AB	SANDOZ	**250MG**	**A064076**	**001**	Sep 30, 1994
AB		**500MG**	**A064076**	**002**	Sep 30, 1994
AB	TEVA	**250MG**	**A061926**	**001**	
AB !		**500MG**	**A061926**	**003**	

AMOXIL

AB	US ANTIBIOTICS	**250MG**	**A062216**	**001**	
AB		**500MG**	**A062216**	**004**	

FOR SUSPENSION;ORAL

AMOXICILLIN

AB	AUROBINDO	**200MG/5ML**	**A065334**	**001**	Dec 28, 2006
AB		**400MG/5ML**	**A065334**	**002**	Dec 28, 2006
AB	AUROBINDO PHARMA LTD	**125MG/5ML**	**A204030**	**001**	Sep 15, 2014
AB		**250MG/5ML**	**A204030**	**002**	Sep 15, 2014
AB	DAVA PHARMS INC	**125MG/5ML**	**A062927**	**001**	Nov 25, 1988
AB		**250MG/5ML**	**A062927**	**002**	Nov 25, 1988
AB	HIKMA	**125MG/5ML**	**A065322**	**002**	Jun 19, 2006
AB		**200MG/5ML**	**A065325**	**002**	Jun 19, 2006
AB		**250MG/5ML**	**A065322**	**001**	Jun 19, 2006
AB		**400MG/5ML**	**A065325**	**001**	Jun 19, 2006
AB	SANDOZ	**125MG/5ML**	**A065387**	**001**	Mar 26, 2007
AB		**200MG/5ML**	**A065378**	**001**	Mar 26, 2007
AB		**250MG/5ML**	**A065387**	**002**	Mar 26, 2007
AB		**400MG/5ML**	**A065378**	**002**	Mar 26, 2007
AB	TEVA	**200MG/5ML**	**A065119**	**001**	Dec 04, 2002
AB !		**250MG/5ML**	**A061931**	**002**	
AB !		**400MG/5ML**	**A065119**	**002**	Dec 04, 2002
AB	WOCKHARDT BIO AG	**400MG/5ML**	**A065319**	**002**	Jun 18, 2007

AMOXICILLIN PEDIATRIC

AB	TEVA	**50MG/ML**	**A061931**	**003**	Dec 01, 1982

AMOXIL

AB	US ANTIBIOTICS	**50MG/ML**	**A062226**	**005**	
AB		**125MG/5ML**	**A062226**	**001**	
AB		**250MG/5ML**	**A062226**	**002**	

LAROTID

AB	US ANTIBIOTICS	**125MG/5ML**	**A062226**	**003**	
AB		**250MG/5ML**	**A062226**	**004**	

TABLET;ORAL

AMOXICILLIN

AB	AUROBINDO	**500MG**	**A065256**	**001**	Nov 09, 2005
AB		**875MG**	**A065256**	**002**	Nov 09, 2005
AB	HIKMA	**875MG**	**A065255**	**001**	Mar 29, 2006
AB	SANDOZ	**500MG**	**A065228**	**001**	Jul 13, 2005
AB		**875MG**	**A065228**	**002**	Jul 13, 2005
AB	TEVA	**500MG**	**A065056**	**001**	Sep 18, 2000
AB !		**875MG**	**A065056**	**002**	Sep 18, 2000

TABLET, CHEWABLE;ORAL

AMOXICILLIN

	TEVA	125MG	A064013	002	Sep 11, 1995
!		250MG	A064013	001	Dec 22, 1992

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)

AB	**!**	RISING	**500MG;500MG;30MG**	**A206006**	**001**	Oct 07, 2016
AB		SANDOZ	**500MG;500MG;30MG**	**A202588**	**001**	Mar 04, 2014

AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET, TABLET;ORAL

VOQUEZNA TRIPLE PAK

	+!	PHATHOM	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA	**125MG/5ML;EQ 31.25MG BASE/5ML**	**A209371**	**001**	Apr 19, 2019
AB			**250MG/5ML;EQ 62.5MG BASE/5ML**	**A209371**	**002**	Apr 19, 2019
AB		AUROBINDO PHARMA LTD	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A201090**	**001**	Dec 20, 2011
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A201090**	**002**	Dec 20, 2011
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A201091**	**001**	Dec 20, 2011
AB		DEVA HOLDING AS	**250MG/5ML;EQ 62.5MG BASE/5ML**	**A210374**	**001**	Nov 29, 2023
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A210416**	**001**	Dec 11, 2023
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A209351**	**001**	Sep 13, 2023
AB		HIKMA PHARMS	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065191**	**002**	Jan 25, 2005
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A065191**	**001**	Jan 25, 2005
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065373**	**001**	Nov 09, 2007
AB		MICRO LABS	**600MG/5ML;EQ 42.9MG BASE/5ML**	**A217805**	**001**	Dec 08, 2023
AB		MICRO LABS LTD INDIA	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A205187**	**001**	May 21, 2021
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A205187**	**002**	May 21, 2021
AB		SANDOZ	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065066**	**001**	Jun 05, 2002
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A065066**	**002**	Jun 05, 2002
AB		SANDOZ INC	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065098**	**001**	Dec 16, 2002
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A065098**	**002**	Dec 16, 2002
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065358**	**001**	Aug 13, 2007
AB		TEVA	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065089**	**001**	May 25, 2004
AB	**!**		**400MG/5ML;EQ 57MG BASE/5ML**	**A065089**	**002**	May 25, 2004
AB	**!**		**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065162**	**001**	Mar 12, 2004
AB		WOCKHARDT BIO AG	**250MG/5ML;EQ 62.5MG BASE/5ML**	**A065431**	**001**	Nov 25, 2008
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065420**	**001**	Dec 02, 2013

AUGMENTIN '125'

AB	**+**	US ANTIBIOTICS	**125MG/5ML;EQ 31.25MG BASE/5ML**	**N050575**	**001**	Aug 06, 1984

AUGMENTIN '250'

AB	**+!**	US ANTIBIOTICS	**250MG/5ML;EQ 62.5MG BASE/5ML**	**N050575**	**002**	Aug 06, 1984

AUGMENTIN ES-600

AB	**+**	US ANTIBIOTICS	**600MG/5ML;EQ 42.9MG BASE/5ML**	**N050755**	**001**	Jun 22, 2001

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	**250MG;EQ 125MG BASE**	**A091569**	**001**	Jan 20, 2012
AB			**500MG;EQ 125MG BASE**	**A091569**	**002**	Jan 20, 2012
AB			**875MG;EQ 125MG BASE**	**A091568**	**001**	Jan 20, 2012
AB		DEVA HOLDING AS	**500MG;EQ 125MG BASE**	**A209992**	**001**	Sep 15, 2023
AB			**875MG;EQ 125MG BASE**	**A209991**	**001**	Sep 15, 2023
AB		HIKMA PHARMS	**875MG;EQ 125MG BASE**	**A203824**	**001**	Aug 23, 2016
AB		MICRO LABS LTD INDIA	**250MG;EQ 125MG BASE**	**A205707**	**001**	Dec 30, 2016
AB			**500MG;EQ 125MG BASE**	**A205707**	**002**	Dec 30, 2016
AB			**875MG;EQ 125MG BASE**	**A204755**	**003**	Dec 30, 2016
AB	**!**	SANDOZ	**250MG;EQ 125MG BASE**	**A065189**	**001**	Aug 23, 2005
AB			**500MG;EQ 125MG BASE**	**A065064**	**001**	Mar 15, 2002
AB	**!**		**875MG;EQ 125MG BASE**	**A065063**	**001**	Mar 14, 2002
AB	**!**	SANDOZ INC	**500MG;EQ 125MG BASE**	**A065117**	**001**	Nov 27, 2002
AB			**875MG;EQ 125MG BASE**	**A065093**	**001**	Nov 21, 2002
AB		TEVA	**500MG;EQ 125MG BASE**	**A065101**	**001**	Oct 30, 2002
AB		TEVA PHARMS USA	**875MG;EQ 125MG BASE**	**A065096**	**001**	Oct 29, 2002

AUGMENTIN '875'

AB	**+**	US ANTIBIOTICS	**875MG;EQ 125MG BASE**	**N050720**	**001**	Feb 13, 1996

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

		TEVA	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005
	!		400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, EXTENDED RELEASE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

!	SANDOZ	1GM;EQ 62.5MG BASE	A090227	001	Apr 21, 2010

AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN

CAPSULE, DELAYED RELEASE;ORAL

TALICIA

+!	REDHILL	250MG;EQ 10MG BASE;12.5MG	N213004	001	Nov 01, 2019

AMOXICILLIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET;ORAL

VOQUEZNA DUAL PAK

+!	PHATHOM	500MG;EQ 20MG BASE	N215153	001	May 03, 2022

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

+	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016
+		EQ 6.3MG BASE	N204326	002	Jan 27, 2016
+		EQ 9.4MG BASE	N204326	003	Jan 27, 2016
+		EQ 12.5MG BASE	N204326	004	Jan 27, 2016
+		EQ 15.7MG BASE	N204326	005	Jan 27, 2016
+!		EQ 18.8MG BASE	N204326	006	Jan 27, 2016

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

ADDERALL XR 10

AB	**+**	TAKEDA PHARMS USA	**2.5MG;2.5MG;2.5MG;2.5MG**	**N021303**	**001**	Oct 11, 2001

ADDERALL XR 15

AB	**+**	TAKEDA PHARMS USA	**3.75MG;3.75MG;3.75MG;3.75MG**	**N021303**	**006**	May 22, 2002

ADDERALL XR 20

AB	**+**	TAKEDA PHARMS USA	**5MG;5MG;5MG;5MG**	**N021303**	**002**	Oct 11, 2001

ADDERALL XR 25

AB	**+**	TAKEDA PHARMS USA	**6.25MG;6.25MG;6.25MG;6.25MG**	**N021303**	**004**	May 22, 2002

ADDERALL XR 30

AB	**+!**	TAKEDA PHARMS USA	**7.5MG;7.5MG;7.5MG;7.5MG**	**N021303**	**003**	Oct 11, 2001

ADDERALL XR 5

AB	**+**	TAKEDA PHARMS USA	**1.25MG;1.25MG;1.25MG;1.25MG**	**N021303**	**005**	May 22, 2002

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		ACTAVIS ELIZABETH	**1.25MG;1.25MG;1.25MG;1.25MG**	**A077302**	**001**	Jun 22, 2012
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A077302**	**002**	Jun 22, 2012
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A077302**	**003**	Jun 22, 2012
AB			**5MG;5MG;5MG;5MG**	**A077302**	**004**	Jun 22, 2012
AB			**6.25MG;6.25MG;6.25MG;6.25MG**	**A077302**	**005**	Jun 22, 2012
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A077302**	**006**	Jun 22, 2012
AB		ANI PHARMS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A205401**	**001**	Jan 22, 2019
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A205401**	**002**	Jan 22, 2019
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A205401**	**003**	Jan 22, 2019
AB			**5MG;5MG;5MG;5MG**	**A205401**	**004**	Jan 22, 2019
AB			**6.25MG;6.25MG;6.25MG;6.25MG**	**A205401**	**005**	Jan 22, 2019
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A205401**	**006**	Jan 22, 2019
AB		ASCENT PHARMS INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A214959**	**001**	Sep 29, 2021
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A214959**	**002**	Sep 29, 2021
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A214959**	**003**	Sep 29, 2021
AB			**5MG;5MG;5MG;5MG**	**A214959**	**004**	Sep 29, 2021
AB			**6.25MG;6.25MG;6.25MG;6.25MG**	**A214959**	**005**	Sep 29, 2021
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A214959**	**006**	Sep 29, 2021
AB		ELITE LABS INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A212037**	**001**	Dec 11, 2019
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A212037**	**002**	Dec 11, 2019
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A212037**	**003**	Dec 11, 2019
AB			**5MG;5MG;5MG;5MG**	**A212037**	**004**	Dec 11, 2019
AB			**6.25MG;6.25MG;6.25MG;6.25MG**	**A212037**	**005**	Dec 11, 2019
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A212037**	**006**	Dec 11, 2019
AB		GRANULES	**1.25MG;1.25MG;1.25MG;1.25MG**	**A217027**	**001**	Jan 23, 2023
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A217027**	**002**	Jan 23, 2023
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A217027**	**003**	Jan 23, 2023
AB			**5MG;5MG;5MG;5MG**	**A217027**	**004**	Jan 23, 2023
AB			**6.25MG;6.25MG;6.25MG;6.25MG**	**A217027**	**005**	Jan 23, 2023
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A217027**	**006**	Jan 23, 2023
AB		IMPAX LABS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A076852**	**001**	Feb 16, 2016
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A076852**	**002**	Feb 16, 2016
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A076852**	**003**	Feb 16, 2016
AB			**5MG;5MG;5MG;5MG**	**A076852**	**004**	Feb 16, 2016

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB			6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016
AB			7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016
AB		LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021
AB			2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021
AB			3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021
AB			5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021
AB			6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021
AB			7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021
AB		RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651	001	May 17, 2019
AB			2.5MG;2.5MG;2.5MG;2.5MG	A210651	002	May 17, 2019
AB			3.75MG;3.75MG;3.75MG;3.75MG	A210651	003	May 17, 2019
AB			5MG;5MG;5MG;5MG	A210651	004	May 17, 2019
AB			6.25MG;6.25MG;6.25MG;6.25MG	A210651	005	May 17, 2019
AB			7.5MG;7.5MG;7.5MG;7.5MG	A210651	006	May 17, 2019
AB		SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019
AB			2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019
AB			3.125MG;3.125MG;3.125MG;3.125MG	A211546	001	Aug 31, 2023
AB			3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019
AB			5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019
AB			6.25MG;6.25MG;6.25MG;6.25MG	A211546	002	Aug 31, 2023
AB			6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019
AB			7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019
AB			9.375MG;9.375MG;9.375MG;9.375MG	A211546	003	Aug 31, 2023
AB			12.5MG;12.5MG;12.5MG;12.5MG	A211546	004	Aug 31, 2023
AB		SUN PHARM INDS INC	3.125MG;3.125MG;3.125MG;3.125MG	A215997	001	Sep 27, 2023
AB			6.25MG;6.25MG;6.25MG;6.25MG	A215997	002	Sep 27, 2023
AB			9.375MG;9.375MG;9.375MG;9.375MG	A215997	003	Sep 27, 2023
AB			12.5MG;12.5MG;12.5MG;12.5MG	A215997	004	Sep 27, 2023
AB		SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019
AB			2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019
AB			3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019
AB			5MG;5MG;5MG;5MG	A211715	004	May 17, 2019
AB			6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019
AB			7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019
AB		TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022
AB			6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022
AB			9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022
AB			12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022

MYDAYIS

AB	+	TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017
AB	+		6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017
AB	+		9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017
AB	+!		12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016
AB			1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016
AB			2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016
AB			3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016
AB			3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016
AB			5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016
AB			7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016
AB		ALKEM LABS LTD	1.25MG;1.25MG;1.25MG;1.25MG	A217787	001	Oct 06, 2023
AB			1.875MG;1.875MG;1.875MG;1.875MG	A217787	002	Oct 06, 2023
AB			2.5MG;2.5MG;2.5MG;2.5MG	A217787	003	Oct 06, 2023
AB			3.125MG;3.125MG;3.125MG;3.125MG	A217787	004	Oct 06, 2023
AB			3.75MG;3.75MG;3.75MG;3.75MG	A217787	005	Oct 06, 2023
AB			5MG;5MG;5MG;5MG	A217787	006	Oct 06, 2023
AB			7.5MG;7.5MG;7.5MG;7.5MG	A217787	007	Oct 06, 2023
AB		ALVOGEN	1.25MG;1.25MG;1.25MG;1.25MG	A207388	001	Jul 28, 2017
AB			1.875MG;1.875MG;1.875MG;1.875MG	A207388	002	Jul 28, 2017
AB			2.5MG;2.5MG;2.5MG;2.5MG	A207388	003	Jul 28, 2017
AB			3.125MG;3.125MG;3.125MG;3.125MG	A207388	004	Jul 28, 2017
AB			3.75MG;3.75MG;3.75MG;3.75MG	A207388	005	Jul 28, 2017
AB			5MG;5MG;5MG;5MG	A207388	006	Jul 28, 2017
AB			7.5MG;7.5MG;7.5MG;7.5MG	A207388	007	Jul 28, 2017
AB		ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A213709	001	Apr 22, 2021
AB			1.875MG;1.875MG;1.875MG;1.875MG	A213709	002	Apr 22, 2021

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		2.5MG;2.5MG;2.5MG;2.5MG	A213709	003	Apr 22, 2021
AB		3.125MG;3.125MG;3.125MG;3.125MG	A213709	004	Apr 22, 2021
AB		3.75MG;3.75MG;3.75MG;3.75MG	A213709	005	Apr 22, 2021
AB		5MG;5MG;5MG;5MG	A213709	006	Apr 22, 2021
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213709	007	Apr 22, 2021
AB	AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A202424	001	Nov 27, 2013
AB		1.875MG;1.875MG;1.875MG;1.875MG	A202424	002	Nov 27, 2013
AB		2.5MG;2.5MG;2.5MG;2.5MG	A202424	003	Nov 27, 2013
AB		3.125MG;3.125MG;3.125MG;3.125MG	A202424	004	Nov 27, 2013
AB		3.75MG;3.75MG;3.75MG;3.75MG	A202424	005	Nov 27, 2013
AB		5MG;5MG;5MG;5MG	A202424	006	Nov 27, 2013
AB		7.5MG;7.5MG;7.5MG;7.5MG	A202424	007	Nov 27, 2013
AB	BARR	1.25MG;1.25MG;1.25MG;1.25MG	A040422	001	Feb 11, 2002
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040422	005	Mar 19, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040422	002	Feb 11, 2002
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040422	006	Mar 19, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040422	007	Mar 19, 2003
AB		5MG;5MG;5MG;5MG	A040422	003	Feb 11, 2002
AB	!	7.5MG;7.5MG;7.5MG;7.5MG	A040422	004	Feb 11, 2002
AB	ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A211352	001	Dec 07, 2018
AB		1.875MG;1.875MG;1.875MG;1.875MG	A211352	002	Dec 07, 2018
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211352	003	Dec 07, 2018
AB		3.125MG;3.125MG;3.125MG;3.125MG	A211352	004	Dec 07, 2018
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211352	005	Dec 07, 2018
AB		5MG;5MG;5MG;5MG	A211352	006	Dec 07, 2018
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211352	007	Dec 07, 2018
AB	EPIC PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014
AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002
AB	GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A215771	001	Dec 28, 2021
AB		1.875MG;1.875MG;1.875MG;1.875MG	A215771	002	Dec 28, 2021
AB		2.5MG;2.5MG;2.5MG;2.5MG	A215771	003	Dec 28, 2021
AB		3.125MG;3.125MG;3.125MG;3.125MG	A215771	004	Dec 28, 2021
AB		3.75MG;3.75MG;3.75MG;3.75MG	A215771	005	Dec 28, 2021
AB		5MG;5MG;5MG;5MG	A215771	006	Dec 28, 2021
AB		7.5MG;7.5MG;7.5MG;7.5MG	A215771	007	Dec 28, 2021
AB	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022
AB		1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022
AB		2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022
AB		3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022
AB		3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022
AB		5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022
AB		7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022
AB	NUVO PHARM	1.25MG;1.25MG;1.25MG;1.25MG	A209799	001	Dec 28, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A209799	002	Dec 28, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A209799	003	Dec 28, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A209799	004	Dec 28, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A209799	005	Dec 28, 2017
AB		5MG;5MG;5MG;5MG	A209799	006	Dec 28, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A209799	007	Dec 28, 2017
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A213111	001	Jan 13, 2021
AB		1.875MG;1.875MG;1.875MG;1.875MG	A213111	002	Jan 13, 2021
AB		2.5MG;2.5MG;2.5MG;2.5MG	A213111	003	Jan 13, 2021
AB		3.125MG;3.125MG;3.125MG;3.125MG	A213111	004	Jan 13, 2021
AB		3.75MG;3.75MG;3.75MG;3.75MG	A213111	005	Jan 13, 2021
AB		5MG;5MG;5MG;5MG	A213111	006	Jan 13, 2021
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213111	007	Jan 13, 2021
AB	SANDOZ	1.25MG;1.25MG;1.25MG;1.25MG	A040439	004	Sep 27, 2002
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040439	001	Jun 14, 2002
AB		5MG;5MG;5MG;5MG	A040439	002	Jun 14, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040439	003	Jun 14, 2002
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A040440**	**005**	Oct 07, 2003
AB		**5MG;5MG;5MG;5MG**	**A040440**	**006**	Oct 07, 2003
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A040440**	**007**	Oct 07, 2003
AB	SUN PHARM INDUSTRIES	**1.25MG;1.25MG;1.25MG;1.25MG**	**A040480**	**001**	Sep 09, 2003
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A040480**	**002**	Sep 09, 2003
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A040480**	**003**	Sep 09, 2003
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A040480**	**004**	Sep 09, 2003
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A040480**	**005**	Sep 09, 2003
AB		**5MG;5MG;5MG;5MG**	**A040480**	**006**	Sep 09, 2003
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A040480**	**007**	Sep 09, 2003
AB	USPHARMA WINDLAS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A210293**	**001**	Apr 03, 2020
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A210293**	**002**	Apr 03, 2020
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A210293**	**003**	Apr 03, 2020
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A210293**	**004**	Apr 03, 2020
AB		**5MG;5MG;5MG;5MG**	**A210293**	**005**	Apr 03, 2020
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A210293**	**006**	Apr 03, 2020
AB	ZYDUS PHARMS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A207340**	**001**	Oct 31, 2017
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A207340**	**002**	Oct 31, 2017
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A207340**	**003**	Oct 31, 2017
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A207340**	**004**	Oct 31, 2017
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A207340**	**005**	Oct 31, 2017
AB		**5MG;5MG;5MG;5MG**	**A207340**	**006**	Oct 31, 2017
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A207340**	**007**	Oct 31, 2017

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	ALKEM LABS LTD	**5MG**	**A213720**	**001**	Oct 27, 2020
AA		**10MG**	**A213720**	**002**	Oct 27, 2020
AA	AMNEAL PHARMS	**5MG**	**A211139**	**001**	Sep 26, 2018
AA		**10MG**	**A211139**	**002**	Sep 26, 2018
AA	AUROLIFE PHARMA LLC	**5MG**	**A211639**	**001**	Apr 17, 2019
AA		**10MG**	**A211639**	**002**	Apr 17, 2019
AA	BIONPHARMA	**5MG**	**A212919**	**001**	Nov 22, 2019
AA		**10MG**	**A212919**	**002**	Nov 22, 2019
AA	CEROVENE INC	**5MG**	**A212582**	**001**	Feb 04, 2020
AA		**10MG**	**A212582**	**002**	Feb 04, 2020
AA	EPIC PHARMA LLC	**5MG**	**A213980**	**001**	Oct 27, 2020
AA		**10MG**	**A213980**	**002**	Oct 27, 2020
AA	GRANULES	**5MG**	**A212619**	**001**	Aug 05, 2019
AA		**10MG**	**A212619**	**002**	Aug 05, 2019
AA	PRINSTON INC	**5MG**	**A211861**	**001**	Mar 11, 2020
AA		**10MG**	**A211861**	**002**	Mar 11, 2020
AA	RHODES PHARMS	**5MG**	**A213852**	**001**	Sep 07, 2021
AA		**10MG**	**A213852**	**002**	Sep 07, 2021
AA	RISE PHARMA	**5MG**	**A212901**	**001**	May 22, 2020
AA		**10MG**	**A212901**	**002**	May 22, 2020
AA	SPECGX LLC	**5MG**	**A213583**	**001**	Jan 22, 2021
AA		**10MG**	**A213583**	**002**	Jan 22, 2021
AA	SUN PHARM INDS INC	**5MG**	**A214574**	**001**	Jan 27, 2021
AA		**10MG**	**A214574**	**002**	Jan 27, 2021

EVEKEO

AA	ARBOR PHARMS LLC	**5MG**	**A200166**	**001**	Aug 09, 2012
AA **!**		**10MG**	**A200166**	**002**	Aug 09, 2012

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+	AZURITY	5MG	N209905	001	Jan 30, 2019
+		10MG	N209905	002	Jan 30, 2019
+		15MG	N209905	003	Jan 30, 2019
+!		20MG	N209905	004	Jan 30, 2019

AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE

SUSPENSION, EXTENDED RELEASE;ORAL

DYANAVEL XR

+!	TRIS PHARMA INC	2MG/ML;EQ 0.5MG BASE/ML	N208147	001	Oct 19, 2015

TABLET, EXTENDED RELEASE;ORAL

DYANAVEL XR 10

+	TRIS PHARMA INC	8MG;EQ 2MG BASE	N210526	002	Nov 04, 2021

AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DYANAVEL XR 15

+	TRIS PHARMA INC	12MG;EQ 3MG BASE	N210526	003	Nov 04, 2021

DYANAVEL XR 20

+!	TRIS PHARMA INC	16MG;EQ 4MG BASE	N210526	004	Nov 04, 2021

DYANAVEL XR 5

+	TRIS PHARMA INC	4MG;EQ 1MG BASE	N210526	001	Nov 04, 2021

AMPHOTERICIN B

INJECTABLE;INJECTION

AMPHOTERICIN B

!	XGEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992

INJECTABLE, LIPID COMPLEX;INJECTION

ABELCET

+!	LEADIANT BIOSCI INC	5MG/ML	N050724	001	Nov 20, 1995

INJECTABLE, LIPOSOMAL;INJECTION

AMBISOME

AB	**+!**	ASTELLAS	**50MG/VIAL**	**N050740**	**001**	Aug 11, 1997

AMPHOTERICIN B

AB		EUGIA PHARMA	**50MG/VIAL**	**A214010**	**001**	Nov 17, 2022
AB		SPIL	**50MG/VIAL**	**A212514**	**001**	Dec 14, 2021

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP		ACS DOBFAR SPA	**EQ 10GM BASE/VIAL**	**A090889**	**001**	Apr 03, 2013
AP		ANTIBIOTICE	**EQ 250MG BASE/VIAL**	**A090354**	**001**	Dec 28, 2009
AP			**EQ 500MG BASE/VIAL**	**A090354**	**002**	Dec 28, 2009
AP			**EQ 1GM BASE/VIAL**	**A090354**	**003**	Dec 28, 2009
AP			**EQ 2GM BASE/VIAL**	**A090354**	**004**	Dec 28, 2009
AP		EUGIA PHARMA SPECLTS	**EQ 250MG BASE/VIAL**	**A065499**	**002**	Aug 17, 2010
AP			**EQ 500MG BASE/VIAL**	**A065499**	**003**	Aug 17, 2010
AP			**EQ 1GM BASE/VIAL**	**A065499**	**004**	Aug 17, 2010
AP			**EQ 2GM BASE/VIAL**	**A065499**	**005**	Aug 17, 2010
AP			**EQ 10GM BASE/VIAL**	**A065493**	**001**	Aug 17, 2010
AP		HQ SPECLT PHARMA	**EQ 250MG BASE/VIAL**	**A062772**	**006**	Apr 15, 1993
AP			**EQ 500MG BASE/VIAL**	**A062772**	**007**	Apr 15, 1993
AP			**EQ 1GM BASE/VIAL**	**A062772**	**001**	Apr 15, 1993
AP			**EQ 2GM BASE/VIAL**	**A062772**	**003**	Apr 15, 1993
AP			**EQ 10GM BASE/VIAL**	**A063142**	**001**	Apr 15, 1993
AP		ISTITUTO BIO ITA SPA	**EQ 10GM BASE/VIAL**	**A201404**	**001**	Dec 20, 2013
AP			**EQ 250MG BASE/VIAL**	**A062719**	**001**	May 12, 1987
AP			**EQ 500MG BASE/VIAL**	**A062719**	**003**	May 12, 1987
AP			**EQ 1GM BASE/VIAL**	**A062719**	**002**	May 12, 1987
AP			**EQ 2GM BASE/VIAL**	**A062797**	**002**	Jul 12, 1993
AP		SAGENT PHARMS INC	**EQ 125MG BASE/VIAL**	**A090583**	**001**	Nov 27, 2015
AP			**EQ 250MG BASE/VIAL**	**A090583**	**002**	Nov 27, 2015
AP			**EQ 500MG BASE/VIAL**	**A090583**	**003**	Nov 27, 2015
AP			**EQ 1GM BASE/VIAL**	**A090583**	**004**	Nov 27, 2015
AP			**EQ 2GM BASE/VIAL**	**A090583**	**005**	Nov 27, 2015
AP			**EQ 10GM BASE/VIAL**	**A090581**	**001**	Oct 20, 2015
AP	**!**	SANDOZ	**EQ 125MG BASE/VIAL**	**A061395**	**001**	
AP	**!**		**EQ 250MG BASE/VIAL**	**A061395**	**002**	
AP	**!**		**EQ 500MG BASE/VIAL**	**A061395**	**003**	
AP	**!**		**EQ 1GM BASE/VIAL**	**A061395**	**004**	
AP	**!**		**EQ 2GM BASE/VIAL**	**A061395**	**005**	
AP	**!**		**EQ 10GM BASE/VIAL**	**A061395**	**006**	
AP		STERISCIENCE	**EQ 1GM BASE/VIAL**	**A201025**	**003**	Apr 09, 2014
AP			**EQ 2GM BASE/VIAL**	**A201025**	**004**	Apr 09, 2014
AP			**EQ 10GM BASE/VIAL**	**A202198**	**001**	Apr 07, 2014

POWDER;INTRAVENOUS

AMPICILLIN SODIUM

AP	**!**	SANDOZ	**EQ 1GM BASE/VIAL**	**A062738**	**001**	Feb 19, 1987
AP	**!**		**EQ 2GM BASE/VIAL**	**A062738**	**002**	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP		ACS DOBFAR	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065406**	**001**	Dec 22, 2009
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065406**	**002**	Dec 22, 2009
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065403**	**001**	Dec 23, 2009
AP		ANTIBIOTICE	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A201406**	**001**	Dec 07, 2015
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A201406**	**002**	Dec 07, 2015
AP		ASTRAL	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A090579**	**001**	Jan 08, 2016
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A090579**	**002**	Jan 08, 2016
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A090578**	**001**	Jan 11, 2016
AP		EUGIA PHARMA SPECLTS	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A090349**	**001**	Sep 20, 2010
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A090349**	**002**	Sep 20, 2010
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A090339**	**001**	Sep 20, 2010
AP		HIKMA	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065074**	**001**	Mar 19, 2002
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065074**	**002**	Mar 19, 2002
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065076**	**001**	Mar 19, 2002
AP		HQ SPECLT PHARMA	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065176**	**001**	Nov 30, 2005
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065176**	**002**	Nov 30, 2005
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065188**	**001**	Nov 25, 2005
AP		ISTITUTO BIO ITA SPA	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065222**	**001**	Nov 29, 2005
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065222**	**002**	Nov 29, 2005
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065314**	**001**	Nov 27, 2006
AP		SANDOZ	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065241**	**001**	Jul 25, 2006
AP			**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065310**	**001**	Jul 25, 2006
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065241**	**002**	Jul 25, 2006
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065310**	**002**	Jul 25, 2006
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065240**	**001**	Jul 25, 2006
AP		STERISCIENCE	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A201024**	**001**	Apr 07, 2014
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A201024**	**002**	Apr 07, 2014
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A202197**	**001**	Apr 07, 2014

UNASYN

AP	**+!**	PFIZER	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**N050608**	**002**	Dec 31, 1986
AP	**+!**		**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**N050608**	**001**	Dec 31, 1986
AP	**+!**		**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**N050608**	**005**	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE

AB		AUROBINDO PHARMA	**EQ 500MG BASE**	**A216554**	**002**	Oct 31, 2023
AB	**!**	SANDOZ	**EQ 500MG BASE**	**A064082**	**002**	Aug 29, 1995
		AUROBINDO PHARMA	EQ 250MG BASE	A216554	001	Oct 31, 2023

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

AGRYLIN

AB		TAKEDA PHARMS USA	**EQ 0.5MG BASE**	**N020333**	**001**	Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

AB		IMPAX LABS	**EQ 0.5MG BASE**	**A076910**	**001**	Apr 18, 2005
AB			**EQ 1MG BASE**	**A076910**	**002**	Apr 18, 2005
AB		IVAX SUB TEVA PHARMS	**EQ 0.5MG BASE**	**A076468**	**001**	Apr 18, 2005
AB	**!**		**EQ 1MG BASE**	**A076468**	**002**	Apr 18, 2005
AB		TORRENT	**EQ 0.5MG BASE**	**A209151**	**001**	Jun 30, 2017
AB			**EQ 1MG BASE**	**A209151**	**002**	Jun 30, 2017

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

AB		ACCORD HLTHCARE	**1MG**	**A090568**	**001**	Jun 28, 2010
AB		BEIJING YILING	**1MG**	**A206037**	**001**	Nov 09, 2018
AB		CIPLA	**1MG**	**A091164**	**001**	Jun 28, 2010
AB		EUGIA PHARMA	**1MG**	**A212434**	**001**	Jul 24, 2020
AB		KENTON	**1MG**	**A078944**	**001**	Jun 28, 2010
AB		NATCO PHARMA LTD	**1MG**	**A079220**	**001**	Jun 28, 2010
AB		TEVA PHARMS	**1MG**	**A078058**	**001**	Jun 28, 2010
AB		ZYDUS PHARMS USA INC	**1MG**	**A078921**	**001**	Jun 28, 2010

ARIMIDEX

AB	**+!**	ANI PHARMS	**1MG**	**N020541**	**001**	Dec 27, 1995

ANGIOTENSIN II ACETATE

SOLUTION;INTRAVENOUS

GIAPREZA

+!	LA JOLLA PHARMA	EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML)	N209360	003	Dec 23, 2021
+!		EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017

ANIDULAFUNGIN

POWDER;INTRAVENOUS

ERAXIS

+!	VICURON HOLDINGS	50MG/VIAL	N021632	001	Feb 17, 2006
+!		100MG/VIAL	N021632	002	Nov 14, 2006

APALUTAMIDE

TABLET;ORAL

ERLEADA

+	JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018
+!		240MG	N210951	002	Feb 17, 2023

APIXABAN

TABLET;ORAL

APIXABAN

AB		ACCORD HLTHCARE	**2.5MG**	**A210180**	**001**	Jul 28, 2020
AB			**5MG**	**A210180**	**002**	Jul 28, 2020
AB		HETERO LABS LTD V	**2.5MG**	**A210066**	**001**	Nov 21, 2023
AB			**5MG**	**A210066**	**002**	Nov 21, 2023
AB		INDOCO	**2.5MG**	**A209898**	**001**	Sep 11, 2020
AB			**5MG**	**A209898**	**002**	Sep 11, 2020

ELIQUIS

AB	**+**	BRISTOL MYERS SQUIBB	**2.5MG**	**N202155**	**001**	Dec 28, 2012
AB	**+!**		**5MG**	**N202155**	**002**	Dec 28, 2012

APOMORPHINE HYDROCHLORIDE

INJECTABLE;SUBCUTANEOUS

APOKYN

AP	**+!**	MDD US	**30MG/3ML (10MG/ML)**	**N021264**	**002**	Apr 20, 2004

APOMORPHINE HYDROCHLORIDE

AP		SAGE CHEMS	**30MG/3ML (10MG/ML)**	**A212025**	**001**	Feb 23, 2022

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

APRACLONIDINE HYDROCHLORIDE

AT		RISING	**EQ 0.5% BASE**	**A077764**	**001**	Mar 12, 2009

IOPIDINE

AT	**+!**	HARROW EYE	**EQ 0.5% BASE**	**N020258**	**001**	Jul 30, 1993
	+!		EQ 1% BASE	N019779	001	Dec 31, 1987

APREMILAST

TABLET;ORAL

APREMILAST

AB		ALKEM LABS LTD	**10MG**	**A211761**	**001**	Sep 21, 2021
AB			**20MG**	**A211761**	**002**	Sep 21, 2021
AB			**30MG**	**A211761**	**003**	Sep 21, 2021
AB		ANNORA	**10MG**	**A211878**	**001**	Jul 26, 2023
AB			**20MG**	**A211878**	**002**	Jul 26, 2023
AB			**30MG**	**A211878**	**003**	Jul 26, 2023
AB		GLENMARK PHARMS LTD	**10MG**	**A211674**	**001**	Oct 16, 2023
AB			**20MG**	**A211674**	**002**	Oct 16, 2023
AB			**30MG**	**A211674**	**003**	Oct 16, 2023
AB		SHILPA	**10MG**	**A211774**	**001**	Apr 07, 2023
AB			**20MG**	**A211774**	**002**	Apr 07, 2023
AB			**30MG**	**A211774**	**003**	Apr 07, 2023

OTEZLA

AB	**+**	AMGEN INC	**10MG**	**N205437**	**001**	Mar 21, 2014
AB	**+**		**20MG**	**N205437**	**002**	Mar 21, 2014
AB	**+!**		**30MG**	**N205437**	**003**	Mar 21, 2014

APREPITANT

CAPSULE;ORAL

APREPITANT

AB		GLENMARK PHARMS SA	**40MG**	**A207777**	**001**	Oct 12, 2017
AB			**80MG**	**A207777**	**002**	Oct 12, 2017
AB			**125MG**	**A207777**	**003**	Oct 12, 2017
AB		SANDOZ	**40MG**	**A090999**	**001**	Sep 24, 2012
AB			**80MG**	**A090999**	**002**	Sep 24, 2012
AB			**125MG**	**A090999**	**003**	Sep 24, 2012

APREPITANT

CAPSULE;ORAL

APREPITANT

AB		TORRENT	**40MG**	**A211835**	**001**	Oct 21, 2020
AB			**80MG**	**A211835**	**002**	Oct 21, 2020
AB			**125MG**	**A211835**	**003**	Oct 21, 2020

EMEND

AB	+	MERCK	**80MG**	**N021549**	**001**	Mar 26, 2003
AB	+!		**125MG**	**N021549**	**002**	Mar 26, 2003

EMULSION;INTRAVENOUS

APONVIE

+!	HERON THERAPS INC	32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022

CINVANTI

+!	HERON THERAPS INC	130MG/18ML (7.2MG/ML)	N209296	001	Nov 09, 2017

FOR SUSPENSION;ORAL

EMEND

+!	MSD MERCK CO	125MG/KIT	N207865	001	Dec 17, 2015

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

AN		ALEMBIC	**EQ 0.015MG BASE/2ML**	**A214779**	**001**	May 10, 2022
AN		CIPLA	**EQ 0.015MG BASE/2ML**	**A207306**	**001**	Jun 22, 2021
AN		LUPIN	**EQ 0.015MG BASE/2ML**	**A213068**	**001**	Feb 07, 2022
AN		MANKIND PHARMA	**EQ 0.015MG BASE/2ML**	**A216128**	**001**	Nov 15, 2022
AN		RITEDOSE CORP	**EQ 0.015MG BASE/2ML**	**A214736**	**001**	Mar 02, 2022
AN		SLATE RUN PHARMA	**EQ 0.015MG BASE/2ML**	**A213762**	**001**	Jun 22, 2021
AN		SLAYBACK PHARMA LLC	**EQ 0.015MG BASE/2ML**	**A216815**	**001**	Nov 25, 2022
AN		SUN PHARM	**EQ 0.015MG BASE/2ML**	**A215385**	**001**	May 26, 2022
AN		TEVA PHARMS USA	**EQ 0.015MG BASE/2ML**	**A200293**	**001**	Nov 09, 2021

BROVANA

AN	+!	LUPIN	**EQ 0.015MG BASE/2ML**	**N021912**	**001**	Oct 06, 2006

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

AP		AMNEAL PHARMS CO	**250MG/2.5ML (100MG/ML)**	**A206698**	**001**	Jan 26, 2018
AP		CAPLIN	**50MG/50ML (1MG/ML)**	**A214235**	**001**	Jan 21, 2021
AP		FRESENIUS KABI USA	**250MG/2.5ML (100MG/ML)**	**N201811**	**001**	Mar 23, 2015
AP		GLAND PHARMA LTD	**50MG/50ML (1MG/ML)**	**A217848**	**001**	Jul 31, 2023
AP	+!	HIKMA PHARM CO LTD	**50MG/50ML (1MG/ML)**	**N203049**	**002**	Sep 30, 2016
AP	+!		**250MG/2.5ML (100MG/ML)**	**N203049**	**001**	Jan 05, 2012
AP	!	HOSPIRA	**250MG/2.5ML (100MG/ML)**	**A204120**	**001**	Sep 21, 2016
AP		MYLAN INSTITUTIONAL	**250MG/2.5ML (100MG/ML)**	**A202626**	**001**	Jun 30, 2014
AP		PAR STERILE PRODUCTS	**250MG/2.5ML (100MG/ML)**	**A091665**	**001**	Jun 30, 2014

INJECTABLE;INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

AP		GLAND PHARMA LTD	**125MG/125ML (1MG/ML)**	**A205570**	**001**	May 22, 2017
AP	+!	SANDOZ	**125MG/125ML (1MG/ML)**	**N022485**	**001**	May 09, 2011

SOLUTION;INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

+!	ACCORD HLTHCARE	50MG/50ML (1MG/ML)	N212035	001	Jun 07, 2021
	EUGIA PHARMA SPECLTS	50MG/50ML (1MG/ML)	N209552	001	Nov 27, 2018

ARGININE HYDROCHLORIDE

INJECTABLE;INJECTION

R-GENE 10

+!	PHARMACIA AND UPJOHN	10GM/100ML	N016931	001	

ARIPIPRAZOLE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ABILIFY MAINTENA KIT

+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013
+		300MG	N202971	003	Sep 29, 2014
+!		400MG/VIAL	N202971	002	Feb 28, 2013
+		400MG	N202971	004	Sep 29, 2014

SOLUTION;ORAL

ARIPIPRAZOLE

AA	!	AMNEAL PHARMS	**1MG/ML**	**A203906**	**001**	Aug 14, 2015
AA		APOTEX	**1MG/ML**	**A204094**	**001**	Sep 30, 2015
AA		AUROBINDO PHARMA LTD	**1MG/ML**	**A210479**	**001**	Jan 29, 2019

ARIPIPRAZOLE

SOLUTION;ORAL

ARIPIPRAZOLE

AA		CHARTWELL RX	**1MG/ML**	**A215595**	**001**	Oct 25, 2022
AA		HETERO LABS LTD III	**1MG/ML**	**A216150**	**001**	Nov 01, 2023
AA		LANNETT CO INC	**1MG/ML**	**A204171**	**001**	Aug 14, 2015
AA		RUBICON	**1MG/ML**	**A216351**	**001**	Oct 27, 2022
AA		VISTAPHARM	**1MG/ML**	**A212870**	**001**	Dec 26, 2019

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ABILIFY ASIMTUFII

	+	OTSUKA	720MG/2.4ML (300MG/ML)	N217006	001	Apr 27, 2023
	+!		960MG/3.2ML (300MG/ML)	N217006	002	Apr 27, 2023

TABLET;ORAL

ABILIFY

AB	**+**	OTSUKA	**2MG**	**N021436**	**006**	Nov 15, 2002
AB	**+**		**5MG**	**N021436**	**005**	Nov 15, 2002
AB	**+!**		**10MG**	**N021436**	**001**	Nov 15, 2002
AB	**+**		**15MG**	**N021436**	**002**	Nov 15, 2002
AB	**+**		**20MG**	**N021436**	**003**	Nov 15, 2002
AB	**+**		**30MG**	**N021436**	**004**	Nov 15, 2002

ARIPIPRAZOLE

AB		ACCORD HLTHCARE	**2MG**	**A206251**	**001**	Dec 07, 2016
AB			**5MG**	**A206251**	**002**	Dec 07, 2016
AB			**10MG**	**A206251**	**003**	Dec 07, 2016
AB			**15MG**	**A206251**	**004**	Dec 07, 2016
AB			**20MG**	**A206251**	**005**	Dec 07, 2016
AB			**30MG**	**A206251**	**006**	Dec 07, 2016
AB		AJANTA PHARMA LTD	**2MG**	**A206174**	**001**	Sep 12, 2016
AB			**5MG**	**A206174**	**002**	Sep 12, 2016
AB			**10MG**	**A206174**	**003**	Sep 12, 2016
AB			**15MG**	**A206174**	**004**	Sep 12, 2016
AB			**20MG**	**A206174**	**005**	Sep 12, 2016
AB			**30MG**	**A206174**	**006**	Sep 12, 2016
AB		ALEMBIC	**2MG**	**A202101**	**001**	Apr 28, 2015
AB			**5MG**	**A202101**	**002**	Apr 28, 2015
AB			**10MG**	**A202101**	**003**	Apr 28, 2015
AB			**15MG**	**A202101**	**004**	Apr 28, 2015
AB			**20MG**	**A202101**	**005**	Apr 28, 2015
AB			**30MG**	**A202101**	**006**	Apr 28, 2015
AB		ALKEM LABS LTD	**2MG**	**A207105**	**001**	Feb 21, 2019
AB			**5MG**	**A207105**	**002**	Feb 21, 2019
AB			**10MG**	**A207105**	**003**	Feb 21, 2019
AB			**15MG**	**A207105**	**004**	Feb 21, 2019
AB			**20MG**	**A207105**	**005**	Feb 21, 2019
AB			**30MG**	**A207105**	**006**	Feb 21, 2019
AB		AMNEAL PHARMS	**2MG**	**A204838**	**001**	Jun 17, 2016
AB			**5MG**	**A204838**	**002**	Jun 17, 2016
AB			**10MG**	**A204838**	**003**	Jun 17, 2016
AB			**15MG**	**A204838**	**004**	Jun 17, 2016
AB			**20MG**	**A204838**	**005**	Jun 17, 2016
AB			**30MG**	**A204838**	**006**	Jun 17, 2016
AB		APOTEX	**2MG**	**A078583**	**001**	Jul 24, 2015
AB			**5MG**	**A078583**	**002**	Jul 24, 2015
AB			**10MG**	**A078583**	**003**	Jul 24, 2015
AB			**15MG**	**A078583**	**004**	Jul 24, 2015
AB			**20MG**	**A078583**	**005**	Jul 24, 2015
AB			**30MG**	**A078583**	**006**	Jul 24, 2015
AB		AUROBINDO PHARMA	**2MG**	**A203908**	**001**	Oct 08, 2015
AB			**5MG**	**A203908**	**002**	Oct 08, 2015
AB			**10MG**	**A203908**	**003**	Oct 08, 2015
AB			**15MG**	**A203908**	**004**	Oct 08, 2015
AB			**20MG**	**A203908**	**005**	Oct 08, 2015
AB			**30MG**	**A203908**	**006**	Oct 08, 2015
AB		BRECKENRIDGE	**2MG**	**A091279**	**001**	Jan 09, 2017
AB			**5MG**	**A091279**	**002**	Jan 09, 2017
AB			**10MG**	**A091279**	**003**	Jan 09, 2017
AB			**15MG**	**A091279**	**004**	Jan 09, 2017
AB			**20MG**	**A091279**	**005**	Jan 09, 2017
AB			**30MG**	**A091279**	**006**	Jan 09, 2017
AB		HETERO LABS LTD V	**2MG**	**A205064**	**001**	Apr 28, 2015
AB			**5MG**	**A205064**	**002**	Apr 28, 2015
AB			**10MG**	**A205064**	**003**	Apr 28, 2015

ARIPIPRAZOLE

TABLET;ORAL

ARIPIPRAZOLE

AB		**15MG**	**A205064**	**004**	Apr 28, 2015
AB		**20MG**	**A205064**	**005**	Apr 28, 2015
AB		**30MG**	**A205064**	**006**	Apr 28, 2015
AB	MACLEODS PHARMS LTD	**2MG**	**A204111**	**001**	Oct 07, 2016
AB		**5MG**	**A204111**	**002**	Oct 07, 2016
AB		**10MG**	**A204111**	**003**	Oct 07, 2016
AB		**15MG**	**A204111**	**004**	Oct 07, 2016
AB		**20MG**	**A204111**	**005**	Oct 07, 2016
AB		**30MG**	**A204111**	**006**	Oct 07, 2016
AB	ORBION PHARMS	**2MG**	**A202683**	**001**	May 23, 2017
AB		**5MG**	**A202683**	**002**	May 23, 2017
AB		**10MG**	**A202683**	**003**	May 23, 2017
AB		**15MG**	**A202683**	**004**	May 23, 2017
AB		**20MG**	**A202683**	**005**	May 23, 2017
AB		**30MG**	**A202683**	**006**	May 23, 2017
AB	PRINSTON INC	**2MG**	**A205363**	**001**	Dec 04, 2017
AB		**5MG**	**A205363**	**002**	Dec 04, 2017
AB		**10MG**	**A205363**	**003**	Dec 04, 2017
AB		**15MG**	**A205363**	**004**	Dec 04, 2017
AB		**20MG**	**A205363**	**005**	Dec 04, 2017
AB		**30MG**	**A205363**	**006**	Dec 04, 2017
AB	SCIEGEN PHARMS INC	**2MG**	**A206383**	**001**	Sep 29, 2016
AB		**5MG**	**A206383**	**002**	Sep 29, 2016
AB		**10MG**	**A206383**	**003**	Sep 29, 2016
AB		**15MG**	**A206383**	**004**	Sep 29, 2016
AB		**20MG**	**A206383**	**005**	Sep 29, 2016
AB		**30MG**	**A206383**	**006**	Sep 29, 2016
AB	SUNSHINE	**2MG**	**A213037**	**001**	Oct 02, 2023
AB		**5MG**	**A213037**	**002**	Oct 02, 2023
AB		**10MG**	**A213037**	**003**	Oct 02, 2023
AB	TORRENT	**2MG**	**A201519**	**001**	Apr 28, 2015
AB		**10MG**	**A201519**	**003**	Apr 28, 2015
AB		**5MG**	**A201519**	**002**	Apr 28, 2015
AB		**15MG**	**A201519**	**004**	Apr 28, 2015
AB		**20MG**	**A201519**	**005**	Apr 28, 2015
AB		**30MG**	**A201519**	**006**	Apr 28, 2015
AB	UNICHEM	**2MG**	**A203025**	**001**	Dec 01, 2021
AB		**5MG**	**A203025**	**002**	Dec 01, 2021
AB		**10MG**	**A203025**	**003**	Dec 01, 2021
AB		**15MG**	**A203025**	**004**	Dec 01, 2021
AB		**20MG**	**A203025**	**005**	Dec 01, 2021
AB		**30MG**	**A203025**	**006**	Dec 01, 2021

ABILIFY MYCITE KIT

+	OTSUKA	2MG	N207202	001	Nov 13, 2017
+!		5MG	N207202	002	Nov 13, 2017
+		10MG	N207202	003	Nov 13, 2017
+		15MG	N207202	004	Nov 13, 2017
+		20MG	N207202	005	Nov 13, 2017
+		30MG	N207202	006	Nov 13, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

ARIPIPRAZOLE

AB	**!** ALEMBIC	**10MG**	**A202102**	**001**	Apr 28, 2015
AB		**15MG**	**A202102**	**002**	Apr 28, 2015
AB	ORBION PHARMS	**10MG**	**A202547**	**001**	Dec 11, 2017
AB		**15MG**	**A202547**	**002**	Dec 11, 2017
AB	SCIEGEN PHARMS INC	**10MG**	**A207240**	**001**	Apr 18, 2018
AB		**15MG**	**A207240**	**002**	Apr 18, 2018
AB	SQUARE PHARMS	**10MG**	**A090165**	**001**	Aug 28, 2018
AB		**15MG**	**A090165**	**002**	Aug 28, 2018
		20MG	A090165	003	Aug 28, 2018
		30MG	A090165	004	Aug 28, 2018

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ARISTADA

+	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015
+		662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015
+!		882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015
+		1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ARISTADA INITIO KIT

+	ALKERMES INC	675MG/2.4ML	N209830	001	Jun 29, 2018

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

AB	AUROBINDO PHARMA LTD	**50MG**	**A206069**	**001**	Mar 06, 2018
AB		**150MG**	**A206069**	**002**	Mar 06, 2018
AB		**200MG**	**A206069**	**004**	Dec 07, 2018
AB		**250MG**	**A206069**	**003**	Mar 06, 2018
AB	LUPIN LTD	**50MG**	**A200751**	**001**	Nov 28, 2016
AB		**150MG**	**A200751**	**003**	Nov 28, 2016
AB		**200MG**	**A200751**	**004**	Nov 28, 2016
AB		**250MG**	**A200751**	**005**	Nov 28, 2016
AB	MYLAN PHARMS INC	**50MG**	**A200043**	**001**	Jun 01, 2012
AB		**100MG**	**A200043**	**004**	May 09, 2019
AB		**150MG**	**A200043**	**002**	Jun 01, 2012
AB		**200MG**	**A200043**	**005**	May 09, 2019
AB		**250MG**	**A200043**	**003**	Jun 01, 2012
AB	NATCO PHARMA LTD	**50MG**	**A202768**	**001**	Nov 28, 2016
AB		**100MG**	**A202768**	**004**	Sep 28, 2017
AB		**150MG**	**A202768**	**002**	Nov 28, 2016
AB		**200MG**	**A202768**	**005**	Sep 28, 2017
AB		**250MG**	**A202768**	**003**	Nov 28, 2016

NUVIGIL

AB	**+** CEPHALON	**50MG**	**N021875**	**001**	Jun 15, 2007
AB	**+**	**150MG**	**N021875**	**003**	Jun 15, 2007
AB	**+**	**200MG**	**N021875**	**005**	Mar 26, 2009
AB	**+!**	**250MG**	**N021875**	**004**	Jun 15, 2007

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

AP	AMNEAL	**1MG/ML**	**A210739**	**001**	Jan 25, 2021
AP		**2MG/ML**	**A210739**	**002**	Aug 19, 2021
AP	AMRING PHARMS	**1MG/ML**	**A210802**	**001**	Nov 13, 2018
AP	EUGIA PHARMA	**2MG/ML**	**A214011**	**001**	Oct 15, 2021
AP	**!** FRESENIUS KABI USA	**1MG/ML**	**A208231**	**001**	Aug 31, 2018
AP	GLAND PHARMA LTD	**1MG/ML**	**A215059**	**002**	Apr 22, 2022
AP		**2MG/ML**	**A215059**	**001**	Oct 07, 2021
AP	INGENUS PHARMS LLC	**1MG/ML**	**A209315**	**001**	Nov 15, 2018
AP	NEXUS	**1MG/ML**	**A209780**	**001**	Nov 15, 2018
AP	ORBICULAR	**1MG/ML**	**A217413**	**001**	Apr 20, 2023
AP		**2MG/ML**	**A217413**	**002**	Apr 20, 2023
AP	PENN LIFE	**1MG/ML**	**A209873**	**001**	May 06, 2019
AP	SANDOZ	**2MG/ML**	**A215359**	**001**	Dec 02, 2021
AP	ZYDUS PHARMS	**1MG/ML**	**A206228**	**001**	Nov 13, 2018
AP		**2MG/ML**	**A206228**	**002**	Aug 30, 2019

TRISENOX

AP	**+!** CEPHALON	**2MG/ML**	**N021248**	**002**	Oct 13, 2017

ARTEMETHER; LUMEFANTRINE

TABLET;ORAL

COARTEM

+!	NOVARTIS	20MG;120MG	N022268	001	Apr 07, 2009

ARTESUNATE

POWDER;INTRAVENOUS

ARTESUNATE

+!	AMIVAS	110MG/VIAL	N213036	001	May 26, 2020

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

ORABLOC

+	PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466	001	Feb 26, 2010
+!		4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466	002	Feb 26, 2010

SEPTOCAINE

+!	DEPROCO	4%; EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	N020971	002	Mar 30, 2006
+!		4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971	001	Apr 03, 2000

ASCIMINIB HYDROCHLORIDE

TABLET;ORAL

SCEMBLIX

+	NOVARTIS	EQ 20MG BASE	N215358	001	Oct 29, 2021
+!		EQ 40MG BASE	N215358	002	Oct 29, 2021

ASCORBIC ACID

SOLUTION;INTRAVENOUS

ASCOR

+!	MCGUFF	25,000MG/50ML (500MG/ML)	N209112	001	Oct 02, 2017

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS

INFUVITE PEDIATRIC

+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	002	Jan 29, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

MOVIPREP

AA	**+!**	SALIX PHARMS	**4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM**	**N021881**	**001**	Aug 02, 2006

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC

AA		NOVEL LABS INC	**4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM**	**A090145**	**001**	Jan 25, 2012

PLENVU

	+!	SALIX	7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM	N209381	001	May 04, 2018

ASENAPINE

SYSTEM;TRANSDERMAL

SECUADO

+!	HISAMITSU	3.8MG/24HR	N212268	001	Oct 11, 2019
+		5.7MG/24HR	N212268	002	Oct 11, 2019
+		7.6MG/24HR	N212268	003	Oct 11, 2019

ASENAPINE MALEATE

TABLET;SUBLINGUAL

ASENAPINE MALEATE

AB		ALEMBIC	**EQ 2.5MG BASE**	**A206098**	**003**	Jul 19, 2021
AB			**EQ 5MG BASE**	**A206098**	**001**	Dec 10, 2020
AB			**EQ 10MG BASE**	**A206098**	**002**	Dec 10, 2020
AB		BRECKENRIDGE	**EQ 2.5MG BASE**	**A205960**	**001**	Dec 10, 2020
AB			**EQ 5MG BASE**	**A205960**	**003**	Mar 08, 2021
AB			**EQ 10MG BASE**	**A205960**	**002**	Dec 10, 2020
AB		SIGMAPHARM LABS LLC	**EQ 5MG BASE**	**A206107**	**001**	Dec 10, 2020
AB			**EQ 10MG BASE**	**A206107**	**002**	Dec 10, 2020

SAPHRIS

AB	**+**	ALLERGAN	**EQ 2.5MG BASE**	**N022117**	**003**	Mar 12, 2015
AB	**+**		**EQ 5MG BASE**	**N022117**	**001**	Aug 13, 2009
AB	**+!**		**EQ 10MG BASE**	**N022117**	**002**	Aug 13, 2009

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA		NOSTRUM LABS INC	**325MG;50MG;40MG**	**A078149**	**001**	Jun 13, 2007

LANORINAL

AA	**!**	LANNETT	**325MG;50MG;40MG**	**A086996**	**002**	Oct 11, 1985

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

!	STRIDES PHARMA	325MG;50MG;40MG	A204195	001	Sep 22, 2016

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB		LGM PHARMA	**325MG;50MG;40MG;30MG**	**A075231**	**001**	Nov 30, 2001
AB	**!**	STEVENS J	**325MG;50MG;40MG;30MG**	**A074951**	**001**	Aug 31, 1998

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENGESIC

		GALT PHARMS	385MG;30MG;25MG	A075141	001	May 29, 1998

ORPHENGESIC FORTE

	!	GALT PHARMS	770MG;60MG;50MG	A075141	002	May 29, 1998

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

AB		AMNEAL PHARMS	**25MG;200MG**	**A206392**	**001**	Mar 08, 2016
AB		BARR	**25MG;200MG**	**A078804**	**001**	Aug 14, 2009
AB		DR REDDYS	**25MG;200MG**	**A209048**	**001**	Oct 10, 2018
AB	!	GLENMARK PHARMS SA	**25MG;200MG**	**A210318**	**001**	May 24, 2019
AB		MICRO LABS	**25MG;200MG**	**A209929**	**001**	Aug 11, 2021
AB		PAR PHARM INC	**25MG;200MG**	**A207944**	**001**	Jan 18, 2017
AB		SANDOZ	**25MG;200MG**	**A206739**	**001**	Jan 18, 2017
AB		ZYDUS PHARMS	**25MG;200MG**	**A206753**	**001**	Aug 29, 2017

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ASPIRIN

	!	LGM PHARMA	500MG;5MG	A205479	001	May 28, 2021

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA		EPIC PHARMA LLC	**325MG;4.8355MG**	**A040910**	**001**	Jul 16, 2020

PERCODAN

AA	**+!**	ENDO PHARMS	**325MG;4.8355MG**	**N007337**	**007**	Aug 05, 2005

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB		AMNEAL	**EQ 150MG BASE**	**A209717**	**002**	Jun 01, 2020
AB			**EQ 200MG BASE**	**A209717**	**003**	Jun 01, 2020
AB			**EQ 300MG BASE**	**A209717**	**004**	Jun 01, 2020
AB		AUROBINDO PHARMA	**EQ 100MG BASE**	**A204806**	**001**	Jun 25, 2018
AB			**EQ 150MG BASE**	**A204806**	**002**	Jun 25, 2018
AB			**EQ 200MG BASE**	**A204806**	**003**	Jun 25, 2018
AB			**EQ 300MG BASE**	**A204806**	**004**	Jun 25, 2018
AB		HETERO LABS LTD III	**EQ 150MG BASE**	**A212278**	**001**	Feb 02, 2022
AB			**EQ 200MG BASE**	**A212278**	**002**	Feb 02, 2022
AB			**EQ 300MG BASE**	**A212278**	**003**	Feb 02, 2022
AB		LAURUS	**EQ 150MG BASE**	**A212579**	**001**	Apr 30, 2021
AB			**EQ 200MG BASE**	**A212579**	**002**	Apr 30, 2021
AB			**EQ 300MG BASE**	**A212579**	**003**	Apr 30, 2021
AB		TEVA PHARMS USA	**EQ 100MG BASE**	**A091673**	**001**	Apr 22, 2014
AB			**EQ 150MG BASE**	**A091673**	**002**	Apr 22, 2014
AB			**EQ 200MG BASE**	**A091673**	**003**	Apr 22, 2014
AB			**EQ 300MG BASE**	**A091673**	**004**	Apr 22, 2014

REYATAZ

AB	**+**	BRISTOL MYERS SQUIBB	**EQ 200MG BASE**	**N021567**	**003**	Jun 20, 2003
AB	**+!**		**EQ 300MG BASE**	**N021567**	**004**	Oct 16, 2006

POWDER;ORAL

REYATAZ

	+!	BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352	001	Jun 02, 2014

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

	+!	BRISTOL	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015

ATENOLOL

TABLET;ORAL

ATENOLOL

AB		AUROBINDO PHARMA	**25MG**	**A078512**	**001**	Oct 31, 2007
AB			**50MG**	**A078512**	**002**	Oct 31, 2007
AB			**100MG**	**A078512**	**003**	Oct 31, 2007
AB		HLTHCARE	**25MG**	**A073026**	**002**	May 01, 1992
AB			**50MG**	**A073026**	**003**	Sep 17, 1991
AB			**100MG**	**A073026**	**001**	Sep 17, 1991
AB		IPCA LABS LTD	**25MG**	**A077877**	**001**	Dec 27, 2006
AB			**50MG**	**A077877**	**002**	Dec 27, 2006

ATENOLOL

TABLET;ORAL

ATENOLOL

AB			**100MG**	**A077877**	**003**	Dec 27, 2006
AB		MYLAN	**25MG**	**A073457**	**002**	Apr 26, 1999
AB			**50MG**	**A073457**	**003**	Jan 24, 1992
AB			**100MG**	**A073457**	**001**	Jan 24, 1992
AB		TEVA	**25MG**	**A074056**	**003**	Jul 19, 2004
AB			**50MG**	**A074056**	**001**	Jan 18, 1995
AB			**100MG**	**A074056**	**002**	Jan 18, 1995
AB		TWI PHARMS	**25MG**	**A072304**	**002**	Jul 31, 1992
AB			**50MG**	**A072304**	**003**	Jul 18, 1988
AB			**100MG**	**A072304**	**001**	Jul 15, 1988
AB		UNICHEM	**25MG**	**A213136**	**001**	Nov 21, 2019
AB			**50MG**	**A213136**	**002**	Nov 21, 2019
AB			**100MG**	**A213136**	**003**	Nov 21, 2019
AB		UNIQUE	**25MG**	**A077443**	**001**	Sep 13, 2006
AB			**50MG**	**A077443**	**002**	Sep 13, 2006
AB			**100MG**	**A077443**	**003**	Sep 13, 2006
AB		ZYDUS PHARMS USA	**25MG**	**A076900**	**001**	Jan 28, 2005
AB			**50MG**	**A076900**	**002**	Jan 28, 2005
AB			**100MG**	**A076900**	**003**	Jan 28, 2005

TENORMIN

AB	**+**	TWI PHARMS	**25MG**	**N018240**	**004**	Apr 09, 1990
AB	**+**		**50MG**	**N018240**	**001**	
AB	**+!**		**100MG**	**N018240**	**002**	

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB		NOVITIUM PHARMA	**50MG;25MG**	**A215560**	**001**	Oct 25, 2021
AB			**100MG;25MG**	**A215560**	**002**	Oct 25, 2021
AB		TWI PHARMS	**50MG;25MG**	**A072302**	**002**	May 31, 1990
AB			**100MG;25MG**	**A072302**	**001**	May 31, 1990
AB		UNICHEM	**50MG;25MG**	**A213302**	**001**	Nov 25, 2020
AB			**100MG;25MG**	**A213302**	**002**	Nov 25, 2020
AB		WATSON LABS	**50MG;25MG**	**A073665**	**001**	Jul 02, 1992
AB			**100MG;25MG**	**A073665**	**002**	Jul 02, 1992
AB		ZYDUS PHARMS	**50MG;25MG**	**A210028**	**001**	Mar 08, 2019
AB			**100MG;25MG**	**A210028**	**002**	Mar 08, 2019

TENORETIC 100

AB	**+!**	TWI PHARMS	**100MG;25MG**	**N018760**	**001**	Jun 08, 1984

TENORETIC 50

AB	**+**	TWI PHARMS	**50MG;25MG**	**N018760**	**002**	Jun 08, 1984

ATOGEPANT

TABLET;ORAL

QULIPTA

+	ABBVIE	10MG	N215206	001	Sep 28, 2021
+		30MG	N215206	002	Sep 28, 2021
+!		60MG	N215206	003	Sep 28, 2021

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		APOTEX	**10MG**	**A078983**	**001**	May 30, 2017
AB			**18MG**	**A078983**	**002**	May 30, 2017
AB			**25MG**	**A078983**	**003**	May 30, 2017
AB			**40MG**	**A078983**	**004**	May 30, 2017
AB			**60MG**	**A078983**	**005**	May 30, 2017
AB			**80MG**	**A078983**	**006**	May 30, 2017
AB			**100MG**	**A078983**	**007**	May 30, 2017
AB		AUROBINDO PHARMA	**10MG**	**A079016**	**001**	May 30, 2017
AB			**18MG**	**A079016**	**002**	May 30, 2017
AB			**25MG**	**A079016**	**003**	May 30, 2017
AB			**40MG**	**A079016**	**004**	May 30, 2017
AB			**60MG**	**A079016**	**005**	May 30, 2017
AB			**80MG**	**A079016**	**006**	May 30, 2017
AB			**100MG**	**A079016**	**007**	May 30, 2017
AB		DR REDDYS	**10MG**	**A090609**	**001**	Feb 23, 2018
AB			**18MG**	**A090609**	**002**	Feb 23, 2018
AB			**25MG**	**A090609**	**003**	Feb 23, 2018
AB			**40MG**	**A090609**	**004**	Feb 23, 2018
AB			**60MG**	**A090609**	**005**	Feb 23, 2018

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB			80MG	A090609	006	Feb 23, 2018
AB			100MG	A090609	007	Feb 23, 2018
AB		GLENMARK PHARMS LTD	10MG	A079019	001	May 30, 2017
AB			18MG	A079019	002	May 30, 2017
AB			25MG	A079019	003	May 30, 2017
AB			40MG	A079019	004	May 30, 2017
AB			60MG	A079019	005	May 30, 2017
AB			80MG	A079019	006	May 30, 2017
AB			100MG	A079019	007	May 30, 2017
AB		HETERO LABS LTD V	10MG	A202682	001	Mar 11, 2021
AB			18MG	A202682	002	Mar 11, 2021
AB			25MG	A202682	003	Mar 11, 2021
AB			40MG	A202682	004	Mar 11, 2021
AB			60MG	A202682	005	Mar 11, 2021
AB			80MG	A202682	006	Mar 11, 2021
AB			100MG	A202682	007	Mar 11, 2021
AB		TEVA PHARMS USA	10MG	A079022	001	May 30, 2017
AB			18MG	A079022	002	May 30, 2017
AB			25MG	A079022	003	May 30, 2017
AB			40MG	A079022	004	May 30, 2017
AB			60MG	A079022	005	May 30, 2017
AB			80MG	A079022	006	May 30, 2017
AB			100MG	A079022	007	May 30, 2017
AB		ZYDUS PHARMS USA INC	10MG	A079017	007	Apr 05, 2023
AB			18MG	A079017	001	Sep 17, 2010
AB			25MG	A079017	002	Sep 17, 2010
AB			40MG	A079017	003	Sep 17, 2010
AB			60MG	A079017	004	Sep 17, 2010
AB			80MG	A079017	005	Sep 17, 2010
AB			100MG	A079017	006	Sep 17, 2010

STRATTERA

AB	+	LILLY	10MG	N021411	002	Nov 26, 2002
AB	+		18MG	N021411	003	Nov 26, 2002
AB	+		25MG	N021411	004	Nov 26, 2002
AB	+		40MG	N021411	005	Nov 26, 2002
AB	+!		60MG	N021411	006	Nov 26, 2002
AB	+		80MG	N021411	007	Feb 14, 2005
AB	+		100MG	N021411	008	Feb 14, 2005

ATORVASTATIN CALCIUM

SUSPENSION;ORAL

ATORVALIQ

	+!	CMP DEV LLC	20MG/5ML	N213260	001	Feb 01, 2023

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		ACCORD HLTHCARE	EQ 10MG BASE	A207687	001	Mar 30, 2018
AB			EQ 20MG BASE	A207687	002	Mar 30, 2018
AB			EQ 40MG BASE	A207687	003	Mar 30, 2018
AB			EQ 80MG BASE	A207687	004	Mar 30, 2018
AB		ACI	EQ 10MG BASE	A217634	001	Dec 21, 2023
AB			EQ 20MG BASE	A217634	002	Dec 21, 2023
AB			EQ 40MG BASE	A217634	003	Dec 21, 2023
AB			EQ 80MG BASE	A217634	004	Dec 21, 2023
AB		AGNITIO	EQ 10MG BASE	A214969	001	Sep 02, 2021
AB			EQ 20MG BASE	A214969	002	Sep 02, 2021
AB			EQ 40MG BASE	A214969	003	Sep 02, 2021
AB			EQ 80MG BASE	A214969	004	Sep 02, 2021
AB		ALKEM LABS LTD	EQ 10MG BASE	A209288	001	Dec 21, 2018
AB			EQ 20MG BASE	A209288	002	Dec 21, 2018
AB			EQ 40MG BASE	A209288	003	Dec 21, 2018
AB			EQ 80MG BASE	A209288	004	Dec 21, 2018
AB		APOTEX INC	EQ 10MG BASE	A090548	001	May 29, 2012
AB			EQ 20MG BASE	A090548	002	May 29, 2012
AB			EQ 40MG BASE	A090548	003	May 29, 2012
AB			EQ 80MG BASE	A090548	004	May 29, 2012
AB		BIOCON PHARMA	EQ 10MG BASE	A216436	001	Nov 23, 2022
AB			EQ 20MG BASE	A216436	002	Nov 23, 2022
AB			EQ 40MG BASE	A216436	003	Nov 23, 2022
AB			EQ 80MG BASE	A216436	004	Nov 23, 2022

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	CADILA PHARMS LTD	**EQ 10MG BASE**	**A212103**	**001**	Oct 16, 2023
AB		**EQ 20MG BASE**	**A212103**	**002**	Oct 16, 2023
AB		**EQ 40MG BASE**	**A212103**	**003**	Oct 16, 2023
AB		**EQ 80MG BASE**	**A212103**	**004**	Oct 16, 2023
AB	DR REDDYS	**EQ 10MG BASE**	**A214659**	**001**	Jul 14, 2021
AB		**EQ 20MG BASE**	**A214659**	**002**	Jul 14, 2021
AB		**EQ 40MG BASE**	**A214659**	**003**	Jul 14, 2021
AB		**EQ 80MG BASE**	**A214659**	**004**	Jul 14, 2021
AB	DR REDDYS LABS LTD	**EQ 10MG BASE**	**A091650**	**001**	Jul 17, 2012
AB		**EQ 20MG BASE**	**A091650**	**002**	Jul 17, 2012
AB		**EQ 40MG BASE**	**A091650**	**003**	Jul 17, 2012
AB		**EQ 80MG BASE**	**A202357**	**001**	Jul 17, 2012
AB	GRAVITI PHARMS	**EQ 10MG BASE**	**A209912**	**001**	Jun 18, 2018
AB		**EQ 20MG BASE**	**A209912**	**002**	Jun 18, 2018
AB		**EQ 40MG BASE**	**A209912**	**003**	Jun 18, 2018
AB		**EQ 80MG BASE**	**A209912**	**004**	Jun 18, 2018
AB	HETERO LABS LTD V	**EQ 10MG BASE**	**A214344**	**001**	Sep 12, 2023
AB		**EQ 20MG BASE**	**A214344**	**002**	Sep 12, 2023
AB		**EQ 40MG BASE**	**A214344**	**003**	Sep 12, 2023
AB		**EQ 80MG BASE**	**A214344**	**004**	Sep 12, 2023
AB	INVAGEN PHARMS	**EQ 10MG BASE**	**A204846**	**001**	Jan 09, 2017
AB		**EQ 20MG BASE**	**A204846**	**002**	Jan 09, 2017
AB		**EQ 40MG BASE**	**A204846**	**003**	Jan 09, 2017
AB		**EQ 80MG BASE**	**A204846**	**004**	Jan 09, 2017
AB	LANNETT CO INC	**EQ 10MG BASE**	**A091624**	**001**	Apr 05, 2013
AB		**EQ 20MG BASE**	**A091624**	**002**	Apr 05, 2013
AB		**EQ 40MG BASE**	**A091624**	**003**	Apr 05, 2013
AB		**EQ 80MG BASE**	**A091624**	**004**	Apr 05, 2013
AB	LUPIN LTD	**EQ 10MG BASE**	**A204991**	**001**	Mar 06, 2019
AB		**EQ 20MG BASE**	**A204991**	**002**	Mar 06, 2019
AB		**EQ 40MG BASE**	**A204991**	**003**	Mar 06, 2019
AB		**EQ 80MG BASE**	**A204991**	**004**	Mar 06, 2019
AB	MANKIND PHARMA	**EQ 10MG BASE**	**A217081**	**001**	Jan 05, 2024
AB		**EQ 20MG BASE**	**A217081**	**002**	Jan 05, 2024
AB		**EQ 40MG BASE**	**A217081**	**003**	Jan 05, 2024
AB		**EQ 80MG BASE**	**A217081**	**004**	Jan 05, 2024
AB	MICRO LABS LTD INDIA	**EQ 10MG BASE**	**A205945**	**001**	Nov 07, 2019
AB		**EQ 20MG BASE**	**A205945**	**002**	Nov 07, 2019
AB		**EQ 40MG BASE**	**A205945**	**003**	Nov 07, 2019
AB		**EQ 80MG BASE**	**A205945**	**004**	Nov 07, 2019
AB	MSN	**EQ 10MG BASE**	**A211933**	**001**	Feb 08, 2019
AB		**EQ 20MG BASE**	**A211933**	**002**	Feb 08, 2019
AB		**EQ 40MG BASE**	**A211933**	**003**	Feb 08, 2019
AB		**EQ 80MG BASE**	**A211933**	**004**	Feb 08, 2019
AB	MYLAN PHARMS INC	**EQ 10MG BASE**	**A091226**	**001**	May 29, 2012
AB		**EQ 20MG BASE**	**A091226**	**002**	May 29, 2012
AB		**EQ 40MG BASE**	**A091226**	**003**	May 29, 2012
AB		**EQ 80MG BASE**	**A091226**	**004**	May 29, 2012
AB	SANDOZ INC	**EQ 10MG BASE**	**A077575**	**001**	May 29, 2012
AB		**EQ 20MG BASE**	**A077575**	**002**	May 29, 2012
AB		**EQ 40MG BASE**	**A077575**	**003**	May 29, 2012
AB		**EQ 80MG BASE**	**A077575**	**004**	May 29, 2012
AB	SCIEGEN PHARMS INC	**EQ 10MG BASE**	**A205519**	**001**	May 19, 2016
AB		**EQ 20MG BASE**	**A205519**	**002**	May 19, 2016
AB		**EQ 40MG BASE**	**A205519**	**003**	May 19, 2016
AB		**EQ 80MG BASE**	**A205519**	**004**	May 19, 2016
AB	SUN PHARM INDS LTD	**EQ 10MG BASE**	**A076477**	**001**	Nov 30, 2011
AB		**EQ 20MG BASE**	**A076477**	**002**	Nov 30, 2011
AB		**EQ 40MG BASE**	**A076477**	**003**	Nov 30, 2011
AB		**EQ 80MG BASE**	**A076477**	**004**	Nov 30, 2011
AB	TEVA PHARMS USA	**EQ 10MG BASE**	**A205300**	**001**	Mar 27, 2017
AB		**EQ 20MG BASE**	**A205300**	**002**	Mar 27, 2017
AB		**EQ 40MG BASE**	**A205300**	**003**	Mar 27, 2017
AB		**EQ 80MG BASE**	**A205300**	**004**	Mar 27, 2017
AB	UMEDICA	**EQ 10MG BASE**	**A213853**	**001**	Aug 19, 2020
AB		**EQ 20MG BASE**	**A213853**	**002**	Aug 19, 2020
AB		**EQ 40MG BASE**	**A213853**	**003**	Aug 19, 2020
AB		**EQ 80MG BASE**	**A213853**	**004**	Aug 19, 2020
AB	ZYDUS PHARMS	**EQ 10MG BASE**	**A206536**	**001**	Nov 20, 2018

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB			**EQ 20MG BASE**	**A206536**	**002**	Nov 20, 2018
AB			**EQ 40MG BASE**	**A206536**	**003**	Nov 20, 2018
AB			**EQ 80MG BASE**	**A206536**	**004**	Nov 20, 2018

LIPITOR

AB	+	UPJOHN	**EQ 10MG BASE**	**N020702**	**001**	Dec 17, 1996
AB	+		**EQ 20MG BASE**	**N020702**	**002**	Dec 17, 1996
AB	+		**EQ 40MG BASE**	**N020702**	**003**	Dec 17, 1996
AB	+!		**EQ 80MG BASE**	**N020702**	**004**	Apr 07, 2000

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LYPQOZET

	ALTHERA PHARMS	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017
		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017
!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB		ABHAI LLC	**750MG/5ML**	**A210510**	**001**	May 31, 2019
AB		ABON PHARMS LLC	**750MG/5ML**	**A214272**	**001**	Oct 25, 2021
AB		AMNEAL PHARMS	**750MG/5ML**	**A202960**	**001**	Mar 18, 2014
AB		APOTEX	**750MG/5ML**	**A209750**	**001**	Oct 11, 2017
AB		BIONPHARMA	**750MG/5ML**	**A212918**	**001**	Mar 30, 2021
AB		CHARTWELL RX	**750MG/5ML**	**A207833**	**001**	Apr 28, 2017
AB		GLENMARK PHARMS	**750MG/5ML**	**A209685**	**001**	Nov 21, 2018
AB		HETERO LABS LTD III	**750MG/5ML**	**A210692**	**001**	Oct 11, 2018
AB		LUPIN LTD	**750MG/5ML**	**A209105**	**001**	Sep 11, 2018

MEPRON

AB	+!	GLAXOSMITHKLINE LLC	**750MG/5ML**	**N020500**	**001**	Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB		GLENMARK GENERICS	**62.5MG;25MG**	**A091211**	**002**	Apr 06, 2015
AB			**250MG;100MG**	**A091211**	**001**	Jan 12, 2011
AB		MYLAN	**62.5MG;25MG**	**A202362**	**001**	May 27, 2014
AB			**250MG;100MG**	**A202362**	**002**	May 27, 2014

MALARONE

AB	+!	GLAXOSMITHKLINE	**250MG;100MG**	**N021078**	**001**	Jul 14, 2000

MALARONE PEDIATRIC

AB	+	GLAXOSMITHKLINE	**62.5MG;25MG**	**N021078**	**002**	Jul 14, 2000

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP		EUGIA PHARMA	**10MG/ML**	**A206011**	**001**	Apr 08, 2015
AP	!	HIKMA	**10MG/ML**	**A074901**	**001**	Jul 18, 1997
AP		HOSPIRA INC	**10MG/ML**	**A090761**	**001**	Oct 18, 2012
AP		MEITHEAL	**10MG/ML**	**A091489**	**001**	Feb 17, 2012

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP		EUGIA PHARMA	**10MG/ML**	**A206010**	**001**	Apr 08, 2015
AP	!	HIKMA	**10MG/ML**	**A074900**	**001**	Jul 18, 1997
AP		HOSPIRA INC	**10MG/ML**	**A090782**	**001**	Oct 18, 2012
AP		MEITHEAL	**10MG/ML**	**A091488**	**001**	Feb 17, 2012

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

AP		ACCORD HLTHCARE	**0.25MG/5ML (0.05MG/ML)**	**A212868**	**001**	Jul 26, 2021
AP	+!		**0.4MG/ML (0.4MG/ML)**	**N214652**	**001**	Sep 29, 2020
AP			**0.5MG/5ML (0.1MG/ML)**	**A212868**	**002**	Jul 26, 2021
AP			**1MG/10ML (0.1MG/ML)**	**A212868**	**003**	Jul 26, 2021
AP	+!		**1MG/ML (1MG/ML)**	**N214652**	**002**	Sep 29, 2020
AP		AM REGENT	**0.4MG/ML (0.4MG/ML)**	**A216120**	**001**	May 26, 2022
AP			**1MG/ML (1MG/ML)**	**A216120**	**002**	May 26, 2022
AP		AMNEAL	**0.5MG/5ML (0.1MG/ML)**	**A215342**	**001**	Jan 26, 2022
AP			**1MG/10ML (0.1MG/ML)**	**A215342**	**002**	Oct 25, 2023
AP	+!	HOSPIRA	**0.25MG/5ML (0.05MG/ML)**	**N021146**	**002**	Jul 09, 2001
AP	+!		**0.5MG/5ML (0.1MG/ML)**	**N021146**	**001**	Jul 09, 2001
AP	+!		**1MG/10ML (0.1MG/ML)**	**N021146**	**003**	Jul 09, 2001

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

AP		INTL MEDICATION SYS	**1MG/10ML (0.1MG/ML)**	**A212461**	**001**	Oct 05, 2020
AP		MEDEFIL INC	**1MG/10ML (0.1MG/ML)**	**A214970**	**001**	Nov 04, 2022

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

AP		ACCORD HLTHCARE	**8MG/20ML (0.4MG/ML)**	**A213424**	**001**	Mar 19, 2021
AP	**+!**	FRESENIUS KABI USA	**8MG/20ML (0.4MG/ML)**	**N209260**	**001**	Jan 26, 2018
AP		HIKMA	**8MG/20ML (0.4MG/ML)**	**A213561**	**001**	Dec 01, 2021

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

AT	**!**	AMNEAL	**1%**	**A214752**	**001**	Jul 14, 2022
AT		APOTEX	**1%**	**A215624**	**001**	Nov 26, 2021
AT		MANKIND PHARMA	**1%**	**A218148**	**001**	Jan 08, 2024
AT	**+**	RISING	**1%**	**N206289**	**001**	Jul 18, 2014
	+!	BAUSCH AND LOMB INC	1%	N213581	001	Mar 15, 2022

ISOPTO ATROPINE

	+!	ALCON LABS INC	1%	N208151	001	Dec 01, 2016

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

	+!	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	!	HIKMA	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA		ANI PHARMS	**0.025MG;2.5MG**	**A086727**	**001**	
AA		BAYSHORE PHARMS LLC	**0.025MG;2.5MG**	**A210819**	**001**	Nov 13, 2018
AA		CHARTWELL RX	**0.025MG;2.5MG**	**A207128**	**001**	Oct 21, 2020
AA		LANNETT	**0.025MG;2.5MG**	**A085372**	**001**	
AA		LEADING	**0.025MG;2.5MG**	**A213413**	**001**	Feb 20, 2020
AA		MYLAN	**0.025MG;2.5MG**	**A085762**	**001**	
AA		SPECGX LLC	**0.025MG;2.5MG**	**A213335**	**001**	Oct 06, 2020
AA		WINDER LABS LLC	**0.025MG;2.5MG**	**A211362**	**001**	Jan 27, 2021

LOMOTIL

AA	**+!**	PFIZER	**0.025MG;2.5MG**	**N012462**	**001**	

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE;INTRAMUSCULAR

DUODOTE

	+!	MMT	2.1MG/0.7ML;600MG/2ML	N021983	001	Sep 28, 2006

AURANOFIN

CAPSULE;ORAL

RIDAURA

	+!	SEBELA IRELAND LTD	3MG	N018689	001	May 24, 1985

AVACINCAPTAD PEGOL SODIUM

SOLUTION;INTRAVITREAL

IZERVAY

	+!	IVERIC BIO	EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)	N217225	001	Aug 04, 2023

AVACOPAN

CAPSULE;ORAL

TAVNEOS

	+!	CHEMOCENTRYX	10MG	N214487	001	Oct 07, 2021

AVANAFIL

TABLET;ORAL

STENDRA

	+	METUCHEN PHARMS	50MG	N202276	001	Apr 27, 2012
	+		100MG	N202276	002	Apr 27, 2012
	+!		200MG	N202276	003	Apr 27, 2012

AVAPRITINIB

TABLET;ORAL

AYVAKIT

	+	BLUEPRINT MEDICINES	25MG	N212608	004	Jun 16, 2021
	+		50MG	N212608	005	Jun 16, 2021
	+		100MG	N212608	001	Jan 09, 2020
	+		200MG	N212608	002	Jan 09, 2020

AVAPRITINIB

TABLET;ORAL

AYVAKIT

+!		300MG	N212608	003	Jan 09, 2020

AVATROMBOPAG MALEATE

TABLET;ORAL

DOPTELET

+!	AKARX INC	EQ 20MG BASE	N210238	001	May 21, 2018

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;INTRAVENOUS

AVYCAZ

+!	ALLERGAN	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015

AXITINIB

TABLET;ORAL

INLYTA

+	PF PRISM CV	1MG	N202324	001	Jan 27, 2012
+!		5MG	N202324	002	Jan 27, 2012

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP		ACCORD HLTHCARE	**100MG/VIAL**	**A207475**	**001**	Jul 02, 2018
AP		ACTAVIS LLC	**100MG/VIAL**	**N208216**	**001**	Apr 29, 2016
AP		AMNEAL	**100MG/VIAL**	**A211549**	**001**	Feb 03, 2022
AP		CIPLA	**100MG/VIAL**	**A209540**	**001**	May 04, 2018
AP		DR REDDYS	**100MG/VIAL**	**A201537**	**001**	Sep 16, 2013
AP		EUGIA PHARMA	**100MG/VIAL**	**A215066**	**001**	Dec 30, 2022
AP		EUROHLTH INTL SARL	**100MG/VIAL**	**A209337**	**001**	Jun 08, 2020
AP		JIANGSU HANSOH PHARM	**100MG/VIAL**	**A215905**	**001**	Jun 28, 2023
AP		MEITHEAL	**100MG/VIAL**	**A212128**	**001**	Nov 02, 2020
AP		NATCO PHARMA LTD	**100MG/VIAL**	**A207234**	**001**	Jun 23, 2017
AP		SHILPA MEDICARE	**100MG/VIAL**	**A207518**	**001**	Sep 29, 2016

VIDAZA

AP	**+!**	BRISTOL-MYERS	**100MG/VIAL**	**N050794**	**001**	May 19, 2004

TABLET;ORAL

ONUREG

+	BRISTOL	200MG	N214120	001	Sep 01, 2020
+!		300MG	N214120	002	Sep 01, 2020

AZATHIOPRINE

TABLET;ORAL

AZASAN

AB		AAIPHARMA LLC	**25MG**	**A075252**	**002**	Feb 03, 2003
AB			**50MG**	**A075252**	**001**	Jun 07, 1999
AB			**75MG**	**A075252**	**003**	Feb 03, 2003
AB			**100MG**	**A075252**	**004**	Feb 03, 2003

AZATHIOPRINE

AB		ALKEM LABS LTD	**25MG**	**A208687**	**001**	Mar 27, 2020
AB			**50MG**	**A208687**	**002**	Mar 27, 2020
AB			**75MG**	**A208687**	**003**	Mar 27, 2020
AB			**100MG**	**A208687**	**004**	Mar 27, 2020
AB		AMNEAL	**50MG**	**A074069**	**001**	Feb 16, 1996
AB			**75MG**	**A074069**	**002**	Nov 02, 2021
AB			**100MG**	**A074069**	**003**	Nov 02, 2021
AB		RISING	**50MG**	**A075568**	**001**	Dec 13, 1999
AB		ZYDUS PHARMS USA	**25MG**	**A077621**	**002**	Sep 05, 2008
AB			**50MG**	**A077621**	**001**	Mar 15, 2007
AB			**75MG**	**A077621**	**003**	Sep 05, 2008
AB			**100MG**	**A077621**	**004**	Sep 05, 2008

IMURAN

AB	**+!**	SEBELA IRELAND LTD	**50MG**	**N016324**	**001**	

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

AZATHIOPRINE SODIUM

!	HIKMA	EQ 100MG BASE/VIAL	A074419	001	Mar 31, 1995

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

FINACEA

+!	LEO PHARMA AS	15%		N207071	001	Jul 29, 2015

CREAM;TOPICAL

AZELEX

+!	ALMIRALL	20%		N020428	001	Sep 13, 1995

GEL;TOPICAL

AZELAIC ACID

AB	ACTAVIS LABS UT INC	**15%**		**A208011**	**001**	Nov 19, 2018
AB	ENCUBE	**15%**		**A208724**	**001**	Nov 19, 2018
AB	GLENMARK PHARMS	**15%**		**A204637**	**001**	Nov 19, 2018
AB	TARO	**15%**		**A210549**	**001**	Aug 23, 2019

FINACEA

AB	**+!** LEO PHARMA AS	**15%**		**N021470**	**001**	Dec 24, 2002

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT	ALEMBIC	**0.05%**		**A209620**	**001**	Mar 20, 2019
AT	APOTEX INC	**0.05%**		**A078621**	**001**	Aug 03, 2009
AT	GLAND PHARMA LTD	**0.05%**		**A210092**	**001**	Feb 25, 2020
AT	**!** SANDOZ	**0.05%**		**A202305**	**001**	May 31, 2012
AT	SOMERSET THERAPS LLC	**0.05%**		**A207411**	**001**	Mar 29, 2019
AT	SUN PHARM	**0.05%**		**A078738**	**001**	Jun 21, 2010

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AB	ALKEM LABS LTD	**0.137MG/SPRAY**		**A208156**	**001**	Aug 18, 2017
AB	AMNEAL	**0.137MG/SPRAY**		**A204660**	**001**	Aug 28, 2017
AB	**!** APOTEX INC	**0.137MG/SPRAY**		**A077954**	**001**	Apr 30, 2009
AB	AUROBINDO PHARMA LTD	**0.137MG/SPRAY**		**A212289**	**001**	May 08, 2020
AB	BIONPHARMA	**0.137MG/SPRAY**		**A090176**	**001**	Jul 28, 2015
AB	EPIC PHARMA LLC	**0.137MG/SPRAY**		**A207610**	**001**	May 17, 2019
AB	HIKMA	**0.137MG/SPRAY**		**A091444**	**001**	Oct 24, 2014
AB	SUN PHARM	**0.137MG/SPRAY**		**A090423**	**001**	May 23, 2012
AB	UPSHER SMITH LABS	**0.137MG/SPRAY**		**A202609**	**001**	Mar 17, 2017
AB	ZYDUS PHARMS	**0.137MG/SPRAY**		**A091409**	**001**	Aug 14, 2017

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB	**!** APOTEX	**0.137MG/SPRAY;0.05MG/SPRAY**		**A207712**	**001**	Apr 28, 2017
AB	PADAGIS ISRAEL	**0.137MG/SPRAY;0.05MG/SPRAY**		**A208111**	**001**	Feb 18, 2021

DYMISTA

AB	**+** MYLAN SPECIALITY LP	**0.137MG/SPRAY;0.05MG/SPRAY**		**N202236**	**001**	May 01, 2012

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

+	AZURITY	EQ 40MG MEDOXOMIL		N200796	001	Feb 25, 2011
+!		EQ 80MG MEDOXOMIL		N200796	002	Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

+	AZURITY	EQ 40MG MEDOXOMIL;12.5MG		N202331	001	Dec 20, 2011
+!		EQ 40MG MEDOXOMIL;25MG		N202331	002	Dec 20, 2011

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB	AMNEAL	**EQ 100MG BASE/5ML**		**A205666**	**001**	Jul 19, 2018
AB		**EQ 200MG BASE/5ML**		**A205666**	**002**	Jul 19, 2018
AB	AUROBINDO PHARMA LTD	**EQ 100MG BASE/5ML**		**A209201**	**001**	Oct 09, 2018
AB		**EQ 200MG BASE/5ML**		**A209201**	**002**	Oct 09, 2018
AB	EPIC PHARMA LLC	**EQ 100MG BASE/5ML**		**A207531**	**001**	Apr 09, 2018
AB		**EQ 200MG BASE/5ML**		**A207531**	**002**	Apr 09, 2018
AB	HAINAN POLY	**EQ 100MG BASE/5ML**		**A217036**	**001**	Jul 27, 2023
AB		**EQ 200MG BASE/5ML**		**A217036**	**002**	Jul 27, 2023
AB	PLIVA	**EQ 100MG BASE/5ML**		**A065246**	**002**	Jul 05, 2006
AB		**EQ 200MG BASE/5ML**		**A065246**	**001**	Jul 05, 2006
AB	ZYDUS	**EQ 100MG BASE/5ML**		**A211147**	**001**	Jul 31, 2018

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB			**EQ 200MG BASE/5ML**	**A211147**	**002**	Jul 31, 2018

ZITHROMAX

AB	**+**	PFIZER	**EQ 100MG BASE/5ML**	**N050710**	**001**	Oct 19, 1995
AB	**+!**		**EQ 200MG BASE/5ML**	**N050710**	**002**	Oct 19, 1995
	+!		EQ 1GM BASE/PACKET	N050693	001	Sep 28, 1994

INJECTABLE;INJECTION

AZITHROMYCIN

AP		EUGIA PHARMA	**EQ 500MG BASE/VIAL**	**A203294**	**001**	Jun 19, 2015
AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A065179**	**001**	Dec 13, 2005
AP		GLAND PHARMA LTD	**EQ 500MG BASE/VIAL**	**A065501**	**001**	Nov 09, 2009
AP		HOSPIRA	**EQ 500MG BASE/VIAL**	**A065500**	**001**	Jun 26, 2009
AP			**EQ 500MG BASE/VIAL**	**A065511**	**001**	Jun 26, 2009
AP		SLATE RUN PHARMA	**EQ 500MG BASE/VIAL**	**A203412**	**001**	Oct 09, 2018
AP		SUN PHARM INDS LTD	**EQ 500MG BASE/VIAL**	**A090923**	**001**	Apr 02, 2013

ZITHROMAX

AP	**+!**	PFIZER	**EQ 500MG BASE/VIAL**	**N050733**	**001**	Jan 30, 1997

SOLUTION/DROPS;OPHTHALMIC

AZASITE

	+!	THEA PHARMA	1%	N050810	001	Apr 27, 2007

TABLET;ORAL

AZITHROMYCIN

AB		ACI	**EQ 250MG BASE**	**A215772**	**001**	Jul 15, 2022
AB			**EQ 500MG BASE**	**A215773**	**001**	Jul 12, 2022
AB		ALEMBIC	**EQ 250MG BASE**	**A211791**	**001**	Jan 28, 2020
AB			**EQ 500MG BASE**	**A211792**	**001**	Jan 28, 2020
AB			**EQ 600MG BASE**	**A211793**	**001**	Jan 27, 2020
AB		AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A207370**	**001**	Jul 05, 2018
AB			**EQ 500MG BASE**	**A207398**	**001**	Jul 05, 2018
AB		BIONPHARMA	**EQ 250MG BASE**	**A210000**	**001**	Feb 26, 2019
AB			**EQ 500MG BASE**	**A210001**	**001**	Feb 26, 2019
AB			**EQ 600MG BASE**	**A209999**	**001**	Dec 26, 2018
AB		CHARTWELL RX	**EQ 250MG BASE**	**A065404**	**001**	Feb 11, 2008
AB			**EQ 500MG BASE**	**A065405**	**001**	Feb 11, 2008
AB			**EQ 600MG BASE**	**A065302**	**003**	Feb 11, 2008
AB		CSPC OUYI	**EQ 250MG BASE**	**A208250**	**001**	Apr 17, 2019
AB			**EQ 500MG BASE**	**A208249**	**001**	Oct 25, 2018
AB			**EQ 600MG BASE**	**A207566**	**001**	Sep 24, 2018
AB		LUPIN LTD	**EQ 250MG BASE**	**A065398**	**001**	May 15, 2015
AB			**EQ 500MG BASE**	**A065399**	**001**	May 15, 2015
AB			**EQ 600MG BASE**	**A065400**	**001**	May 15, 2015
AB		PLIVA	**EQ 250MG BASE**	**A065225**	**001**	Nov 14, 2005
AB			**EQ 500MG BASE**	**A065223**	**001**	Nov 14, 2005
AB	**!**		**EQ 600MG BASE**	**A065218**	**001**	Nov 14, 2005
AB		SANDOZ	**EQ 250MG BASE**	**A065211**	**001**	Nov 14, 2005
AB			**EQ 500MG BASE**	**A065212**	**001**	Nov 14, 2005
AB			**EQ 600MG BASE**	**A065209**	**001**	Nov 14, 2005
AB		SUNSHINE	**EQ 250MG BASE**	**A209045**	**001**	Dec 07, 2018
AB			**EQ 500MG BASE**	**A209044**	**001**	Dec 07, 2018
AB			**EQ 600MG BASE**	**A209043**	**001**	Dec 06, 2018
AB		TEVA	**EQ 500MG BASE**	**A065193**	**001**	Nov 14, 2005
AB		YUNG SHIN PHARM	**EQ 250MG BASE**	**A211317**	**001**	Jul 26, 2022
AB			**EQ 600MG BASE**	**A211068**	**001**	May 08, 2020

ZITHROMAX

AB	**+**	PFIZER	**EQ 250MG BASE**	**N050711**	**001**	Jul 18, 1996
AB	**+**		**EQ 500MG BASE**	**N050784**	**001**	May 24, 2002

AZTREONAM

FOR SOLUTION;INHALATION

CAYSTON

	+!	GILEAD	75MG/VIAL	N050814	001	Feb 22, 2010

INJECTABLE;INJECTION

AZACTAM

AP	**+!**	BRISTOL MYERS SQUIBB	**1GM/VIAL**	**N050580**	**002**	Dec 31, 1986
AP	**+!**		**2GM/VIAL**	**N050580**	**003**	Dec 31, 1986

AZTREONAM

AP		FRESENIUS KABI USA	**1GM/VIAL**	**A065439**	**002**	Jun 18, 2010
AP			**2GM/VIAL**	**A065439**	**003**	Jun 18, 2010
AP		HOSPIRA	**1GM/VIAL**	**A206517**	**001**	Nov 08, 2021

AZTREONAM

INJECTABLE;INJECTION

AZTREONAM

AP			**2GM/VIAL**	**A206517**	**002**	Nov 08, 2021
		FRESENIUS KABI USA	500MG/VIAL	A065439	001	Jun 18, 2010

BACITRACIN

OINTMENT;OPHTHALMIC

BACITRACIN

	!	PADAGIS US	500 UNITS/GM	A061212	001	

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	!	PADAGIS US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

	!	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

LUMI-SPORYN

AT	**+**	CASPER PHARMA LLC	**EQ 400 UNITS/GM;EQ 3.5MG BASE/GM;EQ 10,000 UNITS/GM**	**N050417**	**001**	

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	**!**	BAUSCH AND LOMB	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064064**	**001**	Oct 30, 1995
AT		PADAGIS US	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A060764**	**002**	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		AKORN	**500 UNITS/GM;10,000 UNITS/GM**	**A064028**	**001**	Jan 30, 1995
AT	**!**	BAUSCH AND LOMB	**500 UNITS/GM;10,000 UNITS/GM**	**A064046**	**001**	Jan 26, 1995
AT		PADAGIS US	**500 UNITS/GM;10,000 UNITS/GM**	**A065022**	**001**	Feb 27, 2002

BACLOFEN

GRANULES;ORAL

LYVISPAH

	+	AMNEAL	5MG/PACKET	N215422	001	Nov 22, 2021
	+		10MG/PACKET	N215422	002	Nov 22, 2021
	+!		20MG/PACKET	N215422	003	Nov 22, 2021

INJECTABLE;INTRATHECAL

BACLOFEN

AP		ACIC PHARMS	**0.5MG/ML**	**A216309**	**001**	Aug 10, 2023
AP			**2MG/ML**	**A216309**	**002**	Aug 10, 2023
AP		AMNEAL	**0.05MG/ML**	**A091193**	**001**	May 03, 2016
AP			**0.5MG/ML**	**A091193**	**002**	May 03, 2016
AP			**2MG/ML**	**A091193**	**003**	May 03, 2016
AP		MAIA PHARMS INC	**0.05MG/ML**	**A210777**	**001**	Jan 15, 2021
AP			**0.5MG/ML**	**A210048**	**001**	Sep 11, 2019
AP			**1MG/ML**	**A210315**	**001**	Jul 30, 2019
AP			**2MG/ML**	**A210048**	**002**	Sep 11, 2019
AP		MYLAN LABS LTD	**0.5MG/ML**	**A209592**	**001**	Mar 21, 2018
AP			**1MG/ML**	**A209594**	**001**	Mar 06, 2018
AP			**2MG/ML**	**A209592**	**002**	Mar 21, 2018
AP		RUBICON	**0.5MG/ML**	**A217324**	**001**	Feb 22, 2023
AP			**1MG/ML**	**A217324**	**002**	Feb 22, 2023
AP			**2MG/ML**	**A217324**	**003**	Feb 22, 2023

GABLOFEN

AP	**+!**	PIRAMAL CRITICAL	**0.05MG/ML**	**N022462**	**001**	Nov 19, 2010
AP	**+!**		**0.5MG/ML**	**N022462**	**002**	Nov 19, 2010
AP	**+!**		**1MG/ML**	**N022462**	**004**	Jun 22, 2012
AP	**+!**		**2MG/ML**	**N022462**	**003**	Nov 19, 2010

LIORESAL

AP	**+!**	AMNEAL	**0.05MG/ML**	**N020075**	**003**	Nov 07, 1996
AP	**+!**		**0.5MG/ML**	**N020075**	**001**	Jun 17, 1992
AP	**+!**		**2MG/ML**	**N020075**	**002**	Jun 17, 1992

SOLUTION;ORAL

OZOBAX DS

	+!	METACEL PHARMS LLC	10MG/5ML	N208193	002	Oct 12, 2023

BACLOFEN

SUSPENSION;ORAL

BACLOFEN

AB		ANI PHARMS	**25MG/5ML**	**A217252**	**001**	Jun 08, 2023

FLEQSUVY

AB	**+!**	AZURITY	**25MG/5ML**	**N215602**	**001**	Feb 04, 2022

TABLET;ORAL

BACLOFEN

AB		AURO BINDO PHARMA LTD	**10MG**	**A214099**	**001**	Jul 13, 2021
AB			**20MG**	**A214099**	**002**	Jul 13, 2021
AB		BEXIMCO PHARMS USA	**5MG**	**A214114**	**003**	Sep 19, 2023
AB			**10MG**	**A214114**	**001**	Jul 16, 2021
AB			**20MG**	**A214114**	**002**	Jul 16, 2021
AB		EYWA PHARMA	**5MG**	**A211555**	**003**	Nov 30, 2021
AB			**10MG**	**A211555**	**001**	Feb 01, 2019
AB			**20MG**	**A211555**	**002**	Feb 01, 2019
AB		GRAVITI PHARMS	**10MG**	**A217788**	**001**	Jan 10, 2024
AB			**20MG**	**A217788**	**002**	Jan 10, 2024
AB		IMPAX	**5MG**	**A077971**	**003**	Jul 07, 2021
AB			**10MG**	**A077971**	**001**	Oct 26, 2007
AB			**20MG**	**A077971**	**002**	Oct 26, 2007
AB		INNOGENIX	**5MG**	**A212378**	**003**	Apr 30, 2021
AB			**10MG**	**A212378**	**001**	Oct 09, 2020
AB			**20MG**	**A212378**	**002**	Oct 09, 2020
AB		IVAX SUB TEVA PHARMS	**10MG**	**A072234**	**001**	Jul 21, 1988
AB	**!**		**20MG**	**A072235**	**001**	Jul 21, 1988
AB		LANNETT CO INC	**5MG**	**A077241**	**003**	Sep 22, 2021
AB			**10MG**	**A077241**	**002**	Jul 06, 2007
AB			**20MG**	**A077241**	**001**	Dec 20, 2005
AB		MANKIND PHARMA	**5MG**	**A215885**	**001**	Jan 25, 2022
AB			**10MG**	**A215885**	**002**	Jan 25, 2022
AB			**20MG**	**A215885**	**003**	Jan 25, 2022
AB		MICRO LABS	**5MG**	**A217687**	**001**	Nov 08, 2023
AB			**10MG**	**A217687**	**002**	Nov 08, 2023
AB			**20MG**	**A217687**	**003**	Nov 08, 2023
AB		NORTHSTAR HLTHCARE	**10MG**	**A078401**	**002**	Sep 18, 2009
AB			**20MG**	**A078401**	**001**	Sep 18, 2009
AB		OXFORD PHARMS	**10MG**	**A077088**	**002**	Oct 31, 2007
AB			**20MG**	**A077088**	**001**	Oct 31, 2007
AB		RISING	**5MG**	**A214374**	**001**	Mar 05, 2021
AB			**10MG**	**A214374**	**002**	Mar 05, 2021
AB			**20MG**	**A214374**	**003**	Mar 05, 2021
AB	**!**	RUBICON	**5MG**	**A209102**	**001**	Nov 28, 2017
AB			**10MG**	**A209102**	**002**	Nov 28, 2017
AB			**20MG**	**A209102**	**003**	Nov 28, 2017
AB		UNICHEM	**5MG**	**A212067**	**003**	Mar 09, 2023
AB			**10MG**	**A212067**	**001**	Jul 09, 2020
AB			**20MG**	**A212067**	**002**	Jul 09, 2020
AB		UPSHER SMITH LABS	**10MG**	**A074584**	**001**	Aug 19, 1996
AB			**20MG**	**A074584**	**002**	Aug 19, 1996
AB		VINTAGE PHARMS	**10MG**	**A077068**	**002**	Aug 30, 2005
AB			**20MG**	**A077068**	**001**	Aug 30, 2005
AB		ZYDUS	**5MG**	**A211659**	**003**	Apr 17, 2020
AB			**10MG**	**A211659**	**001**	Nov 23, 2018
AB			**20MG**	**A211659**	**002**	Nov 23, 2018

BALOXAVIR MARBOXIL

FOR SUSPENSION;ORAL

XOFLUZA

	+!	GENENTECH INC	2MG/ML	N214410	001	Nov 23, 2020

TABLET;ORAL

XOFLUZA

	+	GENENTECH INC	40MG	N210854	002	Oct 24, 2018
	+!		80MG	N210854	003	Mar 18, 2021

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB		APOTEX INC	**750MG**	**A077883**	**001**	Dec 28, 2007
AB		HIKMA	**750MG**	**A077806**	**001**	Dec 28, 2007
AB		ZYDUS	**750MG**	**A217592**	**001**	Jun 08, 2023

BALSALAZIDE DISODIUM
CAPSULE;ORAL
COLAZAL

AB	**+!**	VALEANT PHARMS INTL	**750MG**	**N020610**	**001**	Jul 18, 2000

BARICITINIB
TABLET;ORAL
OLUMIANT

	+	ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019
	+		2MG	N207924	001	May 31, 2018
	+!		4MG	N207924	003	May 10, 2022

BARIUM SULFATE
FOR SUSPENSION;ORAL
E-Z-HD

	+!	BRACCO	98% (334GM/BOT)	N208036	001	Jan 11, 2016

E-Z-PAQUE

	+!	BRACCO	96% (169GM/BOT)	N208036	002	Apr 07, 2017

VARIBAR THIN LIQUID

	+!	BRACCO	81% (120GM/BOT)	N208036	004	Apr 30, 2019

PASTE;ORAL
VARIBAR PUDDING

		BRACCO	40%	N208844	001	Oct 14, 2016

SUSPENSION;ORAL
ENTERO VU 24%

	+!	BRACCO	24% (144GM/600ML)	N208143	008	May 29, 2020

LIQUID E-Z-PAQUE

	+!	BRACCO	60% (213GM/BOT)	N208143	003	Mar 01, 2017

READI-CAT 2

	+!	BRACCO	2% (9GM/BOT)	N208143	001	Jan 15, 2016

READI-CAT 2 SMOOTHIE

	+!	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016

TAGITOL V

	+!	BRACCO	40% (8GM/BOT)	N208143	005	Aug 04, 2017

VARIBAR HONEY

	+!	BRACCO	40% (100GM/250ML)	N208143	007	Mar 26, 2018

VARIBAR NECTAR

	+!	BRACCO	40% (96GM/240ML)	N208143	004	Jul 07, 2017

VARIBAR THIN HONEY

	+!	BRACCO	40% (100GM/250ML)	N208143	006	Jan 23, 2018

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
TABLET;ORAL
DUAVEE

	+!	WYETH PHARMS	EQ 20MG BASE;0.45MG	N022247	001	Oct 03, 2013

BECLOMETHASONE DIPROPIONATE
AEROSOL, METERED;INHALATION
QVAR REDIHALER

	+	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017
	+		0.08MG/INH	N207921	002	Aug 03, 2017

AEROSOL, METERED;NASAL
QNASL

	+	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813	002	Dec 17, 2014
	+!		0.08MG/ACTUATION	N202813	001	Mar 23, 2012

BEDAQUILINE FUMARATE
TABLET;ORAL
SIRTURO

	+	JANSSEN THERAP	EQ 20MG BASE	N204384	002	May 27, 2020
	+!		EQ 100MG BASE	N204384	001	Dec 28, 2012

BELINOSTAT
POWDER;INTRAVENOUS
BELEODAQ

	+!	ACROTECH BIOPHARMA	500MG/VIAL	N206256	001	Jul 03, 2014

BELUMOSUDIL MESYLATE
TABLET;ORAL
REZUROCK

	+!	KADMON PHARMS LLC	EQ 200MG BASE	N214783	001	Jul 16, 2021

BELZUTIFAN

TABLET;ORAL

WELIREG

+!	MERCK SHARP DOHME	40MG	N215383	001	Aug 13, 2021

BEMPEDOIC ACID

TABLET;ORAL

NEXLETOL

+!	ESPERION THERAPS INC	180MG	N211616	001	Feb 21, 2020

BEMPEDOIC ACID; EZETIMIBE

TABLET;ORAL

NEXLIZET

+!	ESPERION THERAPS INC	180MG;10MG	N211617	001	Feb 26, 2020

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB		AMNEAL PHARMS	**5MG**	**A076820**	**001**	Feb 03, 2006
AB			**10MG**	**A076820**	**002**	Feb 03, 2006
AB			**20MG**	**A076820**	**003**	Feb 03, 2006
AB			**40MG**	**A076820**	**004**	Feb 03, 2006
AB		ANI PHARMS	**5MG**	**A076333**	**001**	Feb 11, 2004
AB			**10MG**	**A076333**	**002**	Feb 11, 2004
AB			**20MG**	**A076333**	**003**	Feb 11, 2004
AB			**40MG**	**A076333**	**004**	Feb 11, 2004
AB		AUROBINDO PHARMA	**10MG**	**A078212**	**001**	May 22, 2008
AB			**20MG**	**A078212**	**002**	May 22, 2008
AB	!		**40MG**	**A078212**	**003**	May 22, 2008
AB		CADILA	**5MG**	**A078848**	**001**	May 23, 2008
AB			**10MG**	**A078848**	**002**	May 23, 2008
AB			**20MG**	**A078848**	**003**	May 23, 2008
AB			**40MG**	**A078848**	**004**	May 23, 2008
AB		CHARTWELL RX	**5MG**	**A076402**	**001**	Feb 11, 2004
AB			**10MG**	**A076402**	**002**	Feb 11, 2004
AB			**20MG**	**A076402**	**003**	Feb 11, 2004
AB			**40MG**	**A076402**	**004**	Feb 11, 2004
AB		COREPHARMA	**5MG**	**A077128**	**001**	Mar 08, 2006
AB			**10MG**	**A077128**	**002**	Mar 08, 2006
AB			**20MG**	**A077128**	**003**	Mar 08, 2006
AB			**40MG**	**A077128**	**004**	Mar 08, 2006
AB		HERITAGE PHARMA	**5MG**	**A076267**	**001**	Feb 11, 2004
AB			**10MG**	**A076267**	**002**	Feb 11, 2004
AB			**20MG**	**A076267**	**003**	Feb 11, 2004
AB			**40MG**	**A076267**	**004**	Feb 11, 2004
AB		PRINSTON INC	**5MG**	**A076118**	**001**	Feb 11, 2004
AB			**10MG**	**A076118**	**002**	Feb 11, 2004
AB			**20MG**	**A076118**	**003**	Feb 11, 2004
AB			**40MG**	**A076118**	**004**	Feb 11, 2004
AB		SUN PHARM INDS LTD	**5MG**	**A076344**	**001**	Feb 11, 2004
AB			**10MG**	**A076344**	**002**	Feb 11, 2004
AB			**20MG**	**A076344**	**003**	Feb 11, 2004
AB			**40MG**	**A076344**	**004**	Feb 11, 2004
AB		TEVA	**5MG**	**A076211**	**001**	Feb 11, 2004
AB			**10MG**	**A076211**	**002**	Feb 11, 2004
AB			**20MG**	**A076211**	**003**	Feb 11, 2004
AB			**40MG**	**A076211**	**004**	Feb 11, 2004

LOTENSIN

AB	+	VALIDUS PHARMS	**10MG**	**N019851**	**002**	Jun 25, 1991
AB	+		**20MG**	**N019851**	**003**	Jun 25, 1991
AB	+		**40MG**	**N019851**	**004**	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		ANI PHARMS	**5MG;6.25MG**	**A076342**	**001**	Feb 11, 2004
AB			**10MG;12.5MG**	**A076342**	**002**	Feb 11, 2004
AB			**20MG;12.5MG**	**A076342**	**003**	Feb 11, 2004
AB			**20MG;25MG**	**A076342**	**004**	Feb 11, 2004
AB		APOTEX	**5MG;6.25MG**	**A078794**	**001**	Aug 21, 2014
AB			**10MG;12.5MG**	**A078794**	**002**	Aug 21, 2014
AB			**20MG;12.5MG**	**A078794**	**003**	Aug 21, 2014
AB			**20MG;25MG**	**A078794**	**004**	Aug 21, 2014

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		SANDOZ	**5MG;6.25MG**	**A076631**	**001**	Feb 11, 2004
AB			**10MG;12.5MG**	**A076631**	**002**	Feb 11, 2004
AB			**20MG;12.5MG**	**A076631**	**003**	Feb 11, 2004
AB			**20MG;25MG**	**A076631**	**004**	Feb 11, 2004

LOTENSIN HCT

AB	+	VALIDUS PHARMS	**10MG;12.5MG**	**N020033**	**002**	May 19, 1992
AB	+		**20MG;12.5MG**	**N020033**	**004**	May 19, 1992
AB	+!		**20MG;25MG**	**N020033**	**003**	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	**25MG/VIAL**	**A205574**	**001**	Dec 07, 2022
AP			**100MG/VIAL**	**A205574**	**002**	Dec 07, 2022
AP		APOTEX	**25MG/VIAL**	**A204230**	**001**	Jun 05, 2023
AP			**100MG/VIAL**	**A204230**	**002**	Jun 05, 2023
AP		BRECKENRIDGE	**25MG/VIAL**	**A205447**	**001**	Feb 14, 2023
AP			**100MG/VIAL**	**A205447**	**002**	Feb 14, 2023
AP		DR REDDYS	**25MG/VIAL**	**A205376**	**001**	Dec 07, 2022
AP			**100MG/VIAL**	**A205376**	**002**	Dec 07, 2022
AP		EUGIA PHARMA	**25MG/VIAL**	**A214739**	**001**	Jun 05, 2023
AP			**100MG/VIAL**	**A214739**	**002**	Jun 05, 2023
AP		KINDOS	**25MG/VIAL**	**A211001**	**001**	Jun 05, 2023
AP			**100MG/VIAL**	**A211001**	**002**	Jun 05, 2023

TREANDA

AP	+!	CEPHALON	**25MG/VIAL**	**N022249**	**002**	May 01, 2009
AP	+!		**100MG/VIAL**	**N022249**	**001**	Mar 20, 2008

SOLUTION;INTRAVENOUS

BELRAPZO

AP	+!	EAGLE PHARMS	**100MG/4ML (25MG/ML)**	**N205580**	**001**	May 15, 2018

BENDAMUSTINE HYDROCHLORIDE

AP	+!	APOTEX	**100MG/4ML (25MG/ML)**	**N215033**	**001**	Dec 07, 2022
AP	+!	BAXTER HLTHCARE CORP	**100MG/4ML (25MG/ML)**	**N216078**	**001**	Dec 15, 2022

VIVIMUSTA

	+!	SLAYBACK PHARMA LLC	100MG/4ML (25MG/ML)	N212209	001	Dec 07, 2022

SOLUTION;IV (INFUSION)

BENDEKA

	+!	EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC

ALTAFLUOR BENOX

	+!	ALTAIRE PHARMS INC	0.4%;0.25%	N208582	001	Dec 14, 2017

FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE

	+!	BAUSCH LOMB IRELAND	0.4%;0.3%	N211039	001	Mar 09, 2020

BENZNIDAZOLE

TABLET;ORAL

BENZNIDAZOLE

	+	CHEMO RESEARCH SL	12.5MG	N209570	001	Aug 29, 2017
	+!		100MG	N209570	002	Aug 29, 2017

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA		ACELLA	**100MG**	**A091310**	**001**	Jan 16, 2015
AA			**200MG**	**A091310**	**002**	Jan 16, 2015
AA		ASCENT PHARMS INC	**100MG**	**A211518**	**001**	Feb 22, 2019
AA			**200MG**	**A211518**	**003**	Feb 22, 2019
AA		BIONPHARMA	**100MG**	**A081297**	**001**	Jan 29, 1993
AA			**200MG**	**A081297**	**002**	Oct 30, 2007
AA		CSPC-NBP PHARM	**100MG**	**A202765**	**002**	Aug 25, 2017
AA			**200MG**	**A202765**	**001**	Jul 31, 2015
AA		HERITAGE PHARMS LABS	**100MG**	**A040682**	**001**	Jul 30, 2007
AA			**200MG**	**A040682**	**002**	Jul 30, 2007
AA	!	PURACAP PHARM LLC	**100MG**	**A206948**	**001**	Dec 19, 2018
AA	!		**200MG**	**A206948**	**002**	Dec 19, 2018
AA		STRIDES PHARMA	**100MG**	**A091133**	**001**	Jul 30, 2015
AA			**200MG**	**A091133**	**002**	Jul 30, 2015
AA		ZYDUS PHARMS USA	**100MG**	**A040597**	**001**	Jun 08, 2007

BENZONATATE						
CAPSULE;ORAL						
BENZONATATE						
AA			**200MG**	**A040597**	**002**	Jun 08, 2007
TESSALON						
AA	**+**	PFIZER	**100MG**	**N011210**	**001**	
BENZONATATE						
		ASCENT PHARMS INC	150MG	A211518	002	Feb 22, 2019
BENZOYL PEROXIDE						
CREAM;TOPICAL						
EPSOLAY						
	+!	GALDERMA LABS LP	5%	N214510	001	Apr 22, 2022
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE						
GEL;TOPICAL						
ACANYA						
AB	**+!**	BAUSCH	**2.5%;EQ 1.2% BASE**	**N050819**	**001**	Oct 23, 2008
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE						
AB		ACTAVIS LABS UT INC	**2.5%;EQ 1.2% BASE**	**A205128**	**001**	Jun 19, 2015
AB		ENCUBE	**5%;1.2%**	**A212433**	**001**	Apr 28, 2021
AB	**!**	GLENMARK PHARMS	**5%;EQ 1% BASE**	**A209252**	**001**	Mar 14, 2019
AB		MYLAN PHARMS INC	**5%;EQ 1% BASE**	**A065443**	**001**	Aug 11, 2009
AB		PADAGIS ISRAEL	**2.5%;EQ 1.2% BASE**	**A205397**	**001**	Sep 09, 2019
AB			**5%;EQ 1% BASE**	**A202440**	**001**	Sep 21, 2015
AB	**!**		**5%;1.2%**	**A090979**	**001**	Jun 26, 2012
AB		TARO	**2.5%;EQ 1.2% BASE**	**A206575**	**001**	Aug 19, 2019
AB			**3.75%;EQ 1.2% BASE**	**A208683**	**001**	Jun 05, 2018
AB			**5%;EQ 1% BASE**	**A208776**	**001**	May 25, 2018
AB			**5%;1.2%**	**A206218**	**001**	Dec 15, 2017
AB		ZYDUS PHARMS	**5%;1.2%**	**A210794**	**001**	Dec 28, 2018
DUAC						
AB	**+**	STIEFEL	**5%;1.2%**	**N050741**	**001**	Aug 26, 2002
ONEXTON						
AB	**+!**	BAUSCH	**3.75%;EQ 1.2% BASE**	**N050819**	**002**	Nov 24, 2014
BENZOYL PEROXIDE; ERYTHROMYCIN						
GEL;TOPICAL						
BENZAMYCIN						
AB	**+!**	VALEANT INTL	**5%;3%**	**N050557**	**001**	Oct 26, 1984
ERYTHROMYCIN AND BENZOYL PEROXIDE						
AB		LYNE	**5%;3%**	**A065385**	**001**	Sep 18, 2015
BENZOYL PEROXIDE; TRETINOIN						
CREAM;TOPICAL						
TWYNEO						
	+!	GALDERMA LABS LP	3%;0.1%	N214902	001	Jul 26, 2021
BENZPHETAMINE HYDROCHLORIDE						
TABLET;ORAL						
BENZPHETAMINE HYDROCHLORIDE						
AA		CHARTWELL	**50MG**	**A090473**	**002**	Sep 15, 2010
AA		EPIC PHARMA LLC	**50MG**	**A090346**	**001**	Dec 15, 2015
AA	**!**	KVK TECH	**50MG**	**A090968**	**001**	Jul 20, 2010
		CHARTWELL	25MG	A090473	001	Sep 15, 2010
BENZTROPINE MESYLATE						
INJECTABLE;INJECTION						
BENZTROPINE MESYLATE						
AP		FRESENIUS KABI USA	**1MG/ML**	**A090233**	**001**	Jul 28, 2009
AP		HIKMA	**1MG/ML**	**A209442**	**001**	Oct 14, 2021
AP	**!**	HIKMA FARMACEUTICA	**1MG/ML**	**A090287**	**001**	Aug 31, 2009
AP		NAVINTA LLC	**1MG/ML**	**A091525**	**001**	Feb 05, 2013
TABLET;ORAL						
BENZTROPINE MESYLATE						
AA	**!**	ASPEN GLOBAL INC	**0.5MG**	**A204713**	**001**	Apr 14, 2015
AA	**!**		**1MG**	**A204713**	**002**	Apr 14, 2015
AA	**!**		**2MG**	**A204713**	**003**	Apr 14, 2015
AA		CHARTWELL RX	**0.5MG**	**A081265**	**003**	Nov 29, 2023
AA			**1MG**	**A081265**	**002**	Jan 23, 1992
AA			**2MG**	**A081265**	**001**	Jan 23, 1992
AA		EPIC PHARMA LLC	**0.5MG**	**A072264**	**001**	Feb 27, 1989
AA			**1MG**	**A072265**	**001**	Feb 27, 1989
AA			**2MG**	**A072266**	**001**	Feb 27, 1989
AA		INVAGEN PHARMS	**0.5MG**	**A090294**	**001**	Mar 29, 2010

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

AA			**1MG**	**A090294**	**002**	Mar 29, 2010
AA			**2MG**	**A090294**	**003**	Mar 29, 2010
AA		LEADING	**0.5MG**	**A090168**	**001**	Nov 28, 2012
AA			**1MG**	**A090168**	**002**	Nov 28, 2012
AA			**2MG**	**A090168**	**003**	Nov 28, 2012
AA		PLIVA	**0.5MG**	**A089058**	**001**	Aug 10, 1988
AA			**1MG**	**A089059**	**001**	Aug 10, 1988
AA			**2MG**	**A089060**	**001**	Aug 10, 1988
AA		VINTAGE	**0.5MG**	**A040715**	**001**	Aug 27, 2007
AA			**1MG**	**A040715**	**002**	Aug 27, 2007
AA			**2MG**	**A040715**	**003**	Aug 27, 2007

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

AT		ALEMBIC	**1.5%**	**A214588**	**001**	Apr 05, 2023
AT		APOTEX	**1.5%**	**A206066**	**001**	Mar 05, 2019
AT		MYLAN	**1.5%**	**A206220**	**001**	Mar 18, 2019

BEPREVE

AT	**+!**	BAUSCH AND LOMB INC	**1.5%**	**N022288**	**001**	Sep 08, 2009

BEROTRALSTAT HYDROCHLORIDE

CAPSULE;ORAL

ORLADEYO

	+	BIOCRYST	EQ 110MG BASE	N214094	001	Dec 03, 2020
	+!		EQ 150MG BASE	N214094	002	Dec 03, 2020

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS;OPHTHALMIC

BESIVANCE

	+!	BAUSCH AND LOMB	EQ 0.6% BASE	N022308	001	May 28, 2009

BETAINE

FOR SOLUTION;ORAL

BETAINE

AB		ETON	**1GM/SCOOPFUL**	**A210508**	**001**	Jan 28, 2022
AB		NOVITIUM PHARMA	**1GM/SCOOPFUL**	**A214864**	**001**	Nov 23, 2021

CYSTADANE

AB	**+!**	RECORDATI RARE	**1GM/SCOOPFUL**	**N020576**	**001**	Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB		AM REGENT	**3MG/ML;EQ 3MG BASE/ML**	**A090747**	**001**	Jul 31, 2009
AB		HIKMA	**3MG/ML;EQ 3MG BASE/ML**	**A077838**	**001**	Jan 17, 2023

CELESTONE SOLUSPAN

AB	**+!**	ORGANON	**3MG/ML;EQ 3MG BASE/ML**	**N014602**	**001**	

BETAMETHASONE DIPROPIONATE

CREAM;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A070885**	**001**	Feb 03, 1987
AB		COSETTE	**EQ 0.05% BASE**	**A210217**	**001**	Oct 12, 2018
AB	**+!**	FOUGERA PHARMS	**EQ 0.05% BASE**	**N019137**	**001**	Jun 26, 1984
AB		TARO	**EQ 0.05% BASE**	**A073552**	**001**	Apr 30, 1992
AB		ZYDUS PHARMS	**EQ 0.05% BASE**	**A208885**	**001**	Jan 11, 2019

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A076215**	**001**	Dec 09, 2003
AB	**!**	GLENMARK GENERICS	**EQ 0.05% BASE**	**A078930**	**001**	Sep 23, 2008
AB		PADAGIS ISRAEL	**EQ 0.05% BASE**	**A076592**	**001**	Dec 09, 2003
AB		TARO	**EQ 0.05% BASE**	**A076543**	**001**	Dec 09, 2003

GEL, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	**!**	FOUGERA PHARMS	**EQ 0.05% BASE**	**A075276**	**001**	May 13, 2003
AB		TARO	**EQ 0.05% BASE**	**A076508**	**001**	Dec 02, 2003

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		COSETTE	**EQ 0.05% BASE**	**A071467**	**001**	Aug 10, 1987
AB	**!**	FOUGERA PHARMS INC	**EQ 0.05% BASE**	**A070275**	**001**	Aug 12, 1985
AB		PADAGIS US	**EQ 0.05% BASE**	**A072538**	**001**	Jan 31, 1990

BETAMETHASONE DIPROPIONATE

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A077111**	**001**	May 21, 2007
AB		HIKMA	**EQ 0.05% BASE**	**A208849**	**001**	Oct 11, 2019
AB	**!**	TARO	**EQ 0.05% BASE**	**A077477**	**001**	May 21, 2007

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A071012**	**001**	Feb 03, 1987
AB		CADILA	**EQ 0.05% BASE**	**A214048**	**001**	Jul 14, 2020
AB	**+!**	FOUGERA PHARMS INC	**EQ 0.05% BASE**	**N019141**	**001**	Sep 04, 1984
AB		PADAGIS ISRAEL	**EQ 0.05% BASE**	**A215847**	**001**	Apr 12, 2022
AB		TARO	**EQ 0.05% BASE**	**A074271**	**001**	Sep 15, 1994
AB		TASMAN PHARMA	**EQ 0.05% BASE**	**A215186**	**001**	Feb 18, 2022

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A074304**	**001**	Aug 31, 1995
AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A075373**	**001**	Jun 22, 1999
AB		LUPIN LTD	**EQ 0.05% BASE**	**A209106**	**001**	Dec 18, 2019
AB		TARO	**EQ 0.05% BASE**	**A076753**	**001**	Oct 12, 2004

DIPROLENE

AB	**+!**	ORGANON	**EQ 0.05% BASE**	**N018741**	**001**	Jul 27, 1983

SPRAY;TOPICAL

SERNIVO

	+!	PRIMUS PHARMS	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB		GLENMARK PHARMS LTD	**0.064%;0.005%**	**A214688**	**001**	Mar 21, 2023

ENSTILAR

AB	**+!**	LEO PHARMA AS	**0.064%;0.005%**	**N207589**	**001**	Oct 16, 2015

CREAM;TOPICAL

WYNZORA

	+!	MC2	0.064%;0.005%	N213422	001	Jul 20, 2020

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB		PADAGIS ISRAEL	**0.064%;0.005%**	**A200174**	**001**	Dec 12, 2014

TACLONEX

AB	**+!**	LEO PHARMA AS	**0.064%;0.005%**	**N021852**	**001**	Jan 09, 2006

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB		COSETTE	**0.064%;0.005%**	**A210765**	**001**	May 11, 2020
AB		TARO	**0.064%;0.005%**	**A213269**	**001**	Sep 02, 2020

CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE

AB		PADAGIS ISRAEL	**0.064%;0.005%**	**A212367**	**001**	Sep 11, 2020

TACLONEX

AB	**+!**	LEO PHARMA AS	**0.064%;0.005%**	**N022185**	**001**	May 09, 2008

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE;1%**	**A076002**	**001**	Aug 02, 2002
AB		FOUGERA PHARMS	**EQ 0.05% BASE;1%**	**A075502**	**001**	Jun 05, 2001
AB		GLENMARK PHARMS	**EQ 0.05% BASE;1%**	**A202894**	**001**	Oct 30, 2015
AB	**!**	TARO	**EQ 0.05% BASE;1%**	**A075673**	**001**	May 29, 2001

LOTION;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	**EQ 0.05% BASE;1%**	**A076516**	**001**	Jun 16, 2005
AB	**!**	TARO	**EQ 0.05% BASE;1%**	**A076493**	**001**	Jul 28, 2004

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

AB		PADAGIS ISRAEL	**0.12%**	**A078337**	**001**	Nov 26, 2012
AB	**!**	TARO	**0.12%**	**A208204**	**001**	May 24, 2017
AB		XIROMED	**0.12%**	**A210639**	**001**	Apr 18, 2023

CREAM;TOPICAL

BETA-VAL

AB		COSETTE	**EQ 0.1% BASE**	**N018642**	**001**	Mar 24, 1983

BETAMETHASONE VALERATE

CREAM;TOPICAL

BETAMETHASONE VALERATE

AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018861**	**001**	Aug 31, 1983

DERMABET

AB		TARO	**EQ 0.1% BASE**	**A072041**	**001**	Jan 06, 1988

VALNAC

AB		ACTAVIS MID ATLANTIC	**EQ 0.1% BASE**	**A070050**	**001**	Oct 10, 1984

LOTION;TOPICAL

BETAMETHASONE VALERATE

AB		ANIMA	**EQ 0.1% BASE**	**A070052**	**001**	Jul 31, 1985
AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018866**	**001**	Aug 31, 1983

OINTMENT;TOPICAL

BETA-VAL

AB		COSETTE	**EQ 0.1% BASE**	**A070069**	**001**	Dec 19, 1985

BETAMETHASONE VALERATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.1% BASE**	**A070051**	**001**	Oct 10, 1984
AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018865**	**001**	Aug 31, 1983

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT		ACELLA	**EQ 0.5% BASE**	**A078694**	**001**	Nov 16, 2009
AT		MEDIMETRIKS PHARMS	**EQ 0.5% BASE**	**A075630**	**001**	Apr 12, 2001

BETOPTIC

AT	**+!**	SANDOZ	**EQ 0.5% BASE**	**N019270**	**001**	Aug 30, 1985

SUSPENSION/DROPS;OPHTHALMIC

BETOPTIC S

	+!	NOVARTIS	EQ 0.25% BASE	N019845	001	Dec 29, 1989

TABLET;ORAL

BETAXOLOL HYDROCHLORIDE

AB		EPIC PHARMA	**10MG**	**A075541**	**001**	Oct 22, 1999
AB	**!**		**20MG**	**A075541**	**002**	Oct 22, 1999
AB		KVK TECH	**10MG**	**A078962**	**001**	Jun 27, 2008
AB			**20MG**	**A078962**	**002**	Jun 27, 2008

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	**!**	AMNEAL PHARM	**5MG**	**A040855**	**001**	Nov 21, 2007
AA	**!**		**10MG**	**A040855**	**002**	Nov 21, 2007
AA	**!**		**25MG**	**A040855**	**003**	Nov 21, 2007
AA	**!**		**50MG**	**A040855**	**004**	Nov 21, 2007
AA		CHARTWELL RX	**5MG**	**A040728**	**002**	Oct 26, 2007
AA			**10MG**	**A040728**	**003**	Oct 26, 2007
AA			**25MG**	**A040728**	**004**	Oct 26, 2007
AA			**50MG**	**A040728**	**001**	Oct 26, 2007
AA		UPSHER SMITH LABS	**5MG**	**A040633**	**001**	Jun 01, 2005
AA			**10MG**	**A040634**	**001**	Jun 01, 2005
AA			**25MG**	**A040635**	**001**	Jun 01, 2005
AA			**50MG**	**A040636**	**001**	Jun 01, 2005

DUVOID

AA		CHARTWELL RX	**10MG**	**A086262**	**001**	
AA			**25MG**	**A086263**	**001**	
AA			**50MG**	**A085882**	**003**	

BEXAGLIFLOZIN

TABLET;ORAL

BRENZAVVY

	+!	THERACOSBIO	20MG	N214373	001	Jan 20, 2023

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB		AMNEAL PHARMS NY	**75MG**	**A210105**	**001**	Sep 04, 2018
AB		ANI PHARMS	**75MG**	**A209861**	**001**	May 08, 2018
AB		BIONPHARMA	**75MG**	**A203174**	**001**	Aug 12, 2014
AB		HIKMA	**75MG**	**A203663**	**001**	Jun 16, 2020
AB		TEVA PHARMS USA	**75MG**	**A209931**	**001**	Jan 14, 2021
AB		UPSHER SMITH LABS	**75MG**	**A209886**	**001**	Jul 25, 2018

TARGRETIN

AB	**+!**	VALEANT LUXEMBOURG	**75MG**	**N021055**	**001**	Dec 29, 1999

BEXAROTENE

GEL;TOPICAL

BEXAROTENE

AB		AMNEAL	**1%**	**A215398**	**001**	Apr 27, 2022

TARGRETIN

AB	**+!**	BAUSCH	**1%**	**N021056**	**001**	Jun 28, 2000

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB		ACCORD HLTHCARE	**50MG**	**A078917**	**001**	Jul 06, 2009
AB		ADAPTIS	**50MG**	**A079089**	**001**	Jul 06, 2009
AB		APOTEX	**50MG**	**A200274**	**001**	May 21, 2015
AB		BRECKENRIDGE	**50MG**	**A091011**	**001**	Jun 10, 2015
AB		SANDOZ	**50MG**	**A078575**	**001**	Jul 06, 2009
AB		SUN PHARM	**50MG**	**A079110**	**001**	Jul 06, 2009
AB		WATSON LABS TEVA	**50MG**	**A078634**	**001**	Aug 28, 2009

CASODEX

AB	**+!**	ANI PHARMS	**50MG**	**N020498**	**001**	Oct 04, 1995

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

BIKTARVY

	+	GILEAD SCIENCES INC	EQ 30MG BASE;120MG;EQ 15MG BASE	N210251	002	Oct 07, 2021
	+!		EQ 50MG BASE;200MG;EQ 25MG BASE	N210251	001	Feb 07, 2018

BIMATOPROST

IMPLANT;OPHTHALMIC

DURYSTA

	+!	ABBVIE	10MCG	N211911	001	Mar 04, 2020

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT	**!**	ALEMBIC	**0.03%**	**A210263**	**001**	Apr 12, 2019
AT		APOTEX	**0.03%**	**A090449**	**001**	Jul 20, 2015
AT		EUGIA PHARMA	**0.03%**	**A205537**	**001**	Oct 06, 2022
AT		GLAND PHARMA LTD	**0.03%**	**A210126**	**001**	Mar 22, 2019
AT		LUPIN LTD	**0.03%**	**A203991**	**001**	Feb 20, 2015
AT		MICRO LABS	**0.03%**	**A202505**	**001**	Sep 08, 2020
AT		SANDOZ	**0.03%**	**A202565**	**001**	May 05, 2015
AT		SOMERSET THERAPS LLC	**0.03%**	**A207601**	**001**	Jun 19, 2019

LUMIGAN

	+!	ABBVIE	0.01%	N022184	001	Aug 31, 2010

SOLUTION/DROPS;TOPICAL

BIMATOPROST

AT		ALEMBIC	**0.03%**	**A210515**	**001**	Jan 21, 2020
AT		APOTEX	**0.03%**	**A201894**	**001**	Dec 01, 2014
AT		HIKMA	**0.03%**	**A203051**	**001**	Oct 09, 2018
AT		SANDOZ	**0.03%**	**A202719**	**001**	Apr 19, 2016

LATISSE

AT	**+!**	ABBVIE	**0.03%**	**N022369**	**001**	Dec 24, 2008

BINIMETINIB

TABLET;ORAL

MEKTOVI

	+!	ARRAY BIOPHARMA INC	15MG	N210498	001	Jun 27, 2018

BIRCH TRITERPENES

GEL;TOPICAL

FILSUVEZ

	+!	AMRYT	10%	N215064	001	Dec 18, 2023

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB		PAR PHARM	**140MG;125MG;125MG**	**A205770**	**001**	Mar 06, 2023
AB		RICONPHARMA LLC	**140MG;125MG;125MG**	**A217511**	**001**	Jul 03, 2023

PYLERA

AB	**+!**	LABS JUVISE	**140MG;125MG;125MG**	**N050786**	**001**	Sep 28, 2006

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

	!	NOSTRUM LABS INC	262.4MG, N/A, N/A;N/A, 250MG, N/A;N/A, N/A, 500MG	A202584	001	Nov 30, 2018

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB		ALEMBIC	**5MG**	**A204891**	**001**	Jan 11, 2017
AB			**10MG**	**A204891**	**002**	Jan 11, 2017
AB		AUROBINDO PHARMA	**5MG**	**A077910**	**001**	Dec 27, 2006
AB			**10MG**	**A077910**	**002**	Dec 27, 2006
AB		CADILA	**5MG**	**A215680**	**001**	Jul 25, 2022
AB			**10MG**	**A215680**	**002**	Jul 25, 2022
AB		NOVITIUM PHARMA	**5MG**	**A215563**	**001**	Oct 29, 2021
AB			**10MG**	**A215563**	**002**	Oct 29, 2021
AB		PRINSTON INC	**5MG**	**A217368**	**001**	Jul 14, 2023
AB			**10MG**	**A217368**	**002**	Jul 14, 2023
AB		RUBICON	**5MG**	**A075643**	**001**	Nov 16, 2000
AB			**10MG**	**A075643**	**002**	Nov 16, 2000
AB		UNICHEM	**5MG**	**A078635**	**001**	Aug 18, 2009
AB	**!**		**10MG**	**A078635**	**002**	Aug 18, 2009
AB		UNITED RES LABS	**5MG**	**A075474**	**001**	Oct 25, 2002
AB			**10MG**	**A075474**	**002**	Oct 25, 2002

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB		CADILA	**2.5MG;6.25MG**	**A215666**	**001**	Nov 04, 2022
AB			**5MG;6.25MG**	**A215666**	**002**	Nov 04, 2022
AB			**10MG;6.25MG**	**A215666**	**003**	Nov 04, 2022
AB		EDENBRIDGE PHARMS	**2.5MG;6.25MG**	**A212678**	**001**	Jul 09, 2020
AB			**5MG;6.25MG**	**A212678**	**002**	Jul 09, 2020
AB			**10MG;6.25MG**	**A212678**	**003**	Jul 09, 2020
AB		EPIC PHARMA LLC	**2.5MG;6.25MG**	**A075579**	**001**	Sep 25, 2000
AB			**5MG;6.25MG**	**A075579**	**002**	Sep 25, 2000
AB			**10MG;6.25MG**	**A075579**	**003**	Sep 25, 2000
AB		GLENMARK PHARMS LTD	**2.5MG;6.25MG**	**A215995**	**001**	Jan 26, 2022
AB			**5MG;6.25MG**	**A215995**	**002**	Jan 26, 2022
AB			**10MG;6.25MG**	**A215995**	**003**	Jan 26, 2022
AB		MYLAN	**2.5MG;6.25MG**	**A075768**	**001**	Sep 25, 2000
AB			**5MG;6.25MG**	**A075768**	**002**	Sep 25, 2000
AB			**10MG;6.25MG**	**A075768**	**003**	Sep 25, 2000
AB		NOVITIUM PHARMA	**2.5MG;6.25MG**	**A215562**	**001**	Nov 04, 2021
AB			**5MG;6.25MG**	**A215562**	**002**	Nov 04, 2021
AB			**10MG;6.25MG**	**A215562**	**003**	Nov 04, 2021
AB		UNICHEM	**2.5MG;6.25MG**	**A079106**	**001**	Jul 28, 2010
AB			**5MG;6.25MG**	**A079106**	**002**	Jul 28, 2010
AB			**10MG;6.25MG**	**A079106**	**003**	Jul 28, 2010

ZIAC

AB	**+**	TEVA BRANDED PHARM	**2.5MG;6.25MG**	**N020186**	**003**	Mar 26, 1993
AB	**+**		**5MG;6.25MG**	**N020186**	**001**	Mar 26, 1993
AB	**+!**		**10MG;6.25MG**	**N020186**	**002**	Mar 26, 1993

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

ANGIOMAX

AP	**+!**	SANDOZ	**250MG/VIAL**	**N020873**	**001**	Dec 15, 2000

BIVALIRUDIN

AP		ACCORD HLTHCARE	**250MG/VIAL**	**A206551**	**001**	Nov 22, 2017
AP		DR REDDYS	**250MG/VIAL**	**A201577**	**001**	May 26, 2017
AP		EUGIA PHARMA	**250MG/VIAL**	**A205962**	**001**	Jul 27, 2018
AP		FRESENIUS KABI USA	**250MG/VIAL**	**A090189**	**001**	Oct 28, 2016
AP		HOSPIRA	**250MG/VIAL**	**A090811**	**001**	Jul 14, 2015
AP			**250MG/VIAL**	**A090816**	**001**	Jul 14, 2015
AP		MEITHEAL	**250MG/VIAL**	**A091602**	**001**	Jul 16, 2018
AP		MYLAN INSTITUTIONAL	**250MG/VIAL**	**A202471**	**001**	Jun 01, 2018
AP		SHUANGCHENG	**250MG/VIAL**	**A210031**	**001**	Oct 23, 2019
AP		SLATE RUN PHARMA	**250MG/VIAL**	**A213078**	**001**	May 28, 2021

SOLUTION;INTRAVENOUS

ANGIOMAX RTU

	+!	MAIA PHARMS INC	250MG/50ML (5MG/ML)	N211215	001	Jul 25, 2019

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

AP	**!**	FRESENIUS KABI USA	**EQ 15 UNITS BASE/VIAL**	**A065185**	**001**	Jan 28, 2008
AP	**!**		**EQ 30 UNITS BASE/VIAL**	**A065185**	**002**	Jan 28, 2008
AP		HIKMA	**EQ 15 UNITS BASE/VIAL**	**A065042**	**002**	Oct 17, 2001
AP			**EQ 30 UNITS BASE/VIAL**	**A065042**	**001**	Oct 17, 2001
AP		HOSPIRA	**EQ 15 UNITS BASE/VIAL**	**A065031**	**001**	Mar 10, 2000
AP			**EQ 30 UNITS BASE/VIAL**	**A065031**	**002**	Mar 10, 2000
AP		MEITHEAL	**EQ 15 UNITS BASE/VIAL**	**A205030**	**001**	Apr 20, 2018
AP			**EQ 30 UNITS BASE/VIAL**	**A205030**	**002**	Apr 20, 2018
AP		TEVA PHARMS USA	**EQ 15 UNITS BASE/VIAL**	**A065033**	**001**	Jun 27, 2000
AP			**EQ 30 UNITS BASE/VIAL**	**A065033**	**002**	Jun 27, 2000

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

AP		APOTEX	**3.5MG/VIAL**	**A205533**	**001**	May 02, 2022
AP		BAXTER HLTHCARE CORP	**3.5MG/VIAL**	**A213823**	**001**	May 02, 2022
AP		DR REDDYS	**3.5MG/VIAL**	**A202963**	**001**	Jul 26, 2022
AP		EUGIA PHARMA	**3.5MG/VIAL**	**A212825**	**001**	May 02, 2022
AP		FRESENIUS KABI USA	**3.5MG/VIAL**	**A209659**	**001**	May 02, 2022
AP		HOSPIRA	**3.5MG/VIAL**	**A208460**	**001**	Jul 26, 2022
AP		JIANGSU HANSOH PHARM	**3.5MG/VIAL**	**A215011**	**001**	Jul 26, 2022
AP		MEITHEAL	**3.5MG/VIAL**	**A212958**	**001**	Jul 26, 2022
AP		MSN	**3.5MG/VIAL**	**A209622**	**001**	Jul 26, 2022
AP		PHARMASCIENCE INC	**3.5MG/VIAL**	**A208392**	**001**	May 02, 2022
AP		QILU PHARM HAINAN	**3.5MG/VIAL**	**A210824**	**001**	May 02, 2022
AP		SANDOZ	**3.5MG/VIAL**	**A203654**	**001**	Jul 26, 2022
AP		WAVERLEY PHARMA INC	**3.5MG/VIAL**	**A211898**	**001**	Oct 11, 2022
AP		ZYDUS PHARMS	**3.5MG/VIAL**	**A210204**	**001**	May 02, 2022

VELCADE

AP	**+!**	TAKEDA PHARMS USA	**3.5MG/VIAL**	**N021602**	**001**	May 13, 2003

POWDER;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

	+!	HOSPIRA	1MG/VIAL	N209191	001	May 02, 2022
	+!		2.5MG/VIAL	N209191	002	May 02, 2022

BOSENTAN

TABLET;ORAL

BOSENTAN

AB		SUN PHARM	**62.5MG**	**A209324**	**001**	Apr 26, 2019
AB			**125MG**	**A209324**	**002**	Apr 26, 2019
AB		WATSON LABS INC	**62.5MG**	**A207110**	**001**	Apr 26, 2019
AB			**125MG**	**A207110**	**002**	Apr 26, 2019
AB		ZYDUS PHARMS	**62.5MG**	**A207760**	**001**	Apr 26, 2019
AB			**125MG**	**A207760**	**002**	Apr 26, 2019

TRACLEER

AB	**+**	ACTELION	**62.5MG**	**N021290**	**001**	Nov 20, 2001
AB	**+!**		**125MG**	**N021290**	**002**	Nov 20, 2001

TABLET, FOR SUSPENSION;ORAL

TRACLEER

	+!	ACTELION	32MG	N209279	001	Sep 05, 2017

BOSUTINIB MONOHYDRATE

CAPSULE;ORAL

BOSULIF

	+	PF PRISM CV	EQ 50MG BASE	N217729	001	Sep 26, 2023
	+!		EQ 100MG BASE	N217729	002	Sep 26, 2023

TABLET;ORAL

BOSULIF

	+!	PF PRISM CV	EQ 100MG BASE	N203341	001	Sep 04, 2012
	+		EQ 400MG BASE	N203341	003	Oct 27, 2017
	+		EQ 500MG BASE	N203341	002	Sep 04, 2012

BREMELANOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

	+!	PALATIN TECHNOLOGIES	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019

BREXANOLONE
SOLUTION;INTRAVENOUS
ZULRESSO

	+!	SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019

BREXPIPRAZOLE
TABLET;ORAL
BREXPIPRAZOLE

AB		ALKEM LABS LTD	**0.25MG**	**A213782**	**001**	Nov 28, 2023
AB			**0.5MG**	**A213782**	**002**	Nov 28, 2023
AB			**1MG**	**A213782**	**003**	Nov 28, 2023
AB			**2MG**	**A213782**	**004**	Nov 28, 2023
AB			**3MG**	**A213782**	**005**	Nov 28, 2023
AB			**4MG**	**A213782**	**006**	Nov 28, 2023
AB		HETERO LABS LTD V	**0.25MG**	**A213669**	**001**	Nov 20, 2023
AB			**0.5MG**	**A213669**	**002**	Nov 20, 2023
AB			**1MG**	**A213669**	**003**	Nov 20, 2023
AB			**2MG**	**A213669**	**004**	Nov 20, 2023
AB			**3MG**	**A213669**	**005**	Nov 20, 2023
AB			**4MG**	**A213669**	**006**	Nov 20, 2023
AB		OPTIMUS	**0.25MG**	**A213758**	**001**	Oct 25, 2023
AB			**0.5MG**	**A213758**	**002**	Oct 25, 2023
AB			**1MG**	**A213758**	**003**	Oct 25, 2023
AB			**2MG**	**A213758**	**004**	Oct 25, 2023
AB			**3MG**	**A213758**	**005**	Oct 25, 2023
AB			**4MG**	**A213758**	**006**	Oct 25, 2023

REXULTI

AB	**+**	OTSUKA	**0.25MG**	**N205422**	**001**	Jul 10, 2015
AB	**+**		**0.5MG**	**N205422**	**002**	Jul 10, 2015
AB	**+**		**1MG**	**N205422**	**003**	Jul 10, 2015
AB	**+!**		**2MG**	**N205422**	**004**	Jul 10, 2015
AB	**+**		**3MG**	**N205422**	**005**	Jul 10, 2015
AB	**+**		**4MG**	**N205422**	**006**	Jul 10, 2015

BRIGATINIB
TABLET;ORAL
ALUNBRIG

	+	TAKEDA PHARMS USA	30MG	N208772	001	Apr 28, 2017
	+		90MG	N208772	002	Apr 28, 2017
	+!		180MG	N208772	003	Oct 02, 2017

BRILLIANT BLUE G
SOLUTION;OPHTHALMIC
TISSUEBLUE

	+!	DUTCH OPHTHALMIC	0.025%	N209569	001	Dec 20, 2019

BRIMONIDINE TARTRATE
GEL;TOPICAL
BRIMONIDINE TARTRATE

AB		PADAGIS ISRAEL	**EQ 0.33% BASE**	**A209158**	**001**	Sep 23, 2021

MIRVASO

AB	**+!**	GALDERMA LABS LP	**EQ 0.33% BASE**	**N204708**	**001**	Aug 23, 2013

SOLUTION/DROPS;OPHTHALMIC
ALPHAGAN P

AB	**+!**	ABBVIE	**0.1%**	**N021770**	**001**	Aug 19, 2005

BRIMONIDINE TARTRATE

AB		ALEMBIC	**0.1%**	**A216909**	**001**	Aug 01, 2023
AB		APOTEX	**0.1%**	**A078480**	**001**	Dec 21, 2022

ALPHAGAN P

AT	**+!**	ABBVIE	**0.15%**	**N021262**	**001**	Mar 16, 2001

BRIMONIDINE TARTRATE

AT		ALEMBIC	**0.15%**	**A215225**	**001**	Mar 29, 2023
AT		APOTEX	**0.15%**	**A078479**	**001**	Jan 31, 2022
AT	**!**	BAUSCH AND LOMB	**0.2%**	**A076260**	**001**	May 28, 2003
AT		INDOCO	**0.2%**	**A091691**	**001**	Nov 18, 2014
AT		MICRO LABS	**0.2%**	**A217846**	**001**	Nov 22, 2023
AT		RISING	**0.2%**	**A076439**	**001**	Mar 14, 2006
AT		SANDOZ	**0.2%**	**A076254**	**001**	Sep 16, 2003
AT			**0.2%**	**A078075**	**001**	Jan 30, 2008
AT		SOMERSET THERAPS LLC	**0.2%**	**A208992**	**001**	Mar 11, 2019

QOLIANA

AT	**+!**	SANDOZ	**0.15%**	**N021764**	**001**	May 22, 2006

BRIMONIDINE TARTRATE; BRINZOLAMIDE						
SUSPENSION/DROPS;OPHTHALMIC						
SIMBRINZA						
	+!	ALCON LABS INC	0.2%;1%	N204251	001	Apr 19, 2013
BRIMONIDINE TARTRATE; TIMOLOL MALEATE						
SOLUTION/DROPS;OPHTHALMIC						
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE						
AB		ALEMBIC	**0.2%;EQ 0.5% BASE**	**A215230**	**001**	Aug 25, 2023
AB		APOTEX	**0.2%;EQ 0.5% BASE**	**A091442**	**001**	Apr 20, 2022
AB		FLORIDA	**0.2%;EQ 0.5% BASE**	**A201949**	**001**	Oct 04, 2022
AB		SANDOZ	**0.2%;EQ 0.5% BASE**	**A091087**	**001**	Apr 04, 2022
AB		SENTISS	**0.2%;EQ 0.5% BASE**	**A091086**	**001**	Oct 31, 2022
AB		UPSHER SMITH LABS	**0.2%;EQ 0.5% BASE**	**A215598**	**001**	Dec 12, 2022
COMBIGAN						
AB	**+!**	ABBVIE	**0.2%;EQ 0.5% BASE**	**N021398**	**001**	Oct 30, 2007
BRINCIDOFOVIR						
SUSPENSION;ORAL						
TEMBEXA						
	+!	EMERGENT BIODEFENSE	10MG/ML	N214460	001	Jun 04, 2021
TABLET;ORAL						
TEMBEXA						
	+!	EMERGENT BIODEFENSE	100MG	N214461	001	Jun 04, 2021
BRINZOLAMIDE						
SUSPENSION/DROPS;OPHTHALMIC						
AZOPT						
AB	**+!**	SANDOZ	**1%**	**N020816**	**001**	Apr 01, 1998
BRINZOLAMIDE						
AB		BAUSCH AND LOMB	**1%**	**A204884**	**001**	Aug 18, 2021
AB		PADAGIS US	**1%**	**A211914**	**001**	Jul 28, 2023
AB		WATSON LABS INC	**1%**	**A209406**	**001**	Nov 27, 2020
BRIVARACETAM						
SOLUTION;INTRAVENOUS						
BRIVIACT						
	+!	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016
SOLUTION;ORAL						
BRIVIACT						
	+!	UCB INC	10MG/ML	N205838	001	May 12, 2016
TABLET;ORAL						
BRIVIACT						
	+	UCB INC	10MG	N205836	001	May 12, 2016
	+		25MG	N205836	002	May 12, 2016
	+		50MG	N205836	003	May 12, 2016
	+		75MG	N205836	004	May 12, 2016
	+!		100MG	N205836	005	May 12, 2016
BROMFENAC SODIUM						
SOLUTION/DROPS;OPHTHALMIC						
BROMFENAC SODIUM						
AB		LUPIN LTD	**EQ 0.07% ACID**	**A206027**	**001**	Nov 22, 2023
PROLENSA						
AB	**+!**	BAUSCH AND LOMB	**EQ 0.07% ACID**	**N203168**	**001**	Apr 05, 2013
BROMFENAC SODIUM						
AT2	**!**	ALEMBIC	**EQ 0.09% ACID**	**A210560**	**001**	Jun 21, 2019
AT2		EUGIA PHARMA	**EQ 0.09% ACID**	**A204813**	**001**	Mar 18, 2022
AT2		GLAND PHARMA LTD	**EQ 0.09% ACID**	**A211029**	**001**	Mar 17, 2020
AT2		LUPIN LTD	**EQ 0.09% ACID**	**A202903**	**001**	Aug 15, 2023
AT2		SENTISS	**EQ 0.09% ACID**	**A203395**	**001**	Jan 22, 2014
BROMSITE						
	+!	SUN PHARM	EQ 0.075% ACID	N206911	001	Apr 08, 2016
BROMOCRIPTINE MESYLATE						
CAPSULE;ORAL						
BROMOCRIPTINE MESYLATE						
AB	**!**	MYLAN	**EQ 5MG BASE**	**A077226**	**001**	Apr 04, 2005
AB		ZYDUS PHARMS USA INC	**EQ 5MG BASE**	**A078899**	**001**	Jul 30, 2008
PARLODEL						
AB	**+**	SS PHARMA	**EQ 5MG BASE**	**N017962**	**002**	Mar 01, 1982
TABLET;ORAL						
BROMOCRIPTINE MESYLATE						
AB	**!**	PADAGIS US	**EQ 2.5MG BASE**	**A077646**	**001**	Oct 01, 2008
AB		SANDOZ	**EQ 2.5MG BASE**	**A074631**	**001**	Jan 13, 1998

BROMOCRIPTINE MESYLATE

TABLET;ORAL

PARLODEL

AB	**+**	SS PHARMA	**EQ 2.5MG BASE**	**N017962**	**001**	

CYCLOSET

	+!	VEROSCIENCE	EQ 0.8MG BASE	N020866	001	May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

AA	**+**	WOCKHARDT BIO AG	**2MG/5ML;10MG/5ML;30MG/5ML**	**A088811**	**001**	Jun 07, 1985

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		ACELLA	**2MG/5ML;10MG/5ML;30MG/5ML**	**A203375**	**001**	Sep 20, 2016
AA		ALKEM LABS LTD	**2MG/5ML;10MG/5ML;30MG/5ML**	**A210647**	**001**	Jul 14, 2020
AA		CHARTWELL MOLECULAR	**2MG/5ML;10MG/5ML;30MG/5ML**	**A213125**	**001**	Apr 17, 2020
AA		DR REDDYS LABS SA	**2MG/5ML;10MG/5ML;30MG/5ML**	**A207676**	**001**	Dec 04, 2018
AA	**!**	PADAGIS US	**2MG/5ML;10MG/5ML;30MG/5ML**	**A205292**	**001**	Jul 15, 2014
AA		PHARM ASSOC	**2MG/5ML;10MG/5ML;30MG/5ML**	**A202940**	**001**	Jul 21, 2014
AA		TARO	**2MG/5ML;10MG/5ML;30MG/5ML**	**A205112**	**001**	Feb 27, 2017
AA		WES PHARMA INC	**2MG/5ML;10MG/5ML;30MG/5ML**	**A211170**	**001**	Jun 16, 2020

BUDESONIDE

AEROSOL, FOAM;RECTAL

BUDESONIDE

AB		PADAGIS ISRAEL	**2MG/ACTUATION**	**A215328**	**001**	Apr 12, 2023

UCERIS

AB	**+!**	SALIX	**2MG/ACTUATION**	**N205613**	**001**	Oct 07, 2014

CAPSULE, DELAYED RELEASE;ORAL

BUDESONIDE

AB		AMNEAL PHARMS	**3MG**	**A206200**	**001**	Jul 31, 2017
AB		AUROBINDO PHARMA USA	**3MG**	**A090410**	**001**	May 16, 2011
AB		DR REDDYS LABS SA	**3MG**	**A206623**	**001**	Apr 08, 2016
AB		RISING	**3MG**	**A207367**	**001**	Apr 07, 2017
AB		ZYDUS PHARMS	**3MG**	**A206134**	**001**	May 04, 2017

ENTOCORT EC

AB	**+!**	PADAGIS US	**3MG**	**N021324**	**001**	Oct 02, 2001

TARPEYO

	+!	CALLIDITAS	4MG	N215935	001	Dec 15, 2021

POWDER, METERED;INHALATION

PULMICORT FLEXHALER

	+	ASTRAZENECA	0.08MG/INH	N021949	001	Jul 12, 2006
	+!		0.16MG/INH	N021949	002	Jul 12, 2006

SUSPENSION;INHALATION

BUDESONIDE

AN		CIPLA	**0.25MG/2ML**	**A205710**	**001**	Nov 16, 2017
AN			**0.5MG/2ML**	**A205710**	**002**	Nov 16, 2017
AN			**1MG/2ML**	**A205710**	**003**	Nov 16, 2017
AN		EUGIA PHARMA	**0.5MG/2ML**	**A216667**	**001**	Nov 29, 2023
AN		IMPAX LABS INC	**0.25MG/2ML**	**A078404**	**001**	Jul 31, 2012
AN			**0.5MG/2ML**	**A078404**	**002**	Jul 31, 2012
AN		LUPIN	**0.5MG/2ML**	**A210897**	**001**	Nov 09, 2018
AN		NEPHRON	**0.25MG/2ML**	**A078202**	**001**	Mar 30, 2009
AN			**0.5MG/2ML**	**A078202**	**002**	Mar 30, 2009
AN		SANDOZ	**0.25MG/2ML**	**A201966**	**003**	Sep 27, 2013
AN			**0.5MG/2ML**	**A201966**	**002**	Sep 27, 2013
AN			**1MG/2ML**	**A201966**	**001**	Sep 27, 2013
AN		SUN PHARM	**0.25MG/2ML**	**A211922**	**001**	Apr 14, 2021
AN			**0.5MG/2ML**	**A211922**	**002**	Apr 14, 2021
AN			**1MG/2ML**	**A211922**	**003**	Apr 14, 2021
AN		TEVA PHARMS	**0.25MG/2ML**	**A077519**	**001**	Nov 18, 2008
AN			**0.5MG/2ML**	**A077519**	**002**	Nov 18, 2008
AN		TEVA PHARMS USA	**1MG/2ML**	**A204548**	**001**	Mar 08, 2016

PULMICORT RESPULES

AN	**+**	ASTRAZENECA	**0.25MG/2ML**	**N020929**	**001**	Aug 08, 2000
AN	**+**		**0.5MG/2ML**	**N020929**	**002**	Aug 08, 2000
AN	**+!**		**1MG/2ML**	**N020929**	**003**	Aug 08, 2000

TABLET, EXTENDED RELEASE;ORAL

BUDESONIDE

AB		ACTAVIS LABS FL INC	**9MG**	**A205457**	**001**	Jul 03, 2018
AB		MYLAN	**9MG**	**A208851**	**001**	Sep 17, 2020

UCERIS

AB	**+!**	SALIX	**9MG**	**N203634**	**001**	Jan 14, 2013

BUDESONIDE; FORMOTEROL FUMARATE							
AEROSOL, METERED;INHALATION							
SYMBICORT AEROSPHERE							
	+!	ASTRAZENECA	0.16MG/INH;0.0048MG/INH		N216579	001	Apr 28, 2023
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE							
AEROSOL, METERED;INHALATION							
BREYNA							
AB		MYLAN	**0.08MG/INH;0.0045MG/INH**		**A211699**	**001**	Mar 15, 2022
AB			**0.16MG/INH;0.0045MG/INH**		**A211699**	**002**	Mar 15, 2022
SYMBICORT							
AB	**+!**	ASTRAZENECA	**0.08MG/INH;0.0045MG/INH**		**N021929**	**001**	Jul 21, 2006
AB	**+!**		**0.16MG/INH;0.0045MG/INH**		**N021929**	**002**	Jul 21, 2006
BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE							
AEROSOL, METERED;INHALATION							
BREZTRI AEROSPHERE							
	+!	ASTRAZENECA AB	0.16MG/INH;0.0048MG/INH;0.009MG/INH		N212122	001	Jul 23, 2020
BUMETANIDE							
INJECTABLE;INJECTION							
BUMETANIDE							
AP		GLAND PHARMA LTD	**0.25MG/ML**		**A216434**	**001**	May 26, 2022
AP		HOSPIRA	**0.25MG/ML**		**A074332**	**001**	Oct 31, 1994
AP		MSN	**0.25MG/ML**		**A215364**	**001**	Aug 04, 2022
AP		SAGENT	**0.25MG/ML**		**A074441**	**001**	Jan 27, 1995
AP	**!**	WEST-WARD PHARMS INT	**0.25MG/ML**		**A079196**	**001**	Apr 30, 2008
TABLET;ORAL							
BUMETANIDE							
AB		AMNEAL PHARMS CO	**0.5MG**		**A209724**	**001**	Oct 18, 2017
AB			**1MG**		**A209724**	**002**	Oct 18, 2017
AB			**2MG**		**A209724**	**003**	Oct 18, 2017
AB		HERITAGE PHARMA	**0.5MG**		**A074225**	**001**	Apr 24, 1995
AB			**1MG**		**A074225**	**002**	Apr 24, 1995
AB			**2MG**		**A074225**	**003**	Apr 24, 1995
AB		SANDOZ	**0.5MG**		**A074700**	**001**	Nov 21, 1996
AB			**1MG**		**A074700**	**002**	Nov 21, 1996
AB	**!**		**2MG**		**A074700**	**003**	Nov 21, 1996
AB		TARO	**0.5MG**		**A213458**	**001**	Jul 24, 2023
AB			**1MG**		**A213458**	**002**	Jul 24, 2023
AB			**2MG**		**A213458**	**003**	Jul 24, 2023
AB		UPSHER SMITH LABS	**0.5MG**		**A209916**	**001**	Jan 23, 2018
AB			**1MG**		**A209916**	**002**	Jan 23, 2018
AB			**2MG**		**A209916**	**003**	Jan 23, 2018
AB		ZYDUS PHARMS	**0.5MG**		**A202900**	**001**	Apr 30, 2018
AB			**1MG**		**A202900**	**002**	Apr 30, 2018
AB			**2MG**		**A202900**	**003**	Apr 30, 2018
BUMEX							
AB	**+**	VALIDUS PHARMS	**0.5MG**		**N018225**	**002**	Feb 28, 1983
AB	**+**		**1MG**		**N018225**	**001**	Feb 28, 1983
AB	**+**		**2MG**		**N018225**	**003**	Jun 14, 1985
BUMETANIDE							
BX		RISING	0.5MG		A212019	001	Dec 12, 2019
BX			1MG		A212019	002	Dec 12, 2019
BX			2MG		A212019	003	Dec 12, 2019
BUPIVACAINE							
INJECTABLE, LIPOSOMAL;INJECTION							
EXPAREL							
	+!	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)		N022496	001	Oct 28, 2011
	+!		266MG/20ML (13.3MG/ML)		N022496	002	Oct 28, 2011
SOLUTION, EXTENDED RELEASE;INFILTRATION							
POSIMIR							
	+!	INNOCOLL	660MG/5ML (132MG/ML)		N204803	001	Feb 01, 2021
BUPIVACAINE HYDROCHLORIDE							
IMPLANT;IMPLANTATION							
XARACOLL							
	+!	INNOCOLL PHARMS	100MG		N209511	001	Aug 28, 2020
INJECTABLE;INJECTION							
BUPIVACAINE HYDROCHLORIDE							
AP		EUGIA PHARMA	**0.25%**		**A207183**	**001**	May 13, 2016
AP			**0.5%**		**A207183**	**002**	May 13, 2016
AP		HIKMA PHARMS	**0.25%**		**A205141**	**001**	Feb 11, 2021

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP			**0.5%**	**A205141**	**002**	Feb 11, 2021
AP		HOSPIRA	**0.25%**	**A070583**	**001**	Feb 17, 1987
AP			**0.25%**	**A070590**	**001**	Feb 17, 1987
AP			**0.5%**	**A070584**	**001**	Feb 17, 1986
AP			**0.5%**	**A070597**	**001**	Mar 03, 1987
AP			**0.5%**	**A070609**	**001**	Mar 03, 1987
AP			**0.75%**	**A070585**	**001**	Mar 03, 1987
AP		KINDOS	**0.25%**	**A216039**	**001**	Jun 23, 2023
AP			**0.25%**	**A216040**	**001**	Dec 27, 2023
AP			**0.5%**	**A216039**	**002**	Jun 23, 2023
AP			**0.5%**	**A216040**	**002**	Dec 27, 2023
AP			**0.75%**	**A216040**	**003**	Dec 27, 2023
AP		SOMERSET	**0.25%**	**A217792**	**001**	Nov 20, 2023
AP			**0.5%**	**A217792**	**002**	Nov 20, 2023
AP		STERISCIENCE	**0.25%**	**A091503**	**001**	Oct 18, 2011
AP			**0.5%**	**A091503**	**002**	Oct 18, 2011

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

AP		EUGIA PHARMA	**0.25%**	**A203895**	**001**	Nov 05, 2013
AP			**0.5%**	**A203895**	**002**	Nov 05, 2013
AP			**0.75%**	**A203895**	**003**	Nov 05, 2013
AP		HIKMA PHARMS	**0.25%**	**A204842**	**001**	Feb 11, 2021
AP			**0.5%**	**A204842**	**002**	Feb 11, 2021
AP			**0.75%**	**A204842**	**003**	Feb 11, 2021
AP		STERISCIENCE	**0.25%**	**A091487**	**002**	Oct 18, 2011
AP			**0.5%**	**A091487**	**001**	Oct 18, 2011
AP			**0.75%**	**A091487**	**003**	Oct 18, 2011

MARCAINE HYDROCHLORIDE

AP	**+!**	HOSPIRA	**0.25%**	**N016964**	**001**	
AP	**+!**		**0.5%**	**N016964**	**006**	

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	**+!**	HOSPIRA	**0.25%**	**N016964**	**012**	
AP	**+!**		**0.5%**	**N016964**	**005**	
AP	**+!**		**0.75%**	**N016964**	**009**	

SENSORCAINE

AP		FRESENIUS KABI USA	**0.25%**	**A070552**	**001**	May 21, 1986
AP	**+**		**0.25%**	**N018304**	**001**	
AP			**0.5%**	**A070553**	**001**	May 21, 1986
AP	**+**		**0.5%**	**N018304**	**002**	
AP			**0.75%**	**A070554**	**001**	May 21, 1986
AP	**+**		**0.75%**	**N018304**	**003**	

INJECTABLE;SPINAL

BUPIVACAINE HYDROCHLORIDE

AP		B BRAUN MEDICAL INC	**0.75%**	**A209087**	**001**	Apr 02, 2019
AP		HOSPIRA	**0.75%**	**A071810**	**001**	Dec 11, 1987
AP		HUONS	**0.75%**	**A212822**	**001**	Dec 30, 2019

MARCAINE

AP	**+!**	HOSPIRA	**0.75%**	**N018692**	**001**	May 04, 1984

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP	**!**	HOSPIRA	**0.5%;0.005MG/ML**	**A071168**	**001**	Jun 16, 1988
AP			**0.5%;0.005MG/ML**	**A071170**	**001**	Jun 16, 1988
	!		0.25%;0.005MG/ML	A071165	001	Jun 16, 1988
			0.25%;0.005MG/ML	A071167	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

AP	**+!**	HOSPIRA	**0.25%;0.0091MG/ML**	**N016964**	**004**	
AP	**+!**		**0.5%;0.0091MG/ML**	**N016964**	**008**	

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE

AP	**+!**	HOSPIRA	**0.25%;0.0091MG/ML**	**N016964**	**013**	
AP	**+!**		**0.5%;0.0091MG/ML**	**N016964**	**007**	
AP	**+!**		**0.75%;0.0091MG/ML**	**N016964**	**010**	

SENSORCAINE

AP		FRESENIUS KABI USA	**0.25%;0.0091MG/ML**	**A070966**	**001**	Oct 13, 1987
AP			**0.25%;0.0091MG/ML**	**A070967**	**001**	Oct 13, 1987
AP			**0.5%;0.0091MG/ML**	**A070968**	**001**	Oct 13, 1987
AP	**+**		**0.5%;0.0091MG/ML**	**N018304**	**004**	Sep 02, 1983

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

SENSORCAINE

AP	**+**		**0.75%;0.0091MG/ML**	**N018304**	**005**	Sep 02, 1983

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

	!	SEPTODONT	0.5%;0.0091MG/ML	A077250	001	Sep 27, 2006

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE;PERIARTICULAR

ZYNRELEF KIT

	+!	HERON THERAPS INC	200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML)	N211988	002	May 12, 2021
	+!		400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML)	N211988	004	May 12, 2021

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUPRENORPHINE

AB		ALVOGEN	**5MCG/HR**	**A207490**	**001**	May 17, 2022
AB			**10MCG/HR**	**A207490**	**002**	May 17, 2022
AB			**15MCG/HR**	**A207490**	**003**	May 17, 2022
AB			**20MCG/HR**	**A207490**	**004**	May 17, 2022
AB		AMNEAL	**5MCG/HR**	**A211586**	**001**	Apr 14, 2020
AB			**7.5MCG/HR**	**A211586**	**002**	Apr 14, 2020
AB			**10MCG/HR**	**A211586**	**003**	Apr 14, 2020
AB			**15MCG/HR**	**A211586**	**004**	Apr 14, 2020
AB			**20MCG/HR**	**A211586**	**005**	Apr 14, 2020
AB		AVEVA	**5MCG/HR**	**A210272**	**001**	Sep 23, 2021
AB			**7.5MCG/HR**	**A210272**	**002**	Sep 23, 2021
AB			**10MCG/HR**	**A210272**	**003**	Sep 23, 2021
AB			**15MCG/HR**	**A210272**	**004**	Sep 23, 2021
AB			**20MCG/HR**	**A210272**	**005**	Sep 23, 2021
AB		WATSON LABS TEVA	**5MCG/HR**	**A204937**	**001**	Nov 20, 2018
AB			**7.5MCG/HR**	**A204937**	**005**	Jun 29, 2021
AB			**10MCG/HR**	**A204937**	**002**	Nov 20, 2018
AB			**15MCG/HR**	**A204937**	**003**	Nov 20, 2018
AB			**20MCG/HR**	**A204937**	**004**	Nov 20, 2018

BUTRANS

AB	**+**	PURDUE PHARMA LP	**5MCG/HR**	**N021306**	**001**	Jun 30, 2010
AB	**+**		**7.5MCG/HR**	**N021306**	**005**	Jun 30, 2014
AB	**+**		**10MCG/HR**	**N021306**	**002**	Jun 30, 2010
AB	**+**		**15MCG/HR**	**N021306**	**004**	Jul 25, 2013
AB	**+!**		**20MCG/HR**	**N021306**	**003**	Jun 30, 2010

SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

BRIXADI

	+	BRAEBURN	8MG/0.16ML (50MG/ML)	N210136	001	May 23, 2023
	+		16MG/0.32ML (50MG/ML)	N210136	002	May 23, 2023
	+		24MG/0.48ML (50MG/ML)	N210136	003	May 23, 2023
	+		32MG/0.64ML (50MG/ML)	N210136	004	May 23, 2023
	+		64MG/0.18ML (356MG/ML)	N210136	005	May 23, 2023
	+		96MG/0.27ML (356MG/ML)	N210136	006	May 23, 2023
	+!		128MG/0.36ML (356MG/ML)	N210136	007	May 23, 2023

SUBLOCADE

	+	INDIVIOR	100MG/0.5ML (100MG/0.5ML)	N209819	001	Nov 30, 2017
	+!		300MG/1.5ML (200MG/ML)	N209819	002	Nov 30, 2017

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

	+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015
	+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015
	+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015
	+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015
	+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015
	+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015
	+!		EQ 0.9MG BASE	N207932	007	Oct 23, 2015

INJECTABLE;INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP		AM REGENT	**EQ 0.3MG BASE/ML**	**A078331**	**001**	Mar 27, 2007
AP		HIKMA	**EQ 0.3MG BASE/ML**	**A076931**	**001**	Mar 02, 2005
AP		HOSPIRA	**EQ 0.3MG BASE/ML**	**A074137**	**001**	Jun 03, 1996
AP	**!**	PAR STERILE PRODUCTS	**EQ 0.3MG BASE/ML**	**A206586**	**001**	Jul 28, 2015

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 2MG BASE**	**A090819**	**001**	Feb 19, 2015
AB			**EQ 8MG BASE**	**A090819**	**002**	Feb 19, 2015
AB		ETHYPHARM	**EQ 2MG BASE**	**A090622**	**001**	Sep 24, 2010
AB			**EQ 8MG BASE**	**A090622**	**002**	Sep 24, 2010
AB		HIKMA	**EQ 2MG BASE**	**A078633**	**001**	Oct 08, 2009
AB	**!**		**EQ 8MG BASE**	**A078633**	**002**	Oct 08, 2009
AB		RHODES PHARMS	**EQ 2MG BASE**	**A207276**	**001**	Mar 27, 2017
AB			**EQ 8MG BASE**	**A207276**	**002**	Mar 27, 2017
AB		RUBICON	**EQ 2MG BASE**	**A090279**	**001**	Jun 10, 2015
AB			**EQ 8MG BASE**	**A090279**	**002**	Jun 10, 2015
AB		SUN PHARM	**EQ 2MG BASE**	**A201760**	**001**	Jan 29, 2016
AB			**EQ 8MG BASE**	**A201760**	**002**	Jan 29, 2016

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ALVOGEN	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205954**	**001**	Jan 24, 2019
AB			**EQ 4MG BASE;EQ 1MG BASE**	**A205954**	**002**	Jan 24, 2019
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205954**	**003**	Jan 24, 2019
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A205954**	**004**	Jan 24, 2019
AB		AVEVA	**EQ 8MG BASE;EQ 2MG BASE**	**A212756**	**001**	Jun 02, 2022
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A212756**	**002**	Jun 02, 2022
AB		DR REDDYS LABS SA	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205299**	**001**	Jun 14, 2018
AB			**EQ 4MG BASE;EQ 1MG BASE**	**A205806**	**001**	Jun 14, 2018
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205299**	**002**	Jun 14, 2018
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A205806**	**002**	Jun 14, 2018
AB		MYLAN TECHNOLOGIES	**EQ 2MG BASE;EQ 0.5MG BASE**	**A211785**	**001**	Apr 17, 2020
AB			**EQ 4MG BASE;EQ 1MG BASE**	**A211785**	**002**	Apr 17, 2020
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A207607**	**001**	Jun 14, 2018
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A207607**	**002**	Jun 14, 2018

SUBOXONE

AB	**+**	INDIVIOR	**EQ 2MG BASE;EQ 0.5MG BASE**	**N022410**	**001**	Aug 30, 2010
AB	**+**		**EQ 4MG BASE;EQ 1MG BASE**	**N022410**	**003**	Aug 10, 2012
AB	**+**		**EQ 8MG BASE;EQ 2MG BASE**	**N022410**	**002**	Aug 30, 2010
AB	**+!**		**EQ 12MG BASE;EQ 3MG BASE**	**N022410**	**004**	Aug 10, 2012

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 2MG BASE;EQ 0.5MG BASE**	**A091422**	**001**	Feb 22, 2013
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A091422**	**002**	Feb 22, 2013
AB		ALKEM LABS LTD	**EQ 2MG BASE;EQ 0.5MG BASE**	**A214930**	**001**	Jun 15, 2021
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A214930**	**002**	Jun 15, 2021
AB		AMNEAL PHARMS	**EQ 2MG BASE;EQ 0.5MG BASE**	**A203136**	**001**	Feb 22, 2013
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A203136**	**002**	Feb 22, 2013
AB		ETHYPHARM USA CORP	**EQ 2MG BASE;EQ 0.5MG BASE**	**A204431**	**001**	Oct 16, 2015
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A204431**	**002**	Oct 16, 2015
AB		HIKMA	**EQ 2MG BASE;EQ 0.5MG BASE**	**A203326**	**001**	Jun 27, 2014
AB	**!**		**EQ 8MG BASE;EQ 2MG BASE**	**A203326**	**002**	Jun 27, 2014
AB		LANNETT CO INC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205022**	**001**	Sep 19, 2016
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205022**	**002**	Sep 19, 2016
AB		RHODES PHARMS	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205601**	**001**	Mar 30, 2020
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205601**	**002**	Mar 30, 2020
AB		SPECGX LLC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A207000**	**001**	Dec 13, 2017
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A207000**	**002**	Dec 13, 2017
AB		SUN PHARM	**EQ 2MG BASE;EQ 0.5MG BASE**	**A201633**	**001**	Aug 05, 2016
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A201633**	**002**	Aug 05, 2016
AB		WES PHARMA INC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A209069**	**001**	Jul 17, 2020
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A209069**	**002**	Jul 17, 2020

ZUBSOLV

+		OREXO US INC	EQ 0.7MG BASE;EQ 0.18MG BASE	N204242	006	Oct 04, 2016
+			EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013
+			EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015
+			EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013
+			EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014
+!			EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

+	BAUSCH	174MG	N022108	001	Apr 23, 2008
+		348MG	N022108	002	Apr 23, 2008
+!		522MG	N022108	003	Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	ALEMBIC	**75MG**	**A203013**	**001**	Jun 08, 2018
AB		**100MG**	**A203013**	**002**	Jun 08, 2018
AB	APNAR PHARMA LP	**75MG**	**A075584**	**001**	Feb 07, 2000
AB		**100MG**	**A075584**	**002**	Feb 07, 2000
AB	APOTEX INC	**75MG**	**A076143**	**001**	Jan 17, 2006
AB !		**100MG**	**A076143**	**002**	Jan 17, 2006
AB	CADILA PHARMS LTD	**75MG**	**A208606**	**001**	Jan 16, 2020
AB		**100MG**	**A208606**	**002**	Jan 16, 2020
AB	HERITAGE PHARMA	**75MG**	**A206975**	**001**	Aug 19, 2016
AB		**100MG**	**A206975**	**002**	Aug 19, 2016
AB	INVAGEN PHARMS	**75MG**	**A207389**	**001**	Sep 18, 2017
AB		**100MG**	**A207389**	**002**	Sep 18, 2017
AB	MICRO LABS	**75MG**	**A207403**	**001**	Apr 17, 2020
AB		**100MG**	**A207403**	**002**	Apr 17, 2020

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	ACTAVIS LABS FL INC	**100MG**	**A079095**	**001**	Mar 24, 2009
AB1		**150MG**	**A079095**	**002**	Mar 24, 2009
AB1		**200MG**	**A079095**	**003**	Mar 24, 2009
AB1	ANCHEN PHARMS	**100MG**	**A091459**	**001**	Jun 09, 2011
AB1		**150MG**	**A091459**	**002**	Jun 09, 2011
AB1		**200MG**	**A091459**	**003**	Jun 09, 2011
AB1	ANNORA PHARMA	**100MG**	**A216800**	**001**	May 31, 2023
AB1		**150MG**	**A216800**	**002**	May 31, 2023
AB1		**200MG**	**A216800**	**003**	May 31, 2023
AB1	EPIC PHARMA LLC	**100MG**	**A075932**	**001**	Nov 25, 2003
AB1		**150MG**	**A075932**	**002**	Mar 22, 2004
AB1		**200MG**	**A075932**	**003**	Jun 22, 2005
AB1	IMPAX LABS	**100MG**	**A075913**	**001**	Jan 28, 2004
AB1		**150MG**	**A075913**	**002**	Mar 22, 2004
AB1	INVAGEN PHARMS	**100MG**	**A206674**	**001**	Feb 09, 2016
AB1		**150MG**	**A206674**	**002**	Feb 09, 2016
AB1		**200MG**	**A206674**	**003**	Feb 09, 2016
AB1	PRINSTON INC	**100MG**	**A202304**	**001**	May 26, 2015
AB1		**150MG**	**A202304**	**002**	May 26, 2015
AB1		**200MG**	**A202304**	**003**	May 26, 2015
AB1	SCIEGEN PHARMS INC	**100MG**	**A205794**	**001**	Mar 01, 2016
AB1		**150MG**	**A205794**	**002**	Mar 01, 2016
AB1		**200MG**	**A205794**	**003**	Mar 01, 2016
AB1	SUN PHARM	**150MG**	**A078866**	**002**	Apr 06, 2010
AB1		**200MG**	**A078866**	**003**	Apr 06, 2010
AB1	YICHANG HUMANWELL	**100MG**	**A211347**	**001**	Oct 16, 2018
AB1		**150MG**	**A211347**	**002**	Oct 16, 2018
AB1		**200MG**	**A211347**	**003**	Oct 16, 2018

WELLBUTRIN SR

AB1 +	GLAXOSMITHKLINE	**100MG**	**N020358**	**002**	Oct 04, 1996
AB1 +		**150MG**	**N020358**	**003**	Oct 04, 1996
AB1 +!		**200MG**	**N020358**	**004**	Jun 14, 2002

BUPROPION HYDROCHLORIDE

AB2 !	ACTAVIS LABS FL INC	**150MG**	**A079094**	**001**	Mar 24, 2009
AB2	ANCHEN PHARMS	**150MG**	**A091520**	**001**	Jun 09, 2011
AB2	IMPAX LABS	**150MG**	**A075914**	**001**	May 27, 2004
AB2	SANDOZ	**150MG**	**A077475**	**001**	Mar 12, 2008
AB2	SCIEGEN PHARMS INC	**150MG**	**A206122**	**001**	Aug 17, 2016
AB2	YICHANG HUMANWELL	**150MG**	**A216766**	**001**	Jan 09, 2023
AB3	ACCORD HLTHCARE	**150MG**	**A210497**	**001**	Oct 31, 2018
AB3		**300MG**	**A210497**	**002**	Oct 31, 2018
AB3	ACTAVIS LABS FL INC	**150MG**	**A077715**	**001**	Nov 26, 2008
AB3	ANBISON LAB	**150MG**	**A207224**	**001**	Jun 30, 2017
AB3		**300MG**	**A207224**	**002**	Jun 30, 2017
AB3	GRANULES	**150MG**	**A215568**	**001**	Feb 02, 2022
AB3		**300MG**	**A215568**	**002**	Feb 02, 2022
AB3	GRAVITI PHARMS	**150MG**	**A211020**	**001**	Jan 28, 2019

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB3			**300MG**	**A211020**	**002**	Jan 28, 2019
AB3		INVAGEN PHARMS	**150MG**	**A206556**	**001**	Aug 26, 2016
AB3			**300MG**	**A206556**	**002**	Aug 26, 2016
AB3		LUPIN LTD	**150MG**	**A090693**	**001**	Apr 06, 2017
AB3			**300MG**	**A090693**	**002**	Apr 06, 2017
AB3		SCIEGEN PHARMS INC	**150MG**	**A207479**	**001**	Apr 12, 2017
AB3			**300MG**	**A207479**	**002**	Apr 12, 2017
AB3		SCINOPHARM TAIWAN	**150MG**	**A210081**	**001**	Nov 03, 2017
AB3			**300MG**	**A210081**	**002**	Nov 03, 2017
AB3		SINOTHERAPEUTICS INC	**150MG**	**A208652**	**001**	Aug 21, 2017
AB3			**300MG**	**A208652**	**002**	Aug 21, 2017
AB3		SUN PHARM	**150MG**	**A200216**	**001**	Nov 30, 2020
AB3			**300MG**	**A203650**	**001**	Dec 31, 2020
AB3		WATSON LABS INC	**150MG**	**A077285**	**001**	Nov 26, 2008
AB3			**300MG**	**A077285**	**002**	Aug 15, 2008
AB3		WOCKHARDT LTD	**150MG**	**A202189**	**001**	Nov 21, 2012
AB3			**300MG**	**A202189**	**002**	Jan 28, 2022
AB3		YICHANG HUMANWELL	**150MG**	**A210015**	**001**	Jun 14, 2018
AB3			**300MG**	**A210015**	**002**	Jun 14, 2018
AB3		ZHEJIANG JUTAI PHARM	**150MG**	**A211200**	**002**	Apr 29, 2020
AB3			**300MG**	**A211200**	**001**	Sep 05, 2019
AB3		ZYDUS PHARMS	**150MG**	**A201567**	**002**	Jul 23, 2018
AB3			**300MG**	**A201567**	**001**	Jan 17, 2014

WELLBUTRIN XL

AB3	**+**	BAUSCH	**150MG**	**N021515**	**001**	Aug 28, 2003
AB3	**+!**		**300MG**	**N021515**	**002**	Aug 28, 2003

FORFIVO XL

	+!	TWI PHARMS	450MG	N022497	001	Nov 10, 2011

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

AUVELITY

	+!	AXSOME	105MG;45MG	N215430	001	Aug 18, 2022

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

	+!	NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**5MG**	**A202557**	**001**	Dec 30, 2014
AB			**7.5MG**	**A202557**	**002**	Dec 30, 2014
AB			**10MG**	**A202557**	**003**	Dec 30, 2014
AB	**!**		**15MG**	**A202557**	**004**	Dec 30, 2014
AB			**30MG**	**A202557**	**005**	Dec 30, 2014
AB		AMNEAL PHARMS CO	**5MG**	**A208829**	**001**	May 24, 2017
AB			**7.5MG**	**A208829**	**002**	May 24, 2017
AB			**10MG**	**A208829**	**003**	May 24, 2017
AB			**15MG**	**A208829**	**004**	May 24, 2017
AB			**30MG**	**A208829**	**005**	May 24, 2017
AB		AUROBINDO PHARMA LTD	**5MG**	**A078246**	**001**	Feb 27, 2009
AB			**7.5MG**	**A078246**	**005**	Feb 21, 2020
AB			**10MG**	**A078246**	**002**	Feb 27, 2009
AB			**15MG**	**A078246**	**003**	Feb 27, 2009
AB			**30MG**	**A078246**	**004**	Feb 27, 2009
AB		EPIC PHARMA LLC	**5MG**	**A208972**	**001**	Apr 16, 2019
AB			**7.5MG**	**A208972**	**002**	Apr 16, 2019
AB			**10MG**	**A208972**	**003**	Apr 16, 2019
AB			**15MG**	**A208972**	**004**	Apr 16, 2019
AB			**30MG**	**A208972**	**005**	Apr 16, 2019
AB		HERITAGE PHARMA	**5MG**	**A204582**	**001**	Sep 18, 2015
AB			**10MG**	**A204582**	**002**	Sep 18, 2015
AB			**15MG**	**A204582**	**003**	Sep 18, 2015
AB			**30MG**	**A204582**	**004**	Sep 18, 2015
AB		IMPAX LABS INC	**5MG**	**A074253**	**001**	Mar 28, 2001
AB			**10MG**	**A074253**	**002**	Mar 28, 2001

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB		**15MG**	**A074253**	**003**	Mar 13, 2002
AB	INVENTIA HLTHCARE	**5MG**	**A209696**	**001**	May 03, 2018
AB		**7.5MG**	**A209696**	**002**	May 03, 2018
AB		**10MG**	**A209696**	**003**	May 03, 2018
AB		**15MG**	**A209696**	**004**	May 03, 2018
AB		**30MG**	**A209696**	**005**	May 03, 2018
AB	MYLAN	**5MG**	**A076008**	**003**	Mar 01, 2002
AB		**7.5MG**	**A076008**	**002**	Jul 08, 2013
AB		**10MG**	**A076008**	**004**	Mar 01, 2002
AB		**15MG**	**A076008**	**005**	Mar 28, 2001
AB		**30MG**	**A076008**	**001**	Jun 28, 2001
AB	OXFORD PHARMS	**5MG**	**A075388**	**001**	May 09, 2002
AB		**10MG**	**A075388**	**002**	May 09, 2002
AB		**15MG**	**A075388**	**003**	May 09, 2002
AB		**30MG**	**A078302**	**001**	Dec 17, 2007
AB	RUBICON	**5MG**	**A075521**	**001**	Apr 05, 2002
AB		**7.5MG**	**A075521**	**004**	Mar 16, 2021
AB		**10MG**	**A075521**	**002**	Apr 05, 2002
AB		**15MG**	**A075521**	**003**	Apr 05, 2002
AB		**30MG**	**A075521**	**005**	Mar 16, 2021
AB	STRIDES PHARMA	**5MG**	**A202330**	**001**	Aug 25, 2014
AB		**7.5MG**	**A202330**	**005**	Feb 17, 2017
AB		**10MG**	**A202330**	**002**	Aug 25, 2014
AB		**15MG**	**A202330**	**003**	Aug 25, 2014
AB		**30MG**	**A202330**	**004**	Aug 25, 2014
AB	TEVA	**5MG**	**A075022**	**001**	Feb 28, 2002
AB		**10MG**	**A075022**	**002**	Feb 28, 2002
AB		**15MG**	**A075022**	**003**	Feb 28, 2002
AB		**30MG**	**A075022**	**004**	Mar 25, 2004
AB	UNICHEM	**5MG**	**A210907**	**001**	Nov 14, 2019
AB		**10MG**	**A210907**	**002**	Nov 14, 2019
AB		**15MG**	**A210907**	**003**	Nov 14, 2019
AB		**30MG**	**A210907**	**004**	Nov 14, 2019
AB	YILING	**5MG**	**A202087**	**001**	Dec 16, 2015
AB		**10MG**	**A202087**	**002**	Dec 16, 2015
AB		**15MG**	**A202087**	**003**	Dec 16, 2015
AB		**30MG**	**A202087**	**004**	Dec 16, 2015
AB	ZYDUS PHARMS	**5MG**	**A078888**	**001**	Feb 07, 2014
AB		**7.5MG**	**A078888**	**005**	Mar 21, 2023
AB		**10MG**	**A078888**	**002**	Feb 07, 2014
AB		**15MG**	**A078888**	**003**	Feb 07, 2014
AB		**30MG**	**A078888**	**004**	Feb 07, 2014

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP	ACCORD HLTHCARE INC	**6MG/ML**	**A210148**	**001**	Feb 22, 2019
AP	AMNEAL	**6MG/ML**	**A209580**	**001**	Dec 18, 2017
AP	APOTEX	**6MG/ML**	**A210448**	**001**	May 07, 2019
AP	HOSPIRA	**6MG/ML**	**A205672**	**001**	Jul 31, 2018
AP	MEITHEAL	**6MG/ML**	**A212127**	**001**	Oct 23, 2020
AP	MYLAN INSTITUTIONAL	**6MG/ML**	**A208536**	**001**	Nov 20, 2017
AP	NEXUS	**6MG/ML**	**A207794**	**001**	Jan 14, 2019
AP	PHARMASCIENCE INC	**6MG/ML**	**A207050**	**001**	Mar 24, 2017
AP	SHILPA	**6MG/ML**	**A210931**	**001**	Apr 18, 2019

BUSULFEX

AP **+!**	OTSUKA PHARM	**6MG/ML**	**N020954**	**001**	Feb 04, 1999

TABLET;ORAL

MYLERAN

+!	WAYLIS THERAP	2MG	N009386	001	

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

GYNAZOLE-1

!	PADAGIS ISRAEL	2%	A200923	001	May 18, 2012

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE						
AP		HIKMA	**2MG/ML**	**A075046**	**001**	Aug 12, 1998
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A078400**	**001**	May 01, 2009
AP			**2MG/ML**	**A078400**	**002**	May 01, 2009
BUTORPHANOL TARTRATE PRESERVATIVE FREE						
AP		HIKMA	**1MG/ML**	**A075045**	**001**	Aug 12, 1998
AP			**2MG/ML**	**A075045**	**002**	Aug 12, 1998
AP	!	HOSPIRA	**1MG/ML**	**A074626**	**001**	Jan 23, 1997
AP	!		**2MG/ML**	**A074626**	**002**	Jan 23, 1997

SPRAY, METERED;NASAL

BUTORPHANOL TARTRATE						
AB		APOTEX	**1MG/SPRAY**	**A075499**	**001**	Dec 04, 2002
AB		HIKMA	**1MG/SPRAY**	**A075824**	**001**	Mar 12, 2002
AB	!	RISING	**1MG/SPRAY**	**A075759**	**001**	Aug 08, 2001

CABAZITAXEL

SOLUTION;INTRAVENOUS

CABAZITAXEL						
AP		ACCORD HLTHCARE	**60MG/1.5ML (40MG/ML)**	**A207693**	**001**	Oct 26, 2022
AP		DR REDDYS	**60MG/1.5ML (40MG/ML)**	**A207718**	**001**	Feb 10, 2023
JEVTANA KIT						
AP	**+!**	SANOFI AVENTIS US	**60MG/1.5ML (40MG/ML)**	**N201023**	**001**	Jun 17, 2010
CABAZITAXEL						
	+!	ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021

CABERGOLINE

TABLET;ORAL

CABERGOLINE						
AB	!	INGENUS PHARMS LLC	**0.5MG**	**A204735**	**001**	Aug 01, 2018
AB		IVAX SUB TEVA PHARMS	**0.5MG**	**A077750**	**001**	Mar 07, 2007
AB		STRIDES PHARMA	**0.5MG**	**A076310**	**001**	Dec 29, 2005

CABOTEGRAVIR

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

APRETUDE						
	+!	VIIV HLTHCARE	600MG/3ML (200MG/ML)	N215499	001	Dec 20, 2021

CABOTEGRAVIR SODIUM

TABLET;ORAL

VOCABRIA						
	+!	VIIV HLTHCARE	EQ 30MG BASE	N212887	001	Jan 21, 2021

CABOTEGRAVIR; RILPIVIRINE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

CABENUVA KIT						
	+!	VIIV HLTHCARE	400MG/2ML (200MG/ML);600MG/2ML (300MG/ML)	N212888	001	Jan 21, 2021
	+!		600MG/3ML (200MG/ML);900MG/3ML (300MG/ML)	N212888	002	Jan 21, 2021

CABOZANTINIB S-MALATE

CAPSULE;ORAL

COMETRIQ						
	+	EXELIXIS	EQ 20MG BASE	N203756	001	Nov 29, 2012
	+!		EQ 80MG BASE	N203756	002	Nov 29, 2012

TABLET;ORAL

CABOMETYX						
	+	EXELIXIS INC	EQ 20MG BASE	N208692	001	Apr 25, 2016
	+		EQ 40MG BASE	N208692	002	Apr 25, 2016
	+!		EQ 60MG BASE	N208692	003	Apr 25, 2016

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFCIT						
AP	**+!**	HIKMA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N020793**	**001**	Sep 21, 1999
CAFFEINE CITRATE						
AP		AM REGENT	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077906**	**001**	May 15, 2007
AP		EUGIA PHARMA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A205013**	**001**	Sep 22, 2015
AP		EXELA PHARMA SCIENCE	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077233**	**001**	Sep 21, 2006
AP		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077997**	**001**	Jul 20, 2007
AP		MICRO LABS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A207400**	**001**	Dec 14, 2017
AP		SAGENT PHARMS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090827**	**001**	Aug 29, 2012

CAFFEINE CITRATE

SOLUTION;ORAL

CAFFEINE CITRATE

AA	**!**	EXELA PHARMA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077304**	**001**	Sep 21, 2006
AA		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A078002**	**001**	Jan 31, 2008
AA		MICRO LABS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A213202**	**001**	Dec 16, 2019
AA		SAGENT PHARMS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A091102**	**001**	Aug 29, 2012
AA		SUN PHARM	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090357**	**001**	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

+!	COSETTE	100MG;2MG	A086557	001	Oct 04, 1983

TABLET;ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

!	MIKART	100MG;1MG	A040590	001	Sep 16, 2005

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE;ORAL

RAYALDEE

+!	EIRGEN	0.03MG	N208010	001	Jun 17, 2016

CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

SORILUX

+!	MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010

CREAM;TOPICAL

CALCIPOTRIENE

AB		GLENMARK PHARMS	**0.005%**	**A205772**	**001**	Jun 09, 2015

DOVONEX

AB	**+!**	LEO PHARMA AS	**0.005%**	**N020554**	**001**	Jul 22, 1996

OINTMENT;TOPICAL

CALCIPOTRIENE

AB	**!**	GLENMARK PHARMS INC	**0.005%**	**A090633**	**001**	Mar 24, 2010

DOVONEX

AB	**+**	LEO PHARMA AS	**0.005%**	**N020273**	**001**	Dec 29, 1993

SOLUTION;TOPICAL

CALCIPOTRIENE

AT		CHARTWELL RX	**0.005%**	**A207163**	**001**	Dec 26, 2017
AT	**!**	COSETTE	**0.005%**	**A078468**	**001**	Mar 24, 2011
AT		FOUGERA PHARMS	**0.005%**	**A078305**	**001**	May 06, 2008
AT		HIKMA	**0.005%**	**A077579**	**001**	Nov 19, 2009

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

AP		CUSTOPHARM INC	**200 IU/ML**	**A212416**	**001**	May 14, 2021
AP		PAR STERILE PRODUCTS	**200 IU/ML**	**A209358**	**001**	Nov 10, 2021

MIACALCIN

AP	**+!**	MYLAN IRELAND LTD	**200 IU/ML**	**N017808**	**002**	Mar 29, 1991

SPRAY, METERED;NASAL

CALCITONIN-SALMON

!	APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB		AMNEAL PHARMS	**0.25MCG**	**A203289**	**002**	Jun 14, 2017
AB			**0.5MCG**	**A203289**	**001**	Jun 14, 2017
AB		BIONPHARMA	**0.25MCG**	**A091174**	**001**	May 24, 2013
AB			**0.5MCG**	**A091174**	**002**	May 24, 2013
AB		HIKMA	**0.25MCG**	**A076917**	**001**	Mar 27, 2006
AB		STRIDES PHARMA	**0.25MCG**	**A091356**	**001**	Dec 12, 2014
AB	**!**		**0.5MCG**	**A091356**	**002**	Dec 12, 2014
AB		SUN PHARM	**0.25MCG**	**A204556**	**001**	Feb 21, 2019
AB			**0.5MCG**	**A204556**	**002**	Feb 21, 2019
AB		TEVA	**0.25MCG**	**A075765**	**001**	Oct 12, 2001
AB			**0.5MCG**	**A075765**	**002**	Oct 12, 2001

ROCALTROL

AB	**+**	SS PHARMA	**0.25MCG**	**N018044**	**001**	
AB	**+**		**0.5MCG**	**N018044**	**002**	

INJECTABLE;INJECTION

CALCITRIOL

AP		GLAND PHARMA LTD	**0.001MG/ML**	**A211030**	**001**	Feb 03, 2020

CALCITRIOL						
INJECTABLE;INJECTION						
CALCITRIOL						
AP	**!**	LONG GROVE PHARMS	**0.001MG/ML**	**A078066**	**001**	Jan 29, 2008
OINTMENT;TOPICAL						
VECTICAL						
	+!	GALDERMA LABS LP	3MCG/GM	N022087	001	Jan 23, 2009
SOLUTION;ORAL						
CALCITRIOL						
AA		HIKMA	**1MCG/ML**	**A076242**	**001**	Jul 18, 2003
AA		PATRIN	**1MCG/ML**	**A203973**	**001**	Jul 28, 2023
AA		RISING	**1MCG/ML**	**A209798**	**001**	Nov 21, 2018
ROCALTROL						
AA	**+!**	SS PHARMA	**1MCG/ML**	**N021068**	**001**	Nov 20, 1998
CALCIUM ACETATE						
CAPSULE;ORAL						
CALCIUM ACETATE						
AB		CHARTWELL RX	**667MG**	**A091312**	**001**	Jun 01, 2012
AB		HERITAGE PHARMS INC	**667MG**	**A202315**	**001**	Jun 29, 2015
AB		HIKMA	**667MG**	**A077728**	**001**	Feb 26, 2008
AB		INVAGEN PHARMS	**667MG**	**A203135**	**001**	Feb 07, 2013
AB		LUPIN LTD	**667MG**	**A202127**	**001**	Jul 09, 2015
AB		NOSTRUM LABS INC	**667MG**	**A203179**	**001**	Oct 26, 2015
AB		SQUARE PHARMS	**667MG**	**A217205**	**001**	Mar 13, 2023
AB		SUVEN PHARMS	**667MG**	**A211038**	**001**	Feb 21, 2020
PHOSLO GELCAPS						
AB	**+!**	FRESENIUS MEDCL	**667MG**	**N021160**	**003**	Apr 02, 2001
TABLET;ORAL						
CALCIUM ACETATE						
AB	**!**	CHARTWELL MOLECULAR	**667MG**	**A202420**	**001**	Feb 05, 2013
AB		HERITAGE PHARMS INC	**667MG**	**A202885**	**001**	Jan 22, 2015
AB		PADAGIS US	**667MG**	**A091561**	**001**	Apr 13, 2011
CALCIUM CHLORIDE						
INJECTABLE;INJECTION						
CALCIUM CHLORIDE 10%						
AP		AM REGENT	**100MG/ML**	**A209088**	**001**	Jul 27, 2017
AP		INTL MEDICATION SYS	**100MG/ML**	**A203477**	**001**	May 09, 2018
AP		MEDEFIL INC	**100MG/ML**	**A211553**	**001**	May 01, 2019
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER						
AP	**+!**	HOSPIRA	**100MG/ML**	**N021117**	**001**	Jan 28, 2000
CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE						
SOLUTION;IRRIGATION						
BSS PLUS						
	+!	ALCON	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N018469	001	
CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE						
INJECTABLE;INJECTION						
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER						
	+!	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER						
	+!	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER						
	+!	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER						
	+!	BAXTER HLTHCARE CORP	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER						
	+!	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER						
	+!	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09	N021703	004	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

			GM/1000ML;6.46GM/1000ML (5000ML)			

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44 GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46 GM/1000ML (5000ML)	N021703	014	Oct 10, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML**	**N018883**	**001**	Nov 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML**	**N018883**	**004**	Nov 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML**	**N020171**	**001**	Aug 19, 1992

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML**	**N018883**	**002**	Nov 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML**	**N018883**	**005**	Nov 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML**	**N020171**	**002**	Aug 19, 1992

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML**	**N018883**	**003**	Nov 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML**	**N018883**	**006**	Nov 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**18.4MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML**	**N020171**	**003**	Aug 19, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML**	**N020183**	**001**	Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML**	**N020183**	**002**	Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML**	**N020183**	**004**	Dec 04, 1992

DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML**	**N017512**	**012**	Jan 10, 1989

DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML**	**N017512**	**013**	Jul 11, 1990

DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML**	**N017512**	**014**	Jul 11, 1990

DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML**	**N017512**	**015**	Jul 11, 1990

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML**	**N017512**	**004**	
AT	**+**		**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML**	**N020163**	**001**	Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML**	**N017512**	**005**	
AT	**+**		**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML**	**N020163**	**002**	Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML**	**N017512**	**006**	
AT	**+**		**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML**	**N020163**	**003**	Dec 04, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INTRATHECAL

ELLIOTTS B SOLUTION

	+!	LUKARE MEDICAL LLC	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9 MG/ML;7.3MG/ML;0.2MG/ML	N020577	001	Sep 27, 1996

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	**+**	ICU MEDICAL INC	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N017608**	**001**	

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019634**	**003**	Feb 24, 1988

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N016679**	**001**	

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**006**	Apr 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**004**	Apr 05, 1985
AP			**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**005**	Apr 05, 1985
AP	**+**	ICU MEDICAL INC	**20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML**	**N019685**	**002**	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**007**	Apr 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**008**	Apr 05, 1985

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

		B BRAUN	10MG/100ML;2.5GM/100ML;15MG/100ML;300MG /100ML;160MG/100ML	N019634	001	Feb 24, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

		BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	002	Apr 05, 1985
			20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019367	003	Apr 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

		BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	001	Apr 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	+!	HOSPIRA	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML; 16.1MG/ML	N018895	001	Jul 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION;IRRIGATION

BALANCED SALT

AT		B BRAUN	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**A091387**	**001**	Feb 03, 2010

BSS

AT	**+!**	ALCON	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**N020742**	**001**	Dec 10, 1997

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML ;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/10	N207026	001	Jan 13, 2015

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION;PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT		BAXTER HLTHCARE	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**A075323**	**001**	Apr 21, 2000
AT		FRESENIUS KABI USA	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**A214623**	**001**	Feb 18, 2022

PLEGISOL IN PLASTIC CONTAINER

AT	**+!**	HOSPIRA	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**N018608**	**001**	Feb 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**33MG/100ML;30MG/100ML;860MG/100ML**	**N020002**	**001**	Apr 17, 1992
AP		BAXTER HLTHCARE	**33MG/100ML;30MG/100ML;860MG/100ML**	**N016693**	**001**	
AP		ICU MEDICAL INC	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018251**	**001**	

SOLUTION;IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT		B BRAUN	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018156**	**001**	
AT		BAXTER HLTHCARE	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018495**	**001**	Feb 19, 1982
AT		ICU MEDICAL INC	**33MG/100ML;30MG/100ML;860MG/100ML**	**N017635**	**001**	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019632**	**001**	Feb 29, 1988
AP	**+!**	BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N016682**	**001**	
AP		FRESENIUS KABI USA	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**A209338**	**001**	Jan 28, 2019
AP		ICU MEDICAL INC	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N017641**	**001**	

SOLUTION;IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	**+!**	B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018681**	**001**	Dec 27, 1982
AT		BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018494**	**001**	Feb 19, 1982
AT	**+!**		**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018921**	**001**	Apr 03, 1984
AT	**+!**	ICU MEDICAL INC	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019416**	**001**	Jan 17, 1986

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS

CALCIUM GLUCONATE

AP		B BRAUN MEDICAL INC	**10GM/100ML (100MG/ML)**	**A216541**	**001**	Aug 21, 2023
AP	**+!**	FRESENIUS KABI USA	**1GM/10ML (100MG/ML)**	**N208418**	**001**	Jun 15, 2017
AP	**+!**		**5GM/50ML (100MG/ML)**	**N208418**	**002**	Jun 15, 2017
AP	**+!**		**10GM/100ML (100MG/ML)**	**N208418**	**003**	Jun 15, 2017
AP		NIVAGEN PHARMS INC	**1GM/10ML (100MG/ML)**	**A213071**	**001**	Oct 14, 2022
AP			**5GM/50ML (100MG/ML)**	**A213071**	**002**	Oct 19, 2023
AP		SOMERSET	**5GM/50ML (100MG/ML)**	**A217689**	**001**	Oct 19, 2023
AP			**10GM/100ML (100MG/ML)**	**A217689**	**002**	Oct 19, 2023

CALCIUM GLUCONATE IN SODIUM CHLORIDE

AP		AMNEAL	**1GM/50ML (20MG/ML)**	**A217174**	**001**	Sep 05, 2023
AP			**2GM/100ML (20MG/ML)**	**A217174**	**002**	Sep 05, 2023
AP	**+!**	FRESENIUS KABI USA	**1GM/50ML (20MG/ML)**	**N208418**	**004**	Jun 17, 2021
AP	**+!**		**2GM/100ML (20MG/ML)**	**N208418**	**005**	Jun 17, 2021
	+!	HQ SPCLT PHARMA	1GM/50ML (20MG/ML)	N210906	001	Oct 29, 2018
	+!		1GM/100ML (10MG/ML)	N210906	003	Jun 04, 2021
	+!		2GM/100ML (20MG/ML)	N210906	002	Oct 29, 2018

CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE

SOLUTION;ORAL

XYWAV

	+!	JAZZ	0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML	N212690	001	Jul 21, 2020

CANAGLIFLOZIN

TABLET;ORAL

INVOKANA

+	JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013
+!		300MG	N204042	002	Mar 29, 2013

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

INVOKAMET

+	JANSSEN PHARMS	50MG;500MG	N204353	001	Aug 08, 2014
+		50MG;1GM	N204353	002	Aug 08, 2014
+		150MG;500MG	N204353	003	Aug 08, 2014
+!		150MG;1GM	N204353	004	Aug 08, 2014

TABLET, EXTENDED RELEASE;ORAL

INVOKAMET XR

+	JANSSEN PHARMS	50MG;500MG	N205879	001	Sep 20, 2016
+		50MG;1GM	N205879	002	Sep 20, 2016
+		150MG;500MG	N205879	003	Sep 20, 2016
+!		150MG;1GM	N205879	004	Sep 20, 2016

CANDESARTAN CILEXETIL

TABLET;ORAL

ATACAND

AB	**+**	ANI PHARMS	**4MG**	**N020838**	**001**	Jun 04, 1998
AB	**+**		**8MG**	**N020838**	**002**	Jun 04, 1998
AB	**+**		**16MG**	**N020838**	**003**	Jun 04, 1998
AB	**+!**		**32MG**	**N020838**	**004**	Jun 04, 1998

CANDESARTAN CILEXETIL

AB		ALEMBIC	**4MG**	**A210302**	**001**	Dec 04, 2018
AB			**8MG**	**A210302**	**002**	Dec 04, 2018
AB			**16MG**	**A210302**	**003**	Dec 04, 2018
AB			**32MG**	**A209119**	**001**	Jun 20, 2017
AB		MACLEODS PHARMS LTD	**4MG**	**A203813**	**001**	Dec 05, 2016
AB			**8MG**	**A203813**	**002**	Dec 05, 2016
AB			**16MG**	**A203813**	**003**	Dec 05, 2016
AB			**32MG**	**A203813**	**004**	Dec 05, 2016
AB		MYLAN	**4MG**	**A078702**	**001**	May 03, 2013
AB			**8MG**	**A078702**	**002**	May 03, 2013
AB			**16MG**	**A078702**	**003**	May 03, 2013
AB			**32MG**	**A078702**	**004**	May 03, 2013
AB		PRINSTON INC	**8MG**	**A206233**	**001**	Aug 21, 2023
AB			**16MG**	**A206233**	**002**	Aug 21, 2023
AB			**32MG**	**A206233**	**003**	Aug 21, 2023
AB		ZYDUS LIFESCIENCES	**4MG**	**A091390**	**001**	Aug 23, 2017
AB			**8MG**	**A091390**	**002**	Aug 23, 2017
AB			**16MG**	**A091390**	**003**	Aug 23, 2017
AB			**32MG**	**A091390**	**004**	Aug 23, 2017

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ATACAND HCT

AB	**+**	ANI PHARMS	**16MG;12.5MG**	**N021093**	**001**	Sep 05, 2000
AB	**+**		**32MG;12.5MG**	**N021093**	**002**	Sep 05, 2000
AB	**+!**		**32MG;25MG**	**N021093**	**003**	May 16, 2008

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB		DR REDDYS LABS LTD	**16MG;12.5MG**	**A202965**	**001**	Jun 03, 2013
AB			**32MG;12.5MG**	**A202965**	**002**	Jun 03, 2013
AB			**32MG;25MG**	**A202965**	**003**	Jun 03, 2013
AB		MACLEODS PHARMS LTD	**16MG;12.5MG**	**A204100**	**001**	Feb 27, 2015
AB			**32MG;12.5MG**	**A204100**	**002**	Feb 27, 2015
AB			**32MG;25MG**	**A204100**	**003**	Feb 27, 2015
AB		MYLAN	**16MG;12.5MG**	**A090704**	**001**	Dec 04, 2012
AB			**32MG;12.5MG**	**A090704**	**002**	Dec 04, 2012
AB			**32MG;25MG**	**A090704**	**003**	Dec 04, 2012
AB		PRINSTON INC	**16MG;12.5MG**	**A207455**	**001**	Apr 11, 2018
AB			**32MG;12.5MG**	**A207455**	**002**	Apr 11, 2018
AB			**32MG;25MG**	**A207455**	**003**	Apr 11, 2018
AB		ZYDUS LIFESCIENCES	**16MG;12.5MG**	**A203466**	**001**	Nov 27, 2017
AB			**32MG;12.5MG**	**A203466**	**002**	Nov 27, 2017
AB			**32MG;25MG**	**A203466**	**003**	Nov 27, 2017

CANGRELOR
POWDER;INTRAVENOUS
KENGREAL

	+!	CHIESI	50MG/VIAL	N204958	001	Jun 22, 2015

CANNABIDIOL
SOLUTION;ORAL
EPIDIOLEX

	+!	JAZZ PHARMS RES	100MG/ML	N210365	001	Sep 28, 2018

CANTHARIDIN
SOLUTION;TOPICAL
YCANTH

	+!	VERRICA PHARMS	0.7%	N212905	001	Jul 21, 2023

CAPECITABINE
TABLET;ORAL
CAPECITABINE

AB		ACCORD HLTHCARE	**150MG**	**A202593**	**001**	Apr 23, 2015
AB			**500MG**	**A202593**	**002**	Apr 23, 2015
AB		ALKEM LABS LTD	**150MG**	**A207652**	**001**	Nov 24, 2017
AB			**500MG**	**A207652**	**002**	Nov 24, 2017
AB		DR REDDYS	**150MG**	**A204345**	**001**	Dec 04, 2020
AB			**500MG**	**A204345**	**002**	Dec 04, 2020
AB		EUGIA PHARMA	**150MG**	**A210604**	**001**	Apr 17, 2018
AB			**500MG**	**A210604**	**002**	Apr 17, 2018
AB		HIKMA	**150MG**	**A200483**	**001**	Jul 14, 2016
AB			**500MG**	**A200483**	**002**	Jul 14, 2016
AB		MSN	**150MG**	**A209365**	**001**	Jul 02, 2018
AB			**500MG**	**A209365**	**002**	Jul 02, 2018
AB		RELIANCE LIFE	**150MG**	**A211724**	**001**	Apr 27, 2020
AB			**500MG**	**A211724**	**002**	Apr 27, 2020
AB		RISING	**150MG**	**A090943**	**001**	Aug 08, 2014
AB			**500MG**	**A090943**	**002**	Aug 08, 2014
AB		SHILPA	**150MG**	**A207456**	**001**	Dec 12, 2016
AB			**500MG**	**A207456**	**002**	Dec 12, 2016
AB		SUN PHARM	**150MG**	**A204668**	**001**	Jun 21, 2019
AB			**500MG**	**A204668**	**002**	Jun 21, 2019
AB		TEVA PHARMS USA	**150MG**	**A091649**	**001**	Sep 16, 2013
AB			**500MG**	**A091649**	**002**	Sep 16, 2013
AB		TEYRO LABS	**150MG**	**A217237**	**001**	Oct 23, 2023
AB			**500MG**	**A217237**	**002**	Oct 23, 2023

XELODA

AB	**+**	CHEPLAPHARM	**150MG**	**N020896**	**001**	Apr 30, 1998
AB	**+!**		**500MG**	**N020896**	**002**	Apr 30, 1998

CAPIVASERTIB
TABLET;ORAL
TRUQAP

	+	ASTRAZENECA	160MG	N218197	001	Nov 16, 2023
	+!		200MG	N218197	002	Nov 16, 2023

CAPMATINIB HYDROCHLORIDE
TABLET;ORAL
TABRECTA

	+	NOVARTIS PHARM	EQ 150MG BASE	N213591	001	May 06, 2020
	+!		EQ 200MG BASE	N213591	002	May 06, 2020

CAPSAICIN
PATCH;TOPICAL
QUTENZA

	+!	AVERITAS	8%	N022395	001	Nov 16, 2009

CAPTOPRIL
TABLET;ORAL
CAPTOPRIL

AB		AJANTA PHARMA LTD	**12.5MG**	**A212809**	**001**	Dec 13, 2019
AB			**25MG**	**A212809**	**002**	Dec 13, 2019
AB			**50MG**	**A212809**	**003**	Dec 13, 2019
AB			**100MG**	**A212809**	**004**	Dec 13, 2019
AB		CHANGZHOU PHARM	**12.5MG**	**A214442**	**001**	Jan 27, 2023
AB			**25MG**	**A214442**	**002**	Jan 27, 2023
AB			**50MG**	**A214442**	**003**	Jan 27, 2023
AB			**100MG**	**A214442**	**004**	Jan 27, 2023
AB		COREPHARMA	**12.5MG**	**A074737**	**001**	Oct 28, 1998
AB			**25MG**	**A074737**	**002**	Oct 28, 1998

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

AB			**50MG**	**A074737**	**003**	Oct 28, 1998
AB			**100MG**	**A074737**	**004**	Oct 28, 1998
AB		HIKMA INTL PHARMS	**12.5MG**	**A074505**	**001**	Feb 13, 1996
AB			**25MG**	**A074505**	**002**	Feb 13, 1996
AB			**50MG**	**A074505**	**003**	Feb 13, 1996
AB	**!**		**100MG**	**A074505**	**004**	Feb 13, 1996
AB		KENTON	**12.5MG**	**A074677**	**004**	May 30, 1997
AB			**25MG**	**A074677**	**002**	May 30, 1997
AB			**50MG**	**A074677**	**001**	May 30, 1997
AB			**100MG**	**A074677**	**003**	May 30, 1997
AB		PRINSTON INC	**12.5MG**	**A074477**	**001**	Feb 13, 1996
AB			**25MG**	**A074477**	**002**	Feb 13, 1996
AB			**50MG**	**A074477**	**003**	Feb 13, 1996
AB			**100MG**	**A074477**	**004**	Feb 13, 1996
AB		WOCKHARDT	**12.5MG**	**A074532**	**001**	Mar 28, 1997
AB			**25MG**	**A074532**	**002**	Mar 28, 1997
AB			**50MG**	**A074532**	**003**	Mar 28, 1997
AB			**100MG**	**A074532**	**004**	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

	RISING	25MG;15MG	A074896	001	Dec 29, 1997
!		25MG;25MG	A074896	002	Dec 29, 1997
!		50MG;15MG	A074896	004	Dec 29, 1997
		50MG;25MG	A074896	003	Dec 29, 1997

CARBACHOL

SOLUTION;INTRAOCULAR

MIOSTAT

+!	ALCON	0.01%	N016968	001	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		APOTEX INC	**100MG**	**A078986**	**001**	Nov 25, 2011
AB			**200MG**	**A078986**	**002**	Nov 25, 2011
AB			**300MG**	**A078986**	**003**	Nov 25, 2011
AB		NOSTRUM LABS INC	**100MG**	**A076697**	**001**	May 20, 2011
AB			**200MG**	**A076697**	**002**	May 20, 2011
AB			**300MG**	**A076697**	**003**	May 20, 2011
AB		TARO	**100MG**	**A201106**	**001**	Jun 21, 2013
AB			**200MG**	**A201106**	**002**	Jun 21, 2013
AB			**300MG**	**A201106**	**003**	Jun 21, 2013
AB		TEVA PHARMS	**100MG**	**A078592**	**001**	Sep 20, 2012
AB			**200MG**	**A078592**	**002**	Sep 20, 2012
AB			**300MG**	**A078592**	**003**	Sep 20, 2012

CARBATROL

AB	**+**	TAKEDA PHARMS USA	**100MG**	**N020712**	**003**	Sep 30, 1997
AB	**+**		**200MG**	**N020712**	**001**	Sep 30, 1997
AB	**+!**		**300MG**	**N020712**	**002**	Sep 30, 1997

EQUETRO

	+	VALIDUS PHARMS	100MG	N021710	001	Dec 10, 2004
	+		200MG	N021710	002	Dec 10, 2004
	+!		300MG	N021710	003	Dec 10, 2004

SUSPENSION;ORAL

CARBAMAZEPINE

AB		CHARTWELL RX	**100MG/5ML**	**A075714**	**001**	Jun 05, 2002
AB		NOVITIUM PHARMA	**100MG/5ML**	**A214277**	**001**	Oct 06, 2022

TEGRETOL

AB	**+!**	NOVARTIS	**100MG/5ML**	**N018927**	**001**	Dec 18, 1987

TERIL

AB		TARO	**100MG/5ML**	**A076729**	**001**	Sep 20, 2004

TABLET;ORAL

CARBAMAZEPINE

AB		APOTEX INC	**200MG**	**A075948**	**001**	Feb 27, 2002
AB		TARO	**200MG**	**A074649**	**001**	Oct 03, 1996
AB		TORRENT PHARMS	**100MG**	**A077272**	**001**	Dec 07, 2005
AB			**200MG**	**A077272**	**002**	Dec 07, 2005
AB		UMEDICA	**100MG**	**A207798**	**001**	Apr 15, 2020
AB			**200MG**	**A207798**	**002**	Apr 15, 2020

CARBAMAZEPINE

TABLET;ORAL

	CARBAMAZEPINE						
AB		UNICHEM	**200MG**	**A213284**	**001**	Aug 22, 2022	
	EPITOL						
AB		TEVA	**200MG**	**A070541**	**001**	Sep 17, 1986	
	TEGRETOL						
AB	**+!**	NOVARTIS	**200MG**	**N016608**	**001**		
	CARBAMAZEPINE						
		TORRENT PHARMS	300MG	A077272	003	Dec 07, 2005	
			400MG	A077272	004	Dec 07, 2005	

TABLET, CHEWABLE;ORAL

	CARBAMAZEPINE						
AB		TARO PHARM INDS	**100MG**	**A075687**	**001**	Oct 24, 2000	
AB		TORRENT PHARMS	**100MG**	**A075712**	**001**	Jul 05, 2001	
	EPITOL						
AB		TEVA	**100MG**	**A073524**	**001**	Jul 29, 1992	
	CARBAMAZEPINE						
	!	TARO PHARM INDS	200MG	A075687	002	Jul 29, 2002	

TABLET, EXTENDED RELEASE;ORAL

	CARBAMAZEPINE						
AB		AMNEAL PHARMS	**100MG**	**A212704**	**001**	Sep 22, 2023	
AB			**200MG**	**A212704**	**002**	Sep 22, 2023	
AB			**400MG**	**A212704**	**003**	Sep 22, 2023	
AB		ANBISON LAB	**100MG**	**A212948**	**001**	Sep 30, 2021	
AB			**200MG**	**A212948**	**002**	Sep 30, 2021	
AB			**400MG**	**A212948**	**003**	Sep 30, 2021	
AB		CSPC OUYI	**100MG**	**A213311**	**001**	Apr 13, 2021	
AB			**200MG**	**A213311**	**002**	Apr 13, 2021	
AB			**400MG**	**A213311**	**003**	Apr 13, 2021	
AB		RICONPHARMA LLC	**100MG**	**A216404**	**001**	Dec 02, 2022	
AB			**200MG**	**A216404**	**002**	Dec 02, 2022	
AB			**400MG**	**A216404**	**003**	Dec 02, 2022	
AB		SCIECURE PHARMA INC	**100MG**	**A216235**	**001**	Mar 02, 2023	
AB			**200MG**	**A216235**	**002**	Mar 02, 2023	
AB			**400MG**	**A216235**	**003**	Mar 02, 2023	
AB		TARO	**100MG**	**A078115**	**001**	Mar 31, 2009	
AB			**200MG**	**A078115**	**002**	Mar 31, 2009	
AB			**400MG**	**A078115**	**003**	Mar 31, 2009	
AB		UMEDICA	**100MG**	**A216594**	**001**	Aug 18, 2022	
AB			**200MG**	**A216594**	**002**	Aug 18, 2022	
AB			**400MG**	**A216594**	**003**	Aug 18, 2022	
AB		UNIQUE PHARM	**100MG**	**A211623**	**001**	Apr 24, 2020	
AB			**200MG**	**A211623**	**002**	Apr 24, 2020	
AB			**400MG**	**A211623**	**003**	Apr 24, 2020	
AB		ZHEJIANG JIUZHOU	**100MG**	**A215591**	**001**	Mar 31, 2022	
AB			**200MG**	**A215591**	**002**	Mar 31, 2022	
AB			**400MG**	**A215591**	**003**	Mar 31, 2022	
AB		ZYDUS PHARMS	**100MG**	**A205571**	**001**	Feb 07, 2019	
AB			**200MG**	**A205571**	**002**	Feb 07, 2019	
AB			**400MG**	**A205571**	**003**	Feb 07, 2019	
	TEGRETOL-XR						
AB	**+**	NOVARTIS	**100MG**	**N020234**	**001**	Mar 25, 1996	
AB	**+**		**200MG**	**N020234**	**002**	Mar 25, 1996	
AB	**+!**		**400MG**	**N020234**	**003**	Mar 25, 1996	

CARBIDOPA

TABLET;ORAL

	CARBIDOPA						
AB		ALVOGEN	**25MG**	**A204291**	**001**	Jan 08, 2016	
AB		AUROBINDO PHARMA	**25MG**	**A211055**	**001**	Oct 21, 2019	
AB		BEXIMCO PHARMS USA	**25MG**	**A217961**	**001**	Dec 11, 2023	
AB		EDENBRIDGE PHARMS	**25MG**	**A205304**	**001**	Feb 17, 2016	
AB		NOVEL LABS INC	**25MG**	**A204763**	**001**	Oct 20, 2017	
AB		ZYDUS PHARMS	**25MG**	**A209910**	**001**	May 07, 2018	
	LODOSYN						
AB	**+!**	ATON	**25MG**	**N017830**	**001**		

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		RISING	**12.5MG;200MG;50MG**	**A213212**	**001**	Jan 25, 2022
AB			**18.75MG;200MG;75MG**	**A213212**	**002**	Jan 25, 2022
AB			**25MG;200MG;100MG**	**A213212**	**003**	Jan 25, 2022
AB			**31.25MG;200MG;125MG**	**A213212**	**004**	Jan 25, 2022
AB			**37.5MG;200MG;150MG**	**A213212**	**005**	Jan 25, 2022
AB			**50MG;200MG;200MG**	**A213212**	**006**	Jan 25, 2022
AB		SUN PHARM	**25MG;200MG;100MG**	**A079085**	**001**	May 10, 2012
AB			**37.5MG;200MG;150MG**	**A079085**	**002**	May 10, 2012

STALEVO 100

AB	+	ORION PHARMA	**25MG;200MG;100MG**	**N021485**	**002**	Jun 11, 2003

STALEVO 125

AB	+	ORION PHARMA	**31.25MG;200MG;125MG**	**N021485**	**006**	Aug 29, 2008

STALEVO 150

AB	+	ORION PHARMA	**37.5MG;200MG;150MG**	**N021485**	**003**	Jun 11, 2003

STALEVO 200

AB	+!	ORION PHARMA	**50MG;200MG;200MG**	**N021485**	**004**	Aug 02, 2007

STALEVO 50

AB	+!	ORION PHARMA	**12.5MG;200MG;50MG**	**N021485**	**001**	Jun 11, 2003

STALEVO 75

AB	+	ORION PHARMA	**18.75MG;200MG;75MG**	**N021485**	**005**	Aug 29, 2008

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL

RYTARY

+	IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015
+		36.25MG;145MG	N203312	002	Jan 07, 2015
+		48.75MG;195MG	N203312	003	Jan 07, 2015
+!		61.25MG;245MG	N203312	004	Jan 07, 2015

SUSPENSION;ENTERAL

DUOPA

+!	ABBVIE	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015

TABLET;ORAL

CARBIDOPA AND LEVODOPA

AB		ACTAVIS ELIZABETH	**10MG;100MG**	**A074260**	**001**	Sep 03, 1993
AB			**25MG;100MG**	**A074260**	**002**	Sep 03, 1993
AB	!		**25MG;250MG**	**A074260**	**003**	Sep 03, 1993
AB		APOTEX INC	**10MG;100MG**	**A077120**	**001**	Jun 02, 2008
AB			**25MG;100MG**	**A077120**	**002**	Jun 02, 2008
AB			**25MG;250MG**	**A077120**	**003**	Jun 02, 2008
AB		AUROBINDO PHARMA LTD	**10MG;100MG**	**A216537**	**001**	Nov 28, 2022
AB			**25MG;100MG**	**A216537**	**002**	Nov 28, 2022
AB			**25MG;250MG**	**A216537**	**003**	Nov 28, 2022
AB		DR REDDYS LABS SA	**10MG;100MG**	**A073618**	**001**	Aug 28, 1992
AB			**25MG;100MG**	**A073589**	**001**	Aug 28, 1992
AB			**25MG;250MG**	**A073607**	**001**	Aug 28, 1992
AB		MYLAN	**10MG;100MG**	**A090324**	**001**	Sep 28, 2009
AB			**25MG;100MG**	**A090324**	**002**	Sep 28, 2009
AB			**25MG;250MG**	**A090324**	**003**	Sep 28, 2009
AB		RUBICON	**10MG;100MG**	**A216505**	**001**	Sep 21, 2022
AB			**25MG;100MG**	**A216505**	**002**	Sep 21, 2022
AB			**25MG;250MG**	**A216505**	**003**	Sep 21, 2022
AB		SCIEGEN PHARMS INC	**10MG;100MG**	**A214092**	**001**	May 07, 2021
AB			**25MG;100MG**	**A214092**	**002**	May 07, 2021
AB			**25MG;250MG**	**A214092**	**003**	May 07, 2021
AB		SUN PHARM INDS	**10MG;100MG**	**A078536**	**001**	Oct 28, 2008
AB			**25MG;100MG**	**A078536**	**002**	Oct 28, 2008
AB			**25MG;250MG**	**A078536**	**003**	Oct 28, 2008

SINEMET

AB	+	ORGANON	**10MG;100MG**	**N017555**	**001**	
AB	+		**25MG;100MG**	**N017555**	**003**	
AB	+		**25MG;250MG**	**N017555**	**002**	

DHIVY

+!	AVION PHARMS	25MG;100MG	N214869	001	Nov 12, 2021

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

AB		ACCORD HLTHCARE	**25MG;100MG**	**A202323**	**001**	Feb 08, 2013
AB			**50MG;200MG**	**A202323**	**002**	Feb 08, 2013
AB		ALEMBIC	**25MG;100MG**	**A210341**	**001**	Jun 05, 2019
AB			**50MG;200MG**	**A210341**	**002**	Jun 05, 2019

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

AB		APOTEX	**25MG;100MG**	**A076212**	**001**	Jun 16, 2004
AB			**50MG;200MG**	**A076212**	**002**	Jun 16, 2004
AB		IMPAX LABS	**25MG;100MG**	**A076521**	**001**	May 14, 2004
AB			**50MG;200MG**	**A076521**	**002**	May 14, 2004
AB		MYLAN	**25MG;100MG**	**A075091**	**002**	Apr 21, 2000
AB			**50MG;200MG**	**A075091**	**001**	Sep 30, 1999
AB		SCIEGEN PHARMS INC	**25MG;100MG**	**A214091**	**001**	Oct 05, 2021
AB	!		**50MG;200MG**	**A214091**	**002**	Oct 05, 2021
AB		SUN PHARM INDS	**25MG;100MG**	**A077828**	**001**	Aug 23, 2007
AB			**50MG;200MG**	**A077828**	**002**	Aug 23, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

		SUN PHARM	10MG;100MG	A078690	001	Jul 31, 2009
			25MG;100MG	A078690	002	Jul 31, 2009
	!		25MG;250MG	A078690	003	Jul 31, 2009

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

	!	GENUS	4MG/5ML	A040458	001	Apr 25, 2003

SUSPENSION, EXTENDED RELEASE;ORAL

KARBINAL ER

	+!	AYTU	4MG/5ML	N022556	001	Mar 28, 2013

TABLET;ORAL

CARBINOXAMINE MALEATE

AA	!	GENUS	**4MG**	**A040442**	**001**	Mar 19, 2003
AA		INVAGEN PHARMS	**4MG**	**A090435**	**001**	Apr 15, 2010
AA		MISSION PHARMACAL	**4MG**	**A090756**	**001**	May 27, 2011
	!	MIKART	6MG	A207484	001	May 31, 2016

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP		ACCORD HLTHCARE	**50MG/5ML (10MG/ML)**	**A206775**	**001**	Feb 09, 2017
AP			**150MG/15ML (10MG/ML)**	**A206775**	**002**	Feb 09, 2017
AP			**450MG/45ML (10MG/ML)**	**A206775**	**003**	Feb 09, 2017
AP			**600MG/60ML (10MG/ML)**	**A206775**	**004**	Feb 09, 2017
AP		EPIC PHARMA LLC	**50MG/5ML (10MG/ML)**	**A090475**	**001**	Jul 29, 2009
AP			**150MG/15ML (10MG/ML)**	**A090475**	**002**	Jul 29, 2009
AP			**450MG/45ML (10MG/ML)**	**A090475**	**003**	Jul 29, 2009
AP			**600MG/60ML (10MG/ML)**	**A091268**	**002**	Jul 28, 2010
AP		EUGIA PHARMA	**50MG/5ML (10MG/ML)**	**A205487**	**001**	Mar 28, 2016
AP			**150MG/15ML (10MG/ML)**	**A205487**	**002**	Mar 28, 2016
AP			**450MG/45ML (10MG/ML)**	**A205487**	**003**	Mar 28, 2016
AP			**600MG/60ML (10MG/ML)**	**A205487**	**004**	Aug 03, 2020
AP		FRESENIUS KABI USA	**450MG/45ML (10MG/ML)**	**A077247**	**003**	Oct 21, 2004
AP			**450MG/45ML (10MG/ML)**	**A077266**	**003**	Feb 15, 2006
AP			**600MG/60ML (10MG/ML)**	**A077266**	**004**	Feb 15, 2006
AP		GLAND PHARMA LTD	**50MG/5ML (10MG/ML)**	**A207324**	**001**	Feb 15, 2017
AP			**150MG/15ML (10MG/ML)**	**A207324**	**002**	Feb 15, 2017
AP			**450MG/45ML (10MG/ML)**	**A207324**	**003**	Feb 15, 2017
AP			**600MG/60ML (10MG/ML)**	**A207324**	**004**	Feb 15, 2017
AP		HIKMA	**50MG/5ML (10MG/ML)**	**A077244**	**001**	Oct 15, 2004
AP			**150MG/15ML (10MG/ML)**	**A077244**	**002**	Oct 15, 2004
AP			**450MG/45ML (10MG/ML)**	**A077244**	**003**	Oct 15, 2004
AP			**600MG/60ML (10MG/ML)**	**A077244**	**004**	Jan 20, 2006
AP	!	HOSPIRA	**50MG/5ML (10MG/ML)**	**A076517**	**001**	Oct 14, 2004
AP	!		**150MG/15ML (10MG/ML)**	**A076517**	**002**	Oct 14, 2004
AP	!		**450MG/45ML (10MG/ML)**	**A076517**	**003**	Oct 14, 2004
AP	!		**600MG/60ML (10MG/ML)**	**A077059**	**001**	Nov 23, 2004
AP		NOVAST LABS	**50MG/5ML (10MG/ML)**	**A208487**	**001**	Apr 26, 2017
AP			**150MG/15ML (10MG/ML)**	**A208487**	**002**	Apr 26, 2017
AP			**450MG/45ML (10MG/ML)**	**A208487**	**003**	Apr 26, 2017
AP			**600MG/60ML (10MG/ML)**	**A208487**	**004**	Apr 26, 2017
AP		PHARMACHEMIE BV	**50MG/5ML (10MG/ML)**	**A077269**	**001**	Oct 14, 2004
AP			**150MG/15ML (10MG/ML)**	**A077269**	**002**	Oct 14, 2004
AP			**450MG/45ML (10MG/ML)**	**A077269**	**003**	Oct 14, 2004
AP			**600MG/60ML (10MG/ML)**	**A077269**	**004**	Dec 28, 2007
AP		SANDOZ	**50MG/5ML (10MG/ML)**	**A078280**	**001**	May 08, 2008
AP			**150MG/15ML (10MG/ML)**	**A078280**	**002**	May 08, 2008

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP			**450MG/45ML (10MG/ML)**	**A078280**	**003**	May 08, 2008
AP		SUN PHARM	**50MG/5ML (10MG/ML)**	**A077926**	**001**	Sep 19, 2008
AP			**150MG/15ML (10MG/ML)**	**A077926**	**002**	Sep 19, 2008
AP			**450MG/45ML (10MG/ML)**	**A077926**	**003**	Sep 19, 2008
AP		TEYRO LABS	**50MG/5ML (10MG/ML)**	**A077861**	**001**	Jan 18, 2007
AP			**150MG/15ML (10MG/ML)**	**A077861**	**002**	Jan 18, 2007
AP			**450MG/45ML (10MG/ML)**	**A077861**	**003**	Jan 18, 2007
AP			**600MG/60ML (10MG/ML)**	**A077861**	**004**	Jan 18, 2007
	!	ACCORD HLTHCARE	1GM/100ML (10MG/ML)	A206775	005	Apr 06, 2020

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

AP		ALEMBIC	**EQ 0.25MG BASE/ML**	**A217198**	**001**	Jun 15, 2023
AP		AMNEAL	**EQ 0.25MG BASE/ML**	**A215337**	**001**	Jan 27, 2022
AP		CAPLIN	**EQ 0.25MG BASE/ML**	**A216882**	**001**	Feb 13, 2023
AP		DR REDDYS	**EQ 0.25MG BASE/ML**	**A211941**	**001**	Jul 02, 2019
AP		EUGIA PHARMA	**EQ 0.25MG BASE/ML**	**A216939**	**001**	May 25, 2023
AP		GLAND PHARMA LTD	**EQ 0.25MG BASE/ML**	**A217657**	**001**	Aug 07, 2023
AP		LONG GROVE PHARMS	**EQ 0.25MG BASE/ML**	**A214499**	**001**	Aug 09, 2022
AP		SOLA PHARMS	**EQ 0.25MG BASE/ML**	**A216824**	**001**	May 19, 2023
AP		STERISCIENCE	**EQ 0.25MG BASE/ML**	**A216897**	**001**	Jul 25, 2023
AP		SUNNY	**EQ 0.25MG BASE/ML**	**A213118**	**001**	Mar 25, 2021

HEMABATE

AP	**+!**	PFIZER	**EQ 0.25MG BASE/ML**	**N017989**	**001**	

CARFILZOMIB

POWDER;INTRAVENOUS

CARFILZOMIB

AP		DR REDDYS	**60MG/VIAL**	**A209422**	**001**	Sep 09, 2019

KYPROLIS

AP	**+!**	ONYX PHARMS AMGEN	**60MG/VIAL**	**N202714**	**001**	Jul 20, 2012
	+		10MG/VIAL	N202714	003	Jun 07, 2018
	+		30MG/VIAL	N202714	002	Jun 03, 2016

CARGLUMIC ACID

TABLET, FOR SUSPENSION;ORAL

CARBAGLU

AB	**+!**	RECORDATI RARE	**200MG**	**N022562**	**001**	Mar 18, 2010

CARGLUMIC ACID

AB		NAVINTA LLC	**200MG**	**A213395**	**001**	Jun 22, 2022
AB		NOVITIUM PHARMA	**200MG**	**A213729**	**001**	Oct 13, 2021

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

VRAYLAR

	+!	ABBVIE	EQ 1.5MG BASE	N204370	001	Sep 17, 2015
	+		EQ 3MG BASE	N204370	002	Sep 17, 2015
	+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015
	+		EQ 6MG BASE	N204370	004	Sep 17, 2015

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AA		ACCELRX LABS	**350MG**	**A040576**	**001**	Jun 07, 2005
AA		AUROBINDO PHARMA	**350MG**	**A040792**	**001**	Aug 06, 2009
AA		CHARTWELL RX	**350MG**	**A040245**	**001**	Sep 08, 1997
AA		MLV	**350MG**	**A211789**	**001**	Oct 20, 2021
AA		NATCO	**350MG**	**A090988**	**001**	Oct 28, 2014
AA		NOSTRUM LABS INC	**350MG**	**A207237**	**002**	Sep 21, 2020
AA		NOVAST LABS	**350MG**	**A040823**	**001**	Oct 22, 2008
AA		ORIENT PHARMA CO LTD	**350MG**	**A205085**	**001**	Oct 28, 2014
AA		OXFORD PHARMS	**350MG**	**A040188**	**001**	Mar 07, 1997
AA		SCIEGEN PHARMS INC	**350MG**	**A203374**	**001**	Jan 27, 2014
AA		WANBANG BIOPHARMS	**350MG**	**A081025**	**001**	Apr 13, 1989
AA		WATSON LABS	**350MG**	**A087499**	**001**	Apr 20, 1982
AA		WILSHIRE PHARMS INC	**350MG**	**A205126**	**002**	Jul 08, 2015

SOMA

AA	**+**	MYLAN SPECIALITY LP	**350MG**	**N011792**	**001**	

CARISOPRODOL

AB		AUROBINDO PHARMA	**250MG**	**A040792**	**002**	Nov 08, 2016

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AB		NOSTRUM LABS INC	**250MG**	**A207237**	**001**	May 11, 2017
AB		WILSHIRE PHARMS INC	**250MG**	**A205126**	**001**	Jul 08, 2015

SOMA

AB	**+!**	MYLAN SPECIALITY LP	**250MG**	**N011792**	**004**	Sep 13, 2007

CARMUSTINE

IMPLANT;INTRACRANIAL

GLIADEL

	+!	AZURITY	7.7MG	N020637	001	Sep 23, 1996

INJECTABLE;INJECTION

BICNU

AP	**+!**	AVET LIFESCIENCES	**100MG/VIAL**	**N017422**	**001**	

CARMUSTINE

AP		ALEMBIC	**100MG/VIAL**	**A215730**	**001**	Oct 20, 2023
AP		AMNEAL	**100MG/VIAL**	**A211229**	**001**	Oct 16, 2018
AP		DR REDDYS	**100MG/VIAL**	**A213207**	**001**	Oct 22, 2020
AP		HENGRUI PHARMA	**100MG/VIAL**	**A211202**	**001**	Mar 12, 2021
AP		INGENUS PHARMS LLC	**100MG/VIAL**	**A211011**	**001**	Jun 21, 2022
AP		MEITHEAL	**100MG/VIAL**	**A213460**	**001**	Aug 02, 2021
AP		MSN	**100MG/VIAL**	**A214814**	**001**	May 11, 2023
AP		NAVINTA LLC	**100MG/VIAL**	**A210179**	**001**	Sep 11, 2018
AP		PENN LIFE	**100MG/VIAL**	**A209278**	**001**	Apr 02, 2019

POWDER;INTRAVENOUS

CARMUSTINE

	+!	ACCORD HLTHCARE	50MG/VIAL	N215000	001	May 16, 2022
	+!		300MG/VIAL	N215000	002	May 16, 2022

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

	!	SANDOZ	1%	A075476	001	Jan 03, 2000

CARVEDILOL

TABLET;ORAL

CARVEDILOL

AB		AUROBINDO PHARMA	**3.125MG**	**A078332**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078332**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078332**	**003**	Sep 05, 2007
AB			**25MG**	**A078332**	**004**	Sep 05, 2007
AB		BEXIMCO USA	**3.125MG**	**A078384**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078384**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078384**	**003**	Sep 05, 2007
AB			**25MG**	**A078384**	**004**	Sep 05, 2007
AB		CHARTWELL MOLECULAR	**3.125MG**	**A077474**	**001**	Sep 05, 2007
AB			**6.25MG**	**A077474**	**002**	Sep 05, 2007
AB			**12.5MG**	**A077474**	**003**	Sep 05, 2007
AB			**25MG**	**A077474**	**004**	Sep 05, 2007
AB		DR REDDYS LABS LTD	**3.125MG**	**A076649**	**001**	Sep 05, 2007
AB			**6.25MG**	**A076649**	**002**	Sep 05, 2007
AB			**12.5MG**	**A076649**	**003**	Sep 05, 2007
AB			**25MG**	**A076649**	**004**	Sep 05, 2007
AB		GLENMARK GENERICS	**3.125MG**	**A078251**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078251**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078251**	**003**	Sep 05, 2007
AB			**25MG**	**A078251**	**004**	Sep 05, 2007
AB		LUPIN	**3.125MG**	**A078217**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078217**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078217**	**003**	Sep 05, 2007
AB			**25MG**	**A078217**	**004**	Sep 05, 2007
AB		MYLAN	**3.125MG**	**A077316**	**001**	Sep 05, 2007
AB			**6.25MG**	**A077316**	**002**	Sep 05, 2007
AB			**12.5MG**	**A077316**	**003**	Sep 05, 2007
AB			**25MG**	**A077316**	**004**	Sep 05, 2007
AB		RUBICON	**3.125MG**	**A078165**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078165**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078165**	**003**	Sep 05, 2007
AB			**25MG**	**A078165**	**004**	Sep 05, 2007
AB		SANDOZ	**3.125MG**	**A078227**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078227**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078227**	**003**	Sep 05, 2007
AB			**25MG**	**A078227**	**004**	Sep 05, 2007

CARVEDILOL

TABLET;ORAL

CARVEDILOL

AB		SUN PHARM INDS LTD	**3.125MG**	**A076989**	**001**	Sep 05, 2007
AB			**6.25MG**	**A076989**	**002**	Sep 05, 2007
AB			**12.5MG**	**A076989**	**003**	Sep 05, 2007
AB			**25MG**	**A076989**	**004**	Sep 05, 2007
AB		TARO	**3.125MG**	**A077780**	**001**	Sep 05, 2007
AB			**6.25MG**	**A077780**	**002**	Sep 05, 2007
AB			**12.5MG**	**A077780**	**003**	Sep 05, 2007
AB			**25MG**	**A077780**	**004**	Sep 05, 2007
AB		TEVA	**3.125MG**	**A076373**	**001**	Sep 05, 2007
AB			**6.25MG**	**A076373**	**002**	Sep 05, 2007
AB			**12.5MG**	**A076373**	**003**	Sep 05, 2007
AB			**25MG**	**A076373**	**004**	Sep 05, 2007
AB		ZYDUS PHARMS USA INC	**3.125MG**	**A077614**	**004**	Sep 05, 2007
AB			**6.25MG**	**A077614**	**001**	Sep 05, 2007
AB			**12.5MG**	**A077614**	**002**	Sep 05, 2007
AB			**25MG**	**A077614**	**003**	Sep 05, 2007

COREG

AB	+	WOODWARD	**3.125MG**	**N020297**	**004**	May 29, 1997
AB	+		**6.25MG**	**N020297**	**003**	Sep 14, 1995
AB	+!		**12.5MG**	**N020297**	**002**	Sep 14, 1995
AB	+		**25MG**	**N020297**	**001**	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

CARVEDILOL PHOSPHATE

AB		IMPAX LABS INC	**10MG**	**A204717**	**001**	May 07, 2018
AB			**20MG**	**A204717**	**002**	May 07, 2018
AB			**40MG**	**A204717**	**003**	May 07, 2018
AB			**80MG**	**A204717**	**004**	May 07, 2018
AB		SUN PHARM INDUSTRIES	**10MG**	**A090132**	**001**	Oct 25, 2017
AB			**20MG**	**A090132**	**002**	Oct 25, 2017
AB			**40MG**	**A090132**	**003**	Oct 25, 2017
AB			**80MG**	**A090132**	**004**	Oct 25, 2017

COREG CR

AB	+	WOODWARD	**10MG**	**N022012**	**001**	Oct 20, 2006
AB	+		**20MG**	**N022012**	**002**	Oct 20, 2006
AB	+!		**40MG**	**N022012**	**003**	Oct 20, 2006
AB	+		**80MG**	**N022012**	**004**	Oct 20, 2006

CASIMERSEN

SOLUTION;INTRAVENOUS

AMONDYS 45

	+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N213026	001	Feb 25, 2021

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CANCIDAS

AP	+!	MERCK	**50MG/VIAL**	**N021227**	**001**	Jan 26, 2001
AP	+!		**70MG/VIAL**	**N021227**	**002**	Jan 26, 2001

CASPOFUNGIN ACETATE

AP		FRESENIUS KABI USA	**50MG/VIAL**	**N206110**	**001**	Dec 30, 2016
AP			**70MG/VIAL**	**N206110**	**002**	Dec 30, 2016
AP		GLAND	**50MG/VIAL**	**A207092**	**001**	Sep 29, 2017
AP			**70MG/VIAL**	**A207092**	**002**	Sep 29, 2017
AP		HENGRUI PHARMA	**50MG/VIAL**	**A200833**	**001**	Jun 28, 2018
AP			**70MG/VIAL**	**A200833**	**002**	Jun 28, 2018
AP		UBI	**50MG/VIAL**	**A211263**	**001**	Oct 01, 2021
AP			**70MG/VIAL**	**A211263**	**002**	Oct 01, 2021

CEDAZURIDINE; DECITABINE

TABLET;ORAL

INQOVI

	+!	OTSUKA	100MG;35MG	N212576	001	Jul 07, 2020

CEFACLOR

CAPSULE;ORAL						
CEFACLOR						
		YUNG SHIN PHARM	EQ 250MG BASE	A065146	001	Jan 22, 2004
	!		EQ 500MG BASE	A065146	002	Jan 22, 2004
FOR SUSPENSION;ORAL						
CEFACLOR						
		YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012
			EQ 187MG BASE/5ML	A065412	002	Feb 17, 2012
			EQ 250MG BASE/5ML	A065412	003	Feb 17, 2012
	!		EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012
TABLET, EXTENDED RELEASE;ORAL						
CEFACLOR						
		TEVA	EQ 375MG BASE	A065058	001	Sep 04, 2002
	!		EQ 500MG BASE	A065058	002	Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL						
CEFADROXIL						
AB		AUROBINDO PHARMA	**EQ 500MG BASE**	**A065352**	**001**	Jan 25, 2007
AB		LUPIN	**EQ 500MG BASE**	**A065392**	**001**	May 29, 2007
AB	**!**	TEVA PHARMS	**EQ 500MG BASE**	**A065282**	**001**	Jan 20, 2006
FOR SUSPENSION;ORAL						
CEFADROXIL						
AB		AUROBINDO	**EQ 250MG BASE/5ML**	**A065349**	**001**	Apr 25, 2013
AB			**EQ 500MG BASE/5ML**	**A065349**	**002**	Apr 25, 2013
AB		LUPIN	**EQ 250MG BASE/5ML**	**A065396**	**001**	Feb 21, 2008
AB	**!**		**EQ 500MG BASE/5ML**	**A065396**	**002**	Feb 21, 2008
TABLET;ORAL						
CEFADROXIL						
	!	TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE;INJECTION						
CEFAZOLIN SODIUM						
AP		ACS DOBFAR	**EQ 500MG BASE/VIAL**	**A065303**	**001**	Oct 22, 2008
AP			**EQ 1GM BASE/VIAL**	**A065303**	**002**	Oct 22, 2008
AP			**EQ 10GM BASE/VIAL**	**A065306**	**001**	Oct 22, 2008
AP	**!**	HIKMA FARMACEUTICA	**EQ 500MG BASE/VIAL**	**A065047**	**001**	Sep 18, 2001
AP	**!**		**EQ 1GM BASE/VIAL**	**A065047**	**002**	Sep 18, 2001
AP			**EQ 10GM BASE/VIAL**	**A065143**	**001**	Oct 18, 2004
AP		QILU	**EQ 1GM BASE/VIAL**	**A203661**	**001**	Dec 28, 2015
AP	**!**		**EQ 10GM BASE/VIAL**	**A209217**	**001**	Oct 17, 2018
AP		SANDOZ	**EQ 500MG BASE/VIAL**	**A062831**	**001**	Dec 09, 1988
AP			**EQ 1GM BASE/VIAL**	**A062831**	**002**	Dec 09, 1988
AP			**EQ 1GM BASE/VIAL**	**A065345**	**001**	May 09, 2007
AP			**EQ 10GM BASE/VIAL**	**A062831**	**003**	Sep 25, 1992
CEFAZOLIN AND DEXTROSE						
	+!	B BRAUN	EQ 1GM BASE/VIAL	N050779	002	Jul 27, 2000
	+		EQ 2GM BASE/VIAL	N050779	003	Jan 13, 2012
CEFAZOLIN SODIUM						
	!	ACS DOBFAR	EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014
		QILU	EQ 2GM BASE/VIAL	A203661	002	Mar 11, 2022
	!	SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141	001	Nov 29, 2006
	!		EQ 300GM BASE/VIAL	A065141	002	Nov 29, 2006
POWDER;INTRAVENOUS						
CEFAZOLIN SODIUM						
	+!	HIKMA	EQ 2GM BASE/VIAL	N216109	001	Oct 07, 2022
	+!		EQ 3GM BASE/VIAL	N216109	002	Oct 07, 2022
	+!	HQ SPCLT PHARMA	EQ 2GM BASE/VIAL	N211413	001	May 08, 2023
SOLUTION;INTRAVENOUS						
CEFAZOLIN IN PLASTIC CONTAINER						
	+!	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021
	+!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015

CEFDINIR

CAPSULE;ORAL						
CEFDINIR						
AB		ALKEM LABS LTD	**300MG**	**A210220**	**001**	Feb 19, 2021
AB		ANDA REPOSITORY	**300MG**	**A065418**	**001**	Jul 18, 2007
AB		AUROBINDO PHARMA	**300MG**	**A065434**	**001**	Jan 07, 2008
AB		LUPIN	**300MG**	**A065264**	**001**	May 19, 2006
AB	**!**	SANDOZ	**300MG**	**A065330**	**001**	Apr 06, 2007

CEFDINIR						
CAPSULE;ORAL						
CEFDINIR						
AB		TEVA PHARMS	**300MG**	**A065368**	**001**	May 09, 2007
FOR SUSPENSION;ORAL						
CEFDINIR						
AB		ALKEM LABS LTD	**125MG/5ML**	**A210534**	**001**	Feb 19, 2021
AB			**250MG/5ML**	**A210534**	**002**	Feb 19, 2021
AB		ANDA REPOSITORY	**125MG/5ML**	**A065429**	**001**	Jul 18, 2007
AB			**250MG/5ML**	**A065429**	**002**	Jul 18, 2007
AB		AUROBINDO PHARMA	**125MG/5ML**	**A065473**	**001**	Dec 14, 2007
AB	**!**		**250MG/5ML**	**A065473**	**002**	Dec 14, 2007
AB		LUPIN	**125MG/5ML**	**A065259**	**001**	May 31, 2006
AB			**250MG/5ML**	**A065259**	**002**	May 07, 2007
AB		SANDOZ	**125MG/5ML**	**A065337**	**001**	Apr 06, 2007
AB			**250MG/5ML**	**A065337**	**002**	Apr 06, 2007
AB		TEVA PHARMS	**125MG/5ML**	**A065332**	**001**	May 04, 2007
AB			**250MG/5ML**	**A065332**	**002**	May 04, 2007
CEFEPIME HYDROCHLORIDE						
INJECTABLE;INJECTION						
CEFEPIME HYDROCHLORIDE						
AP		ACS DOBFAR	**EQ 1GM BASE/VIAL**	**A065441**	**001**	Mar 20, 2008
AP			**EQ 2GM BASE/VIAL**	**A065441**	**002**	Mar 20, 2008
AP		ASTRAL	**EQ 1GM BASE/VIAL**	**A212721**	**001**	Jul 21, 2020
AP			**EQ 2GM BASE/VIAL**	**A212721**	**002**	Jul 21, 2020
AP	**!**	QILU	**EQ 1GM BASE/VIAL**	**A203704**	**002**	Feb 01, 2016
AP	**!**		**EQ 2GM BASE/VIAL**	**A203704**	**003**	Feb 01, 2016
AP		SAGENT PHARMS INC	**EQ 1GM BASE/VIAL**	**A091048**	**001**	Jan 04, 2017
AP			**EQ 2GM BASE/VIAL**	**A091048**	**002**	Jan 04, 2017
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER						
		B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010
			EQ 2GM BASE/VIAL	N050821	002	May 06, 2010
CEFEPIME HYDROCHLORIDE						
	!	QILU	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016
CEFEPIME IN PLASTIC CONTAINER						
	+!	BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N050817	001	Aug 05, 2008
	+!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N050817	002	Aug 05, 2008
POWDER;INTRAVENOUS						
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER						
		SAMSON MEDCL	EQ 100GM BASE	A209408	001	Aug 21, 2018
CEFIDEROCOL SULFATE TOSYLATE						
POWDER;INTRAVENOUS						
FETROJA						
	+!	SHIONOGI INC	EQ 1GM BASE/VIAL	N209445	001	Nov 14, 2019
CEFIXIME						
CAPSULE;ORAL						
CEFIXIME						
AB		ALKEM LABS LTD	**400MG**	**A210574**	**001**	Oct 09, 2018
SUPRAX						
AB	**+!**	LUPIN LTD	**400MG**	**N203195**	**001**	Jun 01, 2012
FOR SUSPENSION;ORAL						
CEFIXIME						
AB		ALKEM LABS LTD	**100MG/5ML**	**A211775**	**001**	Feb 19, 2021
AB			**200MG/5ML**	**A211775**	**002**	Feb 19, 2021
AB		AUROBINDO PHARMA LTD	**100MG/5ML**	**A204835**	**001**	Apr 14, 2015
AB			**200MG/5ML**	**A204835**	**002**	Apr 14, 2015
AB		BELCHER	**100MG/5ML**	**A206938**	**001**	Feb 06, 2017
AB			**200MG/5ML**	**A206938**	**002**	Feb 06, 2017
AB			**500MG/5ML**	**A206939**	**001**	Feb 06, 2017
SUPRAX						
AB	**+!**	LUPIN LTD	**500MG/5ML**	**N202091**	**001**	Feb 20, 2013
AB	**!**	LUPIN PHARMS	**200MG/5ML**	**A065355**	**001**	Apr 10, 2007
TABLET, CHEWABLE;ORAL						
SUPRAX						
		LUPIN LTD	100MG	A065380	001	Oct 25, 2010
			150MG	A065380	002	Oct 25, 2010
	!		200MG	A065380	003	Oct 25, 2010

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTETAN

!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007
!		EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE;INJECTION

CEFOXITIN

AP	**!**	ACS DOBFAR	**EQ 1GM BASE/VIAL**	**A065414**	**001**	Jun 12, 2009
AP	**!**		**EQ 2GM BASE/VIAL**	**A065414**	**002**	Jun 12, 2009
AP	**!**		**EQ 10GM BASE/VIAL**	**A065415**	**001**	May 19, 2010
AP		HIKMA	**EQ 1GM BASE/VIAL**	**A065051**	**001**	Sep 11, 2000
AP			**EQ 2GM BASE/VIAL**	**A065051**	**002**	Sep 11, 2000
AP			**EQ 10GM BASE/VIAL**	**A065050**	**001**	Sep 11, 2000
AP		HIKMA FARMACEUTICA	**EQ 1GM BASE/VIAL**	**A065238**	**001**	Mar 12, 2010
AP			**EQ 2GM BASE/VIAL**	**A065238**	**002**	Mar 12, 2010
AP			**EQ 10GM BASE/VIAL**	**A065239**	**001**	Mar 02, 2010

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

AP	**+!**	B BRAUN	**EQ 1GM BASE/VIAL**	**N065214**	**001**	Mar 10, 2006
AP	**+!**		**EQ 2GM BASE/VIAL**	**N065214**	**002**	Mar 10, 2006

POWDER;INTRAVENOUS

CEFOXITIN IN PLASTIC CONTAINER

	SAMSON MEDCL	EQ 100GM BASE	A200938	001	Nov 16, 2015

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL

CEFPODOXIME PROXETIL

	AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007
!		EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007

TABLET;ORAL

CEFPODOXIME PROXETIL

AB		ALKEM LABS LTD	**EQ 100MG BASE**	**A210568**	**001**	May 18, 2022
AB			**EQ 200MG BASE**	**A210568**	**002**	May 18, 2022
AB		ANDA REPOSITORY	**EQ 100MG BASE**	**A065388**	**001**	Nov 14, 2007
AB			**EQ 200MG BASE**	**A065388**	**002**	Nov 14, 2007
AB		AUROBINDO PHARMA	**EQ 100MG BASE**	**A065370**	**001**	Jun 11, 2007
AB			**EQ 200MG BASE**	**A065370**	**002**	Jun 11, 2007
AB		SANDOZ	**EQ 100MG BASE**	**A065462**	**001**	May 28, 2008
AB	**!**		**EQ 200MG BASE**	**A065462**	**002**	May 28, 2008

CEFPROZIL

FOR SUSPENSION;ORAL

CEFPROZIL

AB		APOTEX INC	**125MG/5ML**	**A065351**	**001**	Feb 29, 2012
AB			**250MG/5ML**	**A065351**	**002**	Feb 29, 2012
AB		AUROBINDO PHARMA	**125MG/5ML**	**A065381**	**001**	Jan 30, 2007
AB			**250MG/5ML**	**A065381**	**002**	Jan 30, 2007
AB		LUPIN	**125MG/5ML**	**A065261**	**001**	Dec 19, 2005
AB	**!**		**250MG/5ML**	**A065261**	**002**	Dec 19, 2005

TABLET;ORAL

CEFPROZIL

AB		APOTEX INC	**250MG**	**A065327**	**001**	Mar 26, 2008
AB			**500MG**	**A065327**	**002**	Mar 26, 2008
AB		AUROBINDO PHARMA	**250MG**	**A065340**	**001**	May 24, 2007
AB			**500MG**	**A065340**	**002**	May 24, 2007
AB		CHARTWELL RX	**250MG**	**A065235**	**001**	Nov 14, 2005
AB			**500MG**	**A065235**	**002**	Nov 14, 2005
AB		LUPIN	**250MG**	**A065276**	**001**	Dec 08, 2005
AB	**!**		**500MG**	**A065276**	**002**	Dec 08, 2005
AB		TEVA	**250MG**	**A065208**	**001**	Dec 06, 2005
AB			**500MG**	**A065208**	**002**	Dec 06, 2005

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS

TEFLARO

+!	ABBVIE	400MG/VIAL	N200327	001	Oct 29, 2010
+!		600MG/VIAL	N200327	002	Oct 29, 2010

CEFTAZIDIME

INJECTABLE;INJECTION

CEFTAZIDIME

AP	**!**	ACS DOBFAR	**1GM/VIAL**	**A062640**	**002**	Nov 20, 1985
AP	**!**		**2GM/VIAL**	**A062640**	**003**	Nov 20, 1985
AP	**!**		**6GM/VIAL**	**A062640**	**004**	Feb 03, 1992

TAZICEF

AP		HOSPIRA	**1GM/VIAL**	**A062662**	**002**	Mar 06, 1986
AP			**1GM/VIAL**	**A064032**	**001**	Oct 31, 1993
AP			**2GM/VIAL**	**A062662**	**003**	Mar 06, 1986
AP			**2GM/VIAL**	**A064032**	**002**	Oct 31, 1993
AP			**6GM/VIAL**	**A062662**	**004**	Mar 06, 1986

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER;INTRAVENOUS

ZERBAXA

	+!	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL**	**A065329**	**001**	Jul 24, 2008
AP			**EQ 1GM BASE/VIAL**	**A065329**	**002**	Jul 24, 2008
AP			**EQ 2GM BASE/VIAL**	**A065329**	**003**	Jul 24, 2008
AP			**EQ 10GM BASE/VIAL**	**A065328**	**001**	Jul 24, 2008
AP		QILU	**EQ 10GM BASE/VIAL**	**A209218**	**001**	Oct 17, 2018
AP	**!**	SANDOZ	**EQ 10GM BASE/VIAL**	**A065168**	**001**	May 17, 2005
AP	**!**	SANDOZ INC	**EQ 1GM BASE/VIAL**	**A065204**	**001**	May 03, 2005
AP	**!**		**EQ 2GM BASE/VIAL**	**A065204**	**002**	May 03, 2005
AP		WOCKHARDT	**EQ 1GM BASE/VIAL**	**A065180**	**001**	May 12, 2006

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

AP	**+!**	B BRAUN	**EQ 1GM BASE/VIAL**	**N050796**	**001**	Apr 20, 2005
AP	**+!**		**EQ 2GM BASE/VIAL**	**N050796**	**002**	Apr 20, 2005

CEFTRIAXONE SODIUM

AP		ANDA REPOSITORY	**EQ 10GM BASE/VIAL**	**A091117**	**001**	Jan 20, 2017
AP		HIKMA	**EQ 10GM BASE/VIAL**	**A090701**	**001**	Oct 04, 2017

CEFTRIAXONE

		SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014

CEFTRIAXONE IN PLASTIC CONTAINER

	!	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005
	!		EQ 40MG BASE/ML	A065224	002	Aug 23, 2005

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AP		AKORN	**EQ 1GM BASE/VIAL**	**A065305**	**003**	Jan 11, 2008
AP			**EQ 2GM BASE/VIAL**	**A065305**	**004**	Jan 11, 2008
AP			**EQ 250MG BASE/VIAL**	**A065305**	**001**	Jan 11, 2008
AP			**EQ 500MG BASE/VIAL**	**A065305**	**002**	Jan 11, 2008
AP		ASTRAL	**EQ 250MG BASE/VIAL**	**A091049**	**001**	Jun 11, 2018
AP			**EQ 500MG BASE/VIAL**	**A091049**	**002**	Jun 11, 2018
AP			**EQ 1GM BASE/VIAL**	**A091049**	**003**	Jun 11, 2018
AP			**EQ 2GM BASE/VIAL**	**A091049**	**004**	Jun 11, 2018
AP		HIKMA FARMACEUTICA	**EQ 250MG BASE/VIAL**	**A065342**	**001**	Jan 10, 2008
AP			**EQ 500MG BASE/VIAL**	**A065342**	**002**	Jan 10, 2008
AP			**EQ 1GM BASE/VIAL**	**A065342**	**003**	Jan 10, 2008
AP			**EQ 2GM BASE/VIAL**	**A065342**	**004**	Jan 10, 2008
AP		QILU	**EQ 250MG BASE/VIAL**	**A203702**	**001**	Jun 29, 2016
AP			**EQ 500MG BASE/VIAL**	**A203702**	**002**	Jun 29, 2016
AP			**EQ 1GM BASE/VIAL**	**A203702**	**003**	Jun 29, 2016
AP			**EQ 2GM BASE/VIAL**	**A203702**	**004**	Jun 29, 2016
AP	**!**	SANDOZ	**EQ 250MG BASE/VIAL**	**A065169**	**001**	May 09, 2005
AP	**!**		**EQ 500MG BASE/VIAL**	**A065169**	**002**	May 09, 2005
AP	**!**		**EQ 1GM BASE/VIAL**	**A065169**	**003**	May 09, 2005
AP	**!**		**EQ 2GM BASE/VIAL**	**A065169**	**004**	May 09, 2005
AP		WOCKHARDT	**EQ 250MG BASE/VIAL**	**A065391**	**001**	Apr 12, 2007
AP			**EQ 500MG BASE/VIAL**	**A065391**	**002**	Apr 12, 2007
AP			**EQ 2GM BASE/VIAL**	**A065391**	**003**	Apr 12, 2007

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

AB		ALKEM LABS LTD	**EQ 250MG BASE**	**A065496**	**001**	Jun 07, 2010
AB			**EQ 500MG BASE**	**A065496**	**002**	Jun 07, 2010
AB		ANDA REPOSITORY	**EQ 125MG BASE**	**A065359**	**001**	Feb 15, 2008
AB			**EQ 250MG BASE**	**A065359**	**002**	Feb 15, 2008

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

AB			**EQ 500MG BASE**	**A065359**	**003**	Feb 15, 2008
AB		APOTEX	**EQ 250MG BASE**	**A065069**	**001**	Oct 02, 2002
AB			**EQ 500MG BASE**	**A065069**	**002**	Oct 02, 2002
AB		AUROBINDO PHARMA	**EQ 125MG BASE**	**A065308**	**001**	Mar 29, 2006
AB			**EQ 250MG BASE**	**A065308**	**002**	Mar 29, 2006
AB			**EQ 500MG BASE**	**A065308**	**003**	Mar 29, 2006
AB		CHARTWELL RX	**EQ 125MG BASE**	**A065166**	**001**	Jul 29, 2005
AB			**EQ 250MG BASE**	**A065166**	**002**	Jul 29, 2005
AB			**EQ 500MG BASE**	**A065166**	**003**	Jul 29, 2005
AB		LUPIN	**EQ 250MG BASE**	**A065135**	**001**	Jul 25, 2003
AB	**!**		**EQ 500MG BASE**	**A065135**	**002**	Jul 25, 2003

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME SODIUM

AP		ACS DOBFAR SPA	**EQ 1.5GM BASE/VIAL**	**A064125**	**002**	May 30, 1997
AP	**!**	HIKMA	**EQ 1.5GM BASE/VIAL**	**A065048**	**002**	Jan 09, 2004

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

AB		ACS DOBFAR SPA	**EQ 750MG BASE/VIAL**	**A064125**	**001**	May 30, 1997
AB	**!**	HIKMA	**EQ 750MG BASE/VIAL**	**A065048**	**001**	Jan 09, 2004

CELECOXIB

CAPSULE;ORAL

CELEBREX

AB	**+**	UPJOHN	**50MG**	**N020998**	**004**	Dec 15, 2006
AB	**+**		**100MG**	**N020998**	**001**	Dec 31, 1998
AB	**+**		**200MG**	**N020998**	**002**	Dec 31, 1998
AB	**+!**		**400MG**	**N020998**	**003**	Aug 29, 2002

CELECOXIB

AB		ALEMBIC	**50MG**	**A204519**	**001**	Aug 21, 2015
AB			**100MG**	**A204519**	**002**	Aug 21, 2015
AB			**200MG**	**A204519**	**003**	Aug 21, 2015
AB			**400MG**	**A204519**	**004**	Aug 21, 2015
AB		APOTEX	**50MG**	**A204197**	**001**	Jun 02, 2015
AB			**100MG**	**A204197**	**002**	Jun 02, 2015
AB			**200MG**	**A204197**	**003**	Jun 02, 2015
AB		AUROBINDO PHARMA	**50MG**	**A206827**	**001**	Feb 01, 2016
AB			**100MG**	**A206827**	**002**	Feb 01, 2016
AB			**200MG**	**A206827**	**003**	Feb 01, 2016
AB			**400MG**	**A206827**	**004**	Feb 01, 2016
AB		CADILA PHARMS LTD	**50MG**	**A208701**	**001**	Nov 14, 2019
AB			**100MG**	**A208701**	**002**	Nov 14, 2019
AB			**200MG**	**A208701**	**003**	Nov 14, 2019
AB			**400MG**	**A208701**	**004**	Nov 14, 2019
AB		CIPLA	**50MG**	**A207446**	**001**	Sep 23, 2015
AB			**100MG**	**A207446**	**002**	Sep 23, 2015
AB			**200MG**	**A207446**	**003**	Sep 23, 2015
AB			**400MG**	**A207446**	**004**	Sep 23, 2015
AB		CSPC OUYI	**50MG**	**A210071**	**001**	Jan 23, 2018
AB			**100MG**	**A210071**	**002**	Jan 23, 2018
AB			**200MG**	**A210071**	**003**	Jan 23, 2018
AB		LUPIN LTD	**50MG**	**A202240**	**001**	Oct 29, 2014
AB			**100MG**	**A202240**	**002**	Jun 09, 2015
AB			**200MG**	**A202240**	**003**	Jun 09, 2015
AB			**400MG**	**A202240**	**004**	Jun 09, 2015
AB		MACLEODS PHARMS LTD	**50MG**	**A204590**	**001**	Mar 16, 2016
AB			**100MG**	**A204590**	**002**	Mar 16, 2016
AB			**200MG**	**A204590**	**003**	Mar 16, 2016
AB			**400MG**	**A204590**	**004**	Mar 16, 2016
AB		MICRO LABS	**50MG**	**A204776**	**001**	Apr 30, 2018
AB			**100MG**	**A204776**	**002**	Apr 30, 2018
AB			**200MG**	**A204776**	**003**	Apr 30, 2018
AB			**400MG**	**A204776**	**004**	Apr 30, 2018
AB		NANJING	**200MG**	**A213598**	**001**	May 13, 2020
AB		QINGDAO BAHEAL PHARM	**50MG**	**A208856**	**001**	Aug 07, 2019
AB			**100MG**	**A208856**	**002**	Aug 07, 2019
AB			**200MG**	**A208856**	**003**	Aug 07, 2019
AB			**400MG**	**A208856**	**004**	Aug 07, 2019
AB		SCIEGEN PHARMS INC	**50MG**	**A205129**	**001**	Dec 03, 2020

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB		**100MG**	**A205129**	**002**	Dec 03, 2020
AB		**200MG**	**A205129**	**003**	Dec 03, 2020
AB		**400MG**	**A205129**	**004**	Dec 03, 2020
AB	TEVA	**50MG**	**A076898**	**001**	May 30, 2014
AB		**100MG**	**A076898**	**002**	May 30, 2014
AB		**200MG**	**A076898**	**003**	May 30, 2014
AB		**400MG**	**A076898**	**004**	May 30, 2014
AB	TIANJIN TIANYAO	**50MG**	**A207872**	**001**	Feb 25, 2020
AB		**100MG**	**A207872**	**002**	Feb 25, 2020
AB		**200MG**	**A207872**	**003**	Feb 25, 2020
AB		**400MG**	**A207872**	**004**	Feb 25, 2020
AB	TORRENT	**50MG**	**A207677**	**001**	Dec 23, 2015
AB		**100MG**	**A207677**	**002**	Dec 23, 2015
AB		**200MG**	**A207677**	**003**	Dec 23, 2015
AB		**400MG**	**A207677**	**004**	Dec 23, 2015
AB	UMEDICA	**50MG**	**A210628**	**001**	Nov 27, 2019
AB		**100MG**	**A210628**	**002**	Nov 27, 2019
AB		**200MG**	**A210628**	**003**	Nov 27, 2019
AB		**400MG**	**A210628**	**004**	Nov 27, 2019
AB	WATSON LABS INC	**50MG**	**A200562**	**001**	Feb 11, 2015
AB		**100MG**	**A200562**	**002**	Feb 11, 2015
AB		**200MG**	**A200562**	**003**	Feb 11, 2015
AB		**400MG**	**A200562**	**004**	Feb 11, 2015
AB	YILING	**50MG**	**A211412**	**001**	Mar 06, 2020
AB		**100MG**	**A211412**	**002**	Mar 06, 2020
AB		**200MG**	**A211412**	**003**	Mar 06, 2020
AB		**400MG**	**A211412**	**004**	Mar 06, 2020
BX	AMNEAL PHARMS	50MG	A208833	001	May 31, 2018
BX		100MG	A208833	002	May 31, 2018
BX		200MG	A208833	003	May 31, 2018
BX		400MG	A208833	004	May 31, 2018

SOLUTION;ORAL

ELYXYB

+!	SCILEX HLDG	25MG/ML	N212157	001	May 05, 2020

CELECOXIB; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

SEGLENTIS

+!	KOWA PHARMS	56MG;44MG	N213426	001	Oct 15, 2021

CENOBAMATE

TABLET;ORAL

XCOPRI

+!	SK LIFE	12.5MG	N212839	001	Mar 10, 2020
+		25MG	N212839	002	Mar 10, 2020
+		50MG	N212839	003	Mar 10, 2020
+		100MG	N212839	004	Mar 10, 2020
+		150MG	N212839	005	Mar 10, 2020
+		200MG	N212839	006	Mar 10, 2020

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

AB	ALKEM LABS LTD	**EQ 250MG BASE**	**A090836**	**001**	Dec 20, 2010
AB		**EQ 500MG BASE**	**A090836**	**002**	Dec 20, 2010
AB	**!**	**EQ 750MG BASE**	**A090836**	**004**	Mar 29, 2013
AB	ANDA REPOSITORY	**EQ 250MG BASE**	**A065248**	**001**	Jun 28, 2005
AB		**EQ 500MG BASE**	**A065248**	**002**	Jun 28, 2005
AB	AUROBINDO PHARMA	**EQ 250MG BASE**	**A065253**	**001**	Nov 16, 2005
AB		**EQ 500MG BASE**	**A065253**	**002**	Nov 16, 2005
AB		**EQ 750MG BASE**	**A065253**	**003**	Dec 06, 2023
AB	BELCHER PHARMS	**EQ 250MG BASE**	**A062713**	**001**	Jul 15, 1988
AB		**EQ 500MG BASE**	**A062713**	**002**	Jul 15, 1988
AB	CHARTWELL RX	**EQ 250MG BASE**	**A065152**	**001**	Feb 24, 2005
AB		**EQ 500MG BASE**	**A065152**	**002**	Feb 24, 2005
AB	LUPIN	**EQ 250MG BASE**	**A065229**	**001**	Nov 25, 2005
AB		**EQ 500MG BASE**	**A065229**	**002**	Nov 25, 2005
AB	TEVA	**EQ 250MG BASE**	**A062702**	**001**	Feb 13, 1987
AB		**EQ 500MG BASE**	**A062702**	**002**	Feb 13, 1987
	ALKEM LABS LTD	EQ 333MG BASE	A090836	003	Mar 29, 2013

CEPHALEXIN						
FOR SUSPENSION;ORAL						
CEPHALEXIN						
AB		ALKEM LABS LTD	**EQ 125MG BASE/5ML**	**A210221**	**001**	Mar 26, 2019
AB			**EQ 250MG BASE/5ML**	**A210221**	**002**	Mar 26, 2019
AB		LUPIN	**EQ 125MG BASE/5ML**	**A065234**	**001**	Aug 17, 2005
AB			**EQ 250MG BASE/5ML**	**A065234**	**002**	Aug 17, 2005
AB		TEVA	**EQ 125MG BASE/5ML**	**A062703**	**001**	Feb 13, 1987
AB	**!**		**EQ 250MG BASE/5ML**	**A062703**	**002**	Feb 13, 1987
AB		YUNG SHIN PHARM	**EQ 125MG BASE/5ML**	**A065336**	**001**	Jul 25, 2007
AB			**EQ 250MG BASE/5ML**	**A065336**	**002**	Jul 25, 2007
TABLET;ORAL						
CEPHALEXIN						
		TEVA	EQ 250MG BASE	A063023	001	Jan 12, 1989
	!		EQ 500MG BASE	A063024	001	Jan 12, 1989
CERITINIB						
TABLET;ORAL						
ZYKADIA						
	+!	NOVARTIS	150MG	N211225	001	Mar 18, 2019
CETIRIZINE HYDROCHLORIDE						
SOLUTION;INTRAVENOUS						
QUZYTTIR						
	+!	JDP	10MG/ML (10MG/ML)	N211415	001	Oct 04, 2019
SOLUTION/DROPS;OPHTHALMIC						
ZERVIATE						
	+!	HARROW EYE	EQ 0.24% BASE	N208694	001	May 30, 2017
SYRUP;ORAL						
CETIRIZINE HYDROCHLORIDE						
AA		AMNEAL PHARMS	**5MG/5ML**	**A090766**	**001**	Oct 07, 2009
AA		BAJAJ	**5MG/5ML**	**A090191**	**001**	Nov 12, 2009
AA		BIONPHARMA	**5MG/5ML**	**A078488**	**001**	Oct 06, 2008
AA		CHARTWELL MOLECULAR	**5MG/5ML**	**A078876**	**001**	May 11, 2012
AA	**!**	PADAGIS US	**5MG/5ML**	**A078398**	**001**	Jun 17, 2008
AA		TARO	**5MG/5ML**	**A076601**	**001**	Jun 20, 2008
AA		TEVA PHARMS	**5MG/5ML**	**A077279**	**001**	May 27, 2008
CETRORELIX ACETATE						
POWDER;SUBCUTANEOUS						
CETRORELIX ACETATE						
AP		TEVA PHARMS INC	**EQ 0.25MG BASE/VIAL**	**A215737**	**001**	Aug 12, 2022
CETROTIDE						
AP	**+!**	EMD SERONO INC	**EQ 0.25MG BASE/VIAL**	**N021197**	**001**	Aug 11, 2000
CEVIMELINE HYDROCHLORIDE						
CAPSULE;ORAL						
CEVIMELINE HYDROCHLORIDE						
AB		AUROBINDO PHARMA	**30MG**	**A215056**	**001**	Apr 18, 2023
AB		BIONPHARMA	**30MG**	**A218290**	**001**	Nov 08, 2023
AB		HIKMA	**30MG**	**A091591**	**001**	Jul 08, 2013
AB		NOVEL LABS INC	**30MG**	**A204746**	**001**	Dec 30, 2016
AB		RISING	**30MG**	**A203775**	**001**	Jun 04, 2014
AB		RUBICON	**30MG**	**A216682**	**001**	Apr 06, 2023
EVOXAC						
AB	**+!**	COSETTE	**30MG**	**N020989**	**002**	Jan 11, 2000
CHENODIOL						
TABLET;ORAL						
CHENODIOL						
	!	LGM PHARMA	250MG	A091019	001	Oct 22, 2009
CHLORAMBUCIL						
TABLET;ORAL						
LEUKERAN						
	+!	WAYLIS THERAP	2MG	N010669	002	
CHLORAMPHENICOL SODIUM SUCCINATE						
INJECTABLE;INJECTION						
CHLORAMPHENICOL SODIUM SUCCINATE						
	!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365	001	Aug 25, 1982

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB		BARR	**5MG**	**A084768**	**001**	
AB			**10MG**	**A083116**	**001**	
AB	!		**25MG**	**A084769**	**001**	
AB		CHARTWELL RX	**5MG**	**A084678**	**001**	
AB			**10MG**	**A084041**	**001**	
AB			**25MG**	**A084679**	**002**	

LIBRIUM

AB	+	BAUSCH	**25MG**	**A085475**	**001**	
AB	+	VALEANT PHARM INTL	**5MG**	**A085461**	**001**	
AB	+		**10MG**	**A085472**	**001**	

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB		ALEMBIC	**5MG;2.5MG**	**A216969**	**001**	Sep 15, 2023
AB		ALKEM LABS LTD	**5MG;2.5MG**	**A214065**	**001**	Apr 26, 2021
AB		AMNEAL	**5MG;2.5MG**	**A215555**	**001**	Oct 25, 2021
AB		AUROBINDO PHARMA LTD	**5MG;2.5MG**	**A216419**	**001**	Sep 14, 2023
AB		CHARTWELL RX	**5MG;2.5MG**	**A213530**	**001**	Oct 20, 2020
AB		COREPHARMA	**5MG;2.5MG**	**A215453**	**001**	Jul 29, 2022
AB		DR REDDYS	**5MG;2.5MG**	**A214698**	**001**	May 10, 2021
AB		MICRO LABS	**5MG;2.5MG**	**A215835**	**001**	Jul 19, 2022
AB		MISEMER	**5MG;2.5MG**	**A210579**	**001**	Jul 29, 2020
AB		NUVO PHARMS INC	**5MG;2.5MG**	**A211421**	**001**	Jul 07, 2020

LIBRAX

AB	+!	BAUSCH	**5MG;2.5MG**	**N012750**	**001**	

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

AT		BAJAJ	**0.12%**	**A075561**	**001**	Nov 14, 2000
AT		CHARTWELL RX	**0.12%**	**A075006**	**001**	Mar 03, 2004
AT		LYNE	**0.12%**	**A074291**	**001**	Dec 28, 1995
AT		PHARM ASSOC	**0.12%**	**A074522**	**001**	Dec 15, 1995
AT		XTTRIUM	**0.12%**	**A077789**	**001**	Jun 18, 2009

PERIDEX

AT	+!	3M	**0.12%**	**N019028**	**001**	Aug 13, 1986

PERIOGARD

AT		COLGATE-PALMOLIVE CO	**0.12%**	**A203212**	**001**	Jan 28, 2016

CHLOROPROCAINE HYDROCHLORIDE

GEL;OPHTHALMIC

IHEEZO

	+!	HARROW EYE	3%	N216227	001	Sep 27, 2022

INJECTABLE;INJECTION

CHLOROPROCAINE HYDROCHLORIDE

AP		HIKMA	**2%**	**A040273**	**001**	Sep 09, 1998
AP			**3%**	**A040273**	**002**	Sep 09, 1998

NESACAINE

AP	+	FRESENIUS KABI USA	**2%**	**N009435**	**002**	

NESACAINE-MPF

AP	+!	FRESENIUS KABI USA	**2%**	**N009435**	**006**	May 02, 1996
AP	+!		**3%**	**N009435**	**007**	May 02, 1996

NESACAINE

	+!	FRESENIUS KABI USA	1%	N009435	001	

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

AA		IMPAX LABS	**250MG**	**A080880**	**001**	
AA			**500MG**	**A040516**	**001**	Aug 29, 2003
AA		IPCA LABS LTD	**250MG**	**A090610**	**001**	Dec 03, 2009
AA			**500MG**	**A090249**	**001**	Dec 03, 2009
AA	!	NATCO PHARMA LTD	**250MG**	**A091621**	**001**	Jan 21, 2011
AA	!		**500MG**	**A090612**	**001**	Jan 21, 2011
AA		SUVEN PHARMS	**500MG**	**A214756**	**001**	Sep 03, 2021

CHLOROTHIAZIDE

SUSPENSION;ORAL

DIURIL

+!	SALIX PHARMS	250MG/5ML	N011870	001		

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

AP	AM REGENT	**EQ 500MG BASE/VIAL**	**A202561**	**001**	Apr 22, 2013	
AP	FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A090896**	**001**	Oct 16, 2009	
AP	RK PHARMA	**EQ 500MG BASE/VIAL**	**A202493**	**001**	Jun 18, 2014	
AP	! SAGENT PHARMS INC	**EQ 500MG BASE/VIAL**	**A202462**	**001**	May 29, 2015	
AP	SUN PHARM	**EQ 500MG BASE/VIAL**	**A091546**	**001**	Jul 26, 2011	

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL

TUXARIN ER

	MAINPOINTE	8MG;54.3MG	N206323	001	Jun 22, 2015

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

!	PADAGIS US	4MG/5ML;5MG/5ML;60MG/5ML	A204627	001	Apr 29, 2014

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

!	TRIS PHARMA INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091632	001	Oct 01, 2010

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

!	GENUS	30MG/ML	A214542	001	Jun 02, 2021
!		100MG/ML	A214542	002	Jun 02, 2021

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

AP	EUGIA PHARMA	**25MG/ML**	**A211816**	**001**	Jul 07, 2020
AP	+! WEST-WARD PHARMS INT	**25MG/ML**	**A083329**	**001**	

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	ALEMBIC	**10MG**	**A217350**	**001**	Jul 18, 2023
AB		**25MG**	**A217350**	**002**	Jul 18, 2023
AB		**50MG**	**A217350**	**003**	Jul 18, 2023
AB		**100MG**	**A217350**	**004**	Jul 18, 2023
AB		**200MG**	**A217350**	**005**	Jul 18, 2023
AB	AMNEAL PHARMS CO	**10MG**	**A209755**	**001**	Sep 10, 2018
AB		**25MG**	**A209755**	**002**	Sep 10, 2018
AB		**50MG**	**A209755**	**003**	Sep 10, 2018
AB		**100MG**	**A209755**	**004**	Sep 10, 2018
AB		**200MG**	**A209755**	**005**	Sep 10, 2018
AB	APPCO	**10MG**	**A213590**	**001**	Aug 31, 2020
AB		**25MG**	**A213590**	**002**	Aug 31, 2020
AB		**50MG**	**A213590**	**003**	Aug 31, 2020
AB		**100MG**	**A213590**	**004**	Aug 31, 2020
AB		**200MG**	**A213590**	**005**	Aug 31, 2020
AB	CHARTWELL RX	**10MG**	**A212630**	**001**	Nov 29, 2021
AB		**25MG**	**A212630**	**002**	Nov 29, 2021
AB		**50MG**	**A212630**	**003**	Nov 29, 2021
AB		**100MG**	**A212630**	**004**	Nov 29, 2021
AB		**200MG**	**A212630**	**005**	Nov 29, 2021
AB	GLENMARK PHARMS LTD	**10MG**	**A212144**	**001**	Mar 23, 2021
AB		**25MG**	**A212144**	**002**	Mar 23, 2021
AB		**50MG**	**A212144**	**003**	Mar 23, 2021
AB		**100MG**	**A212144**	**004**	Mar 23, 2021
AB		**200MG**	**A212144**	**005**	Mar 23, 2021
AB	LANNETT CO INC	**10MG**	**A212996**	**001**	Jan 22, 2021
AB		**25MG**	**A212996**	**002**	Jan 22, 2021
AB		**50MG**	**A212996**	**003**	Jan 22, 2021
AB		**100MG**	**A212996**	**004**	Jan 22, 2021
AB		**200MG**	**A212996**	**005**	Jan 22, 2021
AB	LUPIN	**10MG**	**A213327**	**001**	Jul 13, 2023
AB		**25MG**	**A213327**	**002**	Jul 13, 2023
AB		**50MG**	**A213327**	**003**	Jul 13, 2023

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB			**100MG**	**A213327**	**004**	Jul 13, 2023
AB			**200MG**	**A213327**	**005**	Jul 13, 2023
AB		MSN	**25MG**	**A214827**	**001**	Jan 27, 2022
AB			**50MG**	**A214827**	**002**	Jan 27, 2022
AB			**100MG**	**A214827**	**003**	Jan 27, 2022
AB			**200MG**	**A214827**	**004**	Jan 27, 2022
AB		SUN PHARM	**10MG**	**A214256**	**001**	Oct 26, 2020
AB			**25MG**	**A214256**	**002**	Oct 26, 2020
AB			**50MG**	**A214256**	**003**	Oct 26, 2020
AB			**100MG**	**A214256**	**004**	Oct 26, 2020
AB			**200MG**	**A214256**	**005**	Oct 26, 2020
AB		TEVA PHARMS	**10MG**	**A215659**	**001**	Oct 25, 2021
AB			**25MG**	**A215659**	**002**	Oct 25, 2021
AB			**50MG**	**A215659**	**003**	Oct 25, 2021
AB			**100MG**	**A215659**	**004**	Oct 25, 2021
AB			**200MG**	**A215659**	**005**	Oct 25, 2021
AB	**+**	UPSHER SMITH LABS	**10MG**	**A083386**	**001**	
AB	**+!**		**25MG**	**A084112**	**001**	
AB	**+**		**50MG**	**A084113**	**001**	
AB	**+!**		**100MG**	**A084114**	**001**	
AB	**+**		**200MG**	**A084115**	**001**	
AB		ZYDUS	**10MG**	**A213368**	**001**	Jan 17, 2020
AB			**25MG**	**A213368**	**002**	Jan 17, 2020
AB			**50MG**	**A213368**	**003**	Jan 17, 2020
AB			**100MG**	**A213368**	**004**	Jan 17, 2020
AB			**200MG**	**A213368**	**005**	Jan 17, 2020

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB		AJANTA PHARMA LTD	**25MG**	**A214129**	**001**	Nov 27, 2020
AB			**50MG**	**A214129**	**002**	Nov 27, 2020
AB		ALEMBIC	**25MG**	**A216262**	**001**	Aug 26, 2022
AB			**50MG**	**A216262**	**002**	Aug 26, 2022
AB		ALKEM LABS LTD	**25MG**	**A213412**	**001**	Feb 11, 2020
AB			**50MG**	**A213412**	**002**	Feb 11, 2020
AB		AMNEAL PHARMS CO	**25MG**	**A207204**	**001**	Jul 01, 2019
AB			**50MG**	**A207204**	**002**	Jul 01, 2019
AB		APPCO	**25MG**	**A210742**	**001**	Oct 12, 2018
AB			**50MG**	**A210742**	**002**	Oct 12, 2018
AB		CHARTWELL RX	**25MG**	**A211063**	**001**	Feb 26, 2019
AB			**50MG**	**A211063**	**002**	Feb 26, 2019
AB		INVENTIA	**25MG**	**A211320**	**001**	Feb 09, 2022
AB			**50MG**	**A211320**	**002**	Feb 09, 2022
AB		MANKIND PHARMA	**25MG**	**A215587**	**001**	Aug 04, 2022
AB			**50MG**	**A215587**	**002**	Aug 04, 2022
AB	**+**	MYLAN	**25MG**	**A086831**	**002**	
AB	**+!**		**50MG**	**A086831**	**001**	
AB		NOVAST LABS	**25MG**	**A206904**	**001**	Mar 30, 2017
AB			**50MG**	**A206904**	**002**	Mar 30, 2017
AB		SUN PHARM INDUSTRIES	**25MG**	**A089286**	**002**	Jul 21, 1986
AB			**50MG**	**A089286**	**001**	Jul 21, 1986
AB		TAGI	**25MG**	**A212878**	**001**	Feb 24, 2022
AB			**50MG**	**A212875**	**001**	Feb 24, 2022
AB		UMEDICA	**25MG**	**A207222**	**001**	May 24, 2018
AB			**50MG**	**A207222**	**002**	May 24, 2018
AB		UNICHEM	**25MG**	**A211627**	**001**	Aug 06, 2019
AB			**50MG**	**A211627**	**002**	Aug 06, 2019
AB		ZYDUS PHARMS	**25MG**	**A207813**	**001**	May 10, 2019
AB			**50MG**	**A207813**	**002**	May 10, 2019

THALITONE

BX	+!	CASPER PHARMA LLC	25MG	N019574	002	Feb 12, 1992
	+		15MG	N019574	001	Dec 20, 1988

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AA		AUROBINDO PHARMA LTD	**500MG**	**A089853**	**001**	May 04, 1988
AA		BELCHER	**250MG**	**A215540**	**001**	Jan 24, 2023
AA		COREPHARMA	**250MG**	**A214702**	**001**	Apr 10, 2023
AA			**500MG**	**A214941**	**002**	Oct 20, 2022
AA		DR REDDYS LABS SA	**500MG**	**A211849**	**002**	Jul 21, 2020
AA		GRAVITI PHARMS	**250MG**	**A216925**	**001**	Aug 09, 2023
AA	!	MIKART	**250MG**	**A207483**	**001**	Jun 24, 2016
AA		NOVITIUM PHARMA	**500MG**	**A212254**	**001**	Sep 12, 2019
AA		RISE PHARMA	**250MG**	**A215158**	**001**	Jul 29, 2021
AA	!	WATSON LABS	**500MG**	**A089859**	**001**	May 04, 1988
AB		APTAPHARMA INC	**375MG**	**A212053**	**001**	Sep 14, 2020
AB			**750MG**	**A212053**	**002**	Sep 14, 2020
AB		AUROBINDO PHARMA LTD	**375MG**	**A089853**	**002**	Aug 17, 2023
AB			**750MG**	**A089853**	**003**	Aug 17, 2023
AB		COREPHARMA	**375MG**	**A214941**	**001**	Oct 20, 2022
AB			**750MG**	**A214941**	**003**	Oct 20, 2022
AB		DR REDDYS LABS SA	**375MG**	**A211849**	**001**	Jul 21, 2020
AB			**750MG**	**A211849**	**003**	Jul 21, 2020
AB	!	MIKART	**375MG**	**A040861**	**001**	Jun 01, 2010
AB	!		**750MG**	**A040861**	**002**	Jun 01, 2010
AB		NOVITIUM PHARMA	**375MG**	**A212253**	**001**	Nov 27, 2019
AB			**750MG**	**A212253**	**002**	Nov 27, 2019
AB		PAR PHARM INC	**375MG**	**A212743**	**002**	Apr 29, 2021
AB			**750MG**	**A212743**	**001**	Nov 02, 2020
AB		RISING	**375MG**	**A213126**	**001**	Apr 05, 2022
AB			**500MG**	**A213126**	**002**	Apr 05, 2022
AB			**750MG**	**A213126**	**003**	Apr 05, 2022
AB		TEVA PHARMS USA INC	**375MG**	**A212898**	**001**	Jun 17, 2020
AB			**750MG**	**A212898**	**002**	Jun 17, 2020
AB		UPSHER SMITH LABS	**375MG**	**A212047**	**001**	Jan 27, 2023
AB			**750MG**	**A212047**	**002**	Jan 27, 2023

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

AB		AJANTA PHARMA LTD	**EQ 4GM RESIN/PACKET**	**A211119**	**001**	Apr 06, 2020
AB			**EQ 4GM RESIN/SCOOPFUL**	**A211119**	**002**	Apr 06, 2020
AB		ALKEM LABS LTD	**EQ 4GM RESIN/PACKET**	**A211856**	**001**	Oct 19, 2021
AB			**EQ 4GM RESIN/SCOOPFUL**	**A211856**	**002**	Oct 19, 2021
AB	!	EPIC PHARMA LLC	**EQ 4GM RESIN/PACKET**	**A074557**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074557**	**002**	Aug 15, 1996
AB		PAR PHARM	**EQ 4GM RESIN/PACKET**	**A077204**	**001**	Aug 26, 2005
AB			**EQ 4GM RESIN/SCOOPFUL**	**A077204**	**002**	Aug 26, 2005
AB		TAGI	**EQ 4GM RESIN/PACKET**	**A209597**	**001**	Mar 09, 2021
AB			**EQ 4GM RESIN/SCOOPFUL**	**A209597**	**002**	Mar 09, 2021
AB		ZYDUS PHARMS	**EQ 4GM RESIN/SCOOPFUL**	**A202901**	**001**	Jul 02, 2018

CHOLESTYRAMINE LIGHT

AB		ALKEM LABS LTD	**EQ 4GM RESIN/PACKET**	**A211799**	**001**	Oct 19, 2021
AB			**EQ 4GM RESIN/SCOOPFUL**	**A211799**	**002**	Oct 19, 2021
AB	!	EPIC PHARMA LLC	**EQ 4GM RESIN/PACKET**	**A074558**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074558**	**002**	Aug 15, 1996
AB		PAR PHARM	**EQ 4GM RESIN/PACKET**	**A077203**	**001**	Aug 26, 2005
AB			**EQ 4GM RESIN/SCOOPFUL**	**A077203**	**002**	Aug 26, 2005
AB		TAGI	**EQ 4GM RESIN/PACKET**	**A209599**	**001**	Nov 12, 2020
AB			**EQ 4GM RESIN/SCOOPFUL**	**A209599**	**002**	Nov 12, 2020
AB		ZYDUS PHARMS	**EQ 4GM RESIN/SCOOPFUL**	**A202902**	**001**	Apr 25, 2017

LOCHOLEST

AB		CHARTWELL RX	**EQ 4GM RESIN/PACKET**	**A074561**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074561**	**002**	Aug 15, 1996

LOCHOLEST LIGHT

AB		CHARTWELL RX	**EQ 4GM RESIN/PACKET**	**A074562**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074562**	**002**	Aug 15, 1996

PREVALITE

AB		UPSHER SMITH LABS	**EQ 4GM RESIN/PACKET**	**A073263**	**001**	Feb 22, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A073263**	**002**	Oct 30, 1997

CHOLIC ACID
CAPSULE;ORAL
CHOLBAM

	+	MIRUM	50MG	N205750	001	Mar 17, 2015
	+!		250MG	N205750	002	Mar 17, 2015

CHOLINE C-11
INJECTABLE;INTRAVENOUS
CHOLINE C-11

AP		DECATUR	**4-33.1mCi/ML**	**A206319**	**001**	Nov 13, 2015
AP	**+!**	MCPRF	**4-33.1mCi/ML**	**N203155**	**001**	Sep 12, 2012

CHOLINE FENOFIBRATE
CAPSULE, DELAYED RELEASE;ORAL
FENOFIBRIC ACID

AB		ACTAVIS ELIZABETH	**EQ 45MG FENOFIBRIC ACID**	**A200920**	**001**	Oct 07, 2015
AB			**EQ 135MG FENOFIBRIC ACID**	**A200920**	**002**	Oct 07, 2015
AB		ALEMBIC	**EQ 45MG FENOFIBRIC ACID**	**A208705**	**001**	May 12, 2017
AB			**EQ 135MG FENOFIBRIC ACID**	**A208705**	**002**	May 12, 2017
AB		ANCHEN PHARMS	**EQ 45MG FENOFIBRIC ACID**	**A201573**	**002**	Jul 18, 2013
AB			**EQ 135MG FENOFIBRIC ACID**	**A201573**	**001**	Jul 18, 2013
AB		AUROBINDO PHARMA LTD	**EQ 45MG FENOFIBRIC ACID**	**A212598**	**001**	Jul 25, 2019
AB			**EQ 135MG FENOFIBRIC ACID**	**A212598**	**002**	Jul 25, 2019
AB		GRAVITI PHARMS	**EQ 45MG FENOFIBRIC ACID**	**A211626**	**001**	Jul 18, 2019
AB			**EQ 135MG FENOFIBRIC ACID**	**A211626**	**002**	Jul 18, 2019
AB		IMPAX LABS INC	**EQ 45MG FENOFIBRIC ACID**	**A200264**	**001**	Sep 07, 2016
AB			**EQ 135MG FENOFIBRIC ACID**	**A200264**	**002**	Sep 07, 2016
AB		LUPIN LTD	**EQ 45MG FENOFIBRIC ACID**	**A200750**	**001**	Dec 04, 2013
AB			**EQ 135MG FENOFIBRIC ACID**	**A200750**	**002**	Dec 04, 2013
AB		MICRO LABS	**EQ 45MG FENOFIBRIC ACID**	**A213450**	**001**	Jun 16, 2020
AB			**EQ 135MG FENOFIBRIC ACID**	**A213450**	**002**	Jun 16, 2020
AB		SCINOPHARM TAIWAN	**EQ 45MG FENOFIBRIC ACID**	**A210469**	**001**	Jul 05, 2019
AB			**EQ 135MG FENOFIBRIC ACID**	**A210469**	**002**	Jul 05, 2019
AB		YICHANG HUMANWELL	**EQ 45MG FENOFIBRIC ACID**	**A212562**	**001**	Dec 23, 2020
AB			**EQ 135MG FENOFIBRIC ACID**	**A212562**	**002**	Dec 23, 2020

TRILIPIX

AB	**+**	ABBVIE	**EQ 45MG FENOFIBRIC ACID**	**N022224**	**001**	Dec 15, 2008
AB	**+!**		**EQ 135MG FENOFIBRIC ACID**	**N022224**	**002**	Dec 15, 2008

CHROMIC CHLORIDE
INJECTABLE;INJECTION
CHROMIC CHLORIDE IN PLASTIC CONTAINER

	+!	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N018961	001	Jun 26, 1986

CICLESONIDE
AEROSOL, METERED;INHALATION
ALVESCO

	+!	COVIS	0.08MG/INH	N021658	002	Jan 10, 2008
	+!		0.16MG/INH	N021658	003	Jan 10, 2008

AEROSOL, METERED;NASAL
ZETONNA

	+!	COVIS	0.037MG/INH	N202129	001	Jan 20, 2012

SPRAY, METERED;NASAL
OMNARIS

	+!	COVIS	0.05MG/SPRAY	N022004	001	Oct 20, 2006

CICLOPIROX
CREAM;TOPICAL
CICLOPIROX

AB		COSETTE	**0.77%**	**A078463**	**001**	Dec 20, 2010
AB		FOUGERA PHARMS	**0.77%**	**A076435**	**001**	Dec 29, 2004
AB		GLENMARK PHARMS	**0.77%**	**A090273**	**001**	Nov 10, 2009
AB		PADAGIS ISRAEL	**0.77%**	**A077364**	**001**	Mar 03, 2006
AB		TARO	**0.77%**	**A076790**	**001**	Apr 12, 2005

LOPROX

AB	**+!**	MEDIMETRIKS PHARMS	**0.77%**	**N018748**	**001**	Dec 30, 1982

GEL;TOPICAL
CICLOPIROX

AB		FOUGERA PHARMS	**0.77%**	**A077896**	**001**	Jun 10, 2008
AB	**!**	GLENMARK GENERICS	**0.77%**	**A091595**	**001**	Feb 29, 2012
AB		PADAGIS US	**0.77%**	**A078266**	**001**	Jan 07, 2009

SHAMPOO;TOPICAL
CICLOPIROX

AT		ACTAVIS MID	**1%**	**A090490**	**001**	Nov 24, 2009

CICLOPIROX

SHAMPOO;TOPICAL

CICLOPIROX

		ATLANTIC				
AT		FOUGERA PHARMS	**1%**	**A090146**	**001**	May 25, 2010
AT		PADAGIS US	**1%**	**A078594**	**001**	Feb 16, 2010
AT		TARO	**1%**	**A090269**	**001**	Feb 23, 2011

LOPROX

AT	**+!**	BAUSCH	**1%**	**N021159**	**001**	Feb 28, 2003

SOLUTION;TOPICAL

CICLOPIROX

AT		ACELLA	**8%**	**A078172**	**001**	Sep 18, 2007
AT		CHARTWELL RX	**8%**	**A078046**	**001**	Sep 18, 2007
AT		COSETTE	**8%**	**A078233**	**001**	Sep 18, 2007
AT		ENCUBE	**8%**	**A077687**	**001**	Sep 18, 2007
AT		HIKMA	**8%**	**A078270**	**001**	Sep 18, 2007
AT	**!**	PADAGIS US	**8%**	**A077623**	**001**	Sep 18, 2007
AT		RISING	**8%**	**A078124**	**001**	Sep 18, 2007
AT		TARO PHARM INDS	**8%**	**A078144**	**001**	Sep 18, 2007

SUSPENSION;TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	**0.77%**	**A076422**	**001**	Aug 06, 2004
AB		PADAGIS ISRAEL	**0.77%**	**A077676**	**001**	Dec 15, 2006
AB		TARO	**0.77%**	**A077092**	**001**	Aug 10, 2005

LOPROX

AB	**+!**	MEDIMETRIKS PHARMS	**0.77%**	**N019824**	**001**	Dec 30, 1988

CIDOFOVIR

INJECTABLE;INJECTION

CIDOFOVIR

AP		AVET LIFESCIENCES	**EQ 75MG BASE/ML**	**A202501**	**001**	Jul 26, 2012
AP	**!**	MYLAN INSTITUTIONAL	**EQ 75MG BASE/ML**	**A201276**	**001**	Jun 27, 2012

CILASTATIN SODIUM; IMIPENEM

POWDER;INTRAVENOUS

IMIPENEM AND CILASTATIN

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL;500MG/VIAL**	**A090577**	**002**	Dec 21, 2011
AP		HQ SPCLT PHARMA	**EQ 500MG BASE/VIAL;500MG/VIAL**	**A207594**	**001**	Dec 12, 2019

PRIMAXIN

AP	**+!**	MERCK	**EQ 500MG BASE/VIAL;500MG/VIAL**	**N050587**	**002**	Nov 26, 1985

IMIPENEM AND CILASTATIN

	!	ACS DOBFAR	EQ 250MG BASE/VIAL;250MG/VIAL	A090577	001	Dec 21, 2011

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

POWDER;INTRAVENOUS

RECARBRIO

	+!	MSD MERCK CO	EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	N212819	001	Jul 16, 2019

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

AB		APOTEX INC	**50MG**	**A077030**	**001**	Dec 10, 2004
AB			**100MG**	**A077030**	**002**	Dec 10, 2004
AB		CHARTWELL RX	**50MG**	**A077831**	**002**	Sep 24, 2012
AB			**100MG**	**A077831**	**001**	Sep 24, 2012
AB		EPIC PHARMA LLC	**50MG**	**A077022**	**002**	Mar 11, 2005
AB			**100MG**	**A077022**	**001**	Nov 23, 2004
AB		SLATE RUN PHARMA	**50MG**	**A077208**	**002**	Mar 29, 2006
AB			**100MG**	**A077208**	**001**	Mar 29, 2006
AB	**!**	TEVA	**50MG**	**A077027**	**001**	Nov 24, 2004
AB	**!**		**100MG**	**A077027**	**002**	Nov 24, 2004

CIMETIDINE

TABLET;ORAL

CIMETIDINE

AB		MYLAN	**200MG**	**A074246**	**001**	May 17, 1994
AB			**300MG**	**A074246**	**002**	May 17, 1994
AB			**400MG**	**A074246**	**003**	May 17, 1994
AB	**!**		**800MG**	**A074246**	**004**	May 17, 1994
AB		TEVA	**200MG**	**A074151**	**001**	May 17, 1994
AB			**300MG**	**A074151**	**002**	May 17, 1994
AB			**400MG**	**A074151**	**003**	May 17, 1994
AB			**800MG**	**A074463**	**001**	May 17, 1994

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

AA	**!**	PAI HOLDINGS PHARM	**EQ 300MG BASE/5ML**	**A074664**	**001**	Oct 28, 1997
AA		PHARM ASSOC	**EQ 300MG BASE/5ML**	**A074553**	**001**	Jan 27, 1997

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 30MG BASE**	**A211892**	**001**	May 15, 2020
AB			**EQ 60MG BASE**	**A211892**	**002**	May 15, 2020
AB			**EQ 90MG BASE**	**A211892**	**003**	May 15, 2020
AB		ALKEM LABS LTD	**EQ 30MG BASE**	**A210570**	**001**	May 17, 2019
AB			**EQ 60MG BASE**	**A210570**	**002**	May 17, 2019
AB			**EQ 90MG BASE**	**A210570**	**003**	May 17, 2019
AB		AUROBINDO PHARMA LTD	**EQ 30MG BASE**	**A206125**	**001**	Mar 08, 2018
AB			**EQ 60MG BASE**	**A206125**	**002**	Mar 08, 2018
AB			**EQ 90MG BASE**	**A206125**	**003**	Mar 08, 2018
AB		CHARTWELL RX	**EQ 30MG BASE**	**A213325**	**001**	May 18, 2020
AB			**EQ 60MG BASE**	**A213325**	**002**	May 18, 2020
AB			**EQ 90MG BASE**	**A213325**	**003**	May 18, 2020
AB		CIPLA	**EQ 30MG BASE**	**A208915**	**001**	Mar 08, 2018
AB			**EQ 60MG BASE**	**A208915**	**002**	Mar 08, 2018
AB			**EQ 90MG BASE**	**A208915**	**003**	Mar 08, 2018
AB		DR REDDYS	**EQ 30MG BASE**	**A208368**	**001**	Sep 18, 2020
AB			**EQ 60MG BASE**	**A208368**	**002**	Sep 18, 2020
AB			**EQ 90MG BASE**	**A208368**	**003**	Sep 18, 2020
AB		HETERO LABS LTD V	**EQ 30MG BASE**	**A209403**	**001**	Oct 07, 2020
AB			**EQ 60MG BASE**	**A209403**	**002**	Oct 07, 2020
AB			**EQ 90MG BASE**	**A209403**	**003**	Oct 07, 2020
AB		SLATE RUN PHARMA	**EQ 30MG BASE**	**A210207**	**001**	Aug 01, 2018
AB			**EQ 60MG BASE**	**A210207**	**002**	Aug 01, 2018
AB			**EQ 90MG BASE**	**A210207**	**003**	Aug 01, 2018
AB		STRIDES PHARMA	**EQ 30MG BASE**	**A209226**	**001**	Apr 30, 2018
AB			**EQ 60MG BASE**	**A209226**	**002**	Apr 30, 2018
AB			**EQ 90MG BASE**	**A209226**	**003**	Apr 30, 2018
AB		SUN PHARM	**EQ 30MG BASE**	**A207008**	**001**	Oct 11, 2018
AB			**EQ 60MG BASE**	**A207008**	**002**	Oct 11, 2018
AB			**EQ 90MG BASE**	**A207008**	**003**	Oct 11, 2018
AB		WATSON LABS TEVA	**EQ 30MG BASE**	**A204377**	**001**	Dec 27, 2018
AB			**EQ 60MG BASE**	**A204377**	**002**	Dec 27, 2018
AB			**EQ 90MG BASE**	**A204377**	**003**	Dec 27, 2018

SENSIPAR

AB	**+**	AMGEN	**EQ 30MG BASE**	**N021688**	**001**	Mar 08, 2004
AB	**+**		**EQ 60MG BASE**	**N021688**	**002**	Mar 08, 2004
AB	**+!**		**EQ 90MG BASE**	**N021688**	**003**	Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION;ORAL

CIPRO

AB	**+**	BAYER HLTHCARE	**250MG/5ML**	**N020780**	**001**	Sep 26, 1997
AB	**+!**		**500MG/5ML**	**N020780**	**002**	Sep 26, 1997

CIPROFLOXACIN

AB		CHARTWELL	**250MG/5ML**	**A200563**	**001**	Mar 05, 2014
AB			**500MG/5ML**	**A200563**	**002**	Mar 05, 2014

INJECTABLE;INJECTION

CIPROFLOXACIN

AP	**!**	BAXTER HLTHCARE CORP	**200MG/20ML (10MG/ML)**	**A078062**	**001**	Apr 29, 2008
AP	**!**		**400MG/40ML (10MG/ML)**	**A078062**	**002**	Apr 29, 2008
AP		HIKMA FARMACEUTICA	**200MG/20ML (10MG/ML)**	**A076717**	**001**	Dec 22, 2009
AP			**400MG/40ML (10MG/ML)**	**A076717**	**002**	Dec 22, 2009

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE CORP	**200MG/100ML**	**A078024**	**001**	Mar 18, 2008
AP			**400MG/200ML**	**A078024**	**002**	Mar 18, 2008
AP		HIKMA FARMACEUTICA	**400MG/200ML**	**A078431**	**001**	Nov 18, 2009
AP	**!**	HOSPIRA	**200MG/100ML**	**A077753**	**001**	Mar 18, 2008
AP	**!**		**400MG/200ML**	**A077753**	**002**	Mar 18, 2008
AP		INFORLIFE	**200MG/100ML**	**A078252**	**001**	Mar 18, 2008
AP			**400MG/200ML**	**A078252**	**002**	Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT;OPHTHALMIC

CILOXAN

	+!	SANDOZ	EQ 0.3% BASE	N020369	001	Mar 30, 1998

SOLUTION/DROPS;OPHTHALMIC

CILOXAN

AT	**+!**	SANDOZ	**EQ 0.3% BASE**	**N019992**	**001**	Dec 31, 1990

CIPROFLOXACIN HYDROCHLORIDE

AT		ALTAIRE PHARMS INC	**EQ 0.3% BASE**	**A204613**	**001**	May 03, 2018
AT		FDC LTD	**EQ 0.3% BASE**	**A077568**	**001**	Jun 30, 2008
AT		RISING	**EQ 0.3% BASE**	**A077689**	**001**	Dec 13, 2006
AT		RUBICON	**EQ 0.3% BASE**	**A075928**	**001**	Jun 09, 2004
AT		WATSON LABS INC	**EQ 0.3% BASE**	**A076673**	**001**	Jan 21, 2005

SOLUTION/DROPS;OTIC

CETRAXAL

	+!	WRASER PHARMS	EQ 0.2% BASE	N021918	001	May 01, 2009

TABLET;ORAL

CIPRO

AB	**+**	BAYER HLTHCARE	**EQ 250MG BASE**	**N019537**	**002**	Oct 22, 1987
AB	**+!**		**EQ 500MG BASE**	**N019537**	**003**	Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

AB		AMNEAL	**EQ 250MG BASE**	**A075939**	**002**	Jun 09, 2004
AB			**EQ 500MG BASE**	**A075939**	**003**	Jun 09, 2004
AB			**EQ 750MG BASE**	**A075939**	**004**	Jun 09, 2004
AB		AUROBINDO PHARMA	**EQ 250MG BASE**	**A077859**	**001**	Apr 26, 2007
AB			**EQ 500MG BASE**	**A077859**	**002**	Apr 26, 2007
AB			**EQ 750MG BASE**	**A077859**	**003**	Apr 26, 2007
AB		CARLSBAD	**EQ 250MG BASE**	**A076126**	**002**	Jun 09, 2004
AB			**EQ 500MG BASE**	**A076126**	**003**	Jun 09, 2004
AB			**EQ 750MG BASE**	**A076126**	**004**	Jun 09, 2004
AB		CHARTWELL	**EQ 250MG BASE**	**A076896**	**001**	Nov 04, 2004
AB			**EQ 500MG BASE**	**A076896**	**002**	Nov 04, 2004
AB			**EQ 750MG BASE**	**A076896**	**003**	Nov 04, 2004
AB		DR REDDYS LABS LTD	**EQ 250MG BASE**	**A075593**	**003**	Jun 09, 2004
AB			**EQ 500MG BASE**	**A075593**	**004**	Jun 09, 2004
AB			**EQ 750MG BASE**	**A075593**	**001**	Jun 09, 2004
AB		HIKMA	**EQ 250MG BASE**	**A076558**	**002**	Jun 09, 2004
AB			**EQ 500MG BASE**	**A076558**	**003**	Jun 09, 2004
AB			**EQ 750MG BASE**	**A076558**	**004**	Jun 09, 2004
AB		IVAX SUB TEVA PHARMS	**EQ 250MG BASE**	**A076089**	**002**	Jun 09, 2004
AB			**EQ 500MG BASE**	**A076089**	**003**	Jun 09, 2004
AB			**EQ 750MG BASE**	**A076089**	**004**	Jun 09, 2004
AB		RISING	**EQ 500MG BASE**	**A075817**	**003**	Jun 09, 2004
AB		UNIQUE	**EQ 250MG BASE**	**A076639**	**001**	Sep 10, 2004
AB			**EQ 500MG BASE**	**A076639**	**002**	Sep 10, 2004
AB			**EQ 750MG BASE**	**A076639**	**003**	Sep 10, 2004
AB		WATSON LABS	**EQ 250MG BASE**	**A076794**	**002**	Jun 09, 2004
AB			**EQ 500MG BASE**	**A076794**	**003**	Jun 09, 2004
AB			**EQ 750MG BASE**	**A076794**	**004**	Jun 09, 2004
AB		YILING	**EQ 250MG BASE**	**A208921**	**001**	Jun 22, 2018
AB			**EQ 500MG BASE**	**A208921**	**002**	Jun 22, 2018

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS;OTIC

OTOVEL

	+!	LABORATORIOS SALVAT	EQ 0.3% BASE;0.025%	N208251	001	Apr 29, 2016

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC

CIPRO HC

	+!	SANDOZ	EQ 0.2% BASE;1%	N020805	001	Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	**!**	ANCHEN PHARMS	**425.2MG;EQ 574.9MG BASE**	**A078166**	**001**	Nov 27, 2007
AB		DR REDDYS LABS LTD	**425.2MG;EQ 574.9MG BASE**	**A077701**	**001**	Mar 26, 2007
	!	ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEX

AB	**+!**	SANDOZ	**0.3%;0.1%**	**N021537**	**001**	Jul 18, 2003

CIPROFLOXACIN AND DEXAMETHASONE

AB		DR REDDYS	**0.3%;0.1%**	**A205548**	**001**	Aug 10, 2020
AB		SENTISS	**0.3%;0.1%**	**A215768**	**001**	Jun 09, 2023
AB		SUN PHARM	**0.3%;0.1%**	**A210470**	**001**	Aug 30, 2022

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP		CAPLIN	**EQ 2MG BASE/ML**	**A217725**	**001**	Jun 09, 2023
AP			**EQ 10MG BASE/ML**	**A217725**	**002**	Jun 09, 2023
AP		EUGIA PHARMA	**EQ 2MG BASE/ML**	**A209144**	**001**	May 08, 2020
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A203183**	**001**	Feb 26, 2015
AP		HENGRUI PHARMA	**EQ 2MG BASE/ML**	**A209334**	**001**	Aug 30, 2017
AP		HIKMA	**EQ 2MG BASE/ML**	**A203078**	**001**	Jun 28, 2022
AP			**EQ 2MG BASE/ML**	**A203079**	**001**	Apr 19, 2023
AP			**EQ 10MG BASE/ML**	**A203078**	**002**	Dec 18, 2023
AP		HOSPIRA	**EQ 2MG BASE/ML**	**A203236**	**001**	Mar 30, 2018
AP			**EQ 2MG BASE/ML**	**A203238**	**001**	Mar 30, 2018
AP			**EQ 10MG BASE/ML**	**A203236**	**002**	Mar 30, 2018
AP		MEITHEAL	**EQ 2MG BASE/ML**	**A211668**	**001**	Apr 25, 2019
AP			**EQ 2MG BASE/ML**	**A211669**	**001**	Apr 25, 2019
AP			**EQ 10MG BASE/ML**	**A211668**	**002**	Apr 25, 2019
AP		PIRAMAL CRITICAL	**EQ 2MG BASE/ML**	**A215516**	**001**	May 24, 2022
AP			**EQ 2MG BASE/ML**	**A215517**	**001**	Dec 14, 2022
AP			**EQ 10MG BASE/ML**	**A215516**	**002**	May 24, 2022
AP		SAGENT PHARMS INC	**EQ 2MG BASE/ML**	**A201836**	**001**	Nov 06, 2020
AP			**EQ 2MG BASE/ML**	**A201851**	**001**	Nov 06, 2020
AP			**EQ 10MG BASE/ML**	**A201836**	**002**	Nov 06, 2020
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A200159**	**001**	Feb 03, 2012
AP		SOMERSET	**EQ 2MG BASE/ML**	**A209132**	**001**	Apr 24, 2019
AP		ZYDUS PHARMS	**EQ 2MG BASE/ML**	**A212171**	**001**	Nov 04, 2019
AP			**EQ 10MG BASE/ML**	**A212171**	**002**	Nov 04, 2019

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP		EUGIA PHARMA	**EQ 2MG BASE/ML**	**A209665**	**001**	Oct 27, 2020
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A203182**	**001**	Feb 26, 2015
AP			**EQ 10MG BASE/ML**	**A203182**	**002**	Feb 26, 2015
AP		HENGRUI PHARMA	**EQ 2MG BASE/ML**	**A204960**	**001**	Jan 27, 2017
AP			**EQ 10MG BASE/ML**	**A204960**	**002**	Sep 19, 2017
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A200154**	**001**	Feb 03, 2012
AP			**EQ 10MG BASE/ML**	**A200154**	**002**	Feb 03, 2012
AP		SOMERSET THERAPS LLC	**EQ 2MG BASE/ML**	**A206791**	**001**	Feb 20, 2019
AP			**EQ 10MG BASE/ML**	**A206791**	**002**	Feb 20, 2019

NIMBEX

AP	**+!**	ABBVIE	**EQ 2MG BASE/ML**	**N020551**	**001**	Dec 15, 1995

NIMBEX PRESERVATIVE FREE

AP	**+!**	ABBVIE	**EQ 2MG BASE/ML**	**N020551**	**003**	Dec 15, 1995
AP	**+!**		**EQ 10MG BASE/ML**	**N020551**	**002**	Dec 15, 1995

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

AP		ACCORD HLTHCARE	**1MG/ML**	**A206774**	**001**	Aug 18, 2015
AP	**!**	FRESENIUS KABI USA	**1MG/ML**	**A074735**	**001**	Jul 16, 1999
AP		GLAND PHARMA LTD	**1MG/ML**	**A207323**	**001**	Mar 17, 2017
AP		HIKMA	**1MG/ML**	**A075036**	**001**	Nov 07, 2000
AP	**+**	HQ SPCLT PHARMA	**1MG/ML**	**N018057**	**004**	Nov 08, 1988
AP		PHARMACHEMIE BV	**1MG/ML**	**A074656**	**001**	May 16, 2000
	+!	HQ SPCLT PHARMA	50MG/VIAL	N018057	002	

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

	+!	ALMATICA	EQ 30MG BASE	N215428	001	Jan 31, 2022

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

AA		AUROBINDO PHARMA	**EQ 10MG BASE/5ML**	**A077812**	**001**	Aug 28, 2006
AA		CHARTWELL MOLECULAR	**EQ 10MG BASE/5ML**	**A077629**	**001**	Jun 14, 2006
AA		HETERO LABS LTD III	**EQ 10MG BASE/5ML**	**A201450**	**001**	Dec 15, 2015
AA	**!**	HIKMA	**EQ 10MG BASE/5ML**	**A077043**	**001**	Dec 13, 2004

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB	**+**	ABBVIE	**EQ 10MG BASE**	**N020822**	**001**	Apr 27, 2000
AB	**+**		**EQ 20MG BASE**	**N020822**	**002**	Jul 17, 1998
AB	**+!**		**EQ 40MG BASE**	**N020822**	**003**	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

AB		AMNEAL PHARMS NY	**EQ 10MG BASE**	**A077289**	**001**	Nov 30, 2006
AB			**EQ 20MG BASE**	**A077289**	**002**	Nov 30, 2006
AB			**EQ 40MG BASE**	**A077289**	**003**	Nov 30, 2006
AB		APOTEX INC	**EQ 10MG BASE**	**A077046**	**001**	Nov 24, 2004
AB		AUROBINDO	**EQ 10MG BASE**	**A077031**	**001**	Oct 28, 2004
AB			**EQ 20MG BASE**	**A077031**	**002**	Oct 28, 2004
AB			**EQ 40MG BASE**	**A077031**	**003**	Oct 28, 2004
AB		CHARTWELL MOLECULAR	**EQ 10MG BASE**	**A077044**	**001**	Nov 05, 2004
AB			**EQ 20MG BASE**	**A077044**	**002**	Nov 05, 2004
AB			**EQ 40MG BASE**	**A077044**	**003**	Nov 05, 2004
AB		COSETTE	**EQ 10MG BASE**	**A077048**	**001**	Nov 16, 2004
AB			**EQ 20MG BASE**	**A077048**	**002**	Nov 16, 2004
AB			**EQ 40MG BASE**	**A077048**	**003**	Nov 16, 2004
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A077038**	**001**	Oct 28, 2004
AB			**EQ 20MG BASE**	**A077038**	**002**	Oct 28, 2004
AB			**EQ 40MG BASE**	**A077038**	**003**	Oct 28, 2004
AB		EPIC PHARMA	**EQ 10MG BASE**	**A077045**	**003**	Apr 29, 2005
AB			**EQ 20MG BASE**	**A077045**	**002**	Apr 29, 2005
AB			**EQ 40MG BASE**	**A077045**	**001**	Apr 29, 2005
AB		GLENMARK GENERICS	**EQ 10MG BASE**	**A077654**	**001**	Feb 27, 2009
AB			**EQ 20MG BASE**	**A077654**	**002**	Feb 27, 2009
AB			**EQ 40MG BASE**	**A077654**	**003**	Feb 27, 2009
AB		INVAGEN PHARMS	**EQ 10MG BASE**	**A077534**	**001**	Oct 03, 2006
AB			**EQ 20MG BASE**	**A077534**	**002**	Oct 03, 2006
AB			**EQ 40MG BASE**	**A077534**	**003**	Oct 03, 2006
AB		MYLAN	**EQ 10MG BASE**	**A077042**	**001**	Nov 05, 2004
AB			**EQ 20MG BASE**	**A077042**	**002**	Nov 05, 2004
AB			**EQ 40MG BASE**	**A077042**	**003**	Nov 05, 2004
AB		TORPHARM	**EQ 20MG BASE**	**A077046**	**002**	Nov 24, 2004
AB			**EQ 40MG BASE**	**A077046**	**003**	Nov 24, 2004
AB		TORRENT PHARMS	**EQ 10MG BASE**	**A078216**	**001**	Mar 27, 2007
AB			**EQ 20MG BASE**	**A078216**	**002**	Mar 27, 2007
AB			**EQ 40MG BASE**	**A078216**	**003**	Mar 27, 2007

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION;IRRIGATION

RENACIDIN

+!	UNITED GUARDIAN	6.602GM/100ML;198MG/100ML;3.177GM/100ML	N019481	001	Oct 02, 1990

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

GEL;VAGINAL

PHEXXI

+!	EVOFEM INC	1%;1.8%;0.4%	N208352	001	May 22, 2020

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID

!	HETERO LABS LTD V	12GM/PACKET;3.5GM/PACKET;10MG/PACKET	A212789	001	Jul 18, 2022

SOLUTION;ORAL

CLENPIQ

+!	FERRING PHARMS INC	12GM/BOT;3.5GM/BOT;10MG/BOT	N209589	001	Nov 28, 2017

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION;ORAL

IDKIT:HP

+!	MERIDIAN BIOSCIENCE	4GM;75MG	N021314	001	Dec 17, 2002

CLADRIBINE

INJECTABLE;INJECTION

CLADRIBINE

AP	**!**	FRESENIUS KABI USA	**1MG/ML**	**A076571**	**001**	Apr 22, 2004
AP		HIKMA	**1MG/ML**	**A075405**	**001**	Feb 28, 2000
AP		HISUN PHARM HANGZHOU	**1MG/ML**	**A210856**	**001**	Nov 25, 2019

TABLET;ORAL

MAVENCLAD

+!	EMD SERONO INC	10MG	N022561	001	Mar 29, 2019

CLARITHROMYCIN						
FOR SUSPENSION;ORAL						
CLARITHROMYCIN						
	SANDOZ	125MG/5ML	A065283	002	Sep 04, 2007
!		250MG/5ML	A065283	003	Sep 04, 2007
TABLET;ORAL						
CLARITHROMYCIN						
AB	ALEMBIC	**250MG**	**A210459**	**001**	Jan 31, 2022
AB		**500MG**	**A210459**	**002**	Jan 31, 2022
AB !	AUROBINDO	**250MG**	**A065489**	**001**	Jul 25, 2012
AB !		**500MG**	**A065489**	**002**	Jul 25, 2012
AB	CHARTWELL	**250MG**	**A065384**	**001**	Aug 20, 2007
AB		**500MG**	**A065384**	**002**	Aug 20, 2007
AB	HEC PHARM	**250MG**	**A203584**	**001**	Sep 28, 2015
AB		**500MG**	**A203584**	**002**	Sep 28, 2015
AB	SANDOZ	**250MG**	**A065144**	**001**	Oct 18, 2005
AB		**500MG**	**A065136**	**001**	Aug 25, 2005
AB	STRIDES PHARMA	**250MG**	**A202710**	**001**	Jun 10, 2013
AB		**500MG**	**A202710**	**002**	Jun 10, 2013
TABLET, EXTENDED RELEASE;ORAL						
CLARITHROMYCIN						
AB	ACTAVIS LABS FL INC	**500MG**	**A065145**	**001**	Jun 24, 2004
AB !	DR REDDYS LABS SA	**500MG**	**A065154**	**001**	May 18, 2005
AB	NOSTRUM LABS INC	**500MG**	**A203243**	**001**	Feb 29, 2016
AB	SUNSHINE	**500MG**	**A208987**	**001**	Jul 09, 2018
CLASCOTERONE						
CREAM;TOPICAL						
WINLEVI						
+!	SUN PHARM	1%	N213433	001	Aug 26, 2020
CLEMASTINE FUMARATE						
SYRUP;ORAL						
CLEMASTINE FUMARATE						
!	GENUS	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994
TABLET;ORAL						
CLEMASTINE FUMARATE						
!	TEVA	2.68MG	A073283	001	Jan 31, 1992
CLEVIDIPINE						
EMULSION;INTRAVENOUS						
CLEVIPREX						
+!	CHIESI	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008
+!		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008
CLINDAMYCIN HYDROCHLORIDE						
CAPSULE;ORAL						
CLEOCIN HYDROCHLORIDE						
AB +	PFIZER	**EQ 75MG BASE**	**N050162**	**001**	
AB +		**EQ 150MG BASE**	**N050162**	**002**	
AB +!		**EQ 300MG BASE**	**N050162**	**003**	Apr 14, 1988
CLINDAMYCIN HYDROCHLORIDE						
AB	AUROBINDO PHARMA	**EQ 150MG BASE**	**A065442**	**001**	Aug 26, 2009
AB		**EQ 300MG BASE**	**A065442**	**002**	Aug 26, 2009
AB	CHARTWELL MOLECULAR	**EQ 75MG BASE**	**A065243**	**002**	Aug 12, 2005
AB	COSETTE	**EQ 150MG BASE**	**A063029**	**001**	Sep 20, 1989
AB		**EQ 300MG BASE**	**A063029**	**002**	Aug 05, 2005
AB	EPIC PHARMA LLC	**EQ 150MG BASE**	**A065194**	**001**	Mar 22, 2004
AB		**EQ 300MG BASE**	**A065194**	**002**	Mar 22, 2004
AB	GLENMARK PHARMS LTD	**EQ 75MG BASE**	**A216957**	**001**	Mar 10, 2023
AB		**EQ 150MG BASE**	**A216957**	**002**	Mar 10, 2023
AB		**EQ 300MG BASE**	**A216957**	**003**	Mar 10, 2023
AB	MICRO LABS	**EQ 75MG BASE**	**A207402**	**001**	Nov 05, 2018
AB		**EQ 150MG BASE**	**A207402**	**002**	Nov 05, 2018
AB		**EQ 300MG BASE**	**A207402**	**003**	Nov 05, 2018
AB	SUN PHARM INDS LTD	**EQ 150MG BASE**	**A065061**	**001**	Feb 02, 2001
AB		**EQ 300MG BASE**	**A065061**	**002**	Feb 02, 2001
AB	ZYDUS PHARMS USA	**EQ 75MG BASE**	**A065217**	**001**	Jan 31, 2005
AB		**EQ 150MG BASE**	**A065217**	**002**	Jan 31, 2005
AB		**EQ 300MG BASE**	**A065217**	**003**	Jan 31, 2005

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

		CLEOCIN				
AA	!	PFIZER	**EQ 75MG BASE/5ML**	**A062644**	**001**	Apr 07, 1986
		CLINDAMYCIN PALMITATE HYDROCHLORIDE				
AA		AMNEAL PHARMS	**EQ 75MG BASE/5ML**	**A203513**	**001**	Mar 13, 2014
AA		AUROBINDO PHARMA LTD	**EQ 75MG BASE/5ML**	**A202409**	**001**	Apr 30, 2013
AA		CHARTWELL RX	**EQ 75MG BASE/5ML**	**A206958**	**001**	May 05, 2017
AA		HERITAGE PHARMS INC	**EQ 75MG BASE/5ML**	**A207047**	**001**	May 11, 2018
AA		LYNE	**EQ 75MG BASE/5ML**	**A201821**	**001**	Aug 28, 2012
AA		PADAGIS US	**EQ 75MG BASE/5ML**	**A090902**	**001**	Jul 07, 2010

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

		CLINDAMYCIN PHOSPHATE				
AT		GLENMARK PHARMS LTD	**1%**	**A210778**	**001**	Sep 20, 2021
AT	!	PADAGIS ISRAEL	**1%**	**A090785**	**001**	Mar 31, 2010
AT		TARO	**1%**	**A210004**	**001**	Mar 11, 2020

CREAM;VAGINAL

		CLEOCIN				
AB	+!	PFIZER	**EQ 2% BASE**	**N050680**	**002**	Mar 02, 1998
		CLINDAMYCIN PHOSPHATE				
AB		FOUGERA PHARMS	**EQ 2% BASE**	**A065139**	**001**	Dec 27, 2004
		CLINDESSE				
	+!	PADAGIS US	EQ 2% BASE	N050793	001	Nov 30, 2004

GEL;TOPICAL

		CLEOCIN T				
AB1	+!	PFIZER	**EQ 1% BASE**	**N050615**	**001**	Jan 07, 1987
		CLINDAMYCIN PHOSPHATE				
AB1		AMNEAL	**EQ 1% BASE**	**A215219**	**001**	Nov 03, 2022
AB1		ENCUBE	**EQ 1% BASE**	**A212438**	**001**	Mar 11, 2021
AB1		FOUGERA PHARMS	**EQ 1% BASE**	**A064160**	**001**	Jan 28, 2000
AB1		GLENMARK PHARMS LTD	**EQ 1% BASE**	**A214251**	**001**	Feb 10, 2021
AB1		PADAGIS ISRAEL	**EQ 1% BASE**	**A212104**	**001**	Dec 31, 2020
AB1		SOLARIS PHARMA CORP	**EQ 1% BASE**	**A211872**	**001**	Jul 29, 2020
AB1		TARO	**EQ 1% BASE**	**A214052**	**001**	Nov 10, 2020
AB1		ZYDUS LIFESCIENCES	**EQ 1% BASE**	**A216587**	**001**	Sep 19, 2023
		CLINDAGEL				
AB2	+!	BAUSCH	**EQ 1% BASE**	**N050782**	**001**	Nov 27, 2000
		CLINDAMYCIN PHOSPHATE				
AB2		AMNEAL	**EQ 1% BASE**	**A214668**	**001**	Aug 05, 2022
AB2		SOLARIS PHARMA CORP	**EQ 1% BASE**	**A212842**	**001**	Aug 13, 2021

GEL;VAGINAL

		XACIATO				
	+!	DARE	EQ 2% BASE	N215650	001	Dec 07, 2021

INJECTABLE;INJECTION

		CLEOCIN PHOSPHATE				
AP		PFIZER	**EQ 150MG BASE/ML**	**A062803**	**001**	Oct 16, 1987
AP	+!		**EQ 150MG BASE/ML**	**N050441**	**001**	
		CLINDAMYCIN PHOSPHATE				
AP		ALMAJECT	**EQ 150MG BASE/ML**	**A062800**	**001**	Jul 24, 1987
AP			**EQ 150MG BASE/ML**	**A062943**	**001**	Sep 29, 1988
AP		FRESENIUS KABI USA	**EQ 150MG BASE/ML**	**A065346**	**001**	Mar 29, 2007
AP			**EQ 150MG BASE/ML**	**A065347**	**001**	May 09, 2007
AP		HIKMA	**EQ 150MG BASE/ML**	**A062889**	**001**	Apr 25, 1988
AP			**EQ 150MG BASE/ML**	**A065206**	**001**	Sep 24, 2004
AP		SAGENT PHARMS INC	**EQ 150MG BASE/ML**	**A090108**	**001**	Sep 30, 2011
AP			**EQ 150MG BASE/ML**	**A090109**	**001**	Sep 30, 2011
		CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER				
AP		BAXTER HLTHCARE CORP	**EQ 6MG BASE/ML**	**A208084**	**001**	Jun 28, 2017
AP			**EQ 12MG BASE/ML**	**A208084**	**002**	Jun 28, 2017
AP			**EQ 18MG BASE/ML**	**A208084**	**003**	Jun 28, 2017
AP		RISING	**EQ 6MG BASE/ML**	**A203048**	**001**	Apr 04, 2013
AP			**EQ 12MG BASE/ML**	**A203048**	**002**	Apr 04, 2013
AP			**EQ 18MG BASE/ML**	**A203048**	**003**	Apr 04, 2013
AP	!	SANDOZ INC	**EQ 6MG BASE/ML**	**A201692**	**001**	May 31, 2012
AP	!		**EQ 12MG BASE/ML**	**A201692**	**002**	May 31, 2012
AP	!		**EQ 18MG BASE/ML**	**A201692**	**003**	May 31, 2012
		CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%				
AP		HIKMA	**EQ 6MG BASE/ML**	**A214401**	**001**	Apr 05, 2023
AP			**EQ 12MG BASE/ML**	**A214401**	**002**	Apr 05, 2023

CLINDAMYCIN PHOSPHATE							
INJECTABLE;INJECTION							
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%							
AP			**EQ 18MG BASE/ML**	**A214401**	**003**	Apr 05, 2023
	+!	ABRAXIS PHARM	EQ 900MG BASE/100ML	N050635	001	Dec 22, 1989
LOTION;TOPICAL							
CLEOCIN T							
AB	**+!**	PFIZER	**EQ 1% BASE**	**N050600**	**001**	May 31, 1989
CLINDAMYCIN PHOSPHATE							
AB		ENCUBE	**EQ 1% BASE**	**A215607**	**001**	Jan 18, 2022
AB		FOUGERA PHARMS	**EQ 1% BASE**	**A065067**	**001**	Jan 31, 2002
AB		PADAGIS ISRAEL	**EQ 1% BASE**	**A214604**	**001**	Mar 08, 2021
AB		TARO	**EQ 1% BASE**	**A214526**	**001**	Jun 28, 2021
SOLUTION;INTRAVENOUS							
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE							
	+!	BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017
	+!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017
	+!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017
SOLUTION;TOPICAL							
CLINDA-DERM							
AT		PADAGIS US	**EQ 1% BASE**	**A063329**	**001**	Sep 30, 1992
CLINDAMYCIN PHOSPHATE							
AT		CADILA	**EQ 1% BASE**	**A208767**	**001**	Jul 16, 2018
AT		CHARTWELL RX	**EQ 1% BASE**	**A209846**	**001**	Feb 08, 2018
AT		ENCUBE ETHICALS	**EQ 1% BASE**	**A209914**	**001**	Jan 28, 2019
AT		FOUGERA PHARMS INC	**EQ 1% BASE**	**A064159**	**001**	Jun 05, 1997
AT	**!**	PADAGIS US	**EQ 1% BASE**	**A064050**	**001**	Nov 30, 1995
AT		TARO PHARM INDS	**EQ 1% BASE**	**A065184**	**001**	Mar 31, 2004
SUPPOSITORY;VAGINAL							
CLEOCIN							
	+!	PFIZER	100MG	N050767	001	Aug 13, 1999
SWAB;TOPICAL							
CLINDAMYCIN PHOSPHATE							
AT		EPIC PHARMA LLC	**EQ 1% BASE**	**A065513**	**001**	Jun 17, 2010
AT	**!**	PADAGIS US	**EQ 1% BASE**	**A065049**	**001**	May 25, 2000
CLINDETS							
AT		PADAGIS US	**EQ 1% BASE**	**A064136**	**001**	Sep 30, 1996
CLINDAMYCIN PHOSPHATE; TRETINOIN							
GEL;TOPICAL							
CLINDAMYCIN PHOSPHATE AND TRETINOIN							
AB1		ACTAVIS MID ATLANTIC	**1.2%;0.025%**	**A202564**	**001**	Jun 12, 2015
ZIANA							
AB1	**+!**	BAUSCH	**1.2%;0.025%**	**N050802**	**001**	Nov 07, 2006
CLINDAMYCIN PHOSPHATE AND TRETINOIN							
AB2		ENCUBE	**1.2%;0.025%**	**A216943**	**001**	Sep 01, 2023
AB2		SOLARIS PHARMA CORP	**1.2%;0.025%**	**A212845**	**001**	Feb 10, 2022
VELTIN							
AB2	**+!**	ALMIRALL	**1.2%;0.025%**	**N050803**	**001**	Jul 16, 2010
CLOBAZAM							
FILM;ORAL							
SYMPAZAN							
	+	OTTER PHARMS	5MG	N210833	001	Nov 01, 2018
	+		10MG	N210833	002	Nov 01, 2018
	+!		20MG	N210833	003	Nov 01, 2018
SUSPENSION;ORAL							
CLOBAZAM							
AB		ALKEM LABS LTD	**2.5MG/ML**	**A213039**	**001**	May 06, 2021
AB		AMNEAL	**2.5MG/ML**	**A210039**	**001**	Oct 22, 2018
AB		AUROBINDO PHARMA LTD	**2.5MG/ML**	**A214404**	**001**	Mar 24, 2022
AB		BIONPHARMA	**2.5MG/ML**	**A208819**	**001**	Oct 22, 2018
AB		CHARTWELL MOLECULAR	**2.5MG/ML**	**A213110**	**001**	Apr 24, 2020
AB		HETERO LABS LTD III	**2.5MG/ML**	**A209796**	**001**	Feb 24, 2020
AB		LUPIN LTD	**2.5MG/ML**	**A210546**	**001**	Dec 28, 2018
AB		TARO	**2.5MG/ML**	**A210978**	**001**	Apr 15, 2019
ONFI							
AB	**+!**	LUNDBECK PHARMS LLC	**2.5MG/ML**	**N203993**	**001**	Dec 14, 2012

CLOBAZAM

TABLET;ORAL

CLOBAZAM

AB		ALKEM LABS LTD	**10MG**	**A212714**	**001**	Sep 06, 2019
AB			**20MG**	**A212714**	**002**	Sep 06, 2019
AB		AMNEAL PHARMS CO	**10MG**	**A209718**	**001**	Oct 22, 2018
AB			**20MG**	**A209718**	**002**	Oct 22, 2018
AB		BIONPHARMA	**10MG**	**A208825**	**001**	Oct 22, 2018
AB			**20MG**	**A208825**	**002**	Oct 22, 2018
AB		BRECKENRIDGE	**10MG**	**A209308**	**001**	Oct 22, 2018
AB			**20MG**	**A209308**	**002**	Oct 22, 2018
AB		HETERO LABS LTD III	**10MG**	**A209795**	**001**	Oct 22, 2018
AB			**20MG**	**A209795**	**002**	Oct 22, 2018
AB		LUPIN LTD	**10MG**	**A210545**	**001**	Dec 14, 2018
AB			**20MG**	**A210545**	**002**	Dec 14, 2018
AB		MICRO LABS	**10MG**	**A211711**	**001**	Jan 30, 2019
AB			**20MG**	**A211711**	**002**	Jan 30, 2019
AB		MSN	**10MG**	**A213404**	**001**	May 11, 2021
AB			**20MG**	**A213404**	**002**	May 11, 2021
AB		PIRAMAL HLTHCARE UK	**10MG**	**A209808**	**001**	Oct 22, 2018
AB			**20MG**	**A209808**	**002**	Oct 22, 2018
AB		UPSHER SMITH LABS	**10MG**	**A209687**	**001**	Oct 22, 2018
AB			**20MG**	**A209687**	**002**	Oct 22, 2018
AB		ZYDUS PHARMS	**10MG**	**A211449**	**001**	Oct 22, 2018
AB			**20MG**	**A211449**	**002**	Oct 22, 2018

ONFI

AB	+	LUNDBECK PHARMS LLC	**10MG**	**N202067**	**002**	Oct 21, 2011
AB	+!		**20MG**	**N202067**	**003**	Oct 21, 2011

CLOBAZAM

		ALKEM LABS LTD	5MG	A212714	003	Dec 21, 2020

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		ALEMBIC	**0.05%**	**A215838**	**001**	Apr 21, 2022
AB1		GLENMARK PHARMS LTD	**0.05%**	**A210809**	**001**	Feb 15, 2019
AB1		PADAGIS ISRAEL	**0.05%**	**A077763**	**001**	Mar 10, 2008
AB1	!	TARO	**0.05%**	**A208779**	**001**	Oct 04, 2018
AB2		GLENMARK PHARMS LTD	**0.05%**	**A211450**	**001**	Sep 09, 2019
AB2	!	PADAGIS ISRAEL	**0.05%**	**A201402**	**001**	Aug 14, 2012

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		ALEMBIC	**0.05%**	**A213291**	**001**	Jan 27, 2020
AB1		AMNEAL	**0.05%**	**A211256**	**001**	Dec 26, 2018
AB1		AUROBINDO PHARMA USA	**0.05%**	**A075338**	**001**	Feb 09, 2001
AB1		COSETTE	**0.05%**	**A074139**	**001**	Aug 03, 1994
AB1	!	ENCUBE	**0.05%**	**A212982**	**001**	Aug 28, 2020
AB1		FOUGERA PHARMS INC	**0.05%**	**A074392**	**001**	Sep 30, 1996
AB1		GLENMARK PHARMS	**0.05%**	**A209095**	**001**	May 10, 2018
AB1		LUPIN LTD	**0.05%**	**A210208**	**001**	Jan 30, 2018
AB1		RISING	**0.05%**	**A211401**	**001**	Jan 11, 2019
AB1		TARO	**0.05%**	**A074249**	**001**	Jul 08, 1996
AB1		XIROMED	**0.05%**	**A210034**	**001**	Jun 15, 2018
AB1		ZYDUS PHARMS	**0.05%**	**A211074**	**001**	Oct 15, 2018

CORMAX

AB1		HIKMA	**0.05%**	**A074220**	**001**	May 16, 1997

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	!	FOUGERA PHARMS	**0.05%**	**A075430**	**001**	May 26, 1999
AB2		TARO	**0.05%**	**A075633**	**001**	May 17, 2000

IMPOYZ

	+!	PRIMUS PHARMS	0.025%	N209483	001	Nov 28, 2017

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB	!	FOUGERA PHARMS	**0.05%**	**A075368**	**001**	Feb 15, 2000
AB		PADAGIS US	**0.05%**	**A075027**	**001**	Oct 31, 1997
AB		TARO	**0.05%**	**A075279**	**001**	May 28, 1999

EMBELINE

AB		HIKMA	**0.05%**	**A076141**	**001**	Apr 12, 2002

LOTION;TOPICAL

CLOBETASOL PROPIONATE

AB		ACTAVIS MID ATLANTIC	**0.05%**	**A078223**	**001**	Dec 04, 2008

CLOBETASOL PROPIONATE

LOTION;TOPICAL

CLOBETASOL PROPIONATE

AB		CADILA	**0.05%**	**A205249**	**001**	Sep 24, 2019
AB		LUPIN LTD	**0.05%**	**A209147**	**001**	Sep 22, 2017
AB		TARO	**0.05%**	**A200302**	**001**	Jul 02, 2012

CLOBEX

AB	**+!**	GALDERMA LABS LP	**0.05%**	**N021535**	**001**	Jul 24, 2003

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB		ALEMBIC	**0.05%**	**A211800**	**001**	Mar 04, 2019
AB		AUROBINDO PHARMA USA	**0.05%**	**A075057**	**001**	Aug 12, 1998
AB		COSETTE	**0.05%**	**A074089**	**001**	Feb 16, 1994
AB		ENCUBE	**0.05%**	**A211295**	**001**	Nov 15, 2019
AB	**!**	FOUGERA PHARMS	**0.05%**	**A074407**	**001**	Feb 23, 1996
AB		GLENMARK PHARMS	**0.05%**	**A208933**	**001**	Mar 20, 2017
AB		MACLEODS PHARMS LTD	**0.05%**	**A215990**	**001**	Dec 28, 2023
AB		NOVEL LABS INC	**0.05%**	**A208841**	**001**	May 04, 2018
AB		TARO	**0.05%**	**A074248**	**001**	Jul 12, 1996
AB		XIROMED	**0.05%**	**A209701**	**001**	Apr 17, 2018
AB		ZYDUS PHARMS	**0.05%**	**A210199**	**001**	Oct 27, 2017

EMBELINE

AB		HIKMA	**0.05%**	**A074221**	**001**	Mar 31, 1995

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE

AB		ALEMBIC	**0.05%**	**A213290**	**001**	May 18, 2020
AB		AMNEAL	**0.05%**	**A214895**	**001**	Jun 14, 2021
AB		HIKMA	**0.05%**	**A209871**	**001**	Oct 27, 2017
AB		PADAGIS ISRAEL	**0.05%**	**A090974**	**001**	Aug 09, 2012
AB		TARO	**0.05%**	**A214867**	**001**	Mar 25, 2021

CLOBEX

AB	**+!**	GALDERMA LABS	**0.05%**	**N021644**	**001**	Feb 05, 2004

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT		ALEMBIC	**0.05%**	**A212881**	**001**	Oct 21, 2019
AT		COSETTE	**0.05%**	**A074331**	**001**	Dec 15, 1995
AT		FOUGERA PHARMS	**0.05%**	**A075391**	**001**	Feb 08, 1999
AT		GLENMARK PHARMS LTD	**0.05%**	**A210190**	**001**	Apr 18, 2018
AT		MACLEODS PHARMS LTD	**0.05%**	**A209361**	**001**	Oct 25, 2017
AT		NOVEL LABS INC	**0.05%**	**A206075**	**001**	Nov 23, 2015
AT		QUAGEN	**0.05%**	**A211240**	**001**	Feb 17, 2022
AT		SAPTALIS PHARMS	**0.05%**	**A211494**	**001**	Oct 02, 2019
AT	**!**	TARO	**0.05%**	**A075224**	**001**	Nov 16, 1998
AT			**0.05%**	**A075363**	**001**	Dec 29, 2000

EMBELINE

AT		HIKMA	**0.05%**	**A074222**	**001**	Dec 06, 1995

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

AT		ALEMBIC	**0.05%**	**A211191**	**001**	Oct 02, 2019
AT		GLENMARK PHARMS	**0.05%**	**A209004**	**001**	Mar 26, 2018
AT		LUPIN LTD	**0.05%**	**A208125**	**001**	Mar 26, 2018
AT		PADAGIS US	**0.05%**	**A090898**	**001**	Jun 16, 2011
AT		TARO	**0.05%**	**A208842**	**001**	Mar 26, 2018
AT		ZYDUS PHARMS	**0.05%**	**A206378**	**001**	Feb 16, 2017

CLOBEX

AT	**+!**	GALDERMA LABS LP	**0.05%**	**N021835**	**001**	Oct 27, 2005

CLOCORTOLONE PIVALATE

CREAM;TOPICAL

CLOCORTOLONE PIVALATE

AB		TARO	**0.1%**	**A206370**	**001**	Apr 21, 2020

CLODERM

AB	**+!**	EPI HLTH	**0.1%**	**N017765**	**001**	

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

AP		ABON PHARMS LLC	**20MG/20ML (1MG/ML)**	**A204029**	**001**	May 09, 2017
AP		ACCORD HLTHCARE	**20MG/20ML (1MG/ML)**	**A212034**	**001**	Feb 22, 2019
AP		AMNEAL	**20MG/20ML (1MG/ML)**	**A208857**	**001**	Nov 06, 2017
AP		DR REDDYS	**20MG/20ML (1MG/ML)**	**A205375**	**001**	Nov 06, 2017
AP		GLAND PHARMA LTD	**20MG/20ML (1MG/ML)**	**A207831**	**001**	Oct 31, 2018
AP		MEITHEAL	**20MG/20ML (1MG/ML)**	**A213461**	**001**	Oct 23, 2020

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

AP		MSN	**20MG/20ML (1MG/ML)**	**A209775**	**001**	Dec 06, 2017
AP		MYLAN LABS LTD	**20MG/20ML (1MG/ML)**	**A208860**	**001**	Nov 06, 2017

CLOLAR

AP	**+!**	GENZYME	**20MG/20ML (1MG/ML)**	**N021673**	**001**	Dec 28, 2004

CLOMIPHENE CITRATE

TABLET;ORAL

CLOMIPHENE CITRATE

	!	COSETTE	50MG	A075528	001	Aug 30, 1999

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

ANAFRANIL

AB	**+!**	SPECGX LLC	**25MG**	**N019906**	**001**	Dec 29, 1989
AB	**+**		**50MG**	**N019906**	**002**	Dec 29, 1989
AB	**+**		**75MG**	**N019906**	**003**	Dec 29, 1989

CLOMIPRAMINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	**25MG**	**A213897**	**001**	Oct 02, 2020
AB			**50MG**	**A213897**	**002**	Oct 02, 2020
AB			**75MG**	**A213897**	**003**	Oct 02, 2020
AB		ALEMBIC	**25MG**	**A211822**	**001**	Aug 04, 2021
AB			**50MG**	**A211822**	**002**	Aug 04, 2021
AB			**75MG**	**A211822**	**003**	Aug 04, 2021
AB		AMNEAL PHARMS CO	**25MG**	**A208632**	**001**	Oct 31, 2018
AB			**50MG**	**A208632**	**002**	Oct 31, 2018
AB			**75MG**	**A208632**	**003**	Oct 31, 2018
AB		AUROBINDO PHARMA	**25MG**	**A216440**	**001**	Mar 20, 2023
AB			**50MG**	**A216440**	**002**	Mar 20, 2023
AB			**75MG**	**A216440**	**003**	Mar 20, 2023
AB		CHEMISTRY HLTH	**25MG**	**A211364**	**001**	Feb 07, 2020
AB			**50MG**	**A211364**	**002**	Feb 07, 2020
AB			**75MG**	**A211364**	**003**	Feb 07, 2020
AB		JUBILANT CADISTA	**25MG**	**A212218**	**001**	Oct 21, 2019
AB			**50MG**	**A212218**	**002**	Oct 21, 2019
AB			**75MG**	**A212218**	**003**	Oct 21, 2019
AB		LUPIN LTD	**25MG**	**A209294**	**001**	Nov 21, 2018
AB			**50MG**	**A209294**	**002**	Nov 21, 2018
AB			**75MG**	**A209294**	**003**	Nov 21, 2018
AB		MANKIND PHARMA	**25MG**	**A211767**	**001**	Apr 08, 2019
AB			**50MG**	**A211767**	**002**	Apr 08, 2019
AB			**75MG**	**A211767**	**003**	Apr 08, 2019
AB		MICRO LABS	**25MG**	**A213219**	**001**	Jun 22, 2020
AB			**50MG**	**A213219**	**002**	Jun 22, 2020
AB			**75MG**	**A213219**	**003**	Jun 22, 2020
AB		MYLAN	**25MG**	**A074947**	**001**	Apr 30, 1998
AB			**50MG**	**A074947**	**002**	Apr 30, 1998
AB			**75MG**	**A074947**	**003**	Apr 30, 1998
AB		RK PHARMA	**25MG**	**A213221**	**001**	Jun 22, 2020
AB			**50MG**	**A213221**	**002**	Jun 22, 2020
AB			**75MG**	**A213221**	**003**	Jun 22, 2020
AB		SANDOZ	**25MG**	**A074364**	**001**	Mar 29, 1996
AB			**25MG**	**A074953**	**001**	Jun 25, 1997
AB			**50MG**	**A074364**	**002**	Mar 29, 1996
AB			**50MG**	**A074953**	**002**	Jun 25, 1997
AB			**75MG**	**A074364**	**003**	Mar 29, 1996
AB			**75MG**	**A074953**	**003**	Jun 25, 1997
AB		TARO	**25MG**	**A074694**	**001**	Dec 31, 1996
AB			**50MG**	**A074694**	**002**	Dec 31, 1996
AB			**75MG**	**A074694**	**003**	Dec 31, 1996
AB		TULEX PHARMS INC	**25MG**	**A210653**	**001**	Apr 03, 2020
AB			**50MG**	**A210653**	**002**	Apr 03, 2020
AB			**75MG**	**A210653**	**003**	Apr 03, 2020
AB		UNIQUE	**25MG**	**A212285**	**001**	Aug 07, 2020
AB			**50MG**	**A212285**	**002**	Aug 07, 2020
AB			**75MG**	**A212285**	**003**	Aug 07, 2020
AB		ZYDUS PHARMS	**25MG**	**A208961**	**001**	Dec 27, 2017
AB			**50MG**	**A208961**	**002**	Dec 27, 2017
AB			**75MG**	**A208961**	**003**	Dec 27, 2017

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB		ACCORD HLTHCARE	0.5MG	A077147	001	May 02, 2005
AB			1MG	A077147	002	May 02, 2005
AB			2MG	A077147	003	May 02, 2005
AB		ACTAVIS ELIZABETH	0.5MG	A074869	001	Oct 31, 1996
AB			1MG	A074869	002	Oct 31, 1996
AB			2MG	A074869	003	Oct 31, 1996
AB		AUROBINDO PHARMA USA	0.5MG	A075150	001	Oct 05, 1998
AB			1MG	A075150	002	Oct 05, 1998
AB			2MG	A075150	003	Oct 05, 1998
AB		PRINSTON INC	0.5MG	A077856	001	Jun 28, 2006
AB			1MG	A077856	002	Jun 28, 2006
AB			2MG	A077856	003	Jun 28, 2006
AB		RUBICON	0.5MG	A075468	001	Oct 06, 2000
AB			1MG	A075468	002	Oct 06, 2000
AB			2MG	A075468	003	Oct 06, 2000
AB		SANDOZ	0.5MG	A074979	001	Aug 29, 1997
AB			1MG	A074979	002	Aug 29, 1997
AB			2MG	A074979	003	Aug 29, 1997
AB		TEVA	0.5MG	A074569	001	Sep 10, 1996
AB			1MG	A074569	002	Sep 10, 1996
AB			2MG	A074569	003	Sep 10, 1996

KLONOPIN

AB	+	CHEPLAPHARM	0.5MG	N017533	001	
AB	+!		1MG	N017533	002	
AB	+		2MG	N017533	003	

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

AB		ALEMBIC	0.125MG	A211033	001	Jun 28, 2019
AB			0.25MG	A211033	002	Jun 28, 2019
AB			0.5MG	A211033	003	Jun 28, 2019
AB			1MG	A211033	004	Jun 28, 2019
AB			2MG	A211033	005	Jun 28, 2019
AB		BARR	0.125MG	A077194	001	Aug 10, 2005
AB			0.25MG	A077194	002	Aug 10, 2005
AB			0.5MG	A077194	003	Aug 10, 2005
AB			1MG	A077194	004	Aug 10, 2005
AB			2MG	A077194	005	Aug 10, 2005
AB		PAR PHARM	0.125MG	A077171	001	Aug 03, 2005
AB			0.25MG	A077171	002	Aug 03, 2005
AB			0.5MG	A077171	003	Aug 03, 2005
AB	!		1MG	A077171	004	Aug 03, 2005
AB			2MG	A077171	005	Aug 03, 2005
AB		SUN PHARM INDS INC	0.125MG	A078654	001	Aug 27, 2014
AB			0.25MG	A078654	002	Aug 27, 2014
AB			0.5MG	A078654	003	Aug 27, 2014
AB			1MG	A078654	004	Aug 27, 2014
AB			2MG	A078654	005	Aug 27, 2014

CLONIDINE

SYSTEM;TRANSDERMAL

CATAPRES-TTS-1

AB	+	LAVIPHARM	0.1MG/24HR	N018891	001	Oct 10, 1984

CATAPRES-TTS-2

AB	+	LAVIPHARM	0.2MG/24HR	N018891	002	Oct 10, 1984

CATAPRES-TTS-3

AB	+!	LAVIPHARM	0.3MG/24HR	N018891	003	Oct 10, 1984

CLONIDINE

AB		ACTAVIS LABS UT INC	0.1MG/24HR	A090873	001	May 06, 2014
AB			0.2MG/24HR	A090873	002	May 06, 2014
AB			0.3MG/24HR	A090873	003	May 06, 2014
AB		AVEVA	0.1MG/24HR	A076157	001	Aug 18, 2009
AB			0.2MG/24HR	A076157	002	Aug 18, 2009
AB			0.3MG/24HR	A076157	003	Aug 18, 2009
AB		DR REDDYS LABS SA	0.1MG/24HR	A079090	001	Aug 20, 2010
AB			0.2MG/24HR	A079090	002	Aug 20, 2010
AB			0.3MG/24HR	A079090	003	Aug 20, 2010
AB		MYLAN TECHNOLOGIES	0.1MG/24HR	A076166	001	Jul 16, 2010
AB			0.2MG/24HR	A076166	002	Jul 16, 2010
AB			0.3MG/24HR	A076166	003	Jul 16, 2010

CLONIDINE

TABLET, EXTENDED RELEASE;ORAL

NEXICLON XR

		ATHENA	EQ 0.17MG BASE	N022500	001	Dec 03, 2009

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP		FRESENIUS KABI USA	**1MG/10ML (0.1MG/ML)**	**A200673**	**001**	Jul 08, 2011
AP			**5MG/10ML (0.5MG/ML)**	**A200673**	**002**	Jul 08, 2011
AP		HIKMA FARMACEUTICA	**1MG/10ML (0.1MG/ML)**	**A200300**	**001**	Jan 26, 2011
AP	!		**5MG/10ML (0.5MG/ML)**	**A200300**	**002**	Jan 26, 2011
AP		XGEN PHARMS	**1MG/10ML (0.1MG/ML)**	**A203167**	**001**	Oct 29, 2013
AP			**5MG/10ML (0.5MG/ML)**	**A203167**	**002**	Oct 29, 2013
AP		ZYDUS PHARMS	**1MG/10ML (0.1MG/ML)**	**A202601**	**001**	Feb 20, 2014
AP			**5MG/10ML (0.5MG/ML)**	**A202601**	**002**	Feb 20, 2014

DURACLON

AP	+	MYLAN INSTITUTIONAL	**1MG/10ML (0.1MG/ML)**	**N020615**	**001**	Oct 02, 1996

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**0.1MG**	**A070974**	**001**	Dec 16, 1986
AB			**0.2MG**	**A070975**	**001**	Dec 16, 1986
AB			**0.3MG**	**A070976**	**001**	Dec 16, 1986
AB		ALEMBIC PHARMS LTD	**0.1MG**	**A091368**	**001**	Dec 06, 2011
AB			**0.2MG**	**A091368**	**002**	Dec 06, 2011
AB			**0.3MG**	**A091368**	**003**	Dec 06, 2011
AB		AUROBINDO PHARMA LTD	**0.1MG**	**A070886**	**002**	Aug 31, 1988
AB			**0.2MG**	**A070886**	**001**	Aug 31, 1988
AB			**0.3MG**	**A070886**	**003**	Aug 31, 1988
AB		CHARTWELL MOLECULES	**0.1MG**	**A071785**	**002**	Apr 05, 1988
AB			**0.2MG**	**A071785**	**003**	Apr 05, 1988
AB			**0.3MG**	**A071785**	**001**	Apr 05, 1988
AB		IMPAX LABS	**0.1MG**	**A078099**	**001**	Aug 27, 2009
AB			**0.2MG**	**A078099**	**002**	Aug 27, 2009
AB			**0.3MG**	**A078099**	**003**	Aug 27, 2009
AB		PRINSTON INC	**0.1MG**	**A077901**	**001**	Mar 09, 2007
AB			**0.2MG**	**A077901**	**002**	Mar 09, 2007
AB			**0.3MG**	**A077901**	**003**	Mar 09, 2007
AB		UNICHEM	**0.1MG**	**A078895**	**001**	Aug 26, 2009
AB			**0.2MG**	**A078895**	**002**	Aug 26, 2009
AB	!		**0.3MG**	**A078895**	**003**	Aug 26, 2009
AB		URL LABS	**0.1MG**	**A070923**	**003**	Sep 04, 1987
AB			**0.2MG**	**A070923**	**002**	Sep 04, 1987
AB			**0.3MG**	**A070923**	**001**	Sep 04, 1987
AB		YUNG SHIN PHARM	**0.1MG**	**A202297**	**001**	Jun 13, 2013
AB			**0.2MG**	**A202297**	**002**	Jun 13, 2013
AB			**0.3MG**	**A202297**	**003**	Jun 13, 2013

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB1		ACTAVIS ELIZABETH	**0.1MG**	**A203320**	**001**	May 15, 2015
AB1	!	AJANTA PHARMA LTD	**0.1MG**	**A209686**	**001**	Nov 20, 2017
AB1		ANCHEN PHARMS	**0.1MG**	**A202984**	**001**	Sep 30, 2013
AB1		JUBILANT GENERICS	**0.1MG**	**A210338**	**001**	Jan 29, 2018
AB1		LUPIN LTD	**0.1MG**	**A209285**	**001**	Oct 23, 2017
AB1		NOVAST LABS	**0.1MG**	**A209675**	**001**	Mar 05, 2019
AB1		XIAMEN LP PHARM CO	**0.1MG**	**A209757**	**001**	Nov 20, 2017

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB		ACCORD HLTHCARE	**EQ 75MG BASE**	**A202925**	**001**	Mar 27, 2013
AB			**EQ 300MG BASE**	**A202925**	**002**	Mar 27, 2013
AB		ACME LABS	**EQ 75MG BASE**	**A078004**	**001**	May 17, 2012
AB		ALKEM LABS LTD	**EQ 75MG BASE**	**A203632**	**001**	Dec 08, 2023
AB		AMNEAL PHARMS	**EQ 75MG BASE**	**A203751**	**001**	Apr 11, 2014
AB		APOTEX INC	**EQ 75MG BASE**	**A076274**	**001**	May 17, 2012
AB	!		**EQ 300MG BASE**	**A076274**	**002**	Mar 04, 2014
AB		AUROBINDO PHARMA LTD	**EQ 75MG BASE**	**A090540**	**001**	May 17, 2012
AB		DR REDDYS	**EQ 75MG BASE**	**A076273**	**001**	Jan 14, 2008
AB		DR REDDYS LABS LTD	**EQ 300MG BASE**	**A091023**	**001**	May 17, 2012
AB		HETERO LABS LTD V	**EQ 75MG BASE**	**A205345**	**001**	Aug 04, 2023
AB			**EQ 300MG BASE**	**A205345**	**002**	Aug 04, 2023

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB		MACLEODS PHARMS LTD	**EQ 75MG BASE**	**A202928**	**001**	Feb 10, 2014
AB		POLYGEN PHARMS	**EQ 75MG BASE**	**A213351**	**001**	Jul 17, 2020
AB			**EQ 300MG BASE**	**A213351**	**002**	Jul 17, 2020
AB		PRINSTON INC	**EQ 75MG BASE**	**A206376**	**001**	May 07, 2018
AB			**EQ 300MG BASE**	**A206376**	**002**	May 07, 2018
AB		RISING	**EQ 75MG BASE**	**A204359**	**001**	Feb 02, 2017
AB		SCIEGEN PHARMS INC	**EQ 75MG BASE**	**A204165**	**001**	Sep 15, 2014
AB			**EQ 300MG BASE**	**A204165**	**002**	Sep 15, 2014
AB		TEVA	**EQ 75MG BASE**	**A076999**	**001**	May 17, 2012
AB		TORRENT PHARMS LTD	**EQ 75MG BASE**	**A090844**	**001**	May 17, 2012

PLAVIX

AB	+	SANOFI AVENTIS US	**EQ 75MG BASE**	**N020839**	**001**	Nov 17, 1997
AB	+		**EQ 300MG BASE**	**N020839**	**002**	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB		AUROBINDO PHARMA	**3.75MG**	**A071858**	**002**	Jul 17, 1987
AB			**7.5MG**	**A071858**	**003**	Jul 17, 1987
AB	!		**15MG**	**A071858**	**001**	Jul 17, 1987
AB		COREPHARMA	**3.75MG**	**A215566**	**001**	Jun 14, 2022
AB			**7.5MG**	**A215566**	**002**	Jun 14, 2022
AB			**15MG**	**A215566**	**003**	Jun 14, 2022
AB		NOVITIUM PHARMA	**3.75MG**	**A213730**	**001**	Jun 16, 2022
AB			**7.5MG**	**A213730**	**002**	Jun 16, 2022
AB			**15MG**	**A213730**	**003**	Dec 16, 2022
AB		TARO	**3.75MG**	**A075731**	**003**	Apr 27, 2000
AB			**7.5MG**	**A075731**	**002**	Apr 27, 2000
AB			**15MG**	**A075731**	**001**	Apr 27, 2000

TRANXENE

AB	+	AJENAT PHARMS	**7.5MG**	**N017105**	**007**

CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE

AB		FOUGERA PHARMS	**1%**	**A078338**	**001**	Sep 02, 2008
AB		GLENMARK PHARMS	**1%**	**A090219**	**001**	Aug 03, 2010
AB	!	TARO	**1%**	**A072640**	**001**	Aug 31, 1993

SOLUTION;TOPICAL

CLOTRIMAZOLE

AT		NOVITIUM PHARMA	**1%**	**A209815**	**001**	Feb 14, 2019
AT		SCIEGEN PHARMS INC	**1%**	**A216569**	**001**	Oct 16, 2023
AT	!	TARO	**1%**	**A074580**	**001**	Jul 29, 1996
AT		TASMAN PHARMA	**1%**	**A212281**	**001**	Jul 25, 2019
AT		TEVA	**1%**	**A073306**	**001**	Feb 28, 1995

TROCHE/LOZENGE;ORAL

CLOTRIMAZOLE

AB	!	HIKMA	**10MG**	**A076387**	**001**	Jul 29, 2004
AB		PADAGIS US	**10MG**	**A076763**	**001**	Oct 28, 2005

CLOZAPINE

SUSPENSION;ORAL

VERSACLOZ

	+!	TASMAN PHARMA	50MG/ML	N203479	001	Feb 06, 2013

TABLET;ORAL

CLOZAPINE

AB		ACCORD HLTHCARE	**25MG**	**A202873**	**001**	Nov 25, 2015
AB			**100MG**	**A202873**	**002**	Nov 25, 2015
AB		AUROBINDO PHARMA	**25MG**	**A206433**	**001**	Nov 29, 2016
AB			**50MG**	**A206433**	**002**	Nov 29, 2016
AB			**100MG**	**A206433**	**003**	Nov 29, 2016
AB			**200MG**	**A206433**	**004**	Nov 29, 2016
AB		IVAX SUB TEVA PHARMS	**25MG**	**A074949**	**001**	Nov 26, 1997
AB			**50MG**	**A074949**	**004**	Apr 25, 2005
AB			**50MG**	**A076809**	**003**	Dec 16, 2005
AB			**100MG**	**A074949**	**002**	Nov 26, 1997
AB			**100MG**	**A076809**	**002**	Dec 16, 2005
AB			**200MG**	**A076809**	**001**	Dec 16, 2005
AB		MYLAN	**25MG**	**A075417**	**001**	May 27, 1999
AB			**50MG**	**A075417**	**004**	Apr 15, 2010

CLOZAPINE

TABLET;ORAL

CLOZAPINE

AB			**100MG**	**A075417**	**002**	May 27, 1999
AB			**200MG**	**A075417**	**005**	Apr 15, 2010
AB		SUN PHARM INDS INC	**25MG**	**A075713**	**001**	Nov 15, 2002
AB			**50MG**	**A075713**	**003**	Aug 19, 2005
AB			**100MG**	**A075713**	**002**	Nov 15, 2002
AB			**200MG**	**A075713**	**004**	Nov 07, 2017

CLOZARIL

AB	+	HERITAGE LIFE	**25MG**	**N019758**	**001**	Sep 26, 1989
AB	+		**50MG**	**N019758**	**003**	May 20, 2019
AB	+!		**100MG**	**N019758**	**002**	Sep 26, 1989
AB	+		**200MG**	**N019758**	**004**	May 20, 2019

CLOZAPINE

	IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

CLOZAPINE

AB		BARR LABS INC	**25MG**	**A090308**	**001**	Nov 25, 2015
AB	!		**100MG**	**A090308**	**002**	Nov 25, 2015
AB		MYLAN	**25MG**	**A201824**	**002**	Sep 15, 2015
AB			**100MG**	**A201824**	**003**	Sep 15, 2015
AB			**150MG**	**A201824**	**004**	Aug 07, 2023
AB			**200MG**	**A201824**	**005**	Aug 07, 2023
AB		TEVA PHARMS USA	**150MG**	**A203039**	**001**	Nov 25, 2015
AB			**200MG**	**A203039**	**002**	Nov 25, 2015

	BARR LABS INC	12.5MG	A090308	003	Apr 09, 2018

COBICISTAT

TABLET;ORAL

TYBOST

+!	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014

COBICISTAT; DARUNAVIR

TABLET;ORAL

PREZCOBIX

+!	JANSSEN PRODS	150MG;800MG	N205395	001	Jan 29, 2015

COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

SYMTUZA

+!	JANSSEN PRODS	150MG;800MG;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

GENVOYA

+!	GILEAD SCIENCES INC	150MG;150MG;200MG;EQ 10MG BASE	N207561	001	Nov 05, 2015

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

STRIBILD

+!	GILEAD SCIENCES INC	150MG;150MG;200MG;300MG	N203100	001	Aug 27, 2012

COBIMETINIB FUMARATE

TABLET;ORAL

COTELLIC

+!	GENENTECH INC	EQ 20MG BASE	N206192	001	Nov 10, 2015

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

GOPRELTO

+!	GENUS LIFESCIENCES	4%	N209963	001	Dec 14, 2017

NUMBRINO

+!	OMNIVIUM PHARMS	4%	N209575	001	Jan 10, 2020

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA	!	PHARM ASSOC	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A040660**	**001**	Dec 07, 2006

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		HIKMA	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A040674**	**001**	Dec 23, 2014

PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		AMNEAL PHARMS	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A200963**	**001**	Aug 26, 2015

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		AMNEAL PHARMS	**10MG/5ML;6.25MG/5ML**	**A200894**	**001**	Apr 24, 2013
AA		HIKMA	**10MG/5ML;6.25MG/5ML**	**A040151**	**001**	Aug 26, 1997
AA		NOSTRUM LABS INC	**10MG/5ML;6.25MG/5ML**	**A090180**	**001**	Mar 17, 2010
AA		QUAGEN	**10MG/5ML;6.25MG/5ML**	**A214238**	**001**	Oct 08, 2020
AA	!	TRIS PHARMA INC	**10MG/5ML;6.25MG/5ML**	**A200386**	**001**	Jun 29, 2012
AA		WOCKHARDT BIO AG	**10MG/5ML;6.25MG/5ML**	**A088875**	**001**	Dec 17, 1984

PROMETHAZINE WITH CODEINE

AA		PHARM ASSOC	**10MG/5ML;6.25MG/5ML**	**A040650**	**001**	Jan 31, 2006

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

TRIACIN-C

	!	ANIMA	10MG/5ML;30MG/5ML;1.25MG/5ML	A088704	001	Mar 22, 1985

CODEINE SULFATE

TABLET;ORAL

CODEINE SULFATE

AB	**+**	HIKMA	**15MG**	**N022402**	**001**	Jul 16, 2009
AB	**+**		**30MG**	**N022402**	**002**	Jul 16, 2009
AB	**+!**		**60MG**	**N022402**	**003**	Jul 16, 2009
AB		LANNETT CO INC	**15MG**	**A203046**	**001**	Jun 13, 2014
AB			**30MG**	**A203046**	**002**	Jun 13, 2014
AB			**60MG**	**A203046**	**003**	Jun 13, 2014

COLCHICINE

CAPSULE;ORAL

COLCHICINE

AB		PAR PHARM INC	**0.6MG**	**A208678**	**001**	Nov 29, 2018

MITIGARE

AB	**+!**	HIKMA INTL PHARMS	**0.6MG**	**N204820**	**001**	Sep 26, 2014

SOLUTION;ORAL

GLOPERBA

	+!	SCILEX PHARMS	0.6MG/5ML	N210942	001	Jan 30, 2019

TABLET;ORAL

COLCHICINE

AB		ALKEM LABS LTD	**0.6MG**	**A211250**	**001**	Feb 08, 2019
AB		AMNEAL PHARMS	**0.6MG**	**A204711**	**001**	Sep 28, 2016
AB		AUROBINDO PHARMA LTD	**0.6MG**	**A215444**	**001**	Jan 06, 2022
AB		DR REDDYS	**0.6MG**	**A209876**	**001**	Sep 06, 2019
AB		GRANULES	**0.6MG**	**A210425**	**001**	Feb 05, 2020
AB		HETERO LABS LTD V	**0.6MG**	**A208993**	**001**	Aug 13, 2021
AB		MYLAN	**0.6MG**	**A209470**	**001**	Sep 16, 2019
AB		PAR PHARM INC	**0.6MG**	**A203976**	**001**	Aug 12, 2021
AB		STRIDES PHARMA	**0.6MG**	**A209173**	**001**	Mar 10, 2022
AB		WATSON LABS INC	**0.6MG**	**A204461**	**001**	Jul 31, 2019
AB		ZYDUS PHARMS	**0.6MG**	**A211519**	**001**	Feb 19, 2019

COLCRYS

AB	**+!**	TAKEDA PHARMS USA	**0.6MG**	**N022352**	**001**	Jul 29, 2009

COLCHICINE

		ZYDUS PHARMS	0.3MG	A211519	002	Nov 14, 2019

LODOCO

	+!	AGEPHA PHARMA FZ	0.5MG	N215727	001	Jun 16, 2023

COLCHICINE; PROBENECID

TABLET;ORAL

COL-PROBENECID

AB	**+!**	WATSON LABS	**0.5MG;500MG**	**A084279**	**001**	

PROBENECID AND COLCHICINE

AB		NOVAST LABS	**0.5MG;500MG**	**A040618**	**001**	May 13, 2008
AB		RISING	**0.5MG;500MG**	**A217030**	**001**	Oct 24, 2023

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

AB		ALKEM LABS LTD	**3.75GM/PACKET**	**A210316**	**001**	May 06, 2019
AB		GLENMARK PHARMS LTD	**3.75GM/PACKET**	**A202190**	**002**	Jul 16, 2018
AB		IMPAX	**3.75GM/PACKET**	**A212886**	**001**	Jan 18, 2023

WELCHOL

AB	**+!**	COSETTE	**3.75GM/PACKET**	**N022362**	**002**	Oct 02, 2009

COLESEVELAM HYDROCHLORIDE

		GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018

COLESEVELAM HYDROCHLORIDE

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

AB		ALKEM LABS LTD	**625MG**	**A209038**	**001**	Oct 05, 2018
AB		BEIJING TIDE PHARM	**625MG**	**A206036**	**001**	Oct 14, 2021
AB		BIONPHARMA	**625MG**	**A208670**	**001**	Sep 13, 2019
AB		DR REDDYS	**625MG**	**A210889**	**001**	Oct 05, 2018
AB		GLENMARK PHARMS LTD	**625MG**	**A203480**	**001**	May 18, 2018
AB		IMPAX LABS INC	**625MG**	**A091600**	**001**	May 16, 2018
AB		INVENTIA	**625MG**	**A212050**	**001**	Dec 04, 2020
AB		ZHEJIANG JINGXIN	**625MG**	**A209946**	**001**	Jul 15, 2020
AB		ZYDUS PHARMS	**625MG**	**A207765**	**001**	Oct 07, 2019

WELCHOL

AB	**+!**	COSETTE	**625MG**	**N021176**	**001**	May 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE;ORAL

COLESTID

AB	**+**	PFIZER	**5GM/SCOOPFUL**	**N017563**	**003**	Sep 22, 1995
AB	**+!**		**5GM/PACKET**	**N017563**	**004**	Sep 22, 1995

COLESTIPOL HYDROCHLORIDE

AB		IMPAX LABS	**5GM/SCOOPFUL**	**A077277**	**001**	May 02, 2006
AB			**5GM/PACKET**	**A077277**	**002**	May 02, 2006

FLAVORED COLESTID

	+	PFIZER	5GM/PACKET	N017563	001	
	+		5GM/SCOOPFUL	N017563	002	

TABLET;ORAL

COLESTID

AB	**+**	PFIZER	**1GM**	**N020222**	**001**	Jul 19, 1994

COLESTIPOL HYDROCHLORIDE

AB		ANI PHARMS	**1GM**	**A216517**	**001**	Mar 10, 2023
AB	**!**	IMPAX LABS	**1GM**	**A077510**	**001**	Oct 24, 2006
AB		ZYDUS PHARMS	**1GM**	**A215223**	**001**	Mar 10, 2022

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

AP		AVET LIFESCIENCES	**EQ 150MG BASE/VIAL**	**A202359**	**001**	Sep 28, 2012
AP		FRESENIUS KABI USA	**EQ 150MG BASE/VIAL**	**A065364**	**001**	Apr 17, 2008
AP		NEXUS	**EQ 150MG BASE/VIAL**	**A065177**	**001**	Mar 19, 2004
AP		SAGENT PHARMS INC	**EQ 150MG BASE/VIAL**	**A201365**	**001**	Feb 19, 2014
AP		XELLIA PHARMS APS	**EQ 150MG BASE/VIAL**	**A205356**	**001**	May 29, 2015
AP		XGEN PHARMS	**EQ 150MG BASE/VIAL**	**A064216**	**001**	Feb 26, 1999

COLY-MYCIN M

AP	**+!**	PAR STERILE PRODUCTS	**EQ 150MG BASE/VIAL**	**N050108**	**002**	

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS;OTIC

COLY-MYCIN S

	+!	ENDO PHARMS INC	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001	

CONIVAPTAN HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

	+!	CUMBERLAND	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008

COPPER

INTRAUTERINE DEVICE;INTRAUTERINE

PARAGARD T 380A

	+!	COOPERSURGICAL	309MG/COPPER	N018680	001	Nov 15, 1984

COPPER CU-64 DOTATATE

SOLUTION;INTRAVENOUS

DETECTNET

	+!	RADIOMEDIX	4mL (1mCi/ML)	N213227	001	Sep 03, 2020

CORTICOTROPIN

INJECTABLE;INJECTION

ACTHAR GEL

	+!	MALLINCKRODT ARD	80 UNITS/ML	N008372	008	

PURIFIED CORTROPHIN GEL

	+!	ANI PHARMS	80 UNITS/ML	N008975	002	

COSYNTROPIN							
INJECTABLE;INJECTION							
CORTROSYN							
AP	**+!**	AMPHASTAR PHARMS INC	**0.25MG/VIAL**	**N016750**	**001**		
COSYNTROPIN							
AP		MYLAN INSTITUTIONAL	**0.25MG/VIAL**	**A090574**	**001**	Dec 17, 2009	
AP		SANDOZ	**0.25MG/VIAL**	**A202147**	**001**	Jun 29, 2012	
CRISABOROLE							
OINTMENT;TOPICAL							
EUCRISA							
	+!	ANACOR PHARMS INC	2%	N207695	001	Dec 14, 2016	
CRIZOTINIB							
CAPSULE;ORAL							
XALKORI							
	+	PF PRISM CV	200MG	N202570	001	Aug 26, 2011	
	+!		250MG	N202570	002	Aug 26, 2011	
CAPSULE, PELLETS;ORAL							
XALKORI							
	+	PF PRISM CV	20MG	N217581	001	Sep 07, 2023	
	+		50MG	N217581	002	Sep 07, 2023	
	+!		150MG	N217581	003	Sep 07, 2023	
CROFELEMER							
TABLET, DELAYED RELEASE;ORAL							
MYTESI							
	+!	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012	
CROMOLYN SODIUM							
CONCENTRATE;ORAL							
CROMOLYN SODIUM							
AA		AILEX PHARMS LLC	**100MG/5ML**	**A209264**	**001**	Oct 16, 2017	
AA		MICRO LABS LTD INDIA	**100MG/5ML**	**A202745**	**001**	Apr 04, 2013	
AA		RISING	**100MG/5ML**	**A202583**	**001**	Oct 27, 2011	
GASTROCROM							
AA	**+!**	MYLAN SPECIALITY LP	**100MG/5ML**	**N020479**	**001**	Feb 29, 1996	
SOLUTION;INHALATION							
CROMOLYN SODIUM							
AN		AILEX PHARMS LLC	**10MG/ML**	**A209453**	**001**	Oct 16, 2017	
AN		MICRO LABS	**10MG/ML**	**A213658**	**001**	Apr 29, 2022	
AN	**!**	TEVA PHARMS	**10MG/ML**	**A075271**	**001**	Jan 18, 2000	
AN		VIRTUS	**10MG/ML**	**A075437**	**001**	Apr 21, 2000	
AN		WOCKHARDT BIO AG	**10MG/ML**	**A075346**	**001**	Oct 25, 1999	
SOLUTION/DROPS;OPHTHALMIC							
CROMOLYN SODIUM							
	!	SANDOZ	4%	A075282	001	Jun 16, 1999	
CROTAMITON							
LOTION;TOPICAL							
CROTAN							
AT		LEGACY PHARMA	**10%**	**A087204**	**001**		
EURAX							
AT	**+!**	JOURNEY	**10%**	**N009112**	**003**		
CUPRIC CHLORIDE							
INJECTABLE;INJECTION							
CUPRIC CHLORIDE							
AP		EXELA PHARMA	**EQ 0.4MG COPPER/ML**	**A212071**	**001**	Oct 31, 2022	
CUPRIC CHLORIDE IN PLASTIC CONTAINER							
AP	**+!**	HOSPIRA	**EQ 0.4MG COPPER/ML**	**N018960**	**001**	Jun 26, 1986	
CUPRIC SULFATE							
INJECTABLE;INJECTION							
CUPRIC SULFATE							
	!	AM REGENT	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022	
CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE							
SOLUTION;INTRAVENOUS							
MULTRYS							
	+!	AM REGENT	EQ 60MCG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG SELENIUM/ML;EQ 1000MCG BASE/ML (1ML)	N209376	003	Jun 30, 2021	
TRALEMENT							
	+!	AM REGENT	EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ	N209376	001	Jul 02, 2020	

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE

SOLUTION;INTRAVENOUS

TRALEMENT

	+!	60MCG SELENIUM/ML;EQ 3MG BASE/ML (1ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (5ML)	N209376	002	Dec 02, 2020

CYANOCOBALAMIN

INJECTABLE;INJECTION

CYANOCOBALAMIN

AP	**+!**	AM REGENT	**1MG/ML**	**A080737**	**001**	
AP		EUGIA PHARMA	**1MG/ML**	**A213874**	**001**	Dec 08, 2020
AP		GLAND PHARMA LTD	**1MG/ML**	**A214390**	**001**	Sep 24, 2020
AP		MYLAN LABS LTD	**1MG/ML**	**A204829**	**001**	Jun 05, 2017
AP		SAGENT PHARMS INC	**1MG/ML**	**A215107**	**001**	Nov 15, 2022
AP		SANDOZ	**1MG/ML**	**A212915**	**001**	Jan 04, 2021
AP		SOLA PHARMS	**1MG/ML**	**A215417**	**001**	Apr 15, 2022
AP		SOMERSET THERAPS LLC	**1MG/ML**	**A206503**	**001**	Dec 11, 2015
AP			**1MG/ML**	**A209429**	**001**	Dec 18, 2018
AP		VITRUVIAS THERAP	**1MG/ML**	**A209255**	**001**	Dec 18, 2018
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A080515**	**002**	
AP		ZYDUS PHARMS	**1MG/ML**	**A214655**	**001**	Apr 15, 2022

DODEX

AP		ACCORD HLTHCARE	**1MG/ML**	**A083022**	**001**	

VIBISONE

AP	**+!**	FRESENIUS KABI USA	**1MG/ML**	**A080557**	**003**	

SPRAY, METERED;NASAL

CYANOCOBALAMIN

AB		LUPIN	**0.5MG/SPRAY**	**A210629**	**001**	Jun 30, 2023
AB		PADAGIS ISRAEL	**0.5MG/SPRAY**	**A212458**	**001**	Sep 09, 2020

NASCOBAL

AB	**+!**	ENDO PHARMS INC	**0.5MG/SPRAY**	**N021642**	**001**	Jan 31, 2005

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

AMRIX

AB	**+**	TEVA PHARMS INTL	**15MG**	**N021777**	**001**	Feb 01, 2007
AB	**+!**		**30MG**	**N021777**	**002**	Feb 01, 2007

CYCLOBENZAPRINE HYDROCHLORIDE

AB		TWI PHARMS INC	**15MG**	**A091281**	**001**	Jan 31, 2013
AB			**30MG**	**A091281**	**002**	Jan 31, 2013

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**5MG**	**A071611**	**002**	Feb 03, 2006
AB			**7.5MG**	**A071611**	**003**	Feb 03, 2006
AB			**10MG**	**A071611**	**001**	May 03, 1989
AB		ANDA REPOSITORY	**5MG**	**A073541**	**002**	Apr 06, 2006
AB			**10MG**	**A073541**	**001**	May 23, 1995
AB		AUROBINDO PHARMA	**5MG**	**A078643**	**001**	Sep 26, 2008
AB			**10MG**	**A078643**	**002**	Sep 26, 2008
AB		CHARTWELL RX	**5MG**	**A078218**	**002**	Jun 19, 2015
AB			**7.5MG**	**A078218**	**003**	Nov 03, 2020
AB			**10MG**	**A078218**	**001**	Apr 18, 2008
AB		INVAGEN PHARMS	**5MG**	**A090478**	**001**	Jul 23, 2010
AB			**10MG**	**A090478**	**002**	Jul 23, 2010
AB		JUBILANT CADISTA	**5MG**	**A077563**	**001**	Apr 19, 2006
AB			**7.5MG**	**A077563**	**003**	Aug 25, 2017
AB			**10MG**	**A077563**	**002**	Apr 19, 2006
AB		KVK TECH	**5MG**	**A078048**	**001**	Feb 28, 2011
AB			**10MG**	**A078048**	**002**	Feb 28, 2011
AB		OXFORD PHARMS	**5MG**	**A077209**	**002**	Feb 03, 2006
AB			**10MG**	**A077209**	**001**	Oct 04, 2005
AB		PRINSTON INC	**5MG**	**A077797**	**001**	Feb 28, 2007
AB			**10MG**	**A077797**	**002**	Feb 28, 2007
AB		RUBICON	**5MG**	**A208170**	**001**	May 31, 2017
AB			**7.5MG**	**A208170**	**002**	May 31, 2017
AB	**!**		**10MG**	**A208170**	**003**	May 31, 2017
AB		SUN PHARM INDS LTD	**5MG**	**A078722**	**001**	May 12, 2008
AB			**7.5MG**	**A078722**	**002**	May 12, 2008
AB			**10MG**	**A078722**	**003**	May 12, 2008
AB		UNICHEM	**5MG**	**A213324**	**001**	Jul 06, 2020
AB			**7.5MG**	**A213324**	**002**	Jul 06, 2020

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB			**10MG**	**A213324**	**003**	Jul 05, 2020

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKPENTOLATE

AT		RISING	**1%**	**A040164**	**001**	Jan 13, 1997
AT			**2%**	**A040165**	**001**	Jan 13, 1997

CYCLOGYL

AT	**+!**	ALCON LABS INC	**1%**	**A084110**	**001**	
AT	**+!**		**2%**	**A084108**	**001**	

PENTOLAIR

AT		BAUSCH AND LOMB	**1%**	**A040075**	**001**	Apr 29, 1994

CYCLOGYL

	+!	ALCON LABS INC	0.5%	A084109	001	

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYCLOMYDRIL

	!	ALCON LABS INC	0.2%;1%	A084300	001	

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

AB		ALEMBIC	**25MG**	**A215892**	**001**	Nov 10, 2022
AB			**50MG**	**A215892**	**002**	Nov 10, 2022
AB		ANIMA	**25MG**	**A209872**	**001**	May 07, 2018
AB			**50MG**	**A209872**	**002**	May 07, 2018
AB		CIPLA	**25MG**	**A211608**	**001**	Jan 18, 2019
AB			**50MG**	**A211608**	**002**	Jan 18, 2019
AB	**+**	HIKMA	**25MG**	**N203856**	**001**	Sep 16, 2013
AB	**+!**		**50MG**	**N203856**	**002**	Sep 16, 2013
AB		ZYDUS LIFESCIENCES	**25MG**	**A211552**	**001**	Dec 13, 2023
AB			**50MG**	**A211552**	**002**	Dec 13, 2023

INJECTABLE;INJECTION

CYCLOPHOSPHAMIDE

AP		AMNEAL	**500MG/VIAL**	**A210046**	**001**	May 25, 2018
AP			**1GM/VIAL**	**A210046**	**002**	May 25, 2018
AP			**2GM/VIAL**	**A210046**	**003**	May 25, 2018
AP	**!**	BAXTER HLTHCARE	**500MG/VIAL**	**A040745**	**001**	May 21, 2008
AP	**!**		**1GM/VIAL**	**A040745**	**002**	May 21, 2008
AP	**!**		**2GM/VIAL**	**A040745**	**003**	May 21, 2008
AP		HENGRUI PHARMA	**500MG/VIAL**	**A204555**	**001**	Oct 31, 2014
AP			**1GM/VIAL**	**A204555**	**002**	Oct 31, 2014
AP			**2GM/VIAL**	**A204555**	**003**	Oct 31, 2014
AP		RK PHARMA	**500MG/VIAL**	**A216958**	**001**	Dec 18, 2023
AP			**1GM/VIAL**	**A216958**	**002**	Dec 18, 2023
AP			**2GM/VIAL**	**A216958**	**003**	Dec 18, 2023
AP		SAGENT PHARMS INC	**500MG/VIAL**	**A214529**	**001**	Jul 17, 2023
AP			**1GM/VIAL**	**A214529**	**002**	Jul 17, 2023
AP			**2GM/VIAL**	**A214529**	**003**	Jul 17, 2023
AP		SUNNY	**500MG/VIAL**	**A215089**	**001**	Oct 26, 2023
AP			**1GM/VIAL**	**A215089**	**002**	Oct 26, 2023
AP			**2GM/VIAL**	**A215089**	**003**	Oct 26, 2023
AP		XGEN PHARMS	**500MG/VIAL**	**A211757**	**001**	Oct 18, 2022
AP			**1GM/VIAL**	**A211757**	**002**	Oct 18, 2022
AP			**2GM/VIAL**	**A211757**	**003**	Oct 18, 2022

SOLUTION;INTRAVENOUS

CYCLOPHOSPHAMIDE

	+!	DR REDDYS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023
	+!		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023
	+!		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023
	+!	EUGIA PHARMA SPECLTS	500MG/2.5ML (200MG/ML)	N210735	001	Aug 25, 2021
	+!		1GM/5ML (200MG/ML)	N210735	002	Aug 25, 2021
	+!		2GM/10ML (200MG/ML)	N210735	003	Nov 20, 2023
	+!	INGENUS PHARMS LLC	500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020
	+!		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020
	+!		2GM/10ML (200MG/ML)	N212501	003	Nov 19, 2021
	+!	SANDOZ	500MG/5ML (100MG/ML)	N217150	001	Sep 12, 2023
	+!		1GM/10ML (100MG/ML)	N217150	002	Sep 12, 2023
	+!		2GM/20ML (100MG/ML)	N217150	003	Sep 12, 2023

CYCLOPHOSPHAMIDE

TABLET;ORAL

CYTOXAN

+	BAXTER HLTHCARE	25MG	N012141	002	
+!		50MG	N012141	001	

CYCLOSERINE

CAPSULE;ORAL

SEROMYCIN

!	CEROVENE INC	250MG	A060593	001	

CYCLOSPORINE

CAPSULE;ORAL

CYCLOSPORINE

AB1	APOTEX	**25MG**	**A210721**	**001**	Jul 10, 2019
AB1		**50MG**	**A210721**	**002**	Jul 10, 2019
AB1		**100MG**	**A210721**	**003**	Jul 10, 2019
AB1	DR REDDYS LABS SA	**25MG**	**A065044**	**002**	Dec 20, 2000
AB1		**100MG**	**A065044**	**001**	Dec 20, 2000
AB1	IVAX SUB TEVA PHARMS	**25MG**	**A065110**	**003**	Mar 29, 2005
AB1		**50MG**	**A065110**	**001**	Mar 29, 2005
AB1		**100MG**	**A065110**	**002**	Mar 29, 2005
AB1	SANDOZ	**25MG**	**A065017**	**002**	Jan 13, 2000
AB1		**100MG**	**A065017**	**001**	Jan 13, 2000
AB1	STRIDES PHARMA	**25MG**	**A216046**	**001**	Aug 02, 2022
AB1		**50MG**	**A216046**	**002**	Aug 02, 2022
AB1		**100MG**	**A216046**	**003**	Aug 02, 2022

GENGRAF

AB1	ABBVIE	**25MG**	**A065003**	**001**	May 12, 2000
AB1		**100MG**	**A065003**	**003**	May 12, 2000

NEORAL

AB1 +	NOVARTIS	**25MG**	**N050715**	**001**	Jul 14, 1995
AB1 +!		**100MG**	**N050715**	**002**	Jul 14, 1995

CYCLOSPORINE

AB2	APOTEX	**25MG**	**A065040**	**001**	May 09, 2002
AB2		**100MG**	**A065040**	**002**	May 09, 2002

SANDIMMUNE

AB2 +	NOVARTIS	**25MG**	**N050625**	**001**	Mar 02, 1990
AB2 +!		**100MG**	**N050625**	**002**	Mar 02, 1990
BX +		50MG	N050625	003	Nov 23, 1992

EMULSION;OPHTHALMIC

CYCLOSPORINE

AB	APOTEX	**0.05%**	**A207606**	**001**	Jan 12, 2023
AB	MYLAN	**0.05%**	**A205894**	**001**	Feb 02, 2022
AB	TEVA PHARMS USA INC	**0.05%**	**A203880**	**001**	Dec 14, 2023

RESTASIS

AB +!	ABBVIE	**0.05%**	**N050790**	**001**	Dec 23, 2002

RESTASIS MULTIDOSE

+!	ABBVIE	0.05%	N050790	002	Oct 27, 2016

VERKAZIA

+!	HARROW EYE	0.1%	N214965	001	Jun 23, 2021

INJECTABLE;INJECTION

CYCLOSPORINE

AP	HIKMA	**50MG/ML**	**A065004**	**001**	Oct 29, 1999
AP	PADAGIS US	**50MG/ML**	**A065151**	**001**	Oct 07, 2003

SANDIMMUNE

AP +!	NOVARTIS	**50MG/ML**	**N050573**	**001**	Nov 14, 1983

SOLUTION;OPHTHALMIC

CEQUA

+!	SUN PHARM	0.09%	N210913	001	Aug 14, 2018

VEVYE

+!	HARROW EYE	0.1%	N217469	001	May 30, 2023

SOLUTION;ORAL

CYCLOSPORINE

AB1	ABBVIE	**100MG/ML**	**A065025**	**001**	Mar 03, 2000
AB1	IVAX SUB TEVA PHARMS	**100MG/ML**	**A065078**	**001**	Mar 25, 2005

NEORAL

AB1 +!	NOVARTIS	**100MG/ML**	**N050716**	**001**	Jul 14, 1995

SANDIMMUNE

+!	NOVARTIS	100MG/ML	N050574	001	Nov 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA		CHARTWELL MOLECULAR	**2MG/5ML**	**A203191**	**001**	Jul 13, 2017
AA		ELYSIUM	**2MG/5ML**	**A209108**	**001**	Oct 16, 2018
AA	!	LYNE	**2MG/5ML**	**A040668**	**001**	Jun 28, 2006
AA		PATRIN	**2MG/5ML**	**A204823**	**001**	Dec 27, 2016
AA		PHARM ASSOC	**2MG/5ML**	**A091295**	**001**	Mar 28, 2013
AA		QUAGEN	**2MG/5ML**	**A212423**	**001**	May 22, 2019

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA		APPCO	**4MG**	**A206553**	**001**	Nov 29, 2016
AA		BEXIMCO PHARMS USA	**4MG**	**A206676**	**001**	Apr 12, 2019
AA		CHARTWELL RX	**4MG**	**A088212**	**001**	May 26, 1983
AA		KENTON	**4MG**	**A040644**	**001**	May 30, 2006
AA		MOUNTAIN	**4MG**	**A040537**	**001**	Sep 30, 2003
AA		NOVAST LABS	**4MG**	**A205087**	**001**	Sep 23, 2015
AA		QUAGEN	**4MG**	**A212491**	**001**	Feb 24, 2021
AA		RISING	**4MG**	**A207555**	**001**	Jan 31, 2017
AA		STRIDES PHARMA	**4MG**	**A209172**	**001**	Apr 11, 2018
AA	!	ZYDUS PHARMS	**4MG**	**A208938**	**001**	May 19, 2017

CYSTEAMINE BITARTRATE

CAPSULE;ORAL

CYSTAGON

+	MYLAN	EQ 50MG BASE	N020392	001	Aug 15, 1994
+!		EQ 150MG BASE	N020392	002	Aug 15, 1994

CAPSULE, DELAYED RELEASE;ORAL

PROCYSBI

+	HORIZON	EQ 25MG BASE	N203389	001	Apr 30, 2013
+!		EQ 75MG BASE	N203389	002	Apr 30, 2013

GRANULE, DELAYED RELEASE;ORAL

PROCYSBI

+	HORIZON	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020
+!		EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYSTADROPS

+!	RECORDATI RARE	EQ 0.37% BASE	N211302	001	Aug 19, 2020

CYSTARAN

+!	LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

ELCYS

+!	EXELA PHARMA	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019
+!		2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

AP	!	FRESENIUS KABI USA	**100MG/ML**	**A076512**	**001**	Jan 15, 2004
AP		GLAND PHARMA LTD	**100MG/VIAL**	**A211937**	**001**	Dec 23, 2019
AP			**2GM/VIAL**	**A211938**	**001**	Dec 23, 2019
AP		HIKMA	**100MG/VIAL**	**A071471**	**001**	Aug 02, 1989
AP	!	HOSPIRA	**20MG/ML**	**A071868**	**001**	Jun 04, 1990
AP	!		**20MG/ML**	**A072168**	**001**	Aug 31, 1990
AP	!		**20MG/ML**	**A072945**	**001**	Feb 28, 1994
AP			**100MG/ML**	**A075383**	**001**	Nov 22, 1999
AP		MEITHEAL	**20MG/ML**	**A208485**	**001**	Feb 28, 2022
AP			**100MG/ML**	**A205696**	**001**	Jul 17, 2018
AP		RISING	**20MG/ML**	**A200915**	**001**	Dec 13, 2011
AP			**100MG/ML**	**A201784**	**001**	Jan 30, 2012
AP	!	WEST-WARD PHARMS INT	**2GM/VIAL**	**A074245**	**002**	Aug 31, 1994
	!	HIKMA	500MG/VIAL	A071472	001	Aug 02, 1989
	!	WEST-WARD PHARMS INT	1GM/VIAL	A074245	001	Aug 31, 1994

CYTARABINE; DAUNORUBICIN							
POWDER;INTRAVENOUS							
VYXEOS							
	+!	CELATOR PHARMS	100MG;44MG	N209401	001	Aug 03, 2017	
DABIGATRAN ETEXILATE MESYLATE							
CAPSULE;ORAL							
DABIGATRAN ETEXILATE MESYLATE							
AB		ALKEM LABS LTD	**EQ 75MG BASE**	**A208040**	**001**	Mar 11, 2020	
AB			**EQ 150MG BASE**	**A208040**	**002**	Mar 11, 2020	
AB		APOTEX	**EQ 75MG BASE**	**A208070**	**001**	Dec 15, 2023	
AB			**EQ 110MG BASE**	**A208070**	**002**	Dec 15, 2023	
AB			**EQ 150MG BASE**	**A208070**	**003**	Dec 15, 2023	
AB		HETERO LABS LTD III	**EQ 75MG BASE**	**A207961**	**001**	May 06, 2020	
AB			**EQ 150MG BASE**	**A207961**	**002**	May 06, 2020	
PRADAXA							
AB	**+**	BOEHRINGER INGELHEIM	**EQ 75MG BASE**	**N022512**	**001**	Oct 19, 2010	
AB	**+**		**EQ 110MG BASE**	**N022512**	**003**	Nov 20, 2015	
AB	**+!**		**EQ 150MG BASE**	**N022512**	**002**	Oct 19, 2010	
PELLETS;ORAL							
PRADAXA							
	+	BOEHRINGER INGELHEIM	EQ 20MG BASE/PACKET	N214358	001	Jun 21, 2021	
	+		EQ 30MG BASE/PACKET	N214358	002	Jun 21, 2021	
	+		EQ 40MG BASE/PACKET	N214358	003	Jun 21, 2021	
	+		EQ 50MG BASE/PACKET	N214358	004	Jun 21, 2021	
	+		EQ 110MG BASE/PACKET	N214358	005	Jun 21, 2021	
	+!		EQ 150MG BASE/PACKET	N214358	006	Jun 21, 2021	
DABRAFENIB MESYLATE							
CAPSULE;ORAL							
TAFINLAR							
	+	NOVARTIS	EQ 50MG BASE	N202806	001	May 29, 2013	
	+!		EQ 75MG BASE	N202806	002	May 29, 2013	
TABLET, FOR SUSPENSION;ORAL							
TAFINLAR							
	+!	NOVARTIS	EQ 10MG BASE	N217514	001	Mar 16, 2023	
DACARBAZINE							
INJECTABLE;INJECTION							
DACARBAZINE							
AP	**!**	FRESENIUS KABI USA	**200MG/VIAL**	**A075371**	**002**	Aug 27, 1999	
AP		HIKMA	**200MG/VIAL**	**A075812**	**001**	Jun 15, 2001	
AP			**500MG/VIAL**	**A075812**	**002**	Oct 31, 2002	
AP		HOSPIRA	**200MG/VIAL**	**A075940**	**001**	Oct 18, 2001	
AP		MEITHEAL	**200MG/VIAL**	**A075259**	**002**	Aug 27, 1998	
AP	**!**		**500MG/VIAL**	**A075259**	**001**	Sep 22, 2000	
	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999	
DACOMITINIB							
TABLET;ORAL							
VIZIMPRO							
	+	PFIZER	15MG	N211288	001	Sep 27, 2018	
	+		30MG	N211288	002	Sep 27, 2018	
	+!		45MG	N211288	003	Sep 27, 2018	
DACTINOMYCIN							
INJECTABLE;INJECTION							
COSMEGEN							
AP	**+!**	RECORDATI RARE	**0.5MG/VIAL**	**N050682**	**001**		
DACTINOMYCIN							
AP		EUGIA PHARMA	**0.5MG/VIAL**	**A203385**	**001**	Nov 09, 2017	
AP		HISUN PHARM HANGZHOU	**0.5MG/VIAL**	**A207232**	**001**	Jul 16, 2019	
AP		MEITHEAL	**0.5MG/VIAL**	**A213463**	**001**	Nov 13, 2020	
AP		XGEN PHARMS	**0.5MG/VIAL**	**A203999**	**001**	May 20, 2019	
DALBAVANCIN HYDROCHLORIDE							
POWDER;INTRAVENOUS							
DALVANCE							
	+!	ABBVIE	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL

AMPYRA

AB	**+!**	ACORDA	**10MG**	**N022250**	**001**	Jan 22, 2010

DALFAMPRIDINE

AB		ACCORD HLTHCARE	**10MG**	**A206863**	**001**	Jul 11, 2018
AB		ACTAVIS LABS FL INC	**10MG**	**A206836**	**001**	Jan 23, 2017
AB		ALKEM LABS LTD	**10MG**	**A206765**	**001**	Jul 30, 2018
AB		AUROBINDO PHARMA	**10MG**	**A206811**	**001**	Jan 23, 2017
AB		MICRO LABS	**10MG**	**A210158**	**001**	Mar 11, 2019
AB		SUN PHARM	**10MG**	**A208292**	**001**	May 21, 2019

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE;INTRAVENOUS

SYNERCID

+!	KING PHARMS	350MG/VIAL;150MG/VIAL	N050748	001	Sep 21, 1999

DALTEPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

FRAGMIN

+	PFIZER	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994
+		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996
+		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002
+		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998
+		10,000IU/4ML (2,500IU/ML)	N020287	012	Mar 15, 2022
+		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007
+		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007
+		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007
+!		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002

DANAZOL

CAPSULE;ORAL

DANAZOL

AB		BARR	**50MG**	**A074582**	**003**	May 29, 1998
AB			**100MG**	**A074582**	**002**	May 29, 1998
AB	**!**		**200MG**	**A074582**	**001**	Aug 09, 1996
AB		LANNETT CO INC	**50MG**	**A077246**	**002**	Apr 19, 2007
AB			**100MG**	**A077246**	**003**	Apr 19, 2007
AB			**200MG**	**A077246**	**001**	Sep 28, 2005

DANTROLENE SODIUM

CAPSULE;ORAL

DANTRIUM

AB	**+**	PAR STERILE PRODUCTS	**25MG**	**N017443**	**001**	
AB	**+**		**50MG**	**N017443**	**003**	
AB	**+!**		**100MG**	**N017443**	**002**	

DANTROLENE SODIUM

AB		ELITE LABS INC	**25MG**	**A076686**	**001**	Oct 24, 2005
AB			**50MG**	**A076686**	**002**	Oct 24, 2005
AB			**100MG**	**A076686**	**003**	Oct 24, 2005
AB		IMPAX LABS	**25MG**	**A076856**	**001**	Mar 01, 2005
AB			**50MG**	**A076856**	**002**	Mar 01, 2005
AB			**100MG**	**A076856**	**003**	Mar 01, 2005

FOR SUSPENSION;INTRAVENOUS

RYANODEX

+!	EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014

INJECTABLE;INJECTION

DANTRIUM

AP	**+!**	PAR STERILE PRODUCTS	**20MG/VIAL**	**N018264**	**001**	

DANTROLENE SODIUM

AP		HIKMA	**20MG/VIAL**	**A204762**	**001**	Jun 19, 2017

REVONTO

AP		USWM	**20MG/VIAL**	**A078378**	**001**	Jul 24, 2007

DAPAGLIFLOZIN

TABLET;ORAL

FARXIGA

+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014
+!		10MG	N202293	002	Jan 08, 2014

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

XIGDUO XR

+	ASTRAZENECA AB	2.5MG;1GM	N205649	005	Jul 28, 2017
+		5MG;500MG	N205649	001	Oct 29, 2014
+		5MG;1GM	N205649	002	Oct 29, 2014
+		10MG;500MG	N205649	003	Oct 29, 2014
+!		10MG;1GM	N205649	004	Oct 29, 2014

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

QTERN

+	ASTRAZENECA AB	5MG;EQ 5MG BASE	N209091	002	May 02, 2019
+!		10MG;EQ 5MG BASE	N209091	001	Feb 27, 2017

DAPRODUSTAT

TABLET;ORAL

JESDUVROQ

+	GLAXOSMITHKLINE	1MG	N216951	001	Feb 01, 2023
+		2MG	N216951	002	Feb 01, 2023
+		4MG	N216951	003	Feb 01, 2023
+		6MG	N216951	004	Feb 01, 2023
+!		8MG	N216951	005	Feb 01, 2023

DAPSONE

GEL;TOPICAL

ACZONE

AB	**+!**	ABBVIE	**5%**	**N021794**	**001**	Jul 07, 2005
AB	**+!**	ALMIRALL	**7.5%**	**N207154**	**001**	Feb 24, 2016

DAPSONE

AB		ALEMBIC	**7.5%**	**A215718**	**001**	Oct 27, 2023
AB		AMNEAL	**5%**	**A209890**	**001**	Oct 19, 2023
AB			**7.5%**	**A212701**	**001**	May 31, 2023
AB		BELOTECA	**5%**	**A213907**	**001**	Jun 06, 2023
AB		COSETTE	**5%**	**A210178**	**001**	Mar 31, 2022
AB		ENCUBE	**5%**	**A212383**	**001**	Oct 13, 2023
AB		MYLAN	**7.5%**	**A213847**	**001**	Feb 04, 2022
AB		PADAGIS ISRAEL	**5%**	**A215087**	**001**	Oct 31, 2023
AB			**7.5%**	**A212657**	**001**	Nov 01, 2023
AB		TARO	**5%**	**A209506**	**001**	Oct 16, 2017
AB			**7.5%**	**A210191**	**001**	Jun 26, 2019
AB		TORRENT	**7.5%**	**A214722**	**001**	Feb 10, 2022

TABLET;ORAL

DAPSONE

AB		ACTAVIS LLC	**25MG**	**A204380**	**001**	Mar 23, 2017
AB			**100MG**	**A204380**	**002**	Mar 23, 2017
AB	**+**	EVEREST LIFE SCI	**25MG**	**A086841**	**001**	
AB	**+**		**100MG**	**A086842**	**001**	
AB		NOSTRUM LABS INC	**25MG**	**A203887**	**001**	May 06, 2016
AB			**100MG**	**A203887**	**002**	May 06, 2016
AB		NOVITIUM PHARMA	**25MG**	**A206505**	**001**	Dec 01, 2016
AB	**!**		**100MG**	**A206505**	**002**	Dec 01, 2016
AB		RISING	**25MG**	**A207165**	**002**	Jul 20, 2023
AB			**100MG**	**A207165**	**001**	May 08, 2019

DAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

AP		ACCORD HLTHCARE	**350MG/VIAL**	**A212667**	**001**	Jul 12, 2019
AP			**500MG/VIAL**	**A211961**	**001**	Jun 24, 2019
AP		ASPIRO	**350MG/VIAL**	**A216445**	**001**	Dec 23, 2022
AP			**500MG/VIAL**	**A216413**	**001**	Sep 23, 2022
AP		BE PHARMS	**350MG/VIAL**	**A213425**	**001**	Aug 20, 2020
AP			**500MG/VIAL**	**A212513**	**001**	Jun 26, 2019
AP		DR REDDYS	**350MG/VIAL**	**A211403**	**001**	Aug 31, 2020
AP			**500MG/VIAL**	**A208375**	**001**	May 01, 2019
AP		EUGIA PHARMA	**500MG/VIAL**	**A213171**	**001**	Sep 02, 2021
AP		FRESENIUS KABI USA	**500MG/VIAL**	**A206077**	**001**	Apr 11, 2018
AP		HAINAN POLY PHARM	**500MG/VIAL**	**A215890**	**001**	Aug 18, 2022
AP		HANGZHOU ZHONGMEI	**500MG/VIAL**	**A215215**	**001**	Nov 26, 2021
AP		HENGRUI PHARMA	**500MG/VIAL**	**A212022**	**001**	Aug 22, 2019
AP		HISUN PHARM HANGZHOU	**500MG/VIAL**	**A212250**	**001**	Apr 21, 2021
AP		MEITHEAL	**350MG/VIAL**	**A213786**	**001**	Jun 29, 2021
AP			**500MG/VIAL**	**A213623**	**001**	Jun 29, 2021

DAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

AP		MYLAN	**500MG/VIAL**	**A213966**	**001**	Aug 07, 2023
AP		MYLAN LABS LTD	**500MG/VIAL**	**A205037**	**001**	Jun 05, 2018
AP	**!**	QILU PHARM HAINAN	**500MG/VIAL**	**A215316**	**001**	Aug 24, 2021
AP	**+!**	SAGENT PHARMS INC	**350MG/VIAL**	**N208385**	**001**	Sep 12, 2017
AP			**500MG/VIAL**	**A207104**	**001**	Nov 15, 2019
AP		TEVA PHARMS USA	**500MG/VIAL**	**A091039**	**001**	Mar 25, 2016
AP		XELLIA PHARMS APS	**500MG/VIAL**	**A206005**	**001**	Jun 15, 2016
	+!	HOSPIRA	350MG/VIAL	N210282	001	Jun 21, 2021
	+!		500MG/VIAL	N210282	002	Jun 21, 2021
	+!	XELLIA PHARMS APS	350MG/VIAL	N209949	001	Oct 20, 2017
	+!		350MG/VIAL	N217415	001	Jan 30, 2023
	+!		500MG/VIAL	N217415	002	Jan 30, 2023

SOLUTION;INTRAVENOUS

DAPTOMYCIN IN 0.9% SODIUM CHLORIDE

	+!	BAXTER HLTHCARE CORP	350MG/50ML (7MG/ML)	N213645	002	Feb 27, 2023
	+!		500MG/50ML (10MG/ML)	N213645	003	Feb 27, 2023
	+!		700MG/100ML (7MG/ML)	N213645	004	Feb 27, 2023
	+!		1GM/100ML (10MG/ML)	N213645	005	Feb 27, 2023

DARIDOREXANT HYDROCHLORIDE

TABLET;ORAL

QUVIVIQ

	+	IDORSIA	EQ 25MG BASE	N214985	001	Apr 07, 2022
	+!		EQ 50MG BASE	N214985	002	Apr 07, 2022

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN

AB		MACLEODS PHARMS LTD	**EQ 7.5MG BASE**	**A207302**	**001**	Jul 28, 2017
AB	**!**		**EQ 15MG BASE**	**A207302**	**002**	Jul 28, 2017

DARIFENACIN HYDROBROMIDE

AB		ALEMBIC	**EQ 7.5MG BASE**	**A207681**	**001**	Dec 08, 2017
AB			**EQ 15MG BASE**	**A207681**	**002**	Dec 08, 2017
AB		AUROBINDO PHARMA	**EQ 7.5MG BASE**	**A206743**	**001**	Sep 19, 2016
AB			**EQ 15MG BASE**	**A206743**	**002**	Sep 19, 2016
AB		CIPLA	**EQ 7.5MG BASE**	**A207664**	**001**	Sep 01, 2016
AB			**EQ 15MG BASE**	**A207664**	**002**	Sep 01, 2016
AB		POLYGEN PHARMS	**EQ 7.5MG BASE**	**A211045**	**001**	Jan 06, 2020
AB			**EQ 15MG BASE**	**A211045**	**002**	Jan 06, 2020
AB		TORRENT	**EQ 7.5MG BASE**	**A205209**	**001**	Nov 17, 2016
AB			**EQ 15MG BASE**	**A205209**	**002**	Nov 17, 2016

DAROLUTAMIDE

TABLET;ORAL

NUBEQA

	+!	BAYER HEALTHCARE	300MG	N212099	001	Jul 30, 2019

DARUNAVIR

SUSPENSION;ORAL

PREZISTA

	+!	JANSSEN PRODS	100MG/ML	N202895	001	Dec 16, 2011

TABLET;ORAL

DARUNAVIR

AB		AMNEAL	**600MG**	**A212493**	**001**	Dec 08, 2023
AB			**800MG**	**A212493**	**002**	Dec 08, 2023
AB		AUROBINDO PHARMA LTD	**600MG**	**A210677**	**001**	Nov 28, 2023
AB			**800MG**	**A210677**	**002**	Nov 28, 2023
AB		CIPLA	**600MG**	**A206288**	**001**	Nov 28, 2023
AB			**800MG**	**A206288**	**002**	Nov 28, 2023
AB		DR REDDYS	**600MG**	**A211578**	**001**	Nov 28, 2023
AB			**800MG**	**A211578**	**002**	Nov 28, 2023
AB		HETERO LABS LTD III	**600MG**	**A202083**	**002**	Sep 14, 2023
AB		LUPIN LTD	**600MG**	**A202073**	**001**	Sep 29, 2022
AB			**800MG**	**A202073**	**002**	Sep 29, 2022
AB		MSN	**600MG**	**A215389**	**001**	Nov 28, 2023
AB			**800MG**	**A215389**	**002**	Nov 28, 2023
AB		TEVA PHARMS USA	**600MG**	**A202118**	**001**	Nov 21, 2017
AB		ZYDUS PHARMS	**600MG**	**A214085**	**001**	Dec 13, 2023
AB			**800MG**	**A214085**	**002**	Dec 13, 2023

DARUNAVIR						
TABLET;ORAL						
PREZISTA						
AB	**+**	JANSSEN PRODS	**600MG**	**N021976**	**002**	Feb 25, 2008
AB	**+!**		**800MG**	**N021976**	**006**	Nov 09, 2012
DARUNAVIR						
		HETERO LABS LTD III	400MG	A202083	001	Sep 14, 2023
PREZISTA						
	+	JANSSEN PRODS	75MG	N021976	004	Dec 18, 2008
	+		150MG	N021976	005	Dec 18, 2008
DASATINIB						
TABLET;ORAL						
PHYRAGO						
	+	NANOCOPOEIA	20MG	N216099	001	Dec 05, 2023
	+		50MG	N216099	002	Dec 05, 2023
	+		70MG	N216099	003	Dec 05, 2023
	+		80MG	N216099	004	Dec 05, 2023
	+!		100MG	N216099	005	Dec 05, 2023
	+		140MG	N216099	006	Dec 05, 2023
SPRYCEL						
	+	BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006
	+		50MG	N021986	002	Jun 28, 2006
	+		70MG	N021986	003	Jun 28, 2006
	+		80MG	N021986	005	Oct 28, 2010
	+!		100MG	N021986	004	May 30, 2008
	+		140MG	N021986	006	Oct 28, 2010
DASIGLUCAGON HYDROCHLORIDE						
SOLUTION;SUBCUTANEOUS						
ZEGALOGUE						
	+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021
ZEGALOGUE (AUTOINJECTOR)						
	+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021
DAUNORUBICIN HYDROCHLORIDE						
INJECTABLE;INJECTION						
CERUBIDINE						
AP	**!**	HIKMA	**EQ 20MG BASE/VIAL**	**A064103**	**001**	Feb 03, 1995
DAUNORUBICIN HYDROCHLORIDE						
AP		FRESENIUS KABI USA	**EQ 20MG BASE/VIAL**	**A065000**	**001**	May 25, 1999
AP	**+!**	HIKMA	**EQ 5MG BASE/ML**	**N050731**	**001**	Jan 30, 1998
AP		HISUN PHARM HANGZHOU	**EQ 5MG BASE/ML**	**A208759**	**001**	Apr 12, 2019
AP		MEITHEAL	**EQ 5MG BASE/ML**	**A065035**	**001**	Jan 24, 2000
		FRESENIUS KABI USA	EQ 5MG BASE/VIAL	A065034	001	Nov 20, 2001
DECITABINE						
INJECTABLE;INTRAVENOUS						
DECITABINE						
AP	**!**	ACCORD HLTHCARE	**50MG/VIAL**	**A203475**	**001**	Feb 27, 2017
AP		CHEMI SPA	**50MG/VIAL**	**A206033**	**001**	Sep 22, 2017
AP		DR REDDYS	**50MG/VIAL**	**A203131**	**001**	Jul 11, 2013
AP		EUGIA PHARMA	**50MG/VIAL**	**A214569**	**001**	Sep 20, 2021
AP		GLAND	**50MG/VIAL**	**A205539**	**001**	Nov 23, 2020
AP		JIANGSU HANSOH PHARM	**50MG/VIAL**	**A213472**	**001**	Apr 15, 2022
AP		LUPIN LTD	**50MG/VIAL**	**A210756**	**001**	Nov 09, 2018
AP		MEITHEAL	**50MG/VIAL**	**A212959**	**001**	Jul 02, 2021
AP		MSN	**50MG/VIAL**	**A212265**	**001**	Aug 28, 2019
AP		NIVAGEN PHARMS INC	**50MG/VIAL**	**A212117**	**001**	Dec 07, 2020
AP		NOVAST LABS	**50MG/VIAL**	**A210984**	**001**	Sep 16, 2019
AP		PHARMASCIENCE INC	**50MG/VIAL**	**A204607**	**001**	May 31, 2017
AP		QILU PHARM HAINAN	**50MG/VIAL**	**A212826**	**001**	Apr 12, 2021
AP		SAGENT PHARMS INC	**50MG/VIAL**	**A207100**	**001**	Mar 16, 2018
AP		SANDOZ	**50MG/VIAL**	**A202969**	**001**	Aug 28, 2014
AP		WOCKHARDT BIO AG	**50MG/VIAL**	**A209056**	**001**	Apr 09, 2019
AP		ZYDUS PHARMS	**50MG/VIAL**	**A214486**	**001**	Nov 19, 2021
POWDER;INTRAVENOUS						
DECITABINE						
	+!	SUN PHARM	50MG/VIAL	N205582	001	Jan 28, 2014

DEFERASIROX

GRANULE;ORAL

DEFERASIROX

AB		ALKEM LABS LTD	**90MG**	**A213374**	**001**	Jul 14, 2020
AB			**180MG**	**A213374**	**002**	Jul 14, 2020
AB			**360MG**	**A213374**	**003**	Jul 14, 2020
AB		ANNORA PHARMA	**90MG**	**A216229**	**003**	Mar 16, 2023
AB			**180MG**	**A216229**	**001**	Sep 22, 2022
AB			**360MG**	**A216229**	**002**	Sep 22, 2022
AB		AUCTA	**90MG**	**A214559**	**001**	Mar 09, 2021
AB			**180MG**	**A214559**	**002**	Mar 09, 2021
AB			**360MG**	**A214559**	**003**	Mar 09, 2021
AB		CIPLA	**90MG**	**A215026**	**001**	Feb 23, 2022
AB			**180MG**	**A215026**	**002**	Feb 23, 2022
AB			**360MG**	**A215026**	**003**	Feb 23, 2022
AB		MSN	**90MG**	**A214650**	**003**	Apr 20, 2022
AB			**180MG**	**A214650**	**001**	Mar 17, 2021
AB			**360MG**	**A214650**	**002**	Mar 17, 2021
AB		TEVA PHARMS USA	**90MG**	**A214180**	**001**	Nov 19, 2021
AB			**180MG**	**A214180**	**002**	Nov 19, 2021
AB			**360MG**	**A214180**	**003**	Nov 19, 2021

JADENU SPRINKLE

AB	+	NOVARTIS	**90MG**	**N207968**	**001**	May 18, 2017
AB	+		**180MG**	**N207968**	**002**	May 18, 2017
AB	+!		**360MG**	**N207968**	**003**	May 18, 2017

TABLET;ORAL

DEFERASIROX

AB		ACTAVIS ELIZABETH	**90MG**	**A208697**	**001**	Dec 13, 2019
AB			**180MG**	**A208697**	**002**	Dec 13, 2019
AB			**360MG**	**A208697**	**003**	Dec 13, 2019
AB		ALEMBIC	**90MG**	**A211824**	**001**	Nov 20, 2019
AB			**180MG**	**A211824**	**003**	Jun 15, 2020
AB			**360MG**	**A211824**	**002**	Nov 20, 2019
AB		ALKEM LABS LTD	**90MG**	**A210555**	**001**	Mar 30, 2020
AB			**180MG**	**A210555**	**003**	Jul 02, 2020
AB			**360MG**	**A210555**	**002**	Mar 30, 2020
AB		ANNORA PHARMA	**90MG**	**A214341**	**001**	May 14, 2021
AB			**180MG**	**A214341**	**002**	May 14, 2021
AB			**360MG**	**A214341**	**003**	May 14, 2021
AB		AUROBINDO PHARMA LTD	**90MG**	**A214474**	**001**	Oct 16, 2023
AB			**180MG**	**A214474**	**002**	Oct 16, 2023
AB			**360MG**	**A214474**	**003**	Oct 16, 2023
AB		CHARTWELL RX	**90MG**	**A212669**	**001**	May 27, 2021
AB			**180MG**	**A212669**	**002**	May 27, 2021
AB			**360MG**	**A212669**	**003**	May 27, 2021
AB		MSN	**90MG**	**A210945**	**001**	Nov 20, 2019
AB			**180MG**	**A210945**	**003**	Jun 16, 2020
AB			**360MG**	**A210945**	**002**	Nov 20, 2019
AB		PIRAMAL HLTHCARE UK	**90MG**	**A212995**	**001**	Dec 30, 2019
AB			**180MG**	**A212995**	**003**	Jun 15, 2020
AB			**360MG**	**A212995**	**002**	Dec 30, 2019
AB		SUN PHARM	**90MG**	**A211641**	**001**	Jan 02, 2020
AB			**180MG**	**A211641**	**003**	Jun 15, 2020
AB			**360MG**	**A211641**	**002**	Jan 02, 2020
AB		ZYDUS PHARMS	**90MG**	**A211383**	**001**	Nov 20, 2019
AB			**180MG**	**A211383**	**003**	Jun 15, 2020
AB			**360MG**	**A211383**	**002**	Nov 20, 2019

JADENU

AB	+	NOVARTIS PHARMS CORP	**90MG**	**N206910**	**001**	Mar 30, 2015
AB	+		**180MG**	**N206910**	**002**	Mar 30, 2015
AB	+!		**360MG**	**N206910**	**003**	Mar 30, 2015

TABLET, FOR SUSPENSION;ORAL

DEFERASIROX

AB		ACTAVIS ELIZABETH	**125MG**	**A203560**	**001**	Jan 26, 2016
AB			**250MG**	**A203560**	**002**	Jan 26, 2016
AB			**500MG**	**A203560**	**003**	Jan 26, 2016
AB		ALEMBIC	**125MG**	**A210060**	**001**	Nov 20, 2019
AB			**250MG**	**A210060**	**002**	Nov 20, 2019
AB			**500MG**	**A210060**	**003**	Nov 20, 2019
AB		ALKEM LABS LTD	**125MG**	**A210519**	**001**	Nov 20, 2019
AB			**250MG**	**A210519**	**002**	Nov 20, 2019

DEFERASIROX

TABLET, FOR SUSPENSION;ORAL

DEFERASIROX

AB			**500MG**	**A210519**	**003**	Nov 20, 2019
AB		BIONPHARMA	**125MG**	**A210920**	**001**	Nov 20, 2019
AB			**250MG**	**A210920**	**002**	Nov 20, 2019
AB			**500MG**	**A210920**	**003**	Nov 20, 2019
AB		ICHNOS	**125MG**	**A209433**	**001**	Jan 06, 2020
AB			**250MG**	**A209433**	**002**	Jan 06, 2020
AB			**500MG**	**A209433**	**003**	Jan 06, 2020
AB		MSN	**125MG**	**A209878**	**001**	Nov 20, 2019
AB			**250MG**	**A209878**	**002**	Nov 20, 2019
AB			**500MG**	**A209878**	**003**	Nov 20, 2019
AB		SUN PHARM	**125MG**	**A209782**	**001**	Nov 20, 2019
AB			**250MG**	**A209782**	**002**	Nov 20, 2019
AB			**500MG**	**A209782**	**003**	Nov 20, 2019

EXJADE

AB	**+**	NOVARTIS	**125MG**	**N021882**	**001**	Nov 02, 2005
AB	**+**		**250MG**	**N021882**	**002**	Nov 02, 2005
AB	**+!**		**500MG**	**N021882**	**003**	Nov 02, 2005

DEFERIPRONE

SOLUTION;ORAL

FERRIPROX

	+!	CHIESI	100MG/ML	N208030	001	Sep 09, 2015

TABLET;ORAL

DEFERIPRONE

AB		HIKMA	**500MG**	**A213239**	**001**	Mar 29, 2021
AB	**!**		**1GM**	**A213239**	**002**	Feb 08, 2022
AB		TARO	**500MG**	**A208800**	**001**	Feb 08, 2019
AB			**1GM**	**A208800**	**002**	Nov 22, 2023

FERRIPROX

AB	**+**	CHIESI	**500MG**	**N021825**	**001**	Oct 14, 2011
AB	**+**		**1GM**	**N021825**	**002**	Jul 25, 2019
	+!		1GM	N212269	001	May 19, 2020

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

DEFEROXAMINE MESYLATE

AP		FRESENIUS KABI USA	**500MG/VIAL**	**A078718**	**001**	Sep 15, 2009
AP			**2GM/VIAL**	**A078718**	**002**	Sep 15, 2009
AP		GLAND PHARMA LTD	**500MG/VIAL**	**A207384**	**001**	Sep 29, 2017
AP			**2GM/VIAL**	**A207384**	**002**	Sep 29, 2017
AP		HOSPIRA	**500MG/VIAL**	**A076019**	**001**	Mar 17, 2004
AP	**!**		**2GM/VIAL**	**A076019**	**002**	Mar 17, 2004
AP		WEST-WARD PHARMS INT	**500MG/VIAL**	**A078086**	**001**	May 30, 2007
AP			**2GM/VIAL**	**A078086**	**002**	May 30, 2007

DESFERAL

AP	**+!**	NOVARTIS	**500MG/VIAL**	**N016267**	**001**	

DEFIBROTIDE SODIUM

SOLUTION;INTRAVENOUS

DEFITELIO

	+!	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016

DEFLAZACORT

SUSPENSION;ORAL

EMFLAZA

	+!	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017

TABLET;ORAL

EMFLAZA

	+	PTC THERAP	6MG	N208684	001	Feb 09, 2017
	+		18MG	N208684	002	Feb 09, 2017
	+		30MG	N208684	003	Feb 09, 2017
	+!		36MG	N208684	004	Feb 09, 2017

DEGARELIX ACETATE

POWDER;SUBCUTANEOUS

FIRMAGON

	+	FERRING	EQ 80MG BASE/VIAL	N022201	001	Dec 24, 2008
	+!		EQ 120MG BASE/VIAL	N022201	002	Dec 24, 2008

DELAFLOXACIN MEGLUMINE

POWDER;INTRAVENOUS

BAXDELA

+!	MELINTA	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017

TABLET;ORAL

BAXDELA

+!	MELINTA	EQ 450MG BASE	N208610	001	Jun 19, 2017

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL

DEMECLOCYCLINE HYDROCHLORIDE

AB		AMNEAL PHARM	**150MG**	**A065425**	**001**	Feb 27, 2008
AB	**!**		**300MG**	**A065425**	**002**	Feb 27, 2008
AB		EPIC PHARMA LLC	**150MG**	**A065389**	**001**	Dec 01, 2008
AB			**150MG**	**A065447**	**001**	Aug 18, 2015
AB			**300MG**	**A065389**	**002**	Dec 01, 2008
AB			**300MG**	**A065447**	**002**	Aug 18, 2015

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS

DEOXYCHOLIC ACID

AP		SLAYBACK PHARMA LLC	**20MG/2ML (10MG/ML)**	**A212296**	**001**	Apr 02, 2021

KYBELLA

AP	**+!**	KYTHERA BIOPHARMS	**20MG/2ML (10MG/ML)**	**N206333**	**001**	Apr 29, 2015

DESFLURANE

LIQUID;INHALATION

DESFLURANE

AN		SHANGHAI HENGRUI	**100%**	**A208234**	**001**	Feb 26, 2018

SUPRANE

AN	**+!**	BAXTER HLTHCARE	**100%**	**N020118**	**001**	Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB		ACTAVIS TOTOWA	**10MG**	**A074430**	**001**	Feb 09, 1996
AB			**25MG**	**A071601**	**001**	Jun 05, 1987
AB			**50MG**	**A071588**	**001**	Jun 05, 1987
AB			**75MG**	**A071602**	**001**	Oct 05, 1987
AB			**100MG**	**A071766**	**001**	Oct 05, 1987
AB			**150MG**	**A074430**	**002**	Feb 09, 1996
AB		ALEMBIC	**10MG**	**A209785**	**001**	Jul 07, 2021
AB			**25MG**	**A209785**	**002**	Jul 07, 2021
AB			**50MG**	**A209785**	**003**	Jul 07, 2021
AB			**75MG**	**A209785**	**004**	Jul 07, 2021
AB			**100MG**	**A209785**	**005**	Jul 07, 2021
AB			**150MG**	**A209785**	**006**	Jul 07, 2021
AB		AMNEAL PHARMS CO	**10MG**	**A208105**	**001**	Mar 17, 2016
AB			**25MG**	**A208105**	**002**	Mar 17, 2016
AB			**50MG**	**A208105**	**003**	Mar 17, 2016
AB			**75MG**	**A208105**	**004**	Mar 17, 2016
AB			**100MG**	**A208105**	**005**	Mar 17, 2016
AB			**150MG**	**A208105**	**006**	Mar 17, 2016
AB		HERITAGE PHARMS	**10MG**	**A207433**	**001**	May 05, 2016
AB			**25MG**	**A207433**	**002**	May 05, 2016
AB			**50MG**	**A207433**	**003**	May 05, 2016
AB			**75MG**	**A207433**	**004**	May 05, 2016
AB			**100MG**	**A207433**	**005**	May 05, 2016
AB			**150MG**	**A207433**	**006**	May 05, 2016
AB		NOVAST LABS	**10MG**	**A204963**	**001**	Dec 26, 2017
AB			**25MG**	**A204963**	**002**	Dec 26, 2017
AB			**50MG**	**A204963**	**003**	Dec 26, 2017
AB			**75MG**	**A204963**	**004**	Dec 26, 2017
AB			**100MG**	**A204963**	**005**	Dec 26, 2017
AB			**150MG**	**A204963**	**006**	Dec 26, 2017
AB		SANDOZ	**10MG**	**A072103**	**002**	May 24, 1988
AB			**25MG**	**A072103**	**003**	May 24, 1988
AB			**50MG**	**A072103**	**004**	May 24, 1988
AB			**75MG**	**A072103**	**005**	Jun 20, 1988
AB			**100MG**	**A072103**	**001**	Jun 20, 1988
AB			**150MG**	**A072103**	**006**	Jun 20, 1988

NORPRAMIN

AB	**+**	VALIDUS PHARMS	**10MG**	**N014399**	**007**	Feb 11, 1982
AB	**+**		**25MG**	**N014399**	**001**	

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

NORPRAMIN

AB	**+**		**50MG**	**N014399**	**003**	
AB	**+**		**75MG**	**N014399**	**004**	
AB	**+!**		**100MG**	**N014399**	**005**	
AB	**+**		**150MG**	**N014399**	**006**	

DESLORATADINE

TABLET;ORAL

CLARINEX

AB	**+!**	ORGANON	**5MG**	**N021165**	**001**	Dec 21, 2001

DESLORATADINE

AB		BELCHER PHARMS	**5MG**	**A078355**	**001**	Apr 19, 2012
AB		DR REDDYS LABS LTD	**5MG**	**A078365**	**001**	Mar 08, 2011
AB		LUPIN PHARMS	**5MG**	**A078352**	**001**	Oct 25, 2010
AB		ORBION PHARMS	**5MG**	**A078357**	**001**	Feb 19, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

DESLORATADINE

	REDDYS	2.5MG	A078367	001	Jul 12, 2010
!		5MG	A078367	002	Jul 12, 2010

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARINEX-D 12 HOUR

+!	ORGANON LLC	2.5MG;120MG	N021313	001	Feb 01, 2006

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

!	DR REDDYS LABS LTD	5MG;240MG	A078366	001	Apr 26, 2011

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION

DDAVP

AP	**+!**	FERRING PHARMS INC	**0.004MG/ML**	**N018938**	**001**	Mar 30, 1984

DESMOPRESSIN ACETATE

AP		DR REDDYS	**0.004MG/ML**	**A215961**	**001**	Aug 19, 2022
AP		GLAND	**0.004MG/ML**	**A216904**	**001**	Mar 20, 2023
AP		GLAND PHARMA LTD	**0.004MG/ML**	**A216922**	**001**	Nov 16, 2022
AP		MEITHEAL	**0.004MG/ML**	**A074888**	**001**	Oct 15, 1997
AP		SAGENT PHARMS INC	**0.004MG/ML**	**A204695**	**001**	Aug 22, 2017
AP			**0.004MG/ML**	**A204751**	**001**	Aug 22, 2017
AP		SUN PHARM INDS LTD	**0.004MG/ML**	**A091280**	**001**	Jan 25, 2013
AP		UBI	**0.004MG/ML**	**A210218**	**001**	Feb 14, 2020
AP			**0.004MG/ML**	**A210223**	**001**	Sep 17, 2020

SPRAY, METERED;NASAL

DESMOPRESSIN ACETATE

AB	**!**	BAUSCH	**0.01MG/SPRAY**	**A074830**	**001**	Jan 25, 1999

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB	**!**	APOTEX	**0.01MG/SPRAY**	**A076703**	**001**	Jan 27, 2005
AB		ZYDUS PHARMS	**0.01MG/SPRAY**	**A091345**	**001**	Oct 03, 2017

TABLET;ORAL

DDAVP

AB	**+**	FERRING PHARMS INC	**0.1MG**	**N019955**	**001**	Sep 06, 1995
AB	**+!**		**0.2MG**	**N019955**	**002**	Sep 06, 1995

DESMOPRESSIN ACETATE

AB		ABHAI LLC	**0.1MG**	**A210371**	**001**	Jan 28, 2019
AB			**0.2MG**	**A210371**	**002**	Jan 28, 2019
AB		ACTAVIS LABS FL INC	**0.1MG**	**A076470**	**001**	Jul 01, 2005
AB			**0.2MG**	**A076470**	**002**	Jul 01, 2005
AB		APOTEX INC	**0.1MG**	**A077414**	**001**	Mar 07, 2006
AB			**0.2MG**	**A077414**	**002**	Mar 07, 2006
AB		GLENMARK PHARMS LTD	**0.1MG**	**A201831**	**001**	May 28, 2015
AB			**0.2MG**	**A201831**	**002**	May 28, 2015
AB		HERITAGE PHARMA	**0.1MG**	**A207880**	**001**	May 26, 2017
AB			**0.2MG**	**A207880**	**002**	May 26, 2017
AB		NOVAST LABS	**0.1MG**	**A208357**	**001**	Jun 06, 2019
AB			**0.2MG**	**A208357**	**002**	Jun 06, 2019

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

BEKYREE

AB		LUPIN LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A202226**	**001**	Aug 12, 2015

CYCLESSA

AB	**+!**	ASPEN GLOBAL INC	**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**N021090**	**001**	Dec 20, 2000

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	!	DURAMED PHARMS BARR	**0.15MG;0.03MG**	**A075256**	**002**	Aug 12, 1999
AB		MYLAN LABS LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A202296**	**001**	Aug 30, 2013
AB		NAARI PTE LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A209170**	**001**	Jun 05, 2017
AB		NOVAST LABS	**0.15MG;0.03MG**	**A091234**	**001**	Jul 12, 2013
AB		WATSON LABS	**0.15MG;0.03MG**	**A076915**	**001**	Jul 29, 2005

ENSKYCE

AB		LUPIN LTD	**0.15MG;0.03MG**	**A201887**	**001**	Mar 07, 2013

ISIBLOOM

AB		XIROMED	**0.15MG;0.03MG**	**A202789**	**001**	Aug 12, 2015

KALLIGA

AB		AUROBINDO PHARMA	**0.15MG;0.03MG**	**A207081**	**001**	May 17, 2017

KARIVA

AB	!	BARR	**0.15MG,N/A;0.02MG,0.01MG**	**A075863**	**001**	Apr 05, 2002

KIMIDESS

AB		VINTAGE PHARMS	**0.15MG,N/A;0.02MG,0.01MG**	**A076681**	**001**	Apr 30, 2015

PIMTREA

AB		NOVAST LABS	**0.15MG,N/A;0.02MG,0.01MG**	**A091247**	**001**	Aug 01, 2013

SIMLIYA

AB		AUROBINDO PHARMA	**0.15MG,N/A;0.02MG,0.01MG**	**A206853**	**001**	Mar 22, 2017

VELIVET

AB		DURAMED PHARMS BARR	**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**A076455**	**001**	Feb 24, 2004

VIORELE

AB		GLENMARK GENERICS	**0.15MG,N/A;0.02MG,0.01MG**	**A091346**	**001**	Apr 02, 2012

VOLNEA

AB		XIROMED	**0.15MG,N/A;0.02MG,0.01MG**	**A202689**	**001**	Sep 09, 2016

DESONIDE

CREAM;TOPICAL

DESONIDE

AB		ALEMBIC	**0.05%**	**A214396**	**001**	Dec 08, 2022
AB		CADILA	**0.05%**	**A210198**	**001**	Nov 20, 2019
AB		COSETTE	**0.05%**	**A074027**	**001**	Sep 28, 1992
AB		GLENMARK PHARMS	**0.05%**	**A209729**	**001**	Jul 24, 2017
AB	+!	PADAGIS US	**0.05%**	**N017010**	**001**	
AB		TARO	**0.05%**	**A073548**	**001**	Jun 30, 1992

DESOWEN

AB		GALDERMA LABS LP	**0.05%**	**N019048**	**001**	Dec 14, 1984

GEL;TOPICAL

DESONIDE

	!	CINTEX SVCS	0.05%	A202470	001	May 11, 2020

LOTION;TOPICAL

DESONIDE

AB		ALEMBIC	**0.05%**	**A213632**	**001**	Aug 24, 2020
AB		FOUGERA PHARMS	**0.05%**	**A075860**	**001**	Mar 19, 2002
AB		GLENMARK PHARMS	**0.05%**	**A209494**	**001**	Sep 26, 2017
AB		TARO	**0.05%**	**A202161**	**001**	Oct 31, 2014

DESOWEN

AB	!	GALDERMA LABS LP	**0.05%**	**A072354**	**001**	Jan 24, 1992

OINTMENT;TOPICAL

DESONIDE

AB		ALEMBIC	**0.05%**	**A212473**	**001**	Oct 23, 2019
AB		ENCUBE ETHICALS	**0.05%**	**A210998**	**001**	Jan 30, 2019
AB		FOUGERA PHARMS	**0.05%**	**A075751**	**001**	Mar 12, 2001
AB		GLENMARK PHARMS LTD	**0.05%**	**A209996**	**001**	Sep 15, 2017
AB		HIKMA	**0.05%**	**A208836**	**001**	Mar 27, 2017
AB	+!	PADAGIS US	**0.05%**	**N017426**	**001**	
AB		TARO	**0.05%**	**A074254**	**001**	Aug 03, 1994

DESOWEN

AB		GALDERMA LABS LP	**0.05%**	**A071425**	**001**	Jun 15, 1988

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE

AB		ACTAVIS MID ATLANTIC	**0.25%**	**A205082**	**001**	Sep 04, 2015
AB		CADILA	**0.25%**	**A205620**	**001**	Sep 28, 2018
AB		COSETTE	**0.25%**	**A209595**	**001**	Mar 04, 2020
AB		FOUGERA PHARMS	**0.25%**	**A078369**	**001**	Jun 29, 2010
AB		LUPIN	**0.05%**	**A208163**	**001**	Jan 10, 2017
AB			**0.25%**	**A208164**	**001**	Jan 09, 2017

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE

AB		PADAGIS ISRAEL	**0.25%**	**A076510**	**001**	Jul 01, 2003
AB		RISING	**0.05%**	**A210980**	**001**	Dec 21, 2018
AB			**0.25%**	**A205594**	**001**	Jul 02, 2018

TOPICORT

AB	**!**	TARO	**0.05%**	**A073210**	**001**	Nov 30, 1990
AB	**!**		**0.25%**	**A073193**	**001**	Nov 30, 1990

GEL;TOPICAL

DESOXIMETASONE

AB		EPIC PHARMA LLC	**0.05%**	**A090727**	**001**	Mar 10, 2011
AB		PADAGIS US	**0.05%**	**A077552**	**001**	Jan 09, 2006
AB		RISING	**0.05%**	**A204675**	**001**	Aug 12, 2016

TOPICORT

AB	**!**	TARO	**0.05%**	**A074904**	**001**	Jul 14, 1998

OINTMENT;TOPICAL

DESOXIMETASONE

AB		ACTAVIS MID ATLANTIC	**0.25%**	**A204965**	**001**	Nov 07, 2016
AB		CADILA	**0.25%**	**A205206**	**001**	Sep 19, 2017
AB		COSETTE	**0.25%**	**A206740**	**001**	Dec 23, 2016
AB		EPIC PHARMA LLC	**0.25%**	**A201005**	**001**	Apr 24, 2014
AB		FOUGERA PHARMS	**0.25%**	**A078657**	**001**	Sep 28, 2012
AB	**!**	GLENMARK GENERICS	**0.25%**	**A202838**	**001**	Sep 20, 2013
AB		LUPIN	**0.05%**	**A208044**	**001**	Dec 12, 2016
AB			**0.25%**	**A208104**	**001**	Dec 01, 2016
AB		NOVEL LABS INC	**0.25%**	**A206792**	**001**	May 10, 2016
AB		PADAGIS ISRAEL	**0.25%**	**A077770**	**001**	Apr 20, 2015
AB		RISING	**0.25%**	**A204272**	**001**	Nov 30, 2016
AB		THE J MOLNER	**0.05%**	**A209973**	**001**	Oct 23, 2018

TOPICORT

AB	**+!**	TARO	**0.05%**	**N018594**	**001**	Jan 17, 1985

SPRAY;TOPICAL

DESOXIMETASONE

AT		LUPIN	**0.25%**	**A208124**	**001**	Mar 16, 2018
AT		PADAGIS ISRAEL	**0.25%**	**A206441**	**001**	Jan 20, 2017

TOPICORT

AT	**+!**	TARO	**0.25%**	**N204141**	**001**	Apr 11, 2013

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

	+	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013
	+!		100MG	N204150	002	Mar 04, 2013

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB		ACTAVIS LABS FL	**EQ 25MG BASE**	**A204065**	**001**	Jul 29, 2016
AB			**EQ 50MG BASE**	**A204065**	**002**	Jul 29, 2016
AB			**EQ 100MG BASE**	**A204065**	**003**	Jul 29, 2016
AB		ALEMBIC	**EQ 25MG BASE**	**A204003**	**003**	Sep 14, 2018
AB			**EQ 50MG BASE**	**A204003**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204003**	**002**	Jun 29, 2015
AB		HIKMA	**EQ 25MG BASE**	**A204082**	**002**	Aug 28, 2017
AB			**EQ 50MG BASE**	**A204082**	**001**	Feb 16, 2016
AB			**EQ 100MG BASE**	**A204083**	**001**	Feb 16, 2016
AB		INTELLIPHARMACEUTICS	**EQ 50MG BASE**	**A204805**	**001**	May 07, 2019
AB			**EQ 100MG BASE**	**A204805**	**002**	May 07, 2019
AB		LUPIN LTD	**EQ 25MG BASE**	**A204172**	**003**	Apr 13, 2022
AB			**EQ 50MG BASE**	**A204172**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204172**	**002**	Jun 29, 2015
AB		RUBICON	**EQ 25MG BASE**	**A204028**	**003**	Dec 07, 2023
AB			**EQ 50MG BASE**	**A204028**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204028**	**002**	Jun 29, 2015
AB		YICHANG HUMANWELL	**EQ 25MG BASE**	**A210014**	**003**	Oct 13, 2020
AB			**EQ 50MG BASE**	**A210014**	**001**	Oct 01, 2018
AB			**EQ 100MG BASE**	**A210014**	**002**	Oct 01, 2018
AB		ZYDUS PHARMS	**EQ 25MG BASE**	**A204020**	**003**	Nov 30, 2022
AB			**EQ 50MG BASE**	**A204020**	**001**	Oct 11, 2017
AB			**EQ 100MG BASE**	**A204020**	**002**	Oct 11, 2017

DESVENLAFAXINE SUCCINATE
TABLET, EXTENDED RELEASE;ORAL
PRISTIQ

AB	**+**	PF PRISM CV	**EQ 25MG BASE**	**N021992**	**003**	Aug 20, 2014
AB	**+**		**EQ 50MG BASE**	**N021992**	**001**	Feb 29, 2008
AB	**+!**		**EQ 100MG BASE**	**N021992**	**002**	Feb 29, 2008

DEUCRAVACITINIB
TABLET;ORAL
SOTYKTU

+!	BRISTOL	6MG	N214958	001	Sep 09, 2022

DEUTETRABENAZINE
TABLET;ORAL
AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017
+		9MG	N208082	002	Apr 03, 2017
+!		12MG	N208082	003	Apr 03, 2017

TABLET, EXTENDED RELEASE;ORAL
AUSTEDO XR

+	TEVA	6MG	N216354	001	Feb 17, 2023
+		12MG	N216354	002	Feb 17, 2023
+!		24MG	N216354	003	Feb 17, 2023

DEXAMETHASONE
CONCENTRATE;ORAL
DEXAMETHASONE INTENSOL

!	HIKMA	1MG/ML	A088252	001	Sep 01, 1983

ELIXIR;ORAL
DEXAMETHASONE

AA	**!**	ANIMA	**0.5MG/5ML**	**A084754**	**001**	
AA		CHARTWELL MOLECULAR	**0.5MG/5ML**	**A091188**	**001**	May 11, 2011
AA		LYNE	**0.5MG/5ML**	**A090891**	**001**	Jul 12, 2011

IMPLANT;INTRAVITREAL
OZURDEX

+!	ABBVIE	0.7MG	N022315	001	Jun 17, 2009

INSERT;OPHTHALMIC
DEXTENZA

+!	OCULAR THERAPEUTIX	0.4MG	N208742	001	Nov 30, 2018

SOLUTION;ORAL
DEXAMETHASONE

+!	HIKMA	0.5MG/5ML	A088248	001	Sep 01, 1983

SUSPENSION;INTRAOCULAR
DEXYCU KIT

+!	EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018

SUSPENSION/DROPS;OPHTHALMIC
MAXIDEX

+!	HARROW EYE	0.1%	N013422	001	

TABLET;ORAL
DEXAMETHASONE

AB		ALVOGEN	**4MG**	**A088481**	**004**	Apr 28, 1983
AB			**6MG**	**A088481**	**001**	Nov 28, 1983
AB		AMNEAL	**2MG**	**A216295**	**001**	Sep 08, 2022
AB			**4MG**	**A215106**	**001**	Oct 14, 2021
AB			**6MG**	**A215106**	**002**	Oct 14, 2021
AB		APOTEX	**0.5MG**	**A217695**	**001**	Aug 23, 2023
AB			**0.75MG**	**A217695**	**002**	Aug 23, 2023
AB			**1MG**	**A217695**	**003**	Aug 23, 2023
AB			**1.5MG**	**A217695**	**004**	Aug 23, 2023
AB			**2MG**	**A217695**	**005**	Aug 23, 2023
AB			**4MG**	**A217695**	**006**	Aug 23, 2023
AB			**6MG**	**A217695**	**007**	Aug 23, 2023
AB		BIONPHARMA	**2MG**	**A217538**	**001**	Apr 26, 2023
AB			**4MG**	**A217001**	**001**	Apr 19, 2023
AB			**6MG**	**A217001**	**002**	Apr 19, 2023
AB	**+**	HIKMA	**0.5MG**	**A084611**	**001**	
AB	**+**		**0.75MG**	**A084613**	**001**	
AB	**+!**		**1MG**	**A088306**	**001**	Sep 15, 1983
AB	**+**		**1.5MG**	**A084610**	**001**	
AB	**+!**		**2MG**	**A087916**	**001**	Aug 26, 1982
AB	**+**		**4MG**	**A084612**	**001**	
AB	**+!**		**6MG**	**A088316**	**001**	Sep 15, 1983
AB		LARKEN LABS INC	**1.5MG**	**A201270**	**001**	Jul 17, 2017
AB		NOVITIUM PHARMA	**0.5MG**	**A215604**	**004**	Oct 05, 2023

DEXAMETHASONE

TABLET;ORAL

DEXAMETHASONE

AB			**0.75MG**	**A215604**	**005**	Oct 05, 2023
AB			**1.5MG**	**A215604**	**001**	Aug 08, 2022
AB			**2MG**	**A217696**	**001**	May 09, 2023
AB			**4MG**	**A215604**	**002**	Aug 08, 2022
AB			**6MG**	**A215604**	**003**	Aug 08, 2022
AB		PRASCO	**4MG**	**A080399**	**002**	Apr 20, 2022
BP		ALVOGEN	0.5MG	A088481	002	Apr 28, 1983
BP			0.75MG	A088481	003	Apr 28, 1983
BP		XSPIRE PHARMA	1.5MG	A088237	001	Apr 28, 1983

HEMADY

	+!	DEXCEL	20MG	N211379	001	Oct 03, 2019

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP		AMNEAL	**EQ 4MG PHOSPHATE/ML**	**A208689**	**001**	Aug 22, 2018
AP		EUGIA PHARMA	**EQ 4MG PHOSPHATE/ML**	**A206781**	**001**	Dec 01, 2015
AP			**EQ 10MG PHOSPHATE/ML**	**A210966**	**001**	Jun 05, 2020
AP			**EQ 10MG PHOSPHATE/ML**	**A210967**	**001**	Jun 07, 2019
AP	**+!**	FRESENIUS KABI USA	**EQ 4MG PHOSPHATE/ML**	**A084916**	**001**	
AP			**EQ 4MG PHOSPHATE/ML**	**A203129**	**001**	Sep 30, 2015
AP	**!**		**EQ 10MG PHOSPHATE/ML**	**A040572**	**001**	Apr 22, 2005
AP			**EQ 10MG PHOSPHATE/ML**	**A209192**	**001**	Jul 06, 2018
AP		GENEYORK PHARMS	**EQ 4MG PHOSPHATE/ML**	**A214891**	**001**	Jul 28, 2023
AP			**EQ 10MG PHOSPHATE/ML**	**A214890**	**001**	Jul 07, 2023
AP		GLAND PHARMA LTD	**EQ 4MG PHOSPHATE/ML**	**A215654**	**001**	Aug 04, 2021
AP			**EQ 10MG PHOSPHATE/ML**	**A215654**	**002**	Sep 25, 2023
AP		HIKMA	**EQ 4MG PHOSPHATE/ML**	**A211451**	**001**	Aug 01, 2023
AP		MYLAN LABS LTD	**EQ 4MG PHOSPHATE/ML**	**A040803**	**001**	Aug 29, 2008
AP			**EQ 10MG PHOSPHATE/ML**	**A040802**	**001**	Aug 29, 2008
AP		SOMERSET	**EQ 4MG PHOSPHATE/ML**	**A207521**	**001**	Jun 08, 2018
AP		SOMERSET THERAPS LLC	**EQ 10MG PHOSPHATE/ML**	**A211036**	**001**	May 10, 2019
AP		WEST-WARD PHARMS INT	**EQ 4MG PHOSPHATE/ML**	**A084282**	**001**	
AP	**!**		**EQ 10MG PHOSPHATE/ML**	**A087702**	**001**	Sep 07, 1982

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP		AMNEAL	**EQ 10MG PHOSPHATE/ML**	**A208690**	**001**	Aug 22, 2018
AP	**!**	FRESENIUS KABI USA	**EQ 10MG PHOSPHATE/ML**	**A040491**	**001**	Apr 11, 2003
AP		SOMERSET THERAPS LLC	**EQ 10MG PHOSPHATE/ML**	**A207442**	**001**	Apr 19, 2018

SOLUTION/DROPS;OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

	!	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069	001	Jul 26, 1996

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MAXITROL

AT	**+!**	SANDOZ	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**N050065**	**002**	

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064063**	**001**	Jul 25, 1994
AT		PADAGIS US	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A062938**	**001**	Jul 31, 1989

SUSPENSION/DROPS;OPHTHALMIC

DEXASPORIN

AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064135**	**001**	Sep 13, 1995

MAXITROL

AT	**+!**	HARROW EYE	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**N050023**	**002**	
AT		SANDOZ	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062341**	**001**	May 22, 1984

DEXAMETHASONE; TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBRADEX

	+!	NOVARTIS	0.1%;0.3%	N050616	001	Sep 28, 1988

SUSPENSION/DROPS;OPHTHALMIC

TOBRADEX

AB	**+!**	SANDOZ	**0.1%;0.3%**	**N050592**	**001**	Aug 18, 1988

TOBRAMYCIN AND DEXAMETHASONE

AB		BAUSCH AND LOMB	**0.1%;0.3%**	**A064134**	**001**	Oct 27, 1999
AB		PADAGIS US	**0.1%;0.3%**	**A212715**	**001**	Feb 11, 2022

TOBRADEX ST

	+!	HARROW EYE	0.05%;0.3%	N050818	001	Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

AA	**+!**	PAI HOLDINGS PHARM	**2MG/5ML**	**A088251**	**001**	Mar 23, 1984

POLMON

AA		CAPELLON PHARMS LLC	**2MG/5ML**	**A202520**	**001**	Jul 16, 2018

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

AB	**+**	TAKEDA PHARMS USA	**30MG**	**N022287**	**001**	Jan 30, 2009
AB	**+!**		**60MG**	**N022287**	**002**	Jan 30, 2009

DEXLANSOPRAZOLE

AB		PAR PHARM INC	**30MG**	**A202294**	**002**	Jun 16, 2022
AB			**60MG**	**A202294**	**001**	Apr 19, 2017
AB		TWI PHARMS	**30MG**	**A202666**	**001**	Sep 16, 2022
AB			**60MG**	**A202666**	**002**	Sep 16, 2022

DEXMEDETOMIDINE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

IGALMI

	+!	BIOXCEL	EQ 0.12MG BASE	N215390	001	Apr 05, 2022
	+!		EQ 0.18MG BASE	N215390	002	Apr 05, 2022

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204023**	**001**	Feb 09, 2016
AP		ACTAVIS INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204686**	**001**	Oct 17, 2016
AP		AMNEAL	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A216604**	**001**	May 15, 2023
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A216604**	**002**	May 15, 2023
AP		AMNEAL PHARMS CO	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A207551**	**001**	May 20, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A207551**	**002**	May 20, 2020
AP		BAXTER HLTHCARE CORP	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A208532**	**001**	Aug 21, 2018
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A208532**	**002**	Aug 21, 2018
AP		EUGIA PHARMA	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205867**	**001**	Mar 17, 2016
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A210321**	**001**	Dec 07, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A210321**	**002**	Dec 07, 2020
AP		FRESENIUS KABI USA	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**A208129**	**001**	Nov 29, 2018
AP			**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A201072**	**001**	Sep 18, 2015
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A208129**	**002**	Nov 29, 2018
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A208129**	**003**	Nov 29, 2018
AP		GLAND	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202126**	**001**	Aug 20, 2015
AP		GLAND PHARMA LTD	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A209307**	**001**	Jun 03, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A209307**	**002**	Jun 03, 2020
AP		HENGRUI PHARMA	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**A209065**	**002**	Jun 12, 2020
AP			**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A209065**	**001**	Sep 19, 2017
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A209065**	**003**	Jun 12, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A209065**	**004**	Jun 12, 2020
AP		HIKMA	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205046**	**001**	Apr 26, 2017
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A206407**	**001**	Jan 30, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A206407**	**002**	Jan 30, 2020
AP		MEITHEAL	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204843**	**001**	Jan 18, 2019
AP		MILLA PHARMS	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A217308**	**001**	Jun 07, 2023
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A217308**	**002**	Jun 07, 2023
AP		MYLAN INSTITUTIONAL	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202881**	**001**	Aug 18, 2014
AP		MYLAN LABS LTD	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A212571**	**001**	Aug 27, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A212571**	**002**	Aug 27, 2020
AP		PAR STERILE PRODUCTS	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A203972**	**001**	Aug 18, 2014
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A208266**	**001**	Sep 15, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A208266**	**002**	Sep 15, 2020
AP		RISING	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202585**	**001**	Nov 24, 2014
AP		SANDOZ	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A091465**	**001**	Jun 14, 2016
AP		SLAYBACK PHARMA LLC	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A212791**	**001**	Dec 04, 2019
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A212791**	**002**	Dec 04, 2019
AP		TAGI	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**A212857**	**001**	Nov 23, 2020
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A212857**	**002**	Nov 23, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A212857**	**003**	Nov 23, 2020
AP		TEVA PHARMS USA	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205272**	**001**	Nov 28, 2017
AP		ZYDUS PHARMS	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A206798**	**001**	Feb 27, 2018

PRECEDEX

AP	**+!**	HOSPIRA	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**N021038**	**004**	Nov 14, 2014
AP	**+!**		**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**N021038**	**001**	Dec 17, 1999
AP	**+!**		**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**N021038**	**002**	Mar 13, 2013

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

PRECEDEX

AP	**+!**		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**N021038**	**003**	Mar 13, 2013
	+!		EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020

SOLUTION;INTRAVENOUS

DEXMEDETOMIDINE HYDROCHLORIDE

+!	HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628	002	Oct 21, 2015
+		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018
+		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001	Oct 21, 2015
+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	ADARE PHARMS INC	**5MG**	**A210279**	**001**	Oct 09, 2018
AB		**10MG**	**A210279**	**002**	Oct 09, 2018
AB		**15MG**	**A210279**	**003**	Oct 09, 2018
AB		**20MG**	**A210279**	**004**	Oct 09, 2018
AB		**25MG**	**A210279**	**005**	Oct 09, 2018
AB		**30MG**	**A210279**	**006**	Oct 09, 2018
AB		**35MG**	**A210279**	**007**	Oct 09, 2018
AB		**40MG**	**A210279**	**008**	Oct 09, 2018
AB	ASCENT PHARMS INC	**5MG**	**A215523**	**001**	Dec 08, 2021
AB		**10MG**	**A215523**	**002**	Dec 08, 2021
AB		**15MG**	**A215523**	**003**	Dec 08, 2021
AB		**20MG**	**A215523**	**004**	Dec 08, 2021
AB		**25MG**	**A215523**	**005**	Dec 08, 2021
AB		**30MG**	**A215523**	**006**	Dec 08, 2021
AB		**35MG**	**A215523**	**007**	Dec 08, 2021
AB		**40MG**	**A215523**	**008**	Dec 08, 2021
AB	GRANULES	**5MG**	**A213813**	**001**	Sep 09, 2020
AB		**10MG**	**A213813**	**002**	Sep 09, 2020
AB		**15MG**	**A213813**	**003**	Sep 09, 2020
AB		**20MG**	**A213813**	**004**	Sep 09, 2020
AB		**25MG**	**A213813**	**005**	Sep 09, 2020
AB		**30MG**	**A213813**	**006**	Sep 09, 2020
AB		**35MG**	**A213813**	**007**	Sep 09, 2020
AB		**40MG**	**A213813**	**008**	Sep 09, 2020
AB	IMPAX LABS INC	**5MG**	**A079108**	**001**	Aug 05, 2015
AB		**10MG**	**A079108**	**002**	Aug 05, 2015
AB		**15MG**	**A079108**	**003**	May 19, 2014
AB		**20MG**	**A079108**	**004**	Dec 21, 2015
AB		**25MG**	**A203614**	**001**	Jul 05, 2017
AB		**30MG**	**A079108**	**005**	Nov 21, 2013
AB		**35MG**	**A203614**	**002**	Jul 05, 2017
AB	INTELLIPHARMACEUTICS	**5MG**	**A078992**	**001**	Nov 23, 2021
AB		**10MG**	**A078992**	**002**	Nov 23, 2021
AB		**15MG**	**A078992**	**003**	Nov 18, 2013
AB		**30MG**	**A078992**	**004**	Nov 18, 2013
AB		**20MG**	**A078992**	**005**	Nov 23, 2021
AB		**40MG**	**A078992**	**006**	Nov 23, 2021
AB	PAR PHARM INC	**5MG**	**A202842**	**001**	Nov 30, 2016
AB		**10MG**	**A202842**	**002**	Nov 30, 2016
AB		**15MG**	**A202842**	**003**	Nov 30, 2016
AB		**20MG**	**A202842**	**004**	Nov 30, 2016
AB		**25MG**	**A202842**	**005**	Nov 30, 2016
AB		**30MG**	**A202842**	**006**	Nov 30, 2016
AB		**35MG**	**A202842**	**007**	Nov 30, 2016
AB		**40MG**	**A202842**	**008**	Nov 30, 2016
AB	SUN PHARM INDS INC	**5MG**	**A206734**	**001**	Nov 05, 2021
AB		**10MG**	**A206734**	**002**	Nov 05, 2021
AB		**15MG**	**A206734**	**003**	Nov 05, 2021
AB		**20MG**	**A206734**	**004**	Nov 05, 2021
AB		**25MG**	**A206734**	**005**	Nov 05, 2021
AB		**30MG**	**A206734**	**006**	Nov 05, 2021
AB		**35MG**	**A206734**	**007**	Nov 05, 2021
AB		**40MG**	**A206734**	**008**	Nov 05, 2021
AB	TEVA PHARMS USA	**5MG**	**A078908**	**001**	Nov 19, 2013
AB		**10MG**	**A078908**	**002**	Nov 19, 2013
AB		**15MG**	**A078908**	**004**	May 19, 2014
AB		**20MG**	**A078908**	**003**	Nov 19, 2013

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB			**25MG**	**A202731**	**001**	Jul 05, 2017
AB			**30MG**	**A202731**	**003**	May 19, 2014
AB			**35MG**	**A202731**	**004**	Jul 05, 2017
AB			**40MG**	**A202731**	**002**	Nov 19, 2013

FOCALIN XR

AB	+	SANDOZ	**5MG**	**N021802**	**001**	May 26, 2005
AB	+		**10MG**	**N021802**	**002**	May 26, 2005
AB	+		**15MG**	**N021802**	**004**	Aug 01, 2006
AB	+		**20MG**	**N021802**	**003**	May 26, 2005
AB	+		**25MG**	**N021802**	**008**	Apr 21, 2011
AB	+		**30MG**	**N021802**	**005**	Oct 23, 2009
AB	+		**35MG**	**N021802**	**007**	Apr 21, 2011
AB	+!		**40MG**	**N021802**	**006**	Aug 11, 2010

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI INC	**2.5MG**	**A206931**	**001**	Dec 04, 2015
AB			**5MG**	**A206931**	**002**	Dec 04, 2015
AB			**10MG**	**A206931**	**003**	Dec 04, 2015
AB		ALKEM LABS LTD	**2.5MG**	**A212631**	**001**	Jul 19, 2019
AB			**5MG**	**A212631**	**002**	Jul 19, 2019
AB			**10MG**	**A212631**	**003**	Jul 19, 2019
AB		CEDIPROF INC	**5MG**	**A209211**	**001**	Sep 19, 2018
AB			**10MG**	**A209211**	**002**	Sep 19, 2018
AB		NOVEL LABS INC	**2.5MG**	**A204534**	**001**	Dec 04, 2015
AB			**5MG**	**A204534**	**002**	Dec 04, 2015
AB			**10MG**	**A204534**	**003**	Dec 04, 2015
AB		RHODES PHARMS	**2.5MG**	**A208756**	**001**	Nov 20, 2017
AB			**5MG**	**A208756**	**002**	Nov 20, 2017
AB			**10MG**	**A208756**	**003**	Nov 20, 2017
AB		SUN PHARM INDUSTRIES	**2.5MG**	**A201231**	**001**	Sep 24, 2015
AB			**5MG**	**A201231**	**002**	Sep 24, 2015
AB			**10MG**	**A201231**	**003**	Sep 24, 2015
AB		TRIS PHARMA INC	**2.5MG**	**A207901**	**001**	Aug 26, 2016
AB			**5MG**	**A207901**	**002**	Aug 26, 2016
AB			**10MG**	**A207901**	**003**	Aug 26, 2016

FOCALIN

AB	+	SANDOZ	**2.5MG**	**N021278**	**001**	Nov 13, 2001
AB	+		**5MG**	**N021278**	**002**	Nov 13, 2001
AB	+!		**10MG**	**N021278**	**003**	Nov 13, 2001

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE;ORAL

AZSTARYS

+	COMMAVE THERAP	EQ 5.2MG BASE;EQ 26.1MG BASE	N212994	001	May 07, 2021
+		EQ 7.8MG BASE;EQ 39.2MG BASE	N212994	002	May 07, 2021
+!		EQ 10.4MG BASE;EQ 52.3MG BASE	N212994	003	May 07, 2021

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP	!	EUGIA PHARMA	**EQ 250MG BASE/VIAL**	**A200752**	**001**	Oct 19, 2011
AP	!		**EQ 500MG BASE/VIAL**	**A200752**	**002**	Oct 19, 2011
AP		GLAND	**EQ 250MG BASE/VIAL**	**A207321**	**002**	Dec 16, 2019
AP			**EQ 500MG BASE/VIAL**	**A207321**	**001**	Nov 28, 2016
AP		HIKMA	**EQ 250MG BASE/VIAL**	**A076068**	**001**	Sep 28, 2004
AP			**EQ 500MG BASE/VIAL**	**A076068**	**002**	Sep 28, 2004

DEXTROAMPHETAMINE

SYSTEM;TRANSDERMAL

XELSTRYM

+	NOVEN PHARMS INC	4.5MG/9HR	N215401	001	Mar 22, 2022
+		9MG/9HR	N215401	002	Mar 22, 2022
+		13.5MG/9HR	N215401	003	Mar 22, 2022
+!		18MG/9HR	N215401	004	Mar 22, 2022

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXEDRINE

AB	+	IMPAX LABS INC	**5MG**	**N017078**	**001**	
AB	+		**10MG**	**N017078**	**002**	
AB	+!		**15MG**	**N017078**	**003**	

DEXTROAMPHETAMINE SULFATE

AB		ACTAVIS ELIZABETH	**5MG**	**A203901**	**001**	Nov 30, 2012
AB			**10MG**	**A203901**	**002**	Nov 30, 2012
AB			**15MG**	**A203901**	**003**	Nov 30, 2012
AB		SPECGX LLC	**5MG**	**A076353**	**001**	May 06, 2003
AB			**10MG**	**A076353**	**002**	May 06, 2003
AB			**15MG**	**A076353**	**003**	May 06, 2003
AB		STRIDES PHARMA	**5MG**	**A205673**	**001**	Oct 31, 2017
AB			**10MG**	**A205673**	**002**	Oct 31, 2017
AB			**15MG**	**A205673**	**003**	Oct 31, 2017

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

AA	!	PRASCO	**5MG/5ML**	**A040776**	**001**	Jan 29, 2008
AA		TRIS PHARMA INC	**5MG/5ML**	**A203644**	**001**	May 29, 2013

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		ARBOR PHARMS LLC	**2.5MG**	**A090533**	**001**	Oct 25, 2011
AA			**5MG**	**A090533**	**002**	Oct 25, 2011
AA			**7.5MG**	**A090533**	**003**	Oct 25, 2011
AA			**10MG**	**A090533**	**004**	Oct 25, 2011
AA			**15MG**	**A090533**	**005**	Oct 25, 2011
AA			**20MG**	**A090533**	**006**	Oct 25, 2011
AA			**30MG**	**A090533**	**007**	Oct 25, 2011
AA		AUROLIFE PHARMA LLC	**5MG**	**A202893**	**001**	Jul 31, 2013
AA			**10MG**	**A202893**	**002**	Jul 31, 2013
AA		AVANTHI INC	**5MG**	**A203548**	**001**	Nov 23, 2015
AA			**10MG**	**A203548**	**002**	Nov 23, 2015
AA		BARR	**5MG**	**A040361**	**001**	Jan 31, 2001
AA	!		**10MG**	**A040361**	**002**	Jan 31, 2001
AA		NOVEL LABS INC	**5MG**	**A204330**	**001**	Mar 16, 2016
AA			**10MG**	**A204330**	**002**	Mar 16, 2016
AA		NUVO PHARM	**5MG**	**A210059**	**001**	Oct 18, 2017
AA			**10MG**	**A210059**	**002**	Oct 18, 2017
AA		SPECGX LLC	**5MG**	**A040436**	**001**	Jan 29, 2002
AA			**10MG**	**A040436**	**002**	Jan 29, 2002
AA		TRIS PHARMA INC	**5MG**	**A206095**	**001**	Aug 18, 2022
AA			**10MG**	**A206095**	**002**	Aug 18, 2022
AA		WINDER LABS LLC	**2.5MG**	**A212160**	**001**	Jun 07, 2021
AA			**5MG**	**A212160**	**002**	Jun 07, 2021
AA			**7.5MG**	**A212160**	**003**	Jun 07, 2021
AA			**10MG**	**A212160**	**004**	Jun 07, 2021
AA			**15MG**	**A212160**	**005**	Jun 07, 2021
AA			**20MG**	**A212160**	**006**	Jun 07, 2021
AA			**30MG**	**A212160**	**007**	Jun 07, 2021

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE DM

AA	!	SLATE RUN PHARMA	**15MG/5ML;6.25MG/5ML**	**A040649**	**001**	Feb 14, 2006

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		AMNEAL PHARMS	**15MG/5ML;6.25MG/5ML**	**A090575**	**001**	Feb 08, 2011
AA		TRIS PHARMA INC	**15MG/5ML;6.25MG/5ML**	**A091687**	**001**	Jun 28, 2012

PROMETHAZINE W/ DEXTROMETHORPHAN

AA		WOCKHARDT BIO AG	**15MG/5ML;6.25MG/5ML**	**A088864**	**001**	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

AB		ACTAVIS ELIZABETH	**20MG;10MG**	**A202934**	**001**	Oct 10, 2017

NUEDEXTA

AB	+!	AVANIR PHARMS	**20MG;10MG**	**N021879**	**001**	Oct 29, 2010

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**10GM/100ML**	**N019626**	**004**	Feb 02, 1988
AP	**+!**	BAXTER HLTHCARE	**10GM/100ML**	**N016694**	**001**	
AP		FRESENIUS KABI USA	**10GM/100ML**	**A209448**	**001**	Jul 16, 2018
AP	**+!**	ICU MEDICAL INC	**10GM/100ML**	**N018080**	**001**	

DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**50MG/ML**	**N016730**	**002**	
AP	**+!**		**5GM/100ML**	**N016730**	**001**	
AP	**+!**		**5GM/100ML**	**N019626**	**002**	Feb 02, 1988
AP	**+!**	BAXTER HLTHCARE	**50MG/ML**	**N016673**	**003**	Oct 30, 1985
AP	**+!**		**50MG/ML**	**N020179**	**002**	Dec 07, 1992
AP	**+!**		**5GM/100ML**	**N016673**	**001**	
AP	**+!**		**5GM/100ML**	**N020179**	**001**	Dec 07, 1992
AP		FRESENIUS KABI USA	**50MG/ML**	**A207449**	**001**	Oct 21, 2016
AP	**+!**	HOSPIRA	**5GM/100ML**	**N019466**	**001**	Jul 15, 1985
AP	**+!**		**5GM/100ML**	**N019479**	**001**	Sep 17, 1985
AP	**+!**	ICU MEDICAL INC	**50MG/ML**	**N016367**	**002**	

DEXTROSE 50%

AP	**+**	HOSPIRA	**500MG/ML**	**N019445**	**001**	Jun 03, 1986
AP		INTL MEDICATION SYS	**500MG/ML**	**A203451**	**001**	Mar 26, 2021

DEXTROSE 50% IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**50GM/100ML**	**N020047**	**001**	Jul 02, 1991
AP	**+!**	ICU MEDICAL INC	**50GM/100ML**	**N018563**	**001**	Mar 23, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**70GM/100ML**	**N019626**	**005**	Feb 18, 2015
AP	**+!**	BAXTER HLTHCARE	**70GM/100ML**	**N020047**	**003**	Jul 02, 1991
AP	**+!**	ICU MEDICAL INC	**70GM/100ML**	**N018561**	**001**	Mar 23, 1982
AP	**+!**		**70GM/100ML**	**N019893**	**001**	Dec 26, 1989

DEXTROSE 20% IN PLASTIC CONTAINER

+!	ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982

DEXTROSE 25%

+!	HOSPIRA	250MG/ML	N019445	002	Nov 23, 1998

DEXTROSE 30% IN PLASTIC CONTAINER

+!	ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985

DEXTROSE 40% IN PLASTIC CONTAINER

+!	ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;21MG/100ML;128MG/100ML;234MG/100ML	N017610	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019873	001	Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML	N017484	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100ML	N019513	001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017609	001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%

AP		FRESENIUS KABI USA	**5GM/100ML;75MG/100ML**	**A212346**	**001**	Sep 10, 2020

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML**	**N017634**	**004**	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%

AP		FRESENIUS KABI USA	**5GM/100ML;150MG/100ML**	**A212346**	**002**	Sep 10, 2020

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML**	**N017634**	**001**	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML**	**N017634**	**002**	

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;150MG/100ML**	**N019699**	**004**	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;300MG/100ML**	**N019699**	**006**	Sep 29, 1989

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

	+	BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634	003	

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML;149MG/100ML	N018371	001	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ

AP		BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;200MG/100ML**	**N018037**	**006**	Apr 13, 1982
AP			**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**007**	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)

AP		BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;200MG/100ML**	**N018037**	**004**	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ

AP		BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**008**	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;200MG/100ML**	**N018037**	**001**	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ

AP		BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;200MG/100ML**	**N018037**	**005**	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;200MG/100ML**	**N018037**	**009**	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ

AP		BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;200MG/100ML**	**N018037**	**002**	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

AP		BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**003**	

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;330MG/100ML**	**N018629**	**005**	Mar 23, 1982
AP			**5GM/100ML;150MG/100ML;330MG/100ML**	**N018629**	**002**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;330MG/100ML**	**N018629**	**003**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;330MG/100ML**	**N018629**	**004**	Mar 23, 1982
AP			**5GM/100ML;300MG/100ML;330MG/100ML**	**N018629**	**006**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;330MG/100ML**	**N018629**	**007**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;330MG/100ML**	**N018629**	**008**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;330MG/100ML**	**N018629**	**001**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;450MG/100ML**	**N018008**	**010**	

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;75MG/100ML;200MG/100ML**	**N019630**	**008**	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;75MG/100ML;330MG/100ML**	**N019630**	**014**	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;75MG/100ML;450MG/100ML**	**N019630**	**020**	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;75MG/100ML;900MG/100ML**	**N019630**	**026**	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;150MG/100ML;200MG/100ML**	**N019630**	**010**	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;150MG/100ML;330MG/100ML**	**N019630**	**016**	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;150MG/100ML;450MG/100ML**	**N019630**	**022**	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;150MG/100ML;900MG/100ML**	**N019630**	**028**	Feb 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;300MG/100ML;200MG/100ML**	**N019630**	**012**	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;300MG/100ML;330MG/100ML**	**N019630**	**018**	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;300MG/100ML;450MG/100ML**	**N019630**	**024**	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;300MG/100ML;900MG/100ML**	**N019630**	**030**	Feb 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**5GM/100ML;149MG/100ML;225MG/100ML**	**A212348**	**001**	Jul 30, 2021

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	**5GM/100ML;74.5MG/100ML;450MG/100ML**	**A213523**	**001**	Mar 09, 2021
AP			**5GM/100ML;149MG/100ML;450MG/100ML**	**A213523**	**005**	Oct 11, 2022

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;450MG/100ML**	**N018008**	**005**	Apr 28, 1982
AP			**5GM/100ML;150MG/100ML;450MG/100ML**	**N018008**	**006**	Apr 28, 1982
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;74.5MG/100ML;450MG/100ML**	**N018362**	**009**	Jul 05, 1983
AP	**+!**		**5GM/100ML;149MG/100ML;450MG/100ML**	**N018362**	**005**	Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**5GM/100ML;149MG/100ML;225MG/100ML**	**A212348**	**002**	Jul 30, 2021
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;149MG/100ML;225MG/100ML**	**N018365**	**001**	

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	**5GM/100ML;149MG/100ML;450MG/100ML**	**A213523**	**002**	Mar 09, 2021

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;450MG/100ML**	**N018008**	**007**	Apr 28, 1982
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;149MG/100ML;450MG/100ML**	**N018362**	**010**	Jul 05, 1983

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

AP		FRESENIUS KABI USA	**5GM/100ML;149MG/100ML;900MG/100ML**	**A213445**	**001**	Mar 09, 2021

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;900MG/100ML**	**N019308**	**005**	Apr 05, 1985
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;149MG/100ML;900MG/100ML**	**N019691**	**005**	Mar 24, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	**5GM/100ML;224MG/100ML;450MG/100ML**	**A213523**	**003**	Mar 09, 2021

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;450MG/100ML**	**N018008**	**008**	Apr 28, 1982
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;224MG/100ML;450MG/100ML**	**N018362**	**002**	

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	**5GM/100ML;298MG/100ML;450MG/100ML**	**A213523**	**004**	Mar 09, 2021

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;450MG/100ML**	**N018008**	**009**	Apr 28, 1982
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;298MG/100ML;450MG/100ML**	**N018362**	**003**	

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

AP		FRESENIUS KABI USA	**5GM/100ML;298MG/100ML;900MG/100ML**	**A213445**	**002**	Mar 09, 2021

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;900MG/100ML**	**N019308**	**007**	Apr 05, 1985
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;298MG/100ML;900MG/100ML**	**N019691**	**009**	Mar 24, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;37MG/100ML;200MG/100ML	N019630	031	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;37MG/100ML;450MG/100ML	N019630	037	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;37MG/100ML;900MG/100ML	N019630	043	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;37MG/100ML;110MG/100ML	N019630	001	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;37MG/100ML;200MG/100ML	N019630	007	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;37MG/100ML;330MG/100ML	N019630	013	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;37MG/100ML;450MG/100ML	N019630	019	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;37MG/100ML;900MG/100ML	N019630	025	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;75MG/100ML;200MG/100ML	N019630	032	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;75MG/100ML;450MG/100ML	N019630	038	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;75MG/100ML;900MG/100ML	N019630	044	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

		B BRAUN	3.3GM/100ML;75MG/100ML;300MG/100ML	N019630	049	May 07, 1992

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;75MG/100ML;110MG/100ML	N019630 002	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;110MG/100ML;200MG/100ML	N019630 033	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;110MG/100ML;450MG/100ML	N019630 039	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;110MG/100ML;900MG/100ML	N019630 045	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;110MG/100ML;300MG/100ML	N019630 050	May 07, 1992
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;110MG/100ML	N019630 003	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;200MG/100ML	N019630 009	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;330MG/100ML	N019630 015	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;450MG/100ML	N019630 021	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;900MG/100ML	N019630 027	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;150MG/100ML;200MG/100ML	N019630 034	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;150MG/100ML;450MG/100ML	N019630 040	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;150MG/100ML;900MG/100ML	N019630 046	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;150MG/100ML;300MG/100ML	N019630 051	May 07, 1992
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;150MG/100ML;110MG/100ML	N019630 004	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;220MG/100ML;200MG/100ML	N019630 035	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;220MG/100ML;450MG/100ML	N019630 041	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;220MG/100ML;900MG/100ML	N019630 047	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;220MG/100ML;300MG/100ML	N019630 052	May 07, 1992
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;220MG/100ML;110MG/100ML	N019630 005	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N019630 011	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N019630 017	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N019630 023	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;220MG/100ML;900MG/100ML	N019630 029	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;300MG/100ML;200MG/100ML	N019630 036	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;300MG/100ML;450MG/100ML	N019630 042	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;300MG/100ML;900MG/100ML	N019630 048	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;300MG/100ML;300MG/100ML	N019630 053	May 07, 1992
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;300MG/100ML;110MG/100ML	N019630 006	Feb 17, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;900MG/100ML	N019308 004	Apr 05, 1985
		5GM/100ML;150MG/100ML;900MG/100ML	N019308 002	Apr 05, 1985
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;900MG/100ML	N019308 003	Apr 05, 1985
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;900MG/100ML	N019308 006	Apr 05, 1985
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008 004	
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308 001	Apr 05, 1985

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		B BRAUN	**2.5GM/100ML;450MG/100ML**	**N019631**	**004**	Feb 24, 1988
AP	**+!**	BAXTER HLTHCARE	**2.5GM/100ML;450MG/100ML**	**N016697**	**001**	
AP		FRESENIUS KABI USA	**2.5GM/100ML;450MG/100ML**	**A211190**	**001**	Dec 20, 2019

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;200MG/100ML**	**N019631**	**007**	Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.225%

AP		FRESENIUS KABI USA	**5GM/100ML;225MG/100ML**	**A211221**	**001**	Sep 15, 2020

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

AP	**+!**	ICU MEDICAL INC	**5GM/100ML;225MG/100ML**	**N017606**	**001**	

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**5GM/100ML;300MG/100ML**	**A211194**	**001**	Aug 26, 2020
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;300MG/100ML**	**N017799**	**001**	

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;330MG/100ML**	**N019631**	**008**	Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	**5GM/100ML;450MG/100ML**	**A211276**	**001**	Sep 15, 2020

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;450MG/100ML**	**N019631**	**009**	Feb 24, 1988
AP	**+**	ICU MEDICAL INC	**5GM/100ML;450MG/100ML**	**N017607**	**001**	

DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

AP		FRESENIUS KABI USA	**5GM/100ML;900MG/100ML**	**A211211**	**001**	Sep 14, 2020

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;900MG/100ML**	**N019631**	**010**	Feb 24, 1988
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;900MG/100ML**	**N017585**	**001**	

DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;200MG/100ML**	**N016689**	**001**	

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;330MG/100ML**	**N016687**	**001**	

DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;450MG/100ML**	**N016683**	**001**	

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;900MG/100ML**	**N016678**	**001**	

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;110MG/100ML	N019631	011	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;200MG/100ML	N019631	012	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;330MG/100ML	N019631	013	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;450MG/100ML	N019631	014	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;900MG/100ML	N019631	015	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

		B BRAUN	2.5GM/100ML;110MG/100ML	N019631	001	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	2.5GM/100ML;200MG/100ML	N019631	002	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

		B BRAUN	2.5GM/100ML;330MG/100ML	N019631	003	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	2.5GM/100ML;900MG/100ML	N019631	005	Feb 24, 1988

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

		B BRAUN	3.3GM/100ML;300MG/100ML	N019631	016	Jan 19, 1990

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;110MG/100ML	N019631	006	Feb 24, 1988

DIATRIZOATE MEGLUMINE

SOLUTION;URETHRAL

CYSTOGRAFIN

	+	BRACCO	30%	N010040	018	

CYSTOGRAFIN DILUTE

	+	BRACCO	18%	N010040	022	Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION;ORAL, RECTAL

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM

AA		ANDA REPOSITORY	**66%;10%**	**A214201**	**001**	Jun 27, 2022
AA		ANNORA PHARMA	**66%;10%**	**A215049**	**001**	Nov 17, 2023

GASTROGRAFIN

AA	**+!**	BRACCO	**66%;10%**	**N011245**	**003**	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM						
SOLUTION;ORAL, RECTAL						
MD-GASTROVIEW						
AA		LIEBEL-FLARSHEIM	**66%;10%**	**A087388**	**001**	
DIAZEPAM						
CONCENTRATE;ORAL						
DIAZEPAM						
AA		CHARTWELL MOLECULAR	**5MG/ML**	**A204433**	**001**	Apr 14, 2014
DIAZEPAM INTENSOL						
AA	**!**	HIKMA	**5MG/ML**	**A071415**	**001**	Apr 03, 1987
GEL;RECTAL						
DIASTAT ACUDIAL						
AB	**+!**	BAUSCH	**10MG/2ML (5MG/ML)**	**N020648**	**007**	Sep 15, 2005
AB	**+!**		**20MG/4ML (5MG/ML)**	**N020648**	**006**	Sep 15, 2005
DIAZEPAM						
AB		NOVEL LABS INC	**10MG/2ML (5MG/ML)**	**A091076**	**001**	May 30, 2023
AB			**20MG/4ML (5MG/ML)**	**A091076**	**002**	May 30, 2023
DIASTAT						
	+!	BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997
INJECTABLE;INJECTION						
DIAZEPAM						
AP	**!**	BELOTECA	**10MG/2ML (5MG/ML)**	**A210363**	**001**	Mar 18, 2019
AP			**50MG/10ML (5MG/ML)**	**A211998**	**001**	Dec 26, 2019
AP		FRESENIUS KABI USA	**10MG/2ML (5MG/ML)**	**A214745**	**001**	Nov 10, 2022
AP		HIKMA	**5MG/ML**	**A070311**	**001**	Dec 16, 1985
AP			**10MG/2ML (5MG/ML)**	**A070313**	**001**	Dec 16, 1985
AP		HOSPIRA	**10MG/2ML (5MG/ML)**	**A072079**	**001**	Dec 20, 1988
AP	**!**		**50MG/10ML (5MG/ML)**	**A071583**	**001**	Oct 13, 1987
SOLUTION;ORAL						
DIAZEPAM						
AA		CHARTWELL MOLECULAR	**5MG/5ML**	**A206477**	**001**	Jun 24, 2016
AA	**!**	HIKMA	**5MG/5ML**	**A070928**	**001**	Apr 03, 1987
SPRAY;NASAL						
VALTOCO						
	+	NEURELIS INC	5MG/SPRAY	N211635	001	Jan 10, 2020
	+		7.5MG/SPRAY	N211635	002	Jan 10, 2020
	+!		10MG/SPRAY	N211635	003	Jan 10, 2020
TABLET;ORAL						
DIAZEPAM						
AB		AUROBINDO PHARMA LTD	**2MG**	**A217843**	**001**	Dec 14, 2023
AB			**5MG**	**A217843**	**002**	Dec 14, 2023
AB			**10MG**	**A217843**	**003**	Dec 14, 2023
AB		DR REDDYS LABS SA	**2MG**	**A071134**	**001**	Feb 03, 1987
AB			**5MG**	**A071135**	**001**	Feb 03, 1987
AB			**10MG**	**A071136**	**001**	Feb 03, 1987
AB		IVAX SUB TEVA PHARMS	**2MG**	**A071307**	**001**	Dec 10, 1986
AB			**5MG**	**A071321**	**001**	Dec 10, 1986
AB			**10MG**	**A071322**	**001**	Dec 10, 1986
AB		MYLAN	**2MG**	**A070325**	**002**	Sep 04, 1985
AB			**5MG**	**A070325**	**003**	Sep 04, 1985
AB			**10MG**	**A070325**	**001**	Sep 04, 1985
AB		NUVO PHARM	**10MG**	**A070464**	**001**	Feb 25, 1986
AB		STRIDES PHARMA	**2MG**	**A077749**	**001**	Mar 31, 2006
AB			**5MG**	**A077749**	**002**	Mar 31, 2006
AB			**10MG**	**A077749**	**003**	Mar 31, 2006
VALIUM						
AB	**+**	WAYLIS THERAP	**2MG**	**N013263**	**002**	
AB	**+**		**5MG**	**N013263**	**004**	
AB	**+!**		**10MG**	**N013263**	**006**	
DIAZOXIDE						
SUSPENSION;ORAL						
DIAZOXIDE						
AB		E5 PHARMA INC	**50MG/ML**	**A211050**	**001**	Dec 20, 2019
AB		NOVITIUM PHARMA	**50MG/ML**	**A210799**	**001**	Jul 08, 2020
PROGLYCEM						
AB	**+!**	TEVA BRANDED PHARM	**50MG/ML**	**N017453**	**001**	

DICHLORPHENAMIDE

TABLET;ORAL

DICHLORPHENAMIDE

AB		TORRENT	**50MG**	**A215924**	**001**	Dec 29, 2022

KEVEYIS

AB	**+!**	XERIS	**50MG**	**N011366**	**002**	Aug 07, 2015

DICLOFENAC EPOLAMINE

SYSTEM;TOPICAL

FLECTOR

	+!	IBSA	1.3%	N021234	001	Jan 31, 2007

LICART

	+!	IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB		AUROBINDO PHARMA LTD	**25MG**	**A213875**	**001**	Oct 19, 2021
AB		BIONPHARMA	**25MG**	**A204648**	**001**	Feb 23, 2016
AB		STRIDES PHARMA	**25MG**	**A210078**	**001**	Dec 03, 2019

ZIPSOR

AB	**+!**	ASSERTIO	**25MG**	**N022202**	**001**	Jun 16, 2009

FOR SOLUTION;ORAL

CAMBIA

AB	**+!**	ASSERTIO	**50MG**	**N022165**	**001**	Jun 17, 2009

DICLOFENAC POTASSIUM

AB		ALKEM LABS LTD	**50MG**	**A216635**	**001**	Jul 20, 2022
AB		ANNORA PHARMA	**50MG**	**A215375**	**001**	Mar 04, 2022
AB		PAR FORM	**50MG**	**A202964**	**001**	May 02, 2016

TABLET;ORAL

CATAFLAM

AB		AMICI	**25MG**	**A076561**	**002**	Jul 21, 2021
AB			**50MG**	**A076561**	**001**	Mar 18, 2004

DICLOFENAC POTASSIUM

AB		NOVAST LABS	**50MG**	**A215585**	**001**	Oct 08, 2021
AB	**!**	RK PHARMA	**50MG**	**A075463**	**001**	Jul 26, 1999
AB		RUBICON	**25MG**	**A075229**	**002**	Sep 16, 2021
AB			**50MG**	**A075229**	**001**	Nov 20, 1998
AB		SENORES PHARMS	**25MG**	**A215787**	**002**	Nov 09, 2023
AB			**50MG**	**A215787**	**001**	Mar 15, 2023
AB		TEVA	**50MG**	**A075219**	**001**	Aug 06, 1998
AB		UMEDICA	**50MG**	**A215750**	**001**	May 11, 2022

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB		ACTAVIS MID ATLANTIC	**3%**	**A206493**	**001**	Dec 02, 2015
AB		ALEMBIC	**3%**	**A212351**	**001**	Jul 27, 2022
AB		AMNEAL	**3%**	**A200936**	**001**	Oct 28, 2013
AB		GLENMARK PHARMS LTD	**3%**	**A208301**	**001**	Sep 13, 2016
AB		PADAGIS ISRAEL	**3%**	**A210893**	**001**	Jul 27, 2018
AB	**!**	TARO	**3%**	**A206298**	**001**	Apr 28, 2016
		CIPLA	1%	A209903	001	Aug 03, 2018

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AB		ALEMBIC	**2%**	**A212506**	**001**	Nov 29, 2022
AB		AMNEAL	**2%**	**A208198**	**001**	Aug 18, 2022
AB		APOTEX	**2%**	**A207714**	**001**	May 06, 2022
AB		AUROLIFE PHARMA LLC	**2%**	**A213040**	**001**	Feb 03, 2023
AB		LUPIN PHARMS	**2%**	**A208021**	**001**	Sep 20, 2022
AB		TARO	**2%**	**A208098**	**001**	Sep 29, 2022

PENNSAID

AB	**+!**	HORIZON	**2%**	**N204623**	**001**	Jan 16, 2014

DICLOFENAC SODIUM

AT		AMNEAL PHARMS	**1.5%**	**A206116**	**001**	Sep 02, 2016
AT		CADILA	**1.5%**	**A206411**	**001**	Apr 17, 2018
AT		EPIC PHARMA LLC	**1.5%**	**A206655**	**001**	Jan 28, 2021
AT		LUPIN LTD	**1.5%**	**A204132**	**001**	Aug 20, 2015
AT		NOVEL LABS INC	**1.5%**	**A205878**	**001**	Dec 09, 2015
AT	**!**	TARO	**1.5%**	**A203818**	**001**	Nov 26, 2014
AT		WATSON LABS INC	**1.5%**	**A202852**	**001**	Nov 24, 2014

DICLOFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

AT		ALTAIRE PHARMS INC	**0.1%**	**A203383**	**001**	Nov 16, 2015
AT	!	BAUSCH AND LOMB	**0.1%**	**A078792**	**001**	Dec 28, 2007
AT		RISING	**0.1%**	**A078553**	**001**	Dec 28, 2007
AT		RUBICON	**0.1%**	**A077600**	**001**	Nov 13, 2008
AT		SANDOZ	**0.1%**	**A078031**	**001**	Feb 06, 2008

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

AB		ACTAVIS ELIZABETH	**50MG**	**A074514**	**001**	Mar 26, 1996
AB			**75MG**	**A074514**	**002**	Mar 26, 1996
AB		CARLSBAD	**25MG**	**A075185**	**002**	Nov 13, 1998
AB			**50MG**	**A075185**	**003**	Nov 13, 1998
AB			**75MG**	**A075185**	**001**	Nov 13, 1998
AB		RUBICON	**25MG**	**A216548**	**001**	May 11, 2023
AB			**50MG**	**A216548**	**002**	May 11, 2023
AB			**75MG**	**A216548**	**003**	May 11, 2023
AB	!	UNIQUE	**25MG**	**A090066**	**001**	Dec 01, 2010
AB	!		**50MG**	**A090066**	**002**	Dec 01, 2010
AB	!		**75MG**	**A077863**	**003**	Jun 08, 2007

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

AB	!	DEXCEL LTD	**100MG**	**A076201**	**001**	Nov 06, 2002
AB		RICONPHARMA LLC	**100MG**	**A216275**	**001**	Sep 23, 2022
AB		VPNA	**100MG**	**A075492**	**001**	Feb 11, 2000

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

ARTHROTEC

AB	+	PFIZER	**50MG;0.2MG**	**N020607**	**001**	Dec 24, 1997
AB	+!		**75MG;0.2MG**	**N020607**	**002**	Dec 24, 1997

DICLOFENAC SODIUM AND MISOPROSTOL

AB		ACTAVIS LABS FL INC	**50MG;0.2MG**	**A201089**	**001**	Jul 09, 2012
AB			**75MG;0.2MG**	**A201089**	**002**	Jul 09, 2012
AB		AMNEAL PHARMS	**50MG;0.2MG**	**A203995**	**001**	Nov 25, 2016
AB			**75MG;0.2MG**	**A203995**	**002**	Nov 25, 2016
AB		MICRO LABS	**50MG;0.2MG**	**A204355**	**001**	Jul 15, 2021
AB			**75MG;0.2MG**	**A204355**	**002**	Jul 15, 2021
AB		SANDOZ	**50MG;0.2MG**	**A200158**	**001**	May 09, 2013
AB			**75MG;0.2MG**	**A200158**	**002**	May 09, 2013
AB		YUNG SHIN PHARM	**50MG;0.2MG**	**A205143**	**001**	Feb 19, 2020
AB			**75MG;0.2MG**	**A205143**	**002**	Feb 19, 2020

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DICLOXACILLIN SODIUM

AB		AUROBINDO PHARMA USA	**EQ 250MG BASE**	**A216845**	**001**	Sep 23, 2022
AB			**EQ 500MG BASE**	**A216845**	**002**	Sep 23, 2022
AB		TEVA	**EQ 250MG BASE**	**A062286**	**001**	Jun 03, 1982
AB	!		**EQ 500MG BASE**	**A062286**	**002**	Jun 03, 1982

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

AB		AUROBINDO PHARMA USA	**10MG**	**A040319**	**001**	Sep 07, 1999
AB		COREPHARMA	**10MG**	**A216639**	**001**	Mar 24, 2023
AB	!	LANNETT	**10MG**	**A084285**	**001**	
AB		PRINSTON INC	**10MG**	**A217531**	**001**	Aug 30, 2023
AB		TWI PHARMS	**10MG**	**A217054**	**001**	Dec 27, 2022
AB		WATSON LABS	**10MG**	**A085082**	**001**	Jun 19, 1986
AB		WEST WARD	**10MG**	**A040204**	**001**	Feb 28, 1997

INJECTABLE;INJECTION

BENTYL

AP	+!	ABBVIE	**10MG/ML**	**N008370**	**001**	Oct 15, 1984

BENTYL PRESERVATIVE FREE

AP	+!	ABBVIE	**10MG/ML**	**N008370**	**002**	Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

AP		AM REGENT	**10MG/ML**	**A208353**	**001**	Feb 17, 2017
AP		FOSUN PHARMA	**10MG/ML**	**A210979**	**001**	Jul 02, 2018
AP		FRESENIUS KABI USA	**10MG/ML**	**A210257**	**001**	Jan 25, 2019
AP		NEXUS	**10MG/ML**	**A206468**	**001**	Feb 01, 2019
AP		SLATE RUN PHARMA	**10MG/ML**	**A207076**	**001**	Nov 02, 2018

DICYCLOMINE HYDROCHLORIDE						
INJECTABLE;INJECTION						
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)						
AP		HIKMA	**10MG/ML**	**A040465**	**001**	Jun 30, 2003
SYRUP;ORAL						
DICYCLOMINE HYDROCHLORIDE						
AA	!	GENERICS	**10MG/5ML**	**A040169**	**001**	Mar 24, 2005
AA		HIKMA	**10MG/5ML**	**A212286**	**001**	May 22, 2020
AA		NOVITIUM PHARMA	**10MG/5ML**	**A214721**	**001**	Apr 23, 2021
TABLET;ORAL						
DICYCLOMINE HYDROCHLORIDE						
AB		AUROBINDO PHARMA USA	**20MG**	**A040317**	**001**	Sep 07, 1999
AB		BIONPHARMA	**20MG**	**A217916**	**001**	Aug 04, 2023
AB		COREPHARMA	**20MG**	**A216760**	**001**	Nov 28, 2022
AB		HIKMA PHARMS	**20MG**	**A040161**	**001**	Oct 01, 1996
AB		LANNETT	**20MG**	**A040230**	**001**	Feb 26, 1999
AB		RUBICON	**20MG**	**A216736**	**001**	Dec 14, 2022
AB		TWI PHARMS	**20MG**	**A216782**	**001**	Jun 01, 2023
AB	!	WATSON LABS	**20MG**	**A085223**	**001**	Jul 30, 1986
DIENOGEST; ESTRADIOL VALERATE						
TABLET;ORAL						
NATAZIA						
	+!	BAYER HLTHCARE	N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A	N022252	001	May 06, 2010
DIETHYLPROPION HYDROCHLORIDE						
TABLET;ORAL						
DIETHYLPROPION HYDROCHLORIDE						
AA		AVANTHI INC	**25MG**	**A201212**	**001**	Dec 22, 2010
AA	!	LANNETT CO INC	**25MG**	**A200177**	**001**	Jul 18, 2011
TABLET, EXTENDED RELEASE;ORAL						
DIETHYLPROPION HYDROCHLORIDE						
	!	LANNETT CO INC	75MG	A091680	001	Oct 24, 2011
DIFELIKEFALIN ACETATE						
SOLUTION;INTRAVENOUS						
KORSUVA						
	+!	CARA THERAP	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021
DIFLORASONE DIACETATE						
CREAM;TOPICAL						
DIFLORASONE DIACETATE						
BX	!	ANI PHARMS	0.05%	A076263	001	Dec 20, 2002
BX	!	TARO	0.05%	A075508	001	Apr 24, 2000
OINTMENT;TOPICAL						
DIFLORASONE DIACETATE						
AB		AVONDALE PHARMS	**0.05%**	**A075374**	**001**	Apr 27, 1999
AB		RISING	**0.05%**	**A207440**	**001**	Feb 27, 2017
AB	!	TARO	**0.05%**	**A075331**	**001**	May 14, 1999
AB		THE J MOLNER	**0.05%**	**A210753**	**001**	Jun 12, 2018
DIFLUNISAL						
TABLET;ORAL						
DIFLUNISAL						
AB		HERITAGE PHARMA	**500MG**	**A202845**	**001**	Mar 08, 2012
AB	!	TEVA	**500MG**	**A073673**	**001**	Jul 31, 1992
AB		ZYDUS PHARMS	**500MG**	**A203547**	**001**	Jun 16, 2017
DIFLUPREDNATE						
EMULSION;OPHTHALMIC						
DIFLUPREDNATE						
AB		AMNEAL	**0.05%**	**A211526**	**001**	Nov 17, 2021
AB		CIPLA	**0.05%**	**A211776**	**001**	Aug 09, 2021
AB		DR REDDYS	**0.05%**	**A214894**	**001**	Nov 16, 2022
DUREZOL						
AB	+!	SANDOZ	**0.05%**	**N022212**	**001**	Jun 23, 2008
DIGOXIN						
ELIXIR;ORAL						
DIGOXIN						
AA		AMICI	**0.05MG/ML**	**A215209**	**001**	Mar 11, 2022
AA	+!	HIKMA	**0.05MG/ML**	**N021648**	**001**	Aug 26, 2004
AA		NOVITIUM PHARMA	**0.05MG/ML**	**A213000**	**001**	Oct 04, 2019

DIGOXIN

INJECTABLE;INJECTION

DIGOXIN

AP		SANDOZ	**0.25MG/ML**	**A040481**	**001**	Aug 21, 2003
AP		WEST-WARD PHARMS INT	**0.25MG/ML**	**A083391**	**001**	

LANOXIN

AP	**+!**	COVIS	**0.25MG/ML**	**N009330**	**002**	

LANOXIN PEDIATRIC

	+!	COVIS	0.1MG/ML	N009330	004	

TABLET;ORAL

DIGOXIN

AB		AURORBINDO PHARMA LTD	**0.0625MG**	**A214982**	**001**	Feb 08, 2022
AB			**0.125MG**	**A214982**	**002**	Feb 08, 2022
AB			**0.25MG**	**A214982**	**003**	Feb 08, 2022
AB		HIKMA INTL PHARMS	**0.125MG**	**A077002**	**002**	Oct 30, 2007
AB			**0.25MG**	**A077002**	**001**	Oct 30, 2007
AB		IMPAX LABS	**0.125MG**	**A078556**	**001**	Jul 20, 2009
AB			**0.25MG**	**A078556**	**002**	Jul 20, 2009
AB		NOVITIUM PHARMA	**0.0625MG**	**A215307**	**003**	Aug 25, 2022
AB			**0.125MG**	**A215307**	**001**	Nov 22, 2021
AB			**0.25MG**	**A215307**	**002**	Nov 22, 2021
AB		RISING	**0.125MG**	**A040282**	**001**	Dec 23, 1999
AB			**0.25MG**	**A040282**	**002**	Dec 23, 1999
AB		STEVENS J	**0.125MG**	**A076268**	**001**	Jul 26, 2002
AB			**0.25MG**	**A076268**	**002**	Jul 26, 2002
AB		SUN PHARM INDS INC	**0.125MG**	**A076363**	**001**	Jan 31, 2003
AB			**0.25MG**	**A076363**	**002**	Jan 31, 2003

LANOXIN

AB	**+**	CONCORDIA	**0.0625MG**	**N020405**	**001**	Sep 30, 1997
AB	**+**		**0.125MG**	**N020405**	**002**	Sep 30, 1997
AB	**+!**		**0.25MG**	**N020405**	**004**	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

DIHYDROERGOTAMINE MESYLATE

AP		GLAND PHARMA LTD	**1MG/ML**	**A215623**	**001**	Aug 18, 2023
AP		HIKMA	**1MG/ML**	**A040453**	**001**	Jun 09, 2003
AP	**!**	HIKMA PHARMS	**1MG/ML**	**A206621**	**001**	Sep 15, 2017
AP		PADAGIS US	**1MG/ML**	**A040475**	**001**	Apr 28, 2003
AP		PROVEPHARM SAS	**1MG/ML**	**A212046**	**001**	Jan 07, 2020
AP		SAGENT PHARMS INC	**1MG/ML**	**A207264**	**001**	Jul 11, 2018

SPRAY, METERED;NASAL

DIHYDROERGOTAMINE MESYLATE

AB		AMNEAL	**0.5MG/SPRAY**	**A214105**	**001**	Jan 04, 2022
AB		CIPLA	**0.5MG/SPRAY**	**A212907**	**001**	May 20, 2020
AB		HIKMA	**0.5MG/SPRAY**	**A211393**	**001**	Feb 28, 2020
AB		RUBICON	**0.5MG/SPRAY**	**A216881**	**001**	Jun 22, 2023

MIGRANAL

AB	**+!**	BAUSCH	**0.5MG/SPRAY**	**N020148**	**001**	Dec 08, 1997

TRUDHESA

	+!	IMPEL PHARMS	0.725MG/SPRAY	N213436	001	Sep 02, 2021

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB1		DR REDDYS LABS SA	**60MG**	**A215775**	**001**	May 05, 2022
AB1			**90MG**	**A215775**	**002**	May 05, 2022
AB1			**120MG**	**A215775**	**003**	May 05, 2022
AB1		GLENMARK PHARMS LTD	**60MG**	**A212317**	**001**	Mar 22, 2021
AB1			**90MG**	**A212317**	**002**	Mar 22, 2021
AB1			**120MG**	**A212317**	**003**	Mar 22, 2021
AB1		MYLAN	**60MG**	**A074910**	**001**	May 02, 1997
AB1			**90MG**	**A074910**	**002**	May 02, 1997
AB1	**!**		**120MG**	**A074910**	**003**	May 02, 1997
AB1		TWI PHARMS	**60MG**	**A217377**	**001**	Mar 01, 2023
AB1			**90MG**	**A217377**	**002**	Mar 01, 2023
AB1			**120MG**	**A217377**	**003**	Mar 01, 2023
AB2		ACCORD HLTHCARE	**120MG**	**A206997**	**001**	Apr 28, 2020
AB2			**180MG**	**A206997**	**002**	Apr 28, 2020
AB2			**240MG**	**A206997**	**003**	Apr 28, 2020
AB2		AMTA	**120MG**	**A216304**	**001**	Aug 08, 2022
AB2			**180MG**	**A216304**	**002**	Aug 08, 2022

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE							
AB2			**240MG**	**A216304**	**003**	Aug 08, 2022
AB2		APOTEX	**120MG**	**A074943**	**003**	Dec 19, 2000
AB2			**180MG**	**A074943**	**002**	Dec 19, 2000
AB2	!		**240MG**	**A074943**	**001**	Aug 06, 1998
CARDIZEM CD							
AB3	+	BAUSCH	**120MG**	**N020062**	**001**	Aug 10, 1992
AB3	+		**180MG**	**N020062**	**002**	Dec 27, 1991
AB3	+		**240MG**	**N020062**	**003**	Dec 27, 1991
AB3	+		**300MG**	**N020062**	**004**	Dec 27, 1991
AB3	+!		**360MG**	**N020062**	**005**	Aug 24, 1999
CARTIA XT							
AB3		ACTAVIS LABS FL INC	**120MG**	**A074752**	**002**	Jul 09, 1998
AB3			**180MG**	**A074752**	**001**	Jul 09, 1998
AB3			**240MG**	**A074752**	**003**	Jul 09, 1998
AB3			**300MG**	**A074752**	**004**	Jul 09, 1998
DILTIAZEM HYDROCHLORIDE							
AB3		ACTAVIS ELIZABETH	**360MG**	**A202463**	**001**	Dec 07, 2012
AB3		NOVAST LABS	**120MG**	**A208783**	**001**	Jun 14, 2019
AB3			**180MG**	**A208783**	**002**	Jun 14, 2019
AB3			**240MG**	**A208783**	**003**	Jun 14, 2019
AB3			**300MG**	**A208783**	**004**	Jun 14, 2019
AB3			**360MG**	**A208783**	**005**	Jun 14, 2019
AB3		PAR PHARM	**120MG**	**A074984**	**001**	Dec 20, 1999
AB3			**180MG**	**A074984**	**002**	Dec 20, 1999
AB3			**240MG**	**A074984**	**003**	Dec 20, 1999
AB3			**300MG**	**A074984**	**004**	Dec 20, 1999
AB3		SUN PHARM	**120MG**	**A203023**	**001**	Jun 08, 2017
AB3			**180MG**	**A203023**	**002**	Jun 08, 2017
AB3			**240MG**	**A203023**	**003**	Jun 08, 2017
AB3			**300MG**	**A203023**	**004**	Jun 08, 2017
AB3			**360MG**	**A090492**	**005**	Oct 28, 2011
AB3			**360MG**	**A203023**	**005**	Jun 08, 2017
AB3		TWI PHARMS	**120MG**	**A205231**	**001**	Aug 30, 2018
AB3			**180MG**	**A205231**	**002**	Aug 30, 2018
AB3			**240MG**	**A205231**	**003**	Aug 30, 2018
AB3			**300MG**	**A205231**	**004**	Aug 30, 2018
AB3			**360MG**	**A205231**	**005**	Aug 30, 2018
AB3		VALEANT PHARMS NORTH	**120MG**	**A075116**	**001**	Dec 23, 1999
AB3			**180MG**	**A075116**	**002**	Dec 23, 1999
AB3			**240MG**	**A075116**	**003**	Dec 23, 1999
AB3			**300MG**	**A075116**	**004**	Dec 23, 1999
AB3		ZYDUS PHARMS	**120MG**	**A206534**	**001**	Aug 08, 2017
AB3			**180MG**	**A206534**	**002**	Aug 08, 2017
AB3			**240MG**	**A206534**	**003**	Aug 08, 2017
AB3			**300MG**	**A206534**	**004**	Aug 08, 2017
AB3			**360MG**	**A206534**	**005**	Aug 08, 2017
AB4		SANDOZ	**120MG**	**A091022**	**001**	Sep 28, 2012
AB4			**180MG**	**A091022**	**002**	Sep 28, 2012
AB4			**240MG**	**A091022**	**003**	Sep 28, 2012
AB4			**300MG**	**A091022**	**004**	Sep 28, 2012
AB4			**360MG**	**A091022**	**005**	Sep 28, 2012
AB4			**420MG**	**A091022**	**006**	Sep 28, 2012
AB4		SUN PHARM	**120MG**	**A090421**	**001**	Nov 15, 2010
AB4			**180MG**	**A090421**	**002**	Nov 15, 2010
AB4			**240MG**	**A090421**	**003**	Nov 15, 2010
AB4			**300MG**	**A090421**	**004**	Nov 15, 2010
AB4			**360MG**	**A090421**	**005**	Nov 15, 2010
AB4		ZYDUS PHARMS	**120MG**	**A206641**	**001**	Aug 11, 2017
AB4			**180MG**	**A206641**	**002**	Aug 11, 2017
AB4			**240MG**	**A206641**	**003**	Aug 11, 2017
AB4			**300MG**	**A206641**	**004**	Aug 11, 2017
AB4			**360MG**	**A206641**	**005**	Aug 11, 2017
AB4			**420MG**	**A206641**	**006**	Aug 11, 2017
TAZTIA XT							
AB4		ACTAVIS LABS FL INC	**120MG**	**A075401**	**001**	Apr 10, 2003
AB4			**180MG**	**A075401**	**002**	Apr 10, 2003
AB4			**240MG**	**A075401**	**003**	Apr 10, 2003
AB4			**300MG**	**A075401**	**004**	Apr 10, 2003
AB4			**360MG**	**A075401**	**005**	Apr 10, 2003

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TIAZAC

AB4	+	BAUSCH	**120MG**	**N020401**	**001**	Sep 11, 1995
AB4	+		**180MG**	**N020401**	**002**	Sep 11, 1995
AB4	+		**240MG**	**N020401**	**003**	Sep 11, 1995
AB4	+		**300MG**	**N020401**	**004**	Sep 11, 1995
AB4	+		**360MG**	**N020401**	**005**	Sep 11, 1995
AB4	+!		**420MG**	**N020401**	**006**	Oct 16, 1998

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP		EUGIA PHARMA	**5MG/ML**	**A216552**	**001**	Mar 29, 2023
AP		HIKMA FARMACEUTICA	**5MG/ML**	**A202651**	**001**	Aug 09, 2012
AP		HOSPIRA	**5MG/ML**	**A074941**	**001**	Apr 15, 1998
AP		RISING	**5MG/ML**	**A075086**	**001**	Apr 09, 1998
AP	!	SAGENT	**5MG/ML**	**A074617**	**001**	Feb 28, 1996
AP		WEST-WARD PHARMS INT	**5MG/ML**	**A078538**	**001**	Dec 17, 2008
	!	HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002

TABLET;ORAL

CARDIZEM

AB	+	BAUSCH	**30MG**	**N018602**	**001**	Nov 05, 1982
AB	+		**60MG**	**N018602**	**002**	Nov 05, 1982
AB	+		**90MG**	**N018602**	**003**	Dec 08, 1986
AB	+!		**120MG**	**N018602**	**004**	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

AB		SCIEGEN PHARMS INC	**30MG**	**A216521**	**001**	Sep 23, 2022
AB			**60MG**	**A216521**	**002**	Sep 23, 2022
AB			**90MG**	**A216521**	**003**	Sep 23, 2022
AB			**120MG**	**A216521**	**004**	Sep 23, 2022
AB		TEVA	**30MG**	**A074185**	**001**	May 31, 1995
AB			**60MG**	**A074185**	**002**	May 31, 1995
AB			**90MG**	**A074185**	**003**	May 31, 1995
AB			**120MG**	**A074185**	**004**	May 31, 1995

TABLET, EXTENDED RELEASE;ORAL

CARDIZEM LA

AB	+	BAUSCH	**120MG**	**N021392**	**001**	Feb 06, 2003
AB	+		**180MG**	**N021392**	**002**	Feb 06, 2003
AB	+		**240MG**	**N021392**	**003**	Feb 06, 2003
AB	+		**300MG**	**N021392**	**004**	Feb 06, 2003
AB	+		**360MG**	**N021392**	**005**	Feb 06, 2003
AB	+!		**420MG**	**N021392**	**006**	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**120MG**	**A077686**	**006**	Mar 15, 2010
AB			**180MG**	**A077686**	**005**	Mar 15, 2010
AB			**240MG**	**A077686**	**004**	Mar 15, 2010
AB			**300MG**	**A077686**	**003**	Mar 15, 2010
AB			**360MG**	**A077686**	**002**	Mar 15, 2010
AB			**420MG**	**A077686**	**001**	Mar 15, 2010
AB		AMTA	**120MG**	**A216439**	**001**	Mar 07, 2023
AB			**180MG**	**A216439**	**002**	Mar 07, 2023
AB			**240MG**	**A216439**	**003**	Mar 07, 2023
AB			**300MG**	**A216439**	**004**	Mar 07, 2023
AB			**360MG**	**A216439**	**005**	Mar 07, 2023
AB			**420MG**	**A216439**	**006**	Mar 07, 2023
AB		SCIEGEN PHARMS INC	**120MG**	**A216327**	**001**	Apr 06, 2023
AB			**180MG**	**A216327**	**002**	Apr 06, 2023
AB			**240MG**	**A216327**	**003**	Apr 06, 2023
AB			**300MG**	**A216327**	**004**	Apr 06, 2023
AB			**360MG**	**A216327**	**005**	Apr 06, 2023
AB			**420MG**	**A216327**	**006**	Apr 06, 2023

DIMENHYDRINATE

INJECTABLE;INJECTION

DIMENHYDRINATE

	!	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004

DIMERCAPROL

INJECTABLE;INJECTION

BAL

	+!	PROVEPHARM SAS	10%	N005939	001	

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

AB		ACCORD HLTHCARE	**120MG**	**A210499**	**001**	Sep 24, 2020
AB			**240MG**	**A210499**	**002**	Sep 24, 2020
AB		ALKEM LABS LTD	**120MG**	**A210440**	**001**	Sep 24, 2020
AB			**240MG**	**A210440**	**002**	Sep 24, 2020
AB		AMNEAL	**120MG**	**A210402**	**001**	Sep 24, 2020
AB			**240MG**	**A210402**	**002**	Sep 24, 2020
AB		AUROBINDO PHARMA	**120MG**	**A210385**	**001**	Dec 22, 2022
AB			**240MG**	**A210385**	**002**	Dec 22, 2022
AB		CIPLA	**120MG**	**A210305**	**001**	Sep 24, 2020
AB			**240MG**	**A210305**	**002**	Sep 24, 2020
AB		GLENMARK PHARMS LTD	**120MG**	**A210309**	**001**	Oct 06, 2020
AB			**240MG**	**A210309**	**002**	Oct 06, 2020
AB		HETERO LABS LTD III	**120MG**	**A210500**	**001**	Sep 24, 2020
AB			**240MG**	**A210500**	**002**	Sep 24, 2020
AB		LUPIN	**120MG**	**A210226**	**001**	Oct 05, 2020
AB			**240MG**	**A210226**	**002**	Oct 05, 2020
AB		MSN	**120MG**	**A210460**	**001**	Sep 24, 2020
AB			**240MG**	**A210460**	**002**	Sep 24, 2020
AB		MYLAN	**120MG**	**A210531**	**001**	Aug 17, 2020
AB			**240MG**	**A210531**	**002**	Aug 17, 2020
AB		PRINSTON INC	**120MG**	**A210414**	**001**	Oct 18, 2022
AB			**240MG**	**A210414**	**002**	Oct 18, 2022
AB		SOLA PHARMS	**120MG**	**A210436**	**001**	Mar 26, 2021
AB			**240MG**	**A210436**	**002**	Mar 26, 2021
AB		TWI PHARMS	**120MG**	**A210382**	**001**	Oct 14, 2020
AB			**240MG**	**A210382**	**002**	Oct 14, 2020

TECFIDERA

AB	**+**	BIOGEN INC	**120MG**	**N204063**	**001**	Mar 27, 2013
AB	**+!**		**240MG**	**N204063**	**002**	Mar 27, 2013

DIMETHYL SULFOXIDE

SOLUTION;INTRAVESICAL

RIMSO-50

	+!	MYLAN INSTITUTIONAL	50%	N017788	001

DINOPROSTONE

GEL;ENDOCERVICAL

PREPIDIL

	+!	PFIZER	0.5MG/3GM	N019617	001	Dec 09, 1992

INSERT, EXTENDED RELEASE;VAGINAL

CERVIDIL

	+!	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

	+!	PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP		APP PHARMS	**50MG/ML**	**A040466**	**001**	May 28, 2002
AP		MICRO LABS	**50MG/ML**	**A205723**	**001**	Aug 22, 2018
AP		MYLAN INSTITUTIONAL	**50MG/ML**	**A040498**	**001**	Jul 12, 2005
AP	**+!**	WEST-WARD PHARMS INT	**50MG/ML**	**A080817**	**002**	

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**50MG/ML**	**A091526**	**001**	Mar 26, 2013

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP	**!**	CHARTWELL INJECTABLE	**5MG/ML**	**A074939**	**001**	Apr 13, 1998
AP		HIKMA	**5MG/ML**	**A074521**	**001**	Oct 18, 1996

TABLET;ORAL

DIPYRIDAMOLE

AB		BARR	**25MG**	**A087184**	**001**	Oct 03, 1990
AB			**50MG**	**A087716**	**001**	Oct 03, 1990
AB			**75MG**	**A087717**	**001**	Oct 03, 1990
AB		IMPAX LABS	**25MG**	**A040782**	**001**	Jul 18, 2007
AB			**50MG**	**A040782**	**002**	Jul 18, 2007
AB			**75MG**	**A040782**	**003**	Jul 18, 2007
AB		OXFORD PHARMS	**25MG**	**A040542**	**001**	Apr 21, 2006

DIPYRIDAMOLE

TABLET;ORAL

DIPYRIDAMOLE

AB			**50MG**	**A040542**	**002**	Apr 21, 2006
AB			**75MG**	**A040542**	**003**	Apr 21, 2006
AB		RISING	**25MG**	**A040733**	**001**	Feb 13, 2007
AB			**50MG**	**A040733**	**002**	Feb 13, 2007
AB			**75MG**	**A040733**	**003**	Feb 13, 2007
AB		ZYDUS PHARMS USA INC	**25MG**	**A040874**	**001**	Jan 28, 2008
AB			**50MG**	**A040874**	**002**	Jan 28, 2008
AB			**75MG**	**A040874**	**003**	Jan 28, 2008

PERSANTINE

AB	**+**	BOEHRINGER INGELHEIM	**25MG**	**N012836**	**003**	Dec 22, 1986
AB	**+**		**50MG**	**N012836**	**004**	Feb 06, 1987
AB	**+!**		**75MG**	**N012836**	**005**	Feb 06, 1987

DIROXIMEL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

VUMERITY

	+!	BIOGEN INC	231MG	N211855	001	Oct 29, 2019

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

AB		DR REDDYS LABS SA	**EQ 100MG BASE**	**A070173**	**001**	May 31, 1985
AB			**EQ 150MG BASE**	**A070173**	**002**	May 31, 1985
AB		TEVA	**EQ 100MG BASE**	**A070101**	**001**	Feb 22, 1985
AB			**EQ 150MG BASE**	**A070102**	**001**	Feb 22, 1985

NORPACE

AB	**+**	PFIZER	**EQ 100MG BASE**	**N017447**	**001**
AB	**+!**		**EQ 150MG BASE**	**N017447**	**002**

CAPSULE, EXTENDED RELEASE;ORAL

NORPACE CR

	+	PFIZER	EQ 100MG BASE	N018655 001	Jul 20, 1982
	+!		EQ 150MG BASE	N018655 002	Jul 20, 1982

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB		ALVOGEN	**250MG**	**A091681**	**001**	Aug 08, 2013
AB		CHARTWELL MOLECULES	**250MG**	**A091563**	**001**	Dec 31, 2012
AB	**!**		**500MG**	**A091563**	**002**	Dec 31, 2012
AB		SIGMAPHARM LABS LLC	**250MG**	**A091619**	**001**	Mar 28, 2011
AB			**500MG**	**A091619**	**002**	Mar 28, 2011

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DEPAKOTE

AB	**+!**	ABBVIE	**EQ 125MG VALPROIC ACID**	**N019680**	**001**	Sep 12, 1989

DIVALPROEX SODIUM

AB		AJANTA PHARMA LTD	**EQ 125MG VALPROIC ACID**	**A213181**	**001**	Mar 02, 2020
AB		DR REDDYS LABS LTD	**EQ 125MG VALPROIC ACID**	**A078979**	**001**	Jan 23, 2009
AB		ZYDUS PHARMS USA INC	**EQ 125MG VALPROIC ACID**	**A078919**	**001**	Jan 27, 2009

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE

AB	**+**	ABBVIE	**EQ 125MG VALPROIC ACID**	**N018723**	**003**	Oct 26, 1984
AB	**+**		**EQ 250MG VALPROIC ACID**	**N018723**	**001**	Mar 10, 1983
AB	**+!**		**EQ 500MG VALPROIC ACID**	**N018723**	**002**	Mar 10, 1983

DIVALPROEX SODIUM

AB		APOTEX	**EQ 125MG VALPROIC ACID**	**A077615**	**003**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A077615**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A077615**	**001**	Jul 29, 2008
AB		AUROBINDO PHARMA LTD	**EQ 125MG VALPROIC ACID**	**A090554**	**001**	Apr 21, 2011
AB			**EQ 250MG VALPROIC ACID**	**A090554**	**002**	Apr 21, 2011
AB			**EQ 500MG VALPROIC ACID**	**A090554**	**003**	Apr 21, 2011
AB		CHARTWELL RX	**EQ 125MG VALPROIC ACID**	**A077296**	**001**	Jul 31, 2008
AB			**EQ 250MG VALPROIC ACID**	**A077296**	**002**	Jul 31, 2008
AB			**EQ 500MG VALPROIC ACID**	**A077296**	**003**	Jul 31, 2008
AB		DR REDDYS LABS LTD	**EQ 125MG VALPROIC ACID**	**A078755**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078755**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078755**	**003**	Jul 29, 2008

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

AB		INVATECH	EQ 125MG VALPROIC ACID	A078290	003	Jul 29, 2008
AB			EQ 250MG VALPROIC ACID	A078290	002	Jul 29, 2008
AB			EQ 500MG VALPROIC ACID	A078290	001	Jul 29, 2008
AB		LUPIN	EQ 125MG VALPROIC ACID	A078790	001	Jul 29, 2008
AB			EQ 250MG VALPROIC ACID	A078790	002	Jul 29, 2008
AB			EQ 500MG VALPROIC ACID	A078790	003	Jul 29, 2008
AB		ORBION PHARMS	EQ 125MG VALPROIC ACID	A078853	001	Nov 25, 2008
AB			EQ 250MG VALPROIC ACID	A078853	002	Nov 25, 2008
AB			EQ 500MG VALPROIC ACID	A078853	003	Nov 25, 2008
AB		PRINSTON INC	EQ 125MG VALPROIC ACID	A090210	001	Nov 30, 2009
AB			EQ 250MG VALPROIC ACID	A090210	002	Nov 30, 2009
AB			EQ 500MG VALPROIC ACID	A090210	003	Nov 30, 2009
AB		SUN PHARM INDS	EQ 125MG VALPROIC ACID	A078597	001	Jul 29, 2008
AB			EQ 250MG VALPROIC ACID	A078597	002	Jul 29, 2008
AB			EQ 500MG VALPROIC ACID	A078597	003	Jul 29, 2008
AB		UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163	001	Apr 05, 2011
AB			EQ 250MG VALPROIC ACID	A079163	002	Apr 05, 2011
AB			EQ 500MG VALPROIC ACID	A079163	003	Apr 05, 2011
AB		UPSHER SMITH LABS	EQ 125MG VALPROIC ACID	A078182	001	Jul 29, 2008
AB			EQ 250MG VALPROIC ACID	A078182	002	Jul 29, 2008
AB			EQ 500MG VALPROIC ACID	A078182	003	Jul 29, 2008
AB		ZYDUS PHARMS USA INC	EQ 125MG VALPROIC ACID	A077100	001	Mar 05, 2009
AB			EQ 250MG VALPROIC ACID	A077100	002	Mar 05, 2009
AB			EQ 500MG VALPROIC ACID	A077100	003	Mar 05, 2009

TABLET, EXTENDED RELEASE;ORAL

DEPAKOTE ER

AB	+	ABBVIE	EQ 250MG VALPROIC ACID	N021168	002	May 31, 2002
AB	+		EQ 500MG VALPROIC ACID	N021168	001	Aug 04, 2000

DIVALPROEX SODIUM

AB		AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015
AB	!		EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015
AB		ANNORA PHARMA	EQ 250MG VALPROIC ACID	A215527	001	Sep 26, 2023
AB			EQ 500MG VALPROIC ACID	A215527	002	Sep 26, 2023
AB		AUROBINDO PHARMA LTD	EQ 250MG VALPROIC ACID	A202419	001	Jun 02, 2014
AB			EQ 500MG VALPROIC ACID	A202419	002	Jun 02, 2014
AB		DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161	001	Mar 15, 2012
AB		LUPIN LTD	EQ 250MG VALPROIC ACID	A209286	001	Oct 18, 2019
AB			EQ 500MG VALPROIC ACID	A209286	002	Oct 18, 2019
AB		MYLAN	EQ 250MG VALPROIC ACID	A077567	001	Jan 29, 2009
AB			EQ 500MG VALPROIC ACID	A077567	002	Jan 29, 2009
AB		REDDYS	EQ 500MG VALPROIC ACID	A090070	001	Mar 12, 2012
AB		UNICHEM	EQ 250MG VALPROIC ACID	A214643	001	Feb 25, 2022
AB			EQ 500MG VALPROIC ACID	A214643	002	Feb 25, 2022
AB		WOCKHARDT	EQ 250MG VALPROIC ACID	A078705	002	Feb 10, 2009
AB			EQ 500MG VALPROIC ACID	A078705	001	Aug 04, 2009
AB		ZYDUS PHARMS USA INC	EQ 250MG VALPROIC ACID	A078239	001	Feb 27, 2009
AB			EQ 500MG VALPROIC ACID	A078239	002	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

AP		HAINAN POLY	EQ 12.5MG BASE/ML	A216131	001	Dec 21, 2022
AP		HIKMA	EQ 12.5MG BASE/ML	A074277	001	Oct 31, 1994
AP	!	HOSPIRA	EQ 12.5MG BASE/ML	A074086	001	Nov 29, 1993

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	EQ 50MG BASE/100ML	N020255	001	Oct 19, 1993
AP	+!		EQ 100MG BASE/100ML	N020255	003	Oct 19, 1993
AP	+!		EQ 200MG BASE/100ML	N020255	004	Oct 19, 1993
AP	+!		EQ 400MG BASE/100ML	N020255	005	Oct 19, 1993
AP	+!	HOSPIRA	EQ 50MG BASE/100ML	N020201	003	Oct 19, 1993
AP	+!		EQ 100MG BASE/100ML	N020201	002	Oct 19, 1993
AP	+!		EQ 200MG BASE/100ML	N020201	001	Oct 19, 1993
AP	+!		EQ 400MG BASE/100ML	N020201	006	Jul 07, 1994

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP	+	ACCORD HLTHCARE	**20MG/ML (20MG/ML)**	**N201195**	**003**	Apr 20, 2012
AP	+		**80MG/4ML (20MG/ML)**	**N201195**	**004**	Apr 20, 2012
AP	+!		**160MG/8ML (20MG/ML)**	**N201195**	**005**	Apr 20, 2012
AP		ACTAVIS	**20MG/ML (20MG/ML)**	**N203551**	**001**	Apr 12, 2013
AP			**80MG/4ML (20MG/ML)**	**N203551**	**002**	Apr 12, 2013
AP			**160MG/8ML (20MG/ML)**	**N203551**	**004**	Sep 21, 2015
AP		ALEMBIC	**20MG/2ML (10MG/ML)**	**A215744**	**001**	Feb 28, 2023
AP			**80MG/8ML (10MG/ML)**	**A215744**	**002**	Feb 28, 2023
AP			**160MG/16ML (10MG/ML)**	**A215744**	**003**	Feb 28, 2023
AP		AMNEAL	**20MG/ML (20MG/ML)**	**A209640**	**001**	Jan 19, 2018
AP			**80MG/4ML (20MG/ML)**	**A209640**	**002**	Jan 19, 2018
AP			**160MG/8ML (20MG/ML)**	**A209640**	**003**	Jan 19, 2018
AP		DR REDDYS	**20MG/ML (20MG/ML)**	**A204193**	**001**	Nov 05, 2014
AP			**80MG/4ML (20MG/ML)**	**A204193**	**002**	Nov 05, 2014
AP		EUGIA PHARMA	**20MG/2ML (10MG/ML)**	**A214575**	**001**	Jun 25, 2021
AP			**80MG/8ML (10MG/ML)**	**A214575**	**002**	Jun 25, 2021
AP			**160MG/16ML (10MG/ML)**	**A214575**	**003**	Jun 25, 2021
AP		GLAND PHARMA LTD	**20MG/2ML (10MG/ML)**	**A213510**	**001**	Jul 01, 2021
AP			**80MG/8ML (10MG/ML)**	**A213510**	**002**	Jul 01, 2021
AP			**160MG/16ML (10MG/ML)**	**A213510**	**003**	Jul 01, 2021
AP		HENGRUI PHARMA	**20MG/ML (20MG/ML)**	**A207252**	**001**	Aug 09, 2017
AP			**80MG/4ML (20MG/ML)**	**A207252**	**002**	Aug 09, 2017
AP			**160MG/8ML (20MG/ML)**	**A207252**	**003**	Aug 09, 2017
AP		HIKMA	**20MG/ML (20MG/ML)**	**A204490**	**001**	Jan 14, 2021
AP			**80MG/4ML (20MG/ML)**	**A204490**	**002**	Jan 14, 2021
AP	+!	HOSPIRA INC	**20MG/2ML (10MG/ML)**	**N022234**	**001**	Mar 08, 2011
AP	+!		**80MG/8ML (10MG/ML)**	**N022234**	**002**	Mar 08, 2011
AP	+!		**160MG/16ML (10MG/ML)**	**N022234**	**003**	Mar 08, 2011
AP		MEITHEAL	**20MG/2ML (10MG/ML)**	**A209634**	**001**	Aug 24, 2018
AP			**80MG/8ML (10MG/ML)**	**A209634**	**002**	Aug 24, 2018
AP			**160MG/16ML (10MG/ML)**	**A209634**	**003**	Aug 24, 2018
AP		MYLAN LABS LTD	**20MG/2ML (10MG/ML)**	**A210072**	**001**	Jul 02, 2018
AP			**80MG/8ML (10MG/ML)**	**A210848**	**001**	Jul 06, 2018
AP			**160MG/8ML (20MG/ML)**	**A208137**	**001**	Apr 01, 2019
AP			**160MG/16ML (10MG/ML)**	**A208859**	**001**	Apr 30, 2018
AP		NOVAST LABS	**80MG/8ML (10MG/ML)**	**A207563**	**002**	Aug 31, 2017
AP			**160MG/16ML (10MG/ML)**	**A207563**	**003**	Aug 31, 2017
AP		SANDOZ	**20MG/2ML (10MG/ML)**	**N201525**	**001**	Jun 29, 2011
AP			**80MG/8ML (10MG/ML)**	**N201525**	**002**	Jun 29, 2011
AP			**160MG/16ML (10MG/ML)**	**N201525**	**003**	Jun 29, 2011
AP		SHILPA	**20MG/ML (20MG/ML)**	**A210327**	**001**	May 16, 2019
AP	+!		**20MG/ML (20MG/ML)**	**N205934**	**001**	Dec 22, 2015
AP			**80MG/4ML (20MG/ML)**	**A210327**	**002**	May 16, 2019
AP	+!		**80MG/4ML (20MG/ML)**	**N205934**	**002**	Dec 22, 2015
AP			**160MG/8ML (20MG/ML)**	**A210327**	**003**	May 16, 2019
AP	+!		**160MG/8ML (20MG/ML)**	**N205934**	**003**	Dec 22, 2015
AP		SUN PHARM	**20MG/ML (20MG/ML)**	**N022534**	**003**	Jan 08, 2019
AP			**80MG/4ML (20MG/ML)**	**N022534**	**004**	Jan 08, 2019
AP			**160MG/8ML (20MG/ML)**	**N022534**	**005**	Jan 08, 2019

TAXOTERE

AP	+!	SANOFI AVENTIS US	**20MG/ML (20MG/ML)**	**N020449**	**003**	Aug 03, 2010
AP	+!		**80MG/4ML (20MG/ML)**	**N020449**	**004**	Aug 02, 2010
AP	+!		**160MG/8ML (20MG/ML)**	**N020449**	**005**	Apr 13, 2012

DOCETAXEL

		ACTAVIS	140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013
	+	HOSPIRA INC	20MG/ML (20MG/ML)	N022234	004	Jun 23, 2016
	+		80MG/4ML (20MG/ML)	N022234	005	Jun 23, 2016
	+		160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017

DOFETILIDE

CAPSULE;ORAL

DOFETILDE

AB		AUROBINDO PHARMA LTD	**0.125MG**	**A210740**	**001**	Jan 22, 2019
AB			**0.25MG**	**A210740**	**002**	Jan 22, 2019
AB			**0.5MG**	**A210740**	**003**	Jan 22, 2019

DOFETILIDE

AB		ACCORD HLTHCARE	**0.125MG**	**A213338**	**001**	Jun 19, 2020
AB			**0.25MG**	**A213338**	**002**	Jun 19, 2020
AB			**0.5MG**	**A213338**	**003**	Jun 19, 2020

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

AB		BIONPHARMA	**0.125MG**	**A208625**	**001**	Apr 10, 2018
AB			**0.25MG**	**A208625**	**002**	Apr 10, 2018
AB			**0.5MG**	**A208625**	**003**	Apr 10, 2018
AB		DR REDDYS LABS SA	**0.125MG**	**A207058**	**001**	Jun 06, 2016
AB			**0.25MG**	**A207058**	**002**	Jun 06, 2016
AB			**0.5MG**	**A207058**	**003**	Jun 06, 2016
AB		GRANULES	**0.125MG**	**A212750**	**001**	Oct 14, 2021
AB			**0.25MG**	**A212750**	**002**	Oct 14, 2021
AB			**0.5MG**	**A212750**	**003**	Oct 14, 2021
AB		MSN	**0.125MG**	**A213220**	**001**	Jan 29, 2020
AB			**0.25MG**	**A213220**	**002**	Jan 29, 2020
AB			**0.5MG**	**A213220**	**003**	Jan 29, 2020
AB		SIGMAPHARM LABS LLC	**0.125MG**	**A207746**	**001**	Mar 26, 2018
AB			**0.25MG**	**A207746**	**002**	Mar 26, 2018
AB			**0.5MG**	**A207746**	**003**	Mar 26, 2018
AB		STRIDES PHARMA	**0.125MG**	**A208519**	**001**	Oct 09, 2018
AB			**0.25MG**	**A208519**	**002**	Oct 09, 2018
AB			**0.5MG**	**A208519**	**003**	Oct 09, 2018
AB		SUN PHARM	**0.125MG**	**A210466**	**001**	Oct 09, 2018
AB			**0.25MG**	**A210466**	**002**	Oct 09, 2018
AB			**0.5MG**	**A210466**	**003**	Oct 09, 2018

TIKOSYN

AB	**+**	PFIZER	**0.125MG**	**N020931**	**001**	Oct 01, 1999
AB	**+**		**0.25MG**	**N020931**	**002**	Oct 01, 1999
AB	**+!**		**0.5MG**	**N020931**	**003**	Oct 01, 1999

DOLASETRON MESYLATE

TABLET;ORAL

ANZEMET

+!	VALIDUS PHARMS	50MG	N020623	001	Sep 11, 1997

DOLUTEGRAVIR SODIUM

TABLET;ORAL

TIVICAY

+	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016
+		EQ 25MG BASE	N204790	003	Jun 09, 2016
+!		EQ 50MG BASE	N204790	001	Aug 12, 2013

TABLET, FOR SUSPENSION;ORAL

TIVICAY PD

+!	VIIV HLTHCARE	EQ 5MG BASE	N213983	001	Jun 12, 2020

DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

DOVATO

+!	VIIV HLTHCARE	EQ 50MG BASE;300MG	N211994	001	Apr 08, 2019

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

JULUCA

+!	VIIV HLTHCARE	EQ 50MG BASE;EQ 25MG BASE	N210192	001	Nov 21, 2017

DONEPEZIL HYDROCHLORIDE

SYSTEM;TRANSDERMAL

ADLARITY

+	CORIUM	5MG/DAY	N212304	001	Mar 11, 2022
+!		10MG/DAY	N212304	002	Mar 11, 2022

TABLET;ORAL

ARICEPT

AB	**+**	EISAI INC	**5MG**	**N020690**	**002**	Nov 25, 1996
AB	**+!**		**10MG**	**N020690**	**001**	Nov 25, 1996
AB	**+!**		**23MG**	**N022568**	**001**	Jul 23, 2010

DONEPEZIL HYDROCHLORIDE

AB	ACI	**5MG**	**A078662**	**001**	May 31, 2011
AB		**10MG**	**A078662**	**002**	May 31, 2011
AB	ALEMBIC PHARMS LTD	**5MG**	**A201724**	**001**	Feb 25, 2013
AB		**10MG**	**A201724**	**002**	Feb 25, 2013
AB	AUROBINDO	**5MG**	**A090056**	**001**	May 31, 2011
AB		**10MG**	**A090056**	**002**	May 31, 2011
AB	CADILA	**5MG**	**A090100**	**001**	Oct 24, 2012
AB		**10MG**	**A090100**	**002**	Oct 24, 2012
AB	CADILA PHARMS LTD	**5MG**	**A204609**	**001**	Sep 19, 2017
AB		**10MG**	**A204609**	**002**	Sep 19, 2017

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB		CHARTWELL RX	**5MG**	**A090425**	**001**	May 31, 2011
AB			**10MG**	**A090425**	**002**	May 31, 2011
AB		CIPLA LTD	**5MG**	**A077518**	**001**	May 31, 2011
AB			**10MG**	**A077518**	**002**	May 31, 2011
AB		DEXCEL	**23MG**	**A203713**	**001**	Feb 19, 2016
AB		DR REDDYS	**23MG**	**A202723**	**001**	Jul 24, 2013
AB		DR REDDYS LABS LTD	**5MG**	**A201001**	**001**	May 31, 2011
AB			**10MG**	**A201001**	**002**	May 31, 2011
AB		HETERO LABS LTD V	**5MG**	**A203034**	**001**	Jan 30, 2015
AB			**10MG**	**A203034**	**002**	Jan 30, 2015
AB		INDICUS PHARMA	**5MG**	**A201634**	**001**	Jun 13, 2012
AB			**10MG**	**A201634**	**002**	Jun 13, 2012
AB		JUBILANT GENERICS	**5MG**	**A090768**	**001**	May 31, 2011
AB			**10MG**	**A090768**	**002**	May 31, 2011
AB		LUPIN LTD	**23MG**	**A202782**	**001**	Oct 30, 2015
AB		MACLEODS PHARMS LTD	**5MG**	**A201146**	**001**	Aug 17, 2012
AB			**10MG**	**A201146**	**002**	Aug 17, 2012
AB			**23MG**	**A202631**	**001**	Jan 22, 2014
AB		PRINSTON INC	**5MG**	**A200292**	**001**	May 31, 2011
AB			**10MG**	**A200292**	**002**	May 31, 2011
AB		RISING	**5MG**	**A202114**	**001**	Jul 05, 2013
AB			**10MG**	**A202114**	**002**	Jul 05, 2013
AB		SCIEGEN PHARMS INC	**5MG**	**A203907**	**001**	Oct 29, 2014
AB			**10MG**	**A203907**	**002**	Oct 29, 2014
AB		STRIDES PHARMA	**5MG**	**A090551**	**001**	May 31, 2011
AB			**10MG**	**A090551**	**002**	May 31, 2011
AB		SUN PHARM INDS	**5MG**	**A090493**	**001**	May 31, 2011
AB			**10MG**	**A090493**	**002**	May 31, 2011
AB		TORRENT PHARMS	**5MG**	**A090686**	**001**	May 31, 2011
AB			**10MG**	**A090686**	**002**	May 31, 2011
AB		TWI PHARMS	**23MG**	**A203104**	**001**	Oct 29, 2014
AB		ZYDUS PHARMS	**23MG**	**A203162**	**001**	Aug 31, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

AB		HISUN PHARM HANGZHOU	**5MG**	**A205269**	**001**	Jul 27, 2018
AB			**10MG**	**A205269**	**002**	Jul 27, 2018
AB		MACLEODS PHARMS LTD	**5MG**	**A201787**	**001**	Dec 14, 2012
AB			**10MG**	**A201787**	**002**	Dec 14, 2012
AB		SANDOZ	**5MG**	**A091198**	**001**	May 10, 2011
AB	**!**		**10MG**	**A091198**	**002**	May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB		ANI PHARMS	**10MG;21MG**	**A208237**	**001**	Dec 15, 2023

NAMZARIC

AB	**+**	ABBVIE	**10MG;21MG**	**N206439**	**004**	Jul 18, 2016
	+		10MG;7MG	N206439	003	Jul 18, 2016
	+		10MG;14MG	N206439	001	Dec 23, 2014
	+!		10MG;28MG	N206439	002	Dec 23, 2014

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

AP		HIKMA INTL PHARMS	**40MG/ML**	**A207707**	**001**	Apr 11, 2018
AP			**80MG/ML**	**A207707**	**002**	Apr 11, 2018
AP	**+!**	HOSPIRA	**40MG/ML**	**N018132**	**001**	
AP	**+!**		**80MG/100ML**	**N018132**	**002**	Feb 04, 1982
AP	**+!**		**80MG/ML**	**N018132**	**004**	Jul 09, 1982
AP	**+!**		**160MG/100ML**	**N018132**	**003**	Feb 04, 1982

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**80MG/100ML**	**N019615**	**001**	Mar 27, 1987
AP	**+!**		**160MG/100ML**	**N019615**	**002**	Mar 27, 1987
AP	**+!**		**320MG/100ML**	**N019615**	**003**	Mar 27, 1987
AP	**+!**	HOSPIRA	**80MG/100ML**	**N018826**	**001**	Sep 30, 1983
AP	**+!**		**160MG/100ML**	**N018826**	**002**	Sep 30, 1983
AP	**+!**		**320MG/100ML**	**N018826**	**003**	Sep 30, 1983
	+!	BAXTER HLTHCARE	640MG/100ML	N019615	004	Mar 27, 1987

DORAVIRINE

TABLET;ORAL

PIFELTRO

+!	MSD MERCK CO	100MG	N210806	001	Aug 30, 2018

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

DELSTRIGO

+!	MSD MERCK CO	100MG;300MG;300MG	N210807	001	Aug 30, 2018

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT		ALEMBIC	**EQ 2% BASE**	**A212639**	**001**	Aug 09, 2019
AT		BAUSCH AND LOMB	**EQ 2% BASE**	**A090143**	**001**	Jun 25, 2009
AT		FDC LTD	**EQ 2% BASE**	**A205294**	**001**	Jan 24, 2019
AT		GLAND PHARMA LTD	**EQ 2% BASE**	**A215660**	**001**	Jan 27, 2022
AT		HIKMA	**EQ 2% BASE**	**A077846**	**001**	Oct 28, 2008
AT		INDOCO	**EQ 2% BASE**	**A202053**	**001**	Sep 11, 2014
AT	!	MICRO LABS	**EQ 2% BASE**	**A204778**	**001**	Nov 08, 2019
AT		RUBICON	**EQ 2% BASE**	**A078395**	**001**	Oct 28, 2008
AT		SANDOZ	**EQ 2% BASE**	**A078748**	**001**	Nov 06, 2008
AT			**EQ 2% BASE**	**A078981**	**001**	Apr 13, 2009

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT

AT1	**+!**	THEA PHARMA	**EQ 2% BASE;EQ 0.5% BASE**	**N020869**	**001**	Apr 07, 1998

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT1		ALEMBIC	**EQ 2% BASE;EQ 0.5% BASE**	**A213099**	**001**	May 04, 2021
AT1		BAUSCH AND LOMB	**EQ 2% BASE;EQ 0.5% BASE**	**A090037**	**001**	Jul 14, 2009
AT1		EPIC PHARMA LLC	**EQ 2% BASE;EQ 0.5% BASE**	**A203058**	**001**	Sep 22, 2014
AT1		EUGIA PHARMA	**EQ 2% BASE;EQ 0.5% BASE**	**A207629**	**001**	May 14, 2021
AT1		FDC LTD	**EQ 2% BASE;EQ 0.5% BASE**	**A205295**	**001**	Jun 13, 2019
AT1		GLAND PHARMA LTD	**EQ 2% BASE;EQ 0.5% BASE**	**A215520**	**001**	Sep 19, 2022
AT1		HIKMA	**EQ 2% BASE;EQ 0.5% BASE**	**A077847**	**001**	Oct 28, 2008
AT1		INDOCO	**EQ 2% BASE;EQ 0.5% BASE**	**A202054**	**001**	Sep 03, 2014
AT1		MICRO LABS	**EQ 2% BASE;EQ 0.5% BASE**	**A204777**	**001**	May 28, 2020
AT1		SANDOZ	**EQ 2% BASE;EQ 0.5% BASE**	**A078749**	**001**	Nov 06, 2008
AT1			**EQ 2% BASE;EQ 0.5% BASE**	**A090604**	**001**	Nov 18, 2009
AT1		SOMERSET	**EQ 2% BASE;EQ 0.5% BASE**	**A207523**	**001**	Jun 25, 2019

COSOPT PF

AT2	**+!**	THEA PHARMA	**EQ 2% BASE;EQ 0.5% BASE**	**N202667**	**001**	Feb 01, 2012

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT2		EUGIA PHARMA	**EQ 2% BASE;EQ 0.5% BASE**	**A207630**	**001**	Jul 24, 2018
AT2		INGENUS PHARMS LLC	**EQ 2% BASE;EQ 0.5% BASE**	**A217260**	**001**	May 01, 2023
AT2		MICRO LABS	**EQ 2% BASE;EQ 0.5% BASE**	**A215936**	**001**	Jan 25, 2022

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM

AP	**+!**	HIKMA	**20MG/ML**	**N014879**	**001**	

DOXAPRAM HYDROCHLORIDE

AP		CHARTWELL INJECTABLE	**20MG/ML**	**A076266**	**001**	Jan 10, 2003

DOXAZOSIN MESYLATE

TABLET;ORAL

CARDURA

AB	**+!**	VIATRIS	**EQ 1MG BASE**	**N019668**	**001**	Nov 02, 1990
AB	**+**		**EQ 2MG BASE**	**N019668**	**002**	Nov 02, 1990
AB	**+**		**EQ 4MG BASE**	**N019668**	**003**	Nov 02, 1990
AB	**+**		**EQ 8MG BASE**	**N019668**	**004**	Nov 02, 1990

DOXAZOSIN MESYLATE

AB		ACCORD HLTHCARE	**EQ 1MG BASE**	**A202824**	**001**	Jun 11, 2014
AB			**EQ 2MG BASE**	**A202824**	**002**	Jun 11, 2014
AB			**EQ 4MG BASE**	**A202824**	**003**	Jun 11, 2014
AB			**EQ 8MG BASE**	**A202824**	**004**	Jun 11, 2014
AB		APOTEX	**EQ 1MG BASE**	**A075580**	**001**	Oct 18, 2000
AB			**EQ 2MG BASE**	**A075580**	**002**	Oct 18, 2000
AB			**EQ 4MG BASE**	**A075580**	**003**	Oct 18, 2000
AB			**EQ 8MG BASE**	**A075580**	**004**	Oct 18, 2000
AB		HERITAGE PHARMA	**EQ 1MG BASE**	**A205210**	**001**	Feb 13, 2018
AB			**EQ 2MG BASE**	**A205210**	**002**	Feb 13, 2018
AB			**EQ 4MG BASE**	**A205210**	**003**	Feb 13, 2018

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB		**EQ 8MG BASE**	**A205210**	**004**	Feb 13, 2018
AB	RISING	**EQ 1MG BASE**	**A212727**	**001**	Mar 15, 2022
AB		**EQ 2MG BASE**	**A212727**	**002**	Mar 15, 2022
AB		**EQ 4MG BASE**	**A212727**	**003**	Mar 15, 2022
AB		**EQ 8MG BASE**	**A212727**	**004**	Mar 15, 2022
AB	TEVA	**EQ 1MG BASE**	**A075536**	**001**	Oct 18, 2000
AB		**EQ 2MG BASE**	**A075536**	**002**	Oct 18, 2000
AB		**EQ 4MG BASE**	**A075536**	**003**	Oct 18, 2000
AB		**EQ 8MG BASE**	**A075536**	**004**	Oct 18, 2000
AB	UNICHEM	**EQ 1MG BASE**	**A212329**	**001**	Jan 10, 2024
AB		**EQ 2MG BASE**	**A212329**	**002**	Jan 10, 2024
AB		**EQ 4MG BASE**	**A212329**	**003**	Jan 10, 2024
AB		**EQ 8MG BASE**	**A212329**	**004**	Jan 10, 2024
AB	UPSHER SMITH LABS	**EQ 1MG BASE**	**A209013**	**001**	Apr 17, 2018
AB		**EQ 2MG BASE**	**A209013**	**002**	Apr 17, 2018
AB		**EQ 4MG BASE**	**A209013**	**003**	Apr 17, 2018
AB		**EQ 8MG BASE**	**A209013**	**004**	Apr 17, 2018
AB	ZYDUS PHARMS	**EQ 1MG BASE**	**A208719**	**001**	Jul 07, 2017
AB		**EQ 2MG BASE**	**A208719**	**002**	Jul 07, 2017
AB		**EQ 4MG BASE**	**A208719**	**003**	Jul 07, 2017
AB		**EQ 8MG BASE**	**A208719**	**004**	Jul 07, 2017

TABLET, EXTENDED RELEASE;ORAL

CARDURA XL

+	VIATRIS	EQ 4MG BASE	N021269	001	Feb 22, 2005
+!		EQ 8MG BASE	N021269	002	Feb 22, 2005

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	AJANTA PHARMA LTD	**EQ 10MG BASE**	**A212624**	**001**	Sep 13, 2019
AB		**EQ 25MG BASE**	**A212624**	**002**	Sep 13, 2019
AB		**EQ 50MG BASE**	**A212624**	**003**	Sep 13, 2019
AB		**EQ 75MG BASE**	**A212624**	**004**	Sep 13, 2019
AB		**EQ 100MG BASE**	**A212624**	**005**	Sep 13, 2019
AB	ALEMBIC	**EQ 10MG BASE**	**A215076**	**001**	Apr 21, 2021
AB		**EQ 25MG BASE**	**A215076**	**002**	Apr 21, 2021
AB		**EQ 50MG BASE**	**A215076**	**003**	Apr 21, 2021
AB		**EQ 75MG BASE**	**A215076**	**004**	Apr 21, 2021
AB		**EQ 100MG BASE**	**A215076**	**005**	Apr 21, 2021
AB	AMNEAL PHARMS CO	**EQ 10MG BASE**	**A207482**	**001**	Jun 28, 2017
AB		**EQ 25MG BASE**	**A207482**	**002**	Jun 28, 2017
AB		**EQ 50MG BASE**	**A207482**	**003**	Jun 28, 2017
AB		**EQ 75MG BASE**	**A207482**	**004**	Jun 28, 2017
AB		**EQ 100MG BASE**	**A207482**	**005**	Jun 28, 2017
AB	APPCO	**EQ 10MG BASE**	**A214908**	**001**	Apr 01, 2021
AB		**EQ 25MG BASE**	**A214908**	**002**	Apr 01, 2021
AB		**EQ 50MG BASE**	**A214908**	**003**	Apr 01, 2021
AB		**EQ 75MG BASE**	**A214908**	**004**	Apr 01, 2021
AB		**EQ 100MG BASE**	**A214908**	**005**	Apr 01, 2021
AB	AUROBINDO PHARMA LTD	**EQ 10MG BASE**	**A211603**	**001**	Mar 27, 2019
AB		**EQ 25MG BASE**	**A211603**	**002**	Mar 27, 2019
AB		**EQ 50MG BASE**	**A211603**	**003**	Mar 27, 2019
AB		**EQ 75MG BASE**	**A211603**	**004**	Mar 27, 2019
AB		**EQ 100MG BASE**	**A211603**	**005**	Mar 27, 2019
AB	CHARTWELL RX	**EQ 10MG BASE**	**A210268**	**001**	Sep 04, 2020
AB		**EQ 25MG BASE**	**A210268**	**002**	Sep 04, 2020
AB		**EQ 50MG BASE**	**A210268**	**003**	Sep 04, 2020
AB		**EQ 75MG BASE**	**A210268**	**004**	Sep 04, 2020
AB		**EQ 100MG BASE**	**A210268**	**005**	Sep 04, 2020
AB	CHEMISTRY HLTH	**EQ 10MG BASE**	**A211619**	**001**	Mar 09, 2021
AB		**EQ 25MG BASE**	**A211619**	**002**	Mar 09, 2021
AB		**EQ 50MG BASE**	**A211619**	**003**	Mar 09, 2021
AB		**EQ 75MG BASE**	**A211619**	**004**	Mar 09, 2021
AB		**EQ 100MG BASE**	**A211619**	**005**	Mar 09, 2021
AB	CONTRACT PHARMACAL	**EQ 10MG BASE**	**A213474**	**001**	Jul 28, 2020
AB		**EQ 25MG BASE**	**A213474**	**002**	Jul 28, 2020
AB		**EQ 50MG BASE**	**A213474**	**003**	Jul 28, 2020
AB		**EQ 75MG BASE**	**A213474**	**004**	Jul 28, 2020
AB		**EQ 100MG BASE**	**A213474**	**005**	Jul 28, 2020

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB		EDENBRIDGE PHARMS	**EQ 150MG BASE**	**A213796**	**001**	Apr 19, 2022
AB		EPIC PHARMA LLC	**EQ 10MG BASE**	**A210675**	**001**	Oct 16, 2020
AB			**EQ 25MG BASE**	**A210675**	**002**	Oct 16, 2020
AB			**EQ 50MG BASE**	**A210675**	**004**	Mar 03, 2022
AB			**EQ 75MG BASE**	**A210675**	**005**	Mar 03, 2022
AB			**EQ 100MG BASE**	**A210675**	**003**	Oct 16, 2020
AB		JUBILANT CADISTA	**EQ 10MG BASE**	**A215483**	**001**	Mar 14, 2022
AB			**EQ 25MG BASE**	**A215483**	**002**	Mar 14, 2022
AB			**EQ 50MG BASE**	**A215483**	**003**	Mar 14, 2022
AB			**EQ 75MG BASE**	**A215483**	**004**	Mar 14, 2022
AB			**EQ 100MG BASE**	**A215483**	**005**	Mar 14, 2022
AB		LEADING	**EQ 150MG BASE**	**A211618**	**001**	Mar 01, 2021
AB		MANKIND PHARMA	**EQ 10MG BASE**	**A215710**	**001**	Feb 09, 2022
AB			**EQ 25MG BASE**	**A215710**	**002**	Feb 09, 2022
AB			**EQ 50MG BASE**	**A215710**	**003**	Feb 09, 2022
AB			**EQ 75MG BASE**	**A215710**	**004**	Feb 09, 2022
AB			**EQ 100MG BASE**	**A215710**	**005**	Feb 09, 2022
AB		MICRO LABS	**EQ 10MG BASE**	**A217688**	**001**	Jun 27, 2023
AB			**EQ 25MG BASE**	**A217688**	**002**	Jun 27, 2023
AB			**EQ 50MG BASE**	**A217688**	**003**	Jun 27, 2023
AB			**EQ 75MG BASE**	**A217688**	**004**	Jun 27, 2023
AB			**EQ 100MG BASE**	**A217688**	**005**	Jun 27, 2023
AB		MSN	**EQ 10MG BASE**	**A215113**	**001**	Jun 24, 2022
AB			**EQ 25MG BASE**	**A215113**	**002**	Jun 24, 2022
AB			**EQ 50MG BASE**	**A215113**	**003**	Jun 24, 2022
AB			**EQ 75MG BASE**	**A215113**	**004**	Jun 24, 2022
AB			**EQ 100MG BASE**	**A215113**	**005**	Jun 24, 2022
AB		MYLAN PHARMS INC	**EQ 10MG BASE**	**A070791**	**002**	May 13, 1986
AB	**!**		**EQ 25MG BASE**	**A070791**	**003**	May 13, 1986
AB			**EQ 50MG BASE**	**A070791**	**001**	May 13, 1986
AB			**EQ 75MG BASE**	**A070791**	**004**	May 13, 1986
AB	**!**		**EQ 100MG BASE**	**A070791**	**005**	May 13, 1986
AB	**!**	PAR PHARM	**EQ 150MG BASE**	**A071422**	**006**	Nov 09, 1987
AB		TARO	**EQ 10MG BASE**	**A213063**	**001**	Jul 01, 2020
AB			**EQ 25MG BASE**	**A213063**	**002**	Jul 01, 2020
AB			**EQ 50MG BASE**	**A213063**	**003**	Jul 01, 2020
AB			**EQ 75MG BASE**	**A213063**	**004**	Jul 01, 2020
AB			**EQ 100MG BASE**	**A213063**	**005**	Jul 01, 2020
AB		UNIQUE PHARM	**EQ 10MG BASE**	**A217975**	**001**	Aug 21, 2023
AB			**EQ 25MG BASE**	**A217975**	**002**	Aug 21, 2023
AB			**EQ 50MG BASE**	**A217975**	**003**	Aug 21, 2023
AB			**EQ 75MG BASE**	**A217975**	**004**	Aug 21, 2023
AB			**EQ 100MG BASE**	**A217975**	**005**	Aug 21, 2023
AB		ZYDUS LIFESCIENCES	**EQ 10MG BASE**	**A210700**	**001**	Mar 23, 2023
AB			**EQ 25MG BASE**	**A210700**	**002**	Mar 23, 2023
AB			**EQ 50MG BASE**	**A210700**	**003**	Mar 23, 2023
AB			**EQ 75MG BASE**	**A210700**	**004**	Mar 23, 2023
AB			**EQ 100MG BASE**	**A210700**	**005**	Mar 23, 2023
AB			**EQ 150MG BASE**	**A210140**	**001**	Mar 21, 2023

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

	!	LANNETT CO INC	EQ 10MG BASE/ML	A074721	001	Dec 29, 1998

CREAM;TOPICAL

DOXEPIN HYDROCHLORIDE

AB		AMNEAL	**5%**	**A212357**	**001**	Aug 16, 2023
AB		TEVA PHARMS	**5%**	**A215408**	**001**	Feb 17, 2023

ZONALON

AB	**+!**	MYLAN	**5%**	**N020126**	**001**	Apr 01, 1994

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 3MG BASE**	**A201951**	**001**	Jul 26, 2013
AB			**EQ 6MG BASE**	**A201951**	**002**	Jul 26, 2013
AB		MSN	**EQ 3MG BASE**	**A214823**	**001**	Apr 03, 2023
AB			**EQ 6MG BASE**	**A214823**	**002**	Apr 03, 2023
AB		RK PHARMA	**EQ 3MG BASE**	**A202337**	**001**	Jan 20, 2016
AB			**EQ 6MG BASE**	**A202337**	**002**	Jan 20, 2016
AB		STRIDES PHARMA	**EQ 3MG BASE**	**A202510**	**001**	Jul 24, 2020
AB			**EQ 6MG BASE**	**A202510**	**002**	Jul 24, 2020

DOXEPIN HYDROCHLORIDE

TABLET;ORAL

SILENOR

AB	**+**	CURRAX	**EQ 3MG BASE**	**N022036**	**001**	Mar 17, 2010
AB	**+!**		**EQ 6MG BASE**	**N022036**	**002**	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE;ORAL

DOXERCALCIFEROL

AB		AVET	**0.5MCG**	**A205360**	**001**	Sep 15, 2020
AB			**1MCG**	**A205360**	**002**	Sep 15, 2020
AB			**2.5MCG**	**A205360**	**003**	Sep 15, 2020
AB		RISING	**0.5MCG**	**A201518**	**001**	Sep 09, 2016
AB			**1MCG**	**A201518**	**002**	Sep 09, 2016
AB			**2.5MCG**	**A201518**	**003**	Sep 09, 2016

HECTOROL

AB	**+**	SANOFI	**0.5MCG**	**N020862**	**002**	Apr 23, 2004
AB	**+**		**1MCG**	**N020862**	**003**	Jul 13, 2009
AB	**+!**		**2.5MCG**	**N020862**	**001**	Jun 09, 1999

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP		ALEMBIC	**4MCG/2ML (2MCG/ML)**	**A215810**	**001**	Jun 15, 2023
AP		AMNEAL	**2MCG/ML (2MCG/ML)**	**A208974**	**001**	May 24, 2017
AP			**4MCG/2ML (2MCG/ML)**	**A208974**	**002**	May 24, 2017
AP		EUGIA PHARMA	**2MCG/ML (2MCG/ML)**	**A213717**	**001**	Jan 24, 2022
AP			**4MCG/2ML (2MCG/ML)**	**A213717**	**002**	Jan 24, 2022
AP		GLAND PHARMA LTD	**4MCG/2ML (2MCG/ML)**	**A210452**	**001**	Sep 26, 2019
AP		HIKMA	**4MCG/2ML (2MCG/ML)**	**A091101**	**001**	Aug 30, 2013
AP	**+**	HOSPIRA	**4MCG/2ML (2MCG/ML)**	**N208614**	**001**	Jul 24, 2018
AP		LUPIN LTD	**4MCG/2ML (2MCG/ML)**	**A210801**	**001**	Nov 01, 2018
AP		MEITHEAL	**4MCG/2ML (2MCG/ML)**	**A211670**	**001**	Feb 07, 2020
AP		SANDOZ	**4MCG/2ML (2MCG/ML)**	**A091333**	**001**	May 05, 2014
AP			**4MCG/2ML (2MCG/ML)**	**A200926**	**001**	Feb 04, 2014

HECTOROL

AP	**+**	SANOFI	**2MCG/ML (2MCG/ML)**	**N021027**	**002**	Apr 06, 2000
AP	**+!**		**4MCG/2ML (2MCG/ML)**	**N021027**	**001**	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP		ACTAVIS INC	**2MG/ML**	**A203622**	**001**	Jun 27, 2014
AP			**200MG/100ML**	**A203622**	**002**	Jun 27, 2014
AP		AMNEAL	**20MG/VIAL**	**A208888**	**001**	Feb 17, 2017
AP			**50MG/VIAL**	**A208888**	**002**	Feb 17, 2017
AP		FRESENIUS KABI USA	**2MG/ML**	**A063277**	**001**	Oct 26, 1995
AP		GLAND PHARMA LTD	**2MG/ML**	**A209825**	**001**	Aug 11, 2017
AP		HIKMA	**2MG/ML**	**A062975**	**001**	Mar 17, 1989
AP	**!**		**20MG/VIAL**	**A062921**	**002**	Mar 17, 1989
AP	**!**		**50MG/VIAL**	**A062921**	**003**	Mar 17, 1989
AP			**200MG/100ML**	**A064097**	**001**	Sep 13, 1994
AP		MYLAN LABS LTD	**50MG/VIAL**	**A200170**	**002**	Oct 28, 2011
AP	**+!**	PFIZER	**2MG/ML**	**N050629**	**001**	Dec 23, 1987
AP	**+!**		**200MG/100ML**	**N050629**	**002**	May 03, 1988
AP		SAGENT PHARMS	**2MG/ML**	**A091495**	**001**	Mar 18, 2013
AP		SUN PHARM INDS	**2MG/ML**	**A091418**	**001**	Feb 15, 2012
	!	HIKMA	10MG/VIAL	A062921	001	Mar 17, 1989
	+	PFIZER	150MG/75ML	N050629	003	Mar 28, 2011

INJECTABLE, LIPOSOMAL;INJECTION

DOXIL (LIPOSOMAL)

AB	**+**	BAXTER HLTHCARE CORP	**20MG/10ML (2MG/ML)**	**N050718**	**001**	Nov 17, 1995
AB	**+**		**50MG/25ML (2MG/ML)**	**N050718**	**002**	Jun 13, 2000

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB		AYANA PHARMA LTD	**20MG/10ML (2MG/ML)**	**A207228**	**001**	Oct 12, 2021
AB			**50MG/25ML (2MG/ML)**	**A207228**	**002**	Oct 12, 2021
AB		BAXTER HLTHCARE CORP	**20MG/10ML (2MG/ML)**	**A212219**	**001**	Oct 19, 2022
AB			**50MG/25ML (2MG/ML)**	**A212219**	**002**	Oct 19, 2022
AB		DR REDDYS	**20MG/10ML (2MG/ML)**	**A208657**	**001**	May 15, 2017
AB			**50MG/25ML (2MG/ML)**	**A208657**	**002**	May 15, 2017
AB	**!**	SUN PHARM	**20MG/10ML (2MG/ML)**	**A203263**	**001**	Feb 04, 2013
AB	**!**		**50MG/25ML (2MG/ML)**	**A203263**	**002**	Feb 04, 2013
AB		ZYDUS	**20MG/10ML (2MG/ML)**	**A212299**	**001**	Sep 10, 2020
AB			**50MG/25ML (2MG/ML)**	**A212299**	**002**	Sep 10, 2020

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB		ALEMBIC	**EQ 75MG BASE**	**A209165**	**001**	Jul 28, 2017
AB			**EQ 100MG BASE**	**A209165**	**002**	Jul 28, 2017
AB		COSETTE	**EQ 50MG BASE**	**A204446**	**001**	May 28, 2015
AB			**EQ 75MG BASE**	**A204446**	**002**	May 28, 2015
AB			**EQ 100MG BASE**	**A204446**	**003**	May 28, 2015
AB		DR REDDYS LABS SA	**EQ 50MG BASE**	**A209396**	**001**	Sep 29, 2017
AB			**EQ 75MG BASE**	**A209396**	**002**	Sep 29, 2017
AB			**EQ 100MG BASE**	**A209396**	**003**	Sep 29, 2017
AB		LUPIN LTD	**EQ 50MG BASE**	**A204234**	**001**	Mar 05, 2014
AB			**EQ 75MG BASE**	**A204234**	**002**	Mar 05, 2014
AB			**EQ 100MG BASE**	**A204234**	**003**	Mar 05, 2014
AB		STRIDES PHARMA	**EQ 50MG BASE**	**A065055**	**001**	Dec 01, 2000
AB			**EQ 100MG BASE**	**A065055**	**002**	Dec 01, 2000
AB	**!**		**EQ 150MG BASE**	**A065055**	**003**	Jul 15, 2005
AB		SUN PHARM INDS LTD	**EQ 50MG BASE**	**A065053**	**001**	Nov 22, 2000
AB			**EQ 75MG BASE**	**A065053**	**003**	Sep 10, 2003
AB	**!**		**EQ 100MG BASE**	**A065053**	**002**	Nov 22, 2000
AB		ZYDUS PHARMS	**EQ 50MG BASE**	**A205115**	**001**	Feb 18, 2016
AB			**EQ 75MG BASE**	**A205115**	**002**	Feb 18, 2016
AB			**EQ 100MG BASE**	**A205115**	**003**	Feb 18, 2016

MONODOX

AB	**+**	CHARTWELL RX	**EQ 50MG BASE**	**N050641**	**002**	Feb 10, 1992
AB	**+**		**EQ 75MG BASE**	**N050641**	**003**	Oct 18, 2006
AB	**+**		**EQ 100MG BASE**	**N050641**	**001**	Dec 29, 1989
AB	**+**		**EQ 150MG BASE**	**N050641**	**004**	Feb 17, 2022

ORACEA

	+!	GALDERMA LABS LP	40MG	N050805	001	May 26, 2006

FOR SUSPENSION;ORAL

DOXYCYCLINE

AB		CHARTWELL	**EQ 25MG BASE/5ML**	**A065454**	**001**	Jul 16, 2008
AB		LUPIN LTD	**EQ 25MG BASE/5ML**	**A201678**	**001**	Mar 18, 2013

VIBRAMYCIN

AB	**+!**	PFIZER	**EQ 25MG BASE/5ML**	**N050006**	**001**	

TABLET;ORAL

DOXYCYCLINE

AB		HERITAGE PHARMS	**EQ 50MG BASE**	**A091605**	**001**	Dec 20, 2011
AB			**EQ 75MG BASE**	**A091605**	**002**	Dec 20, 2011
AB			**EQ 100MG BASE**	**A091605**	**003**	Dec 20, 2011
AB	**!**		**EQ 150MG BASE**	**A091605**	**004**	Dec 20, 2011
AB		LANNETT CO INC	**EQ 50MG BASE**	**A065285**	**001**	Dec 08, 2005
AB			**EQ 75MG BASE**	**A065285**	**003**	Jul 30, 2008
AB			**EQ 100MG BASE**	**A065285**	**002**	Dec 08, 2005
AB			**EQ 150MG BASE**	**A065285**	**004**	Jul 30, 2008
AB		STRIDES PHARMA	**EQ 50MG BASE**	**A065070**	**001**	Dec 15, 2000
AB			**EQ 75MG BASE**	**A065070**	**003**	Dec 30, 2002
AB			**EQ 100MG BASE**	**A065070**	**002**	Dec 15, 2000
AB			**EQ 150MG BASE**	**A065070**	**004**	Jul 14, 2005
AB		SUN PHARM INDS LTD	**EQ 50MG BASE**	**A065356**	**001**	May 31, 2006
AB			**EQ 75MG BASE**	**A065356**	**002**	May 31, 2006
AB			**EQ 100MG BASE**	**A065356**	**003**	May 31, 2006
AB			**EQ 150MG BASE**	**A065356**	**004**	Jul 29, 2010
AB		ZYDUS PHARMS	**EQ 50MG BASE**	**A209582**	**001**	Sep 28, 2017
AB			**EQ 75MG BASE**	**A209582**	**002**	Sep 28, 2017
AB			**EQ 100MG BASE**	**A209582**	**003**	Sep 28, 2017
AB			**EQ 150MG BASE**	**A209582**	**004**	Sep 28, 2017

DOXYCYCLINE CALCIUM

SUSPENSION;ORAL

VIBRAMYCIN

	+!	PFIZER	EQ 50MG BASE/5ML	N050480	001	

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB		ACTAVIS LABS FL INC	**EQ 50MG BASE**	**A062031**	**002**	Oct 13, 1982
AB			**EQ 100MG BASE**	**A062031**	**001**	
AB		ALEMBIC	**EQ 50MG BASE**	**A210527**	**001**	Jun 13, 2018
AB			**EQ 100MG BASE**	**A210527**	**002**	Jun 13, 2018
AB		AMNEAL PHARMS	**EQ 100MG BASE**	**A207289**	**001**	Jun 27, 2016
AB		CADILA	**EQ 50MG BASE**	**A207774**	**001**	May 31, 2018

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB			**EQ 100MG BASE**	**A207774**	**002**	May 31, 2018
AB		CHANGZHOU PHARM	**EQ 100MG BASE**	**A209402**	**001**	Oct 07, 2019
AB		CHARTWELL	**EQ 50MG BASE**	**A062500**	**001**	Sep 11, 1984
AB			**EQ 100MG BASE**	**A062500**	**002**	Sep 11, 1984
AB		HIKMA INTL PHARMS	**EQ 50MG BASE**	**A062396**	**002**	Nov 07, 1984
AB			**EQ 100MG BASE**	**A062396**	**001**	May 07, 1984
AB		SUN PHARM INDUSTRIES	**EQ 50MG BASE**	**A062676**	**002**	Jul 10, 1986
AB			**EQ 100MG BASE**	**A062676**	**001**	Jul 10, 1986

VIBRAMYCIN

AB	**+!**	PFIZER	**EQ 100MG BASE**	**N050007**	**002**	

INJECTABLE;INJECTION

DOXY 100

AP	**!**	FRESENIUS KABI USA	**EQ 100MG BASE/VIAL**	**A062475**	**001**	Dec 09, 1983

DOXY 200

AP	**!**	FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A062475**	**002**	Dec 09, 1983

DOXYCYCLINE

AP		MYLAN LABS LTD	**EQ 100MG BASE/VIAL**	**A091406**	**001**	Aug 21, 2012
AP	**!**	ZYDUS PHARMS	**EQ 100MG BASE/VIAL**	**A207757**	**001**	Sep 28, 2017
AP			**EQ 200MG BASE/VIAL**	**A207757**	**002**	Sep 28, 2017

DOXYCYCLINE HYCLATE

AP		GLAND PHARMA LTD	**EQ 100MG BASE/VIAL**	**A215583**	**001**	Apr 12, 2023
AP		WEST-WARD PHARMS INT	**EQ 100MG BASE/VIAL**	**A062992**	**001**	Feb 16, 1989
AP			**EQ 200MG BASE/VIAL**	**A062992**	**002**	Feb 16, 1989

TABLET;ORAL

ACTICLATE

AB	**+**	ALMIRALL	**EQ 75MG BASE**	**N205931**	**001**	Jul 25, 2014
AB	**+!**		**EQ 150MG BASE**	**N205931**	**002**	Jul 25, 2014

DOXYCYCLINE HYCLATE

AB		ACELLA	**EQ 100MG BASE**	**A210664**	**001**	Mar 16, 2020
AB		ACTAVIS LABS FL INC	**EQ 100MG BASE**	**A062421**	**001**	Feb 02, 1983
AB		AJANTA PHARMA LTD	**EQ 75MG BASE**	**A211584**	**001**	Jun 01, 2020
AB			**EQ 150MG BASE**	**A211584**	**002**	Jun 01, 2020
AB		ALEMBIC	**EQ 20MG BASE**	**A210537**	**001**	Mar 03, 2020
AB			**EQ 50MG BASE**	**A210536**	**002**	Sep 14, 2021
AB			**EQ 75MG BASE**	**A211744**	**001**	Jun 30, 2020
AB			**EQ 150MG BASE**	**A211744**	**002**	Jun 30, 2020
AB		APOTEX	**EQ 75MG BASE**	**A209243**	**001**	Apr 15, 2019
AB			**EQ 150MG BASE**	**A209243**	**002**	Apr 15, 2019
AB		CADILA	**EQ 100MG BASE**	**A207773**	**001**	Oct 30, 2017
AB		CARIBE HOLDINGS	**EQ 50MG BASE**	**A062269**	**003**	Oct 05, 1983
AB	**!**		**EQ 100MG BASE**	**A062269**	**002**	Nov 08, 1982
AB		CHANGZHOU PHARM	**EQ 100MG BASE**	**A211343**	**001**	Oct 09, 2019
AB		CHARTWELL	**EQ 50MG BASE**	**A062505**	**002**	Jul 27, 2021
AB			**EQ 100MG BASE**	**A062505**	**001**	Sep 11, 1984
AB	**!**	CHARTWELL MOLECULAR	**EQ 20MG BASE**	**A065277**	**001**	Nov 10, 2005
AB		DR REDDYS LABS SA	**EQ 75MG BASE**	**A208765**	**001**	Jun 14, 2017
AB			**EQ 150MG BASE**	**A208765**	**002**	Jun 14, 2017
AB		EPIC PHARMA LLC	**EQ 20MG BASE**	**A065182**	**001**	May 13, 2005
AB			**EQ 75MG BASE**	**A214207**	**001**	Dec 16, 2020
AB			**EQ 150MG BASE**	**A214207**	**002**	Dec 16, 2020
AB		HIKMA INTL PHARMS	**EQ 100MG BASE**	**A065095**	**001**	Jul 02, 2003
AB		LARKEN LABS	**EQ 20MG BASE**	**A065287**	**001**	Feb 28, 2006
AB		LUPIN LTD	**EQ 75MG BASE**	**A208818**	**001**	Sep 27, 2017
AB			**EQ 150MG BASE**	**A208818**	**002**	Sep 27, 2017
AB		MYLAN	**EQ 100MG BASE**	**A062432**	**001**	Feb 15, 1983
AB		NOVEL LABS INC	**EQ 100MG BASE**	**A207558**	**001**	Sep 06, 2017
AB		SUN PHARM INDUSTRIES	**EQ 20MG BASE**	**A065134**	**001**	May 13, 2005
AB			**EQ 100MG BASE**	**A062677**	**001**	Jul 10, 1986

TABLET, DELAYED RELEASE;ORAL

DORYX

AB	**+**	MAYNE PHARMA	**EQ 75MG BASE**	**N050795**	**001**	May 06, 2005
AB	**+**		**EQ 150MG BASE**	**N050795**	**003**	Jun 20, 2008
AB	**+**		**EQ 200MG BASE**	**N050795**	**005**	Apr 11, 2013

DOXYCYCLINE HYCLATE

AB		ACTAVIS ELIZABETH	**EQ 50MG BASE**	**A090134**	**003**	May 22, 2018
AB			**EQ 75MG BASE**	**A090134**	**001**	Dec 14, 2011
AB			**EQ 100MG BASE**	**A090134**	**002**	Dec 14, 2011

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

AB			**EQ 200MG BASE**	**A090134**	**004**	May 22, 2018
AB		ALEMBIC	**EQ 75MG BASE**	**A213075**	**001**	Jan 03, 2022
AB			**EQ 100MG BASE**	**A213075**	**002**	Jan 03, 2022
AB			**EQ 150MG BASE**	**A213075**	**003**	Jan 03, 2022
AB			**EQ 200MG BASE**	**A213075**	**004**	Jan 03, 2022
AB		HERITAGE PHARMS	**EQ 75MG BASE**	**A200856**	**001**	Apr 30, 2013
AB			**EQ 100MG BASE**	**A200856**	**002**	Apr 30, 2013
AB			**EQ 150MG BASE**	**A200856**	**003**	Apr 30, 2013
AB	**!**		**EQ 200MG BASE**	**A200856**	**004**	Nov 13, 2018
AB		PRINSTON INC	**EQ 50MG BASE**	**A207494**	**003**	Feb 19, 2019
AB			**EQ 150MG BASE**	**A207494**	**001**	Nov 15, 2016
AB			**EQ 200MG BASE**	**A207494**	**002**	Nov 15, 2016

DORYX

+	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013

DORYX MPC

+	MAYNE PHARMA	EQ 60MG BASE	N050795	007	May 20, 2016

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DICLEGIS

AB	**+!**	DUCHESNAY	**10MG;10MG**	**N021876**	**001**	Apr 08, 2013

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**10MG;10MG**	**A205811**	**001**	Aug 19, 2016
AB		BIONPHARMA	**10MG;10MG**	**A217000**	**001**	Aug 04, 2023
AB		MYLAN PHARMS INC	**10MG;10MG**	**A207825**	**001**	Jul 06, 2020
AB		PAR PHARM INC	**10MG;10MG**	**A208518**	**001**	Dec 06, 2017

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

+!	DUCHESNAY	20MG;20MG	N209661	001	Nov 07, 2016

DRONABINOL

CAPSULE;ORAL

DRONABINOL

AB		ASCENT PHARMS INC	**2.5MG**	**A207421**	**001**	Feb 07, 2020
AB			**5MG**	**A207421**	**002**	Feb 07, 2020
AB			**10MG**	**A207421**	**003**	Feb 07, 2020
AB		HIKMA	**2.5MG**	**A079217**	**001**	Jun 20, 2014
AB			**5MG**	**A079217**	**002**	Jun 20, 2014
AB			**10MG**	**A079217**	**003**	Jun 20, 2014
AB		SVC PHARMA	**2.5MG**	**A078292**	**001**	Jun 27, 2008
AB			**5MG**	**A078292**	**002**	Jun 27, 2008
AB			**10MG**	**A078292**	**003**	Jun 27, 2008

MARINOL

AB	**+**	ALKEM LABS LTD	**2.5MG**	**N018651**	**001**	May 31, 1985
AB	**+!**		**5MG**	**N018651**	**002**	May 31, 1985
AB	**+**		**10MG**	**N018651**	**003**	May 31, 1985

SOLUTION;ORAL

SYNDROS

+!	BENUVIA OPERATIONS	5MG/ML	N205525	001	Mar 23, 2017

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

MULTAQ

+!	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

!	AM REGENT	2.5MG/ML	A072123	001	Oct 24, 1988

DROSPIRENONE

TABLET;ORAL

SLYND

+!	EXELTIS USA INC	4MG	N211367	001	May 23, 2019

DROSPIRENONE; ESTETROL

TABLET;ORAL

NEXTSTELLIS

+!	MAYNE PHARMA	3MG;14.2MG	N214154	001	Apr 15, 2021

DROSPIRENONE; ESTRADIOL

TABLET;ORAL

ANGELIQ

+	BAYER HLTHCARE	0.25MG;0.5MG	N021355	001	Feb 29, 2012
+!		0.5MG;1MG	N021355	002	Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	GLENMARK PHARMS LTD	**3MG;0.02MG**	**A204296**	**001**	Aug 17, 2015
AB	HETERO LABS	**3MG;0.02MG**	**A211944**	**001**	Mar 22, 2019
AB	HLTHCARE	**3MG;0.02MG**	**A203291**	**001**	Jul 18, 2017
AB	MYLAN LABS LTD	**3MG;0.02MG**	**A202594**	**001**	Oct 22, 2015
AB	WATSON LABS	**3MG;0.02MG**	**A078833**	**001**	Nov 28, 2011

LO-ZUMANDIMINE

AB	AUROBINDO PHARMA LTD	**3MG;0.02MG**	**A209632**	**001**	Feb 27, 2018

LORYNA

AB	XIROMED	**3MG;0.02MG**	**A079221**	**001**	Mar 28, 2011

MELAMISA

AB	NOVAST LABS	**3MG;0.02MG**	**A202016**	**001**	Jan 26, 2016

NIKKI

AB	LUPIN LTD	**3MG;0.02MG**	**A201661**	**001**	May 27, 2014

YAZ

AB **+!**	BAYER HLTHCARE	**3MG;0.02MG**	**N021676**	**001**	Mar 16, 2006

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	DR REDDYS LABS SA	**3MG;0.03MG**	**A090081**	**001**	Sep 07, 2010
AB	GLENMARK PHARMS LTD	**3MG;0.03MG**	**A204848**	**001**	Mar 25, 2016
AB	HETERO LABS	**3MG;0.03MG**	**A213034**	**001**	Jan 24, 2020
AB	LUPIN LTD	**3MG;0.03MG**	**A201663**	**001**	Dec 18, 2012
AB	MYLAN LABS LTD	**3MG;0.03MG**	**A202131**	**001**	May 04, 2015
AB	NAARI PTE LTD	**3MG;0.03MG**	**A207245**	**001**	Nov 22, 2016

SYEDA

AB	XIROMED	**3MG;0.03MG**	**A090114**	**001**	Mar 28, 2011

YAELA

AB	NOVAST LABS	**3MG;0.03MG**	**A202015**	**001**	Nov 19, 2014

YASMIN

AB **+!**	BAYER HLTHCARE	**3MG;0.03MG**	**N021098**	**001**	May 11, 2001

ZUMANDIMINE

AB	AUROBINDO PHARMA LTD	**3MG;0.03MG**	**A209407**	**001**	Mar 26, 2018

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

BEYAZ

AB **+!**	BAYER HLTHCARE	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**N022532**	**001**	Sep 24, 2010

DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM

AB	LUPIN LTD	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**A205947**	**001**	Jun 13, 2018
AB	WATSON LABS INC	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**A203593**	**001**	Oct 11, 2016
AB		**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**A203594**	**001**	Oct 11, 2016

SAFYRAL

AB **+!**	BAYER HLTHCARE	**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**N022574**	**001**	Dec 16, 2010

TYDEMY

AB	LUPIN LTD	**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**A205948**	**001**	Dec 12, 2017

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

AB	AJANTA PHARMA LTD	**100MG**	**A214391**	**001**	Feb 18, 2021
AB		**200MG**	**A214391**	**002**	Feb 18, 2021
AB		**300MG**	**A214391**	**003**	Feb 18, 2021
AB	ALKEM LABS LTD	**100MG**	**A213911**	**001**	Feb 18, 2021
AB		**200MG**	**A213911**	**002**	Feb 18, 2021
AB		**300MG**	**A213911**	**003**	Feb 18, 2021
AB	ANNORA	**100MG**	**A211726**	**002**	Aug 09, 2021
AB		**200MG**	**A211726**	**003**	Aug 09, 2021
AB		**300MG**	**A211726**	**001**	Feb 18, 2021
AB	AUROBINDO PHARMA LTD	**100MG**	**A214387**	**001**	Feb 18, 2021
AB		**200MG**	**A214387**	**002**	Feb 18, 2021
AB		**300MG**	**A214387**	**003**	Feb 18, 2021
AB	BIONPHARMA	**100MG**	**A213033**	**001**	Apr 28, 2021
AB		**200MG**	**A213033**	**002**	Apr 28, 2021

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA						
AB			**300MG**	**A213033**	**003**	Apr 28, 2021
AB		BLUEPHARMA INDUSTRIA	**100MG**	**A214543**	**001**	May 05, 2021
AB			**200MG**	**A214543**	**002**	May 05, 2021
AB			**300MG**	**A214543**	**003**	May 05, 2021
AB		LUPIN PHARMS	**100MG**	**A211652**	**001**	Feb 18, 2021
AB			**200MG**	**A211652**	**002**	Feb 18, 2021
AB			**300MG**	**A211652**	**003**	Feb 18, 2021
AB		MSN PHARMS INC	**100MG**	**A211741**	**001**	Feb 18, 2021
AB			**200MG**	**A211741**	**002**	Feb 18, 2021
AB			**300MG**	**A211741**	**003**	Feb 18, 2021
AB		SCIEGEN PHARMS INC	**100MG**	**A214017**	**001**	Feb 18, 2021
AB			**200MG**	**A214017**	**002**	Feb 18, 2021
AB			**300MG**	**A214017**	**003**	Feb 18, 2021
AB		SLATE RUN PHARMA	**100MG**	**A215265**	**001**	Nov 01, 2021
AB			**200MG**	**A215265**	**002**	Nov 01, 2021
AB			**300MG**	**A215265**	**003**	Nov 01, 2021
AB		SUN PHARM	**100MG**	**A214384**	**001**	Feb 18, 2021
AB			**200MG**	**A214384**	**002**	Feb 18, 2021
AB			**300MG**	**A214384**	**003**	Feb 18, 2021
AB		UPSHER SMITH LABS	**100MG**	**A213661**	**001**	Feb 18, 2021
AB			**200MG**	**A213661**	**002**	Feb 18, 2021
AB			**300MG**	**A213661**	**003**	Feb 18, 2021
AB		ZYDUS PHARMS	**100MG**	**A211818**	**001**	Feb 18, 2021
AB			**200MG**	**A211818**	**002**	Feb 18, 2021
AB			**300MG**	**A211818**	**003**	Feb 18, 2021
NORTHERA						
AB	**+**	LUNDBECK NA LTD	**100MG**	**N203202**	**001**	Feb 18, 2014
AB	**+**		**200MG**	**N203202**	**002**	Feb 18, 2014
AB	**+!**		**300MG**	**N203202**	**003**	Feb 18, 2014

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

CYMBALTA						
AB	**+**	LILLY	**EQ 20MG BASE**	**N021427**	**001**	Aug 03, 2004
AB	**+**		**EQ 30MG BASE**	**N021427**	**002**	Aug 03, 2004
AB	**+!**		**EQ 60MG BASE**	**N021427**	**004**	Aug 03, 2004
DULOXETINE HYDROCHLORIDE						
AB		ACTAVIS ELIZABETH	**EQ 20MG BASE**	**A090776**	**001**	Dec 17, 2013
AB			**EQ 30MG BASE**	**A090776**	**002**	Dec 17, 2013
AB			**EQ 60MG BASE**	**A090776**	**003**	Dec 17, 2013
AB		AJANTA PHARMA LTD	**EQ 20MG BASE**	**A208706**	**001**	Jan 06, 2017
AB			**EQ 30MG BASE**	**A208706**	**002**	Jan 06, 2017
AB			**EQ 40MG BASE**	**A208706**	**004**	Mar 11, 2019
AB			**EQ 60MG BASE**	**A208706**	**003**	Jan 06, 2017
AB		ALEMBIC	**EQ 20MG BASE**	**A202949**	**001**	Jun 09, 2014
AB			**EQ 30MG BASE**	**A202949**	**002**	Jun 09, 2014
AB			**EQ 60MG BASE**	**A202949**	**003**	Jun 09, 2014
AB		ALKEM LABS LTD	**EQ 20MG BASE**	**A203197**	**001**	Aug 26, 2015
AB			**EQ 30MG BASE**	**A203197**	**002**	Aug 26, 2015
AB			**EQ 60MG BASE**	**A203197**	**003**	Aug 26, 2015
AB		ANCHEN PHARMS	**EQ 20MG BASE**	**A090780**	**001**	Oct 28, 2015
AB			**EQ 30MG BASE**	**A090780**	**002**	Oct 28, 2015
AB			**EQ 60MG BASE**	**A090780**	**003**	Oct 28, 2015
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A090778**	**001**	Dec 11, 2013
AB			**EQ 30MG BASE**	**A090778**	**002**	Dec 11, 2013
AB			**EQ 60MG BASE**	**A090778**	**003**	Dec 11, 2013
AB		BRECKENRIDGE	**EQ 20MG BASE**	**A203088**	**001**	Jun 11, 2014
AB			**EQ 30MG BASE**	**A203088**	**002**	Jun 11, 2014
AB			**EQ 40MG BASE**	**A203088**	**004**	May 18, 2018
AB			**EQ 60MG BASE**	**A203088**	**003**	Jun 11, 2014
AB		CSPC OUYI	**EQ 20MG BASE**	**A211310**	**001**	Oct 16, 2018
AB			**EQ 30MG BASE**	**A211310**	**002**	Oct 16, 2018
AB			**EQ 60MG BASE**	**A211310**	**003**	Oct 16, 2018
AB		HETERO LABS LTD III	**EQ 20MG BASE**	**A204343**	**001**	Aug 03, 2016
AB			**EQ 30MG BASE**	**A204343**	**002**	Aug 03, 2016
AB			**EQ 60MG BASE**	**A204343**	**003**	Aug 03, 2016
AB		INVENTIA	**EQ 20MG BASE**	**A202336**	**001**	Oct 28, 2015
AB			**EQ 30MG BASE**	**A202336**	**002**	Oct 28, 2015

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB			**EQ 60MG BASE**	**A202336**	**003**	Oct 28, 2015
AB		LUPIN LTD	**EQ 20MG BASE**	**A090694**	**001**	Dec 11, 2013
AB			**EQ 30MG BASE**	**A090694**	**002**	Dec 11, 2013
AB			**EQ 40MG BASE**	**A090694**	**003**	Dec 11, 2013
AB			**EQ 60MG BASE**	**A090694**	**004**	Dec 11, 2013
AB		MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A204815**	**001**	Mar 23, 2017
AB			**EQ 30MG BASE**	**A204815**	**002**	Mar 23, 2017
AB			**EQ 60MG BASE**	**A204815**	**003**	Mar 23, 2017
AB		MARKSANS PHARMA	**EQ 20MG BASE**	**A090723**	**001**	Dec 11, 2013
AB			**EQ 30MG BASE**	**A090723**	**002**	Dec 11, 2013
AB			**EQ 60MG BASE**	**A090723**	**003**	Dec 11, 2013
AB		PRINSTON INC	**EQ 20MG BASE**	**A206653**	**001**	May 18, 2017
AB			**EQ 30MG BASE**	**A206653**	**002**	May 18, 2017
AB			**EQ 60MG BASE**	**A206653**	**003**	May 18, 2017
AB		QINGDAO BAHEAL PHARM	**EQ 20MG BASE**	**A210599**	**001**	Apr 17, 2019
AB			**EQ 30MG BASE**	**A210599**	**002**	Apr 17, 2019
AB			**EQ 60MG BASE**	**A210599**	**003**	Apr 17, 2019
AB		SUN PHARM	**EQ 20MG BASE**	**A090745**	**001**	Dec 11, 2013
AB			**EQ 30MG BASE**	**A090745**	**002**	Dec 11, 2013
AB			**EQ 60MG BASE**	**A090745**	**003**	Dec 11, 2013
AB		SUNSHINE	**EQ 20MG BASE**	**A212328**	**001**	Feb 11, 2021
AB			**EQ 30MG BASE**	**A212328**	**002**	Feb 11, 2021
AB			**EQ 60MG BASE**	**A212328**	**003**	Feb 11, 2021
AB		TORRENT	**EQ 20MG BASE**	**A090774**	**001**	Dec 11, 2013
AB			**EQ 30MG BASE**	**A090774**	**002**	Dec 11, 2013
AB			**EQ 60MG BASE**	**A090774**	**003**	Dec 11, 2013
AB		ZYDUS HLTHCARE	**EQ 20MG BASE**	**A090739**	**001**	Jan 08, 2014
AB			**EQ 30MG BASE**	**A090739**	**002**	Jan 08, 2014
AB			**EQ 40MG BASE**	**A090739**	**004**	Apr 18, 2023
AB			**EQ 60MG BASE**	**A090739**	**003**	Jan 08, 2014
AB		ZYDUS PHARMS	**EQ 20MG BASE**	**A090728**	**001**	Jan 08, 2014
AB			**EQ 30MG BASE**	**A090728**	**002**	Jan 08, 2014
AB			**EQ 60MG BASE**	**A090728**	**003**	Jan 08, 2014

DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

POWDER;INTRAVENOUS

XACDURO (COPACKAGED)

	+!	ENTASIS THERAP	EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL	N216974	001	May 23, 2023

DUTASTERIDE

CAPSULE;ORAL

AVODART

AB	**+!**	WOODWARD	**0.5MG**	**N021319**	**001**	Nov 20, 2001

DUTASTERIDE

AB		ACELLA	**0.5MG**	**A206373**	**001**	Mar 17, 2016
AB		ADAPTIS	**0.5MG**	**A204376**	**001**	Apr 07, 2017
AB		AMNEAL PHARMS	**0.5MG**	**A203118**	**001**	Nov 20, 2015
AB		ASCENT PHARMS INC	**0.5MG**	**A206574**	**001**	Oct 21, 2016
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A202660**	**001**	Nov 20, 2015
AB		BARR	**0.5MG**	**A090095**	**001**	Dec 21, 2010
AB		BIONPHARMA	**0.5MG**	**A200899**	**001**	Nov 20, 2015
AB		CADILA	**0.5MG**	**A204373**	**001**	Oct 04, 2017
AB		HUMANWELL PURACAP	**0.5MG**	**A209909**	**001**	Nov 21, 2017
AB		STRIDES PHARMA	**0.5MG**	**A204262**	**001**	Nov 20, 2015
AB		VINTAGE	**0.5MG**	**A202421**	**001**	Nov 20, 2015

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		ANCHEN PHARMS	**0.5MG;0.4MG**	**A202509**	**001**	Feb 26, 2014
AB		ZYDUS PHARMS	**0.5MG;0.4MG**	**A207769**	**001**	May 24, 2018

JALYN

AB	**+!**	WOODWARD	**0.5MG;0.4MG**	**N022460**	**001**	Jun 14, 2010

DUVELISIB						
CAPSULE;ORAL						
COPIKTRA						
+		SECURA	15MG	N211155	001	Sep 24, 2018
+			25MG	N211155	002	Sep 24, 2018
DYCLONINE HYDROCHLORIDE						
SOLUTION;TOPICAL						
DYCLOPRO						
!		SEPTODONT	0.5%	A200480	001	Nov 20, 2018
!			1%	A200480	002	Nov 20, 2018
ECHOTHIOPHATE IODIDE						
FOR SOLUTION;OPHTHALMIC						
PHOSPHOLINE IODIDE						
+!		FERA PHARMS LLC	0.125%	N011963	001	
ECONAZOLE NITRATE						
AEROSOL, FOAM;TOPICAL						
ECOZA						
+!		RESILIA PHARMS	1%	N205175	001	Oct 24, 2013
CREAM;TOPICAL						
ECONAZOLE NITRATE						
AB	**!**	PADAGIS ISRAEL	**1%**	**A076479**	**001**	Jun 23, 2004
AB		TARO	**1%**	**A076005**	**001**	Nov 26, 2002
EDARAVONE						
SOLUTION;INTRAVENOUS						
RADICAVA						
+!		MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017
+!			60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018
SUSPENSION;ORAL						
RADICAVA ORS						
+!		MITSUBISHI TANABE	105MG/5ML	N215446	001	May 12, 2022
EDETATE CALCIUM DISODIUM						
INJECTABLE;INJECTION						
EDETATE CALCIUM DISODIUM						
!		CASPER PHARMA LLC	200MG/ML	A216435	001	May 03, 2023
EDOXABAN TOSYLATE						
TABLET;ORAL						
SAVAYSA						
+		DAIICHI SANKYO INC	EQ 15MG BASE	N206316	001	Jan 08, 2015
+			EQ 30MG BASE	N206316	002	Jan 08, 2015
+!			EQ 60MG BASE	N206316	003	Jan 08, 2015
EFAVIRENZ						
CAPSULE;ORAL						
EFAVIRENZ						
		AUROBINDO PHARMA	50MG	A078064	001	Dec 15, 2017
			100MG	A078064	002	Dec 15, 2017
!			200MG	A078064	003	Dec 15, 2017
TABLET;ORAL						
EFAVIRENZ						
AB		AUROBINDO PHARMA LTD	**600MG**	**A077673**	**001**	Sep 21, 2018
AB		CIPLA	**600MG**	**A204766**	**001**	Jun 15, 2018
AB	**!**	HETERO LABS LTD III	**600MG**	**A078886**	**001**	Apr 27, 2018
AB		STRIDES PHARMA	**600MG**	**A204869**	**001**	Mar 12, 2018
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE						
TABLET;ORAL						
ATRIPLA						
AB	**+!**	GILEAD SCIENCES	**600MG;200MG;300MG**	**N021937**	**001**	Jul 12, 2006
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE						
AB		AUROBINDO PHARMA	**600MG;200MG;300MG**	**A203041**	**001**	Sep 04, 2018
AB		CIPLA	**600MG;200MG;300MG**	**A206894**	**001**	Jun 03, 2019
AB		HETERO LABS LTD V	**600MG;200MG;300MG**	**A203053**	**001**	Jan 24, 2022
AB		LAURUS	**600MG;200MG;300MG**	**A213541**	**001**	Dec 22, 2021
AB		MACLEODS PHARMS LTD	**600MG;200MG;300MG**	**A204287**	**001**	Sep 13, 2021
AB		TEVA PHARMS USA	**600MG;200MG;300MG**	**A091215**	**001**	Nov 09, 2018
EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE						
AB		STRIDES PHARMA	**600MG;200MG;300MG**	**A201802**	**001**	Oct 03, 2023

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		LAURUS	**400MG;300MG;300MG**	**A213038**	**001**	May 14, 2020
AB			**600MG;300MG;300MG**	**A212786**	**001**	May 14, 2020

SYMFI

AB	**+!**	MYLAN LABS LTD	**600MG;300MG;300MG**	**N022142**	**001**	Mar 22, 2018

SYMFI LO

AB	**+!**	MYLAN	**400MG;300MG;300MG**	**N208255**	**001**	Feb 05, 2018

EFINACONAZOLE

SOLUTION;TOPICAL

EFINACONAZOLE

AB		NIVAGEN PHARMS INC	**10%**	**A211969**	**001**	Jun 21, 2021
AB		TEVA PHARMS USA	**10%**	**A211827**	**001**	Dec 16, 2020

JUBLIA

AB	**+!**	BAUSCH	**10%**	**N203567**	**001**	Jun 06, 2014

EFLORNITHINE HYDROCHLORIDE

TABLET;ORAL

IWILFIN

	+!	USWM	EQ 192MG BASE	N215500	001 Dec 13, 2023

ELACESTRANT DIHYDROCHLORIDE

TABLET;ORAL

ORSERDU

	+	STEMLINE THERAP	EQ 86MG BASE	N217639	001 Jan 27, 2023
	+!		EQ 345MG BASE	N217639	002 Jan 27, 2023

ELAGOLIX SODIUM

TABLET;ORAL

ORILISSA

	+	ABBVIE	EQ 150MG BASE	N210450	001 Jul 23, 2018
	+!		EQ 200MG BASE	N210450	002 Jul 23, 2018

ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM

CAPSULE;ORAL

ORIAHNN (COPACKAGED)

	+!	ABBVIE	EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE	N213388	001 May 29, 2020

ELBASVIR; GRAZOPREVIR

TABLET;ORAL

ZEPATIER

	+!	MSD SUB MERCK	50MG;100MG	N208261	001 Jan 28, 2016

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

AB		AJANTA PHARMA LTD	**EQ 20MG BASE**	**A205186**	**001**	Aug 29, 2017
AB			**EQ 40MG BASE**	**A205186**	**002**	Aug 29, 2017
AB		AUROBINDO PHARMA	**EQ 20MG BASE**	**A210708**	**001**	Jan 15, 2019
AB			**EQ 40MG BASE**	**A210708**	**002**	Jan 15, 2019
AB		BEXIMCO PHARMS USA	**EQ 20MG BASE**	**A215467**	**001**	Jul 13, 2022
AB			**EQ 40MG BASE**	**A215467**	**002**	Jul 13, 2022
AB		MYLAN	**EQ 20MG BASE**	**A205152**	**001**	Aug 11, 2017
AB			**EQ 40MG BASE**	**A205152**	**002**	Aug 11, 2017
AB		TEVA PHARMS USA	**EQ 20MG BASE**	**A202040**	**001**	Jun 27, 2017
AB			**EQ 40MG BASE**	**A202040**	**002**	Jun 27, 2017
AB		ZYDUS PHARMS	**EQ 20MG BASE**	**A206409**	**001**	Jun 16, 2017
AB			**EQ 40MG BASE**	**A206409**	**002**	Jun 16, 2017

RELPAX

AB	**+**	UPJOHN	**EQ 20MG BASE**	**N021016**	**001**	Dec 26, 2002
AB	**+!**		**EQ 40MG BASE**	**N021016**	**002**	Dec 26, 2002

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

GRANULES;ORAL

TRIKAFTA (COPACKAGED)

	+	VERTEX PHARMS INC	80MG, 60MG, 40MG;59.5MG	N217660	001 Apr 26, 2023
	+!		100MG, 75MG, 50MG;75MG	N217660	002 Apr 26, 2023

TABLET;ORAL

TRIKAFTA (COPACKAGED)

	+	VERTEX PHARMS INC	50MG,37.5MG,25MG; 75MG	N212273	002 Jun 08, 2021
	+!		100MG,75MG,50MG; 150MG	N212273	001 Oct 21, 2019

ELIGLUSTAT TARTRATE
CAPSULE;ORAL

CERDELGA						
AB	**+!**	GENZYME CORP	**EQ 84MG BASE**	**N205494**	**001**	Aug 19, 2014
ELIGLUSTAT TARTRATE						
AB		AIZANT	**EQ 84MG BASE**	**A212463**	**001**	Sep 08, 2021
AB		UPSHER SMITH LABS	**EQ 84MG BASE**	**A212420**	**001**	May 02, 2023

ELTROMBOPAG CHOLINE
TABLET;ORAL

ALVAIZ					
+	TEVA PHARMS INC	EQ 9MG BASE	N216774	001	Nov 29, 2023
+		EQ 18MG BASE	N216774	002	Nov 29, 2023
+		EQ 36MG BASE	N216774	003	Nov 29, 2023
+!		EQ 54MG BASE	N216774	004	Nov 29, 2023

ELTROMBOPAG OLAMINE
FOR SUSPENSION;ORAL

PROMACTA KIT					
+	NOVARTIS	EQ 12.5MG ACID/PACKET	N207027	002	Sep 27, 2018
+!		EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015

TABLET;ORAL

PROMACTA					
+	NOVARTIS	EQ 12.5MG ACID	N022291	004	Oct 20, 2011
+		EQ 25MG ACID	N022291	001	Nov 20, 2008
+		EQ 50MG ACID	N022291	002	Nov 20, 2008
+!		EQ 75MG ACID	N022291	003	Sep 08, 2009

ELUXADOLINE
TABLET;ORAL

VIBERZI					
+	ABBVIE	75MG	N206940	001	May 27, 2015
+!		100MG	N206940	002	May 27, 2015

EMPAGLIFLOZIN
TABLET;ORAL

JARDIANCE					
+	BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014
+!		25MG	N204629	002	Aug 01, 2014

EMPAGLIFLOZIN; LINAGLIPTIN
TABLET;ORAL

GLYXAMBI					
+	BOEHRINGER INGELHEIM	10MG;5MG	N206073	001	Jan 30, 2015
+!		25MG;5MG	N206073	002	Jan 30, 2015

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL

TRIJARDY XR					
+	BOEHRINGER INGELHEIM	5MG;2.5MG;1GM	N212614	001	Jan 27, 2020
+		10MG;5MG;1GM	N212614	002	Jan 27, 2020
+		12.5MG;2.5MG;1GM	N212614	003	Jan 27, 2020
+!		25MG;5MG;1GM	N212614	004	Jan 27, 2020

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
TABLET;ORAL

SYNJARDY					
+	BOEHRINGER INGELHEIM	5MG;500MG	N206111	001	Aug 26, 2015
+		5MG;1GM	N206111	002	Aug 26, 2015
+		12.5MG;500MG	N206111	003	Aug 26, 2015
+!		12.5MG;1GM	N206111	004	Aug 26, 2015

TABLET, EXTENDED RELEASE;ORAL

SYNJARDY XR					
+	BOEHRINGER INGELHEIM	5MG;1GM	N208658	001	Dec 09, 2016
+		10MG;1GM	N208658	002	Dec 09, 2016
+		12.5MG;1GM	N208658	003	Dec 09, 2016
+!		25MG;1GM	N208658	004	Dec 09, 2016

EMTRICITABINE						
CAPSULE;ORAL						
EMTRICITABINE						
AB		AUROBINDO PHARMA LTD	**200MG**	**A079188**	**001**	Mar 15, 2023
AB		CIPLA	**200MG**	**A091168**	**001**	Jul 02, 2018
EMTRIVA						
AB	**+!**	GILEAD	**200MG**	**N021500**	**001**	Jul 02, 2003
SOLUTION;ORAL						
EMTRIVA						
	+!	GILEAD	10MG/ML	N021896	001	Sep 28, 2005
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE						
TABLET;ORAL						
ODEFSEY						
	+!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE						
TABLET;ORAL						
COMPLERA						
	+!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE						
TABLET;ORAL						
DESCOVY						
	+	GILEAD SCIENCES INC	120MG;EQ 15MG BASE	N208215	002	Jan 07, 2022
	+!		200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE						
TABLET;ORAL						
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE						
AB		HETERO LABS LTD III	**200MG;300MG**	**A201806**	**001**	Oct 07, 2021
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE						
AB		AMNEAL PHARMS CO	**100MG;150MG**	**A209721**	**001**	Aug 22, 2018
AB			**133MG;200MG**	**A209721**	**002**	Aug 22, 2018
AB			**167MG;250MG**	**A209721**	**003**	Aug 22, 2018
AB			**200MG;300MG**	**A209721**	**004**	Aug 22, 2018
AB		AUROBINDO PHARMA	**200MG;300MG**	**A090513**	**001**	Jan 26, 2018
AB		AUROBINDO PHARMA LTD	**100MG;150MG**	**A211640**	**001**	Mar 09, 2023
AB			**133MG;200MG**	**A211640**	**002**	Mar 09, 2023
AB			**167MG;250MG**	**A211640**	**003**	Mar 09, 2023
AB		LAURUS	**200MG;300MG**	**A212114**	**001**	Jul 26, 2019
AB		LUPIN LTD	**200MG;300MG**	**A204131**	**001**	Jun 04, 2021
AB		MACLEODS PHARMS LTD	**200MG;300MG**	**A203442**	**001**	May 15, 2020
AB		MYLAN	**200MG;300MG**	**A206436**	**001**	Apr 09, 2018
AB		STRIDES PHARMA	**200MG;300MG**	**A091055**	**001**	Jan 13, 2021
AB		TEVA PHARMS USA	**200MG;300MG**	**A090894**	**001**	Jun 08, 2017
AB		ZYDUS PHARMS	**100MG;150MG**	**A212689**	**002**	Jul 01, 2021
AB			**133MG;200MG**	**A212689**	**003**	Jul 01, 2021
AB			**167MG;250MG**	**A212689**	**004**	Jul 01, 2021
AB			**200MG;300MG**	**A212689**	**001**	Feb 28, 2020
TRUVADA						
AB	**+**	GILEAD	**100MG;150MG**	**N021752**	**002**	Mar 10, 2016
AB	**+**		**133MG;200MG**	**N021752**	**003**	Mar 10, 2016
AB	**+**		**167MG;250MG**	**N021752**	**004**	Mar 10, 2016
AB	**+!**		**200MG;300MG**	**N021752**	**001**	Aug 02, 2004
ENALAPRIL MALEATE						
SOLUTION;ORAL						
ENALAPRIL MALEATE						
AB		ALKEM LABS LTD	**1MG/ML**	**A213714**	**001**	Mar 30, 2022
AB		ANNORA PHARMA	**1MG/ML**	**A214467**	**001**	Feb 24, 2022
AB		AUROBINDO PHARMA	**1MG/ML**	**A216458**	**001**	Jan 08, 2024
AB		BIONPHARMA	**1MG/ML**	**A212408**	**001**	Aug 10, 2021
EPANED						
AB	**+!**	AZURITY	**1MG/ML**	**N208686**	**001**	Sep 20, 2016
TABLET;ORAL						
ENALAPRIL MALEATE						
AB		HERITAGE PHARMA	**2.5MG**	**A075479**	**001**	Aug 22, 2000
AB			**5MG**	**A075479**	**002**	Aug 22, 2000
AB			**10MG**	**A075479**	**003**	Aug 22, 2000
AB			**20MG**	**A075479**	**004**	Aug 22, 2000
AB		PRINSTON INC	**2.5MG**	**A213273**	**001**	Jul 07, 2022
AB			**5MG**	**A213273**	**002**	Jul 07, 2022

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

AB			**10MG**	**A213273**	**003**	Jul 07, 2022
AB			**20MG**	**A213273**	**004**	Jul 07, 2022
AB		SANDOZ INC	**2.5MG**	**A075496**	**001**	Aug 22, 2000
AB			**5MG**	**A075496**	**002**	Aug 22, 2000
AB			**10MG**	**A075459**	**001**	Aug 22, 2000
AB			**20MG**	**A075459**	**002**	Aug 22, 2000
AB		TARO	**2.5MG**	**A075657**	**001**	Jan 23, 2001
AB			**5MG**	**A075657**	**002**	Jan 23, 2001
AB			**10MG**	**A075657**	**003**	Jan 23, 2001
AB			**20MG**	**A075657**	**004**	Jan 23, 2001
AB		WOCKHARDT LTD	**2.5MG**	**A075483**	**001**	Aug 22, 2000
AB			**5MG**	**A075483**	**002**	Aug 22, 2000
AB			**10MG**	**A075483**	**003**	Aug 22, 2000
AB			**20MG**	**A075483**	**004**	Aug 22, 2000

VASOTEC

AB	**+**	BAUSCH	**2.5MG**	**N018998**	**005**	Jul 26, 1988
AB	**+**		**5MG**	**N018998**	**001**	Dec 24, 1985
AB	**+**		**10MG**	**N018998**	**002**	Dec 24, 1985
AB	**+!**		**20MG**	**N018998**	**003**	Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB		COSETTE	**5MG;12.5MG**	**A075727**	**001**	Sep 18, 2001
AB			**10MG;25MG**	**A075727**	**002**	Sep 18, 2001
AB		DR REDDYS LABS LTD	**5MG;12.5MG**	**A075909**	**001**	Oct 15, 2001
AB			**10MG;25MG**	**A075909**	**002**	Oct 15, 2001
AB		TARO PHARM INDS	**5MG;12.5MG**	**A075788**	**001**	Sep 18, 2001
AB			**10MG;25MG**	**A075788**	**002**	Sep 18, 2001

VASERETIC

AB	**+**	BAUSCH	**5MG;12.5MG**	**N019221**	**003**	Jul 12, 1995
AB	**+!**		**10MG;25MG**	**N019221**	**001**	Oct 31, 1986

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP		CHARTWELL INJECTABLE	**1.25MG/ML**	**A075634**	**001**	Aug 22, 2000
AP		DR REDDYS	**1.25MG/ML**	**A075578**	**001**	Aug 22, 2000
AP	**!**	HIKMA FARMACEUTICA	**1.25MG/ML**	**A078687**	**001**	Dec 23, 2008
AP		HOSPIRA	**1.25MG/ML**	**A075458**	**001**	Aug 22, 2000

ENASIDENIB MESYLATE

TABLET;ORAL

IDHIFA

	+	BRISTOL MYERS SQUIBB	EQ 50MG BASE	N209606	001	Aug 01, 2017
	+!		EQ 100MG BASE	N209606	002	Aug 01, 2017

ENCORAFENIB

CAPSULE;ORAL

BRAFTOVI

	+!	ARRAY BIOPHARMA INC	75MG	N210496	002	Jun 27, 2018

ENFUVIRTIDE

INJECTABLE;SUBCUTANEOUS

FUZEON

	+!	ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB		AMPHASTAR PHARMS INC	**300MG/3ML (100MG/ML)**	**A208600**	**001**	Mar 14, 2019
AB		NANJING KING-FRIEND	**300MG/3ML (100MG/ML)**	**A214856**	**001**	Jun 14, 2022
AB		SANDOZ INC	**300MG/3ML (100MG/ML)**	**A078660**	**001**	Nov 28, 2011

LOVENOX

AB	**+**	SANOFI AVENTIS US	**300MG/3ML (100MG/ML)**	**N020164**	**009**	Jan 23, 2003

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP		AMPHASTAR PHARM	**30MG/0.3ML (100MG/ML)**	**A076684**	**001**	Sep 19, 2011
AP			**40MG/0.4ML (100MG/ML)**	**A076684**	**002**	Sep 19, 2011
AP			**60MG/0.6ML (100MG/ML)**	**A076684**	**003**	Sep 19, 2011

ENOXAPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP			**80MG/0.8ML (100MG/ML)**	**A076684**	**004**	Sep 19, 2011
AP			**100MG/ML (100MG/ML)**	**A076684**	**005**	Sep 19, 2011
AP			**120MG/0.8ML (150MG/ML)**	**A076684**	**006**	Sep 19, 2011
AP			**150MG/ML (150MG/ML)**	**A076684**	**007**	Sep 19, 2011
AP		BE PHARMS	**30MG/0.3ML (100MG/ML)**	**A214646**	**001**	Jun 06, 2023
AP			**40MG/0.4ML (100MG/ML)**	**A214646**	**002**	Jun 06, 2023
AP			**60MG/0.6ML (100MG/ML)**	**A214646**	**003**	Jun 06, 2023
AP			**80MG/0.8ML (100MG/ML)**	**A214646**	**004**	Jun 06, 2023
AP			**100MG/ML (100MG/ML)**	**A214646**	**005**	Jun 06, 2023
AP			**120MG/0.8ML (150MG/ML)**	**A214646**	**006**	Jun 06, 2023
AP			**150MG/ML (150MG/ML)**	**A214646**	**007**	Jun 06, 2023
AP		GLAND	**30MG/0.3ML (100MG/ML)**	**A078990**	**001**	Sep 28, 2018
AP			**40MG/0.4ML (100MG/ML)**	**A078990**	**002**	Sep 28, 2018
AP			**60MG/0.6ML (100MG/ML)**	**A078990**	**003**	Sep 28, 2018
AP			**80MG/0.8ML (100MG/ML)**	**A078990**	**004**	Sep 28, 2018
AP			**100MG/ML (100MG/ML)**	**A078990**	**005**	Sep 28, 2018
AP			**120MG/0.8ML (150MG/ML)**	**A078990**	**006**	Sep 28, 2018
AP			**150MG/ML (150MG/ML)**	**A078990**	**007**	Sep 28, 2018
AP		NANJING KING-FRIEND	**30MG/0.3ML (100MG/ML)**	**A206834**	**001**	Nov 29, 2019
AP			**40MG/0.4ML (100MG/ML)**	**A206834**	**002**	Nov 29, 2019
AP			**60MG/0.6ML (100MG/ML)**	**A206834**	**003**	Nov 29, 2019
AP			**80MG/0.8ML (100MG/ML)**	**A206834**	**004**	Nov 29, 2019
AP			**100MG/ML (100MG/ML)**	**A206834**	**005**	Nov 29, 2019
AP			**120MG/0.8ML (150MG/ML)**	**A206834**	**006**	Nov 29, 2019
AP			**150MG/ML (150MG/ML)**	**A206834**	**007**	Nov 29, 2019
AP		SANDOZ	**30MG/0.3ML (100MG/ML)**	**A077857**	**002**	Jul 23, 2010
AP			**40MG/0.4ML (100MG/ML)**	**A077857**	**003**	Jul 23, 2010
AP			**60MG/0.6ML (100MG/ML)**	**A077857**	**004**	Jul 23, 2010
AP			**80MG/0.8ML (100MG/ML)**	**A077857**	**005**	Jul 23, 2010
AP			**100MG/ML (100MG/ML)**	**A077857**	**001**	Jul 23, 2010
AP			**120MG/0.8ML (150MG/ML)**	**A077857**	**006**	Jul 23, 2010
AP			**150MG/ML (150MG/ML)**	**A077857**	**007**	Jul 23, 2010
AP		SHENZHEN TECHDOW	**30MG/0.3ML (100MG/ML)**	**A205660**	**001**	Mar 15, 2023
AP			**40MG/0.4ML (100MG/ML)**	**A205660**	**002**	Mar 15, 2023
AP			**60MG/0.6ML (100MG/ML)**	**A205660**	**003**	Mar 15, 2023
AP			**80MG/0.8ML (100MG/ML)**	**A205660**	**004**	Mar 15, 2023
AP			**100MG/ML (100MG/ML)**	**A205660**	**005**	Mar 15, 2023
AP			**120MG/0.8ML (150MG/ML)**	**A205660**	**006**	Mar 15, 2023
AP			**150MG/ML (150MG/ML)**	**A205660**	**007**	Mar 15, 2023
AP		ZYDUS PHARMS	**30MG/0.3ML (100MG/ML)**	**A076726**	**001**	Jun 23, 2014
AP			**40MG/0.4ML (100MG/ML)**	**A076726**	**002**	Jun 23, 2014
AP			**60MG/0.6ML (100MG/ML)**	**A076726**	**003**	Jun 23, 2014
AP			**80MG/0.8ML (100MG/ML)**	**A076726**	**004**	Jun 23, 2014
AP			**100MG/ML (100MG/ML)**	**A076726**	**005**	Jun 23, 2014
AP			**120MG/0.8ML (150MG/ML)**	**A076726**	**006**	Jun 23, 2014
AP			**150MG/ML (150MG/ML)**	**A076726**	**007**	Jun 23, 2014

LOVENOX (PRESERVATIVE FREE)

AP	**+**	SANOFI AVENTIS US	**30MG/0.3ML (100MG/ML)**	**N020164**	**001**	Mar 29, 1993
AP	**+**		**40MG/0.4ML (100MG/ML)**	**N020164**	**002**	Jan 30, 1998
AP	**+**		**60MG/0.6ML (100MG/ML)**	**N020164**	**003**	Mar 27, 1998
AP	**+**		**80MG/0.8ML (100MG/ML)**	**N020164**	**004**	Mar 27, 1998
AP	**+!**		**100MG/ML (100MG/ML)**	**N020164**	**005**	Mar 27, 1998
AP	**+**		**120MG/0.8ML (150MG/ML)**	**N020164**	**007**	Jun 02, 2000
AP	**+**		**150MG/ML (150MG/ML)**	**N020164**	**008**	Jun 02, 2000

ENTACAPONE

TABLET;ORAL

COMTAN

AB	**+!**	ORION PHARMA	**200MG**	**N020796**	**001**	Oct 19, 1999

ENTACAPONE

AB		AJANTA PHARMA LTD	**200MG**	**A205792**	**001**	Aug 31, 2017
AB		ALEMBIC	**200MG**	**A212601**	**001**	Jan 04, 2022
AB		AUROBINDO PHARMA LTD	**200MG**	**A203437**	**001**	Jun 19, 2015
AB		MACLEODS PHARMS LTD	**200MG**	**A207210**	**001**	Jun 05, 2017
AB		SUN PHARM	**200MG**	**A090690**	**001**	Jul 16, 2012
AB		SUNSHINE	**200MG**	**A206669**	**001**	Oct 03, 2018
AB		WOCKHARDT BIO AG	**200MG**	**A078941**	**001**	Aug 16, 2012

ENTECAVIR							
SOLUTION;ORAL							
BARACLUDE							
	+!	BRISTOL MYERS SQUIBB	0.05MG/ML	N021798	001	Mar 29, 2005
TABLET;ORAL							
BARACLUDE							
AB	**+**	BRISTOL MYERS SQUIBB	**0.5MG**	**N021797**	**001**	Mar 29, 2005
AB	**+!**		**1MG**	**N021797**	**002**	Mar 29, 2005
ENTECAVIR							
AB		AMNEAL PHARMS	**0.5MG**	**A206652**	**001**	Nov 12, 2015
AB			**1MG**	**A206652**	**002**	Nov 12, 2015
AB		AUROBINDO PHARMA	**0.5MG**	**A206217**	**001**	Aug 26, 2015
AB			**1MG**	**A206217**	**002**	Aug 26, 2015
AB		BRECKENRIDGE	**0.5MG**	**A208721**	**001**	Mar 15, 2018
AB			**1MG**	**A208721**	**002**	Mar 15, 2018
AB		BRIGHTGENE	**0.5MG**	**A212126**	**001**	Sep 25, 2019
AB			**1MG**	**A212126**	**002**	Sep 25, 2019
AB		CIPLA	**0.5MG**	**A206872**	**001**	Dec 06, 2016
AB			**1MG**	**A206872**	**002**	Dec 06, 2016
AB		HETERO LABS LTD V	**0.5MG**	**A205740**	**001**	Aug 21, 2015
AB			**1MG**	**A205740**	**002**	Aug 21, 2015
AB		PRINSTON INC	**0.5MG**	**A208782**	**001**	Oct 10, 2017
AB			**1MG**	**A208782**	**002**	Oct 10, 2017
AB		VITRUVIAS	**0.5MG**	**A212106**	**001**	Aug 10, 2020
AB			**1MG**	**A212106**	**002**	Aug 10, 2020
AB		ZYDUS PHARMS	**0.5MG**	**A206745**	**001**	Jun 23, 2017
AB			**1MG**	**A206745**	**002**	Jun 23, 2017
ENTRECTINIB							
CAPSULE;ORAL							
ROZLYTREK							
	+	GENENTECH INC	100MG	N212725	001	Aug 15, 2019
	+!		200MG	N212725	002	Aug 15, 2019
PELLETS;ORAL							
ROZLYTREK							
	+!	GENENTECH INC	50MG/PACKET	N218550	001	Oct 20, 2023
ENZALUTAMIDE							
CAPSULE;ORAL							
XTANDI							
	+!	ASTELLAS	40MG	N203415	001	Aug 31, 2012
TABLET;ORAL							
XTANDI							
	+	ASTELLAS	40MG	N213674	001	Aug 04, 2020
	+!		80MG	N213674	002	Aug 04, 2020
EPHEDRINE HYDROCHLORIDE							
SOLUTION;INTRAVENOUS							
REZIPRES							
	+!	DR REDDYS LABS SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021
	+!		47MG/10ML (4.7MG/ML)	N213536	004	Dec 07, 2023
EPHEDRINE SULFATE							
SOLUTION;INTRAVENOUS							
AKOVAZ							
AP	**+!**	EXELA PHARMA	**50MG/ML (50MG/ML)**	**N208289**	**001**	Apr 29, 2016
CORPHEDRA							
AP		PAR STERILE PRODUCTS	**50MG/ML (50MG/ML)**	**N208943**	**001**	Jan 27, 2017
EPHEDRINE SULFATE							
AP		AMNEAL	**50MG/ML (50MG/ML)**	**A212932**	**001**	Oct 23, 2019
AP		DR REDDYS	**50MG/ML (50MG/ML)**	**A212649**	**001**	Oct 03, 2020
AP		EUGIA PHARMA	**50MG/ML (50MG/ML)**	**A214579**	**001**	Jun 14, 2021
AP		FRESENIUS KABI USA	**50MG/ML (50MG/ML)**	**A209646**	**001**	Aug 04, 2020
AP		GLAND PHARMA LTD	**50MG/ML (50MG/ML)**	**A216146**	**001**	Feb 25, 2022
AP		HIKMA	**50MG/ML (50MG/ML)**	**A214334**	**001**	Dec 15, 2020
AP		MANKIND PHARMA	**50MG/ML (50MG/ML)**	**A216129**	**001**	Apr 14, 2022
AP		SAGENT PHARMS INC	**50MG/ML (50MG/ML)**	**A214528**	**001**	Mar 09, 2023
AP		SANDOZ	**50MG/ML (50MG/ML)**	**A209784**	**001**	Aug 23, 2017
AP		XIROMED	**50MG/ML (50MG/ML)**	**A215825**	**001**	Apr 21, 2022
AKOVAZ							
	+!	EXELA PHARMA	25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EMERPHED						
+!	NEXUS	25MG/5ML (5MG/ML)	N213407	002	Feb 28, 2023
+!		50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020
EPHEDRINE SULFATE					
+!	OPERAND PHARMS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022
+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

EPINASTINE HYDROCHLORIDE						
AT		APOTEX	**0.05%**	**A090919**	**001**	Oct 31, 2011
AT		BRECKENRIDGE	**0.05%**	**A090870**	**001**	Mar 14, 2011
AT	!	SOMERSET THERAPS LLC	**0.05%**	**A090951**	**001**	Oct 31, 2011

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE (AUTOINJECTOR)						
AB		TEVA PHARMS USA	**0.15MG/DELIVERY**	**A090589**	**002**	Aug 16, 2018
AB			**0.3MG/DELIVERY**	**A090589**	**001**	Aug 16, 2018
EPIPEN						
AB	**+!**	MYLAN SPECIALITY LP	**0.3MG/DELIVERY**	**N019430**	**001**	Dec 22, 1987
EPIPEN JR.						
AB	**+!**	MYLAN SPECIALITY LP	**0.15MG/DELIVERY**	**N019430**	**002**	Dec 22, 1987
ADRENACLICK						
BX	+!	IMPAX	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009
BX	+!		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ADRENALIN						
AP	**+!**	PAR STERILE PRODUCTS	**EQ 30MG BASE/30ML (EQ 1MG BASE/ML)**	**N204640**	**001**	Dec 18, 2013
EPINEPHRINE						
AP		INTL MEDICATION SYS	**EQ 30MG BASE/30ML (EQ 1MG BASE/ML)**	**A211880**	**001**	Apr 24, 2020
ADRENALIN						
+!		PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012
EPINEPHRINE						
+!		BPI LABS	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

AUVI-Q						
BX	+!	KALEO INC	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012
BX	+		EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012
+			EQ 0.1MG/DELIVERY	N201739	003	Nov 17, 2017
SYMJEPI						
+!		ADAMIS PHARMS CORP	0.3MG/0.3ML (0.3MG/0.3ML)	N207534	001	Jun 15, 2017

SOLUTION;INTRAVENOUS

ADRENALIN						
+!		PAR STERILE PRODUCTS	2MG/250ML (8MCG/ML)	N215875	001	Apr 21, 2023
+!			4MG/250ML (16MCG/ML)	N215875	002	Apr 21, 2023
+!			5MG/250ML (20MCG/ML)	N215875	003	Apr 21, 2023
+!			8MG/250ML (32MCG/ML)	N215875	004	Apr 21, 2023
+!			10MG/250ML (40MCG/ML)	N215875	005	Apr 21, 2023
EPINEPHRINE						
+!		BPI LABS	1MG/ML (1MG/ML)	N205029	003	May 12, 2023
+!		HOSPIRA	1MG/10ML (0.1MG/ML)	N209359	001	Nov 05, 2019
+!		INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	N211363	001	Aug 15, 2022

SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE						
+!		BPI LABS	1MG/ML (1MG/ML)	N205029	001	Jul 29, 2014

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIGNOSPAN FORTE						
+!		DEPROCO	EQ 0.02MG BASE/ML;2%	A088389	001	Jan 22, 1985
LIGNOSPAN STANDARD						
+!		DEPROCO	EQ 0.01MG BASE/ML;2%	A088390	001	Jan 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CITANEST FORTE DENTAL

AP	**+!**	DENTSPLY PHARM	**0.005MG/ML;4%**	**N021383**	**001**	

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP		SEPTODONT INC	**0.005MG/ML;4%**	**A078959**	**001**	Aug 30, 2011

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP		B BRAUN MEDICAL INC	**0.005MG/ML;1.5%**	**A208475**	**001**	Sep 08, 2021
AP		HOSPIRA	**0.005MG/ML;0.5%**	**A089635**	**001**	Jun 21, 1988
AP			**0.005MG/ML;1.5%**	**A088571**	**001**	Sep 13, 1985
AP			**0.005MG/ML;1.5%**	**A089645**	**001**	Jun 21, 1988
AP			**0.005MG/ML;2%**	**A089651**	**001**	Jun 21, 1988
AP			**0.01MG/ML;1%**	**A089644**	**001**	Jun 21, 1988

XYLOCAINE W/ EPINEPHRINE

AP	**+!**	FRESENIUS KABI USA	**0.005MG/ML;0.5%**	**N006488**	**012**	
AP	**+!**		**0.005MG/ML;1.5%**	**N006488**	**017**	
AP	**+!**		**0.005MG/ML;2%**	**N006488**	**019**	Nov 13, 1986
AP	**+!**		**0.01MG/ML;1%**	**N006488**	**004**	

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

	!	HOSPIRA	0.01MG/ML;2%	A089646	001	Jun 21, 1988

XYLOCAINE W/ EPINEPHRINE

	+!	FRESENIUS KABI USA	0.005MG/ML;1%	N006488	018	Nov 13, 1986
	+!		0.02MG/ML;2%	N006488	005	

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

ELLENCE

AP	**+!**	PFIZER INC	**200MG/100ML (2MG/ML)**	**N050778**	**001**	Sep 15, 1999
AP	**+**		**50MG/25ML (2MG/ML)**	**N050778**	**002**	Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

AP		AKORN	**50MG/25ML (2MG/ML)**	**A090163**	**001**	Jun 24, 2009
AP		CIPLA LTD	**50MG/25ML (2MG/ML)**	**A065361**	**001**	Oct 22, 2007
AP			**200MG/100ML (2MG/ML)**	**A065361**	**002**	Oct 22, 2007
AP		HIKMA	**50MG/25ML (2MG/ML)**	**A065289**	**001**	Jun 27, 2007
AP			**200MG/100ML (2MG/ML)**	**A065289**	**002**	Jun 27, 2007
AP		HISUN PHARM HANGZHOU	**50MG/25ML (2MG/ML)**	**A090075**	**001**	Mar 25, 2010
AP			**200MG/100ML (2MG/ML)**	**A090075**	**002**	Mar 25, 2010
AP		IMPAX LABS INC	**50MG/25ML (2MG/ML)**	**A065331**	**001**	Aug 09, 2007
AP			**200MG/100ML (2MG/ML)**	**A065331**	**002**	Aug 09, 2007

EPLERENONE

TABLET;ORAL

EPLERENONE

AB		ACCORD HLTHCARE	**25MG**	**A206922**	**001**	Jul 13, 2017
AB			**50MG**	**A206922**	**002**	Jul 13, 2017
AB		ANNORA PHARMA	**25MG**	**A213812**	**001**	Jun 02, 2023
AB			**50MG**	**A213812**	**002**	Jun 02, 2023
AB		BRECKENRIDGE	**25MG**	**A208283**	**001**	Sep 14, 2018
AB			**50MG**	**A208283**	**002**	Sep 14, 2018
AB		CHARTWELL RX	**25MG**	**A078482**	**001**	Jul 30, 2008
AB			**50MG**	**A078482**	**002**	Jul 30, 2008
AB		PIRAMAL HLTHCARE UK	**25MG**	**A212765**	**001**	Aug 10, 2020
AB			**50MG**	**A212765**	**002**	Aug 10, 2020
AB		PRASCO	**25MG**	**A203896**	**001**	Feb 02, 2017
AB			**50MG**	**A203896**	**002**	Feb 02, 2017
AB		RISING	**25MG**	**A214663**	**001**	Mar 23, 2022
AB			**50MG**	**A214663**	**002**	Mar 23, 2022
AB		SANDOZ	**25MG**	**A078510**	**001**	Aug 01, 2008
AB			**50MG**	**A078510**	**002**	Aug 01, 2008
AB		WESTMINSTER PHARMS	**25MG**	**A207842**	**001**	Oct 25, 2021
AB			**50MG**	**A207842**	**002**	Oct 25, 2021

INSPRA

AB	**+**	UPJOHN	**25MG**	**N021437**	**001**	Sep 27, 2002
AB	**+!**		**50MG**	**N021437**	**002**	Sep 27, 2002

EPLONTERSEN SODIUM

SOLUTION;SUBCUTANEOUS

WAINUA

	+!	IONIS PHARMS INC	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

EPOPROSTENOL SODIUM

AP1		HONG KONG	**EQ 0.5MG BASE/VIAL**	**A078396**	**001**	Apr 23, 2008
AP1			**EQ 1.5MG BASE/VIAL**	**A078396**	**002**	Apr 23, 2008

FLOLAN

AP1	**+!**	GLAXOSMITHKLINE LLC	**EQ 0.5MG BASE/VIAL**	**N020444**	**001**	Sep 20, 1995
AP1	**+!**		**EQ 1.5MG BASE/VIAL**	**N020444**	**002**	Sep 20, 1995

EPOPROSTENOL SODIUM

AP2	**!**	SUN PHARM	**EQ 0.5MG BASE/VIAL**	**A210473**	**001**	Jan 15, 2021
AP2			**EQ 1.5MG BASE/VIAL**	**A210473**	**002**	Jan 15, 2021

VELETRI

AP2	**+**	ACTELION	**EQ 0.5MG BASE/VIAL**	**N022260**	**002**	Jun 28, 2012
AP2	**+!**		**EQ 1.5MG BASE/VIAL**	**N022260**	**001**	Jun 27, 2008

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP		ACCORD HLTHCARE	**2MG/ML**	**A205557**	**001**	Nov 06, 2017
AP			**75MG/100ML**	**A205557**	**002**	Nov 06, 2017
AP		BAXTER HLTHCARE CORP	**75MG/100ML**	**A208554**	**002**	Nov 23, 2018
AP		EUGIA PHARMA	**2MG/ML**	**A206127**	**001**	Dec 08, 2015
AP			**75MG/100ML**	**A206127**	**002**	Dec 08, 2015
AP	**!**	MYLAN LABS LTD	**2MG/ML**	**A203258**	**001**	Jul 20, 2018
AP	**!**		**75MG/100ML**	**A203258**	**002**	Jul 20, 2018
AP		SAGENT PHARMS INC	**2MG/ML**	**A204693**	**001**	Mar 07, 2018
AP			**75MG/100ML**	**A204693**	**002**	Mar 07, 2018
AP		SHUANGCHENG	**2MG/ML**	**A213081**	**001**	Sep 07, 2021
AP			**75MG/100ML**	**A213081**	**002**	Apr 20, 2022
AP		SLATE RUN PHARMA	**2MG/ML**	**A209864**	**001**	Jan 25, 2019
AP			**75MG/100ML**	**A209864**	**002**	Jan 25, 2019
AP		TEVA PHARMS USA	**2MG/ML**	**A090854**	**001**	Jun 12, 2015

ERAVACYCLINE DIHYDROCHLORIDE

POWDER;INTRAVENOUS

XERAVA

	+!	TETRAPHASE PHARMS	EQ 50MG BASE/VIAL	N211109	001	Aug 27, 2018
	+!		EQ 100MG BASE/VIAL	N211109	002	Jun 03, 2020

ERDAFITINIB

TABLET;ORAL

BALVERSA

	+	JANSSEN BIOTECH	3MG	N212018	001	Apr 12, 2019
	+		4MG	N212018	002	Apr 12, 2019
	+!		5MG	N212018	003	Apr 12, 2019

ERGOCALCIFEROL

CAPSULE;ORAL

DRISDOL

AA	**+**	SS PHARMA	**50,000 IU**	**N003444**	**001**	

ERGOCALCIFEROL

AA		CHARTWELL RX	**50,000 IU**	**A040833**	**001**	May 20, 2009
AA		PURACAP PHARM LLC	**50,000 IU**	**A204276**	**001**	Dec 07, 2018
AA	**!**	STRIDES PHARMA	**50,000 IU**	**A090455**	**001**	Aug 03, 2010

VITAMIN D

AA		BIONPHARMA	**50,000 IU**	**A080704**	**001**	

ERGOLOID MESYLATES

TABLET;ORAL

ERGOLOID MESYLATES

	!	SUN PHARM INDUSTRIES	1MG	A081113	001	Oct 31, 1991

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL

ERGOMAR

	!	TERSERA	2MG	A087693	001	Feb 24, 1983

ERIBULIN MESYLATE

SOLUTION;INTRAVENOUS

HALAVEN

	+!	EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

AB		ALEMBIC	**EQ 25MG BASE**	**A214719**	**001**	Jul 08, 2021
AB			**EQ 100MG BASE**	**A214719**	**002**	Jul 08, 2021
AB			**EQ 150MG BASE**	**A214719**	**003**	Jul 08, 2021
AB		APOTEX	**EQ 25MG BASE**	**A208396**	**001**	Nov 05, 2019
AB			**EQ 100MG BASE**	**A208396**	**002**	Nov 05, 2019
AB			**EQ 150MG BASE**	**A208396**	**003**	Nov 05, 2019
AB		MSN	**EQ 25MG BASE**	**A214366**	**001**	May 10, 2021
AB			**EQ 100MG BASE**	**A214366**	**002**	May 10, 2021
AB			**EQ 150MG BASE**	**A214366**	**003**	May 10, 2021
AB		NATCO PHARMA LTD	**EQ 25MG BASE**	**A208488**	**001**	Nov 05, 2019
AB			**EQ 100MG BASE**	**A208488**	**002**	Nov 05, 2019
AB			**EQ 150MG BASE**	**A208488**	**003**	Nov 05, 2019
AB		RISING	**EQ 25MG BASE**	**A091002**	**001**	Jun 11, 2014
AB			**EQ 100MG BASE**	**A091002**	**002**	Jun 11, 2014
AB			**EQ 150MG BASE**	**A091002**	**003**	Jun 11, 2014
AB		SHILPA	**EQ 25MG BASE**	**A211960**	**001**	Nov 05, 2019
AB			**EQ 100MG BASE**	**A211960**	**002**	Nov 05, 2019
AB			**EQ 150MG BASE**	**A211960**	**003**	Nov 05, 2019
AB		SUN PHARM	**EQ 25MG BASE**	**A210300**	**001**	Nov 05, 2019
AB			**EQ 100MG BASE**	**A210300**	**002**	Nov 05, 2019
AB			**EQ 150MG BASE**	**A210300**	**003**	Nov 05, 2019
AB		TEVA PHARMS USA INC	**EQ 25MG BASE**	**A091059**	**001**	Nov 09, 2020
AB			**EQ 100MG BASE**	**A091059**	**002**	Aug 28, 2015
AB			**EQ 150MG BASE**	**A091059**	**003**	Aug 28, 2015
AB		ZYDUS PHARMS	**EQ 25MG BASE**	**A213065**	**001**	Apr 16, 2020
AB			**EQ 100MG BASE**	**A213065**	**002**	Apr 16, 2020
AB	**!**		**EQ 150MG BASE**	**A213065**	**003**	Apr 16, 2020

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP		ACS DOBFAR SPA	**EQ 1GM BASE/VIAL**	**A208790**	**001**	Apr 16, 2018
AP		EUGIA PHARMA	**EQ 1GM BASE/VIAL**	**A209133**	**001**	Jun 25, 2018
AP		GLAND PHARMA LTD	**EQ 1GM BASE/VIAL**	**A212040**	**001**	Mar 26, 2021
AP		SAVIOR LIFETEC CORP	**EQ 1GM BASE/VIAL**	**A207647**	**001**	Mar 19, 2019
AP		SUN PHARM	**EQ 1GM BASE/VIAL**	**A209145**	**001**	May 02, 2023

INVANZ

AP	**+!**	MSD SUB MERCK	**EQ 1GM BASE/VIAL**	**N021337**	**001**	Nov 21, 2001

ERTUGLIFLOZIN

TABLET;ORAL

STEGLATRO

	+	MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017
	+!		15MG	N209803	002	Dec 19, 2017

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

SEGLUROMET

	+	MSD SUB MERCK	2.5MG;500MG	N209806	001	Dec 19, 2017
	+		2.5MG;1GM	N209806	002	Dec 19, 2017
	+		7.5MG;500MG	N209806	003	Dec 19, 2017
	+!		7.5MG;1GM	N209806	004	Dec 19, 2017

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

STEGLUJAN

	+	MSD SUB MERCK	5MG;EQ 100MG BASE	N209805	001	Dec 19, 2017
	+!		15MG;EQ 100MG BASE	N209805	002	Dec 19, 2017

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC

AB	**+!**	DR REDDYS LABS SA	**250MG**	**N050536**	**001**	

ERYTHROMYCIN

AB		ARBOR PHARMS LLC	**250MG**	**A062746**	**001**	Dec 22, 1986

ERYTHROMYCIN							
GEL;TOPICAL							
ERYGEL							
AT	**+!**	MYLAN	**2%**	**N050617**	**001**	Oct 21, 1987
ERYTHROMYCIN							
AT		FOUGERA PHARMS	**2%**	**A064184**	**001**	Sep 30, 1997
AT		PADAGIS US	**2%**	**A063211**	**001**	Jan 29, 1993
OINTMENT;OPHTHALMIC							
ERYTHROMYCIN							
AT		BAUSCH AND LOMB	**0.5%**	**A064067**	**001**	Jul 29, 1994
AT	**!**	PADAGIS US	**0.5%**	**A062447**	**001**	Sep 26, 1983
AT		SENTISS	**0.5%**	**A064030**	**001**	Jul 18, 1996
SOLUTION;TOPICAL							
ERYTHRA-DERM							
AT		MICRO LABS	**2%**	**A062687**	**001**	Feb 05, 1988
ERYTHROMYCIN							
AT	**!**	PADAGIS US	**2%**	**A063038**	**001**	Jan 11, 1991
SWAB;TOPICAL							
ERYTHROMYCIN							
AT		EPIC PHARMA LLC	**2%**	**A090215**	**001**	May 12, 2010
AT	**!**	PADAGIS US	**2%**	**A064126**	**001**	Jul 03, 1996
TABLET;ORAL							
ERYTHROMYCIN							
AB		ALEMBIC	**250MG**	**A215661**	**001**	Aug 24, 2023
AB			**500MG**	**A215661**	**002**	Aug 24, 2023
AB		ALKEM LABS LTD	**250MG**	**A216066**	**001**	Jul 13, 2022
AB			**500MG**	**A216066**	**002**	Jul 13, 2022
AB		AMNEAL PHARMS CO	**250MG**	**A209720**	**001**	Mar 09, 2018
AB			**500MG**	**A209720**	**002**	Mar 09, 2018
AB		ARBOR PHARMS LLC	**250MG**	**A061621**	**001**	
AB			**500MG**	**A061621**	**002**	
AB		CADILA PHARMS LTD	**250MG**	**A213628**	**001**	Jun 28, 2021
AB	**!**		**500MG**	**A213628**	**002**	Jun 28, 2021
AB		TEVA PHARMS USA INC	**250MG**	**A214549**	**001**	Feb 11, 2021
AB			**500MG**	**A214549**	**002**	Feb 11, 2021
AB		TORRENT	**250MG**	**A212015**	**001**	Jul 06, 2020
AB			**500MG**	**A212015**	**002**	Jul 06, 2020
AB		ZYDUS	**250MG**	**A212693**	**001**	Mar 07, 2023
AB			**500MG**	**A212693**	**002**	Mar 07, 2023
TABLET, DELAYED RELEASE;ORAL							
ERY-TAB							
AB		ARBOR PHARMS LLC	**250MG**	**A062298**	**001**	
AB			**333MG**	**A062298**	**003**	Mar 29, 1982
AB	**!**		**500MG**	**A062298**	**002**	
ERYTHROMYCIN							
AB		AMNEAL PHARMS CO	**250MG**	**A210954**	**001**	Jul 02, 2019
AB			**333MG**	**A210954**	**002**	Jul 02, 2019
AB			**500MG**	**A210954**	**003**	Jul 02, 2019
AB		TORRENT	**250MG**	**A211975**	**001**	Jul 26, 2021
AB			**500MG**	**A211975**	**002**	Jul 26, 2021
ERYTHROMYCIN ETHYLSUCCINATE							
GRANULE;ORAL							
E.E.S.							
AB	**+**	AZURITY	**EQ 200MG BASE/5ML**	**N050207**	**001**	
ERYPED							
AB	**+**	AZURITY	**EQ 200MG BASE/5ML**	**N050207**	**003**	Mar 30, 1987
AB	**+!**		**EQ 400MG BASE/5ML**	**N050207**	**002**	
ERYTHROMYCIN ETHYLSUCCINATE							
AB		AMNEAL PHARMS	**EQ 200MG BASE/5ML**	**A211204**	**001**	Nov 01, 2019
AB			**EQ 400MG BASE/5ML**	**A211204**	**002**	Nov 01, 2019
AB		ANI PHARMS	**EQ 200MG BASE/5ML**	**A062055**	**001**	
AB			**EQ 200MG BASE/5ML**	**A062055**	**003**	Nov 02, 2018
AB			**EQ 400MG BASE/5ML**	**A062055**	**002**	Nov 02, 2018
AB		CADILA PHARMS LTD	**EQ 200MG BASE/5ML**	**A216212**	**001**	Nov 21, 2022
AB			**EQ 400MG BASE/5ML**	**A216212**	**002**	Nov 21, 2022
TABLET;ORAL							
E.E.S. 400							
BX	!	ARBOR PHARMS LLC	EQ 400MG BASE	A061905	002	Aug 12, 1982
ERYTHROMYCIN ETHYLSUCCINATE							
BX	!	ARBOR PHARMS LLC	EQ 400MG BASE	A061904	001	

ERYTHROMYCIN LACTOBIONATE						
INJECTABLE;INJECTION						
ERYTHROCIN						
AP		HOSPIRA	**EQ 500MG BASE/VIAL**	**A062638**	**001**	Oct 31, 1986
AP	**+!**		**EQ 500MG BASE/VIAL**	**N050609**	**001**	Sep 24, 1986
ERYTHROMYCIN LACTOBIONATE						
AP		NEXUS	**EQ 500MG BASE/VIAL**	**A215290**	**001**	Feb 14, 2022
ERYTHROMYCIN STEARATE						
TABLET;ORAL						
ERYTHROCIN STEARATE						
	!	ARBOR PHARMS LLC	EQ 250MG BASE	A060359	001	
ESCITALOPRAM OXALATE						
SOLUTION;ORAL						
ESCITALOPRAM OXALATE						
AA		AMNEAL PHARMS	**EQ 5MG BASE/5ML**	**A202227**	**001**	Mar 14, 2012
AA		AUROBINDO PHARMA LTD	**EQ 5MG BASE/5ML**	**A079062**	**001**	Apr 02, 2012
AA		CHARTWELL MOLECULAR	**EQ 5MG BASE/5ML**	**A090477**	**001**	Jun 12, 2013
AA	**!**	HETERO LABS LTD III	**EQ 5MG BASE/5ML**	**A202221**	**001**	Jun 12, 2012
AA		MACLEODS PHARMS LTD	**EQ 5MG BASE/5ML**	**A202754**	**001**	Mar 31, 2016
AA		TARO	**EQ 5MG BASE/5ML**	**A079121**	**001**	May 03, 2012
TABLET;ORAL						
ESCITALOPRAM OXALATE						
AB		ACCORD HLTHCARE	**EQ 5MG BASE**	**A202389**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A202389**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A202389**	**003**	Sep 11, 2012
AB		AMNEAL PHARMS	**EQ 5MG BASE**	**A205619**	**001**	May 17, 2017
AB			**EQ 10MG BASE**	**A205619**	**002**	May 17, 2017
AB			**EQ 20MG BASE**	**A205619**	**003**	May 17, 2017
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A090432**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A090432**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A090432**	**003**	Sep 11, 2012
AB		CADILA	**EQ 5MG BASE**	**A077734**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A077734**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A077734**	**003**	Sep 11, 2012
AB		GRAVITI PHARMS	**EQ 5MG BASE**	**A078777**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078777**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078777**	**003**	Sep 11, 2012
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A078604**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078604**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078604**	**003**	Sep 11, 2012
AB		JUBILANT CADISTA	**EQ 5MG BASE**	**A202280**	**001**	Sep 12, 2012
AB			**EQ 10MG BASE**	**A202280**	**002**	Sep 12, 2012
AB			**EQ 20MG BASE**	**A202280**	**003**	Sep 12, 2012
AB		LUPIN LTD	**EQ 5MG BASE**	**A078169**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078169**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078169**	**003**	Sep 11, 2012
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A202210**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A202210**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A202210**	**003**	Sep 11, 2012
AB		PHARM ASSOC	**EQ 5MG BASE**	**A077512**	**001**	Sep 12, 2012
AB			**EQ 10MG BASE**	**A077512**	**002**	Sep 12, 2012
AB			**EQ 20MG BASE**	**A077512**	**003**	Sep 12, 2012
AB		PRINSTON INC	**EQ 5MG BASE**	**A078032**	**001**	Aug 28, 2015
AB			**EQ 10MG BASE**	**A078032**	**002**	Aug 28, 2015
AB			**EQ 20MG BASE**	**A078032**	**003**	Aug 28, 2015
AB		TORRENT PHARMS LTD	**EQ 5MG BASE**	**A090939**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A090939**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A090939**	**003**	Sep 11, 2012
LEXAPRO						
AB	**+**	ABBVIE	**EQ 5MG BASE**	**N021323**	**001**	Aug 14, 2002
AB	**+**		**EQ 10MG BASE**	**N021323**	**002**	Aug 14, 2002
AB	**+!**		**EQ 20MG BASE**	**N021323**	**003**	Aug 14, 2002
ESKETAMINE HYDROCHLORIDE						
SPRAY;NASAL						
SPRAVATO						
	+!	JANSSEN PHARMS	EQ 28MG BASE	N211243	001	Mar 05, 2019

ESLICARBAZEPINE ACETATE

TABLET;ORAL

APTIOM

AB	+	SUMITOMO PHARMA AM	**200MG**	**N022416**	**001**	Nov 08, 2013
AB	+		**400MG**	**N022416**	**002**	Nov 08, 2013
AB	+		**600MG**	**N022416**	**003**	Nov 08, 2013
AB	+!		**800MG**	**N022416**	**004**	Nov 08, 2013

ESLICARBAZEPINE ACETATE

AB		ALKEM LABS LTD	**200MG**	**A211199**	**001**	Oct 06, 2023
AB			**400MG**	**A211199**	**002**	Oct 06, 2023
AB			**600MG**	**A211199**	**003**	Oct 06, 2023
AB			**800MG**	**A211199**	**004**	Oct 06, 2023
AB		APOTEX	**200MG**	**A211236**	**001**	Dec 07, 2023
AB			**400MG**	**A211236**	**002**	Dec 07, 2023
AB			**600MG**	**A211236**	**003**	Dec 07, 2023
AB			**800MG**	**A211236**	**004**	Dec 07, 2023
AB		DR REDDYS	**200MG**	**A211238**	**001**	Jun 29, 2021
AB			**400MG**	**A211238**	**002**	Jun 29, 2021
AB			**600MG**	**A211238**	**003**	Jun 29, 2021
AB			**800MG**	**A211238**	**004**	Jun 29, 2021
AB		HETERO LABS LTD V	**200MG**	**A211186**	**001**	Aug 03, 2023
AB			**400MG**	**A211186**	**002**	Aug 03, 2023
AB			**600MG**	**A211186**	**003**	Aug 03, 2023
AB			**800MG**	**A211186**	**004**	Aug 03, 2023

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

BREVIBLOC

AP	+!	BAXTER HLTHCARE	**10MG/ML**	**N019386**	**006**	Feb 25, 2003

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	**2GM/100ML**	**N019386**	**005**	Jan 27, 2003

BREVIBLOC IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	**1GM/100ML**	**N019386**	**004**	Feb 16, 2001

ESMOLOL HYDROCHLORIDE

AP		AMNEAL	**1GM/100ML**	**A216603**	**001**	Dec 13, 2022
AP			**2GM/100ML**	**A216603**	**002**	Dec 13, 2022
AP		EUGIA PHARMA	**10MG/ML**	**A205520**	**001**	Jul 23, 2015
AP			**1GM/100ML**	**A216244**	**001**	Mar 21, 2022
AP			**2GM/100ML**	**A216244**	**002**	Mar 21, 2022
AP		GLAND PHARMA LTD	**10MG/ML**	**A208538**	**001**	Aug 14, 2019
AP		HIKMA	**10MG/ML**	**A076323**	**001**	Aug 10, 2004
AP		HQ SPCLT PHARMA	**1GM/100ML**	**A214172**	**001**	Dec 02, 2022
AP			**2GM/100ML**	**A214172**	**002**	Dec 02, 2022
AP		MYLAN INSTITUTIONAL	**10MG/ML**	**A076474**	**001**	May 02, 2005
AP		MYLAN LABS LTD	**1GM/100ML**	**A206608**	**001**	Jun 08, 2018
AP			**2GM/100ML**	**A206608**	**002**	Jun 08, 2018
AP		SAGENT PHARMS INC	**1GM/100ML**	**A207107**	**001**	Jun 08, 2018
AP			**2GM/100ML**	**A207107**	**002**	Jun 08, 2018

SOLUTION;INTRAVENOUS

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

	+!	HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

	+!	HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		ALKEM LABS LTD	**EQ 20MG BASE**	**A208333**	**001**	Oct 20, 2017
AB			**EQ 40MG BASE**	**A208333**	**002**	Oct 20, 2017
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A205606**	**001**	Apr 21, 2016
AB			**EQ 40MG BASE**	**A205606**	**002**	Apr 21, 2016
AB		CISEN	**EQ 20MG BASE**	**A213158**	**001**	Sep 22, 2020
AB			**EQ 40MG BASE**	**A213158**	**002**	Sep 22, 2020
AB		CSPC OUYI	**EQ 20MG BASE**	**A212949**	**001**	Oct 02, 2020
AB			**EQ 40MG BASE**	**A212949**	**002**	Oct 02, 2020
AB		DR REDDYS	**EQ 20MG BASE**	**A078279**	**001**	Sep 25, 2015
AB			**EQ 40MG BASE**	**A078279**	**002**	Sep 25, 2015
AB		ETHYPHARM	**EQ 20MG BASE**	**A090841**	**001**	Mar 31, 2021
AB			**EQ 40MG BASE**	**A090841**	**002**	Mar 31, 2021
AB		GLENMARK PHARMS	**EQ 20MG BASE**	**A209495**	**001**	May 10, 2019
AB			**EQ 40MG BASE**	**A209495**	**002**	May 10, 2019
AB		GRANULES	**EQ 20MG BASE**	**A217427**	**001**	Oct 18, 2023
AB			**EQ 40MG BASE**	**A217427**	**002**	Oct 18, 2023

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		GRAVITI PHARMS	**EQ 20MG BASE**	**A213486**	**001**	Mar 19, 2021
AB			**EQ 40MG BASE**	**A213486**	**002**	Mar 19, 2021
AB		GUANGZHOU NOVAKEN	**EQ 20MG BASE**	**A213859**	**001**	Nov 18, 2020
AB			**EQ 40MG BASE**	**A213859**	**002**	Nov 18, 2020
AB		HETERO LABS LTD III	**EQ 20MG BASE**	**A211977**	**001**	Jun 02, 2020
AB			**EQ 40MG BASE**	**A211977**	**002**	Jun 02, 2020
AB		INDCHEMIE HEALTH	**EQ 20MG BASE**	**A210559**	**001**	Feb 26, 2021
AB			**EQ 40MG BASE**	**A210559**	**002**	Feb 26, 2021
AB		IVAX SUB TEVA PHARMS	**EQ 20MG BASE**	**A078003**	**001**	Jan 26, 2015
AB			**EQ 40MG BASE**	**A078003**	**002**	Jan 26, 2015
AB		LANNETT CO INC	**EQ 20MG BASE**	**A205563**	**001**	Sep 01, 2017
AB			**EQ 40MG BASE**	**A205563**	**002**	Sep 01, 2017
AB		MYLAN	**EQ 20MG BASE**	**A078936**	**001**	Aug 02, 2015
AB			**EQ 40MG BASE**	**A078936**	**002**	Aug 03, 2015
AB		PRINSTON INC	**EQ 20MG BASE**	**A214920**	**001**	Mar 28, 2023
AB			**EQ 40MG BASE**	**A214920**	**002**	Mar 28, 2023
AB		SUN PHARM	**EQ 20MG BASE**	**A209735**	**001**	Apr 30, 2018
AB			**EQ 40MG BASE**	**A209735**	**002**	Apr 30, 2018
AB		ZHEJIANG YONGTAI	**EQ 20MG BASE**	**A217022**	**001**	Dec 27, 2023
AB			**EQ 40MG BASE**	**A217022**	**002**	Dec 27, 2023
AB		ZYDUS PHARMS	**EQ 20MG BASE**	**A206296**	**001**	May 22, 2019
AB			**EQ 40MG BASE**	**A206296**	**002**	May 22, 2019

NEXIUM

AB	**+**	ASTRAZENECA	**EQ 20MG BASE**	**N021153**	**001**	Feb 20, 2001
AB	**+!**		**EQ 40MG BASE**	**N021153**	**002**	Feb 20, 2001

FOR SUSPENSION, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		CIPLA	**EQ 10MG BASE/PACKET**	**A211752**	**001**	Mar 23, 2020
AB			**EQ 20MG BASE/PACKET**	**A211751**	**001**	Mar 23, 2020
AB			**EQ 40MG BASE/PACKET**	**A211751**	**002**	Mar 23, 2020
AB		ZYDUS PHARMS	**EQ 20MG BASE/PACKET**	**A206055**	**001**	Jun 07, 2023
AB			**EQ 40MG BASE/PACKET**	**A206055**	**002**	Jun 07, 2023

NEXIUM

AB	**+**	ASTRAZENECA	**EQ 10MG BASE/PACKET**	**N022101**	**001**	Feb 27, 2008
AB	**+**		**EQ 20MG BASE/PACKET**	**N021957**	**001**	Oct 20, 2006
AB	**+!**		**EQ 40MG BASE/PACKET**	**N021957**	**002**	Oct 20, 2006
	+		EQ 2.5MG BASE/PACKET	N021957	003	Dec 15, 2011
	+		EQ 5MG BASE/PACKET	N021957	004	Dec 15, 2011

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB		AJANTA PHARMA LTD	**EQ 20MG BASE;375MG**	**A213699**	**001**	Oct 06, 2022
AB			**EQ 20MG BASE;500MG**	**A213699**	**002**	Oct 06, 2022
AB		DR REDDYS	**EQ 20MG BASE;375MG**	**A204206**	**001**	Feb 18, 2020
AB	**!**		**EQ 20MG BASE;500MG**	**A204206**	**002**	Feb 18, 2020
AB		SCIEGEN PHARMS INC	**EQ 20MG BASE;375MG**	**A217738**	**001**	Oct 11, 2023
AB			**EQ 20MG BASE;500MG**	**A217738**	**002**	Oct 11, 2023

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP		ACCORD HLTHCARE	**EQ 40MG BASE/VIAL**	**A205379**	**001**	Sep 25, 2015
AP		DEVA HOLDING AS	**EQ 40MG BASE/VIAL**	**A207181**	**001**	Mar 06, 2017
AP		EUGIA PHARMA	**EQ 40MG BASE/VIAL**	**A204657**	**002**	Aug 10, 2016
AP		GLAND PHARMA LTD	**EQ 40MG BASE/VIAL**	**A203349**	**002**	Apr 01, 2020
AP		HAINAN POLY	**EQ 40MG BASE/VIAL**	**A215732**	**001**	Feb 10, 2022
AP		SUN PHARM	**EQ 40MG BASE/VIAL**	**A200882**	**002**	Mar 18, 2013

NEXIUM IV

AP	**+!**	ASTRAZENECA	**EQ 40MG BASE/VIAL**	**N021689**	**002**	Mar 31, 2005

ESOMEPRAZOLE SODIUM

		GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020

ESTAZOLAM

TABLET;ORAL

ESTAZOLAM

AB		DR REDDYS LABS SA	**1MG**	**A074921**	**001**	Jul 10, 1997
AB	**!**		**2MG**	**A074921**	**002**	Jul 10, 1997
AB		NOVITIUM PHARMA	**1MG**	**A074826**	**001**	Jul 03, 1997
AB			**2MG**	**A074826**	**002**	Jul 03, 1997

ESTAZOLAM

TABLET;ORAL

ESTAZOLAM

AB		WATSON LABS	**1MG**	**A074818**	**001**	Aug 19, 1997
AB			**2MG**	**A074818**	**002**	Aug 19, 1997

ESTRADIOL

CREAM;VAGINAL

ESTRACE

AB	**+!**	ALLERGAN	**0.01%**	**A086069**	**001**	Jan 31, 1984

ESTRADIOL

AB		ALVOGEN	**0.01%**	**A209767**	**001**	Mar 05, 2018
AB		MYLAN	**0.01%**	**A208788**	**001**	Dec 29, 2017
AB		PADAGIS ISRAEL	**0.01%**	**A210194**	**001**	Jan 22, 2018
AB		PRASCO	**0.01%**	**A212313**	**001**	Jul 15, 2021
AB		TEVA PHARMS USA	**0.01%**	**A210488**	**001**	Mar 30, 2018

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA

AB	**+**	BAYER HLTHCARE	**0.06MG/24HR**	**N020375**	**006**	May 27, 2003

ESTRADIOL

AB		MYLAN TECHNOLOGIES	**0.06MG/24HR**	**A075182**	**005**	Jul 20, 2006

CLIMARA

AB2	**+**	BAYER HLTHCARE	**0.025MG/24HR**	**N020375**	**004**	Mar 05, 1999
AB2	**+**		**0.0375MG/24HR**	**N020375**	**005**	May 27, 2003
AB2	**+**		**0.05MG/24HR**	**N020375**	**001**	Dec 22, 1994
AB2	**+**		**0.075MG/24HR**	**N020375**	**003**	Mar 23, 1998
AB2	**+!**		**0.1MG/24HR**	**N020375**	**002**	Dec 22, 1994

ESTRADIOL

AB2		MYLAN TECHNOLOGIES	**0.025MG/24HR**	**A075182**	**003**	Jan 26, 2005
AB2			**0.0375MG/24HR**	**A075182**	**004**	Jul 20, 2006
AB2			**0.05MG/24HR**	**A075182**	**006**	Feb 24, 2000
AB2			**0.075MG/24HR**	**A075182**	**002**	Jan 26, 2005
AB2			**0.1MG/24HR**	**A075182**	**001**	Feb 24, 2000
AB3		AMNEAL	**0.025MG/24HR**	**A211396**	**001**	Sep 28, 2020
AB3			**0.0375MG/24HR**	**A211396**	**002**	Sep 28, 2020
AB3			**0.05MG/24HR**	**A211396**	**003**	Sep 28, 2020
AB3			**0.075MG/24HR**	**A211396**	**004**	Sep 28, 2020
AB3			**0.1MG/24HR**	**A211396**	**005**	Sep 28, 2020
AB3		MYLAN TECHNOLOGIES	**0.025MG/24HR**	**A206685**	**001**	Aug 15, 2018
AB3			**0.0375MG/24HR**	**A206685**	**002**	Aug 15, 2018
AB3			**0.05MG/24HR**	**A206685**	**003**	Aug 15, 2018
AB3			**0.075MG/24HR**	**A206685**	**004**	Aug 15, 2018
AB3			**0.1MG/24HR**	**A206685**	**005**	Aug 15, 2018

MINIVELLE

AB3	**+**	NOVEN	**0.025MG/24HR**	**N203752**	**005**	Sep 23, 2014
AB3	**+**		**0.0375MG/24HR**	**N203752**	**001**	Oct 29, 2012
AB3	**+**		**0.05MG/24HR**	**N203752**	**003**	Oct 29, 2012
AB3	**+**		**0.075MG/24HR**	**N203752**	**002**	Oct 29, 2012
AB3	**+!**		**0.1MG/24HR**	**N203752**	**004**	Oct 29, 2012

GEL;TRANSDERMAL

DIVIGEL

AB	**+!**	VERTICAL PHARMS	**0.1%**	**N022038**	**001**	Jun 04, 2007

ESTRADIOL

AB		CHEMO RESEARCH SL	**0.1%**	**A211783**	**001**	Aug 10, 2022
AB		NOVITIUM PHARMA	**0.1%**	**A217610**	**001**	Aug 24, 2023
AB		PADAGIS ISRAEL	**0.1%**	**A216524**	**001**	Nov 14, 2023

GEL, METERED;TRANSDERMAL

ELESTRIN

	+!	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006

ESTROGEL

	+!	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004

INSERT;VAGINAL

IMVEXXY

	+	MAYNE PHARMA	0.004MG	N208564	001	May 29, 2018
	+!		0.01MG	N208564	002	May 29, 2018

INSERT, EXTENDED RELEASE;VAGINAL

ESTRING

	+!	PFIZER	0.0075MG/24HR	N020472	001	Apr 26, 1996

SPRAY;TRANSDERMAL

EVAMIST

	+!	PADAGIS US	1.53MG/SPRAY	N022014	001	Jul 27, 2007

ESTRADIOL

SYSTEM;TRANSDERMAL

ESTRADIOL

AB		ZYDUS PHARMS	**0.014MG/24HR**	**A204379**	**001**	Apr 17, 2023

MENOSTAR

AB	**+!**	BAYER HLTHCARE	**0.014MG/24HR**	**N021674**	**001**	Jun 08, 2004

ESTRADIOL

AB1		AMNEAL	**0.025MG/24HR**	**A211293**	**001**	Feb 04, 2019
AB1			**0.0375MG/24HR**	**A211293**	**002**	Feb 04, 2019
AB1			**0.05MG/24HR**	**A211293**	**003**	Feb 04, 2019
AB1			**0.075MG/24HR**	**A211293**	**004**	Feb 04, 2019
AB1			**0.1MG/24HR**	**A211293**	**005**	Feb 04, 2019
AB1		MYLAN TECHNOLOGIES	**0.025MG/24HR**	**A201675**	**001**	Dec 19, 2014
AB1			**0.0375MG/24HR**	**A201675**	**002**	Dec 19, 2014
AB1			**0.05MG/24HR**	**A201675**	**003**	Dec 19, 2014
AB1			**0.075MG/24HR**	**A201675**	**004**	Dec 19, 2014
AB1			**0.1MG/24HR**	**A201675**	**005**	Dec 19, 2014
AB1		ZYDUS PHARMS	**0.025MG/24HR**	**A206241**	**001**	Dec 01, 2022
AB1			**0.0375MG/24HR**	**A206241**	**002**	Dec 01, 2022
AB1			**0.05MG/24HR**	**A206241**	**003**	Dec 01, 2022
AB1			**0.075MG/24HR**	**A206241**	**004**	Dec 01, 2022
AB1			**0.1MG/24HR**	**A206241**	**005**	Dec 01, 2022

VIVELLE-DOT

AB1	**+**	SANDOZ	**0.025MG/24HR**	**N020538**	**009**	May 03, 2002
AB1	**+**		**0.0375MG/24HR**	**N020538**	**005**	Jan 08, 1999
AB1	**+**		**0.05MG/24HR**	**N020538**	**006**	Jan 08, 1999
AB1	**+**		**0.075MG/24HR**	**N020538**	**007**	Jan 08, 1999
AB1	**+!**		**0.1MG/24HR**	**N020538**	**008**	Jan 08, 1999

TABLET;ORAL

ESTRADIOL

AB		BARR LABS INC	**0.5MG**	**A040197**	**001**	Oct 22, 1997
AB			**1MG**	**A040197**	**002**	Oct 22, 1997
AB	**!**		**2MG**	**A040197**	**003**	Oct 22, 1997
AB		EPIC PHARMA LLC	**0.5MG**	**A040275**	**001**	Dec 29, 1998
AB			**1MG**	**A040275**	**002**	Dec 29, 1998
AB			**2MG**	**A040275**	**003**	Dec 29, 1998
AB		NOVITIUM PHARMA	**0.5MG**	**A217334**	**001**	Sep 06, 2023
AB			**1MG**	**A217334**	**002**	Sep 06, 2023
AB			**2MG**	**A217334**	**003**	Sep 06, 2023

TABLET;VAGINAL

ESTRADIOL

AB		AMNEAL PHARMS	**10MCG**	**A205256**	**001**	May 29, 2015
AB		GLENMARK PHARMS LTD	**10MCG**	**A210264**	**001**	Sep 14, 2018
AB		TEVA PHARMS USA	**10MCG**	**A206388**	**001**	Jul 21, 2017

VAGIFEM

AB	**+!**	NOVO NORDISK INC	**10MCG**	**N020908**	**002**	Nov 25, 2009

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

	+	MILLICENT	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003
	+!		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION

DEPO-ESTRADIOL

	!	PFIZER	5MG/ML	A085470	003	

ESTRADIOL VALERATE

INJECTABLE;INJECTION

DELESTROGEN

AO	**+!**	PAR STERILE PRODUCTS	**10MG/ML**	**N009402**	**002**	
AO	**+!**		**20MG/ML**	**N009402**	**004**	
AO	**+!**		**40MG/ML**	**N009402**	**003**	

ESTRADIOL VALERATE

AO		AM REGENT	**20MG/ML**	**A090920**	**001**	Jan 19, 2010
AO			**40MG/ML**	**A090920**	**002**	Jan 19, 2010
AO		HIKMA	**10MG/ML**	**A203723**	**001**	Apr 21, 2020
AO			**20MG/ML**	**A203723**	**002**	Apr 21, 2020
AO			**40MG/ML**	**A203723**	**003**	Apr 21, 2020
AO		XIROMED	**10MG/ML**	**A216656**	**001**	Apr 28, 2023
AO			**20MG/ML**	**A216656**	**002**	Apr 28, 2023
AO			**40MG/ML**	**A216656**	**003**	Apr 28, 2023

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA PRO

	+!	BAYER HLTHCARE	0.045MG/24HR;0.015MG/24HR	N021258	001	Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE;TRANSDERMAL

COMBIPATCH

	+	NOVEN PHARMS INC	0.05MG/24HR;0.14MG/24HR	N020870	001	Aug 07, 1998
	+!		0.05MG/24HR;0.25MG/24HR	N020870	002	Aug 07, 1998

TABLET;ORAL

ACTIVELLA

AB	**+!**	AMNEAL	**1MG;0.5MG**	**N020907**	**001**	Nov 18, 1998

ESTRADIOL AND NORETHINDRONE ACETATE

AB		BARR	**1MG;0.5MG**	**A079193**	**001**	May 11, 2010
AB		BRECKENRIDGE PHARM	**0.5MG;0.1MG**	**A078324**	**002**	Jun 09, 2011
AB			**1MG;0.5MG**	**A078324**	**001**	Apr 17, 2008
AB		MYLAN LABS LTD	**0.5MG;0.1MG**	**A207261**	**001**	Feb 10, 2017
AB			**1MG;0.5MG**	**A207261**	**002**	Feb 10, 2017
AB		NOVAST LABS	**0.5MG;0.1MG**	**A210612**	**001**	Apr 03, 2019
AB			**1MG;0.5MG**	**A210612**	**002**	Apr 03, 2019

AMABELZ

BX		LUPIN LTD	0.5MG;0.1MG	A203339	001	Jun 20, 2016
BX			1MG;0.5MG	A203339	002	Jun 20, 2016

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

TABLET;ORAL

MYFEMBREE

	+!	MYOVANT SCIENCES	1MG;0.5MG;40MG	N214846	001	May 26, 2021

ESTRADIOL; NORGESTIMATE

TABLET;ORAL

ESTRADIOL AND NORGESTIMATE

	!	BARR	1MG,1MG;N/A,0.09MG	A076812	001	Apr 29, 2005

ESTRADIOL; PROGESTERONE

CAPSULE;ORAL

BIJUVA

	+	MAYNE PHARMA	0.5MG;100MG	N210132	002	Dec 28, 2021
	+!		1MG;100MG	N210132	001	Oct 28, 2018

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE;ORAL

EMCYT

	+!	PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045	001	

ESTROGENS, CONJUGATED

CREAM;TOPICAL, VAGINAL

PREMARIN

	+!	WYETH PHARMS	0.625MG/GM	N020216	001	

INJECTABLE;INJECTION

PREMARIN

	+!	WYETH PHARMS	25MG/VIAL	N010402	001	

TABLET;ORAL

PREMARIN

	+	WYETH PHARMS	0.3MG	N004782	003	
	+		0.45MG	N004782	006	Jul 16, 2003
	+!		0.625MG	N004782	004	
	+!		0.9MG	N004782	005	Jan 26, 1984
	+!		1.25MG	N004782	001	

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET;ORAL-28

PREMPHASE 14/14

	+!	WYETH PHARMS	0.625MG,0.625MG;N/A,5MG	N020527	002	Nov 17, 1995

PREMPRO

	+!	WYETH PHARMS	0.3MG;1.5MG	N020527	005	Jun 04, 2003
	+!		0.45MG;1.5MG	N020527	004	Mar 12, 2003
	+!		0.625MG;2.5MG	N020527	001	Nov 17, 1995
	+!		0.625MG;5MG	N020527	003	Jan 09, 1998

ESTROGENS, ESTERIFIED

TABLET;ORAL

MENEST

	MONARCH PHARMS	0.3MG	A084951	001	
		0.625MG	A084948	001	
		1.25MG	A084950	001	
!		2.5MG	A084949	001	

ESTROPIPATE

TABLET;ORAL

OGEN 5

+	PFIZER	6MG	A083220	004	

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB	AURO BINDO PHARMA	**1MG**	**A208451**	**001**	Sep 15, 2016
AB		**2MG**	**A208451**	**002**	Sep 15, 2016
AB		**3MG**	**A208451**	**003**	Sep 15, 2016
AB	DR REDDYS	**1MG**	**A091024**	**001**	Apr 15, 2014
AB		**2MG**	**A091024**	**002**	Apr 15, 2014
AB		**3MG**	**A091024**	**003**	Apr 15, 2014
AB	GLENMARK GENERICS	**1MG**	**A091166**	**001**	Apr 15, 2014
AB		**2MG**	**A091166**	**002**	Apr 15, 2014
AB		**3MG**	**A091166**	**003**	Apr 15, 2014
AB	HETERO LABS LTD V	**1MG**	**A205504**	**001**	Jan 04, 2024
AB		**2MG**	**A205504**	**002**	Jan 04, 2024
AB		**3MG**	**A205504**	**003**	Jan 04, 2024
AB	IPCA LABS LTD	**1MG**	**A206222**	**001**	Dec 29, 2023
AB		**2MG**	**A206222**	**002**	Dec 29, 2023
AB		**3MG**	**A206222**	**003**	Dec 29, 2023
AB	LUPIN LTD	**1MG**	**A091124**	**001**	Sep 13, 2011
AB		**2MG**	**A091124**	**002**	Sep 13, 2011
AB		**3MG**	**A091124**	**003**	Sep 13, 2011
AB	MACLEODS PHARMS LTD	**1MG**	**A202929**	**001**	Jan 30, 2015
AB		**2MG**	**A202929**	**002**	Jan 30, 2015
AB		**3MG**	**A202929**	**003**	Jan 30, 2015
AB	MYLAN PHARMS INC	**1MG**	**A091151**	**001**	Mar 26, 2013
AB		**2MG**	**A091151**	**002**	Mar 26, 2013
AB		**3MG**	**A091151**	**003**	Mar 26, 2013
AB	ORBION PHARMS	**1MG**	**A091113**	**001**	Jun 10, 2014
AB		**2MG**	**A091113**	**002**	Jun 10, 2014
AB		**3MG**	**A091113**	**003**	Jun 10, 2014
AB	SUN PHARM	**1MG**	**A091103**	**001**	Apr 03, 2013
AB		**2MG**	**A091103**	**002**	Apr 03, 2013
AB		**3MG**	**A091103**	**003**	Apr 03, 2013
AB	TEVA	**1MG**	**A091169**	**001**	May 23, 2011
AB		**2MG**	**A091169**	**002**	May 23, 2011
AB		**3MG**	**A091169**	**003**	May 23, 2011

LUNESTA

AB	**+**	WOODWARD	**1MG**	**N021476**	**001**	Dec 15, 2004
AB	**+**		**2MG**	**N021476**	**002**	Dec 15, 2004
AB	**+!**		**3MG**	**N021476**	**003**	Dec 15, 2004

ETELCALCETIDE

SOLUTION;INTRAVENOUS

PARSABIV

+!	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017
+!		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017
+!		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017

ETEPLIRSEN

SOLUTION;INTRAVENOUS

EXONDYS 51

+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016
+!		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016

ETHACRYNATE SODIUM

INJECTABLE;INJECTION

EDECRIN

AP	**+!** BAUSCH	**EQ 50MG BASE/VIAL**	**N016093**	**001**	

ETHACRYNATE SODIUM

AP	MYLAN INSTITUTIONAL	**EQ 50MG BASE/VIAL**	**A204634**	**001**	Aug 23, 2016
AP	PAR STERILE PRODUCTS	**EQ 50MG BASE/VIAL**	**A205473**	**001**	Jul 29, 2015

ETHACRYNATE SODIUM

INJECTABLE;INJECTION

ETHACRYNATE SODIUM

AP		VPI PHARMS INC	**EQ 50MG BASE/VIAL**	**A208663**	**001**	Jun 09, 2020
AP		ZYDUS PHARMS	**EQ 50MG BASE/VIAL**	**A207758**	**001**	Nov 17, 2017

ETHACRYNIC ACID

TABLET;ORAL

EDECRIN

AB	**+!**	BAUSCH	**25MG**	**N016092**	**001**	

ETHACRYNIC ACID

AB		AGNITIO	**25MG**	**A211809**	**001**	Jul 12, 2019
AB		AMNEAL PHARMS CO	**25MG**	**A208805**	**001**	May 08, 2018
AB		CHARTWELL RX	**25MG**	**A213240**	**001**	Oct 19, 2020
AB		EDENBRIDGE PHARMS	**25MG**	**A205609**	**001**	Jun 30, 2016
AB		LUPIN LTD	**25MG**	**A211719**	**001**	Sep 06, 2019
AB		PAR PHARM INC	**25MG**	**A208501**	**001**	Jul 21, 2017
AB		SCIEGEN PHARMS INC	**25MG**	**A211232**	**001**	Aug 27, 2019
AB		UPSHER SMITH LABS	**25MG**	**A212417**	**001**	Feb 19, 2020

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

AB		EPIC PHARMA LLC	**100MG**	**A075095**	**001**	Nov 30, 1999
AB			**400MG**	**A075095**	**002**	Nov 30, 1999
AB		LUPIN	**100MG**	**A078939**	**001**	Jun 17, 2009
AB			**400MG**	**A078939**	**002**	Jun 17, 2009

MYAMBUTOL

AB	**+**	STI PHARMA LLC	**100MG**	**N016320**	**001**	
AB	**+!**		**400MG**	**N016320**	**003**	

ETHANOLAMINE OLEATE

INJECTABLE;INJECTION

ETHAMOLIN

	+!	QOL MEDCL	50MG/ML	N019357	001	Dec 22, 1988

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB		MYLAN LABS LTD	**0.035MG;1MG**	**A204703**	**001**	Jul 28, 2016
AB			**0.05MG;1MG**	**A204704**	**001**	Feb 09, 2016

KELNOR

AB		BARR	**0.035MG;1MG**	**A076785**	**001**	May 23, 2005

LO-MALMOREDE

AB		NOVAST LABS	**0.035MG;1MG**	**A209548**	**001**	Feb 11, 2019

MALMOREDE

AB		NOVAST LABS	**0.05MG;1MG**	**A209547**	**001**	Jul 25, 2018

ZOVIA 1/50E-28

AB	**!**	WATSON LABS	**0.05MG;1MG**	**A072723**	**001**	Dec 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

ELURYNG

AB		AMNEAL	**0.015MG/24HR;0.12MG/24HR**	**A210830**	**001**	Dec 11, 2019

ENILLORING

AB		XIROMED	**0.015MG/24HR;0.12MG/24HR**	**A211157**	**001**	Jun 29, 2023

ETHINYL ESTRADIOL; ETONOGESTREL

AB		TEVA PHARMS USA INC	**0.015MG/24HR;0.12MG/24HR**	**A204305**	**001**	Jan 13, 2021

HALOETTE

AB		DR REDDYS LABS SA	**0.015MG/24HR;0.12MG/24HR**	**A211328**	**001**	Aug 05, 2022

NUVARING

AB	**+!**	ORGANON USA ORGANON	**0.015MG/24HR;0.12MG/24HR**	**N021187**	**001**	Oct 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

SYSTEM;TRANSDERMAL

TWIRLA

	+!	AGILE	0.03MG/24HR;0.12MG/24HR	N204017	001	Feb 14, 2020

TABLET;ORAL

ASHLYNA

AB		GLENMARK GENERICS	**0.03MG,0.01MG;0.15MG,N/A**	**A203163**	**001**	Feb 23, 2015

DAYSEE

AB		LUPIN LTD	**0.03MG,0.01MG;0.15MG,N/A**	**A091467**	**001**	Apr 10, 2013

DOLISHALE

AB		NOVAST LABS	**0.02MG;0.09MG**	**A091692**	**001**	Oct 22, 2020

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

ICLEVIA						
AB		AUROBINDO PHARMA LTD	**0.03MG;0.15MG**	**A206850**	**001**	Jun 29, 2018
INTROVALE						
AB		XIROMED	**0.03MG;0.15MG**	**A079064**	**001**	Sep 27, 2010
JAIMIESS						
AB		XIROMED	**0.03MG,0.01MG;0.15MG,N/A**	**A203770**	**001**	Dec 27, 2017
LEVONORGESTREL AND ETHINYL ESTRADIOL						
AB		AMNEAL PHARMS	**0.03MG;0.15MG**	**A203871**	**001**	Nov 13, 2015
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A203872**	**001**	Dec 22, 2015
AB		GLENMARK GENERICS	**0.02MG;0.09MG**	**A202791**	**001**	Apr 09, 2015
AB		GLENMARK PHARMS LTD	**0.03MG;0.15MG**	**A203164**	**001**	Jun 12, 2015
AB		LUPIN LTD	**0.03MG;0.15MG**	**A091440**	**001**	Oct 23, 2012
AB		MYLAN LABS LTD	**0.03MG;0.15MG**	**A200490**	**001**	Apr 21, 2015
AB	!	WATSON LABS	**0.02MG;0.09MG**	**A079218**	**001**	Jun 06, 2011
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL						
AB		DR REDDYS LABS SA	**0.03MG,0.01MG;0.15MG,N/A**	**A078834**	**001**	May 31, 2011
AB		LUPIN LTD	**0.02MG,0.1MG;0.01MG,N/A**	**A091674**	**001**	Oct 26, 2011
AB		MYLAN LABS LTD	**0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A**	**A206053**	**001**	Oct 02, 2017
AB			**0.02MG,0.1MG;0.01MG,N/A**	**A200493**	**001**	Jun 17, 2015
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A200492**	**001**	May 27, 2015
AB		XIROMED	**0.02MG,0.1MG;0.01MG,N/A**	**A205131**	**001**	Dec 14, 2017
LO SIMPESSE						
AB		AUROBINDO PHARMA	**0.02MG,0.1MG;0.01MG,N/A**	**A206852**	**001**	Apr 28, 2017
LOSEASONIQUE						
AB		TEVA BRANDED PHARM	**0.02MG,0.1MG;0.01MG,N/A**	**N022262**	**001**	Oct 24, 2008
QUARTETTE						
AB	+!	TEVA BRANDED PHARM	**0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A**	**N204061**	**001**	Mar 28, 2013
QUASENSE						
AB		WATSON LABS	**0.03MG;0.15MG**	**A077101**	**001**	Sep 06, 2006
SEASONALE						
AB	+!	TEVA BRANDED PHARM	**0.03MG;0.15MG**	**N021544**	**001**	Sep 05, 2003
SEASONIQUE						
AB	+!	TEVA BRANDED PHARM	**0.03MG,0.01MG;0.15MG,N/A**	**N021840**	**001**	May 25, 2006
SETLAKIN						
AB		NOVAST LABS	**0.03MG;0.15MG**	**A090716**	**001**	Sep 15, 2014
SIMPESSE						
AB		AUROBINDO PHARMA	**0.03MG,0.01MG;0.15MG,N/A**	**A206851**	**001**	Apr 07, 2017
BALCOLTRA						
AB3	+!	AVION PHARMS	**0.02MG;0.1MG**	**N208612**	**001**	Jan 09, 2018
LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB3		XIROMED	**0.02MG;0.1MG**	**A214640**	**001**	Aug 16, 2023
TYBLUME						
	+!	EXELTIS USA INC	0.02MG;0.1MG	N209405	001	Mar 30, 2020

TABLET;ORAL-28

ALTAVERA						
AB		XIROMED	**0.03MG;0.15MG**	**A079102**	**001**	Aug 03, 2010
AYUNA						
AB		AUROBINDO PHARMA	**0.03MG;0.15MG**	**A206866**	**001**	Sep 23, 2016
ENPRESSE-28						
AB		DURAMED PHARMS BARR	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A075809**	**002**	Jul 16, 2001
KURVELO						
AB		LUPIN LTD	**0.03MG;0.15MG**	**A091408**	**001**	Oct 17, 2012
LEVONEST						
AB		NOVAST LABS LTD	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A090719**	**001**	Dec 29, 2010
LEVONORGESTREL AND ETHINYL ESTRADIOL						
AB		LUPIN LTD	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A200248**	**001**	Nov 19, 2015
AB		MYLAN LABS LTD	**0.03MG;0.15MG**	**A091663**	**001**	Dec 21, 2012
AB		NAARI PTE LTD	**0.03MG;0.15MG**	**A207033**	**001**	Oct 09, 2020
LEVORA 0.15/30-28						
AB	!	DR REDDYS LABS SA	**0.03MG;0.15MG**	**A073594**	**001**	Dec 13, 1993
MARLISSA						
AB		GLENMARK GENERICS	**0.03MG;0.15MG**	**A091452**	**001**	Feb 29, 2012
MYZILRA						
AB		VINTAGE PHARMS LLC	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A077502**	**001**	Nov 23, 2011

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

PORTIA-28						
AB		BARR	**0.03MG;0.15MG**	**A075866**	**002**	May 23, 2002
TRIVORA-28						
AB	!	DR REDDYS LABS SA	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A074538**	**002**	Dec 18, 1997
AFIRMELLE						
AB1		AUROBINDO PHARMA	**0.02MG;0.1MG**	**A206886**	**001**	Nov 14, 2016
AVIANE-28						
AB1		DURAMED PHARMS BARR	**0.02MG;0.1MG**	**A075796**	**001**	Apr 30, 2001
FALMINA						
AB1		NOVAST LABS LTD	**0.02MG;0.1MG**	**A090721**	**001**	Mar 28, 2012
LEVONORGESTREL AND ETHINYL ESTRADIOL						
AB1	!	DR REDDYS LABS SA	**0.02MG;0.1MG**	**A076625**	**001**	Nov 18, 2004
AB1		HETERO LABS	**0.02MG;0.1MG**	**A212298**	**001**	Feb 13, 2023
AB1		LUPIN LTD	**0.02MG;0.1MG**	**A091425**	**001**	Jan 18, 2013
AB1		MYLAN LABS LTD	**0.02MG;0.1MG**	**A200245**	**001**	Oct 09, 2013
AB1		NAARI PTE LTD	**0.02MG;0.1MG**	**A207065**	**001**	Aug 17, 2020
VIENVA						
AB1		XIROMED	**0.02MG;0.1MG**	**A201088**	**001**	May 21, 2015
LESSINA-28						
AB2		BARR	**0.02MG;0.1MG**	**A075803**	**002**	Mar 20, 2002
LEVONORGESTREL AND ETHINYL ESTRADIOL						
AB2	!	DR REDDYS LABS SA	**0.02MG;0.1MG**	**A077681**	**001**	May 31, 2006

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN						
AB		AMNEAL	**0.035MG/24HR;0.15MG/24HR**	**A213950**	**001**	Feb 25, 2021
AB		ZYDUS NOVELTECH INC	**0.035MG/24HR;0.15MG/24HR**	**A214594**	**001**	Sep 14, 2023
ONSURA						
AB		TEVA PHARMS USA	**0.035MG/24HR;0.15MG/24HR**	**A213977**	**001**	Aug 25, 2021
XULANE						
AB	!	MYLAN TECHNOLOGIES	**0.035MG/24HR;0.15MG/24HR**	**A200910**	**001**	Apr 16, 2014

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL

NEXESTA FE						
AB		AUROBINDO PHARMA	**0.035MG;0.4MG**	**A207535**	**001**	Feb 02, 2017
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB		AMNEAL PHARMS	**0.035MG;0.4MG**	**A078892**	**001**	Sep 26, 2011
AB		BARR	**0.035MG;0.4MG**	**A078965**	**001**	Aug 05, 2010
AB		LUPIN LTD	**0.035MG;0.4MG**	**A091332**	**001**	Mar 23, 2016
AB	!	MYLAN LABS LTD	**0.035MG;0.4MG**	**A202086**	**001**	Apr 01, 2015
AB		NAARI PTE LTD	**0.035MG;0.4MG**	**A207066**	**001**	Mar 29, 2017

TABLET;ORAL-21

NORTREL 1/35-21						
AB		BARR	**0.035MG;1MG**	**A072693**	**001**	Feb 28, 1992
NORTREL 7/7/7						
		BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478	001	Aug 30, 2002

TABLET;ORAL-28

ALYACEN 1/35						
AB		GLENMARK GENERICS	**0.035MG;1MG**	**A091634**	**001**	Jan 19, 2012
ALYACEN 7/7/7						
AB		GLENMARK GENERICS	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A091636**	**001**	Jan 19, 2012
ARANELLE						
AB		BARR	**0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG**	**A076783**	**001**	Sep 29, 2004
BALZIVA-28						
AB	!	BARR	**0.035MG;0.4MG**	**A076238**	**001**	Apr 22, 2004
BRIELLYN						
AB		GLENMARK GENERICS	**0.035MG;0.4MG**	**A090538**	**001**	Mar 22, 2011
CYONANZ						
AB		AUROBINDO PHARMA	**0.035MG;0.5MG**	**A207055**	**001**	Oct 21, 2016
DASETTA 1/35						
AB		NOVAST LABS LTD	**0.035MG;1MG**	**A090948**	**001**	Dec 22, 2011
DASETTA 7/7/7						
AB	!	NOVAST LABS LTD	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A090946**	**001**	Dec 22, 2011
GILDAGIA						
AB		VINTAGE PHARMS	**0.035MG;0.4MG**	**A078376**	**001**	Nov 06, 2012

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

AB		NAARI PTE LTD	**0.035MG;1MG**	**A206864**	**001**	Apr 28, 2017
AB		WATSON LABS	**0.035MG;0.4MG**	**A078323**	**001**	Feb 04, 2010
AB		WATSON LABS TEVA	**0.035MG;1MG**	**A070687**	**001**	Jan 29, 1987

NORTREL 0.5/35-28

AB		BARR	**0.035MG;0.5MG**	**A072695**	**001**	Feb 28, 1992

NORTREL 1/35-28

AB	**!**	BARR	**0.035MG;1MG**	**A072696**	**001**	Feb 28, 1992

NORTREL 7/7/7

AB		BARR	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A075478**	**002**	Aug 30, 2002

NYLIA 1/35

AB		AUROBINDO PHARMA	**0.035MG;1MG**	**A207056**	**001**	Oct 21, 2016

NYLIA 7/7/7

AB		AUROBINDO PHARMA	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A207054**	**001**	Oct 21, 2016

PHILITH

AB		NOVAST LABS LTD	**0.035MG;0.4MG**	**A090947**	**001**	Dec 22, 2011

TRI-NORINYL 28-DAY

AB	**+!**	DR REDDYS LABS SA	**0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG**	**N018977**	**002**	Apr 13, 1984

VYFEMLA

AB		LUPIN LTD	**0.035MG;0.4MG**	**A201886**	**001**	Sep 26, 2013

WERA

AB	**!**	NOVAST LABS LTD	**0.035MG;0.5MG**	**A091204**	**001**	Mar 27, 2012

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

		WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071044	001	Apr 01, 1988

TABLET, CHEWABLE;ORAL

KAITLIB FE

AB		LUPIN LTD	**0.025MG;0.8MG**	**A203448**	**001**	Dec 17, 2015

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	**+!**	APIL	**0.025MG;0.8MG**	**N022573**	**001**	Dec 22, 2010
AB		MYLAN LABS LTD	**0.025MG;0.8MG**	**A203371**	**001**	Apr 23, 2014

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

GEMMILY

AB		XIROMED	**0.02MG;1MG**	**A213317**	**001**	Nov 09, 2020

MERZEE

AB		SLAYBACK PHARMA LLC	**0.02MG;1MG**	**A212706**	**001**	Dec 18, 2020

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		AMNEAL PHARMS	**0.02MG;1MG**	**A214292**	**001**	Jul 20, 2021
AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A213418**	**001**	Jul 27, 2022

TAYTULLA

AB	**+!**	APIL	**0.02MG;1MG**	**N204426**	**001**	Apr 19, 2013

TABLET;ORAL

AUROVELA 24 FE

AB		AUROBINDO PHARMA	**0.02MG;1MG**	**A207504**	**001**	Jun 15, 2017

BLISOVI 24 FE

AB		LUPIN LTD	**0.02MG;1MG**	**A091398**	**001**	Oct 28, 2015

FINZALA

AB		TEVA PHARMS USA INC	**0.02MG;1MG**	**A210087**	**001**	Apr 07, 2020

FYAVOLV

AB		LUPIN LTD	**0.005MG;1MG**	**A204213**	**002**	Dec 10, 2015
AB			**0.0025MG;0.5MG**	**A204213**	**001**	Dec 10, 2015

GILDESS 24 FE

AB		VINTAGE PHARMS	**0.02MG;1MG**	**A090293**	**001**	Dec 01, 2014

HAILEY 24 FE

AB	**!**	GLENMARK PHARMS LTD	**0.02MG;1MG**	**A204847**	**001**	Nov 17, 2017

LARIN 24 FE

AB		NOVAST LABS	**0.02MG;1MG**	**A202994**	**001**	Feb 18, 2015

LERIBANE

AB		NOVAST LABS	**0.0025MG;0.5MG**	**A203435**	**002**	Jun 03, 2016
AB			**0.005MG;1MG**	**A203435**	**001**	Jun 03, 2016

MIBELAS 24 FE

AB		LUPIN	**0.02MG;1MG**	**A206287**	**001**	May 24, 2016

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	**!**	BARR LABS INC	**0.005MG;1MG**	**A076221**	**001**	Nov 06, 2009
AB		GLENMARK GENERICS	**0.0025MG;0.5MG**	**A203038**	**001**	Apr 02, 2015
AB			**0.005MG;1MG**	**A203038**	**002**	Apr 02, 2015

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		BARR LABS INC	**0.02MG;1MG**	**A090938**	**001**	Dec 01, 2014

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	!	GLENMARK PHARMS LTD	**0.02MG;1MG**	**A210369**	**001**	Dec 26, 2017
AB		XIROMED	**0.02MG;1MG**	**A209609**	**001**	Jul 16, 2018

OSHIH

AB		AURORBINDO PHARMA	**0.02MG;1MG**	**A216558**	**001**	Dec 06, 2023

LO LOESTRIN FE

	+!	APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010

TABLET;ORAL-21

AUROVELA 1.5/30

AB		AUROBINDO PHARMA	**0.03MG;1.5MG**	**A207581**	**001**	Jun 26, 2017

AUROVELA 1/20

AB		AUROBINDO PHARMA	**0.02MG;1MG**	**A207506**	**001**	Jun 16, 2017

HAILEY 1.5/30

AB		GLENMARK PHARMS	**0.03MG;1.5MG**	**A209297**	**001**	Jun 05, 2018

JUNEL 1.5/30

AB		BARR	**0.03MG;1.5MG**	**A076381**	**001**	May 30, 2003

JUNEL 1/20

AB		BARR	**0.02MG;1MG**	**A076380**	**001**	May 30, 2003

LARIN 1.5/30

AB		NOVAST LABS	**0.03MG;1.5MG**	**A202996**	**001**	Mar 20, 2014

LARIN 1/20

AB		NOVAST LABS	**0.02MG;1MG**	**A202995**	**001**	Dec 04, 2013

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A206969**	**001**	Jan 20, 2016
AB		MYLAN LABS LTD	**0.02MG;1MG**	**A202771**	**001**	Nov 06, 2013
AB			**0.03MG;1.5MG**	**A202770**	**001**	Feb 19, 2015

TABLET;ORAL-28

AUROVELA FE 1.5/30

AB		AUROBINDO PHARMA	**0.03MG;1.5MG**	**A207580**	**001**	Jun 15, 2017

AUROVELA FE 1/20

AB		AUROBINDO PHARMA	**0.02MG;1MG**	**A207505**	**001**	Jun 16, 2017

BLISOVI FE 1/20

AB		LUPIN LTD	**0.02MG;1MG**	**A201584**	**001**	Nov 18, 2015

CHABELINA FE

AB	!	NOVAST LABS	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A202962**	**001**	Apr 15, 2020

HAILEY FE 1.5/30

AB		GLENMARK PHARMS	**0.03MG;1.5MG**	**A209031**	**001**	Jun 05, 2018

HAILEY FE 1/20

AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A206597**	**001**	Nov 21, 2017

JUNEL FE 1.5/30

AB	!	BARR	**0.03MG;1.5MG**	**A076064**	**001**	Sep 18, 2003

JUNEL FE 1/20

AB		BARR	**0.02MG;1MG**	**A076081**	**001**	Sep 18, 2003

LARIN FE 1.5/30

AB		NOVAST LABS	**0.03MG;1.5MG**	**A091453**	**001**	Aug 23, 2013

LARIN FE 1/20

AB		NOVAST LABS	**0.02MG;1MG**	**A091454**	**001**	Aug 26, 2013

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB		MYLAN	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A205069**	**001**	Jun 22, 2018
AB		MYLAN LABS LTD	**0.02MG;1MG**	**A202772**	**001**	Nov 14, 2013
AB			**0.03MG;1.5MG**	**A202741**	**001**	Feb 20, 2015

TRI-LEGEST FE

AB		BARR	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A076105**	**001**	Oct 26, 2007

BLISOVI FE 1.5/30

BX		LUPIN LTD	0.03MG;1.5MG	A201585	001	Nov 18, 2015

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

ESTARYLLA

AB		XIROMED	**0.035MG;0.25MG**	**A090794**	**001**	Jan 30, 2013

MILI

AB		AUROBINDO PHARMA LTD	**0.035MG;0.25MG**	**A205449**	**001**	Jul 07, 2016

MONO-LINYAH

AB		NOVAST LABS LTD	**0.035MG;0.25MG**	**A090523**	**001**	May 23, 2012

NORGESTIMATE AND ETHINYL ESTRADIOL

AB		AMNEAL PHARMS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A203873**	**001**	May 12, 2016
AB	!	GLENMARK GENERICS	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A200494**	**001**	Jun 17, 2011
AB			**0.035MG;0.25MG**	**A200538**	**001**	Apr 05, 2012

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	!	GLENMARK PHARMS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A204057**	**001**	Feb 23, 2016
AB		LUPIN LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A205588**	**001**	Apr 26, 2016
AB			**0.035MG;0.25MG**	**A205630**	**001**	Oct 27, 2016
AB		LUPIN PHARMS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A200541**	**001**	Jun 25, 2012
AB		NAARI PTE LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A200383**	**001**	Apr 07, 2015
AB			**0.035MG;0.25MG**	**A200384**	**001**	Apr 07, 2015
		PREVIFEM				
AB		VINTAGE PHARMS LLC	**0.035MG;0.25MG**	**A076334**	**001**	Jan 09, 2004
		SPRINTEC				
AB	!	BARR	**0.035MG;0.25MG**	**A075804**	**001**	Sep 25, 2002
		TRI LO SPRINTEC				
AB		BARR LABS INC	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A076784**	**001**	Jun 29, 2009
		TRI-ESTARYLLA				
AB		XIROMED	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A090793**	**001**	Jan 30, 2013
		TRI-LINYAH				
AB		NOVAST LABS LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A090524**	**001**	May 30, 2012
		TRI-LO-ESTARYLLA				
AB		XIROMED	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A091232**	**001**	Jun 29, 2015
		TRI-LO-LINYAH				
AB		NOVAST LABS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A090541**	**001**	Sep 02, 2022
		TRI-LO-MILI				
AB		AURODINDO PHARMA	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A205762**	**001**	Nov 04, 2016
		TRI-MILI				
AB		AURODINDO PHARMA LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A205441**	**001**	Jul 06, 2016
		TRI-SPRINTEC				
AB		BARR	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A075808**	**001**	Dec 29, 2003

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

CRYSELLE

AB		DURAMED PHARMS BARR	**0.03MG;0.3MG**	**A075840**	**001**	Nov 30, 2001

TABLET;ORAL-28

CRYSELLE

AB	!	DURAMED PHARMS BARR	**0.03MG;0.3MG**	**A075840**	**002**	Nov 30, 2001
		ELINEST				
AB		NOVAST LABS LTD	**0.03MG;0.3MG**	**A091105**	**001**	Mar 28, 2012
		LOW-OGESTREL-28				
AB		DR REDDYS LABS SA	**0.03MG;0.3MG**	**A075288**	**002**	Jul 28, 1999
		TURQOZ				
AB		LUPIN LTD	**0.03MG;0.3MG**	**A202980**	**001**	Jul 31, 2023

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING;VAGINAL

ANNOVERA

+!	MAYNE PHARMA	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018

ETHIODIZED OIL

OIL;INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

+!	GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190	001	

ETHIONAMIDE

TABLET;ORAL

TRECATOR

+!	WYETH PHARMS	250MG	N013026	002	

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB		AKORN	**250MG**	**A040686**	**001**	May 28, 2008
AB		BIONPHARMA	**250MG**	**A040430**	**001**	Oct 28, 2002
AB		HERITAGE PHARMS INC	**250MG**	**A200892**	**001**	Sep 25, 2012
AB		PURACAP PHARM LLC	**250MG**	**A210654**	**001**	Mar 16, 2020
AB		STRIDES PHARMA	**250MG**	**A211928**	**001**	Feb 19, 2019

ZARONTIN

AB	**+!**	PARKE DAVIS	**250MG**	**N012380**	**001**	

SYRUP;ORAL

ETHOSUXIMIDE

AA		MIKART	**250MG/5ML**	**A040506**	**001**	Dec 22, 2003
AA		PHARM ASSOC	**250MG/5ML**	**A040253**	**001**	Nov 22, 2000

ZARONTIN

AA	**+!**	PARKE-DAVIS	**250MG/5ML**	**A080258**	**001**	

ETODOLAC

CAPSULE;ORAL

ETODOLAC

AB		ANI PHARMS	**200MG**	**A075126**	**001**	Sep 16, 1999
AB			**300MG**	**A075126**	**002**	Sep 16, 1999
AB		APOTEX	**200MG**	**A075419**	**001**	Jul 28, 2000
AB			**300MG**	**A075419**	**002**	Jul 28, 2000
AB		TARO	**200MG**	**A075078**	**001**	Apr 30, 1998
AB	**!**		**300MG**	**A075078**	**002**	Apr 30, 1998

TABLET;ORAL

ETODOLAC

AB		AMNEAL PHARMS CO	**400MG**	**A208834**	**001**	Jun 07, 2018
AB			**500MG**	**A208834**	**002**	Jun 07, 2018
AB		APOTEX INC	**400MG**	**A076004**	**001**	Dec 03, 2002
AB			**500MG**	**A076004**	**002**	Dec 03, 2002
AB		BAYSHORE PHARMS LLC	**400MG**	**A210704**	**001**	Dec 16, 2020
AB			**500MG**	**A210704**	**002**	Dec 16, 2020
AB		SANDOZ	**400MG**	**A074903**	**001**	Apr 11, 1997
AB			**500MG**	**A074903**	**002**	Apr 19, 1999
AB		TARO PHARM INDS	**400MG**	**A075074**	**001**	Mar 11, 1998
AB	**!**		**500MG**	**A075074**	**002**	Apr 25, 2000

TABLET, EXTENDED RELEASE;ORAL

ETODOLAC

AB		BAYSHORE PHARMS LLC	**400MG**	**A212263**	**001**	Nov 24, 2020
AB			**500MG**	**A212263**	**002**	Nov 24, 2020
AB			**600MG**	**A212263**	**003**	Nov 24, 2020
AB		TARO	**400MG**	**A076174**	**001**	Mar 13, 2003
AB			**500MG**	**A076174**	**002**	Mar 13, 2003
AB			**600MG**	**A076174**	**003**	Mar 13, 2003
AB		TEVA	**400MG**	**A075665**	**003**	Feb 05, 2001
AB			**500MG**	**A075665**	**002**	Jul 31, 2000
AB	**!**		**600MG**	**A075665**	**001**	Jul 31, 2000
AB		ZYDUS PHARMS	**400MG**	**A091134**	**001**	Jan 23, 2014
AB			**500MG**	**A091134**	**002**	Jan 23, 2014
AB			**600MG**	**A091134**	**003**	Jan 23, 2014

ETOMIDATE

INJECTABLE;INJECTION

AMIDATE

AP	**+!**	HOSPIRA	**2MG/ML**	**N018227**	**001**	Sep 07, 1982

ETOMIDATE

AP		CAPLIN	**2MG/ML**	**A215028**	**001**	Dec 18, 2020
AP		EUGIA PHARMA	**2MG/ML**	**A206126**	**001**	Feb 24, 2017
AP		GLAND PHARMA LTD	**2MG/ML**	**A209058**	**001**	Apr 18, 2017
AP		HIKMA	**2MG/ML**	**A074593**	**001**	Nov 04, 1996
AP			**2MG/ML**	**A202354**	**001**	Feb 25, 2016
AP		MYLAN LABS LTD	**2MG/ML**	**A201044**	**001**	Feb 07, 2017
AP		ZYDUS PHARMS	**2MG/ML**	**A202360**	**001**	Jul 18, 2014

ETONOGESTREL

IMPLANT;IMPLANTATION

NEXPLANON

	+!	ORGANON	68MG/IMPLANT	N021529	002	May 13, 2011

ETOPOSIDE						
CAPSULE;ORAL						
ETOPOSIDE						
	!	MYLAN	50MG	A075635	001	Sep 19, 2001
INJECTABLE;INJECTION						
ETOPOSIDE						
AP		ACCORD HLTHCARE	**20MG/ML**	**A074513**	**001**	Mar 14, 1996
AP	**!**	FRESENIUS KABI USA	**20MG/ML**	**A074983**	**001**	Sep 30, 1998
AP		HIKMA	**20MG/ML**	**A074290**	**001**	Jul 17, 1995
AP		MEITHEAL	**20MG/ML**	**A074529**	**001**	Jul 24, 1996
ETOPOSIDE PHOSPHATE						
INJECTABLE;INJECTION						
ETOPOPHOS PRESERVATIVE FREE						
	+!	CHEPLAPHARM	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996
ETRASIMOD ARGININE						
TABLET;ORAL						
VELSIPITY						
	+!	PFIZER	EQ 2MG BASE	N216956	001	Oct 12, 2023
ETRAVIRINE						
TABLET;ORAL						
ETRAVIRINE						
AB		AMNEAL	**100MG**	**A214196**	**002**	Jun 14, 2021
AB			**200MG**	**A214196**	**003**	Jun 14, 2021
AB		CARNEGIE	**100MG**	**A215402**	**001**	Apr 13, 2022
AB			**200MG**	**A215402**	**002**	Apr 13, 2022
INTELENCE						
AB	**+**	JANSSEN R AND D	**100MG**	**N022187**	**001**	Jan 18, 2008
AB	**+!**		**200MG**	**N022187**	**002**	Dec 22, 2010
	+		25MG	N022187	003	Mar 26, 2012
EVEROLIMUS						
TABLET;ORAL						
AFINITOR						
AB	**+**	NOVARTIS	**2.5MG**	**N022334**	**003**	Jul 09, 2010
AB	**+!**		**5MG**	**N022334**	**001**	Mar 30, 2009
AB	**+**		**7.5MG**	**N022334**	**004**	Mar 30, 2012
AB	**+**		**10MG**	**N022334**	**002**	Mar 30, 2009
EVEROLIMUS						
AB		ALKEM LABS LTD	**0.25MG**	**A214138**	**001**	Nov 26, 2021
AB			**0.5MG**	**A214138**	**002**	Nov 26, 2021
AB			**0.75MG**	**A214138**	**003**	Nov 26, 2021
AB			**1MG**	**A214138**	**004**	Nov 26, 2021
AB		BIOCON PHARMA	**2.5MG**	**A214182**	**001**	Feb 11, 2021
AB			**5MG**	**A214182**	**002**	Feb 11, 2021
AB			**7.5MG**	**A214182**	**003**	Feb 11, 2021
AB			**10MG**	**A214182**	**004**	Feb 11, 2021
AB		BRECKENRIDGE	**0.25MG**	**A205432**	**001**	May 20, 2021
AB			**0.5MG**	**A205432**	**002**	May 20, 2021
AB			**0.75MG**	**A205432**	**003**	May 20, 2021
AB			**2.5MG**	**A205426**	**001**	Mar 05, 2021
AB			**5MG**	**A205426**	**002**	Mar 05, 2021
AB			**7.5MG**	**A205426**	**003**	Mar 05, 2021
AB			**10MG**	**A205426**	**004**	Mar 05, 2021
AB		HIKMA	**0.25MG**	**A206133**	**001**	Apr 12, 2018
AB			**0.5MG**	**A206133**	**002**	Apr 12, 2018
AB			**0.75MG**	**A206133**	**003**	Apr 12, 2018
AB			**1MG**	**A206133**	**004**	Nov 18, 2021
AB			**2.5MG**	**A207486**	**001**	Jun 08, 2020
AB			**5MG**	**A207486**	**002**	Jun 08, 2020
AB			**7.5MG**	**A207486**	**003**	Jun 08, 2020
AB			**10MG**	**A207486**	**004**	Nov 23, 2021
AB		MYLAN	**2.5MG**	**A212936**	**001**	Jun 08, 2020
AB			**5MG**	**A212936**	**002**	Jun 08, 2020
AB			**7.5MG**	**A212936**	**003**	Jun 08, 2020
AB			**10MG**	**A212936**	**004**	Jun 08, 2020
AB		PAR PHARM	**0.25MG**	**A205775**	**001**	Oct 18, 2021
AB			**0.5MG**	**A205775**	**002**	Oct 18, 2021
AB			**0.75MG**	**A205775**	**003**	Oct 18, 2021
AB			**1MG**	**A205775**	**004**	Oct 18, 2021
AB			**2.5MG**	**A207934**	**001**	Dec 09, 2019
AB			**5MG**	**A207934**	**002**	Dec 09, 2019

EVEROLIMUS

TABLET;ORAL

EVEROLIMUS

AB			**7.5MG**	**A207934**	**003**	Dec 09, 2019
AB			**10MG**	**A207934**	**004**	Dec 09, 2020
AB		TEVA PHARMS USA	**2.5MG**	**A210050**	**001**	Dec 09, 2019
AB			**5MG**	**A210050**	**002**	Dec 09, 2019
AB			**7.5MG**	**A210050**	**003**	Dec 09, 2019
AB			**10MG**	**A210050**	**004**	Dec 09, 2019

ZORTRESS

AB	+	NOVARTIS	**0.25MG**	**N021560**	**001**	Apr 20, 2010
AB	+		**0.5MG**	**N021560**	**002**	Apr 20, 2010
AB	+		**0.75MG**	**N021560**	**003**	Apr 20, 2010
AB	+!		**1MG**	**N021560**	**004**	Aug 10, 2018

TABLET, FOR SUSPENSION;ORAL

AFINITOR DISPERZ

AB	+	NOVARTIS PHARM	**2MG**	**N203985**	**001**	Aug 29, 2012
AB	+		**3MG**	**N203985**	**002**	Aug 29, 2012
AB	+!		**5MG**	**N203985**	**003**	Aug 29, 2012

EVEROLIMUS

AB		MYLAN	**2MG**	**A210130**	**001**	Apr 19, 2019
AB			**3MG**	**A210130**	**002**	Apr 19, 2019
AB			**5MG**	**A210130**	**003**	Apr 19, 2019

EXEMESTANE

TABLET;ORAL

AROMASIN

AB	+!	PFIZER	**25MG**	**N020753**	**001**	Oct 21, 1999

EXEMESTANE

AB		BRECKENRIDGE	**25MG**	**A211031**	**001**	Feb 21, 2019
AB		CIPLA	**25MG**	**A210323**	**001**	Apr 27, 2018
AB		EUGIA PHARMA	**25MG**	**A216454**	**001**	May 20, 2022
AB		HIKMA	**25MG**	**A077431**	**001**	Apr 01, 2011
AB		QILU	**25MG**	**A213547**	**001**	Apr 13, 2020
AB		RISING	**25MG**	**A203315**	**001**	Mar 10, 2017
AB		UPSHER SMITH LABS	**25MG**	**A209208**	**001**	Jul 26, 2017
AB		ZYDUS PHARMS	**25MG**	**A202602**	**001**	Oct 03, 2018

EXENATIDE SYNTHETIC

INJECTABLE;SUBCUTANEOUS

BYETTA

	+!	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005
	+!		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON BCISE

	+!	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017

EZETIMIBE

TABLET;ORAL

EZETIMIBE

AB		ACCORD HLTHCARE	**10MG**	**A211550**	**001**	Oct 26, 2018
AB		ALKEM LABS LTD	**10MG**	**A209234**	**001**	Dec 21, 2017
AB		AMNEAL PHARMS CO	**10MG**	**A208803**	**001**	Jun 12, 2017
AB		AUROBINDO PHARMA	**10MG**	**A209838**	**001**	Aug 25, 2017
AB		GLENMARK PHARMS LTD	**10MG**	**A078560**	**001**	Jun 26, 2015
AB		HETERO LABS LTD III	**10MG**	**A210859**	**001**	Jul 26, 2022
AB		OHM LABS INC	**10MG**	**A207311**	**001**	Jun 12, 2017
AB		ORIENT PHARMA	**10MG**	**A215693**	**001**	Sep 13, 2022
AB		SANDOZ	**10MG**	**A203931**	**001**	Jun 12, 2017
AB		SCIEGEN PHARMS INC	**10MG**	**A210673**	**001**	Oct 23, 2020
AB		WATSON LABS INC	**10MG**	**A200831**	**001**	Jun 12, 2017
AB		ZYDUS PHARMS	**10MG**	**A204331**	**001**	Jun 12, 2017

ZETIA

AB	+!	ORGANON	**10MG**	**N021445**	**001**	Oct 25, 2002

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

AB		ALKEM LABS LTD	**10MG;10MG**	**A209222**	**001**	Dec 22, 2017
AB			**10MG;20MG**	**A209222**	**002**	Dec 22, 2017
AB			**10MG;40MG**	**A209222**	**003**	Dec 22, 2017
AB			**10MG;80MG**	**A209222**	**004**	Dec 22, 2017
AB		AMNEAL PHARMS CO	**10MG;10MG**	**A208831**	**001**	Nov 21, 2017
AB			**10MG;20MG**	**A208831**	**002**	Nov 21, 2017

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

AB			**10MG;40MG**	**A208831**	**003**	Nov 21, 2017
AB			**10MG;80MG**	**A208831**	**004**	Nov 21, 2017
AB		DR REDDYS LABS SA	**10MG;10MG**	**A200909**	**001**	Apr 26, 2017
AB			**10MG;20MG**	**A200909**	**002**	Apr 26, 2017
AB			**10MG;40MG**	**A200909**	**003**	Apr 26, 2017
AB			**10MG;80MG**	**A200909**	**004**	Apr 26, 2017
AB		GLENMARK PHARMS LTD	**10MG;10MG**	**A208699**	**001**	Jun 27, 2019
AB			**10MG;20MG**	**A208699**	**002**	Jun 27, 2019
AB			**10MG;40MG**	**A208699**	**003**	Jun 27, 2019
AB			**10MG;80MG**	**A208699**	**004**	Jun 27, 2019
AB		WATSON LABS INC	**10MG;10MG**	**A202968**	**001**	Apr 26, 2017
AB			**10MG;20MG**	**A202968**	**002**	Apr 26, 2017
AB			**10MG;40MG**	**A202968**	**003**	Apr 26, 2017
AB			**10MG;80MG**	**A202968**	**004**	Apr 26, 2017

VYTORIN

AB	**+**	ORGANON	**10MG;10MG**	**N021687**	**001**	Jul 23, 2004
AB	**+**		**10MG;20MG**	**N021687**	**002**	Jul 23, 2004
AB	**+**		**10MG;40MG**	**N021687**	**003**	Jul 23, 2004
AB	**+!**		**10MG;80MG**	**N021687**	**004**	Jul 23, 2004

FAMCICLOVIR

TABLET;ORAL

FAMCICLOVIR

AB		APOTEX	**125MG**	**A091480**	**001**	Jul 22, 2011
AB			**250MG**	**A091480**	**002**	Jul 22, 2011
AB			**500MG**	**A091480**	**003**	Jul 22, 2011
AB		AUROBINDO PHARMA LTD	**125MG**	**A091114**	**001**	Mar 21, 2011
AB			**250MG**	**A091114**	**002**	Mar 21, 2011
AB			**500MG**	**A091114**	**003**	Mar 21, 2011
AB		HETERO LABS LTD V	**125MG**	**A202438**	**001**	Sep 10, 2014
AB			**250MG**	**A202438**	**002**	Sep 10, 2014
AB			**500MG**	**A202438**	**003**	Sep 10, 2014
AB		MACLEODS PHARMS LTD	**125MG**	**A201022**	**001**	Jan 12, 2012
AB			**250MG**	**A201022**	**002**	Jan 12, 2012
AB			**500MG**	**A201022**	**003**	Jan 12, 2012
AB		TEVA PHARMS	**125MG**	**A077487**	**001**	Aug 24, 2007
AB			**250MG**	**A077487**	**002**	Aug 24, 2007
AB	**!**		**500MG**	**A077487**	**003**	Aug 24, 2007

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB		AJANTA PHARMA LTD	**40MG/5ML**	**A217529**	**001**	Sep 18, 2023
AB		AKORN	**40MG/5ML**	**A201995**	**001**	May 30, 2014
AB		ALKEM LABS LTD	**40MG/5ML**	**A216400**	**001**	May 15, 2023
AB		AMNEALS PHARMS	**40MG/5ML**	**A216427**	**001**	Aug 04, 2022
AB		ANNORA PHARMA	**40MG/5ML**	**A217330**	**001**	Aug 17, 2023
AB		CARNEGIE	**40MG/5ML**	**A217137**	**001**	Jul 07, 2023
AB		LUPIN LTD	**40MG/5ML**	**A090440**	**001**	Jun 29, 2010
AB		MICRO LABS	**40MG/5ML**	**A217842**	**001**	Sep 14, 2023
AB		NAVINTA LLC	**40MG/5ML**	**A091020**	**001**	May 27, 2010
AB		NOVEL LABS INC	**40MG/5ML**	**A201695**	**001**	Dec 17, 2012
AB	**!**	NOVITIUM PHARMA	**40MG/5ML**	**A215043**	**001**	Apr 20, 2021
AB		UPSHER SMITH LABS	**40MG/5ML**	**A217655**	**001**	Jun 16, 2023

INJECTABLE;INJECTION

FAMOTIDINE

AP		FRESENIUS KABI USA	**10MG/ML**	**A075709**	**001**	Apr 16, 2001
AP	**!**	HIKMA	**10MG/ML**	**A075488**	**001**	Apr 16, 2001
AP		MYLAN LABS LTD	**10MG/ML**	**A078641**	**001**	Jun 25, 2008
AP		SAGENT	**10MG/ML**	**A075651**	**001**	Apr 16, 2001
AP			**10MG/ML**	**A075684**	**001**	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**10MG/ML**	**A075813**	**001**	Apr 16, 2001
AP	**!**	HIKMA	**10MG/ML**	**A075486**	**001**	Apr 16, 2001
AP		MYLAN LABS LTD	**10MG/ML**	**A078642**	**001**	Jun 25, 2008
AP		SAGENT	**10MG/ML**	**A075622**	**001**	Apr 16, 2001
AP			**10MG/ML**	**A075825**	**001**	Apr 17, 2001

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

	!	BAXTER HLTHCARE	0.4MG/ML	A075591	001	May 10, 2001

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

AB		ALEMBIC PHARMS LTD	**20MG**	**A078916**	**001**	May 22, 2009
AB			**40MG**	**A078916**	**002**	May 22, 2009
AB		ALKEM LABS LTD	**20MG**	**A215630**	**001**	Jan 07, 2022
AB			**20MG**	**A217375**	**001**	Apr 24, 2023
AB			**40MG**	**A215630**	**002**	Jan 07, 2022
AB			**40MG**	**A217375**	**002**	Apr 24, 2023
AB		ANNORA PHARMA	**20MG**	**A215767**	**001**	Nov 04, 2021
AB			**40MG**	**A215767**	**002**	Nov 04, 2021
AB		APOTEX	**20MG**	**A075611**	**001**	Jul 23, 2001
AB			**40MG**	**A075611**	**002**	Jul 23, 2001
AB		ASCENT PHARMS INC	**20MG**	**A215689**	**001**	Oct 15, 2021
AB			**40MG**	**A215689**	**002**	Oct 15, 2021
AB		AUROBINDO PHARMA LTD	**20MG**	**A206530**	**001**	Dec 22, 2015
AB	**!**		**40MG**	**A206530**	**002**	Dec 22, 2015
AB		CARLSBAD	**20MG**	**A075805**	**001**	Apr 16, 2001
AB			**40MG**	**A075805**	**002**	Apr 16, 2001
AB		CHARTWELL RX	**20MG**	**A075786**	**001**	Apr 16, 2001
AB			**40MG**	**A075786**	**002**	Apr 16, 2001
AB		CONTRACT PHARMACAL	**20MG**	**A217669**	**001**	Dec 20, 2023
AB			**40MG**	**A217669**	**002**	Dec 20, 2023
AB		DR REDDYS LABS LTD	**20MG**	**A075718**	**001**	Apr 16, 2001
AB			**40MG**	**A075718**	**002**	Apr 16, 2001
AB		GRAVITI PHARMS	**20MG**	**A218181**	**001**	Dec 22, 2023
AB			**40MG**	**A218181**	**002**	Dec 22, 2023
AB		IVAX SUB TEVA PHARMS	**20MG**	**A075511**	**001**	Apr 16, 2001
AB			**40MG**	**A075511**	**002**	Apr 16, 2001
AB		MANKIND PHARMA	**20MG**	**A075302**	**001**	Apr 16, 2001
AB			**40MG**	**A075302**	**002**	Apr 16, 2001
AB		ZYDUS PHARMS	**20MG**	**A216441**	**001**	Jun 03, 2022
AB			**40MG**	**A216441**	**002**	Jun 03, 2022

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

DUEXIS

AB	**+!**	HORIZON	**26.6MG;800MG**	**N022519**	**001**	Apr 23, 2011

IBUPROFEN AND FAMOTIDINE

AB		ALKEM LABS LTD	**26.6MG;800MG**	**A211890**	**001**	Aug 03, 2021
AB		ASCENT PHARMS INC	**26.6MG;800MG**	**A216814**	**001**	Mar 15, 2023
AB		TEVA PHARMS USA	**26.6MG;800MG**	**A211278**	**001**	Oct 29, 2021

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

AB		ALEMBIC	**40MG**	**A205421**	**001**	Jul 01, 2019
AB			**80MG**	**A205421**	**002**	Jul 01, 2019
AB		ALKEM LABS LTD	**40MG**	**A212924**	**001**	Dec 07, 2021
AB			**80MG**	**A212924**	**002**	Dec 07, 2021
AB		AUROBINDO PHARMA LTD	**40MG**	**A210741**	**001**	Oct 25, 2023
AB			**80MG**	**A210741**	**002**	Oct 25, 2023
AB		DR REDDYS	**40MG**	**A205374**	**001**	Oct 22, 2020
AB			**80MG**	**A205374**	**002**	Oct 22, 2020
AB		HIKMA	**40MG**	**A205414**	**001**	Oct 15, 2019
AB			**80MG**	**A205414**	**002**	Oct 15, 2019
AB		INDOCO	**40MG**	**A210292**	**001**	Dec 30, 2019
AB			**80MG**	**A210292**	**002**	Dec 30, 2019
AB		MACLEODS PHARMS LTD	**40MG**	**A207293**	**001**	Sep 28, 2023
AB			**80MG**	**A207293**	**002**	Sep 28, 2023
AB		MSN	**40MG**	**A210461**	**001**	Dec 30, 2019
AB			**80MG**	**A210461**	**002**	Dec 30, 2019
AB		PRINSTON INC	**40MG**	**A206266**	**001**	Mar 28, 2022
AB			**80MG**	**A206266**	**002**	Mar 28, 2022
AB		SUN PHARM	**40MG**	**A205467**	**001**	Jul 01, 2019
AB			**80MG**	**A205467**	**002**	Jul 01, 2019
AB		SUNSHINE	**40MG**	**A213069**	**001**	Jun 02, 2020
AB			**80MG**	**A213069**	**002**	Jun 02, 2020
AB		ZYDUS LIFESCIENCES	**40MG**	**A205443**	**001**	Jan 09, 2023
AB			**80MG**	**A205443**	**002**	Jan 09, 2023

FEBUXOSTAT

TABLET;ORAL

ULORIC

AB	**+**	TAKEDA PHARMS USA	**40MG**	**N021856**	**001**	Feb 13, 2009
AB	**+!**		**80MG**	**N021856**	**002**	Feb 13, 2009

FEDRATINIB HYDROCHLORIDE

CAPSULE;ORAL

INREBIC

	+!	IMPACT	EQ 100MG BASE	N212327	001	Aug 16, 2019

FELBAMATE

SUSPENSION;ORAL

FELBAMATE

AB		AMNEAL PHARMS	**600MG/5ML**	**A202385**	**001**	Dec 16, 2011
AB		NOVITIUM PHARMA	**600MG/5ML**	**A211333**	**001**	May 31, 2019
AB		TARO	**600MG/5ML**	**A206314**	**001**	Jun 16, 2017

FELBATOL

AB	**+!**	MYLAN SPECIALITY LP	**600MG/5ML**	**N020189**	**003**	Jul 29, 1993

TABLET;ORAL

FELBAMATE

AB		ALVOGEN	**400MG**	**A204595**	**001**	Jan 11, 2016
AB			**600MG**	**A204595**	**002**	Jan 11, 2016
AB		AMNEAL PHARMS	**400MG**	**A201680**	**001**	Sep 13, 2011
AB			**600MG**	**A201680**	**002**	Sep 13, 2011
AB		ANI PHARMS	**400MG**	**A202284**	**001**	Nov 04, 2015
AB			**600MG**	**A202284**	**002**	Nov 04, 2015
AB		CADILA	**400MG**	**A208970**	**001**	May 30, 2017
AB			**600MG**	**A208970**	**002**	May 30, 2017
AB		TARO	**400MG**	**A207093**	**001**	Apr 20, 2017
AB			**600MG**	**A207093**	**002**	Apr 20, 2017

FELBATOL

AB	**+**	MYLAN SPECIALITY LP	**400MG**	**N020189**	**001**	Jul 29, 1993
AB	**+!**		**600MG**	**N020189**	**002**	Jul 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

AB		AUROBINDO PHARMA LTD	**2.5MG**	**A203417**	**001**	Jan 17, 2013
AB			**5MG**	**A203417**	**002**	Jan 17, 2013
AB			**10MG**	**A203417**	**003**	Jan 17, 2013
AB		GLENMARK GENERICS	**2.5MG**	**A090365**	**001**	Dec 17, 2010
AB			**5MG**	**A090365**	**002**	Dec 17, 2010
AB			**10MG**	**A090365**	**003**	Dec 17, 2010
AB		HERITAGE PHARMS	**2.5MG**	**A201964**	**001**	Nov 08, 2013
AB			**5MG**	**A201964**	**002**	Nov 08, 2013
AB			**10MG**	**A201964**	**003**	Nov 08, 2013
AB		ORBION PHARMS	**2.5MG**	**A203032**	**001**	May 21, 2015
AB			**5MG**	**A203032**	**002**	May 21, 2015
AB			**10MG**	**A203032**	**003**	May 21, 2015
AB		SUN PHARM INDS LTD	**2.5MG**	**A091200**	**001**	Dec 13, 2013
AB			**5MG**	**A091200**	**002**	Dec 13, 2013
AB			**10MG**	**A091200**	**003**	Dec 13, 2013
AB		TORRENT PHARMS LTD	**2.5MG**	**A202170**	**001**	Nov 28, 2011
AB			**5MG**	**A202170**	**002**	Nov 28, 2011
AB	**!**		**10MG**	**A202170**	**003**	Nov 28, 2011
AB		VINTAGE PHARMS LLC	**2.5MG**	**A200815**	**001**	Oct 28, 2011
AB			**5MG**	**A200815**	**002**	Oct 28, 2011
AB			**10MG**	**A200815**	**003**	Oct 28, 2011
AB		YILING	**2.5MG**	**A210847**	**001**	Oct 26, 2018
AB			**5MG**	**A210847**	**002**	Oct 26, 2018
AB			**10MG**	**A210847**	**003**	Oct 26, 2018
AB		YUNG SHIN PHARM	**2.5MG**	**A204800**	**001**	Apr 29, 2019
AB			**5MG**	**A204800**	**002**	Apr 29, 2019
AB			**10MG**	**A204800**	**003**	Apr 29, 2019

FENFLURAMINE HYDROCHLORIDE

SOLUTION;ORAL

FINTEPLA

	+!	UCB INC	EQ 2.2MG BASE/ML	N212102	001	Jun 25, 2020

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

AB	+	LUPIN	**43MG**	**N021695**	**001**	Nov 30, 2004
AB	+!		**130MG**	**N021695**	**003**	Nov 30, 2004

FENOFIBRATE

AB		SUN PHARM INDS LTD	**43MG**	**A201748**	**001**	Oct 31, 2014
AB			**130MG**	**A201748**	**002**	Oct 31, 2014

FENOFIBRATE (MICRONIZED)

AB		AJANTA PHARMA LTD	**67MG**	**A210705**	**001**	Sep 10, 2018
AB			**134MG**	**A210705**	**002**	Sep 10, 2018
AB	!		**200MG**	**A210705**	**003**	Sep 10, 2018
AB		ALEMBIC	**67MG**	**A213842**	**001**	Oct 19, 2020
AB			**134MG**	**A213842**	**002**	Oct 19, 2020
AB			**200MG**	**A213842**	**003**	Oct 19, 2020
AB		ANI PHARMS	**67MG**	**A209504**	**001**	Apr 30, 2018
AB			**134MG**	**A209504**	**002**	Apr 30, 2018
AB			**200MG**	**A209504**	**003**	Apr 30, 2018
AB		APOTEX	**43MG**	**A202252**	**001**	Jul 26, 2013
AB			**130MG**	**A202252**	**002**	Jul 26, 2013
AB		AUROBINDO PHARMA LTD	**67MG**	**A212232**	**001**	Sep 20, 2021
AB			**134MG**	**A212232**	**002**	Sep 20, 2021
AB			**200MG**	**A212232**	**003**	Sep 20, 2021
AB		DR REDDYS LABS SA	**43MG**	**A090859**	**001**	Mar 01, 2012
AB			**130MG**	**A090859**	**002**	Mar 01, 2012
AB		GLENMARK PHARMS LTD	**67MG**	**A205566**	**001**	Apr 07, 2017
AB			**134MG**	**A205566**	**002**	Apr 07, 2017
AB			**200MG**	**A205566**	**003**	Apr 07, 2017
AB		INVAGEN PHARMS	**67MG**	**A207378**	**001**	Mar 28, 2017
AB			**134MG**	**A207378**	**002**	Mar 28, 2017
AB			**200MG**	**A207378**	**003**	Mar 28, 2017
AB		REYOUNG	**67MG**	**A207805**	**001**	Nov 16, 2017
AB			**134MG**	**A207805**	**002**	Nov 16, 2017
AB			**200MG**	**A207805**	**003**	Nov 16, 2017
AB		RHODES PHARMS	**67MG**	**A075753**	**001**	Sep 03, 2002
AB			**134MG**	**A075753**	**002**	Apr 09, 2002
AB			**200MG**	**A075753**	**003**	Apr 09, 2002
AB		TORRENT	**67MG**	**A210782**	**001**	Jun 26, 2018
AB			**134MG**	**A210782**	**002**	Jun 26, 2018
AB			**200MG**	**A210782**	**003**	Jun 26, 2018

LIPOFEN

+	CIPHER PHARMS INC	50MG	N021612	001	Jan 11, 2006
+!		150MG	N021612	003	Jan 11, 2006

TABLET;ORAL

FENOFIBRATE

AB		AJANTA PHARMA LTD	**54MG**	**A210138**	**001**	Jul 23, 2018
AB			**160MG**	**A210138**	**002**	Jul 23, 2018
AB		ALEMBIC	**48MG**	**A210476**	**001**	Aug 09, 2019
AB			**145MG**	**A210476**	**002**	Aug 09, 2019
AB		AMNEAL	**48MG**	**A209951**	**001**	Feb 09, 2018
AB			**54MG**	**A209950**	**001**	Mar 19, 2018
AB			**145MG**	**A209951**	**002**	Feb 09, 2018
AB			**160MG**	**A209950**	**002**	Mar 19, 2018
AB		AUROBINDO PHARMA	**48MG**	**A205118**	**001**	May 05, 2016
AB			**54MG**	**A216798**	**001**	Sep 27, 2022
AB			**145MG**	**A205118**	**002**	May 05, 2016
AB			**160MG**	**A216798**	**002**	Sep 27, 2022
AB		AUSTARPHARMA	**48MG**	**A208476**	**001**	Feb 10, 2021
AB			**54MG**	**A207803**	**001**	Dec 19, 2017
AB			**145MG**	**A208476**	**002**	Feb 10, 2021
AB			**160MG**	**A207803**	**002**	Dec 19, 2017
AB		CHARTWELL RX	**54MG**	**A209660**	**001**	Feb 11, 2019
AB			**160MG**	**A209660**	**002**	Feb 11, 2019
AB		CIPLA	**48MG**	**A208709**	**001**	Dec 15, 2016
AB			**145MG**	**A208709**	**002**	Dec 15, 2016
AB		CREEKWOOD PHARMS	**40MG**	**A217732**	**001**	Sep 07, 2023
AB			**120MG**	**A217732**	**002**	Sep 07, 2023
AB		DR REDDYS	**54MG**	**A210670**	**001**	Sep 06, 2019
AB			**160MG**	**A210670**	**002**	Sep 06, 2019
AB		GRAVITI PHARMS	**48MG**	**A211122**	**001**	Mar 18, 2020
AB			**54MG**	**A210606**	**001**	Aug 17, 2018
AB			**145MG**	**A211122**	**002**	Mar 18, 2020

FENOFIBRATE

TABLET;ORAL

FENOFIBRATE

AB			**160MG**	**A210606**	**002**	Aug 17, 2018
AB		HETERO LABS LTD III	**48MG**	**A204598**	**001**	Jul 12, 2016
AB			**145MG**	**A204598**	**002**	Jul 12, 2016
AB		IMPAX LABS	**54MG**	**A076509**	**001**	Mar 26, 2008
AB	!		**160MG**	**A076509**	**002**	Mar 26, 2008
AB		LUPIN LTD	**48MG**	**A090856**	**001**	Dec 23, 2011
AB			**54MG**	**A204019**	**001**	Aug 17, 2015
AB			**145MG**	**A090856**	**002**	Dec 23, 2011
AB			**160MG**	**A204019**	**002**	Aug 17, 2015
AB		MANKIND PHARMA	**54MG**	**A213864**	**001**	Jun 12, 2020
AB			**160MG**	**A213864**	**002**	Jun 12, 2020
AB		MYLAN	**54MG**	**A076520**	**001**	Oct 25, 2007
AB			**160MG**	**A076520**	**003**	Oct 25, 2007
AB		MYLAN PHARMS INC	**40MG**	**A204475**	**001**	Jun 23, 2016
AB			**48MG**	**A202856**	**001**	Dec 07, 2012
AB			**120MG**	**A204475**	**002**	Jun 23, 2016
AB			**145MG**	**A202856**	**002**	Dec 07, 2012
AB		PRINSTON INC	**48MG**	**A211080**	**001**	Aug 28, 2018
AB			**145MG**	**A211080**	**002**	Aug 28, 2018
AB		RHODES PHARMS	**54MG**	**A076433**	**001**	May 13, 2005
AB			**160MG**	**A076433**	**002**	May 13, 2005
AB		SUN PHARM	**48MG**	**A200884**	**001**	Sep 07, 2017
AB			**145MG**	**A200884**	**002**	Sep 07, 2017
AB		SUN PHARM INDS LTD	**54MG**	**A076635**	**001**	Oct 31, 2005
AB			**160MG**	**A076635**	**003**	Oct 31, 2005
AB		VALEANT PHARMS NORTH	**48MG**	**A090715**	**001**	Apr 05, 2012
AB			**145MG**	**A090715**	**002**	Apr 05, 2012

FENOGLIDE

AB	+	SALIX	**40MG**	**N022118**	**001**	Aug 10, 2007
AB	+!		**120MG**	**N022118**	**002**	Aug 10, 2007

TRICOR

AB	+	ABBVIE	**48MG**	**N021656**	**001**	Nov 05, 2004
AB	+!		**145MG**	**N021656**	**002**	Nov 05, 2004

TRIGLIDE

BX	+	SKYEPHARMA AG	160MG	N021350	002	May 07, 2005

FENOFIBRATE

		SUN PHARM INDS LTD	107MG	A076635	002	Oct 31, 2005

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION

CORLOPAM

AP	+!	HOSPIRA	**EQ 10MG BASE/ML**	**N019922**	**001**	Sep 23, 1997

FENOLDOPAM MESYLATE

AP		HIKMA	**EQ 10MG BASE/ML**	**A076582**	**001**	Oct 12, 2004
AP		SANDOZ	**EQ 10MG BASE/ML**	**A077155**	**001**	Feb 15, 2005

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

AB		MISEMER	**EQ 200MG BASE**	**A215548**	**001**	May 16, 2023
AB			**EQ 400MG BASE**	**A215548**	**003**	May 16, 2023
AB		RISING	**EQ 400MG BASE**	**A214475**	**001**	Jul 18, 2022

NALFON

AB	+	XSPIRE PHARMA	**EQ 200MG BASE**	**N017604**	**003**	
AB	+!		**EQ 400MG BASE**	**N017604**	**004**	Jul 21, 2009

FENOPROFEN CALCIUM

		MISEMER	EQ 300MG BASE	A215548	002	May 16, 2023

TABLET;ORAL

FENOPROFEN CALCIUM

	!	XSPIRE PHARMA	EQ 600MG BASE	A072267	001	Aug 17, 1988

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

AB		AVEVA	**100MCG/HR**	**A077449**	**004**	Oct 20, 2008
AB		KINDEVA	**100MCG/HR**	**A202097**	**005**	Nov 04, 2016
AB		MYLAN TECHNOLOGIES	**100MCG/HR**	**A076258**	**004**	Jan 28, 2005
AB		SPECGX LLC	**100MCG/HR**	**A077154**	**004**	Feb 09, 2011

FENTANYL-12

AB		AVEVA	**12.5MCG/HR**	**A077449**	**005**	Sep 11, 2015

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-12						
AB		KINDEVA	**12.5MCG/HR**	**A202097**	**001**	Nov 04, 2016
AB		MYLAN TECHNOLOGIES	**12.5MCG/HR**	**A076258**	**005**	Jan 23, 2007
AB		SPECGX LLC	**12.5MCG/HR**	**A077154**	**005**	Jun 11, 2015
FENTANYL-25						
AB		AVEVA	**25MCG/HR**	**A077449**	**001**	Oct 20, 2008
AB		KINDEVA	**25MCG/HR**	**A202097**	**002**	Nov 04, 2016
AB		MYLAN TECHNOLOGIES	**25MCG/HR**	**A076258**	**001**	Jan 28, 2005
AB	**!**	SPECGX LLC	**25MCG/HR**	**A077154**	**001**	Feb 09, 2011
FENTANYL-37						
AB		AVEVA	**37.5MCG/HR**	**A077449**	**006**	Dec 06, 2017
AB		MYLAN TECHNOLOGIES	**37.5MCG/HR**	**A076258**	**006**	Dec 29, 2014
AB		SPECGX LLC	**37.5MCG/HR**	**A077154**	**006**	Jan 14, 2020
FENTANYL-50						
AB		AVEVA	**50MCG/HR**	**A077449**	**002**	Oct 20, 2008
AB		KINDEVA	**50MCG/HR**	**A202097**	**003**	Nov 04, 2016
AB		MYLAN TECHNOLOGIES	**50MCG/HR**	**A076258**	**002**	Jan 28, 2005
AB		SPECGX LLC	**50MCG/HR**	**A077154**	**002**	Feb 09, 2011
FENTANYL-62						
AB		AVEVA	**62.5MCG/HR**	**A077449**	**007**	Dec 06, 2017
AB		MYLAN TECHNOLOGIES	**62.5MCG/HR**	**A076258**	**007**	Dec 29, 2014
AB		SPECGX LLC	**62.5MCG/HR**	**A077154**	**007**	Jan 14, 2020
FENTANYL-75						
AB		AVEVA	**75MCG/HR**	**A077449**	**003**	Oct 20, 2008
AB		KINDEVA	**75MCG/HR**	**A202097**	**004**	Nov 04, 2016
AB		MYLAN TECHNOLOGIES	**75MCG/HR**	**A076258**	**003**	Jan 28, 2005
AB		SPECGX LLC	**75MCG/HR**	**A077154**	**003**	Feb 09, 2011
FENTANYL-87						
AB		AVEVA	**87.5MCG/HR**	**A077449**	**008**	Dec 06, 2017
AB		MYLAN TECHNOLOGIES	**87.5MCG/HR**	**A076258**	**008**	Dec 29, 2014

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE						
AP		FRESENIUS KABI USA	**EQ 0.05MG BASE/ML**	**A212086**	**001**	Sep 01, 2020
AP	**+!**	HIKMA	**EQ 0.05MG BASE/ML**	**N019101**	**001**	Jul 11, 1984
AP		HOSPIRA	**EQ 0.05MG BASE/ML**	**N019115**	**001**	Jan 12, 1985
FENTANYL CITRATE PRESERVATIVE FREE						
AP		FRESENIUS KABI USA	**EQ 0.05MG BASE/ML**	**A210762**	**001**	May 03, 2019
AP		HOSPIRA	**EQ 0.05MG BASE/ML**	**A072786**	**001**	Sep 24, 1991
SUBLIMAZE PRESERVATIVE FREE						
AP	**+!**	RISING	**EQ 0.05MG BASE/ML**	**N016619**	**001**	
FENTANYL CITRATE						
	+!	HIKMA	EQ 0.025MG BASE/0.5ML	N019101	002	Jan 20, 2023

TABLET;BUCCAL, SUBLINGUAL

FENTORA					
	+	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006
	+		EQ 0.2MG BASE	N021947	002	Sep 25, 2006
	+!		EQ 0.4MG BASE	N021947	003	Sep 25, 2006
	+		EQ 0.6MG BASE	N021947	004	Sep 25, 2006
	+		EQ 0.8MG BASE	N021947	005	Sep 25, 2006

TROCHE/LOZENGE;TRANSMUCOSAL

ACTIQ					
	+	CEPHALON	EQ 0.2MG BASE	N020747	001	Nov 04, 1998
	+!		EQ 0.4MG BASE	N020747	002	Nov 04, 1998
	+		EQ 0.6MG BASE	N020747	003	Nov 04, 1998
	+		EQ 0.8MG BASE	N020747	004	Nov 04, 1998
	+		EQ 1.2MG BASE	N020747	005	Nov 04, 1998
	+		EQ 1.6MG BASE	N020747	006	Nov 04, 1998

FERRIC CARBOXYMALTOSE

SOLUTION;INTRAVENOUS

INJECTAFER					
	+!	AM REGENT	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013
	+!		100MG IRON/2ML (50MG IRON/ML)	N203565	004	Feb 04, 2022
	+!		500MG IRON/10ML (50MG IRON/ML)	N203565	002	Oct 08, 2020
	+!		1GM IRON/20ML (50MG IRON/ML)	N203565	003	Apr 28, 2021

FERRIC CITRATE
TABLET;ORAL
AURYXIA
+! KERYX BIOPHARMS EQ 210MG IRON N205874 001 Sep 05, 2014

FERRIC DERISOMALTOSE
SOLUTION;INTRAVENOUS
MONOFERRIC
+! PHARMACOSMOS AS 1GM/10ML (100MG/ML) N208171 003 Jan 16, 2020

FERRIC HEXACYANOFERRATE(II)
CAPSULE;ORAL
RADIOGARDASE (PRUSSIAN BLUE)
+! HEYL CHEMISCH 500MG N021626 001 Oct 02, 2003

FERRIC MALTOL
CAPSULE;ORAL
ACCRUFER
+! SHIELD TX 30MG IRON N212320 001 Jul 25, 2019

FERRIC OXYHYDROXIDE
INJECTABLE;INJECTION
FERRLECIT
AB **+!** SANOFI AVENTIS US **EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)** **N020955 001** Feb 18, 1999
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE
AB WEST-WARD PHARMS INT **EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)** **A078215 001** Mar 31, 2011
INFED
BP +! ALLERGAN EQ 100MG IRON/2ML (EQ 50MG IRON/ML) N017441 001
INJECTABLE;INTRAVENOUS
VENOFER
+ AM REGENT EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML) N021135 002 Mar 20, 2005
+! EQ 100MG IRON/5ML (EQ 20MG IRON/ML) N021135 001 Nov 06, 2000
+ EQ 200MG IRON/10ML (EQ 20MG IRON/ML) N021135 004 Feb 09, 2007
TABLET, CHEWABLE;ORAL
VELPHORO
+! VIFOR FRESENIUS EQ 500MG IRON N205109 001 Nov 27, 2013

FERUMOXYTOL
SOLUTION;INTRAVENOUS
FERAHEME
AB **+!** COVIS **EQ 510MG IRON/17ML (EQ 30MG IRON/ML)** **N022180 001** Jun 30, 2009
FERUMOXYTOL
AB SANDOZ **EQ 510MG IRON/17ML (EQ 30MG IRON/ML)** **A206604 001** Jan 15, 2021

FESOTERODINE FUMARATE
TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE
AB ALEMBIC **4MG** **A204973 001** Jan 04, 2023
AB **8MG** **A204973 002** Jan 04, 2023
AB ALKEM LABS LTD **4MG** **A204827 001** Dec 10, 2015
AB **8MG** **A204827 002** Dec 10, 2015
AB AMNEAL PHARMS NY **4MG** **A205002 001** Jan 04, 2023
AB **8MG** **A205002 002** Jan 04, 2023
AB ANI PHARMS **4MG** **A204504 001** Jan 04, 2023
AB **8MG** **A204504 002** Jan 04, 2023
AB AUROBINDO PHARMA **4MG** **A205007 001** Feb 17, 2017
AB **8MG** **A205007 002** Feb 17, 2017
AB DR REDDYS **4MG** **A204975 001** Aug 13, 2019
AB **8MG** **A204975 002** Aug 13, 2019
AB HETERO LABS LTD V **4MG** **A204792 001** Jan 09, 2024
AB **8MG** **A204792 002** Jan 09, 2024
AB ZYDUS PHARMS **4MG** **A204946 001** Oct 03, 2017
AB **8MG** **A204946 002** Oct 03, 2017
TOVIAZ
AB **+** PFIZER **4MG** **N022030 001** Oct 31, 2008
AB **+!** **8MG** **N022030 002** Oct 31, 2008

FEXINIDAZOLE
TABLET;ORAL
FEXINIDAZOLE
+! SANOFI 600MG N214429 001 Jul 16, 2021

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

AB		DR REDDYS LABS LTD	**30MG**	**A076502**	**001**	Apr 11, 2006
AB			**60MG**	**A076502**	**002**	Apr 11, 2006
AB			**180MG**	**A076502**	**003**	Apr 11, 2006
AB		RISING	**60MG**	**A077081**	**003**	Apr 11, 2008
AB			**180MG**	**A077081**	**001**	Apr 16, 2007
AB		TEVA	**30MG**	**A076447**	**001**	Sep 01, 2005
AB			**60MG**	**A076447**	**002**	Sep 01, 2005
AB			**180MG**	**A076447**	**003**	Sep 01, 2005

FEZOLINETANT

TABLET;ORAL

VEOZAH

+!	ASTELLAS	45MG	N216578	001	May 12, 2023

FIDAXOMICIN

FOR SUSPENSION;ORAL

DIFICID

+!	CUBIST PHARMS LLC	40MG/ML	N213138	001	Jan 24, 2020

TABLET;ORAL

DIFICID

+!	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB		ACCORD HLTHCARE	**1MG**	**A091643**	**001**	Nov 05, 2013
AB			**5MG**	**A090121**	**001**	Feb 23, 2010
AB		ALKEM LABS LTD	**1MG**	**A207750**	**001**	Jan 06, 2017
AB			**5MG**	**A204304**	**001**	Jan 05, 2017
AB		AUROBINDO PHARMA	**5MG**	**A078341**	**001**	Oct 30, 2007
AB		AUROBINDO PHARMA LTD	**1MG**	**A203687**	**001**	Nov 05, 2013
AB		CIPLA	**1MG**	**A077335**	**001**	Nov 20, 2014
AB		DR REDDYS LABS INC	**1MG**	**A076436**	**001**	Jul 28, 2006
AB		DR REDDYS LABS LTD	**5MG**	**A076437**	**001**	Feb 28, 2007
AB		HETERO LABS LTD III	**1MG**	**A090060**	**001**	Jul 01, 2013
AB			**5MG**	**A090061**	**001**	Jun 07, 2010
AB		SUN PHARM	**1MG**	**A090508**	**001**	Jul 01, 2013
AB			**5MG**	**A090507**	**001**	Aug 16, 2011
AB		TEVA	**5MG**	**A076511**	**001**	Dec 15, 2006
AB		ZYDUS PHARMS USA INC	**5MG**	**A078900**	**001**	Dec 28, 2009

PROPECIA

AB	**+!**	ORGANON	**1MG**	**N020788**	**001**	Dec 19, 1997

PROSCAR

AB	**+!**	ORGANON	**5MG**	**N020180**	**001**	Jun 19, 1992

FINASTERIDE; TADALAFIL

CAPSULE;ORAL

ENTADFI

+!	BLUE WATER BIOTECH	5MG;5MG	N215423	001	Dec 09, 2021

FINERENONE

TABLET;ORAL

KERENDIA

+	BAYER HLTHCARE	10MG	N215341	001	Jul 09, 2021
+!		20MG	N215341	002	Jul 09, 2021

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 0.5MG BASE**	**A207991**	**001**	Oct 28, 2020
AB		ALKEM LABS LTD	**EQ 0.5MG BASE**	**A208004**	**001**	Dec 30, 2020
AB		APOTEX	**EQ 0.5MG BASE**	**A207993**	**001**	Dec 18, 2020
AB		BIONPHARMA	**EQ 0.5MG BASE**	**A210252**	**001**	May 24, 2023
AB		DR REDDYS	**EQ 0.5MG BASE**	**A208000**	**001**	Mar 05, 2021
AB		EZRA VENTURES	**EQ 0.5MG BASE**	**A207945**	**001**	Dec 06, 2023
AB		GLENMARK PHARMS LTD	**EQ 0.5MG BASE**	**A207985**	**001**	Jun 18, 2020
AB		HEC PHARM CO LTD	**EQ 0.5MG BASE**	**A207939**	**001**	Nov 10, 2021
AB		HETERO LABS LTD V	**EQ 0.5MG BASE**	**A207933**	**001**	May 18, 2020
AB		MYLAN	**EQ 0.5MG BASE**	**A208005**	**001**	Jan 19, 2021
AB		PRINSTON INC	**EQ 0.5MG BASE**	**A208003**	**001**	Sep 07, 2022
AB		SUN PHARM	**EQ 0.5MG BASE**	**A208014**	**001**	Dec 04, 2019

FINGOLIMOD HYDROCHLORIDE
CAPSULE;ORAL
FINGOLIMOD HYDROCHLORIDE

AB		TEVA PHARMS USA	**EQ 0.5MG BASE**	**A208008**	**001**	Jul 02, 2020
AB		ZYDUS PHARMS	**EQ 0.5MG BASE**	**A207994**	**001**	Oct 14, 2020

GILENYA

AB	**+!**	NOVARTIS	**EQ 0.5MG BASE**	**N022527**	**001**	Sep 21, 2010
	+		EQ 0.25MG BASE	N022527	002	May 11, 2018

FINGOLIMOD LAURYL SULFATE
TABLET, ORALLY DISINTEGRATING;ORAL
TASCENSO ODT

+	CYCLE	EQ 0.25MG BASE	N214962	001	Dec 23, 2021
+!		EQ 0.5MG BASE	N214962	002	Dec 09, 2022

FISH OIL TRIGLYCERIDES
EMULSION;INTRAVENOUS
OMEGAVEN

+!	FRESENIUS KABI USA	5GM/50ML (0.1GM/ML)	N210589	001	Jul 27, 2018
+!		10GM/100ML (0.1GM/ML)	N210589	002	Jul 27, 2018

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL
EMULSION;INTRAVENOUS
SMOFLIPID 20%

+!	FRESENIUS KABI USA	3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML)	N207648	001	Jul 13, 2016
+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML)	N207648	002	Jul 13, 2016
+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML)	N207648	003	Jul 13, 2016
+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (1000ML)	N207648	004	Aug 10, 2018

FLAVOXATE HYDROCHLORIDE
TABLET;ORAL
FLAVOXATE HYDROCHLORIDE

AB		EPIC PHARMA	**100MG**	**A076835**	**001**	Nov 30, 2005
AB	**!**	PADAGIS US	**100MG**	**A076831**	**001**	Dec 16, 2004

FLECAINIDE ACETATE
TABLET;ORAL
FLECAINIDE ACETATE

AB		AMNEAL PHARM	**50MG**	**A075442**	**001**	Jul 31, 2001
AB			**100MG**	**A075442**	**002**	Jul 31, 2001
AB			**150MG**	**A075442**	**003**	Jul 31, 2001
AB		ANI PHARMS	**50MG**	**A075882**	**001**	Oct 28, 2002
AB			**100MG**	**A075882**	**002**	Oct 28, 2002
AB			**150MG**	**A075882**	**003**	Oct 28, 2002
AB		AUROBINDO PHARMA LTD	**50MG**	**A202821**	**001**	Nov 03, 2017
AB			**100MG**	**A202821**	**002**	Nov 03, 2017
AB			**150MG**	**A202821**	**003**	Nov 03, 2017
AB		BEXIMCO PHARMS USA	**50MG**	**A210683**	**001**	Sep 16, 2020
AB			**100MG**	**A210683**	**002**	Sep 16, 2020
AB			**150MG**	**A210683**	**003**	Sep 16, 2020
AB		HIKMA	**50MG**	**A076278**	**001**	Jan 14, 2003
AB			**100MG**	**A076278**	**002**	Jan 14, 2003
AB	**!**		**150MG**	**A076278**	**003**	Jan 14, 2003
AB		SUN PHARM INDS LTD	**50MG**	**A076421**	**001**	Mar 28, 2003
AB			**100MG**	**A076421**	**002**	Mar 28, 2003
AB			**150MG**	**A076421**	**003**	Mar 28, 2003
AB		YICHANG HUMANWELL	**50MG**	**A215599**	**001**	Sep 08, 2022
AB			**100MG**	**A215599**	**002**	Sep 08, 2022
AB			**150MG**	**A215599**	**003**	Sep 08, 2022

FLIBANSERIN
TABLET;ORAL
ADDYI

+!	SPROUT PHARMS	100MG	N022526	001	Aug 18, 2015

FLORBETABEN F-18
SOLUTION;INTRAVENOUS
NEURACEQ

+!	LIFE MOLECULAR	1.4-135mCi/ML	N204677	001	Mar 19, 2014

FLORBETAPIR F-18

SOLUTION;INTRAVENOUS

AMYVID

	+!	AVID RADIOPHARMS INC	10-100ML (13.5-51mCi/ML)	N202008	004	Oct 13, 2023
	+!		10-50ML (13.5-51mCi/ML)	N202008	003	Apr 06, 2012

FLORTAUCIPIR F-18

SOLUTION;INTRAVENOUS

TAUVID

	+!	AVID RADIOPHARMS INC	30ML (8.1-51mCi/ML)	N212123	001	May 28, 2020
	+!		50ML (8.1-51mCi/ML)	N212123	002	May 28, 2020
	+!		50ML (8.1-100mCi/ML)	N212123	003	Jul 01, 2022
	+!		100ML (8.1-100mCi/ML)	N212123	004	Jul 01, 2022

FLOTUFOLASTAT F-18 GALLIUM

SOLUTION;INTRAVENOUS

POSLUMA

	+!	BLUE EARTH	25ML (8-158mCi/ML)	N216023	001	May 25, 2023

FLOXURIDINE

INJECTABLE;INJECTION

FLOXURIDINE

AP		FRESENIUS KABI USA	**500MG/VIAL**	**A075837**	**001**	Feb 22, 2001
AP	**!**	HIKMA	**500MG/VIAL**	**A075387**	**001**	Apr 16, 2000

FLUCICLOVINE F-18

SOLUTION;INTRAVENOUS

AXUMIN

	+!	BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016

FLUCONAZOLE

FOR SUSPENSION;ORAL

DIFLUCAN

AB	**+**	PFIZER	**50MG/5ML**	**N020090**	**001**	Dec 23, 1993
AB	**+!**		**200MG/5ML**	**N020090**	**002**	Dec 23, 1993

FLUCONAZOLE

AB		AUROBINDO PHARMA	**50MG/5ML**	**A079150**	**001**	Sep 18, 2009
AB			**200MG/5ML**	**A079150**	**002**	Sep 18, 2009
AB		HAINAN POLY	**200MG/5ML**	**A215738**	**001**	Sep 21, 2023

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP		FRESENIUS KABI USA	**200MG/100ML (2MG/ML)**	**A076145**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076145**	**002**	Jul 29, 2004
AP		HIKMA	**200MG/100ML (2MG/ML)**	**A076087**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076087**	**003**	Jul 29, 2004
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A076736**	**001**	Aug 23, 2005

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**200MG/100ML (2MG/ML)**	**A076766**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076766**	**002**	Jul 29, 2004
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A078698**	**001**	Jan 30, 2012
AP			**400MG/200ML (2MG/ML)**	**A078698**	**002**	Jan 30, 2012
AP		HOSPIRA	**200MG/100ML (2MG/ML)**	**A076303**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076303**	**002**	Jul 29, 2004
AP	**!**	INFORLIFE	**200MG/100ML (2MG/ML)**	**A079104**	**001**	Jul 30, 2009
AP	**!**		**400MG/200ML (2MG/ML)**	**A079104**	**002**	Jul 30, 2009
AP		WEST-WARD PHARMS INT	**200MG/100ML (2MG/ML)**	**A078107**	**001**	Jul 30, 2008
AP			**400MG/200ML (2MG/ML)**	**A078107**	**002**	Jul 30, 2008
AP		WOODWARD	**200MG/100ML (2MG/ML)**	**A077909**	**001**	May 26, 2010
AP			**400MG/200ML (2MG/ML)**	**A077909**	**002**	May 26, 2010

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

		HIKMA	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		WOODWARD	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015

TABLET;ORAL

DIFLUCAN

AB	**+**	PFIZER	**50MG**	**N019949**	**001**	Jan 29, 1990
AB	**+**		**100MG**	**N019949**	**002**	Jan 29, 1990
AB	**+**		**150MG**	**N019949**	**004**	Jun 30, 1994
AB	**+!**		**200MG**	**N019949**	**003**	Jan 29, 1990

FLUCONAZOLE

AB		ANI PHARMS	**50MG**	**A078423**	**001**	Mar 07, 2011
AB			**100MG**	**A078423**	**002**	Mar 07, 2011

FLUCONAZOLE

TABLET;ORAL

FLUCONAZOLE

AB			**150MG**	**A078423**	**003**	Mar 07, 2011
AB			**200MG**	**A078423**	**004**	Mar 07, 2011
AB		AUROBINDO PHARMA	**50MG**	**A077731**	**001**	Oct 07, 2008
AB			**100MG**	**A077731**	**002**	Oct 07, 2008
AB			**150MG**	**A077731**	**003**	Oct 07, 2008
AB			**200MG**	**A077731**	**004**	Oct 07, 2008
AB		CHARTWELL	**50MG**	**A076665**	**001**	Jul 29, 2004
AB			**100MG**	**A076665**	**002**	Jul 29, 2004
AB			**150MG**	**A076665**	**003**	Jul 29, 2004
AB			**200MG**	**A076665**	**004**	Jul 29, 2004
AB		DR REDDYS LABS INC	**50MG**	**A076658**	**001**	Jul 29, 2004
AB			**100MG**	**A076658**	**002**	Jul 29, 2004
AB			**150MG**	**A076658**	**003**	Jul 29, 2004
AB			**200MG**	**A076658**	**004**	Jul 29, 2004
AB		GLENMARK GENERICS	**50MG**	**A077253**	**001**	Jan 25, 2006
AB			**100MG**	**A077253**	**002**	Jan 25, 2006
AB			**150MG**	**A077253**	**003**	Jan 25, 2006
AB			**200MG**	**A077253**	**004**	Jan 25, 2006
AB		TARO	**50MG**	**A076507**	**001**	Jul 29, 2004
AB			**100MG**	**A076507**	**002**	Jul 29, 2004
AB			**150MG**	**A076507**	**003**	Jul 29, 2004
AB			**200MG**	**A076507**	**004**	Jul 29, 2004
AB		THINQ PHARM-CRO PVT	**50MG**	**A076957**	**001**	Sep 28, 2005
AB			**100MG**	**A076957**	**002**	Sep 28, 2005
AB			**150MG**	**A076957**	**004**	Feb 27, 2017
AB			**200MG**	**A076957**	**003**	Sep 28, 2005
AB		ZYDUS PHARMS	**50MG**	**A208963**	**001**	Feb 16, 2017
AB			**100MG**	**A208963**	**002**	Feb 16, 2017
AB			**150MG**	**A208963**	**003**	Feb 16, 2017
AB			**200MG**	**A208963**	**004**	Feb 16, 2017

FLUCYTOSINE

CAPSULE;ORAL

ANCOBON

AB	**+**	BAUSCH	**250MG**	**N017001**	**001**	
AB	**+!**		**500MG**	**N017001**	**002**	

FLUCYTOSINE

AB		AUROBINDO PHARMA LTD	**250MG**	**A213665**	**001**	May 01, 2020
AB			**500MG**	**A213665**	**002**	May 01, 2020
AB		NOVEL LABS INC	**250MG**	**A204652**	**001**	Jul 07, 2017
AB			**500MG**	**A204652**	**002**	Jul 07, 2017
AB		SIGMAPHARM LABS LLC	**250MG**	**A201566**	**001**	Jun 28, 2011
AB			**500MG**	**A201566**	**002**	Jun 28, 2011
AB		STRIDES PHARMA	**250MG**	**A212632**	**001**	Apr 17, 2020
AB			**500MG**	**A212632**	**002**	Apr 17, 2020

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP	**!**	ACTAVIS TOTOWA	**50MG/VIAL**	**A078610**	**001**	Feb 11, 2009
AP		FRESENIUS KABI USA	**50MG/VIAL**	**A078544**	**001**	Oct 15, 2007
AP		HIKMA	**50MG/VIAL**	**A076349**	**001**	Aug 28, 2003
AP1		AREVA PHARMS	**50MG/2ML (25MG/ML)**	**A090724**	**001**	Sep 27, 2010
AP1		FRESENIUS KABI USA	**50MG/2ML (25MG/ML)**	**A078393**	**001**	Oct 15, 2007
AP1		SAGENT PHARMS INC	**50MG/2ML (25MG/ML)**	**A076661**	**001**	Apr 28, 2004

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		3D IMAGING DRUG	**20-300mCi/ML**	**A203778**	**001**	Oct 30, 2015
AP		BIOMEDCL RES FDN	**20-300mCi/ML**	**A203710**	**001**	May 01, 2015
AP			**20-300mCi/ML**	**A203837**	**001**	May 01, 2015
AP		BRIGHAM WOMENS	**20-300mCi/ML**	**A203816**	**001**	Oct 30, 2014
AP		CARDINAL HEALTH 414	**20-300mCi/ML**	**A203603**	**001**	Nov 13, 2015
AP			**20-500mCi/ML**	**A203603**	**002**	Sep 27, 2018
AP		CHILDRENS HOSP MI	**20-300mCi/ML**	**A204385**	**001**	Oct 29, 2014
AP		DECATUR	**20-300mCi/ML**	**A204463**	**001**	Oct 21, 2014
AP	**+!**	FEINSTEIN	**20-400mCi/ML**	**N021870**	**002**	Nov 21, 2008
AP		ISOLOGIC INNOVATIVE	**20-300mCi/ML**	**A204525**	**001**	Oct 29, 2014
AP		JUBILANT DRAXIMAGE	**20-300mCi/ML**	**A203920**	**001**	Jun 23, 2015

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		KETTERING MEDCTR	**4-40mCi/ML**	**A204759**	**001**	Oct 27, 2015
AP		KREITCHMAN PET CTR	**10-100mCi/ML**	**A203942**	**001**	Apr 11, 2016
AP		MA GENERAL HOSP	**20-300mCi/ML**	**A204333**	**001**	Sep 25, 2014
AP		MCPRF	**20-240mCi/ML**	**A203612**	**001**	Aug 05, 2013
AP		MEM SLOAN-KETTERING	**20-300mCi/ML**	**A208679**	**001**	Dec 08, 2016
AP		METHODIST HOSP RES	**20-300mCi/ML**	**A203904**	**001**	Apr 23, 2015
AP		MIPS CRF	**20-300mCi/ML**	**A204472**	**001**	Sep 11, 2015
AP		NCM USA BRONX LLC	**20-300mCi/ML**	**A204512**	**001**	Jan 07, 2015
AP	!	PETNET	**20-200mCi/ML**	**A079086**	**001**	Feb 25, 2011
AP		PHARMALOGIC	**20-300mCi/ML**	**A204264**	**001**	Dec 18, 2014
AP		PHARMALOGIC HLDGS	**20-200mCi/ML**	**A203664**	**001**	Feb 04, 2014
AP		PRECISION NUCLEAR	**20-500mCi/ML**	**A204546**	**001**	Apr 07, 2015
AP	!	QUEEN HAMAMATSU PET	**10-100mCi/ML**	**A203771**	**001**	Aug 31, 2015
AP		SOFIE	**20-300mCi/ML**	**A203591**	**001**	Aug 31, 2015
AP	!		**20-500mCi/ML**	**A203665**	**001**	Feb 14, 2013
AP		TRUSTEES UNIV PA	**20-200mCi/ML**	**A203801**	**001**	Oct 29, 2014
AP	!	UCLA BIOMEDICAL	**4-40mCi/ML**	**A203811**	**001**	Jun 27, 2013
AP		UCSF RODIOPHARM	**20-300mCi/ML**	**A203902**	**001**	May 09, 2014
AP		UIHC PET IMAGING	**20-300mCi/ML**	**A203990**	**001**	Aug 06, 2014
AP		UNIV MICHIGAN	**20-300mCi/ML**	**A204531**	**001**	Jul 17, 2015
AP		UNIV SOUTHERN CA	**20-300mCi/ML**	**A209341**	**001**	Dec 16, 2020
AP		UNIV TX MD ANDERSON	**20-300mCi/ML**	**A203246**	**002**	Jan 13, 2014
AP		UNIV UTAH CYCLOTRON	**20-300mCi/ML**	**A204498**	**001**	Jun 23, 2015
AP		WISCONSIN	**20-500mCi/ML**	**A203709**	**001**	Oct 23, 2013
AP		WUSM CYCLOTRON	**20-300mCi/ML**	**A203935**	**001**	Feb 05, 2014
		NORTHLAND	4-500mCi/ML	A203994	001	Feb 04, 2015
		NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015
		UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

AB		BARR	**0.1MG**	**A040425**	**001**	Jan 21, 2003
AB	!	IMPAX LABS	**0.1MG**	**A040431**	**001**	Mar 18, 2002
AB		NOVITIUM PHARMA	**0.1MG**	**A215279**	**001**	May 31, 2022

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

AP		BAXTER HLTHCARE CORP	**0.5MG/5ML (0.1MG/ML)**	**A076755**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076755**	**001**	Oct 12, 2004
AP		FRESENIUS KABI USA	**0.5MG/5ML (0.1MG/ML)**	**A076955**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076955**	**001**	Oct 12, 2004
AP		HIKMA	**0.5MG/5ML (0.1MG/ML)**	**A076256**	**002**	Oct 12, 2004
AP			**0.5MG/5ML (0.1MG/ML)**	**A076787**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076256**	**001**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076787**	**001**	Oct 12, 2004
AP		HIKMA FARMACEUTICA	**0.5MG/5ML (0.1MG/ML)**	**A078527**	**001**	Mar 23, 2009
AP	!		**1MG/10ML (0.1MG/ML)**	**A078527**	**002**	Mar 23, 2009
AP		RISING	**0.5MG/5ML (0.1MG/ML)**	**A078595**	**001**	May 13, 2008
AP		SAGENT PHARMS	**0.5MG/5ML (0.1MG/ML)**	**A090584**	**001**	Aug 28, 2012
AP			**1MG/10ML (0.1MG/ML)**	**A090584**	**002**	Aug 28, 2012
AP		SANDOZ	**0.5MG/5ML (0.1MG/ML)**	**A077071**	**001**	May 03, 2005
AP			**1MG/10ML (0.1MG/ML)**	**A077071**	**002**	May 03, 2005

FLUNISOLIDE

SPRAY, METERED;NASAL

FLUNISOLIDE

AB	!	BAUSCH	**0.025MG/SPRAY**	**A074805**	**001**	Feb 20, 2002
AB		RICONPHARMA LLC	**0.025MG/SPRAY**	**A207802**	**001**	Jun 16, 2022
AB		RISING	**0.025MG/SPRAY**	**A077704**	**001**	Aug 03, 2006

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

AT		COSETTE	**0.01%**	**A089526**	**001**	Jul 26, 1988
AT			**0.025%**	**A210747**	**001**	Nov 05, 2018
AT		FOUGERA PHARMS INC	**0.01%**	**A088170**	**001**	Dec 16, 1982
AT			**0.025%**	**A088169**	**001**	Dec 16, 1982
AT		TARO	**0.025%**	**A087104**	**001**	Apr 27, 1982

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.01%**	**N012787**	**004**	
AT	**+!**		**0.025%**	**N012787**	**002**	
AT	**+!**		**0.025%**	**N012787**	**005**	

IMPLANT;INTRAVITREAL

ILUVIEN

	+!	ALIMERA SCIENCES INC	0.19MG	N201923	001	Sep 26, 2014

RETISERT

	+!	BAUSCH AND LOMB	0.59MG	N021737	001	Apr 08, 2005

YUTIQ

	+!	ALIMERA SCIENCES INC	0.18MG	N210331	001	Oct 12, 2018

OIL;TOPICAL

DERMA-SMOOTHE/FS

AT	**+!**	HILL DERMAC	**0.01%**	**N019452**	**001**	Feb 03, 1988
AT	**+!**		**0.01%**	**N019452**	**002**	Nov 09, 2005

FLUCINOLONE ACETONIDE

AT		GLENMARK PHARMS LTD	**0.01%**	**A210556**	**001**	Oct 25, 2018

FLUOCINOLONE ACETONIDE

AT		LYNE	**0.01%**	**A090982**	**001**	Apr 25, 2016
AT			**0.01%**	**A203377**	**001**	Apr 25, 2016
AT		NOVEL LABS INC	**0.01%**	**A207345**	**001**	Jul 31, 2023
AT			**0.01%**	**A207347**	**001**	Aug 07, 2023
AT		PADAGIS ISRAEL	**0.01%**	**A202847**	**001**	Aug 09, 2013
AT			**0.01%**	**A202848**	**001**	Aug 09, 2013
AT		QUAGEN	**0.01%**	**A212760**	**001**	Apr 02, 2021
AT			**0.01%**	**A212761**	**001**	Apr 02, 2021
AT		TARO	**0.01%**	**A202368**	**001**	May 19, 2016
AT			**0.01%**	**A209336**	**001**	May 19, 2016

FLUOCINONIDE ACETONIDE

AT		GLENMARK PHARMS LTD	**0.01%**	**A210539**	**001**	Oct 26, 2018

OIL/DROPS;OTIC

DERMOTIC

AT	**+!**	HILL DERMAC	**0.01%**	**N019452**	**003**	Nov 09, 2005

FLAC

AT		PATRIN	**0.01%**	**A210736**	**001**	Apr 11, 2018

FLUOCINOLONE ACETONIDE

AT		LYNE	**0.01%**	**A203378**	**001**	Apr 25, 2016
AT		PADAGIS ISRAEL	**0.01%**	**A202849**	**001**	Jul 17, 2017
AT		QUAGEN	**0.01%**	**A212762**	**001**	Apr 02, 2021
AT		TASMAN PHARMA	**0.01%**	**A213264**	**001**	Feb 05, 2021

FLUOCINONIDE ACETONIDE

AT		GLENMARK PHARMS LTD	**0.01%**	**A211815**	**001**	Dec 14, 2018

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

AT		COSETTE	**0.025%**	**A089524**	**001**	Jul 26, 1988
AT		FOUGERA PHARMS INC	**0.025%**	**A088168**	**001**	Dec 16, 1982
AT		TARO	**0.025%**	**A040041**	**001**	Sep 15, 1994

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.025%**	**N013960**	**001**	

SHAMPOO;TOPICAL

CAPEX

	+!	GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT		CHARTWELL RX	**0.01%**	**A209596**	**001**	Dec 26, 2017
AT		ENCUBE ETHICALS	**0.01%**	**A209913**	**001**	Feb 13, 2019
AT		FOUGERA PHARMS INC	**0.01%**	**A088167**	**001**	Dec 16, 1982
AT		LUPIN	**0.01%**	**A206422**	**001**	Sep 02, 2015
AT		TARO	**0.01%**	**A089124**	**001**	Sep 11, 1985

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.01%**	**N015296**	**001**	

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM;TOPICAL

TRI-LUMA

	+!	GALDERMA LABS LP	0.01%;4%;0.05%	N021112	001	Jan 18, 2002

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-SYNALAR

	!	MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700 001	

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB		AMNEAL	**0.1%**	**A211111 001**	Jun 04, 2018
AB		CADILA	**0.1%**	**A208989 001**	Feb 10, 2020
AB		FOUGERA PHARMS INC	**0.1%**	**A200735 001**	Jul 14, 2014
AB		GLENMARK GENERICS	**0.1%**	**A091282 001**	Jul 14, 2014
AB		PADAGIS ISRAEL	**0.1%**	**A090256 001**	Jan 14, 2014
AB		TARO	**0.1%**	**A200734 001**	Jul 14, 2014

VANOS

AB	**+!**	BAUSCH	**0.1%**	**N021758 001**	Feb 11, 2005

FLUOCINONIDE

AB1	**!**	AMNEAL	**0.05%**	**A210554 001**	Aug 21, 2018
AB1		COSETTE	**0.05%**	**A073085 001**	Feb 14, 1992
AB1		FOUGERA PHARMS INC	**0.05%**	**A073030 001**	Oct 17, 1994
AB1		TARO	**0.05%**	**A071500 001**	Jun 10, 1987
AB1		TEVA	**0.05%**	**A072488 001**	Feb 06, 1989

FLUOCINONIDE EMULSIFIED BASE

AB2		COSETTE	**0.05%**	**A074204 001**	Jun 13, 1995
AB2		FOUGERA PHARMS	**0.05%**	**A076586 001**	Jun 23, 2004
AB2	**!**	TARO	**0.05%**	**A072494 001**	Jan 19, 1989
AB2		TEVA	**0.05%**	**A072490 001**	Feb 07, 1989

GEL;TOPICAL

FLUOCINONIDE

AB	**+**	ALVOGEN	**0.05%**	**N017373 001**	
AB		COSETTE	**0.05%**	**A072537 001**	Feb 07, 1989
AB		FOUGERA PHARMS INC	**0.05%**	**A072933 001**	Dec 30, 1994
AB	**!**	TARO	**0.05%**	**A074935 001**	Jul 29, 1997

OINTMENT;TOPICAL

FLUOCINONIDE

AB		CHARTWELL RX	**0.05%**	**A207538 001**	Jul 31, 2017
AB		FOUGERA PHARMS	**0.05%**	**A074905 001**	Aug 26, 1997
AB	**!**	TARO	**0.05%**	**A075008 001**	Jun 30, 1999
AB		TEVA	**0.05%**	**A073481 001**	Dec 27, 1991
AB		XIROMED	**0.05%**	**A212976 001**	Nov 26, 2019

LIDEX

AB	**+**	ALVOGEN	**0.05%**	**N016909 002**	

SOLUTION;TOPICAL

FLUOCINONIDE

AT		CHARTWELL RX	**0.05%**	**A209118 001**	Apr 23, 2018
AT		COSETTE	**0.05%**	**A071535 001**	Dec 02, 1988
AT		ENCUBE ETHICALS	**0.05%**	**A209699 001**	Nov 29, 2018
AT		FOUGERA PHARMS INC	**0.05%**	**A072934 001**	Feb 27, 1995
AT		MACLEODS PHARMS LTD	**0.05%**	**A209283 001**	Apr 23, 2018
AT		NOVEL LABS INC	**0.05%**	**A206003 001**	Jul 21, 2017
AT	**!**	TARO	**0.05%**	**A074799 001**	Dec 31, 1996
AT		ZYDUS PHARMS	**0.05%**	**A208948 001**	Jul 17, 2018

FLUORESCEIN SODIUM

INJECTABLE;INTRAVENOUS

AK-FLUOR 10%

AP	**+!**	LONG GROVE PHARMS	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N022186 001**	Aug 08, 2008

AK-FLUOR 25%

AP	**+!**	LONG GROVE PHARMS	**EQ 500MG BASE/2ML (EQ 250MG BASE/ML)**	**N022186 002**	Aug 08, 2008

FLUORESCEIN SODIUM

AP		NEXUS PHARMS	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**A215709 001**	Sep 25, 2023
AP			**EQ 500MG BASE/2ML (EQ 250MG BASE/ML)**	**A215709 002**	Sep 25, 2023

FLUORESCITE

AP	**+!**	ALCON LABS INC	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N021980 001**	Mar 28, 2006

FLUORODOPA F-18

SOLUTION;INTRAVENOUS

FLUORODOPA F18

	+!	FEINSTEIN	0.42-8.33mCi/ML	N200655 001	Oct 10, 2019

FLUOROESTRADIOL F-18

SOLUTION;INTRAVENOUS

CERIANNA

	+!	GE HEALTHCARE	50ML (4-100mCi/ML)	N212155	001	May 20, 2020

FLUOROMETHOLONE

SUSPENSION/DROPS;OPHTHALMIC

FLUOROMETHOLONE

AB		AMNEAL	**0.1%**	**A216348**	**001**	Jan 09, 2024

FML

AB	**+!**	ABBVIE	**0.1%**	**N016851**	**002**	Jul 28, 1982

FML FORTE

	+!	ABBVIE	0.25%	N019216	001	Apr 23, 1986

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

FLAREX

	+!	HARROW EYE	0.1%	N019079	001	Feb 11, 1986

FLUOROURACIL

CREAM;TOPICAL

EFUDEX

AB	**+!**	BAUSCH	**5%**	**N016831**	**003**	

FLUOROURACIL

AB		ACCORD HLTHCARE	**5%**	**A214845**	**001**	Oct 07, 2021
AB		DR REDDYS LABS SA	**5%**	**A077524**	**001**	Apr 11, 2008
AB		TARO	**5%**	**A090368**	**001**	Mar 05, 2010

CARAC

	+!	VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000

TOLAK

	+!	HILL DERMACEUTICALS	4%	N022259	001	Sep 18, 2015

INJECTABLE;INJECTION

FLUOROURACIL

AP	**!**	ACCORD HLTHCARE	**500MG/10ML (50MG/ML)**	**A040743**	**002**	Apr 26, 2007
AP	**!**		**1GM/20ML (50MG/ML)**	**A040743**	**001**	Apr 26, 2007
AP	**!**		**2.5GM/50ML (50MG/ML)**	**A040798**	**002**	Apr 26, 2007
AP	**!**		**5GM/100ML (50MG/ML)**	**A040798**	**001**	Apr 26, 2007
AP		ALEMBIC	**2.5GM/50ML (50MG/ML)**	**A217295**	**001**	Mar 03, 2023
AP			**5GM/100ML (50MG/ML)**	**A217676**	**001**	Oct 18, 2023
AP		FRESENIUS KABI USA	**500MG/10ML (50MG/ML)**	**A040279**	**002**	Sep 30, 1998
AP			**1GM/20ML (50MG/ML)**	**A040279**	**001**	Sep 30, 1998
AP			**2.5GM/50ML (50MG/ML)**	**A040278**	**001**	Sep 30, 1998
AP			**5GM/100ML (50MG/ML)**	**A040278**	**002**	Sep 30, 1998
AP		GLAND PHARMA LTD	**500MG/10ML (50MG/ML)**	**A210123**	**001**	Oct 27, 2017
AP			**1GM/20ML (50MG/ML)**	**A210123**	**002**	Oct 27, 2017
AP			**2.5GM/50ML (50MG/ML)**	**A210124**	**001**	Dec 26, 2017
AP			**5GM/100ML (50MG/ML)**	**A210124**	**002**	Dec 26, 2017
AP		SAGENT PHARMS INC	**500MG/10ML (50MG/ML)**	**A203608**	**001**	May 11, 2017
AP			**1GM/20ML (50MG/ML)**	**A203608**	**002**	May 11, 2017
AP			**2.5GM/50ML (50MG/ML)**	**A203609**	**001**	Feb 17, 2016
AP			**5GM/100ML (50MG/ML)**	**A203609**	**002**	Feb 17, 2016

SOLUTION;TOPICAL

EFUDEX

AT	**+!**	BAUSCH	**2%**	**N016831**	**001**	

FLUOROURACIL

AT		ENCUBE	**5%**	**A215612**	**001**	Nov 02, 2023
AT		TARO	**2%**	**A076526**	**001**	Nov 05, 2003
AT	**!**		**5%**	**A076526**	**002**	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**EQ 40MG BASE**	**A090223**	**003**	Mar 19, 2009
AB		APNAR PHARMA LP	**EQ 40MG BASE**	**A075049**	**003**	Jan 29, 2002
AB		AUROBINDO PHARMA	**EQ 40MG BASE**	**A078619**	**003**	Jan 31, 2008
AB		CADILA PHARMS LTD	**EQ 40MG BASE**	**A206993**	**003**	May 23, 2019
AB		HERITAGE PHARMS	**EQ 40MG BASE**	**A201336**	**003**	Oct 01, 2012
AB		IVAX SUB TEVA PHARMS	**EQ 40MG BASE**	**A075245**	**003**	Sep 28, 2004
AB		MARKSANS PHARMA	**EQ 40MG BASE**	**A075465**	**003**	Aug 02, 2001
AB		MICRO LABS	**EQ 40MG BASE**	**A216232**	**003**	Mar 29, 2022
AB		SCIEGEN PHARMS INC	**EQ 40MG BASE**	**A204597**	**003**	Mar 16, 2015
AB		SUN PHARM INDS LTD	**EQ 40MG BASE**	**A076990**	**001**	Dec 13, 2004
AB		TEVA	**EQ 40MG BASE**	**A075452**	**003**	Jan 29, 2002

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

PROZAC

AB	**+!**	ELI LILLY AND CO	**EQ 40MG BASE**	**N018936**	**003**	Jun 15, 1999

FLUOXETINE HYDROCHLORIDE

AB1		ALEMBIC PHARMS LTD	**EQ 10MG BASE**	**A090223**	**001**	Mar 19, 2009
AB1			**EQ 20MG BASE**	**A090223**	**002**	Mar 19, 2009
AB1		APNAR PHARMA LP	**EQ 10MG BASE**	**A075049**	**001**	Aug 02, 2001
AB1			**EQ 20MG BASE**	**A075049**	**002**	Jan 29, 2002
AB1		AUROBINDO PHARMA	**EQ 10MG BASE**	**A078619**	**001**	Jan 31, 2008
AB1			**EQ 20MG BASE**	**A078619**	**002**	Jan 31, 2008
AB1		CADILA PHARMS LTD	**EQ 10MG BASE**	**A206993**	**001**	May 23, 2019
AB1			**EQ 20MG BASE**	**A206993**	**002**	May 23, 2019
AB1		HERITAGE PHARMS	**EQ 10MG BASE**	**A201336**	**001**	Oct 01, 2012
AB1			**EQ 20MG BASE**	**A201336**	**002**	Oct 01, 2012
AB1		IVAX SUB TEVA PHARMS	**EQ 10MG BASE**	**A075245**	**002**	Jan 31, 2002
AB1			**EQ 20MG BASE**	**A075245**	**001**	Jan 31, 2002
AB1		LANDELA PHARM	**EQ 10MG BASE**	**A075464**	**001**	Jan 30, 2002
AB1			**EQ 20MG BASE**	**A075464**	**002**	Jan 30, 2002
AB1		MARKSANS PHARMA	**EQ 10MG BASE**	**A075465**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075465**	**002**	Jan 29, 2002
AB1		MICRO LABS	**EQ 10MG BASE**	**A216232**	**001**	Mar 29, 2022
AB1			**EQ 20MG BASE**	**A216232**	**002**	Mar 29, 2022
AB1		SCIEGEN PHARMS INC	**EQ 10MG BASE**	**A204597**	**001**	Mar 16, 2015
AB1			**EQ 20MG BASE**	**A204597**	**002**	Mar 16, 2015
AB1		TEVA	**EQ 10MG BASE**	**A075452**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075452**	**002**	Jan 29, 2002
AB1		TEVA PHARMS USA	**EQ 10MG BASE**	**A076001**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A076001**	**002**	Jan 29, 2002

PROZAC

AB1	**+**	ELI LILLY AND CO	**EQ 10MG BASE**	**N018936**	**006**	Dec 23, 1992
AB1	**+**		**EQ 20MG BASE**	**N018936**	**001**	Dec 29, 1987

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE

	!	DR REDDYS LABS LTD	EQ 90MG BASE	A078572	001	Mar 22, 2010

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA		APTAPHARMA INC	**EQ 20MG BASE/5ML**	**A216953**	**001**	Nov 15, 2022
AA		AUROBINDO PHARMA	**EQ 20MG BASE/5ML**	**A079209**	**001**	Mar 20, 2009
AA		LANNETT CO INC	**EQ 20MG BASE/5ML**	**A077849**	**001**	Feb 09, 2007
AA		NOSTRUM LABS INC	**EQ 20MG BASE/5ML**	**A075292**	**001**	Feb 07, 2002
AA		NOVITIUM PHARMA	**EQ 20MG BASE/5ML**	**A216448**	**001**	Nov 09, 2022
AA	**!**	PHARM ASSOC	**EQ 20MG BASE/5ML**	**A076015**	**001**	Jan 30, 2002
AA		TEVA	**EQ 20MG BASE/5ML**	**A075506**	**001**	Aug 02, 2001

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB		ALEMBIC	**EQ 10MG BASE**	**A208698**	**001**	Apr 05, 2017
AB			**EQ 20MG BASE**	**A208698**	**002**	Apr 05, 2017
AB		AUROBINDO PHARMA LTD	**EQ 10MG BASE**	**A213286**	**001**	Apr 08, 2020
AB			**EQ 20MG BASE**	**A213286**	**002**	Apr 08, 2020
AB			**EQ 60MG BASE**	**A213265**	**001**	Jun 10, 2020
AB		DR REDDYS	**EQ 10MG BASE**	**A076006**	**001**	Jan 30, 2002
AB	**!**		**EQ 20MG BASE**	**A076006**	**002**	Apr 23, 2018
AB			**EQ 60MG BASE**	**A211721**	**001**	Jan 25, 2019
AB		INVENTIA HLTHCARE	**EQ 60MG BASE**	**A209695**	**001**	Nov 20, 2017
AB		LUPIN LTD	**EQ 10MG BASE**	**A211653**	**001**	Apr 15, 2019
AB			**EQ 20MG BASE**	**A211653**	**002**	Apr 15, 2019
AB			**EQ 60MG BASE**	**A211632**	**001**	Feb 08, 2019
AB		PAR FORM	**EQ 10MG BASE**	**A203836**	**001**	Aug 19, 2016
AB			**EQ 20MG BASE**	**A203836**	**002**	Aug 19, 2016
AB		PAR PHARM INC	**EQ 60MG BASE**	**A209419**	**001**	Nov 16, 2017
AB		SCIEGEN PHARMS INC	**EQ 10MG BASE**	**A210935**	**001**	Mar 20, 2019
AB			**EQ 20MG BASE**	**A210935**	**002**	Mar 20, 2019
AB			**EQ 60MG BASE**	**A211282**	**001**	Jan 10, 2019
AB		TARO	**EQ 60MG BASE**	**A211477**	**001**	Nov 21, 2018
AB		TEVA	**EQ 10MG BASE**	**A075872**	**001**	Jan 29, 2002
AB			**EQ 20MG BASE**	**A075872**	**002**	Jan 04, 2019
AB		TEVA PHARMS USA	**EQ 60MG BASE**	**A211051**	**001**	Dec 03, 2018
AB	**+!**	TWI PHARMS	**EQ 60MG BASE**	**N202133**	**001**	Oct 06, 2011
AB		UPSHER SMITH LABS	**EQ 10MG BASE**	**A211696**	**001**	Jan 30, 2019
AB			**EQ 20MG BASE**	**A211696**	**002**	Jan 30, 2019

FLUOXETINE HYDROCHLORIDE

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

	TORRENT	EQ 10MG BASE	A206937	001	Oct 21, 2016
!		EQ 20MG BASE	A206937	002	Oct 21, 2016

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	**EQ 25MG BASE;EQ 3MG BASE**	**A078901**	**005**	Nov 16, 2012
AB		**EQ 25MG BASE;EQ 6MG BASE**	**A078901**	**001**	Nov 16, 2012
AB		**EQ 25MG BASE;EQ 12MG BASE**	**A078901**	**003**	Nov 16, 2012
AB		**EQ 50MG BASE;EQ 6MG BASE**	**A078901**	**002**	Nov 16, 2012
AB		**EQ 50MG BASE;EQ 12MG BASE**	**A078901**	**004**	Nov 16, 2012
AB	PAR PHARM	**EQ 25MG BASE;EQ 3MG BASE**	**A077742**	**001**	Nov 02, 2012
AB		**EQ 25MG BASE;EQ 6MG BASE**	**A077742**	**002**	Nov 02, 2012
AB		**EQ 25MG BASE;EQ 12MG BASE**	**A077742**	**003**	Nov 02, 2012
AB		**EQ 50MG BASE;EQ 6MG BASE**	**A077742**	**004**	Nov 02, 2012
AB		**EQ 50MG BASE;EQ 12MG BASE**	**A077742**	**005**	Nov 02, 2012
AB	TEVA PHARMS	**EQ 25MG BASE;EQ 3MG BASE**	**A202074**	**001**	Mar 25, 2013
AB		**EQ 25MG BASE;EQ 6MG BASE**	**A077528**	**001**	Jun 19, 2012
AB		**EQ 25MG BASE;EQ 12MG BASE**	**A077528**	**002**	Jun 19, 2012
AB		**EQ 50MG BASE;EQ 6MG BASE**	**A077528**	**003**	Jun 19, 2012
AB		**EQ 50MG BASE;EQ 12MG BASE**	**A077528**	**004**	Jun 19, 2012

SYMBYAX

AB	**+** LILLY	**EQ 25MG BASE;EQ 3MG BASE**	**N021520**	**001**	Apr 09, 2007
AB	**+**	**EQ 25MG BASE;EQ 6MG BASE**	**N021520**	**002**	Dec 24, 2003
AB	**+**	**EQ 25MG BASE;EQ 12MG BASE**	**N021520**	**004**	Dec 24, 2003
AB	**+!**	**EQ 50MG BASE;EQ 6MG BASE**	**N021520**	**003**	Dec 24, 2003
AB	**+**	**EQ 50MG BASE;EQ 12MG BASE**	**N021520**	**005**	Dec 24, 2003

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

AO	EUGIA PHARMA	**25MG/ML**	**A207739**	**001**	Oct 17, 2017
AO	**!** FRESENIUS KABI USA	**25MG/ML**	**A071413**	**001**	Jul 14, 1987
AO	GLAND PHARMA LTD	**25MG/ML**	**A215509**	**001**	Mar 30, 2023
AO	HIKMA	**25MG/ML**	**A074531**	**001**	Aug 30, 1996
AO	MSN	**25MG/ML**	**A215365**	**001**	Nov 02, 2023
AO	MYLAN LABS LTD	**25MG/ML**	**A075918**	**001**	Aug 17, 2001
AO	PAR STERILE PRODUCTS	**25MG/ML**	**A203732**	**001**	Jul 03, 2014

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

FLUPHENAZINE HYDROCHLORIDE

!	PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996

ELIXIR;ORAL

FLUPHENAZINE HYDROCHLORIDE

!	PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996

INJECTABLE;INJECTION

FLUPHENAZINE HYDROCHLORIDE

!	FRESENIUS KABI USA	2.5MG/ML	A089556	001	Apr 16, 1987

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	AJANTA PHARMA LTD	**1MG**	**A217410**	**001**	Jan 05, 2023
AB		**2.5MG**	**A217410**	**002**	Jan 05, 2023
AB		**5MG**	**A217410**	**003**	Jan 05, 2023
AB		**10MG**	**A217410**	**004**	Jan 05, 2023
AB	AMNEAL	**1MG**	**A213647**	**001**	Jul 09, 2020
AB		**2.5MG**	**A213647**	**002**	Jul 09, 2020
AB		**5MG**	**A213647**	**003**	Jul 09, 2020
AB		**10MG**	**A213647**	**004**	Jul 09, 2020
AB	APOTEX	**1MG**	**A216649**	**001**	Jul 15, 2022
AB		**2.5MG**	**A216649**	**002**	Jul 15, 2022
AB		**5MG**	**A216649**	**003**	Jul 15, 2022
AB		**10MG**	**A216649**	**004**	Jul 15, 2022
AB	AUROBINDO PHARMA LTD	**1MG**	**A218055**	**001**	Aug 18, 2023
AB		**2.5MG**	**A218055**	**002**	Aug 18, 2023
AB		**5MG**	**A218055**	**003**	Aug 18, 2023
AB		**10MG**	**A218055**	**004**	Aug 18, 2023
AB	CHARTWELL RX	**1MG**	**A215141**	**001**	Oct 20, 2021
AB		**2.5MG**	**A215141**	**002**	Oct 20, 2021

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB			**5MG**	**A215141**	**003**	Oct 20, 2021
AB			**10MG**	**A215141**	**004**	Oct 20, 2021
AB		DR REDDYS	**1MG**	**A214534**	**001**	Jan 07, 2021
AB			**2.5MG**	**A214534**	**002**	Jan 07, 2021
AB			**5MG**	**A214534**	**003**	Jan 07, 2021
AB			**10MG**	**A214534**	**004**	Jan 07, 2021
AB		GLENMARK PHARMS LTD	**1MG**	**A216350**	**001**	Nov 06, 2023
AB			**2.5MG**	**A216350**	**002**	Nov 06, 2023
AB			**5MG**	**A216350**	**003**	Nov 06, 2023
AB			**10MG**	**A216350**	**004**	Nov 06, 2023
AB		LANNETT CO INC	**1MG**	**A089743**	**002**	Aug 25, 1988
AB			**2.5MG**	**A089743**	**003**	Aug 25, 1988
AB	**!**		**5MG**	**A089743**	**004**	Aug 25, 1988
AB			**10MG**	**A089743**	**001**	Aug 25, 1988
AB		MSN	**1MG**	**A217189**	**001**	Sep 11, 2023
AB			**2.5MG**	**A217189**	**002**	Sep 11, 2023
AB			**5MG**	**A217189**	**003**	Sep 11, 2023
AB			**10MG**	**A217189**	**004**	Sep 11, 2023
AB		NOVITIUM PHARMA	**1MG**	**A214674**	**001**	Mar 01, 2021
AB			**2.5MG**	**A214674**	**002**	Mar 01, 2021
AB			**5MG**	**A214674**	**003**	Mar 01, 2021
AB			**10MG**	**A214674**	**004**	Mar 01, 2021
AB		SANDOZ	**1MG**	**A216891**	**001**	Nov 15, 2022
AB			**2.5MG**	**A216891**	**002**	Nov 15, 2022
AB			**5MG**	**A216891**	**003**	Nov 15, 2022
AB			**10MG**	**A216891**	**004**	Nov 15, 2022
AB		TARO	**1MG**	**A215674**	**001**	Apr 14, 2022
AB			**2.5MG**	**A215674**	**002**	Apr 14, 2022
AB			**5MG**	**A215674**	**003**	Apr 14, 2022
AB			**10MG**	**A215674**	**004**	Apr 14, 2022
AB		TWI PHARMS	**1MG**	**A215848**	**004**	Dec 14, 2022
AB			**2.5MG**	**A215848**	**001**	Apr 01, 2022
AB			**5MG**	**A215848**	**002**	Apr 01, 2022
AB			**10MG**	**A215848**	**003**	Apr 01, 2022
AB		UPSHER SMITH LABS	**1MG**	**A213784**	**001**	Oct 24, 2022
AB			**2.5MG**	**A213784**	**002**	Oct 24, 2022
AB			**5MG**	**A213784**	**003**	Oct 24, 2022
AB			**10MG**	**A213784**	**004**	Oct 24, 2022
AB		ZYDUS	**1MG**	**A214552**	**001**	May 27, 2021
AB			**2.5MG**	**A214552**	**002**	May 27, 2021
AB			**5MG**	**A214552**	**003**	May 27, 2021
AB			**10MG**	**A214552**	**004**	May 27, 2021

FLURANDRENOLIDE

LOTION;TOPICAL

FLURANDRENOLIDE

!	PADAGIS ISRAEL	0.05%	A207133	001	Aug 30, 2016

OINTMENT;TOPICAL

FLURANDRENOLIDE

!	TELIGENT	0.05%	A207851	001	Dec 30, 2016

TAPE;TOPICAL

CORDRAN

+!	ALMIRALL	0.004MG/SQ CM	N016455	001

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

AB		CHARTWELL RX	**15MG**	**A072368**	**001**	Mar 30, 1989
AB			**30MG**	**A072369**	**001**	Mar 30, 1989
AB		RISING	**15MG**	**A070345**	**002**	Nov 27, 1985
AB	**!**		**30MG**	**A070345**	**001**	Nov 27, 1985

FLURBIPROFEN

TABLET;ORAL

FLURBIPROFEN

!	TEVA	100MG	A074431	001	May 31, 1995

FLURBIPROFEN SODIUM							
SOLUTION/DROPS;OPHTHALMIC							
FLURBIPROFEN SODIUM							
	!	BAUSCH AND LOMB	0.03%		A074447	001	Jan 04, 1995
FLUTAMIDE							
CAPSULE;ORAL							
FLUTAMIDE							
	!	WAYLIS THERAP	125MG		A075298	001	Sep 18, 2001
FLUTEMETAMOL F-18							
INJECTABLE;INTRAVENOUS							
VIZAMYL							
	+!	GE HEALTHCARE	121.5mCi/30ML (4.05mCi/ML)		N203137	002	Oct 25, 2013
FLUTICASONE FUROATE							
POWDER;INHALATION							
ARNUITY ELLIPTA							
	+!	GLAXOSMITHKLINE	0.05MG/INH		N205625	003	May 17, 2018
	+!		0.1MG/INH		N205625	001	Aug 20, 2014
	+!		0.2MG/INH		N205625	002	Aug 20, 2014
SPRAY, METERED;NASAL							
VERAMYST							
	+	GLAXOSMITHKLINE	0.0275MG/INH		N022051	001	Apr 27, 2007
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE							
POWDER;INHALATION							
TRELEGY ELLIPTA							
	+!	GLAXOSMITHKLINE	0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH		N209482	001	Sep 18, 2017
	+!		0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH		N209482	002	Sep 09, 2020
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE							
POWDER;INHALATION							
BREO ELLIPTA							
	+	GLAXO GRP LTD	0.05MG/INH;EQ 0.025MG BASE/INH		N204275	003	May 12, 2023
	+!		0.1MG/INH;EQ 0.025MG BASE/INH		N204275	001	May 10, 2013
	+!		0.2MG/INH;EQ 0.025MG BASE/INH		N204275	002	Apr 30, 2015
FLUTICASONE PROPIONATE							
AEROSOL, METERED;INHALATION							
FLOVENT HFA							
	+!	GLAXO GRP LTD	0.044MG/INH		N021433	003	May 14, 2004
	+!		0.11MG/INH		N021433	002	May 14, 2004
	+!		0.22MG/INH		N021433	001	May 14, 2004
CREAM;TOPICAL							
FLUTICASONE PROPIONATE							
AB		COSETTE	**0.05%**		**A077055**	**001**	Jun 30, 2006
AB		FOUGERA PHARMS	**0.05%**		**A076451**	**001**	May 14, 2004
AB	**!**	PADAGIS ISRAEL	**0.05%**		**A076793**	**001**	May 14, 2004
LOTION;TOPICAL							
FLUTICASONE PROPIONATE							
AB	**!**	GLENMARK GENERICS	**0.05%**		**A090759**	**001**	May 02, 2011
AB		PADAGIS ISRAEL	**0.05%**		**A091553**	**001**	Jul 30, 2013
OINTMENT;TOPICAL							
FLUTICASONE PROPIONATE							
AB		COSETTE	**0.005%**		**A077168**	**001**	Mar 03, 2006
AB	**!**	PADAGIS ISRAEL	**0.005%**		**A076668**	**001**	May 14, 2004
POWDER;INHALATION							
ARMONAIR DIGIHALER							
	+	TEVA PHARM	0.055MG/INH		N208798	004	Feb 20, 2020
	+		0.113MG/INH		N208798	005	Feb 20, 2020
	+!		0.232MG/INH		N208798	006	Feb 20, 2020
FLOVENT DISKUS 100							
	+!	GLAXO GRP LTD	0.1MG/INH		N020833	002	Sep 29, 2000
FLOVENT DISKUS 250							
	+!	GLAXO GRP LTD	0.25MG/INH		N020833	003	Sep 29, 2000
FLOVENT DISKUS 50							
	+!	GLAXO GRP LTD	0.05MG/INH		N020833	001	Sep 29, 2000
SPRAY, METERED;NASAL							
FLUTICASONE PROPIONATE							
AB		APOTEX INC	**0.05MG/SPRAY**		**A077538**	**001**	Sep 12, 2007
AB		CHARTWELL RX	**0.05MG/SPRAY**		**A078492**	**001**	Jan 09, 2012
AB	**!**	HIKMA	**0.05MG/SPRAY**		**A076504**	**001**	Feb 22, 2006
AB			**0.05MG/SPRAY**		**A077570**	**001**	Jan 16, 2008

FLUTICASONE PROPIONATE							
SPRAY, METERED;NASAL							
XHANCE							
	+!	OPTINOSE US INC	0.093MG		N209022	001	Sep 18, 2017
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE							
AEROSOL, METERED;INHALATION							
ADVAIR HFA							
	+!	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH		N021254	001	Jun 08, 2006
	+!		0.115MG/INH;EQ 0.021MG BASE/INH		N021254	002	Jun 08, 2006
	+!		0.23MG/INH;EQ 0.021MG BASE/INH		N021254	003	Jun 08, 2006
POWDER;INHALATION							
ADVAIR DISKUS 100/50							
AB	**+!**	GLAXO GRP LTD	**0.1MG/INH;EQ 0.05MG BASE/INH**		**N021077**	**001**	Aug 24, 2000
ADVAIR DISKUS 250/50							
AB	**+!**	GLAXO GRP LTD	**0.25MG/INH;EQ 0.05MG BASE/INH**		**N021077**	**002**	Aug 24, 2000
ADVAIR DISKUS 500/50							
AB	**+!**	GLAXO GRP LTD	**0.5MG/INH;EQ 0.05MG BASE/INH**		**N021077**	**003**	Aug 24, 2000
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE							
AB		HIKMA	**0.1MG/INH;EQ 0.05MG BASE/INH**		**A203433**	**001**	Dec 17, 2020
AB			**0.25MG/INH;EQ 0.05MG BASE/INH**		**A203433**	**002**	Dec 17, 2020
AB			**0.5MG/INH;EQ 0.05MG BASE/INH**		**A203433**	**003**	Dec 19, 2023
AB		TEVA PHARMS USA	**0.1MG/INH;EQ 0.05MG BASE/INH**		**A213948**	**001**	Dec 13, 2021
AB			**0.25MG/INH;EQ 0.05MG BASE/INH**		**A213948**	**002**	Dec 13, 2021
AB			**0.5MG/INH;EQ 0.05MG BASE/INH**		**A213948**	**003**	Dec 13, 2021
WIXELA INHUB							
AB		MYLAN	**0.1MG/INH;EQ 0.05MG BASE/INH**		**A208891**	**001**	Jan 30, 2019
AB			**0.25MG/INH;EQ 0.05MG BASE/INH**		**A208891**	**002**	Jan 30, 2019
AB			**0.5MG/INH;EQ 0.05MG BASE/INH**		**A208891**	**003**	Jan 30, 2019
AIRDUO DIGIHALER							
	+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH		N208799	004	Jul 12, 2019
	+		0.113MG/INH;EQ 0.014MG BASE/INH		N208799	005	Jul 12, 2019
	+		0.232MG/INH;EQ 0.014MG BASE/INH		N208799	006	Jul 12, 2019
AIRDUO RESPICLICK							
	+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH		N208799	001	Jan 27, 2017
	+		0.113MG/INH;EQ 0.014MG BASE/INH		N208799	002	Jan 27, 2017
	+!		0.232MG/INH;EQ 0.014MG BASE/INH		N208799	003	Jan 27, 2017
FLUVASTATIN SODIUM							
CAPSULE;ORAL							
FLUVASTATIN SODIUM							
AB		MYLAN PHARMS INC	**EQ 20MG BASE**		**A090595**	**001**	Apr 11, 2012
AB	**!**		**EQ 40MG BASE**		**A090595**	**002**	Apr 11, 2012
AB		TEVA PHARMS	**EQ 20MG BASE**		**A078407**	**001**	Jun 12, 2012
AB			**EQ 40MG BASE**		**A078407**	**002**	Jun 12, 2012
TABLET, EXTENDED RELEASE;ORAL							
FLUVASTATIN SODIUM							
AB		BEIJING	**EQ 80MG BASE**		**A209397**	**001**	Apr 26, 2021
AB		TEVA PHARMS USA	**EQ 80MG BASE**		**A079011**	**001**	Jan 27, 2016
LESCOL XL							
AB	**+!**	SANDOZ	**EQ 80MG BASE**		**N021192**	**001**	Oct 06, 2000
FLUVOXAMINE MALEATE							
CAPSULE, EXTENDED RELEASE;ORAL							
FLUVOXAMINE MALEATE							
AB		ACTAVIS ELIZABETH	**100MG**		**A091482**	**001**	Apr 23, 2013
AB	**!**		**150MG**		**A091482**	**002**	Nov 18, 2013
AB		ANCHEN PHARMS	**100MG**		**A091476**	**001**	Mar 13, 2013
AB			**150MG**		**A091476**	**002**	Mar 13, 2013
AB		BIONPHARMA	**100MG**		**A212182**	**002**	Sep 16, 2020
AB			**150MG**		**A212182**	**001**	May 11, 2020
TABLET;ORAL							
FLUVOXAMINE MALEATE							
AB		APOTEX	**25MG**		**A075902**	**001**	May 07, 2001
AB			**50MG**		**A075902**	**002**	May 07, 2001
AB			**100MG**		**A075902**	**003**	May 07, 2001
AB		UPSHER SMITH LABS	**25MG**		**A075888**	**001**	Nov 29, 2000
AB			**50MG**		**A075888**	**002**	Nov 29, 2000
AB	**!**		**100MG**		**A075888**	**003**	Nov 29, 2000
LUVOX							
AB	**+**	ANI PHARMS	**25MG**		**N021519**	**001**	Dec 20, 2007
AB	**+**		**50MG**		**N021519**	**002**	Dec 20, 2007
AB	**+**		**100MG**		**N021519**	**003**	Dec 20, 2007

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID

AP	**!**	FRESENIUS KABI USA	**5MG/ML**	**A089202**	**001**	Feb 18, 1986
AP		XGEN PHARMS	**5MG/ML**	**A202522**	**001**	Nov 06, 2019

TABLET;ORAL

FOLIC ACID

AA	**!**	AMNEAL PHARM	**1MG**	**A040625**	**001**	Jul 21, 2005
AA		ATHEM	**1MG**	**A211064**	**001**	Mar 08, 2019
AA		CADILA PHARMS LTD	**1MG**	**A202437**	**001**	Jan 27, 2014
AA		CHARTWELL MOLECULAR	**1MG**	**A090035**	**001**	Jun 09, 2009
AA		LEADING	**1MG**	**A040796**	**001**	Jan 12, 2009
AA		NUVO PHARMS INC	**1MG**	**A204418**	**001**	Jul 28, 2015
AA		QINGDAO BAHEAL PHARM	**1MG**	**A091145**	**001**	Jul 12, 2013
AA	**+!**	WATSON LABS	**1MG**	**A080680**	**001**	

FOMEPIZOLE

INJECTABLE;INJECTION

FOMEPIZOLE

AP		AM REGENT	**1.5GM/1.5ML (1GM/ML)**	**A078368**	**001**	Dec 14, 2007
AP		GLAND PHARMA LTD	**1.5GM/1.5ML (1GM/ML)**	**A216791**	**001**	Jul 06, 2023
AP	**!**	MYLAN INSTITUTIONAL	**1.5GM/1.5ML (1GM/ML)**	**A078639**	**001**	Mar 03, 2008
AP		NAVINTA LLC	**1.5GM/1.5ML (1GM/ML)**	**A078537**	**001**	Mar 06, 2008

FONDAPARINUX SODIUM

INJECTABLE;SUBCUTANEOUS

ARIXTRA

AP	**+!**	MYLAN IRELAND LTD	**2.5MG/0.5ML**	**N021345**	**001**	Dec 07, 2001
AP	**+!**		**5MG/0.4ML**	**N021345**	**002**	May 28, 2004
AP	**+!**		**7.5MG/0.6ML**	**N021345**	**003**	May 28, 2004
AP	**+!**		**10MG/0.8ML**	**N021345**	**004**	May 28, 2004

FONDAPARINUX SODIUM

AP		DR REDDYS LABS LTD	**2.5MG/0.5ML**	**A091316**	**001**	Jul 11, 2011
AP			**5MG/0.4ML**	**A091316**	**002**	Jul 11, 2011
AP			**7.5MG/0.6ML**	**A091316**	**003**	Jul 11, 2011
AP			**10MG/0.8ML**	**A091316**	**004**	Jul 11, 2011
AP		EUGIA PHARMA	**2.5MG/0.5ML**	**A206918**	**001**	Dec 26, 2017
AP			**5MG/0.4ML**	**A206918**	**002**	Dec 26, 2017
AP			**7.5MG/0.6ML**	**A206918**	**003**	Dec 26, 2017
AP			**10MG/0.8ML**	**A206918**	**004**	Dec 26, 2017
AP		HENGRUI PHARMA	**2.5MG/0.5ML**	**A206812**	**001**	May 15, 2018
AP			**5MG/0.4ML**	**A206812**	**002**	May 15, 2018
AP			**7.5MG/0.6ML**	**A206812**	**003**	May 15, 2018
AP			**10MG/0.8ML**	**A206812**	**004**	May 15, 2018
AP		SCINOPHARM TAIWAN	**2.5MG/0.5ML**	**A208615**	**001**	Nov 14, 2018
AP			**5MG/0.4ML**	**A208615**	**002**	Nov 14, 2018
AP			**7.5MG/0.6ML**	**A208615**	**003**	Nov 14, 2018
AP			**10MG/0.8ML**	**A208615**	**004**	Nov 14, 2018

FORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

AN		ALEMBIC	**0.02MG/2ML**	**A215078**	**001**	Nov 22, 2021
AN		AUCTA	**0.02MG/2ML**	**A216486**	**001**	Nov 25, 2022
AN		LUPIN	**0.02MG/2ML**	**A215053**	**001**	Aug 22, 2022
AN		MANKIND PHARMA	**0.02MG/2ML**	**A215883**	**001**	Mar 22, 2023
AN		SLAYBACK PHARMA LLC	**0.02MG/2ML**	**A215621**	**001**	Dec 13, 2022
AN		TEVA PHARMS USA INC	**0.02MG/2ML**	**A091141**	**001**	Jun 22, 2021

PERFOROMIST

AN	**+!**	MYLAN SPECLT	**0.02MG/2ML**	**N022007**	**001**	May 11, 2007

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED;INHALATION

BEVESPI AEROSPHERE

	+!	ASTRAZENECA	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

DULERA

	+	ORGANON LLC	0.005MG/INH;0.05MG/INH	N022518	003	Aug 12, 2019
	+!		0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010
	+!		0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010

FOSAMPRENAVIR CALCIUM

TABLET;ORAL

FOSAMPRENAVIR CALCIUM

AB		MYLAN	**EQ 700MG BASE**	**A204060**	**001**	Apr 15, 2016
AB		SUN PHARM	**EQ 700MG BASE**	**A204024**	**001**	Nov 20, 2019

LEXIVA

AB	**+!**	VIIV HLTHCARE	**EQ 700MG BASE**	**N021548**	**001**	Oct 20, 2003

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

EMEND

AP	**+!**	MERCK AND CO INC	**EQ 150MG BASE/VIAL**	**N022023**	**002**	Nov 12, 2010

FOSAPREPITANT DIMEGLUMINE

AP		ACCORD HLTHCARE	**EQ 150MG BASE/VIAL**	**A204025**	**001**	Aug 26, 2020
AP		ASPIRO	**EQ 150MG BASE/VIAL**	**A214616**	**001**	Jul 29, 2021
AP		BAXTER HLTHCARE CORP	**EQ 150MG BASE/VIAL**	**A211860**	**001**	Sep 05, 2019
AP		BE PHARMS	**EQ 150MG BASE/VIAL**	**A212309**	**001**	Sep 05, 2019
AP		CHIA TAI TIANQING	**EQ 150MG BASE/VIAL**	**A212143**	**001**	Mar 03, 2021
AP		DR REDDYS	**EQ 150MG BASE/VIAL**	**A211160**	**001**	Dec 09, 2020
AP		EUGIA PHARMA	**EQ 150MG BASE/VIAL**	**A210625**	**001**	Jan 12, 2021
AP		FRESENIUS KABI USA	**EQ 150MG BASE/VIAL**	**A206197**	**001**	Jun 09, 2016
AP		LUPIN LTD	**EQ 150MG BASE/VIAL**	**A210689**	**001**	Sep 05, 2019
AP		MSN	**EQ 150MG BASE/VIAL**	**A209965**	**001**	Sep 05, 2019
AP		MYLAN LABS LTD	**EQ 150MG BASE/VIAL**	**A204015**	**002**	Sep 05, 2019
AP		NAVINTA LLC	**EQ 150MG BASE/VIAL**	**A212957**	**002**	Aug 20, 2020
AP		PIRAMAL CRITICAL	**EQ 150MG BASE/VIAL**	**A214683**	**001**	May 16, 2023
AP		QILU PHARM HAINAN	**EQ 150MG BASE/VIAL**	**A213106**	**001**	Sep 08, 2020
		TEVA PHARMS USA	EQ 150MG BASE/VIAL	N210064	001	Sep 05, 2019

SOLUTION;INTRAVENOUS

FOCINVEZ

	+!	STERISCIENCE	EQ 150MG BASE/50ML (EQ 3MG BASE/ML)	N216686	001	Aug 22, 2023

FOSCARNET SODIUM

INJECTABLE;INJECTION

FOSCARNET SODIUM

AP		AVET LIFESCIENCES	**2.4GM/100ML**	**A213807**	**001**	Jun 05, 2023
AP		BEIJING	**2.4GM/100ML**	**A213987**	**001**	Nov 29, 2023
AP		FRESENIUS KABI USA	**2.4GM/100ML**	**A212483**	**001**	Jan 29, 2021
AP		GLAND PHARMA LTD	**2.4GM/100ML**	**A213001**	**001**	Apr 21, 2021

FOSCAVIR

AP	**+!**	CLINIGEN HLTHCARE	**2.4GM/100ML**	**N020068**	**001**	Sep 27, 1991

FOSDENOPTERIN HYDROBROMIDE

POWDER;INTRAVENOUS

NULIBRY

	+!	SENTYNL THERAPS INC	EQ 9.5MG BASE/VIAL	N214018	001	Feb 26, 2021

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL

FOSFOMYCIN TROMETHAMINE

AA		ALKEM LABS LTD	**EQ 3GM BASE/PACKET**	**A214554**	**001**	Oct 21, 2021
AA		CIPLA	**EQ 3GM BASE/PACKET**	**A211881**	**001**	Jan 26, 2022
AA		XIROMED	**EQ 3GM BASE/PACKET**	**A212548**	**001**	Oct 06, 2020

MONUROL

AA	**+!**	ZAMBON SPA	**EQ 3GM BASE/PACKET**	**N050717**	**001**	Dec 19, 1996

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

AB		APOTEX INC	**10MG**	**A076906**	**001**	May 17, 2005
AB			**20MG**	**A076906**	**002**	May 17, 2005
AB			**40MG**	**A076906**	**003**	May 17, 2005
AB		AUROBINDO PHARMA LTD	**10MG**	**A091163**	**001**	Mar 30, 2011
AB			**20MG**	**A091163**	**002**	Mar 30, 2011
AB			**40MG**	**A091163**	**003**	Mar 30, 2011
AB		CHARTWELL RX	**10MG**	**A076483**	**001**	Apr 23, 2004
AB			**20MG**	**A076483**	**002**	Apr 23, 2004
AB			**40MG**	**A076483**	**003**	Apr 23, 2004
AB		INVAGEN PHARMS	**10MG**	**A077222**	**001**	Apr 20, 2005
AB			**20MG**	**A077222**	**002**	Apr 20, 2005
AB			**40MG**	**A077222**	**003**	Apr 20, 2005
AB		PRINSTON INC	**10MG**	**A205670**	**001**	Aug 29, 2016
AB			**20MG**	**A205670**	**002**	Aug 29, 2016

FOSINOPRIL SODIUM
TABLET;ORAL
FOSINOPRIL SODIUM

AB			**40MG**	**A205670**	**003**	Aug 29, 2016
AB		TEVA	**10MG**	**A076139**	**001**	Nov 25, 2003
AB			**20MG**	**A076139**	**002**	Nov 25, 2003
AB	**!**		**40MG**	**A076139**	**003**	Nov 25, 2003

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE
TABLET;ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA	**10MG;12.5MG**	**A079245**	**001**	Jul 09, 2009
AB	**!**		**20MG;12.5MG**	**A079245**	**002**	Jul 09, 2009
AB		INVAGEN PHARMS	**10MG;12.5MG**	**A090228**	**001**	Jul 09, 2009
AB			**20MG;12.5MG**	**A090228**	**002**	Jul 09, 2009
AB		SANDOZ	**10MG;12.5MG**	**A076961**	**001**	Sep 28, 2005
AB			**20MG;12.5MG**	**A076961**	**002**	Sep 28, 2005

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE
SOLUTION;INTRAVENOUS
AKYNZEO

	+!	HELSINN HLTHCARE	EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)	N210493	002	May 27, 2020

FOSPHENYTOIN SODIUM
INJECTABLE;INJECTION
CEREBYX

AP	**+!**	PARKE DAVIS	**EQ 50MG PHENYTOIN NA/ML**	**N020450**	**001**	Aug 05, 1996

FOSPHENYTOIN SODIUM

AP		FRESENIUS KABI USA	**EQ 50MG PHENYTOIN NA/ML**	**A078052**	**001**	Aug 06, 2007
AP		GLAND PHARMA LTD	**EQ 50MG PHENYTOIN NA/ML**	**A214926**	**001**	Oct 13, 2023
AP		HIKMA	**EQ 50MG PHENYTOIN NA/ML**	**A077481**	**001**	Aug 06, 2007
AP			**EQ 50MG PHENYTOIN NA/ML**	**A077989**	**001**	Aug 06, 2007
AP		HIKMA FARMACEUTICA	**EQ 50MG PHENYTOIN NA/ML**	**A078765**	**001**	Dec 02, 2009
AP		SUN PHARM	**EQ 50MG PHENYTOIN NA/ML**	**A078417**	**001**	Mar 18, 2008
AP		WOCKHARDT	**EQ 50MG PHENYTOIN NA/ML**	**A078137**	**001**	Aug 06, 2007

FOSTAMATINIB DISODIUM
TABLET;ORAL
TAVALISSE

	+	RIGEL PHARMS INC	EQ 100MG BASE	N209299	001	Apr 17, 2018
	+!		EQ 150MG BASE	N209299	002	Apr 17, 2018

FOSTEMSAVIR TROMETHAMINE
TABLET, EXTENDED RELEASE;ORAL
RUKOBIA

	+!	VIIV HLTHCARE	EQ 600MG BASE	N212950	001	Jul 02, 2020

FROVATRIPTAN SUCCINATE
TABLET;ORAL
FROVA

AB	**+!**	ENDO PHARMS	**EQ 2.5MG BASE**	**N021006**	**001**	Nov 08, 2001

FROVATRIPTAN SUCCINATE

AB		AMNEAL PHARMS CO	**EQ 2.5MG BASE**	**A211292**	**001**	Nov 06, 2018
AB		GLENMARK PHARMS LTD	**EQ 2.5MG BASE**	**A204730**	**001**	Mar 11, 2016
AB		RENATA	**EQ 2.5MG BASE**	**A213891**	**001**	Apr 06, 2022

FRUQUINTINIB
CAPSULE;ORAL
FRUZAQLA

	+	TAKEDA PHARMS USA	1MG	N217564	001	Nov 08, 2023
	+!		5MG	N217564	002	Nov 08, 2023

FULVESTRANT
SOLUTION;INTRAMUSCULAR
FASLODEX

AO	**+!**	ASTRAZENECA	**250MG/5ML (50MG/ML)**	**N021344**	**001**	Apr 25, 2002

FULVESTRANT

AO		ACCORD HLTHCARE	**250MG/5ML (50MG/ML)**	**A211689**	**001**	Nov 17, 2020
AO		ALEMBIC	**250MG/5ML (50MG/ML)**	**A215077**	**001**	Dec 22, 2022
AO		AMNEAL	**250MG/5ML (50MG/ML)**	**A210044**	**001**	Mar 04, 2019
AO		CHIA TAI TIANQING	**250MG/5ML (50MG/ML)**	**A211422**	**001**	Feb 07, 2020
AO		DR REDDYS	**250MG/5ML (50MG/ML)**	**A209246**	**001**	Aug 07, 2020
AO		EUGIA PHARMA	**250MG/5ML (50MG/ML)**	**A208811**	**001**	Jul 23, 2019
AO			**250MG/5ML (50MG/ML)**	**A215169**	**001**	Jun 30, 2023
AO		GLENMARK PHARMS INC	**250MG/5ML (50MG/ML)**	**A207754**	**001**	Aug 22, 2019

FULVESTRANT

SOLUTION;INTRAMUSCULAR

FULVESTRANT

AO		HBT LABS INC	**250MG/5ML (50MG/ML)**	**A209714**	**001**	Nov 21, 2019
AO		JIANGSU HANSOH PHARM	**250MG/5ML (50MG/ML)**	**A214682**	**001**	Feb 10, 2022
AO		SAGENT PHARMS INC	**250MG/5ML (50MG/ML)**	**A205871**	**001**	Aug 22, 2019
AO		SANDOZ	**250MG/5ML (50MG/ML)**	**A205935**	**001**	May 14, 2019
AO		XIROMED	**250MG/5ML (50MG/ML)**	**A213553**	**001**	Aug 13, 2021
AO		ZYDUS PHARMS	**250MG/5ML (50MG/ML)**	**A215234**	**001**	Jul 29, 2021
		FRESENIUS KABI USA	250MG/5ML (50MG/ML)	N210326	001	May 20, 2019
		TEVA PHARMS USA INC	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

AP		ACCORD HLTHCARE	**10MG/ML**	**A070017**	**001**	Dec 15, 1986
AP		AMNEAL PHARMS CO	**10MG/ML**	**A207552**	**001**	Jul 20, 2016
AP		AREVA PHARMS	**10MG/ML**	**A208435**	**001**	Dec 18, 2020
AP		AVET LIFESCIENCES	**10MG/ML**	**A203428**	**001**	Aug 26, 2014
AP	**!**	BAXTER HLTHCARE CORP	**10MG/ML**	**A202747**	**001**	Jan 27, 2014
AP		EUGIA PHARMA	**10MG/ML**	**A212174**	**001**	May 03, 2019
AP		FRESENIUS KABI USA	**10MG/ML**	**N018902**	**001**	May 22, 1984
AP		GLAND PHARMA LTD	**10MG/ML**	**A213902**	**001**	Jul 01, 2020
AP		HOSPIRA	**10MG/ML**	**A075241**	**001**	May 28, 1999
AP			**10MG/ML**	**N018667**	**001**	May 28, 1982
AP		MANKIND PHARMA	**10MG/ML**	**A216860**	**001**	Dec 16, 2022
AP		MEITHEAL	**10MG/ML**	**A212803**	**001**	Jan 27, 2022
AP		SAGENT	**10MG/ML**	**A214766**	**001**	Jan 27, 2021
AP		WOCKHARDT	**10MG/ML**	**A077941**	**001**	Mar 22, 2007

SOLUTION;ORAL

FUROSEMIDE

	!	HIKMA	10MG/ML	A070434	001	Apr 22, 1987
			40MG/5ML	A070433	001	Apr 22, 1987

SOLUTION;SUBCUTANEOUS

FUROSCIX

	+!	SCPHARMACEUTICALS	80MG/10ML (8MG/ML)	N209988	001	Oct 07, 2022

TABLET;ORAL

FUROSEMIDE

AB		EPIC PHARMA LLC	**20MG**	**N018569**	**002**	
AB			**40MG**	**N018569**	**001**	
AB			**80MG**	**N018569**	**005**	Aug 14, 1984
AB		GRAVITI PHARMS	**20MG**	**A216629**	**001**	Oct 17, 2022
AB			**40MG**	**A216629**	**002**	Oct 17, 2022
AB			**80MG**	**A216629**	**003**	Oct 17, 2022
AB		HIKMA	**20MG**	**N018823**	**001**	Nov 10, 1983
AB			**40MG**	**N018823**	**002**	Nov 10, 1983
AB			**80MG**	**A070086**	**001**	Jan 24, 1986
AB		IPCA LABS LTD	**20MG**	**A078010**	**001**	Sep 18, 2006
AB			**40MG**	**A078010**	**002**	Sep 18, 2006
AB			**80MG**	**A078010**	**003**	Sep 18, 2006
AB		LEADING	**20MG**	**A077293**	**001**	Nov 09, 2005
AB			**40MG**	**A077293**	**002**	Nov 09, 2005
AB			**80MG**	**A077293**	**003**	Nov 09, 2005
AB		MYLAN	**20MG**	**N018487**	**001**	
AB			**40MG**	**N018487**	**002**	
AB			**80MG**	**A070082**	**001**	Oct 29, 1986
AB		PRINSTON INC	**20MG**	**A076796**	**001**	Mar 26, 2004
AB			**40MG**	**A076796**	**002**	Mar 26, 2004
AB			**80MG**	**A076796**	**003**	Mar 26, 2004

LASIX

AB	**+**	VALIDUS PHARMS	**20MG**	**N016273**	**002**	
AB	**+**		**40MG**	**N016273**	**001**	
AB	**+!**		**80MG**	**N016273**	**003**	

FUTIBATINIB

TABLET;ORAL

LYTGOBI

	+!	TAIHO ONCOLOGY	4MG	N214801	001	Sep 30, 2022

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB		ACI	**100MG**	**A206943**	**001**	May 14, 2018
AB			**300MG**	**A206943**	**002**	May 14, 2018
AB			**400MG**	**A206943**	**003**	May 14, 2018
AB		ACTAVIS ELIZABETH	**100MG**	**A075350**	**001**	Sep 12, 2003
AB			**300MG**	**A075350**	**002**	Sep 12, 2003
AB			**400MG**	**A075350**	**003**	Sep 12, 2003
AB		ALKEM	**100MG**	**A090858**	**001**	Dec 17, 2010
AB			**300MG**	**A090858**	**002**	Dec 17, 2010
AB			**400MG**	**A090858**	**003**	Dec 17, 2010
AB		AMNEAL PHARMS NY	**100MG**	**A078428**	**001**	Jul 25, 2007
AB			**300MG**	**A078428**	**002**	Jul 25, 2007
AB			**400MG**	**A078428**	**003**	Jul 25, 2007
AB		ASCENT PHARMS INC	**100MG**	**A214956**	**001**	May 10, 2021
AB			**300MG**	**A214956**	**002**	May 10, 2021
AB			**400MG**	**A214956**	**003**	May 10, 2021
AB		AUROBINDO PHARMA	**100MG**	**A078787**	**001**	Jan 31, 2008
AB			**300MG**	**A078787**	**002**	Jan 31, 2008
AB			**400MG**	**A078787**	**003**	Jan 31, 2008
AB		CSPC OUYI	**100MG**	**A075477**	**001**	Mar 23, 2005
AB			**300MG**	**A075477**	**002**	Mar 23, 2005
AB			**400MG**	**A075477**	**003**	Mar 23, 2005
AB		GRANULES	**100MG**	**A075360**	**001**	Apr 06, 2005
AB			**300MG**	**A075360**	**002**	Apr 06, 2005
AB			**400MG**	**A075360**	**003**	Apr 06, 2005
AB		GRAVITI PHARMS	**100MG**	**A207099**	**001**	Mar 24, 2017
AB			**300MG**	**A207099**	**002**	Mar 24, 2017
AB			**400MG**	**A207099**	**003**	Mar 24, 2017
AB		INVAGEN PHARMS	**100MG**	**A090705**	**001**	Dec 30, 2009
AB			**300MG**	**A090705**	**002**	Dec 30, 2009
AB			**400MG**	**A090705**	**003**	Dec 30, 2009
AB		IPCA LABS LTD	**100MG**	**A208928**	**001**	Nov 20, 2023
AB			**300MG**	**A208928**	**002**	Nov 20, 2023
AB			**400MG**	**A208928**	**003**	Nov 20, 2023
AB		LAURUS	**100MG**	**A217546**	**001**	May 12, 2023
AB			**300MG**	**A217546**	**002**	May 12, 2023
AB			**400MG**	**A217546**	**003**	May 12, 2023
AB		MARKSANS PHARMA	**100MG**	**A090007**	**001**	Jul 21, 2011
AB			**300MG**	**A090007**	**002**	Jul 21, 2011
AB			**400MG**	**A090007**	**003**	Jul 21, 2011
AB		SCIEGEN PHARMS INC	**100MG**	**A204989**	**001**	Feb 18, 2016
AB			**300MG**	**A204989**	**002**	Feb 18, 2016
AB			**400MG**	**A204989**	**003**	Feb 18, 2016
AB		STRIDES PHARMA	**100MG**	**A211314**	**001**	Oct 16, 2018
AB			**300MG**	**A211314**	**002**	Oct 16, 2018
AB			**400MG**	**A211314**	**003**	Oct 16, 2018
AB		SUN PHARM INDS LTD	**100MG**	**A077242**	**001**	Aug 24, 2006
AB			**300MG**	**A077242**	**002**	Aug 24, 2006
AB			**400MG**	**A077242**	**003**	Aug 24, 2006
AB		TARO	**100MG**	**A077261**	**001**	Aug 02, 2013
AB			**300MG**	**A077261**	**002**	Aug 02, 2013
AB			**400MG**	**A077261**	**003**	Aug 02, 2013
AB		ZHEJIANG YONGTAI	**100MG**	**A213603**	**001**	Aug 17, 2020
AB			**300MG**	**A213603**	**002**	Aug 17, 2020
AB			**400MG**	**A213603**	**003**	Aug 17, 2020

NEURONTIN

AB	**+**	VIATRIS	**100MG**	**N020235**	**001**	Dec 30, 1993
AB	**+**		**300MG**	**N020235**	**002**	Dec 30, 1993
AB	**+!**		**400MG**	**N020235**	**003**	Dec 30, 1993

SOLUTION;ORAL

GABAPENTIN

AA		ACELLA PHARMS LLC	**250MG/5ML**	**A076403**	**001**	May 01, 2012
AA		AMNEAL PHARMS	**250MG/5ML**	**A202024**	**001**	Mar 23, 2012
AA		BELCHER	**250MG/5ML**	**A091286**	**001**	Mar 14, 2016
AA		MISSION PHARMACAL	**250MG/5ML**	**A078974**	**001**	Feb 18, 2011
AA		RUBICON	**250MG/5ML**	**A216492**	**001**	Jan 18, 2023
AA		TARO	**250MG/5ML**	**A076672**	**001**	Jul 03, 2013

NEURONTIN

AA	**+!**	VIATRIS	**250MG/5ML**	**N021129**	**001**	Mar 02, 2000

GABAPENTIN

TABLET;ORAL

GABAPENTIN

AB		ACI	**600MG**	**A203244**	**002**	Jul 12, 2013
AB			**800MG**	**A203244**	**001**	Jul 12, 2013
AB		ACTAVIS ELIZABETH	**600MG**	**A075694**	**001**	Oct 21, 2004
AB			**800MG**	**A075694**	**002**	Oct 21, 2004
AB		ALKEM LABS LTD	**600MG**	**A206402**	**001**	Dec 23, 2015
AB			**800MG**	**A206402**	**002**	Dec 23, 2015
AB		APOTEX INC	**100MG**	**A077894**	**001**	Oct 10, 2006
AB			**300MG**	**A077894**	**002**	Oct 10, 2006
AB			**400MG**	**A077894**	**003**	Oct 10, 2006
AB		ASCENT PHARMS INC	**600MG**	**A214957**	**001**	Oct 01, 2021
AB			**800MG**	**A214957**	**002**	Oct 01, 2021
AB		AUROBINDO PHARMA LTD	**600MG**	**A200651**	**001**	Oct 06, 2011
AB			**800MG**	**A200651**	**002**	Oct 06, 2011
AB		CSPC OUYI	**600MG**	**A207057**	**001**	Oct 26, 2017
AB			**800MG**	**A207057**	**002**	Oct 26, 2017
AB		GLENMARK PHARMS LTD	**600MG**	**A077662**	**001**	Aug 18, 2006
AB			**800MG**	**A077662**	**002**	Aug 18, 2006
AB		GRANULES	**600MG**	**A217116**	**001**	Mar 28, 2023
AB			**800MG**	**A217116**	**002**	Mar 28, 2023
AB		INVAGEN PHARMS	**600MG**	**A202764**	**001**	Oct 16, 2012
AB			**800MG**	**A202764**	**002**	Oct 16, 2012
AB		IVAX SUB TEVA PHARMS	**100MG**	**A076017**	**001**	Apr 28, 2004
AB			**300MG**	**A076017**	**002**	Apr 28, 2004
AB			**400MG**	**A076017**	**003**	Apr 28, 2004
AB		RISING	**600MG**	**A217995**	**001**	Jul 19, 2023
AB			**800MG**	**A217995**	**002**	Jul 19, 2023
AB		RUBICON	**600MG**	**A077661**	**004**	Sep 13, 2006
AB			**800MG**	**A077661**	**005**	Sep 13, 2006
AB		SCIEGEN PHARMS INC	**600MG**	**A205101**	**001**	Feb 04, 2016
AB			**800MG**	**A205101**	**002**	Feb 04, 2016
AB		SUN PHARM INDS LTD	**600MG**	**A077525**	**001**	Aug 24, 2006
AB			**800MG**	**A077525**	**002**	Aug 24, 2006
AB		ZYDUS PHARMS USA INC	**600MG**	**A078926**	**001**	Feb 11, 2011
AB			**800MG**	**A078926**	**002**	Feb 11, 2011

NEURONTIN

AB	**+**	VIATRIS	**600MG**	**N020882**	**001**	Oct 09, 1998
AB	**+!**		**800MG**	**N020882**	**002**	Oct 09, 1998

GRALISE

BX	+!	ALMATICA	300MG	N022544	001	Jan 28, 2011
BX	+!		600MG	N022544	002	Jan 28, 2011
	+		450MG	N022544	003	Apr 18, 2023
	+		750MG	N022544	004	Apr 18, 2023
	+		900MG	N022544	005	Apr 18, 2023

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE;ORAL

HORIZANT

	+	AZURITY	300MG	N022399	002	Dec 13, 2011
	+!		600MG	N022399	001	Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE;INTRAVENOUS

MULTIHANCE

	+!	BRACCO	2.645GM/5ML (529MG/ML)	N021357	001	Nov 23, 2004
	+!		5.29GM/10ML (529MG/ML)	N021357	002	Nov 23, 2004
	+!		7.935GM/15ML (529MG/ML)	N021357	003	Nov 23, 2004
	+!		10.58GM/20ML (529MG/ML)	N021357	004	Nov 23, 2004

MULTIHANCE MULTIPACK

	+!	BRACCO	26.45GM/50ML (529MG/ML)	N021358	001	Nov 23, 2004
	+!		52.9GM/100ML (529MG/ML)	N021358	002	Nov 23, 2004

GADOBUTROL

SOLUTION;INTRAVENOUS

GADAVIST

AP	**+!**	BAYER HLTHCARE	**1.20944GM/2ML (604.72MG/ML)**	**N201277**	**006**	Dec 18, 2013
AP	**+!**		**4.5354GM/7.5ML (604.72MG/ML)**	**N201277**	**001**	Mar 14, 2011
AP	**+!**		**6.0472GM/10ML (604.72MG/ML)**	**N201277**	**002**	Mar 14, 2011
AP	**+!**		**9.0708GM/15ML (604.72MG/ML)**	**N201277**	**003**	Mar 14, 2011

GADOBUTROL

SOLUTION;INTRAVENOUS

GADAVIST

AP	**+!**		**18.1416GM/30ML (604.72MG/ML)**	**N201277**	**004**	Mar 14, 2011
AP	**+!**		**39.3068GM/65ML (604.72MG/ML)**	**N201277**	**005**	Mar 14, 2011

GADOBUTROL

AP		HAINAN POLY PHARM	**4.5354GM/7.5ML (604.72MG/ML)**	**A217480**	**001**	Mar 15, 2023
AP			**9.0708GM/15ML (604.72MG/ML)**	**A217480**	**002**	Mar 15, 2023
AP		HENGRUI PHARMA	**1.20944GM/2ML (604.72MG/ML)**	**A215061**	**001**	Nov 17, 2022
AP			**4.5354GM/7.5ML (604.72MG/ML)**	**A215061**	**002**	Nov 17, 2022
AP			**6.0472GM/10ML (604.72MG/ML)**	**A215061**	**003**	Nov 17, 2022
AP			**9.0708GM/15ML (604.72MG/ML)**	**A215061**	**004**	Nov 17, 2022
AP			**18.1416GM/30ML (604.72MG/ML)**	**A216081**	**001**	Sep 08, 2023
AP			**39.3068GM/65ML (604.72MG/ML)**	**A216081**	**002**	Sep 08, 2023

GADODIAMIDE

INJECTABLE;INJECTION

OMNISCAN

+!	GE HEALTHCARE	287MG/ML	N020123	001	Jan 08, 1993
+!		28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007

GADOPICLENOL

SOLUTION;INTRAVENOUS

ELUCIREM

+!	GUERBET	1.4553GM/3ML (485.1MG/ML)	N216986	001	Sep 21, 2022
+!		3.63825GM/7.5ML (485.1MG/ML)	N216986	002	Sep 21, 2022
+!		4.851GM/10ML (485.1MG/ML)	N216986	003	Sep 21, 2022
+!		7.2765GM/15ML (485.1MG/ML)	N216986	004	Sep 21, 2022
+!		14.553GM/30ML (485.1MG/ML)	N216986	005	Sep 21, 2022
+!		24.255GM/50ML (485.1MG/ML)	N216986	006	Sep 21, 2022
+!		48.51GM/100ML (485.1MG/ML)	N216986	007	Sep 21, 2022

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS

CLARISCAN

AP		GE HEALTHCARE	**7.538GM/20ML (376.9MG/ML)**	**A210016**	**003**	Nov 01, 2019
AP			**1.8845GM/5ML (376.9MG/ML)**	**A210016**	**005**	Nov 24, 2020
AP			**3.769GM/10ML (376.9MG/ML)**	**A210016**	**001**	Nov 01, 2019
AP			**5.6535GM/15ML (376.9MG/ML)**	**A210016**	**002**	Nov 01, 2019
AP			**37.69GM/100ML (376.9MG/ML)**	**A210016**	**004**	Aug 04, 2020

DOTAREM

AP	**+!**	GUERBET	**37.69GM/100ML (376.9MG/ML)**	**N204781**	**001**	Mar 20, 2013
AP	**+!**		**1.8845GM/5ML (376.9MG/ML)**	**N204781**	**005**	Mar 31, 2017
AP	**+!**		**3.769GM/10ML (376.9MG/ML)**	**N204781**	**002**	Mar 20, 2013
AP	**+!**		**5.6535GM/15ML (376.9MG/ML)**	**N204781**	**003**	Mar 20, 2013
AP	**+!**		**7.538GM/20ML (376.9MG/ML)**	**N204781**	**004**	Mar 20, 2013

GADOTERATE MEGLUMINE

AP		HENGRUI PHARMA	**1.8845GM/5ML (376.9MG/ML)**	**A215304**	**001**	Apr 11, 2022
AP			**3.769GM/10ML (376.9MG/ML)**	**A215304**	**002**	Apr 11, 2022
AP			**5.6535GM/15ML (376.9MG/ML)**	**A215304**	**003**	Apr 11, 2022
AP			**7.538GM/20ML (376.9MG/ML)**	**A215304**	**004**	Apr 11, 2022
AP			**37.69GM/100ML (376.9MG/ML)**	**A215304**	**005**	Apr 15, 2022

GADOTERIDOL

INJECTABLE;INJECTION

PROHANCE

+!	BRACCO	279.3MG/ML	N020131	001	Nov 16, 1992

PROHANCE MULTIPACK

+!	BRACCO	279.3MG/ML	N021489	001	Oct 09, 2003

GADOXETATE DISODIUM

SOLUTION;INTRAVENOUS

EOVIST

+!	BAYER HLTHCARE	1.8143GM/10ML (181.43MG/ML)	N022090	001	Jul 03, 2008
+		2.72145GM/15ML (181.43MG/ML)	N022090	002	Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

AB	**!**	AUROBINDO PHARMA	**EQ 8MG BASE**	**A204895**	**001**	Aug 05, 2016
AB			**EQ 16MG BASE**	**A204895**	**002**	Aug 05, 2016
AB			**EQ 24MG BASE**	**A204895**	**003**	Aug 05, 2016
AB		BARR	**EQ 8MG BASE**	**A078189**	**001**	Sep 15, 2008
AB			**EQ 16MG BASE**	**A078189**	**002**	Sep 15, 2008
AB			**EQ 24MG BASE**	**A078189**	**003**	Sep 15, 2008

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

AB		SUN PHARM	**EQ 8MG BASE**	**A090178**	**001**	Feb 02, 2011
AB			**EQ 16MG BASE**	**A090178**	**002**	Feb 02, 2011
AB			**EQ 24MG BASE**	**A090178**	**003**	Feb 02, 2011
AB		WATSON LABS	**EQ 8MG BASE**	**A079028**	**001**	Dec 15, 2008
AB			**EQ 16MG BASE**	**A079028**	**002**	Dec 15, 2008
AB			**EQ 24MG BASE**	**A079028**	**003**	Dec 15, 2008

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

	!	HIKMA	4MG/ML	A078185	001	Jan 30, 2009

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

AB		AUROBINDO PHARMA LTD	**EQ 4MG BASE**	**A090957**	**001**	Mar 29, 2011
AB			**EQ 8MG BASE**	**A090957**	**002**	Mar 29, 2011
AB			**EQ 12MG BASE**	**A090957**	**003**	Mar 29, 2011
AB		BARR	**EQ 4MG BASE**	**A077605**	**001**	Aug 28, 2008
AB			**EQ 8MG BASE**	**A077605**	**002**	Aug 28, 2008
AB			**EQ 12MG BASE**	**A077605**	**003**	Aug 28, 2008
AB		DR REDDYS LABS LTD	**EQ 4MG BASE**	**A077593**	**001**	Sep 11, 2008
AB			**EQ 8MG BASE**	**A077593**	**002**	Sep 11, 2008
AB			**EQ 12MG BASE**	**A077593**	**003**	Sep 11, 2008
AB		SANDOZ	**EQ 4MG BASE**	**A077589**	**001**	Jun 22, 2009
AB			**EQ 8MG BASE**	**A077589**	**002**	Jun 22, 2009
AB			**EQ 12MG BASE**	**A077589**	**003**	Jun 22, 2009
AB	**!**	YABAO PHARM	**EQ 4MG BASE**	**A077604**	**001**	Feb 06, 2009
AB			**EQ 8MG BASE**	**A077604**	**002**	Feb 06, 2009
AB			**EQ 12MG BASE**	**A077604**	**003**	Feb 06, 2009
AB		ZYDUS PHARMS USA INC	**EQ 4MG BASE**	**A078898**	**001**	Feb 17, 2011
AB			**EQ 8MG BASE**	**A078898**	**002**	Feb 17, 2011
AB			**EQ 12MG BASE**	**A078898**	**003**	Feb 17, 2011

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION

GALLIUM CITRATE GA 67

BS		CURIUM	2mCi/ML	N018058	001	

GALLIUM DOTATATE GA-68

POWDER;INTRAVENOUS

NETSPOT

	+!	AAA USA INC	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016

GALLIUM GA-68 EDOTREOTIDE

SOLUTION;INTRAVENOUS

GALLIUM GA 68 EDOTREOTIDE

	+!	UIHC PET IMAGING	0.5-4mCi/ML	N210828	001	Aug 21, 2019

GALLIUM GA-68 GOZETOTIDE

POWDER;INTRAVENOUS

ILLUCCIX

	+!	TELIX	N/A	N214032	001	Dec 17, 2021

LOCAMETZ

	+!	NOVARTIS	N/A	N215841	001	Mar 23, 2022

SOLUTION;INTRAVENOUS

GALLIUM GA 68 GOZETOTIDE

	+!	UNIV CA LOS ANGELES	0.5-5mCi/mL	N212642	001	Dec 01, 2020
	+!	UNIV OF CA SAN FRAN	0.5-5mCi/mL	N212643	001	Dec 01, 2020

GANAXOLONE

SUSPENSION;ORAL

ZTALMY

	+!	MARINUS	50MG/ML	N215904	001	Jun 01, 2022

GANCICLOVIR

GEL;OPHTHALMIC

ZIRGAN

	+!	BAUSCH AND LOMB	0.15%	N022211	001	Sep 15, 2009

SOLUTION;INTRAVENOUS

GANZYK-RTU

	+!	EXELA PHARMA	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

GANCICLOVIR SODIUM

AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A090658**	**001**	Jun 21, 2010
AP		HIKMA	**EQ 500MG BASE/VIAL**	**A076222**	**001**	Jul 16, 2003
AP		PAR STERILE PRODUCTS	**EQ 500MG BASE/VIAL**	**A204950**	**001**	Dec 06, 2016
AP	!	PHARMASCIENCE INC	**EQ 500MG BASE/VIAL**	**A207645**	**001**	Dec 08, 2017
AP		SLATE RUN PHARMA	**EQ 500MG BASE/VIAL**	**A204204**	**001**	Nov 08, 2018

GANIRELIX ACETATE

INJECTABLE;INJECTION

FYREMADEL

AP		SUN PHARM	**250MCG/0.5ML**	**A204246**	**001**	Nov 30, 2018

GANIRELIX ACETATE

AP		AMPHASTAR PHARMS INC	**250MCG/0.5ML**	**A212613**	**001**	Apr 07, 2022
AP		GLAND PHARMA LTD	**250MCG/0.5ML**	**A215658**	**001**	Feb 28, 2023
AP		LUPIN LTD	**250MCG/0.5ML**	**A216075**	**001**	Nov 16, 2023
AP		MEITHEAL	**250MCG/0.5ML**	**A214996**	**001**	Jun 06, 2022
AP	+!	ORGANON USA ORGANON	**250MCG/0.5ML**	**N021057**	**001**	Jul 29, 1999

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

AT		HIKMA	**0.5%**	**A203189**	**001**	Sep 03, 2014
AT		LUPIN LTD	**0.5%**	**A202653**	**001**	Aug 28, 2013
AT		SANDOZ	**0.5%**	**A204227**	**001**	Jul 11, 2016

ZYMAXID

AT	+!	ABBVIE	**0.5%**	**N022548**	**001**	May 18, 2010

GEFITINIB

TABLET;ORAL

GEFITINIB

AB		ACTAVIS LABS FL INC	**250MG**	**A208913**	**001**	Apr 26, 2023
AB		APOTEX	**250MG**	**A209532**	**001**	Sep 23, 2022
AB		NATCO	**250MG**	**A212827**	**001**	May 31, 2023
AB		QILU PHARM HAINAN	**250MG**	**A211591**	**001**	Feb 13, 2023

IRESSA

AB	+!	ASTRAZENECA	**250MG**	**N206995**	**001**	Jul 13, 2015

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 200MG BASE/VIAL**	**A091594**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A091594**	**002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A091594**	**003**	Jul 25, 2011
AP		DR REDDYS LABS LTD	**EQ 200MG BASE/VIAL**	**A091365**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A091365**	**002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A202997**	**001**	May 07, 2013
AP		FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A090799**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A090799**	**002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A090242**	**003**	May 16, 2011
AP			**EQ 2GM BASE/VIAL**	**A090799**	**003**	May 16, 2011
AP		GLAND PHARMA LTD	**EQ 200MG BASE/VIAL**	**A204520**	**001**	Jan 05, 2016
AP			**EQ 1GM BASE/VIAL**	**A204520**	**002**	Jan 05, 2016
AP		HIKMA	**200MG/5.26ML (38MG/ML)**	**A213175**	**001**	Mar 07, 2023
AP			**1GM/26.3ML (38MG/ML)**	**A213175**	**002**	Mar 07, 2023
AP			**2GM/52.6ML (38MG/ML)**	**A213175**	**003**	Mar 07, 2023
AP		HIKMA INTL PHARMS	**EQ 200MG BASE/VIAL**	**A206617**	**001**	Jun 25, 2021
AP			**EQ 1GM BASE/VIAL**	**A206617**	**002**	Jun 25, 2021
AP		HOSPIRA	**EQ 200MG BASE/VIAL**	**A078339**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078339**	**002**	Jul 25, 2011
AP	+!	HOSPIRA INC	**200MG/5.26ML (38MG/ML)**	**N200795**	**001**	Aug 04, 2011
AP	+!		**1GM/26.3ML (38MG/ML)**	**N200795**	**002**	Aug 04, 2011
AP	!		**EQ 2GM BASE/VIAL**	**A079183**	**001**	Nov 15, 2010
AP	+!		**2GM/52.6ML (38MG/ML)**	**N200795**	**003**	Aug 04, 2011
AP	!	JIANGSU HANSOH PHARM	**EQ 200MG BASE/VIAL**	**A202485**	**001**	May 07, 2013
AP	!		**EQ 1GM BASE/VIAL**	**A202485**	**002**	May 07, 2013
AP		MEITHEAL	**200MG/5.26ML (38MG/ML)**	**A212129**	**001**	Dec 11, 2020
AP			**1GM/26.3ML (38MG/ML)**	**A212129**	**002**	Dec 11, 2020
AP			**2GM/52.6ML (38MG/ML)**	**A212129**	**003**	Dec 11, 2020
AP		MYLAN LABS LTD	**200MG/5.26ML (38MG/ML)**	**A205242**	**001**	Dec 06, 2017
AP			**1GM/26.3ML (38MG/ML)**	**A205242**	**002**	Dec 06, 2017

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP			**2GM/52.6ML (38MG/ML)**	**A205242**	**003**	Dec 06, 2017
AP		NOVAST LABS	**200MG/5.26ML (38MG/ML)**	**A210383**	**001**	Feb 14, 2019
AP			**1GM/26.3ML (38MG/ML)**	**A210383**	**002**	Feb 14, 2019
AP			**2GM/52.6ML (38MG/ML)**	**A210383**	**003**	Feb 14, 2019
AP		SAGENT PHARMS INC	**200MG/5.26ML (38MG/ML)**	**A209077**	**001**	Jul 20, 2018
AP			**1GM/26.3ML (38MG/ML)**	**A209077**	**002**	Jul 20, 2018
AP			**2GM/52.6ML (38MG/ML)**	**A209077**	**003**	Jul 20, 2018
AP		SHILPA	**EQ 200MG BASE/VIAL**	**A207575**	**001**	Feb 22, 2019
AP			**200MG/5.26ML (38MG/ML)**	**A210991**	**001**	Oct 04, 2019
AP			**EQ 1GM BASE/VIAL**	**A207575**	**002**	Feb 22, 2019
AP			**1GM/26.3ML (38MG/ML)**	**A210991**	**002**	Oct 04, 2019
AP			**2GM/52.6ML (38MG/ML)**	**A210991**	**003**	Oct 04, 2019
AP		SUN PHARM	**EQ 200MG BASE/VIAL**	**A078433**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078433**	**002**	Jul 25, 2011
AP		TEYRO LABS	**EQ 200MG BASE/VIAL**	**A078759**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078759**	**002**	Jul 25, 2011

SOLUTION;INTRAVENOUS

GEMCITABINE HYDROCHLORIDE

	+!	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017
	+!		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017
	+!		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017
	+!		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB		APOTEX	**600MG**	**A075034**	**001**	Jul 20, 1998
AB		ASCENT PHARMS INC	**600MG**	**A214603**	**001**	Jan 13, 2021
AB		AUROBINDO PHARMA LTD	**600MG**	**A202726**	**001**	Sep 16, 2015
AB		CADILA PHARMS LTD	**600MG**	**A203266**	**001**	Jun 17, 2016
AB		CARIBE HOLDINGS	**600MG**	**A078012**	**001**	Mar 26, 2007
AB		CHARTWELL MOLECULES	**600MG**	**A074270**	**001**	Sep 27, 1993
AB		IMPAX PHARMS	**600MG**	**A078207**	**001**	Jun 01, 2007
AB		INVAGEN PHARMS	**600MG**	**A077836**	**001**	Jul 27, 2006
AB		NORTHSTAR HLTHCARE	**600MG**	**A079072**	**001**	Sep 13, 2010

LOPID

AB	**+!**	PFIZER PHARMS	**600MG**	**N018422**	**003**	Nov 20, 1986

GENTAMICIN SULFATE

CREAM;TOPICAL

GENTAMICIN SULFATE

AT		COSETTE	**EQ 0.1% BASE**	**A064056**	**001**	Apr 29, 1994
AT	**!**	PADAGIS US	**EQ 0.1% BASE**	**A062307**	**001**	

INJECTABLE;INJECTION

GENTAMICIN SULFATE

AP		EUGIA PHARMA	**EQ 10MG BASE/ML**	**A215236**	**001**	Jan 08, 2024
AP			**EQ 40MG BASE/ML**	**A215237**	**001**	Jan 08, 2024
AP	**!**	FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A062366**	**002**	Feb 06, 1986
AP	**!**		**EQ 40MG BASE/ML**	**A062366**	**001**	Aug 04, 1983
AP		HIKMA	**EQ 10MG BASE/ML**	**A062251**	**002**	
AP			**EQ 40MG BASE/ML**	**A062251**	**001**	
AP		HOSPIRA	**EQ 10MG BASE/ML**	**A062420**	**001**	Aug 15, 1983
AP			**EQ 40MG BASE/ML**	**A062420**	**002**	Aug 15, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**EQ 1.2MG BASE/ML**	**A062373**	**007**	Sep 07, 1982
AP			**EQ 1.6MG BASE/ML**	**A062373**	**008**	Sep 07, 1982
AP			**EQ 80MG BASE/100ML**	**A062373**	**002**	Sep 07, 1982
AP			**EQ 100MG BASE/100ML**	**A062373**	**005**	Sep 07, 1982
AP		HOSPIRA	**EQ 1.2MG BASE/ML**	**A062414**	**001**	Aug 15, 1983
AP			**EQ 1.6MG BASE/ML**	**A062414**	**003**	Aug 15, 1983
AP			**EQ 80MG BASE/100ML**	**A062414**	**008**	Aug 15, 1983
AP			**EQ 100MG BASE/100ML**	**A062414**	**010**	Aug 15, 1983
	!	BAXTER HLTHCARE	EQ 2MG BASE/ML	A062373	009	Sep 07, 1982
	!		EQ 120MG BASE/100ML	A062373	006	Sep 07, 1982

OINTMENT;OPHTHALMIC

GENTAMICIN SULFATE

	!	FERA PHARMS LLC	EQ 0.3% BASE	A065024	001	Jul 30, 2004

GENTAMICIN SULFATE						
OINTMENT;TOPICAL						
GENTAMICIN SULFATE						
AT		COSETTE	**EQ 0.1% BASE**	**A064054**	**001**	Apr 29, 1994
AT		FOUGERA PHARMS INC	**EQ 0.1% BASE**	**A062533**	**001**	Oct 05, 1984
AT	**!**	PADAGIS US	**EQ 0.1% BASE**	**A062351**	**001**	Feb 18, 1982
AT		TARO	**EQ 0.1% BASE**	**A062477**	**001**	Dec 23, 1983
SOLUTION/DROPS;OPHTHALMIC						
GENTAMICIN SULFATE						
AT		BAUSCH AND LOMB	**EQ 0.3% BASE**	**A064048**	**001**	May 11, 1994
AT		PADAGIS US	**EQ 0.3% BASE**	**A065121**	**001**	Jan 30, 2004
AT	**!**	SANDOZ	**EQ 0.3% BASE**	**A062196**	**001**	
GEPIRONE HYDROCHLORIDE						
TABLET, EXTENDED RELEASE;ORAL						
EXXUA						
	+	FABRE KRAMER	EQ 18.2MG BASE	N021164	001	Sep 22, 2023
	+		EQ 36.3MG BASE	N021164	002	Sep 22, 2023
	+		EQ 54.5MG BASE	N021164	003	Sep 22, 2023
	+!		EQ 72.6MG BASE	N021164	004	Sep 22, 2023
GILTERITINIB FUMARATE						
TABLET;ORAL						
XOSPATA						
	+!	ASTELLAS	EQ 40MG BASE	N211349	001	Nov 28, 2018
GIVOSIRAN SODIUM						
SOLUTION;SUBCUTANEOUS						
GIVLAARI						
	+!	ALNYLAM PHARMS INC	EQ 189MG BASE/ML (EQ 189MG BASE/ML)	N212194	001	Nov 20, 2019
GLASDEGIB MALEATE						
TABLET;ORAL						
DAURISMO						
	+	PFIZER	EQ 25MG BASE	N210656	001	Nov 21, 2018
	+!		EQ 100MG BASE	N210656	002	Nov 21, 2018
GLATIRAMER ACETATE						
INJECTABLE;SUBCUTANEOUS						
COPAXONE						
AP	**+!**	TEVA PHARMS USA	**20MG/ML**	**N020622**	**002**	Feb 12, 2002
AP	**+!**		**40MG/ML**	**N020622**	**003**	Jan 28, 2014
GLATIRAMER ACETATE						
AP		MYLAN	**20MG/ML**	**A091646**	**001**	Oct 03, 2017
AP			**40MG/ML**	**A206936**	**001**	Oct 03, 2017
GLATOPA						
AP		SANDOZ	**20MG/ML**	**A090218**	**001**	Apr 16, 2015
AP			**40MG/ML**	**A206921**	**001**	Feb 12, 2018
GLECAPREVIR; PIBRENTASVIR						
PELLETS;ORAL						
MAVYRET						
	+!	ABBVIE	50MG;20MG/PACKET	N215110	001	Jun 10, 2021
TABLET;ORAL						
MAVYRET						
	+!	ABBVIE	100MG;40MG	N209394	001	Aug 03, 2017
GLIMEPIRIDE						
TABLET;ORAL						
AMARYL						
AB	**+!**	SANOFI AVENTIS US	**1MG**	**N020496**	**001**	Nov 30, 1995
AB	**+**		**2MG**	**N020496**	**002**	Nov 30, 1995
AB	**+**		**4MG**	**N020496**	**003**	Nov 30, 1995
GLIMEPIRIDE						
AB		ACCORD HLTHCARE	**1MG**	**A078181**	**001**	Aug 23, 2007
AB			**2MG**	**A078181**	**002**	Aug 23, 2007
AB			**4MG**	**A078181**	**003**	Aug 23, 2007
AB		AUROBINDO PHARMA LTD	**1MG**	**A202759**	**001**	Jun 29, 2012
AB			**2MG**	**A202759**	**002**	Jun 29, 2012
AB			**4MG**	**A202759**	**003**	Jun 29, 2012
AB		CARLSBAD	**1MG**	**A077911**	**001**	Sep 22, 2009
AB			**2MG**	**A077911**	**002**	Sep 22, 2009
AB			**4MG**	**A077911**	**003**	Sep 22, 2009
AB		CHARTWELL MOLECULAR	**1MG**	**A077295**	**001**	Oct 06, 2005
AB			**2MG**	**A077295**	**002**	Oct 06, 2005

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

AB			**4MG**	**A077295**	**003**	Oct 06, 2005
AB		DR REDDYS LABS LTD	**1MG**	**A077091**	**001**	Oct 06, 2005
AB			**2MG**	**A077091**	**002**	Oct 06, 2005
AB			**4MG**	**A077091**	**003**	Oct 06, 2005
AB		INDOCO REMEDIES	**1MG**	**A202112**	**001**	Apr 17, 2013
AB			**2MG**	**A202112**	**002**	Apr 17, 2013
AB			**4MG**	**A202112**	**003**	Apr 17, 2013
AB		MICRO LABS	**1MG**	**A091220**	**001**	Jun 29, 2012
AB			**2MG**	**A091220**	**002**	Jun 29, 2012
AB			**4MG**	**A091220**	**004**	Jun 29, 2012
AB			**8MG**	**A091220**	**006**	Jun 29, 2012
AB		PRINSTON INC	**1MG**	**A077370**	**001**	Dec 23, 2005
AB			**2MG**	**A077370**	**002**	Dec 23, 2005
AB			**4MG**	**A077370**	**003**	Dec 23, 2005
AB			**8MG**	**A077370**	**004**	Dec 23, 2005
		MICRO LABS	3MG	A091220	003	Jun 29, 2012
			6MG	A091220	005	Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

DUETACT

AB	**+!**	TAKEDA PHARMS USA	**2MG;30MG**	**N021925**	**001**	Jul 28, 2006
AB	**+**		**4MG;30MG**	**N021925**	**002**	Jul 28, 2006

PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE

AB		SANDOZ	**2MG;30MG**	**A201049**	**001**	Jan 04, 2013
AB			**4MG;30MG**	**A201049**	**002**	Jan 04, 2013

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

AB		ACCORD HLTHCARE	**5MG**	**A074550**	**001**	Sep 11, 1997
AB			**10MG**	**A074550**	**002**	Sep 11, 1997
AB		ANI PHARMS	**5MG**	**A074497**	**001**	Aug 31, 1995
AB			**10MG**	**A074497**	**002**	Aug 31, 1995
AB		APOTEX	**5MG**	**A075795**	**001**	Jun 13, 2001
AB	**!**		**10MG**	**A075795**	**002**	Jun 13, 2001
AB		AUROBINDO PHARMA USA	**5MG**	**A074226**	**001**	May 10, 1994
AB			**10MG**	**A074226**	**002**	May 10, 1994
AB		RUBICON	**5MG**	**A214874**	**002**	Oct 03, 2023
AB			**10MG**	**A214874**	**003**	Oct 03, 2023
AB		SANDOZ	**5MG**	**A074305**	**001**	Apr 07, 1995
AB			**10MG**	**A074305**	**002**	Apr 07, 1995
AB		WATSON LABS TEVA	**5MG**	**A074223**	**001**	Feb 27, 1995
AB			**10MG**	**A074223**	**002**	Feb 27, 1995
		RUBICON	2.5MG	A214874	001	Oct 03, 2023

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB		AUROBINDO PHARMA	**2.5MG**	**A206928**	**001**	May 12, 2017
AB			**5MG**	**A206928**	**002**	May 12, 2017
AB			**10MG**	**A206928**	**003**	May 12, 2017
AB		UNIQUE	**2.5MG**	**A204720**	**001**	Dec 29, 2016
AB			**5MG**	**A204720**	**002**	Dec 29, 2016
AB			**10MG**	**A204720**	**003**	Dec 29, 2016
AB		WATSON LABS	**2.5MG**	**A076467**	**003**	Mar 27, 2006
AB			**5MG**	**A076467**	**001**	Sep 08, 2003
AB			**10MG**	**A076467**	**002**	Nov 07, 2003
AB		ZYDUS PHARMS	**2.5MG**	**A203499**	**001**	Jul 16, 2018
AB			**5MG**	**A203499**	**002**	Jul 16, 2018
AB			**10MG**	**A203499**	**003**	Jul 16, 2018

GLUCOTROL XL

AB	**+**	PFIZER	**2.5MG**	**N020329**	**003**	Aug 10, 1999
AB	**+**		**5MG**	**N020329**	**001**	Apr 26, 1994
AB	**+!**		**10MG**	**N020329**	**002**	Apr 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB		EPIC PHARMA LLC	**2.5MG;250MG**	**A077507**	**001**	Oct 27, 2005
AB			**2.5MG;500MG**	**A077507**	**002**	Oct 27, 2005
AB			**5MG;500MG**	**A077507**	**003**	Oct 27, 2005
AB		HERITAGE PHARMS	**2.5MG;250MG**	**A078728**	**001**	Jun 23, 2010
AB			**2.5MG;500MG**	**A078728**	**002**	Jun 23, 2010
AB			**5MG;500MG**	**A078728**	**003**	Jun 23, 2010
AB		TEVA PHARMS	**2.5MG;250MG**	**A077270**	**001**	Oct 28, 2005
AB			**2.5MG;500MG**	**A077270**	**002**	Oct 28, 2005
AB	**!**		**5MG;500MG**	**A077270**	**003**	Oct 28, 2005
AB		ZYDUS PHARMS USA INC	**2.5MG;250MG**	**A078905**	**001**	Jan 31, 2011
AB			**2.5MG;500MG**	**A078905**	**002**	Jan 31, 2011
AB			**5MG;500MG**	**A078905**	**003**	Jan 31, 2011

GLUCAGON

INJECTABLE;INJECTION

GLUCAGON

!	AMPHASTAR PHARMS INC	1MG/VIAL	A208086	001	Dec 28, 2020

POWDER;NASAL

BAQSIMI

+!	AMPHASTAR PHARMS INC	3MG	N210134	001	Jul 24, 2019

SOLUTION;SUBCUTANEOUS

GVOKE HYPOPEN

+!	XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	003	Sep 10, 2019
+!		1MG/0.2ML (1MG/0.2ML)	N212097	004	Sep 10, 2019

GVOKE KIT

+!	XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	005	Aug 20, 2021

GVOKE PFS

+!	XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	002	Sep 10, 2019

GLUCAGON HYDROCHLORIDE

INJECTABLE;INJECTION

GLUCAGEN

+!	NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998

POWDER;INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

+!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015

GLYBURIDE

TABLET;ORAL

GLYBURIDE (MICRONIZED)

AB		TEVA	**1.5MG**	**A074686**	**001**	Apr 20, 1999
AB			**3MG**	**A074686**	**002**	Apr 20, 1999
AB			**6MG**	**A074686**	**004**	Apr 20, 1999

GLYNASE

AB	**+**	PFIZER	**1.5MG**	**N020051**	**001**	Mar 04, 1992
AB	**+**		**3MG**	**N020051**	**002**	Mar 04, 1992
AB	**+!**		**6MG**	**N020051**	**004**	Sep 24, 1993

GLYBURIDE

AB1		CADILA PHARMS LTD	**1.25MG**	**A203379**	**001**	Jan 04, 2019
AB1			**2.5MG**	**A203379**	**002**	Jan 04, 2019
AB1			**5MG**	**A203379**	**003**	Jan 04, 2019
AB1		EPIC PHARMA LLC	**1.25MG**	**A076257**	**001**	Jun 27, 2002
AB1			**2.5MG**	**A076257**	**002**	Jun 27, 2002
AB1			**5MG**	**A076257**	**003**	Jun 27, 2002
AB1		HERITAGE PHARMS	**1.25MG**	**A090937**	**001**	Feb 28, 2011
AB1			**2.5MG**	**A090937**	**002**	Feb 28, 2011
AB1			**5MG**	**A090937**	**003**	Feb 28, 2011
AB1		ORIENT PHARMA CO LTD	**1.25MG**	**A206483**	**001**	Feb 22, 2019
AB1			**2.5MG**	**A206483**	**002**	Feb 22, 2019
AB1			**5MG**	**A206483**	**003**	Feb 22, 2019
AB1		TEVA	**1.25MG**	**A074388**	**001**	Aug 29, 1995
AB1			**2.5MG**	**A074388**	**002**	Aug 29, 1995
AB1	**!**		**5MG**	**A074388**	**003**	Aug 29, 1995
AB1		ZYDUS PHARMS	**1.25MG**	**A206749**	**001**	May 10, 2016
AB1			**2.5MG**	**A206749**	**002**	May 10, 2016
AB1			**5MG**	**A206749**	**003**	May 10, 2016

GLYBURIDE

TABLET;ORAL

DIABETA

AB2	**+**	SANOFI AVENTIS US	**1.25MG**	**N017532**	**001**	May 01, 1984
AB2	**+**		**2.5MG**	**N017532**	**002**	May 01, 1984
AB2	**+!**		**5MG**	**N017532**	**003**	May 01, 1984

GLYBURIDE

AB2		IMPAX LABS INC	**1.25MG**	**A206079**	**001**	Sep 30, 2015
AB2			**2.5MG**	**A206079**	**002**	Sep 30, 2015
AB2			**5MG**	**A206079**	**003**	Sep 30, 2015

GLYBURIDE (MICRONIZED)

		TEVA	4.5MG	A074686	003	Apr 20, 1999

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**1.25MG;250MG**	**A076716**	**001**	Jun 28, 2005
AB			**2.5MG;500MG**	**A076716**	**002**	Jun 28, 2005
AB			**5MG;500MG**	**A076716**	**003**	Jun 28, 2005
AB		AUROBINDO PHARMA	**1.25MG;250MG**	**A077870**	**001**	Nov 14, 2007
AB	**!**		**2.5MG;500MG**	**A077870**	**002**	Nov 14, 2007
AB			**5MG;500MG**	**A077870**	**003**	Nov 14, 2007
AB		IMPAX LABS INC	**1.25MG;250MG**	**A076345**	**001**	Feb 18, 2004
AB			**2.5MG;500MG**	**A076345**	**002**	Feb 18, 2004
AB			**5MG;500MG**	**A076345**	**003**	Feb 18, 2004
AB		ZYDUS PHARMS	**1.25MG;250MG**	**A206748**	**001**	Feb 29, 2016
AB			**2.5MG;500MG**	**A206748**	**002**	Feb 29, 2016
AB			**5MG;500MG**	**A206748**	**003**	Feb 29, 2016

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

	+!	HORIZON THERAP US	1.1GM/ML	N203284	001	Feb 01, 2013

GLYCINE

SOLUTION;IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

AT	**+!**	BAXTER HLTHCARE	**1.5GM/100ML**	**N017865**	**001**

GLYCINE 1.5% IN PLASTIC CONTAINER

AT		B BRAUN	**1.5GM/100ML**	**N016784**	**001**
AT		ICU MEDICAL INC	**1.5GM/100ML**	**N018315**	**001**

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

AP		ACCORD HLTHCARE	**0.2MG/ML**	**A213238**	**001**	Jul 08, 2020
AP		ALEMBIC	**0.2MG/ML**	**A214635**	**001**	Oct 26, 2022
AP		AM REGENT	**0.2MG/ML**	**A089335**	**001**	Jul 23, 1986
AP		AMNEAL	**0.2MG/ML**	**A208973**	**001**	Jun 15, 2017
AP			**0.2MG/ML**	**A215333**	**001**	Oct 21, 2022
AP		APOTEX	**0.2MG/ML**	**A210246**	**001**	Oct 29, 2019
AP		ASPEN	**0.2MG/ML**	**A212871**	**001**	Nov 29, 2022
AP		CAPLIN	**0.2MG/ML**	**A211705**	**001**	Mar 20, 2019
AP		FRESENIUS KABI USA	**0.2MG/ML**	**A209024**	**001**	Oct 31, 2018
AP			**0.2MG/ML**	**A209328**	**001**	Oct 27, 2017
AP		GLAND PHARMA LTD	**0.2MG/ML**	**A212612**	**001**	Sep 30, 2019
AP	**!**	HIKMA FARMACEUTICA	**0.2MG/ML**	**A090963**	**001**	Sep 21, 2011
AP		MEITHEAL	**0.2MG/ML**	**A212802**	**001**	Jul 06, 2021
AP		PIRAMAL CRITICAL	**0.2MG/ML**	**A210842**	**001**	Oct 25, 2018
AP		PRINSTON INC	**0.2MG/ML**	**A210927**	**001**	Oct 31, 2018
AP		SAGENT	**0.2MG/ML**	**A210083**	**001**	Feb 21, 2020
AP		SANDOZ	**0.2MG/ML**	**A211334**	**001**	May 14, 2019
AP		SOMERSET THERAPS LLC	**0.2MG/ML**	**A207639**	**001**	Jun 23, 2017
AP		UMEDICA	**0.2MG/ML**	**A212591**	**001**	Oct 13, 2021
AP		XIROMED	**0.2MG/ML**	**A212227**	**001**	Mar 04, 2021

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

GLYCOPYRROLATE

	+!	FRESENIUS KABI USA	0.6MG/3ML (0.2MG/ML)	N214919	001	Apr 21, 2022

GLYRX-PF

	+!	EXELA PHARMA	0.2MG/ML (0.2MG/ML)	N210997	001	Jul 11, 2018
	+!		0.4MG/2ML (0.2MG/ML)	N210997	002	Jul 11, 2018
	+!		0.6MG/3ML (0.2MG/ML)	N210997	004	Dec 14, 2020
	+!		1MG/5ML (0.2MG/ML)	N210997	003	Apr 09, 2020

GLYCOPYRROLATE

SOLUTION;ORAL

CUVPOSA

AA	**+!**	MERZ PHARMS	**1MG/5ML**	**N022571**	**001**	Jul 28, 2010

GLYCOPYRROLATE

AA		ANNORA PHARMA	**1MG/5ML**	**A213698**	**001**	Jul 05, 2022
AA		PAR PHARM INC	**1MG/5ML**	**A204438**	**001**	Aug 09, 2021
AA		SUVEN PHARMS	**1MG/5ML**	**A212467**	**001**	Jul 05, 2022

TABLET;ORAL

GLYCOPYRROLATE

AA		ALEMBIC	**1MG**	**A203657**	**001**	Nov 30, 2018
AA			**2MG**	**A203657**	**002**	Nov 30, 2018
AA		AUROBINDO PHARMA	**1MG**	**A202675**	**001**	Apr 15, 2013
AA			**2MG**	**A202675**	**002**	Oct 30, 2018
AA		DR REDDYS LABS LTD	**1MG**	**A040847**	**001**	Mar 21, 2008
AA			**2MG**	**A040847**	**002**	Mar 21, 2008
AA		HERITAGE PHARMS INC	**1MG**	**A207201**	**001**	Jan 03, 2017
AA			**2MG**	**A207201**	**002**	Jan 03, 2017
AA		INDOCO	**1MG**	**A091182**	**001**	Feb 03, 2014
AA			**2MG**	**A091182**	**002**	Feb 03, 2014
AA		LEADING	**1MG**	**A090195**	**001**	Sep 21, 2012
AA			**2MG**	**A090195**	**002**	Sep 21, 2012
AA		NATCO	**1MG**	**A091413**	**001**	Jun 20, 2016
AA			**2MG**	**A091413**	**002**	Jun 20, 2016
AA		OXFORD PHARMS	**1MG**	**A090020**	**001**	Oct 19, 2011
AA			**2MG**	**A090020**	**002**	Oct 19, 2011
AA	**!**	PAR PHARM	**1MG**	**A040653**	**001**	Aug 31, 2006
AA	**!**		**2MG**	**A040653**	**002**	Aug 31, 2006
AA		RISING	**1MG**	**A040821**	**001**	Dec 29, 2008
AA			**2MG**	**A040821**	**002**	Dec 29, 2008
AA		SUN PHARM INDS LTD	**1MG**	**A040844**	**001**	Aug 18, 2009
AA			**2MG**	**A040844**	**002**	Aug 18, 2009

ROBINUL

AA	**+**	CASPER PHARMA LLC	**1MG**	**N012827**	**001**	

ROBINUL FORTE

AA	**+**	CASPER PHARMA LLC	**2MG**	**N012827**	**002**	

GLYCOPYRROLATE

		LGM PHARMA	1.5MG	A091522	001	Mar 12, 2012

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

PREVDUO

	+!	SLAYBACK PHARMA LLC	0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023

GLYCOPYRRONIUM TOSYLATE

CLOTH;TOPICAL

QBREXZA

	+!	JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018

GOLODIRSEN

SOLUTION;INTRAVENOUS

VYONDYS 53

	+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N211970	001	Dec 12, 2019

GOSERELIN ACETATE

IMPLANT;IMPLANTATION

ZOLADEX

	+!	TERSERA	EQ 3.6MG BASE	N019726	001	Dec 29, 1989
	+!		EQ 10.8MG BASE	N020578	001	Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT		AMRING PHARMS	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A065187**	**001**	Oct 28, 2005
AT	**!**	BAUSCH AND LOMB	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A064047**	**001**	Jan 31, 1996

NEOSPORIN

AT	**!**	MONARCH PHARMS	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A060582**	**001**	

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL

SANCUSO

	+!	CUMBERLAND	3.1MG/24HR	N022198	001	Sep 12, 2008

INJECTION, EXTENDED RELEASE;SUBCUTANEOUS

SUSTOL

	+!	HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP		AMNEAL	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078262**	**001**	Dec 31, 2007
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078258**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078258**	**002**	Jun 30, 2008
AP		BIONPHARMA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078863**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078880**	**001**	Jun 30, 2008
AP	!	DR REDDYS	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078392**	**001**	Dec 31, 2007
AP	!		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077297**	**001**	Jun 30, 2008
AP		FRESENIUS KABI USA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078522**	**001**	Dec 31, 2007
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078090**	**001**	Jun 30, 2008
AP		HIKMA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A077913**	**001**	Jun 26, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077186**	**001**	Jun 30, 2008
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A077187**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077177**	**001**	Dec 31, 2007
AP		HIKMA FARMACEUTICA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078629**	**001**	Dec 23, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078629**	**002**	Dec 23, 2009
AP		MYLAN ASI	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A091136**	**001**	Apr 09, 2010
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A091136**	**002**	Apr 09, 2010
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A091137**	**002**	Apr 09, 2010
AP		RISING	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A079078**	**001**	Sep 14, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A079078**	**002**	Sep 14, 2009
AP		SANDOZ	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078534**	**001**	Apr 30, 2009
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078531**	**001**	Apr 30, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078531**	**002**	Apr 30, 2009
AP		SANDOZ INC	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078835**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078835**	**002**	Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		BIONPHARMA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078863**	**002**	Jun 30, 2008
AP	!	FRESENIUS KABI USA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078096**	**001**	Jun 30, 2008

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

AB		APOTEX INC	**EQ 1MG BASE**	**A078843**	**001**	Feb 27, 2008
AB		CHARTWELL MOLECULAR	**EQ 1MG BASE**	**A078037**	**001**	Feb 27, 2008
AB		DR REDDYS LABS LTD	**EQ 1MG BASE**	**A078846**	**001**	Feb 27, 2009
AB		NATCO PHARMA	**EQ 1MG BASE**	**A078969**	**001**	Jun 22, 2009
AB	!	ORBION PHARMS	**EQ 1MG BASE**	**A078678**	**001**	Feb 13, 2008
AB		TARO	**EQ 1MG BASE**	**A090817**	**001**	May 28, 2010

GRISEOFULVIN, MICROCRYSTALLINE

TABLET;ORAL

FULVICIN-U/F

	CHARTWELL RX	250MG	A060569	002	
		500MG	A060569	001	

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRISEOFULVIN

AB	!	ACTAVIS MID ATLANTIC	**125MG/5ML**	**A065394**	**001**	Jul 06, 2007
AB		CHARTWELL RX	**125MG/5ML**	**A065200**	**001**	Mar 02, 2005
AB		CIPLA	**125MG/5ML**	**A065354**	**001**	Sep 10, 2007
AB		COSETTE	**125MG/5ML**	**A065438**	**001**	Oct 08, 2010

TABLET;ORAL

GRISEOFULVIN

AB	!	SANDOZ	**500MG**	**A091592**	**002**	Aug 07, 2013
AB		SIGMAPHARM LABS LLC	**500MG**	**A202482**	**001**	Oct 22, 2012
		SANDOZ	250MG	A091592	001	Aug 07, 2013

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G

CHARTWELL RX	125MG	A061996	001	
	250MG	A061996	002	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G 165

		CHARTWELL RX	165MG	A061996	003	Apr 06, 1982

FULVICIN P/G 330

		CHARTWELL RX	330MG	A061996	004	Apr 06, 1982

GRISEOFULVIN, ULTRAMICROSIZE

TABLET;ORAL

GRIS-PEG

AB	**+**	BAUSCH	**125MG**	**N050475**	**001**	
AB	**+**		**250MG**	**N050475**	**002**	

GRISEOFULVIN, ULTRAMICROSIZE

AB		MOUNTAIN	**125MG**	**A204371**	**001**	Jan 09, 2014
AB	**!**		**250MG**	**A204371**	**002**	Jan 09, 2014
AB		SANDOZ	**125MG**	**A202805**	**001**	Dec 26, 2018
AB			**250MG**	**A202805**	**002**	Dec 26, 2018

GRISEOFULVIN,ULTRAMICROSIZE

AB		SIGMAPHARM LABS LLC	**125MG**	**A202545**	**001**	Oct 22, 2012
AB			**250MG**	**A202545**	**002**	Oct 22, 2012

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	**EQ 1MG BASE**	**A217293**	**001**	Apr 27, 2023
AB			**EQ 2MG BASE**	**A217293**	**002**	Apr 27, 2023
AB		AMNEAL PHARM	**EQ 1MG BASE**	**A075109**	**001**	Nov 25, 1998
AB	**!**		**EQ 2MG BASE**	**A075109**	**002**	Nov 25, 1998
AB		AUROBINDO PHARMA USA	**EQ 1MG BASE**	**A074796**	**001**	Jan 27, 1997
AB			**EQ 2MG BASE**	**A074796**	**002**	Jan 27, 1997
AB		EPIC PHARMA LLC	**EQ 1MG BASE**	**A074673**	**001**	Feb 28, 1997
AB			**EQ 2MG BASE**	**A074673**	**002**	Feb 28, 1997
AB		I 3 PHARMS	**EQ 1MG BASE**	**A216828**	**001**	Oct 05, 2023
AB			**EQ 2MG BASE**	**A216828**	**002**	Oct 05, 2023
AB		RUBICON	**EQ 1MG BASE**	**A216762**	**001**	Oct 17, 2023
AB			**EQ 2MG BASE**	**A216762**	**002**	Oct 17, 2023
AB		TWI PHARMS	**EQ 1MG BASE**	**A216399**	**001**	Jun 08, 2022
AB			**EQ 2MG BASE**	**A216399**	**002**	Jun 08, 2022
AB		UNICHEM	**EQ 1MG BASE**	**A214689**	**001**	Mar 03, 2021
AB			**EQ 2MG BASE**	**A214689**	**002**	Mar 03, 2021
AB		WATSON LABS	**EQ 1MG BASE**	**A074145**	**001**	Oct 17, 1995
AB			**EQ 2MG BASE**	**A074145**	**002**	Oct 17, 1995

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 1MG BASE**	**A200881**	**001**	Oct 05, 2012
AB			**EQ 2MG BASE**	**A200881**	**002**	Oct 05, 2012
AB			**EQ 3MG BASE**	**A200881**	**003**	Oct 05, 2012
AB			**EQ 4MG BASE**	**A200881**	**004**	Oct 05, 2012
AB		ALEMBIC	**EQ 1MG BASE**	**A217269**	**001**	Aug 07, 2023
AB			**EQ 2MG BASE**	**A217269**	**002**	Aug 07, 2023
AB			**EQ 3MG BASE**	**A217269**	**003**	Aug 07, 2023
AB			**EQ 4MG BASE**	**A217269**	**004**	Aug 07, 2023
AB		APOTEX	**EQ 1MG BASE**	**A205430**	**001**	Jul 25, 2018
AB			**EQ 2MG BASE**	**A205430**	**002**	Jul 25, 2018
AB			**EQ 3MG BASE**	**A205430**	**003**	Jul 25, 2018
AB			**EQ 4MG BASE**	**A205430**	**004**	Jul 25, 2018
AB		SANDOZ	**EQ 1MG BASE**	**A202568**	**001**	Jun 03, 2015
AB			**EQ 2MG BASE**	**A202568**	**002**	Jun 03, 2015
AB			**EQ 3MG BASE**	**A202568**	**003**	Jun 03, 2015
AB			**EQ 4MG BASE**	**A202568**	**004**	Jun 03, 2015
AB		SUN PHARM	**EQ 1MG BASE**	**A205689**	**001**	Nov 16, 2017
AB			**EQ 2MG BASE**	**A205689**	**002**	Nov 16, 2017
AB			**EQ 3MG BASE**	**A205689**	**003**	Nov 16, 2017
AB			**EQ 4MG BASE**	**A205689**	**004**	Nov 16, 2017
AB		TEVA PHARMS USA	**EQ 1MG BASE**	**A201382**	**001**	Jun 02, 2015
AB			**EQ 2MG BASE**	**A201382**	**002**	Jun 02, 2015
AB			**EQ 3MG BASE**	**A201382**	**003**	Jun 02, 2015
AB			**EQ 4MG BASE**	**A201382**	**004**	Jun 02, 2015
AB		TWI PHARMS	**EQ 1MG BASE**	**A201408**	**001**	Jun 02, 2015
AB			**EQ 2MG BASE**	**A201408**	**002**	Jun 02, 2015
AB			**EQ 3MG BASE**	**A201408**	**003**	Jun 02, 2015
AB			**EQ 4MG BASE**	**A201408**	**004**	Jun 02, 2015
AB		YICHANG HUMANWELL	**EQ 1MG BASE**	**A213428**	**001**	Nov 25, 2020

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB			**EQ 2MG BASE**	**A213428**	**002**	Nov 25, 2020
AB			**EQ 3MG BASE**	**A213428**	**003**	Nov 25, 2020
AB			**EQ 4MG BASE**	**A213428**	**004**	Nov 25, 2020

INTUNIV

AB	**+**	TAKEDA PHARMS USA	**EQ 1MG BASE**	**N022037**	**001**	Sep 02, 2009
AB	**+**		**EQ 2MG BASE**	**N022037**	**002**	Sep 02, 2009
AB	**+**		**EQ 3MG BASE**	**N022037**	**003**	Sep 02, 2009
AB	**+!**		**EQ 4MG BASE**	**N022037**	**004**	Sep 02, 2009

HALCINONIDE

CREAM;TOPICAL

HALCINONIDE

AB		CHARTWELL RX	**0.1%**	**A214723**	**001**	Sep 08, 2021
AB		MYLAN	**0.1%**	**A211027**	**001**	Aug 12, 2019

HALOG

AB	**+!**	SUN PHARM INDS INC	**0.1%**	**N017556**	**001**	

OINTMENT;TOPICAL

HALOG

	+!	SUN PHARM INDS INC	0.1%	N017824	001	

SOLUTION;TOPICAL

HALOG

	+!	SUN PHARM INDS INC	0.1%	N017823	001	

HALOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

HALOBETASOL PROPIONATE

AB		PADAGIS ISRAEL	**0.05%**	**A215266**	**001**	Aug 11, 2023

LEXETTE

AB	**+!**	MAYNE PHARMA	**0.05%**	**N210566**	**001**	May 24, 2018

CREAM;TOPICAL

HALOBETASOL PROPIONATE

AB	**!**	COSETTE	**0.05%**	**A078162**	**001**	Apr 24, 2007
AB		FOUGERA PHARMS	**0.05%**	**A077001**	**001**	Dec 16, 2004
AB		PADAGIS ISRAEL	**0.05%**	**A077123**	**001**	Dec 16, 2004
AB		TARO	**0.05%**	**A077227**	**001**	Aug 04, 2005

LOTION;TOPICAL

BRYHALI

	+!	BAUSCH	0.01%	N209355	001	Nov 06, 2018

ULTRAVATE

	+!	SUN PHARM INDUSTRIES	0.05%	N208183	001	Nov 06, 2015

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

AB		COSETTE	**0.05%**	**A077109**	**001**	Jun 14, 2005
AB	**!**	PADAGIS ISRAEL	**0.05%**	**A076872**	**001**	Dec 16, 2004
AB		QUAGEN	**0.05%**	**A213560**	**001**	Oct 06, 2020
AB		TARO	**0.05%**	**A076994**	**001**	Dec 16, 2004

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION;TOPICAL

DUOBRII

	+!	BAUSCH	0.01%;0.045%	N209354	001	Apr 25, 2019

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB		INNOGENIX	**0.5MG**	**A071173**	**002**	Jan 02, 1987
AB			**1MG**	**A071173**	**003**	Jan 02, 1987
AB			**2MG**	**A071173**	**004**	Jan 02, 1987
AB			**5MG**	**A071173**	**005**	Jan 07, 1988
AB			**10MG**	**A071173**	**001**	Jan 07, 1988
AB			**20MG**	**A071173**	**006**	Jan 07, 1988
AB		MSN	**0.5MG**	**A216004**	**001**	Nov 18, 2022
AB			**1MG**	**A216004**	**002**	Nov 18, 2022
AB			**2MG**	**A216004**	**003**	Nov 18, 2022
AB			**5MG**	**A216004**	**004**	Nov 18, 2022
AB			**10MG**	**A216004**	**005**	Nov 18, 2022
AB			**20MG**	**A216004**	**006**	Nov 18, 2022
AB		MYLAN	**0.5MG**	**A070278**	**006**	Jun 10, 1986
AB			**1MG**	**A070278**	**004**	Jun 10, 1986
AB	**!**		**2MG**	**A070278**	**001**	Jun 10, 1986
AB			**5MG**	**A070278**	**005**	Jun 10, 1986

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB			10MG	A070278	002	Jul 16, 2009
AB			20MG	A070278	003	Jul 16, 2009
AB		SANDOZ	0.5MG	A071209	002	Nov 17, 1986
AB			1MG	A071209	003	Nov 17, 1986
AB			5MG	A071209	001	Nov 17, 1986
AB			10MG	A071210	001	Mar 11, 1988
AB			20MG	A071211	001	Mar 11, 1988
AB		SCIEGEN PHARMS INC	2MG	A071130	001	Feb 17, 1987
AB			5MG	A071131	001	Feb 17, 1987
AB			10MG	A071132	001	May 12, 1987
AB		UPSHER SMITH LABS	0.5MG	A211061	001	Jan 08, 2020
AB			1MG	A211061	002	Jan 08, 2020
AB			2MG	A211061	003	Jan 08, 2020
AB			5MG	A211061	004	Jan 08, 2020
AB			10MG	A211061	005	Jan 08, 2020
AB			20MG	A211061	006	Jan 08, 2020
AB		ZYDUS PHARMS USA	0.5MG	A077580	001	Jan 17, 2023
AB			1MG	A077580	002	Jan 17, 2023
AB			2MG	A077580	006	Jan 17, 2023
AB			5MG	A077580	003	Nov 29, 2007
AB			10MG	A077580	004	Nov 29, 2007
AB			20MG	A077580	005	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALDOL

AO	+!	JANSSEN PHARMS	EQ 50MG BASE/ML	N018701	001	Jan 14, 1986
AO	+!		EQ 100MG BASE/ML	N018701	002	Jan 31, 1997

HALOPERIDOL DECANOATE

AO		FRESENIUS KABI USA	EQ 50MG BASE/ML	A074893	001	Dec 19, 1997
AO			EQ 100MG BASE/ML	A074893	002	Dec 19, 1997
AO		GLAND PHARMA LTD	EQ 50MG BASE/ML	A205241	001	May 12, 2017
AO			EQ 100MG BASE/ML	A205241	002	May 12, 2017
AO		HIKMA	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998
AO			EQ 100MG BASE/ML	A075305	001	Sep 28, 1998
AO		MANKIND PHARMA	EQ 50MG BASE/ML	A216730	001	May 23, 2023
AO			EQ 100MG BASE/ML	A216730	002	May 23, 2023
AO		MEITHEAL	EQ 50MG BASE/ML	A214507	001	Jul 26, 2021
AO			EQ 100MG BASE/ML	A214507	002	Jul 26, 2021
AO		MYLAN LABS LTD	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000
AO			EQ 100MG BASE/ML	A075440	002	Feb 28, 2000
AO		SOMERSET THERAPS LLC	EQ 50MG BASE/ML	A209101	001	Jul 03, 2018
AO			EQ 100MG BASE/ML	A209101	002	Jul 03, 2018
AO		TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999
AO			EQ 100MG BASE/ML	A075393	002	May 11, 1999
AO		ZYDUS PHARMS	EQ 50MG BASE/ML	A211180	001	Oct 22, 2019
AO			EQ 100MG BASE/ML	A211180	002	Oct 22, 2019

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALOPERIDOL

AA		LANNETT CO INC	EQ 2MG BASE/ML	A073364	001	Sep 28, 1993
AA	!	PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993

INJECTABLE;INJECTION

HALOPERIDOL

AP		FRESENIUS KABI USA	EQ 5MG BASE/ML	A075689	001	Mar 09, 2001
AP			EQ 5MG BASE/ML	A210356	001	Jul 01, 2019
AP		GLAND PHARMA LTD	EQ 5MG BASE/ML	A076774	001	Aug 25, 2004
AP		HIKMA	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001
AP	!	MYLAN LABS LTD	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009
AP		SAGENT PHARMS	EQ 5MG BASE/ML	A091637	001	Sep 02, 2011
AP			EQ 5MG BASE/ML	A200742	001	Sep 02, 2011

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

AP		B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018
AP		BE PHARMS	1,000 UNITS/ML	A214804	001	Dec 29, 2020
AP			10,000 UNITS/ML	A214839	001	Dec 29, 2020
AP	+!	FRESENIUS KABI USA	1,000 UNITS/ML	N017029	001	

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM						
AP			5,000 UNITS/ML	A206552	001	Jun 10, 2016
AP	+!		5,000 UNITS/ML	N017651	006	
AP	+!		10,000 UNITS/ML	N017029	003	
AP	+!		20,000 UNITS/ML	N017029	004	
AP		GLAND	1,000 UNITS/ML	A205323	002	Nov 18, 2019
AP			5,000 UNITS/ML	A205323	001	Feb 06, 2017
AP	+!	HIKMA	1,000 UNITS/ML	N017037	001	
AP	+!		5,000 UNITS/ML	N017037	002	
AP			5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986
AP	+!		10,000 UNITS/ML	N017037	003	
AP		HOSPIRA INC	1,000 UNITS/ML	A090571	001	Aug 31, 2009
AP			5,000 UNITS/ML	A090571	002	Aug 31, 2009
AP			10,000 UNITS/ML	A090571	003	Aug 31, 2009
AP		MYLAN LABS LTD	1,000 UNITS/ML	A203851	001	Nov 30, 2017
AP			5,000 UNITS/ML	A203851	002	Nov 30, 2017
AP			10,000 UNITS/ML	A203851	003	Nov 30, 2017
AP			20,000 UNITS/ML	A203852	001	Nov 30, 2017
AP		NANJING KING-FRIEND	1,000 UNITS/ML	A211005	001	Dec 14, 2018
AP			1,000 UNITS/ML	A211007	001	May 28, 2019
AP			5,000 UNITS/ML	A211007	002	May 28, 2019
AP			5,000 UNITS/ML	A212061	001	Jul 15, 2020
AP			10,000 UNITS/ML	A211007	003	May 28, 2019
AP			20,000 UNITS/ML	A211004	001	Feb 24, 2020
AP		SAGENT PHARMS	1,000 UNITS/ML	A090808	001	Jun 30, 2010
AP			5,000 UNITS/ML	A090808	002	Jun 30, 2010
AP			10,000 UNITS/ML	A090808	003	Jun 30, 2010
AP			20,000 UNITS/ML	A090809	001	Jun 30, 2010
AP		SANDOZ	1,000 UNITS/ML	A091682	001	Jun 08, 2011
AP			5,000 UNITS/ML	A091682	002	Jun 08, 2011
AP			10,000 UNITS/ML	A201002	001	Jun 08, 2011
AP		SHENZHEN TECHDOW	1,000 UNITS/ML	A202957	001	Jun 12, 2014
AP			5,000 UNITS/ML	A202733	001	Jun 12, 2014
AP			5,000 UNITS/ML	A202957	002	Jun 12, 2014
AP			10,000 UNITS/ML	A203198	001	Jun 12, 2014
AP			20,000 UNITS/ML	A203198	002	Jun 12, 2014
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	200 UNITS/100ML	N018609	001	Apr 28, 1982
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	+!	B BRAUN	200 UNITS/100ML	N019953	001	Jul 20, 1992
AP		FRESENIUS KABI USA	200 UNITS/100ML	A212441	001	Jul 24, 2020
AP	+!	HOSPIRA	200 UNITS/100ML	N018916	010	Jun 23, 1989
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP		HOSPIRA	10,000 UNITS/100ML	N019339	003	Mar 27, 1985
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	200 UNITS/100ML	N018609	002	Apr 28, 1982
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		FRESENIUS KABI USA	200 UNITS/100ML	A212441	002	Jul 24, 2020
AP	+!	HOSPIRA	200 UNITS/100ML	N018916	011	Jun 23, 1989
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	+!	B BRAUN	5,000 UNITS/100ML	N019952	004	Jul 20, 1992
AP	+!		10,000 UNITS/100ML	N019952	005	Jul 20, 1992
AP		HOSPIRA	5,000 UNITS/100ML	N019339	004	Mar 27, 1985
AP			10,000 UNITS/100ML	N019339	002	Mar 27, 1985
HEPARIN SODIUM IN PLASTIC CONTAINER						
AP	+!	FRESENIUS KABI USA	1,000 UNITS/ML	N017029	013	Dec 05, 1985
AP	+!		5,000 UNITS/ML	N017029	014	Dec 05, 1985
AP	+!		10,000 UNITS/ML	N017029	015	Dec 05, 1985
AP	+!		20,000 UNITS/ML	N017029	016	Dec 05, 1985
HEPARIN SODIUM PRESERVATIVE FREE						
AP	+!	FRESENIUS KABI USA	1,000 UNITS/ML	N017029	010	Apr 28, 1986
AP	+!		10,000 UNITS/ML	N017029	019	Nov 22, 2010
AP		HOSPIRA	10,000 UNITS/ML	A089522	001	May 04, 1987
AP		NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020
AP		SAGENT PHARMS	1,000 UNITS/ML	A090810	001	Jun 30, 2010
AP		SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014
HEPARIN SODIUM						
	+!	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011
	!	HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983
	+!	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011

HEPARIN SODIUM
INJECTABLE;INJECTION
HEPARIN SODIUM
+! 5,000 UNITS/ML N201370 002 Jul 21, 2011
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
HOSPIRA 5,000 UNITS/100ML N019339 001 Mar 27, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
HOSPIRA 5,000 UNITS/100ML N018916 006 Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2,000 UNITS/1000ML N018609 004 Apr 23, 2020
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
+! B BRAUN 200 UNITS/100ML N019953 002 Dec 15, 2023
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
+! B BRAUN 4,000 UNITS/100ML N019952 001 Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
HOSPIRA 5,000 UNITS/100ML N018916 007 Jan 31, 1984
10,000 UNITS/100ML N018916 008 Jan 31, 1984
HEPARIN SODIUM PRESERVATIVE FREE
+! PFIZER 1,000 UNITS/ML N201370 004 Jul 21, 2011

HEPARIN SODIUM; TAUROLIDINE
SOLUTION;N/A
DEFENCATH
+! CORMEDIX 3,000 UNITS/3ML (1,000 UNITS/ML);40.5MG/3ML (13.5MG/ML) N214520 001 Nov 15, 2023
+! 5,000 UNITS/5ML (1,000 UNITS/ML);67.5MG/5ML (13.5MG/ML) N214520 002 Nov 15, 2023

HEXACHLOROPHENE
SPONGE;TOPICAL
PRE-OP
AT +! DAVIS AND GECK **480MG** **N017433 001**
PRE-OP II
AT + DAVIS AND GECK **480MG** **N017433 002**

HEXAMINOLEVULINATE HYDROCHLORIDE
FOR SOLUTION;INTRAVESICAL
CYSVIEW KIT
+! PHOTOCURE ASA 100MG/VIAL N022555 001 May 28, 2010

HISTRELIN ACETATE
IMPLANT;SUBCUTANEOUS
SUPPRELIN LA
+! ENDO PHARM 50MG N022058 001 May 03, 2007

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE
SYRUP;ORAL
HYCODAN
AA + GENUS **1.5MG/5ML;5MG/5ML** **N005213 002** Jul 26, 1988
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE
AA ABHAI LLC **1.5MG/5ML;5MG/5ML** **A207487 001** Feb 21, 2017
AA ACTAVIS MID ATLANTIC **1.5MG/5ML;5MG/5ML** **A088017 001** Jul 05, 1983
AA NOVEL LABS INC **1.5MG/5ML;5MG/5ML** **A203535 001** Feb 13, 2017
AA PADAGIS US **1.5MG/5ML;5MG/5ML** **A205731 001** Feb 15, 2017
AA ! PAI HOLDINGS PHARM **1.5MG/5ML;5MG/5ML** **A040613 001** Feb 08, 2008
AA WOCKHARDT BIO AG **1.5MG/5ML;5MG/5ML** **A088008 001** Mar 03, 1983
TABLET;ORAL
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE
AA ! AVANTHI INC **1.5MG;5MG** **A207176 001** Aug 07, 2017
HYCODAN
AA + GENUS **1.5MG;5MG** **N005213 001** Jul 26, 1988

HYDRALAZINE HYDROCHLORIDE
INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE
AP AM REGENT **20MG/ML** **A040136 001** Jun 30, 1997
AP BEOWULF ASSET **20MG/ML** **A203110 001** Jun 29, 2015
AP EUGIA PHARMA **20MG/ML** **A215147 001** Feb 13, 2023
AP FRESENIUS KABI USA **20MG/ML** **A040388 001** Mar 13, 2001
AP HIKMA **20MG/ML** **A213667 001** Dec 18, 2020
AP NAVINTA LLC **20MG/ML** **A202938 001** Mar 28, 2013
AP ! RISING **20MG/ML** **A040730 001** Apr 21, 2009

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA		ALKEM LABS LTD	**10MG**	**A200737**	**001**	Dec 07, 2012
AA			**25MG**	**A200737**	**002**	Dec 07, 2012
AA			**50MG**	**A200737**	**003**	Dec 07, 2012
AA			**100MG**	**A200737**	**004**	Dec 07, 2012
AA		CADILA PHARMS LTD	**25MG**	**A203845**	**001**	Sep 18, 2014
AA			**50MG**	**A203845**	**002**	Sep 18, 2014
AA			**100MG**	**A203845**	**003**	Sep 18, 2014
AA		GLENMARK PHARMS LTD	**10MG**	**A090527**	**001**	May 27, 2009
AA			**25MG**	**A090527**	**002**	May 27, 2009
AA			**50MG**	**A090527**	**003**	May 27, 2009
AA			**100MG**	**A090527**	**004**	May 27, 2009
AA		HERITAGE PHARMS	**10MG**	**A086242**	**001**	Feb 04, 2010
AA			**25MG**	**A086242**	**003**	
AA			**50MG**	**A086242**	**002**	
AA			**100MG**	**A086242**	**004**	Feb 04, 2010
AA		HERITAGE PHARMS INC	**10MG**	**A040858**	**001**	Feb 26, 2010
AA			**25MG**	**A040858**	**002**	Feb 26, 2010
AA			**50MG**	**A040858**	**003**	Feb 26, 2010
AA			**100MG**	**A040858**	**004**	Feb 26, 2010
AA		HETERO LABS LTD III	**10MG**	**A040901**	**001**	Sep 12, 2008
AA			**25MG**	**A040901**	**002**	Sep 12, 2008
AA			**50MG**	**A040901**	**003**	Sep 12, 2008
AA			**100MG**	**A040901**	**004**	Sep 12, 2008
AA		INVAGEN PHARMS	**10MG**	**A090255**	**001**	Dec 15, 2008
AA			**25MG**	**A090255**	**002**	Dec 15, 2008
AA			**50MG**	**A090255**	**003**	Dec 15, 2008
AA			**100MG**	**A090255**	**004**	Dec 15, 2008
AA	**!**	PLIVA	**10MG**	**A089097**	**001**	Dec 18, 1985
AA	**+!**		**25MG**	**A088467**	**001**	May 01, 1984
AA	**+!**		**50MG**	**A088468**	**001**	May 01, 1984
AA	**!**		**100MG**	**A089098**	**001**	Dec 18, 1985
AA		SCIEGEN PHARMS INC	**10MG**	**A205236**	**001**	May 26, 2017
AA			**25MG**	**A205236**	**002**	May 26, 2017
AA			**50MG**	**A205236**	**003**	May 26, 2017
AA			**100MG**	**A205236**	**004**	May 26, 2017
AA		STRIDES PHARMA	**10MG**	**A087836**	**001**	Oct 05, 1982
AA			**25MG**	**A086961**	**002**	
AA			**25MG**	**A200770**	**001**	May 03, 2013
AA			**50MG**	**A086962**	**001**	
AA			**50MG**	**A200770**	**002**	May 03, 2013
AA			**100MG**	**A088391**	**001**	Sep 27, 1983
AA			**100MG**	**A200770**	**003**	May 03, 2013

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDRA-ZIDE

		STRIDES PHARMA	25MG;25MG	A088957	001	Oct 21, 1985
	!		50MG;50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

BIDIL

AB	**+!**	AZURITY	**37.5MG;20MG**	**N020727**	**001**	Jun 23, 2005

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB		RICONPHARMA LLC	**37.5MG;20MG**	**A215586**	**001**	Apr 06, 2022

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA	**12.5MG**	**A078164**	**001**	Sep 18, 2007
AB		IPCA LABS LTD	**12.5MG**	**A079237**	**001**	Apr 02, 2009
AB		JUBILANT CADISTA	**12.5MG**	**A078391**	**001**	Feb 11, 2008
AB		PRINSTON INC	**12.5MG**	**A075907**	**001**	Sep 17, 2002
AB		SCIEGEN PHARMS INC	**12.5MG**	**A203561**	**001**	Jan 14, 2019
AB		UNICHEM	**12.5MG**	**A090510**	**001**	Jan 19, 2010

MICROZIDE

AB	**+!**	TEVA BRANDED PHARM	**12.5MG**	**N020504**	**001**	Dec 27, 1996

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB	**!**	ACCORD HLTHCARE	**12.5MG**	**A202556**	**001**	Sep 24, 2012
AB			**25MG**	**A202556**	**002**	Sep 24, 2012

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB			50MG	A202556	003	Sep 24, 2012
AB		ACTAVIS ELIZABETH	12.5MG	A040707	001	Feb 27, 2007
AB		AUROBINDO PHARMA	25MG	A040780	001	Jul 20, 2007
AB			50MG	A040780	002	Jul 20, 2007
AB		HERITAGE PHARMS	12.5MG	A085182	003	May 02, 2023
AB			25MG	A085182	002	
AB			50MG	A085182	001	
AB		IPCA LABS LTD	12.5MG	A040807	001	Jul 20, 2007
AB			25MG	A040807	002	Jul 20, 2007
AB			50MG	A040807	003	Jul 20, 2007
AB	+	IVAX SUB TEVA PHARMS	25MG	A083177	001	
AB	+!		50MG	A083177	002	
AB		LEADING	12.5MG	A040702	003	May 10, 2017
AB			25MG	A040702	001	Mar 16, 2007
AB			50MG	A040702	002	Mar 16, 2007
AB		OXFORD PHARMS	25MG	A087059	001	
AB			50MG	A087068	001	
AB		PRINSTON INC	25MG	A040412	001	Mar 29, 2002
AB			50MG	A040412	002	Mar 29, 2002
AB		SCIEGEN PHARMS INC	25MG	A203018	001	Jul 23, 2014
AB			50MG	A203018	002	Jul 23, 2014
AB		UNICHEM	25MG	A040907	001	Aug 15, 2008
AB			50MG	A040907	002	Aug 15, 2008

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

AVALIDE

AB	+!	SANOFI AVENTIS US	12.5MG;150MG	N020758	002	Sep 30, 1997
AB	+!		12.5MG;300MG	N020758	003	Aug 31, 1998

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC	12.5MG;150MG	A091370	001	Oct 15, 2012
AB			12.5MG;300MG	A091370	002	Oct 15, 2012
AB			25MG;300MG	A091370	003	Oct 12, 2016
AB		AUROBINDO PHARMA LTD	12.5MG;150MG	A203630	001	Feb 22, 2013
AB			12.5MG;300MG	A203630	002	Feb 22, 2013
AB			25MG;300MG	A203630	003	Mar 31, 2016
AB		DR REDDYS LABS LTD	12.5MG;150MG	A203500	001	Sep 27, 2012
AB			12.5MG;300MG	A203500	002	Sep 27, 2012
AB		HIKMA	12.5MG;150MG	A090351	001	Oct 15, 2012
AB			12.5MG;300MG	A090351	002	Oct 15, 2012
AB			25MG;300MG	A090351	003	Jun 08, 2017
AB		HISUN PHARM HANGZHOU	12.5MG;150MG	A207896	001	Oct 14, 2016
AB			12.5MG;300MG	A207896	002	Oct 14, 2016
AB		LUPIN LTD	12.5MG;150MG	A201524	001	Feb 27, 2013
AB			12.5MG;300MG	A201524	002	Feb 27, 2013
AB		MACLEODS PHARMS LTD	12.5MG;150MG	A202414	001	Sep 27, 2012
AB			12.5MG;300MG	A202414	002	Sep 27, 2012
AB		PRINSTON INC	12.5MG;150MG	A203072	001	May 09, 2014
AB			12.5MG;300MG	A203072	002	May 09, 2014
AB		SANDOZ	12.5MG;150MG	A077446	001	Sep 27, 2012
AB			12.5MG;300MG	A077446	002	Sep 27, 2012
AB		TEVA	12.5MG;150MG	A077369	001	Mar 30, 2012
AB			12.5MG;300MG	A077369	002	Mar 30, 2012

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO	12.5MG;10MG	A077606	001	Mar 14, 2006
AB			12.5MG;20MG	A077606	002	Mar 14, 2006
AB			25MG;20MG	A077606	003	Mar 14, 2006
AB		INVAGEN PHARMS	12.5MG;10MG	A204058	001	May 23, 2017
AB	!		12.5MG;20MG	A204058	002	May 23, 2017
AB	!		25MG;20MG	A204058	003	May 23, 2017
AB		LUPIN	12.5MG;10MG	A077912	001	Sep 27, 2006
AB			12.5MG;20MG	A077912	002	Sep 27, 2006
AB			25MG;20MG	A077912	003	Sep 27, 2006
AB		PRINSTON INC	12.5MG;10MG	A076230	001	Jul 01, 2002
AB			12.5MG;20MG	A076230	002	Jul 01, 2002

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB			**25MG;20MG**	**A076230**	**003**	Jul 01, 2002
AB		SANDOZ	**12.5MG;10MG**	**A076262**	**001**	Jul 01, 2002
AB			**12.5MG;20MG**	**A076262**	**002**	Jul 01, 2002
AB			**25MG;20MG**	**A076262**	**003**	Jul 01, 2002
AB		SUN PHARM INDS LTD	**12.5MG;10MG**	**A076007**	**001**	Jul 01, 2002
AB			**12.5MG;20MG**	**A076007**	**002**	Jul 01, 2002
AB			**25MG;20MG**	**A076007**	**003**	Jul 01, 2002
AB		WATSON LABS	**12.5MG;10MG**	**A076194**	**003**	Jul 01, 2002
AB			**12.5MG;20MG**	**A076194**	**001**	Jul 01, 2002
AB			**25MG;20MG**	**A076194**	**002**	Jul 01, 2002

ZESTORETIC

AB	+	ALMATICA	**12.5MG;10MG**	**N019888**	**003**	Nov 18, 1993
AB	+		**12.5MG;20MG**	**N019888**	**001**	Sep 20, 1990
AB	+		**25MG;20MG**	**N019888**	**002**	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

HYZAAR

AB	+	ORGANON	**12.5MG;50MG**	**N020387**	**001**	Apr 28, 1995
AB	+		**12.5MG;100MG**	**N020387**	**003**	Oct 20, 2005
AB	+		**25MG;100MG**	**N020387**	**002**	Nov 10, 1998

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**12.5MG;50MG**	**A091617**	**001**	Feb 17, 2012
AB			**12.5MG;100MG**	**A091617**	**002**	Feb 17, 2012
AB			**25MG;100MG**	**A091617**	**003**	Feb 17, 2012
AB		AUROBINDO PHARMA	**12.5MG;50MG**	**A091629**	**001**	Oct 06, 2010
AB			**12.5MG;100MG**	**A091629**	**002**	Oct 06, 2010
AB	!		**25MG;100MG**	**A091629**	**003**	Jan 06, 2010
AB		GRANULES	**12.5MG;50MG**	**A218015**	**001**	Sep 29, 2023
AB			**12.5MG;100MG**	**A218015**	**002**	Sep 29, 2023
AB			**25MG;100MG**	**A218015**	**003**	Sep 29, 2023
AB		IPCA LABS LTD	**12.5MG;50MG**	**A201682**	**001**	Mar 01, 2013
AB			**12.5MG;100MG**	**A201682**	**002**	Mar 01, 2013
AB			**25MG;100MG**	**A201682**	**003**	Mar 01, 2013
AB		JUBILANT CADISTA	**12.5MG;50MG**	**A201845**	**001**	Sep 18, 2012
AB			**12.5MG;100MG**	**A201845**	**002**	Sep 18, 2012
AB			**25MG;100MG**	**A201845**	**003**	Sep 18, 2012
AB		LUPIN LTD	**12.5MG;50MG**	**A078245**	**001**	Oct 06, 2010
AB			**12.5MG;100MG**	**A078245**	**002**	May 21, 2010
AB			**25MG;100MG**	**A078245**	**003**	Oct 06, 2010
AB		MACLEODS PHARMS LTD	**12.5MG;50MG**	**A202289**	**001**	Aug 09, 2012
AB			**12.5MG;100MG**	**A202289**	**002**	Aug 09, 2012
AB			**25MG;100MG**	**A202289**	**003**	Aug 09, 2012
AB		PRINSTON INC	**12.5MG;50MG**	**A204901**	**001**	Nov 06, 2017
AB			**12.5MG;100MG**	**A204901**	**002**	Nov 06, 2017
AB			**25MG;100MG**	**A204901**	**003**	Nov 06, 2017
AB		SANDOZ	**12.5MG;50MG**	**A077948**	**001**	Oct 06, 2010
AB			**12.5MG;100MG**	**A077948**	**003**	Aug 19, 2010
AB			**25MG;100MG**	**A077948**	**002**	Oct 06, 2010
AB		TEVA PHARMS	**12.5MG;50MG**	**A077157**	**001**	Apr 06, 2010
AB			**12.5MG;100MG**	**A077157**	**002**	Apr 06, 2010
AB			**25MG;100MG**	**A077157**	**003**	Apr 06, 2010
AB		UNICHEM	**12.5MG;50MG**	**A204832**	**001**	Jul 21, 2017
AB			**12.5MG;100MG**	**A204832**	**002**	Jul 21, 2017
AB			**25MG;100MG**	**A204832**	**003**	Jul 21, 2017
AB		ZYDUS PHARMS USA INC	**12.5MG;50MG**	**A078385**	**001**	Oct 06, 2010
AB			**25MG;100MG**	**A078385**	**002**	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

LOPRESSOR HCT

AB	+	VALIDUS PHARMS	**25MG;50MG**	**N018303**	**001**	Dec 31, 1984

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC	**25MG;50MG**	**A202870**	**001**	Nov 06, 2013
AB	!		**25MG;100MG**	**A202870**	**002**	Nov 06, 2013
AB			**50MG;100MG**	**A202870**	**003**	Nov 06, 2013
AB		MYLAN	**25MG;50MG**	**A076792**	**001**	Aug 20, 2004
AB			**25MG;100MG**	**A076792**	**002**	Aug 20, 2004
AB			**50MG;100MG**	**A076792**	**003**	Aug 20, 2004
AB		SUN PHARM INDS	**25MG;50MG**	**A090654**	**001**	Jan 19, 2012

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB			**25MG;100MG**	**A090654**	**002**	Jan 19, 2012
AB			**50MG;100MG**	**A090654**	**003**	Jan 19, 2012

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		GLENMARK PHARMS	**12.5MG;7.5MG**	**A090718**	**001**	Mar 17, 2010
AB			**12.5MG;15MG**	**A090718**	**002**	Mar 17, 2010
AB			**25MG;15MG**	**A090718**	**003**	Mar 17, 2010
AB		TEVA	**12.5MG;7.5MG**	**A076980**	**001**	Mar 07, 2007
AB			**12.5MG;15MG**	**A076980**	**003**	Mar 07, 2007
AB	**!**		**25MG;15MG**	**A076980**	**002**	Mar 07, 2007

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR HCT

AB	**+**	COSETTE	**12.5MG;20MG**	**N021532**	**002**	Jun 05, 2003
AB	**+**		**12.5MG;40MG**	**N021532**	**003**	Jun 05, 2003
AB	**+!**		**25MG;40MG**	**N021532**	**005**	Jun 05, 2003

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB		ACCORD HLTHCARE	**12.5MG;20MG**	**A209281**	**001**	Feb 07, 2019
AB			**12.5MG;40MG**	**A209281**	**002**	Feb 07, 2019
AB			**25MG;40MG**	**A209281**	**003**	Feb 07, 2019
AB		ALEMBIC	**12.5MG;20MG**	**A204233**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A204233**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A204233**	**003**	Apr 24, 2017
AB		AUROBINDO PHARMA	**12.5MG;20MG**	**A205391**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A205391**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A205391**	**003**	Apr 24, 2017
AB		MACLEODS PHARMS LTD	**12.5MG;20MG**	**A204801**	**001**	Jun 01, 2023
AB			**12.5MG;40MG**	**A204801**	**002**	Jun 01, 2023
AB			**25MG;40MG**	**A204801**	**003**	Jun 01, 2023
AB		PRINSTON INC	**12.5MG;20MG**	**A207804**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A207804**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A207804**	**003**	Apr 24, 2017
AB		TEVA PHARMS USA	**12.5MG;40MG**	**A200532**	**002**	Apr 24, 2017
AB		UMEDICA	**12.5MG;20MG**	**A208847**	**001**	Sep 17, 2019
AB			**12.5MG;40MG**	**A208847**	**003**	Sep 17, 2019
AB			**25MG;40MG**	**A208847**	**002**	Sep 17, 2019

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		APOTEX	**12.5MG;EQ 10MG BASE**	**A091524**	**001**	Mar 12, 2013
AB			**12.5MG;EQ 20MG BASE**	**A091524**	**002**	Mar 12, 2013
AB			**25MG;EQ 20MG BASE**	**A091524**	**003**	Mar 12, 2013
AB		AUROBINDO PHARMA	**12.5MG;EQ 10MG BASE**	**A078450**	**001**	Aug 24, 2007
AB			**12.5MG;EQ 20MG BASE**	**A078450**	**002**	Aug 24, 2007
AB	**!**		**25MG;EQ 20MG BASE**	**A078450**	**003**	Aug 24, 2007
AB		INVAGEN PHARMS	**12.5MG;EQ 10MG BASE**	**A201356**	**001**	Apr 20, 2011
AB			**12.5MG;EQ 20MG BASE**	**A201356**	**002**	Apr 20, 2011
AB			**25MG;EQ 20MG BASE**	**A201356**	**003**	Apr 20, 2011

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

ALDACTAZIDE

AB	**+**	PFIZER	**25MG;25MG**	**N012616**	**004**	Dec 30, 1982

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	**25MG;25MG**	**A086513**	**001**	
AB		SUN PHARM INDUSTRIES	**25MG;25MG**	**A089534**	**001**	Jul 02, 1987

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

MICARDIS HCT

AB	**+**	BOEHRINGER INGELHEIM	**12.5MG;40MG**	**N021162**	**001**	Nov 17, 2000
AB	**+**		**12.5MG;80MG**	**N021162**	**002**	Nov 17, 2000
AB	**+!**		**25MG;80MG**	**N021162**	**003**	Apr 19, 2004

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC	**12.5MG;40MG**	**A203010**	**001**	Feb 25, 2014
AB			**12.5MG;80MG**	**A203010**	**002**	Feb 25, 2014

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB			**25MG;80MG**	**A203010**	**003**	Feb 25, 2014
AB		AUROBINDO PHARMA	**12.5MG;40MG**	**A208727**	**001**	Dec 15, 2016
AB			**12.5MG;80MG**	**A208727**	**002**	Dec 15, 2016
AB			**25MG;80MG**	**A208727**	**003**	Dec 15, 2016
AB		GLENMARK PHARMS LTD	**12.5MG;40MG**	**A202544**	**001**	Mar 04, 2019
AB			**12.5MG;80MG**	**A202544**	**002**	Mar 04, 2019
AB			**25MG;80MG**	**A202544**	**003**	Mar 04, 2019
AB		LUPIN LTD	**12.5MG;40MG**	**A091351**	**001**	Aug 07, 2014
AB			**12.5MG;80MG**	**A091351**	**002**	Aug 07, 2014
AB			**25MG;80MG**	**A091351**	**003**	Aug 07, 2014
AB		PRINSTON INC	**12.5MG;40MG**	**A209028**	**001**	Nov 06, 2017
AB			**12.5MG;80MG**	**A209028**	**002**	Nov 06, 2017
AB			**25MG;80MG**	**A209028**	**003**	Nov 06, 2017
AB		ZYDUS PHARMS	**12.5MG;40MG**	**A204221**	**001**	Aug 15, 2017
AB			**12.5MG;80MG**	**A204221**	**002**	Aug 15, 2017
AB			**25MG;80MG**	**A204221**	**003**	Aug 15, 2017

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		CADILA	**25MG;37.5MG**	**A208358**	**001**	Feb 11, 2019
AB		LANNETT CO INC	**25MG;37.5MG**	**A201407**	**001**	Dec 09, 2011
AB	**!**	SANDOZ	**25MG;37.5MG**	**A074821**	**001**	Jun 05, 1997

TABLET;ORAL

MAXZIDE

AB	**+!**	AUROBINDO PHARMA USA	**50MG;75MG**	**N019129**	**001**	Oct 22, 1984

MAXZIDE-25

AB	**+**	AUROBINDO PHARMA USA	**25MG;37.5MG**	**N019129**	**003**	May 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		APOTEX INC	**25MG;37.5MG**	**A071251**	**002**	May 05, 1998
AB			**50MG;75MG**	**A071251**	**001**	Apr 17, 1988
AB		RUBICON	**25MG;37.5MG**	**A216211**	**001**	Feb 23, 2022
AB			**50MG;75MG**	**A216211**	**002**	Feb 23, 2022
AB		SANDOZ	**25MG;37.5MG**	**A073281**	**001**	Apr 30, 1992
AB			**50MG;75MG**	**A072011**	**001**	Jun 17, 1988
AB		WATSON LABS	**25MG;37.5MG**	**A073449**	**001**	Sep 23, 1993
AB			**50MG;75MG**	**A071851**	**001**	Nov 30, 1988
AB		ZYDUS PHARMS	**25MG;37.5MG**	**A208360**	**001**	Jun 29, 2018
AB			**50MG;75MG**	**A208360**	**002**	Jun 29, 2018

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

DIOVAN HCT

AB	**+**	NOVARTIS	**12.5MG;80MG**	**N020818**	**001**	Mar 06, 1998
AB	**+**		**12.5MG;160MG**	**N020818**	**002**	Mar 06, 1998
AB	**+**		**12.5MG;320MG**	**N020818**	**004**	Apr 28, 2006
AB	**+**		**25MG;160MG**	**N020818**	**003**	Jan 17, 2002
AB	**+!**		**25MG;320MG**	**N020818**	**005**	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC	**12.5MG;80MG**	**A201662**	**001**	Mar 21, 2013
AB			**12.5MG;160MG**	**A201662**	**002**	Mar 21, 2013
AB			**12.5MG;320MG**	**A201662**	**003**	Mar 21, 2013
AB			**25MG;160MG**	**A201662**	**004**	Mar 21, 2013
AB			**25MG;320MG**	**A201662**	**005**	Mar 21, 2013
AB		AMNEAL PHARMS	**12.5MG;80MG**	**A204382**	**001**	Aug 11, 2023
AB			**12.5MG;160MG**	**A204382**	**002**	Aug 11, 2023
AB			**12.5MG;320MG**	**A204382**	**004**	Aug 11, 2023
AB			**25MG;160MG**	**A204382**	**003**	Aug 11, 2023
AB			**25MG;320MG**	**A204382**	**005**	Aug 11, 2023
AB		AUROBINDO PHARMA LTD	**12.5MG;80MG**	**A202519**	**001**	Mar 21, 2013
AB			**12.5MG;160MG**	**A202519**	**002**	Mar 21, 2013
AB			**12.5MG;320MG**	**A202519**	**003**	Mar 21, 2013
AB			**25MG;160MG**	**A202519**	**004**	Mar 21, 2013
AB			**25MG;320MG**	**A202519**	**005**	Mar 21, 2013
AB		LUPIN LTD	**12.5MG;80MG**	**A078946**	**003**	Mar 21, 2013
AB			**12.5MG;160MG**	**A078946**	**004**	Mar 21, 2013
AB			**12.5MG;320MG**	**A078946**	**001**	Mar 21, 2013
AB			**25MG;160MG**	**A078946**	**005**	Mar 21, 2013

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB			**25MG;320MG**	**A078946**	**002**	Mar 21, 2013
AB		MACLEODS PHARMS LTD	**12.5MG;80MG**	**A203145**	**001**	Apr 19, 2013
AB			**12.5MG;160MG**	**A203145**	**002**	Apr 19, 2013
AB			**12.5MG;320MG**	**A203145**	**003**	Apr 19, 2013
AB			**25MG;160MG**	**A203145**	**004**	Apr 19, 2013
AB			**25MG;320MG**	**A203145**	**005**	Apr 19, 2013
AB		MYLAN PHARMS INC	**12.5MG;80MG**	**A078020**	**001**	Sep 21, 2012
AB			**12.5MG;160MG**	**A078020**	**002**	Sep 21, 2012
AB			**12.5MG;320MG**	**A078020**	**004**	Sep 21, 2012
AB			**25MG;160MG**	**A078020**	**003**	Sep 21, 2012
AB			**25MG;320MG**	**A078020**	**005**	Sep 21, 2012
AB		PRINSTON INC	**12.5MG;80MG**	**A206083**	**001**	Feb 08, 2016
AB			**12.5MG;160MG**	**A206083**	**002**	Feb 08, 2016
AB			**12.5MG;320MG**	**A206083**	**003**	Feb 08, 2016
AB			**25MG;160MG**	**A206083**	**004**	Feb 08, 2016
AB			**25MG;320MG**	**A206083**	**005**	Feb 08, 2016

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

HYDROCODONE BITARTRATE

	!	ALVOGEN	10MG	A206986	001	Jan 21, 2020
			15MG	A206986	002	Jan 21, 2020
			20MG	A206986	003	Jan 21, 2020
			30MG	A206986	004	Jan 21, 2020
			40MG	A206986	005	Jan 21, 2020
			50MG	A206986	006	Jan 21, 2020

TABLET, EXTENDED RELEASE;ORAL

HYDROCODONE BITARTRATE

AB		ALVOGEN	**20MG**	**A208269**	**001**	Mar 01, 2021
AB			**30MG**	**A208269**	**002**	Mar 01, 2021
AB			**40MG**	**A208269**	**003**	Mar 01, 2021
AB			**60MG**	**A208269**	**004**	Mar 01, 2021
AB			**80MG**	**A208269**	**005**	Mar 01, 2021
AB			**100MG**	**A208269**	**006**	Mar 01, 2021
AB			**120MG**	**A208269**	**007**	Mar 01, 2021

HYSINGLA ER

AB	**+!**	PURDUE PHARMA LP	**20MG**	**N206627**	**001**	Nov 20, 2014
AB	**+**		**30MG**	**N206627**	**002**	Nov 20, 2014
AB	**+**		**40MG**	**N206627**	**003**	Nov 20, 2014
AB	**+**		**60MG**	**N206627**	**004**	Nov 20, 2014
AB	**+**		**80MG**	**N206627**	**005**	Nov 20, 2014
AB	**+**		**100MG**	**N206627**	**006**	Nov 20, 2014
AB	**+**		**120MG**	**N206627**	**007**	Nov 20, 2014

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE

AB		NOSTRUM LABS INC	**5MG;200MG**	**A077723**	**003**	Nov 06, 2006

HYDROCODONE BITARTRATE AND IBUPROFEN

AB		ACTAVIS LABS FL INC	**7.5MG;200MG**	**A076604**	**001**	Dec 31, 2003
AB		AMNEAL PHARMS NY	**5MG;200MG**	**A076642**	**002**	Mar 18, 2004
AB	**!**		**7.5MG;200MG**	**A076642**	**001**	Oct 12, 2004
AB		AUROLIFE PHARMA LLC	**7.5MG;200MG**	**A204575**	**001**	Jun 02, 2016
AB		NOSTRUM LABS INC	**7.5MG;200MG**	**A077723**	**001**	Nov 06, 2006
			10MG;200MG	A077723	002	Nov 06, 2006

HYDROCORTISONE

CREAM;TOPICAL

ALA-CORT

AT		CROWN LABS	**2.5%**	**A080706**	**007**	Jan 05, 2016
AT			**1%**	**A080706**	**006**	

ANUSOL HC

AT		SALIX PHARMS	**2.5%**	**A088250**	**001**	Jun 06, 1984

HYDROCORTISONE

AT		ACTAVIS MID ATLANTIC	**1%**	**A087795**	**001**	May 03, 1983
AT			**2.5%**	**A089682**	**001**	Mar 10, 1988
AT	**+!**	FOUGERA PHARMS INC	**1%**	**A080693**	**003**	
AT	**!**		**2.5%**	**A089414**	**001**	Dec 16, 1986
AT		PADAGIS US	**2.5%**	**A085025**	**001**	
AT		RISING	**2.5%**	**A040879**	**001**	Aug 20, 2010

HYDROCORTISONE						
CREAM;TOPICAL						
HYDROCORTISONE						
AT		TARO	**2.5%**	**A088799**	**001**	Nov 09, 1984
ENEMA;RECTAL						
COLOCORT						
AB		CHARTWELL	**100MG/60ML**	**A075172**	**001**	Dec 03, 1999
CORTENEMA						
AB	**+!**	ANI PHARMS	**100MG/60ML**	**N016199**	**001**	
GRANULE;ORAL						
ALKINDI SPRINKLE						
	+	ETON	0.5MG	N213876	001	Sep 29, 2020
	+		1MG	N213876	002	Sep 29, 2020
	+		2MG	N213876	003	Sep 29, 2020
	+!		5MG	N213876	004	Sep 29, 2020
LOTION;TOPICAL						
HYDROCORTISONE						
AT		TARO	**2.5%**	**A040247**	**001**	Jul 23, 1999
STIE-CORT						
AT	**!**	PADAGIS US	**2.5%**	**A089074**	**001**	Nov 26, 1985
ALA-SCALP						
		LEGACY PHARMA	2%	A083231	001	
OINTMENT;TOPICAL						
HYDROCORTISONE						
AT	**+!**	FOUGERA PHARMS	**1%**	**A080692**	**001**	
AT	**!**	FOUGERA PHARMS INC	**2.5%**	**A081203**	**001**	May 28, 1993
AT		PADAGIS US	**2.5%**	**A085027**	**001**	
AT		TARO	**1%**	**A086257**	**001**	
HYDROCORTISONE IN ABSORBASE						
AT		CMP PHARMA INC	**1%**	**A088138**	**001**	Sep 06, 1985
SOLUTION;TOPICAL						
TEXACORT						
	!	MISSION PHARMA	2.5%	A081271	001	Apr 17, 1992
TABLET;ORAL						
CORTEF						
AB	**+**	PHARMACIA AND UPJOHN	**5MG**	**N008697**	**003**	
AB	**+**		**10MG**	**N008697**	**001**	
AB	**+!**		**20MG**	**N008697**	**002**	
HYDROCORTISONE						
AB		AUROBINDO PHARMA LTD	**5MG**	**A214649**	**001**	Jul 17, 2023
AB			**10MG**	**A214649**	**002**	Jul 17, 2023
AB			**20MG**	**A214649**	**003**	Jul 17, 2023
AB		IMPAX LABS INC	**5MG**	**A040646**	**001**	Mar 30, 2007
AB			**10MG**	**A040646**	**002**	Mar 30, 2007
AB			**20MG**	**A040646**	**003**	Mar 30, 2007
AB		STRIDES PHARMA	**5MG**	**A207029**	**001**	Apr 27, 2017
AB			**10MG**	**A207029**	**002**	Apr 27, 2017
AB			**20MG**	**A207029**	**003**	Apr 27, 2017
HYDROCORTISONE ACETATE						
AEROSOL, METERED;RECTAL						
CORTIFOAM						
	+!	MYLAN SPECIALITY LP	10%	N017351	001	Feb 10, 1982
CREAM;TOPICAL						
MICORT-HC						
		SEBELA IRELAND LTD	2.5%	A040396	001	Feb 27, 2001
HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE						
AEROSOL, METERED;TOPICAL						
EPIFOAM						
BX		MYLAN SPECIALITY LP	1%;1%	A086457	001	
PROCTOFOAM HC						
BX	+!	MYLAN SPECIALITY LP	1%;1%	A086195	001	
CREAM;TOPICAL						
PRAMOSONE						
		SEBELA IRELAND LTD	0.5%;1%	A083778	001	
			1%;1%	A085368	001	
LOTION;TOPICAL						
PRAMOSONE						
		SEBELA IRELAND LTD	1%;1%	A085980	001	
			2.5%;1%	A085979	001	

HYDROCORTISONE BUTYRATE						
CREAM;TOPICAL						
HYDROCORTISONE BUTYRATE						
AB1		TARO PHARM INDS	**0.1%**	**A076654**	**001**	Aug 03, 2005
LOCOID						
AB1	**+!**	BAUSCH	**0.1%**	**N018514**	**001**	Mar 31, 1982
HYDROCORTISONE BUTYRATE						
AB2		ACTAVIS MID ATLANTIC	**0.1%**	**A205134**	**001**	Dec 08, 2017
AB2		GLENMARK GENERICS	**0.1%**	**A202145**	**001**	Sep 27, 2013
LOCOID LIPOCREAM						
AB2	**+!**	PRECISION DERMAT	**0.1%**	**N020769**	**001**	Sep 08, 1997
LOTION;TOPICAL						
HYDROCORTISONE BUTYRATE						
AB		LUPIN LTD	**0.1%**	**A210209**	**001**	Aug 17, 2018
AB		THE J MOLNER	**0.1%**	**A209556**	**001**	Nov 21, 2017
LOCOID						
AB	**+!**	BAUSCH	**0.1%**	**N022076**	**001**	May 18, 2007
OINTMENT;TOPICAL						
HYDROCORTISONE BUTYRATE						
AB		TARO	**0.1%**	**A076842**	**001**	Dec 27, 2004
LOCOID						
AB	**+!**	PRECISION DERMAT	**0.1%**	**N018652**	**001**	Oct 29, 1982
SOLUTION;TOPICAL						
HYDROCORTISONE BUTYRATE						
AT		TARO PHARM INDS	**0.1%**	**A076364**	**001**	Jan 14, 2004
LOCOID						
AT	**+!**	BAUSCH	**0.1%**	**N019116**	**001**	Feb 25, 1987
HYDROCORTISONE PROBUTATE						
CREAM;TOPICAL						
PANDEL						
	+!	ANI PHARMS	0.1%	N020453	001	Feb 28, 1997
HYDROCORTISONE SODIUM SUCCINATE						
INJECTABLE;INJECTION						
SOLU-CORTEF						
	+!	PHARMACIA AND UPJOHN	EQ 100MG BASE/VIAL	N009866	001	
	+!		EQ 250MG BASE/VIAL	N009866	002	
	+!		EQ 500MG BASE/VIAL	N009866	003	
	+!		EQ 1GM BASE/VIAL	N009866	004	
HYDROCORTISONE VALERATE						
CREAM;TOPICAL						
HYDROCORTISONE VALERATE						
AB		COSETTE	**0.2%**	**A213724**	**001**	Feb 11, 2021
AB		ENCUBE ETHICALS	**0.2%**	**A211047**	**001**	Nov 04, 2021
AB		GLENMARK PHARMS LTD	**0.2%**	**A211129**	**001**	Oct 12, 2018
AB		LUPIN LTD	**0.2%**	**A210307**	**001**	Aug 15, 2019
AB		PADAGIS ISRAEL	**0.2%**	**A075666**	**001**	May 24, 2000
AB	**!**	TARO	**0.2%**	**A075042**	**001**	Aug 25, 1998
OINTMENT;TOPICAL						
HYDROCORTISONE VALERATE						
AB		COSETTE	**0.2%**	**A211764**	**001**	Mar 04, 2020
AB		GLENMARK PHARMS LTD	**0.2%**	**A211750**	**001**	Dec 14, 2018
AB	**!**	TARO	**0.2%**	**A075043**	**001**	Aug 25, 1998
HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE						
SOLUTION/DROPS;OTIC						
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
AT	**!**	BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064053**	**001**	Dec 29, 1995
AT		SANDOZ	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062423**	**001**	Aug 25, 1983
SUSPENSION/DROPS;OPHTHALMIC						
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
	!	SANDOZ	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988
SUSPENSION/DROPS;OTIC						
CASPORYN HC						
AT	**+!**	CASPER PHARMA LLC	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**N060613**	**001**	
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
AT		AMRING PHARMS	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A065219**	**001**	May 01, 2006
AT		SANDOZ	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062488**	**001**	Nov 06, 1985
OTICAIR						
AT		BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064065**	**001**	Aug 28, 1996

HYDROMORPHONE HYDROCHLORIDE							
INJECTABLE;INJECTION							
DILAUDID							
AP	**+!**	FRESENIUS KABI USA	**1MG/ML**	**N019034**	**003**	Apr 30, 2009	
AP	**+!**		**2MG/ML**	**N019034**	**004**	Apr 30, 2009	
HYDROMORPHONE HYDROCHLORIDE							
AP		HIKMA	**2MG/ML**	**A202159**	**001**	Apr 27, 2018	
AP		HOSPIRA INC	**1MG/ML**	**N200403**	**001**	Dec 01, 2011	
AP			**2MG/ML**	**N200403**	**002**	Dec 01, 2011	
AP			**10MG/ML**	**A078591**	**001**	Jun 17, 2008	
AP		RISING	**10MG/ML**	**A078228**	**001**	Apr 14, 2010	
AP			**10MG/ML**	**A078261**	**001**	Apr 14, 2010	
DILAUDID							
	+!	FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	
HYDROMORPHONE HYDROCHLORIDE							
		HOSPIRA INC	0.25MG/0.5ML	N200403	005	Mar 03, 2023	
			0.5MG/0.5ML	N200403	004	Jun 13, 2022	
			4MG/ML	N200403	003	Dec 01, 2011	
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
HYDROMORPHONE HYDROCHLORIDE							
	+!	HIKMA	40MG/20ML (2MG/ML)	N217812	001	Dec 14, 2023	
SOLUTION;ORAL							
DILAUDID							
AA	**+!**	RHODES PHARMS	**5MG/5ML**	**N019891**	**001**	Dec 07, 1992	
HYDROMORPHONE HYDROCHLORIDE							
AA		ASCENT PHARMS INC	**5MG/5ML**	**A210176**	**001**	Oct 27, 2017	
AA		HIKMA	**5MG/5ML**	**A074653**	**001**	Jul 29, 1998	
TABLET;ORAL							
DILAUDID							
AB	**+**	RHODES PHARMS	**2MG**	**N019892**	**003**	Nov 09, 2007	
AB	**+**		**4MG**	**N019892**	**002**	Nov 09, 2007	
AB	**+!**		**8MG**	**N019892**	**001**	Dec 07, 1992	
HYDROMORPHONE HYDROCHLORIDE							
AB		ASCENT PHARMS INC	**2MG**	**A210506**	**001**	Jan 17, 2018	
AB			**4MG**	**A210506**	**002**	Jan 17, 2018	
AB			**8MG**	**A210506**	**003**	Jan 17, 2018	
AB		AUROLIFE PHARMA LLC	**2MG**	**A205814**	**001**	May 13, 2016	
AB			**4MG**	**A205814**	**002**	May 13, 2016	
AB			**8MG**	**A205814**	**003**	May 13, 2016	
AB		SPECGX LLC	**2MG**	**A076855**	**002**	Sep 19, 2007	
AB			**4MG**	**A076855**	**003**	Sep 19, 2007	
AB			**8MG**	**A076855**	**001**	Dec 23, 2004	
TABLET, EXTENDED RELEASE;ORAL							
HYDROMORPHONE HYDROCHLORIDE							
AB		ASCENT PHARMS INC	**8MG**	**A212133**	**001**	Sep 23, 2020	
AB			**12MG**	**A212133**	**002**	Sep 23, 2020	
AB			**16MG**	**A212133**	**003**	Sep 23, 2020	
AB			**32MG**	**A212133**	**004**	Sep 23, 2020	
AB		OSMOTICA PHARM US	**8MG**	**A205629**	**001**	Jul 07, 2016	
AB			**12MG**	**A205629**	**002**	Jul 07, 2016	
AB			**16MG**	**A205629**	**003**	Jul 07, 2016	
AB	**!**		**32MG**	**A205629**	**004**	Jul 07, 2016	
AB		PADAGIS US	**8MG**	**A204278**	**001**	Apr 06, 2015	
AB			**12MG**	**A204278**	**002**	Apr 06, 2015	
AB			**16MG**	**A204278**	**003**	Apr 06, 2015	
AB			**32MG**	**A204278**	**004**	Sep 20, 2017	
HYDROXOCOBALAMIN							
INJECTABLE;INJECTION							
CYANOKIT							
	+!	BTG INTL	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	
HYDROXOCOBALAMIN							
	!	ACTAVIS	1MG/ML	A085998	001		
HYDROXYCHLOROQUINE SULFATE							
TABLET;ORAL							
HYDROXYCHLOROQUINE SULFATE							
AB		ACCORD HLTHCARE	**100MG**	**A213342**	**002**	Aug 18, 2021	
AB			**200MG**	**A213342**	**001**	Apr 07, 2020	
AB			**300MG**	**A213342**	**003**	Aug 18, 2021	
AB	**!**		**400MG**	**A213342**	**004**	Aug 18, 2021	
AB		ALKALOIDA ZRT	**200MG**	**A201691**	**001**	May 08, 2018	
AB		AMNEAL PHARMS CO	**200MG**	**A210577**	**001**	May 15, 2018	

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

AB		APPCO	**100MG**	**A210441**	**002**	Sep 19, 2022
AB			**200MG**	**A210441**	**001**	May 01, 2018
AB			**300MG**	**A210441**	**003**	Sep 19, 2022
AB			**400MG**	**A210441**	**004**	Sep 19, 2022
AB		AUROBINDO PHARMA USA	**200MG**	**A040274**	**001**	May 29, 1998
AB		CHARTWELL RX	**200MG**	**A210543**	**001**	Jul 06, 2018
AB		IPCA LABS LTD	**200MG**	**A040766**	**001**	Jun 14, 2007
AB		LAURUS	**200MG**	**A210959**	**001**	Jan 15, 2019
AB		RISE PHARMA	**200MG**	**A212902**	**001**	May 14, 2020
AB		SANDOZ	**200MG**	**A040104**	**001**	Nov 30, 1995
AB		ZYDUS PHARMS USA INC	**200MG**	**A040657**	**001**	Sep 21, 2007

PLAQUENIL

AB	**+!**	CONCORDIA	**200MG**	**N009768**	**001**	

SOVUNA

	+	NOVITIUM PHARMA	200MG	N214581	001	Jan 14, 2022
	+!		300MG	N214581	002	Jan 14, 2022

HYDROXYPROPYL CELLULOSE

INSERT;OPHTHALMIC

LACRISERT

	+!	BAUSCH AND LOMB INC	5MG	N018771	001	

HYDROXYUREA

CAPSULE;ORAL

HYDREA

AB	**+!**	CHEPLAPHARM	**500MG**	**N016295**	**001**	

HYDROXYUREA

AB		BARR	**500MG**	**A075143**	**001**	Oct 16, 1998
AB		LEADING	**500MG**	**A213438**	**001**	Apr 08, 2020
AB		PAR PHARM	**500MG**	**A075340**	**001**	Feb 24, 1999

DROXIA

	+	CHEPLAPHARM	200MG	N016295	002	Feb 25, 1998
	+		300MG	N016295	003	Feb 25, 1998
	+		400MG	N016295	004	Feb 25, 1998

TABLET;ORAL

SIKLOS

	+	THERAVIA	100MG	N208843	001	Dec 21, 2017
	+!		1GM	N208843	002	Dec 21, 2017

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDROXYZINE HYDROCHLORIDE

	+!	AM REGENT	25MG/ML	A087408	001	
	+!		50MG/ML	A087408	002	

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

AA	**+!**	CHARTWELL RX	**10MG/5ML**	**A087294**	**001**	Apr 12, 1982
AA		LANNETT CO INC	**10MG/5ML**	**A201674**	**001**	Aug 21, 2013

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB		AMNEAL PHARM	**10MG**	**A040808**	**001**	Sep 24, 2008
AB			**25MG**	**A040808**	**002**	Sep 24, 2008
AB			**50MG**	**A040808**	**003**	Sep 24, 2008
AB		AUROBINDO PHARMA LTD	**10MG**	**A087871**	**002**	Dec 20, 1982
AB			**25MG**	**A087871**	**003**	Dec 20, 1982
AB			**50MG**	**A087871**	**001**	Dec 20, 1982
AB		CHARTWELL RX	**10MG**	**A040804**	**001**	Jun 30, 2008
AB			**25MG**	**A040804**	**002**	Jun 30, 2008
AB			**50MG**	**A040804**	**003**	Jun 30, 2008
AB		EPIC PHARMA LLC	**10MG**	**A040604**	**002**	Dec 28, 2004
AB			**25MG**	**A040604**	**003**	Dec 28, 2004
AB			**50MG**	**A040604**	**001**	Dec 28, 2004
AB		GRAVITI PHARMS	**10MG**	**A217652**	**001**	Aug 17, 2023
AB			**25MG**	**A217652**	**002**	Aug 17, 2023
AB			**50MG**	**A217652**	**003**	Aug 17, 2023
AB		HERITAGE PHARMA	**10MG**	**A204279**	**001**	Aug 20, 2014
AB			**25MG**	**A204279**	**002**	Aug 20, 2014
AB			**50MG**	**A204279**	**003**	Aug 20, 2014

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB		HETERO LABS LTD III	**10MG**	**A040805**	**001**	May 29, 2008
AB			**25MG**	**A040805**	**002**	May 29, 2008
AB			**50MG**	**A040805**	**003**	May 29, 2008
AB		INVAGEN PHARMS	**10MG**	**A040812**	**001**	Mar 12, 2008
AB			**25MG**	**A040812**	**002**	Mar 12, 2008
AB			**50MG**	**A040812**	**003**	Mar 12, 2008
AB		KVK TECH	**10MG**	**A040786**	**001**	Mar 20, 2007
AB			**25MG**	**A040786**	**002**	Mar 20, 2007
AB			**50MG**	**A040786**	**003**	Mar 20, 2007
AB		NORTHSTAR HLTHCARE	**10MG**	**A040840**	**002**	Mar 31, 2008
AB			**25MG**	**A040840**	**003**	Mar 31, 2008
AB			**50MG**	**A040840**	**001**	Mar 31, 2008
AB		NUVO PHARMS INC	**10MG**	**A207121**	**002**	Mar 29, 2017
AB			**25MG**	**A207121**	**001**	Mar 29, 2017
AB			**50MG**	**A207121**	**003**	Mar 29, 2017
AB	**+!**	PLIVA	**10MG**	**A088617**	**001**	Jan 10, 1986
AB	**+!**		**25MG**	**A088618**	**001**	Jan 10, 1986
AB	**+!**		**50MG**	**A088619**	**001**	Jan 10, 1986
AB		PRINSTON INC	**10MG**	**A040580**	**003**	May 27, 2005
AB			**25MG**	**A040580**	**002**	May 27, 2005
AB			**50MG**	**A040580**	**001**	May 27, 2005

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB		BARR	**EQ 25MG HYDROCHLORIDE**	**A088496**	**001**	Jun 15, 1984
AB			**EQ 50MG HYDROCHLORIDE**	**A088487**	**001**	Jun 15, 1984
AB		HERITAGE PHARMA	**EQ 25MG HYDROCHLORIDE**	**A201507**	**001**	Jun 03, 2013
AB			**EQ 50MG HYDROCHLORIDE**	**A201507**	**002**	Jun 03, 2013
AB		IMPAX LABS INC	**EQ 25MG HYDROCHLORIDE**	**A040156**	**001**	Jul 15, 1996
AB			**EQ 50MG HYDROCHLORIDE**	**A040156**	**002**	Jul 15, 1996
AB		SANDOZ	**EQ 25MG HYDROCHLORIDE**	**A087479**	**001**	
AB	**!**		**EQ 50MG HYDROCHLORIDE**	**A086183**	**001**	

VISTARIL

AB	**+**	PFIZER	**EQ 25MG HYDROCHLORIDE**	**N011459**	**002**	
AB	**+**		**EQ 50MG HYDROCHLORIDE**	**N011459**	**004**	

HYDROXYZINE PAMOATE

	BARR	EQ 100MG HYDROCHLORIDE	A088488	001	Jun 15, 1984

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

AP		ACCORD HLTHCARE	**EQ 3MG BASE/3ML**	**A206058**	**001**	Feb 05, 2016
AP	**!**	APOTEX	**EQ 3MG BASE/3ML**	**A204222**	**001**	Oct 16, 2015
AP		EUGIA PHARMA	**EQ 3MG BASE/3ML**	**A205332**	**001**	Aug 19, 2015
AP		MYLAN LABS LTD	**EQ 3MG BASE/3ML**	**A202671**	**001**	Sep 02, 2014
AP		SAGENT PHARMS INC	**EQ 3MG BASE/3ML**	**A202235**	**001**	Sep 02, 2014
AP		SUN PHARM	**EQ 3MG BASE/3ML**	**A090853**	**001**	Feb 14, 2014

TABLET;ORAL

IBANDRONATE SODIUM

AB		APOTEX INC	**EQ 150MG BASE**	**A078948**	**001**	Mar 19, 2012
AB		AUROBINDO PHARMA	**EQ 150MG BASE**	**A204502**	**001**	Mar 11, 2016
AB	**!**	DR REDDYS LABS LTD	**EQ 150MG BASE**	**A078997**	**001**	Apr 30, 2012
AB		MACLEODS PHARMS LTD	**EQ 150MG BASE**	**A206887**	**001**	Oct 31, 2017
AB		ORBION PHARMS	**EQ 150MG BASE**	**A078998**	**001**	Mar 19, 2012
AB		WATSON LABS TEVA	**EQ 150MG BASE**	**A079003**	**001**	Mar 20, 2012

IBREXAFUNGERP CITRATE

TABLET;ORAL

BREXAFEMME

	+!	SCYNEXIS	EQ 150MG BASE	N214900	001	Jun 01, 2021

IBRUTINIB

CAPSULE;ORAL

IMBRUVICA

	+	PHARMACYCLICS LLC	70MG	N205552	002	Dec 20, 2017
	+!		140MG	N205552	001	Nov 13, 2013

SUSPENSION;ORAL

IMBRUVICA

	+!	PHARMACYCLICS LLC	70MG/ML	N217003	001	Aug 24, 2022

IBRUTINIB

TABLET;ORAL

IMBRUVICA

	+	PHARMACYCLICS LLC	140MG	N210563	001	Feb 16, 2018
	+		280MG	N210563	002	Feb 16, 2018
	+		420MG	N210563	003	Feb 16, 2018

IBUPROFEN

SOLUTION;INTRAVENOUS

CALDOLOR

	+!	CUMBERLAND PHARMS	800MG/8ML (100MG/ML)	N022348	002	Jun 11, 2009
	+!		800MG/200ML (4MG/ML)	N022348	003	Jan 25, 2019

SUSPENSION;ORAL

IBUPROFEN

AB	!	ACTAVIS MID ATLANTIC	**100MG/5ML**	**A074978**	**001**	Mar 25, 1998
AB		AUROBINDO PHARMA LTD	**100MG/5ML**	**A209178**	**001**	Feb 16, 2018
AB		PADAGIS US	**100MG/5ML**	**A076925**	**001**	Sep 23, 2004
AB		STRIDES PHARMA	**100MG/5ML**	**A215311**	**001**	May 27, 2022
AB		TARO	**100MG/5ML**	**A209204**	**001**	Jun 23, 2017

TABLET;ORAL

IBUPROFEN

AB		ALKEM LABS LTD	**400MG**	**A214699**	**001**	Sep 13, 2021
AB			**600MG**	**A214699**	**002**	Sep 13, 2021
AB			**800MG**	**A214699**	**003**	Sep 13, 2021
AB		AMNEAL PHARMS NY	**400MG**	**A071334**	**001**	Nov 25, 1986
AB			**400MG**	**A078558**	**001**	Jun 18, 2007
AB			**600MG**	**A071335**	**001**	Nov 25, 1986
AB			**600MG**	**A078558**	**002**	Jun 18, 2007
AB			**800MG**	**A071935**	**001**	Oct 13, 1987
AB			**800MG**	**A078558**	**003**	Jun 18, 2007
AB		AUROBINDO PHARMA LTD	**400MG**	**A213794**	**001**	May 08, 2020
AB			**600MG**	**A213794**	**002**	May 08, 2020
AB			**800MG**	**A213794**	**003**	May 08, 2020
AB		CONTRACT PHARMACAL	**400MG**	**A071268**	**002**	Oct 15, 1986
AB			**600MG**	**A071268**	**001**	Oct 15, 1986
AB			**800MG**	**A071268**	**003**	Jul 01, 1988
AB		DR REDDYS LA	**400MG**	**A075682**	**001**	Nov 14, 2001
AB			**600MG**	**A075682**	**002**	Nov 14, 2001
AB	!		**800MG**	**A075682**	**003**	Nov 14, 2001
AB		DR REDDYS LABS INC	**400MG**	**A076112**	**001**	Oct 31, 2001
AB			**600MG**	**A076112**	**002**	Oct 31, 2001
AB			**800MG**	**A076112**	**003**	Oct 31, 2001
AB		GRANULES	**400MG**	**A091625**	**001**	Sep 15, 2015
AB			**600MG**	**A091625**	**002**	Sep 15, 2015
AB			**800MG**	**A091625**	**003**	Sep 15, 2015
AB		MARKSANS PHARMA	**400MG**	**A090796**	**001**	Dec 21, 2010
AB			**600MG**	**A090796**	**002**	Dec 21, 2010
AB			**800MG**	**A090796**	**003**	Dec 21, 2010
AB		SHANDONG XINHUA	**400MG**	**A202413**	**001**	Nov 23, 2016
AB			**600MG**	**A202413**	**002**	Nov 23, 2016
AB			**800MG**	**A202413**	**003**	Nov 23, 2016
AB		STRIDES PHARMA	**400MG**	**A078329**	**001**	Feb 05, 2009
AB			**600MG**	**A078329**	**002**	Feb 05, 2009
AB			**800MG**	**A078329**	**003**	Feb 05, 2009
AB		YICHANG HUMANWELL	**400MG**	**A215318**	**001**	Mar 30, 2022
AB			**600MG**	**A215318**	**002**	Mar 30, 2022
AB			**800MG**	**A215318**	**003**	Mar 30, 2022

IBUPROFEN LYSINE

INJECTABLE;INTRAVENOUS

IBUPROFEN LYSINE

AP		XGEN PHARMS	**EQ 20MG BASE/2ML (EQ 10MG BASE/ML)**	**A202402**	**001**	Mar 30, 2016

NEOPROFEN

AP	**+!**	RECORDATI RARE	**EQ 20MG BASE/2ML (EQ 10MG BASE/ML)**	**N021903**	**001**	Apr 13, 2006

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

CORVERT

AP	**+!**	PFIZER	**0.1MG/ML**	**N020491**	**001**	Dec 28, 1995

IBUTILIDE FUMARATE

AP		MYLAN INSTITUTIONAL	**0.1MG/ML**	**A090643**	**001**	Jan 11, 2010

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

FIRAZYR

AP	**+!**	TAKEDA PHARMS USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N022150**	**001**	Aug 25, 2011

ICATIBANT ACETATE

AP		CIPLA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A212446**	**001**	Jul 13, 2020
AP		EUGIA PHARMA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A213521**	**001**	Aug 14, 2023
AP		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A208317**	**001**	Jun 18, 2020
AP		JIANGSU HANSOH PHARM	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A211021**	**001**	Mar 09, 2020
AP		NANG KUANG PHARM CO	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A212081**	**001**	Dec 16, 2020
AP		SLAYBACK PHARMA LLC	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A211501**	**001**	Sep 01, 2020
AP		TEVA PHARMS USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A210118**	**001**	Jul 15, 2019

ICODEXTRIN

SOLUTION;INTRAPERITONEAL

EXTRANEAL

	+!	BAXTER HLTHCARE	7.5GM/100ML	N021321	001	Dec 20, 2002

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

AB		APOTEX	**1GM**	**A209437**	**001**	Jun 30, 2021
AB		ASCENT PHARMS INC	**500MG**	**A216811**	**001**	Dec 07, 2023
AB		DR REDDYS	**500MG**	**A209499**	**002**	Mar 08, 2023
AB			**1GM**	**A209499**	**001**	Aug 07, 2020
AB		HIKMA	**500MG**	**A209457**	**002**	Mar 08, 2023
AB			**1GM**	**A209457**	**001**	May 21, 2020
AB		HUMANWELL PURACAP	**500MG**	**A217919**	**001**	Dec 22, 2023
AB			**1GM**	**A217919**	**002**	Dec 22, 2023
AB		STRIDES PHARMA	**500MG**	**A217844**	**001**	Sep 22, 2023
AB			**1GM**	**A217844**	**002**	Sep 22, 2023
AB		TEVA PHARMS USA	**500MG**	**A209525**	**001**	Sep 11, 2020
AB			**1GM**	**A209525**	**002**	Sep 11, 2020
AB		ZYDUS	**500MG**	**A217656**	**001**	Apr 20, 2023
AB			**1GM**	**A217656**	**002**	Apr 20, 2023

VASCEPA

AB	**+**	AMARIN PHARMS	**500MG**	**N202057**	**002**	Feb 16, 2017
AB	**+!**		**1GM**	**N202057**	**001**	Jul 26, 2012

IDARUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

IDAMYCIN PFS

AP	**+!**	PFIZER	**1MG/ML**	**N050734**	**001**	Feb 17, 1997

IDARUBICIN HYDROCHLORIDE

AP		HIKMA	**1MG/ML**	**A065275**	**001**	Dec 14, 2006
AP			**1MG/ML**	**A065288**	**001**	May 15, 2007
AP		MEITHEAL	**1MG/ML**	**A065036**	**001**	May 01, 2002

IDELALISIB

TABLET;ORAL

ZYDELIG

	+	GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014
	+!		150MG	N205858	002	Jul 23, 2014

IFOSFAMIDE

INJECTABLE;INJECTION

IFEX

AP	**+**	BAXTER HLTHCARE	**1GM/VIAL**	**N019763**	**001**	Dec 30, 1988
AP	**+**		**3GM/VIAL**	**N019763**	**002**	Dec 30, 1988

IFOSFAMIDE

AP	**!**	FRESENIUS KABI USA	**1GM/VIAL**	**A076078**	**001**	May 28, 2002
AP	**!**		**3GM/VIAL**	**A076078**	**002**	May 28, 2002
AP		HIKMA	**1GM/20ML (50MG/ML)**	**A076619**	**001**	Jun 29, 2011
AP			**3GM/60ML (50MG/ML)**	**A076619**	**002**	Jun 29, 2011
AP	**!**	MEITHEAL	**1GM/20ML (50MG/ML)**	**A076657**	**001**	Apr 04, 2007
AP	**!**		**3GM/60ML (50MG/ML)**	**A076657**	**002**	Apr 04, 2007

ILOPERIDONE

TABLET;ORAL

FANAPT

	+!	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009
	+		2MG	N022192	002	May 06, 2009
	+		4MG	N022192	003	May 06, 2009
	+		6MG	N022192	004	May 06, 2009
	+		8MG	N022192	005	May 06, 2009
	+		10MG	N022192	006	May 06, 2009
	+		12MG	N022192	007	May 06, 2009

ILOPROST

SOLUTION;INHALATION

VENTAVIS

	+!	ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005
	+!		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009

IMATINIB MESYLATE

TABLET;ORAL

GLEEVEC

AB	**+**	NOVARTIS	**EQ 100MG BASE**	**N021588**	**001**	Apr 18, 2003
AB	**+!**		**EQ 400MG BASE**	**N021588**	**002**	Apr 18, 2003

IMATINIB MESYLATE

AB		APOTEX	**EQ 100MG BASE**	**A079179**	**001**	Aug 05, 2016
AB			**EQ 400MG BASE**	**A079179**	**002**	Aug 05, 2016
AB		CHARTWELL RX	**EQ 100MG BASE**	**A208429**	**001**	Jan 17, 2019
AB			**EQ 400MG BASE**	**A208429**	**002**	Jan 17, 2019
AB		DR REDDYS	**EQ 100MG BASE**	**A206547**	**001**	Aug 13, 2018
AB			**EQ 400MG BASE**	**A206547**	**002**	Aug 13, 2018
AB		EUGIA PHARMA	**EQ 100MG BASE**	**A212773**	**001**	Jul 23, 2020
AB			**EQ 400MG BASE**	**A212773**	**002**	Jul 23, 2020
AB		MYLAN	**EQ 100MG BASE**	**A204644**	**001**	Jun 21, 2017
AB			**EQ 400MG BASE**	**A204644**	**002**	Jun 21, 2017
AB		NATCO PHARMA LTD	**EQ 100MG BASE**	**A207818**	**001**	Mar 01, 2019
AB			**EQ 400MG BASE**	**A207818**	**002**	Mar 01, 2019
AB		QILU PHARM HAINAN	**EQ 100MG BASE**	**A212135**	**001**	Jun 21, 2022
AB			**EQ 400MG BASE**	**A212135**	**002**	Jun 21, 2022
AB		SHILPA	**EQ 100MG BASE**	**A208302**	**001**	Jan 17, 2019
AB			**EQ 400MG BASE**	**A208302**	**002**	Jan 17, 2019
AB		SUN PHARM	**EQ 100MG BASE**	**A078340**	**001**	Dec 03, 2015
AB			**EQ 400MG BASE**	**A078340**	**002**	Dec 03, 2015
AB		TEVA PHARMS USA	**EQ 100MG BASE**	**A204285**	**001**	Aug 04, 2016
AB			**EQ 400MG BASE**	**A204285**	**002**	Aug 04, 2016
AB		ZYDUS PHARMS	**EQ 100MG BASE**	**A210658**	**001**	Apr 08, 2020
AB			**EQ 400MG BASE**	**A210658**	**002**	Apr 08, 2020

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

AB		LEADING	**10MG**	**A040903**	**001**	Oct 24, 2012
AB			**25MG**	**A040903**	**002**	Oct 24, 2012
AB			**50MG**	**A040903**	**003**	Oct 24, 2012
AB		OXFORD PHARMS	**10MG**	**A040751**	**003**	Feb 28, 2008
AB			**25MG**	**A040751**	**002**	Feb 28, 2008
AB			**50MG**	**A040751**	**001**	Feb 28, 2008
AB		SANDOZ	**10MG**	**A084936**	**002**	
AB			**25MG**	**A083745**	**001**	
AB			**50MG**	**A084937**	**001**	
AB	**+**	SPECGX LLC	**10MG**	**A087846**	**002**	May 22, 1984
AB	**+**		**25MG**	**A087846**	**003**	May 22, 1984
AB		STRIDES PHARMA	**10MG**	**A088292**	**001**	Oct 21, 1983
AB			**25MG**	**A088262**	**001**	Oct 21, 1983
AB			**50MG**	**A088276**	**001**	Oct 21, 1983
AB		SUN PHARM INDUSTRIES	**25MG**	**A081049**	**001**	Jun 05, 1990
AB			**50MG**	**A081050**	**001**	Jun 05, 1990

TOFRANIL

AB	**+!**	SPECGX LLC	**50MG**	**A087846**	**001**	May 22, 1984

IMIPRAMINE PAMOATE

CAPSULE;ORAL

IMIPRAMINE PAMOATE

AB	**!**	HIKMA	**EQ 75MG HYDROCHLORIDE**	**A091099**	**001**	Apr 16, 2010
AB			**EQ 100MG HYDROCHLORIDE**	**A091099**	**002**	Apr 16, 2010
AB			**EQ 125MG HYDROCHLORIDE**	**A091099**	**003**	Apr 16, 2010
AB			**EQ 150MG HYDROCHLORIDE**	**A091099**	**004**	Apr 16, 2010
AB		LUPIN LTD	**EQ 75MG HYDROCHLORIDE**	**A090444**	**001**	Apr 16, 2010
AB			**EQ 100MG HYDROCHLORIDE**	**A090444**	**002**	Apr 16, 2010
AB			**EQ 125MG HYDROCHLORIDE**	**A090444**	**003**	Apr 16, 2010
AB			**EQ 150MG HYDROCHLORIDE**	**A090444**	**004**	Apr 16, 2010

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

AB		APOTEX INC	**5%**	**A091308**	**001**	Apr 06, 2012
AB		FOUGERA PHARMS	**5%**	**A078548**	**001**	Feb 25, 2010
AB	**!**	GLENMARK GENERICS	**5%**	**A201994**	**001**	Mar 06, 2012
AB		PADAGIS ISRAEL	**5%**	**A078837**	**001**	Sep 07, 2010
AB		TARO	**3.75%**	**A205971**	**001**	Jan 26, 2021
AB			**5%**	**A200173**	**001**	Apr 15, 2011

ZYCLARA

AB	**+!**	BAUSCH	**3.75%**	**N022483**	**001**	Mar 25, 2010
	+!		2.5%	N022483	002	Jul 15, 2011

INAMRINONE LACTATE

INJECTABLE;INJECTION

AMRINONE LACTATE

	!	HIKMA	EQ 5MG BASE/ML	A075513	001	May 09, 2000

INCLISIRAN SODIUM

SOLUTION;SUBCUTANEOUS

LEQVIO

	+!	NOVARTIS	EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)	N214012	001	Dec 22, 2021

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

AB		ACTAVIS ELIZABETH	**1.25MG**	**A074722**	**001**	Jun 17, 1996
AB			**2.5MG**	**A074722**	**002**	Jun 17, 1996
AB		ANI PHARMS	**1.25MG**	**A074299**	**002**	Apr 29, 1996
AB	**!**		**2.5MG**	**A074299**	**001**	Jul 27, 1995
AB		RISING	**1.25MG**	**A074461**	**002**	Mar 26, 1997
AB			**2.5MG**	**A074461**	**001**	Mar 27, 1996

INDIGOTINDISULFONATE SODIUM

SOLUTION;INTRAVENOUS

BLUDIGO

	+!	PROVEPHARM SAS	40MG/5ML (8MG/ML)	N216264	001	Jul 08, 2022

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION

INDIUM IN 111 CHLORIDE

	+!	CURIUM	5mCi/0.5ML	N019841	001	Sep 27, 1994

INDIUM IN-111 OXYQUINOLINE

INJECTABLE;INJECTION

INDIUM IN 111 OXYQUINOLINE

AP		BWXT ITG	**1mCi/ML**	**A202586**	**001**	Jul 25, 2018
AP	**+!**	GE HEALTHCARE	**1mCi/ML**	**N019044**	**001**	Dec 24, 1985

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE;INTRATHECAL

MPI INDIUM DTPA IN 111

	+!	GE HEALTHCARE	1mCi/ML	N017707	001	Feb 18, 1982

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION

OCTREOSCAN

	+!	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994

INDOCYANINE GREEN						
INJECTABLE;INJECTION						
INDOCYANINE GREEN						
	!	RENEW PHARMS	25MG/VIAL	A040811	001	Nov 21, 2007
POWDER;INTRAVENOUS, INTERSTITIAL						
SPY AGENT GREEN KIT						
	+!	NOVADAQ TECH	25MG/VIAL	N211580	001	Nov 21, 2018
INDOMETHACIN						
CAPSULE;ORAL						
INDOMETHACIN						
AB		CADILA	**25MG**	**A090403**	**001**	Nov 15, 2010
AB			**50MG**	**A090403**	**002**	Nov 15, 2010
AB		CHARTWELL MOLECULES	**25MG**	**N018829**	**002**	Aug 06, 1984
AB			**50MG**	**A070651**	**001**	Mar 05, 1986
AB			**50MG**	**N018829**	**001**	Aug 06, 1984
AB		GLENMARK GENERICS	**25MG**	**A091276**	**001**	Dec 22, 2010
AB	**!**		**50MG**	**A091276**	**002**	Dec 22, 2010
AB		HETERO LABS LTD III	**25MG**	**A091240**	**001**	Apr 12, 2011
AB			**50MG**	**A091240**	**002**	Apr 12, 2011
AB		SANDOZ	**25MG**	**A070673**	**001**	Apr 29, 1987
AB			**50MG**	**A070674**	**001**	Apr 29, 1987
CAPSULE, EXTENDED RELEASE;ORAL						
INDOMETHACIN						
AB		AMNEAL PHARMS	**75MG**	**A091549**	**001**	Dec 01, 2010
AB		AVANTHI INC	**75MG**	**A079175**	**001**	Mar 06, 2009
AB		CHARTWELL RX	**75MG**	**A200529**	**001**	Nov 30, 2010
AB		GLENMARK PHARMS LTD	**75MG**	**A203501**	**001**	Jun 22, 2017
AB	**!**	HETERO LABS LTD III	**75MG**	**A201807**	**001**	Sep 28, 2012
AB		NOVAST LABS	**75MG**	**A204853**	**001**	May 08, 2017
AB		ZYDUS PHARMS	**75MG**	**A202711**	**001**	Sep 25, 2017
INJECTABLE;INJECTION						
INDOMETHACIN						
	+!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N022536	001	Mar 17, 2010
SUPPOSITORY;RECTAL						
INDOMETHACIN						
AB	**!**	COSETTE	**50MG**	**A073314**	**001**	Aug 31, 1992
AB		ZYDUS	**50MG**	**A216184**	**001**	Aug 02, 2023
SUSPENSION;ORAL						
INDOCIN						
	+!	ZYLA	25MG/5ML	N018332	001	Oct 10, 1985
INDOMETHACIN SODIUM						
INJECTABLE;INJECTION						
INDOMETHACIN SODIUM						
AP		HOSPIRA	**EQ 1MG BASE/VIAL**	**A204118**	**001**	Apr 19, 2016
AP	**!**	NAVINTA LLC	**EQ 1MG BASE/VIAL**	**A206561**	**001**	Jul 19, 2017
AP		WEST-WARD PHARMS INT	**EQ 1MG BASE/VIAL**	**A078713**	**001**	Jul 16, 2008
INOTERSEN SODIUM						
SOLUTION;SUBCUTANEOUS						
TEGSEDI						
	+!	AKCEA THERAPS	EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML)	N211172	001	Oct 05, 2018
IOBENGUANE I-131						
SOLUTION;INTRAVENOUS						
AZEDRA						
	+!	PROGENICS PHARMS INC	15mCi/ML	N209607	001	Jul 30, 2018
IOBENGUANE SULFATE I-123						
SOLUTION;INTRAVENOUS						
ADREVIEW						
	+!	GE HEALTHCARE	10mCi/5ML (2mCi/ML)	N022290	001	Sep 19, 2008
IODIXANOL						
INJECTABLE;INJECTION						
IODIXANOL						
AP		HENGRUI PHARMA	**55%**	**A214271**	**001**	May 19, 2022
AP			**65.2%**	**A214271**	**002**	May 19, 2022
VISIPAQUE 270						
AP	**+!**	GE HEALTHCARE	**55%**	**N020351**	**001**	Mar 22, 1996

IODIXANOL

INJECTABLE;INJECTION

VISIPAQUE 320

AP	**+!**	GE HEALTHCARE	**65.2%**	**N020351**	**002**	Mar 22, 1996
			65.2%	N020808	002	Aug 29, 1997

IOFLUPANE I-123

SOLUTION;INTRAVENOUS

DATSCAN

AP	**+!**	GE HLTHCARE INC	**5mCi/2.5ML (2mCi/ML)**	**N022454**	**001**	Jan 14, 2011

IOFLUPANE I-123

AP		CURIUM	**5mCi/2.5ML (2mCi/ML)**	**A213792**	**001**	Mar 30, 2022

IOHEXOL

INJECTABLE;INJECTION

OMNIPAQUE 140

	+!	GE HEALTHCARE	30.2%	N018956	005	Nov 30, 1988

SOLUTION;INJECTION, ORAL

OMNIPAQUE 350

	+!	GE HEALTHCARE	75.5%	N018956	004	Dec 26, 1985
			75.5%	N020608	003	Oct 24, 1995

SOLUTION;INJECTION, ORAL, RECTAL

OMNIPAQUE 180

	+!	GE HEALTHCARE	38.8%	N018956	001	Dec 26, 1985

OMNIPAQUE 240

	+!	GE HEALTHCARE	51.8%	N018956	002	Dec 26, 1985

OMNIPAQUE 300

	+!	GE HEALTHCARE	64.7%	N018956	003	Dec 26, 1985
			64.7%	N020608	002	Oct 24, 1995

SOLUTION;ORAL

OMNIPAQUE 12

	+!	GE HEALTHCARE	2.6%	N018956	009	Apr 17, 2018

OMNIPAQUE 9

	+!	GE HEALTHCARE	1.9%	N018956	008	Apr 17, 2018

IOPAMIDOL

INJECTABLE;INJECTION

IOPAMIDOL

AP		HAINAN POLY	**61%**	**A215382**	**002**	Feb 27, 2023

ISOVUE-M 300

AP	**+!**	BRACCO	**61%**	**N018735**	**004**	Dec 31, 1985

IOPAMIDOL

AP1		HAINAN POLY	**41%**	**A215382**	**001**	Feb 27, 2023

ISOVUE-M 200

AP1	**+!**	BRACCO	**41%**	**N018735**	**001**	Dec 31, 1985

IOPAMIDOL

AP2		HAINAN POLY	**41%**	**A217134**	**001**	Sep 27, 2023

ISOVUE-200

AP2	**+!**	BRACCO	**41%**	**N018735**	**006**	Jul 07, 1987

ISOVUE-250

	+!	BRACCO	51%	N018735	007	Jul 06, 1992

ISOVUE-300

	+!	BRACCO	61%	N018735	002	Dec 31, 1985
	+!		61%	N020327	003	Oct 12, 1994

ISOVUE-370

	+!	BRACCO	76%	N018735	003	Dec 31, 1985
	+!		76%	N020327	004	Oct 12, 1994

IOPROMIDE

INJECTABLE;INJECTION

ULTRAVIST (PHARMACY BULK)

	+!	BAYER HLTHCARE	62.3%	N021425	001	Sep 20, 2002
	+!		76.9%	N021425	002	Sep 20, 2002

ULTRAVIST 300

	+!	BAYER HLTHCARE	62.3%	N020220	002	May 10, 1995

ULTRAVIST 370

	+!	BAYER HLTHCARE	76.9%	N020220	001	May 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION

CONRAY

	+!	LIEBEL-FLARSHEIM	60%	N013295	001	

IOTHALAMATE MEGLUMINE							
SOLUTION;INTRAVESICAL							
CYSTO-CONRAY II							
		LIEBEL-FLARSHEIM	17.2%		N017057	002	
IOTHALAMATE SODIUM I-125							
INJECTABLE;INJECTION							
GLOFIL-125							
		ISOTEX	250-300uCi/ML		N017279	001	
IOVERSOL							
INJECTABLE;INJECTION							
OPTIRAY 300							
	+!	LIEBEL-FLARSHEIM	64%		N019710	004	Jan 22, 1992
	+!		64%		N020923	004	May 13, 1999
OPTIRAY 320							
	+!	LIEBEL-FLARSHEIM	68%		N019710	001	Dec 30, 1988
	+!		68%		N020923	002	May 29, 1998
OPTIRAY 350							
	+!	LIEBEL-FLARSHEIM	74%		N019710	005	Jan 22, 1992
	+!		74%		N020923	003	May 28, 1998
IPRATROPIUM BROMIDE							
AEROSOL, METERED;INHALATION							
ATROVENT HFA							
	+!	BOEHRINGER INGELHEIM	0.021MG/INH		N021527	001	Nov 27, 2004
SOLUTION;INHALATION							
IPRATROPIUM BROMIDE							
AN		LUOXIN AUROVITAS	**0.02%**		**A206543**	**001**	Oct 27, 2016
AN		NEPHRON	**0.02%**		**A075562**	**001**	Sep 27, 2001
AN	**!**	RITEDOSE CORP	**0.02%**		**A075693**	**001**	Jan 26, 2001
AN		SUN PHARM	**0.02%**		**A207903**	**001**	Jan 03, 2017
SPRAY, METERED;NASAL							
IPRATROPIUM BROMIDE							
AB		AMNEAL	**0.021MG/SPRAY**		**A215104**	**001**	Aug 16, 2022
AB			**0.042MG/SPRAY**		**A215105**	**001**	Aug 16, 2022
AB		APOTEX INC	**0.021MG/SPRAY**		**A076156**	**001**	Apr 18, 2003
AB			**0.042MG/SPRAY**		**A076155**	**001**	Apr 18, 2003
AB		BAUSCH	**0.021MG/SPRAY**		**A076025**	**001**	Mar 31, 2003
AB			**0.042MG/SPRAY**		**A076103**	**001**	Mar 31, 2003
AB	**!**	HIKMA	**0.021MG/SPRAY**		**A076664**	**001**	Nov 05, 2003
AB	**!**		**0.042MG/SPRAY**		**A076598**	**001**	Nov 05, 2003
IPTACOPAN HYDROCHLORIDE							
CAPSULE;ORAL							
FABHALTA							
	+!	NOVARTIS	EQ 200MG BASE		N218276	001	Dec 05, 2023
IRBESARTAN							
TABLET;ORAL							
AVAPRO							
AB	**+**	SANOFI AVENTIS US	**75MG**		**N020757**	**001**	Sep 30, 1997
AB	**+**		**150MG**		**N020757**	**002**	Sep 30, 1997
AB	**+!**		**300MG**		**N020757**	**003**	Sep 30, 1997
IRBESARTAN							
AB		ALEMBIC PHARMS LTD	**75MG**		**A091236**	**001**	Oct 15, 2012
AB			**150MG**		**A091236**	**002**	Oct 15, 2012
AB			**300MG**		**A091236**	**003**	Oct 15, 2012
AB		AMNEAL PHARMS	**75MG**		**A204740**	**001**	Apr 17, 2018
AB			**150MG**		**A204740**	**002**	Apr 17, 2018
AB			**300MG**		**A204740**	**003**	Apr 17, 2018
AB		AUROBINDO PHARMA LTD	**75MG**		**A203081**	**001**	Sep 27, 2012
AB			**150MG**		**A203081**	**002**	Sep 27, 2012
AB			**300MG**		**A203081**	**003**	Sep 27, 2012
AB		CHARTWELL MOLECULAR	**75MG**		**A077205**	**001**	Nov 14, 2012
AB			**150MG**		**A077205**	**002**	Nov 14, 2012
AB			**300MG**		**A077205**	**003**	Nov 14, 2012
AB		HETERO LABS LTD V	**75MG**		**A202910**	**001**	Sep 27, 2012
AB			**150MG**		**A202910**	**002**	Sep 27, 2012
AB			**300MG**		**A202910**	**003**	Sep 27, 2012
AB		HISUN PHARM HANGZHOU	**75MG**		**A206194**	**001**	Jun 14, 2016
AB			**150MG**		**A206194**	**002**	Jun 14, 2016

IRBESARTAN

TABLET;ORAL

IRBESARTAN

AB		**300MG**	**A206194**	**003**	Jun 14, 2016
AB	JUBILANT GENERICS	**75MG**	**A203534**	**001**	Feb 23, 2015
AB		**150MG**	**A203534**	**002**	Feb 23, 2015
AB		**300MG**	**A203534**	**003**	Feb 23, 2015
AB	LUPIN LTD	**75MG**	**A201531**	**001**	Oct 15, 2012
AB		**150MG**	**A201531**	**002**	Oct 15, 2012
AB		**300MG**	**A201531**	**003**	Oct 15, 2012
AB	MACLEODS PHARMS LTD	**75MG**	**A202254**	**001**	Oct 03, 2012
AB		**150MG**	**A202254**	**002**	Oct 03, 2012
AB		**300MG**	**A202254**	**003**	Oct 03, 2012
AB	PRINSTON INC	**75MG**	**A203071**	**001**	Sep 27, 2012
AB		**150MG**	**A203071**	**002**	Sep 27, 2012
AB		**300MG**	**A203071**	**003**	Sep 27, 2012
AB	SANDOZ	**75MG**	**A077466**	**001**	Sep 27, 2012
AB		**150MG**	**A077466**	**002**	Sep 27, 2012
AB		**300MG**	**A077466**	**003**	Sep 27, 2012
AB	SCIEGEN PHARMS INC	**75MG**	**A204774**	**001**	Dec 07, 2015
AB		**150MG**	**A204774**	**002**	Dec 07, 2015
AB		**300MG**	**A204774**	**003**	Dec 07, 2015
AB	TEVA PHARMS	**75MG**	**A077159**	**001**	Mar 30, 2012
AB		**150MG**	**A077159**	**002**	Mar 30, 2012
AB		**300MG**	**A077159**	**003**	Mar 30, 2012
AB	UNICHEM	**75MG**	**A203020**	**001**	Dec 07, 2015
AB		**150MG**	**A203020**	**002**	Dec 07, 2015
AB		**300MG**	**A203020**	**003**	Dec 07, 2015
AB	ZYDUS PHARMS USA INC	**75MG**	**A079213**	**001**	Sep 27, 2012
AB		**150MG**	**A079213**	**002**	Sep 27, 2012
AB		**300MG**	**A079213**	**003**	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

CAMPTOSAR

AP	**+!**	PFIZER INC	**40MG/2ML (20MG/ML)**	**N020571**	**001**	Jun 14, 1996
AP	**+!**		**100MG/5ML (20MG/ML)**	**N020571**	**002**	Jun 14, 1996
AP	**+!**		**300MG/15ML (20MG/ML)**	**N020571**	**003**	Aug 05, 2010

IRINOTECAN HYDROCHLORIDE

AP		ACCORD HLTHCARE	**40MG/2ML (20MG/ML)**	**A079068**	**001**	Nov 21, 2008
AP			**100MG/5ML (20MG/ML)**	**A079068**	**002**	Nov 21, 2008
AP		ACTAVIS TOTOWA	**40MG/2ML (20MG/ML)**	**A078589**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A078589**	**002**	Feb 27, 2008
AP			**500MG/25ML (20MG/ML)**	**A078589**	**003**	Nov 18, 2015
AP		AKORN	**40MG/2ML (20MG/ML)**	**A090726**	**001**	Sep 16, 2009
AP			**100MG/5ML (20MG/ML)**	**A090726**	**002**	Sep 16, 2009
AP		EUGIA PHARMA	**40MG/2ML (20MG/ML)**	**A213278**	**001**	Nov 02, 2020
AP			**100MG/5ML (20MG/ML)**	**A213278**	**002**	Nov 02, 2020
AP			**300MG/15ML (20MG/ML)**	**A213278**	**003**	Nov 02, 2020
AP			**500MG/25ML (20MG/ML)**	**A213278**	**004**	Apr 11, 2022
AP		FRESENIUS KABI USA	**40MG/2ML (20MG/ML)**	**A077776**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A077776**	**002**	Feb 27, 2008
AP		GLAND PHARMA LTD	**40MG/2ML (20MG/ML)**	**A212993**	**001**	Nov 18, 2019
AP			**100MG/5ML (20MG/ML)**	**A212993**	**002**	Nov 18, 2019
AP		HENGRUI PHARMA	**40MG/2ML (20MG/ML)**	**A090675**	**002**	Dec 16, 2011
AP			**100MG/5ML (20MG/ML)**	**A090675**	**001**	Dec 16, 2011
AP		HIKMA FARMACEUTICA	**40MG/2ML (20MG/ML)**	**A091032**	**001**	Dec 20, 2010
AP			**100MG/5ML (20MG/ML)**	**A091032**	**002**	Dec 20, 2010
AP		HISUN PHARM HANGZHOU	**40MG/2ML (20MG/ML)**	**A090016**	**001**	Jan 28, 2009
AP			**100MG/5ML (20MG/ML)**	**A090016**	**002**	Jan 28, 2009
AP		HOSPIRA	**40MG/2ML (20MG/ML)**	**A077915**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A077915**	**002**	Feb 27, 2008
AP	**!**		**500MG/25ML (20MG/ML)**	**A078796**	**001**	Feb 27, 2008
AP		INTAS PHARMS USA	**40MG/2ML (20MG/ML)**	**A203054**	**001**	Aug 31, 2017
AP			**100MG/5ML (20MG/ML)**	**A203054**	**002**	Aug 31, 2017
AP		NOVAST LABS	**40MG/2ML (20MG/ML)**	**A206935**	**001**	May 26, 2017
AP			**100MG/5ML (20MG/ML)**	**A206935**	**002**	May 26, 2017
AP		QILU PHARM HAINAN	**40MG/2ML (20MG/ML)**	**A203380**	**001**	May 03, 2016
AP			**100MG/5ML (20MG/ML)**	**A203380**	**002**	May 03, 2016
AP			**300MG/15ML (20MG/ML)**	**A203380**	**003**	May 03, 2016
AP		SHILPA	**40MG/2ML (20MG/ML)**	**A208718**	**001**	Dec 28, 2018

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

IRINOTECAN HYDROCHLORIDE

AP			**100MG/5ML (20MG/ML)**	**A208718**	**002**	Dec 28, 2018
AP			**300MG/15ML (20MG/ML)**	**A208718**	**003**	Aug 16, 2019
AP		TEVA PHARMS USA	**500MG/25ML (20MG/ML)**	**A090101**	**001**	Nov 26, 2008
AP		WEST-WARD PHARMS INT	**40MG/2ML (20MG/ML)**	**A078753**	**001**	Dec 24, 2008
AP			**100MG/5ML (20MG/ML)**	**A078753**	**002**	Dec 24, 2008
AP		ZENNOVA	**40MG/2ML (20MG/ML)**	**A090393**	**002**	May 13, 2011
AP			**100MG/5ML (20MG/ML)**	**A090393**	**003**	May 13, 2011

INJECTABLE, LIPOSOMAL;INTRAVENOUS

ONIVYDE

	+!	IPSEN	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015

ISAVUCONAZONIUM SULFATE

CAPSULE;ORAL

CRESEMBA

	+	ASTELLAS	74.5MG	N207500	002	Nov 22, 2022
	+!		186MG	N207500	001	Mar 06, 2015

POWDER;INTRAVENOUS

CRESEMBA

	+!	ASTELLAS	372MG	N207501	001	Mar 06, 2015

ISOCARBOXAZID

TABLET;ORAL

MARPLAN

	+!	VALIDUS PHARMS INC	10MG	N011961	001	

ISOFLURANE

LIQUID;INHALATION

FORANE

AN	**+!**	BAXTER HLTHCARE	**99.9%**	**N017624**	**001**	

ISOFLURANE

AN		HALOCARBON PRODS	**99.9%**	**A075225**	**001**	Oct 20, 1999
AN		PIRAMAL CRITICAL	**99.9%**	**A074416**	**001**	Sep 30, 1994
AN		PIRAMAL PHARMA	**99.9%**	**A074502**	**001**	Jun 27, 1995

ISONIAZID

INJECTABLE;INJECTION

ISONIAZID

	!	SANDOZ	100MG/ML	A040648	001	Jul 05, 2005

SYRUP;ORAL

ISONIAZID

	+!	CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983

TABLET;ORAL

ISONIAZID

AA	**!**	BARR	**100MG**	**A080936**	**001**	
AA	**!**		**300MG**	**A080937**	**002**	
AA		OMNIVIUM PHARMS	**100MG**	**A040090**	**001**	Jun 26, 1997
AA			**300MG**	**A040090**	**002**	Jun 26, 1997
AA		THEPHARMANETWORK LLC	**100MG**	**A202610**	**001**	Oct 29, 2014
AA			**300MG**	**A202610**	**002**	Oct 29, 2014

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE;INJECTION

ISOPROTERENOL HYDROCHLORIDE

AP		AMNEAL	**0.2MG/ML**	**A210576**	**001**	Oct 17, 2018
AP		AMPHASTAR PHARMS INC	**0.2MG/ML**	**A210106**	**001**	Jun 18, 2018
AP		AMRING PHARMS	**0.2MG/ML**	**A211237**	**001**	May 19, 2021
AP		AVET LIFESCIENCES	**0.2MG/ML**	**A212189**	**001**	Nov 19, 2021
AP		CIPLA	**0.2MG/ML**	**A210322**	**001**	Jun 12, 2018
AP		EUGIA PHARMA	**0.2MG/ML**	**A211864**	**001**	Feb 09, 2021
AP		HIKMA	**0.2MG/ML**	**A211703**	**001**	Apr 26, 2023
AP		MICRO LABS	**0.2MG/ML**	**A210845**	**001**	Feb 16, 2021
AP	**!**	NEXUS	**0.2MG/ML**	**A206961**	**001**	Aug 02, 2017
AP		PENN LIFE	**0.2MG/ML**	**A215542**	**001**	Sep 20, 2022

ISOSORBIDE DINITRATE

TABLET;ORAL

ISORDIL

AB	+	BAUSCH	5MG	N012093	007	Jul 29, 1988
AB	+!		40MG	N012093	001	Jul 29, 1988

ISOSORBIDE DINITRATE

AB		HIKMA INTL PHARMS	5MG	A086067	001	Oct 29, 1987
AB			10MG	A086066	001	Oct 29, 1987
AB			20MG	A088088	001	Nov 02, 1987
AB		PAR PHARM	5MG	A086923	001	Mar 12, 1987
AB			10MG	A086925	001	Mar 12, 1987
AB			20MG	A087537	001	Oct 02, 1987
AB	!		30MG	A087946	001	Jan 12, 1988
AB		PAR PHARM INC	40MG	A211290	001	Nov 23, 2021
AB		RUBICON	5MG	A215723	001	Jul 08, 2022
AB			10MG	A215723	002	Jul 08, 2022
AB			20MG	A215723	003	Jul 08, 2022
AB			30MG	A215723	004	Jul 08, 2022
AB			40MG	A215723	005	Jul 08, 2022
AB		SANDOZ	5MG	A086221	001	Jan 07, 1988
AB			10MG	A086223	001	Jan 07, 1988
AB			20MG	A089367	001	Apr 07, 1988
AB		ZYDUS	5MG	A213057	001	Nov 20, 2019
AB			10MG	A213057	002	Nov 20, 2019
AB			20MG	A213057	003	Nov 20, 2019
AB			30MG	A213057	004	Nov 20, 2019
AB			40MG	A213057	005	Nov 20, 2019

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISOSORBIDE MONONITRATE

AB		ACTAVIS ELIZABETH	10MG	A075037	002	Oct 30, 1998
AB			20MG	A075037	001	Oct 30, 1998

MONOKET

AB	+	GENUS LIFESCIENCES	10MG	N020215	002	Jun 30, 1993
AB	+!		20MG	N020215	001	Jun 30, 1993

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

AB		AUROBINDO PHARMA	30MG	A216557	001	Nov 07, 2022
AB			60MG	A216557	002	Nov 07, 2022
AB			120MG	A216557	003	Nov 07, 2022
AB		CHARTWELL MOLECULAR	30MG	A075155	002	Jan 13, 2000
AB			60MG	A075155	001	Oct 30, 1998
AB	!		120MG	A075155	003	Aug 04, 2000
AB		DEXCEL LTD	30MG	A075522	002	Sep 20, 2016
AB			60MG	A075522	001	Apr 17, 2000
AB			120MG	A210822	001	Aug 29, 2018
AB		RICONPHARMA LLC	30MG	A210918	001	Nov 05, 2018
AB			60MG	A210918	002	Nov 05, 2018
AB			120MG	A210918	003	Nov 05, 2018
AB		TORRENT PHARMS	30MG	A200270	001	Jun 03, 2011
AB			60MG	A200495	001	Jun 03, 2011
AB			120MG	A200495	002	Jun 03, 2011
AB		ZYDUS HLTHCARE	30MG	A075395	001	Mar 16, 2000
AB			60MG	A075395	002	Mar 16, 2000
AB			120MG	A075395	003	Mar 16, 2000

ISOSULFAN BLUE

INJECTABLE;INJECTION

ISOSULFAN BLUE

AP		AM REGENT	1%	A210294	001	May 17, 2023
AP		MEITHEAL	1%	A213130	001	Nov 03, 2021
AP		MSN	1%	A216090	001	Sep 16, 2022
AP	!	MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010

ISOTRETINOIN

CAPSULE;ORAL

AMNESTEEM

AB1		MYLAN PHARMS INC	10MG	A075945	001	Nov 08, 2002
AB1			20MG	A075945	002	Nov 08, 2002
AB1			40MG	A075945	003	Nov 08, 2002

CLARAVIS

AB1		TEVA PHARMS USA	10MG	A076356	001	Apr 11, 2003
AB1			20MG	A076135	002	Apr 11, 2003

ISOTRETINOIN

CAPSULE;ORAL

CLARAVIS

AB1			**30MG**	**A076135**	**003**	May 11, 2006
AB1	**!**		**40MG**	**A076135**	**001**	Apr 11, 2003

ISOTRETINOIN

AB1		AMNEAL PHARMS NY	**10MG**	**A207792**	**001**	Sep 29, 2017
AB1			**20MG**	**A207792**	**002**	Sep 29, 2017
AB1			**30MG**	**A207792**	**003**	Sep 29, 2017
AB1			**40MG**	**A207792**	**004**	Sep 29, 2017
AB1		ZYDUS PHARMS	**10MG**	**A211568**	**001**	Aug 29, 2023
AB1			**20MG**	**A211568**	**002**	Aug 29, 2023
AB1			**30MG**	**A211568**	**003**	Aug 29, 2023
AB1			**40MG**	**A211568**	**004**	Aug 29, 2023

MYORISAN

AB1		UPSHER SMITH LABS	**10MG**	**A076485**	**001**	Jan 19, 2012
AB1			**20MG**	**A076485**	**002**	Jan 19, 2012
AB1			**30MG**	**A076485**	**004**	Aug 25, 2015
AB1			**40MG**	**A076485**	**003**	Jan 19, 2012

ZENATANE

AB1		DR REDDYS LABS LTD	**10MG**	**A202099**	**001**	Mar 25, 2013
AB1			**20MG**	**A202099**	**002**	Mar 25, 2013
AB1			**30MG**	**A202099**	**004**	Feb 23, 2015
AB1			**40MG**	**A202099**	**003**	Mar 25, 2013

ABSORICA

AB2	**+**	SUN PHARM INDS INC	**10MG**	**N021951**	**001**	May 25, 2012
AB2	**+**		**20MG**	**N021951**	**002**	May 25, 2012
AB2	**+**		**25MG**	**N021951**	**005**	Aug 15, 2014
AB2	**+**		**30MG**	**N021951**	**003**	May 25, 2012
AB2	**+**		**35MG**	**N021951**	**006**	Aug 15, 2014
AB2	**+!**		**40MG**	**N021951**	**004**	May 25, 2012

ISOTRETINOIN

AB2		ACTAVIS LABS FL	**10MG**	**A205063**	**001**	Mar 31, 2021
AB2			**20MG**	**A205063**	**002**	Mar 31, 2021
AB2			**25MG**	**A205063**	**003**	Mar 31, 2021
AB2			**30MG**	**A205063**	**004**	Mar 31, 2021
AB2			**35MG**	**A205063**	**005**	Mar 31, 2021
AB2			**40MG**	**A205063**	**006**	Mar 31, 2021
AB2		UPSHER SMITH LABS	**10MG**	**A212333**	**001**	Sep 21, 2021
AB2			**20MG**	**A212333**	**002**	Sep 21, 2021
AB2			**30MG**	**A212333**	**003**	Sep 21, 2021
AB2			**40MG**	**A213571**	**001**	Apr 12, 2021

ABSORICA LD

	+	SUN PHARM	8MG	N211913	001	Nov 05, 2019
	+		16MG	N211913	002	Nov 05, 2019
	+		24MG	N211913	004	Nov 05, 2019
	+!		32MG	N211913	006	Nov 05, 2019

ISRADIPINE

CAPSULE;ORAL

ISRADIPINE

AB		ELITE LABS INC	**2.5MG**	**A077169**	**001**	Apr 24, 2006
AB			**5MG**	**A077169**	**002**	Apr 24, 2006
AB		WATSON LABS TEVA	**2.5MG**	**A077317**	**001**	Jan 05, 2006
AB	**!**		**5MG**	**A077317**	**002**	Jan 05, 2006

ISTRADEFYLLINE

TABLET;ORAL

NOURIANZ

	+	KYOWA KIRIN	20MG	N022075	001	Aug 27, 2019
	+!		40MG	N022075	002	Aug 27, 2019

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE

AB		ACCORD HLTHCARE	**100MG**	**A205991**	**001**	May 26, 2016
AB		ALEMBIC	**100MG**	**A206741**	**001**	Dec 13, 2016
AB		ALKEM LABS LTD	**100MG**	**A208591**	**001**	Jun 12, 2017
AB		AMNEAL PHARMS	**100MG**	**A205080**	**001**	Sep 26, 2016
AB		SANDOZ	**100MG**	**A076104**	**001**	May 28, 2004
AB		TORRENT	**100MG**	**A209460**	**001**	Aug 24, 2018
AB		ZYDUS PHARMS	**100MG**	**A204672**	**001**	Sep 19, 2017

ITRACONAZOLE						
CAPSULE;ORAL						
SPORANOX						
AB	**+!**	JANSSEN PHARMS	**100MG**	**N020083**	**001**	Sep 11, 1992
TOLSURA						
	+!	MAYNE PHARMA	65MG	N208901	001	Dec 11, 2018
SOLUTION;ORAL						
ITRACONAZOLE						
AA		AMNEAL PHARMS	**10MG/ML**	**A205573**	**001**	Oct 30, 2015
AA		ANNORA PHARMA	**10MG/ML**	**A212239**	**001**	Sep 01, 2020
SPORANOX						
AA	**+!**	JANSSEN PHARMS	**10MG/ML**	**N020657**	**001**	Feb 21, 1997
IVABRADINE						
SOLUTION;ORAL						
CORLANOR						
	+!	AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019
IVABRADINE HYDROCHLORIDE						
TABLET;ORAL						
CORLANOR						
AB	**+**	AMGEN INC	**EQ 5MG BASE**	**N206143**	**001**	Apr 15, 2015
AB	**+!**		**EQ 7.5MG BASE**	**N206143**	**002**	Apr 15, 2015
IVABRADINE HYDROCHLORIDE						
AB		ANNORA PHARMA	**EQ 5MG BASE**	**A213366**	**001**	Oct 05, 2022
AB			**EQ 7.5MG BASE**	**A213366**	**002**	Oct 05, 2022
AB		ZYDUS PHARMS	**EQ 5MG BASE**	**A213442**	**001**	Nov 29, 2023
AB			**EQ 7.5MG BASE**	**A213442**	**002**	Nov 29, 2023
IVACAFTOR						
GRANULE;ORAL						
KALYDECO						
	+	VERTEX PHARMS INC	5.8MG/PACKET	N207925	004	May 03, 2023
	+		13.4MG/PACKET	N207925	005	May 03, 2023
	+		25MG/PACKET	N207925	003	Apr 29, 2019
	+		50MG/PACKET	N207925	001	Mar 17, 2015
	+!		75MG/PACKET	N207925	002	Mar 17, 2015
TABLET;ORAL						
KALYDECO						
	+!	VERTEX PHARMS	150MG	N203188	001	Jan 31, 2012
IVACAFTOR; IVACAFTOR, TEZACAFTOR						
TABLET;ORAL						
SYMDEKO (COPACKAGED)						
	+	VERTEX PHARMS INC	75MG;75MG, 50MG	N210491	002	Jun 21, 2019
	+!		150MG;150MG, 100MG	N210491	001	Feb 12, 2018
IVACAFTOR; LUMACAFTOR						
GRANULE;ORAL						
ORKAMBI						
	+	VERTEX PHARMS INC	94MG/PACKET;75MG/PACKET	N211358	003	Sep 02, 2022
	+		125MG/PACKET;100MG/PACKET	N211358	001	Aug 07, 2018
	+!		188MG/PACKET;150MG/PACKET	N211358	002	Aug 07, 2018
TABLET;ORAL						
ORKAMBI						
	+	VERTEX PHARMS INC	125MG;100MG	N206038	002	Sep 28, 2016
	+!		125MG;200MG	N206038	001	Jul 02, 2015
IVERMECTIN						
CREAM;TOPICAL						
IVERMECTIN						
AB		PADAGIS ISRAEL	**1%**	**A210225**	**001**	Apr 13, 2020
AB		TEVA PHARMS USA	**1%**	**A210019**	**001**	Sep 13, 2019
AB		ZYDUS	**1%**	**A215210**	**001**	Aug 02, 2022
SOOLANTRA						
AB	**+!**	GALDERMA LABS LP	**1%**	**N206255**	**001**	Dec 19, 2014
TABLET;ORAL						
IVERMECTIN						
AB		EDENBRIDGE PHARMS	**3MG**	**A204154**	**001**	Oct 24, 2014
STROMECTOL						
AB	**+!**	MERCK SHARP DOHME	**3MG**	**N050742**	**002**	Oct 08, 1998

IVOSIDENIB							
TABLET;ORAL							
TIBSOVO							
	+!	SERVIER	250MG	N211192	001	Jul 20, 2018
IXABEPILONE							
INJECTABLE;INTRAVENOUS							
IXEMPRA KIT							
	+!	R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007
	+!		45MG/VIAL	N022065	002	Oct 16, 2007
IXAZOMIB CITRATE							
CAPSULE;ORAL							
NINLARO							
	+	TAKEDA PHARMS USA	EQ 2.3MG BASE	N208462	001	Nov 20, 2015
	+		EQ 3MG BASE	N208462	002	Nov 20, 2015
	+!		EQ 4MG BASE	N208462	003	Nov 20, 2015
KETAMINE HYDROCHLORIDE							
INJECTABLE;INJECTION							
KETALAR							
AP	**+!**	PAR STERILE PRODUCTS	**EQ 10MG BASE/ML**	**N016812**	**001**	
AP	**+!**		**EQ 50MG BASE/ML**	**N016812**	**002**	
AP	**+!**		**EQ 100MG BASE/ML**	**N016812**	**003**	
KETAMINE HYDROCHLORIDE							
AP		EUGIA PHARMA	**EQ 10MG BASE/ML**	**A076092**	**001**	Sep 30, 2008
AP			**EQ 50MG BASE/ML**	**A076092**	**002**	Dec 28, 2001
AP			**EQ 100MG BASE/ML**	**A076092**	**003**	Oct 25, 2002
AP		GLAND PHARMA LTD	**EQ 10MG BASE/ML**	**A216809**	**001**	Jan 24, 2023
AP			**EQ 50MG BASE/ML**	**A216809**	**002**	Jan 24, 2023
AP			**EQ 100MG BASE/ML**	**A216809**	**003**	Jan 24, 2023
AP		HIKMA	**EQ 50MG BASE/ML**	**A074524**	**001**	Mar 22, 1996
AP			**EQ 100MG BASE/ML**	**A074524**	**002**	Mar 22, 1996
AP		HOSPIRA	**EQ 50MG BASE/ML**	**A074549**	**001**	Jun 27, 1996
AP			**EQ 100MG BASE/ML**	**A074549**	**002**	Jun 27, 1996
KETOCONAZOLE							
AEROSOL, FOAM;TOPICAL							
EXTINA							
AB	**+!**	MYLAN	**2%**	**N021738**	**001**	Jun 12, 2007
KETOCONAZOLE							
AB		PADAGIS ISRAEL	**2%**	**A091550**	**001**	Aug 25, 2011
AB		XIROMED	**2%**	**A213601**	**001**	May 21, 2021
CREAM;TOPICAL							
KETOCONAZOLE							
AB		ENCUBE	**2%**	**A212443**	**001**	May 20, 2021
AB		FOUGERA PHARMS	**2%**	**A076294**	**001**	Apr 28, 2004
AB		TASMAN PHARMA	**2%**	**A215185**	**001**	Nov 17, 2021
AB	**!**	TEVA	**2%**	**A075581**	**001**	Apr 25, 2000
KETOZOLE							
AB		TARO	**2%**	**A075638**	**001**	Dec 18, 2002
SHAMPOO;TOPICAL							
KETOCONAZOLE							
AB	**!**	PADAGIS ISRAEL	**2%**	**A076419**	**001**	Jan 07, 2004
AB		TOLMAR	**2%**	**A076942**	**001**	Apr 11, 2005
TABLET;ORAL							
KETOCONAZOLE							
AB		RISE PHARMA	**200MG**	**A075912**	**001**	Jan 10, 2002
AB		STRIDES PHARMA	**200MG**	**A210457**	**001**	Jun 18, 2018
AB	**!**	TARO	**200MG**	**A075319**	**001**	Jun 15, 1999
KETOPROFEN							
CAPSULE;ORAL							
KETOPROFEN							
AB		MISEMER	**50MG**	**A074014**	**002**	Jan 29, 1993
AB		TEVA	**50MG**	**A073516**	**001**	Dec 22, 1992
		MISEMER	25MG	A074014	001	Jan 29, 1993
	!		75MG	A074014	003	Jan 29, 1993
CAPSULE, EXTENDED RELEASE;ORAL							
KETOPROFEN							
	!	MYLAN	200MG	A075679	001	Feb 20, 2002

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

AP		ALEMBIC	**15MG/ML**	**A214456**	**001**	Nov 02, 2022
AP			**30MG/ML**	**A214456**	**002**	Nov 02, 2022
AP		ASPIRO	**15MG/ML**	**A217166**	**001**	Jun 20, 2023
AP			**30MG/ML**	**A217166**	**002**	Jun 20, 2023
AP		BAXTER HLTHCARE CORP	**15MG/ML**	**A209900**	**002**	Jul 25, 2018
AP			**30MG/ML**	**A209900**	**001**	Sep 15, 2017
AP		CAPLIN	**15MG/ML**	**A217789**	**001**	May 10, 2023
AP			**30MG/ML**	**A217789**	**002**	May 10, 2023
AP		FRESENIUS KABI USA	**15MG/ML**	**A075784**	**001**	Jan 11, 2002
AP			**15MG/ML**	**A203242**	**001**	Oct 07, 2015
AP			**30MG/ML**	**A075784**	**002**	Jan 11, 2002
AP			**30MG/ML**	**A203242**	**002**	Oct 07, 2015
AP		GLAND	**15MG/ML**	**A204216**	**001**	Nov 01, 2016
AP			**30MG/ML**	**A204216**	**002**	Nov 01, 2016
AP		HIKMA	**15MG/ML**	**A075772**	**001**	Jul 21, 2004
AP			**30MG/ML**	**A075772**	**002**	Jul 21, 2004
AP	**!**	HOSPIRA	**15MG/ML**	**A074802**	**001**	Jun 05, 1997
AP	**!**		**30MG/ML**	**A074802**	**002**	Jun 05, 1997
AP			**30MG/ML**	**A074993**	**002**	Jan 27, 1999
AP		NEPHRON	**30MG/ML**	**A211445**	**001**	Aug 20, 2020
AP		SAGENT PHARMS INC	**15MG/ML**	**A091065**	**001**	Nov 27, 2013
AP			**30MG/ML**	**A091065**	**002**	Nov 27, 2013
AP		SANDOZ	**30MG/ML**	**A076271**	**002**	Oct 06, 2004
AP		SUN PHARM	**15MG/ML**	**A078737**	**001**	Oct 06, 2008
AP			**30MG/ML**	**A078737**	**002**	Oct 06, 2008
AP		WOCKHARDT	**15MG/ML**	**A077942**	**001**	Mar 27, 2007
AP			**30MG/ML**	**A077942**	**002**	Mar 27, 2007

SOLUTION/DROPS;OPHTHALMIC

ACULAR

AT	**+!**	ABBVIE	**0.5%**	**N019700**	**001**	Nov 09, 1992

ACULAR LS

AT	**+!**	ABBVIE	**0.4%**	**N021528**	**001**	May 30, 2003

KETOROLAC TROMETHAMINE

AT		APOTEX INC	**0.4%**	**A077308**	**001**	Nov 05, 2009
AT			**0.5%**	**A076109**	**001**	Nov 05, 2009
AT		MICRO LABS LTD INDIA	**0.5%**	**A203410**	**001**	Apr 05, 2019
AT		SANDOZ	**0.5%**	**A076583**	**001**	Nov 05, 2009
AT		SUN PHARM	**0.5%**	**A090017**	**001**	Nov 05, 2009

ACUVAIL

	+!	ABBVIE	0.45%	N022427	001	Jul 22, 2009

SPRAY, METERED;NASAL

SPRIX

	+!	ZYLA	15.75MG/SPRAY	N022382	001	May 14, 2010

TABLET;ORAL

KETOROLAC TROMETHAMINE

AB		ATNAHS PHARMA US	**10MG**	**A216407**	**001**	Oct 21, 2022
AB		BIONPHARMA	**10MG**	**A216759**	**001**	Feb 23, 2023
AB		CHARTWELL RX	**10MG**	**A210616**	**001**	Aug 16, 2018
AB		HETERO LABS LTD III	**10MG**	**A216651**	**001**	Aug 25, 2022
AB		LEADING	**10MG**	**A215745**	**001**	Feb 23, 2023
AB		MYLAN	**10MG**	**A074761**	**001**	May 16, 1997
AB		SENORES PHARMS	**10MG**	**A215788**	**001**	Mar 23, 2022
AB	**!**	TEVA	**10MG**	**A074754**	**001**	May 16, 1997
AB		ZYDUS	**10MG**	**A217038**	**001**	Oct 21, 2022

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE

AT		LUPIN LTD	**EQ 0.3% BASE;EQ 1% BASE**	**A210183**	**001**	Jul 01, 2019

OMIDRIA

AT	**+!**	RAYNER SURGICAL	**EQ 0.3% BASE;EQ 1% BASE**	**N205388**	**001**	May 30, 2014

L-GLUTAMINE

FOR SOLUTION;ORAL

ENDARI

	+	EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017

LABETALOL HYDROCHLORIDE							
INJECTABLE;INJECTION							
LABETALOL HYDROCHLORIDE							
AP		BAXTER HLTHCARE CORP	**5MG/ML**	**A076051**	**001**	Jul 05, 2002
AP		CAPLIN	**5MG/ML**	**A214533**	**001**	Sep 07, 2021
AP		GLAND PHARMA LTD	**5MG/ML**	**A090699**	**001**	Apr 03, 2012
AP		HIKMA	**5MG/ML**	**A075303**	**001**	May 28, 1999
AP	**!**	HOSPIRA	**5MG/ML**	**A075239**	**001**	Nov 29, 1999
AP	**!**		**5MG/ML**	**A075240**	**001**	Nov 29, 1999
AP		RISING	**5MG/ML**	**A075431**	**001**	Nov 29, 1999
SOLUTION;INTRAVENOUS							
LABETALOL HYDROCHLORIDE							
	+!	HIKMA	10MG/2ML (5MG/ML)	N213330	005	Mar 18, 2022
LABETALOL HYDROCHLORIDE IN DEXTROSE							
	+!	HIKMA	200MG/200ML (1MG/ML)	N213330	001	Nov 09, 2020
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE							
	+!	HIKMA	100MG/100ML (1MG/ML)	N213330	002	Nov 09, 2020
	+!		200MG/200ML (1MG/ML)	N213330	003	Nov 09, 2020
	+!		300MG/300ML (1MG/ML)	N213330	004	Nov 09, 2020
TABLET;ORAL							
LABETALOL HYDROCHLORIDE							
AB		APPCO	**100MG**	**A209603**	**001**	Jun 20, 2018
AB			**200MG**	**A209603**	**002**	Jun 20, 2018
AB			**300MG**	**A209603**	**003**	Jun 20, 2018
AB		CADILA PHARMS LTD	**100MG**	**A211325**	**001**	May 13, 2019
AB			**200MG**	**A211325**	**002**	May 13, 2019
AB			**300MG**	**A211325**	**003**	May 13, 2019
AB		EPIC PHARMA LLC	**100MG**	**A212990**	**001**	Sep 30, 2020
AB			**200MG**	**A212990**	**002**	Sep 30, 2020
AB			**300MG**	**A212990**	**003**	Sep 30, 2020
AB		EYWA	**100MG**	**A207863**	**001**	Feb 04, 2019
AB			**200MG**	**A207863**	**002**	Feb 04, 2019
AB			**300MG**	**A207863**	**003**	Feb 04, 2019
AB		HERITAGE PHARMA	**100MG**	**A074787**	**001**	Aug 03, 1998
AB			**200MG**	**A074787**	**002**	Aug 03, 1998
AB			**300MG**	**A074787**	**003**	Aug 03, 1998
AB		INNOGENIX	**100MG**	**A075215**	**001**	Jul 29, 1999
AB			**200MG**	**A075215**	**002**	Jul 29, 1999
AB			**300MG**	**A075215**	**003**	Jul 29, 1999
AB		PAR FORM	**100MG**	**A200908**	**001**	Jul 10, 2012
AB	**!**		**200MG**	**A200908**	**002**	Jul 10, 2012
AB			**300MG**	**A200908**	**003**	Jul 10, 2012
AB		RUBICON	**100MG**	**A211953**	**001**	Aug 18, 2021
AB			**200MG**	**A211953**	**002**	Aug 18, 2021
AB			**300MG**	**A211953**	**003**	Aug 18, 2021
AB		SANDOZ	**100MG**	**A075113**	**001**	Aug 04, 1998
AB	**!**		**200MG**	**A075113**	**002**	Aug 04, 1998
AB			**300MG**	**A075113**	**003**	Aug 04, 1998
AB		WATSON LABS	**100MG**	**A075133**	**001**	Aug 03, 1998
AB			**200MG**	**A075133**	**002**	Aug 03, 1998
AB			**300MG**	**A075133**	**003**	Aug 03, 1998
AB		ZYDUS PHARMS	**100MG**	**A207743**	**001**	Sep 19, 2017
AB			**200MG**	**A207743**	**002**	Sep 19, 2017
AB			**300MG**	**A207743**	**003**	Sep 19, 2017
LACOSAMIDE							
CAPSULE, EXTENDED RELEASE;ORAL							
MOTPOLY XR							
	+	AUCTA	100MG	N216185	001	May 04, 2023
	+		150MG	N216185	002	May 04, 2023
	+!		200MG	N216185	003	May 04, 2023
SOLUTION;INTRAVENOUS							
LACOSAMIDE							
AP		APOTEX	**200MG/20ML (10MG/ML)**	**A216670**	**001**	Nov 13, 2023
AP		ASPIRO	**200MG/20ML (10MG/ML)**	**A216335**	**001**	Sep 14, 2022
AP		FRESENIUS KABI USA	**200MG/20ML (10MG/ML)**	**A214677**	**001**	May 03, 2022
AP		GLAND PHARMA LTD	**200MG/20ML (10MG/ML)**	**A215628**	**001**	Sep 19, 2022
AP		INDOCO	**200MG/20ML (10MG/ML)**	**A214301**	**001**	Apr 07, 2022
AP		MSN	**200MG/20ML (10MG/ML)**	**A215979**	**001**	Feb 09, 2023
AP		ZYDUS PHARMS	**200MG/20ML (10MG/ML)**	**A209465**	**001**	Jun 29, 2022
VIMPAT							
AP	**+!**	UCB INC	**200MG/20ML (10MG/ML)**	**N022254**	**001**	Oct 28, 2008

LACOSAMIDE

SOLUTION;ORAL

LACOSAMIDE

AA		ALKEM LABS LTD	**10MG/ML**	**A214672**	**001**	May 19, 2022
AA		APOTEX	**10MG/ML**	**A206355**	**001**	Sep 26, 2022
AA		HETERO LABS LTD III	**10MG/ML**	**A209301**	**001**	May 31, 2022
AA		LEADING PHARMA	**10MG/ML**	**A216461**	**001**	Feb 06, 2023
AA		MSN	**10MG/ML**	**A215379**	**001**	Dec 22, 2023
AA		NOVITIUM PHARMA	**10MG/ML**	**A216151**	**001**	Aug 26, 2022

VIMPAT

AA	**+!**	UCB INC	**10MG/ML**	**N022255**	**001**	Apr 20, 2010

TABLET;ORAL

LACOSAMIDE

AB		ALEMBIC	**50MG**	**A204974**	**001**	Mar 17, 2022
AB			**100MG**	**A204974**	**002**	Mar 17, 2022
AB			**150MG**	**A204974**	**003**	Mar 17, 2022
AB			**200MG**	**A204974**	**004**	Mar 17, 2022
AB		ALKEM LABS LTD	**50MG**	**A214695**	**001**	Mar 31, 2022
AB			**100MG**	**A214695**	**002**	Mar 31, 2022
AB			**150MG**	**A214695**	**003**	Mar 31, 2022
AB			**200MG**	**A214695**	**004**	Mar 31, 2022
AB		AMNEAL PHARMS	**50MG**	**A204857**	**001**	Mar 17, 2022
AB			**100MG**	**A204857**	**002**	Mar 17, 2022
AB			**150MG**	**A204857**	**003**	Mar 17, 2022
AB			**200MG**	**A204857**	**004**	Mar 17, 2022
AB		AUROBINDO PHARMA LTD	**50MG**	**A204994**	**001**	Jan 05, 2023
AB			**100MG**	**A204994**	**002**	Jan 05, 2023
AB			**150MG**	**A204994**	**003**	Jan 05, 2023
AB			**200MG**	**A204994**	**004**	Jan 05, 2023
AB		GLENMARK PHARMS LTD	**50MG**	**A205006**	**001**	Mar 17, 2022
AB			**100MG**	**A205006**	**002**	Mar 17, 2022
AB			**150MG**	**A205006**	**003**	Mar 17, 2022
AB			**200MG**	**A205006**	**004**	Mar 17, 2022
AB		HETERO LABS LTD V	**50MG**	**A204787**	**001**	Mar 17, 2022
AB			**100MG**	**A204787**	**002**	Mar 17, 2022
AB			**150MG**	**A204787**	**003**	Mar 17, 2022
AB			**200MG**	**A204787**	**004**	Mar 17, 2022
AB		INDOCO	**50MG**	**A208308**	**001**	Mar 17, 2022
AB			**100MG**	**A208308**	**002**	Mar 17, 2022
AB			**150MG**	**A208308**	**003**	Mar 17, 2022
AB			**200MG**	**A208308**	**004**	Mar 17, 2022
AB		MSN LABS PVT LTD	**50MG**	**A204921**	**001**	Mar 17, 2022
AB			**100MG**	**A204921**	**002**	Mar 17, 2022
AB			**150MG**	**A204921**	**003**	Mar 17, 2022
AB			**200MG**	**A204921**	**004**	Mar 17, 2022
AB		SCIEGEN PHARMS INC	**50MG**	**A205237**	**001**	Mar 17, 2022
AB			**100MG**	**A205237**	**002**	Mar 17, 2022
AB			**150MG**	**A205237**	**003**	Mar 17, 2022
AB			**200MG**	**A205237**	**004**	Mar 17, 2022
AB		SUN PHARM	**50MG**	**A205031**	**001**	Mar 17, 2022
AB			**100MG**	**A205031**	**002**	Mar 17, 2022
AB			**150MG**	**A205031**	**003**	Mar 17, 2022
AB			**200MG**	**A205031**	**004**	Mar 17, 2022
AB		ZYDUS PHARMS	**50MG**	**A204947**	**001**	Dec 15, 2023
AB			**100MG**	**A204947**	**002**	Dec 15, 2023
AB			**150MG**	**A204947**	**003**	Dec 15, 2023
AB			**200MG**	**A204947**	**004**	Dec 15, 2023

VIMPAT

AB	**+**	UCB INC	**50MG**	**N022253**	**001**	Oct 28, 2008
AB	**+**		**100MG**	**N022253**	**002**	Oct 28, 2008
AB	**+**		**150MG**	**N022253**	**003**	Oct 28, 2008
AB	**+!**		**200MG**	**N022253**	**004**	Oct 28, 2008

LACTULOSE

FOR SOLUTION;ORAL

LACTULOSE

	!	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997
	!		20GM/PACKET	A074712	002	Dec 10, 1997

SOLUTION;ORAL

LACTULOSE

AA		AUROBINDO PHARMA LTD	**10GM/15ML**	**A074602**	**001**	Nov 14, 1996

LACTULOSE

SOLUTION;ORAL

LACTULOSE

AA		CHARTWELL RX	**10GM/15ML**	**A209517**	**001**	Nov 23, 2018
AA		FRESENIUS KABI	**10GM/15ML**	**A090503**	**001**	Jan 25, 2012
AA	**!**	HIKMA	**10GM/15ML**	**A074076**	**001**	Jul 03, 1995
AA		LANNETT CO INC	**10GM/15ML**	**A075993**	**001**	Jul 26, 2001
AA		PHARM ASSOC	**10GM/15ML**	**A074623**	**001**	Jul 30, 1996
AA		XTTRIUM LABS INC	**10GM/15ML**	**A075911**	**001**	Feb 21, 2002

SOLUTION;ORAL, RECTAL

GENERLAC

AA		WOCKHARDT BIO AG	**10GM/15ML**	**A074603**	**001**	Oct 31, 1996

LACTULOSE

AA		BAJAJ	**10GM/15ML**	**A076645**	**001**	Jul 28, 2003
AA	**!**	FRESENIUS KABI	**10GM/15ML**	**A090502**	**001**	Jan 25, 2012
AA		PAI HOLDINGS PHARM	**10GM/15ML**	**A074077**	**001**	Jul 03, 1995

LAMIVUDINE

SOLUTION;ORAL

EPIVIR

AA	**+!**	VIIV HLTHCARE	**10MG/ML**	**N020596**	**001**	Nov 17, 1995

LAMIVUDINE

AA		AUROBINDO PHARMA	**10MG/ML**	**A077695**	**001**	Nov 21, 2016
AA		CHARTWELL MOLECULAR	**10MG/ML**	**A203564**	**001**	Oct 31, 2014
AA		HETERO LABS LTD III	**10MG/ML**	**A091475**	**001**	Oct 06, 2023

EPIVIR-HBV

	+!	GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998

TABLET;ORAL

EPIVIR

AB	**+**	VIIV HLTHCARE	**150MG**	**N020564**	**001**	Nov 17, 1995
AB	**+!**		**300MG**	**N020564**	**003**	Jun 24, 2002

EPIVIR-HBV

AB	**+!**	GLAXOSMITHKLINE	**100MG**	**N021003**	**001**	Dec 08, 1998

LAMIVUDINE

AB		ANNORA	**100MG**	**A211306**	**001**	Mar 21, 2019
AB		APOTEX	**100MG**	**A202941**	**001**	Jan 02, 2014
AB			**150MG**	**A091606**	**001**	Dec 02, 2011
AB			**300MG**	**A091606**	**002**	Dec 02, 2011
AB		AUROBINDO PHARMA	**150MG**	**A077464**	**001**	Nov 21, 2016
AB			**300MG**	**A077464**	**002**	Nov 21, 2016
AB		BRECKENRIDGE	**150MG**	**A203586**	**001**	Nov 21, 2016
AB		CIPLA	**150MG**	**A077221**	**001**	Mar 03, 2017
AB			**300MG**	**A077221**	**002**	Mar 03, 2017
AB		HETERO LABS LTD V	**100MG**	**A203260**	**001**	Jan 02, 2014
AB			**150MG**	**A203277**	**001**	Jan 06, 2014
AB			**300MG**	**A203277**	**002**	Jan 06, 2014
AB		LUPIN LTD	**150MG**	**A205217**	**001**	Dec 18, 2014
AB			**300MG**	**A205217**	**002**	Dec 18, 2014
AB		MACLEODS PHARMS LTD	**150MG**	**A090198**	**001**	May 01, 2019
AB			**300MG**	**A090198**	**002**	May 01, 2019
AB		MYLAN LABS LTD	**150MG**	**A078545**	**001**	Mar 05, 2019
AB			**300MG**	**A078545**	**002**	Mar 05, 2019
AB		STRIDES PHARMA	**150MG**	**A090457**	**001**	Apr 19, 2018
AB			**300MG**	**A090457**	**002**	Apr 19, 2018
AB		UPSHER SMITH LABS	**150MG**	**A206974**	**001**	Nov 21, 2016
AB			**300MG**	**A206974**	**002**	Nov 21, 2016

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

CIMDUO

	+!	MYLAN LABS LTD	300MG;300MG	N022141	001	Feb 28, 2018

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

COMBIVIR

AB	**+!**	VIIV HLTHCARE	**150MG;300MG**	**N020857**	**001**	Sep 26, 1997

LAMIVUDINE AND ZIDOVUDINE

AB		ANDA REPOSITORY	**150MG;300MG**	**A206375**	**001**	Apr 10, 2018
AB		AUROBINDO PHARMA	**150MG;300MG**	**A077558**	**001**	May 05, 2017
AB		CIPLA	**150MG;300MG**	**A077411**	**001**	Sep 07, 2018
AB		HETERO LABS LTD III	**150MG;300MG**	**A079124**	**001**	Sep 17, 2015
AB		HETERO LABS LTD V	**150MG;300MG**	**A203259**	**001**	Feb 03, 2014
AB		LUPIN LTD	**150MG;300MG**	**A090246**	**001**	May 15, 2012
AB		MACLEODS PHARMS LTD	**150MG;300MG**	**A090679**	**001**	Aug 29, 2018

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

AB		STRIDES PHARMA	**150MG;300MG**	**A079128**	**001**	May 13, 2015

LAMOTRIGINE

TABLET;ORAL

LAMICTAL

AB	**+!**	GLAXOSMITHKLINE LLC	**25MG**	**N020241**	**005**	Dec 27, 1994
AB	**+**		**100MG**	**N020241**	**001**	Dec 27, 1994
AB	**+**		**150MG**	**N020241**	**002**	Dec 27, 1994
AB	**+**		**200MG**	**N020241**	**003**	Dec 27, 1994

LAMOTRIGINE

AB		ALEMBIC PHARMS LTD	**25MG**	**A090607**	**001**	Jan 13, 2011
AB			**100MG**	**A090607**	**002**	Jan 13, 2011
AB			**150MG**	**A090607**	**003**	Jan 13, 2011
AB			**200MG**	**A090607**	**004**	Jan 13, 2011
AB		ALKEM LABS LTD	**25MG**	**A200694**	**001**	Jun 14, 2013
AB			**100MG**	**A200694**	**002**	Jun 14, 2013
AB			**150MG**	**A200694**	**003**	Jun 14, 2013
AB			**200MG**	**A200694**	**004**	Jun 14, 2013
AB		AUROBINDO PHARMA	**25MG**	**A078956**	**001**	Jan 27, 2009
AB			**100MG**	**A078956**	**002**	Jan 27, 2009
AB			**150MG**	**A078956**	**003**	Jan 27, 2009
AB			**200MG**	**A078956**	**004**	Jan 27, 2009
AB		DR REDDYS LABS LTD	**25MG**	**A076708**	**001**	Jan 27, 2009
AB			**100MG**	**A076708**	**002**	Jan 27, 2009
AB			**150MG**	**A076708**	**003**	Jan 27, 2009
AB			**200MG**	**A076708**	**004**	Jan 27, 2009
AB		GLENMARK GENERICS	**25MG**	**A090169**	**001**	May 12, 2012
AB			**100MG**	**A090169**	**002**	May 12, 2012
AB			**150MG**	**A090169**	**003**	May 12, 2012
AB			**200MG**	**A090169**	**004**	May 12, 2012
AB		JUBILANT CADISTA	**25MG**	**A079132**	**001**	Jan 27, 2009
AB			**100MG**	**A079132**	**002**	Jan 27, 2009
AB			**150MG**	**A079132**	**003**	Jan 27, 2009
AB			**200MG**	**A079132**	**004**	Jan 27, 2009
AB		LUPIN LTD	**25MG**	**A078691**	**001**	Jun 01, 2010
AB			**100MG**	**A078691**	**002**	Jun 01, 2010
AB			**150MG**	**A078691**	**003**	Jun 01, 2010
AB			**200MG**	**A078691**	**004**	Jun 01, 2010
AB		RUBICON	**25MG**	**A078625**	**001**	Jan 27, 2009
AB			**100MG**	**A078625**	**002**	Jan 27, 2009
AB			**150MG**	**A078625**	**003**	Jan 27, 2009
AB			**200MG**	**A078625**	**004**	Jan 27, 2009
AB		TARO PHARM INDS	**25MG**	**A078525**	**001**	Jan 27, 2009
AB			**100MG**	**A078525**	**002**	Jan 27, 2009
AB			**150MG**	**A078525**	**003**	Jan 27, 2009
AB			**200MG**	**A078525**	**004**	Jan 27, 2009
AB		TORRENT PHARMS	**25MG**	**A078947**	**001**	Jan 27, 2009
AB			**100MG**	**A078947**	**002**	Jan 27, 2009
AB			**150MG**	**A078947**	**003**	Jan 27, 2009
AB			**200MG**	**A078947**	**004**	Jan 27, 2009
AB		UNICHEM LABS LTD	**25MG**	**A090170**	**001**	Oct 06, 2011
AB			**100MG**	**A090170**	**002**	Oct 06, 2011
AB			**150MG**	**A090170**	**003**	Oct 06, 2011
AB			**200MG**	**A090170**	**004**	Oct 06, 2011
AB		ZYDUS PHARMS USA	**25MG**	**A077633**	**001**	Jan 27, 2009
AB			**100MG**	**A077633**	**003**	Jan 27, 2009
AB			**150MG**	**A077633**	**004**	Jan 27, 2009
AB			**200MG**	**A077633**	**005**	Jan 27, 2009
			50MG	A077633	002	Jan 27, 2009
			250MG	A077633	006	Jan 27, 2009

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

AB	**+**	GLAXOSMITHKLINE LLC	**25MG**	**N022115**	**001**	May 29, 2009
AB	**+!**		**50MG**	**N022115**	**002**	May 29, 2009
AB	**+**		**100MG**	**N022115**	**003**	May 29, 2009
AB	**+!**		**200MG**	**N022115**	**004**	May 29, 2009
AB	**+**		**250MG**	**N022115**	**006**	Jun 21, 2011
AB	**+**		**300MG**	**N022115**	**005**	Apr 14, 2010

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB		ACTAVIS ELIZABETH	**100MG**	**A200672**	**003**	Oct 17, 2013
AB			**200MG**	**A200672**	**004**	Oct 17, 2013
AB			**25MG**	**A200672**	**001**	Oct 17, 2013
AB			**50MG**	**A200672**	**002**	Oct 17, 2013
AB			**250MG**	**A200672**	**006**	Nov 13, 2013
AB			**300MG**	**A200672**	**005**	Oct 17, 2013
AB		AMNEAL PHARMS	**25MG**	**A207497**	**001**	Nov 30, 2018
AB			**50MG**	**A207497**	**002**	Nov 30, 2018
AB			**100MG**	**A207497**	**003**	Nov 30, 2018
AB			**200MG**	**A207497**	**004**	Nov 30, 2018
AB			**250MG**	**A207497**	**005**	Nov 30, 2018
AB			**300MG**	**A207497**	**006**	Nov 30, 2018
AB		ANCHEN PHARMS	**25MG**	**A201374**	**001**	Dec 26, 2012
AB			**50MG**	**A201374**	**002**	Dec 26, 2012
AB			**100MG**	**A201374**	**003**	Dec 26, 2012
AB			**200MG**	**A201374**	**004**	Dec 26, 2012
AB			**250MG**	**A201374**	**005**	Dec 26, 2012
AB			**300MG**	**A201374**	**006**	Dec 26, 2012
AB		DR REDDYS LABS LTD	**25MG**	**A202383**	**001**	Jun 19, 2013
AB			**50MG**	**A202383**	**002**	Jun 19, 2013
AB			**100MG**	**A202383**	**003**	Jun 19, 2013
AB			**200MG**	**A202383**	**004**	Jun 19, 2013
AB			**250MG**	**A202383**	**006**	Sep 06, 2018
AB			**300MG**	**A202383**	**005**	Jun 19, 2013
AB		PAR PHARM	**25MG**	**A201791**	**001**	Jan 18, 2013
AB			**50MG**	**A201791**	**002**	Jan 18, 2013
AB			**100MG**	**A201791**	**003**	Jan 18, 2013
AB			**200MG**	**A201791**	**004**	Jan 18, 2013
AB			**250MG**	**A201791**	**005**	Jan 18, 2013
AB			**300MG**	**A201791**	**006**	Jan 18, 2013
AB		RUBICON	**100MG**	**A202887**	**003**	Jun 17, 2013
AB			**200MG**	**A202887**	**004**	Jun 17, 2013
AB		TORRENT	**25MG**	**A203370**	**001**	Dec 23, 2013
AB			**50MG**	**A203370**	**002**	Dec 23, 2013
AB			**100MG**	**A203370**	**003**	Dec 23, 2013
AB		WOCKHARDT BIO AG	**25MG**	**A202498**	**001**	Jan 04, 2013
AB			**50MG**	**A202498**	**002**	Jan 04, 2013
AB			**100MG**	**A202498**	**003**	Jan 04, 2013
AB			**200MG**	**A202498**	**004**	Jan 04, 2013
AB			**300MG**	**A202498**	**005**	Jan 04, 2013
AB		YILING	**25MG**	**A213949**	**001**	Dec 08, 2021
AB			**50MG**	**A213949**	**002**	Dec 08, 2021
AB			**100MG**	**A213949**	**003**	Dec 08, 2021
AB			**200MG**	**A213949**	**004**	Dec 08, 2021
AB			**250MG**	**A213949**	**005**	Dec 08, 2021
AB			**300MG**	**A213949**	**006**	Dec 08, 2021
AB		ZYDUS PHARMS	**25MG**	**A207763**	**001**	Apr 01, 2020
AB			**50MG**	**A207763**	**002**	Apr 01, 2020
AB			**100MG**	**A207763**	**003**	Apr 01, 2020
AB			**200MG**	**A207763**	**004**	Apr 01, 2020
AB			**250MG**	**A207763**	**005**	Apr 01, 2020
AB			**300MG**	**A207763**	**006**	Apr 01, 2020

TABLET, FOR SUSPENSION;ORAL

LAMICTAL CD

AB	+	GLAXOSMITHKLINE LLC	**2MG**	**N020764**	**004**	Sep 08, 2000
AB	+		**5MG**	**N020764**	**001**	Aug 24, 1998
AB	+!		**25MG**	**N020764**	**002**	Aug 24, 1998

LAMOTRIGINE

AB		ALEMBIC	**5MG**	**A201168**	**001**	Jun 12, 2014
AB			**25MG**	**A201168**	**002**	Jun 12, 2014
AB		AUROBINDO PHARMA	**5MG**	**A090401**	**002**	Nov 04, 2009
AB			**25MG**	**A090401**	**003**	Nov 04, 2009
AB		DR REDDYS LABS LTD	**5MG**	**A076701**	**001**	Jan 22, 2009
AB			**25MG**	**A076701**	**002**	Jan 22, 2009
AB		GLENMARK PHARMS LTD	**5MG**	**A079099**	**001**	Feb 19, 2009
AB			**25MG**	**A079099**	**002**	Feb 19, 2009
AB		TARO	**5MG**	**A079204**	**001**	Feb 04, 2009
AB			**25MG**	**A079204**	**002**	Feb 04, 2009
AB		WATSON LABS	**2MG**	**A076928**	**001**	Jan 22, 2009

LAMOTRIGINE

TABLET, FOR SUSPENSION;ORAL

LAMOTRIGINE

AB			**5MG**	**A076928**	**002**	Jan 22, 2009
AB			**25MG**	**A076928**	**003**	Jan 22, 2009
AB		ZYDUS PHARMS USA INC	**5MG**	**A078009**	**002**	Jan 22, 2009
AB			**25MG**	**A078009**	**003**	Jan 22, 2009

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

AB	+	GLAXOSMITHKLINE LLC	**25MG**	**N022251**	**001**	May 08, 2009
AB	+!		**50MG**	**N022251**	**002**	May 08, 2009
AB	+		**100MG**	**N022251**	**003**	May 08, 2009
AB	+		**200MG**	**N022251**	**004**	May 08, 2009

LAMOTRIGINE

AB		AJANTA PHARMA LTD	**25MG**	**A213271**	**001**	Jan 19, 2021
AB			**50MG**	**A213271**	**002**	Jan 19, 2021
AB			**100MG**	**A213271**	**003**	Jan 19, 2021
AB			**200MG**	**A213271**	**004**	Jan 19, 2021
AB		AMRING PHARMS	**25MG**	**A214124**	**001**	Feb 03, 2022
AB			**50MG**	**A214124**	**002**	Feb 03, 2022
AB			**100MG**	**A214124**	**003**	Feb 03, 2022
AB			**200MG**	**A214124**	**004**	Feb 03, 2022
AB		PAR PHARM	**25MG**	**A204158**	**001**	Oct 27, 2015
AB			**50MG**	**A204158**	**002**	Oct 27, 2015
AB			**100MG**	**A204158**	**003**	Oct 27, 2015
AB			**200MG**	**A204158**	**004**	Oct 27, 2015
AB		SCIEGEN PHARMS INC	**25MG**	**A206382**	**001**	Jun 17, 2016
AB			**50MG**	**A206382**	**002**	Jun 17, 2016
AB			**100MG**	**A206382**	**003**	Jun 17, 2016
AB			**200MG**	**A206382**	**004**	Jun 17, 2016

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

LANREOTIDE ACETATE

+!	INVAGEN PHARMS	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N215395	001	Dec 17, 2021
+!		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N215395	002	Dec 17, 2021
+!		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N215395	003	Dec 17, 2021

SOMATULINE DEPOT

+!	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007
+!		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007
+!		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AB		ALKEM LABS LTD	**15MG**	**A207394**	**001**	Jan 18, 2019
AB			**30MG**	**A207394**	**002**	Jan 18, 2019
AB		CHARTWELL MOLECULAR	**15MG**	**A207156**	**001**	Sep 28, 2017
AB			**30MG**	**A207156**	**002**	Sep 28, 2017
AB		DR REDDYS LABS LTD	**15MG**	**A091269**	**001**	Oct 15, 2010
AB			**30MG**	**A091269**	**002**	Oct 15, 2010
AB		HETERO LABS LTD III	**15MG**	**A203083**	**001**	May 18, 2020
AB			**30MG**	**A203083**	**002**	May 18, 2020
AB		INVENTIA	**15MG**	**A205868**	**001**	Aug 30, 2017
AB			**30MG**	**A205868**	**002**	Aug 30, 2017
AB		MYLAN PHARMS INC	**15MG**	**A090763**	**001**	Nov 10, 2009
AB			**30MG**	**A090763**	**002**	Nov 10, 2009
AB		NATCO PHARMA LTD	**15MG**	**A201921**	**001**	Dec 18, 2012
AB			**30MG**	**A201921**	**002**	Dec 18, 2012
AB		SANDOZ	**15MG**	**A090331**	**001**	Apr 23, 2010
AB			**30MG**	**A090331**	**002**	Apr 23, 2010
AB		SUN PHARM	**15MG**	**A202637**	**001**	Sep 13, 2013
AB			**30MG**	**A091509**	**001**	Sep 13, 2013
AB		TEVA PHARMS	**15MG**	**A077255**	**001**	Nov 10, 2009
AB			**30MG**	**A077255**	**002**	Nov 10, 2009
AB		WOCKHARDT	**15MG**	**A202176**	**001**	Sep 14, 2012
AB			**30MG**	**A202176**	**002**	Sep 14, 2012
AB		XIROMED	**15MG**	**A203203**	**001**	Jul 25, 2016
AB			**30MG**	**A203203**	**002**	Jul 25, 2016
AB		ZYDUS HLTHCARE	**15MG**	**A202366**	**001**	Aug 19, 2013
AB			**30MG**	**A202366**	**002**	Aug 19, 2013

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

PREVACID

AB	**+!**	TAKEDA PHARMS USA	**30MG**	**N020406**	**002**	May 10, 1995

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

AB		AUROBINDO PHARMA LTD	**15MG**	**A207167**	**001**	Mar 28, 2023
AB			**30MG**	**A207167**	**002**	Mar 28, 2023
AB		DR REDDYS	**15MG**	**A210465**	**001**	Feb 01, 2021
AB			**30MG**	**A210465**	**002**	Feb 01, 2021
AB		MYLAN	**15MG**	**A202396**	**001**	Nov 28, 2018
AB			**30MG**	**A202396**	**002**	Nov 28, 2018
AB		TEVA PHARMS USA	**15MG**	**A208784**	**001**	Sep 21, 2017
AB			**30MG**	**A208784**	**002**	Sep 21, 2017
AB		ZYDUS PHARMS	**15MG**	**A200816**	**001**	Nov 27, 2018
AB			**30MG**	**A200816**	**002**	Nov 27, 2018

PREVACID

AB	**+**	TAKEDA PHARMS USA	**15MG**	**N021428**	**001**	Aug 30, 2002
AB	**+!**		**30MG**	**N021428**	**002**	Aug 30, 2002

LANTHANUM CARBONATE

POWDER;ORAL

FOSRENOL

	+	TAKEDA PHARMS USA	EQ 750MG BASE	N204734	001 Sep 24, 2014
	+!		EQ 1GM BASE	N204734	002 Sep 24, 2014

TABLET, CHEWABLE;ORAL

FOSRENOL

AB	**+**	TAKEDA PHARMS USA	**EQ 500MG BASE**	**N021468**	**002**	Oct 26, 2004
AB	**+**		**EQ 750MG BASE**	**N021468**	**003**	Nov 23, 2005
AB	**+!**		**EQ 1GM BASE**	**N021468**	**004**	Nov 23, 2005

LANTHANUM CARBONATE

AB		BARR	**EQ 500MG BASE**	**A090977**	**001**	Jan 27, 2022
AB			**EQ 750MG BASE**	**A090977**	**002**	Jan 27, 2022
AB			**EQ 1GM BASE**	**A090977**	**003**	Jan 27, 2022
AB		INVAGEN PHARMS	**EQ 500MG BASE**	**A206868**	**001**	Jan 24, 2022
AB			**EQ 750MG BASE**	**A206868**	**002**	Jan 24, 2022
AB			**EQ 1GM BASE**	**A206868**	**003**	Jan 24, 2022
AB		NATCO PHARMA LTD	**EQ 500MG BASE**	**A090978**	**001**	Aug 11, 2017
AB			**EQ 750MG BASE**	**A090978**	**002**	Aug 11, 2017
AB			**EQ 1GM BASE**	**A090978**	**003**	Aug 11, 2017

LAPATINIB DITOSYLATE

TABLET;ORAL

LAPATINIB DITOSYLATE

AB		NATCO PHARMA LTD	**EQ 250MG BASE**	**A203007**	**001**	Sep 29, 2020

TYKERB

AB	**+!**	NOVARTIS	**EQ 250MG BASE**	**N022059**	**001**	Mar 13, 2007

LAROTRECTINIB SULFATE

CAPSULE;ORAL

VITRAKVI

	+	BAYER HLTHCARE	EQ 25MG BASE	N210861	001 Nov 26, 2018
	+!		EQ 100MG BASE	N210861	002 Nov 26, 2018

SOLUTION;ORAL

VITRAKVI

	+!	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710	001 Nov 26, 2018

LASMIDITAN SUCCINATE

TABLET;ORAL

REYVOW

	+	ELI LILLY AND CO	EQ 50MG BASE	N211280	001 Jan 31, 2020
	+!		EQ 100MG BASE	N211280	002 Jan 31, 2020

LATANOPROST

EMULSION;OPHTHALMIC

XELPROS

	+!	SUN PHARM	0.005%	N206185	001 Sep 12, 2018

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

AT		AMRING PHARMS	**0.005%**	**A200925**	**001**	Mar 22, 2011
AT		BAUSCH AND LOMB	**0.005%**	**A201006**	**001**	Mar 22, 2011
AT		CARNEGIE	**0.005%**	**A202077**	**001**	Feb 11, 2013
AT		FDC LTD	**0.005%**	**A202442**	**001**	Apr 22, 2016
AT		SANDOZ	**0.005%**	**A091449**	**001**	Mar 22, 2011

LATANOPROST						
SOLUTION/DROPS;OPHTHALMIC						
LATANOPROST						
AT		SOMERSET	**0.005%**	**A201786**	**001**	Mar 22, 2011
XALATAN						
AT	**+!**	UPJOHN	**0.005%**	**N020597**	**001**	Jun 05, 1996
IYUZEH						
	+!	THEA PHARMA	0.005%	N216472	001	Dec 13, 2022
LATANOPROST; NETARSUDIL DIMESYLATE						
SOLUTION/DROPS;OPHTHALMIC						
ROCKLATAN						
	+!	ALCON LABS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019
LATANOPROSTENE BUNOD						
SOLUTION/DROPS;OPHTHALMIC						
VYZULTA						
	+!	BAUSCH AND LOMB	0.024%	N207795	001	Nov 02, 2017
LEDIPASVIR; SOFOSBUVIR						
PELLETS;ORAL						
HARVONI						
	+	GILEAD SCIENCES INC	33.75MG;150MG/PACKET	N212477	001	Aug 28, 2019
	+!		45MG;200MG/PACKET	N212477	002	Aug 28, 2019
TABLET;ORAL						
HARVONI						
	+	GILEAD SCIENCES INC	45MG;200MG	N205834	002	Aug 28, 2019
	+!		90MG;400MG	N205834	001	Oct 10, 2014
LEFAMULIN ACETATE						
TABLET;ORAL						
XENLETA						
	+!	NABRIVA	EQ 600MG BASE	N211672	001	Aug 19, 2019
LEFLUNOMIDE						
TABLET;ORAL						
ARAVA						
AB	**+**	SANOFI AVENTIS US	**10MG**	**N020905**	**001**	Sep 10, 1998
AB	**+!**		**20MG**	**N020905**	**002**	Sep 10, 1998
LEFLUNOMIDE						
AB		ABHAI LLC	**10MG**	**A212453**	**001**	Jun 03, 2019
AB			**20MG**	**A212453**	**002**	Jun 03, 2019
AB		AET PHARMA	**10MG**	**A213497**	**001**	May 10, 2021
AB			**20MG**	**A213497**	**002**	May 10, 2021
AB		ALEMBIC PHARMS LTD	**10MG**	**A091369**	**001**	Nov 21, 2011
AB			**20MG**	**A091369**	**002**	Nov 21, 2011
AB		APOTEX INC	**10MG**	**A077090**	**001**	Sep 13, 2005
AB			**20MG**	**A077090**	**002**	Sep 13, 2005
AB		AUROBINDO PHARMA	**10MG**	**A213652**	**001**	Mar 29, 2021
AB			**20MG**	**A213652**	**002**	Mar 29, 2021
AB		HERITAGE PHARMS	**10MG**	**A077086**	**001**	Sep 13, 2005
AB			**20MG**	**A077086**	**002**	Sep 13, 2005
AB		LUPIN LTD	**10MG**	**A211863**	**001**	Feb 04, 2020
AB			**20MG**	**A211863**	**002**	Feb 04, 2020
AB		WANBANG BIOPHARMS	**10MG**	**A077087**	**001**	Sep 13, 2005
AB			**20MG**	**A077087**	**002**	Sep 13, 2005
AB		ZYDUS	**10MG**	**A212308**	**001**	Apr 24, 2019
AB			**20MG**	**A212308**	**002**	Apr 24, 2019
ARAVA						
	+!	SANOFI AVENTIS US	100MG	N020905	003	Sep 10, 1998
LEMBOREXANT						
TABLET;ORAL						
DAYVIGO						
	+	EISAI INC	5MG	N212028	001	Apr 07, 2020
	+!		10MG	N212028	002	Apr 07, 2020
LENACAPAVIR SODIUM						
SOLUTION;SUBCUTANEOUS						
SUNLENCA						
	+!	GILEAD SCIENCES INC	EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)	N215973	001	Dec 22, 2022
TABLET;ORAL						
SUNLENCA						
	+!	GILEAD SCIENCES INC	EQ 300MG BASE	N215974	001	Dec 22, 2022

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

AB		APOTEX	2.5MG	A211022	005	Mar 07, 2023
AB			5MG	A211022	001	Aug 30, 2022
AB			10MG	A211022	002	Aug 30, 2022
AB			15MG	A211022	003	Aug 30, 2022
AB			20MG	A211022	006	Mar 07, 2023
AB			25MG	A211022	004	Aug 30, 2022
AB		ARROW INTL	2.5MG	A201452	005	Mar 06, 2023
AB			5MG	A201452	001	May 21, 2021
AB			10MG	A201452	002	May 21, 2021
AB			15MG	A201452	003	May 21, 2021
AB			20MG	A201452	006	Mar 06, 2023
AB			25MG	A201452	004	May 21, 2021
AB		CIPLA	2.5MG	A214618	001	Mar 06, 2023
AB			5MG	A210435	001	Sep 06, 2022
AB			10MG	A210435	002	Sep 06, 2022
AB			15MG	A210435	003	Sep 06, 2022
AB			20MG	A210435	005	Mar 06, 2023
AB			25MG	A210435	004	Sep 06, 2022
AB		DR REDDYS	2.5MG	A209348	001	Oct 14, 2021
AB			5MG	A209348	003	Aug 30, 2022
AB			10MG	A209348	004	Aug 30, 2022
AB			15MG	A209348	005	Aug 30, 2022
AB			20MG	A209348	002	Oct 14, 2021
AB			25MG	A209348	006	Aug 30, 2022
AB		EUGIA PHARMA	2.5MG	A213885	001	Mar 06, 2023
AB			5MG	A213885	002	Mar 06, 2023
AB			10MG	A213885	003	Mar 06, 2023
AB			15MG	A213885	004	Mar 06, 2023
AB			20MG	A213885	005	Mar 06, 2023
AB			25MG	A213885	006	Mar 06, 2023
AB		HETERO LABS LTD V	2.5MG	A212414	001	May 11, 2023
AB			5MG	A212414	002	May 11, 2023
AB			10MG	A212414	003	May 11, 2023
AB			15MG	A212414	004	May 11, 2023
AB			20MG	A212414	005	May 11, 2023
AB			25MG	A212414	006	May 11, 2023
AB		LOTUS PHARM CO LTD	2.5MG	A210480	005	Mar 06, 2023
AB			5MG	A210480	001	Aug 31, 2022
AB			10MG	A210480	002	Aug 31, 2022
AB			15MG	A210480	003	Aug 31, 2022
AB			20MG	A210480	006	Mar 06, 2023
AB			25MG	A210480	004	Aug 31, 2022
AB		MYLAN	2.5MG	A213912	005	Mar 06, 2023
AB			5MG	A213912	001	Aug 30, 2022
AB			10MG	A213912	002	Aug 30, 2022
AB			15MG	A213912	003	Aug 30, 2022
AB			20MG	A213912	006	Mar 06, 2023
AB			25MG	A213912	004	Aug 30, 2022
AB		SUN PHARM	2.5MG	A211846	005	Mar 06, 2023
AB			5MG	A211846	001	Feb 08, 2023
AB			10MG	A211846	002	Feb 08, 2023
AB			15MG	A211846	003	Feb 08, 2023
AB			20MG	A211846	006	Mar 06, 2023
AB			25MG	A211846	004	Feb 08, 2023
AB		ZYDUS PHARMS	2.5MG	A210154	005	Mar 06, 2023
AB			5MG	A210154	001	Sep 12, 2022
AB			10MG	A210154	002	Sep 12, 2022
AB			15MG	A210154	003	Sep 12, 2022
AB			20MG	A210154	006	Mar 06, 2023
AB			25MG	A210154	004	Sep 12, 2022

REVLIMID

AB	+	BRISTOL MYERS SQUIBB	2.5MG	N021880	005	Dec 21, 2011
AB	+		5MG	N021880	001	Dec 27, 2005
AB	+		10MG	N021880	002	Dec 27, 2005
AB	+		15MG	N021880	003	Jun 29, 2006
AB	+		20MG	N021880	006	Jun 05, 2013
AB	+!		25MG	N021880	004	Jun 29, 2006

LENIOLISIB PHOSPHATE						
TABLET;ORAL						
JOENJA						
	+!	PHARMING	EQ 70MG BASE	N217759	001	Mar 24, 2023
LENVATINIB MESYLATE						
CAPSULE;ORAL						
LENVIMA						
	+	EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015
	+!		EQ 10MG BASE	N206947	002	Feb 13, 2015
LETERMOVIR						
SOLUTION;INTRAVENOUS						
PREVYMIS						
	+!	MERCK SHARP DOHME	240MG/12ML (20MG/ML)	N209940	001	Nov 08, 2017
	+!		480MG/24ML (20MG/ML)	N209940	002	Nov 08, 2017
TABLET;ORAL						
PREVYMIS						
	+	MERCK SHARP DOHME	240MG	N209939	001	Nov 08, 2017
	+!		480MG	N209939	002	Nov 08, 2017
LETROZOLE						
TABLET;ORAL						
FEMARA						
AB	**+!**	NOVARTIS PHARMS	**2.5MG**	**N020726**	**001**	Jul 25, 1997
LETROZOLE						
AB		ACCORD HLTHCARE	**2.5MG**	**A090934**	**001**	Jun 03, 2011
AB		BEIJING YILING	**2.5MG**	**A205869**	**001**	Nov 14, 2018
AB		CARNEGIE	**2.5MG**	**A091191**	**001**	Jun 03, 2011
AB		EUGIA PHARMA	**2.5MG**	**A211717**	**001**	Jan 11, 2019
AB		NATCO PHARMA LTD	**2.5MG**	**A200161**	**001**	Jun 03, 2011
AB		TEVA PHARMS	**2.5MG**	**A090289**	**001**	Jun 03, 2011
LETROZOLE; RIBOCICLIB SUCCINATE						
TABLET;ORAL						
KISQALI FEMARA CO-PACK (COPACKAGED)						
	+!	NOVARTIS	2.5MG;EQ 200MG BASE	N209935	001	May 04, 2017
LEUCOVORIN CALCIUM						
INJECTABLE;INJECTION						
LEUCOVORIN CALCIUM						
AP		HAINAN POLY	**EQ 50MG BASE/VIAL**	**A217021**	**001**	Jul 10, 2023
AP			**EQ 100MG BASE/VIAL**	**A217021**	**002**	Jul 10, 2023
AP			**EQ 200MG BASE/VIAL**	**A217021**	**003**	Jul 10, 2023
AP			**EQ 500MG BASE/VIAL**	**A217021**	**004**	Jul 10, 2023
AP	**!**	HIKMA	**EQ 50MG BASE/VIAL**	**A089384**	**001**	Sep 14, 1987
AP	**!**		**EQ 100MG BASE/VIAL**	**A089717**	**001**	Mar 28, 1988
AP		KINDOS	**EQ 50MG BASE/VIAL**	**A216590**	**001**	Jul 19, 2023
AP			**EQ 100MG BASE/VIAL**	**A216590**	**002**	Jul 19, 2023
AP			**EQ 200MG BASE/VIAL**	**A216590**	**003**	Jul 19, 2023
AP			**EQ 350MG BASE/VIAL**	**A216590**	**004**	Jul 19, 2023
AP			**EQ 500MG BASE/VIAL**	**A216590**	**005**	Jul 19, 2023
LEUCOVORIN CALCIUM PRESERVATIVE FREE						
AP		FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A040258**	**001**	Feb 26, 1999
AP	**!**		**EQ 500MG BASE/VIAL**	**A040286**	**001**	Feb 26, 1999
AP	**!**	HIKMA	**EQ 200MG BASE/VIAL**	**A040056**	**001**	May 23, 1995
AP	**!**		**EQ 350MG BASE/VIAL**	**A040335**	**001**	Apr 20, 2000
AP		MYLAN LABS LTD	**EQ 100MG BASE/VIAL**	**A203800**	**001**	May 19, 2017
AP			**EQ 200MG BASE/VIAL**	**A203800**	**002**	May 19, 2017
AP			**EQ 350MG BASE/VIAL**	**A203800**	**003**	May 19, 2017
AP		SAGENT PHARMS	**EQ 50MG BASE/VIAL**	**A200753**	**001**	Sep 06, 2012
AP			**EQ 100MG BASE/VIAL**	**A200753**	**002**	Sep 06, 2012
AP			**EQ 200MG BASE/VIAL**	**A200753**	**003**	Sep 06, 2012
AP			**EQ 350MG BASE/VIAL**	**A200855**	**001**	Sep 06, 2012
AP		SAGENT PHARMS INC	**EQ 500MG BASE/VIAL**	**A209110**	**001**	Oct 26, 2017
LEUCOVORIN CALCIUM						
	!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018
	!		EQ 10MG BASE/ML	A207241	001	Mar 14, 2018
TABLET;ORAL						
LEUCOVORIN CALCIUM						
AB		BARR	**EQ 5MG BASE**	**A071198**	**001**	Sep 24, 1987
AB			**EQ 25MG BASE**	**A071199**	**001**	Sep 24, 1987
AB		EPIC PHARMA LLC	**EQ 5MG BASE**	**A074544**	**001**	Aug 28, 1997
AB			**EQ 10MG BASE**	**A074544**	**003**	May 19, 2021
AB			**EQ 15MG BASE**	**A074544**	**004**	May 19, 2021

LEUCOVORIN CALCIUM

TABLET;ORAL

LEUCOVORIN CALCIUM

AB			**EQ 25MG BASE**	**A074544**	**002**	Aug 28, 1997
AB		HIKMA	**EQ 5MG BASE**	**A072733**	**001**	Feb 22, 1993
AB			**EQ 10MG BASE**	**A072734**	**001**	Feb 22, 1993
AB			**EQ 15MG BASE**	**A072735**	**001**	Feb 22, 1993
AB	**!**		**EQ 25MG BASE**	**A072736**	**001**	Feb 22, 1993
AB		LEADING	**EQ 5MG BASE**	**A213929**	**001**	Oct 22, 2020
AB			**EQ 10MG BASE**	**A213929**	**002**	Oct 22, 2020
AB			**EQ 15MG BASE**	**A213929**	**003**	Oct 22, 2020
AB			**EQ 25MG BASE**	**A213929**	**004**	Oct 22, 2020
AB		NOVAST LABS	**EQ 5MG BASE**	**A211132**	**001**	Jul 30, 2020
AB			**EQ 10MG BASE**	**A211132**	**002**	Jul 30, 2020
AB			**EQ 15MG BASE**	**A211132**	**003**	Jul 30, 2020
AB			**EQ 25MG BASE**	**A211132**	**004**	Jul 30, 2020

LEUPROLIDE ACETATE

FOR SUSPENSION;INTRAMUSCULAR

LEUPROLIDE ACETATE FOR DEPOT SUSPENSION

+!	INVAGEN PHARMS	22.5MG/VIAL	N205054	001	Aug 28, 2018

INJECTABLE;INJECTION

LEUPROLIDE ACETATE

AP		AMNEAL	**1MG/0.2ML**	**A215336**	**001**	Oct 28, 2022
AP		EUGIA PHARMA	**1MG/0.2ML**	**A212963**	**001**	Jun 06, 2022
AP		MEITHEAL	**1MG/0.2ML**	**A075471**	**001**	Oct 25, 2000
AP		RK PHARMA	**1MG/0.2ML**	**A213829**	**001**	Aug 13, 2021
AP	**!**	SANDOZ	**1MG/0.2ML**	**A074728**	**001**	Aug 04, 1998
AP		SUN PHARM	**1MG/0.2ML**	**A078885**	**001**	Mar 09, 2009

LUPRON DEPOT

+!	ABBVIE ENDOCRINE INC	3.75MG	N020011	002	Oct 26, 1995
+!		7.5MG	N019732	001	Jan 26, 1989
+!		11.25MG	N020708	001	Mar 07, 1997
+		22.5MG	N020517	001	Dec 22, 1995
+!		30MG	N020517	002	May 30, 1997
+!		45MG	N020517	003	Jun 17, 2011

POWDER;INTRAMUSCULAR

LUPRON DEPOT-PED KIT

+!	ABBVIE ENDOCRINE INC	7.5MG	N020263	002	Apr 16, 1993
+!		11.25MG	N020263	005	Jan 21, 1994
+!		11.25MG	N020263	007	Aug 15, 2011
+!		15MG	N020263	006	Jan 21, 1994
+!		30MG	N020263	008	Aug 15, 2011
+!		45MG	N020263	009	Apr 14, 2023

POWDER;SUBCUTANEOUS

ELIGARD KIT

+!	TOLMAR	7.5MG	N021343	001	Jan 23, 2002
+!		22.5MG	N021379	001	Jul 24, 2002
+!		30MG	N021488	001	Feb 13, 2003
+!		45MG	N021731	001	Dec 14, 2004

FENSOLVI KIT

+!	TOLMAR	45MG	N213150	001	May 01, 2020

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS

CAMCEVI KIT

+!	ACCORD	EQ 42MG BASE	N211488	001	May 25, 2021

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN		CIPLA	**EQ 0.021% BASE**	**A078171**	**002**	Dec 13, 2013
AN			**EQ 0.042% BASE**	**A078171**	**003**	Dec 13, 2013
AN			**EQ 0.0103% BASE**	**A078171**	**001**	Dec 13, 2013
AN		IMPAX LABS INC	**EQ 0.0103% BASE**	**A077756**	**003**	Apr 09, 2008
AN			**EQ 0.021% BASE**	**A077756**	**001**	Apr 09, 2008
AN			**EQ 0.042% BASE**	**A077756**	**002**	Apr 09, 2008
AN		LUOXIN AUROVITAS	**EQ 0.25% BASE**	**A207628**	**001**	Jan 31, 2017
AN			**EQ 0.0103% BASE**	**A207625**	**001**	Dec 30, 2016
AN			**EQ 0.021% BASE**	**A207625**	**002**	Dec 30, 2016
AN			**EQ 0.042% BASE**	**A207625**	**003**	Dec 30, 2016
AN		MYLAN SPECIALITY LP	**EQ 0.25% BASE**	**A078309**	**001**	Mar 20, 2009

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN		RITEDOSE CORP	**EQ 0.0103% BASE**	**A203653**	**001**	Mar 22, 2016
AN			**EQ 0.021% BASE**	**A203653**	**002**	Mar 22, 2016
AN			**EQ 0.042% BASE**	**A203653**	**003**	Mar 22, 2016
AN		SUN PHARM	**EQ 0.0103% BASE**	**A207820**	**001**	Nov 05, 2018
AN			**EQ 0.021% BASE**	**A207820**	**002**	Nov 05, 2018
AN			**EQ 0.042% BASE**	**A207820**	**003**	Nov 05, 2018
AN		TEVA PARENTERAL	**EQ 0.25% BASE**	**A200875**	**001**	Sep 11, 2014
AN		TEVA PHARMS USA	**EQ 0.0103% BASE**	**A090297**	**001**	Apr 26, 2013
AN			**EQ 0.021% BASE**	**A090297**	**002**	Apr 26, 2013
AN			**EQ 0.042% BASE**	**A090297**	**003**	Apr 26, 2013

XOPENEX

AN	**+!**	HIKMA	**EQ 0.0103% BASE**	**N020837**	**003**	Jan 30, 2002
AN	**+!**		**EQ 0.021% BASE**	**N020837**	**001**	Mar 25, 1999
AN	**+!**		**EQ 0.042% BASE**	**N020837**	**002**	Mar 25, 1999
AN	**+!**		**EQ 0.25% BASE**	**N020837**	**004**	Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED;INHALATION

XOPENEX HFA

	+!	LUPIN	EQ 0.045MG BASE/INH	N021730	001	Mar 11, 2005

LEVETIRACETAM

INJECTABLE;INTRAVENOUS

KEPPRA

AP	**+!**	UCB INC	**500MG/5ML (100MG/ML)**	**N021872**	**001**	Jul 31, 2006

LEVETIRACETAM

AP		BAXTER HLTHCARE CORP	**500MG/100ML (5MG/ML)**	**A217059**	**001**	Oct 02, 2023
AP			**1GM/100ML (10MG/ML)**	**A217059**	**002**	Oct 02, 2023
AP			**1.5GM/100ML (15MG/ML)**	**A217059**	**003**	Oct 02, 2023
AP		BEOWULF ASSET	**500MG/5ML (100MG/ML)**	**A091485**	**001**	Aug 05, 2011
AP		EUGIA PHARMA	**500MG/5ML (100MG/ML)**	**A204312**	**001**	Feb 01, 2016
AP		FRESENIUS KABI USA	**500MG/5ML (100MG/ML)**	**A090876**	**001**	Aug 13, 2015
AP		HAINAN POLY PHARM	**500MG/5ML (100MG/ML)**	**A209781**	**001**	Mar 20, 2018
AP		HIKMA FARMACEUTICA	**500MG/5ML (100MG/ML)**	**A090981**	**001**	Oct 13, 2011
AP		HOSPIRA INC	**500MG/5ML (100MG/ML)**	**A202869**	**001**	Apr 06, 2012
AP		MICRO LABS	**500MG/5ML (100MG/ML)**	**A211954**	**001**	Aug 09, 2019
AP		MSN	**500MG/5ML (100MG/ML)**	**A215980**	**001**	Nov 15, 2022
AP		MYLAN LABS LTD	**500MG/5ML (100MG/ML)**	**A203308**	**001**	Sep 16, 2016
AP		PRINSTON INC	**500MG/5ML (100MG/ML)**	**A209474**	**001**	Mar 28, 2022
AP		SAGENT PHARMS	**500MG/5ML (100MG/ML)**	**A091627**	**001**	Jun 26, 2013
AP		SUN PHARM INDS LTD	**500MG/5ML (100MG/ML)**	**A090754**	**001**	Jun 16, 2010

LEVETIRACETAM IN SODIUM CHLORIDE

AP		EUGIA PHARMA	**500MG/100ML (5MG/ML)**	**A207160**	**001**	Jan 04, 2017
AP			**1GM/100ML (10MG/ML)**	**A207160**	**002**	Jan 04, 2017
AP			**1.5GM/100ML (15MG/ML)**	**A207160**	**003**	Jan 04, 2017
AP		FRESENIUS KABI USA	**500MG/100ML (5MG/ML)**	**A208619**	**001**	Jan 31, 2023
AP			**1GM/100ML (10MG/ML)**	**A208619**	**002**	Jan 31, 2023
AP			**1.5GM/100ML (15MG/ML)**	**A208619**	**003**	Jan 31, 2023
AP		GLAND PHARMA LTD	**500MG/100ML (5MG/ML)**	**A206880**	**001**	Oct 25, 2017
AP			**1GM/100ML (10MG/ML)**	**A206880**	**002**	Oct 25, 2017
AP			**1.5GM/100ML (15MG/ML)**	**A206880**	**003**	Oct 25, 2017
AP	**+!**	HQ SPCLT PHARMA	**500MG/100ML (5MG/ML)**	**N202543**	**001**	Nov 09, 2011
AP	**+!**		**1GM/100ML (10MG/ML)**	**N202543**	**002**	Nov 09, 2011
AP	**+!**		**1.5GM/100ML (15MG/ML)**	**N202543**	**003**	Nov 09, 2011
AP		NEXUS	**500MG/100ML (5MG/ML)**	**A213532**	**001**	Jul 06, 2020
AP			**1GM/100ML (10MG/ML)**	**A213532**	**002**	Jul 06, 2020
AP			**1.5GM/100ML (15MG/ML)**	**A213532**	**003**	Jul 06, 2020
	+!	HQ SPCLT PHARMA	250MG/50ML (5MG/ML)	N202543	004	Dec 14, 2020

SOLUTION;ORAL

KEPPRA

AA	**+!**	UCB INC	**100MG/ML**	**N021505**	**001**	Jul 15, 2003

LEVETIRACETAM

AA		ACI	**100MG/ML**	**A078582**	**001**	Jan 15, 2009
AA		ACTAVIS MID ATLANTIC	**100MG/ML**	**A078976**	**001**	Jan 15, 2009
AA		ALEMBIC	**100MG/ML**	**A203067**	**001**	May 09, 2013
AA		AMNEAL PHARMS	**100MG/ML**	**A090992**	**001**	Oct 27, 2009
AA		AUROBINDO PHARMA	**100MG/ML**	**A079063**	**001**	Jan 15, 2009
AA		BELCHER	**100MG/ML**	**A090461**	**001**	Sep 30, 2010
AA		BIONPHARMA	**100MG/ML**	**A079120**	**001**	Jan 16, 2009

LEVETIRACETAM

SOLUTION;ORAL

LEVETIRACETAM

AA		CHARTWELL MOLECULAR	**100MG/ML**	**A090263**	**001**	Apr 03, 2009
AA		HETERO LABS LTD III	**100MG/ML**	**A203052**	**001**	Feb 28, 2013
AA		HIKMA	**100MG/ML**	**A090601**	**001**	Feb 28, 2012
AA		LUPIN LTD	**100MG/ML**	**A090893**	**001**	Oct 17, 2011
AA		MSN	**100MG/ML**	**A214757**	**001**	Jul 15, 2022
AA		PHARM ASSOC	**100MG/ML**	**A201157**	**001**	Jun 04, 2015
AA		QUAGEN	**100MG/ML**	**A090079**	**001**	Apr 11, 2012
AA		STRIDES PHARMA	**100MG/ML**	**A214673**	**001**	Nov 20, 2023
AA		TARO	**100MG/ML**	**A078774**	**001**	Feb 10, 2009

TABLET;ORAL

KEPPRA

AB	+	UCB INC	**250MG**	**N021035**	**001**	Nov 30, 1999
AB	+		**500MG**	**N021035**	**002**	Nov 30, 1999
AB	+		**750MG**	**N021035**	**003**	Nov 30, 1999
AB	+!		**1GM**	**N021035**	**004**	Jan 06, 2006

LEVETIRACETAM

AB		ACCORD HLTHCARE	**250MG**	**A090843**	**001**	Feb 14, 2011
AB			**500MG**	**A090843**	**002**	Feb 14, 2011
AB			**750MG**	**A090843**	**003**	Feb 14, 2011
AB			**1GM**	**A090843**	**004**	Feb 14, 2011
AB		ACI	**250MG**	**A078042**	**001**	Jan 15, 2009
AB			**500MG**	**A078042**	**002**	Jan 15, 2009
AB			**750MG**	**A078042**	**003**	Jan 15, 2009
AB			**1GM**	**A078042**	**004**	Jan 15, 2009
AB		ALKEM LABS LTD	**250MG**	**A216375**	**001**	May 27, 2022
AB			**500MG**	**A216375**	**002**	May 27, 2022
AB			**750MG**	**A216375**	**003**	May 27, 2022
AB			**1GM**	**A216375**	**004**	May 27, 2022
AB		AUROBINDO PHARMA	**250MG**	**A078993**	**001**	Jan 15, 2009
AB			**500MG**	**A078993**	**002**	Jan 15, 2009
AB			**750MG**	**A078993**	**003**	Jan 15, 2009
AB			**1GM**	**A078993**	**004**	Jan 15, 2009
AB		CHARTWELL RX	**250MG**	**A201293**	**001**	Jun 14, 2011
AB			**500MG**	**A201293**	**002**	Jun 14, 2011
AB			**750MG**	**A201293**	**003**	Jun 14, 2011
AB			**1GM**	**A201293**	**004**	Jun 14, 2011
AB		DR REDDYS LABS LTD	**250MG**	**A076920**	**001**	Jan 15, 2009
AB			**500MG**	**A076920**	**002**	Jan 15, 2009
AB			**750MG**	**A076920**	**003**	Jan 15, 2009
AB			**1GM**	**A078904**	**001**	Jan 15, 2009
AB		GRANULES	**250MG**	**A217878**	**001**	Jun 13, 2023
AB			**500MG**	**A217878**	**002**	Jun 13, 2023
AB			**750MG**	**A217878**	**003**	Jun 13, 2023
AB			**1GM**	**A217878**	**004**	Jun 13, 2023
AB		HETERO LABS LTD III	**250MG**	**A090515**	**001**	Oct 08, 2010
AB			**500MG**	**A090515**	**002**	Oct 08, 2010
AB			**750MG**	**A090515**	**003**	Oct 08, 2010
AB			**1GM**	**A090515**	**004**	Oct 08, 2010
AB		INVAGEN PHARMS	**250MG**	**A078234**	**001**	Jan 15, 2009
AB			**500MG**	**A078234**	**002**	Jan 15, 2009
AB			**750MG**	**A078234**	**003**	Jan 15, 2009
AB		LUPIN	**250MG**	**A078154**	**001**	Jan 15, 2009
AB			**500MG**	**A078154**	**002**	Jan 15, 2009
AB			**750MG**	**A078154**	**003**	Jan 15, 2009
AB			**1GM**	**A090025**	**001**	Jan 15, 2009
AB		MSN	**250MG**	**A214815**	**001**	Oct 07, 2022
AB			**500MG**	**A214815**	**002**	Oct 07, 2022
AB			**750MG**	**A214815**	**003**	Oct 07, 2022
AB			**1GM**	**A214815**	**004**	Oct 07, 2022
AB		MYLAN	**500MG**	**A076919**	**002**	Nov 04, 2008
AB			**750MG**	**A076919**	**003**	Nov 04, 2008
AB			**1GM**	**A090261**	**001**	Dec 08, 2009
AB		ORBION PHARMS	**250MG**	**A078526**	**001**	Jan 15, 2009
AB			**500MG**	**A078526**	**002**	Jan 15, 2009
AB			**750MG**	**A078526**	**003**	Jan 15, 2009
AB			**1GM**	**A090484**	**001**	Aug 05, 2010
AB		OXFORD PHARMS	**250MG**	**A077319**	**001**	Mar 20, 2009
AB			**500MG**	**A077319**	**002**	Mar 20, 2009
AB			**750MG**	**A077319**	**003**	Mar 20, 2009

LEVETIRACETAM

TABLET;ORAL

LEVETIRACETAM

AB	PRINSTON INC	**250MG**	**A078106**	**001**	Feb 10, 2009
AB		**500MG**	**A078106**	**002**	Feb 10, 2009
AB		**750MG**	**A078106**	**003**	Feb 10, 2009
AB		**1GM**	**A078106**	**004**	Feb 10, 2009
AB	RISING	**250MG**	**A090767**	**001**	Jul 28, 2010
AB		**500MG**	**A090767**	**002**	Jul 28, 2010
AB		**750MG**	**A090767**	**003**	Jul 28, 2010
AB		**1GM**	**A090767**	**004**	Jul 28, 2010
AB	SCIEGEN PHARMS INC	**250MG**	**A215069**	**003**	May 27, 2022
AB		**500MG**	**A215069**	**004**	May 27, 2022
AB		**750MG**	**A215069**	**001**	Jun 11, 2021
AB		**1GM**	**A215069**	**002**	Jun 11, 2021
AB	STALLION LABS	**250MG**	**A079042**	**001**	Jan 15, 2009
AB		**500MG**	**A079042**	**002**	Jan 15, 2009
AB		**750MG**	**A079042**	**003**	Jan 15, 2009
AB		**1GM**	**A079042**	**004**	Jan 15, 2009
AB	TARO	**250MG**	**A078960**	**004**	Feb 01, 2010
AB		**500MG**	**A078960**	**003**	Feb 01, 2010
AB		**750MG**	**A078960**	**002**	Feb 01, 2010
AB		**1GM**	**A078960**	**001**	Feb 01, 2010
AB	TORRENT PHARMS	**250MG**	**A078858**	**001**	Jan 15, 2009
AB		**500MG**	**A078858**	**002**	Jan 15, 2009
AB		**750MG**	**A078858**	**003**	Jan 15, 2009
AB		**1GM**	**A078858**	**004**	Jan 15, 2009
AB	VIWIT PHARM	**250MG**	**A078869**	**001**	Mar 13, 2009
AB		**500MG**	**A078869**	**002**	Mar 13, 2009
AB		**750MG**	**A078869**	**003**	Mar 13, 2009
AB		**1GM**	**A078869**	**004**	Mar 13, 2009
AB	ZHEJIANG JINGXIN	**250MG**	**A091491**	**001**	Dec 14, 2010
AB		**500MG**	**A091491**	**002**	Dec 14, 2010
AB		**750MG**	**A091491**	**003**	Dec 14, 2010
AB		**1GM**	**A091491**	**004**	Dec 14, 2010
AB	ZYDUS PHARMS USA INC	**250MG**	**A078918**	**001**	Apr 29, 2009
AB		**1GM**	**A078918**	**002**	Apr 29, 2009

TABLET, EXTENDED RELEASE;ORAL

KEPPRA XR

AB	**+**	UCB INC	**500MG**	**N022285**	**001**	Sep 12, 2008
AB	**+!**		**750MG**	**N022285**	**002**	Feb 12, 2009

LEVETIRACETAM

AB		ACTAVIS LABS FL INC	**500MG**	**A091093**	**001**	Sep 12, 2011
AB			**750MG**	**A091093**	**002**	Sep 12, 2011
AB		AIPING PHARM INC	**500MG**	**A204754**	**001**	Aug 26, 2016
AB			**750MG**	**A204754**	**002**	Aug 26, 2016
AB		ANCHEN PHARMS	**500MG**	**A091360**	**001**	Oct 04, 2011
AB			**750MG**	**A091360**	**002**	Oct 04, 2011
AB		ANDA REPOSITORY	**500MG**	**A204511**	**001**	Feb 23, 2016
AB			**750MG**	**A204511**	**002**	Feb 23, 2016
AB		APOTEX INC	**500MG**	**A091261**	**001**	Sep 12, 2011
AB			**750MG**	**A091261**	**002**	Sep 12, 2011
AB		HISUN PHARM HANGZHOU	**500MG**	**A207175**	**001**	Sep 28, 2017
AB			**750MG**	**A207175**	**002**	Sep 28, 2017
AB		LUPIN LTD	**500MG**	**A091399**	**001**	Sep 12, 2011
AB			**750MG**	**A091399**	**002**	Sep 12, 2011
AB		OVERSEAS	**500MG**	**A212688**	**002**	May 05, 2023
AB			**750MG**	**A212688**	**001**	Jun 11, 2020
AB		PHARMADAX INC	**500MG**	**A201464**	**001**	May 25, 2012
AB			**750MG**	**A201464**	**002**	May 25, 2012
AB		PRINSTON INC	**500MG**	**A202533**	**001**	Jul 20, 2012
AB			**500MG**	**A203468**	**001**	May 21, 2015
AB			**750MG**	**A202533**	**002**	Jul 20, 2012
AB			**750MG**	**A203468**	**002**	May 21, 2015
AB		SCIEGEN PHARMS INC	**500MG**	**A205130**	**001**	Nov 27, 2020
AB			**750MG**	**A205130**	**002**	Nov 27, 2020
		APOTEX	1GM	A202958	001	Feb 25, 2015

TABLET, FOR SUSPENSION;ORAL

SPRITAM

+	APRECIA PHARMS	250MG	N207958	001	Jul 31, 2015
+		500MG	N207958	002	Jul 31, 2015

LEVETIRACETAM							
TABLET, FOR SUSPENSION;ORAL							
SPRITAM							
	+		750MG		N207958	003	Jul 31, 2015
	+!		1GM		N207958	004	Jul 31, 2015
LEVOBUNOLOL HYDROCHLORIDE							
SOLUTION/DROPS;OPHTHALMIC							
BETAGAN							
AT	**+!**	ALLERGAN	**0.5%**		**N019219**	**002**	Dec 19, 1985
LEVOBUNOLOL HYDROCHLORIDE							
AT		BAUSCH AND LOMB	**0.5%**		**A074326**	**001**	Mar 04, 1994
LEVOCARNITINE							
INJECTABLE;INJECTION							
CARNITOR							
AP	**+!**	LEADIANT BIOSCI INC	**200MG/ML**		**N020182**	**001**	Dec 16, 1992
LEVOCARNITINE							
AP		AM REGENT	**200MG/ML**		**A075861**	**001**	Jun 22, 2001
AP		HIKMA	**200MG/ML**		**A075567**	**001**	Mar 29, 2001
SOLUTION;ORAL							
CARNITOR							
AA	**+!**	LEADIANT BIOSCI INC	**1GM/10ML**		**N019257**	**001**	Apr 10, 1986
CARNITOR SF							
AA	**+**	LEADIANT BIOSCI INC	**1GM/10ML**		**N019257**	**002**	Mar 28, 2007
LEVOCARNITINE							
AA		HIKMA	**1GM/10ML**		**A077399**	**001**	Oct 25, 2007
AA		LYNE	**1GM/10ML**		**A076851**	**001**	Aug 10, 2004
AA		NOVITIUM PHARMA	**1GM/10ML**		**A211676**	**001**	Aug 14, 2019
AA		SAPTALIS PHARMS	**1GM/10ML**		**A212533**	**001**	Nov 10, 2021
LEVOCARNITINE SF							
AA		NOVITIUM PHARMA	**1GM/10ML**		**A211676**	**002**	Aug 14, 2019
TABLET;ORAL							
CARNITOR							
AB	**+!**	LEADIANT BIOSCI INC	**330MG**		**N018948**	**001**	Dec 27, 1985
LEVOCARNITINE							
AB		NOVITIUM PHARMA	**330MG**		**A216384**	**001**	Dec 09, 2022
AB		RISING	**330MG**		**A076858**	**001**	Sep 20, 2004
LEVOCETIRIZINE DIHYDROCHLORIDE							
SOLUTION;ORAL							
LEVOCETIRIZINE DIHYDROCHLORIDE							
AA		CHARTWELL MOLECULAR	**2.5MG/5ML**		**A204599**	**001**	May 15, 2017
AA	**!**	PADAGIS US	**2.5MG/5ML**		**A091263**	**001**	Nov 07, 2011
AA		TARO	**2.5MG/5ML**		**A202673**	**001**	Jul 26, 2013
LEVOCETIRIZINE HYDROCHLORIDE							
AA		HETERO LABS LTD III	**2.5MG/5ML**		**A210914**	**001**	Apr 01, 2019
TABLET;ORAL							
LEVOCETIRIZINE DIHYDROCHLORIDE							
AB		DR REDDYS LABS LTD	**5MG**		**A090392**	**001**	Feb 24, 2011
AB	**!**	GLENMARK GENERICS	**5MG**		**A090385**	**001**	Feb 24, 2011
AB		HETERO LABS LTD III	**5MG**		**A091264**	**001**	Jun 29, 2012
AB		MACLEODS PHARMS LTD	**5MG**		**A205564**	**001**	Jan 11, 2016
AB		MICRO LABS LTD INDIA	**5MG**		**A202046**	**001**	Sep 17, 2013
AB		SCIEGEN PHARMS INC	**5MG**		**A203646**	**001**	Sep 09, 2014
AB		SUN PHARM	**5MG**		**A090362**	**001**	Jan 31, 2013
AB		SYNTHON PHARMS	**5MG**		**A090229**	**001**	Nov 26, 2010
AB		TEVA PHARMS	**5MG**		**A090199**	**001**	Aug 22, 2011
LEVODOPA							
POWDER;INHALATION							
INBRIJA							
	+!	ACORDA	42MG		N209184	001	Dec 21, 2018
LEVOFLOXACIN							
INJECTABLE;INJECTION							
LEVOFLOXACIN							
AP		BAXTER HLTHCARE CORP	**EQ 500MG/20ML (EQ 25MG/ML)**		**A091436**	**001**	Jun 05, 2013
AP		GLAND PHARMA LTD	**EQ 500MG/20ML (EQ 25MG/ML)**		**A205540**	**001**	Apr 22, 2020
AP			**EQ 750MG/30ML (EQ 25MG/ML)**		**A205540**	**002**	Apr 22, 2020
AP	**!**	RISING	**EQ 500MG/20ML (EQ 25MG/ML)**		**A091644**	**001**	Jun 20, 2011
AP	**!**		**EQ 750MG/30ML (EQ 25MG/ML)**		**A091644**	**002**	Jun 20, 2011

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE CORP	**EQ 250MG/50ML (EQ 5MG/ML)**	**A091397**	**001**	Aug 08, 2013
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A091397**	**002**	Aug 08, 2013
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A091397**	**003**	Aug 08, 2013
AP		FRESENIUS KABI USA	**EQ 250MG/50ML (EQ 5MG/ML)**	**A200674**	**001**	Jun 19, 2013
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A200674**	**002**	Jun 19, 2013
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A200674**	**003**	Jun 19, 2013
AP		GLAND PHARMA LTD	**EQ 250MG/50ML (EQ 5MG/ML)**	**A206908**	**001**	Dec 30, 2020
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A206908**	**002**	Dec 30, 2020
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A206908**	**003**	Dec 30, 2020
AP		HIKMA FARMACEUTICA	**EQ 250MG/50ML (EQ 5MG/ML)**	**A091375**	**001**	Sep 16, 2011
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A091375**	**002**	Sep 16, 2011
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A091375**	**003**	Sep 16, 2011
AP		HOSPIRA	**EQ 250MG/50ML (EQ 5MG/ML)**	**A078579**	**001**	Sep 03, 2015
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A078579**	**002**	Sep 03, 2015
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A078579**	**003**	Sep 03, 2015
AP	!	INFORLIFE	**EQ 250MG/50ML (EQ 5MG/ML)**	**A090343**	**001**	Jul 07, 2011
AP	!		**EQ 500MG/100ML (EQ 5MG/ML)**	**A090343**	**002**	Jul 07, 2011
AP	!		**EQ 750MG/150ML (EQ 5MG/ML)**	**A090343**	**003**	Jul 07, 2011

SOLUTION;ORAL

LEVOFLOXACIN

AA		LANNETT CO INC	**250MG/10ML**	**A205222**	**001**	May 25, 2018
AA	!	NOVITIUM PHARMA	**250MG/10ML**	**A091678**	**001**	Jun 20, 2011

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

		MICRO LABS LTD INDIA	1.5%	A205600	001	Feb 27, 2019
	!	RISING	0.5%	A077700	001	Dec 20, 2010

TABLET;ORAL

LEVOFLOXACIN

AB		APOTEX INC	**250MG**	**A090787**	**001**	Sep 29, 2011
AB			**500MG**	**A090787**	**002**	Sep 29, 2011
AB			**750MG**	**A090787**	**003**	Sep 29, 2011
AB		AUROBINDO PHARMA LTD	**250MG**	**A201043**	**001**	Jun 20, 2011
AB			**500MG**	**A201043**	**002**	Jun 20, 2011
AB	!		**750MG**	**A201043**	**003**	Jun 20, 2011
AB		CADILA	**250MG**	**A077652**	**001**	Sep 07, 2012
AB			**500MG**	**A077652**	**002**	Sep 07, 2012
AB			**750MG**	**A077652**	**003**	Sep 07, 2012
AB		CELLTRION	**250MG**	**A090367**	**001**	Jun 20, 2011
AB			**500MG**	**A090367**	**002**	Jun 20, 2011
AB			**750MG**	**A090367**	**003**	Jun 20, 2011
AB		CHARTWELL MOLECULAR	**250MG**	**A076890**	**001**	Mar 30, 2012
AB			**500MG**	**A076890**	**002**	Mar 30, 2012
AB			**750MG**	**A076890**	**003**	Mar 30, 2012
AB		DR REDDYS LABS INC	**250MG**	**A076710**	**001**	Jun 20, 2011
AB			**500MG**	**A076710**	**002**	Jun 20, 2011
AB			**750MG**	**A076710**	**003**	Jun 20, 2011
AB		GLENMARK GENERICS	**250MG**	**A200250**	**001**	Jun 20, 2011
AB			**500MG**	**A200250**	**002**	Jun 20, 2011
AB			**750MG**	**A200250**	**003**	Jun 20, 2011
AB		HEC PHARM	**250MG**	**A204968**	**001**	Feb 05, 2019
AB			**500MG**	**A204968**	**002**	Feb 05, 2019
AB			**750MG**	**A204968**	**003**	Feb 05, 2019
AB		HETERO LABS LTD V	**250MG**	**A202801**	**001**	Jan 08, 2015
AB			**500MG**	**A202801**	**002**	Jan 08, 2015
AB			**750MG**	**A202801**	**003**	Jan 08, 2015
AB		LUPIN	**250MG**	**A078424**	**001**	Jun 20, 2011
AB			**500MG**	**A078424**	**002**	Jun 20, 2011
AB			**750MG**	**A078424**	**003**	Jun 20, 2011
AB		MACLEODS PHARMS LTD	**250MG**	**A200839**	**001**	Mar 22, 2012
AB			**500MG**	**A200839**	**002**	Mar 22, 2012
AB			**750MG**	**A200839**	**003**	Mar 22, 2012
AB		ORBION PHARMS	**250MG**	**A202200**	**001**	Jan 30, 2012
AB			**500MG**	**A202200**	**002**	Jan 30, 2012
AB			**750MG**	**A202200**	**003**	Jan 30, 2012
AB		SANDOZ	**250MG**	**A077438**	**001**	Jun 20, 2011
AB			**500MG**	**A077438**	**002**	Jun 20, 2011
AB			**750MG**	**A077438**	**003**	Jun 20, 2011

LEVOFLOXACIN
TABLET;ORAL
LEVOFLOXACIN

AB		TEVA	**250MG**	**A076361**	**001**	Jun 20, 2011
AB			**500MG**	**A076361**	**002**	Jun 20, 2011
AB			**750MG**	**A076361**	**003**	Jun 20, 2011

LEVOKETOCONAZOLE
TABLET;ORAL
RECORLEV

	+!	STRONGBRIDGE	150MG	N214133	001	Dec 30, 2021

LEVOLEUCOVORIN
POWDER;INTRAVENOUS
KHAPZORY

	+!	ACROTECH BIOPHARMA	175MG/VIAL	N211226	001	Oct 19, 2018

LEVOLEUCOVORIN CALCIUM
POWDER;INTRAVENOUS
FUSILEV

AP	**+!**	ACROTECH BIOPHARMA	**EQ 50MG BASE/VIAL**	**N020140**	**001**	Mar 07, 2008

LEVOLEUCOVORIN CALCIUM

AP		MEITHEAL	**EQ 50MG BASE/VIAL**	**A211003**	**001**	Aug 22, 2019

SOLUTION;INTRAVENOUS
LEVOLEUCOVORIN CALCIUM

AP		AMNEAL	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A207548**	**001**	Sep 08, 2017
AP		GLAND PHARMA LTD	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A210892**	**001**	Sep 14, 2018
AP	**!**		**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A210892**	**002**	Sep 14, 2018
AP		HAINAN POLY PHARM	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A217314**	**001**	May 22, 2023
AP			**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A217314**	**002**	May 22, 2023
AP	**!**	MEITHEAL	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A211002**	**001**	Aug 16, 2019
AP		SANDOZ	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A203563**	**001**	Mar 09, 2015

LEVOMILNACIPRAN HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
LEVOMILNACIPRAN HYDROCHLORIDE

AB		PRINSTON INC	**EQ 20MG BASE**	**A210771**	**001**	Mar 20, 2023
AB			**EQ 40MG BASE**	**A210771**	**002**	Mar 20, 2023
AB			**EQ 80MG BASE**	**A210771**	**003**	Mar 20, 2023
AB			**EQ 120MG BASE**	**A210771**	**004**	Mar 20, 2023

FETZIMA

	+	ABBVIE	EQ 20MG BASE	N204168	001	Jul 25, 2013
	+		EQ 40MG BASE	N204168	002	Jul 25, 2013
	+		EQ 80MG BASE	N204168	003	Jul 25, 2013
	+!		EQ 120MG BASE	N204168	004	Jul 25, 2013

LEVONORGESTREL
INTRAUTERINE DEVICE;INTRAUTERINE
KYLEENA

	+!	BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016

LILETTA

	+!	MEDICINES360	52MG	N206229	001	Feb 26, 2015

MIRENA

	+!	BAYER HLTHCARE	52MG	N021225	001	Dec 06, 2000

SKYLA

	+!	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013

LEVORPHANOL TARTRATE
TABLET;ORAL
LEVORPHANOL TARTRATE

AB		HIKMA	**2MG**	**A074278**	**001**	Mar 31, 2000
AB		NOVITIUM PHARMA	**2MG**	**A213479**	**001**	Jul 01, 2020
AB	**!**		**3MG**	**A213479**	**002**	Jan 12, 2021
AB		SPECGX LLC	**2MG**	**A212024**	**001**	Dec 13, 2019
AB		SUN PHARM INDS INC	**2MG**	**A213906**	**001**	Jun 17, 2021
AB			**3MG**	**A213906**	**002**	Apr 25, 2023
AB		VIRTUS	**2MG**	**A211484**	**001**	Dec 13, 2018
		NOVITIUM PHARMA	1MG	A213479	003	Jul 20, 2021

LEVOTHYROXINE SODIUM
CAPSULE;ORAL
TIROSINT

	+	IBSA	0.013MG	N021924	013	Aug 01, 2007
	+		0.025MG	N021924	002	Oct 13, 2006
	+		0.0375MG	N021924	014	Jun 22, 2022
	+		0.044MG	N021924	015	Jun 22, 2022

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

TIROSINT

	+		0.05MG	N021924	003	Oct 13, 2006
	+		0.0625MG	N021924	016	Jun 22, 2022
	+		0.075MG	N021924	004	Oct 13, 2006
	+		0.088MG	N021924	010	Oct 02, 2009
	+		0.1MG	N021924	005	Oct 13, 2006
	+		0.112MG	N021924	008	Oct 02, 2009
	+		0.125MG	N021924	006	Oct 13, 2006
	+		0.137MG	N021924	009	Oct 02, 2009
	+		0.15MG	N021924	007	Oct 13, 2006
	+		0.175MG	N021924	011	Apr 25, 2017
	+!		0.2MG	N021924	012	Apr 25, 2017

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	**+!**	FRESENIUS KABI USA	**100MCG/VIAL**	**N202231**	**001**	Jun 24, 2011
AP	**+!**		**200MCG/VIAL**	**N202231**	**002**	Jun 24, 2011
AP	**+!**		**500MCG/VIAL**	**N202231**	**003**	Jun 24, 2011
AP		MAIA PHARMS INC	**100MCG/VIAL**	**A208749**	**001**	Dec 21, 2018
AP			**200MCG/VIAL**	**A208749**	**002**	Dec 21, 2018
AP			**500MCG/VIAL**	**A208749**	**003**	Dec 21, 2018
AP		PIRAMAL CRITICAL	**100MCG/VIAL**	**A206163**	**001**	Jun 29, 2016
AP			**500MCG/VIAL**	**A206163**	**002**	Jun 29, 2016
AP		ZYDUS PHARMS	**100MCG/VIAL**	**A217066**	**001**	Mar 24, 2023
AP			**200MCG/VIAL**	**A217066**	**002**	Mar 24, 2023
AP			**500MCG/VIAL**	**A217066**	**003**	Mar 24, 2023

SOLUTION;INTRAVENOUS

LEVOTHYROXINE SODIUM

	+!	FRESENIUS KABI USA	100MCG/5ML (20MCG/ML)	N210632	001	Apr 11, 2019
	+!		200MCG/5ML (40MCG/ML)	N210632	002	Apr 11, 2019
	+!		500MCG/5ML (100MCG/ML)	N210632	003	Apr 11, 2019
	+!	HIKMA	100MCG/ML	N214253	001	May 17, 2021

SOLUTION;ORAL

ERMEZA

	+!	MYLAN	150MCG/5ML	N215809	001	Apr 29, 2022

THYQUIDITY

	+!	AZURITY	100MCG/5ML	N214047	001	Nov 30, 2020

TIROSINT-SOL

	+	IBSA	13MCG/ML	N206977	001	Dec 15, 2016
	+		25MCG/ML	N206977	002	Dec 15, 2016
	+		37.5MCG/ML	N206977	013	Jan 13, 2021
	+		44MCG/ML	N206977	014	Jan 13, 2021
	+		50MCG/ML	N206977	003	Dec 15, 2016
	+		62.5MCG/ML	N206977	015	Jan 13, 2021
	+		75MCG/ML	N206977	004	Dec 15, 2016
	+		88MCG/ML	N206977	005	Dec 15, 2016
	+		100MCG/ML	N206977	006	Dec 15, 2016
	+		112MCG/ML	N206977	007	Dec 15, 2016
	+		125MCG/ML	N206977	008	Dec 15, 2016
	+		137MCG/ML	N206977	009	Dec 15, 2016
	+		150MCG/ML	N206977	010	Dec 15, 2016
	+		175MCG/ML	N206977	011	Dec 15, 2016
	+!		200MCG/ML	N206977	012	Dec 15, 2016

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

SYNTHROID

-->	**+**	ABBVIE	**--> AB1,AB2**	**0.025MG**	N021402	001	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.05MG**	N021402	002	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.075MG**	N021402	003	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.088MG**	N021402	004	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.1MG**	N021402	005	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.112MG**	N021402	006	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.125MG**	N021402	007	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.137MG**	N021402	008	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.15MG**	N021402	009	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.175MG**	N021402	010	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.2MG**	N021402	012	Jul 24, 2002
-->	**+!**		**--> AB1,AB2**	**0.3MG**	N021402	011	Jul 24, 2002

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

	LEVO-T						
-->		CEDIPROF INC	--> AB1,AB2,AB3	0.025MG	N021342	001	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.05MG	N021342	002	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.075MG	N021342	003	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.088MG	N021342	004	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.1MG	N021342	005	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.112MG	N021342	006	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.125MG	N021342	007	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.137MG	N021342	012	Dec 08, 2003
-->			--> AB1,AB2,AB3	0.15MG	N021342	008	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.175MG	N021342	009	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.2MG	N021342	010	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.3MG	N021342	011	Mar 01, 2002
	LEVOTHYROXINE SODIUM						
-->		LUPIN	--> AB1,AB2,AB3	0.025MG	A209713	001	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.05MG	A209713	002	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.075MG	A209713	003	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.088MG	A209713	004	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.1MG	A209713	005	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.112MG	A209713	006	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.125MG	A209713	007	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.137MG	A209713	008	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.15MG	A209713	009	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.175MG	A209713	010	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.2MG	A209713	011	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.3MG	A209713	012	Jan 18, 2019
	UNITHROID						
-->	+	STEVENS J	--> AB1,AB2,AB3	0.025MG	N021210	001	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.05MG	N021210	002	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.075MG	N021210	003	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.088MG	N021210	004	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.1MG	N021210	005	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.112MG	N021210	006	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.125MG	N021210	007	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.137MG	N021210	012	Feb 08, 2008
-->	+		--> AB1,AB2,AB3	0.15MG	N021210	008	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.175MG	N021210	009	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.2MG	N021210	010	Aug 21, 2000
-->	+!		--> AB1,AB2,AB3	0.3MG	N021210	011	Aug 21, 2000

LEVOTHYROXINE SODIUM **
**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL

	LEVOLET					
-->	GENUS LIFESCIENCES	-->	**0.025MG**	N021137	001	Jun 06, 2003
		AB1,AB2,AB3,AB4				
-->		-->	**0.05MG**	N021137	002	Jun 06, 2003
		AB1,AB2,AB3,AB4				
-->		-->	**0.075MG**	N021137	003	Jun 06, 2003
		AB1,AB2,AB3,AB4				
-->		-->	**0.088MG**	N021137	004	Jun 06, 2003
		AB1,AB2,AB3,AB4				
-->		-->	**0.1MG**	N021137	005	Jun 06, 2003
		AB1,AB2,AB3,AB4				
-->		-->	**0.112MG**	N021137	006	Jun 06, 2003
		AB1,AB2,AB3,AB4				
-->		-->	**0.125MG**	N021137	007	Jun 06, 2003
		AB1,AB2,AB3,AB4				
-->		-->	**0.137MG**	N021137	008	Jun 06, 2003
		AB1,AB2,AB3,AB4				
-->		-->	**0.15MG**	N021137	009	Jun 06, 2003
		AB1,AB2,AB3,AB4				
-->		-->	**0.175MG**	N021137	010	Jun 06, 2003
		AB1,AB2,AB3,AB4				
-->		-->	**0.2MG**	N021137	011	Jun 06, 2003
		AB1,AB2,AB3,AB4				
-->		-->	**0.3MG**	N021137	012	Jun 06, 2003
		AB1,AB2,AB3,AB4				
	LEVOTHYROXINE SODIUM					
-->	ACCORD HLTHCARE	-->	**0.025MG**	A212399	001	Oct 19, 2020
		AB1,AB2,AB3,AB4				
-->		-->	**0.05MG**	A212399	002	Oct 19, 2020
		AB1,AB2,AB3,AB4				
-->		-->	**0.075MG**	A212399	003	Oct 19, 2020
		AB1,AB2,AB3,AB4				
-->		-->	**0.088MG**	A212399	004	Oct 19, 2020
		AB1,AB2,AB3,AB4				
-->		-->	**0.1MG**	A212399	005	Oct 19, 2020
		AB1,AB2,AB3,AB4				
-->		-->	**0.112MG**	A212399	006	Oct 19, 2020
		AB1,AB2,AB3,AB4				
-->		-->	**0.125MG**	A212399	007	Oct 19, 2020
		AB1,AB2,AB3,AB4				
-->		-->	**0.137MG**	A212399	008	Oct 19, 2020
		AB1,AB2,AB3,AB4				
-->		-->	**0.15MG**	A212399	009	Oct 19, 2020
		AB1,AB2,AB3,AB4				
-->		-->	**0.175MG**	A212399	010	Oct 19, 2020
		AB1,AB2,AB3,AB4				
-->		-->	**0.2MG**	A212399	011	Oct 19, 2020
		AB1,AB2,AB3,AB4				
-->		-->	**0.3MG**	A212399	012	Oct 19, 2020
		AB1,AB2,AB3,AB4				
-->	MYLAN	-->	**0.025MG**	A076187	001	Jun 05, 2002
		AB1,AB2,AB3,AB4				
-->		-->	**0.05MG**	A076187	002	Jun 05, 2002
		AB1,AB2,AB3,AB4				
-->		-->	**0.075MG**	A076187	003	Jun 05, 2002
		AB1,AB2,AB3,AB4				
-->		-->	**0.088MG**	A076187	004	Jun 05, 2002
		AB1,AB2,AB3,AB4				
-->		-->	**0.1MG**	A076187	005	Jun 05, 2002
		AB1,AB2,AB3,AB4				
-->		-->	**0.112MG**	A076187	006	Jun 05, 2002
		AB1,AB2,AB3,AB4				
-->		-->	**0.125MG**	A076187	007	Jun 05, 2002
		AB1,AB2,AB3,AB4				
-->		-->	**0.137MG**	A076187	012	Dec 13, 2006
		AB1,AB2,AB3,AB4				
-->		-->	**0.15MG**	A076187	008	Jun 05, 2002
		AB1,AB2,AB3,AB4				
-->		-->	**0.175MG**	A076187	009	Jun 05, 2002
		AB1,AB2,AB3,AB4				
-->		-->	**0.2MG**	A076187	010	Jun 05, 2002
		AB1,AB2,AB3,AB4				
-->	!	-->	**0.3MG**	A076187	011	Jun 05, 2002
		AB1,AB2,AB3,AB4				
	THYRO-TABS					
-->	+ ALVOGEN	-->	**0.025MG**	N021116	001	Oct 24, 2002
		AB1,AB2,AB3,AB4				

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

	THYRO-TABS						
-->	+		--> AB1,AB2,AB3,AB4	0.05MG	N021116	002	Oct 24, 2002
-->	+		--> AB1,AB2,AB3,AB4	0.075MG	N021116	003	Oct 24, 2002
-->	+		--> AB1,AB2,AB3,AB4	0.088MG	N021116	010	Oct 24, 2002
-->	+		--> AB1,AB2,AB3,AB4	0.1MG	N021116	004	Oct 24, 2002
-->	+		--> AB1,AB2,AB3,AB4	0.112MG	N021116	011	Oct 24, 2002
-->	+		--> AB1,AB2,AB3,AB4	0.125MG	N021116	005	Oct 24, 2002
-->	+		--> AB1,AB2,AB3,AB4	0.137MG	N021116	012	Dec 07, 2004
-->	+		--> AB1,AB2,AB3,AB4	0.15MG	N021116	006	Oct 24, 2002
-->	+		--> AB1,AB2,AB3,AB4	0.175MG	N021116	007	Oct 24, 2002
-->	+		--> AB1,AB2,AB3,AB4	0.2MG	N021116	008	Oct 24, 2002
-->	+		--> AB1,AB2,AB3,AB4	0.3MG	N021116	009	Oct 24, 2002
	LEVOXYL						
-->	+	KING PHARMS	--> AB1,AB3	0.025MG	N021301	001	May 25, 2001
-->	+		--> AB1,AB3	0.05MG	N021301	002	May 25, 2001
-->	+		--> AB1,AB3	0.075MG	N021301	003	May 25, 2001
-->	+		--> AB1,AB3	0.088MG	N021301	004	May 25, 2001
-->	+		--> AB1,AB3	0.1MG	N021301	005	May 25, 2001
-->	+		--> AB1,AB3	0.112MG	N021301	006	May 25, 2001
-->	+		--> AB1,AB3	0.125MG	N021301	007	May 25, 2001
-->	+		--> AB1,AB3	0.137MG	N021301	008	May 25, 2001
-->	+		--> AB1,AB3	0.15MG	N021301	009	May 25, 2001
-->	+		--> AB1,AB3	0.175MG	N021301	010	May 25, 2001
-->	+!		--> AB1,AB3	0.2MG	N021301	011	May 25, 2001
	EUTHYROX						
AB2		PROVELL	0.025MG		N021292	001	May 31, 2002
AB2			0.05MG		N021292	002	May 31, 2002
AB2			0.075MG		N021292	003	May 31, 2002
AB2			0.088MG		N021292	004	May 31, 2002
AB2			0.1MG		N021292	005	May 31, 2002
AB2			0.112MG		N021292	006	May 31, 2002
AB2			0.125MG		N021292	007	May 31, 2002
AB2			0.137MG		N021292	008	May 31, 2002
AB2			0.15MG		N021292	009	May 31, 2002
AB2			0.175MG		N021292	010	May 31, 2002
AB2			0.2MG		N021292	011	May 31, 2002
	LEVOTHYROXINE SODIUM						
AB2		MACLEODS PHARMS LTD	0.025MG		A211417	001	Dec 21, 2022
AB2			0.05MG		A211417	002	Dec 21, 2022
AB2			0.075MG		A211417	003	Dec 21, 2022
AB2			0.088MG		A211417	004	Dec 21, 2022
AB2			0.1MG		A211417	005	Dec 21, 2022
AB2			0.112MG		A211417	006	Dec 21, 2022
AB2			0.125MG		A211417	007	Dec 21, 2022
AB2			0.137MG		A211417	008	Dec 21, 2022
AB2			0.15MG		A211417	009	Dec 21, 2022
AB2			0.175MG		A211417	010	Dec 21, 2022
AB2			0.2MG		A211417	011	Dec 21, 2022
AB2			0.3MG		A211417	012	Dec 21, 2022
AB2		WATSON LABS TEVA	0.025MG		A207588	001	May 10, 2022
AB2			0.05MG		A207588	002	May 10, 2022
AB2			0.075MG		A207588	003	May 10, 2022
AB2			0.088MG		A207588	004	May 10, 2022
AB2			0.1MG		A207588	005	May 10, 2022
AB2			0.112MG		A207588	006	May 10, 2022
AB2			0.125MG		A207588	007	May 10, 2022
AB2			0.137MG		A207588	008	May 10, 2022
AB2			0.15MG		A207588	009	May 10, 2022
AB2			0.175MG		A207588	010	May 10, 2022
AB2			0.2MG		A207588	011	May 10, 2022
AB2			0.3MG		A207588	012	May 10, 2022

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOTHYROXINE SODIUM

AB4		ASCENT PHARMS INC	**0.025MG**	**A215259**	**001**	Jan 18, 2023
AB4			**0.05MG**	**A215259**	**002**	Jan 18, 2023
AB4			**0.075MG**	**A215259**	**003**	Jan 18, 2023
AB4			**0.088MG**	**A215259**	**004**	Jan 18, 2023
AB4			**0.1MG**	**A215259**	**005**	Jan 18, 2023
AB4			**0.112MG**	**A215259**	**006**	Jan 18, 2023
AB4			**0.125MG**	**A215259**	**007**	Jan 18, 2023
AB4			**0.137MG**	**A215259**	**008**	Jan 18, 2023
AB4			**0.15MG**	**A215259**	**009**	Jan 18, 2023
AB4			**0.175MG**	**A215259**	**010**	Jan 18, 2023
AB4			**0.2MG**	**A215259**	**011**	Jan 18, 2023
AB4			**0.3MG**	**A215259**	**012**	Jan 18, 2023

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT		ALEMBIC	**5%**	**A211469**	**001**	Nov 23, 2018
AT		ALKEM LABS LTD	**5%**	**A207810**	**001**	Mar 10, 2017
AT		AMNEAL PHARMS	**5%**	**A206297**	**001**	Aug 07, 2015
AT		COSETTE	**5%**	**A211019**	**001**	Dec 12, 2018
AT		DR REDDYS	**5%**	**A208660**	**001**	Jan 05, 2021
AT	**+!**	FOUGERA PHARMS INC	**5%**	**A080198**	**001**	
AT		GLENMARK PHARMS LTD	**5%**	**A206498**	**001**	Sep 09, 2016
AT		MACLEODS PHARMS LTD	**5%**	**A211697**	**001**	Mar 16, 2020
AT		QUAGEN	**5%**	**A212695**	**001**	Apr 20, 2021
AT		SEPTODONT INC	**5%**	**A040911**	**001**	May 23, 2011
AT		STRIDES PHARMA	**5%**	**A210958**	**001**	Dec 11, 2018
AT		TARO	**5%**	**A086724**	**001**	

PATCH;TOPICAL

LIDOCAINE

AB		ACTAVIS LABS UT INC	**5%**	**A200675**	**001**	Aug 23, 2012
AB		AMNEAL	**5%**	**A206463**	**001**	Aug 24, 2020
AB		IBSA	**5%**	**A209190**	**001**	Apr 30, 2020
AB		MYLAN TECHNOLOGIES	**5%**	**A202346**	**001**	Aug 07, 2015
AB		NAL PHARM	**5%**	**A205882**	**001**	Apr 29, 2021

LIDODERM

AB	**+!**	TEIKOKU PHARMA USA	**5%**	**N020612**	**001**	Mar 19, 1999

ZTLIDO

	+!	SCILEX PHARMS	1.8%	N207962	001	Feb 28, 2018

LIDOCAINE HYDROCHLORIDE

GEL;OPHTHALMIC

AKTEN

	+!	THEA PHARMA	3.5%	N022221	001	Oct 07, 2008

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP		AFAXYS	**1%**	**A215132**	**001**	Jun 09, 2022
AP		ASPIRO	**1%**	**A214336**	**001**	Nov 08, 2021
AP			**1%**	**A214339**	**001**	Nov 08, 2021
AP			**2%**	**A214336**	**002**	Dec 13, 2023
AP			**2%**	**A214339**	**002**	Nov 08, 2021
AP		B BRAUN MEDICAL INC	**1%**	**A208474**	**001**	Aug 03, 2018
AP		EUGIA PHARMA	**1%**	**A207182**	**001**	Oct 30, 2017
AP			**2%**	**A207182**	**002**	Oct 30, 2017
AP		FRESENIUS KABI USA	**1%**	**A080404**	**002**	
AP			**2%**	**A080404**	**003**	
AP		HOSPIRA	**0.5%**	**A088328**	**001**	May 17, 1984
AP	**+!**		**1%**	**A083158**	**001**	
AP			**1%**	**A088329**	**001**	May 17, 1984
AP			**2%**	**A040078**	**001**	Jun 23, 1995
AP	**+!**		**2%**	**A083158**	**002**	
AP			**2%**	**A088294**	**001**	May 17, 1984
AP		HUONS	**1%**	**A212821**	**001**	May 07, 2020
AP			**2%**	**A212821**	**002**	Jun 15, 2023
AP		INTL MEDICATION	**1%**	**A083173**	**001**	
AP			**2%**	**A083173**	**002**	
AP		MANKIND PHARMA	**1%**	**A217692**	**001**	Jun 16, 2023
AP			**1%**	**A217692**	**003**	Nov 29, 2023
AP			**1%**	**A217693**	**001**	Jul 11, 2023

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION						
LIDOCAINE HYDROCHLORIDE						
AP			**2%**	**A217692**	**002**	Jun 16, 2023
AP			**2%**	**A217693**	**002**	Jul 11, 2023
AP		SINTETICA US	**1%**	**A214267**	**001**	Sep 19, 2022
AP			**2%**	**A214267**	**002**	Sep 19, 2022
AP			**4%**	**A214269**	**001**	May 05, 2022
AP		SPECTRA MDCL DEVICES	**1%**	**A208017**	**001**	Apr 18, 2018
AP		WEST-WARD PHARMS INT	**1%**	**A080407**	**001**	
AP			**2%**	**A080407**	**002**	
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER						
AP		B BRAUN	**200MG/100ML**	**N019830**	**002**	Apr 08, 1992
AP		BAXTER HLTHCARE	**200MG/100ML**	**N018461**	**002**	
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER						
AP		B BRAUN	**400MG/100ML**	**N019830**	**003**	Apr 08, 1992
AP		BAXTER HLTHCARE	**400MG/100ML**	**N018461**	**003**	
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER						
AP		B BRAUN	**800MG/100ML**	**N019830**	**004**	Apr 08, 1992
AP		BAXTER HLTHCARE	**800MG/100ML**	**N018461**	**004**	Feb 22, 1982
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER						
AP		FRESENIUS KABI USA	**1%**	**A088586**	**001**	Jul 24, 1985
AP		HOSPIRA	**0.5%**	**A088325**	**001**	Jul 31, 1984
AP			**1%**	**A088299**	**001**	Jul 31, 1984
AP			**2%**	**A088327**	**001**	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
AP		EUGIA PHARMA	**1%**	**A203040**	**001**	Mar 14, 2013
AP			**1%**	**A203082**	**001**	Mar 14, 2013
AP			**2%**	**A203040**	**002**	Mar 14, 2013
AP			**2%**	**A203082**	**002**	Mar 14, 2013
AP		FRESENIUS KABI USA	**2%**	**N017584**	**001**	
AP			**4%**	**N017584**	**002**	
AP		HOSPIRA	**1%**	**A080408**	**001**	
AP			**1.5%**	**A080408**	**002**	
AP	**!**		**4%**	**A088295**	**001**	May 17, 1984
AP		WEST-WARD PHARMS INT	**1%**	**A084625**	**001**	
AP			**2%**	**A084625**	**002**	
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER						
AP		HOSPIRA	**1%**	**A040302**	**001**	Sep 28, 1998
AP			**2%**	**A040302**	**002**	Sep 28, 1998
XYLOCAINE						
AP	**+!**	FRESENIUS KABI USA	**0.5%**	**N006488**	**008**	
AP	**+!**		**1%**	**N006488**	**007**	
AP	**+!**		**1.5%**	**N006488**	**010**	
AP	**+!**		**2%**	**N006488**	**002**	
INJECTABLE;SPINAL						
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%						
	+!	HOSPIRA	5%	A083914	001	
JELLY;TOPICAL						
GLYDO						
AT	**!**	SAGENT PHARMS INC	**2%**	**A201094**	**001**	Apr 28, 2014
LIDOCAINE HYDROCHLORIDE						
AT		INTL MEDICATION	**2%**	**A086283**	**001**	
AT		SENTISS	**2%**	**A040433**	**001**	Feb 12, 2003
SOLUTION;ORAL						
LIDOCAINE HYDROCHLORIDE						
AT	**!**	RUBICON	**2%**	**A216780**	**001**	Mar 28, 2023
AT		WOCKHARDT BIO AG	**2%**	**A087872**	**001**	Nov 18, 1982
LIDOCAINE HYDROCHLORIDE VISCOUS						
AT		CHARTWELL MOLECULAR	**2%**	**A040708**	**001**	Feb 27, 2007
LIDOCAINE VISCOUS						
AT		HIKMA	**2%**	**A088802**	**001**	Apr 26, 1985
SOLUTION;TOPICAL						
LARYNG-O-JET KIT						
AT		INTL MEDICATION	**4%**	**A086364**	**001**	
LIDOCAINE HYDROCHLORIDE						
AT	**!**	HIKMA	**4%**	**A088803**	**001**	Apr 03, 1985
AT		LANNETT CO INC	**4%**	**A040710**	**001**	Feb 27, 2007
AT		NOVITIUM PHARMA	**4%**	**A216250**	**001**	Mar 23, 2022
AT		PAI HOLDINGS PHARM	**4%**	**A204494**	**001**	Mar 12, 2014

LIDOCAINE HYDROCHLORIDE

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

AT		TARO	**4%**	**A218182**	**001**	Dec 07, 2023
AT		WOCKHARDT BIO AG	**4%**	**A087881**	**001**	Nov 18, 1982

SYSTEM;INTRADERMAL

ZINGO

		POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

LIDOCAINE AND PRILOCAINE

AB		ALEMBIC	**2.5%;2.5%**	**A213923**	**001**	Apr 08, 2022
AB		ENCUBE	**2.5%;2.5%**	**A076320**	**001**	Aug 27, 2003
AB	**!**	FOUGERA PHARMS	**2.5%;2.5%**	**A076453**	**001**	Aug 18, 2003
AB		HIKMA	**2.5%;2.5%**	**A076290**	**001**	Sep 25, 2003
AB		PADAGIS US	**2.5%;2.5%**	**A212482**	**001**	Jul 27, 2021

GEL;PERIODONTAL

ORAQIX

	+!	DENTSPLY PHARM	2.5%;2.5%	N021451	001	Dec 19, 2003

LIFITEGRAST

SOLUTION/DROPS;OPHTHALMIC

LIFITEGRAST

AB		EUGIA PHARMA	**5%**	**A215063**	**001**	Nov 07, 2023
AB		MICRO LABS	**5%**	**A215081**	**001**	Aug 04, 2023

XIIDRA

AB	**+!**	NOVARTIS	**5%**	**N208073**	**001**	Jul 11, 2016

LINACLOTIDE

CAPSULE;ORAL

LINZESS

	+!	ABBVIE	72MCG	N202811	003	Jan 25, 2017
	+!		145MCG	N202811	001	Aug 30, 2012
	+		290MCG	N202811	002	Aug 30, 2012

LINAGLIPTIN

TABLET;ORAL

LINAGLIPTIN

AB		SUNSHINE	**5MG**	**A208335**	**001**	Aug 31, 2021

TRADJENTA

AB	**+!**	BOEHRINGER INGELHEIM	**5MG**	**N201280**	**001**	May 02, 2011

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

JENTADUETO

AB	**+**	BOEHRINGER INGELHEIM	**2.5MG;500MG**	**N201281**	**001**	Jan 30, 2012
AB	**+**		**2.5MG;850MG**	**N201281**	**002**	Jan 30, 2012
AB	**+!**		**2.5MG;1GM**	**N201281**	**003**	Jan 30, 2012

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB		SUNSHINE	**2.5MG;500MG**	**A208336**	**001**	Aug 30, 2021
AB			**2.5MG;850MG**	**A208336**	**002**	Aug 30, 2021
AB			**2.5MG;1GM**	**A208336**	**003**	Aug 30, 2021

TABLET, EXTENDED RELEASE;ORAL

JENTADUETO XR

	+	BOEHRINGER INGELHEIM	2.5MG;1GM	N208026	001	May 27, 2016
	+!		5MG;1GM	N208026	002	May 27, 2016

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOCIN

AP	**+!**	PFIZER	**EQ 300MG BASE/ML**	**N050317**	**001**	

LINCOMYCIN HYDROCHLORIDE

AP		GLAND PHARMA LTD	**EQ 300MG BASE/ML**	**A215657**	**001**	Sep 26, 2022
AP		MICRO LABS	**EQ 300MG BASE/ML**	**A215082**	**001**	Nov 08, 2021
AP		XGEN PHARMS	**EQ 300MG BASE/ML**	**A201746**	**001**	Jun 04, 2015

LINEZOLID						
FOR SUSPENSION;ORAL						
LINEZOLID						
AB		HETERO LABS	**100MG/5ML**	**A211813**	**001**	Oct 31, 2022
AB		HIKMA	**100MG/5ML**	**A200068**	**001**	Jun 03, 2015
ZYVOX						
AB	**+!**	PFIZER	**100MG/5ML**	**N021132**	**001**	Apr 18, 2000
SOLUTION;INTRAVENOUS						
LINEZOLID						
AP		EUGIA PHARMA	**600MG/300ML (2MG/ML)**	**A206917**	**001**	Aug 04, 2016
AP		FRESENIUS KABI USA	**600MG/300ML (2MG/ML)**	**A204764**	**001**	Mar 15, 2016
AP		HIKMA	**600MG/300ML (2MG/ML)**	**A206454**	**001**	Aug 22, 2022
AP		HQ SPCLT PHARMA	**200MG/100ML (2MG/ML)**	**A207001**	**001**	Jul 07, 2017
AP			**600MG/300ML (2MG/ML)**	**A207001**	**002**	Jul 07, 2017
AP		MYLAN LABS LTD	**200MG/100ML (2MG/ML)**	**A205154**	**001**	Dec 06, 2017
AP			**600MG/300ML (2MG/ML)**	**A205154**	**002**	Dec 06, 2017
AP		NANG KUANG PHARM CO	**200MG/100ML (2MG/ML)**	**A207354**	**001**	Dec 20, 2016
AP			**600MG/300ML (2MG/ML)**	**A207354**	**002**	Dec 20, 2016
AP		SAGENT PHARMS INC	**200MG/100ML (2MG/ML)**	**A204696**	**001**	Mar 02, 2017
AP			**600MG/300ML (2MG/ML)**	**A204696**	**002**	Mar 02, 2017
AP		SANDOZ	**200MG/100ML (2MG/ML)**	**A200904**	**001**	Jul 16, 2015
AP			**600MG/300ML (2MG/ML)**	**A200904**	**002**	Jul 16, 2015
ZYVOX						
AP	**+**	PFIZER	**200MG/100ML (2MG/ML)**	**N021131**	**001**	Apr 18, 2000
AP	**+!**		**600MG/300ML (2MG/ML)**	**N021131**	**003**	Apr 18, 2000
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	+!	HOSPIRA	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015
TABLET;ORAL						
LINEZOLID						
AB		ALEMBIC	**600MG**	**A205233**	**001**	Dec 21, 2015
AB		ALKEM LABS LTD	**600MG**	**A205517**	**001**	Dec 21, 2015
AB		CHARTWELL RX	**600MG**	**A210702**	**001**	Apr 25, 2019
AB		GLENMARK PHARMS	**600MG**	**A078987**	**001**	Dec 21, 2015
AB		HETERO LABS LTD V	**600MG**	**A204239**	**001**	Dec 21, 2015
AB		NOVEL LABS INC	**600MG**	**A207526**	**001**	Aug 22, 2016
AB		RISING	**600MG**	**A078845**	**001**	Dec 21, 2015
AB		ZYDUS PHARMS	**600MG**	**A206097**	**001**	Feb 22, 2017
ZYVOX						
AB	**+!**	PFIZER	**600MG**	**N021130**	**002**	Apr 18, 2000
LIOTHYRONINE SODIUM						
INJECTABLE;INJECTION						
LIOTHYRONINE SODIUM						
	!	XGEN PHARMS	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005
TABLET;ORAL						
CYTOMEL						
AB	**+**	KING PHARMS	**EQ 0.005MG BASE**	**N010379**	**001**	
AB	**+**		**EQ 0.025MG BASE**	**N010379**	**002**	
AB	**+**		**EQ 0.05MG BASE**	**N010379**	**003**	
LIOTHYRONINE SODIUM						
AB		DR REDDYS LABS SA	**EQ 0.005MG BASE**	**A090097**	**001**	Mar 20, 2009
AB			**EQ 0.025MG BASE**	**A090097**	**002**	Mar 20, 2009
AB			**EQ 0.05MG BASE**	**A090097**	**003**	Mar 20, 2009
AB		SIGMAPHARM LABS LLC	**EQ 0.005MG BASE**	**A200295**	**001**	Nov 29, 2012
AB			**EQ 0.025MG BASE**	**A200295**	**002**	Nov 29, 2012
AB	**!**		**EQ 0.05MG BASE**	**A200295**	**003**	Nov 29, 2012
AB		SUN PHARM	**EQ 0.005MG BASE**	**A091382**	**001**	Apr 20, 2016
AB			**EQ 0.025MG BASE**	**A091382**	**002**	Apr 20, 2016
AB			**EQ 0.05MG BASE**	**A091382**	**003**	Apr 20, 2016
AB		TEVA PHARMS USA	**EQ 0.005MG BASE**	**A211510**	**001**	Oct 26, 2018
AB			**EQ 0.025MG BASE**	**A211510**	**002**	Oct 26, 2018
AB			**EQ 0.05MG BASE**	**A211510**	**003**	Oct 26, 2018
AB		ZYDUS	**EQ 0.005MG BASE**	**A214803**	**001**	Jan 22, 2021
AB			**EQ 0.025MG BASE**	**A214803**	**002**	Jan 22, 2021
AB			**EQ 0.05MG BASE**	**A214803**	**003**	Jan 22, 2021
LIRAGLUTIDE RECOMBINANT						
SOLUTION;SUBCUTANEOUS						
SAXENDA						
	+!	NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014
VICTOZA						
	+!	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB	ACTAVIS ELIZABETH	**10MG**	**A202802**	**001**	Aug 25, 2023
AB		**20MG**	**A202802**	**002**	Aug 25, 2023
AB		**30MG**	**A202802**	**003**	Aug 25, 2023
AB		**40MG**	**A202802**	**004**	Aug 25, 2023
AB		**50MG**	**A202802**	**005**	Aug 25, 2023
AB		**60MG**	**A202802**	**006**	Aug 25, 2023
AB		**70MG**	**A202802**	**007**	Aug 25, 2023
AB	ALKEM LABS LTD	**10MG**	**A217194**	**001**	Aug 25, 2023
AB		**20MG**	**A217194**	**002**	Aug 25, 2023
AB		**30MG**	**A217194**	**003**	Aug 25, 2023
AB		**40MG**	**A217194**	**004**	Aug 25, 2023
AB		**50MG**	**A217194**	**005**	Aug 25, 2023
AB		**60MG**	**A217194**	**006**	Aug 25, 2023
AB		**70MG**	**A217194**	**007**	Aug 25, 2023
AB	AMNEAL	**20MG**	**A202830**	**001**	Aug 25, 2023
AB		**30MG**	**A202830**	**002**	Aug 25, 2023
AB		**40MG**	**A202830**	**003**	Aug 25, 2023
AB		**50MG**	**A202830**	**004**	Aug 25, 2023
AB		**60MG**	**A202830**	**005**	Aug 25, 2023
AB		**70MG**	**A202830**	**006**	Aug 25, 2023
AB	APOTEX	**10MG**	**A216944**	**001**	Aug 25, 2023
AB		**20MG**	**A216944**	**002**	Aug 25, 2023
AB		**30MG**	**A216944**	**003**	Aug 25, 2023
AB		**40MG**	**A216944**	**004**	Aug 25, 2023
AB		**50MG**	**A216944**	**005**	Aug 25, 2023
AB		**60MG**	**A216944**	**006**	Aug 25, 2023
AB		**70MG**	**A216944**	**007**	Aug 25, 2023
AB	ASCENT PHARMS INC	**10MG**	**A217442**	**001**	Aug 25, 2023
AB		**20MG**	**A217442**	**002**	Aug 25, 2023
AB		**30MG**	**A217442**	**003**	Aug 25, 2023
AB		**40MG**	**A217442**	**004**	Aug 25, 2023
AB		**50MG**	**A217442**	**005**	Aug 25, 2023
AB		**60MG**	**A217442**	**006**	Aug 25, 2023
AB		**70MG**	**A217442**	**007**	Aug 25, 2023
AB	HIKMA	**20MG**	**A202827**	**001**	Aug 25, 2023
AB		**30MG**	**A202827**	**002**	Aug 25, 2023
AB		**40MG**	**A202827**	**003**	Aug 25, 2023
AB		**50MG**	**A202827**	**004**	Aug 25, 2023
AB		**60MG**	**A202827**	**005**	Aug 25, 2023
AB		**70MG**	**A202827**	**006**	Aug 25, 2023
AB	LANNETT CO INC	**10MG**	**A215802**	**001**	Aug 25, 2023
AB		**20MG**	**A215802**	**002**	Aug 25, 2023
AB		**30MG**	**A215802**	**003**	Aug 25, 2023
AB		**40MG**	**A215802**	**004**	Aug 25, 2023
AB		**50MG**	**A215802**	**005**	Aug 25, 2023
AB		**60MG**	**A215802**	**006**	Aug 25, 2023
AB		**70MG**	**A215802**	**007**	Aug 25, 2023
AB	MYLAN	**10MG**	**A202835**	**001**	Aug 25, 2023
AB		**20MG**	**A202835**	**002**	Aug 25, 2023
AB		**30MG**	**A202835**	**003**	Aug 25, 2023
AB		**40MG**	**A202835**	**004**	Aug 25, 2023
AB		**50MG**	**A202835**	**005**	Aug 25, 2023
AB		**60MG**	**A202835**	**006**	Aug 25, 2023
AB		**70MG**	**A202835**	**007**	Aug 25, 2023
AB	NORWICH	**10MG**	**A214547**	**001**	Aug 25, 2023
AB		**20MG**	**A214547**	**002**	Aug 25, 2023
AB		**30MG**	**A214547**	**003**	Aug 25, 2023
AB		**40MG**	**A214547**	**004**	Aug 25, 2023
AB		**50MG**	**A214547**	**005**	Aug 25, 2023
AB		**60MG**	**A214547**	**006**	Aug 25, 2023
AB		**70MG**	**A214547**	**007**	Aug 25, 2023
AB	PRINSTON INC	**10MG**	**A216266**	**001**	Aug 25, 2023
AB		**20MG**	**A216266**	**002**	Aug 25, 2023
AB		**30MG**	**A216266**	**003**	Aug 25, 2023
AB		**40MG**	**A216266**	**004**	Aug 25, 2023
AB		**50MG**	**A216266**	**005**	Aug 25, 2023
AB		**60MG**	**A216266**	**006**	Aug 25, 2023
AB		**70MG**	**A216266**	**007**	Aug 25, 2023
AB	RHODES PHARMS	**10MG**	**A215330**	**001**	Aug 25, 2023

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB			**20MG**	**A215330**	**002**	Aug 25, 2023
AB			**30MG**	**A215330**	**003**	Aug 25, 2023
AB			**40MG**	**A215330**	**004**	Aug 25, 2023
AB			**50MG**	**A215330**	**005**	Aug 25, 2023
AB			**60MG**	**A215330**	**006**	Aug 25, 2023
AB			**70MG**	**A215330**	**007**	Aug 25, 2023
AB		SPECGX LLC	**10MG**	**A211840**	**001**	Aug 25, 2023
AB			**20MG**	**A211840**	**002**	Aug 25, 2023
AB			**30MG**	**A211840**	**003**	Aug 25, 2023
AB			**40MG**	**A211840**	**004**	Aug 25, 2023
AB			**50MG**	**A211840**	**005**	Aug 25, 2023
AB			**60MG**	**A211840**	**006**	Aug 25, 2023
AB			**70MG**	**A211840**	**007**	Aug 25, 2023
AB		SUN PHARM INDS INC	**10MG**	**A214484**	**001**	Aug 25, 2023
AB			**20MG**	**A214484**	**002**	Aug 25, 2023
AB			**30MG**	**A214484**	**003**	Aug 25, 2023
AB			**40MG**	**A214484**	**004**	Aug 25, 2023
AB			**50MG**	**A214484**	**005**	Aug 25, 2023
AB			**60MG**	**A214484**	**006**	Aug 25, 2023
AB			**70MG**	**A214484**	**007**	Aug 25, 2023

VYVANSE

AB	+	TAKEDA PHARMS USA	**10MG**	**N021977**	**007**	Oct 30, 2014
AB	+		**20MG**	**N021977**	**004**	Dec 10, 2007
AB	+		**30MG**	**N021977**	**001**	Feb 23, 2007
AB	+		**40MG**	**N021977**	**005**	Dec 10, 2007
AB	+		**50MG**	**N021977**	**002**	Feb 23, 2007
AB	+		**60MG**	**N021977**	**006**	Dec 10, 2007
AB	+!		**70MG**	**N021977**	**003**	Feb 23, 2007

TABLET, CHEWABLE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB		ASCENT PHARMS INC	**10MG**	**A217068**	**001**	Aug 25, 2023
AB			**20MG**	**A217068**	**002**	Aug 25, 2023
AB			**30MG**	**A217068**	**003**	Aug 25, 2023
AB			**40MG**	**A217068**	**004**	Aug 25, 2023
AB			**50MG**	**A217068**	**005**	Aug 25, 2023
AB			**60MG**	**A217068**	**006**	Aug 25, 2023
AB		SUN PHARM INDS INC	**10MG**	**A214134**	**001**	Aug 25, 2023
AB			**20MG**	**A214134**	**002**	Aug 25, 2023
AB			**30MG**	**A214134**	**003**	Aug 25, 2023
AB			**40MG**	**A214134**	**004**	Aug 25, 2023
AB			**50MG**	**A214134**	**005**	Aug 25, 2023
AB			**60MG**	**A214134**	**006**	Aug 25, 2023
AB		TEVA PHARMS	**10MG**	**A215415**	**001**	Aug 25, 2023
AB			**20MG**	**A215415**	**002**	Aug 25, 2023
AB			**30MG**	**A215415**	**003**	Aug 25, 2023
AB			**40MG**	**A215415**	**004**	Aug 25, 2023
AB			**50MG**	**A215415**	**005**	Aug 25, 2023
AB			**60MG**	**A215415**	**006**	Aug 25, 2023

VYVANSE

AB	+	TAKEDA PHARMS USA	**10MG**	**N208510**	**001**	Jan 28, 2017
AB	+		**20MG**	**N208510**	**002**	Jan 28, 2017
AB	+		**30MG**	**N208510**	**003**	Jan 28, 2017
AB	+		**40MG**	**N208510**	**004**	Jan 28, 2017
AB	+		**50MG**	**N208510**	**005**	Jan 28, 2017
AB	+!		**60MG**	**N208510**	**006**	Jan 28, 2017

LISINOPRIL

SOLUTION;ORAL

QBRELIS

	+!	AZURITY	1MG/ML	N208401	001	Jul 29, 2016

TABLET;ORAL

LISINOPRIL

AB		ACCORD HLTHCARE	**2.5MG**	**A202554**	**001**	Jul 30, 2013
AB			**5MG**	**A202554**	**002**	Jul 30, 2013
AB			**10MG**	**A202554**	**003**	Jul 30, 2013
AB			**20MG**	**A202554**	**004**	Jul 30, 2013
AB			**30MG**	**A202554**	**005**	Jul 30, 2013
AB			**40MG**	**A202554**	**006**	Jul 30, 2013
AB		ASCENT PHARMS INC	**2.5MG**	**A075903**	**001**	Jul 01, 2002
AB			**5MG**	**A075903**	**002**	Jul 01, 2002

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB		10MG	A075903	003	Jul 01, 2002
AB		20MG	A075903	004	Jul 01, 2002
AB		30MG	A075903	005	Jul 01, 2002
AB		40MG	A075903	006	Jul 01, 2002
AB	AUROBINDO	2.5MG	A077622	001	Feb 22, 2006
AB		5MG	A077622	002	Feb 22, 2006
AB		10MG	A077622	003	Feb 22, 2006
AB		20MG	A077622	004	Feb 22, 2006
AB		30MG	A077622	005	Feb 22, 2006
AB		40MG	A077622	006	Feb 22, 2006
AB	CHARTWELL RX	2.5MG	A075994	001	Jul 01, 2002
AB		5MG	A075994	002	Jul 01, 2002
AB		10MG	A075994	003	Jul 01, 2002
AB		20MG	A075994	004	Jul 01, 2002
AB		30MG	A075994	005	Jul 01, 2002
AB		40MG	A075994	006	Jul 01, 2002
AB	COREPHARMA	2.5MG	A076102	001	Sep 30, 2002
AB		5MG	A076102	002	Sep 30, 2002
AB		10MG	A076102	003	Sep 30, 2002
AB		20MG	A076102	004	Sep 30, 2002
AB		30MG	A076102	005	Sep 30, 2002
AB		40MG	A076102	006	Sep 30, 2002
AB	INVAGEN PHARMS	2.5MG	A203508	001	Oct 29, 2013
AB		5MG	A203508	002	Oct 29, 2013
AB		10MG	A203508	003	Oct 29, 2013
AB		20MG	A203508	004	Oct 29, 2013
AB		30MG	A203508	005	Oct 29, 2013
AB		40MG	A203508	006	Oct 29, 2013
AB	LUPIN	2.5MG	A077321	001	Sep 09, 2005
AB		5MG	A077321	002	Sep 09, 2005
AB		10MG	A077321	003	Sep 09, 2005
AB		20MG	A077321	004	Sep 09, 2005
AB		30MG	A077321	005	Sep 09, 2005
AB		40MG	A077321	006	Sep 09, 2005
AB	PRINSTON INC	2.5MG	A075743	001	Jul 01, 2002
AB		2.5MG	A076164	004	Jul 01, 2002
AB		5MG	A075743	002	Jul 01, 2002
AB		5MG	A076164	005	Jul 01, 2002
AB		10MG	A075743	003	Jul 01, 2002
AB		10MG	A076164	006	Jul 01, 2002
AB		20MG	A075743	004	Jul 01, 2002
AB		20MG	A076164	001	Jul 01, 2002
AB		30MG	A075743	005	Jul 01, 2002
AB		30MG	A076164	002	Jul 01, 2002
AB		40MG	A075743	006	Jul 01, 2002
AB		40MG	A076164	003	Jul 01, 2002
AB	SCIEGEN PHARMS INC	2.5MG	A212041	001	Sep 15, 2020
AB		5MG	A212041	002	Sep 15, 2020
AB		10MG	A212041	003	Sep 15, 2020
AB		20MG	A208920	001	Mar 04, 2021
AB		30MG	A208920	002	Mar 04, 2021
AB		40MG	A208920	003	Mar 04, 2021
AB	SUN PHARM INDS LTD	2.5MG	A075944	001	Jul 01, 2002
AB		5MG	A075944	002	Jul 01, 2002
AB		10MG	A075944	003	Jul 01, 2002
AB		20MG	A075944	004	Jul 01, 2002
AB		30MG	A075944	006	Feb 11, 2003
AB		40MG	A075944	005	Jul 01, 2002
AB	WATSON LABS	2.5MG	A076059	001	Jul 01, 2002
AB		5MG	A076059	002	Jul 01, 2002
AB		10MG	A076059	003	Jul 01, 2002
AB		20MG	A076059	004	Jul 01, 2002
AB		30MG	A076059	005	Jul 01, 2002
AB		40MG	A076059	006	Jul 01, 2002
AB	WOCKHARDT BIO AG	2.5MG	A078402	001	Apr 19, 2007
AB		5MG	A078402	002	Apr 19, 2007
AB		10MG	A078402	003	Apr 19, 2007
AB		20MG	A078402	004	Apr 19, 2007
AB		30MG	A078402	005	Apr 19, 2007

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB			**40MG**	**A078402**	**006**	Apr 19, 2007

ZESTRIL

AB	+	TWI PHARMS	**2.5MG**	**N019777**	**005**	Apr 29, 1993
AB	+		**5MG**	**N019777**	**001**	May 19, 1988
AB	+		**10MG**	**N019777**	**002**	May 19, 1988
AB	+		**20MG**	**N019777**	**003**	May 19, 1988
AB	+		**30MG**	**N019777**	**006**	Jan 20, 1999
AB	+!		**40MG**	**N019777**	**004**	May 19, 1988

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB		ALEMBIC LTD	**150MG**	**A079159**	**001**	Jan 12, 2009
AB			**300MG**	**A079159**	**002**	Jan 12, 2009
AB			**600MG**	**A079159**	**003**	Jan 12, 2009
AB		GLENMARK GENERICS	**150MG**	**A079139**	**001**	Feb 03, 2009
AB			**300MG**	**A079139**	**002**	Feb 03, 2009
AB			**600MG**	**A079139**	**003**	Feb 03, 2009
AB		HETERO LABS LTD III	**150MG**	**A090702**	**001**	Sep 25, 2009
AB			**300MG**	**A090702**	**002**	Sep 25, 2009
AB			**600MG**	**A090702**	**003**	Sep 25, 2009
AB	+	HIKMA	**150MG**	**N017812**	**002**	Jan 28, 1987
AB	+		**300MG**	**N017812**	**001**	
AB	+!		**600MG**	**N017812**	**003**	Jan 28, 1987

TABLET;ORAL

LITHIUM CARBONATE

AB	+!	HIKMA	**300MG**	**N018558**	**001**	Jan 29, 1982
AB		SUN PHARM INDS INC	**300MG**	**A091027**	**001**	Jun 24, 2010

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

AB		GLENMARK GENERICS	**450MG**	**A091616**	**001**	Feb 14, 2011
AB		GLENMARK PHARMS INC	**300MG**	**A091544**	**001**	Dec 27, 2010
AB		HERITAGE PHARMA	**300MG**	**A205532**	**001**	Sep 29, 2016
AB		HIKMA	**300MG**	**A076832**	**001**	Oct 28, 2004
AB	!		**450MG**	**A076691**	**001**	Jan 05, 2004
AB		MYLAN PHARMS INC	**300MG**	**A202288**	**001**	Jun 29, 2012
AB			**450MG**	**A202219**	**001**	Aug 08, 2012
AB		UNIQUE	**300MG**	**A204779**	**001**	Jul 27, 2015
AB			**450MG**	**A205663**	**001**	Jun 05, 2017

LITHOBID

AB	+!	ANI PHARMS	**300MG**	**N018027**	**001**	

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA	!	PAI HOLDINGS PHARM	**EQ 300MG CARBONATE/5ML**	**A070755**	**001**	May 21, 1986
AA		RUBICON	**EQ 300MG CARBONATE/5ML**	**A218036**	**001**	Aug 14, 2023

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ALOMIDE

	+!	NOVARTIS	EQ 0.1% BASE	N020191	001	Sep 23, 1993

LOFEXIDINE HYDROCHLORIDE

TABLET;ORAL

LUCEMYRA

	+!	USWM	EQ 0.18MG BASE	N209229	001	May 16, 2018

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

	+	AMRYT	EQ 5MG BASE	N203858	001	Dec 21, 2012
	+		EQ 10MG BASE	N203858	002	Dec 21, 2012
	+		EQ 20MG BASE	N203858	003	Dec 21, 2012
	+		EQ 30MG BASE	N203858	004	Apr 23, 2015

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

+	CORDEN PHARMA	10MG	N017588	001	
+		40MG	N017588	002	
+!		100MG	N017588	003	

LONAFARNIB

CAPSULE;ORAL

ZOKINVY

+	EIGER BIOPHARMS	50MG	N213969	001	Nov 20, 2020
+!		75MG	N213969	002	Nov 20, 2020

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**2MG**	**A218122**	**001**	Sep 05, 2023
AB		BIONPHARMA	**2MG**	**A215579**	**001**	Oct 22, 2021
AB		EDENBRIDGE PHARMS	**2MG**	**A215001**	**001**	Oct 06, 2021
AB		JUBILANT CADISTA	**2MG**	**A217840**	**001**	Jul 05, 2023
AB	!	MYLAN	**2MG**	**A072741**	**001**	Sep 18, 1991
AB		RUBICON	**2MG**	**A216876**	**001**	Jan 26, 2023
AB		TEVA	**2MG**	**A073192**	**001**	Apr 30, 1992
AB		ZYDUS LIFESCIENCES	**2MG**	**A217471**	**001**	Mar 23, 2023

LOPINAVIR; RITONAVIR

SOLUTION;ORAL

KALETRA

AA	**+!**	ABBVIE	**80MG/ML;20MG/ML**	**N021251**	**001**	Sep 15, 2000

LOPINAVIR AND RITONAVIR

AA		LANNETT CO INC	**80MG/ML;20MG/ML**	**A207407**	**001**	Dec 27, 2016

TABLET;ORAL

KALETRA

AB	**+**	ABBVIE	**100MG;25MG**	**N021906**	**002**	Nov 09, 2007
AB	**+!**		**200MG;50MG**	**N021906**	**001**	Oct 28, 2005

LOPINAVIR AND RITONAVIR

AB		HETERO LABS LTD III	**100MG;25MG**	**A091677**	**001**	Jun 04, 2021
AB			**200MG;50MG**	**A091677**	**002**	Jun 04, 2021
AB		LAURUS	**100MG;25MG**	**A213857**	**001**	Mar 21, 2022
AB			**200MG;50MG**	**A213857**	**002**	Mar 21, 2022

LORAZEPAM

CAPSULE, EXTENDED RELEASE;ORAL

LOREEV XR

+	ALMATICA	1MG	N214826	001	Aug 27, 2021
+		1.5MG	N214826	004	Feb 16, 2022
+		2MG	N214826	002	Aug 27, 2021
+!		3MG	N214826	003	Aug 27, 2021

CONCENTRATE;ORAL

LORAZEPAM

AA		AMNEAL PHARMS	**2MG/ML**	**A091383**	**001**	Dec 23, 2009
AA		HIKMA	**2MG/ML**	**A200169**	**001**	Jan 30, 2012
AA		LUPIN LTD	**2MG/ML**	**A091407**	**001**	Feb 19, 2013
AA		PHARM ASSOC	**2MG/ML**	**A090260**	**001**	Jun 15, 2010

LORAZEPAM INTENSOL

AA	!	HIKMA	**2MG/ML**	**A072755**	**001**	Jun 28, 1991

INJECTABLE;INJECTION

ATIVAN

AP	**+!**	HIKMA	**2MG/ML**	**N018140**	**001**	
AP	**+!**		**4MG/ML**	**N018140**	**002**	

LORAZEPAM

AP		HOSPIRA	**2MG/ML**	**A074243**	**001**	Apr 12, 1994
AP			**2MG/ML**	**A074282**	**001**	May 27, 1994
AP			**4MG/ML**	**A074243**	**002**	Apr 12, 1994
AP			**4MG/ML**	**A074282**	**002**	May 27, 1994
AP		INTL MEDICATION SYS	**2MG/ML**	**A076150**	**001**	Nov 15, 2004
AP		RISING	**2MG/ML**	**A075025**	**001**	Jul 23, 1998

TABLET;ORAL

ATIVAN

AB	**+**	BAUSCH	**0.5MG**	**N017794**	**001**	
AB	**+**		**1MG**	**N017794**	**002**	
AB	**+!**		**2MG**	**N017794**	**003**	

LORAZEPAM

TABLET;ORAL

LORAZEPAM

AB	AUROLIFE PHARMA LLC	**0.5MG**	**A203572**	**001**	Dec 22, 2017
AB		**1MG**	**A203572**	**002**	Dec 22, 2017
AB		**2MG**	**A203572**	**003**	Dec 22, 2017
AB	LEADING	**0.5MG**	**A078203**	**001**	Jul 30, 2007
AB		**1MG**	**A078203**	**002**	Jul 30, 2007
AB		**2MG**	**A078203**	**003**	Jul 30, 2007
AB	OXFORD PHARMS	**0.5MG**	**A077754**	**001**	May 10, 2006
AB		**1MG**	**A077754**	**002**	May 10, 2006
AB		**2MG**	**A077754**	**003**	May 10, 2006
AB	SANDOZ	**0.5MG**	**A071141**	**002**	Apr 21, 1987
AB		**1MG**	**A071141**	**003**	Apr 21, 1987
AB		**2MG**	**A071141**	**001**	Apr 21, 1987
AB	SUN PHARM INDS LTD	**0.5MG**	**A076045**	**001**	Aug 29, 2001
AB		**1MG**	**A076045**	**002**	Aug 29, 2001
AB		**2MG**	**A076045**	**003**	Aug 29, 2001
AB	WATSON LABS	**0.5MG**	**A072926**	**001**	Oct 31, 1991
AB		**1MG**	**A072927**	**001**	Oct 31, 1991
AB		**2MG**	**A072928**	**001**	Oct 31, 1991

LORLATINIB

TABLET;ORAL

LORBRENA

+	PFIZER	25MG	N210868	001	Nov 02, 2018
+!		100MG	N210868	002	Nov 02, 2018

LOSARTAN POTASSIUM

TABLET;ORAL

COZAAR

AB	**+**	ORGANON	**25MG**	**N020386**	**001**	Apr 14, 1995
AB	**+**		**50MG**	**N020386**	**002**	Apr 14, 1995
AB	**+!**		**100MG**	**N020386**	**003**	Oct 13, 1998

LOSARTAN POTASSIUM

AB		ALEMBIC PHARMS LTD	**25MG**	**A090428**	**001**	Oct 06, 2010
AB			**50MG**	**A090428**	**002**	Oct 06, 2010
AB			**100MG**	**A090428**	**003**	Oct 06, 2010
AB		AUROBINDO PHARMA	**25MG**	**A090083**	**001**	Oct 06, 2010
AB			**50MG**	**A090083**	**002**	Oct 06, 2010
AB			**100MG**	**A090083**	**003**	Oct 06, 2010
AB		GRANULES	**25MG**	**A215959**	**001**	Feb 23, 2023
AB			**50MG**	**A215959**	**002**	Feb 23, 2023
AB			**100MG**	**A215959**	**003**	Feb 23, 2023
AB		HETERO LABS LTD V	**25MG**	**A203835**	**001**	Aug 12, 2015
AB			**50MG**	**A203835**	**002**	Aug 12, 2015
AB			**100MG**	**A203835**	**003**	Aug 12, 2015
AB		IPCA LABS LTD	**25MG**	**A200290**	**001**	Aug 30, 2013
AB			**50MG**	**A200290**	**002**	Aug 30, 2013
AB			**100MG**	**A200290**	**003**	Aug 30, 2013
AB		JUBILANT CADISTA	**25MG**	**A201170**	**001**	Sep 18, 2012
AB			**50MG**	**A201170**	**002**	Sep 18, 2012
AB			**100MG**	**A201170**	**003**	Sep 18, 2012
AB		LUPIN LTD	**25MG**	**A078232**	**001**	Oct 06, 2010
AB			**50MG**	**A078232**	**002**	Oct 06, 2010
AB			**100MG**	**A078232**	**003**	Oct 06, 2010
AB		MACLEODS PHARMS LTD	**25MG**	**A202230**	**001**	May 30, 2012
AB			**50MG**	**A202230**	**002**	May 30, 2012
AB			**100MG**	**A202230**	**003**	May 30, 2012
AB		MICRO LABS	**25MG**	**A091541**	**001**	Sep 24, 2012
AB			**50MG**	**A091541**	**002**	Sep 24, 2012
AB			**100MG**	**A091541**	**003**	Sep 24, 2012
AB		MSN	**25MG**	**A217396**	**001**	Aug 14, 2023
AB			**50MG**	**A217396**	**002**	Aug 14, 2023
AB			**100MG**	**A217396**	**003**	Aug 14, 2023
AB		PRINSTON INC	**25MG**	**A091497**	**001**	Jun 06, 2011
AB			**50MG**	**A091497**	**002**	Jun 06, 2011
AB			**100MG**	**A091497**	**003**	Jun 06, 2011
AB		SANDOZ	**25MG**	**A077424**	**001**	Oct 06, 2010
AB			**50MG**	**A077424**	**002**	Oct 06, 2010
AB			**100MG**	**A077424**	**003**	Oct 06, 2010
AB		STRIDES PHARMA	**25MG**	**A090382**	**001**	Oct 06, 2010
AB			**50MG**	**A090382**	**002**	Oct 06, 2010

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB			**100MG**	**A090382**	**003**	Oct 06, 2010
AB		UNICHEM	**25MG**	**A203030**	**001**	Oct 14, 2015
AB			**50MG**	**A203030**	**002**	Oct 14, 2015
AB			**100MG**	**A203030**	**003**	Oct 14, 2015
AB		WATSON LABS	**25MG**	**A091129**	**001**	Oct 06, 2010
AB			**50MG**	**A091129**	**002**	Oct 06, 2010
AB			**100MG**	**A091129**	**003**	Oct 06, 2010
AB		ZYDUS PHARMS USA INC	**25MG**	**A078243**	**001**	Oct 06, 2010
AB			**50MG**	**A078243**	**002**	Oct 06, 2010
AB			**100MG**	**A078243**	**003**	Oct 06, 2010

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEMAX

AB	**+!**	BAUSCH AND LOMB INC	**0.5%**	**N202872**	**001**	Sep 28, 2012

LOTEPREDNOL ETABONATE

AB		SENTISS	**0.5%**	**A212080**	**001**	Feb 10, 2021
AB		SLAYBACK PHARMA LLC	**0.5%**	**A213956**	**001**	Nov 29, 2023
AB		SUN PHARM	**0.5%**	**A215384**	**001**	Aug 09, 2023

LOTEMAX SM

	+!	BAUSCH AND LOMB INC	0.38%	N208219	001	Feb 22, 2019

OINTMENT;OPHTHALMIC

LOTEMAX

	+!	BAUSCH AND LOMB	0.5%	N200738	001	Apr 15, 2011

SUSPENSION/DROPS;OPHTHALMIC

ALREX

AB	**+!**	BAUSCH AND LOMB	**0.2%**	**N020803**	**001**	Mar 09, 1998

LOTEMAX

AB	**+!**	BAUSCH AND LOMB	**0.5%**	**N020583**	**001**	Mar 09, 1998

LOTEPREDNOL ETABONATE

AB		LUPIN LTD	**0.2%**	**A215550**	**001**	Dec 26, 2023
AB		SENTISS	**0.2%**	**A215933**	**001**	Apr 12, 2023
AB			**0.5%**	**A207609**	**001**	Apr 17, 2019
AB		SUN PHARM	**0.5%**	**A212450**	**001**	Feb 26, 2021

EYSUVIS

	+!	ALCON LABS INC	0.25%	N210933	001	Oct 26, 2020

INVELTYS

	+!	ALCON LABS INC	1%	N210565	001	Aug 22, 2018

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

ZYLET

	+!	BAUSCH AND LOMB	0.5%;0.3%	N050804	001	Dec 14, 2004

LOTILANER

SOLUTION/DROPS;OPHTHALMIC

XDEMVY

	+!	TARSUS	0.25%	N217603	001	Jul 24, 2023

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB		ACTAVIS ELIZABETH	**10MG**	**A075828**	**001**	Dec 17, 2001
AB			**20MG**	**A075828**	**002**	Dec 17, 2001
AB			**40MG**	**A075828**	**003**	Dec 17, 2001
AB		CARLSBAD	**10MG**	**A075991**	**001**	Jun 05, 2002
AB			**20MG**	**A075991**	**002**	Jun 05, 2002
AB	**!**		**40MG**	**A075991**	**003**	Jun 05, 2002
AB		CHARTWELL RX	**10MG**	**A075300**	**001**	Dec 17, 2001
AB			**20MG**	**A075300**	**002**	Dec 17, 2001
AB			**40MG**	**A075300**	**003**	Dec 17, 2001
AB		COREPHARMA	**10MG**	**A077748**	**001**	Feb 28, 2007
AB			**20MG**	**A077748**	**002**	Feb 28, 2007
AB			**40MG**	**A077748**	**003**	Feb 28, 2007
AB		EPIC PHARMA LLC	**10MG**	**A075636**	**001**	Dec 17, 2001
AB			**20MG**	**A075636**	**002**	Dec 17, 2001
AB			**40MG**	**A075636**	**003**	Dec 17, 2001
AB		LUPIN	**10MG**	**A078296**	**001**	Mar 14, 2008
AB			**20MG**	**A078296**	**002**	Nov 01, 2007
AB			**40MG**	**A078296**	**003**	Nov 01, 2007
AB		TEVA	**10MG**	**A075551**	**003**	Dec 17, 2001

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB			**20MG**	**A075551**	**002**	Dec 17, 2001
AB			**40MG**	**A075551**	**001**	Dec 17, 2001

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

	+	COVIS	20MG	N021316	002	Jun 26, 2002
	+		40MG	N021316	003	Jun 26, 2002
	+!		60MG	N021316	004	Jun 26, 2002

LOXAPINE

POWDER;INHALATION

ADASUVE

	+!	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

AB		ELITE LABS INC	**EQ 5MG BASE**	**A076868**	**001**	Aug 04, 2005
AB			**EQ 10MG BASE**	**A076868**	**002**	Aug 04, 2005
AB			**EQ 25MG BASE**	**A076868**	**003**	Aug 04, 2005
AB			**EQ 50MG BASE**	**A076868**	**004**	Aug 04, 2005
AB		LANNETT CO INC	**EQ 5MG BASE**	**A090695**	**001**	Sep 26, 2011
AB			**EQ 10MG BASE**	**A090695**	**002**	Sep 26, 2011
AB			**EQ 25MG BASE**	**A090695**	**003**	Sep 26, 2011
AB			**EQ 50MG BASE**	**A090695**	**004**	Sep 26, 2011
AB		WATSON LABS	**EQ 5MG BASE**	**A072204**	**001**	Jun 15, 1988
AB			**EQ 10MG BASE**	**A072205**	**001**	Jun 15, 1988
AB	**!**		**EQ 25MG BASE**	**A072206**	**001**	Jun 15, 1988
AB			**EQ 50MG BASE**	**A072062**	**001**	Jun 15, 1988

LUBIPROSTONE

CAPSULE;ORAL

AMITIZA

AB	**+**	SUCAMPO PHARMA LLC	**8MCG**	**N021908**	**002**	Apr 29, 2008
AB	**+!**		**24MCG**	**N021908**	**001**	Jan 31, 2006

LUBIPROSTONE

AB		AMNEAL	**8MCG**	**A209450**	**001**	Nov 30, 2021
AB			**24MCG**	**A209450**	**002**	Nov 30, 2021
AB		DR REDDYS	**8MCG**	**A206994**	**001**	Feb 08, 2022
AB			**24MCG**	**A206994**	**002**	Feb 08, 2022
AB		TEVA PHARMS USA INC	**8MCG**	**A209920**	**001**	Jan 18, 2022
AB			**24MCG**	**A209920**	**002**	Jan 18, 2022
AB		ZYDUS PHARMS	**8MCG**	**A214131**	**001**	Mar 23, 2023
AB			**24MCG**	**A214131**	**002**	Mar 23, 2023

LULICONAZOLE

CREAM;TOPICAL

LUZU

	+!	BAUSCH	1%	N204153	001	Nov 14, 2013

LUMASIRAN SODIUM

SOLUTION;SUBCUTANEOUS

OXLUMO

	+!	ALNYLAM PHARMS INC	EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML)	N214103	001	Nov 23, 2020

LUMATEPERONE TOSYLATE

CAPSULE;ORAL

CAPLYTA

	+	INTRA-CELLULAR	EQ 10.5MG BASE	N209500	002	Apr 22, 2022
	+		EQ 21MG BASE	N209500	003	Apr 22, 2022
	+!		EQ 42MG BASE	N209500	001	Dec 20, 2019

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LATUDA

AB	**+**	SUNOVION PHARMS INC	**20MG**	**N200603**	**003**	Dec 07, 2011
AB	**+!**		**40MG**	**N200603**	**001**	Oct 28, 2010
AB	**+**		**60MG**	**N200603**	**005**	Jul 12, 2013
AB	**+**		**80MG**	**N200603**	**002**	Oct 28, 2010
AB	**+**		**120MG**	**N200603**	**004**	Apr 26, 2012

LURASIDONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**20MG**	**A208049**	**001**	Jan 03, 2019
AB			**40MG**	**A208049**	**002**	Jan 03, 2019

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB		**60MG**	**A208049**	**003**	Jan 03, 2019
AB		**80MG**	**A208049**	**004**	Jan 03, 2019
AB		**120MG**	**A208049**	**005**	Jan 03, 2019
AB	ALEMBIC	**20MG**	**A213248**	**001**	May 13, 2021
AB		**40MG**	**A213248**	**002**	May 13, 2021
AB		**60MG**	**A213248**	**003**	May 13, 2021
AB		**80MG**	**A213248**	**004**	May 13, 2021
AB		**120MG**	**A213248**	**005**	May 13, 2021
AB	ALKEM LABS LTD	**20MG**	**A212244**	**001**	Dec 13, 2022
AB		**40MG**	**A212244**	**002**	Dec 13, 2022
AB		**60MG**	**A212244**	**003**	Dec 13, 2022
AB		**80MG**	**A212244**	**004**	Dec 13, 2022
AB		**120MG**	**A212244**	**005**	Dec 13, 2022
AB	AMNEAL PHARMS CO	**20MG**	**A208002**	**001**	Jan 03, 2019
AB		**40MG**	**A208002**	**002**	Jan 03, 2019
AB		**60MG**	**A208002**	**003**	Jan 03, 2019
AB		**80MG**	**A208002**	**004**	Jan 03, 2019
AB		**120MG**	**A208002**	**005**	Jan 03, 2019
AB	AUROBINDO PHARMA LTD	**20MG**	**A208045**	**001**	Mar 10, 2023
AB		**40MG**	**A208045**	**002**	Mar 10, 2023
AB		**60MG**	**A208045**	**003**	Mar 10, 2023
AB		**80MG**	**A208045**	**004**	Mar 10, 2023
AB		**120MG**	**A208045**	**005**	Mar 10, 2023
AB	AVET LIFESCIENCES	**20MG**	**A208058**	**001**	Sep 04, 2019
AB		**40MG**	**A208058**	**002**	Sep 04, 2019
AB		**60MG**	**A208058**	**003**	Sep 04, 2019
AB		**80MG**	**A208058**	**004**	Sep 04, 2019
AB		**120MG**	**A208058**	**005**	Feb 28, 2023
AB	DR REDDYS	**20MG**	**A208047**	**001**	Aug 24, 2021
AB		**40MG**	**A208047**	**002**	Aug 24, 2021
AB		**60MG**	**A208047**	**003**	Aug 24, 2021
AB		**80MG**	**A208047**	**004**	Aug 24, 2021
AB	INVAGEN PHARMS	**20MG**	**A208028**	**001**	Jan 03, 2019
AB		**40MG**	**A208028**	**002**	Jan 03, 2019
AB		**60MG**	**A208028**	**003**	Jan 03, 2019
AB		**80MG**	**A208028**	**004**	Jan 03, 2019
AB		**120MG**	**A208028**	**005**	Jan 03, 2019
AB	LUPIN LTD	**20MG**	**A208031**	**001**	Jan 03, 2019
AB		**40MG**	**A208031**	**002**	Jan 03, 2019
AB		**60MG**	**A208031**	**003**	Jan 03, 2019
AB		**80MG**	**A208031**	**004**	Jan 03, 2019
AB		**120MG**	**A208031**	**005**	Jan 03, 2019
AB	MACLEODS PHARMS LTD	**20MG**	**A212124**	**001**	Jun 09, 2023
AB		**40MG**	**A212124**	**002**	Jun 09, 2023
AB		**60MG**	**A212124**	**003**	Jun 09, 2023
AB		**80MG**	**A212124**	**004**	Jun 09, 2023
AB		**120MG**	**A212124**	**005**	Jun 09, 2023
AB	MSN	**20MG**	**A208037**	**001**	Sep 09, 2022
AB		**40MG**	**A208037**	**002**	Sep 09, 2022
AB		**60MG**	**A208037**	**003**	Sep 09, 2022
AB		**80MG**	**A208037**	**004**	Sep 09, 2022
AB		**120MG**	**A208037**	**005**	Sep 09, 2022
AB	PIRAMAL HLTHCARE UK	**20MG**	**A212091**	**001**	Dec 28, 2020
AB		**40MG**	**A212091**	**002**	Dec 28, 2020
AB		**60MG**	**A212091**	**003**	Dec 28, 2020
AB		**80MG**	**A212091**	**004**	Dec 28, 2020
AB		**120MG**	**A212091**	**005**	Dec 28, 2020
AB	SUN PHARM	**20MG**	**A208066**	**001**	Jan 04, 2019
AB		**40MG**	**A208066**	**002**	Jan 04, 2019
AB		**60MG**	**A208066**	**003**	Jan 04, 2019
AB		**80MG**	**A208066**	**004**	Jan 04, 2019
AB		**120MG**	**A208066**	**005**	Jan 04, 2019
AB	TORRENT	**20MG**	**A208055**	**001**	Jan 03, 2019
AB		**40MG**	**A208055**	**002**	Jan 03, 2019
AB		**80MG**	**A208055**	**003**	Jan 03, 2019
AB		**120MG**	**A208055**	**004**	Jan 03, 2019
AB	ZYDUS PHARMS	**20MG**	**A208052**	**001**	Mar 19, 2019
AB		**40MG**	**A208052**	**002**	Mar 19, 2019
AB		**60MG**	**A208052**	**003**	Mar 19, 2019

LURASIDONE HYDROCHLORIDE
TABLET;ORAL
LURASIDONE HYDROCHLORIDE

AB			**80MG**	**A208052**	**004**	Mar 19, 2019
AB			**120MG**	**A208052**	**005**	Mar 19, 2019

LURBINECTEDIN
POWDER;INTRAVENOUS
ZEPZELCA

+!	JAZZ	4MG/VIAL	N213702	001	Jun 15, 2020

LUSUTROMBOPAG
TABLET;ORAL
MULPLETA

+!	VANCOCIN ITALIA	3MG	N210923	001	Jul 31, 2018

LUTETIUM LU 177 DOTATATE
SOLUTION;INTRAVENOUS
LUTATHERA

+!	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
SOLUTION;INTRAVENOUS
PLUVICTO

+!	NOVARTIS	27mCi/ML	N215833	001	Mar 23, 2022

MACITENTAN
TABLET;ORAL
MACITENTAN

AB		APOTEX	**10MG**	**A211195**	**001**	Jan 09, 2024

OPSUMIT

AB	**+!**	ACTELION	**10MG**	**N204410**	**001**	Oct 18, 2013

MAFENIDE ACETATE
CREAM;TOPICAL
SULFAMYLON

+!	RISING	EQ 85MG BASE/GM	N016763	001	

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
INJECTABLE;INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+!	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019696	001	Sep 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
INJECTABLE;INJECTION
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

AP		FRESENIUS KABI USA	**30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML**	**A215370**	**001**	Jun 29, 2022

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4

AP		FRESENIUS KABI USA	**30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML**	**A215371**	**001**	Jun 08, 2022

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML**	**N017378**	**001**	

PLASMA-LYTE A IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML**	**N017378**	**002**	Nov 22, 1982

ISOLYTE S IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019711	001	Sep 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER

	ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017586	001	

SOLUTION;IRRIGATION
PHYSIOLYTE IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019024	001	Jun 08, 1984

PHYSIOSOL IN PLASTIC CONTAINER

	ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017637	002	Jul 08, 1982

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION;INJECTION

NORMOCARB HF 25

+!	DIALYSIS SUPS	0.21GM/100ML;2.8GM/100ML;9.07GM/100ML	N021910	001	Jul 26, 2006

NORMOCARB HF 35

+!	DIALYSIS SUPS	0.21GM/100ML;3.97GM/100ML;8.3GM/100ML	N021910	002	Jul 26, 2006

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE

AP		B BRAUN MEDICAL INC	**2GM/50ML (40MG/ML)**	**A207967**	**001**	Apr 26, 2021
AP			**4GM/100ML (40MG/ML)**	**A207967**	**002**	Apr 26, 2021
AP			**4GM/50ML (80MG/ML)**	**A207967**	**003**	Apr 26, 2021

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN MEDICAL INC	**1GM/100ML**	**A207966**	**001**	Oct 27, 2020
AP		BAXTER HLTHCARE CORP	**1GM/100ML**	**A211965**	**001**	Aug 11, 2020
AP		FRESENIUS KABI USA	**1GM/100ML**	**A206486**	**001**	Mar 07, 2016
AP	**+!**	HOSPIRA	**1GM/100ML**	**N020488**	**001**	Jul 11, 1995
AP		HQ SPCLT PHARMA	**1GM/100ML**	**A207349**	**001**	Mar 02, 2016
AP		MYLAN LABS LTD	**1GM/100ML**	**A209932**	**001**	Sep 10, 2018

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP		AMNEAL	**2GM/50ML (40MG/ML)**	**A216597**	**001**	Feb 15, 2023
AP			**4GM/100ML (40MG/ML)**	**A216597**	**002**	Feb 15, 2023
AP		BAXTER HLTHCARE CORP	**2GM/50ML (40MG/ML)**	**A211966**	**001**	Jun 01, 2020
AP			**4GM/50ML (80MG/ML)**	**A211966**	**002**	Jun 01, 2020
AP			**4GM/100ML (40MG/ML)**	**A211966**	**003**	Jun 01, 2020
AP		FRESENIUS KABI USA	**4GM/100ML (40MG/ML)**	**A206485**	**001**	Mar 15, 2016
AP			**4GM/50ML (80MG/ML)**	**A206485**	**002**	Mar 15, 2016
AP			**2GM/50ML (40MG/ML)**	**A206485**	**003**	Mar 15, 2016
AP			**20GM/500ML (40MG/ML)**	**A206485**	**004**	Mar 15, 2016
AP			**40GM/1000ML (40MG/ML)**	**A206485**	**005**	Mar 15, 2016
AP		GLAND PHARMA LTD	**2GM/50ML (40MG/ML)**	**A213917**	**001**	Jul 10, 2020
AP			**4GM/100ML (40MG/ML)**	**A213917**	**002**	Jul 10, 2020
AP	**+**	HOSPIRA	**2GM/50ML (40MG/ML)**	**N020309**	**003**	Jan 26, 2007
AP	**+!**		**4GM/100ML (40MG/ML)**	**N020309**	**001**	Jun 24, 1994
AP	**+!**		**4GM/50ML (80MG/ML)**	**N020309**	**002**	Jun 24, 1994
AP	**+**		**20GM/500ML (40MG/ML)**	**N020309**	**004**	Jan 18, 1995
AP	**+**		**40GM/1000ML (40MG/ML)**	**N020309**	**005**	Jan 18, 1995
AP		HQ SPCLT PHARMA	**2GM/50ML (40MG/ML)**	**A207350**	**001**	Dec 06, 2017
AP			**4GM/100ML (40MG/ML)**	**A207350**	**002**	Dec 06, 2017
AP			**4GM/50ML (80MG/ML)**	**A207350**	**003**	Dec 06, 2017
AP			**20GM/500ML (40MG/ML)**	**A207350**	**004**	Dec 06, 2017
AP			**40GM/1000ML (40MG/ML)**	**A207350**	**005**	Dec 06, 2017
AP		MILLA PHARMS	**2GM/50ML (40MG/ML)**	**A209642**	**001**	Nov 08, 2021
AP			**4GM/100ML (40MG/ML)**	**A209642**	**002**	Nov 08, 2021
AP			**4GM/50ML (80MG/ML)**	**A209642**	**003**	Nov 08, 2021
AP		MYLAN LABS LTD	**2GM/50ML (40MG/ML)**	**A209911**	**001**	Sep 14, 2018
AP			**4GM/100ML (40MG/ML)**	**A209911**	**002**	Sep 14, 2018

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+!	HOSPIRA	2GM/100ML	N020488	002	Jul 11, 1995

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP		EXELA PHARMA	**5GM/10ML (500MG/ML)**	**A206039**	**001**	Dec 18, 2014
AP	**+!**	FRESENIUS KABI USA	**5GM/10ML (500MG/ML)**	**N019316**	**001**	Sep 08, 1986
AP	**+!**		**10GM/20ML (500MG/ML)**	**N019316**	**003**	Jan 29, 2016
AP	**!**	HOSPIRA	**5GM/10ML (500MG/ML)**	**A075151**	**001**	Apr 25, 2000
AP			**10GM/20ML (500MG/ML)**	**A202411**	**001**	May 14, 2015
	+!	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986
	+!		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

SUFLAVE

+!	BRAINTREE LABS	0.9GM/BOT;178.7GM/BOT;1.12GM/BOT;0.5GM/BOT;7.3GM/BOT	N215344	001	Jun 15, 2023

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

TIS-U-SOL

AT		BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML**	**N018508**	**001**	Feb 19, 1982

TIS-U-SOL IN PLASTIC CONTAINER

AT		BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML**	**N018336**	**001**	

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE

TABLET;ORAL

SUTAB

	+!	BRAINTREE LABS	0.225GM;0.188GM;1.479GM	N213135	001	Nov 10, 2020

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA		ALKEM LABS LTD	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**A213924**	**001**	Dec 29, 2023
AA		NOVEL LABS INC	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**A202511**	**001**	Feb 23, 2017
AA		STRIDES PHARMA	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**A215469**	**001**	Nov 22, 2023

SUPREP BOWEL PREP KIT

AA	**+!**	BRAINTREE LABS	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**N022372**	**001**	Aug 05, 2010

MALATHION

LOTION;TOPICAL

MALATHION

	!	SUVEN PHARMS	0.5%	A091559	001	May 23, 2012

MANGANESE CHLORIDE

INJECTABLE;INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

	+!	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP		B BRAUN	**10GM/100ML**	**N020006**	**002**	Jul 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER

AP		B BRAUN	**15GM/100ML**	**N020006**	**003**	Jul 26, 1993

MANNITOL 20% IN PLASTIC CONTAINER

AP		B BRAUN	**20GM/100ML**	**N020006**	**004**	Jul 26, 1993
AP		ICU MEDICAL INC	**20GM/100ML**	**N019603**	**004**	Jan 08, 1990

MANNITOL 25%

AP		FRESENIUS KABI USA	**12.5GM/50ML**	**A080677**	**001**	
AP		HOSPIRA	**12.5GM/50ML**	**N016269**	**006**	Aug 25, 1994

MANNITOL 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML**	**N020006**	**001**	Jul 26, 1993

OSMITROL 10% IN WATER

AP		BAXTER HLTHCARE	**10GM/100ML**	**N013684**	**002**	

OSMITROL 10% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**10GM/100ML**	**N013684**	**006**	

OSMITROL 15% IN WATER

AP		BAXTER HLTHCARE	**15GM/100ML**	**N013684**	**004**	

OSMITROL 15% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**15GM/100ML**	**N013684**	**008**	

OSMITROL 20% IN WATER

AP		BAXTER HLTHCARE	**20GM/100ML**	**N013684**	**003**	

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20GM/100ML**	**N013684**	**007**	

OSMITROL 5% IN WATER

AP		BAXTER HLTHCARE	**5GM/100ML**	**N013684**	**001**	

OSMITROL 5% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML**	**N013684**	**005**	

POWDER;INHALATION

ARIDOL KIT

	+!	ARNA PHARMA	N/A,5MG,10MG,20MG,40MG	N022368	001	Oct 05, 2010

BRONCHITOL

	+!	CHIESI	40MG	N202049	001	Oct 30, 2020

MANNITOL; SORBITOL
SOLUTION;IRRIGATION
SORBITOL-MANNITOL IN PLASTIC CONTAINER

	+!	ICU MEDICAL INC	540MG/100ML;2.7GM/100ML	N018316	001	

MARALIXIBAT CHLORIDE
SOLUTION;ORAL
LIVMARLI

	+!	MIRUM	EQ 9.5MG BASE/ML	N214662	001	Sep 29, 2021

MARAVIROC
SOLUTION;ORAL
SELZENTRY

	+!	VIIV HLTHCARE	20MG/ML	N208984	001	Nov 04, 2016

TABLET;ORAL

	MARAVIROC					
AB		HETERO LABS LTD III	**150MG**	**A203347**	**001**	Feb 07, 2022
AB			**300MG**	**A203347**	**002**	Feb 07, 2022
AB		I 3 PHARMS	**150MG**	**A217114**	**001**	Aug 17, 2023
AB			**300MG**	**A217114**	**002**	Aug 17, 2023
	SELZENTRY					
AB	**+**	VIIV HLTHCARE	**150MG**	**N022128**	**001**	Aug 06, 2007
AB	**+!**		**300MG**	**N022128**	**002**	Aug 06, 2007
	+		25MG	N022128	003	Nov 04, 2016
	+		75MG	N022128	004	Nov 04, 2016

MARIBAVIR
TABLET;ORAL
LIVTENCITY

	+!	TAKEDA PHARMS USA	200MG	N215596	001	Nov 23, 2021

MAVACAMTEN
CAPSULE;ORAL
CAMZYOS

	+	BRISTOL	2.5MG	N214998	001	Apr 28, 2022
	+!		5MG	N214998	002	Apr 28, 2022
	+		10MG	N214998	003	Apr 28, 2022
	+		15MG	N214998	004	Apr 28, 2022

MEBENDAZOLE
TABLET, CHEWABLE;ORAL
EMVERM

	!	IMPAX LABS INC	100MG	A073580	001	Jan 04, 1995

MECAMYLAMINE HYDROCHLORIDE
TABLET;ORAL
MECAMYLAMINE HYDROCHLORIDE

	!	LGM PHARMA	2.5MG	A204054	001	Mar 19, 2013

MECHLORETHAMINE HYDROCHLORIDE
GEL;TOPICAL
VALCHLOR

	+!	HELSINN	EQ 0.016% BASE	N202317	001	Aug 23, 2013

MECLIZINE HYDROCHLORIDE
TABLET;ORAL

	ANTIVERT					
AA	**+**	CASPER PHARMA LLC	**12.5MG**	**N010721**	**006**	
AA	**+**		**25MG**	**N010721**	**004**	
AA	**+**		**50MG**	**N010721**	**001**	Jan 20, 1982
	MECLIZINE HYDROCHLORIDE					
AA	**!**	AMNEAL PHARMS	**12.5MG**	**A201451**	**001**	Feb 23, 2011
AA	**!**		**25MG**	**A201451**	**002**	Feb 23, 2011
AA		APNAR PHARMA LP	**12.5MG**	**A087128**	**002**	
AA			**25MG**	**A087128**	**001**	
AA		AUROBINDO PHARMA USA	**12.5MG**	**A202640**	**001**	Sep 17, 2012
AA			**25MG**	**A202640**	**002**	Sep 17, 2012
AA			**50MG**	**A202640**	**003**	Sep 17, 2012
AA		EPIC PHARMA LLC	**12.5MG**	**A200294**	**001**	Apr 13, 2012
AA			**25MG**	**A200294**	**002**	Apr 13, 2012
AA		INVAGEN PHARMS	**12.5MG**	**A200432**	**001**	Feb 17, 2022
AA			**25MG**	**A200432**	**002**	Feb 17, 2022
AA			**50MG**	**A200432**	**003**	Feb 17, 2022
AA		INVATECH	**25MG**	**A084092**	**003**	May 22, 1989
AA		JUBILANT CADISTA	**12.5MG**	**A040659**	**001**	Jun 04, 2010
AA			**25MG**	**A040659**	**002**	Jun 04, 2010

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA		LUPIN LTD	**12.5MG**	**A203003**	**001**	Aug 11, 2022
AA			**25MG**	**A203003**	**002**	Aug 11, 2022
AA			**50MG**	**A203003**	**003**	Aug 11, 2022
AA		SANDOZ	**12.5MG**	**A084843**	**002**	May 22, 1989
AA		WILSHIRE PHARMS INC	**12.5MG**	**A205136**	**001**	Feb 22, 2019
AA			**25MG**	**A205136**	**002**	Feb 22, 2019
AA			**50MG**	**A205136**	**003**	Feb 22, 2019
AA		ZYDUS	**12.5MG**	**A213957**	**001**	Jun 23, 2020
AA			**25MG**	**A213957**	**002**	Jun 23, 2020

TABLET, CHEWABLE;ORAL

ANTIVERT

AA	**+**	CASPER PHARMA LLC	**25MG**	**N010721**	**005**	

MECLIZINE HYDROCHLORIDE

AA		INVAGEN PHARMS	**25MG**	**A200791**	**001**	Feb 17, 2022

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

		MYLAN	EQ 50MG BASE	A071081	002	Sep 03, 1986
	!		EQ 100MG BASE	A071081	001	Sep 03, 1986

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

DEPO-PROVERA

AB	**+!**	PFIZER	**150MG/ML**	**N020246**	**001**	Oct 29, 1992

MEDROXYPROGESTERONE ACETATE

AB		AMNEAL	**150MG/ML**	**A215397**	**001**	Jun 07, 2023
AB		AMPHASTAR PHARMS INC	**150MG/ML**	**A077235**	**001**	Nov 28, 2017
AB			**150MG/ML**	**A077334**	**001**	Nov 28, 2017
AB		EUGIA PHARMA	**150MG/ML**	**A212824**	**001**	Aug 22, 2022
AB			**150MG/ML**	**A212844**	**001**	Aug 31, 2022
AB		MEITHEAL	**150MG/ML**	**A076553**	**001**	Jul 28, 2004
AB		MYLAN LABS LTD	**150MG/ML**	**A210227**	**001**	Oct 12, 2018

INJECTABLE;SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

	+!	PFIZER	104MG/0.65ML	N021583	001	Dec 17, 2004

TABLET;ORAL

MEDROXYPROGESTERONE ACETATE

AB		BARR	**2.5MG**	**A040159**	**001**	Aug 09, 1996
AB			**5MG**	**A040159**	**002**	Aug 09, 1996
AB			**10MG**	**A040159**	**003**	Aug 09, 1996

PROVERA

AB	**+**	PFIZER	**2.5MG**	**N011839**	**001**	
AB	**+**		**5MG**	**N011839**	**003**	
AB	**+!**		**10MG**	**N011839**	**004**	

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

AB		BELCHER	**250MG**	**A091608**	**001**	Jun 02, 2014
AB		LUPIN LTD	**250MG**	**A091322**	**001**	Jul 22, 2011
AB		MICRO LABS	**250MG**	**A090562**	**001**	Nov 19, 2010

PONSTEL

AB	**+!**	AVION PHARMS	**250MG**	**N015034**	**003**	

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

MEFLOQUINE HYDROCHLORIDE

AB	**!**	BARR	**250MG**	**A076392**	**001**	Dec 29, 2003
AB		HIKMA	**250MG**	**A076523**	**001**	Oct 01, 2004

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE ES

AB	**+!**	ENDO PHARMS INC	**125MG/ML**	**N021778**	**001**	Jul 05, 2005

MEGESTROL ACETATE

AB		HIKMA	**40MG/ML**	**A203960**	**001**	Jun 09, 2017
AB	**!**	STRIDES PHARMA	**40MG/ML**	**A075671**	**001**	Jul 25, 2001
AB		TWI PHARMS	**125MG/ML**	**A203139**	**001**	Aug 27, 2014

MEGESTROL ACETATE

TABLET;ORAL

MEGESTROL ACETATE

AB		BARR	**20MG**	**A074621**	**002**	Aug 16, 1996
AB			**40MG**	**A074621**	**001**	Nov 30, 1995
AB		STRIDES PHARMA	**20MG**	**A072422**	**001**	Aug 08, 1988
AB	!		**40MG**	**A072423**	**001**	Aug 08, 1988

MELOXICAM

CAPSULE;ORAL

MELOXICAM

AB		LUPIN LTD	**5MG**	**A209487**	**001**	Jun 01, 2020
AB	!		**10MG**	**A209487**	**002**	Jun 01, 2020
AB		NOVITIUM PHARMA	**5MG**	**A211398**	**001**	Mar 09, 2021
AB			**10MG**	**A211398**	**002**	Mar 09, 2021

SUSPENSION;ORAL

MELOXICAM

	+!	AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004

TABLET;ORAL

MELOXICAM

AB		ASCENT PHARMS INC	**7.5MG**	**A217579**	**001**	Jun 07, 2023
AB			**15MG**	**A217579**	**002**	Jun 07, 2023
AB		AUROBINDO PHARMA	**7.5MG**	**A078008**	**001**	Oct 02, 2006
AB			**15MG**	**A078008**	**002**	Oct 02, 2006
AB		CIPLA	**7.5MG**	**A077929**	**001**	Jul 19, 2006
AB			**15MG**	**A077929**	**002**	Jul 19, 2006
AB		COREPHARMA	**7.5MG**	**A077882**	**001**	Jul 20, 2006
AB			**15MG**	**A077882**	**002**	Jul 20, 2006
AB		DR REDDYS LABS INC	**7.5MG**	**A077931**	**001**	Jul 25, 2006
AB			**15MG**	**A077931**	**002**	Jul 25, 2006
AB		GLENMARK GENERICS	**7.5MG**	**A077932**	**001**	Jul 19, 2006
AB			**15MG**	**A077932**	**002**	Jul 19, 2006
AB		LUPIN PHARMS	**7.5MG**	**A077944**	**001**	Jul 19, 2006
AB			**15MG**	**A077944**	**002**	Jul 19, 2006
AB		PURACAP PHARM	**7.5MG**	**A077938**	**001**	Jul 19, 2006
AB			**15MG**	**A077938**	**002**	Jul 19, 2006
AB		STRIDES PHARMA	**7.5MG**	**A077928**	**001**	May 13, 2009
AB			**15MG**	**A077928**	**002**	May 13, 2009
AB		TARO	**7.5MG**	**A078102**	**001**	Nov 07, 2006
AB			**15MG**	**A078102**	**002**	Nov 07, 2006
AB		UNICHEM	**7.5MG**	**A077927**	**001**	Dec 20, 2006
AB			**15MG**	**A077927**	**002**	Dec 20, 2006
AB		YUNG SHIN PHARM	**7.5MG**	**A077918**	**001**	Dec 07, 2006
AB			**15MG**	**A077918**	**002**	Dec 07, 2006
AB		ZYDUS PHARMS USA	**7.5MG**	**A077921**	**001**	Jul 19, 2006
AB			**15MG**	**A077921**	**002**	Jul 19, 2006

MOBIC

AB	+	BOEHRINGER INGELHEIM	**7.5MG**	**N020938**	**001**	Apr 13, 2000
AB	+!		**15MG**	**N020938**	**002**	Aug 23, 2000

MELPHALAN

TABLET;ORAL

MELPHALAN

	!	ALVOGEN	2MG	A207809	001	Mar 22, 2017

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

AP		ACTAVIS LLC	**EQ 50MG BASE/VIAL**	**A206018**	**001**	Dec 19, 2016
AP		ALMAJECT	**EQ 50MG BASE/VIAL**	**A204817**	**001**	May 17, 2019
AP		ARTHUR GRP	**EQ 50MG BASE/VIAL**	**A211463**	**001**	Sep 13, 2019
AP		BPI LABS	**EQ 50MG BASE/VIAL**	**A209197**	**001**	May 08, 2020
AP		DR REDDYS	**EQ 50MG BASE/VIAL**	**A203655**	**001**	Dec 08, 2017
AP		FRESENIUS KABI USA	**EQ 50MG BASE/VIAL**	**A203393**	**001**	Dec 22, 2017
AP		GLAND PHARMA LTD	**EQ 50MG BASE/VIAL**	**A209826**	**001**	May 28, 2019
AP		HIKMA	**EQ 50MG BASE/VIAL**	**A090303**	**001**	Oct 28, 2010
AP		INGENUS PHARMS LLC	**EQ 50MG BASE/VIAL**	**A210947**	**001**	Feb 18, 2020
AP		MEITHEAL	**EQ 50MG BASE/VIAL**	**A212960**	**001**	May 28, 2021
AP	!	MYLAN INSTITUTIONAL	**EQ 50MG BASE/VIAL**	**A090270**	**001**	Jun 09, 2009
AP		SAGENT PHARMS INC	**EQ 50MG BASE/VIAL**	**A201379**	**001**	Feb 28, 2017

POWDER;INTRA-ARTERIAL

HEPZATO

	+!	DELCATH SYSTEMS INC	EQ 50MG BASE/VIAL	N201848	001	Aug 14, 2023

MELPHALAN HYDROCHLORIDE

POWDER;INTRAVENOUS

EVOMELA

+!	ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016

SOLUTION;INTRAVENOUS

MELPHALAN HYDROCHLORIDE

+!	APOTEX	EQ 90MG BASE/ML (EQ 90MG BASE/ML)	N217110	001	Aug 18, 2023

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

AB		AMNEAL PHARMS	**7MG**	**A205825**	**001**	Oct 12, 2016
AB			**14MG**	**A205825**	**002**	Oct 12, 2016
AB			**21MG**	**A205825**	**003**	Oct 12, 2016
AB			**28MG**	**A205825**	**004**	Oct 12, 2016
AB		APOTEX	**7MG**	**A206135**	**001**	Nov 22, 2016
AB			**14MG**	**A206135**	**002**	Nov 22, 2016
AB			**21MG**	**A206135**	**003**	Nov 22, 2016
AB			**28MG**	**A206135**	**004**	Nov 22, 2016
AB		AUROBINDO PHARMA LTD	**7MG**	**A214651**	**001**	Aug 09, 2021
AB			**14MG**	**A214651**	**002**	Aug 09, 2021
AB			**21MG**	**A214651**	**003**	Aug 09, 2021
AB			**28MG**	**A214651**	**004**	Aug 09, 2021
AB		LUPIN LTD	**7MG**	**A206028**	**001**	Sep 28, 2016
AB			**14MG**	**A206028**	**002**	Sep 28, 2016
AB			**21MG**	**A206028**	**003**	Sep 28, 2016
AB			**28MG**	**A206028**	**004**	Sep 28, 2016
AB		XIAMEN LP PHARM CO	**7MG**	**A213985**	**001**	Oct 11, 2022
AB			**14MG**	**A213985**	**002**	Oct 11, 2022
AB			**28MG**	**A213985**	**003**	Oct 11, 2022
AB		YICHANG HUMANWELL	**7MG**	**A211100**	**001**	Apr 02, 2021
AB			**14MG**	**A211100**	**002**	Apr 02, 2021
AB			**21MG**	**A211100**	**003**	Apr 02, 2021
AB			**28MG**	**A211100**	**004**	Apr 02, 2021
AB		ZYDUS PHARMS	**7MG**	**A203293**	**001**	Aug 03, 2017
AB			**14MG**	**A203293**	**002**	Aug 03, 2017
AB			**21MG**	**A203293**	**003**	Aug 03, 2017
AB			**28MG**	**A203293**	**004**	Aug 03, 2017

NAMENDA XR

AB	**+**	ABBVIE	**14MG**	**N022525**	**002**	Jun 21, 2010
AB	**+**		**21MG**	**N022525**	**003**	Jun 21, 2010
AB	**+!**		**28MG**	**N022525**	**004**	Jun 21, 2010

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA		APOTEX	**2MG/ML**	**A209955**	**001**	Feb 09, 2018
AA	**!**	CHARTWELL MOLECULAR	**2MG/ML**	**A204033**	**001**	Oct 13, 2015
AA		MACLEODS PHARMS LTD	**2MG/ML**	**A202790**	**001**	Oct 13, 2015
AA		SETON PHARMS	**2MG/ML**	**A210319**	**001**	Aug 31, 2020

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	**5MG**	**A206528**	**001**	Nov 30, 2015
AB			**10MG**	**A206528**	**002**	Nov 30, 2015
AB		ALEMBIC	**5MG**	**A200891**	**001**	Oct 13, 2015
AB			**10MG**	**A200891**	**002**	Oct 13, 2015
AB		AMNEAL PHARMS	**5MG**	**A090041**	**001**	Apr 10, 2015
AB			**10MG**	**A090041**	**002**	Apr 10, 2015
AB		AUROBINDO PHARMA LTD	**5MG**	**A203175**	**001**	Oct 13, 2015
AB			**10MG**	**A203175**	**002**	Oct 13, 2015
AB		CADILA	**5MG**	**A090961**	**001**	Jul 10, 2017
AB			**10MG**	**A090961**	**002**	Jul 10, 2017
AB		CELLTRION	**5MG**	**A090073**	**001**	Sep 04, 2015
AB			**10MG**	**A090073**	**002**	Sep 04, 2015
AB		DR REDDYS LABS LTD	**5MG**	**A090048**	**001**	Apr 14, 2010
AB			**10MG**	**A090048**	**002**	Apr 14, 2010
AB		HETERO LABS LTD V	**5MG**	**A204389**	**001**	Sep 26, 2022
AB			**10MG**	**A204389**	**002**	Sep 26, 2022
AB		LUPIN LTD	**5MG**	**A090051**	**001**	Apr 10, 2015
AB			**10MG**	**A090051**	**002**	Apr 10, 2015
AB		MACLEODS PHARMS LTD	**5MG**	**A202840**	**001**	Oct 13, 2015
AB			**10MG**	**A202840**	**002**	Oct 13, 2015
AB		POLYGEN PHARMS	**5MG**	**A210587**	**001**	Dec 11, 2020

MEMANTINE HYDROCHLORIDE

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB			**10MG**	**A210587**	**002**	Dec 11, 2020
AB		PURACAP PHARM LLC	**5MG**	**A206855**	**001**	Nov 17, 2015
AB			**10MG**	**A206855**	**002**	Nov 17, 2015
AB		STRIDES PHARMA	**5MG**	**A202350**	**001**	May 23, 2017
AB			**10MG**	**A202350**	**002**	May 23, 2017
AB		SUN PHARM	**5MG**	**A090058**	**001**	May 05, 2010
AB			**10MG**	**A090058**	**002**	May 05, 2010
AB		UNICHEM	**5MG**	**A200022**	**001**	Oct 13, 2015
AB			**10MG**	**A200022**	**002**	Oct 13, 2015
AB		UPSHER SMITH LABS	**5MG**	**A090043**	**001**	Jul 31, 2015
AB			**10MG**	**A090043**	**002**	Jul 31, 2015
AB		WESTMINSTER PHARMS	**5MG**	**A209527**	**001**	May 07, 2018
AB			**10MG**	**A209527**	**002**	May 07, 2018

NAMENDA

AB	**+**	ABBVIE	**5MG**	**N021487**	**001**	Oct 16, 2003
AB	**+!**		**10MG**	**N021487**	**002**	Oct 16, 2003

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEMEROL

AP	**+!**	HOSPIRA	**25MG/ML**	**N021171**	**001**	
AP	**+!**		**50MG/ML**	**N021171**	**002**	
AP	**+!**		**75MG/ML**	**N021171**	**003**	
AP	**+!**		**100MG/ML**	**N021171**	**004**	

MEPERIDINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	**25MG/ML**	**A080445**	**001**	
AP			**25MG/ML**	**A080455**	**007**	
AP			**50MG/ML**	**A080445**	**002**	
AP			**50MG/ML**	**A080455**	**008**	
AP			**75MG/ML**	**A080445**	**003**	
AP			**75MG/ML**	**A080455**	**009**	
AP			**100MG/ML**	**A080445**	**004**	
AP			**100MG/ML**	**A080455**	**010**	

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

	!	WEST-WARD PHARMS INT	10MG/ML	A081002	001	Jul 30, 1993

SYRUP;ORAL

MEPERIDINE HYDROCHLORIDE

	!	HIKMA	50MG/5ML	A088744	001	Jan 30, 1985

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

		EPIC PHARMA LLC	50MG	A040331	001	May 28, 1999
			100MG	A040331	002	May 28, 1999

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CARBOCAINE

AP	**+!**	HOSPIRA	**1%**	**N012250**	**001**	
AP	**+!**		**1.5%**	**N012250**	**005**	
AP	**+!**		**2%**	**N012250**	**002**	

POLOCAINE

AP		FRESENIUS KABI USA	**1%**	**A089407**	**001**	Dec 01, 1986
AP			**2%**	**A089410**	**001**	Dec 01, 1986

POLOCAINE-MPF

AP		FRESENIUS KABI USA	**1%**	**A089406**	**001**	Dec 01, 1986
AP			**1.5%**	**A089408**	**001**	Dec 01, 1986
AP			**2%**	**A089409**	**001**	Dec 01, 1986

SCANDONEST PLAIN

	!	DEPROCO	3%	A088387	001	Oct 10, 1984

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

AA	**!**	ALEMBIC PHARMS LTD	**200MG**	**A090122**	**001**	Feb 18, 2009
AA	**!**		**400MG**	**A090122**	**002**	Feb 18, 2009
AA		INVAGEN PHARMS	**200MG**	**A040797**	**001**	Feb 27, 2008
AA			**400MG**	**A040797**	**002**	Feb 27, 2008

MERCAPTOPURINE

SUSPENSION;ORAL

PURIXAN

+!	NOVA LABS LTD	20MG/ML	N205919	001	Apr 28, 2014

TABLET;ORAL

MERCAPTOPURINE

AB		DR REDDYS LABS SA	**50MG**	**A040461**	**001**	Feb 11, 2004
AB	**!**	HIKMA	**50MG**	**A040528**	**001**	Feb 13, 2004
AB		MYLAN	**50MG**	**A040594**	**001**	Jul 01, 2005

PURINETHOL

AB	**+**	STASON PHARMS	**50MG**	**N009053**	**002**	

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

AP		ACS DOBFAR	**500MG/VIAL**	**A091404**	**001**	Oct 26, 2011
AP			**1GM/VIAL**	**A091404**	**002**	Oct 26, 2011
AP		ACS DOBFAR SPA	**500MG/VIAL**	**A204139**	**001**	Jun 09, 2016
AP			**1GM/VIAL**	**A204139**	**002**	Jun 09, 2016
AP		AMNEAL PHARMS	**500MG/VIAL**	**A205883**	**001**	Apr 12, 2016
AP			**1GM/VIAL**	**A205883**	**002**	Apr 12, 2016
AP		BROOKS STERISCIENCE	**500MG/VIAL**	**A216154**	**001**	Aug 18, 2022
AP			**1GM/VIAL**	**A216154**	**002**	Aug 18, 2022
AP		DAEWOONG PHARM CO	**500MG/VIAL**	**A204854**	**001**	Dec 18, 2015
AP			**1GM/VIAL**	**A204854**	**002**	Dec 18, 2015
AP		EUGIA PHARMA	**500MG/VIAL**	**A205835**	**001**	Mar 27, 2017
AP			**1GM/VIAL**	**A205835**	**002**	Mar 27, 2017
AP		GLAND	**500MG/VIAL**	**A206141**	**001**	Jun 08, 2016
AP			**1GM/VIAL**	**A206141**	**002**	Jun 08, 2016
AP		HQ SPCLT PHARMA	**500MG/VIAL**	**A210773**	**001**	Aug 16, 2019
AP			**1GM/VIAL**	**A210773**	**002**	Aug 16, 2019
AP		SAVIOR LIFETEC CORP	**500MG/VIAL**	**A206086**	**001**	Apr 19, 2016
AP			**1GM/VIAL**	**A206086**	**002**	Apr 19, 2016

MERREM

AP	**+!**	PFIZER	**500MG/VIAL**	**N050706**	**003**	Jun 21, 1996
AP	**+!**		**1GM/VIAL**	**N050706**	**001**	Jun 21, 1996

POWDER;INTRAVENOUS

MEROPENEM

+!	HQ SPCLT PHARMA	2GM/VIAL	N215212	001	Jul 26, 2023

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

	B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015
		1GM/VIAL	N202106	002	Apr 30, 2015

MEROPENEM; VABORBACTAM

POWDER;INTRAVENOUS

VABOMERE

+!	REMPEX	1GM/VIAL;1GM/VIAL	N209776	001	Aug 29, 2017

MESALAMINE

CAPSULE, DELAYED RELEASE;ORAL

DELZICOL

AB	**+!**	ABBVIE	**400MG**	**N204412**	**001**	Feb 01, 2013

MESALAMINE

AB		TEVA PHARMS USA	**400MG**	**A207873**	**001**	May 09, 2019

CAPSULE, EXTENDED RELEASE;ORAL

APRISO

AB	**+!**	SALIX	**375MG**	**N022301**	**001**	Oct 31, 2008

MESALAMINE

AB		ALEMBIC	**375MG**	**A216967**	**001**	Oct 28, 2022
AB		ALKEM LABS LTD	**375MG**	**A214242**	**001**	Jul 15, 2021
AB		AMTA	**375MG**	**A217533**	**001**	Jun 06, 2023
AB		AUROBINDO PHARMA LTD	**375MG**	**A214477**	**001**	Mar 31, 2023
AB		MYLAN	**375MG**	**A207271**	**001**	Nov 20, 2019
AB		SUN PHARM	**500MG**	**A214585**	**001**	May 11, 2022
AB		ZYDUS PHARMS	**375MG**	**A208954**	**001**	Aug 12, 2021

PENTASA

AB	**+!**	TAKEDA PHARMS USA	**500MG**	**N020049**	**002**	Jul 08, 2004
	+		250MG	N020049	001	May 10, 1993

ENEMA;RECTAL

MESALAMINE

AB		ENCUBE	**4GM/60ML**	**A216941**	**001**	May 30, 2023
AB		PADAGIS ISRAEL	**4GM/60ML**	**A076751**	**001**	Sep 17, 2004

MESALAMINE
ENEMA;RECTAL
ROWASA

AB	**+!**	MYLAN SPECIALITY LP	**4GM/60ML**	**N019618**	**001**	Dec 24, 1987

SFROWASA

AB	**+**	MYLAN SPECIALITY LP	**4GM/60ML**	**N019618**	**002**	Jun 20, 2008

SUPPOSITORY;RECTAL
CANASA

AB	**+!**	ABBVIE	**1GM**	**N021252**	**002**	Nov 05, 2004

MESALAMINE

AB		ACTAVIS MID ATLANTIC	**1GM**	**A205654**	**001**	Aug 14, 2020
AB		AMRING PHARMS	**1GM**	**A208362**	**001**	Jun 21, 2019
AB		ANNORA PHARMA	**1GM**	**A213377**	**001**	Mar 19, 2020
AB		MYLAN	**1GM**	**A204354**	**001**	Nov 24, 2015
AB		PHARM SOURCING	**1GM**	**A207448**	**001**	Apr 19, 2019
AB		SANDOZ	**1GM**	**A202065**	**001**	Jun 12, 2019
AB		ZYDUS PHARMS	**1GM**	**A208953**	**001**	Feb 12, 2020

TABLET, DELAYED RELEASE;ORAL
LIALDA

AB	**+!**	TAKEDA PHARMS USA	**1.2GM**	**N022000**	**001**	Jan 16, 2007

MESALAMINE

AB		ACTAVIS LABS FL	**1.2GM**	**A203817**	**001**	Mar 23, 2018
AB		SINOTHERAPEUTICS INC	**1.2GM**	**A217337**	**001**	May 12, 2023
AB		SUN PHARM	**1.2GM**	**A211858**	**001**	Jan 25, 2019
AB		ZYDUS PHARMS	**1.2GM**	**A091640**	**001**	Jun 05, 2017
	!		800MG	A203286	001	Jul 21, 2017

MESNA
INJECTABLE;INTRAVENOUS
MESNA

AP		FRESENIUS KABI USA	**100MG/ML**	**A075811**	**001**	Apr 26, 2001
AP		GLAND	**100MG/ML**	**A206992**	**001**	Dec 18, 2017
AP		HIKMA	**100MG/ML**	**A075739**	**001**	Jan 09, 2004
AP		SAGENT PHARMS INC	**100MG/ML**	**A090913**	**001**	Apr 13, 2010

MESNEX

AP	**+!**	BAXTER HLTHCARE	**100MG/ML**	**N019884**	**001**	Dec 30, 1988

TABLET;ORAL
MESNEX

	+!	BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002

METAPROTERENOL SULFATE
SYRUP;ORAL
METAPROTERENOL SULFATE

	!	ANDA REPOSITORY	10MG/5ML	A073632	001	Jul 22, 1992

METARAMINOL BITARTRATE
INJECTABLE;INJECTION
METARAMINOL BITARTRATE

		SLAYBACK PHARMA LLC	EQ 10MG BASE/ML	A211304	001	Aug 24, 2021

METAXALONE
TABLET;ORAL
METAXALONE

AB		ACTAVIS LABS FL INC	**800MG**	**A203695**	**001**	Jun 15, 2017
AB	**!**	AMNEAL PHARMS	**800MG**	**A203399**	**001**	Jun 21, 2013
AB		LANNETT CO INC	**800MG**	**A204770**	**001**	Nov 22, 2016
AB		MOUNTAIN	**400MG**	**A040486**	**001**	Feb 27, 2015
AB		SANDOZ	**800MG**	**A040445**	**001**	Mar 31, 2010
AB		SCIEGEN PHARMS INC	**400MG**	**A207466**	**002**	Mar 13, 2020
AB			**800MG**	**A207466**	**001**	Aug 31, 2017
BX		APPCO	800MG	A208774	001	Sep 24, 2018

METFORMIN HYDROCHLORIDE
SOLUTION;ORAL
METFORMIN HYDROCHLORIDE

AB	**!**	SAPTALIS PHARMS	**500MG/5ML**	**A211309**	**001**	Mar 03, 2020
AB		VISTAPHARM	**500MG/5ML**	**A212677**	**001**	Aug 19, 2022

TABLET;ORAL
METFORMIN HYDROCHLORIDE

AB		ALKEM	**500MG**	**A091184**	**001**	Nov 01, 2010
AB			**850MG**	**A091184**	**002**	Nov 01, 2010
AB			**1GM**	**A091184**	**003**	Nov 01, 2010
AB		AMNEAL PHARMS NY	**500MG**	**A077880**	**001**	Jun 05, 2006

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AB			**850MG**	**A077880**	**002**	Jun 05, 2006
AB			**1GM**	**A077880**	**003**	Jun 05, 2006
AB		APOTEX	**500MG**	**A075984**	**001**	Apr 23, 2002
AB			**500MG**	**A090666**	**001**	Dec 07, 2011
AB			**850MG**	**A075984**	**002**	Apr 23, 2002
AB			**850MG**	**A090666**	**002**	Dec 07, 2011
AB			**1GM**	**A075984**	**003**	Apr 23, 2002
AB			**1GM**	**A090666**	**003**	Dec 07, 2011
AB		ATLAS PHARMS LLC	**500MG**	**A076033**	**001**	Jan 24, 2002
AB			**850MG**	**A076033**	**002**	Jan 24, 2002
AB			**1GM**	**A076033**	**003**	Jan 24, 2002
AB		AUROBINDO	**500MG**	**A077095**	**001**	Jan 14, 2005
AB			**850MG**	**A077095**	**002**	Jan 14, 2005
AB			**1GM**	**A077095**	**003**	Jan 14, 2005
AB		CHARTWELL	**500MG**	**A075972**	**001**	Jan 24, 2002
AB			**850MG**	**A075972**	**002**	Jan 24, 2002
AB			**1GM**	**A075972**	**003**	Jan 24, 2002
AB		CSPC OUYI	**500MG**	**A205096**	**001**	Jul 11, 2016
AB			**850MG**	**A205096**	**002**	Jul 11, 2016
AB			**1GM**	**A205096**	**003**	Jul 11, 2016
AB		DR REDDYS LABS INC	**500MG**	**A077787**	**001**	Aug 23, 2006
AB			**850MG**	**A077787**	**002**	Aug 23, 2006
AB			**1GM**	**A077787**	**003**	Aug 23, 2006
AB		EPIC PHARMA LLC	**500MG**	**A075965**	**001**	Jan 25, 2002
AB			**850MG**	**A075965**	**002**	Jan 25, 2002
AB			**1GM**	**A075965**	**003**	Jan 25, 2002
AB		GLENMARK GENERICS	**500MG**	**A078170**	**001**	May 23, 2008
AB			**850MG**	**A078170**	**002**	May 23, 2008
AB			**1GM**	**A078170**	**003**	May 23, 2008
AB		GRANULES INDIA	**500MG**	**A090564**	**001**	Apr 22, 2010
AB			**850MG**	**A090564**	**002**	Apr 22, 2010
AB	**!**		**1GM**	**A090564**	**003**	Apr 22, 2010
AB		HARMAN FINOCHEM	**500MG**	**A213320**	**001**	Dec 03, 2021
AB			**850MG**	**A213320**	**002**	Dec 03, 2021
AB			**1GM**	**A213320**	**003**	Dec 03, 2021
AB		LAURUS	**500MG**	**A209882**	**001**	Aug 27, 2018
AB			**850MG**	**A209882**	**002**	Aug 27, 2018
AB			**1GM**	**A209882**	**003**	Aug 27, 2018
AB		MARKSANS PHARMA	**500MG**	**A090888**	**001**	Mar 12, 2012
AB			**850MG**	**A090888**	**002**	Mar 12, 2012
AB			**1GM**	**A090888**	**003**	Mar 12, 2012
AB		MYLAN	**500MG**	**A075973**	**001**	Jan 25, 2002
AB			**850MG**	**A075973**	**002**	Jan 25, 2002
AB			**1GM**	**A075973**	**003**	Jan 25, 2002
AB		SCIEGEN PHARMS INC	**500MG**	**A203769**	**001**	Sep 11, 2013
AB			**850MG**	**A203769**	**002**	Sep 11, 2013
AB			**1GM**	**A203769**	**003**	Sep 11, 2013
AB		ZYDUS HLTHCARE	**500MG**	**A203686**	**001**	Aug 28, 2014
AB			**850MG**	**A203686**	**002**	Aug 28, 2014
AB			**1GM**	**A203686**	**003**	Aug 28, 2014
AB		ZYDUS PHARMS USA	**500MG**	**A077064**	**001**	Apr 18, 2005
AB			**850MG**	**A077064**	**002**	Apr 18, 2005
AB			**1GM**	**A077064**	**003**	Apr 18, 2005
		CHARTWELL	625MG	A075972	005	Jan 24, 2002
			750MG	A075972	004	Jan 24, 2002

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**750MG**	**A076869**	**001**	Apr 12, 2005
AB	**!**	ALKEM LABS LTD	**750MG**	**A206145**	**002**	Oct 22, 2018
AB		AMNEAL PHARMS NY	**750MG**	**A078596**	**002**	Jan 03, 2008
AB		AUROBINDO PHARMA LTD	**750MG**	**A079118**	**002**	Jul 20, 2012
AB		BEXIMCO PHARMS USA	**750MG**	**A207427**	**002**	Dec 13, 2016
AB		CADILA	**750MG**	**A077078**	**001**	Apr 21, 2005
AB		CSPC OUYI	**750MG**	**A078321**	**002**	Apr 17, 2008
AB		GRANULES	**750MG**	**A209313**	**002**	Mar 16, 2018
AB		INTELLIPHARMACEUTICS	**750MG**	**A202306**	**002**	Feb 23, 2017
AB		LAURUS	**750MG**	**A217631**	**002**	Oct 05, 2023
AB		MACLEODS PHARMS LTD	**750MG**	**A206955**	**002**	Dec 07, 2016

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE							
AB		MARKSANS PHARMA	**750MG**	**A090295**	**002**	Apr 29, 2016
AB		NOSTRUM PHARMS LLC	**750MG**	**A076756**	**002**	Dec 12, 2011
AB		PRINSTON INC	**750MG**	**A208880**	**002**	Sep 10, 2018
AB		SUN PHARM INDS (IN)	**750MG**	**A077336**	**002**	Feb 09, 2006
AB		TEVA	**750MG**	**A076864**	**001**	Apr 12, 2005
AB		UNICHEM	**750MG**	**A213359**	**002**	Aug 11, 2021
AB		YICHANG HUMANWELL	**750MG**	**A211052**	**002**	Sep 24, 2018
AB1		ALIGNSCIENCE PHARMA	**500MG**	**A209303**	**001**	Mar 19, 2018
AB1		ALKEM LABS LTD	**500MG**	**A206145**	**001**	Oct 22, 2018
AB1		AMNEAL PHARMS NY	**500MG**	**A078596**	**001**	Jan 03, 2008
AB1		AUROBINDO PHARMA LTD	**500MG**	**A079118**	**001**	Jul 20, 2012
AB1		BEXIMCO PHARMS USA	**500MG**	**A207427**	**001**	Dec 13, 2016
AB1		CADILA	**500MG**	**A077060**	**001**	Apr 20, 2005
AB1		CSPC OUYI	**500MG**	**A078321**	**001**	Apr 17, 2008
AB1		GRANULES	**500MG**	**A209313**	**001**	Mar 16, 2018
AB1		INTELLIPHARMACEUTICS	**500MG**	**A202306**	**001**	Feb 23, 2017
AB1		INVENTIA	**500MG**	**A201991**	**001**	Jan 18, 2012
AB1		LAURUS	**500MG**	**A217631**	**001**	Oct 05, 2023
AB1		MACLEODS PHARMS LTD	**500MG**	**A206955**	**001**	Dec 07, 2016
AB1		MARKSANS PHARMA	**500MG**	**A090295**	**001**	Apr 29, 2016
AB1		NOSTRUM PHARMS LLC	**500MG**	**A076756**	**001**	Jul 26, 2006
AB1		PRINSTON INC	**500MG**	**A208880**	**001**	Sep 10, 2018
AB1		SANDOZ	**500MG**	**A076873**	**001**	Dec 14, 2004
AB1		SUN PHARM INDS (IN)	**500MG**	**A077336**	**001**	Feb 09, 2006
AB1		TEVA	**500MG**	**A076269**	**001**	Jun 18, 2004
AB1		UNICHEM	**500MG**	**A213359**	**001**	Aug 11, 2021
AB1		YICHANG HUMANWELL	**500MG**	**A211052**	**001**	Sep 24, 2018
FORTAMET						
AB2	**+**	ANDRX LABS LLC	**1GM**	**N021574**	**002**	Apr 27, 2004
METFORMIN HYDROCHLORIDE						
AB2		AJANTA PHARMA LTD	**500MG**	**A213651**	**001**	Apr 09, 2020
AB2			**1GM**	**A213651**	**002**	Apr 09, 2020
AB2		LUPIN LTD	**500MG**	**A090692**	**001**	Jun 29, 2011
AB2	**!**		**1GM**	**A090692**	**002**	Jun 29, 2011
AB2		MYLAN PHARMS INC	**500MG**	**A200690**	**001**	Aug 01, 2012
AB2			**1GM**	**A200690**	**002**	Aug 01, 2012
AB2		NOSTRUM LABS INC	**500MG**	**A203832**	**001**	Dec 26, 2017
AB2			**1GM**	**A203832**	**002**	Dec 26, 2017
AB2		NOVAST LABS	**500MG**	**A209674**	**001**	Nov 02, 2018
AB2			**1GM**	**A209674**	**002**	Nov 02, 2018
AB2		QINGDAO BAHEAL PHARM	**500MG**	**A209993**	**001**	Dec 27, 2018
AB2			**1GM**	**A209993**	**002**	Dec 27, 2018
AB2		SCIEGEN PHARMS INC	**500MG**	**A214629**	**001**	Feb 22, 2022
AB2			**1GM**	**A214629**	**002**	Feb 22, 2022
AB2		TWI PHARMS	**500MG**	**A213247**	**001**	Sep 29, 2021
AB2			**1GM**	**A213247**	**002**	Sep 29, 2021
GLUMETZA						
AB3	**+**	SANTARUS INC	**500MG**	**N021748**	**001**	Jun 03, 2005
AB3	**+!**		**1GM**	**N021748**	**002**	Jun 03, 2005
METFORMIN HYDROCHLORIDE						
AB3		ACTAVIS LABS FL INC	**500MG**	**A203755**	**001**	Aug 01, 2016
AB3			**1GM**	**A203755**	**002**	Aug 01, 2016
AB3		AJANTA PHARMA LTD	**500MG**	**A213962**	**001**	Mar 09, 2021
AB3			**1GM**	**A213962**	**002**	Mar 09, 2021
AB3		APOTEX	**500MG**	**A213356**	**001**	Dec 13, 2021
AB3			**1GM**	**A213356**	**002**	Dec 13, 2021
AB3		GLENMARK PHARMS LTD	**500MG**	**A212969**	**001**	Nov 25, 2019
AB3			**1GM**	**A212969**	**002**	Nov 25, 2019
AB3		GRANULES	**500MG**	**A213344**	**001**	Jan 12, 2021
AB3			**1GM**	**A213344**	**002**	Jan 12, 2021
AB3		LUPIN LTD	**500MG**	**A091664**	**001**	Jul 19, 2013
AB3			**1GM**	**A091664**	**002**	Jul 19, 2013
AB3		MICRO LABS	**500MG**	**A212448**	**001**	Jan 10, 2023
AB3			**1GM**	**A212448**	**002**	Jan 10, 2023
AB3		PRINSTON INC	**500MG**	**A212681**	**001**	Jun 09, 2022
AB3			**1GM**	**A212681**	**002**	Jun 09, 2022
AB3		RK PHARMA	**500MG**	**A215629**	**001**	Jun 20, 2023

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB3			**1GM**	**A215629**	**002**	Jun 20, 2023
AB3		SCIEGEN PHARMS INC	**500MG**	**A213334**	**001**	Apr 16, 2021
AB3			**1GM**	**A213334**	**002**	Apr 16, 2021
AB3		SUN PHARM	**500MG**	**A202917**	**001**	Aug 01, 2016
AB3			**1GM**	**A202917**	**002**	Aug 01, 2016

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET

AB	**+!**	TAKEDA PHARMS USA	**850MG;EQ 15MG BASE**	**N021842**	**002**	Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**500MG;EQ 15MG BASE**	**A200823**	**001**	Feb 13, 2013
AB			**850MG;EQ 15MG BASE**	**A200823**	**002**	Feb 13, 2013
AB		MACLEODS PHARMS LTD	**500MG;EQ 15MG BASE**	**A204802**	**001**	Nov 05, 2015
AB			**850MG;EQ 15MG BASE**	**A204802**	**002**	Nov 05, 2015
AB		TEVA PHARMS USA	**500MG;EQ 15MG BASE**	**A091155**	**001**	Mar 10, 2014
AB			**850MG;EQ 15MG BASE**	**A091155**	**002**	Mar 10, 2014

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

AB		DR REDDYS LABS SA	**500MG;EQ 5MG BASE**	**A207678**	**001**	Aug 09, 2023
AB			**1GM;EQ 2.5MG BASE**	**A207678**	**002**	Aug 09, 2023
AB	**!**		**1GM;EQ 5MG BASE**	**A207678**	**003**	Aug 09, 2023

SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB		MYLAN	**500MG;EQ 5MG BASE**	**A205981**	**001**	Jul 31, 2023
AB			**1GM;EQ 2.5MG BASE**	**A205981**	**002**	Jul 31, 2023
AB			**1GM;EQ 5MG BASE**	**A205981**	**003**	Jul 31, 2023
AB		SUN PHARM	**500MG;EQ 5MG BASE**	**A206081**	**001**	Jul 31, 2023
AB			**1GM;EQ 2.5MG BASE**	**A206081**	**002**	Jul 31, 2023
AB			**1GM;EQ 5MG BASE**	**A206081**	**003**	Jul 31, 2023

METFORMIN HYDROCHLORIDE; SITAGLIPTIN

TABLET;ORAL

ZITUVIMET

+		ZYDUS	500MG;50MG	N216743	001 Nov 03, 2023
+!			1GM;50MG	N216743	002 Nov 03, 2023

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUMET

+		MSD SUB MERCK	500MG;EQ 50MG BASE	N022044	001 Mar 30, 2007
+!			1GM;EQ 50MG BASE	N022044	002 Mar 30, 2007

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

+		MSD SUB MERCK	500MG;EQ 50MG BASE	N202270	001 Feb 02, 2012
+			1GM;EQ 50MG BASE	N202270	002 Feb 02, 2012
+!			1GM;EQ 100MG BASE	N202270	003 Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

+!		METHAPHARM	100MG/VIAL	N019193	001 Oct 31, 1986

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

AA		HIKMA	**10MG/ML**	**A040180**	**001**	Apr 30, 1998
AA		LANNETT CO INC	**10MG/ML**	**A212093**	**001**	Nov 02, 2020
AA		SPECGX LLC	**10MG/ML**	**A207368**	**001**	Aug 22, 2019
AA		VISTAPHARM	**10MG/ML**	**A040088**	**001**	Nov 30, 1994

METHADONE HYDROCHLORIDE INTENSOL

AA		HIKMA	**10MG/ML**	**A089897**	**001**	Sep 06, 1988

METHADOSE

AA	**+!**	SPECGX LLC	**10MG/ML**	**N017116**	**002**

INJECTABLE;INJECTION

METHADONE HYDROCHLORIDE

AP		LONG GROVE PHARMS	**10MG/ML**	**A208306**	**001**	Oct 27, 2017
AP	**+!**	MYLAN INSTITUTIONAL	**10MG/ML**	**N021624**	**001**	

METHADONE HYDROCHLORIDE

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

AA	**+!**	HIKMA	**5MG/5ML**	**A087393**	**001**		
AA	**+!**		**10MG/5ML**	**A087997**	**001**	Aug 30, 1982	
AA		SPECGX LLC	**5MG/5ML**	**A207537**	**001**	Oct 02, 2019	
AA			**10MG/5ML**	**A207537**	**002**	Oct 01, 2019	
AA		VISTAPHARM	**5MG/5ML**	**A090707**	**001**	Jun 30, 2010	
AA			**10MG/5ML**	**A090707**	**002**	Jun 30, 2010	

TABLET;ORAL

METHADONE HYDROCHLORIDE

AA		ASCENT PHARMS INC	**5MG**	**A211228**	**001**	Jan 03, 2019	
AA			**10MG**	**A211228**	**002**	Jan 03, 2019	
AA		AUROLIFE PHARMA LLC	**5MG**	**A203502**	**001**	Aug 31, 2015	
AA			**10MG**	**A203502**	**002**	Aug 31, 2015	
AA		EPIC PHARMA LLC	**5MG**	**A090065**	**001**	Aug 18, 2015	
AA			**10MG**	**A090065**	**002**	Aug 18, 2015	
AA		ROXANE	**5MG**	**A088108**	**001**	Mar 08, 1983	
AA			**10MG**	**A088109**	**001**	Mar 08, 1983	
AA	**!**	SPECGX LLC	**5MG**	**A040517**	**001**	Apr 27, 2004	
AA	**!**		**10MG**	**A040517**	**002**	Apr 27, 2004	
AA		THEPHARMANETWORK LLC	**5MG**	**A090635**	**002**	Sep 22, 2020	
AA			**10MG**	**A090635**	**001**	Nov 25, 2009	
AA		VISTAPHARM	**10MG**	**A040241**	**002**	May 29, 1998	
AA			**10MG**	**A204166**	**001**	Mar 16, 2020	

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

AA	**+!**	HIKMA	**40MG**	**N017058**	**001**		
AA		SPECGX LLC	**40MG**	**A077142**	**001**	Jul 12, 2005	
AA		VISTAPHARM	**40MG**	**A075082**	**001**	Mar 25, 1998	

METHADOSE

AA		SPECGX LLC	**40MG**	**A074184**	**001**	Apr 29, 1993	

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

DESOXYN

AA	**+!**	AJENAT PHARMS	**5MG**	**N005378**	**002**		

METHAMPHETAMINE HYDROCHLORIDE

AA		DR REDDYS LABS SA	**5MG**	**A091189**	**001**	Apr 21, 2010	
AA		HIKMA	**5MG**	**A203846**	**001**	Nov 17, 2015	

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

AB		ANI PHARMS	**25MG**	**A040001**	**001**	Jun 30, 1993	
AB			**50MG**	**A040001**	**002**	Jun 30, 1993	
AB		BAUSCH AND LOMB INC	**25MG**	**A207438**	**001**	Oct 05, 2018	
AB			**50MG**	**A207438**	**002**	Oct 05, 2018	
AB		MIKART	**25MG**	**A040062**	**001**	Jan 27, 1994	
AB	**!**		**50MG**	**A040062**	**002**	Jan 27, 1994	
AB		SANDOZ	**25MG**	**A040036**	**001**	Jun 30, 1993	
AB			**50MG**	**A040036**	**002**	Jun 30, 1993	
AB		TAGI	**25MG**	**A215615**	**001**	Oct 18, 2022	
AB			**50MG**	**A215615**	**002**	Oct 18, 2022	

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB	**+**	SS PHARMA	**1GM**	**N017681**	**001**		

METHENAMINE HIPPURATE

AB	**!**	AUROBINDO PHARMA LTD	**1GM**	**A205661**	**001**	Jul 05, 2016	
AB		LYRUS LIFE SCIENCES	**1GM**	**A217675**	**001**	Dec 01, 2023	
AB		MICRO LABS	**1GM**	**A212172**	**001**	Aug 01, 2019	
AB		NOVAST LABS	**1GM**	**A210068**	**001**	Nov 27, 2020	

UREX

AB		ALVOGEN	**1GM**	**N016151**	**001**		

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB		BIONPHARMA	**5MG**	**A218149**	**001**	Sep 25, 2023
AB			**10MG**	**A218149**	**002**	Sep 25, 2023
AB		CHARTWELL RX	**5MG**	**A040411**	**001**	Mar 27, 2001
AB			**10MG**	**A040411**	**002**	Mar 27, 2001
AB		HERITAGE PHARMA	**5MG**	**A040734**	**001**	Dec 14, 2007
AB			**10MG**	**A040734**	**002**	Dec 14, 2007
AB		MACLEODS PHARMS LTD	**5MG**	**A209827**	**001**	May 24, 2023
AB			**10MG**	**A209827**	**002**	May 24, 2023
AB		MYLAN	**5MG**	**A040350**	**001**	Mar 29, 2000
AB	**!**		**10MG**	**A040350**	**002**	Mar 29, 2000
AB		QINGDAO BAHEAL PHARM	**5MG**	**A040547**	**001**	Feb 18, 2005
AB			**10MG**	**A040547**	**002**	Feb 18, 2005
AB		RISING	**5MG**	**A202068**	**001**	Mar 07, 2012
AB			**10MG**	**A202068**	**002**	Mar 07, 2012

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP		AM REGENT	**1GM/10ML (100MG/ML)**	**A207496**	**001**	Jun 22, 2017
AP		EUGIA PHARMA	**1GM/10ML (100MG/ML)**	**A206128**	**001**	May 27, 2016
AP		FRESENIUS KABI USA	**1GM/10ML (100MG/ML)**	**A209331**	**001**	Apr 17, 2018
AP		GLAND PHARMA LTD	**1GM/10ML (100MG/ML)**	**A211504**	**001**	Oct 26, 2018
AP		MONTEREY PHARMS LLC	**1GM/10ML (100MG/ML)**	**A205354**	**001**	Oct 27, 2016
AP		NAVINTA LLC	**1GM/10ML (100MG/ML)**	**A206071**	**001**	Nov 24, 2017
AP		SAGENT PHARMS INC	**1GM/10ML (100MG/ML)**	**A205404**	**001**	Jul 18, 2017
AP		SLATE RUN PHARMA	**1GM/10ML (100MG/ML)**	**A208116**	**001**	Jan 19, 2017
AP		SOMERSET THERAPS LLC	**1GM/10ML (100MG/ML)**	**A207522**	**001**	Jul 31, 2017

ROBAXIN

AP	**+!**	HIKMA	**1GM/10ML (100MG/ML)**	**N011790**	**001**	

TABLET;ORAL

METHOCARBAMOL

AA		ACME LABS	**500MG**	**A203550**	**001**	Feb 08, 2017
AA			**750MG**	**A203550**	**002**	Feb 08, 2017
AA		AUROBINDO PHARMA LTD	**500MG**	**A213967**	**002**	Feb 09, 2023
AA			**750MG**	**A213967**	**001**	Aug 12, 2020
AA		AUSTARPHARMA LLC	**500MG**	**A200958**	**001**	Oct 21, 2011
AA			**750MG**	**A200958**	**002**	Oct 21, 2011
AA		BEXIMCO PHARMS USA	**500MG**	**A208507**	**001**	Jul 21, 2017
AA			**750MG**	**A208507**	**002**	Jul 21, 2017
AA	**!**	GRANULES	**500MG**	**A209312**	**001**	May 07, 2018
AA	**!**		**750MG**	**A209312**	**002**	May 07, 2018
AA		HETERO LABS LTD III	**500MG**	**A090200**	**001**	Nov 06, 2009
AA			**750MG**	**A090200**	**002**	Nov 06, 2009
AA		MLV	**500MG**	**A212623**	**001**	Apr 30, 2021
AA			**750MG**	**A212623**	**002**	Apr 30, 2021
AA		OXFORD PHARMS	**500MG**	**A040489**	**001**	Jan 29, 2003
AA			**750MG**	**A040489**	**002**	Jan 29, 2003
AA		PRINSTON INC	**500MG**	**A086988**	**002**	
AA			**750MG**	**A086988**	**001**	
AB	**!**	AUSTARPHARMA LLC	**1GM**	**A200958**	**003**	Dec 06, 2021
AB		MIKART	**1GM**	**A212707**	**001**	Jun 12, 2023

METHOHEXITAL SODIUM

INJECTABLE;INJECTION

BREVITAL SODIUM

	+!	PAR STERILE PRODUCTS	500MG/VIAL	N011559	001	

METHOTREXATE

SOLUTION;ORAL

JYLAMVO

	+!	SHORLA	2MG/ML	N212479	001	Nov 29, 2022

SOLUTION;SUBCUTANEOUS

OTREXUP

	+!	OTTER PHARMS	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013
	+!		12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016
	+!		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013
	+!		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016
	+!		20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013

METHOTREXATE						
SOLUTION;SUBCUTANEOUS						
OTREXUP						
	+!		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016
	+!		25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013
RASUVO						
	+!	MEDEXUS	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014
	+!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014
	+!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014
	+!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014
	+!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014
	+!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014
	+!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014
	+!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014
	+!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014
METHOTREXATE SODIUM						
INJECTABLE;INJECTION						
METHOTREXATE PRESERVATIVE FREE						
AP		FRESENIUS KABI USA	**EQ 1GM BASE/VIAL**	**A040266**	**001**	Feb 26, 1999
METHOTREXATE SODIUM						
AP	**!**	FRESENIUS KABI USA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040263**	**001**	Feb 26, 1999
AP	**!**	HIKMA	**EQ 100MG BASE/4ML (EQ 25MG BASE/ML)**	**A089341**	**001**	Sep 16, 1986
AP	**+!**	HOSPIRA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**N011719**	**010**	Dec 15, 2004
METHOTREXATE SODIUM PRESERVATIVE FREE						
AP	**!**	ACCORD HLTHCARE	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040767**	**001**	Apr 30, 2007
AP	**!**		**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A040768**	**001**	Apr 30, 2007
AP	**!**		**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A040716**	**001**	Apr 30, 2007
AP	**!**	HIKMA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A089340**	**001**	Sep 16, 1986
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A089343**	**001**	Sep 16, 1986
AP	**+!**	HOSPIRA	**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**N011719**	**012**	Apr 13, 2005
AP		PHARMACHEMIE BV	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040843**	**002**	Jan 11, 2010
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A040843**	**004**	Jan 11, 2010
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A040843**	**001**	Jan 11, 2010
AP		SAGENT PHARMS INC	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A203407**	**001**	Aug 09, 2018
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A203407**	**002**	Aug 09, 2018
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A203407**	**003**	Aug 09, 2018
AP		SANDOZ	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A090039**	**001**	Mar 31, 2009
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A090039**	**002**	Mar 31, 2009
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A090029**	**001**	Mar 31, 2009
METHOTREXATE SODIUM						
	!	HIKMA	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986
METHOTREXATE SODIUM PRESERVATIVE FREE						
	!	HIKMA	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005
		PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012
SOLUTION;ORAL						
XATMEP						
	+!	AZURITY	EQ 2.5MG BASE/ML	N208400	001	Apr 25, 2017
TABLET;ORAL						
METHOTREXATE SODIUM						
AB		ACCORD HLTHCARE	**EQ 2.5MG BASE**	**A213343**	**001**	Jan 24, 2020
AB		AMNEAL PHARMS	**EQ 2.5MG BASE**	**A210040**	**001**	Dec 22, 2017
AB		BARR	**EQ 2.5MG BASE**	**A081099**	**001**	Oct 15, 1990
AB		DAITO	**EQ 2.5MG BASE**	**A213362**	**001**	Aug 07, 2023
AB		EUGIA PHARMA	**EQ 2.5MG BASE**	**A210454**	**001**	Jan 30, 2020
AB	**!**	HIKMA	**EQ 2.5MG BASE**	**A040054**	**001**	Aug 01, 1994
AB		LOTUS PHARM CO LTD	**EQ 2.5MG BASE**	**A209787**	**001**	Apr 23, 2021
AB		MYLAN	**EQ 2.5MG BASE**	**A081235**	**001**	May 15, 1992
AB		SUN PHARM	**EQ 2.5MG BASE**	**A201749**	**001**	May 21, 2015
AB		ZYDUS PHARMS	**EQ 2.5MG BASE**	**A207812**	**001**	Jan 13, 2017
TREXALL						
		BARR	EQ 5MG BASE	A040385	001	Mar 21, 2001
			EQ 7.5MG BASE	A040385	002	Mar 21, 2001
			EQ 10MG BASE	A040385	003	Mar 21, 2001
	!		EQ 15MG BASE	A040385	004	Mar 21, 2001
METHOXSALEN						
CAPSULE;ORAL						
METHOXSALEN						
AB		STRIDES PHARMA	**10MG**	**A202687**	**001**	Jun 05, 2014
OXSORALEN-ULTRA						
AB	**+!**	BAUSCH	**10MG**	**N019600**	**001**	Oct 30, 1986

METHOXSALEN
INJECTABLE;INJECTION
UVADEX

	+!	MALLINCKRODT HOSP	0.02MG/ML	N020969	001	Feb 25, 1999

METHSCOPOLAMINE BROMIDE
TABLET;ORAL
METHSCOPOLAMINE BROMIDE

AA		BAYSHORE PHARMS LLC	**2.5MG**	**A200602**	**001**	Sep 24, 2012
AA	!		**5MG**	**A200602**	**002**	Sep 24, 2012
AA		BRECKENRIDGE PHARM	**2.5MG**	**A040642**	**001**	Dec 06, 2011
AA			**5MG**	**A040642**	**002**	Dec 06, 2011

METHSUXIMIDE
CAPSULE;ORAL
CELONTIN

AB	**+!**	PARKE DAVIS	**300MG**	**N010596**	**008**	

METHSUXIMIDE

AB		NOVITIUM PHARMA	**300MG**	**A217213**	**001**	May 01, 2023

METHYLENE BLUE
SOLUTION;INTRAVENOUS
METHYLENE BLUE

AP		ZYDUS	**10MG/2ML (5MG/ML)**	**A215636**	**001**	Dec 05, 2023
AP			**50MG/10ML (5MG/ML)**	**A215636**	**002**	Dec 05, 2023

PROVAYBLUE

AP	**+!**	PROVEPHARM SAS	**10MG/2ML (5MG/ML)**	**N204630**	**002**	Jul 18, 2019
AP	**+!**		**50MG/10ML (5MG/ML)**	**N204630**	**001**	Apr 08, 2016

METHYLERGONOVINE MALEATE
INJECTABLE;INJECTION
METHERGINE

AP	**+!**	EDISON THERAPS LLC	**0.2MG/ML**	**N006035**	**004**	

METHYLERGONOVINE MALEATE

AP		AM REGENT	**0.2MG/ML**	**A090193**	**001**	Nov 24, 2008
AP		BRECKENRIDGE	**0.2MG/ML**	**A040889**	**001**	Sep 13, 2010

TABLET;ORAL
METHYLERGONOVINE MALEATE

AB		AMNEAL PHARMS	**0.2MG**	**A211483**	**001**	Sep 10, 2018
AB	!	CHARTWELL RX	**0.2MG**	**A091577**	**001**	May 02, 2011
AB		GRANULES	**0.2MG**	**A210424**	**001**	May 15, 2018
AB		RISING	**0.2MG**	**A211919**	**001**	Jan 15, 2021
AB		TEVA PHARMS USA	**0.2MG**	**A211455**	**001**	Mar 20, 2019
AB		TULEX PHARMS INC	**0.2MG**	**A212233**	**001**	May 01, 2020

METHYLNALTREXONE BROMIDE
SOLUTION;SUBCUTANEOUS
RELISTOR

	+!	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010
	+!		12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008
	+!		12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010

TABLET;ORAL
RELISTOR

	+!	SALIX	150MG	N208271	001	Jul 19, 2016

METHYLPHENIDATE
FILM, EXTENDED RELEASE;TRANSDERMAL
DAYTRANA

AB	**+**	NOVEN PHARMS INC	**10MG/9HR (1.1MG/HR)**	**N021514**	**001**	Apr 06, 2006
AB	**+**		**15MG/9HR (1.6MG/HR)**	**N021514**	**002**	Apr 06, 2006
AB	**+**		**20MG/9HR (2.2MG/HR)**	**N021514**	**003**	Apr 06, 2006
AB	**+!**		**30MG/9HR (3.3MG/HR)**	**N021514**	**004**	Apr 06, 2006

METHYLPHENIDATE

AB		MYLAN TECH VIATRIS	**10MG/9HR (1.1MG/HR)**	**A206497**	**001**	Mar 14, 2022
AB			**15MG/9HR (1.6MG/HR)**	**A206497**	**002**	Mar 14, 2022
AB			**20MG/9HR (2.2MG/HR)**	**A206497**	**003**	Mar 14, 2022
AB			**30MG/9HR (3.3MG/HR)**	**A206497**	**004**	Mar 14, 2022

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
COTEMPLA XR-ODT

	+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017
	+		17.3MG	N205489	002	Jun 19, 2017
	+!		25.9MG	N205489	003	Jun 19, 2017

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE							
AB1		DR REDDYS LABS SA	**10MG**	**A200886**	**001**	Feb 26, 2018
AB1			**20MG**	**A078458**	**001**	Dec 01, 2011
AB1			**30MG**	**A078458**	**002**	Dec 01, 2011
AB1			**40MG**	**A078458**	**003**	Dec 01, 2011
AB1	!		**60MG**	**A078458**	**004**	Jun 23, 2016
AB1		GRANULES	**10MG**	**A211796**	**001**	May 23, 2019
AB1			**20MG**	**A211796**	**002**	May 23, 2019
AB1			**30MG**	**A211796**	**003**	May 23, 2019
AB1			**40MG**	**A211796**	**004**	May 23, 2019
AB1			**60MG**	**A211796**	**005**	May 23, 2019
RITALIN LA							
AB1	+	SANDOZ	**10MG**	**N021284**	**004**	Apr 10, 2004
AB1	+		**20MG**	**N021284**	**001**	Jun 05, 2002
AB1	+		**30MG**	**N021284**	**002**	Jun 05, 2002
AB1	+		**40MG**	**N021284**	**003**	Jun 05, 2002
METADATE CD							
AB2	+	AYTU BIOPHARMA	**10MG**	**N021259**	**003**	May 27, 2003
AB2	+		**20MG**	**N021259**	**001**	Apr 03, 2001
AB2	+		**30MG**	**N021259**	**002**	Jun 19, 2003
AB2	+		**40MG**	**N021259**	**004**	Feb 19, 2006
AB2	+		**50MG**	**N021259**	**005**	Feb 19, 2006
AB2	+!		**60MG**	**N021259**	**006**	Feb 19, 2006
METHYLPHENIDATE HYDROCHLORIDE							
AB2		IMPAX LABS INC	**10MG**	**A205105**	**001**	Jul 28, 2016
AB2			**20MG**	**A205105**	**002**	Jul 28, 2016
AB2			**30MG**	**A205105**	**003**	Jul 28, 2016
AB2			**40MG**	**A205105**	**004**	Jul 28, 2016
AB2			**50MG**	**A205105**	**005**	Jul 28, 2016
AB2			**60MG**	**A205105**	**006**	Jul 28, 2016
AB2		SPECGX LLC	**10MG**	**A203583**	**001**	Sep 29, 2015
AB2			**20MG**	**A203583**	**002**	Sep 29, 2015
AB2			**30MG**	**A203583**	**003**	Sep 29, 2015
AB2			**40MG**	**A203583**	**004**	Sep 29, 2015
AB2			**50MG**	**A203583**	**005**	Sep 29, 2015
AB2			**60MG**	**A203583**	**006**	Sep 29, 2015
AB2		TEVA PHARMS	**10MG**	**A077707**	**001**	Jul 19, 2012
AB2			**20MG**	**A077707**	**002**	Jul 19, 2012
AB2			**30MG**	**A077707**	**003**	Jul 19, 2012
AB2			**40MG**	**A078873**	**001**	Jul 19, 2012
AB2			**50MG**	**A078873**	**002**	Jul 19, 2012
AB2			**60MG**	**A078873**	**003**	Jul 19, 2012
APTENSIO XR							
AB3	+	RHODES PHARMS	**10MG**	**N205831**	**001**	Apr 17, 2015
AB3	+		**15MG**	**N205831**	**002**	Apr 17, 2015
AB3	+		**20MG**	**N205831**	**003**	Apr 17, 2015
AB3	+		**30MG**	**N205831**	**004**	Apr 17, 2015
AB3	+		**40MG**	**N205831**	**005**	Apr 17, 2015
AB3	+		**50MG**	**N205831**	**006**	Apr 17, 2015
AB3	+!		**60MG**	**N205831**	**007**	Apr 17, 2015
METHYLPHENIDATE HYDROCHLORIDE							
AB3		ACTAVIS ELIZABETH	**10MG**	**A208861**	**001**	Dec 13, 2018
AB3			**15MG**	**A208861**	**002**	Dec 13, 2018
AB3			**20MG**	**A208861**	**003**	Dec 13, 2018
AB3			**30MG**	**A208861**	**004**	Dec 13, 2018
AB3			**40MG**	**A208861**	**005**	Dec 13, 2018
AB3			**50MG**	**A208861**	**006**	Dec 13, 2018
AB3			**60MG**	**A208861**	**007**	Dec 13, 2018
JORNAY PM							
	+	IRONSHORE PHARMS	20MG	N209311	001	Aug 08, 2018
	+		40MG	N209311	002	Aug 08, 2018
	+		60MG	N209311	003	Aug 08, 2018
	+		80MG	N209311	004	Aug 08, 2018
	+!		100MG	N209311	005	Aug 08, 2018

FOR SUSPENSION, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE							
AB		ACTAVIS LABS FL INC	**5MG/ML**	**A206049**	**001**	May 17, 2018
QUILLIVANT XR							
AB	+!	NEXTWAVE	**5MG/ML**	**N202100**	**001**	Sep 27, 2012

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLIN

AA	**+!**	SPECGX LLC	**5MG/5ML**	**N021419**	**001**	Dec 19, 2002
AA	**+!**		**10MG/5ML**	**N021419**	**002**	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

AA		ABHAI LLC	**5MG/5ML**	**A207485**	**001**	Nov 18, 2016
AA			**10MG/5ML**	**A207485**	**002**	Nov 18, 2016
AA		ALKEM LABS LTD	**5MG/5ML**	**A211647**	**001**	Mar 30, 2020
AA			**10MG/5ML**	**A211647**	**002**	Mar 30, 2020
AA		ASCENT PHARMS INC	**5MG/5ML**	**A207417**	**001**	Jan 29, 2021
AA			**10MG/5ML**	**A207417**	**002**	Jan 29, 2021
AA		BRECKENRIDGE	**5MG/5ML**	**A201466**	**001**	Nov 12, 2013
AA			**10MG/5ML**	**A201466**	**002**	Nov 12, 2013
AA		NOVEL LABS INC	**5MG/5ML**	**A204602**	**001**	Aug 14, 2015
AA			**10MG/5ML**	**A204602**	**002**	Aug 14, 2015
AA		PATRIN	**5MG/5ML**	**A210764**	**001**	Apr 10, 2020
AA			**10MG/5ML**	**A210764**	**002**	Apr 10, 2020
AA		QUAGEN	**5MG/5ML**	**A213567**	**001**	Jun 04, 2020
AA			**10MG/5ML**	**A213567**	**002**	Jun 04, 2020
AA		TRIS PHARMA INC	**5MG/5ML**	**A091601**	**001**	Jul 23, 2010
AA			**10MG/5ML**	**A091601**	**002**	Jul 23, 2010
AA		WES PHARMA INC	**5MG/5ML**	**A210139**	**001**	Oct 03, 2018
AA			**10MG/5ML**	**A210139**	**002**	Oct 03, 2018

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI INC	**5MG**	**A206932**	**001**	May 11, 2017
AB			**10MG**	**A206932**	**002**	May 11, 2017
AB			**20MG**	**A206932**	**003**	May 11, 2017
AB		ACCORD HLTHCARE	**5MG**	**A213936**	**001**	Oct 28, 2020
AB			**10MG**	**A213936**	**002**	Oct 28, 2020
AB			**20MG**	**A213936**	**003**	Oct 28, 2020
AB		ALKEM LABS LTD	**5MG**	**A211779**	**001**	Oct 04, 2019
AB			**10MG**	**A211779**	**002**	Oct 04, 2019
AB			**20MG**	**A211779**	**003**	Oct 04, 2019
AB		ASCENT PHARMS INC	**5MG**	**A207416**	**001**	Sep 22, 2015
AB			**10MG**	**A207416**	**002**	Sep 22, 2015
AB			**20MG**	**A207416**	**003**	Sep 22, 2015
AB		BIONPHARMA	**5MG**	**A209753**	**001**	Mar 02, 2018
AB			**10MG**	**A209753**	**002**	Mar 02, 2018
AB			**20MG**	**A209753**	**003**	Mar 02, 2018
AB		MOUNTAIN	**5MG**	**A091159**	**001**	Mar 12, 2014
AB			**10MG**	**A091159**	**002**	Mar 12, 2014
AB			**20MG**	**A091159**	**003**	Mar 12, 2014
AB		NOVEL LABS INC	**5MG**	**A207884**	**001**	Nov 13, 2015
AB			**10MG**	**A207884**	**002**	Nov 13, 2015
AB			**20MG**	**A207884**	**003**	Nov 13, 2015
AB		OXFORD PHARMS	**5MG**	**A202892**	**001**	Sep 23, 2014
AB			**10MG**	**A202892**	**002**	Sep 23, 2014
AB			**20MG**	**A202892**	**003**	Sep 23, 2014
AB		PRINSTON INC	**5MG**	**A212697**	**001**	Jul 23, 2020
AB			**10MG**	**A212697**	**002**	Jul 23, 2020
AB			**20MG**	**A212697**	**003**	Jul 23, 2020
AB		SPECGX LLC	**5MG**	**A040300**	**001**	Nov 27, 1998
AB			**10MG**	**A040300**	**002**	Nov 27, 1998
AB			**20MG**	**A040300**	**003**	Nov 27, 1998
AB		SUN PHARM INDS INC	**5MG**	**A090710**	**001**	Mar 15, 2012
AB			**10MG**	**A090710**	**002**	Mar 15, 2012
AB			**20MG**	**A090710**	**003**	Mar 15, 2012

RITALIN

AB	**+**	SANDOZ	**5MG**	**N010187**	**003**	
AB	**+**		**10MG**	**N010187**	**006**	
AB	**+!**		**20MG**	**N010187**	**010**	

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ASCENT PHARMS INC	**2.5MG**	**A210354**	**001**	Dec 29, 2017
AB			**5MG**	**A210354**	**002**	Dec 29, 2017
AB	**!**		**10MG**	**A210354**	**003**	Dec 29, 2017
AB		RISING	**2.5MG**	**A205756**	**001**	Nov 07, 2016
AB			**5MG**	**A205756**	**002**	Nov 07, 2016
AB			**10MG**	**A205756**	**003**	Nov 07, 2016

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONCERTA							
AB	**+**	JANSSEN PHARMS	**18MG**	**N021121**	**001**	Aug 01, 2000
AB	**+**		**27MG**	**N021121**	**004**	Apr 01, 2002
AB	**+**		**36MG**	**N021121**	**002**	Aug 01, 2000
AB	**+!**		**54MG**	**N021121**	**003**	Dec 08, 2000
METHYLIN ER							
AB		SPECGX LLC	**10MG**	**A075629**	**001**	May 09, 2000
AB			**20MG**	**A075629**	**002**	May 09, 2000
METHYLPHENIDATE HYDROCHLORIDE							
AB		ABHAI LLC	**10MG**	**A207488**	**001**	Jun 09, 2015
AB	**!**		**20MG**	**A207488**	**002**	Jun 09, 2015
AB		ACTAVIS LABS FL	**18MG**	**A076772**	**001**	Mar 22, 2018
AB			**27MG**	**A076772**	**002**	Mar 22, 2018
AB			**36MG**	**A076772**	**003**	Mar 22, 2018
AB			**54MG**	**A076655**	**001**	Mar 21, 2018
AB			**72MG**	**A076655**	**002**	Feb 28, 2022
AB		ALKEM LABS LTD	**18MG**	**A214447**	**001**	May 23, 2023
AB			**20MG**	**A212288**	**001**	Oct 06, 2020
AB			**27MG**	**A214447**	**002**	May 23, 2023
AB			**36MG**	**A214447**	**003**	May 23, 2023
AB			**54MG**	**A214447**	**004**	May 23, 2023
AB		ANDOR PHARMS	**18MG**	**A211918**	**001**	Apr 24, 2019
AB			**27MG**	**A211918**	**002**	Apr 24, 2019
AB			**36MG**	**A211918**	**003**	Apr 24, 2019
AB			**54MG**	**A211918**	**004**	Apr 24, 2019
AB		ASCENT PHARMS INC	**18MG**	**A211009**	**001**	Sep 03, 2019
AB			**27MG**	**A211009**	**002**	Sep 03, 2019
AB			**36MG**	**A211009**	**003**	Sep 03, 2019
AB			**54MG**	**A211009**	**004**	Sep 03, 2019
AB		AUROLIFE PHARMA LLC	**18MG**	**A206726**	**001**	Oct 21, 2016
AB			**27MG**	**A206726**	**002**	Oct 21, 2016
AB			**36MG**	**A206726**	**003**	Oct 21, 2016
AB			**54MG**	**A206726**	**004**	Oct 21, 2016
AB		DR REDDYS	**18MG**	**A213473**	**001**	Jul 29, 2020
AB			**27MG**	**A213473**	**002**	Jul 29, 2020
AB			**36MG**	**A213473**	**003**	Jul 29, 2020
AB			**54MG**	**A213473**	**004**	Jul 29, 2020
AB		GRANULES	**10MG**	**A210992**	**001**	Nov 21, 2018
AB			**20MG**	**A210992**	**002**	Nov 21, 2018
AB		OSMOTICA PHARM US	**18MG**	**A205327**	**001**	Jul 28, 2017
AB			**27MG**	**A205327**	**002**	Jul 28, 2017
AB			**36MG**	**A205327**	**003**	Jul 28, 2017
AB			**54MG**	**A205327**	**004**	Jul 28, 2017
AB	**!**		**72MG**	**A205327**	**005**	Jul 28, 2017
AB		SUN PHARM INDS INC	**18MG**	**A205135**	**001**	Aug 19, 2020
AB			**27MG**	**A205135**	**002**	Aug 19, 2020
AB			**36MG**	**A205135**	**003**	Aug 19, 2020
AB			**54MG**	**A205135**	**004**	Aug 19, 2020
AB			**72MG**	**A217229**	**001**	Aug 25, 2023
BX		LANNETT CO INC	18MG	A091695	001	Jul 09, 2013
BX			27MG	A091695	002	Jul 09, 2013
BX			36MG	A091695	003	Sep 23, 2013
BX			54MG	A091695	004	Sep 23, 2013
BX		SPECGX LLC	27MG	A202608	001	Dec 28, 2012
BX			36MG	A202608	002	Dec 28, 2012
BX			54MG	A202608	003	Dec 28, 2012
RELEXXII							
	+	OSMOTICA PHARM US	18MG	N216117	001	Jun 23, 2022
	+		27MG	N216117	002	Jun 23, 2022
	+		36MG	N216117	003	Jun 23, 2022
	+		45MG	N216117	004	Jun 23, 2022
	+		54MG	N216117	005	Jun 23, 2022
	+		63MG	N216117	006	Jun 23, 2022
	+!		72MG	N216117	007	Jun 23, 2022

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

QUILLICHEW ER						
	+	NEXTWAVE PHARMS	20MG	N207960	001	Dec 04, 2015
	+		30MG	N207960	002	Dec 04, 2015
	+!		40MG	N207960	003	Dec 04, 2015

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

AB	**+**	PFIZER	**4MG**	**N011153**	**001**	
AB	**+**		**8MG**	**N011153**	**004**	
AB	**+**		**16MG**	**N011153**	**003**	
AB	**+!**		**32MG**	**N011153**	**006**	

METHYLPREDNISOLONE

AB		JUBILANT CADISTA	**4MG**	**A040189**	**001**	Oct 31, 1997
AB			**8MG**	**A040189**	**002**	Oct 31, 1997
AB			**16MG**	**A040189**	**003**	Jul 20, 2007
AB			**32MG**	**A040189**	**004**	Jul 20, 2007
AB		PRAXGEN	**4MG**	**A212262**	**001**	Jun 27, 2019
AB		SANDOZ	**4MG**	**A040194**	**001**	Oct 31, 1997
AB		TIANJIN TIANYAO	**4MG**	**A204072**	**001**	May 14, 2018
AB		VINTAGE PHARMS	**4MG**	**A040183**	**001**	Dec 22, 1998
AB		WATSON LABS	**4MG**	**A040232**	**001**	Oct 16, 1997
AB		ZYDUS PHARMS	**4MG**	**A206751**	**001**	Apr 23, 2018
AB			**8MG**	**A206751**	**002**	Apr 23, 2018
AB			**16MG**	**A206751**	**003**	Apr 23, 2018
AB			**32MG**	**A206751**	**004**	Apr 23, 2018

MEDROL

	+	PFIZER	2MG	N011153	002

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

DEPO-MEDROL

AB	**+**	PFIZER	**40MG/ML**	**N011757**	**001**	
AB	**+**		**80MG/ML**	**N011757**	**004**	

METHYLPREDNISOLONE ACETATE

AB	**!**	AMNEAL	**40MG/ML**	**A210043**	**001**	May 20, 2019
AB			**40MG/ML**	**A216502**	**001**	Nov 03, 2023
AB	**!**		**80MG/ML**	**A210043**	**002**	May 20, 2019
AB			**80MG/ML**	**A216502**	**002**	Nov 03, 2023
AB		EUGIA PHARMA	**40MG/ML**	**A211930**	**001**	Apr 13, 2023
AB			**80MG/ML**	**A211930**	**002**	Apr 13, 2023
AB		MEITHEAL	**40MG/ML**	**A040557**	**001**	Feb 23, 2005
AB			**80MG/ML**	**A040557**	**002**	Feb 23, 2005
AB		PAR STERILE PRODUCTS	**40MG/ML**	**A214297**	**001**	Jan 21, 2022
AB			**80MG/ML**	**A214297**	**002**	Jan 21, 2022
AB	**!**	SAGENT PHARMS INC	**40MG/ML**	**A201835**	**002**	Jun 27, 2018
AB	**!**		**80MG/ML**	**A201835**	**003**	Jun 27, 2018
AB		SANDOZ	**40MG/ML**	**A040719**	**001**	Jan 29, 2009
AB			**40MG/ML**	**A040794**	**001**	Mar 05, 2009
AB			**80MG/ML**	**A040719**	**002**	Jan 29, 2009
AB			**80MG/ML**	**A040794**	**002**	Mar 05, 2009
AB		SLAYBACK PHARMA LLC	**40MG/ML**	**A214870**	**002**	May 10, 2023
AB			**80MG/ML**	**A214870**	**001**	Jan 03, 2023
AB		TEVA PHARMS USA	**40MG/ML**	**A040620**	**001**	Oct 27, 2006
AB			**80MG/ML**	**A040620**	**002**	Oct 27, 2006

DEPO-MEDROL

	+!	PFIZER	20MG/ML	N011757	002

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP		AMNEAL	**EQ 40MG BASE/VIAL**	**A207549**	**001**	Nov 09, 2016
AP			**EQ 125MG BASE/VIAL**	**A207549**	**002**	Nov 09, 2016
AP		FRESENIUS KABI USA	**EQ 40MG BASE/VIAL**	**A040583**	**001**	Jul 30, 2004
AP			**EQ 125MG BASE/VIAL**	**A040583**	**002**	Jul 30, 2004
AP			**EQ 1GM BASE/VIAL**	**A040612**	**001**	Aug 12, 2004
AP		HIKMA	**EQ 40MG BASE/VIAL**	**A203125**	**001**	Sep 26, 2022
AP			**EQ 125MG BASE/VIAL**	**A203125**	**002**	Sep 26, 2022
AP			**EQ 500MG BASE/VIAL**	**A202691**	**001**	Feb 16, 2016
AP			**EQ 1GM BASE/VIAL**	**A202691**	**002**	Feb 16, 2016
AP		SAGENT PHARMS INC	**EQ 40MG BASE/VIAL**	**A040888**	**001**	Jul 18, 2011
AP			**EQ 125MG BASE/VIAL**	**A040888**	**002**	Jul 18, 2011
AP			**EQ 500MG BASE/VIAL**	**A040888**	**003**	Jul 18, 2011
AP			**EQ 1GM BASE/VIAL**	**A040888**	**004**	Jul 18, 2011
AP			**EQ 2GM BASE/VIAL**	**A040888**	**005**	Jul 18, 2011
AP		TIANJIN KINGYORK	**EQ 40MG BASE/VIAL**	**A212396**	**001**	Apr 20, 2021
AP			**EQ 125MG BASE/VIAL**	**A212396**	**002**	Apr 20, 2021
AP			**EQ 500MG BASE/VIAL**	**A212396**	**003**	Apr 20, 2021

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP			**EQ 1GM BASE/VIAL**	**A212396**	**004**	Apr 20, 2021
AP			**EQ 2GM BASE/VIAL**	**A212396**	**005**	Apr 20, 2021

SOLU-MEDROL

AP	**+!**	PHARMACIA AND UPJOHN	**EQ 40MG BASE/VIAL**	**N011856**	**003**	
AP	**+!**		**EQ 125MG BASE/VIAL**	**N011856**	**004**	
AP	**+!**		**EQ 500MG BASE/VIAL**	**N011856**	**005**	
AP	**+!**		**EQ 1GM BASE/VIAL**	**N011856**	**006**	
AP	**+!**		**EQ 2GM BASE/VIAL**	**N011856**	**007**	Feb 27, 1985

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE

AB	**!**	IMPAX LABS INC	**10MG**	**A204851**	**001**	Sep 21, 2015
AB		NOVITIUM PHARMA	**10MG**	**A215270**	**001**	Feb 18, 2022

TABLET;ORAL

ANDROID 25

BP		VALEANT PHARM INTL	25MG	A087147	001	

METHYLTESTOSTERONE

BP		IMPAX LABS	10MG	A080767	002	

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

METOCLOPRAMIDE

AP		AVET LIFESCIENCES	**EQ 5MG BASE/ML**	**A204756**	**001**	Dec 20, 2013

METOCLOPRAMIDE HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 5MG BASE/ML**	**A091392**	**001**	Apr 19, 2013
AP	**!**	HOSPIRA	**EQ 5MG BASE/ML**	**A073118**	**001**	Jan 17, 1991
AP		TEVA PHARMS USA	**EQ 5MG BASE/ML**	**A073135**	**001**	Nov 27, 1991

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA		ANI PHARMS	**EQ 5MG BASE/5ML**	**A071402**	**001**	Jun 25, 1993
AA	**!**	PHARM ASSOC	**EQ 5MG BASE/5ML**	**A072744**	**001**	May 28, 1991

SPRAY, METERED;NASAL

GIMOTI

	+!	EVOKE PHARMA INC	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB		IMPAX LABS INC	**EQ 5MG BASE**	**A071250**	**002**	Dec 28, 1995
AB			**EQ 10MG BASE**	**A071250**	**001**	Feb 03, 1988
AB		IPCA LABS LTD	**EQ 5MG BASE**	**A078807**	**001**	Jun 12, 2008
AB			**EQ 10MG BASE**	**A078807**	**002**	Jun 12, 2008
AB		STRIDES PHARMA	**EQ 5MG BASE**	**A077878**	**001**	Aug 28, 2006
AB			**EQ 10MG BASE**	**A070581**	**001**	Oct 17, 1985
AB			**EQ 10MG BASE**	**A077878**	**002**	Aug 28, 2006
AB		TEVA	**EQ 5MG BASE**	**A072801**	**001**	Jun 15, 1993
AB			**EQ 10MG BASE**	**A070184**	**001**	Jul 29, 1985

REGLAN

AB	**+**	ANI PHARMS	**EQ 5MG BASE**	**N017854**	**002**	May 05, 1987
AB	**+!**		**EQ 10MG BASE**	**N017854**	**001**	

TABLET, ORALLY DISINTEGRATING;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

		NOVEL LABS INC	EQ 5MG BASE	A202191	001	Aug 15, 2014
	!		EQ 10MG BASE	A202191	002	Aug 15, 2014

METOLAZONE

TABLET;ORAL

METOLAZONE

AB		ALEMBIC	**2.5MG**	**A213251**	**001**	Dec 02, 2020
AB			**5MG**	**A213251**	**002**	Dec 02, 2020
AB			**10MG**	**A213251**	**003**	Dec 02, 2020
AB		BAYSHORE PHARMS LLC	**2.5MG**	**A214799**	**001**	Mar 30, 2021
AB			**5MG**	**A214799**	**002**	Mar 30, 2021
AB			**10MG**	**A214799**	**003**	Mar 30, 2021
AB		INNOGENIX	**2.5MG**	**A213827**	**001**	Mar 30, 2021
AB			**5MG**	**A213827**	**002**	Mar 30, 2021
AB			**10MG**	**A213827**	**003**	Mar 30, 2021
AB		MYLAN	**2.5MG**	**A076698**	**001**	Dec 23, 2003
AB			**5MG**	**A076698**	**002**	Oct 19, 2004
AB			**10MG**	**A076698**	**003**	Oct 19, 2004
AB		NE RX PHARMA	**2.5MG**	**A216216**	**001**	Oct 25, 2022

METOLAZONE

TABLET;ORAL

METOLAZONE

AB		**5MG**	**A216216**	**002**	Oct 25, 2022
AB		**10MG**	**A216216**	**003**	Oct 25, 2022
AB	RENATA	**2.5MG**	**A215616**	**001**	Oct 24, 2022
AB		**5MG**	**A215616**	**002**	Oct 24, 2022
AB		**10MG**	**A215616**	**003**	Oct 24, 2022
AB	RUBICON	**2.5MG**	**A215184**	**001**	Aug 20, 2021
AB		**5MG**	**A215184**	**002**	Aug 20, 2021
AB		**10MG**	**A215184**	**003**	Aug 20, 2021
AB	SANDOZ	**2.5MG**	**A076732**	**001**	Dec 19, 2003
AB !		**5MG**	**A076466**	**001**	Dec 19, 2003
AB !		**10MG**	**A076466**	**002**	Dec 19, 2003

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE;ORAL

KAPSPARGO SPRINKLE

+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018
+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018
+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018
+!		EQ 200MG TARTRATE	N210428	004	Jan 26, 2018

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB	ACTAVIS ELIZABETH	**EQ 25MG TARTRATE**	**A204161**	**001**	Nov 25, 2016
AB		**EQ 50MG TARTRATE**	**A204161**	**002**	Nov 25, 2016
AB		**EQ 100MG TARTRATE**	**A204161**	**003**	Nov 25, 2016
AB		**EQ 200MG TARTRATE**	**A204161**	**004**	Nov 25, 2016
AB	ACTAVIS LABS FL INC	**EQ 50MG TARTRATE**	**A076862**	**001**	Aug 03, 2009
AB	ALKEM LABS LTD	**EQ 25MG TARTRATE**	**A211143**	**001**	Nov 25, 2020
AB		**EQ 50MG TARTRATE**	**A211143**	**002**	Nov 25, 2020
AB		**EQ 100MG TARTRATE**	**A211143**	**003**	Nov 25, 2020
AB		**EQ 200MG TARTRATE**	**A211143**	**004**	Nov 25, 2020
AB	CIPLA	**EQ 50MG TARTRATE**	**A207465**	**001**	Oct 26, 2018
AB		**EQ 100MG TARTRATE**	**A207465**	**002**	Oct 26, 2018
AB		**EQ 200MG TARTRATE**	**A207465**	**003**	Oct 26, 2018
AB	DR REDDYS LABS LTD	**EQ 25MG TARTRATE**	**A090617**	**001**	Aug 01, 2012
AB		**EQ 50MG TARTRATE**	**A090617**	**002**	Aug 01, 2012
AB	GRANULES	**EQ 25MG TARTRATE**	**A216509**	**001**	Aug 07, 2023
AB		**EQ 25MG TARTRATE**	**A216916**	**001**	Jun 12, 2023
AB		**EQ 50MG TARTRATE**	**A216509**	**002**	Aug 07, 2023
AB		**EQ 50MG TARTRATE**	**A216916**	**002**	Jun 12, 2023
AB		**EQ 100MG TARTRATE**	**A216509**	**003**	Aug 07, 2023
AB		**EQ 100MG TARTRATE**	**A216916**	**003**	Jun 12, 2023
AB		**EQ 200MG TARTRATE**	**A216509**	**004**	Aug 07, 2023
AB		**EQ 200MG TARTRATE**	**A216916**	**004**	Jun 12, 2023
AB	HETERO LABS LTD III	**EQ 25MG TARTRATE**	**A205541**	**001**	Nov 06, 2020
AB		**EQ 50MG TARTRATE**	**A205541**	**002**	Nov 06, 2020
AB		**EQ 100MG TARTRATE**	**A205541**	**003**	Nov 06, 2020
AB		**EQ 200MG TARTRATE**	**A205541**	**004**	Nov 06, 2020
AB	MYLAN PHARMS INC	**EQ 25MG TARTRATE**	**A202033**	**001**	Dec 15, 2011
AB		**EQ 50MG TARTRATE**	**A202033**	**002**	Dec 15, 2011
AB		**EQ 100MG TARTRATE**	**A202033**	**003**	Dec 15, 2011
AB		**EQ 200MG TARTRATE**	**A202033**	**004**	Dec 15, 2011
AB	NOVAST LABS	**EQ 25MG TARTRATE**	**A204106**	**001**	Feb 06, 2018
AB		**EQ 50MG TARTRATE**	**A204106**	**002**	Feb 06, 2018
AB		**EQ 100MG TARTRATE**	**A204106**	**003**	Feb 06, 2018
AB		**EQ 200MG TARTRATE**	**A204106**	**004**	Feb 06, 2018
AB	PHARMADAX INC	**EQ 25MG TARTRATE**	**A203028**	**001**	Mar 31, 2020
AB		**EQ 50MG TARTRATE**	**A203028**	**002**	Mar 31, 2020
AB		**EQ 100MG TARTRATE**	**A203699**	**001**	Mar 30, 2020
AB		**EQ 200MG TARTRATE**	**A203699**	**002**	Mar 30, 2020
AB	REDDYS	**EQ 100MG TARTRATE**	**A078889**	**001**	Aug 15, 2012
AB		**EQ 200MG TARTRATE**	**A078889**	**002**	Aug 15, 2012
AB	SUNSHINE	**EQ 50MG TARTRATE**	**A214004**	**001**	Sep 26, 2022
AB		**EQ 100MG TARTRATE**	**A214004**	**002**	Sep 26, 2022
AB		**EQ 200MG TARTRATE**	**A214004**	**003**	Sep 26, 2022
AB	VISUM PHARM	**EQ 25MG TARTRATE**	**A207206**	**001**	Dec 19, 2018
AB		**EQ 50MG TARTRATE**	**A207206**	**002**	Dec 19, 2018
AB		**EQ 100MG TARTRATE**	**A207206**	**003**	Dec 19, 2018
AB		**EQ 200MG TARTRATE**	**A207206**	**004**	Dec 19, 2018
AB	WOCKHARDT	**EQ 25MG TARTRATE**	**A090615**	**001**	Jul 22, 2010
AB		**EQ 50MG TARTRATE**	**A090615**	**002**	Jul 22, 2010

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB			**EQ 100MG TARTRATE**	**A090615**	**003**	Jul 22, 2010
AB			**EQ 200MG TARTRATE**	**A090615**	**004**	Jul 22, 2010
AB		YICHANG HUMANWELL	**EQ 25MG TARTRATE**	**A213854**	**004**	Aug 01, 2022
AB			**EQ 50MG TARTRATE**	**A213854**	**003**	Nov 08, 2021
AB			**EQ 100MG TARTRATE**	**A213854**	**001**	Feb 12, 2021
AB			**EQ 200MG TARTRATE**	**A213854**	**002**	Feb 12, 2021
AB		ZYDUS PHARMS	**EQ 25MG TARTRATE**	**A203894**	**001**	Mar 23, 2018
AB			**EQ 50MG TARTRATE**	**A203894**	**002**	Mar 23, 2018
AB			**EQ 100MG TARTRATE**	**A203894**	**003**	Mar 23, 2018
AB			**EQ 200MG TARTRATE**	**A203894**	**004**	Mar 23, 2018

TOPROL-XL

AB	+	TOPROL	**EQ 25MG TARTRATE**	**N019962**	**004**	Feb 05, 2001
AB	+!		**EQ 50MG TARTRATE**	**N019962**	**001**	Jan 10, 1992
AB	+		**EQ 100MG TARTRATE**	**N019962**	**002**	Jan 10, 1992
AB	+!		**EQ 200MG TARTRATE**	**N019962**	**003**	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP		BAXTER HLTHCARE CORP	**1MG/ML**	**A078950**	**001**	Apr 29, 2013
AP		FRESENIUS KABI USA	**1MG/ML**	**A091045**	**001**	Oct 25, 2010
AP		GLAND PHARMA LTD	**1MG/ML**	**A204205**	**001**	Aug 27, 2014
AP		HIKMA	**1MG/ML**	**A076495**	**001**	Jul 07, 2003
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A077761**	**001**	May 30, 2007
AP		HOSPIRA	**1MG/ML**	**A074133**	**001**	Dec 21, 1993
AP	!		**1MG/ML**	**A078085**	**001**	Apr 29, 2008
AP		SANDOZ	**1MG/ML**	**A077360**	**001**	Oct 02, 2007

TABLET;ORAL

LOPRESSOR

AB	+	VALIDUS PHARMS	**50MG**	**N017963**	**001**	
AB	+		**100MG**	**N017963**	**002**	

METOPROLOL TARTRATE

AB		ALEMBIC PHARMS LTD	**25MG**	**A202871**	**001**	May 28, 2013
AB			**50MG**	**A202871**	**002**	May 28, 2013
AB			**100MG**	**A202871**	**003**	May 28, 2013
AB		AUROBINDO PHARMA	**25MG**	**A077739**	**001**	Sep 11, 2007
AB			**37.5MG**	**A077739**	**004**	Dec 07, 2023
AB			**50MG**	**A077739**	**002**	Sep 11, 2007
AB			**75MG**	**A077739**	**005**	Dec 07, 2023
AB			**100MG**	**A077739**	**003**	Sep 11, 2007
AB		IPCA LABS LTD	**25MG**	**A078459**	**001**	Jun 17, 2008
AB			**50MG**	**A078459**	**002**	Jun 17, 2008
AB			**100MG**	**A078459**	**003**	Jun 17, 2008
AB		MYLAN	**25MG**	**A076704**	**001**	Jan 16, 2004
AB			**37.5MG**	**A076704**	**004**	Mar 18, 2015
AB			**50MG**	**A076704**	**002**	Jan 16, 2004
AB			**75MG**	**A076704**	**005**	Mar 18, 2015
AB	!		**100MG**	**A076704**	**003**	Jan 16, 2004
AB		RENATA	**50MG**	**A074453**	**001**	Apr 27, 1995
AB			**100MG**	**A074453**	**002**	Apr 27, 1995
AB		RUBICON	**25MG**	**A200981**	**001**	Oct 28, 2014
AB			**37.5MG**	**A200981**	**004**	Aug 21, 2019
AB			**50MG**	**A200981**	**002**	Oct 28, 2014
AB			**75MG**	**A200981**	**005**	Aug 21, 2019
AB			**100MG**	**A200981**	**003**	Oct 28, 2014
AB		SUN PHARM INDS INC	**25MG**	**A076670**	**001**	Jan 15, 2004
AB			**50MG**	**A074644**	**001**	Dec 10, 1996
AB			**100MG**	**A074644**	**002**	Dec 10, 1996
AB		YOUNGTECH PHARMS INC	**25MG**	**A208955**	**001**	Feb 05, 2020
AB			**50MG**	**A208955**	**002**	Feb 05, 2020
AB			**100MG**	**A208955**	**003**	Feb 05, 2020

METRONIDAZOLE

CAPSULE;ORAL

FLAGYL

AB	+!	PFIZER	**375MG**	**N020334**	**001**	May 03, 1995

METRONIDAZOLE

AB		ALEMBIC	**375MG**	**A079065**	**001**	Jun 23, 2009
AB		CHARTWELL RX	**375MG**	**A076522**	**001**	Jan 29, 2004

METRONIDAZOLE

CREAM;TOPICAL

METROCREAM

AB	**+!**	GALDERMA LABS LP	**0.75%**	**N020531**	**001**	Sep 20, 1995

METRONIDAZOLE

AB		COSETTE	**0.75%**	**A077549**	**001**	Dec 19, 2007
AB		FOUGERA PHARMS	**0.75%**	**A076408**	**001**	May 28, 2004
AB		ZYDUS LIFESCIENCES	**0.75%**	**A217128**	**001**	Apr 21, 2023

NORITATE

	+!	BAUSCH	1%	N020743	001	Sep 26, 1997

GEL;TOPICAL

METROGEL

AB	**+!**	GALDERMA LABS LP	**0.75%**	**N019737**	**001**	Nov 22, 1988
AB	**+!**		**1%**	**N021789**	**001**	Jun 30, 2005

METRONIDAZOLE

AB		ALEMBIC	**1%**	**A212646**	**001**	Sep 03, 2021
AB		COSETTE	**0.75%**	**A078178**	**001**	Jan 19, 2011
AB			**1%**	**A216692**	**001**	Jan 23, 2023
AB		ENCUBE	**0.75%**	**A077547**	**001**	Jul 13, 2006
AB		FOUGERA PHARMS	**0.75%**	**A077018**	**001**	Jun 06, 2006
AB		TARO	**0.75%**	**A077819**	**001**	Jul 18, 2006
AB			**1%**	**A204651**	**001**	Mar 14, 2017

GEL;VAGINAL

METROGEL-VAGINAL

AB	**+!**	BAUSCH	**0.75%**	**N020208**	**001**	Aug 17, 1992

METRONIDAZOLE

AB		COSETTE	**0.75%**	**A216323**	**001**	Jul 12, 2023
AB		ENCUBE	**0.75%**	**A215610**	**001**	Jun 16, 2023
AB		GLENMARK PHARMS LTD	**0.75%**	**A215794**	**001**	Jan 27, 2022
AB		PADAGIS ISRAEL	**0.75%**	**A211786**	**001**	Jul 02, 2019
AB		SOLARIS PHARMA CORP	**0.75%**	**A213648**	**001**	Oct 14, 2021

VANDAZOLE

BX	!	TEVA PHARMS	0.75%	N021806	001	May 20, 2005

NUVESSA

	+!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014

INJECTABLE;INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**500MG/100ML**	**N018657**	**001**	

METRO I.V. IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**500MG/100ML**	**N018900**	**001**	Sep 29, 1983

METRONIDAZOLE IN PLASTIC CONTAINER

AP		AMNEAL	**500MG/100ML**	**A217665**	**001**	May 24, 2023
AP		BAXTER HLTHCARE CORP	**500MG/100ML**	**A078084**	**001**	Mar 31, 2008
AP		GLAND PHARMA LTD	**500MG/100ML**	**A212435**	**001**	Aug 03, 2020
AP	**+!**	HOSPIRA	**500MG/100ML**	**N018890**	**002**	Nov 18, 1983
AP		INFORLIFE	**500MG/100ML**	**A206191**	**001**	Feb 25, 2019

LOTION;TOPICAL

METROLOTION

AB	**+!**	GALDERMA LABS LP	**0.75%**	**N020901**	**001**	Nov 24, 1998

METRONIDAZOLE

AB		FOUGERA PHARMS	**0.75%**	**A077197**	**001**	May 24, 2006

SUSPENSION;ORAL

LIKMEZ

	+!	SAPTALIS PHARMS	500MG/5ML	N216755	001	Sep 22, 2023

TABLET;ORAL

METRONIDAZOLE

AB		ALEMBIC	**250MG**	**A208681**	**001**	Jun 20, 2017
AB			**500MG**	**A208681**	**002**	Jun 20, 2017
AB		ALEMBIC PHARMS LTD	**250MG**	**A079067**	**001**	Mar 13, 2009
AB			**500MG**	**A079067**	**002**	Mar 13, 2009
AB		AUROBINDO PHARMA LTD	**250MG**	**A203974**	**001**	May 29, 2015
AB	**!**		**500MG**	**A203974**	**002**	May 29, 2015
AB		CADILA	**250MG**	**A206560**	**001**	Nov 16, 2016
AB			**500MG**	**A206560**	**002**	Nov 16, 2016
AB		CADILA PHARMS LTD	**250MG**	**A209794**	**001**	Dec 12, 2017
AB			**500MG**	**A209794**	**002**	Dec 12, 2017
AB		FLAMINGO PHARMS	**250MG**	**A207309**	**001**	May 16, 2016
AB			**500MG**	**A207309**	**002**	May 16, 2016
AB		HERITAGE PHARMS INC	**250MG**	**A205245**	**001**	Sep 23, 2015
AB			**500MG**	**A205245**	**002**	Sep 23, 2015
AB		INNOGENIX	**250MG**	**A070772**	**001**	Jul 16, 1986

METRONIDAZOLE
TABLET;ORAL
METRONIDAZOLE

AB		**500MG**	**A070772**	**002**	Jul 16, 1986
AB	LUPIN LTD	**250MG**	**A209096**	**001**	Sep 12, 2017
AB		**500MG**	**A209096**	**002**	Sep 12, 2017
AB	PLIVA	**500MG**	**A070033**	**001**	Dec 06, 1984
AB	STRIDES PHARMA	**250MG**	**A070040**	**001**	Jan 29, 1985
AB		**250MG**	**A208162**	**001**	May 25, 2016
AB		**500MG**	**A070039**	**001**	Jan 29, 1985
AB		**500MG**	**A208162**	**002**	May 25, 2016
AB	TEVA PHARMS USA	**250MG**	**A070027**	**001**	Nov 06, 1984
AB	UNICHEM	**250MG**	**A203458**	**001**	Jan 22, 2014
AB		**500MG**	**A203458**	**002**	Jan 22, 2014
AB	WATSON LABS	**250MG**	**A070035**	**001**	Dec 20, 1984
AB	WATSON LABS INC	**500MG**	**A070044**	**001**	Feb 08, 1985

METYRAPONE
CAPSULE;ORAL
METOPIRONE

+!	HRA PHARMA	250MG	N012911	002	Aug 09, 1996

METYROSINE
CAPSULE;ORAL
DEMSER

AB	**+!** BAUSCH	**250MG**	**N017871**	**001**	

METYROSINE

AB	AMNEAL	**250MG**	**A213734**	**001**	Jul 24, 2020

MEXILETINE HYDROCHLORIDE
CAPSULE;ORAL
MEXILETINE HYDROCHLORIDE

AB	ANI PHARMS	**150MG**	**A074450**	**001**	May 16, 1996
AB		**200MG**	**A074450**	**002**	May 16, 1996
AB		**250MG**	**A074450**	**003**	May 16, 1996
AB	ANNORA PHARMA	**150MG**	**A216463**	**001**	Nov 09, 2022
AB		**200MG**	**A216463**	**002**	Nov 09, 2022
AB		**250MG**	**A216463**	**003**	Nov 09, 2022
AB	CARNEGIE	**150MG**	**A215315**	**001**	Aug 26, 2022
AB		**200MG**	**A215315**	**002**	Aug 26, 2022
AB		**250MG**	**A215315**	**003**	Aug 26, 2022
AB	CHEMISTRY HLTH	**150MG**	**A215876**	**001**	Feb 27, 2023
AB		**200MG**	**A215876**	**002**	Feb 27, 2023
AB		**250MG**	**A215876**	**003**	Feb 27, 2023
AB	CROSSMEDIKA SA	**150MG**	**A213500**	**001**	Jul 22, 2020
AB		**200MG**	**A213500**	**002**	Jul 22, 2020
AB		**250MG**	**A213500**	**003**	Jul 22, 2020
AB	NOVAST LABS	**150MG**	**A214352**	**001**	Jan 25, 2021
AB		**200MG**	**A214352**	**002**	Jan 25, 2021
AB		**250MG**	**A214352**	**003**	Jan 25, 2021
AB	SENORES PHARMS	**150MG**	**A214089**	**001**	Oct 01, 2021
AB		**200MG**	**A214089**	**002**	Oct 01, 2021
AB		**250MG**	**A214089**	**003**	Oct 01, 2021
AB	TEVA	**150MG**	**A074377**	**001**	May 16, 1995
AB		**200MG**	**A074377**	**002**	May 16, 1995
AB	**!**	**250MG**	**A074377**	**003**	May 16, 1995

MICAFUNGIN SODIUM
INJECTABLE;INTRAVENOUS
MICAFUNGIN SODIUM

AP	APOTEX	**EQ 50MG BASE/VIAL**	**A208366**	**001**	Nov 05, 2020
AP		**EQ 100MG BASE/VIAL**	**A208366**	**002**	Nov 05, 2020
AP	FRESENIUS KABI USA	**EQ 50MG BASE/VIAL**	**A207344**	**001**	May 17, 2019
AP		**EQ 100MG BASE/VIAL**	**A207344**	**002**	May 17, 2019
AP	HIKMA	**EQ 50MG BASE/VIAL**	**A213261**	**001**	Jul 09, 2021
AP		**EQ 100MG BASE/VIAL**	**A213261**	**002**	Jul 09, 2021
AP	JIANGSU HANSOH PHARM	**EQ 50MG BASE/VIAL**	**A213363**	**001**	Jul 09, 2021
AP		**EQ 100MG BASE/VIAL**	**A213363**	**002**	Jul 09, 2021
AP	MEITHEAL	**EQ 50MG BASE/VIAL**	**A215381**	**001**	Sep 28, 2022
AP		**EQ 100MG BASE/VIAL**	**A215381**	**002**	Sep 28, 2022
AP	XELLIA PHARMS APS	**EQ 50MG BASE/VIAL**	**A211713**	**001**	Jun 02, 2021
AP		**EQ 100MG BASE/VIAL**	**A211713**	**002**	Jun 02, 2021
AP	ZYDUS PHARMS	**EQ 50MG BASE/VIAL**	**A215241**	**001**	Oct 24, 2022
AP		**EQ 100MG BASE/VIAL**	**A215241**	**002**	Oct 24, 2022

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS

MYCAMINE

AP	**+!**	ASTELLAS	**EQ 50MG BASE/VIAL**	**N021506**	**002**	Mar 16, 2005
AP	**+!**		**EQ 100MG BASE/VIAL**	**N021506**	**003**	Jun 27, 2006

POWDER;INTRAVENOUS

MICAFUNGIN

+!	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	N212156	001	Jun 16, 2021
+!		EQ 100MG BASE/VIAL	N212156	002	Jun 16, 2021

SOLUTION;INTRAVENOUS

MICAFUNGIN IN SODIUM CHLORIDE 0.9%

+!	BAXTER HLTHCARE CORP	EQ 50MG BASE/50ML (EQ 1MG BASE/ML)	N216142	001	Sep 29, 2023
+!		EQ 100MG BASE/100ML (EQ 1MG BASE/ML)	N216142	002	Sep 29, 2023
+!		EQ 150MG BASE/150ML (EQ 1MG BASE/ML)	N216142	003	Sep 29, 2023

MICONAZOLE

TABLET;BUCCAL

ORAVIG

+!	GALT PHARMS	50MG	N022404	001	Apr 16, 2010

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

AB		ACTAVIS PHARMA	**200MG**	**A073508**	**001**	Nov 19, 1993

MONISTAT 3

AB	**+!**	MEDTECH PRODUCTS	**200MG**	**N018888**	**001**	Aug 15, 1984

MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE

OINTMENT;TOPICAL

VUSION

+!	MYLAN	0.25%;81.35%;15%	N021026	001	Feb 16, 2006

MIDAZOLAM

SOLUTION;INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

AP		HIKMA	**50MG/50ML (1MG/ML)**	**A216159**	**001**	Apr 17, 2023
AP			**100MG/100ML (1MG/ML)**	**A216159**	**002**	Apr 17, 2023
AP	**+!**	INFORLIFE	**50MG/50ML (1MG/ML)**	**N211844**	**001**	Mar 22, 2021
AP	**+!**		**100MG/100ML (1MG/ML)**	**N211844**	**002**	Mar 22, 2021

MIDAZOLAM IN 0.8% SODIUM CHLORIDE

+!	EXELA PHARMA	50MG/50ML (1MG/ML)	N215868	001	Jul 20, 2022
+!		100MG/100ML (1MG/ML)	N215868	002	Jul 20, 2022

SPRAY;NASAL

NAYZILAM

+!	UCB INC	5MG/SPRAY	N211321	001	May 17, 2019

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

AP		AKORN	**EQ 1MG BASE/ML**	**A075494**	**001**	Jun 30, 2000
AP			**EQ 5MG BASE/ML**	**A075494**	**002**	Jun 30, 2000
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A075154**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075154**	**001**	Jun 20, 2000
AP		GLAND PHARMA LTD	**EQ 1MG BASE/ML**	**A090696**	**001**	Feb 29, 2012
AP			**EQ 5MG BASE/ML**	**A090850**	**001**	Jan 25, 2012
AP		HIKMA	**EQ 1MG BASE/ML**	**A075243**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A075247**	**002**	Jun 23, 2000
AP			**EQ 1MG BASE/ML**	**A075324**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A075421**	**002**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A212847**	**001**	Dec 11, 2020
AP			**EQ 5MG BASE/ML**	**A075243**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075247**	**001**	Jun 23, 2000
AP			**EQ 5MG BASE/ML**	**A075324**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075421**	**001**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A212847**	**002**	Dec 11, 2020
AP	**!**	HOSPIRA	**EQ 1MG BASE/ML**	**A075293**	**001**	Jun 20, 2000
AP	**!**		**EQ 5MG BASE/ML**	**A075293**	**002**	Jun 20, 2000
AP		MICRO LABS	**EQ 1MG BASE/ML**	**A217504**	**001**	Aug 21, 2023
AP			**EQ 5MG BASE/ML**	**A217504**	**002**	Aug 21, 2023

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A203460**	**001**	Aug 22, 2014
AP			**EQ 5MG BASE/ML**	**A203460**	**002**	Aug 22, 2014
AP	**!**	HOSPIRA	**EQ 1MG BASE/ML**	**A075857**	**001**	Jul 22, 2002

MIDAZOLAM HYDROCHLORIDE						
INJECTABLE;INJECTION						
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE						
AP	**!**		**EQ 5MG BASE/ML**	**A075857**	**002**	Jul 22, 2002
AP		STERISCIENCE	**EQ 1MG BASE/ML**	**A090315**	**001**	Nov 29, 2010
AP			**EQ 5MG BASE/ML**	**A090315**	**002**	Nov 29, 2010
MIDOZALAM HYDROCHLORIDE						
AP		STERISCIENCE	**EQ 1MG BASE/ML**	**A090316**	**001**	May 04, 2011
AP			**EQ 5MG BASE/ML**	**A090316**	**002**	May 04, 2011
MIDAZOLAM HYDROCHLORIDE						
		FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017
SOLUTION;INTRAMUSCULAR						
SEIZALAM						
	+!	MMT	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	N209566	001	Sep 14, 2018
SYRUP;ORAL						
MIDAZOLAM HYDROCHLORIDE						
AA	**!**	HIKMA	**EQ 2MG BASE/ML**	**A075873**	**001**	Apr 30, 2002
AA		PADAGIS US	**EQ 2MG BASE/ML**	**A076379**	**001**	May 02, 2005
MIDODRINE HYDROCHLORIDE						
TABLET;ORAL						
MIDODRINE HYDROCHLORIDE						
AB		ALEMBIC	**2.5MG**	**A214734**	**001**	Jan 21, 2021
AB			**5MG**	**A214734**	**002**	Jan 21, 2021
AB			**10MG**	**A214734**	**003**	Jan 21, 2021
AB		APOTEX	**2.5MG**	**A077746**	**001**	Sep 12, 2006
AB			**5MG**	**A077746**	**002**	Sep 12, 2006
AB			**10MG**	**A077746**	**003**	Sep 12, 2006
AB		AUROBINDO PHARMA LTD	**2.5MG**	**A212774**	**001**	Aug 10, 2020
AB			**5MG**	**A212774**	**002**	Aug 10, 2020
AB			**10MG**	**A212774**	**003**	Aug 10, 2020
AB		IMPAX PHARMS	**2.5MG**	**A076449**	**001**	May 27, 2004
AB			**5MG**	**A076449**	**002**	May 27, 2004
AB			**10MG**	**A076449**	**003**	Dec 16, 2005
AB		MANKIND PHARMA	**2.5MG**	**A217271**	**001**	Nov 01, 2023
AB			**5MG**	**A217271**	**002**	Nov 01, 2023
AB			**10MG**	**A217271**	**003**	Nov 01, 2023
AB		MYLAN PHARMS INC	**2.5MG**	**A076577**	**001**	Sep 10, 2003
AB			**5MG**	**A076577**	**002**	Sep 10, 2003
AB			**10MG**	**A076577**	**003**	Sep 10, 2003
AB		NOVUGEN	**2.5MG**	**A211973**	**001**	Oct 17, 2023
AB			**5MG**	**A211973**	**002**	Oct 17, 2023
AB			**10MG**	**A211973**	**003**	Oct 17, 2023
AB		PAR PHARM INC	**2.5MG**	**A207169**	**001**	Oct 29, 2018
AB			**5MG**	**A207169**	**002**	Oct 29, 2018
AB			**10MG**	**A207169**	**003**	Oct 29, 2018
AB		RUBICON	**2.5MG**	**A212543**	**001**	Aug 19, 2019
AB			**5MG**	**A212543**	**002**	Aug 19, 2019
AB			**10MG**	**A212543**	**003**	Aug 19, 2019
AB		THINQ PHARM-CRO PVT	**2.5MG**	**A207613**	**001**	Nov 02, 2018
AB			**5MG**	**A207613**	**002**	Nov 02, 2018
AB			**10MG**	**A207613**	**003**	Nov 02, 2018
AB		XIROMED	**2.5MG**	**A207849**	**001**	Oct 01, 2020
AB			**5MG**	**A207849**	**002**	Oct 01, 2020
AB			**10MG**	**A207849**	**003**	Oct 01, 2020
AB		ZYDUS	**2.5MG**	**A213055**	**001**	Sep 01, 2020
AB			**5MG**	**A213055**	**002**	Sep 01, 2020
AB			**10MG**	**A213055**	**003**	Sep 01, 2020
ORVATEN						
AB		UPSHER SMITH LABS	**2.5MG**	**A076725**	**001**	Nov 03, 2004
AB	**!**		**5MG**	**A076725**	**002**	Nov 03, 2004
AB			**10MG**	**A076725**	**003**	Nov 03, 2004
MIDOSTAURIN						
CAPSULE;ORAL						
RYDAPT						
	+!	NOVARTIS	25MG	N207997	001	Apr 28, 2017

MIFEPRISTONE
TABLET;ORAL

KORLYM						
AB	**+!**	CORCEPT THERAP	**300MG**	**N202107**	**001**	Feb 17, 2012
MIFEPREX						
AB	**+!**	DANCO LABS LLC	**200MG**	**N020687**	**001**	Sep 28, 2000
MIFEPRISTONE						
AB		GENBIOPRO	**200MG**	**A091178**	**001**	Apr 11, 2019
AB		TEVA PHARMS USA INC	**300MG**	**A211436**	**001**	Aug 03, 2020

MIGALASTAT HYDROCHLORIDE
CAPSULE;ORAL

GALAFOLD						
	+!	AMICUS THERAP US	EQ 123MG BASE	N208623	001	Aug 10, 2018

MIGLITOL
TABLET;ORAL

GLYSET						
AB	**+!**	PFIZER	**25MG**	**N020682**	**001**	Dec 18, 1996
AB	**+**		**50MG**	**N020682**	**002**	Dec 18, 1996
AB	**+**		**100MG**	**N020682**	**003**	Dec 18, 1996
MIGLITOL						
AB		WESTMINSTER PHARMS	**25MG**	**A203965**	**001**	Feb 24, 2015
AB			**50MG**	**A203965**	**002**	Feb 24, 2015
AB			**100MG**	**A203965**	**003**	Feb 24, 2015

MIGLUSTAT
CAPSULE;ORAL

MIGLUSTAT						
AB		ANI PHARMS	**100MG**	**A208342**	**001**	Apr 17, 2018
AB		BRECKENRIDGE	**100MG**	**A209325**	**001**	Feb 03, 2022
YARGESA						
AB		EDENBRIDGE PHARMS	**100MG**	**A209821**	**001**	Aug 06, 2020
ZAVESCA						
AB	**+!**	ACTELION	**100MG**	**N021348**	**001**	Jul 31, 2003
OPFOLDA						
	+!	AMICUS THERAP US	65MG	N215211	001	Sep 28, 2023

MILNACIPRAN HYDROCHLORIDE
TABLET;ORAL

SAVELLA						
	+	ABBVIE	12.5MG	N022256	001	Jan 14, 2009
	+		25MG	N022256	002	Jan 14, 2009
	+!		50MG	N022256	003	Jan 14, 2009
	+		100MG	N022256	004	Jan 14, 2009

MILRINONE LACTATE
INJECTABLE;INJECTION

MILRINONE LACTATE						
AP		CAPLIN	**EQ 1MG BASE/ML**	**A214380**	**001**	Apr 16, 2021
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A075936**	**001**	May 28, 2002
AP		HIKMA	**EQ 1MG BASE/ML**	**A075530**	**001**	May 28, 2002
AP			**EQ 1MG BASE/ML**	**A075660**	**001**	May 28, 2002
AP	**!**	HIKMA FARMACEUTICA	**EQ 1MG BASE/ML**	**A077966**	**001**	Dec 03, 2010
AP		HOSPIRA	**EQ 1MG BASE/ML**	**A203280**	**001**	Sep 03, 2014
AP		MEITHEAL	**EQ 1MG BASE/ML**	**A211671**	**001**	Mar 24, 2020
AP		SHANDONG	**EQ 1MG BASE/ML**	**A216373**	**001**	Jan 23, 2023
MILRINONE LACTATE IN DEXTROSE 5%						
AP		EUGIA PHARMA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A209666**	**001**	Sep 03, 2020
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A209666**	**002**	Sep 03, 2020
AP		WOODWARD	**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A077151**	**002**	Jul 20, 2005
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	**!**	BAXTER HLTHCARE	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A075834**	**001**	May 28, 2002
AP	**!**		**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A075834**	**002**	May 28, 2002
AP		GLAND PHARMA LTD	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A213585**	**001**	Jul 16, 2020
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A213585**	**002**	Jul 16, 2020
AP		WEST-WARD PHARMS INT	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A078113**	**001**	May 21, 2008
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A078113**	**002**	May 21, 2008
MILRINONE LACTATE IN PLASTIC CONTAINER						
AP		HIKMA FARMACEUTICA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A090038**	**001**	Jan 21, 2010
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A090038**	**002**	Jan 21, 2010

MILTEFOSINE

CAPSULE;ORAL

IMPAVIDO

	+!	KNIGHT THERAPS	50MG	N204684	001	Mar 19, 2014

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL

AMZEEQ

	+!	JOURNEY	EQ 4% BASE	N212379	001	Oct 18, 2019

ZILXI

	+!	JOURNEY	EQ 1.5% BASE	N213690	001	May 28, 2020

CAPSULE;ORAL

MINOCIN

AB	**+**	BAUSCH	**EQ 50MG BASE**	**N050649**	**001**	May 31, 1990
AB	**+**		**EQ 100MG BASE**	**N050649**	**002**	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

AB		AUROBINDO PHARMA	**EQ 50MG BASE**	**A065470**	**001**	Mar 11, 2008
AB			**EQ 75MG BASE**	**A065470**	**002**	Mar 11, 2008
AB			**EQ 100MG BASE**	**A065470**	**003**	Mar 11, 2008
AB		IMPAX LABS	**EQ 50MG BASE**	**A065005**	**001**	Mar 23, 1999
AB			**EQ 75MG BASE**	**A065005**	**003**	Apr 18, 2001
AB			**EQ 100MG BASE**	**A065005**	**002**	Mar 23, 1999
AB		SUN PHARM INDS INC	**EQ 50MG BASE**	**A090867**	**001**	May 13, 2013
AB			**EQ 75MG BASE**	**A090867**	**002**	May 13, 2013
AB			**EQ 100MG BASE**	**A090867**	**003**	May 13, 2013
AB		TORRENT	**EQ 50MG BASE**	**A065062**	**001**	Nov 30, 2000
AB			**EQ 75MG BASE**	**A065062**	**002**	Nov 30, 2000
AB			**EQ 100MG BASE**	**A065062**	**003**	Nov 30, 2000
AB		WATSON LABS	**EQ 75MG BASE**	**A063065**	**002**	Jun 10, 1999
AB			**EQ 100MG BASE**	**A063065**	**001**	Dec 30, 1991
AB		WATSON LABS TEVA	**EQ 50MG BASE**	**A063181**	**001**	Dec 30, 1991
AB		ZYDUS	**EQ 50MG BASE**	**A063011**	**001**	Mar 02, 1992
AB			**EQ 75MG BASE**	**A063009**	**002**	Aug 12, 2003
AB	**!**		**EQ 100MG BASE**	**A063009**	**001**	Mar 02, 1992

INJECTABLE;INJECTION

MINOCIN

	+!	REMPEX	EQ 100MG BASE/VIAL	N050444	001	

POWDER, EXTENDED RELEASE;DENTAL

ARESTIN

	+!	ORAPHARMA	EQ 1MG BASE	N050781	001	Feb 16, 2001

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**EQ 50MG BASE**	**A213662**	**001**	May 01, 2020
AB			**EQ 75MG BASE**	**A213662**	**002**	May 01, 2020
AB			**EQ 100MG BASE**	**A213662**	**003**	May 01, 2020
AB		BEXIMCO PHARMS USA	**EQ 50MG BASE**	**A215466**	**001**	May 27, 2022
AB			**EQ 75MG BASE**	**A215466**	**002**	May 27, 2022
AB			**EQ 100MG BASE**	**A215466**	**003**	May 27, 2022
AB		DR REDDYS LABS LTD	**EQ 50MG BASE**	**A065436**	**001**	Dec 26, 2007
AB			**EQ 75MG BASE**	**A065436**	**002**	Dec 26, 2007
AB			**EQ 100MG BASE**	**A065436**	**003**	Dec 26, 2007
AB		STRIDES PHARMA	**EQ 50MG BASE**	**A065131**	**001**	Apr 16, 2003
AB			**EQ 75MG BASE**	**A065131**	**002**	Apr 16, 2003
AB	**!**		**EQ 100MG BASE**	**A065131**	**003**	Apr 16, 2003
AB		SUN PHARM INDUSTRIES	**EQ 50MG BASE**	**A090217**	**001**	Jan 29, 2016
AB			**EQ 75MG BASE**	**A090217**	**002**	Jan 29, 2016
AB			**EQ 100MG BASE**	**A090217**	**003**	Jan 29, 2016
AB		TORRENT	**EQ 50MG BASE**	**A065156**	**001**	Jan 06, 2004
AB			**EQ 75MG BASE**	**A065156**	**002**	Jan 06, 2004
AB			**EQ 100MG BASE**	**A065156**	**003**	Jan 06, 2004

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		ALKEM LABS LTD	**EQ 45MG BASE**	**A204453**	**001**	Sep 28, 2016
AB			**EQ 55MG BASE**	**A204453**	**008**	Dec 19, 2019
AB			**EQ 65MG BASE**	**A204453**	**006**	Mar 16, 2018
AB			**EQ 80MG BASE**	**A204453**	**002**	Sep 28, 2016
AB			**EQ 90MG BASE**	**A204453**	**003**	Sep 28, 2016
AB			**EQ 105MG BASE**	**A204453**	**004**	Sep 28, 2016
AB			**EQ 115MG BASE**	**A204453**	**007**	Mar 16, 2018
AB			**EQ 135MG BASE**	**A204453**	**005**	Sep 28, 2016
AB		AUROBINDO PHARMA	**EQ 45MG BASE**	**A202261**	**001**	Nov 19, 2012

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

		LTD				
AB			**EQ 55MG BASE**	**A202261**	**008**	Aug 21, 2019
AB			**EQ 65MG BASE**	**A202261**	**002**	Sep 28, 2018
AB			**EQ 80MG BASE**	**A202261**	**006**	Jun 13, 2016
AB			**EQ 90MG BASE**	**A202261**	**003**	Nov 19, 2012
AB			**EQ 105MG BASE**	**A202261**	**007**	Jun 13, 2016
AB			**EQ 115MG BASE**	**A202261**	**004**	Sep 28, 2018
AB			**EQ 135MG BASE**	**A202261**	**005**	Nov 19, 2012
AB		LUPIN LTD	**EQ 45MG BASE**	**A091424**	**001**	Nov 30, 2011
AB			**EQ 55MG BASE**	**A091424**	**002**	Nov 30, 2011
AB			**EQ 90MG BASE**	**A091424**	**003**	Nov 30, 2011
AB			**EQ 135MG BASE**	**A091424**	**004**	Nov 30, 2011
AB		SANDOZ	**EQ 45MG BASE**	**A090422**	**001**	Aug 13, 2009
AB			**EQ 90MG BASE**	**A090422**	**002**	Aug 13, 2009
AB	**!**		**EQ 135MG BASE**	**A090422**	**003**	Aug 13, 2009
AB		SIDMAK LABS INDIA	**EQ 45MG BASE**	**A204394**	**001**	Dec 30, 2015
AB			**EQ 55MG BASE**	**A204394**	**002**	Oct 07, 2022
AB			**EQ 65MG BASE**	**A204394**	**003**	Oct 07, 2022
AB			**EQ 80MG BASE**	**A204394**	**004**	Dec 30, 2015
AB			**EQ 105MG BASE**	**A204394**	**005**	Dec 30, 2015
AB			**EQ 115MG BASE**	**A204394**	**006**	Oct 07, 2022
AB			**EQ 135MG BASE**	**A204394**	**007**	Dec 30, 2015
AB		SUN PHARM INDS LTD	**EQ 45MG BASE**	**A091118**	**001**	Sep 25, 2014
AB			**EQ 65MG BASE**	**A091118**	**003**	Dec 03, 2019
AB			**EQ 80MG BASE**	**A091118**	**004**	Sep 25, 2014
AB			**EQ 90MG BASE**	**A091118**	**005**	Sep 25, 2014
AB			**EQ 105MG BASE**	**A091118**	**006**	Sep 25, 2014
AB			**EQ 115MG BASE**	**A091118**	**007**	Dec 03, 2019
AB			**EQ 135MG BASE**	**A091118**	**008**	Sep 25, 2014
AB		ZYDUS PHARMS	**EQ 45MG BASE**	**A203553**	**001**	Nov 16, 2017
AB			**EQ 55MG BASE**	**A203553**	**002**	Jun 16, 2023
AB			**EQ 65MG BASE**	**A203553**	**003**	Jun 16, 2023
AB			**EQ 80MG BASE**	**A203553**	**004**	Nov 16, 2017
AB			**EQ 90MG BASE**	**A203553**	**005**	Nov 16, 2017
AB			**EQ 105MG BASE**	**A203553**	**006**	Nov 16, 2017
AB			**EQ 115MG BASE**	**A203553**	**007**	Jun 16, 2023
AB			**EQ 135MG BASE**	**A203553**	**008**	Nov 16, 2017
	SOLODYN					
AB	**+**	BAUSCH	**EQ 55MG BASE**	**N050808**	**008**	Aug 27, 2010
AB	**+**		**EQ 65MG BASE**	**N050808**	**004**	Jul 23, 2009
AB	**+**		**EQ 80MG BASE**	**N050808**	**007**	Aug 27, 2010
AB	**+**		**EQ 105MG BASE**	**N050808**	**006**	Aug 27, 2010
AB	**+!**		**EQ 115MG BASE**	**N050808**	**005**	Jul 23, 2009
	MINOLIRA					
		EPI HLTH	EQ 105MG BASE	N209269	001	May 08, 2017
	!		EQ 135MG BASE	N209269	002	May 08, 2017

MINOXIDIL

TABLET;ORAL

MINOXIDIL

AB		PAR PHARM	**2.5MG**	**A071826**	**001**	Nov 14, 1988
AB			**10MG**	**A071839**	**001**	Nov 14, 1988
AB		SUN PHARM INDUSTRIES	**2.5MG**	**A072709**	**002**	Dec 14, 1995
AB			**10MG**	**A072709**	**001**	Dec 14, 1995
AB		WATSON LABS	**2.5MG**	**A071344**	**001**	Mar 03, 1987
AB	**!**		**10MG**	**A071345**	**001**	Mar 03, 1987

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MYRBETRIQ GRANULES

+!	APGDI	8MG/ML	N213801	001	Mar 25, 2021

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

AB		LUPIN LTD	**25MG**	**A209485**	**001**	Sep 28, 2022
AB			**50MG**	**A209485**	**002**	Sep 28, 2022
	MYRBETRIQ					
AB	**+!**	APGDI	**25MG**	**N202611**	**001**	Jun 28, 2012
AB	**+!**		**50MG**	**N202611**	**002**	Jun 28, 2012

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

AB		APOTEX INC	**15MG**	**A077666**	**001**	Aug 22, 2007
AB			**30MG**	**A077666**	**002**	Aug 22, 2007
AB			**45MG**	**A077666**	**003**	Aug 22, 2007
AB		AUROBINDO	**7.5MG**	**A076921**	**001**	Oct 22, 2004
AB			**15MG**	**A076921**	**002**	Oct 22, 2004
AB			**30MG**	**A076921**	**003**	Oct 22, 2004
AB			**45MG**	**A076921**	**004**	Oct 22, 2004
AB		MYLAN	**15MG**	**A076122**	**001**	Jun 19, 2003
AB			**30MG**	**A076122**	**002**	Jun 19, 2003
AB			**45MG**	**A076122**	**003**	Jun 19, 2003
AB		PRASCO	**7.5MG**	**A216751**	**001**	Jan 18, 2023
AB			**15MG**	**A216751**	**002**	Jan 18, 2023
AB			**30MG**	**A216751**	**003**	Jan 18, 2023
AB			**45MG**	**A216751**	**004**	Jan 18, 2023
AB	**!**	SUN PHARM INDS INC	**7.5MG**	**A076541**	**004**	Apr 22, 2004
AB			**15MG**	**A076541**	**001**	Apr 22, 2004
AB			**30MG**	**A076541**	**002**	Apr 22, 2004
AB			**45MG**	**A076541**	**003**	Apr 22, 2004
AB		TEVA	**15MG**	**A076119**	**001**	Jan 24, 2003
AB			**30MG**	**A076119**	**002**	Jan 24, 2003
AB			**45MG**	**A076119**	**003**	Jun 19, 2003
AB		UPSHER SMITH LABS	**15MG**	**A076219**	**001**	Jun 19, 2003
AB			**30MG**	**A076219**	**002**	Jun 19, 2003
AB			**45MG**	**A076219**	**003**	Jun 19, 2003

REMERON

AB	**+!**	ORGANON	**15MG**	**N020415**	**001**	Jun 14, 1996
AB	**+**		**30MG**	**N020415**	**002**	Jun 14, 1996

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

AB		AUROBINDO PHARMA	**15MG**	**A077376**	**002**	Dec 08, 2005
AB			**30MG**	**A077376**	**003**	Dec 08, 2005
AB			**45MG**	**A077376**	**004**	Feb 28, 2006
AB		SQUARE PHARMS	**15MG**	**A205798**	**001**	Jun 01, 2017
AB			**30MG**	**A205798**	**002**	Jun 01, 2017
AB			**45MG**	**A205798**	**003**	Jun 01, 2017

REMERON SOLTAB

AB	**+!**	ORGANON USA ORGANON	**15MG**	**N021208**	**001**	Jan 12, 2001
AB	**+**		**30MG**	**N021208**	**002**	Jan 12, 2001
AB	**+**		**45MG**	**N021208**	**003**	Jan 12, 2001

MISOPROSTOL

TABLET;ORAL

CYTOTEC

AB	**+**	PFIZER	**0.1MG**	**N019268**	**003**	Sep 21, 1990
AB	**+!**		**0.2MG**	**N019268**	**001**	Dec 27, 1988

MISOPROSTOL

AB		ANI PHARMS	**0.1MG**	**A076095**	**001**	Jul 10, 2002
AB			**0.2MG**	**A076095**	**002**	Jul 10, 2002
AB		MICRO LABS	**0.1MG**	**A216872**	**001**	Oct 17, 2022
AB			**0.2MG**	**A216872**	**002**	Oct 17, 2022

MITAPIVAT SULFATE

TABLET;ORAL

PYRUKYND

	+	AGIOS PHARMS INC	EQ 5MG BASE	N216196	001	Feb 17, 2022
	+		EQ 20MG BASE	N216196	002	Feb 17, 2022
	+!		EQ 50MG BASE	N216196	003	Feb 17, 2022

MITOMYCIN

FOR SOLUTION;TOPICAL

MITOSOL

	+!	MOBIUS THERAP	0.2MG/VIAL	N022572	001	Feb 07, 2012

INJECTABLE;INJECTION

MITOMYCIN

AP	**!**	ACCORD HLTHCARE	**5MG/VIAL**	**A064144**	**001**	Apr 30, 1998
AP	**!**		**20MG/VIAL**	**A064144**	**002**	Apr 30, 1998
AP	**!**		**40MG/VIAL**	**A064144**	**003**	Aug 11, 2009
AP		EUGIA PHARMA	**5MG/VIAL**	**A216732**	**001**	Oct 30, 2023
AP			**20MG/VIAL**	**A216732**	**002**	Oct 30, 2023
AP			**40MG/VIAL**	**A216732**	**003**	Oct 30, 2023
AP		GLAND PHARMA LTD	**5MG/VIAL**	**A215687**	**001**	Oct 20, 2021

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

AP			**20MG/VIAL**	**A215687**	**002**	Oct 20, 2021
AP			**40MG/VIAL**	**A216648**	**001**	Nov 22, 2022
AP		HIKMA	**5MG/VIAL**	**A064180**	**001**	Dec 23, 1999
AP			**20MG/VIAL**	**A064117**	**002**	Apr 19, 1995
AP			**20MG/VIAL**	**A064180**	**002**	Dec 23, 1999
AP			**40MG/VIAL**	**A064117**	**003**	Jun 02, 1999
AP		MEITHEAL	**5MG/VIAL**	**A214505**	**001**	Sep 08, 2022
AP			**20MG/VIAL**	**A214505**	**002**	Sep 08, 2022
AP			**40MG/VIAL**	**A214504**	**001**	Sep 06, 2022
AP		RK PHARMA	**5MG/VIAL**	**A202670**	**001**	Oct 13, 2017
AP			**20MG/VIAL**	**A202670**	**002**	Oct 13, 2017
AP			**40MG/VIAL**	**A203386**	**001**	Oct 13, 2017

POWDER;PYELOCALYCEAL

JELMYTO

+!	UROGEN PHARMA	40MG/VIAL	N211728	001	Apr 15, 2020

MITOTANE

TABLET;ORAL

LYSODREN

+!	HRA PHARMA	500MG	N016885	001	

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION

MITOXANTRONE HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A077496**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A077496**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A077496**	**003**	Apr 11, 2006
AP		HIKMA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A076611**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A076611**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A076611**	**003**	Apr 11, 2006
AP	**!**	HOSPIRA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A076871**	**001**	Apr 11, 2006
AP	**!**		**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A076871**	**002**	Apr 11, 2006
AP	**!**		**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A076871**	**003**	Apr 11, 2006
AP		MEITHEAL	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A077356**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A077356**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A077356**	**003**	Apr 11, 2006

MIVACURIUM CHLORIDE

SOLUTION;INTRAVENOUS

MIVACURIUM CHLORIDE

	WOODWARD	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	A209708	001	Oct 12, 2021
		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A209708	002	Oct 12, 2021

MOBOCERTINIB SUCCINATE

CAPSULE;ORAL

EXKIVITY

+!	TAKEDA PHARMS USA	EQ 40MG BASE	N215310	001	Sep 15, 2021

MODAFINIL

TABLET;ORAL

MODAFINIL

AB		ALEMBIC	**100MG**	**A202700**	**001**	Oct 18, 2012
AB			**200MG**	**A202700**	**002**	Oct 18, 2012
AB		APOTEX	**100MG**	**A077667**	**001**	Feb 03, 2014
AB			**200MG**	**A077667**	**002**	Feb 03, 2014
AB		APPCO	**100MG**	**A207196**	**001**	Aug 16, 2017
AB			**200MG**	**A207196**	**002**	Aug 16, 2017
AB		AUROBINDO PHARMA LTD	**100MG**	**A202566**	**001**	Sep 27, 2012
AB			**200MG**	**A202566**	**002**	Sep 27, 2012
AB		CADILA	**100MG**	**A209966**	**001**	Sep 14, 2017
AB			**200MG**	**A209966**	**002**	Sep 14, 2017
AB		ORBION PHARMS	**100MG**	**A078963**	**001**	Sep 26, 2012
AB			**200MG**	**A078963**	**002**	Sep 26, 2012
AB		WATSON LABS INC	**100MG**	**A076715**	**001**	Nov 01, 2012
AB			**200MG**	**A076715**	**002**	Nov 01, 2012

PROVIGIL

AB	**+**	CEPHALON	**100MG**	**N020717**	**001**	Dec 24, 1998
AB	**+!**		**200MG**	**N020717**	**002**	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE

AB		APOTEX INC	**7.5MG**	**A078454**	**001**	Jun 02, 2008
AB			**15MG**	**A078454**	**002**	Jun 02, 2008
AB		CHARTWELL RX	**7.5MG**	**A077536**	**001**	Nov 30, 2006
AB			**15MG**	**A077536**	**002**	Nov 30, 2006
AB		GLENMARK GENERICS	**7.5MG**	**A090416**	**001**	Mar 30, 2010
AB			**15MG**	**A090416**	**002**	Mar 30, 2010
AB		TEVA	**7.5MG**	**A076204**	**001**	May 08, 2003
AB	!		**15MG**	**A076204**	**002**	May 08, 2003

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

	EPIC PHARMA LLC	5MG	A090453	001	Mar 20, 2015
		10MG	A090453	002	Mar 20, 2015
!		25MG	A090453	003	Mar 20, 2015

MOMELOTINIB DIHYDROCHLORIDE

TABLET;ORAL

OJJAARA

+	GLAXOSMITHKLINE	EQ 100MG BASE	N216873	001	Sep 15, 2023
+		EQ 150MG BASE	N216873	002	Sep 15, 2023
+!		EQ 200MG BASE	N216873	003	Sep 15, 2023

MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

ASMANEX HFA

+	ORGANON LLC	0.05MG/INH	N205641	003	Aug 12, 2019
+		0.10MG/INH	N205641	001	Apr 25, 2014
+!		0.20MG/INH	N205641	002	Apr 25, 2014

CREAM;TOPICAL

MOMETASONE FUROATE

AB		COSETTE	**0.1%**	**A077447**	**001**	May 22, 2006
AB	!	GLENMARK GENERICS	**0.1%**	**A078541**	**001**	May 28, 2008
AB		TARO	**0.1%**	**A076679**	**001**	Dec 21, 2004

IMPLANT;IMPLANTATION

SINUVA

+	INTERSECT ENT INC	1.35MG	N209310	001	Dec 08, 2017

LOTION;TOPICAL

MOMETASONE FUROATE

AB		COSETTE	**0.1%**	**A077678**	**001**	Nov 21, 2007
AB		FOUGERA PHARMS	**0.1%**	**A075919**	**001**	Nov 29, 2007
AB		GLENMARK GENERICS	**0.1%**	**A090506**	**001**	Aug 09, 2010
AB	!	PADAGIS ISRAEL	**0.1%**	**A077180**	**001**	Apr 06, 2005
AB		TARO	**0.1%**	**A076788**	**001**	Mar 15, 2006

OINTMENT;TOPICAL

MOMETASONE FUROATE

AB		COSETTE	**0.1%**	**A077401**	**001**	Jun 20, 2006
AB		FOUGERA PHARMS	**0.1%**	**A077061**	**001**	Mar 28, 2005
AB	!	GLENMARK GENERICS	**0.1%**	**A078571**	**001**	May 28, 2008
AB		PADAGIS US	**0.1%**	**A076067**	**001**	Mar 18, 2002

POWDER;INHALATION

ASMANEX TWISTHALER

+	ORGANON LLC	0.11MG/INH	N021067	002	Feb 01, 2008
+!		0.22MG/INH	N021067	001	Mar 30, 2005

SPRAY, METERED;NASAL

MOMETASONE FUROATE

AB		AMNEAL PHARMS	**0.05MG/SPRAY**	**A207989**	**001**	Apr 03, 2017
AB	!	APOTEX	**0.05MG/SPRAY**	**A091161**	**001**	Mar 22, 2016

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL

RYALTRIS

+!	GLENMARK SPECIALTY	0.025MG/SPRAY;0.665MG/SPRAY	N211746	001	Jan 13, 2022

MONOMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

BAFIERTAM

+!	BANNER LIFE SCIENCES	95MG	N210296	001	Apr 28, 2020

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	**EQ 4MG BASE/PACKET**	**A203438**	**001**	Jul 31, 2015
AB		AUROBINDO PHARMA LTD	**EQ 4MG BASE/PACKET**	**A213471**	**001**	Feb 18, 2020
AB		DR REDDYS LABS LTD	**EQ 4MG BASE/PACKET**	**A202906**	**001**	Sep 17, 2012
AB		TEVA PHARMS	**EQ 4MG BASE/PACKET**	**A090955**	**001**	Aug 03, 2012
AB		TORRENT	**EQ 4MG BASE/PACKET**	**A210431**	**001**	Jul 31, 2018

SINGULAIR

AB	**+!**	ORGANON	**EQ 4MG BASE/PACKET**	**N021409**	**001**	Jul 26, 2002

TABLET;ORAL

MONTELUKAST SODIUM

AB		ACCORD HLTHCARE	**EQ 10MG BASE**	**A202717**	**001**	Sep 21, 2012
AB		AMNEAL PHARMS	**EQ 10MG BASE**	**A204604**	**001**	Sep 04, 2015
AB		ANBISON LAB	**EQ 10MG BASE**	**A205683**	**001**	Jan 12, 2016
AB		AUROBINDO PHARMA LTD	**EQ 10MG BASE**	**A202468**	**001**	Aug 03, 2012
AB		CHARTWELL MOLECULAR	**EQ 10MG BASE**	**A201522**	**001**	Aug 03, 2012
AB		CIPLA	**EQ 10MG BASE**	**A207463**	**001**	Oct 28, 2016
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A201582**	**001**	Aug 06, 2012
AB		GLENMARK GENERICS	**EQ 10MG BASE**	**A090926**	**001**	Aug 03, 2012
AB		GRAVITI PHARMS	**EQ 10MG BASE**	**A209012**	**001**	Apr 24, 2017
AB		HETERO LABS LTD V	**EQ 10MG BASE**	**A202843**	**001**	Sep 10, 2014
AB		MACLEODS PHARMS LTD	**EQ 10MG BASE**	**A203366**	**001**	Sep 11, 2014
AB		SANDOZ INC	**EQ 10MG BASE**	**A200889**	**001**	Aug 03, 2012
AB		TEVA PHARMS	**EQ 10MG BASE**	**A078605**	**001**	Aug 03, 2012
AB		TORRENT PHARMS LTD	**EQ 10MG BASE**	**A201515**	**001**	Aug 03, 2012
AB		UNICHEM	**EQ 10MG BASE**	**A204290**	**001**	Oct 08, 2015
AB		UNIMARK REMEDIES LTD	**EQ 10MG BASE**	**A202859**	**001**	Oct 30, 2014

SINGULAIR

AB	**+!**	ORGANON	**EQ 10MG BASE**	**N020829**	**002**	Feb 20, 1998

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AB		AMNEAL PHARMS	**EQ 4MG BASE**	**A205107**	**001**	Sep 04, 2020
AB			**EQ 5MG BASE**	**A205107**	**002**	Sep 04, 2020
AB		ANBISON LAB	**EQ 4MG BASE**	**A205695**	**001**	Nov 05, 2015
AB			**EQ 5MG BASE**	**A205695**	**002**	Nov 05, 2015
AB		AUROBINDO PHARMA LTD	**EQ 4MG BASE**	**A202096**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A202096**	**002**	Aug 03, 2012
AB		CHARTWELL MOLECULAR	**EQ 4MG BASE**	**A207464**	**001**	Dec 06, 2018
AB			**EQ 5MG BASE**	**A207464**	**002**	Dec 06, 2018
AB		DR REDDYS LABS LTD	**EQ 4MG BASE**	**A201581**	**001**	Aug 06, 2012
AB			**EQ 5MG BASE**	**A201581**	**002**	Aug 06, 2012
AB		HETERO LABS LTD V	**EQ 4MG BASE**	**A204093**	**001**	May 22, 2015
AB			**EQ 5MG BASE**	**A204093**	**002**	May 22, 2015
AB		LANNETT CO INC	**EQ 4MG BASE**	**A200405**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A200405**	**002**	Aug 03, 2012
AB		MACLEODS PHARMS LTD	**EQ 4MG BASE**	**A203582**	**001**	Mar 12, 2015
AB			**EQ 5MG BASE**	**A203582**	**002**	Mar 12, 2015
AB		RISING	**EQ 4MG BASE**	**A209011**	**001**	Apr 18, 2017
AB			**EQ 5MG BASE**	**A209011**	**002**	Apr 18, 2017
AB		SANDOZ INC	**EQ 4MG BASE**	**A091414**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A091414**	**002**	Aug 03, 2012
AB		TEVA PHARMS	**EQ 4MG BASE**	**A078723**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A078723**	**002**	Aug 03, 2012
AB		TORRENT PHARMS LTD	**EQ 4MG BASE**	**A090984**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A090984**	**002**	Aug 03, 2012
AB		UNIMARK REMEDIES LTD	**EQ 4MG BASE**	**A203037**	**001**	Oct 30, 2014
AB			**EQ 5MG BASE**	**A203037**	**002**	Oct 30, 2014

SINGULAIR

AB	**+**	ORGANON	**EQ 4MG BASE**	**N020830**	**002**	Mar 03, 2000
AB	**+!**		**EQ 5MG BASE**	**N020830**	**001**	Feb 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

	ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013
		45MG	A079040	002	Jan 16, 2013
		60MG	A079040	003	Jan 16, 2013
		75MG	A079040	004	Jan 16, 2013

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

			90MG	A079040	005	Jan 16, 2013
	!		120MG	A079040	006	Jan 16, 2013
	!	UPSHER SMITH LABS	10MG	A202104	001	Jun 03, 2013
			20MG	A202104	002	Jun 03, 2013
			30MG	A202104	003	Jun 03, 2013
			50MG	A202104	004	Jun 03, 2013
			60MG	A202104	005	Jun 03, 2013
			80MG	A202104	006	Jun 03, 2013
	!		100MG	A202104	007	Jun 03, 2013

INJECTABLE;INJECTION

DURAMORPH PF

AP	**+!**	HIKMA	**0.5MG/ML**	**N018565**	**001**	Sep 18, 1984
AP	**+!**		**1MG/ML**	**N018565**	**002**	Sep 18, 1984

INFUMORPH

AP	**+!**	HIKMA	**10MG/ML**	**N018565**	**003**	Jul 19, 1991
AP	**+!**		**25MG/ML**	**N018565**	**004**	Jul 19, 1991

MITIGO

AP		PIRAMAL CRITICAL	**10MG/ML**	**A204393**	**001**	Jul 16, 2018
AP			**25MG/ML**	**A204393**	**002**	Jul 16, 2018

MORPHINE SULFATE

AP		HIKMA	**2MG/ML**	**A211452**	**001**	Jan 12, 2023
AP	**!**		**4MG/ML**	**A205758**	**001**	May 21, 2015
AP			**4MG/ML**	**A211452**	**002**	Jan 12, 2023
AP	**!**		**8MG/ML**	**A205758**	**002**	May 21, 2015
AP			**8MG/ML**	**A211452**	**003**	Jan 12, 2023
AP			**10MG/ML**	**A205758**	**003**	May 21, 2015
AP			**10MG/ML**	**A211452**	**004**	Jan 12, 2023
AP		HOSPIRA	**0.5MG/ML**	**A071849**	**001**	May 11, 1988
AP			**0.5MG/ML**	**A073509**	**001**	Sep 30, 1992
AP			**1MG/ML**	**A073510**	**001**	Sep 30, 1992
AP	**+!**	HOSPIRA INC	**2MG/ML**	**N202515**	**001**	Nov 14, 2011
AP	**+**		**4MG/ML**	**N202515**	**002**	Nov 14, 2011
AP	**+**		**8MG/ML**	**N202515**	**003**	Nov 14, 2011
AP	**+**		**10MG/ML**	**N202515**	**004**	Nov 14, 2011
		HIKMA	15MG/ML	A211452	005	Jan 12, 2023
	+!	HOSPIRA INC	50MG/ML	N202515	006	Apr 29, 2021
		INTL MEDICATION SYS	1MG/ML	A202861	001	Apr 29, 2021

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MORPHINE SULFATE

	+!	FRESENIUS KABI USA	2MG/ML (2MG/ML)	N204223	001	Oct 30, 2013
	+!		4MG/ML (4MG/ML)	N204223	002	Oct 30, 2013
	+!		5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013
	+!		8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013
	+!		10MG/ML (10MG/ML)	N204223	005	Oct 30, 2013

SOLUTION;ORAL

MORPHINE SULFATE

AA	**+**	HIKMA	**10MG/5ML**	**N022195**	**001**	Mar 17, 2008
AA	**+**		**20MG/5ML**	**N022195**	**002**	Mar 17, 2008
AA			**100MG/5ML**	**A208809**	**001**	Jul 06, 2017
AA	**+!**		**100MG/5ML**	**N022195**	**003**	Jan 25, 2010
AA		PADAGIS US	**100MG/5ML**	**A201574**	**001**	Aug 06, 2012
AA		PHARM ASSOC	**10MG/5ML**	**A206573**	**002**	Sep 12, 2023
AA			**100MG/5ML**	**A206573**	**001**	Nov 14, 2016
AA		RHODES PHARMS	**10MG/5ML**	**A206308**	**001**	Jun 22, 2017
AA			**20MG/5ML**	**A206420**	**001**	Jul 12, 2016
AA			**100MG/5ML**	**A206308**	**002**	Jun 22, 2017
AA		SPECGX LLC	**100MG/5ML**	**A202348**	**001**	Jul 15, 2011
AA		TRIS PHARMA INC	**10MG/5ML**	**A203518**	**001**	May 12, 2015
AA			**100MG/5ML**	**A203518**	**002**	May 12, 2015

TABLET;ORAL

MORPHINE SULFATE

AB		ALKEM LABS LTD	**15MG**	**A212451**	**001**	Dec 03, 2020
AB			**30MG**	**A212451**	**002**	Dec 03, 2020
AB	**+**	HIKMA	**15MG**	**N022207**	**001**	Mar 17, 2008
AB	**+!**		**30MG**	**N022207**	**002**	Mar 17, 2008
AB		SPECGX LLC	**15MG**	**A215194**	**001**	Aug 21, 2023
AB			**30MG**	**A215194**	**002**	Aug 21, 2023
AB		UPSHER SMITH LABS	**15MG**	**A210610**	**001**	Jul 22, 2019
AB			**30MG**	**A210610**	**002**	Jul 22, 2019

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

AB		ACTAVIS ELIZABETH	**15MG**	**A203849**	**001**	Apr 06, 2015
AB			**30MG**	**A203849**	**002**	Apr 06, 2015
AB			**60MG**	**A203849**	**003**	Apr 06, 2015
AB			**100MG**	**A203849**	**004**	Apr 06, 2015
AB			**200MG**	**A203849**	**005**	Apr 06, 2015
AB		DAVA PHARMS INC	**15MG**	**A075407**	**001**	Jan 28, 2000
AB		NOVEL LABS INC	**15MG**	**A203602**	**001**	Dec 16, 2015
AB			**30MG**	**A203602**	**002**	Dec 16, 2015
AB			**60MG**	**A203602**	**003**	Dec 16, 2015
AB			**100MG**	**A203602**	**004**	Dec 16, 2015
AB			**200MG**	**A203602**	**005**	Dec 16, 2015
AB		RHODES PHARMS	**15MG**	**A074862**	**001**	Jul 07, 1998
AB			**30MG**	**A074862**	**002**	Jul 07, 1998
AB			**60MG**	**A074862**	**003**	Jul 07, 1998
AB			**100MG**	**A074769**	**001**	Jul 02, 1998
AB			**200MG**	**A074769**	**002**	Jul 02, 1998
AB		SPECGX LLC	**15MG**	**A076412**	**001**	Jul 31, 2003
AB			**30MG**	**A076412**	**002**	Jul 31, 2003
AB			**60MG**	**A076412**	**003**	Jul 31, 2003
AB			**100MG**	**A076438**	**001**	Jul 03, 2003
AB			**200MG**	**A076438**	**002**	Jul 03, 2003
AB		STRIDES PHARMA	**15MG**	**A075295**	**001**	Oct 28, 1998
AB			**30MG**	**A075295**	**002**	Oct 28, 1998
AB			**60MG**	**A075295**	**003**	Oct 28, 1998
AB			**100MG**	**A075295**	**004**	Sep 15, 2000
AB			**200MG**	**A075295**	**005**	Sep 15, 2000
AB		SUN PHARM INDS LTD	**15MG**	**A078761**	**001**	May 11, 2012
AB			**30MG**	**A078761**	**002**	May 11, 2012
AB			**60MG**	**A078761**	**003**	May 11, 2012
AB			**100MG**	**A078761**	**004**	May 11, 2012
AB			**200MG**	**A078761**	**005**	May 11, 2012

MS CONTIN

AB	+	PURDUE PHARMA LP	**15MG**	**N019516**	**003**	Sep 12, 1989
AB	+		**30MG**	**N019516**	**001**	May 29, 1987
AB	+		**60MG**	**N019516**	**002**	Apr 08, 1988
AB	+!		**100MG**	**N019516**	**004**	Jan 16, 1990
AB	+		**200MG**	**N019516**	**005**	Nov 08, 1993

MOTIXAFORTIDE ACETATE

POWDER;SUBCUTANEOUS

APHEXDA

	+!	BIOLINERX LTD	EQ 62MG BASE/VIAL	N217159	001	Sep 08, 2023

MOXIDECTIN

TABLET;ORAL

MOXIDECTIN

	+!	MDGH	2MG	N210867	001	Jun 13, 2018

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;INTRAVENOUS

MOXIFLOXACIN HYDROCHLORIDE

	+!	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015

MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

	!	MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1		ALEMBIC	**EQ 0.5% BASE**	**A209469**	**001**	Feb 13, 2019
AT1		APOTEX	**EQ 0.5% BASE**	**A090080**	**001**	Jun 30, 2017
AT1		EUGIA PHARMA	**EQ 0.5% BASE**	**A206242**	**001**	Oct 04, 2017
AT1		GLAND PHARMA LTD	**EQ 0.5% BASE**	**A208778**	**001**	Mar 30, 2020
AT1		INDOCO	**EQ 0.5% BASE**	**A202525**	**001**	Mar 06, 2015
AT1		LUPIN LTD	**EQ 0.5% BASE**	**A202867**	**001**	Sep 04, 2014
AT1		MYLAN	**EQ 0.5% BASE**	**A206447**	**001**	Mar 30, 2020
AT1		UPSHER SMITH LABS	**EQ 0.5% BASE**	**A212616**	**001**	Feb 10, 2021

VIGAMOX

AT1	+!	NOVARTIS	**EQ 0.5% BASE**	**N021598**	**001**	Apr 15, 2003

MOXIFLOXACIN HYDROCHLORIDE

	!	LUPIN LTD	EQ 0.5% BASE	A204079	001	May 28, 2015

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**EQ 400MG BASE**	**A202632**	**001**	Mar 04, 2014
AB		CHARTWELL RX	**EQ 400MG BASE**	**A207285**	**001**	Feb 13, 2017
AB		CROSSMEDIKA SA	**EQ 400MG BASE**	**A205348**	**001**	Jan 14, 2016
AB	!	DR REDDYS	**EQ 400MG BASE**	**A076938**	**001**	Mar 04, 2014
AB		HETERO LABS LTD V	**EQ 400MG BASE**	**A204836**	**001**	Mar 02, 2023
AB		MSN	**EQ 400MG BASE**	**A208682**	**001**	Sep 22, 2017
AB		TEVA PHARMS USA	**EQ 400MG BASE**	**A077437**	**001**	Feb 18, 2014

MUPIROCIN

OINTMENT;TOPICAL

MUPIROCIN

AB		FOUGERA PHARMS	**2%**	**A065192**	**001**	Nov 30, 2005
AB		GLENMARK PHARMS	**2%**	**A090480**	**001**	Jun 08, 2011
AB	!	PADAGIS ISRAEL	**2%**	**A065123**	**001**	Nov 07, 2003
AB		TARO	**2%**	**A065170**	**001**	Sep 23, 2005
AB		TEVA	**2%**	**A065085**	**001**	Nov 07, 2003

CENTANY

BX		PADAGIS US	2%	N050788	001	Dec 04, 2002

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

AB		ALEMBIC	**EQ 2% BASE**	**A213053**	**001**	Nov 16, 2021
AB		AMNEAL	**EQ 2% BASE**	**A214811**	**001**	Nov 15, 2022
AB		ENCUBE	**EQ 2% BASE**	**A213076**	**001**	Aug 31, 2021
AB	!	GLENMARK PHARMS INC	**EQ 2% BASE**	**A201587**	**001**	Jan 24, 2013
AB		TARO	**EQ 2% BASE**	**A207116**	**001**	Apr 27, 2020

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

CELLCEPT

AB	**+!**	ROCHE PALO	**250MG**	**N050722**	**001**	May 03, 1995

MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	**250MG**	**A090253**	**001**	May 04, 2009
AB		ALKEM LABS LTD	**250MG**	**A200197**	**001**	Jun 13, 2013
AB		AUROBINDO PHARMA LTD	**250MG**	**A217828**	**001**	Jan 05, 2024
AB		CONCORD BIOTECH LTD	**250MG**	**A210181**	**001**	Jan 08, 2019
AB		HIKMA	**250MG**	**A065410**	**001**	Jul 29, 2008
AB		MYLAN	**250MG**	**A065520**	**001**	May 04, 2009
AB		SANDOZ	**250MG**	**A065379**	**001**	Oct 15, 2008
AB		STRIDES PHARMA	**250MG**	**A090055**	**001**	Jun 10, 2010
AB		TEVA PHARMS	**250MG**	**A065491**	**001**	May 06, 2009
AB		ZHEJIANG HISUN PHARM	**250MG**	**A204077**	**001**	Nov 13, 2017

FOR SUSPENSION;ORAL

CELLCEPT

AB	**+!**	ROCHE PALO	**200MG/ML**	**N050759**	**001**	Oct 01, 1998

MYCOPHENOLATE MOFETIL

AB		ALKEM LABS LTD	**200MG/ML**	**A203005**	**001**	Nov 14, 2014
AB		AMNEAL	**200MG/ML**	**A214871**	**001**	Nov 02, 2021
AB		HETERO LABS LTD V	**200MG/ML**	**A213955**	**001**	Sep 11, 2023
AB		LANNETT CO INC	**200MG/ML**	**A214525**	**001**	Jul 29, 2021
AB		STRIDES PHARMA	**200MG/ML**	**A212634**	**001**	Aug 29, 2023
AB		TEVA PHARMS USA	**200MG/ML**	**A211272**	**001**	Jan 25, 2022
AB		VISTAPHARM	**200MG/ML**	**A210370**	**001**	Feb 12, 2019

TABLET;ORAL

CELLCEPT

AB	**+!**	ROCHE PALO	**500MG**	**N050723**	**001**	Jun 19, 1997

MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	**500MG**	**A065416**	**001**	May 04, 2009
AB		ALKEM LABS LTD	**500MG**	**A091249**	**001**	Nov 04, 2011
AB		AMNEAL	**500MG**	**A090606**	**001**	Jul 16, 2010
AB		CONCORD BIOTECH LTD	**500MG**	**A212087**	**001**	Jul 31, 2020
AB		HIKMA	**500MG**	**A065413**	**001**	Jul 29, 2008
AB		MYLAN	**500MG**	**A065521**	**001**	May 04, 2009
AB		SANDOZ	**500MG**	**A065451**	**001**	Oct 15, 2008
AB		STRIDES PHARMA	**500MG**	**A090456**	**001**	Jun 10, 2010
AB		ZHEJIANG HISUN PHARM	**500MG**	**A204076**	**001**	Nov 16, 2017

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

CELLCEPT

AP	**+!**	ROCHE PALO	**500MG/VIAL**	**N050758**	**001**	Aug 12, 1998

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP		BPI LABS	**500MG/VIAL**	**A214283**	**001**	Jun 01, 2023
AP		MEITHEAL	**500MG/VIAL**	**A212130**	**001**	Jan 15, 2021
AP		MYLAN LABS LTD	**500MG/VIAL**	**A203859**	**001**	Mar 31, 2017
AP		PAR STERILE PRODUCTS	**500MG/VIAL**	**A203575**	**001**	Oct 28, 2016
AP		RISING	**500MG/VIAL**	**A204043**	**001**	Feb 28, 2017
AP		STERISCIENCE	**500MG/VIAL**	**A216390**	**001**	Dec 23, 2022
AP		ZYDUS PHARMS	**500MG/VIAL**	**A204473**	**001**	Aug 31, 2017

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC SODIUM

AB		ACCORD HLTHCARE	**EQ 180MG BASE**	**A202555**	**001**	Aug 23, 2017
AB			**EQ 360MG BASE**	**A202555**	**002**	Aug 23, 2017
AB		AIRIS PHARMA PVT LTD	**EQ 180MG BASE**	**A217031**	**001**	Nov 29, 2023
AB			**EQ 360MG BASE**	**A217031**	**002**	Nov 29, 2023
AB		ALKEM LABS LTD	**EQ 180MG BASE**	**A208315**	**001**	Sep 23, 2021
AB			**EQ 360MG BASE**	**A208315**	**002**	Sep 23, 2021
AB		AMTA	**EQ 180MG BASE**	**A214376**	**001**	Feb 10, 2021
AB			**EQ 360MG BASE**	**A214376**	**002**	Feb 10, 2021
AB		APOTEX INC	**EQ 180MG BASE**	**A091558**	**001**	Aug 21, 2012
AB			**EQ 360MG BASE**	**A091558**	**002**	Aug 19, 2014
AB		BIOCON PHARMA	**EQ 180MG BASE**	**A214630**	**001**	Nov 29, 2021
AB			**EQ 360MG BASE**	**A214630**	**002**	Nov 29, 2021
AB		CONCORD BIOTECH LTD	**EQ 180MG BASE**	**A211173**	**001**	Dec 13, 2019
AB			**EQ 360MG BASE**	**A211173**	**002**	Dec 13, 2019
AB		RK PHARMA	**EQ 180MG BASE**	**A091248**	**002**	Jan 08, 2014
AB			**EQ 360MG BASE**	**A091248**	**001**	Jan 08, 2014
AB		TWI PHARMS	**EQ 180MG BASE**	**A214289**	**001**	Nov 03, 2021
AB			**EQ 360MG BASE**	**A214289**	**002**	Nov 03, 2021

MYFORTIC

AB	**+**	NOVARTIS	**EQ 180MG BASE**	**N050791**	**001**	Feb 27, 2004
AB	**+!**		**EQ 360MG BASE**	**N050791**	**002**	Feb 27, 2004

NABILONE

CAPSULE;ORAL

CESAMET

	+!	BAUSCH	1MG	N018677	001	Dec 26, 1985

NABUMETONE

TABLET;ORAL

NABUMETONE

AB		ANNORA PHARMA	**500MG**	**A090445**	**001**	Jan 12, 2011
AB			**750MG**	**A090445**	**002**	Jan 12, 2011
AB		CHARTWELL MOLECULES	**500MG**	**A076009**	**001**	Jan 24, 2003
AB			**750MG**	**A076009**	**002**	Jan 24, 2003
AB		CHARTWELL RX	**500MG**	**A075280**	**001**	Feb 25, 2002
AB			**750MG**	**A075280**	**002**	Feb 25, 2002
AB		INVAGEN PHARMS	**500MG**	**A078671**	**001**	Mar 07, 2008
AB	**!**		**750MG**	**A078671**	**002**	Mar 07, 2008
AB		LGM PHARMA	**500MG**	**A203166**	**001**	Aug 30, 2019
AB			**750MG**	**A203166**	**002**	Aug 30, 2019
AB		SCIEGEN PHARMS INC	**500MG**	**A078420**	**001**	Sep 24, 2008
AB			**750MG**	**A078420**	**002**	Sep 24, 2008
AB		WATSON LABS	**500MG**	**A091083**	**001**	Jun 13, 2011
AB			**750MG**	**A091083**	**002**	Jun 13, 2011
		LGM PHARMA	1GM	A203166	003	Aug 30, 2019

NADOLOL

TABLET;ORAL

CORGARD

AB	**+**	USWM	**20MG**	**N018063**	**005**	Oct 28, 1986
AB	**+**		**40MG**	**N018063**	**001**	
AB	**+!**		**80MG**	**N018063**	**002**	

NADOLOL

AB		ALEMBIC	**20MG**	**A211763**	**001**	Jun 02, 2023
AB			**40MG**	**A211763**	**002**	Jun 02, 2023
AB			**80MG**	**A211763**	**003**	Jun 02, 2023
AB		AMNEAL PHARMS CO	**20MG**	**A208832**	**001**	Jun 02, 2017

NADOLOL

TABLET;ORAL

NADOLOL

AB			**40MG**	**A208832**	**002**	Jun 02, 2017
AB			**80MG**	**A208832**	**003**	Jun 02, 2017
AB		AUROBINDO PHARMA	**20MG**	**A201893**	**003**	Jun 07, 2022
AB			**40MG**	**A201893**	**001**	Sep 16, 2015
AB			**80MG**	**A201893**	**002**	Sep 16, 2015
AB		BEXIMCO PHARMS USA	**20MG**	**A210955**	**001**	Jul 23, 2018
AB			**40MG**	**A210955**	**002**	Jul 23, 2018
AB			**80MG**	**A210955**	**003**	Jul 23, 2018
AB		CHARTWELL RX	**20MG**	**A209309**	**001**	Oct 05, 2017
AB			**40MG**	**A209309**	**002**	Oct 05, 2017
AB			**80MG**	**A209309**	**003**	Oct 05, 2017
AB		INVAGEN PHARMS	**20MG**	**A203455**	**001**	Dec 18, 2015
AB			**40MG**	**A203455**	**002**	Dec 18, 2015
AB			**80MG**	**A203455**	**003**	Dec 18, 2015
AB		RISING	**20MG**	**A074172**	**001**	Oct 31, 1993
AB			**40MG**	**A074172**	**002**	Oct 31, 1993
AB			**80MG**	**A074172**	**003**	Oct 31, 1993
AB		RK PHARMA	**20MG**	**A212856**	**001**	Sep 13, 2019
AB			**40MG**	**A212856**	**002**	Sep 13, 2019
AB			**80MG**	**A212856**	**003**	Sep 13, 2019
AB		SANDOZ	**20MG**	**A074501**	**001**	Nov 09, 1995
AB			**40MG**	**A074501**	**002**	Nov 09, 1995
AB			**80MG**	**A074501**	**003**	Nov 09, 1995
AB		ZYDUS PHARMS	**20MG**	**A207761**	**001**	Jul 28, 2017
AB			**40MG**	**A207761**	**002**	Jul 28, 2017
AB			**80MG**	**A207761**	**003**	Jul 28, 2017

NAFARELIN ACETATE

SPRAY, METERED;NASAL

SYNAREL

	+!	PFIZER	EQ 0.2MG BASE/SPRAY	N019886	001	Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

AP		ANTIBIOTICE	**EQ 1GM BASE/VIAL**	**A090560**	**001**	Oct 03, 2011
AP			**EQ 2GM BASE/VIAL**	**A090560**	**002**	Oct 03, 2011
AP	**!**	EUGIA PHARMA SPECLTS	**EQ 1GM BASE/VIAL**	**A091613**	**001**	Dec 26, 2012
AP	**!**		**EQ 2GM BASE/VIAL**	**A091613**	**002**	Dec 26, 2012
AP	**!**		**EQ 10GM BASE/VIAL**	**A091614**	**001**	Dec 26, 2012
AP		FRESENIUS	**EQ 10GM BASE/VIAL**	**A206761**	**001**	Jun 02, 2020
AP		ISTITUTO BIO ITA SPA	**EQ 1GM BASE/VIAL**	**A090002**	**001**	Jun 30, 2011
AP			**EQ 2GM BASE/VIAL**	**A090002**	**002**	Jun 30, 2011
AP			**EQ 10GM BASE/VIAL**	**A090005**	**001**	Apr 20, 2011
AP		SAGENT PHARMS	**EQ 1GM BASE/VIAL**	**A090582**	**001**	Aug 24, 2012
AP			**EQ 2GM BASE/VIAL**	**A090582**	**002**	Aug 24, 2012
AP			**EQ 10GM BASE/VIAL**	**A090580**	**001**	Aug 24, 2012
AP		STERISCIENCE	**EQ 1GM BASE/VIAL**	**A200002**	**001**	Apr 07, 2014
AP			**EQ 2GM BASE/VIAL**	**A200002**	**002**	Apr 07, 2014

NALLPEN IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989
	+!		EQ 2GM BASE/100ML	N050655	002	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB		AMNEAL	**2%**	**A206960**	**001**	Apr 10, 2017
AB		TARO	**2%**	**A206901**	**001**	Jan 06, 2016
AB		XIROMED	**2%**	**A210038**	**001**	Sep 22, 2020

NAFTIN

AB	**+!**	SEBELA IRELAND LTD	**2%**	**N019599**	**002**	Jan 13, 2012

NAFTIFINE HYDROCHLORIDE

	!	TARO	1%	A205975	001	Sep 08, 2016

GEL;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB		AMNEAL	**1%**	**A206165**	**001**	Mar 20, 2019
AB		TARO	**2%**	**A208201**	**001**	Apr 10, 2019

NAFTIN

AB	**+!**	SEBELA IRELAND LTD	**1%**	**N019356**	**001**	Jun 18, 1990

NAFTIFINE HYDROCHLORIDE
GEL;TOPICAL
NAFTIN

AB	**+!**		**2%**	**N204286**	**001**	Jun 27, 2013

NALBUPHINE HYDROCHLORIDE
INJECTABLE;INJECTION
NALBUPHINE HYDROCHLORIDE

AP	**!**	HOSPIRA	**10MG/ML**	**A070914**	**001**	Feb 03, 1989
AP	**!**		**10MG/ML**	**A070915**	**001**	Feb 03, 1989
AP	**!**		**20MG/ML**	**A070916**	**001**	Feb 03, 1989
AP	**!**		**20MG/ML**	**A070918**	**001**	Feb 03, 1989

NALDEMEDINE TOSYLATE
TABLET;ORAL
SYMPROIC

+!	BDSI	EQ 0.2MG BASE	N208854	001	Mar 23, 2017

NALMEFENE HYDROCHLORIDE
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
NALMEFENE HYDROCHLORIDE

AP		CHENGDU SHUODE	**EQ 2MG BASE/2ML (EQ 1MG BASE/ML)**	**A216007**	**002**	Nov 15, 2023
AP	**!**	PURDUE PHARMA LP	**EQ 2MG BASE/2ML (EQ 1MG BASE/ML)**	**A212955**	**001**	Feb 08, 2022
		CHENGDU SHUODE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023

SPRAY;NASAL
OPVEE

+!	INDIVIOR	EQ 2.7MG BASE/SPRAY	N217470	001	May 22, 2023

NALOXEGOL OXALATE
TABLET;ORAL
MOVANTIK

+	VALINOR	EQ 12.5MG BASE	N204760	001	Sep 16, 2014
+!		EQ 25MG BASE	N204760	002	Sep 16, 2014

NALOXONE HYDROCHLORIDE
INJECTABLE;INJECTION
NALOXONE

AP		HIKMA	**0.4MG/ML**	**A070299**	**001**	Sep 24, 1986

NALOXONE HYDROCHLORIDE

AP		ACCORD HLTHCARE	**0.4MG/ML**	**A216624**	**001**	Oct 26, 2022
AP			**1MG/ML**	**A216624**	**002**	Oct 26, 2022
AP		BAXTER HLTHCARE CORP	**0.4MG/ML**	**A214785**	**001**	Jan 29, 2021
AP			**0.4MG/ML**	**A214792**	**001**	Nov 07, 2022
AP		BPI LABS	**1MG/ML**	**A216977**	**001**	Oct 06, 2023
AP		DR REDDYS	**1MG/ML**	**A213209**	**001**	Mar 16, 2020
AP		EUGIA PHARMA	**0.4MG/ML**	**A212455**	**001**	Oct 15, 2019
AP			**1MG/ML**	**A213279**	**001**	Jan 14, 2021
AP			**0.4MG/ML**	**A212456**	**001**	Nov 04, 2019
AP		HIKMA	**1MG/ML**	**A212300**	**001**	Jun 10, 2022
AP	**!**	HOSPIRA	**0.4MG/ML**	**A070172**	**001**	Sep 24, 1986
AP	**!**		**0.4MG/ML**	**A070256**	**001**	Jan 07, 1987
AP	**!**		**0.4MG/ML**	**A070257**	**001**	Jan 07, 1987
AP	**!**	INTL MEDICATION	**1MG/ML**	**A072076**	**001**	Mar 24, 1988
AP		MYLAN INSTITUTIONAL	**0.4MG/ML**	**A204997**	**001**	Mar 06, 2014
AP			**0.4MG/ML**	**A205014**	**001**	Jun 29, 2016
AP		MYLAN LABS LTD	**1MG/ML**	**A213843**	**001**	Jun 09, 2022
AP		RISING	**0.4MG/ML**	**A208871**	**001**	Feb 28, 2017
AP			**0.4MG/ML**	**A208872**	**001**	Mar 14, 2017
AP		SOMERSET THERAPS LLC	**0.4MG/ML**	**A207633**	**001**	Aug 08, 2017
AP			**0.4MG/ML**	**A207634**	**001**	Jul 26, 2017

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
ZIMHI

+!	ADAMIS PHARMS CORP	5MG/0.5ML (5MG/0.5ML)	N212854	001	Oct 15, 2021

SPRAY;NASAL
KLOXXADO

+!	HIKMA	8MG/SPRAY	N212045	001	Apr 29, 2021

SPRAY, METERED;NASAL
NALOXONE HYDROCHLORIDE

	TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB		LUPIN	**EQ 0.5MG BASE;EQ 50MG BASE**	**A075735**	**001**	Jul 11, 2001
AB		SUN PHARM INDS LTD	**EQ 0.5MG BASE;EQ 50MG BASE**	**A075523**	**001**	Mar 17, 2000
AB	!	WATSON LABS	**EQ 0.5MG BASE;EQ 50MG BASE**	**A074736**	**001**	Jan 21, 1997

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

NALTREXONE

AP		TEVA PHARMS USA INC	**380MG/VIAL**	**A213195**	**001**	Jul 06, 2023

VIVITROL

AP	**+!**	ALKERMES	**380MG/VIAL**	**N021897**	**001**	Apr 13, 2006

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**50MG**	**A091205**	**001**	Aug 17, 2011
AB		BARR	**50MG**	**A074918**	**001**	May 08, 1998
AB		CHARTWELL	**50MG**	**A207905**	**001**	Jul 21, 2017
AB		ELITE LABS	**50MG**	**A075274**	**001**	May 26, 1999
AB	!	SPECGX LLC	**50MG**	**A076264**	**002**	Mar 22, 2002
AB		SUN PHARM	**50MG**	**A090356**	**001**	Feb 24, 2012
		SPECGX LLC	25MG	A076264	001	Mar 22, 2002
			100MG	A076264	003	Mar 22, 2002

NAPROXEN

SUSPENSION;ORAL

NAPROSYN

AB	**+**	ATNAHS PHARMA US	**25MG/ML**	**N018965**	**001**	Mar 23, 1987

NAPROXEN

AB		AMNEAL	**25MG/ML**	**A212705**	**001**	Jul 31, 2020
AB		HETERO LABS LTD III	**25MG/ML**	**A215776**	**001**	Jun 07, 2022
AB	!	HIKMA	**25MG/ML**	**A074190**	**001**	Mar 30, 1994
AB		NOVITIUM PHARMA	**25MG/ML**	**A211910**	**001**	Mar 10, 2021

TABLET;ORAL

NAPROSYN

AB	**+!**	ATNAHS PHARMA US	**500MG**	**N017581**	**004**	Apr 15, 1982

NAPROXEN

AB		AMNEAL PHARMS NY	**250MG**	**A075927**	**001**	Dec 18, 2001
AB			**375MG**	**A075927**	**002**	Dec 18, 2001
AB			**500MG**	**A075927**	**003**	Dec 18, 2001
AB		AUROBINDO PHARMA	**250MG**	**A200429**	**001**	Nov 08, 2011
AB			**375MG**	**A200429**	**002**	Nov 08, 2011
AB			**500MG**	**A200429**	**003**	Nov 08, 2011
AB		GLENMARK GENERICS	**250MG**	**A078250**	**001**	Mar 28, 2007
AB			**375MG**	**A078250**	**002**	Mar 28, 2007
AB			**500MG**	**A078250**	**003**	Mar 28, 2007
AB		GRANULES	**250MG**	**A074140**	**001**	Dec 21, 1993
AB			**375MG**	**A074140**	**002**	Dec 21, 1993
AB			**500MG**	**A074140**	**003**	Dec 21, 1993
AB		INVAGEN PHARMS	**250MG**	**A091305**	**001**	Aug 24, 2011
AB			**375MG**	**A091305**	**002**	Aug 24, 2011
AB			**500MG**	**A091305**	**003**	Aug 24, 2011
AB		MARKSANS PHARMA	**250MG**	**A091416**	**001**	Feb 14, 2011
AB			**375MG**	**A091416**	**002**	Feb 14, 2011
AB			**500MG**	**A091416**	**003**	Feb 14, 2011
AB		SCIEGEN PHARMS INC	**250MG**	**A212517**	**001**	Feb 21, 2020
AB			**375MG**	**A212517**	**002**	Feb 21, 2020
AB			**500MG**	**A212517**	**003**	Feb 21, 2020
AB		TEVA	**250MG**	**A074201**	**001**	Dec 21, 1993
AB			**375MG**	**A074201**	**002**	Dec 21, 1993
AB			**500MG**	**A074201**	**003**	Dec 21, 1993
AB		ZYDUS PHARMS USA	**250MG**	**A078620**	**001**	Jun 07, 2007
AB			**375MG**	**A078620**	**002**	Jun 07, 2007
AB			**500MG**	**A078620**	**003**	Jun 07, 2007

TABLET, DELAYED RELEASE;ORAL

EC-NAPROSYN

AB	**+!**	ATNAHS PHARMA US	**375MG**	**N020067**	**002**	Oct 14, 1994
AB	**+!**		**500MG**	**N020067**	**003**	Oct 14, 1994

NAPROXEN

AB		NUVO PHARMS INC	**375MG**	**A091432**	**001**	Sep 19, 2011
AB			**500MG**	**A091432**	**002**	Sep 19, 2011
AB		TEVA	**375MG**	**A075227**	**001**	Jun 30, 1998

NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

AB			**500MG**	**A075227**	**002**	Jun 30, 1998
AB		TULEX PHARMS INC	**375MG**	**A216908**	**001**	May 31, 2023
AB			**500MG**	**A216908**	**002**	May 31, 2023

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX DS

AB	**+!**	ATNAHS PHARMA US	**EQ 500MG BASE**	**N018164**	**003**	Sep 30, 1987

NAPROXEN SODIUM

AB		AMNEAL PHARMS NY	**EQ 250MG BASE**	**A078432**	**001**	Apr 25, 2007
AB			**EQ 500MG BASE**	**A078432**	**002**	Apr 25, 2007
AB		AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A200629**	**001**	Oct 31, 2011
AB			**EQ 500MG BASE**	**A200629**	**002**	Oct 31, 2011
AB		DR REDDYS LABS LTD	**EQ 250MG BASE**	**A078486**	**001**	Jul 26, 2007
AB			**EQ 500MG BASE**	**A078486**	**002**	Jul 26, 2007
AB		GLENMARK PHARMS LTD	**EQ 250MG BASE**	**A078314**	**001**	Apr 27, 2007
AB			**EQ 500MG BASE**	**A078314**	**002**	Apr 27, 2007
AB		SCIEGEN PHARMS INC	**EQ 250MG BASE**	**A212199**	**001**	Oct 30, 2019
AB			**EQ 500MG BASE**	**A212199**	**002**	Oct 30, 2019

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

AB	**+**	TWI PHARMS	**EQ 375MG BASE**	**N020353**	**001**	Jan 05, 1996
AB	**+**		**EQ 500MG BASE**	**N020353**	**002**	Jan 05, 1996
AB	**+!**		**EQ 750MG BASE**	**N020353**	**003**	Jan 05, 1996

NAPROXEN SODIUM

AB		ACTAVIS LABS FL INC	**EQ 375MG BASE**	**A075416**	**002**	Apr 23, 2003
AB			**EQ 500MG BASE**	**A075416**	**001**	Aug 27, 2002
AB			**EQ 750MG BASE**	**A075416**	**003**	Aug 11, 2016

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

AB		AUROBINDO PHARMA LTD	**500MG;EQ 85MG BASE**	**A207457**	**001**	Feb 15, 2018
AB		RISING	**500MG;EQ 85MG BASE**	**A090872**	**001**	Sep 04, 2018
AB		SUN PHARM	**500MG;EQ 85MG BASE**	**A202803**	**001**	Jul 20, 2018

TREXIMET

AB	**+!**	CURRAX	**500MG;EQ 85MG BASE**	**N021926**	**001**	Apr 15, 2008

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

AB		HERITAGE PHARMS	**EQ 1MG BASE**	**A200502**	**001**	Feb 28, 2011
AB	**!**		**EQ 2.5MG BASE**	**A200502**	**002**	Feb 28, 2011
AB		HIKMA	**EQ 1MG BASE**	**A090381**	**001**	Jul 07, 2010
AB			**EQ 2.5MG BASE**	**A090381**	**002**	Jul 07, 2010
AB		ORBION PHARMS	**EQ 1MG BASE**	**A091441**	**001**	Apr 30, 2012
AB			**EQ 2.5MG BASE**	**A091441**	**002**	Apr 30, 2012
AB		PADAGIS US	**EQ 1MG BASE**	**A091326**	**001**	Jul 08, 2010
AB			**EQ 2.5MG BASE**	**A091326**	**002**	Jul 08, 2010
AB		SUN PHARM INDS LTD	**EQ 2.5MG BASE**	**A091552**	**001**	Feb 14, 2011

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

	+!	HARROW EYE	5%	N050514	001	

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

AB		CADILA PHARMS LTD	**60MG**	**A206432**	**001**	Apr 19, 2019
AB			**120MG**	**A206432**	**002**	Apr 19, 2019
AB		DR REDDYS LABS LTD	**60MG**	**A077461**	**001**	Sep 09, 2009
AB			**120MG**	**A077461**	**002**	Sep 09, 2009
AB		RISING	**60MG**	**A205544**	**001**	Jun 18, 2018
AB			**120MG**	**A205544**	**002**	Jun 18, 2018
AB		STRIDES PHARMA	**60MG**	**A077463**	**001**	Sep 09, 2009
AB			**120MG**	**A077463**	**002**	Sep 09, 2009
AB		WATSON LABS	**60MG**	**A077462**	**001**	Mar 30, 2011
AB			**120MG**	**A077462**	**002**	Mar 30, 2011
AB		ZYDUS PHARMS	**60MG**	**A205248**	**001**	Jul 06, 2016

NATEGLINIDE
TABLET;ORAL
NATEGLINIDE

AB	!		**120MG**	**A205248**	**002**	Jul 06, 2016

NEBIVOLOL HYDROCHLORIDE
TABLET;ORAL
BYSTOLIC

AB	+	ALLERGAN	**EQ 2.5MG BASE**	**N021742**	**002**	Dec 17, 2007
AB	+		**EQ 5MG BASE**	**N021742**	**003**	Dec 17, 2007
AB	+		**EQ 10MG BASE**	**N021742**	**004**	Dec 17, 2007
AB	+!		**EQ 20MG BASE**	**N021742**	**005**	Oct 08, 2008

NEBIVOLOL HYDROCHLORIDE

AB		ANI PHARMS	**EQ 2.5MG BASE**	**A203659**	**001**	Apr 16, 2015
AB			**EQ 5MG BASE**	**A203659**	**002**	Apr 16, 2015
AB			**EQ 10MG BASE**	**A203659**	**003**	Apr 16, 2015
AB			**EQ 20MG BASE**	**A203659**	**004**	Apr 16, 2015
AB		AUROBINDO PHARMA LTD	**EQ 2.5MG BASE**	**A211053**	**001**	Dec 17, 2021
AB			**EQ 5MG BASE**	**A211053**	**002**	Dec 17, 2021
AB			**EQ 10MG BASE**	**A211053**	**003**	Dec 17, 2021
AB			**EQ 20MG BASE**	**A211053**	**004**	Dec 17, 2021
AB		BEXIMCO PHARMS USA	**EQ 2.5MG BASE**	**A216568**	**001**	Mar 30, 2023
AB			**EQ 5MG BASE**	**A216568**	**002**	Mar 30, 2023
AB			**EQ 10MG BASE**	**A216568**	**003**	Mar 30, 2023
AB			**EQ 20MG BASE**	**A216568**	**004**	Mar 30, 2023
AB		CADILA PHARMS LTD	**EQ 2.5MG BASE**	**A208717**	**001**	Dec 17, 2021
AB			**EQ 5MG BASE**	**A208717**	**002**	Dec 17, 2021
AB			**EQ 10MG BASE**	**A208717**	**003**	Dec 17, 2021
AB			**EQ 20MG BASE**	**A208717**	**004**	Dec 17, 2021
AB		HETERO LABS LTD III	**EQ 2.5MG BASE**	**A203825**	**001**	Nov 03, 2020
AB			**EQ 5MG BASE**	**A203825**	**002**	Nov 03, 2020
AB			**EQ 10MG BASE**	**A203825**	**003**	Nov 03, 2020
AB			**EQ 20MG BASE**	**A203825**	**004**	Nov 03, 2020
AB		INDCHEMIE HEALTH	**EQ 2.5MG BASE**	**A203828**	**001**	Jul 29, 2015
AB			**EQ 5MG BASE**	**A203828**	**002**	Jul 29, 2015
AB			**EQ 10MG BASE**	**A203828**	**003**	Jul 29, 2015
AB			**EQ 20MG BASE**	**A203828**	**004**	Jul 29, 2015
AB		MANKIND PHARMA	**EQ 2.5MG BASE**	**A216172**	**001**	Nov 14, 2022
AB			**EQ 5MG BASE**	**A216172**	**002**	Nov 14, 2022
AB			**EQ 10MG BASE**	**A216172**	**003**	Nov 14, 2022
AB			**EQ 20MG BASE**	**A216172**	**004**	Nov 14, 2022
AB		PRINSTON INC	**EQ 2.5MG BASE**	**A212682**	**001**	Apr 07, 2022
AB			**EQ 5MG BASE**	**A212682**	**002**	Apr 07, 2022
AB			**EQ 10MG BASE**	**A212682**	**003**	Apr 07, 2022
AB			**EQ 20MG BASE**	**A212682**	**004**	Apr 07, 2022
AB		REYOUNG	**EQ 2.5MG BASE**	**A212917**	**001**	Dec 17, 2021
AB			**EQ 5MG BASE**	**A212917**	**002**	Dec 17, 2021
AB			**EQ 10MG BASE**	**A212917**	**003**	Dec 17, 2021
AB			**EQ 20MG BASE**	**A212917**	**004**	Dec 17, 2021
AB		TORRENT	**EQ 2.5MG BASE**	**A203966**	**001**	Mar 02, 2018
AB			**EQ 5MG BASE**	**A203966**	**002**	Mar 02, 2018
AB			**EQ 10MG BASE**	**A203966**	**003**	Mar 02, 2018
AB			**EQ 20MG BASE**	**A203966**	**004**	Mar 02, 2018

NEBIVOLOL HYDROCHLORIDE; VALSARTAN
TABLET;ORAL
VYDUO

	PRINSTON INC	EQ 5MG BASE;80MG	A210596	001	Sep 19, 2022

NEDOSIRAN SODIUM
SOLUTION;INJECTION
RIVFLOZA

+!	NOVO	EQ 80MG BASE/0.5ML (EQ 160MG BASE/ML)	N215842	001	Sep 29, 2023
+!		EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML)	N215842	002	Sep 29, 2023
+!		EQ 160MG BASE/ML (EQ 160MG BASE/ML)	N215842	003	Sep 29, 2023

NEFAZODONE HYDROCHLORIDE
TABLET;ORAL
NEFAZODONE HYDROCHLORIDE

	TEVA	50MG	A076037	001	Sep 16, 2003
		100MG	A076037	002	Sep 16, 2003
		150MG	A076037	003	Sep 16, 2003
		200MG	A076037	004	Sep 16, 2003
!		250MG	A076037	005	Sep 16, 2003

NELARABINE

INJECTABLE;INTRAVENOUS

ARRANON

AP	**+!**	SANDOZ	**250MG/50ML (5MG/ML)**	**N021877**	**001**	Oct 28, 2005

NELARABINE

AP		AMNEAL	**250MG/50ML (5MG/ML)**	**A216346**	**001**	Apr 04, 2023
AP		DR REDDYS	**250MG/50ML (5MG/ML)**	**A216934**	**001**	Dec 23, 2022
AP		GLAND PHARMA LTD	**250MG/50ML (5MG/ML)**	**A212605**	**001**	Jan 03, 2024
AP		KINDOS	**250MG/50ML (5MG/ML)**	**A216038**	**001**	Jan 10, 2023
AP		NEXUS	**250MG/50ML (5MG/ML)**	**A215057**	**001**	Jun 02, 2023
AP		SHORLA	**250MG/50ML (5MG/ML)**	**A214809**	**001**	Mar 03, 2023
AP		ZYDUS PHARMS	**250MG/50ML (5MG/ML)**	**A215037**	**001**	Nov 17, 2021

NELFINAVIR MESYLATE

TABLET;ORAL

VIRACEPT

	+!	AGOURON PHARMS	EQ 250MG BASE	N020779	001	Mar 14, 1997
	+!		EQ 625MG BASE	N021503	001	Apr 30, 2003

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

AA	**!**	TEVA	**500MG**	**A060304**	**001**	
AA		XGEN PHARMS	**500MG**	**A065220**	**001**	Jul 28, 2006

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT		WATSON LABS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A062664**	**001**	Apr 08, 1986
AT		XGEN PHARMS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A065106**	**001**	Jan 31, 2006
AT			**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A065108**	**001**	Jan 31, 2006

NEOSPORIN G.U. IRRIGANT

AT	**!**	MONARCH PHARMS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A060707**	**001**	

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

BLOXIVERZ

AP	**+!**	EXELA PHARMA	**5MG/10ML (0.5MG/ML)**	**N204078**	**001**	May 31, 2013
AP	**+!**		**10MG/10ML (1MG/ML)**	**N204078**	**002**	May 31, 2013

NEOSTIGMINE METHYLSULFATE

AP		AMNEAL	**5MG/10ML (0.5MG/ML)**	**A210051**	**001**	Jun 15, 2018
AP			**10MG/10ML (1MG/ML)**	**A210051**	**002**	Jun 15, 2018
AP		AMPHASTAR PHARMS INC	**5MG/10ML (0.5MG/ML)**	**A209933**	**001**	Sep 25, 2017
AP			**10MG/10ML (1MG/ML)**	**A209933**	**002**	Sep 25, 2017
AP		AMRING PHARMS	**5MG/10ML (0.5MG/ML)**	**A210989**	**001**	Aug 22, 2018
AP			**10MG/10ML (1MG/ML)**	**A210989**	**002**	Aug 22, 2018
AP		BE PHARMS	**5MG/10ML (0.5MG/ML)**	**A212512**	**001**	May 13, 2019
AP			**10MG/10ML (1MG/ML)**	**A212512**	**002**	May 13, 2019
AP		CAPLIN	**5MG/10ML (0.5MG/ML)**	**A213074**	**001**	Apr 20, 2021
AP			**10MG/10ML (1MG/ML)**	**A213074**	**002**	Apr 20, 2021
AP		DR REDDYS	**3MG/3ML (1MG/ML)**	**A216291**	**001**	Jul 06, 2022
AP			**5MG/10ML (0.5MG/ML)**	**A209135**	**001**	Jul 10, 2018
AP			**10MG/10ML (1MG/ML)**	**A209135**	**002**	Jul 10, 2018
AP		EUGIA PHARMA	**5MG/10ML (0.5MG/ML)**	**A213244**	**001**	Nov 02, 2023
AP			**10MG/10ML (1MG/ML)**	**A213244**	**002**	Nov 02, 2023
AP	**+!**	FRESENIUS KABI USA	**3MG/3ML (1MG/ML)**	**N203629**	**003**	Sep 18, 2018
AP		GLAND PHARMA LTD	**5MG/10ML (0.5MG/ML)**	**A212968**	**001**	Oct 16, 2019
AP			**10MG/10ML (1MG/ML)**	**A212968**	**002**	Oct 16, 2019
AP		HIKMA	**3MG/3ML (1MG/ML)**	**A216206**	**001**	Jul 13, 2022
AP			**5MG/10ML (0.5MG/ML)**	**A207042**	**001**	Dec 28, 2015
AP			**10MG/10ML (1MG/ML)**	**A207042**	**002**	Dec 28, 2015
AP		INDOCO	**5MG/10ML (0.5MG/ML)**	**A210652**	**001**	Oct 01, 2021
AP			**10MG/10ML (1MG/ML)**	**A210652**	**002**	Oct 01, 2021
AP		MEITHEAL	**5MG/10ML (0.5MG/ML)**	**A212804**	**001**	Apr 05, 2021
AP			**10MG/10ML (1MG/ML)**	**A212804**	**002**	Apr 05, 2021
AP		PAR STERILE PRODUCTS	**5MG/10ML (0.5MG/ML)**	**A208405**	**001**	Apr 26, 2017
AP			**10MG/10ML (1MG/ML)**	**A208405**	**002**	Apr 26, 2017
AP		SAGENT PHARMS INC	**5MG/10ML (0.5MG/ML)**	**A216542**	**001**	Feb 17, 2023
AP			**10MG/10ML (1MG/ML)**	**A216542**	**002**	Feb 17, 2023
AP		UMEDICA	**5MG/10ML (0.5MG/ML)**	**A212627**	**001**	Nov 03, 2022
AP			**10MG/10ML (1MG/ML)**	**A212627**	**002**	Nov 03, 2022

NEOSTIGMINE METHYLSULFATE
SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYSULFATE						
AP		AVET LIFESCIENCES	**5MG/10ML (0.5MG/ML)**	**A208230**	**001**	Nov 25, 2022
AP			**10MG/10ML (1MG/ML)**	**A208230**	**002**	Nov 25, 2022
BLOXIVERZ						
	+!	EXELA PHARMA	5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023
NEOSTIGMINE METHYLSULFATE						
	+!	FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015
	+!		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015

NEPAFENAC
SUSPENSION/DROPS;OPHTHALMIC

ILEVRO						
	+!	HARROW EYE	0.3%	N203491	001	Oct 16, 2012
NEVANAC						
	+!	HARROW EYE	0.1%	N021862	001	Aug 19, 2005

NERATINIB MALEATE
TABLET;ORAL

NERLYNX						
	+!	PUMA BIOTECH	EQ 40MG BASE	N208051	001	Jul 17, 2017

NETARSUDIL MESYLATE
SOLUTION/DROPS;OPHTHALMIC

RHOPRESSA						
	+!	ALCON LABS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017

NETUPITANT; PALONOSETRON HYDROCHLORIDE
CAPSULE;ORAL

AKYNZEO						
	+!	HELSINN HLTHCARE	300MG;EQ 0.5MG BASE	N205718	001	Oct 10, 2014

NEVIRAPINE
SUSPENSION;ORAL

NEVIRAPINE						
AA		AUROBINDO	**50MG/5ML**	**A077702**	**001**	May 22, 2012
AA		CIPLA	**50MG/5ML**	**A207684**	**001**	Aug 03, 2017
VIRAMUNE						
AA	**+!**	BOEHRINGER INGELHEIM	**50MG/5ML**	**N020933**	**001**	Sep 11, 1998

TABLET;ORAL

NEVIRAPINE						
AB		AUROBINDO	**200MG**	**A077521**	**001**	May 22, 2012
AB		CIPLA	**200MG**	**A077956**	**001**	May 22, 2012
AB		HETERO LABS LTD III	**200MG**	**A078584**	**001**	May 22, 2012
AB	**!**	MACLEODS PHARMS LTD	**200MG**	**A090688**	**001**	Jan 14, 2019
AB		MICRO LABS LTD	**200MG**	**A203080**	**001**	May 22, 2012
AB		MYLAN PHARMS INC	**200MG**	**A202523**	**001**	May 22, 2012
AB		STRIDES PHARMA	**200MG**	**A078195**	**001**	May 22, 2012

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE						
AB		MACLEODS PHARMS LTD	**400MG**	**A206879**	**001**	Oct 06, 2017
AB		MYLAN	**400MG**	**A205651**	**001**	Oct 27, 2014
AB		SANDOZ	**400MG**	**A203411**	**001**	Apr 03, 2014
VIRAMUNE XR						
AB	**+!**	BOEHRINGER INGELHEIM	**400MG**	**N201152**	**001**	Mar 25, 2011
	+		100MG	N201152	002	Nov 08, 2012

NIACIN
TABLET;ORAL

NIACOR						
	!	AVONDALE PHARMS	500MG	A040378	001	May 03, 2000

TABLET, EXTENDED RELEASE;ORAL

NIACIN						
AB		AMNEAL PHARMS	**500MG**	**A203578**	**001**	Jul 24, 2015
AB			**750MG**	**A204178**	**001**	Dec 11, 2015
AB			**1GM**	**A203578**	**002**	Jul 24, 2015
AB		AUROBINDO PHARMA LTD	**500MG**	**A209236**	**001**	Feb 01, 2018
AB			**750MG**	**A209236**	**002**	Feb 01, 2018
AB			**1GM**	**A209236**	**003**	Feb 01, 2018
AB		BARR	**500MG**	**A076378**	**001**	Apr 26, 2005
AB			**750MG**	**A076378**	**002**	Apr 26, 2005
AB			**1GM**	**A076250**	**001**	Apr 14, 2005

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

AB		EYWA	**500MG**	**A213090**	**001**	Aug 25, 2023
AB			**750MG**	**A213090**	**002**	Aug 25, 2023
AB			**1GM**	**A213090**	**003**	Aug 25, 2023
AB		LANNETT CO INC	**500MG**	**A203899**	**001**	Jun 16, 2017
AB			**1GM**	**A203899**	**002**	Jun 16, 2017
AB		LUPIN LTD	**500MG**	**A090860**	**001**	Mar 20, 2014
AB			**750MG**	**A090892**	**001**	Mar 20, 2014
AB			**1GM**	**A090446**	**001**	Mar 20, 2014
AB		MACLEODS PHARMS LTD	**500MG**	**A204934**	**001**	Mar 03, 2022
AB			**1GM**	**A204934**	**002**	Mar 03, 2022
AB		SUN PHARM	**500MG**	**A200484**	**001**	Apr 23, 2014
AB	**!**		**750MG**	**A201273**	**001**	Apr 23, 2014
AB	**!**		**1GM**	**A200484**	**002**	Apr 23, 2014

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB		ANI PHARMS	**20MG**	**A074670**	**001**	Oct 28, 1996
AB			**30MG**	**A074670**	**002**	Oct 28, 1996
AB		BIONPHARMA	**20MG**	**A217555**	**001**	May 03, 2023
AB			**30MG**	**A217555**	**002**	May 03, 2023
AB		EPIC PHARMA LLC	**20MG**	**A074928**	**001**	Mar 19, 1998
AB	**!**		**30MG**	**A074928**	**002**	Mar 19, 1998
AB		GLENMARK PHARMS LTD	**20MG**	**A216357**	**001**	Dec 16, 2022
AB			**30MG**	**A216357**	**002**	Dec 16, 2022
AB		SENORES PHARMS	**20MG**	**A215377**	**001**	Jul 17, 2023
AB			**30MG**	**A215377**	**002**	Jul 17, 2023

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AP	**!**	AM REGENT	**25MG/10ML (2.5MG/ML)**	**A090534**	**001**	Nov 17, 2009
AP		EUGIA PHARMA	**25MG/10ML (2.5MG/ML)**	**A211121**	**001**	Apr 08, 2021
AP	**+!**	HIKMA INTL PHARMS	**25MG/10ML (2.5MG/ML)**	**N022276**	**001**	Jul 24, 2008
AP		MICRO LABS	**25MG/10ML (2.5MG/ML)**	**A216420**	**001**	Jul 07, 2023

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+!	CHIESI	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+!	CHIESI	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+!	CHIESI	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

+!	HIKMA INTL PHARMS	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016
+!		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016

NICOTINE

INHALANT;ORAL

NICOTROL

+!	PFIZER	4MG/CARTRIDGE	N020714	001	May 02, 1997

SPRAY, METERED;NASAL

NICOTROL

+!	PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB		ACELLA	**10MG**	**A072781**	**001**	Jul 30, 1993
AB		ACTAVIS ELIZABETH	**10MG**	**A072579**	**001**	Jan 08, 1991
AB			**20MG**	**A072556**	**001**	Sep 20, 1990
AB		HERITAGE PHARMA	**10MG**	**A202644**	**001**	Apr 25, 2013
AB			**20MG**	**A202644**	**002**	Apr 25, 2013
AB		LEADING	**10MG**	**A073250**	**001**	Oct 08, 1991
AB			**20MG**	**A074045**	**001**	Apr 30, 1992

PROCARDIA

AB	**+!**	PFIZER	**10MG**	**N018482**	**001**	

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB1		AUROBINDO PHARMA	**30MG**	**A213361**	**001**	Jul 19, 2021
AB1			**60MG**	**A213361**	**002**	Jul 19, 2021
AB1			**90MG**	**A213361**	**003**	Jul 19, 2021
AB1		NOVAST LABS	**30MG**	**A202987**	**001**	Aug 25, 2016
AB1	**!**		**60MG**	**A202987**	**002**	Aug 25, 2016

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB1	**!**		**90MG**	**A202987**	**003**	Aug 25, 2016
AB1		VALEANT PHARMS NORTH	**30MG**	**A075269**	**001**	Dec 04, 2000
AB1			**60MG**	**A075269**	**002**	Dec 04, 2000
AB1			**90MG**	**A076070**	**001**	Aug 16, 2002
AB1		ZYDUS PHARMS	**30MG**	**A210184**	**001**	Jun 29, 2018
AB1			**60MG**	**A210184**	**002**	Jun 29, 2018
AB1			**90MG**	**A210184**	**003**	Jun 29, 2018
AB2		ALEMBIC	**30MG**	**A216896**	**001**	Nov 18, 2022
AB2			**60MG**	**A216896**	**002**	Nov 18, 2022
AB2			**90MG**	**A216896**	**003**	Nov 18, 2022
AB2		ALKEM LABS LTD	**30MG**	**A216067**	**001**	Mar 29, 2022
AB2			**60MG**	**A216067**	**002**	Mar 29, 2022
AB2			**90MG**	**A216067**	**003**	Mar 29, 2022
AB2		ELITE PHARM SOLUTION	**90MG**	**A212016**	**001**	Nov 18, 2020
AB2		NOVAST LABS	**30MG**	**A210614**	**001**	Mar 12, 2019
AB2			**60MG**	**A210614**	**002**	Mar 12, 2019
AB2			**90MG**	**A210614**	**003**	Mar 12, 2019
AB2		OSMOTICA PHARM US	**30MG**	**A077127**	**001**	Nov 21, 2005
AB2			**60MG**	**A077127**	**002**	Nov 21, 2005
AB2			**90MG**	**A077127**	**003**	Oct 03, 2007
AB2		SPIL	**30MG**	**A210838**	**001**	Apr 16, 2019
AB2			**60MG**	**A210838**	**002**	Apr 16, 2019
AB2			**90MG**	**A210838**	**003**	Apr 16, 2019
AB2		TWI PHARMS	**30MG**	**A203126**	**001**	Apr 03, 2014
AB2			**60MG**	**A203126**	**002**	Apr 03, 2014
AB2			**90MG**	**A203126**	**003**	Apr 03, 2014
AB2		VALEANT PHARMS NORTH	**30MG**	**A075289**	**002**	Feb 06, 2001
AB2			**60MG**	**A075289**	**001**	Sep 27, 2000
AB2		ZYDUS PHARMS	**30MG**	**A210012**	**001**	Dec 19, 2017
AB2			**60MG**	**A210012**	**002**	Dec 19, 2017
AB2			**90MG**	**A210012**	**003**	Dec 19, 2017

PROCARDIA XL

AB2	**+**	PFIZER	**30MG**	**N019684**	**001**	Sep 06, 1989
AB2	**+**		**60MG**	**N019684**	**002**	Sep 06, 1989
AB2	**+!**		**90MG**	**N019684**	**003**	Sep 06, 1989

NIFURTIMOX

TABLET;ORAL

LAMPIT

	+	BAYER HEALTHCARE	30MG	N213464	001	Aug 06, 2020
	+!		120MG	N213464	002	Aug 06, 2020

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

NILOTINIB HYDROCHLORIDE

AB		APOTEX	**EQ 50MG BASE**	**A203640**	**001**	Jan 05, 2024
AB			**EQ 150MG BASE**	**A203640**	**002**	Jan 05, 2024
AB			**EQ 200MG BASE**	**A203640**	**003**	Jan 05, 2024

TASIGNA

AB	**+**	NOVARTIS	**EQ 50MG BASE**	**N022068**	**003**	Mar 22, 2018
AB	**+**		**EQ 150MG BASE**	**N022068**	**002**	Jun 17, 2010
AB	**+!**		**EQ 200MG BASE**	**N022068**	**001**	Oct 29, 2007

NILUTAMIDE

TABLET;ORAL

NILANDRON

AB	**+!**	CONCORDIA	**150MG**	**N020169**	**002**	Apr 30, 1999

NILUTAMIDE

AB		ANI PHARMS	**150MG**	**A207631**	**001**	Jul 15, 2016

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

AB	**!**	BIONPHARMA	**30MG**	**A076740**	**001**	Jan 17, 2008
AB		HERITAGE PHARMS	**30MG**	**A077811**	**001**	May 02, 2007
AB		THEPHARMANETWORK LLC	**30MG**	**A090103**	**001**	Apr 07, 2014

NIMODIPINE						
SOLUTION;ORAL						
NYMALIZE						
+!	AZURITY	6MG/ML		N203340	002	Apr 08, 2020
NINTEDANIB ESYLATE						
CAPSULE;ORAL						
OFEV						
+	BOEHRINGER INGELHEIM	EQ 100MG BASE		N205832	001	Oct 15, 2014
+!		EQ 150MG BASE		N205832	002	Oct 15, 2014
NIRAPARIB TOSYLATE						
CAPSULE;ORAL						
ZEJULA						
+!	GLAXOSMITHKLINE	EQ 100MG BASE		N208447	001	Mar 27, 2017
TABLET;ORAL						
ZEJULA						
+	GLAXOSMITHKLINE	EQ 100MG BASE		N214876	001	Apr 26, 2023
+		EQ 200MG BASE		N214876	002	Apr 26, 2023
+!		EQ 300MG BASE		N214876	003	Apr 26, 2023
NIRMATRELVIR; RITONAVIR						
TABLET;ORAL						
PAXLOVID (COPACKAGED)						
+	PFIZER	150MG;100MG		N217188	001	May 25, 2023
+!		300MG;100MG		N217188	002	May 25, 2023
NIROGACESTAT HYDROBROMIDE						
TABLET;ORAL						
OGSIVEO						
+!	SPRINGWORKS	EQ 50MG BASE		N217677	001	Nov 27, 2023
NISOLDIPINE						
TABLET, EXTENDED RELEASE;ORAL						
NISOLDIPINE						
AB	MYLAN	**8.5MG**		**A091001**	**001**	Jan 26, 2011
AB		**17MG**		**A091001**	**002**	Jan 26, 2011
AB		**34MG**		**A091001**	**004**	Jan 26, 2011
SULAR						
AB **+!**	COVIS	**8.5MG**		**N020356**	**008**	Jan 02, 2008
AB **+!**		**17MG**		**N020356**	**007**	Jan 02, 2008
AB **+!**		**34MG**		**N020356**	**005**	Jan 02, 2008
NISOLDIPINE						
!	MYLAN	20MG		A079051	001	Jul 25, 2008
		25.5MG		A091001	003	Jan 26, 2011
		30MG		A079051	002	Jul 25, 2008
!		40MG		A079051	003	Jul 25, 2008
NITAZOXANIDE						
FOR SUSPENSION;ORAL						
ALINIA						
+!	ROMARK	100MG/5ML		N021498	001	Nov 22, 2002
TABLET;ORAL						
ALINIA						
AB **+!**	ROMARK	**500MG**		**N021497**	**001**	Jul 21, 2004
NITAZOXANIDE						
AB	RISING	**500MG**		**A213820**	**001**	Nov 27, 2020
NITISINONE						
CAPSULE;ORAL						
NITISINONE						
AB	ETON	**2MG**		**A216201**	**001**	May 25, 2023
AB		**5MG**		**A216201**	**002**	May 25, 2023
AB		**10MG**		**A216201**	**003**	May 25, 2023
AB		**20MG**		**A216201**	**004**	May 25, 2023
AB	MEDUNIK	**2MG**		**A212390**	**001**	May 26, 2022
AB		**5MG**		**A212390**	**002**	May 26, 2022
AB		**10MG**		**A212390**	**003**	May 26, 2022
AB		**20MG**		**A212390**	**004**	Apr 27, 2023
AB	NOVITIUM PHARMA	**2MG**		**A211041**	**001**	Aug 26, 2019
AB		**5MG**		**A211041**	**002**	Aug 26, 2019
AB		**10MG**		**A211041**	**003**	Aug 26, 2019
AB	TORRENT	**2MG**		**A215908**	**001**	Jan 09, 2023
AB		**5MG**		**A215908**	**002**	Jan 09, 2023
AB		**10MG**		**A215908**	**003**	Jan 09, 2023

NITISINONE

CAPSULE;ORAL

NITISINONE						
AB			**20MG**	**A215908**	**004**	Jan 09, 2023
ORFADIN						
AB	+	SWEDISH ORPHAN	**2MG**	**N021232**	**001**	Jan 18, 2002
AB	+		**5MG**	**N021232**	**002**	Jan 18, 2002
AB	+		**10MG**	**N021232**	**003**	Jan 18, 2002
AB	+!		**20MG**	**N021232**	**004**	Jun 13, 2016

SUSPENSION;ORAL

ORFADIN						
	+!	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016

TABLET;ORAL

NITYR						
	+	CYCLE	2MG	N209449	001	Jul 26, 2017
	+		5MG	N209449	002	Jul 26, 2017
	+!		10MG	N209449	003	Jul 26, 2017

NITRIC OXIDE

GAS;INHALATION

INOMAX						
AA	+!	MALLINCKRODT HOSP	**800PPM**	**N020845**	**003**	Dec 23, 1999
NOXIVENT						
AA		LINDE GAS EQUIP	**800PPM**	**A207141**	**002**	Oct 02, 2018
ULSPIRA						
AA		AIRGAS THERAP	**800PPM**	**A203144**	**001**	Jul 27, 2023
GENOSYL						
	+!	VERO BIOTECH INC	800PPM	N202860	001	Dec 20, 2019
NOXIVENT						
		LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018

NITROFURANTOIN

SUSPENSION;ORAL

FURADANTIN						
AB	+	CASPER PHARMA LLC	**25MG/5ML**	**N009175**	**001**	
NITROFURANTOIN						
AB		ACTAVIS MID ATLANTIC	**25MG/5ML**	**A205180**	**001**	May 03, 2016
AB		AMNEAL PHARMS	**25MG/5ML**	**A201679**	**001**	May 11, 2011
AB		AUROBINDO PHARMA	**25MG/5ML**	**A212607**	**001**	May 11, 2023
AB		NOSTRUM LABS INC	**25MG/5ML**	**A201355**	**001**	Aug 14, 2013
AB		NOVEL LABS INC	**25MG/5ML**	**A201693**	**001**	Sep 08, 2014
AB		NOVITIUM PHARMA	**25MG/5ML**	**A216385**	**001**	Apr 14, 2023
FURADANTIN						
	+!	CASPER PHARMA LLC	50MG/5ML	N009175	002	Jun 09, 2023

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN						
AB	+	ALMATICA	**25MG**	**N016620**	**003**	
AB	+		**50MG**	**N016620**	**001**	
AB	+!		**100MG**	**N016620**	**002**	
NITROFURANTOIN						
AB		ACTAVIS LABS FL INC	**25MG**	**A091095**	**001**	Jun 18, 2015
AB			**50MG**	**A091095**	**002**	Jun 18, 2015
AB			**100MG**	**A091095**	**003**	Jun 18, 2015
AB		ALEMBIC	**25MG**	**A211935**	**001**	Jun 25, 2021
AB			**50MG**	**A211935**	**002**	Jun 25, 2021
AB			**100MG**	**A211935**	**003**	Jun 25, 2021
AB		AUROBINDO PHARMA USA	**50MG**	**A074967**	**001**	Jul 09, 1997
AB			**100MG**	**A074967**	**002**	Jul 09, 1997
AB			**100MG**	**A077025**	**001**	Aug 18, 2004
AB		IMPAX LABS INC	**50MG**	**A073671**	**001**	Jan 28, 1993
AB			**100MG**	**A073652**	**001**	Jan 28, 1993
AB		MANKIND PHARMA	**25MG**	**A217272**	**001**	Mar 21, 2023
AB			**50MG**	**A217272**	**002**	Mar 21, 2023
AB			**100MG**	**A217272**	**003**	Mar 21, 2023
AB		NOVEL LABS INC	**50MG**	**A203233**	**001**	Jul 09, 2018
AB			**100MG**	**A203233**	**002**	Jul 09, 2018
AB		SUN PHARM INDUSTRIES	**25MG**	**A201722**	**001**	Feb 16, 2016
AB			**50MG**	**A201722**	**002**	Feb 16, 2016
AB			**100MG**	**A201722**	**003**	Feb 16, 2016

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

AB		ZYDUS PHARMS	**50MG**	**A205005**	**001**	Dec 12, 2017
AB			**100MG**	**A205005**	**002**	Dec 12, 2017

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACROBID

AB	**+!**	ALMATICA	**75MG;25MG**	**N020064**	**001**	Dec 24, 1991

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		AMNEAL PHARMS	**75MG;25MG**	**A207372**	**001**	May 15, 2017
AB		AUROBINDO PHARMA	**75MG;25MG**	**A209225**	**001**	Mar 30, 2023
AB		INVENTIA	**75MG;25MG**	**A211013**	**001**	Feb 18, 2022
AB		MANKIND PHARMA	**75MG;25MG**	**A217357**	**001**	Jul 11, 2023
AB		OMSAV PHARMA	**75MG;25MG**	**A217073**	**001**	Nov 03, 2023
AB		SANDOZ	**75MG;25MG**	**A077066**	**001**	Apr 05, 2005
AB		SUNNY	**75MG;25MG**	**A208516**	**001**	May 24, 2018
AB		WATSON LABS INC	**75MG;25MG**	**A202250**	**001**	Jul 08, 2015

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL

NITROMIST

	+!	EVUS	0.4MG/SPRAY	N021780	001	Nov 02, 2006

FILM, EXTENDED RELEASE;TRANSDERMAL

NITROGLYCERIN

AB2	**!**	MYLAN TECHNOLOGIES	**0.1MG/HR**	**A074559**	**004**	Feb 06, 1998
AB2	**!**		**0.2MG/HR**	**A074559**	**003**	Aug 30, 1996
AB2	**!**		**0.4MG/HR**	**A074559**	**002**	Aug 30, 1996
AB2	**!**		**0.6MG/HR**	**A074559**	**001**	Aug 30, 1996
AB2		ZYDUS PHARMS	**0.1MG/HR**	**A089885**	**002**	Oct 30, 2017
AB2			**0.2MG/HR**	**A089884**	**001**	Oct 30, 1998
AB2			**0.4MG/HR**	**A089885**	**001**	Oct 30, 1998
AB2			**0.6MG/HR**	**A089886**	**001**	Oct 30, 1998

NITRO-DUR

	+!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995
	+!		0.2MG/HR	N020145	002	Apr 04, 1995
	+!		0.3MG/HR	N020145	003	Apr 04, 1995
	+!		0.4MG/HR	N020145	004	Apr 04, 1995
	+!		0.6MG/HR	N020145	005	Apr 04, 1995
	+!		0.8MG/HR	N020145	006	Apr 04, 1995

INJECTABLE;INJECTION

NITROGLYCERIN

	!	AM REGENT	5MG/ML	A072034	001	May 24, 1988

NITROGLYCERIN IN DEXTROSE 5%

	+!	BAXTER HLTHCARE	10MG/100ML	N019970	001	Dec 29, 1989
	+!		20MG/100ML	N019970	002	Dec 29, 1989
	+!		40MG/100ML	N019970	003	Dec 29, 1989

OINTMENT;INTRA-ANAL

RECTIV

	+!	ABBVIE	0.4%	N021359	001	Jun 21, 2011

OINTMENT;TRANSDERMAL

NITROGLYCERIN

	+!	FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988

SPRAY, METERED;SUBLINGUAL

NITROGLYCERIN

AB		PADAGIS ISRAEL	**0.4MG/SPRAY**	**A091496**	**001**	Sep 20, 2013

NITROLINGUAL PUMPSPRAY

AB	**+!**	POHL BOSKAMP	**0.4MG/SPRAY**	**N018705**	**002**	Jan 10, 1997

TABLET;SUBLINGUAL

NITROGLYCERIN

AB		AUROBINDO PHARMA	**0.3MG**	**A217879**	**001**	Oct 26, 2023
AB			**0.4MG**	**A217879**	**002**	Oct 26, 2023
AB			**0.6MG**	**A217879**	**003**	Oct 26, 2023
AB		DR REDDYS	**0.3MG**	**A208191**	**001**	Aug 26, 2016
AB			**0.4MG**	**A208191**	**002**	Aug 26, 2016
AB			**0.6MG**	**A208191**	**003**	Aug 26, 2016
AB		GLENMARK PHARMS SA	**0.3MG**	**A206391**	**001**	Sep 19, 2017
AB			**0.4MG**	**A206391**	**002**	Sep 19, 2017
AB			**0.6MG**	**A206391**	**003**	Sep 19, 2017
AB		MANKIND PHARMA	**0.3MG**	**A217970**	**001**	Dec 05, 2023
AB			**0.4MG**	**A217970**	**002**	Dec 05, 2023
AB			**0.6MG**	**A217970**	**003**	Dec 05, 2023

NITROGLYCERIN

TABLET;SUBLINGUAL

NITROGLYCERIN						
AB		NATCO	**0.3MG**	**A211604**	**001**	Apr 30, 2019
AB			**0.4MG**	**A211604**	**002**	Apr 30, 2019
AB			**0.6MG**	**A211604**	**003**	Apr 30, 2019
AB		RUBICON	**0.3MG**	**A209779**	**001**	May 03, 2021
AB			**0.4MG**	**A209779**	**002**	May 03, 2021
AB			**0.6MG**	**A209779**	**003**	May 03, 2021
NITROSTAT						
AB	**+**	VIATRIS	**0.3MG**	**N021134**	**001**	May 01, 2000
AB	**+**		**0.4MG**	**N021134**	**002**	May 01, 2000
AB	**+!**		**0.6MG**	**N021134**	**003**	May 01, 2000

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE						
AB		DR REDDYS LABS LTD	**150MG**	**A077314**	**001**	Sep 15, 2005
AB			**300MG**	**A077314**	**002**	Sep 15, 2005
AB		EPIC PHARMA LLC	**150MG**	**A076178**	**001**	Jul 05, 2002
AB			**300MG**	**A076178**	**002**	Jul 05, 2002
AB		GLENMARK GENERICS	**150MG**	**A090618**	**001**	Jul 15, 2011
AB			**300MG**	**A090618**	**002**	Jul 15, 2011
AB		WATSON LABS	**150MG**	**A075616**	**001**	Jul 09, 2002
AB	**!**		**300MG**	**A075616**	**002**	Jul 09, 2002

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

LEVOPHED						
AP	**+!**	HOSPIRA	**EQ 1MG BASE/ML**	**N007513**	**001**	
NOREPINEPHRINE BITARTRATE						
AP		AMNEAL	**EQ 1MG BASE/ML**	**A210839**	**001**	Dec 17, 2018
AP		BAXTER HLTHCARE CORP	**EQ 1MG BASE/ML**	**A040859**	**001**	Mar 27, 2012
AP		BRECKENRIDGE	**EQ 1MG BASE/ML**	**A214455**	**001**	Jan 22, 2021
AP		CAPLIN	**EQ 1MG BASE/ML**	**A217575**	**001**	Sep 15, 2023
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A211382**	**001**	Nov 03, 2020
AP		GLAND PHARMA LTD	**EQ 1MG BASE/ML**	**A214323**	**001**	May 06, 2021
AP		HIKMA	**EQ 1MG BASE/ML**	**A040462**	**001**	Oct 31, 2003
AP			**EQ 1MG BASE/ML**	**A203662**	**001**	Nov 07, 2018
AP		MEITHEAL	**EQ 1MG BASE/ML**	**A040455**	**001**	Mar 03, 2003
AP		MYLAN LABS LTD	**EQ 1MG BASE/ML**	**A211242**	**001**	Oct 04, 2018
AP		SANDOZ	**EQ 1MG BASE/ML**	**A211359**	**001**	Oct 18, 2018
AP		SUN PHARM	**EQ 1MG BASE/ML**	**A211980**	**001**	Jan 29, 2021

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE					
+!	INFORLIFE	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N215700	001	Sep 15, 2022
+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N215700	002	Sep 15, 2022
+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N215700	003	Sep 15, 2022
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE					
+!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021
+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021
+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214313	003	Nov 21, 2023

NORETHINDRONE

TABLET;ORAL-28

CAMILA						
AB1		DR REDDYS LABS SA	**0.35MG**	**A076177**	**001**	Oct 21, 2002
HEATHER						
AB1		GLENMARK GENERICS	**0.35MG**	**A090454**	**001**	Apr 23, 2010
INCASSIA						
AB1		AUROBINDO PHARMA	**0.35MG**	**A207304**	**001**	Sep 23, 2016
NOR-QD						
AB1	**+!**	TEVA BRANDED PHARM	**0.35MG**	**N017060**	**001**	
NORETHINDRONE						
AB1		LUPIN LTD	**0.35MG**	**A091325**	**001**	Sep 19, 2011
AB1		MYLAN LABS LTD	**0.35MG**	**A201483**	**001**	Jun 24, 2013
AB1		NAARI PTE LTD	**0.35MG**	**A206807**	**001**	Dec 13, 2016
AB1		NOVAST LABS	**0.35MG**	**A202014**	**001**	Sep 13, 2013
EMZAHH						
AB2		AUROBINDO PHARMA	**0.35MG**	**A216796**	**001**	Jan 06, 2023
ERRIN						
AB2		DR REDDYS LABS SA	**0.35MG**	**A076225**	**001**	Oct 21, 2002

NORETHINDRONE

TABLET;ORAL-28

JENCYCLA

AB2		LUPIN LTD	0.35MG	A091323	001	Mar 28, 2013

NORETHINDRONE

AB2		GLENMARK GENERICS	0.35MG	A091209	001	Jul 22, 2010
AB2	!	MYLAN LABS LTD	0.35MG	A200980	001	Jun 12, 2013
AB2		NOVAST LABS	0.35MG	A200961	001	Sep 13, 2013

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

AB		AMNEAL PHARMS	5MG	A200275	001	Jul 30, 2012
AB	!	BARR	5MG	A075951	001	May 25, 2001
AB		GLENMARK GENERICS	5MG	A091090	001	Jul 21, 2010
AB		MYLAN LABS LTD	5MG	A205278	001	Nov 10, 2016
AB		NOVAST LABS	5MG	A206490	001	Nov 05, 2018

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB		DR REDDYS LABS SA	EQ 10MG BASE	A073556	002	Mar 30, 1992
AB			EQ 25MG BASE	A073556	003	Mar 30, 1992
AB			EQ 50MG BASE	A073556	004	Mar 30, 1992
AB			EQ 75MG BASE	A073556	001	Mar 30, 1992
AB		TARO	EQ 10MG BASE	A075520	004	May 08, 2000
AB			EQ 25MG BASE	A075520	003	May 08, 2000
AB			EQ 50MG BASE	A075520	001	May 08, 2000
AB			EQ 75MG BASE	A075520	002	May 08, 2000
AB		TEVA	EQ 10MG BASE	A074132	001	Mar 27, 1995
AB			EQ 25MG BASE	A074132	002	Mar 27, 1995
AB			EQ 50MG BASE	A074132	003	Mar 27, 1995
AB			EQ 75MG BASE	A074132	004	Mar 27, 1995

PAMELOR

AB	+	SPECGX LLC	EQ 10MG BASE	N018013	001	
AB	+		EQ 25MG BASE	N018013	002	
AB	+		EQ 50MG BASE	N018013	004	
AB	+!		EQ 75MG BASE	N018013	003	

SOLUTION;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AA	!	PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 23, 2000
AA		RUBICON	EQ 10MG BASE/5ML	A217731	001	Aug 15, 2023

NUSINERSEN SODIUM

SOLUTION;INTRATHECAL

SPINRAZA

	+!	BIOGEN IDEC	EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)	N209531	001	Dec 23, 2016

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT		ACTAVIS MID ATLANTIC	100,000 UNITS/GM	A062949	001	Jun 13, 1988
AT		COSETTE	100,000 UNITS/GM	A061966	001	
AT		CROWN LABS INC	100,000 UNITS/GM	A207733	001	Sep 26, 2017
AT		FOUGERA PHARMS	100,000 UNITS/GM	A062129	001	
AT		MACLEODS PHARMS LTD	100,000 UNITS/GM	A213566	001	Aug 10, 2021
AT		PADAGIS US	100,000 UNITS/GM	A062225	001	
AT	!	TARO	100,000 UNITS/GM	A064022	001	Jan 29, 1993
AT		TORRENT	100,000 UNITS/GM	A212557	001	Jul 24, 2019

OINTMENT;TOPICAL

NYSTATIN

AT		ACTAVIS MID ATLANTIC	100,000 UNITS/GM	A062840	001	Nov 13, 1987
AT		CADILA	100,000 UNITS/GM	A207767	001	May 25, 2018
AT		COSETTE	100,000 UNITS/GM	A209114	001	Oct 06, 2017
AT	!	FOUGERA PHARMS	100,000 UNITS/GM	A062124	002	Sep 23, 1982
AT		LYNE	100,000 UNITS/GM	A209082	001	May 21, 2018
AT		MACLEODS PHARMS LTD	100,000 UNITS/GM	A213826	001	Jan 14, 2021
AT		PADAGIS US	100,000 UNITS/GM	A062472	001	Feb 13, 1984

POWDER;TOPICAL

NYSTATIN

AT		BEOWULF ASSET	100,000 UNITS/GM	A065175	001	Dec 17, 2004
AT	!	DR REDDYS LABS SA	100,000 UNITS/GM	A065203	001	Jul 15, 2004
AT		EPIC PHARMA LLC	100,000 UNITS/GM	A210532	001	Apr 30, 2018

NYSTATIN

POWDER;TOPICAL

NYSTATIN

AT		LUPIN	**100,000 UNITS/GM**	**A065138**	**001**	Jul 23, 2004
AT		LYNE	**100,000 UNITS/GM**	**A208838**	**001**	May 30, 2017
AT		UPSHER SMITH LABS	**100,000 UNITS/GM**	**A065183**	**001**	May 03, 2005
AT		ZYDUS PHARMS	**100,000 UNITS/GM**	**A208581**	**001**	Jun 08, 2017

NYSTOP

AT		PADAGIS US	**100,000 UNITS/GM**	**A064118**	**001**	Aug 16, 1996

SUSPENSION;ORAL

NYSTATIN

AA		FOUGERA PHARMS INC	**100,000 UNITS/ML**	**A062517**	**001**	Jun 07, 1984
AA		GENUS	**100,000 UNITS/ML**	**A065148**	**001**	Jun 28, 2005
AA		LEADING	**100,000 UNITS/ML**	**A214346**	**001**	Mar 10, 2022
AA		MLV	**100,000 UNITS/ML**	**A062832**	**001**	Dec 27, 1991
AA		PHARM ASSOC	**100,000 UNITS/ML**	**A203621**	**001**	Jan 07, 2016
AA		TARO	**100,000 UNITS/ML**	**A062876**	**001**	Feb 29, 1988
AA	!	WOCKHARDT BIO AG	**100,000 UNITS/ML**	**A062512**	**001**	Oct 29, 1984

TABLET;ORAL

NYSTATIN

AA		HERITAGE PHARMS	**500,000 UNITS**	**A062474**	**001**	Dec 22, 1983
AA		SUN PHARM INDUSTRIES	**500,000 UNITS**	**A062838**	**001**	Dec 22, 1988
AA	!	TEVA	**500,000 UNITS**	**A062506**	**001**	Jan 16, 1984

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

AT		COSETTE	**100,000 UNITS/GM;0.1%**	**A062367**	**001**	May 28, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		ALEMBIC	**100,000 UNITS/GM;0.1%**	**A214090**	**001**	Mar 31, 2021
AT		AMNEAL	**100,000 UNITS/GM;0.1%**	**A209990**	**001**	Feb 15, 2018
AT		CROWN LABS INC	**100,000 UNITS/GM;0.1%**	**A207730**	**001**	Dec 26, 2017
AT		DR REDDYS	**100,000 UNITS/GM;0.1%**	**A208326**	**001**	Oct 26, 2016
AT		FOUGERA PHARMS INC	**100,000 UNITS/GM;0.1%**	**A062599**	**001**	Oct 08, 1985
AT		GLENMARK PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A208136**	**001**	Oct 24, 2016
AT		LUPIN LTD	**100,000 UNITS/GM;0.1%**	**A208205**	**001**	May 31, 2018
AT		MACLEODS PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A214181**	**001**	Jul 13, 2022
AT		PADAGIS ISRAEL	**100,000 UNITS/GM;0.1%**	**A208479**	**001**	Aug 14, 2017
AT	!	TARO	**100,000 UNITS/GM;0.1%**	**A062364**	**001**	Dec 22, 1987

OINTMENT;TOPICAL

MYKACET

AT		COSETTE	**100,000 UNITS/GM;0.1%**	**A062733**	**001**	Mar 06, 1987

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		ALEMBIC	**100,000 UNITS/GM;0.1%**	**A214186**	**001**	Mar 04, 2022
AT		CADILA	**100,000 UNITS/GM;0.1%**	**A207764**	**001**	Nov 08, 2018
AT		DR REDDYS	**100,000 UNITS/GM;0.1%**	**A207741**	**001**	Jan 31, 2017
AT		EPIC PHARMA LLC	**100,000 UNITS/GM;0.1%**	**A207217**	**001**	Aug 04, 2017
AT		FOUGERA PHARMS INC	**100,000 UNITS/GM;0.1%**	**A062602**	**001**	Oct 09, 1985
AT		GLENMARK PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A208300**	**001**	Jun 23, 2016
AT		MACLEODS PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A214751**	**001**	Aug 17, 2021
AT		PADAGIS ISRAEL	**100,000 UNITS/GM;0.1%**	**A207380**	**001**	Dec 20, 2016
AT		RISING	**100,000 UNITS/GM;0.1%**	**A206785**	**001**	Dec 29, 2016
AT		STRIDES PHARMA	**100,000 UNITS/GM;0.1%**	**A210077**	**001**	Jan 29, 2018
AT	!	TARO	**100,000 UNITS/GM;0.1%**	**A063305**	**001**	Mar 29, 1993

OBETICHOLIC ACID

TABLET;ORAL

OCALIVA

	+	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016
	+!		10MG	N207999	002	May 27, 2016

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE;ORAL

MYCAPSSA

	+!	CHIESI	EQ 20MG BASE	N208232	001	Jun 26, 2020

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP		FRESENIUS KABI USA	**EQ 0.2MG BASE/ML**	**A077450**	**001**	Feb 10, 2006
AP			**EQ 1MG BASE/ML**	**A077450**	**002**	Feb 10, 2006
AP		GLAND PHARMA LTD	**EQ 0.1MG BASE/ML**	**A216839**	**002**	Jun 22, 2023
AP			**EQ 0.2MG BASE/ML**	**A216807**	**001**	Jun 13, 2023
AP			**EQ 0.5MG BASE/ML**	**A216839**	**001**	Jun 22, 2023

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP			**EQ 1MG BASE/ML**	**A216807**	**002**	Jun 13, 2023
AP		HERITAGE PHARMS	**EQ 0.05MG BASE/ML**	**A204669**	**001**	Dec 27, 2018
AP			**EQ 0.1MG BASE/ML**	**A204669**	**002**	Dec 27, 2018
AP			**EQ 0.2MG BASE/ML**	**A203765**	**001**	Sep 07, 2018
AP			**EQ 0.5MG BASE/ML**	**A204669**	**003**	Dec 27, 2018
AP			**EQ 1MG BASE/ML**	**A203765**	**002**	Sep 07, 2018
AP		MEITHEAL	**EQ 0.05MG BASE/ML**	**A075957**	**001**	Oct 03, 2005
AP			**EQ 0.1MG BASE/ML**	**A075957**	**002**	Oct 03, 2005
AP			**EQ 0.2MG BASE/ML**	**A075959**	**001**	Nov 21, 2005
AP			**EQ 0.5MG BASE/ML**	**A075957**	**003**	Oct 03, 2005
AP			**EQ 1MG BASE/ML**	**A075959**	**002**	Nov 21, 2005
AP		SAGENT PHARMS INC	**EQ 0.2MG BASE/ML**	**A091041**	**001**	Nov 12, 2013
AP			**EQ 1MG BASE/ML**	**A091041**	**002**	Nov 12, 2013
AP		TEVA PHARMS USA INC	**EQ 10MG BASE/VIAL**	**A210317**	**001**	Dec 05, 2023
AP			**EQ 20MG BASE/VIAL**	**A210317**	**002**	Dec 05, 2023
AP			**EQ 30MG BASE/VIAL**	**A210317**	**003**	Dec 05, 2023
AP	**!**	WEST-WARD PHARMS INT	**EQ 0.2MG BASE/ML**	**A076330**	**001**	Apr 08, 2005
AP	**!**		**EQ 1MG BASE/ML**	**A076330**	**002**	Apr 08, 2005

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP		FRESENIUS KABI USA	**EQ 0.05MG BASE/ML**	**A077457**	**001**	Feb 10, 2006
AP			**EQ 0.1MG BASE/ML**	**A077457**	**002**	Feb 10, 2006
AP			**EQ 0.5MG BASE/ML**	**A077457**	**003**	Feb 10, 2006
AP		MYLAN INSTITUTIONAL	**EQ 0.05MG BASE/ML**	**A079198**	**001**	Feb 10, 2011
AP			**EQ 0.1MG BASE/ML**	**A079198**	**002**	Feb 10, 2011
AP			**EQ 0.5MG BASE/ML**	**A079198**	**003**	Feb 10, 2011
AP		SAGENT PHARMS INC	**EQ 0.05MG BASE/ML**	**A090834**	**001**	Nov 12, 2013
AP			**EQ 0.1MG BASE/ML**	**A090834**	**002**	Nov 12, 2013
AP			**EQ 0.5MG BASE/ML**	**A090834**	**003**	Nov 12, 2013
AP	**!**	WEST-WARD PHARMS INT	**EQ 0.05MG BASE/ML**	**A076313**	**001**	Mar 28, 2005
AP	**!**		**EQ 0.1MG BASE/ML**	**A076313**	**003**	Mar 28, 2005
AP	**!**		**EQ 0.5MG BASE/ML**	**A076313**	**002**	Mar 28, 2005

SANDOSTATIN

AP	**+!**	NOVARTIS	**EQ 0.05MG BASE/ML**	**N019667**	**001**	Oct 21, 1988
AP	**+!**		**EQ 0.1MG BASE/ML**	**N019667**	**002**	Oct 21, 1988
AP	**+!**		**EQ 0.5MG BASE/ML**	**N019667**	**003**	Oct 21, 1988

SANDOSTATIN LAR

AP	**+**	NOVARTIS	**EQ 10MG BASE/VIAL**	**N021008**	**001**	Nov 25, 1998
AP	**+**		**EQ 20MG BASE/VIAL**	**N021008**	**002**	Nov 25, 1998
AP	**+!**		**EQ 30MG BASE/VIAL**	**N021008**	**003**	Nov 25, 1998

ODEVIXIBAT

CAPSULE;ORAL

BYLVAY

	+	ALBIREO	0.4MG	N215498	002	Jul 20, 2021
	+!		1.2MG	N215498	004	Jul 20, 2021

CAPSULE, PELLETS;ORAL

BYLVAY

	+	ALBIREO	0.2MG	N215498	001	Jul 20, 2021
	+!		0.6MG	N215498	003	Jul 20, 2021

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OCUFLOX

AT	**+!**	ALLERGAN	**0.3%**	**N019921**	**001**	Jul 30, 1993

OFLOXACIN

AT		ALTAIRE PHARMS INC	**0.3%**	**A202692**	**001**	Apr 29, 2013
AT		APOTEX INC	**0.3%**	**A076513**	**001**	May 14, 2004
AT		BAUSCH AND LOMB	**0.3%**	**A076622**	**001**	May 14, 2004
AT		FDC LTD	**0.3%**	**A078559**	**001**	Feb 25, 2009
AT		MANKIND PHARMA	**0.3%**	**A215886**	**001**	Nov 23, 2022
AT		SENTISS	**0.3%**	**A076407**	**001**	Apr 15, 2008

SOLUTION/DROPS;OTIC

OFLOXACIN

AT		AMNEAL	**0.3%**	**A211525**	**001**	Aug 30, 2019
AT		APOTEX INC	**0.3%**	**A076527**	**001**	Sep 28, 2007
AT	**!**	BAUSCH AND LOMB	**0.3%**	**A076128**	**001**	Mar 17, 2008
AT		CAPLIN	**0.3%**	**A217903**	**001**	Jan 05, 2024
AT		HIKMA	**0.3%**	**A076616**	**001**	Mar 17, 2008
AT		MANKIND PHARMA	**0.3%**	**A216130**	**001**	Jul 14, 2022

OFLOXACIN

TABLET;ORAL

OFLOXACIN

AB		CADILA PHARMS LTD	**200MG**	**A091656**	**001**	Sep 18, 2014
AB			**300MG**	**A091656**	**002**	Sep 18, 2014
AB			**400MG**	**A091656**	**003**	Sep 18, 2014
AB		DR REDDYS LABS LTD	**200MG**	**A077098**	**001**	Feb 10, 2006
AB			**300MG**	**A077098**	**002**	Feb 10, 2006
AB			**400MG**	**A077098**	**003**	Feb 10, 2006
AB		LARKEN LABS	**400MG**	**A076093**	**003**	Sep 02, 2003
AB		TEVA	**200MG**	**A076182**	**001**	Sep 02, 2003
AB			**300MG**	**A076182**	**002**	Sep 02, 2003
AB	**!**		**400MG**	**A076182**	**003**	Sep 02, 2003

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

OLANZAPINE

AP		AM REGENT	**10MG/VIAL**	**A201741**	**001**	Mar 20, 2012
AP		ASPIRO	**10MG/VIAL**	**A217466**	**001**	Mar 22, 2023
AP		EUGIA PHARMA	**10MG/VIAL**	**A210968**	**001**	Oct 22, 2020
AP		SANDOZ INC	**10MG/VIAL**	**A201588**	**001**	Oct 24, 2011

ZYPREXA

AP	**+!**	CHEPLAPHARM	**10MG/VIAL**	**N021253**	**001**	Mar 29, 2004

TABLET;ORAL

OLANZAPINE

AB		ALKEM LABS LTD	**2.5MG**	**A202295**	**001**	Oct 20, 2015
AB			**5MG**	**A202295**	**002**	Oct 20, 2015
AB			**7.5MG**	**A202295**	**003**	Oct 20, 2015
AB			**10MG**	**A202295**	**004**	Oct 20, 2015
AB			**15MG**	**A202295**	**005**	Oct 20, 2015
AB			**20MG**	**A202295**	**006**	Oct 20, 2015
AB		APOTEX INC	**2.5MG**	**A090798**	**001**	Apr 23, 2012
AB			**5MG**	**A090798**	**002**	Apr 23, 2012
AB			**7.5MG**	**A090798**	**003**	Apr 23, 2012
AB			**10MG**	**A090798**	**004**	Apr 23, 2012
AB			**15MG**	**A090798**	**005**	Apr 23, 2012
AB			**20MG**	**A090798**	**006**	Apr 23, 2012
AB		AUROBINDO PHARMA LTD	**2.5MG**	**A202050**	**001**	Apr 23, 2012
AB			**5MG**	**A202050**	**002**	Apr 23, 2012
AB			**7.5MG**	**A202050**	**003**	Apr 23, 2012
AB			**10MG**	**A202050**	**004**	Apr 23, 2012
AB			**15MG**	**A202050**	**005**	Apr 23, 2012
AB			**20MG**	**A202050**	**006**	Apr 23, 2012
AB		CADILA PHARMS LTD	**2.5MG**	**A210022**	**001**	Feb 24, 2023
AB			**5MG**	**A210022**	**002**	Feb 24, 2023
AB			**7.5MG**	**A210022**	**003**	Feb 24, 2023
AB			**10MG**	**A210022**	**004**	Feb 24, 2023
AB			**15MG**	**A210022**	**005**	Feb 24, 2023
AB			**20MG**	**A210022**	**006**	Feb 24, 2023
AB		CHARTWELL MOLECULAR	**2.5MG**	**A203333**	**001**	Mar 15, 2016
AB			**5MG**	**A203333**	**002**	Mar 15, 2016
AB			**7.5MG**	**A203333**	**003**	Mar 15, 2016
AB			**10MG**	**A203333**	**004**	Mar 15, 2016
AB			**15MG**	**A203333**	**005**	Mar 15, 2016
AB			**20MG**	**A203333**	**006**	Mar 15, 2016
AB		DR REDDYS LABS LTD	**2.5MG**	**A076255**	**001**	Apr 23, 2012
AB			**5MG**	**A076255**	**002**	Apr 23, 2012
AB			**7.5MG**	**A076255**	**003**	Apr 23, 2012
AB			**10MG**	**A076255**	**004**	Apr 23, 2012
AB			**15MG**	**A076133**	**001**	Apr 23, 2012
AB			**20MG**	**A076133**	**002**	Oct 24, 2011
AB		INDOCO	**2.5MG**	**A206155**	**001**	Jul 31, 2020
AB			**5MG**	**A206155**	**002**	Jul 31, 2020
AB			**7.5MG**	**A206155**	**003**	Jul 31, 2020
AB			**10MG**	**A206155**	**004**	Jul 31, 2020
AB			**15MG**	**A206155**	**005**	Jul 31, 2020
AB			**20MG**	**A206155**	**006**	Jul 31, 2020
AB		MACLEODS PHARMS LTD	**2.5MG**	**A202862**	**001**	Aug 15, 2014
AB			**5MG**	**A202862**	**002**	Aug 15, 2014
AB			**7.5MG**	**A202862**	**003**	Aug 15, 2014
AB			**10MG**	**A202862**	**004**	Aug 15, 2014
AB			**15MG**	**A202862**	**005**	Aug 15, 2014

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB			20MG	A202862	006	Aug 15, 2014
AB		ORBION PHARMS	2.5MG	A202287	001	Apr 23, 2012
AB			5MG	A202287	002	Apr 23, 2012
AB			7.5MG	A202287	003	Apr 23, 2012
AB			10MG	A202287	004	Apr 23, 2012
AB			15MG	A202287	005	Apr 23, 2012
AB			20MG	A202287	006	Apr 23, 2012
AB		QILU	2.5MG	A204319	001	Jan 27, 2016
AB			5MG	A204319	002	Jan 27, 2016
AB			7.5MG	A204319	003	Jan 27, 2016
AB			10MG	A204319	004	Jan 27, 2016
AB			15MG	A204319	005	Jan 27, 2016
AB			20MG	A204319	006	Jan 27, 2016
AB		SUN PHARM INDS	2.5MG	A091038	001	Apr 23, 2012
AB			5MG	A091038	002	Apr 23, 2012
AB			7.5MG	A091038	003	Apr 23, 2012
AB			10MG	A091038	004	Apr 23, 2012
AB			15MG	A091038	005	Apr 23, 2012
AB			20MG	A091038	006	Apr 23, 2012
AB		ZYDUS PHARMS	2.5MG	A090459	001	Jul 16, 2018
AB			5MG	A090459	002	Jul 16, 2018
AB			7.5MG	A090459	003	Jul 16, 2018
AB			10MG	A090459	004	Jul 16, 2018
AB			15MG	A090459	005	Jul 16, 2018
AB			20MG	A090459	006	Jul 16, 2018

ZYPREXA

AB	+	CHEPLAPHARM	2.5MG	N020592	001	Sep 30, 1996
AB	+!		5MG	N020592	002	Sep 30, 1996
AB	+		7.5MG	N020592	003	Sep 30, 1996
AB	+		10MG	N020592	004	Sep 30, 1996
AB	+		15MG	N020592	005	Sep 09, 1997
AB	+		20MG	N020592	006	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB		APOTEX INC	5MG	A091265	001	Oct 24, 2011
AB			10MG	A091265	002	Oct 24, 2011
AB			15MG	A091265	003	Oct 24, 2011
AB			20MG	A091265	004	Oct 24, 2011
AB		AUROBINDO PHARMA LTD	5MG	A203708	001	May 15, 2014
AB			10MG	A203708	002	May 15, 2014
AB			15MG	A203708	003	May 15, 2014
AB			20MG	A203708	004	May 15, 2014
AB		BARR LABS INC	5MG	A077243	001	Jan 30, 2012
AB			10MG	A077243	002	Jan 30, 2012
AB			15MG	A077243	003	Jan 30, 2012
AB			20MG	A077243	004	Jan 30, 2012
AB		CHARTWELL MOLECULAR	5MG	A203456	001	Mar 16, 2016
AB			10MG	A203456	002	Mar 16, 2016
AB			15MG	A203456	003	Mar 16, 2016
AB			20MG	A203456	004	Mar 16, 2016
AB		DR REDDYS LABS LTD	5MG	A076534	001	Oct 24, 2011
AB			10MG	A076534	002	Oct 24, 2011
AB			15MG	A076534	003	Oct 24, 2011
AB			20MG	A076534	004	Oct 24, 2011
AB		HEC PHARM	5MG	A208146	001	Jul 02, 2018
AB			10MG	A208146	002	Jul 02, 2018
AB			15MG	A208146	003	Jul 02, 2018
AB			20MG	A208146	004	Jul 02, 2018
AB		HISUN PHARM HANGZHOU	5MG	A206892	001	Dec 31, 2020
AB			10MG	A206892	002	Dec 31, 2020
AB			15MG	A206892	003	Dec 31, 2020
AB			20MG	A206892	004	Dec 31, 2020
AB		JUBILANT GENERICS	5MG	A200221	001	Sep 12, 2012
AB			10MG	A200221	002	Sep 12, 2012
AB			15MG	A200221	003	Sep 12, 2012
AB			20MG	A200221	004	Sep 12, 2012
AB		MACLEODS PHARMS LTD	5MG	A203044	001	Feb 20, 2015
AB			10MG	A203044	002	Feb 20, 2015

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB			**15MG**	**A203044**	**003**	Feb 20, 2015
AB			**20MG**	**A203044**	**004**	Feb 20, 2015
AB		MYLAN	**5MG**	**A202285**	**001**	May 12, 2014
AB			**10MG**	**A202285**	**002**	May 12, 2014
AB			**15MG**	**A202285**	**003**	May 12, 2014
AB			**20MG**	**A202285**	**004**	May 12, 2014
AB		ORBION PHARMS	**5MG**	**A202937**	**001**	Mar 02, 2015
AB			**10MG**	**A202937**	**002**	Mar 02, 2015
AB			**15MG**	**A202937**	**003**	Mar 02, 2015
AB			**20MG**	**A202937**	**004**	Mar 02, 2015
AB		STRIDES PHARMA	**5MG**	**A078109**	**001**	Oct 24, 2011
AB			**10MG**	**A078109**	**002**	Oct 24, 2011
AB			**15MG**	**A078109**	**003**	Oct 24, 2011
AB			**20MG**	**A078109**	**004**	Oct 24, 2011
AB		SUN PHARM INDS	**5MG**	**A090881**	**001**	Feb 28, 2012
AB			**10MG**	**A090881**	**002**	Feb 28, 2012
AB			**15MG**	**A090881**	**003**	Feb 28, 2012
AB			**20MG**	**A090881**	**004**	Feb 28, 2012
AB		TORRENT	**5MG**	**A091415**	**001**	Oct 25, 2011
AB			**10MG**	**A091415**	**002**	Oct 25, 2011
AB			**15MG**	**A091415**	**003**	Oct 25, 2011
AB			**20MG**	**A091415**	**004**	Oct 25, 2011

ZYPREXA ZYDIS

AB	**+!**	CHEPLAPHARM	**5MG**	**N021086**	**001**	Apr 06, 2000
AB	**+**		**10MG**	**N021086**	**002**	Apr 06, 2000
AB	**+**		**15MG**	**N021086**	**003**	Apr 06, 2000
AB	**+**		**20MG**	**N021086**	**004**	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV

+	CHEPLAPHARM	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009
+		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009
+!		EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009

OLANZAPINE; SAMIDORPHAN L-MALATE

TABLET;ORAL

LYBALVI

+!	ALKERMES INC	5MG;EQ 10MG BASE	N213378	001	May 28, 2021
+		10MG;EQ 10MG BASE	N213378	002	May 28, 2021
+		15MG;EQ 10MG BASE	N213378	003	May 28, 2021
+		20MG;EQ 10MG BASE	N213378	004	May 28, 2021

OLAPARIB

TABLET;ORAL

LYNPARZA

+	ASTRAZENECA	100MG	N208558	001	Aug 17, 2017
+!		150MG	N208558	002	Aug 17, 2017

OLICERIDINE

SOLUTION;INTRAVENOUS

OLINVYK

+!	TREVENA	1MG/ML (1MG/ML)	N210730	001	Oct 30, 2020
+!		2MG/2ML (1MG/ML)	N210730	002	Oct 30, 2020
+!		30MG/30ML (1MG/ML)	N210730	003	Oct 30, 2020

OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

CLINOLIPID 20%

+!	BAXTER HLTHCARE CORP	16%(160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013

OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR

AB	**+**	COSETTE	**5MG**	**N021286**	**001**	Apr 25, 2002
AB	**+**		**20MG**	**N021286**	**003**	Apr 25, 2002
AB	**+!**		**40MG**	**N021286**	**004**	Apr 25, 2002

OLMESARTAN MEDOXOMIL

AB		ACCORD HLTHCARE	**5MG**	**A207662**	**001**	Apr 24, 2017
AB			**20MG**	**A207662**	**002**	Apr 24, 2017
AB			**40MG**	**A207662**	**003**	Apr 24, 2017
AB		ALEMBIC	**5MG**	**A203012**	**001**	Apr 24, 2017

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB			**20MG**	**A203012**	**002**	Apr 24, 2017
AB			**40MG**	**A203012**	**003**	Apr 24, 2017
AB		ALKEM LABS LTD	**5MG**	**A206763**	**001**	Apr 24, 2017
AB			**20MG**	**A206763**	**002**	Apr 24, 2017
AB			**40MG**	**A206763**	**003**	Apr 24, 2017
AB		AUROBINDO PHARMA	**5MG**	**A204798**	**001**	Apr 24, 2017
AB			**20MG**	**A204798**	**002**	Apr 24, 2017
AB			**40MG**	**A204798**	**003**	Apr 24, 2017
AB		GLENMARK PHARMS LTD	**5MG**	**A203281**	**001**	May 25, 2017
AB			**20MG**	**A203281**	**002**	May 25, 2017
AB			**40MG**	**A203281**	**003**	May 25, 2017
AB		MACLEODS PHARMS LTD	**5MG**	**A204814**	**001**	Apr 24, 2017
AB			**20MG**	**A204814**	**002**	Apr 24, 2017
AB			**40MG**	**A204814**	**003**	Apr 24, 2017
AB		MICRO LABS	**5MG**	**A206372**	**001**	Sep 17, 2019
AB			**20MG**	**A206372**	**002**	Sep 17, 2019
AB			**40MG**	**A206372**	**003**	Sep 17, 2019
AB		MSN	**5MG**	**A217399**	**001**	Jan 18, 2023
AB			**20MG**	**A217399**	**002**	Jan 18, 2023
AB			**40MG**	**A217399**	**003**	Jan 18, 2023
AB		PRINSTON INC	**5MG**	**A206720**	**001**	Dec 02, 2022
AB			**20MG**	**A206720**	**002**	Dec 02, 2022
AB			**40MG**	**A206720**	**003**	Dec 02, 2022
AB		QILU	**5MG**	**A210552**	**001**	Jan 10, 2019
AB			**20MG**	**A210552**	**002**	Jan 10, 2019
AB			**40MG**	**A210552**	**003**	Jan 10, 2019
AB		SCIEGEN PHARMS INC	**5MG**	**A208130**	**001**	Jun 29, 2018
AB			**20MG**	**A208130**	**002**	Jun 29, 2018
AB			**40MG**	**A208130**	**003**	Jun 29, 2018
AB		SUNSHINE	**5MG**	**A211049**	**001**	Feb 22, 2019
AB			**20MG**	**A211049**	**002**	Feb 22, 2019
AB			**40MG**	**A211049**	**003**	Feb 22, 2019
AB		UMEDICA	**5MG**	**A207135**	**001**	Jul 18, 2019
AB			**20MG**	**A207135**	**002**	Jul 18, 2019
AB			**40MG**	**A207135**	**003**	Jul 18, 2019
AB		ZYDUS PHARMS	**5MG**	**A205192**	**001**	Apr 24, 2017
AB			**20MG**	**A205192**	**002**	Apr 24, 2017
AB			**40MG**	**A205192**	**003**	Apr 24, 2017

OLODATEROL HYDROCHLORIDE

SPRAY, METERED;INHALATION

STRIVERDI RESPIMAT

+!	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH	N203108	001	Jul 31, 2014

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION

STIOLTO RESPIMAT

+!	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

AB	**!**	AMNEAL	**0.665MG/SPRAY**	**A210901**	**001**	Jan 28, 2020
AB		APOTEX INC	**0.665MG/SPRAY**	**A091572**	**001**	Oct 08, 2014
AB		HIKMA	**0.665MG/SPRAY**	**A213757**	**001**	Aug 19, 2020
AB		PADAGIS ISRAEL	**0.665MG/SPRAY**	**A202853**	**001**	Jan 31, 2017

OLSALAZINE SODIUM

CAPSULE;ORAL

DIPENTUM

+!	MYLAN SPCLT VIATRIS	250MG	N019715	001	Jul 31, 1990

OLUTASIDENIB
CAPSULE;ORAL
REZLIDHIA
+! RIGEL PHARMS INC 150MG N215814 001 Dec 01, 2022

OMACETAXINE MEPESUCCINATE
POWDER;SUBCUTANEOUS
SYNRIBO
+! TEVA PHARMS INTL 3.5MG/VIAL N203585 001 Oct 26, 2012

OMADACYCLINE TOSYLATE
POWDER;INTRAVENOUS
NUZYRA
+! PARATEK PHARMS INC EQ 100MG BASE/VIAL N209817 001 Oct 02, 2018
TABLET;ORAL
NUZYRA
+! PARATEK PHARMS INC EQ 150MG BASE N209816 001 Oct 02, 2018

OMAVELOXOLONE
CAPSULE;ORAL
SKYCLARYS
+! REATA PHARMS 50MG N216718 001 Feb 28, 2023

OMEGA-3-ACID ETHYL ESTERS
CAPSULE;ORAL
LOVAZA

AB	**+!**	WOODWARD	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**N021654**	**001**	Nov 10, 2004

OMEGA-3-ACID ETHYL ESTERS

AB		AMNEAL PHARMS	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A204940**	**001**	Nov 27, 2015
AB		APOTEX	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A090973**	**001**	Sep 30, 2014
AB		ASCENT PHARMS INC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A207420**	**001**	Feb 25, 2019
AB		BIONPHARMA	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A206455**	**001**	Aug 07, 2019
AB		CSPC-NBP PHARM	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A211979**	**001**	May 12, 2020
AB		GLW	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A091028**	**001**	Apr 07, 2014
AB			**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A212504**	**001**	Aug 19, 2020
AB		MANKIND PHARMA	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A215458**	**001**	Nov 15, 2021
AB		PURACAP PHARM LLC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A210093**	**001**	Jun 15, 2020
AB		SLAYBACK PHARMA LLC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A211345**	**001**	Dec 07, 2023
AB		SOFGEN PHARMS	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A211355**	**001**	Jul 10, 2019
AB		STRIDES PHARMA	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A203893**	**001**	Sep 19, 2017
AB		SUN PHARM	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A210834**	**001**	Jan 09, 2020

OMEPRAZOLE
CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB		ACTAVIS LABS FL INC	**10MG**	**A075347**	**001**	May 30, 2008
AB			**20MG**	**A075347**	**002**	May 30, 2008
AB			**40MG**	**A075347**	**003**	May 30, 2008
AB		APOTEX	**10MG**	**A076048**	**001**	Oct 22, 2007
AB			**20MG**	**A076048**	**002**	Oct 22, 2007
AB			**40MG**	**A076048**	**003**	Jan 21, 2009
AB		AUROBINDO PHARMA	**10MG**	**A203270**	**001**	Aug 19, 2015
AB			**20MG**	**A203270**	**002**	Aug 19, 2015
AB			**40MG**	**A203270**	**003**	Aug 19, 2015
AB		BRECKENRIDGE	**10MG**	**A203481**	**001**	Jul 03, 2017
AB			**20MG**	**A203481**	**002**	Jul 03, 2017
AB			**40MG**	**A203481**	**003**	Jul 03, 2017
AB		DR REDDYS LABS LTD	**10MG**	**A075576**	**003**	Oct 22, 2007
AB			**10MG**	**A078490**	**002**	Mar 16, 2009
AB			**20MG**	**A075576**	**002**	Oct 22, 2007
AB			**20MG**	**A078490**	**003**	Mar 16, 2009
AB			**40MG**	**A075576**	**001**	Jan 21, 2009
AB			**40MG**	**A078490**	**001**	Apr 17, 2009
AB		GLENMARK GENERICS	**10MG**	**A091672**	**001**	Oct 31, 2014

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB			**20MG**	**A091672**	**002**	Oct 31, 2014
AB			**40MG**	**A091672**	**003**	Oct 31, 2014
AB		HETERO LABS LTD III	**10MG**	**A204012**	**001**	Sep 26, 2019
AB			**20MG**	**A204012**	**002**	Sep 26, 2019
AB		IMPAX LABS	**10MG**	**A075785**	**001**	Oct 22, 2007
AB			**20MG**	**A075785**	**002**	Oct 22, 2007
AB			**40MG**	**A075785**	**003**	Jan 21, 2009
AB		LANNETT CO INC	**10MG**	**A075410**	**001**	Nov 01, 2002
AB			**20MG**	**A075410**	**002**	Nov 01, 2002
AB			**40MG**	**A075410**	**003**	Jan 23, 2009
AB		SANDOZ	**10MG**	**A075757**	**001**	Jan 28, 2003
AB	**!**		**20MG**	**A075757**	**002**	Jan 28, 2003
AB	**!**		**40MG**	**A076515**	**001**	Jan 21, 2009
AB		TEVA PHARMS USA	**20MG**	**A204661**	**001**	Jun 13, 2017
AB		XIROMED	**10MG**	**A212977**	**001**	Dec 10, 2020
AB			**20MG**	**A212977**	**002**	Dec 10, 2020
AB		ZYDUS PHARMS USA INC	**10MG**	**A091352**	**001**	Nov 19, 2012
AB			**20MG**	**A091352**	**002**	Nov 19, 2012
AB			**40MG**	**A091352**	**003**	Nov 19, 2012

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

	+	COVIS	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008
	+!		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	**20MG;1.1GM**	**A204228**	**001**	Jul 15, 2016
AB			**40MG;1.1GM**	**A204228**	**002**	Jul 15, 2016
AB		ANDA REPOSITORY	**20MG;1.1GM**	**A212587**	**001**	Apr 30, 2020
AB			**40MG;1.1GM**	**A212587**	**002**	Apr 30, 2020
AB		AUROLIFE PHARMA LLC	**20MG;1.1GM**	**A204922**	**001**	Aug 19, 2016
AB			**40MG;1.1GM**	**A204922**	**002**	Aug 19, 2016
AB		DR REDDYS	**20MG;1.1GM**	**A204068**	**001**	Jul 15, 2016
AB			**40MG;1.1GM**	**A204068**	**002**	Jul 15, 2016
AB		SCIEGEN PHARMS INC	**20MG;1.1GM**	**A207476**	**001**	Dec 06, 2016
AB			**40MG;1.1GM**	**A207476**	**002**	Dec 06, 2016
AB		ZYDUS PHARMS	**20MG;1.1GM**	**A203290**	**001**	May 25, 2018
AB			**40MG;1.1GM**	**A203290**	**002**	May 25, 2018

ZEGERID

AB	**+**	SALIX	**20MG;1.1GM**	**N021849**	**001**	Feb 27, 2006
AB	**+!**		**40MG;1.1GM**	**N021849**	**002**	Feb 27, 2006

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	**20MG/PACKET;1.68GM/PACKET**	**A205545**	**001**	Jul 27, 2016
AB			**40MG/PACKET;1.68GM/PACKET**	**A205545**	**002**	Jul 27, 2016
AB		STRIDES PHARMA	**20MG/PACKET;1.68GM/PACKET**	**A079182**	**001**	Apr 19, 2013
AB			**40MG/PACKET;1.68GM/PACKET**	**A079182**	**002**	Apr 19, 2013

ZEGERID

AB	**+**	SALIX	**20MG/PACKET;1.68GM/PACKET**	**N021636**	**001**	Jun 15, 2004
AB	**+!**		**40MG/PACKET;1.68GM/PACKET**	**N021636**	**002**	Dec 21, 2004

KONVOMEP

	+!	AZURITY	2MG/ML;84MG/ML	N213593	001	Aug 30, 2022

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB		AUROBINDO PHARMA	**4MG**	**A090469**	**001**	Apr 12, 2010
AB	**!**		**8MG**	**A090469**	**002**	Apr 12, 2010
AB		CHARTWELL MOLECULES	**4MG**	**A077406**	**003**	Dec 26, 2006
AB			**8MG**	**A077406**	**004**	Dec 26, 2006
AB		GLENMARK GENERICS	**4MG**	**A078152**	**001**	Jun 27, 2007
AB			**8MG**	**A078152**	**002**	Jun 27, 2007
AB		IPCA LABS LTD	**4MG**	**A209389**	**001**	Oct 30, 2023
AB			**8MG**	**A209389**	**002**	Oct 30, 2023
AB		MYLAN	**4MG**	**A078139**	**001**	Jun 25, 2007
AB			**8MG**	**A078139**	**002**	Jun 25, 2007
AB		SANDOZ	**4MG**	**A078050**	**001**	Aug 13, 2007

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB			**8MG**	**A078050**	**002**	Aug 13, 2007
AB		SUN PHARM INDS	**4MG**	**A077557**	**001**	Aug 02, 2007
AB			**8MG**	**A077557**	**002**	Aug 02, 2007
AB		SUN PHARM INDS LTD	**4MG**	**A078602**	**001**	Feb 24, 2011
AB			**8MG**	**A078602**	**002**	Feb 24, 2011
	!	CHARTWELL MOLECULES	16MG	A077406	001	Dec 26, 2006
	!		24MG	A077406	002	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 2MG BASE/ML**	**A206846**	**001**	Jul 13, 2015
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A076974**	**001**	Dec 26, 2006
AP		GLAND PHARMA LTD	**EQ 2MG BASE/ML**	**A079224**	**001**	Sep 25, 2009
AP	**!**		**EQ 2MG BASE/ML**	**A090648**	**001**	Jun 15, 2012
AP		HIKMA	**EQ 2MG BASE/ML**	**A076967**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A077365**	**001**	Dec 26, 2006
AP		HIKMA FARMACEUTICA	**EQ 2MG BASE/ML**	**A076781**	**001**	Dec 26, 2006
AP		HOSPIRA	**EQ 2MG BASE/ML**	**A077473**	**001**	Dec 26, 2006
AP	**!**	QILU PHARM HAINAN	**EQ 2MG BASE/ML**	**A203711**	**001**	Sep 08, 2014
AP		SANDOZ	**EQ 2MG BASE/ML**	**A077430**	**001**	Jun 27, 2007
AP		WOCKHARDT	**EQ 2MG BASE/ML**	**A077577**	**001**	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		ACCORD HLTHCARE	**EQ 2MG BASE/ML**	**A206845**	**001**	Mar 10, 2016
AP	**!**	BAXTER HLTHCARE CORP	**EQ 2MG BASE/ML**	**A078287**	**001**	Feb 22, 2013
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A076972**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A202253**	**001**	Jul 19, 2013
AP		HIKMA	**EQ 2MG BASE/ML**	**A077011**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A077541**	**001**	Dec 26, 2006
AP		HOSPIRA	**EQ 2MG BASE/ML**	**A077548**	**001**	Dec 26, 2006
AP		SANDOZ	**EQ 2MG BASE/ML**	**A077551**	**001**	Jun 27, 2007
AP		WOCKHARDT	**EQ 2MG BASE/ML**	**A077716**	**001**	Dec 26, 2006

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

AA		AMNEAL PHARMS	**EQ 4MG BASE/5ML**	**A091483**	**001**	Jan 31, 2011
AA		AUROBINDO PHARMA	**EQ 4MG BASE/5ML**	**A078776**	**001**	Nov 28, 2007
AA		CHARTWELL MOLECULAR	**EQ 4MG BASE/5ML**	**A091342**	**001**	Jan 27, 2011
AA	**!**	HIKMA	**EQ 4MG BASE/5ML**	**A076960**	**001**	Dec 26, 2006
AA		PHARM ASSOC	**EQ 4MG BASE/5ML**	**A078127**	**001**	Jun 25, 2007
AA		TARO	**EQ 4MG BASE/5ML**	**A077009**	**001**	Nov 30, 2007

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

AB		APOTEX	**EQ 4MG BASE**	**A077306**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077306**	**002**	Jun 25, 2007
AB		AUROBINDO PHARMA	**EQ 4MG BASE**	**A078539**	**001**	Jul 31, 2007
AB			**EQ 8MG BASE**	**A078539**	**002**	Jul 31, 2007
AB		CHARTWELL MOLECULES	**EQ 4MG BASE**	**A077303**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077303**	**002**	Jun 25, 2007
AB		DR REDDYS LABS LTD	**EQ 4MG BASE**	**A076183**	**003**	Dec 26, 2006
AB			**EQ 8MG BASE**	**A076183**	**002**	Dec 26, 2006
AB		GLENMARK GENERICS	**EQ 4MG BASE**	**A077535**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077535**	**002**	Jun 25, 2007
AB		IPCA LABS LTD	**EQ 4MG BASE**	**A203761**	**001**	Jan 23, 2014
AB			**EQ 8MG BASE**	**A203761**	**002**	Jan 23, 2014
AB		NATCO PHARMA LTD	**EQ 4MG BASE**	**A077851**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077851**	**002**	Jun 25, 2007
AB		SUN PHARM INDS (IN)	**EQ 4MG BASE**	**A077050**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077050**	**002**	Jun 25, 2007
	!	CHARTWELL MOLECULES	EQ 24MG BASE	A077303	004	Jun 25, 2007

OPICAPONE

CAPSULE;ORAL

ONGENTYS

	+	NEUROCRINE	25MG	N212489	001	Apr 24, 2020
	+!		50MG	N212489	002	Apr 24, 2020

ORITAVANCIN DIPHOSPHATE

POWDER;INTRAVENOUS

KIMYRSA

+!	MELINTA THERAP	EQ 1.2GM BASE/VIAL	N214155	001	Mar 12, 2021

ORBACTIV

+!	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014

ORLISTAT

CAPSULE;ORAL

XENICAL

+!	CHEPLAPHARM	120MG	N020766	001	Apr 23, 1999

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

ORPHENADRINE CITRATE

AP	HIKMA	**30MG/ML**	**A040463**	**001**	Mar 04, 2003
AP !	RISING	**30MG/ML**	**A040484**	**001**	May 24, 2006
AP	SAGENT PHARMS	**30MG/ML**	**A090585**	**001**	Aug 30, 2011
AP	WATSON LABS	**30MG/ML**	**A084779**	**001**	Mar 15, 1982

TABLET, EXTENDED RELEASE;ORAL

ORPHENADRINE CITRATE

AB	BAYSHORE PHARMS LLC	**100MG**	**A091158**	**001**	Jul 27, 2012
AB !	LUPIN	**100MG**	**A040284**	**001**	Jun 19, 1998
AB	RISING	**100MG**	**A040249**	**001**	Jan 29, 1999
AB	SANDOZ	**100MG**	**A040327**	**001**	Feb 15, 2000

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	ALEMBIC	**EQ 30MG BASE**	**A211823**	**001**	Jun 24, 2019
AB		**EQ 45MG BASE**	**A211823**	**002**	Jun 24, 2019
AB		**EQ 75MG BASE**	**A211823**	**003**	Jun 24, 2019
AB	AMNEAL PHARMS	**EQ 30MG BASE**	**A209093**	**001**	May 17, 2017
AB		**EQ 45MG BASE**	**A209093**	**002**	May 17, 2017
AB		**EQ 75MG BASE**	**A209093**	**003**	May 17, 2017
AB	EPIC PHARMA LLC	**EQ 30MG BASE**	**A215208**	**001**	Oct 01, 2021
AB		**EQ 45MG BASE**	**A215208**	**002**	Oct 01, 2021
AB		**EQ 75MG BASE**	**A215208**	**003**	Oct 01, 2021
AB	HAINAN POLY	**EQ 75MG BASE**	**A218009**	**001**	Nov 24, 2023
AB	HETERO LABS LTD III	**EQ 30MG BASE**	**A209438**	**001**	Feb 23, 2018
AB		**EQ 45MG BASE**	**A209438**	**002**	Feb 23, 2018
AB		**EQ 75MG BASE**	**A209438**	**003**	Feb 23, 2018
AB	INVAGEN PHARMS	**EQ 30MG BASE**	**A217467**	**001**	Oct 03, 2023
AB		**EQ 45MG BASE**	**A217467**	**002**	Oct 03, 2023
AB		**EQ 75MG BASE**	**A217467**	**003**	Oct 03, 2023
AB	LUPIN	**EQ 30MG BASE**	**A208348**	**001**	Jan 09, 2018
AB		**EQ 45MG BASE**	**A208348**	**002**	Jan 09, 2018
AB		**EQ 75MG BASE**	**A208348**	**003**	Jan 09, 2018
AB	MACLEODS PHARMS LTD	**EQ 30MG BASE**	**A207211**	**001**	Sep 14, 2017
AB		**EQ 45MG BASE**	**A207211**	**002**	Sep 14, 2017
AB		**EQ 75MG BASE**	**A207211**	**003**	Sep 14, 2017
AB	MSN	**EQ 30MG BASE**	**A212544**	**001**	May 20, 2020
AB		**EQ 45MG BASE**	**A212544**	**002**	May 20, 2020
AB		**EQ 75MG BASE**	**A212544**	**003**	May 20, 2020
AB	NATCO	**EQ 30MG BASE**	**A202595**	**001**	Aug 03, 2016
AB		**EQ 45MG BASE**	**A202595**	**002**	Aug 03, 2016
AB		**EQ 75MG BASE**	**A202595**	**003**	Aug 03, 2016
AB	STRIDES PHARMA	**EQ 30MG BASE**	**A209421**	**001**	Jun 08, 2018
AB		**EQ 45MG BASE**	**A209421**	**002**	Jun 08, 2018
AB		**EQ 75MG BASE**	**A209421**	**003**	Jun 08, 2018
AB	SUNSHINE	**EQ 30MG BASE**	**A212739**	**001**	Mar 04, 2020
AB		**EQ 45MG BASE**	**A212739**	**002**	Mar 04, 2020
AB		**EQ 75MG BASE**	**A212739**	**003**	Mar 04, 2020
AB	ZYDUS PHARMS	**EQ 30MG BASE**	**A208578**	**001**	Feb 24, 2017
AB		**EQ 45MG BASE**	**A208578**	**002**	Feb 24, 2017
AB		**EQ 75MG BASE**	**A208578**	**003**	Feb 24, 2017

TAMIFLU

AB +	ROCHE	**EQ 30MG BASE**	**N021087**	**003**	Jul 02, 2007
AB +		**EQ 45MG BASE**	**N021087**	**002**	Jul 02, 2007
AB +!		**EQ 75MG BASE**	**N021087**	**001**	Oct 27, 1999

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	AJANTA PHARMA LTD	**EQ 6MG BASE/ML**	**A212784**	**001**	May 27, 2020
AB	ALVOGEN	**EQ 6MG BASE/ML**	**A208823**	**001**	Oct 31, 2017

OSELTAMIVIR PHOSPHATE
FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE

AB		AMNEAL PHARMS NY	**EQ 6MG BASE/ML**	**A210186**	**001**	Feb 27, 2018
AB		APTAPHARMA INC	**EQ 6MG BASE/ML**	**A212858**	**001**	Aug 30, 2021
AB		EPIC PHARMA LLC	**EQ 6MG BASE/ML**	**A215538**	**001**	Feb 14, 2023
AB		HETERO LABS LTD V	**EQ 6MG BASE/ML**	**A209590**	**001**	Mar 28, 2022
AB		LUPIN	**EQ 6MG BASE/ML**	**A208347**	**001**	Feb 20, 2018
AB		MSN	**EQ 6MG BASE/ML**	**A215313**	**001**	May 02, 2022
AB		STRIDES PHARMA	**EQ 6MG BASE/ML**	**A211894**	**001**	Jan 13, 2022
AB		SUNSHINE	**EQ 6MG BASE/ML**	**A213594**	**001**	Jan 05, 2022
AB		TEVA PHARMS USA	**EQ 6MG BASE/ML**	**A211125**	**001**	Feb 27, 2019
AB		ZYDUS PHARMS	**EQ 6MG BASE/ML**	**A209113**	**001**	Sep 14, 2017

TAMIFLU

AB	**+!**	ROCHE	**EQ 6MG BASE/ML**	**N021246**	**002**	Mar 21, 2011

OSILODROSTAT PHOSPHATE
TABLET;ORAL
ISTURISA

+		RECORDATI RARE	EQ 1MG BASE	N212801	001 Mar 06, 2020
+			EQ 5MG BASE	N212801	002 Mar 06, 2020

OSIMERTINIB MESYLATE
TABLET;ORAL
TAGRISSO

+		ASTRAZENECA	EQ 40MG BASE	N208065	001 Nov 13, 2015
+!			EQ 80MG BASE	N208065	002 Nov 13, 2015

OSPEMIFENE
TABLET;ORAL
OSPHENA

+!		DUCHESNAY	60MG	N203505	001 Feb 26, 2013

OTESECONAZOLE
CAPSULE;ORAL
VIVJOA

+!		MYCOVIA PHARMS	150MG	N215888	001 Apr 26, 2022

OXACILLIN SODIUM
INJECTABLE;INJECTION
OXACILLIN SODIUM

AP		EUGIA PHARMA SPECLTS	**EQ 1GM BASE/VIAL**	**A201539**	**001**	Jan 18, 2013
AP			**EQ 2GM BASE/VIAL**	**A201539**	**002**	Jan 18, 2013
AP			**EQ 10GM BASE/VIAL**	**A201538**	**001**	Jan 18, 2013
AP		FRESENIUS KABI USA	**EQ 1GM BASE/VIAL**	**A206198**	**001**	Jul 20, 2020
AP			**EQ 2GM BASE/VIAL**	**A206198**	**002**	Jul 20, 2020
AP			**EQ 10GM BASE/VIAL**	**A206199**	**001**	Jul 27, 2020
AP	**!**	SAGENT PHARMS	**EQ 1GM BASE/VIAL**	**A091246**	**001**	Mar 30, 2012
AP	**!**		**EQ 2GM BASE/VIAL**	**A091246**	**002**	Mar 30, 2012
AP	**!**		**EQ 10GM BASE/VIAL**	**A091245**	**001**	Mar 30, 2012
AP		STERISCIENCE	**EQ 2GM BASE/VIAL**	**A091486**	**002**	Aug 25, 2014
AP		WOCKHARDT BIO AG	**EQ 1GM BASE/VIAL**	**A207147**	**001**	Jul 31, 2017
AP			**EQ 2GM BASE/VIAL**	**A207147**	**002**	Jul 31, 2017
AP			**EQ 10GM BASE/VIAL**	**A207148**	**001**	Nov 24, 2017

BACTOCILL IN PLASTIC CONTAINER

+!		BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640	001 Oct 26, 1989
+!			EQ 40MG BASE/ML	N050640	002 Oct 26, 1989

OXALIPLATIN
INJECTABLE;INTRAVENOUS
ELOXATIN

AP	**+!**	SANOFI AVENTIS US	**50MG/10ML (5MG/ML)**	**N021759**	**001**	Jan 31, 2005
AP	**+!**		**100MG/20ML (5MG/ML)**	**N021759**	**002**	Jan 31, 2005

OXALIPLATIN

AP		ACCORD HLTHCARE	**50MG/10ML (5MG/ML)**	**A207474**	**001**	Mar 21, 2017
AP			**100MG/20ML (5MG/ML)**	**A207474**	**002**	Mar 21, 2017
AP		ACTAVIS	**50MG/10ML (5MG/ML)**	**A204880**	**001**	Mar 05, 2018
AP			**100MG/20ML (5MG/ML)**	**A204880**	**002**	Mar 05, 2018
AP	**!**	ACTAVIS TOTOWA	**50MG/VIAL**	**A078803**	**001**	Aug 08, 2012
AP	**!**		**100MG/VIAL**	**A078803**	**002**	Aug 08, 2012
AP		EUGIA PHARMA	**50MG/10ML (5MG/ML)**	**A205529**	**001**	Sep 06, 2017
AP			**100MG/20ML (5MG/ML)**	**A205529**	**002**	Sep 06, 2017
AP		FRESENIUS KABI USA	**50MG/10ML (5MG/ML)**	**A078811**	**001**	Jun 10, 2010
AP			**100MG/20ML (5MG/ML)**	**A078811**	**002**	Jun 10, 2010
AP			**50MG/VIAL**	**A078819**	**001**	Jun 02, 2010

OXALIPLATIN
INJECTABLE;INTRAVENOUS
OXALIPLATIN

AP			**50MG/10ML (5MG/ML)**	**A090030**	**001**	Jan 31, 2017
AP			**100MG/VIAL**	**A078819**	**002**	Jun 02, 2010
AP			**100MG/20ML (5MG/ML)**	**A090030**	**002**	Jan 31, 2017
AP		GLAND	**50MG/10ML (5MG/ML)**	**A207325**	**001**	Feb 10, 2017
AP			**100MG/20ML (5MG/ML)**	**A207325**	**002**	Feb 10, 2017
AP		GLAND PHARMA LTD	**50MG/VIAL**	**A207385**	**001**	May 23, 2017
AP			**100MG/VIAL**	**A207385**	**002**	May 23, 2017
AP		HENGRUI PHARMA	**50MG/10ML (5MG/ML)**	**A203869**	**001**	Jun 18, 2014
AP			**100MG/20ML (5MG/ML)**	**A203869**	**002**	Jun 18, 2014
AP		HOSPIRA WORLDWIDE	**50MG/10ML (5MG/ML)**	**A078813**	**001**	Aug 07, 2009
AP			**100MG/20ML (5MG/ML)**	**A078813**	**002**	Aug 07, 2009
AP		MYLAN LABS LTD	**50MG/10ML (5MG/ML)**	**A091358**	**001**	Aug 07, 2012
AP			**100MG/20ML (5MG/ML)**	**A091358**	**002**	Aug 07, 2012
AP		NOVAST LABS	**50MG/10ML (5MG/ML)**	**A207562**	**001**	Oct 16, 2018
AP			**100MG/20ML (5MG/ML)**	**A207562**	**002**	Oct 16, 2018
AP		QILU PHARM HAINAN	**50MG/10ML (5MG/ML)**	**A204368**	**001**	Jun 07, 2016
AP			**50MG/VIAL**	**A204616**	**001**	May 11, 2016
AP			**100MG/20ML (5MG/ML)**	**A204368**	**002**	Jun 07, 2016
AP			**100MG/VIAL**	**A204616**	**002**	May 11, 2016
AP		SANDOZ	**50MG/10ML (5MG/ML)**	**A078817**	**001**	Jan 24, 2011
AP			**100MG/20ML (5MG/ML)**	**A078817**	**002**	Jan 24, 2011
AP	**+!**	TEVA PHARMS	**50MG/10ML (5MG/ML)**	**N022160**	**001**	Aug 07, 2009
AP	**+!**		**100MG/20ML (5MG/ML)**	**N022160**	**002**	Aug 07, 2009
	!	QILU PHARM HAINAN	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016

OXAPROZIN
CAPSULE;ORAL
COXANTO

	+!	SOLUBIOMIX	300MG	N217927	001	Oct 20, 2023

TABLET;ORAL
DAYPRO

AB	**+!**	PFIZER	**600MG**	**N018841**	**004**	Oct 29, 1992

OXAPROZIN

AB		AMNEAL PHARMS CO	**600MG**	**A208633**	**001**	May 04, 2017
AB		CHARTWELL	**600MG**	**A075987**	**001**	Sep 02, 2004
AB		DR REDDYS LABS LTD	**600MG**	**A075855**	**001**	Jan 31, 2001
AB		SANDOZ	**600MG**	**A075845**	**001**	Jan 31, 2001
AB		TEVA	**600MG**	**A075849**	**001**	Jul 03, 2002

OXAZEPAM
CAPSULE;ORAL
OXAZEPAM

AB		ACTAVIS ELIZABETH	**10MG**	**A072253**	**002**	Apr 14, 1988
AB			**15MG**	**A072253**	**003**	Apr 14, 1988
AB	**!**		**30MG**	**A072253**	**001**	Apr 14, 1988
AB		EPIC PHARMA LLC	**10MG**	**A071813**	**001**	Apr 19, 1988
AB			**15MG**	**A071756**	**001**	Apr 19, 1988
AB			**30MG**	**A071814**	**001**	Apr 19, 1988
AB		UNITED RES LABS	**10MG**	**A071026**	**002**	Aug 10, 1987
AB			**15MG**	**A071026**	**003**	Aug 10, 1987
AB			**30MG**	**A071026**	**001**	Aug 10, 1987

OXCARBAZEPINE
SUSPENSION;ORAL
OXCARBAZEPINE

AB		AMNEAL PHARMS	**300MG/5ML**	**A202961**	**001**	Sep 17, 2012
AB		AUCTA	**300MG/5ML**	**A215332**	**001**	Nov 30, 2022
AB		BIONPHARMA	**300MG/5ML**	**A209652**	**001**	Nov 04, 2022
AB		CHARTWELL RX	**300MG/5ML**	**A212428**	**001**	Jun 21, 2021
AB		HETERO LABS LTD III	**300MG/5ML**	**A216749**	**001**	Oct 20, 2023
AB		RUBICON	**300MG/5ML**	**A215726**	**001**	Aug 30, 2022
AB		SUN PHARM INDS LTD	**300MG/5ML**	**A078734**	**001**	Jun 26, 2009

TRILEPTAL

AB	**+!**	NOVARTIS	**300MG/5ML**	**N021285**	**001**	May 25, 2001

TABLET;ORAL
OXCARBAZEPINE

AB		ANNORA PHARMA	**150MG**	**A215939**	**001**	Jan 11, 2022
AB			**300MG**	**A215939**	**002**	Jan 11, 2022
AB			**600MG**	**A215939**	**003**	Jan 11, 2022
AB		BRECKENRIDGE PHARM	**150MG**	**A078069**	**001**	Jan 11, 2008
AB			**300MG**	**A078069**	**002**	Jan 11, 2008

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

AB			**600MG**	**A078069**	**003**	Jan 11, 2008
AB		GLENMARK PHARMS LTD	**150MG**	**A077802**	**001**	Oct 09, 2007
AB			**300MG**	**A077802**	**002**	Oct 09, 2007
AB			**600MG**	**A077802**	**003**	Oct 09, 2007
AB		RUBICON	**150MG**	**A077747**	**001**	Apr 09, 2008
AB			**300MG**	**A077747**	**002**	Apr 09, 2008
AB			**600MG**	**A077747**	**003**	Apr 09, 2008
AB		SUN PHARM INDS	**150MG**	**A077794**	**001**	Oct 09, 2007
AB			**300MG**	**A077794**	**002**	Oct 09, 2007
AB			**600MG**	**A077794**	**003**	Oct 09, 2007
AB		TARO	**150MG**	**A077801**	**001**	Nov 15, 2007
AB			**300MG**	**A077801**	**002**	Nov 15, 2007
AB			**600MG**	**A077801**	**003**	Nov 15, 2007
AB		ZYDUS	**150MG**	**A211747**	**001**	Jul 03, 2023
AB			**300MG**	**A211747**	**002**	Jul 03, 2023
AB			**600MG**	**A211747**	**003**	Jul 03, 2023

TRILEPTAL

AB	**+**	NOVARTIS	**150MG**	**N021014**	**001**	Jan 14, 2000
AB	**+**		**300MG**	**N021014**	**002**	Jan 14, 2000
AB	**+!**		**600MG**	**N021014**	**003**	Jan 14, 2000

TABLET, EXTENDED RELEASE;ORAL

OXTELLAR XR

	+	SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012
	+		300MG	N202810	002	Oct 19, 2012
	+!		600MG	N202810	003	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

AB		TARO	**EQ 1% BASE**	**A205076**	**001**	Mar 07, 2016

OXISTAT

AB	**+!**	FOUGERA PHARMS	**EQ 1% BASE**	**N019828**	**001**	Dec 30, 1988

LOTION;TOPICAL

OXISTAT

	+!	ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL

	+!	ALLERGAN	3.9MG/24HR	N021351	002	Feb 26, 2003

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

AA		CHARTWELL RX	**5MG/5ML**	**A075039**	**001**	Jan 29, 1999
AA	**!**	LANNETT CO INC	**5MG/5ML**	**A074520**	**001**	Mar 29, 1996
AA		PHARM ASSOC	**5MG/5ML**	**A075137**	**001**	Dec 18, 1998

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB		ABHAI LLC	**5MG**	**A209335**	**001**	Dec 22, 2017
AB		BEXIMCO PHARMS USA	**5MG**	**A213550**	**001**	Jul 14, 2022
AB		LEADING	**5MG**	**A212798**	**001**	Apr 06, 2020
AB		NOVAST LABS	**5MG**	**A210611**	**001**	Oct 30, 2019
AB		NOVITIUM PHARMA	**5MG**	**A209823**	**001**	Oct 23, 2017
AB		RISING	**5MG**	**A209025**	**001**	Dec 21, 2017
AB	**!**	STRIDES PHARMA	**5MG**	**A075079**	**001**	Oct 31, 1997
AB			**5MG**	**A208165**	**001**	Dec 17, 2020
AB		TEVA PHARMS USA	**5MG**	**A071655**	**001**	Nov 14, 1988
AB		TULEX PHARMS INC	**5MG**	**A210125**	**001**	Sep 06, 2018
AB		UPSHER SMITH LABS	**5MG**	**A074625**	**001**	Jul 31, 1996
BX		EYWA	5MG	A211062	001	Feb 06, 2019
	!	RISING	2.5MG	A209025	002	Feb 07, 2023

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

AB		ACCORD HLTHCARE	**5MG**	**A207138**	**001**	Feb 29, 2016
AB			**10MG**	**A207138**	**002**	Feb 29, 2016
AB	**!**		**15MG**	**A207138**	**003**	Feb 29, 2016
AB		AJANTA PHARMA LTD	**5MG**	**A211655**	**001**	Feb 28, 2019
AB			**10MG**	**A211655**	**002**	Feb 28, 2019
AB			**15MG**	**A211655**	**003**	Feb 28, 2019
AB		AMNEAL PHARMS	**5MG**	**A204010**	**001**	Nov 23, 2015

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

AB			**10MG**	**A204010**	**002**	Nov 23, 2015
AB			**15MG**	**A204010**	**003**	Nov 23, 2015
AB		BIONPHARMA	**5MG**	**A210717**	**001**	Dec 17, 2019
AB			**10MG**	**A210717**	**002**	Dec 17, 2019
AB			**15MG**	**A210717**	**003**	Dec 17, 2019
AB		OSMOTICA PHARM US	**5MG**	**A078503**	**001**	Feb 04, 2009
AB			**10MG**	**A078503**	**002**	Feb 04, 2009
AB			**15MG**	**A078503**	**003**	Feb 04, 2009
AB		RUBICON	**5MG**	**A214415**	**001**	Oct 27, 2020
AB			**10MG**	**A214415**	**002**	Oct 27, 2020
AB			**15MG**	**A214415**	**003**	Oct 27, 2020
AB		UNIQUE	**5MG**	**A206121**	**001**	May 27, 2016
AB			**10MG**	**A206121**	**002**	May 27, 2016
AB			**15MG**	**A206121**	**003**	May 27, 2016
AB		ZYDUS PHARMS	**5MG**	**A202332**	**001**	Jun 26, 2017
AB			**10MG**	**A202332**	**002**	Jun 26, 2017
AB			**15MG**	**A202332**	**003**	Jun 26, 2017

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL

XTAMPZA ER

+		COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016
+			13.5MG	N208090	002	Apr 26, 2016
+			18MG	N208090	003	Apr 26, 2016
+			27MG	N208090	004	Apr 26, 2016
+!			36MG	N208090	005	Apr 26, 2016

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB		ANI PHARMS	**5MG**	**A205177**	**001**	Mar 31, 2016
AB		AVANTHI INC	**5MG**	**A202773**	**001**	Aug 17, 2015
AB	**+!**	GENUS LIFESCIENCES	**5MG**	**N200534**	**001**	Oct 20, 2010
AB		NOVEL LABS INC	**5MG**	**A204752**	**001**	Aug 24, 2015

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA		ABHAI LLC	**5MG/5ML**	**A208593**	**001**	Jul 21, 2017
AA			**100MG/5ML**	**A208593**	**002**	Jul 21, 2017
AA		ALKEM LABS LTD	**5MG/5ML**	**A211748**	**001**	Feb 07, 2019
AA			**100MG/5ML**	**A211749**	**001**	Feb 04, 2019
AA		ANI PHARMS	**5MG/5ML**	**A204979**	**001**	Jun 01, 2015
AA		ASCENT PHARMS INC	**5MG/5ML**	**A209021**	**001**	Nov 09, 2017
AA			**100MG/5ML**	**A209021**	**002**	Nov 09, 2017
AA	**+**	GENUS LIFESCIENCES	**5MG/5ML**	**N200535**	**002**	Aug 22, 2013
AA	**+!**		**100MG/5ML**	**N200535**	**001**	Oct 20, 2010
AA	**!**	HIKMA	**5MG/5ML**	**A204037**	**001**	Jul 15, 2013
AA			**5MG/5ML**	**A208817**	**001**	Aug 10, 2017
AA			**100MG/5ML**	**A208795**	**001**	Aug 07, 2017
AA		PHARM ASSOC	**5MG/5ML**	**A206914**	**001**	Feb 01, 2019
AA			**100MG/5ML**	**A206822**	**001**	Aug 15, 2017
AA		QUAGEN	**5MG/5ML**	**A213761**	**001**	Jun 02, 2021
AA			**100MG/5ML**	**A213761**	**002**	Jun 02, 2021
AA		SPECGX LLC	**5MG/5ML**	**A210758**	**001**	Apr 30, 2018
AA			**100MG/5ML**	**A210758**	**002**	Apr 30, 2018
AA		WES PHARMA INC	**5MG/5ML**	**A207511**	**001**	Nov 23, 2016
AA			**100MG/5ML**	**A209897**	**001**	Sep 06, 2017

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB		ALVOGEN	**5MG**	**A202116**	**001**	Dec 30, 2011
AB			**15MG**	**A202116**	**002**	Dec 30, 2011
AB			**30MG**	**A202116**	**003**	Dec 30, 2011
AB		AMNEAL PHARMS	**5MG**	**A203638**	**001**	Jun 03, 2014
AB			**10MG**	**A203638**	**002**	Jun 03, 2014
AB			**15MG**	**A203638**	**003**	Jun 03, 2014
AB			**20MG**	**A203638**	**004**	Jun 03, 2014
AB			**30MG**	**A203638**	**005**	Jun 03, 2014
AB		ASCENT PHARMS INC	**15MG**	**A207418**	**001**	Aug 07, 2017
AB			**30MG**	**A207418**	**002**	Aug 07, 2017
AB		AUROLIFE PHARMA LLC	**5MG**	**A202160**	**001**	Nov 19, 2012
AB			**15MG**	**A202160**	**002**	Nov 19, 2012

OXYCODONE HYDROCHLORIDE							
TABLET;ORAL							
OXYCODONE HYDROCHLORIDE							
AB			**30MG**	**A202160**	**003**	Nov 19, 2012
AB		AVANTHI INC	**5MG**	**A091393**	**001**	Aug 31, 2009
AB	**!**		**10MG**	**A091393**	**002**	Aug 31, 2009
AB			**15MG**	**A091393**	**003**	Aug 31, 2009
AB			**20MG**	**A091393**	**004**	Aug 31, 2009
AB			**30MG**	**A091393**	**005**	Aug 31, 2009
AB		EPIC PHARMA LLC	**5MG**	**A090895**	**001**	Aug 24, 2009
AB			**5MG**	**A202662**	**001**	Sep 22, 2015
AB			**10MG**	**A202662**	**002**	Sep 22, 2015
AB			**15MG**	**A090895**	**002**	Aug 24, 2009
AB			**15MG**	**A202662**	**003**	Sep 22, 2015
AB			**20MG**	**A202662**	**005**	Apr 27, 2017
AB			**30MG**	**A090895**	**003**	Aug 24, 2009
AB			**30MG**	**A202662**	**004**	Sep 22, 2015
AB		NOVEL LABS INC	**5MG**	**A204021**	**001**	Jun 12, 2017
AB			**10MG**	**A204021**	**002**	Jun 12, 2017
AB			**15MG**	**A204021**	**003**	Jun 12, 2017
AB			**20MG**	**A204021**	**004**	Jun 12, 2017
AB			**30MG**	**A204021**	**005**	Jun 12, 2017
AB		NUVO PHARM	**5MG**	**A207119**	**001**	Apr 12, 2016
AB			**10MG**	**A207119**	**002**	Apr 12, 2016
AB			**15MG**	**A207119**	**003**	Apr 12, 2016
AB			**20MG**	**A207119**	**004**	Apr 12, 2016
AB			**30MG**	**A207119**	**005**	Apr 12, 2016
AB		RHODES PHARMS	**5MG**	**A091490**	**001**	Mar 09, 2011
AB			**10MG**	**A091490**	**002**	Mar 09, 2011
AB			**15MG**	**A091490**	**003**	Mar 09, 2011
AB			**20MG**	**A091490**	**004**	Mar 09, 2011
AB			**30MG**	**A091490**	**005**	Mar 09, 2011
AB		SPECGX LLC	**5MG**	**A076758**	**003**	Mar 19, 2007
AB			**10MG**	**A076758**	**004**	Oct 12, 2021
AB			**15MG**	**A076758**	**001**	Jun 30, 2004
AB			**20MG**	**A076758**	**005**	Oct 12, 2021
AB			**30MG**	**A076758**	**002**	Jun 30, 2004
AB		SUN PHARM INDS INC	**5MG**	**A090659**	**001**	Apr 10, 2009
AB			**10MG**	**A090659**	**005**	Nov 06, 2012
AB			**15MG**	**A090659**	**002**	Apr 10, 2009
AB			**20MG**	**A090659**	**004**	Nov 06, 2012
AB			**30MG**	**A090659**	**003**	Apr 10, 2009
ROXICODONE							
AB	**+**	SPECGX LLC	**5MG**	**N021011**	**003**	May 15, 2009
AB	**+!**		**15MG**	**N021011**	**001**	Aug 31, 2000
AB	**+**		**30MG**	**N021011**	**002**	Aug 31, 2000
ROXYBOND							
		PROTEGA PHARMS	5MG	N209777	001	Apr 20, 2017
			15MG	N209777	002	Apr 20, 2017
			30MG	N209777	003	Apr 20, 2017
TABLET, EXTENDED RELEASE;ORAL							
OXYCONTIN							
	+	PURDUE PHARMA LP	10MG	N022272	001	Apr 05, 2010
	+		15MG	N022272	002	Apr 05, 2010
	+		20MG	N022272	003	Apr 05, 2010
	+		30MG	N022272	004	Apr 05, 2010
	+!		40MG	N022272	005	Apr 05, 2010
	+		60MG	N022272	006	Apr 05, 2010
	+		80MG	N022272	007	Apr 05, 2010
OXYMETAZOLINE HYDROCHLORIDE							
CREAM;TOPICAL							
RHOFADE							
	+!	MAYNE PHARMA	1%	N208552	001	Jan 18, 2017
SOLUTION/DROPS;OPHTHALMIC							
UPNEEQ							
	+!	RVL PHARMS	0.1%	N212520	001	Jul 08, 2020

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL

KOVANAZE

	+!	ST RENATUS	0.1MG/SPRAY;6MG/SPRAY	N208032	001	Jun 29, 2016

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	**5MG**	**A210175**	**001**	Feb 02, 2018
AB			**10MG**	**A210175**	**002**	Feb 02, 2018
AB		AUROLIFE PHARMA LLC	**5MG**	**A204459**	**001**	Apr 26, 2016
AB			**10MG**	**A204459**	**002**	Apr 26, 2016
AB		AVANTHI INC	**5MG**	**A203601**	**001**	Jan 30, 2013
AB	**!**		**10MG**	**A203601**	**002**	Jan 30, 2013
AB		EPIC PHARMA LLC	**5MG**	**A201187**	**001**	Dec 15, 2014
AB			**10MG**	**A201187**	**002**	Dec 15, 2014
AB		HIKMA	**5MG**	**A090964**	**001**	Sep 27, 2010
AB			**10MG**	**A090964**	**002**	Sep 27, 2010
AB		TEVA	**5MG**	**A091443**	**002**	Feb 15, 2011
AB			**10MG**	**A091443**	**001**	Feb 15, 2011

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

		IMPAX LABS	5MG	A079087	001	Jun 14, 2010
			7.5MG	A079087	002	Dec 21, 2010
			10MG	A079087	003	Jun 14, 2010
			15MG	A079087	004	Dec 21, 2010
			20MG	A079087	005	Jun 14, 2010
			30MG	A079087	006	Jul 22, 2010
	!		40MG	A079087	007	Jun 14, 2010

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP	**+!**	FRESENIUS KABI USA	**10USP UNITS/ML (10USP UNITS/ML)**	**N018248**	**001**	
AP	**+!**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018248**	**002**	
AP	**+!**	HIKMA	**10USP UNITS/ML (10USP UNITS/ML)**	**N018243**	**001**	
AP	**+!**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018243**	**002**	Jan 10, 2007
AP		HIKMA FARMACEUTICA	**10USP UNITS/ML (10USP UNITS/ML)**	**A200219**	**001**	Feb 13, 2013
AP		SAGENT PHARMS INC	**10USP UNITS/ML (10USP UNITS/ML)**	**A091676**	**001**	Jul 13, 2018
AP			**100USP UNITS/10ML (10USP UNITS/ML)**	**A091676**	**002**	Jul 13, 2018

PITOCIN

AP	**+!**	PAR STERILE PRODUCTS	**10USP UNITS/ML (10USP UNITS/ML)**	**N018261**	**001**	
AP	**+**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018261**	**002**	Jul 27, 2007

OXYTOCIN

	+!	FRESENIUS KABI USA	300USP UNITS/30ML (10USP UNITS/ML)	N018248	003	Jul 27, 2007

PITOCIN

	+	PAR STERILE PRODUCTS	500USP UNITS/50ML (10USP UNITS/ML)	N018261	003	Sep 05, 2012

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA

	+	CELGENE INTL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020
	+		EQ 0.46MG BASE	N209899	002	Mar 25, 2020
	+!		EQ 0.92MG BASE	N209899	003	Mar 25, 2020

OZENOXACIN

CREAM;TOPICAL

XEPI

	+!	FERRER INTERNACIONAL	1%	N208945	001	Dec 11, 2017

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

AP		ACCORD HLTHCARE	**6MG/ML**	**A205720**	**001**	Aug 17, 2018
AP		ACTAVIS TOTOWA	**6MG/ML**	**A090130**	**001**	Dec 09, 2009
AP		ALEMBIC	**6MG/ML**	**A216874**	**001**	Oct 20, 2022
AP		FRESENIUS KABI USA	**6MG/ML**	**A077574**	**001**	Nov 27, 2006
AP		GLAND PHARMA LTD	**6MG/ML**	**A207326**	**001**	Aug 23, 2016
AP		HIKMA	**6MG/ML**	**A075190**	**001**	Jan 28, 2002
AP	**!**	HOSPIRA	**6MG/ML**	**A076131**	**001**	May 08, 2002
AP		MSN	**6MG/ML**	**A213434**	**001**	Aug 24, 2020
AP		TEVA PHARMS	**6MG/ML**	**A075184**	**001**	Jan 25, 2002

PACLITAXEL							
POWDER;INTRAVENOUS							
ABRAXANE							
	+!	BRISTOL-MYERS	100MG/VIAL	N021660	001	Jan 07, 2005
PACLITAXEL							
	+!	AM REGENT	100MG/VIAL	N211875	001	Jul 27, 2022
PACRITINIB CITRATE							
CAPSULE;ORAL							
VONJO							
	+!	CTI BIOPHARMA CORP	EQ 100MG BASE	N208712	001	Feb 28, 2022
PAFOLACIANINE SODIUM							
SOLUTION;INTRAVENOUS							
CYTALUX							
	+!	ON TARGET LABS	EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML)	N214907	001	Nov 29, 2021
PALBOCICLIB							
CAPSULE;ORAL							
IBRANCE							
	+	PFIZER	75MG	N207103	001	Feb 03, 2015
	+		100MG	N207103	002	Feb 03, 2015
	+!		125MG	N207103	003	Feb 03, 2015
TABLET;ORAL							
IBRANCE							
AB	**+**	PFIZER	**75MG**	**N212436**	**001**	Nov 01, 2019
AB	**+**		**100MG**	**N212436**	**002**	Nov 01, 2019
AB	**+!**		**125MG**	**N212436**	**003**	Nov 01, 2019
PALBOCICLIB							
AB		SYNTHON PHARMS INC	**75MG**	**A215570**	**001**	Aug 28, 2023
AB			**100MG**	**A215570**	**002**	Aug 28, 2023
AB			**125MG**	**A215570**	**003**	Aug 28, 2023
PALIPERIDONE							
TABLET, EXTENDED RELEASE;ORAL							
INVEGA							
AB	**+**	JANSSEN PHARMS	**1.5MG**	**N021999**	**006**	Aug 26, 2008
AB	**+**		**3MG**	**N021999**	**001**	Dec 19, 2006
AB	**+!**		**6MG**	**N021999**	**002**	Dec 19, 2006
AB	**+**		**9MG**	**N021999**	**003**	Dec 19, 2006
PALIPERIDONE							
AB		ACTAVIS LABS FL INC	**1.5MG**	**A202645**	**001**	Aug 03, 2015
AB			**3MG**	**A202645**	**002**	Aug 03, 2015
AB			**6MG**	**A202645**	**003**	Aug 03, 2015
AB			**9MG**	**A202645**	**004**	Aug 03, 2015
AB		AMNEAL PHARMS	**1.5MG**	**A204707**	**001**	Sep 23, 2019
AB			**3MG**	**A204707**	**002**	Sep 23, 2019
AB			**6MG**	**A204707**	**003**	Sep 23, 2019
AB			**9MG**	**A204707**	**004**	Sep 23, 2019
AB		ASCENT PHARMS INC	**1.5MG**	**A216174**	**001**	Aug 23, 2023
AB			**3MG**	**A216174**	**002**	Aug 23, 2023
AB			**6MG**	**A216174**	**003**	Aug 23, 2023
AB			**9MG**	**A216174**	**004**	Aug 23, 2023
AB		CSPC OUYI	**1.5MG**	**A212807**	**001**	Oct 29, 2020
AB			**3MG**	**A212807**	**002**	Oct 29, 2020
AB			**6MG**	**A212807**	**003**	Oct 29, 2020
AB			**9MG**	**A212807**	**004**	Oct 29, 2020
AB		INVENTIA	**1.5MG**	**A204452**	**001**	Jun 12, 2019
AB			**3MG**	**A204452**	**002**	Jun 12, 2019
AB			**6MG**	**A204452**	**003**	Jun 12, 2019
AB			**9MG**	**A204452**	**004**	Jun 12, 2019
AB		LUPIN LTD	**1.5MG**	**A208643**	**001**	Jun 29, 2022
AB			**3MG**	**A208643**	**002**	Jun 29, 2022
AB			**6MG**	**A208643**	**003**	Jun 29, 2022
AB			**9MG**	**A208643**	**004**	Jun 29, 2022
AB		RK PHARMA	**1.5MG**	**A203802**	**001**	Sep 24, 2015
AB			**3MG**	**A203802**	**002**	Sep 24, 2015
AB			**6MG**	**A203802**	**003**	Sep 24, 2015
AB			**9MG**	**A203802**	**004**	Sep 24, 2015
AB		SUN PHARM	**1.5MG**	**A205618**	**001**	Apr 06, 2018
AB			**3MG**	**A205618**	**002**	Apr 06, 2018
AB			**6MG**	**A205618**	**003**	Apr 06, 2018
AB			**9MG**	**A205618**	**004**	Apr 06, 2018

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA HAFYERA

+	JANSSEN PHARMS	1.092GM/3.5ML (312MG/ML)	N207946	005	Aug 30, 2021
+		1.560GM/5ML (312MG/ML)	N207946	006	Aug 30, 2021

INVEGA SUSTENNA

+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009
+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009
+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009
+!		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009
+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009

INVEGA TRINZA

+	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015
+		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015
+		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015
+!		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP		AVET LIFESCIENCES	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A202951**	**002**	Jun 29, 2021
AP		BAXTER HLTHCARE CORP	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206916**	**001**	Nov 12, 2021
AP		CHARTWELL RX	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A209287**	**001**	Sep 19, 2018
AP	**!**	DR REDDYS	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A201533**	**002**	Apr 21, 2016
AP		EUGIA PHARMA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A204702**	**001**	Nov 06, 2018
AP		FRESENIUS KABI USA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206801**	**001**	Sep 19, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206802**	**001**	Sep 19, 2018
AP		HOSPIRA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A207005**	**001**	Sep 19, 2018
AP		MYLAN INSTITUTIONAL	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206416**	**001**	Sep 19, 2018
AP		NANJING KING-FRIEND	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A215861**	**001**	Aug 14, 2023
AP		QILU PHARM HAINAN	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A205648**	**001**	Sep 19, 2018
AP		SAGENT PHARMS INC	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A204289**	**001**	Sep 19, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A205870**	**001**	Sep 19, 2018
AP		SANDOZ	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A202521**	**001**	Oct 13, 2015
AP		TEVA PHARMS USA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A090713**	**001**	Mar 23, 2018
	!	AVET LIFESCIENCES	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021

PALOVAROTENE

CAPSULE;ORAL

SOHONOS

+	IPSEN	1MG	N215559	001	Aug 16, 2023
+		1.5MG	N215559	002	Aug 16, 2023
+		2.5MG	N215559	003	Aug 16, 2023
+		5MG	N215559	004	Aug 16, 2023
+!		10MG	N215559	005	Aug 16, 2023

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

AP		AREVA PHARMS	**30MG/VIAL**	**A077433**	**001**	Nov 26, 2008
AP			**90MG/VIAL**	**A077433**	**003**	Nov 26, 2008
AP		DR REDDYS	**60MG/10ML (6MG/ML)**	**A078156**	**002**	Aug 19, 2008
AP		HIKMA	**30MG/VIAL**	**A075290**	**001**	Apr 30, 2001
AP			**90MG/VIAL**	**A075290**	**003**	Apr 30, 2001
AP	**!**	HOSPIRA	**60MG/10ML (6MG/ML)**	**A075841**	**002**	Jun 27, 2002
AP1	**+!**	HIKMA	**30MG/10ML (3MG/ML)**	**N021113**	**001**	Mar 04, 2002
AP1	**+!**		**90MG/10ML (9MG/ML)**	**N021113**	**002**	Mar 04, 2002
AP1		SAGENT PHARMS INC	**30MG/10ML (3MG/ML)**	**A078373**	**001**	Dec 23, 2008
AP1			**90MG/10ML (9MG/ML)**	**A078373**	**002**	Dec 23, 2008
AP2		DR REDDYS	**30MG/10ML (3MG/ML)**	**A078156**	**001**	Aug 19, 2008
AP2			**90MG/10ML (9MG/ML)**	**A078156**	**003**	Aug 19, 2008
AP2		HOSPIRA	**30MG/10ML (3MG/ML)**	**A075841**	**001**	Jun 27, 2002
AP2			**90MG/10ML (9MG/ML)**	**A075841**	**003**	Jun 27, 2002
AP2		MYLAN LABS LTD	**30MG/10ML (3MG/ML)**	**A078520**	**001**	Oct 31, 2008
AP2			**90MG/10ML (9MG/ML)**	**A078520**	**002**	Oct 31, 2008
		AREVA PHARMS	60MG/VIAL	A077433	002	Nov 26, 2008

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDE

AP	**!**	DR REDDYS	**1MG/ML**	**A072759**	**001**	Jul 31, 1990
AP		HOSPIRA	**1MG/ML**	**A072320**	**001**	Jan 19, 1989
	!	DR REDDYS	2MG/ML	A072760	001	Jul 31, 1990

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB		AJANTA PHARMA LTD	**EQ 40MG BASE**	**A217416**	**001**	Feb 09, 2023
AB		ANNORA PHARMA	**EQ 40MG BASE**	**A216139**	**001**	Oct 27, 2023
AB		DEXCEL	**EQ 40MG BASE**	**A216247**	**001**	Jun 16, 2023
AB		SUN PHARM	**EQ 40MG BASE**	**A213725**	**001**	Jun 30, 2020

PROTONIX

AB	**+!**	WYETH PHARMS	**EQ 40MG BASE**	**N022020**	**001**	Nov 14, 2007

INJECTABLE;INTRAVENOUS

PANTOPRAZOLE SODIUM

AP		ACIC PHARMS	**EQ 40MG BASE/VIAL**	**A209524**	**001**	Aug 30, 2021
AP		AKORN	**EQ 40MG BASE/VIAL**	**A079197**	**001**	Nov 08, 2012
AP		ASPIRO	**EQ 40MG BASE/VIAL**	**A213778**	**001**	May 18, 2022
AP		BE PHARMS	**EQ 40MG BASE/VIAL**	**A216171**	**001**	May 18, 2022
AP		EUGIA PHARMA	**EQ 40MG BASE/VIAL**	**A205675**	**001**	Mar 30, 2016
AP		GLAND PHARMA LTD	**EQ 40MG BASE/VIAL**	**A204400**	**001**	May 18, 2022
AP		KNACK	**EQ 40MG BASE/VIAL**	**A214680**	**001**	May 19, 2022
AP		MEITHEAL	**EQ 40MG BASE/VIAL**	**A215860**	**001**	Aug 29, 2022
AP		SANDOZ	**EQ 40MG BASE/VIAL**	**A090296**	**001**	Jul 14, 2015
AP		SUN PHARM	**EQ 40MG BASE/VIAL**	**A077674**	**001**	Aug 19, 2019

PROTONIX IV

AP	**+!**	WYETH PHARMS	**EQ 40MG BASE/VIAL**	**N020988**	**001**	Mar 22, 2001

POWDER;INTRAVENOUS

PANTOPRAZOLE SODIUM

	+!	HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB		ACTAVIS TOTOWA	**EQ 20MG BASE**	**A090797**	**001**	Feb 07, 2011
AB			**EQ 40MG BASE**	**A090797**	**002**	Feb 07, 2011
AB		AMNEAL PHARMS	**EQ 20MG BASE**	**A205119**	**001**	Jan 26, 2016
AB			**EQ 40MG BASE**	**A205119**	**002**	Jan 26, 2016
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A202038**	**001**	Sep 28, 2012
AB			**EQ 40MG BASE**	**A202038**	**002**	Sep 28, 2012
AB		DR REDDYS LABS LTD	**EQ 20MG BASE**	**A077619**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A077619**	**002**	Jan 19, 2011
AB		GRANULES	**EQ 20MG BASE**	**A217282**	**001**	Dec 11, 2023
AB			**EQ 40MG BASE**	**A217282**	**002**	Dec 11, 2023
AB		HETERO LABS LTD V	**EQ 20MG BASE**	**A202882**	**001**	Sep 10, 2014
AB			**EQ 40MG BASE**	**A202882**	**002**	Sep 10, 2014
AB		INGENUS PHARMS LLC	**EQ 40MG BASE**	**A211368**	**001**	Mar 01, 2019
AB		LANNETT CO INC	**EQ 20MG BASE**	**A078281**	**001**	Jan 20, 2011
AB			**EQ 40MG BASE**	**A078281**	**002**	Jan 20, 2011
AB		MANKIND PHARMA	**EQ 40MG BASE**	**A215880**	**001**	Jul 26, 2022
AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A090970**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A090970**	**002**	Jan 19, 2011
AB		ORBION PHARMS	**EQ 20MG BASE**	**A202052**	**001**	Dec 02, 2014
AB			**EQ 40MG BASE**	**A202052**	**002**	Dec 02, 2014
AB		RUBICON	**EQ 20MG BASE**	**A090807**	**001**	May 02, 2012
AB			**EQ 40MG BASE**	**A090807**	**002**	May 02, 2012
AB		TORRENT PHARMS	**EQ 20MG BASE**	**A090074**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A090074**	**002**	Jan 19, 2011
AB		WOCKHARDT BIO AG	**EQ 20MG BASE**	**A091231**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A091231**	**002**	Jan 19, 2011

PROTONIX

AB	**+**	WYETH PHARMS	**EQ 20MG BASE**	**N020987**	**002**	Jun 12, 2001
AB	**+!**		**EQ 40MG BASE**	**N020987**	**001**	Feb 02, 2000

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB		AMNEAL PHARMS	**1MCG**	**A204327**	**001**	Jan 13, 2016
AB			**2MCG**	**A204327**	**002**	Jan 13, 2016
AB			**4MCG**	**A204327**	**003**	Jan 13, 2016
AB		AUROBINDO PHARMA LTD	**1MCG**	**A207672**	**001**	Jan 14, 2016

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB			**2MCG**	**A207672**	**002**	Jan 14, 2016
AB			**4MCG**	**A207672**	**003**	Jan 14, 2016
AB		BIONPHARMA	**1MCG**	**A202539**	**001**	Mar 27, 2014
AB			**2MCG**	**A202539**	**002**	Mar 27, 2014
AB			**4MCG**	**A202539**	**003**	Mar 27, 2014
AB		DR REDDYS	**1MCG**	**A091412**	**001**	Jun 24, 2014
AB			**2MCG**	**A091412**	**002**	Jun 24, 2014
AB			**4MCG**	**A091412**	**003**	Jun 24, 2014
AB		MARKSANS PHARMA	**1MCG**	**A204948**	**001**	Oct 07, 2016
AB			**2MCG**	**A204948**	**002**	Oct 07, 2016
AB			**4MCG**	**A204948**	**003**	Oct 07, 2016
AB		RISING	**1MCG**	**A202124**	**001**	Jun 24, 2014
AB			**2MCG**	**A202124**	**002**	Jun 24, 2014
AB			**4MCG**	**A202124**	**003**	Jun 24, 2014
AB		TEVA PHARMS USA	**1MCG**	**A090829**	**001**	Sep 27, 2013
AB			**2MCG**	**A090829**	**002**	Sep 27, 2013
AB	**!**		**4MCG**	**A090829**	**003**	Sep 27, 2013

ZEMPLAR

AB	**+**	ABBVIE	**1MCG**	**N021606**	**001**	May 26, 2005
AB	**+**		**2MCG**	**N021606**	**002**	May 26, 2005

SOLUTION;INTRAVENOUS

PARICALCITOL

AP		ACCORD HLTHCARE	**0.002MG/ML (0.002MG/ML)**	**N207174**	**001**	Feb 04, 2016
AP			**0.005MG/ML (0.005MG/ML)**	**N207174**	**002**	Feb 04, 2016
AP			**0.01MG/2ML (0.005MG/ML)**	**N207174**	**003**	Feb 04, 2016
AP		AMNEAL PHARMS CO	**0.002MG/ML (0.002MG/ML)**	**A206699**	**001**	Mar 09, 2017
AP			**0.005MG/ML (0.005MG/ML)**	**A206699**	**002**	Mar 09, 2017
AP			**0.01MG/2ML (0.005MG/ML)**	**A206699**	**003**	Mar 09, 2017
AP		DR REDDYS	**0.002MG/ML (0.002MG/ML)**	**A204910**	**001**	Aug 17, 2016
AP			**0.005MG/ML (0.005MG/ML)**	**A204910**	**002**	Aug 17, 2016
AP			**0.01MG/2ML (0.005MG/ML)**	**A204910**	**003**	Aug 17, 2016
AP		EUGIA PHARMA	**0.002MG/ML (0.002MG/ML)**	**A205982**	**001**	Oct 09, 2018
AP			**0.005MG/ML (0.005MG/ML)**	**A205982**	**002**	Oct 09, 2018
AP			**0.01MG/2ML (0.005MG/ML)**	**A205982**	**003**	Oct 09, 2018
AP		HIKMA PHARMS	**0.002MG/ML (0.002MG/ML)**	**N205917**	**001**	Nov 18, 2014
AP			**0.005MG/ML (0.005MG/ML)**	**N205917**	**002**	Nov 18, 2014
AP			**0.01MG/2ML (0.005MG/ML)**	**N205917**	**003**	Nov 18, 2014
AP		HOSPIRA	**0.002MG/ML (0.002MG/ML)**	**N201657**	**001**	Oct 21, 2014
AP			**0.005MG/ML (0.005MG/ML)**	**N201657**	**002**	Oct 21, 2014
AP			**0.01MG/2ML (0.005MG/ML)**	**N201657**	**003**	Oct 21, 2014
AP		RISING	**0.005MG/ML (0.005MG/ML)**	**A203897**	**002**	Nov 02, 2017
AP			**0.01MG/2ML (0.005MG/ML)**	**A203897**	**003**	Nov 02, 2017
AP		SANDOZ	**0.002MG/ML (0.002MG/ML)**	**A091108**	**001**	Jul 27, 2011
AP			**0.005MG/ML (0.005MG/ML)**	**A091108**	**002**	Jul 27, 2011
AP			**0.01MG/2ML (0.005MG/ML)**	**A091108**	**003**	Jul 27, 2011

ZEMPLAR

AP	**+!**	ABBVIE	**0.002MG/ML (0.002MG/ML)**	**N020819**	**002**	Feb 01, 2000
AP	**+!**		**0.005MG/ML (0.005MG/ML)**	**N020819**	**001**	Apr 17, 1998
AP	**+!**		**0.01MG/2ML (0.005MG/ML)**	**N020819**	**003**	Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE;ORAL

PAROMOMYCIN SULFATE

	!	HERITAGE PHARMS	EQ 250MG BASE	A065173	001	Dec 14, 2007

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAROXETINE HYDROCHLORIDE

AB		NOVITIUM PHARMA	**EQ 10MG BASE/5ML**	**A215003**	**001**	Sep 03, 2021

PAXIL

AB	**+!**	APOTEX	**EQ 10MG BASE/5ML**	**N020710**	**001**	Jun 25, 1997

TABLET;ORAL

PAROXETINE

AB		PRINSTON INC	**EQ 10MG BASE**	**A203854**	**001**	Oct 31, 2014
AB			**EQ 20MG BASE**	**A203854**	**002**	Oct 31, 2014
AB			**EQ 30MG BASE**	**A203854**	**003**	Oct 31, 2014
AB			**EQ 40MG BASE**	**A203854**	**004**	Oct 31, 2014

PAROXETINE HYDROCHLORIDE

AB		APOTEX	**EQ 10MG BASE**	**A075356**	**001**	Jul 30, 2003
AB			**EQ 20MG BASE**	**A075356**	**002**	Jul 30, 2003

PAROXETINE HYDROCHLORIDE

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

AB			**EQ 30MG BASE**	**A075356**	**003**	Jul 30, 2003
AB			**EQ 40MG BASE**	**A075356**	**004**	Jul 30, 2003
AB		AUROBINDO PHARMA	**EQ 10MG BASE**	**A078406**	**001**	Jul 25, 2007
AB			**EQ 20MG BASE**	**A078406**	**002**	Jul 25, 2007
AB			**EQ 30MG BASE**	**A078406**	**003**	Jul 25, 2007
AB			**EQ 40MG BASE**	**A078406**	**004**	Jul 25, 2007
AB		CHARTWELL RX	**EQ 10MG BASE**	**A076618**	**001**	Aug 15, 2005
AB			**EQ 20MG BASE**	**A076618**	**002**	Aug 15, 2005
AB			**EQ 30MG BASE**	**A076618**	**003**	Aug 15, 2005
AB			**EQ 40MG BASE**	**A076618**	**004**	Aug 15, 2005
AB		MYLAN	**EQ 10MG BASE**	**A078902**	**001**	Mar 13, 2008
AB			**EQ 20MG BASE**	**A078902**	**002**	Mar 13, 2008
AB			**EQ 30MG BASE**	**A078902**	**003**	Mar 13, 2008
AB			**EQ 40MG BASE**	**A078902**	**004**	Mar 13, 2008
AB		OXFORD PHARMS	**EQ 10MG BASE**	**A076968**	**001**	Jun 21, 2010
AB			**EQ 20MG BASE**	**A076968**	**002**	Jun 21, 2010
AB			**EQ 30MG BASE**	**A076968**	**003**	Jun 21, 2010
AB			**EQ 40MG BASE**	**A076968**	**004**	Jun 21, 2010
AB		YILING	**EQ 10MG BASE**	**A211248**	**001**	Nov 02, 2021
AB			**EQ 20MG BASE**	**A211248**	**002**	Nov 02, 2021
AB			**EQ 30MG BASE**	**A211248**	**003**	Nov 02, 2021
AB			**EQ 40MG BASE**	**A211248**	**004**	Nov 02, 2021
AB		ZYDUS PHARMS USA	**EQ 10MG BASE**	**A077584**	**001**	Mar 07, 2007
AB			**EQ 20MG BASE**	**A077584**	**002**	Mar 07, 2007
AB			**EQ 30MG BASE**	**A077584**	**003**	Mar 07, 2007
AB			**EQ 40MG BASE**	**A077584**	**004**	Mar 07, 2007

PAXIL

AB	**+**	APOTEX	**EQ 10MG BASE**	**N020031**	**001**	Dec 29, 1992
AB	**+**		**EQ 20MG BASE**	**N020031**	**002**	Dec 29, 1992
AB	**+**		**EQ 30MG BASE**	**N020031**	**003**	Dec 29, 1992
AB	**+!**		**EQ 40MG BASE**	**N020031**	**005**	Dec 29, 1992

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

AB		AUROBINDO PHARMA USA	**EQ 12.5MG BASE**	**A077873**	**001**	Jun 29, 2007
AB			**EQ 25MG BASE**	**A077873**	**002**	Jun 29, 2007
AB			**EQ 37.5MG BASE**	**A091427**	**001**	Apr 14, 2011
AB		CADILA PHARMS LTD	**EQ 12.5MG BASE**	**A212645**	**001**	Aug 27, 2021
AB			**EQ 25MG BASE**	**A212645**	**002**	Aug 27, 2021
AB			**EQ 37.5MG BASE**	**A212645**	**003**	Aug 27, 2021
AB		CSPC OUYI	**EQ 12.5MG BASE**	**A213485**	**001**	Feb 16, 2021
AB			**EQ 25MG BASE**	**A213485**	**002**	Feb 16, 2021
AB			**EQ 37.5MG BASE**	**A213485**	**003**	Feb 16, 2021
AB		LANNETT CO INC	**EQ 12.5MG BASE**	**A204744**	**001**	Jun 10, 2016
AB			**EQ 25MG BASE**	**A204744**	**002**	Jun 10, 2016
AB			**EQ 37.5MG BASE**	**A204744**	**003**	Jun 10, 2016
AB		LUPIN LTD	**EQ 12.5MG BASE**	**A204134**	**001**	Jan 20, 2017
AB			**EQ 25MG BASE**	**A204134**	**002**	Jan 20, 2017
AB			**EQ 37.5MG BASE**	**A204134**	**003**	Jan 20, 2017
AB		PRINSTON INC	**EQ 12.5MG BASE**	**A209748**	**001**	Jan 04, 2024
AB			**EQ 25MG BASE**	**A209748**	**002**	Jan 04, 2024
AB		SCIECURE PHARMA INC	**EQ 12.5MG BASE**	**A209293**	**001**	Jun 12, 2018
AB			**EQ 25MG BASE**	**A209293**	**002**	Jun 12, 2018
AB			**EQ 37.5MG BASE**	**A209293**	**003**	Jun 12, 2018

PAXIL CR

AB	**+**	APOTEX	**EQ 12.5MG BASE**	**N020936**	**001**	Feb 16, 1999
AB	**+**		**EQ 25MG BASE**	**N020936**	**002**	Feb 16, 1999
AB	**+!**		**EQ 37.5MG BASE**	**N020936**	**003**	Dec 06, 2000

PAROXETINE MESYLATE

CAPSULE;ORAL

BRISDELLE

AB	**+!**	SEBELA IRELAND LTD	**EQ 7.5MG BASE**	**N204516**	**001**	Jun 28, 2013

PAROXETINE MESYLATE

AB		ACTAVIS LABS FL INC	**EQ 7.5MG BASE**	**A207139**	**001**	Jun 20, 2017
AB		PRINSTON INC	**EQ 7.5MG BASE**	**A207188**	**001**	Aug 18, 2017

PASIREOTIDE DIASPARTATE

SOLUTION;SUBCUTANEOUS

SIGNIFOR

+	RECORDATI RARE	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012
+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012
+!		EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012

PASIREOTIDE PAMOATE

FOR SUSPENSION;INTRAMUSCULAR

SIGNIFOR LAR KIT

+	RECORDATI RARE	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018
+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014
+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014
+!		EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014

PATIROMER SORBITEX CALCIUM

POWDER;ORAL

VELTASSA

+	VIFOR PHARMA	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023
+		EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015
+		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015
+!		EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015

PATISIRAN SODIUM

SOLUTION;INTRAVENOUS

ONPATTRO

+!	ALNYLAM PHARMS INC	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N210922	001	Aug 10, 2018

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

PAZOPANIB HYDROCHLORIDE

AB		APOTEX	**EQ 200MG BASE**	**A217713**	**001**	Oct 19, 2023
AB		SUN PHARM	**EQ 200MG BASE**	**A215837**	**001**	Oct 19, 2023
AB		TEVA PHARMS INC	**EQ 200MG BASE**	**A217517**	**001**	Oct 19, 2023

VOTRIENT

AB	**+!**	NOVARTIS	**EQ 200MG BASE**	**N022465**	**001**	Oct 19, 2009

PEGCETACOPLAN

SOLUTION;INTRAVITREAL

SYFOVRE

+!	APELLIS PHARMS	15MG/0.1ML (15MG/0.1ML)	N217171	001	Feb 17, 2023

SOLUTION;SUBCUTANEOUS

EMPAVELI

+!	APELLIS PHARMS	1080MG/20ML (54MG/ML)	N215014	001	May 14, 2021

PEMETREXED

SOLUTION;INTRAVENOUS

PEMETREXED

+!	ACTAVIS	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020
+!		500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020
+!		1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020

PEMFEXY

+!	EAGLE PHARMS	500MG/20ML (25MG/ML)	N209472	001	Feb 08, 2020

PEMETREXED DISODIUM

POWDER;INTRAVENOUS

ALIMTA

AP	**+!**	LILLY	**EQ 100MG BASE/VIAL**	**N021462**	**002**	Sep 07, 2007
AP	**+!**		**EQ 500MG BASE/VIAL**	**N021462**	**001**	Feb 04, 2004

PEMETREXED DISODIUM

AP		ACCORD HLTHCARE	**EQ 100MG BASE/VIAL**	**A203485**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A203485**	**002**	May 25, 2022
AP			**EQ 1GM BASE/VIAL**	**A203485**	**003**	May 25, 2022
AP		APOTEX	**EQ 100MG BASE/VIAL**	**A203774**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A203774**	**002**	May 25, 2022
AP			**EQ 750MG BASE/VIAL**	**A209851**	**001**	May 25, 2022
AP			**EQ 1GM BASE/VIAL**	**A209085**	**001**	May 25, 2022
AP		BAXTER HLTHCARE CORP	**EQ 100MG BASE/VIAL**	**A214436**	**001**	Aug 18, 2022
AP			**EQ 500MG BASE/VIAL**	**A214436**	**002**	Aug 18, 2022
AP		DR REDDYS	**EQ 100MG BASE/VIAL**	**A202596**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A202596**	**002**	May 25, 2022
AP			**EQ 1GM BASE/VIAL**	**A202596**	**003**	May 25, 2022
AP		EUGIA PHARMA	**EQ 100MG BASE/VIAL**	**A214632**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A214632**	**002**	May 25, 2022

PEMETREXED DISODIUM

POWDER;INTRAVENOUS

PEMETREXED DISODIUM

AP			**EQ 1GM BASE/VIAL**	**A214632**	**003**	May 25, 2022
AP		FRESENIUS KABI USA	**EQ 100MG BASE/VIAL**	**A090384**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A090384**	**002**	May 25, 2022
AP	**!**		**EQ 750MG BASE/VIAL**	**A090384**	**003**	May 25, 2022
AP	**!**		**EQ 1GM BASE/VIAL**	**A090384**	**004**	May 25, 2022
AP		JIANGSU HANSOH PHARM	**EQ 100MG BASE/VIAL**	**A208696**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A208696**	**002**	May 25, 2022
AP		MEITHEAL	**EQ 100MG BASE/VIAL**	**A215479**	**001**	Dec 13, 2022
AP			**EQ 500MG BASE/VIAL**	**A215479**	**002**	Dec 13, 2022
AP			**EQ 750MG BASE/VIAL**	**A215479**	**003**	Dec 13, 2022
AP			**EQ 1GM BASE/VIAL**	**A215479**	**004**	Dec 13, 2022
AP		NANG KUANG PHARM CO	**EQ 100MG BASE/VIAL**	**A207352**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A207352**	**002**	May 25, 2022
AP		PRINSTON INC	**EQ 100MG BASE/VIAL**	**A216582**	**001**	Dec 11, 2023
AP		QILU PHARM HAINAN	**EQ 100MG BASE/VIAL**	**A204890**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A204890**	**002**	May 25, 2022
AP		WAVERLEY PHARMA INC	**EQ 100MG BASE/VIAL**	**A211899**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A211899**	**002**	May 25, 2022
AP		ZYDUS PHARMS	**EQ 100MG BASE/VIAL**	**A214073**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A214073**	**002**	May 25, 2022
AP			**EQ 1GM BASE/VIAL**	**A214073**	**003**	May 25, 2022

SOLUTION;INTRAVENOUS

PEMETREXED

+!	SHILPA	EQ 100MG/10ML BASE (10MG/ML)	N215179	001	May 22, 2023
+!		EQ 500MG/50ML BASE (10MG/ML)	N215179	002	May 22, 2023
+!		EQ 1GM/100ML BASE (10MG/ML)	N215179	003	May 22, 2023

PEMETREXED DISODIUM

+!	ACCORD HLTHCARE	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214408	001	Jul 19, 2022
+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214408	002	Jul 19, 2022
+!		EQ 850MG BASE/34ML (EQ 25MG BASE/ML)	N214408	003	Jul 19, 2022
+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214408	004	Jul 19, 2022
+!	HOSPIRA	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214218	001	Jun 22, 2022
+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214218	002	Jun 22, 2022
+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214218	003	Jun 22, 2022
+!	SANDOZ	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214657	001	May 26, 2022
+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657	002	May 26, 2022
+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657	003	May 26, 2022

PEMETREXED DITROMETHAMINE

POWDER;INTRAVENOUS

PEMETREXED DITROMETHAMINE

+!	HOSPIRA	EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022
+!		EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022

PEMIGATINIB

TABLET;ORAL

PEMAZYRE

+	INCYTE CORP	4.5MG	N213736	001	Apr 17, 2020
+		9MG	N213736	002	Apr 17, 2020
+!		13.5MG	N213736	003	Apr 17, 2020

PENCICLOVIR

CREAM;TOPICAL

DENAVIR

AB	**+!**	MYLAN	**1%**	**N020629**	**001**	Sep 24, 1996

PENCICLOVIR

AB		TEVA PHARMS USA	**1%**	**A212710**	**001**	Nov 09, 2022
AB		TORRENT	**1%**	**A216981**	**001**	Aug 07, 2023

PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

AB	**+!**	VALEANT PHARMS INTL	**250MG**	**N019853**	**001**	

PENICILLAMINE

AB		ANI PHARMS	**250MG**	**A209921**	**001**	May 07, 2019
AB		APOTEX	**250MG**	**A213310**	**001**	Apr 28, 2020
AB		BRECKENRIDGE	**250MG**	**A215409**	**001**	Aug 23, 2021
AB		DR REDDYS	**250MG**	**A211867**	**001**	Aug 04, 2020
AB		GRANULES	**250MG**	**A211735**	**001**	Dec 02, 2020
AB		INVAGEN PHARMS	**250MG**	**A213293**	**001**	Aug 19, 2021
AB		NAVINTA LLC	**250MG**	**A214363**	**001**	Oct 08, 2021

PENICILLAMINE
CAPSULE;ORAL
PENICILLAMINE

AB		PAR PHARM INC	**250MG**	**A211231**	**001**	Dec 23, 2019
AB		WATSON LABS INC	**250MG**	**A210976**	**001**	Jun 24, 2019

TABLET;ORAL
DEPEN

AB	**+!**	MYLAN SPECIALITY LP	**250MG**	**N019854**	**001**	

PENICILLAMINE

AB		LUPIN LTD	**250MG**	**A212933**	**001**	Nov 30, 2020
AB		PAR PHARM INC	**250MG**	**A211196**	**001**	Dec 23, 2019

PENICILLIN G BENZATHINE
INJECTABLE;INJECTION
BICILLIN L-A

BC	+!	KING PHARMS LLC	600,000 UNITS/ML	N050141	001	

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE
INJECTABLE;INJECTION
BICILLIN C-R

	+!	KING PHARMS LLC	300,000 UNITS/ML;300,000 UNITS/ML	N050138	001	

BICILLIN C-R 900/300

	+!	KING PHARMS LLC	900,000 UNITS/2ML;300,000 UNITS/2ML	N050138	003	

PENICILLIN G POTASSIUM
INJECTABLE;INJECTION
PENICILLIN G POTASSIUM

AP		ACS DOBFAR SPA	**20,000,000 UNITS/VIAL**	**A205043**	**002**	Oct 26, 2018
AP			**5,000,000 UNITS/VIAL**	**A205043**	**001**	Oct 26, 2018
AP		HQ SPECLT PHARMA	**5,000,000 UNITS/VIAL**	**A065149**	**002**	Jul 23, 2009
AP			**20,000,000 UNITS/VIAL**	**A065149**	**003**	Jul 23, 2009
AP		ISTITUTO BIO ITA SPA	**5,000,000 UNITS/VIAL**	**A065448**	**001**	Aug 18, 2009
AP			**20,000,000 UNITS/VIAL**	**A065448**	**002**	Aug 18, 2009
AP		SANDOZ	**5,000,000 UNITS/VIAL**	**A065079**	**002**	Aug 30, 2002
AP			**20,000,000 UNITS/VIAL**	**A065079**	**003**	Aug 30, 2002

PFIZERPEN

AP	**!**	PFIZER	**5,000,000 UNITS/VIAL**	**A060657**	**002**	
AP	**!**		**20,000,000 UNITS/VIAL**	**A060657**	**003**	

PENICILLIN G POTASSIUM

		HQ SPECLT PHARMA	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	20,000 UNITS/ML	N050638	001	Jun 25, 1990
	+!		40,000 UNITS/ML	N050638	002	Jun 25, 1990
	+!		60,000 UNITS/ML	N050638	003	Jun 25, 1990

PENICILLIN G PROCAINE
INJECTABLE;INJECTION
PENICILLIN G PROCAINE

	!	KING PHARMS LLC	300,000 UNITS/ML	A060101	002	
	!		600,000 UNITS/ML	A060101	001	

PENICILLIN G SODIUM
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
PENICILLIN G SODIUM

	!	SANDOZ	5,000,000 UNITS/VIAL	A065068	001	Feb 26, 2001

PENICILLIN V POTASSIUM
FOR SOLUTION;ORAL
PENICILLIN-VK

		TEVA	EQ 125MG BASE/5ML	A060456	001	
	!		EQ 250MG BASE/5ML	A060456	002	

TABLET;ORAL
PENICILLIN V POTASSIUM

AB		AUROBINDO PHARMA	**EQ 250MG BASE**	**A065435**	**001**	Apr 29, 2008
AB			**EQ 500MG BASE**	**A065435**	**002**	Apr 29, 2008
AB		CHARTWELL RX	**EQ 250MG BASE**	**A062936**	**001**	Nov 25, 1988
AB			**EQ 500MG BASE**	**A062935**	**001**	Nov 23, 1988
AB		HIKMA PHARMS	**EQ 250MG BASE**	**A090549**	**001**	Oct 11, 2013
AB			**EQ 500MG BASE**	**A090549**	**002**	Oct 11, 2013
AB		SANDOZ	**EQ 250MG BASE**	**A064071**	**001**	Nov 30, 1995
AB	**!**		**EQ 500MG BASE**	**A064071**	**002**	Nov 30, 1995

PENICILLIN-VK

AB		TEVA	**EQ 250MG BASE**	**A060711**	**002**	
AB			**EQ 500MG BASE**	**A060711**	**003**	

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION

NEBUPENT

AN	**+!**	FRESENIUS KABI USA	**300MG/VIAL**	**N019887**	**001**	Jun 15, 1989

PENTAMIDINE ISETHIONATE

AN		SETON PHARMS	**300MG/VIAL**	**A206667**	**001**	Apr 24, 2019
AN		X-GEN PHARMS INC	**300MG/VIAL**	**A206983**	**001**	Jan 20, 2023

INJECTABLE;INJECTION

PENTAM

AP	**+!**	FRESENIUS KABI USA	**300MG/VIAL**	**N019264**	**001**	Oct 16, 1984

PENTAMIDINE ISETHIONATE

AP		AVET LIFESCIENCES	**300MG/VIAL**	**A213806**	**001**	Jan 07, 2021
AP		SETON PHARMS	**300MG/VIAL**	**A206666**	**001**	Sep 28, 2017
AP		XGEN PHARMS	**300MG/VIAL**	**A206982**	**001**	Mar 17, 2022

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION

NEMBUTAL SODIUM

AP	**+!**	RISING	**50MG/ML**	**A083246**	**001**	

PENTOBARBITAL SODIUM

AP		BPI LABS	**50MG/ML**	**A206677**	**001**	Nov 27, 2017
AP		HIKMA	**50MG/ML**	**A203619**	**001**	Nov 13, 2017
AP		SAGENT PHARMS INC	**50MG/ML**	**A206404**	**001**	May 23, 2016

PENTOSAN POLYSULFATE SODIUM

CAPSULE;ORAL

ELMIRON

	+!	JANSSEN PHARMS	100MG	N020193	001	Sep 26, 1996

PENTOSTATIN

INJECTABLE;INJECTION

NIPENT

AP	**+!**	HOSPIRA INC	**10MG/VIAL**	**N020122**	**001**	Oct 11, 1991

PENTOSTATIN

AP		WEST-WARD PHARMS INT	**10MG/VIAL**	**A077841**	**001**	Aug 07, 2007

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

AB	**!**	APOTEX	**400MG**	**A075191**	**001**	Jun 09, 1999
AB		VALEANT PHARMS	**400MG**	**A075028**	**001**	Jul 20, 1998

PERAMIVIR

SOLUTION;INTRAVENOUS

RAPIVAB

	+!	BIOCRYST	200MG/20ML (10MG/ML)	N206426	001	Dec 19, 2014

PERAMPANEL

SUSPENSION;ORAL

FYCOMPA

	+!	CATALYST PHARMS	0.5MG/ML	N208277	001	Apr 29, 2016

TABLET;ORAL

FYCOMPA

	+	CATALYST PHARMS	2MG	N202834	001	Oct 22, 2012
	+		4MG	N202834	002	Oct 22, 2012
	+		6MG	N202834	003	Oct 22, 2012
	+		8MG	N202834	004	Oct 22, 2012
	+		10MG	N202834	005	Oct 22, 2012
	+!		12MG	N202834	006	Oct 22, 2012

PERFLUOROHEXYLOCTANE

SOLUTION/DROPS;OPHTHALMIC

MIEBO

	+!	BAUSCH AND LOMB INC	1.338GM/ML	N216675	001	May 18, 2023

PERFLUTREN

INJECTABLE;INTRAVENOUS

DEFINITY

	+!	LANTHEUS MEDCL	13.04MG/2ML (6.52MG/ML)	N021064	001	Jul 31, 2001

DEFINITY RT

	+!	LANTHEUS MEDCL	13.04MG/2ML (6.52MG/ML)	N021064	002	Nov 17, 2020

PERINDOPRIL ERBUMINE
TABLET;ORAL
PERINDOPRIL ERBUMINE

		AUROBINDO PHARMA	2MG	A079070	001	Nov 10, 2009
			4MG	A079070	002	Nov 10, 2009
	!		8MG	A079070	003	Nov 10, 2009

PERMETHRIN
CREAM;TOPICAL
ELIMITE

AB	**+**	AUROBINDO PHARMA USA	**5%**	**N019855**	**001**	Aug 25, 1989

PERMETHRIN

AB		ACTAVIS LABS	**5%**	**A074806**	**001**	Jan 23, 1998
AB		DR REDDYS LABS EU	**5%**	**A209732**	**001**	Aug 01, 2023
AB		ENCUBE ETHICALS	**5%**	**A211303**	**001**	Apr 03, 2019
AB	**!**	PADAGIS ISRAEL	**5%**	**A076369**	**001**	Apr 21, 2003

PERPHENAZINE
TABLET;ORAL
PERPHENAZINE

AB		APPCO	**2MG**	**A210163**	**001**	May 18, 2022
AB			**4MG**	**A210163**	**002**	May 18, 2022
AB			**8MG**	**A210163**	**003**	May 18, 2022
AB			**16MG**	**A210163**	**004**	May 18, 2022
AB		RISING	**2MG**	**A205056**	**001**	Mar 01, 2019
AB			**4MG**	**A205056**	**002**	Mar 01, 2019
AB			**8MG**	**A205056**	**003**	Mar 01, 2019
AB			**16MG**	**A205056**	**004**	Mar 01, 2019
AB		SANDOZ	**2MG**	**A089685**	**002**	Dec 08, 1988
AB			**4MG**	**A089685**	**003**	Dec 08, 1988
AB			**8MG**	**A089685**	**001**	Dec 08, 1988
AB	**!**		**16MG**	**A089685**	**004**	Dec 08, 1988
AB		VINTAGE PHARMS	**2MG**	**A040226**	**001**	Dec 31, 1998
AB			**4MG**	**A040226**	**002**	Dec 31, 1998
AB			**8MG**	**A040226**	**003**	Dec 31, 1998
AB			**16MG**	**A040226**	**004**	Dec 31, 1998
AB		WATSON LABS INC	**2MG**	**A207582**	**001**	Oct 17, 2016
AB			**4MG**	**A207582**	**002**	Oct 17, 2016
AB			**8MG**	**A207582**	**003**	Oct 17, 2016
AB			**16MG**	**A207582**	**004**	Oct 17, 2016
AB		WILSHIRE PHARMS INC	**2MG**	**A205973**	**001**	Dec 17, 2015
AB			**4MG**	**A205973**	**002**	Dec 17, 2015
AB			**8MG**	**A205973**	**003**	Dec 17, 2015
AB			**16MG**	**A205973**	**004**	Dec 17, 2015
AB		ZYDUS PHARMS	**2MG**	**A205232**	**001**	Apr 06, 2020
AB			**4MG**	**A205232**	**002**	Apr 06, 2020
AB			**8MG**	**A205232**	**003**	Apr 06, 2020
AB			**16MG**	**A205232**	**004**	Apr 06, 2020

PEXIDARTINIB HYDROCHLORIDE
CAPSULE;ORAL
TURALIO

	+	DAIICHI SANKYO INC	EQ 125MG BASE	N211810	002	Oct 14, 2022

PHENDIMETRAZINE TARTRATE
CAPSULE, EXTENDED RELEASE;ORAL
PHENDIMETRAZINE TARTRATE

	+!	VIRTUS	105MG	N018074	001	

TABLET;ORAL
BONTRIL PDM

AA	**+!**	VALEANT	**35MG**	**A085272**	**001**	

PHENDIMETRAZINE TARTRATE

AA		CHARTWELL	**35MG**	**A089452**	**001**	Oct 30, 1991
AA		ELITE LABS INC	**35MG**	**A040762**	**001**	Jan 28, 2008
AA		KVK TECH	**35MG**	**A091042**	**001**	Aug 31, 2010
AA		VIRTUS	**35MG**	**A085588**	**001**	

PHENELZINE SULFATE
TABLET;ORAL
NARDIL

AB	**+!**	PARKE DAVIS	**EQ 15MG BASE**	**N011909**	**002**	

PHENELZINE SULFATE

AB		NOVEL LABS INC	**EQ 15MG BASE**	**A200181**	**001**	Dec 08, 2010

PHENOBARBITAL SODIUM

POWDER;INTRAVENOUS

SEZABY

	+!	SUN PHARM INDS INC	100MG/VIAL	N215910	001	Nov 17, 2022

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIBENZYLINE

AB	**+**	CONCORDIA	**10MG**	**N008708**	**001**	

PHENOXYBENZAMINE HYDROCHLORIDE

AB		AMNEAL	**10MG**	**A212568**	**001**	Oct 27, 2020
AB		AUROBINDO PHARMA	**10MG**	**A215600**	**001**	May 08, 2023
AB		NOVITIUM PHARMA	**10MG**	**A215042**	**001**	Jul 19, 2022
AB	**!**	PAR PHARM INC	**10MG**	**A204522**	**001**	Jan 24, 2017
AB		RISING	**10MG**	**A204551**	**001**	Jun 20, 2023

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

ADIPEX-P

AA	**+!**	TEVA	**37.5MG**	**A088023**	**001**	Aug 02, 1983

PHENTERMINE HYDROCHLORIDE

AA		AUROLIFE PHARMA LLC	**15MG**	**A204318**	**001**	Nov 09, 2016
AA			**30MG**	**A204318**	**002**	Nov 09, 2016
AA		ELITE LABS	**15MG**	**A202248**	**001**	Sep 28, 2012
AA			**30MG**	**A202248**	**002**	Sep 28, 2012
AA		ELITE LABS INC	**37.5MG**	**A040228**	**001**	Jun 19, 1997
AA		INVAGEN PHARMS	**15MG**	**A202858**	**001**	Feb 14, 2014
AA			**30MG**	**A202858**	**002**	Feb 14, 2014
AA			**30MG**	**A204414**	**001**	May 05, 2014
AA			**37.5MG**	**A202846**	**001**	Feb 05, 2014
AA		KVK TECH	**15MG**	**A040886**	**002**	Mar 31, 2008
AA			**30MG**	**A040875**	**001**	Mar 21, 2008
AA			**30MG**	**A040886**	**001**	Mar 31, 2008
AA			**37.5MG**	**A040887**	**001**	Apr 24, 2008
AA		NUVO PHARM	**15MG**	**A205019**	**001**	Dec 05, 2014
AA			**30MG**	**A205019**	**002**	Dec 05, 2014
AA			**37.5MG**	**A205017**	**001**	Sep 25, 2014
AA	**+!**	SANDOZ	**15MG**	**A087190**	**002**	
AA	**+!**		**30MG**	**A086945**	**001**	Jul 20, 1983
AA	**+!**		**30MG**	**A087190**	**001**	

TABLET;ORAL

ADIPEX-P

AA	**+!**	TEVA	**37.5MG**	**A085128**	**001**	

LOMAIRA

AA	**!**	AVANTHI INC	**8MG**	**A203495**	**001**	Sep 12, 2016

PHENTERMINE HYDROCHLORIDE

AA		AUROLIFE PHARMA LLC	**37.5MG**	**A203068**	**001**	Aug 06, 2014
AA		ELITE LABS	**37.5MG**	**A200272**	**001**	Jan 31, 2011
AA		ELITE LABS INC	**37.5MG**	**A040190**	**001**	May 30, 1997
AA		INVAGEN PHARMS	**37.5MG**	**A202942**	**001**	Feb 05, 2014
AA		KVK TECH	**37.5MG**	**A040876**	**001**	Mar 31, 2008
AA		KVK TECH INC	**8MG**	**A203436**	**001**	Mar 17, 2017
AA		MERRO PHARM USA	**37.5MG**	**A206342**	**001**	Nov 18, 2016
AA		NUVO PHARM	**37.5MG**	**A205008**	**001**	Sep 25, 2014
AA		PRINSTON INC	**37.5MG**	**A040377**	**001**	Jan 04, 2002
AA		SUN PHARM INDUSTRIES	**37.5MG**	**A040526**	**001**	Oct 23, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

PHENTERMINE HYDROCHLORIDE

		ZYDUS PHARMS	15MG	A204663	001	Jun 28, 2017
			30MG	A204663	002	Jun 28, 2017
			37.5MG	A204663	003	Jun 28, 2017

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

QSYMIA

	+	VIVUS	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012
	+		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012
	+		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012
	+!		EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION

PHENTOLAMINE MESYLATE

AP	**!**	HIKMA	**5MG/VIAL**	**A040235**	**001**	Mar 11, 1998
AP		PRECISION DOSE INC	**5MG/VIAL**	**A207686**	**001**	Jul 14, 2017

ORAVERSE

	+!	SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008

SOLUTION;OPHTHALMIC

RYZUMVI

	+!	OCUPHIRE	EQ 0.75% BASE	N217064	001	Sep 25, 2023

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1		ACCORD HLTHCARE	**10MG/ML (10MG/ML)**	**A213237**	**001**	Jul 01, 2020
AP1			**50MG/5ML (10MG/ML)**	**A213237**	**002**	Jul 01, 2020
AP1			**100MG/10ML (10MG/ML)**	**A213237**	**003**	Jul 01, 2020
AP1		AMNEAL	**10MG/ML (10MG/ML)**	**A211079**	**001**	Jul 05, 2018
AP1			**50MG/5ML (10MG/ML)**	**A211078**	**001**	Jul 19, 2018
AP1			**100MG/10ML (10MG/ML)**	**A211078**	**002**	Jul 19, 2018
AP1		CAPLIN	**10MG/ML (10MG/ML)**	**A213318**	**001**	Jun 11, 2020
AP1			**50MG/5ML (10MG/ML)**	**A213318**	**002**	Jun 11, 2020
AP1			**100MG/10ML (10MG/ML)**	**A213318**	**003**	Jun 11, 2020
AP1		EUGIA PHARMA	**50MG/5ML (10MG/ML)**	**A210697**	**001**	Nov 13, 2020
AP1			**100MG/10ML (10MG/ML)**	**A210697**	**002**	Nov 13, 2020
AP1		FRESENIUS KABI USA	**50MG/5ML (10MG/ML)**	**A210666**	**001**	Jan 30, 2019
AP1			**100MG/10ML (10MG/ML)**	**A210666**	**002**	Jan 30, 2019
AP1		GLAND PHARMA LTD	**10MG/ML (10MG/ML)**	**A211920**	**003**	Apr 08, 2021
AP1			**50MG/5ML (10MG/ML)**	**A211920**	**001**	Jun 05, 2020
AP1			**100MG/10ML (10MG/ML)**	**A211920**	**002**	Jun 05, 2020
AP1		MANKIND PHARMA	**10MG/ML (10MG/ML)**	**A217069**	**001**	Aug 30, 2022
AP1			**50MG/5ML (10MG/ML)**	**A217069**	**002**	Aug 30, 2022
AP1			**100MG/10ML (10MG/ML)**	**A217069**	**003**	Aug 30, 2022
AP1		MEITHEAL	**50MG/5ML (10MG/ML)**	**A210333**	**001**	Apr 27, 2018
AP1			**100MG/10ML (10MG/ML)**	**A210333**	**002**	Apr 27, 2018
AP1		PAR STERILE PRODUCTS	**50MG/5ML (10MG/ML)**	**A210025**	**002**	Dec 21, 2018
AP1			**100MG/10ML (10MG/ML)**	**A210025**	**003**	Dec 21, 2018
AP1		PROVEPHARM SAS	**10MG/ML (10MG/ML)**	**A211081**	**001**	Jul 17, 2020
AP1			**50MG/5ML (10MG/ML)**	**A211081**	**002**	Jul 17, 2020
AP1			**100MG/10ML (10MG/ML)**	**A211081**	**003**	Jul 17, 2020
AP1		SAGENT PHARMS INC	**10MG/ML (10MG/ML)**	**A209967**	**001**	Jan 16, 2020
AP1			**50MG/5ML (10MG/ML)**	**A209967**	**002**	Jan 16, 2020
AP1			**100MG/10ML (10MG/ML)**	**A209967**	**003**	Jan 16, 2020
AP1		SANDOZ	**10MG/ML (10MG/ML)**	**A208905**	**001**	Jan 31, 2019
AP1			**50MG/5ML (10MG/ML)**	**A208905**	**002**	Jan 31, 2019
AP1			**100MG/10ML (10MG/ML)**	**A208905**	**003**	Jan 31, 2019

VAZCULEP

AP1	**+!**	EXELA PHARMA	**10MG/ML (10MG/ML)**	**N204300**	**001**	Jun 27, 2014
AP1	**+!**		**50MG/5ML (10MG/ML)**	**N204300**	**002**	Jun 27, 2014
AP1	**+!**		**100MG/10ML (10MG/ML)**	**N204300**	**003**	Jun 27, 2014

PHENYLEPHRINE HYDROCHLORIDE

AP2		AVET LIFESCIENCES	**10MG/ML (10MG/ML)**	**A209968**	**001**	Feb 28, 2023
AP2		BE PHARMS	**10MG/ML (10MG/ML)**	**A217521**	**001**	Jun 26, 2023
AP2			**50MG/5ML (10MG/ML)**	**A217521**	**002**	Jun 26, 2023
AP2			**100MG/10ML (10MG/ML)**	**A217521**	**003**	Jun 26, 2023
AP2		EUGIA PHARMA	**10MG/ML (10MG/ML)**	**A210696**	**001**	Jan 07, 2021
AP2		FRESENIUS KABI USA	**10MG/ML (10MG/ML)**	**A210665**	**001**	Jan 29, 2019
AP2	**+!**	HIKMA	**10MG/ML (10MG/ML)**	**N203826**	**001**	Dec 20, 2012
AP2		MEITHEAL	**10MG/ML (10MG/ML)**	**A210334**	**001**	Apr 27, 2018

BIORPHEN

	+!	DR REDDYS LABS SA	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019

IMMPHENTIV

	+!	HIKMA	0.5MG/5ML (0.1MG/ML)	N203826	004	Mar 09, 2023
	+!		1MG/10ML (0.1MG/ML)	N203826	005	Mar 09, 2023

PHENYLEPHRINE HYDROCHLORIDE

	+!	HIKMA	50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019
	+!		100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	**+**	ALCON	**2.5%**	**N207926**	**001**	Jan 15, 2015
AT	**+**		**10%**	**N207926**	**002**	Jan 15, 2015
AT	**!**	MANKIND PHARMA	**2.5%**	**A216859**	**001**	Sep 29, 2022

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	**!**		**10%**	**A216496**	**001**	Jan 11, 2023
AT	**+!**	PARAGON BIOTECK	**2.5%**	**N203510**	**001**	Mar 21, 2013
AT	**+!**		**10%**	**N203510**	**002**	Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA		HIKMA	**5MG/5ML;6.25MG/5ML**	**A040675**	**001**	Dec 23, 2014
AA	**!**	PHARM ASSOC	**5MG/5ML;6.25MG/5ML**	**A040654**	**001**	Dec 07, 2006

PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE

AA		AMNEAL PHARMS	**5MG/5ML;6.25MG/5ML**	**A040902**	**001**	Aug 25, 2009

PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE

SPRAY, METERED;OPHTHALMIC

MYDCOMBI

	+!	EYENOVIA	2.5%;1%	N215352	001	May 05, 2023

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-125

AB	**+!**	VIATRIS	**125MG/5ML**	**N008762**	**001**	

PHENYTOIN

AB		PAI HOLDINGS PHARM	**125MG/5ML**	**A040420**	**001**	Apr 19, 2002
AB		TARO	**125MG/5ML**	**A040521**	**001**	Mar 08, 2004
AB		VISTAPHARM	**125MG/5ML**	**A040342**	**001**	Jan 31, 2001
AB			**125MG/5ML**	**A040342**	**002**	Aug 18, 2005

TABLET, CHEWABLE;ORAL

DILANTIN

AB	**+!**	PHARMACIA	**50MG**	**A084427**	**001**	

PHENYTOIN

AB		EPIC PHARMA LLC	**50MG**	**A040884**	**001**	Nov 28, 2014
AB		RISING	**50MG**	**A200691**	**001**	Dec 26, 2012
AB		TARO	**50MG**	**A200565**	**001**	Apr 17, 2014

PHENYTOIN SODIUM

CAPSULE;ORAL

DILANTIN

AB	**+!**	VIATRIS	**100MG EXTENDED**	**A084349**	**002**	

EXTENDED PHENYTOIN SODIUM

AB		AMNEAL PHARMS NY	**100MG EXTENDED**	**A040765**	**001**	Nov 12, 2008
AB		SUN PHARM INDS	**200MG EXTENDED**	**A040731**	**001**	Jun 30, 2008
AB			**300MG EXTENDED**	**A040731**	**002**	Jun 30, 2008
AB		TARO	**100MG EXTENDED**	**A040684**	**001**	Sep 05, 2006

PHENYTEK

AB		MYLAN	**200MG EXTENDED**	**A040298**	**002**	Dec 06, 2001
AB	**!**		**300MG EXTENDED**	**A040298**	**003**	Dec 06, 2001

PHENYTOIN SODIUM

AB		AURO BINDO PHARMA	**100MG EXTENDED**	**A204309**	**001**	Jun 10, 2015

DILANTIN

	+!	VIATRIS	30MG EXTENDED	A084349	001	

INJECTABLE;INJECTION

PHENYTOIN SODIUM

AP		ACELLA	**50MG/ML**	**A040573**	**001**	Sep 13, 2006
AP	**+!**	WEST-WARD PHARMS INT	**50MG/ML**	**A084307**	**001**	

PHYTONADIONE

INJECTABLE;INJECTION

PHYTONADIONE

AB1		DR REDDYS	**10MG/ML**	**A207719**	**001**	May 22, 2019

VITAMIN K1

AB1	**+!**	HOSPIRA	**10MG/ML**	**A087955**	**001**	Jul 25, 1983

PHYTONADIONE

BP	+!	INTL MEDICATION	1MG/0.5ML	A083722	001	

VITAMIN K1

BP	+!	HOSPIRA	1MG/0.5ML	A087954	001	Jul 25, 1983

PHYTONADIONE

	!	CIPLA	1MG/0.5ML	A214596	001	Apr 22, 2022
	!		10MG/ML	A214596	002	Apr 22, 2022

TABLET;ORAL

PHYTONADIONE

AB		AGNITIO	**5MG**	**A213336**	**001**	Oct 12, 2023

PHYTONADIONE

TABLET;ORAL

PHYTONADIONE

AB		AMNEAL PHARMS CO	**5MG**	**A209373**	**001**	May 11, 2018
AB		SCIEGEN PHARMS INC	**5MG**	**A213329**	**001**	Jul 28, 2023
AB	!	ZYDUS	**5MG**	**A210189**	**001**	Feb 20, 2019

PIFLUFOLASTAT F-18

SOLUTION;INTRAVENOUS

PYLARIFY

	+!	PROGENICS PHARMS INC	50ML (1-80mCi/ML)	N214793	001	May 26, 2021

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

ISOPTO CARPINE

AT	**+!**	SANDOZ	**1%**	**N200890**	**001**	Jun 22, 2010
AT	**+!**		**2%**	**N200890**	**002**	Jun 22, 2010
AT	**+!**		**4%**	**N200890**	**003**	Jun 22, 2010

PILOCARPINE HYDROCHLORIDE

AT		AMNEAL	**1%**	**A214193**	**001**	Sep 21, 2020
AT			**2%**	**A214193**	**002**	Sep 21, 2020
AT			**4%**	**A214193**	**003**	Sep 21, 2020
AT		RISING	**1%**	**A204398**	**001**	Sep 27, 2017
AT			**2%**	**A204398**	**002**	Sep 27, 2017
AT			**4%**	**A204398**	**003**	Sep 27, 2017
AT		SOMERSET THERAPS LLC	**1%**	**A210384**	**001**	Nov 25, 2019
AT			**2%**	**A210384**	**002**	Nov 25, 2019
AT			**4%**	**A210384**	**003**	Nov 25, 2019

QLOSI

	+!	ORASIS PHARMS	0.4%	N217836	001	Oct 17, 2023

VUITY

	+!	ABBVIE	1.25%	N214028	001	Oct 28, 2021

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**5MG**	**A212377**	**001**	Aug 13, 2019
AB			**7.5MG**	**A212377**	**002**	Aug 13, 2019
AB		IMPAX LABS	**5MG**	**A077248**	**001**	Mar 31, 2006
AB			**7.5MG**	**A077248**	**002**	Mar 31, 2006
AB		INNOGENIX	**5MG**	**A076963**	**001**	Dec 22, 2004
AB			**7.5MG**	**A076963**	**002**	Feb 27, 2007
AB		LANNETT CO INC	**5MG**	**A077220**	**001**	Oct 14, 2005
AB			**7.5MG**	**A077220**	**002**	May 06, 2009
AB		PADAGIS US	**5MG**	**A076746**	**001**	Nov 16, 2004

SALAGEN

AB	**+**	CONCORDIA	**5MG**	**N020237**	**001**	Mar 22, 1994
AB	**+!**		**7.5MG**	**N020237**	**002**	Apr 18, 2003

PIMAVANSERIN TARTRATE

CAPSULE;ORAL

NUPLAZID

	+!	ACADIA PHARMS INC	EQ 34MG BASE	N210793	001	Jun 28, 2018

TABLET;ORAL

NUPLAZID

	+!	ACADIA PHARMS INC	EQ 10MG BASE	N207318	002	Jun 28, 2018

PIMECROLIMUS

CREAM;TOPICAL

ELIDEL

AB	**+!**	BAUSCH	**1%**	**N021302**	**001**	Dec 13, 2001

PIMECROLIMUS

AB		ACTAVIS LABS UT INC	**1%**	**A209345**	**001**	Dec 27, 2018
AB		GLENMARK PHARMS LTD	**1%**	**A211769**	**001**	Aug 29, 2019

PIMOZIDE

TABLET;ORAL

PIMOZIDE

		PAR PHARM	1MG	A204521	001	Sep 28, 2015
	!		2MG	A204521	002	Sep 28, 2015

PINDOLOL

TABLET;ORAL

PINDOLOL

AB		ANI PHARMS	**5MG**	**A073609**	**002**	Mar 29, 1993
AB			**10MG**	**A073609**	**001**	Mar 29, 1993
AB		AUROBINDO PHARMA USA	**5MG**	**A074019**	**001**	Sep 03, 1992
AB	!		**10MG**	**A074019**	**002**	Sep 03, 1992
AB		BAYSHORE PHARMS LLC	**5MG**	**A211712**	**001**	Aug 01, 2019
AB			**10MG**	**A211712**	**002**	Aug 01, 2019
AB		NOSTRUM LABS INC	**5MG**	**A205415**	**001**	Jan 13, 2016
AB			**10MG**	**A205415**	**002**	Jan 13, 2016
AB		SUN PHARM INDUSTRIES	**5MG**	**A074063**	**001**	Jan 27, 1994
AB			**10MG**	**A074063**	**002**	Jan 27, 1994

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOS

AB	+	TAKEDA PHARMS USA	**EQ 15MG BASE**	**N021073**	**001**	Jul 15, 1999
AB	+		**EQ 30MG BASE**	**N021073**	**002**	Jul 15, 1999
AB	+!		**EQ 45MG BASE**	**N021073**	**003**	Jul 15, 1999

PIOGLITAZONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 15MG BASE**	**A200044**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A200044**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A200044**	**003**	Feb 13, 2013
AB		ANNORA PHARMA	**EQ 15MG BASE**	**A204133**	**001**	Apr 07, 2014
AB			**EQ 30MG BASE**	**A204133**	**002**	Apr 07, 2014
AB			**EQ 45MG BASE**	**A204133**	**003**	Apr 07, 2014
AB		AUROBINDO PHARMA LTD	**EQ 15MG BASE**	**A200268**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A200268**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A200268**	**003**	Feb 13, 2013
AB		CHARTWELL RX	**EQ 15MG BASE**	**A076798**	**001**	Oct 26, 2012
AB			**EQ 30MG BASE**	**A076798**	**002**	Oct 26, 2012
AB			**EQ 45MG BASE**	**A076798**	**003**	Oct 26, 2012
AB		MACLEODS PHARMS LTD	**EQ 15MG BASE**	**A202467**	**001**	Feb 06, 2013
AB			**EQ 30MG BASE**	**A202467**	**002**	Feb 06, 2013
AB			**EQ 45MG BASE**	**A202467**	**003**	Feb 06, 2013
AB		PRINSTON INC	**EQ 15MG BASE**	**A207806**	**001**	Apr 17, 2018
AB			**EQ 30MG BASE**	**A207806**	**002**	Apr 17, 2018
AB			**EQ 45MG BASE**	**A207806**	**003**	Apr 17, 2018
AB		PURACAP PHARM LLC	**EQ 15MG BASE**	**A206738**	**001**	Oct 06, 2017
AB			**EQ 30MG BASE**	**A206738**	**002**	Oct 06, 2017
AB			**EQ 45MG BASE**	**A206738**	**003**	Oct 06, 2017
AB		SANDOZ	**EQ 15MG BASE**	**A078670**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A078670**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A078670**	**003**	Feb 13, 2013
AB		SHUANGCHENG	**EQ 15MG BASE**	**A210165**	**001**	Jan 22, 2021
AB			**EQ 30MG BASE**	**A210165**	**002**	Jan 22, 2021
AB			**EQ 45MG BASE**	**A210165**	**003**	Jan 22, 2021
AB		TEVA PHARMS USA	**EQ 15MG BASE**	**A077210**	**001**	Jan 10, 2014
AB			**EQ 30MG BASE**	**A077210**	**002**	Jan 10, 2014
AB			**EQ 45MG BASE**	**A077210**	**003**	Jan 10, 2014
AB		ZYDUS PHARMS USA INC	**EQ 15MG BASE**	**A202456**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A202456**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A202456**	**003**	Feb 13, 2013

PIPERACILLIN SODIUM

INJECTABLE;INJECTION

PIPERACILLIN

	!	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003
	!		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003
	!		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003
	!		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		ASTRAL	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A212287**	**001**	Jul 29, 2019
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A212287**	**002**	Jul 29, 2019
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A212287**	**003**	Jul 29, 2019
AP		EUGIA PHARMA	**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A217409**	**002**	Oct 12, 2023

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A217409**	**001**	Oct 12, 2023
AP		EUGIA PHARMA SPECLTS	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065498**	**001**	May 23, 2011
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065498**	**002**	May 23, 2011
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065498**	**003**	May 23, 2011
AP		FRESENIUS KABI	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A203719**	**001**	May 18, 2018
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A203719**	**002**	May 18, 2018
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A203719**	**003**	May 18, 2018
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A203720**	**001**	May 11, 2018
AP		FRESENIUS KABI USA	**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A206204**	**001**	May 11, 2018
AP		ISTITUTO BIO ITA SPA	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065523**	**001**	May 31, 2011
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065523**	**002**	May 31, 2011
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065523**	**003**	May 31, 2011
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A090498**	**001**	May 31, 2011
AP		PROVEPHARM SAS	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A207847**	**001**	Jan 13, 2017
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A207847**	**002**	Jan 13, 2017
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A207848**	**002**	Jan 13, 2017
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A207847**	**003**	Jan 13, 2017
AP			**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A207848**	**001**	May 11, 2018
AP		SAGENT PHARMS INC	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A208674**	**001**	Feb 16, 2021
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A208674**	**002**	Feb 16, 2021
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A208674**	**003**	Feb 16, 2021
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A208675**	**001**	Feb 16, 2021
AP		SANDOZ	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065362**	**001**	Oct 21, 2010
AP			**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065363**	**001**	Oct 21, 2010
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065362**	**002**	Oct 21, 2010
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065363**	**002**	Oct 21, 2010
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065362**	**003**	Oct 21, 2010
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065363**	**003**	Oct 21, 2010
AP	**!**		**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A203557**	**001**	Oct 29, 2014
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A203557**	**002**	Jul 08, 2021
AP		SHANDONG	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A204959**	**001**	Aug 10, 2018
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A204959**	**002**	Aug 10, 2018
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A204959**	**003**	Aug 10, 2018
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A217243**	**001**	Apr 14, 2023
AP		STERISCIENCE	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065458**	**001**	Aug 15, 2014
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065458**	**002**	Aug 15, 2014
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065458**	**003**	Aug 15, 2014
AP	**!**	WOCKHARDT BIO AG	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A206996**	**001**	Mar 22, 2017
AP	**!**		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A206996**	**002**	Mar 22, 2017
AP	**!**		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A206996**	**003**	Mar 22, 2017
AP	**!**		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A207146**	**001**	Mar 17, 2017
	ZOSYN IN PLASTIC CONTAINER					
	+!	BAXTER HLTHCARE CORP	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998
	+!		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998
	+!		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998

PIRFENIDONE

CAPSULE;ORAL

ESBRIET

AB	**+!**	GENENTECH INC	**267MG**	**N022535**	**001**	Oct 15, 2014

PIRFENIDONE

AB		ACCORD HLTHCARE	**267MG**	**A212731**	**001**	Jan 20, 2022
AB		AMNEAL	**267MG**	**A212569**	**001**	Jan 03, 2022
AB		LAURUS	**267MG**	**A212724**	**001**	Jul 19, 2022
AB		SANDOZ	**267MG**	**A212600**	**001**	Jun 13, 2022
AB		SCIEGEN PHARMS INC	**267MG**	**A212077**	**001**	Aug 01, 2022

TABLET;ORAL

ESBRIET

AB	**+**	GENENTECH INC	**267MG**	**N208780**	**001**	Jan 11, 2017
AB	**+!**		**801MG**	**N208780**	**003**	Jan 11, 2017

PIRFENIDONE

AB		ACCORD HLTHCARE	**267MG**	**A212730**	**001**	Jan 25, 2022
AB			**801MG**	**A212730**	**002**	Jan 25, 2022
AB		AIZANT	**267MG**	**A212747**	**001**	Jul 21, 2022
AB			**534MG**	**A212747**	**002**	Jul 21, 2022
AB			**801MG**	**A212747**	**003**	Jul 21, 2022
AB		ALEMBIC	**267MG**	**A212708**	**001**	May 20, 2022

PIRFENIDONE

TABLET;ORAL

PIRFENIDONE

AB			**801MG**	**A212708**	**002**	May 20, 2022
AB		AMNEAL	**267MG**	**A212570**	**001**	Mar 25, 2022
AB			**801MG**	**A212570**	**002**	Mar 25, 2022
AB		APOTEX	**267MG**	**A212709**	**001**	May 31, 2023
AB			**801MG**	**A212709**	**002**	May 31, 2023
AB		HETERO LABS LTD V	**267MG**	**A212674**	**001**	Sep 21, 2022
AB			**801MG**	**A212674**	**002**	Sep 21, 2022
AB		LAURUS	**267MG**	**A212722**	**001**	Jul 19, 2022
AB			**534MG**	**A212722**	**002**	Jul 19, 2022
AB			**801MG**	**A212722**	**003**	Jul 19, 2022
AB		MICRO LABS	**267MG**	**A212680**	**001**	May 18, 2022
AB			**801MG**	**A212680**	**002**	May 18, 2022
AB		MSN	**267MG**	**A212772**	**001**	May 24, 2022
AB			**801MG**	**A212772**	**002**	May 24, 2022
AB		SANDOZ	**267MG**	**A212560**	**001**	Apr 28, 2022
AB			**801MG**	**A212560**	**002**	Apr 28, 2022
AB		SCIEGEN PHARMS INC	**267MG**	**A212078**	**001**	Aug 01, 2022
AB			**801MG**	**A212078**	**002**	Aug 01, 2022
AB		TEVA PHARMS USA	**267MG**	**A212759**	**001**	Jan 25, 2022
AB			**801MG**	**A212759**	**002**	Jan 25, 2022

PIROXICAM

CAPSULE;ORAL

FELDENE

AB	**+**	PFIZER	**10MG**	**N018147**	**002**	Apr 06, 1982
AB	**+!**		**20MG**	**N018147**	**003**	Apr 06, 1982

PIROXICAM

AB		CADILA	**10MG**	**A205585**	**001**	Jul 17, 2018
AB			**20MG**	**A205585**	**002**	Jul 17, 2018
AB		FLAMINGO PHARMS	**10MG**	**A207938**	**001**	Sep 09, 2016
AB			**20MG**	**A207938**	**002**	Sep 09, 2016
AB		MICRO LABS	**10MG**	**A206152**	**001**	Dec 29, 2017
AB			**20MG**	**A206152**	**002**	Dec 29, 2017
AB		NOSTRUM LABS INC	**10MG**	**A074118**	**002**	Jun 15, 1993
AB			**20MG**	**A074118**	**001**	Jun 15, 1993
AB		STRIDES PHARMA	**10MG**	**A206136**	**001**	Jun 20, 2017
AB			**10MG**	**A210347**	**001**	Jan 26, 2018
AB			**20MG**	**A206136**	**002**	Jun 20, 2017
AB			**20MG**	**A210347**	**002**	Jan 26, 2018
AB		TEVA	**10MG**	**A074131**	**001**	Dec 11, 1992
AB			**20MG**	**A074131**	**002**	Dec 11, 1992
AB		UNICHEM	**10MG**	**A208340**	**001**	Apr 13, 2017
AB			**20MG**	**A208340**	**002**	Apr 13, 2017

PIRTOBRUTINIB

TABLET;ORAL

JAYPIRCA

	+	LOXO ONCOL	50MG	N216059	001	Jan 27, 2023
	+!		100MG	N216059	002	Jan 27, 2023

PITAVASTATIN CALCIUM

TABLET;ORAL

LIVALO

AB	**+**	KOWA CO	**EQ 1MG BASE**	**N022363**	**001**	Aug 03, 2009
AB	**+**		**EQ 2MG BASE**	**N022363**	**002**	Aug 03, 2009
AB	**+!**		**EQ 4MG BASE**	**N022363**	**003**	Aug 03, 2009

PITAVASTATIN CALCIUM

AB		AUROBINDO PHARMA	**EQ 1MG BASE**	**A206015**	**001**	Dec 20, 2016
AB			**EQ 2MG BASE**	**A206015**	**002**	Dec 20, 2016
AB			**EQ 4MG BASE**	**A206015**	**003**	Dec 20, 2016
AB		LUPIN LTD	**EQ 1MG BASE**	**A206029**	**001**	Nov 20, 2023
AB			**EQ 2MG BASE**	**A206029**	**002**	Nov 20, 2023
AB			**EQ 4MG BASE**	**A206029**	**003**	Nov 20, 2023
AB		MYLAN	**EQ 1MG BASE**	**A206070**	**001**	Apr 04, 2019
AB			**EQ 2MG BASE**	**A206070**	**002**	Apr 04, 2019
AB			**EQ 4MG BASE**	**A206070**	**003**	Apr 04, 2019
AB		ORIENT PHARMA CO LTD	**EQ 1MG BASE**	**A205932**	**001**	Feb 03, 2017
AB			**EQ 2MG BASE**	**A205932**	**002**	Feb 03, 2017
AB			**EQ 4MG BASE**	**A205932**	**003**	Feb 03, 2017
AB		SAWAI USA	**EQ 1MG BASE**	**A205955**	**001**	Feb 03, 2017

PITAVASTATIN CALCIUM
TABLET;ORAL
PITAVASTATIN CALCIUM

AB			**EQ 2MG BASE**	**A205955**	**002**	Feb 03, 2017
AB			**EQ 4MG BASE**	**A205955**	**003**	Feb 03, 2017
AB		ZYDUS PHARMS	**EQ 1MG BASE**	**A206047**	**001**	Feb 22, 2023
AB			**EQ 2MG BASE**	**A206047**	**002**	Feb 22, 2023
AB			**EQ 4MG BASE**	**A206047**	**003**	Feb 22, 2023

PITAVASTATIN MAGNESIUM
TABLET;ORAL
ZYPITAMAG

	+	MEDICURE	EQ 2MG BASE	N208379	002	Jul 14, 2017
	+!		EQ 4MG BASE	N208379	003	Jul 14, 2017

PITOLISANT HYDROCHLORIDE
TABLET;ORAL
WAKIX

	+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019
	+!		EQ 17.8MG BASE	N211150	002	Aug 14, 2019

PLAZOMICIN SULFATE
SOLUTION;INTRAVENOUS
ZEMDRI

	+!	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018

PLECANATIDE
TABLET;ORAL
TRULANCE

	+!	SALIX	3MG	N208745	001	Jan 19, 2017

PLERIXAFOR
SOLUTION;SUBCUTANEOUS
MOZOBIL

AP	**+!**	GENZYME	**24MG/1.2ML (20MG/ML)**	**N022311**	**001**	Dec 15, 2008

PLERIXAFOR

AP		AMNEAL	**24MG/1.2ML (20MG/ML)**	**A215334**	**001**	Jul 24, 2023
AP		DR REDDYS	**24MG/1.2ML (20MG/ML)**	**A205182**	**001**	Jul 24, 2023
AP		EUGIA PHARMA	**24MG/1.2ML (20MG/ML)**	**A213672**	**001**	Jul 24, 2023
AP		KINDOS	**24MG/1.2ML (20MG/ML)**	**A215698**	**001**	Jul 24, 2023
AP		MSN	**24MG/1.2ML (20MG/ML)**	**A211901**	**001**	Jul 24, 2023
AP		TEVA PHARMS USA INC	**24MG/1.2ML (20MG/ML)**	**A205197**	**001**	Jul 24, 2023
AP		ZYDUS PHARMS	**24MG/1.2ML (20MG/ML)**	**A208980**	**001**	Jul 26, 2023

PODOFILOX
GEL;TOPICAL
CONDYLOX

AB	**+!**	ALLERGAN	**0.5%**	**N020529**	**001**	Mar 13, 1997

PODOFILOX

AB		PADAGIS US	**0.5%**	**A211871**	**001**	Nov 22, 2023

SOLUTION;TOPICAL
CONDYLOX

AT	**+!**	TEVA BRANDED PHARM	**0.5%**	**N019795**	**001**	Dec 13, 1990

PODOFILOX

AT		PADAGIS US	**0.5%**	**A075600**	**001**	Jan 29, 2002

POLIDOCANOL
SOLUTION;INTRAVENOUS
ASCLERA

	+	CHEMISCH FBRK KRSSLR	10MG/2ML (5MG/ML)	N021201	001	Mar 30, 2010
	+!		20MG/2ML (10MG/ML)	N021201	002	Mar 30, 2010

VARITHENA

	+!	PROVENSIS	180MG/18ML (10MG/ML)	N205098	001	Nov 25, 2013

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
FOR SOLUTION;ORAL
NULYTELY

AA	**+!**	BRAINTREE	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**N019797**	**001**	Apr 22, 1991

NULYTELY-FLAVORED

AA	**+!**	BRAINTREE	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**N019797**	**002**	Nov 18, 1994

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

AA		STRIDES PHARMA	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A204559**	**001**	Apr 13, 2015

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE WITH FLAVOR PACKS

AA		MYLAN SPECIALITY LP	**240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT**	**N018983**	**012**	Oct 08, 1998

GOLYTELY

AA	**+!**	BRAINTREE	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**N019011**	**001**	Jul 13, 1984

PEG 3350 AND ELECTROLYTES

AA		NOVEL LABS INC	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**A090231**	**001**	Jun 01, 2009
AA			**240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT**	**A090186**	**001**	Jun 01, 2009

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

AA		STRIDES PHARMA	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**A204558**	**001**	Dec 21, 2018

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

AP		BEOWULF ASSET	**EQ 500,000 UNITS BASE/VIAL**	**A063000**	**001**	Sep 30, 1994
AP		EUGIA PHARMA	**EQ 500,000 UNITS BASE/VIAL**	**A206589**	**001**	Apr 04, 2016
AP		FRESENIUS KABI USA	**EQ 500,000 UNITS BASE/VIAL**	**A065372**	**001**	Jan 10, 2008
AP		GLAND	**EQ 500,000 UNITS BASE/VIAL**	**A207322**	**001**	Apr 14, 2016
AP	**!**	XELLIA PHARMS APS	**EQ 500,000 UNITS BASE/VIAL**	**A202766**	**001**	Jan 15, 2014

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		AKORN	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A065006**	**001**	Dec 17, 1998
AT		BAUSCH AND LOMB	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A064120**	**001**	Feb 14, 1997
AT	**!**	SANDOZ	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A064211**	**001**	Apr 13, 1998

POMALIDOMIDE

CAPSULE;ORAL

POMALYST

+	BRISTOL	1MG	N204026	001	Feb 08, 2013
+		2MG	N204026	002	Feb 08, 2013
+		3MG	N204026	003	Feb 08, 2013
+!		4MG	N204026	004	Feb 08, 2013

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

+	TAKEDA PHARMS USA	EQ 10MG BASE	N203469	004	Dec 18, 2020
+		EQ 15MG BASE	N203469	001	Dec 14, 2012
+		EQ 30MG BASE	N203469	003	Apr 23, 2015
+!		EQ 45MG BASE	N203469	002	Dec 14, 2012

PONESIMOD

TABLET;ORAL

PONVORY

+!	JANSSEN PHARMS	2MG	N213498	001	Mar 18, 2021
+		3MG	N213498	002	Mar 18, 2021
+		4MG	N213498	003	Mar 18, 2021
+		5MG	N213498	004	Mar 18, 2021
+		6MG	N213498	005	Mar 18, 2021
+		7MG	N213498	006	Mar 18, 2021
+		8MG	N213498	007	Mar 18, 2021
+		9MG	N213498	008	Mar 18, 2021
+		10MG	N213498	009	Mar 18, 2021
+		20MG	N213498	010	Mar 18, 2021

PORFIMER SODIUM

INJECTABLE;INJECTION

PHOTOFRIN

	PINNACLE BIOLGS	75MG/VIAL	N020451	001	Dec 27, 1995

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL

NOXAFIL POWDERMIX KIT

+!	MSD MERCK CO	300MG	N214770	001	May 31, 2021

SOLUTION;INTRAVENOUS

NOXAFIL

AP	**+!**	MERCK SHARP DOHME	**300MG/16.7ML (18MG/ML)**	**N205596**	**001**	Mar 13, 2014

POSACONAZOLE

SOLUTION;INTRAVENOUS

POSACONAZOLE						
AP		EUGIA PHARMA	**300MG/16.7ML (18MG/ML)**	**A214842**	**001**	Dec 26, 2023
AP		FRESENIUS KABI USA	**300MG/16.7ML (18MG/ML)**	**A209983**	**001**	Dec 26, 2023
AP		GLAND PHARMA LTD	**300MG/16.7ML (18MG/ML)**	**A217553**	**001**	Dec 26, 2023
AP		MYLAN LABS LTD	**300MG/16.7ML (18MG/ML)**	**A211500**	**001**	Dec 26, 2023
AP		PAR STERILE PRODUCTS	**300MG/16.7ML (18MG/ML)**	**A208768**	**001**	May 25, 2022

SUSPENSION;ORAL

NOXAFIL						
AB	**+!**	SCHERING	**40MG/ML**	**N022003**	**001**	Sep 15, 2006
POSACONAZOLE						
AB		HIKMA	**40MG/ML**	**A208773**	**001**	May 15, 2020

TABLET, DELAYED RELEASE;ORAL

NOXAFIL						
AB	**+!**	MERCK SHARP DOHME	**100MG**	**N205053**	**001**	Nov 25, 2013
POSACONAZOLE						
AB		AET PHARMA	**100MG**	**A213454**	**001**	Feb 01, 2021
AB		AMNEAL	**100MG**	**A216626**	**001**	Dec 22, 2022
AB		BIOCON PHARMA	**100MG**	**A214476**	**001**	Feb 04, 2022
AB		DR REDDYS	**100MG**	**A212500**	**001**	Apr 07, 2022
AB		HETERO LABS LTD III	**100MG**	**A214321**	**001**	Dec 08, 2022
AB		I 3 PHARMS	**100MG**	**A216488**	**001**	Aug 28, 2023
AB		SINOTHERAPEUTICS INC	**100MG**	**A212411**	**001**	Aug 21, 2019
AB		SPECGX LLC	**100MG**	**A212226**	**001**	May 10, 2022
AB		WESTMINSTER PHARMS	**100MG**	**A216326**	**001**	Jun 20, 2023

POTASSIUM ACETATE

INJECTABLE;INJECTION

POTASSIUM ACETATE						
AP		EXELA PHARMA	**2MEQ/ML**	**A206203**	**001**	Dec 29, 2015
AP			**2MEQ/ML**	**A212692**	**001**	Oct 20, 2021
AP	**+!**	HOSPIRA	**2MEQ/ML**	**N018896**	**001**	Jul 20, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

KLOR-CON						
AB		UPSHER SMITH LABS	**8MEQ**	**A203106**	**001**	Jul 10, 2015
AB			**10MEQ**	**A203106**	**002**	Jul 10, 2015
POTASSIUM CHLORIDE						
AB		ACTAVIS LABS FL INC	**8MEQ**	**A077419**	**001**	Jun 02, 2008
AB	**!**		**10MEQ**	**A077419**	**002**	Jun 02, 2008
AB		ADARE PHARMS INC	**8MEQ**	**A208864**	**001**	Mar 17, 2017
AB			**10MEQ**	**A208864**	**002**	Mar 17, 2017
AB		AMNEAL PHARMS	**10MEQ**	**A202128**	**001**	Feb 22, 2013
AB		ANCHEN PHARMS	**8MEQ**	**A202886**	**001**	Dec 26, 2013
AB			**10MEQ**	**A202886**	**002**	Dec 26, 2013
AB		GLENMARK PHARMS LTD	**10MEQ**	**A202868**	**001**	Jan 19, 2016
AB		GRANULES	**8MEQ**	**A214686**	**001**	Feb 16, 2021
AB			**10MEQ**	**A214686**	**002**	Feb 16, 2021
AB		LUPIN LTD	**8MEQ**	**A203002**	**001**	Dec 18, 2015
AB			**10MEQ**	**A203002**	**002**	Dec 18, 2015
AB		NOVEL LABS INC	**8MEQ**	**A204828**	**001**	Aug 16, 2016
AB			**10MEQ**	**A204828**	**002**	Aug 16, 2016
AB		PADAGIS US	**8MEQ**	**A200185**	**001**	May 18, 2011
AB			**10MEQ**	**A200185**	**002**	May 18, 2011
AB		PRINSTON INC	**8MEQ**	**A209026**	**001**	Jun 11, 2019
AB			**10MEQ**	**A209026**	**002**	Jun 11, 2019
AB		STRIDES PHARMA	**8MEQ**	**A205549**	**001**	Dec 08, 2015
AB			**10MEQ**	**A205549**	**002**	Dec 08, 2015
AB		ZYDUS PHARMS	**8MEQ**	**A208445**	**001**	Mar 11, 2019
AB			**10MEQ**	**A208445**	**002**	Mar 11, 2019

FOR SOLUTION;ORAL

KLOR-CON						
AA		UPSHER SMITH LABS	**20MEQ**	**A209662**	**001**	Oct 23, 2017
POTASSIUM CHLORIDE						
AA		AMNEAL	**20MEQ**	**A210902**	**001**	May 23, 2019
AA		BELCHER	**20MEQ**	**A212183**	**001**	May 06, 2019
AA		EPIC PHARMA LLC	**20MEQ**	**A210200**	**001**	Nov 23, 2018
AA		GRANULES	**20MEQ**	**A213467**	**001**	Jan 27, 2022
AA		NOVEL LABS INC	**20MEQ**	**A210241**	**001**	Nov 21, 2018
AA		NOVITIUM PHARMA	**20MEQ**	**A212816**	**001**	Jul 12, 2023

POTASSIUM CHLORIDE

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

AA	+	PHARMA RES SOFTWARE	**20MEQ**	**N208019**	**001**	Aug 19, 2015
AA		RUBICON	**20MEQ**	**A214108**	**001**	Mar 24, 2022
AA		STRIDES PHARMA	**20MEQ**	**A211667**	**001**	Mar 11, 2021

POKONZA

	+	PHARMA RES SOFTWARE	10MEQ	N208019	002	Aug 25, 2023

POTASSIUM CHLORIDE

	+!	PHARMA RES SOFTWARE	40MEQ	N208019	003	Aug 25, 2023

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

AP		B BRAUN	**2MEQ/ML**	**A085870**	**001**	
AP	**+!**	HOSPIRA	**2MEQ/ML**	**A080205**	**001**	
AP		NEXUS PHARMS	**2MEQ/ML**	**A217704**	**001**	Aug 14, 2023

POTASSIUM CHLORIDE 10MEQ

AP		FRESENIUS KABI USA	**14.9MG/ML**	**A211087**	**001**	Sep 09, 2020
AP			**746MG/100ML**	**A211087**	**002**	Sep 09, 2020
AP		NEXUS	**14.9MG/ML**	**A214727**	**001**	Mar 18, 2021
AP			**745MG/100ML**	**A214727**	**002**	Mar 18, 2021

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**14.9MG/ML**	**N019904**	**001**	Dec 26, 1989
AP	**+!**		**746MG/100ML**	**N019904**	**005**	Dec 17, 1990
AP	**+!**	ICU MEDICAL INC	**14.9MG/ML**	**N020161**	**005**	Nov 30, 1992
AP	**+!**		**745MG/100ML**	**N020161**	**001**	Nov 30, 1992

POTASSIUM CHLORIDE 20MEQ

AP		FRESENIUS KABI USA	**29.8MG/ML**	**A211087**	**003**	Sep 09, 2020
AP			**1.49GM/100ML**	**A211087**	**005**	May 07, 2021
AP		NEXUS	**29.8MG/ML**	**A214727**	**003**	Mar 18, 2021
AP			**1.49GM/100ML**	**A214727**	**004**	Mar 18, 2021

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**29.8MG/ML**	**N019904**	**002**	Dec 26, 1989
AP	**+!**		**1.49GM/100ML**	**N019904**	**006**	Dec 17, 1990
AP	**+!**	ICU MEDICAL INC	**29.8MG/ML**	**N020161**	**006**	Aug 11, 1998
AP	**+!**		**1.49GM/100ML**	**N020161**	**002**	Nov 30, 1992

POTASSIUM CHLORIDE 40MEQ

AP		FRESENIUS KABI USA	**2.98GM/100ML**	**A211087**	**004**	Sep 09, 2020
AP		NEXUS	**2.98GM/100ML**	**A214727**	**005**	Mar 18, 2021

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**2.98GM/100ML**	**N019904**	**004**	Dec 26, 1989
AP	**+!**	ICU MEDICAL INC	**2.98GM/100ML**	**N020161**	**004**	Aug 11, 1998

POTASSIUM CHLORIDE IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**2MEQ/ML**	**A088901**	**001**	Jan 25, 1985
AP			**2MEQ/ML**	**A088908**	**001**	Jan 25, 1985

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	2.24GM/100ML	N019904	003	Dec 26, 1989

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA		AMNEAL	**20MEQ/15ML**	**A210041**	**001**	Jul 19, 2018
AA			**40MEQ/15ML**	**A210041**	**002**	Jul 19, 2018
AA		ANDA REPOSITORY	**20MEQ/15ML**	**A214892**	**001**	Dec 30, 2022
AA			**40MEQ/15ML**	**A214892**	**002**	Dec 30, 2022
AA		APOTEX	**20MEQ/15ML**	**A211067**	**001**	Aug 08, 2018
AA			**40MEQ/15ML**	**A211067**	**002**	Aug 08, 2018
AA		BELCHER	**20MEQ/15ML**	**A216156**	**001**	Mar 07, 2023
AA			**40MEQ/15ML**	**A216156**	**002**	Mar 07, 2023
AA	+	GENUS LIFESCIENCES	**20MEQ/15ML**	**N206814**	**001**	Dec 22, 2014
AA	**+!**		**40MEQ/15ML**	**N206814**	**002**	Dec 22, 2014
AA		GRANULES	**20MEQ/15ML**	**A213392**	**001**	Jan 29, 2021
AA			**40MEQ/15ML**	**A213392**	**002**	Jan 29, 2021
AA		NOVEL LABS INC	**20MEQ/15ML**	**A209786**	**001**	Aug 29, 2018
AA			**40MEQ/15ML**	**A209786**	**002**	Aug 29, 2018
AA		PHARM ASSOC	**20MEQ/15ML**	**A210766**	**001**	Mar 29, 2019
AA			**40MEQ/15ML**	**A210766**	**002**	Mar 29, 2019
AA		RUBICON	**20MEQ/15ML**	**A214656**	**001**	Jan 13, 2022
AA			**40MEQ/15ML**	**A214656**	**002**	Jan 13, 2022
AA		SAPTALIS PHARMS	**20MEQ/15ML**	**A211648**	**001**	May 21, 2021
AA			**40MEQ/15ML**	**A211648**	**002**	May 21, 2021
AA		WES PHARMA INC	**20MEQ/15ML**	**A213062**	**001**	Jun 06, 2022
AA			**40MEQ/15ML**	**A213062**	**002**	Jun 06, 2022

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KLOR-CON M10						
AB1		UPSHER SMITH LABS	**10MEQ**	**A074726**	**002**	Aug 09, 2000
KLOR-CON M15						
AB1		UPSHER SMITH LABS	**15MEQ**	**A074726**	**003**	Jun 06, 2003
KLOR-CON M20						
AB1	!	UPSHER SMITH LABS	**20MEQ**	**A074726**	**001**	Nov 20, 1998
POTASSIUM CHLORIDE						
AB1		ACTAVIS LABS FL INC	**10MEQ**	**A075604**	**001**	Apr 10, 2002
AB1			**20MEQ**	**A075604**	**002**	Apr 10, 2002
AB1		ADARE PHARMS INC	**10MEQ**	**A076368**	**002**	Jun 05, 2019
AB1			**20MEQ**	**A076368**	**001**	Aug 18, 2004
AB1		AMNEAL	**10MEQ**	**A212861**	**001**	May 08, 2020
AB1			**20MEQ**	**A212861**	**003**	May 08, 2020
AB1		ASCENT PHARMS INC	**10MEQ**	**A214422**	**001**	Dec 29, 2020
AB1			**15MEQ**	**A214422**	**002**	Dec 29, 2020
AB1			**20MEQ**	**A214422**	**003**	Dec 29, 2020
AB1		GLENMARK PHARMS LTD	**10MEQ**	**A203562**	**001**	Jul 26, 2016
AB1			**20MEQ**	**A203562**	**002**	Jul 26, 2016
AB1		GRANULES	**10MEQ**	**A214452**	**001**	Oct 21, 2020
AB1			**20MEQ**	**A214452**	**002**	Oct 21, 2020
AB1		GUANGZHOU NOVAKEN	**10MEQ**	**A214395**	**001**	Jan 28, 2021
AB1			**20MEQ**	**A214395**	**002**	Jan 28, 2021
AB1		NOVEL LABS INC	**10MEQ**	**A206347**	**001**	Jan 21, 2016
AB1			**20MEQ**	**A206347**	**002**	Jan 21, 2016
AB1		PRINSTON INC	**10MEQ**	**A209922**	**001**	Apr 30, 2019
AB1			**15MEQ**	**A209922**	**002**	Apr 30, 2019
AB1			**20MEQ**	**A209922**	**003**	Apr 30, 2019
AB1		RUBICON	**10MEQ**	**A216321**	**001**	Jun 16, 2023
AB1			**15MEQ**	**A216321**	**002**	Jun 16, 2023
AB1			**20MEQ**	**A216321**	**003**	Jun 16, 2023
AB1		ZYDUS PHARMS	**10MEQ**	**A210395**	**001**	Sep 17, 2020
AB1			**20MEQ**	**A210395**	**002**	Sep 17, 2020
KLOR-CON						
AB2	+	UPSHER SMITH LABS	**8MEQ**	**N019123**	**001**	Apr 17, 1986
AB2	+!		**10MEQ**	**N019123**	**002**	Apr 17, 1986
POTASSIUM CHLORIDE						
AB2		AUROBINDO PHARMA	**8MEQ**	**A210921**	**001**	Dec 19, 2018
AB2			**10MEQ**	**A210921**	**002**	Dec 19, 2018
AB2		GRANULES	**8MEQ**	**A211797**	**001**	Mar 04, 2020
AB2			**10MEQ**	**A211797**	**002**	Mar 04, 2020
AB2		MYLAN	**8MEQ**	**A204662**	**001**	Aug 21, 2014
AB2			**10MEQ**	**A204662**	**002**	Aug 21, 2014
AB2		NOVEL LABS INC	**8MEQ**	**A206759**	**001**	Aug 09, 2016
AB2			**10MEQ**	**A206759**	**002**	Aug 09, 2016
AB2		PADAGIS US	**8MEQ**	**A205993**	**001**	Nov 05, 2015
AB2			**10MEQ**	**A205993**	**002**	Nov 05, 2015
AB2		RISING	**8MEQ**	**A217412**	**001**	Dec 19, 2023
AB2			**10MEQ**	**A217412**	**002**	Dec 19, 2023
AB2		STRIDES PHARMA	**8MEQ**	**A210733**	**001**	Aug 31, 2018
AB2			**10MEQ**	**A210733**	**002**	Aug 31, 2018
AB2		YICHANG HUMANWELL	**8MEQ**	**A209314**	**001**	Jun 22, 2018
AB2			**10MEQ**	**A209314**	**002**	Jun 22, 2018
AB3		RUBICON	**10MEQ**	**A215725**	**001**	Jul 25, 2022
AB3			**20MEQ**	**A215725**	**002**	Jul 25, 2022
AB3		TWI PHARMS	**10MEQ**	**A209688**	**001**	Jan 12, 2018
AB3	!		**20MEQ**	**A209688**	**002**	Jan 12, 2018
AB3		YICHANG HUMANWELL	**10MEQ**	**A212561**	**001**	Sep 30, 2019
AB3			**20MEQ**	**A212561**	**002**	Sep 30, 2019

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	**149MG/100ML;450MG/100ML**	**A078446**	**001**	Sep 10, 2008
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%						
AP	+!	BAXTER HLTHCARE	**150MG/100ML;450MG/100ML**	**N017648**	**005**	Nov 26, 2002
AP		FRESENIUS KABI USA	**150MG/100ML;450MG/100ML**	**A212347**	**001**	Sep 17, 2020
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%						
AP	+!	BAXTER HLTHCARE	**150MG/100ML;900MG/100ML**	**N017648**	**001**	
AP		FRESENIUS KABI USA	**150MG/100ML;900MG/100ML**	**A212347**	**003**	Jun 02, 2021

POTASSIUM CHLORIDE; SODIUM CHLORIDE						
INJECTABLE;INJECTION						
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		B BRAUN	**150MG/100ML;900MG/100ML**	**N019708**	**004**	Sep 29, 1989
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%						
AP	**+!**	BAXTER HLTHCARE	**300MG/100ML;900MG/100ML**	**N017648**	**002**	
AP		FRESENIUS KABI USA	**300MG/100ML;900MG/100ML**	**A212347**	**002**	Sep 17, 2020
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	**149MG/100ML;900MG/100ML**	**N019686**	**001**	Oct 17, 1988
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	**298MG/100ML;900MG/100ML**	**N019686**	**002**	Oct 17, 1988
POTASSIUM CITRATE						
TABLET, EXTENDED RELEASE;ORAL						
POTASSIUM CITRATE						
AB		ANI PHARMS	**10MEQ**	**A212779**	**001**	Jan 14, 2020
AB			**15MEQ**	**A212779**	**002**	Jan 14, 2020
AB		ASCENT PHARMS INC	**5MEQ**	**A214420**	**001**	Feb 05, 2021
AB			**10MEQ**	**A214420**	**002**	Feb 05, 2021
AB			**15MEQ**	**A214420**	**003**	Feb 05, 2021
AB		BIONPHARMA	**10MEQ**	**A212799**	**001**	Jun 29, 2020
AB			**15MEQ**	**A212799**	**002**	Jun 29, 2020
AB		EYWA	**5MEQ**	**A214426**	**001**	Feb 19, 2021
AB			**10MEQ**	**A214426**	**002**	Feb 19, 2021
AB			**15MEQ**	**A214426**	**003**	Feb 19, 2021
AB		RISING	**5MEQ**	**A077440**	**001**	Jun 09, 2006
AB			**10MEQ**	**A077440**	**002**	Jun 09, 2006
AB		STRIDES PHARMA	**5MEQ**	**A206813**	**001**	Sep 11, 2017
AB			**10MEQ**	**A206813**	**002**	Sep 11, 2017
AB			**15MEQ**	**A206813**	**003**	Sep 11, 2017
AB		TEVA PHARMS USA INC	**5MEQ**	**A209758**	**001**	Mar 05, 2018
AB			**10MEQ**	**A209758**	**002**	Mar 05, 2018
AB			**15MEQ**	**A209758**	**003**	Mar 05, 2018
AB		ZYDUS PHARMS	**5MEQ**	**A203546**	**001**	Aug 06, 2014
AB			**10MEQ**	**A203546**	**002**	Aug 06, 2014
AB			**15MEQ**	**A203546**	**003**	Aug 06, 2014
UROCIT-K						
AB	**+**	MISSION PHARMA	**5MEQ**	**N019071**	**001**	Aug 30, 1985
AB	**+**		**10MEQ**	**N019071**	**002**	Aug 31, 1992
AB	**+!**		**15MEQ**	**N019071**	**003**	Dec 30, 2009
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC						
SOLUTION;INTRAVENOUS						
POTASSIUM PHOSPHATES						
AP		AM REGENT	**1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)**	**A216274**	**001**	Oct 02, 2023
AP			**3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)**	**A216274**	**002**	Oct 02, 2023
AP			**11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)**	**A216274**	**003**	Oct 02, 2023
AP		AMNEAL	**1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)**	**A216344**	**001**	Oct 10, 2023
AP			**3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)**	**A216344**	**002**	Oct 10, 2023
AP			**11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)**	**A216344**	**003**	Oct 10, 2023
AP	**+!**	FRESENIUS KABI USA	**1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)**	**N212832**	**001**	Nov 26, 2019
AP	**+!**		**3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)**	**N212832**	**002**	Nov 26, 2019
AP	**+!**		**11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)**	**N212832**	**003**	Nov 26, 2019
	+!	CMP DEV LLC	4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)	N212121	001	Sep 19, 2019
POVIDONE-IODINE						
SOLUTION/DROPS;OPHTHALMIC						
BETADINE						
	+!	ALCON PHARMS LTD	5%	N018634	001	Dec 17, 1986

PRALATREXATE

SOLUTION;INTRAVENOUS

FOLOTYN

+	ACROTECH BIOPHARMA	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009
+!		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009

PRALIDOXIME CHLORIDE

INJECTABLE;INJECTION

PROTOPAM CHLORIDE

+!	BAXTER HLTHCARE CORP	1GM/VIAL	N014134	001	

PRALSETINIB

CAPSULE;ORAL

GAVRETO

+!	GENENTECH INC	100MG	N213721	001	Sep 04, 2020

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**0.125MG**	**A202633**	**001**	Oct 26, 2012
AB			**0.25MG**	**A202633**	**002**	Oct 26, 2012
AB			**0.5MG**	**A202633**	**003**	Oct 26, 2012
AB			**0.75MG**	**A202633**	**004**	Oct 26, 2012
AB			**1MG**	**A202633**	**005**	Oct 26, 2012
AB			**1.5MG**	**A202633**	**006**	Oct 26, 2012
AB		GLENMARK GENERICS	**0.125MG**	**A090781**	**001**	Oct 08, 2010
AB	!		**0.25MG**	**A090781**	**002**	Oct 08, 2010
AB			**0.5MG**	**A090781**	**003**	Oct 08, 2010
AB			**0.75MG**	**A090781**	**006**	Sep 11, 2015
AB			**1MG**	**A090781**	**004**	Oct 08, 2010
AB			**1.5MG**	**A090781**	**005**	Oct 08, 2010
AB		RISING	**0.25MG**	**A211088**	**001**	Oct 03, 2018
AB			**0.5MG**	**A211088**	**002**	Oct 03, 2018
AB			**0.75MG**	**A211088**	**003**	Oct 03, 2018
AB			**1MG**	**A211088**	**004**	Oct 03, 2018
AB			**1.5MG**	**A211088**	**005**	Oct 03, 2018
AB		SCIEGEN PHARMS INC	**0.125MG**	**A203855**	**001**	Oct 28, 2014
AB			**0.25MG**	**A203855**	**002**	Oct 28, 2014
AB			**0.5MG**	**A203855**	**003**	Oct 28, 2014
AB			**0.75MG**	**A203855**	**004**	Oct 28, 2014
AB			**1MG**	**A203855**	**005**	Oct 28, 2014
AB			**1.5MG**	**A203855**	**006**	Oct 28, 2014
AB		STRIDES PHARMA	**0.125MG**	**A202702**	**001**	Jun 03, 2014
AB			**0.25MG**	**A202702**	**002**	Jun 03, 2014
AB			**0.5MG**	**A202702**	**003**	Jun 03, 2014
AB			**0.75MG**	**A202702**	**004**	Jun 03, 2014
AB			**1MG**	**A202702**	**005**	Jun 03, 2014
AB			**1.5MG**	**A202702**	**006**	Jun 03, 2014
AB		TORRENT PHARMS	**0.125MG**	**A090865**	**001**	Oct 08, 2010
AB			**0.25MG**	**A090865**	**002**	Oct 08, 2010
AB			**0.5MG**	**A090865**	**003**	Oct 08, 2010
AB			**0.75MG**	**A090865**	**004**	Oct 08, 2010
AB			**1MG**	**A090865**	**005**	Oct 08, 2010
AB			**1.5MG**	**A090865**	**006**	Oct 08, 2010
AB		ZENNOVA	**0.125MG**	**A090151**	**001**	Apr 30, 2012
AB			**0.25MG**	**A090151**	**002**	Apr 30, 2012
AB			**0.5MG**	**A090151**	**003**	Apr 30, 2012
AB			**0.75MG**	**A090151**	**006**	Apr 30, 2012
AB			**1MG**	**A090151**	**004**	Apr 30, 2012
AB			**1.5MG**	**A090151**	**005**	Apr 30, 2012
AB		ZYDUS PHARMS USA INC	**0.125MG**	**A078920**	**001**	Jul 06, 2010
AB			**0.25MG**	**A078920**	**002**	Jul 06, 2010
AB			**0.5MG**	**A078920**	**003**	Jul 06, 2010
AB			**0.75MG**	**A078920**	**006**	Nov 23, 2022
AB			**1MG**	**A078920**	**004**	Jul 06, 2010
AB			**1.5MG**	**A078920**	**005**	Jul 06, 2010

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER

AB	+!	BOEHRINGER INGELHEIM	**0.375MG**	**N022421**	**001**	Feb 19, 2010
AB	+		**0.75MG**	**N022421**	**002**	Feb 19, 2010
AB	+		**1.5MG**	**N022421**	**003**	Feb 19, 2010

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER

AB	**+**		**2.25MG**	**N022421**	**006**	Jun 17, 2011
AB	**+**		**3MG**	**N022421**	**004**	Feb 19, 2010
AB	**+**		**3.75MG**	**N022421**	**007**	Jun 17, 2011
AB	**+**		**4.5MG**	**N022421**	**005**	Feb 19, 2010

PRAMIPEXOLE DIHYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**0.375MG**	**A201963**	**001**	Apr 21, 2016
AB			**0.75MG**	**A201963**	**002**	Apr 21, 2016
AB			**1.5MG**	**A201963**	**003**	Apr 21, 2016
AB			**2.25MG**	**A203615**	**001**	Oct 14, 2016
AB			**3MG**	**A201963**	**004**	Apr 21, 2016
AB			**3.75MG**	**A203615**	**002**	Jan 03, 2017
AB			**4.5MG**	**A201963**	**005**	Apr 21, 2016
AB		ALEMBIC	**0.375MG**	**A204518**	**001**	Jan 02, 2019
AB			**0.75MG**	**A204518**	**002**	Jan 02, 2019
AB			**1.5MG**	**A204518**	**003**	Jan 02, 2019
AB			**2.25MG**	**A204518**	**004**	Jan 02, 2019
AB			**3MG**	**A204518**	**005**	Jan 02, 2019
AB			**3.75MG**	**A204518**	**006**	Jan 02, 2019
AB			**4.5MG**	**A204518**	**007**	Jan 02, 2019
AB		DR REDDYS	**0.375MG**	**A203354**	**001**	Aug 07, 2015
AB			**0.75MG**	**A203354**	**002**	Aug 07, 2015
AB			**1.5MG**	**A203354**	**003**	Aug 07, 2015
AB			**3MG**	**A203354**	**004**	Aug 07, 2015
AB			**4.5MG**	**A203354**	**005**	Aug 07, 2015
AB		MACLEODS PHARMS LTD	**0.375MG**	**A206156**	**001**	Jun 24, 2016
AB			**0.75MG**	**A206156**	**002**	Jun 24, 2016
AB			**1.5MG**	**A206156**	**003**	Jun 24, 2016
AB			**2.25MG**	**A206156**	**004**	Jun 24, 2016
AB			**3MG**	**A206156**	**005**	Jun 24, 2016
AB			**3.75MG**	**A206156**	**007**	Jan 23, 2017
AB			**4.5MG**	**A206156**	**006**	Jun 24, 2016
AB		NOVAST LABS	**0.375MG**	**A213444**	**001**	Feb 03, 2022
AB			**0.75MG**	**A213444**	**002**	Feb 03, 2022
AB			**1.5MG**	**A213444**	**003**	Feb 03, 2022
AB			**2.25MG**	**A213444**	**004**	Feb 03, 2022
AB			**3MG**	**A213444**	**005**	Feb 03, 2022
AB			**3.75MG**	**A213444**	**006**	Feb 03, 2022
AB			**4.5MG**	**A213444**	**007**	Feb 03, 2022
AB		SANDOZ	**0.375MG**	**A202353**	**001**	Dec 04, 2014
AB			**0.75MG**	**A202353**	**002**	Dec 04, 2014
AB			**1.5MG**	**A202353**	**003**	Dec 04, 2014
AB			**3MG**	**A202353**	**004**	Dec 04, 2014
AB			**4.5MG**	**A202353**	**005**	Dec 04, 2014
AB		XIAMEN LP PHARM CO	**0.375MG**	**A212797**	**001**	Jun 11, 2021
AB			**0.75MG**	**A212797**	**002**	Jun 11, 2021
AB		ZYDUS PHARMS	**0.375MG**	**A202891**	**001**	Dec 12, 2017
AB			**0.75MG**	**A202891**	**002**	Dec 12, 2017
AB			**1.5MG**	**A202891**	**003**	Dec 12, 2017
AB			**2.25MG**	**A202891**	**004**	Dec 12, 2017
AB			**3MG**	**A202891**	**005**	Dec 12, 2017
AB			**3.75MG**	**A202891**	**006**	Dec 12, 2017
AB			**4.5MG**	**A202891**	**007**	Dec 12, 2017

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMLIN

+	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007
+!		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007

PRASTERONE

INSERT;VAGINAL

INTRAROSA

+!	MILLICENT	6.5MG	N208470	001	Nov 16, 2016

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

EFFIENT

AB	**+**	COSETTE	**EQ 5MG BASE**	**N022307**	**001**	Jul 10, 2009
AB	**+!**		**EQ 10MG BASE**	**N022307**	**002**	Jul 10, 2009

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

AB		ACCORD HLTHCARE	**EQ 5MG BASE**	**A205987**	**001**	Feb 02, 2018
AB			**EQ 10MG BASE**	**A205987**	**002**	Feb 02, 2018
AB		AMNEAL PHARMS	**EQ 5MG BASE**	**A205913**	**001**	Jun 19, 2018
AB			**EQ 10MG BASE**	**A205913**	**002**	Jun 19, 2018
AB		AUROBINDO PHARMA	**EQ 5MG BASE**	**A205888**	**001**	Oct 16, 2017
AB			**EQ 10MG BASE**	**A205888**	**002**	Oct 16, 2017
AB		HEC PHARM	**EQ 5MG BASE**	**A206021**	**001**	Jan 16, 2019
AB			**EQ 10MG BASE**	**A206021**	**002**	Jan 16, 2019
AB		MYLAN	**EQ 5MG BASE**	**A205927**	**001**	Jul 12, 2017
AB			**EQ 10MG BASE**	**A205927**	**002**	Jul 12, 2017
AB		PANACEA	**EQ 5MG BASE**	**A205897**	**001**	Oct 16, 2017
AB			**EQ 10MG BASE**	**A205897**	**002**	Oct 16, 2017

PRASUGREL HYDROCHLORIDE

AB		UNICHEM	**EQ 5MG BASE**	**A213315**	**001**	Aug 28, 2023
AB			**EQ 10MG BASE**	**A213315**	**002**	Aug 28, 2023

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB		ACCORD HLTHCARE	**10MG**	**A207068**	**001**	Nov 17, 2016
AB			**20MG**	**A207068**	**002**	Nov 17, 2016
AB			**40MG**	**A207068**	**003**	Nov 17, 2016
AB			**80MG**	**A207068**	**004**	Nov 17, 2016
AB		APNAR PHARMA LP	**10MG**	**A077491**	**002**	Oct 23, 2006
AB			**20MG**	**A077491**	**003**	Oct 23, 2006
AB			**40MG**	**A077491**	**004**	Oct 23, 2006
AB			**80MG**	**A077491**	**001**	Feb 11, 2008
AB		APOTEX	**10MG**	**A076341**	**001**	Oct 23, 2006
AB			**20MG**	**A076341**	**002**	Oct 23, 2006
AB			**40MG**	**A076341**	**003**	Oct 23, 2006
AB			**80MG**	**A076341**	**004**	Dec 28, 2007
AB		AUROBINDO PHARMA	**10MG**	**A203367**	**001**	Feb 02, 2017
AB			**20MG**	**A203367**	**002**	Feb 02, 2017
AB			**40MG**	**A203367**	**003**	Feb 02, 2017
AB			**80MG**	**A203367**	**004**	Feb 02, 2017
AB		BIOCON PHARMA	**10MG**	**A209869**	**001**	Apr 13, 2018
AB			**20MG**	**A209869**	**002**	Apr 13, 2018
AB			**40MG**	**A209869**	**003**	Apr 13, 2018
AB			**80MG**	**A209869**	**004**	Apr 13, 2018
AB		CHARTWELL RX	**10MG**	**A077917**	**001**	Jan 08, 2008
AB			**20MG**	**A077917**	**002**	Jan 08, 2008
AB			**40MG**	**A077917**	**003**	Jan 08, 2008
AB			**80MG**	**A077917**	**004**	Jan 08, 2008
AB		CIPLA	**10MG**	**A077904**	**001**	Oct 23, 2006
AB			**20MG**	**A077904**	**002**	Oct 23, 2006
AB			**40MG**	**A077904**	**003**	Oct 23, 2006
AB			**80MG**	**A077904**	**004**	Mar 22, 2016
AB		DR REDDYS LABS INC	**10MG**	**A076714**	**001**	Oct 23, 2006
AB			**20MG**	**A076714**	**002**	Oct 23, 2006
AB			**40MG**	**A076714**	**003**	Oct 23, 2006
AB			**80MG**	**A076714**	**004**	Dec 28, 2007
AB		GLENMARK GENERICS	**10MG**	**A077987**	**001**	May 11, 2007
AB			**20MG**	**A077987**	**002**	May 11, 2007
AB			**40MG**	**A077987**	**003**	May 11, 2007
AB			**80MG**	**A077987**	**004**	Dec 28, 2007
AB		TEVA	**10MG**	**A076056**	**001**	Apr 24, 2006
AB			**20MG**	**A076056**	**002**	Apr 24, 2006
AB			**40MG**	**A076056**	**003**	Apr 24, 2006
AB	!	TEVA PHARMS	**80MG**	**A077793**	**001**	Jan 15, 2008
AB		WATSON LABS	**10MG**	**A076939**	**004**	Oct 23, 2006
AB			**20MG**	**A076939**	**003**	Oct 23, 2006
AB			**40MG**	**A076939**	**002**	Oct 23, 2006
AB			**80MG**	**A076939**	**001**	Dec 28, 2007
AB		ZYDUS PHARMS USA	**20MG**	**A077751**	**002**	Apr 30, 2008
AB			**40MG**	**A077751**	**003**	Apr 30, 2008
AB			**80MG**	**A077751**	**004**	Apr 30, 2008

PRAZIQUANTEL

TABLET;ORAL

BILTRICIDE

AB	**+!**	BAYER HLTHCARE	**600MG**	**N018714**	**001**	Dec 29, 1982

PRAZIQUANTEL

AB		PAR PHARM INC	**600MG**	**A208820**	**001**	Nov 27, 2017

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

MINIPRESS

AB	**+**	PFIZER	**EQ 1MG BASE**	**N017442**	**002**	
AB	**+!**		**EQ 2MG BASE**	**N017442**	**003**	
AB	**+**		**EQ 5MG BASE**	**N017442**	**001**	

PRAZOSIN HYDROCHLORIDE

AB		ALEMBIC	**EQ 1MG BASE**	**A217268**	**001**	Mar 06, 2023
AB			**EQ 2MG BASE**	**A217268**	**002**	Mar 06, 2023
AB			**EQ 5MG BASE**	**A217268**	**003**	Mar 06, 2023
AB		APPCO	**EQ 1MG BASE**	**A213406**	**001**	Oct 21, 2022
AB			**EQ 2MG BASE**	**A213406**	**002**	Oct 21, 2022
AB			**EQ 5MG BASE**	**A213406**	**003**	Oct 21, 2022
AB		AUROBINDO PHARMA LTD	**EQ 1MG BASE**	**A213052**	**001**	Mar 31, 2023
AB			**EQ 2MG BASE**	**A213052**	**002**	Mar 31, 2023
AB			**EQ 5MG BASE**	**A213052**	**003**	Mar 31, 2023
AB		GRANULES	**EQ 1MG BASE**	**A214608**	**001**	Dec 23, 2021
AB			**EQ 2MG BASE**	**A214608**	**002**	Dec 23, 2021
AB			**EQ 5MG BASE**	**A214608**	**003**	Dec 23, 2021
AB		LANNETT CO INC	**EQ 1MG BASE**	**A214083**	**001**	Jan 03, 2024
AB			**EQ 2MG BASE**	**A214083**	**002**	Jan 03, 2024
AB			**EQ 5MG BASE**	**A214083**	**003**	Jan 03, 2024
AB		MANKIND PHARMA	**EQ 1MG BASE**	**A215697**	**001**	Dec 30, 2022
AB			**EQ 2MG BASE**	**A215697**	**002**	Dec 30, 2022
AB			**EQ 5MG BASE**	**A215697**	**003**	Dec 30, 2022
AB		MYLAN	**EQ 1MG BASE**	**A072575**	**003**	May 16, 1989
AB			**EQ 2MG BASE**	**A072575**	**002**	May 16, 1989
AB			**EQ 5MG BASE**	**A072575**	**001**	May 16, 1989
AB		NOVITIUM PHARMA	**EQ 1MG BASE**	**A210971**	**001**	Oct 03, 2018
AB			**EQ 2MG BASE**	**A210971**	**002**	Oct 03, 2018
AB			**EQ 5MG BASE**	**A210971**	**003**	Oct 03, 2018
AB		TEVA PHARMS	**EQ 1MG BASE**	**A071745**	**002**	Sep 12, 1988
AB			**EQ 2MG BASE**	**A071745**	**003**	Sep 12, 1988
AB			**EQ 5MG BASE**	**A071745**	**001**	Sep 12, 1988

PREDNICARBATE

OINTMENT;TOPICAL

PREDNICARBATE

	!	FOUGERA PHARMS	0.1%	A077236	001	Mar 09, 2007

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

AA	**!**	CHARTWELL RX	**15MG/5ML**	**A040323**	**001**	May 13, 1999
AA		HIKMA	**15MG/5ML**	**A040401**	**001**	Feb 27, 2003
AA		LANNETT CO INC	**15MG/5ML**	**A040775**	**001**	Sep 21, 2007
AA		PHARM ASSOC	**15MG/5ML**	**A040399**	**001**	Mar 05, 2003
AA			**15MG/5ML**	**A040571**	**001**	Aug 25, 2005

PRELONE

AA		TEVA	**15MG/5ML**	**A089081**	**001**	Feb 04, 1986

TABLET;ORAL

PREDNISOLONE

AB		AUROBINDO PHARMA LTD	**5MG**	**A215673**	**001**	Mar 17, 2023
AB	**+!**	WATSON LABS	**5MG**	**A080354**	**001**	
BX		CHARTWELL MOLECULAR	5MG	A080531	002	

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

OMNIPRED

AB	**+!**	SANDOZ	**1%**	**N017469**	**001**	

PRED FORTE

AB	**+!**	ABBVIE	**1%**	**N017011**	**001**	

PRED MILD

	+!	ABBVIE	0.12%	N017100	001	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PEDIAPRED

AA	**+!**	SETON PHARM	**EQ 5MG BASE/5ML**	**N019157**	**001**	May 28, 1986

PREDNISOLONE SODIUM PHOSPHATE

AA		AMNEAL	**EQ 15MG BASE/5ML**	**A216715**	**001**	Oct 25, 2022
AA		CHARTWELL RX	**EQ 5MG BASE/5ML**	**A075988**	**001**	May 25, 2004
AA		EDENBRIDGE PHARMS	**EQ 10MG BASE/5ML**	**A203559**	**001**	Dec 20, 2016
AA			**EQ 15MG BASE/5ML**	**A203559**	**003**	Feb 06, 2023
AA			**EQ 20MG BASE/5ML**	**A203559**	**002**	Dec 20, 2016
AA			**EQ 25MG BASE/5ML**	**A203559**	**004**	Feb 06, 2023
AA		HIKMA	**EQ 5MG BASE/5ML**	**A075183**	**001**	Mar 26, 2003
AA	**!**	MISSION PHARMA	**EQ 25MG BASE/5ML**	**A091396**	**001**	Sep 13, 2010
AA	**!**	PHARM ASSOC	**EQ 10MG BASE/5ML**	**A078465**	**001**	Mar 07, 2008
AA	**!**		**EQ 15MG BASE/5ML**	**A076913**	**001**	Apr 25, 2005
AA	**!**		**EQ 20MG BASE/5ML**	**A078988**	**001**	Jun 09, 2008
			EQ 30MG BASE/5ML	A204962	001	Mar 11, 2020

SOLUTION/DROPS;OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

	!	BAUSCH AND LOMB	EQ 0.9% PHOSPHATE	A040070	001	Jul 29, 1994

TABLET, ORALLY DISINTEGRATING;ORAL

ORAPRED ODT

	+	CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006
	+		EQ 15MG BASE	N021959	002	Jun 01, 2006
	+!		EQ 30MG BASE	N021959	003	Jun 01, 2006

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

	!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995

PREDNISONE

SOLUTION;ORAL

PREDNISONE

	+!	HIKMA	5MG/5ML	A088703	001	Nov 08, 1984

PREDNISONE INTENSOL

	!	HIKMA	5MG/ML	A088810	001	Feb 20, 1985

TABLET;ORAL

PREDNISONE

AB		AMNEAL	**1MG**	**A213385**	**001**	Jun 16, 2020
AB			**5MG**	**A213385**	**002**	Jun 16, 2020
AB			**10MG**	**A213386**	**001**	Jun 24, 2020
AB			**20MG**	**A213386**	**002**	Jun 24, 2020
AB		AUROBINDO PHARMA LTD	**1MG**	**A215671**	**001**	Nov 16, 2021
AB			**2.5MG**	**A215672**	**001**	Mar 28, 2022
AB			**5MG**	**A215672**	**002**	Mar 28, 2022
AB			**10MG**	**A215672**	**003**	Mar 28, 2022
AB			**20MG**	**A215672**	**004**	Mar 28, 2022
AB			**50MG**	**A215672**	**005**	Mar 28, 2022
AB		GENEYORK PHARMS	**1MG**	**A211496**	**001**	Dec 28, 2018
AB			**2.5MG**	**A210525**	**004**	Dec 07, 2018
AB			**5MG**	**A210525**	**005**	Dec 07, 2018
AB			**10MG**	**A210525**	**001**	Dec 04, 2018
AB			**20MG**	**A210525**	**002**	Dec 04, 2018
AB			**50MG**	**A210525**	**003**	Dec 04, 2018
AB		GRANULATION TECH	**5MG**	**A212629**	**001**	Dec 05, 2023
AB			**10MG**	**A212629**	**002**	Dec 05, 2023
AB			**20MG**	**A212629**	**003**	Dec 05, 2023
AB	**+!**	HIKMA	**1MG**	**A087800**	**001**	Apr 22, 1982
AB	**+!**		**2.5MG**	**A087801**	**001**	Apr 22, 1982
AB	**+!**		**5MG**	**A080352**	**001**	
AB	**+!**		**10MG**	**A084122**	**001**	
AB	**+!**		**20MG**	**A087342**	**001**	
AB	**+!**		**50MG**	**A084283**	**001**	
AB		JUBILANT CADISTA	**1MG**	**A040611**	**001**	Jun 06, 2005
AB			**2.5MG**	**A040362**	**004**	Apr 17, 2023
AB			**5MG**	**A040362**	**002**	Aug 29, 2001
AB			**10MG**	**A040362**	**001**	Aug 29, 2001
AB			**20MG**	**A040362**	**003**	Jun 29, 2005
AB			**50MG**	**A040362**	**005**	Apr 17, 2023
AB		MYLAN	**5MG**	**A080292**	**001**	
AB			**10MG**	**A088832**	**001**	Dec 04, 1985

PREDNISONE

TABLET;ORAL

PREDNISONE

AB			**20MG**	**A083677**	**001**	
AB		NOVITIUM PHARMA	**1MG**	**A215246**	**001**	Jul 06, 2021
AB			**2.5MG**	**A211575**	**001**	Nov 15, 2019
AB			**5MG**	**A211575**	**002**	Nov 15, 2019
AB			**10MG**	**A211575**	**003**	Nov 15, 2019
AB			**20MG**	**A211575**	**004**	Nov 15, 2019
AB			**50MG**	**A211575**	**005**	Nov 15, 2019
AB		STRIDES PHARMA	**1MG**	**A210785**	**001**	Sep 02, 2020
AB			**2.5MG**	**A209727**	**001**	Nov 20, 2020
AB			**5MG**	**A209727**	**002**	Nov 20, 2020
AB			**10MG**	**A208412**	**001**	Feb 11, 2021
AB			**20MG**	**A208412**	**002**	Feb 11, 2021
AB			**50MG**	**A208412**	**003**	Jan 11, 2022
AB		SUN PHARM INDUSTRIES	**5MG**	**A089247**	**002**	Dec 04, 1985
AB			**10MG**	**A089247**	**003**	Dec 04, 1985
AB			**20MG**	**A089247**	**001**	Dec 04, 1985
AB		VINTAGE PHARMS	**1MG**	**A040584**	**001**	Dec 21, 2004
AB			**2.5MG**	**A040581**	**001**	Dec 21, 2004
AB			**5MG**	**A040256**	**001**	Jul 12, 2002
AB			**10MG**	**A040256**	**002**	Jul 12, 2002
AB			**20MG**	**A040392**	**001**	Feb 12, 2003
AB		WATSON LABS	**5MG**	**A080356**	**001**	
AB			**10MG**	**A085162**	**001**	
AB			**20MG**	**A085161**	**001**	

TABLET, DELAYED RELEASE;ORAL

PREDNISONE

AB		ACTAVIS LABS FL INC	**1MG**	**A204867**	**001**	Apr 25, 2017
AB			**2MG**	**A204867**	**002**	Apr 25, 2017
AB			**5MG**	**A204867**	**003**	Apr 25, 2017

RAYOS

AB	+	HORIZON	**1MG**	**N202020**	**001**	Jul 26, 2012
AB	+		**2MG**	**N202020**	**002**	Jul 26, 2012
AB	+!		**5MG**	**N202020**	**003**	Jul 26, 2012

PREGABALIN

CAPSULE;ORAL

LYRICA

AB	+	UPJOHN	**25MG**	**N021446**	**001**	Dec 30, 2004
AB	+		**50MG**	**N021446**	**002**	Dec 30, 2004
AB	+		**75MG**	**N021446**	**003**	Dec 30, 2004
AB	+		**100MG**	**N021446**	**004**	Dec 30, 2004
AB	+		**150MG**	**N021446**	**005**	Dec 30, 2004
AB	+		**200MG**	**N021446**	**006**	Dec 30, 2004
AB	+		**225MG**	**N021446**	**007**	Dec 30, 2004
AB	+!		**300MG**	**N021446**	**008**	Dec 30, 2004

PREGABALIN

AB		ACTAVIS ELIZABETH	**25MG**	**A091025**	**001**	Jul 09, 2020
AB			**50MG**	**A091025**	**002**	Jul 09, 2020
AB			**75MG**	**A091025**	**003**	Jul 09, 2020
AB			**100MG**	**A091025**	**004**	Jul 09, 2020
AB			**150MG**	**A091025**	**005**	Jul 09, 2020
AB			**200MG**	**A091025**	**006**	Jul 09, 2020
AB			**225MG**	**A091025**	**007**	Jul 09, 2020
AB			**300MG**	**A091025**	**008**	Jul 09, 2020
AB		ADAPTIS	**25MG**	**A216197**	**001**	Jul 18, 2022
AB			**50MG**	**A216197**	**002**	Jul 18, 2022
AB			**75MG**	**A216197**	**003**	Jul 18, 2022
AB			**100MG**	**A216197**	**004**	Jul 18, 2022
AB			**150MG**	**A216197**	**005**	Jul 18, 2022
AB			**200MG**	**A216197**	**006**	Jul 18, 2022
AB			**225MG**	**A216197**	**007**	Jul 18, 2022
AB			**300MG**	**A216197**	**008**	Jul 18, 2022
AB		ALEMBIC	**25MG**	**A203459**	**001**	Jul 19, 2019
AB			**50MG**	**A203459**	**002**	Jul 19, 2019
AB			**75MG**	**A203459**	**003**	Jul 19, 2019
AB			**100MG**	**A203459**	**004**	Jul 19, 2019
AB			**150MG**	**A203459**	**005**	Jul 19, 2019
AB			**200MG**	**A203459**	**006**	Jul 19, 2019
AB			**225MG**	**A203459**	**007**	Jul 19, 2019

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB		**300MG**	**A203459**	**008**	Jul 19, 2019
AB	ALKEM LABS LTD	**25MG**	**A207799**	**007**	Sep 30, 2019
AB		**50MG**	**A207799**	**008**	Sep 30, 2019
AB		**75MG**	**A207799**	**001**	Jul 19, 2019
AB		**100MG**	**A207799**	**002**	Jul 19, 2019
AB		**150MG**	**A207799**	**003**	Jul 19, 2019
AB		**200MG**	**A207799**	**004**	Jul 19, 2019
AB		**225MG**	**A207799**	**005**	Jul 19, 2019
AB		**300MG**	**A207799**	**006**	Jul 19, 2019
AB	AMNEAL PHARMS CO	**25MG**	**A209743**	**001**	Jul 19, 2019
AB		**50MG**	**A209743**	**002**	Jul 19, 2019
AB		**75MG**	**A209743**	**003**	Jul 19, 2019
AB		**100MG**	**A209743**	**004**	Jul 19, 2019
AB		**150MG**	**A209743**	**005**	Jul 19, 2019
AB		**200MG**	**A209743**	**006**	Jul 19, 2019
AB		**225MG**	**A209743**	**007**	Jul 19, 2019
AB		**300MG**	**A209743**	**008**	Jul 19, 2019
AB	APOTEX	**25MG**	**A211685**	**001**	Jul 07, 2021
AB		**50MG**	**A211685**	**002**	Jul 07, 2021
AB		**75MG**	**A211685**	**003**	Jul 07, 2021
AB		**100MG**	**A211685**	**004**	Jul 07, 2021
AB		**150MG**	**A211685**	**005**	Jul 07, 2021
AB		**200MG**	**A211685**	**006**	Jul 07, 2021
AB		**225MG**	**A211685**	**007**	Jul 07, 2021
AB		**300MG**	**A211685**	**008**	Jul 07, 2021
AB	AUROBINDO PHARMA	**25MG**	**A205321**	**001**	Mar 29, 2023
AB		**50MG**	**A205321**	**002**	Mar 29, 2023
AB		**75MG**	**A205321**	**003**	Mar 29, 2023
AB		**100MG**	**A205321**	**004**	Mar 29, 2023
AB		**150MG**	**A205321**	**005**	Mar 29, 2023
AB		**200MG**	**A205321**	**006**	Mar 29, 2023
AB		**225MG**	**A205321**	**007**	Mar 29, 2023
AB		**300MG**	**A205321**	**008**	Mar 29, 2023
AB	CADILA PHARMS LTD	**25MG**	**A206452**	**001**	Jul 12, 2023
AB		**50MG**	**A206452**	**002**	Jul 12, 2023
AB		**75MG**	**A206452**	**003**	Jul 12, 2023
AB		**100MG**	**A206452**	**004**	Jul 12, 2023
AB		**150MG**	**A206452**	**005**	Jul 12, 2023
AB		**200MG**	**A206452**	**006**	Jul 12, 2023
AB		**225MG**	**A206452**	**007**	Jul 12, 2023
AB		**300MG**	**A206452**	**008**	Jul 12, 2023
AB	CHANGZHOU PHARM	**50MG**	**A214322**	**001**	Jul 15, 2021
AB		**75MG**	**A214322**	**002**	Jul 15, 2021
AB		**100MG**	**A214322**	**003**	Jul 15, 2021
AB		**150MG**	**A214322**	**004**	Jul 15, 2021
AB		**200MG**	**A214322**	**005**	Jul 15, 2021
AB		**225MG**	**A214322**	**006**	Jul 15, 2021
AB		**300MG**	**A214322**	**007**	Jul 15, 2021
AB	CHARTWELL RX	**50MG**	**A212865**	**001**	Mar 20, 2020
AB		**75MG**	**A212865**	**002**	Mar 20, 2020
AB		**100MG**	**A212865**	**003**	Mar 20, 2020
AB		**150MG**	**A212865**	**004**	Mar 20, 2020
AB	CIPLA	**25MG**	**A212280**	**001**	Jan 10, 2020
AB		**50MG**	**A212280**	**002**	Jan 10, 2020
AB		**75MG**	**A212280**	**003**	Jan 10, 2020
AB		**100MG**	**A212280**	**004**	Jan 10, 2020
AB		**150MG**	**A212280**	**005**	Jan 10, 2020
AB		**200MG**	**A212280**	**006**	Jan 10, 2020
AB		**225MG**	**A212280**	**007**	Jan 10, 2020
AB		**300MG**	**A212280**	**008**	Jan 10, 2020
AB	CREEKWOOD PHARMS	**25MG**	**A213423**	**001**	Mar 23, 2020
AB		**50MG**	**A213423**	**002**	Mar 23, 2020
AB		**75MG**	**A213423**	**003**	Mar 23, 2020
AB		**100MG**	**A213423**	**004**	Mar 23, 2020
AB		**150MG**	**A213423**	**005**	Mar 23, 2020
AB		**200MG**	**A213423**	**006**	Mar 23, 2020
AB		**225MG**	**A213423**	**007**	Mar 23, 2020
AB		**300MG**	**A213423**	**008**	Mar 23, 2020
AB	DR REDDYS	**25MG**	**A209664**	**001**	Jul 19, 2019

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB		50MG	A209664	002	Jul 19, 2019
AB		75MG	A209664	003	Jul 19, 2019
AB		100MG	A209664	004	Jul 19, 2019
AB		150MG	A209664	005	Jul 19, 2019
AB		200MG	A209664	006	Jul 19, 2019
AB		225MG	A209664	007	Jul 19, 2019
AB		300MG	A209664	008	Jul 19, 2019
AB	ESKAYEF	25MG	A212988	001	Mar 08, 2022
AB		50MG	A212988	002	Mar 08, 2022
AB		75MG	A212988	003	Mar 08, 2022
AB		100MG	A212988	004	Mar 08, 2022
AB		150MG	A212988	005	Mar 08, 2022
AB		200MG	A212988	006	Mar 08, 2022
AB		225MG	A212988	007	Mar 08, 2022
AB		300MG	A212988	008	Mar 08, 2022
AB	HETERO LABS LTD III	25MG	A206912	001	Oct 08, 2019
AB		50MG	A206912	002	Oct 08, 2019
AB		75MG	A206912	003	Oct 08, 2019
AB		100MG	A206912	004	Oct 08, 2019
AB		150MG	A206912	005	Oct 08, 2019
AB		200MG	A206912	006	Oct 08, 2019
AB		225MG	A206912	007	Oct 08, 2019
AB		300MG	A206912	008	Oct 08, 2019
AB	INVAGEN PHARMS	25MG	A211384	001	Jul 19, 2019
AB		50MG	A211384	002	Jul 19, 2019
AB		75MG	A211384	003	Jul 19, 2019
AB		100MG	A211384	004	Jul 19, 2019
AB		150MG	A211384	005	Jul 19, 2019
AB		200MG	A211384	006	Jul 19, 2019
AB		225MG	A211384	007	Jul 19, 2019
AB		300MG	A211384	008	Jul 19, 2019
AB	MSN	25MG	A209357	001	Jul 19, 2019
AB		50MG	A209357	002	Jul 19, 2019
AB		75MG	A209357	003	Jul 19, 2019
AB		100MG	A209357	004	Jul 19, 2019
AB		150MG	A209357	005	Jul 19, 2019
AB		200MG	A209357	006	Jul 19, 2019
AB		225MG	A209357	007	Jul 19, 2019
AB		300MG	A209357	008	Jul 19, 2019
AB	PRINSTON INC	25MG	A207883	001	Sep 01, 2022
AB		50MG	A207883	002	Sep 01, 2022
AB		75MG	A207883	003	Sep 01, 2022
AB		100MG	A207883	004	Sep 01, 2022
AB		150MG	A207883	005	Sep 01, 2022
AB		200MG	A207883	006	Sep 01, 2022
AB		225MG	A207883	007	Sep 01, 2022
AB		300MG	A207883	008	Sep 01, 2022
AB	RENATA	50MG	A210585	001	Dec 26, 2019
AB		75MG	A210585	002	Dec 26, 2019
AB		100MG	A210585	003	Dec 26, 2019
AB		150MG	A210585	004	Dec 26, 2019
AB		200MG	A210585	005	Dec 26, 2019
AB		300MG	A210585	006	Dec 26, 2019
AB	RISING	25MG	A210432	001	Jul 19, 2019
AB		50MG	A210432	002	Jul 19, 2019
AB		75MG	A210432	003	Jul 19, 2019
AB		100MG	A210432	004	Jul 19, 2019
AB		150MG	A210432	005	Jul 19, 2019
AB		200MG	A210432	006	Jul 19, 2019
AB		225MG	A210432	007	Jul 19, 2019
AB		300MG	A210432	008	Jul 19, 2019
AB	SCIEGEN PHARMS INC	25MG	A208677	001	Jul 19, 2019
AB		50MG	A208677	002	Jul 19, 2019
AB		75MG	A208677	003	Jul 19, 2019
AB		100MG	A208677	004	Jul 19, 2019
AB		150MG	A208677	005	Jul 19, 2019
AB		200MG	A208677	006	Jul 19, 2019
AB		225MG	A208677	007	Jul 19, 2019
AB		300MG	A208677	008	Jul 19, 2019

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB		SUN PHARM	**25MG**	**A091157**	**001**	Nov 29, 2019
AB			**50MG**	**A091157**	**002**	Nov 29, 2019
AB			**75MG**	**A091157**	**003**	Nov 29, 2019
AB			**100MG**	**A091157**	**004**	Nov 29, 2019
AB			**150MG**	**A091157**	**005**	Nov 29, 2019
AB			**200MG**	**A091157**	**006**	Nov 29, 2019
AB			**225MG**	**A091157**	**007**	Nov 29, 2019
AB			**300MG**	**A091157**	**008**	Nov 29, 2019
AB		TEVA PHARMS	**25MG**	**A091219**	**001**	Jul 19, 2019
AB			**50MG**	**A091219**	**002**	Jul 19, 2019
AB			**75MG**	**A091224**	**001**	Jul 19, 2019
AB			**100MG**	**A091224**	**002**	Jul 19, 2019
AB			**150MG**	**A091224**	**003**	Jul 19, 2019
AB			**200MG**	**A091224**	**004**	Jul 19, 2019
AB			**225MG**	**A091224**	**005**	Jul 19, 2019
AB			**300MG**	**A091224**	**006**	Jul 19, 2019
AB		YILING	**75MG**	**A210891**	**001**	Sep 30, 2019
AB			**300MG**	**A210891**	**002**	Sep 30, 2019

SOLUTION;ORAL

LYRICA

AA	**+!**	UPJOHN	**20MG/ML**	**N022488**	**001**	Jan 04, 2010

PREGABALIN

AA		ALKEM LABS LTD	**20MG/ML**	**A207623**	**001**	Jul 19, 2019
AA		PATRIN	**20MG/ML**	**A212604**	**001**	Feb 18, 2022

TABLET, EXTENDED RELEASE;ORAL

LYRICA CR

AB	**+**	UPJOHN	**82.5MG**	**N209501**	**001**	Oct 11, 2017
AB	**+**		**165MG**	**N209501**	**002**	Oct 11, 2017
AB	**+!**		**330MG**	**N209501**	**003**	Oct 11, 2017

PREGABALIN

AB		ALVOGEN	**82.5MG**	**A211593**	**001**	Apr 13, 2021
AB			**165MG**	**A211593**	**002**	Apr 13, 2021
AB			**330MG**	**A211593**	**003**	Apr 13, 2021
AB		APOTEX	**165MG**	**A213313**	**001**	Apr 13, 2021
AB			**330MG**	**A213313**	**002**	Apr 13, 2021
AB		EPIC PHARMA LLC	**82.5MG**	**A214496**	**001**	Jun 01, 2023
AB			**165MG**	**A214496**	**002**	Jun 01, 2023
AB			**330MG**	**A214496**	**003**	Jun 01, 2023
AB		MSN	**82.5MG**	**A213226**	**001**	Apr 13, 2021
AB			**165MG**	**A213226**	**002**	Apr 13, 2021
AB			**330MG**	**A213226**	**003**	Apr 13, 2021
AB		RUBICON	**82.5MG**	**A215249**	**001**	Mar 22, 2022
AB			**165MG**	**A215249**	**002**	Mar 22, 2022
AB			**330MG**	**A215249**	**003**	Mar 22, 2022
AB		SUN PHARM	**82.5MG**	**A211889**	**001**	Apr 13, 2021
AB			**165MG**	**A211889**	**002**	Apr 13, 2021
AB			**330MG**	**A211889**	**003**	Apr 13, 2021

PRETOMANID

TABLET;ORAL

PRETOMANID

	+!	MYLAN IRELAND LTD	200MG	N212862	001	Aug 14, 2019

PRILOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

PRILOCAINE HYDROCHLORIDE

	!	SEPTODONT INC	4%	A079235	001	Sep 29, 2010

PRIMAQUINE PHOSPHATE

TABLET;ORAL

PRIMAQUINE

AB	**+!**	SANOFI AVENTIS US	**EQ 15MG BASE**	**N008316**	**001**	

PRIMAQUINE PHOSPHATE

AB		BAYSHORE PHARMS LLC	**EQ 15MG BASE**	**A204476**	**001**	Feb 25, 2014
AB		NOVAST LABS	**EQ 15MG BASE**	**A206043**	**001**	Jun 23, 2016

PRIMIDONE

TABLET;ORAL

MYSOLINE

AB	**+!**	VALEANT	**50MG**	**N009170**	**003**	
AB	**+**		**250MG**	**N009170**	**002**	

PRIMIDONE

AB		AMNEAL PHARM	**50MG**	**A040866**	**001**	Apr 23, 2008
AB			**250MG**	**A040866**	**002**	Apr 23, 2008
AB		ANDA REPOSITORY	**50MG**	**A040626**	**001**	Sep 29, 2005
AB			**250MG**	**A040626**	**002**	Sep 29, 2005
AB		LANNETT	**50MG**	**A084903**	**002**	May 24, 2001
AB			**250MG**	**A084903**	**001**	
AB		OXFORD PHARMS	**50MG**	**A040586**	**001**	Feb 24, 2005
AB			**250MG**	**A040586**	**002**	Feb 24, 2005
AB		RUBICON	**50MG**	**A214896**	**001**	Jun 28, 2022
AB			**250MG**	**A214896**	**002**	Jun 28, 2022
AB		WATSON LABS	**250MG**	**A083551**	**001**	
		RUBICON	125MG	A214896	003	Dec 28, 2022

PROBENECID

TABLET;ORAL

PROBALAN

AB		LANNETT	**500MG**	**A080966**	**001**	

PROBENECID

AB		RISING	**500MG**	**A217020**	**001**	Nov 20, 2023
AB	**!**	WATSON LABS TEVA	**500MG**	**A084442**	**004**	Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

AP	**!**	HOSPIRA	**100MG/ML**	**A089069**	**001**	Feb 12, 1986
AP	**!**		**500MG/ML**	**A089070**	**001**	Feb 12, 1986
AP		INTL MEDICATION	**100MG/ML**	**A088636**	**001**	Jul 31, 1984
AP		NEXUS	**100MG/ML**	**A206332**	**001**	Oct 13, 2017
AP			**500MG/ML**	**A206332**	**002**	Oct 13, 2017

PROCARBAZINE HYDROCHLORIDE

CAPSULE;ORAL

MATULANE

	+!	LEADIANT BIOSCI INC	EQ 50MG BASE	N016785	001	

PROCHLORPERAZINE

SUPPOSITORY;RECTAL

COMPRO

AB		PADAGIS US	**25MG**	**A040246**	**001**	Jun 28, 2000

PROCHLORPERAZINE

AB	**!**	COSETTE	**25MG**	**A040058**	**001**	Nov 24, 1993

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

AP		AMNEAL	**EQ 5MG BASE/ML**	**A214192**	**001**	Nov 28, 2022
AP	**!**	AVET LIFESCIENCES	**EQ 5MG BASE/ML**	**A204147**	**001**	Oct 15, 2013
AP		CAPLIN	**EQ 5MG BASE/ML**	**A214379**	**001**	Apr 22, 2021
AP		EUGIA PHARMA	**EQ 5MG BASE/ML**	**A213873**	**001**	Jul 14, 2022
AP		GLAND PHARMA LTD	**EQ 5MG BASE/ML**	**A214107**	**001**	Sep 22, 2021
AP		HIKMA	**EQ 5MG BASE/ML**	**A089903**	**001**	Aug 29, 1989
AP			**EQ 5MG BASE/ML**	**A213630**	**001**	Nov 22, 2022
AP		MYLAN LABS LTD	**EQ 5MG BASE/ML**	**A210710**	**001**	Oct 25, 2018
AP		NEXUS	**EQ 5MG BASE/ML**	**A204860**	**001**	Feb 15, 2019
AP		SAGENT	**EQ 5MG BASE/ML**	**A040540**	**001**	May 28, 2004
AP		VIWIT PHARM	**EQ 5MG BASE/ML**	**A213626**	**001**	Sep 28, 2021

PROCHLORPERAZINE MALEATE

TABLET;ORAL

PROCHLORPERAZINE MALEATE

AB		AMNEAL	**EQ 5MG BASE**	**A216598**	**001**	Apr 17, 2023
AB			**EQ 10MG BASE**	**A216598**	**002**	Apr 17, 2023
AB		BIONPHARMA	**EQ 5MG BASE**	**A217478**	**001**	Apr 04, 2023
AB			**EQ 10MG BASE**	**A217478**	**002**	Apr 04, 2023
AB		GLENMARK PHARMS LTD	**EQ 5MG BASE**	**A216595**	**001**	Mar 17, 2023
AB			**EQ 10MG BASE**	**A216595**	**002**	Mar 17, 2023
AB		NOVITIUM PHARMA	**EQ 5MG BASE**	**A216202**	**001**	Jun 13, 2022
AB			**EQ 10MG BASE**	**A216202**	**002**	Jun 13, 2022
AB		ZYDUS	**EQ 5MG BASE**	**A216495**	**001**	Aug 08, 2022

PROCHLORPERAZINE MALEATE

TABLET;ORAL

PROCHLORPERAZINE MALEATE

AB			**EQ 10MG BASE**	**A216495**	**002**	Aug 08, 2022

PROCOMP

AB		JUBILANT CADISTA	**EQ 5MG BASE**	**A040268**	**001**	Feb 27, 1998
AB	**!**		**EQ 10MG BASE**	**A040268**	**002**	Feb 27, 1998

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

AB		AMNEAL PHARMS NY	**100MG**	**A207724**	**001**	Sep 07, 2017
AB			**200MG**	**A207724**	**002**	Sep 07, 2017
AB		BIONPHARMA	**100MG**	**A200900**	**001**	Aug 16, 2013
AB			**200MG**	**A200900**	**002**	Aug 16, 2013
AB		DR REDDYS	**100MG**	**A208801**	**001**	Feb 28, 2017
AB			**200MG**	**A208801**	**002**	Feb 28, 2017
AB		EUGIA PHARMA	**100MG**	**A211285**	**001**	Oct 26, 2018
AB			**200MG**	**A211285**	**002**	Oct 26, 2018
AB		SOFGEN PHARMS	**100MG**	**A200456**	**001**	Sep 28, 2012
AB			**200MG**	**A200456**	**002**	Sep 28, 2012
AB		XIROMED	**100MG**	**A205229**	**001**	Oct 20, 2017
AB			**200MG**	**A205229**	**002**	Oct 20, 2017

PROMETRIUM

AB	**+**	VIRTUS	**100MG**	**N019781**	**001**	May 14, 1998
AB	**+!**		**200MG**	**N019781**	**002**	Oct 15, 1999

GEL;VAGINAL

CRINONE

	+!	ALLERGAN	4%	N020701	001	Jul 31, 1997
	+!		8%	N020701	002	Jul 31, 1997

INJECTABLE;INJECTION

PROGESTERONE

AO		ACCORD HLTHCARE	**50MG/ML**	**A217707**	**001**	Nov 21, 2023
AO	**!**	EUGIA PHARMA	**50MG/ML**	**A210965**	**001**	Dec 06, 2018
AO		FRESENIUS KABI USA	**50MG/ML**	**A075906**	**001**	Apr 25, 2001
AO		HIKMA FARMACEUTICA	**50MG/ML**	**A091033**	**001**	Oct 28, 2010
AO		XIROMED	**50MG/ML**	**A215634**	**001**	Jan 05, 2022

INSERT;VAGINAL

ENDOMETRIN

	+!	FERRING	100MG	N022057	001	Jun 21, 2007

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	**+!**	WEST-WARD PHARMS INT	**25MG/ML**	**A083312**	**001**	
AP	**+!**		**50MG/ML**	**A083312**	**002**	
AP		XGEN PHARMS	**25MG/ML**	**A040737**	**001**	Apr 24, 2008
AP			**50MG/ML**	**A040737**	**002**	Apr 24, 2008

SUPPOSITORY;RECTAL

PROMETHAZINE HYDROCHLORIDE

AB		ANNORA PHARMA	**12.5MG**	**A216446**	**001**	Nov 02, 2022
AB			**25MG**	**A216446**	**002**	Nov 02, 2022
AB		COSETTE	**12.5MG**	**A040428**	**002**	Mar 31, 2003
AB	**!**		**25MG**	**A040428**	**001**	Feb 05, 2002
AB		PADAGIS ISRAEL	**12.5MG**	**A040500**	**001**	Jun 30, 2003
AB			**25MG**	**A040500**	**002**	Jun 30, 2003
AB		TARO	**12.5MG**	**A040603**	**001**	Oct 26, 2006
AB			**25MG**	**A040603**	**002**	Oct 26, 2006

PROMETHEGAN

	!	COSETTE	50MG	A087165	001	Aug 14, 1987

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

AA		CHARTWELL RX	**6.25MG/5ML**	**A040026**	**001**	Sep 25, 1998
AA		NOSTRUM LABS INC	**6.25MG/5ML**	**A040891**	**001**	Mar 13, 2009
AA		QUAGEN	**6.25MG/5ML**	**A213890**	**001**	Jul 12, 2021
AA		TARO	**6.25MG/5ML**	**A040718**	**001**	Apr 04, 2007
AA		TRIS PHARMA INC	**6.25MG/5ML**	**A091675**	**001**	Jun 28, 2012

PROMETHAZINE PLAIN

AA	**+!**	WOCKHARDT BIO AG	**6.25MG/5ML**	**A087953**	**001**	Nov 15, 1982

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB		AMNEAL PHARMS NY	**12.5MG**	**A091179**	**001**	Dec 13, 2010
AB			**25MG**	**A091179**	**002**	Dec 13, 2010

PROMETHAZINE HYDROCHLORIDE

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB			**50MG**	**A091179**	**003**	Dec 13, 2010
AB		KVK TECH	**12.5MG**	**A040712**	**002**	May 04, 2007
AB			**25MG**	**A040712**	**001**	Jul 31, 2006
AB			**50MG**	**A040712**	**003**	Jul 31, 2006
AB		PRINSTON INC	**12.5MG**	**A040622**	**001**	Jul 18, 2006
AB			**25MG**	**A040622**	**002**	Jul 18, 2006
AB			**50MG**	**A040622**	**003**	Jul 18, 2006
AB		QUAGEN	**12.5MG**	**A040673**	**001**	Mar 05, 2008
AB			**25MG**	**A040673**	**002**	Mar 05, 2008
AB			**50MG**	**A040673**	**003**	Mar 05, 2008
AB	**+**	SANDOZ	**25MG**	**A084176**	**003**	
AB	**+!**		**50MG**	**A084176**	**001**	
AB		STRIDES PHARMA	**12.5MG**	**A209177**	**001**	Jun 30, 2017
AB			**25MG**	**A209177**	**002**	Jun 30, 2017
AB			**50MG**	**A209177**	**003**	Jun 30, 2017
AB		WATSON LABS	**25MG**	**A083426**	**001**	
AB			**50MG**	**A083711**	**001**	
AB		ZYDUS PHARMS USA	**12.5MG**	**A040596**	**001**	Nov 18, 2005
AB			**25MG**	**A040596**	**002**	Nov 18, 2005
AB			**50MG**	**A040596**	**003**	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**225MG**	**A213096**	**001**	Feb 21, 2023
AB			**325MG**	**A213096**	**002**	Feb 21, 2023
AB			**425MG**	**A213096**	**003**	Feb 21, 2023
AB		GLENMARK PHARMS LTD	**225MG**	**A205268**	**001**	Sep 08, 2017
AB			**325MG**	**A205268**	**002**	Sep 08, 2017
AB			**425MG**	**A205268**	**003**	Sep 08, 2017
AB		RISING	**225MG**	**A205956**	**001**	Jul 02, 2018
AB			**325MG**	**A205956**	**002**	Jul 02, 2018
AB			**425MG**	**A205956**	**003**	Jul 02, 2018
AB		SCINOPHARM TAIWAN	**225MG**	**A212928**	**001**	Jun 18, 2020
AB			**325MG**	**A212928**	**002**	Jun 18, 2020
AB			**425MG**	**A212928**	**003**	Jun 18, 2020
AB		STRIDES PHARMA	**225MG**	**A078540**	**001**	Oct 18, 2010
AB			**325MG**	**A078540**	**002**	Oct 18, 2010
AB	**!**		**425MG**	**A078540**	**003**	Oct 18, 2010
AB		UPSHER SMITH LABS	**225MG**	**A212744**	**001**	Jun 25, 2020
AB			**325MG**	**A212744**	**002**	Jun 25, 2020
AB			**425MG**	**A212744**	**003**	Jun 25, 2020
AB		WATSON LABS INC	**225MG**	**A202688**	**001**	Aug 24, 2015
AB			**325MG**	**A202688**	**002**	Aug 24, 2015
AB			**425MG**	**A202688**	**003**	Aug 24, 2015
AB		ZYDUS	**225MG**	**A214184**	**001**	Apr 21, 2021
AB			**325MG**	**A214184**	**002**	Apr 21, 2021
AB			**425MG**	**A214184**	**003**	Apr 21, 2021
BX		SINOTHERAPEUTICS INC	225MG	A210339	001	Jan 04, 2019
BX			325MG	A210339	002	Jan 04, 2019
BX			425MG	A210339	003	Jan 04, 2019

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB		ANI PHARMS	**150MG**	**A076550**	**001**	Apr 23, 2004
AB			**225MG**	**A076550**	**002**	Apr 23, 2004
AB			**300MG**	**A076550**	**003**	Apr 23, 2004
AB		AUROBINDO PHARMA	**150MG**	**A202445**	**001**	May 11, 2016
AB			**225MG**	**A202445**	**002**	May 11, 2016
AB			**300MG**	**A202445**	**003**	May 11, 2016
AB		STRIDES PHARMA	**150MG**	**A075938**	**001**	Oct 17, 2002
AB			**225MG**	**A075938**	**002**	Oct 17, 2002
AB	**!**		**300MG**	**A075938**	**003**	Oct 17, 2002
AB		SUN PHARM INDUSTRIES	**150MG**	**A075998**	**001**	Nov 29, 2001
AB			**225MG**	**A075998**	**002**	Nov 29, 2001
AB			**300MG**	**A075998**	**003**	Nov 29, 2001
AB		WATSON LABS	**150MG**	**A075203**	**001**	Oct 24, 2000
AB			**225MG**	**A075203**	**002**	Oct 24, 2000

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALCAINE

AT		ALCON LABS INC	**0.5%**	**A080027**	**001**	

PROPARACAINE HYDROCHLORIDE

AT	**!**	BAUSCH AND LOMB	**0.5%**	**A040074**	**001**	Sep 29, 1995
AT		RISING	**0.5%**	**A040277**	**001**	Mar 16, 2000

PROPOFOL

INJECTABLE;INJECTION

DIPRIVAN

AB	**+!**	FRESENIUS KABI USA	**10MG/ML**	**N019627**	**002**	Jun 11, 1996

PROPOFOL

AB		AVET LIFESCIENCES	**10MG/ML**	**A206408**	**001**	Oct 12, 2021
AB		DR REDDYS	**10MG/ML**	**A205067**	**001**	Nov 15, 2018
AB		HIKMA	**10MG/ML**	**A074848**	**001**	Apr 19, 2005
AB		HOSPIRA	**10MG/ML**	**A077908**	**001**	Mar 17, 2006
AB		INNOPHARMA	**10MG/ML**	**A205576**	**001**	Sep 16, 2020
AB		SAGENT PHARMS INC	**10MG/ML**	**A075102**	**001**	Jan 04, 1999

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INDERAL LA

AB	**+**	ANI PHARMS	**60MG**	**N018553**	**004**	Mar 18, 1987
AB	**+**		**80MG**	**N018553**	**002**	Apr 19, 1983
AB	**+**		**120MG**	**N018553**	**003**	Apr 19, 1983
AB	**+!**		**160MG**	**N018553**	**001**	Apr 19, 1983

PROPRANOLOL HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**60MG**	**A078494**	**001**	Aug 10, 2007
AB			**80MG**	**A078494**	**002**	Aug 10, 2007
AB			**120MG**	**A078494**	**003**	Aug 10, 2007
AB			**160MG**	**A078494**	**004**	Aug 10, 2007
AB		ADARE PHARMS INC	**60MG**	**A078703**	**001**	Jul 15, 2011
AB			**80MG**	**A078703**	**002**	Jul 15, 2011
AB			**120MG**	**A078703**	**003**	Jul 15, 2011
AB			**160MG**	**A078703**	**004**	Jul 15, 2011
AB		AMTA	**60MG**	**A212026**	**001**	Jan 06, 2020
AB			**80MG**	**A212026**	**002**	Jan 06, 2020
AB			**120MG**	**A212026**	**003**	Jan 06, 2020
AB			**160MG**	**A212026**	**004**	Jan 06, 2020
AB		NORTEC DEV ASSOC	**60MG**	**A078065**	**001**	Jan 26, 2007
AB			**80MG**	**A078065**	**002**	Jan 26, 2007
AB			**120MG**	**A078065**	**003**	Jan 26, 2007
AB			**160MG**	**A078065**	**004**	Jan 26, 2007
AB		ZYDUS PHARMS USA INC	**60MG**	**A090321**	**001**	Mar 25, 2011
AB			**80MG**	**A090321**	**002**	Mar 25, 2011
AB			**120MG**	**A090321**	**003**	Mar 25, 2011
AB			**160MG**	**A090321**	**004**	Mar 25, 2011

INNOPRAN XL

BX	+	ANI PHARMS	80MG	N021438	001	Mar 12, 2003
BX	+!		120MG	N021438	002	Mar 12, 2003

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

AP		FRESENIUS KABI USA	**1MG/ML**	**A075826**	**001**	Aug 31, 2001
AP	**!**	HIKMA FARMACEUTICA	**1MG/ML**	**A077760**	**001**	Jan 31, 2008

SOLUTION;ORAL

HEMANGEOL

	+!	PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014

PROPRANOLOL HYDROCHLORIDE

	!	HIKMA	20MG/5ML	A070979	001	May 15, 1987
	!		40MG/5ML	A070690	001	May 15, 1987

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB		IMPAX LABS INC	**10MG**	**A071972**	**001**	Apr 06, 1988
AB			**20MG**	**A071972**	**002**	Apr 06, 1988
AB			**40MG**	**A071972**	**003**	Apr 06, 1988
AB			**60MG**	**A071976**	**002**	May 13, 1986
AB	**!**		**80MG**	**A071976**	**001**	Apr 06, 1988
AB		INNOGENIX	**10MG**	**A070322**	**002**	Oct 22, 1985
AB			**20MG**	**A070322**	**003**	Oct 22, 1985
AB			**40MG**	**A070322**	**004**	Oct 22, 1985
AB			**60MG**	**A070322**	**005**	Sep 24, 1986
AB			**80MG**	**A070322**	**001**	Aug 04, 1986

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB		IPCA LABS LTD	**10MG**	**A078955**	**001**	Jun 02, 2008
AB			**20MG**	**A078955**	**002**	Jun 02, 2008
AB			**40MG**	**A078955**	**003**	Jun 02, 2008
AB			**60MG**	**A078955**	**004**	Jun 02, 2008
AB			**80MG**	**A078955**	**005**	Jun 02, 2008
AB		MYLAN	**10MG**	**A070213**	**002**	Nov 19, 1985
AB			**20MG**	**A070213**	**003**	Nov 19, 1985
AB			**40MG**	**A070213**	**001**	Nov 19, 1985
AB			**60MG**	**A070213**	**005**	Apr 08, 2011
AB			**80MG**	**A070213**	**004**	Nov 19, 1985
AB		NORTHSTAR HLTHCARE	**10MG**	**A078213**	**001**	Jan 10, 2008
AB			**20MG**	**A078213**	**002**	Jan 10, 2008
AB			**40MG**	**A078213**	**003**	Jan 10, 2008
AB			**60MG**	**A078213**	**004**	Jan 10, 2008
AB			**80MG**	**A078213**	**005**	Jan 10, 2008
AB		VINTAGE PHARMS	**10MG**	**A070221**	**002**	Aug 01, 1986
AB			**20MG**	**A070221**	**003**	Aug 01, 1986
AB			**40MG**	**A070221**	**004**	Aug 01, 1986
AB			**60MG**	**A070221**	**005**	Sep 24, 1986
AB			**80MG**	**A070221**	**001**	Apr 14, 1986
AB		WATSON LABS	**10MG**	**A070175**	**001**	May 13, 1986
AB			**20MG**	**A070176**	**001**	May 13, 1986
AB			**40MG**	**A070177**	**001**	May 13, 1986
AB			**80MG**	**A070178**	**001**	May 13, 1986

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

AB	**+!**	DAVA PHARMS INC	**50MG**	**N006188**	**001**	
AB		MACLEODS PHARMS LTD	**50MG**	**A208867**	**001**	May 10, 2023
BD		ACTAVIS ELIZABETH	50MG	A080172	001	
BD		QUAGEN	50MG	A080154	001	

PROTAMINE SULFATE

INJECTABLE;INJECTION

PROTAMINE SULFATE

	!	FRESENIUS KABI USA	10MG/ML	A089454	001	Apr 07, 1987

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

PROTRIPTYLINE HYDROCHLORIDE

AB		EPIC PHARMA LLC	**5MG**	**A202220**	**001**	Nov 19, 2012
AB			**10MG**	**A202220**	**002**	Nov 19, 2012
AB		HIKMA	**5MG**	**A078913**	**001**	Sep 16, 2008
AB	**!**		**10MG**	**A078913**	**002**	Sep 16, 2008
AB		SIGMAPHARM LABS LLC	**5MG**	**A090462**	**001**	May 03, 2010
AB			**10MG**	**A090462**	**002**	May 03, 2010

PRUCALOPRIDE SUCCINATE

TABLET;ORAL

MOTEGRITY

	+	TAKEDA PHARMS USA	EQ 1MG BASE	N210166	001	Dec 14, 2018
	+!		EQ 2MG BASE	N210166	002	Dec 14, 2018

PYRAZINAMIDE

TABLET;ORAL

PYRAZINAMIDE

AB	**!**	HIKMA	**500MG**	**A081319**	**001**	Jun 30, 1992
AB		MACLEODS PHARMS LTD	**500MG**	**A212541**	**001**	Jul 27, 2020
AB	**+**	NOVITIUM PHARMA	**500MG**	**A080157**	**001**	

PYRIDOSTIGMINE BROMIDE

INJECTABLE;INJECTION

MESTINON

AP	**+!**	BAUSCH	**5MG/ML**	**N009830**	**001**	

REGONOL

AP		SANDOZ	**5MG/ML**	**N017398**	**001**	

SYRUP;ORAL

MESTINON

AA	**+!**	BAUSCH	**60MG/5ML**	**N015193**	**001**	

PYRIDOSTIGMINE BROMIDE

AA		AMNEAL	**60MG/5ML**	**A212702**	**001**	Jan 10, 2020

PYRIDOSTIGMINE BROMIDE

SYRUP;ORAL

PYRIDOSTIGMINE BROMIDE

AA		MILLA PHARMS	**60MG/5ML**	**A212405**	**001**	Apr 19, 2022
AA		MSN	**60MG/5ML**	**A216512**	**001**	Sep 21, 2023
AA		NOVITIUM PHARMA	**60MG/5ML**	**A211694**	**001**	Mar 08, 2019
AA		RISING	**60MG/5ML**	**A208797**	**001**	Jan 09, 2020

TABLET;ORAL

MESTINON

AB	**+!**	BAUSCH	**60MG**	**N009829**	**002**	

PYRIDOSTIGMINE BROMIDE

AB		EYWA	**30MG**	**A211181**	**002**	May 14, 2019
AB			**60MG**	**A211181**	**001**	Jul 20, 2018
AB		IMPAX LABS	**30MG**	**A040502**	**002**	Jun 28, 2022
AB			**60MG**	**A040502**	**001**	Apr 24, 2003
AB		ZYDUS PHARMS	**60MG**	**A205650**	**001**	Jun 22, 2015

TABLET, EXTENDED RELEASE;ORAL

MESTINON

AB	**+!**	BAUSCH	**180MG**	**N011665**	**001**	

PYRIDOSTIGMINE BROMIDE

AB		ALVOGEN	**180MG**	**A204737**	**001**	Jun 26, 2015
AB		IMPAX LABS INC	**180MG**	**A203184**	**001**	Sep 15, 2015
AB		RISING	**180MG**	**A205464**	**001**	Aug 15, 2017

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

PYRIDOXINE HYDROCHLORIDE

	+!	FRESENIUS KABI USA	100MG/ML	A080618	001	

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

AB	**+!**	TILDE SCIENCES	**25MG**	**N008578**	**001**	

PYRIMETHAMINE

AB		ALVOGEN	**25MG**	**A211271**	**001**	Jul 27, 2021
AB		AUROBINDO PHARMA LTD	**25MG**	**A216983**	**001**	Oct 25, 2022
AB		CEROVENE INC	**25MG**	**A207127**	**001**	Feb 28, 2020
AB		TEVA PHARMS	**25MG**	**A215506**	**001**	Aug 13, 2021

QUAZEPAM

TABLET;ORAL

DORAL

	+!	GALT PHARMS	15MG	N018708	001	Dec 27, 1985

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE	**EQ 25MG BASE**	**A202152**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A202152**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A202152**	**003**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A202152**	**004**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A202152**	**005**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A202152**	**006**	Mar 27, 2012
AB		ALKEM LABS LTD	**EQ 25MG BASE**	**A201504**	**001**	Feb 12, 2013
AB			**EQ 50MG BASE**	**A201504**	**002**	Feb 12, 2013
AB			**EQ 100MG BASE**	**A201504**	**003**	Feb 12, 2013
AB			**EQ 150MG BASE**	**A201504**	**004**	Feb 12, 2013
AB			**EQ 200MG BASE**	**A201504**	**005**	Feb 12, 2013
AB			**EQ 300MG BASE**	**A201504**	**006**	Feb 12, 2013
AB			**EQ 400MG BASE**	**A201504**	**007**	Feb 12, 2013
AB		AUROBINDO PHARMA LTD	**EQ 25MG BASE**	**A091388**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A091388**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A091388**	**003**	Mar 27, 2012
AB			**EQ 150MG BASE**	**A091388**	**004**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A091388**	**005**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A091388**	**006**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A091388**	**007**	Mar 27, 2012
AB		DR REDDYS LABS LTD	**EQ 25MG BASE**	**A077380**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A077380**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A077380**	**003**	Mar 27, 2012
AB			**EQ 150MG BASE**	**A077380**	**004**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A077380**	**005**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A077380**	**006**	Mar 27, 2012

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB			**EQ 400MG BASE**	**A077380**	**007**	Mar 27, 2012
AB		HETERO LABS LTD V	**EQ 25MG BASE**	**A204316**	**001**	Jun 16, 2022
AB			**EQ 50MG BASE**	**A204316**	**002**	Jun 16, 2022
AB			**EQ 100MG BASE**	**A204316**	**003**	Jun 16, 2022
AB			**EQ 200MG BASE**	**A204316**	**004**	Jun 16, 2022
AB			**EQ 300MG BASE**	**A204316**	**005**	Jun 16, 2022
AB			**EQ 400MG BASE**	**A204316**	**006**	Jun 16, 2022
AB		HIKMA	**EQ 25MG BASE**	**A090120**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A090749**	**001**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A090749**	**002**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A090749**	**003**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A090749**	**004**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A090749**	**005**	Mar 27, 2012
AB		LUPIN LTD	**EQ 25MG BASE**	**A201109**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A201109**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A201109**	**003**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A201109**	**004**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A201109**	**005**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A201109**	**006**	Mar 27, 2012
AB		MACLEODS PHARMS LTD	**EQ 25MG BASE**	**A203359**	**001**	May 17, 2016
AB			**EQ 50MG BASE**	**A203359**	**002**	May 17, 2016
AB			**EQ 100MG BASE**	**A203359**	**003**	May 17, 2016
AB			**EQ 200MG BASE**	**A203359**	**004**	May 17, 2016
AB			**EQ 300MG BASE**	**A203359**	**005**	May 17, 2016
AB			**EQ 400MG BASE**	**A203359**	**006**	May 17, 2016
AB		PRINSTON INC	**EQ 25MG BASE**	**A206954**	**001**	Aug 24, 2022
AB			**EQ 50MG BASE**	**A206954**	**002**	Aug 24, 2022
AB			**EQ 100MG BASE**	**A206954**	**003**	Aug 24, 2022
AB			**EQ 200MG BASE**	**A206954**	**004**	Aug 24, 2022
AB			**EQ 300MG BASE**	**A206954**	**005**	Aug 24, 2022
AB			**EQ 400MG BASE**	**A206954**	**006**	Aug 24, 2022
AB		SANDOZ	**EQ 25MG BASE**	**A078679**	**001**	Dec 14, 2012
AB			**EQ 50MG BASE**	**A078679**	**002**	Dec 14, 2012
AB			**EQ 100MG BASE**	**A078679**	**003**	Dec 14, 2012
AB			**EQ 150MG BASE**	**A078679**	**004**	Dec 14, 2012
AB			**EQ 200MG BASE**	**A078679**	**005**	Dec 14, 2012
AB			**EQ 300MG BASE**	**A078679**	**006**	Dec 14, 2012
AB			**EQ 400MG BASE**	**A078679**	**007**	Dec 14, 2012
AB		SUN PHARM	**EQ 25MG BASE**	**A201190**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A201190**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A201190**	**003**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A201190**	**004**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A201190**	**005**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A201190**	**006**	Mar 27, 2012
AB		TEVA PHARMS	**EQ 25MG BASE**	**A077745**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A077745**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A077745**	**003**	Mar 27, 2012
AB			**EQ 150MG BASE**	**A077745**	**004**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A077745**	**005**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A077745**	**006**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A077745**	**007**	Mar 27, 2012
AB		UNICHEM	**EQ 25MG BASE**	**A202674**	**001**	Mar 08, 2016
AB			**EQ 50MG BASE**	**A202674**	**002**	Mar 08, 2016
AB			**EQ 100MG BASE**	**A202674**	**003**	Mar 08, 2016
AB			**EQ 200MG BASE**	**A202674**	**004**	Mar 08, 2016
AB			**EQ 300MG BASE**	**A202674**	**005**	Mar 08, 2016
AB			**EQ 400MG BASE**	**A202674**	**006**	Mar 08, 2016
AB		ZENNOVA	**EQ 25MG BASE**	**A090960**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A090960**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A090960**	**003**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A090960**	**004**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A090960**	**005**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A090960**	**006**	Mar 27, 2012

SEROQUEL

AB	**+!**	ASTRAZENECA	**EQ 25MG BASE**	**N020639**	**001**	Sep 26, 1997
AB	**+**		**EQ 50MG BASE**	**N020639**	**007**	Oct 04, 2005
AB	**+**		**EQ 100MG BASE**	**N020639**	**002**	Sep 26, 1997
AB	**+**		**EQ 200MG BASE**	**N020639**	**003**	Sep 26, 1997
AB	**+!**		**EQ 300MG BASE**	**N020639**	**005**	Jul 26, 2000

QUETIAPINE FUMARATE

TABLET;ORAL

SEROQUEL

AB	+		**EQ 400MG BASE**	**N020639**	**006**	Oct 04, 2005

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE	**EQ 50MG BASE**	**A206252**	**001**	Nov 29, 2017
AB			**EQ 150MG BASE**	**A090681**	**001**	May 09, 2017
AB			**EQ 200MG BASE**	**A090681**	**002**	May 09, 2017
AB			**EQ 300MG BASE**	**A090681**	**003**	May 09, 2017
AB			**EQ 400MG BASE**	**A090681**	**004**	Nov 01, 2016
AB		ALIGNSCIENCE PHARMA	**EQ 150MG BASE**	**A209497**	**001**	Sep 28, 2018
AB			**EQ 200MG BASE**	**A209497**	**002**	Sep 28, 2018
AB		AUROBINDO PHARMA	**EQ 50MG BASE**	**A207655**	**001**	Nov 29, 2017
AB			**EQ 150MG BASE**	**A207655**	**002**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A207655**	**003**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A207655**	**004**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A207655**	**005**	Nov 29, 2017
AB		INTELLIPHARMACEUTICS	**EQ 50MG BASE**	**A202939**	**001**	May 09, 2017
AB			**EQ 150MG BASE**	**A202939**	**002**	May 09, 2017
AB			**EQ 200MG BASE**	**A202939**	**003**	May 09, 2017
AB			**EQ 300MG BASE**	**A202939**	**004**	May 09, 2017
AB			**EQ 400MG BASE**	**A202939**	**005**	May 09, 2017
AB		LUPIN LTD	**EQ 50MG BASE**	**A204203**	**001**	May 17, 2017
AB			**EQ 150MG BASE**	**A204203**	**002**	May 17, 2017
AB			**EQ 200MG BASE**	**A204203**	**003**	May 17, 2017
AB			**EQ 300MG BASE**	**A204203**	**004**	May 17, 2017
AB			**EQ 400MG BASE**	**A204203**	**005**	May 17, 2017
AB		MACLEODS PHARMS LTD	**EQ 150MG BASE**	**A204253**	**001**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A204253**	**002**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A204253**	**003**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A204253**	**004**	Nov 29, 2017
AB		NOVAST LABS	**EQ 50MG BASE**	**A208947**	**001**	Nov 29, 2017
AB			**EQ 150MG BASE**	**A208947**	**002**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A208947**	**003**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A208947**	**004**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A208947**	**005**	Nov 29, 2017
AB		PAR PHARM	**EQ 50MG BASE**	**A090482**	**001**	May 09, 2017
AB			**EQ 150MG BASE**	**A090482**	**002**	May 09, 2017
AB			**EQ 200MG BASE**	**A090482**	**003**	May 09, 2017
AB			**EQ 300MG BASE**	**A090482**	**004**	May 09, 2017
AB			**EQ 400MG BASE**	**A090482**	**005**	May 09, 2017
AB		PHARMADAX INC	**EQ 50MG BASE**	**A206260**	**001**	May 09, 2017
AB			**EQ 150MG BASE**	**A206260**	**002**	May 09, 2017
AB			**EQ 200MG BASE**	**A206260**	**003**	May 09, 2017
AB			**EQ 300MG BASE**	**A206260**	**004**	May 09, 2017
AB			**EQ 400MG BASE**	**A206260**	**005**	May 09, 2017
AB		PRINSTON INC	**EQ 50MG BASE**	**A208781**	**001**	Apr 26, 2022
AB			**EQ 150MG BASE**	**A208781**	**002**	Apr 26, 2022
AB			**EQ 200MG BASE**	**A208781**	**003**	Apr 26, 2022
AB			**EQ 300MG BASE**	**A208781**	**004**	Apr 26, 2022
AB		SCIEGEN PHARMS INC	**EQ 50MG BASE**	**A209635**	**005**	Nov 16, 2018
AB			**EQ 150MG BASE**	**A209635**	**001**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A209635**	**002**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A209635**	**003**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A209635**	**004**	Nov 29, 2017
AB		UNICHEM	**EQ 50MG BASE**	**A215478**	**001**	Aug 15, 2022
AB			**EQ 150MG BASE**	**A215478**	**002**	Aug 15, 2022
AB			**EQ 200MG BASE**	**A215478**	**003**	Aug 15, 2022
AB			**EQ 300MG BASE**	**A215478**	**004**	Aug 15, 2022
AB			**EQ 400MG BASE**	**A215478**	**005**	Aug 15, 2022

SEROQUEL XR

AB	+	ASTRAZENECA	**EQ 50MG BASE**	**N022047**	**001**	May 17, 2007
AB	+		**EQ 150MG BASE**	**N022047**	**005**	Aug 11, 2008
AB	+!		**EQ 200MG BASE**	**N022047**	**002**	May 17, 2007
AB	+		**EQ 300MG BASE**	**N022047**	**003**	May 17, 2007
AB	+		**EQ 400MG BASE**	**N022047**	**004**	May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A202725**	**001**	Apr 29, 2013
AB			**EQ 10MG BASE**	**A202725**	**002**	Apr 29, 2013
AB			**EQ 20MG BASE**	**A202725**	**003**	Apr 29, 2013
AB			**EQ 40MG BASE**	**A202725**	**004**	Apr 29, 2013
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A078457**	**001**	Aug 24, 2007
AB			**EQ 10MG BASE**	**A078457**	**002**	Aug 24, 2007
AB			**EQ 20MG BASE**	**A078457**	**003**	Aug 24, 2007
AB			**EQ 40MG BASE**	**A078457**	**004**	Aug 24, 2007
AB		LUPIN	**EQ 5MG BASE**	**A077690**	**001**	Jun 20, 2006
AB			**EQ 10MG BASE**	**A077690**	**002**	Jun 20, 2006
AB			**EQ 20MG BASE**	**A077690**	**003**	Jun 20, 2006
AB	**!**		**EQ 40MG BASE**	**A077690**	**004**	Jun 20, 2006
AB		PRINSTON INC	**EQ 5MG BASE**	**A205823**	**001**	Sep 15, 2016
AB			**EQ 10MG BASE**	**A205823**	**002**	Sep 15, 2016
AB			**EQ 20MG BASE**	**A205823**	**003**	Sep 15, 2016
AB			**EQ 40MG BASE**	**A205823**	**004**	Sep 15, 2016

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

AB		EYWA	**324MG**	**A212589**	**001**	Sep 17, 2021
AB	**!**	SUN PHARM INDUSTRIES	**324MG**	**A089338**	**001**	Feb 11, 1987

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

	!	EPIC PHARMA LLC	200MG	A088072	002	
	!		300MG	A088072	001	Sep 26, 1983

QUININE SULFATE

CAPSULE;ORAL

QUALAQUIN

AB	**+!**	SUN PHARM INDUSTRIES	**324MG**	**N021799**	**001**	Aug 12, 2005

QUININE SULFATE

AB		AMNEAL PHARMS	**324MG**	**A203729**	**001**	Jul 15, 2015
AB		LUPIN LTD	**324MG**	**A203112**	**001**	Apr 24, 2015
AB		NOVAST LABS	**324MG**	**A204372**	**001**	Jul 22, 2015
AB		TEVA PHARMS	**324MG**	**A091661**	**001**	Sep 28, 2012

QUIZARTINIB DIHYDROCHLORIDE

TABLET;ORAL

VANFLYTA

	+	DAIICHI SANKYO INC	EQ 17.7MG BASE	N216993	001	Jul 20, 2023
	+!		EQ 26.5MG BASE	N216993	002	Jul 20, 2023

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

AB	**+!**	WOODWARD	**20MG**	**N020973**	**002**	Aug 19, 1999

RABEPRAZOLE SODIUM

AB		ALKEM LABS LTD	**20MG**	**A208644**	**001**	Apr 24, 2018
AB		AMNEAL PHARMS	**20MG**	**A204179**	**001**	Jul 31, 2015
AB		AUROBINDO PHARMA	**20MG**	**A205761**	**001**	Feb 17, 2017
AB		DR REDDYS	**20MG**	**A076824**	**001**	Nov 08, 2013
AB		LANNETT CO INC	**20MG**	**A090678**	**001**	Nov 08, 2013
AB		LUPIN LTD	**20MG**	**A078964**	**001**	Nov 08, 2013
AB		RUBICON	**20MG**	**A204237**	**001**	Nov 18, 2015
AB		TORRENT	**20MG**	**A202376**	**001**	Nov 08, 2013

RADIUM RA-223 DICHLORIDE

SOLUTION;INTRAVENOUS

XOFIGO

	+!	BAYER HLTHCARE	162mCi/6ML (27mCi/ML)	N203971	001	May 15, 2013

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

EVISTA

AB	**+!**	LILLY	**60MG**	**N020815**	**001**	Dec 09, 1997

RALOXIFENE HYDROCHLORIDE

AB		AMNEAL PHARMS	**60MG**	**A208206**	**001**	Apr 08, 2016
AB		AUROBINDO PHARMA	**60MG**	**A204310**	**001**	Aug 28, 2015
AB		CADILA PHARMS LTD	**60MG**	**A211324**	**001**	Aug 18, 2020
AB		GLENMARK PHARMS LTD	**60MG**	**A204491**	**001**	Mar 22, 2016
AB		INVAGEN PHARMS	**60MG**	**A090842**	**001**	Sep 24, 2014
AB		SCIEGEN PHARMS INC	**60MG**	**A206384**	**001**	Oct 12, 2016
AB		TEVA PHARMS USA	**60MG**	**A078193**	**001**	Mar 04, 2014
AB		WATSON LABS INC	**60MG**	**A200825**	**001**	Jan 21, 2015

RALTEGRAVIR POTASSIUM

POWDER;ORAL

ISENTRESS

	+!	MSD SUB MERCK	EQ 100MG BASE/PACKET	N205786	001	Dec 20, 2013

TABLET;ORAL

ISENTRESS

	+!	MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007

ISENTRESS HD

	+!	MSD SUB MERCK	EQ 600MG BASE	N022145	002	May 26, 2017

TABLET, CHEWABLE;ORAL

ISENTRESS

	+	MSD SUB MERCK	EQ 25MG BASE	N203045	001	Dec 21, 2011
	+!		EQ 100MG BASE	N203045	002	Dec 21, 2011

RAMELTEON

TABLET;ORAL

RAMELTEON

AB		ACTAVIS LABS FL INC	**8MG**	**A091610**	**001**	Aug 19, 2015
AB		AUROBINDO PHARMA LTD	**8MG**	**A215972**	**001**	Jul 10, 2023
AB		DR REDDYS LABS SA	**8MG**	**A091693**	**001**	Jul 26, 2013
AB		GRANULES	**8MG**	**A213186**	**001**	Aug 21, 2020
AB		I3 PHARMS	**8MG**	**A212650**	**001**	Apr 10, 2020
AB		INNOGENIX	**8MG**	**A215435**	**001**	Aug 24, 2022
AB		MICRO LABS	**8MG**	**A215243**	**001**	Feb 09, 2023
AB		UPSHER SMITH LABS	**8MG**	**A213815**	**001**	Oct 26, 2020
AB		XIROMED	**8MG**	**A216209**	**001**	Nov 25, 2022
AB		ZYDUS PHARMS	**8MG**	**A211567**	**001**	Jul 22, 2019

ROZEREM

AB	**+!**	TAKEDA PHARMS USA	**8MG**	**N021782**	**001**	Jul 22, 2005

RAMIPRIL

CAPSULE;ORAL

ALTACE

AB	**+**	KING PHARMS LLC	**1.25MG**	**N019901**	**001**	Jan 28, 1991
AB	**+**		**2.5MG**	**N019901**	**002**	Jan 28, 1991
AB	**+**		**5MG**	**N019901**	**003**	Jan 28, 1991
AB	**+!**		**10MG**	**N019901**	**004**	Jan 28, 1991

RAMIPRIL

AB		ACCORD HLTHCARE	**1.25MG**	**A202392**	**001**	Apr 15, 2014
AB			**2.5MG**	**A202392**	**002**	Apr 15, 2014
AB			**5MG**	**A202392**	**003**	Apr 15, 2014
AB			**10MG**	**A202392**	**004**	Apr 15, 2014
AB		AUROBINDO PHARMA LTD	**1.25MG**	**A091604**	**001**	Jun 08, 2011
AB			**2.5MG**	**A091604**	**002**	Jun 08, 2011
AB			**5MG**	**A091604**	**003**	Jun 08, 2011
AB			**10MG**	**A091604**	**004**	Jun 08, 2011
AB		CHARTWELL MOLECULAR	**1.25MG**	**A078745**	**001**	Jun 18, 2008
AB			**2.5MG**	**A078745**	**002**	Jun 18, 2008
AB			**5MG**	**A078745**	**003**	Jun 18, 2008
AB			**10MG**	**A078745**	**004**	Jun 18, 2008
AB		COREPHARMA	**1.25MG**	**A079116**	**001**	Jun 20, 2008
AB			**2.5MG**	**A079116**	**002**	Jun 20, 2008
AB			**5MG**	**A079116**	**003**	Jun 20, 2008
AB			**10MG**	**A079116**	**004**	Jun 20, 2008
AB		DR REDDYS LABS LTD	**1.25MG**	**A078191**	**001**	Jun 18, 2008
AB			**2.5MG**	**A078191**	**002**	Jun 18, 2008
AB			**5MG**	**A078191**	**003**	Jun 18, 2008
AB			**10MG**	**A078191**	**004**	Jun 18, 2008

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB	HIKMA	**1.25MG**	**A077900**	**001**	Jun 18, 2008
AB		**2.5MG**	**A077900**	**002**	Jun 18, 2008
AB		**5MG**	**A077900**	**003**	Jun 18, 2008
AB		**10MG**	**A077900**	**004**	Jun 18, 2008
AB	LUPIN	**1.25MG**	**A077626**	**001**	Jun 09, 2008
AB		**2.5MG**	**A077626**	**002**	Jun 09, 2008
AB		**5MG**	**A077626**	**003**	Jun 09, 2008
AB		**10MG**	**A077626**	**004**	Jun 09, 2008
AB	WATSON LABS	**1.25MG**	**A076549**	**001**	Oct 24, 2005
AB		**2.5MG**	**A076549**	**002**	Oct 24, 2005
AB		**10MG**	**A076549**	**004**	Oct 24, 2005
AB	ZYDUS PHARMS USA	**1.25MG**	**A078832**	**001**	Sep 02, 2008
AB		**2.5MG**	**A078832**	**002**	Sep 02, 2008
AB		**5MG**	**A078832**	**003**	Sep 02, 2008
AB		**10MG**	**A078832**	**004**	Sep 02, 2008

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	**EQ 150MG BASE**	**A075742**	**001**	Nov 29, 2000
AB		**EQ 300MG BASE**	**A075742**	**002**	Nov 29, 2000
AB	SANDOZ	**EQ 150MG BASE**	**A074655**	**001**	Oct 22, 1997
AB **!**		**EQ 300MG BASE**	**A074655**	**002**	Oct 22, 1997

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA	LANNETT CO INC	**EQ 15MG BASE/ML**	**A091288**	**001**	Dec 09, 2010
AA **!**	PHARM ASSOC	**EQ 15MG BASE/ML**	**A077405**	**001**	Sep 21, 2007

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB	APOTEX	**EQ 150MG BASE**	**A074680**	**001**	Sep 12, 1997
AB		**EQ 300MG BASE**	**A074680**	**002**	Sep 12, 1997
AB	DR REDDYS LABS INC	**EQ 150MG BASE**	**A076705**	**001**	Jul 27, 2005
AB		**EQ 300MG BASE**	**A076705**	**002**	Jul 27, 2005
AB	GLENMARK PHARMS INC	**EQ 150MG BASE**	**A078542**	**001**	Nov 19, 2008
AB		**EQ 300MG BASE**	**A078542**	**002**	Nov 19, 2008
AB	PAR PHARM	**EQ 150MG BASE**	**A075180**	**001**	Jan 28, 1999
AB		**EQ 300MG BASE**	**A075180**	**002**	Jan 28, 1999
AB	SANDOZ	**EQ 150MG BASE**	**A074467**	**001**	Aug 29, 1997
AB		**EQ 300MG BASE**	**A074467**	**002**	Aug 29, 1997
AB	VKT PHARMA	**EQ 150MG BASE**	**A211289**	**001**	Jan 31, 2019
AB		**EQ 300MG BASE**	**A211289**	**002**	Jan 31, 2019

RANOLAZINE

GRANULES, EXTENDED RELEASE;ORAL

ASPRUZYO SPRINKLE

+	SPIL	500MG	N216018	001	Feb 28, 2022
+!		1GM	N216018	002	Feb 28, 2022

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB	ACTAVIS ELIZABETH	**500MG**	**A208862**	**001**	May 28, 2019
AB		**1GM**	**A208862**	**002**	May 28, 2019
AB	AJANTA PHARMA LTD	**500MG**	**A210054**	**001**	May 28, 2019
AB		**1GM**	**A210054**	**002**	May 28, 2019
AB	ALKEM LABS LTD	**500MG**	**A209953**	**001**	Nov 30, 2020
AB		**1GM**	**A209953**	**002**	Nov 30, 2020
AB	AUROBINDO PHARMA	**500MG**	**A209081**	**001**	Dec 23, 2022
AB		**1GM**	**A209081**	**002**	Dec 23, 2022
AB	CADILA	**500MG**	**A210188**	**001**	Aug 19, 2019
AB		**1GM**	**A210188**	**002**	Aug 19, 2019
AB	GLENMARK PHARMS LTD	**500MG**	**A211082**	**001**	Jul 05, 2019
AB		**1GM**	**A211082**	**002**	Jul 05, 2019
AB	HETERO LABS LTD III	**500MG**	**A212788**	**001**	May 05, 2022
AB		**1GM**	**A212788**	**002**	May 05, 2022
AB	I3 PHARMS	**500MG**	**A213517**	**001**	Apr 27, 2022
AB		**1GM**	**A213517**	**002**	Apr 27, 2022
AB	LUPIN LTD	**500MG**	**A201046**	**001**	Jul 29, 2013
AB		**1GM**	**A201046**	**002**	Jul 29, 2013
AB	MANKIND PHARMA	**500MG**	**A212284**	**001**	Feb 12, 2020
AB		**1GM**	**A212284**	**002**	Feb 12, 2020
AB	MICRO LABS	**500MG**	**A211745**	**001**	Feb 27, 2020

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB			**1GM**	**A211745**	**002**	Feb 27, 2020
AB		NOVAST LABS	**500MG**	**A210668**	**001**	Sep 27, 2023
AB			**1GM**	**A210668**	**002**	Sep 27, 2023
AB		PIRAMAL HLTHCARE UK	**1GM**	**A213085**	**002**	Jul 25, 2023
AB			**500MG**	**A213085**	**001**	Jul 25, 2023
AB		PRAXGEN	**500MG**	**A212781**	**001**	Mar 23, 2020
AB			**1GM**	**A212781**	**002**	Mar 23, 2020
AB		RISING	**500MG**	**A212889**	**001**	Jan 28, 2021
AB			**1GM**	**A212889**	**002**	Jan 28, 2021
AB		SCIEGEN PHARMS INC	**500MG**	**A211829**	**001**	Jun 04, 2019
AB			**1GM**	**A211829**	**002**	Jun 04, 2019
AB		SUN PHARM	**500MG**	**A211707**	**001**	May 28, 2019
AB	**!**		**1GM**	**A211707**	**002**	May 28, 2019
AB		SUNSHINE	**500MG**	**A211865**	**001**	Mar 23, 2020
AB			**1GM**	**A211865**	**002**	Mar 23, 2020
AB		UNICHEM	**500MG**	**A213083**	**001**	Mar 16, 2023
AB			**1GM**	**A213083**	**002**	Mar 16, 2023
AB		VKT PHARMA	**500MG**	**A214035**	**001**	Jan 19, 2022
AB			**1GM**	**A214035**	**002**	Jan 19, 2022

RASAGILINE MESYLATE

TABLET;ORAL

AZILECT

AB	**+**	TEVA	**EQ 0.5MG BASE**	**N021641**	**001**	May 16, 2006
AB	**+!**		**EQ 1MG BASE**	**N021641**	**002**	May 16, 2006

RASAGILINE MESYLATE

AB		ALKEM LABS LTD	**EQ 0.5MG BASE**	**A201889**	**001**	Oct 30, 2017
AB			**EQ 1MG BASE**	**A201889**	**002**	Oct 30, 2017
AB		AUROBINDO PHARMA USA	**EQ 0.5MG BASE**	**A201971**	**001**	May 15, 2017
AB			**EQ 1MG BASE**	**A201971**	**002**	May 15, 2017
AB		CHARTWELL RX	**EQ 0.5MG BASE**	**A201892**	**001**	Jul 27, 2018
AB			**EQ 1MG BASE**	**A201892**	**002**	Jul 27, 2018
AB		INDOCO	**EQ 0.5MG BASE**	**A206153**	**001**	Oct 04, 2019
AB			**EQ 1MG BASE**	**A206153**	**002**	Oct 04, 2019
AB		MICRO LABS	**EQ 0.5MG BASE**	**A207004**	**001**	Mar 29, 2019
AB			**EQ 1MG BASE**	**A207004**	**002**	Mar 29, 2019
AB		ORBION PHARMS	**EQ 0.5MG BASE**	**A201970**	**001**	Mar 15, 2016
AB			**EQ 1MG BASE**	**A201970**	**002**	Mar 15, 2016

REGADENOSON

SOLUTION;INTRAVENOUS

LEXISCAN

AP	**+!**	ASTELLAS	**0.4MG/5ML (0.08MG/ML)**	**N022161**	**001**	Apr 10, 2008

REGADENOSON

AP		ACCORD HLTHCARE	**0.4MG/5ML (0.08MG/ML)**	**A213236**	**001**	Apr 11, 2022
AP		APOTEX	**0.4MG/5ML (0.08MG/ML)**	**A207604**	**001**	Apr 11, 2022
AP		BAXTER HLTHCARE CORP	**0.4MG/5ML (0.08MG/ML)**	**A217455**	**001**	May 23, 2023
AP		DR REDDYS	**0.4MG/5ML (0.08MG/ML)**	**A213210**	**001**	Apr 11, 2022
AP		EUGIA PHARMA	**0.4MG/5ML (0.08MG/ML)**	**A216437**	**001**	Oct 26, 2022
AP		GLAND PHARMA LTD	**0.4MG/5ML (0.08MG/ML)**	**A207320**	**001**	Jul 12, 2022
AP		HIKMA	**0.4MG/5ML (0.08MG/ML)**	**A215827**	**001**	Feb 02, 2023
AP		HOSPIRA	**0.4MG/5ML (0.08MG/ML)**	**A214349**	**001**	Aug 31, 2022
AP		IMS LTD	**0.4MG/5ML (0.08MG/ML)**	**A214252**	**001**	May 23, 2022
AP		MEITHEAL	**0.4MG/5ML (0.08MG/ML)**	**A212806**	**001**	Apr 11, 2022
AP		MYLAN	**0.4MG/5ML (0.08MG/ML)**	**A213856**	**001**	Apr 04, 2023

REGORAFENIB

TABLET;ORAL

STIVARGA

	+!	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012

RELUGOLIX

TABLET;ORAL

ORGOVYX

	+!	SUMITOMO PHARMA	120MG	N214621	001	Dec 18, 2020

REMDESIVIR							
POWDER;INTRAVENOUS							
VEKLURY							
	+!	GILEAD SCIENCES INC	100MG/VIAL	N214787	001	Oct 22, 2020
SOLUTION;INTRAVENOUS							
VEKLURY							
	+!	GILEAD SCIENCES INC	100MG/20ML (5MG/ML)	N214787	002	Oct 22, 2020
REMIFENTANIL HYDROCHLORIDE							
INJECTABLE;INJECTION							
REMIFENTANIL HYDROCHLORIDE							
AP		FRESENIUS KABI USA	**EQ 1MG BASE/VIAL**	**A206223**	**001**	Jan 16, 2018
AP			**EQ 2MG BASE/VIAL**	**A206223**	**002**	Jan 16, 2018
AP			**EQ 5MG BASE/VIAL**	**A206223**	**003**	Jan 16, 2018
AP		HIKMA	**EQ 1MG BASE/VIAL**	**A210594**	**001**	Oct 13, 2020
AP			**EQ 2MG BASE/VIAL**	**A210594**	**002**	Oct 13, 2020
AP			**EQ 5MG BASE/VIAL**	**A210594**	**003**	Oct 13, 2020
ULTIVA							
AP	+	MYLAN INSTITUTIONAL	**EQ 1MG BASE/VIAL**	**N020630**	**001**	Jul 12, 1996
AP	+		**EQ 2MG BASE/VIAL**	**N020630**	**002**	Jul 12, 1996
AP	+!		**EQ 5MG BASE/VIAL**	**N020630**	**003**	Jul 12, 1996
REMIMAZOLAM BESYLATE							
POWDER;INTRAVENOUS							
BYFAVO							
	+!	ACACIA	EQ 20MG BASE/VIAL	N212295	001	Oct 06, 2020
REPAGLINIDE							
TABLET;ORAL							
REPAGLINIDE							
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A203820**	**001**	Jan 22, 2014
AB			**1MG**	**A203820**	**002**	Jan 22, 2014
AB	!		**2MG**	**A203820**	**003**	Jan 22, 2014
AB		CHARTWELL RX	**0.5MG**	**A078555**	**001**	Nov 22, 2013
AB			**1MG**	**A078555**	**002**	Jan 22, 2014
AB			**2MG**	**A078555**	**003**	Jan 22, 2014
AB		MACLEODS PHARMS LTD	**0.5MG**	**A207209**	**001**	Mar 22, 2023
AB			**1MG**	**A207209**	**002**	Mar 22, 2023
AB			**2MG**	**A207209**	**003**	Mar 22, 2023
AB		PADAGIS US	**0.5MG**	**A201189**	**001**	Jul 17, 2013
AB			**1MG**	**A201189**	**002**	Jan 22, 2014
AB			**2MG**	**A201189**	**003**	Jan 22, 2014
AB		SUN PHARM INDS INC	**1MG**	**A077571**	**002**	Jul 11, 2013
AB			**2MG**	**A077571**	**003**	Jul 11, 2013
REPOTRECTINIB							
CAPSULE;ORAL							
AUGTYRO							
	+!	BRISTOL	40MG	N218213	001	Nov 15, 2023
RETAPAMULIN							
OINTMENT;TOPICAL							
ALTABAX							
	+!	ALMIRALL	1%	N022055	001	Apr 12, 2007
REVEFENACIN							
SOLUTION;INHALATION							
YUPELRI							
	+!	MYLAN IRELAND LTD	175MCG/3ML	N210598	001	Nov 09, 2018
REZAFUNGIN ACETATE							
POWDER;INTRAVENOUS							
REZZAYO							
	+!	CIDARA THERAPS	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023
RIBAVIRIN							
CAPSULE;ORAL							
RIBAVIRIN							
AB	!	AUROBINDO PHARMA	**200MG**	**A079117**	**001**	Sep 17, 2009
AB		ZYDUS PHARMS USA	**200MG**	**A077224**	**001**	Oct 28, 2005
FOR SOLUTION;INHALATION							
RIBAVIRIN							
AN		NAVINTA LLC	**6GM/VIAL**	**A207366**	**001**	Oct 06, 2016
VIRAZOLE							
AN	+!	BAUSCH	**6GM/VIAL**	**N018859**	**001**	Dec 31, 1985

RIBAVIRIN
TABLET;ORAL
RIBAVIRIN

AB		AUROBINDO PHARMA	**200MG**	**A079111**	**001**	Sep 17, 2009
AB		SANDOZ	**200MG**	**A077743**	**001**	Oct 03, 2006
AB		ZYDUS PHARMS USA	**200MG**	**A077094**	**001**	Dec 05, 2005

RIBOCICLIB SUCCINATE
TABLET;ORAL
KISQALI

	+!	NOVARTIS	EQ 200MG BASE	N209092	001 Mar 13, 2017

RIBOFLAVIN 5'-PHOSPHATE
SOLUTION/DROPS;OPHTHALMIC
PHOTREXA

	+!	GLAUKOS	0.146%	N203324	001 Apr 15, 2016

PHOTREXA VISCOUS IN DEXTRAN 20%

	+!	GLAUKOS	0.146%	N203324	002 Apr 15, 2016

RIFABUTIN
CAPSULE;ORAL
MYCOBUTIN

AB	**+!**	PFIZER	**150MG**	**N050689**	**001**	Dec 23, 1992

RIFABUTIN

AB		LUPIN LTD	**150MG**	**A090033**	**001**	Feb 24, 2014
AB		NOVITIUM PHARMA	**150MG**	**A215041**	**001**	Dec 17, 2021

RIFAMPIN
CAPSULE;ORAL
RIFAMPIN

AB		CHARTWELL MOLECULAR	**150MG**	**A065390**	**001**	Mar 28, 2008
AB			**300MG**	**A065390**	**002**	Mar 28, 2008
AB		EPIC PHARMA LLC	**150MG**	**A064150**	**002**	Jan 02, 1998
AB			**300MG**	**A064150**	**001**	May 28, 1997
AB		HIKMA	**150MG**	**A065028**	**001**	Mar 14, 2001
AB			**300MG**	**A065028**	**002**	Mar 14, 2001
AB		LUPIN PHARMS	**150MG**	**A090034**	**001**	Aug 21, 2013
AB	**!**		**300MG**	**A090034**	**002**	Aug 21, 2013

RIMACTANE

AB		OXFORD PHARMS	**300MG**	**N050429**	**001**	

INJECTABLE;INJECTION
RIFADIN

AP	**+!**	SANOFI AVENTIS US	**600MG/VIAL**	**N050627**	**001**	May 25, 1989

RIFAMPIN

AP		EPIC PHARMA LLC	**600MG/VIAL**	**A065502**	**001**	Sep 21, 2010
AP		FRESENIUS KABI USA	**600MG/VIAL**	**A091181**	**001**	Aug 21, 2014
AP		HIKMA	**600MG/VIAL**	**A064217**	**001**	Oct 29, 1999
AP		HIKMA PHARMS	**600MG/VIAL**	**A205039**	**001**	Mar 03, 2016
AP		MYLAN LABS LTD	**600MG/VIAL**	**A065421**	**001**	May 22, 2008

RIFAMYCIN SODIUM
TABLET, DELAYED RELEASE;ORAL
AEMCOLO

	+!	REDHILL	EQ 194MG BASE	N210910	001 Nov 16, 2018

RIFAPENTINE
TABLET;ORAL
PRIFTIN

	+!	SANOFI AVENTIS US	150MG	N021024	001 Jun 22, 1998

RIFAXIMIN
TABLET;ORAL
XIFAXAN

	+!	SALIX PHARMS	200MG	N021361	001 May 25, 2004
	+!		550MG	N021361	002 Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE
TABLET;ORAL
EDURANT

	+!	JANSSEN PRODS	EQ 25MG BASE	N202022	001 May 20, 2011

RILUZOLE
FILM;ORAL
EXSERVAN
+! AQUESTIVE 50MG N212640 001 Nov 22, 2019
SUSPENSION;ORAL
TIGLUTIK KIT
+! ITALFARMACO SA 50MG/10ML N209080 001 Sep 05, 2018
TABLET;ORAL
RILUTEK
AB +! COVIS **50MG** **N020599 001** Dec 12, 1995
RILUZOLE
AB ALKEM LABS LTD **50MG** **A204048 001** Mar 30, 2016
AB GLENMARK PHARMS LTD **50MG** **A091394 001** Jun 18, 2013
AB IMPAX LABS **50MG** **A076173 001** Jan 29, 2003
AB KENTON **50MG** **A206045 001** Dec 09, 2019
AB MYLAN PHARMS INC **50MG** **A203042 001** Jul 01, 2013
AB SUN PHARM INDS LTD **50MG** **A091417 001** Jun 18, 2013

RIMANTADINE HYDROCHLORIDE
TABLET;ORAL
RIMANTADINE HYDROCHLORIDE
! IMPAX LABS 100MG A076132 001 Aug 30, 2002

RIMEGEPANT SULFATE
TABLET, ORALLY DISINTEGRATING;ORAL
NURTEC ODT
+! PFIZER EQ 75MG BASE N212728 001 Feb 27, 2020

RIOCIGUAT
TABLET;ORAL
ADEMPAS
AB + BAYER HLTHCARE **0.5MG** **N204819 001** Oct 08, 2013
AB + **1MG** **N204819 002** Oct 08, 2013
AB + **1.5MG** **N204819 003** Oct 08, 2013
AB + **2MG** **N204819 004** Oct 08, 2013
AB +! **2.5MG** **N204819 005** Oct 08, 2013
RIOCIGUAT
AB MSN **0.5MG** **A211135 001** Sep 01, 2022
AB **1MG** **A211135 002** Sep 01, 2022
AB **1.5MG** **A211135 003** Sep 01, 2022
AB **2MG** **A211135 004** Sep 01, 2022
AB **2.5MG** **A211135 005** Sep 01, 2022

RIPRETINIB
TABLET;ORAL
QINLOCK
+! DECIPHERA PHARMS 50MG N213973 001 May 15, 2020

RISDIPLAM
FOR SOLUTION;ORAL
EVRYSDI
+! GENENTECH INC 0.75MG/ML N213535 001 Aug 07, 2020

RISEDRONATE SODIUM
TABLET;ORAL
ACTONEL
AB +! APIL **35MG** **N020835 003** May 25, 2002
AB +! **150MG** **N020835 005** Apr 22, 2008
RISEDRONATE SODIUM
AB APOTEX **35MG** **A090877 001** Nov 30, 2015
AB **75MG** **A090877 002** Jun 10, 2014
AB **150MG** **A090877 003** Jun 10, 2014
AB AUROBINDO PHARMA **150MG** **A206768 001** Oct 21, 2016
AB AUROBINDO PHARMA LTD **5MG** **A200296 001** Nov 30, 2015
AB **30MG** **A200296 002** Nov 30, 2015
AB **35MG** **A200296 003** Nov 30, 2015
AB MACLEODS PHARMS LTD **5MG** **A203533 001** Dec 09, 2015
AB **30MG** **A203533 002** Dec 09, 2015
AB **35MG** **A203533 003** Nov 29, 2016
AB ORBION PHARMS **30MG** **A205280 001** May 13, 2019
AB **35MG** **A205280 002** May 13, 2019
AB SUN PHARM **5MG** **A090886 001** Nov 30, 2015
AB **30MG** **A090886 002** Nov 30, 2015
AB **35MG** **A090886 003** Nov 30, 2015
AB **75MG** **A090886 004** Jun 10, 2014

RISEDRONATE SODIUM

TABLET;ORAL

RISEDRONATE SODIUM

AB			**150MG**	**A090886**	**005**	Jun 10, 2014
AB		TEVA PHARMS USA	**5MG**	**A077132**	**001**	Oct 05, 2007
AB			**30MG**	**A077132**	**002**	Oct 05, 2007
AB			**35MG**	**A077132**	**003**	Oct 05, 2007
AB			**150MG**	**A079215**	**001**	Jun 13, 2014

TABLET, DELAYED RELEASE;ORAL

ATELVIA

AB	**+!**	APIL	**35MG**	**N022560**	**001**	Oct 08, 2010

RISEDRONATE SODIUM

AB		SUN PHARM	**35MG**	**A203925**	**001**	Jul 09, 2019
AB		TEVA PHARMS USA	**35MG**	**A203217**	**001**	May 18, 2015

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RYKINDO

	+!	SHANDONG LUYE	12.5MG	N212849	001	Jan 13, 2023
	+!		25MG	N212849	002	Jan 13, 2023
	+!		37.5MG	N212849	003	Jan 13, 2023
	+!		50MG	N212849	004	Jan 13, 2023

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

PERSERIS KIT

	+	INDIVIOR	90MG	N210655	001	Jul 27, 2018
	+!		120MG	N210655	002	Jul 27, 2018

INJECTABLE;INTRAMUSCULAR

RISPERDAL CONSTA

AP	**+**	JANSSEN PHARMS	**12.5MG/VIAL**	**N021346**	**004**	Apr 12, 2007
AP	**+!**		**25MG/VIAL**	**N021346**	**001**	Oct 29, 2003
AP	**+**		**37.5MG/VIAL**	**N021346**	**002**	Oct 29, 2003
AP	**+**		**50MG/VIAL**	**N021346**	**003**	Oct 29, 2003

RISPERIDONE

AP		TEVA PHARMS USA INC	**12.5MG/VIAL**	**A214068**	**001**	Dec 05, 2023
AP			**25MG/VIAL**	**A214068**	**002**	Dec 05, 2023
AP			**37.5MG/VIAL**	**A214068**	**003**	Dec 05, 2023
AP			**50MG/VIAL**	**A214068**	**004**	Dec 05, 2023

SOLUTION;ORAL

RISPERDAL

AA	**+!**	JANSSEN PHARMS	**1MG/ML**	**N020588**	**001**	Jun 10, 1996

RISPERIDONE

AA		AMNEAL PHARMS	**1MG/ML**	**A091384**	**001**	May 25, 2011
AA		AUROBINDO PHARMA LTD	**1MG/ML**	**A078452**	**001**	Sep 04, 2009
AA		CHARTWELL MOLECULAR	**1MG/ML**	**A202386**	**001**	Jan 12, 2015
AA		HIKMA	**1MG/ML**	**A076904**	**001**	Jul 29, 2009
AA		LANNETT CO INC	**1MG/ML**	**A079158**	**001**	Dec 03, 2010
AA		PHARM ASSOC	**1MG/ML**	**A077719**	**001**	Jul 29, 2009
AA		TARO	**1MG/ML**	**A090347**	**001**	Feb 07, 2011
AA		TRIS PHARMA INC	**1MG/ML**	**A079059**	**001**	Dec 12, 2012

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

UZEDY

	+	TEVA	50MG/0.14ML (50MG/0.14ML)	N213586	001	Apr 28, 2023
	+		75MG/0.21ML (75MG/0.21ML)	N213586	002	Apr 28, 2023
	+		100MG/0.28ML (100MG/0.28ML)	N213586	003	Apr 28, 2023
	+		125MG/0.35ML (125MG/0.35ML)	N213586	004	Apr 28, 2023
	+		150MG/0.42ML (150MG/0.42ML)	N213586	005	Apr 28, 2023
	+		200MG/0.56ML (200MG/0.56ML)	N213586	006	Apr 28, 2023
	+!		250MG/0.7ML (250MG/0.7ML)	N213586	007	Apr 28, 2023

TABLET;ORAL

RISPERDAL

AB	**+**	JANSSEN PHARMS	**0.25MG**	**N020272**	**008**	May 10, 1999
AB	**+**		**0.5MG**	**N020272**	**007**	Jan 27, 1999
AB	**+!**		**1MG**	**N020272**	**001**	Dec 29, 1993
AB	**+**		**2MG**	**N020272**	**002**	Dec 29, 1993
AB	**+**		**3MG**	**N020272**	**003**	Dec 29, 1993
AB	**+**		**4MG**	**N020272**	**004**	Dec 29, 1993

RISPERIDONE

AB		AJANTA PHARMA LTD	**0.25MG**	**A201003**	**001**	Aug 24, 2011
AB			**0.5MG**	**A201003**	**002**	Aug 24, 2011
AB			**1MG**	**A201003**	**003**	Aug 24, 2011
AB			**2MG**	**A201003**	**004**	Aug 24, 2011
AB			**3MG**	**A201003**	**005**	Aug 24, 2011

RISPERIDONE

TABLET;ORAL

RISPERIDONE

AB		**4MG**	**A201003**	**006**	Aug 24, 2011
AB	AMNEAL	**0.25MG**	**A078071**	**001**	Jun 17, 2009
AB		**0.5MG**	**A078071**	**002**	Jun 17, 2009
AB		**1MG**	**A078071**	**003**	Jun 17, 2009
AB		**2MG**	**A078071**	**004**	Jun 17, 2009
AB		**3MG**	**A078071**	**005**	Jun 17, 2009
AB		**4MG**	**A078071**	**006**	Jun 17, 2009
AB	APOTEX INC	**0.25MG**	**A077953**	**001**	Sep 15, 2008
AB		**0.5MG**	**A077953**	**002**	Sep 15, 2008
AB		**1MG**	**A077953**	**003**	Sep 15, 2008
AB		**2MG**	**A077953**	**004**	Sep 15, 2008
AB		**3MG**	**A077953**	**005**	Sep 15, 2008
AB		**4MG**	**A077953**	**006**	Sep 15, 2008
AB	CELLTRION	**0.25MG**	**A078871**	**001**	Oct 09, 2008
AB		**0.5MG**	**A078871**	**002**	Oct 09, 2008
AB		**1MG**	**A078871**	**003**	Oct 09, 2008
AB		**2MG**	**A078871**	**004**	Oct 09, 2008
AB		**3MG**	**A078871**	**005**	Oct 09, 2008
AB		**4MG**	**A078871**	**006**	Oct 09, 2008
AB	CHARTWELL MOLECULAR	**0.25MG**	**A077543**	**001**	May 18, 2011
AB		**0.5MG**	**A077543**	**002**	May 18, 2011
AB		**1MG**	**A077543**	**003**	May 18, 2011
AB		**2MG**	**A077543**	**004**	May 18, 2011
AB		**3MG**	**A077543**	**005**	May 18, 2011
AB		**4MG**	**A077543**	**006**	May 18, 2011
AB	DR REDDYS LABS LTD	**0.25MG**	**A076879**	**001**	Oct 24, 2008
AB		**0.5MG**	**A076879**	**002**	Oct 24, 2008
AB		**1MG**	**A076879**	**003**	Oct 24, 2008
AB		**2MG**	**A076879**	**004**	Oct 24, 2008
AB		**3MG**	**A076879**	**005**	Oct 24, 2008
AB		**4MG**	**A076879**	**006**	Oct 24, 2008
AB	PRINSTON INC	**0.25MG**	**A077493**	**001**	Nov 29, 2011
AB		**0.5MG**	**A077493**	**002**	Nov 29, 2011
AB		**1MG**	**A077493**	**003**	Nov 29, 2011
AB		**2MG**	**A077493**	**004**	Nov 29, 2011
AB		**3MG**	**A077493**	**005**	Nov 29, 2011
AB		**4MG**	**A077493**	**006**	Nov 29, 2011
AB	RISING	**0.25MG**	**A078269**	**001**	Oct 08, 2008
AB		**0.5MG**	**A078269**	**002**	Oct 08, 2008
AB		**1MG**	**A078269**	**003**	Oct 08, 2008
AB		**2MG**	**A078269**	**004**	Oct 08, 2008
AB		**3MG**	**A078269**	**005**	Oct 08, 2008
AB		**4MG**	**A078269**	**006**	Oct 08, 2008
AB	SANDOZ	**0.25MG**	**A078528**	**001**	Oct 16, 2009
AB		**0.5MG**	**A078528**	**002**	Oct 16, 2009
AB		**1MG**	**A078528**	**003**	Oct 16, 2009
AB		**2MG**	**A078528**	**004**	Oct 16, 2009
AB		**3MG**	**A078528**	**005**	Oct 16, 2009
AB		**4MG**	**A078528**	**006**	Oct 16, 2009
AB	TORRENT PHARMS	**0.25MG**	**A079088**	**001**	Oct 30, 2008
AB		**0.5MG**	**A079088**	**002**	Oct 30, 2008
AB		**1MG**	**A079088**	**003**	Oct 30, 2008
AB		**2MG**	**A079088**	**004**	Oct 30, 2008
AB		**3MG**	**A079088**	**005**	Oct 30, 2008
AB		**4MG**	**A079088**	**006**	Oct 30, 2008
AB	WESTMINSTER PHARMS	**0.25MG**	**A078707**	**001**	Dec 29, 2008
AB		**0.5MG**	**A078707**	**002**	Dec 29, 2008
AB		**1MG**	**A078707**	**003**	Dec 29, 2008
AB		**2MG**	**A078707**	**004**	Dec 29, 2008
AB		**3MG**	**A078707**	**005**	Dec 29, 2008
AB		**4MG**	**A078707**	**006**	Dec 29, 2008
AB	ZYDUS PHARMS USA INC	**0.25MG**	**A078040**	**001**	Oct 16, 2008
AB		**0.5MG**	**A078040**	**002**	Oct 16, 2008
AB		**1MG**	**A078040**	**003**	Oct 16, 2008
AB		**2MG**	**A078040**	**004**	Oct 16, 2008
AB		**3MG**	**A078040**	**005**	Oct 16, 2008
AB		**4MG**	**A078040**	**006**	Oct 16, 2008

RISPERIDONE						
TABLET, ORALLY DISINTEGRATING;ORAL						
RISPERIDONE						
AB		DR REDDYS LABS LTD	**0.5MG**	**A077328**	**001**	Feb 24, 2009
AB			**1MG**	**A077328**	**002**	Oct 05, 2009
AB			**2MG**	**A077328**	**003**	Feb 24, 2009
AB			**3MG**	**A077328**	**004**	Nov 30, 2009
AB			**4MG**	**A077328**	**005**	Nov 30, 2009
AB		JUBILANT GENERICS	**0.5MG**	**A090839**	**001**	Nov 04, 2011
AB	!		**1MG**	**A090839**	**002**	Nov 04, 2011
AB			**2MG**	**A090839**	**003**	Nov 04, 2011
AB			**3MG**	**A090839**	**004**	Nov 04, 2011
AB			**4MG**	**A090839**	**005**	Nov 04, 2011
AB		PAR PHARM	**0.5MG**	**A077494**	**002**	Apr 30, 2009
AB			**1MG**	**A077494**	**003**	Oct 26, 2009
AB			**2MG**	**A077494**	**004**	Apr 30, 2009
AB			**3MG**	**A077494**	**005**	Apr 30, 2009
AB			**4MG**	**A077494**	**006**	Apr 30, 2009
AB		SANDOZ	**0.5MG**	**A078116**	**001**	Dec 22, 2009
AB			**1MG**	**A078116**	**002**	Dec 22, 2009
AB			**2MG**	**A078116**	**003**	Dec 22, 2009
AB			**3MG**	**A078116**	**004**	Dec 22, 2009
AB			**4MG**	**A078116**	**005**	Dec 22, 2009
AB		SUN PHARM INDS LTD	**0.5MG**	**A077542**	**001**	Aug 06, 2010
AB			**0.5MG**	**A078464**	**001**	Apr 08, 2013
AB			**1MG**	**A077542**	**002**	Aug 06, 2010
AB			**1MG**	**A078464**	**002**	Apr 08, 2013
AB			**2MG**	**A077542**	**003**	Aug 06, 2010
AB			**2MG**	**A078464**	**003**	Apr 08, 2013
AB			**3MG**	**A078464**	**004**	Apr 08, 2013
AB			**3MG**	**A078474**	**001**	Aug 06, 2010
AB			**4MG**	**A078464**	**005**	Apr 08, 2013
AB			**4MG**	**A078474**	**002**	Aug 06, 2010
AB		ZYDUS PHARMS USA	**0.5MG**	**A078516**	**001**	May 01, 2009
AB			**2MG**	**A078516**	**003**	May 01, 2009
		PAR PHARM	0.25MG	A077494	001	Apr 30, 2009
RITLECITINIB TOSYLATE						
CAPSULE;ORAL						
LITFULO						
	+!	PFIZER	EQ 50MG BASE	N215830	001	Jun 23, 2023
RITONAVIR						
POWDER;ORAL						
NORVIR						
	+!	ABBVIE	100MG/PACKET	N209512	001	Jun 07, 2017
TABLET;ORAL						
NORVIR						
AB	**+!**	ABBVIE	**100MG**	**N022417**	**001**	Feb 10, 2010
RITONAVIR						
AB		AMNEAL	**100MG**	**A208890**	**001**	Sep 17, 2018
AB		AUROBINDO PHARMA LTD	**100MG**	**A206614**	**001**	Sep 17, 2018
AB		CIPLA	**100MG**	**A202573**	**001**	Jan 15, 2015
AB			**100MG**	**A203759**	**001**	May 10, 2022
AB		HETERO LABS LTD III	**100MG**	**A204587**	**001**	Sep 17, 2018
RIVAROXABAN						
FOR SUSPENSION;ORAL						
XARELTO						
	+!	JANSSEN PHARMS	1MG/ML	N215859	001	Dec 20, 2021
TABLET;ORAL						
XARELTO						
	+	JANSSEN PHARMS	2.5MG	N022406	004	Oct 11, 2018
	+		10MG	N022406	001	Jul 01, 2011
	+		15MG	N022406	002	Nov 04, 2011
	+!		20MG	N022406	003	Nov 04, 2011
RIVASTIGMINE						
FILM, EXTENDED RELEASE;TRANSDERMAL						
EXELON						
AB	**+**	SANDOZ	**4.6MG/24HR**	**N022083**	**001**	Jul 06, 2007
AB	**+!**		**9.5MG/24HR**	**N022083**	**002**	Jul 06, 2007
AB	**+**		**13.3MG/24HR**	**N022083**	**005**	Aug 31, 2012

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

AB		ALVOGEN	**4.6MG/24HR**	**A204403**	**001**	Sep 03, 2015
AB			**9.5MG/24HR**	**A204403**	**002**	Sep 03, 2015
AB			**13.3MG/24HR**	**A204403**	**003**	Aug 31, 2015
AB		AMNEAL PHARMS	**4.6MG/24HR**	**A207308**	**001**	Jan 08, 2019
AB			**9.5MG/24HR**	**A207308**	**002**	Jan 08, 2019
AB			**13.3MG/24HR**	**A207308**	**003**	Jan 08, 2019
AB		BRECKENRIDGE	**4.6MG/24HR**	**A209063**	**001**	Nov 26, 2019
AB			**9.5MG/24HR**	**A209063**	**002**	Nov 26, 2019
AB			**13.3MG/24HR**	**A209063**	**003**	Nov 26, 2019
AB		MYLAN TECHNOLOGIES	**4.6MG/24HR**	**A205622**	**001**	Jun 20, 2018
AB			**9.5MG/24HR**	**A205622**	**002**	Jun 20, 2018
AB			**13.3MG/24HR**	**A205622**	**003**	Jun 20, 2018
AB		ZYDUS PHARMS	**4.6MG/24HR**	**A206318**	**001**	Mar 04, 2019
AB			**9.5MG/24HR**	**A206318**	**002**	Mar 04, 2019
AB			**13.3MG/24HR**	**A206318**	**003**	Mar 04, 2019

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB		ALEMBIC PHARMS LTD	**EQ 1.5MG BASE**	**A091689**	**001**	Jun 12, 2012
AB			**EQ 3MG BASE**	**A091689**	**002**	Jun 12, 2012
AB			**EQ 4.5MG BASE**	**A091689**	**003**	Jun 12, 2012
AB			**EQ 6MG BASE**	**A091689**	**004**	Jun 12, 2012
AB		AUROBINDO PHARMA	**EQ 1.5MG BASE**	**A204572**	**001**	Mar 25, 2016
AB			**EQ 3MG BASE**	**A204572**	**002**	Mar 25, 2016
AB			**EQ 4.5MG BASE**	**A204572**	**003**	Mar 25, 2016
AB			**EQ 6MG BASE**	**A204572**	**004**	Mar 25, 2016
AB		CADILA PHARMS LTD	**EQ 1.5MG BASE**	**A203844**	**001**	Feb 13, 2017
AB			**EQ 3MG BASE**	**A203844**	**002**	Feb 13, 2017
AB			**EQ 4.5MG BASE**	**A203844**	**003**	Feb 13, 2017
AB			**EQ 6MG BASE**	**A203844**	**004**	Feb 13, 2017
AB		CHARTWELL RX	**EQ 1.5MG BASE**	**A207797**	**001**	Sep 28, 2017
AB			**EQ 3MG BASE**	**A207797**	**002**	Sep 28, 2017
AB			**EQ 4.5MG BASE**	**A207797**	**003**	Sep 28, 2017
AB			**EQ 6MG BASE**	**A207797**	**004**	Sep 28, 2017
AB	**!**	DR REDDYS LABS INC	**EQ 1.5MG BASE**	**A077130**	**001**	Oct 31, 2007
AB			**EQ 3MG BASE**	**A077130**	**002**	Oct 31, 2007
AB			**EQ 4.5MG BASE**	**A077130**	**003**	Oct 31, 2007
AB	**!**		**EQ 6MG BASE**	**A077130**	**004**	Oct 31, 2007
AB		MACLEODS PHARMS LTD	**EQ 1.5MG BASE**	**A203148**	**001**	Aug 22, 2014
AB			**EQ 3MG BASE**	**A203148**	**002**	Aug 22, 2014
AB			**EQ 4.5MG BASE**	**A203148**	**003**	Aug 22, 2014
AB			**EQ 6MG BASE**	**A203148**	**004**	Aug 22, 2014
AB		ORBION PHARMS	**EQ 1.5MG BASE**	**A090879**	**001**	Jun 10, 2015
AB			**EQ 3MG BASE**	**A090879**	**002**	Jun 10, 2015
AB			**EQ 4.5MG BASE**	**A090879**	**003**	Jun 10, 2015
AB			**EQ 6MG BASE**	**A090879**	**004**	Jun 10, 2015
AB		SUN PHARM	**EQ 1.5MG BASE**	**A077131**	**001**	Oct 22, 2007
AB			**EQ 3MG BASE**	**A077131**	**002**	Oct 22, 2007
AB			**EQ 4.5MG BASE**	**A077131**	**003**	Oct 22, 2007
AB			**EQ 6MG BASE**	**A077131**	**004**	Oct 22, 2007
AB		WATSON LABS	**EQ 1.5MG BASE**	**A077129**	**001**	Jan 08, 2008
AB			**EQ 3MG BASE**	**A077129**	**002**	Jan 08, 2008
AB			**EQ 4.5MG BASE**	**A077129**	**003**	Jan 08, 2008
AB			**EQ 6MG BASE**	**A077129**	**004**	Jan 08, 2008

RIZATRIPTAN BENZOATE

FILM;ORAL

RIZAFILM

	+!	GENSCO	EQ 10MG BASE	N205394	001	Apr 14, 2023

TABLET;ORAL

MAXALT

AB	**+!**	ORGANON LLC	**EQ 10MG BASE**	**N020864**	**002**	Jun 29, 1998

RIZATRIPTAN BENZOATE

AB		ALKEM LABS LTD	**EQ 5MG BASE**	**A203269**	**001**	Feb 18, 2016
AB			**EQ 10MG BASE**	**A203269**	**002**	Feb 18, 2016
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A202490**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A202490**	**002**	Dec 31, 2012
AB		CHARTWELL RX	**EQ 5MG BASE**	**A077526**	**001**	Mar 26, 2013
AB			**EQ 10MG BASE**	**A077526**	**002**	Mar 26, 2013

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB		CREEKWOOD PHARMS	**EQ 5MG BASE**	**A202047**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A202047**	**002**	Dec 31, 2012
AB		GLENMARK GENERICS	**EQ 5MG BASE**	**A201967**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A201967**	**002**	Dec 31, 2012
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A204339**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A204339**	**002**	Jul 01, 2013
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A203147**	**001**	Feb 11, 2014
AB			**EQ 10MG BASE**	**A203147**	**002**	Feb 11, 2014
AB		MYLAN PHARMS INC	**EQ 5MG BASE**	**A201993**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A201993**	**002**	Dec 31, 2012
AB		NATCO PHARMA LTD	**EQ 5MG BASE**	**A200482**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A200482**	**002**	Dec 31, 2012
AB		TEVA PHARMS	**EQ 5MG BASE**	**A077263**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A077263**	**002**	Dec 31, 2012

TABLET, ORALLY DISINTEGRATING;ORAL

MAXALT-MLT

AB	**+!**	ORGANON	**EQ 10MG BASE**	**N020865**	**002**	Jun 29, 1998

RIZATRIPTAN BENZOATE

AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A203062**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A203062**	**002**	Jul 01, 2013
AB		GLENMARK PHARMS LTD	**EQ 5MG BASE**	**A201914**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A201914**	**002**	Jul 01, 2013
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A203146**	**001**	Sep 19, 2014
AB			**EQ 10MG BASE**	**A203146**	**002**	Sep 19, 2014
AB		NATCO PHARMA LTD	**EQ 5MG BASE**	**A203478**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A203478**	**002**	Jul 01, 2013
AB		PANACEA	**EQ 5MG BASE**	**A204722**	**001**	Jan 11, 2017
AB			**EQ 10MG BASE**	**A204722**	**002**	Jan 11, 2017

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP		CAPLIN	**50MG/5ML (10MG/ML)**	**A216234**	**001**	Mar 02, 2023
AP			**100MG/10ML (10MG/ML)**	**A216234**	**002**	Mar 02, 2023
AP		EUGIA PHARMA	**50MG/5ML (10MG/ML)**	**A206206**	**001**	Apr 12, 2017
AP			**100MG/10ML (10MG/ML)**	**A206206**	**002**	Apr 12, 2017
AP		FRESENIUS KABI USA	**50MG/5ML (10MG/ML)**	**A078651**	**001**	Dec 29, 2008
AP			**100MG/10ML (10MG/ML)**	**A078651**	**002**	Dec 29, 2008
AP		GLAND PHARMA LTD	**50MG/5ML (10MG/ML)**	**A205656**	**001**	Apr 04, 2018
AP			**100MG/10ML (10MG/ML)**	**A205656**	**002**	Apr 04, 2018
AP		HIKMA	**50MG/5ML (10MG/ML)**	**A217034**	**001**	May 24, 2023
AP		HOSPIRA	**50MG/5ML (10MG/ML)**	**A078519**	**001**	Nov 26, 2008
AP			**100MG/10ML (10MG/ML)**	**A078519**	**002**	Nov 26, 2008
AP		MEITHEAL	**50MG/5ML (10MG/ML)**	**A213453**	**001**	May 08, 2023
AP			**100MG/10ML (10MG/ML)**	**A213453**	**002**	May 08, 2023
AP		MYLAN INSTITUTIONAL	**50MG/5ML (10MG/ML)**	**A079199**	**001**	Nov 26, 2008
AP			**100MG/10ML (10MG/ML)**	**A079199**	**002**	Nov 26, 2008
AP		PIRAMAL CRITICAL	**50MG/5ML (10MG/ML)**	**A210437**	**001**	Aug 13, 2019
AP			**100MG/10ML (10MG/ML)**	**A210437**	**002**	Aug 13, 2019
AP		PRINSTON INC	**50MG/5ML (10MG/ML)**	**A212668**	**001**	May 26, 2022
AP			**100MG/10ML (10MG/ML)**	**A212668**	**002**	May 26, 2022
AP		SAGENT PHARMS INC	**50MG/5ML (10MG/ML)**	**A091458**	**001**	Jul 28, 2010
AP			**100MG/10ML (10MG/ML)**	**A091458**	**002**	Jul 28, 2010
AP	**!**	SANDOZ	**50MG/5ML (10MG/ML)**	**A079195**	**001**	Dec 05, 2008
AP	**!**		**100MG/10ML (10MG/ML)**	**A079195**	**002**	Dec 05, 2008
AP		TAMARANG	**50MG/5ML (10MG/ML)**	**A091115**	**001**	Aug 27, 2012
AP			**100MG/10ML (10MG/ML)**	**A091115**	**002**	Aug 27, 2012
AP		WEST WARD PHARM CORP	**50MG/5ML (10MG/ML)**	**A204679**	**001**	Feb 28, 2017
AP			**100MG/10ML (10MG/ML)**	**A204679**	**002**	Feb 28, 2017

ROFLUMILAST

CREAM;TOPICAL

ZORYVE

	+!	ARCUTIS	0.3%	N215985	001	Jul 29, 2022

FOAM;TOPICAL

ZORYVE

	+!	ARCUTIS	0.3%	N217242	001	Dec 15, 2023

ROFLUMILAST

TABLET;ORAL

DALIRESP

AB	**+**	ASTRAZENECA	**250MCG**	**N022522**	**002**	Jan 23, 2018
AB	**+!**		**500MCG**	**N022522**	**001**	Feb 28, 2011

ROFLUMILAST

AB		ALKEM LABS LTD	**250MCG**	**A212490**	**001**	Apr 18, 2023
AB			**500MCG**	**A212490**	**002**	Apr 18, 2023
AB		AUROBINDO PHARMA LTD	**500MCG**	**A213298**	**001**	Apr 17, 2023
AB		BRECKENRIDGE	**250MCG**	**A208236**	**002**	Oct 19, 2023
AB		HETERO LABS LTD III	**250MCG**	**A208213**	**002**	Apr 18, 2023
AB			**500MCG**	**A208213**	**001**	Nov 23, 2018
AB		MICRO LABS	**250MCG**	**A208180**	**002**	Apr 18, 2023
AB			**500MCG**	**A208180**	**001**	Mar 22, 2019
AB		MSN	**250MCG**	**A208256**	**001**	Sep 07, 2022
AB			**500MCG**	**A208256**	**002**	Sep 07, 2022
AB		MYLAN	**500MCG**	**A208257**	**001**	Jul 13, 2018
AB		PRINSTON INC	**500MCG**	**A208299**	**001**	May 10, 2022
AB		STRIDES PHARMA	**250MCG**	**A208247**	**002**	Jun 20, 2023
AB			**500MCG**	**A208247**	**001**	Mar 30, 2020
AB		ZYDUS PHARMS	**250MCG**	**A208303**	**002**	Apr 18, 2023
AB			**500MCG**	**A208303**	**001**	Feb 10, 2022

ROLAPITANT HYDROCHLORIDE

TABLET;ORAL

VARUBI

	+!	TERSERA	EQ 90MG BASE	N206500	001	Sep 01, 2015

ROMIDEPSIN

POWDER;INTRAVENOUS

ISTODAX

AP	**+!**	BRISTOL-MYERS	**10MG/VIAL**	**N022393**	**001**	Nov 05, 2009

ROMIDEPSIN

AP		FRESENIUS KABI USA	**10MG/VIAL**	**A206254**	**001**	Oct 12, 2021

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 0.25MG BASE**	**A204022**	**001**	Feb 28, 2017
AB			**EQ 0.5MG BASE**	**A204022**	**002**	Feb 28, 2017
AB			**EQ 1MG BASE**	**A204022**	**003**	Feb 28, 2017
AB			**EQ 2MG BASE**	**A204022**	**004**	Feb 28, 2017
AB			**EQ 3MG BASE**	**A204022**	**005**	Feb 28, 2017
AB			**EQ 4MG BASE**	**A204022**	**006**	Feb 28, 2017
AB			**EQ 5MG BASE**	**A204022**	**007**	Feb 28, 2017
AB		ALEMBIC LTD	**EQ 0.25MG BASE**	**A090429**	**001**	Mar 24, 2010
AB			**EQ 0.5MG BASE**	**A090429**	**002**	Mar 24, 2010
AB			**EQ 1MG BASE**	**A090429**	**003**	Mar 24, 2010
AB			**EQ 2MG BASE**	**A090429**	**004**	Mar 24, 2010
AB			**EQ 3MG BASE**	**A090429**	**005**	Mar 24, 2010
AB			**EQ 4MG BASE**	**A090429**	**006**	Mar 24, 2010
AB			**EQ 5MG BASE**	**A090429**	**007**	Mar 24, 2010
AB		CADILA	**EQ 0.25MG BASE**	**A090411**	**001**	Jun 01, 2009
AB			**EQ 0.5MG BASE**	**A090411**	**002**	Jun 01, 2009
AB			**EQ 1MG BASE**	**A090411**	**003**	Jun 01, 2009
AB			**EQ 2MG BASE**	**A090411**	**004**	Jun 01, 2009
AB			**EQ 3MG BASE**	**A090411**	**005**	Jun 01, 2009
AB			**EQ 4MG BASE**	**A090411**	**006**	Jun 01, 2009
AB			**EQ 5MG BASE**	**A090411**	**007**	Jun 01, 2009
AB		CHARTWELL RX	**EQ 0.25MG BASE**	**A079050**	**001**	May 29, 2008
AB			**EQ 0.5MG BASE**	**A079050**	**002**	May 29, 2008
AB			**EQ 1MG BASE**	**A079050**	**003**	May 29, 2008
AB			**EQ 2MG BASE**	**A079050**	**004**	May 29, 2008
AB			**EQ 3MG BASE**	**A079050**	**005**	May 29, 2008
AB			**EQ 4MG BASE**	**A079050**	**006**	May 29, 2008
AB			**EQ 5MG BASE**	**A079050**	**007**	May 29, 2008
AB		GLENMARK GENERICS	**EQ 0.25MG BASE**	**A090135**	**001**	Feb 25, 2010
AB			**EQ 0.5MG BASE**	**A090135**	**002**	Feb 25, 2010
AB			**EQ 1MG BASE**	**A090135**	**003**	Feb 25, 2010
AB			**EQ 2MG BASE**	**A090135**	**004**	Feb 25, 2010
AB			**EQ 3MG BASE**	**A090135**	**005**	Feb 25, 2010
AB			**EQ 4MG BASE**	**A090135**	**006**	Feb 25, 2010
AB			**EQ 5MG BASE**	**A090135**	**007**	Feb 25, 2010

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		MLV	**EQ 0.25MG BASE**	**A079165**	**001**	Feb 07, 2012
AB			**EQ 0.5MG BASE**	**A079165**	**002**	Feb 07, 2012
AB			**EQ 1MG BASE**	**A079165**	**003**	Feb 07, 2012
AB			**EQ 2MG BASE**	**A079165**	**004**	Feb 07, 2012
AB			**EQ 3MG BASE**	**A079165**	**005**	Feb 07, 2012
AB			**EQ 4MG BASE**	**A079165**	**006**	Feb 07, 2012
AB			**EQ 5MG BASE**	**A079165**	**007**	Feb 07, 2012
AB		ORBION PHARMS	**EQ 0.25MG BASE**	**A079229**	**001**	Nov 28, 2012
AB			**EQ 0.5MG BASE**	**A079229**	**002**	Nov 28, 2012
AB			**EQ 1MG BASE**	**A079229**	**003**	Nov 28, 2012
AB			**EQ 2MG BASE**	**A079229**	**004**	Nov 28, 2012
AB			**EQ 3MG BASE**	**A079229**	**005**	Nov 28, 2012
AB			**EQ 4MG BASE**	**A079229**	**006**	Nov 28, 2012
AB			**EQ 5MG BASE**	**A079229**	**007**	Nov 28, 2012
AB	!	PRINSTON INC	**EQ 0.25MG BASE**	**A078110**	**001**	May 05, 2008
AB			**EQ 0.5MG BASE**	**A078110**	**002**	May 05, 2008
AB			**EQ 1MG BASE**	**A078110**	**003**	May 05, 2008
AB			**EQ 2MG BASE**	**A078110**	**004**	May 05, 2008
AB			**EQ 3MG BASE**	**A078110**	**005**	May 05, 2008
AB			**EQ 4MG BASE**	**A078110**	**006**	May 05, 2008
AB			**EQ 5MG BASE**	**A078110**	**007**	Jul 11, 2008

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 2MG BASE**	**A090869**	**001**	May 17, 2012
AB			**EQ 4MG BASE**	**A090869**	**002**	May 17, 2012
AB			**EQ 6MG BASE**	**A090869**	**003**	May 17, 2012
AB			**EQ 8MG BASE**	**A090869**	**004**	May 17, 2012
AB			**EQ 12MG BASE**	**A090869**	**005**	May 17, 2012
AB		ALEMBIC	**EQ 2MG BASE**	**A202786**	**001**	Apr 22, 2013
AB			**EQ 4MG BASE**	**A202786**	**002**	Apr 22, 2013
AB			**EQ 6MG BASE**	**A202786**	**003**	Apr 22, 2013
AB			**EQ 8MG BASE**	**A202786**	**004**	Apr 22, 2013
AB			**EQ 12MG BASE**	**A202786**	**005**	Apr 22, 2013
AB		CHARTWELL RX	**EQ 2MG BASE**	**A091395**	**001**	Aug 27, 2012
AB			**EQ 4MG BASE**	**A091395**	**002**	Aug 27, 2012
AB			**EQ 6MG BASE**	**A091395**	**003**	Aug 27, 2012
AB			**EQ 8MG BASE**	**A091395**	**004**	Aug 27, 2012
AB			**EQ 12MG BASE**	**A091395**	**005**	Aug 27, 2012
AB	!	DR REDDYS LABS LTD	**EQ 2MG BASE**	**A201576**	**001**	Jun 06, 2012
AB			**EQ 4MG BASE**	**A201576**	**002**	Jun 06, 2012
AB			**EQ 6MG BASE**	**A201576**	**003**	Jun 06, 2012
AB			**EQ 8MG BASE**	**A201576**	**004**	Jun 06, 2012
AB			**EQ 12MG BASE**	**A201576**	**005**	Jun 06, 2012
AB		PRINSTON INC	**EQ 2MG BASE**	**A204413**	**001**	May 11, 2022
AB			**EQ 4MG BASE**	**A204413**	**002**	May 11, 2022
AB			**EQ 6MG BASE**	**A204413**	**003**	May 11, 2022
AB			**EQ 8MG BASE**	**A204413**	**004**	May 11, 2022
AB			**EQ 12MG BASE**	**A204413**	**005**	May 11, 2022
AB		SANDOZ INC	**EQ 2MG BASE**	**A201047**	**001**	Jun 06, 2012
AB			**EQ 4MG BASE**	**A201047**	**003**	Jun 06, 2012
AB			**EQ 6MG BASE**	**A201047**	**004**	Jun 06, 2012
AB			**EQ 8MG BASE**	**A201047**	**005**	Jun 06, 2012
AB			**EQ 12MG BASE**	**A201047**	**006**	Jun 06, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

AP	+	FRESENIUS KABI USA	**20MG/10ML (2MG/ML)**	**N020533**	**001**	May 01, 1998
AP	+		**40MG/20ML (2MG/ML)**	**N020533**	**002**	Sep 24, 1996
AP	+		**100MG/20ML (5MG/ML)**	**N020533**	**003**	May 01, 1998
AP	+		**100MG/10ML (10MG/ML)**	**N020533**	**005**	Sep 24, 1996
AP	+		**150MG/20ML (7.5MG/ML)**	**N020533**	**004**	Sep 24, 1996
AP	+		**150MG/30ML (5MG/ML)**	**N020533**	**008**	Sep 24, 1996
AP	+		**200MG/100ML (2MG/ML)**	**N020533**	**006**	Sep 24, 1996
AP	+!		**200MG/20ML (10MG/ML)**	**N020533**	**011**	Sep 24, 1996
AP	+		**400MG/200ML (2MG/ML)**	**N020533**	**007**	Sep 24, 1996
AP	+		**500MG/100ML (5MG/ML)**	**N020533**	**009**	Jan 04, 2011
AP	+		**1GM/200ML (5MG/ML)**	**N020533**	**010**	Jan 04, 2011

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	AMNEAL	**200MG/100ML (2MG/ML)**	**A216605**	**001**	Mar 08, 2023
AP		**400MG/200ML (2MG/ML)**	**A216605**	**002**	Mar 08, 2023
AP		**500MG/100ML (5MG/ML)**	**A216605**	**003**	Mar 07, 2023
AP		**1GM/200ML (5MG/ML)**	**A216605**	**004**	Mar 07, 2023
AP	CAPLIN	**40MG/20ML (2MG/ML)**	**A212808**	**001**	Apr 09, 2020
AP		**100MG/20ML (5MG/ML)**	**A212808**	**002**	Apr 09, 2020
AP		**150MG/30ML (5MG/ML)**	**A212808**	**003**	Apr 09, 2020
AP		**200MG/20ML (10MG/ML)**	**A212808**	**004**	Apr 09, 2020
AP	EUGIA PHARMA	**40MG/20ML (2MG/ML)**	**A205612**	**001**	Jul 13, 2016
AP		**100MG/20ML (5MG/ML)**	**A205612**	**003**	Jul 13, 2016
AP		**100MG/10ML (10MG/ML)**	**A205612**	**006**	Jul 13, 2016
AP		**150MG/30ML (5MG/ML)**	**A205612**	**004**	Jul 13, 2016
AP		**150MG/20ML (7.5MG/ML)**	**A205612**	**005**	Jul 13, 2016
AP		**200MG/100ML (2MG/ML)**	**A205612**	**002**	Jul 13, 2016
AP		**200MG/20ML (10MG/ML)**	**A205612**	**007**	Jul 13, 2016
AP	GLAND PHARMA LTD	**200MG/100ML (2MG/ML)**	**A210102**	**001**	Aug 18, 2022
AP		**400MG/200ML (2MG/ML)**	**A210102**	**002**	Aug 18, 2022
AP	HIKMA	**40MG/20ML (2MG/ML)**	**A214074**	**001**	Jul 20, 2020
AP		**150MG/30ML (5MG/ML)**	**A214074**	**002**	Jul 20, 2020
AP		**150MG/20ML (7.5MG/ML)**	**A214074**	**003**	Jul 20, 2020
AP		**200MG/20ML (10MG/ML)**	**A214074**	**004**	Jul 20, 2020
AP	HOSPIRA	**20MG/10ML (2MG/ML)**	**A090194**	**001**	Sep 23, 2014
AP		**40MG/20ML (2MG/ML)**	**A090194**	**005**	Sep 23, 2014
AP		**100MG/10ML (10MG/ML)**	**A090194**	**004**	Sep 23, 2014
AP		**150MG/30ML (5MG/ML)**	**A090194**	**002**	Sep 23, 2014
AP		**150MG/20ML (7.5MG/ML)**	**A090194**	**003**	Sep 23, 2014
AP		**200MG/20ML (10MG/ML)**	**A090194**	**006**	Sep 23, 2014
AP	INFORLIFE	**200MG/100ML (2MG/ML)**	**A206166**	**001**	Jun 11, 2018
AP		**400MG/200ML (2MG/ML)**	**A206166**	**002**	Jun 11, 2018
AP		**500MG/100ML (5MG/ML)**	**A206166**	**003**	Jun 11, 2018
AP		**1GM/200ML (5MG/ML)**	**A206166**	**004**	Jun 11, 2018
AP	MYLAN LABS LTD	**200MG/100ML (2MG/ML)**	**A206091**	**001**	Oct 26, 2023
AP		**400MG/200ML (2MG/ML)**	**A206091**	**002**	Oct 26, 2023
AP	NAVINTA LLC	**150MG/30ML (5MG/ML)**	**A078601**	**002**	Jul 17, 2014
AP		**200MG/20ML (10MG/ML)**	**A078601**	**003**	Jul 17, 2014
AP	RISING	**200MG/100ML (2MG/ML)**	**A204636**	**001**	Mar 16, 2018
AP		**400MG/200ML (2MG/ML)**	**A204636**	**002**	Mar 16, 2018
AP		**150MG/30ML (5MG/ML)**	**A203955**	**001**	Apr 11, 2016
AP	SOMERSET THERAPS LLC	**20MG/10ML (2MG/ML)**	**A207636**	**001**	Jun 15, 2018
AP		**40MG/20ML (2MG/ML)**	**A207636**	**002**	Jun 15, 2018
AP		**100MG/20ML (5MG/ML)**	**A207636**	**003**	Jun 15, 2018
AP		**100MG/10ML (10MG/ML)**	**A207636**	**006**	Jun 15, 2018
AP		**150MG/30ML (5MG/ML)**	**A207636**	**004**	Jun 15, 2018
AP		**150MG/20ML (7.5MG/ML)**	**A207636**	**005**	Jun 15, 2018
AP		**200MG/20ML (10MG/ML)**	**A207636**	**007**	Jun 15, 2018

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

AB	**+** IPR	**EQ 5MG BASE**	**N021366**	**002**	Aug 12, 2003
AB	**+**	**EQ 10MG BASE**	**N021366**	**003**	Aug 12, 2003
AB	**+**	**EQ 20MG BASE**	**N021366**	**004**	Aug 12, 2003
AB	**+!**	**EQ 40MG BASE**	**N021366**	**005**	Aug 12, 2003

ROSUVASTATIN CALCIUM

AB	ACCORD HLTHCARE	**EQ 5MG BASE**	**A206434**	**001**	Oct 31, 2016
AB		**EQ 10MG BASE**	**A206434**	**002**	Oct 31, 2016
AB		**EQ 20MG BASE**	**A206434**	**003**	Oct 31, 2016
AB		**EQ 40MG BASE**	**A206434**	**004**	Oct 31, 2016
AB	ALKEM LABS LTD	**EQ 5MG BASE**	**A206465**	**001**	Mar 21, 2017
AB		**EQ 10MG BASE**	**A206465**	**002**	Mar 21, 2017
AB		**EQ 20MG BASE**	**A206465**	**003**	Mar 21, 2017
AB		**EQ 40MG BASE**	**A206465**	**004**	Mar 21, 2017
AB	AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A079170**	**001**	Jul 19, 2016
AB		**EQ 10MG BASE**	**A079170**	**002**	Jul 19, 2016
AB		**EQ 20MG BASE**	**A079170**	**003**	Jul 19, 2016
AB		**EQ 40MG BASE**	**A079170**	**004**	Jul 19, 2016
AB	BIOCON PHARMA	**EQ 5MG BASE**	**A207752**	**001**	Oct 31, 2016
AB		**EQ 10MG BASE**	**A207752**	**002**	Oct 31, 2016

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

AB		**EQ 20MG BASE**	**A207752**	**003**	Oct 31, 2016
AB		**EQ 40MG BASE**	**A207752**	**004**	Oct 31, 2016
AB	CADILA PHARMS LTD	**EQ 5MG BASE**	**A207453**	**001**	Nov 23, 2016
AB		**EQ 10MG BASE**	**A207453**	**002**	Nov 23, 2016
AB		**EQ 20MG BASE**	**A207453**	**003**	Nov 23, 2016
AB		**EQ 40MG BASE**	**A207453**	**004**	Nov 23, 2016
AB	CHANGZHOU PHARM	**EQ 5MG BASE**	**A207408**	**001**	Oct 31, 2016
AB		**EQ 10MG BASE**	**A207408**	**002**	Oct 31, 2016
AB		**EQ 20MG BASE**	**A207408**	**003**	Oct 31, 2016
AB		**EQ 40MG BASE**	**A207408**	**004**	Oct 31, 2016
AB	CHARTWELL RX	**EQ 5MG BASE**	**A079168**	**001**	Jul 19, 2016
AB		**EQ 10MG BASE**	**A079168**	**002**	Jul 19, 2016
AB		**EQ 20MG BASE**	**A079168**	**003**	Jul 19, 2016
AB		**EQ 40MG BASE**	**A079168**	**004**	Jul 19, 2016
AB	GLENMARK PHARMS	**EQ 5MG BASE**	**A079172**	**001**	Jul 19, 2016
AB		**EQ 10MG BASE**	**A079172**	**002**	Jul 19, 2016
AB		**EQ 20MG BASE**	**A079172**	**003**	Jul 19, 2016
AB		**EQ 40MG BASE**	**A079172**	**004**	Jul 19, 2016
AB	HETERO LABS LTD V	**EQ 5MG BASE**	**A207616**	**001**	Oct 31, 2016
AB		**EQ 10MG BASE**	**A207616**	**002**	Oct 31, 2016
AB		**EQ 20MG BASE**	**A207616**	**003**	Oct 31, 2016
AB		**EQ 40MG BASE**	**A207616**	**004**	Oct 31, 2016
AB	LUPIN	**EQ 5MG BASE**	**A205587**	**001**	Jul 31, 2017
AB		**EQ 10MG BASE**	**A205587**	**002**	Jul 31, 2017
AB		**EQ 20MG BASE**	**A205587**	**003**	Jul 31, 2017
AB		**EQ 40MG BASE**	**A205587**	**004**	Jul 31, 2017
AB	MSN	**EQ 5MG BASE**	**A208898**	**001**	Nov 22, 2017
AB		**EQ 10MG BASE**	**A208898**	**002**	Nov 22, 2017
AB		**EQ 20MG BASE**	**A208898**	**003**	Nov 22, 2017
AB		**EQ 40MG BASE**	**A208898**	**004**	Nov 22, 2017
AB	RENATA	**EQ 5MG BASE**	**A207062**	**001**	Oct 31, 2016
AB		**EQ 10MG BASE**	**A207062**	**002**	Oct 31, 2016
AB		**EQ 20MG BASE**	**A207062**	**003**	Oct 31, 2016
AB		**EQ 40MG BASE**	**A207062**	**004**	Oct 31, 2016
AB	SANDOZ	**EQ 5MG BASE**	**A079171**	**001**	Jul 19, 2016
AB		**EQ 10MG BASE**	**A079171**	**002**	Jul 19, 2016
AB		**EQ 20MG BASE**	**A079171**	**003**	Jul 19, 2016
AB		**EQ 40MG BASE**	**A079171**	**004**	Jul 19, 2016
AB	SCIEGEN PHARMS INC	**EQ 5MG BASE**	**A206381**	**001**	Apr 24, 2019
AB		**EQ 10MG BASE**	**A206381**	**002**	Apr 24, 2019
AB		**EQ 20MG BASE**	**A206381**	**003**	Apr 24, 2019
AB		**EQ 40MG BASE**	**A206381**	**004**	Apr 24, 2019
AB	SHANDONG	**EQ 5MG BASE**	**A207375**	**001**	May 07, 2019
AB		**EQ 10MG BASE**	**A207375**	**002**	May 07, 2019
AB		**EQ 20MG BASE**	**A207375**	**003**	May 07, 2019
AB		**EQ 40MG BASE**	**A207375**	**004**	May 07, 2019
AB	SUN PHARM	**EQ 5MG BASE**	**A079169**	**001**	Jul 19, 2016
AB		**EQ 10MG BASE**	**A079169**	**002**	Jul 19, 2016
AB		**EQ 20MG BASE**	**A079169**	**003**	Jul 19, 2016
AB		**EQ 40MG BASE**	**A079169**	**004**	Jul 19, 2016
AB	TORRENT	**EQ 5MG BASE**	**A201619**	**001**	Oct 31, 2016
AB		**EQ 10MG BASE**	**A201619**	**002**	Oct 31, 2016
AB		**EQ 20MG BASE**	**A201619**	**003**	Oct 31, 2016
AB		**EQ 40MG BASE**	**A201619**	**004**	Oct 31, 2016
AB	UMEDICA	**EQ 5MG BASE**	**A207626**	**001**	Apr 09, 2019
AB		**EQ 10MG BASE**	**A207626**	**002**	Apr 09, 2019
AB		**EQ 20MG BASE**	**A207626**	**003**	Apr 09, 2019
AB		**EQ 40MG BASE**	**A207626**	**004**	Apr 09, 2019
AB	WATSON LABS INC	**EQ 5MG BASE**	**A079167**	**001**	Apr 29, 2016
AB		**EQ 10MG BASE**	**A079167**	**002**	Apr 29, 2016
AB		**EQ 20MG BASE**	**A079167**	**003**	Apr 29, 2016
AB		**EQ 40MG BASE**	**A079167**	**004**	Apr 29, 2016
AB	ZHEJIANG YONGTAI	**EQ 5MG BASE**	**A212059**	**001**	Nov 04, 2019
AB		**EQ 10MG BASE**	**A212059**	**002**	Nov 04, 2019
AB		**EQ 20MG BASE**	**A212059**	**003**	Nov 04, 2019
AB		**EQ 40MG BASE**	**A212059**	**004**	Nov 04, 2019

ROTIGOTINE
FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO
+ UCB INC 1MG/24HR N021829 004 Apr 02, 2012
+! 2MG/24HR N021829 001 May 09, 2007
+ 3MG/24HR N021829 005 Apr 02, 2012
+ 4MG/24HR N021829 002 May 09, 2007
+ 6MG/24HR N021829 003 May 09, 2007
+ 8MG/24HR N021829 006 Apr 02, 2012

RUBIDIUM CHLORIDE RB-82
INJECTABLE;INJECTION
CARDIOGEN-82
BRACCO N/A N019414 001 Dec 29, 1989
SOLUTION;INTRAVENOUS
RUBY-FILL
JUBILANT N/A N202153 001 Sep 30, 2016

RUCAPARIB CAMSYLATE
TABLET;ORAL
RUBRACA
+ ZR PHARMA EQ 200MG BASE N209115 001 Dec 19, 2016
+ EQ 250MG BASE N209115 003 May 01, 2017
+! EQ 300MG BASE N209115 002 Dec 19, 2016

RUFINAMIDE
SUSPENSION;ORAL
BANZEL
AB +! EISAI INC **40MG/ML** **N201367 001** Mar 03, 2011
RUFINAMIDE
AB ALKEM LABS LTD **40MG/ML** **A213410 001** Feb 23, 2021
AB AUROBINDO PHARMA **40MG/ML** **A216549 001** Oct 26, 2022
AB BIONPHARMA **40MG/ML** **A211388 001** Apr 23, 2019
AB CHARTWELL RX **40MG/ML** **A214009 001** Nov 07, 2022
AB HETERO LABS LTD III **40MG/ML** **A216841 001** Dec 05, 2023
AB HIKMA **40MG/ML** **A207363 001** Apr 23, 2019
AB LUPIN LTD **40MG/ML** **A213457 001** Dec 18, 2020
TABLET;ORAL
BANZEL
AB + EISAI INC **200MG** **N021911 002** Nov 14, 2008
AB +! **400MG** **N021911 003** Nov 14, 2008
RUFINAMIDE
AB AUROBINDO PHARMA **200MG** **A217230 001** Jun 16, 2023
AB **400MG** **A217230 002** Jun 16, 2023
AB GLENMARK PHARMS LTD **200MG** **A205075 001** May 16, 2016
AB **400MG** **A205075 002** May 16, 2016
AB HETERO LABS LTD III **200MG** **A204993 001** May 11, 2021
AB **400MG** **A204993 002** May 11, 2021
AB HIKMA **200MG** **A204988 001** May 16, 2016
AB **400MG** **A204988 002** May 16, 2016
AB LUPIN LTD **200MG** **A204964 002** Aug 17, 2022
AB **400MG** **A204964 003** Aug 17, 2022
AB MICRO LABS **200MG** **A216688 001** May 15, 2023
AB **400MG** **A216688 002** May 15, 2023
AB MYLAN **200MG** **A205095 001** May 16, 2016
AB **400MG** **A205095 002** May 16, 2016
LUPIN LTD 100MG A204964 001 Aug 17, 2022

RUXOLITINIB PHOSPHATE
CREAM;TOPICAL
OPZELURA
+! INCYTE CORP EQ 1.5% BASE N215309 001 Sep 21, 2021
TABLET;ORAL
JAKAFI
+ INCYTE CORP EQ 5MG BASE N202192 001 Nov 16, 2011
+ EQ 10MG BASE N202192 002 Nov 16, 2011
+ EQ 15MG BASE N202192 003 Nov 16, 2011
+ EQ 20MG BASE N202192 004 Nov 16, 2011
+! EQ 25MG BASE N202192 005 Nov 16, 2011

SACUBITRIL; VALSARTAN

TABLET;ORAL

ENTRESTO

+	NOVARTIS PHARMS CORP	24MG;26MG	N207620	001	Jul 07, 2015
+		49MG;51MG	N207620	002	Jul 07, 2015
+!		97MG;103MG	N207620	003	Jul 07, 2015

SAFINAMIDE MESYLATE

TABLET;ORAL

XADAGO

+	MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017
+!		EQ 100MG BASE	N207145	002	Mar 21, 2017

SALMETEROL XINAFOATE

POWDER;INHALATION

SEREVENT

+!	GLAXOSMITHKLINE	EQ 0.05MG BASE/INH	N020692	001	Sep 19, 1997

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

KUVAN

AB	**+!**	BIOMARIN PHARM	**100MG/PACKET**	**N205065**	**001**	Dec 19, 2013
AB	**+**		**500MG/PACKET**	**N205065**	**002**	Oct 27, 2015

SAPROPTERIN DIHYDROCHLORIDE

AB		ANNORA PHARMA	**100MG/PACKET**	**A215420**	**001**	Aug 18, 2022
AB			**500MG/PACKET**	**A215420**	**002**	Aug 18, 2022
AB		DR REDDYS	**100MG/PACKET**	**A209452**	**001**	Mar 30, 2021
AB			**500MG/PACKET**	**A215798**	**001**	May 13, 2022
AB		PAR PHARM INC	**100MG/PACKET**	**A207207**	**001**	Aug 20, 2019
AB			**500MG/PACKET**	**A210027**	**001**	Aug 20, 2019

TABLET;ORAL

KUVAN

AB	**+!**	BIOMARIN PHARM	**100MG**	**N022181**	**001**	Dec 13, 2007

SAPROPTERIN DIHYDROCHLORIDE

AB		ANNORA PHARMA	**100MG**	**A215534**	**001**	Aug 23, 2022
AB		DR REDDYS	**100MG**	**A207685**	**001**	Jun 15, 2021
AB		PAR PHARM INC	**100MG**	**A207200**	**001**	May 10, 2019

SARECYCLINE HYDROCHLORIDE

TABLET;ORAL

SEYSARA

+	ALMIRALL	EQ 60MG BASE	N209521	001	Oct 01, 2018
+		EQ 100MG BASE	N209521	002	Oct 01, 2018
+!		EQ 150MG BASE	N209521	003	Oct 01, 2018

SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

SAXAGLIPTIN

AB		AMNEAL	**EQ 2.5MG BASE**	**A205941**	**001**	Jul 31, 2023
AB			**EQ 5MG BASE**	**A205941**	**002**	Jul 31, 2023
AB		AUROBINDO PHARMA	**EQ 2.5MG BASE**	**A205972**	**001**	Jul 31, 2023
AB			**EQ 5MG BASE**	**A205972**	**002**	Jul 31, 2023
AB		GLENMARK PHARMS LTD	**EQ 2.5MG BASE**	**A205994**	**001**	Jul 31, 2023
AB			**EQ 5MG BASE**	**A205994**	**002**	Jul 31, 2023
AB		MYLAN	**EQ 2.5MG BASE**	**A205980**	**001**	Jul 31, 2023
AB	**!**		**EQ 5MG BASE**	**A205980**	**002**	Jul 31, 2023
AB		SUN PHARM	**EQ 2.5MG BASE**	**A206078**	**001**	Jul 31, 2023
AB			**EQ 5MG BASE**	**A206078**	**002**	Jul 31, 2023

SCOPOLAMINE

SYSTEM;TRANSDERMAL

SCOPOLAMINE

AB		ACTAVIS LABS UT INC	**1MG/72HR**	**A208769**	**001**	Jan 10, 2022
AB		MYLAN TECHNOLOGIES	**1MG/72HR**	**A203753**	**001**	Jun 19, 2019
AB		PADAGIS US	**1MG/72HR**	**A078830**	**001**	Jan 30, 2015
AB		RICONPHARMA LLC	**1MG/72HR**	**A212342**	**001**	Nov 24, 2020

TRANSDERM SCOP

AB	**+!**	BAXTER HLTHCARE CORP	**1MG/72HR**	**N017874**	**001**	

SECNIDAZOLE
GRANULE;ORAL
SOLOSEC

	+!	LUPIN	2GM/PACKET	N209363	001	Sep 15, 2017

SECRETIN SYNTHETIC HUMAN
FOR SOLUTION;INTRAVENOUS
CHIRHOSTIM

	+!	CHIRHOCLIN	16MCG/VIAL	N021256	001	Apr 09, 2004
	+		40MCG/VIAL	N021256	002	Jun 21, 2007

SELEGILINE
FILM, EXTENDED RELEASE;TRANSDERMAL
EMSAM

	+!	SOMERSET	6MG/24HR	N021336	001	Feb 27, 2006
	+		9MG/24HR	N021336	002	Feb 27, 2006
	+		12MG/24HR	N021336	003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE
CAPSULE;ORAL
SELEGILINE HYDROCHLORIDE

AB	**!**	APOTEX	**5MG**	**A075321**	**001**	Dec 04, 1998
AB		NOVITIUM PHARMA	**5MG**	**A075352**	**001**	Nov 30, 1998
AB		RISING	**5MG**	**A206803**	**001**	Apr 02, 2019

TABLET;ORAL
SELEGILINE HYDROCHLORIDE

AB	**!**	APOTEX INC	**5MG**	**A074871**	**001**	Jun 06, 1997
AB		I3 PHARMS	**5MG**	**A074672**	**001**	Apr 01, 1997

TABLET, ORALLY DISINTEGRATING;ORAL
ZELAPAR

	+!	BAUSCH	1.25MG	N021479	001	Jun 14, 2006

SELENIOUS ACID
SOLUTION;INTRAVENOUS
SELENIOUS ACID

	+!	AM REGENT	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	N209379	003	Aug 30, 2021
	+!		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021
	+!		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	N209379	001	Apr 30, 2019

SELENIUM SULFIDE
LOTION/SHAMPOO;TOPICAL
SELENIUM SULFIDE

	!	PADAGIS US	2.5%	A089996	001	Jan 10, 1991

SELEXIPAG
POWDER;INTRAVENOUS
UPTRAVI

	+!	ACTELION	1.8MG/VIAL	N214275	001	Jul 29, 2021

TABLET;ORAL
SELEXIPAG

AB		ALEMBIC	**0.2MG**	**A214414**	**001**	Oct 11, 2023
AB			**0.4MG**	**A214414**	**002**	Oct 11, 2023
AB			**0.6MG**	**A214414**	**003**	Oct 11, 2023
AB			**0.8MG**	**A214414**	**004**	Oct 11, 2023
AB			**1.4MG**	**A214414**	**005**	Oct 11, 2023
AB			**1.6MG**	**A214414**	**006**	Oct 11, 2023

UPTRAVI

AB	**+**	ACTELION	**0.2MG**	**N207947**	**001**	Dec 21, 2015
AB	**+!**		**0.4MG**	**N207947**	**002**	Dec 21, 2015
AB	**+**		**0.6MG**	**N207947**	**003**	Dec 21, 2015
AB	**+**		**0.8MG**	**N207947**	**004**	Dec 21, 2015
AB	**+**		**1.4MG**	**N207947**	**007**	Dec 21, 2015
AB	**+**		**1.6MG**	**N207947**	**008**	Dec 21, 2015
	+		1MG	N207947	005	Dec 21, 2015
	+		1.2MG	N207947	006	Dec 21, 2015

SELINEXOR
TABLET;ORAL
XPOVIO

	+	KARYOPHARM THERAPS	20MG	N212306	001	Jul 03, 2019
	+		40MG	N212306	002	Apr 15, 2021
	+		50MG	N212306	003	Apr 15, 2021
	+!		60MG	N212306	004	Apr 15, 2021

SELPERCATINIB
CAPSULE;ORAL
RETEVMO
+ LOXO ONCOL ELI LILLY | 40MG | N213246 001 May 08, 2020
+! | 80MG | N213246 002 May 08, 2020

SELUMETINIB SULFATE
CAPSULE;ORAL
KOSELUGO
+ ASTRAZENECA | EQ 10MG BASE | N213756 001 Apr 10, 2020
+! | EQ 25MG BASE | N213756 002 Apr 10, 2020

SEMAGLUTIDE
SOLUTION;SUBCUTANEOUS
OZEMPIC
+! NOVO | 2MG/1.5ML (1.34MG/ML) | N209637 001 Dec 05, 2017
+! | 2MG/3ML (0.68MG/ML) | N209637 004 Oct 06, 2022
+! | 4MG/3ML (1.34MG/ML) | N209637 002 Apr 09, 2019
+! | 8MG/3ML (2.68MG/ML) | N209637 003 Mar 28, 2022
WEGOVY
+! NOVO | 0.25MG/0.5ML (0.25MG/0.5ML) | N215256 001 Jun 04, 2021
+! | 0.5MG/0.5ML (0.5MG/0.5ML) | N215256 002 Jun 04, 2021
+! | 1MG/0.5ML (1MG/0.5ML) | N215256 003 Jun 04, 2021
+! | 1.7MG/0.75ML (1.7MG/0.75ML) | N215256 004 Jun 04, 2021
+! | 2.4MG/0.75ML (2.4MG/0.75ML) | N215256 005 Jun 04, 2021
TABLET;ORAL
RYBELSUS
+ NOVO | 3MG | N213051 001 Sep 20, 2019
+ | 7MG | N213051 002 Sep 20, 2019
+! | 14MG | N213051 003 Sep 20, 2019

SERTACONAZOLE NITRATE
CREAM;TOPICAL
ERTACZO
+! LACER PHARMA | 2% | N021385 001 Dec 10, 2003

SERTRALINE HYDROCHLORIDE
CAPSULE;ORAL
SERTRALINE HYDROCHLORIDE
+! ALMATICA | EQ 150MG BASE | N215133 001 Oct 04, 2021
+ | EQ 200MG BASE | N215133 002 Oct 04, 2021
CONCENTRATE;ORAL
SERTRALINE HYDROCHLORIDE
AA ACI | **EQ 20MG BASE/ML** | **A076934 001** Jun 30, 2006
AA AUROBINDO PHARMA | **EQ 20MG BASE/ML** | **A078861 001** Oct 31, 2008
ZOLOFT
AA **+!** VIATRIS | **EQ 20MG BASE/ML** | **N020990 001** Dec 07, 1999
TABLET;ORAL
SERTRALINE HYDROCHLORIDE
AB ACCORD HLTHCARE | **EQ 25MG BASE** | **A202825 001** Nov 07, 2014
AB | **EQ 50MG BASE** | **A202825 002** Nov 07, 2014
AB | **EQ 100MG BASE** | **A202825 003** Nov 07, 2014
AB ACI | **EQ 25MG BASE** | **A076881 001** Feb 06, 2007
AB | **EQ 50MG BASE** | **A076881 002** Feb 06, 2007
AB | **EQ 100MG BASE** | **A076881 003** Feb 06, 2007
AB ASCENT PHARMS INC | **EQ 25MG BASE** | **A214790 001** May 03, 2021
AB | **EQ 50MG BASE** | **A214790 002** May 03, 2021
AB | **EQ 100MG BASE** | **A214790 003** May 03, 2021
AB AUROBINDO PHARMA | **EQ 25MG BASE** | **A077206 001** Feb 06, 2007
AB | **EQ 50MG BASE** | **A077206 002** Feb 06, 2007
AB | **EQ 100MG BASE** | **A077206 003** Feb 06, 2007
AB GRANULES | **EQ 25MG BASE** | **A078403 001** Jan 08, 2008
AB | **EQ 50MG BASE** | **A078403 002** Jan 08, 2008
AB | **EQ 100MG BASE** | **A078403 003** Jan 08, 2008
AB HERITAGE PHARMA AVET | **EQ 25MG BASE** | **A076465 001** Aug 11, 2006
AB | **EQ 50MG BASE** | **A076465 002** Aug 11, 2006
AB | **EQ 100MG BASE** | **A076465 003** Aug 11, 2006
AB INVAGEN PHARMS | **EQ 25MG BASE** | **A077397 001** Feb 06, 2007
AB | **EQ 50MG BASE** | **A077397 002** Feb 06, 2007
AB | **EQ 100MG BASE** | **A077397 003** Feb 06, 2007
AB LUPIN | **EQ 25MG BASE** | **A077670 001** Feb 06, 2007
AB | **EQ 50MG BASE** | **A077670 002** Feb 06, 2007
AB | **EQ 100MG BASE** | **A077670 003** Feb 06, 2007

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB		OXFORD PHARMS	**EQ 25MG BASE**	**A078175**	**001**	Jul 21, 2010
AB			**EQ 50MG BASE**	**A078175**	**002**	Jul 21, 2010
AB			**EQ 100MG BASE**	**A078175**	**003**	Jul 21, 2010
AB		REYOUNG	**EQ 25MG BASE**	**A078677**	**001**	Mar 04, 2009
AB			**EQ 50MG BASE**	**A078677**	**002**	Mar 04, 2009
AB			**EQ 100MG BASE**	**A078677**	**003**	Mar 04, 2009
AB		SCIEGEN PHARMS INC	**EQ 25MG BASE**	**A076442**	**001**	Apr 30, 2007
AB			**EQ 50MG BASE**	**A076442**	**002**	Apr 30, 2007
AB			**EQ 100MG BASE**	**A076442**	**003**	Apr 30, 2007
AB		VIWIT PHARM	**EQ 25MG BASE**	**A076882**	**001**	Feb 06, 2007
AB			**EQ 50MG BASE**	**A076882**	**002**	Feb 06, 2007
AB			**EQ 100MG BASE**	**A076882**	**003**	Feb 06, 2007

ZOLOFT

AB	**+**	VIATRIS	**EQ 25MG BASE**	**N019839**	**005**	Mar 06, 1996
AB	**+**		**EQ 50MG BASE**	**N019839**	**001**	Dec 30, 1991
AB	**+!**		**EQ 100MG BASE**	**N019839**	**002**	Dec 30, 1991

SETMELANOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

IMCIVREE

	+!	RHYTHM	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N213793	001	Nov 25, 2020

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

RENVELA

AB	**+**	GENZYME	**800MG/PACKET**	**N022318**	**001**	Aug 12, 2009
AB	**+!**		**2.4GM/PACKET**	**N022318**	**002**	Feb 18, 2009

SEVELAMER CARBONATE

AB		AUROBINDO PHARMA	**800MG/PACKET**	**A207624**	**001**	Jun 13, 2017
AB			**2.4GM/PACKET**	**A207624**	**002**	Jun 13, 2017
AB		BIONPHARMA	**800MG/PACKET**	**A209374**	**001**	May 17, 2021
AB		CHARTWELL RX	**800MG/PACKET**	**A217319**	**001**	Mar 02, 2023
AB			**2.4GM/PACKET**	**A217319**	**002**	Mar 02, 2023
AB		DR REDDYS	**800MG/PACKET**	**A210464**	**001**	Oct 25, 2018
AB			**2.4GM/PACKET**	**A210464**	**002**	Oct 25, 2018
AB		IMPAX	**800MG/PACKET**	**A211316**	**001**	Nov 20, 2020
AB			**2.4GM/PACKET**	**A211316**	**002**	Nov 20, 2020
AB		STRIDES PHARMA	**800MG/PACKET**	**A211917**	**001**	Sep 08, 2023
AB			**2.4GM/PACKET**	**A211917**	**002**	Sep 08, 2023

TABLET;ORAL

RENVELA

AB	**+!**	SANOFI	**800MG**	**N022127**	**001**	Oct 19, 2007

SEVELAMER CARBONATE

AB		AMNEAL PHARMS CO	**800MG**	**A207288**	**001**	Nov 28, 2017
AB		ANXIN	**800MG**	**A212970**	**001**	Apr 09, 2020
AB		ARTHUR GRP	**800MG**	**A200959**	**001**	Mar 20, 2018
AB		AUROBINDO PHARMA	**800MG**	**A207179**	**001**	Jul 17, 2017
AB		DR REDDYS	**800MG**	**A206094**	**001**	Sep 29, 2017
AB		INVAGEN PHARMS	**800MG**	**A203860**	**001**	Oct 26, 2017
AB		MACLEODS PHARMS LTD	**800MG**	**A206100**	**001**	Apr 19, 2023
AB		MICRO LABS	**800MG**	**A215537**	**001**	Feb 07, 2022
AB		RISING	**800MG**	**A204451**	**001**	Nov 29, 2018
AB		ZYDUS PHARMS	**800MG**	**A207759**	**001**	Aug 11, 2020

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

RENAGEL

AB	**+**	GENZYME	**400MG**	**N021179**	**001**	Jul 12, 2000
AB	**+!**		**800MG**	**N021179**	**002**	Jul 12, 2000

SEVELAMER HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**400MG**	**A212599**	**001**	Jul 11, 2023
AB			**800MG**	**A212599**	**002**	Jul 11, 2023
AB		GLENMARK PHARMS LTD	**400MG**	**A204724**	**001**	Feb 08, 2019
AB			**800MG**	**A204724**	**002**	Feb 08, 2019
AB		LUPIN LTD	**400MG**	**A213145**	**001**	Jun 16, 2021
AB			**800MG**	**A213145**	**002**	Jun 16, 2021
AB		MACLEODS PHARMS LTD	**400MG**	**A206883**	**001**	May 26, 2023
AB			**800MG**	**A206883**	**002**	May 26, 2023

SEVOFLURANE						
LIQUID;INHALATION						
SEVOFLURANE						
AN		BAXTER HLTHCARE	**100%**	**A075895**	**001**	Jul 02, 2002
AN		HALOCARBON PRODS	**100%**	**A078650**	**001**	Nov 19, 2007
AN		SHANDONG	**100%**	**A214382**	**001**	Aug 18, 2023
AN		SHANGHAI HENGRUI	**100%**	**A203793**	**001**	Nov 03, 2015
SOJOURN						
AN		PIRAMAL CRITICAL	**100%**	**A077867**	**001**	May 02, 2007
ULTANE						
AN	**+!**	ABBVIE	**100%**	**N020478**	**001**	Jun 07, 1995
SILDENAFIL CITRATE						
FOR SUSPENSION;ORAL						
REVATIO						
AB	**+!**	VIATRIS	**EQ 10MG BASE/ML**	**N203109**	**001**	Aug 30, 2012
SILDENAFIL CITRATE						
AB		AJANTA PHARMA LTD	**EQ 10MG BASE/ML**	**A212883**	**001**	Nov 27, 2019
AB		ALKEM LABS LTD	**EQ 10MG BASE/ML**	**A212440**	**001**	Nov 27, 2019
AB		AMNEAL PHARMS	**EQ 10MG BASE/ML**	**A211092**	**001**	Nov 27, 2019
AB		APPCO	**EQ 10MG BASE/ML**	**A213814**	**001**	Apr 29, 2021
AB		APTAPHARMA INC	**EQ 10MG BASE/ML**	**A213041**	**001**	Aug 06, 2020
AB		AUROBINDO PHARMA LTD	**EQ 10MG BASE/ML**	**A214773**	**001**	Dec 23, 2022
AB		GRANULES	**EQ 10MG BASE/ML**	**A214556**	**001**	Dec 01, 2023
AB		HETERO LABS LTD V	**EQ 10MG BASE/ML**	**A213014**	**001**	May 11, 2021
AB		LUPIN LTD	**EQ 10MG BASE/ML**	**A211638**	**001**	Mar 23, 2022
AB		MSN	**EQ 10MG BASE/ML**	**A214641**	**001**	Feb 08, 2022
AB		NOVITIUM PHARMA	**EQ 10MG BASE/ML**	**A212260**	**001**	May 31, 2019
AB		TARO	**EQ 10MG BASE/ML**	**A215522**	**001**	Nov 16, 2021
AB		TEVA PHARMS USA	**EQ 10MG BASE/ML**	**A211534**	**001**	May 29, 2020
AB		ZYDUS	**EQ 10MG BASE/ML**	**A215708**	**001**	Sep 29, 2022
SOLUTION;INTRAVENOUS						
REVATIO						
AP	**+!**	VIATRIS	**EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)**	**N022473**	**001**	Nov 18, 2009
SILDENAFIL CITRATE						
AP		EUGIA PHARMA	**EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)**	**A203988**	**001**	Apr 01, 2015
SUSPENSION;ORAL						
LIQREV						
	+!	CMP DEV LLC	EQ 10MG BASE/ML	N214952	001	Apr 28, 2023
TABLET;ORAL						
REVATIO						
AB	**+!**	VIATRIS	**EQ 20MG BASE**	**N021845**	**001**	Jun 03, 2005
SILDENAFIL CITRATE						
AB		AJANTA PHARMA LTD	**EQ 20MG BASE**	**A210394**	**001**	May 04, 2018
AB			**EQ 25MG BASE**	**A206401**	**001**	Oct 12, 2018
AB			**EQ 50MG BASE**	**A206401**	**002**	Oct 12, 2018
AB			**EQ 100MG BASE**	**A206401**	**003**	Oct 12, 2018
AB		AMNEAL PHARMS	**EQ 20MG BASE**	**A202025**	**001**	Feb 28, 2013
AB		AMNEAL PHARMS NY	**EQ 25MG BASE**	**A202023**	**001**	Jun 27, 2018
AB			**EQ 50MG BASE**	**A202023**	**002**	Jun 27, 2018
AB			**EQ 100MG BASE**	**A202023**	**003**	Jun 27, 2018
AB		APPCO	**EQ 25MG BASE**	**A207178**	**001**	Mar 02, 2020
AB			**EQ 50MG BASE**	**A207178**	**002**	Mar 02, 2020
AB			**EQ 100MG BASE**	**A207178**	**003**	Mar 02, 2020
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A203963**	**001**	Nov 18, 2015
AB			**EQ 25MG BASE**	**A203962**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A203962**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A203962**	**003**	Jun 11, 2018
AB		CADILA PHARMS LTD	**EQ 25MG BASE**	**A218045**	**001**	Nov 28, 2023
AB			**EQ 50MG BASE**	**A218045**	**002**	Nov 28, 2023
AB			**EQ 100MG BASE**	**A218045**	**003**	Nov 28, 2023
AB		CHARTWELL RX	**EQ 20MG BASE**	**A202598**	**001**	Nov 06, 2012
AB		HETERO LABS LTD V	**EQ 20MG BASE**	**A203623**	**001**	Nov 26, 2014
AB			**EQ 25MG BASE**	**A202659**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A202659**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A202659**	**003**	Jun 11, 2018
AB		LUPIN LTD	**EQ 25MG BASE**	**A212051**	**001**	Mar 22, 2019
AB			**EQ 50MG BASE**	**A212051**	**002**	Mar 22, 2019
AB			**EQ 100MG BASE**	**A212051**	**003**	Mar 22, 2019
AB		MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A203814**	**001**	Dec 17, 2013
AB			**EQ 25MG BASE**	**A202255**	**001**	Apr 19, 2023

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB			**EQ 50MG BASE**	**A202255**	**002**	Apr 19, 2023
AB			**EQ 100MG BASE**	**A202255**	**003**	Apr 19, 2023
AB		MYLAN	**EQ 25MG BASE**	**A201171**	**001**	Mar 25, 2019
AB			**EQ 50MG BASE**	**A201171**	**002**	Mar 25, 2019
AB			**EQ 100MG BASE**	**A201171**	**003**	Mar 25, 2019
AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A201150**	**001**	Nov 09, 2012
AB		NOVITIUM PHARMA	**EQ 25MG BASE**	**A216383**	**001**	Aug 29, 2023
AB			**EQ 50MG BASE**	**A216383**	**002**	Aug 29, 2023
AB			**EQ 100MG BASE**	**A216383**	**003**	Aug 29, 2023
AB		REYOUNG	**EQ 25MG BASE**	**A208494**	**001**	Jun 12, 2020
AB			**EQ 50MG BASE**	**A208494**	**002**	Jun 12, 2020
AB			**EQ 100MG BASE**	**A208494**	**003**	Jun 12, 2020
AB		RUBICON	**EQ 20MG BASE**	**A204883**	**001**	Jun 20, 2016
AB			**EQ 25MG BASE**	**A204882**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A204882**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A204882**	**003**	Jun 11, 2018
AB		SUNSHINE	**EQ 25MG BASE**	**A213032**	**001**	Jun 11, 2020
AB			**EQ 50MG BASE**	**A213032**	**002**	Jun 11, 2020
AB			**EQ 100MG BASE**	**A213032**	**003**	Jun 11, 2020
AB		TEVA	**EQ 25MG BASE**	**A077342**	**001**	Mar 09, 2016
AB			**EQ 50MG BASE**	**A077342**	**002**	Mar 09, 2016
AB			**EQ 100MG BASE**	**A077342**	**003**	Mar 09, 2016
AB		TEVA PHARMS	**EQ 20MG BASE**	**A078380**	**001**	Jan 07, 2013
AB		TORRENT	**EQ 25MG BASE**	**A091448**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A091448**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A091448**	**003**	Jun 11, 2018
AB		TORRENT PHARMS LTD	**EQ 20MG BASE**	**A091479**	**001**	Nov 06, 2012
AB		UMEDICA	**EQ 25MG BASE**	**A209302**	**003**	Jun 15, 2021
AB			**EQ 50MG BASE**	**A209302**	**001**	Aug 25, 2020
AB			**EQ 100MG BASE**	**A209302**	**002**	Aug 25, 2020
AB		WATSON LABS INC	**EQ 20MG BASE**	**A202503**	**001**	Nov 06, 2012

VIAGRA

AB	**+**	VIATRIS	**EQ 25MG BASE**	**N020895**	**001**	Mar 27, 1998
AB	**+**		**EQ 50MG BASE**	**N020895**	**002**	Mar 27, 1998
AB	**+!**		**EQ 100MG BASE**	**N020895**	**003**	Mar 27, 1998

SILODOSIN

CAPSULE;ORAL

RAPAFLO

AB	**+!**	ALLERGAN	**4MG**	**N022206**	**001**	Oct 08, 2008
AB	**+**		**8MG**	**N022206**	**002**	Oct 08, 2008

SILODOSIN

AB		AJANTA PHARMA LTD	**4MG**	**A211060**	**001**	Dec 03, 2018
AB			**8MG**	**A211060**	**002**	Dec 03, 2018
AB		AMNEAL PHARMS CO	**4MG**	**A209745**	**001**	Dec 03, 2018
AB			**8MG**	**A209745**	**002**	Dec 03, 2018
AB		AUROBINDO PHARMA LTD	**4MG**	**A210626**	**001**	Dec 10, 2018
AB			**8MG**	**A210626**	**002**	Dec 10, 2018
AB		CREEKWOOD PHARMS	**4MG**	**A213230**	**001**	Jan 03, 2022
AB			**8MG**	**A213230**	**002**	Jan 03, 2022
AB		HETERO LABS LTD V	**4MG**	**A204793**	**001**	Feb 14, 2020
AB			**8MG**	**A204793**	**002**	Feb 14, 2020
AB		LUPIN LTD	**4MG**	**A206541**	**001**	Dec 03, 2018
AB			**8MG**	**A206541**	**002**	Dec 03, 2018
AB		MACLEODS PHARMS LTD	**4MG**	**A211166**	**001**	Dec 03, 2018
AB			**8MG**	**A211166**	**002**	Dec 03, 2018
AB		MSN	**4MG**	**A210687**	**001**	Dec 03, 2018
AB			**8MG**	**A210687**	**002**	Dec 03, 2018
AB		PRINSTON INC	**4MG**	**A209029**	**001**	Jan 04, 2022
AB			**8MG**	**A209029**	**002**	Jan 04, 2022
AB		SANDOZ	**4MG**	**A204726**	**001**	Mar 31, 2017
AB			**8MG**	**A204726**	**002**	Mar 31, 2017

SILVER SULFADIAZINE

CREAM;TOPICAL

SILVADENE

AB	**+!**	KING PHARMS LLC	**1%**	**N017381**	**001**	

SSD

AB		DR REDDYS LA	**1%**	**N018578**	**001**	Feb 25, 1982

SILVER SULFADIAZINE						
CREAM;TOPICAL						
THERMAZENE						
AB		THEPHARMANETWORK LLC	**1%**	**N018810**	**001**	Dec 23, 1985
SIMVASTATIN						
SUSPENSION;ORAL						
FLOLIPID						
	+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016
	+!		40MG/5ML	N206679	002	Apr 21, 2016
TABLET;ORAL						
SIMVASTATIN						
AB		ACCORD HLTHCARE	**5MG**	**A078155**	**005**	Apr 05, 2013
AB			**10MG**	**A078155**	**002**	Feb 26, 2008
AB			**20MG**	**A078155**	**003**	Feb 26, 2008
AB			**40MG**	**A078155**	**004**	Feb 26, 2008
AB			**80MG**	**A078155**	**001**	Feb 26, 2008
AB		AUROBINDO PHARMA	**5MG**	**A077691**	**001**	Dec 20, 2006
AB			**10MG**	**A077691**	**002**	Dec 20, 2006
AB			**20MG**	**A077691**	**003**	Dec 20, 2006
AB			**40MG**	**A077691**	**004**	Dec 20, 2006
AB			**80MG**	**A077691**	**005**	Dec 20, 2006
AB		BIOCON PHARMA	**5MG**	**A078034**	**001**	Dec 20, 2006
AB			**10MG**	**A078034**	**002**	Dec 20, 2006
AB			**20MG**	**A078034**	**003**	Dec 20, 2006
AB			**40MG**	**A078034**	**004**	Dec 20, 2006
AB			**80MG**	**A078034**	**005**	Dec 20, 2006
AB		DR REDDYS LABS INC	**5MG**	**A077752**	**005**	Jan 23, 2008
AB			**10MG**	**A077752**	**001**	Dec 20, 2006
AB			**20MG**	**A077752**	**002**	Dec 20, 2006
AB			**40MG**	**A077752**	**003**	Dec 20, 2006
AB			**80MG**	**A077752**	**004**	Dec 20, 2006
AB		HETERO LABS LTD III	**5MG**	**A200895**	**001**	Nov 25, 2014
AB			**10MG**	**A200895**	**002**	Nov 25, 2014
AB			**20MG**	**A200895**	**003**	Nov 25, 2014
AB			**40MG**	**A200895**	**004**	Nov 25, 2014
AB			**80MG**	**A200895**	**005**	Nov 25, 2014
AB		INVAGEN PHARMS	**10MG**	**A206557**	**001**	Nov 13, 2017
AB			**20MG**	**A206557**	**002**	Nov 13, 2017
AB			**40MG**	**A206557**	**003**	Nov 13, 2017
AB			**80MG**	**A206557**	**004**	Nov 13, 2017
AB		LUPIN	**5MG**	**A078103**	**005**	Apr 14, 2009
AB			**10MG**	**A078103**	**001**	May 11, 2007
AB			**20MG**	**A078103**	**002**	May 11, 2007
AB			**40MG**	**A078103**	**003**	May 11, 2007
AB	!		**80MG**	**A078103**	**004**	May 11, 2007
AB		MICRO LABS	**5MG**	**A090383**	**001**	Sep 16, 2011
AB			**10MG**	**A090383**	**002**	Sep 16, 2011
AB			**20MG**	**A090383**	**003**	Sep 16, 2011
AB			**40MG**	**A090383**	**004**	Sep 16, 2011
AB			**80MG**	**A090383**	**005**	Sep 16, 2011
AB		OXFORD PHARMS	**5MG**	**A078735**	**001**	Aug 30, 2010
AB			**10MG**	**A078735**	**002**	Aug 30, 2010
AB			**20MG**	**A078735**	**003**	Aug 30, 2010
AB			**40MG**	**A078735**	**004**	Aug 30, 2010
AB			**80MG**	**A078735**	**005**	Aug 30, 2010
AB		ZYDUS PHARMS USA	**5MG**	**A077837**	**001**	Dec 20, 2006
AB			**10MG**	**A077837**	**002**	Dec 20, 2006
AB			**20MG**	**A077837**	**003**	Dec 20, 2006
AB			**40MG**	**A077837**	**004**	Dec 20, 2006
AB			**80MG**	**A077837**	**005**	Dec 20, 2006
ZOCOR						
AB	+	ORGANON	**5MG**	**N019766**	**001**	Dec 23, 1991
AB	+		**10MG**	**N019766**	**002**	Dec 23, 1991
AB	+		**20MG**	**N019766**	**003**	Dec 23, 1991
AB	+		**40MG**	**N019766**	**004**	Dec 23, 1991

SINCALIDE
INJECTABLE;INJECTION
KINEVAC
+! BRACCO 0.005MG/VIAL N017697 001
POWDER;INTRAVENOUS
SINCALIDE
+! MAIA PHARMS INC 0.005MG/VIAL N210850 001 Nov 22, 2022

SINECATECHINS
OINTMENT;TOPICAL
VEREGEN
+! ANI PHARMS 15% N021902 001 Oct 31, 2006

SIPONIMOD
TABLET;ORAL
MAYZENT
+ NOVARTIS EQ 0.25MG BASE N209884 001 Mar 26, 2019
+ EQ 1MG BASE N209884 003 Aug 24, 2021
+! EQ 2MG BASE N209884 002 Mar 26, 2019

SIROLIMUS
GEL;TOPICAL
HYFTOR
+! NOBELPHARMA 0.2% N213478 001 Mar 22, 2022
POWDER;INTRAVENOUS
FYARRO
+! AADI 100MG/VIAL N213312 001 Nov 22, 2021
SOLUTION;ORAL
RAPAMUNE
AA **+!** PF PRISM CV **1MG/ML** **N021083 001** Sep 15, 1999
SIROLIMUS
AA AMNEAL **1MG/ML** **A211212 001** Oct 18, 2019
AA APOTEX **1MG/ML** **A211406 001** Oct 22, 2019
AA MSN **1MG/ML** **A216728 001** Jan 19, 2023
AA NOVITIUM PHARMA **1MG/ML** **A211040 001** Jan 28, 2019
TABLET;ORAL
RAPAMUNE
AB **+** PF PRISM CV **0.5MG** **N021110 004** Jan 25, 2010
AB **+** **1MG** **N021110 001** Aug 25, 2000
AB **+!** **2MG** **N021110 002** Aug 22, 2002
SIROLIMUS
AB ALKEM LABS LTD **0.5MG** **A214753 001** Mar 12, 2021
AB **1MG** **A214753 002** Mar 12, 2021
AB **2MG** **A214753 003** Mar 12, 2021
AB DR REDDYS **1MG** **A201578 001** Oct 27, 2014
AB **2MG** **A201578 002** Oct 27, 2014
AB GLENMARK PHARMS LTD **0.5MG** **A208691 001** Oct 16, 2020
AB **1MG** **A208691 002** Oct 16, 2020
AB **2MG** **A208691 003** Oct 16, 2020
AB ZYDUS PHARMS **1MG** **A201676 001** Feb 15, 2023
AB **2MG** **A201676 002** Feb 15, 2023
AB **0.5MG** **A201676 003** Jan 08, 2014

SITAGLIPTIN
TABLET;ORAL
ZITUVIO
+ ZYDUS 25MG N211566 001 Oct 18, 2023
+ 50MG N211566 002 Oct 18, 2023
+! 100MG N211566 003 Oct 18, 2023

SITAGLIPTIN PHOSPHATE
TABLET;ORAL
JANUVIA
+ MERCK SHARP DOHME EQ 25MG BASE N021995 001 Oct 16, 2006
+ EQ 50MG BASE N021995 002 Oct 16, 2006
+! EQ 100MG BASE N021995 003 Oct 16, 2006

SODIUM ACETATE
INJECTABLE;INJECTION
SODIUM ACETATE
AP FRESENIUS KABI USA **4MEQ/ML** **A206687 001** Oct 30, 2017
AP **+!** HOSPIRA **2MEQ/ML** **N018893 001** May 04, 1983
AP MILLA PHARMS **2MEQ/ML** **A214805 001** May 04, 2021
AP **4MEQ/ML** **A214805 002** Aug 25, 2023

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;INTRAVENOUS

AMMONUL

AP	**+!**	BAUSCH	**10%;10% (5GM/50ML;5GM/50ML)**	**N020645**	**001**	Feb 17, 2005

SODIUM PHENYLACETATE AND SODIUM BENZOATE

AP		AILEX PHARMS LLC	**10%;10% (5GM/50ML;5GM/50ML)**	**A207096**	**001**	Feb 24, 2016
AP		MAIA PHARMS INC	**10%;10% (5GM/50ML;5GM/50ML)**	**A208521**	**001**	May 08, 2017
AP	**+!**		**10%;10% (2GM/20ML;2GM/20ML)**	**N215025**	**001**	Jun 10, 2021
AP		NAVINTA LLC	**10%;10% (5GM/50ML;5GM/50ML)**	**A205880**	**001**	Aug 04, 2016
AP			**10%;10% (2GM/20ML; 2GM/20ML)**	**A217526**	**001**	Jul 14, 2023

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

AP	**!**	EXELA PHARMA	**0.5MEQ/ML**	**A211091**	**001**	Jun 20, 2019
AP	**!**		**0.9MEQ/ML**	**A211091**	**002**	Jun 20, 2019
AP	**!**		**1MEQ/ML**	**A211091**	**003**	Jun 20, 2019
AP		HOSPIRA	**0.5MEQ/ML**	**A202679**	**001**	Mar 07, 2017
AP	**!**		**0.5MEQ/ML**	**A202981**	**001**	Mar 04, 2016
AP			**0.9MEQ/ML**	**A202494**	**001**	Mar 06, 2017
AP			**1MEQ/ML**	**A202432**	**001**	Sep 26, 2017
AP			**1MEQ/ML**	**A202494**	**002**	Mar 06, 2017
AP		INTL MEDICATION SYS	**1MEQ/ML**	**A203449**	**001**	Sep 19, 2017
AP		OMNIVIUM PHARMS	**1MEQ/ML**	**A216364**	**001**	Jun 15, 2023
AP		STERISCIENCE	**1MEQ/ML**	**A217594**	**001**	Jun 28, 2023
		HOSPIRA	1MEQ/ML	A202495	001	Mar 06, 2017

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	**+**	B BRAUN	**450MG/100ML**	**N019635**	**001**	Mar 09, 1988
AP	**+!**	BAXTER HLTHCARE	**450MG/100ML**	**N018016**	**001**	
AP		FRESENIUS KABI USA	**450MG/100ML**	**A208122**	**001**	Jul 23, 2018
AP		HOSPIRA	**450MG/100ML**	**N019759**	**001**	Jun 08, 1988
AP	**+!**	ICU MEDICAL INC	**450MG/100ML**	**N018090**	**001**	

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**900MG/100ML**	**N017464**	**001**	
AP	**+!**		**900MG/100ML**	**N019635**	**002**	Mar 09, 1988
AP		FRESENIUS KABI USA	**900MG/100ML**	**A207310**	**001**	Sep 19, 2017
AP		FRESENIUS MEDCL	**900MG/100ML**	**A078177**	**001**	Apr 12, 2007
AP		HAEMONETICS	**900MG/100ML**	**A076316**	**001**	Oct 27, 2004
AP	**+!**	HOSPIRA	**900MG/100ML**	**N019480**	**001**	Sep 17, 1985
AP	**+!**	ICU MEDICAL INC	**900MG/100ML**	**N016366**	**001**	
AP		LABORATORIOS GRIFOLS	**900MG/100ML**	**A207956**	**001**	May 25, 2017

SODIUM CHLORIDE 23.4%

AP		FRESENIUS KABI USA	**234MG/ML**	**A212248**	**001**	Apr 28, 2021
AP			**234MG/ML**	**A217796**	**001**	Jul 11, 2023

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

AP		B BRAUN	**3GM/100ML**	**N019635**	**003**	Mar 09, 1988
AP	**+!**	BAXTER HLTHCARE	**3GM/100ML**	**N019022**	**001**	Nov 01, 1983
AP		FRESENIUS KABI USA	**3GM/100ML**	**A209476**	**001**	Mar 13, 2019

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML**	**N019635**	**004**	Mar 09, 1988
AP	**+**	BAXTER HLTHCARE	**5GM/100ML**	**N019022**	**002**	Nov 01, 1983

SODIUM CHLORIDE 0.9%

	+!	MEDEFIL INC	90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	LIEBEL-FLARSHEIM	1.125GM/125ML (9MG/ML)	N021569	002	Jul 27, 2006

SOLUTION;INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**90MG/10ML (9MG/ML)**	**A088911**	**002**	May 17, 1985
AP			**270MG/30ML (9MG/ML)**	**A088911**	**001**	Feb 07, 1985
AP	**+!**	HOSPIRA	**90MG/10ML (9MG/ML)**	**N018800**	**001**	Oct 29, 1982
AP	**+!**		**180MG/20ML (9MG/ML)**	**N018800**	**002**	Oct 29, 1982
AP	**+!**		**270MG/30ML (9MG/ML)**	**N018800**	**003**	Oct 29, 1982

SODIUM CHLORIDE 0.9%

AP		HIKMA	**90MG/10ML (9MG/ML)**	**A201833**	**002**	Jan 07, 2015
AP			**90MG/10ML (9MG/ML)**	**A201850**	**001**	Jan 20, 2012
AP		NEXUS PHARMS	**90MG/10ML (9MG/ML)**	**A217535**	**001**	Aug 23, 2023
AP			**180MG/20ML (9MG/ML)**	**A217535**	**002**	Aug 23, 2023
AP		SPECTRA MDCL DEVICES	**45MG/5ML (9MG/ML)**	**A206171**	**001**	Jul 21, 2017
AP			**90MG/10ML (9MG/ML)**	**A206171**	**002**	Jul 21, 2017

SODIUM CHLORIDE

SOLUTION;INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**450MG/50ML (9MG/ML)**	**N016677**	**003**		
AP	**+**		**450MG/50ML (9MG/ML)**	**N020178**	**002**	Dec 07, 1992	
AP	**+!**		**900MG/100ML**	**N016677**	**001**		
AP	**+!**		**900MG/100ML**	**N020178**	**001**	Dec 07, 1992	
AP	**!**	FRESENIUS KABI USA	**90MG/10ML (9MG/ML)**	**A088912**	**001**	Jan 10, 1985	
AP	**!**		**180MG/20ML (9MG/ML)**	**A088912**	**002**	Jan 10, 1985	
AP	**!**		**270MG/30ML (9MG/ML)**	**A088912**	**003**	Jan 10, 1985	
AP	**+!**	HOSPIRA	**90MG/10ML (9MG/ML)**	**N018803**	**001**	Oct 29, 1982	
AP	**+!**		**180MG/20ML (9MG/ML)**	**N018803**	**002**	Oct 29, 1982	
AP	**+!**		**450MG/50ML (9MG/ML)**	**N018803**	**003**	Oct 29, 1982	
AP	**+**		**450MG/50ML (9MG/ML)**	**N019465**	**002**	Jul 15, 1985	
AP	**+!**		**900MG/100ML**	**N019465**	**001**	Jul 15, 1985	
AP		NEPHRON	**450MG/50ML (9MG/ML)**	**A211968**	**001**	Apr 23, 2020	
AP			**900MG/100ML**	**A211968**	**002**	Apr 23, 2020	
AP	**!**	TARO	**45MG/5ML (9MG/ML)**	**A077407**	**001**	Aug 11, 2006	
AP	**!**		**90MG/10ML (9MG/ML)**	**A077407**	**002**	Aug 11, 2006	

SODIUM CHLORIDE 0.9%

+	B BRAUN	90MG/10ML (9MG/ML)	N019635	005	Aug 08, 2016	
	HIKMA	18MG/2ML (9MG/ML)	A201833	001	Sep 24, 2013	

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	225MG/25ML (9MG/ML)	N016677	004	Oct 30, 1985	
!	FRESENIUS KABI USA	18MG/2ML (9MG/ML)	A088912	004	Nov 29, 1985	

SOLUTION;INTRAVENOUS

SODIUM CHLORIDE 14.6%

AP		FRESENIUS KABI USA	**100MEQ/40ML (2.5MEQ/ML)**	**A212070**	**002**	Apr 28, 2021	
AP	**+!**	HOSPIRA	**100MEQ/40ML (2.5MEQ/ML)**	**N018897**	**002**	Jul 20, 1984	

SODIUM CHLORIDE 23.4%

AP		FRESENIUS KABI USA	**400MEQ/100ML (4MEQ/ML)**	**A212070**	**003**	Feb 14, 2022	
AP	**+!**	HOSPIRA	**400MEQ/100ML (4MEQ/ML)**	**N018897**	**003**	Jun 18, 2020	

SODIUM CHLORIDE 14.6%

	FRESENIUS KABI USA	50MEQ/20ML (2.5MEQ/ML)	A212070	001	Apr 28, 2021	

SOLUTION;IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT	**+!**	B BRAUN	**900MG/100ML**	**N016733**	**001**		
AT		BAXTER HLTHCARE	**900MG/100ML**	**N017427**	**001**		
AT			**900MG/100ML**	**N017867**	**001**		
AT	**+**	ICU MEDICAL INC	**900MG/100ML**	**N017514**	**001**		
AT			**900MG/100ML**	**N018314**	**001**		

SOLUTION FOR SLUSH;IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

+!	BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985	

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP	3D IMAGING DRUG	**10-200mCi/ML**	**A203777**	**001**	Oct 19, 2015	
AP	BAMF	**10-200mCi/ML**	**A216126**	**001**	Dec 06, 2022	
AP	BIOMEDCL RES FDN	**10-200mCi/ML**	**A204351**	**001**	Jan 09, 2015	
AP	CARDINAL HEALTH 414	**10-200mCi/ML**	**A203780**	**001**	Jul 30, 2015	
AP	ESSENTIAL ISOTOPES	**10-200mCi/ML**	**A204541**	**001**	Oct 29, 2014	
AP	HOT SHOTS NM LLC	**10-200mCi/ML**	**A204530**	**001**	Jul 29, 2015	
AP	JUBILANT DRAXIMAGE	**10-200mCi/ML**	**A203968**	**001**	Oct 23, 2015	
AP	KREITCHMAN PET CTR	**10-200mCi/ML**	**A203936**	**001**	May 19, 2016	
AP	MIDWEST MEDCL	**10-200mCi/ML**	**A204440**	**001**	Nov 17, 2015	
AP	MIPS CRF	**10-200mCi/ML**	**A204517**	**001**	Jul 21, 2015	
AP	NCM USA BRONX LLC	**10-200mCi/ML**	**A204513**	**001**	Nov 28, 2014	
AP	NUKEMED	**10-200mCi/ML**	**A203912**	**001**	Apr 22, 2015	
AP	PETNET	**10-200mCi/ML**	**A203890**	**001**	Sep 28, 2015	
AP	PRECISION NUCLEAR	**10-200mCi/ML**	**A204542**	**001**	Feb 27, 2015	
AP	SOFIE	**10-200mCi/ML**	**A203592**	**001**	Aug 18, 2015	
AP	**!**	**10-200mCi/ML**	**A203544**	**001**	Dec 26, 2012	
AP	UNIV UTAH CYCLOTRON	**10-200mCi/ML**	**A204497**	**001**	Apr 20, 2015	
!	MCPRF	10-91.5mCi/ML	A203605	001	Jun 28, 2013	
	THE FEINSTEIN INST	20-600mCi/ML	A204328	001	Nov 19, 2014	

SODIUM IODIDE I-123						
CAPSULE;ORAL						
SODIUM IODIDE I 123						
AA	**+!**	CARDINAL HEALTH 418	**100uCi**	**N018671**	**001**	May 27, 1982
AA	**+!**		**200uCi**	**N018671**	**002**	May 27, 1982
AA		CURIUM	**100uCi**	**A071909**	**001**	Feb 28, 1989
AA			**200uCi**	**A071910**	**001**	Feb 28, 1989
SODIUM IODIDE I-131						
CAPSULE;ORAL						
SODIUM IODIDE I 131						
	+	JUBILANT	0.009-0.1mCi	N021305	006	May 19, 2005
SOLUTION;ORAL						
HICON						
AA	**+!**	JUBILANT	**250-1000mCi**	**N021305**	**007**	Dec 05, 2011
SODIUM IODIDE I 131						
AA		INTL ISOTOPES	**250-1000mCi**	**A209166**	**001**	Feb 05, 2020
SODIUM NITRITE						
SOLUTION;INTRAVENOUS						
SODIUM NITRITE						
	+!	HOPE PHARMS	300MG/10ML (30MG/ML)	N203922	001	Feb 14, 2012
SODIUM NITRITE; SODIUM THIOSULFATE						
SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS						
NITHIODOTE						
	+!	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML (250MG/ML)	N201444	001	Jan 14, 2011
SODIUM NITROPRUSSIDE						
INJECTABLE;INJECTION						
SODIUM NITROPRUSSIDE						
AP		AMNEAL	**25MG/ML**	**A209493**	**001**	Nov 07, 2017
AP		BE PHARMS	**25MG/ML**	**A214971**	**001**	Jul 12, 2021
AP		CAPLIN	**25MG/ML**	**A211016**	**001**	Nov 29, 2019
AP		DR REDDYS	**25MG/ML**	**A210114**	**001**	Apr 10, 2019
AP		HAINAN POLY PHARM	**25MG/ML**	**A214199**	**001**	Aug 25, 2020
AP	**!**	MICRO LABS	**25MG/ML**	**A209352**	**001**	Dec 08, 2017
AP		MYLAN	**25MG/ML**	**A209584**	**001**	Aug 10, 2018
AP		MYLAN LABS LTD	**25MG/ML**	**A210763**	**001**	Apr 17, 2018
AP		NEXUS	**25MG/ML**	**A207499**	**001**	May 25, 2017
AP		SAGENT PHARMS INC	**25MG/ML**	**A207426**	**001**	Dec 08, 2016
AP		SOMERSET THERAPS LLC	**25MG/ML**	**A210882**	**001**	Aug 17, 2018
AP		XIROMED	**25MG/ML**	**A211277**	**001**	Oct 29, 2020
SOLUTION;INTRAVENOUS						
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%						
AP	**+!**	EXELA PHARMA	**20MG/100ML (0.2MG/ML)**	**N209387**	**003**	Jul 13, 2018
AP	**+!**		**50MG/100ML (0.5MG/ML)**	**N209387**	**001**	Mar 08, 2017
SODIUM NITROPRUSSIDE						
AP		HAINAN POLY	**20MG/100ML (0.2MG/ML)**	**A215846**	**002**	Aug 26, 2022
AP			**50MG/100ML (0.5MG/ML)**	**A215846**	**003**	Aug 26, 2022
			10MG/50ML (0.2MG/ML)	A215846	001	Aug 26, 2022
SODIUM OXYBATE						
FOR SUSPENSION, EXTENDED RELEASE;ORAL						
LUMRYZ						
	+!	AVADEL CNS	4.5GM/PACKET	N214755	001	May 01, 2023
	+		6GM/PACKET	N214755	002	May 01, 2023
	+		7.5GM/PACKET	N214755	003	May 01, 2023
	+		9GM/PACKET	N214755	004	May 01, 2023
SOLUTION;ORAL						
XYREM						
	+!	JAZZ PHARMS	0.5GM/ML	N021196	001	Jul 17, 2002
SODIUM PHENYLBUTYRATE						
FOR SUSPENSION;ORAL						
OLPRUVA						
	+	ACER	2GM/PACKET	N214860	001	Dec 22, 2022
	+		3GM/PACKET	N214860	002	Dec 22, 2022
	+		4GM/PACKET	N214860	003	Dec 22, 2022
	+		5GM/PACKET	N214860	004	Dec 22, 2022
	+		6GM/PACKET	N214860	005	Dec 22, 2022
	+!		6.67GM/PACKET	N214860	006	Dec 22, 2022

SODIUM PHENYLBUTYRATE

PELLETS;ORAL

PHEBURANE

	+!	MEDUNIK	84GM/BOT	N216513	001	Jun 17, 2022

POWDER;ORAL

BUPHENYL

AB	**+!**	HORIZON THERAP US	**3GM/TEASPOONFUL**	**N020573**	**001**	Apr 30, 1996

SODIUM PHENYLBUTYRATE

AB		PAR PHARM	**3GM/TEASPOONFUL**	**A203918**	**001**	Jun 15, 2016
AB		SIGMAPHARM LABS LLC	**3GM/TEASPOONFUL**	**A202819**	**001**	Mar 22, 2013

TABLET;ORAL

BUPHENYL

AB	**+!**	HORIZON THERAP US	**500MG**	**N020572**	**001**	May 13, 1996

SODIUM PHENYLBUTYRATE

AB		GLENMARK PHARMS LTD	**500MG**	**A216462**	**001**	Nov 01, 2022
AB		PAR PHARM	**500MG**	**A204395**	**001**	Apr 15, 2016

SODIUM PHENYLBUTYRATE; TAURURSODIOL

FOR SUSPENSION;ORAL

RELYVRIO

	+!	AMYLYX	3GM/PACKET; 1GM/PACKET	N216660	001	Sep 29, 2022

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

	!	NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION

SODIUM PHOSPHATES

AP	**!**	FRESENIUS KABI USA	**142MG/ML;276MG/ML**	**A209997**	**001**	Mar 30, 2022

SODIUM PHOSPHATES IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**142MG/ML;276MG/ML**	**N018892**	**001**	May 10, 1983

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KALEXATE

AA	**!**	KVK TECH	**454GM/BOT**	**A040905**	**001**	Mar 30, 2009

KIONEX

AA		ANI PHARMS	**454GM/BOT**	**A040029**	**001**	Feb 06, 1998

SODIUM POLYSTYRENE SULFONATE

AA		BELCHER	**454GM/BOT**	**A205727**	**001**	Feb 23, 2016
AA		CHARTWELL RX	**454GM/BOT**	**A206815**	**001**	Feb 18, 2016
AA		CMP PHARMA INC	**454GM/BOT**	**A089910**	**001**	Jan 19, 1989
AA		EPIC PHARMA LLC	**453.6GM/BOT**	**A202333**	**001**	Mar 19, 2014
AA		NUVO PHARMS INC	**454GM/BOT**	**A204071**	**001**	Nov 28, 2014
AA		UPSHER SMITH LABS	**453.6GM/BOT**	**A090313**	**001**	Dec 21, 2011

KALEXATE

		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015

SODIUM POLYSTYRENE SULFONATE

		NUVO PHARMS INC	15GM/BOT	A204071	002	Nov 28, 2014

SUSPENSION;ORAL, RECTAL

KIONEX

AA		ANI PHARMS	**15GM/60ML**	**A040028**	**001**	Sep 17, 2007

SPS

AA	**+!**	CMP PHARMA INC	**15GM/60ML**	**A087859**	**001**	Dec 08, 1982

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SODIUM TETRADECYL SULFATE

AP		HIKMA	**60MG/2ML (30MG/ML)**	**A209937**	**001**	Dec 09, 2019

SOTRADECOL

AP	**!**	MYLAN INSTITUTIONAL	**60MG/2ML (30MG/ML)**	**A040541**	**002**	Nov 12, 2004
	!		20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004

SODIUM THIOSULFATE

SOLUTION;INTRAVENOUS

PEDMARK

	+!	FENNEC PHARMS INC	12.5GM/100ML (125MG/ML)	N212937	001	Sep 20, 2022

SODIUM THIOSULFATE

	+!	HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923	001	Feb 14, 2012

SODIUM ZIRCONIUM CYCLOSILICATE

FOR SUSPENSION;ORAL

LOKELMA

+	ASTRAZENECA	5GM/PACKET	N207078	001	May 18, 2018
+!		10GM/PACKET	N207078	002	May 18, 2018

SOFOSBUVIR

PELLETS;ORAL

SOVALDI

+	GILEAD SCIENCES INC	150MG/PACKET	N212480	001	Aug 28, 2019
+!		200MG/PACKET	N212480	002	Aug 28, 2019

TABLET;ORAL

SOVALDI

+	GILEAD SCIENCES INC	200MG	N204671	002	Aug 28, 2019
+!		400MG	N204671	001	Dec 06, 2013

SOFOSBUVIR; VELPATASVIR

PELLETS;ORAL

EPCLUSA

+	GILEAD SCIENCES INC	150MG;37.5MG/PACKET	N214187	001	Jun 10, 2021
+!		200MG;50MG/PACKET	N214187	002	Jun 10, 2021

TABLET;ORAL

EPCLUSA

+	GILEAD SCIENCES INC	200MG;50MG	N208341	002	Mar 19, 2020
+!		400MG;100MG	N208341	001	Jun 28, 2016

SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

TABLET;ORAL

VOSEVI

+!	GILEAD SCIENCES INC	400MG;100MG;100MG	N209195	001	Jul 18, 2017

SOLIFENACIN SUCCINATE

SUSPENSION;ORAL

VESICARE LS

+!	ASTELLAS	1MG/ML	N209529	001	May 26, 2020

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB		ALEMBIC	**5MG**	**A205575**	**001**	May 20, 2019
AB			**10MG**	**A205575**	**002**	May 20, 2019
AB		ALKEM LABS LTD	**5MG**	**A210224**	**001**	May 20, 2019
AB			**10MG**	**A210224**	**002**	May 20, 2019
AB		ANNORA PHARMA	**5MG**	**A215761**	**001**	Jun 15, 2022
AB			**10MG**	**A215761**	**002**	Jun 15, 2022
AB		AUROBINDO PHARMA	**5MG**	**A206817**	**001**	Dec 27, 2022
AB			**10MG**	**A206817**	**002**	Dec 27, 2022
AB		AUSTARPHARMA	**5MG**	**A210281**	**001**	May 20, 2019
AB			**10MG**	**A210281**	**002**	May 20, 2019
AB		CHARTWELL RX	**5MG**	**A210582**	**001**	May 20, 2019
AB			**10MG**	**A210582**	**002**	May 20, 2019
AB		GLENMARK PHARMS INC	**5MG**	**A209239**	**001**	May 20, 2019
AB			**10MG**	**A209239**	**002**	May 20, 2019
AB		MSN	**5MG**	**A210688**	**001**	May 20, 2019
AB			**10MG**	**A210688**	**002**	May 20, 2019
AB		QILU	**5MG**	**A209333**	**001**	May 20, 2019
AB			**10MG**	**A209333**	**002**	May 20, 2019
AB		RISING	**5MG**	**A211423**	**001**	Dec 11, 2019
AB			**10MG**	**A211423**	**002**	Dec 11, 2019
AB		SCIEGEN PHARMS INC	**5MG**	**A211657**	**001**	May 20, 2019
AB			**10MG**	**A211657**	**002**	May 20, 2019
AB		STRIDES PHARMA	**5MG**	**A212214**	**001**	Sep 26, 2019
AB			**10MG**	**A212214**	**002**	Sep 26, 2019
AB		TEVA PHARMS USA	**5MG**	**A091464**	**001**	Apr 02, 2014
AB			**10MG**	**A091464**	**002**	Apr 02, 2014
AB		UNICHEM	**5MG**	**A211701**	**001**	Aug 27, 2019
AB			**10MG**	**A211701**	**002**	Aug 27, 2019
AB		WATSON LABS INC	**5MG**	**A202551**	**001**	May 20, 2019
AB			**10MG**	**A202551**	**002**	May 20, 2019

VESICARE

AB	**+**	ASTELLAS	**5MG**	**N021518**	**001**	Nov 19, 2004
AB	**+!**		**10MG**	**N021518**	**002**	Nov 19, 2004

SOLRIAMFETOL HYDROCHLORIDE						
TABLET;ORAL						
SUNOSI						
	+	AXSOME MALTA	EQ 75MG BASE	N211230	001	Jun 17, 2019
	+!		EQ 150MG BASE	N211230	002	Jun 17, 2019
SONIDEGIB PHOSPHATE						
CAPSULE;ORAL						
ODOMZO						
	+!	SUN PHARM	EQ 200MG BASE	N205266	001	Jul 24, 2015
SORAFENIB TOSYLATE						
TABLET;ORAL						
NEXAVAR						
AB	**+!**	BAYER HLTHCARE	**EQ 200MG BASE**	**N021923**	**001**	Dec 20, 2005
SORAFENIB TOSYLATE						
AB		DR REDDYS	**EQ 200MG BASE**	**A216073**	**001**	Jun 07, 2022
AB		MYLAN	**EQ 200MG BASE**	**A207012**	**001**	Sep 10, 2020
AB		TEVA PHARMS USA INC	**EQ 200MG BASE**	**A209567**	**001**	Nov 12, 2020
AB		TORRENT	**EQ 200MG BASE**	**A217095**	**001**	Apr 12, 2023
AB		YABAO PHARM	**EQ 200MG BASE**	**A209050**	**001**	Nov 09, 2022
SORBITOL						
SOLUTION;IRRIGATION						
SORBITOL 3% IN PLASTIC CONTAINER						
		BAXTER HLTHCARE	3GM/100ML	N017863	001	
SORBITOL 3.3% IN PLASTIC CONTAINER						
		B BRAUN	3.3GM/100ML	N016741	001	
SOTAGLIFLOZIN						
TABLET;ORAL						
INPEFA						
	+	LEXICON PHARMS INC	200MG	N216203	001	May 26, 2023
	+!		400MG	N216203	002	May 26, 2023
SOTALOL HYDROCHLORIDE						
SOLUTION;INTRAVENOUS						
SOTALOL HYDROCHLORIDE						
	+!	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009
SOLUTION;ORAL						
SOTYLIZE						
	+!	AZURITY	5MG/ML (5MG/ML)	N205108	001	Oct 22, 2014
TABLET;ORAL						
BETAPACE						
AB	**+**	LEGACY PHARMA	**80MG**	**N019865**	**001**	Oct 30, 1992
AB	**+**		**120MG**	**N019865**	**005**	Apr 20, 1994
AB	**+!**		**160MG**	**N019865**	**002**	Oct 30, 1992
AB	**+**		**240MG**	**N019865**	**003**	Oct 30, 1992
BETAPACE AF						
AB	**+**	LEGACY PHARMA	**80MG**	**N021151**	**001**	Feb 22, 2000
AB	**+**		**120MG**	**N021151**	**002**	Feb 22, 2000
AB	**+!**		**160MG**	**N021151**	**003**	Feb 22, 2000
SORINE						
AB		AIPING PHARM INC	**80MG**	**A075500**	**001**	Apr 27, 2001
AB			**120MG**	**A075500**	**004**	Apr 27, 2001
AB			**160MG**	**A075500**	**002**	Apr 27, 2001
AB			**240MG**	**A075500**	**003**	Apr 27, 2001
SOTALOL HYDROCHLORIDE						
AB		APOTEX	**80MG**	**A076140**	**001**	Sep 26, 2002
AB			**80MG**	**A076214**	**001**	Aug 27, 2003
AB			**120MG**	**A076140**	**002**	Sep 26, 2002
AB			**120MG**	**A076214**	**002**	Aug 27, 2003
AB			**160MG**	**A076140**	**003**	Sep 26, 2002
AB			**160MG**	**A076214**	**003**	Aug 27, 2003
AB			**240MG**	**A076140**	**004**	Sep 26, 2002
AB		AUROBINDO PHARMA USA	**80MG**	**A077616**	**001**	Feb 07, 2007
AB			**120MG**	**A077616**	**002**	Feb 07, 2007
AB			**160MG**	**A077616**	**003**	Feb 07, 2007
AB		BEXIMCO PHARMS USA	**80MG**	**A207428**	**001**	Oct 21, 2016
AB			**80MG**	**A207429**	**001**	Nov 02, 2018
AB			**120MG**	**A207428**	**002**	Oct 21, 2016
AB			**120MG**	**A207429**	**002**	Nov 02, 2018
AB			**160MG**	**A207428**	**003**	Oct 21, 2016

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

AB			**160MG**	**A207429**	**003**	Nov 02, 2018
AB		EPIC PHARMA LLC	**80MG**	**A077070**	**001**	Nov 04, 2005
AB			**120MG**	**A077070**	**002**	Nov 04, 2005
AB			**160MG**	**A077070**	**003**	Nov 04, 2005
AB		OXFORD PHARMS	**80MG**	**A075563**	**001**	Nov 07, 2003
AB			**120MG**	**A075563**	**002**	Nov 07, 2003
AB			**160MG**	**A075563**	**003**	Nov 07, 2003
AB			**240MG**	**A075563**	**004**	Nov 07, 2003
AB		TEVA	**80MG**	**A075429**	**001**	May 01, 2000
AB			**120MG**	**A075429**	**002**	May 01, 2000
AB			**160MG**	**A075429**	**003**	May 01, 2000
AB			**240MG**	**A075429**	**004**	May 01, 2000

SOTORASIB

TABLET;ORAL

LUMAKRAS

+	AMGEN INC	120MG	N214665	001	May 28, 2021
+!		320MG	N214665	002	Jan 20, 2023

SOYBEAN OIL

INJECTABLE;INJECTION

INTRALIPID 20%

AP	**+!**	FRESENIUS	**20%**	**N018449**	**001**	
AP	**+!**		**20%**	**N020248**	**001**	Aug 07, 1996

NUTRILIPID 20%

AP	**+!**	B BRAUN	**20%**	**N019531**	**002**	May 28, 1993

INTRALIPID 30%

+!	FRESENIUS	30%	N019942	001	Dec 30, 1993

NUTRILIPID 10%

+!	B BRAUN	10%	N019531	001	May 28, 1993

SPARSENTAN

TABLET;ORAL

FILSPARI

+	TRAVERE	200MG	N216403	001	Feb 17, 2023
+!		400MG	N216403	002	Feb 17, 2023

SPINOSAD

SUSPENSION;TOPICAL

NATROBA

+!	PARAPRO LLC	0.9%	N022408	001	Jan 18, 2011

SPIRONOLACTONE

SUSPENSION;ORAL

CAROSPIR

AB	**+!**	CMP DEV LLC	**25MG/5ML**	**N209478**	**001**	Aug 04, 2017

SPIRONOLACTONE

AB		AMNEAL	**25MG/5ML**	**A215572**	**001**	Sep 05, 2023

TABLET;ORAL

ALDACTONE

AB	**+**	PFIZER	**25MG**	**N012151**	**009**	Dec 30, 1983
AB	**+**		**50MG**	**N012151**	**008**	Dec 30, 1982
AB	**+!**		**100MG**	**N012151**	**010**	Dec 30, 1983

SPIRONOLACTONE

AB	ACCORD HLTHCARE	**25MG**	**A203512**	**001**	Sep 19, 2016
AB		**50MG**	**A203512**	**002**	Sep 19, 2016
AB		**100MG**	**A203512**	**003**	Sep 19, 2016
AB	AMNEAL PHARMS	**25MG**	**A091426**	**001**	Jul 02, 2010
AB		**50MG**	**A091426**	**002**	Jul 02, 2010
AB		**100MG**	**A091426**	**003**	Jul 02, 2010
AB	AUROBINDO PHARMA	**25MG**	**A202187**	**001**	Mar 06, 2014
AB		**50MG**	**A202187**	**002**	Mar 06, 2014
AB		**100MG**	**A202187**	**003**	Mar 06, 2014
AB	JUBILANT GENERICS	**25MG**	**A203253**	**001**	Apr 23, 2014
AB		**50MG**	**A203253**	**002**	Apr 23, 2014
AB		**100MG**	**A203253**	**003**	Apr 23, 2014
AB	MYLAN	**25MG**	**A040424**	**001**	Aug 20, 2001
AB		**50MG**	**A040424**	**002**	Aug 20, 2001
AB		**100MG**	**A040424**	**003**	Aug 20, 2001
AB	OXFORD PHARMS	**25MG**	**A040750**	**001**	Aug 29, 2006
AB		**50MG**	**A040750**	**002**	Aug 29, 2006
AB		**100MG**	**A040750**	**003**	Aug 29, 2006

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AB		SUN PHARM INDUSTRIES	**25MG**	**A089424**	**001**	Jul 23, 1986
AB			**50MG**	**A089424**	**002**	Aug 11, 1999
AB			**100MG**	**A089424**	**003**	Aug 11, 1999
AB		ZYDUS PHARMS	**25MG**	**A205936**	**001**	Jul 18, 2018
AB			**50MG**	**A205936**	**002**	Jul 18, 2018
AB			**100MG**	**A205936**	**003**	Jul 18, 2018

STERILE WATER FOR INJECTION

LIQUID;N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**100%**	**N018802**	**001**	Oct 27, 1982

STERILE WATER FOR INJECTION

AP		AM REGENT	**100% (10ML)**	**A217341**	**001**	Aug 29, 2023
AP			**100% (20ML)**	**A217341**	**002**	Aug 29, 2023
AP		FRESENIUS KABI USA	**100%**	**A209689**	**001**	Nov 24, 2017
AP		HIKMA	**100% (10ML)**	**A206369**	**001**	Sep 02, 2015
AP			**100%**	**A212735**	**001**	Jan 31, 2023
AP	**+!**	HOSPIRA	**100% (10ML)**	**N018801**	**002**	Oct 27, 1982
AP	**+!**		**100% (20ML)**	**N018801**	**003**	Oct 27, 1982
AP	**!**	MEDEFIL INC	**100% (5ML)**	**A211188**	**004**	Dec 02, 2019
AP			**100% (10ML)**	**A211188**	**005**	Dec 02, 2019
AP		NEPHRON	**100% (5ML)**	**A211222**	**001**	Feb 10, 2021
AP		NEXUS	**100% (10ML)**	**A217536**	**001**	Jul 11, 2023
AP			**100% (20ML)**	**A217536**	**002**	Jul 11, 2023

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**100%**	**N019633**	**001**	Feb 29, 1988
AP	**+!**	BAXTER HLTHCARE	**100%**	**N018632**	**001**	Jun 30, 1982
AP	**+!**		**100%**	**N018632**	**002**	Apr 19, 1988
AP		FRESENIUS KABI USA	**100%**	**A088400**	**001**	Jan 16, 1984
AP	**+!**	ICU MEDICAL INC	**100%**	**N018233**	**001**	
AP	**+!**		**100%**	**N019869**	**001**	Dec 26, 1989
AP		TARO	**100%**	**A077393**	**001**	Aug 11, 2006

STERILE WATER FOR INJECTION

+!	HOSPIRA	100% (50ML)	N018801	004	Oct 27, 1982
+!		100% (100ML)	N018801	005	Oct 27, 1982
	MEDEFIL INC	100% (1ML)	A211188	001	Dec 02, 2019
!		100% (2.5ML)	A211188	002	Dec 02, 2019
!		100% (3ML)	A211188	003	Dec 02, 2019

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER

AT	**+**	BAXTER HLTHCARE	**100%**	**N017428**	**001**	

STERILE WATER IN PLASTIC CONTAINER

AT	**+**	B BRAUN	**100%**	**N016734**	**001**	
AT		BAXTER HLTHCARE	**100%**	**N017866**	**001**	
AT		ICU MEDICAL INC	**100%**	**N017513**	**001**	
AT			**100%**	**N018313**	**001**	

STIRIPENTOL

CAPSULE;ORAL

DIACOMIT

+	BIOCODEX SA	250MG	N206709	001	Aug 20, 2018
+!		500MG	N206709	002	Aug 20, 2018

FOR SUSPENSION;ORAL

DIACOMIT

+	BIOCODEX SA	250MG/PACKET	N207223	001	Aug 20, 2018
+!		500MG/PACKET	N207223	002	Aug 20, 2018

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION

STREPTOMYCIN SULFATE

!	XGEN PHARMS	EQ 1GM BASE/VIAL	A064210	001	Jun 30, 1998

STREPTOZOCIN

INJECTABLE;INJECTION

ZANOSAR

+!	TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982

STRONTIUM CHLORIDE SR-89						
INJECTABLE;INJECTION						
METASTRON						
AP	**+!**	Q BIOMED	**1mCi/ML**	**N020134**	**001**	Jun 18, 1993
STRONTIUM CHLORIDE SR-89						
AP		Q BIOMED	**1mCi/ML**	**A075941**	**001**	Jan 06, 2003
SUCCIMER						
CAPSULE;ORAL						
CHEMET						
	+!	RECORDATI RARE	100MG	N019998	002	Jan 30, 1991
SUCCINYLCHOLINE CHLORIDE						
INJECTABLE;INJECTION						
ANECTINE						
AP	**+!**	SANDOZ	**20MG/ML**	**N008453**	**002**	
QUELICIN						
AP	**+!**	HOSPIRA	**20MG/ML**	**N008845**	**006**	
SUCCINYLCHOLINE CHLORIDE						
AP		ACCORD HLTHCARE	**20MG/ML**	**A213705**	**001**	May 20, 2020
AP		AMNEAL	**20MG/ML**	**A211432**	**001**	Nov 16, 2018
AP		AMRING PHARMS	**20MG/ML**	**A210231**	**001**	Jun 04, 2018
AP		ASPIRO	**20MG/ML**	**A213810**	**001**	May 04, 2020
AP		BE PHARMS	**20MG/ML**	**A216003**	**001**	Feb 07, 2022
AP		DEVA HOLDING AS	**20MG/ML**	**A214491**	**001**	Dec 21, 2020
AP		DR REDDYS	**20MG/ML**	**A210698**	**001**	Aug 02, 2019
AP		EUGIA PHARMA	**20MG/ML**	**A217808**	**001**	Oct 16, 2023
AP		FRESENIUS KABI USA	**20MG/ML**	**A211346**	**001**	Nov 20, 2020
AP		GLAND PHARMA LTD	**20MG/ML**	**A214246**	**001**	Jun 16, 2020
AP		HIKMA	**20MG/ML**	**A213229**	**001**	Jun 12, 2020
AP		INDOCO	**20MG/ML**	**A214308**	**001**	May 22, 2020
AP		MEITHEAL	**20MG/ML**	**A214514**	**001**	Oct 19, 2021
AP		MICRO LABS	**20MG/ML**	**A214879**	**001**	Nov 24, 2020
AP		NEXUS	**20MG/ML**	**A213552**	**001**	Oct 27, 2020
AP		SAGENT PHARMS INC	**20MG/ML**	**A215022**	**001**	Mar 29, 2021
AP		SOMERSET THERAPS LLC	**20MG/ML**	**A211589**	**001**	Jan 15, 2020
AP		UMEDICA	**20MG/ML**	**A211625**	**001**	May 19, 2020
AP	**!**	ZYDUS PHARMS	**20MG/ML**	**A209467**	**001**	May 04, 2018
SOLUTION;INTRAMUSCULAR, INTRAVENOUS						
SUCCINYLCHOLINE CHLORIDE						
	+!	HIKMA	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021
SUCRALFATE						
SUSPENSION;ORAL						
CARAFATE						
AB	**+!**	ABBVIE	**1GM/10ML**	**N019183**	**001**	Dec 16, 1993
SUCRALFATE						
AB		AMNEAL	**1GM/10ML**	**A209356**	**001**	Dec 02, 2019
AB		MYLAN	**1GM/10ML**	**A212913**	**001**	Sep 12, 2022
AB		VISTAPHARM	**1GM/10ML**	**A211884**	**001**	Mar 15, 2022
TABLET;ORAL						
CARAFATE						
AB	**+!**	ABBVIE	**1GM**	**N018333**	**001**	
SUCRALFATE						
AB		AMNEAL PHARMS	**1GM**	**A215576**	**001**	Apr 15, 2022
AB		NOSTRUM LABS INC	**1GM**	**A074415**	**001**	Jun 08, 1998
AB		TEVA	**1GM**	**A070848**	**001**	Mar 29, 1996
AB		ZYDUS LIFESCIENCES	**1GM**	**A215705**	**001**	May 03, 2023
SUFENTANIL CITRATE						
INJECTABLE;INJECTION						
SUFENTA PRESERVATIVE FREE						
AP	**+!**	RISING	**EQ 0.05MG BASE/ML**	**N019050**	**001**	May 04, 1984
SUFENTANIL CITRATE						
AP		HIKMA	**EQ 0.05MG BASE/ML**	**A074413**	**001**	Dec 15, 1995
AP		HOSPIRA	**EQ 0.05MG BASE/ML**	**A074534**	**001**	Dec 11, 1996
TABLET;SUBLINGUAL						
DSUVIA						
	+!	VERTICAL PHARMS	EQ 0.03MG BASE	N209128	001	Nov 02, 2018

SUGAMMADEX SODIUM							
SOLUTION;INTRAVENOUS							
BRIDION							
AP	**+**	MSD SUB MERCK	**EQ 200MG BASE/2ML (EQ 100MG BASE/ML)**	**N022225**	**002**	Dec 15, 2015
AP	**+!**		**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N022225**	**001**	Dec 15, 2015
SUGAMMADEX SODIUM							
AP		ASPIRO	**EQ 200MG BASE/2ML (EQ 100MG BASE/ML)**	**A214337**	**001**	Jun 09, 2023
AP			**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**A214337**	**002**	Jun 09, 2023
AP		ZYDUS PHARMS	**EQ 200MG BASE/2ML (EQ 100MG BASE/ML)**	**A214290**	**001**	Oct 04, 2023
AP			**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**A214290**	**002**	Oct 04, 2023
SULCONAZOLE NITRATE							
CREAM;TOPICAL							
EXELDERM							
	+!	JOURNEY	1%	N018737	001	Feb 28, 1989
SOLUTION;TOPICAL							
EXELDERM							
	+!	JOURNEY	1%	N018738	001	Aug 30, 1985
SULFACETAMIDE SODIUM							
LOTION;TOPICAL							
KLARON							
AB	**+!**	BAUSCH	**10%**	**N019931**	**001**	Dec 23, 1996
SULFACETAMIDE SODIUM							
AB		FOUGERA PHARMS	**10%**	**A077015**	**001**	Nov 17, 2006
AB		PADAGIS US	**10%**	**A078649**	**001**	Mar 23, 2009
AB		TARO	**10%**	**A078668**	**001**	May 20, 2009
OINTMENT;OPHTHALMIC							
SULFACETAMIDE SODIUM							
	!	PADAGIS US	10%	A080029	001		
SOLUTION/DROPS;OPHTHALMIC							
SULFACETAMIDE SODIUM							
AT		BAUSCH AND LOMB	**10%**	**A040066**	**001**	Dec 28, 1994
AT		SANDOZ	**10%**	**A089560**	**001**	Oct 18, 1988
SULFADIAZINE							
TABLET;ORAL							
SULFADIAZINE							
	!	EPIC PHARMA LLC	500MG	A040091	001	Jul 29, 1994
SULFAMETHOXAZOLE; TRIMETHOPRIM							
INJECTABLE;INJECTION							
SULFAMETHOXAZOLE AND TRIMETHOPRIM							
AP	**!**	MYLAN LABS LTD	**80MG/ML;16MG/ML**	**A206607**	**001**	Aug 30, 2017
AP		SOMERSET	**80MG/ML;16MG/ML**	**A212231**	**001**	Jun 26, 2019
AP		TEVA PHARMS USA	**80MG/ML;16MG/ML**	**A073303**	**001**	Oct 31, 1991
SUSPENSION;ORAL							
SULFAMETHOXAZOLE AND TRIMETHOPRIM							
AB		AUROBINDO PHARMA	**200MG/5ML;40MG/5ML**	**A091348**	**001**	Jun 08, 2010
AB		CHARTWELL MOLECULAR	**200MG/5ML;40MG/5ML**	**A077785**	**001**	Jan 24, 2007
AB	**!**	HIKMA	**200MG/5ML;40MG/5ML**	**A074650**	**001**	Dec 29, 1997
AB		NOVITIUM PHARMA	**200MG/5ML;40MG/5ML**	**A214330**	**001**	Feb 08, 2022
AB		PRASCO	**200MG/5ML;40MG/5ML**	**A077612**	**001**	Nov 13, 2006
SULFATRIM PEDIATRIC							
AB		PHARM ASSOC	**200MG/5ML;40MG/5ML**	**N018615**	**001**	Jan 07, 1983
TABLET;ORAL							
BACTRIM							
AB	**+**	SUN PHARM INDUSTRIES	**400MG;80MG**	**N017377**	**001**	
BACTRIM DS							
AB	**+!**	SUN PHARM INDUSTRIES	**800MG;160MG**	**N017377**	**002**	
SEPTRA							
AB		MONARCH PHARMS	**400MG;80MG**	**N017376**	**001**	
SEPTRA DS							
AB		MONARCH PHARMS	**800MG;160MG**	**N017376**	**002**	
SULFAMETHOXAZOLE AND TRIMETHOPRIM							
AB		AMNEAL PHARMS NY	**400MG;80MG**	**A076899**	**001**	Jan 27, 2005
AB			**800MG;160MG**	**A076899**	**002**	Jan 27, 2005
AB		AUROBINDO PHARMA	**400MG;80MG**	**A090624**	**001**	Feb 16, 2010
AB			**800MG;160MG**	**A090624**	**002**	Feb 16, 2010
AB		CHARTWELL MOLECULES	**400MG;80MG**	**A078060**	**002**	Jan 25, 2007
AB			**800MG;160MG**	**A078060**	**001**	Jan 25, 2007
AB		GLENMARK GENERICS	**400MG;80MG**	**A090828**	**002**	Dec 22, 2010
AB			**800MG;160MG**	**A090828**	**001**	Dec 22, 2010

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	SUN PHARM INDUSTRIES	**400MG;80MG**	**A071017 002**	Aug 25, 1986
AB		**800MG;160MG**	**A071017 001**	Aug 25, 1986
AB	VISTA PHARMS	**400MG;80MG**	**A076817 001**	Oct 07, 2005
AB		**800MG;160MG**	**A076817 002**	Oct 07, 2005

SULFASALAZINE

TABLET;ORAL

AZULFIDINE

AB	**+!** PFIZER	**500MG**	**N007073 001**	

SULFASALAZINE

AB	CHARTWELL	**500MG**	**A080197 001**	
AB	NUVO PHARMS INC	**500MG**	**A040349 001**	Jan 11, 2002
AB	WATSON LABS	**500MG**	**A085828 001**	

TABLET, DELAYED RELEASE;ORAL

AZULFIDINE EN-TABS

AB	**+!** PFIZER	**500MG**	**N007073 002**	Apr 06, 1983

SULFASALAZINE

AB	NUVO PHARMS INC	**500MG**	**A075339 001**	Jan 11, 2002

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

FOR SUSPENSION;INTRAVENOUS

LUMASON

	+! BRACCO	60.7MG/25MG	N203684 001	Oct 15, 2014

SULINDAC

TABLET;ORAL

SULINDAC

AB	EPIC PHARMA	**150MG**	**A072710 001**	Mar 25, 1991
AB		**200MG**	**A072711 001**	Mar 25, 1991
AB	SUN PHARM INDUSTRIES	**150MG**	**A072050 001**	Apr 17, 1991
AB		**200MG**	**A072051 001**	Apr 17, 1991
AB	WATSON LABS	**150MG**	**A071891 001**	Apr 03, 1990
AB	**!**	**200MG**	**A071795 001**	Apr 03, 1990

SUMATRIPTAN

SPRAY;NASAL

IMITREX

AB	**+!** GLAXOSMITHKLINE	**5MG/SPRAY**	**N020626 001**	Aug 26, 1997
AB	**+!**	**20MG/SPRAY**	**N020626 003**	Aug 26, 1997

SUMATRIPTAN

AB	CIPLA	**20MG/SPRAY**	**A214209 001**	Feb 22, 2021
AB	FLORIDA	**20MG/SPRAY**	**A208967 001**	Feb 17, 2021
AB	LANNETT CO INC	**5MG/SPRAY**	**A204841 001**	Feb 19, 2016
AB		**20MG/SPRAY**	**A204841 002**	Feb 19, 2016
AB	PADAGIS ISRAEL	**5MG/SPRAY**	**A213465 002**	Sep 21, 2020
AB		**20MG/SPRAY**	**A213465 001**	Sep 21, 2020

TOSYMRA

+!	TONIX MEDS	10MG/SPRAY	N210884 001	Jan 25, 2019

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

IMITREX STATDOSE

AB	**+!** GLAXOSMITHKLINE	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**N020080 003**	Dec 23, 1996

SUMATRIPTAN SUCCINATE

AB	DR REDDYS	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090495 001**	Jan 29, 2014
AB	SUN PHARM	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090358 001**	Jun 21, 2011

IMITREX

AP	**+!** GLAXOSMITHKLINE	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**N020080 001**	Dec 28, 1992

SUMATRIPTAN SUCCINATE

AP	EUGIA PHARMA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A202758 001**	Apr 23, 2013
AP	FRESENIUS KABI USA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A079242 001**	Mar 02, 2009
AP	HIKMA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A200183 001**	Sep 16, 2013
AP	PAR PHARM	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A077332 001**	Oct 09, 2009
AP	SOMERSET	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A213998 001**	Jul 13, 2021
AP	WEST-WARD PHARMS INT	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A079123 001**	Feb 06, 2009
AP	WOCKHARDT	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A078593 001**	Feb 06, 2009

IMITREX STATDOSE

	+! GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080 002	Feb 01, 2006

SUMATRIPTAN SUCCINATE

POWDER;NASAL

ONZETRA XSAIL

	+!	CURRAX	EQ 11MG BASE	N206099	001	Jan 27, 2016

SOLUTION;SUBCUTANEOUS

ZEMBRACE SYMTOUCH

	+	TONIX MEDS	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016

TABLET;ORAL

IMITREX

AB	**+**	GLAXOSMITHKLINE	**EQ 25MG BASE**	**N020132**	**002**	Jun 01, 1995
AB	**+**		**EQ 50MG BASE**	**N020132**	**003**	Jun 01, 1995
AB	**+!**		**EQ 100MG BASE**	**N020132**	**001**	Jun 01, 1995

SUMATRIPTAN SUCCINATE

AB		AUROBINDO PHARMA	**EQ 25MG BASE**	**A078327**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078327**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078327**	**003**	Aug 10, 2009
AB		COREPHARMA	**EQ 25MG BASE**	**A200263**	**001**	Jun 19, 2012
AB			**EQ 50MG BASE**	**A200263**	**002**	Jun 19, 2012
AB			**EQ 100MG BASE**	**A200263**	**003**	Jun 19, 2012
AB		DR REDDYS LABS INC	**EQ 25MG BASE**	**A076847**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A076847**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A076847**	**003**	Aug 10, 2009
AB		MYLAN	**EQ 25MG BASE**	**A077744**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A077744**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A077744**	**003**	Aug 10, 2009
AB		ORBION PHARMS	**EQ 25MG BASE**	**A078284**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078284**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078284**	**003**	Aug 10, 2009
AB		SUN PHARM INDS	**EQ 25MG BASE**	**A078295**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078295**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078295**	**003**	Aug 10, 2009
AB		WATSON LABS	**EQ 25MG BASE**	**A076933**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A076933**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A076933**	**003**	Aug 10, 2009

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB		DR REDDYS	**EQ 12.5MG BASE**	**A215843**	**001**	Apr 11, 2022
AB			**EQ 25MG BASE**	**A215843**	**002**	Apr 11, 2022
AB			**EQ 37.5MG BASE**	**A215843**	**003**	Apr 11, 2022
AB			**EQ 50MG BASE**	**A215843**	**004**	Apr 11, 2022
AB		MYLAN	**EQ 12.5MG BASE**	**A201275**	**001**	Dec 06, 2021
AB			**EQ 25MG BASE**	**A201275**	**002**	Dec 06, 2021
AB			**EQ 37.5MG BASE**	**A201275**	**003**	Dec 06, 2021
AB			**EQ 50MG BASE**	**A201275**	**004**	Dec 06, 2021
AB		NATCO PHARMA	**EQ 12.5MG BASE**	**A218024**	**001**	Oct 24, 2023
AB			**EQ 25MG BASE**	**A218024**	**002**	Oct 24, 2023
AB			**EQ 37.5MG BASE**	**A218024**	**003**	Oct 24, 2023
AB			**EQ 50MG BASE**	**A218024**	**004**	Oct 24, 2023
AB		NOVUGEN	**EQ 12.5MG BASE**	**A218012**	**001**	Aug 21, 2023
AB			**EQ 25MG BASE**	**A218012**	**002**	Aug 21, 2023
AB			**EQ 37.5MG BASE**	**A218012**	**003**	Aug 21, 2023
AB			**EQ 50MG BASE**	**A218012**	**004**	Aug 21, 2023
AB		SUN PHARM	**EQ 12.5MG BASE**	**A213914**	**001**	Aug 16, 2021
AB			**EQ 25MG BASE**	**A213914**	**002**	Aug 16, 2021
AB			**EQ 37.5MG BASE**	**A213914**	**003**	Aug 16, 2021
AB			**EQ 50MG BASE**	**A213914**	**004**	Aug 16, 2021
AB		TEVA PHARMS USA	**EQ 12.5MG BASE**	**A213803**	**001**	Nov 30, 2021
AB			**EQ 25MG BASE**	**A213803**	**002**	Nov 30, 2021
AB			**EQ 37.5MG BASE**	**A213803**	**003**	Nov 30, 2021
AB			**EQ 50MG BASE**	**A213803**	**004**	Nov 30, 2021

SUTENT

AB	**+**	CPPI CV	**EQ 12.5MG BASE**	**N021938**	**001**	Jan 26, 2006
AB	**+**		**EQ 25MG BASE**	**N021938**	**002**	Jan 26, 2006
AB	**+**		**EQ 37.5MG BASE**	**N021938**	**004**	Mar 31, 2009
AB	**+!**		**EQ 50MG BASE**	**N021938**	**003**	Jan 26, 2006

SUVOREXANT

TABLET;ORAL

BELSOMRA

	+	MERCK SHARP DOHME	5MG	N204569	001	Aug 13, 2014
	+		10MG	N204569	002	Aug 13, 2014
	+		15MG	N204569	003	Aug 13, 2014
	+!		20MG	N204569	004	Aug 13, 2014

TACROLIMUS

CAPSULE;ORAL

PROGRAF

AB	**+**	ASTELLAS	**EQ 0.5MG BASE**	**N050708**	**003**	Aug 24, 1998
AB	**+**		**EQ 1MG BASE**	**N050708**	**001**	Apr 08, 1994
AB	**+!**		**EQ 5MG BASE**	**N050708**	**002**	Apr 08, 1994

TACROLIMUS

AB		ALKEM LABS LTD	**EQ 0.5MG BASE**	**A203740**	**001**	Nov 12, 2020
AB			**EQ 1MG BASE**	**A203740**	**002**	Nov 12, 2020
AB			**EQ 5MG BASE**	**A203740**	**003**	Nov 12, 2020
AB		BELCHER	**EQ 0.5MG BASE**	**A206651**	**001**	Nov 30, 2017
AB			**EQ 1MG BASE**	**A206651**	**002**	Nov 30, 2017
AB			**EQ 5MG BASE**	**A206651**	**003**	Nov 30, 2017
AB		BIOCON PHARMA	**EQ 0.5MG BASE**	**A212297**	**001**	Nov 10, 2020
AB			**EQ 1MG BASE**	**A212297**	**002**	Nov 10, 2020
AB			**EQ 5MG BASE**	**A212297**	**003**	Nov 10, 2020
AB		CONCORD BIOTECH LTD	**EQ 1MG BASE**	**A213112**	**002**	Nov 10, 2020
AB			**EQ 5MG BASE**	**A213112**	**003**	Nov 10, 2020
AB		DR REDDYS LABS LTD	**EQ 0.5MG BASE**	**A090509**	**001**	May 12, 2010
AB			**EQ 1MG BASE**	**A090509**	**002**	May 12, 2010
AB			**EQ 5MG BASE**	**A090509**	**003**	May 12, 2010
AB		GLENMARK PHARMS LTD	**EQ 0.5MG BASE**	**A206662**	**001**	Nov 10, 2020
AB			**EQ 1MG BASE**	**A206662**	**002**	Nov 10, 2020
AB			**EQ 5MG BASE**	**A206662**	**003**	Nov 10, 2020
AB		HANGZHOU ZHONGMEI	**EQ 0.5MG BASE**	**A210929**	**001**	Apr 17, 2023
AB			**EQ 1MG BASE**	**A210929**	**002**	Apr 17, 2023
AB			**EQ 5MG BASE**	**A210929**	**003**	Apr 17, 2023
AB		MYLAN	**EQ 0.5MG BASE**	**A090596**	**001**	Sep 17, 2010
AB			**EQ 1MG BASE**	**A090596**	**002**	Sep 17, 2010
AB			**EQ 5MG BASE**	**A090596**	**003**	Sep 17, 2010
AB		PANACEA	**EQ 0.5MG BASE**	**A090802**	**001**	Sep 28, 2012
AB			**EQ 1MG BASE**	**A090802**	**002**	Sep 28, 2012
AB			**EQ 5MG BASE**	**A090802**	**003**	Sep 28, 2012
AB		SANDOZ	**EQ 0.5MG BASE**	**A065461**	**001**	Aug 10, 2009
AB			**EQ 1MG BASE**	**A065461**	**002**	Aug 10, 2009
AB			**EQ 5MG BASE**	**A065461**	**003**	Aug 10, 2009
AB		STRIDES PHARMA	**EQ 0.5MG BASE**	**A090687**	**001**	Jul 22, 2014
AB			**EQ 1MG BASE**	**A090687**	**002**	Jul 22, 2014
AB			**EQ 5MG BASE**	**A090687**	**003**	Jul 22, 2014
BX		ACCORD HLTHCARE	EQ 0.5MG BASE	A091195	001	Aug 31, 2011
BX			EQ 1MG BASE	A091195	002	Aug 31, 2011
BX			EQ 5MG BASE	A091195	003	Aug 31, 2011

CAPSULE, EXTENDED RELEASE;ORAL

ASTAGRAF XL

	+	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013
	+		EQ 1MG BASE	N204096	002	Jul 19, 2013
	+!		EQ 5MG BASE	N204096	003	Jul 19, 2013

FOR SUSPENSION;ORAL

PROGRAF

	+	ASTELLAS	EQ 0.2MG BASE/PACKET	N210115	001	May 24, 2018
	+!		EQ 1MG BASE/PACKET	N210115	002	May 24, 2018

INJECTABLE;INJECTION

PROGRAF

	+!	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994

OINTMENT;TOPICAL

PROTOPIC

AB	**+!**	LEO PHARMA AS	**0.03%**	**N050777**	**001**	Dec 08, 2000
AB	**+!**		**0.1%**	**N050777**	**002**	Dec 08, 2000

TACROLIMUS

AB		ACCORD HLTHCARE	**0.03%**	**A211688**	**001**	Jan 31, 2019
AB			**0.1%**	**A211688**	**002**	Jan 31, 2019
AB		ENCUBE	**0.1%**	**A212387**	**001**	Oct 10, 2023
AB		FOUGERA PHARMS INC	**0.03%**	**A200744**	**001**	Sep 09, 2014
AB			**0.1%**	**A200744**	**002**	Sep 09, 2014
AB		GLENMARK PHARMS LTD	**0.03%**	**A210393**	**002**	Aug 16, 2023

TACROLIMUS						
OINTMENT;TOPICAL						
TACROLIMUS						
AB			**0.1%**	**A210393**	**001**	Apr 16, 2018
TABLET, EXTENDED RELEASE;ORAL						
ENVARSUS XR						
+	VELOXIS PHARMS INC		EQ 0.75MG BASE	N206406	001	Jul 10, 2015
+			EQ 1MG BASE	N206406	002	Jul 10, 2015
+!			EQ 4MG BASE	N206406	003	Jul 10, 2015
TADALAFIL						
SUSPENSION;ORAL						
TADLIQ						
+!	CMP DEV LLC		20MG/5ML	N214522	001	Jun 17, 2022
TABLET;ORAL						
CIALIS						
AB1	**+**	LILLY	**2.5MG**	**N021368**	**004**	Jan 07, 2008
AB1	**+**		**5MG**	**N021368**	**001**	Nov 21, 2003
AB1	**+**		**10MG**	**N021368**	**002**	Nov 21, 2003
AB1	**+!**		**20MG**	**N021368**	**003**	Nov 21, 2003
TADALAFIL						
AB1		ACCORD HLTHCARE	**2.5MG**	**A209167**	**001**	Mar 26, 2019
AB1			**5MG**	**A209167**	**002**	Mar 26, 2019
AB1			**10MG**	**A209167**	**003**	Oct 23, 2019
AB1			**20MG**	**A209167**	**004**	Mar 26, 2019
AB1		AJANTA PHARMA LTD	**2.5MG**	**A209654**	**001**	Mar 26, 2019
AB1			**5MG**	**A209654**	**002**	Mar 26, 2019
AB1			**10MG**	**A209654**	**003**	Mar 26, 2019
AB1			**20MG**	**A209654**	**004**	Mar 26, 2019
AB1		ALEMBIC	**2.5MG**	**A204809**	**001**	Mar 26, 2019
AB1			**5MG**	**A204809**	**002**	Mar 26, 2019
AB1			**10MG**	**A204809**	**003**	Mar 26, 2019
AB1			**20MG**	**A204809**	**004**	Mar 26, 2019
AB1		AMNEAL PHARMS CO	**2.5MG**	**A209744**	**001**	Mar 26, 2019
AB1			**5MG**	**A209744**	**002**	Mar 26, 2019
AB1			**10MG**	**A209744**	**003**	Mar 26, 2019
AB1			**20MG**	**A209744**	**004**	Mar 26, 2019
AB1		AUROBINDO PHARMA LTD	**2.5MG**	**A206285**	**001**	Mar 26, 2019
AB1			**5MG**	**A206285**	**002**	Mar 26, 2019
AB1			**10MG**	**A206285**	**003**	Mar 26, 2019
AB1			**20MG**	**A206285**	**004**	Mar 26, 2019
AB1		AUSTARPHARMA	**2.5MG**	**A208824**	**001**	Oct 27, 2020
AB1			**5MG**	**A208824**	**002**	Oct 27, 2020
AB1			**10MG**	**A208824**	**003**	Oct 27, 2020
AB1			**20MG**	**A208824**	**004**	Oct 27, 2020
AB1		CIPLA	**2.5MG**	**A209539**	**001**	Mar 26, 2019
AB1			**5MG**	**A209539**	**002**	Mar 26, 2019
AB1			**10MG**	**A209539**	**003**	Mar 26, 2019
AB1			**20MG**	**A209539**	**004**	Mar 26, 2019
AB1		DR REDDYS	**2.5MG**	**A210069**	**001**	Mar 26, 2019
AB1			**5MG**	**A210069**	**002**	Mar 26, 2019
AB1			**10MG**	**A210069**	**003**	Mar 26, 2019
AB1			**20MG**	**A210069**	**004**	Mar 26, 2019
AB1		HETERO LABS LTD III	**2.5MG**	**A209908**	**001**	Mar 26, 2019
AB1			**5MG**	**A209908**	**002**	Mar 26, 2019
AB1			**10MG**	**A209908**	**003**	Mar 26, 2019
AB1			**20MG**	**A209908**	**004**	Mar 26, 2019
AB1		LUPIN LTD	**2.5MG**	**A210567**	**001**	Mar 26, 2019
AB1			**5MG**	**A210567**	**002**	Mar 26, 2019
AB1			**10MG**	**A210567**	**003**	Mar 26, 2019
AB1			**20MG**	**A210567**	**004**	Mar 26, 2019
AB1		MACLEODS PHARMS LTD	**2.5MG**	**A207244**	**001**	Oct 07, 2019
AB1			**5MG**	**A207244**	**002**	Oct 07, 2019
AB1			**10MG**	**A207244**	**003**	Oct 07, 2019
AB1			**20MG**	**A207244**	**004**	Oct 07, 2019
AB1		NOVITIUM PHARMA	**5MG**	**A215949**	**001**	Mar 03, 2023
AB1			**10MG**	**A215949**	**002**	Mar 03, 2023
AB1			**20MG**	**A215949**	**003**	Mar 03, 2023
AB1		PRINSTON INC	**2.5MG**	**A210609**	**001**	Aug 11, 2022
AB1			**5MG**	**A210609**	**002**	Aug 11, 2022
AB1			**10MG**	**A210609**	**003**	Aug 11, 2022
AB1			**20MG**	**A210609**	**004**	Aug 11, 2022

TADALAFIL

TABLET;ORAL

TADALAFIL

AB1	QILU PHARM HAINAN	**2.5MG**	**A210420**	**001**	Mar 26, 2019
AB1		**5MG**	**A210420**	**002**	Mar 26, 2019
AB1		**10MG**	**A210420**	**003**	Mar 26, 2019
AB1		**20MG**	**A210420**	**004**	Mar 26, 2019
AB1	SUN PHARM	**2.5MG**	**A208934**	**001**	Mar 26, 2019
AB1		**5MG**	**A208934**	**002**	Mar 26, 2019
AB1		**10MG**	**A208934**	**003**	Mar 26, 2019
AB1		**20MG**	**A208934**	**004**	Mar 26, 2019
AB1	SUNSHINE	**2.5MG**	**A211335**	**001**	Mar 26, 2019
AB1		**5MG**	**A211335**	**002**	Mar 26, 2019
AB1		**10MG**	**A211335**	**003**	Mar 26, 2019
AB1		**20MG**	**A211335**	**004**	Mar 26, 2019
AB1	TEVA PHARMS USA	**2.5MG**	**A090141**	**001**	May 22, 2018
AB1		**5MG**	**A090141**	**002**	May 22, 2018
AB1		**10MG**	**A090141**	**003**	May 22, 2018
AB1		**20MG**	**A090141**	**004**	May 22, 2018
AB1	TORRENT	**2.5MG**	**A211839**	**001**	Mar 26, 2019
AB1		**5MG**	**A211839**	**002**	Mar 26, 2019
AB1		**10MG**	**A211839**	**003**	Mar 26, 2019
AB1		**20MG**	**A211839**	**004**	Mar 26, 2019
AB1	UMEDICA	**2.5MG**	**A211298**	**001**	Oct 23, 2020
AB1		**5MG**	**A211298**	**002**	Oct 23, 2020
AB1		**10MG**	**A211298**	**003**	Oct 23, 2020
AB1		**20MG**	**A211298**	**004**	Oct 23, 2020
AB1	UNICHEM	**2.5MG**	**A209250**	**001**	Mar 26, 2019
AB1		**5MG**	**A209250**	**002**	Mar 26, 2019
AB1		**10MG**	**A209250**	**003**	Mar 26, 2019
AB1		**20MG**	**A209250**	**004**	Mar 26, 2019
AB1	VKT PHARMA	**2.5MG**	**A215556**	**001**	Nov 04, 2021
AB1		**5MG**	**A215556**	**002**	Nov 04, 2021
AB1		**10MG**	**A215556**	**003**	Nov 04, 2021
AB1		**20MG**	**A215556**	**004**	Nov 04, 2021
AB1	WATSON LABS INC	**2.5MG**	**A205885**	**001**	Mar 29, 2019
AB1		**5MG**	**A205885**	**002**	Mar 29, 2019
AB1		**10MG**	**A205885**	**003**	Mar 29, 2019
AB1		**20MG**	**A205885**	**004**	Mar 29, 2019
AB1	ZYDUS PHARMS	**2.5MG**	**A206693**	**001**	Mar 26, 2019
AB1		**5MG**	**A206693**	**002**	Mar 26, 2019
AB1		**10MG**	**A206693**	**003**	Mar 26, 2019
AB1		**20MG**	**A206693**	**004**	Mar 26, 2019

ADCIRCA

AB2	**+!** ELI LILLY CO	**20MG**	**N022332**	**001**	May 22, 2009

ALYQ

AB2	TEVA PHARMS INC	**20MG**	**A216932**	**001**	Oct 12, 2022
AB2	TEVA PHARMS USA	**20MG**	**A209942**	**001**	Feb 05, 2019

TADALAFIL

AB2	AJANTA PHARMA LTD	**20MG**	**A210392**	**001**	Feb 05, 2019
AB2	AUROBINDO PHARMA LTD	**20MG**	**A206286**	**001**	Feb 05, 2019
AB2	CHARTWELL RX	**20MG**	**A210572**	**001**	Feb 05, 2019
AB2	CIPLA	**20MG**	**A210255**	**001**	Feb 05, 2019
AB2	DR REDDYS	**20MG**	**A210145**	**001**	Feb 05, 2019
AB2	HETERO LABS LTD III	**20MG**	**A209907**	**001**	Feb 05, 2019
AB2	MACLEODS PHARMS LTD	**20MG**	**A207290**	**001**	Oct 16, 2019
AB2	PRINSTON INC	**20MG**	**A210608**	**001**	Aug 11, 2022
AB2	SUNSHINE	**20MG**	**A213496**	**001**	Nov 23, 2020
AB2	TORRENT	**20MG**	**A212062**	**001**	Mar 26, 2019

TAFAMIDIS

CAPSULE;ORAL

VYNDAMAX

+!	FOLDRX PHARMS	61MG	N212161	001	May 03, 2019

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL

VYNDAQEL

+!	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019

TAFENOQUINE SUCCINATE

TABLET;ORAL

ARAKODA

	+!	60 DEGREES PHARMS	EQ 100MG BASE	N210607	001	Aug 08, 2018

KRINTAFEL

	+!	GLAXOSMITHKLINE	EQ 150MG BASE	N210795	001	Jul 20, 2018

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

TAFLUPROST

AT		MICRO LABS	**0.0015%**	**A209051**	**001**	Aug 19, 2019
AT		SANDOZ	**0.0015%**	**A209040**	**001**	Jan 28, 2022

ZIOPTAN

AT	**+!**	THEA PHARMA	**0.0015%**	**N202514**	**001**	Feb 10, 2012

TALAZOPARIB TOSYLATE

CAPSULE;ORAL

TALZENNA

	+	PFIZER	EQ 0.1MG BASE	N211651	005	Jun 20, 2023
	+		EQ 0.25MG BASE	N211651	001	Oct 16, 2018
	+		EQ 0.35MG BASE	N211651	006	Jun 20, 2023
	+		EQ 0.5MG BASE	N211651	003	Sep 20, 2021
	+		EQ 0.75MG BASE	N211651	004	Sep 20, 2021
	+!		EQ 1MG BASE	N211651	002	Oct 16, 2018

TALC

AEROSOL;INTRAPLEURAL

SCLEROSOL

	+!	SCIARRA LABS	4GM/SPRAY	N020587	001	Dec 24, 1997

POWDER;INTRAPLEURAL

STERITALC

	+	NOVATECH SA	2GM/VIAL	N205555	001	May 01, 2017
	+		3GM/VIAL	N205555	002	May 01, 2017
	+!		4GM/VIAL	N205555	003	May 01, 2017

TALC

	+!	SCIARRA LABS	5GM/BOT	N021388	001	Dec 15, 2003

TAMOXIFEN CITRATE

SOLUTION;ORAL

SOLTAMOX

	+!	MAYNE PHARMA COMMRCL	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005

TABLET;ORAL

TAMOXIFEN CITRATE

AB		ACTAVIS LABS FL INC	**EQ 10MG BASE**	**A070929**	**001**	Feb 20, 2003
AB			**EQ 20MG BASE**	**A070929**	**002**	Feb 20, 2003
AB		APOTEX	**EQ 10MG BASE**	**A090878**	**001**	Sep 23, 2011
AB			**EQ 20MG BASE**	**A090878**	**002**	Sep 23, 2011
AB		DR REDDYS LABS SA	**EQ 10MG BASE**	**A075797**	**001**	Feb 20, 2003
AB	**!**		**EQ 20MG BASE**	**A075797**	**002**	Feb 20, 2003
AB		EUGIA PHARMA	**EQ 10MG BASE**	**A213358**	**001**	Aug 14, 2020
AB			**EQ 20MG BASE**	**A213358**	**002**	Aug 14, 2020
AB		MYLAN	**EQ 10MG BASE**	**A074732**	**002**	Feb 20, 2003
AB			**EQ 20MG BASE**	**A074732**	**001**	Feb 20, 2003
AB		ZYDUS PHARMS	**EQ 10MG BASE**	**A206694**	**001**	Oct 27, 2017
AB			**EQ 20MG BASE**	**A206694**	**002**	Oct 27, 2017

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

FLOMAX

AB	**+!**	SANOFI	**0.4MG**	**N020579**	**001**	Apr 15, 1997

TAMSULOSIN HYDROCHLORIDE

AB		ALKEM LABS LTD	**0.4MG**	**A207405**	**001**	Aug 11, 2017
AB		AUROBINDO PHARMA LTD	**0.4MG**	**A202433**	**001**	Apr 30, 2013
AB		CHARTWELL RX	**0.4MG**	**A211885**	**001**	Oct 17, 2019
AB		IMPAX LABS	**0.4MG**	**A090377**	**001**	Mar 02, 2010
AB		MACLEODS PHARMS LTD	**0.4MG**	**A204645**	**001**	Jan 20, 2017
AB		SANDOZ	**0.4MG**	**A078015**	**001**	Apr 27, 2010
AB		SUN PHARM INDS LTD	**0.4MG**	**A090931**	**001**	Jul 15, 2010
AB		SYNTHON PHARMS	**0.4MG**	**A078801**	**001**	Apr 27, 2010
AB		TEVA PHARMS	**0.4MG**	**A077630**	**001**	Apr 27, 2010
AB		WOCKHARDT	**0.4MG**	**A078938**	**001**	Apr 27, 2010
AB		ZYDUS PHARMS USA INC	**0.4MG**	**A078225**	**001**	Apr 27, 2010

TAPENTADOL HYDROCHLORIDE

TABLET;ORAL

NUCYNTA

+	COLLEGIUM PHARM INC	EQ 50MG BASE	N022304	001	Nov 20, 2008
+		EQ 75MG BASE	N022304	002	Nov 20, 2008
+!		EQ 100MG BASE	N022304	003	Nov 20, 2008

TABLET, EXTENDED RELEASE;ORAL

NUCYNTA ER

+	COLLEGIUM PHARM INC	EQ 50MG BASE	N200533	001	Aug 25, 2011
+		EQ 100MG BASE	N200533	002	Aug 25, 2011
+		EQ 150MG BASE	N200533	003	Aug 25, 2011
+		EQ 200MG BASE	N200533	004	Aug 25, 2011
+!		EQ 250MG BASE	N200533	005	Aug 25, 2011

TAPINAROF

CREAM;TOPICAL

VTAMA

+!	DERMAVANT SCI	1%	N215272	001	May 23, 2022

TASIMELTEON

CAPSULE;ORAL

HETLIOZ

AB	**+!**	VANDA PHARMS INC	**20MG**	**N205677**	**001**	Jan 31, 2014

TASIMELTEON

AB		APOTEX	**20MG**	**A211607**	**001**	Dec 20, 2022
AB		MSN	**20MG**	**A211654**	**001**	Jan 12, 2023
AB		TEVA PHARMS USA INC	**20MG**	**A211601**	**001**	Dec 12, 2022

SUSPENSION;ORAL

HETLIOZ LQ

+!	VANDA PHARMS INC	4MG/ML	N214517	001	Dec 01, 2020

TAVABOROLE

SOLUTION;TOPICAL

KERYDIN

AB	**+!**	ANACOR PHARMS INC	**5%**	**N204427**	**001**	Jul 07, 2014

TAVABOROLE

AB		ALEMBIC	**5%**	**A212188**	**001**	Oct 21, 2020
AB		AMNEAL	**5%**	**A212256**	**001**	Nov 25, 2020
AB		CHARTWELL RX	**5%**	**A211963**	**001**	Feb 03, 2021
AB		CIPLA	**5%**	**A212224**	**001**	Feb 09, 2021
AB		ENCUBE	**5%**	**A211297**	**001**	Oct 13, 2020
AB		LUPIN LTD	**5%**	**A212168**	**001**	Feb 08, 2021
AB		PADAGIS US	**5%**	**A211848**	**001**	Oct 13, 2020
AB		TARO	**5%**	**A212215**	**001**	May 07, 2021
AB		ZYDUS LIFESCIENCES	**5%**	**A212294**	**001**	Apr 10, 2023

TAZAROTENE

AEROSOL, FOAM;TOPICAL

FABIOR

+!	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012

CREAM;TOPICAL

AVAGE

AB	**+!**	ALLERGAN	**0.1%**	**N021184**	**003**	Sep 30, 2002

TAZAROTENE

AB		COSETTE	**0.1%**	**A208662**	**001**	Dec 22, 2017
AB		TARO	**0.1%**	**A208258**	**001**	Apr 03, 2017

TAZORAC

AB	**+!**	ALLERGAN	**0.1%**	**N021184**	**002**	Sep 29, 2000
	+!		0.05%	N021184	001	Sep 29, 2000

GEL;TOPICAL

TAZAROTENE

AB		COSETTE	**0.05%**	**A215433**	**001**	Sep 13, 2022
AB			**0.1%**	**A214136**	**001**	Sep 13, 2022
AB		PADAGIS ISRAEL	**0.05%**	**A213079**	**001**	Apr 25, 2023
AB			**0.1%**	**A213079**	**002**	Apr 25, 2023
AB		SOLARIS PHARMA CORP	**0.05%**	**A213644**	**001**	Mar 20, 2023
AB			**0.1%**	**A213644**	**002**	Mar 20, 2023

TAZORAC

AB	**+!**	ALLERGAN	**0.05%**	**N020600**	**001**	Jun 13, 1997
AB	**+!**		**0.1%**	**N020600**	**002**	Jun 13, 1997

LOTION;TOPICAL

ARAZLO

+!	BAUSCH	0.045%	N211882	001	Dec 18, 2019

TAZEMETOSTAT HYDROBROMIDE
TABLET;ORAL
TAZVERIK
+! EPIZYME INC EQ 200MG BASE N211723 001 Jan 23, 2020

TECHNETIUM TC-99M BICISATE KIT
INJECTABLE;INJECTION
NEUROLITE
+! LANTHEUS MEDCL N/A N020256 001 Nov 23, 1994

TECHNETIUM TC-99M EXAMETAZIME KIT
INJECTABLE;INJECTION
CERETEC
+! GE HEALTHCARE N/A N019829 001 Dec 30, 1988
POWDER;INTRAVENOUS
DRAX EXAMETAZIME
JUBILANT N/A N208870 001 Aug 17, 2017

TECHNETIUM TC-99M LABELED CARBON
AEROSOL;INHALATION
TECHNEGAS KIT
+! CYCLOMEDICA N/A N022335 001 Sep 29, 2023

TECHNETIUM TC-99M MEBROFENIN KIT
INJECTABLE;INJECTION
CHOLETEC
AP **+!** BRACCO **N/A** **N018963 001** Jan 21, 1987
TECHNETIUM TC-99M MEBROFENIN
AP SUN PHARM INDS INC **N/A** **A078242 001** Jan 29, 2008

TECHNETIUM TC-99M MEDRONATE
INJECTABLE;INJECTION
DRAXIMAGE MDP-25
+! JUBILANT N/A N018035 002 Feb 27, 2004

TECHNETIUM TC-99M MEDRONATE KIT
INJECTABLE;INJECTION
CIS-MDP
AP SUN PHARM INDS INC **N/A** **N018124 001**
TECHNETIUM TC-99M MEDRONATE KIT
AP CARDINAL HEALTH 414 **N/A** **N018107 001**

TECHNETIUM TC-99M MERTIATIDE KIT
INJECTABLE;INJECTION
TECHNESCAN MAG3
AP **+!** CURIUM **N/A** **N019882 001** Jun 15, 1990
TECHNETIUM TC99M MERTIATIDE KIT
AP MEDI-RADIOPHARMA **N/A** **A206489 001** Feb 06, 2020
AP SUN PHARM INDS INC **N/A** **A208994 001** Jul 12, 2019
POWDER;INTRAVENOUS
TECHNETIUM TC 99M MERTIATIDE KIT
+! JUBILANT DRAXIMAGE N/A N216820 001 Jan 30, 2023

TECHNETIUM TC-99M OXIDRONATE KIT
INJECTABLE;INJECTION
TECHNESCAN
+! CURIUM N/A N018321 001

TECHNETIUM TC-99M PENTETATE KIT
INJECTABLE;INJECTION
DRAXIMAGE DTPA
+! JUBILANT N/A N018511 001 Dec 29, 1989

TECHNETIUM TC-99M PYROPHOSPHATE KIT
INJECTABLE;INJECTION
CIS-PYRO
AP SUN PHARM INDS INC **N/A** **N019039 001** Jun 30, 1987
TECHNESCAN PYP KIT
AP CURIUM **N/A** **N017538 001**

TECHNETIUM TC-99M RED BLOOD CELL KIT
INJECTABLE;INJECTION
ULTRATAG
+! CURIUM N/A N019981 001 Jun 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT							
INJECTABLE;INJECTION							
CARDIOLITE							
AP	**+!**	LANTHEUS MEDCL	**N/A**	**N019785**	**001**	Dec 21, 1990
TECHNETIUM TC 99M SESTAMIBI							
AP		CARDINAL HEALTH 414	**N/A**	**A078809**	**001**	Apr 28, 2009
AP		CURIUM	**N/A**	**A078098**	**001**	Sep 22, 2008
AP		JUBILANT DRAXIMAGE	**N/A**	**A078806**	**001**	Apr 29, 2009
AP		SUN PHARM INDS INC	**10-30mCi**	**A079157**	**001**	Jul 10, 2009
TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR							
SOLUTION;INTRAVENOUS							
TECHNELITE							
	+!	LANTHEUS MEDCL	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014
ULTRA-TECHNEKOW FM							
	+!	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014
TECHNETIUM TC-99M SUCCIMER							
POWDER;INTRAVENOUS							
NEPHROSCAN							
	+!	THERAGNOSTICS	N/A	N214993	001	Feb 18, 2022
TECHNETIUM TC-99M SULFUR COLLOID KIT							
SOLUTION;INJECTION, ORAL							
AN-SULFUR COLLOID							
AP	**+!**	SUN PHARM INDS INC	**N/A**	**N017858**	**001**	
TECHNETIUM TC-99M SULFUR COLLOID KIT							
AP		JUBILANT	**N/A**	**A213516**	**001**	Nov 09, 2023
TECHNETIUM TC-99M TETROFOSMIN KIT							
INJECTABLE;INJECTION							
MYOVIEW							
	+!	GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996
MYOVIEW 30ML							
	+!	GE HEALTHCARE	N/A	N020372	002	Jul 07, 2005
TECHNETIUM TC-99M TILMANOCEPT							
INJECTABLE;INJECTION							
LYMPHOSEEK KIT							
	+!	CARDINAL HEALTH 414	N/A	N202207	001	Mar 13, 2013
TECOVIRIMAT							
CAPSULE;ORAL							
TPOXX							
	+!	SIGA TECHNOLOGIES	200MG	N208627	001	Jul 13, 2018
SOLUTION;INTRAVENOUS							
TPOXX							
	+!	SIGA TECHNOLOGIES	200MG/20ML (10MG/ML)	N214518	001	May 18, 2022
TEDIZOLID PHOSPHATE							
POWDER;INTRAVENOUS							
SIVEXTRO							
	+!	CUBIST PHARMS LLC	200MG/VIAL	N205436	001	Jun 20, 2014
TABLET;ORAL							
SIVEXTRO							
	+!	CUBIST PHARMS LLC	200MG	N205435	001	Jun 20, 2014
TEDUGLUTIDE RECOMBINANT							
POWDER;SUBCUTANEOUS							
GATTEX KIT							
	+!	TAKEDA PHARMS USA	5MG/VIAL	N203441	001	Dec 21, 2012
TELAVANCIN HYDROCHLORIDE							
POWDER;INTRAVENOUS							
VIBATIV							
	+!	CUMBERLAND	EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009
TELMISARTAN							
TABLET;ORAL							
MICARDIS							
AB	**+**	BOEHRINGER INGELHEIM	**20MG**	**N020850**	**003**	Apr 04, 2000
AB	**+**		**40MG**	**N020850**	**001**	Nov 10, 1998
AB	**+!**		**80MG**	**N020850**	**002**	Nov 10, 1998
TELMISARTAN							
AB		ALEMBIC	**20MG**	**A202130**	**001**	Jul 07, 2014
AB			**40MG**	**A202130**	**002**	Jul 07, 2014
AB			**80MG**	**A202130**	**003**	Jul 07, 2014

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB	AMNEAL PHARMS	**20MG**	**A204415**	**001**	Sep 08, 2015
AB		**40MG**	**A204415**	**002**	Sep 08, 2015
AB		**80MG**	**A204415**	**003**	Sep 08, 2015
AB	AUROBINDO PHARMA	**20MG**	**A206511**	**001**	Sep 03, 2015
AB		**40MG**	**A206511**	**002**	Sep 03, 2015
AB		**80MG**	**A206511**	**003**	Sep 03, 2015
AB	CADILA PHARMS LTD	**20MG**	**A208605**	**001**	Jul 25, 2017
AB		**40MG**	**A208605**	**002**	Jul 25, 2017
AB		**80MG**	**A208605**	**003**	Jul 25, 2017
AB	CHARTWELL RX	**20MG**	**A078710**	**001**	Jan 08, 2014
AB		**40MG**	**A078710**	**002**	Jan 08, 2014
AB		**80MG**	**A078710**	**003**	Jan 08, 2014
AB	GLENMARK PHARMS LTD	**20MG**	**A090032**	**001**	Jul 07, 2014
AB		**40MG**	**A090032**	**002**	Jul 07, 2014
AB		**80MG**	**A090032**	**003**	Jul 07, 2014
AB	HETERO LABS LTD V	**20MG**	**A205901**	**001**	Apr 22, 2016
AB		**40MG**	**A205901**	**002**	Apr 22, 2016
AB		**80MG**	**A205901**	**003**	Apr 22, 2016
AB	INVENTIA	**20MG**	**A205150**	**001**	Oct 30, 2015
AB		**40MG**	**A205150**	**002**	Oct 30, 2015
AB		**80MG**	**A205150**	**003**	Oct 30, 2015
AB	MICRO LABS	**20MG**	**A207016**	**001**	Oct 03, 2017
AB		**40MG**	**A207016**	**002**	Oct 03, 2017
AB		**80MG**	**A207016**	**003**	Oct 03, 2017
AB	MYLAN	**20MG**	**A202397**	**001**	Jul 07, 2014
AB		**40MG**	**A202397**	**002**	Jul 07, 2014
AB		**80MG**	**A202397**	**003**	Jul 07, 2014
AB	PRINSTON INC	**20MG**	**A207882**	**001**	May 03, 2017
AB		**40MG**	**A207882**	**002**	May 03, 2017
AB		**80MG**	**A207882**	**003**	May 03, 2017
AB	SANDOZ	**20MG**	**A203867**	**001**	Nov 03, 2014
AB		**40MG**	**A203867**	**002**	Nov 03, 2014
AB		**80MG**	**A203867**	**003**	Nov 03, 2014
AB	ZYDUS PHARMS	**20MG**	**A203325**	**001**	Aug 26, 2014
AB		**40MG**	**A203325**	**002**	Aug 26, 2014
AB		**80MG**	**A203325**	**003**	Aug 26, 2014

TELOTRISTAT ETIPRATE

TABLET;ORAL

XERMELO

+!	TERSERA	EQ 250MG BASE	N208794	001	Feb 28, 2017

TEMAZEPAM

CAPSULE;ORAL

RESTORIL

AB	**+**	SPECGX LLC	**7.5MG**	**N018163**	**003**	Oct 25, 1991
AB	**+**		**15MG**	**N018163**	**001**	
AB	**+**		**22.5MG**	**N018163**	**004**	Nov 02, 2004
AB	**+!**		**30MG**	**N018163**	**002**	

TEMAZEPAM

AB	ACTAVIS ELIZABETH	**15MG**	**A071620**	**002**	Aug 07, 1987
AB		**30MG**	**A071620**	**001**	Aug 07, 1987
AB	ALEMBIC	**7.5MG**	**A211542**	**001**	Nov 23, 2018
AB		**15MG**	**A211542**	**002**	Nov 23, 2018
AB		**22.5MG**	**A211542**	**003**	Nov 23, 2018
AB		**30MG**	**A211542**	**004**	Nov 23, 2018
AB	ALKEM LABS LTD	**7.5MG**	**A217875**	**001**	Aug 24, 2023
AB		**15MG**	**A217875**	**002**	Aug 24, 2023
AB		**22.5MG**	**A217875**	**003**	Aug 24, 2023
AB		**30MG**	**A217875**	**004**	Aug 24, 2023
AB	AMNEAL PHARMS	**7.5MG**	**A203482**	**001**	May 23, 2016
AB		**15MG**	**A203482**	**002**	May 23, 2016
AB		**22.5MG**	**A203482**	**003**	May 23, 2016
AB		**30MG**	**A203482**	**004**	May 23, 2016
AB	NOVEL LABS INC	**7.5MG**	**A071457**	**002**	Jun 22, 2012
AB		**15MG**	**A071456**	**001**	Apr 21, 1987
AB		**22.5MG**	**A071457**	**003**	Jun 22, 2012
AB		**30MG**	**A071457**	**001**	Apr 21, 1987
AB	PRINSTON INC	**7.5MG**	**A201781**	**001**	Jun 04, 2015
AB		**15MG**	**A201781**	**002**	Jun 04, 2015

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

AB			**22.5MG**	**A201781**	**003**	Jun 04, 2015
AB			**30MG**	**A201781**	**004**	Jun 04, 2015
AB		SANDOZ	**15MG**	**A071427**	**001**	Jan 12, 1988
AB			**30MG**	**A071428**	**001**	Jan 12, 1988
AB		SUN PHARM INDUSTRIES	**7.5MG**	**A078581**	**001**	Sep 08, 2009

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB		ACCORD HLTHCARE	**5MG**	**A201528**	**001**	Feb 27, 2017
AB			**20MG**	**A201528**	**002**	Feb 27, 2017
AB			**100MG**	**A201528**	**003**	Feb 27, 2017
AB			**140MG**	**A201528**	**004**	Feb 27, 2017
AB			**180MG**	**A201528**	**005**	Feb 27, 2017
AB	**!**		**250MG**	**A201528**	**006**	Feb 27, 2017
AB		AMNEAL PHARMS	**5MG**	**A203691**	**001**	May 08, 2015
AB			**20MG**	**A203691**	**002**	May 08, 2015
AB			**100MG**	**A203691**	**003**	May 08, 2015
AB			**140MG**	**A203691**	**004**	May 08, 2015
AB			**180MG**	**A203691**	**005**	May 08, 2015
AB			**250MG**	**A203691**	**006**	May 08, 2015
AB		CHARTWELL	**5MG**	**A206413**	**001**	Apr 12, 2016
AB			**20MG**	**A206413**	**002**	Apr 12, 2016
AB			**100MG**	**A206413**	**003**	Apr 12, 2016
AB			**140MG**	**A206413**	**004**	Apr 12, 2016
AB			**180MG**	**A206413**	**005**	Apr 12, 2016
AB			**250MG**	**A206413**	**006**	Apr 12, 2016
AB		CHEMI SPA	**5MG**	**A204639**	**001**	Nov 23, 2016
AB			**20MG**	**A204639**	**002**	Nov 23, 2016
AB			**100MG**	**A204639**	**003**	Nov 23, 2016
AB			**140MG**	**A204639**	**004**	Nov 23, 2016
AB			**180MG**	**A204639**	**005**	Nov 23, 2016
AB			**250MG**	**A204639**	**006**	Nov 23, 2016
AB		DEVA HOLDING AS	**5MG**	**A207658**	**001**	Apr 26, 2017
AB			**20MG**	**A207658**	**002**	Apr 26, 2017
AB			**100MG**	**A207658**	**003**	Apr 26, 2017
AB			**140MG**	**A207658**	**004**	Apr 26, 2017
AB			**180MG**	**A207658**	**005**	Apr 26, 2017
AB			**250MG**	**A207658**	**006**	Apr 26, 2017
AB		NIVAGEN PHARMS INC	**5MG**	**A213328**	**001**	Nov 23, 2021
AB			**20MG**	**A213328**	**002**	Nov 23, 2021
AB			**100MG**	**A213328**	**003**	Nov 23, 2021
AB			**140MG**	**A213328**	**004**	Nov 23, 2021
AB			**180MG**	**A213328**	**005**	Nov 23, 2021
AB			**250MG**	**A213328**	**006**	Nov 23, 2021
AB		RISING	**5MG**	**A206309**	**001**	Apr 27, 2016
AB			**20MG**	**A206309**	**002**	Apr 27, 2016
AB			**100MG**	**A206309**	**003**	Apr 27, 2016
AB			**140MG**	**A206309**	**004**	Apr 27, 2016
AB			**180MG**	**A206309**	**005**	Apr 27, 2016
AB			**250MG**	**A206309**	**006**	Apr 27, 2016
AB		SUN PHARM	**5MG**	**A201742**	**001**	Feb 12, 2014
AB			**20MG**	**A201742**	**002**	Feb 12, 2014
AB			**100MG**	**A201742**	**003**	Feb 12, 2014
AB			**140MG**	**A201742**	**004**	Feb 12, 2014
AB			**180MG**	**A201742**	**005**	Feb 12, 2014
AB			**250MG**	**A201742**	**006**	Feb 12, 2014
AB		ZYDUS PHARMS	**5MG**	**A206750**	**001**	Jul 31, 2017
AB			**20MG**	**A206750**	**002**	Jul 31, 2017
AB			**100MG**	**A206750**	**003**	Jul 31, 2017
AB			**140MG**	**A206750**	**004**	Jul 31, 2017
AB			**180MG**	**A206750**	**005**	Jul 31, 2017
AB			**250MG**	**A206750**	**006**	Jul 31, 2017

POWDER;INTRAVENOUS

TEMODAR

	+!	MERCK SHARP DOHME	100MG/VIAL	N022277	001	Feb 27, 2009

TEMSIROLIMUS

SOLUTION;INTRAVENOUS

TEMSIROLIMUS

AP		ACCORD HLTHCARE	**25MG/ML (25MG/ML)**	**A203153**	**001**	Jul 30, 2018
AP		GLAND PHARMA LTD	**25MG/ML (25MG/ML)**	**A207383**	**001**	Aug 16, 2019

TORISEL

AP	**+!**	PF PRISM CV	**25MG/ML (25MG/ML)**	**N022088**	**001**	May 30, 2007

TENAPANOR HYDROCHLORIDE

TABLET;ORAL

IBSRELA

+!	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019

XPHOZAH

+	ARDELYX INC	EQ 10MG BASE	N213931	001	Oct 17, 2023
+		EQ 20MG BASE	N213931	002	Oct 17, 2023
+!		EQ 30MG BASE	N213931	003	Oct 17, 2023

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

TENOFOVIR ALAFENAMIDE

AB		LUPIN LTD	**EQ 25MG BASE**	**A214226**	**001**	Mar 30, 2023

VEMLIDY

AB	**+!**	GILEAD SCIENCES INC	**EQ 25MG BASE**	**N208464**	**001**	Nov 10, 2016

TENOFOVIR DISOPROXIL FUMARATE

POWDER;ORAL

VIREAD

	+!	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577	001	Jan 18, 2012

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB		AUROBINDO PHARMA	**150MG**	**A090647**	**001**	Jan 26, 2018
AB			**200MG**	**A090647**	**002**	Jan 26, 2018
AB			**250MG**	**A090647**	**003**	Jan 26, 2018
AB			**300MG**	**A090647**	**004**	Jan 26, 2018
AB		CHARTWELL	**300MG**	**A206481**	**001**	Jul 26, 2018
AB		CIPLA	**300MG**	**A078800**	**001**	Jan 26, 2018
AB		HETERO LABS LTD III	**300MG**	**A090636**	**001**	Jan 26, 2018
AB		MACLEODS PHARMS LTD	**300MG**	**A203232**	**001**	Jan 26, 2018
AB		QILU	**200MG**	**A209498**	**001**	Mar 02, 2018
AB			**250MG**	**A209498**	**002**	Mar 02, 2018
AB			**300MG**	**A209498**	**003**	Mar 02, 2018
AB		REYOUNG	**300MG**	**A211337**	**001**	Mar 02, 2023
AB		STRIDES PHARMA	**300MG**	**A090742**	**001**	Jan 26, 2018
AB		TEVA PHARMS USA	**150MG**	**A091612**	**002**	Jan 26, 2018
AB			**200MG**	**A091612**	**003**	Jan 26, 2018
AB			**250MG**	**A091612**	**004**	Jan 26, 2018
AB			**300MG**	**A091612**	**001**	Mar 18, 2015

VIREAD

AB	**+**	GILEAD SCIENCES INC	**150MG**	**N021356**	**002**	Jan 18, 2012
AB	**+**		**200MG**	**N021356**	**003**	Jan 18, 2012
AB	**+**		**250MG**	**N021356**	**004**	Jan 18, 2012
AB	**+!**		**300MG**	**N021356**	**001**	Oct 26, 2001

TEPOTINIB HYDROCHLORIDE

TABLET;ORAL

TEPMETKO

	+!	EMD SERONO INC	EQ 225MG BASE	N214096	001	Feb 03, 2021

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB		APNAR PHARMA LP	**EQ 1MG BASE**	**A074823**	**001**	Mar 30, 1998
AB			**EQ 2MG BASE**	**A074823**	**002**	Mar 30, 1998
AB			**EQ 5MG BASE**	**A074823**	**003**	Mar 30, 1998
AB			**EQ 10MG BASE**	**A074823**	**004**	Mar 30, 1998
AB		HERITAGE PHARMA AVET	**EQ 1MG BASE**	**A075614**	**002**	Jan 30, 2001
AB			**EQ 2MG BASE**	**A075614**	**001**	Jan 30, 2001
AB			**EQ 5MG BASE**	**A075614**	**003**	Jan 30, 2001
AB			**EQ 10MG BASE**	**A075614**	**004**	Jan 30, 2001
AB	**!**	JUBILANT CADISTA	**EQ 1MG BASE**	**A075317**	**001**	Dec 20, 2004
AB			**EQ 2MG BASE**	**A075317**	**002**	Dec 20, 2004
AB			**EQ 5MG BASE**	**A075317**	**003**	Dec 20, 2004
AB			**EQ 10MG BASE**	**A075317**	**004**	Dec 20, 2004

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

AB	**!**	AUROBINDO PHARMA	**EQ 250MG BASE**	**A078297**	**001**	Jul 02, 2007
AB		BRECKENRIDGE PHARM	**EQ 250MG BASE**	**A077714**	**001**	Jun 04, 2010
AB		CHARTWELL	**EQ 250MG BASE**	**A078199**	**001**	Jul 02, 2007
AB		CIPLA	**EQ 250MG BASE**	**A077137**	**001**	Jul 02, 2007
AB		DR REDDYS LABS INC	**EQ 250MG BASE**	**A076390**	**001**	Jul 02, 2007
AB		EMED MEDCL	**EQ 250MG BASE**	**A077919**	**001**	Jul 02, 2007
AB		GLENMARK GENERICS	**EQ 250MG BASE**	**A078157**	**001**	Jul 02, 2007
AB		INVAGEN PHARMS	**EQ 250MG BASE**	**A077533**	**001**	Jul 02, 2007
AB		ORBION PHARMS	**EQ 250MG BASE**	**A078163**	**001**	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

AP	**!**	CHARTWELL INJECTABLE	**1MG/ML**	**A076770**	**001**	Apr 23, 2004
AP		FRESENIUS KABI USA	**1MG/ML**	**A076887**	**001**	May 26, 2004
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A078630**	**001**	May 20, 2009
AP		UNITED BIOMEDCL	**1MG/ML**	**A200122**	**001**	Nov 08, 2013

TABLET;ORAL

BRETHINE

AB	**+**	ANI PHARMS	**2.5MG**	**N017849**	**001**	
AB	**+**		**5MG**	**N017849**	**002**	

TERBUTALINE SULFATE

AB		IMPAX LABS	**2.5MG**	**A075877**	**001**	Jun 26, 2001
AB			**5MG**	**A075877**	**002**	Jun 26, 2001
AB		LANNETT CO INC	**2.5MG**	**A077152**	**001**	Mar 25, 2005
AB	**!**		**5MG**	**A077152**	**002**	Mar 25, 2005
AB		TWI PHARMS	**2.5MG**	**A211832**	**001**	Jun 19, 2020
AB			**5MG**	**A211832**	**002**	Jun 19, 2020

TERCONAZOLE

CREAM;VAGINAL

TERCONAZOLE

AB		FOUGERA PHARMS	**0.4%**	**A076712**	**001**	Feb 18, 2005
AB	**!**	TARO	**0.4%**	**A076043**	**001**	Jan 19, 2005
BX	+!	FOUGERA PHARMS INC	0.8%	N021735	001	Oct 01, 2004
BX	!	TARO	0.8%	A075953	001	Apr 06, 2004

SUPPOSITORY;VAGINAL

TERCONAZOLE

AB	**!**	PADAGIS ISRAEL	**80MG**	**A077149**	**001**	Mar 17, 2006
AB		TARO	**80MG**	**A077553**	**001**	Mar 09, 2007

TERIFLUNOMIDE

TABLET;ORAL

AUBAGIO

AB	**+**	SANOFI AVENTIS US	**7MG**	**N202992**	**001**	Sep 12, 2012
AB	**+!**		**14MG**	**N202992**	**002**	Sep 12, 2012

TERIFLUNOMIDE

AB		ACCORD HLTHCARE	**7MG**	**A209690**	**001**	Jan 07, 2019
AB			**14MG**	**A209690**	**002**	Jan 07, 2019
AB		ALEMBIC	**7MG**	**A209572**	**001**	Apr 19, 2019
AB			**14MG**	**A209572**	**002**	Apr 19, 2019
AB		AMNEAL PHARMS CO	**7MG**	**A209613**	**001**	Sep 28, 2018
AB			**14MG**	**A209613**	**002**	Sep 28, 2018
AB		APOTEX	**7MG**	**A209601**	**001**	Nov 02, 2018
AB			**14MG**	**A209601**	**002**	Nov 02, 2018
AB		AUROBINDO PHARMA	**7MG**	**A209638**	**001**	Oct 26, 2018
AB			**14MG**	**A209638**	**002**	Oct 26, 2018
AB		BIOCON PHARMA	**7MG**	**A209639**	**001**	Mar 13, 2023
AB			**14MG**	**A209639**	**002**	Mar 13, 2023
AB		GLENMARK PHARMS	**7MG**	**A209663**	**001**	Nov 15, 2018
AB			**14MG**	**A209663**	**002**	Nov 15, 2018
AB		HETERO LABS LTD V	**7MG**	**A209598**	**001**	Mar 13, 2023
AB			**14MG**	**A209598**	**002**	Mar 13, 2023
AB		MSN	**7MG**	**A209623**	**001**	Apr 24, 2019
AB			**14MG**	**A209623**	**002**	Apr 24, 2019
AB		MYLAN	**7MG**	**A209702**	**001**	Feb 28, 2020
AB			**14MG**	**A209702**	**002**	Feb 28, 2020
AB		NATCO	**7MG**	**A209555**	**001**	May 15, 2023
AB			**14MG**	**A209555**	**002**	May 15, 2023
AB		SANDOZ	**7MG**	**A209710**	**001**	Jan 03, 2019

TERIFLUNOMIDE						
TABLET;ORAL						
TERIFLUNOMIDE						
AB			**14MG**	**A209710**	**002**	Jan 03, 2019
AB		SOLA PHARMS	**7MG**	**A209677**	**002**	Sep 28, 2023
AB			**14MG**	**A209677**	**001**	Jun 17, 2020
AB		TEVA PHARMS USA	**7MG**	**A209700**	**001**	Sep 04, 2018
AB			**14MG**	**A209700**	**002**	Sep 04, 2018
AB		ZYDUS PHARMS	**7MG**	**A209668**	**001**	Nov 30, 2018
AB			**14MG**	**A209668**	**002**	Nov 30, 2018
TERIPARATIDE						
SOLUTION;SUBCUTANEOUS						
FORTEO						
AP	**+!**	LILLY	**0.6MG/2.4ML (0.25MG/ML)**	**N021318**	**002**	Jun 25, 2008
TERIPARATIDE						
AP		APOTEX	**0.6MG/2.4ML (0.25MG/ML)**	**A211097**	**001**	Nov 16, 2023
AP		TEVA PHARMS USA	**0.6MG/2.4ML (0.25MG/ML)**	**A208569**	**001**	Nov 16, 2023
BONSITY						
		ALVOGEN	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019
TERLIPRESSIN ACETATE						
POWDER;INTRAVENOUS						
TERLIVAZ						
	+!	MALLINCKRODT IRELAND	EQ 0.85MG BASE/VIAL	N022231	001	Sep 14, 2022
TESTOSTERONE						
GEL;TRANSDERMAL						
TESTOSTERONE						
AB1		ACTAVIS LABS UT INC	**25MG/2.5GM PACKET**	**A076737**	**001**	Jan 27, 2006
AB1	**!**		**50MG/5GM PACKET**	**A076737**	**002**	Jan 27, 2006
AB1		ENCUBE	**50MG/5GM PACKET**	**A212984**	**001**	Nov 09, 2021
AB1		STRIDES PHARMA	**25MG/2.5GM PACKET**	**A076744**	**001**	May 23, 2007
AB1			**50MG/5GM PACKET**	**A076744**	**002**	May 23, 2007
TESTIM						
AB2	**+!**	AUXILIUM PHARMS LLC	**50MG/5GM PACKET**	**N021454**	**001**	Oct 31, 2002
TESTOSTERONE						
AB2		ACTAVIS LABS UT INC	**1.62% (20.25MG/1.25GM PACKET)**	**A204570**	**002**	Jul 17, 2020
AB2			**1.62% (40.5MG/2.5GM PACKET)**	**A204570**	**003**	Jul 17, 2020
AB2			**50MG/5GM PACKET**	**A091073**	**001**	Sep 18, 2017
AB2		PADAGIS ISRAEL	**1.62% (20.25MG/1.25GM PACKET)**	**A205781**	**001**	Jul 12, 2017
AB2	**!**		**1.62% (40.5MG/2.5GM PACKET)**	**A205781**	**002**	Jul 12, 2017
VOGELXO						
AB2		UPSHER SMITH LABS	**50MG/5GM PACKET**	**N204399**	**002**	Jun 04, 2014
GEL, METERED;NASAL						
NATESTO						
	+!	ACERUS	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014
GEL, METERED;TRANSDERMAL						
ANDROGEL						
AB	**+!**	BESINS HLTHCARE	**1.62% (20.25MG/1.25GM ACTUATION)**	**N022309**	**001**	Apr 29, 2011
FORTESTA						
AB	**+!**	ENDO PHARMS	**10MG/0.5GM ACTUATION**	**N021463**	**001**	Dec 29, 2010
TESTOSTERONE						
AB		ACTAVIS LABS UT INC	**1.62% (20.25MG/1.25GM ACTUATION)**	**A204570**	**001**	Apr 10, 2019
AB			**10MG/0.5GM ACTUATION**	**A204571**	**001**	Aug 05, 2015
AB		AMNEAL	**1.62% (20.25MG/1.25GM ACTUATION)**	**A207373**	**001**	Apr 10, 2019
AB		ENCUBE	**1.62% (20.25MG/1.25GM ACTUATION)**	**A208620**	**001**	Apr 10, 2019
AB		LUPIN	**1.62% (20.25MG/1.25GM ACTUATION)**	**A208560**	**001**	Apr 10, 2019
AB		PADAGIS ISRAEL	**1.62% (20.25MG/1.25GM ACTUATION)**	**A204268**	**001**	Aug 04, 2015
AB		TWI PHARMS	**1.62% (20.25MG/1.25GM ACTUATION)**	**A209390**	**001**	Sep 23, 2019
AB		XIROMED	**1.62% (20.25MG/1.25GM ACTUATION)**	**A210835**	**001**	Apr 16, 2020
BX	!	ACTAVIS LABS UT INC	12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015
VOGELXO						
BX		UPSHER SMITH LABS	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014
PELLET;IMPLANTATION						
TESTOPEL						
	!	AUXILIUM PHARMS INC	75MG	A080911	001	
SOLUTION, METERED;TRANSDERMAL						
TESTOSTERONE						
AT		ACTAVIS LABS UT INC	**30MG/1.5ML ACTUATION**	**A205328**	**001**	Aug 07, 2017
AT		CIPLA	**30MG/1.5ML ACTUATION**	**A209533**	**001**	Jan 29, 2018
AT		DASH PHARMS	**30MG/1.5ML ACTUATION**	**A212301**	**001**	Jan 11, 2021
AT		LUPIN LTD	**30MG/1.5ML ACTUATION**	**A208061**	**001**	Oct 23, 2017

TESTOSTERONE

SOLUTION, METERED;TRANSDERMAL

TESTOSTERONE

AT	**!**	PADAGIS ISRAEL	**30MG/1.5ML ACTUATION**	**A204255**	**001**	Feb 28, 2017
AT		TWI PHARMS	**30MG/1.5ML ACTUATION**	**A209836**	**001**	Sep 03, 2021

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

DEPO-TESTOSTERONE

AO	**+!**	PFIZER	**100MG/ML**	**A085635**	**002**	
AO	**+!**		**200MG/ML**	**A085635**	**003**	

TESTOSTERONE CYPIONATE

AO		AM REGENT	**200MG/ML**	**A207742**	**001**	Jun 16, 2017
AO		CIPLA	**100MG/ML**	**A210362**	**001**	Jun 19, 2018
AO			**200MG/ML**	**A210362**	**002**	Jun 19, 2018
AO		EUGIA PHARMA	**100MG/ML**	**A211817**	**001**	Oct 20, 2023
AO			**200MG/ML**	**A211817**	**002**	Oct 20, 2023
AO		HIKMA	**100MG/ML**	**A090387**	**001**	Jul 15, 2010
AO			**200MG/ML**	**A090387**	**002**	Jul 15, 2010
AO		HIKMA FARMACEUTICA	**200MG/ML**	**A091244**	**001**	May 01, 2012
AO		PADAGIS US	**200MG/ML**	**A040530**	**001**	Jan 31, 2005
AO		SANDOZ	**100MG/ML**	**A040615**	**001**	Aug 10, 2006
AO			**200MG/ML**	**A040615**	**002**	Aug 10, 2006
AO		SUN PHARM INDS LTD	**100MG/ML**	**A201720**	**001**	Jun 03, 2013
AO			**200MG/ML**	**A201720**	**002**	Jun 03, 2013
AO		WATSON PHARMS INC	**200MG/ML**	**A086030**	**001**	
AO		WILSHIRE PHARMS INC	**200MG/ML**	**A206368**	**001**	Apr 24, 2019
AO		XIROMED	**100MG/ML**	**A215351**	**001**	Apr 13, 2023
AO			**200MG/ML**	**A215351**	**002**	Apr 13, 2023

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

TESTOSTERONE ENANTHATE

AO		HIKMA FARMACEUTICA	**200MG/ML**	**A091120**	**001**	Sep 18, 2012
AO		NEXUS	**200MG/ML**	**A040575**	**001**	Jun 14, 2006
AO	**!**	WATSON PHARMS INC	**200MG/ML**	**A085598**	**001**	

SOLUTION;SUBCUTANEOUS

XYOSTED (AUTOINJECTOR)

	+!	ANTARES PHARMA INC	50MG/0.5ML (50MG/0.5ML)	N209863	001	Sep 28, 2018
	+!		75MG/0.5ML (75MG/0.5ML)	N209863	002	Sep 28, 2018
	+!		100MG/0.5ML (100MG/0.5ML)	N209863	003	Sep 28, 2018

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL

JATENZO

	+	TOLMAR	158MG	N206089	001	Mar 27, 2019
	+		198MG	N206089	002	Mar 27, 2019
	+!		237MG	N206089	003	Mar 27, 2019

KYZATREX

	+	MARIUS PHARMS LLC	100MG	N213953	001	Jul 27, 2022
	+		150MG	N213953	002	Jul 27, 2022
	+!		200MG	N213953	003	Jul 27, 2022

TLANDO

	+!	ANTARES PHARMA INC	112.5MG	N208088	001	Mar 28, 2022

INJECTABLE;INTRAMUSCULAR

AVEED

	+!	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

AB		ACTAVIS LABS FL INC	**25MG**	**A206686**	**001**	Jul 07, 2017
AB		APOTEX	**12.5MG**	**A206093**	**001**	Mar 17, 2020
AB			**25MG**	**A206093**	**002**	Mar 17, 2020
AB		BIONPHARMA	**12.5MG**	**A208826**	**001**	Dec 18, 2017
AB			**25MG**	**A208826**	**002**	Dec 18, 2017
AB		CHARTWELL RX	**12.5MG**	**A210544**	**001**	Apr 20, 2018
AB			**25MG**	**A210544**	**002**	Apr 20, 2018
AB		DR REDDYS	**12.5MG**	**A209284**	**001**	Jan 08, 2018
AB			**25MG**	**A209284**	**002**	Jan 08, 2018
AB		HETERO LABS LTD V	**12.5MG**	**A204574**	**001**	Feb 03, 2016
AB			**25MG**	**A204574**	**002**	Feb 03, 2016
AB		MYLAN	**12.5MG**	**A207682**	**001**	Jan 31, 2017
AB			**25MG**	**A207682**	**002**	Jan 31, 2017

TETRABENAZINE
TABLET;ORAL
TETRABENAZINE

AB		PIRAMAL HLTHCARE UK	**12.5MG**	**A213316**	**001**	Jan 22, 2020
AB			**25MG**	**A213316**	**002**	Jan 22, 2020

XENAZINE

AB	+	BAUSCH	**12.5MG**	**N021894**	**001**	Aug 15, 2008
AB	+!		**25MG**	**N021894**	**002**	Aug 15, 2008

TETRACAINE HYDROCHLORIDE
SOLUTION;OPHTHALMIC
TETRACAINE HYDROCHLORIDE

	+!	ALCON LABS	0.5%	N208135	001 Feb 29, 2016
	+!	BAUSCH LOMB IRELAND	0.5%	N210821	001 Mar 12, 2019

TETRACYCLINE HYDROCHLORIDE
CAPSULE;ORAL
TETRACYCLINE HYDROCHLORIDE

AB		AMNEAL PHARMS NY	**250MG**	**A210674**	**001**	Sep 18, 2018
AB	!		**500MG**	**A210674**	**002**	Sep 18, 2018
AB		BRECKENRIDGE	**250MG**	**A210662**	**001**	Nov 07, 2018
AB			**500MG**	**A210662**	**002**	Nov 07, 2018
AB		CHARTWELL TETRA	**250MG**	**A062752**	**001**	Aug 12, 1988
AB			**500MG**	**A062752**	**002**	Aug 12, 1988
AB		STRIDES PHARMA	**250MG**	**A212635**	**001**	Mar 03, 2020
AB			**500MG**	**A212635**	**002**	Mar 03, 2020
AB		WATSON LABS	**250MG**	**A061837**	**001**	
AB			**500MG**	**A061837**	**002**	

TETRAHYDROZOLINE HYDROCHLORIDE
SOLUTION;NASAL
TYZINE

	!	FOUGERA PHARMS	0.05%	A086576	002
			0.1%	A086576	001

SPRAY;NASAL
TYZINE

	!	FOUGERA PHARMS	0.1%	A086576	003

THALIDOMIDE
CAPSULE;ORAL
THALOMID

	+	BRISTOL-MYERS	50MG	N020785	001 Jul 16, 1998
	+		100MG	N020785	002 Jan 17, 2003
	+		150MG	N020785	004 Jan 10, 2007
	+!		200MG	N020785	003 Jan 17, 2003

THALLOUS CHLORIDE TL-201
INJECTABLE;INJECTION
THALLOUS CHLORIDE TL 201

	+!	CURIUM	1mCi/ML	N018150	001

THEOPHYLLINE
CAPSULE, EXTENDED RELEASE;ORAL
THEO-24

		AUXILIUM PHARMS LLC	100MG	A087943	002	Aug 22, 1983
	+		200MG	A087943	001	Aug 22, 1983
			300MG	A087943	003	Aug 22, 1983
	!		400MG	A087943	004	Feb 28, 1992

SOLUTION;ORAL
THEOPHYLLINE

AA	!	CHARTWELL MOLECULAR	**80MG/15ML**	**A091156**	**001**	Apr 13, 2011
AA		TRIS PHARMA INC	**80MG/15ML**	**A091586**	**001**	Jun 15, 2012

SOLUTION, ELIXIR;ORAL
ELIXOPHYLLIN

AA	+!	NOSTRUM LABS INC	**80MG/15ML**	**A085186**	**001**	

THEOPHYLLINE

AA		PHARM ASSOC	**80MG/15ML**	**A206344**	**001**	Dec 16, 2016

TABLET, EXTENDED RELEASE;ORAL
THEOCHRON

AB		NOSTRUM PHARMS LLC	**300MG**	**A087400**	**002**	Jan 11, 1983
AB			**450MG**	**A087400**	**005**	Aug 09, 2023

THEOPHYLLINE

AB		ALEMBIC	**300MG**	**A090430**	**001**	Oct 27, 2010
AB	!		**450MG**	**A090430**	**002**	Oct 27, 2010
AB		AMNEAL	**300MG**	**A216276**	**001**	Mar 20, 2023

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

AB			**450MG**	**A216276**	**002**	Mar 20, 2023
AB		ANNORA PHARMA	**300MG**	**A217422**	**001**	Sep 08, 2023
AB			**450MG**	**A217422**	**002**	Sep 08, 2023
AB		BIONPHARMA	**300MG**	**A216300**	**001**	Apr 26, 2023
AB			**450MG**	**A216300**	**002**	Apr 26, 2023
AB		GLENMARK GENERICS	**400MG**	**A090355**	**001**	Jul 13, 2010
AB			**600MG**	**A090355**	**002**	Jul 13, 2010
AB		GLENMARK PHARMS LTD	**300MG**	**A212184**	**001**	Jun 03, 2021
AB			**450MG**	**A212184**	**002**	Jun 03, 2021
AB		HARMAN FINOCHEM	**300MG**	**A214806**	**001**	Oct 24, 2023
AB			**450MG**	**A214806**	**002**	Oct 24, 2023
AB		HERITAGE PHARMA AVET	**300MG**	**A089763**	**001**	Apr 30, 1990
AB			**450MG**	**A081236**	**001**	Nov 09, 1992
AB		LEADING	**300MG**	**A214950**	**001**	Jan 30, 2023
AB			**450MG**	**A214950**	**002**	Jan 30, 2023
AB		NOSTRUM LABS INC	**400MG**	**A040560**	**003**	Apr 21, 2006
AB	**!**		**600MG**	**A040560**	**002**	Apr 21, 2006
AB		RHODES PHARMS	**300MG**	**A214113**	**001**	May 11, 2023
AB	**+**		**400MG**	**A040086**	**002**	Sep 01, 1982
AB			**600MG**	**A040086**	**001**	Apr 15, 1996
AB		TEVA PHARMS INC	**300MG**	**A216961**	**001**	Oct 12, 2022
AB			**450MG**	**A216961**	**002**	Oct 12, 2022

THEOCHRON

	NOSTRUM PHARMS LLC	100MG	A087400	003	Feb 21, 1985
		200MG	A087400	004	Feb 21, 1985

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

AP	CAPLIN	**100MG/ML**	**A215692**	**001**	Mar 06, 2023
AP	DR REDDYS	**100MG/ML**	**A080571**	**001**	
AP	EUGIA PHARMA	**100MG/ML**	**A208703**	**001**	Apr 20, 2022
AP **+!**	FRESENIUS KABI USA	**100MG/ML**	**A080556**	**001**	
AP	MYLAN INSTITUTIONAL	**100MG/ML**	**A091623**	**001**	Jun 25, 2012
AP	SAGENT PHARMS INC	**100MG/ML**	**A206106**	**001**	Dec 01, 2017
AP	WEST-WARD PHARMS INT	**100MG/ML**	**A080575**	**001**	
!	DR REDDYS	200MG/ML	A080571	002	

THIOGUANINE

TABLET;ORAL

THIOGUANINE

+!	WAYLIS THERAP	40MG	N012429	001	

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

	MYLAN	10MG	A088004	002	Mar 15, 1983
		25MG	A088004	003	Mar 15, 1983
		50MG	A088004	004	Mar 15, 1983
!		100MG	A088004	001	Nov 18, 1983

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

AP	BELOTECA	**15MG/VIAL**	**A211831**	**001**	Dec 08, 2021
AP	DR REDDYS	**15MG/VIAL**	**A210337**	**001**	May 04, 2018
AP	HENGRUI PHARMA	**15MG/VIAL**	**A209150**	**001**	May 04, 2018
AP	PENN LIFE	**15MG/VIAL**	**A208242**	**001**	Jan 10, 2020
AP **!**	WEST-WARD PHARMS INT	**15MG/VIAL**	**A075547**	**001**	Apr 02, 2001

POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

TEPADINA

AP **+!**	ADIENNE SA	**15MG/VIAL**	**N208264**	**001**	Jan 26, 2017
AP **+!**		**100MG/VIAL**	**N208264**	**002**	Jan 26, 2017

THIOTEPA

AP	GLAND PHARMA LTD	**15MG/VIAL**	**A214222**	**001**	Mar 08, 2021
AP		**100MG/VIAL**	**A214222**	**002**	Jan 03, 2022
AP	HIKMA	**100MG/VIAL**	**A211755**	**001**	Sep 05, 2023
AP	KINDOS	**15MG/VIAL**	**A216037**	**001**	Dec 26, 2023
AP		**100MG/VIAL**	**A216037**	**002**	Dec 26, 2023

THIOTEPA						
POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL						
THIOTEPA						
AP		MSN	**15MG/VIAL**	**A213049**	**001**	Mar 04, 2020
AP			**100MG/VIAL**	**A213049**	**002**	Mar 04, 2020
THIOTHIXENE						
CAPSULE;ORAL						
THIOTHIXENE						
AB		AMNEAL	**1MG**	**A215456**	**001**	Feb 28, 2022
AB			**2MG**	**A215456**	**002**	Feb 28, 2022
AB			**5MG**	**A215456**	**003**	Feb 28, 2022
AB			**10MG**	**A215456**	**004**	Feb 28, 2022
AB		NOVITIUM PHARMA	**1MG**	**A211642**	**001**	Apr 05, 2019
AB			**2MG**	**A211642**	**002**	Apr 05, 2019
AB	!		**5MG**	**A211642**	**003**	Apr 05, 2019
AB			**10MG**	**A211642**	**004**	Apr 05, 2019
AB		RISING	**1MG**	**A071093**	**002**	Jun 23, 1987
AB			**2MG**	**A071093**	**003**	Jun 23, 1987
AB			**5MG**	**A071093**	**004**	Jun 23, 1987
AB			**10MG**	**A071093**	**001**	Jun 23, 1987
TIAGABINE HYDROCHLORIDE						
TABLET;ORAL						
GABITRIL						
AB	+	CEPHALON	**2MG**	**N020646**	**005**	Apr 16, 1999
AB	+!		**4MG**	**N020646**	**001**	Sep 30, 1997
AB	+		**12MG**	**N020646**	**002**	Sep 30, 1997
AB	+		**16MG**	**N020646**	**003**	Sep 30, 1997
TIAGABINE HYDROCHLORIDE						
AB		MSN	**2MG**	**A214816**	**001**	Nov 16, 2021
AB			**4MG**	**A214816**	**002**	Nov 16, 2021
AB			**12MG**	**A214816**	**003**	Nov 16, 2021
AB			**16MG**	**A214816**	**004**	Nov 16, 2021
AB		SUN PHARM INDS	**2MG**	**A077555**	**001**	Nov 04, 2011
AB			**4MG**	**A077555**	**002**	Nov 04, 2011
TICAGRELOR						
TABLET;ORAL						
BRILINTA						
AB	+!	ASTRAZENECA	**90MG**	**N022433**	**001**	Jul 20, 2011
TICAGRELOR						
AB		ALKEM LABS LTD	**90MG**	**A208567**	**001**	Apr 21, 2023
AB		HISUN PHARM HANGZHOU	**90MG**	**A208575**	**001**	Jan 23, 2019
BRILINTA						
	+	ASTRAZENECA	60MG	N022433	002	Sep 03, 2015
TICLOPIDINE HYDROCHLORIDE						
TABLET;ORAL						
TICLOPIDINE HYDROCHLORIDE						
	!	APOTEX	250MG	A075089	001	Jul 01, 1999
TIGECYCLINE						
POWDER;INTRAVENOUS						
TIGECYCLINE						
AP		AMNEAL	**50MG/VIAL**	**N211158**	**001**	Aug 02, 2018
AP		APOTEX	**50MG/VIAL**	**A204439**	**001**	Dec 21, 2018
AP		EUGIA PHARMA	**50MG/VIAL**	**A206335**	**001**	Jun 11, 2019
AP	+!	FRESENIUS KABI USA	**50MG/VIAL**	**N205645**	**001**	Dec 01, 2016
AP		MEITHEAL	**50MG/VIAL**	**A214020**	**001**	May 13, 2021
AP		SANDOZ	**50MG/VIAL**	**A091620**	**001**	May 27, 2015
TYGACIL						
AP	+!	PF PRISM CV	**50MG/VIAL**	**N021821**	**001**	Jun 15, 2005
TIGECYCLINE						
		ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018
TIMOLOL						
SOLUTION/DROPS;OPHTHALMIC						
BETIMOL						
	+!	THEA PHARMA	EQ 0.25% BASE	N020439	001	Mar 31, 1995
	+!		EQ 0.5% BASE	N020439	002	Mar 31, 1995

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AB	**!**	ALEMBIC	**EQ 0.25% BASE**	**A212942**	**001**	Oct 22, 2020
AB	**!**		**EQ 0.5% BASE**	**A212942**	**002**	Oct 22, 2020
AB		DR REDDYS	**EQ 0.25% BASE**	**A215733**	**001**	Sep 22, 2022
AB			**EQ 0.5% BASE**	**A215733**	**002**	Sep 22, 2022
AB		EUGIA PHARMA	**EQ 0.5% BASE**	**A213540**	**001**	Mar 23, 2023
AB		GLAND PHARMA LTD	**EQ 0.25% BASE**	**A214645**	**001**	Jun 24, 2022
AB			**EQ 0.5% BASE**	**A214645**	**002**	Feb 14, 2023
AB	**+!**	SANDOZ	**EQ 0.25% BASE**	**N020963**	**001**	Oct 21, 1998
AB	**+!**		**EQ 0.5% BASE**	**N020963**	**002**	Oct 21, 1998

TIMOPTIC-XE

AB	**+**	BAUSCH AND LOMB INC	**EQ 0.25% BASE**	**N020330**	**001**	Nov 04, 1993
AB	**+**		**EQ 0.5% BASE**	**N020330**	**002**	Nov 04, 1993

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AT1		BAUSCH AND LOMB	**EQ 0.25% BASE**	**A074778**	**001**	Mar 25, 1997
AT1			**EQ 0.5% BASE**	**A074776**	**001**	Mar 25, 1997
AT1		FDC LTD	**EQ 0.25% BASE**	**A077259**	**001**	Apr 30, 2008
AT1			**EQ 0.5% BASE**	**A077259**	**002**	Apr 30, 2008
AT1		MANKIND PHARMA	**EQ 0.25% BASE**	**A078771**	**001**	Sep 28, 2009
AT1			**EQ 0.5% BASE**	**A078771**	**002**	Sep 28, 2009
AT1		MICRO LABS	**EQ 0.25% BASE**	**A217343**	**001**	May 26, 2023
AT1			**EQ 0.5% BASE**	**A217343**	**002**	May 26, 2023
AT1		PACIFIC PHARMA	**EQ 0.25% BASE**	**A074746**	**001**	Mar 25, 1997
AT1			**EQ 0.5% BASE**	**A074747**	**001**	Mar 25, 1997
AT1	**!**	SANDOZ	**EQ 0.25% BASE**	**A074261**	**001**	Apr 28, 1995
AT1	**!**		**EQ 0.5% BASE**	**A074262**	**001**	Apr 28, 1995

TIMOPTIC

AT1	**+**	BAUSCH AND LOMB INC	**EQ 0.25% BASE**	**N018086**	**001**	
AT1	**+**		**EQ 0.5% BASE**	**N018086**	**002**	

ISTALOL

AT2	**+!**	BAUSCH AND LOMB	**EQ 0.5% BASE**	**N021516**	**001**	Jun 04, 2004

TIMOLOL MALEATE

AT2		APOTEX	**EQ 0.5% BASE**	**A204936**	**001**	Apr 17, 2015
AT3		AMRING PHARMS	**EQ 0.25% BASE**	**A212592**	**001**	Dec 13, 2021
AT3			**EQ 0.5% BASE**	**A212592**	**002**	Dec 13, 2021
AT3		EPIC PHARMA LLC	**EQ 0.5% BASE**	**A212291**	**001**	Sep 11, 2020
AT3		INGENUS PHARMS LLC	**EQ 0.25% BASE**	**A216533**	**001**	Sep 13, 2022
AT3			**EQ 0.5% BASE**	**A216533**	**002**	Sep 13, 2022
AT3		MICRO LABS	**EQ 0.5% BASE**	**A216596**	**001**	Sep 07, 2022
AT3		SENTISS PHARMA	**EQ 0.5% BASE**	**A217195**	**001**	May 08, 2023

TIMOPTIC IN OCUDOSE

AT3	**+!**	BAUSCH AND LOMB INC	**EQ 0.25% BASE**	**N019463**	**001**	Nov 05, 1986
AT3	**+!**		**EQ 0.5% BASE**	**N019463**	**002**	Nov 05, 1986

TABLET;ORAL

TIMOLOL MALEATE

AB		MYLAN	**5MG**	**A072668**	**002**	Jun 08, 1990
AB			**10MG**	**A072668**	**003**	Jun 08, 1990
AB	**!**		**20MG**	**A072668**	**001**	Jun 08, 1990
AB		RISING	**5MG**	**A207556**	**001**	May 02, 2019
AB			**10MG**	**A207556**	**002**	May 02, 2019
AB			**20MG**	**A207556**	**003**	May 02, 2019

TINIDAZOLE

TABLET;ORAL

TINDAMAX

AB	**+**	MISSION PHARMA	**250MG**	**N021618**	**001**	May 17, 2004
AB	**+!**		**500MG**	**N021618**	**002**	May 17, 2004

TINIDAZOLE

AB		CHARTWELL RX	**250MG**	**A202044**	**001**	Apr 30, 2012
AB			**500MG**	**A202044**	**002**	Apr 30, 2012
AB		EDENBRIDGE PHARMS	**250MG**	**A203808**	**001**	Aug 04, 2015
AB			**500MG**	**A203808**	**002**	Aug 04, 2015
AB		THINQ PHARM-CRO PVT	**250MG**	**A202489**	**001**	Oct 09, 2013
AB			**500MG**	**A202489**	**002**	Oct 09, 2013

TIOPRONIN						
TABLET;ORAL						
THIOLA						
AB	**+!**	MISSION PHARMA	**100MG**	**N019569**	**001**	Aug 11, 1988
TIOPRONIN						
AB		PAR PHARM INC	**100MG**	**A216198**	**001**	Jun 02, 2022
AB		TEVA PHARMS USA INC	**100MG**	**A214326**	**001**	Apr 26, 2021
TABLET, DELAYED RELEASE;ORAL						
THIOLA EC						
AB	**+!**	MISSION PHARMACAL	**300MG**	**N211843**	**002**	Jun 28, 2019
TIOPRONIN						
AB		AMNEAL	**300MG**	**A216278**	**001**	Aug 15, 2023
THIOLA EC						
	+	MISSION PHARMACAL	100MG	N211843	001	Jun 28, 2019
TIOTROPIUM BROMIDE						
POWDER;INHALATION						
SPIRIVA						
AB	**+!**	BOEHRINGER INGELHEIM	**EQ 0.018MG BASE/INH**	**N021395**	**001**	Jan 30, 2004
TIOTROPIUM BROMIDE						
AB		LUPIN	**EQ 0.018MG BASE/INH**	**A211287**	**001**	Jun 20, 2023
SPRAY, METERED;INHALATION						
SPIRIVA RESPIMAT						
	+!	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015
	+!		EQ 0.0025MG BASE/INH	N021936	001	Sep 24, 2014
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE						
TABLET;ORAL						
LONSURF						
AB	**+**	TAIHO ONCOLOGY	**EQ 6.14MG BASE;15MG**	**N207981**	**001**	Sep 22, 2015
AB	**+!**		**EQ 8.19MG BASE;20MG**	**N207981**	**002**	Sep 22, 2015
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE						
AB		NATCO	**EQ 6.14MG BASE;15MG**	**A214008**	**001**	Jun 13, 2023
AB			**EQ 8.19MG BASE;20MG**	**A214008**	**002**	Jun 13, 2023
TIPRANAVIR						
CAPSULE;ORAL						
APTIVUS						
	+!	BOEHRINGER INGELHEIM	250MG	N021814	001	Jun 22, 2005
TIRBANIBULIN						
OINTMENT;TOPICAL						
KLISYRI						
	+!	ALMIRALL	1%	N213189	001	Dec 14, 2020
TIROFIBAN HYDROCHLORIDE						
SOLUTION;INJECTION						
AGGRASTAT						
	+!	MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	N020912	002	Aug 31, 2016
SOLUTION;INTRAVENOUS						
AGGRASTAT						
AP	**+**	MEDICURE	**EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)**	**N020913**	**002**	May 17, 2002
AP	**+!**		**EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)**	**N020913**	**003**	Apr 20, 2000
TIROFIBAN HYDROCHLORIDE						
AP		EUGIA PHARMA	**EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)**	**A216379**	**001**	May 01, 2023
AP			**EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)**	**A216379**	**002**	May 01, 2023
AP		GLAND PHARMA LTD	**EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)**	**A206888**	**001**	Apr 08, 2021
AP		NEXUS	**EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)**	**A213947**	**001**	Feb 07, 2023
AP			**EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)**	**A213947**	**002**	Jul 24, 2023
TIRZEPATIDE						
SOLUTION;SUBCUTANEOUS						
MOUNJARO						
	+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	001	May 13, 2022
	+!		5MG/0.5ML (5MG/0.5ML)	N215866	002	May 13, 2022
	+!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	003	May 13, 2022
	+!		10MG/0.5ML (10MG/0.5ML)	N215866	004	May 13, 2022
	+!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	005	May 13, 2022
	+!		15MG/0.5ML (15MG/0.5ML)	N215866	006	May 13, 2022

TIRZEPATIDE

SOLUTION;SUBCUTANEOUS

ZEPBOUND

+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	001	Nov 08, 2023
+!		5MG/0.5ML (5MG/0.5ML)	N217806	002	Nov 08, 2023
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	003	Nov 08, 2023
+!		10MG/0.5ML (10MG/0.5ML)	N217806	004	Nov 08, 2023
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	005	Nov 08, 2023
+!		15MG/0.5ML (15MG/0.5ML)	N217806	006	Nov 08, 2023

TIVOZANIB HYDROCHLORIDE

CAPSULE;ORAL

FOTIVDA

+	AVEO PHARMS	EQ 0.89MG BASE	N212904	001	Mar 10, 2021
+!		EQ 1.34MG BASE	N212904	002	Mar 10, 2021

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALEMBIC	**EQ 2MG BASE**	**A213223**	**001**	Jan 13, 2020
AB		**EQ 4MG BASE**	**A213223**	**002**	Jan 13, 2020
AB		**EQ 6MG BASE**	**A213223**	**003**	Jan 13, 2020
AB	ALKEM LABS LTD	**EQ 2MG BASE**	**A212196**	**001**	Mar 27, 2019
AB		**EQ 4MG BASE**	**A212196**	**002**	Mar 27, 2019
AB		**EQ 6MG BASE**	**A212196**	**003**	Mar 27, 2019
AB	APOTEX INC	**EQ 2MG BASE**	**A078868**	**001**	Feb 03, 2012
AB		**EQ 4MG BASE**	**A078868**	**002**	Feb 03, 2012
AB		**EQ 6MG BASE**	**A078868**	**003**	Feb 03, 2012
AB	AUROBINDO PHARMA LTD	**EQ 2MG BASE**	**A213544**	**001**	Mar 24, 2020
AB		**EQ 4MG BASE**	**A213544**	**002**	Mar 24, 2020
AB		**EQ 6MG BASE**	**A213544**	**003**	Mar 24, 2020
AB	CADILA PHARMS LTD	**EQ 2MG BASE**	**A210021**	**001**	Mar 26, 2019
AB		**EQ 4MG BASE**	**A210021**	**002**	Mar 26, 2019
AB		**EQ 6MG BASE**	**A210021**	**003**	Mar 26, 2019
AB	JUBILANT GENERICS	**EQ 2MG BASE**	**A209605**	**001**	Aug 04, 2017
AB		**EQ 4MG BASE**	**A209605**	**002**	Aug 04, 2017
AB		**EQ 6MG BASE**	**A209605**	**003**	Aug 04, 2017
AB	NOVAST LABS	**EQ 2MG BASE**	**A210267**	**001**	Mar 12, 2019
AB		**EQ 4MG BASE**	**A210267**	**002**	Mar 12, 2019
AB		**EQ 6MG BASE**	**A210267**	**003**	Mar 12, 2019
AB	RUBICON	**EQ 2MG BASE**	**A213798**	**001**	May 27, 2020
AB		**EQ 4MG BASE**	**A213798**	**002**	May 27, 2020
AB		**EQ 6MG BASE**	**A213798**	**003**	May 27, 2020
AB	ZYDUS PHARMS	**EQ 2MG BASE**	**A208622**	**001**	Mar 03, 2017
AB		**EQ 4MG BASE**	**A208622**	**002**	Mar 03, 2017
AB		**EQ 6MG BASE**	**A208622**	**003**	Mar 03, 2017

ZANAFLEX

AB	**+** LEGACY PHARMA USA	**EQ 2MG BASE**	**N021447**	**001**	Aug 29, 2002
AB	**+**	**EQ 4MG BASE**	**N021447**	**002**	Aug 29, 2002
AB	**+!**	**EQ 6MG BASE**	**N021447**	**003**	Aug 29, 2002

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	**EQ 2MG BASE**	**A211798**	**001**	Jan 25, 2019
AB		**EQ 4MG BASE**	**A211798**	**002**	Jan 25, 2019
AB	APOTEX	**EQ 2MG BASE**	**A076533**	**001**	Jan 16, 2004
AB		**EQ 4MG BASE**	**A076533**	**002**	Jan 16, 2004
AB	CADILA	**EQ 2MG BASE**	**A208187**	**001**	Mar 09, 2018
AB		**EQ 4MG BASE**	**A208187**	**002**	Mar 09, 2018
AB	CASI PHARMS INC	**EQ 2MG BASE**	**A076280**	**001**	Nov 26, 2002
AB		**EQ 4MG BASE**	**A076280**	**002**	Jun 27, 2002
AB	DR REDDYS LABS INC	**EQ 2MG BASE**	**A076286**	**001**	Jul 03, 2002
AB		**EQ 4MG BASE**	**A076286**	**002**	Jul 03, 2002
AB	EPIC PHARMA LLC	**EQ 2MG BASE**	**A076347**	**001**	Oct 11, 2002
AB		**EQ 4MG BASE**	**A076347**	**002**	Oct 11, 2002
AB	OXFORD PHARMS	**EQ 2MG BASE**	**A076281**	**001**	Oct 20, 2003
AB		**EQ 4MG BASE**	**A076281**	**002**	Oct 20, 2003
AB	SUN PHARM INDS INC	**EQ 2MG BASE**	**A076416**	**001**	Sep 29, 2003
AB		**EQ 4MG BASE**	**A076416**	**002**	Sep 29, 2003
AB	UNICHEM LABS LTD	**EQ 2MG BASE**	**A091283**	**001**	Nov 28, 2012
AB		**EQ 4MG BASE**	**A091283**	**002**	Nov 28, 2012

ZANAFLEX

AB	**+!** LEGACY PHARMA USA	**EQ 4MG BASE**	**N020397**	**001**	Nov 27, 1996

TOBRAMYCIN							
OINTMENT;OPHTHALMIC							
TOBREX							
	+!	NOVARTIS	0.3%	N050555	001		
POWDER;INHALATION							
TOBI PODHALER							
	+!	MYLAN SPECIALITY LP	28MG	N201688	001	Mar 22, 2013	
SOLUTION;INHALATION							
BETHKIS							
AN	**+!**	CHIESI	**300MG/4ML**	**N201820**	**001**	Oct 12, 2012	
KITABIS PAK							
AN		PULMOFLOW INC	**300MG/5ML**	**N205433**	**001**	Dec 02, 2014	
TOBI							
AN	**+!**	MYLAN SPECIALITY LP	**300MG/5ML**	**N050753**	**001**	Dec 22, 1997	
TOBRAMYCIN							
AN		ALKEM LABS LTD	**300MG/5ML**	**A212848**	**001**	Apr 01, 2021	
AN		AMNEAL PHARMS	**300MG/5ML**	**A205501**	**001**	Jul 13, 2015	
AN		DR REDDYS LABS SA	**300MG/5ML**	**A207080**	**001**	Jul 09, 2018	
AN		HIKMA	**300MG/5ML**	**A201422**	**001**	May 28, 2014	
AN		LUPIN	**300MG/5ML**	**A208964**	**001**	Mar 22, 2017	
AN		MANKIND PHARMA	**300MG/5ML**	**A214478**	**001**	Jun 30, 2023	
AN			**300MG/4ML**	**A216725**	**001**	Sep 22, 2022	
AN		MICRO LABS	**300MG/5ML**	**A217344**	**001**	Jul 27, 2023	
AN		SUN PHARM	**300MG/5ML**	**A207136**	**001**	Dec 26, 2019	
AN		TEVA PHARMS USA	**300MG/5ML**	**A091589**	**001**	Oct 10, 2013	
AN			**300MG/4ML**	**A210915**	**001**	Jun 26, 2019	
SOLUTION/DROPS;OPHTHALMIC							
TOBRAMYCIN							
AT		ALEMBIC	**0.3%**	**A211847**	**001**	Apr 19, 2019	
AT		BAUSCH AND LOMB	**0.3%**	**A064052**	**001**	Nov 29, 1993	
AT		CHARTWELL RX	**0.3%**	**A065026**	**001**	Sep 11, 2001	
AT		GLAND PHARMA LTD	**0.3%**	**A212628**	**001**	Mar 09, 2021	
AT		SOMERSET THERAPS LLC	**0.3%**	**A207444**	**001**	Jun 28, 2017	
TOBREX							
AT	**+!**	NOVARTIS	**0.3%**	**N050541**	**001**		
AT		SANDOZ	**0.3%**	**A062535**	**001**	Dec 13, 1984	
TOBRAMYCIN SULFATE							
INJECTABLE;INJECTION							
TOBRAMYCIN SULFATE							
AP		BAXTER HLTHCARE CORP	**EQ 40MG BASE/ML**	**A206965**	**001**	Jul 01, 2016	
AP		EUGIA PHARMA	**EQ 1.2GM BASE/VIAL**	**A217519**	**001**	Jun 21, 2023	
AP	**!**	FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A065122**	**001**	Nov 29, 2002	
AP	**!**		**EQ 40MG BASE/ML**	**A065122**	**002**	Nov 29, 2002	
AP			**EQ 1.2GM BASE/VIAL**	**N050789**	**001**	Jul 13, 2004	
AP		GLAND PHARMA LTD	**EQ 10MG BASE/ML**	**A209621**	**001**	Feb 11, 2021	
AP			**EQ 40MG BASE/ML**	**A209621**	**002**	Feb 11, 2021	
AP			**EQ 1.2GM BASE/VIAL**	**A211189**	**001**	May 18, 2021	
AP		HAINAN POLY	**EQ 1.2GM BASE/VIAL**	**A217029**	**001**	Feb 01, 2023	
AP		HIKMA	**EQ 40MG BASE/ML**	**A063117**	**001**	Apr 26, 1991	
AP		HOSPIRA	**EQ 40MG BASE/ML**	**A063111**	**001**	Apr 30, 1991	
AP		MYLAN LABS LTD	**EQ 40MG BASE/ML**	**A065407**	**001**	Mar 11, 2008	
AP		XELLIA PHARMS APS	**EQ 1.2GM BASE/VIAL**	**A205685**	**001**	Sep 16, 2014	
AP	**!**	XGEN PHARMS	**EQ 1.2GM BASE/VIAL**	**A065013**	**001**	Aug 17, 2001	
TOBRAMYCIN SULFATE (PHARMACY BULK)							
AP	**!**	FRESENIUS KABI USA	**EQ 40MG BASE/ML**	**A065120**	**001**	Nov 29, 2002	
AP		GLAND PHARMA LTD	**EQ 40MG BASE/ML**	**A209346**	**001**	Feb 09, 2021	
TOFACITINIB CITRATE							
SOLUTION;ORAL							
TOFACITINIB CITRATE							
AA		SLAYBACK PHARMA LLC	**EQ 1MG BASE/ML**	**A216878**	**001**	Sep 25, 2023	
XELJANZ							
AA	**+!**	PFIZER	**EQ 1MG BASE/ML**	**N213082**	**001**	Sep 25, 2020	
TABLET;ORAL							
XELJANZ							
	+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	
	+!		EQ 10MG BASE	N203214	002	May 30, 2018	
TABLET, EXTENDED RELEASE;ORAL							
XELJANZ XR							
	+	PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	
	+!		EQ 22MG BASE	N208246	002	Dec 12, 2019	

TOFERSEN						
SOLUTION;INTRATHECAL						
QALSODY						
	+!	BIOGEN MA	100MG/15ML (6.7MG/ML)	N215887	001	Apr 25, 2023
TOLCAPONE						
TABLET;ORAL						
TASMAR						
AB	**+!**	BAUSCH	**100MG**	**N020697**	**001**	Jan 29, 1998
TOLCAPONE						
AB		NOVAST LABS	**100MG**	**A208937**	**001**	Aug 07, 2018
AB		PAR PHARM INC	**100MG**	**A204584**	**001**	Mar 26, 2015
TOLMETIN SODIUM						
CAPSULE;ORAL						
TOLMETIN SODIUM						
		RISING	EQ 400MG BASE	A073393	001	May 27, 1993
TABLET;ORAL						
TOLMETIN SODIUM						
	!	RISING	EQ 600MG BASE	A074473	001	Aug 30, 1994
TOLTERODINE TARTRATE						
CAPSULE, EXTENDED RELEASE;ORAL						
DETROL LA						
AB	**+**	UPJOHN	**2MG**	**N021228**	**001**	Dec 22, 2000
AB	**+!**		**4MG**	**N021228**	**002**	Dec 22, 2000
TOLTERODINE TARTRATE						
AB		AJANTA PHARMA LTD	**2MG**	**A213397**	**001**	May 19, 2020
AB			**4MG**	**A213397**	**002**	May 19, 2020
AB		AMTA	**2MG**	**A213858**	**001**	Feb 02, 2021
AB			**4MG**	**A213858**	**002**	Feb 02, 2021
AB		HETERO LABS LTD III	**2MG**	**A206419**	**001**	Dec 12, 2017
AB			**4MG**	**A206419**	**002**	Dec 12, 2017
AB		INVENTIA HLTHCARE	**2MG**	**A204562**	**001**	Aug 19, 2019
AB			**4MG**	**A204562**	**002**	Aug 19, 2019
AB		TEVA PHARMS USA	**2MG**	**A079141**	**001**	Nov 22, 2016
AB			**4MG**	**A079141**	**002**	Nov 22, 2016
AB		TORRENT	**2MG**	**A203016**	**001**	Aug 11, 2015
AB			**4MG**	**A203016**	**002**	Aug 11, 2015
TABLET;ORAL						
DETROL						
AB	**+**	UPJOHN	**1MG**	**N020771**	**001**	Mar 25, 1998
AB	**+!**		**2MG**	**N020771**	**002**	Mar 25, 1998
TOLTERODINE TARTRATE						
AB		ELYSIUM	**1MG**	**A210775**	**001**	Dec 30, 2019
AB			**2MG**	**A210775**	**002**	Dec 30, 2019
AB		HETERO LABS LTD V	**1MG**	**A204397**	**001**	Aug 02, 2021
AB			**2MG**	**A204397**	**002**	Aug 02, 2021
AB		IVAX SUB TEVA PHARMS	**1MG**	**A077006**	**001**	Feb 23, 2015
AB			**2MG**	**A077006**	**002**	Feb 23, 2015
AB		MACLEODS PHARMS LTD	**1MG**	**A203409**	**001**	Aug 31, 2015
AB			**2MG**	**A203409**	**002**	Aug 31, 2015
AB		UNICHEM	**1MG**	**A205399**	**001**	Aug 05, 2020
AB			**2MG**	**A205399**	**002**	Aug 05, 2020
AB		UNIQUE	**1MG**	**A204721**	**001**	Jan 24, 2020
AB			**2MG**	**A204721**	**002**	Jan 24, 2020
TOLVAPTAN						
TABLET;ORAL						
SAMSCA						
AB	**+**	OTSUKA	**15MG**	**N022275**	**001**	May 19, 2009
AB	**+!**		**30MG**	**N022275**	**002**	May 19, 2009
TOLVAPTAN						
AB		ALKEM LABS LTD	**15MG**	**A211891**	**003**	Sep 06, 2022
AB			**30MG**	**A211891**	**001**	May 19, 2020
AB		APOTEX	**15MG**	**A207605**	**002**	Sep 06, 2022
AB			**30MG**	**A207605**	**001**	May 19, 2020
AB		HETERO LABS LTD V	**15MG**	**A205646**	**002**	Sep 06, 2022
AB			**30MG**	**A205646**	**001**	Jul 16, 2021
AB		MSN	**15MG**	**A216949**	**001**	Jun 21, 2023
AB			**30MG**	**A216949**	**002**	Jun 21, 2023
AB		PAR PHARM INC	**15MG**	**A206119**	**001**	Feb 15, 2022
AB			**30MG**	**A206119**	**002**	Feb 15, 2022

TOLVAPTAN							
TABLET;ORAL							
JYNARQUE							
	+	OTSUKA	15MG	N204441	001	Apr 23, 2018
	+		30MG	N204441	002	Apr 23, 2018
	+!		45MG	N204441	003	Apr 23, 2018
	+		60MG	N204441	004	Apr 23, 2018
	+		90MG	N204441	005	Apr 23, 2018
TOLVAPTAN							
		ALKEM LABS LTD	60MG	A211891	002	May 19, 2020
TOPIRAMATE							
CAPSULE;ORAL							
TOPAMAX							
AB	**+**	JANSSEN PHARMS	**15MG**	**N020844**	**001**	Oct 26, 1998
AB	**+!**		**25MG**	**N020844**	**002**	Oct 26, 1998
TOPIRAMATE							
AB		AUROBINDO PHARMA LTD	**15MG**	**A215449**	**001**	Sep 27, 2023
AB			**25MG**	**A215449**	**002**	Sep 27, 2023
AB		TEVA	**15MG**	**A076575**	**001**	Apr 17, 2009
AB			**25MG**	**A076575**	**002**	Apr 17, 2009
AB		TWI PHARMS	**15MG**	**A217694**	**001**	Dec 05, 2023
AB			**25MG**	**A217694**	**002**	Dec 05, 2023
AB		ZYDUS PHARMS USA INC	**15MG**	**A078877**	**001**	Oct 14, 2009
AB			**25MG**	**A078877**	**002**	Oct 14, 2009
CAPSULE, EXTENDED RELEASE;ORAL							
TOPIRAMATE							
AB1		ACTAVIS LABS FL	**25MG**	**A206210**	**001**	Mar 10, 2023
AB1			**50MG**	**A206210**	**002**	Mar 10, 2023
AB1			**100MG**	**A206210**	**003**	Mar 10, 2023
AB1			**200MG**	**A206210**	**004**	Mar 10, 2023
AB1		AJANTA PHARMA LTD	**25MG**	**A215663**	**001**	Aug 15, 2023
AB1			**50MG**	**A215663**	**002**	Aug 15, 2023
AB1			**100MG**	**A215663**	**003**	Aug 15, 2023
AB1			**200MG**	**A215663**	**004**	Aug 15, 2023
AB1		ALKEM LABS LTD	**25MG**	**A217248**	**001**	Jun 20, 2023
AB1			**50MG**	**A217248**	**002**	Jun 20, 2023
AB1			**100MG**	**A217248**	**003**	Jun 20, 2023
AB1			**200MG**	**A217248**	**004**	Jun 20, 2023
AB1		DR REDDYS	**25MG**	**A217231**	**001**	Nov 17, 2023
AB1			**50MG**	**A217231**	**002**	Nov 17, 2023
AB1			**100MG**	**A217231**	**003**	Nov 17, 2023
AB1			**200MG**	**A217231**	**004**	Nov 17, 2023
AB1		PAR PHARM	**25MG**	**A205976**	**002**	May 04, 2023
AB1			**50MG**	**A205976**	**003**	May 04, 2023
AB1			**100MG**	**A205976**	**004**	May 04, 2023
AB1			**200MG**	**A205976**	**001**	Mar 01, 2023
AB1		ZYDUS	**25MG**	**A207382**	**001**	Nov 24, 2017
AB1			**50MG**	**A207382**	**002**	Nov 24, 2017
AB1			**100MG**	**A207382**	**003**	Nov 24, 2017
AB1			**200MG**	**A207382**	**004**	Oct 30, 2023
TROKENDI XR							
AB1	**+**	SUPERNUS PHARMS	**25MG**	**N201635**	**001**	Aug 16, 2013
AB1	**+**		**50MG**	**N201635**	**002**	Aug 16, 2013
AB1	**+**		**100MG**	**N201635**	**003**	Aug 16, 2013
AB1	**+!**		**200MG**	**N201635**	**004**	Aug 16, 2013
QUDEXY XR							
AB2	**+**	UPSHER SMITH LABS	**25MG**	**N205122**	**001**	Mar 11, 2014
AB2	**+**		**50MG**	**N205122**	**002**	Mar 11, 2014
AB2	**+**		**100MG**	**N205122**	**003**	Mar 11, 2014
AB2	**+**		**150MG**	**N205122**	**004**	Mar 11, 2014
AB2	**+!**		**200MG**	**N205122**	**005**	Mar 11, 2014
TOPIRAMATE							
AB2		GLENMARK PHARMS LTD	**25MG**	**A210278**	**001**	Feb 01, 2021
AB2			**50MG**	**A210278**	**002**	Feb 01, 2021
AB2			**100MG**	**A210278**	**003**	Feb 01, 2021
AB2			**150MG**	**A210278**	**004**	Feb 01, 2021
AB2			**200MG**	**A210278**	**005**	Feb 01, 2021
AB2		ZYDUS	**25MG**	**A208949**	**001**	Nov 29, 2022
AB2			**50MG**	**A208949**	**002**	Nov 29, 2022
AB2			**100MG**	**A208949**	**003**	Nov 29, 2022

TOPIRAMATE							
CAPSULE, EXTENDED RELEASE;ORAL							
TOPIRAMATE							
AB2			**150MG**	**A208949**	**004**	Nov 29, 2022
AB2			**200MG**	**A208949**	**005**	Nov 29, 2022
SOLUTION;ORAL							
EPRONTIA							
+!	AZURITY		25MG/ML	N214679	001	Nov 05, 2021
TABLET;ORAL							
TOPAMAX							
AB	+	JANSSEN PHARMS	**25MG**	**N020505**	**004**	Dec 24, 1996
AB	+		**50MG**	**N020505**	**005**	Dec 24, 1996
AB	+!		**100MG**	**N020505**	**001**	Dec 24, 1996
AB	+		**200MG**	**N020505**	**002**	Dec 24, 1996
TOPIRAMATE							
AB		ACCORD HLTHCARE	**25MG**	**A076311**	**001**	Mar 27, 2009
AB			**50MG**	**A076311**	**002**	Mar 27, 2009
AB			**100MG**	**A076311**	**003**	Mar 27, 2009
AB			**200MG**	**A076311**	**004**	Mar 27, 2009
AB		ASCENT PHARMS INC	**25MG**	**A215414**	**001**	Aug 26, 2021
AB			**50MG**	**A215414**	**002**	Aug 26, 2021
AB			**100MG**	**A215414**	**003**	Aug 26, 2021
AB			**200MG**	**A215414**	**004**	Aug 26, 2021
AB		AUROBINDO PHARMA	**25MG**	**A078462**	**001**	Mar 27, 2009
AB			**50MG**	**A078462**	**002**	Mar 27, 2009
AB			**100MG**	**A078462**	**003**	Mar 27, 2009
AB			**200MG**	**A078462**	**004**	Mar 27, 2009
AB		CIPLA LTD	**25MG**	**A076343**	**001**	Mar 27, 2009
AB			**50MG**	**A076343**	**002**	Mar 27, 2009
AB			**100MG**	**A076343**	**003**	Mar 27, 2009
AB			**200MG**	**A076343**	**004**	Mar 27, 2009
AB		GLENMARK GENERICS	**25MG**	**A077627**	**001**	Mar 27, 2009
AB			**50MG**	**A077627**	**002**	Mar 27, 2009
AB			**100MG**	**A077627**	**003**	Mar 27, 2009
AB			**200MG**	**A077627**	**004**	Mar 27, 2009
AB		INVAGEN PHARMS	**25MG**	**A079162**	**001**	Mar 27, 2009
AB			**50MG**	**A079162**	**002**	Mar 27, 2009
AB			**100MG**	**A079162**	**003**	Mar 27, 2009
AB			**200MG**	**A079162**	**004**	Mar 27, 2009
AB		SUN PHARM	**25MG**	**A090278**	**001**	Mar 27, 2009
AB			**50MG**	**A090278**	**002**	Mar 27, 2009
AB			**100MG**	**A090278**	**003**	Mar 27, 2009
AB			**200MG**	**A090278**	**004**	Mar 27, 2009
AB		SUN PHARM INDS LTD	**25MG**	**A076327**	**001**	Mar 27, 2009
AB			**100MG**	**A076327**	**002**	Mar 27, 2009
AB			**200MG**	**A076327**	**003**	Mar 27, 2009
AB		UNICHEM LABS LTD	**25MG**	**A090162**	**001**	Mar 27, 2009
AB			**50MG**	**A090162**	**002**	Mar 27, 2009
AB			**100MG**	**A090162**	**003**	Mar 27, 2009
AB			**200MG**	**A090162**	**004**	Feb 19, 2013
AB		VIWIT PHARM	**25MG**	**A077733**	**001**	Mar 27, 2009
AB			**50MG**	**A077733**	**002**	Mar 27, 2009
AB			**100MG**	**A077733**	**003**	Mar 27, 2009
AB			**200MG**	**A077733**	**004**	Mar 27, 2009
AB		ZYDUS PHARMS USA INC	**25MG**	**A078235**	**001**	Mar 27, 2009
AB			**50MG**	**A078235**	**002**	Mar 27, 2009
AB			**100MG**	**A078235**	**003**	Mar 27, 2009
AB			**200MG**	**A078235**	**004**	Mar 27, 2009
TOPOTECAN HYDROCHLORIDE							
CAPSULE;ORAL							
HYCAMTIN							
+	SANDOZ		EQ 0.25MG BASE	N020981	001	Oct 11, 2007
+!			EQ 1MG BASE	N020981	002	Oct 11, 2007
INJECTABLE;INJECTION							
HYCAMTIN							
AP	**+!**	SANDOZ	**EQ 4MG BASE/VIAL**	**N020671**	**001**	May 28, 1996
TOPOTECAN HYDROCHLORIDE							
AP		ACCORD HLTHCARE	**EQ 4MG BASE/VIAL**	**A202351**	**001**	Jun 26, 2013
AP		ACTAVIS TOTOWA	**EQ 4MG BASE/VIAL**	**A090620**	**001**	Dec 02, 2010
AP		DR REDDYS LABS LTD	**EQ 4MG BASE/VIAL**	**A201191**	**001**	Mar 09, 2011
AP		FRESENIUS KABI USA	**EQ 4MG BASE/VIAL**	**A091089**	**001**	Nov 29, 2010

TOPOTECAN HYDROCHLORIDE
INJECTABLE;INJECTION
TOPOTECAN HYDROCHLORIDE

AP		NOVAST LABS	**EQ 4MG BASE/VIAL**	**A206962**	**001**	Nov 30, 2016
AP		SAGENT PHARMS	**EQ 4MG BASE/VIAL**	**A091284**	**001**	Jan 26, 2011
AP		TEYRO LABS	**EQ 4MG BASE/VIAL**	**A091199**	**001**	Dec 01, 2010

SOLUTION;INTRAVENOUS
TOPOTECAN HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A204406**	**002**	Jul 06, 2017
AP	**+!**	HOSPIRA INC	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**N200582**	**001**	Feb 02, 2011
AP		MEITHEAL	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**N022453**	**001**	Dec 20, 2012
		ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017

TOREMIFENE CITRATE
TABLET;ORAL
FARESTON

AB	**+!**	KYOWA KIRIN	**EQ 60MG BASE**	**N020497**	**001**	May 29, 1997

TOREMIFENE CITRATE

AB		MSN	**EQ 60MG BASE**	**A212818**	**001**	Aug 18, 2020
AB		RISING	**EQ 60MG BASE**	**A208813**	**001**	Dec 04, 2018

TORSEMIDE
TABLET;ORAL
TORSEMIDE

AB		AUROBINDO PHARMA	**5MG**	**A078249**	**001**	Oct 17, 2007
AB			**10MG**	**A078249**	**002**	Oct 17, 2007
AB			**20MG**	**A078249**	**003**	Oct 17, 2007
AB			**100MG**	**A078249**	**004**	Oct 17, 2007
AB		COREPHARMA	**5MG**	**A076894**	**001**	May 31, 2005
AB			**10MG**	**A076894**	**002**	May 31, 2005
AB			**20MG**	**A076894**	**003**	May 31, 2005
AB			**100MG**	**A076894**	**004**	May 31, 2005
AB		HETERO LABS LTD III	**5MG**	**A079234**	**001**	Jan 27, 2009
AB			**10MG**	**A079234**	**002**	Jan 27, 2009
AB			**20MG**	**A079234**	**003**	Jan 27, 2009
AB			**100MG**	**A079234**	**004**	Jan 27, 2009
AB		HIKMA	**5MG**	**A076943**	**001**	Mar 01, 2005
AB			**10MG**	**A076943**	**002**	Mar 01, 2005
AB			**20MG**	**A076943**	**003**	Mar 01, 2005
AB		PLIVA PHARM IND	**5MG**	**A076346**	**001**	May 30, 2003
AB			**10MG**	**A076346**	**002**	May 30, 2003
AB	**!**		**20MG**	**A076346**	**003**	May 30, 2003
AB			**100MG**	**A076346**	**004**	Oct 19, 2004
AB		STRIDES PHARMA	**5MG**	**A076226**	**001**	May 27, 2003
AB			**5MG**	**A090613**	**001**	Mar 22, 2011
AB			**10MG**	**A076226**	**002**	May 27, 2003
AB			**10MG**	**A090613**	**002**	Mar 22, 2011
AB			**20MG**	**A076226**	**003**	May 27, 2003
AB			**20MG**	**A090613**	**003**	Mar 22, 2011
AB			**100MG**	**A076226**	**004**	May 27, 2003
AB			**100MG**	**A090613**	**004**	Mar 22, 2011

SOAANZ

	+	SARFE PHARMS	40MG	N213218	003	Nov 17, 2021

TRABECTEDIN
POWDER;INTRAVENOUS
YONDELIS

	+!	JANSSEN PRODS	1MG/VIAL	N207953	001	Oct 23, 2015

TRAMADOL HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
CONZIP

	+!	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010
	+		200MG	N022370	002	May 07, 2010
	+		300MG	N022370	003	May 07, 2010

SOLUTION;ORAL
QDOLO

	+!	ATHENA	5MG/ML	N214044	001	Sep 01, 2020

TABLET;ORAL
TRAMADOL HYDROCHLORIDE

AB		ACI	**50MG**	**A202075**	**001**	Nov 28, 2011
AB		AMNEAL PHARMS	**50MG**	**A076003**	**001**	Jun 20, 2002
AB		APOTEX	**50MG**	**A075981**	**001**	Jul 10, 2002
AB		AUROBINDO PHARMA	**50MG**	**A203494**	**001**	Mar 31, 2014

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

		LTD				
AB		CSPC OUYI PHARM CO	**50MG**	**A091498**	**001**	Mar 29, 2013
AB		IPCA LABS LTD	**50MG**	**A201973**	**001**	Nov 16, 2012
AB		MERRO PHARM USA	**50MG**	**A206706**	**001**	Jul 02, 2019
AB		RUBICON	**50MG**	**A208708**	**001**	Jun 28, 2019
AB	**!**	SUN PHARM INDS INC	**50MG**	**A075964**	**001**	Jun 19, 2002
AB		TEVA	**50MG**	**A075977**	**001**	Jun 19, 2002
AB		UNICHEM	**50MG**	**A211825**	**001**	Aug 09, 2019
AB		ZYDUS PHARMS USA INC	**50MG**	**A090404**	**001**	Jan 31, 2011
		RUBICON	25MG	A208708	003	Nov 27, 2023
			100MG	A208708	002	Jun 28, 2019

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

AB1	**!**	LUPIN LTD	**100MG**	**A200503**	**001**	Aug 29, 2011
AB1			**200MG**	**A200503**	**002**	Aug 29, 2011
AB1			**300MG**	**A200503**	**003**	Aug 29, 2011
AB1		SUN PHARM	**100MG**	**A201384**	**001**	Dec 07, 2011
AB1			**200MG**	**A201384**	**002**	Dec 07, 2011
AB1			**300MG**	**A201384**	**003**	Dec 07, 2011
	!		100MG	A091607	001	Dec 30, 2011
			300MG	A091607	003	Dec 30, 2011

TRAMETINIB DIMETHYL SULFOXIDE

SOLUTION;ORAL

MEKINIST

	+!	NOVARTIS	EQ 0.05MG BASE/ML	N217513	001	Mar 16, 2023

TABLET;ORAL

MEKINIST

	+	NOVARTIS	EQ 0.5MG	N204114	001	May 29, 2013
	+!		EQ 2MG	N204114	003	May 29, 2013

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

AB		AUROBINDO PHARMA	**1MG**	**A078438**	**001**	Jun 12, 2007
AB			**2MG**	**A078438**	**002**	Jun 12, 2007
AB			**4MG**	**A078438**	**003**	Jun 12, 2007
AB		EPIC PHARMA	**1MG**	**A078508**	**003**	Jun 18, 2008
AB			**2MG**	**A078508**	**001**	Jun 18, 2008
AB			**4MG**	**A078508**	**002**	Jun 18, 2008
AB		LUPIN	**1MG**	**A077522**	**001**	Jun 12, 2007
AB			**2MG**	**A077522**	**002**	Jun 12, 2007
AB	**!**		**4MG**	**A077522**	**003**	Jun 12, 2007

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

		GLENMARK GENERICS	1MG;240MG	A079135	004	Aug 30, 2010
			2MG;180MG	A079135	001	May 26, 2010
			2MG;240MG	A079135	002	May 26, 2010
	!		4MG;240MG	A079135	003	May 05, 2010

TRANEXAMIC ACID

INJECTABLE;INJECTION

CYKLOKAPRON

AP	**+!**	PFIZER	**100MG/ML**	**N019281**	**001**	Dec 30, 1986

TRANEXAMIC ACID

AP		ACIC PHARMS	**100MG/ML**	**A202436**	**001**	Feb 11, 2014
AP		AM REGENT	**100MG/ML**	**A201885**	**001**	Aug 10, 2011
AP		AMNEAL PHARMS CO	**100MG/ML**	**A208840**	**001**	Feb 28, 2017
AP		APOTEX	**100MG/ML**	**A209860**	**001**	Jan 14, 2020
AP		AVET LIFESCIENCES	**100MG/ML**	**A203521**	**001**	Aug 12, 2014
AP		CAPLIN	**100MG/ML**	**A212360**	**001**	Jul 17, 2019
AP		EPIC PHARMA LLC	**100MG/ML**	**A202373**	**001**	Nov 17, 2011
AP		EUGIA PHARMA	**100MG/ML**	**A205035**	**001**	Jan 14, 2016
AP		FRESENIUS KABI USA	**100MG/ML**	**A091596**	**001**	Mar 02, 2012
AP		GLAND	**100MG/ML**	**A207239**	**001**	Feb 13, 2017
AP		MICRO LABS	**100MG/ML**	**A206713**	**001**	Jun 27, 2017
AP		MYLAN INSTITUTIONAL	**100MG/ML**	**A091657**	**001**	Nov 03, 2011
AP		PROVEPHARM SAS	**100MG/ML**	**A212676**	**001**	Jul 17, 2019
AP		XGEN PHARMS	**100MG/ML**	**A201580**	**001**	Jun 14, 2013

TRANEXAMIC ACID

SOLUTION;INTRAVENOUS

TRANEXAMIC ACID

AP		AMNEAL	**1GM/100ML (10MG/ML)**	**A217155**	**001**	Oct 16, 2023
AP	**+!**	EXELA PHARMA	**1GM/100ML (10MG/ML)**	**N212020**	**001**	Apr 15, 2019

TABLET;ORAL

LYSTEDA

AB	**+!**	AMRING PHARMS	**650MG**	**N022430**	**001**	Nov 13, 2009

TRANEXAMIC ACID

AB		ACTAVIS LABS FL INC	**650MG**	**A202093**	**001**	Dec 27, 2012
AB		ANI PHARMS	**650MG**	**A203256**	**001**	Jul 25, 2016
AB		AUROBINDO PHARMA USA	**650MG**	**A205133**	**001**	Sep 21, 2015

TRANYLCYPROMINE SULFATE

TABLET;ORAL

PARNATE

AB	**+!**	CONCORDIA	**EQ 10MG BASE**	**N012342**	**003**	Aug 16, 1985

TRANYLCYPROMINE SULFATE

AB		CROSSMEDIKA SA	**EQ 10MG BASE**	**A213503**	**001**	Jun 27, 2022
AB		NOVITIUM PHARMA	**EQ 10MG BASE**	**A206856**	**001**	Apr 17, 2018
AB		STRIDES PHARMA	**EQ 10MG BASE**	**A040640**	**001**	Jun 29, 2006

TRAVOPROST

IMPLANT;INTRACAMERAL

IDOSE TR

	+!	GLAUKOS	75MCG	N218010	001	Dec 13, 2023

SOLUTION/DROPS;OPHTHALMIC

TRAVATAN Z

AT	**+!**	SANDOZ	**0.004%**	**N021994**	**001**	Sep 21, 2006

TRAVOPROST

AT		APOTEX	**0.004%**	**A203431**	**001**	Jul 10, 2015
AT		MICRO LABS	**0.004%**	**A203767**	**001**	Mar 19, 2021
AT		MYLAN	**0.004%**	**A205050**	**001**	Jul 07, 2017
AT1		ALEMBIC	**0.004%**	**A210458**	**001**	Dec 20, 2019
AT1	**!**	CHARTWELL RX	**0.004%**	**A091340**	**001**	Mar 01, 2013

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**50MG**	**A206923**	**001**	Sep 08, 2017
AB			**100MG**	**A206923**	**002**	Sep 08, 2017
AB			**150MG**	**A206923**	**003**	Sep 08, 2017
AB			**300MG**	**A206923**	**004**	Sep 08, 2017
AB		APOTEX	**50MG**	**A071258**	**001**	Mar 25, 1987
AB	**!**	APOTEX INC	**100MG**	**A071196**	**001**	Mar 25, 1987
AB			**150MG**	**A071196**	**002**	Apr 26, 1999
AB			**300MG**	**A071196**	**003**	Apr 26, 1999
AB		AUROBINDO PHARMA	**50MG**	**A204852**	**001**	Feb 05, 2020
AB			**100MG**	**A204852**	**002**	Feb 05, 2020
AB			**150MG**	**A204852**	**003**	Feb 05, 2020
AB			**300MG**	**A204852**	**004**	Feb 05, 2020
AB		OXFORD PHARMS	**50MG**	**A072192**	**001**	Feb 02, 1989
AB			**100MG**	**A072193**	**001**	Feb 02, 1989
AB		PLIVA	**150MG**	**A071525**	**001**	Mar 09, 1988
AB		SUN PHARM INDUSTRIES	**50MG**	**A073137**	**002**	Mar 24, 1993
AB			**100MG**	**A073137**	**001**	Mar 24, 1993
AB			**150MG**	**A073137**	**003**	Dec 22, 1995
AB		TEVA PHARMS USA	**50MG**	**A071523**	**001**	Dec 11, 1987
AB			**100MG**	**A071524**	**001**	Dec 11, 1987
AB		TORRENT	**50MG**	**A202180**	**001**	Nov 27, 2013
AB			**100MG**	**A202180**	**002**	Nov 27, 2013
AB			**150MG**	**A202180**	**003**	Nov 27, 2013
AB			**300MG**	**A202180**	**004**	Nov 27, 2013
AB		ZYDUS PHARMS	**50MG**	**A205253**	**001**	Oct 10, 2017
AB			**100MG**	**A205253**	**002**	Oct 10, 2017
AB			**150MG**	**A205253**	**003**	Oct 10, 2017
AB			**300MG**	**A205253**	**004**	Oct 10, 2017

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

REMODULIN

AP	**+!**	UNITED THERAP	**1MG/ML**	**N021272**	**001**	May 21, 2002
AP	**+!**		**2.5MG/ML**	**N021272**	**002**	May 21, 2002
AP	**+!**		**5MG/ML**	**N021272**	**003**	May 21, 2002
AP	**+!**		**10MG/ML**	**N021272**	**004**	May 21, 2002

TREPROSTINIL

AP		ALEMBIC GLOBAL	**1MG/ML**	**A211574**	**001**	Feb 11, 2021
AP			**2.5MG/ML**	**A211574**	**002**	Feb 11, 2021
AP			**5MG/ML**	**A211574**	**003**	Feb 11, 2021
AP			**10MG/ML**	**A211574**	**004**	Feb 11, 2021
AP		DR REDDYS	**1MG/ML**	**A210214**	**001**	May 22, 2020
AP			**2.5MG/ML**	**A210214**	**002**	May 22, 2020
AP			**5MG/ML**	**A210214**	**003**	May 22, 2020
AP			**10MG/ML**	**A210214**	**004**	May 22, 2020
AP		PAR STERILE PRODUCTS	**1MG/ML**	**A209382**	**001**	Sep 24, 2019
AP			**2.5MG/ML**	**A209382**	**002**	Sep 24, 2019
AP			**5MG/ML**	**A209382**	**003**	Sep 24, 2019
AP			**10MG/ML**	**A209382**	**004**	Sep 24, 2019
AP		SANDOZ	**1MG/ML**	**A203649**	**001**	Nov 30, 2017
AP			**2.5MG/ML**	**A203649**	**002**	Nov 30, 2017
AP			**5MG/ML**	**A203649**	**003**	Nov 30, 2017
AP			**10MG/ML**	**A203649**	**004**	Nov 30, 2017
AP		TEVA PHARMS USA	**1MG/ML**	**A206648**	**001**	Sep 26, 2019
AP			**2.5MG/ML**	**A206648**	**002**	Sep 26, 2019
AP			**5MG/ML**	**A206648**	**003**	Sep 26, 2019
AP			**10MG/ML**	**A206648**	**004**	Sep 26, 2019

REMODULIN

+!	UNITED THERAP	0.1MG/ML	N021272	006	Sep 28, 2023
+!		0.2MG/ML	N021272	007	Sep 28, 2023
+!		0.4MG/ML	N021272	008	Sep 28, 2023
+!		20MG/ML	N021272	005	Jul 30, 2021

POWDER;INHALATION

TYVASO DPI

+	UNITED THERAP	0.016MG/INH	N214324	001	May 23, 2022
+		0.032MG/INH	N214324	002	May 23, 2022
+		0.048MG/INH	N214324	003	May 23, 2022
+!		0.064MG/INH	N214324	004	May 23, 2022

SOLUTION;INHALATION

TYVASO

+!	UNITED THERAP	0.6MG/ML	N022387	001	Jul 30, 2009

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL

ORENITRAM

+	UNITED THERAP	EQ 0.125MG BASE	N203496	001	Dec 20, 2013
+		EQ 0.25MG BASE	N203496	002	Dec 20, 2013
+!		EQ 1MG BASE	N203496	003	Dec 20, 2013
+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013
+		EQ 5MG BASE	N203496	005	Oct 07, 2016

TRETINOIN

CAPSULE;ORAL

TRETINOIN

AB		ANCHEN PHARMS	**10MG**	**A201687**	**001**	Oct 24, 2012
AB	**!**	BARR LABS INC	**10MG**	**A077684**	**001**	Jun 22, 2007
AB		GLENMARK PHARMS LTD	**10MG**	**A208279**	**001**	Dec 23, 2016

CREAM;TOPICAL

AVITA

AB		MYLAN PHARMS INC	**0.025%**	**N020404**	**003**	Jan 14, 1997

RETIN-A

AB	**+!**	BAUSCH	**0.025%**	**N019049**	**001**	Sep 16, 1988
AB	**+!**	VALEANT PHARMS NORTH	**0.1%**	**N017340**	**001**	

TRETINOIN

AB		PADAGIS US	**0.025%**	**A075264**	**001**	Dec 24, 1998
AB			**0.1%**	**A075213**	**001**	Dec 24, 1998
AB		TARO	**0.025%**	**A215713**	**001**	Jan 05, 2023
AB			**0.1%**	**A211645**	**001**	Jan 22, 2019

RETIN-A

AB1	**+!**	VALEANT BERMUDA	**0.05%**	**N017522**	**001**	

TRETINOIN							
CREAM;TOPICAL							
TRETINOIN							
AB1		PADAGIS US	**0.05%**	**A075265**	**001**	Dec 24, 1998
AB1		TARO	**0.05%**	**A211644**	**001**	Jan 25, 2019
RENOVA							
	+!	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000
GEL;TOPICAL							
ATRALIN							
AB	**+!**	DOW PHARM	**0.05%**	**N022070**	**001**	Jul 26, 2007
RETIN-A							
AB	**+!**	VALEANT INTL	**0.01%**	**N017955**	**001**	
AB	**+!**		**0.025%**	**N017579**	**002**	
RETIN-A-MICRO							
AB	**+!**	BAUSCH	**0.08%**	**N020475**	**003**	Jan 28, 2014
TRETINOIN							
AB		MYLAN	**0.05%**	**A207955**	**001**	Aug 13, 2015
AB		PADAGIS US	**0.01%**	**A075589**	**001**	Jun 11, 2002
AB			**0.025%**	**A075529**	**001**	Feb 22, 2000
TRETINOIN MICROSPHERE							
AB		ENCUBE	**0.08%**	**A215609**	**001**	Aug 22, 2023
RETIN-A MICRO							
	+!	BAUSCH	0.04%	N020475	002	May 10, 2002
	+!		0.1%	N020475	001	Feb 07, 1997
RETIN-A-MICRO							
	+!	BAUSCH	0.06%	N020475	004	Oct 23, 2017
LOTION;TOPICAL							
ALTRENO							
	+!	DOW PHARM	0.05%	N209353	001	Aug 23, 2018
TRIAMCINOLONE ACETONIDE							
CREAM;TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT		ALKEM LABS LTD	**0.025%**	**A207651**	**001**	Dec 26, 2017
AT			**0.1%**	**A207651**	**002**	Dec 26, 2017
AT			**0.5%**	**A207651**	**003**	Dec 26, 2017
AT		CHARTWELL RX	**0.025%**	**A208763**	**001**	Feb 01, 2017
AT			**0.1%**	**A208763**	**002**	Feb 01, 2017
AT			**0.5%**	**A208763**	**003**	Feb 01, 2017
AT		COSETTE	**0.025%**	**A089797**	**001**	May 31, 1991
AT			**0.1%**	**A089798**	**001**	May 31, 1991
AT		ENCUBE	**0.1%**	**A208848**	**001**	Sep 18, 2017
AT	**+!**	FOUGERA PHARMS	**0.025%**	**A085692**	**001**	
AT	**+!**		**0.1%**	**A085692**	**003**	
AT	**+!**		**0.5%**	**A085692**	**002**	
AT		GLENMARK PHARMS LTD	**0.1%**	**A207117**	**001**	Aug 05, 2016
AT		MACLEODS PHARMS LTD	**0.025%**	**A209535**	**001**	May 18, 2018
AT			**0.1%**	**A209535**	**002**	May 18, 2018
AT			**0.5%**	**A209535**	**003**	May 18, 2018
AT		MICRO LABS	**0.025%**	**A040671**	**001**	Jun 09, 2006
AT			**0.1%**	**A040671**	**002**	Jun 09, 2006
AT		PADAGIS US	**0.025%**	**A086413**	**002**	
AT			**0.1%**	**A086413**	**003**	
AT			**0.5%**	**A086413**	**001**	
AT		STRIDES PHARMA	**0.025%**	**A210346**	**001**	Feb 11, 2019
AT			**0.1%**	**A210346**	**002**	Feb 11, 2019
AT			**0.5%**	**A210346**	**003**	Feb 11, 2019
AT		TARO	**0.1%**	**A040039**	**001**	Nov 26, 1997
TRIDERM							
AT		CROWN LABS	**0.025%**	**A088042**	**002**	Mar 25, 2015
AT			**0.1%**	**A088042**	**001**	Mar 19, 1984
AT			**0.5%**	**A088042**	**003**	Mar 25, 2015
FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR							
ZILRETTA							
	+!	PACIRA PHARMS INC	32MG/VIAL	N208845	001	Oct 06, 2017
INJECTABLE;INJECTION							
KENALOG-40							
AB	**+!**	APOTHECON	**40MG/ML**	**N014901**	**001**	
TRIAMCINOLONE ACETONIDE							
AB		AMNEAL	**40MG/ML**	**A207550**	**001**	Dec 11, 2017
AB		EUGIA PHARMA	**40MG/ML**	**A212400**	**001**	Jul 05, 2022
AB		LONG GROVE PHARMS	**40MG/ML**	**A213543**	**001**	Jan 19, 2022

TRIAMCINOLONE ACETONIDE

INJECTABLE;INJECTION

TRIAMCINOLONE ACETONIDE

AB		MYLAN LABS LTD	**40MG/ML**	**A212567**	**001**	Nov 02, 2022
AB		TEVA PHARMS USA	**40MG/ML**	**A209852**	**001**	Oct 05, 2018

KENALOG-10

	+	APOTHECON	10MG/ML	N012041	001	

KENALOG-80

	+!	APOTHECON	80MG/ML	N014901	002	Apr 12, 2019

INJECTABLE;INTRAVITREAL

TRIESENCE

	+!	HARROW EYE	40MG/ML (40MG/ML)	N022048	001	Nov 29, 2007

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		COSETTE	**0.1%**	**A089129**	**001**	Aug 14, 1986
AT		EPIC PHARMA LLC	**0.025%**	**A202374**	**001**	May 08, 2013
AT			**0.1%**	**A202374**	**002**	May 08, 2013
AT		FOUGERA PHARMS	**0.025%**	**A040467**	**001**	Apr 21, 2003
AT			**0.1%**	**A040467**	**002**	Apr 21, 2003
AT		MICRO LABS	**0.1%**	**A040672**	**002**	Dec 13, 2006
AT		QUAGEN	**0.025%**	**A213559**	**001**	Jul 01, 2020
AT			**0.1%**	**A213559**	**002**	Jul 01, 2020
AT	!	WOCKHARDT BIO AG	**0.025%**	**A088450**	**001**	Apr 01, 1985
AT	!		**0.1%**	**A088451**	**001**	Apr 03, 1985

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		CHARTWELL RX	**0.05%**	**A214532**	**001**	Jan 27, 2023
AT			**0.1%**	**A207365**	**001**	Oct 12, 2018
AT		CINTEX SVCS	**0.05%**	**A213619**	**001**	Nov 10, 2020
AT		COSETTE	**0.025%**	**A089795**	**001**	Dec 23, 1988
AT			**0.1%**	**A089796**	**001**	Dec 23, 1988
AT			**0.5%**	**A208925**	**001**	Oct 06, 2017
AT	!	ENCUBE	**0.05%**	**A212384**	**001**	Nov 29, 2019
AT			**0.1%**	**A205373**	**001**	May 13, 2016
AT		FOUGERA PHARMS	**0.025%**	**A085691**	**001**	
AT			**0.1%**	**A085691**	**003**	
AT			**0.5%**	**A085691**	**002**	
AT		GLENMARK PHARMS	**0.1%**	**A208320**	**001**	Aug 22, 2017
AT		GLENMARK PHARMS LTD	**0.5%**	**A206379**	**001**	Jul 22, 2016
AT		MACLEODS PHARMS LTD	**0.025%**	**A209828**	**001**	Nov 23, 2018
AT			**0.05%**	**A216625**	**001**	Aug 18, 2023
AT			**0.1%**	**A209828**	**002**	Nov 23, 2018
AT			**0.5%**	**A209828**	**003**	Nov 23, 2018
AT		PADAGIS ISRAEL	**0.05%**	**A212460**	**001**	Feb 05, 2021
AT	+!	PADAGIS US	**0.025%**	**A087385**	**002**	
AT	+!		**0.1%**	**A087385**	**003**	
AT	+!		**0.5%**	**A087385**	**001**	
AT		STRIDES PHARMA	**0.05%**	**A212356**	**001**	Jun 01, 2020
AT		TARO	**0.1%**	**A040037**	**001**	Sep 30, 1994

PASTE;DENTAL

TRIAMCINOLONE ACETONIDE

AT		AKORN	**0.1%**	**A206312**	**001**	Aug 11, 2016
AT		COSETTE	**0.1%**	**A205592**	**001**	Jan 12, 2017
AT		LYNE	**0.1%**	**A040771**	**001**	Jul 01, 2010
AT		QUAGEN	**0.1%**	**A214582**	**001**	Dec 09, 2022
AT	!	TARO	**0.1%**	**A070730**	**001**	Oct 01, 1986

SPRAY;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		AKORN	**0.147MG/GM**	**A207094**	**001**	Dec 07, 2016
AT	!	PADAGIS ISRAEL	**0.147MG/GM**	**A205782**	**001**	Apr 13, 2015
AT		RISING	**0.147MG/GM**	**A206786**	**001**	Sep 08, 2017

SUSPENSION;INJECTION

XIPERE

	+!	BAUSCH AND LOMB INC	40MG/ML	N211950	001	Oct 22, 2021

TRIAMTERENE

CAPSULE;ORAL

DYRENIUM

AB	+	CONCORDIA	**50MG**	**N013174**	**001**	
AB	+!		**100MG**	**N013174**	**002**	

TRIAMTERENE

AB		AGNITIO	**50MG**	**A211581**	**001**	Aug 19, 2019
AB			**100MG**	**A211581**	**002**	Aug 19, 2019

TRIAZOLAM

TABLET;ORAL

HALCION

AB	**+**	PFIZER	**0.125MG**	**N017892**	**003**	Apr 26, 1985
AB	**+!**		**0.25MG**	**N017892**	**001**	Nov 15, 1982

TRIAZOLAM

AB		HIKMA	**0.125MG**	**A074224**	**001**	Jun 01, 1994
AB			**0.25MG**	**A074224**	**002**	Jun 01, 1994
AB		NOVAST LABS	**0.125MG**	**A214219**	**001**	Oct 20, 2020
AB			**0.25MG**	**A214219**	**002**	Oct 20, 2020
AB		SANDOZ	**0.125MG**	**A216890**	**001**	Nov 08, 2022
AB			**0.25MG**	**A216890**	**002**	Nov 08, 2022
AB		ZYDUS PHARMS	**0.125MG**	**A213003**	**001**	Dec 28, 2022
AB			**0.25MG**	**A213003**	**002**	Dec 28, 2022

TRICLABENDAZOLE

TABLET;ORAL

EGATEN

	+!	NOVARTIS	250MG	N208711	001 Feb 13, 2019

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

SYPRINE

AB	**+!**	BAUSCH	**250MG**	**N019194**	**001**	Nov 08, 1985

TRIENTINE HYDROCHLORIDE

AB		DR REDDYS	**250MG**	**A211076**	**001**	Jul 03, 2019
AB		ECI PHARMS LLC	**250MG**	**A209945**	**001**	Aug 13, 2021
AB		HETERO LABS LTD III	**250MG**	**A216356**	**001**	Jun 23, 2022
AB		MSN	**250MG**	**A211134**	**001**	May 22, 2019
AB		NAVINTA LLC	**250MG**	**A211251**	**001**	Jan 16, 2019
AB		PAR PHARM INC	**250MG**	**A210096**	**001**	Sep 25, 2019
AB		RISING	**250MG**	**A212238**	**001**	Feb 20, 2020
AB		WATSON LABS TEVA	**250MG**	**A207567**	**001**	Feb 07, 2018
AB		ZYDUS PHARMS	**250MG**	**A211554**	**001**	Apr 26, 2019
		RISING	500MG	A212238	002	Sep 22, 2023

TRIENTINE TETRAHYDROCHLORIDE

TABLET;ORAL

CUVRIOR

	+!	ORPHALAN	300MG	N215760	001	Apr 28, 2022

TRIFAROTENE

CREAM;TOPICAL

AKLIEF

	+!	GALDERMA LABS LP	0.005%	N211527	001	Oct 04, 2019

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET;ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

AB		MYLAN	**EQ 1MG BASE**	**A040209**	**001**	Jul 07, 1997
AB			**EQ 2MG BASE**	**A040209**	**002**	Jul 07, 1997
AB			**EQ 5MG BASE**	**A040209**	**003**	Jul 07, 1997
AB	**!**		**EQ 10MG BASE**	**A040209**	**004**	Jul 07, 1997
AB		SANDOZ	**EQ 1MG BASE**	**A085785**	**001**	
AB			**EQ 2MG BASE**	**A085786**	**001**	
AB			**EQ 5MG BASE**	**A085789**	**001**	
AB			**EQ 10MG BASE**	**A085788**	**001**	

TRIFLURIDINE

SOLUTION/DROPS;OPHTHALMIC

TRIFLURIDINE

AT		SANDOZ	**1%**	**A074311**	**001**	Oct 06, 1995

VIROPTIC

AT	**+!**	MONARCH PHARMS	**1%**	**N018299**	**001**	

TRIHEPTANOIN

LIQUID;ORAL

DOJOLVI

	+!	ULTRAGENYX PHARM INC	100% w/w	N213687	001	Jun 30, 2020

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR;ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

AA		MIKART	**2MG/5ML**	**A040251**	**001**	Sep 27, 1999
AA	**!**	PHARM ASSOC	**2MG/5ML**	**A040177**	**001**	Apr 17, 1997

TABLET;ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

AA		NATCO PHARMA LTD	**2MG**	**A091630**	**001**	Nov 17, 2010
AA			**5MG**	**A091630**	**002**	Nov 17, 2010
AA		NOVITIUM PHARMA	**2MG**	**A040254**	**001**	Dec 24, 1998
AA			**5MG**	**A040254**	**002**	Dec 24, 1998
AA	**!**	WATSON LABS	**2MG**	**A084363**	**001**	
AA	**!**		**5MG**	**A084364**	**001**	

TRILACICLIB DIHYDROCHLORIDE

POWDER;INTRAVENOUS

COSELA

	+!	G1 THERAP	EQ 300MG BASE/VIAL	N214200 001	Feb 12, 2021

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB		AVET LIFESCIENCES	**300MG**	**A205950**	**001**	Nov 21, 2023
AB		LUPIN	**300MG**	**A076546**	**001**	Aug 20, 2003
AB	**!**	SUN PHARM INDUSTRIES	**300MG**	**A076570**	**001**	Aug 28, 2003

INJECTABLE;INJECTION

TIGAN

	+!	PAR STERILE PRODUCTS	100MG/ML	N017530 001	

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

AB	**+!**	DR REDDYS LABS SA	**100MG**	**N018679**	**001**	Jul 30, 1982
AB		NOVEL LABS INC	**100MG**	**A091437**	**001**	Jun 15, 2011
AB		NOVITIUM PHARMA	**100MG**	**A216393**	**001**	Oct 28, 2022
AB		WATSON LABS	**100MG**	**A070049**	**001**	Jun 06, 1985

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

TRIMIPRAMINE MALEATE

AB		CROSSMEDIKA SA	**EQ 25MG BASE**	**A208127**	**001**	Apr 15, 2016
AB	**!**		**EQ 50MG BASE**	**A208127**	**002**	Apr 15, 2016
AB			**EQ 100MG BASE**	**A208127**	**003**	Apr 15, 2016
AB		ELITE LABS INC	**EQ 25MG BASE**	**A077361**	**001**	Aug 02, 2006
AB			**EQ 50MG BASE**	**A077361**	**002**	Aug 02, 2006
AB			**EQ 100MG BASE**	**A077361**	**003**	Aug 02, 2006

TRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

TRIPTODUR KIT

	+!	AZURITY	EQ 22.5MG BASE/VIAL	N208956 001	Jun 29, 2017

INJECTABLE;INTRAMUSCULAR

TRELSTAR

	+!	VERITY	EQ 3.75MG BASE/VIAL	N020715 001	Jun 15, 2000
	+!		EQ 11.25MG BASE/VIAL	N021288 001	Jun 29, 2001
	+!		EQ 22.5MG BASE/VIAL	N022437 001	Mar 10, 2010

TROFINETIDE

SOLUTION;ORAL

DAYBUE

	+!	ACADIA PHARMS INC	200MG/ML	N217026 001	Mar 10, 2023

TROMETHAMINE

SOLUTION;INJECTION

THAM

	+!	HOSPIRA	18GM/500ML (3.6GM/100ML)	N013025 002	

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

MYDRIACYL

AT	**+!**	ALCON LABS INC	**1%**	**A084306**	**001**	
AT	**+!**	SANDOZ	**0.5%**	**A084305**	**001**	

TROPICACYL

AT		EPIC PHARMA LLC	**0.5%**	**A040314**	**001**	Sep 29, 2000
AT		RISING	**1%**	**A040315**	**001**	Sep 29, 2000

TROPICAMIDE
SOLUTION/DROPS;OPHTHALMIC
TROPICAMIDE

AT		BAUSCH AND LOMB	**0.5%**	**A040067**	**001**	Jul 27, 1994
AT			**1%**	**A040064**	**001**	Jul 27, 1994
AT		SOMERSET THERAPS LLC	**1%**	**A207524**	**001**	Dec 12, 2019

TROSPIUM CHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
TROSPIUM CHLORIDE

AB	**!**	ACTAVIS LABS FL INC	**60MG**	**A091289**	**001**	Oct 12, 2012
AB		AMTA	**60MG**	**A214760**	**001**	Apr 30, 2021
AB		GRANULES	**60MG**	**A213185**	**001**	Apr 23, 2020
AB		PADAGIS US	**60MG**	**A201291**	**001**	May 24, 2013

TABLET;ORAL
TROSPIUM CHLORIDE

AB		APOTEX	**20MG**	**A091513**	**001**	Dec 06, 2011
AB		CHARTWELL RX	**20MG**	**A215781**	**001**	Feb 16, 2022
AB	**!**	GLENMARK GENERICS	**20MG**	**A091575**	**001**	Aug 13, 2010
AB		HERITAGE PHARMS INC	**20MG**	**A204945**	**001**	Aug 30, 2016
AB		INVAGEN PHARMS	**20MG**	**A091688**	**001**	Aug 23, 2016
AB		PADAGIS US	**20MG**	**A091573**	**001**	Nov 17, 2010

TRYPAN BLUE
SOLUTION;OPHTHALMIC
VISIONBLUE

	+!	DORC	0.06%	N021670	001	Dec 16, 2004

TUCATINIB
TABLET;ORAL
TUKYSA

	+	SEAGEN	50MG	N213411	001	Apr 17, 2020
	+!		150MG	N213411	002	Apr 17, 2020

UBROGEPANT
TABLET;ORAL
UBRELVY

	+	ABBVIE	50MG	N211765	001	Dec 23, 2019
	+!		100MG	N211765	002	Dec 23, 2019

ULIPRISTAL ACETATE
TABLET;ORAL
ELLA

AB	**+!**	LAB HRA PHARMA	**30MG**	**N022474**	**001**	Aug 13, 2010

LOGILIA

AB		TEVA PHARMS USA	**30MG**	**A207952**	**001**	Feb 13, 2017

UMECLIDINIUM BROMIDE
POWDER;INHALATION
INCRUSE ELLIPTA

	+!	GLAXO GRP ENGLAND	EQ 62.5MCG BASE/INH	N205382	001	Apr 30, 2014

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE
POWDER;INHALATION
ANORO ELLIPTA

	+!	GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N203975	001	Dec 18, 2013

UPADACITINIB
TABLET, EXTENDED RELEASE;ORAL
RINVOQ

	+	ABBVIE	15MG	N211675	001	Aug 16, 2019
	+		30MG	N211675	002	Jan 14, 2022
	+!		45MG	N211675	003	Mar 16, 2022

UREA, C-14
CAPSULE;ORAL
PYTEST

	+!	AVENT	1uCi	N020617	001	May 09, 1997

URIDINE TRIACETATE
GRANULE;ORAL
VISTOGARD

	+!	BTG INTL	10GM/PACKET	N208159	001	Dec 11, 2015

XURIDEN

	+!	BTG INTL	2GM/PACKET	N208169	001	Sep 04, 2015

URSODIOL

CAPSULE;ORAL

ACTIGALL

AB	**+!**	TEVA BRANDED PHARM	**300MG**	**N019594**	**002**	Dec 31, 1987

URSODIOL

AB		ABHAI LLC	**300MG**	**A210707**	**001**	May 17, 2018
AB		AMNEAL PHARMS CO	**300MG**	**A211301**	**001**	Oct 16, 2018
AB		AUROBINDO PHARMA LTD	**300MG**	**A214849**	**001**	Nov 28, 2022
AB		CHARTWELL RX	**300MG**	**A213555**	**001**	Aug 17, 2020
AB		EPIC PHARMA	**300MG**	**A075517**	**001**	Mar 14, 2000
AB		EYWA PHARMA	**300MG**	**A212452**	**001**	Oct 30, 2019
AB		LANNETT CO INC	**300MG**	**A079082**	**001**	Dec 15, 2008
AB		RISING	**300MG**	**A213200**	**001**	Feb 12, 2020
AB		RK PHARMA	**300MG**	**A214329**	**001**	Jul 28, 2021
AB		STRIDES PHARMA	**300MG**	**A210344**	**001**	Jan 22, 2021
AB		ZYDUS	**300MG**	**A214295**	**001**	Oct 16, 2020
		LGM PHARMA	200MG	A205789	001	May 08, 2020
	!		400MG	A205789	002	May 08, 2020

TABLET;ORAL

URSO 250

AB	**+**	ALLERGAN	**250MG**	**N020675**	**001**	Dec 10, 1997

URSO FORTE

AB	**+!**	ALLERGAN	**500MG**	**N020675**	**002**	Jul 21, 2004

URSODIOL

AB		GLENMARK GENERICS	**250MG**	**A090801**	**001**	Jul 12, 2011
AB			**500MG**	**A090801**	**002**	Jul 12, 2011
AB		PAR PHARM	**250MG**	**A202540**	**001**	Feb 14, 2013
AB			**500MG**	**A202540**	**002**	Feb 14, 2013
AB		STRIDES PHARMA	**250MG**	**A213504**	**001**	Aug 20, 2020
AB			**500MG**	**A213504**	**002**	Aug 20, 2020
AB		ZYDUS	**250MG**	**A211145**	**001**	Oct 30, 2018
AB			**500MG**	**A211145**	**002**	Oct 30, 2018

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB		ADAPTIS	**EQ 500MG BASE**	**A079012**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A079012**	**002**	May 24, 2010
AB		APOTEX	**EQ 500MG BASE**	**A090500**	**001**	Apr 04, 2014
AB			**EQ 1GM BASE**	**A090500**	**002**	Apr 04, 2014
AB		AUROBINDO PHARMA	**EQ 500MG BASE**	**A090682**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A090682**	**002**	May 24, 2010
AB		CADILA	**EQ 500MG BASE**	**A079137**	**001**	Dec 29, 2017
AB			**EQ 1GM BASE**	**A079137**	**002**	Dec 29, 2017
AB		CHARTWELL RX	**EQ 500MG BASE**	**A090216**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A090216**	**002**	May 24, 2010
AB		CIPLA	**EQ 500MG BASE**	**A077135**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A077135**	**002**	May 24, 2010
AB		HETERO LABS LTD V	**EQ 500MG BASE**	**A203047**	**001**	Apr 08, 2015
AB			**EQ 1GM BASE**	**A203047**	**002**	Apr 08, 2015
AB		JUBILANT GENERICS	**EQ 500MG BASE**	**A201506**	**001**	Apr 03, 2012
AB			**EQ 1GM BASE**	**A201506**	**002**	Apr 03, 2012
AB		MYLAN PHARMS INC	**EQ 500MG BASE**	**A078518**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A078518**	**002**	May 24, 2010
AB		SANDOZ	**EQ 500MG BASE**	**A077478**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A077478**	**002**	May 24, 2010
AB		SUN PHARM INDS LTD	**EQ 500MG BASE**	**A076588**	**001**	Jan 31, 2007
AB			**EQ 1GM BASE**	**A076588**	**002**	Jan 31, 2007
AB		YILING	**EQ 500MG BASE**	**A209553**	**001**	Mar 18, 2020
AB			**EQ 1GM BASE**	**A209553**	**002**	Mar 18, 2020

VALTREX

AB	**+**	GLAXOSMITHKLINE	**EQ 500MG BASE**	**N020487**	**001**	Jun 23, 1995
AB	**+!**		**EQ 1GM BASE**	**N020487**	**002**	Jun 23, 1995

VALBENAZINE TOSYLATE

CAPSULE;ORAL

INGREZZA

	+	NEUROCRINE	EQ 40MG BASE	N209241	001	Apr 11, 2017
	+		EQ 60MG BASE	N209241	003	Apr 23, 2021
	+!		EQ 80MG BASE	N209241	002	Oct 04, 2017

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

AB	**+!**	CHEPLAPHARM	**50MG/ML**	**N022257**	**001**	Aug 28, 2009

VALGANCICLOVIR HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**50MG/ML**	**A205220**	**001**	Jul 18, 2016
AB		AJANTA PHARMA LTD	**50MG/ML**	**A212890**	**001**	Jan 13, 2020
AB		APPCO	**50MG/ML**	**A216317**	**001**	Apr 11, 2023
AB		AUROBINDO PHARMA	**50MG/ML**	**A215124**	**001**	Nov 17, 2022
AB		GRANULES	**50MG/ML**	**A213306**	**001**	Jan 31, 2020
AB		HETERO LABS LTD V	**50MG/ML**	**A211475**	**001**	Oct 04, 2022
AB		MSN	**50MG/ML**	**A210169**	**001**	Feb 17, 2022

TABLET;ORAL

VALCYTE

AB	**+!**	CHEPLAPHARM	**EQ 450MG BASE**	**N021304**	**001**	Mar 29, 2001

VALGANCICLOVIR HYDROCHLORIDE

AB		AJANTA PHARMA LTD	**EQ 450MG BASE**	**A212234**	**001**	Dec 26, 2019
AB		AUROBINDO PHARMA LTD	**EQ 450MG BASE**	**A204750**	**001**	Mar 31, 2016
AB		DR REDDYS	**EQ 450MG BASE**	**A203511**	**001**	Nov 04, 2014
AB			**EQ 450MG BASE**	**A206876**	**001**	Dec 12, 2017
AB		HETERO LABS LTD V	**EQ 450MG BASE**	**A205166**	**001**	Mar 18, 2016
AB		STRIDES PHARMA	**EQ 450MG BASE**	**A200790**	**001**	Nov 04, 2014

VALPROATE SODIUM

INJECTABLE;INJECTION

VALPROATE SODIUM

AP		FRESENIUS KABI USA	**EQ 100MG BASE/ML**	**A076539**	**001**	Jun 26, 2003
AP	**!**	HIKMA FARMACEUTICA	**EQ 100MG BASE/ML**	**A078523**	**001**	Feb 17, 2010
AP		SAGENT	**EQ 100MG BASE/ML**	**A076295**	**001**	Nov 14, 2002

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB	**!**	BIONPHARMA	**250MG**	**A073484**	**001**	Jun 29, 1993
AB		CATALENT	**250MG**	**A073229**	**001**	Oct 29, 1991
AB		SUN PHARM INDS LTD	**250MG**	**A091037**	**001**	Feb 22, 2013
BX		EYWA	250MG	A207611	001	Aug 05, 2019

SYRUP;ORAL

VALPROIC ACID

AA		ANI PHARMS	**250MG/5ML**	**A073178**	**001**	Aug 25, 1992
AA		CHARTWELL RX	**250MG/5ML**	**A075782**	**001**	Dec 22, 2000
AA		HIKMA	**250MG/5ML**	**A074060**	**001**	Jan 13, 1995
AA	**!**	PHARM ASSOC	**250MG/5ML**	**A075379**	**001**	Dec 15, 2000
AA		SCIEGEN PHARMS INC	**250MG/5ML**	**A090517**	**001**	May 28, 2010

VALRUBICIN

SOLUTION;INTRAVESICAL

VALRUBICIN

AO		HIKMA	**40MG/ML**	**A206430**	**001**	Apr 19, 2019

VALSTAR PRESERVATIVE FREE

AO	**+!**	ENDO PHARM	**40MG/ML**	**N020892**	**001**	Sep 25, 1998

VALSARTAN

SOLUTION;ORAL

VALSARTAN

	!	NOVITIUM PHARMA	20MG/5ML	A214102	001	Nov 02, 2021

TABLET;ORAL

DIOVAN

AB	**+**	NOVARTIS	**40MG**	**N021283**	**004**	Aug 14, 2002
AB	**+**		**80MG**	**N021283**	**001**	Jul 18, 2001
AB	**+**		**160MG**	**N021283**	**002**	Jul 18, 2001
AB	**+!**		**320MG**	**N021283**	**003**	Jul 18, 2001

VALSARTAN

AB		ALEMBIC	**40MG**	**A091367**	**001**	Jan 05, 2015
AB			**80MG**	**A091367**	**002**	Jan 05, 2015
AB			**160MG**	**A091367**	**003**	Jan 05, 2015
AB			**320MG**	**A091367**	**004**	Jan 05, 2015
AB		ALKEM LABS LTD	**40MG**	**A205536**	**001**	Mar 12, 2019
AB			**80MG**	**A205536**	**002**	Mar 12, 2019
AB			**160MG**	**A205536**	**003**	Mar 12, 2019
AB			**320MG**	**A205536**	**004**	Mar 12, 2019
AB		AMNEAL PHARMS	**40MG**	**A204011**	**001**	Jan 11, 2016
AB			**80MG**	**A204011**	**002**	Jan 11, 2016
AB			**160MG**	**A204011**	**003**	Jan 11, 2016

VALSARTAN

TABLET;ORAL

VALSARTAN

AB			**320MG**	**A204011**	**004**	Jan 11, 2016
AB		AUROBINDO PHARMA LTD	**40MG**	**A202223**	**001**	Jan 05, 2015
AB			**80MG**	**A202223**	**002**	Jan 05, 2015
AB			**160MG**	**A202223**	**003**	Jan 05, 2015
AB			**320MG**	**A202223**	**004**	Jan 05, 2015
AB		DR REDDYS	**40MG**	**A201618**	**001**	Oct 05, 2021
AB			**80MG**	**A201618**	**002**	Oct 05, 2021
AB			**160MG**	**A201618**	**003**	Oct 05, 2021
AB			**320MG**	**A201618**	**004**	Oct 05, 2021
AB		HETERO LABS LTD V	**40MG**	**A203311**	**001**	Jan 05, 2015
AB			**80MG**	**A203311**	**002**	Jan 05, 2015
AB			**160MG**	**A203311**	**003**	Jan 05, 2015
AB			**320MG**	**A203311**	**004**	Jan 05, 2015
AB		JUBILANT GENERICS	**40MG**	**A203536**	**001**	Jan 05, 2015
AB			**80MG**	**A203536**	**002**	Jan 05, 2015
AB			**160MG**	**A203536**	**003**	Jan 05, 2015
AB			**320MG**	**A203536**	**004**	Jan 05, 2015
AB		LUPIN LTD	**40MG**	**A201677**	**001**	Jan 05, 2015
AB			**80MG**	**A201677**	**002**	Jan 05, 2015
AB			**160MG**	**A201677**	**003**	Jan 05, 2015
AB			**320MG**	**A201677**	**004**	Jan 05, 2015
AB		MACLEODS PHARMS LTD	**40MG**	**A202696**	**001**	Sep 16, 2016
AB			**80MG**	**A202696**	**002**	Sep 16, 2016
AB			**160MG**	**A202696**	**003**	Sep 16, 2016
AB			**320MG**	**A202696**	**004**	Sep 16, 2016
AB		MYLAN	**40MG**	**A090866**	**001**	Jan 05, 2015
AB			**80MG**	**A090866**	**002**	Jan 05, 2015
AB			**160MG**	**A090866**	**003**	Jan 05, 2015
AB			**320MG**	**A090866**	**004**	Jan 05, 2015
AB		OHM LABS INC	**40MG**	**A077492**	**001**	Jun 26, 2014
AB			**80MG**	**A077492**	**002**	Jun 26, 2014
AB			**160MG**	**A077492**	**003**	Jun 26, 2014
AB			**320MG**	**A077492**	**004**	Jun 26, 2014
AB		PRINSTON INC	**40MG**	**A204821**	**001**	Jun 09, 2015
AB			**80MG**	**A204821**	**002**	Jun 09, 2015
AB			**160MG**	**A204821**	**003**	Jun 09, 2015
AB			**320MG**	**A204821**	**004**	Jun 09, 2015
AB		SCIEGEN PHARMS INC	**40MG**	**A204038**	**001**	Oct 27, 2021
AB			**80MG**	**A204038**	**002**	Oct 27, 2021
AB			**160MG**	**A204038**	**003**	Oct 27, 2021
AB			**320MG**	**A204038**	**004**	Oct 27, 2021
AB		SQUARE PHARMS	**40MG**	**A205347**	**001**	Apr 09, 2018
AB			**80MG**	**A205347**	**002**	Apr 09, 2018
AB			**160MG**	**A205347**	**003**	Apr 09, 2018
AB			**320MG**	**A205347**	**004**	Apr 09, 2018

VAMOROLONE

SUSPENSION;ORAL

AGAMREE

+!		CATALYST PHARMS	40MG/ML	N215239	001	Oct 26, 2023

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOCIN HYDROCHLORIDE

AB	**+**	ANI PHARMS	**EQ 125MG BASE**	**N050606**	**001**	Apr 15, 1986
AB	**+!**		**EQ 250MG BASE**	**N050606**	**002**	Apr 15, 1986

VANCOMYCIN HYDROCHLORIDE

AB		LUPIN LTD	**EQ 125MG BASE**	**A090439**	**001**	Jan 28, 2015
AB			**EQ 250MG BASE**	**A090439**	**002**	Jan 28, 2015
AB		ORIENT PHARMA CO LTD	**EQ 125MG BASE**	**A210729**	**001**	Apr 29, 2019
AB			**EQ 250MG BASE**	**A210729**	**002**	Apr 29, 2019
AB		PAI HOLDINGS PHARM	**EQ 125MG BASE**	**A065478**	**001**	Apr 09, 2012
AB			**EQ 250MG BASE**	**A065478**	**002**	Apr 09, 2012
AB		STRIDES PHARMA	**EQ 125MG BASE**	**A065490**	**001**	Apr 09, 2012
AB			**EQ 250MG BASE**	**A065490**	**002**	Apr 09, 2012

FOR SOLUTION;ORAL

VANCOCIN HYDROCHLORIDE

AA	**!**	ANI PHARMS	**EQ 250MG BASE/5ML**	**A061667**	**002**	Jul 13, 1983

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION;ORAL

VANCOMYCIN HYDROCHLORIDE

AA		AMNEAL	**EQ 250MG BASE/5ML**	**A215338**	**001**	Jun 23, 2023

FIRVANQ KIT

AB	**+!**	AZURITY	**EQ 25MG BASE/ML**	**N208910**	**001**	Jan 26, 2018
AB	**+!**		**EQ 50MG BASE/ML**	**N208910**	**002**	Jan 26, 2018

VANCOMYCIN HYDROCHLORIDE

AB		ALKEM LABS LTD	**EQ 25MG BASE/ML**	**A214913**	**001**	Nov 14, 2022
AB			**EQ 50MG BASE/ML**	**A214913**	**002**	Nov 14, 2022

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP		ASPIRO	**EQ 500MG BASE/VIAL**	**A216591**	**001**	Jul 06, 2022
AP			**EQ 1GM BASE/VIAL**	**A216591**	**002**	Jul 06, 2022
AP		EUGIA PHARMA	**EQ 500MG BASE/VIAL**	**A205780**	**001**	Mar 31, 2016
AP			**EQ 1GM BASE/VIAL**	**A205780**	**002**	Mar 31, 2016
AP			**EQ 5GM BASE/VIAL**	**A205779**	**001**	Mar 29, 2016
AP			**EQ 10GM BASE/VIAL**	**A205779**	**002**	Mar 29, 2016
AP	**!**	FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A062663**	**001**	Mar 17, 1987
AP			**EQ 750MG BASE/VIAL**	**A062663**	**005**	Aug 17, 2016
AP	**!**		**EQ 1GM BASE/VIAL**	**A062663**	**002**	Jul 31, 1987
AP	**!**		**EQ 5GM BASE/VIAL**	**A062663**	**003**	Jun 03, 1988
AP	**!**		**EQ 10GM BASE/VIAL**	**A062663**	**004**	Nov 28, 1997
AP		GLAND PHARMA LTD	**EQ 500MG BASE/VIAL**	**A205694**	**001**	Jan 21, 2016
AP			**EQ 1GM BASE/VIAL**	**A205694**	**002**	Jan 21, 2016
AP			**EQ 5GM BASE/VIAL**	**A205694**	**003**	Jun 06, 2023
AP			**EQ 10GM BASE/VIAL**	**A205694**	**004**	Jun 06, 2023
AP		HAINAN POLY	**EQ 5GM BASE/VIAL**	**A215821**	**001**	Nov 18, 2021
AP			**EQ 10GM BASE/VIAL**	**A215821**	**002**	Nov 18, 2021
AP		HAINAN POLY PHARM	**EQ 500MG BASE/VIAL**	**A212332**	**001**	Jun 12, 2019
AP			**EQ 1GM BASE/VIAL**	**A212332**	**002**	Jun 12, 2019
AP		HIKMA	**EQ 1GM BASE/VIAL**	**A203300**	**002**	Aug 11, 2020
AP			**EQ 5GM BASE/VIAL**	**A204360**	**001**	Oct 15, 2018
AP			**EQ 10GM BASE/VIAL**	**A204360**	**002**	Oct 15, 2018
AP		HIKMA PHARMS	**EQ 750MG BASE/VIAL**	**A206616**	**001**	Oct 03, 2018
AP	**!**	HOSPIRA	**EQ 500MG BASE/VIAL**	**A062911**	**001**	Aug 04, 1988
AP	**!**		**EQ 500MG BASE/VIAL**	**A062931**	**001**	Oct 29, 1992
AP			**EQ 750MG BASE/VIAL**	**A062912**	**002**	Jan 07, 2009
AP			**EQ 750MG BASE/VIAL**	**A062933**	**002**	May 27, 2009
AP	**!**		**EQ 1GM BASE/VIAL**	**A062912**	**001**	Aug 04, 1988
AP	**!**		**EQ 1GM BASE/VIAL**	**A062933**	**001**	Oct 29, 1992
AP	**!**		**EQ 5GM BASE/VIAL**	**A063076**	**001**	Dec 21, 1990
AP			**EQ 10GM BASE/VIAL**	**A063076**	**002**	Sep 14, 2020
AP		HOSPIRA INC	**EQ 10GM BASE/VIAL**	**A065455**	**001**	Apr 29, 2009
AP		MEITHEAL	**EQ 500MG BASE/VIAL**	**A215197**	**001**	Jul 28, 2022
AP			**EQ 750MG BASE/VIAL**	**A215195**	**001**	Sep 15, 2022
AP			**EQ 1GM BASE/VIAL**	**A215197**	**002**	Jul 28, 2022
AP			**EQ 5GM BASE/VIAL**	**A215196**	**001**	Jul 27, 2022
AP			**EQ 10GM BASE/VIAL**	**A215196**	**002**	Jul 27, 2022
AP		MYLAN LABS LTD	**EQ 500MG BASE/VIAL**	**A065397**	**001**	Dec 30, 2008
AP			**EQ 1GM BASE/VIAL**	**A065397**	**002**	Dec 30, 2008
AP			**EQ 5GM BASE/VIAL**	**A065432**	**001**	Dec 30, 2008
AP	**!**		**EQ 10GM BASE/VIAL**	**A091554**	**001**	Sep 19, 2011
AP		PHARM ASSOC	**EQ 500MG BASE/VIAL**	**A065401**	**001**	Jun 30, 2008
AP			**EQ 1GM BASE/VIAL**	**A065401**	**002**	Jun 30, 2008
AP		SAGENT PHARMS	**EQ 5GM BASE/VIAL**	**A200837**	**001**	Aug 10, 2012
AP			**EQ 10GM BASE/VIAL**	**A200837**	**002**	Sep 02, 2014
AP		SANDOZ INC	**EQ 5GM BASE/VIAL**	**A201048**	**001**	Aug 10, 2012
AP			**EQ 10GM BASE/VIAL**	**A201048**	**002**	Aug 10, 2012
AP		XELLIA PHARMS APS	**EQ 5GM BASE/VIAL**	**A204125**	**001**	Dec 28, 2015
AP			**EQ 10GM BASE/VIAL**	**A204125**	**002**	Dec 28, 2015
AP			**EQ 500MG BASE/VIAL**	**A204107**	**001**	Dec 28, 2015
AP			**EQ 1GM BASE/VIAL**	**A204107**	**002**	Dec 28, 2015

VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993
+!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010
+!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999

VANCOMYCIN HYDROCHLORIDE

!	HOSPIRA	EQ 1.5GM BASE/VIAL	A062912	003	Jul 10, 2020

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

AP		EUGIA PHARMA	**EQ 1.25GM BASE/VIAL**	**A217401**	**001**	Aug 04, 2023

VANCOMYCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

AP			**EQ 1.5GM BASE/VIAL**	**A217401**	**002**	Aug 04, 2023
AP		HIKMA	**EQ 1.25GM BASE/VIAL**	**A217489**	**001**	Jun 29, 2023
AP			**EQ 1.5GM BASE/VIAL**	**A217489**	**002**	Jun 29, 2023
AP	**+!**	MYLAN LABS LTD	**EQ 1.25GM BASE/VIAL**	**N209481**	**003**	Jul 10, 2018
AP	**+!**		**EQ 1.5GM BASE/VIAL**	**N209481**	**004**	Jul 10, 2018
	+!		EQ 750MG BASE/VIAL	N209481	002	Jul 10, 2018

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

		SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016

POWDER;INTRAVENOUS, ORAL

VANCOMYCIN HYDROCHLORIDE

	+!	ZHEJIANG NOVUS PHARM	EQ 500MG BASE/VIAL	N210274	001	Jan 20, 2023
	+!		EQ 1GM BASE/VIAL	N210274	002	Jan 20, 2023
	+!		EQ 5GM BASE/VIAL	N210274	003	Jan 20, 2023
	+!		EQ 10GM BASE/VIAL	N210274	004	Jan 20, 2023

SOLUTION;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

	+!	XELLIA PHARMS APS	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019
	+!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020
	+!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019
	+!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020
	+!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019
	+!		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020
	+!		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019

VANDETANIB

TABLET;ORAL

CAPRELSA

	+	GENZYME CORP	100MG	N022405	001	Apr 06, 2011
	+!		300MG	N022405	002	Apr 06, 2011

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

VARDENAFIL HYDROCHLORIDE

AB		ALEMBIC	**EQ 2.5MG BASE**	**A214031**	**001**	Aug 04, 2020
AB			**EQ 5MG BASE**	**A214031**	**002**	Aug 04, 2020
AB			**EQ 10MG BASE**	**A214031**	**003**	Aug 04, 2020
AB			**EQ 20MG BASE**	**A214031**	**004**	Aug 04, 2020
AB		CROSSMEDIKA SA	**EQ 2.5MG BASE**	**A209057**	**001**	Oct 31, 2018
AB			**EQ 5MG BASE**	**A209057**	**002**	Oct 31, 2018
AB			**EQ 10MG BASE**	**A209057**	**003**	Oct 31, 2018
AB			**EQ 20MG BASE**	**A209057**	**004**	Oct 31, 2018
AB		MACLEODS PHARMS LTD	**EQ 2.5MG BASE**	**A204632**	**001**	Oct 22, 2019
AB			**EQ 5MG BASE**	**A204632**	**002**	Oct 22, 2019
AB			**EQ 10MG BASE**	**A204632**	**003**	Oct 22, 2019
AB			**EQ 20MG BASE**	**A204632**	**004**	Oct 22, 2019
AB		TEVA PHARMS	**EQ 2.5MG BASE**	**A091347**	**001**	May 03, 2012
AB			**EQ 5MG BASE**	**A091347**	**002**	May 03, 2012
AB			**EQ 10MG BASE**	**A091347**	**003**	May 03, 2012
AB			**EQ 20MG BASE**	**A091347**	**004**	May 03, 2012
AB		ZYDUS PHARMS	**EQ 2.5MG BASE**	**A208960**	**001**	Oct 31, 2018
AB			**EQ 5MG BASE**	**A208960**	**002**	Oct 31, 2018
AB			**EQ 10MG BASE**	**A208960**	**003**	Oct 31, 2018
AB	**!**		**EQ 20MG BASE**	**A208960**	**004**	Oct 31, 2018

TABLET, ORALLY DISINTEGRATING;ORAL

VARDENAFIL HYDROCHLORIDE

AB	**!**	ALEMBIC	**10MG**	**A208324**	**001**	Nov 16, 2018
AB		MACLEODS PHARMS LTD	**10MG**	**A205988**	**001**	Mar 10, 2020

VARENICLINE TARTRATE

SPRAY;NASAL

TYRVAYA

	+!	OYSTER POINT PHARMA	EQ 0.03MG BASE/SPRAY	N213978	001	Oct 15, 2021

TABLET;ORAL

VARENICLINE TARTRATE

AB		ALKEM LABS LTD	**EQ 0.5MG BASE**	**A214557**	**001**	Aug 23, 2023
AB			**EQ 1MG BASE**	**A214557**	**002**	Aug 23, 2023
AB		APOTEX	**EQ 0.5MG BASE**	**A201962**	**001**	Jan 25, 2023
AB			**EQ 1MG BASE**	**A201962**	**002**	Jan 25, 2023
AB		HETERO LABS LTD III	**EQ 0.5MG BASE**	**A214571**	**001**	Oct 23, 2023
AB			**EQ 1MG BASE**	**A214571**	**002**	Oct 23, 2023

VARENICLINE TARTRATE

TABLET;ORAL

VARENICLINE TARTRATE

AB		LEADING PHARMA	**EQ 0.5MG BASE**	**A217151**	**001**	Jul 25, 2023
AB			**EQ 1MG BASE**	**A217151**	**002**	Jul 25, 2023
AB		LUPIN LTD	**EQ 0.5MG BASE**	**A211862**	**001**	Dec 04, 2023
AB			**EQ 1MG BASE**	**A211862**	**002**	Dec 04, 2023
AB		MANKIND PHARMA	**EQ 0.5MG BASE**	**A214255**	**001**	Aug 01, 2023
AB			**EQ 1MG BASE**	**A214255**	**002**	Aug 01, 2023
AB		PAR PHARM INC	**EQ 0.5MG BASE**	**A201785**	**001**	Aug 11, 2021
AB	**!**		**EQ 1MG BASE**	**A201785**	**002**	Aug 11, 2021
AB		ZYDUS	**EQ 0.5MG BASE**	**A216723**	**001**	Jun 12, 2023
AB			**EQ 1MG BASE**	**A216723**	**002**	Jun 12, 2023

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOPRESSIN

AP		AMNEAL	**20UNITS/ML (20UNITS/ML)**	**A212944**	**001**	Aug 05, 2022
AP		AMPHASTAR PHARMS INC	**20UNITS/ML (20UNITS/ML)**	**A211857**	**001**	Jul 18, 2022
AP		CIPLA	**20UNITS/100ML (0.2UNITS/ML)**	**A217987**	**001**	Dec 06, 2023
AP		EAGLE PHARMS	**20UNITS/ML (20UNITS/ML)**	**A211538**	**001**	Dec 15, 2021
AP		EUGIA PHARMA	**20UNITS/ML (20UNITS/ML)**	**A214314**	**001**	Aug 15, 2022
AP		FRESENIUS KABI USA	**20UNITS/ML (20UNITS/ML)**	**A213206**	**001**	May 26, 2023

VASOSTRICT

AP	**+!**	PAR STERILE PRODUCTS	**20UNITS/ML (20UNITS/ML)**	**N204485**	**001**	Apr 17, 2014
AP	**+!**		**20UNITS/100ML (0.2UNITS/ML)**	**N204485**	**005**	Apr 21, 2021

VASOPRESSIN

+!	AM REGENT	20UNITS/ML (20UNITS/ML)	N212593	001	Aug 03, 2020
+!		200UNITS/10ML (20UNITS/ML)	N212593	002	Jun 09, 2023

VASOPRESSIN IN SODIUM CHLORIDE 0.9%

+!	BAXTER HLTHCARE CORP	20UNITS/100ML (0.2UNITS/ML)	N217569	001	Sep 29, 2023
+!		40UNITS/100ML (0.4UNITS/ML)	N217569	002	Sep 29, 2023

VASOSTRICT

+!	PAR STERILE PRODUCTS	40UNITS/100ML (0.4UNITS/ML)	N204485	003	Apr 15, 2020
+!		200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016

VECURONIUM BROMIDE

INJECTABLE;INJECTION

VECURONIUM BROMIDE

AP		EUGIA PHARMA	**10MG/VIAL**	**A206670**	**001**	Dec 20, 2018
AP			**20MG/VIAL**	**A206670**	**002**	Dec 20, 2018
AP		GLAND	**10MG/VIAL**	**A205390**	**001**	May 26, 2016
AP			**20MG/VIAL**	**A205390**	**002**	May 26, 2016
AP		HIKMA	**10MG/VIAL**	**A075549**	**001**	Jun 13, 2000
AP			**10MG/VIAL**	**A203725**	**001**	Jul 30, 2019
AP			**20MG/VIAL**	**A075549**	**002**	Jun 13, 2000
AP			**20MG/VIAL**	**A203725**	**002**	Jul 30, 2019
AP		HOSPIRA	**10MG/VIAL**	**A075164**	**001**	Oct 21, 1999
AP			**20MG/VIAL**	**A075164**	**002**	Oct 21, 1999
AP		MEITHEAL	**10MG/VIAL**	**A074688**	**001**	Aug 25, 1999
AP			**20MG/VIAL**	**A074688**	**002**	Aug 25, 1999
AP		MYLAN LABS LTD	**10MG/VIAL**	**A090243**	**001**	May 11, 2010
AP			**20MG/VIAL**	**A090243**	**002**	May 11, 2010
AP		SAGENT PHARMS INC	**10MG/VIAL**	**A078274**	**001**	Dec 29, 2008
AP			**20MG/VIAL**	**A078274**	**002**	Dec 29, 2008
AP	**!**	SUN PHARM	**10MG/VIAL**	**A079001**	**001**	Jun 17, 2009
AP	**!**		**20MG/VIAL**	**A079001**	**002**	Jun 17, 2009

VEMURAFENIB

TABLET;ORAL

ZELBORAF

+!	HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011

VENETOCLAX

TABLET;ORAL

VENCLEXTA

+	ABBVIE	10MG	N208573	001	Apr 11, 2016
+		50MG	N208573	002	Apr 11, 2016
+!		100MG	N208573	003	Apr 11, 2016

VENLAFAXINE BESYLATE

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE BESYLATE

	+!	ALMATICA	EQ 112.5MG BASE	N215429	001	Jun 29, 2022

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EFFEXOR XR

AB	**+**	UPJOHN	**EQ 37.5MG BASE**	**N020699**	**001**	Oct 20, 1997
AB	**+**		**EQ 75MG BASE**	**N020699**	**002**	Oct 20, 1997
AB	**+!**		**EQ 150MG BASE**	**N020699**	**004**	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

AB		ANNORA PHARMA	**EQ 37.5MG BASE**	**A212277**	**001**	Jul 08, 2019
AB			**EQ 75MG BASE**	**A212277**	**002**	Jul 08, 2019
AB			**EQ 150MG BASE**	**A212277**	**003**	Jul 08, 2019
AB		AUROBINDO PHARMA LTD	**EQ 37.5MG BASE**	**A200834**	**001**	Apr 14, 2011
AB			**EQ 75MG BASE**	**A200834**	**002**	Apr 14, 2011
AB			**EQ 150MG BASE**	**A200834**	**003**	Apr 14, 2011
AB		DR REDDYS LABS LTD	**EQ 37.5MG BASE**	**A078421**	**001**	May 06, 2011
AB			**EQ 75MG BASE**	**A078421**	**002**	May 06, 2011
AB			**EQ 150MG BASE**	**A078421**	**003**	May 06, 2011
AB		GRANULES	**EQ 37.5MG BASE**	**A217390**	**001**	May 18, 2023
AB			**EQ 75MG BASE**	**A217390**	**002**	May 18, 2023
AB			**EQ 150MG BASE**	**A217390**	**003**	May 18, 2023
AB		INTELLIPHARMACEUTICS	**EQ 37.5MG BASE**	**A201272**	**001**	Nov 23, 2018
AB			**EQ 75MG BASE**	**A201272**	**002**	Nov 23, 2018
AB			**EQ 150MG BASE**	**A201272**	**003**	Nov 23, 2018
AB		INVENTIA HLTHCARE	**EQ 37.5MG BASE**	**A203332**	**001**	Mar 12, 2020
AB			**EQ 75MG BASE**	**A203332**	**002**	Mar 12, 2020
AB			**EQ 150MG BASE**	**A203332**	**003**	Mar 12, 2020
AB		MACLEODS PHARMS LTD	**EQ 37.5MG BASE**	**A204889**	**001**	Oct 05, 2017
AB			**EQ 75MG BASE**	**A204889**	**002**	Oct 05, 2017
AB			**EQ 150MG BASE**	**A204889**	**003**	Oct 05, 2017
AB		NOSTRUM PHARMS LLC	**EQ 37.5MG BASE**	**A200430**	**001**	Apr 04, 2023
AB			**EQ 75MG BASE**	**A200430**	**002**	Apr 04, 2023
AB			**EQ 150MG BASE**	**A200430**	**003**	Apr 04, 2023
AB		ORBION PHARMS	**EQ 37.5MG BASE**	**A091123**	**001**	Jul 11, 2011
AB			**EQ 75MG BASE**	**A091123**	**002**	Jul 11, 2011
AB			**EQ 150MG BASE**	**A091123**	**003**	Jul 11, 2011
AB		TEVA	**EQ 37.5MG BASE**	**A076565**	**001**	Jun 28, 2010
AB			**EQ 75MG BASE**	**A076565**	**002**	Jun 28, 2010
AB			**EQ 150MG BASE**	**A076565**	**003**	Jun 28, 2010
AB		VALEANT PHARMS NORTH	**EQ 37.5MG BASE**	**A090071**	**001**	Apr 15, 2011
AB			**EQ 75MG BASE**	**A090071**	**002**	Apr 15, 2011
AB			**EQ 150MG BASE**	**A090071**	**003**	Apr 15, 2011
AB		WOCKHARDT BIO AG	**EQ 37.5MG BASE**	**A078865**	**001**	Apr 14, 2011
AB			**EQ 75MG BASE**	**A078865**	**002**	Apr 14, 2011
AB			**EQ 150MG BASE**	**A078865**	**003**	Apr 14, 2011
AB		YICHANG HUMANWELL	**EQ 37.5MG BASE**	**A214654**	**001**	Aug 06, 2021
AB			**EQ 75MG BASE**	**A214654**	**002**	Aug 06, 2021
AB			**EQ 150MG BASE**	**A214654**	**003**	Aug 06, 2021
AB		ZYDUS PHARMS USA INC	**EQ 37.5MG BASE**	**A090174**	**001**	Apr 14, 2011
AB			**EQ 75MG BASE**	**A090174**	**002**	Apr 14, 2011
AB			**EQ 150MG BASE**	**A090174**	**003**	Apr 14, 2011

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**EQ 25MG BASE**	**A078932**	**001**	Dec 14, 2010
AB			**EQ 37.5MG BASE**	**A078932**	**002**	Dec 14, 2010
AB			**EQ 50MG BASE**	**A078932**	**003**	Dec 14, 2010
AB			**EQ 75MG BASE**	**A078932**	**004**	Dec 14, 2010
AB			**EQ 100MG BASE**	**A078932**	**005**	Dec 14, 2010
AB		AMNEAL PHARMS	**EQ 25MG BASE**	**A079098**	**001**	May 11, 2010
AB			**EQ 37.5MG BASE**	**A079098**	**002**	May 11, 2010
AB			**EQ 50MG BASE**	**A079098**	**003**	May 11, 2010
AB			**EQ 75MG BASE**	**A079098**	**004**	May 11, 2010
AB			**EQ 100MG BASE**	**A079098**	**005**	May 11, 2010
AB		AUROBINDO PHARMA	**EQ 25MG BASE**	**A090555**	**001**	Apr 07, 2010
AB			**EQ 37.5MG BASE**	**A090555**	**002**	Apr 07, 2010
AB			**EQ 50MG BASE**	**A090555**	**003**	Apr 07, 2010
AB			**EQ 75MG BASE**	**A090555**	**004**	Apr 07, 2010

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB			EQ 100MG BASE	A090555	005	Apr 07, 2010
AB		CADILA PHARMS LTD	EQ 25MG BASE	A206250	001	Nov 21, 2018
AB			EQ 37.5MG BASE	A206250	002	Nov 21, 2018
AB			EQ 50MG BASE	A206250	003	Nov 21, 2018
AB			EQ 75MG BASE	A206250	004	Nov 21, 2018
AB			EQ 100MG BASE	A206250	005	Nov 21, 2018
AB		DR REDDYS LABS LTD	EQ 25MG BASE	A078301	001	Jun 13, 2008
AB			EQ 37.5MG BASE	A078301	002	Jun 13, 2008
AB			EQ 50MG BASE	A078301	003	Jun 13, 2008
AB			EQ 75MG BASE	A078301	004	Jun 13, 2008
AB			EQ 100MG BASE	A078301	005	Jun 13, 2008
AB		HERITAGE PHARMS	EQ 25MG BASE	A078554	001	Jan 09, 2009
AB			EQ 37.5MG BASE	A078554	002	Jan 09, 2009
AB			EQ 50MG BASE	A078554	003	Jan 09, 2009
AB			EQ 75MG BASE	A078554	004	Jan 09, 2009
AB			EQ 100MG BASE	A078554	005	Jan 09, 2009
AB		SUN PHARM INDS INC	EQ 25MG BASE	A078627	001	Jun 13, 2008
AB			EQ 37.5MG BASE	A078627	002	Jun 13, 2008
AB			EQ 50MG BASE	A078627	003	Jun 13, 2008
AB			EQ 75MG BASE	A078627	004	Jun 13, 2008
AB			EQ 100MG BASE	A078627	005	Jun 13, 2008
AB		TEVA	EQ 25MG BASE	A076690	001	Aug 03, 2006
AB			EQ 37.5MG BASE	A076690	002	Aug 03, 2006
AB	!		EQ 50MG BASE	A076690	003	Aug 03, 2006
AB			EQ 75MG BASE	A076690	004	Aug 03, 2006
AB			EQ 100MG BASE	A076690	005	Aug 03, 2006
AB		YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015
AB			EQ 37.5MG BASE	A202036	002	May 28, 2015
AB			EQ 50MG BASE	A202036	003	May 28, 2015
AB			EQ 75MG BASE	A202036	004	May 28, 2015
AB			EQ 100MG BASE	A202036	005	May 28, 2015
AB		ZYDUS PHARMS USA	EQ 25MG BASE	A077653	001	Jun 13, 2008
AB			EQ 37.5MG BASE	A077653	002	Jun 13, 2008
AB			EQ 50MG BASE	A077653	003	Jun 13, 2008
AB			EQ 75MG BASE	A077653	004	Jun 13, 2008
AB			EQ 100MG BASE	A077653	005	Jun 13, 2008

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	EQ 37.5MG BASE	A214691	001	Apr 12, 2023
AB			EQ 75MG BASE	A214691	002	Apr 12, 2023
AB			EQ 150MG BASE	A214691	003	Apr 12, 2023
AB			EQ 225MG BASE	A214691	004	Apr 12, 2023
AB		ALKEM LABS LTD	EQ 37.5MG BASE	A214127	001	Jun 10, 2021
AB			EQ 75MG BASE	A214127	002	Jun 10, 2021
AB			EQ 150MG BASE	A214127	003	Jun 10, 2021
AB			EQ 225MG BASE	A214127	004	Jun 10, 2021
AB		APPCO	EQ 150MG BASE	A214609	001	Jun 30, 2021
AB			EQ 225MG BASE	A214609	002	Jun 30, 2021
AB		ASCENT PHARMS INC	EQ 37.5MG BASE	A214419	001	Oct 21, 2020
AB			EQ 75MG BASE	A214419	002	Oct 21, 2020
AB			EQ 150MG BASE	A214419	003	Oct 21, 2020
AB			EQ 225MG BASE	A214419	004	Oct 21, 2020
AB		CADILA PHARMS LTD	EQ 75MG BASE	A211323	001	Aug 29, 2019
AB			EQ 150MG BASE	A211323	002	Aug 29, 2019
AB			EQ 225MG BASE	A211323	003	Aug 29, 2019
AB		DEXCEL	EQ 75MG BASE	A213927	001	Jan 21, 2021
AB			EQ 150MG BASE	A209193	001	Oct 31, 2019
AB			EQ 225MG BASE	A209193	002	Oct 31, 2019
AB		NOSTRUM LABS INC	EQ 150MG BASE	A205468	002	Mar 24, 2017
AB			EQ 225MG BASE	A205468	003	Mar 24, 2017
AB	+	OSMOTICA PHARM US	EQ 37.5MG BASE	N022104	001	May 20, 2008
AB	+		EQ 75MG BASE	N022104	002	May 20, 2008
AB	+!		EQ 150MG BASE	N022104	003	May 20, 2008
AB	+		EQ 225MG BASE	N022104	004	May 20, 2008
AB		SUN PHARM	EQ 37.5MG BASE	A091272	001	Aug 18, 2010
AB			EQ 75MG BASE	A091272	002	Aug 18, 2010
AB			EQ 150MG BASE	A091272	003	Aug 18, 2010
AB			EQ 225MG BASE	A091272	004	Jan 08, 2019
AB		UNIQUE	EQ 37.5MG BASE	A216044	001	Nov 28, 2022

VENLAFAXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB			**EQ 75MG BASE**	**A216044**	**002**	Nov 28, 2022
AB			**EQ 150MG BASE**	**A216044**	**003**	Nov 28, 2022
AB			**EQ 225MG BASE**	**A216044**	**004**	Nov 28, 2022
AB		ZYDUS PHARMS	**EQ 37.5MG BASE**	**A215622**	**001**	Aug 30, 2022
AB			**EQ 75MG BASE**	**A215622**	**002**	Aug 30, 2022
AB			**EQ 150MG BASE**	**A215622**	**003**	Aug 30, 2022
AB			**EQ 225MG BASE**	**A215622**	**004**	Aug 30, 2022

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

AB		MYLAN	**120MG**	**A075138**	**001**	Apr 20, 1999
AB			**180MG**	**A075138**	**002**	Apr 20, 1999
AB			**240MG**	**A075138**	**003**	Apr 20, 1999

VERELAN

AB	**+**	SOCIETAL CDMO	**120MG**	**N019614**	**001**	May 29, 1990
AB	**+**		**180MG**	**N019614**	**003**	Jan 09, 1992
AB	**+**		**240MG**	**N019614**	**002**	May 29, 1990
	+!		360MG	N019614	004	May 10, 1996

VERELAN PM

	+	SOCIETAL CDMO	100MG	N020943	001	Nov 25, 1998
	+		200MG	N020943	002	Nov 25, 1998
	+!		300MG	N020943	003	Nov 25, 1998

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

AP		ACIC PHARMS	**2.5MG/ML**	**A215829**	**001**	Mar 17, 2022
AP	**!**	EUGIA PHARMA	**2.5MG/ML**	**A212965**	**001**	Jul 06, 2020
AP		GLAND PHARMA LTD	**2.5MG/ML**	**A214361**	**001**	Oct 15, 2020
AP		MANKIND PHARMA	**2.5MG/ML**	**A214653**	**001**	Jun 15, 2022
AP		ZYDUS PHARMS	**2.5MG/ML**	**A214215**	**001**	Oct 15, 2020

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP		AMNEAL	**5MG/2ML (2.5MG/ML)**	**A210994**	**001**	Jul 13, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A210994**	**002**	Jul 13, 2018
AP		AREVA PHARMS	**5MG/2ML (2.5MG/ML)**	**A213352**	**002**	Sep 16, 2020
AP			**10MG/4ML (2.5MG/ML)**	**A213352**	**001**	Mar 17, 2020
AP		CAPLIN	**5MG/2ML (2.5MG/ML)**	**A213232**	**001**	Mar 25, 2020
AP			**10MG/4ML (2.5MG/ML)**	**A213232**	**002**	Mar 25, 2020
AP		EXELA PHARMA	**5MG/2ML (2.5MG/ML)**	**N018925**	**001**	Mar 30, 1984
AP	**!**	HOSPIRA	**5MG/2ML (2.5MG/ML)**	**A070738**	**001**	May 06, 1987
AP	**!**		**5MG/2ML (2.5MG/ML)**	**A075136**	**001**	Oct 20, 1998
AP	**!**		**5MG/2ML (2.5MG/ML)**	**A070737**	**001**	May 06, 1987
AP	**!**		**10MG/4ML (2.5MG/ML)**	**A070737**	**002**	May 06, 1987
AP		MICRO LABS	**5MG/2ML (2.5MG/ML)**	**A211370**	**001**	Dec 28, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A211370**	**002**	Dec 28, 2018
AP		SOMERSET	**5MG/2ML (2.5MG/ML)**	**A211035**	**001**	Jun 18, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A211035**	**002**	Jun 18, 2018
AP		SOMERSET THERAPS LLC	**5MG/2ML (2.5MG/ML)**	**A211015**	**001**	Jun 18, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A211015**	**002**	Jun 18, 2018

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

AB		HERITAGE PHARMS	**40MG**	**A071881**	**002**	Oct 14, 2015
AB			**80MG**	**A071881**	**003**	Apr 05, 1988
AB	**!**		**120MG**	**A071881**	**001**	Apr 05, 1988
AB		WATSON LABS	**40MG**	**A072924**	**001**	Jun 29, 1993
AB			**80MG**	**A070995**	**001**	Oct 01, 1986
AB			**120MG**	**A070994**	**001**	Oct 01, 1986

TABLET, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

AB		CADILA PHARMS LTD	**120MG**	**A206173**	**003**	Nov 14, 2022
AB			**180MG**	**A206173**	**001**	May 05, 2017
AB			**240MG**	**A206173**	**002**	May 05, 2017
AB	**!**	GLENMARK GENERICS	**120MG**	**A090700**	**001**	Aug 03, 2011
AB	**!**		**180MG**	**A090700**	**002**	Aug 03, 2011
AB	**!**		**240MG**	**A078906**	**001**	Sep 17, 2009
AB		STRIDES PHARMA	**120MG**	**A075072**	**001**	May 25, 1999
AB			**240MG**	**A075072**	**003**	May 25, 1999

VERICIGUAT

TABLET;ORAL

VERQUVO

+	MERCK SHARP DOHME	2.5MG	N214377	001	Jan 19, 2021
+		5MG	N214377	002	Jan 19, 2021
+!		10MG	N214377	003	Jan 19, 2021

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

+!	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000

VIBEGRON

TABLET;ORAL

GEMTESA

+!	UROVANT	75MG	N213006	001	Dec 23, 2020

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

AA	**+!** LUNDBECK PHARMS LLC	**500MG/PACKET**	**N022006**	**001**	Aug 21, 2009

VIGABATRIN

AA	ALKEM LABS LTD	**500MG/PACKET**	**A213375**	**001**	Dec 02, 2020
AA	AMNEAL PHARMS	**500MG/PACKET**	**A210155**	**001**	Mar 13, 2018
AA	ANNORA PHARMA	**500MG/PACKET**	**A213519**	**001**	Jan 26, 2021
AA	AUROBINDO PHARMA LTD	**500MG/PACKET**	**A213899**	**001**	Sep 29, 2021
AA	DEXCEL	**500MG/PACKET**	**A214992**	**001**	May 13, 2021
AA	DR REDDYS	**500MG/PACKET**	**A211481**	**001**	Nov 20, 2018
AA	INVAGEN PHARMS	**500MG/PACKET**	**A211592**	**001**	Dec 03, 2019
AA	MSN	**500MG/PACKET**	**A215363**	**001**	Sep 07, 2022
AA	PAR PHARM INC	**500MG/PACKET**	**A208218**	**001**	Apr 27, 2017
AA	PROPEL PHARMA	**500MG/PACKET**	**A213390**	**001**	Jul 29, 2021
AA	TEVA PHARMS USA	**500MG/PACKET**	**A209824**	**001**	Apr 23, 2018

VIGADRONE

AA	AUCTA	**500MG/PACKET**	**A210196**	**001**	Jun 21, 2018

VIGPODER

AA	PYROS PHARMS	**500MG/PACKET**	**A214961**	**001**	Jun 24, 2022

TABLET;ORAL

SABRIL

AB	**+!** LUNDBECK PHARMS LLC	**500MG**	**N020427**	**001**	Aug 21, 2009

VIGABATRIN

AB	AMNEAL PHARMS	**500MG**	**A210042**	**001**	Jun 22, 2022
AB	AUROBINDO PHARMA LTD	**500MG**	**A215601**	**001**	May 10, 2022
AB	DEXCEL	**500MG**	**A215109**	**001**	Sep 23, 2021
AB	DR REDDYS	**500MG**	**A211539**	**001**	Jan 29, 2021
AB	HIKMA	**500MG**	**A213104**	**001**	Aug 29, 2022
AB	PROPEL PHARMA	**500MG**	**A215519**	**001**	Apr 28, 2023
AB	TEVA PHARMS USA	**500MG**	**A209822**	**001**	Jan 14, 2019
AB	UPSHER SMITH LABS	**500MG**	**A214749**	**001**	Jun 29, 2023
AB	ZYDUS	**500MG**	**A215707**	**001**	Jan 19, 2022

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

AB	**+!** ABBVIE	**10MG**	**N022567**	**001**	Jan 21, 2011
AB	**+**	**20MG**	**N022567**	**002**	Jan 21, 2011
AB	**+**	**40MG**	**N022567**	**003**	Jan 21, 2011

VILAZODONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	**10MG**	**A208209**	**001**	Apr 27, 2021
AB		**20MG**	**A208209**	**002**	Apr 27, 2021
AB		**40MG**	**A208209**	**003**	Apr 27, 2021
AB	ALEMBIC	**10MG**	**A208202**	**001**	Jan 10, 2020
AB		**20MG**	**A208202**	**002**	Jan 10, 2020
AB		**40MG**	**A208202**	**003**	Jan 10, 2020
AB	APOTEX	**10MG**	**A208228**	**001**	Jul 07, 2023
AB		**20MG**	**A208228**	**002**	Jul 07, 2023
AB		**40MG**	**A208228**	**003**	Jul 07, 2023
AB	INVAGEN PHARMS	**10MG**	**A208200**	**001**	Apr 07, 2021
AB		**20MG**	**A208200**	**003**	Dec 06, 2022
AB		**40MG**	**A208200**	**002**	Apr 07, 2021
AB	TEVA PHARMS USA	**10MG**	**A208212**	**001**	Sep 30, 2019
AB		**20MG**	**A208212**	**002**	Sep 30, 2019
AB		**40MG**	**A208212**	**003**	Sep 30, 2019

VILOXAZINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
QELBREE

+		SUPERNUS PHARMS	EQ 100MG BASE	N211964	001	Apr 02, 2021
+			EQ 150MG BASE	N211964	002	Apr 02, 2021
+!			EQ 200MG BASE	N211964	003	Apr 02, 2021

VILTOLARSEN
SOLUTION;INTRAVENOUS
VILTEPSO

+!		NIPPON SHINYAKU	250MG/5ML (50MG/ML)	N212154	001	Aug 12, 2020

VINBLASTINE SULFATE
INJECTABLE;INJECTION
VINBLASTINE SULFATE

!		FRESENIUS KABI USA	1MG/ML	A089515	001	Apr 29, 1987
!		HIKMA	10MG/VIAL	A089395	001	Apr 09, 1987

VINCRISTINE SULFATE
INJECTABLE;INJECTION
VINCRISTINE SULFATE PFS

!		HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988

VINORELBINE TARTRATE
INJECTABLE;INJECTION
VINORELBINE TARTRATE

AP		ACTAVIS TOTOWA	**EQ 10MG BASE/ML**	**A078011**	**001**	Jul 22, 2009
AP		DR REDDYS	**EQ 10MG BASE/ML**	**A202017**	**001**	Sep 12, 2013
AP		HIKMA	**EQ 10MG BASE/ML**	**A075992**	**001**	Jun 10, 2003
AP			**EQ 10MG BASE/ML**	**A076461**	**001**	Dec 11, 2003
AP	**!**	JIANGSU HANSOH PHARM	**EQ 10MG BASE/ML**	**A091106**	**001**	Sep 26, 2012

VISMODEGIB
CAPSULE;ORAL
ERIVEDGE

+!		GENENTECH	150MG	N203388	001	Jan 30, 2012

VITAMIN A PALMITATE
INJECTABLE;INJECTION
AQUASOL A

+!		CASPER PHARMA LLC	EQ 50,000 UNITS BASE/ML	N006823	001	

VOCLOSPORIN
CAPSULE;ORAL
LUPKYNIS

+!		AURINIA	7.9MG	N213716	001	Jan 22, 2021

VONOPRAZAN FUMARATE
TABLET;ORAL
VOQUEZNA

+		PHATHOM	EQ 10MG BASE	N215151	001	Nov 01, 2023
+!			EQ 20MG BASE	N215151	002	Nov 01, 2023

VORAPAXAR SULFATE
TABLET;ORAL
ZONTIVITY

+!		XSPIRE PHARMA	EQ 2.08MG BASE	N204886	001	May 08, 2014

VORICONAZOLE
FOR SUSPENSION;ORAL
VFEND

AB	**+!**	PF PRISM CV	**200MG/5ML**	**N021630**	**001**	Dec 19, 2003

VORICONAZOLE

AB		AMNEAL PHARMS	**200MG/5ML**	**A205034**	**001**	Apr 13, 2016
AB		HAINAN POLY	**200MG/5ML**	**A216805**	**001**	Jan 02, 2024
AB		NOVEL LABS INC	**200MG/5ML**	**A206799**	**001**	May 31, 2016

INJECTABLE;INTRAVENOUS
VFEND

AP	**+!**	PF PRISM CV	**200MG/VIAL**	**N021267**	**001**	May 24, 2002

VORICONAZOLE

AP		ALMAJECT	**200MG/VIAL**	**A206398**	**001**	Mar 23, 2016
AP		GLAND PHARMA LTD	**200MG/VIAL**	**A211099**	**001**	Mar 31, 2020
AP		MEITHEAL	**200MG/VIAL**	**A214516**	**001**	May 09, 2022
AP		SANDOZ INC	**200MG/VIAL**	**A090862**	**001**	May 30, 2012
AP		SLATE RUN PHARMA	**200MG/VIAL**	**A211661**	**001**	Nov 30, 2018
AP		UBI	**200MG/VIAL**	**A211264**	**001**	Mar 09, 2023
AP		XELLIA PHARMS APS	**200MG/VIAL**	**N208562**	**001**	Mar 09, 2017

VORICONAZOLE
INJECTABLE;INTRAVENOUS
VORICONAZOLE

AP		ZYDUS PHARMS	**200MG/VIAL**	**A208983**	**001**	Jul 16, 2018

TABLET;ORAL
VFEND

AB	+	PF PRISM CV	**50MG**	**N021266**	**001**	May 24, 2002
AB	+!		**200MG**	**N021266**	**002**	May 24, 2002

VORICONAZOLE

AB		AJANTA PHARMA LTD	**50MG**	**A206181**	**001**	May 24, 2016
AB			**200MG**	**A206181**	**002**	May 24, 2016
AB		AUROBINDO PHARMA LTD	**50MG**	**A206837**	**001**	Jan 22, 2016
AB			**200MG**	**A206837**	**002**	Jan 22, 2016
AB		CADILA	**50MG**	**A206747**	**001**	May 24, 2016
AB			**200MG**	**A206747**	**002**	May 24, 2016
AB		CHARTWELL RX	**50MG**	**A207371**	**001**	May 24, 2016
AB			**200MG**	**A207371**	**002**	May 24, 2016
AB		EPIC PHARMA LLC	**50MG**	**A207049**	**001**	Sep 07, 2016
AB			**200MG**	**A207049**	**002**	Sep 07, 2016
AB		GLENMARK PHARMS LTD	**50MG**	**A203503**	**001**	Sep 02, 2015
AB			**200MG**	**A203503**	**002**	Sep 02, 2015
AB		MYLAN PHARMS INC	**50MG**	**A090547**	**001**	Apr 22, 2010
AB			**200MG**	**A090547**	**002**	Apr 22, 2010
AB		PRINSTON INC	**50MG**	**A206654**	**001**	Aug 08, 2016
AB			**200MG**	**A206654**	**002**	Aug 08, 2016
AB		RISING	**50MG**	**A206762**	**001**	May 24, 2016
AB			**200MG**	**A206762**	**002**	May 24, 2016
AB		SANDOZ INC	**50MG**	**A200265**	**001**	Dec 12, 2011
AB			**200MG**	**A200265**	**002**	Dec 12, 2011

VORINOSTAT
CAPSULE;ORAL
ZOLINZA

	+!	MSD SUB MERCK	100MG	N021991	001	Oct 06, 2006

VORTIOXETINE HYDROBROMIDE
TABLET;ORAL
TRINTELLIX

	+	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013
	+		EQ 10MG BASE	N204447	002	Sep 30, 2013
	+!		EQ 20MG BASE	N204447	004	Sep 30, 2013

VOSORITIDE
POWDER;SUBCUTANEOUS
VOXZOGO

	+!	BIOMARIN PHARM	0.4MG/VIAL	N214938	001	Nov 19, 2021
	+!		0.56MG/VIAL	N214938	002	Nov 19, 2021
	+!		1.2MG/VIAL	N214938	003	Nov 19, 2021

VOXELOTOR
TABLET;ORAL
OXBRYTA

	+	GLOBAL BLOOD THERAPS	300MG	N213137	002	Oct 14, 2022
	+!		500MG	N213137	001	Nov 25, 2019

TABLET, FOR SUSPENSION;ORAL
OXBRYTA

	+!	GLOBAL BLOOD THERAPS	300MG	N216157	001	Dec 17, 2021

VUTRISIRAN SODIUM
SOLUTION;SUBCUTANEOUS
AMVUTTRA

	+!	ALNYLAM PHARMS INC	EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)	N215515	001	Jun 13, 2022

WARFARIN SODIUM
TABLET;ORAL
JANTOVEN

AB		UPSHER SMITH LABS	**1MG**	**A040416**	**001**	Oct 02, 2003
AB			**2MG**	**A040416**	**002**	Oct 02, 2003
AB			**2.5MG**	**A040416**	**003**	Oct 02, 2003
AB			**3MG**	**A040416**	**004**	Oct 02, 2003
AB			**4MG**	**A040416**	**005**	Oct 02, 2003
AB			**5MG**	**A040416**	**006**	Oct 02, 2003
AB			**6MG**	**A040416**	**007**	Oct 02, 2003

WARFARIN SODIUM

TABLET;ORAL

JANTOVEN

AB		**7.5MG**	**A040416**	**008**	Oct 02, 2003
AB		**10MG**	**A040416**	**009**	Oct 02, 2003

WARFARIN SODIUM

AB	AMNEAL PHARMS	**1MG**	**A202202**	**001**	Mar 04, 2013
AB		**2MG**	**A202202**	**002**	Mar 04, 2013
AB		**2.5MG**	**A202202**	**003**	Mar 04, 2013
AB		**3MG**	**A202202**	**004**	Mar 04, 2013
AB		**4MG**	**A202202**	**005**	Mar 04, 2013
AB		**5MG**	**A202202**	**006**	Mar 04, 2013
AB		**6MG**	**A202202**	**007**	Mar 04, 2013
AB		**7.5MG**	**A202202**	**008**	Mar 04, 2013
AB		**10MG**	**A202202**	**009**	Mar 04, 2013
AB	BARR	**1MG**	**A040145**	**001**	Mar 26, 1997
AB		**2MG**	**A040145**	**002**	Mar 26, 1997
AB		**2.5MG**	**A040145**	**003**	Mar 26, 1997
AB		**3MG**	**A040145**	**008**	Nov 05, 1998
AB		**4MG**	**A040145**	**004**	Mar 26, 1997
AB		**5MG**	**A040145**	**005**	Mar 26, 1997
AB		**6MG**	**A040145**	**009**	Nov 05, 1998
AB		**7.5MG**	**A040145**	**006**	Mar 26, 1997
AB		**10MG**	**A040145**	**007**	Mar 26, 1997
AB	INVAGEN PHARMS	**1MG**	**A090935**	**001**	May 25, 2011
AB		**2MG**	**A090935**	**002**	May 25, 2011
AB		**2.5MG**	**A090935**	**003**	May 25, 2011
AB		**3MG**	**A090935**	**004**	May 25, 2011
AB		**4MG**	**A090935**	**005**	May 25, 2011
AB		**5MG**	**A090935**	**006**	May 25, 2011
AB		**6MG**	**A090935**	**007**	May 25, 2011
AB		**7.5MG**	**A090935**	**008**	May 25, 2011
AB		**10MG**	**A090935**	**009**	May 25, 2011
AB	IPCA LABS LTD	**1MG**	**A200104**	**001**	Jun 27, 2013
AB		**2MG**	**A200104**	**002**	Jun 27, 2013
AB		**2.5MG**	**A200104**	**003**	Jun 27, 2013
AB		**3MG**	**A200104**	**004**	Jun 27, 2013
AB		**4MG**	**A200104**	**005**	Jun 27, 2013
AB		**5MG**	**A200104**	**006**	Jun 27, 2013
AB		**6MG**	**A200104**	**007**	Jun 27, 2013
AB		**7.5MG**	**A200104**	**008**	Jun 27, 2013
AB		**10MG**	**A200104**	**009**	Jun 27, 2013
AB	PLIVA	**1MG**	**A040616**	**009**	Jul 05, 2006
AB		**2MG**	**A040616**	**001**	Jul 05, 2006
AB		**2.5MG**	**A040616**	**002**	Jul 05, 2006
AB		**3MG**	**A040616**	**003**	Jul 05, 2006
AB		**4MG**	**A040616**	**004**	Jul 05, 2006
AB		**5MG**	**A040616**	**005**	Jul 05, 2006
AB		**6MG**	**A040616**	**006**	Jul 05, 2006
AB		**7.5MG**	**A040616**	**007**	Jul 05, 2006
AB !		**10MG**	**A040616**	**008**	Jul 05, 2006
AB	TARO	**1MG**	**A040301**	**002**	Jul 15, 1999
AB		**2MG**	**A040301**	**003**	Jul 15, 1999
AB		**2.5MG**	**A040301**	**004**	Jul 15, 1999
AB		**3MG**	**A040301**	**005**	Jul 15, 1999
AB		**4MG**	**A040301**	**006**	Jul 15, 1999
AB		**5MG**	**A040301**	**007**	Jul 15, 1999
AB		**6MG**	**A040301**	**008**	Jul 15, 1999
AB		**7.5MG**	**A040301**	**009**	Jul 15, 1999
AB		**10MG**	**A040301**	**001**	Jul 15, 1999
AB	ZYDUS PHARMS USA	**1MG**	**A040663**	**001**	May 30, 2006
AB		**2MG**	**A040663**	**002**	May 30, 2006
AB		**2.5MG**	**A040663**	**003**	May 30, 2006
AB		**3MG**	**A040663**	**004**	May 30, 2006
AB		**4MG**	**A040663**	**005**	May 30, 2006
AB		**5MG**	**A040663**	**006**	May 30, 2006
AB		**6MG**	**A040663**	**007**	May 30, 2006
AB		**7.5MG**	**A040663**	**008**	May 30, 2006
AB		**10MG**	**A040663**	**009**	May 30, 2006

XENON XE-129 HYPERPOLARIZED						
GAS;INHALATION						
XENOVIEW						
	+!	POLAREAN	N/A	N214375	001	Dec 23, 2022
XENON XE-133						
GAS;INHALATION						
XENON XE 133						
		CURIUM	10mCi/VIAL	N018327	001	Mar 09, 1982
			20mCi/VIAL	N018327	002	Mar 09, 1982
		LANTHEUS MEDCL	10mCi/VIAL	N017284	001	
			20mCi/VIAL	N017284	002	
ZAFIRLUKAST						
TABLET;ORAL						
ACCOLATE						
AB	**+**	STRIDES PHARMA	**10MG**	**N020547**	**003**	Sep 17, 1999
AB	**+!**		**20MG**	**N020547**	**001**	Sep 26, 1996
ZAFIRLUKAST						
AB		ANNORA PHARMA	**10MG**	**A212475**	**001**	Sep 10, 2020
AB			**20MG**	**A212475**	**002**	Sep 10, 2020
AB		AUROBINDO PHARMA	**10MG**	**A213163**	**001**	Nov 27, 2023
AB			**20MG**	**A213163**	**002**	Nov 27, 2023
AB		DR REDDYS LABS LTD	**10MG**	**A090372**	**001**	Nov 18, 2010
AB			**20MG**	**A090372**	**002**	Nov 18, 2010
AB		RISING PHARMS	**10MG**	**A204928**	**001**	Aug 25, 2022
AB			**20MG**	**A204928**	**002**	Aug 25, 2022
ZALEPLON						
CAPSULE;ORAL						
SONATA						
AB	**+**	PFIZER	**5MG**	**N020859**	**001**	Aug 13, 1999
AB	**+!**		**10MG**	**N020859**	**002**	Aug 13, 1999
ZALEPLON						
AB		AUROBINDO PHARMA	**5MG**	**A078829**	**001**	Jun 06, 2008
AB			**10MG**	**A078829**	**002**	Jun 06, 2008
AB		CHARTWELL MOLECULAR	**5MG**	**A077505**	**001**	Jun 20, 2008
AB			**10MG**	**A077505**	**002**	Jun 20, 2008
AB		HIKMA	**5MG**	**A077237**	**001**	Jun 06, 2008
AB			**10MG**	**A077237**	**002**	Jun 06, 2008
AB		ORBION PHARMS	**5MG**	**A090374**	**001**	Sep 17, 2009
AB			**10MG**	**A090374**	**002**	Sep 17, 2009
AB		UNICHEM	**5MG**	**A078989**	**001**	Jun 06, 2008
AB			**10MG**	**A078989**	**002**	Jun 06, 2008
ZANAMIVIR						
POWDER;INHALATION						
RELENZA						
	+!	GLAXOSMITHKLINE	5MG	N021036	001	Jul 26, 1999
ZANUBRUTINIB						
CAPSULE;ORAL						
BRUKINSA						
	+!	BEIGENE	80MG	N213217	001	Nov 14, 2019
ZAVEGEPANT HYDROCHLORIDE						
SPRAY, METERED;NASAL						
ZAVZPRET						
	+!	PFIZER	EQ 10MG BASE/SPRAY	N216386	001	Mar 09, 2023
ZICONOTIDE ACETATE						
INJECTABLE;INTRATHECAL						
PRIALT						
	+!	TERSERA	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004
	+!		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004
	+!		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004
ZIDOVUDINE						
CAPSULE;ORAL						
RETROVIR						
AB	**+!**	VIIV HLTHCARE	**100MG**	**N019655**	**001**	Mar 19, 1987
ZIDOVUDINE						
AB		AUROBINDO PHARMA LTD	**100MG**	**A078128**	**001**	Mar 27, 2006
AB		CIPLA LTD	**100MG**	**A078349**	**001**	May 23, 2007

ZIDOVUDINE							
INJECTABLE;INJECTION							
RETROVIR							
	+!	VIIV HLTHCARE	10MG/ML	N019951	001	Feb 02, 1990
SOLUTION;ORAL							
RETROVIR							
AA	**+!**	VIIV HLTHCARE	**50MG/5ML**	**N019910**	**001**	Sep 28, 1989
ZIDOVUDINE							
AA		AUROBINDO	**50MG/5ML**	**A077268**	**001**	Sep 19, 2005
AA		CIPLA LTD	**50MG/5ML**	**A077981**	**001**	Jun 26, 2008
TABLET;ORAL							
ZIDOVUDINE							
AB		AUROBINDO	**300MG**	**A077267**	**001**	Sep 19, 2005
AB		CIPLA	**300MG**	**A090561**	**001**	Oct 27, 2010
AB	**!**	HETERO LABS LTD III	**300MG**	**A090092**	**001**	Apr 25, 2008
AB		MYLAN PHARMS INC	**300MG**	**A078922**	**001**	Feb 14, 2008
ZILEUTON							
TABLET;ORAL							
ZYFLO							
	+!	CHIESI	600MG	N020471	003	Dec 09, 1996
TABLET, EXTENDED RELEASE;ORAL							
ZILEUTON							
AB		AIZANT	**600MG**	**A211390**	**001**	Oct 23, 2020
AB		ANNORA PHARMA	**600MG**	**A215742**	**001**	Oct 11, 2022
AB	**!**	RISING	**600MG**	**A204929**	**001**	Mar 17, 2017
AB		STRIDES PHARMA	**600MG**	**A212670**	**001**	Dec 16, 2019
ZILUCOPLAN SODIUM							
SOLUTION;SUBCUTANEOUS							
ZILBRYSQ							
	+!	UCB INC	EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML)	N216834	001	Oct 17, 2023
	+!		EQ 23MG BASE/0.574ML (EQ 23MG BASE/0.574ML)	N216834	002	Oct 17, 2023
	+!		EQ 32.4MG BASE/0.81ML (EQ 32.4 BASE/0.81ML)	N216834	003	Oct 17, 2023
ZINC ACETATE							
CAPSULE;ORAL							
GALZIN							
	+	TEVA	EQ 25MG ZINC	N020458	001	Jan 28, 1997
	+!		EQ 50MG ZINC	N020458	002	Jan 28, 1997
ZINC CHLORIDE							
INJECTABLE;INJECTION							
ZINC CHLORIDE							
AP		EXELA PHARMA	**EQ 1MG ZINC/ML**	**A212007**	**001**	May 21, 2021
ZINC CHLORIDE IN PLASTIC CONTAINER							
AP	**+!**	HOSPIRA	**EQ 1MG ZINC/ML**	**N018959**	**001**	Jun 26, 1986
ZINC SULFATE							
SOLUTION;INTRAVENOUS							
ZINC SULFATE							
AP	**+!**	AM REGENT	**EQ 10MG BASE/10ML (EQ 1MG BASE/ML)**	**N209377**	**003**	Apr 15, 2020
AP	**+!**		**EQ 25MG BASE/5ML (EQ 5MG BASE/ML)**	**N209377**	**002**	Jul 18, 2019
AP	**+!**		**EQ 30MG BASE/10ML (EQ 3MG BASE/ML)**	**N209377**	**001**	Jul 18, 2019
AP		FRESENIUS KABI USA	**EQ 10MG BASE/10ML (EQ 1MG BASE/ML)**	**A216145**	**001**	Dec 27, 2022
AP			**EQ 25MG BASE/5ML (EQ 5MG BASE/ML)**	**A216145**	**002**	Dec 27, 2022
AP			**EQ 30MG BASE/10ML (EQ 3MG BASE/ML)**	**A216145**	**003**	Dec 27, 2022
AP		GLAND PHARMA LTD	**EQ 10MG BASE/10ML (EQ 1MG BASE/ML)**	**A216249**	**003**	Sep 01, 2023
AP			**EQ 25MG BASE/5ML (EQ 5MG BASE/ML)**	**A216249**	**001**	May 03, 2022
AP			**EQ 30MG BASE/10ML (EQ 3MG BASE/ML)**	**A216249**	**002**	May 03, 2022
AP		ZYDUS PHARMS	**EQ 30MG BASE/10ML (EQ 3MG BASE/ML)**	**A217074**	**003**	Aug 22, 2023
AP			**EQ 10MG BASE/10ML (EQ 1MG BASE/ML)**	**A217074**	**001**	Aug 22, 2023
AP			**EQ 25MG BASE/5ML (EQ 5MG BASE/ML)**	**A217074**	**002**	Aug 22, 2023
ZIPRASIDONE HYDROCHLORIDE							
CAPSULE;ORAL							
GEODON							
AB	**+!**	VIATRIS	**EQ 20MG BASE**	**N020825**	**001**	Feb 05, 2001
AB	**+**		**EQ 40MG BASE**	**N020825**	**002**	Feb 05, 2001
AB	**+**		**EQ 60MG BASE**	**N020825**	**003**	Feb 05, 2001
AB	**+**		**EQ 80MG BASE**	**N020825**	**004**	Feb 05, 2001

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX	**EQ 20MG BASE**	**A077561**	**001**	Mar 02, 2012
AB			**EQ 40MG BASE**	**A077561**	**002**	Mar 02, 2012
AB			**EQ 60MG BASE**	**A077561**	**003**	Mar 02, 2012
AB			**EQ 80MG BASE**	**A077561**	**004**	Mar 02, 2012
AB		AUROBINDO PHARMA	**EQ 20MG BASE**	**A204117**	**001**	Dec 27, 2016
AB			**EQ 40MG BASE**	**A204117**	**002**	Dec 27, 2016
AB			**EQ 60MG BASE**	**A204117**	**003**	Dec 27, 2016
AB			**EQ 80MG BASE**	**A204117**	**004**	Dec 27, 2016
AB		CADILA	**EQ 20MG BASE**	**A208988**	**001**	Aug 22, 2017
AB			**EQ 40MG BASE**	**A208988**	**002**	Aug 22, 2017
AB			**EQ 60MG BASE**	**A208988**	**003**	Aug 22, 2017
AB			**EQ 80MG BASE**	**A208988**	**004**	Aug 22, 2017
AB		CHARTWELL RX	**EQ 20MG BASE**	**A090348**	**001**	Sep 05, 2012
AB			**EQ 40MG BASE**	**A090348**	**002**	Sep 05, 2012
AB			**EQ 60MG BASE**	**A090348**	**003**	Sep 05, 2012
AB			**EQ 80MG BASE**	**A090348**	**004**	Sep 05, 2012
AB		DR REDDYS LABS INC	**EQ 20MG BASE**	**A077565**	**001**	Mar 02, 2012
AB			**EQ 40MG BASE**	**A077565**	**002**	Mar 02, 2012
AB			**EQ 60MG BASE**	**A077565**	**003**	Mar 02, 2012
AB			**EQ 80MG BASE**	**A077565**	**004**	Mar 02, 2012
AB		LUPIN PHARMS	**EQ 20MG BASE**	**A077560**	**001**	Mar 02, 2012
AB			**EQ 40MG BASE**	**A077560**	**002**	Mar 02, 2012
AB			**EQ 60MG BASE**	**A077560**	**003**	Mar 02, 2012
AB			**EQ 80MG BASE**	**A077560**	**004**	Mar 02, 2012
AB		MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A204375**	**001**	Feb 17, 2017
AB			**EQ 40MG BASE**	**A204375**	**002**	Feb 17, 2017
AB			**EQ 60MG BASE**	**A204375**	**003**	Feb 17, 2017
AB			**EQ 80MG BASE**	**A204375**	**004**	Feb 17, 2017
AB		SANDOZ INC	**EQ 20MG BASE**	**A077562**	**001**	Jun 01, 2012
AB			**EQ 40MG BASE**	**A077562**	**002**	Jun 01, 2012
AB			**EQ 60MG BASE**	**A077562**	**003**	Jun 01, 2012
AB			**EQ 80MG BASE**	**A077562**	**004**	Jun 01, 2012

ZIPRASIDONE MESYLATE

POWDER;INTRAMUSCULAR

GEODON

AP	**+!**	VIATRIS	**EQ 20MG BASE/VIAL**	**N020919**	**001**	Jun 21, 2002

ZIPRASIDONE MESYLATE

AP		GLAND PHARMA LTD	**EQ 20MG BASE/VIAL**	**A211908**	**001**	Dec 26, 2019
AP		MSN	**EQ 20MG BASE/VIAL**	**A216091**	**001**	Sep 15, 2022

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

RECLAST

AP	**+!**	SANDOZ	**EQ 5MG BASE/100ML**	**N021817**	**001**	Apr 16, 2007

ZOLEDRONIC

AP	**!**	GLAND PHARMA LTD	**EQ 4MG BASE/100ML**	**A205749**	**001**	Jun 29, 2018

ZOLEDRONIC ACID

AP		ACCORD HLTHCARE	**EQ 4MG BASE/5ML**	**A205279**	**001**	Nov 28, 2016
AP		AMNEAL	**EQ 4MG BASE/100ML**	**A210174**	**001**	Oct 27, 2017
AP		APOTEX	**EQ 5MG BASE/100ML**	**A204367**	**001**	Dec 24, 2015
AP		AVET LIFESCIENCES	**EQ 4MG BASE/5ML**	**A201783**	**001**	Mar 12, 2013
AP		BPI LABS	**EQ 4MG BASE/5ML**	**A207341**	**001**	Dec 29, 2017
AP		CHARTWELL RX	**EQ 4MG BASE/5ML**	**A202571**	**001**	May 07, 2013
AP			**EQ 5MG BASE/100ML**	**A202163**	**001**	Aug 05, 2013
AP	**!**	DR REDDYS LABS LTD	**EQ 4MG BASE/5ML**	**A091186**	**001**	Mar 04, 2013
AP			**EQ 5MG BASE/100ML**	**A091363**	**001**	Mar 29, 2013
AP		EPIC PHARMA LLC	**EQ 4MG BASE/5ML**	**A202548**	**001**	May 22, 2014
AP			**EQ 5MG BASE/100ML**	**A200918**	**001**	Aug 21, 2014
AP		FRESENIUS KABI USA	**EQ 4MG BASE/5ML**	**A091516**	**001**	Apr 23, 2015
AP		GLAND	**EQ 5MG BASE/100ML**	**A204217**	**001**	Aug 18, 2016
AP		GLAND PHARMA LTD	**EQ 4MG BASE/5ML**	**A202930**	**001**	Aug 05, 2013
AP			**EQ 5MG BASE/100ML**	**A209578**	**001**	Aug 08, 2019
AP		HIKMA FARMACEUTICA	**EQ 4MG BASE/5ML**	**A202182**	**001**	Jun 03, 2013
AP		HOSPIRA	**EQ 4MG BASE/5ML**	**A090621**	**001**	Mar 19, 2015
AP		HOSPIRA INC	**EQ 5MG BASE/100ML**	**A202837**	**001**	Apr 05, 2013
AP	**+!**	INFORLIFE	**EQ 4MG BASE/100ML**	**N203231**	**001**	Aug 02, 2013
AP			**EQ 5MG BASE/100ML**	**A202828**	**001**	Sep 23, 2013
AP		MEITHEAL	**EQ 5MG BASE/100ML**	**A213371**	**001**	Jun 05, 2023
AP		MYLAN LABS LTD	**EQ 4MG BASE/5ML**	**A202650**	**001**	Mar 04, 2013

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

ZOLEDRONIC ACID

AP			**EQ 5MG BASE/100ML**	**A203841**	**001**	Feb 14, 2017
AP			**EQ 5MG BASE/100ML**	**A205254**	**001**	Oct 27, 2017
AP		SAGENT PHARMS INC	**EQ 4MG BASE/5ML**	**A091493**	**001**	Nov 24, 2014
AP		USV	**EQ 4MG BASE/5ML**	**A202923**	**001**	Sep 04, 2014

SOLUTION;INTRAVENOUS

ZOLEDRONIC ACID

		HOSPIRA	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015

ZOLMITRIPTAN

SPRAY;NASAL

ZOLMITRIPTAN

AB		PADAGIS ISRAEL	**2.5MG/SPRAY**	**A212469**	**001**	Sep 30, 2021
AB			**5MG/SPRAY**	**A212469**	**002**	Sep 30, 2021

ZOMIG

AB	**+**	AMNEAL	**2.5MG/SPRAY**	**N021450**	**003**	Sep 16, 2013
AB	**+!**		**5MG/SPRAY**	**N021450**	**004**	Sep 30, 2003

TABLET;ORAL

ZOLMITRIPTAN

AB		AJANTA PHARMA LTD	**2.5MG**	**A204041**	**001**	May 20, 2016
AB	**!**		**5MG**	**A204041**	**002**	May 20, 2016
AB		ALEMBIC	**2.5MG**	**A204232**	**001**	Sep 30, 2015
AB			**5MG**	**A204232**	**002**	Sep 30, 2015
AB		APPCO	**2.5MG**	**A206973**	**001**	Jun 30, 2017
AB			**5MG**	**A206973**	**002**	Jun 30, 2017
AB		AUROBINDO PHARMA	**2.5MG**	**A207021**	**001**	May 11, 2016
AB			**5MG**	**A207021**	**002**	May 11, 2016
AB		GLENMARK GENERICS	**2.5MG**	**A201779**	**001**	May 14, 2013
AB			**5MG**	**A201779**	**002**	May 14, 2013
AB		INVAGEN PHARMS	**2.5MG**	**A204284**	**001**	Apr 09, 2014
AB			**5MG**	**A204284**	**002**	Apr 09, 2014
AB		JUBILANT GENERICS	**2.5MG**	**A202279**	**001**	Nov 20, 2014
AB			**5MG**	**A202279**	**002**	Nov 20, 2014
AB		ORBION PHARMS	**2.5MG**	**A203726**	**001**	Oct 21, 2019
AB			**5MG**	**A203726**	**002**	Oct 21, 2019
AB		PLD ACQUISITIONS LLC	**2.5MG**	**A207867**	**001**	Feb 27, 2017
AB			**5MG**	**A207867**	**002**	Feb 27, 2017
AB		ZYDUS PHARMS	**2.5MG**	**A203019**	**001**	Jul 11, 2018
AB			**5MG**	**A203019**	**002**	Jul 11, 2018

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

AB		ALEMBIC	**2.5MG**	**A205074**	**001**	Dec 01, 2016
AB			**5MG**	**A205074**	**002**	Dec 01, 2016
AB		GLENMARK GENERICS	**2.5MG**	**A202560**	**001**	May 14, 2013
AB			**5MG**	**A202560**	**002**	May 14, 2013
AB		JUBILANT GENERICS	**2.5MG**	**A202956**	**001**	Sep 17, 2015
AB			**5MG**	**A202956**	**002**	Sep 17, 2015
AB		ZYDUS PHARMS USA INC	**2.5MG**	**A202890**	**001**	May 15, 2013
AB	**!**		**5MG**	**A202890**	**002**	May 15, 2013

ZOLPIDEM TARTRATE

CAPSULE;ORAL

ZOLPIDEM TARTRATE

	+!	ALMATICA	7.5MG	N215721	001	May 09, 2023

TABLET;ORAL

AMBIEN

AB	**+**	SANOFI AVENTIS US	**5MG**	**N019908**	**001**	Dec 16, 1992
AB	**+!**		**10MG**	**N019908**	**002**	Dec 16, 1992

ZOLPIDEM TARTRATE

AB		ACME LABS	**5MG**	**A077214**	**001**	Apr 23, 2007
AB			**10MG**	**A077214**	**002**	Apr 23, 2007
AB		APOTEX INC	**5MG**	**A077884**	**001**	Apr 23, 2007
AB			**10MG**	**A077884**	**002**	Apr 23, 2007
AB		AUROBINDO PHARMA	**5MG**	**A078413**	**001**	May 04, 2007
AB			**10MG**	**A078413**	**002**	May 04, 2007
AB		CHARTWELL MOLECULAR	**5MG**	**A077388**	**001**	Jul 30, 2012
AB			**10MG**	**A077388**	**002**	Jul 30, 2012
AB		INVAGEN PHARMS	**5MG**	**A078184**	**001**	Sep 07, 2007
AB			**10MG**	**A078184**	**002**	Sep 07, 2007
AB		SANDOZ	**5MG**	**A077322**	**001**	Apr 23, 2007

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

AB			**10MG**	**A077322**	**002**	Apr 23, 2007
AB		TEVA	**5MG**	**A076410**	**001**	Apr 23, 2007
AB			**10MG**	**A076410**	**002**	Apr 23, 2007
AB		TORRENT PHARMS	**5MG**	**A077903**	**001**	Aug 17, 2007
AB			**10MG**	**A077903**	**002**	Aug 17, 2007

TABLET;SUBLINGUAL

EDLUAR

AB	+	MYLAN SPECIALITY LP	**5MG**	**N021997**	**001**	Mar 13, 2009
AB	+!		**10MG**	**N021997**	**002**	Mar 13, 2009

ZOLPIDEM TARTRATE

AB		DR REDDYS	**1.75MG**	**A204503**	**001**	Nov 18, 2016
AB			**3.5MG**	**A204503**	**002**	Nov 18, 2016
AB		NOVEL LABS INC	**1.75MG**	**A204299**	**001**	Jun 03, 2015
AB	!		**3.5MG**	**A204299**	**002**	Jun 03, 2015
AB		PAR FORM	**5MG**	**A201509**	**001**	Aug 01, 2016
AB			**10MG**	**A201509**	**002**	Aug 01, 2016
AB		PAR PHARM INC	**1.75MG**	**A204229**	**001**	Sep 11, 2017
AB			**3.5MG**	**A204229**	**002**	Sep 11, 2017

TABLET, EXTENDED RELEASE;ORAL

AMBIEN CR

AB	+	SANOFI AVENTIS US	**6.25MG**	**N021774**	**002**	Sep 02, 2005
AB	+!		**12.5MG**	**N021774**	**001**	Sep 02, 2005

ZOLPIDEM TARTRATE

AB		APOTEX	**6.25MG**	**A200266**	**001**	Sep 10, 2013
AB			**12.5MG**	**A200266**	**002**	Sep 10, 2013
AB		LUPIN LTD	**6.25MG**	**A078970**	**001**	Sep 11, 2013
AB			**12.5MG**	**A078970**	**002**	Sep 11, 2013
AB		SANDOZ	**6.25MG**	**A090107**	**001**	Jul 01, 2011
AB			**12.5MG**	**A090107**	**002**	Jul 01, 2011
AB		SUN PHARM	**6.25MG**	**A204170**	**001**	Jan 24, 2017
AB			**12.5MG**	**A204170**	**002**	Jan 24, 2017

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	+	CONCORDIA	**25MG**	**N020789**	**003**	Aug 22, 2003
AB	+!		**100MG**	**N020789**	**001**	Mar 27, 2000

ZONISAMIDE

AB		APOTEX INC	**25MG**	**A077642**	**001**	Dec 22, 2005
AB			**50MG**	**A077642**	**002**	Dec 22, 2005
AB			**100MG**	**A077642**	**003**	Dec 22, 2005
AB		AUROBINDO PHARMA LTD	**25MG**	**A077645**	**002**	Sep 29, 2006
AB			**50MG**	**A077645**	**003**	Sep 29, 2006
AB			**100MG**	**A077645**	**001**	Dec 22, 2005
AB		BIONPHARMA	**25MG**	**A077813**	**001**	Aug 16, 2006
AB			**50MG**	**A077813**	**002**	Aug 16, 2006
AB			**100MG**	**A077813**	**003**	Aug 16, 2006
AB		CADILA	**25MG**	**A077625**	**001**	Oct 16, 2006
AB			**50MG**	**A077625**	**002**	Oct 16, 2006
AB			**100MG**	**A077625**	**003**	Oct 16, 2006
AB		GLENMARK GENERICS	**25MG**	**A077651**	**001**	Jan 30, 2006
AB			**50MG**	**A077651**	**002**	Jan 30, 2006
AB			**100MG**	**A077651**	**003**	Jan 30, 2006
AB		GRANULES	**25MG**	**A077636**	**003**	Jul 27, 2006
AB			**50MG**	**A077636**	**002**	Jul 27, 2006
AB			**100MG**	**A077636**	**001**	Dec 22, 2005
AB		INVAGEN PHARMS	**25MG**	**A077869**	**001**	May 31, 2006
AB			**50MG**	**A077869**	**002**	May 31, 2006
AB			**100MG**	**A077869**	**003**	May 31, 2006
AB		SUN PHARM INDS (IN)	**25MG**	**A077634**	**001**	Mar 17, 2006
AB			**50MG**	**A077634**	**002**	Mar 17, 2006
AB			**100MG**	**A077634**	**003**	Mar 17, 2006
AB		UNICHEM	**25MG**	**A214492**	**001**	Jan 26, 2021
AB			**50MG**	**A214492**	**002**	Jan 26, 2021
AB			**100MG**	**A214492**	**003**	Jan 26, 2021

SUSPENSION;ORAL

ZONISADE

	+!	AZURITY	100MG/5ML	N214273	001	Jul 15, 2022

ZURANOLONE

CAPSULE;ORAL

ZURZUVAE

+	BIOGEN INC	20MG	N217369	001	Oct 31, 2023
+		25MG	N217369	002	Oct 31, 2023
+!		30MG	N217369	003	Oct 31, 2023

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN					
	COSETTE	120MG	N018060	001	
		325MG	A072344	001	Mar 27, 1992
		650MG	A072237	001	Mar 27, 1992
ACETAMINOPHEN					
	PERRIGO NEW YORK	120MG	A070607	001	Apr 06, 1987
		650MG	A070608	001	Dec 01, 1986
+	TARO	120MG	N018337	003	Sep 12, 1983
+		325MG	N018337	002	
+!		650MG	N018337	001	
INFANTS' FEVERALL					
+	TARO	80MG	N018337	004	Aug 26, 1992

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN					
	AUROBINDO PHARMA	650MG	A207229	001	Nov 09, 2016
	GRANULES	650MG	A211544	001	Apr 16, 2019
	HERITAGE PHARMA	650MG	A207035	001	May 31, 2018
	MARKSANS PHARMA	650MG	A215486	001	Aug 25, 2021
	OHM LABS	650MG	A076200	001	Mar 19, 2002
	PERRIGO	650MG	A075077	001	Feb 25, 2000
	SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011
TYLENOL					
+!	J AND J CONSUMER INC	650MG	N019872	001	Jun 08, 1994
+!		650MG	N019872	002	Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE					
	AUROBINDO PHARMA LTD	250MG;250MG;65MG	A211695	001	Feb 02, 2022
	GRANULES	250MG;250MG;65MG	A214039	001	Feb 23, 2021
	PERRIGO	250MG;250MG;65MG	A075794	001	Nov 26, 2001
EXCEDRIN (MIGRAINE RELIEF)					
+!	GLAXOSMITHKLINE CONS	250MG;250MG;65MG	N020802	001	Jan 14, 1998

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN					
	BIONPHARMA	250MG;125MG	A216999	001	Aug 01, 2023
	GRANULES	250MG;125MG	A216592	001	Jul 13, 2023
	L PERRIGO CO	250MG;125MG	A214836	001	Feb 28, 2023
	MARKSANS PHARMA	250MG;125MG	A216994	001	Jul 10, 2023
ADVIL DUAL ACTION WITH ACETAMINOPHEN					
+!	GLAXOSMITHKLINE	250MG;125MG	N211733	001	Feb 28, 2020

ADAPALENE

GEL;TOPICAL

ADAPALENE					
	GLENMARK GENERICS	0.1%	A091314	001	Jul 01, 2010
	P AND L	0.1%	A090962	001	Jun 02, 2010
	TARO	0.1%	A215940	001	Jan 14, 2022
DIFFERIN					
+!	GALDERMA LABS LP	0.1%	N020380	002	Jul 08, 2016

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

LASTACAFT					
+!	ABBVIE	0.25%	N022134	001	Jul 28, 2010

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

AVAGARD					
+!	3M	61%;1%	N021074	001	Jun 07, 2001

ASPIRIN

CAPSULE;ORAL

VAZALORE					
+	PLX PHARMA	81MG	N203697	002	Feb 26, 2021
+!		325MG	N203697	001	Jan 14, 2013

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM;TOPICAL					
ANTHELIOS SX					
+!	LOREAL USA	2%;2%;10%	N021502	001	Jul 21, 2006
CAPITAL SOLEIL 15					
+!	LOREAL USA	2%;3%;10%	N021501	001	Oct 02, 2006

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM;TOPICAL					
ANTHELIOS 20					
+!	LOREAL USA	2%;2%;10%;2%	N021471	001	Oct 05, 2006
ANTHELIOS 40					
+!	LOREAL USA	2%;3%;10%;5%	N022009	001	Mar 31, 2008
+!		2%;3%;10%;5%	N022009	002	Oct 29, 2009

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL					
ASTEPRO ALLERGY					
+!	BAYER HLTHCARE	0.2055MG/SPRAY	N213872	001	Jun 17, 2021
CHILDREN'S ASTEPRO ALLERGY					
+!	BAYER HLTHCARE	0.2055MG/SPRAY	N213872	002	Jun 17, 2021

BENTOQUATAM

LOTION;TOPICAL					
IVY BLOCK					
+!	STAND HOMEOPATH	5%	N020532	001	Aug 26, 1996

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC					
LUMIFY					
+!	BAUSCH AND LOMB INC	0.025%	N208144	001	Dec 22, 2017

BUDESONIDE

SPRAY, METERED;NASAL					
BUDESONIDE					
	APOTEX INC	0.032MG/SPRAY	A078949	002	Nov 20, 2015
RHINOCORT ALLERGY					
+!	J AND J CONSUMER INC	0.032MG/SPRAY	N020746	003	Mar 23, 2015

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL					
BUTENAFINE HYDROCHLORIDE					
	TARO	1%	A205181	001	Nov 16, 2017
LOTRIMIN ULTRA					
+!	BAYER HEALTHCARE LLC	1%	N021307	001	Dec 07, 2001

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL					
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE					
	PERRIGO R AND D	800MG;10MG;165MG	A077355	001	Feb 06, 2008
PEPCID COMPLETE					
+!	J AND J CONSUMER INC	800MG;10MG;165MG	N020958	001	Oct 16, 2000

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
	AUROBINDO PHARMA LTD	10MG	A209107	001	Jul 20, 2018
+	BIONPHARMA	5MG	N022429	001	Jul 23, 2009
+!		10MG	N022429	004	Jul 23, 2009
	CATALENT	10MG	A213105	001	Sep 21, 2020
	STRIDES PHARMA	10MG	A205291	001	Jul 21, 2017
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	AUROBINDO PHARMA LTD	10MG	A209107	002	Jul 20, 2018
+	BIONPHARMA	5MG	N022429	003	Jul 23, 2009
+!		10MG	N022429	002	Jul 23, 2009
SYRUP;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
	AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009
	AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010
	BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011
	CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011
	HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013
		5MG/5ML	A090254	002	Apr 09, 2008
	QUAGEN	5MG/5ML	A212266	001	May 16, 2019
	TARO	5MG/5ML	A090182	002	Apr 22, 2008
		5MG/5ML	A201546	001	May 20, 2011

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009
	AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010
	BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011
	CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011
	PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008
	TARO	5MG/5ML	A090182	001	Apr 22, 2008
		5MG/5ML	A201546	002	May 20, 2011

CHILDREN'S ZYRTEC ALLERGY

+!	J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+!	J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	AMNEAL PHARMS NY	5MG	A078780	001	Jan 21, 2010
		10MG	A078780	004	Jan 21, 2010
	APOTEX INC	5MG	A078317	001	Dec 27, 2007
		10MG	A078317	002	Dec 27, 2007
	AUROBINDO PHARMA LTD	5MG	A090760	001	Aug 05, 2015
		10MG	A090760	003	Aug 05, 2015
	CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007
		10MG	A076047	002	Dec 27, 2007
	DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008
		10MG	A078343	003	Jan 15, 2008
	GLENMARK PHARMS INC	5MG	A078427	003	Dec 28, 2007
		10MG	A078427	004	Dec 28, 2007
	GRANULES	10MG	A209274	001	Dec 22, 2017
	IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014
		10MG	A202277	004	Mar 11, 2014
	MARKSANS PHARMA	5MG	A078933	001	Jun 15, 2010
		10MG	A078933	002	Jun 15, 2010
	MYLAN	5MG	A076677	001	Dec 27, 2007
		10MG	A076677	002	Dec 27, 2007
	ORBION PHARMS	5MG	A078862	001	Feb 19, 2009
		10MG	A078862	002	Feb 19, 2009
	PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
		10MG	A078336	002	Dec 27, 2007
	PLD ACQUISITIONS	5MG	A077946	001	Dec 27, 2007
		10MG	A077946	002	Dec 27, 2007
	SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007
		10MG	A077498	002	Dec 27, 2007
	TARO	5MG	A078072	001	Jul 22, 2009
		5MG	A078072	003	Jul 22, 2009
	UNIQUE	5MG	A077829	001	Aug 26, 2009
		10MG	A077829	004	Aug 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
		10MG	A078343	002	Jan 15, 2008
	IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014
		10MG	A202277	003	Mar 11, 2014
	MARKSANS PHARMA	5MG	A078933	003	Jun 15, 2010
		10MG	A078933	004	Jun 15, 2010
	MYLAN	5MG	A076677	004	Dec 27, 2007
		10MG	A076677	003	Dec 27, 2007
	ORBION PHARMS	5MG	A078862	003	Feb 19, 2009
		10MG	A078862	004	Feb 19, 2009
	PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
		10MG	A078336	004	Dec 27, 2007
	SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007
		10MG	A077498	004	Dec 27, 2007
	UNIQUE	5MG	A077829	003	Aug 26, 2009
!		10MG	A077829	002	Aug 26, 2009

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL					
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
		10MG	A078780	002	Jan 21, 2010
	AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015
		10MG	A090760	004	Aug 05, 2015
	TARO	10MG	A078072	002	Jul 22, 2009
		10MG	A078072	004	Jul 22, 2009
ZYRTEC ALLERGY					
+!	J AND J CONSUMER INC	10MG	N019835	004	Nov 16, 2007
TABLET, CHEWABLE;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
	JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015
		10MG	A091116	002	Feb 19, 2015
	NOVEL LABS INC	5MG	A206793	001	Mar 08, 2016
		10MG	A206793	002	Mar 08, 2016
	SANDOZ	5MG	A078692	001	Feb 14, 2008
!		10MG	A078692	002	Feb 14, 2008
	SUN PHARM	5MG	A090142	001	Aug 30, 2011
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015
		10MG	A091116	004	Feb 19, 2015
	SUN PHARM	5MG	A090142	003	Aug 30, 2011
CHILDREN'S ZYRTEC ALLERGY					
+	J AND J CONSUMER INC	2.5MG	N021621	007	Nov 30, 2020
+		10MG	N021621	004	Nov 16, 2007
TABLET, ORALLY DISINTEGRATING;ORAL					
CETIRIZINE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	10MG	A213557	001	Sep 11, 2020
CETIRIZINE HYDROCHLORIDE ALLERGY					
	PERRIGO R AND D	10MG	A205490	001	Sep 02, 2015
ZYRTEC ALLERGY					
+!	J AND J CONSUMER INC	10MG	N022578	001	Sep 03, 2010

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	IVAX SUB TEVA PHARMS	5MG;120MG	A077170	001	Feb 25, 2008
	PERRIGO R AND D	5MG;120MG	A210719	001	Nov 16, 2018
	PLD ACQUISITIONS	5MG;120MG	A077991	001	Mar 05, 2008
	SUN PHARM INDS LTD	5MG;120MG	A090922	001	Sep 28, 2012
ZYRTEC-D 12 HOUR					
+!	J AND J CONSUMER INC	5MG;120MG	N021150	002	Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL					
EXIDINE					
+!	XTTRIUM	4%	N019127	001	Dec 24, 1984
CLOTH;TOPICAL					
CHLORHEXIDINE GLUCONATE					
+!	SAGE PRODS	2%	N021669	001	Apr 25, 2005
READYPREP CHG					
	MEDLINE INDUSTRIES	2%	N207964	001	Nov 20, 2018
SOLUTION;TOPICAL					
CHG SCRUB					
	ECOLAB	4%	N019258	002	Jul 22, 1986
CHLORHEXIDINE GLUCONATE					
	BAJAJ	0.75%	N020111	001	Sep 11, 1997
CIDA-STAT					
	ECOLAB	2%	N019258	001	Jul 22, 1986
EXIDINE					
+!	XTTRIUM	2%	N019422	001	Dec 17, 1985
		4%	N019125	001	Dec 24, 1984
HIBICLENS					
+!	MOLNLYCKE HLTH	4%	N017768	001	

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

HIBISTAT

+!	MOLNLYCKE HLTH	0.5%	N018300	001	

SPONGE;TOPICAL

BIOSCRUB

	GRIFFEN	4%	N019822	001	Mar 31, 1989

CHLORHEXIDINE GLUCONATE

!	BECTON DICKINSON	4%	A072525	001	Oct 24, 1989

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

SOLUPREP S

+!	3M HEALTH CARE	2%;70%	N208288	001	Aug 08, 2018

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+!	BECTON DICKINSON CO	2%;70% (3ML)	N020832	001	Jul 14, 2000
+!		2%;70% (10.5ML)	N020832	004	Aug 20, 2003
+!		2%;70% (26ML)	N020832	006	Nov 21, 2006
+!		2%;70% (1ML)	N020832	008	Oct 23, 2008

CHLORAPREP ONE-STEP FREPP

+!	BECTON DICKINSON CO	2%;70% (1.5ML)	N020832	003	Apr 26, 2002

CHLORAPREP WITH TINT

+!	BECTON DICKINSON CO	2%;70% (26ML)	N020832	002	May 03, 2005
+!		2%;70% (10.5ML)	N020832	005	Apr 03, 2006
+!		2%;70% (3ML)	N020832	007	Oct 10, 2006

SWAB;TOPICAL

CHLORAPREP ONE-STEP SEPP

+!	BECTON DICKINSON CO	2%;70% (0.67ML)	N021555	001	Oct 07, 2002

CHLORAPREP SINGLE SWABSTICK

+!	BECTON DICKINSON CO	2%;70% (1.75ML)	N021555	002	May 10, 2005

CHLORAPREP TRIPLE SWABSTICK

+!	BECTON DICKINSON CO	2%;70% (5.25ML)	N021555	003	Jun 10, 2009

PREVANTICS MAXI SWABSTICK

+!	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005

PREVANTICS SWAB

+!	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005

PREVANTICS SWABSTICK

+!	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

!	AVANTHI INC	12MG	A040829	001	May 13, 2009

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL ALLERGY AND CONGESTION RELIEF

+!	GLAXOSMITHKLINE	4MG;200MG;10MG	N022113	001	Dec 21, 2011

ADVIL MULTI-SYMPTOM COLD & FLU

+!	GLAXOSMITHKLINE	4MG;200MG;10MG	N022113	002	Apr 28, 2017

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+!	GLAXOSMITHKLINE	1MG/5ML;100MG/5ML;15MG/5ML	N021587	001	Feb 24, 2004

TABLET;ORAL

ADVIL ALLERGY SINUS

+!	GLAXOSMITHKLINE	2MG;200MG;30MG	N021441	001	Dec 19, 2002

CIMETIDINE

TABLET;ORAL

CIMETIDINE

	APOTEX	100MG	A074948	001	Jun 19, 1998
		200MG	A074948	002	Jul 26, 2002
	L PERRIGO CO	200MG	A075285	001	Oct 29, 1998

TAGAMET HB

+!	MEDTECH PRODUCTS	200MG	N020238	002	Aug 21, 1996

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

!	P AND L	1%	A074165	001	Jul 16, 1993
	TARO	1%	A072641	001	Dec 04, 1995

TRIVAGIZOLE 3

	TARO	2%	N021143	001	Apr 12, 2000

CROMOLYN SODIUM

SPRAY, METERED;NASAL

CROMOLYN SODIUM

!	BAUSCH AND LOMB	5.2MG/SPRAY	A075702	001	Jul 03, 2001

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

	ACTAVIS LABS FL	30MG;600MG	A091070	001	Aug 31, 2015
		60MG;1.2GM	A091070	002	Aug 31, 2015
	AMNEAL PHARMS	30MG;600MG	A209692	001	Nov 01, 2018
		60MG;1.2GM	A209692	002	Nov 01, 2018
	AUROBINDO PHARMA	30MG;600MG	A206941	001	Mar 17, 2017
		60MG;1.2GM	A206941	002	Mar 17, 2017
	DR REDDYS	30MG;600MG	A217340	001	Aug 01, 2023
		60MG;1.2GM	A217340	002	Aug 01, 2023
	PERRIGO R AND D	30MG;600MG	A207602	002	Mar 05, 2018
		60MG;1.2GM	A207602	001	Mar 05, 2018
	SUN PHARM	30MG;600MG	A214781	001	Jul 01, 2021
		60MG;1.2GM	A214781	002	Jul 01, 2021

MUCINEX DM

+	RB HLTH	30MG;600MG	N021620	002	Apr 29, 2004
+!		60MG;1.2GM	N021620	001	Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

+!	RB HLTH	EQ 30MG HYDROBROMIDE/5ML	N018658	001	Oct 08, 1982

DEXTROMETHORPHAN POLISTIREX

	AMNEAL	EQ 30MG HYDROBROMIDE/5ML	A203133	001	Jul 28, 2017
	TRIS PHARMA INC	EQ 30MG HYDROBROMIDE/5ML	A091135	001	May 25, 2012

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016
	AUROLIFE PHARMA LLC	1%	A204306	001	May 06, 2019
	ENCUBE	1%	A210986	001	Jan 27, 2020
	HIKMA	1%	A209484	001	Nov 21, 2018
	PERRIGO PHARMA INTL	1%	A211253	001	May 16, 2019

VOLTAREN ARTHRITIS PAIN

+!	GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

ADVIL PM

+!	GLAXOSMITHKLINE	38MG;200MG	N021394	001	Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

	AUROBINDO PHARMA	38MG;200MG	A216204	001	May 31, 2022
	DR REDDYS LABS LTD	38MG;200MG	A090619	001	Jul 08, 2009
	PERRIGO R AND D	38MG;200MG	A079113	001	Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

ADVIL PM

+!	GLAXOSMITHKLINE	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	N021393	001	Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A210676	001	Feb 14, 2019
	BIONPHARMA	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010
	STRIDES PHARMA	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+!	BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

	AMNEAL PHARMS CO	25MG;220MG	A209726	001	Oct 23, 2018
	COREPHARMA	25MG;220MG	A211830	001	Aug 22, 2019
	GRANULES	25MG;220MG	A213663	001	Sep 24, 2020
	PERRIGO R AND D	25MG;220MG	A208499	001	May 10, 2019

DOCOSANOL

CREAM;TOPICAL

ABREVA

+!	GLAXOSMITHKLINE	10%	N020941	001	Jul 25, 2000

DOCOSANOL

	ALEMBIC	10%	A215839	001	May 03, 2022
	ENCUBE	10%	A212385	001	Oct 07, 2022
	P AND L	10%	A208754	001	Nov 19, 2018
	TARO	10%	A214454	001	Oct 26, 2023

DOXYLAMINE SUCCINATE

TABLET;ORAL

DOXYLAMINE SUCCINATE

	LNK	25MG	A040564	001	Aug 27, 2004
	PERRIGO	25MG	A040167	001	Sep 18, 1996

UNISOM

+!	CHATTEM	25MG	N018066	001	

EPINEPHRINE

AEROSOL, METERED;INHALATION

PRIMATENE MIST

+!	ARMSTRONG PHARMS	0.125MG/INH	N205920	001	Nov 07, 2018

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

	AMNEAL PHARMS NY	EQ 20MG BASE	A209716	001	Jun 05, 2019
	ANDA REPOSITORY	EQ 20MG BASE	A216149	001	Mar 15, 2023
	AUROBINDO PHARMA	EQ 20MG BASE	A209339	001	Oct 16, 2017
	DR REDDYS	EQ 20MG BASE	A207673	001	May 15, 2018
	GRAVITI PHARMS	EQ 20MG BASE	A216349	001	Jun 24, 2022
	HETERO LABS LTD III	EQ 20MG BASE	A212507	001	Jun 02, 2020
	MARKSANS PHARMA	EQ 20MG BASE	A217264	001	Sep 29, 2023
	PERRIGO R AND D	EQ 20MG BASE	A207193	001	Aug 18, 2017
	SUN PHARM	EQ 20MG BASE	A212866	001	May 04, 2020

NEXIUM 24HR

+!	ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

	AUROBINDO PHARMA LTD	EQ 20MG BASE	A214473	001	Jul 12, 2023
	DR REDDYS	EQ 20MG BASE	A211571	001	May 14, 2020
	MYLAN	EQ 20MG BASE	A212088	001	Jun 25, 2020

NEXIUM 24HR

+!	ASTRAZENECA LP	EQ 20MG BASE	N207920	001	Nov 23, 2015

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

	ANNORA PHARMA	10MG	A215766	001	Nov 08, 2021
		20MG	A215766	002	Nov 08, 2021
	ASCENT PHARMS INC	10MG	A216030	001	Nov 03, 2021
		20MG	A216030	002	Nov 03, 2021
	AUROBINDO PHARMA	10MG	A206531	001	Apr 26, 2016
		20MG	A206531	002	Apr 26, 2016
	DR REDDYS LABS LTD	10MG	A077367	002	Aug 17, 2001
		20MG	A077367	001	Sep 25, 2006
	GLENMARK PHARMS INC	10MG	A077146	001	Mar 07, 2005
		20MG	A090837	001	Aug 04, 2010
	MARKSANS PHARMA	10MG	A217543	001	Mar 08, 2023
		20MG	A217543	002	Mar 08, 2023
	P AND L	10MG	A075512	001	Jul 26, 2001
	PERRIGO	10MG	A075400	001	Mar 18, 2005
	PERRIGO R AND D	20MG	A077351	001	Sep 25, 2006
	SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

		20MG	A090283	002	Nov 17, 2009
	VKT PHARMA	10MG	A215822	001	Jan 28, 2022
		20MG	A215822	002	Jan 28, 2022

PEPCID AC

+	J AND J CONSUMER INC	10MG	N020325	001	Apr 28, 1995
		10MG	N020902	001	Aug 05, 1999
+!		20MG	N020325	002	Sep 23, 2003

TABLET, CHEWABLE;ORAL

PEPCID AC

+!	J AND J CONSUMER INC	20MG	N020801	002	Dec 17, 2007

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ALLEGRA ALLERGY

+!	CHATTEM SANOFI	30MG/5ML	N201373	001	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	P AND L	30MG/5ML	A203330	001	Nov 18, 2014
	TARO	30MG/5ML	A208123	001	Nov 09, 2017

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

!	P AND L	30MG/5ML	A203330	002	Nov 18, 2014
	TARO	30MG/5ML	A208123	002	Nov 09, 2017

FEXOFENADINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	30MG/5ML	A213466	001	May 23, 2023

TABLET;ORAL

ALLEGRA ALLERGY

+	CHATTEM SANOFI	60MG	N020872	007	Jan 24, 2011
+!		180MG	N020872	010	Jan 24, 2011

ALLEGRA HIVES

+!	CHATTEM SANOFI	180MG	N020872	009	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	AUROBINDO PHARMA LTD	30MG	A202039	001	Nov 19, 2014
	DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011
	HETERO LABS LTD V	30MG	A204097	001	Aug 19, 2016
	TEVA	30MG	A076447	004	Apr 13, 2011
	WOCKHARDT	30MG	A079112	002	Feb 08, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011
	TEVA	30MG	A076447	005	Apr 13, 2011
	WOCKHARDT	30MG	A079112	001	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE

	L PERRIGO CO	60MG	A212971	001	Feb 24, 2020
		180MG	A212971	002	Feb 24, 2020

FEXOFENADINE HYDROCHLORIDE ALLERGY

	AUROBINDO PHARMA LTD	60MG	A202039	002	Nov 19, 2014
		180MG	A202039	003	Nov 19, 2014
	DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011
		180MG	A076502	008	Apr 12, 2011
	GRANULES	60MG	A211075	001	Oct 18, 2019
		180MG	A211075	002	Oct 18, 2019
	HETERO LABS LTD V	60MG	A204097	002	Aug 19, 2016
		180MG	A204097	003	Aug 19, 2016
	RISING	60MG	A077081	006	Jul 21, 2011
		180MG	A077081	008	Jul 21, 2011
	SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015
		180MG	A204507	003	Sep 16, 2015
	SUN PHARM INDS	180MG	A091567	006	Feb 06, 2012
	TEVA	60MG	A076447	006	Apr 13, 2011
		180MG	A076447	008	Apr 13, 2011
	UNIQUE	180MG	A210137	001	Aug 13, 2018
	WOCKHARDT	60MG	A079112	004	Feb 08, 2012
		180MG	A079112	006	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011
		180MG	A076502	009	Apr 12, 2011
	RISING	60MG	A077081	007	Jul 21, 2011
		180MG	A077081	009	Jul 21, 2011

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE HIVES

	SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015
		180MG	A204507	005	Sep 16, 2015
	SUN PHARM INDS	180MG	A091567	005	Feb 06, 2012
	TEVA	60MG	A076447	007	Apr 13, 2011
	WOCKHARDT	60MG	A079112	003	Feb 08, 2012
		180MG	A079112	005	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+!	CHATTEM SANOFI	60MG;120MG	N020786	002	Jan 24, 2011

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+!	CHATTEM SANOFI	180MG;240MG	N021704	002	Jan 24, 2011

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA	60MG;120MG	A209116	001	Oct 30, 2017
	DR REDDYS	60MG;120MG	A076667	001	Nov 18, 2014
		60MG;120MG	A215434	001	May 31, 2022
	DR REDDYS LABS LTD	180MG;240MG	A079043	002	Jun 22, 2011
	SUN PHARM	60MG;120MG	A090818	001	Jan 29, 2015

FLUTICASONE FUROATE

SPRAY, METERED;NASAL

FLONASE SENSIMIST ALLERGY RELIEF

+!	GLAXOSMITHKLINE CONS	0.0275MG/SPRAY	N022051	002	Aug 02, 2016

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

+	GLAXOSMITHKLINE CONS	0.05MG/SPRAY	N205434	001	Jul 23, 2014

FLUTICASONE PROPIONATE

	APOTEX	0.05MG/SPRAY	A208150	001	Feb 29, 2016
!	HIKMA	0.05MG/SPRAY	A207957	001	May 26, 2016
		0.05MG/SPRAY	A208024	001	Apr 17, 2019

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

	ACTAVIS LABS FL	1.2GM	A091009	002	Sep 03, 2015
	AMNEAL PHARMS	600MG	A207342	001	Jul 11, 2018
		1.2GM	A207342	002	Jul 11, 2018
	AUROBINDO PHARMA	600MG	A210453	001	Oct 21, 2019
		1.2GM	A210453	002	Oct 21, 2019
	DR REDDYS	600MG	A215932	001	Mar 15, 2022
		1.2GM	A215932	002	Mar 15, 2022
	GRANULES	600MG	A213420	001	May 08, 2020
		1.2GM	A213420	002	May 08, 2020
	GUARDIAN DRUG	600MG	A209215	001	Sep 06, 2017
		1.2GM	A209215	002	Sep 06, 2017
	MARKSANS PHARMA	600MG	A217780	001	Aug 21, 2023
		1.2GM	A217780	002	Aug 21, 2023
	OHM LABS INC	600MG	A209254	001	Jul 16, 2018
		1.2GM	A209254	002	Jul 16, 2018
	PERRIGO R AND D	600MG	A078912	001	Nov 23, 2011
		1.2GM	A078912	002	Nov 05, 2020

MUCINEX

+	RB HLTH	600MG	N021282	001	Jul 12, 2002
+!		1.2GM	N021282	002	Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

	ACTAVIS LABS FL	600MG;60MG	A091071	001	May 27, 2015
		1.2GM;120MG	A091071	002	May 27, 2015
	AUROBINDO PHARMA LTD	600MG;60MG	A213203	001	Mar 25, 2020
		1.2GM;120MG	A213203	002	Mar 25, 2020
	DR REDDYS	600MG;60MG	A208369	001	Dec 29, 2017
		1.2GM;120MG	A208369	002	Dec 29, 2017
	L PERRIGO CO	600MG;60MG	A214407	001	Feb 01, 2022
		1.2GM;120MG	A214407	002	Feb 01, 2022

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	SUN PHARM INDS INC	600MG;60MG	A212542	001	Apr 28, 2020
		1.2GM;120MG	A212542	002	Apr 28, 2020
MUCINEX D					
+	RB HLTH	600MG;60MG	N021585	001	Jun 22, 2004
+!		1.2GM;120MG	N021585	002	Jun 22, 2004

IBUPROFEN

CAPSULE;ORAL

ADVIL LIQUI-GELS					
+!	GLAXOSMITHKLINE	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	001	Apr 20, 1995
ADVIL MIGRAINE LIQUI-GELS					
+!	GLAXOSMITHKLINE	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	002	Mar 16, 2000
IBUPROFEN					
	AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A202300	001	Dec 23, 2011
	ASCENT PHARMS INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A206999	001	Dec 21, 2017
	AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A207753	001	Jun 29, 2018
		EQ 200MG FREE ACID AND POTASSIUM SALT	A215777	001	Sep 14, 2023
	BIONPHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009
	HUMANWELL PURACAP	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016
	MARKSANS PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A079205	001	Jun 26, 2009
	P AND L DEV LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009
	SOFGEN PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A203599	001	Sep 07, 2016
	STRIDES PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469	001	Mar 28, 2018
MIDOL LIQUID GELS					
+!	BIONPHARMA	200MG	N021472	001	Oct 18, 2002

SUSPENSION;ORAL

CHILDREN'S ADVIL					
	GLAXOSMITHKLINE	100MG/5ML	N020589	001	Jun 27, 1996
CHILDREN'S ADVIL-FLAVORED					
	GLAXOSMITHKLINE	100MG/5ML	N020589	002	Nov 07, 1997
CHILDREN'S IBUPROFEN					
	PERRIGO	100MG/5ML	A074937	001	Dec 22, 1998
CHILDREN'S MOTRIN					
+!	J AND J CONSUMER INC	100MG/5ML	N020516	001	Jun 16, 1995
IBUPROFEN					
	APTAPHARMA INC	100MG/5ML	A210602	001	Nov 23, 2018
	AUROBINDO PHARMA LTD	100MG/5ML	A209179	001	Apr 17, 2018
	GUARDIAN DRUG	100MG/5ML	A210149	001	Aug 17, 2018
	P AND L	100MG/5ML	A074916	001	Apr 30, 1999
	TARO	100MG/5ML	A209207	001	Jun 27, 2017

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN					
+!	J AND J CONSUMER INC	40MG/ML	N020603	001	Jun 10, 1996
IBUPROFEN					
	GUARDIAN DRUG	40MG/ML	A210755	001	Sep 26, 2018
	L PERRIGO CO	40MG/ML	A075217	001	Dec 16, 1998
	TARO	40MG/ML	A217261	001	Aug 08, 2023
	TRIS PHARMA INC	40MG/ML	A079058	001	Aug 31, 2009
INFANT'S ADVIL					
+!	GLAXOSMITHKLINE	50MG/1.25ML	N020812	002	Jan 12, 2000

TABLET;ORAL

ADVIL					
+!	GLAXOSMITHKLINE	200MG	N018989	001	May 18, 1984
IBUPROFEN					
	AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014
	AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987
		200MG	A072199	001	May 23, 1988
	AUROBINDO PHARMA	200MG	A208865	001	Nov 08, 2017
	AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003
	CONTRACT PHARMACAL	200MG	A072299	001	Jul 01, 1988
	DR REDDYS LA	200MG	A075661	001	Dec 12, 2001
	DR REDDYS LABS INC	200MG	A076117	001	Nov 20, 2001
	GRANULES	200MG	A202312	001	Oct 07, 2016
	GRANULES INDIA	200MG	A079174	001	Dec 10, 2010
	LNK	200MG	A075010	001	Mar 01, 1999
		200MG	A075139	001	Mar 01, 1999
	MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011

IBUPROFEN

TABLET;ORAL

IBUPROFEN

		200MG	A091239	001	Feb 01, 2011
	MCNEIL	200MG	A073019	001	Mar 30, 1994
	PERRIGO	200MG	A072096	001	Dec 08, 1987
!	PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005
	SHANDONG XINHUA	200MG	A207095	001	May 05, 2017
		200MG	A207095	002	Aug 21, 2018
	STRIDES PHARMA	200MG	A070481	001	Sep 24, 1986
		200MG	A079129	001	Mar 28, 2011
		200MG	A091355	001	Apr 04, 2011
		200MG	A206989	001	Jun 29, 2018
		200MG	A207052	001	May 30, 2017
	VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987

JUNIOR STRENGTH ADVIL

	GLAXOSMITHKLINE	100MG	N020267	002	Dec 13, 1996

JUNIOR STRENGTH MOTRIN

	J AND J CONSUMER INC	100MG	N020602	001	Jun 10, 1996

MOTRIN IB

+	J AND J CONSUMER INC	200MG	N019012	003	Dec 17, 1990

TABLET, CHEWABLE;ORAL

CHILDREN'S ADVIL

	GLAXOSMITHKLINE	50MG	N020944	001	Dec 18, 1998

IBUPROFEN

!	PERRIGO	100MG	A076359	002	Jan 16, 2004

JUNIOR STRENGTH ADVIL

	GLAXOSMITHKLINE	100MG	N020944	002	Dec 18, 1998

IBUPROFEN SODIUM

TABLET;ORAL

ADVIL

+!	GLAXOSMITHKLINE	EQ 200MG BASE	N201803	001	Jun 12, 2012

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL CONGESTION RELIEF

+!	GLAXOSMITHKLINE	200MG;10MG	N022565	001	May 27, 2010

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

	PERRIGO R AND D	200MG;10MG	A203200	001	Jul 03, 2014

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

ADVIL COLD AND SINUS

+!	GLAXOSMITHKLINE	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	N021374	001	May 30, 2002

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	A209235	001	Dec 01, 2017

SUSPENSION;ORAL

CHILDREN'S ADVIL COLD

	GLAXOSMITHKLINE	100MG/5ML;15MG/5ML	N021373	001	Apr 18, 2002

CHILDREN'S MOTRIN COLD

+!	J AND J CONSUMER INC	100MG/5ML;15MG/5ML	N021128	001	Aug 01, 2000

TABLET;ORAL

ADVIL COLD AND SINUS

+!	GLAXOSMITHKLINE	200MG;30MG	N019771	001	Sep 19, 1989

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS LABS LTD	200MG;30MG	A077628	001	Aug 14, 2006

IBUPROHM COLD AND SINUS

	OHM LABS	200MG;30MG	A074567	001	Apr 17, 2001

SINE-AID IB

	J AND J CONSUMER INC	200MG;30MG	N019899	001	Dec 31, 1992

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

DURAPREP

+!	3M	EQ 0.7% IODINE;74% (6ML)	N021586	001	Sep 29, 2006
+!		EQ 0.7% IODINE;74% (26ML)	N021586	002	Sep 29, 2006

ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

ZURAGARD

+!	ZUREX PHARMA	70%	N210872	001	Apr 26, 2019

IVERMECTIN

LOTION;TOPICAL

IVERMECTIN

	TARO	0.5%	A210720	001	May 06, 2020

SKLICE

+!	ARBOR PHARMS LLC	0.5%	N202736	001	Feb 07, 2012

KETOCONAZOLE

SHAMPOO;TOPICAL

NIZORAL ANTI-DANDRUFF

+!	KRAMER	1%	N020310	001	Oct 10, 1997

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

+!	BAUSCH AND LOMB	EQ 0.025% BASE	N021996	001	Dec 01, 2006
	BAUSCH AND LOMB INC	EQ 0.025% BASE	A208158	001	Sep 24, 2020

CHILDREN'S ALAWAY

+	BAUSCH AND LOMB	EQ 0.025% BASE	N021996	002	Feb 11, 2015

KETOTIFEN FUMARATE

	APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006
	BAYSHORE PHARMS LLC	EQ 0.025% BASE	A204059	001	Jun 01, 2020
	SENTISS	EQ 0.025% BASE	A077958	001	Jul 26, 2007

ZADITOR

!	ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

	DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012
	GLENMARK PHARMS INC	15MG	A202727	001	May 18, 2012
	NATCO	15MG	A203306	001	Jan 13, 2016
	PERRIGO R AND D	15MG	A202319	001	May 18, 2012

PREVACID 24 HR

+!	PERRIGO PHARMA INTL	15MG	N022327	001	May 18, 2009

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

	DEXCEL	15MG	N208025	001	Jun 07, 2016

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+!	CHATTEM SANOFI	2.5MG/5ML	N209090	001	Jan 31, 2017

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	APOTEX	5MG	A211443	001	Apr 21, 2021
	DR REDDYS	5MG	A210375	001	Jan 19, 2018
	HETERO LABS LTD III	5MG	A213513	001	Apr 29, 2020
	MICRO LABS	5MG	A211551	001	Nov 20, 2018
	PERRIGO R AND D	5MG	A211983	001	Mar 28, 2019

XYZAL ALLERGY 24HR

+!	CHATTEM SANOFI	5MG	N209089	001	Jan 31, 2017

LEVONORGESTREL

TABLET;ORAL

ATHENTIA NEXT

	AUROBINDO PHARMA	1.5MG	A206867	001	Dec 08, 2015

FALLBACK SOLO

	LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014

HER STYLE

	NOVAST LABS	1.5MG	A207976	001	Mar 11, 2016

LEVONORGESTREL

	GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016
	LABORATOIRE HRA	1.5MG	A204044	001	Jul 03, 2018
	MYLAN LABS LTD	1.5MG	A202739	001	Oct 31, 2014
	NAARI PTE LTD	1.5MG	A202380	001	May 29, 2015
	NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013
	PERRIGO R AND D	1.5MG	A202334	001	Aug 20, 2014
	XIROMED	1.5MG	A205329	001	Sep 18, 2018

LEVONORGESTREL

TABLET;ORAL					
OPCICON ONE-STEP					
	SUN PHARM	1.5MG	A202635	001	Sep 11, 2014
PLAN B ONE-STEP					
+!	FDN CONSUMER	1.5MG	N021998	001	Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL					
LOPERAMIDE HYDROCHLORIDE					
+	BIONPHARMA	1MG	N021855	001	Aug 04, 2005
+!		2MG	N021855	002	Aug 04, 2005
	STRIDES PHARMA	2MG	A213070	001	Aug 11, 2021
SOLUTION;ORAL					
IMODIUM A-D					
+!	J AND J CONSUMER INC	1MG/5ML	N019487	001	Mar 01, 1988
LOPERAMIDE HYDROCHLORIDE					
	WOCKHARDT BIO AG	1MG/5ML	A074730	001	Aug 28, 1997
SUSPENSION;ORAL					
IMODIUM A-D					
+!	J AND J CONSUMER INC	1MG/7.5ML	N019487	002	Jul 08, 2004
LOPERAMIDE HYDROCHLORIDE					
	PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011
TABLET;ORAL					
IMODIUM A-D					
+!	J AND J CONSUMER INC	2MG	N019860	001	Nov 22, 1989
LOPERAMIDE HYDROCHLORIDE					
	AUROBINDO PHARMA	2MG	A206548	001	Dec 15, 2015
	L PERRIGO CO	2MG	A075232	001	Jan 06, 2000
	LNK	2MG	A076497	001	Jun 10, 2003
	OHM LABS	2MG	A074091	001	Dec 10, 1992

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL					
IMODIUM MULTI-SYMPTOM RELIEF					
+!	J AND J CONSUMER INC	2MG;125MG	N021140	001	Nov 30, 2000
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE					
	AUROBINDO PHARMA LTD	2MG;125MG	A211059	001	Dec 14, 2020
	BIONPHARMA	2MG;125MG	A213484	001	Sep 10, 2021
	GUARDIAN DRUG	2MG;125MG	A214541	001	May 27, 2021
	HETERO LABS LTD V	2MG;125MG	A211438	001	Jun 17, 2021
	PERRIGO R AND D	2MG;125MG	A209837	001	Sep 05, 2018
	SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006

LORATADINE

CAPSULE;ORAL					
CLARITIN					
+!	BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008
LORATADINE					
	BIONPHARMA	10MG	A202538	001	Dec 21, 2018
	MARKSANS PHARMA	10MG	A206214	001	Sep 23, 2016
SUSPENSION;ORAL					
LORATADINE					
+!	TARO	1MG/ML	N021734	001	Oct 04, 2005
SYRUP;ORAL					
CLARITIN					
+!	BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002
LORATADINE					
	AUROBINDO PHARMA LTD	1MG/ML	A208931	001	Jun 29, 2018
	HETERO LABS LTD III	1MG/ML	A210409	001	May 07, 2021
	LANNETT CO INC	1MG/ML	A077421	001	Jun 29, 2006
	PERRIGO	1MG/ML	A075728	001	Aug 20, 2004
	TARO	1MG/ML	A076805	001	Aug 20, 2004
		1MG/ML	A201865	001	Jul 31, 2015
	WOCKHARDT BIO AG	1MG/ML	A075815	001	Aug 20, 2004

LORATADINE

TABLET;ORAL					
CLARITIN					
+!	BAYER HEALTHCARE LLC	10MG	N019658	002	Nov 27, 2002
CLARITIN HIVES RELIEF					
+!	BAYER HEALTHCARE LLC	10MG	N019658	003	Nov 19, 2003
LORATADINE					
	APOTEX INC	10MG	A076471	001	Feb 14, 2006
	AUROBINDO PHARMA LTD	10MG	A208314	001	Apr 16, 2018
	GRANULES	10MG	A210722	001	Dec 23, 2019
	GUARDIAN DRUG	10MG	A207569	001	Mar 12, 2019
	HETERO LABS LTD V	10MG	A211718	001	Jul 28, 2023
	MYLAN	10MG	A076154	001	Aug 20, 2003
	PERRIGO	10MG	A076301	001	Jun 25, 2004
	PLD ACQUISITIONS LLC	10MG	A075209	001	Jan 21, 2003
	SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003
	UNIQUE PHARM	10MG	A214684	001	Jan 07, 2021
TABLET, CHEWABLE;ORAL					
CHILDREN'S CLARITIN					
+	BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006
CLARITIN					
+!	BAYER HEALTHCARE LLC	10MG	N021891	002	Nov 21, 2018
LORATADINE					
	PERRIGO PHARMA INTL	5MG	A210033	001	Jun 12, 2019
	SUN PHARM	5MG	A210088	001	Apr 16, 2018
TABLET, ORALLY DISINTEGRATING;ORAL					
ALAVERT					
	FDN CONSUMER	10MG	N021375	001	Dec 19, 2002
CLARITIN HIVES RELIEF REDITAB					
+!	BAYER HEALTHCARE LLC	10MG	N020704	003	Nov 19, 2003
CLARITIN REDITABS					
+!	BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006
+!		10MG	N020704	002	Nov 27, 2002
LORATADINE					
	AUROBINDO PHARMA LTD	10MG	A208477	001	Apr 11, 2018
	PERRIGO PHARMA INTL	10MG	A076011	001	Sep 29, 2003
	RUBICON	10MG	A214280	001	Sep 10, 2020
	TENSHI	5MG	A212795	001	Sep 18, 2020
		10MG	A213294	001	Oct 30, 2020
LORATADINE REDIDOSE					
	SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL					
CLARITIN-D					
+!	BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002
CLARITIN-D 24 HOUR					
+!	BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002
LORATADINE AND PSEUDOEPHEDRINE SULFATE					
	P AND L	10MG;240MG	A075706	001	Feb 21, 2003
	PERRIGO PHARMA INTL	5MG;120MG	A076050	001	Jan 30, 2003
		10MG;240MG	A075989	001	Mar 04, 2004
	SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL					
SALONPAS					
+!	HISAMITSU PHARM CO	3%;10%	N022029	001	Feb 20, 2008
+		3%;10%	N022029	002	Nov 05, 2012

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK					
	PERRIGO	2%,4%	A076357	001	Mar 30, 2004
MONISTAT 3 COMBINATION PACK					
+	MEDTECH PRODUCTS	2%,4%	N021261	003	Jun 17, 2003
MONISTAT 3 COMBINATION PACK (PREFILLED)					
+!	MEDTECH PRODUCTS	2%,4%	N021261	001	Feb 02, 2001

CREAM;VAGINAL

MICONAZOLE 3					
	TARO	4%	A076773	001	Mar 02, 2005
MICONAZOLE 7					
	P AND L	2%	A074164	001	Mar 29, 1996
MICONAZOLE NITRATE					
	COSETTE	2%	A074366	001	Feb 22, 1996
	PERRIGO	2%	A074760	001	May 15, 1997
	PERRIGO R AND D	4%	A091366	001	Jan 15, 2010
	TARO	2%	A074444	001	Jan 13, 1997
MONISTAT 3					
+!	MEDTECH PRODUCTS	4%	N020827	001	Mar 30, 1998
MONISTAT 7					
+!	MEDTECH PRODUCTS	2%	N017450	002	Feb 15, 1991

CREAM, INSERT;TOPICAL, VAGINAL

MICONAZOLE NITRATE					
	PERRIGO R AND D	2%,1.2GM	A079114	001	Jun 02, 2010
MONISTAT 1 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,1.2GM	N021308	001	Jun 29, 2001

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK					
	P AND L	2%,200MG	A074926	001	Apr 16, 1999
MICONAZOLE NITRATE COMBINATION PACK					
	L PERRIGO CO	2%,200MG	A075329	001	Apr 20, 1999
MONISTAT 3 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,200MG	N020670	002	Apr 16, 1996
MONISTAT 7 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,100MG	N020288	002	Apr 26, 1993

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE					
	COSETTE	100MG	A074414	001	Apr 30, 1997
	P AND L	100MG	A073507	001	Nov 19, 1993
MONISTAT 7					
+!	MEDTECH PRODUCTS	100MG	N018520	002	Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MEN'S ROGAINE					
+!	JOHNSON AND JOHNSON	5%	N021812	001	Jan 20, 2006
MINOXIDIL					
	PERRIGO PHARMA INTL	5%	A091344	001	Apr 28, 2011
MINOXIDIL (FOR MEN)					
	P AND L	5%	A208092	001	Feb 17, 2017
	TARO	5%	A209074	001	Dec 31, 2018
MINOXIDIL (FOR WOMEN)					
	P AND L	5%	A208092	002	Jul 27, 2017
	TARO	5%	A209074	002	Apr 22, 2019
WOMEN'S ROGAINE					
+!	JOHNSON AND JOHNSON	5%	N021812	002	Feb 28, 2014

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)					
	AUROBINDO PHARMA LTD	2%	A074767	001	Feb 28, 1997
	L PERRIGO CO	2%	A075357	001	Jul 30, 1999
	P AND L	2%	A074588	001	Apr 05, 1996
MINOXIDIL (FOR WOMEN)					
	L PERRIGO CO	2%	A075357	002	Jul 30, 1999
MINOXIDIL EXTRA STRENGTH (FOR MEN)					
	AUROBINDO PHARMA LTD	5%	A075438	001	Feb 27, 2003
	P AND L	5%	A075518	001	Nov 17, 2000
	PERRIGO	5%	A075598	001	Jun 13, 2001
ROGAINE (FOR MEN)					
+!	JOHNSON AND JOHNSON	2%	N019501	002	Feb 09, 1996

MINOXIDIL

SOLUTION;TOPICAL

ROGAINE (FOR WOMEN)

+!	JOHNSON AND JOHNSON	2%	N019501	003	Feb 09, 1996

ROGAINE EXTRA STRENGTH (FOR MEN)

+!	JOHNSON AND JOHNSON	5%	N020834	001	Nov 14, 1997

THEROXIDIL

	PURE SOURCE	2%	A078176	001	Nov 09, 2007
		5%	A076239	001	Aug 24, 2004

MOMETASONE FUROATE

SPRAY, METERED;NASAL

NASONEX 24HR ALLERGY

+!	PERRIGO PHARMA INTL	0.05MG/SPRAY	N215712	001	Mar 17, 2022

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

NALOXONE HYDROCHLORIDE

	PADAGIS ISRAEL	4MG/SPRAY	A211951	001	Jun 21, 2022

NARCAN

+!	EMERGENT	4MG/SPRAY	N208411	001	Nov 18, 2015

RIVIVE

+!	HARM REDUCTION THERP	3MG/SPRAY	N217722	001	Jul 28, 2023

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

	ALTAIRE PHARMS INC	0.02675%;0.315%	A078208	001	Sep 27, 2010
	RISING	0.025%;0.3%	A202795	001	Jan 24, 2013

NAPHCON-A

+!	ALCON	0.025%;0.3%	N020226	001	Jun 08, 1994

OPCON-A

+!	BAUSCH AND LOMB	0.02675%;0.315%	N020065	001	Jun 08, 1994

VISINE

+!	JOHNSON AND JOHNSON	0.025%;0.3%	N020485	001	Jan 31, 1996

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+!	BIONPHARMA	EQ 200MG BASE	N021920	001	Feb 17, 2006
	CATALENT	EQ 200MG BASE	A202807	001	Jan 04, 2019
	PATHEON SOFTGELS	EQ 200MG BASE	A214463	001	Jan 10, 2023
	PURACAP PHARM LLC	EQ 200MG BASE	A208363	001	Mar 15, 2018

TABLET;ORAL

ALEVE

+!	BAYER	220MG	N020204	002	Jan 11, 1994

NAPROXEN SODIUM

	AMNEAL PHARMS NY	220MG	A079096	001	Dec 16, 2008
	AUROBINDO PHARMA LTD	220MG	A205497	001	Mar 18, 2016
	CONTRACT PHARMACAL	220MG	A074635	001	Jan 13, 1997
	DR REDDYS LABS INC	220MG	A075168	001	Jul 28, 1998
	GRANULES INDIA	220MG	A091353	001	Sep 20, 2011
	HETERO LABS LTD V	220MG	A211065	001	Oct 28, 2022
	LNK INTL INC	220MG	A204872	001	Jan 23, 2017
	MARKSANS PHARMA	220MG	A090545	001	Mar 16, 2011
	NOVELGENIX THERAPS	220MG	A207612	001	Nov 16, 2018
	PERRIGO	220MG	A074661	001	Jan 13, 1997
	SUN PHARM INDS LTD	220MG	A091183	001	May 20, 2011
	YICHANG HUMANWELL	220MG	A212033	001	Aug 30, 2019

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS LABS INC	220MG;120MG	A077381	001	Sep 27, 2006
!	PERRIGO	220MG;120MG	A076518	001	Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

+	DR REDDYS LABS SA	7MG/24HR	N020076	004	Nov 12, 1999
+		14MG/24HR	N020076	005	Nov 12, 1999
+!		21MG/24HR	N020076	006	Nov 12, 1999

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

NICODERM CQ					
+	CHATTEM SANOFI	7MG/24HR	N020165	006	Aug 02, 1996
+		14MG/24HR	N020165	005	Aug 02, 1996
+!		21MG/24HR	N020165	004	Aug 02, 1996
NICOTINE					
	AVEVA	7MG/24HR	A074612	002	Jul 28, 2003
		14MG/24HR	A074612	003	Oct 20, 1997
		21MG/24HR	A074612	001	Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE					
+	GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996
+		EQ 2MG BASE	N018612	004	Sep 25, 2000
+!		EQ 4MG BASE	N020066	002	Feb 09, 1996
+		EQ 4MG BASE	N020066	004	Sep 25, 2000
NICORETTE (MINT)					
+	GLAXOSMITHKLINE	EQ 2MG BASE	N018612	003	Dec 23, 1998
+		EQ 4MG BASE	N020066	003	Dec 23, 1998
NICOTINE POLACRILEX					
	L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004
		EQ 2MG BASE	A076777	001	Sep 16, 2004
		EQ 4MG BASE	A076779	001	Sep 16, 2004
		EQ 4MG BASE	A076789	001	Sep 16, 2004
	P AND L	EQ 2MG BASE	A074507	001	Mar 15, 1999
		EQ 2MG BASE	A076569	001	Jul 29, 2004
		EQ 2MG BASE	A078699	001	Dec 29, 2008
		EQ 2MG BASE	A079044	001	Jul 08, 2009
		EQ 2MG BASE	A079216	001	Jul 08, 2009
		EQ 2MG BASE	A204794	001	May 10, 2016
		EQ 4MG BASE	A074707	001	Mar 19, 1999
		EQ 4MG BASE	A076568	002	Jul 29, 2004
		EQ 4MG BASE	A078697	001	Dec 29, 2008
		EQ 4MG BASE	A079038	001	Jul 08, 2009
		EQ 4MG BASE	A079219	001	Jul 08, 2009
		EQ 4MG BASE	A204833	001	Feb 26, 2016
	PERRIGO R AND D	EQ 2MG BASE	A078325	001	Oct 30, 2006
		EQ 2MG BASE	A078547	001	May 24, 2007
		EQ 2MG BASE	A091349	001	Jul 20, 2011
		EQ 2MG BASE	A206394	001	Dec 15, 2016
		EQ 4MG BASE	A078326	001	Oct 30, 2006
		EQ 4MG BASE	A078546	001	May 24, 2007
		EQ 4MG BASE	A091354	001	Jul 20, 2011
		EQ 4MG BASE	A206393	001	Dec 15, 2016

TROCHE/LOZENGE;ORAL

NICORETTE					
+	GLAXOSMITHKLINE	EQ 2MG BASE	N022360	001	May 18, 2009
+!		EQ 4MG BASE	N022360	002	May 18, 2009
+	GLAXOSMITHKLINE CONS	EQ 2MG BASE	N021330	001	Oct 31, 2002
+!		EQ 4MG BASE	N021330	002	Oct 31, 2002
NICOTINE POLACRILEX					
	AUROBINDO PHARMA	EQ 2MG BASE	A213266	001	Aug 03, 2021
		EQ 4MG BASE	A213266	002	Aug 03, 2021
	AUROBINDO PHARMA LTD	EQ 2MG BASE	A215357	001	May 13, 2022
		EQ 4MG BASE	A215357	002	May 13, 2022
	DR REDDYS LABS SA	EQ 2MG BASE	A212796	001	Jan 08, 2020
		EQ 2MG BASE	A212983	001	Feb 21, 2020
		EQ 2MG BASE	A213233	001	Aug 04, 2020
		EQ 4MG BASE	A212796	002	Jan 08, 2020
		EQ 4MG BASE	A212983	002	Feb 21, 2020
		EQ 4MG BASE	A213233	002	Aug 04, 2020
	P AND L	EQ 2MG BASE	A208875	001	Oct 31, 2019
		EQ 2MG BASE	A209206	001	Jun 26, 2018
		EQ 2MG BASE	A209519	001	Jul 02, 2018
		EQ 2MG BASE	A209520	001	Oct 31, 2019
		EQ 2MG BASE	A210711	001	Oct 31, 2019
		EQ 2MG BASE	A210712	001	Sep 06, 2019
		EQ 2MG BASE	A212056	001	Jul 26, 2019
		EQ 2MG BASE	A212057	001	May 14, 2020

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

		EQ 4MG BASE	A208875	002	Oct 31, 2019
		EQ 4MG BASE	A209206	002	Jun 26, 2018
		EQ 4MG BASE	A209519	002	Jul 02, 2018
		EQ 4MG BASE	A209520	002	Oct 31, 2019
		EQ 4MG BASE	A210711	002	Oct 31, 2019
		EQ 4MG BASE	A210712	002	Sep 06, 2019
		EQ 4MG BASE	A212056	002	Jul 26, 2019
		EQ 4MG BASE	A212057	002	May 14, 2020
	PERRIGO R AND D	EQ 2MG BASE	A077007	001	Jan 31, 2006
		EQ 2MG BASE	A090711	001	Jul 10, 2009
		EQ 2MG BASE	A090821	001	Jul 10, 2009
		EQ 2MG BASE	A203690	001	Oct 09, 2012
		EQ 4MG BASE	A077007	002	Jan 31, 2006
		EQ 4MG BASE	A090711	002	Jul 10, 2009
		EQ 4MG BASE	A090821	002	Jul 10, 2009
		EQ 4MG BASE	A203690	002	Oct 09, 2012
	PLD ACQUISITIONS	EQ 2MG BASE	A207868	001	Feb 07, 2019
		EQ 4MG BASE	A207868	002	Feb 07, 2019

NIZATIDINE

TABLET;ORAL

AXID AR

+!	GLAXOSMITHKLINE	75MG	N020555	001	May 09, 1996

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

	ALEMBIC	EQ 0.1% BASE	A209919	001	Dec 07, 2018
		EQ 0.2% BASE	A209420	001	Apr 29, 2019
	APOTEX	EQ 0.1% BASE	A078350	001	Dec 07, 2015
		EQ 0.2% BASE	A090918	001	Dec 05, 2017
	BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015
	EUGIA PHARMA	EQ 0.1% BASE	A204812	001	Dec 18, 2015
		EQ 0.2% BASE	A209995	001	Apr 04, 2019
	GLAND PHARMA LTD	EQ 0.1% BASE	A209619	001	Aug 02, 2019
		EQ 0.2% BASE	A209752	001	May 20, 2020
	USV	EQ 0.1% BASE	A203152	001	Dec 07, 2015

PATADAY ONCE DAILY RELIEF

+!	ALCON LABS INC	EQ 0.2% BASE	N021545	001	Dec 22, 2004
+!		EQ 0.7% BASE	N206276	001	Jan 30, 2015

PATADAY TWICE DAILY RELIEF

+!	ALCON LABS INC	EQ 0.1% BASE	N020688	001	Dec 18, 1996

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

	APOTEX	20MG	A210070	001	Feb 11, 2019
+!	DEXCEL PHARMA	20MG	N022032	001	Dec 04, 2007
	DR REDDYS	20MG	A207740	001	Nov 05, 2018
	SUN PHARM	20MG	A207891	001	Oct 12, 2018

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

OMEPRAZOLE

+!	DEXCEL	20MG	N209400	001	Jul 05, 2017

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

!	DR REDDYS LABS LTD	EQ 20MG BASE	A078878	001	Jun 05, 2009
	L PERRIGO CO	EQ 20MG BASE	A216096	001	May 24, 2022
	SPIL	EQ 20MG BASE	A210593	001	Jul 20, 2018

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

	AUROBINDO PHARMA	EQ 20MG BASE	A206877	001	Jun 06, 2018
	HETERO LABS LTD III	EQ 20MG BASE	A211732	001	Mar 25, 2020
	P AND L	EQ 20MG BASE	A206582	001	Jun 01, 2020

PRILOSEC OTC

+!	ASTRAZENECA	EQ 20MG BASE	N021229	001	Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL					
OMEPRAZOLE AND SODIUM BICARBONATE					
	AUROBINDO PHARMA	20MG;1.1GM	A204923	001	Nov 07, 2016
	PERRIGO R AND D	20MG;1.1GM	A201361	001	Jul 15, 2016
	ZYDUS	20MG;1.1GM	A203345	001	Mar 16, 2018
ZEGERID OTC					
+!	RILEY CONSUMER	20MG;1.1GM	N022281	001	Dec 01, 2009
FOR SUSPENSION;ORAL					
ZEGERID OTC					
+!	RILEY CONSUMER	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013

ORLISTAT

CAPSULE;ORAL					
ALLI					
+!	GLAXOSMITHKLINE CONS	60MG	N021887	001	Feb 07, 2007

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL					
OXYTROL FOR WOMEN					
+!	ABBVIE	3.9MG/24HR	N202211	001	Jan 25, 2013

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC					
VISINE L.R.					
+!	JOHNSON AND JOHNSON	0.025%	N019407	001	Mar 31, 1989

PERMETHRIN

LOTION;TOPICAL					
NIX					
+!	MEDTECH PRODUCTS	1%	N019918	001	May 02, 1990
PERMETHRIN					
	ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000
	PERRIGO NEW YORK	1%	A076090	001	Dec 20, 2001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL					
MIRALAX					
+!	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006
POLYETHYLENE GLYCOL 3350					
	ANI PHARMS	17GM/SCOOPFUL	A202850	001	Dec 15, 2015
	ANNORA PHARMA	17GM/SCOOPFUL	A214990	001	Apr 14, 2021
	AUROBINDO PHARMA LTD	17GM/SCOOPFUL	A209017	001	Apr 09, 2018
	ELYSIUM	17GM/SCOOPFUL	A202071	001	Dec 28, 2012
	LGM PHARMA	17GM/SCOOPFUL	A090812	001	Oct 07, 2009
	MYLAN	17GM/PACKET	A078915	001	Oct 06, 2009
		17GM/SCOOPFUL	A078915	002	Oct 06, 2009
	NOVEL LABS INC	17GM/SCOOPFUL	A091077	001	Oct 06, 2009
	NUVO PHARMS INC	17GM/SCOOPFUL	A206105	001	Oct 28, 2016
	PERRIGO R AND D	17GM/PACKET	A090685	001	Oct 06, 2009
		17GM/SCOOPFUL	A090685	002	Oct 06, 2009
	STRIDES PHARMA	17GM/SCOOPFUL	A079214	001	Jan 31, 2013
		17GM/SCOOPFUL	A203928	001	Aug 24, 2016
		17GM/PACKET	A203928	002	Aug 24, 2016

POTASSIUM IODIDE

SOLUTION;ORAL					
POTASSIUM IODIDE					
!	MISSION PHARMACAL	65MG/ML	A206211	001	Mar 24, 2016
TABLET;ORAL					
IOSAT					
+	ANBEX	65MG	N018664	002	May 12, 2011
+!		130MG	N018664	001	Oct 14, 1982
THYROSAFE					
!	BTG INTL	65MG	A076350	001	Sep 10, 2002

POVIDONE-IODINE

SOLUTION;TOPICAL					
POVIDONE IODINE					
+!	ALLEGIANCE HLTHCARE	1%	N019522	001	Mar 31, 1989

POVIDONE-IODINE

SPONGE;TOPICAL

E-Z SCRUB 201

+!	BECTON DICKINSON	20%	N019240	001	Nov 29, 1985

E-Z SCRUB 241

+!	BECTON DICKINSON	10%	N019476	001	Jan 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA	120MG	A209008	001	Jun 09, 2017
!	L PERRIGO CO	120MG	A075153	001	Feb 26, 1999
	SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005

SUDAFED 24 HOUR

+!	J AND J CONSUMER INC	240MG	N020021	002	Dec 15, 1992

PURIFIED WATER

SOLUTION;OPHTHALMIC

PUR-WASH

+!	NIAGARA PHARMS	98.3%	N022305	001	Sep 01, 2011

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	DR REDDYS LABS LTD	EQ 75MG BASE	A075294	001	Mar 28, 2000
		EQ 150MG BASE	A078192	001	Aug 31, 2007
	THINQ PHARM-CRO PVT	EQ 75MG BASE	A210250	001	Aug 30, 2019

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+!	GLAXOSMITHKLINE CONS	1%	N021958	001	Jul 24, 2006

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL

LAMISIL

+!	GLAXOSMITHKLINE	1%	N020980	001	Mar 09, 1999

TERBINAFINE HYDROCHLORIDE

	TARO	1%	A077511	001	Jul 02, 2007

SOLUTION;TOPICAL

LAMISIL AT

+!	GLAXOSMITHKLINE CONS	1%	N021124	001	Mar 17, 2000

SPRAY;TOPICAL

LAMISIL AT

+!	GLAXOSMITHKLINE CONS	1%	N021124	002	Mar 17, 2000

TIOCONAZOLE

OINTMENT;VAGINAL

TIOCONAZOLE

	PERRIGO	6.5%	A075915	001	Nov 21, 2001

VAGISTAT-1

+!	COMBE	6.5%	N020676	001	Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR

+!	CHATTEM SANOFI	0.055MG/SPRAY	N020468	002	Oct 11, 2013

TRIAMCINOLONE ACETONIDE

	APOTEX	0.055MG/SPRAY	A214615	001	Jan 19, 2023
	PERRIGO PHARMA INTL	0.055MG/SPRAY	A078104	002	Nov 14, 2014

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

0.9% SODIUM CHLORIDE INJECTION USP SOLUTION
INJECTABLE; INJECTION
NONE
FRESENIUS KABI AG — N125695 — Sep 05, 2019

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP
INJECTABLE; INJECTION
NONE
HAEMONETICS MANUFACTURING INC — N760305 — Jun 30, 1978

NONE
CSL PLASMA INC — A125750 — Apr 25, 2022

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)
INJECTABLE; INJECTION
NONE
CITRA LABS LLC — N020037 — Aug 26, 2003
ACD-A SOLUTION
TERUMO BCT INC — A010228 — Feb 25, 2002
ADSOL WITH ACD-A
FENWAL INC — N000922 — Aug 29, 2002
ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A
HAEMONETICS CORP — A980728 — Feb 06, 2002
AS3 SOLUTION/ACD-A
TERUMO BCT INC — N001214 — May 29, 2002
ANTICOAGULANT CITRATE DEXTROSE SOLUTION A
TERUMO BCT INC — A110057 — May 11, 2012

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP
INJECTABLE; INJECTION
NONE
FENWAL INC — N160918 — Mar 17, 1978

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)
INJECTABLE; INJECTION
CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3
HAEMONETICS CORP — N000127 — Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION
INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP — N820528 — Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)
INJECTABLE; INJECTION
CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS
FENWAL INC — N770420 — May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP
INJECTABLE; INJECTION
BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER
FENWAL INC — N940404 — Jul 28, 1994

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS MANUFACTURING INC		N800077	Nov 06, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

FENWAL INC		N900223	Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER

FENWAL INC		N900224	Dec 27, 1991

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB

MACOPHARMA		N040083	Nov 21, 2005

NONE

TERUMO BCT INC		A070025	Jan 06, 2009

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC		N170401	Dec 06, 1977
		N811012	Jun 28, 1983
GLOBAL LIFE SCIENCE SOLUTIONS USA, LLC		N800222	Aug 23, 1982
TERUMO MEDICAL CORP		N781211	Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC		N811104	May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP		N880217	Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS MANUFACTURING INC	0.042GM/100ML;0.276GM/100ML; 0.410GM/100ML;0.30GM/100ML; 1.10GM/100ML;0.588GM/100ML	N820915	Oct 19, 1984

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP	0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML	N820915	Sep 22, 1983

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS CORPORATION		N980123	Mar 03, 2000
LABORATORIES GRIFOIS, S.A.		A125697	Oct 25, 2019
TERUMO BCT		A125608	Jun 26, 2018

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CITRA LABS, LLC		N010409	Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC		N770923	Jan 20, 1978
TERUMO MEDICAL CORP		N781214	Feb 08, 1980

CORD BLOOD STERILE COLLECTION BAG, ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

STERILE CORD BLOOD COLLECTION UNIT

NONE

MACOPHARMA		N125552	Dec 21, 2016

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB		N830715	Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

HOSPIRA INC	10GM/100ML;5GM/100ML	A720563	Oct 30, 1992

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

HOSPIRA INC	10GM/100ML;0.9GM/100ML	A720562	Oct 30, 1992

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC	6GM/100ML	N200952	Mar 31, 1999

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
HOSPIRA INC	6GM/100ML;0.9GM/100ML	A740193	Jan 30, 1995
HESPAN IN PLASTIC CONTAINER			
B BRAUN MEDICAL INC	6GM/100ML;0.9GM/100ML	N890105	Apr 04, 1991
NONE			
TEVA PHARMACEUTICALS USA INC	6GM/100ML;0.9GM/100ML	A740592	Nov 12, 1998

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINER

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

ISOPLATE SOLUTION			
TERUMO BCT		N90067	Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND SOLX ADDITIVE

INJECTABLE; INJECTION

LEUKOSEP HWB-600-XL			
HEMERUS MEDICAL, LLC		N110059	Apr 25, 2013

RED BLOOD CELL PROCESSING SOLUTION

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

REJUVESOL			
CITRA LABS LLC		N950522	Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE, DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

INTERSOL SOLUTION			
FRESENIUS KABI USA, LLC	2.26GM/500ML;2.21GM/500ML;1.59GM/500ML;1.53GM/500ML;0.465GM/500ML	N080041	Dec 09, 2009

ABACAVIR SULFATE
TABLET;ORAL
ABACAVIR SULFATE
APOTEX INC EQ 300MG BASE A201570 001 Dec 17, 2012
ZIAGEN
+ VIIV HLTHCARE EQ 300MG BASE N020977 001 Dec 17, 1998

ABACAVIR SULFATE; LAMIVUDINE
TABLET;ORAL
ABACAVIR SULFATE AND LAMIVUDINE
AUROBINDO PHARMA EQ 600MG BASE;300MG A206151 001 Mar 28, 2017
TEVA PHARMS USA EQ 600MG BASE;300MG A079246 001 Sep 29, 2016
ZYDUS PHARMS EQ 600MG BASE;300MG A208990 001 Nov 15, 2018

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE
TABLET;ORAL
TRIZIVIR
+ VIIV HLTHCARE EQ 300MG BASE;150MG;300MG N021205 001 Nov 14, 2000

ABAMETAPIR
LOTION;TOPICAL
XEGLYZE
+ HATCHTECH 0.74% N206966 001 Jul 24, 2020

ABARELIX
INJECTABLE;INTRAMUSCULAR
PLENAXIS
SPECIALITY EUROPEAN 100MG/VIAL N021320 001 Nov 25, 2003

ABIRATERONE ACETATE
TABLET;ORAL
ABIRATERONE ACETATE
TEVA PHARMS USA 125MG A212206 001 Jun 24, 2022

ACAMPROSATE CALCIUM
TABLET, DELAYED RELEASE;ORAL
ACAMPROSATE CALCIUM
BARR LABS DIV TEVA 333MG A200143 001 Nov 18, 2013
CAMPRAL
+ FOREST LABS 333MG ** N021431 001 Jul 29, 2004

ACARBOSE
TABLET;ORAL
ACARBOSE
DASH PHARMS 25MG A091053 001 Jan 06, 2011
50MG A091053 002 Jan 06, 2011
100MG A091053 003 Jan 06, 2011
HANGZHOU ZHONGMEI 25MG A213821 001 Aug 18, 2020
50MG A213821 002 Aug 18, 2020
100MG A213821 003 Aug 18, 2020
PRECOSE
+ BAYER HLTHCARE 25MG ** N020482 004 May 29, 1997
+ 50MG ** N020482 001 Sep 06, 1995
+ 100MG ** N020482 002 Sep 06, 1995

ACEBUTOLOL HYDROCHLORIDE
CAPSULE;ORAL
ACEBUTOLOL HYDROCHLORIDE
MYLAN EQ 200MG BASE A074288 001 Apr 24, 1995
EQ 400MG BASE A074288 002 Apr 24, 1995
SECTRAL
+ PROMIUS PHARMA EQ 200MG BASE ** N018917 001 Dec 28, 1984
+ EQ 400MG BASE ** N018917 003 Dec 28, 1984

ACETAMINOPHEN
INJECTABLE;INJECTION
INJECTAPAP
ORTHO MCNEIL PHARM 100MG/ML N017785 001 Mar 07, 1986
POWDER;INTRAVENOUS
ACETAMINOPHEN
+ RISING 1GM/VIAL N206610 001 Jan 15, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN

SOLUTION;INTRAVENOUS				
ACETAMINOPHEN				
	ZYDUS PHARMS	1GM/100ML (10MG/ML)	A216467 001	Oct 25, 2022
OFIRMEV				
+	MALLINCKRODT HOSP	1GM/100ML (10MG/ML)	N022450 001	Nov 02, 2010
SUPPOSITORY;RECTAL				
ACEPHEN				
	COSETTE	120MG	A072218 001	Mar 27, 1992
		325MG	N018060 003	Dec 18, 1986
		650MG	N018060 002	
ACETAMINOPHEN				
	ABLE	120MG	A073106 001	Feb 27, 1995
		325MG	A073107 001	Feb 27, 1995
		650MG	A073108 001	Feb 27, 1995
	ACINO PRODS	120MG	A071010 001	May 12, 1987
		650MG	A071011 001	May 12, 1987
NEOPAP				
	POLYMEDICA	120MG	N016401 001	
TYLENOL				
	J AND J CONSUMER INC	120MG	N017756 002	
		650MG	N017756 001	
TABLET, EXTENDED RELEASE;ORAL				
ACETAMINOPHEN				
	SUN PHARM INDS LTD	650MG	A090205 001	Nov 18, 2009

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE;ORAL				
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE				
	MIKART	150MG;180MG;15MG	A081095 001	Oct 26, 1990
		150MG;180MG;30MG	A081096 001	Oct 26, 1990
		150MG;180MG;60MG	A081097 001	Oct 26, 1990
CODEINE, ASPIRIN, APAP FORMULA NO. 2				
+	SCHERER LABS	150MG;180MG;15MG	A085640 001	
CODEINE, ASPIRIN, APAP FORMULA NO. 3				
+	SCHERER LABS	150MG;180MG;30MG	A085639 001	
CODEINE, ASPIRIN, APAP FORMULA NO. 4				
	SCHERER LABS	150MG;180MG;60MG	A085638 001	

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL				
APADAZ				
+	ZEVRA THERAP	325MG;EQ 4.08MG BASE	N208653 002	Jan 04, 2019
+		325MG;EQ 6.12MG BASE	N208653 001	Feb 23, 2018
+		325MG;EQ 8.16MG BASE	N208653 003	Jan 04, 2019

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL				
BANCAP				
	FOREST PHARMS	325MG;50MG	A088889 001	Jan 16, 1986
BUCET				
	MALLINCKRODT	650MG;50MG	A088991 001	Jun 28, 1985
PHRENILIN FORTE				
	VALEANT	650MG;50MG	A088831 001	Jun 19, 1985
TENCON				
	MALLINCKRODT	650MG;50MG	A089405 001	May 15, 1990
TRIAPRIN				
	DUNHALL	325MG;50MG	A089268 001	Jul 02, 1987
TABLET;ORAL				
BUTALBITAL AND ACETAMINOPHEN				
	ALVOGEN	300MG;50MG	A207635 001	Jun 05, 2017
		325MG;50MG	A205120 001	Oct 30, 2015
	HALSEY	325MG;50MG	A089568 001	Oct 05, 1988
+	WATSON LABS	325MG;50MG	A087550 001	Oct 19, 1984
BUTAPAP				
	MIKART	650MG;50MG	A089988 001	Oct 26, 1992
PHRENILIN				
+	VALEANT	325MG;50MG **	A087811 001	Jun 19, 1985
SEDAPAP				
	MAYRAND	650MG;50MG	A088944 001	Oct 17, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL					
ANOQUAN					
	SHIRE	325MG;50MG;40MG	A087628	001	Oct 01, 1986
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
+	GILBERT LABS	325MG;50MG;40MG **	A088825	001	Dec 05, 1984
	GRAHAM DM	325MG;50MG;40MG	A088743	001	Jul 18, 1985
		325MG;50MG;40MG	A088765	001	Mar 27, 1985
		325MG;50MG;40MG	A089067	001	Apr 19, 1985
	HIKMA	300MG;50MG;40MG	A215135	001	Mar 25, 2022
		325MG;50MG;40MG	A215135	002	Mar 25, 2022
		500MG;50MG;40MG	A040261	001	Oct 28, 1998
	MALLINCKRODT	325MG;50MG;40MG	A088758	001	Mar 27, 1985
ESGIC-PLUS					
	MIKART	500MG;50MG;40MG	A040085	001	Mar 28, 1996
FEMCET					
	MALLINCKRODT	325MG;50MG;40MG	A089102	001	Jun 19, 1985
MEDIGESIC PLUS					
	US CHEM	325MG;50MG;40MG	A089115	001	Jan 14, 1986
TRIAD					
	MALLINCKRODT	325MG;50MG;40MG	A089023	001	Jun 19, 1985
TABLET;ORAL					
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
	ABLE	325MG;50MG;40MG	A040390	001	Jul 23, 2001
		500MG;50MG;40MG	A040394	001	Jul 23, 2001
	ALVOGEN	325MG;50MG;40MG	A204984	001	Jan 10, 2017
	GILBERT LABS	325MG;50MG;40MG	A087629	001	Nov 13, 1984
	HIKMA	500MG;50MG;40MG	A040336	001	Aug 18, 1999
	HIKMA PHARMS	325MG;50MG;40MG	A089718	001	Jun 12, 1995
	MIKART	750MG;50MG;40MG	A040496	001	Dec 23, 2003
	MIRROR PHARMS LLC	500MG;50MG;40MG	A040883	001	Dec 23, 2008
	NESHER PHARMS	325MG;50MG;40MG	A211543	001	Jul 17, 2020
	SPECGX LLC	325MG;50MG;40MG	A087804	001	Jan 24, 1985
	SUN PHARM INDUSTRIES	325MG;50MG;40MG	A040601	001	Jul 29, 2005
	VINTAGE PHARMS	500MG;50MG;40MG	A040513	001	Aug 25, 2003
	WATSON LABS	325MG;50MG;40MG	A089536	001	Feb 16, 1988
		500MG;50MG;40MG	A040267	001	Jul 30, 1998
ESGIC					
	FOREST PHARMS	325MG;50MG;40MG	A089660	001	Dec 23, 1988
ESGIC-PLUS					
	MIKART	500MG;50MG;40MG	A089451	001	May 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL					
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE					
	ABLE	325MG;50MG;40MG;30MG	A076528	001	Aug 21, 2003
	HIKMA INTL PHARMS	325MG;50MG;40MG;30MG	A075618	001	Mar 23, 2001
PHRENILIN WITH CAFFEINE AND CODEINE					
	VALEANT	325MG;50MG;40MG;30MG	A074911	001	Aug 22, 2001

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL					
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE					
	MIKART	356.4MG;30MG;16MG	A040109	001	Aug 26, 1997
	WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007
DHC PLUS					
	PHARM RES ASSOC	356.4MG;30MG;16MG	A088584	001	Mar 04, 1986
SYNALGOS-DC-A					
	LEITNER PHARMS	356.4MG;30MG;16MG	A089166	001	May 14, 1986
TABLET;ORAL					
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE					
	LARKEN LABS INC	325MG;30MG;16MG	A204209	001	Sep 30, 2016
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE					
	BOCA PHARMA LLC	712.8MG;60MG;32MG	A040701	001	Apr 03, 2007
	MIKART	712.8MG;60MG;32MG	A040316	001	Apr 28, 1999
	WEST-WARD PHARM CORP	712.8MG;60MG;32MG	A040637	001	Sep 22, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL					
TAVIST ALLERGY/SINUS/HEADACHE					
	NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N021082	001	Mar 01, 2001

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE;ORAL					
ACETAMINOPHEN AND CODEINE PHOSPHATE					
	TEVA	300MG;15MG	A088537	001	Jun 04, 1984
		300MG;30MG	A088324	001	Dec 29, 1983
		300MG;60MG	A088599	001	Jun 01, 1984
PHENAPHEN W/ CODEINE NO. 2					
	ROBINS AH	325MG;15MG	A084444	001	
PHENAPHEN W/ CODEINE NO. 3					
+	ROBINS AH	325MG;30MG	A084445	001	
PHENAPHEN W/ CODEINE NO. 4					
+	ROBINS AH	325MG;60MG	A084446	001	
PROVAL #3					
	SOLVAY	325MG;30MG	A085685	001	
TYLENOL W/ CODEINE NO. 3					
	ORTHO MCNEIL PHARM	300MG;30MG	A087422	001	
TYLENOL W/ CODEINE NO. 4					
	ORTHO MCNEIL PHARM	300MG;60MG	A087421	001	
SOLUTION;ORAL					
ACETAMINOPHEN AND CODEINE PHOSPHATE					
	ACI	120MG/5ML;12MG/5ML	A086366	001	
+	ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001	
	CHARTWELL MOLECULAR	120MG/5ML;12MG/5ML	A091238	001	Nov 10, 2011
	DAVA PHARMS INC	120MG/5ML;12MG/5ML	A040098	001	Sep 20, 1996
	WOCKHARDT BIO AG	120MG/5ML;12MG/5ML	A087006	001	
TYLENOL W/ CODEINE					
+	ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A085057	001	
SUSPENSION;ORAL					
CAPITAL AND CODEINE					
	ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001	
	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024	001	
TABLET;ORAL					
ACETAMINOPHEN AND CODEINE PHOSPHATE					
	ABLE	300MG;30MG	A040452	001	Aug 01, 2002
		300MG;60MG	A040459	001	Aug 01, 2002
	AM THERAP	300MG;15MG	A089478	001	Mar 03, 1987
		300MG;15MG	A089481	001	Mar 03, 1987
		300MG;30MG	A089479	001	Mar 03, 1987
		300MG;30MG	A089482	001	Mar 03, 1987
		300MG;60MG	A089480	001	Mar 03, 1987
		300MG;60MG	A089483	001	Mar 03, 1987
	CHARTWELL	300MG;15MG	A089997	001	Dec 28, 1994
		300MG;30MG	A089998	001	Dec 28, 1994
		300MG;60MG	A089999	001	Dec 28, 1994
	DURAMED PHARMS BARR	300MG;15MG	A040223	001	Nov 18, 1997
		300MG;15MG	A088353	001	Feb 06, 1984
		300MG;30MG	A040223	002	Nov 18, 1997
		300MG;30MG	A088354	001	Feb 06, 1984
		300MG;60MG	A040223	003	Nov 18, 1997
		300MG;60MG	A088355	001	Feb 06, 1984
	EVERYLIFE	325MG;30MG	A085217	001	
	FOSUN PHARMA	300MG;30MG	A081250	001	Jul 16, 1992
		300MG;60MG	A081249	001	Jul 16, 1992
	HALSEY	300MG;15MG	A083871	001	
		300MG;30MG	A083872	001	
		300MG;60MG	A086549	001	
	KV PHARM	300MG;30MG	A085288	001	
		300MG;60MG	A085365	001	
		325MG;15MG	A085364	001	
		325MG;45MG **	A085363	001	
	LEDERLE	300MG;30MG	A087141	001	
	MIKART	300MG;30MG	A089238	001	Feb 25, 1986
		300MG;60MG	A089244	001	Feb 25, 1986
		650MG;30MG	A089231	001	Mar 03, 1986
		650MG;60MG	A089363	001	Sep 09, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE					
	MUTUAL PHARM	300MG;15MG	A085795	001	
		300MG;30MG	A085794	001	
		300MG;60MG	A087653	001	Apr 13, 1982
	NOSTRUM LABS INC	300MG;15MG	A088629	002	Mar 06, 1985
		300MG;30MG	A088629	003	Mar 06, 1985
+		300MG;60MG	A088629	001	Mar 06, 1985
	PURACAP PHARM	300MG;30MG	A087762	001	Dec 10, 1982
+	PUREPAC PHARM	300MG;30MG	A086681	001	
		300MG;30MG	A089080	001	Jul 17, 1986
		300MG;60MG	A086683	001	
	RHODES PHARMS	300MG;15MG	A089673	002	Feb 10, 1988
		300MG;30MG	A089673	003	Feb 10, 1988
		300MG;60MG	A089673	001	Feb 10, 1988
	ROXANE	300MG;15MG	A084659	001	
		300MG;30MG	A084656	001	
		300MG;60MG	A084667	001	
		500MG;15MG	A089511	001	Apr 25, 1989
		500MG;30MG	A089512	001	Apr 25, 1989
		500MG;60MG	A089513	001	Apr 25, 1989
+	SANDOZ	300MG;15MG	A087433	001	
		300MG;30MG	A085291	002	
+		300MG;30MG	A085917	001	
		300MG;60MG	A085964	001	
		300MG;60MG	A087423	001	
	STRIDES PHARMA	300MG;15MG	A089990	001	Sep 30, 1988
		300MG;30MG	A089805	001	Sep 30, 1988
		300MG;60MG	A089828	001	Sep 30, 1988
	SUPERPHARM	300MG;15MG	A089183	001	Oct 18, 1985
		300MG;30MG	A089184	001	Oct 18, 1985
		300MG;30MG	A089253	001	May 19, 1986
		300MG;60MG	A089185	001	Oct 18, 1985
		300MG;60MG	A089254	001	May 19, 1986
	USL PHARMA	300MG;30MG	A087919	001	Jun 22, 1982
		300MG;60MG	A087920	001	Jun 22, 1982
	VALEANT PHARM INTL	300MG;30MG	A085896	001	
	VITARINE	300MG;30MG	A085676	001	
	WARNER CHILCOTT	300MG;15MG	A085992	001	
		300MG;30MG	A085218	002	
		300MG;60MG	A087306	001	
	WATSON LABS	300MG;15MG	A087277	001	May 26, 1982
		300MG;30MG	A087276	001	May 26, 1982
		300MG;60MG	A087275	001	May 26, 1982
	WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003
		300MG;30MG	A040443	002	Jan 22, 2003
		300MG;60MG	A040443	003	Jan 22, 2003
	WHITEWORTH TOWN PLSN	300MG;30MG	A084360	001	
		300MG;60MG	A085607	001	
CAPITAL AND CODEINE					
	CARNRICK	325MG;30MG	A083643	001	
CODRIX					
	WATSON LABS FLORIDA	500MG;15MG	A040447	001	Feb 26, 2003
		500MG;30MG	A040441	001	Mar 27, 2003
		500MG;60MG	A040488	001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3					
	GLAXOSMITHKLINE	300MG;30MG	A083951	001	
EMPRACET W/ CODEINE PHOSPHATE #4					
	GLAXOSMITHKLINE	300MG;60MG	A083951	002	
PAPA-DEINE #3					
	VANGARD	300MG;30MG	A088037	001	Mar 20, 1984
PAPA-DEINE #4					
	VANGARD	300MG;60MG	A088715	001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE					
	ROBINS AH	650MG;30MG	A085856	001	
TYLENOL W/ CODEINE					
	ORTHO MCNEIL PHARM	325MG;7.5MG **	A085056	001	
		325MG;15MG **	A085056	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; CODEINE PHOSPHATE				
TABLET;ORAL				
TYLENOL W/ CODEINE				
	325MG;30MG **	A085056	003	
	325MG;60MG **	A085056	004	
TYLENOL W/ CODEINE NO. 1				
JANSSEN PHARMS	300MG;7.5MG	A085055	001	
TYLENOL W/ CODEINE NO. 2				
+ JANSSEN PHARMS	300MG;15MG	A085055	002	
TYLENOL W/ CODEINE NO. 3				
+ JANSSEN PHARMS	300MG;30MG	A085055	003	
TYLENOL W/ CODEINE NO. 4				
+ JANSSEN PHARMS	300MG;60MG	A085055	004	
ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE				
TABLET, EXTENDED RELEASE;ORAL				
DRIXORAL PLUS				
SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987
ACETAMINOPHEN; HYDROCODONE BITARTRATE				
CAPSULE;ORAL				
ACETAMINOPHEN AND HYDROCODONE BITARTRATE				
CENT PHARMS	500MG;5MG	A088898	001	Mar 27, 1985
ALLAY				
IVAX PHARMS	500MG;5MG	A089907	001	Jan 13, 1989
BANCAP HC				
FOREST PHARMS	500MG;5MG	A087961	001	Mar 17, 1983
CO-GESIC				
CENT PHARMS	500MG;5MG	A089360	001	Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT	500MG;5MG	A088956	001	Jul 19, 1985
	500MG;5MG	A089006	001	Aug 09, 1985
MIKART	500MG;5MG	A081067	001	Nov 30, 1989
	500MG;5MG	A081068	001	Nov 30, 1989
	500MG;5MG	A081069	001	Nov 30, 1989
	500MG;5MG	A081070	001	Nov 30, 1989
	500MG;5MG	A089008	001	Feb 21, 1986
LORCET-HD				
MALLINCKRODT	500MG;5MG	A087336	001	Jul 08, 1982
SOLUTION;ORAL				
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
GENUS	325MG/15ML;7.5MG/15ML	A200343	001	Jan 25, 2012
MALLINCKRODT	500MG/15ML;7.5MG/15ML	A040418	001	Jun 27, 2001
MALLINCKRODT INC	500MG/15ML;10MG/15ML	A040508	001	Aug 29, 2003
MIKART	500MG/15ML;5MG/15ML	A081226	001	Oct 27, 1992
	500MG/15ML;5MG/15ML	A089557	001	Apr 29, 1992
	500MG/15ML;7.5MG/15ML	A081051	001	Aug 28, 1992
NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366	001	Jan 23, 2002
PHARM ASSOC	500MG/15ML;7.5MG/15ML	A040182	001	Mar 13, 1998
TRIS PHARMA INC	300MG/15ML;10MG/15ML	A201295	002	Dec 30, 2021
	325MG/15ML;7.5MG/15ML	A201295	001	Dec 30, 2021
VINTAGE PHARMS	500MG/15ML;7.5MG/15ML	A040520	001	Oct 30, 2003
ZYFREL				
CYPRESS PHARM INC	325MG/15ML;7.5MG/15ML	A090468	001	Apr 14, 2016
TABLET;ORAL				
ANEXSIA				
MALLINCKRODT	500MG;5MG	A089160	001	Apr 23, 1987
	750MG;10MG	A040468	001	Oct 31, 2002
ANEXSIA 7.5/650				
MALLINCKRODT	650MG;7.5MG	A089725	001	Sep 30, 1987
CO-GESIC				
UCB INC	500MG;5MG	A087757	001	May 03, 1982
DURADYNE DHC				
FOREST PHARMS	500MG;5MG	A087809	001	Mar 17, 1983
HY-PHEN				
ASCHER	500MG;5MG	A087677	001	May 03, 1982
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
ABLE	325MG;5MG	A040478	001	Nov 08, 2002
	325MG;7.5MG	A040464	001	Oct 23, 2002
	325MG;10MG	A040464	002	Oct 23, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	500MG;5MG	A040477	001	Nov 06, 2002
	500MG;7.5MG	A040490	001	May 21, 2003
	500MG;10MG	A040473	001	Nov 06, 2002
	650MG;7.5MG	A040474	001	Jan 02, 2003
	650MG;10MG	A040476	001	Oct 23, 2002
	750MG;7.5MG	A040469	001	Oct 25, 2002
ACTAVIS LABS FL INC	300MG;5MG	A206470	001	Jun 02, 2016
	300MG;7.5MG	A206470	002	Jun 02, 2016
	300MG;10MG	A206470	003	Jun 02, 2016
ALVOGEN	300MG;5MG	A208540	001	Nov 08, 2018
	300MG;7.5MG	A208540	002	Nov 08, 2018
	300MG;10MG	A208540	003	Nov 08, 2018
	325MG;2.5MG	A209958	001	Oct 24, 2018
	325MG;5MG	A209958	002	Oct 24, 2018
	325MG;7.5MG	A209958	003	Oct 24, 2018
	325MG;10MG	A209958	004	Oct 24, 2018
AMNEAL PHARMS NY	500MG;5MG	A040729	001	Aug 25, 2006
	500MG;7.5MG	A040748	001	Aug 25, 2006
	500MG;10MG	A040813	001	Feb 23, 2007
	650MG;7.5MG	A040754	001	Aug 25, 2006
	650MG;10MG	A040757	001	Aug 25, 2006
	750MG;7.5MG	A040769	001	Aug 28, 2006
APIL	500MG;10MG	A040148	002	Feb 14, 1997
BARR	500MG;2.5MG	A040307	001	Jul 26, 2000
	500MG;5MG	A040308	001	Jul 26, 2000
	500MG;5MG	A088577	001	Dec 21, 1984
	500MG;7.5MG	A040307	002	Jul 26, 2000
	500MG;10MG	A040309	001	Jul 26, 2000
	650MG;7.5MG	A040307	003	Jul 26, 2000
	650MG;10MG	A040307	004	Jul 26, 2000
	750MG;7.5MG	A040308	002	Jul 26, 2000
CARACO	500MG;5MG	A090265	001	Dec 23, 2008
	500MG;7.5MG	A090265	002	Dec 23, 2008
	500MG;10MG	A090265	003	Dec 23, 2008
	650MG;7.5MG	A090380	001	Dec 23, 2008
	650MG;10MG	A090380	002	Dec 23, 2008
	660MG;10MG	A090380	003	Dec 23, 2008
	750MG;7.5MG	A090380	004	Dec 23, 2008
CEROVENE INC	325MG;5MG	A211690	001	Feb 07, 2020
	325MG;7.5MG	A211690	002	Feb 07, 2020
	325MG;10MG	A211690	003	Feb 07, 2020
CHARTWELL	325MG;7.5MG	A040248	001	Apr 28, 2000
	325MG;10MG	A040248	002	Apr 28, 2000
GRANULES	325MG;5MG	A211729	001	Jan 03, 2020
	325MG;7.5MG	A211729	002	Jan 03, 2020
	325MG;10MG	A211729	003	Jan 03, 2020
HALSEY	500MG;5MG	A089554	001	Jun 12, 1987
IVAX PHARMS	500MG;5MG	A089696	001	Apr 21, 1988
LANNETT CO INC	300MG;5MG	A207171	001	Jun 20, 2017
	300MG;7.5MG	A207171	002	Jun 20, 2017
	300MG;10MG	A207171	003	Jun 20, 2017
	325MG;5MG	A207172	001	Jun 22, 2017
	325MG;7.5MG	A207172	002	Jun 22, 2017
	325MG;10MG	A207172	003	Jun 22, 2017
MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995
	500MG;7.5MG	A040201	001	Feb 27, 1998
	500MG;10MG	A040201	002	Feb 27, 1998
	650MG;10MG	A040084	004	Oct 16, 1996
	660MG;10MG	A040084	003	Jul 29, 1996
	750MG;7.5MG	A040084	001	Jun 01, 1995
MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010
	500MG;2.5MG	A089698	001	Aug 25, 1989
	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
	500MG;7.5MG	A089699	001	Aug 25, 1989
	650MG;5MG	A040849	001	Jun 09, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	650MG;7.5MG	A089689	001	Jun 29, 1988
	650MG;10MG	A081223	001	May 29, 1992
MUTUAL PHARM	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
NOSTRUM LABS INC	325MG;2.5MG	A209924	001	Nov 16, 2018
	325MG;5MG	A209924	002	Nov 16, 2018
	325MG;7.5MG	A209924	003	Nov 16, 2018
	325MG;10MG	A209924	004	Nov 16, 2018
NOVEL LABS INC	300MG;5MG	A206142	001	Nov 14, 2016
	300MG;7.5MG	A206142	002	Nov 14, 2016
	300MG;10MG	A206142	003	Nov 14, 2016
	325MG;5MG	A206245	001	Dec 01, 2016
	325MG;7.5MG	A206245	002	Dec 01, 2016
	325MG;10MG	A206245	003	Dec 01, 2016
RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007
	500MG;10MG	A040824	001	Aug 16, 2007
RANBAXY LABS LTD	750MG;7.5MG	A040822	001	Aug 16, 2007
SANDOZ	500MG;5MG	A040149	001	Jan 27, 1997
	750MG;7.5MG	A040149	002	Jan 27, 1997
STRIDES PHARMA	300MG;5MG	A205001	001	Jul 05, 2016
	300MG;7.5MG	A205001	002	Jul 05, 2016
	300MG;10MG	A205001	003	Jul 05, 2016
SUN PHARM INDS INC	325MG;5MG	A090118	001	Dec 23, 2008
	325MG;7.5MG	A090118	002	Dec 23, 2008
	325MG;10MG	A090118	003	Dec 23, 2008
SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007
UCB INC	500MG;10MG	A040210	001	Aug 13, 1997
	650MG;7.5MG	A040134	001	Nov 21, 1996
UPSHER SMITH LABS	325MG;5MG	A206484	001	Mar 24, 2017
	325MG;7.5MG	A206484	002	Mar 24, 2017
	325MG;10MG	A206484	003	Mar 24, 2017
USL PHARMA	500MG;5MG	A089290	001	May 29, 1987
	500MG;5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	300MG;5MG	A090415	001	Jan 24, 2011
	300MG;7.5MG	A090415	002	Jan 24, 2011
	300MG;10MG	A090415	003	Jan 24, 2011
	500MG;2.5MG	A040144	002	Apr 25, 1997
	500MG;5MG	A089831	001	Sep 07, 1988
	500MG;5MG	A089971	001	Dec 02, 1988
	500MG;7.5MG	A040144	001	Feb 22, 1996
	500MG;10MG	A040356	001	May 31, 2000
	650MG;7.5MG	A040155	001	Apr 14, 1997
	650MG;10MG	A040143	001	Feb 22, 1996
	660MG;10MG	A040358	001	May 31, 2000
	750MG;7.5MG	A040157	001	Apr 12, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040281	001	Sep 30, 1998
	500MG;7.5MG	A040280	001	Sep 30, 1998
	650MG;7.5MG	A040280	002	Sep 30, 1998
	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998
WATSON LABS	500MG;2.5MG	A040123	003	Mar 04, 1996
	500MG;2.5MG	A081079	001	Aug 30, 1991
	500MG;5MG	A040122	001	Mar 04, 1996
	500MG;5MG	A089883	001	Dec 01, 1988
	500MG;7.5MG	A040123	004	Mar 04, 1996
	500MG;7.5MG	A081080	001	Aug 30, 1991
	650MG;7.5MG	A040094	001	Sep 29, 1995
	650MG;7.5MG	A040123	001	Mar 04, 1996
	650MG;10MG	A040094	002	Sep 29, 1995
	650MG;10MG	A040123	002	Mar 04, 1996
	660MG;10MG	A040094	003	Aug 08, 2000
	750MG;7.5MG	A040122	002	Mar 04, 1996
	750MG;7.5MG	A081083	001	Aug 30, 1991
	750MG;10MG	A040094	004	Mar 22, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL				
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003
	660MG;10MG	A040495	001	May 28, 2003
	750MG;7.5MG	A040494	001	May 28, 2003
LORTAB				
UCB INC	500MG;5MG	A087722	001	Jul 09, 1982
	500MG;10MG	A040100	001	Jan 26, 1996
NORCET				
ABANA	500MG;5MG	A088871	001	May 15, 1986
NORCO				
APIL	325MG;2.5MG	A040148	004	Jul 07, 2014
	325MG;5MG	A040099	001	Jun 25, 1997
	325MG;5MG	A040148	005	Jul 07, 2014
	325MG;7.5MG	A040148	003	Sep 12, 2000
	325MG;10MG	A040148	001	Feb 14, 1997
TYCOLET				
ORTHO MCNEIL PHARM	500MG;5MG	A089385	001	Aug 27, 1986
VICODIN				
ABBOTT	500MG;5MG	A085667	001	
ABBVIE	500MG;5MG	A088058	001	Jan 07, 1983
VICODIN ES				
ABBVIE	750MG;7.5MG	A089736	001	Dec 09, 1988
VICODIN HP				
ABBVIE	660MG;10MG	A040117	001	Sep 23, 1996
ZYDONE				
VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998
	400MG;7.5MG	A040288	002	Nov 27, 1998
	400MG;10MG	A040288	003	Nov 27, 1998

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL				
COMBOGESIC				
+ AFT PHARMS LTD	325MG;97.5MG	N209471	001	Mar 01, 2023

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL				
OXYCODONE AND ACETAMINOPHEN				
ACTAVIS ELIZABETH	500MG;5MG	A040199	001	Dec 30, 1998
BARR	500MG;5MG	A040304	001	Oct 02, 2000
DURAMED PHARMS BARR	500MG;5MG	A040289	001	Mar 16, 1999
HALSEY	500MG;5MG	A089994	001	May 04, 1989
MALLINCKRODT	500MG;5MG	A040257	001	Aug 04, 1998
MUTUAL PHARM	500MG;5MG	A040219	001	Jan 22, 1998
VINTAGE PHARMS	500MG;5MG	A040106	001	Jul 30, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040303	001	Dec 30, 1999
WATSON LABS	500MG;5MG	A040234	001	Oct 30, 1997
ROXILOX				
ROXANE	500MG;5MG	A040061	001	Jul 03, 1995
TYLOX				
JANSSEN PHARMS	500MG;5MG	A088790	001	Dec 12, 1984
TYLOX-325				
ORTHO MCNEIL PHARM	325MG;5MG	A088246	001	Nov 08, 1984
SOLUTION;ORAL				
OXYCODONE AND ACETAMINOPHEN				
SPECGX LLC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN				
VINTAGE PHARMS	325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014
ROXICET				
HIKMA	325MG/5ML;5MG/5ML **	A089351	001	Dec 03, 1986
TABLET;ORAL				
OXYCODONE 2.5/APAP 500				
BRISTOL MYERS SQUIBB	500MG;2.5MG	A085910	001	
OXYCODONE 5/APAP 500				
BRISTOL MYERS SQUIBB	500MG;5MG	A085911	001	
OXYCODONE AND ACETAMINOPHEN				
ACTAVIS ELIZABETH	325MG;5MG	A040203	001	Mar 15, 1999
	325MG;7.5MG	A040800	001	Apr 03, 2012
	325MG;10MG	A040800	002	Apr 03, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AMNEAL PHARMS NY	500MG;7.5MG	A040789	001	Nov 27, 2007
	650MG;10MG	A040789	002	Nov 27, 2007
BARR	325MG;5MG	A087406	001	
CEROVENE INC	325MG;5MG	A207574	001	Dec 13, 2016
DR REDDYS LABS SA	325MG;2.5MG	A090177	001	Oct 20, 2008
	325MG;5MG	A090177	002	Oct 20, 2008
	325MG;7.5MG	A090177	003	Oct 20, 2008
	325MG;10MG	A090177	004	Oct 20, 2008
	500MG;7.5MG	A090177	005	Oct 20, 2008
	650MG;10MG	A090177	006	Oct 20, 2008
DURAMED PHARMS BARR	325MG;5MG	A040272	001	Jun 30, 1998
GRANULES	325MG;2.5MG	A211708	001	Oct 31, 2019
	325MG;5MG	A211708	002	Oct 31, 2019
	325MG;7.5MG	A211708	003	Oct 31, 2019
	325MG;10MG	A211708	004	Oct 31, 2019
LANNETT CO INC	325MG;5MG	A207333	001	Sep 25, 2017
	325MG;10MG	A207333	002	Sep 25, 2017
MALLINCKRODT	500MG;7.5MG	A040550	001	Jun 30, 2004
	650MG;10MG	A040550	002	Jun 30, 2004
MIKART	400MG;2.5MG	A040679	001	May 16, 2006
	400MG;5MG	A040687	001	Apr 27, 2006
	400MG;7.5MG	A040698	001	Apr 27, 2006
	400MG;10MG	A040692	001	Apr 27, 2006
	500MG;10MG	A040676	001	Apr 19, 2006
NESHER PHARMS	325MG;2.5MG	A210079	001	Dec 28, 2017
	325MG;5MG	A210079	002	Dec 28, 2017
	325MG;7.5MG	A210079	003	Dec 28, 2017
	325MG;10MG	A210079	004	Dec 28, 2017
NOSTRUM LABS INC	325MG;5MG	A209385	001	Jul 02, 2018
	325MG;7.5MG	A209385	002	Jul 02, 2018
	325MG;10MG	A209385	003	Jul 02, 2018
SUN PHARM INDS INC	325MG;2.5MG	A090535	001	Dec 26, 2013
	325MG;5MG	A090535	002	Dec 26, 2013
	325MG;7.5MG	A090535	003	Dec 26, 2013
	325MG;10MG	A090535	004	Dec 26, 2013
VINTAGE PHARMS	325MG;2.5MG	A090733	001	Jul 11, 2013
	325MG;5MG	A040105	001	Jul 30, 1996
	325MG;7.5MG	A090734	001	Jul 11, 2013
	325MG;10MG	A090734	002	Jul 11, 2013
WATSON LABS	325MG;5MG	A040171	001	Oct 30, 1997
	325MG;7.5MG	A040535	001	Sep 05, 2003
	325MG;10MG	A040535	002	Sep 05, 2003
	500MG;7.5MG	A040371	001	Dec 29, 2000
	650MG;10MG	A040371	002	Dec 29, 2000

PERCOCET

+ VINTAGE PHARMS LLC	325MG;5MG **	A085106	002	
	500MG;7.5MG	A040341	001	Jul 26, 1999
	650MG;10MG	A040341	002	Jul 26, 1999

ROXICET

+ HIKMA	325MG;5MG	A087003	001	

ROXICET 5/500

ROXANE	500MG;5MG	A089775	001	Jan 12, 1989

TABLET, EXTENDED RELEASE;ORAL

XARTEMIS XR

+ MALLINCKRODT INC	325MG;7.5MG **	N204031	001	Mar 11, 2014

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE;ORAL

TYLOX

ORTHO MCNEIL PHARM	500MG;4.5MG;0.38MG	A085375	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL				
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE				
GAVIS PHARMS	650MG;EQ 25MG BASE	A076202	001	Aug 02, 2002
WATSON LABS	650MG;EQ 25MG BASE	A074699	001	Mar 24, 2000
TALACEN				
SANOFI AVENTIS US	650MG;EQ 25MG BASE	N018458	001	Sep 23, 1982

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET;ORAL				
DARVOCET				
AAIPHARMA LLC	325MG;32.5MG	N016844	001	
DOLENE AP-65				
LEDERLE	650MG;65MG	A085100	001	
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN				
MYLAN	325MG;32MG	A083689	001	
	650MG;65MG	A083978	001	
SANDOZ	650MG;65MG	A089959	001	Jul 18, 1989
VINTAGE PHARMS	650MG;65MG	A040507	001	Jul 30, 2003
WATSON LABS	650MG;65MG	A040139	001	Dec 16, 1996
WYGESIC				
CARACO	650MG;65MG	A084999	001	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET;ORAL				
DARVOCET A500				
XANODYNE PHARM	500MG;100MG	A076429	001	Sep 10, 2003
DARVOCET-N 100				
XANODYNE PHARM	650MG;100MG	N017122	002	
DARVOCET-N 50				
XANODYNE PHARM	325MG;50MG	N017122	001	
PROPACET 100				
TEVA	650MG;100MG	A070107	001	Jun 12, 1985
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN				
ABLE	650MG;100MG	A075838	001	Jul 11, 2001
ACTAVIS ELIZABETH	650MG;100MG	A070910	001	Jan 02, 1987
CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004
	500MG;100MG	A076750	001	Jun 28, 2004
HALSEY	325MG;50MG	A072105	001	May 13, 1988
	650MG;100MG	A072106	001	May 13, 1988
IVAX SUB TEVA PHARMS	650MG;100MG	A070146	001	Aug 02, 1985
MALLINCKRODT	650MG;100MG	A075738	001	Feb 02, 2001
MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008
MUTUAL PHARM	325MG;50MG	A070115	001	Jun 12, 1985
	650MG;100MG	A070116	001	Jun 12, 1985
	650MG;100MG	A070615	001	Mar 21, 1986
	650MG;100MG	A070771	001	Mar 21, 1986
	650MG;100MG	A070775	001	Mar 21, 1986
MYLAN	650MG;100MG	A072195	001	Feb 16, 1988
MYLAN PHARMS INC	650MG;100MG	A070145	001	Jun 12, 1985
SANDOZ	650MG;100MG	A070443	001	Jan 23, 1986
SUPERPHARM	650MG;100MG	A071319	001	Jan 06, 1987
TEVA	650MG;100MG	A070732	001	Jan 03, 1986
	650MG;100MG	A074119	001	Dec 19, 1994
VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001
	650MG;100MG	A074843	001	Feb 12, 1997
WATSON LABS	325MG;50MG	A070398	001	Dec 18, 1986
	650MG;100MG	A070399	001	Dec 18, 1986
WATSON LABS FLORIDA	500MG;100MG	A077196	001	Jun 28, 2005
	650MG;100MG	A076609	001	Nov 16, 2004
WOCKHARDT LTD	325MG;50MG	A077677	001	Mar 16, 2007
	650MG;100MG	A077677	002	Mar 16, 2007

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL				
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN				
CHARTWELL RX	325MG;37.5MG	A076475	001	Apr 21, 2005
GRAVITI PHARMS	325MG;37.5MG	A076914	001	Jul 26, 2006
MACLEODS PHARMS LTD	325MG;37.5MG	A206885	001	May 02, 2017
NOSTRUM LABS INC	325MG;37.5MG	A078778	001	Apr 07, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

ULTRACET

+	JANSSEN PHARMS	325MG;37.5MG	N021123	001	Aug 15, 2001

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

	RISING	500MG	A203917	001	Jun 18, 2019

DIAMOX

+	TEVA BRANDED PHARM	500MG **	N012945	001	

TABLET;ORAL

ACETAZOLAMIDE

	ALRA	250MG	A083320	001	
	ASCOT	250MG	A087686	001	Oct 20, 1982
	BRECKENRIDGE	125MG	A207503	001	Apr 30, 2020
		250MG	A207503	002	Apr 30, 2020
	HERITAGE PHARMA	250MG	A088882	001	Oct 22, 1985
	SUN PHARM INDUSTRIES	125MG	A089753	002	Jun 22, 1988
		250MG	A089753	001	Jun 22, 1988
	VANGARD	250MG	A087654	001	Feb 05, 1982
	WATSON LABS	250MG	A084498	002	

DIAMOX

+	TEVA BRANDED PHARM	125MG **	N008943	001	
+		250MG **	N008943	002	

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

	HOSPIRA	EQ 500MG BASE/VIAL	A040108	001	Oct 30, 1995
	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017

DIAMOX

+	TEVA WOMENS	EQ 500MG BASE/VIAL **	N009388	001	

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETASOL

	ACTAVIS MID ATLANTIC	2%	A087146	001	

ACETIC ACID

	CHARTWELL RX	2%	A040166	001	Jul 26, 1996
	KV PHARM	2%	A085493	001	

ORLEX

	WARNER CHILCOTT	2%	A086845	001	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

	BAUSCH AND LOMB	2%;0.79%	A040063	001	Feb 25, 1994

BOROFAIR

	PHARMAFAIR	2%;0.79%	A088606	001	Aug 21, 1985

DOMEBORO

+	BAYER PHARMS	2%;0.79%	A084476	001	

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS;OTIC

TRIDESILON

	BAYER PHARMS	2%;0.05%	N017914	001	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

ACETASOL HC

	ACTAVIS MID ATLANTIC	2%;1%	A087143	001	Jan 13, 1982

ACETIC ACID W/ HYDROCORTISONE

	KV PHARM	2%;1%	A085492	001	

HYDROCORTISONE AND ACETIC ACID

	BAUSCH AND LOMB	2%;1%	A040097	001	Oct 31, 1994
	WOCKHARDT	2%;1%	A040168	001	Aug 30, 1996

ORLEX HC

	WARNER CHILCOTT	2%;1%	A086844	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS;OTIC				
NEO-CORT-DOME				
	BAYER PHARMS	2%;1%;EQ 0.35% BASE	N050238 001	

ACETOHEXAMIDE

TABLET;ORAL				
ACETOHEXAMIDE				
	ANI PHARMS	250MG	A070870 002	Feb 09, 1987
		500MG	A070870 001	Feb 09, 1987
	USL PHARMA	250MG	A070753 001	Nov 03, 1986
		500MG	A070754 001	Nov 03, 1986
	WATSON LABS TEVA	250MG	A071893 001	Nov 25, 1987
		500MG	A071894 001	Nov 25, 1987
DYMELOR				
	LILLY	250MG	N013378 002	
		500MG	N013378 001	

ACETOPHENAZINE MALEATE

TABLET;ORAL				
TINDAL				
	SCHERING	20MG	N012254 002	

ACETRIZOATE SODIUM

SOLUTION;INTRAUTERINE				
SALPIX				
	ORTHO MCNEIL PHARM	53%	N009008 001	

ACETYLCHOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC				
MIOCHOL				
+	NOVARTIS	20MG/VIAL **	N016211 001	

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS				
ACETYLCYSTEINE				
	EXELA PHARMA	6GM/30ML (200MG/ML)	A204797 001	Apr 15, 2021
SOLUTION;INHALATION, ORAL				
ACETYLCYSTEINE				
	HOSPIRA	10%	A071364 001	May 01, 1989
		20%	A071365 001	May 01, 1989
	ROXANE	10%	A072323 001	Apr 30, 1992
		10%	A072621 001	Sep 30, 1992
		20%	A072324 001	Apr 30, 1992
		20%	A072622 001	Sep 30, 1992
MUCOMYST				
+	APOTHECON	10% **	N013601 002	
+		20% **	N013601 001	
MUCOSIL-10				
	DEY	10%	A070575 001	Oct 14, 1986
MUCOSIL-20				
	DEY	20%	A070576 001	Oct 14, 1986
TABLET, EFFERVESCENT;ORAL				
CETYLEV				
+	ARBOR PHARMS LLC	500MG	N207916 001	Jan 29, 2016
+		2.5GM	N207916 002	Jan 29, 2016

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION;INHALATION				
MUCOMYST W/ ISOPROTERENOL				
	MEAD JOHNSON	10%;0.05%	N017366 001	

ACETYLDIGITOXIN

TABLET;ORAL				
ACYLANID				
	NOVARTIS	0.1MG	N009436 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACITRETIN					
CAPSULE;ORAL					
ACITRETIN					
	MYLAN	17.5MG	A203707	001	Sep 10, 2015
		22.5MG	A203707	002	Sep 10, 2015
SORIATANE					
+	STIEFEL LABS INC	10MG **	N019821	001	Oct 28, 1996
+		17.5MG **	N019821	003	Aug 06, 2009
+		22.5MG **	N019821	004	Aug 06, 2009
+		25MG **	N019821	002	Oct 28, 1996
ACRISORCIN					
CREAM;TOPICAL					
AKRINOL					
	SCHERING	2MG/GM	N012470	001	
ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE					
CAPSULE;ORAL					
SEMPREX-D					
+	AUXILIUM PHARMS LLC	8MG;60MG	N019806	001	Mar 25, 1994
ACYCLOVIR					
CAPSULE;ORAL					
ACYCLOVIR					
	ACTAVIS ELIZABETH	200MG	A074906	001	Aug 26, 1997
	AUROBINDO PHARMA USA	200MG	A074727	001	Apr 22, 1997
	CHARTWELL MOLECULES	200MG	A074872	001	Apr 22, 1997
	IVAX SUB TEVA PHARMS	200MG	A074674	001	Apr 22, 1997
	LEK PHARM	200MG	A074750	001	Apr 22, 1997
	MYLAN	200MG	A074977	001	Apr 13, 1998
	RANBAXY	200MG	A074975	001	Sep 30, 1998
	ROXANE	200MG	A074570	002	Apr 22, 1997
	STRIDES PHARMA	200MG	A074833	001	Apr 22, 1997
	TEVA	200MG	A074828	001	Apr 22, 1997
	TEVA PHARMS	200MG	A074914	001	Nov 26, 1997
	WATSON LABS	200MG	A075101	001	Apr 15, 1998
ZOVIRAX					
+	MYLAN	200MG **	N018828	001	Jan 25, 1985
OINTMENT;OPHTHALMIC					
AVACLYR					
+	FERA PHARMS LLC	3% **	N202408	001	Mar 29, 2019
OINTMENT;TOPICAL					
ACYCLOVIR					
	ANDA REPOSITORY	5%	A206437	001	Jul 31, 2017
	PADAGIS ISRAEL	5%	A205659	001	Feb 20, 2019
	PRINSTON INC	5%	A212202	001	Nov 15, 2021
SUSPENSION;ORAL					
ACYCLOVIR					
	VISTAPHARM	200MG/5ML	A213951	001	Jan 11, 2021
ZOVIRAX					
+	MYLAN	200MG/5ML	N019909	001	Dec 22, 1989
TABLET;ORAL					
ACYCLOVIR					
	ACTAVIS ELIZABETH	400MG	A074870	001	Jun 05, 1997
		800MG	A074870	002	Jun 05, 1997
	AUROBINDO PHARMA USA	400MG	A075211	001	Sep 28, 1998
		800MG	A075211	002	Sep 28, 1998
	CHARTWELL MOLECULES	400MG	A074834	001	Apr 24, 1997
		800MG	A074834	002	Apr 24, 1997
	IVAX SUB TEVA PHARMS	400MG	A074836	001	Apr 22, 1997
		800MG	A074836	002	Apr 22, 1997
	LEK PHARM	400MG	A074658	001	Apr 22, 1997
		800MG	A074658	002	Apr 22, 1997
	MYLAN	400MG	A074976	001	Apr 13, 1998
		800MG	A074976	002	Apr 13, 1998
	SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998
		800MG	A074980	002	Sep 30, 1998
	TEVA	200MG **	A074556	001	Apr 22, 1997
	TEVA PHARMS	400MG	A075021	001	Mar 18, 1998
		800MG	A075021	002	Mar 18, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACYCLOVIR					
TABLET;ORAL					
ZOVIRAX					
+	MYLAN	400MG **	N020089	001	Apr 30, 1991
+		800MG **	N020089	002	Apr 30, 1991
ACYCLOVIR SODIUM					
INJECTABLE;INJECTION					
ACYCLOVIR					
	ABBVIE	EQ 50MG BASE/ML	A075114	001	Jul 26, 1999
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE					
	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997
		EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997
ACYCLOVIR SODIUM					
	APOTHECON	EQ 500MG BASE/VIAL	A074897	001	Feb 27, 1998
		EQ 1GM BASE/VIAL	A074897	002	Feb 27, 1998
	CHARTWELL INJECTABLE	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997
		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997
	DR REDDYS	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020
	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997
		EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997
	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998
	HIKMA	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016
		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016
	HOSPIRA	EQ 25MG BASE/ML	A074720	001	Apr 22, 1997
		EQ 50MG BASE/ML	A075065	001	Feb 25, 1999
		EQ 500MG BASE/VIAL	A074663	001	Apr 22, 1997
		EQ 500MG BASE/VIAL	A074758	001	Apr 22, 1997
		EQ 1GM BASE/VIAL	A074663	002	Apr 22, 1997
		EQ 1GM BASE/VIAL	A074758	002	Apr 22, 1997
	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017
		EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017
	TEVA PARENTERAL	EQ 50MG BASE/ML	A075627	001	Mar 28, 2001
		EQ 500MG BASE/VIAL	A074969	001	Aug 26, 1997
		EQ 1GM BASE/VIAL	A074969	002	Aug 26, 1997
	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017
		EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017
ZOVIRAX					
+	GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N018603	003	Aug 30, 1983
+		EQ 500MG BASE/VIAL **	N018603	001	Oct 22, 1982
+		EQ 1GM BASE/VIAL **	N018603	002	Jun 29, 1989
ADAPALENE					
SOLUTION;TOPICAL					
DIFFERIN					
+	GALDERMA LABS LP	0.1% **	N020338	001	May 31, 1996
ADAPALENE; BENZOYL PEROXIDE					
GEL;TOPICAL					
ADAPALENE AND BENZOYL PEROXIDE					
	ACTAVIS MID ATLANTIC	0.1%;2.5%	A203790	001	Sep 30, 2015
ADENOSINE					
INJECTABLE;INJECTION					
ADENOCARD					
+	ASTELLAS	3MG/ML **	N019937	002	Oct 30, 1989
ADENOSINE					
	AM REGENT	3MG/ML	A090010	001	Apr 28, 2009
	HIKMA	3MG/ML	A076501	001	Jun 16, 2004
	MYLAN LABS LTD	3MG/ML	A078640	001	Mar 21, 2014
	TEVA PHARMS USA	3MG/ML	A076564	001	Jun 16, 2004
		3MG/ML	A078676	001	Jul 31, 2008
	WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009
SOLUTION;INTRAVENOUS					
ADENOSCAN					
+	ASTELLAS	60MG/20ML (3MG/ML) **	N020059	001	May 18, 1995
+		90MG/30ML (3MG/ML) **	N020059	002	May 18, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALATROFLOXACIN MESYLATE				
INJECTABLE;INJECTION				
TROVAN PRESERVATIVE FREE				
PFIZER	EQ 200MG BASE/VIAL	N020760	001	Dec 18, 1997
	EQ 300MG BASE/VIAL	N020760	002	Dec 18, 1997
ALBENDAZOLE				
TABLET;ORAL				
ALBENDAZOLE				
CHARTWELL RX	200MG	A211636	001	Jun 10, 2020
CIPLA LTD	200MG	A210434	001	Sep 21, 2018
ALBENZA				
+ IMPAX LABS INC	200MG	N020666	001	Jun 11, 1996
ALBUTEROL				
AEROSOL, METERED;INHALATION				
ALBUTEROL				
ARMSTRONG PHARMS	0.09MG/INH	A072273	001	Aug 14, 1996
GENPHARM	0.09MG/INH	A073045	001	Aug 19, 1997
IVAX SUB TEVA PHARMS	0.09MG/INH	A073272	001	Dec 28, 1995
PLIVA	0.09MG/INH	A074072	001	Aug 01, 1996
PROVENTIL				
SCHERING	0.09MG/INH	N017559	001	
VENTOLIN				
GLAXOSMITHKLINE	0.09MG/INH	N018473	001	
ALBUTEROL SULFATE				
AEROSOL, METERED;INHALATION				
ALBUTEROL SULFATE				
PADAGIS US	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020
CAPSULE;INHALATION				
VENTOLIN ROTACAPS				
GLAXOSMITHKLINE	EQ 0.2MG BASE	N019489	001	May 04, 1988
SOLUTION;INHALATION				
ACCUNEB				
+ MYLAN SPECIALITY LP	EQ 0.021% BASE **	N020949	002	Apr 30, 2001
+	EQ 0.042% BASE **	N020949	001	Apr 30, 2001
ALBUTEROL SULFATE				
ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533	001	Sep 26, 1995
APOTEX INC	EQ 0.021% BASE	A078623	001	Apr 05, 2010
	EQ 0.042% BASE	A078623	002	Apr 05, 2010
	EQ 0.083% BASE	A075717	001	Feb 02, 2007
	EQ 0.5% BASE	A076391	001	Apr 01, 2003
BAUSCH	EQ 0.083% BASE	A075358	001	Mar 29, 2000
	EQ 0.5% BASE	A075050	001	Jun 18, 1998
COPLEY PHARM	EQ 0.083% BASE	A073495	001	May 28, 1993
	EQ 0.5% BASE	A073307	001	Nov 27, 1991
EPIC PHARMA LLC	EQ 0.083% BASE	A075063	001	Feb 09, 1999
LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006
LUOXIN AUROVITAS	EQ 0.021% BASE	A211888	001	Apr 20, 2020
	EQ 0.042% BASE	A211888	002	Apr 20, 2020
MYLAN SPECLT	EQ 0.083% BASE **	A072652	001	Feb 21, 1992
ROXANE	EQ 0.083% BASE	A075129	001	Feb 13, 2001
TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999
WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003
WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394	001	Nov 22, 1999
PROVENTIL				
+ SCHERING	EQ 0.083% BASE **	N019243	002	Jan 14, 1987
+	EQ 0.5% BASE **	N019243	001	Jan 14, 1987
VENTOLIN				
+ GLAXOSMITHKLINE	EQ 0.083% BASE **	N019773	001	Apr 23, 1992
	EQ 0.5% BASE **	N019269	002	Jan 16, 1987
SYRUP;ORAL				
ALBUTEROL SULFATE				
ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262	001	Mar 30, 1999
MOVA	EQ 2MG BASE/5ML	A074302	001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165	001	Apr 29, 1993
PROVENTIL				
+ SCHERING	EQ 2MG BASE/5ML **	N018062	001	Jan 19, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALBUTEROL SULFATE

SYRUP;ORAL				
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE/5ML **	N019621	001	Jun 10, 1987
TABLET;ORAL				
ALBUTEROL SULFATE				
AM THERAP	EQ 2MG BASE	A072449	001	Dec 05, 1989
	EQ 4MG BASE	A072450	001	Dec 05, 1989
AUROBINDO PHARMA LTD	EQ 2MG BASE	A213657	001	May 14, 2020
	EQ 4MG BASE	A213657	002	May 14, 2020
CHARTWELL RX	EQ 2MG BASE	A072151	001	Dec 05, 1989
	EQ 4MG BASE	A072151	002	Dec 05, 1989
COPLEY PHARM	EQ 2MG BASE	A072966	001	Nov 22, 1991
	EQ 4MG BASE	A072967	001	Nov 22, 1991
EYWA	EQ 2MG BASE	A213524	001	Oct 08, 2020
	EQ 4MG BASE	A213524	002	Oct 08, 2020
PLIVA	EQ 2MG BASE	A072316	001	Dec 05, 1989
	EQ 4MG BASE	A072317	001	Dec 05, 1989
STRIDES PHARMA	EQ 2MG BASE	A072860	002	Dec 20, 1989
	EQ 4MG BASE	A072860	001	Dec 20, 1989
TEVA	EQ 2MG BASE	A072619	001	Dec 05, 1989
	EQ 2MG BASE	A072779	001	Jun 25, 1993
	EQ 2MG BASE	A072938	001	Mar 30, 1990
	EQ 4MG BASE	A072620	001	Dec 05, 1989
	EQ 4MG BASE	A072780	001	Jun 25, 1993
	EQ 4MG BASE	A072939	001	Mar 30, 1990
UCB INC	EQ 2MG BASE	A073120	001	Sep 29, 1992
	EQ 4MG BASE	A073121	001	Sep 29, 1992
WARNER CHILCOTT	EQ 2MG BASE	A072817	001	Jan 09, 1990
	EQ 4MG BASE	A072818	001	Jan 09, 1990
WATSON LABS	EQ 2MG BASE	A072629	001	Jan 31, 1991
	EQ 2MG BASE	A072764	001	Aug 28, 1991
	EQ 4MG BASE	A072630	001	Jan 31, 1991
	EQ 4MG BASE	A072765	001	Aug 28, 1991
PROVENTIL				
+ SCHERING	EQ 2MG BASE **	N017853	001	May 07, 1982
+	EQ 4MG BASE **	N017853	002	May 07, 1982
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE	N019112	001	Jul 10, 1986
	EQ 4MG BASE	N019112	002	Jul 10, 1986
TABLET, EXTENDED RELEASE;ORAL				
ALBUTEROL SULFATE				
RISING	EQ 4MG BASE	A078092	002	Jan 29, 2007
	EQ 8MG BASE	A078092	001	Jan 29, 2007
PROVENTIL				
SCHERING	EQ 4MG BASE	N019383	001	Jul 13, 1987
VOLMAX				
+ MURO	EQ 4MG BASE	N019604	002	Dec 23, 1992
+	EQ 8MG BASE	N019604	001	Dec 23, 1992
VOSPIRE ER				
STRIDES PHARMA	EQ 4MG BASE	A076130	002	Sep 26, 2002
	EQ 8MG BASE	A076130	003	Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION				
COMBIVENT				
BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996
SOLUTION;INHALATION				
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE				
APOTEX INC	EQ 0.083% BASE;0.017%	A077117	001	Dec 31, 2007
FOSUN PHARMA	EQ 0.083% BASE;0.017%	A076867	001	Dec 21, 2006
LUOXIN AUROVITAS	EQ 0.083% BASE;0.017%	A206532	001	Jul 08, 2020
TEVA PHARMS	EQ 0.083% BASE;0.017%	A076724	001	Dec 31, 2007
WATSON LABS TEVA	EQ 0.083% BASE;0.017%	A077063	001	Dec 31, 2007
DUONEB				
+ MYLAN SPECIALITY LP	EQ 0.083% BASE;0.017% **	N020950	001	Mar 21, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALCAFTADINE				
SOLUTION/DROPS;OPHTHALMIC				
ALCAFTADINE				
EUGIA PHARMA	0.25%	A210659	001	Jun 23, 2023
ALCLOMETASONE DIPROPIONATE				
CREAM;TOPICAL				
ACLOVATE				
+ FOUGERA PHARMS	0.05% **	N018707	001	Dec 14, 1982
OINTMENT;TOPICAL				
ACLOVATE				
+ FOUGERA PHARMS	0.05% **	N018702	001	Dec 14, 1982
ALENDRONATE SODIUM				
SOLUTION;ORAL				
FOSAMAX				
+ MERCK	EQ 70MG BASE/75ML **	N021575	001	Sep 17, 2003
TABLET;ORAL				
ALENDRONATE SODIUM				
CHARTWELL RX	EQ 5MG BASE	A075871	001	Apr 22, 2009
	EQ 5MG BASE	A079049	003	Aug 04, 2008
	EQ 10MG BASE	A075871	002	Apr 22, 2009
	EQ 10MG BASE	A079049	004	Aug 04, 2008
	EQ 35MG BASE	A075871	004	Apr 22, 2009
	EQ 35MG BASE	A079049	001	Aug 04, 2008
	EQ 40MG BASE	A075871	003	Apr 22, 2009
	EQ 70MG BASE	A075871	005	Apr 22, 2009
	EQ 70MG BASE	A079049	002	Aug 04, 2008
IMPAX LABS INC	EQ 5MG BASE	A075710	001	Feb 06, 2008
	EQ 10MG BASE	A075710	002	Feb 06, 2008
	EQ 35MG BASE	A075710	003	Feb 06, 2008
	EQ 40MG BASE	A075710	004	Feb 06, 2008
	EQ 70MG BASE	A075710	005	Feb 06, 2008
JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010
	EQ 10MG BASE	A090557	002	Feb 18, 2010
	EQ 35MG BASE	A090557	003	Feb 18, 2010
	EQ 70MG BASE	A090557	004	Feb 18, 2010
MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008
	EQ 70MG BASE	A078638	002	Aug 04, 2008
RISING	EQ 5MG BASE	A076584	001	Aug 04, 2008
	EQ 10MG BASE	A076584	002	Aug 04, 2008
	EQ 35MG BASE	A076584	003	Aug 04, 2008
	EQ 70MG BASE	A076584	004	Aug 04, 2008
TEVA PHARMS	EQ 35MG BASE	A076184	002	Aug 04, 2008
	EQ 70MG BASE	A076184	001	Feb 06, 2008
FOSAMAX				
+ ORGANON	EQ 5MG BASE **	N020560	003	Apr 25, 1997
+	EQ 10MG BASE **	N020560	001	Sep 29, 1995
+	EQ 35MG BASE **	N020560	004	Oct 20, 2000
+	EQ 40MG BASE **	N020560	002	Sep 29, 1995
ALFUZOSIN HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
ALFUZOSIN HYDROCHLORIDE				
CHARTWELL RX	10MG	A079056	001	Jul 18, 2011
MYLAN	10MG	A079014	001	Jul 18, 2011
TORRENT PHARMS	10MG	A079054	001	Jul 18, 2011
WOCKHARDT	10MG	A090221	001	Aug 10, 2012
ALISKIREN HEMIFUMARATE				
CAPSULE, PELLET;ORAL				
TEKTURNA				
+ NODEN PHARMA	EQ 37.5MG BASE	N210709	001	Nov 14, 2017
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE				
TABLET;ORAL				
TEKAMLO				
NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010
	EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010
	EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010
	EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL					
AMTURNIDE					
	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010
		EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010
		EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010
		EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010
		EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL					
TEKTURNA HCT					
+	NODEN PHARMA	EQ 150MG BASE;12.5MG **	N022107	001	Jan 18, 2008
+		EQ 150MG BASE;25MG **	N022107	002	Jan 18, 2008
+		EQ 300MG BASE;12.5MG **	N022107	003	Jan 18, 2008
+		EQ 300MG BASE;25MG **	N022107	004	Jan 18, 2008

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET;ORAL					
VALTURNA					
	NOVARTIS	EQ 150MG BASE;160MG	N022217	001	Sep 16, 2009
		EQ 300MG BASE;320MG	N022217	002	Sep 16, 2009

ALKAVERVIR

TABLET;ORAL					
VERILOID					
	3M	2MG	N007336	002	
		3MG	N007336	003	

ALLOPURINOL

TABLET;ORAL					
ALLOPURINOL					
	AIPING PHARM INC	100MG	A070268	001	Dec 31, 1985
	MUTUAL PHARM	100MG	A070466	001	Dec 24, 1985
		300MG	A070467	001	Dec 24, 1985
	PURACAP PHARM	100MG	A070150	001	Dec 10, 1985
		300MG	A070147	001	Dec 10, 1985
	PUREPAC PHARM	100MG	A070579	001	Apr 14, 1986
		300MG	A070580	001	Apr 14, 1986
	SANDOZ	300MG	A070269	001	Dec 31, 1985
	SUN PHARM INDS INC	100MG	A078390	001	Aug 30, 2007
		300MG	A078390	002	Aug 30, 2007
	SUPERPHARM	100MG	A070950	001	Nov 30, 1988
		300MG	A070951	001	Nov 30, 1988
	WATSON LABS	100MG	N018241	001	Nov 16, 1984
		100MG	N018785	001	Sep 28, 1984
		300MG	N018241	002	Nov 16, 1984
		300MG	N018785	002	Sep 28, 1984
LOPURIN					
	ABBOTT	100MG	N018297	001	
		300MG	N018297	002	

ALLOPURINOL; LESINURAD

TABLET;ORAL					
DUZALLO					
+	IRONWOOD PHARMS INC	200MG;200MG	N209203	001	Aug 18, 2017
+		300MG;200MG	N209203	002	Aug 18, 2017

ALMOTRIPTAN MALATE

TABLET;ORAL					
AXERT					
+	JANSSEN PHARMS	EQ 6.25MG BASE **	N021001	001	May 07, 2001
+		EQ 12.5MG BASE **	N021001	002	May 07, 2001

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL					
OSENI					
+	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE **	N022426	004	Jan 25, 2013
+		EQ 12.5MG BASE;EQ 45MG BASE **	N022426	006	Jan 25, 2013

ALOSETRON HYDROCHLORIDE				
TABLET;ORAL				
ALOSETRON HYDROCHLORIDE				
EYWA PHARMA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019
	EQ 1MG BASE	A211621	002	Sep 16, 2019
HIKMA	EQ 0.5MG BASE	A200652	001	May 04, 2015
	EQ 1MG BASE	A200652	002	May 04, 2015
PAR PHARM INC	EQ 0.5MG BASE	A206113	001	Feb 23, 2018
	EQ 1MG BASE	A206113	002	Feb 23, 2018
ALPRAZOLAM				
SOLUTION;ORAL				
ALPRAZOLAM				
ROXANE	0.5MG/5ML	A074314	001	Oct 31, 1993
TABLET;ORAL				
ALPRAZOLAM				
ANI PHARMS	0.25MG	A074085	001	Feb 16, 1994
	0.5MG	A074085	002	Feb 16, 1994
	1MG	A074085	003	Feb 16, 1994
	2MG	A074085	004	Feb 26, 1996
IVAX SUB TEVA PHARMS	0.25MG	A074294	001	Jul 29, 1994
	0.5MG	A074294	002	Jul 29, 1994
	1MG	A074294	003	Jul 29, 1994
	2MG	A074294	004	Jul 29, 1994
MYLAN	0.25MG	A074215	001	Jan 27, 1994
	0.5MG	A074215	002	Jan 27, 1994
	1MG	A074215	003	Jan 27, 1994
	2MG	A074215	004	Jan 27, 1994
MYLAN PHARMS INC	0.25MG	A074046	001	Oct 19, 1993
	0.5MG	A074046	002	Oct 19, 1993
	1MG	A074046	003	Oct 19, 1993
	2MG	A074046	004	May 07, 1997
OXFORD PHARMS	0.25MG	A078491	001	Sep 25, 2008
	0.5MG	A078491	002	Sep 25, 2008
	1MG	A078491	003	Sep 25, 2008
	2MG	A078491	004	Dec 12, 2008
ROXANE	0.25MG	A074199	001	Oct 19, 1993
	0.5MG	A074199	002	Oct 19, 1993
	1MG	A074199	003	Oct 19, 1993
WATSON LABS	0.25MG	A074456	001	Aug 31, 1995
	0.25MG	A074479	001	Jan 21, 1997
	0.5MG	A074456	002	Aug 31, 1995
	0.5MG	A074479	002	Jan 21, 1997
	1MG	A074456	003	Aug 31, 1995
	1MG	A074479	003	Jan 21, 1997
TABLET, EXTENDED RELEASE;ORAL				
ALPRAZOLAM				
ACTAVIS LABS FL INC	0.5MG	A077198	001	May 13, 2010
	1MG	A077198	002	May 13, 2010
	2MG	A077198	003	May 13, 2010
	3MG	A077198	004	May 13, 2010
ANI PHARMS	0.5MG	A077725	001	Jul 31, 2006
	0.5MG	A077979	001	Feb 28, 2007
	1MG	A077725	002	Jul 31, 2006
	1MG	A077979	002	Feb 28, 2007
	2MG	A077725	004	Jul 31, 2006
	2MG	A077979	003	Feb 28, 2007
	3MG	A077725	003	Jul 31, 2006
	3MG	A077979	004	Feb 28, 2007
HERITAGE PHARMS INC	0.5MG	A078489	001	Oct 17, 2008
	1MG	A078489	002	Oct 17, 2008
	2MG	A078489	003	Oct 17, 2008
	3MG	A078489	004	Oct 17, 2008
IMPAX LABS	0.5MG	A077968	004	May 24, 2007
	1MG	A077968	003	May 24, 2007
	2MG	A077968	002	May 24, 2007
	3MG	A077968	001	May 24, 2007
IMPAX LABS INC	0.5MG	A077996	001	Jan 31, 2007
	1MG	A077996	002	Jan 31, 2007
	2MG	A077996	003	Jan 31, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL					
ALPRAZOLAM					
		3MG	A077996	004	Jan 31, 2007
	MYLAN	0.5MG	A077391	002	Jan 26, 2006
		1MG	A077391	003	Jan 26, 2006
		2MG	A077391	004	Jan 26, 2006
		3MG	A077391	001	Jan 26, 2006
	SANDOZ INC	0.5MG	A077777	001	Jun 30, 2006
		1MG	A077777	002	Jun 30, 2006
		2MG	A077777	003	Jun 30, 2006
		3MG	A077777	004	Jun 30, 2006
	VINTAGE PHARMS	0.5MG	A078442	001	Oct 15, 2007
		1MG	A078442	002	Oct 15, 2007
		2MG	A078442	003	Oct 15, 2007
		3MG	A078442	004	Oct 15, 2007
TABLET, ORALLY DISINTEGRATING;ORAL					
NIRAVAM					
+	UCB INC	0.25MG **	N021726	001	Jan 19, 2005
+		0.5MG **	N021726	002	Jan 19, 2005
+		1MG **	N021726	003	Jan 19, 2005
+		2MG **	N021726	004	Jan 19, 2005

ALPROSTADIL

INJECTABLE;INJECTION					
CAVERJECT					
+	PFIZER	0.005MG/VIAL	N020379	003	Jun 27, 1996
		0.005MG/ML	N020755	001	Oct 31, 1997
		0.01MG/ML	N020755	002	Oct 01, 1997
		0.02MG/ML	N020755	003	Oct 01, 1997
EDEX					
	AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997
SUPPOSITORY;URETHRAL					
MUSE					
+	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996

ALSEROXYLON

TABLET;ORAL					
RAUTENSIN					
	NOVARTIS	2MG	N009215	001	
RAUWILOID					
	3M	2MG	N008867	001	

ALTRETAMINE

CAPSULE;ORAL					
HEXALEN					
+	EISAI INC	50MG	N019926	001	Dec 26, 1990

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL					
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE					
	PENNEX	80MG;20MG	A089449	001	Nov 27, 1987
FOAMCOAT					
	GUARDIAN DRUG	80MG;20MG	A071793	001	Sep 04, 1987
FOAMICON					
	NOVARTIS	80MG;20MG	A072687	001	Jun 28, 1989
GAVISCON					
+	CHATTEM SANOFI	80MG;20MG **	N018685	001	Dec 09, 1983
+		160MG;40MG **	N018685	002	Dec 09, 1983

ALVIMOPAN

CAPSULE;ORAL					
ENTEREG					
+	CUBIST PHARMS	12MG	N021775	001	May 20, 2008

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL					
AMANTADINE HYDROCHLORIDE					
	ACTAVIS ELIZABETH	100MG	A077659	001	Feb 23, 2006
	CHARTWELL MOLECULAR	100MG	A209221	001	Jun 15, 2017
	INVAGEN PHARMS	100MG	A207570	001	Sep 30, 2016
	WATSON LABS	100MG	A071382	001	Jan 21, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL				
AMANTADINE HYDROCHLORIDE				
WATSON LABS INC	100MG	A208107	001	Dec 06, 2016
SYMADINE				
SOLVAY	100MG	A071000	001	Sep 04, 1986
SYMMETREL				
+ ENDO PHARMS	100MG **	N016020	001	
SYRUP;ORAL				
AMANTADINE HYDROCHLORIDE				
ANDA REPOSITORY	50MG/5ML	A076352	001	Sep 10, 2004
G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990
TEVA PHARMS	50MG/5ML	A073115	001	Aug 23, 1991
VINTAGE	50MG/5ML	A077992	001	Dec 12, 2006
XTTRIUM LABS INC	50MG/5ML	A075060	001	Dec 24, 1998
SYMMETREL				
+ ENDO PHARMS	50MG/5ML **	N016023	002	
TABLET;ORAL				
AMANTADINE HYDROCHLORIDE				
EDENBRIDGE PHARMS	100MG	A212407	001	May 27, 2022
INVAGEN PHARMS	100MG	A207571	001	Jan 31, 2017
JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018
SYMMETREL				
+ ENDO PHARMS	100MG **	N018101	001	
TABLET, EXTENDED RELEASE;ORAL				
OSMOLEX ER				
+ ADAMAS OPERATIONS	EQ 161MG BASE	N209410	004	Apr 22, 2020
+	EQ 258MG BASE	N209410	003	Feb 16, 2018

AMBENONIUM CHLORIDE

TABLET;ORAL				
MYTELASE				
SANOFI AVENTIS US	10MG	N010155	002	

AMCINONIDE

CREAM;TOPICAL				
CYCLOCORT				
+ ASTELLAS	0.025% **	N018116	001	
+	0.1% **	N018116	002	
LOTION;TOPICAL				
CYCLOCORT				
+ ASTELLAS	0.1%	N019729	001	Jun 13, 1988
OINTMENT;TOPICAL				
CYCLOCORT				
+ ASTELLAS	0.1% **	N018498	001	

AMDINOCILLIN

INJECTABLE;INJECTION				
COACTIN				
ROCHE	250MG/VIAL	N050565	001	Dec 21, 1984
	500MG/VIAL	N050565	002	Dec 21, 1984
	1GM/VIAL	N050565	003	Dec 21, 1984

AMIFOSTINE

INJECTABLE;INJECTION				
AMIFOSTINE				
EUGIA PHARMA SPECLTS	500MG/VIAL	A204363	001	Jul 17, 2017
SUN PHARM	500MG/VIAL	A077126	001	Mar 14, 2008
ETHYOL				
CLINIGEN	375MG/VIAL	N020221	002	Sep 10, 1999

AMIKACIN SULFATE

INJECTABLE;INJECTION				
AMIKACIN SULFATE				
ABBOTT	EQ 250MG BASE/ML	A063265	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063266	001	Oct 31, 1994
FRESENIUS KABI USA	EQ 50MG BASE/ML	A205605	001	Dec 09, 2015
HIKMA	EQ 50MG BASE/ML	A063274	001	May 18, 1992
	EQ 250MG BASE/ML	A063275	001	May 18, 1992
HOSPIRA	EQ 50MG BASE/ML	A063263	001	Nov 30, 1994
	EQ 50MG BASE/ML	A063350	001	Jul 30, 1993
	EQ 62.5MG BASE/ML	A063283	001	Oct 31, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMIKACIN SULFATE					
INJECTABLE;INJECTION					
AMIKACIN SULFATE					
		EQ 250MG BASE/ML	A063264	001	Nov 30, 1994
		EQ 250MG BASE/ML	A063350	002	Jul 30, 1993
		EQ 250MG BASE/ML	A064098	001	Jun 26, 1995
		EQ 250MG BASE/ML	A064099	001	Jun 20, 1995
	IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995
		EQ 250MG BASE/ML	A063169	001	Dec 14, 1995
	MEITHEAL	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997
AMIKIN					
	APOTHECON	EQ 50MG BASE/ML	A062311	001	
		EQ 50MG BASE/ML	A062562	001	Sep 20, 1984
+		EQ 50MG BASE/ML **	N050495	001	
		EQ 250MG BASE/ML	A062311	002	
		EQ 250MG BASE/ML	A062562	002	Sep 20, 1984
+		EQ 250MG BASE/ML **	N050495	002	
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	APOTHECON	EQ 5MG BASE/ML	N050618	002	Nov 30, 1987
		EQ 10MG BASE/ML	N050618	001	Nov 30, 1987
AMILORIDE HYDROCHLORIDE					
TABLET;ORAL					
AMILORIDE HYDROCHLORIDE					
	CHARTWELL RX	5MG	A204180	001	Aug 07, 2015
AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE					
TABLET;ORAL					
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	CHARTWELL RX	EQ 5MG ANHYDROUS;50MG	A073357	001	Nov 27, 1991
	TEVA	EQ 5MG ANHYDROUS;50MG	A070795	001	Apr 17, 1988
	WATSON LABS	EQ 5MG ANHYDROUS;50MG	A073334	001	Jul 19, 1991
HYDRO-RIDE					
	PAR PHARM	EQ 5MG ANHYDROUS;50MG	A070347	001	Dec 25, 1990
MODURETIC 5-50					
+	MERCK	EQ 5MG ANHYDROUS;50MG **	N018201	001	
AMINO ACIDS					
INJECTABLE;INJECTION					
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE					
	HOSPIRA	5.2% (5.2GM/100ML)	N018901	001	Apr 06, 1984
AMINOSYN 10%					
	ICU MEDICAL INC	10% (10GM/100ML)	N017673	003	
AMINOSYN 10% (PH6)					
	ICU MEDICAL INC	10% (10GM/100ML)	N017673	008	Nov 18, 1985
AMINOSYN 3.5%					
	ICU MEDICAL INC	3.5% (3.5GM/100ML)	N017789	004	
AMINOSYN 3.5% IN PLASTIC CONTAINER					
	ABBOTT	3.5% (3.5GM/100ML)	N018804	001	May 15, 1984
		3.5% (3.5GM/100ML)	N018875	001	Aug 08, 1984
AMINOSYN 5%					
	ICU MEDICAL INC	5% (5GM/100ML)	N017673	001	
AMINOSYN 7%					
	ICU MEDICAL INC	7% (7GM/100ML)	N017673	002	
AMINOSYN 7% (PH6)					
	ICU MEDICAL INC	7% (7GM/100ML)	N017673	006	Nov 18, 1985
AMINOSYN 8.5%					
	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	004	
AMINOSYN 8.5% (PH6)					
	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985
AMINOSYN II 10%					
	ICU MEDICAL INC	10% (10GM/100ML)	N019438	005	Apr 03, 1986
AMINOSYN II 3.5%					
	ICU MEDICAL INC	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986
AMINOSYN II 3.5% IN PLASTIC CONTAINER					
	ABBOTT	3.5% (3.5GM/100ML)	N019491	001	Oct 10, 1986
AMINOSYN II 5%					
	ICU MEDICAL INC	5% (5GM/100ML)	N019438	002	Apr 03, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINO ACIDS

INJECTABLE;INJECTION

AMINOSYN II 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N019438	003	Apr 03, 1986
AMINOSYN II 8.5%				
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986
AMINOSYN-HBC 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N019374	001	Jul 12, 1985
AMINOSYN-HBC 7% IN PLASTIC CONTAINER				
ABBOTT	7% (7GM/100ML)	N019400	001	Jul 23, 1986
AMINOSYN-HF 8%				
ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996
AMINOSYN-RF 5.2%				
ICU MEDICAL INC	5.2% (5.2GM/100ML)	N018429	001	
BRANCHAMIN 4%				
BAXTER HLTHCARE	4% (4GM/100ML)	N018678	001	Sep 28, 1984
BRANCHAMIN 4% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984
FREAMINE 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	001	
FREAMINE HBC 6.9%				
B BRAUN	6.9% (6.9GM/100ML)	N016822	006	May 17, 1983
FREAMINE II 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	002	
FREAMINE III 10%				
B BRAUN	10% (10GM/100ML)	N016822	005	
FREAMINE III 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	004	
HEPATAMINE 8%				
B BRAUN	8% (8GM/100ML)	N018676	001	Aug 03, 1982
HEPATASOL 8%				
BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996
NEOPHAM 6.4%				
HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984
NEPHRAMINE 5.4%				
B BRAUN	5.4% (5.4GM/100ML)	N017766	001	
NOVAMINE 11.4%				
HOSPIRA INC	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982
NOVAMINE 15%				
HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML) **	N020107	001	Feb 05, 1993
NOVAMINE 8.5%				
HOSPIRA INC	8.5% (8.5GM/100ML)	N017957	002	Aug 09, 1982
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006	
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004	
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005	

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PROCALAMINE				
B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N018582	001	May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	001	Sep 12, 1988
HOSPIRA INC	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	001	Nov 07, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	002	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	002	Nov 07, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	004	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	003	Nov 07, 1988

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019714	003	Sep 12, 1988
HOSPIRA INC	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019683	004	Nov 07, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N019118	001	Oct 11, 1984

AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N019120	001	Oct 11, 1984

AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N019119	001	Oct 11, 1984

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N019505	002	Nov 07, 1986
	3.5%;25GM/100ML	N019713	006	Sep 09, 1988
HOSPIRA	3.5%;25GM/100ML	N019681	001	Nov 01, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N019506	001	Nov 07, 1986
	3.5%;5GM/100ML	N019713	002	Sep 09, 1988
HOSPIRA	3.5%;5GM/100ML	N019681	002	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML	N019713	001	Sep 09, 1988
HOSPIRA	4.25%;10GM/100ML	N019681	004	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

ABBOTT	4.25%;20GM/100ML	N019713	004	Sep 09, 1988
HOSPIRA	4.25%;20GM/100ML	N019681	005	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N019504	002	Nov 07, 1986
	4.25%;25GM/100ML	N019713	005	Sep 09, 1988
HOSPIRA	4.25%;25GM/100ML	N019681	003	Nov 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	5%;25GM/100ML	N019565	001	Dec 17, 1986
	5%;25GM/100ML	N019713	003	Sep 09, 1988
HOSPIRA	5%;25GM/100ML	N019681	006	Nov 01, 1988

TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML	N019520	002	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML	N019520	003	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;20GM/100ML	N019520	004	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML	N019520	005	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML	N019520	001	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML	N019520	007	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;15GM/100ML	N019520	008	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML	N019520	009	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML	N019520	010	Sep 23, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML	N019520	006	Sep 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100 ML;22.4MG/100ML;104.5MG/100ML;205MG/100 ML	N019712	002	Sep 08, 1988
HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100 ML;22.4MG/100ML;104.5MG/100ML;205MG/100 ML	N019682	003	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML ;261MG/100ML;205MG/100ML	N019564	002	Dec 16, 1986

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100M L;261MG/100ML;205MG/100ML	N019564	004	Dec 16, 1986

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML	N019564	001	Dec 16, 1986
	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML	N019712	001	Sep 08, 1988
HOSPIRA INC	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML	N019682	001	Nov 01, 1988

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;30MG/100ML;97MG/100ML; 120MG/100ML;49.3MG/100ML	N019564	003	Dec 16, 1986
HOSPIRA INC	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;1 20MG/100ML;49.3MG/100ML	N019682	002	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147	002	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147	003	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;20GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147	004	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147	005	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML;51MG/100ML;261MG/100ML; 216MG/100ML;112MG/100ML	N020147	001	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147	007	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;15GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147	008	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147	009	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147	010	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML;51MG/100ML;261MG/100ML; 297MG/100ML;77MG/100ML	N020147	006	Oct 23, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES

B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML;440MG/100ML;690MG/100ML	N016822	007	Jul 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N017789	003	

AMINOSYN 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N018804	002	May 15, 1984
	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N018875	002	Aug 08, 1984

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

FREAMINE III 3% W/ ELECTROLYTES

B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N016822	003	

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789	005	

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;32MG/100ML;128MG/100ML;222MG/100ML;49MG/100ML	N019493	001	Oct 16, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

VEINAMINE 8%

HOSPIRA INC	8%;61MG/100ML;211MG/100ML;56MG/100ML;38MG/100ML	N017957	001	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

ICU MEDICAL INC	10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	004	Apr 03, 1986

AMINOSYN II 7% W/ ELECTROLYTES

ICU MEDICAL INC	7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	006	Apr 03, 1986

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	005	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE;INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML	N017673	009	Oct 25, 2002

AMINOSYN II 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;492MG/100ML;60MG/100ML;425MG/100ML	N019437	008	Oct 25, 2002

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M

ICU MEDICAL INC	3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML	N019437	007	Apr 03, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION				
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177 001	Oct 23, 1995
TRAVASOL 3.5% W/ ELECTROLYTES				
	BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N017493 003	
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N020173 001	Oct 27, 1995
TRAVASOL 5.5% W/ ELECTROLYTES				
	BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N017493 001	
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N020173 002	Oct 27, 1995
TRAVASOL 8.5% W/ ELECTROLYTES				
	BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N017493 002	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION				
AMINOSYN 7% W/ ELECTROLYTES				
	ICU MEDICAL INC	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789 002	
AMINOSYN 8.5% W/ ELECTROLYTES				
	ICU MEDICAL INC	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673 005	

AMINOCAPROIC ACID

INJECTABLE;INJECTION				
AMICAR				
+	EPIC PHARMA LLC	250MG/ML **	N015229 002	
AMINOCAPROIC ACID				
	ABRAXIS PHARM	250MG/ML	A070522 001	Jun 17, 1986
	BAXTER HLTHCARE	250MG/ML	N018590 001	Oct 29, 1982
	HOSPIRA	250MG/ML	A070888 001	Jun 16, 1988
SOLUTION;ORAL				
AMINOCAPROIC ACID				
	EPIC PHARMA LLC	0.25GM/ML	A074759 001	Sep 02, 1998
	VISTAPHARM	0.25GM/ML	A212814 001	Feb 26, 2020
TABLET;ORAL				
AMINOCAPROIC				
	HIKMA	500MG	A075602 001	May 24, 2001
AMINOCAPROIC ACID				
	EDENBRIDGE PHARMS	500MG	A212110 001	Jun 14, 2021

AMINOGLUTETHIMIDE

TABLET;ORAL				
CYTADREN				
	NOVARTIS	250MG	N018202 001	

AMINOHIPPURATE SODIUM

INJECTABLE;INJECTION				
AMINOHIPPURATE SODIUM				
	MERCK	20%	N005619 001	

AMINOPHYLLINE

ENEMA;RECTAL				
SOMOPHYLLIN				
	FISONS	300MG/5ML	N018232 001	Apr 02, 1982
INJECTABLE;INJECTION				
AMINOPHYLLIN				
+	GD SEARLE LLC	25MG/ML	A087243 001	May 24, 1982
+		25MG/ML	A087621 001	May 24, 1982
AMINOPHYLLINE				
	ABRAXIS PHARM	25MG/ML	A084568 001	
		25MG/ML	A087200 001	
		25MG/ML	A087250 001	Jan 06, 1982
		25MG/ML	A087886 001	Aug 30, 1983
		25MG/ML	A088407 001	Jan 25, 1984
	AM REGENT	25MG/ML	A087600 001	
	ELKINS SINN	25MG/ML	A087239 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINOPHYLLINE

INJECTABLE;INJECTION				
AMINOPHYLLINE				
HOSPIRA	25MG/ML	A087601	001	Jul 23, 1982
INTL MEDICATION	25MG/ML	A087209	001	Feb 01, 1982
	25MG/ML	A087867	001	Nov 10, 1983
	25MG/ML	A087868	001	Nov 10, 1983
KING PHARMS	25MG/ML	A086606	001	
LUITPOLD	25MG/ML	A087240	001	
LYPHOMED	25MG/ML	A087431	001	
PHARMA SERVE NY	25MG/ML	A087387	001	Jun 03, 1983
	25MG/ML	A087392	001	Dec 15, 1983
SMITH AND NEPHEW	25MG/ML	A088429	001	May 30, 1985
	25MG/ML	A088749	001	May 30, 1985
TEVA PARENTERAL	25MG/ML	A081142	001	Sep 25, 1991
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%				
HOSPIRA	100MG/100ML	A088147	002	May 03, 1983
	200MG/100ML	A088147	003	May 03, 1983
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
HOSPIRA	100MG/100ML	N018924	001	Dec 12, 1984
	200MG/100ML	N018924	002	Dec 12, 1984
	400MG/100ML	N018924	003	Dec 12, 1984
	500MG/100ML	N018924	004	Dec 12, 1984
SOLUTION;ORAL				
AMINOPHYLLINE				
MORTON GROVE	105MG/5ML	A088156	001	Dec 05, 1983
ROXANE	105MG/5ML	A088126	001	Aug 19, 1983
AMINOPHYLLINE DYE FREE				
ACTAVIS MID ATLANTIC	105MG/5ML	A087727	001	Apr 16, 1982
SOMOPHYLLIN				
FISONS	105MG/5ML	A086466	001	
SOMOPHYLLIN-DF				
FISONS	105MG/5ML	A087045	001	
SUPPOSITORY;RECTAL				
TRUPHYLLINE				
COSETTE	250MG	A085498	001	Mar 23, 1983
	500MG	A085498	002	Jan 03, 1983
TABLET;ORAL				
AMINOPHYLLIN				
GD SEARLE LLC	100MG	N002386	002	
	200MG	N002386	003	
AMINOPHYLLINE				
ANI PHARMS	100MG	A085261	004	
	200MG	A085261	002	
ASCOT	100MG	A087522	001	Feb 12, 1982
	200MG	A087523	001	Feb 12, 1982
BARR	100MG	A088297	001	Aug 19, 1983
	200MG	A088298	001	Aug 19, 1983
CHARTWELL MOLECULAR	100MG	A084588	001	
	200MG	A084588	002	
DURAMED PHARMS BARR	100MG	A088182	001	Mar 31, 1983
	200MG	A088183	001	Mar 31, 1983
HALSEY	100MG	A084674	001	
HIKMA INTL PHARMS	100MG	A084540	001	
	200MG	A085003	001	
IMPAX LABS	100MG	A084574	001	
	200MG	A084576	001	
KV PHARM	100MG	A085284	001	
	200MG	A085289	001	
PAL PAK	100MG	A084533	001	
PANRAY	100MG	A084552	001	
	200MG	A084552	002	
PUREPAC PHARM	100MG	A084699	001	
	200MG	A085333	001	
ROXANE	100MG	A087500	001	Feb 09, 1982
	200MG	A087501	001	Feb 09, 1982
VALEANT PHARM INTL	200MG	A084563	001	
VANGARD	100MG	A088314	001	Oct 03, 1983
	200MG	A088319	001	Oct 03, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINOPHYLLINE

TABLET;ORAL				
AMINOPHYLLINE				
	VINTAGE PHARMS	100MG	A085409 001	
		200MG	A085410 001	
	WATSON LABS	100MG	A085567 001	
		200MG	A085564 001	
TABLET, DELAYED RELEASE;ORAL				
AMINOPHYLLINE				
	IMPAX LABS	100MG	A084577 001	
		200MG	A084575 001	
	TABLICAPS	100MG	A084632 002	
	VALE	100MG	A084531 001	
		200MG	A084530 001	
TABLET, EXTENDED RELEASE;ORAL				
PHYLLOCONTIN				
	PHARM RES ASSOC	225MG	A086760 001	

AMINOSALICYLATE SODIUM

POWDER;ORAL				
P.A.S. SODIUM				
	CENTURY PHARMS	4GM/PACKET	A080947 001	
SODIUM AMINOSALICYLATE				
	HEXCEL	100%	A080097 001	
TABLET;ORAL				
PARASAL SODIUM				
	PANRAY	500MG	N006811 006	
		1GM	N006811 011	
SODIUM P.A.S.				
	LANNETT	500MG	A080138 002	
TEEBACIN				
	CONSOLIDATED MIDLAND	500MG	N007320 002	

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET;ORAL				
NEOPASALATE				
	MEDPOINTE PHARM HLC	846MG;112MG	A080059 002	

AMINOSALICYLIC ACID

TABLET;ORAL				
PARASAL				
	PANRAY	500MG	N006811 001	
		1GM	N006811 002	

AMINOSALICYLIC ACID RESIN COMPLEX

POWDER;ORAL				
REZIPAS				
	BRISTOL MYERS SQUIBB	EQ 500MG BASE/GM	N009052 001	

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION				
AMIODARONE HYDROCHLORIDE				
	BEDFORD	50MG/ML	A076018 001	Oct 15, 2002
	BEDFORD LABS	50MG/ML	A076299 001	Oct 24, 2002
	BEN VENUE	50MG/ML	A076088 001	Oct 15, 2002
	DR REDDYS	50MG/ML	A076163 001	Sep 05, 2003
	EPIC PHARMA LLC	50MG/ML	A076232 001	Jul 05, 2006
	EUGIA PHARMA	50MG/ML	A204550 001	Oct 25, 2017
	HOSPIRA	50MG/ML	A075955 001	Oct 18, 2002
		50MG/ML	A076108 001	Oct 15, 2002
		50MG/ML	A203885 001	Nov 25, 2013
	INTL MEDICATION SYS	50MG/ML	N021594 001	Feb 04, 2004
	PAR STERILE PRODUCTS	50MG/ML	A076394 001	Apr 25, 2003
CORDARONE				
+	WYETH PHARMS INC	50MG/ML **	N020377 001	Aug 03, 1995
NEXTERONE				
+	BAXTER HLTHCARE	50MG/ML **	N022325 001	Dec 24, 2008
TABLET;ORAL				
AMIODARONE HYDROCHLORIDE				
	MYLAN	200MG	A075188 001	Feb 24, 1999
	TEVA	200MG	A074895 001	Apr 16, 1999
	UPSHER SMITH LABS	200MG	A075315 001	Dec 23, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMIODARONE HYDROCHLORIDE				
TABLET;ORAL				
AMIODARONE HYDROCHLORIDE				
	400MG	A075315	002	Jun 30, 2000
CORDARONE				
+ WYETH PHARMS	200MG **	N018972	001	Dec 24, 1985
AMITRIPTYLINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
ENDEP				
+ ROCHE	40MG/ML **	A085749	001	
INJECTABLE;INJECTION				
AMITRIPTYLINE HYDROCHLORIDE				
WATSON LABS	10MG/ML	A085594	001	
ELAVIL				
ASTRAZENECA	10MG/ML	N012704	001	
TABLET;ORAL				
AMITID				
BRISTOL MYERS SQUIBB	10MG	A086454	001	
	25MG	A086454	002	
	50MG	A086454	003	
	75MG	A086454	004	
	100MG	A086454	005	
AMITRIL				
WARNER CHILCOTT	10MG	A083939	001	
	25MG	A083937	001	
	50MG	A083938	002	
	75MG	A084957	001	
	100MG	A085093	001	
	150MG	A086295	001	
AMITRIPTYLINE HYDROCHLORIDE				
AIPING PHARM INC	10MG	A212654	002	Sep 29, 2021
	25MG	A212654	001	Apr 07, 2020
	50MG	A212654	003	Sep 29, 2021
	75MG	A212654	004	Sep 29, 2021
	100MG	A212654	005	Sep 29, 2021
	150MG	A212654	006	Sep 29, 2021
AM THERAP	25MG	A088672	001	Nov 20, 1984
	50MG	A088673	001	Nov 20, 1984
	75MG	A088674	001	Nov 20, 1984
	100MG	A088675	001	Nov 20, 1984
ANI PHARMS	10MG	A085031	002	
	25MG	A085031	001	
	50MG	A085031	003	
	75MG	A085031	004	
AUROBINDO PHARMA USA	10MG	A086009	002	
	25MG	A086009	003	
	50MG	A086009	001	
	75MG	A086009	004	
	100MG	A086009	005	
	150MG	A086009	006	
COPLEY PHARM	10MG	A088421	001	Apr 30, 1984
	25MG	A088422	001	Apr 30, 1984
	50MG	A088423	001	Apr 30, 1984
	75MG	A088424	001	Apr 30, 1984
	100MG	A088425	001	Apr 30, 1984
	150MG	A088426	001	Apr 30, 1984
HALSEY	10MG	A085923	001	
	25MG	A085922	001	
	50MG	A085925	001	
	50MG	A087557	001	Mar 05, 1982
	75MG	A085926	001	May 20, 1983
	100MG	A085927	001	May 20, 1983
LEDERLE	10MG	A086744	001	
	10MG	A087366	001	Jan 04, 1982
	25MG	A086746	001	
	25MG	A087367	001	May 03, 1982
	50MG	A086743	001	
	50MG	A087181	001	Jan 04, 1982
	75MG	A086745	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	75MG	A087369	001	Jan 04, 1982
	100MG	A086747	001	
	100MG	A087368	001	May 03, 1982
	150MG	A087370	001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744	001	
	25MG	A085627	001	
	50MG	A085745	001	
	75MG	A085743	001	
	100MG	A085742	002	May 11, 1982
	150MG	A089423	001	Feb 17, 1987
PAR PHARM	10MG	A088697	001	Sep 25, 1984
	25MG	A088698	001	Sep 25, 1984
	50MG	A088699	001	Sep 25, 1984
	75MG	A088700	001	Sep 25, 1984
	100MG	A088701	001	Sep 25, 1984
	150MG	A088702	001	Sep 25, 1984
PLIVA	10MG	A088883	001	Sep 26, 1984
	25MG	A088884	001	Sep 26, 1984
	50MG	A088885	001	Sep 26, 1984
	75MG	A088886	001	Sep 26, 1984
	100MG	A088887	001	Sep 26, 1984
	150MG	A088888	001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075	001	Sep 16, 1983
	10MG	A088084	001	Jul 18, 1983
	25MG	A088076	001	May 20, 1983
	25MG	A088085	001	Jul 18, 1983
	50MG	A088077	001	Sep 16, 1983
	50MG	A088105	001	Jul 18, 1983
	75MG	A088078	001	Sep 16, 1983
	75MG	A088106	001	Jul 18, 1983
	100MG	A088079	001	Sep 16, 1983
	100MG	A088107	001	Jul 18, 1983
ROXANE	10MG	A086002	001	
	10MG	A086144	001	
	25MG	A085944	001	
	25MG	A086145	001	
	50MG	A085945	001	
	50MG	A086143	001	
	75MG	A086004	001	
	75MG	A086147	001	
	100MG	A086003	001	
	100MG	A086146	001	
	150MG	A086090	001	
	150MG	A086148	001	
SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008
	25MG	A040816	001	Jun 27, 2008
	50MG	A040816	003	Jun 27, 2008
	75MG	A040816	004	Jun 27, 2008
	100MG	A040816	005	Jun 27, 2008
	150MG	A040816	006	Jun 27, 2008
SUPERPHARM	10MG	A088853	001	Nov 13, 1984
	25MG	A088854	001	Nov 13, 1984
	50MG	A088855	001	Nov 13, 1984
	75MG	A088856	001	Nov 13, 1984
	100MG	A088857	001	Nov 13, 1984
TEVA	10MG	A086610	001	
	25MG	A086859	001	
	50MG	A086857	001	
	75MG	A086860	001	
	100MG	A085836	001	
	100MG	A086854	001	
	150MG	A086853	001	
UCB INC	10MG	A085864	001	
	25MG	A085935	001	
	50MG	A085936	001	
	75MG	A086337	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL				
AMITRIPTYLINE HYDROCHLORIDE				
		100MG	A086336 001	
		150MG	A086335 001	
	USL PHARMA	25MG	A087775 001	Feb 10, 1982
	VANGARD	10MG	A087632 001	Feb 01, 1982
		50MG	A087616 001	Feb 08, 1982
		75MG	A087617 001	Feb 05, 1982
		100MG	A087639 001	Feb 08, 1982
	VINTAGE PHARMS	10MG	A040218 001	Sep 11, 1997
		25MG	A040218 002	Sep 11, 1997
		50MG	A040218 003	Sep 11, 1997
		75MG	A040218 004	Sep 11, 1997
		100MG	A040218 005	Sep 11, 1997
		150MG	A040218 006	Sep 11, 1997
	WATSON LABS	10MG	A085816 001	
		10MG	A088620 001	Mar 02, 1984
		25MG	A085817 001	
		25MG	A088621 001	Mar 02, 1984
		50MG	A085815 001	
		50MG	A088622 001	Mar 02, 1984
		75MG	A085819 001	
		75MG	A088633 001	Mar 02, 1984
		100MG	A085820 001	
		100MG	A088634 001	Mar 02, 1984
		150MG	A085821 001	
		150MG	A088635 001	Mar 02, 1984
	WEST WARD	10MG	A087647 001	Mar 05, 1982
		25MG	A087278 001	
ELAVIL				
+	ASTRAZENECA	10MG **	N012703 001	
+		25MG **	N012703 003	
+		50MG **	N012703 004	
+		75MG **	N012703 005	
+		100MG **	N012703 006	
+		150MG **	N012703 007	
ENDEP				
	ROCHE	10MG	A083639 001	
		25MG	A083639 002	
		50MG	A083639 003	
		75MG	A083639 004	
		100MG	A083639 005	
		150MG	A085303 001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL				
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE				
	ANDA REPOSITORY	EQ 12.5MG BASE;5MG	A070765 001	Dec 10, 1986
		EQ 25MG BASE;10MG	A070766 001	Dec 10, 1986
	CHARTWELL RX	EQ 12.5MG BASE;5MG	A072277 001	May 09, 1988
		EQ 25MG BASE;10MG	A072278 001	May 09, 1988
	HERITAGE PHARMA	EQ 12.5MG BASE;5MG	A072052 001	Dec 16, 1988
		EQ 25MG BASE;10MG	A072053 001	Dec 16, 1988
	USL PHARMA	EQ 12.5MG BASE;5MG	A070477 001	Jan 12, 1988
		EQ 25MG BASE;10MG	A070478 001	Jan 12, 1988
LIMBITROL				
+	CHARTWELL RX	EQ 12.5MG BASE;5MG **	N016949 001	
LIMBITROL DS				
+	CHARTWELL RX	EQ 25MG BASE;10MG **	N016949 002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL				
ETRAFON 2-10				
	SCHERING	10MG;2MG **	N014713 007	
ETRAFON 2-25				
	SCHERING	25MG;2MG **	N014713 004	
ETRAFON-A				
	SCHERING	10MG;4MG **	N014713 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL				
ETRAFON-FORTE				
SCHERING	25MG;4MG **	N014713	006	
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE				
CHARTWELL RX	10MG;2MG	A073007	001	Oct 17, 1991
	10MG;4MG	A073009	001	Oct 17, 1991
	25MG;2MG	A073008	001	Oct 17, 1991
	25MG;4MG	A073010	001	Oct 17, 1991
FOSUN PHARMA	10MG;2MG	A071062	001	Nov 27, 1987
	10MG;4MG	A071862	001	Dec 21, 1987
	25MG;2MG	A071063	001	Nov 27, 1987
	25MG;4MG	A071064	001	Nov 27, 1987
	50MG;4MG	A071863	001	Dec 21, 1987
IVAX SUB TEVA PHARMS	10MG;2MG	A070935	001	Sep 11, 1986
	10MG;4MG	A070937	001	Sep 11, 1986
	25MG;2MG	A070936	001	Sep 11, 1986
	25MG;4MG	A070938	001	Sep 11, 1986
	50MG;4MG	A070939	001	Sep 12, 1986
PAR PHARM	10MG;2MG	A070565	001	Sep 11, 1986
	10MG;4MG	A070620	001	Sep 11, 1986
	25MG;2MG	A070621	001	Sep 11, 1986
	25MG;4MG	A070595	001	Sep 11, 1986
	50MG;4MG	A070574	001	Sep 11, 1986
SUN PHARM INDUSTRIES	10MG;2MG	A071077	001	Nov 12, 1986
	10MG;4MG	A071078	001	Nov 12, 1986
	25MG;2MG	A070297	001	Nov 12, 1986
	25MG;4MG	A071079	001	Nov 12, 1986
WATSON LABS	10MG;2MG	A070373	001	Aug 25, 1986
	10MG;2MG	A072539	001	Feb 15, 1989
	10MG;4MG	A070375	001	Aug 25, 1986
	10MG;4MG	A072540	001	Feb 15, 1989
	25MG;2MG	A070374	001	Aug 25, 1986
	25MG;2MG	A072541	001	Feb 15, 1989
	25MG;4MG	A070376	001	Aug 25, 1986
	25MG;4MG	A072134	001	Feb 15, 1989
	50MG;4MG	A070377	001	Nov 04, 1986
	50MG;4MG	A071558	001	Mar 02, 1987
	50MG;4MG	A072135	001	Feb 15, 1989
TRIAVIL 2-10				
NEW RIVER	10MG;2MG **	N014715	004	
TRIAVIL 2-25				
NEW RIVER	25MG;2MG **	N014715	002	
TRIAVIL 4-10				
NEW RIVER	10MG;4MG **	N014715	003	
TRIAVIL 4-25				
NEW RIVER	25MG;4MG **	N014715	005	
TRIAVIL 4-50				
NEW RIVER	50MG;4MG **	N014715	006	

AMLEXANOX

PASTE;DENTAL				
APHTHASOL				
ULURU	5%	N020511	001	Dec 17, 1996
PATCH;TOPICAL				
AMLEXANOX				
ULURU	2MG	N021727	001	Sep 29, 2004

AMLODIPINE BENZOATE

SUSPENSION;ORAL				
AMLODIPINE BENZOATE				
AMNEAL	EQ 1MG BASE/ML	A215035	001	Jun 13, 2023

AMLODIPINE BESYLATE

TABLET;ORAL				
AMLODIPINE BESYLATE				
AMNEAL PHARMS NY	EQ 2.5MG BASE	A078477	001	Jan 16, 2008
	EQ 5MG BASE	A078477	002	Jan 16, 2008
	EQ 10MG BASE	A078477	003	Jan 16, 2008
CHARTWELL RX	EQ 2.5MG BASE	A076859	001	Sep 10, 2007
	EQ 5MG BASE	A076859	002	Sep 10, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

	EQ 10MG BASE	A076859	003	Sep 10, 2007
GEDEON RICHTER USA	EQ 2.5MG BASE	A077333	001	Jul 17, 2007
	EQ 5MG BASE	A077333	002	Jul 17, 2007
	EQ 10MG BASE	A077333	003	Jul 17, 2007
GENPHARM	EQ 2.5MG BASE	A077362	001	Jul 09, 2007
	EQ 5MG BASE	A077362	002	Jul 09, 2007
	EQ 10MG BASE	A077362	003	Jul 09, 2007
HIKMA	EQ 2.5MG BASE	A077262	001	Jul 09, 2007
	EQ 5MG BASE	A077262	002	Jul 09, 2007
	EQ 10MG BASE	A077262	003	Jul 09, 2007
HIKMA PHARMS	EQ 2.5MG BASE	A077771	001	Apr 12, 2011
	EQ 5MG BASE	A077771	002	Apr 12, 2011
	EQ 10MG BASE	A077771	003	Apr 12, 2011
MACLEODS PHARMS LTD	EQ 5MG BASE	A201380	001	Apr 13, 2012
	EQ 10MG BASE	A201380	002	Apr 13, 2012
MYLAN	EQ 2.5MG BASE	A076418	001	Oct 03, 2005
	EQ 2.5MG BASE	A078224	001	Feb 27, 2008
	EQ 5MG BASE	A076418	002	Oct 03, 2005
	EQ 5MG BASE	A078224	002	Feb 27, 2008
	EQ 10MG BASE	A076418	003	Oct 03, 2005
	EQ 10MG BASE	A078224	003	Feb 27, 2008
PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007
	EQ 5MG BASE	A078131	002	Sep 04, 2007
	EQ 10MG BASE	A078131	003	Sep 04, 2007
SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015
	EQ 5MG BASE	A204900	002	Jul 23, 2015
	EQ 10MG BASE	A204900	003	Jul 23, 2015
SUN PHARM INDS INC	EQ 2.5MG BASE	A078231	001	Nov 30, 2007
	EQ 5MG BASE	A078231	002	Nov 30, 2007
	EQ 10MG BASE	A078231	003	Nov 30, 2007
SUN PHARM INDUSTRIES	EQ 2.5MG BASE	A078081	001	Jan 31, 2008
	EQ 5MG BASE	A078081	002	Jan 31, 2008
	EQ 10MG BASE	A078081	003	Jan 31, 2008
SUNSHINE	EQ 2.5MG BASE	A206524	001	May 04, 2018
	EQ 5MG BASE	A206524	002	May 04, 2018
	EQ 10MG BASE	A206524	003	May 04, 2018
SYNTHON PHARMS	EQ 2.5MG BASE	A077080	001	Jun 27, 2007
	EQ 5MG BASE	A077080	002	Jun 27, 2007
	EQ 10MG BASE	A077080	003	Jun 27, 2007
TORRENT PHARMS	EQ 2.5MG BASE	A078573	001	Sep 22, 2008
	EQ 5MG BASE	A078573	002	Sep 22, 2008
	EQ 10MG BASE	A078573	003	Sep 22, 2008
UPSHER SMITH LABS	EQ 2.5MG BASE	A077759	001	Jul 09, 2007
	EQ 5MG BASE	A077759	002	Jul 09, 2007
	EQ 10MG BASE	A077759	003	Jul 09, 2007
WATSON LABS	EQ 2.5MG BASE	A077671	001	Jul 19, 2007
	EQ 5MG BASE	A077671	002	Jul 19, 2007
	EQ 10MG BASE	A077671	003	Jul 19, 2007
WOCKHARDT	EQ 2.5MG BASE	A078500	001	Sep 06, 2007
	EQ 5MG BASE	A078500	002	Sep 06, 2007
	EQ 10MG BASE	A078500	003	Sep 06, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

AMLODIPINE BESYLATE

+ SYNTHON PHARMS	EQ 2.5MG BASE	N022026	001	Sep 27, 2007
+	EQ 5MG BASE	N022026	002	Sep 27, 2007
+	EQ 10MG BASE	N022026	003	Sep 27, 2007

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

MYLAN	EQ 2.5MG BASE;EQ 10MG BASE	A200465	001	Nov 29, 2013
	EQ 2.5MG BASE;EQ 20MG BASE	A200465	002	Nov 29, 2013
	EQ 2.5MG BASE;EQ 40MG BASE	A200465	003	Nov 29, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

CIPLA	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018
	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018
	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018
	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018
MYLAN	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010
	EQ 5MG BASE;10MG	A077375	002	May 21, 2010
	EQ 5MG BASE;20MG	A077375	003	May 21, 2010
	EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011
	EQ 10MG BASE;20MG	A077375	004	May 21, 2010
	EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011
STRIDES PHARMA	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010
	EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010
	EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010
	EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010
	EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010
	EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010
TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179	001	May 18, 2007
	EQ 5MG BASE;10MG	A077179	002	May 18, 2007
	EQ 5MG BASE;20MG	A077179	003	May 18, 2007
	EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011
	EQ 10MG BASE;20MG	A077179	004	May 18, 2007
	EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011

AMLODIPINE BESYLATE; CELECOXIB

TABLET;ORAL

CONSENSI

+	PURPLE BIOTECH	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018
+		EQ 5MG BASE;200MG	N210045	002	May 31, 2018
+		EQ 10MG BASE;200MG	N210045	003	May 31, 2018

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

TEVA PHARMS	EQ 5MG BASE;12.5MG;160MG	A200435	001	Sep 25, 2012
	EQ 5MG BASE;25MG;160MG	A200435	002	Sep 25, 2012
	EQ 10MG BASE;12.5MG;160MG	A200435	005	Sep 25, 2012
	EQ 10MG BASE;25MG;160MG	A200435	003	Sep 25, 2012
	EQ 10MG BASE;25MG;320MG	A200435	004	Sep 25, 2012
TORRENT	EQ 5MG BASE;12.5MG;160MG	A201593	001	Jun 03, 2015
	EQ 5MG BASE;25MG;160MG	A201593	002	Jun 03, 2015
	EQ 10MG BASE;12.5MG;160MG	A201593	003	Jun 03, 2015
	EQ 10MG BASE;25MG;160MG	A201593	004	Jun 03, 2015
	EQ 10MG BASE;25MG;320MG	A201593	005	Jun 03, 2015

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600	001	Aug 30, 2018
	EQ 5MG BASE;40MG	A209600	003	Aug 30, 2018
	EQ 10MG BASE;20MG	A209600	002	Aug 30, 2018
	EQ 10MG BASE;40MG	A209600	004	Aug 30, 2018
JUBILANT GENERICS	EQ 5MG BASE;20MG	A207450	001	May 15, 2017
	EQ 5MG BASE;40MG	A207450	002	May 15, 2017
	EQ 10MG BASE;20MG	A207450	003	May 15, 2017
	EQ 10MG BASE;40MG	A207450	004	May 15, 2017
SCIEGEN PHARMS INC	EQ 5MG BASE;20MG	A209010	001	Dec 03, 2018
	EQ 5MG BASE;40MG	A209010	002	Dec 03, 2018
	EQ 10MG BASE;20MG	A209010	003	Dec 03, 2018
	EQ 10MG BASE;40MG	A209010	004	Dec 03, 2018
TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016
	EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016
	EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016
	EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016
TORRENT	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016
	EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016
	EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016
	EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMLODIPINE BESYLATE; TELMISARTAN				
TABLET;ORAL				
TELMISARTAN AND AMLODIPINE				
	ALEMBIC	EQ 5MG BASE;40MG	A205234 001	Nov 17, 2016
		EQ 5MG BASE;80MG	A205234 003	Nov 17, 2016
		EQ 10MG BASE;40MG	A205234 002	Nov 17, 2016
		EQ 10MG BASE;80MG	A205234 004	Nov 17, 2016
	TORRENT	EQ 5MG BASE;40MG	A202517 001	Jan 08, 2014
		EQ 5MG BASE;80MG	A202517 003	Jan 08, 2014
		EQ 10MG BASE;40MG	A202517 002	Jan 08, 2014
		EQ 10MG BASE;80MG	A202517 004	Jan 08, 2014
TWYNSTA				
+	BOEHRINGER INGELHEIM	EQ 5MG BASE;40MG **	N022401 001	Oct 16, 2009
+		EQ 5MG BASE;80MG **	N022401 003	Oct 16, 2009
+		EQ 10MG BASE;40MG **	N022401 002	Oct 16, 2009
+		EQ 10MG BASE;80MG **	N022401 004	Oct 16, 2009
AMLODIPINE BESYLATE; VALSARTAN				
TABLET;ORAL				
AMLODIPINE BESYLATE AND VALSARTAN				
	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235 001	Mar 30, 2015
		EQ 5MG BASE;320MG	A091235 003	Mar 30, 2015
		EQ 10MG BASE;160MG	A091235 002	Mar 30, 2015
		EQ 10MG BASE;320MG	A091235 004	Mar 30, 2015
	TORRENT	EQ 5MG BASE;160MG	A202377 001	Mar 30, 2015
		EQ 5MG BASE;320MG	A202377 002	Mar 30, 2015
		EQ 10MG BASE;160MG	A202377 003	Mar 30, 2015
		EQ 10MG BASE;320MG	A202377 004	Mar 30, 2015
AMLODIPINE MALEATE				
TABLET;ORAL				
AMVAZ				
	DR REDDYS LABS INC	2.5MG	N021435 001	Oct 31, 2003
		5MG	N021435 002	Oct 31, 2003
		10MG	N021435 003	Oct 31, 2003
AMMONIA N-13				
INJECTABLE;INTRAVENOUS				
AMMONIA N 13				
	CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539 001	Jun 23, 2015
	ESSENTIAL ISOTOPES	3.75mCi-260mCi/ML	A205687 001	Dec 17, 2015
	SHERTECH LABS LLC	3.75mCi-260mCi/ML	A204366 001	Sep 19, 2014
	SOFIE	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667 001	Apr 22, 2015
	UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933 001	Jun 27, 2014
	WISCONSIN	3.75mCi-260mCi/ML	A204356 001	Dec 18, 2014
AMMONIUM CHLORIDE				
INJECTABLE;INJECTION				
AMMONIUM CHLORIDE				
	ABBOTT	5MEQ/ML	A083130 001	
	GD SEARLE LLC	3MEQ/ML	A086205 001	
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE				
	MCGAW	900MG/100ML	N006580 001	
AMMONIUM CHLORIDE 2.14%				
	B BRAUN	40MEQ/100ML	A085734 001	
AMMONIUM LACTATE				
CREAM;TOPICAL				
AMMONIUM LACTATE				
	WATSON LABS INC	EQ 12% BASE	A076829 001	Feb 07, 2006
LAC-HYDRIN				
+	SUN PHARM INDS INC	EQ 12% BASE **	N020508 001	Aug 29, 1996
LOTION;TOPICAL				
AMMONIUM LACTATE				
	WATSON LABS INC	EQ 12% BASE	A075575 001	Jun 11, 2002
LAC-HYDRIN				
+	SUN PHARM INDS INC	EQ 12% BASE **	N019155 001	Apr 24, 1985

AMODIAQUINE HYDROCHLORIDE				
TABLET;ORAL				
CAMOQUIN HYDROCHLORIDE				
PARKE DAVIS	EQ 200MG BASE	N006441 001		
AMOXAPINE				
TABLET;ORAL				
AMOXAPINE				
CHARTWELL RX	25MG	A072943 001	Jun 28, 1991	
	50MG	A072944 001	Jun 28, 1991	
	100MG	A072878 001	Jun 28, 1991	
	150MG	A072879 001	Jun 28, 1991	
WATSON PHARMS TEVA	25MG	A072418 001	Aug 01, 1989	
	50MG	A072419 001	Aug 01, 1989	
	100MG	A072420 001	May 11, 1989	
	150MG	A072421 001	May 11, 1989	
ASENDIN				
LEDERLE	25MG	N018021 001		
	50MG	N018021 002		
	100MG	N018021 003		
	150MG	N018021 004		
AMOXICILLIN				
CAPSULE;ORAL				
AMOXICILLIN				
LABS ATRAL	250MG	A062528 001	Aug 07, 1985	
	500MG	A062528 002	Aug 07, 1985	
MYLAN	250MG	A062067 001		
	500MG	A062067 002		
STRIDES PHARMA	250MG	A062884 001	Feb 25, 1988	
	500MG	A062881 001	Feb 25, 1988	
SUN PHARM INDS LTD	250MG	A065016 001	Apr 08, 1999	
	500MG	A065016 002	Apr 08, 1999	
TEVA	250MG	A062853 001	Dec 22, 1987	
	250MG	A063030 001	Feb 28, 1989	
	500MG	A062854 001	Dec 22, 1987	
	500MG	A063031 001	Feb 28, 1989	
AMOXIL				
+ GLAXOSMITHKLINE	250MG **	N050459 001		
+	500MG **	N050459 002		
TRIMOX				
APOTHECON	250MG	A061885 001		
	250MG	A062098 001		
	250MG	A062152 001		
	250MG	A063099 001	Mar 20, 1992	
	500MG	A061885 002		
	500MG	A062098 002		
	500MG	A062152 002		
	500MG	A063099 002	Mar 20, 1992	
UTIMOX				
PARKE DAVIS	250MG	A062107 001		
	500MG	A062107 002		
WYMOX				
WYETH AYERST	250MG	A062120 001		
	500MG	A062120 002		
FOR SUSPENSION;ORAL				
AMOXICILLIN				
CHARTWELL RX	125MG/5ML	A062059 001		
	250MG/5ML	A062059 002		
MYLAN	125MG/5ML	A062090 001		
	250MG/5ML	A062090 002		
SUN PHARM INDS LTD	200MG/5ML	A065113 001	Nov 29, 2002	
	400MG/5ML	A065113 002	Nov 29, 2002	
TEVA	125MG/5ML	A061931 001		
	125MG/5ML	A062946 001	Nov 01, 1988	
	250MG/5ML	A063001 001	Jan 06, 1989	
AMOXIL				
+ GLAXOSMITHKLINE	50MG/ML **	N050460 005		
+	125MG/5ML **	N050460 001		
+	250MG/5ML **	N050460 002		

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMOXICILLIN					
FOR SUSPENSION;ORAL					
AMOXIL					
+	US ANTIBIOTICS	200MG/5ML **	N050760	001	Apr 15, 1999
+		400MG/5ML **	N050760	002	Apr 15, 1999
LAROTID					
+	GLAXOSMITHKLINE	50MG/ML **	N050460	006	
POLYMOX					
	APOTHECON	125MG/5ML	A061851	001	
		125MG/5ML	A062323	001	
		250MG/5ML	A061851	002	
		250MG/5ML	A062323	002	
TRIMOX					
	APOTHECON	50MG/ML	A061886	001	
		125MG/5ML	A061886	002	
		125MG/5ML	A062099	001	
		125MG/5ML	A062154	001	
		125MG/5ML	A062885	001	Mar 08, 1988
		250MG/5ML	A061886	003	
		250MG/5ML	A062099	002	
		250MG/5ML	A062154	002	
		250MG/5ML	A062885	002	Mar 08, 1988
UTIMOX					
	PARKE DAVIS	125MG/5ML	A062127	001	
		250MG/5ML	A062127	002	
WYMOX					
	WYETH AYERST	125MG/5ML	A062131	001	
		250MG/5ML	A062131	002	
TABLET;ORAL					
AMOXICILLIN					
	CHARTWELL RX	875MG	A065344	001	Jan 15, 2009
	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000
		875MG	A065059	002	Nov 24, 2000
AMOXIL					
+	US ANTIBIOTICS	500MG **	N050754	002	Jul 10, 1998
+		875MG **	N050754	001	Jul 10, 1998
TABLET, CHEWABLE;ORAL					
AMOXICILLIN					
	APOTHECON	125MG	A064131	001	May 06, 1996
		250MG	A064131	002	May 06, 1996
	CHARTWELL RX	125MG	A064139	001	Jan 29, 1996
		250MG	A064139	002	Jan 29, 1996
	HIKMA	125MG	A205274	001	Jun 25, 2020
		250MG	A205274	002	Jun 25, 2020
	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999
		200MG	A065060	001	Nov 29, 2000
		250MG	A065021	002	Dec 23, 1999
		400MG	A065060	002	Nov 29, 2000
	TEVA	125MG	A064031	001	Dec 19, 1996
		250MG	A064031	002	Dec 19, 1996
AMOXIL					
+	US ANTIBIOTICS	125MG **	N050542	002	
		200MG	N050761	001	Apr 15, 1999
+		250MG **	N050542	001	
		400MG	N050761	002	Apr 15, 1999
TABLET, EXTENDED RELEASE;ORAL					
MOXATAG					
+	PRAGMA	775MG	N050813	001	Jan 23, 2008
TABLET, FOR SUSPENSION;ORAL					
AMOXICILLIN					
	AUROBINDO PHARMA LTD	200MG	A065324	001	Jan 17, 2007
		400MG	A065324	002	Jan 17, 2007
DISPERMOX					
	RANBAXY LABS LTD	200MG	A065080	002	Aug 11, 2003
		400MG	A065080	001	Aug 11, 2003
		600MG	A065159	001	Dec 04, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL					
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)					
	ANI PHARMS	500MG;500MG;30MG	A200218	001	Aug 30, 2013
PREVPAC (COPACKAGED)					
+	TAKEDA PHARMS USA	500MG;500MG;30MG **	N050757	001	Dec 02, 1997

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL					
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN					
+	CUMBERLAND	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG **	N050824	001	Feb 08, 2011

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL					
AMOXICILLIN AND CLAVULANATE POTASSIUM					
	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003
		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003
		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007
AUGMENTIN '200'					
+	US ANTIBIOTICS	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996
AUGMENTIN '400'					
+	US ANTIBIOTICS	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996
TABLET;ORAL					
AMOXICILLIN AND CLAVULANATE POTASSIUM					
	APOTEX INC	250MG;EQ 125MG BASE	A065333	001	Feb 24, 2009
		500MG;EQ 125MG BASE	A065333	002	Feb 24, 2009
		875MG;EQ 125MG BASE	A065317	003	Oct 20, 2008
	SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002
		875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002
AUGMENTIN '250'					
+	US ANTIBIOTICS	250MG;EQ 125MG BASE **	N050564	001	Aug 06, 1984
AUGMENTIN '500'					
+	US ANTIBIOTICS	500MG;EQ 125MG BASE **	N050564	002	Aug 06, 1984
TABLET, CHEWABLE;ORAL					
AMOXICILLIN AND CLAVULANATE POTASSIUM					
	SANDOZ	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002
		400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002
	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003
		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003
AUGMENTIN '125'					
+	US ANTIBIOTICS	125MG;EQ 31.25MG BASE **	N050597	001	Jul 22, 1985
AUGMENTIN '200'					
+	US ANTIBIOTICS	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996
AUGMENTIN '250'					
+	US ANTIBIOTICS	250MG;EQ 62.5MG BASE **	N050597	002	Jul 22, 1985
AUGMENTIN '400'					
+	US ANTIBIOTICS	400MG;EQ 57MG BASE	N050726	002	May 31, 1996
TABLET, EXTENDED RELEASE;ORAL					
AUGMENTIN XR					
+	US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL					
ADZENYS ER					
+	NEOS THERAPS INC	EQ 1.25MG BASE/ML	N204325	001	Sep 15, 2017
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL					
AMPHETAMINE					
	ACTAVIS LABS FL INC	EQ 3.1MG BASE	A209253	001	Jun 22, 2023
		EQ 6.3MG BASE	A209253	002	Jun 22, 2023
		EQ 9.4MG BASE	A209253	003	Jun 22, 2023
		EQ 12.5MG BASE	A209253	004	Jun 22, 2023
		EQ 15.7MG BASE	A209253	005	Jun 22, 2023
		EQ 18.8MG BASE	A209253	006	Jun 22, 2023

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE;ORAL				
DELCOBESE				
	TEVA	1.25MG;1.25MG;1.25MG;1.25MG **	A083564 001	
		2.5MG;2.5MG;2.5MG;2.5MG **	A083564 002	
		3.75MG;3.75MG;3.75MG;3.75MG **	A083564 003	
		5MG;5MG;5MG;5MG **	A083564 004	
TABLET;ORAL				
DELCOBESE				
	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A083563 004	
		2.5MG;2.5MG;2.5MG;2.5MG	A083563 003	
		3.75MG;3.75MG;3.75MG;3.75MG	A083563 002	
		5MG;5MG;5MG;5MG	A083563 001	

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL				
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE				
	AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211876 001	Jun 24, 2020
		2.5MG;2.5MG;2.5MG;2.5MG	A211876 002	Jun 24, 2020
		3.75MG;3.75MG;3.75MG;3.75MG	A211876 003	Jun 24, 2020
		5MG;5MG;5MG;5MG	A211876 004	Jun 24, 2020
		6.25MG;6.25MG;6.25MG;6.25MG	A211876 005	Jun 24, 2020
		7.5MG;7.5MG;7.5MG;7.5MG	A211876 006	Jun 24, 2020
	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210080 001	Jul 17, 2019
		2.5MG;2.5MG;2.5MG;2.5MG	A210080 002	Jul 17, 2019
		3.75MG;3.75MG;3.75MG;3.75MG	A210080 003	Jul 17, 2019
		5MG;5MG;5MG;5MG	A210080 004	Jul 17, 2019
		6.25MG;6.25MG;6.25MG;6.25MG	A210080 005	Jul 17, 2019
		7.5MG;7.5MG;7.5MG;7.5MG	A210080 006	Jul 17, 2019
	PAR PHARM INC	1.25MG;1.25MG;1.25MG;1.25MG	A206159 001	May 31, 2019
		2.5MG;2.5MG;2.5MG;2.5MG	A206159 002	May 31, 2019
		3.75MG;3.75MG;3.75MG;3.75MG	A206159 003	May 31, 2019
		5MG;5MG;5MG;5MG	A206159 004	May 31, 2019
		6.25MG;6.25MG;6.25MG;6.25MG	A206159 005	May 31, 2019
		7.5MG;7.5MG;7.5MG;7.5MG	A206159 006	May 31, 2019
	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488 001	Apr 29, 2013
		2.5MG;2.5MG;2.5MG;2.5MG	A077488 002	Apr 29, 2013
		3.75MG;3.75MG;3.75MG;3.75MG	A077488 003	Apr 29, 2013
		5MG;5MG;5MG;5MG	A077488 004	Apr 29, 2013
		6.25MG;6.25MG;6.25MG;6.25MG	A077488 005	Apr 29, 2013
		7.5MG;7.5MG;7.5MG;7.5MG	A077488 006	Apr 29, 2013
DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE				
	BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A076536 001	Feb 12, 2013
		2.5MG;2.5MG;2.5MG;2.5MG	A076536 002	Feb 12, 2013
		3.75MG;3.75MG;3.75MG;3.75MG	A076536 003	Feb 12, 2013
		5MG;5MG;5MG;5MG	A076536 004	Feb 12, 2013
		6.25MG;6.25MG;6.25MG;6.25MG	A076536 005	Feb 12, 2013
		7.5MG;7.5MG;7.5MG;7.5MG	A076536 006	Feb 12, 2013
TABLET;ORAL				
ADDERALL 10				
+	TEVA WOMENS	2.5MG;2.5MG;2.5MG;2.5MG **	N011522 007	Feb 13, 1996
ADDERALL 12.5				
+	TEVA WOMENS	3.125MG;3.125MG;3.125MG;3.125MG **	N011522 012	Aug 31, 2000
ADDERALL 15				
+	TEVA WOMENS	3.75MG;3.75MG;3.75MG;3.75MG **	N011522 013	Aug 31, 2000
ADDERALL 20				
+	TEVA WOMENS	5MG;5MG;5MG;5MG **	N011522 008	Feb 13, 1996
ADDERALL 30				
+	TEVA WOMENS	7.5MG;7.5MG;7.5MG;7.5MG **	N011522 010	May 12, 1997
ADDERALL 5				
+	TEVA WOMENS	1.25MG;1.25MG;1.25MG;1.25MG **	N011522 009	May 12, 1997
ADDERALL 7.5				
+	TEVA WOMENS	1.875MG;1.875MG;1.875MG;1.875MG **	N011522 011	Aug 31, 2000
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE				
	ACCORD HLTHCARE	1.25MG;1.25MG;1.25MG;1.25MG	A214347 001	Nov 22, 2021
		1.875MG;1.875MG;1.875MG;1.875MG	A214347 002	Nov 22, 2021
		2.5MG;2.5MG;2.5MG;2.5MG	A214347 003	Nov 22, 2021
		3.125MG;3.125MG;3.125MG;3.125MG	A214347 004	Nov 22, 2021
		3.75MG;3.75MG;3.75MG;3.75MG	A214347 005	Nov 22, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

		5MG;5MG;5MG;5MG	A214347	006	Nov 22, 2021
		7.5MG;7.5MG;7.5MG;7.5MG	A214347	007	Nov 22, 2021
	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May 06, 2003
		2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May 06, 2003
		5MG;5MG;5MG;5MG	A040456	003	May 06, 2003
		7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May 06, 2003
	CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022
		2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022
		3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022
		5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022
		7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022
	MYLAN	1.25MG;1.25MG;1.25MG;1.25MG	A206721	001	Nov 10, 2015
		1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov 10, 2015
		2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov 10, 2015
		3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov 10, 2015
		3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov 10, 2015
		5MG;5MG;5MG;5MG	A206721	006	Nov 10, 2015
		7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov 10, 2015
	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472	001	Sep 30, 2003
		2.5MG;2.5MG;2.5MG;2.5MG	A040472	002	Sep 30, 2003
		5MG;5MG;5MG;5MG	A040472	003	Sep 30, 2003
		7.5MG;7.5MG;7.5MG;7.5MG	A040472	004	Sep 30, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL

BIPHETAMINE 12.5

	UCB INC	EQ 6.25MG BASE;EQ 6.25MG BASE	N010093	007

BIPHETAMINE 20

	UCB INC	EQ 10MG BASE;EQ 10MG BASE	N010093	003

BIPHETAMINE 7.5

	UCB INC	EQ 3.75MG BASE;EQ 3.75MG BASE	N010093	009

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

	DR REDDYS LABS SA	5MG	A213898	001	Jul 14, 2020
		10MG	A213898	002	Jul 14, 2020
	GLENMARK PHARMS LTD	5MG	A212186	001	Jan 27, 2021
		10MG	A212186	002	Jan 27, 2021
+	LANNETT	5MG	A083901	001	Aug 31, 1984
+		10MG	A083901	002	Aug 31, 1984
	NOVAST LABS	5MG	A213763	001	Aug 24, 2020
		10MG	A213763	002	Aug 24, 2020

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+	AZURITY	2.5MG **	N209905	005	Apr 16, 2021

AMPHOTERICIN B

CREAM;TOPICAL

FUNGIZONE

	APOTHECON	3%	N050314	001

INJECTABLE;INJECTION

AMPHOTERICIN B

	ABBOTT	50MG/VIAL	A064141	001	Dec 23, 1996
	ABRAXIS PHARM	50MG/VIAL	A062728	001	Apr 13, 1987
	TEVA PARENTERAL	50MG/VIAL	A064062	001	Mar 31, 1995

FUNGIZONE

	APOTHECON	50MG/VIAL	A060517	001

INJECTABLE, LIPID COMPLEX;INJECTION

AMPHOTEC

	ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996
		100MG/VIAL	N050729	002	Nov 22, 1996

LOTION;TOPICAL

FUNGIZONE

	APOTHECON	3%	A060570	001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPHOTERICIN B				
OINTMENT;TOPICAL				
FUNGIZONE				
APOTHECON	3%	N050313	001	
SUSPENSION;ORAL				
FUNGIZONE				
BRISTOL MYERS SQUIBB	100MG/ML	N050341	003	
AMPICILLIN SODIUM				
INJECTABLE;INJECTION				
AMPICILLIN SODIUM				
ACS DOBFAR SPA	EQ 500MG BASE/VIAL	A090884	001	Apr 03, 2013
	EQ 1GM BASE/VIAL	A090884	002	Apr 03, 2013
	EQ 2GM BASE/VIAL	A090884	003	Apr 03, 2013
APOTHECON	EQ 125MG BASE/VIAL	A062860	001	Feb 05, 1988
	EQ 250MG BASE/VIAL	A062860	002	Feb 05, 1988
	EQ 500MG BASE/VIAL	A062860	003	Feb 05, 1988
	EQ 1GM BASE/VIAL	A062860	004	Feb 05, 1988
	EQ 2GM BASE/VIAL	A062860	005	Feb 05, 1988
CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	A061936	005	
	EQ 250MG BASE/VIAL	A061936	001	
	EQ 500MG BASE/VIAL	A061936	002	
	EQ 1GM BASE/VIAL	A061936	003	
	EQ 2GM BASE/VIAL	A061936	004	
EUGIA PHARMA SPECLTS	EQ 125MG BASE/VIAL	A065499	001	Aug 17, 2010
HIKMA	EQ 125MG BASE/VIAL	A062692	001	Jun 24, 1986
	EQ 250MG BASE/VIAL	A062692	002	Jun 24, 1986
	EQ 500MG BASE/VIAL	A062692	003	Jun 24, 1986
	EQ 1GM BASE/VIAL	A062692	004	Jun 24, 1986
	EQ 2GM BASE/VIAL	A062692	005	Jun 24, 1986
	EQ 10GM BASE/VIAL	A062692	006	Jun 24, 1986
HOSPIRA	EQ 250MG BASE/VIAL	A202864	001	Sep 04, 2015
	EQ 500MG BASE/VIAL	A202864	002	Sep 04, 2015
	EQ 1GM BASE/VIAL	A202864	003	Sep 04, 2015
	EQ 2GM BASE/VIAL	A202864	004	Sep 04, 2015
	EQ 10GM BASE/VIAL	A202865	001	Sep 04, 2015
HQ SPECLT PHARMA	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993
	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993
	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993
	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993
INTL MEDICATION	EQ 1GM BASE/VIAL	A062634	002	Jan 09, 1987
	EQ 2GM BASE/VIAL	A062634	003	Jan 09, 1987
ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993
LILLY	EQ 500MG BASE/VIAL	A062565	001	Apr 04, 1985
	EQ 1GM BASE/VIAL	A062565	002	Apr 04, 1985
	EQ 2GM BASE/VIAL	A062565	003	Jun 24, 1986
STERISCIENCE	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014
	EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014
WATSON LABS INC	EQ 125MG BASE/VIAL	A062816	001	Oct 24, 1988
	EQ 250MG BASE/VIAL	A062816	002	Oct 24, 1988
	EQ 500MG BASE/VIAL	A062816	003	Oct 24, 1988
	EQ 1GM BASE/VIAL	A062816	004	Oct 24, 1988
	EQ 2GM BASE/VIAL	A062816	005	Oct 24, 1988
	EQ 10GM BASE/VIAL	A062994	001	Sep 15, 1988
OMNIPEN-N				
WYETH AYERST	EQ 125MG BASE/VIAL	A060626	001	
	EQ 125MG BASE/VIAL	A062718	001	Dec 16, 1986
	EQ 250MG BASE/VIAL	A060626	002	
	EQ 250MG BASE/VIAL	A062718	002	Dec 16, 1986
	EQ 500MG BASE/VIAL	A060626	003	
	EQ 500MG BASE/VIAL	A062718	003	Dec 16, 1986
	EQ 1GM BASE/VIAL	A060626	004	
	EQ 1GM BASE/VIAL	A062718	004	Dec 16, 1986
	EQ 2GM BASE/VIAL	A060626	005	
	EQ 2GM BASE/VIAL	A062718	005	Dec 16, 1986
PENBRITIN-S				
+ WYETH AYERST	EQ 125MG BASE/VIAL **	N050072	001	
+	EQ 250MG BASE/VIAL **	N050072	002	
+	EQ 500MG BASE/VIAL **	N050072	003	
+	EQ 1GM BASE/VIAL **	N050072	004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPICILLIN SODIUM				
INJECTABLE;INJECTION				
PENBRITIN-S				
+	EQ 2GM BASE/VIAL **	N050072	005	
+	EQ 4GM BASE/VIAL **	N050072	006	
POLYCILLIN-N				
BRISTOL	EQ 125MG BASE/VIAL **	N050309	001	
	EQ 250MG BASE/VIAL **	N050309	002	
	EQ 500MG BASE/VIAL **	N050309	003	
	EQ 1GM BASE/VIAL **	N050309	004	
	EQ 2GM BASE/VIAL **	N050309	005	
TOTACILLIN-N				
GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	A060677	001	
	EQ 250MG BASE/VIAL	A060677	002	
	EQ 500MG BASE/VIAL	A060677	003	
	EQ 1GM BASE/VIAL	A060677	004	
	EQ 1GM BASE/VIAL	A062727	001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A060677	005	
	EQ 2GM BASE/VIAL	A062727	002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A060677	006	
AMPICILLIN SODIUM; SULBACTAM SODIUM				
INJECTABLE;INJECTION				
AMPICILLIN AND SULBACTAM				
EUGIA PHARMA SPECLTS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340	001	Sep 20, 2010
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340	002	Sep 20, 2010
HOSPIRA INC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090375	001	Dec 21, 2011
	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090653	001	Dec 21, 2011
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090375	002	Dec 21, 2011
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090653	002	Dec 21, 2011
	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090646	001	Dec 21, 2011
PHARM ASSOC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007
UNASYN				
PFIZER	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A062901	002	Feb 27, 1992
	EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL	N050608	003	Dec 31, 1986
	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A062901	001	Nov 23, 1988
AMPICILLIN/AMPICILLIN TRIHYDRATE				
CAPSULE;ORAL				
AMCILL				
PARKE DAVIS	EQ 250MG BASE	A062041	001	
	EQ 500MG BASE	A062041	002	
AMPICILLIN TRIHYDRATE				
BELCHER PHARMS	EQ 250MG BASE	A061602	001	
	EQ 500MG BASE	A061602	002	
CHARTWELL RX	EQ 250MG BASE	A061502	001	
	EQ 500MG BASE	A061502	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A060765	001	
	EQ 500MG BASE	A060765	002	
LEDERLE	EQ 250MG BASE	A062208	001	
	EQ 500MG BASE	A062208	002	
MYLAN	EQ 250MG BASE	A061755	001	
	EQ 500MG BASE	A061755	002	
PUREPAC PHARM	EQ 250MG BASE	A061853	001	
	EQ 500MG BASE	A061853	002	
SANDOZ	EQ 250MG BASE	A064082	001	Aug 29, 1995
STRIDES PHARMA	EQ 250MG BASE	A062883	001	Feb 25, 1988
	EQ 500MG BASE	A062882	001	Feb 25, 1988
VITARINE	EQ 250MG BASE	A061387	001	
	EQ 500MG BASE	A061387	003	
OMNIPEN (AMPICILLIN)				
WYETH AYERST	250MG	A060624	001	
	500MG	A060624	002	
PENBRITIN				
WYETH AYERST	EQ 250MG BASE	A060908	001	
	EQ 500MG BASE	A060908	002	
PFIZERPEN-A				
PFIZER	EQ 250MG BASE	A062050	001	
	EQ 500MG BASE	A062050	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL				
POLYCILLIN				
BRISTOL	EQ 250MG BASE		N050310 001	
	EQ 500MG BASE		N050310 002	
PRINCIPEN				
APOTHECON	EQ 250MG BASE		A062888 001	Mar 04, 1988
	EQ 500MG BASE		A062888 002	Mar 04, 1988
BRISTOL MYERS SQUIBB	EQ 250MG BASE		A061392 001	
	EQ 500MG BASE		A061392 002	
PRINCIPEN '250'				
APOTHECON	EQ 250MG BASE		A062157 002	
+	EQ 250MG BASE		N050056 001	
PRINCIPEN '500'				
APOTHECON	EQ 500MG BASE		A062157 001	
+	EQ 500MG BASE		N050056 002	
TOTACILLIN				
GLAXOSMITHKLINE	EQ 250MG BASE		A060060 001	
	EQ 250MG BASE		A062212 001	
	EQ 500MG BASE		A060060 002	
	EQ 500MG BASE		A062212 002	
FOR SUSPENSION;ORAL				
AMCILL				
PARKE DAVIS	EQ 125MG BASE/5ML		A062030 001	
	EQ 250MG BASE/5ML		A062030 002	
AMPICILLIN TRIHYDRATE				
BELCHER PHARMS	EQ 125MG BASE/5ML		A061601 001	
	EQ 250MG BASE/5ML		A061601 002	
DAVA PHARMS INC	EQ 125MG BASE/5ML		A062982 001	Feb 10, 1989
	EQ 250MG BASE/5ML		A062982 002	Feb 10, 1989
MYLAN	EQ 125MG BASE/5ML		A061829 002	
	EQ 250MG BASE/5ML		A061829 001	
PUREPAC PHARM	EQ 125MG BASE/5ML		A061980 001	
	EQ 250MG BASE/5ML		A061980 002	
TEVA	EQ 125MG BASE/5ML		A061370 001	
	EQ 250MG BASE/5ML		A061370 002	
OMNIPEN (AMPICILLIN)				
WYETH AYERST	100MG/ML		A060625 001	
	125MG/5ML		A060625 002	
	250MG/5ML		A060625 003	
	500MG/5ML		A060625 004	
PENBRITIN				
WYETH AYERST	EQ 100MG BASE/ML		N050019 001	
	EQ 125MG BASE/5ML		N050019 002	
	EQ 250MG BASE/5ML		N050019 003	
PFIZERPEN-A				
PFIZER	EQ 125MG BASE/5ML		A062049 001	
	EQ 250MG BASE/5ML		A062049 002	
POLYCILLIN				
APOTHECON	EQ 125MG BASE/5ML		A062297 001	
	EQ 250MG BASE/5ML		A062297 002	
BRISTOL	EQ 100MG BASE/ML		N050308 004	
	EQ 125MG BASE/5ML		N050308 001	
	EQ 250MG BASE/5ML		N050308 002	
	EQ 500MG BASE/5ML		N050308 003	
PRINCIPEN				
APOTHECON	EQ 100MG BASE/ML		A061394 001	
	EQ 125MG BASE/5ML		A061394 002	
	EQ 250MG BASE/5ML		A061394 003	
PRINCIPEN '125'				
APOTHECON	EQ 125MG BASE/5ML		A060127 002	
	EQ 125MG BASE/5ML		A062151 001	
PRINCIPEN '250'				
APOTHECON	EQ 250MG BASE/5ML		A060127 001	
	EQ 250MG BASE/5ML		A062151 002	
TOTACILLIN				
GLAXOSMITHKLINE	EQ 125MG BASE/5ML		A060666 001	
	EQ 125MG BASE/5ML		A062223 001	
	EQ 250MG BASE/5ML		A060666 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION;ORAL

TOTACILLIN

	EQ 250MG BASE/5ML		A062223	002

TABLET, CHEWABLE;ORAL

POLYCILLIN

BRISTOL	EQ 125MG BASE		N050093	001

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE;ORAL

PRINCIPEN W/ PROBENECID

APOTHECON	EQ 389MG BASE;111MG		A062150	001
	EQ 389MG BASE;111MG		N050488	001

FOR SUSPENSION;ORAL

POLYCILLIN-PRB

APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT		A061898	001
BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT		N050457	001

PROBAMPACIN

COSETTE	EQ 3.5GM BASE/BOT;1GM/BOT		A061741	001

AMPRENAVIR

CAPSULE;ORAL

AGENERASE

GLAXOSMITHKLINE	50MG		N021007	001 Apr 15, 1999
	150MG		N021007	002 Apr 15, 1999

SOLUTION;ORAL

AGENERASE

+ GLAXOSMITHKLINE	15MG/ML **		N021039	001 Apr 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

AGRYLIN

+ TAKEDA PHARMS USA	EQ 1MG BASE **		N020333	002 Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

BARR	EQ 0.5MG BASE		A076530	001 Apr 18, 2005
	EQ 1MG BASE		A076530	002 Apr 18, 2005
CHARTWELL RX	EQ 0.5MG BASE		A076683	001 Apr 18, 2005
	EQ 1MG BASE		A076683	002 Apr 18, 2005
NATCO PHARMA USA	EQ 0.5MG BASE		A076811	001 Apr 18, 2005
	EQ 1MG BASE		A076811	002 Apr 18, 2005
RISING	EQ 0.5MG BASE		A077613	001 Jun 27, 2006
	EQ 1MG BASE		A077613	002 Jun 27, 2006
ROXANE	EQ 0.5MG BASE		A076489	001 Apr 18, 2005
	EQ 1MG BASE		A076489	002 Apr 18, 2005
WATSON LABS	EQ 0.5MG BASE		A076417	001 Apr 18, 2005
	EQ 1MG BASE		A076417	002 Apr 18, 2005

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

APOTEX INC	1MG		A200654	001 May 11, 2012
CHARTWELL MOLECULAR	1MG		A091331	001 Jan 05, 2011
CHARTWELL RX	1MG		A090732	001 Jun 28, 2010
FRESENIUS KABI USA	1MG		A090088	001 Jun 28, 2010
HIKMA	1MG		A078485	001 Jun 28, 2010
IMPAX LABS INC	1MG		A091242	001 May 31, 2012
MYLAN	1MG		A091051	001 Jun 28, 2010
SANDOZ	1MG		A079007	001 Jun 28, 2010
SUN PHARM INDS LTD	1MG		A091177	001 Jul 15, 2011
SYNTHON PHARMS	1MG		A078322	001 Jun 28, 2010
WATSON LABS TEVA	1MG		A078984	001 Jun 28, 2010

ANGIOTENSIN II ACETATE

SOLUTION;INTRAVENOUS

GIAPREZA

+ LA JOLLA PHARMA	EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)		N209360	002 Dec 21, 2017

ANILERIDINE HYDROCHLORIDE
TABLET;ORAL
LERITINE
MERCK EQ 25MG BASE N010585 002

ANILERIDINE PHOSPHATE
INJECTABLE;INJECTION
LERITINE
MERCK 25MG/ML N010520 003

ANISINDIONE
TABLET;ORAL
MIRADON
SCHERING 50MG N010909 003

ANISOTROPINE METHYLBROMIDE
TABLET;ORAL
ANISOTROPINE METHYLBROMIDE
WATSON LABS 50MG A086046 001
VALPIN 50
ENDO PHARMS 50MG N013428 001

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
VASOCON-A
NOVARTIS 0.5%;0.05% N018746 002 Jul 11, 1994

APIXABAN
TABLET;ORAL
APIXABAN

AUROBINDO PHARMA LTD	2.5MG	A210026	001	May 26, 2023
	5MG	A210026	002	May 26, 2023
BIONPHARMA	2.5MG	A210152	001	Apr 08, 2020
	5MG	A210152	002	Apr 08, 2020
BRECKENRIDGE	2.5MG	A209845	001	Jul 26, 2021
	5MG	A209845	002	Jul 26, 2021
MICRO LABS	2.5MG	A210013	001	Dec 23, 2019
	5MG	A210013	002	Dec 23, 2019
MYLAN	2.5MG	A210128	001	Dec 23, 2019
	5MG	A210128	002	Dec 23, 2019
ZYDUS PHARMS	2.5MG	A210185	001	Feb 27, 2023
	5MG	A210185	002	Feb 27, 2023

APOMORPHINE HYDROCHLORIDE
FILM;SUBLINGUAL
KYNMOBI

+ SUMITOMO PHARMA AM	10MG	N210875	001	May 21, 2020
+	15MG	N210875	002	May 21, 2020
+	20MG	N210875	003	May 21, 2020
+	25MG	N210875	004	May 21, 2020
+	30MG	N210875	005	May 21, 2020

INJECTABLE;SUBCUTANEOUS
APOKYN
MDD US 20MG/2ML (10MG/ML) N021264 001 Apr 20, 2004

APREMILAST
TABLET;ORAL
APREMILAST

AMNEAL	10MG	A211782	001	Jun 30, 2021
	20MG	A211782	002	Jun 30, 2021
	30MG	A211782	003	Jun 30, 2021
AUROBINDO PHARMA LTD	10MG	A211716	001	Jul 19, 2023
	20MG	A211716	002	Jul 19, 2023
	30MG	A211716	003	Jul 19, 2023
DR REDDYS	10MG	A211756	001	Jul 14, 2023
	20MG	A211756	002	Jul 14, 2023
	30MG	A211756	003	Jul 14, 2023
TEVA PHARMS USA INC	10MG	A211897	001	Aug 18, 2022
	20MG	A211897	002	Aug 18, 2022
	30MG	A211897	003	Aug 18, 2022
UNICHEM	10MG	A211819	001	Feb 17, 2021
	20MG	A211819	002	Feb 17, 2021
	30MG	A211819	003	Feb 17, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

APREPITANT					
CAPSULE;ORAL					
EMEND					
+	MERCK	40MG **	N021549	003	Jun 30, 2006
ARBUTAMINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
GENESA					
	GENSIA AUTOMEDICS	0.05MG/ML	N020420	001	Sep 12, 1997
ARDEPARIN SODIUM					
INJECTABLE;INJECTION					
NORMIFLO					
+	PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML **	N020227	002	May 23, 1997
+		10,000 UNITS/0.5ML **	N020227	001	May 23, 1997
ARFORMOTEROL TARTRATE					
SOLUTION;INHALATION					
ARFORMOTEROL TARTRATE					
	GLENMARK PHARMS LTD	EQ 0.015MG BASE/2ML	A213132	001	Jun 22, 2021
ARGATROBAN					
INJECTABLE;INJECTION					
ARGATROBAN					
+	SANDOZ	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000
INJECTABLE;INTRAVENOUS					
ARGATROBAN IN 0.9% SODIUM CHLORIDE					
	TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014
ARGATROBAN IN SODIUM CHLORIDE					
+	CIPLA	50MG/50ML (1MG/ML) **	N022434	001	Jun 29, 2011
SOLUTION;INTRAVENOUS					
ARGATROBAN IN DEXTROSE					
	SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011
ARIPIPRAZOLE					
INJECTABLE;INTRAMUSCULAR					
ABILIFY					
	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006
SOLUTION;ORAL					
ABILIFY					
+	OTSUKA	1MG/ML **	N021713	001	Dec 10, 2004
TABLET;ORAL					
ARIPIPRAZOLE					
	MYLAN	2MG	A206240	001	Sep 19, 2018
		5MG	A206240	002	Sep 19, 2018
		10MG	A206240	003	Sep 19, 2018
		15MG	A206240	004	Sep 19, 2018
		20MG	A206240	005	Sep 19, 2018
		30MG	A206240	006	Sep 19, 2018
	TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015
		5MG	A078607	002	Apr 28, 2015
		10MG	A078608	001	Apr 28, 2015
		15MG	A078708	001	Apr 28, 2015
		20MG	A078708	002	Apr 28, 2015
		30MG	A078708	003	Apr 28, 2015
	ZYDUS PHARMS	2MG	A090472	001	Jan 07, 2019
		5MG	A090472	002	Jan 07, 2019
		10MG	A090472	003	Jan 07, 2019
		15MG	A090472	004	Jan 07, 2019
		20MG	A090472	005	Jan 07, 2019
		30MG	A090472	006	Jan 07, 2019
TABLET, ORALLY DISINTEGRATING;ORAL					
ABILIFY					
+	OTSUKA	10MG **	N021729	002	Jun 07, 2006
+		15MG **	N021729	003	Jun 07, 2006
+		20MG **	N021729	004	Jun 07, 2006
+		30MG **	N021729	005	Jun 07, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ARMODAFINIL

TABLET;ORAL					
ARMODAFINIL					
	COREPHARMA	50MG	A201514	001	Mar 25, 2019
		150MG	A201514	002	Mar 25, 2019
		250MG	A201514	003	Mar 25, 2019
	WATSON LABS INC	100MG	A200156	002	Aug 29, 2012
		200MG	A200156	004	Aug 29, 2012
NUVIGIL					
+	CEPHALON	100MG **	N021875	002	Mar 26, 2009

ARSENIC TRIOXIDE

INJECTABLE;INJECTION					
ARSENIC TRIOXIDE					
	INGENUS PHARMS LLC	2MG/ML	A209315	002	Jan 14, 2021
TRISENOX					
+	CEPHALON	1MG/ML **	N021248	001	Sep 25, 2000

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION					
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE					
	HOSPIRA	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	A079138	001	Jun 18, 2010
ULTACAN					
	HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751	001	Jul 11, 2017
ULTACAN FORTE					
	HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION;INTRAVENOUS					
M.V.I. PEDIATRIC					
+	HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N018920	001	Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION					
BEROCCA PN					
	ROCHE	50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML;100 IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;	N006071	003	Oct 10, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION					
M.V.C. 9+3					
	ABRAXIS PHARM	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018440	002	Aug 08, 1985
M.V.I.-12 ADULT					
	HOSPIRA	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N008809	004	Aug 08, 1985
+		20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML	N008809	006	Sep 09, 2004
MVC PLUS					
	WATSON LABS	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018439	002	Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE;INTRAVENOUS					
M.V.I. ADULT					
+	HOSPIRA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N021625	001	Jan 30, 2004
M.V.I. ADULT (PHARMACY BULK PACKAGE)					
+	HOSPIRA	200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML	N021643	001	Feb 18, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION					
M.V.I.-12 ADULT					
	HOSPIRA	20MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/M	N008809	005	Apr 22, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION					
M.V.I.-12 LYOPHILIZED					
	TELIGENT	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION					
VITAPED					
	HOSPIRA	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A,0.001MG/VIAL;400 IU/10ML,N/A;N/A,0.14MG/VIAL;N/A,17MG/VIAL;N/A,5MG/VIAL;0.2MG/10ML,N/A;N/A,1MG/VIAL;N/A,1.4MG/VIAL;N/A,1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML,N/A;7 IU/10ML,N/A	N020176	001	Dec 29, 1993

ASPIRIN

CAPSULE, EXTENDED RELEASE;ORAL					
DURLAZA					
+	HESP	162.5MG	N200671	001	Sep 04, 2015
TABLET;ORAL					
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN					
	BAYER	500MG	N021317	001	Oct 18, 2001
TABLET, EXTENDED RELEASE;ORAL					
8-HOUR BAYER					
	BAYER	650MG	N016030	001	
MEASURIN					
	BAYER	650MG	N016030	002	

ASPIRIN; BUTALBITAL

TABLET;ORAL					
AXOTAL					
	SAVAGE LABS	650MG;50MG	A088305	001	Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL					
BUTALBITAL, ASPIRIN AND CAFFEINE					
	LGM PHARMA	500MG;50MG;40MG	A205230	001	Oct 18, 2021
	WATSON LABS	325MG;50MG;40MG	A086231	002	Feb 12, 1985
FIORINAL					
+	ALLERGAN	325MG;50MG;40MG **	N017534	005	Apr 16, 1986
TABLET;ORAL					
BUTALBITAL, ASPIRIN AND CAFFEINE					
	ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710	002	Aug 23, 1983
	FOSUN PHARMA	325MG;50MG;40MG	A086398	002	Apr 06, 1984
	HALSEY	325MG;50MG;40MG	A089448	001	Dec 01, 1986
+	HIKMA INTL PHARMS	325MG;50MG;40MG	A086162	002	Feb 16, 1984
	IVAX PHARMS	325MG;50MG;40MG	A085441	002	Oct 31, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

	PURACAP PHARM	325MG;50MG;40MG	A087048	002	Dec 09, 1983
	QUANTUM PHARMICS	325MG;50MG;40MG	A088972	001	Jun 18, 1985
	WATSON LABS	325MG;50MG;40MG	A086237	002	Mar 23, 1984

FIORINAL

+	ALLERGAN	325MG;50MG;40MG **	N017534	003	Apr 16, 1986

LANORINAL

	LANNETT	325MG;50MG;40MG	A086986	002	Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

	DR REDDYS LABS SA	325MG;50MG;40MG;30MG	A203335	001	Oct 30, 2015
	STRIDES PHARMA	325MG;50MG;40MG;30MG	A075351	001	Mar 05, 1999
	WATSON LABS	325MG;50MG;40MG;30MG	A074359	001	Aug 31, 1995

FIORINAL W/CODEINE

+	ALLERGAN	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

SYNALGOS-DC

+	SUN PHARM INDUSTRIES	356.4MG;30MG;16MG	N011483	004	Sep 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

INVAGESIC

	SANDOZ	385MG;30MG;25MG	A074817	001	Nov 27, 1996

INVAGESIC FORTE

	SANDOZ	770MG;60MG;50MG	A074817	002	Nov 27, 1996

NORGESIC

+	BAUSCH	385MG;30MG;25MG **	N013416	003	Oct 27, 1982

NORGESIC FORTE

+	BAUSCH	770MG;60MG;50MG **	N013416	004	Oct 27, 1982

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

	SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996
		770MG;60MG;50MG	A074654	002	Dec 31, 1996
	STEVENS J	385MG;30MG;25MG	A074988	001	Apr 30, 1999
		770MG;60MG;50MG	A074988	002	Apr 30, 1999

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL

COMPOUND 65

	ALRA	389MG;32.4MG;65MG	A084553	002	Aug 17, 1983

DARVON COMPOUND

	XANODYNE PHARM	389MG;32.4MG;32MG	N010996	006	Mar 08, 1983

DARVON COMPOUND-65

	XANODYNE PHARM	389MG;32.4MG;65MG	N010996	007	Mar 08, 1983

PROPOXYPHENE COMPOUND 65

	IVAX SUB TEVA PHARMS	389MG;32.4MG;65MG	A083077	002	Dec 07, 1984
+	SANDOZ	389MG;32.4MG;65MG	A080044	002	Sep 16, 1983
	TEVA	389MG;32.4MG;65MG	A089025	001	Mar 29, 1985

PROPOXYPHENE COMPOUND-65

	SANDOZ	389MG;32.4MG;65MG	A083101	002	Jun 24, 1985

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE

	WATSON LABS	389MG;32.4MG;65MG	A085732	002	Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

	CHARTWELL RX	325MG;200MG	A089594	001	Mar 31, 1989
	NOVAST LABS	325MG;200MG	A040832	001	Jan 07, 2010
	OXFORD PHARMS	325MG;200MG	A040252	001	Dec 10, 1997
	SANDOZ	325MG;200MG	A040116	001	Apr 25, 1996

CARISOPRODOL COMPOUND

	WATSON LABS	325MG;200MG	A088809	001	Oct 03, 1985

SOMA COMPOUND

	MEDA PHARMS	325MG;200MG **	N012365	005	Jul 11, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL					
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE					
	INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010
	OXFORD PHARMS	325MG;200MG;16MG	A040283	001	Dec 29, 1998
	SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996
SOMA COMPOUND W/ CODEINE					
	MEDA PHARMS	325MG;200MG;16MG **	N012366	002	Jul 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL					
AGGRENOX					
+	BOEHRINGER INGELHEIM	25MG;200MG **	N020884	001	Nov 22, 1999
ASPIRIN AND DIPYRIDAMOLE					
	ANI PHARMS	25MG;200MG	A206964	001	Jan 18, 2017
	CHARTWELL MOLECULAR	25MG;200MG	A204552	001	Mar 20, 2019
	SUN PHARM	25MG;200MG	A208572	001	Aug 21, 2018

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL					
AZDONE					
	SCHWARZ PHARMA	500MG;5MG **	A089420	001	Jan 25, 1988
VICOPRIN					
	ABBOTT	500MG;5MG	A086333	001	Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET;ORAL					
EQUAGESIC					
	SUN PHARM INDUSTRIES	325MG;200MG	N011702	003	Dec 29, 1983
MEPRO-ASPIRIN					
	SANDOZ	325MG;200MG	A089127	001	Mar 02, 1987
MEPROBAMATE AND ASPIRIN					
	PAR PHARM	325MG;200MG	A089126	001	Aug 19, 1986
MICRAININ					
	MEDPOINTE PHARM HLC	325MG;200MG	A084978	001	
Q-GESIC					
	QUANTUM PHARMICS	325MG;200MG	A088740	001	Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET;ORAL					
METHOCARBAMOL AND ASPIRIN					
	IVAX SUB TEVA PHARMS	325MG;400MG	A087211	001	Dec 22, 1982
	MCNEIL	325MG;400MG	A089193	001	Feb 12, 1986
	PAR PHARM	325MG;400MG	A089657	001	Nov 04, 1988
	STEVENS J	325MG;400MG	A081145	001	Jan 31, 1995
ROBAXISAL					
+	ROBINS AH	325MG;400MG	N012281	001	

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL					
YOSPRALA					
+	GENUS LIFESCIENCES	81MG;40MG	N205103	001	Sep 14, 2016
+		325MG;40MG	N205103	002	Sep 14, 2016

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL					
OXYCODONE AND ASPIRIN					
	ACTAVIS LABS FL INC	325MG;4.8355MG	A090084	001	Mar 22, 2011
	DR REDDYS LABS SA	325MG;4.8355MG	A091670	001	Mar 16, 2011

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL					
CODOXY					
	HALSEY	325MG;4.5MG;0.38MG	A087464	001	Jul 01, 1982
OXYCODONE AND ASPIRIN					
	ANI PHARMS	325MG;4.5MG;0.38MG	A040255	001	Feb 27, 1998
	SUN PHARM INDUSTRIES	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998
		325MG;4.5MG;0.38MG	A087794	001	May 26, 1982
OXYCODONE AND ASPIRIN (HALF-STRENGTH)					
	ROXANE	325MG;2.25MG;0.19MG	A087742	001	Jun 04, 1982
PERCODAN					
	ENDO PHARMS	325MG;4.5MG;0.38MG **	N007337	006	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL				
PERCODAN-DEMI				
	ENDO PHARMS	325MG;2.25MG;0.19MG **	N007337 005	
ROXIPRIN				
	ROXANE	325MG;4.5MG;0.38MG	A087743 001	Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL				
TALWIN COMPOUND				
+	SANOFI AVENTIS US	325MG;EQ 12.5MG BASE **	N016891 001	

ASPIRIN; PRAVASTATIN SODIUM

TABLET;ORAL				
PRAVIGARD PAC (COPACKAGED)				
	BRISTOL MYERS SQUIBB	81MG;20MG	N021387 001	Jun 24, 2003
		81MG;40MG	N021387 002	Jun 24, 2003
		81MG;80MG	N021387 003	Jun 24, 2003
		325MG;20MG	N021387 004	Jun 24, 2003
		325MG;40MG	N021387 005	Jun 24, 2003
		325MG;80MG	N021387 006	Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL				
DARVON W/ ASA				
	XANODYNE PHARM	325MG;65MG	N010996 005	

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE;ORAL				
DARVON-N W/ ASA				
	AAIPHARMA LLC	325MG;100MG	N016829 001	
TABLET;ORAL				
DARVON-N W/ ASA				
	AAIPHARMA LLC	325MG;100MG	N016863 001	

ATAZANAVIR SULFATE

CAPSULE;ORAL				
ATAZANAVIR SULFATE				
	AMNEAL	EQ 100MG BASE	A209717 001	Jun 01, 2020
	CIPLA	EQ 100MG BASE	A200626 001	Aug 09, 2018
		EQ 150MG BASE	A200626 002	Aug 09, 2018
		EQ 200MG BASE	A200626 003	Aug 09, 2018
		EQ 300MG BASE	A200626 004	Aug 09, 2018
	MYLAN	EQ 150MG BASE	A208177 001	Sep 24, 2018
		EQ 200MG BASE	A208177 002	Sep 24, 2018
		EQ 300MG BASE	A208177 003	Sep 24, 2018
	ZYDUS PHARMS	EQ 150MG BASE	A210575 001	Jun 04, 2020
		EQ 200MG BASE	A210575 002	Jun 04, 2020
		EQ 300MG BASE	A210575 003	Jun 04, 2020
REYATAZ				
+	BRISTOL MYERS SQUIBB	EQ 100MG BASE **	N021567 001	Jun 20, 2003
+		EQ 150MG BASE **	N021567 002	Jun 20, 2003

ATENOLOL

INJECTABLE;INJECTION				
TENORMIN				
+	ASTRAZENECA	0.5MG/ML **	N019058 001	Sep 13, 1989
TABLET;ORAL				
ATENOLOL				
	ABLE	25MG	A076907 001	Jul 30, 2004
		50MG	A076907 002	Jul 30, 2004
		100MG	A076907 003	Jul 30, 2004
	APOTHECON	50MG	A073317 001	Mar 20, 1992
		100MG	A073318 001	Mar 20, 1992
	CHARTWELL RX	25MG	A074265 001	Feb 28, 1994
		50MG	A074265 002	Feb 28, 1994
		100MG	A074265 003	Feb 28, 1994
	MYLAN	25MG	A074126 003	Aug 26, 1998
		50MG	A074126 001	Mar 23, 1994
		100MG	A074126 002	Mar 23, 1994
	NORTHSTAR HLTHCARE	25MG	A078254 001	Sep 25, 2009
		50MG	A078254 002	Sep 25, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ATENOLOL

TABLET;ORAL

ATENOLOL

	100MG	A078254	003	Sep 25, 2009
NOSTRUM LABS	50MG	A074127	001	Feb 21, 1995
	100MG	A074127	002	Feb 21, 1995
PLIVA	25MG	A074101	001	Jul 17, 1997
	50MG	A074101	002	Jul 17, 1997
	100MG	A074101	003	Jul 17, 1997
SCS	50MG	A073676	001	Oct 30, 1992
	100MG	A073676	002	Oct 30, 1992
STRIDES PHARMA	25MG	A074099	001	Apr 28, 1992
	50MG	A073542	001	Dec 19, 1991
	100MG	A073543	001	Dec 19, 1991
SUN PHARM INDS INC	25MG	A078210	001	Jul 10, 2007
	50MG	A078210	002	Jul 10, 2007
	100MG	A078210	003	Jul 10, 2007
SUN PHARM INDUSTRIES	25MG	A074499	001	Jul 30, 1997
	50MG	A073475	001	Mar 30, 1993
	100MG	A073476	001	Mar 30, 1993
TEVA	50MG	A073315	001	May 28, 1993
	100MG	A073316	001	May 28, 1993
TEVA PHARMS	50MG	A074120	001	Feb 24, 1995
	100MG	A074120	002	Feb 24, 1995
WATSON LABS	50MG	A073352	001	Dec 27, 1991
WATSON LABS TEVA	100MG	A073353	001	Dec 27, 1991

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AUROBINDO PHARMA USA	50MG;25MG	A074203	001	Oct 31, 1993
	100MG;25MG	A074203	002	Oct 31, 1993
NOSTRUM LABS	50MG;25MG	A074404	001	May 14, 1998
	100MG;25MG	A074404	002	May 14, 1998
PLIVA	50MG;25MG	A074107	001	Sep 24, 1997
	100MG;25MG	A074107	002	Sep 24, 1997
SUN PHARM INDUSTRIES	50MG;25MG	A073582	002	Apr 29, 1993
	100MG;25MG	A073582	001	Apr 29, 1993

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

STRIDES PHARMA	10MG	A079021	001	Feb 18, 2021
	18MG	A079021	002	Feb 18, 2021
	25MG	A079021	003	Feb 18, 2021
	40MG	A079021	004	Feb 18, 2021
	60MG	A079021	005	Feb 18, 2021
	80MG	A079021	006	Feb 18, 2021
	100MG	A079021	007	Feb 18, 2021

STRATTERA

LILLY	5MG	N021411	001	Nov 26, 2002

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

LEPU PHARM	EQ 10MG BASE	A216848	001	Nov 03, 2022
	EQ 20MG BASE	A216848	002	Nov 03, 2022
	EQ 40MG BASE	A216848	003	Nov 03, 2022
	EQ 80MG BASE	A216848	004	Nov 03, 2022
PERRIGO R AND D	EQ 10MG BASE	A208478	001	Jun 23, 2020
	EQ 20MG BASE	A208478	002	Jun 23, 2020
TEVA PHARMS	EQ 10MG BASE	A078773	001	May 29, 2012
	EQ 20MG BASE	A078773	002	May 29, 2012
	EQ 40MG BASE	A078773	003	May 29, 2012
	EQ 80MG BASE	A078773	004	May 29, 2012

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL					
LIPTRUZET					
+	ORGANON	EQ 10MG BASE;10MG **	N200153	001	May 03, 2013
+		EQ 20MG BASE;10MG **	N200153	002	May 03, 2013
+		EQ 40MG BASE;10MG **	N200153	003	May 03, 2013
+		EQ 80MG BASE;10MG **	N200153	004	May 03, 2013

ATOVAQUONE

TABLET;ORAL					
MEPRON					
+	GLAXOSMITHKLINE LLC	250MG **	N020259	001	Nov 25, 1992

ATRACURIUM BESYLATE

INJECTABLE;INJECTION					
ATRACURIUM BESYLATE					
	BAXTER HLTHCARE	10MG/ML	A074824	001	Sep 30, 1997
	BAXTER HLTHCARE CORP	10MG/ML	A074753	001	Jan 23, 1997
	HOSPIRA	10MG/ML	A074632	001	Dec 23, 1996
		10MG/ML	A074740	001	Mar 28, 1997
	MYLAN LABS LTD	10MG/ML	A206096	001	Jun 22, 2017
	TEVA PARENTERAL	10MG/ML	A074784	001	Jun 11, 1997
	WATSON PHARMS TEVA	10MG/ML	A074945	001	Jul 28, 1998
ATRACURIUM BESYLATE PRESERVATIVE FREE					
	BAXTER HLTHCARE	10MG/ML	A074825	001	Sep 30, 1997
	BAXTER HLTHCARE CORP	10MG/ML	A074768	001	Jan 23, 1997
	HOSPIRA	10MG/ML	A074633	001	Dec 23, 1996
		10MG/ML	A074639	001	Mar 25, 1997
		10MG/ML	A074741	001	Mar 28, 1997
	MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017
	WATSON LABS INC	10MG/ML	A074944	001	Jul 28, 1998
TRACRIUM					
+	HOSPIRA	10MG/ML **	N018831	002	Jun 20, 1985
TRACRIUM PRESERVATIVE FREE					
+	HOSPIRA	10MG/ML **	N018831	001	Nov 23, 1983

ATROPINE

SOLUTION;INTRAMUSCULAR					
ATROPEN					
+	MMT	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004
+		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003
+		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003
+		EQ 2MG SULFATE/0.7ML	N017106	001	
ATROPINE					
	ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987
ATROPINE (AUTOINJECTOR)					
	RAFA LABS LTD	EQ 2MG SULFATE/0.7ML (EQ 2MG SULFATE/0.7ML)	N212319	001	Jul 09, 2018

ATROPINE SULFATE

AEROSOL, METERED;INHALATION					
ATROPINE SULFATE					
	US ARMY	EQ 0.36MG BASE/INH	N020056	001	Sep 19, 1990

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL					
MOTOFEN HALF-STRENGTH					
	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE;ORAL					
DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE					
	SCHERER RP	0.025MG;2.5MG	A086440	001	
SOLUTION;ORAL					
COLONAID					
	MEDPOINTE PHARM HLC	0.025MG/5ML;2.5MG/5ML	A085735	001	
LOMANATE					
	ALPHARMA US PHARMS	0.025MG/5ML;2.5MG/5ML	A085746	001	
LOMOTIL					
	GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL				
COLONAID				
	MEDPOINTE PHARM HLC	0.025MG;2.5MG	A085737 001	
DI-ATRO				
	MD PHARM	0.025MG;2.5MG	A085266 001	
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE				
	ABLE	0.025MG;2.5MG	A040395 001	Nov 27, 2000
	ASCOT	0.025MG;2.5MG	A087934 001	Jul 19, 1983
	DR REDDYS LABS SA	0.025MG;2.5MG	A210789 001	Jun 03, 2020
	FOSUN PHARMA	0.025MG;2.5MG	A086173 001	
	HEATHER	0.025MG;2.5MG	A086798 001	
	HIKMA	0.025MG;2.5MG	A087765 001	Mar 15, 1982
	INWOOD LABS	0.025MG;2.5MG	A085509 001	
	KV PHARM	0.025MG;2.5MG	A085659 001	
	LEDERLE	0.025MG;2.5MG	A086950 001	
	PARKE DAVIS	0.025MG;2.5MG	A087131 001	
	PVT FORM	0.025MG;2.5MG	A085766 001	
	R AND S PHARMA	0.025MG;2.5MG	A085035 001	
	ROXANE	0.025MG;2.5MG	A086057 001	
	STRIDES PHARMA	0.025MG;2.5MG	A040357 001	May 02, 2000
	SUN PHARM INDUSTRIES	0.025MG;2.5MG	A085506 001	
	UPSHER SMITH LABS	0.025MG;2.5MG	A210571 001	Aug 31, 2018
	USL PHARMA	0.025MG;2.5MG	A087842 001	Mar 29, 1982
	VALEANT PHARM INTL	0.025MG;2.5MG	A087195 001	Feb 16, 1982
	WATSON LABS	0.025MG;2.5MG	A085876 001	
LO-TROL				
	VANGARD	0.025MG;2.5MG	A088009 001	Mar 25, 1983
LOGEN				
	SUPERPHARM	0.025MG;2.5MG	A088962 001	May 10, 1985
LONOX				
	FOSUN PHARMA	0.025MG;2.5MG	A085311 002	
LOW-QUEL				
	HALSEY	0.025MG;2.5MG	A085211 001	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION				
ENLON-PLUS				
+	MYLAN	0.14MG/ML;10MG/ML	N019678 001	Nov 06, 1991
	MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019677 001	Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION				
ATROPINE AND DEMEROL				
	ABBVIE	0.4MG/ML;50MG/ML	A087853 001	Nov 26, 1982
		0.4MG/ML;75MG/ML	A087847 001	Nov 26, 1982
		0.4MG/ML;100MG/ML	A087848 001	Nov 26, 1982
MEPERIDINE AND ATROPINE SULFATE				
	WYETH AYERST	0.4MG/ML;50MG/ML	A085121 001	
		0.4MG/ML;75MG/ML	A085121 002	
		0.4MG/ML;100MG/ML	A085121 003	

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE;INTRAMUSCULAR				
ATNAA				
	US ARMY	2.1MG/0.7ML;600MG/2ML	N021175 001	Jan 17, 2002

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL				
SHADE UVAGUARD				
+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045 001	Dec 07, 1992

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS				
AZACITIDINE				
	LUPIN LTD	100MG/VIAL	A210748 001	Feb 27, 2019
	MYLAN INSTITUTIONAL	100MG/VIAL	A204949 001	Apr 28, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AZATADINE MALEATE

TABLET;ORAL

OPTIMINE

SCHERING	1MG	N017601	001	

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

TRINALIN

SCHERING	1MG;120MG	N018506	001	Mar 23, 1982

AZATHIOPRINE

TABLET;ORAL

IMURAN

+ SEBELA IRELAND LTD	25MG **	N016324	002	

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

IMURAN

+ CASPER PHARMA LLC	EQ 100MG BASE/VIAL **	N017391	001	

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

AZELAIC ACID

TEVA PHARMS USA	15%	A210928	001	Oct 07, 2020

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

EPIC PHARMA LLC	0.05%	A203660	001	Nov 08, 2016

OPTIVAR

+ MYLAN SPECIALITY LP	0.05% **	N021127	001	May 22, 2000

SPRAY, METERED;NASAL

ASTELIN

+ MYLAN SPCLT VIATRIS	0.137MG/SPRAY **	N020114	001	Nov 01, 1996

ASTEPRO

+ MYLAN SPECIALITY LP	0.137MG/SPRAY **	N022203	001	Oct 15, 2008
	0.2055MG/SPRAY **	N022203	002	Aug 31, 2009

AZELASTINE HYDROCHLORIDE

AKORN	0.2055MG/SPRAY	A210032	001	Aug 23, 2019
AMNEAL	0.2055MG/SPRAY	A208199	001	Dec 15, 2017
APOTEX INC	0.2055MG/SPRAY	A201846	001	Aug 31, 2012
AUROBINDO PHARMA LTD	0.2055MG/SPRAY	A212775	001	Nov 12, 2020
HIKMA	0.2055MG/SPRAY	A207243	001	Sep 22, 2017
PADAGIS ISRAEL	0.2055MG/SPRAY	A202743	001	May 08, 2014

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

AZILSARTAN MEDOXOMIL

LUPIN LTD	EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022
	EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022

AZITHROMYCIN

CAPSULE;ORAL

ZITHROMAX

+ PFIZER	EQ 250MG BASE **	N050670	001	Nov 01, 1991

FOR SUSPENSION;ORAL

AZITHROMYCIN

CHARTWELL RX	EQ 100MG BASE/5ML	A065488	001	May 15, 2015
	EQ 200MG BASE/5ML	A065488	002	May 15, 2015
SANDOZ	EQ 100MG BASE/5ML	A065297	001	Sep 18, 2006
	EQ 200MG BASE/5ML	A065297	002	Sep 18, 2006
TARO	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019
TEVA PHARMS	EQ 100MG BASE/5ML	A065419	001	Jun 24, 2008
	EQ 200MG BASE/5ML	A065419	002	Jun 24, 2008

FOR SUSPENSION, EXTENDED RELEASE;ORAL

ZMAX

+ PF PRISM CV	EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005

INJECTABLE;INJECTION

AZITHROMYCIN

HIKMA	EQ 500MG BASE/VIAL	A065265	001	Jan 18, 2007
MYLAN ASI	EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009
RISING	EQ 500MG BASE/VIAL	A204732	001	Jan 26, 2017
TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809	001	Dec 19, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AZITHROMYCIN				
INJECTABLE;INJECTION				
AZITHROMYCIN				
	EQ 2.5GM BASE/VIAL	N050809	002	Dec 19, 2006
TABLET;ORAL				
AZITHROMYCIN				
APOTEX CORP	EQ 250MG BASE	A065507	001	Jul 13, 2011
	EQ 500MG BASE	A065509	001	Jul 13, 2011
	EQ 600MG BASE	A065508	001	Jul 13, 2011
AUROBINDO PHARMA USA	EQ 600MG BASE	A065360	001	Jan 08, 2007
MYLAN	EQ 250MG BASE	A065365	001	May 30, 2007
	EQ 500MG BASE	A065366	001	May 30, 2007
TEVA	EQ 250MG BASE	A065153	001	Nov 14, 2005
	EQ 600MG BASE	A065150	001	Nov 14, 2005
YUNG SHIN PHARM	EQ 500MG BASE	A211318	001	Mar 17, 2021
ZYDUS PHARMS	EQ 250MG BASE	A213275	001	Apr 11, 2023
	EQ 500MG BASE	A213056	001	Apr 07, 2023
ZITHROMAX				
+ PFIZER	EQ 600MG BASE **	N050730	001	Jun 12, 1996
AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE				
FOR SUSPENSION, TABLET;ORAL				
TROVAN/ZITHROMAX COMPLIANCE PAK				
PFIZER	EQ 1GM BASE,N/A;N/A,EQ 100MG BASE	N050762	001	Dec 18, 1998
AZLOCILLIN SODIUM				
INJECTABLE;INJECTION				
AZLIN				
BAYER PHARMS	EQ 2GM BASE/VIAL	A062388	001	Sep 08, 1982
	EQ 2GM BASE/VIAL	A062417	001	Oct 12, 1982
	EQ 2GM BASE/VIAL	N050562	001	Sep 03, 1982
	EQ 3GM BASE/VIAL	A062388	002	Sep 08, 1982
	EQ 3GM BASE/VIAL	A062417	002	Oct 12, 1982
	EQ 3GM BASE/VIAL	N050562	002	Sep 03, 1982
	EQ 4GM BASE/VIAL	A062388	003	Sep 08, 1982
	EQ 4GM BASE/VIAL	A062417	003	Oct 12, 1982
	EQ 4GM BASE/VIAL	N050562	003	Sep 03, 1982
AZTREONAM				
INJECTABLE;INJECTION				
AZACTAM				
BRISTOL MYERS SQUIBB	500MG/VIAL **	N050580	001	Dec 31, 1986
AZACTAM IN PLASTIC CONTAINER				
BRISTOL MYERS SQUIBB	10MG/ML	N050632	003	May 24, 1989
+	20MG/ML	N050632	002	May 24, 1989
+	40MG/ML	N050632	001	May 24, 1989
AZTREONAM				
HIKMA	1GM/VIAL	A065286	001	Mar 23, 2011
	2GM/VIAL	A065286	002	Mar 23, 2011
BACAMPICILLIN HYDROCHLORIDE				
FOR SUSPENSION;ORAL				
SPECTROBID				
PFIZER	125MG/5ML	N050556	001	Mar 23, 1982
TABLET;ORAL				
SPECTROBID				
PFIZER	400MG	N050520	001	
	800MG	N050520	002	Sep 12, 1983
BACITRACIN				
OINTMENT;OPHTHALMIC				
BACIGUENT				
PHARMACIA AND UPJOHN	500 UNITS/GM	A060734	001	
BACITRACIN				
LILLY	500 UNITS/GM	A060687	001	
PHARMADERM	500 UNITS/GM	A062158	001	
PHARMAFAIR	500 UNITS/GM	A062453	001	Mar 28, 1984
OINTMENT;TOPICAL				
BACITRACIN				
COMBE	500 UNITS/GM	A062799	001	May 14, 1987
NASKA	500 UNITS/GM	A062857	001	Nov 13, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BACITRACIN

POWDER;FOR RX COMPOUNDING

BACI-RX

	X GEN PHARMS	5,000,000 UNITS/BOT	A061580 001	

BACITRACIN

	APOTHEKERNES	5,000,000 UNITS/BOT	A061699 001	
	PADDOCK LLC	5,000,000 UNITS/BOT	A062456 001	Jul 27, 1983

BACITRACIN ZINC

POWDER;FOR RX COMPOUNDING

ZIBA-RX

	X GEN PHARMS	500,000 UNITS/BOT	A061737 001	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

CORTISPORIN

+	CASPER PHARMA LLC	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **	N050416 002	

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

	AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213 001	Jul 25, 2012

ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE

	PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062389 001	Jul 02, 1982

OINTMENT;TOPICAL

CORTISPORIN

+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168 002	May 04, 1984

NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE

	PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062381 001	Sep 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL

LANABIOTIC

	COMBE	400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM	A062499 001	Jun 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

	PHARMAFAIR	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062386 001	Sep 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN

	PHARMADERM	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062167 001	

NEO-POLYCIN

	DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060647 001	

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

	AKORN	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065088 001	Feb 06, 2004

OINTMENT;TOPICAL

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

	NASKA	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062833 001	Nov 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL;TOPICAL

POLYSPORIN

	GLAXOSMITHKLINE	10,000 UNITS/GM;2,000,000 UNITS/GM	N050167 002	Mar 01, 1985

OINTMENT;OPHTHALMIC

OCUMYCIN

	PHARMAFAIR	500 UNITS/GM;10,000 UNITS/GM	A062430 001	Apr 08, 1983

POLYSPORIN

	MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM **	A061229 001	

OINTMENT;TOPICAL

BACITRACIN ZINC-POLYMYXIN B SULFATE

	NASKA	500 UNITS/GM;10,000 UNITS/GM	A062849 001	Nov 13, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060731 002	

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MYCITRACIN

	PHARMACIA AND UPJOHN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A061048 001	

BACITRACIN; POLYMYXIN B SULFATE

DISC;TOPICAL

LANABIOTIC

	COMBE	500 UNITS/GM;5,000 UNITS/GM	N050598 001	Sep 22, 1986

BACLOFEN

SOLUTION;ORAL

OZOBAX

+	METACEL PHARMS LLC	5MG/5ML	N208193 001	Sep 18, 2019

TABLET;ORAL

BACLOFEN

	APPCO	10MG	A090334 001	Feb 18, 2010
		20MG	A090334 002	Feb 18, 2010
	MYLAN	10MG	A077181 001	Jul 29, 2005
		20MG	A077121 002	Jul 29, 2005
	SUN PHARM INDS INC	10MG	A077862 001	Aug 14, 2006
		20MG	A077862 002	Aug 14, 2006
	TEVA	10MG	A073043 001	Feb 27, 1992
		20MG	A073044 001	Feb 27, 1992
	USL PHARMA	10MG	A071260 001	May 06, 1988
		20MG	A071261 001	May 06, 1988
	WATSON LABS	10MG	A072824 001	Sep 18, 1991
		10MG	A073092 001	Jan 28, 1994
		10MG	A074698 001	Aug 20, 1996
		20MG	A072825 001	Sep 18, 1991
		20MG	A073093 001	Jan 28, 1994
		20MG	A074698 002	Aug 20, 1996

LIORESAL

+	NOVARTIS	10MG **	N017851 001	
+		20MG **	N017851 003	Jan 20, 1982

TABLET, ORALLY DISINTEGRATING;ORAL

KEMSTRO

+	UCB INC	10MG	N021589 001	Oct 30, 2003
+		20MG	N021589 002	Oct 30, 2003

BALOXAVIR MARBOXIL

TABLET;ORAL

XOFLUZA

+	GENENTECH INC	20MG	N210854 001	Oct 24, 2018

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

	DASH PHARMS NATCO	750MG	A077807 001	Dec 28, 2007

TABLET;ORAL

BALSALAZIDE DISODIUM

	STRIDES PHARMA	1.1GM	A206336 001	Sep 08, 2015

GIAZO

+	VALEANT PHARMS INTL	1.1GM **	N022205 001	Feb 03, 2012

BARIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-CAT DRY

+	BRACCO	40% (9GM/POUCH)	N208036 003	Jan 03, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION				
BECLOVENT				
	GLAXOSMITHKLINE	0.042MG/INH	N018153 001	
QVAR 40				
+	TEVA BRANDED PHARM	0.04MG/INH **	N020911 002	Sep 15, 2000
QVAR 80				
+	TEVA BRANDED PHARM	0.08MG/INH **	N020911 001	Sep 15, 2000
VANCERIL				
	SCHERING	0.042MG/INH	N017573 001	
VANCERIL DOUBLE STRENGTH				
	SCHERING	0.084MG/INH	N020486 001	Dec 24, 1996
AEROSOL, METERED;NASAL				
BECONASE				
	GLAXOSMITHKLINE	0.042MG/INH	N018584 001	
VANCENASE				
	SCHERING	0.042MG/INH	N018521 001	

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED;NASAL				
BECONASE AQ				
+	GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N019389 001	Jul 27, 1987
VANCENASE AQ				
	SCHERING	EQ 0.042MG DIPROP/SPRAY	N019589 001	Dec 23, 1987
		EQ 0.084MG DIPROP/SPRAY	N020469 001	Jun 26, 1996

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL				
BENAZEPRIL HYDROCHLORIDE				
	GENPHARM	5MG	A076476 001	Feb 11, 2004
		10MG	A076476 002	Feb 11, 2004
		20MG	A076476 003	Feb 11, 2004
		40MG	A076476 004	Feb 11, 2004
	RISING	5MG	A076430 001	Feb 11, 2004
		10MG	A076430 002	Feb 11, 2004
		20MG	A076430 003	Feb 11, 2004
		40MG	A076430 004	Feb 11, 2004
LOTENSIN				
+	VALIDUS PHARMS	5MG **	N019851 001	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
	ANI PHARMS	5MG;6.25MG	A076348 001	Feb 11, 2004
		10MG;12.5MG	A076348 002	Feb 11, 2004
		20MG;12.5MG	A076348 003	Feb 11, 2004
		20MG;25MG	A076348 004	Feb 11, 2004
	AUROBINDO PHARMA USA	5MG;6.25MG	A076688 001	Feb 11, 2004
		10MG;12.5MG	A076688 002	Feb 11, 2004
		20MG;12.5MG	A076688 003	Feb 11, 2004
		20MG;25MG	A076688 004	Feb 11, 2004
	MYLAN PHARMS INC	5MG;6.25MG	A076612 001	Feb 11, 2004
		10MG;12.5MG	A076612 002	Feb 11, 2004
		20MG;12.5MG	A076612 003	Feb 11, 2004
		20MG;25MG	A076612 004	Feb 11, 2004
	SUN PHARM INDS LTD	5MG;6.25MG	A077483 001	Sep 08, 2005
		10MG;12.5MG	A077483 002	Sep 08, 2005
		20MG;12.5MG	A077483 003	Sep 08, 2005
		20MG;25MG	A077483 004	Sep 08, 2005
LOTENSIN HCT				
+	VALIDUS PHARMS	5MG;6.25MG **	N020033 001	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)				
BENDAMUSTINE HYDROCHLORIDE				
	MYLAN LABS LTD	25MG/VIAL	A204104 001	Apr 28, 2023
		100MG/VIAL	A204104 002	Apr 28, 2023
	NANG KUANG PHARM CO	25MG/VIAL	A206554 001	Jun 07, 2023
		100MG/VIAL	A206554 002	Jun 07, 2023

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BENDAMUSTINE HYDROCHLORIDE				
SOLUTION;INTRAVENOUS				
BENDAMUSTINE HYDROCHLORIDE				
+ HOSPIRA	25MG/ML (25MG/ML)	N211530	001	Dec 15, 2022
+	100MG/4ML (25MG/ML)	N211530	002	Dec 15, 2022
+	200MG/8ML (25MG/ML)	N211530	003	Dec 15, 2022
SOLUTION;IV (INFUSION)				
TREANDA				
+ CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013
+	180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013
BENDROFLUMETHIAZIDE				
TABLET;ORAL				
NATURETIN-10				
APOTHECON	10MG	N012164	003	
NATURETIN-2.5				
APOTHECON	2.5MG	N012164	001	
NATURETIN-5				
APOTHECON	5MG	N012164	002	
BENDROFLUMETHIAZIDE; NADOLOL				
TABLET;ORAL				
CORZIDE				
+ KING PHARMS LLC	5MG;40MG **	N018647	001	May 25, 1983
+	5MG;80MG **	N018647	002	May 25, 1983
NADOLOL AND BENDROFLUMETHIAZIDE				
IMPAX LABS	5MG;40MG	A077833	001	Mar 30, 2007
	5MG;80MG	A077833	002	Mar 30, 2007
MYLAN	5MG;40MG	A078688	001	Feb 15, 2008
	5MG;80MG	A078688	002	Feb 15, 2008
BENOXINATE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
BENOXINATE HYDROCHLORIDE				
SOLA BARNES HIND	0.4%	A084149	001	
BENTIROMIDE				
SOLUTION;ORAL				
CHYMEX				
SAVAGE LABS	500MG/7.5ML	N018366	001	Dec 29, 1983
BENZONATATE				
CAPSULE;ORAL				
BENZONATATE				
CHARTWELL RX	100MG	A210562	001	Nov 09, 2018
	150MG	A210562	002	Nov 09, 2018
	200MG	A210562	003	Nov 09, 2018
MIKART	100MG	A040851	001	Nov 09, 2009
	150MG	A040851	002	Nov 09, 2009
	200MG	A040851	003	Nov 09, 2009
NESHER PHARMS	100MG	A040795	001	Oct 31, 2007
	200MG	A040795	002	Oct 31, 2007
SUN PHARM INDS INC	100MG	A040587	001	Mar 19, 2008
	200MG	A040587	002	Mar 19, 2008
THEPHARMANETWORK LLC	100MG	A040627	001	Mar 30, 2007
	150MG	A040627	003	Sep 24, 2014
	200MG	A040627	002	Jul 25, 2007
TESSALON				
+ PFIZER	200MG **	N011210	003	Jun 25, 1999
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE				
GEL;TOPICAL				
BENZACLIN				
+ BAUSCH	5%;EQ 1% BASE	N050756	001	Dec 21, 2000
	5%;EQ 1% BASE	N050756	002	Apr 20, 2007
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE				
CHARTWELL RX	5%;1.2%	A203688	001	Aug 25, 2016
ENCUBE	2.5%;EQ 1.2% BASE	A207194	001	Aug 19, 2019
	5%;EQ 1% BASE	A204087	001	Jun 27, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BENZOYL PEROXIDE; ERYTHROMYCIN				
GEL;TOPICAL				
AKTIPAK				
+	BIOFRONTERA	5%;3%	N050769 001	Nov 27, 2000
ERYTHROMYCIN AND BENZOYL PEROXIDE				
	ENCUBE	5%;3%	A065112 001	Mar 29, 2004
BENZPHETAMINE HYDROCHLORIDE				
TABLET;ORAL				
BENZPHETAMINE HYDROCHLORIDE				
	AVET LIFESCIENCES	50MG	A202061 001	Jan 27, 2012
	EPIC PHARMA LLC	50MG	A040714 001	Oct 29, 2007
	IMPAX LABS	50MG	A040845 001	Nov 18, 2008
	SCINOPHARM TAIWAN	50MG	A040578 001	Apr 17, 2006
	SPECGX LLC	50MG	A040773 001	Apr 25, 2007
	TEDOR PHARM	25MG	A040747 002	Nov 20, 2015
		50MG	A040747 001	Mar 30, 2007
DIDREX				
+	PFIZER	25MG **	N012427 003	
+		50MG **	N012427 002	
BENZQUINAMIDE HYDROCHLORIDE				
INJECTABLE;INJECTION				
EMETE-CON				
	PFIZER	EQ 50MG BASE/VIAL	N016820 001	
SUPPOSITORY;RECTAL				
EMETE-CON				
	ROERIG	EQ 100MG BASE	N016818 006	
BENZTHIAZIDE				
TABLET;ORAL				
AQUATAG				
	SOLVAY	25MG	N016001 001	
		50MG	N016001 002	
BENZTHIAZIDE				
	PVT FORM	50MG	A083206 001	
EXNA				
	AH ROBINS INC	50MG	N012489 001	
FOVANE				
	PFIZER	50MG	N012128 002	
URESE				
	PFIZER	25MG	N012128 003	
BENZTROPINE MESYLATE				
INJECTABLE;INJECTION				
BENZTROPINE MESYLATE				
	LUITPOLD	1MG/ML	A091152 001	Mar 29, 2010
COGENTIN				
+	EPIC PHARMA LLC	1MG/ML **	N012015 001	
TABLET;ORAL				
BENZTROPINE MESYLATE				
	AIPING PHARM INC	0.5MG	A040103 001	Dec 12, 1996
		1MG	A040103 002	Dec 12, 1996
		2MG	A040103 003	Dec 12, 1996
	LANNETT CO INC	0.5MG **	A088877 001	Apr 11, 1985
		1MG **	A088894 001	Apr 11, 1985
		2MG **	A088895 001	Apr 11, 1985
	OXFORD PHARMS	0.5MG	A040706 002	Feb 14, 2008
		1MG	A040706 003	Feb 14, 2008
		2MG	A040706 001	Feb 14, 2008
	QUANTUM PHARMICS	0.5MG	A088514 001	Jan 31, 1984
		1MG	A088510 001	Jan 31, 1984
		2MG	A088511 001	Jan 31, 1984
	USL PHARMA	0.5MG	A089211 001	Jun 14, 1988
		1MG	A089212 001	Jun 14, 1988
		2MG	A089213 001	Jun 14, 1988
COGENTIN				
+	MERCK	0.5MG **	N009193 004	
+		1MG **	N009193 003	
+		2MG **	N009193 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BENZYL ALCOHOL				
LOTION;TOPICAL				
ULESFIA				
+ SHIONOGI INC	5% **	N022129	001	Apr 09, 2009
BENZYL BENZOATE				
EMULSION;TOPICAL				
BENZYL BENZOATE				
LANNETT	50%	A084535	001	
BEPRIDIL HYDROCHLORIDE				
TABLET;ORAL				
BEPADIN				
MEDPOINTE PHARM HLC	200MG	N019001	001	Dec 28, 1990
	300MG	N019001	002	Dec 28, 1990
	400MG	N019001	003	Dec 28, 1990
VASCOR				
JOHNSON AND JOHNSON	200MG	N019002	001	Dec 28, 1990
	300MG	N019002	002	Dec 28, 1990
	400MG	N019002	003	Dec 28, 1990
BETA CAROTENE				
CAPSULE;ORAL				
SOLATENE				
ROCHE	30MG	N017589	001	
BETAMETHASONE				
CREAM;TOPICAL				
CELESTONE				
SCHERING	0.2%	N014762	001	
SYRUP;ORAL				
CELESTONE				
MERCK SHARP DOHME	0.6MG/5ML	N014215	002	
TABLET;ORAL				
CELESTONE				
SCHERING	0.6MG	N012657	003	
BETAMETHASONE BENZOATE				
CREAM;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%	N016998	002	
GEL;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%	N017244	001	
LOTION;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%	N017528	001	
OINTMENT;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%	N018089	001	
BETAMETHASONE DIPROPIONATE				
CREAM;TOPICAL				
ALPHATREX				
SAVAGE LABS	EQ 0.05% BASE	N019138	001	Jun 26, 1984
BETAMETHASONE DIPROPIONATE				
PERRIGO NEW YORK	EQ 0.05% BASE	A072536	001	Jan 31, 1990
	EQ 0.05% BASE	A074579	001	Nov 26, 1997
PHARMADERM	EQ 0.05% BASE	N019136	001	Jun 26, 1984
TARO	EQ 0.05% BASE	A071143	001	Jun 17, 1987
TEVA	EQ 0.05% BASE	A071476	001	Aug 10, 1987
DIPROSONE				
SCHERING	EQ 0.05% BASE	N017536	001	
CREAM, AUGMENTED;TOPICAL				
BETAMETHASONE DIPROPIONATE				
ANDA REPOSITORY	EQ 0.05% BASE	A076603	001	Jan 23, 2004
DIPROLENE				
SCHERING	EQ 0.05% BASE	N019408	001	Jan 31, 1986
DIPROLENE AF				
+ ORGANON	EQ 0.05% BASE **	N019555	001	Apr 27, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BETAMETHASONE DIPROPIONATE				
DISC;TOPICAL				
DIPROSONE				
SCHERING	EQ 0.1% BASE	N017829 001		
GEL, AUGMENTED;TOPICAL				
DIPROLENE				
SCHERING	EQ 0.05% BASE	N019408 002	Nov 22, 1991	
LOTION;TOPICAL				
ALPHATREX				
SAVAGE LABS	EQ 0.05% BASE	A070273 001	Aug 12, 1985	
BETAMETHASONE DIPROPIONATE				
ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A070281 001	Jul 31, 1985	
ALPHARMA US PHARMS	EQ 0.05% BASE	A071085 001	Feb 03, 1987	
COSETTE	EQ 0.05% BASE	A071882 001	Jun 06, 1988	
HIKMA	EQ 0.05% BASE	A209896 001	Feb 06, 2018	
SHREE HARI INTL	EQ 0.05% BASE	A070274 001	Aug 12, 1985	
TARO	EQ 0.05% BASE	A072276 001	Aug 24, 1988	
	EQ 0.05% BASE	A074272 001	Sep 30, 1994	
DIPROSONE				
+ SCHERING	EQ 0.05% BASE **	N017781 001		
LOTION, AUGMENTED;TOPICAL				
BETAMETHASONE DIPROPIONATE				
VERTICE	EQ 0.05% BASE	A206389 001	Feb 13, 2018	
DIPROLENE				
+ ORGANON	EQ 0.05% BASE **	N019716 001	Aug 01, 1988	
OINTMENT;TOPICAL				
ALPHATREX				
SAVAGE LABS	EQ 0.05% BASE	N019143 001	Sep 04, 1984	
BETAMETHASONE DIPROPIONATE				
PERRIGO NEW YORK	EQ 0.05% BASE	A072526 001	Jan 31, 1990	
PHARMADERM	EQ 0.05% BASE	N019140 001	Sep 04, 1984	
TEVA	EQ 0.05% BASE	A071477 001	Aug 10, 1987	
DIPROSONE				
SCHERING	EQ 0.05% BASE	N017691 001		
OINTMENT, AUGMENTED;TOPICAL				
BETAMETHASONE DIPROPIONATE				
PAI HOLDINGS PHARM	EQ 0.05% BASE	A206118 001	Nov 09, 2017	
SPRAY;TOPICAL				
BETAMETHASONE DIPROPIONATE				
TARO	EQ 0.05% BASE/SPRAY	A211722 001	Jun 17, 2020	
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE				
OINTMENT;TOPICAL				
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE				
CHARTWELL RX	0.064%;0.005%	A201615 001	Jan 14, 2013	
BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE				
CREAM;TOPICAL				
LOTRISONE				
+ ORGANON	EQ 0.05% BASE;1%	N018827 001	Jul 10, 1984	
LOTION;TOPICAL				
LOTRISONE				
+ MERCK SHARP DOHME	EQ 0.05% BASE;1% **	N020010 001	Dec 08, 2000	
BETAMETHASONE SODIUM PHOSPHATE				
INJECTABLE;INJECTION				
BETAMETHASONE SODIUM PHOSPHATE				
WATSON LABS	EQ 3MG BASE/ML	A085738 001		
CELESTONE				
+ SCHERING	EQ 3MG BASE/ML **	N017561 001		
BETAMETHASONE VALERATE				
AEROSOL, FOAM;TOPICAL				
BETAMETHASONE VALERATE				
NOVAST LABS	0.12%	A207144 001	May 24, 2017	
LUXIQ				
+ MYLAN	0.12%	N020934 001	Feb 28, 1999	
CREAM;TOPICAL				
BETADERM				
ROACO	EQ 0.1% BASE	N018839 001	Jun 30, 1983	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BETAMETHASONE VALERATE

CREAM;TOPICAL				
BETAMETHASONE VALERATE				
PERRIGO NEW YORK	EQ 0.1% BASE	A070053	001	Jun 10, 1986
PHARMADERM	EQ 0.1% BASE	N018860	002	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070485	001	May 29, 1987
TARO	EQ 0.1% BASE	A070062	001	May 14, 1985
BETATREX				
SAVAGE LABS	EQ 0.1% BASE	N018862	001	Aug 31, 1983
VALISONE				
SCHERING	EQ 0.01% BASE	N016322	002	
	EQ 0.1% BASE	N016322	001	
LOTION;TOPICAL				
BETA-VAL				
COSETTE	EQ 0.1% BASE	A070072	001	Jun 27, 1985
BETAMETHASONE VALERATE				
PHARMADERM	EQ 0.1% BASE	N018870	001	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070484	001	May 29, 1987
TEVA PHARMS	EQ 0.1% BASE	A071883	001	Apr 22, 1988
BETATREX				
SAVAGE LABS	EQ 0.1% BASE	N018867	001	Aug 31, 1983
VALISONE				
SCHERING	EQ 0.1% BASE	N016932	001	
OINTMENT;TOPICAL				
BETAMETHASONE VALERATE				
PERRIGO NEW YORK	EQ 0.1% BASE	A071478	001	Dec 23, 1987
PHARMADERM	EQ 0.1% BASE	N018864	001	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070486	001	May 29, 1987
BETATREX				
SAVAGE LABS	EQ 0.1% BASE	N018863	001	Aug 31, 1983
VALISONE				
SCHERING	EQ 0.1% BASE	N016740	001	

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
BETAXOLOL HYDROCHLORIDE				
AKORN	EQ 0.5% BASE	A075386	001	Jun 30, 2000
APOTEX INC	EQ 0.5% BASE	A075446	001	Sep 28, 2000
TABLET;ORAL				
KERLONE				
SANOFI AVENTIS US	10MG **	N019507	001	Oct 27, 1989
	20MG **	N019507	002	Oct 27, 1989

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET;ORAL				
KERLEDEX				
SANOFI AVENTIS US	5MG;12.5MG	N019807	001	Oct 30, 1992
	10MG;12.5MG	N019807	002	Oct 30, 1992

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS;OPHTHALMIC				
BETOPTIC PILO				
ALCON	EQ 0.25% BASE;1.75%	N020619	001	Apr 17, 1997

BETAZOLE HYDROCHLORIDE

INJECTABLE;INJECTION				
HISTALOG				
LILLY	50MG/ML	N009344	001	

BETHANECHOL CHLORIDE

INJECTABLE;INJECTION				
URECHOLINE				
+ ODYSSEY PHARMS	5MG/ML **	N006536	001	
TABLET;ORAL				
BETHANECHOL CHLORIDE				
ABLE	5MG	A040492	001	Jul 27, 2004
	10MG	A040483	001	Jul 27, 2004
	25MG	A040485	001	Jul 27, 2004
	50MG	A040509	001	Jul 27, 2004
ACTAVIS ELIZABETH	5MG	A040552	001	Oct 28, 2004
	10MG	A040553	001	Oct 28, 2004
	25MG	A040554	001	Oct 28, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

	50MG	A040551	001	Oct 28, 2004
ASCOT	10MG	A088288	001	Jun 08, 1983
	25MG	A088289	001	Jun 08, 1983
HERITAGE PHARMA	5MG	A091256	001	May 04, 2010
	10MG	A091256	002	May 04, 2010
	25MG	A091256	003	May 04, 2010
	50MG	A091256	004	May 04, 2010
IMPAX LABS	5MG	A040721	001	Nov 01, 2006
	10MG	A040721	002	Nov 01, 2006
	25MG	A040721	003	Nov 01, 2006
	50MG	A040721	004	Nov 01, 2006
IVAX SUB TEVA PHARMS	25MG	A084689	001	
LANNETT	5MG	A084702	001	
	10MG	A084712	001	
	25MG	A084074	001	
LANNETT CO INC	5MG	A040677	002	Mar 27, 2008
	10MG	A040677	003	Mar 27, 2008
	25MG	A040677	004	Mar 27, 2008
	50MG	A040677	001	Mar 27, 2008
SANDOZ	5MG	A084353	001	
	10MG	A084378	001	
	10MG	A084379	001	
	25MG	A084383	001	
	25MG	A084384	001	
SUN PHARM INDS INC	5MG	A040897	001	Apr 22, 2009
	10MG	A040897	002	Apr 22, 2009
	25MG	A040897	003	Apr 22, 2009
	50MG	A040897	004	Apr 22, 2009
WATSON LABS	5MG	A084402	001	
	5MG	A085230	002	
	5MG	A085841	001	
	10MG	A084408	001	
	10MG	A085228	001	
	10MG	A085842	001	
	25MG	A084441	001	
	25MG	A085229	001	
	25MG	A085839	001	
	50MG	A087397	001	
	50MG	A087444	001	
WOCKHARDT	5MG	A040532	001	Sep 29, 2003
	10MG	A040533	001	Sep 29, 2003
	25MG	A040534	001	Sep 29, 2003
	50MG	A040518	001	Sep 29, 2003

MYOTONACHOL

GLENWOOD	5MG	A084188	001	
	10MG	A084188	003	
	25MG	A084188	004	

URECHOLINE

ODYSSEY PHARMS	5MG	A089095	001	Dec 19, 1985
+	5MG **	N006536	003	
+	10MG	A088440	001	May 29, 1984
+	10MG **	N006536	002	
+	25MG	A088441	001	May 29, 1984
+	25MG **	N006536	004	
	50MG	A089096	001	Dec 19, 1985
+	50MG **	N006536	005	

BETHANIDINE SULFATE

TABLET;ORAL

TENATHAN

ROBINS AH	10MG	N017675	001	
	25MG	N017675	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BETRIXABAN

CAPSULE;ORAL				
BEVYXXA				
+	PORTOLA PHARMS INC	40MG	N208383 001	Jun 23, 2017
+		80MG	N208383 002	Jun 23, 2017

BICALUTAMIDE

TABLET;ORAL				
BICALUTAMIDE				
	FRESENIUS KABI USA	50MG	A079045 001	May 13, 2010
	KUDCO IRELAND	50MG	A077995 001	Jul 06, 2009
	MYLAN	50MG	A079185 001	Jul 06, 2009
	ROXANE	50MG	A078285 001	Mar 24, 2011
	SYNTHON PHARMS	50MG	A077973 001	Jul 06, 2009
	TEVA	50MG	A076932 001	Jul 06, 2009

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC				
BIMATOPROST				
	HIKMA	0.03%	A203299 001	Nov 08, 2018
LUMIGAN				
+	ABBVIE	0.03% **	N021275 001	Mar 16, 2001

BIPERIDEN HYDROCHLORIDE

TABLET;ORAL				
AKINETON				
	ABBVIE	2MG	N012003 001	

BIPERIDEN LACTATE

INJECTABLE;INJECTION				
AKINETON				
	ABBVIE	5MG/ML	N012418 002	

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL				
HALFLYTELY				
+	BRAINTREE	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM **	N021551 003	Jul 16, 2010
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL				
	NOVEL LABS INC	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM	A202217 001	Aug 20, 2014

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL				
HELIDAC				
+	CASPER PHARMA LLC	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG **	N050719 001	Aug 15, 1996

BISOPROLOL FUMARATE

TABLET;ORAL				
BISOPROLOL FUMARATE				
	DASH PHARMS NATCO	5MG	A075831 001	Dec 14, 2005
		10MG	A075831 002	Dec 14, 2005
	TEVA PHARMS	5MG	A075644 001	Jun 26, 2001
		10MG	A075644 002	Jun 26, 2001
ZEBETA				
+	TEVA WOMENS	5MG **	N019982 002	Jul 31, 1992
+		10MG **	N019982 001	Jul 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE				
	ACTAVIS ELIZABETH	2.5MG;6.25MG	A075672 001	Sep 25, 2000
		5MG;6.25MG	A075672 002	Sep 25, 2000
		10MG;6.25MG	A075672 003	Sep 25, 2000
	APOTHECON	2.5MG;6.25MG	A075642 002	Dec 27, 2000
		5MG;6.25MG	A075642 001	Dec 27, 2000
		10MG;6.25MG	A075642 003	Dec 27, 2000
	CHARTWELL RX	2.5MG;6.25MG	A075527 001	Sep 25, 2000
		5MG;6.25MG	A075527 003	Sep 25, 2000
		10MG;6.25MG	A075527 002	Sep 25, 2000
	IVAX SUB TEVA PHARMS	2.5MG;6.25MG	A075632 001	Sep 27, 2000
		5MG;6.25MG	A075632 002	Sep 27, 2000
		10MG;6.25MG	A075632 003	Sep 27, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE				
TEVA	2.5MG;6.25MG	A075686	001	Jan 19, 2001
	5MG;6.25MG	A075686	002	Jan 19, 2001
	10MG;6.25MG	A075686	003	Jan 19, 2001
WATSON LABS TEVA	2.5MG;6.25MG	A075469	001	Sep 25, 2000
	5MG;6.25MG	A075469	002	Sep 25, 2000
	10MG;6.25MG	A075469	003	Sep 25, 2000

BITOLTEROL MESYLATE

AEROSOL, METERED;INHALATION				
TORNALATE				
SANOFI AVENTIS US	0.37MG/INH	N018770	001	Dec 28, 1984
SOLUTION;INHALATION				
TORNALATE				
SANOFI AVENTIS US	0.2%	N019548	001	Feb 19, 1992

BIVALIRUDIN

INJECTABLE;INTRAVENOUS				
BIVALIRUDIN				
APOTEX	250MG/VIAL	A204876	001	Jul 06, 2017
SOLUTION;INTRAVENOUS				
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE				
+ BAXTER HLTHCARE CORP	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017
+	500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017

BLEOMYCIN SULFATE

INJECTABLE;INJECTION				
BLENOXANE				
+ BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL **	N050443	001	
+	EQ 30 UNITS BASE/VIAL **	N050443	002	Sep 07, 1995
BLEOMYCIN SULFATE				
CIPLA	EQ 15 UNITS BASE/VIAL	A209439	001	Mar 11, 2019
PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201	001	Dec 13, 2007
TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL	A064084	001	Jun 01, 1996
	EQ 30 UNITS BASE/VIAL	A064084	002	Jun 01, 1996

BOCEPREVIR

CAPSULE;ORAL				
VICTRELIS				
MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS				
BORTEZOMIB				
ACCORD HLTHCARE	3.5MG/VIAL	A204405	001	Jul 26, 2022
MYLAN LABS LTD	3.5MG/VIAL	A205160	001	Oct 31, 2022
SCINOPHARM TAIWAN	3.5MG/VIAL	A216912	001	Sep 26, 2023
TEVA PHARMS USA	3.5MG/VIAL	A205857	001	May 02, 2022
POWDER;INTRAVENOUS				
BORTEZOMIB				
DR REDDYS	3.5MG/VIAL	N206927	001	Oct 04, 2019
FRESENIUS KABI USA	3.5MG/VIAL	N205004	001	Nov 06, 2017
SOLUTION;INTRAVENOUS				
BORTEZOMIB				
+ ACCORD HLTHCARE	2.5MG/ML (2.5MG/ML) **	N215441	001	Jul 26, 2022
+	3.5MG/1.4ML (2.5MG/ML) **	N215441	002	Jul 26, 2022
+ MAIA PHARMS INC	3.5MG/3.5ML (1MG/ML)	N215331	001	Jul 27, 2022
+	3.5MG/1.4ML (2.5MG/ML)	N215331	002	Jul 27, 2022

BOSENTAN

TABLET;ORAL				
BOSENTAN				
ALEMBIC	62.5MG	A211461	001	Jan 23, 2020
	125MG	A211461	002	Jan 23, 2020
ALVOGEN PINE BROOK	62.5MG	A206002	001	Apr 26, 2019
	125MG	A206002	002	Apr 26, 2019
AMNEAL PHARMS CO	62.5MG	A209742	001	Apr 26, 2019
	125MG	A209742	002	Apr 26, 2019
CHARTWELL MOLECULAR	62.5MG	A210342	001	Jan 03, 2020
	125MG	A210342	002	Jan 03, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BOSENTAN

TABLET;ORAL

BOSENTAN

HIKMA	62.5MG	A208695	001	Apr 26, 2019
	125MG	A208695	002	Apr 26, 2019
MYLAN	62.5MG	A205173	001	Jan 15, 2020
	125MG	A205173	002	Jan 15, 2020
NATCO PHARMA LTD	62.5MG	A206987	001	Apr 26, 2019
	125MG	A206987	002	Apr 26, 2019
PAR PHARM INC	62.5MG	A205699	001	Apr 26, 2019
	125MG	A205699	002	Apr 26, 2019

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

ABRAXIS PHARM	50MG/ML	A070134	001	Apr 29, 1986
	100MG/ML	A071298	001	Feb 13, 1987
ASTRAZENECA	50MG/ML	A071151	001	Aug 10, 1987
	50MG/ML	A071152	001	Aug 10, 1987
	50MG/ML	A071153	001	Aug 10, 1987
BRECKENRIDGE	50MG/ML	A204386	001	Dec 21, 2018
HIKMA	50MG/ML	A070545	001	May 14, 1986
	50MG/ML	A070546	001	May 14, 1986
+ HOSPIRA	50MG/ML **	N019030	001	Apr 29, 1986
	50MG/ML	N019033	001	Apr 29, 1986
INTL MEDICATION	50MG/ML	A070119	001	Apr 29, 1986
LUITPOLD	50MG/ML	A070891	001	Jul 26, 1988

BRETYLIUM TOSYLATE IN DEXTROSE 5%

ABBOTT	200MG/100ML	N019005	002	Apr 29, 1986
	400MG/100ML	N019005	003	Apr 29, 1986
	800MG/100ML	N019005	001	Apr 29, 1986

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986
	200MG/100ML	N019121	002	Apr 29, 1986
	400MG/100ML	N019121	003	Apr 29, 1986
BAXTER HLTHCARE	200MG/100ML	N019837	002	Apr 12, 1989
	400MG/100ML	N019837	001	Apr 12, 1989
HOSPIRA INC	200MG/100ML	N019008	002	Apr 29, 1986
	400MG/100ML	N019008	003	Apr 29, 1986
	800MG/100ML	N019008	001	Apr 29, 1986

BRETYLOL

HOSPIRA	50MG/ML	N017954	001	

BREXPIPRAZOLE

TABLET;ORAL

BREXPIPRAZOLE

AJANTA PHARMA LTD	0.25MG	A213718	001	Feb 03, 2023
	0.5MG	A213718	002	Feb 03, 2023
	1MG	A213718	003	Feb 03, 2023
	2MG	A213718	004	Feb 03, 2023
	3MG	A213718	005	Feb 03, 2023
	4MG	A213718	006	Feb 03, 2023
AMNEAL	0.25MG	A213562	001	Jan 31, 2023
	0.5MG	A213562	002	Jan 31, 2023
	1MG	A213562	003	Jan 31, 2023
	2MG	A213562	004	Jan 31, 2023
	3MG	A213562	005	Jan 31, 2023
	4MG	A213562	006	Jan 31, 2023
AUROBINDO PHARMA LTD	0.25MG	A213659	001	Nov 02, 2023
	0.5MG	A213659	002	Nov 02, 2023
	1MG	A213659	003	Nov 02, 2023
	2MG	A213659	004	Nov 02, 2023
	3MG	A213659	005	Nov 02, 2023
	4MG	A213659	006	Nov 02, 2023
LUPIN LTD	0.25MG	A213512	001	Mar 17, 2023
	0.5MG	A213512	002	Mar 17, 2023
	1MG	A213512	003	Mar 17, 2023
	2MG	A213512	004	Mar 17, 2023
	3MG	A213512	005	Mar 17, 2023
	4MG	A213512	006	Mar 17, 2023

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BREXPIPRAZOLE				
TABLET;ORAL				
BREXPIPRAZOLE				
SANDOZ	0.25MG	A213570	001	Sep 26, 2022
	0.5MG	A213570	002	Sep 26, 2022
	1MG	A213570	003	Sep 26, 2022
	2MG	A213570	004	Sep 26, 2022
	3MG	A213570	005	Sep 26, 2022
	4MG	A213570	006	Sep 26, 2022
TEVA PHARMS USA INC	0.25MG	A213692	001	Aug 11, 2022
	0.5MG	A213692	002	Aug 11, 2022
	1MG	A213692	003	Aug 11, 2022
	2MG	A213692	004	Aug 11, 2022
	3MG	A213692	005	Aug 11, 2022
	4MG	A213692	006	Aug 11, 2022
ZYDUS PHARMS	0.25MG	A213660	001	Jan 10, 2023
	0.5MG	A213660	002	Jan 10, 2023
	1MG	A213660	003	Jan 10, 2023
	2MG	A213660	004	Jan 10, 2023
	3MG	A213660	005	Jan 10, 2023
	4MG	A213660	006	Jan 10, 2023
BRIMONIDINE TARTRATE				
SOLUTION/DROPS;OPHTHALMIC				
ALPHAGAN				
+ ALLERGAN	0.2% **	N020613	001	Sep 06, 1996
	0.5%	N020490	001	Mar 13, 1997
BRIMONIDINE TARTRATE				
TEVA PARENTERAL	0.2%	A076372	001	Sep 10, 2004
BRIVARACETAM				
TABLET;ORAL				
BRIVARACETAM				
AUROBINDO PHARMA LTD	50MG	A214848	001	Jan 06, 2023
	100MG	A214848	002	Jan 06, 2023
LUPIN LTD	10MG	A214918	001	Dec 20, 2022
	25MG	A214918	002	Dec 20, 2022
	50MG	A214918	003	Dec 20, 2022
	75MG	A214918	004	Dec 20, 2022
	100MG	A214918	005	Dec 20, 2022
SUNSHINE	10MG	A214748	001	Jun 09, 2022
	25MG	A214748	002	Jun 09, 2022
	50MG	A214748	003	Jun 09, 2022
	75MG	A214748	004	Jun 09, 2022
	100MG	A214748	005	Jun 09, 2022
ZYDUS PHARMS	10MG	A214501	001	Oct 03, 2022
	25MG	A214501	002	Oct 03, 2022
	50MG	A214501	003	Oct 03, 2022
	75MG	A214501	004	Oct 03, 2022
	100MG	A214501	005	Oct 03, 2022
BROMFENAC SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
BROMDAY				
+ BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664	002	Oct 16, 2010
BROMFENAC SODIUM				
AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013
APOTEX	EQ 0.09% ACID	A202435	001	Jun 19, 2014
	EQ 0.09% ACID	A202620	001	Jun 23, 2014
CHARTWELL RX	EQ 0.09% ACID	A201941	001	Feb 10, 2015
COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011
RISING	EQ 0.09% ACID	A203368	001	Jun 03, 2019
XIBROM				
+ BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664	001	Mar 24, 2005

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL				
BROMOCRIPTINE MESYLATE				
	LEK PHARM	EQ 5MG BASE	A075100 001	Dec 10, 1998
TABLET;ORAL				
BROMOCRIPTINE MESYLATE				
	AUROBINDO PHARMA USA	EQ 2.5MG BASE	A076962 001	Sep 24, 2004

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
AMBODRYL				
	PARKE DAVIS	25MG	N007984 001	

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP;ORAL				
AMBENYL				
	FOREST LABS	12.5MG/5ML;10MG/5ML	N009319 006	Jan 10, 1984
BROMANYL				
	ALPHARMA US PHARMS	12.5MG/5ML;10MG/5ML	A088343 001	Aug 15, 1984
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE				
	WOCKHARDT	12.5MG/5ML;10MG/5ML	A088626 001	Oct 12, 1984

BROMPHENIRAMINE MALEATE

ELIXIR;ORAL				
BROMPHENIRAMINE MALEATE				
	ALPHARMA US PHARMS	2MG/5ML	A086936 001	
	KV PHARM	2MG/5ML	A085466 001	
	PHARM ASSOC	2MG/5ML	A087517 001	
	USL PHARMA	2MG/5ML	A087964 001	Jan 25, 1983
INJECTABLE;INJECTION				
BROMPHENIRAMINE MALEATE				
	WATSON LABS	10MG/ML	A083821 001	
		100MG/ML	A083820 001	
DIMETANE-TEN				
	WYETH AYERST	10MG/ML	N011418 002	
TABLET;ORAL				
BROMPHENIRAMINE MALEATE				
	BARR	4MG	A084468 001	
	IVAX SUB TEVA PHARMS	4MG	A084351 001	
	NEWTRON PHARMS	4MG	A086987 001	
	NEXGEN PHARMA INC	4MG	A086187 001	
	PAR PHARM	4MG	A087009 001	
	PIONEER PHARMS	4MG	A088604 001	Jul 13, 1984
	UPSHER SMITH LABS	4MG	A083215 001	
	VITARINE	4MG	A085850 001	
	WATSON LABS	4MG	A083123 001	
		4MG	A085769 001	
DIMETANE				
	WYETH CONS	4MG	N010799 003	
TABLET, EXTENDED RELEASE;ORAL				
DIMETANE				
	WYETH CONS	8MG	N010799 010	Jun 10, 1983
		12MG	N010799 011	Jun 10, 1983

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL				
BROMANATE DM				
	ALPHARMA US PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A088722 001	Mar 07, 1985
BROMFED-DM				
	WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A089681 001	Dec 22, 1988
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE				
	BIONPHARMA	2MG/5ML;10MG/5ML;30MG/5ML	A203997 001	Sep 30, 2020
	RHODES PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A202955 001	Nov 05, 2020
DIMETANE-DX				
+	ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML **	N019279 001	Aug 24, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE					
	ALZA	16MG;240MG	N019672	001	Mar 29, 1996

BUCLIZINE HYDROCHLORIDE

TABLET;ORAL					
BUCLADIN-S					
	STUART PHARMS	50MG	N010911	006	

BUDESONIDE

AEROSOL, METERED;NASAL					
RHINOCORT					
	ASTRAZENECA	0.032MG/INH	N020233	001	Feb 14, 1994
CAPSULE, DELAYED RELEASE;ORAL					
BUDESONIDE					
	BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014
	NATCO	3MG	A206724	001	Nov 23, 2016
	SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017
ORTIKOS					
+	SUN PHARM INDS INC	6MG	N211929	001	Jun 13, 2019
+		9MG	N211929	002	Jun 13, 2019
POWDER, METERED;INHALATION					
PULMICORT					
	ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997
		0.32MG/INH	N020441	003	Jun 24, 1997

BUMETANIDE

INJECTABLE;INJECTION					
BUMETANIDE					
	HOSPIRA	0.25MG/ML	A074160	001	Oct 30, 1997
	TEVA PARENTERAL	0.25MG/ML	A074613	001	Nov 18, 1997
BUMEX					
+	VALIDUS PHARMS	0.25MG/ML **	N018226	001	Feb 28, 1983

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION					
BUPIVACAINE HYDROCHLORIDE					
	CIVICA	0.5%	A211096	001	Feb 19, 2019
	HOSPIRA	0.25%	A070586	001	Mar 03, 1987
		0.25%	N018053	002	
		0.5%	N018053	001	
		0.75%	A070587	001	Mar 03, 1987
		0.75%	N018053	003	
BUPIVACAINE HYDROCHLORIDE KIT					
	HOSPIRA	0.075%	N019978	001	Sep 03, 1992
		0.114%	N019978	002	Sep 03, 1992
		0.23%	N019978	003	Sep 03, 1992
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
	INTL MEDICATED	0.25%	A076012	001	Jan 09, 2002
		0.5%	A076012	002	Jan 09, 2002
		0.75%	A076012	003	Jan 09, 2002
INJECTABLE;SPINAL					
BUPIVACAINE HYDROCHLORIDE					
	BAXTER HLTHCARE CORP	0.75%	A207266	001	Jul 25, 2016
SENSORCAINE					
	FRESENIUS KABI USA	0.75%	A071202	001	Apr 15, 1987

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE;INJECTION					
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE					
	HOSPIRA	0.25%;0.005MG/ML	A071166	001	Jun 16, 1988
		0.5%;0.005MG/ML	A071169	001	Jun 16, 1988
		0.75%;0.005MG/ML	A071171	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION					
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE					
+	HOSPIRA	0.5%;0.0091MG/ML	N022046	001	Jul 13, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION					
DUOCAINE					
	AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496	001	May 23, 2003

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE;PERIARTICULAR					
ZYNRELEF KIT					
+	HERON THERAPS INC	60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML)	N211988	001	May 12, 2021
+		300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML)	N211988	003	May 12, 2021

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL					
BUPRENORPHINE					
	ALVOGEN	7.5MCG/HR	A207490	005	Mar 21, 2023
	MYLAN TECH VIATRIS	5MCG/HR	A210162	001	May 03, 2021
		7.5MCG/HR	A210162	002	May 03, 2021
		10MCG/HR	A210162	003	May 03, 2021
		15MCG/HR	A210162	004	May 03, 2021
		20MCG/HR	A210162	005	May 03, 2021

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL					
BUPRENORPHINE HYDROCHLORIDE					
	ALVOGEN	EQ 0.075MG BASE	A211594	001	Aug 03, 2021
		EQ 0.15MG BASE	A211594	002	Aug 03, 2021
		EQ 0.3MG BASE	A211594	003	Aug 03, 2021
		EQ 0.45MG BASE	A211594	004	Aug 03, 2021
		EQ 0.6MG BASE	A211594	005	Aug 03, 2021
		EQ 0.75MG BASE	A211594	006	Aug 03, 2021
		EQ 0.9MG BASE	A211594	007	Aug 03, 2021
IMPLANT;IMPLANTATION					
PROBUPHINE					
+	TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016
INJECTABLE;INJECTION					
BUPRENEX					
+	INDIVIOR	EQ 0.3MG BASE/ML **	N018401	001	
TABLET;SUBLINGUAL					
BUPRENORPHINE HYDROCHLORIDE					
	BARR	EQ 2MG BASE	A090360	001	May 07, 2010
		EQ 8MG BASE	A090360	002	May 07, 2010
	MYLAN	EQ 2MG BASE	A201066	001	Mar 06, 2015
		EQ 8MG BASE	A201066	002	Mar 06, 2015
SUBUTEX					
+	INDIVIOR	EQ 2MG BASE **	N020732	002	Oct 08, 2002
+		EQ 8MG BASE **	N020732	003	Oct 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL					
BUNAVAIL					
+	BDSI	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637	001	Jun 06, 2014
+		EQ 4.2MG BASE;EQ 0.7MG BASE	N205637	002	Jun 06, 2014
+		EQ 6.3MG BASE;EQ 1MG BASE	N205637	003	Jun 06, 2014
FILM;SUBLINGUAL					
CASSIPA					
+	TEVA PHARMS USA	EQ 16MG BASE;EQ 4MG BASE	N208042	001	Sep 07, 2018
TABLET;SUBLINGUAL					
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE					
	DR REDDYS LABS SA	EQ 2MG BASE;EQ 0.5MG BASE	A206953	001	Jul 17, 2020
		EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020
	TEVA PHARMS USA	EQ 2MG BASE;EQ 0.5MG BASE	A091149	001	Sep 08, 2014
		EQ 8MG BASE;EQ 2MG BASE	A091149	002	Sep 08, 2014
SUBOXONE					
+	INDIVIOR	EQ 2MG BASE;EQ 0.5MG BASE **	N020733	001	Oct 08, 2002
+		EQ 8MG BASE;EQ 2MG BASE **	N020733	002	Oct 08, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BUPROPION HYDROCHLORIDE

TABLET;ORAL					
BUPROPION HYDROCHLORIDE					
	AUROBINDO PHARMA USA	75MG	A075491	001	Apr 17, 2000
		100MG	A075491	002	Apr 17, 2000
	HERITAGE PHARMA	75MG	A075310	001	Nov 29, 1999
		100MG	A075310	002	Nov 29, 1999
	INVATECH	75MG	A075613	002	Oct 10, 2000
		100MG	A075613	001	Oct 10, 2000
WELLBUTRIN					
+	GLAXOSMITHKLINE	50MG **	N018644	001	Dec 30, 1985
+		75MG **	N018644	002	Dec 30, 1985
+		100MG **	N018644	003	Dec 30, 1985
TABLET, EXTENDED RELEASE;ORAL					
BUPROPION HYDROCHLORIDE					
	ACTAVIS LABS FL INC	300MG	A077715	002	Jun 13, 2007
	ANCHEN PHARMS	150MG	A077284	001	Dec 14, 2006
		300MG	A077284	002	Dec 14, 2006
	AUROBINDO PHARMA USA	100MG	A090325	001	Apr 08, 2010
		150MG	A090325	002	Apr 08, 2010
		150MG	A090942	001	Jul 14, 2010
		200MG	A090325	003	Apr 08, 2010
		300MG	A090942	002	Jul 14, 2010
	IMPAX LABS	150MG	A077415	001	Nov 26, 2008
		200MG	A076711	001	Dec 03, 2004
		300MG	A077415	002	Dec 15, 2006
	JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013
		150MG	A202774	002	Oct 11, 2013
		150MG	A202775	001	Oct 11, 2013
		150MG	A207459	001	Jun 30, 2017
		200MG	A202774	003	Oct 11, 2013
		300MG	A207459	002	Jun 30, 2017
	MYLAN	150MG	A090941	001	May 03, 2010
	SANDOZ	100MG	A076845	001	Jul 14, 2005
		150MG	A076834	001	Jul 14, 2005
		150MG	A076845	002	Jul 14, 2005
	SUN PHARM	100MG	A078866	001	Apr 06, 2010
		150MG	A200695	001	Dec 18, 2014
	TORRENT	100MG	A203969	001	Oct 31, 2014
		150MG	A203969	002	Oct 31, 2014
		200MG	A203969	003	Oct 31, 2014
	WATSON LABS INC	100MG	A077455	001	Jul 19, 2010
		150MG	A077455	002	Mar 12, 2008
		200MG	A077455	003	Jul 19, 2010
	WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012
		150MG	A201331	002	Aug 30, 2012
		200MG	A201331	003	Aug 30, 2012
WELLBUTRIN SR					
	GLAXOSMITHKLINE	50MG	N020358	001	Oct 04, 1996
ZYBAN					
	GLAXOSMITHKLINE	100MG	N020711	002	May 14, 1997
+		150MG **	N020711	003	May 14, 1997

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL					
BUSPAR					
+	BRISTOL MYERS SQUIBB	5MG **	N021190	001	Dec 20, 2000
+		7.5MG **	N021190	002	Dec 20, 2000
+		10MG **	N021190	003	Dec 20, 2000
+		15MG **	N021190	004	Dec 20, 2000
TABLET;ORAL					
BUSPAR					
+	BRISTOL MYERS SQUIBB	5MG **	N018731	001	Sep 29, 1986
+		10MG **	N018731	002	Sep 29, 1986
+		15MG **	N018731	003	Apr 22, 1996
+		30MG **	N018731	004	Apr 22, 1996
BUSPIRONE HYDROCHLORIDE					
	EGIS	5MG	A075119	001	Mar 14, 2002
		10MG	A075119	002	Mar 14, 2002
		15MG	A075119	003	Jan 23, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BUSPIRONE HYDROCHLORIDE				
TABLET;ORAL				
BUSPIRONE HYDROCHLORIDE				
IVAX SUB TEVA PHARMS	5MG **	A075385	001	Mar 01, 2002
	10MG **	A075385	002	Mar 01, 2002
	15MG **	A075385	003	Mar 01, 2002
MYLAN	5MG	A075467	001	Feb 28, 2002
	7.5MG	A075467	002	Mar 28, 2001
	10MG	A075467	003	Feb 28, 2002
	15MG	A075467	004	Feb 28, 2002
NESHER PHARMS	5MG	A075572	001	Feb 27, 2002
	10MG	A075572	002	Feb 27, 2002
	15MG	A075572	003	Feb 27, 2002
RISING	5MG	A075413	001	Mar 19, 2002
	10MG	A075413	002	Mar 19, 2002
	15MG	A075413	003	Mar 19, 2002
BUSULFAN				
INJECTABLE;INJECTION				
BUSULFAN				
ACTAVIS	6MG/ML	A205139	001	Dec 08, 2017
AM REGENT	6MG/ML	A202259	001	Dec 22, 2015
ARTHUR GRP	6MG/ML	A205106	001	Sep 21, 2018
MYLAN LABS LTD	6MG/ML	A205184	001	Jul 13, 2018
BUTABARBITAL SODIUM				
CAPSULE;ORAL				
BUTICAPS				
MEDPOINTE PHARM HLC	15MG	A085381	001	
	30MG	A085381	002	
	50MG	A085381	003	
	100MG	A085381	004	
ELIXIR;ORAL				
BUTABARB				
ALPHARMA US PHARMS	30MG/5ML	A085873	001	
BUTABARBITAL SODIUM				
WOCKHARDT	30MG/5ML	A085383	001	
BUTALAN				
LANNETT	33.3MG/5ML	A085880	001	
BUTISOL SODIUM				
MEDA PHARMS	30MG/5ML	A085380	001	
SARISOL				
HALSEY	30MG/5ML	A084723	001	
TABLET;ORAL				
BUTABARBITAL				
BUNDY	30MG	A085550	001	
BUTABARBITAL SODIUM				
SANDOZ	15MG	A084292	003	Feb 09, 1982
+	15MG	A085938	001	
	30MG	A084272	002	
	30MG	A085934	001	
SOLVAY	16.2MG	A083606	001	
	32.4MG	A083898	001	
	48.6MG	A083897	001	
	97.2MG	A083896	001	
TEVA	15MG	A088632	001	May 18, 1985
	30MG	A088631	001	May 01, 1985
WATSON LABS	15MG	A085764	001	
	30MG	A085772	001	
WHITEWORTH TOWN PLSN	15MG	A083325	002	
	30MG	A083337	001	
BUTISOL SODIUM				
MYLAN SPECIALITY LP	15MG **	N000793	002	
+	30MG	N000793	004	
	50MG **	N000793	003	
	100MG **	N000793	005	
SARISOL NO. 1				
HALSEY	15MG	A084719	001	
SARISOL NO. 2				
HALSEY	30MG	A084719	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BUTABARBITAL SODIUM

TABLET;ORAL				
SODIUM BUTABARBITAL				
HIKMA	15MG	A085418 001		
	30MG	A085432 001		
IVAX SUB TEVA PHARMS	15MG	A083484 001		
	30MG	A084040 001		
LANNETT	15MG	A085849 001		
	30MG	A085866 001		
	100MG	A085881 001		
MARSHALL PHARMA	16.2MG	A083524 001		
	32.4MG	A083858 001		

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL				
MENTAX				
+ MYLAN	1%	N020524 001	Oct 18, 1996	
MENTAX-TC				
MYLAN	1%	N021408 001	Oct 17, 2002	

BUTOCONAZOLE NITRATE

CREAM;VAGINAL				
BUTOCONAZOLE NITRATE				
PADAGIS US	2%	N019881 001	Feb 07, 1997	
FEMSTAT				
ROCHE PALO	2%	N019215 001	Nov 25, 1985	
FEMSTAT 3				
+ BAYER	2%	N020421 001	Dec 21, 1995	
SUPPOSITORY;VAGINAL				
FEMSTAT				
ROCHE PALO	100MG	N019359 001	Nov 25, 1985	

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION				
BUTORPHANOL TARTRATE				
BAXTER HLTHCARE CORP	2MG/ML	A075697 001	Oct 23, 2001	
HIKMA FARMACEUTICA	2MG/ML	A078247 001	Apr 29, 2009	
HOSPIRA	1MG/ML	A075342 001	Nov 04, 1999	
	1MG/ML	A075559 001	Mar 20, 2000	
	2MG/ML	A075342 002	Nov 04, 1999	
	2MG/ML	A075559 002	Mar 20, 2000	
BUTORPHANOL TARTRATE PRESERVATIVE FREE				
BAXTER HLTHCARE CORP	1MG/ML	A075695 001	Oct 23, 2001	
	2MG/ML	A075695 002	Oct 23, 2001	
HOSPIRA	1MG/ML	A074620 001	Jan 22, 1997	
	1MG/ML	A075170 001	Sep 28, 1998	
	2MG/ML	A074620 002	Jan 22, 1997	
	2MG/ML	A075170 002	Sep 28, 1998	
STADOL				
+ APOTHECON	2MG/ML **	N017857 004		
STADOL PRESERVATIVE FREE				
+ APOTHECON	1MG/ML **	N017857 001		
+	2MG/ML **	N017857 002		
SPRAY, METERED;NASAL				
STADOL				
BRISTOL MYERS SQUIBB	1MG/SPRAY **	N019890 001	Dec 12, 1991	

CABAZITAXEL

SOLUTION;INTRAVENOUS				
CABAZITAXEL				
APOTEX	60MG/1.5ML (40MG/ML)	A207736 001	Feb 10, 2023	
BRECKENRIDGE	60MG/1.5ML (40MG/ML)	A207619 001	Jun 23, 2022	
MYLAN LABS LTD	60MG/1.5ML (40MG/ML)	A207381 001	Jul 05, 2023	

CABERGOLINE

TABLET;ORAL				
CABERGOLINE				
ACTAVIS LABS FL INC	0.5MG	A078035 001	Apr 21, 2008	
APOTEX CORP	0.5MG	A201503 001	Mar 08, 2013	
IMPAX LABS INC	0.5MG	A077843 001	Jul 03, 2007	
MYLAN	0.5MG	A202947 001	Dec 02, 2013	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CABERGOLINE					
TABLET;ORAL					
DOSTINEX					
+	PFIZER	0.5MG **	N020664	001	Dec 23, 1996
CAFFEINE CITRATE					
SOLUTION;INTRAVENOUS					
CAFFEINE CITRATE					
	SUN PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090077	001	Sep 30, 2009
SOLUTION;ORAL					
CAFCIT					
+	HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML) **	N020793	002	Apr 12, 2000
CAFFEINE CITRATE					
	AM REGENT	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090064	001	Nov 20, 2009
CAFFEINE; ERGOTAMINE TARTRATE					
SUPPOSITORY;RECTAL					
CAFERGOT					
+	NOVARTIS	100MG;2MG **	N009000	002	
TABLET;ORAL					
CAFERGOT					
	NOVARTIS	100MG;1MG	N006620	001	
+	SANDOZ	100MG;1MG	A084294	001	
ERGOTAMINE TARTRATE AND CAFFEINE					
	HIKMA INTL PHARMS	100MG;1MG	A040510	001	Sep 17, 2004
WIGRAINE					
	ORGANON USA INC	100MG;1MG	A086562	001	
CALCIFEDIOL					
CAPSULE;ORAL					
CALDEROL					
	ORGANON USA INC	0.02MG	N018312	001	
		0.05MG	N018312	002	
CALCIPOTRIENE					
CREAM;TOPICAL					
CALCIPOTRIENE					
	CHARTWELL RX	0.005%	A200935	001	May 30, 2012
SOLUTION;TOPICAL					
CALCIPOTRIENE					
	CHARTWELL RX	0.005%	A077029	001	Nov 20, 2009
DOVONEX					
+	LEO PHARM	0.005% **	N020611	001	Mar 03, 1997
CALCITONIN HUMAN					
INJECTABLE;INJECTION					
CIBACALCIN					
	NOVARTIS	0.5MG/VIAL	N018470	001	Oct 31, 1986
CALCITONIN SALMON					
INJECTABLE;INJECTION					
CALCIMAR					
+	SANOFI AVENTIS US	200 IU/ML **	N017769	001	
		400 IU/VIAL	N017497	001	
CALCITONIN-SALMON					
	IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995
MIACALCIN					
+	MYLAN IRELAND LTD	100 IU/ML **	N017808	001	Jul 03, 1986
SPRAY, METERED;NASAL					
CALCITONIN-SALMON					
	PAR PHARM	200 IU/SPRAY	A076979	001	Jun 08, 2009
MIACALCIN					
+	MYLAN IRELAND LTD	200 IU/SPRAY **	N020313	002	Aug 17, 1995
CALCITONIN SALMON RECOMBINANT					
SPRAY, METERED;NASAL					
FORTICAL					
	UPSHER SMITH LABS	200 IU/SPRAY **	N021406	001	Aug 12, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCITRIOL

INJECTABLE;INJECTION					
CALCIJEX					
+	ABBVIE	0.001MG/ML **	N018874	001	Sep 25, 1986
+		0.002MG/ML **	N018874	002	Sep 25, 1986
CALCITRIOL					
	AM REGENT	0.001MG/ML	A075746	001	Sep 26, 2003
		0.002MG/ML	A075746	002	Sep 26, 2003
	FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002
		0.002MG/ML	A075836	002	Dec 31, 2002
	FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003
		0.002MG/ML	A075766	002	Feb 20, 2003
	HOSPIRA	0.001MG/ML	A075816	001	Jan 16, 2004
		0.002MG/ML	A075816	002	Jan 16, 2004
	LONG GROVE PHARMS	0.002MG/ML	A078066	002	Jan 29, 2008
	ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003
	SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006
	TEVA PARENTERAL	0.001MG/ML	A075823	001	Mar 31, 2003
		0.002MG/ML	A075823	002	Mar 31, 2003

CALCIUM ACETATE

CAPSULE;ORAL					
CALCIUM ACETATE					
	AMNEAL PHARMS	667MG	A201658	001	Oct 06, 2014
	LOTUS PHARM CO LTD	667MG	A203298	001	Jul 26, 2016
PHOSLO					
	FRESENIUS MEDCL	333.5MG	N021160	001	Apr 02, 2001
		667MG	N021160	002	Apr 02, 2001
SOLUTION;ORAL					
PHOSLYRA					
+	FRESENIUS MEDCL	667MG/5ML	N022581	001	Apr 18, 2011
TABLET;ORAL					
CALCIUM ACETATE					
	HIKMA	667MG	A077693	001	Jan 30, 2008
ELIPHOS					
	CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008
PHOSLO					
+	FRESENIUS MEDCL	667MG **	N019976	001	Dec 10, 1990

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL					
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE					
	PERRIGO R AND D	800MG;10MG;165MG	A204782	001	Aug 29, 2016

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET;ORAL					
ACTONEL WITH CALCIUM (COPACKAGED)					
+	WARNER CHILCOTT	EQ 500MG BASE;35MG **	N021823	001	Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION					
METHOTREXATE SODIUM					
	EPIC PHARMA LLC	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N020079	001	Feb 26, 1999

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008
PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER					
	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
PRISMASOL BGK 4/0 IN PLASTIC CONTAINER					
	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006
PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER					
	BAXTER HLTHCARE CORP	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006
PRISMASOL BK 0/0 IN PLASTIC CONTAINER					
	BAXTER HLTHCARE CORP	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE CORP	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006
PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER					
	BAXTER HLTHCARE CORP	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION					
NAVSTEL					
	ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N022193	001	Jul 24, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N019864	001	Jun 10, 1993
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N018271	001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION					
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019867	001	Dec 20, 1993
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018269	002	Jan 17, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION					
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML **	N017390	001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION;INTRAPERITONEAL					
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER					
	B BRAUN	510MG/100ML;30GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807	001	Aug 26, 1983
		510MG/100ML;30GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML	N018807	003	Aug 26, 1983
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER					
	B BRAUN	510MG/100ML;50GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807	002	Aug 26, 1983
		510MG/100ML;50GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML	N018807	004	Aug 26, 1983
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	B BRAUN	29MG/100ML;2.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	006	Jan 29, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION;INTRAPERITONEAL					
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	B BRAUN	29MG/100ML;1.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	001	
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	B BRAUN	29MG/100ML;4.25GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	003	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL					
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	002	
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	003	
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	007	Jun 24, 1988
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	001	
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	004	Jul 07, 1982
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	005	Jul 07, 1982
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	008	Jun 24, 1988
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	006	Jul 07, 1982
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	B BRAUN	26MG/100ML;1.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	007	Jan 29, 1986
		26MG/100ML;1.5GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N018460	002	
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	B BRAUN	26MG/100ML;2.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	005	Nov 02, 1983
		26MG/100ML;5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	008	Jan 29, 1986
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	B BRAUN	26MG/100ML;4.25GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	009	Jan 29, 1986
		26MG/100ML;4.25GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N018460	004	
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	001	
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	003	
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	002	
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	003	Dec 04, 1992
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	007	Jul 09, 1984
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	008	Jul 09, 1984
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	009	Jul 09, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

	FRESENIUS	18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	001	Jun 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

	FRESENIUS	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	002	Jun 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

	FRESENIUS	18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	003	Jun 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

	FRESENIUS	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	004	Jun 13, 1994

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N018258	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

	HOSPIRA	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N018254	001	

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N018256	001	
		33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N020000	001	Apr 17, 1992
	BAXTER HLTHCARE	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N016695	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	4MG/100ML;4GM/100ML;6MG/100ML;120MG/100ML;62MG/100ML	N019634	002	Feb 24, 1988

DEXTROSE 5% AND LACTATED RINGER'S

	FRESENIUS KABI USA	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	A210332	001	Mar 28, 2022

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N017510	001	
	MILES	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018499	001	

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	005	Oct 17, 1988
+		20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685	006	Oct 17, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	007	Oct 17, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	FRESENIUS KABI USA	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	A211428	001	Nov 09, 2021
+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685	008	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	003	Oct 17, 1988

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685	004	Oct 17, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	001	Oct 17, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL				
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;538MG/100ML;448MG/100ML	N019395	001	Mar 26, 1986
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;538MG/100ML;448MG/100ML	N019395	002	Mar 26, 1986
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;538MG/100ML;448MG/100ML	N019395	003	Mar 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION				
TPN ELECTROLYTES IN PLASTIC CONTAINER				
ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N019399	001	Jun 16, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION				
ISOLYTE E IN PLASTIC CONTAINER				
B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018899	001	Oct 31, 1983
	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019718	001	Sep 29, 1989
SOLUTION;IRRIGATION				
BALANCED SALT				
EPIC PHARMA LLC	0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML	A075503	001	Sep 27, 2006

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION				
PLASMA-LYTE R IN PLASTIC CONTAINER				
BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML	N017438	001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION				
ACETATED RINGER'S IN PLASTIC CONTAINER				
B BRAUN	20MG/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N018725	001	Nov 29, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION				
RINGER'S IN PLASTIC CONTAINER				
B BRAUN	33MG/100ML;30MG/100ML;860MG/100ML	N018721	001	Nov 09, 1982
SOLUTION;IRRIGATION				
RINGER'S IN PLASTIC CONTAINER				
ABBOTT	33MG/100ML;30MG/100ML;860MG/100ML	N018462	001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION				
LACTATED RINGER'S IN PLASTIC CONTAINER				
ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N019485	001	Oct 24, 1985
B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018023	001	
MILES	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018417	001	
SOLUTION;IRRIGATION				
LACTATED RINGER'S IN PLASTIC CONTAINER				
BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N019933	001	Aug 29, 1989

CALCIUM GLUCEPTATE

INJECTABLE;INJECTION				
CALCIUM GLUCEPTATE				
+ ABBOTT	EQ 90MG CALCIUM/5ML	A080001	001	
	EQ 90MG CALCIUM/5ML	A083159	001	
ABRAXIS PHARM	EQ 90MG CALCIUM/5ML	A089373	001	Apr 30, 1987
LILLY	EQ 90MG CALCIUM/5ML	N006470	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE;INJECTION				
ISOPAQUE 440				
	GE HEALTHCARE	0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML	N016847 001	

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE;INJECTION				
ISOPAQUE 280				
	GE HEALTHCARE	0.35MG/ML;140.1MG/ML;461.8MG/ML	N017506 001	

CANDESARTAN CILEXETIL

TABLET;ORAL				
CANDESARTAN CILEXETIL				
	APOTEX	4MG	A202079 001	Jan 10, 2014
		8MG	A202079 002	Jan 10, 2014
		16MG	A202079 003	Jan 10, 2014
		32MG	A202079 004	Jan 10, 2014

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE				
	APOTEX INC	16MG;12.5MG	A202884 001	Dec 04, 2012
		32MG;12.5MG	A202884 002	Dec 04, 2012
		32MG;25MG	A202884 003	Jun 03, 2013

CANDICIDIN

OINTMENT;VAGINAL				
VANOBID				
	SANOFI AVENTIS US	0.6MG/GM	A061596 001	
TABLET;VAGINAL				
VANOBID				
	SANOFI AVENTIS US	3MG	A061613 001	

CAPECITABINE

TABLET;ORAL				
CAPECITABINE				
	AMNEAL PHARMS	150MG	A204741 001	Feb 28, 2017
		500MG	A204741 002	Feb 28, 2017

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION				
CAPASTAT SULFATE				
+	EPIC PHARMA LLC	EQ 1GM BASE/VIAL	N050095 001	
CAPREOMYCIN SULFATE				
	HISUN PHARM HANGZHOU	EQ 1GM BASE/VIAL	A204796 001	Oct 18, 2018
	MYLAN LABS LTD	EQ 1GM BASE/VIAL	A202634 001	Nov 27, 2017

CAPTOPRIL

TABLET;ORAL				
CAPOTEN				
+	STRIDES PHARMA	12.5MG **	N018343 005	Jan 17, 1985
+		25MG **	N018343 002	
+		37.5MG **	N018343 006	Sep 17, 1986
+		50MG **	N018343 001	
+		75MG **	N018343 007	Jun 13, 1995
+		100MG **	N018343 003	
+		150MG **	N018343 004	Jun 13, 1995
CAPTOPRIL				
	APOTHECON	12.5MG	A074472 001	Mar 31, 1995
		25MG	A074472 002	Mar 31, 1995
		50MG	A074472 003	Mar 31, 1995
		100MG	A074472 004	Mar 31, 1995
	AUROBINDO PHARMA USA	12.5MG	A074434 001	Feb 13, 1996
		25MG	A074434 002	Feb 13, 1996
		50MG	A074434 003	Feb 13, 1996
		100MG	A074434 004	Feb 13, 1996
	CHARTWELL RX	12.5MG	A074363 001	Nov 09, 1995
		12.5MG	A074519 001	Feb 13, 1996
		25MG	A074363 002	Nov 09, 1995
		25MG	A074519 002	Feb 13, 1996
		50MG	A074363 003	Nov 09, 1995
		50MG	A074519 003	Feb 13, 1996
		100MG	A074363 004	Nov 09, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

	100MG	A074519	004	Feb 13, 1996
COSETTE	12.5MG	A074433	001	Feb 13, 1996
	12.5MG	A074462	001	Feb 13, 1996
	12.5MG	A074483	001	Feb 13, 1996
	25MG	A074433	002	Feb 13, 1996
	25MG	A074462	002	Feb 13, 1996
	25MG	A074483	002	Feb 13, 1996
	50MG	A074433	003	Feb 13, 1996
	50MG	A074462	003	Feb 13, 1996
	50MG	A074483	003	Feb 13, 1996
	100MG	A074433	004	Feb 13, 1996
	100MG	A074462	004	Feb 13, 1996
	100MG	A074483	004	Feb 13, 1996
DAVA PHARMS INC	12.5MG	A074423	001	Feb 13, 1996
	25MG	A074423	002	Feb 13, 1996
	50MG	A074423	003	Feb 13, 1996
	100MG	A074423	004	Feb 13, 1996
EGIS PHARMS	12.5MG	A074748	004	May 29, 1997
	25MG	A074748	002	May 29, 1997
	50MG	A074748	001	May 29, 1997
	100MG	A074748	003	May 29, 1997
G AND W LABS INC	12.5MG	A074590	004	Aug 30, 1996
	25MG	A074590	002	Aug 30, 1996
	50MG	A074590	001	Aug 30, 1996
	100MG	A074590	003	Aug 30, 1996
OXFORD PHARMS	12.5MG	A074418	001	Feb 13, 1996
	25MG	A074418	002	Feb 13, 1996
	50MG	A074418	003	Feb 13, 1996
	100MG	A074418	004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640	001	Mar 31, 1997
	25MG	A074640	002	Mar 31, 1997
	50MG	A074640	003	Mar 31, 1997
	100MG	A074640	004	Mar 31, 1997
SANDOZ	12.5MG	A074481	001	Feb 13, 1996
	25MG	A074481	002	Feb 13, 1996
	50MG	A074481	003	Feb 13, 1996
	100MG	A074481	004	Feb 13, 1996
SETON PHARMS	12.5MG	A212223	001	Oct 30, 2019
	25MG	A212223	002	Oct 30, 2019
	50MG	A212223	003	Oct 30, 2019
	100MG	A212223	004	Oct 30, 2019
STRIDES PHARMA	12.5MG	A074493	001	Feb 13, 1996
	25MG	A074493	002	Feb 13, 1996
	50MG	A074493	003	Feb 13, 1996
	100MG	A074493	004	Feb 13, 1996
TEVA	12.5MG	A074322	001	Feb 13, 1996
	25MG	A074322	002	Feb 13, 1996
	50MG	A074322	003	Feb 13, 1996
	100MG	A074322	004	Feb 13, 1996
WATSON LABS	12.5MG	A074386	001	May 23, 1996
	12.5MG	A074451	001	Feb 13, 1996
	12.5MG	A074576	001	Apr 23, 1996
	25MG	A074386	002	May 23, 1996
	25MG	A074451	002	Feb 13, 1996
	25MG	A074576	002	Apr 23, 1996
	50MG	A074386	003	May 23, 1996
	50MG	A074451	003	Feb 13, 1996
	50MG	A074576	003	Apr 23, 1996
	100MG	A074386	004	May 23, 1996
	100MG	A074451	004	Feb 13, 1996
	100MG	A074576	004	Apr 23, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
CAPOZIDE 25/15				
+ APOTHECON	25MG;15MG **	N018709	001	Oct 12, 1984
CAPOZIDE 25/25				
+ APOTHECON	25MG;25MG **	N018709	002	Oct 12, 1984
CAPOZIDE 50/15				
+ APOTHECON	50MG;15MG **	N018709	004	Oct 12, 1984
CAPOZIDE 50/25				
+ APOTHECON	50MG;25MG **	N018709	003	Oct 12, 1984
CAPTOPRIL AND HYDROCHLOROTHIAZIDE				
COSETTE	25MG;15MG	A074827	001	Dec 29, 1997
	25MG;25MG	A074827	002	Dec 29, 1997
	50MG;15MG	A074827	004	Dec 29, 1997
	50MG;25MG	A074827	003	Dec 29, 1997
IVAX SUB TEVA PHARMS	25MG;15MG	A075055	001	Jun 18, 1998
	25MG;25MG	A075055	002	Jun 18, 1998
	50MG;15MG	A075055	004	Jun 18, 1998
	50MG;25MG	A075055	003	Jun 18, 1998
STRIDES PHARMA	25MG;15MG	A074788	001	Dec 29, 1997
	25MG;25MG	A074788	002	Dec 29, 1997
	50MG;15MG	A074788	004	Dec 29, 1997
	50MG;25MG	A074788	003	Dec 29, 1997
WATSON LABS	50MG;25MG	A074832	001	Dec 29, 1997

CARBACHOL

SOLUTION;INTRAOCULAR				
CARBACHOL				
PHARMAFAIR	0.01%	A070292	001	May 21, 1986
CARBASTAT				
NOVARTIS	0.01%	A073677	001	Apr 28, 1995

CARBAMAZEPINE

SOLUTION;INTRAVENOUS				
CARNEXIV				
+ LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016
SUSPENSION;ORAL				
CARBAMAZEPINE				
TARO	100MG/5ML	A075875	001	Dec 21, 2000
TABLET;ORAL				
CARBAMAZEPINE				
ACTAVIS ELIZABETH	200MG	A071696	001	Nov 09, 1987
INWOOD LABS	200MG	A070231	001	Aug 14, 1986
PLIVA	200MG	A071479	001	Jul 24, 1987
RK PHARMA	200MG	A214328	001	Aug 16, 2021
USL PHARMA	200MG	A070300	001	May 15, 1986
WARNER CHILCOTT	200MG	A070429	001	Jan 02, 1987
TERIL				
TARO	200MG	A076525	001	Sep 26, 2003
TABLET, CHEWABLE;ORAL				
CARBAMAZEPINE				
JUBILANT CADISTA	100MG	A071940	001	Feb 01, 1988
TEGRETOL				
+ NOVARTIS	100MG **	N018281	001	
TABLET, EXTENDED RELEASE;ORAL				
CARBAMAZEPINE				
AJANTA PHARMA LTD	100MG	A216193	001	Mar 24, 2023
	200MG	A216193	002	Mar 24, 2023
	400MG	A216193	003	Mar 24, 2023

CARBENICILLIN DISODIUM

INJECTABLE;INJECTION				
GEOPEN				
ROERIG	EQ 1GM BASE/VIAL	N050306	001	
	EQ 2GM BASE/VIAL	N050306	004	
	EQ 5GM BASE/VIAL	N050306	002	
	EQ 10GM BASE/VIAL	N050306	006	
	EQ 30GM BASE/VIAL	N050306	007	
PYOPEN				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050298	001	
	EQ 2GM BASE/VIAL	N050298	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARBENICILLIN DISODIUM				
INJECTABLE;INJECTION				
PYOPEN				
	EQ 5GM BASE/VIAL		N050298 003	
	EQ 10GM BASE/VIAL		N050298 006	
	EQ 20GM BASE/VIAL		N050298 007	
CARBENICILLIN INDANYL SODIUM				
TABLET;ORAL				
GEOCILLIN				
PFIZER	EQ 382MG BASE		N050435 001	
CARBIDOPA				
TABLET;ORAL				
CARBIDOPA				
ANI PHARMS	25MG		A203261 001	Mar 10, 2014
CARBIDOPA; ENTACAPONE; LEVODOPA				
TABLET;ORAL				
CARBIDOPA, LEVODOPA AND ENTACAPONE				
MYLAN	12.5MG;200MG;50MG		A203424 001	Aug 13, 2020
	18.75MG;200MG;75MG		A203424 002	Aug 13, 2020
	25MG;200MG;100MG		A203424 003	Aug 13, 2020
	31.25MG;200MG;125MG		A203424 004	Aug 13, 2020
	37.5MG;200MG;150MG		A203424 005	Aug 13, 2020
	50MG;200MG;200MG		A203424 006	Aug 13, 2020
WOCKHARDT LTD	12.5MG;200MG;50MG		A090786 001	Nov 20, 2012
	18.75MG;200MG;75MG		A090833 001	Nov 20, 2012
	25MG;200MG;100MG		A090833 002	Nov 20, 2012
	31.25MG;200MG;125MG		A090833 003	Nov 20, 2012
	37.5MG;200MG;150MG		A090833 004	Nov 20, 2012
	50MG;200MG;200MG		A090833 005	Nov 20, 2012
CARBIDOPA; LEVODOPA				
TABLET;ORAL				
CARBIDOPA AND LEVODOPA				
ANI PHARMS	10MG;100MG		A073587 002	Jun 29, 1995
	25MG;100MG		A073587 001	Jun 29, 1995
	25MG;250MG		A073587 003	Jun 29, 1995
SCS	10MG;100MG		A074080 001	Mar 25, 1994
	25MG;100MG		A074080 002	Mar 25, 1994
	25MG;250MG		A074080 003	Mar 25, 1994
WATSON LABS	10MG;100MG		A073381 001	Sep 28, 1993
	25MG;100MG		A073382 001	Sep 28, 1993
	25MG;250MG		A073383 001	Sep 28, 1993
ZYDUS PHARMS	10MG;100MG		A215999 001	Apr 04, 2023
	25MG;100MG		A215999 002	Apr 04, 2023
	25MG;250MG		A215999 003	Apr 04, 2023
TABLET, EXTENDED RELEASE;ORAL				
CARBIDOPA AND LEVODOPA				
KV PHARM	50MG;200MG		A076663 001	Jun 24, 2004
SINEMET CR				
+ ORGANON LLC	25MG;100MG **		N019856 002	Dec 24, 1992
+	50MG;200MG **		N019856 001	May 30, 1991
TABLET, FOR SUSPENSION;ORAL				
CARBILEV				
RANBAXY	10MG;100MG		A076643 001	Jun 10, 2005
	25MG;100MG		A076643 002	Jun 10, 2005
	25MG;250MG		A076643 003	Jun 10, 2005
TABLET, ORALLY DISINTEGRATING;ORAL				
CARBIDOPA AND LEVODOPA				
IMPAX LABS	10MG;100MG		A090631 001	Jun 08, 2010
	25MG;100MG		A090631 002	Jun 08, 2010
	25MG;250MG		A090631 003	Jun 08, 2010
RISING	10MG;100MG		A078893 001	Sep 18, 2008
	25MG;100MG		A078893 002	Sep 18, 2008
	25MG;250MG		A078893 003	Sep 18, 2008
PARCOPA				
UCB INC	10MG;100MG **		A076699 001	Aug 27, 2004
	25MG;100MG **		A076699 002	Aug 27, 2004
	25MG;250MG **		A076699 003	Aug 27, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARBINOXAMINE MALEATE

ELIXIR;ORAL				
CLISTIN				
+	MCNEIL	4MG/5ML **	N008955 001	
SOLUTION;ORAL				
CARBINOXAMINE MALEATE				
	CYPRESS PHARM	4MG/5ML	A090418 001	May 04, 2010
	VINTAGE PHARMS	4MG/5ML	A040814 001	Feb 26, 2008
TABLET;ORAL				
CARBINOXAMINE MALEATE				
	CYPRESS PHARM	4MG	A090417 001	Aug 23, 2010
	STRIDES PHARMA	4MG	A040639 002	May 30, 2008
CLISTIN				
+	ORTHO MCNEIL PHARM	4MG **	N008915 001	

CARBOPLATIN

INJECTABLE;INJECTION				
CARBOPLATIN				
	CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006
		150MG/VIAL	A077383 002	Jan 27, 2006
		450MG/VIAL	A077383 003	Jan 27, 2006
	FRESENIUS KABI USA	50MG/VIAL	A076235 001	Oct 14, 2004
		150MG/VIAL	A076235 002	Oct 14, 2004
		450MG/VIAL	A076235 003	Oct 14, 2004
	HIKMA	50MG/VIAL	A076099 001	Oct 14, 2004
		150MG/VIAL	A076099 002	Oct 14, 2004
		450MG/VIAL	A076099 003	Oct 14, 2004
	HOSPIRA	50MG/VIAL	A076473 001	Oct 27, 2004
		150MG/VIAL	A076473 002	Oct 27, 2004
		450MG/VIAL	A076473 003	Oct 27, 2004
	NATCO PHARMA USA	50MG/VIAL	A091510 001	May 29, 2012
		150MG/VIAL	A091510 002	May 29, 2012
		450MG/VIAL	A091510 003	May 29, 2012
	PLIVA	50MG/VIAL	A076602 001	Nov 16, 2004
		150MG/VIAL	A076602 002	Nov 16, 2004
		450MG/VIAL	A076602 003	Nov 16, 2004
	SANDOZ	50MG/VIAL	A076959 001	Mar 18, 2005
		150MG/VIAL	A076959 002	Mar 18, 2005
		450MG/VIAL	A076959 003	Mar 18, 2005
	WATSON LABS TEVA	50MG/VIAL	A076162 001	Oct 14, 2004
		150MG/VIAL	A076162 002	Oct 14, 2004
		450MG/VIAL	A076162 003	Oct 14, 2004
PARAPLATIN				
+	CORDEN PHARMA	50MG/VIAL **	N019880 001	Mar 03, 1989
+		150MG/VIAL **	N019880 002	Mar 03, 1989
+		450MG/VIAL **	N019880 003	Mar 03, 1989
INJECTABLE;INTRAVENOUS				
CARBOPLATIN				
	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012
		150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012
		450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012
		600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012
	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077432 001	Sep 29, 2006
		150MG/15ML (10MG/ML)	A077432 002	Sep 29, 2006
		450MG/45ML (10MG/ML)	A077432 003	Sep 29, 2006
		50MG/5ML (10MG/ML)	A077247 001	Oct 21, 2004
		50MG/5ML (10MG/ML)	A077266 001	Feb 15, 2006
		150MG/15ML (10MG/ML)	A077247 002	Oct 21, 2004
		150MG/15ML (10MG/ML)	A077266 002	Feb 15, 2006
	MEITHEAL	50MG/5ML (10MG/ML)	A077096 001	Jun 14, 2005
		150MG/15ML (10MG/ML)	A077096 002	Jun 14, 2005
		450MG/45ML (10MG/ML)	A077096 003	Jun 14, 2005
		600MG/60ML (10MG/ML)	A077096 004	Jun 03, 2013
	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998 001	Apr 24, 2007
		150MG/15ML (10MG/ML)	A077998 002	Apr 24, 2007
		450MG/45ML (10MG/ML)	A077998 003	Apr 24, 2007
	MYLAN LABS LTD	50MG/5ML (10MG/ML)	A091063 001	Nov 09, 2011
		150MG/15ML (10MG/ML)	A091063 002	Nov 09, 2011
		450MG/45ML (10MG/ML)	A091063 003	Nov 09, 2011
		600MG/60ML (10MG/ML)	A091063 004	Nov 09, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARBOPLATIN				
INJECTABLE;INTRAVENOUS				
CARBOPLATIN				
	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011
PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009
	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009
	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009
PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008
	150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008
	450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008
	600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008
TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007
	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007
	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007
TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005
	150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005
	450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005
	600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005
PARAPLATIN				
+ CORDENPHARMA	50MG/5ML (10MG/ML) **	N020452	001	Jul 14, 2003
+	150MG/15ML (10MG/ML) **	N020452	002	Jul 14, 2003
+	450MG/45ML (10MG/ML) **	N020452	003	Jul 14, 2003
+	600MG/60ML (10MG/ML) **	N020452	004	Jan 15, 2004
CARFILZOMIB				
POWDER;INTRAVENOUS				
CARFILZOMIB				
APOTEX	30MG/VIAL	A211185	001	Mar 20, 2020
	60MG/VIAL	A209425	001	Mar 16, 2020
BRECKENRIDGE	10MG/VIAL	A209330	001	Jun 11, 2021
	60MG/VIAL	A209330	002	Jun 11, 2021
CARIPRAZINE HYDROCHLORIDE				
CAPSULE;ORAL				
CARIPRAZINE HYDROCHLORIDE				
SUN PHARM	EQ 1.5MG BASE	A213932	001	Sep 30, 2022
	EQ 3MG BASE	A213932	002	Sep 30, 2022
	EQ 4.5MG BASE	A213932	003	Sep 30, 2022
	EQ 6MG BASE	A213932	004	Sep 30, 2022
ZYDUS	EQ 1.5MG BASE	A213984	001	Sep 09, 2022
	EQ 3MG BASE	A213984	002	Sep 09, 2022
	EQ 4.5MG BASE	A213984	003	Sep 09, 2022
	EQ 6MG BASE	A213984	004	Sep 09, 2022
CARISOPRODOL				
CAPSULE;ORAL				
SOMA				
+ MYLAN SPECIALITY LP	250MG	N011792	003	
TABLET;ORAL				
CARISOPRODOL				
ABLE	350MG	A040421	001	Jun 21, 2001
EPIC PHARMA LLC	350MG	A040397	001	Sep 21, 2000
HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996
PIONEER PHARMS	350MG	A089390	001	Oct 13, 1988
SANDOZ	350MG	A089566	001	Aug 30, 1988
STRIDES PHARMA	250MG	A205513	001	Nov 12, 2015
	350MG	A205513	002	Nov 12, 2015
SUN PHARM INDS LTD	350MG	A040755	001	Feb 27, 2007
SUN PHARM INDUSTRIES	350MG	A089346	001	Oct 17, 1991
WATSON LABS	350MG	A040152	001	Dec 03, 1996
	350MG	A085433	001	
WATSON LABS TEVA	350MG	A086179	001	
RELA				
SCHERING	350MG	N012155	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARMUSTINE
INJECTABLE;INJECTION
CARMUSTINE

ACCORD HLTHCARE	100MG/VIAL	A214117	001	Dec 27, 2022
MYLAN LABS LTD	100MG/VIAL	A215368	001	Mar 03, 2023

CARPHENAZINE MALEATE
CONCENTRATE;ORAL
PROKETAZINE

WYETH AYERST	50MG/ML	N014173	001	

TABLET;ORAL
PROKETAZINE

WYETH AYERST	12.5MG	N012768	001	
	25MG	N012768	002	
	50MG	N012768	004	

CARPROFEN
TABLET;ORAL
RIMADYL

ROCHE	100MG	N018550	002	Dec 31, 1987
	150MG	N018550	003	Dec 31, 1987

CARTEOLOL HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
CARTEOLOL HYDROCHLORIDE

APOTEX INC	1%	A076097	001	Feb 06, 2002
BAUSCH AND LOMB	1%	A075546	001	Jan 20, 2000

OCUPRESS

+	NOVARTIS	1% **	N019972	001	May 23, 1990

TABLET;ORAL
CARTROL

ABBVIE	2.5MG	N019204	001	Dec 28, 1988
	5MG	N019204	002	Dec 28, 1988
	10MG	N019204	003	Dec 28, 1988

CARVEDILOL
TABLET;ORAL
CARVEDILOL

ACI	3.125MG	A078786	001	Dec 22, 2009
	6.25MG	A078786	002	Dec 22, 2009
	12.5MG	A078786	003	Dec 22, 2009
	25MG	A078786	004	Dec 22, 2009
HIKMA	3.125MG	A077887	001	Sep 07, 2007
	6.25MG	A077887	002	Sep 07, 2007
	12.5MG	A077887	003	Sep 07, 2007
	25MG	A077887	004	Sep 07, 2007
PLIVA HRVATSKA DOO	3.125MG	A078240	001	Oct 30, 2007
	6.25MG	A078240	002	Oct 30, 2007
	12.5MG	A078240	003	Oct 30, 2007
	25MG	A078240	004	Oct 30, 2007
SUN PHARM INDS INC	3.125MG	A077346	004	Sep 05, 2007
	6.25MG	A077346	001	Sep 05, 2007
	12.5MG	A077346	002	Sep 05, 2007
	25MG	A077346	003	Sep 05, 2007

CASPOFUNGIN ACETATE
POWDER;INTRAVENOUS
CASPOFUNGIN ACETATE

CIPLA	50MG/VIAL	A209489	001	Jul 12, 2018
	70MG/VIAL	A209489	002	Jul 12, 2018
MYLAN LABS LTD	50MG/VIAL	A207650	001	Sep 29, 2017
	70MG/VIAL	A207650	002	Sep 29, 2017
XELLIA PHARMS APS	50MG/VIAL	A205923	001	Jul 02, 2018
	70MG/VIAL	A205923	002	Jul 02, 2018

CEFACLOR
CAPSULE;ORAL
CECLOR

+ LILLY	EQ 250MG BASE **	N050521	001	
+	EQ 500MG BASE **	N050521	002	

CEFACLOR

CEPH INTL	EQ 250MG BASE	A062205	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFACLOR

CAPSULE;ORAL				
CEFACLOR				
	EQ 500MG BASE	A062205 002		
CHARTWELL RX	EQ 250MG BASE	A064148 001		May 23, 1996
	EQ 500MG BASE	A064148 002		May 23, 1996
DAVA PHARMS INC	EQ 250MG BASE	A064107 001		Apr 27, 1995
	EQ 500MG BASE	A064107 002		Apr 27, 1995
HIKMA	EQ 250MG BASE	A065350 001		Apr 03, 2007
	EQ 500MG BASE	A065350 002		Apr 03, 2007
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A064061 001		Apr 27, 1995
	EQ 500MG BASE	A064061 002		Apr 27, 1995
RANBAXY	EQ 250MG BASE	A064156 001		Aug 28, 1997
	EQ 500MG BASE	A064156 002		Aug 28, 1997
TEVA	EQ 250MG BASE	A064081 001		Sep 16, 1996
	EQ 250MG BASE	A064145 001		Jun 24, 1996
	EQ 500MG BASE	A064081 002		Sep 16, 1996
	EQ 500MG BASE	A064145 002		Jun 24, 1996
FOR SUSPENSION;ORAL				
CECLOR				
+ LILLY	EQ 125MG BASE/5ML **	N050522 001		
+	EQ 250MG BASE/5ML **	N050522 002		
CEFACLOR				
DAVA PHARMS INC	EQ 125MG BASE/5ML	A064114 001		Apr 28, 1995
	EQ 187MG BASE/5ML	A064115 001		Apr 28, 1995
	EQ 250MG BASE/5ML	A064116 001		Apr 28, 1995
	EQ 375MG BASE/5ML	A064110 001		Apr 28, 1995
FACTA FARMA	EQ 125MG BASE/5ML	A062206 001		
	EQ 187MG BASE/5ML	A062206 003		Apr 20, 1988
	EQ 250MG BASE/5ML	A062206 002		
	EQ 375MG BASE/5ML	A062206 004		Apr 20, 1988
IVAX SUB TEVA PHARMS	EQ 125MG BASE/5ML	A064087 001		Apr 28, 1995
	EQ 187MG BASE/5ML	A064086 001		Apr 28, 1995
	EQ 250MG BASE/5ML	A064085 001		Apr 28, 1995
	EQ 375MG BASE/5ML	A064070 001		Apr 28, 1995
RANBAXY	EQ 125MG BASE/5ML	A064166 001		Oct 02, 1997
	EQ 187MG BASE/5ML	A064165 001		Oct 02, 1997
	EQ 250MG BASE/5ML	A064164 001		Oct 02, 1997
	EQ 375MG BASE/5ML	A064155 001		Oct 02, 1997
WATSON LABS INC	EQ 125MG BASE/5ML	A064204 001		Feb 18, 1998
	EQ 187MG BASE/5ML	A064205 001		Feb 18, 1998
	EQ 250MG BASE/5ML	A064206 001		Feb 18, 1998
	EQ 375MG BASE/5ML	A064207 001		Feb 18, 1998
TABLET, CHEWABLE;ORAL				
RANICLOR				
RANBAXY LABS LTD	EQ 125MG BASE	A065092 001		Dec 22, 2003
	EQ 187MG BASE	A065092 002		Dec 22, 2003
	EQ 250MG BASE	A065092 003		Dec 22, 2003
	EQ 375MG BASE	A065092 004		Dec 22, 2003
TABLET, EXTENDED RELEASE;ORAL				
CECLOR CD				
LILLY	EQ 375MG BASE **	N050673 001		Jun 28, 1996
	EQ 500MG BASE **	N050673 002		Jun 28, 1996
CEFACLOR				
WORLD GEN	EQ 500MG BASE	A065057 001		Jan 05, 2001

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL				
CEFADROXIL				
CHARTWELL RX	EQ 500MG BASE	A065309 001		Sep 18, 2006
CSPC OUYI	EQ 500MG BASE	A205072 001		Jul 28, 2017
HIKMA	EQ 500MG BASE	A065311 001		Feb 07, 2006
IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766 001		Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE	A063017 001		Jan 05, 1989
RANBAXY LABS LTD	EQ 500MG BASE	A065015 001		Jun 22, 1999
SANDOZ	EQ 500MG BASE	A062291 001		
TEVA	EQ 500MG BASE	A062695 001		Feb 10, 1989
DURICEF				
WARNER CHILCOTT	EQ 250MG BASE	N050512 002		
+	EQ 500MG BASE **	N050512 001		

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL				
ULTRACEF				
	BRISTOL	EQ 500MG BASE	A062378 001	Mar 16, 1982
FOR SUSPENSION;ORAL				
CEFADROXIL				
	ANI PHARMS	EQ 125MG BASE/5ML	A062698 001	Mar 01, 1989
		EQ 250MG BASE/5ML	A062698 002	Mar 01, 1989
		EQ 250MG BASE/5ML	A065278 001	Jan 20, 2006
		EQ 500MG BASE/5ML	A062698 003	Mar 01, 1989
		EQ 500MG BASE/5ML	A065278 002	Jan 20, 2006
	APOTHECON	EQ 125MG BASE/5ML	A062334 001	
		EQ 250MG BASE/5ML	A062334 002	
		EQ 500MG BASE/5ML	A062334 003	
	CHARTWELL RX	EQ 250MG BASE/5ML	A065307 002	Oct 16, 2006
		EQ 500MG BASE/5ML	A065307 003	Oct 16, 2006
	HIKMA PHARMS	EQ 250MG BASE/5ML	A091036 001	Nov 28, 2012
		EQ 500MG BASE/5ML	A091036 002	Nov 28, 2012
	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115 001	Mar 26, 2003
		EQ 250MG BASE/5ML	A065115 002	Mar 26, 2003
		EQ 500MG BASE/5ML	A065115 003	Mar 26, 2003
DURICEF				
+	WARNER CHILCOTT	EQ 125MG BASE/5ML **	N050527 002	
+		EQ 250MG BASE/5ML **	N050527 003	
+		EQ 500MG BASE/5ML **	N050527 001	
ULTRACEF				
	BRISTOL	EQ 125MG BASE/5ML	A062376 001	Mar 16, 1982
		EQ 250MG BASE/5ML	A062376 002	Mar 16, 1982
		EQ 500MG BASE/5ML	A062376 003	Mar 16, 1982
TABLET;ORAL				
CEFADROXIL				
	CHARTWELL RX	EQ 1GM BASE	A065301 001	Sep 18, 2006
	HIKMA	EQ 1GM BASE	A065260 001	Mar 30, 2006
	RANBAXY	EQ 1GM BASE	A065018 001	Apr 23, 1999
DURICEF				
+	WARNER CHILCOTT	EQ 1GM BASE **	N050528 001	
ULTRACEF				
	APOTHECON	EQ 1GM BASE	A062390 001	Jun 10, 1982
	BRISTOL	EQ 1GM BASE	A062408 001	Aug 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE;INJECTION				
MANDOL				
	LILLY	EQ 500MG BASE/VIAL	N050504 001	
		EQ 1GM BASE/VIAL	A062560 001	Sep 10, 1985
		EQ 1GM BASE/VIAL	N050504 002	
		EQ 2GM BASE/VIAL	A062560 002	Sep 10, 1985
		EQ 2GM BASE/VIAL	N050504 003	
		EQ 10GM BASE/VIAL	N050504 004	

CEFAZOLIN SODIUM

INJECTABLE;INJECTION				
ANCEF				
+	GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N050461 001	
+		EQ 500MG BASE/VIAL	N050461 002	
+		EQ 1GM BASE/VIAL **	N050461 003	
+		EQ 5GM BASE/VIAL **	N050461 004	
+		EQ 10GM BASE/VIAL **	N050461 005	
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 003	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566 004	Jun 08, 1983
ANCEF IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002 001	Mar 28, 1991
		EQ 20MG BASE/ML	A063002 002	Mar 28, 1991
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 001	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566 002	Jun 08, 1983
CEFAZOLIN AND DEXTROSE				
	B BRAUN	EQ 500MG BASE/VIAL	N050779 001	Jul 27, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFAZOLIN SODIUM

INJECTABLE;INJECTION					
CEFAZOLIN SODIUM					
	ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062688	002	Nov 17, 1986
		EQ 1GM BASE/VIAL	A062688	003	Nov 17, 1986
		EQ 10GM BASE/VIAL	A062688	004	Nov 17, 1986
		EQ 20GM BASE/VIAL	A062688	005	Aug 03, 1987
	AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065395	001	Aug 08, 2008
		EQ 1GM BASE/VIAL	A065395	002	Aug 08, 2008
	BEDFORD	EQ 250MG BASE/VIAL	A062894	001	Jul 21, 1988
		EQ 500MG BASE/VIAL	A062894	002	Jul 21, 1988
		EQ 1GM BASE/VIAL	A062894	003	Jul 21, 1988
		EQ 5GM BASE/VIAL	A062894	004	Jul 21, 1988
		EQ 10GM BASE/VIAL	A062894	005	Jul 21, 1988
	CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	A065280	001	Mar 18, 2009
		EQ 1GM BASE/VIAL	A065280	002	Mar 18, 2009
		EQ 10GM BASE/VIAL	A065295	001	Mar 18, 2009
		EQ 20GM BASE/VIAL	A065296	001	Mar 18, 2009
	DR REDDYS	EQ 250MG BASE/VIAL	A062988	001	Dec 29, 1989
		EQ 500MG BASE/VIAL	A062988	002	Dec 29, 1989
		EQ 1GM BASE/VIAL	A062988	003	Dec 29, 1989
		EQ 5GM BASE/VIAL	A062989	001	Dec 29, 1989
		EQ 10GM BASE/VIAL	A062989	002	Dec 29, 1989
		EQ 20GM BASE/VIAL	A062989	003	Dec 29, 1989
	FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991
		EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991
		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991
		EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999
	FRESENIUS KABI USA	EQ 500MG BASE/VIAL **	A064169	001	Aug 14, 1998
		EQ 1GM BASE/VIAL **	A064169	002	Aug 14, 1998
		EQ 10GM BASE/VIAL **	A064170	001	Mar 18, 1998
		EQ 20GM BASE/VIAL **	A064170	002	Mar 18, 1998
	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A064033	001	Oct 31, 1993
	HIKMA	EQ 250MG BASE/VIAL	A062807	001	Jan 12, 1988
		EQ 500MG BASE/VIAL	A062807	002	Jan 12, 1988
		EQ 1GM BASE/VIAL	A062807	003	Jan 12, 1988
		EQ 5GM BASE/VIAL	A062807	004	Jan 12, 1988
		EQ 10GM BASE/VIAL	A062807	005	Jan 12, 1988
		EQ 20GM BASE/VIAL	A062807	006	Jan 12, 1988
	HOSPIRA	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016
	HOSPIRA INC	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005
		EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005
		EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005
		EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005
	STERI PHARMA	EQ 500MG BASE/VIAL	A063216	001	Dec 27, 1991
		EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991
	TEVA PHARMS	EQ 250MG BASE/VIAL	A063016	001	Mar 14, 1989
		EQ 500MG BASE/VIAL	A063016	002	Mar 14, 1989
		EQ 1GM BASE/VIAL	A063016	003	Mar 14, 1989
		EQ 5GM BASE/VIAL	A063018	001	Mar 05, 1990
		EQ 10GM BASE/VIAL	A063018	002	Mar 05, 1990
KEFZOL					
	ACS DOBFAR	EQ 250MG BASE/VIAL	A061773	001	
		EQ 500MG BASE/VIAL	A061773	002	
		EQ 1GM BASE/VIAL	A061773	003	
		EQ 10GM BASE/VIAL	A061773	004	
		EQ 20GM BASE/VIAL	A061773	005	Sep 08, 1987
	LILLY	EQ 500MG BASE/VIAL	A062557	001	Sep 10, 1985
		EQ 1GM BASE/VIAL	A062557	002	Sep 10, 1985

CEFDINIR

CAPSULE;ORAL					
OMNICEF					
+	ABBVIE	300MG **	N050739	001	Dec 04, 1997
FOR SUSPENSION;ORAL					
OMNICEF					
+	ABBVIE	125MG/5ML **	N050749	001	Dec 04, 1997
+		250MG/5ML **	N050749	002	Jul 29, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFDITOREN PIVOXIL

TABLET;ORAL				
SPECTRACEF				
	VANSEN PHARMA	200MG	N021222 001	Aug 29, 2001
		400MG	N021222 002	Jul 21, 2008

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION				
CEFEPIME HYDROCHLORIDE				
	FOSUN PHARMA	EQ 500MG BASE/VIAL	A090291 001	Dec 21, 2010
		EQ 1GM BASE/VIAL	A090291 002	Dec 21, 2010
		EQ 2GM BASE/VIAL	A090291 003	Dec 21, 2010
	HOSPIRA INC	EQ 500MG BASE/VIAL	A065369 001	Jun 18, 2007
		EQ 1GM BASE/VIAL	A065369 002	Jun 18, 2007
		EQ 1GM BASE/VIAL	A202268 001	Jul 30, 2012
		EQ 2GM BASE/VIAL	A065369 003	Jun 18, 2007
		EQ 2GM BASE/VIAL	A202268 002	Jul 30, 2012
MAXIPIME				
+	HOSPIRA INC	EQ 500MG BASE/VIAL	N050679 001	Jan 18, 1996
+		EQ 1GM BASE/VIAL	N050679 002	Jan 18, 1996
+		EQ 2GM BASE/VIAL	N050679 003	Jan 18, 1996

CEFIXIME

FOR SUSPENSION;ORAL				
CEFIXIME				
	SANDOZ	100MG/5ML	A206144 001	Nov 17, 2017
		200MG/5ML	A206144 002	Nov 17, 2017
SUPRAX				
+	LEDERLE	100MG/5ML **	N050622 001	Apr 28, 1989
	LUPIN PHARMS	100MG/5ML	A065129 001	Feb 23, 2004
TABLET;ORAL				
SUPRAX				
+	LEDERLE	200MG **	N050621 001	Apr 28, 1989
+		400MG **	N050621 002	Apr 28, 1989
	LUPIN PHARMS	400MG	A065130 001	Feb 12, 2004

CEFMENOXIME HYDROCHLORIDE

INJECTABLE;INJECTION				
CEFMAX				
	TAP PHARM	EQ 500MG BASE/VIAL	N050571 001	Dec 30, 1987
		EQ 1GM BASE/VIAL	N050571 002	Dec 30, 1987
		EQ 2GM BASE/VIAL	N050571 003	Dec 30, 1987

CEFMETAZOLE SODIUM

INJECTABLE;INJECTION				
ZEFAZONE				
+	PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL **	N050637 001	Dec 11, 1989
+		EQ 2GM BASE/VIAL **	N050637 002	Dec 11, 1989
ZEFAZONE IN PLASTIC CONTAINER				
+	PHARMACIA AND UPJOHN	EQ 20MG BASE/ML **	N050683 001	Dec 29, 1992
+		EQ 40MG BASE/ML **	N050683 002	Dec 29, 1992

CEFONICID SODIUM

INJECTABLE;INJECTION				
MONOCID				
	GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N050579 001	May 23, 1984
		EQ 1GM BASE/VIAL	A063295 001	Jul 26, 1993
		EQ 1GM BASE/VIAL	N050579 002	May 23, 1984
		EQ 2GM BASE/VIAL	N050579 003	May 23, 1984
		EQ 10GM BASE/VIAL	N050579 004	May 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE;INJECTION				
CEFOBID				
	PFIZER	EQ 1GM BASE/VIAL	A063333 001	Mar 31, 1995
		EQ 1GM BASE/VIAL	N050551 001	Nov 18, 1982
		EQ 2GM BASE/VIAL	A063333 002	Mar 31, 1995
		EQ 2GM BASE/VIAL	N050551 002	Nov 18, 1982
		EQ 10GM BASE/VIAL	N050551 003	Mar 05, 1990
CEFOBID IN PLASTIC CONTAINER				
	PFIZER	EQ 20MG BASE/ML	N050613 002	Jul 31, 1987
		EQ 40MG BASE/ML	N050613 001	Jul 23, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFORANIDE

INJECTABLE;INJECTION

PRECEF

APOTHECON	500MG/VIAL	A062579	001	Nov 26, 1984
	1GM/VIAL	A062579	002	Nov 26, 1984
	2GM/VIAL	A062579	003	Nov 26, 1984
	10GM/VIAL	A062579	004	Nov 26, 1984
	20GM/VIAL	A062579	005	Nov 26, 1984
BRISTOL	500MG/VIAL	N050554	001	May 24, 1984
	1GM/VIAL	N050554	002	May 24, 1984
	2GM/VIAL	N050554	003	May 24, 1984
	10GM/VIAL	N050554	004	May 24, 1984
	20GM/VIAL	N050554	005	May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE;INJECTION

CEFOTAXIME

FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064200	001	Mar 24, 2000
	EQ 1GM BASE/VIAL	A064200	002	Mar 24, 2000
	EQ 2GM BASE/VIAL	A064200	003	Mar 24, 2000
	EQ 10GM BASE/VIAL	A064201	001	Mar 24, 2000
	EQ 20GM BASE/VIAL	A064201	002	Mar 24, 2000
HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002
	EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002
	EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002
	EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002
WOCKHARDT	EQ 1GM BASE/VIAL	A065197	001	Aug 29, 2006

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

B BRAUN	EQ 2GM BASE	N050792	001	Jul 29, 2004

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

B BRAUN	EQ 1GM BASE	N050792	002	Jul 29, 2004

CEFOTAXIME SODIUM

AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009
	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009
	EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009
CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan 25, 2010
HOSPIRA	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016
	EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016
HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006
	EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006
	EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006
	EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006
	EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006
	EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006
LUPIN	EQ 500MG BASE/VIAL	A065124	001	Sep 24, 2003
	EQ 1GM BASE/VIAL	A065124	002	Sep 24, 2003
	EQ 2GM BASE/VIAL	A065124	003	Sep 24, 2003
WOCKHARDT	EQ 500MG BASE/VIAL	A065197	002	Jun 20, 2008
	EQ 2GM BASE/VIAL	A065197	003	Jun 20, 2008

CLAFORAN

	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659	001	Jan 13, 1987
		EQ 2GM BASE/VIAL	A062659	002	Jan 13, 1987
+	VALIDUS PHARMS	EQ 500MG BASE/VIAL **	N050547	001	
+		EQ 1GM BASE/VIAL **	N050547	002	
+		EQ 2GM BASE/VIAL **	N050547	003	
+		EQ 10GM BASE/VIAL **	N050547	004	Dec 29, 1983

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	002	May 20, 1985
	EQ 40MG BASE/ML	N050596	004	May 20, 1985

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	001	May 20, 1985
	EQ 40MG BASE/ML	N050596	003	May 20, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFOTETAN DISODIUM

INJECTABLE;INJECTION					
CEFOTAN					
+	PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL **	N050588	001	Dec 27, 1985
+		EQ 2GM BASE/VIAL **	N050588	002	Dec 27, 1985
		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988
	TELIGENT	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993
		EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993
CEFOTAN IN PLASTIC CONTAINER					
	PAI HOLDINGS PHARM	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993
		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993
CEFOTETAN					
	FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065375	001	Aug 09, 2007
	HIKMA	EQ 1GM BASE/VIAL	A091031	001	Oct 26, 2011
		EQ 2GM BASE/VIAL	A091031	002	Oct 26, 2011
	WEST-WARD PHARM CORP	EQ 10GM BASE/VIAL	A091030	001	Oct 26, 2011
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER					
+	B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007
+		EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007

CEFOTIAM HYDROCHLORIDE

INJECTABLE;INJECTION					
CERADON					
	TAKEDA	EQ 1GM BASE/VIAL	N050601	001	Dec 30, 1988

CEFOXITIN SODIUM

INJECTABLE;INJECTION					
CEFOXITIN					
	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011
		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011
		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011
	FRESENIUS KABI USA	EQ 1GM BASE/VIAL **	A065012	001	Jul 03, 2000
		EQ 2GM BASE/VIAL **	A065012	002	Jul 03, 2000
		EQ 10GM BASE/VIAL	A065011	001	Jul 03, 2000
	HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006
		EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006
		EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006
MEFOXIN					
	MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987
+		EQ 1GM BASE/VIAL **	N050517	001	
		EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987
+		EQ 2GM BASE/VIAL **	N050517	002	
+		EQ 10GM BASE/VIAL **	N050517	003	
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	MERCK	EQ 20MG BASE/ML **	N050581	003	Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581	004	Sep 20, 1984
MEFOXIN IN PLASTIC CONTAINER					
	MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993
		EQ 40MG BASE/ML	A063182	002	Jan 25, 1993
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	MERCK	EQ 20MG BASE/ML **	N050581	002	Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581	001	Sep 20, 1984

CEFPIRAMIDE SODIUM

INJECTABLE;INJECTION					
CEFPIRAMIDE SODIUM					
	WYETH AYERST	EQ 1GM BASE/VIAL	N050633	002	Jan 31, 1989
		EQ 2GM BASE/VIAL	N050633	003	Jan 31, 1989
		EQ 10GM BASE/VIAL	N050633	005	Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL					
BANAN					
	SANKYO	EQ 50MG BASE/5ML	N050688	002	Aug 07, 1992
		EQ 100MG BASE/5ML	N050688	001	Aug 07, 1992
CEFPODOXIME PROXETIL					
	SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009
		EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009
	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002
		EQ 100MG BASE/5ML	A065082	002	May 31, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL					
VANTIN					
+	PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML **	N050675	001	Aug 07, 1992
+		EQ 100MG BASE/5ML **	N050675	002	Aug 07, 1992
TABLET;ORAL					
BANAN					
	SANKYO	EQ 100MG BASE	N050687	001	Aug 07, 1992
		EQ 200MG BASE	N050687	002	Aug 07, 1992
CEFPODOXIME PROXETIL					
	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003
		EQ 200MG BASE	A065083	002	Aug 20, 2003
VANTIN					
+	PHARMACIA AND UPJOHN	EQ 100MG BASE **	N050674	001	Aug 07, 1992
+		EQ 200MG BASE **	N050674	002	Aug 07, 1992

CEFPROZIL

FOR SUSPENSION;ORAL					
CEFPROZIL					
	CHARTWELL RX	125MG/5ML	A065236	001	Dec 08, 2005
		250MG/5ML	A065236	002	Dec 08, 2005
	ORCHID HLTHCARE	125MG/5ML	A065284	002	Dec 30, 2005
		250MG/5ML	A065284	001	Dec 30, 2005
	RANBAXY LABS LTD	125MG/5ML	A065202	001	Jun 30, 2006
		250MG/5ML	A065202	002	Jun 30, 2006
	SANDOZ	125MG/5ML	A065257	001	Dec 08, 2005
		250MG/5ML	A065257	002	Dec 08, 2005
CEFZIL					
+	CORDEN PHARMA	125MG/5ML **	N050665	001	Dec 23, 1991
+		250MG/5ML **	N050665	002	Dec 23, 1991
TABLET;ORAL					
CEFPROZIL					
	ORCHID HLTHCARE	250MG	A065267	001	Dec 19, 2005
		500MG	A065267	002	Dec 19, 2005
	RANBAXY LABS LTD	250MG	A065198	001	Dec 13, 2006
		500MG	A065198	002	Dec 13, 2006
	WOCKHARDT	250MG	A065428	001	Jun 14, 2007
		500MG	A065428	002	Jun 14, 2007
CEFZIL					
+	CORDEN PHARMA	250MG **	N050664	001	Dec 23, 1991
+		500MG **	N050664	002	Dec 23, 1991

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS					
CEFTAROLINE FOSAMIL					
	APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021
		600MG/VIAL	A208075	002	Sep 21, 2021

CEFTAZIDIME

INJECTABLE;INJECTION					
CEFTAZIDIME					
	ACS DOBFAR	500MG/VIAL	A062640	001	Nov 20, 1985
	AUROBINDO PHARMA LTD	500MG/VIAL	A065481	001	May 28, 2010
		1GM/VIAL	A065481	002	May 28, 2010
		2GM/VIAL	A065481	003	May 28, 2010
		6GM/VIAL	A065482	001	May 28, 2010
	WOCKHARDT	1GM/VIAL	A065196	001	Oct 15, 2008
CEFTAZIDIME IN DEXTROSE CONTAINER					
+	B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011
+		EQ 2GM BASE	N050823	002	Jun 13, 2011
CEPTAZ					
	GLAXOSMITHKLINE	500MG/VIAL	N050646	001	Sep 27, 1990
		1GM/VIAL	N050646	002	Sep 27, 1990
		2GM/VIAL	N050646	003	Sep 27, 1990
		10GM/VIAL	N050646	004	Sep 27, 1990
FORTAZ					
+	PAI HOLDINGS PHARM	500MG/VIAL	N050578	001	Jul 19, 1985
+		1GM/VIAL	N050578	002	Jul 19, 1985
+		2GM/VIAL	N050578	003	Jul 19, 1985
+		6GM/VIAL	N050578	004	Jul 19, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFTAZIDIME

INJECTABLE;INJECTION				
PENTACEF				
GLAXOSMITHKLINE	1GM/VIAL	A063322	001	Nov 07, 1995
	1GM/VIAL	A064006	001	Mar 31, 1992
	2GM/VIAL	A063322	002	Nov 07, 1995
	2GM/VIAL	A064006	002	Mar 31, 1992
	6GM/VIAL	A064008	001	Mar 31, 1992
	10GM/VIAL	A064008	002	Mar 31, 1992
TAZICEF				
HOSPIRA	500MG/VIAL	A062662	001	Mar 06, 1986
TAZIDIME				
LILLY	1GM/VIAL	A062655	001	Nov 20, 1985
	2GM/VIAL	A062655	002	Nov 20, 1985
TAZIDIME IN PLASTIC CONTAINER				
LILLY	1GM/VIAL	A062739	001	Jul 10, 1986
	2GM/VIAL	A062739	002	Jul 10, 1986

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION				
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 10MG BASE/ML	A063221	001	Apr 29, 1993
	EQ 20MG BASE/ML	A063221	002	Apr 29, 1993
	EQ 40MG BASE/ML	A063221	003	Apr 29, 1993
FORTAZ IN PLASTIC CONTAINER				
PAI HOLDINGS PHARM	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989
+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989
+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE;ORAL				
CEDAX				
SI PHARMS	EQ 400MG BASE	N050685	002	Dec 20, 1995
FOR SUSPENSION;ORAL				
CEDAX				
+ SI PHARMS	EQ 90MG BASE/5ML **	N050686	001	Dec 20, 1995
+	EQ 180MG BASE/5ML **	N050686	002	Dec 20, 1995

CEFTIZOXIME SODIUM

INJECTABLE;INJECTION				
CEFIZOX				
ASTELLAS	EQ 500MG BASE/VIAL	N050560	001	Sep 15, 1983
	EQ 1GM BASE/VIAL	A063294	002	Mar 31, 1994
	EQ 1GM BASE/VIAL	N050560	002	Sep 15, 1983
	EQ 2GM BASE/VIAL	A063294	003	Mar 31, 1994
	EQ 2GM BASE/VIAL	N050560	003	Sep 15, 1983
	EQ 10GM BASE/VIAL	N050560	005	Mar 19, 1993
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER				
ASTELLAS	EQ 20MG BASE/ML	N050589	001	Oct 03, 1984
	EQ 40MG BASE/ML	N050589	002	Oct 03, 1984
CEFIZOX IN PLASTIC CONTAINER				
ASTELLAS	EQ 20MG BASE/ML	N050589	003	Apr 13, 1995
	EQ 40MG BASE/ML	N050589	004	Apr 13, 1995

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION				
CEFTRIAXONE				
AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065504	001	Jul 31, 2008
BEDFORD	EQ 10GM BASE/VIAL	A065475	001	Aug 18, 2008
FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007
FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065252	001	Feb 15, 2006
HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005
	EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012
	EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005
	EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012
	EQ 10GM BASE/VIAL	A065232	001	Aug 02, 2005
LUPIN	EQ 10GM BASE/VIAL	A065263	001	Sep 12, 2006
TEVA	EQ 10GM BASE/VIAL	A065274	001	May 01, 2006
ROCEPHIN				
HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	A063239	001	Aug 13, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION					
ROCEPHIN					
		EQ 500MG BASE/VIAL	A062654	001	Apr 30, 1987
		EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993
		EQ 1GM BASE/VIAL	A062654	002	Apr 30, 1987
		EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993
		EQ 2GM BASE/VIAL	A062654	003	Apr 30, 1987
+		EQ 10GM BASE/VIAL **	N050585	005	Dec 21, 1984
	ROCHE	EQ 250MG BASE/VIAL	A062510	001	Mar 12, 1985
		EQ 500MG BASE/VIAL	A062510	002	Mar 12, 1985
		EQ 1GM BASE/VIAL	A062510	003	Mar 12, 1985
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER					
+	HOFFMANN LA ROCHE	EQ 10MG BASE/ML **	N050624	001	Feb 11, 1987
+		EQ 20MG BASE/ML **	N050624	002	Feb 11, 1987
+		EQ 40MG BASE/ML **	N050624	003	Feb 11, 1987
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
CEFTRIAXONE					
	AUROBINDO PHARMA LTD	EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008
		EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008
		EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008
		EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008
	BEDFORD	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008
		EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008
		EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008
		EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008
	CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	A065294	001	Mar 26, 2007
		EQ 500MG BASE/VIAL	A065294	002	Mar 26, 2007
		EQ 1GM BASE/VIAL	A065294	003	Mar 26, 2007
		EQ 2GM BASE/VIAL	A065294	004	Mar 26, 2007
	FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007
		EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007
	FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006
		EQ 500MG BASE/VIAL	A065245	002	Feb 15, 2006
		EQ 1GM BASE/VIAL	A065245	003	Feb 15, 2006
		EQ 2GM BASE/VIAL	A065245	004	Feb 15, 2006
	HOSPIRA INC	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005
		EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005
		EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005
		EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005
	LUPIN	EQ 250MG BASE/VIAL	A065125	001	Sep 30, 2003
		EQ 500MG BASE/VIAL	A065125	002	Sep 30, 2003
		EQ 1GM BASE/VIAL	A065125	003	Sep 30, 2003
		EQ 2GM BASE/VIAL	A065125	004	Sep 30, 2003
	TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006
		EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006
	TEVA PHARMS USA	EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007
		EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007
		EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007
		EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007
ROCEPHIN					
+	HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL **	N050585	001	Dec 21, 1984
+		EQ 500MG BASE/VIAL **	N050585	002	Dec 21, 1984
+		EQ 1GM BASE/VIAL **	N050585	003	Dec 21, 1984
+		EQ 2GM BASE/VIAL **	N050585	004	Dec 21, 1984

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE;INJECTION					
ROCEPHIN KIT					
	HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL,N/A;N/A,1%	N050585	007	May 08, 1996
		EQ 1GM BASE/VIAL,N/A;N/A,1%	N050585	006	May 08, 1996

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL					
CEFTIN					
+	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994
+		EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997
CEFUROXIME AXETIL					
	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008
		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFUROXIME AXETIL

TABLET;ORAL				
CEFTIN				
+ GLAXOSMITHKLINE	EQ 125MG BASE **	N050605	001	Dec 28, 1987
+	EQ 250MG BASE **	N050605	002	Dec 28, 1987
+	EQ 500MG BASE **	N050605	003	Dec 28, 1987
CEFUROXIME AXETIL				
ANI PHARMS	EQ 250MG BASE	A065190	001	Oct 18, 2004
	EQ 500MG BASE	A065190	002	Oct 18, 2004
FOSUN PHARMA	EQ 250MG BASE	A065126	001	Oct 28, 2003
	EQ 500MG BASE	A065126	002	Oct 28, 2003
RANBAXY LABS LTD	EQ 125MG BASE	A065043	003	Feb 15, 2002
	EQ 250MG BASE	A065043	002	Feb 15, 2002
	EQ 500MG BASE	A065043	001	Feb 15, 2002
SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003
	EQ 250MG BASE	A065118	002	Apr 25, 2003
	EQ 500MG BASE	A065118	003	Apr 25, 2003

CEFUROXIME SODIUM

INJECTABLE;INJECTION				
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER				
+ B BRAUN	EQ 750MG BASE/VIAL	N050780	001	Feb 21, 2001
+	EQ 1.5GM BASE/VIAL	N050780	002	Feb 21, 2001
CEFUROXIME SODIUM				
ACS DOBFAR SPA	EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997
FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001	002	May 30, 2001
	EQ 7.5GM BASE/VIAL	A065002	001	Sep 28, 1998
HIKMA	EQ 7.5GM BASE/VIAL	A065046	001	Jan 09, 2004
HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483	002	Oct 15, 2008
	EQ 1.5GM BASE/VIAL	A065503	001	Oct 15, 2008
	EQ 7.5GM BASE/VIAL	A065484	001	Oct 15, 2008
TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191	001	Apr 16, 1998
WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035	002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036	001	Feb 26, 1993
CEFUROXIME SODIUM IN PLASTIC CONTAINER				
SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251	001	Dec 30, 2009
	EQ 225GM BASE/VIAL	A065251	002	Dec 30, 2009
KEFUROX				
ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591	002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591	003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592	002	Jan 10, 1986
KEFUROX IN PLASTIC CONTAINER				
LILLY	EQ 1.5GM BASE/VIAL	A062590	002	Jan 10, 1986
ZINACEF				
+ PAI HOLDINGS PHARM	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983
+	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986
ZINACEF IN PLASTIC CONTAINER				
PAI HOLDINGS PHARM	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989
+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS				
CEFUROXIME SODIUM				
FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001	001	May 30, 2001
HOSPIRA INC	EQ 750MG BASE/VIAL	A065483	001	Oct 15, 2008
TEVA PHARMS	EQ 750MG BASE/VIAL	A064192	002	Apr 16, 1998
	EQ 1.5GM BASE/VIAL	A064192	001	Apr 16, 1998
WATSON LABS INC	EQ 750MG BASE/VIAL	A064035	001	Feb 26, 1993
KEFUROX				
ACS DOBFAR	EQ 750MG BASE/VIAL	A062591	001	Jan 10, 1986
ZINACEF				
+ PAI HOLDINGS PHARM	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983
INJECTABLE;INTRAVENOUS				
KEFUROX				
LILLY	EQ 750MG BASE/VIAL	A062592	001	Jan 10, 1986
KEFUROX IN PLASTIC CONTAINER				
LILLY	EQ 750MG BASE/VIAL	A062590	001	Jan 10, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CELECOXIB				
CAPSULE;ORAL				
CELECOXIB				
ACIC PHARMS	200MG	A212925	001	Dec 09, 2020
	400MG	A212925	002	Dec 09, 2020
JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017
	100MG	A207061	002	Apr 04, 2017
	200MG	A207061	003	Apr 04, 2017
	400MG	A207061	004	Apr 04, 2017
MYLAN	50MG	A078857	001	May 30, 2014
	100MG	A078857	002	Feb 11, 2015
	200MG	A078857	003	Feb 11, 2015
	400MG	A078857	004	Feb 11, 2015
UNICHEM	50MG	A213301	001	Jan 12, 2021
	100MG	A213301	002	Jan 12, 2021
	200MG	A213301	003	Jan 12, 2021
	400MG	A213301	004	Jan 12, 2021
YABAO PHARM	100MG	A212564	001	Apr 10, 2023
	200MG	A212564	002	Apr 10, 2023
	400MG	A212564	003	Apr 10, 2023
CELLULOSE SODIUM PHOSPHATE				
POWDER;ORAL				
CALCIBIND				
MISSION PHARMA	2.5GM/PACKET	N018757	002	Dec 28, 1982
	300GM/BOT	N018757	003	Oct 16, 1984
CEPHALEXIN				
CAPSULE;ORAL				
CEPHALEXIN				
APOTHECON	EQ 250MG BASE	A062973	001	Nov 08, 1988
	EQ 250MG BASE	A063063	001	Sep 29, 1989
	EQ 250MG BASE	A063186	001	Dec 30, 1994
	EQ 500MG BASE	A062974	001	Nov 23, 1988
	EQ 500MG BASE	A063063	002	Sep 29, 1989
	EQ 500MG BASE	A063186	002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773	001	Jun 26, 1987
	EQ 500MG BASE	A062775	001	Apr 22, 1987
FACTA FARMA	EQ 250MG BASE	A062118	001	
	EQ 500MG BASE	A062118	002	
HIKMA	EQ 250MG BASE	A065215	001	Jan 24, 2006
	EQ 500MG BASE	A065215	002	Jan 24, 2006
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969	001	
	EQ 500MG BASE	A061969	002	
PUREPAC PHARM	EQ 250MG BASE	A062809	001	Apr 22, 1987
	EQ 500MG BASE	A062809	002	Apr 22, 1987
STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988
	EQ 500MG BASE	A062869	001	Mar 17, 1988
SUN PHARM INDS (IN)	EQ 250MG BASE	A062791	001	Jun 11, 1987
	EQ 500MG BASE	A062791	002	Jun 11, 1987
SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999
	EQ 500MG BASE	A065007	002	Sep 16, 1999
TEVA	EQ 250MG BASE	A062760	001	Apr 24, 1987
	EQ 250MG BASE	A062821	001	Feb 05, 1988
	EQ 500MG BASE	A062761	001	Apr 24, 1987
	EQ 500MG BASE	A062823	001	Feb 05, 1988
YOSHITOMI	EQ 250MG BASE	A062872	001	Jun 20, 1988
	EQ 500MG BASE	A062871	001	Jul 05, 1988
KEFLEX				
+ PRAGMA	EQ 250MG BASE **	N050405	002	
+	EQ 333MG BASE **	N050405	004	May 12, 2006
+	EQ 500MG BASE **	N050405	003	
+	EQ 750MG BASE **	N050405	005	May 12, 2006
FOR SUSPENSION;ORAL				
CEPHALEXIN				
APOTHECON	EQ 125MG BASE/5ML	A062986	001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987	001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778	001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777	001	Aug 06, 1987
CHARTWELL RX	EQ 125MG BASE/5ML	A065326	001	Jul 10, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEPHALEXIN

FOR SUSPENSION;ORAL				
CEPHALEXIN				
	EQ 250MG BASE/5ML	A065326	002	Jul 10, 2006
FACTA FARMA	EQ 100MG BASE/ML **	A062117	001	
	EQ 125MG BASE/5ML **	A062117	002	
	EQ 250MG BASE/5ML **	A062117	003	
HIKMA PHARMS	EQ 125MG BASE/5ML	A065444	001	Aug 28, 2009
	EQ 250MG BASE/5ML	A065444	002	Aug 28, 2009
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001
	EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001
TEVA	EQ 125MG BASE/5ML	A062767	001	Jun 16, 1987
	EQ 125MG BASE/5ML	A062873	001	May 23, 1988
	EQ 250MG BASE/5ML	A062768	001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867	001	Apr 15, 1988
VITARINE	EQ 125MG BASE/5ML	A062779	001	Dec 22, 1987
	EQ 250MG BASE/5ML	A062781	001	Dec 22, 1987
KEFLEX				
+ PRAGMA	EQ 100MG BASE/ML **	N050406	003	
+	EQ 125MG BASE/5ML **	N050406	001	
+	EQ 250MG BASE/5ML **	N050406	002	
TABLET;ORAL				
CEPHALEXIN				
BARR	EQ 250MG BASE	A062826	001	Aug 17, 1987
	EQ 500MG BASE	A062827	001	Aug 17, 1987
VITARINE	EQ 250MG BASE	A062863	001	Aug 11, 1988
	EQ 500MG BASE	A062863	002	Aug 11, 1988
	EQ 1GM BASE	A062863	003	Aug 11, 1988
KEFLET				
LILLY	EQ 250MG BASE	A062745	001	Dec 01, 1986
	EQ 250MG BASE	N050440	003	Feb 26, 1987
	EQ 500MG BASE	A062745	002	Dec 01, 1986
	EQ 500MG BASE	N050440	001	
	EQ 1GM BASE	N050440	002	
TABLET, FOR SUSPENSION;ORAL				
PANIXINE DISPERDOSE				
RANBAXY LABS LTD	EQ 125MG BASE	A065100	002	Sep 11, 2003
	EQ 250MG BASE	A065100	001	Sep 11, 2003

CEPHALEXIN HYDROCHLORIDE

TABLET;ORAL				
KEFTAB				
LILLY	EQ 250MG BASE	N050614	001	Oct 29, 1987
	EQ 333MG BASE	N050614	003	May 16, 1988
	EQ 500MG BASE	N050614	002	Oct 29, 1987

CEPHALOGLYCIN

CAPSULE;ORAL				
KAFOCIN				
LILLY	250MG	N050219	001	

CEPHALOTHIN SODIUM

INJECTABLE;INJECTION				
CEPHALOTHIN				
INTL MEDICATION	EQ 500MG BASE/VIAL	A062426	001	May 03, 1985
	EQ 1GM BASE/VIAL	A062426	002	May 03, 1985
	EQ 2GM BASE/VIAL	A062426	003	May 03, 1985
	EQ 4GM BASE/VIAL	A062426	004	May 03, 1985
CEPHALOTHIN SODIUM				
ABBOTT	EQ 1GM BASE/VIAL	A062547	001	Sep 11, 1985
	EQ 1GM BASE/VIAL	A062548	001	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062547	002	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062548	002	Sep 11, 1985
ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062666	002	Jun 10, 1987
	EQ 2GM BASE/VIAL	A062666	001	Jun 10, 1987
BRISTOL	EQ 1GM BASE/VIAL	A062464	001	May 07, 1984
	EQ 2GM BASE/VIAL	A062464	002	May 07, 1984
	EQ 4GM BASE/VIAL	A062464	003	May 07, 1984
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422	003	Jan 31, 1984
	EQ 20MG BASE/ML	A062422	005	Jul 16, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEPHALOTHIN SODIUM

INJECTABLE;INJECTION				
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER				
	EQ 20MG BASE/ML	A062730	001	Mar 05, 1987
	EQ 40MG BASE/ML	A062422	004	Jan 31, 1984
	EQ 40MG BASE/ML	A062422	006	Jul 16, 1991
	EQ 40MG BASE/ML	A062730	002	Mar 05, 1987
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422	001	Jan 31, 1984
	EQ 40MG BASE/ML	A062422	002	Jan 31, 1984
KEFLIN				
LILLY	EQ 1GM BASE/VIAL	N050482	001	
	EQ 2GM BASE/VIAL	N050482	002	
	EQ 4GM BASE/VIAL	N050482	003	
	EQ 20GM BASE/VIAL	N050482	007	
KEFLIN IN PLASTIC CONTAINER				
LILLY	EQ 1GM BASE/VIAL	A062549	001	Sep 10, 1985
	EQ 2GM BASE/VIAL	A062549	002	Sep 10, 1985
SEFFIN				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A062435	001	Nov 15, 1983
	EQ 2GM BASE/VIAL	A062435	002	Nov 15, 1983
	EQ 10GM BASE/VIAL	A062435	003	Nov 15, 1983

CEPHAPIRIN SODIUM

INJECTABLE;INJECTION				
CEFADYL				
APOTHECON	EQ 500MG BASE/VIAL	A062961	001	Sep 20, 1988
	EQ 500MG BASE/VIAL	N050446	005	
	EQ 1GM BASE/VIAL	A061769	001	
	EQ 1GM BASE/VIAL	A062724	001	Dec 23, 1986
	EQ 1GM BASE/VIAL	A062961	002	Sep 20, 1988
	EQ 1GM BASE/VIAL	N050446	001	
	EQ 2GM BASE/VIAL	A061769	002	
	EQ 2GM BASE/VIAL	A062724	002	Dec 23, 1986
	EQ 2GM BASE/VIAL	A062961	003	Sep 20, 1988
	EQ 2GM BASE/VIAL	N050446	002	
	EQ 4GM BASE/VIAL	A061769	003	
	EQ 4GM BASE/VIAL	A062961	004	Sep 20, 1988
	EQ 4GM BASE/VIAL	N050446	003	
	EQ 20GM BASE/VIAL	N050446	004	
CEPHAPIRIN SODIUM				
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062723	001	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062723	002	Nov 17, 1986
	EQ 2GM BASE/VIAL	A062723	003	Nov 17, 1986
	EQ 4GM BASE/VIAL	A062723	004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062723	005	Nov 17, 1986
HIKMA	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987
	EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987
	EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987
	EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987

CEPHRADINE

CAPSULE;ORAL				
ANSPOR				
GLAXOSMITHKLINE	250MG	A061859	001	
	500MG	A061859	002	
CEPHRADINE				
BARR	250MG	A062850	001	Apr 22, 1988
	500MG	A062851	001	Apr 22, 1988
IVAX SUB TEVA PHARMS	250MG	A062762	001	Mar 06, 1987
	500MG	A062762	002	Mar 06, 1987
TEVA	250MG	A062683	001	Jan 09, 1987
	500MG	A062683	002	Jan 09, 1987
VITARINE	250MG	A062813	001	Feb 25, 1988
	500MG	A062813	002	Feb 25, 1988
VELOSEF				
APOTHECON	250MG	A061764	001	
	500MG	A061764	002	
VELOSEF '250'				
ERSANA	250MG	N050548	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEPHRADINE

CAPSULE;ORAL				
VELOSEF '500'				
ERSANA	500MG	N050548	002	
FOR SUSPENSION;ORAL				
ANSPOR				
GLAXOSMITHKLINE	125MG/5ML	A061866	001	
	250MG/5ML	A061866	002	
CEPHRADINE				
BARR	125MG/5ML	A062858	001	May 19, 1988
	250MG/5ML	A062859	001	May 19, 1988
TEVA	125MG/5ML	A062693	001	Jan 09, 1987
	250MG/5ML	A062693	002	Jan 09, 1987
VELOSEF '125'				
APOTHECON	125MG/5ML	A061763	001	
VELOSEF '250'				
APOTHECON	250MG/5ML	A061763	002	
INJECTABLE;INJECTION				
VELOSEF				
APOTHECON	250MG/VIAL	A061976	001	
	500MG/VIAL	A061976	002	
	1GM/VIAL	A061976	004	
	2GM/VIAL	A061976	003	
	4GM/VIAL	A061976	005	
TABLET;ORAL				
VELOSEF				
BRISTOL MYERS SQUIBB	1GM	N050530	001	

CERITINIB

CAPSULE;ORAL				
ZYKADIA				
+ NOVARTIS	150MG	N205755	001	Apr 29, 2014

CERIVASTATIN SODIUM

TABLET;ORAL				
BAYCOL				
BAYER PHARMS	0.05MG	N020740	001	Jun 26, 1997
	0.1MG	N020740	002	Jun 26, 1997
	0.2MG	N020740	003	Jun 26, 1997
	0.3MG	N020740	004	Jun 26, 1997
	0.4MG	N020740	005	May 24, 1999
	0.8MG	N020740	006	Jul 24, 2000

CERULETIDE DIETHYLAMINE

INJECTABLE;INJECTION				
TYMTRAN				
PHARMACIA AND UPJOHN	0.02MG/ML	N018296	001	

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL				
CETIRIZINE HYDROCHLORIDE ALLERGY				
APOTEX	10MG	A207235	001	Aug 12, 2016
SYRUP;ORAL				
CETIRIZINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010
APOZEAL PHARMS	5MG/5ML	A078870	001	Apr 27, 2009
AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009
LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009
PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008
RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008
WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY				
APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009
CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008
CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008
PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008
RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008
TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF				
APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009
CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008
PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008
RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008
TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012

ZYRTEC

J AND J CONSUMER INC	5MG/5ML **	N020346	001	Sep 27, 1996

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

CIPLA LTD	5MG	A077318	001	Jul 25, 2013
	10MG	A077318	002	Jul 25, 2013
HERITAGE PHARMA	5MG	A078615	003	Dec 28, 2007
	10MG	A078615	004	Dec 28, 2007
SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007
	10MG	A077499	002	Dec 27, 2007
TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010
	10MG	A079191	004	Apr 15, 2010
UNICHEM	5MG	A078680	003	Jun 26, 2009
	10MG	A078680	004	Jun 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007
	10MG	A077499	004	Dec 27, 2007
UNICHEM	5MG	A078680	001	Jun 26, 2009
	10MG	A078680	002	Jun 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010
	10MG	A079191	002	Apr 15, 2010

ZYRTEC ALLERGY

+ J AND J CONSUMER INC	5MG	N019835	003	Nov 16, 2007

ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC	5MG	N019835	005	Nov 16, 2007
+	10MG	N019835	006	Nov 16, 2007

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS INC	5MG	A077631	004	Jan 11, 2008
	10MG	A077631	003	Jan 11, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC	5MG	A077631	001	Jan 11, 2008
	10MG	A077631	002	Jan 11, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM	10MG	A090142	002	Aug 30, 2011

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM	10MG	A090142	004	Aug 30, 2011

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC	5MG **	N021621	003	Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC	5MG **	N021621	005	Nov 16, 2007
+	10MG **	N021621	006	Nov 16, 2007

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	5MG;120MG	A212409	001	Mar 08, 2023

CETRORELIX ACETATE

POWDER;SUBCUTANEOUS

CETROTIDE

+ EMD SERONO INC	EQ 3MG BASE/VIAL	N021197	002	Aug 11, 2000

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION;INTRATRACHEAL

EXOSURF NEONATAL

GLAXOSMITHKLINE	12MG/VIAL;108MG/VIAL;8MG/VIAL	N020044	001	Aug 02, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL				
CEVIMELINE HYDROCHLORIDE				
APOTEX INC	30MG		A091260 001	Aug 25, 2011

CHENODIOL

TABLET;ORAL				
CHENIX				
+ LEADIANT BIOSCI INC	250MG **		N018513 002	Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP;ORAL				
ULO				
3M	25MG/5ML		N012126 001	

CHLORAMPHENICOL

CREAM;TOPICAL				
CHLOROMYCETIN				
PARKE DAVIS	1%		N050183 001	
FOR SOLUTION;OPHTHALMIC				
CHLOROMYCETIN				
PARKEDALE	25MG/VIAL		N050143 001	
INJECTABLE;INJECTION				
CHLOROMYCETIN				
PARKE DAVIS	250MG/ML		N050153 001	
OINTMENT;OPHTHALMIC				
CHLORAMPHENICOL				
ALTANA	1%		A060133 001	
CHLOROFAIR				
PHARMAFAIR	1%		A062439 001	Apr 21, 1983
CHLOROMYCETIN				
PARKEDALE	1%		N050156 001	
CHLOROPTIC S.O.P.				
ALLERGAN	1%		A061187 001	
ECONOCHLOR				
ALCON	1%		A061648 001	
SOLUTION/DROPS;OPHTHALMIC				
CHLORAMPHENICOL				
AKORN	0.5%		A062042 001	
ALCON	0.5%		A062628 001	Sep 25, 1985
CHLOROFAIR				
PHARMAFAIR	0.5%		A062437 001	Apr 14, 1983
CHLOROPTIC				
ALLERGAN	0.5%		N050091 001	
ECONOCHLOR				
ALCON	0.5%		A061645 001	
OPHTHOCHLOR				
PARKEDALE	0.5%		A061220 001	
OPTOMYCIN				
OPTOPICS	0.5%		A062171 001	Mar 31, 1982
SOLUTION/DROPS;OTIC				
CHLOROMYCETIN				
PARKEDALE	0.5%		N050205 001	

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION				
CHLORAMPHENICOL				
ELKINS SINN	EQ 1GM BASE/VIAL		A062406 001	Nov 09, 1982
CHLORAMPHENICOL SODIUM SUCCINATE				
GRUPPO LEPETIT	EQ 1GM BASE/VIAL		A062278 001	
CHLOROMYCETIN				
+ PARKEDALE	EQ 1GM BASE/VIAL		N050155 001	
MYCHEL-S				
ANGUS	EQ 1GM BASE/VIAL		A060132 001	

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION;OPHTHALMIC				
CHLOROMYCETIN HYDROCORTISONE				
PARKEDALE	12.5MG/VIAL;25MG/VIAL		N050202 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
OPHTHOCORT				
	PARKEDALE	10MG/GM;5MG/GM;10,000 UNITS/GM	N050201 002	
CHLORAMPHENICOL; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
CHLOROMYXIN				
	PARKE DAVIS	1%;10,000 UNITS/GM	N050203 002	
CHLORAMPHENICOL; PREDNISOLONE				
OINTMENT;OPHTHALMIC				
CHLOROPTIC-P S.O.P.				
	ALLERGAN	1%;0.5%	A061188 001	
CHLORDIAZEPOXIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
LIBRELEASE				
	VALEANT PHARM INTL	30MG	N017813 001	Sep 12, 1983
TABLET;ORAL				
LIBRITABS				
	VALEANT PHARM INTL	5MG	A085482 001	
		10MG	A085481 001	
		25MG	A085488 001	
CHLORDIAZEPOXIDE HYDROCHLORIDE				
CAPSULE;ORAL				
A-POXIDE				
	ABBOTT	5MG	A085447 001	
		5MG	A085517 001	
		10MG	A085447 002	
		10MG	A085518 001	
		25MG	A085447 003	
		25MG	A085513 001	
CHLORDIAZACHEL				
	RACHELLE	5MG	A085086 001	
		10MG	A084639 001	
		25MG	A085087 001	
CHLORDIAZEPOXIDE HYDROCHLORIDE				
	ASCOT	5MG	A087525 001	Jan 07, 1982
		10MG	A087524 001	Jan 07, 1982
		25MG	A087512 001	Jan 07, 1982
	FERRANTE	5MG	A085118 001	
		10MG	A085119 001	
		25MG	A085120 001	
	HALSEY	5MG	A085340 001	
		10MG	A085339 001	
		25MG	A084685 001	
	IMPAX LABS	5MG	A086213 001	
		10MG	A085113 001	
		25MG	A086212 001	
	IVAX SUB TEVA PHARMS	5MG	A083741 001	
		10MG	A083742 001	
		25MG	A083570 001	
	LEDERLE	5MG	A086892 001	
		5MG	A087234 001	
		10MG	A086876 001	
		10MG	A087037 001	
		25MG	A086893 001	
		25MG	A087231 001	
	MAST MM	10MG	A086217 001	
	MYLAN	5MG	A084886 001	
		10MG	A084601 001	
		25MG	A084887 001	
	PARKE DAVIS	5MG	A085163 001	
		10MG	A084598 001	
		25MG	A085164 001	
	PIONEER PHARMS	10MG	A089533 001	Jul 15, 1988
		25MG	A089558 001	Jul 15, 1988
	PUREPAC PHARM	5MG	A085155 001	
		10MG	A084939 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL					
CHLORDIAZEPOXIDE HYDROCHLORIDE					
		25MG	A085144	001	
	ROXANE	5MG	A084706	001	
		10MG	A084700	001	
		25MG	A084705	001	
	SUPERPHARM	5MG	A088987	001	Apr 25, 1985
		10MG	A088986	001	Apr 25, 1985
		25MG	A088988	001	Apr 25, 1985
	TEVA	5MG	A088705	001	Jan 18, 1985
		10MG	A088706	001	Jan 18, 1985
		25MG	A086494	001	
		25MG	A088707	001	Jan 18, 1985
	UPSHER SMITH LABS	5MG	A084919	001	
+		10MG	A084920	001	
		25MG	A084823	001	
	USL PHARMA	5MG	A084644	001	
		10MG	A084623	001	
		25MG	A084645	001	
	VANGARD	5MG	A088129	001	Mar 28, 1983
		10MG	A088010	001	Mar 28, 1983
		25MG	A088130	001	Mar 28, 1983
	WATSON LABS	5MG	A086383	001	
		10MG	A086294	001	
		25MG	A086382	001	
	WEST WARD	5MG	A085014	001	
		10MG	A085000	001	
		25MG	A085294	001	
LIBRIUM					
+	VALEANT PHARM INTL	5MG **	N012249	002	
+		10MG **	N012249	001	
+		25MG **	N012249	003	
LYGEN					
	ALRA	5MG	A085107	001	
		10MG	A085009	001	
		25MG	A085108	001	
INJECTABLE;INJECTION					
LIBRIUM					
	BAUSCH	100MG/AMP	N012301	001	

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL					
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE					
	TEVA PHARMS USA	5MG;2.5MG	A211476	001	Nov 02, 2021
	TORRENT	5MG;2.5MG	A217385	001	Dec 14, 2023

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET;ORAL					
MENRIUM 10-4					
	ROCHE	10MG;0.4MG	N014740	006	
MENRIUM 5-2					
	ROCHE	5MG;0.2MG	N014740	002	
MENRIUM 5-4					
	ROCHE	5MG;0.4MG	N014740	004	

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL					
CHLORHEXIDINE GLUCONATE					
	AKORN	0.12%	A074356	001	May 07, 1996
PAROEX					
	SUNSTAR AMERICAS	0.12%	A076434	001	Nov 29, 2005
PERIOGARD					
	COLGATE PALMOLIVE CO	0.12%	A073695	001	Jan 14, 1994
SOLUTION;TOPICAL					
BRIAN CARE					
	SOAPCO	4%	A071419	001	Dec 17, 1987
EXIDINE					
	XTTRIUM	2.5%	N019421	001	Dec 17, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL				
MICRODERM				
	J AND J	4%	A072255 001	Apr 15, 1991
PREVACARE R				
	J AND J	0.5%	A072292 001	Jan 28, 1992
STERI-STAT				
	MATRIX MEDCL	4%	A070104 001	Jul 24, 1986
SPONGE;TOPICAL				
CHLORHEXIDINE GLUCONATE				
	KENDALL IL	4%	N019490 001	Mar 27, 1987
E-Z SCRUB				
	BECTON DICKINSON	4%	A073416 001	Mar 14, 2000
HIBICLENS				
+	MOLNLYCKE HLTH	4% **	N018423 001	
MICRODERM				
	J AND J	4%	A072295 001	Feb 28, 1991
PHARMASEAL SCRUB CARE				
	CAREFUSION 2200	4%	N019793 001	Dec 02, 1988
TABLET;DENTAL				
PERIOCHIP				
+	DEXCEL PHARMA	2.5MG	N020774 001	May 15, 1998

CHLORMERODRIN HG-197

INJECTABLE;INJECTION				
CHLORMERODRIN HG 197				
	BRACCO	0.6-1.4mCi/ML	N017269 001	

CHLORMEZANONE

TABLET;ORAL				
TRANCOPAL				
	SANOFI AVENTIS US	100MG	N011467 003	
		200MG	N011467 005	

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
CHLOROPROCAINE HYDROCHLORIDE				
	HOSPIRA	2%	A087447 001	Apr 16, 1982
		3%	A087446 001	Apr 16, 1982
NESACAINE-MPF				
	FRESENIUS KABI USA	2%	N009435 003	
		3%	N009435 004	
SOLUTION;INTRATHECAL				
CLOROTEKAL				
+	B BRAUN MEDICAL INC	50MG/5ML (10MG/ML)	N208791 001	Sep 26, 2017

CHLOROQUINE HYDROCHLORIDE

INJECTABLE;INJECTION				
ARALEN HYDROCHLORIDE				
	SANOFI AVENTIS US	EQ 40MG BASE/ML	N006002 002	

CHLOROQUINE PHOSPHATE

TABLET;ORAL				
ARALEN				
+	SANOFI AVENTIS US	500MG **	N006002 001	
CHLOROQUINE PHOSPHATE				
	HIKMA PHARMS	250MG **	A083082 001	
		500MG **	A083082 002	Sep 17, 1999
	MD PHARM	250MG	A087228 001	
	PUREPAC PHARM	250MG	A080886 001	
	TEVA	250MG	A087504 001	Jan 13, 1982
	WATSON LABS	250MG	A087979 001	Dec 21, 1982
		500MG	A088030 001	Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET;ORAL				
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE				
	SANOFI AVENTIS US	EQ 300MG BASE;EQ 45MG BASE	N014860 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLOROTHIAZIDE

TABLET;ORAL				
CHLOROTHIAZIDE				
	ABC HOLDING	250MG	A085569 001	
	HIKMA INTL PHARMS	250MG	A086028 001	Jul 14, 1982
		500MG	A087736 001	Jul 14, 1982
	LEDERLE	250MG	A086940 001	
		500MG	A086938 001	
	MYLAN	250MG	A084217 002	
		500MG	A084217 001	
	SANDOZ	250MG	A085485 001	
	WATSON LABS	250MG	A085165 001	
		250MG	A085173 001	
		250MG	A086795 001	Aug 15, 1983
		500MG	A084026 001	Sep 01, 1982
		500MG	A086796 001	Aug 15, 1983
DIURIL				
+	RISING	250MG **	N011145 004	
+		500MG **	N011145 002	

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION				
DIURIL				
+	RISING	EQ 500MG BASE/VIAL	N011145 005	

CHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL				
ALDOCLOR-150				
	MERCK	150MG;250MG	N016016 001	
ALDOCLOR-250				
	MERCK	250MG;250MG	N016016 002	
METHYLDOPA AND CHLOROTHIAZIDE				
	PAR PHARM	150MG;250MG	A070783 001	Nov 06, 1987
		250MG;250MG	A070654 001	Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET;ORAL				
CHLOROTHIAZIDE AND RESERPINE				
	HIKMA	250MG;0.125MG	A088557 001	Dec 22, 1983
		500MG;0.125MG	A088365 001	Dec 22, 1983
CHLOROTHIAZIDE W/ RESERPINE				
	WATSON LABS	250MG;0.125MG	A084853 001	
		500MG;0.125MG	A088151 001	Jun 09, 1983
CHLOROTHIAZIDE-RESERPINE				
	MYLAN	250MG;0.125MG	A087744 001	May 06, 1982
		500MG;0.125MG	A087745 001	May 06, 1982
DIUPRES-250				
	MERCK	250MG;0.125MG	N011635 003	Aug 26, 1987
DIUPRES-500				
	MERCK	500MG;0.125MG	N011635 006	Aug 26, 1987

CHLOROTRIANISENE

CAPSULE;ORAL				
CHLOROTRIANISENE				
	BANNER PHARMACAPS	12MG	A084652 001	
TACE				
	SANOFI AVENTIS US	12MG	N008102 004	
		25MG	N011444 001	
		72MG	N016235 001	

CHLOROXINE

SHAMPOO;TOPICAL				
CAPITROL				
	WESTWOOD SQUIBB	2%	N017594 001	

CHLORPHENESIN CARBAMATE

TABLET;ORAL				
MAOLATE				
	PAMLAB LLC	400MG	N014217 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL				
CHLORPHENIRAMINE MALEATE				
AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988
TELDRIN				
GLAXOSMITHKLINE	8MG	N017369	001	
	12MG	N017369	002	
INJECTABLE;INJECTION				
CHLOR-TRIMETON				
SCHERING PLOUGH	10MG/ML	N008826	001	
	100MG/ML	N008794	001	
CHLORPHENIRAMINE MALEATE				
BEL MAR	10MG/ML	A080821	001	
ELKINS SINN	10MG/ML	A080797	001	
WATSON LABS	10MG/ML	A083593	001	
	10MG/ML	A086096	001	
	100MG/ML	A086095	001	
PYRIDAMAL 100				
BEL MAR	100MG/ML	A083733	001	
SYRUP;ORAL				
CHLOR-TRIMETON				
SCHERING	2MG/5ML	N006921	006	
CHLORPHENIRAMINE MALEATE				
PHARM ASSOC	2MG/5ML	A087520	001	Feb 10, 1982
TABLET;ORAL				
ANTAGONATE				
BAYER PHARMS	4MG	A083381	001	
CHLOR-TRIMETON				
SCHERING	4MG	N006921	002	
CHLORPHENIRAMINE MALEATE				
ANABOLIC	4MG	A083078	001	
AUROLIFE PHARMA LLC	4MG	A080961	001	
BELL PHARMA	4MG	A083062	001	
ELKINS SINN	4MG	A080938	001	
IMPAX LABS	4MG	A080809	001	
IVAX SUB TEVA PHARMS	4MG	A080779	001	
KV PHARM	4MG	A087164	001	
LEDERLE	4MG	A086941	001	
NEWTRON PHARMS	4MG	A086519	001	
PANRAY	4MG	A083243	001	
PHARMAVITE	4MG	A085104	001	
PHARMERAL	4MG	A083753	001	
PIONEER PHARMS	4MG	A088556	001	Jul 13, 1984
PUREPAC PHARM	4MG	A086306	001	
PVT FORM	4MG	A080786	001	
ROXANE	4MG	A080626	001	
SUN PHARM INDUSTRIES	4MG	A080700	001	
VITARINE	4MG	A085837	001	
WATSON LABS	4MG	A080696	001	
	4MG	A080791	001	
	4MG	A085139	001	
WEST WARD	4MG	A083787	001	
KLOROMIN				
HALSEY	4MG	A083629	001	
PHENETRON				
LANNETT	4MG	A080846	001	
TABLET, EXTENDED RELEASE;ORAL				
CHLOR-TRIMETON				
+ BAYER HEALTHCARE LLC	8MG **	N007638	001	
+	12MG **	N007638	002	
EFIDAC 24 CHLORPHENIRAMINE MALEATE				
ALZA	16MG	N019746	002	Nov 18, 1994

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL				
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE				
ACELLA	4MG/5ML;5MG/5ML	A206891	001	Jun 09, 2017
TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

VITUZ					
+	PERSION	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	APOZEAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017
	MAYNE PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015
	TRIS PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A203838	001	Nov 26, 2014
ZUTRIPRO					
+	PERSION	4MG/5ML;5MG/5ML;60MG/5ML **	N022439	001	Jun 08, 2011

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

COLD CAPSULE IV					
	GRAHAM DM	12MG;75MG	N018793	001	Apr 25, 1985
COLD CAPSULE V					
	GRAHAM DM	8MG;75MG	N018794	001	Apr 23, 1985

TABLET, EXTENDED RELEASE;ORAL

TRIAMINIC-12					
	NOVARTIS	12MG;75MG	N018115	001	

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CODIMAL-L.A. 12					
	SCHWARZ PHARMA	12MG;120MG	N018935	001	Apr 15, 1985
ISOCLOR					
	FISONS	8MG;120MG	N018747	001	Mar 06, 1986
PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE					
	CENT PHARMS	8MG;120MG	N019428	001	Aug 02, 1988
	GRAHAM DM	8MG;120MG	N018844	001	Mar 20, 1985
		12MG;120MG	N018843	001	Mar 18, 1985
	KV PHARM	12MG;120MG	A071455	001	Mar 01, 1989

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON					
+	BAYER HEALTHCARE LLC	8MG;120MG	N018397	001	

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

CODEPREX					
	LANNETT CO INC	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N021369	001	Jun 21, 2004
PENNTUSS					
	FISONS	EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML	N018928	001	Aug 14, 1985
TUZISTRA XR					
+	TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE;ORAL

TUSSICAPS					
	ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007
		EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007

SUSPENSION, EXTENDED RELEASE;ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX					
	NEOS THERAPS INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671	001	Jun 29, 2012
TUSSIONEX PENNKINETIC					
+	UCB INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **	N019111	001	Dec 31, 1987

CHLORPHENTERMINE HYDROCHLORIDE

TABLET;ORAL

PRE-SATE					
	PARKE DAVIS	EQ 65MG BASE	N014696	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPROMAZINE

SUPPOSITORY;RECTAL				
THORAZINE				
+	GLAXOSMITHKLINE	25MG **	N009149 024	
+		100MG **	N009149 033	

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
THORAZINE				
	GLAXOSMITHKLINE	30MG	N011120 016	
		75MG	N011120 017	
		150MG	N011120 018	
		200MG	N011120 019	
		300MG	N011120 020	
CONCENTRATE;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
	ACTAVIS MID ATLANTIC	100MG/ML	A086863 001	
	PHARM ASSOC	30MG/ML	A040231 001	Dec 30, 1999
		100MG/ML	A040224 001	Jan 26, 1999
	WOCKHARDT	30MG/ML	A087032 001	Jul 08, 1982
		100MG/ML	A087053 001	
CHLORPROMAZINE HYDROCHLORIDE INTENSOL				
	HIKMA	30MG/ML	A088157 001	Apr 27, 1983
		100MG/ML	A088158 001	Apr 27, 1983
SONAZINE				
	FOSUN PHARMA	30MG/ML	A080983 004	
		100MG/ML	A080983 005	
THORAZINE				
+	GLAXOSMITHKLINE	30MG/ML **	N009149 032	
+		100MG/ML **	N009149 043	
INJECTABLE;INJECTION				
CHLORPROMAZINE HYDROCHLORIDE				
	ABRAXIS PHARM	25MG/ML	A084911 001	
	DR REDDYS	25MG/ML	A080365 001	
	MARSAM PHARMS LLC	25MG/ML	A089563 001	Apr 15, 1988
	WATSON LABS	25MG/ML	A085591 001	
	WYETH AYERST	25MG/ML	A080370 001	
THORAZINE				
+	GLAXOSMITHKLINE	25MG/ML **	N009149 011	
SYRUP;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
	ALPHARMA US PHARMS	10MG/5ML	A086712 001	
SONAZINE				
	FOSUN PHARMA	10MG/5ML	A083040 001	
THORAZINE				
+	GLAXOSMITHKLINE	10MG/5ML **	N009149 022	
TABLET;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
	ABBOTT	10MG	A084414 001	
		25MG	A084415 001	
		50MG	A084411 001	
		100MG	A084412 001	
		200MG	A084413 001	
	CYCLE	10MG	A085331 001	
		25MG	A085331 002	
		50MG	A085331 003	
		100MG	A085331 004	
		200MG	A085331 005	
	IVAX SUB TEVA PHARMS	10MG	A083549 001	
		25MG	A083549 002	
		50MG	A083549 003	
		100MG	A083574 001	
		200MG	A083575 001	
	KV PHARM	10MG	A085750 002	Jan 04, 1982
		25MG	A085751 001	
		50MG	A085484 001	
		100MG	A085752 001	
		200MG	A085748 002	Jan 04, 1982
	LEDERLE	10MG	A084803 001	
		25MG	A084801 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

	50MG	A084800 001	
	100MG	A084789 001	
	200MG	A084802 001	
PUREPAC PHARM	10MG	A080403 004	
	25MG	A080403 001	
	50MG	A080403 002	
	100MG	A080403 003	
	200MG	A080403 005	
PVT FORM	25MG	A080340 001	
	50MG	A080340 002	
	200MG	A080340 003	
SANDOZ	10MG **	A080439 001	
	25MG **	A080439 002	
	50MG **	A080439 003	
	100MG **	A080439 004	
	200MG **	A080439 005	
VANGARD	10MG	A088038 001	Aug 16, 1982
	25MG	A087645 001	
	50MG	A087646 001	
WATSON LABS	10MG	A085959 001	
	25MG	A085956 001	
	50MG	A085960 001	
	100MG	A085957 001	
	200MG	A085958 001	
WEST WARD	10MG	A087783 001	Sep 16, 1982
	25MG	A087865 001	Sep 16, 1982
	50MG	A087878 001	Sep 15, 1982
	100MG	A087884 001	Sep 15, 1982
	200MG	A087880 001	Sep 16, 1982

PROMAPAR

PARKE DAVIS	10MG	A086886 001	
	25MG	A084423 001	
	50MG	A086887 001	
	100MG	A086888 001	
	200MG	A086885 001	

THORAZINE

GLAXOSMITHKLINE	10MG **	N009149 002	
	25MG **	N009149 007	
	50MG **	N009149 013	
	100MG **	N009149 018	
	200MG **	N009149 020	

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

ANI PHARMS	100MG	A088768 001	Oct 11, 1984
	100MG	A088812 001	Oct 19, 1984
	100MG	A088840 001	Oct 25, 1984
	100MG	A088918 001	Oct 16, 1984
	100MG	A088921 001	Apr 12, 1985
	100MG	A089446 001	Nov 17, 1986
	250MG	A087353 001	
	250MG	A088813 001	Oct 19, 1984
	250MG	A088826 001	Sep 26, 1984
	250MG	A088919 001	Oct 16, 1984
	250MG	A088922 001	Apr 12, 1985
	250MG	A089447 001	Nov 17, 1986
DAVA PHARMS INC	100MG	A089561 001	Sep 04, 1987
	250MG	A089562 001	Sep 04, 1987
HALSEY	100MG	A089321 001	Jan 16, 1986
	250MG	A088662 001	Jan 09, 1986
MYLAN	100MG	A088549 002	Jun 01, 1984
	250MG	A088549 001	Jun 01, 1984
PAR PHARM	100MG	A088175 001	Feb 27, 1984
	250MG	A088176 001	Feb 27, 1984
RISING	100MG	A088725 001	Aug 31, 1984
	250MG	A088726 001	Aug 31, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPROPAMIDE

TABLET;ORAL				
CHLORPROPAMIDE				
SANDOZ	250MG	A084669	001	
SUPERPHARM	100MG	A088694	001	Sep 17, 1984
	250MG	A088695	001	Sep 17, 1984
USL PHARMA	100MG	A088708	001	Aug 30, 1984
	250MG	A088709	001	Aug 30, 1984
WATSON LABS	100MG	A086865	001	Sep 24, 1984
	100MG	A088608	001	Apr 12, 1984
	250MG	A086866	001	
	250MG	A088568	001	Apr 12, 1984
WATSON LABS TEVA	100MG	A088852	001	Sep 26, 1984
DIABINESE				
+ PFIZER	100MG	N011641	003	
+	250MG	N011641	006	
GLUCAMIDE				
ANI PHARMS	250MG	A088641	001	Oct 11, 1984

CHLORPROTHIXENE

CONCENTRATE;ORAL				
TARACTAN				
ROCHE	100MG/5ML	N016149	002	
INJECTABLE;INJECTION				
TARACTAN				
ROCHE	12.5MG/ML	N012487	001	
TABLET;ORAL				
TARACTAN				
ROCHE	10MG	N012486	005	
	25MG	N012486	004	
	50MG	N012486	003	
	100MG	N012486	001	

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT;OPHTHALMIC				
AUREOMYCIN				
LEDERLE	1%	N050404	001	

CHLORTHALIDONE

TABLET;ORAL				
CHLORTHALIDONE				
ABBOTT	25MG	A087364	001	
	50MG	A087384	001	
ANI PHARMS	25MG	A087296	001	
	25MG	A087706	001	
	25MG	A088164	001	Jan 09, 1984
	50MG	A087689	001	
ASCOT	25MG	A087698	001	Oct 20, 1982
	50MG	A087699	001	Oct 20, 1982
BARR LABS INC	25MG	A088902	001	Sep 19, 1985
	50MG	A088903	001	Sep 19, 1985
COSETTE	50MG	A088651	001	May 30, 1985
DAVA PHARMS INC	25MG	A087451	001	
	50MG	A087450	001	
IVAX PHARMS	25MG	A087555	001	
	50MG	A087176	001	
	50MG	A087947	001	Feb 27, 1984
KV PHARM	25MG	A087311	001	
	50MG	A087312	001	
MUTUAL PHARM	25MG	A087292	001	
	25MG	A089738	001	Sep 19, 1988
	50MG	A087293	001	
	50MG	A089739	001	Sep 19, 1988
PIONEER PHARMS	50MG	A089591	001	Jul 21, 1988
PUREPAC PHARM	25MG	A088139	001	Jul 16, 1986
	50MG	A088140	001	Aug 11, 1983
SANDOZ	25MG	A087380	001	
	50MG	A087118	001	
	50MG	A087381	001	
SUNNY	25MG	A209068	001	Jan 25, 2022
	50MG	A209068	002	Jan 25, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

SUPERPHARM	25MG	A087473	001	Feb 09, 1983
	50MG	A087247	001	Feb 09, 1983
USL PHARMA	25MG	A089051	001	Jun 01, 1987
	50MG	A089052	001	Jun 01, 1987
VANGARD	25MG	A088012	001	Jul 14, 1982
	50MG	A088073	001	Mar 25, 1983
WARNER CHILCOTT	25MG	A087515	001	Jan 24, 1983
	50MG	A087516	001	Feb 09, 1983
WATSON LABS	25MG	A087050	001	
	25MG	A087100	001	
	50MG	A087029	001	
	50MG	A087082	001	
	50MG	A087521	001	

HYGROTON

+ SANOFI AVENTIS US	25MG **	N012283	004	
+	50MG **	N012283	003	

THALITONE

MONARCH PHARMS	25MG	A088051	001	Nov 12, 1982

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM	15MG;0.1MG	A071179	001	Dec 16, 1987
	15MG;0.2MG	A071178	001	Dec 16, 1987
	15MG;0.3MG	A071142	001	Dec 16, 1987

CLORPRES

MYLAN	15MG;0.1MG	A071325	003	Feb 09, 1987
	15MG;0.2MG	A071325	002	Feb 09, 1987
	15MG;0.3MG	A071325	001	Feb 09, 1987

COMBIPRES

+ BOEHRINGER INGELHEIM	15MG;0.1MG **	N017503	001	
+	15MG;0.2MG **	N017503	002	
+	15MG;0.3MG **	N017503	003	Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE;ORAL

LOPRESSIDONE

NOVARTIS	25MG;100MG	N019451	001	Dec 31, 1987
	25MG;200MG	N019451	002	Dec 31, 1987

CHLORTHALIDONE; RESERPINE

TABLET;ORAL

DEMI-REGROTON

SANOFI AVENTIS US	25MG;0.125MG	N015103	002	

REGROTON

SANOFI AVENTIS US	50MG;0.25MG	N015103	001	

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

ACME LABS	500MG	A214365	001	Apr 27, 2023
ACTAVIS ELIZABETH	250MG	A088928	001	May 08, 1987
	500MG	A040113	001	Sep 29, 1995
BARR	500MG	A089895	001	May 04, 1988
GLENMARK PHARMS LTD	375MG	A212185	001	May 26, 2020
	750MG	A212185	002	May 26, 2020
OHM LABS	250MG	A081298	001	Dec 29, 1993
	500MG	A081299	001	Dec 29, 1993
PIONEER PHARMS	250MG	A089592	001	Jan 06, 1989
	500MG	A089948	001	Jan 06, 1989
RISING	250MG	A089852	001	May 04, 1988
STRIDES PHARMA	250MG	A087981	001	Sep 20, 1983
SUN PHARM INDUSTRIES	500MG	A089970	001	Sep 27, 1990
WATSON LABS	250MG	A086901	001	
	250MG	A086948	001	Aug 09, 1982
	500MG	A040137	001	Aug 09, 1996
	500MG	A081019	001	Jul 29, 1991
	500MG	A081040	001	Aug 22, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORZOXAZONE				
TABLET;ORAL				
PARAFLEX				
+ ORTHO MCNEIL PHARM	250MG **	N011300	003	
PARAFON FORTE DSC				
+ JANSSEN R AND D	500MG **	N011529	002	Jun 15, 1987
STRIFON FORTE DSC				
FERNDALE LABS	500MG	A081008	001	Dec 23, 1988
CHOLESTYRAMINE				
BAR, CHEWABLE;ORAL				
CHOLYBAR				
PARKE DAVIS	EQ 4GM RESIN/BAR	A071621	001	May 26, 1988
	EQ 4GM RESIN/BAR	A071739	001	May 26, 1988
POWDER;ORAL				
CHOLESTYRAMINE				
ANI PHARMS	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996
	EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996
IVAX SUB TEVA PHARMS	EQ 4GM RESIN/PACKET	A074771	001	Jul 09, 1997
	EQ 4GM RESIN/SCOOPFUL	A074771	002	Jul 09, 1997
TEVA	EQ 4GM RESIN/PACKET	A074347	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074347	002	May 28, 1998
UPSHER SMITH LABS	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022
	EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022
CHOLESTYRAMINE LIGHT				
TEVA	EQ 4GM RESIN/PACKET	A074348	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074348	002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074555	001	Sep 30, 1998
	EQ 4GM RESIN/SCOOPFUL	A074555	002	Sep 30, 1998
QUESTRAN				
+ BRISTOL MYERS	EQ 4GM RESIN/PACKET **	N016640	001	
+	EQ 4GM RESIN/SCOOPFUL **	N016640	003	
QUESTRAN LIGHT				
+ BRISTOL MYERS	EQ 4GM RESIN/PACKET **	N019669	001	Dec 05, 1988
+	EQ 4GM RESIN/SCOOPFUL **	N019669	003	Dec 05, 1988
TABLET;ORAL				
QUESTRAN				
APOTHECON	EQ 800MG RESIN	A073403	002	Dec 27, 1999
	EQ 1GM RESIN	A073403	001	Apr 28, 1994
CHOLINE C-11				
INJECTABLE;INTRAVENOUS				
CHOLINE C-11				
UCSF RODIOPHARM	4-33.1mCi/ML	A208444	001	Nov 20, 2017
UNIV TX MD ANDERSON	4-100mCi/ML	A205690	001	Oct 29, 2015
WA UNIV SCH MED	4-33.1mCi/ML	A208413	001	Jan 10, 2017
CHOLINE FENOFIBRATE				
CAPSULE, DELAYED RELEASE;ORAL				
FENOFIBRIC ACID				
MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913	001	Mar 25, 2013
	EQ 135MG FENOFIBRIC ACID	A200913	002	Mar 25, 2013
CHROMIC CHLORIDE				
INJECTABLE;INJECTION				
CHROMIC CHLORIDE				
ABRAXIS PHARM	EQ 0.004MG CHROMIUM/ML	N019271	001	May 05, 1987
CHROMIC PHOSPHATE P-32				
INJECTABLE;INJECTION				
PHOSPHOCOL P32				
CURIUM	5mCi/ML	N017084	001	
CICLOPIROX				
GEL;TOPICAL				
CICLOPIROX				
+ ALVOGEN	0.77% **	N020519	001	Jul 21, 1997
SHAMPOO;TOPICAL				
CICLOPIROX				
VERTICE	1%	A209975	001	Apr 05, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CICLOPIROX

SOLUTION;TOPICAL				
CICLOPIROX				
	EPIC PHARMA LLC	8%	A078975 001	Feb 17, 2010
	MYLAN PHARMS INC	8%	A078567 001	Sep 18, 2007
	TEVA PHARMS	8%	A078079 001	Sep 18, 2007
PENLAC				
+	VALEANT BERMUDA	8% **	N021022 001	Dec 17, 1999

CIDOFOVIR

INJECTABLE;INJECTION				
VISTIDE				
+	GILEAD SCIENCES INC	EQ 75MG BASE/ML **	N020638 001	Jun 26, 1996

CILASTATIN SODIUM; IMIPENEM

INJECTABLE;INJECTION				
PRIMAXIN				
	MERCK	EQ 250MG BASE/VIAL;250MG/VIAL	A062756 001	Jan 08, 1987
		EQ 500MG BASE/VIAL;500MG/VIAL	A062756 002	Jan 08, 1987
POWDER;INTRAMUSCULAR				
PRIMAXIN				
	MERCK	EQ 500MG BASE/VIAL;500MG/VIAL	N050630 001	Dec 14, 1990
		EQ 750MG BASE/VIAL;750MG/VIAL	N050630 002	Dec 14, 1990
POWDER;INTRAVENOUS				
IMIPENEM AND CILASTATIN				
	HOSPIRA INC	EQ 250MG BASE/VIAL;250MG/VIAL	A090825 001	Nov 16, 2011
		EQ 500MG BASE/VIAL;500MG/VIAL	A090825 002	Nov 16, 2011
		EQ 500MG BASE/VIAL;500MG/VIAL	A091007 001	Nov 16, 2011
PRIMAXIN				
+	MERCK	EQ 250MG BASE/VIAL;250MG/VIAL **	N050587 001	Nov 26, 1985

CILOSTAZOL

TABLET;ORAL				
CILOSTAZOL				
	ACTAVIS ELIZABETH	100MG	A077028 002	Nov 26, 2004
	AUROBINDO PHARMA USA	50MG	A077019 001	Nov 23, 2004
		100MG	A077019 002	Nov 23, 2004
	CASI PHARMS INC	50MG	A077310 001	Nov 08, 2005
		100MG	A077021 001	Nov 23, 2004
	HIKMA	50MG	A077024 001	May 17, 2005
		100MG	A077024 002	May 17, 2005
	IVAX SUB TEVA PHARMS	100MG	A077020 002	Mar 01, 2005
	MYLAN	50MG	A077323 002	Apr 20, 2006
		100MG	A077323 001	Apr 20, 2006
	NOSTRUM LABS INC	50MG	A077708 001	Sep 28, 2009
		100MG	A077708 002	Sep 28, 2009
	PLIVA HRVATSKA DOO	50MG	A077898 001	Oct 29, 2007
		100MG	A077898 002	Oct 29, 2007
PLETAL				
+	OTSUKA	50MG **	N020863 001	Jan 15, 1999
+		100MG **	N020863 002	Jan 15, 1999

CIMETIDINE

SUSPENSION;ORAL				
TAGAMET HB 200				
	GLAXOSMITHKLINE	200MG/20ML	N020951 001	Jul 09, 1999
TABLET;ORAL				
CIMETIDINE				
	CHARTWELL MOLECULES	200MG	A074329 002	May 17, 1994
		300MG	A074329 003	May 17, 1994
		400MG	A074329 004	May 17, 1994
		800MG	A074329 001	May 17, 1994
	CHARTWELL RX	200MG	A074100 001	Jan 31, 1995
		300MG	A074100 002	Jan 31, 1995
		400MG	A074100 003	Jan 31, 1995
		800MG	A074100 004	Jan 31, 1995
	CONTRACT PHARMACAL	200MG	A074961 001	Jun 19, 1998
		200MG	A074963 001	Jun 19, 1998
	CYCLE	300MG	A074361 001	Dec 23, 1994
		400MG	A074361 002	Dec 23, 1994
		800MG	A074371 001	Dec 23, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CIMETIDINE

TABLET;ORAL

CIMETIDINE

HIKMA	200MG	A074890	001	Dec 18, 1998
	300MG	A074890	002	Dec 18, 1998
	400MG	A074890	003	Dec 18, 1998
	800MG	A074890	004	Dec 18, 1998
IVAX SUB TEVA PHARMS	200MG	A074401	001	May 30, 1995
	200MG	A074424	001	Jul 28, 1995
	200MG	A075345	001	Jun 16, 1999
	300MG	A074401	002	May 30, 1995
	300MG	A074424	002	Jul 28, 1995
	400MG	A074401	003	May 30, 1995
	400MG	A074424	003	Jul 28, 1995
	800MG	A074402	001	May 30, 1995
	800MG	A074424	004	Jul 28, 1995
NOVITIUM PHARMA	300MG	A074340	001	Jun 23, 1995
	400MG	A074340	002	Jun 23, 1995
	800MG	A074339	001	Jun 23, 1995
PERRIGO	100MG	A074972	001	Jun 19, 1998
PLIVA	200MG	A074568	001	Feb 27, 1997
	300MG	A074568	002	Feb 27, 1997
	400MG	A074568	003	Feb 27, 1997
	800MG	A074566	001	Feb 27, 1997
SANDOZ	100MG	A075122	001	Jun 19, 1998
	200MG	A074250	001	Jun 29, 1995
	200MG	A075122	002	Jun 19, 1998
	300MG	A074250	002	Jun 29, 1995
	400MG	A074250	003	Jun 29, 1995
	800MG	A074250	004	Jun 29, 1995
TEVA	200MG	A074365	001	Feb 28, 1995
	300MG	A074365	002	Feb 28, 1995
	400MG	A074365	003	Feb 28, 1995
	800MG	A074365	004	Feb 28, 1995
UPSHER SMITH LABS	200MG	A074506	001	Jan 24, 1996
	300MG	A074506	002	Jan 24, 1996
	400MG	A074506	003	Jan 24, 1996
	800MG	A074506	004	Jan 24, 1996
WATSON LABS INC	200MG	A074349	001	Aug 30, 1996
	300MG	A074349	002	Aug 30, 1996
	400MG	A074349	003	Aug 30, 1996
	800MG	A074316	001	Feb 28, 1996
WATSON LABS TEVA	200MG	A075425	001	Jul 29, 1999

TAGAMET

+	GLAXOSMITHKLINE	200MG **	N017920	002	
+		300MG **	N017920	003	
+		400MG **	N017920	004	Dec 14, 1983
+		800MG **	N017920	005	Apr 30, 1986

TAGAMET HB

+	MEDTECH PRODUCTS	100MG **	N020238	001	Jun 19, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CIMETIDINE HYDROCHLORIDE

DAVA PHARMS INC	EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996
HOSPIRA	EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074344	001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074345	001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074412	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074422	001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML	A074353	001	Dec 20, 1994
TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252	001	Nov 26, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005	001	Aug 31, 1994

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 6MG BASE/ML	A074269	001	Dec 27, 1994
	EQ 90MG BASE/100ML	A074468	005	Dec 29, 1994
	EQ 120MG BASE/100ML	A074468	006	Dec 29, 1994
	EQ 180MG BASE/100ML	A074468	003	Dec 29, 1994
	EQ 240MG BASE/100ML	A074468	004	Dec 29, 1994
	EQ 360MG BASE/100ML	A074468	001	Dec 29, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CIMETIDINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
		EQ 480MG BASE/100ML	A074468	002	Dec 29, 1994
TAGAMET					
	GLAXOSMITHKLINE	EQ 300MG BASE/2ML **	N017939	002	
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	GLAXOSMITHKLINE	EQ 6MG BASE/ML **	N019434	001	Oct 31, 1985
SOLUTION;ORAL					
CIMETIDINE HYDROCHLORIDE					
	ANI PHARMS	EQ 300MG BASE/5ML	A074610	001	Sep 26, 1996
		EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998
		EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998
	CHARTWELL MOLECULAR	EQ 300MG BASE/5ML	A074251	001	Dec 22, 1994
	CYCLE	EQ 300MG BASE/5ML	A074541	001	Aug 05, 1997
	G AND W LABS INC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994
	PHARM ASSOC	EQ 300MG BASE/5ML	A075560	001	Mar 15, 2000
	PHARMOBEDIENT CNSLTG	EQ 300MG BASE/5ML	A074757	001	Oct 17, 1997
TAGAMET					
	GLAXOSMITHKLINE	EQ 300MG BASE/5ML **	N017924	001	
CINACALCET HYDROCHLORIDE					
TABLET;ORAL					
CINACALCET HYDROCHLORIDE					
	LUPIN LTD	EQ 30MG BASE	A210548	001	Jun 28, 2019
		EQ 60MG BASE	A210548	002	Jun 28, 2019
		EQ 90MG BASE	A210548	003	Jun 28, 2019
	MYLAN	EQ 30MG BASE	A203422	001	Oct 16, 2018
		EQ 60MG BASE	A203422	002	Oct 16, 2018
		EQ 90MG BASE	A203422	003	Oct 16, 2018
	STEVENS J	30MG	A204364	001	Dec 02, 2021
		60MG	A204364	002	Dec 02, 2021
		90MG	A204364	003	Dec 02, 2021
CINOXACIN					
CAPSULE;ORAL					
CINOBAC					
	LILLY	250MG	N018067	001	
		500MG	N018067	002	
CINOXACIN					
	TEVA	250MG	A073005	001	Feb 28, 1992
		500MG	A073006	001	Feb 28, 1992
CIPROFLOXACIN					
INJECTABLE;INJECTION					
CIPRO					
+	BAYER HLTHCARE	400MG/40ML (10MG/ML) **	N019847	001	Dec 26, 1990
+		200MG/20ML (10MG/ML) **	N019847	002	Dec 26, 1990
		1200MG/120ML (10MG/ML) **	N019847	003	Dec 26, 1990
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	BAYER HLTHCARE	200MG/100ML **	N019857	001	Dec 26, 1990
+		400MG/200ML **	N019857	002	Dec 26, 1990
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	BAYER PHARMS	200MG/100ML	N019858	001	Dec 26, 1990
CIPROFLOXACIN					
	BEDFORD LABS	200MG/20ML (10MG/ML)	A076992	001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A076992	002	Aug 28, 2006
		1200MG/120ML (10MG/ML)	A076993	001	Aug 28, 2006
	DR REDDYS	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006
	FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A076484	001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A076484	002	Aug 28, 2006
	HOSPIRA	200MG/20ML (10MG/ML)	A077245	001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A077245	002	Aug 28, 2006
CIPROFLOXACIN IN DEXTROSE 5%					
	HIKMA FARMACEUTICA	200MG/100ML	A076757	001	Apr 21, 2008
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	200MG/100ML	A077888	001	Mar 18, 2008
		400MG/200ML	A077888	002	Mar 18, 2008
	BEDFORD	200MG/100ML	A078114	001	Mar 18, 2008
		400MG/200ML	A078114	002	Mar 18, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CIPROFLOXACIN

INJECTABLE;INJECTION				
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
TEVA PHARMS	200MG/100ML	A077138	001	Mar 18, 2008
	400MG/200ML	A077138	002	Mar 18, 2008
INJECTABLE, SUSPENSION;OTIC				
OTIPRIO				
+ ALK ABELLO	6% (60MG/ML)	N207986	001	Dec 10, 2015

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
CIPROFLOXACIN HYDROCHLORIDE				
AKORN	EQ 0.3% BASE	A076555	001	Dec 11, 2008
AMRING PHARMS	EQ 0.3% BASE	A078598	001	Jan 16, 2008
PAI HOLDINGS PHARM	EQ 0.3% BASE	A076754	001	Jun 09, 2004
TABLET;ORAL				
CIPRO				
+ BAYER HLTHCARE	EQ 100MG BASE **	N019537	001	Apr 08, 1996
+	EQ 750MG BASE **	N019537	004	Oct 22, 1987
CIPROFLOXACIN HYDROCHLORIDE				
AIPING PHARM INC	EQ 250MG BASE	A076593	002	Jun 09, 2004
	EQ 500MG BASE	A076593	003	Jun 09, 2004
	EQ 750MG BASE	A076593	004	Jun 09, 2004
AMNEAL	EQ 100MG BASE	A075939	001	Mar 03, 2005
BARR	EQ 250MG BASE	A074124	001	Jun 09, 2004
	EQ 500MG BASE	A074124	002	Jun 09, 2004
	EQ 750MG BASE	A074124	003	Jun 09, 2004
DR REDDYS LABS LTD	EQ 100MG BASE	A075593	002	Jun 09, 2004
MYLAN	EQ 250MG BASE	A075685	002	Jun 09, 2004
	EQ 500MG BASE	A075685	003	Jun 09, 2004
	EQ 750MG BASE	A075685	001	Jun 09, 2004
NOSTRUM LABS	EQ 250MG BASE	A076138	001	Jun 09, 2004
	EQ 500MG BASE	A076138	002	Jun 09, 2004
	EQ 750MG BASE	A076138	003	Jun 09, 2004
PLIVA	EQ 100MG BASE	A076426	001	Jun 15, 2005
	EQ 250MG BASE	A076426	002	Jun 15, 2005
	EQ 500MG BASE	A076426	003	Jun 15, 2005
	EQ 750MG BASE	A076426	004	Jun 15, 2005
RISING	EQ 100MG BASE	A075817	001	Jun 25, 2007
	EQ 250MG BASE	A075817	002	Jun 09, 2004
	EQ 750MG BASE	A075817	004	Jun 09, 2004
SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004
	EQ 500MG BASE	A075747	002	Jun 09, 2004
	EQ 750MG BASE	A075747	003	Jun 09, 2004
TARO	EQ 100MG BASE	A076912	001	Feb 18, 2005
	EQ 250MG BASE	A076912	002	Oct 06, 2004
	EQ 500MG BASE	A076912	003	Oct 06, 2004
	EQ 750MG BASE	A076912	004	Oct 06, 2004
TEVA	EQ 250MG BASE	A076136	001	Jun 09, 2004
	EQ 500MG BASE	A076136	002	Jun 09, 2004
	EQ 750MG BASE	A076136	003	Jun 09, 2004
WATSON LABS	EQ 100MG BASE	A076794	001	Feb 10, 2005
TABLET, EXTENDED RELEASE;ORAL				
PROQUIN XR				
DEPOMED INC	EQ 500MG BASE	N021744	001	May 19, 2005

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
CIPRO XR				
BAYER HLTHCARE	212.6MG;EQ 287.5MG BASE **	N021473	001	Dec 13, 2002
	425.2MG;EQ 574.9MG BASE **	N021473	002	Aug 28, 2003
CIPROFLOXACIN EXTENDED RELEASE				
ANI PHARMS	212.6MG;EQ 287.5MG BASE	A077809	002	Nov 30, 2010
	425.2MG;EQ 574.9MG BASE	A077809	001	Nov 30, 2010
DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701	002	Oct 31, 2007
FOSUN PHARMA	212.6MG;EQ 287.5MG BASE	A078712	001	Dec 11, 2007
RISING	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007
	425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CISAPRIDE MONOHYDRATE

SUSPENSION;ORAL				
PROPULSID				
	JANSSEN PHARMS	EQ 1MG BASE/ML	N020398 001	Sep 15, 1995
TABLET;ORAL				
PROPULSID				
	JANSSEN PHARMS	EQ 10MG BASE	N020210 001	Jul 29, 1993
		EQ 20MG BASE	N020210 002	Dec 23, 1993
TABLET, ORALLY DISINTEGRATING;ORAL				
PROPULSID QUICKSOLV				
	JANSSEN PHARMA	EQ 20MG BASE	N020767 001	Nov 07, 1997

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION				
CISATRACURIUM BESYLATE				
	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873 001	Jun 16, 2017
	PIRAMAL HLTHCARE UK	EQ 2MG BASE/ML	A212190 001	May 04, 2020
		EQ 2MG BASE/ML	A212432 001	Mar 11, 2022
		EQ 10MG BASE/ML	A212432 002	Mar 11, 2022
	ZYDUS PHARMS	EQ 2MG BASE/ML	A213527 001	Aug 31, 2020
CISATRACURIUM BESYLATE PRESERVATIVE FREE				
	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872 001	Jun 16, 2017
		EQ 10MG BASE/ML	A205872 002	Jun 16, 2017

CISPLATIN

INJECTABLE;INJECTION				
CISPLATIN				
	BEDFORD	10MG/VIAL	A074713 001	Nov 14, 2000
		50MG/VIAL	A074713 002	Nov 14, 2000
	MYLAN LABS LTD	1MG/ML	A091062 001	Apr 18, 2012
	TEVA PHARMS USA	1MG/ML	A074814 001	May 16, 2000
PLATINOL				
+	HQ SPCLT PHARMA	10MG/VIAL	N018057 001	
PLATINOL-AQ				
+	HQ SPCLT PHARMA	0.5MG/ML	N018057 003	Jul 18, 1984

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL				
CITALOPRAM HYDROBROMIDE				
	MYLAN PHARMS INC	EQ 10MG BASE	A077668 001	Feb 28, 2007
		EQ 20MG BASE	A077668 002	Feb 28, 2007
		EQ 40MG BASE	A077668 003	Feb 28, 2007
SOLUTION;ORAL				
CELEXA				
+	FOREST LABS	EQ 10MG BASE/5ML **	N021046 001	Dec 22, 1999
CITALOPRAM HYDROBROMIDE				
	PHARM ASSOC	EQ 10MG BASE/5ML	A077601 001	Nov 15, 2005
TABLET;ORAL				
CELEXA				
	ABBVIE	EQ 60MG BASE	N020822 004	Jul 17, 1998
CITALOPRAM HYDROBROMIDE				
	EPIC PHARMA LLC	EQ 10MG BASE	A077036 001	Oct 28, 2004
		EQ 20MG BASE	A077036 002	Oct 28, 2004
		EQ 40MG BASE	A077036 003	Oct 28, 2004
	FOSUN PHARMA	EQ 10MG BASE	A077035 001	Oct 28, 2004
		EQ 10MG BASE	A077040 001	Aug 17, 2005
		EQ 20MG BASE	A077035 002	Oct 28, 2004
		EQ 20MG BASE	A077040 002	Aug 17, 2005
		EQ 40MG BASE	A077035 003	Oct 28, 2004
		EQ 40MG BASE	A077040 003	Aug 17, 2005
	HERITAGE PHARMA	EQ 10MG BASE	A077033 001	Oct 28, 2004
		EQ 10MG BASE	A077034 001	Jun 30, 2005
		EQ 10MG BASE	A077213 001	Mar 31, 2006
		EQ 10MG BASE	A077232 001	Oct 31, 2005
		EQ 20MG BASE	A077033 002	Oct 28, 2004
		EQ 20MG BASE	A077034 002	Jun 30, 2005
		EQ 20MG BASE	A077213 002	Mar 31, 2006
		EQ 20MG BASE	A077232 002	Oct 31, 2005
		EQ 40MG BASE	A077033 003	Oct 28, 2004
		EQ 40MG BASE	A077034 003	Jun 30, 2005
		EQ 40MG BASE	A077213 003	Mar 31, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CITALOPRAM HYDROBROMIDE

TABLET;ORAL					
CITALOPRAM HYDROBROMIDE					
		EQ 40MG BASE	A077232	003	Oct 31, 2005
	JUBILANT GENERICS	EQ 10MG BASE	A205407	001	Dec 23, 2015
		EQ 20MG BASE	A205407	002	Dec 23, 2015
		EQ 40MG BASE	A205407	003	Dec 23, 2015
	MYLAN	EQ 10MG BASE	A077039	001	Feb 03, 2005
		EQ 20MG BASE	A077039	002	Feb 03, 2005
		EQ 40MG BASE	A077039	003	Feb 03, 2005
	MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004
		EQ 20MG BASE	A077037	002	Nov 05, 2004
		EQ 40MG BASE	A077037	003	Nov 05, 2004
	NATCO PHARMA LTD	EQ 20MG BASE	A077141	002	Apr 10, 2008
		EQ 40MG BASE	A077141	001	Apr 10, 2008
	ROXANE	EQ 10MG BASE	A077041	001	Nov 23, 2004
		EQ 20MG BASE	A077041	002	Nov 23, 2004
		EQ 40MG BASE	A077041	003	Nov 23, 2004
	SUN PHARM INDS INC	EQ 10MG BASE	A077032	001	Nov 12, 2004
		EQ 20MG BASE	A077032	002	Nov 12, 2004
		EQ 40MG BASE	A077032	003	Nov 12, 2004
	SUN PHARM INDUSTRIES	EQ 10MG BASE	A077052	001	Jul 03, 2006
		EQ 20MG BASE	A077052	002	Jul 03, 2006
		EQ 40MG BASE	A077052	003	Jul 03, 2006
	TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006
		EQ 20MG BASE	A077278	002	Mar 22, 2006
		EQ 40MG BASE	A077278	003	Mar 22, 2006
TABLET, ORALLY DISINTEGRATING;ORAL					
CITALOPRAM HYDROBROMIDE					
+	BIOVAIL LABS INTL	EQ 10MG BASE	N021763	001	Dec 20, 2005
+		EQ 20MG BASE	N021763	002	Dec 20, 2005
+		EQ 40MG BASE	N021763	003	Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION;IRRIGATION					
IRRIGATING SOLUTION G IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML;430MG/100ML	N018519	001	Jun 22, 1982
UROLOGIC G IN PLASTIC CONTAINER					
	HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N018904	001	May 27, 1983

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL					
PREPOPIK					
+	FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACKET **	N202535	001	Jul 16, 2012

CLADRIBINE

INJECTABLE;INJECTION					
CLADRIBINE					
	MYLAN LABS LTD	1MG/ML	A200510	001	Oct 06, 2011
LEUSTATIN					
+	JANSSEN PHARMS	1MG/ML **	N020229	001	Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION;ORAL					
BIAXIN					
+	ABBVIE	125MG/5ML	N050698	001	Dec 23, 1993
		187MG/5ML	N050698	003	Sep 30, 1998
+		250MG/5ML	N050698	002	Dec 23, 1993
CLARITHROMYCIN					
	SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007
		250MG/5ML	A065382	002	Aug 30, 2007
TABLET;ORAL					
BIAXIN					
+	ABBVIE	250MG **	N050662	001	Oct 31, 1991
+		500MG **	N050662	002	Oct 31, 1991
CLARITHROMYCIN					
	AJANTA PHARMA LTD	250MG	A206714	001	Apr 25, 2019
		500MG	A206714	002	Apr 25, 2019
	HIKMA	250MG	A065178	002	May 25, 2004
		500MG	A065178	001	May 25, 2004
	IVAX SUB TEVA PHARMS	250MG	A065137	001	May 31, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLARITHROMYCIN

TABLET;ORAL					
CLARITHROMYCIN					
	500MG		A065137	002	May 31, 2005
MYLAN	250MG		A065195	001	Mar 11, 2005
	500MG		A065195	002	Mar 11, 2005
SUN PHARM INDS LTD	250MG		A065174	001	Sep 24, 2004
	500MG		A065174	002	Sep 24, 2004
TEVA	250MG		A065155	001	May 31, 2005
	500MG		A065155	002	May 31, 2005
WOCKHARDT	250MG		A065266	001	May 31, 2006
	500MG		A065266	002	May 31, 2006
TABLET, EXTENDED RELEASE;ORAL					
BIAXIN XL					
+ ABBVIE	500MG **		N050775	001	Mar 03, 2000
CLARITHROMYCIN					
ANI PHARMS	500MG		A065250	001	Aug 25, 2005
LUPIN LTD	500MG		A202532	001	Sep 15, 2015
RANBAXY	1GM		A065210	001	Jan 26, 2005

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION					
TIMENTIN					
GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL		A062691	001	Dec 19, 1986
	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL		N050590	001	Apr 01, 1985
	EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL		N050590	002	Apr 01, 1985
	EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL		N050590	003	Aug 18, 1987
TIMENTIN IN PLASTIC CONTAINER					
GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML		N050658	001	Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP;ORAL					
CLEMASTINE FUMARATE					
ACTAVIS MID ATLANTIC	EQ 0.5MG BASE/5ML		A074075	001	Oct 31, 1993
APOTEX INC	EQ 0.5MG BASE/5ML		A075703	001	Nov 27, 2000
CHARTWELL MOLECULAR	EQ 0.5MG BASE/5ML		A074884	001	Dec 17, 1997
TEVA PHARMS	EQ 0.5MG BASE/5ML		A073095	001	Apr 21, 1992
WOCKHARDT BIO AG	EQ 0.5MG BASE/5ML		A074863	001	Mar 13, 1998
TAVIST					
+ NOVARTIS	EQ 0.5MG BASE/5ML **		N018675	001	Jun 28, 1985
TABLET;ORAL					
CLEMASTINE FUMARATE					
ANI PHARMS	1.34MG		A073282	001	Jan 31, 1992
	1.34MG		A073282	002	Dec 03, 1992
L PERRIGO CO	1.34MG		A074512	001	Nov 22, 1995
PLD ACQUISITIONS LLC	1.34MG		A073458	001	Oct 31, 1993
SANDOZ	2.68MG		A073459	001	Oct 31, 1993
TAVIST					
+ NOVARTIS	2.68MG		N017661	001	
TAVIST-1					
+ GLAXOSMITHKLINE CONS	1.34MG **		N020925	001	Aug 21, 1992
NOVARTIS	1.34MG		N017661	002	
	1.34MG		N017661	003	Aug 21, 1992

CLEVIDIPINE

EMULSION;INTRAVENOUS					
CLEVIPREX					
+ CHIESI	125MG/250ML (0.5MG/ML)		N022156	003	Nov 08, 2013

CLIDINIUM BROMIDE

CAPSULE;ORAL					
QUARZAN					
ROCHE	2.5MG		N010355	001	
	5MG		N010355	002	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL					
CLEOCIN					
PHARMACIA AND UPJOHN	EQ 75MG BASE		A061809	001	
	EQ 150MG BASE		A061809	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLINDAMYCIN HYDROCHLORIDE				
CAPSULE;ORAL				
CLINDAMYCIN HYDROCHLORIDE				
CHARTWELL MOLECULAR	EQ 150MG BASE	A065243	003	Aug 12, 2005
	EQ 300MG BASE	A065243	001	Aug 12, 2005
MYLAN PHARMS INC	EQ 75MG BASE	A091225	001	May 31, 2011
	EQ 150MG BASE	A091225	002	May 31, 2011
	EQ 300MG BASE	A091225	003	May 31, 2011
TEVA	EQ 75MG BASE	A063027	001	Sep 20, 1989
WATSON LABS	EQ 75MG BASE	A063082	001	Jul 31, 1991
	EQ 150MG BASE	A063083	001	Jul 31, 1991
	EQ 300MG BASE	A063083	002	Mar 18, 2003
CLINDAMYCIN PALMITATE HYDROCHLORIDE				
FOR SOLUTION;ORAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML **	A061827	001	
CLINDAMYCIN PALMITATE HYDROCHLORIDE				
MYLAN	EQ 75MG BASE/5ML	A203063	001	May 25, 2016
CLINDAMYCIN PHOSPHATE				
AEROSOL, FOAM;TOPICAL				
EVOCLIN				
+ MYLAN	1%	N050801	001	Oct 22, 2004
CREAM;VAGINAL				
CLEOCIN				
PFIZER	EQ 2% BASE	N050680	001	Aug 11, 1992
INJECTABLE;INJECTION				
CLEOCIN PHOSPHATE				
PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	A061839	001	
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
+ PFIZER	EQ 6MG BASE/ML **	N050639	001	Aug 30, 1989
+	EQ 12MG BASE/ML **	N050639	002	Aug 30, 1989
+	EQ 18MG BASE/ML **	N050639	003	Apr 10, 1991
CLINDAMYCIN PHOSPHATE				
ABRAXIS PHARM	EQ 150MG BASE/ML	A062747	001	Jun 03, 1988
ALMAJECT	EQ 150MG BASE/ML	A062801	001	Jul 24, 1987
BEDFORD	EQ 150MG BASE/ML	A063163	001	Jun 30, 1994
BRISTOL MYERS SQUIBB	EQ 150MG BASE/ML	A062908	001	Feb 01, 1989
HIKMA	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987
	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988
	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989
IGI LABS INC	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989
LOCH	EQ 150MG BASE/ML	A062905	001	May 09, 1988
MARSAM PHARMS LLC	EQ 150MG BASE/ML	A062913	001	Oct 20, 1988
RISING	EQ 150MG BASE/ML	A204748	001	Oct 10, 2017
	EQ 150MG BASE/ML	A204749	001	Oct 10, 2017
SOLOPAK	EQ 150MG BASE/ML	A062819	001	Mar 15, 1988
	EQ 150MG BASE/ML	A062852	001	Mar 17, 1988
TEVA PARENTERAL	EQ 150MG BASE/ML	A063041	001	Dec 29, 1989
	EQ 150MG BASE/ML	A063282	001	May 29, 1992
WATSON LABS	EQ 150MG BASE/ML	A062900	001	Jun 08, 1988
	EQ 150MG BASE/ML	A063079	001	Mar 05, 1990
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%				
ABRAXIS PHARM	EQ 12MG BASE/ML	N050636	001	Dec 22, 1989
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT LABS	EQ 6MG BASE/ML	A065027	001	Jun 29, 2001
	EQ 12MG BASE/ML	A065027	002	Jun 29, 2001
	EQ 18MG BASE/ML	A065027	003	Jun 29, 2001
BAXTER HLTHCARE	EQ 6MG BASE/ML	N050648	001	Dec 29, 1989
	EQ 12MG BASE/ML	N050648	002	Dec 29, 1989
	EQ 900MG BASE/100ML	N050648	003	Dec 29, 1989
SOLUTION;TOPICAL				
CLEOCIN T				
+ PFIZER	EQ 1% BASE **	N050537	001	
PHARMACIA AND UPJOHN	EQ 1% BASE	A062363	001	Feb 08, 1982
CLINDAMYCIN PHOSPHATE				
BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989
FOUGERA PHARMS	EQ 1% BASE	A065254	001	Feb 14, 2006
G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLINDAMYCIN PHOSPHATE

SOLUTION;TOPICAL					
CLINDAMYCIN PHOSPHATE					
	NOVAST LABS	EQ 1% BASE	A064108	001	Sep 27, 1996
	PAI HOLDINGS PHARM	EQ 1% BASE	A206945	001	Dec 30, 2016
	VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989
		EQ 1% BASE	A203343	001	May 29, 2015
	XTTRIUM LABS INC	EQ 1% BASE	A063304	001	Jul 15, 1997
SWAB;TOPICAL					
CLEOCIN					
+	PFIZER	EQ 1% BASE	N050537	002	Feb 22, 1994

CLIOQUINOL; NYSTATIN

OINTMENT;TOPICAL					
NYSTAFORM					
	BAYER PHARMS	10MG/GM;100,000 UNITS/GM	N050235	001	

CLOBAZAM

SUSPENSION;ORAL					
CLOBAZAM					
	ACCORD HLTHCARE	2.5MG/ML	A216008	001	Sep 06, 2022
	HIKMA	2.5MG/ML	A209715	001	Oct 22, 2018
	MYLAN	2.5MG/ML	A211259	001	Oct 22, 2018
	TEVA PHARMS USA	2.5MG/ML	A211032	001	Jan 31, 2020
	UPSHER SMITH LABS	2.5MG/ML	A210569	001	Oct 22, 2018
	VISTAPHARM	2.5MG/ML	A210746	001	Jul 10, 2019
TABLET;ORAL					
CLOBAZAM					
	ACCORD HLTHCARE	10MG	A212398	001	May 23, 2019
		20MG	A212398	002	May 23, 2019
	APOTEX	10MG	A209853	001	Jun 09, 2020
		20MG	A209853	002	Jun 09, 2020
	BRECKENRIDGE	5MG	A209308	003	Oct 19, 2021
	CELLTRION	10MG	A211959	001	Dec 09, 2020
		20MG	A211959	002	Dec 09, 2020
	CHARTWELL MOLECULAR	10MG	A212092	001	Oct 30, 2019
		20MG	A212092	002	Oct 30, 2019
	HIKMA	10MG	A208785	001	Oct 22, 2018
		20MG	A208785	002	Oct 22, 2018
	TARO	10MG	A209440	001	Oct 22, 2018
		20MG	A209440	002	Oct 22, 2018
ONFI					
+	LUNDBECK PHARMS LLC	5MG **	N202067	001	Oct 21, 2011

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL					
CLOBETASOL PROPIONATE					
	NOVAST LABS	0.05%	A206805	001	Jul 31, 2017
OLUX					
+	MYLAN	0.05%	N021142	001	May 26, 2000
OLUX E					
+	MYLAN	0.05%	N022013	001	Jan 12, 2007
CREAM;TOPICAL					
CLOBETASOL PROPIONATE					
	CHARTWELL RX	0.05%	A211207	001	Mar 26, 2021
	PAI HOLDINGS PHARM	0.05%	A209974	001	Apr 17, 2018
	TEVA PHARMS USA	0.05%	A074087	001	Feb 16, 1994
	TORRENT	0.05%	A211836	001	Dec 30, 2019
CLOBETASOL PROPIONATE (EMOLLIENT)					
	ANI PHARMS	0.05%	A075733	001	Aug 22, 2001
	PAI HOLDINGS PHARM	0.05%	A209411	001	Aug 21, 2017
EMBELINE E					
	HIKMA	0.05%	A075325	001	Dec 24, 1998
TEMOVATE					
+	FOUGERA PHARMS	0.05% **	N019322	001	Dec 27, 1985
TEMOVATE E					
+	FOUGERA PHARMS	0.05% **	N020340	001	Jun 17, 1994
GEL;TOPICAL					
CLOBETASOL PROPIONATE					
	PAI HOLDINGS PHARM	0.05%	A208881	001	Mar 06, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLOBETASOL PROPIONATE					
GEL;TOPICAL					
TEMOVATE					
+	FOUGERA PHARMS	0.05% **	N020337	001	Apr 29, 1994
LOTION;TOPICAL					
CLOBETASOL PROPIONATE					
	EPIC PHARMA LLC	0.05%	A211348	001	Oct 26, 2018
	PAI HOLDINGS PHARM	0.05%	A208667	001	Nov 29, 2016
IMPEKLO					
+	MYLAN	0.05%	N213691	001	May 19, 2020
OINTMENT;TOPICAL					
CLOBETASOL PROPIONATE					
	ACTAVIS MID ATLANTIC	0.05%	A074128	001	Aug 03, 1994
	AMNEAL	0.05%	A210551	001	Aug 21, 2018
	PAI HOLDINGS PHARM	0.05%	A208589	001	Jan 23, 2019
	TORRENT	0.05%	A212926	001	Oct 25, 2019
TEMOVATE					
+	FOUGERA PHARMS	0.05% **	N019323	001	Dec 27, 1985
SHAMPOO;TOPICAL					
CLOBETASOL PROPIONATE					
	ACTAVIS MID ATLANTIC	0.05%	A078854	001	Jun 07, 2011
SOLUTION;TOPICAL					
CLOBETASOL PROPIONATE					
	ENCUBE	0.05%	A076977	001	Aug 05, 2005
	PRINSTON INC	0.05%	A213139	001	Feb 08, 2021
	WOCKHARDT BIO AG	0.05%	A075205	001	Nov 13, 1998
TEMOVATE					
+	FOUGERA PHARMS	0.05% **	N019966	001	Feb 22, 1990
SPRAY;TOPICAL					
CLOBETASOL PROPIONATE					
	AKORN	0.05%	A207218	001	Apr 28, 2017
	APOTEX	0.05%	A210446	001	Apr 17, 2018
CLOFARABINE					
SOLUTION;INTRAVENOUS					
CLOFARABINE					
	EUGIA PHARMA	20MG/20ML (1MG/ML)	A212457	001	Oct 03, 2022
	HOSPIRA	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018
	NOVAST LABS	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018
CLOFAZIMINE					
CAPSULE;ORAL					
LAMPRENE					
+	NOVARTIS	50MG	N019500	002	Dec 15, 1986
		100MG	N019500	001	Dec 15, 1986
CLOFIBRATE					
CAPSULE;ORAL					
ATROMID-S					
	WYETH AYERST	500MG	N016099	002	
CLOFIBRATE					
	BANNER PHARMACAPS	500MG	A073396	001	Mar 20, 1992
	SANDOZ	500MG	A072191	001	May 02, 1988
	TEVA	500MG	A072600	001	Jul 25, 1991
	USL PHARMA	500MG	A070531	001	Jun 16, 1986
	WATSON LABS	500MG	A071603	001	Sep 18, 1987
CLOMIPHENE CITRATE					
TABLET;ORAL					
CLOMID					
+	SANOFI AVENTIS US	50MG **	N016131	002	
MILOPHENE					
	GRANATA BIO	50MG	A072196	001	Dec 20, 1988
SEROPHENE					
	EMD SERONO	50MG	N018361	001	Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL					
CLOMIPRAMINE HYDROCHLORIDE					
	TEVA	25MG	A074849	001	Apr 04, 1997
		25MG	A074958	001	Aug 26, 1997
		50MG	A074849	002	Apr 04, 1997
		50MG	A074958	002	Aug 26, 1997
		75MG	A074849	003	Apr 04, 1997
		75MG	A074958	003	Aug 26, 1997
	WATSON LABS	25MG	A074600	001	Nov 27, 1996
		25MG	A074751	001	Sep 30, 1998
		50MG	A074600	002	Nov 27, 1996
		50MG	A074751	002	Sep 30, 1998
		75MG	A074600	003	Nov 27, 1996
		75MG	A074751	003	Sep 30, 1998

CLONAZEPAM

TABLET;ORAL					
CLONAZEPAM					
	CHARTWELL RX	0.5MG	A074925	001	Sep 30, 1997
		1MG	A074925	002	Sep 30, 1997
		2MG	A074925	003	Sep 30, 1997
	MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997
		1MG	A074940	002	Oct 30, 1997
		2MG	A074940	003	Oct 30, 1997
	SUN PHARM INDS INC	0.5MG	A075423	001	Apr 27, 2001
		1MG	A075423	002	Apr 27, 2001
		2MG	A075423	003	Apr 27, 2001
	TEVA	0.5MG	A074920	001	Aug 04, 1998
		1MG	A074920	002	Aug 04, 1998
		2MG	A074920	003	Aug 04, 1998
	WATSON LABS	0.5MG	A074964	001	Dec 30, 1997
		1MG	A074964	002	Dec 30, 1997
		2MG	A074964	003	Dec 30, 1997
KLONOPIN					
	CHEPLAPHARM	0.125MG	N017533	005	Apr 09, 1997
		0.25MG	N017533	006	Apr 09, 1997
TABLET, ORALLY DISINTEGRATING;ORAL					
KLONOPIN RAPIDLY DISINTEGRATING					
+	ROCHE	0.125MG **	N020813	001	Dec 23, 1997
+		0.25MG **	N020813	002	Dec 23, 1997
+		0.5MG **	N020813	003	Dec 23, 1997
+		1MG **	N020813	004	Dec 23, 1997
+		2MG **	N020813	005	Dec 23, 1997

CLONIDINE

SUSPENSION, EXTENDED RELEASE;ORAL					
CLONIDINE					
	TRIS PHARMA INC	EQ 0.09MG BASE/ML	N022499	001	Dec 03, 2009
TABLET, EXTENDED RELEASE;ORAL					
NEXICLON XR					
	ATHENA	EQ 0.26MG BASE	N022500	002	Dec 03, 2009

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION					
CLONIDINE HYDROCHLORIDE					
	AM REGENT	1MG/10ML (0.1MG/ML)	A091104	001	Oct 08, 2009
		5MG/10ML (0.5MG/ML)	A091104	002	Oct 08, 2009
DURACLON					
+	MYLAN INSTITUTIONAL	5MG/10ML (0.5MG/ML) **	N020615	002	Apr 27, 1999
TABLET;ORAL					
CATAPRES					
+	BOEHRINGER INGELHEIM	0.1MG **	N017407	001	
+		0.2MG **	N017407	002	
+		0.3MG **	N017407	003	
CLONIDINE HYDROCHLORIDE					
	AM THERAP	0.1MG	A070881	001	Jul 08, 1986
		0.2MG	A070882	001	Jul 08, 1986
		0.3MG	A070883	001	Jul 08, 1986
	DURAMED PHARMS BARR	0.1MG	A071103	001	Aug 14, 1986
		0.2MG	A071102	001	Aug 14, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

		0.3MG	A071101	001	Aug 14, 1986
	INTERPHARM	0.1MG	A071252	001	Oct 01, 1986
		0.2MG	A071253	001	Oct 01, 1986
		0.3MG	A071254	001	Oct 01, 1986
	PAR PHARM	0.1MG	A070461	001	Jul 08, 1986
		0.2MG	A070460	001	Jul 08, 1986
		0.3MG	A070459	001	Jul 08, 1986
	RISING	0.1MG	A070317	002	Jul 09, 1987
		0.2MG	A070317	003	Jun 09, 1987
		0.3MG	A070317	001	Jun 09, 1987
	SUN PHARM INDS INC	0.1MG	A090329	001	Jul 03, 2014
		0.2MG	A090329	002	Jul 03, 2014
		0.3MG	A090329	003	Jul 03, 2014
	TEVA	0.1MG	A070747	001	Jul 08, 1986
		0.2MG	A070702	001	Jul 08, 1986
		0.3MG	A070659	001	Jul 08, 1986
	WARNER CHILCOTT	0.1MG	A072138	001	Jun 13, 1988
		0.2MG	A072139	001	Jun 13, 1988
		0.3MG	A072140	001	Jun 13, 1988
	WATSON LABS	0.1MG	A070395	001	Mar 23, 1987
		0.1MG	A070965	001	Jul 08, 1986
		0.2MG	A070396	001	Mar 23, 1987
		0.2MG	A070964	001	Jul 08, 1986
		0.3MG	A070397	001	Mar 23, 1987
		0.3MG	A070963	001	Jul 08, 1986

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015
		0.2MG	A202792	002	May 15, 2015
		0.2MG	A203320	002	May 15, 2015
	AMNEAL PHARMS NY	0.1MG	A210052	001	Nov 20, 2017
	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014
		0.2MG	A202983	002	Apr 02, 2014
		0.2MG	A202984	002	Sep 30, 2013
	DR REDDYS LABS SA	0.1MG	A210680	001	Apr 30, 2018
	UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018

JENLOGA

+	CONCORDIA PHARMS INC	0.1MG **	N022331	001	Sep 30, 2009
+		0.2MG **	N022331	002	May 25, 2010

KAPVAY

+	CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010
+		0.2MG **	N022331	004	Sep 28, 2010

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

	ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013
	ANI PHARMS	EQ 300MG BASE	A090625	001	May 17, 2012
		EQ 300MG BASE	A091216	001	May 17, 2012
	CADILA	EQ 75MG BASE	A201686	001	Oct 10, 2012
	CHARTWELL RX	EQ 75MG BASE	A202266	001	Aug 14, 2012
		EQ 300MG BASE	A202266	002	Nov 20, 2012
	RISING	EQ 75MG BASE	A077665	001	May 17, 2012
		EQ 300MG BASE	A077665	002	May 17, 2012
	SUN PHARM	EQ 75MG BASE	A090494	001	May 17, 2012
	SUN PHARM INDUSTRIES	EQ 75MG BASE	A078133	001	Jun 10, 2013

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

	ABLE	3.75MG	A071777	001	Jul 14, 1987
		7.5MG	A071778	001	Jul 14, 1987
		15MG	A071779	001	Jul 14, 1987
	AM THERAP	3.75MG	A071429	001	Jun 23, 1987
		7.5MG	A071430	001	Jun 23, 1987
		15MG	A071431	001	Jun 23, 1987
	DASH PHARMS	3.75MG	A071509	001	Oct 19, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL					
CLORAZEPATE DIPOTASSIUM					
		7.5MG	A071510	001	Oct 19, 1987
		15MG	A071511	001	Oct 19, 1987
	DAVA PHARMS INC	3.75MG	A071742	001	Dec 14, 1987
		7.5MG	A071743	001	Dec 14, 1987
		15MG	A071744	001	Dec 14, 1987
	GD SEARLE LLC	3.75MG	A071727	001	Dec 18, 1987
		7.5MG	A071728	001	Dec 18, 1987
		15MG	A071729	001	Dec 18, 1987
	PUREPAC PHARM	3.75MG	A071924	001	Apr 25, 1988
		7.5MG	A071925	001	Apr 25, 1988
		15MG	A071926	001	Apr 25, 1988
	QUANTUM PHARMICS	3.75MG	A071549	001	Sep 12, 1988
		7.5MG	A071550	001	Sep 12, 1988
		15MG	A071522	001	Sep 12, 1988
	RISING	3.75MG	A072112	002	Aug 26, 1988
		7.5MG	A072112	003	Aug 26, 1988
		15MG	A072112	001	Aug 26, 1988
	USL PHARMA	3.75MG	A071242	001	Jun 23, 1987
		7.5MG	A071243	001	Jun 23, 1987
		15MG	A071244	001	Jun 23, 1987
	WARNER CHILCOTT	3.75MG	A071774	001	Mar 01, 1988
		7.5MG	A071775	001	Mar 01, 1988
		15MG	A071776	001	Mar 01, 1988
	WATSON LABS	3.75MG	A071878	001	Mar 15, 1988
		7.5MG	A071879	001	Mar 15, 1988
		15MG	A071860	001	Mar 15, 1988
TRANXENE					
+	AJENAT PHARMS	3.75MG **	N017105	001	
+		7.5MG **	N017105	002	
+		15MG **	N017105	003	
TABLET;ORAL					
CLORAZEPATE DIPOTASSIUM					
	ABLE	3.75MG	A071780	001	Jun 26, 1987
		7.5MG	A071781	001	Jun 26, 1987
		15MG	A071782	001	Jun 26, 1987
	AM THERAP	3.75MG	A071747	001	Jun 23, 1987
		7.5MG	A071748	001	Jun 23, 1987
		15MG	A071749	001	Jun 23, 1987
	AUROLIFE PHARMA LLC	3.75MG	A072514	002	May 11, 1990
		7.5MG	A072514	003	May 11, 1990
		15MG	A072514	001	May 11, 1990
	LEDERLE	3.75MG	A072013	001	Dec 15, 1987
		7.5MG	A072014	001	Dec 15, 1987
		15MG	A072015	001	Dec 15, 1987
	PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
		7.5MG	A072331	001	Aug 08, 1988
		15MG	A072332	001	Aug 08, 1988
	QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
		7.5MG	A071731	001	Oct 26, 1987
		15MG	A071702	001	Oct 26, 1987
	SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004
		7.5MG	A076911	002	Sep 29, 2004
		15MG	A076911	003	Sep 29, 2004
	WARNER CHILCOTT	3.75MG	A071828	001	Mar 03, 1988
		7.5MG	A071829	001	Mar 03, 1988
		15MG	A071830	001	Mar 03, 1988
	WATSON LABS	3.75MG	A071852	001	Feb 09, 1988
		7.5MG	A071853	001	Feb 09, 1988
		15MG	A071854	001	Feb 09, 1988
GEN-XENE					
	ALRA	3.75MG	A071787	001	Apr 26, 1988
		7.5MG	A071788	001	Apr 26, 1988
		15MG	A071789	001	Apr 26, 1988
TRANXENE					
+	AJENAT PHARMS	3.75MG **	N017105	006	
+		15MG **	N017105	008	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL				
TRANXENE SD				
+ AJENAT PHARMS	11.25MG **	N017105	005	
+	22.5MG **	N017105	004	

CLOTRIMAZOLE

CREAM;TOPICAL				
LOTRIMIN				
+ SCHERING PLOUGH	1% **	N017619	001	
MYCELEX				
BAYER HEALTHCARE LLC	1%	N018183	001	
CREAM;VAGINAL				
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	1% **	N018052	002	Nov 30, 1990
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	2%	N020574	001	Nov 24, 1998
MYCELEX-7				
BAYER HEALTHCARE LLC	1%	N018230	002	Dec 26, 1991
CREAM, TABLET;TOPICAL, VAGINAL				
GYNE-LOTRIMIN 3 COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,200MG	N020526	002	Jul 29, 1996
GYNE-LOTRIMIN COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,100MG	N020289	002	Apr 26, 1993
MYCELEX-7 COMBINATION PACK				
BAYER HEALTHCARE LLC	1%,100MG	N020389	002	Jun 23, 1994
LOTION;TOPICAL				
LOTRIMIN				
SCHERING	1%	N018813	001	Feb 17, 1984
SOLUTION;TOPICAL				
LOTRIMIN				
+ SCHERING PLOUGH	1% **	N017613	001	
MYCELEX				
+ BAYER HLTHCARE	1% **	N018181	001	
TABLET;VAGINAL				
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	100MG	N017717	002	Nov 30, 1990
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	200MG	N020525	001	Jul 29, 1996
GYNIX				
TEVA PHARMS	100MG	A073249	001	Feb 13, 1998
MYCELEX-7				
BAYER HEALTHCARE LLC	100MG	N018182	002	Dec 26, 1991
MYCELEX-G				
BAYER PHARMS	500MG	N019069	001	Apr 19, 1985
TROCHE/LOZENGE;ORAL				
MYCELEX				
+ BAYER HLTHCARE	10MG **	N018713	001	Jun 17, 1983

CLOXACILLIN SODIUM

CAPSULE;ORAL				
CLOXACILLIN SODIUM				
APOTHECON	EQ 250MG BASE	A061452	001	
	EQ 500MG BASE	A061452	002	
TEVA	EQ 250MG BASE	A062240	001	
	EQ 500MG BASE	A062240	002	
CLOXAPEN				
GLAXOSMITHKLINE	EQ 250MG BASE	A061806	001	
	EQ 250MG BASE	A062233	001	
	EQ 500MG BASE	A061806	002	
	EQ 500MG BASE	A062233	002	
FOR SOLUTION;ORAL				
CLOXACILLIN SODIUM				
TEVA	EQ 125MG BASE/5ML	A062268	001	
	EQ 125MG BASE/5ML	A062978	001	Apr 06, 1989
TEGOPEN				
APOTHECON	EQ 125MG BASE/5ML	A061453	001	
	EQ 125MG BASE/5ML	N050192	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLOZAPINE

TABLET;ORAL					
CLOZAPINE					
	DR REDDYS LABS SA	25MG	A203807	001	Sep 17, 2015
		50MG	A203807	003	Aug 22, 2017
		100MG	A203807	002	Sep 17, 2015
		200MG	A203807	004	Aug 22, 2017
	MYLAN	12.5MG	A075417	003	Apr 15, 2010
	PAR PHARM	25MG	A075162	001	Apr 26, 2005
		100MG	A075162	002	Apr 26, 2005
	SANDOZ	25MG	A074546	001	Aug 30, 1996
		100MG	A074546	002	Aug 30, 1996
	ZYDUS PHARMS	25MG	A209480	001	Dec 06, 2017
		50MG	A209480	002	Dec 06, 2017
		100MG	A209480	003	Dec 06, 2017
		200MG	A209480	004	Dec 06, 2017
TABLET, ORALLY DISINTEGRATING;ORAL					
FAZACLO ODT					
+	JAZZ	12.5MG **	N021590	004	May 30, 2007
+		25MG **	N021590	001	Feb 10, 2004
		50MG **	N021590	003	Jun 03, 2005
+		100MG **	N021590	002	Feb 10, 2004
+		150MG **	N021590	005	Jul 09, 2010
+		200MG **	N021590	006	Jul 09, 2010

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL					
PHENERGAN VC W/ CODEINE					
+	ANI PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML **	N008306	005	Apr 02, 1984
PHERAZINE VC W/ CODEINE					
	HALSEY	10MG/5ML;5MG/5ML;6.25MG/5ML	A088870	001	Mar 02, 1987
PROMETH VC W/ CODEINE					
	NOSTRUM LABS INC	10MG/5ML;5MG/5ML;6.25MG/5ML	A088764	001	Oct 31, 1984
PROMETHAZINE VC W/ CODEINE					
	CENCI	10MG/5ML;5MG/5ML;6.25MG/5ML	A088816	001	Nov 22, 1985
	WOCKHARDT	10MG/5ML;5MG/5ML;6.25MG/5ML	A088896	001	Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL					
PHENERGAN W/ CODEINE					
+	ANI PHARMS	10MG/5ML;6.25MG/5ML **	N008306	004	Apr 02, 1984
PHERAZINE W/ CODEINE					
	HALSEY	10MG/5ML;6.25MG/5ML	A088739	001	Dec 23, 1988
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE					
+	ACTAVIS MID ATLANTIC	10MG/5ML;6.25MG/5ML	A088763	001	Oct 31, 1984
	PHARM ASSOC	10MG/5ML;6.25MG/5ML	A089647	001	Dec 22, 1988
PROMETHAZINE W/ CODEINE					
	CENCI	10MG/5ML;6.25MG/5ML	A088814	001	Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL					
ACTIFED W/ CODEINE					
	GLAXOSMITHKLINE	10MG/5ML;30MG/5ML;1.25MG/5ML **	N012575	003	Apr 04, 1984
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE					
	CENCI	10MG/5ML;30MG/5ML;1.25MG/5ML	A089018	001	Jul 23, 1986
TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE					
	WOCKHARDT	10MG/5ML;30MG/5ML;1.25MG/5ML	A088833	001	Nov 16, 1984

CODEINE SULFATE

SOLUTION;ORAL					
CODEINE SULFATE					
	HIKMA	30MG/5ML	N202245	001	Jun 30, 2011

COLCHICINE; PROBENECID

TABLET;ORAL					
COLBENEMID					
+	MERCK	0.5MG;500MG **	N012383	001	
PROBEN-C					
	WATSON LABS	0.5MG;500MG	A085552	001	
PROBENECID AND COLCHICINE					
	ANI PHARMS	0.5MG;500MG	A083734	001	
	BEECHAM	0.5MG;500MG	A084321	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

COLCHICINE; PROBENECID				
TABLET;ORAL				
PROBENECID AND COLCHICINE				
	IMPAX LABS	0.5MG;500MG	A083720 002	
	SANDOZ	0.5MG;500MG	A086130 001	
PROBENECID W/ COLCHICINE				
	LEDERLE	0.5MG;500MG	A086954 001	
	WATSON LABS	0.5MG;500MG	A083221 001	
COLESEVELAM HYDROCHLORIDE				
BAR, CHEWABLE;ORAL				
WELCHOL				
+	COSETTE	3.75GM	N210895 001	Apr 03, 2019
CAPSULE;ORAL				
WELCHOL				
	COSETTE	375MG	N021141 001	May 26, 2000
FOR SUSPENSION;ORAL				
COLESEVELAM HYDROCHLORIDE				
	WATSON LABS INC	1.875GM/PACKET	A202178 001	Sep 01, 2020
		3.75GM/PACKET	A202178 002	Sep 01, 2020
WELCHOL				
+	COSETTE	1.875GM/PACKET **	N022362 001	Oct 02, 2009
TABLET;ORAL				
COLESEVELAM HYDROCHLORIDE				
	CHARTWELL RX	625MG	A201354 001	Dec 17, 2020
	INVAGEN PHARMS	625MG	A212602 001	Apr 20, 2020
	UNITED RES LABS	625MG	A213456 001	Jan 21, 2022
	WATSON LABS INC	625MG	A200830 001	Sep 02, 2020
COLISTIN SULFATE				
SUSPENSION;ORAL				
COLY-MYCIN S				
	PARKE DAVIS	EQ 25MG BASE/5ML	N050355 001	
CONIVAPTAN HYDROCHLORIDE				
INJECTABLE;INTRAVENOUS				
VAPRISOL				
	CUMBERLAND	20MG/4ML (5MG/ML)	N021697 001	Dec 29, 2005
COPANLISIB DIHYDROCHLORIDE				
POWDER;INTRAVENOUS				
ALIQOPA				
+	BAYER HEALTHCARE	60MG/VIAL	N209936 001	Sep 14, 2017
COPPER				
INTRAUTERINE DEVICE;INTRAUTERINE				
CU-7				
	GD SEARLE LLC	89MG	N017408 001	
TATUM-T				
	GD SEARLE LLC	120MG	N018205 001	
CORTICOTROPIN				
INJECTABLE;INJECTION				
ACTH				
	PARKEDALE	25 UNITS/VIAL	N008317 002	
		40 UNITS/VIAL	N008317 004	
ACTHAR				
	SANOFI AVENTIS US	25 UNITS/VIAL	N007504 002	
		40 UNITS/VIAL	N007504 003	
ACTHAR GEL				
	MALLINCKRODT ARD	40 UNITS/ML	N008372 006	
CORTICOTROPIN				
	ORGANICS LAGRANGE	40 UNITS/ML	N010831 001	
		80 UNITS/ML	N010831 002	
	WATSON LABS	40 UNITS/VIAL	A088772 001	Nov 21, 1984
PURIFIED CORTROPHIN GEL				
	ANI PHARMS	40 UNITS/ML	N008975 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CORTICOTROPIN-ZINC HYDROXIDE				
INJECTABLE;INJECTION				
CORTROPHIN-ZINC				
	ANI PHARMS	40 UNITS/ML	N009854 001	
CORTISONE ACETATE				
INJECTABLE;INJECTION				
CORTISONE ACETATE				
	PHARMACIA AND UPJOHN	25MG/ML	N008126 002	
	WATSON LABS	25MG/ML	A083147 003	
		25MG/ML	A085677 001	
		50MG/ML	A083147 004	
		50MG/ML	A085677 002	
CORTONE				
	MERCK	25MG/ML	N007110 002	
		50MG/ML	N007110 003	
TABLET;ORAL				
CORTISONE ACETATE				
	BARR	25MG	A083471 001	
	CHARTWELL MOLECULAR	25MG	A080694 001	
	ELKINS SINN	25MG	A080836 001	
	EVERYLIFE	25MG	A084246 001	
	HEATHER	25MG	A085736 001	
	HIKMA INTL PHARMS	25MG	A080776 002	
	IMPAX LABS	25MG	N009458 001	
	INWOOD LABS	25MG	A080731 001	
	IVAX SUB TEVA PHARMS	25MG	A080630 001	
		25MG	A083536 001	
	PANRAY	5MG	N008284 002	
		25MG	N008284 001	
	PHARMACIA AND UPJOHN	5MG	N008126 003	
		10MG	N008126 004	
		25MG	N008126 001	
	PUREPAC PHARM	25MG	A080493 001	
	VITARINE	25MG	A080333 001	
	WATSON LABS	25MG	A085884 001	
	WHITEWORTH TOWN PLSN	25MG	A080341 001	
CORTONE				
+	MERCK	25MG **	N007750 003	
COSYNTROPIN				
SOLUTION;INTRAVENOUS				
COSYNTROPIN				
	SANDOZ	0.25MG/ML (0.25MG/ML)	N022028 001	Feb 21, 2008
CROMOLYN SODIUM				
AEROSOL, METERED;INHALATION				
INTAL				
	KING PHARMS LLC	0.8MG/INH	N018887 001	Dec 05, 1985
CAPSULE;INHALATION				
INTAL				
+	SANOFI AVENTIS US	20MG **	N016990 001	
CAPSULE;ORAL				
GASTROCROM				
	UCB INC	100MG	N019188 001	Dec 22, 1989
CONCENTRATE;ORAL				
CROMOLYN SODIUM				
	GENERA PHARMS	100MG/5ML	A090954 001	Dec 18, 2009
SOLUTION;INHALATION				
CROMOLYN SODIUM				
	ACTAVIS MID ATLANTIC	10MG/ML	A075067 001	Jul 19, 1999
	BAUSCH	10MG/ML	A075585 001	Dec 21, 2000
	EUGIA PHARMA	10MG/ML	A074209 001	Apr 26, 1994
	HIKMA	10MG/ML	A075333 001	Apr 30, 2002
	ROXANE	10MG/ML	A075175 001	Sep 30, 1999
	WATSON LABS	10MG/ML	A076469 001	Jun 17, 2005
INTAL				
+	KING PHARMS LLC	10MG/ML **	N018596 001	May 28, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CROMOLYN SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
CROLOM				
BAUSCH AND LOMB	4%	A074443	001	Jan 30, 1995
CROMOLYN SODIUM				
AKORN	4%	A074706	001	Apr 29, 1998
APOTEX INC	4%	A075615	001	Jan 26, 2001
CROMOPTIC				
KING PHARMS	4%	A075088	001	Apr 27, 1999
OPTICROM				
+ ALLERGAN	4% **	N018155	001	Oct 03, 1984
SPRAY, METERED;NASAL				
CROMOLYN SODIUM				
ACTAVIS MID ATLANTIC	5.2MG/SPRAY	A074800	001	Jul 26, 2001
HH AND P	5.2MG/SPRAY	A077976	001	Sep 07, 2007
PERRIGO	5.2MG/SPRAY	A075427	001	Dec 12, 2001
NASALCROM				
+ BLACKSMITH BRANDS	5.2MG/SPRAY **	N020463	001	Jan 03, 1997
CROTAMITON				
CREAM;TOPICAL				
EURAX				
+ JOURNEY	10%	N006927	001	
CRYPTENAMINE ACETATES				
INJECTABLE;INJECTION				
UNITENSEN				
MEDPOINTE PHARM HLC	260CSR UNIT/ML	N008814	001	
CRYPTENAMINE TANNATES				
TABLET;ORAL				
UNITENSEN				
MEDPOINTE PHARM HLC	260CSR UNIT	N009217	001	
CUPRIC SULFATE				
INJECTABLE;INJECTION				
CUPRIC SULFATE				
+ ABRAXIS PHARM	EQ 0.4MG COPPER/ML **	N019350	001	May 05, 1987
CYANOCOBALAMIN				
GEL, METERED;NASAL				
NASCOBAL				
PAR PHARM	0.5MG/INH	N019722	001	Nov 05, 1996
INJECTABLE;INJECTION				
BERUBIGEN				
PHARMACIA AND UPJOHN	1MG/ML	N006798	001	
BETALIN 12				
LILLY	0.1MG/ML	A080855	001	
	1MG/ML	A080855	002	
COBAVITE				
WATSON LABS	0.1MG/ML	A083013	001	
	1MG/ML	A083064	001	
CYANOCOBALAMIN				
ABRAXIS PHARM	0.03MG/ML	A080510	003	
	0.1MG/ML	A080510	001	
	1MG/ML	A080510	002	
AKORN	1MG/ML	A087969	001	Nov 10, 1983
DELL LABS	0.03MG/ML	A080689	001	
	0.1MG/ML	A080689	002	
	1MG/ML	A080689	003	
DR REDDYS	0.1MG/ML	A080573	002	
	1MG/ML	A080573	001	
FRESENIUS KABI USA	0.1MG/ML	A080557	002	
LUITPOLD	0.03MG/ML	A080668	001	
LYPHOMED	1MG/ML	A083075	001	
MYLAN INSTITUTIONAL	1MG/ML	A040451	001	Sep 23, 2003
SANOFI AVENTIS US	1MG/ML	A080564	001	
SOLOPAK	1MG/ML	A087551	001	Feb 29, 1984
WARNER CHILCOTT	1MG/ML	N007085	002	
WATSON LABS	0.1MG/ML	A083120	001	
	1MG/ML	A083120	002	
WYETH AYERST	0.1MG/ML	A080554	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CYANOCOBALAMIN				
INJECTABLE;INJECTION				
CYANOCOBALAMIN				
	1MG/ML	A080554	002	
XIROMED	1MG/ML	A215046	001	Aug 20, 2021
REDISOL				
MERCK	1MG/ML	N006668	010	
RUBIVITE				
BEL MAR	0.03MG/ML	N010791	004	
	0.05MG/ML	N010791	001	
	0.1MG/ML	N010791	002	
	0.12MG/ML	N010791	005	
	1MG/ML	N010791	003	
RUBRAMIN PC				
BRISTOL MYERS SQUIBB	0.1MG/ML	N006799	002	
+	1MG/ML **	N006799	004	
+	1MG/ML **	N006799	010	Apr 28, 1988
RUVITE				
SAVAGE LABS	1MG/ML	A080570	002	
VI-TWEL				
BAYER HLTHCARE	1MG/ML	N007012	002	
SPRAY, METERED;NASAL				
CALOMIST				
PAR PHARM	25MCG/SPRAY	N022102	001	Jul 27, 2007
TABLET;ORAL				
CYANOCOBALAMIN				
WEST WARD	1MG	A084264	001	
CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58				
N/A;N/A				
DICOPAC KIT				
GE HEALTHCARE	N/A;N/A;N/A	N017406	001	
CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE				
INJECTABLE;INJECTION				
DEPINAR				
ARMOUR PHARM	0.5MG/ML;2.3MG/ML;1MG/ML	N011208	001	
CYCLACILLIN				
FOR SUSPENSION;ORAL				
CYCLAPEN-W				
WYETH AYERST	125MG/5ML	N050508	001	
	250MG/5ML	N050508	002	
	500MG/5ML	N050508	003	
TABLET;ORAL				
CYCLACILLIN				
TEVA	250MG	A062895	001	Aug 04, 1988
	500MG	A062895	002	Aug 04, 1988
CYCLAPEN-W				
WYETH AYERST	250MG	N050509	001	
	500MG	N050509	002	
CYCLIZINE LACTATE				
INJECTABLE;INJECTION				
MAREZINE				
GLAXOSMITHKLINE	50MG/ML	N009495	001	
CYCLOBENZAPRINE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
CYCLOBENZAPRINE HYDROCHLORIDE				
APOTEX	15MG	A206703	001	Jul 24, 2018
	30MG	A206703	002	Jul 24, 2018
TABLET;ORAL				
CYCLOBENZAPRINE HYDROCHLORIDE				
CHARTWELL RX	5MG	A072854	002	Feb 03, 2006
	10MG	A072854	001	Nov 19, 1991
PLIVA	10MG	A074421	001	Sep 29, 1995
RISING	5MG	A073144	002	Feb 03, 2006
	7.5MG	A073144	003	Mar 25, 2013
	10MG	A073144	001	May 30, 1991
SANDOZ	10MG	A073683	001	Feb 26, 1993
WATSON LABS	10MG	A073143	001	Nov 27, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CYCLOBENZAPRINE HYDROCHLORIDE				
TABLET;ORAL				
CYCLOBENZAPRINE HYDROCHLORIDE				
	10MG	A074436	001	Nov 30, 1994
FLEXERIL				
+ JANSSEN RES AND DEV	5MG **	N017821	001	
+	10MG **	N017821	002	
CYCLOPENTOLATE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
AK-PENTOLATE				
AKORN	1%	A085555	001	
CYCLOPENTOLATE HYDROCHLORIDE				
AKORN	0.5%	A205937	001	Dec 09, 2015
ALCON PHARMS LTD	1%	A089162	001	Jan 24, 1991
SOLA BARNES HIND	1%	A084150	001	
	1%	A084863	001	
PENTOLAIR				
PHARMAFAIR	0.5%	A088643	001	Feb 09, 1987
	1%	A088150	001	Feb 25, 1983
CYCLOPHOSPHAMIDE				
CAPSULE;ORAL				
CYCLOPHOSPHAMIDE				
ANI PHARMS	25MG	A207014	001	Mar 19, 2018
	50MG	A207014	002	Mar 19, 2018
INJECTABLE;INJECTION				
CYCLOPHOSPHAMIDE				
BAXTER HLTHCARE	100MG/VIAL	A088371	001	Jul 03, 1986
	200MG/VIAL	A088372	001	Jul 03, 1986
	500MG/VIAL	A088373	001	Jul 03, 1986
	1GM/VIAL	A088374	001	Sep 24, 1986
CYTOXAN				
+ BAXTER HLTHCARE	100MG/VIAL **	N012142	001	
+	200MG/VIAL **	N012142	002	
CYTOXAN (LYOPHILIZED)				
+ BAXTER HLTHCARE	500MG/VIAL **	N012142	003	
+	500MG/VIAL **	N012142	008	Jan 04, 1984
+	1GM/VIAL **	N012142	004	Aug 30, 1982
+	1GM/VIAL **	N012142	010	Sep 24, 1985
+	2GM/VIAL **	N012142	005	Aug 30, 1982
+	2GM/VIAL **	N012142	009	Dec 10, 1985
LYOPHILIZED CYTOXAN				
+ BAXTER HLTHCARE	100MG/VIAL **	N012142	006	Dec 05, 1985
+	200MG/VIAL **	N012142	007	Dec 10, 1985
NEOSAR				
BEDFORD	100MG/VIAL	A087442	001	Feb 16, 1982
	200MG/VIAL	A087442	002	Feb 16, 1982
	500MG/VIAL	A087442	003	Feb 16, 1982
	1GM/VIAL	A087442	004	Jul 08, 1983
	2GM/VIAL	A087442	005	Mar 30, 1989
TEVA PARENTERAL	100MG/VIAL	A040015	001	Apr 29, 1993
	200MG/VIAL	A040015	002	Apr 29, 1993
	500MG/VIAL	A040015	003	Apr 29, 1993
	1GM/VIAL	A040015	004	Apr 29, 1993
	2GM/VIAL	A040015	005	Apr 29, 1993
SOLUTION;INTRAVENOUS				
CYCLOPHOSPHAMIDE				
+ NEVAKAR INJECTABLES	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023
+	1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023
TABLET;ORAL				
CYCLOPHOSPHAMIDE				
ROXANE	25MG	A040032	001	Aug 17, 1999
	50MG	A040032	002	Aug 17, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CYCLOSPORINE					
CAPSULE;ORAL					
GENGRAF					
	ABBVIE	50MG	A065003	002	May 12, 2000
NEORAL					
+	NOVARTIS	50MG **	N050715	003	Jul 14, 1995
SOLUTION;ORAL					
CYCLOSPORINE					
	DR REDDYS LABS SA	100MG/ML	A065054	001	Dec 18, 2001
	PHARM ASSOC	100MG/ML	A065167	001	Jan 05, 2005
	PHARMOBEDIENT CNSLTG	100MG/ML	A065133	001	Sep 17, 2004
CYCLOTHIAZIDE					
TABLET;ORAL					
ANHYDRON					
	LILLY	2MG	N013157	002	
FLUIDIL					
	PHARMACIA AND UPJOHN	2MG	N018173	001	
CYCRIMINE HYDROCHLORIDE					
TABLET;ORAL					
PAGITANE					
	LILLY	1.25MG	N008951	001	
		2.5MG	N008951	002	
CYPROHEPTADINE HYDROCHLORIDE					
SYRUP;ORAL					
CYPROHEPTADINE HYDROCHLORIDE					
+	ACTAVIS MID ATLANTIC	2MG/5ML **	A086833	001	
	HALSEY	2MG/5ML	A089199	001	Jul 03, 1986
	MORTON GROVE	2MG/5ML	A087001	001	Nov 04, 1982
	NASKA	2MG/5ML	A089021	001	Dec 21, 1987
	TRIS PHARMA INC	2MG/5ML	A205431	001	Dec 21, 2021
PERIACTIN					
+	MERCK	2MG/5ML **	N013220	002	
TABLET;ORAL					
CYPROHEPTADINE HYDROCHLORIDE					
	AM THERAP	4MG	A088798	001	Feb 15, 1985
	ASCOT	4MG	A087685	001	Oct 25, 1982
	DURAMED PHARMS BARR	4MG	A088232	001	Oct 25, 1983
	FOSUN PHARMA	4MG	A086808	001	
	HALSEY	4MG	A089057	001	Jul 03, 1986
+	HERITAGE PHARMA	4MG	A087056	001	
	KV PHARM	4MG	A086737	001	
	MD PHARM	4MG	A087566	001	Nov 10, 1982
	MYLAN	4MG	A086678	001	
	PIONEER PHARMS	4MG	A087839	001	Feb 08, 1984
	PLIVA	4MG	A088205	001	Jul 26, 1983
	RISING	4MG	A207783	001	Dec 29, 2016
	STRIDES PHARMA	4MG	A087129	001	
	SUPERPHARM	4MG	A087405	001	
	VITARINE	4MG	A087284	001	
	WATSON LABS	4MG	A085245	001	
		4MG	A086165	001	
		4MG	A086580	001	
PERIACTIN					
+	MERCK	4MG **	N012649	001	
CYSTEINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
CYSTEINE HYDROCHLORIDE					
+	HOSPIRA	7.25% **	N019523	001	Oct 22, 1986
SOLUTION;INTRAVENOUS					
NOURESS					
+	BAXTER HLTHCARE CORP	500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CYTARABINE					
INJECTABLE;INJECTION					
CYTARABINE					
	MEITHEAL	20MG/ML	A206189	001	Jun 26, 2020
		20MG/ML	A206190	001	Nov 09, 2017
	MYLAN LABS LTD	20MG/ML	A200916	001	Dec 13, 2011
	RISING	20MG/ML	A200914	001	Dec 13, 2011
+	TEVA PARENTERAL	100MG/VIAL **	N016793	001	
+		500MG/VIAL **	N016793	002	
+		1GM/VIAL **	N016793	003	Dec 21, 1987
+		2GM/VIAL **	N016793	004	Dec 21, 1987
CYTOSAR-U					
	TEVA PHARMS USA	100MG/VIAL	A075206	001	Dec 30, 1998
		500MG/VIAL	A075206	002	Dec 30, 1998
		1GM/VIAL	A075206	004	Dec 30, 1998
		2GM/VIAL	A075206	003	Dec 30, 1998
INJECTABLE, LIPOSOMAL;INJECTION					
DEPOCYT					
+	PACIRA PHARMS INC	10MG/ML	N021041	001	Apr 01, 1999
DACARBAZINE					
INJECTABLE;INJECTION					
DACARBAZINE					
	ABRAXIS PHARM	100MG/VIAL	A070962	001	Aug 28, 1986
		200MG/VIAL	A070990	001	Aug 28, 1986
DTIC-DOME					
+	BAYER HLTHCARE	100MG/VIAL **	N017575	001	
+		200MG/VIAL **	N017575	002	
DACLATASVIR DIHYDROCHLORIDE					
TABLET;ORAL					
DAKLINZA					
+	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015
+		EQ 60MG BASE	N206843	002	Jul 24, 2015
+		EQ 90MG BASE	N206843	003	Apr 13, 2016
DACTINOMYCIN					
INJECTABLE;INJECTION					
DACTINOMYCIN					
	AM REGENT	0.5MG/VIAL	A202562	001	Aug 23, 2013
	HIKMA	0.5MG/VIAL	A090304	001	Mar 16, 2010
DALFAMPRIDINE					
TABLET, EXTENDED RELEASE;ORAL					
DALFAMPRIDINE					
	HIKMA	10MG	A206646	001	Oct 24, 2018
	RISING	10MG	A206858	001	Jul 06, 2020
DALFOPRISTIN; QUINUPRISTIN					
INJECTABLE;INTRAVENOUS					
SYNERCID					
	KING PHARMS	420MG/VIAL;180MG/VIAL	N050748	002	Aug 24, 2000
DALTEPARIN SODIUM					
INJECTABLE;INJECTION					
FRAGMIN					
	PFIZER	7,500 IU/0.75ML	N020287	008	Apr 04, 2002
INJECTABLE;SUBCUTANEOUS					
FRAGMIN					
	PFIZER	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007
		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002
DANAPAROID SODIUM					
INJECTABLE;INJECTION					
ORGARAN					
	ASPEN GLOBAL INC	750 UNITS/0.6ML	N020430	001	Dec 24, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DANAZOL

CAPSULE;ORAL				
DANAZOL				
	AM THERAP	200MG	A071569 001	Dec 30, 1987
DANOCRINE				
	SANOFI AVENTIS US	50MG **	N017557 003	
		100MG **	N017557 004	
		200MG **	N017557 002	

DANTROLENE SODIUM

INJECTABLE;INJECTION				
DANTROLENE SODIUM				
	EUGIA PHARMA SPECLTS	20MG/VIAL	A205239 001	Feb 18, 2016

DAPAGLIFLOZIN

TABLET;ORAL				
DAPAGLIFLOZIN				
	ZYDUS PHARMS	5MG	A211582 001	Feb 22, 2022
		10MG	A211582 002	Feb 22, 2022

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
QTERNMET XR				
+	ASTRAZENECA AB	2.5MG;1GM;EQ 2.5MG BASE	N210874 001	May 02, 2019
+		5MG;1GM;EQ 2.5MG BASE	N210874 002	May 02, 2019
+		5MG;1GM;EQ 5MG BASE	N210874 003	May 02, 2019
+		10MG;1GM;EQ 5MG BASE	N210874 004	May 02, 2019

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
DAPIPRAZOLE HYDROCHLORIDE				
+	FERA PHARMS	0.5% **	N019849 001	Dec 31, 1990
	WOODWARD	0.5%	A204902 001	May 30, 2019

DAPSONE

TABLET;ORAL				
DAPSONE				
	ALVOGEN	25MG	A205429 001	Jan 07, 2016
		100MG	A205429 002	Jan 07, 2016
	CHARTWELL RX	25MG	A204074 001	May 10, 2016
		100MG	A204074 002	May 10, 2016
	TARO	25MG	A209430 001	Mar 01, 2019
		100MG	A209430 002	Mar 01, 2019

DAPTOMYCIN

POWDER;INTRAVENOUS				
CUBICIN				
	CUBIST PHARMS LLC	250MG/VIAL **	N021572 001	Sep 12, 2003
+		500MG/VIAL **	N021572 002	Sep 12, 2003
CUBICIN RF				
+	CUBIST PHARMS LLC	500MG/VIAL **	N021572 003	Jul 06, 2016
DAPTOMYCIN				
	HOSPIRA	500MG/VIAL	A202857 001	Sep 12, 2014
DAPZURA RT				
+	BAXTER HLTHCARE CORP	500MG/VIAL **	N213645 001	Jan 25, 2022

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL				
DARIFENACIN HYDROBROMIDE				
	ANCHEN PHARMS	EQ 7.5MG BASE	A091190 001	Mar 13, 2015
		EQ 15MG BASE	A091190 002	Mar 13, 2015
	JUBILANT GENERICS	EQ 7.5MG BASE	A205550 001	Oct 12, 2016
		EQ 15MG BASE	A205550 002	Oct 12, 2016
	XIROMED	EQ 7.5MG BASE	A209571 002	Oct 22, 2019
		EQ 15MG BASE	A209571 001	Oct 22, 2019
ENABLEX				
+	ABBVIE	EQ 7.5MG BASE **	N021513 001	Dec 22, 2004
+		EQ 15MG BASE **	N021513 002	Dec 22, 2004

DARUNAVIR

TABLET;ORAL				
PREZISTA				
+	JANSSEN PRODS	300MG **	N021976 001	Jun 23, 2006
+		400MG **	N021976 003	Oct 21, 2008

DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR

TABLET;ORAL				
VIEKIRA PAK (COPACKAGED)				
+	ABBVIE	EQ 250MG BASE;12.5MG, 75MG, 50MG	N206619 001	Dec 19, 2014

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, EXTENDED RELEASE;ORAL				
VIEKIRA XR				
+	ABBVIE	EQ 200MG BASE;8.33MG;50MG;33.33MG **	N208624 001	Jul 22, 2016

DASATINIB

TABLET;ORAL				
DASATINIB				
	APOTEX	20MG	A202103 001	Jun 10, 2016
		50MG	A202103 002	Jun 10, 2016
		70MG	A202103 003	Jun 10, 2016
		80MG	A203180 001	Nov 23, 2021
		100MG	A202103 004	Jun 10, 2016
		140MG	A203180 002	Nov 23, 2021

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL;INJECTION				
DAUNOXOME				
	GALEN (UK)	EQ 2MG BASE/ML	N050704 002	Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION				
CERUBIDINE				
	SANOFI AVENTIS US	EQ 20MG BASE/VIAL	A061876 001	
	WYETH AYERST	EQ 20MG BASE/VIAL **	N050484 001	
DAUNORUBICIN HYDROCHLORIDE				
	HISUN PHARM HANGZHOU	EQ 20MG BASE/VIAL	A206195 001	Apr 25, 2019
	TEVA PARENTERAL	EQ 20MG BASE/VIAL	A064212 001	Jun 23, 1998
		EQ 50MG BASE/VIAL	A064212 002	May 03, 1999

DECAMETHONIUM BROMIDE

INJECTABLE;INJECTION				
SYNCURINE				
	GLAXOSMITHKLINE	1MG/ML	N006931 002	

DECITABINE

INJECTABLE;INTRAVENOUS				
DACOGEN				
+	OTSUKA	50MG/VIAL	N021790 001	May 02, 2006
DECITABINE				
	CIPLA	50MG/VIAL	A208601 001	Nov 16, 2017

DEFERASIROX

GRANULE;ORAL				
DEFERASIROX				
	AMNEAL	90MG	A214194 003	Aug 02, 2021
		180MG	A214194 001	Feb 09, 2021
		360MG	A214194 002	Feb 09, 2021
TABLET;ORAL				
DEFERASIROX				
	CIPLA	90MG	A211852 001	Feb 11, 2020
		180MG	A211852 003	Jun 15, 2020
		360MG	A211852 002	Feb 11, 2020
	STEVENS J	90MG	A210727 001	Dec 27, 2019
		180MG	A210727 003	Jun 15, 2020
		360MG	A210727 002	Dec 27, 2019
	TEVA PHARMS USA	90MG	A209223 001	Nov 25, 2019
		180MG	A209223 003	Apr 24, 2020
		360MG	A209223 002	Nov 25, 2019
TABLET, FOR SUSPENSION;ORAL				
DEFERASIROX				
	TEVA PHARMS USA	125MG	A207124 001	Sep 23, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEFERASIROX
TABLET, FOR SUSPENSION;ORAL
DEFERASIROX

	250MG	A207124	002	Sep 23, 2022
	500MG	A207124	003	Sep 23, 2022
ZYDUS PHARMS	125MG	A208882	001	May 05, 2020
	250MG	A208882	002	May 05, 2020
	500MG	A208882	003	May 05, 2020

DEFERIPRONE
SOLUTION;ORAL
FERRIPROX

+ CHIESI	80MG/ML	N208030	002	Apr 20, 2018

DEFEROXAMINE MESYLATE
INJECTABLE;INJECTION
DEFEROXAMINE MESYLATE

DR REDDYS	500MG/VIAL	A076806	001	Mar 31, 2006
	2GM/VIAL	A076806	002	Mar 31, 2006

DESFERAL

+ NOVARTIS	2GM/VIAL **	N016267	002	May 25, 2000

DELAVIRDINE MESYLATE
TABLET;ORAL
RESCRIPTOR

+ VIIV HLTHCARE	100MG	N020705	001	Apr 04, 1997
+	200MG	N020705	002	Jul 14, 1999

DEMECARIUM BROMIDE
SOLUTION/DROPS;OPHTHALMIC
HUMORSOL

MERCK	0.125%	N011860	002	
	0.25%	N011860	001	

DEMECLOCYCLINE HYDROCHLORIDE
CAPSULE;ORAL
DECLOMYCIN

LEDERLE	150MG	N050262	001	

SYRUP;ORAL
DECLOMYCIN

LEDERLE	75MG/5ML	N050257	001	

TABLET;ORAL
DECLOMYCIN

COREPHARMA	75MG **	N050261	001	
	150MG **	N050261	002	
	300MG **	N050261	003	

DEMECLOCYCLINE HYDROCHLORIDE

BARR	150MG	A065171	001	Dec 13, 2004
	300MG	A065171	002	Dec 13, 2004
IMPAX LABS	150MG	A065094	001	Mar 22, 2004
	300MG	A065094	002	Mar 22, 2004

DESERPIDINE
TABLET;ORAL
HARMONYL

ABBVIE	0.1MG	N010796	001	
	0.25MG	N010796	002	

DESERPIDINE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
ORETICYL 25

ABBVIE	0.125MG;25MG	N012148	001	

ORETICYL 50

ABBVIE	0.125MG;50MG	N012148	003	

ORETICYL FORTE

ABBVIE	0.25MG;25MG	N012148	002	

DESERPIDINE; METHYCLOTHIAZIDE

TABLET;ORAL				
ENDURONYL				
	ABBOTT	0.25MG;5MG	N012775 001	
ENDURONYL FORTE				
	ABBOTT	0.5MG;5MG	N012775 002	
METHYCLOTHIAZIDE AND DESERPIDINE				
	WATSON LABS	0.25MG;5MG	A088486 001	Aug 10, 1984
		0.5MG;5MG	A088452 001	Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
PERTOFRANE				
	SANOFI AVENTIS US	25MG	N013621 001	
		50MG	N013621 002	
TABLET;ORAL				
DESIPRAMINE HYDROCHLORIDE				
	ANI PHARMS	10MG	A205153 001	Oct 28, 2016
		25MG	A071803 002	Dec 08, 1987
		25MG	A205153 002	Oct 28, 2016
		50MG	A071803 003	Dec 08, 1987
		50MG	A205153 003	Oct 28, 2016
		75MG	A071803 004	Dec 08, 1987
		75MG	A205153 004	Oct 28, 2016
		100MG	A071803 001	May 29, 1997
		100MG	A205153 005	Oct 28, 2016
		150MG	A071803 005	May 29, 1997
		150MG	A205153 006	Oct 28, 2016
	USL PHARMA	25MG	A071864 001	Sep 09, 1987
		50MG	A071865 001	Sep 09, 1987
		75MG	A071866 001	Sep 09, 1987
		100MG	A071867 001	Sep 09, 1987

DESLANOSIDE

INJECTABLE;INJECTION				
CEDILANID-D				
	NOVARTIS	0.2MG/ML	N009282 002	

DESLORATADINE

SOLUTION;ORAL				
CLARINEX				
+	MERCK SHARP DOHME	0.5MG/ML **	N021300 001	Sep 01, 2004
DESLORATADINE				
	TARO	0.5MG/ML	A202592 001	Jun 30, 2015
		0.5MG/ML	A202936 001	May 26, 2016
TABLET;ORAL				
DESLORATADINE				
	DASH PHARMS	5MG	A078351 001	Feb 10, 2012
	PERRIGO	5MG	A078361 001	Dec 22, 2011
	SANDOZ	5MG	A078364 001	Dec 03, 2010
	SUN PHARM INDS	5MG	A078359 001	Nov 16, 2010
TABLET, ORALLY DISINTEGRATING;ORAL				
CLARINEX				
+	ORGANON	2.5MG **	N021312 002	Jul 14, 2005
+		5MG **	N021312 001	Jun 26, 2002

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
CLARINEX D 24 HOUR				
+	ORGANON	5MG;240MG **	N021605 001	Mar 03, 2005

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION				
DDAVP				
	FERRING PHARMS INC	0.015MG/ML	N018938 002	Apr 25, 1995
DESMOPRESSIN ACETATE				
	AM REGENT	0.004MG/ML	A091374 001	Feb 14, 2019
	BEDFORD	0.004MG/ML	A074575 001	Feb 18, 2000
	HOSPIRA	0.004MG/ML	A075220 001	Aug 28, 2000
DESMOPRESSIN ACETATE PRESERVATIVE FREE				
	BEDFORD	0.004MG/ML	A074574 001	Feb 18, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DESMOPRESSIN ACETATE

SOLUTION;NASAL				
CONCENTRAID				
FERRING	0.01%	N019776	001	Dec 26, 1990
DDAVP				
+ FERRING PHARMS INC	0.01%	N017922	001	
DESMOPRESSIN ACETATE				
SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012
SPRAY, METERED;NASAL				
DDAVP				
+ FERRING PHARMS INC	0.01MG/SPRAY **	N017922	002	Feb 06, 1989
DDAVP (NEEDS NO REFRIGERATION)				
+ FERRING PHARMS INC	0.01MG/SPRAY	N017922	003	Aug 07, 1996
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)				
SUN PHARM	0.01MG/SPRAY	A078271	001	Dec 23, 2013
MINIRIN				
+ FERRING	0.01MG/SPRAY	N021333	001	Sep 16, 2002
NOCTIVA				
+ ACERUS PHARMS	0.00083MG/SPRAY	N201656	001	Mar 03, 2017
+	0.00166MG/SPRAY	N201656	002	Mar 03, 2017
STIMATE				
FERRING PHARMS INC	0.15MG/SPRAY	N020355	001	Mar 07, 1994
STIMATE (NEEDS NO REFRIGERATION)				
+ FERRING PHARMS INC	0.15MG/SPRAY	N020355	002	Oct 24, 2007
TABLET;ORAL				
DESMOPRESSIN ACETATE				
FERRING	0.1MG	N021795	001	May 08, 2008
	0.2MG	N021795	002	May 08, 2008
IMPAX LABS INC	0.1MG	A077122	001	Jan 25, 2006
	0.2MG	A077122	002	Jan 25, 2006
NATCO PHARMA USA	0.1MG	A200653	001	Jun 27, 2014
	0.2MG	A200653	002	Jun 27, 2014
TABLET;SUBLINGUAL				
NOCDURNA				
+ FERRING PHARMS INC	0.0277MG	N022517	001	Jun 21, 2018
+	0.0553MG	N022517	002	Jun 21, 2018

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-21				
DESOGEN				
ORGANON USA INC	0.15MG;0.03MG	N020071	001	Dec 10, 1992
DESOGESTREL AND ETHINYL ESTRADIOL				
DURAMED PHARMS BARR	0.15MG;0.03MG	A075256	001	Aug 12, 1999
ORTHO-CEPT				
+ JANSSEN PHARMS	0.15MG;0.03MG **	N020301	001	Dec 14, 1992
TABLET;ORAL-28				
DESOGEN				
ORGANON USA INC	0.15MG;0.03MG	N020071	002	Dec 10, 1992
DESOGESTREL AND ETHINYL ESTRADIOL				
DR REDDYS LABS SA	0.15MG,N/A;0.02MG,0.01MG	A076916	001	Dec 29, 2008
	0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	A077182	001	Jan 24, 2006
MYLAN LABS LTD	0.15MG;0.03MG	A202085	001	May 20, 2015
NAARI PTE LTD	0.15MG;0.03MG	A207067	001	Sep 13, 2018
EMOQUETTE				
VINTAGE PHARMS LLC	0.15MG;0.03MG	A076675	001	Feb 25, 2011
MIRCETTE				
+ TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG **	N020713	001	Apr 22, 1998
ORTHO-CEPT				
+ JANSSEN PHARMS	0.15MG;0.03MG **	N020301	002	Dec 14, 1992

DESONIDE

AEROSOL, FOAM;TOPICAL				
VERDESO				
+ ALMIRALL	0.05%	N021978	001	Sep 19, 2006
GEL;TOPICAL				
DESONATE				
+ LEO PHARMA AS	0.05% **	N021844	001	Oct 20, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DESONIDE

LOTION;TOPICAL				
DESONIDE				
PAI HOLDINGS PHARM	0.05%	A207855	001	Sep 28, 2017
OINTMENT;TOPICAL				
DESONIDE				
PAI HOLDINGS PHARM	0.05%	A212002	001	Mar 12, 2019

DESOXIMETASONE

CREAM;TOPICAL				
DESOXIMETASONE				
AKORN	0.05%	A203787	001	Jan 06, 2017
	0.25%	A203234	001	Jun 12, 2015
TOPICORT				
+ TARO	0.25% **	N017856	001	
TOPICORT LP				
+ TARO	0.05% **	N018309	001	
GEL;TOPICAL				
TOPICORT				
+ TARO	0.05% **	N018586	001	Mar 29, 1982
OINTMENT;TOPICAL				
DESOXIMETASONE				
ALTANA	0.25%	A073440	001	Apr 01, 1998
PAI HOLDINGS PHARM	0.25%	A208101	001	Feb 25, 2016
TOPICORT				
TARO	0.25%	A074286	001	Jun 07, 1996
+	0.25% **	N018763	001	Sep 30, 1983

DESOXYCORTICOSTERONE ACETATE

INJECTABLE;INJECTION				
DOCA				
ORGANON USA INC	5MG/ML	N001104	001	
PELLET;IMPLANTATION				
PERCORTEN				
NOVARTIS	125MG	N005151	001	

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE;INJECTION				
PERCORTEN				
NOVARTIS	25MG/ML	N008822	001	

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL				
KHEDEZLA				
OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013
	100MG	N204683	002	Jul 10, 2013

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL				
DESVENLAFAXINE				
+ SUN PHARM	EQ 50MG BASE	N205583	001	Jan 28, 2014
+	EQ 100MG BASE	N205583	002	Jan 28, 2014
TEVA PHARMS USA	EQ 50MG BASE	N205208	001	Oct 11, 2013
	EQ 100MG BASE	N205208	002	Oct 11, 2013

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL				
DESVENLAFAXINE SUCCINATE				
MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015
	EQ 100MG BASE	A204095	002	Jun 29, 2015

DEXAMETHASONE

AEROSOL;TOPICAL				
AEROSEB-DEX				
ALLERGAN HERBERT	0.01% **	A083296	002	
DECASPRAY				
+ MERCK	0.04% **	N012731	002	
ELIXIR;ORAL				
DECADRON				
MERCK	0.5MG/5ML	N012376	002	
DEXAMETHASONE				
ALPHARMA US PHARMS	0.5MG/5ML	A088997	001	Oct 10, 1986
+ PHARMOBEDIENT CNSLTG	0.5MG/5ML	A088254	001	Jul 27, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXAMETHASONE				
ELIXIR;ORAL				
HEXADROL				
	ASPEN GLOBAL INC	0.5MG/5ML	N012674 001	
GEL;TOPICAL				
DECADERM				
	MERCK	0.1%	N013538 001	
SUSPENSION/DROPS;OPHTHALMIC				
DEXAMETHASONE				
	WATSON LABS	0.1%	A089170 001	May 09, 1989
TABLET;ORAL				
DECADRON				
+	MERCK	0.25MG **	N011664 004	
+		0.5MG **	N011664 001	
+		0.75MG **	N011664 002	
+		1.5MG **	N011664 003	
+		4MG **	N011664 005	
+		6MG **	N011664 006	Jul 30, 1982
DEXAMETHASONE				
	BAUSCH	1.5MG	A040700 001	Aug 15, 2008
	CHARTWELL RX	1.5MG	A085456 001	
	IMPAX LABS	0.75MG	A085376 001	
	PHOENIX LABS NY	0.75MG	A083806 001	
	PRASCO	0.75MG	A080399 001	
	PVT FORM	0.75MG	A083420 001	
	ROXANE	0.25MG	A084614 001	
	STRIDES PHARMA	0.25MG	A088149 001	Apr 28, 1983
	SUN PHARM INDUSTRIES	0.25MG	A084013 001	
		0.25MG	A084764 001	
		0.5MG	A084084 001	
		0.5MG	A084766 001	
		0.75MG	A084081 001	
		0.75MG	A084765 001	
		1.5MG	A084086 001	
		1.5MG	A084763 001	
	UPSHER SMITH	0.75MG	A087534 001	
		1.5MG	A087533 001	
	WATSON LABS	0.25MG	A085455 001	
		0.5MG	A085458 001	
		0.75MG	A080968 001	
		0.75MG	A084457 001	
		0.75MG	A085818 001	
		1.5MG	A085840 001	
	WHITEWORTH TOWN PLSN	0.75MG	A084327 001	
DEXONE 0.5				
	SOLVAY	0.5MG	A084991 001	
DEXONE 0.75				
	SOLVAY	0.75MG	A084993 001	
DEXONE 1.5				
	SOLVAY	1.5MG	A084990 001	
DEXONE 4				
	SOLVAY	4MG	A084992 001	
HEXADROL				
	ASPEN GLOBAL INC	0.5MG	N012675 004	
		0.75MG	N012675 007	
		1.5MG	N012675 009	
		4MG	N012675 010	
DEXAMETHASONE ACETATE				
INJECTABLE;INJECTION				
DECADRON-LA				
+	MERCK	EQ 8MG BASE/ML **	N016675 001	
DEXAMETHASONE ACETATE				
	WATSON LABS	EQ 8MG BASE/ML	A084315 001	
	WATSON LABS TEVA	EQ 16MG BASE/ML	A087711 001	May 24, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL;NASAL				
DEXACORT				
	UCB INC	EQ 0.1MG PHOSPHATE/INH	N014242 001	
AEROSOL, METERED;INHALATION				
DEXACORT				
	UCB INC	EQ 0.1MG PHOSPHATE/INH	N013413 001	
CREAM;TOPICAL				
DECADRON				
	MERCK	EQ 0.1% PHOSPHATE	N011983 002	
INJECTABLE;INJECTION				
DECADRON				
+	MERCK	EQ 4MG PHOSPHATE/ML **	N012071 002	
+		EQ 24MG PHOSPHATE/ML **	N012071 004	
DEXACEN-4				
	CENT PHARMS	EQ 4MG PHOSPHATE/ML	A084342 001	
DEXAMETHASONE				
	ABRAXIS PHARM	EQ 4MG PHOSPHATE/ML	A088448 001	Jan 25, 1984
	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A088469 001	Jan 25, 1984
DEXAMETHASONE SODIUM PHOSPHATE				
	AKORN	EQ 4MG PHOSPHATE/ML	A084493 001	
	BEL MAR	EQ 4MG PHOSPHATE/ML	A084752 001	
	DELL LABS	EQ 4MG PHOSPHATE/ML	A083161 001	
	DR REDDYS	EQ 4MG PHOSPHATE/ML	A089169 001	Apr 09, 1986
	INTL MEDICATION	EQ 20MG PHOSPHATE/ML	A088522 001	Feb 17, 1984
+	LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440 001	Jul 21, 1982
	LYPHOMED	EQ 4MG PHOSPHATE/ML	A087065 001	
	TEVA PARENTERAL	EQ 4MG PHOSPHATE/ML	A081125 001	Aug 31, 1990
		EQ 10MG PHOSPHATE/ML	A081126 001	Aug 31, 1990
	WATSON LABS	EQ 4MG PHOSPHATE/ML	A083702 001	
		EQ 4MG PHOSPHATE/ML	A084355 001	
		EQ 10MG PHOSPHATE/ML	A087668 001	Jul 01, 1982
		EQ 24MG PHOSPHATE/ML	A085606 001	
	WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641 001	
HEXADROL				
+	ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML **	N014694 002	
+		EQ 10MG PHOSPHATE/ML **	N014694 003	
		EQ 20MG PHOSPHATE/ML	N014694 004	
OINTMENT;OPHTHALMIC				
DECADRON				
	MERCK	EQ 0.05% PHOSPHATE	N011977 001	
DEXAIR				
	PHARMAFAIR	EQ 0.05% PHOSPHATE	A088071 001	Dec 28, 1982
MAXIDEX				
	ALCON	EQ 0.05% PHOSPHATE	A083342 001	
SOLUTION/DROPS;OPHTHALMIC				
DEXAIR				
	PHARMAFAIR	EQ 0.1% PHOSPHATE	A088433 001	Dec 15, 1983
DEXAMETHASONE SODIUM PHOSPHATE				
	SOLA BARNES HIND	EQ 0.1% PHOSPHATE	A084170 001	
		EQ 0.1% PHOSPHATE	A084173 001	
SOLUTION/DROPS;OPHTHALMIC, OTIC				
DECADRON				
+	MERCK	EQ 0.1% PHOSPHATE	N011984 001	
DEXAMETHASONE SODIUM PHOSPHATE				
	SANDOZ	EQ 0.1% PHOSPHATE	A088771 001	Jan 16, 1985
SOLUTION/DROPS;OTIC				
DEXAMETHASONE SODIUM PHOSPHATE				
	AKORN	EQ 0.1% PHOSPHATE	A084855 001	

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
DECADRON W/ XYLOCAINE				
	MERCK	EQ 4MG PHOSPHATE/ML;10MG/ML	N013334 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT;OPHTHALMIC				
NEODECADRON				
	MERCK	EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM	N050324 001	
SOLUTION/DROPS;OPHTHALMIC				
NEODECADRON				
	MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N050322 001	
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE				
	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A064055 001	Oct 30, 1995
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE				
	ALCON PHARMS LTD	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062714 001	Jul 21, 1986
	PHARMAFAIR	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062539 001	Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
DEXACIDIN				
	NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062566 001	Feb 22, 1985
DEXASPORIN				
	PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062411 001	May 16, 1983
SUSPENSION/DROPS;OPHTHALMIC				
DEXACIDIN				
	NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062544 001	Oct 29, 1984
DEXASPORIN				
	PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062428 001	May 18, 1983
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE				
	ALCON PHARMS LTD	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062721 001	Nov 17, 1986

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC				
TOBRAMYCIN AND DEXAMETHASONE				
	AMNEAL	0.1%;0.3%	A212991 001	Jul 15, 2021

DEXBROMPHENIRAMINE MALEATE

SYRUP;ORAL				
DISOMER				
	SCHERING	2MG/5ML	N011814 002	
TABLET;ORAL				
DISOMER				
	SCHERING	2MG	N011814 001	

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET;ORAL				
DISOPHROL				
	SCHERING	2MG;60MG	N012394 002	
TABLET, EXTENDED RELEASE;ORAL				
BROMPHERIL				
	COPLEY PHARM	6MG;120MG	A089116 001	Jan 22, 1987
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE				
	AVANTHI INC	6MG;120MG	A078648 001	Feb 27, 2013
DISOBROM				
	SANDOZ	6MG;120MG	A070770 001	Sep 30, 1991
DISOPHROL				
	SCHERING PLOUGH	6MG;120MG	N013483 004	Sep 13, 1982
DRIXORAL				
+	SCHERING PLOUGH	6MG;120MG **	N013483 003	Sep 13, 1982
RESPORAL				
	PIONEER PHARMS	6MG;120MG	A089139 001	Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL				
POLARAMINE				
	SCHERING	2MG/5ML	A086837 001	Jul 19, 1982
TABLET;ORAL				
DEXCHLORPHENIRAMINE MALEATE				
	ANI PHARMS	2MG	A088682 001	Jan 17, 1986
POLARAMINE				
+	SCHERING	2MG	A086835 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

DEXILANT SOLUTAB					
+	TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE					
	AM REGENT	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017
	PIRAMAL CRITICAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A214794	001	Sep 03, 2021
	SLAYBACK PHARMA LLC	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A212791	003	May 08, 2020

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE					
	AUROLIFE PHARMA LLC	5MG	A204266	001	Aug 25, 2015
		10MG	A204266	002	Aug 25, 2015
		15MG	A204266	003	Aug 25, 2015
		20MG	A204266	004	Dec 21, 2015
		25MG	A204266	005	May 04, 2021
		30MG	A202580	001	Aug 28, 2013
		35MG	A204266	006	May 04, 2021
		40MG	A204266	007	Aug 25, 2015

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE					
	BIONPHARMA	5MG	A209754	001	Mar 24, 2020
		10MG	A209754	002	Mar 24, 2020
	LANNETT CO INC	2.5MG	A209468	001	Sep 25, 2017
		5MG	A209468	002	Sep 25, 2017
		10MG	A209468	003	Sep 25, 2017
	TEVA PHARMS	2.5MG	A077107	003	Jan 29, 2007
		5MG	A077107	001	Jan 29, 2007
		10MG	A077107	002	Jan 29, 2007

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

TOTECT					
+	CLINIGEN	EQ 500MG BASE/VIAL **	N022025	001	Sep 06, 2007
ZINECARD					
+	PFIZER	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995
+		EQ 500MG BASE/VIAL	N020212	002	May 26, 1995

DEXTROAMPHETAMINE SULFATE

CAPSULE;ORAL

DEXAMPEX					
	TEVA	15MG	A085355	001	

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE					
	ABLE	5MG	A076814	001	Aug 25, 2004
		10MG	A076814	002	Aug 25, 2004
		15MG	A076814	003	Aug 25, 2004
	DR REDDYS LABS SA	5MG	A076137	001	Jan 18, 2002
		10MG	A076137	002	Jan 18, 2002
		15MG	A076137	003	Jan 18, 2002
	MYLAN	5MG	A206735	001	Jan 27, 2016
		10MG	A206735	002	Jan 27, 2016
		15MG	A206735	003	Jan 27, 2016
	NESHER PHARMS	5MG	A209111	001	Jun 27, 2017
		10MG	A209111	002	Jun 27, 2017
		15MG	A209111	003	Jun 27, 2017
	STRIDES PHARMA	5MG	A205077	001	Jun 21, 2019
		10MG	A205077	002	Jun 21, 2019
		15MG	A205077	003	Jun 21, 2019

ELIXIR;ORAL

DEXEDRINE					
	GLAXOSMITHKLINE	5MG/5ML **	A083902	001	

TABLET;ORAL

DEXAMPEX					
	TEVA	5MG	A083735	001	
		10MG	A083735	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL				
DEXEDRINE				
+	GLAXOSMITHKLINE	5MG **	A084935 001	
DEXTROAMPHETAMINE SULFATE				
	ANI PHARMS	5MG	A085370 001	
	EPIC PHARMA LLC	5MG	A090652 001	Mar 07, 2014
		10MG	A090652 002	Mar 07, 2014
	HALSEY	10MG	A083930 001	
	LANNETT	5MG	A083903 001	
		10MG	A083903 003	
		15MG	A085652 001	
	MAST MM	5MG	A086521 001	
	NESHER PHARMS	5MG	A040365 001	Oct 31, 2002
		5MG	A206588 001	Mar 28, 2016
		10MG	A040367 001	Oct 31, 2002
		10MG	A206588 002	Mar 28, 2016
	PUREPAC PHARM	5MG	A084125 001	
	SANDOZ	10MG	A085371 001	
	STRIDES PHARMA	5MG	A040299 001	May 13, 1999
	VITARINE	5MG	A084986 001	
		10MG	A085892 001	
DEXTROSTAT				
+	SHIRE	5MG **	A084051 001	
+		10MG **	A084051 002	
FERNDEX				
	FERNDALE LABS	5MG	A084001 001	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL				
PHERAZINE DM				
	HALSEY	15MG/5ML;6.25MG/5ML	A088913 001	Mar 02, 1987
PROMETH W/ DEXTROMETHORPHAN				
	G AND W LABS INC	15MG/5ML;6.25MG/5ML **	A088762 001	Oct 31, 1984
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE				
+	ANI PHARMS	15MG/5ML;6.25MG/5ML **	N011265 002	Apr 02, 1984
	HIKMA	15MG/5ML;6.25MG/5ML	A040027 001	Jul 31, 1996

DEXTROSE

INJECTABLE;INJECTION				
DEXTROSE 10% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML	N018046 001	
	MILES	10GM/100ML	N018504 001	
DEXTROSE 2.5% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML	N018358 001	
		2.5GM/100ML	N019626 001	Feb 02, 1988
DEXTROSE 20% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	20GM/100ML **	N017521 004	
DEXTROSE 30% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	30GM/100ML **	N017521 003	
DEXTROSE 38.5% IN PLASTIC CONTAINER				
	ABBOTT	38.5GM/100ML	N018923 001	Sep 19, 1984
DEXTROSE 40% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	40GM/100ML **	N017521 002	
DEXTROSE 5% IN PLASTIC CONTAINER				
	DHL	5GM/100ML	N019971 001	Sep 28, 1995
+	ICU MEDICAL INC	50MG/ML	N019222 001	Jul 13, 1984
DEXTROSE 50% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	50GM/100ML **	N017521 001	
	ICU MEDICAL INC	50GM/100ML	N019894 001	Dec 26, 1989
DEXTROSE 60%				
	B BRAUN	60GM/100ML	N017995 002	Sep 22, 1982
DEXTROSE 60% IN PLASTIC CONTAINER				
	B BRAUN	60GM/100ML	N017995 001	
+	BAXTER HLTHCARE	60GM/100ML **	N017521 005	Mar 26, 1982
		60GM/100ML	N020047 002	Jul 02, 1991
	HOSPIRA	60GM/100ML	N019346 001	Jan 25, 1985
DEXTROSE 7.7% IN PLASTIC CONTAINER				
	B BRAUN	7.7GM/100ML	N019626 003	Feb 02, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 70% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	70GM/100ML **	N017521	006	Mar 26, 1982

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML;32MG/100ML;128MG/100ML;234MG/100ML	N017385	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019025	001	Dec 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML;100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML	N019515	001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N019844	001	Jun 10, 1993

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N018273	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019843	001	Aug 09, 1993

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018274	001	

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017451	001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;37MG/100ML	N019699	001	Sep 29, 1989

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;75MG/100ML	N018744	001	Nov 09, 1982
		5GM/100ML;75MG/100ML	N019699	002	Sep 29, 1989

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;110MG/100ML	N019699	003	Sep 29, 1989

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;150MG/100ML	N018744	002	Nov 09, 1982

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;220MG/100ML	N018744	003	Nov 09, 1982
		5GM/100ML;220MG/100ML	N019699	005	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;300MG/100ML	N018744	004	Nov 09, 1982

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML;224MG/100ML	N018371	003	

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML;298MG/100ML	N018371	002	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML;146MG/100ML;207MG/100ML	N019514	001	May 08, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG /100ML;91MG/100ML	N019870 001	Jun 10, 1993	

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG /100ML;91MG/100ML	N018270 001		

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;120MG /100ML;220MG/100ML	N018840 001	Jun 29, 1983	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N018268 009		

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N018268 004		

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N018268 005		

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N018268 006		

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N018268 011	Jan 18, 1986	

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N018268 012	Jan 18, 1986	

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N018268 013	Jan 18, 1986	

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N018268 014	Jan 18, 1986	

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N018268 010		

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N018268 001		

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N018268 002		

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N018268 003		

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008 003		

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 001		

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008 002		

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML **	N018365 002	Jul 05, 1983	
+		5GM/100ML;149MG/100ML;225MG/100ML **	N018365 006	Mar 28, 1988	

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876 001	Jan 17, 1986	
	5GM/100ML;149MG/100ML;300MG/100ML	N018876 006	Mar 28, 1988	

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 002	Mar 24, 1988	
+		5GM/100ML;149MG/100ML;900MG/100ML	N019691 004	Mar 24, 1988	

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML **	N018365 008	Mar 28, 1988	

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876 007	Mar 28, 1988	

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

+	ICU MEDICAL INC	5GM/100ML;224MG/100ML;450MG/100ML	N018362 006	Mar 28, 1988	

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML	N019691 006	Mar 24, 1988	

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+	ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML **	N018365 009	Mar 28, 1988	

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N018876 008	Mar 28, 1988	

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

+	ICU MEDICAL INC	5GM/100ML;298MG/100ML;450MG/100ML	N018362 007	Mar 28, 1988	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML;298MG/100ML;900MG/100ML	N019691	008	Mar 24, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;149MG/100ML;300MG/100ML	N018876	002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML **	N018365	003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876	003	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML	N019691	007	Mar 24, 1988
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML **	N018365	004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N018876	004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML **	N018365	005	Mar 28, 1988
		5GM/100ML;149MG/100ML;225MG/100ML **	N018365	007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	005	Mar 28, 1988
		5GM/100ML;149MG/100ML;300MG/100ML	N018876	009	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988
+		5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	001	Mar 24, 1988
+		5GM/100ML;149MG/100ML;900MG/100ML	N019691	003	Mar 24, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER					
	B BRAUN	10GM/100ML;200MG/100ML	N018386	001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	B BRAUN	10GM/100ML;450MG/100ML	N018229	001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	10GM/100ML;900MG/100ML	N018047	001	
	BAXTER HLTHCARE	10GM/100ML;900MG/100ML	N016696	001	
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	B BRAUN	2.5GM/100ML;450MG/100ML	N018030	001	
	HOSPIRA	2.5GM/100ML;450MG/100ML	N018096	001	
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	2.5GM/100ML;900MG/100ML	N018376	001	
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ABBOTT	3.3GM/100ML;300MG/100ML	N018055	001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;110MG/100ML	N018030	005	
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;200MG/100ML	N018030	004	
	MILES	5GM/100ML;200MG/100ML	N018399	001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ABBOTT	5GM/100ML;225MG/100ML	N019482	001	Oct 04, 1985
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ABBOTT	5GM/100ML;300MG/100ML	N019486	001	Oct 04, 1985
	MILES	5GM/100ML;300MG/100ML	N018501	001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;330MG/100ML	N018030	003	
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	ABBOTT	5GM/100ML;450MG/100ML	N019484	001	Oct 04, 1985
	B BRAUN	5GM/100ML;450MG/100ML	N018030	002	
	MILES	5GM/100ML;450MG/100ML	N018400	001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	ABBOTT	5GM/100ML;900MG/100ML	N019483	001	Oct 04, 1985
	B BRAUN	5GM/100ML;900MG/100ML	N018026	001	
	MILES	5GM/100ML;900MG/100ML	N018500	001	

DEXTROTHYROXINE SODIUM				
TABLET;ORAL				
CHOLOXIN				
ABBVIE	1MG		N012302 005	
	2MG		N012302 002	
	4MG		N012302 004	
	6MG		N012302 006	
DEZOCINE				
INJECTABLE;INJECTION				
DALGAN				
ASTRAZENECA	5MG/ML		N019082 001	Dec 29, 1989
	10MG/ML		N019082 002	Dec 29, 1989
	15MG/ML		N019082 003	Dec 29, 1989
DIATRIZOATE MEGLUMINE				
INJECTABLE;INJECTION				
ANGIOVIST 282				
BAYER HLTHCARE	60%		A087726 001	Sep 23, 1982
CARDIOGRAFIN				
BRACCO	85%		N011620 002	
DIATRIZOATE MEGLUMINE				
BRACCO	76%		N010040 017	
HYPAQUE				
GE HEALTHCARE	30%		N016403 002	
	60%		N016403 001	
RENO-60				
BRACCO	60%		N010040 016	
RENO-DIP				
BRACCO	30%		N010040 012	
UROVIST MEGLUMINE DIU/CT				
BAYER HLTHCARE	30%		A087739 001	Sep 23, 1982
SOLUTION;URETERAL				
RENO-30				
BRACCO	30%		N010040 021	
UROVIST CYSTO				
BAYER HLTHCARE	30%		A087729 001	Sep 23, 1982
UROVIST CYSTO PEDIATRIC				
BAYER HLTHCARE	30%		A087731 001	Sep 23, 1982
SOLUTION;URETHRAL				
HYPAQUE-CYSTO				
GE HEALTHCARE	30%		N016403 003	
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM				
INJECTABLE;INJECTION				
ANGIOVIST 292				
BAYER HLTHCARE	52%;8%		A087724 001	Sep 23, 1982
ANGIOVIST 370				
BAYER HLTHCARE	66%;10%		A087723 001	Sep 23, 1982
DIATRIZOATE-60				
INTL MEDICATION	52%;8%		A088166 001	Jun 17, 1983
HYPAQUE-76				
GE HEALTHCARE	66%;10%		A086505 001	
HYPAQUE-M,75%				
GE HEALTHCARE	50%;25%		N010220 003	
HYPAQUE-M,90%				
GE HEALTHCARE	60%;30%		N010220 002	
MD-60				
MALLINCKRODT	52%;8%		A087074 001	
MD-76				
MALLINCKRODT	66%;10%		A087073 001	
MD-76R				
+ LIEBEL-FLARSHEIM	66%;10%		N019292 001	Sep 29, 1989
RENOCAL-76				
BRACCO	66%;10%		A089347 001	Jun 01, 1988
RENOGRAFIN-60				
BRACCO	52%;8%		N010040 006	
RENOGRAFIN-76				
+ BRACCO	66%;10%		N010040 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM				
INJECTABLE;INJECTION				
RENOVIST				
	BRACCO	34.3%;35%	N010040 020	
RENOVIST II				
	BRACCO	28.5%;29.1%	N010040 019	
SOLUTION;ORAL, RECTAL				
GASTROVIST				
	BAYER HLTHCARE	66%;10%	A087728 001	Sep 23, 1982
DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE				
SOLUTION;INTRAUTERINE				
SINOGRAFIN				
+	BRACCO	52.7%;26.8%	N011324 002	
DIATRIZOATE SODIUM				
FOR SOLUTION;ORAL, RECTAL				
HYPAQUE				
	GE HEALTHCARE	100%	N011386 001	
INJECTABLE;INJECTION				
HYPAQUE				
	GE HEALTHCARE	25%	N009561 003	
		50%	N009561 001	
MD-50				
	MALLINCKRODT	50%	A087075 001	
UROVIST SODIUM 300				
	BAYER HLTHCARE	50%	A087725 001	Sep 23, 1982
SOLUTION;ORAL, RECTAL				
HYPAQUE				
	GE HEALTHCARE	40%	N011386 003	
SOLUTION;URETERAL				
HYPAQUE SODIUM 20%				
	GE HEALTHCARE	20%	N009561 002	
DIAZEPAM				
CAPSULE, EXTENDED RELEASE;ORAL				
VALRELEASE				
	ROCHE	15MG	N018179 001	
GEL;RECTAL				
DIASTAT				
+	BAUSCH	5MG/ML (5MG/ML) **	N020648 002	Jul 29, 1997
+		10MG/2ML (5MG/ML) **	N020648 003	Jul 29, 1997
+		15MG/3ML (5MG/ML) **	N020648 004	Jul 29, 1997
+		20MG/4ML (5MG/ML) **	N020648 005	Jul 29, 1997
INJECTABLE;INJECTION				
DIAZEPAM				
	ABRAXIS PHARM	5MG/ML	A070662 001	Jun 25, 1986
	HIKMA	5MG/ML	A070312 001	Dec 16, 1985
		5MG/ML	A071308 001	Jul 17, 1987
		5MG/ML	A071309 001	Jul 17, 1987
		5MG/ML	A071310 001	Jul 17, 1987
	HOSPIRA	5MG/ML	A071584 001	Oct 13, 1987
	MARSAM PHARMS LLC	5MG/ML	A072371 001	Jan 29, 1993
	PARENTA PHARMS	5MG/ML	A076815 001	Apr 15, 2004
	US ARMY	5MG/ML **	N020124 001	Dec 05, 1990
	WARNER CHILCOTT	5MG/ML	A071613 001	Oct 22, 1987
		5MG/ML	A071614 001	Oct 22, 1987
	WATSON LABS	5MG/ML	A070296 001	Feb 12, 1986
		5MG/ML	A070911 001	Aug 28, 1986
		5MG/ML	A070912 001	Aug 28, 1986
		5MG/ML	A070930 001	Dec 01, 1986
	WATSON LABS INC	5MG/ML	A072370 001	Jan 29, 1993
		5MG/ML	A072397 001	Jan 29, 1993
DIZAC				
	PHARMACIA AND UPJOHN	5MG/ML **	N019287 001	Jun 18, 1993
VALIUM				
+	ROCHE	5MG/ML **	N016087 001	
TABLET;ORAL				
DIAZEPAM				
	ACTAVIS ELIZABETH	2MG	A070781 001	Mar 19, 1986
		5MG	A070706 001	Mar 19, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIAZEPAM

TABLET;ORAL				
DIAZEPAM				
	10MG	A070707	001	Mar 19, 1986
BARR	2MG	A070152	001	Nov 01, 1985
	10MG	A070154	001	Nov 01, 1985
CHARTWELL RX	2MG	A070302	001	Dec 20, 1985
	5MG	A070303	001	Dec 20, 1985
	10MG	A070304	001	Dec 20, 1985
DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985
	5MG	A070228	003	Sep 26, 1985
	10MG	A070228	001	Sep 26, 1985
DURAMED PHARMS BARR	2MG	A070894	001	Aug 27, 1986
	5MG	A070895	001	Aug 27, 1986
	10MG	A070896	001	Aug 27, 1986
FERNDALE LABS	2MG	A070903	001	Apr 01, 1987
	5MG	A070904	001	Apr 01, 1987
	10MG	A070905	001	Apr 01, 1987
HALSEY	2MG	A070987	001	Aug 15, 1986
	5MG	A070996	001	Aug 15, 1986
	10MG	A070956	001	Aug 15, 1986
IVAX SUB TEVA PHARMS	2MG	A070360	001	Sep 04, 1985
	5MG	A070361	001	Sep 04, 1985
	10MG	A070362	001	Sep 04, 1985
MARTEC USA LLC	10MG	A072402	001	Apr 25, 1989
PIONEER PHARMS	2MG	A070787	001	Aug 02, 1988
	5MG	A070788	001	Aug 02, 1988
	10MG	A070776	001	Aug 02, 1988
ROXANE	2MG	A070356	001	Jun 17, 1986
	5MG	A070357	001	Jun 17, 1986
	10MG	A070358	001	Jun 17, 1986
TEVA PHARMS	5MG	A070153	001	Nov 01, 1985
VIRTUS	2MG	A070462	001	Feb 25, 1986
	5MG	A070463	001	Feb 25, 1986
WARNER CHILCOTT	2MG	A070209	001	Sep 04, 1985
	5MG	A070210	001	Sep 04, 1985
	10MG	A070222	001	Sep 04, 1985
WATSON LABS	2MG	A070456	001	Nov 01, 1985
	5MG	A070457	001	Nov 01, 1985
	10MG	A070458	001	Nov 01, 1985
Q-PAM				
QUANTUM PHARMICS	2MG	A070423	001	Dec 12, 1985
	2MG	A072431	001	Apr 29, 1988
	5MG	A070424	001	Dec 12, 1985
	5MG	A072432	001	Apr 29, 1988
	10MG	A070425	001	Dec 12, 1985
	10MG	A072433	001	Apr 29, 1988

DIAZOXIDE

CAPSULE;ORAL				
PROGLYCEM				
TEVA BRANDED PHARM	50MG	N017425	001	
	100MG	N017425	002	
INJECTABLE;INJECTION				
DIAZOXIDE				
ABRAXIS PHARM	15MG/ML	A071519	001	Aug 26, 1987
HYPERSTAT				
SCHERING	15MG/ML	N016996	001	

DIBUCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
HEAVY SOLUTION NUPERCAINE				
NOVARTIS	2.5MG/ML	N006203	001	

DICHLORPHENAMIDE

TABLET;ORAL				
DARANIDE				
+ XERIS	50MG **	N011366	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DICLOFENAC					
CAPSULE;ORAL					
ZORVOLEX					
+	ZYLA	18MG **	N204592	001	Oct 18, 2013
+		35MG	N204592	002	Oct 18, 2013
DICLOFENAC POTASSIUM					
TABLET;ORAL					
CATAFLAM					
+	NOVARTIS	25MG **	N020142	001	Nov 24, 1993
+		50MG **	N020142	002	Nov 24, 1993
DICLOFENAC POTASSIUM					
	CHARTWELL RX	50MG	A075582	001	Feb 23, 2001
	SUN PHARM INDUSTRIES	50MG	A075470	001	Feb 21, 2002
	WATSON LABS TEVA	50MG	A075152	001	Nov 27, 1998
DICLOFENAC SODIUM					
GEL;TOPICAL					
SOLARAZE					
+	FOUGERA PHARMS	3% **	N021005	001	Oct 16, 2000
SOLUTION;INTRAVENOUS					
DICLOFENAC SODIUM					
	RISING	37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019
DYLOJECT					
+	JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML) **	N022396	001	Dec 23, 2014
SOLUTION;TOPICAL					
DICLOFENAC SODIUM					
	APOTEX	1.5%	A202027	001	May 27, 2014
	PAI HOLDINGS PHARM	1.5%	A202769	001	Jul 08, 2015
	RISING	1.5%	A206715	001	Aug 07, 2017
	TWI PHARMS	1.5%	A202393	001	Nov 24, 2014
PENNSAID					
+	NUVO PHARMS INC	1.5% **	N020947	001	Nov 04, 2009
SOLUTION/DROPS;OPHTHALMIC					
DICLOFENAC SODIUM					
	AKORN	0.1%	A077845	001	Apr 17, 2008
	FALCON PHARMS	0.1%	N020809	001	May 04, 1998
VOLTAREN					
+	NOVARTIS	0.1%	N020037	001	Mar 28, 1991
TABLET, DELAYED RELEASE;ORAL					
DICLOFENAC SODIUM					
	AUROBINDO PHARMA USA	50MG	A075281	002	Feb 12, 2002
		75MG	A075281	003	Feb 12, 2002
	CHARTWELL RX	25MG	A074376	001	Sep 28, 1995
		50MG	A074376	002	Sep 28, 1995
		75MG	A074394	001	Nov 30, 1995
	MICRO LABS	50MG	A074986	001	Feb 26, 1999
		75MG	A074986	002	Feb 26, 1999
	PLIVA	50MG	A074432	002	Jul 29, 1999
		75MG	A074432	003	Jul 29, 1999
	ROXANE	25MG	A074391	001	Jun 29, 1995
		50MG	A074391	002	Jun 29, 1995
		75MG	A074391	003	Jun 29, 1995
	TEVA	50MG	A074723	001	Mar 30, 1999
		75MG	A074390	001	Aug 15, 1996
	TEVA PHARMS	25MG	A074459	001	Jun 25, 1997
		50MG	A074459	002	Jun 25, 1997
		75MG	A074459	003	Jun 25, 1997
VOLTAREN					
+	NOVARTIS	25MG **	N019201	001	Jul 28, 1988
+		50MG **	N019201	002	Jul 28, 1988
+		75MG **	N019201	003	Jul 28, 1988
TABLET, EXTENDED RELEASE;ORAL					
DICLOFENAC SODIUM					
	ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002
	AUROBINDO PHARMA USA	100MG	A076152	001	Dec 13, 2001
VOLTAREN-XR					
+	NOVARTIS	100MG **	N020254	001	Mar 08, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL				
DICLOFENAC SODIUM AND MISOPROSTOL				
EXELA HOLDINGS	50MG;0.2MG	A200540	001	Mar 14, 2014
	75MG;0.2MG	A200540	002	Mar 14, 2014
ZYDUS PHARMS	50MG;0.2MG	A206771	001	Jun 12, 2023
	75MG;0.2MG	A206771	002	Jun 12, 2023

DICLOXACILLIN SODIUM

CAPSULE;ORAL				
DICLOXACILLIN SODIUM				
SANDOZ	EQ 125MG BASE	A061454	002	
	EQ 250MG BASE	A061454	001	
	EQ 500MG BASE	A061454	003	
DYCILL				
GLAXOSMITHKLINE	EQ 250MG BASE	A060254	002	
	EQ 250MG BASE	A062238	001	
	EQ 500MG BASE	A060254	003	
	EQ 500MG BASE	A062238	002	
PATHOCIL				
+ WYETH AYERST	EQ 250MG BASE **	N050011	002	
+	EQ 500MG BASE **	N050011	003	Mar 28, 1983
FOR SUSPENSION;ORAL				
DICLOXACILLIN SODIUM				
APOTHECON	EQ 62.5MG BASE/5ML	A061455	001	
DYNAPEN				
APOTHECON	EQ 62.5MG BASE/5ML	N050337	002	
PATHOCIL				
WYETH AYERST	EQ 62.5MG BASE/5ML	N050092	001	

DICUMAROL

CAPSULE;ORAL				
DICUMAROL				
LILLY	25MG	N005509	003	
	50MG	N005509	001	
TABLET;ORAL				
DICUMAROL				
ABBVIE	25MG	N005545	003	
	50MG	N005545	004	
	100MG	N005545	005	

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL				
BENTYL				
+ ALLERGAN	10MG **	N007409	003	Oct 15, 1984
DICYCLOMINE HYDROCHLORIDE				
PIONEER PHARMS	10MG	A089361	001	Jan 10, 1989
SUN PHARM INDUSTRIES	10MG	A084505	001	Oct 21, 1986
WATSON LABS	10MG	A083179	001	Feb 12, 1986
INJECTABLE;INJECTION				
DICYCLOMINE HYDROCHLORIDE				
DR REDDYS	10MG/ML	A080614	001	Feb 11, 1986
HIKMA	10MG/ML	A210788	001	Feb 11, 2019
PRAXGEN PHARMS	10MG/ML	A212058	001	Apr 26, 2019
RENEW PHARMS	10MG/ML	A207084	001	May 04, 2018
SYRUP;ORAL				
BENTYL				
+ APTALIS PHARMA US	10MG/5ML **	N007961	002	Oct 15, 1984
DICYCLOMINE HYDROCHLORIDE				
ALPHARMA US PHARMS	10MG/5ML	A084479	001	
TABLET;ORAL				
BENTYL				
+ ALLERGAN	20MG **	N007409	001	Oct 15, 1984
DICYCLOMINE HYDROCHLORIDE				
PIONEER PHARMS	20MG	A088585	001	Aug 20, 1986
SUN PHARM INDUSTRIES	20MG	A084600	001	Jul 29, 1985
WATSON LABS	20MG	A084361	001	Feb 06, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL				
DIDANOSINE				
AUROBINDO PHARMA	125MG	A090094	001	Sep 24, 2008
	200MG	A090094	002	Sep 24, 2008
	250MG	A090094	003	Sep 24, 2008
	400MG	A090094	004	Sep 24, 2008
BARR	200MG	A077167	001	Dec 03, 2004
	250MG	A077167	002	Dec 03, 2004
	400MG	A077167	003	Dec 03, 2004
MYLAN PHARMS INC	125MG	A090788	001	Apr 08, 2010
	200MG	A090788	002	Apr 08, 2010
	250MG	A090788	003	Apr 08, 2010
	400MG	A090788	004	Apr 08, 2010
VIDEX EC				
+ BRISTOL MYERS SQUIBB	125MG **	N021183	001	Oct 31, 2000
+	200MG **	N021183	002	Oct 31, 2000
+	250MG **	N021183	003	Oct 31, 2000
+	400MG **	N021183	004	Oct 31, 2000
FOR SOLUTION;ORAL				
DIDANOSINE				
AUROBINDO PHARMA	10MG/ML	A078112	001	Mar 08, 2007
VIDEX				
+ BRISTOL	10MG/ML	N020156	001	Oct 09, 1991
BRISTOL MYERS SQUIBB	100MG/PACKET	N020155	003	Oct 09, 1991
	167MG/PACKET	N020155	004	Oct 09, 1991
	250MG/PACKET	N020155	005	Oct 09, 1991
	375MG/PACKET	N020155	006	Oct 09, 1991
TABLET, CHEWABLE;ORAL				
VIDEX				
+ BRISTOL MYERS SQUIBB	25MG **	N020154	002	Oct 09, 1991
+	50MG **	N020154	003	Oct 09, 1991
+	100MG **	N020154	004	Oct 09, 1991
+	150MG **	N020154	005	Oct 09, 1991
+	200MG **	N020154	006	Oct 28, 1999
TABLET, FOR SUSPENSION;ORAL				
DIDANOSINE				
AUROBINDO	100MG	A077275	001	Aug 14, 2012
	150MG	A077275	002	Aug 14, 2012
	200MG	A077275	003	Aug 14, 2012

DIENESTROL

CREAM;VAGINAL				
DIENESTROL				
ORTHO MCNEIL PHARM	0.01%	N006110	005	
DV				
SANOFI AVENTIS US	0.01%	A083518	001	
ESTRAGUARD				
SOLVAY	0.01%	A084436	001	
SUPPOSITORY;VAGINAL				
DV				
SANOFI AVENTIS US	0.7MG	A083517	001	

DIETHYLCARBAMAZINE CITRATE

TABLET;ORAL				
HETRAZAN				
LEDERLE	50MG	N006459	001	

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL				
DIETHYLPROPION HYDROCHLORIDE				
CHARTWELL RX	25MG	A088267	001	Aug 25, 1983
	25MG	A088268	001	Aug 25, 1983
EPIC PHARMA LLC	25MG	A040828	001	Nov 05, 2008
SANDOZ	25MG	A085916	001	
TEVA	25MG	A088642	001	Sep 20, 1984
UCB INC	25MG	A085544	001	
WATSON LABS	25MG	A085741	001	
TENUATE				
+ NOSTRUM LABS INC	25MG **	N011722	002	
SANOFI AVENTIS US	25MG	N017668	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIETHYLPROPION HYDROCHLORIDE			
TABLET;ORAL			
TEPANIL			
3M	25MG		N011673 001
TABLET, EXTENDED RELEASE;ORAL			
TENUATE			
SANOFI AVENTIS US	75MG		N017669 001
TENUATE DOSPAN			
+ NOSTRUM LABS INC	75MG **		N012546 001
TEPANIL TEN-TAB			
3M	75MG		N017956 001
DIETHYLSTILBESTROL			
INJECTABLE;INJECTION			
STILBESTROL			
BRISTOL MYERS SQUIBB	0.2MG/ML		N004056 003
	0.5MG/ML		N004056 004
	1MG/ML		N004056 005
	5MG/ML		N004056 006
SUPPOSITORY;VAGINAL			
DIETHYLSTILBESTROL			
LILLY	0.1MG		N004040 001
	0.5MG		N004040 002
STILBESTROL			
BRISTOL MYERS SQUIBB	0.1MG		N004056 001
	0.5MG		N004056 002
TABLET;ORAL			
DIETHYLSTILBESTROL			
LILLY	0.1MG		N004041 002
	0.5MG		N004041 003
	1MG		N004041 004
	5MG		N004041 005
STILBESTROL			
TABLICAPS	0.5MG		A083004 001
	1MG		A083002 001
	5MG		A083006 001
STILBETIN			
BRISTOL MYERS SQUIBB	0.1MG		N004056 007
	0.25MG		N004056 017
	0.5MG		N004056 008
	1MG		N004056 009
	5MG		N004056 010
TABLET, DELAYED RELEASE;ORAL			
DIETHYLSTILBESTROL			
LILLY	0.1MG		N004039 002
	0.25MG		N004039 005
	0.5MG		N004039 003
	1MG		N004039 004
	5MG		N004039 006
STILBESTROL			
TABLICAPS	0.5MG		A083003 001
	1MG		A083005 001
	5MG		A083007 001
STILBETIN			
BRISTOL MYERS SQUIBB	0.1MG		N004056 011
	0.5MG		N004056 012
	1MG		N004056 013
	5MG		N004056 014
DIETHYLSTILBESTROL DIPHOSPHATE			
INJECTABLE;INJECTION			
STILPHOSTROL			
BAYER PHARMS	250MG/5ML		N010010 001
TABLET;ORAL			
STILPHOSTROL			
BAYER PHARMS	50MG		N010010 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIFLORASONE DIACETATE				
CREAM;TOPICAL				
DIFLORASONE DIACETATE				
AVONDALE PHARMS	0.05%	A075187	001	Mar 30, 1998
FLORONE				
PFIZER	0.05% **	N017741	001	
FLORONE E				
PFIZER	0.05%	N019259	001	Aug 28, 1985
PSORCON				
+ TARO PHARMS NORTH	0.05% **	N020205	001	Nov 20, 1992
OINTMENT;TOPICAL				
DIFLORASONE DIACETATE				
AKORN	0.05%	A206572	001	Jul 24, 2015
PSORCON				
+ PFIZER	0.05%	N019260	001	Aug 28, 1985
PSORCON E				
PFIZER	0.05%	N017994	001	
DIFLUNISAL				
TABLET;ORAL				
DIFLUNISAL				
ANI PHARMS	500MG	A074604	001	Jun 10, 1996
DASTECH INTL	250MG	A073562	001	Nov 27, 1992
	500MG	A073563	001	Nov 27, 1992
PUREPAC PHARM	250MG	A074285	001	May 07, 1996
	500MG	A074285	002	May 07, 1996
TEVA	250MG	A073679	001	Jul 31, 1992
WATSON LABS	250MG	A074400	001	Jul 17, 1997
	500MG	A074400	002	Jul 17, 1997
DOLOBID				
+ MERCK	250MG **	N018445	001	Apr 19, 1982
+	500MG **	N018445	002	Apr 19, 1982
DIGITOXIN				
INJECTABLE;INJECTION				
CRYSTODIGIN				
LILLY	0.2MG/ML	A084100	005	
DIGOXIN				
CAPSULE;ORAL				
LANOXICAPS				
GLAXOSMITHKLINE LLC	0.05MG	N018118	002	Jul 26, 1982
	0.1MG	N018118	003	Jul 26, 1982
	0.15MG	N018118	004	Sep 24, 1984
	0.2MG	N018118	001	Jul 26, 1982
INJECTABLE;INJECTION				
DIGOXIN				
ABRAXIS PHARM	0.25MG/ML	A083217	001	
HOSPIRA	0.25MG/ML	A040093	001	May 16, 1996
	0.25MG/ML	A040206	001	Aug 28, 1998
WYETH AYERST	0.25MG/ML	A084386	001	
DIGOXIN PEDIATRIC				
HOSPIRA	0.1MG/ML	A040092	001	Apr 25, 1996
TABLET;ORAL				
LANOXIN				
+ CONCORDIA	0.1875MG	N020405	003	Sep 30, 1997
	0.375MG	N020405	005	Sep 30, 1997
	0.5MG	N020405	006	Sep 30, 1997
DIHYDROERGOTAMINE MESYLATE				
INJECTABLE;INJECTION				
D.H.E. 45				
+ BAUSCH	1MG/ML **	N005929	001	
DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
EMBOLEX				
NOVARTIS	0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5ML	N018885	001	Nov 30, 1984
	0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7ML	N018885	002	Nov 30, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
CARDIZEM SR					
+	BIOVAIL	60MG **	N019471	001	Jan 23, 1989
+		90MG **	N019471	002	Jan 23, 1989
+		120MG **	N019471	003	Jan 23, 1989
+		180MG **	N019471	004	Jan 23, 1989
DILACOR XR					
+	ALLERGAN	120MG **	N020092	001	May 29, 1992
+		180MG **	N020092	002	May 29, 1992
+		240MG **	N020092	003	May 29, 1992
DILT-CD					
	APOTEX	120MG	A076151	001	May 20, 2004
		180MG	A076151	002	May 20, 2004
		240MG	A076151	003	May 20, 2004
		300MG	A076151	004	May 20, 2004
DILTIAZEM HYDROCHLORIDE					
	ACTAVIS LABS FL INC	120MG	A074852	001	Oct 10, 1997
		180MG	A074852	002	Oct 10, 1997
		240MG	A074852	003	Oct 10, 1997
	BIOVAIL	60MG	A074845	001	Sep 15, 1999
		90MG	A074845	002	Sep 15, 1999
		120MG	A074845	003	Sep 15, 1999
		120MG	N020939	001	Jan 28, 2000
		180MG	N020939	002	Jan 28, 2000
		240MG	N020939	003	Jan 28, 2000
		300MG	N020939	004	Jan 28, 2000
		360MG	N020939	005	Sep 14, 2001
		420MG	N020939	006	Sep 14, 2001
	MYLAN	120MG	A075124	002	Mar 18, 1998
		180MG	A075124	003	Mar 18, 1998
		240MG	A075124	001	Mar 18, 1998
	NESHER PHARMS	120MG	A076563	002	Sep 12, 2006
		180MG	A076563	003	Sep 12, 2006
		240MG	A076563	004	Sep 12, 2006
		300MG	A076563	005	Sep 12, 2006
		360MG	A076563	006	Sep 12, 2006
		420MG	A076563	001	Sep 12, 2006
	PAR PHARM	360MG	A209766	001	May 30, 2018
	SUN PHARM	120MG	A090492	001	Oct 28, 2011
		180MG	A090492	002	Oct 28, 2011
		240MG	A090492	003	Oct 28, 2011
		300MG	A090492	004	Oct 28, 2011
	TEVA	60MG	A074079	001	Nov 30, 1993
		90MG	A074079	002	Nov 30, 1993
		120MG	A074079	003	Nov 30, 1993
DILTZAC					
	APOTEX	120MG	A076395	001	Feb 01, 2006
		180MG	A076395	002	Feb 01, 2006
		240MG	A076395	003	Feb 01, 2006
		300MG	A076395	004	Feb 01, 2006
		360MG	A076395	005	Feb 01, 2006
INJECTABLE;INJECTION					
CARDIZEM					
	BIOVAIL	100MG/VIAL **	N020792	001	Sep 05, 1997
+	BIOVAIL LABS INTL	5MG/ML **	N020027	001	Oct 24, 1991
+		25MG/VIAL **	N020027	003	Aug 18, 1995
DILTIAZEM HYDROCHLORIDE					
	DR REDDYS	5MG/ML	A074894	001	Aug 26, 1997
	HOSPIRA	5MG/ML	A075004	001	Feb 16, 2000
		5MG/ML	A075106	001	Apr 29, 1999
	INTL MEDICATION	5MG/ML	A075749	001	Nov 21, 2001
	MYLAN LABS LTD	5MG/ML	A075375	001	Sep 30, 1999
SOLUTION;INTRAVENOUS					
DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%					
+	EXELA PHARMA	125MG/125ML (1MG/ML)	N215252	001	Oct 28, 2021
+		250MG/250ML (1MG/ML)	N215252	002	Oct 28, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DILTIAZEM HYDROCHLORIDE

TABLET;ORAL

DILTIAZEM HYDROCHLORIDE

APOTHECON	30MG	A074051	001	Mar 31, 1993
	60MG	A074051	002	Mar 31, 1993
	90MG	A074051	003	Mar 31, 1993
	120MG	A074051	004	Mar 31, 1993
CHARTWELL MOLECULES	30MG	A074093	001	Nov 05, 1992
	60MG	A074093	002	Nov 05, 1992
	90MG	A074093	003	Nov 05, 1992
	120MG	A074093	004	Nov 05, 1992
EDENBRIDGE PHARMS	30MG	A211596	001	Nov 18, 2019
	60MG	A211596	002	Nov 18, 2019
	90MG	A211596	003	Nov 18, 2019
	120MG	A211596	004	Nov 18, 2019
IVAX SUB TEVA PHARMS	30MG	A074168	001	Mar 03, 1995
	60MG	A074168	002	Mar 03, 1995
	90MG	A074168	003	Mar 03, 1995
	120MG	A074168	004	Mar 03, 1995
RISING	30MG	A072838	004	Nov 05, 1992
	60MG	A072838	003	Nov 05, 1992
	90MG	A072838	002	Nov 05, 1992
	120MG	A072838	001	Nov 05, 1992
TEVA	30MG	A074084	001	Feb 25, 1994
	60MG	A074084	002	Feb 25, 1994
TEVA PHARMS	30MG	A074067	001	Nov 05, 1992
	60MG	A074067	002	Nov 05, 1992
	90MG	A074067	003	Nov 05, 1992
	120MG	A074067	004	Nov 05, 1992

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE;ORAL

TIAMATE

MERCK	EQ 120MG HYDROCHLORIDE	N020506	001	Oct 04, 1996
	EQ 180MG HYDROCHLORIDE	N020506	002	Oct 04, 1996
	EQ 240MG HYDROCHLORIDE	N020506	003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE;ORAL

TECZEM

BIOVAIL	EQ 180MG HYDROCHLORIDE;5MG	N020507	001	Oct 04, 1996

DIMENHYDRINATE

INJECTABLE;INJECTION

DIMENHYDRINATE

BAXTER HLTHCARE	50MG/ML	A084767	001
WATSON LABS	50MG/ML	A083531	001
+ WATSON LABS TEVA	50MG/ML	A080615	001
WYETH AYERST	50MG/ML	A084316	001

LIQUID;ORAL

DIMENHYDRINATE

ALRA	12.5MG/4ML	A080715	001

TABLET;ORAL

DIMENHYDRINATE

HEATHER	50MG	A080841	001
NEXGEN PHARMA INC	50MG	A085985	001
+ WATSON LABS	50MG	A085166	001

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

SAWAI USA	120MG	A210285	001	Dec 21, 2021
	240MG	A210285	002	Dec 21, 2021
ZYDUS PHARMS	120MG	A210538	001	Sep 24, 2020
	240MG	A210538	002	Sep 24, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIMETHYL SULFOXIDE				
SOLUTION;INTRAVESICAL				
DIMETHYL SULFOXIDE				
MYLAN INSTITUTIONAL	50%	A076185	001	Nov 29, 2002
DIMYRISTOYL LECITHIN; PERFLEXANE				
INJECTABLE;INTRAVENOUS				
IMAGENT				
VESSELON SPV LLC	0.92MG/VIAL;0.092MG/VIAL	N021191	001	May 31, 2002
DINOPROST TROMETHAMINE				
INJECTABLE;INJECTION				
PROSTIN F2 ALPHA				
PHARMACIA AND UPJOHN	EQ 5MG BASE/ML	N017434	001	
DINOPROSTONE				
SUPPOSITORY;VAGINAL				
PROSTIN E2				
+ PFIZER	20MG	N017810	001	
DIPHEMANIL METHYLSULFATE				
TABLET;ORAL				
PRANTAL				
SCHERING	100MG	N008114	004	
DIPHENHYDRAMINE HYDROCHLORIDE				
CAPSULE;ORAL				
BENADRYL				
MCNEIL CONS	25MG	N005845	007	
	50MG	N005845	001	
DIPHENHYDRAMINE HYDROCHLORIDE				
ALRA	25MG	A080519	004	
	50MG	A080519	003	
ANABOLIC	50MG	A083275	001	
ELKINS SINN	25MG	A085701	001	
	50MG	A085701	002	
FOSUN PHARMA	25MG	A080832	001	
	25MG	A080845	002	
	50MG	A080832	002	
	50MG	A080845	001	
HALSEY	50MG	A087914	001	Jun 04, 1984
HEATHER	25MG	A084524	001	
	50MG	A083953	001	
HERITAGE PHARMA	50MG	A080727	001	
	50MG	A080738	001	
HIKMA INTL PHARMS	50MG	A083567	001	
IMPAX LABS	25MG	A080807	001	
	50MG	A080807	002	
IVAX SUB TEVA PHARMS	25MG	A080762	001	
	50MG	A080762	002	
LANNETT	25MG	A080868	001	
	50MG	A080868	002	
LEDERLE	25MG	A086874	001	
	50MG	A086875	001	
LNK	25MG	A087977	001	Jan 27, 1983
	50MG	A087978	001	Jan 27, 1983
MK LABS	25MG	A083087	001	
	50MG	A083087	002	
MUTUAL PHARM	25MG	A084506	001	
NEWTRON PHARMS	25MG	A086543	001	
	50MG	A086544	001	
NEXGEN PHARMA INC	25MG	A083634	001	
PERRIGO	25MG	A083061	001	
	50MG	A083061	002	
PIONEER PHARMS	25MG	A089101	001	Dec 20, 1985
	50MG	A088880	001	Dec 20, 1985
PUREPAC PHARM	25MG	A085156	001	
	50MG	A085150	001	
PVT FORM	25MG	A083027	001	
	50MG	A083027	002	
ROXANE	50MG	A080635	001	
SUN PHARM INDUSTRIES	25MG	A089488	001	Jan 02, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
DIPHENHYDRAMINE HYDROCHLORIDE				
	50MG	A089489	001	Jan 02, 1987
SUPERPHARM	25MG	A089040	001	May 15, 1985
	50MG	A089041	001	May 15, 1985
TEVA	25MG	A085874	001	
	50MG	A085874	002	
VALEANT PHARM INTL	25MG	A080596	001	
	50MG	A080592	001	
VANGARD	25MG	A088034	001	Oct 27, 1982
	50MG	A087630	001	
WATSON LABS	25MG	A080728	001	
	25MG	A083797	001	
	25MG	A085138	001	
	50MG	A083797	002	
	50MG	A085083	001	
WHITEWORTH TOWN PLSN	25MG	A083441	001	
	50MG	A080800	001	
ELIXIR;ORAL				
BELIX				
HALSEY	12.5MG/5ML	A086586	001	Oct 03, 1983
BENADRYL				
MCNEIL CONS	12.5MG/5ML	N005845	004	
DIBENIL				
CENCI	12.5MG/5ML	A088304	001	Dec 16, 1983
DIPHEN				
USL PHARMA	12.5MG/5ML	A084640	001	
DIPHENHYDRAMINE HYDROCHLORIDE				
BUNDY	12.5MG/5ML	A083674	001	
CENCI	12.5MG/5ML	A087941	001	Dec 17, 1982
KV PHARM	12.5MG/5ML	A085621	001	
LANNETT	12.5MG/5ML	A080939	002	
LEDERLE	12.5MG/5ML	A086937	001	
MK LABS	12.5MG/5ML	A083088	002	
NASKA	12.5MG/5ML	A088680	001	May 31, 1985
PERRIGO	12.5MG/5ML	A083063	001	
PUREPAC PHARM	12.5MG/5ML	A083237	001	Jan 25, 1982
PVT FORM	12.5MG/5ML	A085287	001	
ROXANE	12.5MG/5ML	A080643	001	
HYDRAMINE				
ALPHARMA US PHARMS	12.5MG/5ML	A080763	002	
INJECTABLE;INJECTION				
BENADRYL				
MCNEIL CONS	10MG/ML	N006146	001	
+	50MG/ML **	N006146	002	
BENADRYL PRESERVATIVE FREE				
+ MCNEIL CONS	50MG/ML **	N009486	001	
DIPHENHYDRAMINE HYDROCHLORIDE				
BEL MAR	10MG/ML	A080822	001	
DR REDDYS	10MG/ML	A080873	001	
	50MG/ML	A080873	002	
EUROHLTH INTL SARL	50MG/ML	A083183	001	
HOSPIRA	50MG/ML	A040140	001	Nov 20, 1998
LYPHOMED	10MG/ML	A087066	001	
WATSON LABS	10MG/ML	A083533	001	
WYETH AYERST	50MG/ML	A080577	001	
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE				
ABRAXIS PHARM	50MG/ML	A080586	002	
DR REDDYS	50MG/ML	A080873	003	
INTL MEDICATION	50MG/ML	A084094	001	
SYRUP;ORAL				
ANTITUSSIVE				
PERRIGO	12.5MG/5ML	A071292	001	Apr 10, 1987
BELDIN				
HALSEY	12.5MG/5ML	A089179	001	Jun 05, 1986
BENYLIN				
PARKE DAVIS	12.5MG/5ML	N006514	004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP;ORAL				
DIPHEN				
	MORTON GROVE	12.5MG/5ML	A070118 001	Oct 01, 1985
DIPHENHYDRAMINE HYDROCHLORIDE				
	AKORN	12.5MG/5ML	A072416 001	Sep 28, 1990
	ALPHARMA US PHARMS	12.5MG/5ML	A070497 001	Apr 25, 1989
	CUMBERLAND SWAN	12.5MG/5ML	A073611 001	Aug 20, 1992
HYDRAMINE				
	ALPHARMA US PHARMS	12.5MG/5ML	A070205 001	Jan 28, 1986
SILPHEN				
	LANNETT CO INC	12.5MG/5ML	A072646 001	Feb 27, 1992
VICKS FORMULA 44				
	WARNER CHILCOTT	12.5MG/5ML	A070524 001	Jan 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL				
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE				
	P AND L	25MG;220MG	A207597 001	Jan 25, 2019

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL				
BENYLIN				
	PARKE DAVIS	12.5MG/5ML;30MG/5ML	N019014 001	Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET;ORAL				
VONTROL				
	GLAXOSMITHKLINE	EQ 25MG BASE	N016033 001	

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
HISPRIL				
	GLAXOSMITHKLINE	5MG	N011945 001	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
AKPRO				
	EPIC PHARMA LLC	0.1%	A074382 001	Sep 29, 1995
DIPIVEFRIN HYDROCHLORIDE				
	BAUSCH AND LOMB	0.1%	A074188 001	May 19, 1995
	FALCON PHARMS	0.1%	A073636 001	Jun 30, 1994
PROPINE				
	ALLERGAN	0.1%	N018239 001	

DIPYRIDAMOLE

INJECTABLE;INJECTION				
DIPYRIDAMOLE				
	DR REDDYS	5MG/ML	A074952 001	Nov 26, 1997
	EUGIA PHARMA SPECLTS	5MG/ML	A075769 001	Nov 27, 2002
	FRESENIUS KABI USA	5MG/ML	A074956 001	Sep 30, 1998
	HOSPIRA	5MG/ML	A074601 001	Dec 19, 1997
IV PERSANTINE				
+	BOEHRINGER INGELHEIM	5MG/ML **	N019817 001	Dec 13, 1990
TABLET;ORAL				
DIPYRIDAMOLE				
	ANDA REPOSITORY	25MG	A040898 001	Apr 23, 2008
		50MG	A040898 002	Apr 23, 2008
		75MG	A040898 003	Apr 23, 2008
	ANI PHARMS	25MG	A086944 002	Apr 16, 1991
		50MG	A086944 001	Feb 25, 1992
		75MG	A086944 003	Feb 25, 1992
	GLENMARK GENERICS	25MG	A088999 001	Feb 05, 1991
		50MG	A089000 001	Feb 05, 1991
		75MG	A089001 001	Feb 05, 1991
	PUREPAC PHARM	25MG	A089425 001	Jul 12, 1990
		50MG	A089426 001	Jul 12, 1990
		75MG	A089427 001	Jul 12, 1990
	WATSON LABS	50MG	A087160 001	Jun 07, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIRITHROMYCIN

TABLET, DELAYED RELEASE;ORAL				
DYNABAC				
LILLY RES LABS	250MG	N050678	001	Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL				
DISOPYRAMIDE PHOSPHATE				
INTERPHARM	EQ 100MG BASE	A071190	001	Jan 15, 1987
	EQ 150MG BASE	A071191	001	Jan 15, 1987
IVAX SUB TEVA PHARMS	EQ 100MG BASE	A070186	001	Nov 18, 1985
	EQ 150MG BASE	A070187	001	Nov 18, 1985
MYLAN	EQ 100MG BASE	A070138	001	Jun 14, 1985
	EQ 150MG BASE	A070139	001	Jun 14, 1985
RISING	EQ 100MG BASE	A070470	001	Dec 10, 1985
	EQ 150MG BASE	A070471	001	Dec 10, 1985
SUN PHARM INDUSTRIES	EQ 100MG BASE	A070351	001	Dec 17, 1985
	EQ 150MG BASE	A070352	001	Dec 17, 1985
SUPERPHARM	EQ 100MG BASE	A070940	001	Feb 09, 1987
	EQ 150MG BASE	A070941	001	Feb 09, 1987
WATSON LABS	EQ 100MG BASE	A070240	001	Feb 02, 1986
	EQ 150MG BASE	A070241	001	Feb 02, 1986
CAPSULE, EXTENDED RELEASE;ORAL				
DISOPYRAMIDE PHOSPHATE				
NESHER PHARMS	EQ 150MG BASE	A071200	001	Dec 15, 1987

DISULFIRAM

TABLET;ORAL				
ANTABUSE				
+ ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983
+	500MG	A088483	001	Dec 08, 1983
+ TEVA WOMENS	250MG **	N007883	003	
+	500MG **	N007883	002	
DISULFIRAM				
DASH PHARMS	250MG	A203916	001	Mar 04, 2015
	500MG	A203916	002	Mar 04, 2015
HIKMA	250MG	A202652	001	Feb 05, 2014
	500MG	A202652	002	Feb 05, 2014
STRIDES PHARMA	250MG	A088792	001	Aug 14, 1984
	500MG	A088793	001	Aug 14, 1984
WATSON LABS	250MG	A086889	001	
	250MG	A087973	001	Aug 05, 1983
	500MG	A087974	001	Aug 05, 1983
WATSON LABS TEVA	500MG	A086890	001	

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL				
DIVALPROEX SODIUM				
RISING	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011
TEVA PHARMS USA	EQ 125MG VALPROIC ACID	A211505	001	Nov 17, 2020
TABLET, DELAYED RELEASE;ORAL				
DEPAKOTE CP				
ABBOTT	EQ 250MG BASE	N019794	001	Jul 11, 1990
	EQ 500MG BASE	N019794	002	Jul 11, 1990
DIVALPROEX SODIUM				
ACTAVIS LABS FL INC	EQ 500MG VALPROIC ACID	A079080	001	Feb 25, 2011
ANCHEN PHARMS	EQ 500MG VALPROIC ACID	A078411	001	Nov 03, 2008
MYLAN	EQ 125MG VALPROIC ACID	A077254	001	Jul 29, 2008
	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009
	EQ 250MG VALPROIC ACID	A077254	002	Jul 29, 2008
	EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009
	EQ 500MG VALPROIC ACID	A077254	003	Jul 29, 2008
	EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009
TEVA	EQ 125MG VALPROIC ACID	A076941	001	Jul 29, 2008
	EQ 250MG VALPROIC ACID	A076941	002	Jul 29, 2008
	EQ 500MG VALPROIC ACID	A076941	003	Jul 29, 2008
TABLET, EXTENDED RELEASE;ORAL				
DIVALPROEX SODIUM				
AMTA	EQ 250MG VALPROIC ACID	A214462	001	Mar 15, 2021
	EQ 500MG VALPROIC ACID	A214462	002	Mar 15, 2021
ANCHEN PHARMS	EQ 250MG VALPROIC ACID	A078445	001	Feb 26, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

	EQ 500MG VALPROIC ACID	A078445	002	Aug 04, 2009
COSETTE	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009
IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009
	EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

BAXTER HLTHCARE	EQ 12.5MG BASE/ML	A074381	001	Sep 26, 1996
DR REDDYS	EQ 12.5MG BASE/ML	A074995	001	Mar 31, 1998
HOSPIRA	EQ 12.5MG BASE/ML	A074292	001	Feb 16, 1995
	EQ 1.25GM BASE/100ML	A074634	001	Sep 27, 1996
LUITPOLD	EQ 12.5MG BASE/ML	A074545	001	Jun 25, 1998
TELIGENT	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995
TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206	001	Oct 19, 1993
WATSON LABS	EQ 12.5MG BASE/ML	A074114	001	Nov 30, 1993
WATSON LABS INC	EQ 12.5MG BASE/ML	A074279	001	Feb 18, 1998

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA	EQ 50MG BASE/100ML	N020269	001	Oct 19, 1993
	EQ 100MG BASE/100ML	N020269	002	Oct 19, 1993
	EQ 200MG BASE/100ML	N020269	003	Oct 19, 1993

DOBUTREX

+	LILLY	EQ 12.5MG BASE/ML **	N017820	002	

DOCETAXEL

INJECTABLE;INJECTION

DOCEFREZ

+	SUN PHARM	20MG/VIAL	N022534	001	May 03, 2011
+		80MG/VIAL	N022534	002	May 03, 2011

DOCETAXEL

+	ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011
+		80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011
	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012
		80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012
	DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20, 2017
		80MG/4ML (20MG/ML)	A206177	002	Jan 20, 2017
		200MG/10ML (20MG/ML)	A206177	003	Jan 20, 2017
	HENGRUI PHARMA	40MG/ML	A203170	001	Feb 15, 2017
+	HOSPIRA INC	120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016
	MYLAN LABS LTD	20MG/ML (20MG/ML)	A203892	001	May 11, 2023
		80MG/4ML (20MG/ML)	A203892	002	May 11, 2023
	NOVAST LABS	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017
	PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014
		80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014
		130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014
		200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014
	TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015
		80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015

TAXOTERE

+	SANOFI AVENTIS US	40MG/ML **	N020449	001	May 14, 1996

SOLUTION;INTRAVENOUS

DOCETAXEL

+	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022
+		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022
+		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

NOVAST LABS	0.125MG	A212410	001	Dec 27, 2019
	0.25MG	A212410	002	Dec 27, 2019
	0.5MG	A212410	003	Dec 27, 2019
PRINSTON INC	0.125MG	A211223	001	Dec 17, 2019
	0.25MG	A211223	002	Dec 17, 2019
	0.5MG	A211223	003	Dec 17, 2019
RK PHARMA	0.125MG	A215323	001	Apr 14, 2022
	0.25MG	A215323	002	Apr 14, 2022
	0.5MG	A215323	003	Apr 14, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOFETILIDE					
CAPSULE;ORAL					
DOFETILIDE					
	TEVA PHARMS USA	0.125MG	A210018	001	Apr 15, 2022
		0.25MG	A210018	002	Apr 15, 2022
		0.5MG	A210018	003	Apr 15, 2022
DOLASETRON MESYLATE					
INJECTABLE;INJECTION					
ANZEMET					
+	VALIDUS PHARMS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997
		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001
TABLET;ORAL					
ANZEMET					
+	VALIDUS PHARMS	100MG	N020623	002	Sep 11, 1997
DONEPEZIL HYDROCHLORIDE					
SOLUTION;ORAL					
ARICEPT					
+	EISAI INC	5MG/5ML	N021719	001	Oct 18, 2004
TABLET;ORAL					
DONEPEZIL HYDROCHLORIDE					
	ACCORD HLTHCARE	5MG	A201335	001	Aug 29, 2011
		10MG	A201335	002	Aug 29, 2011
	ACTAVIS ELIZABETH	23MG	A202415	001	Dec 17, 2015
	APOTEX	5MG	A078841	001	Jun 02, 2011
		10MG	A078841	002	Jun 02, 2011
	CHARTWELL RX	23MG	A203419	001	Apr 12, 2016
	HERITAGE PHARMA	5MG	A077344	001	May 31, 2011
		10MG	A077344	002	May 31, 2011
	HIKMA PHARMS	5MG	A090247	001	May 31, 2011
		10MG	A090247	002	May 31, 2011
	HISUN PHARM HANGZHOU	23MG	A202410	001	Mar 24, 2017
	MYLAN PHARMS INC	5MG	A090521	001	May 31, 2011
		10MG	A090521	002	May 31, 2011
	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016
	PAR PHARM	23MG	A202542	001	Jul 24, 2013
	RISING	23MG	A202656	001	Oct 22, 2015
	SANDOZ	5MG	A090290	001	May 31, 2011
		10MG	A090290	002	May 31, 2011
	SUN PHARM	23MG	A204293	001	Jun 05, 2015
	SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010
		10MG	A076786	002	Nov 26, 2010
	UNICHEM	5MG	A203656	001	Jun 23, 2016
		10MG	A203656	002	Jun 23, 2016
	WOCKHARDT	5MG	A091267	001	May 31, 2011
		10MG	A091267	002	May 31, 2011
TABLET, ORALLY DISINTEGRATING;ORAL					
ARICEPT ODT					
+	EISAI INC	5MG	N021720	001	Oct 18, 2004
+		10MG	N021720	002	Oct 18, 2004
DONEPEZIL HYDROCHLORIDE					
	CHARTWELL RX	5MG	A078388	002	Nov 26, 2010
		10MG	A078388	001	Nov 26, 2010
	SUN PHARM INDUSTRIES	5MG	A077975	002	Dec 11, 2009
		10MG	A077975	001	Dec 11, 2009
	UNICHEM	5MG	A204831	001	Nov 10, 2016
		10MG	A204831	002	Nov 10, 2016
	ZYDUS PHARMS USA INC	5MG	A090175	001	May 10, 2011
		10MG	A090175	002	May 10, 2011
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE					
CAPSULE, EXTENDED RELEASE;ORAL					
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE					
	AMNEAL PHARMS	10MG;14MG	A208328	001	Jan 27, 2017
		10MG;28MG	A208328	002	Jan 27, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

	ABBOTT	40MG/ML	A070656	001	Jan 24, 1989
		80MG/ML	A070657	001	Jan 24, 1989
	ABRAXIS PHARM	40MG/ML	A070012	001	Jun 12, 1985
		40MG/ML	A070058	001	Mar 20, 1985
		80MG/ML	A070013	001	Jun 12, 1985
		80MG/ML	A070059	001	Mar 20, 1985
		160MG/ML	A070364	001	Dec 04, 1985
	AM REGENT	40MG/ML	A070799	001	Feb 11, 1987
		80MG/ML	A070820	001	Feb 11, 1987
		160MG/ML	A070826	001	Feb 11, 1987
	BAXTER HLTHCARE	40MG/ML	N018398	001	
		80MG/ML	N018398	002	Mar 22, 1982
	HOSPIRA	40MG/ML	A074403	001	May 23, 1996
	IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985
		80MG/ML	A070089	001	Oct 23, 1985
		80MG/ML	A070090	001	Oct 23, 1985
		80MG/ML	A070091	001	Oct 23, 1985
		160MG/ML	A070092	001	Oct 23, 1985
		160MG/ML	A070093	001	Oct 23, 1985
		160MG/ML	A070094	001	Oct 23, 1985
	INTL MEDICATION	40MG/ML	N018014	001	
	LYPHOMED	40MG/ML	N018549	001	Mar 11, 1983
	SMITH AND NEPHEW	40MG/ML	A070011	001	Aug 29, 1985
		40MG/ML	A070046	001	Aug 29, 1985
		80MG/ML	A070047	001	Aug 29, 1985
	TELIGENT	40MG/ML	N018656	001	Jun 28, 1983
	TEVA PARENTERAL	40MG/ML	A072999	001	Oct 23, 1991
		80MG/ML	A073000	001	Oct 23, 1991
	WARNER CHILCOTT	40MG/ML	A070558	001	Sep 20, 1985
		40MG/ML	N018138	001	
		80MG/ML	A070559	001	Sep 20, 1985

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

+	B BRAUN	80MG/100ML	N019099	002	Oct 15, 1986
+		320MG/100ML	N019099	004	Oct 15, 1986

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

+	B BRAUN	40MG/100ML	N019099	001	Oct 15, 1986
+		160MG/100ML	N019099	003	Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%

	HOSPIRA	1.6MG/ML	N020542	001	Aug 30, 1995

INTROPIN

	HOSPIRA	40MG/ML	N017395	001	
		80MG/ML	N017395	002	
		160MG/ML	N017395	003	

DORIPENEM

INJECTABLE;INTRAVENOUS

DORIBAX

+	SHIONOGI INC	250MG/VIAL **	N022106	002	Oct 05, 2010
+		500MG/VIAL **	N022106	001	Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

	AM REGENT	EQ 2% BASE	A079186	001	Nov 18, 2009
	TEVA PHARMS	EQ 2% BASE	A078756	001	Dec 04, 2008
	ZAMBON SPA	EQ 2% BASE	A091034	001	Dec 04, 2013

TRUSOPT

+	MSD SUB MERCK	EQ 2% BASE **	N020408	001	Dec 09, 1994

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

	CHARTWELL MOLECULAR	EQ 2% BASE;EQ 0.5% BASE	A201998	001	Dec 17, 2014
	RUBICON	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008
	TEVA PHARMS	EQ 2% BASE;EQ 0.5% BASE	A078704	001	Sep 28, 2009
	ZAMBON SPA	EQ 2% BASE;EQ 0.5% BASE	A091180	001	Dec 04, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXACURIUM CHLORIDE

INJECTABLE;INJECTION

NUROMAX

ABBVIE	EQ 1MG BASE/ML	N019946	001	Mar 07, 1991

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOXAPRAM HYDROCHLORIDE

WATSON LABS	20MG/ML	A073529	001	Jan 30, 1992

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH	EQ 1MG BASE	A075574	001	Oct 18, 2000
	EQ 2MG BASE	A075574	002	Oct 18, 2000
	EQ 4MG BASE	A075574	003	Oct 18, 2000
	EQ 8MG BASE	A075574	004	Oct 18, 2000
ANI PHARMS	EQ 1MG BASE	A075432	001	Oct 18, 2000
	EQ 2MG BASE	A075432	002	Oct 18, 2000
	EQ 4MG BASE	A075432	003	Oct 18, 2000
	EQ 8MG BASE	A075432	004	Oct 18, 2000
AUROBINDO PHARMA USA	EQ 1MG BASE	A075509	001	Oct 19, 2000
	EQ 2MG BASE	A075509	002	Oct 19, 2000
	EQ 4MG BASE	A075509	003	Oct 19, 2000
	EQ 8MG BASE	A075509	004	Oct 19, 2000
CHARTWELL RX	EQ 1MG BASE	A075646	001	Oct 18, 2000
	EQ 2MG BASE	A075646	002	Oct 18, 2000
	EQ 4MG BASE	A075646	003	Oct 18, 2000
	EQ 8MG BASE	A075646	004	Oct 18, 2000
GENPHARM	EQ 1MG BASE	A075466	001	Oct 18, 2000
	EQ 2MG BASE	A075466	002	Oct 18, 2000
	EQ 4MG BASE	A075466	003	Oct 18, 2000
	EQ 8MG BASE	A075466	004	Oct 18, 2000
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075453	001	Oct 18, 2000
	EQ 2MG BASE	A075453	002	Oct 18, 2000
	EQ 4MG BASE	A075453	003	Oct 18, 2000
	EQ 8MG BASE	A075453	004	Oct 18, 2000
NESHER PHARMS	EQ 1MG BASE	A075609	001	Oct 18, 2000
	EQ 2MG BASE	A075609	002	Oct 18, 2000
	EQ 4MG BASE	A075609	003	Oct 18, 2000
	EQ 8MG BASE	A075609	004	Oct 18, 2000
PLIVA	EQ 1MG BASE	A075750	001	Jun 08, 2001
	EQ 2MG BASE	A075750	002	Jun 08, 2001
	EQ 4MG BASE	A075750	003	Jun 08, 2001
	EQ 8MG BASE	A075750	004	Jun 08, 2001
STRIDES PHARMA	EQ 1MG BASE	A076161	001	Jun 10, 2004
	EQ 2MG BASE	A076161	002	Jun 10, 2004
	EQ 4MG BASE	A076161	003	Jun 10, 2004
	EQ 8MG BASE	A076161	004	Jun 10, 2004
TEVA	EQ 1MG BASE	A075353	001	Jan 12, 2001
	EQ 2MG BASE	A075353	002	Jan 12, 2001
	EQ 4MG BASE	A075353	003	Jan 12, 2001
	EQ 8MG BASE	A075353	004	Jan 12, 2001
WATSON LABS INC	EQ 1MG BASE	A075426	001	Oct 18, 2000
	EQ 2MG BASE	A075426	002	Oct 18, 2000
	EQ 4MG BASE	A075426	003	Oct 18, 2000
	EQ 8MG BASE	A075426	004	Oct 18, 2000

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

DAVA PHARMS INC	EQ 10MG BASE	A071685	001	Jan 05, 1988
	EQ 25MG BASE	A071686	001	Jan 05, 1988
	EQ 50MG BASE	A071673	001	Jan 05, 1988
	EQ 75MG BASE	A071674	001	Jan 05, 1988
	EQ 100MG BASE	A071675	001	Jan 05, 1988
	EQ 150MG BASE	A071676	001	Jan 05, 1988
LANNETT CO INC	EQ 10MG BASE	A212997	001	Jul 24, 2020
	EQ 25MG BASE	A212997	002	Jul 24, 2020
	EQ 50MG BASE	A212997	003	Jul 24, 2020
	EQ 75MG BASE	A212997	004	Jul 24, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL					
DOXEPIN HYDROCHLORIDE					
		EQ 100MG BASE	A212997	005	Jul 24, 2020
	NEW RIVER	EQ 10MG BASE	N016987	001	
		EQ 25MG BASE	N016987	002	
		EQ 50MG BASE	N016987	003	
		EQ 75MG BASE	N016987	006	
		EQ 100MG BASE	N016987	004	
		EQ 150MG BASE	N016987	007	Apr 13, 1987
	PAR PHARM	EQ 10MG BASE	A071422	002	Nov 09, 1987
		EQ 25MG BASE	A071422	003	Nov 09, 1987
		EQ 50MG BASE	A071422	004	Nov 09, 1987
		EQ 75MG BASE	A071422	005	Nov 09, 1987
		EQ 100MG BASE	A071422	001	Nov 09, 1987
	PUREPAC PHARM	EQ 10MG BASE	A073054	001	Dec 28, 1990
		EQ 25MG BASE	A072109	001	Dec 28, 1990
		EQ 50MG BASE	A073055	001	Dec 28, 1990
		EQ 75MG BASE	A072386	001	Sep 08, 1988
		EQ 100MG BASE	A072110	001	Sep 08, 1988
		EQ 150MG BASE	A072387	001	Sep 08, 1988
	QUANTUM PHARMICS	EQ 10MG BASE	A070972	001	Sep 29, 1987
		EQ 25MG BASE	A070973	001	Sep 29, 1987
		EQ 50MG BASE	A070931	001	Sep 29, 1987
		EQ 75MG BASE	A070932	001	Sep 29, 1987
		EQ 100MG BASE	A072375	001	Mar 15, 1989
		EQ 150MG BASE	A072376	001	Mar 15, 1989
	SANDOZ	EQ 10MG BASE	A071487	001	Mar 02, 1987
		EQ 25MG BASE	A070827	001	May 15, 1986
		EQ 50MG BASE	A070828	001	May 15, 1986
		EQ 75MG BASE	A070825	001	May 15, 1986
		EQ 100MG BASE	A071562	001	Mar 02, 1987
	SUN PHARM INDUSTRIES	EQ 25MG BASE	A071502	001	Feb 18, 1988
		EQ 50MG BASE	A071653	001	Feb 18, 1988
		EQ 75MG BASE	A071654	001	Feb 18, 1988
		EQ 100MG BASE	A071521	001	Feb 18, 1988
	WATSON LABS	EQ 10MG BASE	A070952	001	Mar 04, 1987
		EQ 10MG BASE	A071485	001	Apr 30, 1987
		EQ 10MG BASE	A072985	001	Mar 29, 1991
		EQ 25MG BASE	A070953	001	May 15, 1986
		EQ 25MG BASE	A071486	001	Apr 30, 1987
		EQ 25MG BASE	A072986	001	Mar 29, 1991
		EQ 50MG BASE	A070954	001	May 15, 1986
		EQ 50MG BASE	A071238	001	Apr 30, 1987
		EQ 75MG BASE	A071326	001	Apr 30, 1987
		EQ 75MG BASE	A071763	001	Feb 09, 1988
		EQ 100MG BASE	A070955	001	May 15, 1986
		EQ 100MG BASE	A071239	001	Apr 30, 1987
		EQ 150MG BASE	A071764	001	Feb 09, 1988
	WATSON LABS TEVA	EQ 50MG BASE	A072987	001	Mar 29, 1991
SINEQUAN					
+	PFIZER	EQ 10MG BASE **	N016798	003	
+		EQ 25MG BASE **	N016798	001	
+		EQ 50MG BASE **	N016798	002	
+		EQ 75MG BASE **	N016798	006	
+		EQ 100MG BASE **	N016798	005	
+		EQ 150MG BASE **	N016798	007	
CONCENTRATE;ORAL					
DOXEPIN HYDROCHLORIDE					
	PHARM ASSOC	EQ 10MG BASE/ML	A075924	001	Jan 15, 2004
	PHARMOBEDIENT CNSLTG	EQ 10MG BASE/ML	A071918	001	Jul 20, 1988
	TEVA PHARMS	EQ 10MG BASE/ML	A071609	001	Nov 09, 1987
SINEQUAN					
+	PFIZER	EQ 10MG BASE/ML **	N017516	001	
TABLET;ORAL					
DOXEPIN HYDROCHLORIDE					
	ZYDUS PHARMS	EQ 3MG BASE	A202761	001	Aug 16, 2023
		EQ 6MG BASE	A202761	002	Aug 16, 2023

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXERCALCIFEROL				
CAPSULE;ORAL				
DOXERCALCIFEROL				
HIKMA	0.5MCG	A091433	001	Sep 23, 2011
	1MCG	A091433	002	Jan 14, 2014
	2.5MCG	A091433	003	Jan 14, 2014
INJECTABLE;INJECTION				
DOXERCALCIFEROL				
AMNEAL	4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017
EPIC PHARMA LLC	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016
	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015
+ HOSPIRA	10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018
SUN PHARM	2MCG/ML (2MCG/ML)	A203875	001	Nov 14, 2019
	4MCG/2ML (2MCG/ML)	A203875	002	Nov 14, 2019
DOXORUBICIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
ADRIAMYCIN PFS				
PFIZER	2MG/ML	A063165	001	Jan 30, 1991
	200MG/100ML	A063165	002	Jan 30, 1991
DOXORUBICIN HYDROCHLORIDE				
ALMAJECT	2MG/ML	A065515	001	Nov 08, 2012
HISUN PHARM HANGZHOU	20MG/VIAL	A206062	001	May 13, 2019
HLTHCARE	2MG/ML	A200146	001	Jul 18, 2012
MYLAN LABS LTD	2MG/ML	A200901	001	Feb 14, 2012
	10MG/VIAL	A200170	001	Oct 28, 2011
PFIZER	10MG/VIAL	N050467	001	
	20MG/VIAL	N050467	003	May 20, 1985
	50MG/VIAL	N050467	002	
	150MG/VIAL	N050467	004	Jul 22, 1987
PHARMACHEMIE BV	2MG/ML	A063336	001	Feb 28, 1995
	10MG/VIAL	A063097	001	May 21, 1990
	20MG/VIAL	A063097	002	May 21, 1990
	50MG/VIAL	A063097	003	May 21, 1990
	200MG/100ML	A063336	004	Feb 28, 1995
TEVA PHARMS USA	2MG/ML	A064140	001	Jul 28, 1995
	200MG/100ML	A064140	002	Jul 28, 1995
RUBEX				
BRISTOL MYERS SQUIBB	10MG/VIAL	A062926	001	Apr 13, 1989
	50MG/VIAL	A062926	002	Apr 13, 1989
	100MG/VIAL	A062926	003	Apr 13, 1989
DOXYCYCLINE				
CAPSULE;ORAL				
DOXYCYCLINE				
IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011
RISING	EQ 50MG BASE	A208942	001	Jan 21, 2021
	EQ 75MG BASE	A208942	002	Jan 21, 2021
	EQ 100MG BASE	A208942	003	Jan 21, 2021
SANDOZ INC	EQ 50MG BASE	A065032	001	Jun 30, 2000
	EQ 100MG BASE	A065032	002	Jun 30, 2000
STRIDES PHARMA	EQ 75MG BASE	A065055	004	Apr 18, 2005
	EQ 150MG BASE	A202778	001	Jun 08, 2012
WATSON LABS	EQ 50MG BASE	A065041	001	Apr 28, 2000
	EQ 100MG BASE	A065041	002	Apr 28, 2000
FOR SUSPENSION;ORAL				
DOXYCHEL				
RACHELLE	EQ 25MG BASE/5ML	A061720	001	
TABLET;ORAL				
DOXYCYCLINE				
APPCO	EQ 50MG BASE	A065377	001	Nov 07, 2006
	EQ 75MG BASE	A065377	002	Nov 07, 2006
	EQ 100MG BASE	A065377	003	Nov 07, 2006
	EQ 150MG BASE	A065427	001	Jun 07, 2007
SANDOZ INC	EQ 50MG BASE	A065353	001	Nov 27, 2006
	EQ 75MG BASE	A065353	002	Nov 27, 2006
	EQ 100MG BASE	A065353	003	Nov 27, 2006
SUN PHARM INDUSTRIES	EQ 50MG BASE	A065471	001	Apr 17, 2009
	EQ 75MG BASE	A065471	002	Apr 17, 2009
	EQ 100MG BASE	A065471	003	Apr 17, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXYCYCLINE HYCLATE

CAPSULE;ORAL				
ACTICLATE CAP				
+ ALMIRALL	EQ 75MG BASE	N208253	001	Apr 26, 2016
DOXY-LEMMON				
TEVA	EQ 50MG BASE	A062497	001	Aug 23, 1984
	EQ 100MG BASE	A062497	002	Jun 15, 1984
DOXYCYCLINE HYCLATE				
AJANTA PHARMA LTD	EQ 50MG BASE	A211012	001	Sep 24, 2018
	EQ 100MG BASE	A211012	002	Sep 24, 2018
HALSEY	EQ 50MG BASE	A062119	002	May 24, 1985
	EQ 100MG BASE	A062119	001	May 24, 1985
HEATHER	EQ 50MG BASE	A062463	001	Dec 07, 1983
	EQ 100MG BASE	A062463	002	Dec 07, 1983
HIKMA INTL PHARMS	EQ 20MG BASE	A065103	001	May 13, 2005
INTERPHARM	EQ 50MG BASE	A062763	001	Sep 02, 1988
	EQ 100MG BASE	A062763	002	Sep 02, 1988
MUTUAL PHARM	EQ 50MG BASE	A062418	001	Jan 28, 1983
	EQ 100MG BASE	A062418	002	Jan 28, 1983
NESHER PHARMS	EQ 50MG BASE	A208263	001	Nov 22, 2021
	EQ 100MG BASE	A208263	002	Nov 22, 2021
NOSTRUM LABS INC	EQ 50MG BASE	A209393	001	Dec 10, 2020
	EQ 100MG BASE	A209393	002	Dec 10, 2020
PAR PHARM	EQ 50MG BASE	A062434	001	Oct 19, 1984
	EQ 100MG BASE	A062442	001	Dec 22, 1983
PVT FORM	EQ 50MG BASE	A062631	001	Jul 24, 1986
	EQ 100MG BASE	A062631	002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479	001	Dec 23, 1983
	EQ 100MG BASE	A062479	002	Dec 23, 1983
STRIDES PHARMA	EQ 50MG BASE	A062337	001	Mar 29, 1982
	EQ 100MG BASE	A062337	002	Mar 29, 1982
SUPERPHARM	EQ 50MG BASE	A062469	001	Oct 31, 1984
	EQ 100MG BASE	A062469	002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594	001	Dec 05, 1985
	EQ 100MG BASE	A062594	002	Dec 05, 1985
WATSON LABS	EQ 50MG BASE	A061717	001	
	EQ 50MG BASE	A062142	001	
	EQ 100MG BASE	A061717	002	
	EQ 100MG BASE	A062142	002	
ZHEJIANG YONGTAI	EQ 50MG BASE	A212610	001	Mar 31, 2020
	EQ 100MG BASE	A212610	002	Mar 31, 2020
PERIOSTAT				
+ COLLAGENEX	EQ 20MG BASE **	N050744	001	Sep 30, 1998
VIBRAMYCIN				
+ PFIZER	EQ 50MG BASE **	N050007	001	
CAPSULE, COATED PELLETS;ORAL				
DOXYCYCLINE HYCLATE				
PLIVA	EQ 100MG BASE	A063187	001	Jun 30, 1992
CAPSULE, DELAYED RELEASE;ORAL				
DORYX				
+ MAYNE PHARMA	EQ 75MG BASE	N050582	002	Aug 13, 2001
+	EQ 100MG BASE	N050582	001	Jul 22, 1985
WARNER CHILCOTT	EQ 100MG BASE	A062653	001	Oct 30, 1985
DOXYCYCLINE HYCLATE				
BAUSCH	EQ 75MG BASE	A065281	001	Dec 21, 2005
	EQ 100MG BASE	A065281	002	Dec 21, 2005
INJECTABLE;INJECTION				
DOXYCHEL HYCLATE				
RACHELLE	EQ 100MG BASE/VIAL	A061953	001	
DOXYCYCLINE				
HIKMA	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983
	EQ 100MG BASE/VIAL	A062569	001	Mar 09, 1988
	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988
DOXYCYCLINE HYCLATE				
PAR STERILE PRODUCTS	EQ 100MG BASE/VIAL	A216690	001	Dec 07, 2022
VIBRAMYCIN				
+ PFIZER	EQ 100MG BASE/VIAL **	N050442	002	
+	EQ 200MG BASE/VIAL **	N050442	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXYCYCLINE HYCLATE

SYSTEM, EXTENDED RELEASE;PERIODONTAL				
ATRIDOX				
+ DEN-MAT	50MG	N050751	001	Sep 03, 1998
TABLET;ORAL				
DOXY-LEMMON				
TEVA	EQ 100MG BASE	A062581	001	Mar 15, 1985
DOXYCYCLINE HYCLATE				
ALEMBIC	EQ 100MG BASE	A210536	001	May 14, 2020
AMNEAL	EQ 100MG BASE	A216599	001	Oct 24, 2022
AMNEAL PHARMS CO	EQ 75MG BASE	A209372	001	Oct 06, 2017
	EQ 150MG BASE	A209372	002	Oct 06, 2017
AVET LIFESCIENCES	EQ 100MG BASE	A209969	001	Nov 09, 2018
HEATHER	EQ 100MG BASE	A062462	001	May 11, 1983
HERITAGE PHARMA	EQ 20MG BASE	A065163	001	May 13, 2005
INTERPHARM	EQ 100MG BASE	A062764	001	Sep 02, 1988
MUTUAL PHARM	EQ 100MG BASE	A062391	001	Sep 30, 1982
PHARMOBEDIENT	EQ 100MG BASE	A213475	001	Mar 10, 2021
PRAXGEN	EQ 100MG BASE	A212487	001	Mar 30, 2022
RISING	EQ 75MG BASE	A209987	001	Oct 05, 2020
	EQ 150MG BASE	A209987	002	Oct 05, 2020
STRIDES PHARMA	EQ 100MG BASE	A062538	001	Apr 07, 1986
SUPERPHARM	EQ 100MG BASE	A062494	001	Feb 20, 1985
WARNER CHILCOTT	EQ 100MG BASE	A062593	001	Aug 28, 1985
WATSON LABS	EQ 50MG BASE	A062392	001	Mar 31, 1983
	EQ 100MG BASE	A062392	002	Mar 31, 1983
LYMEPAK				
+ CHARTWELL PHARMA	EQ 100MG BASE	N209844	001	Jun 15, 2018
PERIOSTAT				
+ GALDERMA LABS LP	EQ 20MG BASE **	N050783	001	Feb 02, 2001
VIBRA-TABS				
+ PFIZER	EQ 100MG BASE **	N050533	001	
TABLET, DELAYED RELEASE;ORAL				
DORYX				
+ MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014
+	EQ 100MG BASE	N050795	002	May 06, 2005
DORYX MPC				
+ MAYNE PHARMA	EQ 120MG BASE	N050795	008	May 20, 2016
DOXYCYCLINE HYCLATE				
AUROBINDO PHARMA USA	EQ 150MG BASE	A091052	001	Feb 08, 2012
IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010
	EQ 100MG BASE	A090505	002	Dec 28, 2010
LUPIN	EQ 50MG BASE	A208741	001	Aug 11, 2023
	EQ 60MG BASE	A208741	002	Aug 11, 2023
	EQ 75MG BASE	A208741	003	Aug 11, 2023
	EQ 80MG BASE	A208741	004	Aug 11, 2023
	EQ 100MG BASE	A208741	005	Aug 11, 2023
	EQ 120MG BASE	A208741	006	Aug 11, 2023
	EQ 150MG BASE	A208741	007	Aug 11, 2023
	EQ 200MG BASE	A208741	008	Aug 11, 2023
RISING	EQ 50MG BASE	A090431	003	May 23, 2016
	EQ 75MG BASE	A090431	001	Dec 28, 2010
	EQ 80MG BASE	A090431	004	Apr 29, 2016
	EQ 100MG BASE	A090431	002	Dec 28, 2010
	EQ 200MG BASE	A090431	005	May 19, 2016
ZYDUS PHARMS	EQ 75MG BASE	A206772	001	Dec 21, 2018
	EQ 100MG BASE	A206772	002	Dec 21, 2018
	EQ 150MG BASE	A206772	003	Dec 21, 2018

DOXYLAMINE SUCCINATE

CAPSULE;ORAL				
UNISOM				
PFIZER	25MG	N019440	001	Feb 05, 1986
TABLET;ORAL				
DECAPRYN				
SANOFI AVENTIS US	12.5MG	N006412	015	
	25MG	N006412	014	
DOXY-SLEEP-AID				
PAR PHARM	25MG	A070156	001	Jul 02, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXYLAMINE SUCCINATE

TABLET;ORAL

DOXYLAMINE SUCCINATE

COPLEY PHARM	25MG	A088900	002	Feb 12, 1988
QUANTUM PHARMICS	25MG	A088603	001	Aug 07, 1984

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BENDECTIN

SANOFI AVENTIS US	10MG;10MG **	N010598	002	

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

ACTAVIS LABS FL INC	20MG;20MG	A212472	001	Mar 01, 2022

DROMOSTANOLONE PROPIONATE

INJECTABLE;INJECTION

DROLBAN

LILLY	50MG/ML	N012936	001	

DRONABINOL

CAPSULE;ORAL

DRONABINOL

INSYS THERAP	2.5MG	A078501	001	Aug 19, 2011
	5MG	A078501	002	Aug 19, 2011
	10MG	A078501	003	Aug 19, 2011
LANNETT CO INC	2.5MG	A201463	001	May 18, 2018
	5MG	A201463	002	May 18, 2018
	10MG	A201463	003	May 18, 2018

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

ABRAXIS PHARM	2.5MG/ML	A070992	001	Nov 17, 1986
	2.5MG/ML	A070993	001	Nov 17, 1986
ASTRAZENECA	2.5MG/ML	A072018	001	Oct 20, 1988
HIKMA	2.5MG/ML	A208197	001	Dec 14, 2017
HOSPIRA	2.5MG/ML	A071645	001	Apr 07, 1988
	2.5MG/ML	A071981	001	Feb 29, 1988
	2.5MG/ML	A072272	001	Aug 31, 1995
IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988
	2.5MG/ML	A072020	001	Oct 19, 1988
	2.5MG/ML	A072021	001	Oct 19, 1988
LUITPOLD	2.5MG/ML	A072335	001	Oct 24, 1988
SMITH AND NEPHEW	2.5MG/ML	A071750	001	Sep 06, 1988
SOLOPAK	2.5MG/ML	A071754	001	Sep 06, 1988
	2.5MG/ML	A071755	001	Sep 06, 1988
WATSON LABS	2.5MG/ML	A073520	001	Nov 27, 1991
	2.5MG/ML	A073521	001	Nov 27, 1991
	2.5MG/ML	A073523	001	Nov 27, 1991

INAPSINE

+ RISING	2.5MG/ML	N016796	001	

DROPERIDOL; FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	A072026	001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072027	001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072028	001	Apr 13, 1989
HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	A071982	001	May 04, 1988

INNOVAR

EPIC PHARMA LLC	2.5MG/ML;EQ 0.05MG BASE/ML	N016049	001	

DROSPIRENONE

TABLET, CHEWABLE;ORAL

DROSPIRENONE

+ EXELTIS USA INC	3.5MG	N216285	001	Jun 29, 2022

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

BARR	3MG;0.02MG	A078515	001	Mar 30, 2009
JUBILANT CADISTA	3MG;0.02MG	A209423	001	Dec 22, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL				
KYRA				
	SUN PHARM	3MG;0.02MG	A202318 001	Jul 23, 2019
TABLET;ORAL-28				
DROSPIRENONE AND ETHINYL ESTRADIOL				
	APOTEX	3MG;0.03MG	A205876 001	Sep 21, 2016
	BARR	3MG;0.03MG	A077527 001	May 09, 2008
	JUBILANT CADISTA	3MG;0.03MG	A210017 001	Sep 10, 2018
KEMEYA				
	SUN PHARM	3MG;0.03MG	A202138 001	Mar 13, 2019

DROXIDOPA

CAPSULE;ORAL				
DROXIDOPA				
	CHARTWELL RX	100MG	A214217 001	May 05, 2022
		200MG	A214217 002	May 05, 2022
		300MG	A214217 003	May 05, 2022
	HIKMA	100MG	A212835 001	Feb 18, 2021
		200MG	A212835 002	Feb 18, 2021
		300MG	A212835 003	Feb 18, 2021
	TEVA PHARMS USA INC	100MG	A213162 001	Feb 18, 2021
		200MG	A213162 002	Feb 18, 2021
		300MG	A213162 003	Feb 18, 2021

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL				
DRIZALMA SPRINKLE				
+	SUN PHARM	EQ 20MG BASE	N212516 001	Jul 19, 2019
+		EQ 30MG BASE	N212516 002	Jul 19, 2019
+		EQ 40MG BASE	N212516 003	Jul 19, 2019
+		EQ 60MG BASE	N212516 004	Jul 19, 2019
DULOXETINE HYDROCHLORIDE				
	APOTEX	EQ 20MG BASE	A202045 001	Jun 11, 2014
		EQ 30MG BASE	A202045 002	Jun 11, 2014
		EQ 60MG BASE	A202045 003	Jun 11, 2014
	TEVA PHARMS USA	EQ 20MG BASE	A090783 001	Dec 11, 2013
		EQ 30MG BASE	A090783 002	Dec 11, 2013
		EQ 60MG BASE	A090783 003	Dec 11, 2013
	YAOPHARMA CO LTD	EQ 20MG BASE	A207219 001	Aug 16, 2019
		EQ 30MG BASE	A207219 002	Aug 16, 2019
		EQ 60MG BASE	A207219 003	Aug 16, 2019

DUTASTERIDE

CAPSULE;ORAL				
DUTASTERIDE				
	ACTAVIS LABS FL INC	0.5MG	A202808 001	Nov 20, 2015
	APOTEX	0.5MG	A204292 001	Nov 24, 2015
	HERITAGE PHARMS INC	0.5MG	A207935 001	Oct 13, 2017
	HIKMA	0.5MG	A202204 001	Nov 23, 2015
	MYLAN	0.5MG	A203241 001	Jun 14, 2016
	NOSTRUM LABS INC	0.5MG	A204705 001	Nov 20, 2015
	RISING	0.5MG	A202530 001	Nov 20, 2015
	STRIDES PHARMA	0.5MG	A208227 001	Jun 22, 2018

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL				
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE				
	ACTAVIS LABS FL INC	0.5MG;0.4MG	A202975 001	Nov 20, 2015

DYCLONINE HYDROCHLORIDE

SOLUTION;TOPICAL				
DYCLONE				
+	ASTRAZENECA	0.5% **	N009925 002	
+		1% **	N009925 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DYDROGESTERONE
TABLET;ORAL
GYNOREST
+ SOLVAY 5MG ** N017388 001
+ 10MG ** N017388 002

DYPHYLLINE
ELIXIR;ORAL
NEOTHYLLINE
TEVA 160MG/15ML N007794 003
INJECTABLE;INJECTION
NEOTHYLLINE
TEVA 250MG/ML N009088 001
TABLET;ORAL
DILOR
SAVAGE LABS 200MG A084514 001
DILOR-400
SAVAGE LABS 400MG A084751 001
LUFYLLIN
MYLAN SPECIALITY LP 200MG A084566 001
400MG A084566 002
NEOTHYLLINE
TEVA 200MG N007794 001
400MG N007794 002

ECHOTHIOPHATE IODIDE
FOR SOLUTION;OPHTHALMIC
PHOSPHOLINE IODIDE
FERA PHARMS LLC 0.03% N011963 002
0.06% N011963 004
0.25% N011963 003

ECONAZOLE NITRATE
CREAM;TOPICAL
ECONAZOLE NITRATE
AUROBINDO PHARMA USA 1% A210364 001 Apr 18, 2018
CHARTWELL RX 1% A076075 001 Nov 26, 2002
VERTICE 1% A076574 001 Dec 17, 2004
SPECTAZOLE
+ ALVOGEN 1% ** N018751 001 Dec 23, 1982

EDETATE CALCIUM DISODIUM
INJECTABLE;INJECTION
CALCIUM DISODIUM VERSENATE
+ BAUSCH 200MG/ML ** N008922 001
TABLET;ORAL
CALCIUM DISODIUM VERSENATE
BAUSCH 500MG N008922 002

EDROPHONIUM CHLORIDE
INJECTABLE;INJECTION
EDROPHONIUM CHLORIDE
HOSPIRA 10MG/ML A040131 001 Feb 24, 1998
WATSON LABS 10MG/ML A040044 001 Mar 20, 1996
EDROPHONIUM CHLORIDE PRESERVATIVE FREE
WATSON LABS 10MG/ML A040043 001 Mar 20, 1996
ENLON
MYLAN INSTITUTIONAL 10MG/ML A088873 001 Aug 06, 1985
REVERSOL
ORGANON USA INC 10MG/ML A089624 001 May 13, 1988
TENSILON
+ PAI HOLDINGS PHARM 10MG/ML ** N007959 001
TENSILON PRESERVATIVE FREE
+ PAI HOLDINGS PHARM 10MG/ML ** N007959 002

EFAVIRENZ
CAPSULE;ORAL
SUSTIVA
+ BRISTOL MYERS SQUIBB 50MG N020972 001 Sep 17, 1998
+ 100MG ** N020972 002 Sep 17, 1998
+ 200MG N020972 003 Sep 17, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EFAVIRENZ
TABLET;ORAL
EFAVIRENZ

	AUROBINDO PHARMA	600MG	A205322	001	Aug 30, 2018
	MYLAN	600MG	A091471	001	Feb 17, 2016
	STRIDES PHARMA	600MG	A078509	001	Jun 16, 2021

SUSTIVA

+	BRISTOL MYERS SQUIBB	300MG **	N021360	001	Feb 01, 2002
+		600MG	N021360	002	Feb 01, 2002

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
TABLET;ORAL
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

+	AUROBINDO PHARMA LTD	600MG;300MG;300MG	N022343	001	Aug 15, 2018
	MACLEODS PHARMS LTD	400MG;300MG;300MG	N210649	001	Mar 15, 2019

EFINACONAZOLE
SOLUTION;TOPICAL
EFINACONAZOLE

	AUROBINDO PHARMA LTD	10%	A212066	001	Mar 29, 2021
	LUPIN LTD	10%	A212169	001	Mar 02, 2022
	PADAGIS US	10%	A211851	001	Dec 16, 2020
	ZYDUS	10%	A212178	001	Jul 15, 2022

EFLORNITHINE HYDROCHLORIDE
CREAM;TOPICAL
VANIQA

+	SKINMEDICA	13.9%	N021145	001	Jul 27, 2000

INJECTABLE;INJECTION
ORNIDYL

	SANOFI AVENTIS US	200MG/ML	N019879	002	Nov 28, 1990

ELETRIPTAN HYDROBROMIDE
TABLET;ORAL
ELETRIPTAN HYDROBROMIDE

	STEVENS J	EQ 20MG BASE	A206787	001	May 25, 2018
		EQ 40MG BASE	A206787	002	May 25, 2018
	YUNG SHIN PHARM	EQ 20MG BASE	A209680	001	Jul 13, 2020
		EQ 40MG BASE	A209680	002	Jul 13, 2020

ELIGLUSTAT TARTRATE
CAPSULE;ORAL
ELIGLUSTAT TARTRATE

	DR REDDYS	EQ 84MG BASE	A212449	001	Aug 17, 2022
	TEVA PHARMS USA INC	EQ 84MG BASE	A212474	001	Dec 27, 2021

ELTROMBOPAG OLAMINE
TABLET;ORAL
PROMACTA

+	NOVARTIS	EQ 100MG ACID **	N022291	005	Nov 16, 2012

ELVITEGRAVIR
TABLET;ORAL
VITEKTA

+	GILEAD SCIENCES INC	85MG	N203093	001	Sep 24, 2014
+		150MG	N203093	002	Sep 24, 2014

EMEDASTINE DIFUMARATE
SOLUTION/DROPS;OPHTHALMIC
EMADINE

+	NOVARTIS	0.05%	N020706	001	Dec 29, 1997

EMPAGLIFLOZIN
TABLET;ORAL
EMPAGLIFLOZIN

	ZYDUS PHARMS	10MG	A212138	001	Aug 03, 2022
		25MG	A212138	002	Aug 03, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL				
EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE				
ZYDUS PHARMS	5MG;500MG	A212198	001	Jul 07, 2022
	5MG;1GM	A212198	002	Jul 07, 2022
	12.5MG;500MG	A212198	003	Jul 07, 2022
	12.5MG;1GM	A212198	004	Jul 07, 2022

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL				
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE				
APOTEX	200MG;300MG	A208740	001	Jun 16, 2021
CIPLA	200MG;300MG	A090958	001	Apr 02, 2021

ENALAPRIL MALEATE

FOR SOLUTION;ORAL				
EPANED KIT				
+ SILVERGATE PHARMS	1MG/ML **	N204308	001	Aug 13, 2013
SOLUTION;ORAL				
ENALAPRIL MALEATE				
AMNEAL	1MG/ML	A212894	001	Jun 29, 2022
TABLET;ORAL				
ENALAPRIL MALEATE				
AIPING PHARM INC	2.5MG	A075178	002	Mar 23, 2001
	5MG	A075178	001	Mar 23, 2001
	10MG	A075178	003	Mar 23, 2001
	20MG	A075178	004	Mar 23, 2001
APOTHECON	2.5MG	A075583	001	Aug 22, 2000
	5MG	A075583	002	Aug 22, 2000
	10MG	A075583	003	Aug 22, 2000
	20MG	A075583	004	Aug 22, 2000
AUROBINDO PHARMA USA	2.5MG	A075480	001	Aug 22, 2000
	5MG	A075480	002	Aug 22, 2000
	10MG	A075480	003	Aug 22, 2000
	20MG	A075480	004	Aug 22, 2000
BEXIMCO PHARMS USA	2.5MG	A075621	001	Aug 22, 2000
	5MG	A075621	002	Aug 22, 2000
	10MG	A075621	003	Aug 22, 2000
	20MG	A075621	004	Aug 22, 2000
CHARTWELL RX	2.5MG	A075048	001	Aug 22, 2000
	5MG	A075048	002	Aug 22, 2000
	10MG	A075048	003	Aug 22, 2000
	20MG	A075048	004	Aug 22, 2000
IVAX SUB TEVA PHARMS	2.5MG	A075482	001	Aug 22, 2000
	5MG	A075482	002	Aug 22, 2000
	10MG	A075482	003	Aug 22, 2000
	20MG	A075482	004	Aug 22, 2000
KRKA DD NOVO MESTO	2.5MG	A075370	001	Aug 22, 2000
	5MG	A075370	002	Aug 22, 2000
	10MG	A075369	001	Aug 22, 2000
	20MG	A075369	002	Aug 22, 2000
MYLAN	2.5MG	A075472	001	Aug 22, 2000
	5MG	A075472	002	Aug 22, 2000
	10MG	A075472	003	Aug 22, 2000
	20MG	A075472	004	Aug 22, 2000
SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000
	5MG	A075556	002	Aug 22, 2000
	10MG	A075556	003	Aug 22, 2000
	20MG	A075556	004	Aug 22, 2000
WATSON LABS	2.5MG	A075501	001	Aug 22, 2000
	5MG	A075501	002	Aug 22, 2000
	10MG	A075501	003	Aug 22, 2000
	20MG	A075501	004	Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE;ORAL				
LEXXEL				
ASTRAZENECA	5MG;2.5MG	N020668	002	Oct 28, 1998
	5MG;5MG	N020668	001	Dec 27, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE					
TABLET;ORAL					
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE					
	CHARTWELL RX	5MG;12.5MG	A076116	001	Sep 19, 2001
		10MG;25MG	A076116	002	Sep 19, 2001
	IVAX SUB TEVA PHARMS	5MG;12.5MG	A075736	001	Mar 25, 2003
		10MG;25MG	A075736	002	Mar 25, 2003
	NOSTRUM LABS INC	5MG;12.5MG	A076486	001	Oct 27, 2004
		10MG;25MG	A076486	002	Oct 27, 2004
	RISING	5MG;12.5MG	A075624	001	Sep 18, 2001
		10MG;25MG	A075624	002	Sep 18, 2001
ENALAPRILAT					
INJECTABLE;INJECTION					
ENALAPRILAT					
	HOSPIRA	1.25MG/ML	A075456	001	Aug 22, 2000
		1.25MG/ML	A075571	001	Aug 22, 2000
VASOTEC					
+	BIOVAIL LABS INTL	1.25MG/ML **	N019309	001	Feb 09, 1988
ENCORAFENIB					
CAPSULE;ORAL					
BRAFTOVI					
+	ARRAY BIOPHARMA INC	50MG	N210496	001	Jun 27, 2018
ENFLURANE					
LIQUID;INHALATION					
ENFLURANE					
	ABBOTT	99.9%	A070803	001	Sep 08, 1987
	PIRAMAL CRITICAL	99.9%	A074396	001	Jul 29, 1994
ETHRANE					
	BAXTER HLTHCARE	99.9%	N017087	001	
ENOXACIN					
TABLET;ORAL					
PENETREX					
	SANOFI AVENTIS US	200MG	N019616	004	Dec 31, 1991
		400MG	N019616	005	Dec 31, 1991
ENOXAPARIN SODIUM					
INJECTABLE;SUBCUTANEOUS					
LOVENOX (PRESERVATIVE FREE)					
+	SANOFI AVENTIS US	90MG/0.6ML (150MG/ML) **	N020164	006	Jun 02, 2000
ENTACAPONE					
TABLET;ORAL					
ENTACAPONE					
	MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013
ENTECAVIR					
TABLET;ORAL					
ENTECAVIR					
	ACCORD HLTHCARE	0.5MG	A205824	001	Aug 25, 2017
		1MG	A205824	002	Aug 25, 2017
	CASI PHARMS INC	0.5MG	A206672	001	May 11, 2017
		1MG	A206672	002	May 11, 2017
	CHARTWELL RX	0.5MG	A206294	001	Nov 23, 2016
		1MG	A206294	002	Nov 23, 2016
	RISING	0.5MG	A206226	001	Mar 26, 2019
		1MG	A206226	002	Mar 26, 2019
	SUNSHINE	0.5MG	A211978	001	May 20, 2020
		1MG	A211978	002	May 20, 2020
	TEVA PHARMS USA	0.5MG	A202122	001	Aug 26, 2014
		1MG	A202122	002	Aug 26, 2014
	YAOPHARMA CO LTD	0.5MG	A212201	001	Nov 04, 2019
		1MG	A212201	002	Nov 04, 2019
	YUNG SHIN PHARM	0.5MG	A208195	001	Nov 10, 2021
		1MG	A208195	002	Nov 10, 2021

ENZALUTAMIDE

CAPSULE;ORAL					
ENZALUTAMIDE					
	ACTAVIS LABS FL INC	40MG	A209614	001	May 14, 2021
	APOTEX	40MG	A209645	001	Apr 22, 2022

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS					
REZIPRES					
+	DR REDDYS LABS SA	47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021
+		47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS					
EPHEDRINE SULFATE					
	RENEW PHARMS	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017
	ZYDUS PHARMS	50MG/ML (50MG/ML)	A217276	001	May 16, 2023

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC					
ELESTAT					
+	ALLERGAN	0.05%	N021565	001	Oct 16, 2003
EPINASTINE HYDROCHLORIDE					
	CHARTWELL RX	0.05%	A203384	001	Dec 07, 2016
	EPIC PHARMA LLC	0.05%	A204055	001	May 05, 2017
	SUN PHARM INDS	0.05%	A091626	001	Oct 31, 2011

EPINEPHRINE

AEROSOL, METERED;INHALATION					
BRONKAID MIST					
	STERLING	0.25MG/INH	N016803	001	
EPINEPHRINE					
	ARMSTRONG PHARMS	0.2MG/INH	A087907	001	May 23, 1984
PRIMATENE MIST					
	WYETH CONS	0.2MG/INH	N016126	001	
INJECTABLE;INJECTION					
SUS-PHRINE SULFITE FREE					
	FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999
		5MG/ML	N007942	001	
INJECTABLE;INTRAMUSCULAR					
EPI E Z PEN JR					
	MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	004	Aug 03, 1995
EPIPEN E Z PEN					
	MYLAN SPECIALITY LP	0.3MG/DELIVERY	N019430	003	Aug 03, 1995
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS					
TWINJECT 0.15					
	IMPAX	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004
TWINJECT 0.3					
	IMPAX	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS					
EPINEPHRINE					
	AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
SYMJEPI					
+	ADAMIS PHARMS CORP	0.15MG/0.3ML (0.15MG/0.3ML)	N207534	002	Sep 27, 2018

EPINEPHRINE BITARTRATE

AEROSOL, METERED;INHALATION					
BRONITIN MIST					
	WYETH CONS	0.3MG/INH	N016126	002	
MEDIHALER-EPI					
	3M	0.3MG/INH	N010374	003	

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION					
DURANEST					
+	ASTRAZENECA	0.005MG/ML;1% **	N017751	006	
+		0.005MG/ML;1.5% **	N017751	007	
+	DENTSPLY PHARM	0.005MG/ML;1.5% **	N021384	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
CITANEST FORTE				
	ASTRAZENECA	0.005MG/ML;4%	N014763 008	

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
DURANEST				
+	ASTRAZENECA	0.005MG/ML;0.5% **	N017751 004	

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE				
	CARLISLE	0.01MG/ML;2%	A084720 001	
		0.02MG/ML;2%	A084732 001	
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
	BELMORA LLC	0.01MG/ML;2%	A080504 004	Oct 19, 1983
		0.02MG/ML;2%	A080504 005	Oct 19, 1983
	EASTMAN KODAK	0.01MG/ML;2%	A040057 002	Feb 26, 1993
		0.02MG/ML;2%	A040057 001	Feb 26, 1993
	HOSPIRA	0.005MG/ML;1%	A089649 001	Jun 21, 1988
		0.005MG/ML;1.5%	A089650 001	Jun 21, 1988
		0.01MG/ML;2%	A078772 001	May 12, 2008
		0.02MG/ML;2%	A078772 002	May 12, 2008
	WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406 001	
		0.01MG/ML;2%	A080406 002	
LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE				
	ABBOTT	0.01MG/ML;1%	A083154 001	
	BEL MAR	0.01MG/ML;1%	A080820 001	
		0.01MG/ML;2%	A080757 001	
	DELL LABS	0.01MG/ML;1%	A083389 001	
		0.01MG/ML;2%	A083390 001	
	INTL MEDICATION	0.01MG/ML;1%	A086402 001	
	WATSON LABS	0.01MG/ML;1%	A080377 003	
		0.01MG/ML;1%	A085463 001	
		0.01MG/ML;2%	A080377 004	
LIDOCATON				
	PHARMATON	0.01MG/ML;2%	A084729 001	Aug 17, 1983
		0.02MG/ML;2%	A084728 001	Aug 17, 1983
OCTOCAINE				
	SEPTODONT	0.01MG/ML;2%	A084048 001	
		0.02MG/ML;2%	A084048 002	
XYLOCAINE DENTAL WITH EPINEPHRINE				
	DENTSPLY PHARM	0.01MG/ML;2% **	N021381 001	
		0.02MG/ML;2% **	N021381 002	
XYLOCAINE W/ EPINEPHRINE				
	ASTRAZENECA	0.005MG/ML;1%	N010418 006	
		0.005MG/ML;1.5%	N010418 010	
		0.005MG/ML;2%	N010418 008	
	FRESENIUS KABI USA	0.01MG/ML;2%	N006488 003	
PATCH;IONTOPHORESIS, TOPICAL				
LIDOSITE TOPICAL SYSTEM KIT				
	VYTERIS	1.05MG/PATCH;100MG/PATCH	N021504 001	May 06, 2004
SOLUTION;IONTOPHORESIS				
IONTOCAINE				
	IOMED	0.01MG/ML;2%	N020530 001	Dec 21, 1995
SOLUTION;IONTOPHORESIS, TOPICAL				
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
	EMPI	0.01MG/ML;2%	N021486 001	Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
PROCAINE HYDROCHLORIDE W/ EPINEPHRINE				
	BEL MAR	0.02MG/ML;1%	A080758 001	
		0.02MG/ML;2%	A080759 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION					
EPIRUBICIN HYDROCHLORIDE					
	ACTAVIS TOTOWA	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008
		50MG/25ML (2MG/ML)	A065445	002	Sep 18, 2008
		200MG/100ML (2MG/ML)	A065445	003	Sep 18, 2008
	EBEWE PHARMA	50MG/25ML (2MG/ML)	A065339	001	Dec 22, 2009
		200MG/100ML (2MG/ML)	A065339	002	Dec 22, 2009
	FRESENIUS KABI USA	10MG/5ML (2MG/ML)	A065408	001	Oct 15, 2007
		50MG/25ML (2MG/ML)	A065408	002	Oct 15, 2007
		150MG/75ML (2MG/ML)	A065408	003	Oct 15, 2007
		200MG/100ML (2MG/ML)	A065408	004	Oct 15, 2007
		200MG/100ML (2MG/ML)	A065411	001	Aug 20, 2007
		50MG/25ML (2MG/ML)	A065411	002	Aug 20, 2007
	HOSPIRA	10MG/5ML (2MG/ML)	A065343	001	Apr 19, 2007
		50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007
		150MG/75ML (2MG/ML)	A065343	003	Apr 19, 2007
		200MG/100ML (2MG/ML)	A065343	004	Apr 19, 2007
	MYLAN INSTITUTIONAL	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007
		200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007
	MYLAN LABS LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012
		200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012
	ZENNOVA	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011
		200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011
POWDER;INTRAVENOUS					
EPIRUBICIN HYDROCHLORIDE					
	HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006
		200MG/VIAL	N050807	002	Sep 15, 2006

EPLERENONE

TABLET;ORAL					
INSPRA					
	UPJOHN	100MG	N021437	003	Sep 27, 2002

EPROSARTAN MESYLATE

TABLET;ORAL					
EPROSARTAN MESYLATE					
	MYLAN PHARMS INC	EQ 400MG BASE	A202012	001	Nov 16, 2011
		EQ 600MG BASE	A202012	002	Nov 16, 2011
TEVETEN					
	ABBVIE	EQ 300MG BASE **	N020738	004	Dec 22, 1997
+		EQ 400MG BASE **	N020738	005	Dec 22, 1997
+		EQ 600MG BASE **	N020738	006	May 27, 1999

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL					
TEVETEN HCT					
	ABBVIE	600MG;12.5MG	N021268	001	Nov 01, 2001
		600MG;25MG	N021268	002	Nov 01, 2001

EPTIFIBATIDE

INJECTABLE;INJECTION					
EPTIFIBATIDE					
	AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016
		75MG/100ML	A205581	002	Dec 08, 2016
	BAXTER HLTHCARE CORP	2MG/ML	A208554	001	Nov 23, 2018
	HYBIO	2MG/ML	A207864	001	Mar 20, 2020
		75MG/100ML	A207864	002	Mar 20, 2020
	RISING	2MG/ML	A204589	001	Apr 18, 2017
		75MG/100ML	A204589	002	Apr 18, 2017
	TEVA PHARMS USA	75MG/100ML	A091555	001	Jun 05, 2015
	USV	2MG/ML	A204361	001	Mar 14, 2019
		2MG/ML	A204362	001	Mar 11, 2019
		75MG/100ML	A204361	002	Mar 14, 2019
INTEGRILIN					
+	MSD SUB MERCK	2MG/ML **	N020718	001	May 18, 1998
+		75MG/100ML **	N020718	002	May 18, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERGOCALCIFEROL				
CAPSULE;ORAL				
DELTALIN				
LILLY	50,000 IU	A080884	001	
ERGOCALCIFEROL				
SIGMAPHARM LABS LLC	50,000 IU	A091004	001	Jul 14, 2010
SUN PHARM INDS INC	50,000 IU	A040865	001	Dec 29, 2009
VITAMIN D				
CHARTWELL MOLECULAR	50,000 IU	A080825	001	
CHASE CHEM	50,000 IU	A080747	001	
EVERYLIFE	50,000 IU	A080956	001	
IMPAX LABS	50,000 IU	A080951	001	
VITARINE	50,000 IU	A084053	001	
WEST WARD	50,000 IU	A083102	001	
ERGOLOID MESYLATES				
CAPSULE;ORAL				
HYDERGINE LC				
NOVARTIS	1MG	N018706	001	Jan 18, 1983
SOLUTION;ORAL				
HYDERGINE				
NOVARTIS	1MG/ML	N018418	001	
TABLET;ORAL				
ERGOLOID MESYLATES				
MUTUAL PHARM	1MG	A088891	001	Nov 01, 1985
WATSON LABS	1MG	A086433	001	May 27, 1982
	1MG	A087244	001	Aug 16, 1982
GERIMAL				
WATSON LABS	1MG	A088207	001	Mar 22, 1984
HYDERGINE				
NOVARTIS	0.5MG **	N017993	003	
+	1MG **	N017993	001	
TABLET;SUBLINGUAL				
ALKERGOT				
SANDOZ	0.5MG	A085153	001	
	1MG	A087417	001	
CIRCANOL				
3M	0.5MG	A084868	001	
	1MG	A085809	001	
DEAPRIL-ST				
BRISTOL MYERS SQUIBB	1MG	A085020	002	
ERGOLOID MESYLATES				
KV PHARM	0.5MG	A085899	001	
	0.5MG	A086265	001	
	1MG	A085900	001	
	1MG	A086264	001	
LEDERLE	0.5MG	A086984	001	
	1MG	A086985	001	
SUN PHARM INDUSTRIES	0.5MG	A087407	001	
	1MG	A087552	001	
SUPERPHARM	0.5MG	A089233	001	Sep 23, 1986
	1MG	A089234	001	Sep 23, 1986
VANGARD	0.5MG	A088013	001	Sep 20, 1982
	1MG	A088014	001	Sep 20, 1982
WATSON LABS	0.5MG	A084930	001	
	0.5MG	A087233	001	
	1MG	A085177	001	
	1MG	A087183	001	
GERIMAL				
WATSON LABS	0.5MG	A086189	001	
	1MG	A086188	001	
HYDERGINE				
NOVARTIS	0.5MG	N009087	002	
	1MG	N009087	001	
HYDROGENATED ERGOT ALKALOIDS				
IVAX PHARMS	0.5MG	A087186	001	
	1MG	A087185	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERGOTAMINE TARTRATE

AEROSOL, METERED;INHALATION				
MEDIHALER ERGOTAMINE				
	3M	0.36MG/INH	N012102 001	
TABLET;SUBLINGUAL				
ERGOSTAT				
	WATSON LABS INC	2MG	A088337 001	Jun 08, 1984
WIGRETTES				
	ORGANON USA INC	2MG	A086750 001	Jul 29, 1982

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL				
ERLOTINIB HYDROCHLORIDE				
	ACCORD HLTHCARE	EQ 25MG BASE	A211083 001	Jul 02, 2020
		EQ 100MG BASE	A211083 002	Jul 02, 2020
		EQ 150MG BASE	A211083 003	Jul 02, 2020
	EUGIA PHARMA	EQ 25MG BASE	A216342 001	Jun 22, 2022
		EQ 100MG BASE	A216342 002	Jun 22, 2022
		EQ 150MG BASE	A216342 003	Jun 22, 2022
TARCEVA				
+	OSI PHARMS	EQ 25MG BASE	N021743 001	Nov 18, 2004
+		EQ 100MG BASE	N021743 002	Nov 18, 2004
+		EQ 150MG BASE	N021743 003	Nov 18, 2004

ERTUGLIFLOZIN

TABLET;ORAL				
ERTUGLIFLOZIN				
	AUROBINDO PHARMA LTD	5MG	A216947 001	Jul 13, 2023
		15MG	A216947 002	Jul 13, 2023

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL				
ERYC				
	PARKE DAVIS	250MG	A062546 001	Jul 25, 1985
		250MG	A062618 001	Sep 25, 1985
	WARNER CHILCOTT LLC	250MG	A062338 001	
ERYC 125				
	PARKE DAVIS	125MG	A062648 001	Oct 24, 1985
ERYC SPRINKLES				
	HOSPIRA	125MG	N050593 001	Jul 22, 1985
ERYTHROMYCIN				
	BARR	250MG	A063098 001	May 04, 1989
GEL;TOPICAL				
E-GLADES				
	MYLAN	2%	A065009 001	Mar 18, 2002
EMGEL				
	ALTANA	2%	A063107 001	Aug 23, 1991
ERYTHROMYCIN				
	VERTICE	2%	A208154 001	Jul 19, 2017
LOTION;TOPICAL				
E-SOLVE 2				
	SYOSSET	2%	A062467 001	Jul 03, 1985
OINTMENT;OPHTHALMIC				
ERYTHROMYCIN				
	PHARMADERM	5MG/GM	A062446 001	Sep 26, 1983
	PHARMAFAIR	5MG/GM	A062481 001	Apr 05, 1984
ILOTYCIN				
	DISTA	0.5% **	N050368 001	
OINTMENT;TOPICAL				
AKNE-MYCIN				
+	BAUSCH	2%	N050584 001	Jan 10, 1985
POWDER;FOR RX COMPOUNDING				
ERYTHROMYCIN				
	PADDOCK LLC	100%	N050610 001	Nov 07, 1986
SOLUTION;TOPICAL				
A/T/S				
	TARO	2%	A062405 001	Nov 18, 1982
C-SOLVE-2				
	FOUGERA PHARMS	2%	A062468 001	Jul 03, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERYTHROMYCIN				
SOLUTION;TOPICAL				
ERYDERM				
ARBOR PHARMS INC	2%	A062290 001		
ERYMAX				
MERZ PHARMS	2%	A062508 002		Jul 11, 1985
ERYTHRO-STATIN				
EPIC PHARMA LLC	2%	A064101 001		Oct 22, 1996
ERYTHROMYCIN				
ALPHARMA US PHARMS	1.5%	A062328 001		Apr 19, 1982
	2%	A062326 001		Apr 19, 1982
	2%	A062327 001		Apr 19, 1982
	2%	A062342 001		Feb 25, 1982
	2%	A062957 001		Jul 21, 1988
BAUSCH	2%	A064039 001		Jan 27, 1994
FOUGERA PHARMS	2%	A064187 001		Sep 30, 1997
LILLY	2%	N050532 001		
PAI HOLDINGS PHARM	2%	A208100 001		Nov 20, 2017
PHARMAFAIR	1.5%	A062485 001		Jul 11, 1984
	2%	A062616 001		Jul 25, 1985
PHARMOBEDIENT CNSLTG	2%	A062825 001		Oct 23, 1987
RENAISSANCE PHARMA	2%	A064127 001		Feb 14, 1997
SANSAC				
DOW PHARM	2%	A062522 001		Jan 24, 1985
STATICIN				
+ WESTWOOD SQUIBB	1.5% **	N050526 001		
T-STAT				
WESTWOOD SQUIBB	2% **	A062436 001		Mar 09, 1983
SWAB;TOPICAL				
C-SOLVE-2				
IVAX SUB TEVA PHARMS	2%	A062751 001		Jul 30, 1993
ERYCETTE				
+ JOHNSON AND JOHNSON	2% **	N050594 001		Feb 15, 1985
ERYTHROMYCIN				
FOUGERA PHARMS	2%	A065320 001		Jul 25, 2006
MYLAN	2%	A064128 001		Jul 03, 1996
T-STAT				
WESTWOOD SQUIBB	2%	A062748 001		Jul 23, 1987
TABLET;ORAL				
ERYTHROMYCIN				
ZYDUS PHARMS	250MG	A215440 001		Aug 31, 2023
	500MG	A215440 002		Aug 31, 2023
TABLET, COATED PARTICLES;ORAL				
PCE				
+ AZURITY	333MG	N050611 001		Sep 09, 1986
+	500MG	N050611 002		Aug 22, 1990
TABLET, DELAYED RELEASE;ORAL				
E-BASE				
BARR	333MG	A063028 001		May 15, 1990
	333MG	A063086 001		May 15, 1990
	500MG	A062999 001		Nov 25, 1988
E-MYCIN				
ARBOR PHARMS INC	250MG	A060272 001		
	333MG	A060272 002		
ILOTYCIN				
DISTA	250MG	A061910 001		
R-P MYCIN				
SOLVAY	250MG	A061659 001		
ROBIMYCIN				
ROBINS AH	250MG	A061633 001		
ERYTHROMYCIN ESTOLATE				
CAPSULE;ORAL				
ERYTHROMYCIN ESTOLATE				
BARR	EQ 125MG BASE	A062162 001		
	EQ 250MG BASE	A062162 002		
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A062237 001		
WATSON LABS	EQ 250MG BASE	A062087 001		

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERYTHROMYCIN ESTOLATE

CAPSULE;ORAL				
ILOSONE				
	LILLY	EQ 125MG BASE	A061897 001	
		EQ 250MG BASE	A061897 002	
FOR SUSPENSION;ORAL				
ILOSONE				
	DISTA	EQ 125MG BASE/5ML	A061893 001	
SUSPENSION;ORAL				
ERYTHROMYCIN ESTOLATE				
	ALPHARMA US PHARMS	EQ 125MG BASE/5ML	A062353 001	Nov 18, 1982
		EQ 250MG BASE/5ML	A062409 001	Dec 16, 1982
	COSETTE	EQ 125MG BASE/5ML	A062169 001	Oct 17, 1990
		EQ 250MG BASE/5ML	A062169 002	Oct 17, 1990
	LIFE LABS	EQ 250MG BASE/5ML	A062362 001	Dec 17, 1982
ILOSONE				
	LILLY	EQ 125MG BASE/5ML	A061894 001	
		EQ 125MG BASE/5ML	N050010 001	
		EQ 250MG BASE/5ML	A061894 002	
		EQ 250MG BASE/5ML	N050010 002	
SUSPENSION/DROPS;ORAL				
ILOSONE				
	LILLY	EQ 100MG BASE/ML	A061894 003	
TABLET;ORAL				
ILOSONE				
	LILLY	EQ 500MG BASE	A061896 001	
TABLET, CHEWABLE;ORAL				
ILOSONE				
	DISTA	EQ 125MG BASE	A061895 001	
		EQ 250MG BASE	A061895 002	

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION;ORAL				
ILOSONE SULFA				
	LILLY	EQ 125MG BASE/5ML;EQ 600MG BASE/5ML	N050599 001	Sep 29, 1989

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL				
ERYTHROMYCIN ETHYLSUCCINATE				
	PAR PHARM INC	EQ 200MG BASE/5ML	A211991 001	Oct 23, 2019
		EQ 400MG BASE/5ML	A211991 002	Oct 23, 2019
PEDIAMYCIN				
	ROSS LABS	EQ 200MG BASE/5ML	A062305 001	
SUSPENSION;ORAL				
E-MYCIN E				
	PHARMACIA AND UPJOHN	EQ 200MG BASE/5ML	A062198 001	
		EQ 400MG BASE/5ML	A062198 002	
E.E.S. 200				
	ARBOR PHARMS LLC	EQ 200MG BASE/5ML **	A061639 001	
E.E.S. 400				
	ARBOR PHARMS LLC	EQ 400MG BASE/5ML **	A061639 002	
ERYTHROMYCIN ETHYLSUCCINATE				
	ALPHARMA US PHARMS	EQ 200MG BASE/5ML	A062200 001	
		EQ 400MG BASE/5ML	A062200 002	
	DISTA	EQ 200MG BASE/5ML	A062177 001	
		EQ 400MG BASE/5ML	A062177 002	
	NASKA	EQ 400MG BASE/5ML	A062674 001	Mar 10, 1987
	PARKE DAVIS	EQ 200MG BASE/5ML	A062231 001	
		EQ 400MG BASE/5ML	A062231 002	
	PHARMAFAIR	EQ 200MG BASE/5ML	A062559 001	Mar 15, 1985
		EQ 400MG BASE/5ML	A062558 001	Mar 15, 1985
PEDIAMYCIN				
	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A062304 001	
PEDIAMYCIN 400				
	ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A062304 002	
WYAMYCIN E				
	WYETH AYERST	EQ 200MG BASE/5ML	A062123 002	
		EQ 400MG BASE/5ML	A062123 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERYTHROMYCIN ETHYLSUCCINATE				
SUSPENSION/DROPS;ORAL				
PEDIAMYCIN				
	ROSS LABS	EQ 100MG BASE/2.5ML	A062305 002	
TABLET;ORAL				
E.E.S. 400				
	ARBOR PHARMS LLC	EQ 400MG BASE	A061905 001	
ERYTHROMYCIN ETHYLSUCCINATE				
	AUROBINDO PHARMA USA	EQ 400MG BASE	A062847 001	Sep 14, 1988
	BARR	EQ 400MG BASE	A062256 001	
TABLET, CHEWABLE;ORAL				
E.E.S.				
	AZURITY	EQ 200MG BASE	N050297 002	
ERYPED				
	AZURITY	EQ 200MG BASE	N050297 003	Jul 05, 1988
PEDIAMYCIN				
	ROSS LABS	EQ 200MG BASE	A062306 001	
ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL				
GRANULE;ORAL				
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL				
	BARR	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	A062759 001	May 20, 1988
ERYZOLE				
	ALRA	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	A062758 001	Jun 15, 1988
PEDIAZOLE				
	ROSS LABS	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML **	N050529 001	
ERYTHROMYCIN GLUCEPTATE				
INJECTABLE;INJECTION				
ILOTYCIN GLUCEPTATE				
	DISTA	EQ 250MG BASE/VIAL	N050370 001	
		EQ 500MG BASE/VIAL	N050370 002	
		EQ 1GM BASE/VIAL	N050370 003	
ERYTHROMYCIN LACTOBIONATE				
INJECTABLE;INJECTION				
ERYTHROCIN				
	ABBOTT	EQ 500MG BASE/VIAL	A062586 001	Jan 04, 1988
		EQ 1GM BASE/VIAL	A062586 002	Jan 04, 1988
	HOSPIRA	EQ 500MG BASE/VIAL	N050182 002	
		EQ 1GM BASE/VIAL	A062638 002	Oct 31, 1986
		EQ 1GM BASE/VIAL	N050182 003	
+		EQ 1GM BASE/VIAL	N050609 002	Sep 24, 1986
ERYTHROMYCIN				
	ELKINS SINN	EQ 500MG BASE/VIAL	A062563 001	Mar 28, 1985
		EQ 1GM BASE/VIAL	A062563 002	Mar 28, 1985
ERYTHROMYCIN LACTOBIONATE				
	ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062604 001	Nov 24, 1986
		EQ 1GM BASE/VIAL	A062604 002	Nov 24, 1986
	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	A062993 001	May 09, 1989
		EQ 1GM BASE/VIAL	A062993 002	May 09, 1989
	EXELA PHARMA	EQ 500MG BASE/VIAL	A211086 001	Sep 17, 2020
	TEVA PARENTERAL	EQ 500MG BASE/VIAL	A063253 001	Jul 30, 1993
		EQ 1GM BASE/VIAL	A063253 002	Jul 30, 1993
ERYTHROMYCIN STEARATE				
TABLET;ORAL				
BRISTAMYCIN				
	BRISTOL	EQ 250MG BASE	A061304 001	
		EQ 250MG BASE	A061887 001	
ERYPAR				
	PARKE DAVIS	EQ 250MG BASE	A062032 001	
		EQ 500MG BASE	A062032 002	
	WARNER CHILCOTT	EQ 250MG BASE	A062322 001	
ERYTHROCIN STEARATE				
	ARBOR PHARMS LLC	EQ 125MG BASE	A060359 002	
		EQ 500MG BASE	A060359 003	
ERYTHROMYCIN STEARATE				
	ANI PHARMS	EQ 250MG BASE	A061461 001	
		EQ 250MG BASE	A061591 001	
		EQ 500MG BASE	A061461 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERYTHROMYCIN STEARATE				
TABLET;ORAL				
ERYTHROMYCIN STEARATE				
	EQ 500MG BASE	A063179 001	May 15, 1990	
LEDERLE	EQ 250MG BASE	A062089 001		
	EQ 500MG BASE	A062089 002		
MYLAN	EQ 250MG BASE	A061505 001		
	EQ 500MG BASE	A061505 002		
PUREPAC PHARM	EQ 250MG BASE	A061743 001		
WATSON LABS	EQ 250MG BASE	A062121 002		
	EQ 500MG BASE	A062121 001		
ETHRIL 250				
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061605 001		
ETHRIL 500				
BRISTOL MYERS SQUIBB	EQ 500MG BASE	A061605 002		
PFIZER-E				
PFIZER	EQ 250MG BASE	A061791 001		
	EQ 500MG BASE	A061791 002		
WYAMYCIN S				
WYETH AYERST	EQ 250MG BASE	A061675 001		
	EQ 500MG BASE	A061675 002		
ESCITALOPRAM OXALATE				
CAPSULE;ORAL				
ESCITALOPRAM OXALATE				
MYLAN PHARMS INC	EQ 5MG BASE	A077660 001	Jul 31, 2007	
	EQ 10MG BASE	A077660 002	Jul 31, 2007	
	EQ 20MG BASE	A077660 003	Jul 31, 2007	
SOLUTION;ORAL				
ESCITALOPRAM OXALATE				
ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967 001	May 26, 2015	
LEXAPRO				
+ ABBVIE	EQ 5MG BASE/5ML **	N021365 001	Nov 27, 2002	
TABLET;ORAL				
ESCITALOPRAM OXALATE				
DASH PHARMS	EQ 5MG BASE	A077550 001	May 14, 2015	
	EQ 10MG BASE	A077550 002	May 14, 2015	
	EQ 20MG BASE	A077550 003	May 14, 2015	
HIKMA PHARMS	EQ 5MG BASE	A078766 001	Sep 11, 2012	
	EQ 10MG BASE	A078766 002	Sep 11, 2012	
	EQ 20MG BASE	A078766 003	Sep 11, 2012	
TEVA PHARMS USA	EQ 5MG BASE	A076765 001	Mar 14, 2012	
	EQ 10MG BASE	A076765 002	Mar 14, 2012	
	EQ 20MG BASE	A076765 003	Mar 14, 2012	
ESMOLOL HYDROCHLORIDE				
INJECTABLE;INJECTION				
BREVIBLOC				
BAXTER HLTHCARE	10MG/ML	N019386 003	Aug 15, 1988	
	20MG/ML	N019386 007	May 28, 2003	
ESMOLOL HYDROCHLORIDE				
AM REGENT	10MG/ML	A201126 001	Feb 20, 2015	
FRESENIUS KABI USA	10MG/ML	A076573 001	May 02, 2005	
	20MG/ML	A076573 002	Aug 23, 2023	
ESOMEPRAZOLE MAGNESIUM				
CAPSULE, DELAYED REL PELLETS;ORAL				
ESOMEPRAZOLE MAGNESIUM				
AMNEAL PHARMS NY	EQ 20MG BASE	A209647 001	Apr 10, 2019	
	EQ 40MG BASE	A209647 002	Apr 10, 2019	
HEC PHARM	EQ 20MG BASE	A207265 002	May 18, 2018	
	EQ 40MG BASE	A207265 001	May 18, 2018	
HETERO LABS LTD III	EQ 20MG BASE	A202784 001	Sep 21, 2015	
	EQ 40MG BASE	A202784 002	Sep 21, 2015	
TORRENT	EQ 20MG BASE	A203636 001	Oct 19, 2015	
	EQ 40MG BASE	A203636 002	Oct 19, 2015	
CAPSULE, DELAYED RELEASE;ORAL				
ESOMEPRAZOLE MAGNESIUM				
HETERO LABS LTD III	EQ 20MG BASE	A208939 001	May 28, 2020	
MYLAN	EQ 20MG BASE	A212376 001	Oct 16, 2019	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ESOMEPRAZOLE MAGNESIUM					
TABLET, DELAYED RELEASE;ORAL					
ESOMEPRAZOLE MAGNESIUM					
	P AND L	EQ 20MG BASE	A209202	001	Mar 05, 2019
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL					
ESOMEPRAZOLE MAGNESIUM					
+	DEXCEL	EQ 20MG BASE	N214278	001	Oct 20, 2020
ESOMEPRAZOLE MAGNESIUM; NAPROXEN					
TABLET, DELAYED RELEASE;ORAL					
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM					
	ACTAVIS LABS FL INC	EQ 20MG BASE;375MG	A204470	001	Aug 24, 2022
		EQ 20MG BASE;500MG	A204470	002	Aug 24, 2022
	MYLAN	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021
		EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021
VIMOVO					
+	HORIZON	EQ 20MG BASE;375MG **	N022511	002	Apr 30, 2010
+		EQ 20MG BASE;500MG **	N022511	001	Apr 30, 2010
ESOMEPRAZOLE SODIUM					
INJECTABLE;INTRAVENOUS					
ESOMEPRAZOLE SODIUM					
	EUGIA PHARMA	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016
	MYLAN	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017
		EQ 40MG BASE/VIAL	A202686	002	May 17, 2017
	SUN PHARM	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013
NEXIUM IV					
+	ASTRAZENECA	EQ 20MG BASE/VIAL **	N021689	001	Mar 31, 2005
ESOMEPRAZOLE STRONTIUM					
CAPSULE, DELAYED RELEASE;ORAL					
ESOMEPRAZOLE STRONTIUM					
+	BELCHER	24.65MG	N202342	001	Aug 06, 2013
+		49.3MG	N202342	002	Aug 06, 2013
ESTAZOLAM					
TABLET;ORAL					
PROSOM					
+	ABBOTT	1MG **	N019080	001	Dec 26, 1990
+		2MG **	N019080	002	Dec 26, 1990
ESTRADIOL					
FILM, EXTENDED RELEASE;TRANSDERMAL					
ALORA					
	ABBVIE	0.025MG/24HR	N020655	004	Apr 05, 2002
		0.05MG/24HR	N020655	001	Dec 20, 1996
		0.075MG/24HR	N020655	002	Dec 20, 1996
		0.1MG/24HR	N020655	003	Dec 20, 1996
ESTRADIOL					
	ZYDUS PHARMS	0.025MG/24HR	A202985	001	Mar 29, 2023
		0.0375MG/24HR	A202985	002	Mar 29, 2023
		0.05MG/24HR	A202985	003	Mar 29, 2023
		0.06MG/24HR	A202985	004	Mar 29, 2023
		0.075MG/24HR	A202985	005	Mar 29, 2023
		0.1MG/24HR	A202985	006	Mar 29, 2023
FEMPATCH					
	PARKE DAVIS	0.025MG/24HR	N020417	001	Dec 03, 1996
GEL;TOPICAL					
ESTROGEL					
	ASCEND THERAPS US	0.06%	N021166	001	Feb 09, 2004
SYSTEM;TRANSDERMAL					
ESCLIM					
	WOMEN FIRST HLTHCARE	0.025MG/24HR	N020847	001	Aug 04, 1998
		0.0375MG/24HR	N020847	002	Aug 04, 1998
		0.05MG/24HR	N020847	003	Aug 04, 1998
		0.075MG/24HR	N020847	004	Aug 04, 1998
		0.1MG/24HR	N020847	005	Aug 04, 1998
ESTRADERM					
+	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986
+		0.1MG/24HR	N019081	003	Sep 10, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ESTRADIOL					
SYSTEM;TRANSDERMAL					
ESTRADIOL					
	ORTHO MCNEIL PHARM	0.05MG/24HR	N021048	001	Sep 20, 1999
		0.075MG/24HR	N021048	002	Sep 20, 1999
		0.1MG/24HR	N021048	003	Sep 20, 1999
VIVELLE					
	SANDOZ	0.025MG/24HR	N020323	005	Aug 16, 2000
		0.0375MG/24HR	N020323	001	Oct 28, 1994
		0.05MG/24HR	N020323	002	Oct 28, 1994
		0.075MG/24HR	N020323	003	Oct 28, 1994
		0.1MG/24HR	N020323	004	Oct 28, 1994
TABLET;ORAL					
ESTRACE					
	BRISTOL MYERS SQUIBB	0.5MG	A081295	001	Jun 30, 1993
+		1MG	A084499	001	
+		2MG	A084500	001	
ESTRADIOL					
	DR REDDYS LABS SA	0.5MG	A040114	003	Mar 14, 1996
		1MG	A040114	001	Mar 14, 1996
		2MG	A040114	002	Mar 14, 1996
	LANNETT CO INC	0.5MG	A040138	001	Jan 30, 1998
		1MG	A040138	002	Jan 30, 1998
		2MG	A040138	003	Jan 30, 1998
	MYLAN	0.5MG	A040326	001	Apr 21, 1999
		1MG	A040326	002	Apr 21, 1999
		2MG	A040326	003	Apr 21, 1999
	USL PHARMA	0.5MG	A040297	001	Apr 17, 2002
		1MG	A040297	002	Apr 17, 2002
		2MG	A040297	003	Apr 17, 2002
GYNODIOL					
	DURAMED PHARMS BARR	0.5MG	A040212	001	Dec 29, 1997
		1MG	A040212	002	Dec 29, 1997
		1.5MG	A040212	003	Dec 29, 1997
		2MG	A040212	004	Dec 29, 1997
INNOFEM					
	NOVO NORDISK INC	0.5MG	A040312	001	Nov 19, 1999
		1MG	A040312	002	Nov 19, 1999
		2MG	A040312	003	Nov 19, 1999
TABLET;VAGINAL					
VAGIFEM					
+	NOVO NORDISK INC	25MCG **	N020908	001	Mar 26, 1999
ESTRADIOL ACETATE					
TABLET;ORAL					
FEMTRACE					
+	APIL	0.45MG	N021633	001	Aug 20, 2004
+		0.9MG	N021633	002	Aug 20, 2004
+		1.8MG	N021633	003	Aug 20, 2004
ESTRADIOL CYPIONATE					
INJECTABLE;INJECTION					
DEPO-ESTRADIOL					
	PFIZER	1MG/ML	A085470	001	
		3MG/ML	A085470	002	
ESTRADIOL CYPIONATE					
	DR REDDYS	5MG/ML	A085620	001	
ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE					
INJECTABLE;INTRAMUSCULAR					
LUNELLE					
	PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N020874	001	Oct 05, 2000
ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE					
INJECTABLE;INJECTION					
DEPO-TESTADIOL					
	PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N017968	001	
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE					
	WATSON LABS	2MG/ML;50MG/ML	A085603	001	Mar 13, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ESTRADIOL HEMIHYDRATE					
EMULSION;TOPICAL					
ESTRASORB					
+	EXELTIS USA INC	0.25%	N021371	001	Oct 09, 2003
ESTRADIOL VALERATE					
INJECTABLE;INJECTION					
ESTRADIOL VALERATE					
	DR REDDYS	20MG/ML	A083547	001	
		40MG/ML	A083714	001	
	FOSUN PHARMA	10MG/ML	A040628	001	Oct 04, 2007
		20MG/ML	A040628	002	Oct 04, 2007
		40MG/ML	A040628	003	Oct 04, 2007
	WATSON LABS	10MG/ML	A083546	001	
ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE					
INJECTABLE;INJECTION					
DITATE-DS					
	SAVAGE LABS	8MG/ML;180MG/ML	A086423	001	
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE					
	WATSON LABS	4MG/ML;90MG/ML	A085865	001	
		8MG/ML;180MG/ML	A085860	001	
ESTRADIOL; NORETHINDRONE ACETATE					
TABLET;ORAL					
ACTIVELLA					
+	AMNEAL	0.5MG;0.1MG **	N020907	002	Dec 28, 2006
ESTRADIOL AND NORETHINDRONE ACETATE					
	NAARI PTE LTD	1MG;0.5MG	A210233	001	Feb 28, 2018
	TEVA PHARMS USA	0.5MG;0.1MG	A200747	001	Mar 08, 2012
ETYQA					
	AUROBINDO PHARMA LTD	0.5MG;0.1MG	A214729	001	Jun 30, 2023
		1MG;0.5MG	A214729	002	Jun 30, 2023
ESTRADIOL; NORGESTIMATE					
TABLET;ORAL					
PREFEST					
+	TEVA WOMENS	1MG,1MG;N/A,0.09MG **	N021040	001	Oct 22, 1999
ESTRADIOL; PROGESTERONE					
CAPSULE;ORAL					
ESTRADIOL AND PROGESTERONE					
	AMNEAL PHARMS	1MG;100MG	A214293	001	May 16, 2022
ESTROGENS, CONJUGATED					
TABLET;ORAL					
PREMARIN					
	WYETH PHARMS	2.5MG	N004782	002	
ESTROGENS, CONJUGATED SYNTHETIC A					
CREAM;VAGINAL					
SYNTHETIC CONJUGATED ESTROGENS A					
	TEVA WOMENS	0.625MG/GM	N021788	001	Nov 28, 2008
TABLET;ORAL					
CENESTIN					
+	ASPEN	0.3MG **	N020992	001	Jun 21, 2002
+		0.45MG **	N020992	005	Feb 05, 2004
+		0.625MG **	N020992	002	Mar 24, 1999
+		0.9MG **	N020992	003	Mar 24, 1999
+		1.25MG **	N020992	004	Mar 13, 2000
ESTROGENS, CONJUGATED SYNTHETIC B					
TABLET;ORAL					
ENJUVIA					
	ASPEN	0.3MG	N021443	001	Dec 20, 2004
		0.45MG	N021443	002	Dec 20, 2004
		0.625MG **	N021443	003	May 10, 2004
		0.9MG	N021443	005	Apr 27, 2007
		1.25MG **	N021443	004	May 10, 2004

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE				
TABLET;ORAL-28				
PREMPHASE (PREMARIN;CYCRIN 14/14)				
	WYETH PHARMS INC	0.625MG,0.625MG;N/A,5MG	N020303 002	Dec 30, 1994
PREMPRO (PREMARIN;CYCRIN)				
	WYETH PHARMS INC	0.625MG,0.625MG;2.5MG,2.5MG	N020303 001	Dec 30, 1994
ESTROGENS, CONJUGATED; MEPROBAMATE				
TABLET;ORAL				
MILPREM-200				
	MEDPOINTE PHARM HLC	0.45MG;200MG	N011045 002	
MILPREM-400				
	MEDPOINTE PHARM HLC	0.45MG;400MG	N011045 001	
PMB 200				
	WYETH AYERST	0.45MG;200MG	N010971 005	
PMB 400				
	WYETH AYERST	0.45MG;400MG	N010971 003	
ESTROGENS, ESTERIFIED				
TABLET;ORAL				
AMNESTROGEN				
	BRISTOL MYERS SQUIBB	0.3MG	A083266 001	
		0.625MG	A083266 002	
		1.25MG	A083266 003	
		2.5MG	A083266 004	
ESTERIFIED ESTROGENS				
	PVT FORM	0.625MG	A083414 001	
		1.25MG	A083765 001	
		2.5MG	A085907 001	
	SANDOZ	1.25MG	A085302 001	
ESTRATAB				
	SOLVAY	0.3MG	A086715 001	
		0.625MG	A083209 001	
		1.25MG	A083856 001	
		2.5MG	A083857 001	
EVEX				
	ROCHE PALO	0.625MG	A084215 001	
		1.25MG	A083376 002	
FEMOGEN				
	PVT FORM	0.625MG	A085076 001	
		1.25MG	A085008 001	
		2.5MG	A085007 001	
ESTRONE				
INJECTABLE;INJECTION				
ESTROGENIC SUBSTANCE				
	WYETH AYERST	2MG/ML	A083488 001	
ESTRONE				
	DR REDDYS	5MG/ML	A085239 001	
	WATSON LABS	2MG/ML	A083397 001	
NATURAL ESTROGENIC SUBSTANCE-ESTRONE				
	WATSON LABS	2MG/ML	A085237 001	Nov 23, 1982
THEELIN				
	PARKEDALE	1MG/ML	N003977 001	
		2MG/ML	N003977 002	
		5MG/ML	N003977 003	
ESTROPIPATE				
CREAM;VAGINAL				
OGEN				
	PHARMACIA AND UPJOHN	1.5MG/GM	A084710 001	
TABLET;ORAL				
ESTROPIPATE				
	BARR	0.75MG	A040135 001	Nov 27, 1996
		1.5MG	A040135 002	Nov 27, 1996
		3MG	A040135 003	Nov 27, 1996
	DURAMED PHARMS BARR	0.75MG	A040296 001	Nov 01, 1999
		1.5MG	A040296 002	Nov 01, 1999
		3MG	A040296 003	Nov 01, 1999
	MYLAN	0.75MG	A040359 001	Aug 26, 1999
		1.5MG	A040359 002	Aug 26, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ESTROPIPATE				
TABLET;ORAL				
ESTROPIPATE				
	3MG	A040359	003	Aug 26, 1999
WATSON LABS	0.75MG	A081213	001	Sep 23, 1993
	1.5MG	A081214	001	Sep 23, 1993
	6MG	A081216	001	Sep 23, 1993
WATSON LABS TEVA	3MG	A081215	001	Sep 23, 1993
OGEN .625				
+ PFIZER	0.75MG	A083220	001	
OGEN 1.25				
+ PFIZER	1.5MG	A083220	002	
OGEN 2.5				
+ PFIZER	3MG	A083220	003	
ORTHO-EST				
SUN PHARM INDS INC	0.75MG	A089567	001	Feb 27, 1991
	1.5MG	A089582	001	Jul 17, 1991
ESZOPICLONE				
TABLET;ORAL				
ESZOPICLONE				
CHARTWELL RX	1MG	A091165	001	Jul 14, 2011
	2MG	A091165	002	Jul 14, 2011
	3MG	A091165	003	Jul 14, 2011
HIKMA	1MG	A091153	001	Apr 15, 2014
	2MG	A091153	002	Apr 15, 2014
	3MG	A091153	003	Apr 15, 2014
NOSTRUM LABS INC	1MG	A203087	001	May 08, 2019
	2MG	A203087	002	May 08, 2019
	3MG	A203087	003	May 08, 2019
ETHACRYNIC ACID				
TABLET;ORAL				
EDECRIN				
BAUSCH	50MG	N016092	002	
ETHACRYNIC ACID				
ALVOGEN	25MG	A205709	001	Jul 24, 2018
HIKMA	25MG	A207262	001	Feb 23, 2017
ETHAMBUTOL HYDROCHLORIDE				
TABLET;ORAL				
ETHAMBUTOL HYDROCHLORIDE				
BARR	400MG	A076057	001	Nov 26, 2001
MYAMBUTOL				
STI PHARMA LLC	200MG	N016320	002	
	500MG	N016320	004	
ETHCHLORVYNOL				
CAPSULE;ORAL				
ETHCHLORVYNOL				
BANNER PHARMACAPS	100MG	A084463	001	
	200MG	A084463	002	
	500MG	A084463	003	
	750MG	A084463	004	
PLACIDYL				
ABBVIE	100MG	N010021	004	
	200MG	N010021	007	
	500MG	N010021	002	
	750MG	N010021	010	
ETHINAMATE				
CAPSULE;ORAL				
VALMID				
DISTA	500MG	N009750	001	
ETHINYL ESTRADIOL				
TABLET;ORAL				
ESTINYL				
SCHERING	0.02MG	N005292	001	
	0.05MG	N005292	002	
	0.5MG	N005292	003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL

TABLET;ORAL

FEMINONE				
PHARMACIA AND UPJOHN	0.05MG	N016649	001	
LYNORAL				
ORGANON USA INC	0.01MG	N005490	003	
	0.05MG	N005490	002	

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21

DEMULEN 1/35-21				
GD SEARLE LLC	0.035MG;1MG **	N018168	001	
DEMULEN 1/50-21				
GD SEARLE LLC	0.05MG;1MG	N016927	001	
ZOVIA 1/35E-21				
WATSON PHARMS TEVA	0.035MG;1MG	A072720	001	Dec 30, 1991
ZOVIA 1/50E-21				
WATSON LABS	0.05MG;1MG	A072722	001	Dec 30, 1991

TABLET;ORAL-28

DEMULEN 1/35-28				
GD SEARLE LLC	0.035MG;1MG **	N018160	001	
DEMULEN 1/50-28				
GD SEARLE LLC	0.05MG;1MG **	N016936	001	
ZOVIA 1/35E-28				
DR REDDYS LABS SA	0.035MG;1MG	A072721	001	Dec 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

VERARING				
DR REDDYS LABS SA	0.015MG/24HR;0.12MG/24HR	A207577	001	Dec 09, 2021

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET;ORAL-28

NORQUEST FE				
PFIZER	0.035MG;75MG;1MG	N018926	001	Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET;ORAL-28

NORLESTRIN FE 1/50				
PARKE DAVIS	0.05MG;75MG;1MG	N016766	001	
NORLESTRIN FE 2.5/50				
PARKE DAVIS	0.05MG;75MG;2.5MG	N016854	001	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

FAYOSIM				
LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	A205943	001	Mar 29, 2016
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL				
DR REDDYS LABS SA	0.02MG,0.1MG;0.01MG,N/A	A200407	001	Oct 25, 2011
LYBREL				
+ WYETH PHARMS INC	0.02MG;0.09MG **	N021864	001	May 22, 2007
PREVEN EMERGENCY CONTRACEPTIVE KIT				
TEVA BRANDED PHARM	0.05MG;0.25MG	N020946	001	Sep 01, 1998
SYLEVIA				
SUN PHARM	0.03MG;0.15MG	A202988	001	Feb 06, 2019

TABLET;ORAL-21

ALESSE				
+ CADENCE HEALTH	0.02MG;0.1MG **	N020683	001	Mar 27, 1997
AVIANE-21				
DURAMED PHARMS BARR	0.02MG;0.1MG	A075796	002	Apr 30, 2001
ENPRESSE-21				
DURAMED PHARMS BARR	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A075809	001	Jul 16, 2001
LESSINA-21				
BARR	0.02MG;0.1MG	A075803	001	Mar 20, 2002
LEVLITE				
+ BAYER HLTHCARE	0.02MG;0.1MG **	N020860	001	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL				
BARR	0.02MG;0.1MG	A075862	001	Apr 29, 2003
LEVORA 0.15/30-21				
WATSON LABS	0.03MG;0.15MG	A073592	001	Dec 13, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-21					
NORDETTE-21					
	TEVA BRANDED PHARM	0.03MG;0.15MG	N018668	001	May 10, 1982
PORTIA-21					
	BARR	0.03MG;0.15MG	A075866	001	May 23, 2002
TRIPHASIL-21					
+	WYETH PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **	N019192	001	Nov 01, 1984
TRIVORA-21					
	DR REDDYS LABS SA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538	001	Dec 18, 1997
TABLET;ORAL-28					
ALESSE					
+	CADENCE HEALTH	0.02MG;0.1MG **	N020683	002	Mar 27, 1997
CERINTA					
	SUN PHARM	0.02MG;0.1MG	A202817	001	Jan 07, 2019
ELIFEMME					
	XIROMED	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202507	001	Dec 04, 2015
LEVLITE					
+	BAYER HLTHCARE	0.02MG;0.1MG **	N020860	002	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL					
	AMNEAL PHARMS	0.02MG;0.1MG	A201108	001	Feb 05, 2014
		0.03MG;0.15MG	A201095	001	Dec 08, 2014
	BARR	0.02MG;0.1MG	A075862	002	Apr 29, 2003
	MYLAN LABS LTD	0.02MG;0.1MG	A202247	001	Dec 08, 2014
		0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018
NORDETTE-28					
+	TEVA BRANDED PHARM	0.03MG;0.15MG **	N018782	001	Jul 21, 1982
ORSYTHIA					
	VINTAGE PHARMS LLC	0.02MG;0.1MG	A077099	001	May 11, 2011
TRIPHASIL-28					
+	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **	N019190	001	Nov 01, 1984

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL					
ORTHO EVRA					
+	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR **	N021180	001	Nov 20, 2001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL					
FEMCON FE					
+	APIL	0.035MG;0.4MG **	N021490	001	Nov 14, 2003
TABLET;ORAL-21					
BALZIVA-21					
	BARR	0.035MG;0.4MG	A076198	001	Apr 22, 2004
BREVICON 21-DAY					
	ALLERGAN	0.035MG;0.5MG	N017566	001	
GENCEPT 10/11-21					
	BARR	0.035MG,0.035MG;0.5MG,1MG	A072694	001	Feb 28, 1992
MODICON 21					
	ORTHO MCNEIL PHARM	0.035MG;0.5MG **	N017488	001	
N.E.E. 1/35 21					
	LPI	0.035MG;1MG	A071541	001	Dec 14, 1987
NORCEPT-E 1/35 21					
	ORTHO MCNEIL PHARM	0.035MG;1MG	A071545	001	Feb 09, 1989
NORETHIN 1/35E-21					
	WATSON PHARMS TEVA	0.035MG;1MG	A071480	001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL					
	WATSON LABS	0.035MG;0.4MG	A078379	001	Feb 23, 2010
		0.035MG;0.5MG	A070684	001	Jan 29, 1987
	WATSON PHARMS TEVA	0.035MG;1MG	A070685	001	Jan 29, 1987
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)					
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071043	001	Apr 01, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)					
	WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep 24, 1991
NORINYL 1+35 21-DAY					
	ALLERGAN	0.035MG;1MG	N017565	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21					
NORTREL 0.5/35-21					
	BARR	0.035MG;0.5MG	A072692	001	Feb 28, 1992
ORTHO-NOVUM 1/35-21					
	ORTHO MCNEIL PHARM	0.035MG;1MG **	N017489	002	
ORTHO-NOVUM 10/11-21					
+	ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG **	N018354	001	Jan 11, 1982
ORTHO-NOVUM 7/14-21					
	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG **	N019004	001	Apr 04, 1984
ORTHO-NOVUM 7/7/7-21					
	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N018985	001	Apr 04, 1984
OVCON-35					
+	WARNER CHILCOTT	0.035MG;0.4MG **	N018127	001	
OVCON-50					
	WARNER CHILCOTT	0.05MG;1MG	N018128	001	
TRI-NORINYL 21-DAY					
	DR REDDYS LABS SA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	001	Apr 13, 1984
TABLET;ORAL-28					
BREVICON 28-DAY					
	ALLERGAN	0.035MG;0.5MG	N017743	001	
CYCLAFEM 0.5/35					
	VINTAGE PHARMS	0.035MG;0.5MG	A203413	001	Dec 16, 2015
CYCLAFEM 1/35					
	VINTAGE PHARMS LLC	0.035MG;1MG	A076337	001	Nov 12, 2010
CYCLAFEM 7/7/7					
	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076338	001	Nov 16, 2010
GENCEPT 10/11-28					
	BARR	0.035MG,0.035MG;0.5MG,1MG	A072697	001	Feb 28, 1992
MODICON 28					
+	JANSSEN PHARMS	0.035MG;0.5MG	N017735	001	
N.E.E. 1/35 28					
	LPI	0.035MG;1MG	A071542	001	Dec 14, 1987
NORCEPT-E 1/35 28					
	ORTHO MCNEIL PHARM	0.035MG;1MG	A071546	001	Feb 09, 1989
NORETHIN 1/35E-28					
	WATSON LABS	0.035MG;1MG	A071481	001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL					
	DR REDDYS LABS SA	0.035MG;0.5MG	A070686	001	Jan 29, 1987
	MYLAN LABS LTD	0.035MG;0.4MG	A200897	001	May 11, 2015
		0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A200486	001	Dec 28, 2015
		0.035MG;0.5MG	A200488	001	Oct 21, 2015
		0.035MG;1MG	A200489	001	Oct 21, 2015
		0.05MG;1MG	A203006	001	Aug 05, 2013
	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076393	001	Feb 04, 2010
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)					
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071042	001	Sep 24, 1991
NORINYL 1+35 28-DAY					
	ALLERGAN	0.035MG;1MG	N017565	002	
ORTHO-NOVUM 1/35-28					
+	JANSSEN PHARMS	0.035MG;1MG **	N017919	002	
ORTHO-NOVUM 10/11-28					
+	ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG	N018354	002	Jan 11, 1982
ORTHO-NOVUM 7/14-28					
	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG **	N019004	002	Apr 04, 1984
ORTHO-NOVUM 7/7/7-28					
+	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG **	N018985	002	Apr 04, 1984
OVCON-35					
+	WARNER CHILCOTT LLC	0.035MG;0.4MG **	N017716	001	
OVCON-50					
	WARNER CHILCOTT LLC	0.05MG;1MG **	N017576	001	
PIRMELLA 1/35					
	LUPIN LTD	0.035MG;1MG	A201512	001	Apr 24, 2013
PIRMELLA 7/7/7					
	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,	A201510	001	Apr 24, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28					
PIRMELLA 7/7/7					
		1MG			
RHUZDAH					
	AUROBINDO PHARMA	0.035MG;0.4MG	A207585	001	Oct 11, 2022

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL					
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	DR REDDYS LABS SA	0.02MG;1MG	A213901	001	Apr 28, 2022
TABLET;ORAL					
FEMHRT					
+	APIL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005
+		0.005MG;1MG **	N021065	002	Oct 15, 1999
LOESTRIN 24 FE					
+	TEVA BRANDED PHARM	0.02MG;1MG **	N021871	001	Feb 17, 2006
MINASTRIN 24 FE					
+	APIL	0.02MG;1MG	N203667	001	May 08, 2013
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
	MYLAN LABS LTD	0.0025MG;0.5MG	A207260	001	Feb 02, 2017
		0.005MG;1MG	A207259	001	Dec 27, 2016
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	MYLAN LABS LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009
		0.02MG;1MG	A207514	001	Sep 11, 2017
	APOTEX	0.02MG;1MG	A208639	001	Mar 21, 2018
	MYLAN LABS LTD	0.02MG;1MG	A202742	001	Oct 30, 2014
		0.02MG;1MG	A206120	001	Sep 12, 2017
TABLET;ORAL-21					
ESTROSTEP 21					
+	APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG **	N020130	001	Oct 09, 1996
GILDESS 1.5/30					
	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	002	Jul 24, 2012
GILDESS 1/20					
	VINTAGE PHARMS LLC	0.02MG;1MG	A077077	002	Jul 24, 2012
LOESTRIN 21 1.5/30					
+	TEVA BRANDED PHARM	0.03MG;1.5MG	N017875	001	
LOESTRIN 21 1/20					
+	TEVA BRANDED PHARM	0.02MG;1MG **	N017876	001	
LOESTRIN FE 1.5/30					
+	TEVA BRANDED PHARM	0.03MG;1.5MG	N017355	001	
MICROGESTIN 1.5/30					
	DR REDDYS LABS SA	0.03MG;1.5MG	A075548	002	Jul 30, 2003
MICROGESTIN 1/20					
	DR REDDYS LABS SA	0.02MG;1MG	A075647	002	Jul 30, 2003
NORLESTRIN 21 1/50					
	PARKE DAVIS	0.05MG;1MG	N016749	001	
NORLESTRIN 21 2.5/50					
	PARKE DAVIS	0.05MG;2.5MG	N016852	001	
TRI-LEGEST 21					
	BARR	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076405	001	Oct 26, 2007
TABLET;ORAL-28					
ESTROSTEP FE					
+	APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG **	N020130	002	Oct 09, 1996
GILDESS FE 1.5/30					
	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	001	Apr 28, 2005
GILDESS FE 1/20					
	VINTAGE PHARMS LLC	0.02MG;1MG	A077077	001	May 20, 2005
LOESTRIN FE 1/20					
+	TEVA BRANDED PHARM	0.02MG;1MG	N017354	001	
MICROGESTIN FE 1.5/30					
	DR REDDYS LABS SA	0.03MG;1.5MG	A075548	001	Feb 05, 2001
MICROGESTIN FE 1/20					
	DR REDDYS LABS SA	0.02MG;1MG	A075647	001	Feb 05, 2001
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
	DR REDDYS LABS SA	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076629	001	Mar 18, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-28				
NORLESTRIN 28 1/50				
	PARKE DAVIS	0.05MG;1MG	N016723 001	
TABLET, CHEWABLE, TABLET;ORAL				
LO MINASTRIN FE				
+	APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654 001	Jul 24, 2013

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-21				
ORTHO CYCLEN-21				
	JANSSEN PHARMS	0.035MG;0.25MG **	N019653 001	Dec 29, 1989
ORTHO TRI-CYCLEN				
	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG **	N019697 002	Jul 03, 1992
TABLET;ORAL-28				
NORGESTIMATE AND ETHINYL ESTRADIOL				
	AMNEAL PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A203870 001	Nov 12, 2015
		0.035MG;0.25MG	A203865 001	Oct 27, 2015
	MYLAN	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A201897 001	Jan 27, 2016
		0.035MG;0.25MG	A201896 001	Jan 27, 2016
	MYLAN LABS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A202132 001	Sep 09, 2015
	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479 001	Mar 09, 2011
		0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076626 001	Aug 17, 2006
		0.035MG;0.25MG	A076627 001	Aug 17, 2006
ORTHO CYCLEN-28				
+	JANSSEN PHARMS	0.035MG;0.25MG **	N019653 002	Dec 29, 1989
ORTHO TRI-CYCLEN				
+	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG **	N019697 001	Jul 03, 1992
ORTHO TRI-CYCLEN LO				
+	JANSSEN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG **	N021241 001	Aug 22, 2002
TRI-PREVIFEM				
	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076335 001	Mar 26, 2004

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21				
LO/OVRAL				
+	CADENCE HEALTH	0.03MG;0.3MG	N017612 001	
LOW-OGESTREL-21				
	DR REDDYS LABS SA	0.03MG;0.3MG	A075288 001	Jul 28, 1999
OGESTREL 0.5/50-21				
	WATSON LABS	0.05MG;0.5MG **	A075406 001	Dec 15, 1999
OVRAL				
	WYETH PHARMS	0.05MG;0.5MG	N016672 001	
TABLET;ORAL-28				
LO/OVRAL-28				
+	WYETH PHARMS	0.03MG;0.3MG **	N017802 001	
NORGESTREL AND ETHINYL ESTRADIOL				
	MYLAN LABS LTD	0.03MG;0.3MG	A201828 001	Jun 21, 2016
		0.05MG;0.5MG	A202875 001	May 08, 2017
OGESTREL 0.5/50-28				
	WATSON LABS	0.05MG;0.5MG	A075406 002	Dec 15, 1999
OVRAL-28				
	WYETH PHARMS	0.05MG;0.5MG	N016806 001	

ETHOPROPAZINE HYDROCHLORIDE

TABLET;ORAL				
PARSIDOL				
	PARKE DAVIS	10MG	N009078 003	
		50MG	N009078 006	
		100MG	N009078 008	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHOSUXIMIDE				
SYRUP;ORAL				
ETHOSUXIMIDE				
	TEVA PHARMS	250MG/5ML	A081306 001	Jul 30, 1993
ETHOTOIN				
TABLET;ORAL				
PEGANONE				
+	RECORDATI RARE	250MG	N010841 001	
		500MG	N010841 003	
ETHOXZOLAMIDE				
TABLET;ORAL				
CARDRASE				
	PHARMACIA AND UPJOHN	62.5MG	N011047 002	
		125MG	N011047 001	
ETHAMIDE				
	ALLERGAN	125MG	N016144 001	
ETHYLESTRENOL				
ELIXIR;ORAL				
MAXIBOLIN				
	ORGANON USA INC	2MG/5ML	N014006 002	
TABLET;ORAL				
MAXIBOLIN				
	ORGANON USA INC	2MG	N014005 002	
ETHYNODIOL DIACETATE; MESTRANOL				
TABLET;ORAL-20				
OVULEN				
	GD SEARLE LLC	1MG;0.1MG	N016029 002	
TABLET;ORAL-21				
OVULEN-21				
	GD SEARLE LLC	1MG;0.1MG	N016029 003	
TABLET;ORAL-28				
OVULEN-28				
	GD SEARLE LLC	1MG;0.1MG	N016705 001	
ETIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DURANEST				
+	ASTRAZENECA	0.5% **	N017751 003	
+		1% **	N017751 005	
ETIDRONATE DISODIUM				
INJECTABLE;INJECTION				
DIDRONEL				
	MGI PHARMA INC	50MG/ML	N019545 001	Apr 20, 1987
TABLET;ORAL				
DIDRONEL				
+	APIL	200MG **	N017831 001	
+		400MG **	N017831 002	
ETIDRONATE DISODIUM				
	MYLAN	200MG	A075800 001	Jan 24, 2003
		400MG	A075800 002	Jan 24, 2003
ETODOLAC				
CAPSULE;ORAL				
ETODOLAC				
	ANI PHARMS	200MG	A074840 001	Aug 29, 1997
		200MG	A074844 001	Dec 23, 1997
		200MG	A074899 001	Jul 08, 1997
		300MG	A074840 002	Aug 29, 1997
		300MG	A074844 002	Dec 23, 1997
		300MG	A074899 002	Jul 08, 1997
	BIOPHARM	300MG	A074929 001	Jan 30, 1998
	CHARTWELL MOLECULES	200MG	A074842 001	Jul 17, 1997
		300MG	A074842 002	Jul 17, 1997
	MYLAN	200MG	A074932 001	May 16, 1997
		200MG	A075071 001	Sep 30, 1998
		300MG	A074932 002	May 16, 1997
		300MG	A075071 002	Sep 30, 1998
	SANDOZ	200MG	A074942 001	Sep 30, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETODOLAC

CAPSULE;ORAL					
ETODOLAC					
		300MG	A074942	002	Sep 30, 1997
LODINE					
+	WYETH PHARMS INC	200MG **	N018922	002	Jan 31, 1991
+		300MG	N018922	003	Jan 31, 1991
TABLET;ORAL					
ETODOLAC					
	BIOPHARM	400MG	A074927	001	Oct 30, 1997
	CHARTWELL MOLECULES	400MG	A074841	001	Jun 27, 1997
	EDENBRIDGE PHARMS	400MG	A209888	001	Nov 30, 2018
		500MG	A209888	002	Nov 30, 2018
	IVAX SUB TEVA PHARMS	400MG	A074883	001	Feb 28, 1997
		500MG	A074883	002	Nov 20, 1998
	MYLAN	400MG	A075012	001	Sep 30, 1998
		400MG	A075104	001	Feb 06, 1998
		500MG	A075012	002	Sep 30, 1998
		500MG	A075104	002	Nov 20, 1998
	OXFORD PHARMS	400MG	A074819	001	Feb 28, 1997
		500MG	A074819	002	Apr 28, 1998
	RANBAXY LABS LTD	400MG	A075226	001	Nov 24, 1998
		500MG	A075226	002	Nov 24, 1998
	SHREE HARI INTL	400MG	A074839	001	Jul 11, 1997
		400MG	A074846	001	Feb 28, 1997
	TEVA	400MG	A074847	001	Apr 23, 1999
		400MG	A075009	001	Nov 26, 1997
		500MG	A074847	002	Apr 23, 1999
		500MG	A075009	002	Dec 28, 1999
	WATSON LABS	400MG	A074892	001	Apr 16, 1997
		400MG	A075069	001	Apr 16, 1998
		500MG	A074892	002	Oct 29, 1998
LODINE					
+	WYETH PHARMS INC	400MG **	N018922	004	Jul 29, 1993
+		500MG **	N018922	005	Jun 28, 1996
TABLET, EXTENDED RELEASE;ORAL					
ETODOLAC					
	ACTAVIS ELIZABETH	400MG	A075696	001	Jul 31, 2000
	ANI PHARMS	400MG	A075943	001	Jul 26, 2002
		500MG	A075943	002	Jul 26, 2002
		600MG	A075943	003	Jul 26, 2002
	WATSON LABS FLORIDA	400MG	A075829	001	Nov 30, 2001
		500MG	A075829	002	Nov 30, 2001
LODINE XL					
	WYETH PHARMS INC	400MG **	N020584	001	Oct 25, 1996
		500MG **	N020584	003	Jan 20, 1998
+		600MG **	N020584	002	Oct 25, 1996

ETOMIDATE

INJECTABLE;INJECTION					
ETOMIDATE					
	AVET LIFESCIENCES	2MG/ML	A204618	001	Aug 13, 2014
	LUITPOLD	2MG/ML	A078867	001	Dec 22, 2009
	PAR STERILE PRODUCTS	2MG/ML	A091297	001	Jun 20, 2012
	RISING	2MG/ML	A078289	001	Jan 02, 2009

ETONOGESTREL

IMPLANT;IMPLANTATION					
IMPLANON					
	ORGANON	68MG/IMPLANT	N021529	001	Jul 17, 2006

ETOPOSIDE

CAPSULE;ORAL					
VEPESID					
+	STRIDES PHARMA	50MG	N019557	001	Dec 30, 1986
+		100MG	N019557	002	Dec 30, 1986
INJECTABLE;INJECTION					
ETOPOSIDE					
	DASH PHARMS	20MG/ML	A204927	001	Oct 31, 2017
	DASH PHARMS NATCO	20MG/ML	A203507	001	Nov 20, 2017
	HOSPIRA	20MG/ML	A074320	001	Aug 30, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETOPOSIDE				
INJECTABLE;INJECTION				
ETOPOSIDE				
	20MG/ML		A074351 001	Aug 30, 1995
PHARMACHEMIE BV	20MG/ML		A074227 001	Feb 22, 1996
PIERRE FABRE	20MG/ML		A074813 001	Jul 09, 1997
TEVA PARENTERAL	20MG/ML		A074510 001	Jun 29, 1995
TEVA PHARMS USA	20MG/ML		A074284 001	Feb 10, 1994
WATSON LABS	20MG/ML		A074228 001	Oct 15, 1996
WATSON LABS INC	20MG/ML		A074968 001	Jan 09, 1998
TOPOSAR				
TEVA PARENTERAL	20MG/ML		A074166 001	Feb 27, 1995
VEPESID				
+ CORDEN PHARMA	20MG/ML **		N018768 001	Nov 10, 1983
ETOPOSIDE PHOSPHATE				
INJECTABLE;INJECTION				
ETOPOPHOS PRESERVATIVE FREE				
BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL		N020906 001	Feb 27, 1998
	EQ 1GM BASE/VIAL		N020906 002	Feb 27, 1998
ETRAVIRINE				
TABLET;ORAL				
ETRAVIRINE				
AMNEAL	25MG		A214196 001	Jun 14, 2021
ETRETINATE				
CAPSULE;ORAL				
TEGISON				
ROCHE	10MG		N019369 001	Sep 30, 1986
	25MG		N019369 002	Sep 30, 1986
EVANS BLUE				
INJECTABLE;INJECTION				
EVANS BLUE				
PARKE DAVIS	0.5% **		N008041 001	
EXEMESTANE				
TABLET;ORAL				
EXEMESTANE				
ALVOGEN	25MG		A200898 001	Jul 28, 2014
AMNEAL PHARMS	25MG		A206421 001	Dec 28, 2018
DR REDDYS LABS SA	25MG		A208764 001	Aug 08, 2019
EXENATIDE SYNTHETIC				
FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS				
BYDUREON				
+ ASTRAZENECA AB	2MG/VIAL		N022200 001	Jan 27, 2012
BYDUREON PEN				
+ ASTRAZENECA AB	2MG		N022200 002	Feb 28, 2014
EZETIMIBE				
TABLET;ORAL				
EZETIMIBE				
APOTEX	10MG		A208332 001	Jun 12, 2017
RISING	10MG		A201790 001	Apr 26, 2019
TEVA PHARMS USA	10MG		A078724 001	Jun 12, 2017
EZETIMIBE; ROSUVASTATIN CALCIUM				
TABLET;ORAL				
ROSZET				
+ ALTHERA PHARMS	10MG;EQ 5MG BASE		N213072 001	Mar 23, 2021
+	10MG;EQ 10MG BASE		N213072 002	Mar 23, 2021
+	10MG;EQ 20MG BASE		N213072 003	Mar 23, 2021
+	10MG;EQ 40MG BASE		N213072 004	Mar 23, 2021
EZETIMIBE; SIMVASTATIN				
TABLET;ORAL				
EZETIMIBE AND SIMVASTATIN				
ANI PHARMS	10MG;10MG		A201890 001	Apr 26, 2017
	10MG;20MG		A201890 002	Apr 26, 2017
	10MG;40MG		A201890 003	Apr 26, 2017
	10MG;80MG		A201890 004	Apr 26, 2017
AUROBINDO PHARMA USA	10MG;10MG		A200082 001	Dec 17, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EZETIMIBE; SIMVASTATIN
TABLET;ORAL
EZETIMIBE AND SIMVASTATIN

		10MG;20MG	A200082	002	Dec 17, 2020
		10MG;40MG	A200082	003	Dec 17, 2020
		10MG;80MG	A200082	004	Dec 17, 2020

EZOGABINE
TABLET;ORAL
POTIGA

+	GLAXOSMITHKLINE	50MG	N022345	001	Jun 10, 2011
+		200MG	N022345	002	Jun 10, 2011
+		300MG	N022345	003	Jun 10, 2011
+		400MG	N022345	004	Jun 10, 2011

FAMCICLOVIR
TABLET;ORAL
FAMCICLOVIR

	CIPLA	125MG	A078278	001	Mar 21, 2011
		250MG	A078278	002	Mar 21, 2011
		500MG	A078278	003	Mar 21, 2011
	HIKMA	125MG	A090128	001	Mar 21, 2011
		250MG	A090128	002	Mar 21, 2011
		500MG	A090128	003	Mar 21, 2011
	MYLAN	125MG	A201333	001	Mar 24, 2011
		250MG	A201333	002	Mar 24, 2011
		500MG	A201333	003	Mar 24, 2011

FAMVIR

+	NOVARTIS	125MG **	N020363	003	Dec 11, 1995
+		250MG **	N020363	001	Apr 26, 1996
+		500MG **	N020363	002	Jun 29, 1994

FAMOTIDINE
FOR SUSPENSION;ORAL
PEPCID

+	SALIX PHARMS	40MG/5ML **	N019527	001	Feb 02, 1987

INJECTABLE;INJECTION
FAMOTIDINE

	APOTEX INC	10MG/ML	A075942	001	Aug 02, 2002
	APOTHECON	10MG/ML	A075707	001	Apr 16, 2001
	HIKMA	10MG/ML	A075799	001	Apr 30, 2002
	HOSPIRA	10MG/ML	A075705	001	Apr 16, 2001
		10MG/ML	A075870	001	Nov 23, 2001
		10MG/ML	A075905	001	Nov 23, 2001
	ZYDUS PHARMS	10MG/ML	A215828	001	Nov 22, 2022

FAMOTIDINE PRESERVATIVE FREE

	AKORN	10MG/ML	A076324	001	Nov 27, 2002
	APOTHECON	10MG/ML	A075708	001	Apr 16, 2001
	HIKMA	10MG/ML	A075789	001	Apr 30, 2002
	HOSPIRA	10MG/ML	A075669	001	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

	AKORN	10MG/ML	A076322	001	Nov 27, 2002

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

	ABBVIE	0.4MG/ML	A075729	001	Dec 17, 2001

PEPCID

+	MERCK	10MG/ML **	N019510	001	Nov 04, 1986

PEPCID PRESERVATIVE FREE

+	MERCK	10MG/ML **	N019510	004	Nov 04, 1986

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

+	MERCK SHARP DOHME	0.4MG/ML **	N020249	001	Feb 18, 1994

TABLET;ORAL
FAMOTIDINE

	ACTAVIS ELIZABETH	20MG	A075650	001	Sep 14, 2001
		40MG	A075650	002	Sep 14, 2001
	APOTEX	10MG	A075610	001	Mar 12, 2002
	MYLAN	10MG	A075674	001	Dec 21, 2001
	MYLAN PHARMS INC	20MG	A075457	001	Apr 18, 2001
		40MG	A075457	002	Apr 18, 2001
	PERRIGO R AND D	20MG	A077352	002	Jul 27, 2005
		40MG	A077352	001	Jul 27, 2005
	RISING	20MG	A075704	001	Apr 16, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FAMOTIDINE

TABLET;ORAL					
FAMOTIDINE					
	40MG		A075704	002	Apr 16, 2001
SANDOZ	10MG		A076101	001	Oct 21, 2002
	20MG		A075607	001	May 10, 2001
	20MG		A075793	001	Apr 16, 2001
	40MG		A075607	002	May 10, 2001
	40MG		A075793	002	Apr 16, 2001
SUN PHARM INDUSTRIES	20MG		A075639	002	Dec 12, 2001
	40MG		A075639	001	Dec 12, 2001
TEVA	10MG		A075312	001	May 31, 2001
	20MG		A075311	001	Apr 16, 2001
	40MG		A075311	002	Apr 16, 2001
WATSON LABS	10MG		A075404	001	Nov 28, 2001
	20MG		A075062	002	Apr 16, 2001
	40MG		A075062	001	Apr 16, 2001
PEPCID					
+ BAUSCH	20MG	**	N019462	001	Oct 15, 1986
+	40MG	**	N019462	002	Oct 15, 1986
TABLET, CHEWABLE;ORAL					
FAMOTIDINE					
PERRIGO	10MG		A075715	001	Aug 22, 2003
PEPCID AC					
+ J AND J CONSUMER INC	10MG	**	N020801	001	Sep 24, 1998
TABLET, ORALLY DISINTEGRATING;ORAL					
FLUXID					
UCB INC	20MG		N021712	001	Sep 24, 2004
	40MG		N021712	002	Sep 24, 2004
PEPCID RPD					
MERCK	20MG		N020752	001	May 28, 1998
	40MG		N020752	002	May 28, 1998

FEBUXOSTAT

TABLET;ORAL					
FEBUXOSTAT					
MYLAN	40MG		A205385	001	Jul 01, 2019
	80MG		A205385	002	Jul 01, 2019
TORRENT	40MG		A211837	001	Dec 19, 2023
	80MG		A211837	002	Dec 19, 2023

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL					
FELODIPINE					
JUBILANT GENERICS	2.5MG		A203983	001	Aug 19, 2016
	5MG		A203983	002	Aug 19, 2016
	10MG		A203983	003	Aug 19, 2016
MYLAN	2.5MG		A078855	001	Apr 17, 2008
	5MG		A078855	002	Apr 17, 2008
	10MG		A078855	003	Apr 17, 2008
SUN PHARM INDUSTRIES	2.5MG		A075896	001	Nov 02, 2004
	5MG		A075896	002	Nov 02, 2004
	10MG		A075896	003	Nov 02, 2004
WOCKHARDT	2.5MG		A091484	001	Aug 15, 2012
	5MG		A091484	002	Aug 15, 2012
	10MG		A091484	003	Aug 15, 2012
PLENDIL					
+ ASTRAZENECA	2.5MG	**	N019834	004	Sep 22, 1994
+	5MG	**	N019834	001	Jul 25, 1991
+	10MG	**	N019834	002	Jul 25, 1991

FENOFIBRATE

CAPSULE;ORAL					
ANTARA (MICRONIZED)					
+ LUPIN	30MG	**	N021695	004	Oct 18, 2013
	87MG		N021695	002	Nov 30, 2004
+	90MG		N021695	005	Oct 18, 2013
FENOFIBRATE (MICRONIZED)					
IMPAX LABS	67MG		A075868	001	Oct 27, 2003
	134MG		A075868	002	Oct 27, 2003
	200MG		A075868	003	Oct 27, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FENOFIBRATE				
CAPSULE;ORAL				
FENOFIBRATE (MICRONIZED)				
MYLAN PHARMS INC	43MG	A202579	001	Jan 10, 2013
	130MG	A202579	002	Jan 10, 2013
NOVAST LABS	67MG	A207564	001	Apr 19, 2019
	134MG	A207564	002	Apr 19, 2019
	200MG	A207564	003	Apr 19, 2019
RISING	67MG	A202676	001	Oct 23, 2012
	134MG	A202676	002	Oct 23, 2012
	200MG	A202676	003	Oct 23, 2012
LIPIDIL				
ABBVIE	100MG	N019304	001	Dec 31, 1993
LIPOFEN				
CIPHER PHARMS INC	100MG	N021612	002	Jan 11, 2006
TRICOR (MICRONIZED)				
+ ABBVIE	67MG **	N019304	002	Feb 09, 1998
+	134MG **	N019304	003	Jun 30, 1999
+	200MG **	N019304	004	Jun 30, 1999
TABLET;ORAL				
FENOFIBRATE				
ALEMBIC	54MG	A213252	001	Jan 17, 2020
	160MG	A213252	002	Jan 17, 2020
MYLAN	107MG	A076520	002	Dec 29, 2005
TRICOR				
+ ABBVIE	54MG **	N021203	001	Sep 04, 2001
+	160MG **	N021203	003	Sep 04, 2001
TRIGLIDE				
SKYEPHARMA AG	50MG	N021350	001	May 07, 2005
FENOFIBRIC ACID				
TABLET;ORAL				
FIBRICOR				
+ ATHENA	35MG	N022418	001	Aug 14, 2009
+	105MG	N022418	002	Aug 14, 2009
FENOLDOPAM MESYLATE				
INJECTABLE;INJECTION				
FENOLDOPAM MESYLATE				
LUITPOLD	EQ 10MG BASE/ML	A076656	001	Dec 01, 2003
TEVA PARENTERAL	EQ 10MG BASE/ML	A077826	001	Mar 07, 2007
FENOPROFEN CALCIUM				
CAPSULE;ORAL				
FENOPROFEN CALCIUM				
AM THERAP	EQ 200MG BASE	A072307	001	Aug 22, 1988
	EQ 300MG BASE	A072308	001	Aug 22, 1988
HALSEY	EQ 200MG BASE	A072355	001	Aug 17, 1988
	EQ 300MG BASE	A072356	001	Aug 17, 1988
PAR PHARM	EQ 200MG BASE	A072437	001	Aug 22, 1988
	EQ 300MG BASE	A072438	001	Aug 22, 1988
QUANTUM PHARMICS	EQ 200MG BASE	A072214	001	Aug 17, 1988
	EQ 300MG BASE	A071738	001	Aug 17, 1988
RISING	EQ 200MG BASE	A072394	001	Oct 17, 1988
	EQ 300MG BASE	A072395	001	Oct 17, 1988
WARNER CHILCOTT	EQ 200MG BASE	A072946	001	Apr 30, 1991
	EQ 300MG BASE	A072472	001	Apr 30, 1991
WATSON LABS	EQ 200MG BASE	A072294	001	Aug 17, 1988
	EQ 200MG BASE	A072981	001	Aug 19, 1991
	EQ 300MG BASE	A072293	001	Aug 17, 1988
	EQ 300MG BASE	A072982	001	Aug 19, 1991
NALFON				
XSPIRE PHARMA	EQ 300MG BASE	N017604	002	
TABLET;ORAL				
FENOPROFEN CALCIUM				
AM THERAP	EQ 600MG BASE	A072309	001	Aug 17, 1988
ANI PHARMS	EQ 600MG BASE	A072274	001	May 02, 1988
DAVA PHARMS INC	EQ 600MG BASE	A072326	001	Aug 17, 1988
HALSEY	EQ 600MG BASE	A072357	001	Aug 17, 1988
IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557	001	Aug 29, 1988
QUANTUM PHARMICS	EQ 600MG BASE	A072194	001	Aug 17, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FENOPROFEN CALCIUM

TABLET;ORAL

FENOPROFEN CALCIUM

	RISING	EQ 600MG BASE	A072396	001	Oct 17, 1988
	STRIDES PHARMA	EQ 600MG BASE	A072429	001	Aug 17, 1988
	SUN PHARM INDUSTRIES	EQ 600MG BASE	A072902	001	Dec 21, 1990
	USL PHARMA	EQ 600MG BASE	A072362	001	Aug 17, 1988
	WATSON LABS	EQ 600MG BASE	A072165	001	Aug 17, 1988
		EQ 600MG BASE	A072602	001	Oct 11, 1988
	WATSON LABS TEVA	EQ 600MG BASE	A072407	001	Aug 17, 1988

NALFON

+	DISTA	EQ 600MG BASE	N017710	001	

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

DURAGESIC-100

+	JANSSEN PHARMS	100MCG/HR **	N019813	001	Aug 07, 1990

DURAGESIC-12

+	JANSSEN PHARMS	12.5MCG/HR **	N019813	005	Feb 04, 2005

DURAGESIC-25

+	JANSSEN PHARMS	25MCG/HR **	N019813	004	Aug 07, 1990

DURAGESIC-37

+	JANSSEN PHARMS	37.5MCG/HR **	N019813	006	Jan 24, 2018

DURAGESIC-50

+	JANSSEN PHARMS	50MCG/HR **	N019813	003	Aug 07, 1990

DURAGESIC-75

+	JANSSEN PHARMS	75MCG/HR **	N019813	002	Aug 07, 1990

FENTANYL-100

	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007
	LAVIPHARM LABS	100MCG/HR	A077051	004	Aug 04, 2006
	MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007
	NOVEN	100MCG/HR	A077775	004	Oct 16, 2009
	ZYDUS PHARMS	100MCG/HR	A209655	008	Jan 24, 2023

FENTANYL-12

	ZYDUS PHARMS	12.5MCG/HR	A209655	001	Jan 24, 2023

FENTANYL-25

	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007
	LAVIPHARM LABS	25MCG/HR	A077051	001	Aug 04, 2006
	MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007
	NOVEN	25MCG/HR	A077775	001	Oct 16, 2009
	ZYDUS PHARMS	25MCG/HR	A209655	002	Jan 24, 2023

FENTANYL-37

	ZYDUS PHARMS	37.5MCG/HR	A209655	003	Jan 24, 2023

FENTANYL-50

	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007
	LAVIPHARM LABS	50MCG/HR	A077051	002	Aug 04, 2006
	MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007
	NOVEN	50MCG/HR	A077775	002	Oct 16, 2009
	ZYDUS PHARMS	50MCG/HR	A209655	004	Jan 24, 2023

FENTANYL-62

	ZYDUS PHARMS	62.5MCG/HR	A209655	005	Jan 24, 2023

FENTANYL-75

	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007
	LAVIPHARM LABS	75MCG/HR	A077051	003	Aug 04, 2006
	MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007
	NOVEN	75MCG/HR	A077775	003	Oct 16, 2009
	ZYDUS PHARMS	75MCG/HR	A209655	006	Jan 24, 2023

FENTANYL-87

	ZYDUS PHARMS	87.5MCG/HR	A209655	007	Jan 24, 2023

SPRAY;SUBLINGUAL

SUBSYS

+	BTCP PHARMA	0.1MG **	N202788	001	Jan 04, 2012
+		0.2MG **	N202788	002	Jan 04, 2012
+		0.4MG **	N202788	003	Jan 04, 2012
+		0.6MG **	N202788	004	Jan 04, 2012
+		0.8MG **	N202788	005	Jan 04, 2012
+		1.2MG **	N202788	006	Aug 30, 2012
+		1.6MG **	N202788	007	Aug 30, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FENTANYL CITRATE

FILM;BUCCAL				
ONSOLIS				
ADALVO	EQ 0.2MG BASE	N022266	001	Jul 16, 2009
	EQ 0.4MG BASE	N022266	002	Jul 16, 2009
	EQ 0.6MG BASE	N022266	003	Jul 16, 2009
	EQ 0.8MG BASE	N022266	004	Jul 16, 2009
	EQ 1.2MG BASE	N022266	005	Jul 16, 2009
INJECTABLE;INJECTION				
FENTANYL CITRATE				
ABBOTT	EQ 0.05MG BASE/ML	A070636	001	Apr 30, 1990
	EQ 0.05MG BASE/ML	A070637	001	Apr 30, 1990
WATSON LABS	EQ 0.05MG BASE/ML	A073488	001	Jun 30, 1992
FENTANYL CITRATE PRESERVATIVE FREE				
DR REDDYS	EQ 0.05MG BASE/ML	A074917	001	Feb 03, 1998
SOLUTION;INTRAVENOUS				
FENTANYL CITRATE				
+ EXELA PHARMA	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023
+	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N215870	002	Feb 08, 2023
SPRAY, METERED;NASAL				
LAZANDA				
+ BTCP PHARMA	EQ 0.1MG BASE **	N022569	001	Jun 30, 2011
+	EQ 0.3MG BASE **	N022569	003	Dec 21, 2015
+	EQ 0.4MG BASE **	N022569	002	Jun 30, 2011
TABLET;BUCCAL, SUBLINGUAL				
FENTANYL CITRATE				
DR REDDYS LABS SA	EQ 0.1MG BASE	A206329	001	Aug 22, 2022
	EQ 0.2MG BASE	A206329	002	Aug 22, 2022
	EQ 0.3MG BASE	A206329	003	Aug 22, 2022
	EQ 0.4MG BASE	A206329	004	Aug 22, 2022
	EQ 0.6MG BASE	A206329	005	Aug 22, 2022
	EQ 0.8MG BASE	A206329	006	Aug 22, 2022
WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011
	EQ 0.2MG BASE	A079075	002	Jan 07, 2011
	EQ 0.4MG BASE	A079075	003	Jan 07, 2011
	EQ 0.6MG BASE	A079075	004	Jan 07, 2011
	EQ 0.8MG BASE	A079075	005	Jan 07, 2011
FENTORA				
+ CEPHALON	EQ 0.3MG BASE **	N021947	006	Mar 02, 2007
TABLET;SUBLINGUAL				
ABSTRAL				
+ SENTYNL THERAPS INC	EQ 0.1MG BASE **	N022510	001	Jan 07, 2011
+	EQ 0.2MG BASE **	N022510	002	Jan 07, 2011
+	EQ 0.3MG BASE **	N022510	003	Jan 07, 2011
+	EQ 0.4MG BASE **	N022510	004	Jan 07, 2011
+	EQ 0.6MG BASE **	N022510	005	Jan 07, 2011
+	EQ 0.8MG BASE **	N022510	006	Jan 07, 2011
FENTANYL CITRATE				
ACTAVIS LABS FL INC	EQ 0.1MG BASE	A207338	001	Nov 17, 2017
	EQ 0.2MG BASE	A207338	002	Nov 17, 2017
	EQ 0.3MG BASE	A207338	003	Nov 17, 2017
	EQ 0.4MG BASE	A207338	004	Nov 17, 2017
	EQ 0.6MG BASE	A207338	005	Nov 17, 2017
	EQ 0.8MG BASE	A207338	006	Nov 17, 2017
TROCHE/LOZENGE;ORAL				
FENTANYL				
CEPHALON	EQ 0.1MG BASE	N020195	007	Oct 30, 1995
	EQ 0.2MG BASE	N020195	001	Oct 04, 1993
	EQ 0.3MG BASE	N020195	002	Oct 04, 1993
	EQ 0.4MG BASE	N020195	003	Oct 04, 1993
TROCHE/LOZENGE;TRANSMUCOSAL				
FENTANYL CITRATE				
PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009
	EQ 0.4MG BASE	A077312	002	Oct 30, 2009
	EQ 0.6MG BASE	A077312	003	Oct 30, 2009
	EQ 0.8MG BASE	A077312	004	Oct 30, 2009
	EQ 1.2MG BASE	A077312	005	Oct 30, 2009
	EQ 1.6MG BASE	A077312	006	Oct 30, 2009
SPECGX LLC	EQ 0.2MG BASE	A078907	001	Oct 30, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FENTANYL CITRATE					
TROCHE/LOZENGE;TRANSMUCOSAL					
FENTANYL CITRATE					
		EQ 0.4MG BASE	A078907	002	Oct 30, 2009
		EQ 0.6MG BASE	A078907	003	Oct 30, 2009
		EQ 0.8MG BASE	A078907	004	Oct 30, 2009
		EQ 1.2MG BASE	A078907	005	Oct 30, 2009
		EQ 1.6MG BASE	A078907	006	Oct 30, 2009
FENTANYL HYDROCHLORIDE					
SYSTEM;IONTOPHORESIS, TRANSDERMAL					
IONSYS					
+	THE MEDICINES CO	EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006
FERRIC AMMONIUM CITRATE					
FOR SOLUTION;ORAL					
FERRISELTZ					
	OTSUKA	600MG/PACKET	N020292	001	Oct 14, 1997
FERRIC DERISOMALTOSE					
SOLUTION;INTRAVENOUS					
MONOFERRIC					
+	PHARMACOSMOS AS	100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020
+		500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020
FERRIC OXYHYDROXIDE					
INJECTABLE;INJECTION					
DEXFERRUM					
	AM REGENT	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996
IRON DEXTRAN					
	SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787	002	
PROFERDEX					
	NEW RIVER	EQ 50MG IRON/ML	N017807	001	
INJECTABLE;INTRAVENOUS					
VENOFER					
	AM REGENT	EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)	N021135	005	Mar 29, 2013
		EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)	N021135	003	Mar 29, 2005
FERRIC PYROPHOSPHATE CITRATE					
POWDER;INTRAVENOUS					
TRIFERIC					
+	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016
SOLUTION;INTRAVENOUS					
TRIFERIC					
+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015
+		272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015
TRIFERIC AVNU					
+	ROCKWELL MEDICAL INC	6.75MG IRON/4.5ML (1.5MG IRON/ML)	N212860	001	Mar 27, 2020
FERROUS CITRATE, FE-59					
INJECTABLE;INJECTION					
FERROUS CITRATE FE 59					
	MALLINCKRODT	25uCi/ML	N016729	001	
FERROUS SULFATE; FOLIC ACID					
CAPSULE;ORAL					
FOLVRON					
	LEDERLE	182MG;0.33MG	N006012	003	
FERUMOXIDES					
INJECTABLE;INJECTION					
FERIDEX I.V.					
	AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416	001	Aug 30, 1996
FERUMOXSIL					
SUSPENSION;ORAL					
GASTROMARK					
	AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410	001	Dec 06, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL				
FESOTERODINE FUMARATE				
ACCORD HLTHCARE	4MG	A205012	001	Jan 04, 2023
	8MG	A205012	002	Jan 04, 2023
ACTAVIS LABS FL INC	4MG	A204868	001	Jan 04, 2023
	8MG	A204868	002	Jan 04, 2023
LUPIN LTD	4MG	A204983	001	Jan 05, 2023
	8MG	A204983	002	Jan 05, 2023

FEXOFENADINE HYDROCHLORIDE

CAPSULE;ORAL				
ALLEGRA				
CHATTEM SANOFI	60MG **	N020625	001	Jul 25, 1996
FEXOFENADINE HYDROCHLORIDE				
BARR	60MG	A076169	001	Jul 13, 2005
SUSPENSION;ORAL				
ALLEGRA				
+ CHATTEM SANOFI	30MG/5ML	N021963	001	Oct 16, 2006
CHILDREN'S ALLEGRA HIVES				
+ CHATTEM SANOFI	30MG/5ML **	N201373	002	Jan 24, 2011
FEXOFENADINE HYDROCHLORIDE				
P AND L	30MG/5ML	A201311	001	Jul 25, 2012
TABLET;ORAL				
ALLEGRA HIVES				
+ CHATTEM SANOFI	60MG	N020872	008	Jan 24, 2011
CHILDREN'S ALLEGRA ALLERGY				
+ CHATTEM SANOFI	30MG **	N020872	005	Jan 24, 2011
CHILDREN'S ALLEGRA HIVES				
+ CHATTEM SANOFI	30MG	N020872	006	Jan 24, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY				
RISING	30MG	A077081	004	Jul 21, 2011
SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES				
RISING	30MG	A077081	005	Jul 21, 2011
SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012
FEXOFENADINE HYDROCHLORIDE				
BARR	30MG	A076191	001	Aug 31, 2005
	60MG	A076191	002	Aug 31, 2005
	180MG	A076191	003	Aug 31, 2005
RISING	30MG	A077081	002	Apr 11, 2008
FEXOFENADINE HYDROCHLORIDE ALLERGY				
SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012
FEXOFENADINE HYDROCHLORIDE HIVES				
SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012
TABLET, ORALLY DISINTEGRATING;ORAL				
CHILDREN'S ALLEGRA ALLERGY				
+ CHATTEM SANOFI	30MG	N021909	002	Jan 24, 2011
CHILDREN'S ALLEGRA HIVES				
+ CHATTEM SANOFI	30MG **	N021909	003	Jan 24, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY				
DR REDDYS LABS LTD	30MG	A202978	001	Jan 18, 2013
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES				
DR REDDYS LABS LTD	30MG	A202978	002	Jan 18, 2013

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
BARR	60MG;120MG	A076236	001	Apr 14, 2005
IMPAX PHARMS	60MG;120MG	A076298	001	Nov 12, 2010

FINAFLOXACIN

SUSPENSION/DROPS;OTIC				
XTORO				
+ FONSECA BIOSCIENCES	0.3%	N206307	001	Dec 17, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FINASTERIDE				
TABLET;ORAL				
FINASTERIDE				
	ACTAVIS TOTOWA	1MG	A078371 001	Nov 05, 2013
	ACTAVIS TOTOWA TEVA	5MG	A077914 001	Mar 28, 2007
	GEDEON RICHTER USA	5MG	A077251 001	Dec 22, 2006
	IVAX SUB TEVA PHARMS	5MG	A076340 001	Jun 19, 2006
	MYLAN	1MG	A078161 001	Nov 05, 2013
		5MG	A077578 001	Dec 18, 2006
	TEVA	1MG	A076905 001	Nov 05, 2013
FINGOLIMOD HYDROCHLORIDE				
CAPSULE;ORAL				
FINGOLIMOD HYDROCHLORIDE				
	BIOCON LTD	EQ 0.5MG BASE	A207979 001	Dec 04, 2019
	CHARTWELL RX	EQ 0.5MG BASE	A207971 001	Jun 29, 2020
	TEVA PHARMS USA	EQ 0.25MG BASE	A212152 001	Nov 12, 2021
FLAVOXATE HYDROCHLORIDE				
TABLET;ORAL				
FLAVOXATE HYDROCHLORIDE				
	IMPAX PHARMS	100MG	A076234 001	Aug 28, 2003
URISPAS				
	ORTHO MCNEIL JANSSEN	100MG	N016769 001	
FLECAINIDE ACETATE				
TABLET;ORAL				
FLECAINIDE ACETATE				
	ANI PHARMS	50MG	A076030 001	Oct 28, 2002
		100MG	A076030 002	Oct 28, 2002
		150MG	A076030 003	Oct 28, 2002
	CHARTWELL	50MG	A079164 001	Jul 09, 2009
		100MG	A079164 002	Jul 09, 2009
		150MG	A079164 003	Jul 09, 2009
TAMBOCOR				
+	ALVOGEN	50MG **	N018830 004	Aug 23, 1988
+		100MG **	N018830 001	Oct 31, 1985
+		150MG **	N018830 003	Jun 03, 1988
		200MG **	N018830 002	Oct 31, 1985
FLORBETAPIR F-18				
SOLUTION;INTRAVENOUS				
AMYVID				
+	AVID RADIOPHARMS INC	10ML (13.5-51mCi/ML)	N202008 001	Apr 06, 2012
+		10-30ML (13.5-51mCi/ML)	N202008 002	Apr 06, 2012
FLOXURIDINE				
INJECTABLE;INJECTION				
FLOXURIDINE				
	AM REGENT	500MG/VIAL	A203008 001	Nov 22, 2017
FUDR				
+	HOSPIRA	500MG/VIAL **	N016929 001	
FLUCONAZOLE				
FOR SUSPENSION;ORAL				
FLUCONAZOLE				
	HIKMA	50MG/5ML	A076246 001	Jul 29, 2004
		200MG/5ML	A076246 002	Jul 29, 2004
	IVAX SUB TEVA PHARMS	50MG/5ML	A077523 001	Sep 12, 2007
		200MG/5ML	A077523 002	Sep 12, 2007
	SUN PHARM INDS LTD	50MG/5ML	A076332 001	Jul 29, 2004
		200MG/5ML	A076332 002	Jul 29, 2004
	TARO PHARM INDS	50MG/5ML	A076918 001	Dec 18, 2006
		200MG/5ML	A076918 002	Dec 18, 2006
INJECTABLE;INJECTION				
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	PFIZER	200MG/100ML (2MG/ML)	N019950 003	Sep 29, 1992
+		400MG/200ML (2MG/ML)	N019950 005	Jul 08, 1994
DIFLUCAN IN SODIUM CHLORIDE 0.9%				
+	PFIZER	200MG/100ML (2MG/ML)	N019950 001	Jan 29, 1990
+		400MG/200ML (2MG/ML)	N019950 006	Jan 29, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUCONAZOLE

INJECTABLE;INJECTION					
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	PFIZER	200MG/100ML (2MG/ML)	N019950	002	Jan 29, 1990
+		400MG/200ML (2MG/ML)	N019950	004	Jan 29, 1990
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764	001	Jan 30, 2012
		400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012
	HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004
		400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004
	MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005
		400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005
	WOODWARD	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010
		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%					
	BAXTER HLTHCARE CORP	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010
		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010
	DR REDDYS	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004
		400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	DR REDDYS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005
		400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005
	HOSPIRA	200MG/100ML (2MG/ML)	A076617	001	Jul 29, 2004
		400MG/200ML (2MG/ML)	A076617	002	Jul 29, 2004
	MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005
		400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005
TABLET;ORAL					
FLUCONAZOLE					
	ANI PHARMS	50MG	A076086	001	Jul 29, 2004
		100MG	A076086	002	Jul 29, 2004
		150MG	A076086	003	Jul 29, 2004
		200MG	A076086	004	Jul 29, 2004
	GEDEON RICHTER USA	50MG	A076432	001	Jul 29, 2004
		100MG	A076432	002	Jul 29, 2004
		150MG	A076432	003	Jul 29, 2004
		200MG	A076432	004	Jul 29, 2004
	IVAX SUB TEVA PHARMS	50MG	A076077	001	Jul 29, 2004
		100MG	A076077	002	Jul 29, 2004
		150MG	A076077	003	Jul 29, 2004
		200MG	A076077	004	Jul 29, 2004
	LUPIN LTD	50MG	A209146	001	Oct 20, 2023
		100MG	A209146	002	Oct 20, 2023
		150MG	A209146	003	Oct 20, 2023
		200MG	A209146	004	Oct 20, 2023
	MYLAN	50MG	A076351	001	Jul 29, 2004
		100MG	A076351	002	Jul 29, 2004
		150MG	A076351	003	Jul 29, 2004
		200MG	A076351	004	Jul 29, 2004
	MYLAN PHARMS INC	50MG	A076042	001	Jul 29, 2004
		100MG	A076042	002	Jul 29, 2004
		150MG	A076042	003	Jul 29, 2004
		200MG	A076042	004	Jul 29, 2004
	PLIVA	50MG	A076424	001	Jul 29, 2004
		100MG	A076424	002	Jul 29, 2004
		150MG	A076424	003	Jul 29, 2004
		200MG	A076424	004	Jul 29, 2004
	RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004
		100MG	A076386	002	Jul 29, 2004
		150MG	A076386	003	Jul 29, 2004
		200MG	A076386	004	Jul 29, 2004
	ROXANE	50MG	A076213	001	Jul 29, 2004
		100MG	A076213	002	Jul 29, 2004
		150MG	A076213	003	Jul 29, 2004
		200MG	A076213	004	Jul 29, 2004
	TEVA	50MG	A074681	001	Jul 29, 2004
		100MG	A074681	002	Jul 29, 2004
		150MG	A074681	003	Jul 29, 2004
		200MG	A074681	004	Jul 29, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUCYTOSINE				
CAPSULE;ORAL				
FLUCYTOSINE				
HIKMA	250MG	A206550	001	Oct 17, 2017
	500MG	A206550	002	Oct 17, 2017
STRIDES PHARMA	250MG	A207536	001	Jun 18, 2018
	500MG	A207536	002	Jun 18, 2018
FLUDARABINE PHOSPHATE				
INJECTABLE;INJECTION				
FLUDARA				
+ GENZYME CORP	50MG/VIAL **	N020038	001	Apr 18, 1991
FLUDARABINE PHOSPHATE				
ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017
HOSPIRA	50MG/VIAL	A077790	001	Apr 06, 2007
MYLAN LABS LTD	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011
	50MG/VIAL	A200648	001	Oct 16, 2012
+ SANDOZ	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007
TABLET;ORAL				
OFORTA				
SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008
FLUDEOXYGLUCOSE F-18				
INJECTABLE;INJECTION				
FLUDEOXYGLUCOSE F18				
+ DOWNSTATE CLINCL	4-40mCi/ML **	N020306	001	Aug 19, 1994
+	4-90mCi/ML **	N020306	002	Sep 25, 2001
INJECTABLE;INTRAVENOUS				
FLUDEOXYGLUCOSE F18				
ESSENTIAL ISOTOPES	20-300mCi/ML	A203946	001	Feb 05, 2014
+ FEINSTEIN	20-200mCi/ML **	N021870	001	Aug 19, 2005
HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014
MIDWEST MEDCL	20-200mCi/ML	A203736	001	Nov 19, 2015
UNIV TX SW MEDCTR	20-200mCi/ML	A210265	001	Feb 06, 2020
WEILL MEDCL COLL	10-100mCi/ML **	N021768	001	Aug 05, 2004
FLUDROCORTISONE ACETATE				
TABLET;ORAL				
FLORINEF				
+ CASPER PHARMA LLC	0.1MG **	N010060	001	
FLUDROCORTISONE ACETATE				
HIKMA	0.1MG	A216013	001	Oct 27, 2022
HIKMA PHARMS	0.1MG	A091302	001	Jul 22, 2011
FLUMAZENIL				
INJECTABLE;INJECTION				
FLUMAZENIL				
DR REDDYS	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004
	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004
RISING	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008
ROMAZICON				
+ HOFFMANN LA ROCHE	1MG/10ML (0.1MG/ML) **	N020073	001	Dec 20, 1991
+	0.5MG/5ML (0.1MG/ML) **	N020073	002	Dec 20, 1991
FLUMETHASONE PIVALATE				
CREAM;TOPICAL				
LOCORTEN				
NOVARTIS	0.03%	N016379	001	
FLUNISOLIDE				
AEROSOL, METERED;INHALATION				
AEROBID				
ROCHE PALO	0.25MG/INH	N018340	001	Aug 17, 1984
AEROSPAN HFA				
+ MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006
SPRAY, METERED;NASAL				
FLUNISOLIDE				
APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007
NASALIDE				
+ IVAX RES	0.025MG/SPRAY **	N018148	001	
NASAREL				
TEVA BRANDED PHARM	0.029MG/SPRAY	N020409	001	Mar 08, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL					
FLUOCET					
	ALPHARMA US PHARMS	0.025%	A088360	001	Jan 16, 1984
FLUOCINOLONE ACETONIDE					
	ALLIED	0.01%	A088047	001	Dec 16, 1982
	ALPHARMA US PHARMS	0.01%	A088361	001	Jan 16, 1984
	COSETTE	0.025%	A089525	001	Jul 26, 1988
	INVATECH	0.025%	A088045	001	Dec 16, 1982
	PERRIGO NEW YORK	0.01%	A086810	001	Mar 04, 1982
		0.025%	A086811	001	Mar 04, 1982
	PHARMAFAIR	0.01%	A088499	001	Aug 02, 1984
		0.025%	A088506	001	Aug 02, 1984
	TARO	0.01%	A040035	001	Oct 31, 1994
		0.01%	A087102	001	Apr 27, 1982
		0.025%	A040042	001	Oct 31, 1994
	USL PHARMA	0.01%	A088757	001	Feb 11, 1985
		0.025%	A088756	001	Mar 28, 1985
FLUONID					
	ALLERGAN HERBERT	0.025%	A087156	002	Sep 06, 1984
FLUOTREX					
	SAVAGE LABS	0.01%	A088174	001	May 06, 1983
		0.025%	A088173	001	Mar 09, 1983
SYNALAR-HP					
	MEDIMETRIKS PHARMS	0.2%	N016161	002	
GEL;TOPICAL					
FLUONID					
	ALLERGAN HERBERT	0.025%	A087300	001	May 27, 1982
OIL;TOPICAL					
FLUOCINOLONE ACETONIDE					
	AKORN	0.01%	A091514	001	Jun 25, 2015
	AMNEAL	0.01%	A201759	001	Oct 17, 2011
		0.01%	A201764	001	Oct 17, 2011
OIL/DROPS;OTIC					
FLUOCINOLONE ACETONIDE					
	AKORN	0.01%	A202705	001	Sep 09, 2016
	AMNEAL	0.01%	A091306	001	Oct 17, 2011
OINTMENT;TOPICAL					
FLUOCINOLONE ACETONIDE					
	PHARMADERM	0.025%	A088046	001	Dec 16, 1982
	PHARMAFAIR	0.025%	A088507	001	Feb 27, 1984
	USL PHARMA	0.025%	A088742	001	Feb 08, 1985
FLUONID					
	ALLERGAN HERBERT	0.025%	A087157	001	Sep 06, 1984
FLUOTREX					
	SAVAGE LABS	0.025%	A088172	001	Mar 09, 1983
SOLUTION;TOPICAL					
FLUOCINOLONE ACETONIDE					
	ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016
	ALLIED	0.01%	A088048	001	Dec 16, 1982
	ALPHARMA US PHARMS	0.01%	A087159	001	Jun 16, 1982
	BAUSCH AND LOMB	0.01%	A040059	001	Dec 20, 1993
	COSETTE	0.01%	A207441	001	Sep 28, 2016
	PAI HOLDINGS PHARM	0.01%	A088312	001	Jan 27, 1984
	PHARMAFAIR	0.01%	A088449	001	Feb 08, 1984
FLUONID					
	ALLERGAN HERBERT	0.01%	A087158	001	Mar 17, 1983
FLUOTREX					
	SAVAGE LABS	0.01%	A088171	001	Mar 09, 1983

FLUOCINONIDE

CREAM;TOPICAL					
FLUOCINONIDE					
	ENCUBE	0.05%	A211410	001	Oct 16, 2018
	PAI HOLDINGS PHARM	0.1%	A211758	001	Apr 03, 2019
	PERRIGO NEW YORK	0.05%	A071790	001	Jul 13, 1988
+	TARO	0.05% **	N019117	001	Jun 26, 1984
LIDEX					
+	ALVOGEN	0.05% **	N016908	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUOCINONIDE					
CREAM;TOPICAL					
LIDEX-E					
+	ALVOGEN	0.05% **	N016908	003	
GEL;TOPICAL					
FLUOCINONIDE					
	PAI HOLDINGS PHARM	0.05%	A209030	001	Jun 19, 2018
OINTMENT;TOPICAL					
FLUOCINONIDE					
	PAI HOLDINGS PHARM	0.05%	A207680	001	Sep 28, 2018
SOLUTION;TOPICAL					
FLUOCINONIDE					
	PAI HOLDINGS PHARM	0.05%	A207554	001	Mar 18, 2019
	TARO	0.05%	A072857	001	Aug 02, 1989
	TEVA	0.05%	A072511	001	Feb 07, 1989
	TEVA PHARMS	0.05%	A072522	001	Sep 28, 1990
LIDEX					
+	ALVOGEN	0.05%	N018849	001	Apr 06, 1984
FLUORESCEIN SODIUM					
INJECTABLE;INJECTION					
FUNDUSCEIN-25					
+	NOVARTIS	25% **	N017869	001	
FLUOROMETHOLONE					
CREAM;TOPICAL					
OXYLONE					
	PHARMACIA AND UPJOHN	0.025%	N011748	001	
OINTMENT;OPHTHALMIC					
FML					
+	ALLERGAN	0.1%	N017760	001	Sep 04, 1985
SUSPENSION/DROPS;OPHTHALMIC					
FLUOR-OP					
	NOVARTIS	0.1%	A070185	001	Feb 27, 1986
FLUOROMETHOLONE ACETATE; TOBRAMYCIN					
SUSPENSION/DROPS;OPHTHALMIC					
TOBRASONE					
	HARROW EYE	0.1%;0.3%	N050628	001	Jul 21, 1989
FLUOROMETHOLONE; SULFACETAMIDE SODIUM					
SUSPENSION/DROPS;OPHTHALMIC					
FML-S					
	ALLERGAN	0.1%;10%	N019525	001	Sep 29, 1989
FLUOROURACIL					
CREAM;TOPICAL					
FLUOROPLEX					
+	CHARTWELL RX	1%	N016988	001	
FLUOROURACIL					
	MYLAN	0.5%	A203122	001	Apr 20, 2015
INJECTABLE;INJECTION					
ADRUCIL					
	PHARMACIA AND UPJOHN	50MG/ML	A081222	001	Jun 28, 1991
+		50MG/ML **	N017959	001	
	TEVA PARENTERAL	50MG/ML	A040023	001	Oct 18, 1991
		50MG/ML	A081225	001	Aug 28, 1991
FLUOROURACIL					
	ABIC	50MG/ML	A088929	001	Mar 04, 1986
	ABRAXIS PHARM	50MG/ML	A089152	001	Mar 21, 1986
		50MG/ML	A089428	001	Jan 12, 1987
		50MG/ML	A089519	001	Mar 12, 1987
	BEDFORD	50MG/ML	A089508	001	Jan 26, 1988
	EBEWE PHARMA	500MG/10ML (50MG/ML)	A040772	001	Aug 11, 2008
	EUGIA PHARMA SPECLTS	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012
		1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012
		2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012
		5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012
	FRESENIUS KABI USA	50MG/ML	A040291	001	Mar 24, 1999
		50MG/ML	A040379	001	Nov 15, 2000
	MARCHAR	50MG/ML	A087791	001	Jan 18, 1983
	NOVAST LABS	500MG/10ML (50MG/ML)	A209219	001	Dec 12, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUOROURACIL

INJECTABLE;INJECTION					
FLUOROURACIL					
		1GM/20ML (50MG/ML)	A209219	002	Dec 12, 2019
		2.5GM/50ML (50MG/ML)	A209271	002	Dec 11, 2019
		5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019
	SANDOZ	2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011
		5GM/100ML (50MG/ML)	A091299	002	May 02, 2011
	SMITH AND NEPHEW	50MG/ML	A088766	001	Dec 28, 1984
		50MG/ML	A088767	001	Dec 28, 1984
		50MG/ML	A089434	001	Mar 26, 1987
	SPECTRUM PHARMS	50MG/ML	A087792	001	Oct 13, 1982
+		500MG/10ML (50MG/ML) **	N012209	001	
+		2.5GM/50ML (50MG/ML) **	N012209	002	Jul 29, 2016
	TEVA PHARMS USA	500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000
		2.5GM/50ML (50MG/ML)	A040334	001	Feb 25, 2000
		5GM/100ML (50MG/ML)	A040334	002	Feb 25, 2000
SOLUTION;TOPICAL					
EFUDEX					
+	BAUSCH	5% **	N016831	002	
FLUOROPLEX					
	ELORAC	1%	N016765	001	

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL					
FLUOXETINE					
	SUN PHARM INDUSTRIES	EQ 10MG BASE	A075787	001	Jan 29, 2002
		EQ 20MG BASE	A075787	002	Jan 29, 2002
	WATSON LABS	EQ 10MG BASE	A075662	001	Jan 29, 2002
		EQ 20MG BASE	A075662	002	Jan 29, 2002
FLUOXETINE HYDROCHLORIDE					
	ACCORD HLTHCARE	EQ 10MG BASE	A202729	001	Aug 27, 2020
		EQ 20MG BASE	A202729	002	Aug 27, 2020
		EQ 40MG BASE	A202729	003	Aug 27, 2020
	ANI PHARMS	EQ 10MG BASE	A076287	001	May 20, 2008
		EQ 20MG BASE	A076287	002	May 20, 2008
	BARR	EQ 10MG BASE	A074803	002	Jan 30, 2002
		EQ 20MG BASE	A074803	001	Aug 02, 2001
		EQ 40MG BASE	A076251	001	May 18, 2005
	BEXIMCO PHARMS USA	EQ 10MG BASE	A075807	001	Jan 29, 2002
		EQ 20MG BASE	A075807	002	Jan 29, 2002
	CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002
		EQ 20MG BASE	A076022	002	Jan 30, 2002
	CR DOUBLE CRANE	EQ 10MG BASE	A076165	001	Feb 01, 2002
		EQ 20MG BASE	A076165	002	Feb 01, 2002
	GRANULES	EQ 10MG BASE	A078143	001	Jan 16, 2008
		EQ 20MG BASE	A078143	002	Jan 16, 2008
		EQ 40MG BASE	A078143	003	Jan 16, 2008
	MYLAN	EQ 10MG BASE	A075207	001	Jan 30, 2002
		EQ 20MG BASE	A075207	002	Jan 30, 2002
		EQ 40MG BASE	A075207	003	May 25, 2007
	MYLAN PHARMS INC	EQ 10MG BASE	A075577	001	Jan 29, 2002
		EQ 20MG BASE	A075577	002	Jan 29, 2002
	NATCO PHARMA USA	EQ 10MG BASE	A078045	001	Nov 17, 2008
		EQ 20MG BASE	A078045	002	Nov 17, 2008
	SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008
		EQ 20MG BASE	A077469	002	Nov 17, 2008
	SPECGX LLC	EQ 10MG BASE	A075658	001	Jan 29, 2002
		EQ 20MG BASE	A075658	002	Jan 29, 2002
	STRIDES PHARMA	EQ 10MG BASE	A076922	001	Dec 16, 2004
		EQ 20MG BASE	A076922	002	Dec 16, 2004
		EQ 40MG BASE	A076922	003	Dec 16, 2004
PROZAC					
	ELI LILLY AND CO	EQ 60MG BASE	N018936	004	Jun 15, 1999
SARAFEM					
+	ELI LILLY AND CO	EQ 10MG BASE **	N018936	007	Jul 06, 2000
+		EQ 20MG BASE **	N018936	008	Jul 06, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL				
FLUOXETINE HYDROCHLORIDE				
	BARR	EQ 90MG BASE	A076237 001	Mar 24, 2010
PROZAC WEEKLY				
+	LILLY	EQ 90MG BASE **	N021235 001	Feb 26, 2001
SOLUTION;ORAL				
FLUOXETINE HYDROCHLORIDE				
	ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690 001	Jan 31, 2002
	AKORN	EQ 20MG BASE/5ML	A075525 001	Jun 27, 2002
	CHARTWELL MOLECULAR	EQ 20MG BASE/5ML	A076458 001	May 14, 2004
	PHARMOBEDIENT CNSLTG	EQ 20MG BASE/5ML	A075514 001	Aug 29, 2002
	SPECGX LLC	EQ 20MG BASE/5ML	A075920 001	Jan 29, 2002
PROZAC				
+	LILLY	EQ 20MG BASE/5ML **	N020101 001	Apr 24, 1991
TABLET;ORAL				
FLUOXETINE HYDROCHLORIDE				
	BARR	EQ 10MG BASE	A075810 001	Feb 01, 2002
	FOSUN PHARMA	EQ 10MG BASE	A076024 001	Jan 29, 2002
	G AND W LABS INC	EQ 60MG BASE	A212191 001	Jul 05, 2019
	IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865 001	Feb 28, 2002
		EQ 40MG BASE	A075865 003	Aug 30, 2004
	RISING	EQ 10MG BASE	A075755 001	Aug 02, 2001
		EQ 20MG BASE	A075755 002	Aug 02, 2001
	SLATE RUN PHARMA	EQ 10MG BASE	A211444 001	Sep 13, 2022
		EQ 20MG BASE	A211444 002	Sep 13, 2022
PROZAC				
+	LILLY	EQ 10MG BASE **	N020974 001	Mar 09, 1999
+		EQ 20MG BASE **	N020974 002	Mar 09, 1999
SARAFEM				
+	APIL	EQ 10MG BASE **	N021860 001	May 19, 2006
+		EQ 15MG BASE **	N021860 002	May 19, 2006
+		EQ 20MG BASE **	N021860 003	May 19, 2006
SELFEMRA				
	TEVA PHARMS USA	EQ 10MG BASE	A200151 001	Feb 03, 2014
		EQ 15MG BASE	A200151 002	Feb 03, 2014
		EQ 20MG BASE	A200151 003	Feb 03, 2014

FLUOXYMESTERONE

TABLET;ORAL				
ANDROID-F				
	VALEANT PHARM INTL	10MG	A087196 001	
FLUOXYMESTERONE				
	UPSHER SMITH LABS	10MG	A088342 001	Oct 21, 1983
	VALEANT PHARM INTL	10MG	A088221 001	May 05, 1983
	WATSON LABS	2MG	A088260 001	Dec 06, 1983
		5MG	A088265 001	Dec 06, 1983
		10MG	A088309 001	Dec 06, 1983
HALOTESTIN				
	PHARMACIA AND UPJOHN	2MG	N010611 002	
		5MG	N010611 006	
		10MG	N010611 010	
ORA-TESTRYL				
	BRISTOL MYERS SQUIBB	2MG	N011359 001	
		5MG	N011359 002	

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION				
FLUPHENAZINE DECANOATE				
	HOSPIRA	25MG/ML	A074966 001	Apr 16, 1998
	TEVA PARENTERAL	25MG/ML	A074795 001	Sep 10, 1996
PROLIXIN DECANOATE				
+	BRISTOL MYERS SQUIBB	25MG/ML **	N016727 001	

FLUPHENAZINE ENANTHATE

INJECTABLE;INJECTION				
PROLIXIN ENANTHATE				
	APOTHECON	25MG/ML **	N016110 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUPHENAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
	ANI PHARMS	5MG/ML	A073058 001	Aug 30, 1991
PERMITIL				
	SCHERING	5MG/ML **	N016008 001	
PROLIXIN				
	APOTHECON	5MG/ML	A070533 001	Nov 07, 1985
ELIXIR;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
	ANI PHARMS	2.5MG/5ML	A081310 001	Apr 29, 1993
PROLIXIN				
+	APOTHECON	2.5MG/5ML **	N012145 003	
INJECTABLE;INJECTION				
PROLIXIN				
	APOTHECON	2.5MG/ML **	N011751 005	
TABLET;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
	PRASCO	1MG	A089804 002	Aug 12, 1988
		2.5MG	A089804 003	Aug 12, 1988
		5MG	A089804 004	Aug 12, 1988
		10MG	A089804 001	Aug 12, 1988
	SANDOZ	1MG	A089586 002	Oct 16, 1987
		2.5MG	A089586 003	Oct 16, 1987
		5MG	A089586 004	Oct 16, 1987
		10MG	A089586 001	Oct 16, 1987
	WATSON LABS	1MG	A088555 001	Dec 18, 1987
		2.5MG	A088544 001	Dec 18, 1987
		5MG	A088527 001	Dec 18, 1987
		10MG	A088550 001	Dec 18, 1987
PERMITIL				
	SCHERING	0.25MG	N012034 001	
		2.5MG	N012034 004	
		5MG	N012034 005	
		10MG	N012034 006	
PROLIXIN				
+	APOTHECON	1MG **	N011751 004	
+		2.5MG **	N011751 001	
+		5MG **	N011751 003	
+		10MG **	N011751 002	
TABLET, EXTENDED RELEASE;ORAL				
PERMITIL				
	SCHERING	1MG	N012419 004	
FLUPREDNISOLONE				
TABLET;ORAL				
ALPHADROL				
	PHARMACIA AND UPJOHN	1.5MG	N012259 002	
FLURANDRENOLIDE				
CREAM;TOPICAL				
CORDRAN SP				
+	ALMIRALL	0.025% **	N012806 003	
+		0.05%	N012806 002	
FLURANDRENOLIDE				
	CHARTWELL RX	0.05%	A205342 001	Apr 13, 2016
LOTION;TOPICAL				
CORDRAN				
+	ALMIRALL	0.05%	N013790 001	
FLURANDRENOLIDE				
	ALPHARMA US PHARMS	0.05%	A087203 001	Apr 29, 1982
	CHARTWELL RX	0.05%	A205343 001	Dec 22, 2016
OINTMENT;TOPICAL				
CORDRAN				
+	ALMIRALL	0.025% **	N012806 004	
+		0.05%	N012806 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM;TOPICAL				
CORDRAN N				
	LILLY	0.05%;EQ 3.5MG BASE/GM	N050346 001	
OINTMENT;TOPICAL				
CORDRAN N				
	LILLY	0.05%;EQ 3.5MG BASE/GM	N050345 001	

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL				
DALMANE				
	VALEANT PHARM INTL	15MG **	N016721 001	
+		30MG **	N016721 002	
FLURAZEPAM HYDROCHLORIDE				
	CHARTWELL RX	15MG	A071205 001	Nov 25, 1986
		30MG	A071068 001	Nov 25, 1986
	HALSEY	15MG	A071808 001	Jan 07, 1988
		30MG	A071809 001	Jan 07, 1988
	HIKMA	30MG	A071108 001	Dec 08, 1986
	HIKMA INTL PHARMS	15MG	A071107 001	Dec 08, 1986
	PUREPAC PHARM	15MG	A071927 001	Sep 09, 1987
		30MG	A071551 001	Sep 09, 1987
	RISING	15MG	A071717 002	Jul 31, 1991
		30MG	A071717 001	Jul 31, 1991
	STRIDES PHARMA	15MG	A070444 001	Mar 20, 1986
		30MG	A070445 001	Mar 20, 1986
	SUN PHARM INDUSTRIES	15MG	A070454 001	Aug 04, 1986
		30MG	A070455 001	Aug 04, 1986
	SUPERPHARM	15MG	A071659 001	Aug 04, 1988
		30MG	A071660 001	Aug 04, 1988
	USL PHARMA	15MG	A070562 001	Jul 09, 1987
		30MG	A070563 001	Jul 09, 1987
	WARNER CHILCOTT	15MG	A071767 001	Dec 04, 1987
		30MG	A071768 001	Dec 04, 1987

FLURBIPROFEN

TABLET;ORAL				
ANSAID				
+	PHARMACIA AND UPJOHN	50MG	N018766 002	Oct 31, 1988
+		100MG	N018766 003	Oct 31, 1988
FLURBIPROFEN				
	IVAX SUB TEVA PHARMS	50MG	A074411 001	May 31, 1995
		100MG	A074411 002	May 31, 1995
	MYLAN	50MG	A074358 001	Jun 20, 1994
		100MG	A074358 002	Jun 20, 1994
	PLIVA	50MG	A074647 001	Apr 01, 1997
		100MG	A074647 002	Apr 01, 1997
	RISING	50MG	A074448 001	Jul 28, 1995
		100MG	A074448 002	Jul 28, 1995
	SUN PHARM INDS INC	50MG	A075058 001	Apr 27, 2001
		100MG	A075058 002	Apr 27, 2001
	TEVA	50MG	A074405 002	May 24, 1995
		100MG	A074405 001	May 24, 1995
	THERAGEN	100MG	A074560 002	May 16, 1997

FLURBIPROFEN SODIUM

SOLUTION/DROPS;OPHTHALMIC				
OCUFEN				
+	ALLERGAN	0.03% **	N019404 001	Dec 31, 1986

FLUTAMIDE

CAPSULE;ORAL				
EULEXIN				
+	SCHERING	125MG **	N018554 001	Jan 27, 1989
FLUTAMIDE				
	ACTAVIS LABS FL INC	125MG	A075820 001	Sep 18, 2001
	CHARTWELL RX	125MG	A075818 001	Sep 18, 2001
	CIPLA	125MG	A075780 001	Sep 19, 2001
	MYLAN	125MG	A076224 001	May 09, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUTEMETAMOL F-18				
INJECTABLE;INTRAVENOUS				
VIZAMYL				
+	GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137 001	Oct 25, 2013
FLUTICASONE PROPIONATE				
AEROSOL, METERED;INHALATION				
FLOVENT				
	GLAXOSMITHKLINE	0.044MG/INH	N020548 001	Mar 27, 1996
		0.11MG/INH	N020548 002	Mar 27, 1996
		0.22MG/INH	N020548 003	Mar 27, 1996
CREAM;TOPICAL				
CUTIVATE				
+	FOUGERA PHARMS	0.05% **	N019958 001	Dec 18, 1990
FLUTICASONE PROPIONATE				
	ENCUBE	0.05%	A076633 001	May 14, 2004
	NESHER PHARMS	0.05%	A076865 001	Sep 10, 2004
LOTION;TOPICAL				
CUTIVATE				
+	FOUGERA PHARMS	0.05% **	N021152 001	Mar 31, 2005
OINTMENT;TOPICAL				
CUTIVATE				
+	FOUGERA PHARMS	0.005% **	N019957 001	Dec 14, 1990
FLUTICASONE PROPIONATE				
	BRIGHT	0.005%	A215343 001	Sep 01, 2023
	FOUGERA PHARMS	0.005%	A076300 001	May 14, 2004
	TARO PHARM INDS	0.005%	A077145 001	Jun 14, 2005
POWDER;INHALATION				
ARMONAIR DIGIHALER				
+	TEVA PHARM	0.03MG/INH	N208798 008	Apr 08, 2022
ARMONAIR RESPICLICK				
+	TEVA PHARM	0.03MG/INH	N208798 007	Jul 09, 2021
+		0.055MG/INH	N208798 001	Jan 27, 2017
+		0.113MG/INH	N208798 002	Jan 27, 2017
+		0.232MG/INH	N208798 003	Jan 27, 2017
FLOVENT				
	GLAXOSMITHKLINE	0.044MG/INH	N020549 001	Nov 07, 1997
		0.088MG/INH	N020549 002	Nov 07, 1997
		0.22MG/INH	N020549 003	Nov 07, 1997
SPRAY, METERED;NASAL				
FLONASE				
+	GLAXOSMITHKLINE	0.05MG/SPRAY **	N020121 001	Oct 19, 1994
FLUVASTATIN SODIUM				
CAPSULE;ORAL				
LESCOL				
+	NOVARTIS	EQ 20MG BASE **	N020261 001	Dec 31, 1993
+		EQ 40MG BASE **	N020261 002	Dec 31, 1993
TABLET, EXTENDED RELEASE;ORAL				
FLUVASTATIN SODIUM				
	MYLAN	EQ 80MG BASE	A202458 001	Sep 11, 2015
FLUVOXAMINE MALEATE				
CAPSULE, EXTENDED RELEASE;ORAL				
FLUVOXAMINE MALEATE				
	TORRENT	100MG	A203240 001	Oct 31, 2014
		150MG	A203240 002	Oct 31, 2014
LUVOX CR				
+	JAZZ PHARMS	100MG **	N022033 001	Feb 28, 2008
+		150MG **	N022033 002	Feb 28, 2008
TABLET;ORAL				
FLUVOXAMINE MALEATE				
	ACTAVIS ELIZABETH	25MG	A075901 001	Dec 28, 2000
		50MG	A075901 002	Dec 28, 2000
		100MG	A075901 003	Dec 28, 2000
	ANI PHARMS	25MG	A075897 001	Jan 25, 2001
		25MG	A075898 001	Mar 12, 2001
		50MG	A075897 002	Jan 25, 2001
		50MG	A075898 002	Mar 12, 2001
		100MG	A075897 003	Jan 25, 2001
		100MG	A075898 003	Mar 12, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUVOXAMINE MALEATE

TABLET;ORAL

FLUVOXAMINE MALEATE					
	CHARTWELL RX	25MG	A075900	001	Feb 23, 2006
		50MG	A075900	002	Feb 23, 2006
		100MG	A075900	003	Feb 23, 2006
	HERITAGE PHARMA	25MG	A075894	001	Apr 18, 2001
		50MG	A075894	002	Apr 18, 2001
		100MG	A075894	003	Apr 18, 2001
	MYLAN	25MG	A075889	001	Nov 29, 2000
		50MG	A075889	002	Nov 29, 2000
		50MG	A075950	001	Oct 15, 2001
		100MG	A075889	003	Nov 29, 2000
		100MG	A075950	002	Oct 15, 2001
	SUN PHARM INDUSTRIES	25MG	A076125	001	Apr 29, 2002
		50MG	A076125	002	Apr 29, 2002
		100MG	A076125	003	Apr 29, 2002
	SYNTHON PHARMS	25MG	A075899	001	Jan 17, 2001
		50MG	A075899	002	Jan 17, 2001
		100MG	A075899	003	Jan 17, 2001
	TEVA	25MG	A075893	001	Sep 10, 2002
		50MG	A075893	002	Sep 10, 2002
		100MG	A075893	003	Sep 10, 2002
	UPSHER SMITH LABS	25MG	A075887	001	Jan 05, 2001
		50MG	A075887	002	Jan 05, 2001
		100MG	A075887	003	Jan 05, 2001
LUVOX					
+	SOLVAY	25MG **	N020243	001	Dec 05, 1994
+		50MG **	N020243	002	Dec 05, 1994
+		100MG **	N020243	003	Dec 05, 1994
+		150MG **	N020243	004	Dec 05, 1994

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID					
	BEN VENUE	5MG/ML	A081066	001	Dec 29, 1993
FOLVITE					
+	WYETH PHARMS INC	5MG/ML **	N005897	008	

TABLET;ORAL

FOLIC ACID					
	BARR	1MG	A089177	001	Jan 08, 1986
	CONTRACT PHARMACAL	1MG	A085061	001	
	EVERYLIFE	1MG	A080755	001	
	HALSEY	1MG	A083598	001	
	HIKMA PHARMS	1MG	A080600	001	
	IMPAX LABS	1MG	A080686	001	
	IVAX SUB TEVA PHARMS	1MG	A083000	001	
	JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005
	LANNETT	1MG	A080816	001	
	LILLY	1MG **	N006135	003	
	MK LABS	1MG	A083526	001	
	NEXGEN PHARMA INC	1MG	A084915	001	
	PHARMERAL	1MG	A084158	001	
	PIONEER PHARMS	1MG	A088949	001	Sep 13, 1985
	PUREPAC PHARM	1MG	A080784	001	
	SANDOZ	1MG	A084472	001	
	SUN PHARM INDUSTRIES	1MG	A040582	001	Jul 18, 2005
	TABLICAPS	1MG	A083133	002	
	UDL	1MG	A088199	001	Mar 29, 1983
	USL PHARMA	1MG	A087828	001	May 13, 1982
	VALEANT PHARM INTL	1MG	A080903	001	
	VANGARD	1MG	A088730	001	Mar 23, 1984
	VINTAGE	1MG	A040756	001	Jun 04, 2010
	VINTAGE PHARMS	1MG	A086296	001	
	WATSON LABS	1MG	A083141	001	
		1MG	A085141	002	
	WHITEWORTH TOWN PLSN	1MG	A080691	002	
FOLICET					
	MISSION PHARMA	1MG	A087438	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FOLIC ACID					
TABLET;ORAL					
FOLVITE					
	WYETH PHARMS INC	1MG **	N005897	004	
FOMEPIZOLE					
INJECTABLE;INJECTION					
ANTIZOL					
+	PAR PHARM INC	1.5GM/1.5ML (1GM/ML) **	N020696	001	Dec 04, 1997
FOMEPIZOLE					
	MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009
FOMIVIRSEN SODIUM					
INJECTABLE;INJECTION					
VITRAVENE PRESERVATIVE FREE					
	NOVARTIS	6.6MG/ML	N020961	001	Aug 26, 1998
FORMOTEROL FUMARATE					
POWDER;INHALATION					
FORADIL					
+	NOVARTIS	0.012MG/INH **	N020831	001	Feb 16, 2001
FORADIL CERTIHALER					
	NOVARTIS	0.0085MG/INH	N021592	001	Dec 15, 2006
FOSAMPRENAVIR CALCIUM					
SUSPENSION;ORAL					
LEXIVA					
+	VIIV HLTHCARE	EQ 50MG BASE/ML	N022116	001	Jun 14, 2007
FOSAPREPITANT DIMEGLUMINE					
POWDER;INTRAVENOUS					
EMEND					
+	MERCK AND CO INC	EQ 115MG BASE/VIAL **	N022023	001	Jan 25, 2008
FOSAPREPITANT DIMEGLUMINE					
	APOTEX	EQ 150MG BASE/VIAL	A205020	001	Sep 05, 2019
	ARTHUR GRP	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019
		EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021
	MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015	001	Sep 05, 2019
	SANDOZ	EQ 150MG BASE/VIAL	A203939	001	Dec 08, 2020
FOSCARNET SODIUM					
INJECTABLE;INJECTION					
FOSCARNET SODIUM					
	HOSPIRA	2.4GM/100ML	A077174	001	May 31, 2005
FOSINOPRIL SODIUM					
TABLET;ORAL					
FOSINOPRIL SODIUM					
	ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004
		20MG	A076620	002	Oct 15, 2004
		40MG	A076620	003	Oct 15, 2004
	RANBAXY LABS LTD	10MG	A076580	001	Apr 23, 2004
		20MG	A076580	002	Apr 23, 2004
		40MG	A076580	003	Apr 23, 2004
	UPSHER SMITH LABS	10MG	A076188	001	Oct 08, 2004
		20MG	A076188	002	Oct 08, 2004
		40MG	A076188	003	Oct 08, 2004
	WATSON LABS	10MG	A076987	001	Dec 23, 2004
		10MG	A077531	001	Aug 31, 2006
		20MG	A076987	002	Dec 23, 2004
		20MG	A077531	002	Aug 31, 2006
		40MG	A076987	003	Dec 23, 2004
		40MG	A077531	003	Aug 31, 2006
MONOPRIL					
+	BRISTOL MYERS SQUIBB	10MG **	N019915	002	May 16, 1991
+		20MG **	N019915	003	May 16, 1991
+		40MG **	N019915	004	Mar 28, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

ANI PHARMS	10MG;12.5MG	A076608	001	Dec 03, 2004
	10MG;12.5MG	A077144	001	Aug 16, 2005
	20MG;12.5MG	A076608	002	Dec 03, 2004
	20MG;12.5MG	A077144	002	Aug 16, 2005
AVET LIFESCIENCES	10MG;12.5MG	A079025	001	Sep 17, 2010
	20MG;12.5MG	A079025	002	Sep 17, 2010
MYLAN	10MG;12.5MG	A077705	001	Aug 14, 2006
	20MG;12.5MG	A077705	002	Aug 14, 2006
SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004
	20MG;12.5MG	A076739	002	Dec 17, 2004
TEVA	10MG;12.5MG	A076945	001	Jul 05, 2006
	20MG;12.5MG	A076945	002	Jul 05, 2006

MONOPRIL-HCT

+ BRISTOL MYERS SQUIBB	10MG;12.5MG **	N020286	002	Nov 30, 1994
+	20MG;12.5MG **	N020286	001	Nov 30, 1994

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER;INTRAVENOUS

AKYNZEO

+ HELSINN HLTHCARE	EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL	N210493	001	Apr 19, 2018

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

FOSPHENYTOIN SODIUM

AM REGENT	EQ 50MG PHENYTOIN NA/ML	A078277	001	Aug 06, 2007
	EQ 50MG PHENYTOIN NA/ML	A090099	001	May 13, 2010
AMNEAL	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008
APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126	001	Aug 06, 2007
DR REDDYS	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007
HOSPIRA	EQ 50MG PHENYTOIN NA/ML	A078158	001	Aug 06, 2007
MYLAN LABS LTD	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010

SOLUTION;INTRAVENOUS

SESQUIENT

+ LUPIN	EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864	001	Nov 05, 2020
+	EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864	002	Nov 05, 2020

FOSPROPOFOL DISODIUM

SOLUTION;INTRAVENOUS

LUSEDRA

EISAI INC	1050MG/30ML (35MG/ML)	N022244	001	Dec 12, 2008

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVATRIPTAN SUCCINATE

MYLAN	EQ 2.5MG BASE	A202931	001	Aug 28, 2014

FULVESTRANT

SOLUTION;INTRAMUSCULAR

FASLODEX

+ ASTRAZENECA	125MG/2.5ML (50MG/ML)	N021344	002	Apr 25, 2002

FULVESTRANT

APOTEX	250MG/5ML (50MG/ML)	A211730	001	Jun 11, 2021

FURAZOLIDONE

SUSPENSION;ORAL

FUROXONE

SHIRE	50MG/15ML	N011323	002	

TABLET;ORAL

FUROXONE

SHIRE	100MG	N011270	002	

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

ABRAXIS PHARM	10MG/ML	N018507	001	Jul 30, 1982
	10MG/ML	N019036	001	Aug 13, 1984
+ AM REGENT	10MG/ML **	N018579	001	Nov 30, 1983
ASTRAZENECA	10MG/ML	A070014	001	Sep 09, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FUROSEMIDE

INJECTABLE;INJECTION				
FUROSEMIDE				
HIKMA	10MG/ML	A071439	001	Sep 14, 1990
	10MG/ML	N018267	001	
HOSPIRA	10MG/ML	A070578	001	Jul 08, 1987
	10MG/ML	A072080	001	Aug 13, 1991
	10MG/ML	A074337	001	Oct 31, 1994
IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985
	10MG/ML	A070096	001	Sep 09, 1985
INTL MEDICATION	10MG/ML	N018025	001	
MARSAM PHARMS LLC	10MG/ML	A074017	001	Jun 30, 1994
SMITH AND NEPHEW	10MG/ML	A070023	001	Feb 05, 1986
	10MG/ML	A070078	001	Feb 05, 1986
WARNER CHILCOTT	10MG/ML	N018420	001	Feb 26, 1982
WATSON LABS	10MG/ML	A070019	001	Sep 22, 1986
	10MG/ML	A070604	001	Jan 02, 1987
WYETH AYERST	10MG/ML	N018670	001	Jul 20, 1982
LASIX				
+ SANOFI AVENTIS US	10MG/ML **	N016363	001	
SOLUTION;ORAL				
FUROSEMIDE				
PHARMOBEDIENT CNSLTG	10MG/ML	A070655	001	Oct 02, 1987
LASIX				
SANOFI AVENTIS US	10MG/ML	N017688	001	
TABLET;ORAL				
FUROSEMIDE				
ANI PHARMS	20MG	A071379	001	Jan 02, 1987
	40MG	A070413	001	Feb 26, 1986
	80MG	A071594	001	Feb 09, 1988
CHARTWELL RX	20MG	N018413	001	Nov 30, 1983
	40MG	N018413	002	Nov 30, 1983
EPIC PHARMA LLC	40MG	N018750	002	Jul 30, 1984
INTL MEDICATION	20MG	N018753	001	Feb 28, 1984
	40MG	N018753	002	Feb 28, 1984
KALAPHARM	20MG	N018868	001	Jun 28, 1983
	40MG	N018868	002	Jun 28, 1983
STRIDES PHARMA	20MG	N018415	001	Jul 27, 1982
	40MG	N018415	002	Jul 27, 1982
	80MG	N018415	003	Nov 26, 1984
SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014
	40MG	A091258	002	Apr 01, 2014
	40MG	N018790	001	Nov 29, 1983
	80MG	A091258	003	Apr 01, 2014
SUN PHARM INDUSTRIES	20MG	A070043	001	Sep 26, 1985
	80MG	A070100	001	Jan 26, 1988
SUPERPHARM	20MG	N018370	002	Jun 26, 1984
	40MG	N018370	001	Feb 10, 1983
WARNER CHILCOTT	20MG	N018419	001	Jan 31, 1983
	40MG	N018419	002	Jan 31, 1983
	80MG	N018419	003	Nov 13, 1984
WATSON LABS	20MG	A070412	001	Feb 26, 1986
	20MG	N018369	001	May 14, 1982
	40MG	A070450	001	Nov 22, 1985
	40MG	N018369	002	May 14, 1982
WATSON LABS TEVA	20MG	A070449	001	Nov 22, 1985
	80MG	A070528	001	Jan 07, 1986

GABAPENTIN

CAPSULE;ORAL				
GABAPENTIN				
CHARTWELL RX	100MG	A091008	001	Oct 26, 2017
	300MG	A091008	002	Oct 26, 2017
	400MG	A091008	003	Oct 26, 2017
HIKMA	100MG	A078150	001	Sep 25, 2007
	300MG	A078150	002	Sep 25, 2007
	400MG	A078150	003	Sep 25, 2007
MYLAN	100MG	A090158	001	Feb 14, 2011
	300MG	A090158	002	Feb 14, 2011
	400MG	A090158	003	Feb 14, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GABAPENTIN

CAPSULE;ORAL				
GABAPENTIN				
SANDOZ	100MG	A075428	001	Jan 24, 2006
	100MG	A075539	001	Apr 06, 2005
	300MG	A075428	002	Jan 24, 2006
	300MG	A075539	002	Apr 06, 2005
	400MG	A075428	003	Jan 24, 2006
	400MG	A075539	003	Apr 06, 2005
SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005
	300MG	A076606	002	Oct 07, 2005
	400MG	A076606	003	Oct 07, 2005
SUN PHARM INDUSTRIES	100MG	A076537	001	Jun 30, 2005
	300MG	A076537	002	Jun 30, 2005
	400MG	A076537	003	Jun 30, 2005
TEVA PHARMS	100MG	A075435	001	Oct 08, 2004
	300MG	A075435	002	Oct 08, 2004
	400MG	A075435	003	Oct 08, 2004
WATSON LABS	100MG	A075485	003	May 11, 2007
	300MG	A075485	002	May 11, 2007
	400MG	A075485	001	May 11, 2007
SOLUTION;ORAL				
GABAPENTIN				
PAI HOLDINGS PHARM	250MG/5ML	A211330	001	Dec 03, 2019
TABLET;ORAL				
GABAPENTIN				
CHARTWELL RX	600MG	A076120	001	Jan 27, 2006
	800MG	A076120	002	Jan 27, 2006
HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011
	800MG	A078782	002	Jul 21, 2011
INVATECH	600MG	A076877	001	Jul 06, 2006
	800MG	A076877	002	Jul 06, 2006
IVAX SUB TEVA PHARMS	600MG	A076017	004	Apr 29, 2005
	800MG	A076017	005	Apr 29, 2005
LUPIN LTD	600MG	A209306	001	Aug 24, 2018
	800MG	A209306	002	Aug 24, 2018
MYLAN PHARMS INC	600MG	A090335	001	Jun 01, 2010
	800MG	A090335	002	Jun 01, 2010
RANBAXY	600MG	A076605	001	Sep 14, 2005
	800MG	A076605	002	Sep 14, 2005
TEVA	600MG	A075827	001	Dec 15, 2004
	800MG	A075827	002	Dec 15, 2004
TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017
	800MG	A205807	002	Mar 10, 2017

GADODIAMIDE

INJECTABLE;INJECTION				
OMNISCAN				
GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007

GADOFOSVESET TRISODIUM

SOLUTION;INTRAVENOUS				
ABLAVAR				
LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711	001	Dec 22, 2008
	3660MG/15ML (244MG/ML)	N021711	002	Dec 22, 2008

GADOPENTETATE DIMEGLUMINE

INJECTABLE;INJECTION				
MAGNEVIST				
+ BAYER HLTHCARE	469.01MG/ML	N019596	001	Jun 02, 1988
+	469.01MG/ML	N021037	001	Mar 10, 2000

GADOVERSETAMIDE

INJECTABLE;INJECTION				
OPTIMARK				
+ LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999
+	3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999
+	4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999
+	6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999
+	16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GADOVERSETAMIDE

INJECTABLE;INJECTION				
OPTIMARK IN PLASTIC CONTAINER				
+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976 002	Dec 08, 1999
+		4963.5MG/15ML (330.9MG/ML)	N020976 003	Dec 08, 1999
+		6618MG/20ML (330.9MG/ML)	N020976 004	Dec 08, 1999
+		9927MG/30ML (330.9MG/ML)	N020976 001	Dec 08, 1999

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL				
GALANTAMINE HYDROBROMIDE				
	IMPAX LABS	EQ 8MG BASE	A078484 001	May 27, 2009
		EQ 16MG BASE	A078484 002	May 27, 2009
		EQ 24MG BASE	A078484 003	May 27, 2009
	MYLAN	EQ 8MG BASE	A090900 001	Jan 24, 2011
		EQ 16MG BASE	A090900 002	Jan 24, 2011
		EQ 24MG BASE	A090900 003	Jan 24, 2011
RAZADYNE ER				
+	JANSSEN PHARMS	EQ 8MG BASE	N021615 001	Apr 01, 2005
+		EQ 16MG BASE	N021615 002	Apr 01, 2005
+		EQ 24MG BASE	N021615 003	Apr 01, 2005
SOLUTION;ORAL				
RAZADYNE				
	JANSSEN PHARMS	4MG/ML **	N021224 001	Jun 22, 2001
TABLET;ORAL				
GALANTAMINE HYDROBROMIDE				
	APOTEX INC	EQ 4MG BASE	A077781 001	Sep 27, 2011
		EQ 8MG BASE	A077781 002	Sep 27, 2011
		EQ 12MG BASE	A077781 003	Sep 27, 2011
	CHARTWELL RX	EQ 4MG BASE	A077587 001	Jul 09, 2009
		EQ 8MG BASE	A077587 002	Jul 09, 2009
		EQ 12MG BASE	A077587 003	Jul 09, 2009
	HERITAGE PHARMA	EQ 4MG BASE	A077585 001	Sep 15, 2009
		EQ 8MG BASE	A077585 002	Sep 15, 2009
		EQ 12MG BASE	A077585 003	Sep 15, 2009
	HIKMA	EQ 4MG BASE	A077608 001	Feb 11, 2009
		EQ 8MG BASE	A077608 002	Feb 11, 2009
		EQ 12MG BASE	A077608 003	Feb 11, 2009
	MYLAN	EQ 4MG BASE	A077590 001	May 29, 2009
		EQ 4MG BASE	A077603 001	Aug 28, 2008
		EQ 8MG BASE	A077590 002	May 29, 2009
		EQ 8MG BASE	A077603 002	Aug 28, 2008
		EQ 12MG BASE	A077590 003	May 29, 2009
		EQ 12MG BASE	A077603 003	Aug 28, 2008
RAZADYNE				
+	JANSSEN PHARMS	EQ 4MG BASE **	N021169 001	Feb 28, 2001
+		EQ 8MG BASE **	N021169 002	Feb 28, 2001
+		EQ 12MG BASE **	N021169 003	Feb 28, 2001

GALLAMINE TRIETHIODIDE

INJECTABLE;INJECTION				
FLAXEDIL				
	DAVIS AND GECK	20MG/ML	N007842 001	
		100MG/ML	N007842 002	

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION				
GALLIUM CITRATE GA 67				
	GE HEALTHCARE	1mCi/ML	N017700 001	
	LANTHEUS MEDCL	2mCi/ML	N017478 001	
NEOSCAN				
	GE HEALTHCARE	2mCi/ML	N017655 001	

GALLIUM NITRATE

INJECTABLE;INJECTION				
GANITE				
	CHAPTER 7 TRUSTEE	25MG/ML **	N019961 002	Jan 17, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GANCICLOVIR				
CAPSULE;ORAL				
CYTOVENE				
+ ROCHE PALO	250MG **	N020460	001	Dec 22, 1994
+	500MG **	N020460	002	Dec 12, 1997
GANCICLOVIR				
RANBAXY LABS LTD	250MG	A076457	001	Jun 27, 2003
	500MG	A076457	002	Jun 27, 2003
IMPLANT;IMPLANTATION				
VITRASERT				
BAUSCH AND LOMB	4.5MG	N020569	001	Mar 04, 1996
GANCICLOVIR SODIUM				
INJECTABLE;INJECTION				
CYTOVENE				
+ CHEPLAPHARM	EQ 500MG BASE/VIAL **	N019661	001	Jun 23, 1989
GANCICLOVIR SODIUM				
AM REGENT	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013
CUSTOPHARM INC	EQ 500MG BASE/VIAL	A212001	001	Jun 20, 2019
STERISCIENCE	EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017
GATIFLOXACIN				
SOLUTION/DROPS;OPHTHALMIC				
GATIFLOXACIN				
APOTEX INC	0.3%	A079084	001	Aug 19, 2011
RISING	0.5%	A206446	001	Jun 08, 2018
TORRENT	0.5%	A213542	001	Nov 03, 2021
ZYMAR				
+ ALLERGAN	0.3%	N021493	001	Mar 28, 2003
GEFITINIB				
TABLET;ORAL				
IRESSA				
ASTRAZENECA	250MG	N021399	001	May 05, 2003
GEMCITABINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
GEMCITABINE HYDROCHLORIDE				
ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016
	1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016
	2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016
ACTAVIS TOTOWA	EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011
	EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011
	EQ 2GM BASE/VIAL	A079160	003	Jul 28, 2016
AM REGENT	EQ 200MG BASE/VIAL	A202031	001	May 07, 2013
	EQ 1GM BASE/VIAL	A202031	002	May 07, 2013
APOTEX	200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017
	1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017
	2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017
EMCURE PHARMS LTD	EQ 200MG BASE/VIAL	A202063	001	Sep 11, 2012
	EQ 1GM BASE/VIAL	A202063	002	Sep 11, 2012
HAMELN RDS GMBH	EQ 200MG BASE/VIAL	A090663	001	Sep 10, 2012
	EQ 1GM BASE/VIAL	A090663	002	Sep 10, 2012
MYLAN LABS LTD	EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011
	EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011
	EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011
SAGENT PHARMS	EQ 200MG BASE/VIAL	A091597	001	May 07, 2013
	EQ 1GM BASE/VIAL	A091597	002	May 07, 2013
TEVA PHARMS	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011
	EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011
GEMZAR				
+ LILLY	EQ 200MG BASE/VIAL **	N020509	001	May 15, 1996
+	EQ 1GM BASE/VIAL **	N020509	002	May 15, 1996
SOLUTION;INTRAVENOUS				
INFUGEM				
+ SUN PHARM	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313	001	Jul 16, 2018
+	EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002	Jul 16, 2018
+	EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018
+	EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018
+	EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018
+	EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GEMCITABINE HYDROCHLORIDE				
SOLUTION;INTRAVENOUS				
INFUGEM				
+	EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018
+	EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018
+	EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018
+	EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018
GEMFIBROZIL				
CAPSULE;ORAL				
GEMFIBROZIL				
MYLAN	300MG	A073466	001	Jan 25, 1993
PUREPAC PHARM	300MG	A072929	001	Jan 29, 1993
LOPID				
PFIZER PHARMS	200MG	N018422	001	
	300MG	N018422	002	
TABLET;ORAL				
GEMFIBROZIL				
CADILA	600MG	A204189	001	Aug 28, 2018
CHARTWELL RX	600MG	A074615	001	Sep 29, 1995
HIKMA PHARMS	600MG	A078599	001	Aug 16, 2010
MYLAN	600MG	A074452	001	Feb 16, 1995
PUREPAC PHARM	600MG	A074360	001	Aug 31, 1994
SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008
TEVA	600MG	A074256	001	Oct 31, 1993
WATSON LABS	600MG	A074156	001	Oct 24, 1994
	600MG	A074442	001	Apr 28, 1995
GEMIFLOXACIN MESYLATE				
TABLET;ORAL				
FACTIVE				
+ LG CHEM LTD	EQ 320MG BASE **	N021158	001	Apr 04, 2003
GEMIFLOXACIN MESYLATE				
ORBION PHARMS	EQ 320MG BASE	A090466	001	Jun 15, 2015
GENTAMICIN SULFATE				
CREAM;TOPICAL				
GARAMYCIN				
SCHERING	EQ 0.1% BASE **	A060462	001	
GENTAFAIR				
PHARMAFAIR	EQ 0.1% BASE	A062458	001	Sep 01, 1983
GENTAMICIN SULFATE				
ALPHARMA US PHARMS	EQ 0.1% BASE	A062471	001	Sep 27, 1983
FOUGERA PHARMS INC	EQ 0.1% BASE	A062531	001	Jul 05, 1984
PHARMADERM	EQ 1MG BASE/GM	A062530	001	Jul 05, 1984
TARO	EQ 0.1% BASE	A062427	001	May 26, 1983
INJECTABLE;INJECTION				
APOGEN				
KING PHARMS	EQ 10MG BASE/ML	A062289	001	
	EQ 40MG BASE/ML	A062289	002	
BRISTAGEN				
BRISTOL	EQ 40MG BASE/ML	A062288	001	
GARAMYCIN				
SCHERING	EQ 1MG BASE/ML **	A061716	002	
	EQ 10MG BASE/ML **	A061739	001	
	EQ 40MG BASE/ML **	A061716	001	
GENTAFAIR				
PHARMAFAIR	EQ 40MG BASE/ML	A062493	001	Aug 28, 1985
GENTAMICIN				
INTL MEDICATION	EQ 1MG BASE/ML	A062325	003	Jun 23, 1982
	EQ 40MG BASE/ML	A062325	001	
	EQ 100MG BASE/100ML	A062325	004	Jun 23, 1982
GENTAMICIN SULFATE				
ABBOTT	EQ 1.2MG BASE/ML	A062413	001	Aug 11, 1983
	EQ 1.4MG BASE/ML	A062413	002	Aug 11, 1983
	EQ 1.6MG BASE/ML	A062413	003	Aug 11, 1983
	EQ 1.8MG BASE/ML	A062413	004	Aug 11, 1983
	EQ 2MG BASE/ML	A062413	005	Aug 11, 1983
	EQ 60MG BASE/100ML	A062413	006	Aug 11, 1983
	EQ 70MG BASE/100ML	A062413	007	Aug 11, 1983
	EQ 80MG BASE/100ML	A062413	008	Aug 11, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GENTAMICIN SULFATE

INJECTABLE;INJECTION				
GENTAMICIN SULFATE				
	EQ 90MG BASE/100ML	A062413	009	Aug 11, 1983
	EQ 100MG BASE/100ML	A062413	010	Aug 11, 1983
FRESENIUS KABI USA	EQ 10MG BASE/ML	A062356	001	Mar 04, 1982
	EQ 40MG BASE/ML	A062356	002	Mar 04, 1982
HOSPIRA	EQ 10MG BASE/ML	A062612	004	Feb 20, 1986
KALAPHARM	EQ 40MG BASE/ML	A062354	001	Apr 05, 1982
PHARM SPEC	EQ 40MG BASE/ML	A062340	001	Mar 28, 1983
SOLOPAK	EQ 10MG BASE/ML	A062507	001	Jun 06, 1985
	EQ 40MG BASE/ML	A062507	002	Jun 06, 1985
TEVA PARENTERAL	EQ 10MG BASE/ML	A063149	001	Nov 21, 1991
	EQ 40MG BASE/ML	A063106	002	Nov 21, 1991
WATSON LABS	EQ 10MG BASE/ML	A062318	002	
	EQ 40MG BASE/ML	A062318	001	
WYETH AYERST	EQ 10MG BASE/ML	A062264	001	
	EQ 40MG BASE/ML	A062264	002	
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	EQ 0.8MG BASE/ML	A062814	001	Aug 28, 1987
	EQ 1.2MG BASE/ML	A062814	002	Aug 28, 1987
	EQ 1.4MG BASE/ML	A062814	003	Aug 28, 1987
	EQ 1.6MG BASE/ML	A062814	004	Aug 28, 1987
	EQ 1.8MG BASE/ML	A062814	005	Aug 28, 1987
	EQ 2MG BASE/ML	A062814	006	Aug 28, 1987
	EQ 2.4MG BASE/ML	A062814	007	Aug 28, 1987
	EQ 40MG BASE/100ML	A062814	008	Aug 28, 1987
	EQ 60MG BASE/100ML	A062814	009	Aug 28, 1987
	EQ 70MG BASE/100ML	A062814	010	Aug 28, 1987
	EQ 80MG BASE/100ML	A062814	011	Aug 28, 1987
	EQ 90MG BASE/100ML	A062814	012	Aug 28, 1987
	EQ 100MG BASE/100ML	A062814	013	Aug 28, 1987
	EQ 120MG BASE/100ML	A062814	014	Aug 28, 1987
BAXTER HLTHCARE	EQ 0.8MG BASE/ML	A062373	001	Sep 07, 1982
	EQ 2.4MG BASE/ML	A062373	010	Sep 07, 1982
	EQ 40MG BASE/100ML	A062373	003	Sep 07, 1982
	EQ 60MG BASE/100ML	A062373	004	Sep 07, 1982
HOSPIRA	EQ 1.2MG BASE/ML	A062588	001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062414	002	Aug 15, 1983
	EQ 1.4MG BASE/ML	A062588	002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588	003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062414	004	Aug 15, 1983
	EQ 1.8MG BASE/ML	A062588	004	Jan 06, 1986
	EQ 2MG BASE/ML	A062414	005	Aug 15, 1983
	EQ 2MG BASE/ML	A062588	005	Jan 06, 1986
	EQ 60MG BASE/100ML	A062414	006	Aug 15, 1983
	EQ 60MG BASE/100ML	A062588	006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062414	007	Aug 15, 1983
	EQ 70MG BASE/100ML	A062588	007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062588	008	Jan 06, 1986
	EQ 90MG BASE/100ML	A062414	009	Aug 15, 1983
	EQ 90MG BASE/100ML	A062588	009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588	010	Jan 06, 1986
U-GENCIN				
PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248	001	
	EQ 40MG BASE/ML	A062248	002	
INJECTABLE;INTRATHECAL				
GARAMYCIN				
+ SCHERING	EQ 2MG BASE/ML **	N050505	001	
OINTMENT;OPHTHALMIC				
GARAMYCIN				
SCHERING	EQ 0.3% BASE	N050425	001	
GENTACIDIN				
NOVARTIS	EQ 0.3% BASE	A062501	001	Jul 26, 1984
GENTAFAIR				
PHARMAFAIR	EQ 3MG BASE/GM	A062443	001	May 26, 1983
GENTAMICIN SULFATE				
AKORN	EQ 0.3% BASE	A064093	001	Aug 31, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GENTAMICIN SULFATE				
OINTMENT;TOPICAL				
GARAMYCIN				
SCHERING	EQ 0.1% BASE **	A060463	001	
GENTAFAIR				
PHARMAFAIR	EQ 0.1% BASE	A062444	001	May 26, 1983
GENTAMICIN SULFATE				
ALPHARMA US PHARMS	EQ 0.1% BASE	A062496	001	Mar 14, 1984
PHARMADERM	EQ 0.1% BASE	A062534	001	Oct 10, 1984
VERTICE	EQ 0.1% BASE	A209233	001	Dec 31, 2018
SOLUTION/DROPS;OPHTHALMIC				
GARAMYCIN				
+ SCHERING	EQ 0.3% BASE **	N050039	002	
GENOPTIC				
ALLERGAN	EQ 0.3% BASE	A062452	001	Oct 10, 1984
GENTACIDIN				
NOVARTIS	EQ 0.3% BASE	A062480	001	Mar 30, 1984
GENTAFAIR				
PHARMAFAIR	EQ 0.3% BASE	A062440	001	May 03, 1983
GENTAK				
AKORN	EQ 0.3% BASE	A064163	001	Oct 12, 2001
GENTAMICIN SULFATE				
AKORN	EQ 0.3% BASE	A062635	001	Jan 08, 1987
ALCON PHARMS LTD	EQ 0.3% BASE	A062523	001	Nov 25, 1985
PACO	EQ 3MG BASE/ML	A062932	001	Nov 07, 1988
GENTAMICIN SULFATE; PREDNISOLONE ACETATE				
OINTMENT;OPHTHALMIC				
PRED-G				
+ ALLERGAN	EQ 0.3% BASE;0.6%	N050612	001	Dec 01, 1989
SUSPENSION/DROPS;OPHTHALMIC				
PRED-G				
+ ALLERGAN	EQ 0.3% BASE;1%	N050586	001	Jun 10, 1988
GENTIAN VIOLET				
SUPPOSITORY;VAGINAL				
GVS				
SAVAGE LABS	0.4%	A083513	001	
TAMPON;VAGINAL				
GENAPAX				
KEY PHARMS	5MG	A085017	001	
GLATIRAMER ACETATE				
FOR SOLUTION;SUBCUTANEOUS				
COPAXONE				
+ TEVA PHARMS USA	20MG/VIAL	N020622	001	Dec 20, 1996
GLIMEPIRIDE				
TABLET;ORAL				
GLIMEPIRIDE				
ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010
	2MG	A076995	002	Apr 27, 2010
	4MG	A076995	003	Apr 27, 2010
EPIC PHARMA LLC	1MG	A077274	001	Oct 06, 2005
	2MG	A077274	002	Oct 06, 2005
	4MG	A077274	003	Oct 06, 2005
HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013
	2MG	A078952	002	Aug 01, 2013
	4MG	A078952	003	Aug 01, 2013
MYLAN	1MG	A077486	001	Feb 10, 2006
	1MG	A077624	001	Nov 28, 2005
	2MG	A077486	002	Feb 10, 2006
	2MG	A077624	002	Nov 28, 2005
	4MG	A077486	003	Feb 10, 2006
	4MG	A077624	003	Nov 28, 2005
RANBAXY	3MG	A077366	001	Oct 06, 2005
	6MG	A077366	002	Oct 06, 2005
RANBAXY LABS LTD	1MG	A076875	001	Oct 06, 2005
	2MG	A076875	002	Oct 06, 2005
	4MG	A076875	003	Oct 06, 2005
	8MG	A076875	004	Oct 06, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GLIMEPIRIDE

TABLET;ORAL					
GLIMEPIRIDE					
	TEVA	1MG	A076802	001	Oct 06, 2005
		2MG	A076802	002	Oct 06, 2005
		4MG	A076802	003	Oct 06, 2005
	WATSON LABS	1MG	A077280	001	Feb 03, 2006
		2MG	A077280	002	Feb 03, 2006
		4MG	A077280	003	Feb 03, 2006

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL					
AVANDARYL					
+	SB PHARMCO	1MG;4MG **	N021700	001	Nov 23, 2005
+		2MG;4MG **	N021700	002	Nov 23, 2005
+		2MG;8MG **	N021700	004	Mar 30, 2007
+		4MG;4MG **	N021700	003	Nov 23, 2005
+		4MG;8MG **	N021700	005	Mar 30, 2007
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE					
	TEVA PHARMS USA	1MG;4MG	A078709	001	Apr 01, 2016
		2MG;4MG	A078709	002	Apr 01, 2016
		2MG;8MG	A078709	004	Apr 01, 2016
		4MG;4MG	A078709	003	Apr 01, 2016
		4MG;8MG	A078709	005	Apr 01, 2016

GLIPIZIDE

TABLET;ORAL					
GLIPIZIDE					
	ANI PHARMS	5MG	A074387	001	Mar 04, 1996
		10MG	A074387	002	Mar 04, 1996
	BARR LABS INC	5MG	A074619	001	Apr 04, 1997
		10MG	A074619	002	Apr 04, 1997
	CHARTWELL RX	5MG	A074542	001	Jun 20, 1995
		10MG	A074542	002	Jun 20, 1995
	MYLAN	5MG	A074438	001	Jun 20, 1995
		10MG	A074438	002	Jun 20, 1995
	OXFORD PHARMS	5MG	A074378	001	Nov 28, 1994
		10MG	A074378	002	Nov 28, 1994
	SUN PHARM INDS INC	5MG	A077820	001	Jul 11, 2006
		10MG	A077820	002	Jul 11, 2006
	WATSON LABS	5MG	A074370	001	Nov 22, 1994
		10MG	A074370	002	Nov 22, 1994
GLUCOTROL					
+	PFIZER	2.5MG **	N017783	003	May 11, 1993
+		5MG	N017783	001	May 08, 1984
+		10MG	N017783	002	May 08, 1984
TABLET, EXTENDED RELEASE;ORAL					
GLIPIZIDE					
	MYLAN	2.5MG	A202298	001	May 19, 2015
		5MG	A202298	002	May 19, 2015
		10MG	A202298	003	May 19, 2015
	PAR PHARM	5MG	A076159	002	Sep 20, 2013
		10MG	A076159	001	Sep 20, 2013

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL					
GLIPIZIDE AND METFORMIN HYDROCHLORIDE					
	DASH PHARMS	2.5MG;250MG	A078083	001	Apr 12, 2007
		2.5MG;500MG	A078083	002	Apr 12, 2007
		5MG;500MG	A078083	003	Apr 12, 2007
	SUN PHARM INDS INC	2.5MG;250MG	A077620	001	Jan 11, 2008
		2.5MG;500MG	A077620	002	Jan 11, 2008
		5MG;500MG	A077620	003	Jan 11, 2008
METAGLIP					
+	BRISTOL MYERS SQUIBB	2.5MG;250MG **	N021460	001	Oct 21, 2002
+		2.5MG;500MG **	N021460	002	Oct 21, 2002
+		5MG;500MG **	N021460	003	Oct 21, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GLUCAGON				
INJECTABLE;INJECTION				
GLUCAGON				
+ LILLY	1MG/VIAL	N020928	001	Sep 11, 1998
SOLUTION;SUBCUTANEOUS				
GVOKE PFS				
+ XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	001	Sep 10, 2019
GLUCAGON HYDROCHLORIDE				
INJECTABLE;INJECTION				
GLUCAGON				
+ LILLY	EQ 1MG BASE/VIAL **	N012122	001	
+	EQ 10MG BASE/VIAL **	N012122	002	
GLUTETHIMIDE				
CAPSULE;ORAL				
DORIDEN				
SANOFI AVENTIS US	500MG	N009519	008	
TABLET;ORAL				
DORIDEN				
SANOFI AVENTIS US	250MG	N009519	002	
	500MG	N009519	005	
GLUTETHIMIDE				
HALSEY	250MG	A089458	001	Oct 10, 1986
	500MG	A089459	001	Oct 10, 1986
LANNETT	250MG	A083475	001	
	500MG	A085571	001	
UCB INC	500MG	A085171	001	
UPSHER SMITH LABS	500MG	A083234	002	
VITARINE	500MG	A087297	001	
WATSON LABS	500MG	A084362	001	
	500MG	A085763	001	
GLYBURIDE				
TABLET;ORAL				
GLYBURIDE				
ACTAVIS ELIZABETH	1.5MG	A075947	001	Nov 14, 2002
	3MG	A075947	002	Nov 14, 2002
	6MG	A075947	003	Nov 14, 2002
AUROBINDO PHARMA	1.25MG	A077537	001	Oct 18, 2007
	2.5MG	A077537	002	Oct 18, 2007
	5MG	A077537	003	Oct 18, 2007
CHARTWELL RX	1.25MG	A203581	001	Apr 14, 2016
	2.5MG	A203581	002	Apr 14, 2016
	5MG	A203581	003	Apr 14, 2016
GLYBURIDE (MICRONIZED)				
CHARTWELL RX	1.5MG	A075174	001	Jun 22, 1998
	3MG	A075174	002	Jun 22, 1998
HIKMA	1.5MG	A075890	001	Jul 31, 2003
	3MG	A075890	002	Jul 31, 2003
	6MG	A075890	003	Jul 31, 2003
MYLAN	1.5MG	A074792	001	Jun 26, 1998
	3MG	A074792	002	Jun 26, 1998
	6MG	A074792	003	Aug 17, 1999
SANOFI AVENTIS US	1.5MG	N020055	001	Apr 17, 1992
	3MG	N020055	002	Apr 17, 1992
	6MG	N020055	003	Mar 08, 2000
STRIDES PHARMA	1.5MG	A074591	001	Dec 22, 1997
	3MG	A074591	002	Dec 22, 1997
	4.5MG	A074591	003	Dec 22, 1997
	6MG	A074591	004	Dec 22, 1997
GLYNASE				
+ PFIZER	4.5MG **	N020051	003	Sep 24, 1993
MICRONASE				
+ PFIZER	1.25MG **	N017498	001	May 01, 1984
	2.5MG	N017498	002	May 01, 1984
+	5MG **	N017498	003	May 01, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL					
GLUCOVANCE					
+	BRISTOL MYERS SQUIBB	1.25MG;250MG **	N021178	001	Jul 31, 2000
+		2.5MG;500MG **	N021178	002	Jul 31, 2000
+		5MG;500MG **	N021178	003	Jul 31, 2000
GLYBURIDE AND METFORMIN HYDROCHLORIDE					
	HERITAGE PHARMS	1.25MG;250MG	A079009	001	Jun 03, 2009
		2.5MG;500MG	A079009	002	Jun 03, 2009
		5MG;500MG	A079009	003	Jun 03, 2009
	IMPAX LABS INC	1.25MG;250MG	A076731	001	Nov 19, 2004
		2.5MG;500MG	A076731	002	Nov 19, 2004
		5MG;500MG	A076731	003	Nov 19, 2004
	TEVA	1.25MG;250MG	A076821	001	Jan 27, 2005
		2.5MG;500MG	A076821	002	Jan 27, 2005
		5MG;500MG	A076821	003	Jan 27, 2005

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL					
GLYCEROL PHENYLBUTYRATE					
	PAR PHARM INC	1.1GM/ML	A205742	001	Dec 02, 2021

GLYCINE

SOLUTION;IRRIGATION					
GLYCINE 1.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	1.5GM/100ML	N018522	001	Feb 19, 1982
	HOSPIRA	1.5GM/100ML	N017633	001	

GLYCOPYRROLATE

INJECTABLE;INJECTION					
GLYCOPYRROLATE					
	ABRAXIS PHARM	0.2MG/ML	A088475	001	Jun 12, 1984
	EUGIA PHARMA	0.2MG/ML	A210244	001	Nov 28, 2018
	HOSPIRA	0.2MG/ML	A089393	001	Jun 15, 1988
	LUPIN LTD	0.2MG/ML	A213655	001	Feb 07, 2023
	MANKIND PHARMA	0.2MG/ML	A217354	001	Feb 27, 2023
	TEVA PARENTERAL	0.2MG/ML	A081169	001	Sep 10, 1991
	WATSON LABS	0.2MG/ML	A086947	001	Jun 24, 1983
	ZYDUS PHARMS	0.2MG/ML	A214213	001	Nov 09, 2021
ROBINUL					
+	HIKMA	0.2MG/ML **	N017558	001	
	ROBINS AH	0.2MG/ML	N014764	001	
POWDER;INHALATION					
SEEBRI					
+	NOVARTIS	15.6MCG/INH	N207923	001	Oct 29, 2015
SOLUTION;INHALATION					
LONHALA MAGNAIR KIT					
+	SUMITOMO PHARMA AM	25MCG/ML	N208437	001	Dec 05, 2017
TABLET;ORAL					
GLYCOPYRROLATE					
	CHARTWELL RX	1MG	A040568	001	Dec 22, 2004
		2MG	A040568	002	Dec 22, 2004
	HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009
		2MG	A040836	002	Mar 05, 2009
	WATSON LABS	1MG	A085562	001	
		1MG	A086902	001	
		2MG	A085563	001	
		2MG	A086178	001	
		2MG	A086900	001	
TABLET, ORALLY DISINTEGRATING;ORAL					
DARTISLA ODT					
	EDENBRIDGE PHARMS	0.85MG	N215019	002	Oct 11, 2023
+		1.7MG	N215019	001	Dec 16, 2021

GLYCOPYRROLATE; INDACATEROL MALEATE

POWDER;INHALATION					
UTIBRON					
+	NOVARTIS	15.6MCG/INH;27.5MCG/INH	N207930	001	Oct 29, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GONADORELIN ACETATE

INJECTABLE;INJECTION				
LUTREPULSE KIT				
FERRING	0.8MG/VIAL	N019687	001	Oct 10, 1989
	3.2MG/VIAL	N019687	002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE;INJECTION				
FACTREL				
HIKMA	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC				
NEO-POLYCIN				
DOW PHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A060427	001	
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN				
IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062818	001	Oct 11, 1988
WATSON LABS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062788	001	Jun 11, 1987
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN				
PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062383	001	Aug 31, 1982

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION				
GRANISETRON HYDROCHLORIDE				
AKORN	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A079119	001	Sep 10, 2009
AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274	001	Sep 22, 2010
BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008
EUGIA PHARMA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016
MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454	001	Apr 04, 2017
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454	002	Apr 04, 2017
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017
SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008
TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963	001	Jan 03, 2008
WOCKHARDT USA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078566	001	Feb 29, 2008
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078564	001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078565	001	Jun 30, 2008
YUNG SHIN PHARM	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647	001	Mar 06, 2020
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A202648	001	Jun 29, 2020
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A202648	002	Jun 29, 2020
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE				
DR REDDYS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007
KYTRIL				
+ ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **	N020239	003	Sep 17, 2004
+	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N020239	004	Mar 11, 1994
+	EQ 3MG BASE/ML **	N020239	001	Dec 29, 1993
+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N020239	002	Mar 11, 1994
SOLUTION;ORAL				
GRANISOL				
INTRA SANA LABS	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008
KYTRIL				
+ ROCHE	EQ 2MG BASE/10ML **	N021238	001	Jun 27, 2001
TABLET;ORAL				
GRANISETRON HYDROCHLORIDE				
AUROBINDO PHARMA USA	EQ 1MG BASE	A078725	001	Jan 30, 2008
BARR	EQ 1MG BASE	A078221	001	Dec 31, 2007
EPIC PHARMA LLC	EQ 1MG BASE	A078260	001	Dec 31, 2007
HIKMA	EQ 1MG BASE	A077842	001	Dec 31, 2007
TEVA PHARMS	EQ 1MG BASE	A078080	001	Dec 31, 2007
KYTRIL				
+ ROCHE	EQ 1MG BASE **	N020305	001	Mar 16, 1995
+	EQ 2MG BASE **	N020305	002	Jun 15, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GREPAFLOXACIN HYDROCHLORIDE

TABLET;ORAL				
RAXAR				
OTSUKA	EQ 200MG BASE	N020695	001	Nov 06, 1997
	EQ 400MG BASE	N020695	002	May 14, 1998
	EQ 600MG BASE	N020695	003	May 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE;ORAL				
GRISACTIN				
WYETH AYERST	125MG	N050051	002	
	250MG	N050051	001	
SUSPENSION;ORAL				
GRIFULVIN V				
+ JOHNSON AND JOHNSON	125MG/5ML **	N050448	001	
TABLET;ORAL				
GRIFULVIN V				
J AND J	125MG	A060618	001	
	250MG	A060618	002	
	500MG	A060618	003	
VALEANT LUXEMBOURG	125MG	A062279	001	
	250MG **	A062279	002	
GRISACTIN				
WYETH AYERST	500MG	A060212	001	

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL				
GRIFULVIN V				
VALEANT LUXEMBOURG	125MG/5ML **	A062483	001	Jan 26, 1984
TABLET;ORAL				
GRIFULVIN V				
VALEANT LUXEMBOURG	500MG	A062279	003	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL				
GRISACTIN ULTRA				
WYETH AYERST	125MG	A062178	001	
	165MG	A062438	001	Nov 17, 1983
	250MG	A062178	002	
	330MG	A062438	002	Nov 17, 1983
ULTRAGRIS-165				
PLIVA	165MG	A062645	001	Jun 30, 1992
ULTRAGRIS-330				
PLIVA	330MG	A062646	001	Jun 30, 1992

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL				
FLOWTUSS				
CHARTWELL RX	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015
OBREDON				
+ SOVEREIGN PHARMS	200MG/5ML;2.5MG/5ML	N205474	001	Nov 14, 2014
TABLET;ORAL				
XTRELUS				
+ ECI PHARMS LLC	400MG;5MG	N208085	001	Apr 25, 2018

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL				
HYCOFENIX				
+ CHARTWELL RX	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE				
GRANULES	600MG;60MG	A216082	001	Aug 22, 2022
	1.2GM;120MG	A216082	002	Aug 22, 2022

GUANABENZ ACETATE

TABLET;ORAL				
GUANABENZ ACETATE				
ANI PHARMS	EQ 4MG BASE	A074149	001	Apr 07, 1995
	EQ 4MG BASE	A074267	001	Jun 01, 1994
	EQ 8MG BASE	A074149	002	Apr 07, 1995
	EQ 8MG BASE	A074267	002	Jun 01, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GUANABENZ ACETATE

TABLET;ORAL				
GUANABENZ ACETATE				
CHARTWELL RX	EQ 4MG BASE	A074517	001	Sep 30, 1998
	EQ 8MG BASE	A074517	002	Sep 30, 1998
WATSON LABS	EQ 4MG BASE	A074025	001	Feb 28, 1994
	EQ 8MG BASE	A074025	002	Feb 28, 1994
WYTENSIN				
WYETH AYERST	EQ 4MG BASE	N018587	001	Sep 07, 1982
	EQ 8MG BASE	N018587	002	Sep 07, 1982
	EQ 16MG BASE	N018587	003	Sep 07, 1982

GUANADREL SULFATE

TABLET;ORAL				
HYLOREL				
PHARMACIA AND UPJOHN	10MG	N018104	001	Dec 29, 1982
	25MG	N018104	002	Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET;ORAL				
GUANETHIDINE MONOSULFATE				
WATSON LABS	EQ 10MG SULFATE	A086113	001	Mar 26, 1985
	EQ 25MG SULFATE	A086114	001	Mar 26, 1985
ISMELIN				
NOVARTIS	EQ 10MG SULFATE	N012329	001	
	EQ 25MG SULFATE	N012329	002	

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
ESIMIL				
NOVARTIS	10MG;25MG	N013553	001	

GUANFACINE HYDROCHLORIDE

TABLET;ORAL				
GUANFACINE HYDROCHLORIDE				
WATSON LABS	EQ 1MG BASE	A074762	001	Jun 25, 1997
	EQ 2MG BASE	A074762	002	Jun 25, 1997
TENEX				
+ PROMIUS PHARMA	EQ 1MG BASE **	N019032	001	Oct 27, 1986
+	EQ 2MG BASE **	N019032	002	Nov 07, 1988
	EQ 3MG BASE **	N019032	003	Nov 07, 1988
TABLET, EXTENDED RELEASE;ORAL				
GUANFACINE HYDROCHLORIDE				
IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015
	EQ 2MG BASE	A202238	002	Oct 20, 2015
	EQ 3MG BASE	A202238	003	Oct 20, 2015
	EQ 4MG BASE	A202238	004	Oct 20, 2015
MYLAN	EQ 1MG BASE	A202578	001	Jun 02, 2015
	EQ 2MG BASE	A202578	002	Jun 02, 2015
	EQ 3MG BASE	A202578	003	Jun 02, 2015
	EQ 4MG BASE	A202578	004	Jun 02, 2015

GUANIDINE HYDROCHLORIDE

TABLET;ORAL				
GUANIDINE HYDROCHLORIDE				
MERCK SHARP DOHME	125MG	N001546	001	

HALAZEPAM

TABLET;ORAL				
PAXIPAM				
SCHERING	20MG	N017736	003	
	40MG	N017736	004	

HALCINONIDE

CREAM;TOPICAL				
HALOG				
WESTWOOD SQUIBB	0.025%	N017818	001	
HALOG-E				
SUN PHARM INDS INC	0.1%	N018234	001	
OINTMENT;TOPICAL				
HALOG				
BRISTOL MYERS SQUIBB	0.025%	N018125	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HALOBETASOL PROPIONATE					
CREAM;TOPICAL					
ULTRAVATE					
+	SUN PHARM INDS INC	0.05% **	N019967	001	Dec 27, 1990
LOTION;TOPICAL					
HALOBETASOL PROPIONATE					
	PADAGIS ISRAEL	0.05%	A211464	001	Jun 03, 2020
OINTMENT;TOPICAL					
HALOBETASOL PROPIONATE					
	COSETTE	0.05%	A077721	001	Sep 07, 2006
	FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004
	VERTICE	0.05%	A209978	001	Mar 20, 2018
ULTRAVATE					
+	SUN PHARM INDS INC	0.05% **	N019968	001	Dec 17, 1990
HALOFANTRINE HYDROCHLORIDE					
TABLET;ORAL					
HALFAN					
	GLAXOSMITHKLINE	250MG	N020250	001	Jul 24, 1992
HALOPERIDOL					
TABLET;ORAL					
HALDOL					
+	ORTHO MCNEIL	0.5MG **	N015921	001	
+		1MG **	N015921	002	
+		2MG **	N015921	003	
+		5MG **	N015921	004	
+		10MG **	N015921	005	
+		20MG **	N015921	006	Feb 02, 1982
HALDOL SOLUTAB					
	ORTHO MCNEIL PHARM	1MG	N017079	001	
HALOPERIDOL					
	ACTAVIS GROUP	0.5MG	A200854	001	Jul 01, 2022
		1MG	A200854	002	Jul 01, 2022
		2MG	A200854	003	Jul 01, 2022
		5MG	A200854	004	Jul 01, 2022
		10MG	A200854	005	Jul 01, 2022
		20MG	A200854	006	Jul 01, 2022
	AIPING PHARM INC	0.5MG	A071128	001	Feb 17, 1987
		1MG	A071129	001	Feb 17, 1987
		20MG	A071133	001	May 12, 1987
	DURAMED PHARMS BARR	0.5MG	A071216	001	Dec 04, 1986
		1MG	A071217	001	Dec 04, 1986
		2MG	A071218	001	Dec 04, 1986
		5MG	A071219	001	Dec 04, 1986
		10MG	A071220	001	Jul 07, 1987
		20MG	A071221	001	Jul 07, 1987
	LEDERLE	0.5MG	A072727	001	Sep 19, 1989
		1MG	A072728	001	Sep 19, 1989
		2MG	A072729	001	Sep 19, 1989
		5MG	A072730	001	Sep 19, 1989
		10MG	A072731	001	Sep 19, 1989
		20MG	A072732	001	Sep 19, 1989
	PAR PHARM	20MG	A071328	001	Jul 20, 1987
	PUREPAC PHARM	0.5MG	A071071	001	Nov 03, 1986
		1MG	A071072	001	Nov 03, 1986
		2MG	A071073	001	Nov 03, 1986
		5MG	A071074	001	Nov 03, 1986
		10MG	A071075	001	Aug 04, 1987
		20MG	A071076	001	Aug 04, 1987
	QUANTUM PHARMICS	0.5MG	A071255	001	Feb 17, 1987
		1MG	A071269	001	Feb 17, 1987
		2MG	A071256	001	Feb 17, 1987
		5MG	A071257	001	Feb 17, 1987
	ROYCE LABS	0.5MG	A071722	001	Dec 24, 1987
		1MG	A071723	001	Dec 24, 1987
		2MG	A071724	001	Dec 24, 1987
		5MG	A071725	001	Dec 24, 1987
		10MG	A072121	001	Dec 24, 1987
		20MG	A072122	001	Dec 24, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

SANDOZ	2MG	A071209	004	Nov 17, 1986
SCS	0.5MG	A070720	001	Jun 10, 1986
	1MG	A070721	001	Jun 10, 1986
	2MG	A070722	001	Jun 10, 1986
	5MG	A070723	001	Jun 10, 1986
	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
STRIDES PHARMA	0.5MG	A071235	002	Nov 03, 1986
	1MG	A071235	003	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071235	004	Nov 03, 1986
	10MG	A071235	005	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALDOL

+ ORTHO MCNEIL	EQ 2MG BASE/ML **	N015922	001	

HALOPERIDOL

ALPHARMA	EQ 2MG BASE/ML	A070318	001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710	001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726	001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015	001	Aug 25, 1987
TEVA PHARMS	EQ 2MG BASE/ML	A071617	001	Dec 01, 1988

HALOPERIDOL INTENSOL

HIKMA	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988

INJECTABLE;INJECTION

HALDOL

+ JANSSEN PHARMS	EQ 5MG BASE/ML **	N015923	001	

HALOPERIDOL

ABRAXIS PHARM	EQ 5MG BASE/ML	A071187	001	Jan 20, 1987
BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004
	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004
EPIC PHARMA LLC	EQ 5MG BASE/ML	A204849	001	Sep 06, 2017
FOSUN PHARMA	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516	001	Feb 25, 1993
	EQ 5MG BASE/ML	A072517	001	Feb 25, 1993
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802	001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML	A070800	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070801	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070864	001	Dec 14, 1987
TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001
WATSON LABS	EQ 5MG BASE/ML	A070713	001	May 17, 1988
	EQ 5MG BASE/ML	A070714	001	May 17, 1988
	EQ 5MG BASE/ML	A070744	001	May 17, 1988

SOLUTION;ORAL

HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML	A074536	001	Nov 02, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HALOPROGIN

CREAM;TOPICAL				
HALOTEX				
	WESTWOOD SQUIBB	1%	N016942 001	
SOLUTION;TOPICAL				
HALOTEX				
	WESTWOOD SQUIBB	1%	N016943 001	

HALOTHANE

LIQUID;INHALATION				
FLUOTHANE				
	WYETH AYERST	99.99%	N011338 001	
HALOTHANE				
	BH	99.99%	A084977 001	
	HALOCARBON	99.99%	A080810 001	
	HOSPIRA	99.99%	A083254 001	

HEPARIN CALCIUM

INJECTABLE;INJECTION				
CALCIPARINE				
	SANOFI AVENTIS US	25,000 UNITS/ML	N018237 001	

HEPARIN SODIUM

INJECTABLE;INJECTION				
HEPARIN LOCK FLUSH				
	HOSPIRA	100 UNITS/ML	N005264 010	
	INTL MEDICATION	10 UNITS/ML	A086357 001	
		500 UNITS/ML	A086357 002	
	LUITPOLD	10 UNITS/ML	A089063 001	Oct 09, 1985
		100 UNITS/ML	A089064 001	Oct 09, 1985
	PARKE DAVIS	10 UNITS/ML	N017346 006	
	SMITH AND NEPHEW	10 UNITS/ML	A087904 001	Apr 20, 1983
		10 UNITS/ML	A087958 001	Apr 20, 1983
		10 UNITS/ML	A088458 001	Jul 26, 1984
		10 UNITS/ML	A088580 001	Oct 25, 1984
		100 UNITS/ML	A087906 001	Apr 20, 1983
		100 UNITS/ML	A087959 001	Apr 20, 1983
		100 UNITS/ML	A088460 001	Jul 26, 1984
		100 UNITS/ML	A088581 001	Oct 25, 1984
	SOLOPAK	10 UNITS/ML	A087903 001	Apr 20, 1983
		10 UNITS/ML	A088457 001	Oct 25, 1984
		100 UNITS/ML	A087905 001	Apr 20, 1983
		100 UNITS/ML	A088459 001	Jul 26, 1984
HEPARIN SODIUM				
	ABRAXIS PHARM	1,000 UNITS/ML	N017033 001	
		1,000 UNITS/ML	N017979 001	
		5,000 UNITS/ML	N017979 003	
		10,000 UNITS/ML	N017979 002	
	CASI PHARMS INC	5,000 UNITS/ML	A091659 001	Jun 08, 2011
	CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130 001	
		5,000 UNITS/ML	N017130 002	
		10,000 UNITS/ML	N017130 003	
		20,000 UNITS/ML	N017130 004	
	DELL LABS	1,000 UNITS/ML	N017540 001	
		5,000 UNITS/ML	N017540 002	
		10,000 UNITS/ML	N017540 003	
		20,000 UNITS/ML	N017540 004	
		40,000 UNITS/ML	N017540 005	
	DR REDDYS	1,000 UNITS/ML	A040007 001	Jun 07, 1996
		1,000 UNITS/ML	N017064 002	
		2,500 UNITS/ML	N017064 015	
		3,000 UNITS/ML	N017064 016	
		4,000 UNITS/ML	N017064 017	
		5,000 UNITS/ML	N017064 003	
		6,000 UNITS/ML	N017064 018	
		7,500 UNITS/ML	N017064 019	
		10,000 UNITS/ML	N017064 004	
		20,000 UNITS/ML	N017064 005	
		40,000 UNITS/ML	N017064 006	
	EPIC PHARMA LLC	1,000 UNITS/ML	N017486 001	
		5,000 UNITS/ML	N017486 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM					
		10,000 UNITS/ML	N017486	003	
		20,000 UNITS/ML	N017486	004	
		40,000 UNITS/ML	N017486	005	
	FRESENIUS KABI USA	1,000 UNITS/ML	N017651	005	
		5,000 UNITS/ML	N017029	002	
		10,000 UNITS/ML	N017651	003	
		20,000 UNITS/ML	N017651	008	
+	HIKMA	1,000 UNITS/ML **	N017007	001	
+		2,500 UNITS/ML **	N017007	007	
+		5,000 UNITS/ML **	N017007	002	
+		5,000 UNITS/0.5ML **	N017007	010	
+		7,500 UNITS/ML **	N017007	003	
+		10,000 UNITS/ML **	N017007	004	
+		15,000 UNITS/ML **	N017007	005	
+		20,000 UNITS/ML **	N017007	006	
	HOSPIRA	2,500 UNITS/ML	A088099	001	Apr 28, 1983
		10,000 UNITS/ML	A040095	001	Jul 26, 1996
	LILLY	1,000 UNITS/ML	N005521	001	
		10,000 UNITS/ML	N005521	002	
		20,000 UNITS/ML	N005521	004	
	LUITPOLD	1,000 UNITS/ML	A087452	001	Oct 31, 1983
	ORGANON USA INC	1,000 UNITS/ML	N000552	008	
		5,000 UNITS/ML	N000552	009	
		10,000 UNITS/ML	N000552	010	
	PARKE DAVIS	1,000 UNITS/ML	N017346	001	
		5,000 UNITS/ML	N017346	002	
		7,500 UNITS/ML	N017346	003	
		10,000 UNITS/ML	N017346	004	
		20,000 UNITS/ML	N017346	005	
+	PFIZER	10,000 UNITS/ML	N201370	003	Jul 21, 2011
	PHARM SPEC	1,000 UNITS/ML	N017780	001	
		5,000 UNITS/ML	N017780	002	
		10,000 UNITS/ML	N017780	003	
		20,000 UNITS/ML	N017780	004	
		40,000 UNITS/ML	N017780	005	
	PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
		5,000 UNITS/ML	N004570	002	
		10,000 UNITS/ML	N004570	003	
	SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
	SOLOPAK	1,000 UNITS/ML	A087043	001	
		5,000 UNITS/ML	A087077	001	
		5,000 UNITS/0.5ML	A087395	001	
		10,000 UNITS/ML	A087107	001	
		10,000 UNITS/0.5ML	A087363	001	
	WATSON LABS INC	1,000 UNITS/ML	A040008	001	Oct 10, 1995
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
	MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%					
	HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%					
	HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
		10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%					
	HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
		10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%					
	HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%					
	HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
		5,000 UNITS/100ML	N018916	003	Jan 31, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
HOSPIRA	4,000 UNITS/100ML	N019805	001	Jan 25, 1989
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985
	10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
	10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HOSPIRA	5,000 UNITS/100ML	N019805	002	Jan 25, 1989
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
	10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
	5,000 UNITS/100ML	N019802	003	Jul 20, 1992
HOSPIRA	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
	100 UNITS/ML	N018916	004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	1,000 UNITS/100ML	N019042	004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE				
DR REDDYS	1,000 UNITS/ML	A089464	001	Jun 03, 1986
HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	2,500 UNITS/ML	N005264	014	Apr 07, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	
LIPO-HEPIN				
3M	1,000 UNITS/0.5ML	N017027	001	
	1,000 UNITS/ML	N017027	006	
	5,000 UNITS/0.5ML	N017027	002	
	5,000 UNITS/ML	N017027	008	
	7,500 UNITS/0.5ML	N017027	010	
	10,000 UNITS/0.5ML	N017027	003	
	10,000 UNITS/ML	N017027	009	
	15,000 UNITS/0.5ML	N017027	011	
	20,000 UNITS/0.5ML	N017027	004	
	20,000 UNITS/ML	N017027	007	
	40,000 UNITS/ML	N017027	005	
LIQUAEMIN LOCK FLUSH				
ORGANON USA INC	100 UNITS/ML	N000552	007	
LIQUAEMIN SODIUM				
ORGANON USA INC	1,000 UNITS/ML	N000552	004	
	5,000 UNITS/ML	N000552	003	
	10,000 UNITS/ML	N000552	005	
	20,000 UNITS/ML	N000552	001	
	40,000 UNITS/ML	N000552	002	
LIQUAEMIN SODIUM PRESERVATIVE FREE				
ORGANON USA INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986
	5,000 UNITS/ML	N000552	012	Apr 11, 1986
	10,000 UNITS/ML	N000552	013	Apr 11, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HEPARIN SODIUM				
INJECTABLE;INJECTION				
PANHEPRIN				
	HOSPIRA	1,000 UNITS/ML	N005264 004	
		5,000 UNITS/ML	N005264 006	
		10,000 UNITS/ML	N005264 007	
		20,000 UNITS/ML	N005264 008	
		40,000 UNITS/ML	N005264 009	
SODIUM HEPARIN				
	ABRAXIS PHARM	5,000 UNITS/ML	N017033 002	
		10,000 UNITS/ML	N017033 003	
		20,000 UNITS/ML	N017033 004	
	BAXTER HLTHCARE	1,000 UNITS/ML	N017036 001	Mar 04, 1988
HETACILLIN				
FOR SUSPENSION;ORAL				
VERSAPEN				
	BRISTOL	EQ 112.5MG AMPICIL/ML	A061398 001	
		EQ 112.5MG AMPICIL/5ML	N050060 001	
		EQ 112.5MG AMPICIL/ML	N050060 003	
		EQ 225MG AMPICIL/5ML	A061398 002	
HETACILLIN POTASSIUM				
CAPSULE;ORAL				
VERSAPEN-K				
	BRISTOL	EQ 225MG AMPICIL	A061396 001	
		EQ 450MG AMPICIL	A061396 002	
HEXACHLOROPHENE				
AEROSOL;TOPICAL				
SEPTISOL				
	VESTAL LABS	0.23%	N017424 001	
TURGEX				
	XTTRIUM	3%	N018375 001	
EMULSION;TOPICAL				
HEXA-GERM				
	HUNTINGTON LABS	3%	N017411 001	
PHISOHEX				
	SANOFI AVENTIS US	3%	N006882 001	
		3%	N008402 001	
SOY-DOME				
	BAYER PHARMS	3%	N017405 001	
TURGEX				
	XTTRIUM	3%	N019055 001	Nov 30, 1984
SOAP;TOPICAL				
GAMOPHEN				
	ARBROOK	2%	N006270 003	
SOLUTION;TOPICAL				
DIAL				
	DIAL	0.25%	N017421 002	
GERMA-MEDICA				
	HUNTINGTON LABS	1%	N017412 001	
GERMA-MEDICA "MG"				
	HUNTINGTON LABS	0.25%	N017412 002	
SEPTI-SOFT				
	CALGON	0.25%	N017460 001	
SEPTISOL				
	VESTAL LABS	0.25%	N017423 001	
SPONGE;TOPICAL				
E-Z SCRUB				
	BECTON DICKINSON	450MG	N017452 001	
HEXASCRUB				
	PROF DSPLS	3%	N018363 001	
PHISO-SCRUB				
	SANOFI AVENTIS US	3%	N017446 001	
SCRUBTEAM SURGICAL SPONGEBRUSH				
	3M	330MG	N017413 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HEXAFLUORENIUM BROMIDE

INJECTABLE;INJECTION				
MYLAXEN				
	MEDPOINTE PHARM HLC	20MG/ML	N009789 003	

HEXOCYCLIUM METHYLSULFATE

TABLET;ORAL				
TRAL				
	ABBVIE	25MG	N010599 001	

HEXYLCAINE HYDROCHLORIDE

SOLUTION;TOPICAL				
CYCLAINE				
	MERCK	5%	N008472 001	

HISTAMINE PHOSPHATE

INJECTABLE;INJECTION				
HISTAMINE PHOSPHATE				
	LILLY	EQ 0.1MG BASE/ML	N000734 003	
		EQ 0.2MG BASE/ML	N000734 002	
		EQ 1MG BASE/ML	N000734 001	

HISTRELIN ACETATE

IMPLANT;SUBCUTANEOUS				
VANTAS				
+	ENDO PHARM	50MG	N021732 001	Oct 12, 2004
INJECTABLE;INJECTION				
SUPPRELIN				
	SHIRE	EQ 0.2MG BASE/ML	N019836 001	Dec 24, 1991
		EQ 0.5MG BASE/ML	N019836 002	Dec 24, 1991
		EQ 1MG BASE/ML	N019836 003	Dec 24, 1991

HOMATROPINE METHYLBROMIDE

TABLET;ORAL				
HOMAPIN-10				
	MISSION PHARMA	10MG	A086308 001	
HOMAPIN-5				
	MISSION PHARMA	5MG	A086309 001	
TABLET, CHEWABLE;ORAL				
EQUIPIN				
	MISSION PHARMA	3MG	A086310 001	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL				
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE				
	APOZEAL PHARMS	1.5MG/5ML;5MG/5ML	A204765 001	Mar 06, 2017
	IVAX SUB TEVA PHARMS	1.5MG/5ML;5MG/5ML	A040285 001	Jul 19, 1999
	NOSTRUM LABS INC	1.5MG/5ML;5MG/5ML	A210663 001	Jun 11, 2019
HYDROPANE				
	HALSEY	1.5MG/5ML;5MG/5ML	A088066 001	Jun 28, 1985
TABLET;ORAL				
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE				
	ACTAVIS ELIZABETH	1.5MG;5MG	A040295 001	Dec 01, 2000
	NOVEL LABS INC	1.5MG;5MG	A091528 001	Apr 20, 2011
TUSSIGON				
	KING PHARMS	1.5MG;5MG	A088508 001	Jul 30, 1985

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION				
APRESOLINE				
+	NOVARTIS	20MG/ML **	N008303 003	
HYDRALAZINE HYDROCHLORIDE				
	ABRAXIS PHARM	20MG/ML	A089532 001	Aug 11, 1987
	MYLAN INSTITUTIONAL	20MG/ML	A204680 001	Apr 28, 2016
	SMITH AND NEPHEW	20MG/ML	A088518 001	Apr 20, 1984
	SOLOPAK	20MG/ML	A088517 001	Aug 22, 1985
	TEVA PARENTERAL	20MG/ML	A040373 001	Feb 23, 2000
TABLET;ORAL				
APRESOLINE				
+	NOVARTIS	10MG **	N008303 004	
+		25MG **	N008303 001	
+		50MG **	N008303 002	
+		100MG **	N008303 005	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

DRALZINE				
TEVA	25MG	A084301	001	
HYDRALAZINE HYDROCHLORIDE				
ACTAVIS ELIZABETH	25MG	A088560	001	Oct 04, 1984
	50MG	A088649	001	Oct 18, 1984
ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013
	25MG	A091679	002	Mar 04, 2013
	50MG	A091679	003	Mar 04, 2013
	100MG	A091679	004	Mar 04, 2013
ANDA REPOSITORY	10MG	A089359	001	Jul 25, 1986
	25MG	A089258	001	May 05, 1986
	50MG	A089259	001	May 05, 1986
	100MG	A088729	001	Apr 11, 1985
ASCOT	25MG	A088310	001	Dec 19, 1984
	50MG	A088311	001	Dec 19, 1984
CHARTWELL RX	10MG	A088846	001	Feb 26, 1985
	25MG	A088847	001	Feb 26, 1985
	50MG	A088848	001	Feb 26, 1985
	100MG	A088849	001	Feb 26, 1985
HALSEY	10MG	A089218	001	Jan 22, 1986
	25MG	A089130	001	Jan 15, 1986
	50MG	A089222	001	Jan 22, 1986
	100MG	A089178	001	Jan 15, 1986
IMPAX LABS	25MG	A084922	001	
	50MG	A084923	001	
IVAX SUB TEVA PHARMS	10MG	A084443	001	
	25MG	A084437	001	
	50MG	A084469	002	
	100MG	A084581	001	
MUTUAL PHARM	10MG	A088728	001	Apr 11, 1985
	25MG	A084106	002	
	50MG	A084107	002	
MYLAN	10MG	A090413	001	Dec 08, 2010
	25MG	A090413	002	Dec 08, 2010
	50MG	A090413	003	Dec 08, 2010
	100MG	A090413	004	Dec 08, 2010
PUREPAC PHARM	25MG	A088177	001	Jul 29, 1983
	50MG	A088178	001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671	001	May 01, 1984
	25MG	A088657	001	Jun 15, 1984
	50MG	A088652	001	May 08, 1984
	100MG	A088686	001	May 01, 1984
RISING	10MG	A209251	001	Jul 09, 2018
	25MG	A209251	002	Jul 09, 2018
	50MG	A209251	003	Jul 09, 2018
	100MG	A209251	004	Jul 09, 2018
STRIDES PHARMA	10MG	A200770	004	Jun 25, 2019
SUPERPHARM	10MG	A088787	001	Aug 28, 1984
	25MG	A088788	001	Aug 28, 1984
	50MG	A088789	001	Aug 28, 1984
UPSHER SMITH LABS	10MG	A083241	001	
	25MG	A083560	001	
	50MG	A083561	001	
	50MG	A085088	001	
USL PHARMA	25MG	A087780	001	Mar 29, 1982
	50MG	A087751	001	Mar 29, 1982
VANGARD	25MG	A087712	001	
	50MG	A087908	001	May 07, 1982
VITARINE	25MG	A086088	001	
WATSON LABS	25MG	A084504	001	
	25MG	A085532	002	May 24, 1982
	50MG	A084503	001	
	50MG	A085533	002	May 25, 1982
WEST WARD	25MG	A088240	001	May 27, 1983
	50MG	A088241	001	May 27, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL				
APRESAZIDE				
+ NOVARTIS	25MG;25MG	A084735	001	
+	50MG;50MG	A084810	001	
	100MG;50MG	A084811	001	
HYDRA-ZIDE				
STRIDES PHARMA	100MG;50MG	A088961	001	Oct 21, 1985
HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
SOLVAY	25MG;25MG	A087608	001	Feb 08, 1982
	50MG;50MG	A087213	001	Feb 08, 1982
	100MG;50MG	A087609	001	Feb 08, 1982
SUPERPHARM	25MG;25MG	A089200	001	Feb 09, 1987
	50MG;50MG	A089201	001	Feb 09, 1987
WATSON LABS	25MG;25MG	A085457	001	Mar 04, 1982
	50MG;50MG	A085446	001	Mar 04, 1982
	100MG;50MG	A085440	001	Mar 04, 1982
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50				
IVAX PHARMS	100MG;50MG	A088358	001	Apr 10, 1984
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25				
IVAX PHARMS	25MG;25MG	A088356	001	Apr 10, 1984
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50				
IVAX PHARMS	50MG;50MG	A088357	001	Apr 10, 1984
TABLET;ORAL				
APRESOLINE-ESIDRIX				
NOVARTIS	25MG;15MG	N012026	002	
HYDRALAZINE AND HYDROCHLOROTHIAZIDE				
WATSON LABS	25MG;15MG	A085827	001	
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE				
WATSON LABS	25MG;15MG	A085373	001	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL				
CAM-AP-ES				
CHARTWELL RX	25MG;15MG;0.1MG	A084897	001	
HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE				
IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A084291	001	
HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE				
MYLAN	25MG;15MG;0.1MG	A087085	001	
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE				
WATSON LABS	25MG;15MG;0.1MG	A085771	001	
HYDRAP-ES				
SANDOZ	25MG;15MG;0.1MG	A084876	001	
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE				
WATSON LABS	25MG;15MG;0.1MG	A083770	001	
HYDROSERPINE PLUS (R-H-H)				
IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A083877	001	
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
SOLVAY	25MG;15MG;0.1MG	A088376	001	Oct 28, 1983
SUN PHARM INDUSTRIES	25MG;15MG;0.1MG	A088570	001	Apr 10, 1984
WATSON LABS	25MG;15MG;0.1MG	A085549	001	
	25MG;15MG;0.1MG	A087556	001	
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE				
LEDERLE	25MG;15MG;0.1MG	A087709	001	May 13, 1982
SER-A-GEN				
SOLVAY	25MG;15MG;0.1MG	A087210	001	
SER-AP-ES				
NOVARTIS	25MG;15MG;0.1MG	N012193	005	
UNIPRES				
SOLVAY	25MG;15MG;0.1MG	A085893	001	
	25MG;15MG;0.1MG	A086298	001	

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET;ORAL				
DRALSERP				
SANDOZ	25MG;0.1MG	A084617	001	
SERPASIL-APRESOLINE				
NOVARTIS	25MG;0.1MG	N009296	004	
	50MG;0.2MG	N009296	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL					
HYDROCHLOROTHIAZIDE					
	ALEMBIC PHARMS LTD	12.5MG	A200645	001	Nov 30, 2010
	APOTEX	12.5MG	A078389	001	May 16, 2008
	CHARTWELL MOLECULAR	12.5MG	A091662	001	Jan 27, 2012
	HIKMA INTL PHARMS	12.5MG	A077885	001	Nov 26, 2007
	IVAX SUB TEVA PHARMS	12.5MG	A077005	001	Jul 13, 2005
	MYLAN	12.5MG	A075640	001	Jan 28, 2000
	SUN PHARM INDS INC	12.5MG	A090651	001	Apr 07, 2014
SOLUTION;ORAL					
HYDROCHLOROTHIAZIDE					
	MORTON GROVE	50MG/5ML	A089661	001	Jun 20, 1988
+	ROXANE	50MG/5ML **	A088587	001	Jul 02, 1984
HYDROCHLOROTHIAZIDE INTENSOL					
	ROXANE	100MG/ML	A088588	001	Jul 02, 1984
TABLET;ORAL					
ESIDRIX					
	NOVARTIS	25MG	N011793	005	
		50MG	N011793	008	
		100MG	N011793	009	
HYDRO-D					
	HALSEY	25MG	A086504	001	
		50MG	A083891	002	
HYDROCHLOROTHIAZIDE					
	ABC HOLDING	50MG	A085672	001	
	ACTAVIS ELIZABETH	25MG	A085054	002	
		50MG	A085208	001	
	ALRA	25MG	A086369	001	
		50MG	A083554	001	
	APOTEX	25MG	A040774	001	Oct 03, 2007
		50MG	A040774	002	Oct 03, 2007
	ASCOT	25MG	A087539	001	Feb 03, 1982
		50MG	A087540	001	Feb 03, 1982
	AUROLIFE PHARMA LLC	25MG	A083899	001	
		50MG	A085219	001	
	BARR	50MG	A084771	001	
	CHARTWELL RX	25MG	A085683	001	
		25MG	A087565	001	Mar 09, 1982
		50MG	A083965	001	
		50MG	A084912	001	
	DAVA PHARMS INC	100MG	A087060	001	
	ELKINS SINN	50MG	A085152	002	
	HEATHER	50MG	A084135	001	
	HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006
		50MG	A084878	001	
	IMPAX LABS	25MG	A084029	001	
		50MG	A083607	002	
		100MG	A085098	001	
	INWOOD LABS	25MG	A084776	001	
		25MG	A085067	001	
		50MG	A084776	002	
	IVAX SUB TEVA PHARMS	50MG	A084658	001	
+		100MG	A085022	001	
	JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007
		50MG	A040809	002	Sep 04, 2007
	LANNETT CO INC	25MG	A084325	001	
		50MG	A084324	001	
	MAST MM	25MG	A086192	001	
		50MG	A086192	002	
	MYLAN	25MG	A084880	001	
		50MG	A085112	001	
	MYLAN PHARMS INC	12.5MG	A040770	001	Jan 23, 2007
		25MG	A040735	002	Jan 23, 2007
		50MG	A040735	003	Jan 23, 2007
	PVT FORM	50MG	A086597	001	
	ROXANE	25MG	A085004	001	
		50MG	A084536	002	
		50MG	A085005	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE				
	SOLVAY	25MG	A085323 001	
	SUN PHARM INDS INC	12.5MG	A040857 001	May 30, 2008
		25MG	A040810 001	Mar 27, 2007
		50MG	A040810 002	Mar 27, 2007
	SUN PHARM INDUSTRIES	25MG	A083972 001	
		50MG	A083972 002	
		100MG	A083972 003	
	SUPERPHARM	25MG	A088827 001	Dec 28, 1984
		50MG	A088828 001	Dec 28, 1984
		100MG	A088829 001	Dec 28, 1984
	TEVA	25MG	A088924 001	Feb 07, 1985
		50MG	A088923 001	Feb 07, 1985
	USL PHARMA	25MG	A087827 001	Apr 19, 1982
		50MG	A087752 001	Apr 19, 1982
	VANGARD	25MG	A087638 001	
		50MG	A087610 001	
	WARNER CHILCOTT	25MG	A087586 001	May 03, 1982
		50MG	A087587 001	May 03, 1982
	WATSON LABS	25MG	A081189 001	Jan 24, 1992
		25MG	A083458 001	
		25MG	A085232 002	
		50MG	A083456 001	
		50MG	A085233 001	
		50MG	A086087 001	
		50MG	A086594 001	
		100MG	A081190 001	Jan 24, 1992
		100MG	A085099 001	
		100MG	A087002 001	
	WATSON LABS TEVA	50MG	A083232 001	
	WEST WARD	25MG	A084899 001	
	WHITEWORTH TOWN PLSN	25MG	A083809 002	
		50MG	A083809 001	
		100MG	A085347 001	
HYDRODIURIL				
+	MERCK	25MG **	N011835 003	
+		50MG **	N011835 006	
+		100MG **	N011835 007	
ORETIC				
	ABBVIE	25MG	N011971 001	
		50MG	N011971 002	
ZIDE				
	SOLVAY	50MG	A083925 001	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

AVALIDE				
+	SANOFI AVENTIS US	12.5MG;75MG **	N020758 001	Sep 30, 1997
+		25MG;300MG **	N020758 004	Mar 15, 2005
IRBESARTAN AND HYDROCHLOROTHIAZIDE				
	APOTEX INC	12.5MG;150MG	A201505 001	Oct 15, 2012
		12.5MG;300MG	A201505 002	Oct 15, 2012
	ATLAS PHARMS LLC	12.5MG;150MG	A203036 001	Jan 15, 2016
		12.5MG;300MG	A203036 002	Jan 15, 2016
		25MG;300MG	A203036 003	Jan 15, 2016
	MYLAN PHARMS INC	12.5MG;150MG	A077969 001	Sep 27, 2012
		12.5MG;300MG	A077969 002	Sep 27, 2012
		25MG;300MG	A077969 003	Jul 20, 2016
	TEVA	25MG;300MG	A077369 003	Mar 30, 2012
	UNICHEM	12.5MG;150MG	A207018 001	Sep 19, 2017
		12.5MG;300MG	A207018 002	Sep 19, 2017
	WATSON LABS INC	12.5MG;150MG	A091539 001	Oct 22, 2012
		12.5MG;300MG	A091539 002	Oct 22, 2012

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET;ORAL

NORMOZIDE

SCHERING	25MG;100MG	N019046	001	Apr 06, 1987
	25MG;200MG	N019046	002	Apr 06, 1987
	25MG;300MG	N019046	003	Apr 06, 1987
	25MG;400MG	N019046	004	Apr 06, 1987

TRANDATE HCT

GLAXOSMITHKLINE	25MG;100MG	N019174	001	Apr 10, 1987
	25MG;200MG	N019174	002	Apr 10, 1987
	25MG;300MG	N019174	003	Apr 10, 1987
	25MG;400MG	N019174	004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

CHARTWELL RX	12.5MG;10MG	A075776	001	Jul 01, 2002
	12.5MG;20MG	A075776	002	Jul 01, 2002
	25MG;20MG	A075776	003	Jul 01, 2002
COREPHARMA	12.5MG;10MG	A076674	001	Oct 05, 2004
	12.5MG;20MG	A076674	002	Oct 05, 2004
	25MG;20MG	A076674	003	Oct 05, 2004
EPIC PHARMA LLC	12.5MG;10MG	A075926	001	Jul 01, 2002
	12.5MG;20MG	A075926	002	Jul 01, 2002
	25MG;20MG	A075926	003	Jul 01, 2002
HIKMA INTL PHARMS	12.5MG;10MG	A076265	001	Jul 08, 2002
	12.5MG;20MG	A076265	002	Jul 08, 2002
	25MG;20MG	A076265	003	Jul 08, 2002
MYLAN	12.5MG;10MG	A076113	001	Jul 01, 2002
	12.5MG;20MG	A076113	002	Jul 01, 2002
	25MG;20MG	A076113	003	Jul 01, 2002
TEVA	12.5MG;10MG	A075869	001	Jul 01, 2002
	12.5MG;20MG	A075869	002	Jul 01, 2002
	25MG;20MG	A075869	003	Jul 01, 2002

PRINZIDE

+	MERCK	12.5MG;10MG **	N019778	003	Nov 18, 1993
+		12.5MG;20MG **	N019778	001	Feb 16, 1989
+		25MG;20MG **	N019778	002	Feb 16, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

APOTEX	12.5MG;50MG	A090150	001	Oct 06, 2010
	12.5MG;100MG	A090150	002	Aug 11, 2010
	25MG;100MG	A090150	003	Oct 06, 2010
HIKMA	12.5MG;50MG	A077732	002	Oct 06, 2010
	12.5MG;100MG	A077732	001	Apr 06, 2010
	25MG;100MG	A077732	003	Oct 06, 2010
MYLAN	12.5MG;50MG	A091652	001	Oct 06, 2010
	12.5MG;100MG	A091652	002	Apr 06, 2010
	25MG;100MG	A091652	003	Oct 06, 2010
TORRENT PHARMS	12.5MG;50MG	A090528	001	Oct 06, 2010
	12.5MG;100MG	A090528	003	Apr 06, 2010
	25MG;100MG	A090528	002	Oct 06, 2010
WATSON LABS	12.5MG;50MG	A200180	001	Jan 12, 2011
	12.5MG;100MG	A200180	002	Jan 12, 2011
	25MG;100MG	A200180	003	Jan 12, 2011

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

ALDORIL 15

MERCK	15MG;250MG	N013402	001	

ALDORIL 25

MERCK	25MG;250MG	N013402	002	

ALDORIL D30

MERCK	30MG;500MG	N013402	003	

ALDORIL D50

MERCK	50MG;500MG	N013402	004	

METHYLDOPA AND HYDROCHLOROTHIAZIDE

CHARTWELL RX	15MG;250MG	A070182	001	Jan 15, 1986
	25MG;250MG	A070183	001	Jan 15, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	30MG;500MG	A070543	001	Jan 15, 1986
	50MG;500MG	A070544	001	Jan 15, 1986
DAVA PHARMS INC	15MG;250MG	A072507	001	Jun 02, 1989
	25MG;250MG	A072508	001	Jun 02, 1989
	30MG;500MG	A072509	001	Jun 02, 1989
	50MG;500MG	A072510	001	Jun 02, 1989
IVAX SUB TEVA PHARMS	15MG;250MG	A071458	001	Mar 08, 1988
	25MG;250MG	A071459	001	Mar 08, 1988
	30MG;500MG	A071460	001	Mar 08, 1988
	50MG;500MG	A071461	001	Mar 08, 1988
PARKE DAVIS	15MG;250MG	A071897	001	Nov 23, 1987
	25MG;250MG	A071898	001	Nov 23, 1987
	30MG;500MG	A071899	001	Nov 23, 1987
	50MG;500MG	A071900	001	Nov 23, 1987
PUREPAC PHARM	15MG;250MG	A070853	001	Oct 08, 1986
	25MG;250MG	A070688	001	Apr 24, 1986
	30MG;500MG	A070854	001	Oct 08, 1986
	50MG;500MG	A070689	001	Apr 24, 1986
RISING	15MG;250MG	A070265	002	Jan 23, 1986
	25MG;250MG	A070265	001	Jan 23, 1986
SANDOZ	15MG;250MG	A070829	001	Mar 09, 1987
	25MG;250MG	A070830	001	Mar 09, 1987
STRIDES PHARMA	15MG;250MG	A070616	001	Feb 02, 1987
	25MG;250MG	A070612	001	Feb 02, 1987
	30MG;500MG	A070613	001	Feb 02, 1987
	50MG;500MG	A070614	001	Feb 02, 1987
TEVA	15MG;250MG	A071819	001	Apr 08, 1988
	25MG;250MG	A071820	001	Apr 08, 1988
	30MG;500MG	A071821	001	Apr 08, 1988
	50MG;500MG	A071822	001	Apr 08, 1988
WATSON LABS	15MG;250MG	A070365	001	Mar 19, 1986
	15MG;250MG	A070958	001	Feb 06, 1989
	15MG;250MG	A071920	001	Aug 29, 1988
	25MG;250MG	A070366	001	Apr 16, 1986
	25MG;250MG	A070959	001	Jan 19, 1989
	25MG;250MG	A071921	001	Aug 29, 1988
	30MG;500MG	A070367	001	Mar 19, 1986
	30MG;500MG	A071069	001	Jan 19, 1989
	30MG;500MG	A071922	001	Aug 29, 1988
	50MG;500MG	A070368	001	Apr 16, 1986
	50MG;500MG	A070960	001	Feb 06, 1989
	50MG;500MG	A071923	001	Aug 29, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DUTOPROL

+	CONCORDIA	12.5MG;EQ 25MG TARTRATE **	N021956	001	Aug 28, 2006
+		12.5MG;EQ 50MG TARTRATE **	N021956	002	Aug 28, 2006
+		12.5MG;EQ 100MG TARTRATE **	N021956	003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

LOPRESSOR HCT

+	VALIDUS PHARMS	25MG;100MG **	N018303	002	Dec 31, 1984
+		50MG;100MG **	N018303	003	Dec 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

CHARTWELL RX	12.5MG;7.5MG	A090096	001	Sep 25, 2008
	12.5MG;15MG	A090096	002	Sep 25, 2008
	25MG;15MG	A090096	003	Sep 25, 2008
HERITAGE PHARMS	12.5MG;7.5MG	A202150	001	Mar 07, 2014
	12.5MG;15MG	A202150	002	Mar 07, 2014
	25MG;15MG	A202150	003	Mar 07, 2014

UNIRETIC

UCB INC	12.5MG;7.5MG **	N020729	001	Jun 27, 1997
	12.5MG;15MG **	N020729	003	Feb 14, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL					
UNIRETIC					
		25MG;15MG **	N020729	002	Jun 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL					
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE					
	NATCO PHARMA USA	12.5MG;20MG	A078827	001	Oct 26, 2016
		12.5MG;40MG	A078827	002	Oct 26, 2016
		25MG;40MG	A078827	003	Oct 26, 2016
	TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017
		25MG;40MG	A200532	003	Apr 24, 2017
	TORRENT	12.5MG;20MG	A206515	001	May 03, 2017
		12.5MG;40MG	A206515	002	May 03, 2017
		25MG;40MG	A206515	003	May 03, 2017
	ZYDUS PHARMS	12.5MG;20MG	A206377	001	Feb 24, 2023
		12.5MG;40MG	A206377	002	Feb 24, 2023
		25MG;40MG	A206377	003	Feb 24, 2023

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET;ORAL					
VISKAZIDE					
	NOVARTIS	25MG;5MG	N018872	001	Jul 22, 1987
		25MG;10MG	N018872	002	Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
INDERIDE LA 120/50					
	WYETH AYERST	50MG;120MG	N019059	002	Jul 03, 1985
INDERIDE LA 160/50					
	WYETH AYERST	50MG;160MG	N019059	003	Jul 03, 1985
INDERIDE LA 80/50					
	WYETH AYERST	50MG;80MG	N019059	001	Jul 03, 1985
TABLET;ORAL					
INDERIDE-40/25					
+	WYETH PHARMS INC	25MG;40MG **	N018031	001	
INDERIDE-80/25					
+	WYETH PHARMS INC	25MG;80MG **	N018031	002	
PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE					
	DURAMED PHARMS BARR	25MG;40MG	A071126	001	Mar 02, 1987
		25MG;80MG	A071127	001	Mar 02, 1987
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	ACTAVIS ELIZABETH	25MG;40MG	A070851	001	May 15, 1986
		25MG;80MG	A070852	001	May 15, 1986
	ANI PHARMS	25MG;40MG	A070705	002	Oct 01, 1986
		25MG;40MG	A072043	002	Mar 14, 1988
		25MG;80MG	A070705	001	Oct 01, 1986
		25MG;80MG	A072043	001	Mar 14, 1988
	CHARTWELL RX	25MG;40MG	A071060	001	Aug 26, 1987
		25MG;80MG	A071061	001	Aug 26, 1987
	IVAX SUB TEVA PHARMS	25MG;40MG	A071552	001	Dec 01, 1988
		25MG;80MG	A071553	001	Dec 01, 1988
	RISING	25MG;40MG	A070947	002	Mar 04, 1987
		25MG;80MG	A070947	001	Apr 01, 1987
	WARNER CHILCOTT	25MG;40MG	A071771	001	Jan 26, 1988
		25MG;80MG	A071772	001	Jan 26, 1988
	WATSON LABS	25MG;40MG	A070301	001	Apr 18, 1986
		25MG;40MG	A071498	001	Dec 18, 1991
		25MG;80MG	A070305	001	Apr 18, 1986
		25MG;80MG	A071501	001	Dec 18, 1991

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL					
ACCURETIC					
+	PFIZER PHARMS	12.5MG;EQ 10MG BASE	N020125	001	Dec 28, 1999
+		12.5MG;EQ 20MG BASE	N020125	002	Dec 28, 1999
+		25MG;EQ 20MG BASE	N020125	003	Dec 28, 1999
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	CHARTWELL RX	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004
		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL				
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
	25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004
MYLAN	12.5MG;EQ 10MG BASE	A077093	001	Mar 28, 2005
	12.5MG;EQ 20MG BASE	A077093	002	Mar 28, 2005
	25MG;EQ 20MG BASE	A077093	003	Mar 28, 2005
SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009
	12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009
	25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL				
H.R.-50				
WHITEWORTH TOWN PLSN	50MG;0.125MG	A085338	001	
HYDRO-RESERP				
ABC HOLDING	50MG;0.125MG	A084714	002	Jun 29, 1982
HYDRO-SERP "25"				
SANDOZ	25MG;0.125MG	A084827	001	
HYDRO-SERP "50"				
SANDOZ	50MG;0.125MG	A085213	001	
HYDROCHLOROTHIAZIDE W/ RESERPINE				
IVAX SUB TEVA PHARMS	25MG;0.1MG	A083572	001	
	25MG;0.125MG	A083571	001	
	50MG;0.1MG	A083568	001	
	50MG;0.125MG	A083573	001	
PHARMERAL	25MG;0.125MG	A085421	001	
	50MG;0.125MG	A085420	001	
ROXANE	50MG;0.125MG	A084603	001	
WATSON LABS	25MG;0.125MG	A084466	001	
	25MG;0.125MG	A085317	001	
	25MG;0.125MG	A086330	002	
	50MG;0.125MG	A083666	001	
	50MG;0.125MG	A084467	001	
	50MG;0.125MG	A086331	001	
HYDROPRES 25				
MERCK	25MG;0.125MG	N011958	002	
HYDROPRES 50				
MERCK	50MG;0.125MG	N011958	003	
RESERPINE AND HYDROCHLOROTHIAZIDE				
BARR	25MG;0.125MG	A084580	001	
	50MG;0.125MG	A084579	001	
SANDOZ	50MG;0.125MG	A088200	001	Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50				
WEST WARD	50MG;0.125MG	A088189	001	May 10, 1984
SERPASIL-ESIDRIX #1				
NOVARTIS	25MG;0.1MG	N011878	003	
SERPASIL-ESIDRIX #2				
NOVARTIS	50MG;0.1MG	N011878	005	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL				
ALDACTAZIDE				
+ PFIZER	50MG;50MG	N012616	005	Dec 30, 1982
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE				
ASCOT	25MG;25MG	A088025	001	Nov 23, 1984
CHARTWELL RX	25MG;25MG	A086881	001	
MUTUAL PHARM	25MG;25MG	A087267	001	
PUREPAC PHARM	25MG;25MG	A087999	001	Nov 06, 1985
SUPERPHARM	25MG;25MG	A089137	001	Aug 26, 1985
WATSON LABS	25MG;25MG	A087398	001	
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE				
IVAX PHARMS	25MG;25MG	A087004	002	May 24, 1982
LEDERLE	25MG;25MG	A087511	001	
PARKE DAVIS	25MG;25MG	A087948	001	Feb 22, 1983
PUREPAC PHARM	25MG;25MG	A088054	001	Aug 18, 1983
UPSHER SMITH	25MG;25MG	A087553	001	
USL PHARMA	25MG;25MG	A087651	001	
VANGARD	25MG;25MG	A087655	001	
WATSON LABS	25MG;25MG	A085974	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

	25MG;25MG	A086026	001	

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

MACLEODS PHARMS LTD	12.5MG;40MG	A204169	001	Nov 02, 2015
	12.5MG;80MG	A204169	002	Nov 02, 2015
	25MG;80MG	A204169	003	Nov 02, 2015
MYLAN	12.5MG;40MG	A091648	001	Feb 25, 2014
	12.5MG;80MG	A091648	002	Feb 25, 2014
	25MG;80MG	A091648	003	Feb 25, 2014
TORRENT	12.5MG;40MG	A201192	001	Feb 25, 2014
	12.5MG;80MG	A201192	002	Feb 25, 2014
	25MG;80MG	A201192	003	Feb 25, 2014

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET;ORAL

TIMOLIDE 10-25

MERCK	25MG;10MG	N018061	001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

DYAZIDE

+	GLAXOSMITHKLINE LLC	25MG;37.5MG **	N016042	003	Mar 03, 1994
		25MG;50MG **	N016042	002	

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

ANI PHARMS	25MG;37.5MG	A074970	001	Jan 06, 1998
	25MG;50MG	A074259	001	Mar 30, 1995
CHARTWELL RX	25MG;50MG	A073191	001	Jul 31, 1991
DURAMED PHARMS BARR	25MG;37.5MG	A075052	001	Jun 18, 1999
MYLAN	25MG;37.5MG	A074701	001	Jun 07, 1996
NOVARTIS	25MG;37.5MG	A074857	001	Sep 09, 1997
VITARINE	25MG;50MG	A071737	001	Feb 12, 1988

TABLET;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AM THERAP	50MG;75MG	A072022	001	Apr 17, 1988
ANI PHARMS	50MG;75MG	A073467	001	Jan 31, 1996
PLIVA	25MG;37.5MG	A074026	001	Apr 26, 1996
QUANTUM PHARMICS	50MG;75MG	A071980	001	Apr 17, 1988
WATSON LABS	50MG;75MG	A071969	001	Apr 17, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013
	12.5MG;160MG	A203026	002	Mar 21, 2013
	12.5MG;320MG	A203026	003	Mar 21, 2013
	25MG;160MG	A203026	004	Mar 21, 2013
	25MG;320MG	A203026	005	Mar 21, 2013
CADILA	12.5MG;80MG	A203000	001	Mar 15, 2019
	12.5MG;160MG	A203000	002	Mar 15, 2019
	12.5MG;320MG	A203000	003	Mar 15, 2019
	25MG;160MG	A203000	004	Mar 15, 2019
	25MG;320MG	A203000	005	Mar 15, 2019
WATSON LABS TEVA	12.5MG;80MG	A091519	001	Mar 21, 2013
	12.5MG;160MG	A091519	002	Mar 21, 2013
	12.5MG;320MG	A091519	003	Mar 21, 2013
	25MG;160MG	A091519	004	Mar 21, 2013
	25MG;320MG	A091519	005	Mar 21, 2013

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

+	RECRO GAINESVILLE	10MG	N202880	001	Oct 25, 2013
+		15MG	N202880	002	Oct 25, 2013
+		20MG	N202880	003	Oct 25, 2013
+		30MG	N202880	004	Oct 25, 2013
+		40MG	N202880	005	Oct 25, 2013
+		50MG	N202880	006	Oct 25, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL

VANTRELA ER

+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017
+		30MG	N207975	002	Jan 17, 2017
+		45MG	N207975	003	Jan 17, 2017
+		60MG	N207975	004	Jan 17, 2017
+		90MG	N207975	005	Jan 17, 2017

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

	ANI PHARMS	5MG;200MG	A077454	001	Jun 23, 2010
	SUN PHARM INDS INC	2.5MG;200MG	A091633	001	May 28, 2013
		5MG;200MG	A091633	002	May 28, 2013
		7.5MG;200MG	A091633	003	May 28, 2013
		10MG;200MG	A091633	004	May 28, 2013
	TEVA	7.5MG;200MG	A076023	001	Apr 11, 2003

REPREXAIN

	AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007
		10MG;200MG	A076642	004	Oct 19, 2007

VICOPROFEN

+	ABBVIE	7.5MG;200MG **	N020716	001	Sep 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP;ORAL

CODAMINE

	ALPHARMA US PHARMS	5MG/5ML;25MG/5ML	A075103	001	Sep 29, 2000

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	APOZEAL PHARMS	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019
	MAYNE PHARMA INC	5MG/5ML;60MG/5ML	A205658	001	Nov 17, 2015
	PADAGIS US	5MG/5ML;60MG/5ML	A204658	001	Apr 29, 2014
	TRIS PHARMA INC	5MG/5ML;60MG/5ML	A203839	001	Oct 28, 2014

REZIRA

+	PERSION	5MG/5ML;60MG/5ML **	N022442	001	Jun 08, 2011

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT;TOPICAL

MAGNACORT

	PFIZER	0.5%	N010554	001	

HYDROCORTISONE

AEROSOL;TOPICAL

AEROSEB-HC

	ALLERGAN HERBERT	0.5%	A085805	001	

CREAM;TOPICAL

CORT-DOME

	BAYER PHARMS	0.5%	N009585	003	
		1%	N009585	001	

DERMACORT

	MONARCH PHARMS	1%	A083011	002	

ELDECORT

	VALEANT PHARM INTL	1%	A080459	001	
		2.5%	A084055	001	

FLEXICORT

	WESTWOOD SQUIBB	0.5%	A087136	003	Apr 08, 1982
		1%	A087136	002	Apr 08, 1982
		2.5%	A087136	001	Apr 08, 1982

H-CORT

	PHARM ASSOC	0.5%	A086823	001	

HC #1

	BAYER PHARMS	0.5%	A080438	001	

HC #4

	BAYER PHARMS	1%	A080438	002	

HC (HYDROCORTISONE)

	C AND M PHARMA	0.5%	A080482	003	
		1%	A080482	004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE				
CREAM;TOPICAL				
HI-COR				
C AND M PHARMA	2.5%	A080483	001	
HYDROCORTISONE				
ALPHARMA US PHARMS	2.5%	A089754	001	Feb 01, 1989
ALTANA	0.5%	A080848	002	
	1%	A080848	003	
AMBIX	1%	A086080	001	
	2.5%	A086271	001	
CHARTWELL MOLECULAR	2.5%	A040503	001	Mar 12, 2004
ENCUBE	2.5%	A203810	001	Jul 23, 2018
EVERYLIFE	0.5%	A080452	001	
	1%	A080452	002	
G AND W LABS	1%	A084059	001	
INGRAM PHARM	0.5%	A080456	002	
	1%	A080456	003	
IVAX PHARMS	1%	A085733	001	
NASKA	1%	A089706	001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084970	002	
	1%	A085026	001	
PHARMADERM	1%	A088845	001	Feb 27, 1986
	2.5%	A089413	001	Dec 16, 1986
PHARMAFAIR	1%	A087838	001	Jul 28, 1982
STIEFEL	1%	A086170	001	
SYOSSET	0.5%	A085527	001	
TARO	0.5%	A086154	001	
	1%	A086155	001	
TEVA	0.5%	A080400	002	
	1%	A080400	003	
	1%	A085191	001	
	2.5%	A080400	004	
TOPIDERM	1%	A089273	001	Feb 17, 1989
USL PHARMA	1%	A088027	001	Sep 27, 1983
	2.5%	A088029	001	Sep 27, 1983
WHITEWORTH TOWN PLSN	1%	A080496	002	
HYTONE				
+ VALEANT INTL	1% **	A080472	003	
+	2.5% **	A080472	004	
NOGENIC HC				
IVAX PHARMS	1%	A087427	001	Apr 04, 1988
NUTRACORT				
BAUSCH	0.5%	A080442	002	
	1%	A080442	003	
PENECORT				
ALLERGAN HERBERT	1%	A088216	001	Jun 06, 1984
PROCTOCORT				
MONARCH PHARMS	1%	A083011	001	
SYNACORT				
BAUSCH	0.5%	A087459	001	
+	1%	A087458	001	
+	2.5%	A087457	001	
ENEMA;RECTAL				
HYDROCORTISONE				
TEVA PHARMS	100MG/60ML	A074171	001	May 27, 1994
GEL;TOPICAL				
NUTRACORT				
HEALTHPOINT	1%	A084698	001	
PENECORT				
ALLERGAN HERBERT	1%	A088215	001	Jun 06, 1984
INJECTABLE;INJECTION				
CORTEF				
PHARMACIA AND UPJOHN	50MG/ML	N009864	001	
LOTION;TOPICAL				
ACTICORT				
BAKER NORTON	1%	A086535	001	
ALA-CORT				
CROWN LABS	1%	A083201	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE

LOTION;TOPICAL				
BALNEOL-HC				
SOLVAY	1%	A088041	001	Dec 03, 1982
BETA-HC				
BETA DERMAC	1%	A089495	001	Jan 25, 1988
CETACORT				
BAUSCH	0.5%	A080426	002	
	1%	A080426	001	
CORT-DOME				
BAYER PHARMS	0.5%	N009895	003	
	1%	N009895	001	
DERMACORT				
SOLVAY	0.5%	A084573	002	
	1%	A086462	001	
EPICORT				
BLULINE	0.5%	A083219	002	
GLYCORT				
HERAN	1%	A087489	001	Oct 03, 1983
H-CORT				
PHARM ASSOC	0.5%	A086824	001	
HYDROCORTISONE				
ALPHARMA US PHARMS	0.5%	A087317	001	Jun 07, 1982
	1%	A087315	001	Jun 07, 1982
CHARTWELL MOLECULAR	2.5%	A040417	001	Jul 30, 2003
FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000
MERICON	0.5%	A085282	001	
	1%	A085282	002	Feb 26, 1987
NASKA	1%	A089705	001	Apr 25, 1988
PERRIGO NEW YORK	0.5%	A085662	001	
	1%	A085663	001	
TARO	1%	A089024	001	Feb 12, 1986
VERTICE	2.5%	A203804	001	Jul 27, 2018
HYTONE				
+ VALEANT INTL	1% **	A080473	003	
+	2.5% **	A080473	004	Nov 30, 1982
NUTRACORT				
DOW PHARM	0.5%	A080443	002	
	1%	A080443	003	
	2.5%	A087644	001	Aug 24, 1982
STIE-CORT				
PADAGIS US	1%	A089066	001	Nov 25, 1985
OINTMENT;TOPICAL				
CORTRIL				
PFIZER GLOBAL	1%	N009176	001	
	2.5%	N009176	002	
HC (HYDROCORTISONE)				
C AND M PHARMA	0.5%	A080481	001	
	1%	A080481	002	
HYDROCORTISONE				
ACTAVIS MID ATLANTIC	1%	A087796	001	Oct 13, 1982
ALTANA	0.5%	A080489	002	
	1%	A080489	003	
AMBIX	1%	A086079	001	
	2.5%	A086272	001	
NASKA	1%	A089704	001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084969	003	
	1%	A085028	001	
PHARMADERM	1%	A088842	001	Feb 09, 1987
TARO	0.5%	A086256	001	
	2.5%	A040310	001	Dec 29, 2000
USL PHARMA	1%	A088061	001	Sep 27, 1983
	2.5%	A088039	001	Sep 27, 1983
HYTONE				
+ DERMIK LABS	1% **	A080474	003	
+	2.5% **	A080474	004	
PENECORT				
ALLERGAN HERBERT	2.5%	A088217	001	Jun 06, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE				
POWDER;FOR RX COMPOUNDING				
H-CORT				
TORCH	100%	A087834	001	Mar 29, 1982
HYDRO-RX				
X GEN PHARMS	100%	A085982	001	
HYDROCORTISONE				
PADDOCK LLC	100%	A088082	001	Apr 08, 1983
SOLUTION;TOPICAL				
PENECORT				
+ ALLERGAN HERBERT	1%	A088214	001	Jun 06, 1984
TEXACORT				
MISSION PHARMA	1%	A080425	001	
TABLET;ORAL				
CORTRIL				
PFIZER	10MG	N009127	005	
	20MG	N009127	003	
HYDROCORTISONE				
BARR	20MG	A083999	001	
CHARTWELL MOLECULAR	20MG	A085070	001	
ELKINS SINN	20MG	A080624	001	
FERRANTE	10MG	A080568	001	
	20MG	A080568	002	
HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015
	10MG	A083365	003	Feb 23, 2015
	20MG	A083365	001	
IMPAX LABS	20MG	A080781	001	
INWOOD LABS	20MG	A080732	001	
NEXGEN PHARMA INC	20MG	A083140	001	
PANRAY	10MG	N009659	001	
	20MG	N009659	002	
PARKE DAVIS	20MG	A084243	001	
PUREPAC PHARM	10MG	A084247	003	Aug 31, 1982
	20MG	A080395	001	
	20MG	A084247	002	
ROXANE	10MG	A088539	001	Mar 21, 1984
SANDOZ	20MG	A080642	002	
STRIDES PHARMA	5MG	A040761	001	Jul 16, 2007
	10MG	A040761	002	Jul 16, 2007
	20MG	A040761	003	Jul 16, 2007
WATSON LABS	20MG	A080355	001	
WHITEWORTH TOWN PLSN	10MG	A080344	001	
	20MG	A080344	002	
HYDROCORTONE				
MERCK	10MG	N008506	007	
	20MG	N008506	011	
TABLET;VAGINAL				
CORTRIL				
PFIPHARMECS	10MG	N009796	001	
HYDROCORTISONE ACETATE				
CREAM;TOPICAL				
CARMOL HC				
+ FOUGERA PHARMS	1%	A080505	001	
HEMSOL-HC				
ABLE	1%	A081274	001	Jun 19, 1992
HYDROCORTISONE ACETATE				
CENCI	1%	A080419	001	Jan 25, 1982
IMPERIUM	2.5%	A040259	001	Jul 29, 1999
PARKE DAVIS	1%	A089914	001	Jan 03, 1989
PUREPAC PHARM	0.5%	A086050	001	
+	1%	A086052	001	
MICORT-HC				
SEBELA IRELAND LTD	2%	A040398	001	Mar 29, 2002
U-CORT				
TARO	1%	A089472	001	Jun 13, 1988
INJECTABLE;INJECTION				
CORTEF ACETATE				
PHARMACIA AND UPJOHN	50MG/ML	N009378	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE ACETATE

INJECTABLE;INJECTION				
CORTRIL				
	PFIZER	25MG/ML	N009164 001	
HYDROCORTISONE ACETATE				
	BEL MAR	25MG/ML	A083739 001	
		50MG/ML	A083739 002	
	EPIC PHARMA LLC	25MG/ML	N009637 001	
		50MG/ML	N009637 002	
	WATSON LABS	25MG/ML	A083128 001	
		25MG/ML	A083759 001	
		50MG/ML	A083759 002	
		50MG/ML	A085214 001	
HYDROCORTONE				
	MERCK	25MG/ML	N008228 001	
		50MG/ML	N008228 004	
LOTION;TOPICAL				
DRICORT				
	INGRAM PHARM	0.5%	A086207 001	
OINTMENT;OPHTHALMIC				
HYDROCORTISONE ACETATE				
	FERA PHARMS	0.5%	A080828 001	
OINTMENT;OPHTHALMIC, OTIC				
HYDROCORTONE				
	MERCK	1.5%	N009018 003	
OINTMENT;TOPICAL				
CORTEF ACETATE				
	PHARMACIA AND UPJOHN	1%	N008917 002	
+		2.5% **	N008917 001	
PASTE;TOPICAL				
ORABASE HCA				
	COLGATE	0.5%	A083205 001	
POWDER;FOR RX COMPOUNDING				
HYDROCORTISONE ACETATE				
	X GEN PHARMS	100%	A085981 001	

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM;TOPICAL				
NEO-CORTEF				
	PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	A061049 001	
		2.5%;EQ 3.5MG BASE/GM	A061049 002	
OINTMENT;OPHTHALMIC				
NEO-CORTEF				
	PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060610 001	
		1.5%;EQ 3.5MG BASE/GM	A060610 002	
OINTMENT;TOPICAL				
NEO-CORTEF				
	PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060751 001	
		1%;EQ 3.5MG BASE/GM	A060751 002	
		2.5%;EQ 3.5MG BASE/GM	A060751 003	
SUSPENSION/DROPS;OPHTHALMIC				
COR-OTICIN				
	EPIC PHARMA LLC	1.5%;EQ 3.5MG BASE/ML	A060188 001	
NEO-CORTEF				
	PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML	A060612 002	
		1.5%;EQ 3.5MG BASE/ML	A060612 001	

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL				
CORTISPORIN				
+	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218 001	Aug 09, 1985

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION;OPHTHALMIC				
TERRA-CORTRIL				
	PFIZER	1.5%;EQ 5MG BASE/ML	A061016 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL				
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%				
GENUS	1%;1%	A089440	001	May 17, 1988
LOTION;TOPICAL				
PRAMOSONE				
FERNDALE LABS	0.5%;1%	A083213	002	

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL				
LOCOID				
YAMANOUCHI	0.1%	N018795	001	Jan 07, 1983
OINTMENT;TOPICAL				
LOCOID				
YAMANOUCHI	0.1%	N019106	001	Jul 03, 1984
SOLUTION;TOPICAL				
LOCOID				
YAMANOUCHI	0.1%	N019819	001	Sep 15, 1988

HYDROCORTISONE CYPIONATE

SUSPENSION;ORAL				
CORTEF				
PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N009900	001	

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE;INJECTION				
HYDROCORTONE				
+ MERCK	EQ 50MG BASE/ML	N012052	001	

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION				
A-HYDROCORT				
ABBOTT	EQ 100MG BASE/VIAL	A085928	001	
	EQ 100MG BASE/VIAL	A089577	001	Apr 11, 1989
	EQ 250MG BASE/VIAL	A089578	001	Apr 11, 1989
	EQ 500MG BASE/VIAL	A089579	001	Apr 11, 1989
	EQ 1GM BASE/VIAL	A089580	001	Apr 11, 1989
HOSPIRA	EQ 100MG BASE/VIAL	A040666	001	Apr 06, 2006
	EQ 100MG BASE/VIAL	A085929	001	
	EQ 250MG BASE/VIAL	A085930	001	
	EQ 500MG BASE/VIAL	A085931	001	
	EQ 1GM BASE/VIAL	A085932	001	
HYDROCORTISONE SODIUM SUCCINATE				
ABRAXIS PHARM	EQ 100MG BASE/VIAL	A088667	001	Jun 08, 1984
	EQ 100MG BASE/VIAL	A088712	001	Jun 08, 1984
	EQ 250MG BASE/VIAL	A088668	001	Jun 08, 1984
	EQ 500MG BASE/VIAL	A088669	001	Jun 08, 1984
	EQ 1GM BASE/VIAL	A088670	001	Jun 08, 1984
BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A086619	001	
	EQ 250MG BASE/VIAL	A087567	001	
	EQ 500MG BASE/VIAL	A087568	001	
	EQ 1GM BASE/VIAL	A087569	001	
INTL MEDICATION	EQ 100MG BASE/VIAL	A087532	001	Mar 19, 1982
WATSON LABS	EQ 100MG BASE/VIAL	A084737	002	
	EQ 100MG BASE/VIAL	A084738	001	
	EQ 250MG BASE/VIAL	A084737	001	
	EQ 500MG BASE/VIAL	A084747	001	
	EQ 1GM BASE/VIAL	A084748	001	

HYDROCORTISONE VALERATE

CREAM;TOPICAL				
HYDROCORTISONE VALERATE				
COSETTE	0.2%	A074489	001	Aug 12, 1998
WESTCORT				
+ SUN PHARM INDS INC	0.2% **	N017950	001	
OINTMENT;TOPICAL				
HYDROCORTISONE VALERATE				
FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001
WESTCORT				
+ SUN PHARM INDS INC	0.2% **	N018726	001	Aug 08, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM;TOPICAL				
NEO-CORT-DOME				
BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM	N050237	006	Jun 05, 1984
	1%;EQ 3.5MG BASE/GM	N050237	005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC				
CORTISPORIN				
+ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML **	N050479	001	
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE				
AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062394	001	Sep 29, 1982
OTOCORT				
WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060730	002	
SUSPENSION/DROPS;OPHTHALMIC				
CORTISPORIN				
MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001	
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062623	001	Sep 24, 1985
SUSPENSION/DROPS;OTIC				
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062617	001	Sep 18, 1985
OTICAIR				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062399	001	Nov 18, 1982
OTOBIONE				
SCHERING	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A061816	001	
OTOCORT				
ACTAVIS LABS FL INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062521	001	Jul 11, 1985
PEDIOTIC				
MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822	001	Sep 29, 1987

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC				
OTOBIOTIC				
SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML	A062302	001	
PYOCIDIN				
FOREST LABS	5MG/ML;EQ 10,000 UNITS BASE/ML	A061606	001	

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT;OPHTHALMIC				
ACHROMYCIN				
LEDERLE	1.5%;1%	N050272	001	

HYDROCORTISONE; UREA

CREAM;TOPICAL				
ALPHADERM				
BIOGLAN	1%;10%	A086008	001	
CALMURID HC				
PHARMACIA AND UPJOHN	1%;10%	A083947	001	

HYDROFLUMETHIAZIDE

TABLET;ORAL				
DIUCARDIN				
WYETH AYERST	50MG	A083383	001	
HYDROFLUMETHIAZIDE				
PAR PHARM	50MG	A088850	001	May 31, 1985
WATSON LABS	50MG	A088031	001	Apr 06, 1983
	50MG	A088528	001	Aug 15, 1984
SALURON				
+ SHIRE LLC	50MG	N011949	001	

HYDROFLUMETHIAZIDE; RESERPINE

TABLET;ORAL				
HYDROFLUMETHIAZIDE AND RESERPINE				
USL PHARMA	50MG;0.125MG	A088195	001	Oct 26, 1983
WATSON LABS	25MG;0.125MG	A088127	001	Mar 22, 1983
	50MG;0.125MG	A088110	001	Mar 22, 1983
RESERPINE AND HYDROFLUMETHIAZIDE				
IVAX PHARMS	50MG;0.125MG	A088932	001	Jan 11, 1985
PAR PHARM	50MG;0.125MG	A088907	001	Sep 20, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROFLUMETHIAZIDE; RESERPINE				
TABLET;ORAL				
SALUTENSIN				
	SHIRE	50MG;0.125MG	N012359 003	
SALUTENSIN-DEMI				
	SHIRE	25MG;0.125MG	N012359 004	
HYDROGEN PEROXIDE				
SOLUTION;TOPICAL				
ESKATA				
+	ACLARIS	40%	N209305 001	Dec 14, 2017
HYDROMORPHONE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
PALLADONE				
	PURDUE PHARMA LP	12MG	N021044 001	Sep 24, 2004
		16MG	N021044 002	Sep 24, 2004
		24MG	N021044 003	Sep 24, 2004
		32MG	N021044 004	Sep 24, 2004
INJECTABLE;INJECTION				
DILAUDID				
+	FRESENIUS KABI USA	4MG/ML	N019034 005	Apr 30, 2009
DILAUDID-HP				
+	FRESENIUS KABI USA	10MG/ML	N019034 001	Jan 11, 1984
		250MG/VIAL	N019034 002	Aug 04, 1994
HYDROMORPHONE HYDROCHLORIDE				
	BARR	10MG/ML	A076444 001	Apr 25, 2003
	HOSPIRA	10MG/ML	A074598 001	Jun 19, 1997
	WATSON LABS	10MG/ML	A074317 001	Aug 23, 1995
SOLUTION;ORAL				
HYDROMORPHONE HYDROCHLORIDE				
	ANDA REPOSITORY	5MG/5ML	A207108 001	Apr 22, 2020
TABLET;ORAL				
HYDROMORPHONE HYDROCHLORIDE				
	ANDA REPOSITORY	2MG	A077471 002	Dec 09, 2009
		4MG	A077471 003	Dec 09, 2009
		8MG	A077471 001	Dec 09, 2009
	HIKMA	4MG	A074597 003	May 29, 2009
		8MG	A074597 001	Jul 29, 1998
	NESHER PHARMS	2MG	A077311 001	Nov 09, 2005
		4MG	A077311 002	Nov 09, 2005
		8MG	A077311 003	Nov 09, 2005
	NOSTRUM LABS INC	8MG	A076723 001	Oct 18, 2005
TABLET, EXTENDED RELEASE;ORAL				
EXALGO				
+	SPECGX LLC	8MG **	N021217 001	Mar 01, 2010
+		12MG **	N021217 002	Mar 01, 2010
+		16MG **	N021217 003	Mar 01, 2010
+		32MG **	N021217 004	Aug 24, 2012
HYDROMORPHONE HYDROCHLORIDE				
	ACTAVIS LABS FL INC	8MG	A202144 001	May 12, 2014
		12MG	A202144 002	May 12, 2014
		16MG	A202144 003	May 12, 2014
		32MG	A202144 004	Jun 30, 2016
HYDROXOCOBALAMIN				
INJECTABLE;INJECTION				
ALPHAREDISOL				
	MERCK	1MG/ML	A080778 001	
CYANOKIT				
	BTG INTL	2.5GM/VIAL (5GM/KIT)	N022041 002	Dec 15, 2006
HYDROXOCOBALAMIN				
	ABRAXIS PHARM	1MG/ML	A084921 001	
	WATSON LABS	1MG/ML	A085528 001	
HYDROXOMIN				
	BEL MAR	1MG/ML	A084629 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROXYAMPHETAMINE HYDROBROMIDE				
SOLUTION/DROPS;OPHTHALMIC				
PAREDRINE				
	PHARMICS	1%	N000004 004	
HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE				
SOLUTION/DROPS;OPHTHALMIC				
PAREMYD				
+	EPIC PHARMA LLC	1%;0.25%	N019261 001	Jan 30, 1992
HYDROXYCHLOROQUINE SULFATE				
TABLET;ORAL				
HYDROXYCHLOROQUINE SULFATE				
	HIKMA PHARMS	200MG	A040760 001	Aug 15, 2007
	INVATECH	200MG	A040150 001	Jan 27, 1996
	TEVA PHARMS	200MG	A040081 001	Sep 30, 1994
	WATSON LABS	200MG	A040133 001	Nov 30, 1995
HYDROXYPROGESTERONE CAPROATE				
INJECTABLE;INJECTION				
HYDROXYPROGESTERONE CAPROATE				
	ALLERGAN	125MG/ML	N017439 001	
		250MG/ML	N017439 002	
	EPIC PHARMA LLC	125MG/ML	N018004 001	
SOLUTION;INTRAMUSCULAR				
DELALUTIN				
+	BRISTOL MYERS SQUIBB	125MG/ML (125MG/ML) **	N010347 004	
+		125MG/ML (125MG/ML) **	N016911 001	
+		250MG/ML (250MG/ML) **	N010347 002	
+		250MG/ML (250MG/ML) **	N016911 002	
HYDROXYPROGESTERONE CAPROATE				
	ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)	A200271 001	Aug 24, 2015
	EUGIA PHARMA	1250MG/5ML (250MG/ML)	A211142 001	May 09, 2019
HYDROXYSTILBAMIDINE ISETHIONATE				
INJECTABLE;INJECTION				
HYDROXYSTILBAMIDINE ISETHIONATE				
	SANOFI AVENTIS US	225MG/AMP	N009166 001	
HYDROXYUREA				
CAPSULE;ORAL				
HYDROXYUREA				
	BARR	250MG	A075143 002	Sep 21, 2000
	BARR LABS INC	250MG	A075020 002	Jun 26, 2000
		500MG	A075020 001	Jul 30, 1998
	ROXANE	500MG	A074476 001	Aug 18, 1995
TABLET;ORAL				
HYDROXYUREA				
	BARR	1GM	A075734 001	Aug 29, 2000
HYDROXYZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
HYDROXYZINE				
	BAXTER HLTHCARE	50MG/ML	A085551 002	
HYDROXYZINE HYDROCHLORIDE				
	ALTANA	25MG/ML	A087273 001	Apr 20, 1982
		50MG/ML	A087273 002	Apr 20, 1982
	BAXTER HLTHCARE	25MG/ML	A085551 001	
	DR REDDYS	50MG/ML	A085779 001	
	FRESENIUS KABI USA	25MG/ML	A087329 001	
		25MG/ML	A088184 001	Mar 31, 1983
		50MG/ML	A087329 002	
		50MG/ML	A088185 001	Mar 31, 1983
	HOSPIRA	25MG/ML	A087416 001	
		50MG/ML	A086821 001	
		50MG/ML	A087546 001	
	PHARMAFAIR	25MG/ML	A088862 001	Feb 14, 1986
		25MG/ML	A089106 001	Feb 14, 1986
		50MG/ML	A088881 001	Feb 14, 1986
		50MG/ML	A089107 001	Feb 14, 1986
	SMITH AND NEPHEW	25MG/ML	A087592 001	
	SOLOPAK	25MG/ML	A086822 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION					
HYDROXYZINE HYDROCHLORIDE					
		25MG/ML	A087591	001	
		50MG/ML	A087310	001	
		50MG/ML	A087593	001	
		50MG/ML	A087595	001	
		50MG/ML	A087596	001	
	WATSON LABS	25MG/ML	A085778	001	
		25MG/ML	A087274	001	
		50MG/ML	A087274	002	
	WYETH AYERST	25MG/ML	A086258	001	
		50MG/ML	A086258	002	
ORGATRAX					
	ORGANON USA INC	25MG/ML	A087014	001	
		50MG/ML	A087014	002	
VISTARIL					
+	PFIZER	25MG/ML **	N011111	001	
+		50MG/ML **	N011111	002	
SYRUP;ORAL					
ATARAX					
	ROERIG	10MG/5ML **	N010485	001	
HYDROXYZINE HYDROCHLORIDE					
	ALPHARMA US PHARMS	10MG/5ML	A088785	001	Feb 03, 1988
	ANIMA	10MG/5ML	A086880	001	
	APOZEAL PHARMS	10MG/5ML	A210634	001	Feb 26, 2019
	HIKMA	10MG/5ML	A040010	001	Oct 28, 1994
	KV PHARM	10MG/5ML	A087730	001	Jul 01, 1982
	PAI HOLDINGS PHARM	10MG/5ML	A040391	001	Apr 10, 2002
TABLET;ORAL					
ATARAX					
+	PFIZER	10MG **	N010392	001	
+		25MG **	N010392	004	
+		50MG **	N010392	006	
+		100MG **	N010392	005	
HYDROXYZINE HYDROCHLORIDE					
	ABLE	10MG	A040559	001	Jul 22, 2004
		25MG	A040562	001	Jul 22, 2004
		50MG	A040563	001	Jul 22, 2004
	ACTAVIS ELIZABETH	10MG	A089071	001	Jul 22, 1986
		25MG	A089072	001	Jul 22, 1986
		50MG	A089073	001	Jul 22, 1986
	HALSEY	10MG	A089366	001	May 02, 1988
		25MG	A089117	001	May 02, 1988
		50MG	A089396	001	May 02, 1988
	IVAX PHARMS	10MG	A087216	001	
		25MG	A087410	001	
		50MG	A087411	001	
	KV PHARM	10MG	A087819	001	Jun 23, 1982
		25MG	A087820	001	Jun 23, 1982
		50MG	A087821	001	Jun 23, 1982
		100MG	A087822	001	Jun 23, 1982
	MUTUAL PHARM	10MG	A088409	001	Nov 15, 1983
		25MG	A087857	001	Apr 18, 1983
		50MG	A087860	001	Apr 18, 1983
	PLIVA	100MG	A081054	001	Sep 25, 1995
	PUREPAC PHARM	10MG	A088120	001	Sep 25, 1984
		25MG	A088121	001	Sep 25, 1984
		50MG	A088122	001	Sep 25, 1984
	QUANTUM PHARMICS	10MG	A088540	001	Oct 22, 1985
		25MG	A088551	001	Oct 22, 1985
		50MG	A088529	001	Oct 22, 1985
	RISING	10MG	A091176	001	Jun 07, 2010
		25MG	A091176	002	Jun 07, 2010
		50MG	A091176	003	Jun 07, 2010
	SANDOZ	10MG	A087246	002	
		25MG	A085247	001	
		50MG	A087245	001	
	STRIDES PHARMA	10MG	A087602	001	Jan 22, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROXYZINE HYDROCHLORIDE				
TABLET;ORAL				
HYDROXYZINE HYDROCHLORIDE				
	25MG	A087603	001	Jan 22, 1982
	50MG	A087604	001	Jan 22, 1982
SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008
	25MG	A040899	002	Jun 10, 2008
	50MG	A040899	003	Jun 10, 2008
SUN PHARM INDUSTRIES	10MG	A089381	001	May 19, 1986
	25MG	A089382	001	May 19, 1986
	50MG	A089383	001	May 19, 1986
	100MG	A087862	001	Apr 18, 1983
SUPERPHARM	10MG	A088794	001	Dec 05, 1984
	25MG	A088795	001	Dec 05, 1984
	50MG	A088796	001	Dec 05, 1984
USL PHARMA	10MG	A089121	001	Mar 20, 1986
	25MG	A089122	001	Mar 20, 1986
	50MG	A089123	001	Mar 20, 1986
WATSON LABS	10MG	A081149	001	Mar 18, 1994
	10MG	A086827	001	
	10MG	A088348	001	Sep 15, 1983
	25MG	A081150	001	Mar 18, 1994
	25MG	A086829	001	
	25MG	A088349	001	Sep 15, 1983
	50MG	A081151	001	Mar 18, 1994
	50MG	A086836	001	
	50MG	A088350	001	Sep 15, 1983
HYDROXYZINE PAMOATE				
CAPSULE;ORAL				
HY-PAM "25"				
TEVA	EQ 25MG HYDROCHLORIDE	A088713	001	Mar 04, 1985
HYDROXYZINE PAMOATE				
BEXIMCO PHARMS USA	EQ 25MG HYDROCHLORIDE	A081127	001	Jun 28, 1991
DURAMED PHARMS BARR	EQ 25MG HYDROCHLORIDE	A088593	001	Feb 29, 1984
	EQ 50MG HYDROCHLORIDE	A088594	001	Feb 29, 1984
	EQ 100MG HYDROCHLORIDE	A088595	001	Feb 29, 1984
IVAX SUB TEVA PHARMS	EQ 25MG HYDROCHLORIDE	A087761	001	Mar 05, 1982
	EQ 50MG HYDROCHLORIDE	A087760	001	Mar 05, 1982
PAR PHARM	EQ 25MG HYDROCHLORIDE	A087656	001	Jun 11, 1982
	EQ 25MG HYDROCHLORIDE	A089145	001	Mar 17, 1986
	EQ 50MG HYDROCHLORIDE	A087657	001	Jun 11, 1982
	EQ 50MG HYDROCHLORIDE	A089146	001	Mar 17, 1986
	EQ 100MG HYDROCHLORIDE	A087658	001	Jun 11, 1982
SANDOZ	EQ 50MG HYDROCHLORIDE	A081128	001	Jun 28, 1991
	EQ 100MG HYDROCHLORIDE	A081129	001	Jun 28, 1991
SUPERPHARM	EQ 25MG HYDROCHLORIDE	A089031	001	Jan 02, 1987
	EQ 50MG HYDROCHLORIDE	A089032	001	Jan 02, 1987
	EQ 100MG HYDROCHLORIDE	A089033	001	Jan 02, 1987
VANGARD	EQ 25MG HYDROCHLORIDE	A088392	001	Sep 19, 1983
	EQ 50MG HYDROCHLORIDE	A088393	001	Sep 19, 1983
WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991
	EQ 25MG HYDROCHLORIDE	A086698	001	
	EQ 25MG HYDROCHLORIDE	A086840	001	Jul 01, 1982
	EQ 50MG HYDROCHLORIDE	A086695	001	
	EQ 50MG HYDROCHLORIDE	A086705	001	Jul 01, 1982
	EQ 50MG HYDROCHLORIDE	A087767	001	Aug 16, 1982
	EQ 100MG HYDROCHLORIDE	A086697	001	
	EQ 100MG HYDROCHLORIDE	A086728	001	Oct 05, 1982
	EQ 100MG HYDROCHLORIDE	A087790	001	Aug 16, 1982
VISTARIL				
PFIZER	EQ 100MG HYDROCHLORIDE **	N011459	006	
SUSPENSION;ORAL				
VISTARIL				
PFIZER	EQ 25MG HYDROCHLORIDE/5ML	N011795	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IBANDRONATE SODIUM				
INJECTABLE;INTRAVENOUS				
BONIVA				
+	ROCHE	EQ 3MG BASE/3ML **	N021858 001	Jan 06, 2006
IBANDRONATE SODIUM				
	AVET LIFESCIENCES	EQ 3MG BASE/3ML	A203987 001	Sep 02, 2014
	NANG KUANG PHARM CO	EQ 3MG BASE/3ML	A204329 001	Jun 16, 2021
TABLET;ORAL				
BONIVA				
+	HOFFMANN LA ROCHE	EQ 2.5MG BASE **	N021455 001	May 16, 2003
+		EQ 150MG BASE **	N021455 002	Mar 24, 2005
IBANDRONATE SODIUM				
	MYLAN PHARMS INC	EQ 150MG BASE	A078995 001	Mar 19, 2012
	SUN PHARM INDUSTRIES	EQ 150MG BASE	A078996 001	Aug 15, 2012
IBRUTINIB				
CAPSULE;ORAL				
IBRUTINIB				
	ZYDUS	70MG	A211344 001	Mar 31, 2021
		140MG	A211344 002	Mar 31, 2021
TABLET;ORAL				
IMBRUVICA				
+	PHARMACYCLICS LLC	560MG	N210563 004	Feb 16, 2018
IBUPROFEN				
CAPSULE;ORAL				
IBUPROFEN				
	CONTRACT PHARMACAL	200MG	A074782 001	Jul 06, 1998
MIDOL				
	BAYER	200MG **	A070626 001	Sep 02, 1987
		200MG **	A071002 001	Sep 02, 1987
SOLUTION;INTRAVENOUS				
CALDOLOR				
	CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348 001	Jun 11, 2009
SUSPENSION;ORAL				
CHILDREN'S ADVIL				
	GLAXOSMITHKLINE	100MG/5ML	N019833 002	Sep 19, 1989
CHILDREN'S ELIXSURE				
	MOBERG PHARMA NORTH	100MG/5ML	N021604 001	Jan 07, 2004
IBU				
	ABBOTT	100MG/5ML	N019784 001	Dec 18, 1989
IBUPROFEN				
	ARISE	100MG/5ML	A200457 001	Aug 18, 2011
	PAI HOLDINGS PHARM	100MG/5ML	A205647 001	Nov 03, 2016
	STRIDES PHARMA	100MG/5ML	A211666 001	Feb 22, 2021
MOTRIN				
+	MCNEIL CONSUMER	100MG/5ML **	N019842 001	Sep 19, 1989
SUSPENSION/DROPS;ORAL				
IBUPROFEN				
	STRIDES PHARMA	50MG/1.25ML	A214071 001	Jun 09, 2022
MOTRIN				
	MCNEIL	40MG/ML	N020476 001	May 25, 1995
PEDIATRIC ADVIL				
+	GLAXOSMITHKLINE	100MG/2.5ML	N020812 001	Jan 30, 1998
TABLET;ORAL				
ACHES-N-PAIN				
	LEDERLE	200MG	A071065 001	May 28, 1987
CAP-PROFEN				
	PERRIGO	200MG	A072097 001	Dec 08, 1987
IBU				
	BASF	400MG	A070083 001	Feb 22, 1985
		400MG	N018197 001	
		600MG	A070088 001	Feb 08, 1985
		600MG	A070099 001	Mar 29, 1985
		800MG	A070745 001	Jul 23, 1986
IBU-TAB				
	ALRA	400MG	A071058 001	Aug 11, 1988
		600MG	A071059 001	Aug 11, 1988
		800MG	A071965 001	Aug 11, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IBUPROFEN

TABLET;ORAL

IBU-TAB 200				
ALRA	200MG	A071057	001	Aug 11, 1988
IBUPRIN				
PLIVA	200MG	A071773	001	Jul 16, 1987
IBUPROFEN				
ABBOTT	600MG	A070556	001	Jun 14, 1985
	800MG	A071264	001	Jul 25, 1986
ANI PHARMS	200MG	A071144	001	Jan 20, 1987
	200MG	A072901	001	Dec 19, 1991
	200MG	A072903	001	Dec 19, 1991
CONTRACT PHARMACAL	200MG	A071265	001	Oct 15, 1986
	200MG	A071265	002	Sep 10, 1987
	200MG	A071735	001	Sep 10, 1987
	200MG	A073691	001	Feb 25, 1994
	200MG	A074931	001	Jul 20, 1998
HALSEY	200MG	A071027	001	Sep 29, 1987
	300MG	A071028	001	Mar 23, 1987
	400MG	A071029	001	Mar 23, 1987
	600MG	A071030	001	Mar 23, 1987
	800MG	A072137	001	Feb 05, 1988
IVAX SUB TEVA PHARMS	200MG	A071154	001	Oct 27, 1987
	200MG	A072040	001	Apr 29, 1988
	400MG	A071145	001	Sep 23, 1986
	600MG	A071146	001	Sep 23, 1986
	800MG	A071769	001	May 08, 1987
J AND J CONSUMER INC	400MG	A070081	001	Jun 16, 1986
L PERRIGO CO	400MG	A077114	001	Jul 18, 2005
	600MG	A077114	002	Jul 18, 2005
	800MG	A077114	003	Jul 18, 2005
LEDERLE	400MG	A070629	001	Sep 19, 1986
	600MG	A070630	001	Sep 19, 1986
LEINER	300MG	A071266	001	Oct 15, 1986
LNK	100MG	A076741	001	Jun 17, 2004
MCNEIL	600MG	A070476	001	Jun 16, 1986
MERRO PHARM	200MG	A070985	001	Oct 02, 1987
MYLAN	200MG	A071870	001	May 05, 1988
	400MG	A070045	001	Sep 24, 1985
	600MG	A070057	001	Sep 24, 1985
	800MG	A071999	001	Dec 03, 1987
NORTHSTAR HLTHCARE	400MG	A078132	001	Sep 10, 2007
	600MG	A078132	002	Sep 10, 2007
	800MG	A078132	003	Sep 10, 2007
OHM	200MG	A071163	001	Jul 15, 1986
OHM LABS	400MG	A070818	001	Dec 26, 1985
P AND L DEV LLC	200MG	A070733	001	Sep 19, 1986
PAR PHARM	300MG	A070328	001	Aug 06, 1985
PERRIGO	200MG	A072098	001	Dec 08, 1987
	200MG	A075995	001	Mar 14, 2002
PLIVA	400MG	A071666	001	Jun 18, 1987
	600MG	A071667	001	Jun 18, 1987
	800MG	A071668	001	Jun 18, 1987
PUREPAC PHARM	200MG	A071122	001	Oct 03, 1986
	200MG	A071664	001	Feb 03, 1987
	300MG	A071123	001	Sep 19, 1986
	400MG	A071124	001	Sep 19, 1986
	600MG	A071125	001	Sep 19, 1986
	800MG	A071964	001	Feb 01, 1988
RISING	300MG	A070736	002	Jun 12, 1986
	400MG	A070736	003	Jun 12, 1986
	600MG	A070736	001	Jun 12, 1986
	800MG	A071938	001	Jan 14, 1988
SANDOZ	200MG	A071807	001	Feb 25, 1988
	200MG	A074525	001	Dec 15, 1995
	200MG	A074533	001	Dec 15, 1995
	400MG	A072064	001	Jan 14, 1988
	600MG	A072065	001	Jan 14, 1988
	800MG	A072169	001	Dec 11, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IBUPROFEN

TABLET;ORAL					
IBUPROFEN					
STRIDES PHARMA	200MG		A071575	001	May 08, 1987
	400MG		A070329	001	Aug 06, 1985
	600MG		A070330	001	Aug 06, 1985
	800MG		A070986	001	Jul 25, 1986
SUN PHARM INDUSTRIES	200MG		A070493	001	Dec 24, 1985
	200MG		A070908	001	Sep 26, 1986
	200MG		A071462	001	Oct 02, 1986
	400MG		A070079	001	Jul 24, 1985
	600MG		A070080	001	Jul 24, 1985
	800MG		A071448	001	Feb 18, 1987
SUNSHINE	400MG		A204062	001	Sep 10, 2018
	600MG		A204062	002	Sep 10, 2018
	800MG		A204062	003	Sep 10, 2018
SUPERPHARM	600MG		A070709	001	Apr 25, 1986
TEVA	200MG		A073141	001	May 29, 1992
	400MG		A073343	001	Jun 30, 1992
	600MG		A073344	001	Jun 30, 1992
	800MG		A073345	001	Jun 30, 1992
ULTRATAB LABS INC	200MG		A209076	001	Jan 06, 2020
VINTAGE PHARMS	200MG		A071639	001	Feb 02, 1988
	200MG		A072249	001	Jan 10, 1989
	300MG		A071230	001	Oct 22, 1986
	400MG		A071231	001	Oct 22, 1986
	400MG		A071644	001	Feb 01, 1988
	600MG		A071232	001	Oct 22, 1986
	800MG		A072004	001	Nov 18, 1987
WATSON LABS	200MG		A070435	001	Mar 05, 1986
	200MG		A071765	001	Sep 04, 1987
	200MG		A071905	001	Mar 08, 1988
	300MG		A071338	001	Dec 01, 1986
	400MG		A070038	001	Sep 06, 1985
	400MG		A070436	001	Aug 21, 1985
	600MG		A070041	001	Sep 06, 1985
	600MG		A070437	001	Aug 21, 1985
	800MG		A071547	001	Jul 02, 1987
	800MG		A071911	001	Oct 13, 1987
YICHANG HUMANWELL	200MG		A214003	001	Oct 19, 2020
IBUPROHM					
OHM LABS	200MG		A071214	001	Dec 01, 1986
	400MG		A070469	001	Aug 29, 1985
JUNIOR STRENGTH IBUPROFEN					
L PERRIGO CO	100MG		A075367	001	Apr 22, 1999
MEDIPREN					
MCNEIL	200MG		A070475	001	Feb 06, 1986
	200MG		A071215	001	Jun 26, 1986
MIDOL					
BAYER	200MG		A070591	001	Sep 02, 1987
	200MG		A071001	001	Sep 02, 1987
MOTRIN					
+ MCNEIL CONSUMER	300MG	**	N017463	003	
+	400MG	**	N017463	002	
+	600MG	**	N017463	004	
+	800MG	**	N017463	005	May 22, 1985
MCNEIL PED	100MG		N020418	001	Nov 16, 1994
MOTRIN MIGRAINE PAIN					
J AND J CONSUMER INC	200MG		N019012	004	Feb 25, 2000
NUPRIN					
BRISTOL MYERS	200MG		A072035	001	Feb 16, 1988
	200MG		A072036	001	Feb 16, 1988
J AND J CONSUMER INC	200MG		N019012	001	May 18, 1984
	200MG		N019012	002	Jul 29, 1987
RUFEN					
BASF	600MG		N018197	002	Mar 05, 1984
TAB-PROFEN					
PERRIGO	200MG		A072095	001	Dec 08, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IBUPROFEN
TABLET, CHEWABLE;ORAL
CHILDREN'S MOTRIN
+ J AND J CONSUMER INC 50MG N020601 001 Nov 15, 1996
IBUPROFEN
PERRIGO 50MG A076359 001 Jan 16, 2004
JUNIOR STRENGTH MOTRIN
+ J AND J CONSUMER INC 100MG N020601 003 Nov 15, 1996
MOTRIN
MCNEIL PED 50MG N020135 001 Nov 16, 1994
100MG N020135 002 Nov 16, 1994

IBUPROFEN SODIUM
TABLET;ORAL
IBUPROFEN SODIUM
PERRIGO R AND D EQ 200MG BASE A206581 001 Aug 03, 2015

IBUPROFEN; OXYCODONE HYDROCHLORIDE
TABLET;ORAL
COMBUNOX
+ FOREST LABS 400MG;5MG ** N021378 001 Nov 26, 2004
OXYCODONE HYDROCHLORIDE AND IBUPROFEN
ACTAVIS ELIZABETH 400MG;5MG A078769 001 Jan 04, 2008
BARR LABS INC 400MG;5MG A078316 001 Nov 29, 2007
WATSON LABS 400MG;5MG A078394 001 Nov 26, 2007

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
SUSPENSION;ORAL
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
PERRIGO 100MG/5ML;15MG/5ML A076478 001 Nov 05, 2003
TABLET;ORAL
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
AUROBINDO PHARMA LTD 200MG;30MG A213565 001 Mar 10, 2023
CONTRACT PHARMACAL 200MG;30MG A075588 001 Apr 08, 2002

IBUTILIDE FUMARATE
INJECTABLE;INJECTION
IBUTILIDE FUMARATE
LUITPOLD 0.1MG/ML A090240 001 Jan 11, 2010
MYLAN INSTITUTIONAL 0.1MG/ML A090924 001 Jan 11, 2010

ICATIBANT ACETATE
INJECTABLE;SUBCUTANEOUS
ICATIBANT ACETATE
DR REDDYS EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A213054 001 Oct 05, 2020
GLENMARK PHARMS LTD EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A213222 001 May 21, 2021

IDARUBICIN HYDROCHLORIDE
INJECTABLE;INJECTION
IDAMYCIN
PFIZER 5MG/VIAL N050661 002 Sep 27, 1990
10MG/VIAL N050661 001 Sep 27, 1990
20MG/VIAL N050661 003 Apr 25, 1995
IDARUBICIN HYDROCHLORIDE
FRESENIUS KABI USA 1MG/ML A065440 001 Aug 04, 2009
MYLAN LABS LTD 1MG/ML A200144 001 Oct 11, 2012
SANDOZ 1MG/ML A091293 001 Mar 29, 2011
TEVA PARENTERAL 5MG/VIAL A065037 003 May 01, 2002
10MG/VIAL A065037 002 May 01, 2002
20MG/VIAL A065037 001 May 01, 2002

IDOXURIDINE
OINTMENT;OPHTHALMIC
STOXIL
GLAXOSMITHKLINE 0.5% N015868 001
SOLUTION/DROPS;OPHTHALMIC
DENDRID
+ ALCON 0.1% N014169 001
HERPLEX
ALLERGAN 0.1% N013935 002
STOXIL
GLAXOSMITHKLINE 0.1% N013934 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IFOSFAMIDE				
INJECTABLE;INJECTION				
IFOSFAMIDE				
FRESENIUS KABI USA	1GM/20ML (50MG/ML)	A090181	001	Sep 22, 2009
	3GM/60ML (50MG/ML)	A090181	002	Sep 22, 2009
MYLAN LABS LTD	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012
	3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012
IFOSFAMIDE; MESNA				
INJECTABLE;INJECTION				
IFEX/MESNEX KIT				
BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N019763	003	Oct 10, 1992
	3GM/VIAL;100MG/ML	N019763	004	Oct 10, 1992
INJECTABLE;INTRAVENOUS				
IFOSFAMIDE/MESNA KIT				
TEVA PHARMS USA	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	001	Feb 26, 2002
	3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	002	Feb 26, 2002
ILOPERIDONE				
TABLET;ORAL				
ILOPERIDONE				
INVENTIA	1MG	A207231	001	Nov 28, 2016
	2MG	A207231	002	Nov 28, 2016
	4MG	A207231	003	Nov 28, 2016
	6MG	A207231	004	Nov 28, 2016
	8MG	A207231	005	Nov 28, 2016
	10MG	A207231	006	Nov 28, 2016
	12MG	A207231	007	Nov 28, 2016
LUPIN LTD	1MG	A206890	001	May 05, 2022
	2MG	A206890	002	May 05, 2022
	4MG	A206890	003	May 05, 2022
	6MG	A206890	004	May 05, 2022
	8MG	A206890	005	May 05, 2022
	10MG	A206890	006	May 05, 2022
	12MG	A206890	007	May 05, 2022
TARO	1MG	A207098	001	Jul 22, 2019
	2MG	A207098	002	Jul 22, 2019
	4MG	A207098	003	Jul 22, 2019
	6MG	A207098	004	Jul 22, 2019
	8MG	A207098	005	Jul 22, 2019
	10MG	A207098	006	Jul 22, 2019
	12MG	A207098	007	Jul 22, 2019
ILOPROST				
SOLUTION;INHALATION				
VENTAVIS				
ACTELION	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004
IMATINIB MESYLATE				
CAPSULE;ORAL				
GLEEVEC				
+ NOVARTIS	EQ 50MG BASE **	N021335	001	May 10, 2001
+	EQ 100MG BASE **	N021335	002	May 10, 2001
TABLET;ORAL				
IMATINIB MESYLATE				
AMNEAL PHARMS	EQ 100MG BASE	A207495	001	Feb 08, 2019
	EQ 400MG BASE	A207495	002	Feb 08, 2019
BRECKENRIDGE	EQ 100MG BASE	A205990	001	Feb 08, 2019
	EQ 400MG BASE	A205990	002	Feb 08, 2019
HIKMA	EQ 100MG BASE	A207586	001	Jul 13, 2018
	EQ 400MG BASE	A207586	002	Jul 13, 2018
IMIPRAMINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
IMIPRAMINE HYDROCHLORIDE				
NOVARTIS	25MG/ML	A086765	001	
INJECTABLE;INJECTION				
TOFRANIL				
NOVARTIS	12.5MG/ML	N011838	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL				
IMIPRAMINE HYDROCHLORIDE				
CHARTWELL	10MG	A090441	002	Mar 11, 2010
	25MG	A090441	003	Mar 11, 2010
	50MG	A090441	001	Mar 11, 2010
LEDERLE	10MG	A086269	001	
	25MG	A086267	001	
	50MG	A086268	001	
PAR PHARM	10MG	A089422	001	Jul 14, 1987
	25MG	A089497	001	Jul 14, 1987
ROXANE	10MG	A083799	001	
	25MG	A083799	002	
	50MG	A083799	003	
SANDOZ	10MG	A085200	001	
	25MG	A084869	002	
	50MG	A085133	001	
SUN PHARM INDUSTRIES	10MG	A081048	001	Jun 05, 1990
TEVA	10MG	A083729	001	
	25MG	A083729	004	
	50MG	A083729	003	
USL PHARMA	25MG	A087776	001	Feb 10, 1982
VANGARD	10MG	A088036	001	Nov 03, 1982
	25MG	A087619	001	Feb 09, 1982
	50MG	A087631	001	Jan 04, 1982
WATSON LABS	10MG	A085220	001	
	10MG	A085875	001	
	25MG	A084252	002	
	25MG	A085878	001	
	50MG	A085221	001	
	50MG	A085877	001	
WEST WARD	25MG	A088222	001	May 26, 1983
	50MG	A088223	001	May 26, 1983
JANIMINE				
ABBOTT	10MG	N017895	001	
	25MG	N017895	002	
	50MG	N017895	003	
PRAMINE				
ALRA	10MG	A083827	001	
	25MG	A083827	002	
	50MG	A083827	003	
PRESAMINE				
SANOFI AVENTIS US	10MG	N011836	006	
	25MG	N011836	003	
	50MG	N011836	007	

IMIPRAMINE PAMOATE

CAPSULE;ORAL				
IMIPRAMINE PAMOATE				
RISING	EQ 75MG HYDROCHLORIDE	A202338	001	Jun 28, 2013
	EQ 100MG HYDROCHLORIDE	A202338	002	Jun 28, 2013
	EQ 125MG HYDROCHLORIDE	A202338	003	Jun 28, 2013
	EQ 150MG HYDROCHLORIDE	A202338	004	Jun 28, 2013
TOFRANIL-PM				
+ SPECGX LLC	EQ 75MG HYDROCHLORIDE **	N017090	001	
+	EQ 100MG HYDROCHLORIDE **	N017090	004	
+	EQ 125MG HYDROCHLORIDE **	N017090	003	
+	EQ 150MG HYDROCHLORIDE **	N017090	002	

IMIQUIMOD

CREAM;TOPICAL				
ALDARA				
+ BAUSCH	5%	N020723	001	Feb 27, 1997
IMIQUIMOD				
COSETTE	5%	A200481	001	Apr 18, 2011
ENCUBE	5%	A091044	001	Feb 28, 2011
STRIDES PHARMA	5%	A202002	001	Jun 24, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INAMRINONE LACTATE				
INJECTABLE;INJECTION				
AMRINONE LACTATE				
	BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A075542 001	May 10, 2000
	HOSPIRA	EQ 5MG BASE/ML	A074616 001	Aug 03, 1998
INOCOR				
	SANOFI AVENTIS US	EQ 5MG BASE/ML	N018700 001	Jul 31, 1984
INDACATEROL MALEATE				
POWDER;INHALATION				
ARCAPTA NEOHALER				
+	NOVARTIS	EQ 75MCG BASE	N022383 001	Jul 01, 2011
INDAPAMIDE				
TABLET;ORAL				
INDAPAMIDE				
	ANI PHARMS	1.25MG	A074498 002	Feb 12, 1998
		1.25MG	A075201 001	Dec 04, 1998
		2.5MG	A074498 001	Oct 31, 1996
		2.5MG	A075201 002	Dec 04, 1998
	AUROBINDO PHARMA USA	1.25MG	A075105 001	Jul 23, 1998
		2.5MG	A075105 002	Jul 23, 1998
	CHARTWELL RX	1.25MG	A074594 001	May 23, 1996
		2.5MG	A074594 002	May 23, 1996
	TEVA	1.25MG	A074665 001	Apr 04, 1997
		2.5MG	A074665 002	Apr 04, 1997
	WATSON LABS	1.25MG	A074585 001	Sep 26, 1996
		2.5MG	A074585 002	Sep 26, 1996
LOZOL				
+	SANOFI AVENTIS US	1.25MG **	N018538 002	Apr 29, 1993
+		2.5MG **	N018538 001	Jul 06, 1983
INDECAINIDE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
DECABID				
	LILLY	EQ 50MG BASE	N019693 001	Dec 29, 1989
		EQ 75MG BASE	N019693 002	Dec 29, 1989
		EQ 100MG BASE	N019693 003	Dec 29, 1989
INDINAVIR SULFATE				
CAPSULE;ORAL				
CRIXIVAN				
	MERCK SHARP DOHME	EQ 100MG BASE	N020685 006	Apr 19, 2000
+		EQ 200MG BASE	N020685 003	Mar 13, 1996
		EQ 333MG BASE	N020685 005	Dec 17, 1998
+		EQ 400MG BASE	N020685 001	Mar 13, 1996
INDIUM IN-111 CHLORIDE				
INJECTABLE;INJECTION				
INDICLOR				
+	GE HEALTHCARE	2mCi/0.2ML	N019862 001	Dec 29, 1992
INDOCYANINE GREEN				
INJECTABLE;INJECTION				
IC-GREEN				
	RENEW PHARMS	10MG/VIAL **	N011525 003	
+		25MG/VIAL	N011525 001	
		40MG/VIAL **	N011525 004	
		50MG/VIAL **	N011525 002	
INDOMETHACIN				
CAPSULE;ORAL				
INDO-LEMMON				
	TEVA	25MG	A070266 001	Nov 07, 1985
		50MG	A070267 001	Nov 07, 1985
INDOCIN				
+	ZYLA LIFE SCIENCES	25MG **	N016059 001	
+		50MG **	N016059 002	
INDOMETHACIN				
	ABLE	25MG	A076666 001	Dec 17, 2003
		50MG	A076666 002	Dec 17, 2003
	ANI PHARMS	25MG	A071148 001	Mar 18, 1987
		50MG	A071149 001	Mar 18, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INDOMETHACIN

CAPSULE;ORAL					
INDOMETHACIN					
	CYCLE	25MG	A070353	001	Jun 18, 1985
		50MG	A070354	001	Jun 18, 1985
	DURAMED PHARMS BARR	25MG	A070326	001	Oct 18, 1985
		50MG	A070327	001	Oct 18, 1985
	HALSEY	25MG	A070782	001	Jun 03, 1987
		50MG	A070635	001	Jun 03, 1987
	HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986
		50MG	A070756	001	Feb 12, 1986
	HERITAGE PHARMS	25MG	N018851	001	May 18, 1984
		50MG	N018851	002	May 18, 1984
	IVAX SUB TEVA PHARMS	25MG	N018730	001	May 04, 1984
		50MG	N018730	002	May 04, 1984
	JUBILANT GENERICS	25MG	A205215	001	Aug 25, 2017
		50MG	A205215	002	Aug 25, 2017
	MUTUAL PHARM	25MG	A070067	001	Oct 03, 1986
		50MG	A070068	001	Oct 03, 1986
	PARKE DAVIS	25MG	N018806	001	Nov 23, 1984
		50MG	N018806	002	Nov 23, 1984
	PIONEER PHARMS	25MG	A070813	001	Aug 11, 1986
		50MG	A070592	001	Aug 11, 1986
	RISING	25MG	N018858	001	Apr 20, 1984
		50MG	A070624	001	Sep 04, 1985
		50MG	N018858	002	Apr 20, 1984
	SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013
		50MG	A091401	002	Mar 28, 2013
	SUN PHARM INDUSTRIES	25MG	A070900	002	Feb 09, 1987
		50MG	A070900	001	Feb 09, 1987
	SUPERPHARM	25MG	A070487	001	Oct 10, 1986
		50MG	A070488	001	Oct 10, 1986
	TEVA	25MG	A071342	001	Apr 18, 1988
		50MG	A071343	001	Apr 18, 1988
	WATSON LABS	25MG	A070529	001	Oct 18, 1985
		25MG	A070784	001	Aug 20, 1986
		25MG	A072996	001	Jul 31, 1991
		25MG	N018690	001	Jul 31, 1984
		50MG	A070530	001	Oct 18, 1985
		50MG	A070785	001	Aug 20, 1986
		50MG	A071635	001	May 18, 1987
		50MG	A072997	001	Jul 31, 1991
		50MG	N018690	002	Jul 31, 1984
TIVORBEX					
+	GENUS	20MG	N204768	001	Feb 24, 2014
+		40MG	N204768	002	Feb 24, 2014
CAPSULE, EXTENDED RELEASE;ORAL					
INDOCIN SR					
+	ZYLA	75MG **	N018185	001	Feb 23, 1982
INDOMETHACIN					
	ABLE	75MG	A076114	001	Feb 06, 2002
	AUROBINDO PHARMA	75MG	A204243	001	Dec 27, 2016
	INWOOD LABS	75MG	A072410	001	Mar 15, 1989
	JUBILANT GENERICS	75MG	A202706	001	Oct 05, 2015
	RISING	75MG	A202139	001	Mar 20, 2014
	SANDOZ	75MG	A074464	001	May 28, 1998
	WATSON LABS INC	75MG	A202572	001	Dec 09, 2013
SUPPOSITORY;RECTAL					
INDOCIN					
+	ZYLA LIFE SCIENCES	50MG **	N017814	001	Aug 13, 1984
SUSPENSION;ORAL					
INDOMETHACIN					
	HIKMA	25MG/5ML	A071412	001	Mar 18, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INDOMETHACIN SODIUM				
INJECTABLE;INJECTION				
INDOCIN				
+	RECORDATI RARE	EQ 1MG BASE/VIAL **	N018878 001	Jan 30, 1985
INFIGRATINIB PHOSPHATE				
CAPSULE;ORAL				
TRUSELTIQ				
+	HELSINN HLTHCARE	25MG	N214622 001	May 28, 2021
+		100MG	N214622 002	May 28, 2021
INGENOL MEBUTATE				
GEL;TOPICAL				
INGENOL MEBUTATE				
	PADAGIS ISRAEL	0.015%	A209018 001	Jan 07, 2019
		0.05%	A209019 001	Jan 09, 2019
PICATO				
+	LEO LABS	0.015%	N202833 001	Jan 23, 2012
+		0.05%	N202833 002	Jan 23, 2012
INULIN				
INJECTABLE;INJECTION				
INULIN AND SODIUM CHLORIDE				
	ISO TEX	100MG/ML	N002282 001	
INVERT SUGAR				
INJECTABLE;INJECTION				
TRAVERT 10% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	10GM/100ML	N016717 001	
IOBENGUANE SULFATE I-131				
INJECTABLE;INJECTION				
IOBENGUANE SULFATE I 131				
	PHARMALUCENCE	2.3mCi/ML	N020084 001	Mar 25, 1994
IOCETAMIC ACID				
TABLET;ORAL				
CHOLEBRINE				
	MALLINCKRODT	750MG	N017129 001	
IODAMIDE MEGLUMINE				
INJECTABLE;INJECTION				
RENOVUE-65				
	BRACCO	65%	N017902 001	
RENOVUE-DIP				
	BRACCO	24%	N017903 001	
IODIPAMIDE MEGLUMINE				
INJECTABLE;INJECTION				
CHOLOGRAFIN MEGLUMINE				
	BRACCO	10.3%	N009321 007	
+		52%	N009321 003	
IODIPAMIDE SODIUM				
INJECTABLE;INJECTION				
CHOLOGRAFIN SODIUM				
	BRACCO	20%	N009321 001	
IODIXANOL				
INJECTABLE;INJECTION				
VISIPAQUE 270				
	GE HEALTHCARE	55%	N020808 001	Aug 29, 1997
IODOHIPPURATE SODIUM I-123				
INJECTABLE;INJECTION				
NEPHROFLOW				
	GE HEALTHCARE	1mCi/ML	N018289 001	Dec 28, 1984
IODOHIPPURATE SODIUM I-131				
INJECTABLE;INJECTION				
HIPPURAN I 131				
	MALLINCKRODT	0.25mCi/ML	N016666 001	
HIPPUTOPE				
	BRACCO	1-2mCi/VIAL	N015419 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IODOHIPPURATE SODIUM I-131
INJECTABLE;INJECTION
IODOHIPPURATE SODIUM I 131

PHARMALUCENCE	0.2mCi/ML	N017313	001	

IODOXAMATE MEGLUMINE
INJECTABLE;INJECTION
CHOLOVUE

BRACCO	9.9%	N018077	001	
	40.3%	N018076	001	

IOFETAMINE HYDROCHLORIDE I-123
INJECTABLE;INJECTION
SPECTAMINE

IMP	1mCi/ML	N019432	001	Dec 24, 1987

IOHEXOL
FOR SOLUTION;ORAL
ORALTAG

INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015

INJECTABLE;INJECTION
OMNIPAQUE 210

GE HEALTHCARE	45.3%	N018956	006	Jun 30, 1989

SOLUTION;INJECTION, ORAL, RECTAL
OMNIPAQUE 240

GE HEALTHCARE	51.8%	N020608	001	Oct 24, 1995

SOLUTION;URETHRAL
OMNIPAQUE 70

GE HEALTHCARE	15.1%	N018956	007	Jun 01, 1994

IOPAMIDOL
INJECTABLE;INJECTION
IOPAMIDOL

BAXTER HLTHCARE	41%	A074629	001	Nov 06, 1996
	51%	A074629	004	Mar 31, 1998
	61%	A074629	002	Nov 06, 1996
	76%	A074629	003	Nov 06, 1996
HOSPIRA	61%	A074734	001	Dec 10, 1996
	76%	A074734	002	Dec 10, 1996

IOPAMIDOL-200

COOK IMAGING	41%	A074881	001	Jul 28, 2000
HOSPIRA	41%	A074898	001	Dec 30, 1997

IOPAMIDOL-200 IN PLASTIC CONTAINER

HOSPIRA	41%	A074636	001	Dec 30, 1997

IOPAMIDOL-250

COOK IMAGING	51%	A074881	002	Jul 28, 2000
FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997
HOSPIRA	51%	A074898	002	Dec 30, 1997
	51%	A075005	001	Feb 24, 1998

IOPAMIDOL-250 IN PLASTIC CONTAINER

HOSPIRA	51%	A074636	002	Dec 30, 1997

IOPAMIDOL-300

ABBVIE	61%	A074638	001	Apr 30, 1997
COOK IMAGING	61%	A074881	003	Jul 28, 2000
FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997
HOSPIRA	61%	A074898	003	Dec 30, 1997
	61%	A075005	002	Feb 24, 1998

IOPAMIDOL-300 IN PLASTIC CONTAINER

HOSPIRA	61%	A074636	003	Dec 30, 1997
	61%	A074637	001	Apr 03, 1997

IOPAMIDOL-370

COOK IMAGING	76%	A074881	004	Jul 28, 2000
FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997
HOSPIRA	76%	A074898	004	Dec 30, 1997
	76%	A075005	003	Feb 24, 1998

IOPAMIDOL-370 IN PLASTIC CONTAINER

HOSPIRA	76%	A074636	004	Dec 30, 1997

ISOVUE-128

BRACCO	26%	N018735	005	Oct 21, 1986

ISOVUE-200

BRACCO	41%	N020327	001	Oct 12, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IOPAMIDOL
INJECTABLE;INJECTION
ISOVUE-250
+ BRACCO 51% N020327 002 Oct 12, 1994
SCANLUX-300
SANOCHEMIA CORP USA 61% A090394 001 Jun 18, 2010
SCANLUX-370
SANOCHEMIA CORP USA 76% A090394 002 Jun 18, 2010

IOPANOIC ACID
TABLET;ORAL
TELEPAQUE
GE HEALTHCARE 500MG N008032 001

IOPHENDYLATE
INJECTABLE;INJECTION
PANTOPAQUE
ALCON 100% N005319 001

IOPROMIDE
INJECTABLE;INJECTION
ULTRAVIST (PHARMACY BULK)
+ BAYER HLTHCARE 49.9% N021425 003 Mar 12, 2004
ULTRAVIST 150
+ BAYER HLTHCARE 31.2% N020220 004 May 10, 1995
ULTRAVIST 240
+ BAYER HLTHCARE 49.9% N020220 003 May 10, 1995
ULTRAVIST 300 IN PLASTIC CONTAINER
+ BAYER HLTHCARE 62.3% N020220 005 Nov 18, 2008

IOTHALAMATE MEGLUMINE
INJECTABLE;INJECTION
CONRAY 30
+ LIEBEL-FLARSHEIM 30% N016983 001
CONRAY 43
+ LIEBEL-FLARSHEIM 43% N013295 002

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM
INJECTABLE;INJECTION
VASCORAY
MALLINCKRODT 52%;26% N016783 001

IOTHALAMATE SODIUM
INJECTABLE;INJECTION
ANGIO-CONRAY
MALLINCKRODT 80% N013319 001
CONRAY 325
MALLINCKRODT 54.3% N017685 001
CONRAY 400
MALLINCKRODT 66.8% N014295 001

IOTROLAN
INJECTABLE;INTRATHECAL
OSMOVIST 190
BAYER HLTHCARE 40.6% N019580 001 Dec 07, 1989
OSMOVIST 240
BAYER HLTHCARE 51.3% N019580 002 Dec 07, 1989

IOVERSOL
INJECTABLE;INJECTION
OPTIRAY 160
LIEBEL-FLARSHEIM 34% N019710 003 Dec 30, 1988
OPTIRAY 240
+ LIEBEL-FLARSHEIM 51% N019710 002 Dec 30, 1988
51% N020923 001 May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM
INJECTABLE;INJECTION
HEXABRIX
GUERBET 39.3%;19.6% N018905 002 Jul 26, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IOXILAN

INJECTABLE;INJECTION				
OXILAN-300				
GUERBET	62%	N020316	001	Dec 21, 1995
OXILAN-350				
GUERBET	73%	N020316	002	Dec 21, 1995

IPODATE CALCIUM

GRANULE;ORAL				
ORAGRAFIN CALCIUM				
BRACCO	3GM/PACKET	N012968	001	

IPODATE SODIUM

CAPSULE;ORAL				
BILIVIST				
BAYER HLTHCARE	500MG	A087768	001	Aug 11, 1982
ORAGRAFIN SODIUM				
BRACCO	500MG	N012967	001	

IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION				
ATROVENT				
BOEHRINGER INGELHEIM	0.018MG/INH	N019085	001	Dec 29, 1986
SOLUTION;INHALATION				
ATROVENT				
+ BOEHRINGER INGELHEIM	0.02% **	N020228	001	Sep 29, 1993
IPRATROPIUM BROMIDE				
ACTAVIS MID ATLANTIC	0.02%	A075111	001	Apr 22, 1999
APOTEX INC	0.02%	A075441	001	Mar 28, 2001
BAUSCH	0.02%	A075835	001	Oct 15, 2001
LANDELA PHARM	0.02%	A077072	001	Jul 19, 2005
MYLAN SPECIALITY LP	0.02%	A074755	001	Jan 10, 1997
ROXANE	0.02%	A075867	001	Jul 22, 2002
TEVA PHARMS USA	0.02%	A075313	001	Feb 07, 2000
WATSON LABS	0.02%	A076291	001	May 09, 2005
ZENNOVA	0.02%	A075507	001	Jan 19, 2001
SPRAY, METERED;NASAL				
ATROVENT				
+ BOEHRINGER INGELHEIM	0.021MG/SPRAY **	N020393	001	Oct 20, 1995
+	0.042MG/SPRAY **	N020394	001	Oct 20, 1995
IPRATROPIUM BROMIDE				
AUROBINDO PHARMA USA	0.021MG/SPRAY	A075552	001	Mar 31, 2003
	0.042MG/SPRAY	A075553	001	Mar 31, 2003

IRBESARTAN

TABLET;ORAL				
IRBESARTAN				
AJANTA PHARMA LTD	75MG	A203685	001	Dec 10, 2015
	150MG	A203685	002	Dec 10, 2015
	300MG	A203685	003	Dec 10, 2015
APOTEX INC	75MG	A200832	001	Oct 15, 2012
	150MG	A200832	002	Oct 15, 2012
	300MG	A200832	003	Oct 15, 2012
CHARTWELL RX	75MG	A203161	001	Sep 27, 2012
	150MG	A203161	002	Sep 27, 2012
	300MG	A203161	003	Sep 27, 2012
HIKMA	75MG	A090201	001	Oct 15, 2012
	150MG	A090201	002	Oct 15, 2012
	300MG	A090201	003	Oct 15, 2012
UPSHER SMITH LABS	75MG	A200461	001	Sep 27, 2012
	150MG	A200461	002	Sep 27, 2012
	300MG	A200461	003	Sep 27, 2012
WATSON LABS INC	75MG	A090720	001	Oct 12, 2012
	150MG	A090720	002	Oct 12, 2012
	300MG	A090720	003	Oct 12, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION					
IRINOTECAN HYDROCHLORIDE					
	CHARTWELL RX	40MG/2ML (20MG/ML)	A078953	001	Apr 15, 2010
		100MG/5ML (20MG/ML)	A078953	002	Apr 15, 2010
	CIPLA LTD	40MG/2ML (20MG/ML)	A077219	001	Feb 20, 2008
		100MG/5ML (20MG/ML)	A077219	002	Feb 20, 2008
	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771	001	Feb 14, 2012
		100MG/5ML (20MG/ML)	A200771	002	Feb 14, 2012
	FRESENIUS KABI USA	40MG/2ML (20MG/ML)	A078188	001	Feb 27, 2008
		100MG/5ML (20MG/ML)	A078188	002	Feb 27, 2008
	PLIVA LACHEMA	40MG/2ML (20MG/ML)	A078122	001	Oct 31, 2008
		100MG/5ML (20MG/ML)	A078122	002	Oct 31, 2008
	SANDOZ	40MG/2ML (20MG/ML)	A077994	001	Feb 27, 2008
		40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009
		100MG/5ML (20MG/ML)	A077994	002	Feb 27, 2008
		100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009
	SUN PHARMA GLOBAL	40MG/2ML (20MG/ML)	A078805	001	Apr 21, 2008
		100MG/5ML (20MG/ML)	A078805	002	Apr 21, 2008
	TEVA PHARMS USA	40MG/2ML (20MG/ML)	A090101	002	Feb 27, 2008
		100MG/5ML (20MG/ML)	A090101	003	Feb 27, 2008

ISOETHARINE HYDROCHLORIDE

SOLUTION;INHALATION					
BETA-2					
	NEPHRON	1%	A086711	001	
BRONKOSOL					
	SANOFI AVENTIS US	0.25%	N012339	009	
		1%	N012339	008	
ISOETHARINE HYDROCHLORIDE					
	ALPHARMA US PHARMS	1%	A087101	001	
+	ASTRAZENECA	0.062%	A087937	001	Nov 15, 1982
		0.062%	A089614	001	Jun 13, 1991
+		0.125%	A087938	001	Nov 15, 1982
		0.125%	A089615	001	Jun 13, 1991
+		0.167%	A088470	001	Mar 14, 1984
		0.167%	A089616	001	Jun 13, 1991
+		0.2%	A088471	001	Mar 14, 1984
		0.2%	A089617	001	Jun 13, 1991
+		0.25%	A088472	001	Mar 14, 1984
		0.25%	A089618	001	Jun 13, 1991
	BAXTER HLTHCARE	0.08%	A088144	001	Jul 29, 1983
		0.14%	A088145	001	Mar 26, 1984
		0.25%	A088146	001	Aug 01, 1983
	DEY	0.08%	A088187	001	Dec 03, 1982
		0.1%	A087389	001	
		0.17%	A087390	001	
		0.25%	A088188	001	Dec 03, 1982
+		1%	A086763	001	
	INTL MEDICATION	0.077%	A086651	001	
		0.08%	A086651	002	
		0.1%	A086651	003	
		0.143%	A086651	004	
		0.167%	A086651	005	
		0.2%	A086651	006	
		0.25%	A086651	007	
		1%	A086651	008	
	PARKE DAVIS	0.5%	A085997	001	
		1%	A085889	001	
	ROXANE	0.1%	A087396	001	
		0.125%	A087025	001	
		0.167%	A088226	001	Sep 16, 1983
		0.2%	A087324	001	
		0.25%	A088275	001	Jun 03, 1983
		1%	A086899	001	
ISOETHARINE HYDROCHLORIDE S/F					
	DEY	0.08%	A089817	001	Nov 22, 1988
		0.1%	A089818	001	Nov 22, 1988
		0.17%	A089819	001	Nov 22, 1988
		0.25%	A089820	001	Nov 22, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISOETHARINE HYDROCHLORIDE				
SOLUTION;INHALATION				
ISOETHARINE HYDROCHLORIDE S/F				
	1%	A089252	001	Sep 15, 1986
ISOETHARINE MESYLATE				
AEROSOL, METERED;INHALATION				
BRONKOMETER				
SANOFI AVENTIS US	0.34MG/INH	N012339	007	
ISOETHARINE MESYLATE				
ALPHARMA US PHARMS	0.34MG/INH	A087858	001	Aug 21, 1984
ISOFLURANE				
LIQUID;INHALATION				
ISOFLURANE				
HOSPIRA	99.9%	A074097	001	Jan 25, 1993
WATSON LABS INC	99.9%	A074393	001	May 12, 1995
ISOFLUROPHATE				
OINTMENT;OPHTHALMIC				
FLOROPRYL				
MERCK	0.025%	N010656	001	
ISONIAZID				
INJECTABLE;INJECTION				
NYDRAZID				
SANDOZ	100MG/ML **	N008662	001	
RIMIFON				
ROCHE	25MG/ML	N008420	002	
	100MG/ML	N008420	003	
SYRUP;ORAL				
ISONIAZID				
CHARTWELL RX	50MG/5ML	A081118	001	Jul 21, 1997
LANIAZID				
LANNETT	50MG/5ML	A089243	001	Feb 03, 1986
RIMIFON				
ROCHE	50MG/5ML	N008420	001	
TABLET;ORAL				
DOW-ISONIAZID				
DOW PHARM	300MG	A080330	002	
HYZYD				
MEDPOINTE PHARM HLC	100MG	A080134	003	
	300MG	A080134	004	
INH				
NOVARTIS	300MG	A080935	001	
ISONIAZID				
DURAMED PHARMS BARR	100MG	A088231	001	Mar 17, 1983
	300MG	A088119	001	Mar 17, 1983
+ EPIC PHARMA LLC	100MG **	N008678	002	
+	300MG **	N008678	003	
HALSEY	50MG	A083632	001	
HIKMA INTL PHARMS	100MG	A080212	001	
	300MG	A087425	001	
IMPAX LABS	100MG	A080153	001	
IVAX SUB TEVA PHARMS	100MG	A080270	001	
	300MG	A083610	001	
LILLY	100MG	N008499	002	
	300MG	N008499	003	
MK LABS	100MG	A080941	001	
NEXGEN PHARMA INC	100MG	A084050	001	
PANRAY	50MG	N008428	001	
	100MG	N008428	002	
	300MG	N008428	003	
PERRIGO	100MG	A083060	001	
PHARMAVITE	100MG	A085091	001	
PHOENIX LABS NY	50MG	A080368	001	
	100MG	A080368	002	
PUREPAC PHARM	50MG	A080132	003	Jul 14, 1982
	100MG	A080132	004	Jul 14, 1982
SUN PHARM INDUSTRIES	100MG	A080136	001	
	300MG	A083633	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISONIAZID				
TABLET;ORAL				
ISONIAZID				
	WATSON LABS	50MG	A080522 001	
		100MG	A080401 001	
		100MG	A080523 001	
		100MG	A085790 001	
		300MG	A080521 001	
		300MG	A083178 001	
		300MG	A085784 001	
	WHITEWORTH TOWN PLSN	100MG	A080120 002	
LANIAZID				
	CHARTWELL MOLECULAR	50MG	A080140 001	
		100MG	A080140 002	
		300MG	A089776 001	Jun 13, 1988
NYDRAZID				
	BRISTOL MYERS SQUIBB	100MG	N008392 003	
STANOZIDE				
	EVERYLIFE	100MG	A080126 001	
		300MG	A080126 002	
ISONIAZID; PYRAZINAMIDE; RIFAMPIN				
TABLET;ORAL				
RIFATER				
+	SANOFI AVENTIS US	50MG;300MG;120MG	N050705 001	May 31, 1994
ISONIAZID; RIFAMPIN				
CAPSULE;ORAL				
RIFAMATE				
	SANOFI AVENTIS US	150MG;300MG	A061884 001	
RIFAMPIN AND ISONIAZID				
	HIKMA INTL PHARMS	150MG;300MG	A065221 001	Jul 29, 2005
ISOPROPAMIDE IODIDE				
TABLET;ORAL				
DARBID				
	GLAXOSMITHKLINE	EQ 5MG BASE	N010744 001	
ISOPROTERENOL HYDROCHLORIDE				
AEROSOL, METERED;INHALATION				
ISOPROTERENOL HYDROCHLORIDE				
	3M	0.12MG/INH	N010375 004	
	ALPHARMA US PHARMS	0.12MG/INH	A085904 001	
ISUPREL				
	SANOFI AVENTIS US	0.103MG/INH	N011178 001	
DISC;INHALATION				
NORISODRINE AEROTROL				
	ABBOTT	0.25%	N016814 001	
INJECTABLE;INJECTION				
ISOPROTERENOL HYDROCHLORIDE				
	ABRAXIS PHARM	0.2MG/ML	A083431 001	
	AM REGENT	0.2MG/ML	A214775 001	Oct 19, 2022
	BAXTER HLTHCARE	0.2MG/ML	A083486 001	
	CIPLA	0.2MG/ML	A211738 001	Jun 28, 2019
	HOSPIRA	0.02MG/ML	A083283 001	
		0.2MG/ML	A083346 001	
	INTL MEDICATION	0.2MG/ML	A083724 001	
	MYLAN LABS LTD	0.2MG/ML	A212573 001	Sep 06, 2022
	ZYDUS PHARMS	0.2MG/ML	A215557 001	Apr 14, 2023
ISUPREL				
+	BAUSCH	0.2MG/ML	N010515 001	
SOLUTION;INHALATION				
AEROLONE				
	LILLY	0.25%	N007245 001	
ISOPROTERENOL HYDROCHLORIDE				
	ARMOUR PHARM	0.031%	A087935 001	Nov 18, 1982
		0.062%	A087936 001	Nov 18, 1982
	DEY	0.5%	A086764 001	Jan 04, 1982
	PARKE DAVIS	0.25%	A085994 001	
		0.5%	A085540 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISOPROTERENOL HYDROCHLORIDE					
SOLUTION;INHALATION					
ISUPREL					
	SANOFI AVENTIS US	0.5%	N006327	002	
		1%	N006327	003	
VAPO-ISO					
	FISONS	0.5%	N016813	001	
TABLET;RECTAL, SUBLINGUAL					
ISUPREL					
	SANOFI AVENTIS US	10MG	N006328	001	
		15MG	N006328	002	
ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE					
AEROSOL, METERED;INHALATION					
DUO-MEDIHALER					
	3M	0.16MG/INH;0.24MG/INH	N013296	001	
ISOPROTERENOL SULFATE					
AEROSOL, METERED;INHALATION					
MEDIHALER-ISO					
	3M	0.08MG/INH	N010375	003	
POWDER;INHALATION					
NORISODRINE					
	ABBVIE	10%	N006905	003	
		25%	N006905	002	
ISOSORBIDE					
SOLUTION;ORAL					
ISMOTIC					
	ALCON	100GM/220ML	N017063	001	
ISOSORBIDE DINITRATE					
CAPSULE, EXTENDED RELEASE;ORAL					
DILATRATE-SR					
+	AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988
ISORDIL					
	WYETH AYERST	40MG	N012882	002	Jul 29, 1988
TABLET;ORAL					
ISORDIL					
+	BAUSCH	10MG **	N012093	002	Jul 29, 1988
+		20MG **	N012093	006	Jul 29, 1988
+		30MG **	N012093	005	Jul 29, 1988
ISOSORBIDE DINITRATE					
	ANI PHARMS	10MG	A086032	001	Jan 07, 1988
	HIKMA INTL PHARMS	30MG	A040591	001	Jan 10, 2007
	SUN PHARM INDUSTRIES	5MG	A086166	002	Sep 19, 1986
		10MG	A086169	001	Sep 19, 1986
		20MG	A086167	001	Sep 19, 1986
		30MG	A087564	001	Sep 18, 1986
	SUPERPHARM	5MG	A089190	001	Feb 17, 1987
		10MG	A089191	001	Feb 17, 1987
		20MG	A089192	001	Feb 17, 1987
	WATSON LABS	5MG	A086034	001	Jan 06, 1988
SORBITRATE					
	ASTRAZENECA	5MG	N016192	001	Apr 01, 1996
		10MG	N016192	002	Apr 01, 1996
		20MG	A086405	002	Aug 21, 1990
		30MG	A088124	001	Aug 21, 1990
		40MG	A088125	001	Aug 21, 1990
TABLET;SUBLINGUAL					
ISORDIL					
+	BIOVAIL	2.5MG **	N012940	004	Jul 29, 1988
+		5MG **	N012940	003	Jul 29, 1988
+		10MG **	N012940	005	Jul 29, 1988
ISOSORBIDE DINITRATE					
	HIKMA INTL PHARMS	2.5MG	A086054	001	Oct 29, 1987
		5MG	A086055	001	Nov 02, 1987
	SANDOZ	2.5MG	A086225	001	Feb 19, 1988
		5MG	A086222	001	Feb 19, 1988
	SUN PHARM INDUSTRIES	2.5MG	A084204	001	Sep 18, 1986
		5MG	A086168	001	Sep 18, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISOSORBIDE DINITRATE				
TABLET;SUBLINGUAL				
ISOSORBIDE DINITRATE				
	10MG		A087545 001	Sep 18, 1986
WATSON LABS	2.5MG **		A086033 001	Feb 26, 1988
WATSON LABS TEVA	5MG **		A086031 001	Sep 29, 1987
SORBITRATE				
ASTRAZENECA	2.5MG		N016191 002	Apr 01, 1996
	5MG		N016191 001	Apr 01, 1996
TABLET, CHEWABLE;ORAL				
SORBITRATE				
ASTRAZENECA	5MG		N016776 002	Apr 01, 1996
	10MG		N016776 003	Apr 01, 1996
TABLET, EXTENDED RELEASE;ORAL				
ISORDIL				
WYETH AYERST	40MG		N012882 001	Jul 29, 1988
ISOSORBIDE DINITRATE				
IMPAX LABS INC	40MG		A040723 001	Mar 17, 2008
SUN PHARM INDS INC	40MG		A040009 001	Dec 30, 1998
ISOSORBIDE MONONITRATE				
TABLET;ORAL				
ISMO				
PROMIUS PHARMA	20MG		N019091 001	Dec 30, 1991
ISOSORBIDE MONONITRATE				
ANI PHARMS	20MG		A075147 001	Nov 27, 1998
HIKMA PHARMS	20MG		A075361 001	Oct 05, 2000
TABLET, EXTENDED RELEASE;ORAL				
IMDUR				
+ SCHERING PLOUGH	30MG **		N020225 001	Aug 12, 1993
+	60MG **		N020225 002	Aug 12, 1993
+	120MG **		N020225 003	Mar 30, 1995
ISOSORBIDE MONONITRATE				
ACCORD HLTHCARE	30MG		A209684 001	Oct 24, 2017
	60MG		A209684 002	Oct 24, 2017
	120MG		A209684 003	Oct 24, 2017
ACTAVIS ELIZABETH	30MG		A075306 001	Dec 31, 1998
	60MG		A075306 002	Dec 31, 1998
ALKERMES GAINESVILLE	60MG		A075041 001	Sep 22, 1998
HIKMA INTL PHARMS	30MG		A076813 002	Mar 30, 2006
	60MG		A076813 001	Jan 07, 2005
IVAX SUB TEVA PHARMS	30MG		A075448 002	Aug 07, 2001
	60MG		A075448 001	Jun 19, 2000
	120MG		A075448 003	Aug 07, 2001
SHANDONG	120MG		A214115 001	Apr 29, 2022
SKYEPHARMA AG	60MG		A075166 001	Oct 07, 1999
STRIDES PHARMA	30MG		A090598 001	Aug 11, 2010
	60MG		A090598 002	Aug 11, 2010
	120MG		A090598 003	Aug 11, 2010
ISOSULFAN BLUE				
INJECTABLE;INJECTION				
ISOSULFAN BLUE				
BELOTECA	1%		A210714 001	Jan 16, 2019
EUGIA PHARMA	1%		A206831 001	Feb 02, 2016
FRESENIUS KABI USA	1%		A211869 001	Sep 08, 2022
SOMERSET THERAPS LLC	1%		A210558 001	Jul 12, 2019
LYMPHAZURIN				
+ COVIDIEN	1% **		N018310 001	
ISOTRETINOIN				
CAPSULE;ORAL				
ABSORICA LD				
+ SUN PHARM	20MG		N211913 003	Nov 05, 2019
+	28MG		N211913 005	Nov 05, 2019
ACCUTANE				
+ HOFFMANN LA ROCHE	10MG **		N018662 002	May 07, 1982
+	20MG **		N018662 004	Mar 28, 1983
+	40MG **		N018662 003	May 07, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISOTRETINOIN				
CAPSULE;ORAL				
SOTRET				
	SUN PHARM INDS LTD	10MG	A076041 001	Dec 24, 2002
		20MG	A076041 002	Dec 24, 2002
		30MG	A076503 001	Jun 20, 2003
		40MG	A076041 003	Dec 24, 2002
ISRADIPINE				
CAPSULE;ORAL				
DYNACIRC				
+	SMITHKLINE BEECHAM	2.5MG **	N019546 001	Dec 20, 1990
+		5MG **	N019546 002	Dec 20, 1990
TABLET, EXTENDED RELEASE;ORAL				
DYNACIRC CR				
+	GLAXOSMITHKLINE LLC	5MG **	N020336 001	Jun 01, 1994
+		10MG **	N020336 002	Jun 01, 1994
ISRADIPINE				
	MYLAN	5MG	A201067 001	Nov 27, 2015
		10MG	A201067 002	Nov 27, 2015
ITRACONAZOLE				
CAPSULE;ORAL				
ITRACONAZOLE				
	JUBILANT GENERICS	100MG	A203445 001	Feb 23, 2017
	MYLAN PHARMS INC	100MG	A200463 001	Jul 20, 2012
	PAR PHARM INC	100MG	A205724 001	Dec 13, 2016
	STRIDES PHARMA	100MG	A206410 001	Jul 02, 2019
INJECTABLE;INJECTION				
SPORANOX				
	JANSSEN PHARMS	10MG/ML	N020966 001	Mar 30, 1999
SOLUTION;ORAL				
ITRACONAZOLE				
	APOTEX	10MG/ML	A208481 001	Aug 02, 2019
TABLET;ORAL				
ONMEL				
+	SEBELA IRELAND LTD	200MG	N022484 001	Apr 29, 2010
IVABRADINE HYDROCHLORIDE				
TABLET;ORAL				
IVABRADINE HYDROCHLORIDE				
	INGENUS PHARMS LLC	EQ 5MG BASE	A214051 001	Dec 30, 2021
		EQ 7.5MG BASE	A214051 002	Dec 30, 2021
IVERMECTIN				
LOTION;TOPICAL				
IVERMECTIN				
	TEVA PHARMS USA	0.5%	A212485 001	Mar 21, 2022
TABLET;ORAL				
STROMECTOL				
+	MERCK SHARP DOHME	6MG **	N050742 001	Nov 22, 1996
KANAMYCIN SULFATE				
CAPSULE;ORAL				
KANTREX				
	APOTHECON	EQ 500MG BASE	A060516 001	
		EQ 500MG BASE	A061911 001	
		EQ 500MG BASE	A062726 001	Mar 06, 1987
INJECTABLE;INJECTION				
KANAMYCIN				
	HIKMA	EQ 75MG BASE/2ML	A062324 001	
		EQ 500MG BASE/2ML	A062324 002	
		EQ 1GM BASE/3ML	A062324 003	
KANAMYCIN SULFATE				
	ABRAXIS PHARM	EQ 75MG BASE/2ML	A062504 001	Apr 05, 1984
		EQ 500MG BASE/2ML	A062504 002	Apr 05, 1984
		EQ 1GM BASE/3ML	A062504 003	Apr 05, 1984
	FRESENIUS KABI USA	EQ 500MG BASE/2ML	A065111 001	Dec 17, 2002
		EQ 1GM BASE/3ML	A065111 002	Dec 17, 2002
	INTL MEDICATION	EQ 500MG BASE/2ML	A062466 001	Sep 30, 1983
		EQ 1GM BASE/3ML	A062466 002	Sep 30, 1983
	LOCH	EQ 75MG BASE/2ML	A063021 001	Jul 31, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

KANAMYCIN SULFATE				
INJECTABLE;INJECTION				
KANAMYCIN SULFATE				
	EQ 500MG BASE/2ML	A063022	001	Jul 31, 1992
	EQ 1GM BASE/3ML	A063025	001	Jul 31, 1992
PHARMAFAIR	EQ 75MG BASE/2ML	A062668	001	May 07, 1987
	EQ 500MG BASE/2ML	A062672	001	May 07, 1987
	EQ 1GM BASE/3ML	A062669	001	May 07, 1987
SOLOPAK	EQ 75MG BASE/2ML	A062605	003	Feb 26, 1986
	EQ 500MG BASE/2ML	A062605	001	Feb 26, 1986
	EQ 1GM BASE/3ML	A062605	002	Feb 26, 1986
WARNER CHILCOTT	EQ 1GM BASE/3ML	A063092	001	Oct 11, 1989
WATSON LABS	EQ 1GM BASE/3ML	A062520	003	May 09, 1985
KANTREX				
APOTHECON	EQ 75MG BASE/2ML	A061655	003	
	EQ 75MG BASE/2ML	A061901	003	
	EQ 75MG BASE/2ML	A062564	001	Sep 21, 1984
	EQ 500MG BASE/2ML	A061655	001	
	EQ 500MG BASE/2ML	A061901	001	
	EQ 500MG BASE/2ML	A062564	002	Sep 21, 1984
	EQ 1GM BASE/3ML	A061655	002	
	EQ 1GM BASE/3ML	A061901	002	
	EQ 1GM BASE/3ML	A062564	003	Sep 21, 1984
KLEBCIL				
KING PHARMS	EQ 75MG BASE/2ML	A062170	001	
	EQ 500MG BASE/2ML	A062170	002	
	EQ 1GM BASE/3ML	A062170	003	
KETAMINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
KETAMINE HYDROCHLORIDE				
FRESENIUS KABI USA	EQ 10MG BASE/ML	A215808	001	Jan 13, 2023
	EQ 50MG BASE/ML	A215808	002	Jan 13, 2023
KETOCONAZOLE				
CREAM;TOPICAL				
NIZORAL				
+ JANSSEN PHARMA	2% **	N019084	001	Dec 31, 1985
GEL;TOPICAL				
XOLEGEL				
+ ALMIRALL	2%	N021946	001	Jul 28, 2006
SHAMPOO;TOPICAL				
NIZORAL				
+ JANSSEN PHARMS	2% **	N019927	001	Aug 31, 1990
SUSPENSION;ORAL				
NIZORAL				
JANSSEN PHARMA	100MG/5ML	A070767	001	Nov 07, 1986
TABLET;ORAL				
KETOCONAZOLE				
AAIPHARMA LLC	200MG	A075341	001	Jul 27, 1999
AUROBINDO PHARMA USA	200MG	A075597	001	Dec 23, 1999
CHARTWELL RX	200MG	A074971	001	Jun 15, 1999
HERITAGE PHARMA	200MG	A075362	001	Jun 15, 1999
SUN PHARM INDUSTRIES	200MG	A075314	001	Jun 15, 1999
TEVA	200MG	A075273	001	Jun 15, 1999
NIZORAL				
+ JANSSEN PHARMS	200MG **	N018533	001	
KETOPROFEN				
CAPSULE;ORAL				
KETOPROFEN				
RISING	50MG	A074024	001	Dec 29, 1995
	50MG	A074035	002	Dec 31, 1996
	75MG	A074024	002	Dec 29, 1995
	75MG	A074035	003	Dec 31, 1996
TEVA	25MG	A073515	001	Dec 22, 1992
	75MG	A073517	001	Dec 22, 1992
ORUDIS				
+ WYETH AYERST	25MG **	N018754	001	Jul 31, 1987
+	50MG **	N018754	002	Jan 09, 1986
+	75MG **	N018754	003	Jan 09, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

KETOPROFEN

CAPSULE, EXTENDED RELEASE;ORAL				
KETOPROFEN				
ACTAVIS LABS FL INC	100MG	A075270	002	Mar 24, 1999
	150MG	A075270	003	Mar 24, 1999
	200MG	A075270	001	Mar 24, 1999
ALKERMES GAINESVILLE	200MG	A074879	001	Dec 10, 1997
MYLAN	100MG	A075679	003	Feb 20, 2002
	150MG	A075679	002	Feb 20, 2002
ORUVAIL				
+ WYETH PHARMS INC	100MG **	N019816	003	Feb 08, 1995
+	150MG **	N019816	002	Feb 08, 1995
+	200MG **	N019816	001	Sep 24, 1993
FILM;ORAL				
NEXCEDE				
NOVARTIS	12.5MG	N022470	001	Nov 25, 2009
TABLET;ORAL				
ACTRON				
BAYER	12.5MG	N020499	001	Oct 06, 1995
KETOPROFEN				
PERRIGO	12.5MG	A075364	001	Feb 07, 2002
ORUDIS KT				
+ WYETH CONS	12.5MG **	N020429	001	Oct 06, 1995

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION				
KETOROLAC TROMETHAMINE				
AMPHASTAR PHARM	15MG/ML	A076209	001	Jul 21, 2004
	30MG/ML	A076209	002	Jul 21, 2004
APOTEX INC	30MG/ML	A075626	001	Jul 24, 2001
	30MG/ML	A077201	001	Oct 14, 2005
APOTHECON	15MG/ML	A075348	001	Nov 28, 2000
	30MG/ML	A075348	002	Nov 28, 2000
BAXTER HLTHCARE CORP	15MG/ML	A075631	002	Jun 29, 2001
	30MG/ML	A075631	001	Jun 29, 2001
BEDFORD	15MG/ML	A075230	002	Oct 25, 1999
	30MG/ML	A075230	001	Oct 25, 1999
EUGIA PHARMA	15MG/ML	A212939	001	Oct 20, 2020
	30MG/ML	A212939	002	Oct 20, 2020
GLAND PHARMA LTD	15MG/ML	A076722	001	Jul 27, 2004
	30MG/ML	A076722	002	Jul 27, 2004
HIKMA	15MG/ML **	A075222	001	Apr 26, 1999
	15MG/ML	A075299	001	Nov 03, 1999
	30MG/ML **	A075222	002	Apr 26, 1999
	30MG/ML **	A075228	001	Apr 26, 1999
	30MG/ML	A075299	002	Nov 03, 1999
HOSPIRA	15MG/ML	A074801	001	Jun 05, 1997
	15MG/ML	A074993	001	Jan 27, 1999
	30MG/ML	A074801	002	Jun 05, 1997
LUITPOLD	15MG/ML	A078145	001	Jan 14, 2008
	30MG/ML	A078145	002	Jan 14, 2008
SANDOZ	15MG/ML	A076271	001	Oct 06, 2004
STERISCIENCE	15MG/ML	A078299	001	Jul 16, 2007
	15MG/ML	A201155	001	Aug 04, 2014
	30MG/ML	A078299	002	Jul 16, 2007
	30MG/ML	A201155	002	Aug 04, 2014
WOCKHARDT BIO AG	30MG/ML	A077943	001	Mar 27, 2007
TORADOL				
+ ROCHE PALO	15MG/ML **	N019698	001	Nov 30, 1989
+	30MG/ML **	N019698	002	Nov 30, 1989
SOLUTION/DROPS;OPHTHALMIC				
ACULAR PRESERVATIVE FREE				
ALLERGAN	0.5%	N020811	001	Nov 03, 1997
KETOROLAC TROMETHAMINE				
AKORN	0.4%	A078399	001	Nov 05, 2009
	0.45%	A203376	001	Feb 10, 2014
CHARTWELL RX	0.5%	A078434	001	Nov 05, 2009
EUGIA PHARMA	0.4%	A205191	001	Nov 15, 2018
	0.5%	A205190	001	Dec 03, 2020
SANDOZ	0.4%	A078721	001	Nov 05, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

KETOROLAC TROMETHAMINE

TABLET;ORAL					
KETOROLAC TROMETHAMINE					
	CHARTWELL RX	10MG	A074790	001	Jun 26, 1997
	PLIVA	10MG	A075284	001	Jun 23, 1999
	WATSON LABS	10MG	A074955	001	Sep 19, 1997
TORADOL					
+	ROCHE PALO	10MG **	N019645	001	Dec 20, 1991

KETOTIFEN FUMARATE

DRUG-ELUTING CONTACT LENS;OPHTHALMIC					
ACUVUE THERAVISION WITH KETOTIFEN					
+	JOHNSON JOHNSON VISN	EQ 19MCG BASE	N022388	001	Feb 25, 2022
SOLUTION/DROPS;OPHTHALMIC					
ZADITOR					
+	ALCON PHARMA	EQ 0.025% BASE **	N021066	002	Oct 19, 2006

KRYPTON, KR-81M

GAS;INHALATION					
MPI KRYPTON 81M GENERATOR					
	GE HEALTHCARE	N/A	N018088	001	

L-GLUTAMINE

FOR SOLUTION;ORAL					
NUTRESTORE					
+	EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION					
LABETALOL HYDROCHLORIDE					
	APOTHECON	5MG/ML	A075355	001	Nov 29, 1999
	HOSPIRA	5MG/ML	A075242	001	Sep 30, 1999
	RISING	5MG/ML	A075524	001	Nov 29, 1999
	STERISCIENCE	5MG/ML	A079134	001	Feb 03, 2010
NORMODYNE					
+	SCHERING	5MG/ML **	N018686	001	Aug 01, 1984
TRANDATE					
+	SEBELA IRELAND LTD	5MG/ML **	N019425	001	Dec 31, 1985
TABLET;ORAL					
LABETALOL HYDROCHLORIDE					
	APOTHECON	100MG	A075223	001	Nov 20, 1998
		200MG	A075223	002	Nov 20, 1998
		300MG	A075223	003	Nov 20, 1998
	TEVA	100MG	A074989	001	Sep 30, 1998
		200MG	A074989	002	Sep 30, 1998
		300MG	A074989	003	Sep 30, 1998
	UNICHEM	100MG	A212719	001	Aug 08, 2022
		200MG	A212719	002	Aug 08, 2022
		300MG	A212719	003	Aug 08, 2022
NORMODYNE					
+	SCHERING	100MG **	N018687	001	Aug 31, 1987
+		200MG **	N018687	002	Aug 01, 1984
+		300MG **	N018687	003	Aug 01, 1984
+		400MG **	N018687	004	Aug 01, 1984
TRANDATE					
+	ALVOGEN	100MG	N018716	001	May 24, 1985
+		200MG	N018716	002	Aug 01, 1984
+		300MG	N018716	003	Aug 01, 1984
+		400MG **	N018716	004	Aug 01, 1984

LACOSAMIDE

TABLET;ORAL					
LACOSAMIDE					
	ACCORD HLTHCARE	50MG	A205011	001	Jul 12, 2022
		100MG	A205011	002	Jul 12, 2022
		150MG	A205011	003	Jul 12, 2022
		200MG	A205011	004	Jul 12, 2022
	ACTAVIS LABS FL INC	50MG	A204855	001	Jan 05, 2023
		100MG	A204855	002	Jan 05, 2023
		150MG	A204855	003	Jan 05, 2023
		200MG	A204855	004	Jan 05, 2023
	APOTEX	50MG	A214567	001	Sep 23, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LACOSAMIDE
TABLET;ORAL
LACOSAMIDE

	100MG	A214567	002	Sep 23, 2022
	150MG	A214567	003	Sep 23, 2022
	200MG	A214567	004	Sep 23, 2022

LACTITOL
FOR SOLUTION;ORAL
PIZENSY

+	BRAINTREE LABS	10GM	N211281	001	Feb 12, 2020

LACTULOSE
SOLUTION;ORAL

CHRONULAC					
+	SANOFI AVENTIS US	10GM/15ML **	N017884	001	
CONSTILAC					
	ALRA	10GM/15ML	A071054	001	Jul 26, 1988
CONSTULOSE					
	ACTAVIS MID ATLANTIC	10GM/15ML	A070288	001	Aug 15, 1988
DUPHALAC					
	SOLVAY	10GM/15ML	A072372	001	Mar 22, 1989
EVALOSE					
	TEVA PHARMS	10GM/15ML	A073497	001	May 28, 1993
LACTULOSE					
	ANI PHARMS	10GM/15ML	A078430	001	Nov 28, 2007
	APOZEAL PHARMS	10GM/15ML	A207786	001	Jun 11, 2018
	HIKMA	10GM/15ML	A073591	001	May 29, 1992
	MORTON GROVE	10GM/15ML	A071841	001	Sep 22, 1988
	PACO	10GM/15ML	A073160	001	Aug 25, 1992
	VISTAPHARM	10GM/15ML	A074138	001	Sep 30, 1992
LAXILOSE					
	NOSTRUM LABS	10GM/15ML	A073686	001	May 28, 1993

SOLUTION;ORAL, RECTAL

ACILAC					
	NOSTRUM LABS	10GM/15ML	A073685	001	May 28, 1993
CEPHULAC					
+	SANOFI AVENTIS US	10GM/15ML **	N017657	001	
CHOLAC					
	ALRA	10GM/15ML	A071331	001	Jul 26, 1988
ENULOSE					
	ACTAVIS MID ATLANTIC	10GM/15ML	A071548	001	Aug 15, 1988
GENERLAC					
	MORTON GROVE	10GM/15ML	A071842	001	Sep 27, 1988
HEPTALAC					
	TEVA PHARMS	10GM/15ML	A073504	001	May 28, 1993
LACTULOSE					
	ANI PHARMS	10GM/15ML	A090426	001	Nov 21, 2008
	APOZEAL PHARMS	10GM/15ML	A203762	001	Mar 27, 2015
	PACO	10GM/15ML	A072029	001	Aug 25, 1992
	ROXANE	10GM/15ML	A073590	001	May 29, 1992
	SOLVAY	10GM/15ML	N017906	001	
PORTALAC					
	SOLVAY	10GM/15ML	A072374	001	Mar 22, 1989

LAMIVUDINE
TABLET;ORAL
LAMIVUDINE

	AUROBINDO PHARMA LTD	150MG	A202032	001	Nov 17, 2011
		300MG	A202032	002	Nov 17, 2011
	AUROBINDO PHARMA USA	100MG	A204002	001	Dec 31, 2014
	MYLAN	150MG	A204528	001	Mar 04, 2016
		300MG	A204528	002	Mar 04, 2016

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE
TABLET;ORAL
LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

+	MICRO LABS	150MG;200MG;300MG	N205626	001	Aug 13, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET;ORAL

DUTREBIS

MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

+	AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018

TEMIXYS

+	CHARTWELL RX	300MG;300MG	N211284	001	Nov 16, 2018

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

AUROBINDO PHARMA LTD	150MG;300MG	A202418	001	May 15, 2012
CHARTWELL RX	150MG;300MG	A079081	001	May 25, 2011
MYLAN	150MG;300MG	A204005	001	Aug 28, 2014
MYLAN LABS LTD	150MG;300MG	A079079	001	Aug 12, 2019
PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017

LAMOTRIGINE

TABLET;ORAL

LAMICTAL

+	GLAXOSMITHKLINE LLC	50MG **	N020241	006	Dec 27, 1994
+		250MG **	N020241	004	Dec 27, 1994

LAMOTRIGINE

ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011
	100MG	A078669	002	Apr 08, 2011
	150MG	A078669	003	Apr 08, 2011
	200MG	A078669	004	Apr 08, 2011
CHARTWELL MOLECULAR	25MG	A077783	001	Nov 01, 2010
	100MG	A077783	002	Nov 01, 2010
	150MG	A077783	003	Nov 01, 2010
	200MG	A077783	004	Nov 01, 2010
GRANULES	25MG	A078982	001	Jan 27, 2009
	100MG	A078982	002	Jan 27, 2009
	150MG	A078982	003	Jan 27, 2009
	200MG	A078982	004	Jan 27, 2009
HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011
	100MG	A078134	002	Apr 19, 2011
	150MG	A078134	003	Apr 19, 2011
	200MG	A078134	004	Apr 19, 2011
MYLAN	25MG	A077428	001	Jan 27, 2009
	100MG	A077428	002	Jan 27, 2009
	150MG	A077428	003	Jan 27, 2009
	200MG	A077428	004	Jan 27, 2009
MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009
	100MG	A078443	002	Feb 11, 2009
	150MG	A078443	003	Feb 11, 2009
	200MG	A078443	004	Feb 11, 2009
RISING	25MG	A077420	001	Jan 27, 2009
	100MG	A077420	002	Jan 27, 2009
	150MG	A077420	003	Jan 27, 2009
	200MG	A077420	004	Jan 27, 2009
ROXANE	25MG	A077392	001	Jan 27, 2009
	100MG	A077392	002	Jan 27, 2009
	150MG	A077392	003	Jan 27, 2009
	200MG	A077392	004	Jan 27, 2009
SANDOZ	25MG	A078645	001	Jan 27, 2009
	100MG	A078645	002	Jan 27, 2009
	150MG	A078645	003	Jan 27, 2009
	200MG	A078645	004	Jan 27, 2009
TEVA	25MG	A076388	001	Aug 30, 2006
	100MG	A076388	002	Aug 30, 2006
	150MG	A076388	003	Aug 30, 2006
	200MG	A076388	004	Aug 30, 2006
ZENNOVA	25MG	A078310	001	Feb 04, 2009
	100MG	A078310	002	Feb 04, 2009
	150MG	A078310	003	Feb 04, 2009
	200MG	A078310	004	Feb 04, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL				
LAMOTRIGINE				
RUBICON	25MG	A202887	001	Jun 17, 2013
	50MG	A202887	002	Jun 17, 2013
TORRENT	200MG	A203370	004	Dec 23, 2013
TABLET, FOR SUSPENSION;ORAL				
LAMICTAL CD				
GLAXOSMITHKLINE LLC	100MG	N020764	003	Aug 24, 1998
LAMOTRIGINE				
JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011
	25MG	A200220	002	Feb 28, 2011
MYLAN	5MG	A076630	001	Jan 22, 2009
	25MG	A076630	002	Jan 22, 2009
SANDOZ	5MG	A078409	002	Jan 22, 2009
	25MG	A078409	003	Jan 22, 2009
TEVA	5MG	A076420	001	Jun 21, 2006
	25MG	A076420	002	Jun 21, 2006
TABLET, ORALLY DISINTEGRATING;ORAL				
LAMOTRIGINE				
IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013
	50MG	A200828	002	Jul 15, 2013
	100MG	A200828	003	Jul 15, 2013
	200MG	A200828	004	Jul 15, 2013

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL				
LANSOPRAZOLE				
AJANTA PHARMA LTD	15MG	A203957	001	Oct 14, 2016
	30MG	A203957	002	Oct 14, 2016
BRECKENRIDGE	15MG	A203964	001	Oct 17, 2018
	30MG	A203964	002	Oct 17, 2018
KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013
	30MG	A091212	002	Sep 16, 2013
LANNETT CO INC	15MG	A207157	001	Sep 29, 2017
MYLAN	15MG	A203187	001	Jun 01, 2016
PREVACID				
+ TAKEDA PHARMS USA	15MG	N020406	001	May 10, 1995
FOR SUSPENSION, DELAYED RELEASE;ORAL				
PREVACID				
TAKEDA PHARMS NA	15MG/PACKET	N021281	001	May 03, 2001
	30MG/PACKET	N021281	002	May 03, 2001
INJECTABLE;INTRAVENOUS				
PREVACID IV				
+ TAKEDA PHARMS NA	30MG/VIAL **	N021566	001	May 27, 2004
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL				
LANSOPRAZOLE				
ANI PHARMS	15MG	A078730	001	Oct 15, 2010
	30MG	A078730	002	Oct 15, 2010

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET;ORAL				
PREVACID NAPRAPAC 250 (COPACKAGED)				
+ TAKEDA PHARMS NA	15MG,N/A;N/A,250MG **	N021507	002	Nov 14, 2003
PREVACID NAPRAPAC 375 (COPACKAGED)				
TAKEDA PHARMS NA	15MG,N/A;N/A,375MG	N021507	003	Nov 14, 2003
PREVACID NAPRAPAC 500 (COPACKAGED)				
TAKEDA PHARMS NA	15MG,N/A;N/A,500MG	N021507	004	Nov 14, 2003

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL				
FOSRENOL				
TAKEDA PHARMS USA	EQ 250MG BASE	N021468	001	Oct 26, 2004

LAPYRIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX

SOLUTION;TOPICAL				
VIRAC REX				
CHESEBROUGH PONDS	0.5%;1.8%	N011914	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LASMIDITAN SUCCINATE				
TABLET;ORAL				
REYVOW				
+	ELI LILLY AND CO	EQ 200MG BASE	N211280 003	Dec 18, 2020
LATANOPROST				
SOLUTION/DROPS;OPHTHALMIC				
LATANOPROST				
	APOTEX INC	0.005%	A077697 001	Mar 22, 2011
	EPIC PHARMA LLC	0.005%	A090887 001	Jul 19, 2011
	EUGIA PHARMA	0.005%	A206519 001	Sep 03, 2019
LEFAMULIN ACETATE				
SOLUTION;INTRAVENOUS				
XENLETA				
+	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673 001	Aug 19, 2019
LEFLUNOMIDE				
TABLET;ORAL				
LEFLUNOMIDE				
	BARR	10MG	A077083 001	Sep 13, 2005
		20MG	A077083 002	Sep 13, 2005
	SANDOZ	10MG	A077085 001	Sep 13, 2005
		20MG	A077085 002	Sep 13, 2005
	TEVA PHARMS	10MG	A077084 001	Sep 13, 2005
		20MG	A077084 002	Sep 13, 2005
LENALIDOMIDE				
CAPSULE;ORAL				
LENALIDOMIDE				
	TORRENT	10MG	A213405 001	Feb 17, 2023
		20MG	A213405 003	Aug 03, 2023
		25MG	A213405 002	Feb 17, 2023
LESINURAD				
TABLET;ORAL				
ZURAMPIC				
+	IRONWOOD PHARMS INC	200MG	N207988 001	Dec 22, 2015
LETROZOLE				
TABLET;ORAL				
LETROZOLE				
	ACTAVIS TOTOWA	2.5MG	A090292 001	Jul 13, 2011
	APOTEX INC	2.5MG	A091303 001	Apr 19, 2012
	CHARTWELL RX	2.5MG	A202716 001	May 16, 2013
	FRESENIUS KABI USA	2.5MG	A090491 001	Jun 03, 2011
	HIKMA	2.5MG	A090838 001	Jun 03, 2011
	HIKMA PHARMS	2.5MG	A203796 001	Jun 03, 2016
	IMPAX LABS	2.5MG	A091638 001	Jun 03, 2011
	INDICUS PHARMA	2.5MG	A201804 001	Jun 03, 2011
	LANNETT CO INC	2.5MG	A091098 001	Jun 03, 2011
		2.5MG	A202048 001	Oct 29, 2014
	MYLAN	2.5MG	A078190 001	Dec 24, 2008
	STRIDES PHARMA	2.5MG	A090789 001	Jun 03, 2011
	SUN PHARM INDS LTD	2.5MG	A091466 001	Jun 03, 2011
	SYNTHON PHARMS	2.5MG	A090196 001	Jun 03, 2011
LEUCOVORIN CALCIUM				
FOR SOLUTION;ORAL				
LEUCOVORIN CALCIUM				
	HOSPIRA	EQ 60MG BASE/VIAL	N008107 003	Jan 30, 1987
INJECTABLE;INJECTION				
LEUCOVORIN CALCIUM				
	ABIC	EQ 3MG BASE/ML	A089352 001	Jun 01, 1988
		EQ 50MG BASE/VIAL	A089353 001	Jun 01, 1988
	ABRAXIS PHARM	EQ 50MG BASE/VIAL	A088939 001	Dec 01, 1986
	ELKINS SINN	EQ 50MG BASE/VIAL	A070480 001	Jan 02, 1987
		EQ 100MG BASE/VIAL	A081224 001	Jun 03, 1994
+	HOSPIRA	EQ 3MG BASE/ML **	N008107 001	
+		EQ 50MG BASE/VIAL **	N008107 002	
+		EQ 100MG BASE/VIAL **	N008107 004	May 23, 1988
+		EQ 350MG BASE/VIAL **	N008107 005	Apr 05, 1989
	NOVAST LABS	EQ 10MG BASE/ML	A210917 001	Nov 23, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEUCOVORIN CALCIUM				
INJECTABLE;INJECTION				
LEUCOVORIN CALCIUM				
PHARMACHEMIE	EQ 350MG BASE/VIAL	A040262	001	Dec 15, 1999
PHARMACHEMIE USA	EQ 50MG BASE/VIAL	A089628	001	Apr 17, 1997
	EQ 100MG BASE/VIAL	A089915	001	Apr 17, 1997
TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993
TEVA PHARMS USA	EQ 100MG BASE/VIAL	A081277	001	Sep 28, 1993
	EQ 350MG BASE/VIAL	A040174	001	Jun 12, 1997
LEUCOVORIN CALCIUM PRESERVATIVE FREE				
AM REGENT	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001
HIKMA	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000
HOSPIRA	EQ 10MG BASE/ML **	A040147	001	Jun 25, 1997
TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999
WELLCOVORIN				
GLAXOSMITHKLINE	EQ 5MG BASE/ML	A087439	001	Oct 19, 1982
	EQ 25MG BASE/VIAL	A089833	001	Jan 23, 1989
	EQ 50MG BASE/VIAL	A089465	001	Jan 23, 1989
	EQ 100MG BASE/VIAL	A089834	001	Jan 23, 1989
TABLET;ORAL				
LEUCOVORIN CALCIUM				
ANI PHARMS	EQ 15MG BASE	A075327	001	Mar 24, 1999
PAR PHARM	EQ 5MG BASE	A071600	001	Oct 14, 1987
	EQ 25MG BASE	A071598	001	Oct 14, 1987
PHARMACHEMIE	EQ 5MG BASE	A073099	001	Mar 28, 1997
	EQ 25MG BASE	A073101	001	Mar 28, 1997
XANODYNE PHARM	EQ 5MG BASE	N018459	001	Jan 30, 1986
	EQ 10MG BASE	A071962	001	Nov 19, 1987
	EQ 15MG BASE	A071104	001	Mar 04, 1987
WELLCOVORIN				
+ GLAXOSMITHKLINE	EQ 5MG BASE **	N018342	001	Jul 08, 1983
+	EQ 25MG BASE **	N018342	002	Jul 08, 1983
LEUPROLIDE ACETATE				
IMPLANT;IMPLANTATION				
VIADUR				
ORTHO MCNEIL JANSSEN	EQ 65MG BASE	N021088	001	Mar 03, 2000
INJECTABLE;INJECTION				
LEUPROLIDE ACETATE				
GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001
LUPRON				
+ ABBVIE ENDOCRINE INC	1MG/0.2ML **	N019010	001	Apr 09, 1985
LUPRON DEPOT				
+ ABBVIE ENDOCRINE INC	3.75MG/VIAL **	N020011	001	Oct 22, 1990
POWDER;INTRAMUSCULAR				
LUPRON DEPOT-PED KIT				
+ ABBVIE ENDOCRINE INC	3.75MG,7.5MG **	N020263	003	Apr 16, 1993
+	7.5MG,7.5MG **	N020263	004	Apr 16, 1993
LEUPROLIDE ACETATE; NORETHINDRONE ACETATE				
INJECTABLE, TABLET;INTRAMUSCULAR, ORAL				
LUPANETA PACK				
+ ABBVIE ENDOCRINE	3.75MG/VIAL,N/A;N/A,5MG	N203696	001	Dec 14, 2012
+	11.25MG/VIAL,N/A;N/A,5MG	N203696	002	Dec 14, 2012
LEVALBUTEROL HYDROCHLORIDE				
SOLUTION;INHALATION				
LEVALBUTEROL HYDROCHLORIDE				
MYLAN SPECIALITY LP	EQ 0.0103% BASE	A077800	001	Mar 15, 2013
	EQ 0.021% BASE	A077800	002	Mar 15, 2013
	EQ 0.042% BASE	A077800	003	Mar 15, 2013
LEVALLORPHAN TARTRATE				
INJECTABLE;INJECTION				
LORFAN				
ROCHE	1MG/ML	N010423	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVAMISOLE HYDROCHLORIDE				
TABLET;ORAL				
ERGAMISOL				
	JANSSEN PHARMA	EQ 50MG BASE	N020035 001	Jun 18, 1990
LEVAMLODIPINE MALEATE				
TABLET;ORAL				
CONJUPRI				
+	CSPC OUYI	EQ 1.25MG BASE	N212895 001	Dec 19, 2019
+		EQ 2.5MG BASE	N212895 002	Dec 19, 2019
+		EQ 5MG BASE	N212895 003	Dec 19, 2019
LEVETIRACETAM				
INJECTABLE;INTRAVENOUS				
LEVETIRACETAM				
	AKORN	500MG/5ML (100MG/ML)	A209934 001	May 04, 2018
	AM REGENT	500MG/5ML (100MG/ML)	A202143 001	Jan 31, 2012
	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090813 001	May 26, 2010
	JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838 001	Jun 02, 2016
SOLUTION;ORAL				
LEVETIRACETAM				
	APOTEX INC	100MG/ML	A090187 001	Aug 05, 2011
	PHARMOBEDIENT CNSLTG	100MG/ML	A090028 001	Mar 03, 2010
	TOLMAR	100MG/ML	A079107 001	Jan 15, 2009
TABLET;ORAL				
LEVETIRACETAM				
	ACTAVIS LABS FL INC	250MG	A077408 001	Mar 02, 2009
		500MG	A077408 002	Mar 02, 2009
		750MG	A077408 003	Mar 02, 2009
	FOSUN PHARMA	250MG	A077324 001	Jan 15, 2009
		500MG	A077324 002	Jan 15, 2009
		750MG	A077324 003	Jan 15, 2009
		1GM	A077324 004	Jan 15, 2009
	LOTUS PHARM CO LTD	250MG	A090906 002	Oct 31, 2016
		500MG	A090906 001	Nov 05, 2010
		750MG	A090906 003	Oct 31, 2016
		1GM	A090906 004	Oct 31, 2016
	MYLAN	250MG	A076919 001	Nov 04, 2008
		250MG	A078731 001	Feb 10, 2009
		500MG	A078731 002	Feb 10, 2009
		750MG	A078731 003	Feb 10, 2009
		1GM	A078731 004	Feb 10, 2009
	NOSTRUM LABS INC	250MG	A090511 001	Aug 18, 2011
		500MG	A090511 002	Aug 18, 2011
		750MG	A090511 003	Aug 18, 2011
		1GM	A090511 004	Aug 18, 2011
	SECAN PHARMS	500MG	A205102 004	Dec 16, 2015
		1GM	A205102 003	Dec 16, 2015
	TEVA PHARMS	250MG	A078101 001	Jan 15, 2009
		500MG	A078101 002	Jan 15, 2009
		750MG	A078101 003	Jan 15, 2009
		1GM	A078101 004	Jan 15, 2009
	WATSON LABS INC	250MG	A078797 002	Jan 15, 2009
		500MG	A078797 003	Jan 15, 2009
		750MG	A078797 004	Jan 15, 2009
		1GM	A078797 001	Jan 15, 2009
TABLET, EXTENDED RELEASE;ORAL				
ELEPSIA XR				
+	TRIPOINT	1GM	N204417 001	Dec 20, 2018
+		1.5GM	N204417 002	Dec 20, 2018
LEVETIRACETAM				
	ACTAVIS ELIZABETH	500MG	A091557 001	Sep 12, 2011
		750MG	A091557 002	Sep 12, 2011
	AUROBINDO PHARMA USA	500MG	A200475 001	Dec 19, 2011
		750MG	A200475 002	Dec 19, 2011
		1GM	A200475 003	Dec 07, 2015
	CHARTWELL RX	500MG	A091291 001	Sep 12, 2011
		750MG	A091291 002	Sep 12, 2011
	DEXCEL	500MG	A202167 001	Sep 04, 2015
		750MG	A202167 002	Sep 04, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVETIRACETAM				
TABLET, EXTENDED RELEASE;ORAL				
LEVETIRACETAM				
LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016
	750MG	A202095	001	Jun 06, 2016
ROUSES POINT PHARMS	500MG	A202524	001	Aug 27, 2012
	750MG	A202524	002	Aug 27, 2012
SANDOZ	500MG	A091668	001	Nov 01, 2012
	750MG	A091668	002	Nov 01, 2012
SUN PHARM	500MG	A203059	001	Sep 09, 2013
	750MG	A203059	002	Sep 09, 2013
SUN PHARM INDUSTRIES	500MG	A091285	001	Sep 12, 2011
	750MG	A091285	002	Sep 12, 2011
TEVA PHARMS	500MG	A091430	001	Sep 12, 2011
	750MG	A091430	002	Sep 12, 2011
TORRENT PHARMS LTD	500MG	A091338	001	May 29, 2012
	750MG	A091338	002	May 29, 2012
LEVOBETAXOLOL HYDROCHLORIDE				
SUSPENSION/DROPS;OPHTHALMIC				
BETAXON				
ALCON PHARMS LTD	EQ 0.5% BASE	N021114	001	Feb 23, 2000
LEVOBUNOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
AKBETA				
AKORN	0.5%	A074780	001	Oct 29, 1996
EPIC PHARMA LLC	0.25%	A074779	001	Oct 29, 1996
BETAGAN				
+ ALLERGAN	0.25% **	N019814	001	Jun 28, 1989
LEVOBUNOLOL HYDROCHLORIDE				
ALCON LABS INC	0.25%	A074851	001	Oct 28, 1996
APOTEX INC	0.25%	A075473	001	Aug 03, 2000
	0.5%	A075475	001	Aug 03, 2000
BAUSCH AND LOMB	0.25%	A074307	001	Mar 04, 1994
SANDOZ	0.5%	A074850	001	Oct 28, 1996
LEVOBUPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CHIROCAINE				
PURDUE PHARMA LP	EQ 2.5MG BASE/ML **	N020997	001	Aug 05, 1999
	EQ 5MG BASE/ML **	N020997	002	Aug 05, 1999
	EQ 7.5MG BASE/ML **	N020997	003	Aug 05, 1999
LEVOCABASTINE HYDROCHLORIDE				
SUSPENSION/DROPS;OPHTHALMIC				
LIVOSTIN				
NOVARTIS	EQ 0.05% BASE	N020219	001	Nov 10, 1993
LEVOCARNITINE				
INJECTABLE;INJECTION				
LEVOCARNITINE				
TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001
SOLUTION;ORAL				
CARNITOR				
LEADIANT BIOSCI INC	1GM/10ML	N018948	002	Apr 27, 1988
LEVOCETIRIZINE DIHYDROCHLORIDE				
SOLUTION;ORAL				
LEVOCETIRIZINE DIHYDROCHLORIDE				
APOTEX	2.5MG/5ML	A202915	001	Aug 21, 2014
XYZAL				
+ CHATTEM SANOFI	2.5MG/5ML **	N022157	001	Jan 28, 2008
TABLET;ORAL				
LEVOCETIRIZINE DIHYDROCHLORIDE				
APOTEX	5MG	A203027	001	Feb 13, 2015
GRANULES	5MG	A090486	001	Mar 26, 2013
SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015
US ANTIBIOTICS	5MG	A204323	001	Dec 20, 2016
XYZAL				
+ CHATTEM SANOFI	5MG **	N022064	001	May 25, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVODOPA

CAPSULE;ORAL				
BENDOPA				
	VALEANT PHARM INTL	100MG	N016948 003	
		250MG	N016948 001	
		500MG	N016948 002	
DOPAR				
	SHIRE	100MG	N016913 003	
		250MG	N016913 001	
		500MG	N016913 002	
LARODOPA				
	ROCHE	100MG	N016912 002	
		250MG	N016912 001	
		500MG	N016912 006	
TABLET;ORAL				
DOPAR				
	SHIRE	250MG	N016913 004	
		500MG	N016913 005	
LARODOPA				
	ROCHE	100MG	N016912 005	
		250MG	N016912 003	
		500MG	N016912 004	

LEVOFLOXACIN

INJECTABLE;INJECTION				
LEVAQUIN				
+	JANSSEN PHARMS	EQ 500MG/20ML (EQ 25MG/ML) **	N020635 001	Dec 20, 1996
+		EQ 750MG/30ML (EQ 25MG/ML) **	N020635 004	Dec 20, 1996
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML) **	N020635 002	Dec 20, 1996
+		EQ 500MG/100ML (EQ 5MG/ML) **	N020635 003	Dec 20, 1996
+		EQ 750MG/150ML (EQ 5MG/ML) **	N020635 005	Dec 20, 1996
LEVOFLOXACIN				
	AVET LIFESCIENCES	EQ 500MG/20ML (EQ 25MG/ML)	A202590 001	Jan 24, 2013
		EQ 750MG/30ML (EQ 25MG/ML)	A202590 002	Jan 24, 2013
	EUGIA PHARMA	EQ 500MG/20ML (EQ 25MG/ML)	A202328 001	Jan 24, 2013
		EQ 750MG/30ML (EQ 25MG/ML)	A202328 002	Jan 24, 2013
	HOSPIRA	EQ 500MG/20ML (EQ 25MG/ML)	A078577 001	Aug 12, 2015
		EQ 750MG/30ML (EQ 25MG/ML)	A078577 002	Aug 12, 2015
	MYLAN ASI	EQ 500MG/20ML (EQ 25MG/ML)	A200560 001	Jun 20, 2011
		EQ 750MG/30ML (EQ 25MG/ML)	A200560 002	Jun 20, 2011
	ZYDUS PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A205968 001	Jun 01, 2017
		EQ 750MG/30ML (EQ 25MG/ML)	A205968 002	Jun 01, 2017
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
	EUGIA PHARMA	EQ 250MG/50ML (EQ 5MG/ML)	A206919 001	Feb 10, 2016
		EQ 500MG/100ML (EQ 5MG/ML)	A206919 002	Feb 10, 2016
		EQ 750MG/150ML (EQ 5MG/ML)	A206919 003	Feb 10, 2016
SOLUTION;ORAL				
LEVAQUIN				
+	JANSSEN PHARMS	250MG/10ML	N021721 001	Oct 21, 2004
SOLUTION/DROPS;OPHTHALMIC				
IQUIX				
+	SANTEN	1.5% **	N021571 001	Mar 01, 2004
LEVOFLOXACIN				
	AKORN	0.5%	A090268 001	Dec 20, 2010
	MYLAN LABS LTD	0.5%	A204899 001	Dec 08, 2017
	RUBICON	0.5%	A078282 001	Dec 20, 2010
	WATSON LABS TEVA	0.5%	A076826 001	Feb 10, 2011
QUIXIN				
+	SANTEN	0.5% **	N021199 001	Aug 18, 2000
TABLET;ORAL				
LEVAQUIN				
+	JANSSEN PHARMS	250MG **	N020634 001	Dec 20, 1996
+		500MG **	N020634 002	Dec 20, 1996
+		750MG **	N020634 003	Sep 08, 2000
LEVOFLOXACIN				
	JUBILANT GENERICS	250MG	A203613 001	Jun 19, 2015
		500MG	A203613 002	Jun 19, 2015
	MYLAN	250MG	A076276 001	Jun 20, 2011
		500MG	A076276 002	Jun 20, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVOFLOXACIN

TABLET;ORAL					
LEVOFLOXACIN					
	750MG		A077097	001	Jun 20, 2011
TORRENT PHARMS	250MG		A090722	001	Jun 20, 2011
	500MG		A090722	002	Jun 20, 2011
	750MG		A090722	003	Jun 20, 2011
WATSON LABS INC	250MG		A201484	001	Nov 22, 2013
	500MG		A201484	002	Nov 22, 2013
	750MG		A201484	003	Nov 22, 2013

LEVOLEUCOVORIN

POWDER;INTRAVENOUS					
KHAPZORY					
+ ACROTECH BIOPHARMA	300MG/VIAL		N211226	002	Oct 19, 2018

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS					
LEVOLEUCOVORIN CALCIUM					
ACTAVIS LLC	EQ 50MG BASE/VIAL		A206516	001	Feb 13, 2017
+	EQ 175MG BASE/VIAL		N208723	001	Sep 29, 2016
AMNEAL	EQ 50MG BASE/VIAL		A207547	001	Feb 13, 2017
HIKMA	EQ 50MG BASE/VIAL		A206263	001	Jun 16, 2016
SOLUTION;INTRAVENOUS					
FUSILEV					
+ ACROTECH BIOPHARMA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) **		N020140	002	Apr 29, 2011
+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **		N020140	003	Apr 29, 2011
LEVOLEUCOVORIN CALCIUM					
AILEX PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A213797	001	Nov 02, 2021
MEITHEAL	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A211002	002	Aug 16, 2019
MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A203576	001	Oct 20, 2015
	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A203576	002	Oct 20, 2015
NOVAST LABS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A210623	001	May 03, 2018
	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A210623	002	May 03, 2018
SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A203563	002	Mar 09, 2015

LEVOMEPROMAZINE

INJECTABLE;INJECTION					
LEVOPROME					
IMMUNEX	20MG/ML		N015865	001	

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE;ORAL					
ORLAAM					
+ ROXANE	10MG/ML **		N020315	001	Jul 09, 1993

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
LEVOMILNACIPRAN HYDROCHLORIDE					
AMNEAL PHARMS CO	EQ 20MG BASE		A210790	001	Feb 04, 2019
	EQ 40MG BASE		A210790	002	Feb 04, 2019
	EQ 80MG BASE		A210790	003	Feb 04, 2019
	EQ 120MG BASE		A210790	004	Feb 04, 2019
AUROBINDO PHARMA LTD	EQ 20MG BASE		A210826	001	Jan 06, 2023
	EQ 40MG BASE		A210826	002	Jan 06, 2023
	EQ 80MG BASE		A210826	003	Jan 06, 2023
	EQ 120MG BASE		A210826	004	Jan 06, 2023
HIKMA	EQ 20MG BASE		A210732	001	Nov 05, 2020
	EQ 40MG BASE		A210732	002	Nov 05, 2020
	EQ 80MG BASE		A210732	003	Nov 05, 2020
	EQ 120MG BASE		A210732	004	Nov 05, 2020

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION					
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN					
SOLVAY	0.05MG/ML;2%		A085010	001	
CARBOCAINE W/ NEO-COBEFRIN					
EASTMAN KODAK	0.05MG/ML;2%		N012125	002	
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN					
SEPTODONT	0.05MG/ML;2%		A084697	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN				
	BELMORA LLC	0.05MG/ML;2%	A084850 002	Oct 21, 1983
POLOCAINE W/ LEVONORDEFRIN				
	DENTSPLY PHARM	0.05MG/ML;2%	A089517 001	Apr 14, 1988
SCANDONEST L				
	DEPROCO	0.05MG/ML;2%	A088388 001	Oct 10, 1984

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN				
	EASTMAN KODAK	0.05MG/ML;2%;0.4%	N008592 007	

LEVONORGESTREL

IMPLANT;IMPLANTATION				
JADELLE				
+	POPULATION COUNCIL	75MG/IMPLANT **	N020544 001	Nov 01, 1996
LEVONORGESTREL				
	WYETH PHARMS INC	75MG/IMPLANT	N020627 001	Aug 15, 1996
NORPLANT				
	POPULATION COUNCIL	36MG/IMPLANT	N019897 001	Dec 10, 1990
NORPLANT SYSTEM IN PLASTIC CONTAINER				
	WYETH PHARMS INC	36MG/IMPLANT	N020088 001	Dec 10, 1990
TABLET;ORAL				
LEVONORGESTREL				
	ALVOGEN	1.5MG	A202246 001	Jun 05, 2015
	FDN CONSUMER	0.75MG **	A078665 001	Aug 28, 2009
		1.5MG	A200670 001	Jul 12, 2012
	L PERRIGO CO	0.75MG	A090740 001	Dec 30, 2010
	LOTUS PHARM CO LTD	0.75MG	A202684 001	Sep 02, 2016
	LUPIN LTD	0.75MG	A091328 001	Jan 23, 2013
	MYLAN LABS LTD	0.75MG	A202740 001	Sep 02, 2016
	NAARI PTE LTD	1.5MG	A207660 001	May 02, 2019
	WATSON LABS	0.75MG	A078666 001	Jun 24, 2009
PLAN B				
+	FDN CONSUMER	0.75MG **	N021045 001	Jul 28, 1999
+		0.75MG **	N021045 002	Aug 24, 2006

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

CAPSULE;ORAL				
NOVRAD				
	LILLY	EQ 50MG BASE	N012928 006	
		EQ 100MG BASE	N012928 004	
SUSPENSION;ORAL				
NOVRAD				
	LILLY	EQ 50MG BASE/5ML	N012928 002	

LEVORPHANOL TARTRATE

INJECTABLE;INJECTION				
LEVO-DROMORAN				
	VALEANT PHARM INTL	2MG/ML	N008719 001	Dec 19, 1991
TABLET;ORAL				
LEVO-DROMORAN				
+	VALEANT PHARM INTL	2MG **	N008720 001	Dec 19, 1991
LEVORPHANOL TARTRATE				
	HIKMA	1MG	A074278 002	Jun 18, 2018
		3MG	A074278 003	Jun 18, 2018

LEVOTHYROXINE SODIUM

CAPSULE;ORAL				
LEVOTHYROXINE SODIUM				
	TEVA PHARMS USA INC	0.075MG	A211369 001	Oct 28, 2020
		0.088MG	A213256 001	Jan 06, 2021
		0.1MG	A213256 002	Jan 06, 2021
		0.112MG	A211369 003	Apr 16, 2021
		0.125MG	A213256 003	Jan 06, 2021
		0.137MG	A211369 005	May 02, 2023
		0.15MG	A211369 002	Oct 28, 2020
		0.175MG	A211369 006	May 02, 2023
		0.2MG	A211369 004	Nov 09, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVOTHYROXINE SODIUM				
POWDER;INTRAVENOUS				
LEVOTHYROXINE SODIUM				
DR REDDYS	100MCG/VIAL	A208837	001	Mar 27, 2020
PAR STERILE PRODUCTS	200MCG/VIAL	A205366	001	Dec 07, 2015
TABLET;ORAL				
EUTHYROX				
PROVELL	0.3MG	N021292	012	May 31, 2002
LEVOTHYROXINE SODIUM				
AMNEAL	0.025MG	A210831	001	Feb 19, 2019
	0.05MG	A210831	002	Feb 19, 2019
	0.075MG	A210831	003	Feb 19, 2019
	0.088MG	A210831	004	Feb 19, 2019
	0.1MG	A210831	005	Feb 19, 2019
	0.112MG	A210831	006	Feb 19, 2019
	0.125MG	A210831	007	Feb 19, 2019
	0.137MG	A210831	008	Feb 19, 2019
	0.15MG	A210831	009	Feb 19, 2019
	0.175MG	A210831	010	Feb 19, 2019
	0.2MG	A210831	011	Feb 19, 2019
	0.3MG	A210831	012	Feb 19, 2019
MERCK KGAA	0.025MG	A076752	001	Jun 16, 2005
	0.05MG	A076752	002	Jun 16, 2005
	0.075MG	A076752	003	Jun 16, 2005
	0.088MG	A076752	004	Jun 16, 2005
	0.1MG	A076752	005	Jun 16, 2005
	0.112MG	A076752	006	Jun 16, 2005
	0.125MG	A076752	007	Jun 16, 2005
	0.15MG	A076752	008	Jun 16, 2005
	0.175MG	A076752	009	Jun 16, 2005
	0.2MG	A076752	010	Jun 16, 2005
	0.3MG	A076752	011	Jun 16, 2005
LEVOXYL				
+ KING PHARMS	0.3MG **	N021301	012	May 25, 2001
LIDOCAINE				
AEROSOL;ORAL				
XYLOCAINE				
ASTRAZENECA	10%	N014394	001	
FILM, EXTENDED RELEASE;BUCCAL				
DENTIPATCH				
NOVEN	23MG/PATCH	N020575	001	May 21, 1996
OINTMENT;TOPICAL				
ALPHACAINE				
CARLISLE	5%	A084944	001	
	5%	A084946	001	
	5%	A084947	001	
LIDOCAINE				
AILEX PHARMS LLC	5%	A212486	001	Oct 17, 2019
BELMORA LLC	5%	A080210	001	
RISING	5%	A208604	001	Sep 20, 2017
TEVA PHARMS USA	5%	A210256	001	Jan 16, 2018
VERTICE	5%	A205318	001	Feb 01, 2016
VITRUVIAS THERAP	5%	A208822	001	Sep 25, 2017
XYLOCAINE				
+ ASTRAZENECA	5% **	N008048	001	
PATCH;TOPICAL				
DENTIPATCH				
NOVEN	46.1MG/PATCH	N020575	002	May 21, 1996
LIDOCAINE				
NOVEN PHARMS INC	5%	A203265	001	Dec 01, 2020
SOLUTION;TOPICAL				
XYLOCAINE				
ASTRAZENECA	5%	N014127	001	
SUPPOSITORY;RECTAL				
XYLOCAINE				
ASTRAZENECA	100MG	N013077	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION			
ALPHACAINE HYDROCHLORIDE			
CARLISLE	2%	A084721 001	
LIDOCAINE HYDROCHLORIDE			
ABBOTT	10%	A087980 001	Feb 02, 1983
	20%	A089362 001	May 25, 1988
ABRAXIS PHARM	1%	A080420 001	
	1%	A086761 001	
	1.5%	A080420 005	
	2%	A080420 002	
	2%	A080420 004	
	2%	A086761 002	
	2%	N017508 001	
	4%	N017508 002	
	20%	N017508 004	
AKORN	1%	A085037 001	
	2%	A085037 002	
AM REGENT	1%	A080850 001	
	1%	A091564 001	Aug 14, 2015
BEL MAR	1%	A080710 001	
	2%	A080760 001	
BELMORA LLC	2%	A080504 001	
DELL LABS	1%	A083387 001	
	2%	A083388 001	
ELKINS SINN	0.5%	A085131 001	
	4%	A084626 001	
GD SEARLE LLC	1%	A083135 001	
	2%	A083135 002	
HOSPIRA	1%	A040013 001	Jun 23, 1995
	1.5%	A088330 001	May 17, 1984
	2%	A088331 001	May 17, 1984
	20%	A083158 003	
INTL MEDICATION	1%	N017701 002	
	2%	N017701 001	
	1GM/VIAL	N018543 001	
	2GM/VIAL	N018543 002	
LUITPOLD	2%	A083198 001	
LYPHOMED	1%	A080390 001	
	2%	A080390 002	
MILES	1%	A080414 001	
	2%	A080414 002	
RISING	0.5%	A091056 001	Dec 08, 2010
	0.5%	A091058 001	Sep 30, 2010
	1%	A091056 002	Dec 08, 2010
	1%	A091058 002	Sep 30, 2010
	2%	A202242 001	Apr 11, 2014
WATSON LABS	1%	A080377 001	
	1%	A083627 001	
	2%	A080377 002	
	2%	A083627 002	
WYETH AYERST	1%	A083083 001	
	2%	A083083 002	
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	100MG/100ML	N018461 001	
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	200MG/100ML	N018967 001	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%			
HOSPIRA	200MG/100ML	A083158 005	
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER			
ABBOTT	200MG/100ML	N018954 001	Jul 09, 1985
HOSPIRA	200MG/100ML	N018388 001	
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	400MG/100ML	N018967 002	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%			
HOSPIRA	400MG/100ML	A083158 006	
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	400MG/100ML	N018388 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION					
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	800MG/100ML	N018967	003	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER					
	HOSPIRA	800MG/100ML	N018388	003	Nov 05, 1982
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER					
	HOSPIRA	1.5%	A088326	001	Jul 31, 1984
		10%	A088367	001	Jul 31, 1984
		20%	A088368	001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
	INTL MEDICATION	4%	N017702	002	
		20%	N017702	001	
	MYLAN LABS LTD	2%	A090665	001	Sep 27, 2010
LIDOCATON					
	PHARMATON	2%	A084727	001	Aug 17, 1983
LIDOPEN					
	MERIDIAN MEDCL TECHN	10%	N017549	001	
XYLOCAINE					
	ASTRAZENECA	1%	N010418	005	
		1.5%	N010418	009	
		2%	N010418	007	
XYLOCAINE 4% PRESERVATIVE FREE					
+	FRESENIUS KABI USA	4%	N010417	001	
XYLOCAINE DENTAL					
	DENTSPLY PHARM	2%	N021380	001	
XYLOCAINE PRESERVATIVE FREE					
+	FRESENIUS KABI USA	1% **	N016801	005	Jan 19, 1988
+		2% **	N016801	001	
+		4% **	N016801	002	
		10% **	N016801	003	
+		20% **	N016801	004	
INJECTABLE;SPINAL					
XYLOCAINE 1.5% W/ DEXTROSE 7.5%					
	FRESENIUS KABI USA	1.5%	N016297	001	
XYLOCAINE 5% W/ GLUCOSE 7.5%					
	ASTRAZENECA	5%	N010496	002	Jul 07, 1982
JELLY;TOPICAL					
ANESTACON					
	BIONPHARMA	2%	A080429	001	
LIDOCAINE HYDROCHLORIDE					
	COSETTE	2%	A081318	001	Apr 29, 1993
	WATSON LABS INC	2%	A040837	001	Mar 23, 2011
XYLOCAINE					
+	EPIC PHARMA LLC	2% **	N008816	001	
SOLUTION;ORAL					
LIDOCAINE HYDROCHLORIDE					
	HIKMA	2%	A040014	001	Jul 10, 1995
LIDOCAINE HYDROCHLORIDE VISCOUS					
	ACTAVIS MID ATLANTIC	2%	A086578	001	
	INTL MEDICATION	2%	A086389	001	Feb 02, 1982
XYLOCAINE VISCOUS					
+	FRESENIUS KABI USA	2% **	N009470	001	
SOLUTION;TOPICAL					
LARYNGOTRACHEAL ANESTHESIA KIT					
	KENDALL IL	4%	A087931	001	Jun 10, 1983
LIDOCAINE HYDROCHLORIDE					
	PACO	4%	A089688	001	Jun 30, 1989
LTA II KIT					
	HOSPIRA	4%	A080409	001	
		4%	A088542	001	Jul 31, 1984
PEDIATRIC LTA KIT					
	ABBOTT	2%	A088572	001	Jul 31, 1984
	HOSPIRA	2%	A085995	001	
XYLOCAINE 4% PRESERVATIVE FREE					
+	FRESENIUS KABI USA	4% **	N010417	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE				
INJECTABLE;INJECTION				
TERRAMYCIN				
	PFIZER	2%;50MG/ML	A060567 001	
		2%;125MG/ML	A060567 002	
LIDOCAINE; PRILOCAINE				
CREAM;TOPICAL				
EMLA				
+	TEVA BRANDED PHARM	2.5%;2.5%	N019941 001	Dec 30, 1992
LIDOCAINE AND PRILOCAINE				
	PAI HOLDINGS PHARM	2.5%;2.5%	A205887 001	Jun 29, 2018
	RHODES PHARMS	2.5%;2.5%	A213253 001	Sep 21, 2020
DISC;TOPICAL				
EMLA				
	ASTRAZENECA	2.5%;2.5%	N020962 001	Feb 04, 1998
LIDOCAINE; TETRACAINE				
CREAM;TOPICAL				
PLIAGLIS				
+	TARO	7%;7%	N021717 001	Jun 29, 2006
PATCH;TOPICAL				
SYNERA				
+	GALEN SPECIALTY	70MG;70MG	N021623 001	Jun 23, 2005
LINACLOTIDE				
CAPSULE;ORAL				
LINACLOTIDE				
	AUROBINDO PHARMA	145MCG	A209611 001	Feb 07, 2023
		290MCG	A209611 002	Feb 07, 2023
	MYLAN	145MCG	A209564 001	Feb 09, 2021
		290MCG	A209564 002	Feb 09, 2021
LINAGLIPTIN				
TABLET;ORAL				
LINAGLIPTIN				
	ZYDUS PHARMS	5MG	A208448 001	Mar 30, 2023
LINAGLIPTIN; METFORMIN HYDROCHLORIDE				
TABLET;ORAL				
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE				
	ZYDUS PHARMS	2.5MG;500MG	A208449 001	Mar 30, 2023
		2.5MG;850MG	A208449 002	Mar 30, 2023
		2.5MG;1GM	A208449 003	Mar 30, 2023
LINCOMYCIN HYDROCHLORIDE				
CAPSULE;ORAL				
LINCOCIN				
	PHARMACIA AND UPJOHN	EQ 250MG BASE	N050316 001	
		EQ 500MG BASE	N050316 002	
INJECTABLE;INJECTION				
LINCOMYCIN HYDROCHLORIDE				
	GENEYORK PHARMS	EQ 300MG BASE/ML	A212770 001	Mar 12, 2021
	SLATE RUN PHARMA	EQ 300MG BASE/ML	A216662 001	Dec 21, 2022
	WATSON LABS	EQ 300MG BASE/ML	A063180 001	Apr 16, 1991
LINDANE				
CREAM;TOPICAL				
KWELL				
	REED AND CARNRICK	1%	A084218 001	
		1%	N006309 001	
LOTION;TOPICAL				
GAMENE				
	SOLA BARNES HIND	1%	A084989 001	
KWELL				
	REED AND CARNRICK	1%	A084218 002	
		1%	N006309 003	
LINDANE				
	OLTA PHARMS	1%	A087313 001	
	WOCKHARDT BIO AG	1%	A088190 001	Aug 16, 1984
SCABENE				
	STIEFEL	1%	A086769 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LINDANE				
SHAMPOO;TOPICAL				
GAMENE				
SOLA BARNES HIND	1%	A084988	001	
KWELL				
REED AND CARNRICK	1%	A084219	001	
	1%	N010718	001	
LINDANE				
OLTA PHARMS	1%	A087266	001	
WOCKHARDT BIO AG	1%	A088191	001	Sep 18, 1984
SCABENE				
STIEFEL	1%	A087940	001	Apr 08, 1983
LINEZOLID				
SOLUTION;INTRAVENOUS				
LINEZOLID				
HOSPIRA	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015
TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012
ZYVOX				
+ PFIZER	400MG/200ML (2MG/ML) **	N021131	002	Apr 18, 2000
TABLET;ORAL				
LINEZOLID				
AMNEAL PHARMS	600MG	A204536	001	Dec 21, 2015
GATE PHARMS	600MG	A091210	001	Feb 05, 2016
TEVA PHARMS USA	600MG	A078061	001	May 18, 2015
ZYVOX				
+ PFIZER	400MG **	N021130	001	Apr 18, 2000
LIOTHYRONINE SODIUM				
INJECTABLE;INJECTION				
TRIOSTAT				
+ PAR STERILE PRODUCTS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991
TABLET;ORAL				
LIOTHYRONINE SODIUM				
MYLAN	EQ 0.005MG BASE	A090326	001	Jul 14, 2009
	EQ 0.025MG BASE	A090326	002	Jul 14, 2009
	EQ 0.05MG BASE	A090326	003	Jul 14, 2009
WATSON LABS	EQ 0.025MG BASE	A085755	001	Jan 25, 1982
	EQ 0.05MG BASE	A085753	001	Feb 03, 1982
LIOTRIX (T4;T3)				
TABLET;ORAL				
EUTHROID-0.5				
PARKE DAVIS	0.03MG;0.0075MG	N016680	001	
EUTHROID-1				
PARKE DAVIS	0.06MG;0.015MG	N016680	002	
EUTHROID-2				
PARKE DAVIS	0.12MG;0.03MG	N016680	003	
EUTHROID-3				
PARKE DAVIS	0.18MG;0.045MG	N016680	004	
THYROLAR-0.25				
+ ALLERGAN	0.0125MG;0.0031MG	N016807	001	
THYROLAR-0.5				
+ ALLERGAN	0.025MG;0.0063MG	N016807	005	
THYROLAR-1				
+ ALLERGAN	0.05MG;0.0125MG	N016807	004	
THYROLAR-2				
+ ALLERGAN	0.1MG;0.025MG	N016807	002	
THYROLAR-3				
+ ALLERGAN	0.15MG;0.0375MG	N016807	003	
THYROLAR-5				
ALLERGAN	0.25MG;0.0625MG	N016807	006	
LISINOPRIL				
TABLET;ORAL				
LISINOPRIL				
HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002
	5MG	A075752	002	Jul 01, 2002
	10MG	A075752	003	Jul 01, 2002
	20MG	A075752	004	Jul 01, 2002
	30MG	A075752	005	Jul 01, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LISINOPRIL				
TABLET;ORAL				
LISINOPRIL				
	40MG	A075752	006	Jul 01, 2002
HIKMA INTL PHARMS	2.5MG	A076063	001	Jul 01, 2002
	5MG	A076063	002	Jul 01, 2002
	10MG	A076063	003	Jul 01, 2002
	20MG	A076063	004	Jul 01, 2002
	30MG	A076063	006	Jun 27, 2003
	40MG	A076063	005	Jul 01, 2002
RISING	2.5MG	A075999	001	Jul 01, 2002
	5MG	A075999	002	Jul 01, 2002
	10MG	A075999	003	Jul 01, 2002
	20MG	A075999	004	Jul 01, 2002
	30MG	A075999	005	Jul 01, 2002
	40MG	A075999	006	Jul 01, 2002
STRIDES PHARMA	2.5MG	A076071	001	Jul 01, 2002
	5MG	A076071	002	Jul 01, 2002
	10MG	A076071	003	Jul 01, 2002
	20MG	A076071	004	Jul 01, 2002
	30MG	A076071	005	Jul 01, 2002
	40MG	A076071	006	Jul 01, 2002
TEVA	2.5MG	A075783	001	Jul 01, 2002
	5MG	A075783	002	Jul 01, 2002
	10MG	A075783	003	Jul 01, 2002
	20MG	A075783	004	Jul 01, 2002
	30MG	A075783	005	Jul 01, 2002
	40MG	A075783	006	Jul 01, 2002
PRINIVIL				
MERCK	2.5MG	N019558	006	Jan 28, 1994
	5MG	N019558	001	Dec 29, 1987
	10MG	N019558	002	Dec 29, 1987
	20MG	N019558	003	Dec 29, 1987
	40MG	N019558	004	Oct 25, 1988
LITHIUM CARBONATE				
CAPSULE;ORAL				
ESKALITH				
NOVEN THERAP	300MG	N016860	001	
LITHIUM CARBONATE				
ABLE	150MG	A076823	001	Jun 29, 2004
	300MG	A076121	001	Sep 27, 2001
	300MG	A076823	002	Jun 29, 2004
	600MG	A076823	003	Jun 29, 2004
APOTEX INC	300MG	A076795	001	Nov 22, 2004
MYLAN	150MG	A076243	002	Feb 24, 2003
	300MG	A076243	001	Jun 27, 2002
	600MG	A078763	001	Apr 15, 2008
USL PHARMA	300MG	A072542	001	Feb 01, 1989
WATSON LABS	300MG	A070407	001	Mar 19, 1987
LITHONATE				
SOLVAY	300MG	N016782	001	
TABLET;ORAL				
ESKALITH				
JDS PHARMS	300MG	N017971	001	
LITHANE				
BAYER PHARMS	300MG	N018833	001	Jul 18, 1985
LITHIUM CARBONATE				
HIKMA INTL PHARMS	300MG	A078715	001	Dec 28, 2010
PFIZER	300MG	N016834	001	
LITHOTABS				
SOLVAY	300MG	N016980	001	
TABLET, EXTENDED RELEASE;ORAL				
ESKALITH CR				
JDS PHARMS	450MG **	N018152	001	Mar 29, 1982
LITHIUM CARBONATE				
ABLE	300MG	A076382	001	Apr 21, 2003
ALEMBIC	300MG	A204445	001	Jun 10, 2015
HERITAGE PHARMA	300MG	A076170	001	Jun 10, 2002
	450MG	A076366	001	Aug 21, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LITHIUM CARBONATE
TABLET, EXTENDED RELEASE;ORAL
LITHIUM CARBONATE

	HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003

LITHIUM CITRATE
SYRUP;ORAL
LITHIUM CITRATE

+	HIKMA	EQ 300MG CARBONATE/5ML **	N018421	001	

LITHONATE

	SOLVAY	EQ 300MG CARBONATE/5ML	N017672	001	

LOMEFLOXACIN HYDROCHLORIDE
TABLET;ORAL
MAXAQUIN

	PHARMACIA	EQ 400MG BASE	N020013	001	Feb 21, 1992

LOMITAPIDE MESYLATE
CAPSULE;ORAL
JUXTAPID

+	AMRYT	EQ 40MG BASE	N203858	005	Apr 23, 2015
+		EQ 60MG BASE	N203858	006	Apr 23, 2015

LOMUSTINE
CAPSULE;ORAL
GLEOSTINE

+	CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014

LOPERAMIDE HYDROCHLORIDE
CAPSULE;ORAL
IMODIUM

	J AND J CONSUMER INC	2MG **	N017690	001	
+		2MG **	N017694	001	

LOPERAMIDE HYDROCHLORIDE

	CHARTWELL RX	2MG	A072993	001	Aug 28, 1992
	ROXANE	2MG	A073080	001	Nov 27, 1991
	TEVA	2MG	A073122	001	Aug 30, 1991

SOLUTION;ORAL
IMODIUM

	JANSSEN PHARMS	1MG/5ML	N019037	001	Jul 31, 1984

LOPERAMIDE HYDROCHLORIDE

	AKORN	1MG/5ML	A074352	001	Nov 17, 1995
	ALLIED	1MG/5ML	A073079	001	Apr 30, 1992
	ALPHARMA US PHARMS	1MG/5ML	A073187	001	Sep 15, 1992
	DURAMED PHARMS BARR	1MG/5ML	A074991	001	Dec 29, 1997
	PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
	TEVA	1MG/5ML	A073478	001	Jun 23, 1995
	WATSON LABS	1MG/5ML	A073062	001	May 28, 1993

TABLET;ORAL
LOPERAMIDE HYDROCHLORIDE

	ABLE	2MG	A073528	001	Nov 30, 1993
	CONTRACT PHARMACAL	2MG	A073254	001	Jul 30, 1993
	PERRIGO	2MG	A074194	001	Oct 30, 1992

TABLET, CHEWABLE;ORAL
IMODIUM A-D EZ CHEWS

+	J AND J CONSUMER INC	2MG	N020448	001	Jul 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE
TABLET;ORAL
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

	GRANULES	2MG;125MG	A215981	001	Aug 29, 2022

TABLET, CHEWABLE;ORAL
IMODIUM MULTI-SYMPTOM RELIEF

+	J AND J CONSUMER INC	2MG;125MG	N020606	001	Jun 26, 1996

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

	PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002

LOPINAVIR; RITONAVIR				
CAPSULE;ORAL				
KALETRA				
ABBVIE	133.3MG;33.3MG	N021226	001	Sep 15, 2000
LORACARBEF				
CAPSULE;ORAL				
LORABID				
KING PHARMS	200MG	N050668	001	Dec 31, 1991
	400MG	N050668	002	Apr 05, 1996
FOR SUSPENSION;ORAL				
LORABID				
KING PHARMS	100MG/5ML	N050667	001	Dec 31, 1991
	200MG/5ML	N050667	002	Dec 31, 1991
LORATADINE				
CAPSULE;ORAL				
LORATADINE				
AUROBINDO PHARMA	10MG	A211900	001	Mar 24, 2023
STRIDES PHARMA	10MG	A211926	001	Jan 15, 2020
SYRUP;ORAL				
CLARITIN HIVES RELIEF				
+ BAYER HEALTHCARE LLC	1MG/ML **	N020641	003	Nov 19, 2003
LORATADINE				
PHARM ASSOC	1MG/ML	A075565	001	Oct 05, 2004
RANBAXY LABS LTD	1MG/ML	A076529	001	Aug 20, 2004
TEVA	1MG/ML	A075505	001	Nov 07, 2003
TABLET;ORAL				
LORATADINE				
MYLAN	10MG	A075790	001	Nov 07, 2008
	10MG	A078447	001	Aug 12, 2011
PERRIGO	10MG	N021512	001	Jun 24, 2004
TABLET, ORALLY DISINTEGRATING;ORAL				
LORATADINE				
ACTAVIS LABS FL INC	10MG	A075990	001	Nov 03, 2003
GLAXOSMITHKLINE	10MG	A075822	001	Feb 10, 2003
LORATADINE; PSEUDOEPHEDRINE SULFATE				
TABLET, EXTENDED RELEASE;ORAL				
LORATADINE AND PSEUDOEPHEDRINE SULFATE				
HERITAGE PHARMA	5MG;120MG	A076208	001	Jan 28, 2004
LORAZEPAM				
CONCENTRATE;ORAL				
LORAZEPAM				
CHARTWELL MOLECULAR	2MG/ML	A079244	001	Apr 28, 2009
INJECTABLE;INJECTION				
LORAZEPAM				
AKORN	2MG/ML	A074974	001	Jul 23, 1998
BEDFORD	2MG/ML	A077076	001	Jul 13, 2005
	4MG/ML	A077076	002	Jul 13, 2005
DAVA PHARMS INC	2MG/ML	A074793	001	Mar 16, 2000
	4MG/ML	A074793	002	Mar 16, 2000
DR REDDYS	1MG/0.5ML	A074551	003	Sep 12, 1996
	2MG/ML	A074535	001	Sep 12, 1996
	2MG/ML	A074551	001	Sep 12, 1996
	4MG/ML	A074535	002	Sep 12, 1996
	4MG/ML	A074551	002	Sep 12, 1996
HIKMA	2MG/ML	A074496	001	Sep 28, 1998
	4MG/ML	A074496	002	Sep 28, 1998
HOSPIRA	2MG/ML	A074280	001	May 27, 1994
	2MG/ML	A074300	001	Apr 12, 1994
	4MG/ML	A074280	002	May 27, 1994
	4MG/ML	A074300	003	Mar 19, 1997
RISING	2MG/ML	A200217	001	Apr 04, 2017
	2MG/ML	A200542	001	Apr 28, 2017
	4MG/ML	A200217	002	Apr 04, 2017
	4MG/ML	A200542	002	Apr 28, 2017
WATSON LABS	2MG/ML	A074276	001	Apr 15, 1994
	4MG/ML	A074276	002	Apr 15, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LORAZEPAM

INJECTABLE;INJECTION				
LORAZEPAM PRESERVATIVE FREE				
BEDFORD LABS	2MG/ML	A077074	001	Jul 13, 2005
	4MG/ML	A077074	002	Jul 13, 2005
SOLUTION;ORAL				
LORAZEPAM				
ROXANE	0.5MG/5ML	A074648	001	Mar 18, 1997
TABLET;ORAL				
LORAZ				
QUANTUM PHARMICS	0.5MG	A070200	001	Aug 09, 1985
	1MG	A070201	001	Aug 09, 1985
	2MG	A070202	001	Aug 09, 1985
LORAZEPAM				
AM THERAP	0.5MG	A070727	001	Mar 07, 1986
	1MG	A070728	001	Mar 07, 1986
	2MG	A070729	001	Mar 07, 1986
AMNEAL PHARMS	0.5MG	A078826	001	Jun 23, 2010
	1MG	A078826	002	Jun 23, 2010
	2MG	A078826	003	Jun 23, 2010
ANDA REPOSITORY	0.5MG	A072555	002	Mar 29, 1991
	1MG	A072555	003	Mar 29, 1991
	2MG	A072555	001	Mar 29, 1991
ANI PHARMS	0.5MG	A077396	001	Dec 13, 2006
	1MG	A077396	002	Dec 13, 2006
	2MG	A077396	003	Dec 13, 2006
CHARTWELL RX	0.5MG	A071591	002	Oct 13, 1987
	1MG	A071591	003	Oct 13, 1987
	2MG	A071591	001	Oct 13, 1987
HALSEY	0.5MG	A071434	001	Sep 01, 1987
	1MG	A071435	001	Sep 01, 1987
	2MG	A071436	001	Sep 01, 1987
MUTUAL PHARM	0.5MG	A070472	001	Dec 10, 1985
	1MG	A070473	001	Dec 10, 1985
	2MG	A070474	001	Dec 10, 1985
PAR PHARM	0.5MG	A070675	001	Dec 01, 1986
	1MG	A070676	001	Dec 01, 1986
	2MG	A070677	001	Dec 01, 1986
RISING	0.5MG	A077657	001	Mar 16, 2006
	1MG	A077657	002	Mar 16, 2006
	2MG	A077657	003	Mar 16, 2006
SANDOZ	0.5MG	A071193	001	Apr 15, 1988
	1MG	A071194	001	Apr 15, 1988
	2MG	A071195	001	Apr 15, 1988
SUPERPHARM	0.5MG	A071245	001	Feb 09, 1987
	1MG	A071246	001	Feb 09, 1987
	2MG	A071247	001	Feb 09, 1987
USL PHARMA	1MG	A070539	001	Dec 22, 1986
	2MG	A070540	001	Dec 22, 1986
WARNER CHILCOTT	1MG	A071038	001	Jan 12, 1988
	2MG	A071039	001	Jan 12, 1988
WATSON LABS	0.5MG	A071086	001	Mar 23, 1987
	0.5MG	A071117	001	Jul 24, 1986
	1MG	A071087	001	Mar 23, 1987
	1MG	A071118	001	Jul 24, 1986
	2MG	A071088	001	Mar 23, 1987
	2MG	A071110	001	Jul 24, 1986

LOSARTAN POTASSIUM

TABLET;ORAL				
LOSARTAN POTASSIUM				
APOTEX CORP	25MG	A090790	001	Oct 06, 2010
	50MG	A090790	002	Oct 06, 2010
	100MG	A090790	003	Oct 06, 2010
HIKMA	25MG	A077459	001	Oct 06, 2010
	50MG	A077459	002	Oct 06, 2010
	100MG	A077459	003	Oct 06, 2010
HISUN PHARM HANGZHOU	25MG	A204795	001	Apr 04, 2019
	50MG	A204795	002	Apr 04, 2019
	100MG	A204795	003	Apr 04, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LOSARTAN POTASSIUM				
TABLET;ORAL				
LOSARTAN POTASSIUM				
MYLAN	25MG	A091590	001	Oct 06, 2010
	50MG	A091590	002	Oct 06, 2010
	100MG	A091590	003	Oct 06, 2010
TEVA	25MG	A076958	001	Apr 06, 2010
	50MG	A076958	002	Apr 06, 2010
	100MG	A076958	003	Apr 06, 2010
TORRENT PHARMS	25MG	A090467	001	Oct 06, 2010
	50MG	A090467	002	Oct 06, 2010
	100MG	A090467	003	Oct 06, 2010
UPSHER SMITH LABS	25MG	A090544	001	Oct 06, 2010
	50MG	A090544	002	Oct 06, 2010
	100MG	A090544	003	Oct 06, 2010
LOTEPREDNOL ETABONATE				
SUSPENSION/DROPS;OPHTHALMIC				
LOTEMAX				
PHARMOS	0.5%	N020841	001	Mar 09, 1998
LOVASTATIN				
TABLET;ORAL				
LOVASTATIN				
AUROBINDO PHARMA USA	10MG	A075451	001	Dec 17, 2001
	10MG	A075935	001	Dec 17, 2001
	20MG	A075451	002	Dec 17, 2001
	20MG	A075935	002	Dec 17, 2001
	40MG	A075451	003	Dec 17, 2001
	40MG	A075935	003	Dec 17, 2001
SUN PHARM INDUSTRIES	10MG	A077520	001	Apr 14, 2006
	20MG	A077520	002	Apr 14, 2006
	40MG	A077520	003	Apr 14, 2006
MEVACOR				
+ MERCK	10MG **	N019643	002	Mar 28, 1991
+	20MG **	N019643	003	Aug 31, 1987
+	40MG **	N019643	004	Dec 14, 1988
TABLET, EXTENDED RELEASE;ORAL				
ALTOPREV				
COVIS	10MG	N021316	001	Jun 26, 2002
LOXAPINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
LOXITANE C				
TEVA BRANDED PHARM	EQ 25MG BASE/ML	N017658	001	
INJECTABLE;INJECTION				
LOXITANE IM				
ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001	
LOXAPINE SUCCINATE				
CAPSULE;ORAL				
LOXAPINE SUCCINATE				
RISING	EQ 5MG BASE	A076762	001	Nov 01, 2004
	EQ 10MG BASE	A076762	002	Nov 01, 2004
	EQ 25MG BASE	A076762	003	Nov 01, 2004
	EQ 50MG BASE	A076762	004	Nov 01, 2004
LOXITANE				
+ TEVA BRANDED PHARM	EQ 5MG BASE **	N017525	001	
+	EQ 10MG BASE **	N017525	002	
+	EQ 25MG BASE **	N017525	003	
+	EQ 50MG BASE **	N017525	004	
TABLET;ORAL				
LOXITANE				
+ TEVA BRANDED PHARM	EQ 10MG BASE **	N017525	006	
+	EQ 25MG BASE **	N017525	007	
+	EQ 50MG BASE **	N017525	008	

LUBIPROSTONE
CAPSULE;ORAL
LUBIPROSTONE

ANCHEN PHARMS	8MCG	A201442	001	Jun 27, 2022
	24MCG	A201442	002	Jun 27, 2022

LUCINACTANT
SUSPENSION;INTRATRACHEAL
SURFAXIN

LEES PHARM HK	8.5ML	N021746	001	Mar 06, 2012

LURASIDONE HYDROCHLORIDE
TABLET;ORAL
LURASIDONE HYDROCHLORIDE

TEVA PHARMS USA	20MG	A208060	001	May 17, 2019
	40MG	A208060	002	May 17, 2019
	60MG	A208060	003	May 17, 2019
	80MG	A208060	004	May 17, 2019
	120MG	A208060	005	May 17, 2019
WATSON LABS TEVA	20MG	A208016	001	Feb 02, 2021
	40MG	A208016	002	Feb 02, 2021
	60MG	A208016	003	Feb 02, 2021
	80MG	A208016	004	Feb 02, 2021
	120MG	A208016	005	Feb 02, 2021

LYPRESSIN
SOLUTION;NASAL
DIAPID

NOVARTIS	0.185MG/ML	N016755	001	

MACIMORELIN ACETATE
FOR SOLUTION;ORAL
MACRILEN

+	NOVO	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017

MACITENTAN
TABLET;ORAL
MACITENTAN

AUROBINDO PHARMA LTD	10MG	A211198	001	Apr 18, 2023
ZYDUS	10MG	A211224	001	Apr 06, 2021

MAFENIDE ACETATE
FOR SOLUTION;TOPICAL
MAFENIDE ACETATE

NOVAST LABS	5%	A206716	001	Jul 31, 2017
PAR FORM	5%	A201511	001	Feb 12, 2013

SULFAMYLON

+	MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE
INJECTABLE;INJECTION
PLASMA-LYTE 56 IN PLASTIC CONTAINER

BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
INJECTABLE;INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019006	001	Apr 04, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
INJECTABLE;INJECTION
ISOLYTE S IN PLASTIC CONTAINER

B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018252	001	

SOLUTION;IRRIGATION
PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA INC	14MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	001	

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	002	Jul 08, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION;IRRIGATION

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG /100ML;502MG/100ML	N019326 001	Jan 25, 1985

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET;ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

SANTARUS	343MG;20MG;750MG	N022456 001	Dec 04, 2009
	343MG;40MG;750MG	N022456 002	Dec 04, 2009

TABLET, CHEWABLE;ORAL

ZEGERID

SANTARUS	700MG;20MG;600MG	N021850 001	Mar 24, 2006
	700MG;40MG;600MG	N021850 002	Mar 24, 2006

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION;ORAL

SUCLEAR

+	BRAINTREE LABS	1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A ,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86G M,5.6GM **	N203595 001	Jan 18, 2013

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

POWDER;ORAL

COLPREP KIT

+	GATOR PHARMS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N204553 001	Dec 27, 2016

MALATHION

LOTION;TOPICAL

MALATHION

MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009

OVIDE

+	TARO	0.5% **	N018613 001	Aug 02, 1982

MANGAFODIPIR TRISODIUM

INJECTABLE;INJECTION

TESLASCAN

IC TARGETS	37.9MG/ML	N020652 001	Nov 26, 1997

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION;ORAL

LUMENHANCE

BRACCO	3.49MG/GM	N020686 001	Dec 19, 1997

MANGANESE SULFATE

INJECTABLE;INJECTION

MANGANESE SULFATE

+	ABRAXIS PHARM	EQ 0.1MG MANGANESE/ML **	N019228 001	May 05, 1987

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10%

B BRAUN	10GM/100ML	N016080 002	
HOSPIRA	10GM/100ML	N016269 002	
MILES	10GM/100ML	N016472 002	

MANNITOL 10% IN PLASTIC CONTAINER

ICU MEDICAL INC	10GM/100ML	N019603 002	Jan 08, 1987

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER

B BRAUN	10GM/100ML	N016080 006	

MANNITOL 15%

B BRAUN	15GM/100ML	N016080 003	
HOSPIRA	15GM/100ML	N016269 003	
MILES	15GM/100ML	N016472 005	

MANNITOL 15% IN PLASTIC CONTAINER

ICU MEDICAL INC	15GM/100ML	N019603 003	Jan 08, 1990

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

B BRAUN	15GM/100ML	N016080 005	

MANNITOL 20%

B BRAUN	20GM/100ML	N014738 001	
	20GM/100ML	N016080 004	
HOSPIRA	20GM/100ML	N016269 004	
MILES	20GM/100ML	N016472 004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MANNITOL

INJECTABLE;INJECTION				
MANNITOL 25%				
	ABRAXIS PHARM	12.5GM/50ML	A086754 001	
	HOSPIRA	12.5GM/50ML	N016269 005	
	IGI LABS INC	12.5GM/50ML	A089239 001	May 06, 1987
		12.5GM/50ML	A089240 001	May 06, 1987
	INTL MEDICATION	12.5GM/50ML	A083051 001	
	LUITPOLD	12.5GM/50ML	A087409 001	Jan 21, 1982
	MERCK	12.5GM/50ML	N005620 001	
	WATSON LABS	12.5GM/50ML	A087460 001	Jun 27, 1983
MANNITOL 5%				
	B BRAUN	5GM/100ML	N016080 001	
	HOSPIRA	5GM/100ML	N016269 001	
MANNITOL 5% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML	N019603 001	Jan 08, 1987
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%				
	B BRAUN	5GM/100ML	N016080 007	
SOLUTION;IRRIGATION				
RESECTISOL				
	B BRAUN	5GM/100ML	N016704 002	
RESECTISOL IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML	N016772 002	

MANNITOL; SORBITOL

SOLUTION;IRRIGATION				
SORBITOL-MANNITOL				
	HOSPIRA	540MG/100ML;2.7GM/100ML	A080224 001	
SORBITOL-MANNITOL IN PLASTIC CONTAINER				
	HOSPIRA	540MG/100ML;2.7GM/100ML	N017636 001	

MAPROTILINE HYDROCHLORIDE

TABLET;ORAL				
LUDIOMIL				
	NOVARTIS	25MG	N017543 001	
		50MG	N017543 002	
		75MG	N017543 003	Sep 30, 1982
MAPROTILINE HYDROCHLORIDE				
	AM THERAP	25MG	A072129 001	Jan 14, 1988
		50MG	A072130 001	Jan 14, 1988
		75MG	A072131 001	Jan 14, 1988
	HERITAGE PHARMA	25MG	A072162 001	Jun 01, 1988
		50MG	A072163 001	Jun 01, 1988
	RISING	25MG	A072285 002	Oct 03, 1988
		50MG	A072285 001	Oct 03, 1988
		75MG	A072285 003	Oct 03, 1988
	WATSON LABS	25MG	A071943 001	Dec 30, 1987
		50MG	A071944 001	Dec 30, 1987
		75MG	A071945 001	Dec 30, 1987
		75MG	A072164 001	Jun 01, 1988

MASOPROCOL

CREAM;TOPICAL				
ACTINEX				
	UNIV AZ CANCER CTR	10%	N019940 001	Sep 04, 1992

MAZINDOL

TABLET;ORAL				
MAZANOR				
	WYETH AYERST	1MG	N017980 002	
		2MG	N017980 001	
SANOREX				
+	NOVARTIS	1MG **	N017247 001	
+		2MG **	N017247 002	

MEBENDAZOLE

TABLET, CHEWABLE;ORAL				
VERMOX				
+	JANSSEN PHARMS	100MG **	N017481 001	
+		500MG	N208398 001	Oct 19, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEBUTAMATE

TABLET;ORAL				
DORMATE				
	MEDPOINTE PHARM HLC	600MG	N017374 001	

MECAMYLAMINE HYDROCHLORIDE

TABLET;ORAL				
INVERSINE				
+	TARGACEPT	2.5MG **	N010251 001	

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE;INJECTION				
MUSTARGEN				
+	RECORDATI RARE	10MG/VIAL	N006695 001	

MECLIZINE HYDROCHLORIDE

TABLET;ORAL				
MECLIZINE HYDROCHLORIDE				
	ABC HOLDING	12.5MG	A085253 001	
		25MG	A085252 001	
	AMNEAL PHARMS	50MG	A201451 003	Feb 23, 2011
	ANABOLIC	25MG	A085891 001	
	ANI PHARMS	12.5MG	A084657 002	
		12.5MG	A085269 001	
		12.5MG	A088732 001	Dec 11, 1985
		25MG	A084657 001	
		25MG	A085740 001	
	BUNDY	12.5MG	A084382 001	
		25MG	A084872 001	
	IVAX SUB TEVA PHARMS	12.5MG	A083784 001	
	KV PHARM	12.5MG	A085524 001	
		25MG	A085523 001	
	PLIVA	25MG	A088734 001	Dec 11, 1985
	RISING	12.5MG	A040179 001	Jan 30, 1997
		25MG	A040179 002	Jan 30, 1997
	STRIDES PHARMA	50MG	A089674 001	Mar 31, 1988
	SUPERPHARM	12.5MG	A089113 001	Aug 20, 1985
		25MG	A089114 001	Aug 20, 1985
	UDL	12.5MG	A088256 001	Jun 13, 1983
		25MG	A088257 001	Jun 13, 1983
	VANGARD	12.5MG	A087877 001	Apr 20, 1982
		25MG	A087620 001	Jan 04, 1982
	WATSON LABS	12.5MG	A085195 001	
TABLET, CHEWABLE;ORAL				
MECLIZINE HYDROCHLORIDE				
	IVAX SUB TEVA PHARMS	25MG	A084976 001	
	NEXGEN PHARMA INC	25MG	A086392 001	
	PLIVA	25MG	A088733 001	Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

CREAM;TOPICAL				
MECLAN				
	JOHNSON AND JOHNSON	1%	N050518 001	

MECLOFENAMATE SODIUM

CAPSULE;ORAL				
MECLODIUM				
	QUANTUM PHARMICS	EQ 50MG BASE	A071380 001	Jul 14, 1987
		EQ 100MG BASE	A071381 001	Jul 14, 1987
MECLOFENAMATE SODIUM				
	AM THERAP	EQ 50MG BASE	A071362 001	Feb 10, 1987
		EQ 100MG BASE	A071363 001	Feb 10, 1987
	ANI PHARMS	EQ 50MG BASE	A071469 002	Apr 15, 1987
		EQ 100MG BASE	A071469 001	Apr 15, 1987
	BARR	EQ 50MG BASE	A072848 001	Mar 20, 1989
		EQ 100MG BASE	A072809 001	Mar 20, 1989
	CHARTWELL RX	EQ 50MG BASE	A072262 001	Nov 29, 1988
		EQ 100MG BASE	A072263 001	Nov 29, 1988
	PAR PHARM	EQ 50MG BASE	A072077 001	Mar 10, 1988
		EQ 100MG BASE	A072078 001	Mar 10, 1988
	USL PHARMA	EQ 50MG BASE	A071007 001	Mar 25, 1988
		EQ 100MG BASE	A071008 001	Mar 25, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MECLOFENAMATE SODIUM

CAPSULE;ORAL				
MECLOFENAMATE SODIUM				
VITARINE	EQ 50MG BASE	A071710	001	Jun 15, 1988
	EQ 100MG BASE	A071684	001	Jun 15, 1988
WATSON LABS	EQ 50MG BASE	A070400	001	Nov 25, 1986
	EQ 50MG BASE	A071640	001	Aug 11, 1987
	EQ 100MG BASE	A070401	001	Nov 25, 1986
	EQ 100MG BASE	A071641	001	Aug 11, 1987
MECLOMEN				
PARKE DAVIS	EQ 50MG BASE	N018006	001	
	EQ 100MG BASE	N018006	002	

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION				
DEPO-PROVERA				
+ PFIZER	100MG/ML **	N012541	002	
+	400MG/ML	N012541	003	
MEDROXYPROGESTERONE ACETATE				
CIPLA	150MG/ML	A210335	001	Jan 25, 2019
HIKMA	150MG/ML	A214309	001	Jan 05, 2023
SANDOZ	150MG/ML	A078711	001	May 20, 2009
SUN PHARM	150MG/ML	A210760	001	May 01, 2019
	150MG/ML	A210761	001	Apr 24, 2019
TEVA PHARMS USA	150MG/ML	A076552	001	Oct 27, 2004
TABLET;ORAL				
AMEN				
AMARIN PHARMS	10MG	A083242	001	
CURRETAB				
SOLVAY	10MG	A085686	001	
CYCRIN				
ESI	2.5MG	A081239	001	Oct 30, 1992
	5MG	A081240	001	Oct 30, 1992
	10MG	A089386	001	Sep 09, 1987
MEDROXYPROGESTERONE ACETATE				
DURAMED PHARMS BARR	2.5MG	A040311	001	Dec 01, 1999
	5MG	A040311	002	Dec 01, 1999
	10MG	A040311	003	Dec 01, 1999
UPSHER SMITH LABS	10MG	A088484	001	Jul 26, 1984

MEDRYSONE

SUSPENSION;OPHTHALMIC				
HMS				
ALLERGAN	1%	N016624	003	

MEFENAMIC ACID

CAPSULE;ORAL				
MEFENAMIC ACID				
CHARTWELL RX	250MG	A209209	001	Sep 18, 2020
NOSTRUM LABS INC	250MG	A090359	001	Feb 05, 2013

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL				
LARIAM				
+ ROCHE	250MG **	N019591	001	May 02, 1989
MEFLOQUINE HYDROCHLORIDE				
HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010
SANDOZ	250MG	A076175	001	Feb 20, 2002
US ARMY WALTER REED	250MG **	N019578	001	May 02, 1989

MEGESTROL ACETATE

SUSPENSION;ORAL				
MEGACE				
+ BRISTOL MYERS SQUIBB	40MG/ML **	N020264	001	Sep 10, 1993
MEGESTROL ACETATE				
BIONPHARMA	125MG/ML	A204688	001	Dec 01, 2017
HIKMA	40MG/ML	A075997	001	Feb 15, 2002
NOVITIUM PHARMA	40MG/ML	A077404	001	Feb 16, 2006
TEVA PHARMS	40MG/ML	A075681	001	May 05, 2003
XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEGESTROL ACETATE				
TABLET;ORAL				
MEGACE				
+ BRISTOL MYERS SQUIBB	20MG **	N016979	001	
+	40MG **	N016979	002	
MEGESTROL ACETATE				
HIKMA	20MG	A074458	001	Sep 29, 1995
	40MG	A074458	002	Sep 29, 1995
TEVA	40MG	A074745	001	Feb 27, 1998
USL PHARMA	20MG	A070646	001	Oct 02, 1987
	40MG	A070647	001	Oct 02, 1987
MELOXICAM				
CAPSULE;ORAL				
VIVLODEX				
+ ICEUTICA OPERATIONS	5MG **	N207233	001	Oct 22, 2015
+	10MG **	N207233	002	Oct 22, 2015
SOLUTION;INTRAVENOUS				
ANJESO				
+ BAUDAX	30MG/ML (30MG/ML) **	N210583	001	Feb 20, 2020
TABLET;ORAL				
MELOXICAM				
ANDA REPOSITORY	7.5MG	A077935	001	Jul 19, 2006
	15MG	A077935	002	Jul 19, 2006
CHARTWELL RX	7.5MG	A077936	001	Jul 19, 2006
	15MG	A077936	002	Jul 19, 2006
CR DOUBLE CRANE	7.5MG	A078039	001	Dec 14, 2006
	15MG	A078039	002	Dec 14, 2006
IMPAX LABS INC	7.5MG	A077930	001	Jul 19, 2006
	15MG	A077930	002	Jul 19, 2006
MYLAN	7.5MG	A077923	001	Jul 19, 2006
	7.5MG	A077934	001	Jul 20, 2006
	15MG	A077923	002	Jul 19, 2006
	15MG	A077934	002	Jul 20, 2006
ROXANE	7.5MG	A077925	001	Jul 19, 2006
	15MG	A077925	002	Jul 19, 2006
SCIEGEN PHARMS INC	7.5MG	A077920	001	Jul 19, 2006
	15MG	A077920	002	Jul 19, 2006
SUN PHARM INDS INC	7.5MG	A077937	001	Jul 19, 2006
	15MG	A077937	002	Jul 19, 2006
YABAO PHARM	7.5MG	A077933	001	Jul 19, 2006
	15MG	A077933	002	Jul 19, 2006
TABLET, ORALLY DISINTEGRATING;ORAL				
QMIIZ ODT				
+ TERSERA	7.5MG	N211210	001	Oct 19, 2018
+	15MG	N211210	002	Oct 19, 2018
MELPHALAN				
TABLET;ORAL				
ALKERAN				
+ APOTEX	2MG **	N014691	002	
MELPHALAN FLUFENAMIDE HYDROCHLORIDE				
POWDER;INTRAVENOUS				
PEPAXTO				
+ ONCOPEPTIDES AB	EQ 20MG BASE/VIAL	N214383	001	Feb 26, 2021
MELPHALAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
ALKERAN				
+ APOTEX	EQ 50MG BASE/VIAL **	N020207	001	Nov 18, 1992
MELPHALAN HYDROCHLORIDE				
MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090299	001	Oct 27, 2009
PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016
USWM	EQ 50MG BASE/VIAL	A207032	001	May 03, 2019
POWDER;INTRAVENOUS				
MELPHALAN HYDROCHLORIDE				
ACTAVIS LLC	EQ 50MG BASE/VIAL	A209323	001	Mar 06, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
MEMANTINE HYDROCHLORIDE				
ANCHEN PHARMS	7MG	A205784	001	Jun 09, 2017
	14MG	A205784	002	Jun 09, 2017
	21MG	A205784	003	Jun 09, 2017
	28MG	A205784	004	Jun 09, 2017
ANI PHARMS	7MG	A205365	001	Feb 28, 2020
	14MG	A205365	002	Feb 28, 2020
	21MG	A205365	003	Feb 28, 2020
	28MG	A205365	004	Feb 28, 2020
RISING	7MG	A206032	001	Sep 28, 2016
	14MG	A206032	002	Sep 28, 2016
	21MG	A206032	003	Sep 28, 2016
	28MG	A206032	004	Sep 28, 2016
SUN PHARM	7MG	A205905	001	Sep 28, 2016
	14MG	A205905	002	Sep 28, 2016
	21MG	A205905	003	Sep 28, 2016
	28MG	A205905	004	Sep 28, 2016
NAMENDA XR				
+ ABBVIE	7MG	N022525	001	Jun 21, 2010
SOLUTION;ORAL				
MEMANTINE HYDROCHLORIDE				
APOZEAL PHARMS	2MG/ML	A205446	001	Dec 07, 2015
NAMENDA				
+ ALLERGAN	2MG/ML	N021627	001	Apr 18, 2005
TABLET;ORAL				
MEMANTINE HYDROCHLORIDE				
CHARTWELL	5MG	A090244	001	Jul 11, 2018
	10MG	A090244	002	Jul 11, 2018
HIKMA	5MG	A208173	001	Feb 28, 2020
	10MG	A208173	002	Feb 28, 2020
JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015
	10MG	A091585	002	Oct 13, 2015
LANNETT CO INC	5MG	A207236	001	Nov 10, 2016
	10MG	A207236	002	Nov 10, 2016
ORBION PHARMS	5MG	A090044	001	Mar 12, 2012
	10MG	A090044	002	Mar 12, 2012
RISING	5MG	A079225	001	Jan 30, 2015
	10MG	A079225	002	Jan 30, 2015
TEVA PHARMS	5MG	A090052	001	Oct 25, 2011
	10MG	A090052	002	Oct 25, 2011
TORRENT	5MG	A200155	001	Oct 13, 2015
	10MG	A200155	002	Oct 13, 2015
YILING	5MG	A212947	001	Apr 03, 2020
	10MG	A212947	002	Apr 03, 2020

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE;INJECTION				
KAPPADIONE				
LILLY	10MG/ML	N005725	001	
SYNKAYVITE				
ROCHE	5MG/ML	N003718	004	
	10MG/ML	N003718	006	
	37.5MG/ML	N003718	008	
TABLET;ORAL				
SYNKAYVITE				
ROCHE	5MG	N003718	010	

MENADIONE

TABLET;ORAL				
MENADIONE				
LILLY	5MG	N002139	003	

MEPENZOLATE BROMIDE

SOLUTION;ORAL				
CANTIL				
SANOFI AVENTIS US	25MG/5ML	N010679	004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEPENZOLATE BROMIDE

TABLET;ORAL

CANTIL

+	SANOFI AVENTIS US	25MG	N010679	003	

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEMEROL

	VALIDUS PHARMS	25MG/ML	N005010	007	
		50MG/ML	N005010	002	
		75MG/ML	N005010	009	
		100MG/ML	N005010	003	

MEPERIDINE HYDROCHLORIDE

	ABBOTT	25MG/ML	A080388	001	
		50MG/ML	A080385	001	
		50MG/ML	A080387	001	
		75MG/ML	A080389	001	
		100MG/ML	A080386	001	
	BAXTER HLTHCARE	25MG/ML	A088279	001	Jun 15, 1984
		50MG/ML	A088280	001	Jun 15, 1984
		75MG/ML	A088281	001	Jun 15, 1984
		100MG/ML	A088282	001	Jun 15, 1984
	IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989
		50MG/ML	A089782	001	Mar 31, 1989
		50MG/ML	A089783	001	Mar 31, 1989
		50MG/ML	A089784	001	Mar 31, 1989
		75MG/ML	A089785	001	Mar 31, 1989
		100MG/ML	A089786	001	Mar 31, 1989
		100MG/ML	A089787	001	Mar 31, 1989
		100MG/ML	A089788	001	Mar 31, 1989
	INTL MEDICATION	10MG/ML	A086332	001	
	PARKE DAVIS	50MG/ML	A080364	002	
		75MG/ML	A080364	003	
		100MG/ML	A080364	001	
	WATSON LABS	50MG/ML	A073444	001	Mar 17, 1992
		100MG/ML	A073445	001	Mar 17, 1992

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

	HOSPIRA	10MG/ML	A040305	001	Mar 10, 1999
+	ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984
	INTL MEDICATION	10MG/ML	A081309	001	Aug 30, 1993
	SPECGX LLC	10MG/ML	A040163	001	May 12, 1997
	WATSON LABS	10MG/ML	A073443	001	Mar 17, 1992

SYRUP;ORAL

DEMEROL

	VALIDUS PHARMS	50MG/5ML **	N005010	005	

TABLET;ORAL

DEMEROL

+	VALIDUS PHARMS	50MG **	N005010	001	
+		100MG	N005010	004	

MEPERIDINE HYDROCHLORIDE

	ANDA REPOSITORY	50MG	A040893	001	Jun 24, 2009
		75MG	A040893	002	Jun 24, 2009
		100MG	A040893	003	Jun 24, 2009
		150MG	A040893	004	Jun 24, 2009
	BARR	50MG	A088639	001	Jul 02, 1984
		100MG	A088640	001	Sep 19, 1984
	DURAMED PHARMS BARR	50MG	A040318	001	Oct 05, 1999
		100MG	A040318	002	Oct 05, 1999
	HIKMA	50MG	A040110	001	Mar 12, 1997
		100MG	A040110	002	Mar 12, 1997
	SPECGX LLC	50MG	A040352	001	Jun 13, 2000
		100MG	A040352	002	Jun 13, 2000
	STRIDES PHARMA	50MG	A040191	001	Dec 17, 1998
		100MG	A040191	002	Dec 17, 1998
	SUN PHARM INDS INC	50MG	A040446	001	Aug 08, 2002
		100MG	A040446	002	Aug 08, 2002
	SUN PHARM INDUSTRIES	50MG	A080448	001	
		100MG	A080448	002	
	WATSON LABS	50MG	A040186	001	Jun 30, 1997
		100MG	A040186	002	Jun 30, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEPERIDINE HYDROCHLORIDE

TABLET;ORAL				
MEPERIDINE HYDROCHLORIDE				
	WYETH AYERST	50MG	A080454 001	

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION				
MEPERGAN				
	HIKMA	25MG/ML;25MG/ML	N011730 001	

MEPHENTERMINE SULFATE

INJECTABLE;INJECTION				
WYAMINE SULFATE				
	BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N008248 002	
		EQ 30MG BASE/ML	N008248 001	

MEPHENYTOIN

TABLET;ORAL				
MESANTOIN				
+	NOVARTIS	100MG **	N006008 001	

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
ARESTOCAINE HYDROCHLORIDE				
	SOLVAY	3%	A084777 002	Apr 18, 1982
CARBOCAINE				
+	EASTMAN KODAK	3% **	N012125 003	
ISOCAINE HYDROCHLORIDE				
	SEPTODONT	3%	A080925 001	
MEPIVACAINE HYDROCHLORIDE				
	BELMORA LLC	3%	A083559 001	
	HOSPIRA INC	3%	A040806 001	Apr 28, 2008
	INTL MEDICATION SYS	1%	A087509 001	Oct 05, 1982
	WATSON LABS	1%	A088769 001	Nov 20, 1984
		2%	A088770 001	Nov 20, 1984
POLOCAINE				
	DENTSPLY PHARM	3%	A088653 001	Aug 21, 1984

MEPREDNISONE

TABLET;ORAL				
BETAPAR				
	SCHERING	4MG	N016053 002	

MEPROBAMATE

CAPSULE;ORAL				
EQUANIL				
	WYETH AYERST	400MG	N012455 002	
CAPSULE, EXTENDED RELEASE;ORAL				
MEPROSPAN				
	MEDPOINTE PHARM HLC	200MG	N011284 001	
		400MG	N011284 002	
TABLET;ORAL				
AMOSENE				
	FERNDALE LABS	400MG	A084030 001	
BAMATE				
	ALRA	200MG	A080380 001	
		400MG	A080380 002	
EQUANIL				
	WYETH AYERST	200MG	N010028 005	
		400MG	N010028 004	
MEPRIAM				
	TEVA	400MG	N016069 001	
MEPROBAMATE				
	ACELLA	400MG	A084153 001	
	BARR	600MG	A084230 001	
	CHARTWELL MOLECULAR	200MG	N014882 002	
		400MG	N014882 001	
	ELKINS SINN	200MG	N015426 002	
		400MG	N015426 001	
	HEATHER	400MG	N016928 003	
		600MG	A084329 001	
	IMPAX LABS	200MG	N014322 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

		400MG	N014322	001	
	IVAX SUB TEVA PHARMS	200MG	N015438	001	
		400MG	N015438	002	
		600MG	A084181	001	
	LEDERLE	400MG	A086299	001	
	LEE KM	400MG	A089538	001	Nov 25, 1987
	MALLARD	400MG	N015072	002	
	MK LABS	200MG	N014368	004	
		400MG	N014368	002	
	MYLAN	400MG	A083618	001	
	NEXGEN PHARMA INC	200MG	A084220	001	
		400MG	A084589	001	
	PARKE DAVIS	200MG	A084744	001	
		400MG	A084744	002	
	PERRIGO	200MG	A084546	001	
		400MG	A084547	001	
	PHARMAVITE	400MG	A084438	001	
	PUREPAC PHARM	200MG	A084804	001	
		400MG	A084804	002	
	PVT FORM	400MG	N014601	001	
	RISING	400MG	A080655	001	
	ROXANE	600MG	A084332	001	
	SANDOZ	200MG	N014547	002	
		400MG	N014547	001	
	SCHERER LABS	400MG	A083343	001	
	SOLVAY	200MG	A084435	001	
	STANLABS PHARM	200MG	N014474	002	
		400MG	N014474	004	
	SUN PHARM INDUSTRIES	200MG	A080699	001	
		400MG	A080699	002	
	TABLICAPS	400MG	A083494	001	
	TARO	200MG	A200998	001	May 23, 2011
		400MG	A200998	002	May 23, 2011
	USL PHARMA	200MG	A087825	001	Mar 18, 1982
		400MG	A087826	001	Mar 18, 1982
	VALEANT PHARM INTL	200MG	N015139	006	
		400MG	N015139	005	
	VANGARD	400MG	A088011	001	Jul 14, 1982
+	WATSON LABS	200MG	A083304	001	
		200MG	A085720	001	
+		400MG	A083308	001	
		400MG	A085721	001	
		600MG	A084274	001	
		600MG	A085719	001	
	WEST WARD	200MG	N015417	003	
		400MG	N015417	002	
	WHITEWORTH TOWN PLSN	200MG	A083830	001	
		400MG	A083442	001	

MILTOWN

+	MEDPOINTE PHARM HLC	200MG **	N009698	004	
+		400MG **	N009698	002	
		600MG	A083919	001	

NEURAMATE

	HALSEY	200MG	N014359	002	
		400MG	N014359	001	

TRANMEP

	SOLVAY	400MG	A084369	001	
		400MG	N016249	001	

MEQUINOL; TRETINOIN

SOLUTION;TOPICAL

SOLAGE

	ALMIRALL	2%;0.01%	N020922	001	Dec 10, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEROPENEM

INJECTABLE;INJECTION				
MEROPENEM				
HOSPIRA INC	500MG/VIAL	A090940	001	Jun 22, 2010
	1GM/VIAL	A090940	002	Jun 22, 2010
SANDOZ	500MG/VIAL	A091201	001	Mar 29, 2011
	1GM/VIAL	A091201	002	Mar 29, 2011

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE;INJECTION				
MERSALYL-THEOPHYLLINE				
WATSON LABS	100MG/ML;50MG/ML	A084875	001	

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL				
MESALAMINE				
TEVA PHARMS USA	375MG	A209970	001	May 06, 2022
ENEMA;RECTAL				
MESALAMINE				
G AND W LABS INC	4GM/60ML	A076841	001	Sep 30, 2004
SUPPOSITORY;RECTAL				
CANASA				
ABBVIE	500MG	N021252	001	Jan 05, 2001
MESALAMINE				
AMNEAL	1GM	A210509	001	Jan 02, 2020
ROWASA				
+ MEDA PHARMS	500MG **	N019919	001	Dec 18, 1990
TABLET, DELAYED RELEASE;ORAL				
ASACOL				
APIL	400MG	N019651	001	Jan 31, 1992
ASACOL HD				
+ ABBVIE	800MG **	N021830	001	May 29, 2008
MESALAMINE				
MYLAN	1.2GM	A203574	001	Nov 20, 2018

MESNA

INJECTABLE;INTRAVENOUS				
MESNA				
MYLAN INSTITUTIONAL	100MG/ML	A076488	001	Mar 08, 2012
MYLAN LABS LTD	100MG/ML	A203364	001	Jul 18, 2014
TEVA PHARMS USA	100MG/ML	A075764	001	Apr 27, 2001

MESORIDAZINE BESYLATE

CONCENTRATE;ORAL				
SERENTIL				
NOVARTIS	EQ 25MG BASE/ML	N016997	001	
INJECTABLE;INJECTION				
SERENTIL				
NOVARTIS	EQ 25MG BASE/ML	N016775	001	
TABLET;ORAL				
SERENTIL				
NOVARTIS	EQ 10MG BASE **	N016774	001	
	EQ 25MG BASE **	N016774	002	
	EQ 50MG BASE **	N016774	003	
	EQ 100MG BASE **	N016774	004	

MESTRANOL; NORETHINDRONE

TABLET;ORAL-20				
NORINYL				
ACTAVIS LABS UT INC	0.1MG;2MG	N013625	004	
TABLET;ORAL-21				
NORETHIN 1/50M-21				
HERITAGE PHARMA	0.05MG;1MG	A071539	001	Apr 12, 1988
NORETHINDRONE AND MESTRANOL				
WATSON LABS	0.05MG;1MG	A070758	001	Jul 01, 1988
NORINYL 1+50 21-DAY				
ACTAVIS LABS UT INC	0.05MG;1MG	N013625	002	
NORINYL 1+80 21-DAY				
GD SEARLE LLC	0.08MG;1MG	N016724	001	
ORTHO-NOVUM 1/50 21				
ORTHO MCNEIL PHARM	0.05MG;1MG	N012728	004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MESTRANOL; NORETHINDRONE

TABLET;ORAL-21				
ORTHO-NOVUM 1/80 21				
	ORTHO MCNEIL PHARM	0.08MG;1MG	N016715 001	
ORTHO-NOVUM 10-21				
	ORTHO MCNEIL PHARM	0.06MG;10MG	N012728 001	
ORTHO-NOVUM 2-21				
	ORTHO MCNEIL PHARM	0.1MG;2MG	N012728 005	
TABLET;ORAL-28				
NORETHIN 1/50M-28				
	HERITAGE PHARMA	0.05MG;1MG	A071540 001	Apr 12, 1988
NORETHINDRONE AND MESTRANOL				
	WATSON LABS	0.05MG;1MG	A070759 001	Jul 01, 1988
NORINYL 1+50 28-DAY				
+	ACTAVIS LABS UT INC	0.05MG;1MG	N016659 001	
NORINYL 1+80 28-DAY				
	GD SEARLE LLC	0.08MG;1MG	N016725 001	
ORTHO-NOVUM 1/50 28				
	ORTHO MCNEIL JANSSEN	0.05MG;1MG	N016709 001	
ORTHO-NOVUM 1/80 28				
	ORTHO MCNEIL PHARM	0.08MG;1MG	N016715 002	

MESTRANOL; NORETHYNODREL

TABLET;ORAL				
ENOVID				
	GD SEARLE LLC	0.075MG;5MG	N010976 008	
		0.15MG;9.85MG	N010976 005	
TABLET;ORAL-20				
ENOVID				
	GD SEARLE LLC	0.075MG;5MG	N010976 004	
ENOVID-E				
	GD SEARLE LLC	0.1MG;2.5MG	N010976 006	
TABLET;ORAL-21				
ENOVID-E 21				
	GD SEARLE LLC	0.1MG;2.5MG	N010976 007	

METAPROTERENOL SULFATE

AEROSOL, METERED;INHALATION				
ALUPENT				
	BOEHRINGER INGELHEIM	0.65MG/INH	N016402 001	
SOLUTION;INHALATION				
ALUPENT				
	BOEHRINGER INGELHEIM	0.4%	N018761 002	Oct 10, 1986
		0.6%	N018761 001	Jun 30, 1983
		5%	N017659 001	
METAPROTERENOL SULFATE				
	APOTEX INC	0.4%	A075402 001	Feb 28, 2001
		0.6%	A075403 001	Feb 28, 2001
	ASTRAZENECA	0.4%	A071275 001	Jul 27, 1988
		0.6%	A071018 001	Jul 27, 1988
	DEY	0.33%	A071806 001	Aug 05, 1988
		0.5%	A071805 001	Aug 05, 1988
		5%	A070805 001	Aug 17, 1987
	MYLAN SPECIALITY LP	0.4%	A071786 001	Aug 05, 1988
		0.6%	A070804 001	Aug 17, 1987
	NEPHRON	0.4%	A071855 001	Jul 14, 1988
		0.6%	A071726 001	Jul 14, 1988
	WOCKHARDT	0.4%	A075586 001	May 30, 2002
		0.6%	A075586 002	May 30, 2002
		5%	A072190 001	Jun 07, 1988
PROMETA				
	MURO	5%	A073340 001	Mar 30, 1992
SYRUP;ORAL				
ALUPENT				
	BOEHRINGER INGELHEIM	10MG/5ML	N017571 001	
METAPROTERENOL SULFATE				
	APOTEX INC	10MG/5ML	A075235 001	Jan 27, 2000
	COSETTE	10MG/5ML	A072761 001	Feb 27, 1992
	G AND W LABS INC	10MG/5ML	A073034 001	Aug 30, 1991
	MORTON GROVE	10MG/5ML	A071656 001	Oct 13, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METAPROTERENOL SULFATE				
SYRUP;ORAL				
METAPROTERENOL SULFATE				
WOCKHARDT	10MG/5ML	A074702	001	Mar 24, 1997
PROMETA				
MURO	10MG/5ML	A072023	001	Sep 15, 1988
TABLET;ORAL				
ALUPENT				
BOEHRINGER INGELHEIM	10MG	N015874	002	
	20MG	N015874	001	
METAPROTERENOL SULFATE				
AM THERAP	10MG	A072054	001	Jun 23, 1988
	20MG	A072055	001	Jun 23, 1988
HERITAGE PHARMA	10MG	A072519	001	Mar 30, 1990
	20MG	A072520	001	Mar 30, 1990
STRIDES PHARMA	10MG	A072024	001	Jun 28, 1988
	20MG	A072025	001	Jun 28, 1988
USL PHARMA	10MG	A071013	001	Jan 25, 1988
	20MG	A071014	001	Jan 25, 1988
WATSON LABS	10MG	A073013	001	Jan 31, 1991
	20MG	A072795	001	Jan 31, 1991
METARAMINOL BITARTRATE				
INJECTABLE;INJECTION				
ARAMINE				
+ MERCK	EQ 10MG BASE/ML **	N009509	002	Dec 22, 1987
METARAMINOL BITARTRATE				
ABRAXIS PHARM	EQ 10MG BASE/ML	A080431	001	
ELKINS SINN	EQ 10MG BASE/ML	A083363	001	
FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722	001	
GD SEARLE LLC	EQ 10MG BASE/ML	A086418	001	
	EQ 20MG BASE/ML	A086418	002	
METAXALONE				
TABLET;ORAL				
METAXALONE				
INGENUS PHARMS LLC	800MG	A213836	001	Oct 21, 2020
+ PRIMUS PHARMS	640MG **	N022503	001	Jun 01, 2015
SKELAXIN				
+ KING PHARMS	400MG **	N013217	001	
+	800MG	N013217	003	Aug 30, 2002
METFORMIN HYDROCHLORIDE				
FOR SUSPENSION, EXTENDED RELEASE;ORAL				
RIOMET ER				
+ SUN PHARM	500MG/5ML	N212595	001	Aug 29, 2019
SOLUTION;ORAL				
RIOMET				
+ RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003
TABLET;ORAL				
GLUCOPHAGE				
+ EMD SERONO INC	500MG **	N020357	001	Mar 03, 1995
+	625MG **	N020357	003	Nov 05, 1998
+	750MG **	N020357	004	Nov 05, 1998
+	850MG **	N020357	002	Mar 03, 1995
+	1GM **	N020357	005	Nov 05, 1998
METFORMIN HYDROCHLORIDE				
BARR	500MG	A075971	001	Jan 25, 2002
	850MG	A075971	002	Jan 25, 2002
	1GM	A075971	003	Jan 25, 2002
HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002
	850MG	A075978	002	Jan 25, 2002
	1GM	A075978	003	Nov 05, 2002
INDICUS PHARMA	500MG	A079148	001	Nov 25, 2008
	850MG	A079148	002	Nov 25, 2008
	1GM	A079148	003	Nov 25, 2008
IPCA LABS LTD	500MG	A078422	001	Aug 06, 2007
	850MG	A078422	002	Aug 06, 2007
	1GM	A078422	003	Aug 06, 2007
IVAX SUB TEVA PHARMS	500MG	A075975	001	Jan 24, 2002
	625MG	A075975	004	Jan 24, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METFORMIN HYDROCHLORIDE

TABLET;ORAL						
METFORMIN HYDROCHLORIDE						
		750MG		A075975	005	Jan 24, 2002
		850MG		A075975	002	Jan 24, 2002
		1GM		A075975	003	Jan 24, 2002
	MACLEODS PHARMS LTD	500MG		A205330	001	Oct 31, 2017
		850MG		A205330	002	Oct 31, 2017
		1GM		A205330	003	Oct 31, 2017
	MYLAN	500MG		A075976	001	Jan 24, 2002
		850MG		A075976	002	Jan 24, 2002
		1GM		A075976	003	Jan 24, 2002
	MYLAN PHARMS INC	500MG		A075969	001	Jan 29, 2002
		850MG		A075969	002	Jan 29, 2002
		1GM		A075969	003	Jan 29, 2002
	PROVIDENT PHARM	500MG		A077853	001	Jul 28, 2006
		850MG		A077853	002	Jul 28, 2006
		1GM		A077853	003	Jul 28, 2006
	SANDOZ	500MG		A075985	001	Jan 25, 2002
		850MG		A075985	002	Jan 25, 2002
		1GM		A075985	003	Jan 25, 2002
	SUN PHARM INDS INC	500MG		A075967	001	Jan 29, 2002
		850MG		A075967	002	Jan 29, 2002
		1GM		A075967	003	Jan 29, 2002
	SUN PHARM INDUSTRIES	500MG		A076038	001	Feb 21, 2002
		850MG		A076038	002	Feb 21, 2002
		1GM		A076038	003	Feb 21, 2002
	SUNSHINE	500MG		A208999	001	Oct 12, 2018
		850MG		A208999	002	Oct 12, 2018
		1GM		A208999	003	Oct 12, 2018
	TEVA	500MG		A076328	001	Dec 16, 2002
		850MG		A076328	002	Dec 16, 2002
		1GM		A076328	003	Dec 16, 2002
	TORRENT PHARMS	500MG		A077711	001	Jan 24, 2007
		850MG		A077711	002	Jan 24, 2007
		1GM		A077711	003	Jan 24, 2007
	WATSON LABS	500MG		A075979	001	Jan 24, 2002
		850MG		A075979	002	Jan 24, 2002
		1GM		A075979	003	Jan 24, 2002
	WATSON LABS FLORIDA	500MG		A075961	001	Jan 25, 2002
		850MG		A075961	002	Jan 25, 2002
		1GM		A075961	003	Jan 25, 2002
TABLET, EXTENDED RELEASE;ORAL						
FORTAMET						
+	ANDRX LABS LLC	500MG	**	N021574	001	Apr 27, 2004
GLUCOPHAGE XR						
+	EMD SERONO INC	500MG	**	N021202	001	Oct 13, 2000
+		750MG	**	N021202	004	Apr 11, 2003
METFORMIN HYDROCHLORIDE						
	ACTAVIS ELIZABETH	500MG		A076450	001	Oct 01, 2004
		750MG		A076878	001	Apr 13, 2005
	ACTAVIS LABS FL INC	500MG		A076172	001	Jun 16, 2004
	AMTA	500MG		A213394	001	Aug 03, 2021
		1GM		A213394	002	Aug 03, 2021
	APOTEX	500MG		A076706	001	Dec 14, 2004
		750MG		A076706	002	Dec 29, 2005
	BARR	500MG		A076496	001	Nov 25, 2005
		750MG		A076863	001	Oct 14, 2004
	IMPAX LABS	500MG		A076249	001	Jul 30, 2004
		750MG		A076985	001	Sep 13, 2005
	IVAX SUB TEVA PHARMS	500MG		A076545	001	Dec 01, 2003
	MYLAN	500MG		A076650	001	Sep 13, 2005
		750MG		A077113	001	Sep 08, 2005
	RANBAXY LABS LTD	500MG		A076413	001	Jun 18, 2004
		750MG		A077211	001	Jun 29, 2005
	SANDOZ	500MG		A076223	001	Dec 14, 2004
	SUN PHARM INDUSTRIES	500MG		A077124	001	Dec 21, 2005
	TORRENT	500MG		A090014	001	Dec 30, 2009
	TORRENT PHARMS LTD	750MG		A079226	001	Feb 18, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE					
	WATSON LABS INC	500MG	A076818	001	Dec 14, 2004

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET					
+	TAKEDA PHARMS USA	500MG;EQ 15MG BASE **	N021842	001	Aug 29, 2005
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE					
	MYLAN	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011
		850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011
	SANDOZ	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013
		850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013
	TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013
		850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR					
+	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009
+		1GM;EQ 30MG BASE	N022024	002	May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

PRANDIMET					
+	NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008
+		500MG;2MG	N022386	002	Jun 23, 2008
REPAGLINIDE AND METFORMIN HYDROCHLORIDE					
	LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015
		500MG;2MG	A200624	002	Jul 15, 2015

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET					
+	SB PHARMCO	500MG;EQ 1MG BASE **	N021410	001	Oct 10, 2002
+		500MG;EQ 2MG BASE **	N021410	002	Oct 10, 2002
+		500MG;EQ 4MG BASE **	N021410	003	Oct 10, 2002
+		1GM;EQ 2MG BASE **	N021410	004	Aug 25, 2003
+		1GM;EQ 4MG BASE **	N021410	005	Aug 25, 2003
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE					
	TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014
		500MG;EQ 1MG BASE	A077337	005	May 19, 2017
		500MG;EQ 4MG BASE	A077337	002	May 07, 2014
		1GM;EQ 4MG BASE	A077337	004	May 07, 2014
		1GM;EQ 2MG BASE	A077337	003	May 07, 2014

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KOMBIGLYZE XR					
+	ASTRAZENECA AB	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010
+		1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010
+		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE					
+	METHAPHARM	1600MG/VIAL	N019193	002	Aug 29, 2016

METHACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

RONDOMYCIN				
	MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641	001
		EQ 280MG BASE	A060641	002

SYRUP;ORAL

RONDOMYCIN				
	MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641	003

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE					
	LANNETT CO INC	10MG/ML	A212094	001	Mar 03, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHADONE HYDROCHLORIDE				
POWDER;FOR RX COMPOUNDING				
METHADONE HYDROCHLORIDE				
MALLINCKRODT INC	50GM/BOT		N006383 002	
	100GM/BOT		N006383 003	
	500GM/BOT		N006383 004	
SYRUP;ORAL				
DOLOPHINE HYDROCHLORIDE				
HIKMA	10MG/30ML		N006134 004	
TABLET;ORAL				
DOLOPHINE HYDROCHLORIDE				
+ HIKMA	5MG **		N006134 002	
+	10MG **		N006134 010	
METHADONE HYDROCHLORIDE				
NOSTRUM LABS INC	5MG		A210484 001	Aug 02, 2018
	10MG		A210484 002	Aug 02, 2018
ROXANE	40MG		A074081 001	Apr 28, 1995
SUN PHARM INDUSTRIES	5MG		A208305 001	Mar 30, 2018
	10MG		A208305 002	Mar 30, 2018
VISTAPHARM	5MG		A040241 001	May 29, 1998
METHADOSE				
SPECGX LLC	5MG		A040050 001	Apr 15, 1993
	10MG		A040050 002	Apr 15, 1993
TABLET, DISPERSIBLE;ORAL				
WESTADONE				
SANDOZ	2.5MG		N017108 001	
TABLET, EFFERVESCENT;ORAL				
WESTADONE				
SANDOZ	5MG		N017108 002	
	10MG		N017108 003	
	40MG		N017108 004	
METHAMPHETAMINE HYDROCHLORIDE				
TABLET;ORAL				
METHAMPEX				
TEVA	10MG		A083889 001	
METHAMPHETAMINE HYDROCHLORIDE				
ABLE	5MG		A040529 001	Feb 25, 2004
REXAR	5MG		A084931 001	
	10MG		A084931 002	
TEVA	5MG		A086359 001	
TABLET, EXTENDED RELEASE;ORAL				
DESOXYN				
AJENAT PHARMS	5MG		N005378 004	
	10MG		N005378 003	
	15MG		N005378 005	
METHANTHELINE BROMIDE				
TABLET;ORAL				
BANTHINE				
SHIRE	50MG		N007390 001	
METHARBITAL				
TABLET;ORAL				
GEMONIL				
ABBVIE	100MG		N008322 001	
METHAZOLAMIDE				
TABLET;ORAL				
METHAZOLAMIDE				
APPLIED ANAL	25MG		A040011 001	Jul 17, 1997
	50MG		A040011 002	Jul 17, 1997
ATHEM	25MG		A040102 001	Aug 28, 1996
	50MG		A040102 002	Aug 28, 1996
NEPTAZANE				
+ LEDERLE	25MG **		N011721 002	Nov 25, 1991
+	50MG **		N011721 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHDILAZINE				
TABLET, CHEWABLE;ORAL				
TACARYL				
	WESTWOOD SQUIBB	3.6MG	N011950 009	
METHDILAZINE HYDROCHLORIDE				
SYRUP;ORAL				
METHDILAZINE HYDROCHLORIDE				
	ALPHARMA US PHARMS	4MG/5ML	A087122 001	
TACARYL				
	WESTWOOD SQUIBB	4MG/5ML	N011950 007	
TABLET;ORAL				
TACARYL				
	WESTWOOD SQUIBB	8MG	N011950 006	
METHENAMINE HIPPURATE				
TABLET;ORAL				
METHENAMINE HIPPURATE				
	IMPAX LABS INC	1GM	A076411 001	Jun 20, 2003
METHICILLIN SODIUM				
INJECTABLE;INJECTION				
STAPHCILLIN				
	APOTHECON	EQ 900MG BASE/VIAL	A061449 001	
		EQ 900MG BASE/VIAL	N050117 001	
		EQ 3.6GM BASE/VIAL	A061449 002	
		EQ 3.6GM BASE/VIAL	N050117 002	
		EQ 5.4GM BASE/VIAL	A061449 003	
		EQ 5.4GM BASE/VIAL	N050117 003	
METHIMAZOLE				
TABLET;ORAL				
METHIMAZOLE				
	DISCOVERY THERAP	15MG	A040619 003	Jul 12, 2005
	MYLAN	20MG	A040350 003	Jun 07, 2001
	QINGDAO BAHEAL PHARM	20MG	A040547 004	Feb 18, 2005
	SUN PHARM INDS INC	5MG	A040870 001	Sep 25, 2007
		10MG	A040870 002	Sep 25, 2007
TAPAZOLE				
+	KING PHARMS	5MG **	N007517 002	
+		10MG **	N007517 004	
	KING PHARMS LLC	5MG	A040320 001	Mar 31, 2000
		10MG	A040320 002	Mar 31, 2000
METHIXENE HYDROCHLORIDE				
TABLET;ORAL				
TREST				
	NOVARTIS	1MG	N013420 001	
METHOCARBAMOL				
INJECTABLE;INJECTION				
METHOCARBAMOL				
	DR REDDYS	100MG/ML	A086459 001	
	MARSAM PHARMS LLC	100MG/ML	A089849 001	Dec 27, 1991
SOLUTION;IM-IV				
METHOCARBAMOL				
	BAXTER HLTHCARE CORP	1GM/10ML (100MG/ML)	A215065 001	Jul 14, 2022
	MYLAN INSTITUTIONAL	1GM/10ML (100MG/ML)	A204404 001	Dec 05, 2014
TABLET;ORAL				
DELAXIN				
	FERNDALE LABS	500MG	A085454 001	
FORBAXIN				
	FOREST LABS	750MG	A085136 001	
METHOCARBAMOL				
	ABLE	500MG	A040413 001	Mar 17, 2003
		750MG	A040413 002	Mar 17, 2003
	AM THERAP	500MG	A089417 001	Feb 11, 1987
		750MG	A089418 001	Feb 11, 1987
	ANI PHARMS	500MG	A084277 001	
		750MG	A084276 002	
	ASCOT	500MG	A087660 001	Oct 27, 1982
		750MG	A087661 001	Oct 27, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHOCARBAMOL				
TABLET;ORAL				
METHOCARBAMOL				
CHARTWELL MOLECULAR	500MG	A084756	002	Mar 31, 2003
	750MG	A084756	001	
CLONMEL HLTHCARE	500MG	A085961	001	
	750MG	A085963	001	
FOSUN PHARMA	500MG	A084616	001	
	750MG	A084615	001	
HEATHER	500MG	A084675	001	
	750MG	A084924	001	
HIKMA INTL PHARMS	500MG	A085159	001	
	750MG	A085123	001	
IMPAX LABS	500MG	A084927	001	
	750MG	A084928	001	
INWOOD LABS	500MG	A085137	001	
IVAX SUB TEVA PHARMS	500MG	A084648	001	
	750MG	A084649	001	
KV PHARM	500MG	A085660	001	
	750MG	A085658	001	
MYLAN	500MG	A084259	001	
	750MG	A084323	001	
NYLOS	750MG	A085033	001	
PIONEER PHARMS	500MG	A088731	001	Dec 13, 1985
	750MG	A089082	001	Dec 13, 1985
PURACAP PHARM	500MG	A084231	002	
	750MG	A084471	001	
PUREPAC PHARM	500MG	A085718	001	
	750MG	A085718	002	
ROXANE	500MG	A088646	001	Feb 29, 1984
	750MG	A088647	001	Feb 29, 1984
SANDOZ	500MG	A087283	001	
	750MG	A087282	001	
SOLVAY	500MG	A084448	001	
	750MG	A084449	001	
SUN PHARM INDUSTRIES	500MG	A084488	001	
	750MG	A084486	001	
SUPERPHARM	500MG	A087589	001	Jan 22, 1982
	750MG	A087590	001	Jan 22, 1982
TABLICAPS	500MG	A084846	001	
UPSHER SMITH	500MG	A087453	001	
	750MG	A087454	001	
WATSON LABS	500MG	A083605	001	
	500MG	A085180	001	
	750MG	A083605	002	
	750MG	A085192	001	
ROBAXIN				
+ AUXILIUM PHARMS LLC	500MG **	N011011	004	
ROBAXIN-750				
+ AUXILIUM PHARMS LLC	750MG **	N011011	006	
METHOHEXITAL SODIUM				
INJECTABLE;INJECTION				
BREVITAL SODIUM				
PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012
+	2.5GM/VIAL	N011559	002	
	5GM/VIAL	N011559	003	
METHOTREXATE				
SOLUTION;INTRAVENOUS				
METHOTREXATE				
+ ACCORD HLTHCARE	5GM/50ML (100MG/ML)	N214121	001	Aug 24, 2020
SOLUTION;SUBCUTANEOUS				
OTREXUP				
+ OTTER PHARMS	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014
OTREXUP PFS				
+ OTTER PHARMS	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017
+	15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017
+	17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017
+	20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHOTREXATE					
SOLUTION;SUBCUTANEOUS					
OTREXUP PFS					
+		22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017
+		25MG/ML (25MG/ML)	N204824	014	May 31, 2017
RASUVO					
+	MEDEXUS	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014
REDITREX					
+	NORDIC GRP	7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019
+		10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019
+		12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019
+		15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019
+		17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019
+		20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019
+		22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019
+		25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019
METHOTREXATE SODIUM					
INJECTABLE;INJECTION					
ABITREXATE					
	ABIC	EQ 25MG BASE/ML	A089161	001	Mar 10, 1987
		EQ 50MG BASE/VIAL	A089354	001	Jul 17, 1987
		EQ 100MG BASE/VIAL	A089355	001	Jul 17, 1987
		EQ 250MG BASE/VIAL	A089356	001	Jul 17, 1987
FOLEX					
+	PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695	001	Apr 08, 1983
		EQ 50MG BASE/VIAL	A087695	002	Apr 08, 1983
+		EQ 100MG BASE/VIAL	A087695	003	Apr 08, 1983
		EQ 250MG BASE/VIAL	A088954	001	Oct 24, 1985
FOLEX PFS					
	PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	A081242	001	Aug 23, 1991
		EQ 25MG BASE/ML	A089180	001	Jan 03, 1986
METHOTREXATE LPF					
+	HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982
METHOTREXATE PRESERVATIVE FREE					
	FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999
+	HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005
+		EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **	N011719	013	Apr 13, 2005
+		EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005
METHOTREXATE SODIUM					
	ABRAXIS PHARM	EQ 2.5MG BASE/ML	A089323	001	Jun 13, 1986
		EQ 20MG BASE/VIAL	A088935	001	Oct 11, 1985
		EQ 25MG BASE/ML	A089263	001	Jun 13, 1986
		EQ 25MG BASE/ML	A089322	001	Jun 13, 1986
		EQ 50MG BASE/VIAL	A088936	001	Oct 11, 1985
		EQ 100MG BASE/VIAL	A088937	001	Oct 11, 1985
	FRESENIUS KABI USA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040263	002	Feb 26, 1999
+	HOSPIRA	EQ 2.5MG BASE/ML	N011719	004	
+		EQ 20MG BASE/VIAL	N011719	001	
+		EQ 25MG BASE/ML	N011719	005	
+		EQ 50MG BASE/VIAL	N011719	003	
+		EQ 100MG BASE/VIAL	N011719	006	
	NORBROOK	EQ 25MG BASE/ML	A088648	001	May 09, 1986
	PHARMACHEMIE USA	EQ 25MG BASE/ML	A089158	001	Jul 08, 1988
METHOTREXATE SODIUM PRESERVATIVE FREE					
	EUGIA PHARMA SPECLTS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012
		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012
		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012
		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012
+	HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988
	MYLAN	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012
MEXATE					
+	BRISTOL	EQ 20MG BASE/VIAL	A086358	001	
+		EQ 50MG BASE/VIAL	A086358	002	
+		EQ 100MG BASE/VIAL	A086358	003	
+		EQ 250MG BASE/VIAL	A086358	004	
MEXATE-AQ					
+	BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHOTREXATE SODIUM				
INJECTABLE;INJECTION				
MEXATE-AQ PRESERVED				
	BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	A089887 001	Apr 14, 1989
TABLET;ORAL				
METHOTREXATE SODIUM				
	DURAMED PHARMS BARR	EQ 2.5MG BASE	A040233 001	Jun 17, 1999
+	STRIDES PHARMA	EQ 2.5MG BASE **	N008085 002	
METHOXAMINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
VASOXYL				
	GLAXOSMITHKLINE	10MG/ML	N006772 002	
		20MG/ML	N006772 001	
METHOXSALEN				
CAPSULE;ORAL				
8-MOP				
+	VALEANT PHARM INTL	10MG	N009048 001	
METHOXSALEN				
	ACTAVIS INC	10MG	A202603 001	Jun 09, 2015
	ANI PHARMS	10MG	A087781 001	Jun 08, 1982
LOTION;TOPICAL				
OXSORALEN				
+	VALEANT PHARM INTL	1%	N009048 002	
METHSCOPOLAMINE BROMIDE				
TABLET;ORAL				
METHSCOPOLAMINE BROMIDE				
	CHARTWELL RX	2.5MG	A040624 001	Dec 28, 2006
		5MG	A040624 002	Dec 28, 2006
	PVT FORM	2.5MG	A080970 001	
PAMINE				
	FOUGERA PHARMS	2.5MG **	N008848 001	
PAMINE FORTE				
	FOUGERA PHARMS	5MG **	N008848 002	Mar 25, 2003
METHSUXIMIDE				
CAPSULE;ORAL				
CELONTIN				
+	PARKE DAVIS	150MG	N010596 007	
METHYCLOTHIAZIDE				
TABLET;ORAL				
AQUATENSEN				
	MEDPOINTE PHARM HLC	5MG	N017364 001	
ENDURON				
+	ABBVIE	2.5MG **	N012524 001	
+		5MG **	N012524 004	
METHYCLOTHIAZIDE				
	CHARTWELL RX	2.5MG	A089835 001	Aug 18, 1988
		5MG	A089837 001	Aug 18, 1988
	IVAX PHARMS	2.5MG	A087913 001	Jun 03, 1982
		5MG	A087786 001	May 18, 1982
	MYLAN	2.5MG	A087671 001	Aug 17, 1982
	MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982
	PAR PHARM	2.5MG	A089135 001	Feb 12, 1986
		5MG	A089136 001	Feb 12, 1986
	USL PHARMA	5MG	A088745 001	Mar 21, 1985
	WATSON LABS	2.5MG	A085487 001	Mar 11, 1982
		2.5MG	A088750 001	Sep 06, 1984
		5MG	A085476 001	Mar 11, 1982
		5MG	A088724 001	Sep 06, 1984
METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE				
TABLET;ORAL				
EUTRON				
	ABBOTT	5MG;25MG	N016047 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYCLOTHIAZIDE; RESERPINE				
TABLET;ORAL				
DIUTENSEN-R				
MEDPOINTE PHARM HLC	2.5MG;0.1MG	N012708	005	
METHYL AMINOLEVULINATE HYDROCHLORIDE				
CREAM;TOPICAL				
METVIXIA				
GALDERMA LABS LP	EQ 16.8% BASE	N021415	001	Jul 27, 2004
METHYLDOPA				
SUSPENSION;ORAL				
ALDOMET				
MERCK	250MG/5ML	N018389	001	
TABLET;ORAL				
ALDOMET				
+ MERCK	125MG **	N013400	003	
+	250MG **	N013400	001	
+	500MG **	N013400	002	
METHYLDOPA				
ACCORD HLTHCARE	125MG	A070070	003	Oct 15, 1985
	250MG	A070084	001	Oct 15, 1985
	500MG	A070085	001	Oct 15, 1985
CHARTWELL RX	125MG	A071700	001	Mar 02, 1988
	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984
DURAMED PHARMS BARR	250MG	A071006	001	Dec 16, 1986
	500MG	A071009	001	Dec 16, 1986
HALSEY	125MG	A071751	001	Mar 28, 1988
	250MG	A071752	001	Mar 28, 1988
	500MG	A071753	001	Mar 28, 1988
HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986
	500MG	A070343	001	Feb 20, 1986
PARKE DAVIS	125MG	A070331	001	Apr 15, 1986
	250MG	A070332	001	Apr 15, 1986
	500MG	A070333	001	Apr 15, 1986
PLIVA	125MG	A072126	001	Jul 07, 1988
	250MG	A072127	001	Jul 07, 1988
	500MG	A072128	001	Jul 07, 1988
PUREPAC PHARM	125MG	A070749	001	Feb 07, 1986
	250MG	A070750	001	Feb 07, 1986
	500MG	A070452	001	Feb 07, 1986
RISING	250MG	A070076	002	Apr 18, 1985
	500MG	A070076	001	Apr 18, 1985
ROXANE	125MG	A070192	001	Apr 25, 1986
	250MG	A070193	001	Apr 25, 1986
	500MG	A070194	001	Apr 25, 1986
STRIDES PHARMA	125MG	A070535	001	Jan 02, 1987
	250MG	A070536	001	Jan 02, 1987
	500MG	A070537	001	Jan 02, 1987
SUN PHARM INDUSTRIES	125MG	A070073	001	Oct 09, 1986
	250MG	A070060	001	Oct 09, 1986
	500MG	A070074	001	Oct 09, 1986
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986
	500MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986
	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985
	500MG	A070625	001	Jun 06, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLDOPATE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ALDOMET				
+ MERCK	50MG/ML **	N013401	001	
METHYLDOPATE HYDROCHLORIDE				
ABRAXIS PHARM	50MG/ML	A070652	001	Jun 03, 1986
AM REGENT	50MG/ML	A071279	001	Oct 02, 1987
BAXTER HLTHCARE	50MG/ML	A070291	001	Jul 01, 1986
HOSPIRA	50MG/ML	A070691	001	Jun 19, 1987
	50MG/ML	A070698	001	Jun 15, 1987
	50MG/ML	A070699	001	Jun 15, 1987
	50MG/ML	A070849	001	Jun 19, 1987
MARSAM PHARMS LLC	50MG/ML	A071812	001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841	001	Jan 02, 1987
TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991
METHYLERGONOVINE MALEATE				
TABLET;ORAL				
METHERGINE				
+ EDISON THERAPS LLC	0.2MG **	N006035	003	
METHYLPHENIDATE				
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL				
METHYLPHENIDATE				
ACTAVIS ELIZABETH	8.6MG	A210924	001	Jun 19, 2020
	17.3MG	A210924	002	Jun 19, 2020
	25.9MG	A210924	003	Jun 19, 2020
METHYLPHENIDATE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
ADHANSIA XR				
+ PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019
+	35MG	N212038	002	Feb 27, 2019
+	45MG	N212038	003	Feb 27, 2019
+	55MG	N212038	004	Feb 27, 2019
+	70MG	N212038	005	Feb 27, 2019
+	85MG	N212038	006	Feb 27, 2019
METHYLPHENIDATE HYDROCHLORIDE				
BARR LABS INC	10MG	A079031	004	Oct 15, 2014
	20MG	A079031	001	Jul 13, 2012
	30MG	A079031	002	Jul 13, 2012
	40MG	A079031	003	Jul 13, 2012
RITALIN LA				
+ SANDOZ	60MG **	N021284	005	Oct 27, 2014
SOLUTION;ORAL				
METHYLPHENIDATE HYDROCHLORIDE				
CHARTWELL MOLECULAR	5MG/5ML	A207414	001	Dec 16, 2020
	10MG/5ML	A207414	002	Dec 16, 2020
TABLET;ORAL				
METHYLPHENIDATE HYDROCHLORIDE				
ABLE	5MG	A040404	001	Mar 29, 2001
	10MG	A040404	002	Mar 29, 2001
	20MG	A040404	003	Mar 29, 2001
ACTAVIS ELIZABETH	5MG	A040321	001	Feb 05, 2002
	10MG	A040321	002	Feb 05, 2002
	20MG	A040321	003	Feb 05, 2002
ALVOGEN	5MG	A206840	001	Sep 15, 2016
	10MG	A206840	002	Sep 15, 2016
	20MG	A206840	003	Sep 15, 2016
AUROLIFE PHARMA LLC	5MG	A209276	001	Oct 25, 2018
	10MG	A209276	002	Oct 25, 2018
	20MG	A209276	003	Oct 25, 2018
CEDIPROF INC	5MG	A208737	001	Feb 01, 2019
	10MG	A208737	002	Feb 01, 2019
	20MG	A208737	003	Feb 01, 2019
LANNETT CO INC	5MG	A086429	001	
	10MG	A085799	001	
	20MG	A086428	001	
NOSTRUM LABS INC	5MG	A207587	001	Mar 03, 2017
	10MG	A207587	002	Mar 03, 2017
	20MG	A207587	003	Mar 03, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLPHENIDATE HYDROCHLORIDE					
TABLET;ORAL					
METHYLPHENIDATE HYDROCHLORIDE					
WATSON LABS	5MG		A040220	001	Aug 29, 1997
	10MG		A040220	002	Aug 29, 1997
	20MG		A040220	003	Aug 29, 1997
TABLET, CHEWABLE;ORAL					
METHYLIN					
+ SPECGX LLC	2.5MG **		N021475	001	Apr 15, 2003
+	5MG **		N021475	002	Apr 15, 2003
+	10MG **		N021475	003	Apr 15, 2003
METHYLPHENIDATE HYDROCHLORIDE					
NOSTRUM LABS INC	2.5MG		A204954	001	Jan 26, 2017
	5MG		A204954	002	Jan 26, 2017
	10MG		A204954	003	Jan 26, 2017
NOVEL LABS INC	2.5MG		A204115	001	Feb 25, 2015
	5MG		A204115	002	Feb 25, 2015
	10MG		A204115	003	Feb 25, 2015
TABLET, EXTENDED RELEASE;ORAL					
METADATE ER					
LANNETT CO INC	10MG		A040306	001	Oct 20, 1999
	20MG		A089601	001	Jun 01, 1988
METHYLPHENIDATE HYDROCHLORIDE					
ABLE	20MG		A076032	001	May 09, 2001
ALVOGEN	10MG		A204772	001	Feb 29, 2016
	18MG		A210818	001	Nov 30, 2018
	20MG		A204772	002	Feb 29, 2016
	27MG		A210818	002	Nov 30, 2018
	36MG		A210818	003	Nov 30, 2018
	54MG		A210818	004	Nov 30, 2018
AMNEAL PHARMS	18MG		A207515	001	Feb 01, 2018
	27MG		A207515	002	Feb 01, 2018
	36MG		A207515	003	Feb 01, 2018
	54MG		A207515	004	Feb 01, 2018
ANI PHARMS	18MG		A208607	001	Jul 14, 2017
	27MG		A208607	002	Jul 14, 2017
	36MG		A208607	003	Jul 14, 2017
	54MG		A208607	004	Jul 14, 2017
HERITAGE PHARMA	20MG		A075450	001	Dec 21, 2001
RHODES PHARMS	18MG		A214111	001	May 31, 2022
	27MG		A214111	002	May 31, 2022
	36MG		A214111	003	May 31, 2022
	54MG		A214111	004	May 31, 2022
STRIDES PHARMA	36MG		A204659	001	Jul 15, 2019
	54MG		A204659	002	Jul 15, 2019
WATSON LABS	20MG		A040410	001	Feb 09, 2001
RITALIN-SR					
+ NOVARTIS	20MG **		N018029	001	Mar 30, 1982
METHYLPREDNISOLONE					
TABLET;ORAL					
MEDROL					
PFIZER	24MG		N011153	005	
METHYLPREDNISOLONE					
AMNEAL	4MG		A207481	001	Sep 21, 2021
	8MG		A207481	002	Sep 21, 2021
	16MG		A207481	003	Sep 21, 2021
	32MG		A207481	004	Sep 21, 2021
CHARTWELL RX	2MG		A209097	001	Feb 22, 2019
	4MG		A209097	002	Feb 22, 2019
	8MG		A209097	003	Feb 22, 2019
	16MG		A209097	004	Feb 22, 2019
	32MG		A209097	005	Feb 22, 2019
DURAMED PHARMS BARR	4MG		A088497	001	Feb 21, 1984
HEATHER	4MG		A085650	001	
INVATECH	4MG		A087341	001	
NOVAST LABS	4MG		A210985	001	Jan 09, 2019
PAR PHARM	16MG		A089207	001	Apr 25, 1988
	24MG		A089208	001	Apr 25, 1988
	32MG		A089209	001	Apr 25, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLPREDNISOLONE				
TABLET;ORAL				
METHYLPREDNISOLONE				
WATSON LABS	4MG	A086161	001	Feb 09, 1982
	16MG	A086159	001	Feb 09, 1982
METHYLPREDNISOLONE ACETATE				
ENEMA;RECTAL				
MEDROL				
PHARMACIA AND UPJOHN	40MG/BOT	N018102	001	
INJECTABLE;INJECTION				
M-PREDROL				
BEL MAR	40MG/ML	A086666	001	
	80MG/ML	A087135	001	
METHYLPREDNISOLONE ACETATE				
AKORN	40MG/ML	A086903	001	Oct 20, 1982
	80MG/ML	A086903	002	Oct 20, 1982
SAGENT PHARMS INC	20MG/ML	A201835	001	Jun 27, 2018
WATSON LABS	20MG/ML	A085597	001	
	20MG/ML	A087248	001	
	40MG/ML	A085374	001	
	40MG/ML	A085600	001	
	80MG/ML	A085595	001	
	80MG/ML	A086507	001	
OINTMENT;TOPICAL				
MEDROL ACETATE				
PHARMACIA AND UPJOHN	0.25%	N012421	001	
	1%	N012421	002	
METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE				
CREAM;TOPICAL				
NEO-MEDROL ACETATE				
PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	A060611	002	
	1%;EQ 3.5MG BASE/GM	A060611	001	
METHYLPREDNISOLONE SODIUM SUCCINATE				
INJECTABLE;INJECTION				
A-METHAPRED				
ABBOTT	EQ 40MG BASE/VIAL	A089573	001	Feb 22, 1991
	EQ 125MG BASE/VIAL	A089574	001	Feb 22, 1991
	EQ 500MG BASE/VIAL	A089575	001	Feb 22, 1991
	EQ 1GM BASE/VIAL	A089576	001	Feb 22, 1991
HOSPIRA	EQ 40MG BASE/VIAL	A040664	001	Dec 20, 2005
	EQ 40MG BASE/VIAL	A085853	001	
	EQ 125MG BASE/VIAL	A040665	001	Dec 20, 2005
	EQ 125MG BASE/VIAL	A085855	001	
	EQ 500MG BASE/VIAL	A085854	001	
	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987
	EQ 1GM BASE/VIAL	A085852	001	
	EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987
HOSPIRA INC	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008
	EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008
METHYLPREDNISOLONE				
ELKINS SINN	EQ 125MG BASE/VIAL	A086906	002	
	EQ 500MG BASE/VIAL	A086906	003	
	EQ 1GM BASE/VIAL	A086906	004	
ORGANON USA INC	EQ 500MG BASE/VIAL	A087535	001	Jun 25, 1982
	EQ 1GM BASE/VIAL	A087535	002	Jun 25, 1982
METHYLPREDNISOLONE SODIUM SUCCINATE				
ABRAXIS PHARM	EQ 40MG BASE/VIAL	A088676	001	Jun 08, 1984
	EQ 40MG BASE/VIAL	A089143	001	Mar 28, 1986
	EQ 125MG BASE/VIAL	A088677	001	Jun 08, 1984
	EQ 125MG BASE/VIAL	A089144	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A088678	001	Jun 08, 1984
	EQ 500MG BASE/VIAL	A089186	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A089187	001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A088679	001	Jun 08, 1984
	EQ 1GM BASE/VIAL	A089188	001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A089189	001	Mar 28, 1986
BEDFORD LABS	EQ 40MG BASE/VIAL	A040662	001	Feb 21, 2007
	EQ 125MG BASE/VIAL	A040641	002	Feb 21, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLPREDNISOLONE SODIUM SUCCINATE				
INJECTABLE;INJECTION				
METHYLPREDNISOLONE SODIUM SUCCINATE				
	EQ 500MG BASE/VIAL	A040641	003	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040709	001	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040641	004	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040709	002	Feb 21, 2007
ELKINS SINN	EQ 40MG BASE/VIAL	A086906	001	
EUGIA PHARMA	EQ 40MG BASE/VIAL	A207667	001	Dec 15, 2015
	EQ 125MG BASE/VIAL	A207667	002	Dec 15, 2015
	EQ 500MG BASE/VIAL	A207667	003	Dec 15, 2015
	EQ 2GM BASE/VIAL	A207667	004	Dec 15, 2015
INTL MEDICATION	EQ 40MG BASE/VIAL	A087812	001	Feb 09, 1983
	EQ 125MG BASE/VIAL	A087813	001	Feb 09, 1983
	EQ 500MG BASE/VIAL	A087851	001	Feb 09, 1983
	EQ 1GM BASE/VIAL	A087852	001	Feb 09, 1983
TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992
	EQ 500MG BASE/VIAL	A081267	001	Nov 30, 1992
	EQ 1GM BASE/VIAL	A081268	001	Nov 30, 1992
WATSON LABS	EQ 40MG BASE/VIAL	A086953	001	Jul 22, 1982
	EQ 125MG BASE/VIAL	A087030	001	Jul 22, 1982
	EQ 500MG BASE/VIAL	A088523	001	Jul 24, 1984
	EQ 1GM BASE/VIAL	A088524	001	Jul 24, 1984
METHYLPREDNISOLONE; NEOMYCIN SULFATE				
OINTMENT;OPHTHALMIC				
NEO-MEDROL				
PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	A060645	001	
METHYLTESTOSTERONE				
CAPSULE;ORAL				
METHYLTESTOSTERONE				
HEATHER	10MG	A084967	001	
TESTRED				
+ BAUSCH	10MG	A083976	001	
VIRILON				
CHARTWELL	10MG	A087750	001	Nov 24, 1982
TABLET;BUCCAL				
ANDROID 5				
VALEANT PHARM INTL	5MG	A087222	001	
ORETON				
SCHERING	10MG	A080281	001	
TABLET;BUCCAL, SUBLINGUAL				
METANDREN				
NOVARTIS	5MG	N003240	004	
	10MG	N003240	001	
	10MG	N003240	005	
	25MG	N003240	003	
METHYLTESTOSTERONE				
IMPAX LABS	10MG	A084287	001	
LILLY	10MG	A080256	001	
	25MG	A080256	002	
PUREPAC PHARM	10MG	A080308	001	
	10MG	A080475	001	
	10MG	A080475	002	
	25MG	A080475	003	
PVT FORM	5MG	A083836	001	
TABLICAPS	10MG	A085125	001	
USL PHARMA	10MG	A080271	001	
TABLET;ORAL				
ANDROID 10				
VALEANT PHARMS NORTH	10MG	A086450	001	
METHYLTESTOSTERONE				
IMPAX LABS	25MG	A084310	001	
INWOOD LABS	10MG	A080839	001	
	25MG	A080973	001	
KV PHARM	10MG	A084312	001	
LANNETT	10MG	A087092	001	Nov 05, 1982
	25MG	A087111	001	Jan 27, 1983
PARKE DAVIS	10MG	A084244	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLTESTOSTERONE				
TABLET;ORAL				
METHYLTESTOSTERONE				
	25MG		A084241 001	
PUREPAC PHARM	10MG		A080309 001	
	25MG		A080310 001	
PVT FORM	5MG		A080214 001	
	10MG		A080214 002	
	25MG		A080214 003	
TABLICAPS	10MG		A080313 001	
	25MG		A085270 001	
WATSON LABS	10MG		A080933 001	
	25MG		A080931 001	
WEST WARD	10MG		A084331 001	
	25MG		A084331 002	
	25MG		A084642 001	
ORETON METHYL				
SCHERING	10MG		N003158 001	
	25MG		N003158 002	
METHYPRYLON				
CAPSULE;ORAL				
NOLUDAR				
ROCHE	300MG		N009660 008	
ELIXIR;ORAL				
NOLUDAR				
ROCHE	50MG/5ML		N009660 007	
TABLET;ORAL				
NOLUDAR				
ROCHE	50MG		N009660 002	
	200MG		N009660 004	
METHYSERGIDE MALEATE				
TABLET;ORAL				
SANSERT				
NOVARTIS	2MG		N012516 001	
METIPRANOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
METIPRANOLOL				
SANDOZ	0.3%		A075720 001	Aug 06, 2001
OPTIPRANOLOL				
+ BAUSCH AND LOMB	0.3% **		N019907 001	Dec 29, 1989
METOCLOPRAMIDE HYDROCHLORIDE				
CONCENTRATE;ORAL				
METOCLOPRAMIDE INTENSOL				
ROXANE	EQ 10MG BASE/ML		A072995 001	Jan 30, 1992
INJECTABLE;INJECTION				
METOCLOPRAMIDE HYDROCHLORIDE				
BEDFORD	EQ 5MG BASE/ML		A072155 001	Mar 30, 1992
	EQ 5MG BASE/ML		A072244 001	Mar 30, 1992
	EQ 5MG BASE/ML		A072247 001	May 18, 1992
HOSPIRA	EQ 5MG BASE/ML		A070505 001	Jun 23, 1989
	EQ 5MG BASE/ML		A070506 001	Jun 22, 1989
	EQ 5MG BASE/ML		A070847 001	Nov 07, 1988
	EQ 5MG BASE/ML		A071291 001	Mar 03, 1989
	EQ 5MG BASE/ML		A071990 001	Jan 18, 1989
	EQ 5MG BASE/ML		A073117 001	Jan 17, 1991
	EQ 5MG BASE/ML		A074147 001	Aug 02, 1996
LYPHOMED	EQ 10MG BASE/2ML		A070293 001	Jan 24, 1986
NORBROOK	EQ 10MG BASE/2ML		A070892 001	Aug 26, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML		A070623 001	Mar 02, 1987
	EQ 10MG BASE/2ML		A070622 001	Mar 02, 1987
REGLAN				
+ HIKMA	EQ 5MG BASE/ML **		N017862 001	
	EQ 10MG BASE/ML **		N017862 004	May 28, 1987
SOLUTION;ORAL				
METOCLOPRAMIDE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML		A071340 001	Aug 18, 1988
CHARTWELL MOLECULAR	EQ 5MG BASE/5ML		A073680 001	Oct 27, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METOCLOPRAMIDE HYDROCHLORIDE				
SOLUTION;ORAL				
METOCLOPRAMIDE HYDROCHLORIDE				
MORTON GROVE	EQ 5MG BASE/5ML	A070949	001	Mar 06, 1987
PACO	EQ 5MG BASE/5ML	A071665	001	Dec 05, 1988
PHARMOBEDIENT CNSLTG	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997
ROXANE	EQ 5MG BASE/5ML	A072038	001	Dec 05, 1988
TEVA	EQ 5MG BASE/5ML	A070819	001	Jul 10, 1987
	EQ 5MG BASE/5ML	A071315	001	Jun 30, 1993
VISTAPHARM	EQ 5MG BASE/5ML	A075051	001	Jan 26, 2001
REGLAN				
+ ROBINS AH	EQ 5MG BASE/5ML **	N018821	001	Mar 25, 1983
TABLET;ORAL				
CLOPRA				
QUANTUM PHARMICS	EQ 5MG BASE	A072384	001	Jun 02, 1988
	EQ 10MG BASE	A070294	001	Jul 29, 1985
CLOPRA-"YELLOW"				
QUANTUM PHARMICS	EQ 10MG BASE	A070632	001	Oct 28, 1985
MAXOLON				
KING PHARMS	EQ 10MG BASE	A070106	001	Mar 04, 1986
METOCLOPRAMIDE HYDROCHLORIDE				
AIPING PHARM INC	EQ 10MG BASE	A072215	001	Jan 30, 1990
CHARTWELL RX	EQ 5MG BASE	A074478	001	Oct 05, 1995
	EQ 10MG BASE	A074478	002	Oct 05, 1995
CLONMEL	EQ 10MG BASE	A072639	001	May 09, 1991
HALSEY	EQ 10MG BASE	A070906	001	Oct 28, 1986
INTERPHARM	EQ 10MG BASE	A071213	001	Sep 24, 1986
MUTUAL PHARM	EQ 10MG BASE	A070660	001	Feb 10, 1987
NORTHSTAR HLTHCARE	EQ 5MG BASE	A078374	001	Nov 30, 2007
	EQ 10MG BASE	A078374	002	Nov 30, 2007
PAR PHARM	EQ 10MG BASE	A070342	001	Mar 25, 1986
SANDOZ	EQ 5MG BASE	A072436	001	Jun 22, 1989
	EQ 10MG BASE	A070850	001	Feb 03, 1987
SCHERING	EQ 10MG BASE	A070598	001	Feb 02, 1987
SUN PHARM INDUSTRIES	EQ 5MG BASE	A071536	002	Jan 16, 1997
	EQ 10MG BASE	A071536	001	Apr 28, 1993
SUPERPHARM	EQ 10MG BASE	A070926	001	Jun 26, 1987
USL PHARMA	EQ 10MG BASE	A070339	001	Jul 29, 1985
WATSON LABS	EQ 10MG BASE	A070363	001	Mar 02, 1987
	EQ 10MG BASE	A070453	001	Jun 06, 1986
	EQ 10MG BASE	A070511	001	Jan 22, 1986
	EQ 10MG BASE	A070645	001	May 11, 1987
TABLET, ORALLY DISINTEGRATING;ORAL				
METOZOLV ODT				
+ SALIX PHARMS	EQ 5MG BASE **	N022246	001	Sep 04, 2009
+	EQ 10MG BASE **	N022246	002	Sep 04, 2009
REGLAN ODT				
MEDA PHARMS	EQ 5MG BASE	N021793	001	Jun 10, 2005
	EQ 10MG BASE	N021793	002	Jun 10, 2005
METOCURINE IODIDE				
INJECTABLE;INJECTION				
METUBINE IODIDE				
LILLY	2MG/ML	N006632	003	
METOLAZONE				
TABLET;ORAL				
DIULO				
GD SEARLE LLC	2.5MG	N018535	001	
	5MG	N018535	002	
	10MG	N018535	003	
METOLAZONE				
ANI PHARMS	2.5MG	A075543	001	Jan 06, 2004
	5MG	A075543	002	Mar 01, 2004
	10MG	A075543	003	Dec 24, 2003
ROXANE	10MG	A076482	002	Apr 29, 2004
WATSON LABS	10MG	A076891	001	Jul 21, 2004
MYKROX				
CHARTWELL MOLECULAR	0.5MG	N019532	001	Oct 30, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METOLAZONE				
TABLET;ORAL				
ZAROXOLYN				
+	I3 PHARMS	2.5MG **	N017386 001	
+		5MG **	N017386 002	
+		10MG **	N017386 003	
METOPROLOL FUMARATE				
TABLET, EXTENDED RELEASE;ORAL				
LOPRESSOR				
	NOVARTIS	EQ 100MG TARTRATE	N019786 001	Dec 27, 1989
		EQ 200MG TARTRATE	N019786 002	Dec 27, 1989
		EQ 300MG TARTRATE	N019786 003	Dec 27, 1989
		EQ 400MG TARTRATE	N019786 004	Dec 27, 1989
METOPROLOL SUCCINATE				
TABLET, EXTENDED RELEASE;ORAL				
METOPROLOL SUCCINATE				
	ACCORD HLTHCARE	EQ 25MG TARTRATE	A215637 001	Oct 18, 2022
		EQ 50MG TARTRATE	A215637 002	Oct 18, 2022
		EQ 100MG TARTRATE	A215637 003	Oct 18, 2022
		EQ 200MG TARTRATE	A215637 004	Oct 18, 2022
	ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862 002	Aug 03, 2009
		EQ 100MG TARTRATE	A077298 001	Apr 15, 2010
		EQ 200MG TARTRATE	A077298 002	Apr 15, 2010
	LUPIN	EQ 25MG TARTRATE	A209272 001	Aug 15, 2023
		EQ 50MG TARTRATE	A209272 002	Aug 15, 2023
		EQ 100MG TARTRATE	A209272 003	Aug 15, 2023
		EQ 200MG TARTRATE	A209272 004	Aug 15, 2023
	NESHER PHARMS	EQ 25MG TARTRATE	A077779 001	Mar 20, 2008
		EQ 50MG TARTRATE	A077176 001	May 14, 2008
		EQ 100MG TARTRATE	A076640 002	May 18, 2007
		EQ 200MG TARTRATE	A076640 001	May 18, 2007
	PRINSTON INC	EQ 100MG TARTRATE	A210597 001	Jan 04, 2022
		EQ 200MG TARTRATE	A210597 002	Jan 04, 2022
	SANDOZ	EQ 25MG TARTRATE	A076969 001	Jul 31, 2006
		EQ 50MG TARTRATE	A076969 002	May 18, 2007
		EQ 100MG TARTRATE	A076969 003	Mar 20, 2008
		EQ 200MG TARTRATE	A076969 004	Mar 20, 2008
METOPROLOL TARTRATE				
INJECTABLE;INJECTION				
LOPRESSOR				
+	NOVARTIS	1MG/ML **	N018704 001	Mar 30, 1984
METOPROLOL TARTRATE				
	AM REGENT	1MG/ML	A090386 001	Sep 30, 2009
	HOSPIRA	1MG/ML	A075160 001	Jul 06, 1998
	LUITPOLD	1MG/ML	A091307 001	Dec 29, 2010
	STERISCIENCE	1MG/ML	A090317 001	Apr 19, 2010
	WATSON LABS	1MG/ML	A074032 001	Dec 21, 1993
TABLET;ORAL				
METOPROLOL TARTRATE				
	APOTHECON	50MG	A074258 001	Jan 27, 1994
		100MG	A074258 002	Jan 27, 1994
	CHARTWELL RX	50MG	A073288 001	Mar 25, 1994
		100MG	A073289 001	Mar 25, 1994
	HERITAGE PHARMA	50MG	A074141 001	Jan 31, 1995
		100MG	A074141 002	Jan 31, 1995
	MYLAN	50MG	A073666 001	Dec 21, 1993
		100MG	A073666 002	Dec 21, 1993
	PUREPAC PHARM	50MG	A074380 001	Jul 29, 1994
		100MG	A074380 002	Jul 29, 1994
	SUN PHARM INDUSTRIES	25MG	A073654 002	Jul 15, 2009
		50MG	A073654 003	Dec 21, 1993
		100MG	A073654 001	Dec 21, 1993
	TEVA	50MG	A074143 001	Sep 30, 1994
		100MG	A074143 002	Sep 30, 1994
	TEVA PHARMS	50MG	A074333 001	Jan 27, 1994
		100MG	A074333 002	Jan 27, 1994
	WATSON LABS	50MG	A074217 001	May 27, 1994
		100MG	A074217 002	May 27, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METOPROLOL TARTRATE				
TABLET;ORAL				
METOPROLOL TARTRATE				
ZYDUS PHARMS	25MG	A212402	001	Apr 19, 2023
	50MG	A212402	002	Apr 19, 2023
	100MG	A212402	003	Apr 19, 2023
METRIZAMIDE				
INJECTABLE;INJECTION				
AMIPAQUE				
GE HEALTHCARE	2.5GM/VIAL	N017982	003	Sep 12, 1983
	3.75GM/VIAL	N017982	001	
	6.75GM/VIAL	N017982	002	
	13.5GM/VIAL	N017982	004	Sep 12, 1983
METRONIDAZOLE				
CAPSULE;ORAL				
METRONIDAZOLE				
ABLE	375MG	A076505	001	Nov 13, 2003
GEL;TOPICAL				
METRONIDAZOLE				
CHARTWELL RX	1%	A090903	001	Jul 22, 2011
GEL;VAGINAL				
METRONIDAZOLE				
ENCUBE	0.75%	A077264	001	Oct 31, 2006
INJECTABLE;INJECTION				
FLAGYL I.V. RTU IN PLASTIC CONTAINER				
PFIZER	500MG/100ML	N018353	002	
METRO I.V.				
B BRAUN	500MG/100ML	N018674	001	Aug 31, 1982
METRONIDAZOLE				
ABBOTT	500MG/100ML	N018889	001	Nov 18, 1983
ABRAXIS PHARM	500MG/100ML	A070071	001	Dec 03, 1984
HIKMA	500MG/100ML	N018907	001	Mar 30, 1984
INTL MEDICATION	500MG/100ML	A070004	001	May 08, 1985
WATSON LABS	500MG/100ML	A070042	001	Dec 20, 1984
	500MG/100ML	A070170	001	Apr 01, 1986
METRONIDAZOLE IN PLASTIC CONTAINER				
RISING	500MG/100ML	A205531	001	May 09, 2017
TABLET;ORAL				
FLAGYL				
+ PFIZER	250MG	N012623	001	
+	500MG	N012623	003	
METROMIDOL				
LABS AF	250MG	A074523	001	Oct 24, 1996
	500MG	A074523	002	Oct 24, 1996
METRONIDAZOLE				
ABLE	250MG	A076519	001	Jun 27, 2003
	500MG	A076519	002	Jun 27, 2003
CHARTWELL MOLECULES	250MG	N018845	001	Aug 18, 1983
	500MG	N018930	001	Aug 18, 1983
FOSUN PHARMA	250MG	N018620	001	Mar 04, 1982
	250MG	N018740	001	Oct 22, 1982
	500MG	N018620	002	Jun 02, 1983
	500MG	N018740	002	Oct 22, 1982
HALSEY	250MG	A070021	001	Apr 02, 1985
	500MG	A070593	001	Feb 27, 1986
IVAX SUB TEVA PHARMS	250MG	N018517	001	
	500MG	N018517	002	May 05, 1982
LNK	250MG	N019029	001	Apr 10, 1984
MUTUAL PHARM	250MG	N018818	001	Feb 16, 1983
	500MG	N018818	002	Feb 16, 1983
SUPERPHARM	250MG	A070008	001	Dec 11, 1984
	500MG	A070009	001	Dec 11, 1984
WATSON LABS	250MG	N018599	001	Sep 17, 1982
	250MG	N018764	001	Sep 17, 1982
	500MG	N018599	002	Feb 13, 1984
	500MG	N018764	002	Dec 20, 1982
PROTOSTAT				
ORTHO MCNEIL PHARM	250MG	N018871	001	Mar 02, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METRONIDAZOLE				
TABLET;ORAL				
PROTOSTAT				
	500MG	N018871	002	Mar 02, 1983
SATRIC				
SAVAGE LABS	250MG	A070029	001	Mar 19, 1985
	500MG	A070731	001	Jun 08, 1987
TABLET, EXTENDED RELEASE;ORAL				
FLAGYL ER				
+ PFIZER	750MG	N020868	001	Nov 26, 1997
METRONIDAZOLE				
ABLE	750MG	A076462	001	Jun 25, 2003
ALEMBIC	750MG	A090222	001	May 05, 2010
METRONIDAZOLE HYDROCHLORIDE				
INJECTABLE;INJECTION				
FLAGYL I.V.				
PFIZER	EQ 500MG BASE/VIAL **	N018353	001	
METRONIDAZOLE HYDROCHLORIDE				
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A070295	001	Oct 15, 1985
METYRAPONE				
TABLET;ORAL				
METOPIRONE				
HRA PHARMA	250MG	N012911	001	
MEXILETINE HYDROCHLORIDE				
CAPSULE;ORAL				
MEXILETINE HYDROCHLORIDE				
WATSON LABS	150MG	A074711	001	Feb 26, 1997
	150MG	A074865	001	Apr 13, 1998
	200MG	A074711	002	Feb 26, 1997
	200MG	A074865	002	Apr 13, 1998
	250MG	A074711	003	Feb 26, 1997
	250MG	A074865	003	Apr 13, 1998
MEXITIL				
+ BOEHRINGER INGELHEIM	150MG	N018873	002	Dec 30, 1985
+	200MG	N018873	003	Dec 30, 1985
+	250MG	N018873	004	Dec 30, 1985
MEZLOCILLIN SODIUM MONOHYDRATE				
INJECTABLE;INJECTION				
MEZLIN				
BAYER PHARMS	EQ 1GM BASE/VIAL	A062333	001	
	EQ 1GM BASE/VIAL	A062372	005	Jan 13, 1983
	EQ 1GM BASE/VIAL	N050549	001	
	EQ 2GM BASE/VIAL	A062333	002	
	EQ 2GM BASE/VIAL	A062372	001	May 13, 1982
	EQ 2GM BASE/VIAL	N050549	002	
	EQ 3GM BASE/VIAL	A062333	003	
	EQ 3GM BASE/VIAL	A062372	002	May 13, 1982
	EQ 3GM BASE/VIAL	A062697	001	Jan 22, 1987
	EQ 3GM BASE/VIAL	N050549	003	
	EQ 4GM BASE/VIAL	A062333	004	
	EQ 4GM BASE/VIAL	A062372	003	May 13, 1982
	EQ 4GM BASE/VIAL	A062697	002	Jan 22, 1987
	EQ 4GM BASE/VIAL	N050549	004	
	EQ 20GM BASE/VIAL	A062372	004	Mar 02, 1988
	EQ 20GM BASE/VIAL	N050549	005	Mar 02, 1988
MICAFUNGIN SODIUM				
POWDER;INTRAVENOUS				
MICAFUNGIN				
+ TEVA PHARMS USA INC	EQ 50MG BASE/VIAL	N212125	001	Jul 30, 2021
+	EQ 100MG BASE/VIAL	N212125	002	Jul 30, 2021

MICONAZOLE				
INJECTABLE;INJECTION				
MONISTAT				
JANSSEN PHARMA	10MG/ML	N018040	001	
MICONAZOLE NITRATE				
CREAM;TOPICAL				
MONISTAT-DERM				
INSIGHT PHARMS	2%	N017494	001	
CREAM;VAGINAL				
MICONAZOLE NITRATE				
TEVA	2%	A074136	001	Jan 04, 1995
TEVA PHARMS	2%	A074030	001	Oct 30, 1992
CREAM, SUPPOSITORY;TOPICAL, VAGINAL				
M-ZOLE 7 DUAL PACK				
ACTAVIS MID ATLANTIC	2%,100MG	A074586	001	Jul 17, 1997
MICONAZOLE 7 COMBINATION PACK				
COSETTE	2%,100MG	A076585	001	Mar 26, 2004
LOTION;TOPICAL				
MONISTAT-DERM				
INSIGHT PHARMS	2%	N017739	001	
SUPPOSITORY;VAGINAL				
MICONAZOLE NITRATE				
PERRIGO	100MG	A074395	001	Mar 20, 1997
TAMPON;VAGINAL				
MONISTAT 5				
PERSONAL PRODS	100MG	N018592	001	Oct 27, 1989
MIDAZOLAM HYDROCHLORIDE				
INJECTABLE;INJECTION				
MIDAZOLAM HYDROCHLORIDE				
APOTHECON	EQ 1MG BASE/ML	A075620	001	Nov 01, 2000
	EQ 5MG BASE/ML	A075620	002	Nov 01, 2000
	EQ 5MG BASE/ML	A075641	001	Oct 19, 2000
BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000
	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000
BEDFORD	EQ 5MG BASE/ML	A075249	001	Jun 23, 2000
BEN VENUE	EQ 5MG BASE/ML	A075455	001	Jun 20, 2000
HOSPIRA	EQ 1MG BASE/ML	A075396	001	Jun 20, 2000
	EQ 1MG BASE/ML	A075856	001	Jun 13, 2002
	EQ 5MG BASE/ML	A075396	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075484	001	Jun 20, 2000
	EQ 5MG BASE/ML	A075856	002	Jun 13, 2002
HOSPIRA INC	EQ 1MG BASE/ML	A075409	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075409	001	Jun 20, 2000
IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000
INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005
	EQ 5MG BASE/ML	A076144	002	Jan 26, 2005
INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004
	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004
PAI HOLDINGS	EQ 1MG BASE/ML	A078141	001	May 30, 2008
	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008
	EQ 5MG BASE/ML	A078141	002	May 30, 2008
	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008
RISING	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000
VERSED				
+ HLR	EQ 1MG BASE/ML **	N018654	002	May 26, 1987
+	EQ 5MG BASE/ML **	N018654	001	Dec 20, 1985
SOLUTION;INTRAMUSCULAR				
MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)				
+ RAFA LABS LTD	EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML)	N216359	001	Aug 08, 2022
SYRUP;ORAL				
MIDAZOLAM HYDROCHLORIDE				
AKORN	EQ 2MG BASE/ML	A075958	001	Sep 04, 2003
PHARM ASSOC	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005
SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002
VERSED				
+ ROCHE	EQ 2MG BASE/ML **	N020942	001	Oct 15, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MIDODRINE HYDROCHLORIDE

TABLET;ORAL					
MIDODRINE HYDROCHLORIDE					
	CHARTWELL RX	2.5MG	A076514	001	Sep 11, 2003
		5MG	A076514	002	Sep 11, 2003
		10MG	A076514	003	Jul 02, 2004
PROAMATINE					
+	TAKEDA PHARMS USA	2.5MG **	N019815	001	Sep 06, 1996
+		5MG **	N019815	002	Sep 06, 1996
+		10MG **	N019815	003	Mar 20, 2002

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL					
MILNACIPRAN HYDROCHLORIDE					
	AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016
		25MG	A205081	002	Apr 22, 2016
		50MG	A205081	003	Apr 22, 2016
		100MG	A205081	004	Apr 22, 2016
	USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016
		25MG	A205071	002	Jan 27, 2016
		50MG	A205071	003	Jan 27, 2016
		100MG	A205071	004	Jan 27, 2016

MILRINONE LACTATE

INJECTABLE;INJECTION					
MILRINONE LACTATE					
	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004
	GLAND PHARMA LTD	EQ 1MG BASE/ML	A077190	001	Oct 31, 2006
	HIKMA	EQ 1MG BASE/ML	A075852	001	May 28, 2002
	HOSPIRA	EQ 1MG BASE/ML	A075830	001	May 28, 2002
		EQ 1MG BASE/ML	A075884	001	May 28, 2002
	INTL MEDICATED	EQ 1MG BASE/ML	A076013	001	Aug 02, 2002
	MYLAN INSTITUTIONAL	EQ 1MG BASE/ML	A076428	001	Jun 16, 2003
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414	001	Aug 18, 2004
	BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076259	001	Aug 08, 2002
	HIKMA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002
	HOSPIRA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075885	001	May 28, 2002
		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A075885	002	May 28, 2002
	WOODWARD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005
PRIMACOR					
+	SANOFI AVENTIS US	EQ 1MG BASE/ML **	N019436	001	Dec 31, 1987
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	SANOFI AVENTIS US	EQ 10MG BASE/100ML **	N020343	001	Aug 09, 1994
+		EQ 15MG BASE/100ML **	N020343	002	Aug 09, 1994
+		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) **	N020343	003	Aug 09, 1994
+		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) **	N020343	004	Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL					
DYNACIN					
	ALVOGEN	EQ 50MG BASE	A063067	003	Aug 14, 1990
		EQ 75MG BASE	A063067	002	Sep 15, 1999
		EQ 100MG BASE	A063067	001	Jul 31, 1990
MINOCIN					
+	BAUSCH	EQ 75MG BASE **	N050649	003	Feb 12, 2001
	TRIAX PHARMS	EQ 50MG BASE	N050315	002	
		EQ 100MG BASE	N050315	001	
CAPSULE, EXTENDED RELEASE;ORAL					
XIMINO					
	JOURNEY	EQ 45MG BASE	N201922	001	Jul 11, 2012
		EQ 67.5MG BASE	N201922	002	Jul 11, 2012
		EQ 90MG BASE	N201922	003	Jul 11, 2012
		EQ 112.5MG BASE	N201922	004	Jul 11, 2012
		EQ 135MG BASE	N201922	005	Jul 11, 2012
INJECTABLE;INJECTION					
MINOCIN					
	LEDERLE	EQ 100MG BASE/VIAL	A062139	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MINOCYCLINE HYDROCHLORIDE				
SUSPENSION;ORAL				
MINOCIN				
	BAUSCH	EQ 50MG BASE/5ML	N050445 001	
TABLET;ORAL				
MINOCYCLINE HYDROCHLORIDE				
+	TRIAX PHARMS	EQ 50MG BASE **	N050451 003	Aug 10, 1982
+		EQ 100MG BASE **	N050451 002	Aug 10, 1982
TABLET, EXTENDED RELEASE;ORAL				
MINOCYCLINE HYDROCHLORIDE				
	BARR LABS INC	EQ 45MG BASE	A065485 001	Mar 17, 2009
		EQ 65MG BASE	A065485 004	May 18, 2012
		EQ 80MG BASE	A065485 007	Apr 26, 2017
		EQ 90MG BASE	A065485 002	Mar 17, 2009
		EQ 105MG BASE	A065485 008	Apr 26, 2017
		EQ 115MG BASE	A065485 005	May 18, 2012
		EQ 135MG BASE	A065485 003	Mar 17, 2009
	IMPAX LABS INC	EQ 45MG BASE	A090024 001	Feb 03, 2009
		EQ 90MG BASE	A090024 002	Feb 03, 2009
		EQ 135MG BASE	A090024 003	Feb 03, 2009
	MYLAN PHARMS INC	EQ 45MG BASE	A090911 001	Jul 20, 2010
		EQ 90MG BASE	A090911 002	Jul 20, 2010
		EQ 135MG BASE	A090911 003	Jul 20, 2010
	RISING	EQ 55MG BASE	A203443 001	Aug 21, 2019
		EQ 65MG BASE	A201467 001	Jul 30, 2019
		EQ 80MG BASE	A203443 002	Aug 22, 2014
		EQ 105MG BASE	A203443 003	Aug 22, 2014
		EQ 115MG BASE	A201467 002	Jul 30, 2019
SOLODYN				
+	BAUSCH	EQ 45MG BASE **	N050808 001	May 08, 2006
+		EQ 90MG BASE **	N050808 002	May 08, 2006
+		EQ 135MG BASE **	N050808 003	May 08, 2006
MINOXIDIL				
SOLUTION;TOPICAL				
MINOXIDIL (FOR MEN)				
	APOTEX INC	2%	A074924 001	Apr 29, 1998
	BAUSCH AND LOMB	2%	A074643 001	Apr 09, 1996
	COPLEY PHARM	2%	A074500 001	May 23, 1996
	HIKMA	2%	A074731 001	Dec 24, 1996
	SIGHT PHARMS	2%	A074743 002	Oct 18, 1996
	TEVA	2%	A074589 001	Apr 05, 1996
MINOXIDIL (FOR WOMEN)				
	APOTEX INC	2%	A074924 002	Apr 29, 1998
	HIKMA	2%	A074731 002	May 11, 2005
	SIGHT PHARMS	2%	A074743 001	Oct 18, 1996
MINOXIDIL EXTRA STRENGTH (FOR MEN)				
	APOTEX INC	5%	A075839 001	Oct 01, 2001
	AVACOR PRODS	5%	A075619 001	Nov 17, 2000
	PERRIGO NEW YORK	5%	A075737 001	Mar 15, 2002
TABLET;ORAL				
LONITEN				
+	PFIZER	2.5MG **	N018154 001	
+		10MG **	N018154 003	
MINODYL				
	QUANTUM PHARMICS	2.5MG	A072153 001	Jul 13, 1988
		10MG	A071534 001	Mar 19, 1987
MINOXIDIL				
	ROYCE LABS	2.5MG	A071799 001	Nov 10, 1987
		10MG	A071796 001	Nov 10, 1987
	USL PHARMA	2.5MG	A071537 001	Dec 16, 1988
MIPOMERSEN SODIUM				
SOLUTION;SUBCUTANEOUS				
KYNAMRO				
+	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568 001	Jan 29, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MIRABEGRON
TABLET, EXTENDED RELEASE;ORAL
MIRABEGRON

SAWAI USA	25MG	A209446	001	Dec 27, 2019
ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022
	50MG	A209488	002	Sep 29, 2022

MIRTAZAPINE
TABLET;ORAL
MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076241	001	Jun 25, 2003
	15MG	A076308	001	Jun 20, 2003
	30MG	A076241	002	Jun 25, 2003
	30MG	A076308	002	Jun 20, 2003
	45MG	A076241	003	Jun 25, 2003
	45MG	A076308	003	Jun 20, 2003
ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003
	30MG	A076336	002	Jun 20, 2003
	45MG	A076336	003	Jun 20, 2003
IVAX SUB TEVA PHARMS	15MG	A076244	001	Dec 22, 2003
	30MG	A076244	002	Dec 22, 2003
	45MG	A076244	003	Dec 22, 2003
MYLAN PHARMS INC	15MG	A076176	001	Jun 19, 2003
	30MG	A076176	002	Jun 19, 2003
	45MG	A076176	003	Jun 19, 2003
ROXANE	15MG	A076270	001	Jun 19, 2003
	30MG	A076270	002	Jun 19, 2003
	45MG	A076270	003	Jun 19, 2003
UPSHER SMITH LABS	15MG	A076189	001	Jun 19, 2003
	30MG	A076189	002	Jun 19, 2003
	45MG	A076189	003	Jun 19, 2003
WATSON LABS	15MG	A076312	001	Jun 19, 2003
	30MG	A076312	002	Jun 19, 2003
	45MG	A076312	003	Jun 19, 2003

REMERON

+	ORGANON	45MG **	N020415	003	Mar 17, 1997

TABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076689	001	Aug 31, 2005
	15MG	A077959	001	Feb 14, 2011
	30MG	A076689	002	Aug 31, 2005
	30MG	A077959	002	Feb 14, 2011
	45MG	A076689	003	Aug 31, 2005
	45MG	A077959	003	Feb 14, 2011
ACTAVIS LABS FL INC	15MG	A076307	001	Dec 17, 2003
	30MG	A076307	002	Dec 17, 2003
	45MG	A076307	003	Feb 28, 2006
IMPAX LABS INC	15MG	A076901	001	Jun 28, 2005
	30MG	A076901	002	Jun 28, 2005
	45MG	A076901	003	Jun 28, 2005

MISOPROSTOL
TABLET;ORAL
MISOPROSTOL

ACQ PHARMA	0.1MG	A210201	001	Jul 02, 2019
	0.2MG	A210201	002	Jul 02, 2019
NOVEL LABS INC	0.1MG	A091667	001	Jul 25, 2012
	0.2MG	A091667	002	Jul 25, 2012

MITOMYCIN
INJECTABLE;INJECTION
MITOMYCIN

HIKMA	5MG/VIAL	A064117	001	Apr 19, 1995
HOSPIRA	20MG/VIAL	A064106	001	Nov 29, 1995

MITOZYTREX

+	SUPERGEN	5MG/VIAL **	N050763	001	Nov 14, 2002

MUTAMYCIN

+	BRISTOL	5MG/VIAL **	N050450	001	
+		20MG/VIAL **	N050450	002	
	BRISTOL MYERS	5MG/VIAL	A062336	001	
		20MG/VIAL	A062336	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MITOMYCIN				
INJECTABLE;INJECTION				
MUTAMYCIN				
	40MG/VIAL **		A062336 003	Mar 10, 1988
MITOXANTRONE HYDROCHLORIDE				
INJECTABLE;INJECTION				
MITOXANTRONE HYDROCHLORIDE				
FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)		A078606 001	May 14, 2008
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)		A078606 002	May 14, 2008
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)		A078606 003	May 14, 2008
MYLAN LABS LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)		A201014 001	Dec 11, 2012
RISING	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)		A078980 001	Apr 13, 2009
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)		A078980 002	Apr 13, 2009
NOVANTRONE				
+ EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML) **		N019297 001	Dec 23, 1987
+	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) **		N019297 002	Dec 23, 1987
+	EQ 30MG BASE/15ML (EQ 2MG BASE/ML) **		N019297 003	Dec 23, 1987
MIVACURIUM CHLORIDE				
INJECTABLE;INJECTION				
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBVIE	EQ 0.5MG BASE/ML		N020098 002	Jan 22, 1992
	EQ 50MG BASE/100ML		N020098 003	Jan 22, 1992
MIVACURIUM CHLORIDE				
RISING	EQ 2MG BASE/ML		A078562 001	Apr 30, 2009
SOLUTION;INTRAVENOUS				
MIVACRON				
+ ABBVIE	EQ 2MG BASE/ML (EQ 2MG BASE/ML) **		N020098 001	Jan 22, 1992
+	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)		N020098 004	Jan 22, 1992
+	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)		N020098 005	Jan 22, 1992
MODAFINIL				
TABLET;ORAL				
MODAFINIL				
HIKMA PHARMS	100MG		A090543 001	Sep 26, 2012
	200MG		A090543 002	Sep 26, 2012
MYLAN PHARMS INC	100MG		A076594 001	Jul 16, 2012
	200MG		A076594 002	Jul 16, 2012
MOEXIPRIL HYDROCHLORIDE				
TABLET;ORAL				
UNIVASC				
UCB INC	7.5MG **		N020312 001	Apr 19, 1995
	15MG **		N020312 002	Apr 19, 1995
MOLINDONE HYDROCHLORIDE				
CAPSULE;ORAL				
MOBAN				
+ CHARTWELL RX	5MG **		N017111 001	
+	10MG **		N017111 002	
+	25MG **		N017111 003	
CONCENTRATE;ORAL				
MOBAN				
ENDO PHARMS	20MG/ML		N017938 001	
TABLET;ORAL				
MOBAN				
+ CHARTWELL RX	5MG **		N017111 004	
+	10MG **		N017111 005	
+	25MG **		N017111 006	
+	50MG **		N017111 007	
+	100MG **		N017111 008	
MOMETASONE FUROATE				
CREAM;TOPICAL				
ELOCON				
ORGANON	0.1% **		N019625 001	May 06, 1987
+	0.1% **		N019625 002	Apr 19, 2013
MOMETASONE FUROATE				
ANDA REPOSITORY	0.1%		A076591 001	Apr 18, 2007
FOUGERA PHARMS	0.1%		A076171 001	Apr 08, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MOMETASONE FUROATE				
LOTION;TOPICAL				
ELOCON				
+ ORGANON	0.1% **	N019796	001	Mar 30, 1989
MOMETASONE FUROATE				
ENCUBE	0.1%	A076499	001	Nov 21, 2007
OINTMENT;TOPICAL				
ELOCON				
+ ORGANON	0.1%	N019543	001	Apr 30, 1987
MOMETASONE FUROATE				
ENCUBE	0.1%	A076481	001	Nov 14, 2003
TARO	0.1%	A076624	001	Dec 03, 2004
TORRENT	0.1%	A207899	001	Jul 13, 2018
SPRAY, METERED;NASAL				
MOMETASONE FUROATE				
AMNEAL	0.05MG/SPRAY	A217460	001	Jun 14, 2023
NASONEX				
+ ORGANON LLC	0.05MG/SPRAY **	N020762	001	Oct 01, 1997
MONOBENZONE				
CREAM;TOPICAL				
BENOQUIN				
VALEANT PHARM INTL	20%	N008173	003	
MONOCTANOIN				
LIQUID;PERFUSION, BILIARY				
MOCTANIN				
ETHITEK	100%	N019368	001	Oct 29, 1985
MONTELUKAST SODIUM				
GRANULE;ORAL				
MONTELUKAST SODIUM				
MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012
TABLET;ORAL				
MONTELUKAST SODIUM				
AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015
APOTEX CORP	EQ 10MG BASE	A201294	001	Aug 03, 2012
BRECKENRIDGE	EQ 10MG BASE	A205319	001	Oct 30, 2020
HIKMA	EQ 10MG BASE	A090655	001	Aug 03, 2012
L PERRIGO CO	EQ 10MG BASE	A206112	001	Apr 26, 2017
MYLAN PHARMS INC	EQ 10MG BASE	A079103	001	Aug 03, 2012
STRIDES PHARMA	EQ 10MG BASE	A091576	001	Aug 03, 2012
TABLET, CHEWABLE;ORAL				
MONTELUKAST SODIUM				
AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015
	EQ 5MG BASE	A203328	002	Jul 31, 2015
APOTEX INC	EQ 4MG BASE	A201508	001	Aug 03, 2012
	EQ 5MG BASE	A201508	002	Aug 03, 2012
HIKMA	EQ 4MG BASE	A091128	001	Aug 03, 2012
	EQ 5MG BASE	A091128	002	Aug 03, 2012
JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015
	EQ 5MG BASE	A203795	002	Feb 27, 2015
MYLAN PHARMS INC	EQ 4MG BASE	A079142	001	Aug 03, 2012
	EQ 5MG BASE	A079142	002	Aug 03, 2012
STRIDES PHARMA	EQ 4MG BASE	A091588	001	Aug 03, 2012
	EQ 5MG BASE	A091588	002	Aug 03, 2012
UNICHEM	EQ 4MG BASE	A208621	001	Jul 02, 2018
	EQ 5MG BASE	A208621	002	Jul 02, 2018
MORICIZINE HYDROCHLORIDE				
TABLET;ORAL				
ETHMOZINE				
SHIRE	200MG	N019753	001	Jun 19, 1990
	250MG	N019753	002	Jun 19, 1990
	300MG	N019753	003	Jun 19, 1990

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL					
AVINZA					
	KING PHARMS LLC	30MG	N021260	001	Mar 20, 2002
		45MG	N021260	005	Dec 18, 2008
		60MG	N021260	002	Mar 20, 2002
		75MG	N021260	006	Dec 18, 2008
		90MG	N021260	003	Mar 20, 2002
		120MG	N021260	004	Mar 20, 2002
KADIAN					
+	ALLERGAN	10MG	N020616	008	Apr 20, 2007
+		20MG	N020616	001	Jul 03, 1996
+		30MG	N020616	004	Mar 09, 2001
+		40MG	N020616	009	Jul 09, 2012
+		50MG	N020616	002	Jul 03, 1996
+		60MG	N020616	005	Mar 09, 2001
+		70MG	N020616	010	Jul 09, 2012
+		80MG	N020616	006	Oct 27, 2006
+		100MG	N020616	003	Jul 03, 1996
+		130MG	N020616	011	Jul 09, 2012
+		150MG	N020616	012	Jul 09, 2012
+		200MG	N020616	007	Feb 27, 2007
MORPHINE SULFATE					
	IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016
		30MG	A200411	002	Apr 12, 2016
		40MG	A200411	007	Jul 25, 2018
		50MG	A200411	003	Apr 12, 2016
		60MG	A200411	004	Apr 12, 2016
		80MG	A200411	005	Apr 12, 2016
		100MG	A200411	006	Apr 12, 2016
	NORTEC DEV ASSOC	20MG	A203158	001	Aug 04, 2021
		30MG	A203158	002	Aug 04, 2021
		50MG	A203158	003	Aug 04, 2021
		60MG	A203158	004	Aug 04, 2021
		80MG	A203158	005	Aug 04, 2021
		100MG	A203158	006	Aug 04, 2021
	STRIDES PHARMA	20MG	A200812	001	Nov 10, 2011
		30MG	A200812	002	Nov 10, 2011
		50MG	A200812	003	Nov 10, 2011
		60MG	A200812	004	Nov 10, 2011
		80MG	A200812	005	Nov 10, 2011
		100MG	A200812	006	Nov 10, 2011
	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014
		30MG	A202718	002	Dec 29, 2014
		40MG	A202718	007	Jun 03, 2015
		50MG	A202718	003	Dec 29, 2014
		60MG	A202718	004	Dec 29, 2014
		70MG	A202718	008	Jun 03, 2015
		80MG	A202718	005	Dec 29, 2014
		100MG	A202718	006	Dec 29, 2014
INJECTABLE;INJECTION					
ASTRAMORPH PF					
	FRESENIUS KABI USA	0.5MG/ML	A071050	001	Oct 07, 1986
		0.5MG/ML	A071051	001	Oct 07, 1986
		1MG/ML	A071052	001	Oct 07, 1986
		1MG/ML	A071053	001	Oct 07, 1986
MORPHINE SULFATE					
	HOSPIRA	1MG/ML	A071850	001	May 11, 1988
+	HOSPIRA INC	15MG/ML	N202515	005	Nov 14, 2011
	ICU MEDICAL INC	0.5MG/ML	N019917	001	Oct 30, 1992
+		1MG/ML **	N019916	001	Oct 30, 1992
+		5MG/ML **	N019916	002	Oct 27, 2006
	SPECGX LLC	1MG/ML	N020631	001	Jul 03, 1996
		2MG/ML	N020631	002	Jul 03, 1996
	WATSON LABS	0.5MG/ML	A073373	001	Sep 30, 1991
		0.5MG/ML	A073375	001	Sep 30, 1991
		1MG/ML	A073374	001	Sep 30, 1991
		1MG/ML	A073376	001	Sep 30, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MORPHINE SULFATE

INJECTABLE, LIPOSOMAL;EPIDURAL				
DEPODUR				
PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671	001	May 18, 2004
	15MG/1.5ML (10MG/ML)	N021671	002	May 18, 2004
	20MG/2ML (10MG/ML)	N021671	003	May 18, 2004
SOLUTION;INTRAMUSCULAR				
MORPHINE SULFATE (AUTOINJECTOR)				
+ MERIDIAN MEDCL TECHN	10MG/0.7ML (10MG/0.7ML)	N019999	001	Jul 12, 1990
SOLUTION;ORAL				
MORPHINE SULFATE				
ANI PHARMS	10MG/5ML	A205509	001	Apr 17, 2018
	20MG/5ML	A205509	002	Apr 17, 2018
	100MG/5ML	A205509	003	Apr 17, 2018
CHARTWELL MOLECULAR	10MG/5ML	A202309	001	Nov 25, 2015
	20MG/5ML	A202310	001	Oct 30, 2015
	100MG/5ML	N201517	001	Jun 23, 2011
NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014
	20MG/5ML	A201011	002	Feb 05, 2014
	100MG/5ML	A201011	003	Oct 06, 2016
TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016
VISTAPHARM	10MG/5ML	A201947	001	Jan 05, 2012
	20MG/5ML	A201947	002	Jan 05, 2012
WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021
	20MG/5ML	A211454	002	Feb 12, 2021
	100MG/5ML	A211454	003	Feb 12, 2021
TABLET;ORAL				
MORPHINE SULFATE				
DR REDDYS LABS SA	15MG	A207270	001	Jan 12, 2022
	30MG	A207270	002	Jan 12, 2022
INGENUS PHARMS NJ	15MG	A215584	001	Feb 07, 2022
	30MG	A215584	002	Feb 07, 2022
TABLET, EXTENDED RELEASE;ORAL				
ARYMO ER				
+ ZYLA	15MG	N208603	001	Jan 09, 2017
+	30MG	N208603	002	Jan 09, 2017
+	60MG	N208603	003	Jan 09, 2017
MORPHABOND ER				
+ OHEMO LIFE	15MG	N206544	001	Oct 02, 2015
+	30MG	N206544	002	Oct 02, 2015
+	60MG	N206544	003	Oct 02, 2015
+	100MG	N206544	004	Oct 02, 2015
MORPHINE SULFATE				
DR REDDYS LABS SA	15MG	A205386	001	Oct 28, 2016
	30MG	A205386	002	Oct 28, 2016
	60MG	A205386	003	Oct 28, 2016
	100MG	A205386	004	Oct 28, 2016
EPIC PHARMA LLC	15MG	A091357	001	Jun 23, 2016
	30MG	A091357	002	Jun 23, 2016
	60MG	A091357	003	Jun 23, 2016
	100MG	A091357	004	Jun 23, 2016
	200MG	A091357	005	Jun 23, 2016
NESHER PHARMS	15MG	A076733	001	May 19, 2004
	30MG	A076720	002	Dec 23, 2005
	60MG	A076720	001	May 19, 2004
	100MG	A077855	001	Sep 27, 2007
	200MG	A077855	002	Sep 27, 2007
RISING	15MG	A200824	001	Oct 18, 2011
	30MG	A200824	002	Oct 18, 2011
	60MG	A200824	003	Oct 18, 2011
	100MG	A200824	004	Oct 18, 2011
	200MG	A200824	005	Oct 18, 2011
SUN PHARM INDUSTRIES	15MG	A205634	001	Aug 25, 2016
	30MG	A205634	002	Aug 25, 2016
	60MG	A205634	003	Aug 25, 2016
	100MG	A205634	004	Aug 25, 2016
	200MG	A205634	005	Aug 25, 2016
WATSON LABS	100MG	A075656	001	Jan 30, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
ORAMORPH SR				
	XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994
		30MG	N019977 001	Aug 15, 1991
		60MG	N019977 002	Aug 15, 1991
		100MG	N019977 003	Aug 15, 1991

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
EMBEDA				
+	ALPHARMA PHARMS	20MG;0.8MG **	N022321 001	Aug 13, 2009
+		30MG;1.2MG **	N022321 002	Aug 13, 2009
+		50MG;2MG **	N022321 003	Aug 13, 2009
+		60MG;2.4MG **	N022321 004	Aug 13, 2009
+		80MG;3.2MG **	N022321 005	Aug 13, 2009
+		100MG;4MG **	N022321 006	Aug 13, 2009

MOXALACTAM DISODIUM

INJECTABLE;INJECTION				
MOXAM				
	LILLY	EQ 250MG BASE/VIAL	N050550 001	
		EQ 500MG BASE/VIAL	N050550 002	
		EQ 1GM BASE/VIAL	N050550 003	
		EQ 2GM BASE/VIAL	N050550 004	
		EQ 10GM BASE/VIAL	N050550 008	

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;INTRAVENOUS				
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER				
+	BAYER HLTHCARE	400MG/250ML (1.6MG/ML) **	N021277 001	Nov 30, 2001
SOLUTION/DROPS;OPHTHALMIC				
MOXEZA				
+	HARROW EYE	EQ 0.5% BASE	N022428 001	Nov 19, 2010
MOXIFLOXACIN HYDROCHLORIDE				
	AKORN	EQ 0.5% BASE	A202916 001	Nov 09, 2017
TABLET;ORAL				
AVELOX				
+	BAYER HLTHCARE	EQ 400MG BASE **	N021085 001	Dec 10, 1999
MOXIFLOXACIN HYDROCHLORIDE				
	MYLAN	EQ 400MG BASE	A204635 001	Aug 31, 2015
	SUNSHINE	EQ 400MG BASE	A206295 001	Sep 28, 2018
	TORRENT	EQ 400MG BASE	A200160 001	Apr 03, 2014

MUPIROCIN

OINTMENT;TOPICAL				
BACTROBAN				
+	GLAXOSMITHKLINE	2% **	N050591 001	Dec 31, 1987

MUPIROCIN CALCIUM

CREAM;TOPICAL				
BACTROBAN				
+	GLAXOSMITHKLINE	EQ 2% BASE **	N050746 001	Dec 11, 1997
MUPIROCIN				
	PADAGIS ISRAEL	EQ 2% BASE	A212465 001	Aug 03, 2022
OINTMENT;NASAL				
BACTROBAN				
+	GLAXOSMITHKLINE	EQ 2% BASE	N050703 001	Sep 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL				
MYCOPHENOLATE MOFETIL				
	APOTEX CORP	250MG	A090419 001	Apr 22, 2009
	DR REDDYS LABS LTD	250MG	A091315 001	Oct 27, 2011
	JUBILANT CADISTA	250MG	A090762 001	Dec 15, 2014
	STRIDES PHARMA	250MG	A090111 001	Dec 22, 2009
	ZYDUS PHARMS USA INC	250MG	A065433 001	May 04, 2009
TABLET;ORAL				
MYCOPHENOLATE MOFETIL				
	APOTEX	500MG	A090499 001	Apr 22, 2009
	DR REDDYS LABS LTD	500MG	A090464 001	Sep 13, 2010
	JUBILANT CADISTA	500MG	A090661 001	Dec 15, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MYCOPHENOLATE MOFETIL

TABLET;ORAL

MYCOPHENOLATE MOFETIL

TEVA PHARMS	500MG	A065457	001	May 04, 2009
ZYDUS PHARMS USA INC	500MG	A065477	001	May 04, 2009

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AMNEAL	500MG/VIAL	A211374	001	Mar 05, 2021

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC SODIUM

TEVA PHARMS USA	EQ 180MG BASE	A202720	001	Oct 30, 2014
	EQ 360MG BASE	A202720	002	Oct 30, 2014

NABUMETONE

TABLET;ORAL

NABUMETONE

AUROBINDO PHARMA USA	500MG	A090516	001	Jul 12, 2010
	750MG	A090516	002	Jul 12, 2010
COPLEY PHARM	750MG	A075179	001	Jun 06, 2000
EPIC PHARMA LLC	500MG	A075590	001	Feb 25, 2002
	750MG	A075590	002	Feb 25, 2002
IMPAX LABS INC	500MG	A075189	001	May 26, 2000
	750MG	A075189	002	Sep 24, 2001
NOSTRUM LABS INC	500MG	A090427	001	Dec 30, 2011
	750MG	A090427	002	Dec 30, 2011
OXFORD PHARMS	500MG	A079093	001	Feb 27, 2009
	750MG	A079093	002	Feb 27, 2009

RELAFEN

+	SMITHKLINE BEECHAM	500MG **	N019583	001	Dec 24, 1991
+		750MG **	N019583	002	Dec 24, 1991

NADOLOL

TABLET;ORAL

CORGARD

USWM	120MG	N018063	003	
	160MG	N018063	004	

NADOLOL

HERITAGE PHARMA	20MG	A074229	001	Aug 30, 1996
	40MG	A074229	002	Aug 30, 1996
	80MG	A074255	001	Jan 24, 1996
	120MG	A074255	002	Jan 24, 1996
	160MG	A074255	003	Jan 24, 1996
NOVAST LABS	20MG	A210786	001	Jun 01, 2018
	40MG	A210786	002	Jun 01, 2018
	80MG	A210786	003	Jun 01, 2018
TEVA PHARMS	80MG	A074368	001	Aug 31, 1994
	120MG	A074368	002	Aug 31, 1994
	160MG	A074368	003	Aug 31, 1994

NAFCILLIN SODIUM

CAPSULE;ORAL

UNIPEN

WYETH AYERST	EQ 250MG BASE	N050111	001	

FOR SOLUTION;ORAL

UNIPEN

WYETH AYERST	EQ 250MG BASE/5ML	N050199	001	

INJECTABLE;INJECTION

NAFCILLIN SODIUM

APOTHECON	EQ 500MG BASE/VIAL	A061984	001	
	EQ 1GM BASE/VIAL	A061984	002	
	EQ 2GM BASE/VIAL	A061984	003	
	EQ 4GM BASE/VIAL	A061984	005	
FRESENIUS	EQ 1GM BASE/VIAL	A206682	001	Dec 10, 2019
	EQ 2GM BASE/VIAL	A206682	002	Dec 10, 2019
SANDOZ	EQ 500MG BASE/VIAL	A062527	001	Aug 02, 1984
	EQ 1GM BASE/VIAL	A062527	002	Aug 02, 1984
	EQ 1GM BASE/VIAL	A062732	001	Dec 23, 1986
	EQ 2GM BASE/VIAL	A062527	003	Aug 02, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NAFCILLIN SODIUM

INJECTABLE;INJECTION				
NAFCILLIN SODIUM				
	EQ 2GM BASE/VIAL	A062732	002	Dec 23, 1986
	EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984
WATSON LABS INC	EQ 500MG BASE/VIAL	A062844	001	Oct 26, 1988
	EQ 1GM BASE/VIAL	A062844	002	Oct 26, 1988
	EQ 1.5GM BASE/VIAL	A062844	003	Oct 26, 1988
	EQ 2GM BASE/VIAL	A062844	004	Oct 26, 1988
	EQ 4GM BASE/VIAL	A062844	005	Oct 26, 1988
	EQ 10GM BASE/VIAL	A063008	001	Sep 29, 1988
NALLPEN				
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	A061999	001	
	EQ 1GM BASE/VIAL	A061999	002	
	EQ 1GM BASE/VIAL	A062755	001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A061999	003	
	EQ 2GM BASE/VIAL	A062755	002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A061999	004	
UNIPEN				
WYETH AYERST	EQ 500MG BASE/VIAL **	A062717	001	Dec 16, 1986
+	EQ 500MG BASE/VIAL **	N050320	001	
	EQ 1GM BASE/VIAL **	A062717	002	Dec 16, 1986
	EQ 2GM BASE/VIAL **	A062717	004	Dec 16, 1986
+	EQ 2GM BASE/VIAL **	N050320	003	
+	EQ 4GM BASE/VIAL **	N050320	004	
+	EQ 10GM BASE/VIAL **	N050320	005	
+	EQ 20GM BASE/VIAL **	N050320	006	
UNIPEN IN PLASTIC CONTAINER				
+ WYETH AYERST	EQ 1GM BASE/VIAL **	N050320	002	
TABLET;ORAL				
UNIPEN				
WYETH AYERST	EQ 500MG BASE	N050462	001	

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL				
NAFTIN				
+ SEBELA IRELAND LTD	1% **	N019599	001	Feb 29, 1988

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION				
NALBUPHINE				
ABRAXIS PHARM	10MG/ML	A070751	001	Jul 02, 1986
	20MG/ML	A070752	001	Sep 24, 1986
NALBUPHINE HYDROCHLORIDE				
ABBOTT	20MG/ML	A070917	001	Feb 03, 1989
ABBVIE	1.5MG/ML	N020200	001	Mar 12, 1993
DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998
	20MG/ML	A074471	002	Mar 19, 1998
IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989
	10MG/ML	A072071	001	Apr 10, 1989
	10MG/ML	A072072	001	Apr 10, 1989
	20MG/ML	A072073	001	Apr 10, 1989
	20MG/ML	A072074	001	Apr 10, 1989
	20MG/ML	A072075	001	Apr 10, 1989
RISING	10MG/ML	A206506	001	Feb 06, 2019
	10MG/ML	A207595	001	Jan 11, 2019
	20MG/ML	A206506	002	Feb 06, 2019
	20MG/ML	A207595	002	Jan 11, 2019
NUBAIN				
+ PAR PHARM INC	10MG/ML **	N018024	001	
+	20MG/ML **	N018024	002	May 27, 1982

NALIDIXIC ACID

SUSPENSION;ORAL				
NEGGRAM				
SANOFI AVENTIS US	250MG/5ML	N017430	001	
TABLET;ORAL				
NALIDIXIC ACID				
SUN PHARM INDUSTRIES	250MG	A070270	001	Jun 29, 1988
	500MG	A070271	001	Jun 29, 1988
	1GM	A070272	001	Jun 29, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NALIDIXIC ACID

TABLET;ORAL

NALIDIXIC ACID				
WATSON LABS	250MG	A071936	001	Jun 29, 1988
	500MG	A072061	001	Jun 29, 1988
	1GM	A071919	001	Jun 29, 1988
NEGGRAM				
SANOFI AVENTIS US	250MG	N014214	002	
	500MG	N014214	004	
	1GM	N014214	005	

NALMEFENE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

REVEX				
+ HIKMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **	N020459	001	Apr 17, 1995
+	EQ 2MG BASE/2ML (EQ 1MG BASE/ML) **	N020459	002	Apr 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE				
HIKMA	0.4MG/ML	A070298	001	Sep 24, 1986
	0.4MG/ML	A070496	001	Sep 24, 1986
WYETH AYERST	0.02MG/ML	A070188	001	Sep 24, 1986
	0.02MG/ML	A070189	001	Sep 24, 1986
	0.4MG/ML	A070190	001	Sep 24, 1986
	0.4MG/ML	A070191	001	Sep 24, 1986
NALOXONE HYDROCHLORIDE				
ABRAXIS PHARM	0.02MG/ML	A070648	001	Nov 17, 1986
	0.02MG/ML	A070661	001	Nov 17, 1986
	0.4MG/ML	A070649	001	Nov 17, 1986
	1MG/ML	A071604	001	Dec 16, 1988
ASTRAZENECA	0.02MG/ML	A072081	001	Apr 11, 1989
CHARTWELL RX	0.4MG/ML	A207846	001	Dec 17, 2018
HIKMA	0.02MG/ML	A071272	001	May 24, 1988
	1MG/ML	A071273	001	May 24, 1988
	1MG/ML	A071274	001	May 24, 1988
	1MG/ML	A071287	001	May 24, 1988
HOSPIRA	0.02MG/ML	A070171	001	Sep 24, 1986
	0.02MG/ML	A070252	001	Jan 16, 1987
	0.02MG/ML	A070253	001	Jan 16, 1987
	0.4MG/ML	A070254	001	Jan 07, 1987
	0.4MG/ML	A070255	001	Jan 07, 1987
IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989
	0.02MG/ML	A072083	001	Apr 11, 1989
	0.02MG/ML	A072084	001	Apr 11, 1989
	0.02MG/ML	A072085	001	Apr 11, 1989
	0.4MG/ML	A072086	001	Apr 11, 1989
	0.4MG/ML	A072087	001	Apr 11, 1989
	0.4MG/ML	A072088	001	Apr 11, 1989
	0.4MG/ML	A072089	001	Apr 11, 1989
	0.4MG/ML	A072090	001	Apr 11, 1989
	1MG/ML	A072091	001	Apr 11, 1989
	1MG/ML	A072092	001	Apr 11, 1989
	1MG/ML	A072093	001	Apr 11, 1989
INTL MEDICATION	0.4MG/ML	A070417	001	Sep 24, 1986
	0.4MG/ML	A070639	001	Sep 24, 1986
	1MG/ML	A072115	001	Apr 27, 1988
MARSAM PHARMS LLC	0.4MG/ML	A071811	001	Jul 19, 1988
PAR STERILE PRODUCTS	0.4MG/ML	A211286	001	Jan 17, 2020
	1MG/ML	A215964	001	Jul 29, 2022
SMITH AND NEPHEW	0.02MG/ML	A071671	001	Nov 17, 1987
	0.4MG/ML	A071681	001	Nov 17, 1987
	0.4MG/ML	A071682	001	Nov 17, 1987
SOLOPAK	0.02MG/ML	A071672	001	Nov 17, 1987
	0.4MG/ML	A071683	001	Nov 17, 1987
WATSON LABS	0.4MG/ML	A071339	001	Nov 18, 1987
NARCAN				
+ ADAPT	0.02MG/ML **	N016636	002	
+	0.4MG/ML **	N016636	001	
+	1MG/ML **	N016636	003	Jun 14, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NALOXONE HYDROCHLORIDE					
INJECTABLE;INJECTION					
NARCAN					
	BRISTOL MYERS SQUIBB	0.4MG/ML	A071083	001	Jul 28, 1988
		1MG/ML	A071084	001	Jul 28, 1988
		1MG/ML	A071311	001	Jul 28, 1988
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
EVZIO					
+	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014
EVZIO (AUTOINJECTOR)					
+	KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016
NALOXONE HYDROCHLORIDE (AUTOINJECTOR)					
+	KALEO INC	10MG/0.4ML (10MG/0.4ML)	N215457	001	Feb 28, 2022
SPRAY, METERED;NASAL					
NARCAN					
+	EMERGENT	2MG/SPRAY **	N208411	002	Jan 24, 2017
REXTOVY					
+	AMPHASTAR PHARMS INC	4MG/SPRAY	N208969	001	Mar 07, 2023
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE					
TABLET, EXTENDED RELEASE;ORAL					
TARGINIQ					
+	PURDUE PHARMA LP	5MG;10MG	N205777	001	Jul 23, 2014
+		10MG;20MG	N205777	002	Jul 23, 2014
+		20MG;40MG	N205777	003	Jul 23, 2014
NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE					
TABLET;ORAL					
TALWIN NX					
	SANOFI AVENTIS US	EQ 0.5MG BASE;EQ 50MG BASE **	N018733	001	Dec 16, 1982
NALTREXONE HYDROCHLORIDE					
TABLET;ORAL					
NALTREXONE HYDROCHLORIDE					
	FOSUN PHARMA	50MG	A075434	001	Mar 08, 2000
REVIA					
+	TEVA WOMENS	50MG	N018932	001	Nov 20, 1984
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE					
CAPSULE, EXTENDED RELEASE;ORAL					
TROXYCA ER					
	PFIZER	1.2MG;10MG	N207621	001	Aug 19, 2016
		2.4MG;20MG	N207621	002	Aug 19, 2016
		3.6MG;30MG	N207621	003	Aug 19, 2016
		4.8MG;40MG	N207621	004	Aug 19, 2016
		7.2MG;60MG	N207621	005	Aug 19, 2016
		9.6MG;80MG	N207621	006	Aug 19, 2016
NANDROLONE DECANOATE					
INJECTABLE;INJECTION					
DECA-DURABOLIN					
	WOODWARD SPECL	50MG/ML	N013132	001	Jun 12, 1986
		100MG/ML	N013132	002	Jun 12, 1986
+		200MG/ML **	N013132	003	Jun 12, 1986
NANDROLONE DECANOATE					
	ABRAXIS PHARM	100MG/ML	A088290	001	Oct 03, 1983
		200MG/ML	A088317	001	Oct 14, 1983
	AKORN	100MG/ML	A087519	001	Sep 28, 1983
	AM REGENT	200MG/ML	A091252	001	Aug 30, 2010
	WATSON LABS	50MG/ML	A086385	001	Jan 13, 1984
		50MG/ML	A087598	001	Oct 06, 1983
		50MG/ML	A088554	001	Feb 10, 1986
		100MG/ML	A086598	001	Jan 13, 1984
		100MG/ML	A087599	001	Oct 06, 1983
+		200MG/ML	A088128	001	Dec 05, 1983

NANDROLONE PHENPROPIONATE				
INJECTABLE;INJECTION				
DURABOLIN				
ORGANON USA INC	25MG/ML	N011891	001	
	50MG/ML	N011891	002	
NANDROLONE PHENPROPIONATE				
WATSON LABS	25MG/ML	A086386	001	Jun 17, 1983
	50MG/ML	A087488	001	Jun 17, 1983
NAPHAZOLINE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
ALBALON				
ALLERGAN	0.1% **	A080248	001	
NAFAZAIR				
BAUSCH AND LOMB	0.1%	A040073	001	May 25, 1994
PHARMAFAIR	0.1%	A088101	001	Apr 15, 1983
NAPHAZOLINE HYDROCHLORIDE				
RISING	0.1%	A083590	001	
NAPHCON FORTE				
+ ALCON	0.1%	A080229	001	
OPCON				
BAUSCH AND LOMB	0.1%	A087506	001	
VASOCON				
NOVARTIS	0.1%	A080235	002	Mar 24, 1983
NAPROXEN				
TABLET;ORAL				
NAPROSYN				
+ ATNAHS PHARMA US	250MG	N017581	002	
+	375MG	N017581	003	
NAPROXEN				
CHARTWELL MOLECULES	250MG	A074410	001	Apr 28, 1995
	375MG	A074410	002	Apr 28, 1995
	500MG	A074410	003	Apr 28, 1995
DAVA PHARMS INC	250MG	A074105	001	Dec 21, 1993
	375MG	A074105	002	Dec 21, 1993
	500MG	A074105	003	Dec 21, 1993
HAMILTON PHARMS	250MG	A074110	001	Oct 30, 1992
	375MG	A074110	002	Oct 30, 1992
	500MG	A074110	003	Oct 30, 1992
HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004
	375MG	A076494	002	Jan 14, 2004
	500MG	A076494	003	Jan 14, 2004
IVAX SUB TEVA PHARMS	250MG	A074111	001	Feb 28, 1995
	375MG	A074111	002	Feb 28, 1995
	500MG	A074111	003	Feb 28, 1995
L PERRIGO CO	250MG	A077339	001	Apr 27, 2005
	375MG	A077339	002	Apr 27, 2005
	500MG	A077339	003	Apr 27, 2005
MYLAN	250MG	A074121	001	Dec 21, 1993
	375MG	A074121	002	Dec 21, 1993
	500MG	A074121	003	Dec 21, 1993
PLIVA	250MG	A074182	001	Jun 27, 1996
	375MG	A074182	002	Jun 27, 1996
	500MG	A074182	003	Jun 27, 1996
PUREPAC PHARM	250MG	A074263	001	Dec 21, 1993
	375MG	A074263	002	Dec 21, 1993
	500MG	A074263	003	Dec 21, 1993
ROXANE	250MG	A074211	001	Feb 28, 1994
	375MG	A074211	002	Feb 28, 1994
	500MG	A074211	003	Feb 28, 1994
TEVA	250MG	A074129	001	Dec 21, 1993
	250MG	A074216	001	Apr 11, 1996
	375MG	A074129	002	Dec 21, 1993
	375MG	A074216	002	Apr 11, 1996
	500MG	A074129	003	Dec 21, 1993
	500MG	A074216	003	Apr 11, 1996
TEVA PHARMS	250MG	A074207	001	Dec 21, 1993
	375MG	A074207	002	Dec 21, 1993
	500MG	A074207	003	Dec 21, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NAPROXEN

TABLET;ORAL

NAPROXEN

WATSON LABS	250MG	A074457	001	May 31, 1995
	375MG	A074457	002	May 31, 1995
	500MG	A074457	003	May 31, 1995
WATSON LABS TEVA	250MG	A074163	001	Feb 10, 1995
	375MG	A074163	002	Feb 10, 1995
	500MG	A074163	003	Feb 10, 1995

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

ACTAVIS ELIZABETH	375MG	A074936	001	Feb 24, 1998
	500MG	A074936	002	Feb 24, 1998
AUROBINDO PHARMA USA	375MG	A075390	001	Apr 19, 2001
	500MG	A075390	002	Apr 19, 2001
FOSUN PHARMA	375MG	A075061	001	Feb 18, 1998
	500MG	A075061	002	Feb 18, 1998
PLIVA	375MG	A075337	001	May 26, 1999
	500MG	A075337	002	May 26, 1999

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

STRIDES PHARMA	EQ 200MG BASE	A215472	001	Aug 17, 2022

TABLET;ORAL

ANAPROX

+ ATNAHS PHARMA US	EQ 250MG BASE **	N018164	001	

NAPROXEN SODIUM

ABLE	EQ 250MG BASE	A076544	001	Aug 22, 2003
	EQ 500MG BASE	A076544	002	Aug 22, 2003
CONTRACT PHARMACAL	220MG	A074789	001	Feb 27, 1997
HAMILTON PHARMS	EQ 250MG BASE	A074106	001	Aug 31, 1993
	EQ 500MG BASE	A074106	002	Aug 31, 1993
HIKMA	EQ 250MG BASE	A074480	002	Feb 18, 1998
	EQ 500MG BASE	A074480	001	May 14, 1996
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A074230	001	Mar 14, 1995
	EQ 500MG BASE	A074230	002	Mar 14, 1995
MYLAN	EQ 250MG BASE	A074367	001	Aug 31, 1994
	EQ 500MG BASE	A074367	002	Aug 31, 1994
PLD ACQUISITIONS LLC	220MG	A074646	001	Jan 13, 1997
PLIVA	EQ 250MG BASE	A074242	001	Jun 20, 1996
	EQ 500MG BASE	A074242	002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319	001	Mar 20, 1995
	EQ 500MG BASE	A074319	002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257	001	Dec 21, 1993
	EQ 500MG BASE	A074257	002	Dec 21, 1993
SANDOZ	EQ 250MG BASE	A074162	001	Dec 21, 1993
	EQ 250MG BASE	A074495	001	Dec 05, 1994
	EQ 500MG BASE	A074162	002	Dec 21, 1993
	EQ 500MG BASE	A074495	002	Dec 05, 1994
TEVA	EQ 250MG BASE	A074142	001	Dec 21, 1993
	EQ 250MG BASE	A074198	001	Dec 21, 1993
	EQ 500MG BASE	A074142	002	Dec 21, 1993
	EQ 500MG BASE	A074198	002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289	001	Jan 27, 1994
	EQ 500MG BASE	A074289	002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195	001	Dec 21, 1993
	EQ 250MG BASE	A074455	001	May 31, 1995
	EQ 500MG BASE	A074195	002	Dec 21, 1993
	EQ 500MG BASE	A074455	002	May 31, 1995

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+ BAYER	220MG;120MG **	N021076	001	Nov 29, 1999

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA	220MG;120MG	A211360	001	Jun 01, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL					
TREXIMET					
+	CURRAX	60MG;EQ 10MG BASE	N021926	002	May 14, 2015

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL					
AMERGE					
+	GLAXOSMITHKLINE LLC	EQ 1MG BASE	N020763	002	Feb 10, 1998
+		EQ 2.5MG BASE	N020763	001	Feb 10, 1998
NARATRIPTAN					
	ANI PHARMS	EQ 1MG BASE	A078751	001	Jul 07, 2010
		EQ 2.5MG BASE	A078751	002	Jul 07, 2010
	APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011
		EQ 2.5MG BASE	A091373	002	Apr 22, 2011
	AUROBINDO PHARMA USA	EQ 1MG BASE	A202431	001	May 31, 2012
		EQ 2.5MG BASE	A202431	002	May 31, 2012
	CHARTWELL RX	EQ 1MG BASE	A090288	001	Jul 07, 2010
		EQ 2.5MG BASE	A090288	002	Jul 07, 2010

NATEGLINIDE

TABLET;ORAL					
NATEGLINIDE					
	ALVOGEN	60MG	A205055	001	Dec 11, 2015
		120MG	A205055	002	Dec 11, 2015
	TEVA PHARMS	60MG	A077467	001	Sep 09, 2009
		120MG	A077467	002	Sep 09, 2009
STARLIX					
+	NOVARTIS	60MG **	N021204	001	Dec 22, 2000
+		120MG **	N021204	002	Dec 22, 2000

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL					
NEBIVOLOL HYDROCHLORIDE					
	AJANTA PHARMA LTD	EQ 2.5MG BASE	A213349	001	Mar 31, 2022
		EQ 5MG BASE	A213349	002	Mar 31, 2022
		EQ 10MG BASE	A213349	003	Mar 31, 2022
		EQ 20MG BASE	A213349	004	Mar 31, 2022
	ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015
		EQ 5MG BASE	A203741	002	Jun 24, 2015
		EQ 10MG BASE	A203741	003	Jun 24, 2015
		EQ 20MG BASE	A203741	004	Jun 24, 2015
	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017
		EQ 5MG BASE	A203821	002	May 25, 2017
		EQ 10MG BASE	A203821	003	May 25, 2017
		EQ 20MG BASE	A203821	004	May 25, 2017
	UNICHEM	EQ 2.5MG BASE	A213830	001	Mar 15, 2022
		EQ 5MG BASE	A213830	002	Mar 15, 2022
		EQ 10MG BASE	A213830	003	Mar 15, 2022
		EQ 20MG BASE	A213830	004	Mar 15, 2022
	WATSON LABS INC	EQ 2.5MG BASE	A203683	001	Nov 27, 2015
		EQ 5MG BASE	A203683	002	Nov 27, 2015
		EQ 10MG BASE	A203683	003	Nov 27, 2015
		EQ 20MG BASE	A203683	004	Nov 27, 2015

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL					
BYVALSON					
+	ABBVIE	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016

NEDOCROMIL SODIUM

AEROSOL, METERED;INHALATION					
TILADE					
	KING PHARMS LLC	1.75MG/INH	N019660	001	Dec 30, 1992
SOLUTION;INHALATION					
TILADE					
	SANOFI AVENTIS US	0.5%	N020750	001	Oct 01, 1997
SOLUTION/DROPS;OPHTHALMIC					
ALOCRIL					
+	ALLERGAN	2%	N021009	001	Dec 08, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NEDOCROMIL SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
NEDOCROMIL SODIUM				
AKORN	2%	A090638	001	Aug 22, 2012
NEFAZODONE HYDROCHLORIDE				
TABLET;ORAL				
NEFAZODONE HYDROCHLORIDE				
ANI PHARMS	50MG	A076072	001	Sep 16, 2003
	100MG	A076072	002	Sep 16, 2003
	150MG	A076072	003	Sep 16, 2003
	200MG	A076072	004	Sep 16, 2003
	250MG	A076072	005	Sep 16, 2003
AUROBINDO PHARMA USA	100MG	A076129	002	Sep 16, 2003
	150MG	A076129	003	Sep 16, 2003
	200MG	A076129	004	Sep 16, 2003
	250MG	A076129	005	Sep 16, 2003
DR REDDYS LABS INC	50MG	A076309	001	Sep 16, 2003
	100MG	A076309	002	Sep 16, 2003
	150MG	A076309	003	Sep 16, 2003
	200MG	A076309	004	Sep 16, 2003
	250MG	A076309	005	Sep 16, 2003
FOSUN PHARMA	50MG	A076302	001	Sep 16, 2003
	100MG	A076302	002	Sep 16, 2003
	150MG	A076302	003	Sep 16, 2003
	200MG	A076302	004	Sep 16, 2003
	250MG	A076302	005	Sep 16, 2003
IVAX SUB TEVA PHARMS	50MG	A075763	001	Sep 16, 2003
	100MG	A075763	002	Sep 16, 2003
	150MG	A075763	003	Sep 16, 2003
	200MG	A075763	004	Sep 16, 2003
	250MG	A075763	005	Sep 16, 2003
ROXANE	50MG	A076196	001	Sep 16, 2003
	100MG	A076196	002	Sep 16, 2003
	150MG	A076196	003	Sep 16, 2003
	200MG	A076196	004	Sep 16, 2003
	250MG	A076196	005	Sep 16, 2003
SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003
	100MG	A076409	002	Sep 16, 2003
	150MG	A076409	003	Sep 16, 2003
	200MG	A076409	004	Sep 16, 2003
	250MG	A076409	005	Sep 16, 2003
WATSON LABS	100MG	A076073	002	Sep 16, 2003
	150MG	A076073	003	Sep 16, 2003
	200MG	A076073	004	Sep 16, 2003
	250MG	A076073	005	Sep 16, 2003
SERZONE				
+ BRISTOL MYERS SQUIBB	50MG **	N020152	001	Dec 22, 1994
+	100MG **	N020152	002	Dec 22, 1994
+	150MG **	N020152	003	Dec 22, 1994
+	200MG **	N020152	004	Dec 22, 1994
+	250MG **	N020152	005	Dec 22, 1994
+	300MG **	N020152	006	Dec 22, 1994
NELFINAVIR MESYLATE				
POWDER;ORAL				
VIRACEPT				
AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL	N020778	001	Mar 14, 1997
NEOMYCIN SULFATE				
SOLUTION;ORAL				
MYCIFRADIN				
PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285	001	
NEO-FRADIN				
X GEN PHARMS	EQ 87.5MG BASE/5ML	A065010	001	May 23, 2002
TABLET;ORAL				
MYCIFRADIN				
PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520	001	
NEOBIOTIC				
PFIZER	EQ 350MG BASE	A060475	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

BRISTOL MYERS SQUIBB	500MG	A060365 001		
CHARTWELL MOLECULAR	500MG	A204435 001		Jun 10, 2016
LANNETT	500MG	A060607 001		
LILLY	500MG	A060385 001		
NOSTRUM LABS INC	500MG	A065468 001		Mar 29, 2010
ROXANE	500MG	A062173 001		
SANDOZ	500MG	A061586 001		

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL

NEOSPORIN

GLAXOSMITHKLINE	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050176 002	Jan 14, 1985

OINTMENT;OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050344 002	

SOLUTION/DROPS;OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	A062339 001	Nov 30, 1984
	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N050456 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

POLY-PRED

ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081 002	

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM;0.25%	A061039 002	
	EQ 3.5MG BASE/GM;0.5%	A061039 001	

SUSPENSION/DROPS;OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/ML;0.25%	A061037 001	

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC

NEO-HYDELTRASOL

MERCK	EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE	N050378 001	

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYTREX A

SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062598 001	Jul 21, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062600 001	Jul 21, 1986
PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062595 001	Jul 21, 1986

OINTMENT;TOPICAL

MYTREX A

SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062609 001	May 23, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062608 001	May 23, 1986
PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062607 001	May 23, 1986

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AM REGENT	5MG/10ML (0.5MG/ML)	A209182 001	May 04, 2018
	10MG/10ML (1MG/ML)	A209182 002	May 04, 2018

NESIRITIDE RECOMBINANT

FOR SOLUTION;INTRAVENOUS

NATRECOR

+	SCIOS LLC	1.5MG/VIAL **	N020920 001	Aug 10, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NETILMICIN SULFATE				
INJECTABLE;INJECTION				
NETROMYCIN				
SCHERING	EQ 10MG BASE/ML	N050544	001	Feb 28, 1983
	EQ 25MG BASE/ML	N050544	002	Feb 28, 1983
	EQ 100MG BASE/ML	N050544	003	Feb 28, 1983
NEVIRAPINE				
TABLET;ORAL				
NEVIRAPINE				
APOTEX INC	200MG	A203021	001	May 22, 2012
MYLAN LABS	200MG	A078864	001	May 22, 2012
PRINSTON INC	200MG	A078644	001	May 22, 2012
TECH ORGANIZED	200MG	A203176	001	May 22, 2012
VIRAMUNE				
+ BOEHRINGER INGELHEIM	200MG	N020636	001	Jun 21, 1996
TABLET, EXTENDED RELEASE;ORAL				
NEVIRAPINE				
ALVOGEN	100MG	A204621	002	Nov 09, 2015
	400MG	A204621	001	Jul 10, 2015
APOTEX	400MG	A205258	001	Apr 03, 2014
AUROBINDO PHARMA	100MG	A208616	001	Nov 23, 2016
	400MG	A207698	001	Feb 28, 2017
CIPLA	400MG	A206448	001	Oct 15, 2015
MYLAN	100MG	A206271	001	Nov 09, 2015
TECH ORGANIZED	100MG	A207467	001	Jul 31, 2017
	400MG	A207467	002	Jul 31, 2017
NIACIN				
CAPSULE;ORAL				
WAMPOCAP				
MEDPOINTE PHARM HLC	500MG	N011073	003	
TABLET;ORAL				
NIACIN				
EVERYLIFE	500MG	A083203	001	
HALSEY	500MG	A083453	001	
HIKMA	500MG	A083718	001	
IMPAX LABS	500MG	A083115	001	
IVAX SUB TEVA PHARMS	500MG	A083180	001	
MK LABS	500MG	A083525	001	
PUREPAC PHARM	500MG	A083271	001	
SANDOZ	500MG	A083306	001	
TABLICAPS	500MG	A084237	001	
WATSON LABS	500MG	A083136	001	
	500MG	A083305	001	
	500MG	A085172	001	
WOCKHARDT	500MG	A081134	001	Apr 28, 1992
NICOLAR				
+ SANOFI AVENTIS US	500MG	A083823	001	
TABLET, EXTENDED RELEASE;ORAL				
NIACIN				
BEIJING	500MG	A214428	001	Nov 22, 2021
	1GM	A214428	002	Nov 22, 2021
JUBILANT GENERICS	500MG	A209156	001	May 14, 2018
	750MG	A209156	002	May 14, 2018
	1GM	A209156	003	May 14, 2018
RISING	500MG	A203742	001	Feb 22, 2019
	750MG	A203742	002	Feb 22, 2019
	1GM	A203742	003	Feb 22, 2019
YICHANG HUMANWELL	500MG	A212017	001	Jun 10, 2019
	750MG	A212017	002	Jun 10, 2019
	1GM	A212017	003	Jun 10, 2019
NIASPAN				
ABBVIE	375MG	N020381	001	Jul 28, 1997
+	500MG **	N020381	002	Jul 28, 1997
+	750MG **	N020381	003	Jul 28, 1997
+	1GM **	N020381	004	Jul 28, 1997
NIASPAN TITRATION STARTER PACK				
ABBVIE	375MG;500MG;750MG	N020381	005	Jul 28, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION;ORAL				
TPN				
	INTL MINERALS	15MG/5ML;3.75MG/5ML;600MG/5ML	N008378 003	

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL				
CARDENE				
+	CHIESI	20MG **	N019488 001	Dec 21, 1988
+		30MG **	N019488 002	Dec 21, 1988
NICARDIPINE HYDROCHLORIDE				
	ANI PHARMS	20MG	A074439 001	Dec 10, 1996
		20MG	A074540 001	Oct 28, 1996
		30MG	A074439 002	Dec 10, 1996
		30MG	A074540 002	Oct 28, 1996
	MYLAN	20MG	A074642 001	Jul 18, 1996
		30MG	A074642 002	Jul 18, 1996
CAPSULE, EXTENDED RELEASE;ORAL				
CARDENE SR				
+	CHIESI	30MG **	N020005 001	Feb 21, 1992
+		45MG **	N020005 002	Feb 21, 1992
+		60MG **	N020005 003	Feb 21, 1992
INJECTABLE;INJECTION				
CARDENE				
+	CHIESI	25MG/10ML (2.5MG/ML) **	N019734 001	Jan 30, 1992
NICARDIPINE HYDROCHLORIDE				
	NAVINTA LLC	25MG/10ML (2.5MG/ML)	A090125 001	Nov 17, 2009
	RK PHARMA	25MG/10ML (2.5MG/ML)	A090664 001	Nov 17, 2009
	SUN PHARM	25MG/10ML (2.5MG/ML)	N078405 001	Nov 17, 2009
	WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714 001	Dec 28, 2009
	WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671 001	Nov 17, 2009
INJECTABLE;INTRAVENOUS				
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER				
+	CHIESI	40MG/200ML (0.2MG/ML)	N019734 005	Nov 07, 2008

NICLOSAMIDE

TABLET, CHEWABLE;ORAL				
NICLOCIDE				
	BAYER PHARMS	500MG	N018669 001	May 14, 1982

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL				
NICOTROL				
	MCNEIL CONS	15MG/16HR	N020536 001	Jul 03, 1996
PROSTEP				
	AVEVA	11MG/24HR	N019983 003	Dec 23, 1998
		22MG/24HR	N019983 004	Dec 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL				
NICOTINE POLACRILEX				
	FERTIN PHARMA	EQ 4MG BASE	A214354 001	Dec 21, 2022
	IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880 001	Feb 18, 2009
		EQ 4MG BASE	A077850 001	Feb 18, 2009
	L PERRIGO CO	EQ 2MG BASE	A076776 001	Sep 16, 2004
		EQ 4MG BASE	A076778 001	Sep 16, 2004
	PERRIGO R AND D	EQ 2MG BASE	A078967 001	Apr 23, 2008
		EQ 4MG BASE	A078968 001	Apr 23, 2008
THRIVE				
	GLAXOSMITHKLINE CONS	EQ 2MG BASE	A077658 001	Jun 19, 2007
		EQ 4MG BASE	A077656 001	Jun 19, 2007

NIFEDIPINE

CAPSULE;ORAL				
ADALAT				
	BAYER PHARMS	10MG	N019478 001	Nov 27, 1985
		20MG	N019478 002	Sep 17, 1986
NIFEDIPINE				
	CHASE LABS NJ	10MG	A072409 001	Jul 04, 1990
		20MG	A073421 001	Jun 19, 1991
	TEVA	10MG	A072651 001	Feb 19, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NIFEDIPINE					
CAPSULE;ORAL					
PROCARDIA					
+	PFIZER	20MG **	N018482	002	Jul 24, 1986
TABLET, EXTENDED RELEASE;ORAL					
ADALAT CC					
+	NORWICH	30MG **	N020198	001	Apr 21, 1993
+		60MG **	N020198	002	Apr 21, 1993
+		90MG **	N020198	003	Apr 21, 1993
AFEDITAB CR					
	WATSON LABS	60MG	A075659	001	Oct 26, 2001
	WATSON LABS TEVA	30MG	A075128	001	Mar 10, 2000
NIFEDIPINE					
	AUROBINDO PHARMA USA	30MG	A090649	001	Jun 21, 2010
		60MG	A090649	002	Jun 21, 2010
		90MG	A090649	003	Jun 21, 2010
	MARTEC USA LLC	90MG	A075414	003	Mar 23, 2004
	MYLAN	30MG	A075108	001	Dec 17, 1999
	PAR PHARM	30MG	A077899	001	Dec 13, 2006
		60MG	A077899	002	Dec 13, 2006
		90MG	A077899	003	May 25, 2012
	RISING	30MG	A090602	001	Sep 13, 2010
		30MG	A201071	001	Dec 03, 2010
		60MG	A090602	002	Sep 13, 2010
		60MG	A201071	002	Dec 03, 2010
		90MG	A090602	003	Sep 13, 2010
		90MG	A201071	003	Dec 03, 2010
	VITRUVIAS	30MG	A216019	001	Nov 18, 2022
		60MG	A216019	002	Nov 18, 2022
NILUTAMIDE					
TABLET;ORAL					
NILANDRON					
	CONCORDIA	50MG	N020169	001	Sep 19, 1996
NIMODIPINE					
CAPSULE;ORAL					
NIMODIPINE					
	SOFGEN PHARMS	30MG	A201832	001	Jul 24, 2015
	SUN PHARM INDS INC	30MG	A077067	001	Apr 17, 2007
NIMOTOP					
+	BAYER PHARMS	30MG **	N018869	001	Dec 28, 1988
SOLUTION;ORAL					
NYMALIZE					
+	AZURITY	3MG/ML **	N203340	001	May 10, 2013
NISOLDIPINE					
TABLET, EXTENDED RELEASE;ORAL					
NISOLDIPINE					
	AMTA	8.5MG	A216606	001	Apr 10, 2023
SULAR					
+	COVIS	10MG **	N020356	001	Feb 02, 1995
+		20MG **	N020356	002	Feb 02, 1995
+		25.5MG **	N020356	006	Jan 02, 2008
+		30MG **	N020356	003	Feb 02, 1995
+		40MG **	N020356	004	Feb 02, 1995
NITRIC OXIDE					
GAS;INHALATION					
INOMAX					
+	MALLINCKRODT HOSP	100PPM **	N020845	002	Dec 23, 1999
NITROFURANTOIN					
CAPSULE;ORAL					
NITROFURANTOIN					
	WATSON LABS	50MG	A084326	001	
		100MG	A084326	002	
TABLET;ORAL					
FURADANTIN					
	PROCTER AND GAMBLE	50MG	N008693	001	
		100MG	N008693	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NITROFURANTOIN
TABLET;ORAL
FURALAN
CHARTWELL MOLECULAR 50MG A080017 001
100MG A080017 002
NITROFURANTOIN
ELKINS SINN 50MG A080003 001
100MG A080003 002
IVAX SUB TEVA PHARMS 50MG A080078 002
100MG A080078 001
SANDOZ 50MG A080043 001
100MG A080043 002
WATSON LABS 50MG A080447 001
50MG A085797 001
100MG A080447 002
100MG A085796 001
WHITEWORTH TOWN PLSN 100MG A084085 002

NITROFURANTOIN SODIUM
INJECTABLE;INJECTION
IVADANTIN
PROCTER AND GAMBLE EQ 180MG BASE/VIAL N012402 001

NITROFURANTOIN, MACROCRYSTALLINE
CAPSULE;ORAL
NITROFURANTOIN
ATHEM 25MG A074336 001 Jan 25, 1995
50MG A074336 002 Jan 25, 1995
100MG A074336 003 Jan 25, 1995
WATSON LABS 25MG A073696 001 Dec 31, 1992
50MG A073696 002 Dec 31, 1992
100MG A073696 003 Dec 31, 1992
NITROFURANTOIN MACROCRYSTALLINE
WATSON LABS 50MG A070248 001 Jun 24, 1988
100MG A070249 001 Jun 24, 1988

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE
CAPSULE;ORAL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
ALVOGEN 75MG;25MG A215002 001 Jul 20, 2022
AUROBINDO PHARMA USA 75MG;25MG A076648 001 Mar 22, 2004
RANBAXY LABS LTD 75MG;25MG A076951 001 Mar 30, 2005

NITROFURAZONE
CREAM;TOPICAL
FURACIN
SHIRE 0.2% A083789 001
DRESSING;TOPICAL
ACTIN-N
SHERWOOD MEDCL 0.2% N017343 001
OINTMENT;TOPICAL
FURACIN
SHIRE 0.2% N005795 001
NITROFURAZONE
AMBIX 0.2% A086077 001
LANNETT 0.2% A084393 001
PERRIGO NEW YORK 0.2% A084968 001
TARO 0.2% A086156 001
WENDT 0.2% A086766 001
POWDER;TOPICAL
FURACIN
SHIRE 0.2% A083791 001
SOLUTION;TOPICAL
NITROFURAZONE
PERRIGO NEW YORK 0.2% A085130 001
WENDT 0.2% A087081 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NITROGLYCERIN

AEROSOL;SUBLINGUAL					
NITROLINGUAL					
	POHL BOSKAMP	0.4MG/SPRAY	N018705	001	Oct 31, 1985
FILM, EXTENDED RELEASE;TRANSDERMAL					
MINITRAN					
	BAUSCH	0.4MG/HR	A089773	001	Aug 30, 1996
	VALEANT PHARMS	0.1MG/HR	A089771	001	Aug 30, 1996
		0.6MG/HR	A089774	001	Aug 30, 1996
	VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996
NITROGLYCERIN					
	LANNETT CO INC	0.2MG/HR	A075115	001	Aug 10, 2004
		0.4MG/HR	A075115	002	Aug 10, 2004
	MYLAN TECHNOLOGIES	0.1MG/HR	A074992	004	Nov 12, 1999
		0.2MG/HR	A074992	003	Nov 12, 1999
		0.4MG/HR	A074992	002	Nov 12, 1999
		0.6MG/HR	A074992	001	Nov 12, 1999
TRANSDERM-NITRO					
+	NOVARTIS	0.1MG/HR **	N020144	001	Feb 27, 1996
+		0.2MG/HR **	N020144	002	Feb 27, 1996
+		0.4MG/HR **	N020144	003	Feb 27, 1996
+		0.6MG/HR **	N020144	004	Feb 27, 1996
+		0.8MG/HR **	N020144	005	Feb 27, 1996
INJECTABLE;INJECTION					
NITRO IV					
	POHL BOSKAMP	5MG/ML	N018672	002	Aug 30, 1983
NITRO-BID					
	SANOFI AVENTIS US	5MG/ML	N018621	001	Jan 05, 1982
		10MG/ML	A071159	001	Feb 28, 1990
NITROGLYCERIN					
	ABRAXIS PHARM	5MG/ML	A070077	001	Dec 13, 1985
		5MG/ML	A071203	001	May 08, 1987
+	HOSPIRA	5MG/ML **	N018531	001	
	INTL MEDICATION	5MG/ML	A070026	001	Sep 10, 1985
	LUITPOLD	5MG/ML	A071492	001	May 24, 1988
	SMITH AND NEPHEW	5MG/ML	A070633	001	Jun 19, 1986
		5MG/ML	A070634	001	Jun 19, 1986
NITROGLYCERIN IN DEXTROSE 5%					
	HOSPIRA	0.1MG/ML	A074083	001	Oct 26, 1994
		10MG/100ML	A071846	001	Aug 31, 1990
		20MG/100ML	A071847	001	Aug 31, 1990
		40MG/100ML	A071848	001	Aug 31, 1990
NITROL					
	RORER	0.8MG/ML	N018774	001	Jan 19, 1983
NITRONAL					
	POHL BOSKAMP	1MG/ML	N018672	001	Aug 30, 1983
NITROSTAT					
	PARKE DAVIS	0.8MG/ML	N018588	001	
		5MG/ML	A070863	001	Jan 08, 1987
		5MG/ML	N018588	002	Dec 23, 1983
		10MG/ML	A070871	001	Jan 08, 1987
		10MG/ML	A070872	001	Jan 08, 1987
TRIDIL					
	HOSPIRA	0.5MG/ML	N018537	002	Jun 16, 1983
		5MG/ML	N018537	001	
POWDER;SUBLINGUAL					
GONITRO					
+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016
TABLET;SUBLINGUAL					
NITROGLYCERIN					
	ACTAVIS LABS FL INC	0.3MG	A203693	001	Oct 16, 2017
		0.4MG	A203693	002	Oct 16, 2017
		0.6MG	A203693	003	Oct 16, 2017
	SIGMAPHARM LABS LLC	0.3MG	A207745	001	May 07, 2018
		0.4MG	A207745	002	May 07, 2018
		0.6MG	A207745	003	May 07, 2018
	ZYDUS PHARMS	0.3MG	A210153	001	Mar 08, 2022
		0.4MG	A210153	002	Mar 08, 2022
		0.6MG	A210153	003	Mar 08, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NIZATIDINE

CAPSULE;ORAL				
AXID				
	SMITHKLINE BEECHAM	150MG	N019508 001	Apr 12, 1988
		300MG	N019508 002	Apr 12, 1988
NIZATIDINE				
	ANI PHARMS	150MG	A075461 001	Jul 08, 2002
		150MG	A075668 001	Sep 12, 2002
		300MG	A075461 002	Jul 08, 2002
		300MG	A075668 002	Sep 12, 2002
	APOTEX INC	150MG	A076383 001	Jan 23, 2003
		300MG	A076383 002	Jan 23, 2003
	MYLAN PHARMS INC	150MG	A075806 001	Jul 05, 2002
		150MG	A075934 001	Jul 09, 2002
		300MG	A075806 002	Jul 05, 2002
		300MG	A075934 002	Jul 09, 2002
SOLUTION;ORAL				
AXID				
+	BRAINTREE	15MG/ML **	N021494 001	May 25, 2004
NIZATIDINE				
	AMNEAL PHARMS	15MG/ML	A090576 001	Nov 18, 2009

NONOXYNOL-9

AEROSOL;VAGINAL				
DELFEN				
	PERSONAL PRODS	12.5%	N014349 002	
SPONGE;VAGINAL				
TODAY				
+	MAYER LABS INC	1GM	N018683 001	Apr 01, 1983

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION				
NOREPINEPHRINE BITARTRATE				
	METRICS PHARM	EQ 1MG BASE/ML	A040522 001	Sep 30, 2004
	ZYDUS PHARMS	EQ 1MG BASE/ML	A216341 001	Jul 19, 2022
SOLUTION;INTRAVENOUS				
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE				
+	LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628 001	Oct 06, 2022
+		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628 002	Oct 06, 2022
+		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628 003	Oct 06, 2022

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
RAVOCAINE AND NOVOCAIN W/ LEVOPHED				
	EASTMAN KODAK	EQ 0.033MG BASE/ML;2%;0.4%	N008592 003	

NORETHINDRONE

TABLET;ORAL				
NORLUTIN				
	PARKE DAVIS	5MG	N010895 002	
TABLET;ORAL-28				
MICRONOR				
+	JANSSEN PHARMS	0.35MG **	N016954 001	
NORETHINDRONE				
	AMNEAL PHARMS	0.35MG	A202260 001	Aug 01, 2013

NORETHINDRONE ACETATE

TABLET;ORAL				
AYGESTIN				
+	DURAMED RES	5MG **	N018405 001	Apr 21, 1982
NORETHINDRONE ACETATE				
	AUROBINDO PHARMA LTD	5MG	A204236 001	Jan 08, 2016
NORLUTATE				
	PARKE DAVIS	5MG	N012184 002	

NORFLOXACIN

SOLUTION/DROPS;OPHTHALMIC				
CHIBROXIN				
	MERCK	0.3%	N019757 001	Jun 17, 1991
TABLET;ORAL				
NOROXIN				
+	MERCK	400MG **	N019384 002	Oct 31, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NORGESTREL				
TABLET;ORAL				
OPILL				
+ LABORATOIRE HRA	0.075MG	N017031 001		
NORTRIPTYLINE HYDROCHLORIDE				
CAPSULE;ORAL				
AVENTYL HYDROCHLORIDE				
LILLY	EQ 10MG BASE	N014684 001		
	EQ 25MG BASE	N014684 002		
NORTRIPTYLINE HYDROCHLORIDE				
ANI PHARMS	EQ 10MG BASE	A074054 001	Dec 31, 1992	
	EQ 25MG BASE	A074054 002	Dec 31, 1992	
	EQ 50MG BASE	A074054 003	Dec 31, 1992	
	EQ 75MG BASE	A074054 004	Dec 31, 1992	
AUROBINDO PHARMA LTD	EQ 10MG BASE	A074835 001	Jun 30, 1997	
	EQ 25MG BASE	A074835 002	Jun 30, 1997	
	EQ 50MG BASE	A074835 003	Jun 30, 1997	
	EQ 75MG BASE	A074835 004	Jun 30, 1997	
MYLAN	EQ 10MG BASE	A074234 001	Jul 26, 1993	
	EQ 25MG BASE	A074234 002	Jul 26, 1993	
	EQ 50MG BASE	A074234 003	Jul 26, 1993	
	EQ 75MG BASE	A074234 004	Jul 26, 1993	
TEVA	EQ 10MG BASE	A073667 001	Apr 11, 1996	
	EQ 25MG BASE	A073667 002	Apr 11, 1996	
	EQ 50MG BASE	A073667 003	Apr 11, 1996	
	EQ 75MG BASE	A073667 004	Apr 11, 1996	
ZYDUS	EQ 10MG BASE	A213441 001	Feb 24, 2021	
	EQ 25MG BASE	A213441 002	Feb 24, 2021	
	EQ 50MG BASE	A213441 003	Feb 24, 2021	
	EQ 75MG BASE	A213441 004	Feb 24, 2021	
SOLUTION;ORAL				
AVENTYL				
+ RANBAXY	EQ 10MG BASE/5ML **	N014685 001		
NORTRIPTYLINE HYDROCHLORIDE				
TARO	EQ 10MG BASE/5ML	A077965 001	Jun 20, 2006	
PAMELOR				
SPECGX LLC	EQ 10MG BASE/5ML	N018012 001		
NYSTATIN				
CREAM;TOPICAL				
CANDEX				
BAYER PHARMS	100,000 UNITS/GM	A061810 001		
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060575 001		
MYKINAC				
ALPHARMA US PHARMS	100,000 UNITS/GM	A062387 001	Jul 29, 1982	
NILSTAT				
LEDERLE	100,000 UNITS/GM	A061445 001		
NYSTATIN				
STRIDES PHARMA	100,000 UNITS/GM	A065315 001	May 31, 2006	
TARO	100,000 UNITS/GM	A062457 001	Jul 28, 1983	
LOTION;TOPICAL				
CANDEX				
BAYER PHARMS	100,000 UNITS/ML	N050233 001		
OINTMENT;TOPICAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060571 001		
MYKINAC				
ALPHARMA US PHARMS	100,000 UNITS/GM	A062731 001	Sep 22, 1986	
NILSTAT				
LEDERLE	100,000 UNITS/GM	A061444 001		
NYSTATIN				
TORRENT	100,000 UNITS/GM	A211838 001	Jan 28, 2019	
PASTILLE;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	200,000 UNITS	N050619 001	Apr 09, 1987	
POWDER;ORAL				
BARSTATIN 100				
BARLAN	100%	A062489 001	Apr 27, 1988	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NYSTATIN

POWDER;ORAL				
NILSTAT				
+ STRIDES PHARMA	100% **	N050576	001	Dec 22, 1983
NYSTATIN				
PADDOCK LLC	100%	A062613	001	Nov 26, 1985
POWDER;TOPICAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060578	001	
NYSTATIN				
NESHER PHARMS	100,000 UNITS/GM	A065321	001	Aug 18, 2006
SUPPOSITORY;VAGINAL				
NYSERT				
WARNER CHILCOTT	100,000 UNITS	N050478	001	
SUSPENSION;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/ML	A061533	001	
NILSTAT				
+ CHARTWELL MOLECULES	100,000 UNITS/ML **	N050299	001	
NYSTATIN				
AKORN	100,000 UNITS/ML	A064042	001	Feb 28, 1994
ALPHARMA US PHARMS	100,000 UNITS/ML	A062571	001	Oct 29, 1985
COSETTE	100,000 UNITS/ML	A062776	001	Dec 17, 1987
G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982
MORTON GROVE	100,000 UNITS/ML	A062835	001	Nov 19, 1987
PHARMADERM	100,000 UNITS/ML	A062518	001	Jul 06, 1984
PHARMAFAIR	100,000 UNITS/ML	A062541	001	Jan 16, 1985
TEVA	100,000 UNITS/ML	A062670	001	Jun 18, 1987
VISTAPHARM	100,000 UNITS/ML	A064142	001	Jun 25, 1998
	100,000 UNITS/ML	A064142	002	Mar 07, 2011
NYSTEX				
SAVAGE LABS	100,000 UNITS/ML	A062519	001	Jul 06, 1984
TABLET;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	500,000 UNITS	A060574	001	
NILSTAT				
LEDERLE	500,000 UNITS	A061151	001	
NYSTATIN				
CHARTWELL RX	500,000 UNITS	A062524	001	Nov 26, 1985
QUANTUM PHARMICS	500,000 UNITS	A062525	001	Oct 29, 1984
SANDOZ	500,000 UNITS	A062065	001	
WATSON LABS	500,000 UNITS	A062402	001	Dec 16, 1982
TABLET;VAGINAL				
KOROSTATIN				
HOLLAND RANTOS	100,000 UNITS	A061718	001	
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS	A060577	001	
NILSTAT				
LEDERLE	100,000 UNITS	A061325	001	
NYSTATIN				
FOUGERA	100,000 UNITS	A062459	001	Nov 09, 1983
ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985
PHARMADERM	100,000 UNITS	A062460	001	Nov 09, 1983
QUANTUM PHARMICS	100,000 UNITS	A062509	001	Apr 03, 1984
SANDOZ	100,000 UNITS	A061965	001	
TEVA	100,000 UNITS	A062502	001	Dec 23, 1983
WATSON LABS	100,000 UNITS	A062176	001	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL				
MYCO-TRIACET II				
TEVA	100,000 UNITS/GM;0.1%	A061954	002	Sep 20, 1985
MYCOLOG-II				
DELCOR ASSET CORP	100,000 UNITS/GM;0.1% **	A060576	002	May 01, 1985
MYLAN	100,000 UNITS/GM;0.1% **	A062606	001	May 15, 1985
MYTREX F				
SAVAGE LABS	100,000 UNITS/GM;0.1%	A062597	001	Oct 08, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE				
ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	A063010	001	Dec 20, 1988
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062186	002	Jun 06, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

PHARMAFAIR	100,000 UNITS/GM;0.1%	A062657	001	Jul 30, 1986
TARO	100,000 UNITS/GM;0.1%	A062347	001	Mar 30, 1987
TORRENT	100,000 UNITS/GM;0.1%	A213142	001	Jul 14, 2020

NYSTATIN TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062596	001	Oct 08, 1985

OINTMENT;TOPICAL

MYCO-TRIACET II

TEVA	100,000 UNITS/GM;0.1%	A062045	002	Nov 26, 1985

MYCOLOG-II

MYLAN	100,000 UNITS/GM;0.1% **	A060572	001	Jun 28, 1985

MYTREX F

SAVAGE LABS	100,000 UNITS/GM;0.1%	A062601	001	Oct 09, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

CHARTWELL RX	100,000 UNITS/GM;0.1%	A207316	001	Nov 18, 2019
CROWN LABS INC	100,000 UNITS/GM;0.1%	A207731	001	Dec 26, 2017
PAI HOLDINGS PHARM	100,000 UNITS/GM;0.1%	A208287	001	Dec 30, 2016
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062280	002	Oct 10, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	A062656	001	Jul 30, 1986

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062603	001	Oct 09, 1985

OBETICHOLIC ACID

TABLET;ORAL

OBETICHOLIC ACID

APOTEX	5MG	A214862	001	May 30, 2023
	10MG	A214862	002	May 30, 2023
LUPIN LTD	5MG	A214980	001	May 30, 2023
	10MG	A214980	002	May 30, 2023
MSN	5MG	A215017	001	May 30, 2023
	10MG	A215017	002	May 30, 2023

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

SUN PHARM INDS	EQ 0.05MG BASE/ML	A077329	001	Mar 04, 2008
	EQ 0.05MG BASE/ML	A077372	001	Aug 14, 2007
	EQ 0.1MG BASE/ML	A077329	002	Mar 04, 2008
	EQ 0.1MG BASE/ML	A077372	002	Aug 14, 2007
	EQ 0.2MG BASE/ML	A077330	001	Mar 04, 2008
	EQ 0.2MG BASE/ML	A077373	001	Aug 14, 2007
	EQ 0.5MG BASE/ML	A077329	003	Mar 04, 2008
	EQ 0.5MG BASE/ML	A077372	003	Aug 14, 2007
	EQ 1MG BASE/ML	A077331	001	Mar 04, 2008
	EQ 1MG BASE/ML	A077373	002	Aug 14, 2007
WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011
	EQ 1MG BASE/ML	A090986	002	May 11, 2011

OCTREOTIDE ACETATE PRESERVATIVE FREE

WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011
	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011
	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011

SANDOSTATIN

+	NOVARTIS	EQ 0.2MG BASE/ML **	N019667	004	Jun 12, 1991
+		EQ 1MG BASE/ML **	N019667	005	Jun 12, 1991

OFLOXACIN

INJECTABLE;INJECTION

FLOXIN

ORTHO MCNEIL PHARM	20MG/ML	N020087	002	Mar 31, 1992
	40MG/ML	N020087	003	Mar 31, 1992

FLOXIN IN DEXTROSE 5%

ORTHO MCNEIL PHARM	400MG/100ML	N020087	001	Mar 31, 1992

FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

ORTHO MCNEIL PHARM	4MG/ML	N020087	004	Mar 31, 1992
	400MG/100ML	N020087	005	Mar 31, 1992

OFLOXACIN

BEDFORD	40MG/ML	A075762	001	Jan 16, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC					
OFLOXACIN					
	AKORN	0.3%	A076615	001	May 14, 2004
	ALVOGEN	0.3%	A076830	001	Aug 31, 2004
	SANDOZ	0.3%	A076231	001	May 14, 2004
		0.3%	A076848	001	Nov 25, 2008
SOLUTION/DROPS;OTIC					
FLOXIN OTIC					
+	DAIICHI	0.3% **	N020799	001	Dec 16, 1997
OFLOXACIN					
	ALVOGEN	0.3%	A090395	001	Aug 11, 2009
	FDC LTD	0.3%	A215038	001	Jan 19, 2022
	SANDOZ	0.3%	A078222	001	Mar 17, 2008
TABLET;ORAL					
FLOXIN					
+	JANSSEN PHARMS	200MG **	N019735	001	Dec 28, 1990
+		300MG **	N019735	002	Dec 28, 1990
+		400MG **	N019735	003	Dec 28, 1990
OFLOXACIN					
	LARKEN LABS	200MG	A076093	001	Sep 02, 2003
		300MG	A076093	002	Sep 02, 2003
	RANBAXY LABS LTD	200MG	A076220	001	Sep 02, 2003
		300MG	A076220	002	Sep 02, 2003
		400MG	A076220	003	Sep 02, 2003

OLANZAPINE

TABLET;ORAL					
OLANZAPINE					
	AJANTA PHARMA LTD	2.5MG	A206711	001	Aug 30, 2016
		5MG	A206711	002	Aug 30, 2016
		7.5MG	A206711	003	Aug 30, 2016
		10MG	A206711	004	Aug 30, 2016
		15MG	A206711	005	Aug 30, 2016
		20MG	A206711	006	Aug 30, 2016
	HIKMA	2.5MG	A204866	001	Jun 16, 2017
		5MG	A204866	002	Jun 16, 2017
		7.5MG	A204866	003	Jun 16, 2017
		10MG	A204866	004	Jun 16, 2017
		15MG	A204866	005	Jun 16, 2017
		20MG	A204866	006	Jun 16, 2017
	HISUN PHARM HANGZHOU	2.5MG	A206924	001	Dec 31, 2020
		5MG	A206924	002	Dec 31, 2020
		7.5MG	A206924	003	Dec 31, 2020
		10MG	A206924	004	Dec 31, 2020
		15MG	A206924	005	Dec 31, 2020
		20MG	A206924	006	Dec 31, 2020
	IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015
	JIANGSU HANSOH PHARM	2.5MG	A209399	001	Sep 24, 2018
		5MG	A209399	002	Sep 24, 2018
		10MG	A209399	003	Sep 24, 2018
	MYLAN	2.5MG	A076866	001	Apr 23, 2012
		5MG	A076866	002	Apr 23, 2012
		7.5MG	A076866	003	Apr 23, 2012
		10MG	A076866	004	Apr 23, 2012
		15MG	A076866	005	Apr 23, 2012
		20MG	A076866	006	Apr 23, 2012
	SUNSHINE	2.5MG	A206238	001	Nov 19, 2018
		5MG	A206238	002	Nov 19, 2018
		7.5MG	A206238	003	Nov 19, 2018
		10MG	A206238	004	Nov 19, 2018
		15MG	A206238	005	Nov 19, 2018
		20MG	A206238	006	Nov 19, 2018
	TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011
		5MG	A076000	002	Oct 24, 2011
		7.5MG	A076000	003	Oct 24, 2011
		10MG	A076000	004	Oct 24, 2011
		15MG	A076000	005	Oct 24, 2011
	TORRENT PHARMS LTD	2.5MG	A091434	001	Apr 23, 2012
		5MG	A091434	002	Apr 23, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OLANZAPINE

TABLET;ORAL					
OLANZAPINE					
	7.5MG		A091434	003	Apr 23, 2012
	10MG		A091434	004	Apr 23, 2012
	15MG		A091434	005	Apr 23, 2012
	20MG		A091434	006	Apr 23, 2012
TABLET, ORALLY DISINTEGRATING;ORAL					
OLANZAPINE					
AJANTA PHARMA LTD	5MG		A204320	001	May 30, 2017
	10MG		A204320	002	May 30, 2017
	15MG		A204320	003	May 30, 2017
	20MG		A204320	004	May 30, 2017
ZYDUS PHARMS	5MG		A202889	001	Mar 09, 2023
	10MG		A202889	002	Mar 09, 2023
	15MG		A202889	003	Mar 09, 2023
	20MG		A202889	004	Mar 09, 2023

OLAPARIB

CAPSULE;ORAL					
LYNPARZA					
+ ASTRAZENECA	50MG		N206162	001	Dec 19, 2014

OLMESARTAN MEDOXOMIL

TABLET;ORAL					
OLMESARTAN MEDOXOMIL					
AMNEAL	5MG		A207480	001	Jul 11, 2023
	20MG		A207480	002	Jul 11, 2023
	40MG		A207480	003	Jul 11, 2023
INVENTIA	5MG		A208659	001	May 18, 2020
	20MG		A208659	002	May 18, 2020
	40MG		A208659	003	May 18, 2020
JUBILANT GENERICS	5MG		A205482	001	Apr 24, 2017
	20MG		A205482	002	Apr 24, 2017
	40MG		A205482	003	Apr 24, 2017
LUPIN LTD	5MG		A206631	001	Apr 27, 2017
	20MG		A206631	002	Apr 27, 2017
	40MG		A206631	003	Apr 27, 2017
RISING	5MG		A078276	001	Oct 26, 2016
	20MG		A078276	002	Oct 26, 2016
	40MG		A078276	003	Oct 26, 2016
SANDOZ	5MG		A090237	001	Apr 13, 2020
	20MG		A090237	002	Apr 13, 2020
	40MG		A090237	003	Apr 13, 2020
TEVA PHARMS USA	5MG		A091079	001	Apr 24, 2017
	20MG		A091079	002	Apr 24, 2017
	40MG		A091079	003	Apr 24, 2017
TORRENT	5MG		A202375	001	Apr 24, 2017
	20MG		A202375	002	Apr 24, 2017
	40MG		A202375	003	Apr 24, 2017

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC					
OLOPATADINE HYDROCHLORIDE					
AKORN	EQ 0.1% BASE		A204532	001	Jan 10, 2017
	EQ 0.2% BASE		A204723	001	Dec 05, 2017
BAUSCH AND LOMB INC	EQ 0.1% BASE		A206046	001	Jul 26, 2017
	EQ 0.2% BASE		A206087	001	Dec 05, 2017
FDC LTD	EQ 0.1% BASE		A209282	001	Sep 26, 2019
FLORIDA	EQ 0.7% BASE		A208637	001	Feb 19, 2020
GLENMARK PHARMS INC	EQ 0.1% BASE		A200810	001	Jun 28, 2017
RISING	EQ 0.1% BASE		A204392	001	Mar 21, 2018
	EQ 0.2% BASE		A204620	001	Jun 16, 2020
ZAMBON SPA	EQ 0.1% BASE		A204706	001	Dec 07, 2015
SPRAY, METERED;NASAL					
PATANASE					
+ NOVARTIS	0.665MG/SPRAY		N021861	001	Apr 15, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL					
TECHNIVIE					
+	ABBVIE	12.5MG;75MG;50MG **	N207931	001	Jul 24, 2015

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL					
OMEGA-3-ACID ETHYL ESTERS					
	STRIDES PHARMA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014
	ZYDUS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210107	001	Jun 14, 2019

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE;ORAL					
OMTRYG					
+	OSMOTICA PHARM US	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL					
EPANOVA					
+	ASTRAZENECA	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL					
OMEPRAZOLE					
	LUPIN LTD	40MG	A202384	001	Aug 25, 2015
	MYLAN	10MG	A205070	001	Jun 29, 2018
		20MG	A205070	002	Jun 29, 2018
		40MG	A205070	003	Jun 29, 2018
	STRIDES PHARMA	10MG	A075876	001	May 29, 2003
		20MG	A075876	002	May 29, 2003
		40MG	A075876	003	Jan 21, 2009
	TEVA PHARMS USA	40MG	A204661	002	Jun 13, 2017
PRILOSEC					
+	ASTRAZENECA	10MG **	N019810	003	Oct 05, 1995
+		20MG **	N019810	001	Sep 14, 1989
+		40MG **	N019810	002	Jan 15, 1998

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL					
OMEPRAZOLE MAGNESIUM					
	AUROBINDO PHARMA LTD	EQ 20MG BASE	A213201	001	Apr 28, 2023
TABLET, DELAYED RELEASE;ORAL					
OMEPRAZOLE MAGNESIUM					
	PERRIGO R AND D	EQ 20MG BASE	A204152	001	Jul 30, 2015

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL					
OMEPRAZOLE AND SODIUM BICARBONATE					
	CHARTWELL RX	20MG;1.1GM	A204137	001	Jul 15, 2016
	STRIDES PHARMA	20MG;1.1GM	A078966	001	May 25, 2010
		20MG;1.1GM	A201946	001	Jul 15, 2016
		40MG;1.1GM	A078966	002	May 25, 2010

OMIDENEPAG ISOPROPYL

SOLUTION;OPHTHALMIC					
OMLONTI					
+	VISIOX PHARMA	0.002%	N215092	001	Sep 22, 2022

ONDANSETRON

FILM;ORAL					
ZUPLENZ					
+	AQUESTIVE	4MG	N022524	001	Jul 02, 2010
+		8MG	N022524	002	Jul 02, 2010
TABLET, ORALLY DISINTEGRATING;ORAL					
ONDANSETRON					
	BARR	4MG	A076693	001	Jun 25, 2007
		8MG	A076693	002	Jun 25, 2007
	NESHER PHARMS	4MG	A077717	001	Jun 25, 2007
		8MG	A077717	002	Jun 25, 2007
	TEVA	4MG	A076810	001	Jun 25, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL				
ONDANSETRON				
	8MG		A076810 002	Jun 25, 2007
ZOFRAN ODT				
+ SANDOZ	4MG **		N020781 001	Jan 27, 1999
+	8MG **		N020781 002	Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION			
ONDANSETRON HYDROCHLORIDE			
APOTEX INC	EQ 2MG BASE/ML	A077368 001	Dec 26, 2006
AVET LIFESCIENCES	EQ 2MG BASE/ML	A090424 001	Apr 16, 2010
BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078288 001	Feb 22, 2013
CHARTWELL MOLECULAR	EQ 2MG BASE/ML	A090116 001	Apr 14, 2010
EUGIA PHARMA	EQ 2MG BASE/ML	A202599 001	Dec 21, 2012
HOSPIRA	EQ 2MG BASE/ML	A076695 001	Dec 26, 2006
	EQ 2MG BASE/ML	A077840 001	Jan 19, 2007
LANNETT CO INC	EQ 2MG BASE/ML	A090883 001	Aug 05, 2010
LUITPOLD	EQ 2MG BASE/ML	A077582 001	Dec 26, 2006
	EQ 2MG BASE/ML	A079039 001	Nov 18, 2008
PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544 001	Dec 26, 2006
RISING	EQ 2MG BASE/ML	A204906 001	Jul 31, 2017
SAGENT PHARMS	EQ 2MG BASE/ML	A078180 001	Mar 26, 2007
STERISCIENCE	EQ 2MG BASE/ML	A078257 001	Apr 23, 2008
SUN PHARM INDS (IN)	EQ 2MG BASE/ML	A077172 001	Dec 26, 2006
TEVA	EQ 2MG BASE/ML	A076876 001	Nov 22, 2006
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER			
HOSPIRA	EQ 0.64MG BASE/ML	A076978 001	Feb 26, 2007
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE			
AM REGENT	EQ 2MG BASE/ML	A079032 001	Nov 18, 2008
APOTEX INC	EQ 2MG BASE/ML	A077343 001	Dec 26, 2006
AVET LIFESCIENCES	EQ 2MG BASE/ML	A078945 001	Jan 03, 2013
EUGIA PHARMA	EQ 2MG BASE/ML	A202600 001	Dec 21, 2012
HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076780 001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076696 001	Dec 26, 2006
LUITPOLD	EQ 2MG BASE/ML	A077387 001	Dec 26, 2006
STERISCIENCE	EQ 2MG BASE/ML	A078244 001	Apr 23, 2008
SUN PHARM INDS LTD	EQ 2MG BASE/ML	A077173 001	Dec 26, 2006
TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014 001	Mar 21, 2008
TEVA	EQ 2MG BASE/ML	A076759 001	Nov 22, 2006
ZOFRAN			
+ SANDOZ	EQ 2MG BASE/ML **	N020007 001	Jan 04, 1991
ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER			
+ GLAXOSMITHKLINE	EQ 0.64MG BASE/ML **	N020403 001	Jan 31, 1995
ZOFRAN PRESERVATIVE FREE			
+ SANDOZ	EQ 2MG BASE/ML **	N020007 003	Dec 10, 1993
SOLUTION;ORAL			
ZOFRAN			
+ SANDOZ	EQ 4MG BASE/5ML	N020605 001	Jan 24, 1997
TABLET;ORAL			
ONDANSETRON HYDROCHLORIDE			
AUROBINDO PHARMA	EQ 24MG BASE	A078539 003	Jul 31, 2007
CASI PHARMS INC	EQ 4MG BASE	A077517 001	Jun 25, 2007
	EQ 8MG BASE	A077517 002	Jun 25, 2007
	EQ 24MG BASE	A077517 003	Jun 25, 2007
DR REDDYS LABS LTD	EQ 16MG BASE	A076183 004	Dec 26, 2006
	EQ 24MG BASE	A076183 001	Dec 26, 2006
GLENMARK GENERICS	EQ 24MG BASE	A077535 003	Jun 25, 2007
HIKMA INTL PHARMS	EQ 4MG BASE	A077545 001	Sep 06, 2007
	EQ 8MG BASE	A077545 002	Sep 06, 2007
	EQ 24MG BASE	A077545 003	Sep 06, 2007
PLIVA HRVATSKA DOO	EQ 4MG BASE	A077112 001	Jun 25, 2007
	EQ 8MG BASE	A077112 002	Jun 25, 2007
	EQ 24MG BASE	A077112 003	Jun 25, 2007
RISING	EQ 4MG BASE	A076930 001	Jun 25, 2007
	EQ 8MG BASE	A076930 002	Jun 25, 2007
	EQ 24MG BASE	A076930 004	Jun 25, 2007
TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011
	EQ 8MG BASE	A077729 002	Mar 28, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ONDANSETRON HYDROCHLORIDE				
TABLET;ORAL				
ONDANSETRON HYDROCHLORIDE				
	EQ 24MG BASE	A077729	003	Mar 28, 2011
TEVA	EQ 4MG BASE	A076252	001	Jun 25, 2007
	EQ 8MG BASE	A076252	002	Jun 25, 2007
	EQ 24MG BASE	A076252	003	Jun 25, 2007
ZOFRAN				
+ SANDOZ	EQ 4MG BASE **	N020103	001	Dec 31, 1992
+	EQ 8MG BASE **	N020103	002	Dec 31, 1992
+	EQ 24MG BASE **	N020103	003	Aug 27, 1999
ORPHENADRINE CITRATE				
INJECTABLE;INJECTION				
NORFLEX				
+ PAI HOLDINGS PHARM	30MG/ML **	N013055	001	
ORPHENADRINE CITRATE				
WATSON LABS	30MG/ML	A087062	001	
TABLET, EXTENDED RELEASE;ORAL				
NORFLEX				
+ BAUSCH	100MG **	N012157	001	
ORPHENADRINE CITRATE				
ASCOT	100MG	A088067	001	Apr 06, 1983
IMPAX PHARMS	100MG	A040368	001	Jun 23, 2000
SANDOZ	100MG	A085046	001	
WATSON LABS	100MG	A084303	001	
ORPHENADRINE HYDROCHLORIDE				
TABLET;ORAL				
DISIPAL				
3M	50MG	N010653	001	
OSELTAMIVIR PHOSPHATE				
CAPSULE;ORAL				
OSELTAMIVIR PHOSPHATE				
ACCORD HLTHCARE	EQ 30MG BASE	A214726	001	Jul 25, 2022
	EQ 45MG BASE	A214726	002	Jul 25, 2022
	EQ 75MG BASE	A214726	003	Jul 25, 2022
RISING	EQ 30MG BASE	A210157	001	Jan 21, 2021
	EQ 45MG BASE	A210157	002	Jan 21, 2021
	EQ 75MG BASE	A210157	003	Jan 21, 2021
FOR SUSPENSION;ORAL				
OSELTAMIVIR PHOSPHATE				
CHEMISTRY HLTH	EQ 6MG BASE/ML	A214949	001	Feb 28, 2022
TAMIFLU				
ROCHE	EQ 12MG BASE/ML	N021246	001	Dec 14, 2000
OSILODROSTAT PHOSPHATE				
TABLET;ORAL				
ISTURISA				
+ RECORDATI RARE	EQ 10MG BASE	N212801	003	Mar 06, 2020
OXACILLIN SODIUM				
CAPSULE;ORAL				
BACTOCILL				
GLAXOSMITHKLINE	EQ 250MG BASE	A061336	001	
	EQ 250MG BASE	A062241	001	
	EQ 500MG BASE	A061336	002	
	EQ 500MG BASE	A062241	002	
OXACILLIN SODIUM				
ANI PHARMS	EQ 250MG BASE	A062222	001	
	EQ 500MG BASE	A062222	002	
APOTHECON	EQ 250MG BASE	A061450	002	
	EQ 500MG BASE	A061450	001	
PROSTAPHLIN				
APOTHECON	EQ 500MG BASE	N050118	002	
FOR SOLUTION;ORAL				
BACTOCILL				
GLAXOSMITHKLINE	EQ 250MG BASE/5ML	A062321	001	
OXACILLIN SODIUM				
APOTHECON	EQ 250MG BASE/5ML	A061457	001	
TEVA	EQ 250MG BASE/5ML	A062252	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXACILLIN SODIUM				
FOR SOLUTION;ORAL				
PROSTAPHLIN				
APOTHECON	EQ 250MG BASE/5ML	N050194	001	
INJECTABLE;INJECTION				
BACTOCILL				
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL **	A061334	009	Mar 26, 1982
	EQ 1GM BASE/VIAL **	A061334	006	Mar 26, 1982
	EQ 1GM BASE/VIAL **	A062736	001	Dec 19, 1986
	EQ 2GM BASE/VIAL **	A061334	007	Mar 26, 1982
	EQ 2GM BASE/VIAL **	A062736	002	Dec 19, 1986
	EQ 4GM BASE/VIAL **	A061334	008	Mar 26, 1982
	EQ 10GM BASE/VIAL **	A061334	010	
OXACILLIN SODIUM				
+ APOTHECON	EQ 250MG BASE/VIAL **	N050195	001	
+	EQ 500MG BASE/VIAL **	N050195	002	
+	EQ 1GM BASE/VIAL **	N050195	003	
+	EQ 2GM BASE/VIAL **	N050195	004	
+	EQ 4GM BASE/VIAL **	N050195	005	
ELKINS SINN	EQ 250MG BASE/VIAL	A062711	001	Feb 03, 1989
	EQ 500MG BASE/VIAL	A062711	002	Feb 03, 1989
	EQ 1GM BASE/VIAL	A062711	003	Feb 03, 1989
	EQ 2GM BASE/VIAL	A062711	004	Feb 03, 1989
	EQ 4GM BASE/VIAL	A062711	005	Feb 03, 1989
	EQ 10GM BASE/VIAL	A062711	006	Feb 03, 1989
HOSPIRA	EQ 1GM BASE/VIAL	A203950	001	Dec 11, 2015
	EQ 2GM BASE/VIAL	A203950	002	Dec 11, 2015
ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062798	003	Dec 11, 1995
	EQ 250MG BASE/VIAL	A062798	004	Dec 11, 1995
	EQ 500MG BASE/VIAL	A062798	005	Dec 11, 1995
	EQ 1GM BASE/VIAL	A062798	001	Dec 11, 1995
	EQ 2GM BASE/VIAL	A062798	002	Dec 11, 1995
PIRAMAL CRITICAL	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017
	EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017
	EQ 10GM BASE/VIAL	A206760	001	Oct 26, 2017
SANDOZ	EQ 250MG BASE/VIAL	A061490	001	
	EQ 500MG BASE/VIAL	A061490	002	
	EQ 1GM BASE/VIAL	A061490	003	
	EQ 2GM BASE/VIAL	A061490	004	
	EQ 10GM BASE/VIAL	A061490	006	May 09, 1991
STERISCIENCE	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014
WATSON LABS INC	EQ 250MG BASE/VIAL	A062856	001	Oct 26, 1988
	EQ 500MG BASE/VIAL	A062856	002	Oct 26, 1988
	EQ 1GM BASE/VIAL	A062856	003	Oct 26, 1988
	EQ 2GM BASE/VIAL	A062856	004	Oct 26, 1988
	EQ 4GM BASE/VIAL	A062856	005	Oct 26, 1988
	EQ 10GM BASE/VIAL	A062984	001	Sep 29, 1988
POWDER;INTRAVENOUS				
OXACILLIN SODIUM				
SANDOZ	EQ 1GM BASE/VIAL	A062737	001	Dec 23, 1986
	EQ 2GM BASE/VIAL	A062737	002	Dec 23, 1986
OXALIPLATIN				
INJECTABLE;INTRAVENOUS				
ELOXATIN				
+ SANOFI AVENTIS US	50MG/VIAL **	N021492	001	Aug 09, 2002
+	100MG/VIAL **	N021492	002	Aug 09, 2002
+	200MG/40ML (5MG/ML) **	N021759	003	Nov 17, 2006
OXALIPLATIN				
ACCORD HLTHCARE	200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017
AM REGENT	50MG/10ML (5MG/ML)	A204378	001	May 12, 2017
	100MG/20ML (5MG/ML)	A204378	002	May 12, 2017
CHARTWELL MOLECULAR	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017
	100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017
FRESENIUS KABI ONCOL	50MG/VIAL	A078810	001	Aug 07, 2009
	100MG/VIAL	A078810	002	Aug 07, 2009
FRESENIUS KABI USA	200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017
GLAND	200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017
HOSPIRA INC	50MG/VIAL	A078815	001	Sep 30, 2009
	100MG/VIAL	A078815	002	Sep 30, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXALIPLATIN

INJECTABLE;INTRAVENOUS				
OXALIPLATIN				
	MYLAN LABS LTD	50MG/VIAL	A200979 001	Aug 08, 2012
		100MG/VIAL	A200979 002	Aug 08, 2012
		200MG/40ML (5MG/ML)	A091358 003	Nov 14, 2017
	SANDOZ	50MG/10ML (5MG/ML)	A078812 001	Aug 07, 2009
		50MG/VIAL	A090849 001	Apr 28, 2011
		100MG/20ML (5MG/ML)	A078812 002	Aug 07, 2009
		100MG/VIAL	A090849 002	Apr 28, 2011
	SUN PHARM	50MG/VIAL	A078818 001	Aug 07, 2009
		50MG/10ML (5MG/ML)	A202922 001	Apr 08, 2014
		100MG/VIAL	A078818 002	Aug 07, 2009
		100MG/20ML (5MG/ML)	A202922 002	Apr 08, 2014
		200MG/40ML (5MG/ML)	A202922 003	Feb 15, 2019

OXAMNIQUINE

CAPSULE;ORAL				
VANSIL				
	PFIZER	250MG	N018069 001	

OXANDROLONE

TABLET;ORAL				
OXANDROLONE				
	PAR PHARM	2.5MG	A077827 001	Jun 22, 2007
		10MG	A077827 002	Jun 22, 2007
	ROXANE	2.5MG	A077249 001	Jul 10, 2007
		10MG	A077249 002	Jul 10, 2007
	SANDOZ	2.5MG	A076897 001	Dec 01, 2006
		10MG	A076897 002	Dec 01, 2006
	UPSHER SMITH LABS	2.5MG	A076761 001	Dec 01, 2006
		10MG	A078033 001	Mar 22, 2007

OXAPROZIN

TABLET;ORAL				
OXAPROZIN				
	ACTAVIS ELIZABETH	600MG	A075843 001	Oct 03, 2001
	BEXIMCO PHARMS USA	600MG	A075842 001	Apr 12, 2001
	IVAX SUB TEVA PHARMS	600MG	A075846 001	May 13, 2002
	MYLAN	600MG	A075851 001	Aug 17, 2001
	MYLAN PHARMS INC	600MG	A075847 001	Feb 28, 2001
	SANDOZ	600MG	A075850 001	Apr 27, 2001
	SUN PHARM INDS INC	600MG	A075844 001	Jan 03, 2002
	WATSON LABS	600MG	A075848 001	Feb 09, 2001

OXAPROZIN POTASSIUM

TABLET;ORAL				
DAYPRO ALTA				
	PFIZER	600MG	N020776 001	Oct 17, 2002

OXAZEPAM

CAPSULE;ORAL				
OXAZEPAM				
	AM THERAP	10MG	A071955 001	Mar 03, 1988
		15MG	A071956 001	Mar 03, 1988
		30MG	A071957 001	Mar 03, 1988
	IVAX SUB TEVA PHARMS	10MG	A070943 001	Aug 03, 1987
		15MG	A070944 001	Aug 03, 1987
		30MG	A070945 001	Aug 03, 1987
	MYLAN	10MG	A071713 001	Oct 20, 1987
		15MG	A071714 001	Oct 20, 1987
		30MG	A071715 001	Oct 20, 1987
	WATSON LABS	15MG	A072953 001	Sep 28, 1990
		30MG	A072954 001	Sep 28, 1990
	WATSON LABS TEVA	10MG	A072952 001	Sep 28, 1990
SERAX				
+	ALPHARMA US PHARMS	10MG **	N015539 002	
+		15MG **	N015539 004	
+		30MG **	N015539 006	
ZAXOPAM				
	QUANTUM PHARMICS	10MG	A070650 001	Mar 01, 1988
		15MG	A070640 001	Mar 01, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXAZEPAM				
CAPSULE;ORAL				
ZAXOPAM				
	30MG	A070641	001	Mar 01, 1988
TABLET;ORAL				
OXAZEPAM				
PARKE DAVIS	15MG	A071508	001	Feb 02, 1987
SUN PHARM INDUSTRIES	15MG	A070683	001	Jan 16, 1987
WATSON LABS	15MG	A071494	001	Apr 21, 1987
SERAX				
ALPHARMA US PHARMS	15MG **	N015539	008	
OXCARBAZEPINE				
SUSPENSION;ORAL				
OXCARBAZEPINE				
HIKMA	300MG/5ML	A201193	001	Oct 03, 2012
RENEW PHARMS	300MG/5ML	A211420	001	Jul 09, 2021
TABLET;ORAL				
OXCARBAZEPINE				
ANI PHARMS	150MG	A078005	001	Dec 11, 2007
	300MG	A078005	002	Dec 11, 2007
	600MG	A078005	003	Dec 11, 2007
HIKMA	150MG	A077795	001	Oct 09, 2007
	300MG	A077795	002	Oct 09, 2007
	600MG	A077795	003	Oct 09, 2007
JUBILANT CADISTA	150MG	A090239	001	Jan 25, 2010
	300MG	A090239	002	Jan 25, 2010
	600MG	A090239	003	Jan 25, 2010
TABLET, EXTENDED RELEASE;ORAL				
OXCARBAZEPINE				
APOTEX	150MG	A213369	001	Jul 13, 2023
	300MG	A213369	002	Jul 13, 2023
	600MG	A213369	003	Jul 13, 2023
OXPRENOLOL HYDROCHLORIDE				
CAPSULE;ORAL				
TRASICOR				
NOVARTIS	20MG	N018166	001	Dec 28, 1983
	40MG	N018166	002	Dec 28, 1983
	80MG	N018166	003	Dec 28, 1983
	160MG	N018166	004	Dec 28, 1983
OXTRIPHYLLINE				
SOLUTION;ORAL				
CHOLEDYL				
PARKE DAVIS	100MG/5ML	N009268	012	Nov 27, 1984
OXTRIPHYLLINE				
MORTON GROVE	100MG/5ML	A088243	001	Dec 05, 1983
SYRUP;ORAL				
CHOLEDYL				
PARKE DAVIS	50MG/5ML	N009268	011	
OXTRIPHYLLINE PEDIATRIC				
MORTON GROVE	50MG/5ML	A088242	001	Dec 05, 1983
TABLET, DELAYED RELEASE;ORAL				
CHOLEDYL				
PARKE DAVIS	100MG	N009268	003	
	200MG	N009268	007	
OXTRIPHYLLINE				
WATSON LABS	100MG	A087866	001	Aug 25, 1983
	200MG	A087835	001	Aug 25, 1983
TABLET, EXTENDED RELEASE;ORAL				
CHOLEDYL SA				
WARNER CHILCOTT LLC	400MG	A087863	001	May 24, 1983
	600MG	A086742	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXYBUTYNIN					
FILM, EXTENDED RELEASE;TRANSDERMAL					
OXYBUTYNIN					
	BARR LABS DIV TEVA	3.9MG/24HR	A090526	001	Mar 04, 2014
GEL, METERED;TRANSDERMAL					
GELNIQUE 3%					
+	ALLERGAN	3%	N202513	001	Dec 07, 2011
OXYBUTYNIN CHLORIDE					
GEL;TRANSDERMAL					
GELNIQUE					
+	ABBVIE	10% (100MG/PACKET)	N022204	001	Jan 27, 2009
OXYBUTYNIN CHLORIDE					
	CHARTWELL RX	10% (100MG/PACKET)	A207329	001	May 31, 2018
SYRUP;ORAL					
DITROPAN					
+	ORTHO MCNEIL JANSSEN	5MG/5ML **	N018211	001	
OXYBUTYNIN CHLORIDE					
	LANNETT CO INC	5MG/5ML	A076682	001	Dec 28, 2004
	PHARM ASSOC	5MG/5ML	A074997	001	Oct 15, 1997
	PHARMOBEDIENT CNSLTG	5MG/5ML	A074868	001	Feb 12, 1997
TABLET;ORAL					
DITROPAN					
+	JANSSEN PHARMS	5MG **	N017577	001	
OXYBUTYNIN CHLORIDE					
	AVET LIFESCIENCES	5MG	A211682	001	May 10, 2019
	QUANTUM PHARMICS	5MG	A072296	001	Dec 08, 1988
	USL PHARMA	5MG	A070746	001	Mar 10, 1988
	WATSON LABS	5MG	A072485	001	Apr 19, 1989
TABLET, EXTENDED RELEASE;ORAL					
DITROPAN XL					
+	JANSSEN PHARMS	5MG	N020897	001	Dec 16, 1998
+		10MG	N020897	002	Dec 16, 1998
+		15MG **	N020897	003	Jun 22, 1999
OXYBUTYNIN CHLORIDE					
	IMPAX PHARMS	5MG	A076745	002	May 09, 2007
		10MG	A076745	003	May 09, 2007
		15MG	A076745	001	Nov 09, 2006
	MYLAN	5MG	A076702	001	Nov 09, 2006
	MYLAN PHARMS INC	10MG	A076644	001	Nov 09, 2006
		15MG	A076644	002	May 10, 2007
OXYCODONE HYDROCHLORIDE					
CAPSULE;ORAL					
OXYCODONE HYDROCHLORIDE					
	DR REDDYS LABS SA	5MG	A203107	001	Jul 26, 2012
	LANNETT CO INC	5MG	A203823	001	Aug 01, 2014
SOLUTION;ORAL					
OXYCODONE HYDROCHLORIDE					
	ANI PHARMS	100MG/5ML	A203447	001	Aug 30, 2017
	AUROLIFE PHARMA LLC	5MG/5ML	A212429	001	Jan 27, 2020
		100MG/5ML	A212429	002	Jan 27, 2020
	CHARTWELL MOLECULAR	100MG/5ML	A204085	001	Sep 09, 2014
	DR REDDYS LABS SA	100MG/5ML	A204092	001	Jun 05, 2014
	HIKMA	100MG/5ML	A203208	001	Jul 12, 2013
	NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015
	PHARMOBEDIENT CNSLTG	5MG/5ML	A206456	001	Jun 16, 2015
	RHODES PHARMS	100MG/5ML	A205853	001	Apr 29, 2020
+	VISTAPHARM	5MG/5ML	N201194	001	Jan 12, 2012
		100MG/5ML	A202537	001	Jul 30, 2012
TABLET;ORAL					
OXAYDO					
+	ZYLA	5MG	N202080	001	Jun 17, 2011
+		7.5MG	N202080	002	Jun 17, 2011
OXYCODONE HYDROCHLORIDE					
	ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015
		15MG	A076636	001	Feb 06, 2004
		30MG	A076636	002	Feb 06, 2004
	DR REDDYS LABS SA	5MG	A091313	001	Feb 18, 2011
		10MG	A091313	004	Apr 29, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXYCODONE HYDROCHLORIDE					
TABLET;ORAL					
OXYCODONE HYDROCHLORIDE					
		15MG	A091313	002	Feb 18, 2011
		20MG	A091313	005	Apr 29, 2016
		30MG	A091313	003	Feb 18, 2011
	NESHER PHARMS	5MG	A077290	001	Dec 08, 2005
		10MG	A077290	002	Dec 08, 2005
		15MG	A077290	003	Dec 08, 2005
		20MG	A077290	004	Dec 08, 2005
		30MG	A077290	005	Dec 08, 2005
	STRIDES PHARMA	5MG	A077712	003	Mar 02, 2009
		10MG	A077712	004	Apr 13, 2015
		15MG	A077712	001	Jan 31, 2007
		20MG	A077712	005	Apr 13, 2015
		30MG	A077712	002	Jan 31, 2007
TABLET, EXTENDED RELEASE;ORAL					
ROXICODONE					
	ROXANE	10MG	N020932	001	Oct 26, 1998
		30MG	N020932	002	Oct 26, 1998
OXYMETAZOLINE HYDROCHLORIDE					
CREAM;TOPICAL					
OXYMETAZOLINE HYDROCHLORIDE					
	TARO	1%	A213584	001	Oct 04, 2021
SOLUTION/DROPS;OPHTHALMIC					
OCUCLEAR					
	BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986
OXYMETHOLONE					
TABLET;ORAL					
ANADROL-50					
+	MYLAN SPECIALITY LP	50MG	N016848	001	
OXYMORPHONE HYDROCHLORIDE					
INJECTABLE;INJECTION					
OPANA					
+	ENDO PHARMS	1MG/ML	N011707	002	
		1.5MG/ML	N011707	001	
SUPPOSITORY;RECTAL					
NUMORPHAN					
	ENDO PHARMS	5MG	N011738	004	
TABLET;ORAL					
OPANA					
+	ENDO PHARMS	5MG **	N021611	001	Jun 22, 2006
+		10MG **	N021611	002	Jun 22, 2006
OXYMORPHONE HYDROCHLORIDE					
	SPECGX LLC	5MG	A202321	001	Apr 25, 2013
		10MG	A202321	002	Apr 25, 2013
TABLET, EXTENDED RELEASE;ORAL					
OPANA ER					
+	ENDO PHARMS	5MG **	N021610	001	Jun 22, 2006
+		5MG	N201655	001	Dec 09, 2011
+		7.5MG **	N021610	005	Feb 29, 2008
+		7.5MG	N201655	002	Dec 09, 2011
+		10MG **	N021610	002	Jun 22, 2006
+		10MG	N201655	003	Dec 09, 2011
+		15MG **	N021610	006	Feb 29, 2008
+		15MG	N201655	004	Dec 09, 2011
+		20MG **	N021610	003	Jun 22, 2006
+		20MG	N201655	005	Dec 09, 2011
+		30MG **	N021610	007	Feb 29, 2008
+		30MG	N201655	006	Dec 09, 2011
+		40MG **	N021610	004	Jun 22, 2006
+		40MG	N201655	007	Dec 09, 2011
OXYMORPHONE HYDROCHLORIDE					
	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013
		7.5MG	A079046	001	Dec 13, 2010
		10MG	A079046	004	Jul 11, 2013
		15MG	A079046	002	Dec 13, 2010
		20MG	A079046	005	Jul 11, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXYMORPHONE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
OXYMORPHONE HYDROCHLORIDE				
	30MG	A079046	006	Jul 11, 2013
	40MG	A079046	007	Jul 11, 2013
HIKMA	5MG	A200822	002	Jul 15, 2013
	7.5MG	A200822	003	Jul 15, 2013
	10MG	A200822	004	Jul 15, 2013
	15MG	A200822	005	Jul 15, 2013
	20MG	A200822	006	Jul 15, 2013
	30MG	A200822	007	Jul 15, 2013
	40MG	A200822	001	Jul 15, 2013
PAR PHARM	5MG	A200792	001	Oct 24, 2014
	7.5MG	A200792	002	Oct 24, 2014
	10MG	A200792	003	Oct 24, 2014
	15MG	A200792	004	Oct 24, 2014
	20MG	A200792	005	Oct 24, 2014
	30MG	A200792	006	Oct 24, 2014
	40MG	A200792	007	Oct 24, 2014
SPECGX LLC	5MG	A202946	001	Jun 27, 2014
	7.5MG	A202946	002	Jun 27, 2014
	10MG	A202946	003	Jun 27, 2014
	15MG	A202946	004	Jun 27, 2014
	20MG	A202946	005	Jun 27, 2014
	30MG	A202946	006	Jun 27, 2014
	40MG	A202946	007	Jun 27, 2014
SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015
	7.5MG	A203506	002	Apr 24, 2015
	10MG	A203506	003	Apr 24, 2015
	15MG	A203506	004	Apr 24, 2015
	20MG	A203506	005	Apr 24, 2015
	30MG	A203506	006	Apr 24, 2015
	40MG	A203506	007	Apr 24, 2015
OXYPHENBUTAZONE				
TABLET;ORAL				
OXYPHENBUTAZONE				
WATSON LABS	100MG	A088399	001	Sep 17, 1984
TANDEARIL				
NOVARTIS	100MG	N012542	004	Sep 03, 1982
OXYPHENCYCLIMINE HYDROCHLORIDE				
TABLET;ORAL				
DARICON				
PFIZER	10MG	N011612	001	
OXYPHENONIUM BROMIDE				
TABLET;ORAL				
ANTRENYL				
NOVARTIS	5MG	N008492	002	
OXYTETRACYCLINE				
TABLET;ORAL				
TERRAMYCIN				
PFIZER	250MG	N050287	001	
OXYTETRACYCLINE CALCIUM				
SYRUP;ORAL				
TERRAMYCIN				
PFIZER	EQ 125MG BASE/5ML	A060595	001	
OXYTETRACYCLINE HYDROCHLORIDE				
CAPSULE;ORAL				
OXY-KESSO-TETRA				
FERRANTE	EQ 250MG BASE	A060179	001	
OXYTETRACYCLINE HYDROCHLORIDE				
HIKMA	EQ 250MG BASE	A060770	001	
IMPAX LABS	EQ 250MG BASE	A060760	001	
PROTER	EQ 250MG BASE	A060869	001	
PUREPAC PHARM	EQ 250MG BASE	A060634	001	
TERRAMYCIN				
PFIZER	EQ 125MG BASE	N050286	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL				
TERRAMYCIN				
		EQ 250MG BASE	N050286 002	
INJECTABLE;INJECTION				
TERRAMYCIN				
	PFIZER	EQ 250MG BASE/VIAL	A060586 001	
		EQ 500MG BASE/VIAL	A060586 002	

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
TERRAMYCIN W/ POLYMYXIN B SULFATE				
	CASPER PHARMA LLC	EQ 5MG BASE/GM;10,000 UNITS/GM	N061015 001	
OINTMENT;OTIC				
TERRAMYCIN W/ POLYMYXIN				
	PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM	A061841 001	
TABLET;VAGINAL				
TERRAMYCIN-POLYMYXIN				
	PFIZER	EQ 100MG BASE;100,000 UNITS	A061009 001	

OXYTOCIN

INJECTABLE;INJECTION				
OXYTOCIN				
	DR REDDYS	10USP UNITS/ML (10USP UNITS/ML)	A077453 001	Jan 24, 2008
		100USP UNITS/10ML (10USP UNITS/ML)	A077453 002	Jan 24, 2008
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%				
+	ABBOTT	1USP UNITS/100ML **	N019185 004	Mar 29, 1985
+		2USP UNITS/100ML **	N019185 003	Mar 29, 1985
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%				
+	ABBOTT	2USP UNITS/100ML **	N019185 002	Mar 29, 1985
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%				
+	ABBOTT	1USP UNITS/100ML **	N019185 001	Mar 29, 1985
SYNTOCINON				
	NOVARTIS	10USP UNITS/ML	N018245 001	
SOLUTION;NASAL				
SYNTOCINON				
	RTRX	40USP UNITS/ML	N012285 001	

PACLITAXEL

INJECTABLE;INJECTION				
PACLITAXEL				
	ACCORD HLTHCARE	6MG/ML	A075436 001	Nov 12, 2004
	DASH PHARMS	6MG/ML	A091540 001	Sep 29, 2011
	HOSPIRA	6MG/ML	A076233 001	Aug 01, 2002
	MYLAN	6MG/ML	A075278 001	Jan 25, 2002
	PLIVA LACHEMA	6MG/ML	A077413 001	Mar 12, 2008
	SANDOZ	6MG/ML	A078167 001	Dec 26, 2007
	TEVA PHARMS USA	6MG/ML	A075297 001	Jan 25, 2002
TAXOL				
+	HQ SPCLT PHARMA	6MG/ML **	N020262 001	Dec 29, 1992
POWDER;INTRAVENOUS				
PACLITAXEL				
+	TEVA PHARMS INC	100MG/VIAL	N216338 001	May 11, 2023

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL				
INVEGA				
+	JANSSEN PHARMS	12MG **	N021999 004	Dec 19, 2006

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR				
PALIPERIDONE PALMITATE				
	TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149 001	Jul 06, 2021
		78MG/0.5ML (78MG/0.5ML)	A211149 002	Jul 06, 2021
		117MG/0.75ML (117MG/0.75ML)	A211149 003	Jul 06, 2021
		156MG/ML (156MG/ML)	A211149 004	Jul 06, 2021
		234MG/1.5ML (156MG/ML)	A211149 005	Jul 06, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PALONOSETRON HYDROCHLORIDE					
CAPSULE;ORAL					
ALOXI					
+	HELSINN HLTHCARE	EQ 0.5MG BASE **	N022233	001	Aug 22, 2008
INJECTABLE;INTRAVENOUS					
ALOXI					
+	HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **	N021372	002	Feb 29, 2008
+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **	N021372	001	Jul 25, 2003
PALONOSETRON HYDROCHLORIDE					
	ACCORD HLTHCARE	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021
	CIPLA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206396	001	Sep 19, 2018
	DR REDDYS	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016
	HOSPIRA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A207005	002	Sep 19, 2018
	NOVAST LABS	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020
	QILU PHARM HAINAN	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648	002	Sep 19, 2018
	TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018
SOLUTION;INTRAVENOUS					
PALONOSETRON HYDROCHLORIDE					
	AVYXA PHARMA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016
		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016
+	FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109	001	Nov 21, 2017
	HIKMA	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001	Aug 22, 2016
PAMIDRONATE DISODIUM					
INJECTABLE;INJECTION					
AREDIA					
+	NOVARTIS	30MG/VIAL **	N020036	001	Oct 31, 1991
		60MG/VIAL	N020036	003	May 06, 1993
		90MG/VIAL	N020036	004	May 06, 1993
PAMIDRONATE DISODIUM					
	AESGEN	30MG/VIAL	A075594	001	May 06, 2002
		90MG/VIAL	A075594	002	May 06, 2002
	AM REGENT	30MG/10ML (3MG/ML)	A078942	001	Jul 25, 2008
		90MG/10ML (9MG/ML)	A078942	002	Jul 25, 2008
	FRESENIUS KABI USA	30MG/VIAL	A075773	001	May 06, 2002
		30MG/10ML (3MG/ML)	A076207	001	May 17, 2002
		90MG/VIAL	A075773	002	May 06, 2002
		90MG/10ML (9MG/ML)	A076207	002	May 17, 2002
	MN PHARMS	30MG/VIAL	A078300	001	Mar 10, 2009
		90MG/VIAL	A078300	002	Mar 10, 2009
	SUN PHARMA GLOBAL	30MG/VIAL	A077703	001	Dec 24, 2008
		90MG/VIAL	A077703	002	Dec 24, 2008
	TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002
		90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002
PANCURONIUM BROMIDE					
INJECTABLE;INJECTION					
PANCURONIUM BROMIDE					
	ELKINS SINN	1MG/ML	A072058	001	Mar 23, 1988
		2MG/ML	A072059	001	Mar 23, 1988
		2MG/ML	A072060	001	Mar 23, 1988
	HOSPIRA	2MG/ML	A072321	001	Jan 19, 1989
	IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988
		2MG/ML	A072211	001	Mar 31, 1988
		2MG/ML	A072212	001	Mar 31, 1988
		2MG/ML	A072213	001	Mar 31, 1988
PAVULON					
+	ORGANON USA INC	1MG/ML **	N017015	002	
+		2MG/ML **	N017015	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PANOBINOSTAT LACTATE
CAPSULE;ORAL
FARYDAK
+ SECURA EQ 10MG BASE N205353 001 Feb 23, 2015
+ EQ 15MG BASE N205353 002 Feb 23, 2015
+ EQ 20MG BASE N205353 003 Feb 23, 2015

PANTOPRAZOLE SODIUM
INJECTABLE;INTRAVENOUS
PANTOPRAZOLE SODIUM
MYLAN LABS LTD EQ 40MG BASE/VIAL A208580 001 May 04, 2018
TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM
JUBILANT GENERICS EQ 20MG BASE A090901 001 Aug 30, 2011
EQ 40MG BASE A090901 002 Aug 30, 2011
L PERRIGO CO EQ 20MG BASE A203024 001 May 07, 2014
MACLEODS PHARMS LTD EQ 20MG BASE A200821 001 Feb 16, 2012
EQ 40MG BASE A200821 002 Feb 16, 2012
SUN PHARM EQ 20MG BASE A077058 001 Sep 10, 2007
EQ 40MG BASE A077058 002 Sep 10, 2007
SUN PHARM INDS LTD EQ 20MG BASE A200794 001 May 02, 2012
EQ 40MG BASE A200794 002 May 02, 2012
TEVA EQ 20MG BASE A077056 001 Aug 02, 2007
EQ 40MG BASE A077056 002 Aug 02, 2007

PARAMETHADIONE
CAPSULE;ORAL
PARADIONE
ABBVIE 150MG N006800 003
300MG N006800 001
SOLUTION;ORAL
PARADIONE
ABBVIE 300MG/ML N006800 002

PARAMETHASONE ACETATE
TABLET;ORAL
HALDRONE
LILLY 1MG N012772 005
2MG N012772 006

PARGYLINE HYDROCHLORIDE
TABLET;ORAL
EUTONYL
ABBOTT 10MG N013448 002
25MG N013448 003
50MG N013448 004

PARICALCITOL
CAPSULE;ORAL
PARICALCITOL
LOTUS PHARM CO LTD 1MCG A206710 001 Feb 24, 2016
2MCG A206710 002 Feb 24, 2016
4MCG A206710 003 Feb 24, 2016
ZEMPLAR
+ ABBVIE 4MCG ** N021606 003 May 26, 2005
SOLUTION;INTRAVENOUS
PARICALCITOL
AKORN 0.01MG/2ML (0.005MG/ML) A207692 001 Oct 16, 2017
RISING 0.002MG/ML (0.002MG/ML) A203897 001 Nov 02, 2017

PAROMOMYCIN SULFATE
CAPSULE;ORAL
HUMATIN
KING PFIZER EQ 250MG BASE A062310 001
PARKEDALE EQ 250MG BASE A060521 001
PAROMOMYCIN SULFATE
SUN PHARM INDS INC EQ 250MG BASE A064171 001 Jun 30, 1997
SYRUP;ORAL
HUMATIN
PARKE DAVIS EQ 125MG BASE/5ML A060522 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PAROXETINE HYDROCHLORIDE

CAPSULE;ORAL				
PAXIL				
+	APOTEX	EQ 10MG BASE **	N020885 001	Oct 09, 1998
+		EQ 20MG BASE **	N020885 002	Oct 09, 1998
+		EQ 30MG BASE **	N020885 003	Oct 09, 1998
+		EQ 40MG BASE **	N020885 004	Oct 09, 1998
SUSPENSION;ORAL				
PAROXETINE HYDROCHLORIDE				
	APOTEX INC	EQ 10MG BASE/5ML	A077395 001	Dec 05, 2006
TABLET;ORAL				
PAROXETINE HYDROCHLORIDE				
	JUBILANT GENERICS	EQ 10MG BASE	A205528 001	Nov 27, 2015
		EQ 20MG BASE	A205528 002	Nov 27, 2015
		EQ 30MG BASE	A205528 003	Nov 27, 2015
		EQ 40MG BASE	A205528 004	Nov 27, 2015
	MYLAN PHARMS INC	EQ 10MG BASE	A075716 001	Mar 08, 2004
		EQ 20MG BASE	A075716 002	Mar 08, 2004
		EQ 30MG BASE	A075716 003	Mar 08, 2004
		EQ 40MG BASE	A075716 004	Mar 08, 2004
	ROXANE	EQ 10MG BASE	A078026 001	Jun 29, 2007
		EQ 20MG BASE	A078026 002	Jun 29, 2007
		EQ 30MG BASE	A078026 003	Jun 29, 2007
		EQ 40MG BASE	A078026 004	Jun 29, 2007
	SUN PHARM INDS INC	EQ 10MG BASE	A078194 001	Jun 29, 2007
		EQ 20MG BASE	A078194 002	Jun 29, 2007
		EQ 30MG BASE	A078194 003	Jun 29, 2007
		EQ 40MG BASE	A078194 004	Jun 29, 2007
	TEVA PHARMS	EQ 10MG BASE	A077082 001	Jun 29, 2007
		EQ 20MG BASE	A077082 002	Jun 29, 2007
		EQ 30MG BASE	A077082 003	Jun 29, 2007
		EQ 40MG BASE	A077082 004	Jun 29, 2007
	UPSHER SMITH LABS	EQ 10MG BASE	A075566 001	Mar 08, 2004
		EQ 20MG BASE	A075566 002	Mar 08, 2004
		EQ 30MG BASE	A075566 003	Mar 08, 2004
		EQ 40MG BASE	A075566 004	Mar 08, 2004
PAXIL				
	APOTEX	EQ 50MG BASE	N020031 004	Dec 29, 1992
TABLET, EXTENDED RELEASE;ORAL				
PAROXETINE HYDROCHLORIDE				
	EPIC PHARMA LLC	EQ 12.5MG BASE	A213612 001	Aug 11, 2021
		EQ 25MG BASE	A213612 002	Aug 11, 2021
		EQ 37.5MG BASE	A213612 003	May 26, 2022

PAROXETINE MESYLATE

TABLET;ORAL				
PEXEVA				
+	SEBELA IRELAND LTD	EQ 10MG BASE	N021299 001	Jul 03, 2003
+		EQ 20MG BASE	N021299 002	Jul 03, 2003
+		EQ 30MG BASE	N021299 003	Jul 03, 2003
+		EQ 40MG BASE	N021299 004	Jul 03, 2003

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL				
VOTRIENT				
+	NOVARTIS	EQ 400MG BASE **	N022465 002	Oct 19, 2009

PEGAPTANIB SODIUM

INJECTABLE;INTRAVITREAL				
MACUGEN				
+	BAUSCH AND LOMB INC	EQ 0.3MG ACID/0.09ML	N021756 001	Dec 17, 2004

PEGINESATIDE ACETATE

SOLUTION;INTRAVENOUS, SUBCUTANEOUS				
OMONTYS				
	TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012
		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012
OMONTYS PRESERVATIVE FREE				
	TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012
		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012
		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PEGINESATIDE ACETATE				
SOLUTION;INTRAVENOUS, SUBCUTANEOUS				
OMONTYS PRESERVATIVE FREE				
	EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012
	EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012
	EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012
PEMETREXED DISODIUM				
POWDER;INTRAVENOUS				
PEMETREXED DISODIUM				
AMNEAL	EQ 100MG BASE/VIAL	A210047	002	May 08, 2023
	EQ 500MG BASE/VIAL	A210047	001	Aug 04, 2022
BIOCON PHARMA	EQ 1GM BASE/VIAL	A211090	001	May 25, 2022
HOSPIRA	EQ 100MG BASE/VIAL	A202111	001	May 25, 2022
	EQ 500MG BASE/VIAL	A202111	002	May 25, 2022
	EQ 1GM BASE/VIAL	A202111	003	May 25, 2022
MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023
PEMETREXED DITROMETHAMINE				
POWDER;INTRAVENOUS				
PEMETREXED DITROMETHAMINE				
+ HOSPIRA	EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022
PEMIROLAST POTASSIUM				
SOLUTION/DROPS;OPHTHALMIC				
ALAMAST				
SANTEN	0.1%	N021079	001	Sep 24, 1999
PEMOLINE				
TABLET;ORAL				
CYLERT				
ABBOTT	18.75MG	N016832	001	
	37.5MG	N016832	002	
	75MG	N016832	003	
PEMOLINE				
ACTAVIS ELIZABETH	18.75MG	A075595	001	Feb 28, 2000
	37.5MG	A075595	002	Feb 28, 2000
	75MG	A075595	003	Feb 28, 2000
FOSUN PHARMA	18.75MG	A075286	001	Dec 27, 1999
	37.5MG	A075286	002	Jun 30, 1999
	75MG	A075286	003	Jun 30, 1999
MALLINCKRODT	18.75MG	A075726	003	Mar 30, 2001
	37.5MG	A075726	002	Mar 30, 2001
	75MG	A075726	001	Mar 30, 2001
TEVA PHARMS	18.75MG	A075030	003	Feb 22, 2000
	37.5MG	A075030	001	Jan 29, 1999
	75MG	A075030	002	Jan 29, 1999
VINTAGE PHARMS	18.75MG	A075328	001	Apr 19, 2000
	37.5MG	A075328	002	Apr 19, 2000
	75MG	A075328	003	Apr 19, 2000
WATSON LABS	18.75MG	A075287	001	Jun 13, 2001
	37.5MG	A075287	002	Sep 18, 2000
	75MG	A075287	003	Sep 18, 2000
TABLET, CHEWABLE;ORAL				
CYLERT				
ABBOTT	37.5MG	N017703	001	
PEMOLINE				
ACTAVIS ELIZABETH	37.5MG	A075678	001	Jul 26, 2000
TEVA PHARMS	37.5MG	A075555	001	Feb 18, 2000
PENBUTOLOL SULFATE				
TABLET;ORAL				
LEVATOL				
+ AUXILIUM PHARMS LLC	10MG **	N018976	001	Dec 30, 1987
+	20MG **	N018976	004	Jan 05, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENICILLAMINE				
CAPSULE;ORAL				
CUPRIMINE				
	VALEANT PHARMS INTL	125MG	N019853 002	
TABLET;ORAL				
PENICILLAMINE				
	TEVA PHARMS USA	250MG	A211497 001	Feb 13, 2020
PENICILLIN G BENZATHINE				
INJECTABLE;INJECTION				
BICILLIN L-A				
+	KING PHARMS LLC	300,000 UNITS/ML	N050141 003	
	WYETH AYERST	300,000 UNITS/ML	N050131 001	
PERMAPEN				
	CASPER PHARMA LLC	600,000 UNITS/ML	N060014 001	
SUSPENSION;ORAL				
BICILLIN				
	WYETH AYERST	300,000 UNITS/5ML	N050126 002	
TABLET;ORAL				
BICILLIN				
	WYETH AYERST	200,000 UNITS	N050128 001	
PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE				
INJECTABLE;INJECTION				
BICILLIN C-R				
+	KING PHARMS LLC	150,000 UNITS/ML;150,000 UNITS/ML	N050138 002	
PENICILLIN G POTASSIUM				
FOR SOLUTION;ORAL				
PENICILLIN				
	TEVA	200,000 UNITS/5ML	A060307 002	
		400,000 UNITS/5ML	A060307 004	
PENICILLIN G POTASSIUM				
	MYLAN	200,000 UNITS/5ML	A060752 003	
		250,000 UNITS/5ML	A060752 002	
		400,000 UNITS/5ML	A060752 001	
	PUREPAC PHARM	250,000 UNITS/5ML	A061740 001	
		400,000 UNITS/5ML	A061740 002	
PENICILLIN-2				
	TEVA	250,000 UNITS/5ML	A060307 003	
PENTIDS '200'				
	APOTHECON	200,000 UNITS/5ML	A062149 001	
PENTIDS '400'				
	APOTHECON	400,000 UNITS/5ML	A062149 002	
PFIZERPEN G				
	PFIZER	400,000 UNITS/5ML	A060587 001	
INJECTABLE;INJECTION				
PENICILLIN G POTASSIUM				
	APOTHECON	1,000,000 UNITS/VIAL	A060362 001	
		5,000,000 UNITS/VIAL	A060362 003	
		10,000,000 UNITS/VIAL	A060362 004	
		20,000,000 UNITS/VIAL	A060362 002	
	CONSOLIDATED PHARM	500,000 UNITS/VIAL	A060806 001	
		1,000,000 UNITS/VIAL	A060806 002	
		5,000,000 UNITS/VIAL	A060806 003	
		10,000,000 UNITS/VIAL	A060806 004	
	LILLY	200,000 UNITS/VIAL	A060384 004	
		500,000 UNITS/VIAL	A060384 003	
		1,000,000 UNITS/VIAL	A060384 002	
		5,000,000 UNITS/VIAL	A060384 001	
		20,000,000 UNITS/VIAL	A060384 005	
		20,000,000 UNITS/VIAL	A060601 001	
	PARKE DAVIS	1,000,000 UNITS/VIAL	A062003 001	
		5,000,000 UNITS/VIAL	A062003 002	
	PFIZER	20,000,000 UNITS/VIAL	A060074 003	
	SANDOZ	1,000,000 UNITS/VIAL **	A065079 001	Aug 30, 2002
	WATSON LABS INC	1,000,000 UNITS/VIAL	A062991 001	Sep 13, 1988
		5,000,000 UNITS/VIAL	A062991 002	Sep 13, 1988
		10,000,000 UNITS/VIAL	A062991 003	Sep 13, 1988
		20,000,000 UNITS/VIAL	A062991 004	Sep 13, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENICILLIN G POTASSIUM				
INJECTABLE;INJECTION				
PFIZERPEN				
	PFIZER	1,000,000 UNITS/VIAL **	A060657	001
TABLET;ORAL				
PENICILLIN G POTASSIUM				
	APOTHECON	250,000 UNITS	A060392	003
	IVAX SUB TEVA PHARMS	400,000 UNITS	A060073	004
	LILLY	250,000 UNITS	A060403	001
	MYLAN	200,000 UNITS	A060781	001
		250,000 UNITS	A060781	002
		400,000 UNITS	A060781	003
		500,000 UNITS	A060781	005
		800,000 UNITS	A060781	004
	PUREPAC PHARM	200,000 UNITS	A061588	001
		250,000 UNITS	A061588	002
		400,000 UNITS	A061588	003
	TEVA	200,000 UNITS	A060306	001
		250,000 UNITS	A060306	002
		400,000 UNITS	A060306	003
		500,000 UNITS	A060306	004
	WYETH AYERST	200,000 UNITS	A060413	001
		250,000 UNITS	A060413	002
		400,000 UNITS	A060413	003
PENTIDS '200'				
	APOTHECON	200,000 UNITS	A062155	001
PENTIDS '250'				
	APOTHECON	250,000 UNITS	A062155	002
PENTIDS '400'				
	APOTHECON	400,000 UNITS	A060392	004
		400,000 UNITS	A062155	003
PENTIDS '800'				
	APOTHECON	800,000 UNITS	A060392	005
		800,000 UNITS	A062155	004
PFIZERPEN G				
	PFIZER	50,000 UNITS	A060075	001
		100,000 UNITS	A060075	002
		200,000 UNITS	A060075	003
		250,000 UNITS	A060075	004
		400,000 UNITS	A060075	005
		800,000 UNITS	A060075	006
PENICILLIN G PROCAINE				
INJECTABLE;INJECTION				
DURACILLIN A.S.				
	LILLY	300,000 UNITS/ML	A060093	001
PENICILLIN G PROCAINE				
	CONSOLIDATED PHARM	300,000 UNITS/ML	A060800	001
		600,000 UNITS/1.2ML	A060800	002
	PARKE DAVIS	300,000 UNITS/ML	A062029	001
	PFIZER	300,000 UNITS/VIAL	A060099	001
		1,500,000 UNITS/VIAL	A060099	002
PFIZERPEN-AS				
	PFIZER	300,000 UNITS/ML	A060286	001
		600,000 UNITS/ML	A060286	002
PENICILLIN G SODIUM				
INJECTABLE;INJECTION				
PENICILLIN G SODIUM				
	BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL	A061935	001
	COPANOS	5,000,000 UNITS/VIAL	A061051	001
	PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL	A061046	001
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS				
PENICILLIN G SODIUM				
	WATSON LABS INC	5,000,000 UNITS/VIAL	A063014	001 Sep 13, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENICILLIN V				
FOR SUSPENSION;ORAL				
V-CILLIN				
LILLY	125MG/0.6ML		A060002 001	
PENICILLIN V POTASSIUM				
FOR SOLUTION;ORAL				
BEEPEN-VK				
GLAXOSMITHKLINE	EQ 125MG BASE/5ML		A062270 001	
	EQ 250MG BASE/5ML		A062270 002	
BETAPEN-VK				
APOTHECON	EQ 125MG BASE/5ML		A061149 001	
	EQ 250MG BASE/5ML		A061149 002	
LEDERCILLIN VK				
LEDERLE	EQ 125MG BASE/5ML		A060136 001	
	EQ 250MG BASE/5ML		A060136 002	
PEN-VEE K				
WYETH AYERST	EQ 125MG BASE/5ML		A060007 001	
	EQ 250MG BASE/5ML		A060007 002	
PENAPAR-VK				
PARKE DAVIS	EQ 125MG BASE/5ML		A062002 001	
	EQ 250MG BASE/5ML		A062002 002	
PENICILLIN V POTASSIUM				
BELCHER PHARMS	EQ 125MG BASE/5ML		A061529 001	
	EQ 250MG BASE/5ML		A061529 002	
CHARTWELL RX	EQ 125MG BASE/5ML		A062981 001	Feb 10, 1989
	EQ 250MG BASE/5ML		A062981 002	Feb 10, 1989
MYLAN	EQ 125MG BASE/5ML		A061624 002	
	EQ 250MG BASE/5ML		A061624 001	
PUREPAC PHARM	EQ 125MG BASE/5ML		A061758 001	
	EQ 250MG BASE/5ML		A061758 002	
PFIZERPEN VK				
PFIZER	EQ 125MG BASE/5ML		A061815 001	
	EQ 250MG BASE/5ML		A061815 002	
V-CILLIN K				
LILLY	EQ 125MG BASE/5ML		A060004 001	
	EQ 250MG BASE/5ML		A060004 002	
VEETIDS				
APOTHECON	EQ 125MG BASE/5ML		A061410 001	
	EQ 250MG BASE/5ML		A061410 002	
VEETIDS '125'				
APOTHECON	EQ 125MG BASE/5ML		A061206 001	
	EQ 125MG BASE/5ML		A062153 001	
VEETIDS '250'				
APOTHECON	EQ 250MG BASE/5ML		A061206 002	
	EQ 250MG BASE/5ML		A062153 002	
TABLET;ORAL				
BEEPEN-VK				
GLAXOSMITHKLINE	EQ 250MG BASE		A062273 001	
	EQ 500MG BASE		A062273 002	
BETAPEN-VK				
BRISTOL	EQ 250MG BASE		A061150 001	
	EQ 500MG BASE		A061150 002	
LEDERCILLIN VK				
LEDERLE	EQ 250MG BASE		A060134 001	
	EQ 500MG BASE		A060134 002	
PEN-VEE K				
WYETH AYERST	EQ 125MG BASE		A060006 001	
	EQ 250MG BASE		A060006 002	
	EQ 500MG BASE		A060006 003	
PENAPAR-VK				
PARKE DAVIS	EQ 250MG BASE		A062001 001	
	EQ 500MG BASE		A062001 002	
PENICILLIN V POTASSIUM				
BELCHER PHARMS	EQ 250MG BASE		A061528 001	
	EQ 500MG BASE		A061528 002	
IVAX SUB TEVA PHARMS	EQ 125MG BASE		A060518 001	
	EQ 250MG BASE		A060518 002	
	EQ 500MG BASE		A060518 003	
MYLAN	EQ 250MG BASE		A061530 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENICILLIN V POTASSIUM
TABLET;ORAL
PENICILLIN V POTASSIUM

	EQ 500MG BASE		A061530	002
PUREPAC PHARM	EQ 125MG BASE		A061571	001
	EQ 250MG BASE		A061571	002
	EQ 500MG BASE		A061571	003

PFIZERPEN VK

PFIZER	EQ 250MG BASE		A061836	001
	EQ 500MG BASE		A061836	002

UTICILLIN VK

PHARMACIA AND UPJOHN	EQ 250MG BASE		A061651	001
	EQ 500MG BASE		A061651	002

V-CILLIN K

LILLY	EQ 125MG BASE **		A060003	001
	EQ 250MG BASE **		A060003	002
	EQ 500MG BASE **		A060003	003

VEETIDS

APOTHECON	EQ 250MG BASE		A061411	001
	EQ 500MG BASE		A061411	002

VEETIDS '250'

APOTHECON	EQ 250MG BASE		A061164	001
	EQ 250MG BASE		A062156	002

VEETIDS '500'

APOTHECON	EQ 500MG BASE		A061164	002
	EQ 500MG BASE		A062156	001

PENTAGASTRIN
INJECTABLE;INJECTION
PEPTAVLON

+ WYETH AYERST	0.25MG/ML **		N017048	001

PENTAMIDINE ISETHIONATE
FOR SOLUTION;INHALATION
NEBUPENT

FRESENIUS KABI USA	600MG/VIAL		N019887	002 Mar 22, 1996

INJECTABLE;INJECTION
PENTACARINAT

ARMOUR PHARM	300MG/VIAL		A073447	001 Apr 28, 1994

PENTAMIDINE ISETHIONATE

BAXTER HLTHCARE	300MG/VIAL		A073617	001 Dec 18, 1995
HOSPIRA	300MG/VIAL		A073479	001 Jun 30, 1992
WATSON LABS	300MG/VIAL		A074303	001 Aug 17, 1995

PENTAZOCINE HYDROCHLORIDE
TABLET;ORAL
TALWIN 50

SANOFI AVENTIS US	EQ 50MG BASE		N016732	001

PENTAZOCINE LACTATE
INJECTABLE;INJECTION
TALWIN

+ HOSPIRA	EQ 30MG BASE/ML		N016194	001

PENTETATE CALCIUM TRISODIUM
SOLUTION;INHALATION, INTRAVENOUS
PENTETATE CALCIUM TRISODIUM

+ HAMELN	EQ 1GM BASE/5ML (EQ 200MG BASE/ML) **		N021749	001 Aug 11, 2004

PENTETATE CALCIUM TRISODIUM YB-169
INJECTABLE;INJECTION
YTTERBIUM YB 169 DTPA

3M	2mCi/ML		N017518	001

PENTETATE ZINC TRISODIUM
SOLUTION;INHALATION, INTRAVENOUS
PENTETATE ZINC TRISODIUM

+ HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML) **		N021751	001 Aug 11, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENTOBARBITAL				
ELIXIR;ORAL				
NEMBUTAL				
AKORN	18.2MG/5ML	A083244	001	
PENTOBARBITAL SODIUM				
CAPSULE;ORAL				
NEMBUTAL SODIUM				
AKORN	30MG	A084095	001	
	50MG	A084093	001	
	100MG	A083245	001	
PENTOBARBITAL SODIUM				
LANNETT	50MG	A085937	001	
	100MG	A085915	001	
VITARINE	100MG	A083284	001	
WHITEWORTH TOWN PLSN	100MG	A083338	001	
SODIUM PENTOBARBITAL				
ANABOLIC	100MG	A084590	001	
ELKINS SINN	100MG	A083368	001	
EVERYLIFE	100MG	A083259	001	
HALSEY	100MG	A084677	001	
IVAX SUB TEVA PHARMS	50MG	A083461	001	
	100MG	A083461	002	
PARKE DAVIS	100MG	A084156	001	
PERRIGO	100MG	A084560	001	
PUREPAC PHARM	100MG	A083301	001	
VALEANT PHARM INTL	100MG	A083264	001	
WATSON LABS	100MG	A085791	001	
WYETH AYERST	100MG	A083239	001	
INJECTABLE;INJECTION				
PENTOBARBITAL SODIUM				
ELKINS SINN	50MG/ML	A083270	001	
SODIUM PENTOBARBITAL				
WYETH AYERST	50MG/ML	A083261	001	
SUPPOSITORY;RECTAL				
NEMBUTAL				
AKORN	30MG	A083247	001	Jan 25, 1982
	60MG	A083247	002	Jan 25, 1982
	120MG	A083247	003	Jan 25, 1982
	200MG	A083247	004	Jan 25, 1982
TABLET;ORAL				
PENTOBARBITAL SODIUM				
VITARINE	100MG	A083285	001	
SODIUM PENTOBARBITAL				
NEXGEN PHARMA INC	100MG	A084238	001	
PENTOLINIUM TARTRATE				
INJECTABLE;INJECTION				
ANSOLYSEN				
WYETH AYERST	10MG/ML	N009372	001	
PENTOSTATIN				
INJECTABLE;INJECTION				
PENTOSTATIN				
RISING	10MG/VIAL	A203554	001	Sep 19, 2014
PENTOXIFYLLINE				
TABLET, EXTENDED RELEASE;ORAL				
PENTOXIFYLLINE				
ANI PHARMS	400MG	A074878	001	Jul 09, 1997
	400MG	A075107	001	Sep 04, 1998
	400MG	A075199	001	Sep 03, 1999
HERITAGE PHARMS	400MG	A074877	001	Jul 08, 1997
IMPAX LABS	400MG	A075093	001	Aug 10, 1999
PLIVA	400MG	A074874	001	May 25, 1999
RISING	400MG	A074425	001	Jul 08, 1997
PENTOXIL				
UPSHER SMITH LABS	400MG	A074962	001	Mar 31, 1999
TRENTAL				
+ VALIDUS PHARMS	400MG **	N018631	001	Aug 30, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PERFLUBRON				
LIQUID;ORAL				
IMAGENT				
ALLIANCE PHARM	100%	N020091	001	Aug 13, 1993
PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE				
PASTE;TOPICAL				
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS				
US ARMY MED RES	50%;50%	N021084	001	Feb 17, 2000
PERGOLIDE MESYLATE				
TABLET;ORAL				
PERGOLIDE MESYLATE				
IVAX SUB TEVA PHARMS	EQ 0.05MG BASE	A076094	001	Sep 04, 2003
	EQ 0.25MG BASE	A076094	002	Sep 04, 2003
	EQ 1MG BASE	A076094	003	Sep 04, 2003
STRIDES PHARMA	EQ 0.05MG BASE	A076061	001	Nov 27, 2002
	EQ 0.25MG BASE	A076061	002	Nov 27, 2002
	EQ 1MG BASE	A076061	003	Nov 27, 2002
PERMAX				
VALEANT PHARM INTL	EQ 0.05MG BASE	N019385	001	Dec 30, 1988
	EQ 0.25MG BASE	N019385	002	Dec 30, 1988
	EQ 1MG BASE	N019385	003	Dec 30, 1988
PERINDOPRIL ERBUMINE				
TABLET;ORAL				
ACEON				
+ SYMPLMED PHARMS LLC	2MG	N020184	001	Dec 30, 1993
+	4MG	N020184	002	Dec 30, 1993
+	8MG	N020184	003	Dec 30, 1993
PERINDOPRIL ERBUMINE				
ANI PHARMS	2MG	A078138	001	Nov 10, 2009
	4MG	A078138	002	Nov 10, 2009
	8MG	A078138	003	Nov 10, 2009
APOTEX	2MG	A090463	001	Aug 30, 2010
	4MG	A090463	002	Aug 30, 2010
	8MG	A090463	003	Aug 30, 2010
HIKMA	2MG	A090072	001	Nov 10, 2009
	4MG	A090072	002	Nov 10, 2009
	8MG	A090072	003	Nov 10, 2009
LUPIN LTD	2MG	A078263	001	Jan 27, 2010
	4MG	A078263	002	Jan 27, 2010
	8MG	A078263	003	Jan 27, 2010
PERMETHRIN				
LOTION;TOPICAL				
NIX				
GLAXOSMITHKLINE	1% **	N019435	001	Mar 31, 1986
PERPHENAZINE				
CONCENTRATE;ORAL				
PERPHENAZINE				
PHARM ASSOC	16MG/5ML	A040360	001	May 25, 2001
TRILAFON				
SCHERING	16MG/5ML	N011557	001	
INJECTABLE;INJECTION				
TRILAFON				
SCHERING	5MG/ML	N011213	002	
SYRUP;ORAL				
TRILAFON				
SCHERING	2MG/5ML	N011294	002	
TABLET;ORAL				
PERPHENAZINE				
ANI PHARMS	2MG **	A089707	001	Sep 10, 1987
	4MG **	A089708	001	Sep 10, 1987
	8MG	A089456	001	Sep 10, 1987
	16MG	A089457	001	Sep 10, 1987
MYLAN	2MG	A206691	001	Apr 14, 2017
	4MG	A206691	002	Apr 14, 2017
	8MG	A206691	003	Apr 14, 2017
	16MG	A206691	004	Apr 14, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PERPHENAZINE

TABLET;ORAL				
TRILAFON				
+	SCHERING	2MG **	N010775 001	
+		4MG **	N010775 002	
+		8MG **	N010775 003	
+		16MG **	N010775 004	
TABLET, EXTENDED RELEASE;ORAL				
TRILAFON				
	SCHERING	8MG	N011361 002	

PEXIDARTINIB HYDROCHLORIDE

CAPSULE;ORAL				
TURALIO				
+	DAIICHI SANKYO INC	EQ 200MG BASE	N211810 001	Aug 02, 2019

PHENACEMIDE

TABLET;ORAL				
PHENURONE				
+	ABBVIE	500MG **	N007707 001	

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET;ORAL				
AZO GANTANOL				
+	ROCHE	100MG;500MG **	N013294 001	Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL				
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE				
	ABLE	200MG,N/A,N/A;N/A,800MG,160MG	N021105 001	Jun 26, 2001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET;ORAL				
AZO GANTRISIN				
+	ROCHE	50MG;500MG **	N019358 001	Aug 31, 1990

PHENDIMETRAZINE TARTRATE

CAPSULE;ORAL				
PHENAZINE				
	MAST MM	35MG	A086523 001	
		35MG	A086524 001	
		35MG	A086525 001	
PHENDIMETRAZINE TARTRATE				
	SANDOZ	35MG	A085633 001	
		35MG	A085694 001	
		35MG	A085702 001	
	VIRTUS	35MG	A085695 001	
	VITARINE	35MG	A085634 001	
		35MG	A085645 001	
		35MG	A085670 001	
		35MG	A086403 001	
		35MG	A086408 001	
		35MG	A086410 001	
		35MG	A087424 001	
SPRX-3				
	SOLVAY	35MG	A085897 001	
STATOBEX				
	TEVA	35MG	A085507 001	
X-TROZINE				
	SHIRE RICHWOOD	35MG	A087394 001	Sep 22, 1982
CAPSULE, EXTENDED RELEASE;ORAL				
BONTRIL				
	VALEANT	105MG	A088021 001	Sep 21, 1982
MELFIAT-105				
	NUMARK	105MG	A087487 001	Oct 13, 1982
PHENDIMETRAZINE TARTRATE				
	GRAHAM DM	105MG	A087214 001	May 26, 1982
		105MG	A088020 001	Aug 16, 1982
		105MG	A088028 001	Aug 16, 1982
		105MG	A088062 001	Sep 13, 1982
		105MG	A088063 001	Sep 10, 1982
		105MG	A088111 001	Oct 18, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL				
PHENDIMETRAZINE TARTRATE				
VIRTUS	105MG	A087378	001	
SPRX-105				
NUMARK	105MG	A088024	001	Dec 22, 1982
X-TROZINE L.A.				
SHIRE RICHWOOD	105MG	A087371	001	Aug 24, 1982
TABLET;ORAL				
ADPHEN				
FERNDALE LABS	35MG	A083655	001	
ALPHAZINE				
SANDOZ	35MG	A085034	001	
CAM-METRAZINE				
ABC HOLDING	35MG	A085511	001	
CAMALL	35MG	A085756	001	
CHARTWELL RX	35MG	A083922	001	
	35MG	A085318	001	
	35MG	A085320	001	
	35MG	A085321	001	
DI-METREX				
PVT FORM	35MG	A085698	001	
MELFIAT				
NUMARK	35MG	A083790	002	
METRA				
FOREST PHARMS	35MG	A083754	001	
PHENAZINE				
MAST MM	35MG	A087305	001	
PHENAZINE-35				
ABC HOLDING	35MG	A085512	001	
PHENDIMETRAZINE TARTRATE				
BARR	35MG	A083644	001	
	35MG	A083684	001	
	35MG	A083686	001	
	35MG	A083687	001	
	35MG	A084831	001	
	35MG	A084834	001	
	35MG	A084835	001	
CHARTWELL RX	35MG	A085761	001	
	35MG	A085941	001	Jun 27, 1983
FERNDALE LABS	35MG	A086834	001	Sep 15, 1983
INWOOD LABS	35MG	A084740	001	
	35MG	A084741	001	
	35MG	A084742	001	
	35MG	A084743	001	
IVAX PHARMS	35MG	A085611	001	
	35MG	A085612	001	
IVAX SUB TEVA PHARMS	35MG	A083682	001	
KV PHARM	35MG	A084138	001	
	35MG	A084141	001	
	35MG	A085525	001	
MFG CHEMISTS	35MG	A085914	001	
NEXGEN PHARMA INC	35MG	A086020	001	
NOSTRUM LABS INC	35MG	A203600	001	Dec 27, 2017
NUMARK	35MG	A083790	001	
PVT FORM	35MG	A085199	001	
	35MG	A085697	001	
SANDOZ	35MG	A085402	001	
	35MG	A085830	001	
	35MG	A086370	001	
SOLVAY	35MG	A083993	001	
UPSHER SMITH LABS	35MG	A084399	001	
USL PHARMA	35MG	A083805	001	
	35MG	A084398	001	
VIRTUS	35MG	A085497	001	
	35MG	A086365	001	
VITARINE	35MG	A085519	001	
	35MG	A086005	001	
	35MG	A086106	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENDIMETRAZINE TARTRATE

TABLET;ORAL				
PHENDIMETRAZINE TARTRATE				
WATSON LABS	35MG	A085767	001	
	35MG	A085768	001	
	35MG	A085770	001	
	35MG	A085773	001	
PLEGINE				
WYETH AYERST	35MG **	N012248	001	
STATOBEX				
TEVA	35MG	A086013	001	
STATOBEX-G				
TEVA	35MG	A085095	001	
X-TROZINE				
SHIRE RICHWOOD	35MG	A086550	001	
	35MG	A086551	001	
	35MG	A086552	001	
	35MG	A086553	001	
	35MG	A086554	001	

PHENINDIONE

TABLET;ORAL				
HEDULIN				
SANOFI AVENTIS US	50MG	N008767	002	

PHENMETRAZINE HYDROCHLORIDE

TABLET;ORAL				
PRELUDIN				
BOEHRINGER INGELHEIM	25MG	N010460	005	
TABLET, EXTENDED RELEASE;ORAL				
PRELUDIN				
BOEHRINGER INGELHEIM	50MG	N011752	004	
	75MG	N011752	003	

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL				
PHENOXYBENZAMINE HYDROCHLORIDE				
HIKMA	10MG	A201050	001	Jul 16, 2012

PHENPROCOUMON

TABLET;ORAL				
LIQUAMAR				
ORGANON USA INC	3MG	N011228	001	

PHENSUXIMIDE

CAPSULE;ORAL				
MILONTIN				
PARKE DAVIS	500MG	N008855	004	

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL				
FASTIN				
GLAXOSMITHKLINE	30MG **	N017352	001	
OBESTIN-30				
FERNDALE LABS	30MG	A087144	001	
OBY-TRIM				
SHIRE RICHWOOD	30MG	A087764	001	Mar 18, 1982
ONA-MAST				
MAST MM	30MG	A086511	001	
	30MG	A086516	001	
PHENTERMINE HYDROCHLORIDE				
ABC HOLDING	30MG	A085411	001	
ABLE	15MG	A040497	001	Mar 13, 2003
	30MG	A040403	001	Aug 30, 2001
	30MG	A040427	001	Aug 30, 2001
BARR	15MG	A090591	001	Mar 18, 2010
	30MG	A090591	002	Mar 18, 2010
CAMALL	15MG	A086735	001	
	30MG	A087226	001	
CHARTWELL RX	18.75MG	A088576	001	May 23, 1984
	30MG	A085417	001	
	30MG	A086732	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL					
PHENTERMINE HYDROCHLORIDE					
		30MG	A087215	001	
		37.5MG	A087915	001	Dec 22, 1983
		37.5MG	A087918	001	Dec 22, 1983
		37.5MG	A087930	001	Oct 14, 1983
		37.5MG	A088610	001	Jun 04, 1984
		37.5MG	A088611	001	Jun 04, 1984
		37.5MG	A088625	001	Aug 23, 1984
	DURAMED PHARMS BARR	30MG	A088948	001	Apr 25, 1986
	ELITE LABS INC	15MG	A040460	001	Jan 14, 2003
		30MG	A040227	001	Jun 18, 1997
		30MG	A040448	001	Jan 22, 2003
	IVAX PHARMS	30MG	A086329	001	
	LANNETT	15MG	A087022	002	Jan 20, 2012
		30MG	A087022	001	Feb 03, 1983
	LANNETT CO INC	30MG	A091359	001	Jul 16, 2010
		37.5MG	A201961	001	Jul 20, 2011
	SANDOZ	30MG	A087208	001	
		30MG	A087223	001	
		37.5MG	A088414	001	Oct 19, 1983
	SUN PHARM INDUSTRIES	30MG	A040525	001	Oct 23, 2003
		37.5MG	A040527	001	Oct 23, 2003
	TEVA	30MG	A086911	001	
		30MG	A087126	001	
		30MG	A087777	001	Nov 01, 1985
		30MG	A088612	001	Apr 04, 1984
		30MG	A088613	001	Apr 09, 1984
		30MG	A088614	001	Apr 09, 1984
	TG UNITED INC	30MG	A040083	001	Mar 07, 1997
	UPSHER SMITH LABS	30MG	A084487	001	Apr 09, 1982
		30MG	A088430	001	Mar 27, 1984
	USL PHARMA	30MG	A088797	001	Dec 10, 1984
	VITARINE	30MG	A087202	001	
		30MG	A087235	001	
	WATSON LABS	30MG	A086740	001	Mar 21, 1985
TABLET;ORAL					
ONA-MAST					
	MAST MM	8MG	A086260	001	
PHENTERMINE HYDROCHLORIDE					
	ABLE	37.5MG	A040402	001	Aug 30, 2001
	ACTAVIS ELIZABETH	37.5MG	A040276	001	Nov 25, 1998
	BARR	37.5MG	A090470	001	Aug 31, 2009
	CHARTWELL RX	8MG	A083923	001	
		8MG	A085319	001	
		37.5MG	A087805	001	Dec 06, 1982
		37.5MG	A088596	001	Apr 04, 1984
	IVAX PHARMS	8MG	A085553	001	
	LANNETT	37.5MG	A040555	001	Apr 15, 2005
	NOVAST LABS	37.5MG	A091451	001	Sep 21, 2012
	SANDOZ	8MG	A085671	001	
		8MG	A085689	001	
	SANDOZ INC	30MG	A088605	001	Sep 28, 1987
	SUN PHARM INDS INC	37.5MG	A040790	001	Aug 21, 2007
+	USL PHARMA	8MG	A083804	001	
		37.5MG	A088910	001	Jul 17, 1985
		37.5MG	A088917	001	Jul 17, 1985
	VITARINE	8MG	A086453	001	
		8MG	A086456	001	
	WATSON LABS	8MG	A085739	001	
TORA					
	SOLVAY	8MG	A084035	001	
WILPO					
+	SANDOZ	8MG **	N012737	001	
TABLET, ORALLY DISINTEGRATING;ORAL					
SUPRENZA					
	CITIUS PHARMS	15MG **	N202088	001	Jun 13, 2011
		30MG **	N202088	002	Jun 13, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENTERMINE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL				
SUPRENZA				
	37.5MG **	N202088	003	Mar 27, 2012

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL				
IONAMIN				
UCB INC	EQ 15MG BASE **	N011613	004	
	EQ 30MG BASE **	N011613	002	
PHENTERMINE RESIN 30				
QUANTUM PHARMICS	EQ 30MG BASE	A089120	001	Feb 04, 1988
PHENTERMINE RESIN COMPLEX				
LANNETT CO INC	EQ 15MG BASE	A040872	001	Jul 28, 2011
	EQ 30MG BASE	A040872	002	Jul 28, 2011

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION				
REGITINE				
+ NOVARTIS	5MG/VIAL **	N008278	003	

PHENYL AMINOSALICYLATE

POWDER;ORAL				
PHENY-PAS-TEBAMIN				
PHARM RES ASSOC	50%	N011695	002	
TABLET;ORAL				
PHENY-PAS-TEBAMIN				
PHARM RES ASSOC	500MG	N011695	003	

PHENYLBUTAZONE

CAPSULE;ORAL				
AZOLID				
SANOFI AVENTIS US	100MG	A087260	001	
BUTAZOLIDIN				
NOVARTIS	100MG	N008319	009	
PHENYLBUTAZONE				
FOSUN PHARMA	100MG	A087774	001	Jun 16, 1982
IVAX PHARMS	100MG	A088218	001	Jun 24, 1983
SUN PHARM INDUSTRIES	100MG	A088994	001	Dec 04, 1985
WATSON LABS	100MG	A087756	001	Dec 17, 1982
TABLET;ORAL				
AZOLID				
SANOFI AVENTIS US	100MG	A087091	001	
BUTAZOLIDIN				
NOVARTIS	100MG	N008319	008	
PHENYLBUTAZONE				
FOSUN PHARMA	100MG	A084339	001	
SUN PHARM INDUSTRIES	100MG	A088863	001	Dec 04, 1985
WATSON LABS	100MG	A086151	001	
	100MG	A087674	001	Apr 21, 1982

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS				
BIORPHEN				
+ DR REDDYS LABS SA	10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021
PHENYLEPHRINE HYDROCHLORIDE				
PAR STERILE PRODUCTS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL				
PHENERGAN VC				
+ ANI PHARMS	5MG/5ML;6.25MG/5ML **	N008604	003	Apr 02, 1984
PHERAZINE VC				
HALSEY	5MG/5ML;6.25MG/5ML	A088868	001	Mar 02, 1987
PROMETH VC PLAIN				
+ G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984
PROMETHAZINE VC PLAIN				
CENCI	5MG/5ML;6.25MG/5ML	A088815	001	Nov 22, 1985
XTTRIUM LABS INC	5MG/5ML;6.25MG/5ML	A088897	001	Jan 04, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE				
SOLUTION/DROPS;OPHTHALMIC				
PREFRIN-A				
	ALLERGAN	0.12%;0.1%	N007953 001	
PHENYTOIN				
SUSPENSION;ORAL				
DILANTIN-30				
	VIATRIS	30MG/5ML	N008762 002	
PHENYTOIN				
	ACTAVIS MID ATLANTIC	125MG/5ML	A089892 001	Sep 25, 1992
PHENYTOIN SODIUM				
CAPSULE;ORAL				
DIPHENYLAN SODIUM				
	CHARTWELL MOLECULAR	30MG PROMPT	A080857 001	
		100MG PROMPT	A080857 002	
EXTENDED PHENYTOIN SODIUM				
	ANI PHARMS	100MG EXTENDED	A040435 001	Jun 20, 2003
		100MG EXTENDED	A089441 001	Dec 18, 1986
	LUPIN LTD	100MG EXTENDED	A211633 001	Sep 30, 2019
	MYLAN	100MG EXTENDED	A040298 001	Dec 28, 1998
	SUN PHARM INDS (IN)	100MG EXTENDED	A040621 001	Dec 11, 2006
	UNICHEM	100MG EXTENDED	A213834 001	Oct 13, 2022
	WOCKHARDT	30MG EXTENDED	A040759 001	Dec 18, 2007
	WOCKHARDT USA	100MG EXTENDED	A040732 001	Jan 30, 2008
PHENYTEX				
	WATSON LABS	100MG EXTENDED	A088711 001	Dec 21, 1984
PHENYTOIN SODIUM				
	PHARMERAL	100MG PROMPT	A085435 001	
	WATSON LABS	100MG PROMPT	A085894 001	
PROMPT PHENYTOIN SODIUM				
	ANI PHARMS	100MG PROMPT	A080259 001	
	WATSON LABS	100MG PROMPT	A080905 001	
INJECTABLE;INJECTION				
DILANTIN				
	PARKE DAVIS	50MG/ML	N010151 001	
PHENYTOIN SODIUM				
	AM REGENT	50MG/ML	A040781 001	Dec 04, 2007
	FRESENIUS KABI USA	50MG/ML	A089003 001	May 31, 1985
	HOSPIRA	50MG/ML	A089521 001	Mar 17, 1987
		50MG/ML	A089744 001	Dec 18, 1987
	MARSAM PHARMS LLC	50MG/ML	A089501 001	Oct 13, 1987
		50MG/ML	A089779 001	Nov 27, 1992
	SMITH AND NEPHEW	50MG/ML	A088519 001	Dec 19, 1984
		50MG/ML	A088521 001	Dec 18, 1984
	SOLOPAK	50MG/ML	A088520 001	Dec 17, 1984
	WARNER CHILCOTT	50MG/ML	A089900 001	Mar 30, 1990
	WATSON LABS	50MG/ML	A085434 001	
PHYTONADIONE				
INJECTABLE;INJECTION				
AQUAMEPHYTON				
+	PAI HOLDINGS PHARM	1MG/0.5ML **	N012223 002	
+		10MG/ML **	N012223 001	
KONAKION				
	ROCHE	1MG/0.5ML	N011745 001	
		10MG/ML	N011745 003	
PHYTONADIONE				
	CIPLA	1MG/0.5ML	A212424 001	Apr 22, 2022
		10MG/ML	A212424 002	Apr 22, 2022
	GLAXOSMITHKLINE	1MG/0.5ML	A084060 001	
		10MG/ML	A084060 002	
VITAMIN K1				
	HOSPIRA	10MG/ML	A087956 001	Jul 25, 1983
TABLET;ORAL				
MEPHYTON				
+	BAUSCH	5MG **	N010104 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PILOCARPINE				
INSERT, EXTENDED RELEASE;OPHTHALMIC				
OCUSERT PILO-20				
	EPIC PHARMA LLC	5MG	N017431 001	
OCUSERT PILO-40				
	EPIC PHARMA LLC	11MG	N017548 001	
PILOCARPINE HYDROCHLORIDE				
GEL;OPHTHALMIC				
PILOPINE HS				
	ALCON	4%	N018796 001	Oct 01, 1984
PIMAVANSERIN TARTRATE				
TABLET;ORAL				
NUPLAZID				
+	ACADIA PHARMS INC	EQ 17MG BASE	N207318 001	Apr 29, 2016
PIMOZIDE				
TABLET;ORAL				
ORAP				
+	TEVA	1MG **	N017473 003	Aug 27, 1997
+		2MG **	N017473 001	Jul 31, 1984
PINACIDIL				
CAPSULE, EXTENDED RELEASE;ORAL				
PINDAC				
	LEO PHARM	12.5MG	N019456 001	Dec 28, 1989
		25MG	N019456 002	Dec 28, 1989
PINDOLOL				
TABLET;ORAL				
PINDOLOL				
	COSETTE	5MG	A073661 001	Oct 31, 1993
		5MG	A073687 001	Feb 26, 1993
		5MG	A074123 001	Apr 17, 1997
		10MG	A073661 002	Oct 31, 1993
		10MG	A073687 002	Feb 26, 1993
		10MG	A074123 002	Apr 17, 1997
	MYLAN PHARMS INC	5MG	A074013 001	Sep 24, 1992
		10MG	A074018 001	Sep 24, 1992
	NOSTRUM LABS	5MG	A074474 001	Oct 28, 1996
		10MG	A074474 002	Oct 28, 1996
	PUREPAC PHARM	5MG	A074125 001	Apr 28, 1993
		10MG	A074125 002	Apr 28, 1993
	WATSON LABS	5MG	A074437 001	Feb 27, 1995
		10MG	A074437 002	Feb 27, 1995
	ZYDUS PHARMS	5MG	A209866 001	Aug 18, 2017
		10MG	A209866 002	Aug 18, 2017
VISKEN				
+	NOVARTIS	5MG **	N018285 001	Sep 03, 1982
+		10MG **	N018285 002	Sep 03, 1982
PIOGLITAZONE HYDROCHLORIDE				
TABLET;ORAL				
PIOGLITAZONE HYDROCHLORIDE				
	CHARTWELL RX	EQ 15MG BASE	A078383 001	Mar 12, 2013
		EQ 30MG BASE	A078383 002	Mar 12, 2013
		EQ 45MG BASE	A078383 003	Mar 12, 2013
	MYLAN PHARMS INC	EQ 15MG BASE	A076801 001	Aug 17, 2012
		EQ 30MG BASE	A076801 002	Aug 17, 2012
		EQ 45MG BASE	A076801 003	Aug 17, 2012
	NOSTRUM LABS INC	EQ 15MG BASE	A078472 001	Feb 13, 2013
		EQ 30MG BASE	A078472 002	Feb 13, 2013
		EQ 45MG BASE	A078472 003	Feb 13, 2013
	TORRENT PHARMS LTD	EQ 15MG BASE	A091298 001	Feb 13, 2013
		EQ 30MG BASE	A091298 002	Feb 13, 2013
		EQ 45MG BASE	A091298 003	Feb 13, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PIPECURONIUM BROMIDE

INJECTABLE;INJECTION					
ARDUAN					
	ORGANON USA INC	10MG/VIAL	N019638	001	Jun 26, 1990

PIPERACETAZINE

TABLET;ORAL					
QUIDE					
	DOW PHARM	10MG	N013615	001	
		25MG	N013615	002	

PIPERACILLIN SODIUM

INJECTABLE;INJECTION					
PIPRACIL					
	WYETH PHARMS INC	EQ 2GM BASE/VIAL	A062750	001	Oct 13, 1987
+		EQ 2GM BASE/VIAL **	N050545	002	
		EQ 3GM BASE/VIAL	A062750	002	Oct 13, 1987
+		EQ 3GM BASE/VIAL **	N050545	003	
		EQ 4GM BASE/VIAL	A062750	003	Oct 13, 1987
+		EQ 4GM BASE/VIAL **	N050545	004	
+		EQ 40GM BASE/VIAL **	N050545	006	Sep 30, 1985

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION					
PIPERACILLIN AND TAZOBACTAM					
	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009
		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009
		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009
		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009
ZOSYN					
+	WYETH PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **	N050684	001	Oct 22, 1993
+		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **	N050684	002	Oct 22, 1993
+		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **	N050684	003	Oct 22, 1993
+		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **	N050684	004	Oct 22, 1993

PIPERAZINE CITRATE

SYRUP;ORAL					
ANTEPAR					
	GLAXOSMITHKLINE	EQ 500MG BASE/5ML	N009102	001	
BRYREL					
	SANOFI AVENTIS US	EQ 500MG BASE/5ML	N017796	001	
MULTIFUGE					
	BLULINE	EQ 500MG BASE/5ML	N009452	001	
PIPERAZINE CITRATE					
	ALPHARMA US PHARMS	EQ 500MG BASE/5ML	A080774	001	
	LANNETT	EQ 500MG BASE/5ML	A080963	001	
	LUITPOLD	EQ 500MG BASE/5ML	A080671	001	
VERMIDOL					
	SOLVAY	EQ 500MG BASE/5ML	A080992	001	
TABLET;ORAL					
ANTEPAR					
	GLAXOSMITHKLINE	EQ 500MG BASE	N009102	003	
PIPERAZINE CITRATE					
	IMPAX LABS	EQ 250MG BASE	A080874	001	

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL;TOPICAL					
RID MOUSSE					
	BAYER HEALTHCARE LLC	4%;EQ 0.33% BASE	N021043	001	Mar 07, 2000

PIPOBROMAN

TABLET;ORAL					
VERCYTE					
	ABBOTT	10MG	N016245	001	
		25MG	N016245	002	

PIRBUTEROL ACETATE

AEROSOL, METERED;INHALATION					
MAXAIR					
	BAUSCH	EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986
		EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PIRFENIDONE
CAPSULE;ORAL
PIRFENIDONE

	APOTEX	267MG	A212687	001	Jun 09, 2023
	LUPIN LTD	267MG	A212404	001	Aug 28, 2023

TABLET;ORAL
ESBRIET

+	GENENTECH INC	534MG **	N208780	002	Jan 11, 2017

PIRFENIDONE

	LUPIN LTD	267MG	A212403	001	Aug 23, 2023
		801MG	A212403	002	Aug 23, 2023

PIROXICAM
CAPSULE;ORAL
PIROXICAM

	BRECKENRIDGE	10MG	A208991	001	Feb 21, 2018
		20MG	A208991	002	Feb 21, 2018
	CYCLE	10MG	A073651	001	Feb 26, 1993
		20MG	A073651	002	Feb 26, 1993
	EGIS	10MG	A074808	001	Jul 08, 1997
		20MG	A074808	002	Jul 08, 1997
	HIKMA	10MG	A209256	001	Aug 11, 2017
		20MG	A209256	002	Aug 11, 2017
	IVAX SUB TEVA PHARMS	10MG	A074148	001	Jun 03, 1996
		20MG	A074148	002	Jun 03, 1996
	MYLAN	10MG	A074043	001	Sep 22, 1992
		10MG	A074102	001	Jul 31, 1992
		20MG	A074043	002	Sep 22, 1992
		20MG	A074102	002	Jul 31, 1992
	SCS	10MG	A074036	001	May 29, 1992
		20MG	A074036	002	May 29, 1992
	SUN PHARM INDUSTRIES	10MG	A073536	002	Jan 23, 2008
		20MG	A073536	001	Mar 12, 1993
	TEVA	10MG	A073637	001	Jan 28, 1994
		20MG	A073638	001	Jan 28, 1994
	TEVA PHARMS	10MG	A074103	001	Aug 28, 1992
		20MG	A074103	002	Aug 28, 1992
	WATSON LABS	10MG	A074287	001	May 16, 1996
		10MG	A074460	001	Sep 29, 1995
		20MG	A074287	002	May 16, 1996
		20MG	A074460	002	Sep 29, 1995

PITAVASTATIN MAGNESIUM
TABLET;ORAL
ZYPITAMAG

+	MEDICURE	EQ 1MG BASE	N208379	001	Jul 14, 2017

PITAVASTATIN SODIUM
TABLET;ORAL
NIKITA

+	LUPIN LTD	EQ 1MG BASE	N209875	001	Aug 04, 2017
+		EQ 2MG BASE	N209875	002	Aug 04, 2017
+		EQ 4MG BASE	N209875	003	Aug 04, 2017

PLICAMYCIN
INJECTABLE;INJECTION
MITHRACIN

	PFIZER	2.5MG/VIAL	N050109	001	

PODOFILOX
SOLUTION;TOPICAL
PODOFILOX

	BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010

POLIDOCANOL
SOLUTION;INTRAVENOUS
VARITHENA

+	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POLYESTRADIOL PHOSPHATE

INJECTABLE;INJECTION				
ESTRADURIN				
	WYETH AYERST	40MG/AMP	N010753 001	

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL				
GLYCOLAX				
	LANNETT CO INC	17GM/SCOOPFUL	A076652 001	Jul 02, 2004
		17GM/PACKET	A090600 001	Oct 06, 2009
		17GM/SCOOPFUL	A090600 002	Oct 06, 2009
POLYETHYLENE GLYCOL 3350				
	BRECKENRIDGE PHARM	17GM/SCOOPFUL	A077736 001	May 26, 2006
	NEXGEN PHARMA INC	17GM/SCOOPFUL	A077706 001	Sep 27, 2006
	PADDOCK LLC	17GM/SCOOPFUL	A077893 001	May 26, 2006
		17GM/SCOOPFUL	A090567 001	Oct 15, 2009
	TEVA PHARMS	17GM/SCOOPFUL	A077445 001	May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL				
LAX-LYTE WITH FLAVOR PACKS				
	L PERRIGO CO	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A079232 001	Feb 25, 2010
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE				
	MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090409 001	Apr 02, 2010
	NOSTRUM LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A202060 001	Mar 08, 2017
	NOVEL LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090019 001	May 27, 2009
TRILYTE				
	AUROBINDO PHARMA USA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A076491 001	Feb 05, 2004

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL				
CLENZ-LYTE				
	PADDOCK LLC	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090769 001	Jun 07, 2010
SOLUTION;ORAL				
OCL				
	HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML;146MG/100ML;1.29GM/100ML	N019284 001	Apr 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL				
COLYTE				
	MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET **	N018983 005	Oct 26, 1984
		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET **	N018983 004	Oct 26, 1984
		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT **	N018983 010	Jan 31, 1989
		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT **	N018983 007	Jun 12, 1987
		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET **	N018983 006	Oct 26, 1984
COLYTE-FLAVORED				
	MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT **	N018983 008	Nov 14, 1991
		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT **	N018983 009	Nov 14, 1991
GOLYTELY				
+	BRAINTREE	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N019011 002	Jun 02, 1992
PEG 3350 AND ELECTROLYTES				
	MYLAN	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928 001	Jan 28, 2010
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES				
	PADDOCK LLC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090712 001	Feb 25, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS				
FOR SUSPENSION;ORAL				
CO-LAV				
	VINTAGE PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A073428 001	Jan 28, 1992
COLOVAGE				
	DYNAPHARM	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	A071320 001	Apr 20, 1988
E-Z-EM PREP LYTE				
	E Z EM	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A071278 001	Nov 21, 1988
GLYCOPREP				
	GOLDLINE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A072319 001	Dec 23, 1988
GO-EVAC				
	VINTAGE PHARMS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073433 001	Apr 28, 1992
PEG-LYTE				
	SANDOZ	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073098 001	Aug 31, 1993
POLYMYXIN B SULFATE				
INJECTABLE;INJECTION				
AEROSPORIN				
	GLAXOSMITHKLINE	EQ 500,000 UNITS BASE/VIAL	A062036 001	
POLYMYXIN B SULFATE				
	HIKMA	EQ 500,000 UNITS BASE/VIAL	A060716 001	
	RISING	EQ 500,000 UNITS BASE/VIAL	A090110 001	Jun 29, 2011
POWDER;FOR RX COMPOUNDING				
POLY-RX				
	X GEN PHARMS	100,000,000 UNITS/BOT	A061578 001	
POLYMYXIN B SULFATE				
	PADDOCK LLC	100,000,000 UNITS/BOT	A062455 001	Jul 27, 1983
POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE				
SOLUTION/DROPS;OPHTHALMIC				
POLYTRIM				
+	ALLERGAN	10,000 UNITS/ML;EQ 1MG BASE/ML	N050567 001	Oct 20, 1988
POLYTHIAZIDE				
TABLET;ORAL				
RENESE				
	PFIZER	1MG	N012845 001	
		2MG	N012845 002	
		4MG	N012845 003	
POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
MINIZIDE				
	PFIZER	0.5MG;EQ 1MG BASE	N017986 001	
		0.5MG;EQ 2MG BASE	N017986 002	
		0.5MG;EQ 5MG BASE	N017986 003	
POLYTHIAZIDE; RESERPINE				
TABLET;ORAL				
RENESE-R				
	PFIZER	2MG;0.25MG	N013636 001	
POMALIDOMIDE				
CAPSULE;ORAL				
POMALIDOMIDE				
	BRECKENRIDGE	1MG	A210111 001	Oct 30, 2020
		2MG	A210111 002	Oct 30, 2020
		3MG	A210111 003	Oct 30, 2020
		4MG	A210111 004	Oct 30, 2020
	EUGIA PHARMA	1MG	A210249 001	Oct 30, 2020
		2MG	A210249 002	Oct 30, 2020
		3MG	A210249 003	Oct 30, 2020
		4MG	A210249 004	Oct 30, 2020
	MYLAN	1MG	A210275 001	Jan 26, 2022
		2MG	A210275 002	Jan 26, 2022
		3MG	A210275 003	Jan 26, 2022
		4MG	A210275 004	Jan 26, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POMALIDOMIDE				
CAPSULE;ORAL				
POMALIDOMIDE				
TEVA PHARMS USA	1MG	A209956	001	May 04, 2022
	2MG	A209956	002	May 04, 2022
	3MG	A209956	003	May 04, 2022
	4MG	A209956	004	May 04, 2022
PONATINIB HYDROCHLORIDE				
TABLET;ORAL				
PONATINIB HYDROCHLORIDE				
APOTEX	EQ 15MG BASE	A215893	001	Jul 14, 2023
	EQ 45MG BASE	A215893	002	Jul 14, 2023
POSACONAZOLE				
TABLET, DELAYED RELEASE;ORAL				
POSACONAZOLE				
ACTAVIS LABS FL INC	100MG	A207355	001	Nov 30, 2022
POTASSIUM AMINOSALICYLATE				
CAPSULE;ORAL				
PASKALIUM				
GLENWOOD	500MG	N009395	004	
POWDER;ORAL				
POTASSIUM AMINOSALICYLATE				
HEXCEL	100%	A080098	001	
TABLET;ORAL				
PASKALIUM				
GLENWOOD	1GM	N009395	003	
POTASSIUM CHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
K-LEASE				
SAVAGE LABS	8MEQ	A073398	001	Jan 28, 1992
	10MEQ	A072427	001	Mar 28, 1990
MICRO-K				
+ NESHER PHARMS	8MEQ **	N018238	001	
MICRO-K 10				
+ NESHER PHARMS	10MEQ **	N018238	002	May 14, 1984
POTASSIUM CHLORIDE				
CHARTWELL MOLECULAR	8MEQ	A204210	001	Mar 28, 2016
	10MEQ	A204210	002	Mar 28, 2016
NESHER PHARMS	10MEQ	A070980	001	Feb 17, 1987
TEVA	8MEQ	A073531	001	Apr 26, 1996
	10MEQ	A073532	001	Apr 26, 1996
TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016
	10MEQ	A201944	002	Mar 04, 2016
FOR SUSPENSION, EXTENDED RELEASE;ORAL				
MICRO-K LS				
+ KV PHARM	20MEQ/PACKET **	N019561	003	Aug 26, 1988
INJECTABLE;INJECTION				
POTASSIUM CHLORIDE				
+ ABRAXIS PHARM	2MEQ/ML	A080204	001	
	2MEQ/ML	A084290	001	
	2MEQ/ML	A086713	001	
	2MEQ/ML	A086714	001	
	2MEQ/ML	A087787	001	Apr 20, 1982
	2MEQ/ML	A087885	001	Feb 03, 1983
AKORN	2MEQ/ML	A088286	001	Sep 05, 1985
BAXTER HLTHCARE	2MEQ/ML	A080203	001	
	2MEQ/ML	A085499	001	
+ FRESENIUS KABI USA	2MEQ/ML	A080225	001	
	2MEQ/ML	A087817	001	Oct 20, 1982
	3MEQ/ML	A080225	003	
GD SEARLE LLC	1MEQ/ML	A086219	001	
	2MEQ/ML	A086219	002	
	2MEQ/ML	A086220	002	
	3MEQ/ML	A086219	003	
	3MEQ/ML	A086220	001	
	4MEQ/ML	A086219	004	
HOSPIRA	1MEQ/ML	A080205	003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POTASSIUM CHLORIDE

INJECTABLE;INJECTION				
POTASSIUM CHLORIDE				
	1MEQ/ML		A083345 003	
	1.5MEQ/ML		A083345 001	
	2MEQ/ML		A083345 002	
	2.4MEQ/ML		A080205 004	
	3.2MEQ/ML		A080205 005	
INTL MEDICATION	2MEQ/ML		A083163 001	
LILLY	2MEQ/ML		N007865 002	
LUITPOLD	2MEQ/ML		A080221 001	
	2MEQ/ML		A080736 001	
	2MEQ/ML		A087584 001	
	2MEQ/ML		A087585 001	
MILES	1MEQ/ML		A080195 002	
	2MEQ/ML		A080195 001	
	3MEQ/ML		A080195 003	
	4MEQ/ML		A080195 004	
PHARMA SERVE NY	2MEQ/ML		A086297 001	
	2MEQ/ML		A087362 001	Mar 08, 1983
WATSON LABS	2MEQ/ML		A086208 001	
	2MEQ/ML		A089163 001	Mar 10, 1988
	2MEQ/ML		A089421 001	Jan 02, 1987
	3MEQ/ML		A086210 001	
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER				
+ ICU MEDICAL INC	2.24GM/100ML		N020161 003	Aug 11, 1998
SOLUTION;ORAL				
POTASSIUM CHLORIDE				
STRIDES PHARMA	40MEQ/15ML		A211665 001	Nov 17, 2022
TRIS PHARMA INC	20MEQ/15ML		A214076 001	Jan 26, 2022
	40MEQ/15ML		A214076 002	Jan 26, 2022
TABLET, EXTENDED RELEASE;ORAL				
K+10				
FUTURE PAK	10MEQ		A070999 001	Oct 22, 1987
K+8				
FUTURE PAK	8MEQ		A070998 001	Jan 25, 1993
K-TAB				
+ ABBVIE	8MEQ **		N018279 002	Aug 01, 1988
+	10MEQ **		N018279 001	
+	20MEQ **		N018279 003	Nov 25, 2013
KAON CL				
SAVAGE LABS	6.7MEQ		N017046 001	
KAON CL-10				
SAVAGE LABS	10MEQ		N017046 002	
KLOTRIX				
APOTHECON	10MEQ		N017850 001	
POTASSIUM CHLORIDE				
AMNEAL	15MEQ		A212861 002	May 08, 2020
AUROBINDO PHARMA LTD	10MEQ		A214728 001	Mar 31, 2021
	15MEQ		A214728 002	Mar 31, 2021
	20MEQ		A214728 003	Mar 31, 2021
BRECKENRIDGE	10MEQ		A213588 001	Aug 21, 2020
	20MEQ		A213588 002	Aug 21, 2020
CHARTWELL RX	20MEQ		A210098 001	Apr 26, 2019
COPLEY PHARM	8MEQ		A070618 001	Sep 09, 1987
NESHER PHARMS	20MEQ		A076044 001	Apr 05, 2002
+ SCHERING	10MEQ **		N019439 002	Jun 13, 1986
+	20MEQ **		N019439 001	Jun 13, 1986
SIGMAPHARM LABS LLC	8MEQ		A207528 001	Aug 19, 2016
	10MEQ		A207528 002	Aug 19, 2016
STRIDES PHARMA	8MEQ		A206881 001	Jan 22, 2019
	10MEQ		A206630 001	Mar 29, 2019
	10MEQ		A206881 002	Jan 22, 2019
	10MEQ		A210097 001	Jun 17, 2019
	15MEQ		A206630 002	Mar 29, 2019
	20MEQ		A206630 003	Mar 29, 2019
SLOW-K				
NOVARTIS	8MEQ		N017476 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POTASSIUM CHLORIDE
TABLET, EXTENDED RELEASE;ORAL
TEN-K
NOVARTIS 10MEQ N019381 001 Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE
INJECTABLE;INJECTION
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 37MG/100ML;900MG/100ML N019708 001 Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 75MG/100ML;900MG/100ML N019708 002 Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 110MG/100ML;900MG/100ML N019708 003 Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 220MG/100ML;900MG/100ML N019708 005 Sep 29, 1989
POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%
\+ BAXTER HLTHCARE 224MG/100ML;900MG/100ML N017648 003
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 300MG/100ML;900MG/100ML N019708 006 Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%
BAXTER HLTHCARE 75MG/100ML;900MG/100ML N017648 004
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
B BRAUN 75MG/100ML;900MG/100ML N018722 001 Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
B BRAUN 150MG/100ML;900MG/100ML N018722 002 Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
B BRAUN 220MG/100ML;900MG/100ML N018722 003 Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 300MG/100ML;900MG/100ML N018722 004 Nov 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE
INJECTABLE;INJECTION
THAM-E
HOSPIRA 370MG/VIAL;1.75GM/VIAL;36GM/VIAL N013025 001

POTASSIUM CITRATE
FOR SOLUTION;ORAL
POTASSIUM CITRATE
\+ UT SW MEDCTR 10MEQ/PACKET ** N019647 002 Oct 13, 1988
\+ 20MEQ/PACKET ** N019647 001 Oct 13, 1988

POTASSIUM IODIDE
SOLUTION;ORAL
POTASSIUM IODIDE
\+ ROXANE 1GM/ML ** N018551 001 Feb 19, 1982
THYROSHIELD
ARCO PHARMS LLC 65MG/ML A077218 001 Jan 12, 2005
TABLET;ORAL
THYRO-BLOCK
MEDA PHARMS 130MG N018307 001

POTASSIUM PERCHLORATE
CAPSULE;ORAL
PERCHLORACAP
MALLINCKRODT 200MG N017551 001

POVIDONE-IODINE
SOLUTION;TOPICAL
E-Z PREP
CLINIPAD 10% N019382 001 Jul 25, 1989
SPONGE;TOPICAL
E-Z PREP
CLINIPAD 5% N019382 002 Jul 25, 1989
E-Z PREP 220
CLINIPAD 5% N019382 003 Jul 25, 1989

PRALIDOXIME CHLORIDE
INJECTABLE;INJECTION
PRALIDOXIME CHLORIDE
BAXTER HLTHCARE CORP 300MG/ML N018799 001 Dec 13, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PRALIDOXIME CHLORIDE					
SOLUTION;INTRAMUSCULAR					
PRALIDOXIME CHLORIDE (AUTOINJECTOR)					
+	MERIDIAN MEDCL TECHN	600MG/2ML (300MG/ML)	N018986	001	Apr 26, 1983
TABLET;ORAL					
PROTOPAM CHLORIDE					
	WYETH AYERST	500MG	N014122	002	
PRAMIPEXOLE DIHYDROCHLORIDE					
TABLET;ORAL					
MIRAPEX					
+	BOEHRINGER INGELHEIM	0.125MG **	N020667	001	Jul 01, 1997
+		0.25MG **	N020667	002	Jul 01, 1997
+		0.5MG **	N020667	006	Feb 12, 1998
+		0.75MG **	N020667	007	Jul 30, 2007
+		1MG **	N020667	003	Jul 01, 1997
		1.25MG	N020667	004	Jul 01, 1997
+		1.5MG **	N020667	005	Jul 01, 1997
PRAMIPEXOLE DIHYDROCHLORIDE					
	ALEMBIC	0.125MG	A078894	001	Oct 08, 2010
		0.25MG	A078894	002	Oct 08, 2010
		0.5MG	A078894	003	Oct 08, 2010
		1MG	A078894	004	Oct 08, 2010
		1.5MG	A078894	005	Oct 08, 2010
	CHARTWELL RX	0.125MG	A090241	001	Oct 08, 2010
		0.25MG	A090241	002	Oct 08, 2010
		0.5MG	A090241	003	Oct 08, 2010
		0.75MG	A090241	004	Oct 08, 2010
		1MG	A090241	005	Oct 08, 2010
		1.5MG	A090241	006	Oct 08, 2010
	HERITAGE PHARMA AVET	0.125MG	A077724	001	Feb 19, 2008
		0.125MG	A078551	001	Oct 08, 2010
		0.125MG	A091254	001	Nov 30, 2010
		0.25MG	A077724	002	Feb 19, 2008
		0.25MG	A078551	002	Oct 08, 2010
		0.25MG	A091254	002	Nov 30, 2010
		0.5MG	A077724	003	Feb 19, 2008
		0.5MG	A078551	003	Oct 08, 2010
		0.5MG	A091254	003	Nov 30, 2010
		0.75MG	A091254	004	Nov 30, 2010
		1MG	A077724	004	Feb 19, 2008
		1MG	A078551	004	Oct 08, 2010
		1MG	A091254	005	Nov 30, 2010
		1.5MG	A077724	005	Feb 19, 2008
		1.5MG	A078551	005	Oct 08, 2010
		1.5MG	A091254	006	Nov 30, 2010
	MACLEODS PHARMS LTD	0.125MG	A202164	001	Sep 20, 2012
		0.25MG	A202164	002	Sep 20, 2012
		0.5MG	A202164	003	Sep 20, 2012
		1MG	A202164	004	Sep 20, 2012
		1.5MG	A202164	005	Sep 20, 2012
	MYLAN	0.125MG	A077854	001	Oct 08, 2010
		0.25MG	A077854	002	Oct 08, 2010
		0.5MG	A077854	003	Oct 08, 2010
		0.75MG	A090764	001	Apr 09, 2010
		1MG	A077854	004	Oct 08, 2010
		1.5MG	A077854	005	Oct 08, 2010
	NOSTRUM LABS INC	0.125MG	A091450	001	Oct 08, 2010
		0.25MG	A091450	002	Oct 08, 2010
		0.5MG	A091450	003	Oct 08, 2010
		1MG	A091450	004	Oct 08, 2010
		1.5MG	A091450	005	Oct 08, 2010
	SANDOZ	0.125MG	A090190	001	Jul 06, 2010
		0.25MG	A090190	002	Jul 06, 2010
		0.5MG	A090190	003	Jul 06, 2010
		0.75MG	A090190	006	Oct 08, 2010
		1MG	A090190	004	Jul 06, 2010
		1.5MG	A090190	005	Jul 06, 2010
	SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013
		0.25MG	A091683	002	Mar 27, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL					
PRAMIPEXOLE DIHYDROCHLORIDE					
		0.5MG	A091683	003	Mar 27, 2013
		0.75MG	A091683	004	Mar 27, 2013
		1MG	A091683	005	Mar 27, 2013
		1.5MG	A091683	006	Mar 27, 2013
	UNICHEM	0.125MG	A207011	001	Dec 19, 2018
		0.25MG	A207011	002	Dec 19, 2018
		0.5MG	A207011	003	Dec 19, 2018
		0.75MG	A207011	004	Dec 19, 2018
		1MG	A207011	005	Dec 19, 2018
		1.5MG	A207011	006	Dec 19, 2018
TABLET, EXTENDED RELEASE;ORAL					
PRAMIPEXOLE DIHYDROCHLORIDE					
	ANCHEN PHARMS	0.375MG	A202206	001	Feb 06, 2014
		0.75MG	A202206	002	Feb 06, 2014
		1.5MG	A202206	003	Feb 06, 2014
		2.25MG	A202206	004	Feb 06, 2014
		3MG	A202206	005	Feb 06, 2014
		3.75MG	A202206	006	Feb 06, 2014
		4.5MG	A202206	007	Feb 06, 2014

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS					
SYMLIN					
	ASTRAZENECA AB	EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005

PRASUGREL HYDROCHLORIDE

TABLET;ORAL					
PRASUGREL					
	CHARTWELL RX	EQ 5MG BASE	A205790	001	Oct 16, 2017
		EQ 10MG BASE	A205790	002	Oct 16, 2017
	DR REDDYS	EQ 5MG BASE	A205926	001	Jul 07, 2020
		EQ 10MG BASE	A205926	002	Jul 07, 2020
	LUPIN LTD	EQ 5MG BASE	A205930	001	Jan 09, 2023
		EQ 10MG BASE	A205930	002	Jan 09, 2023

PRAVASTATIN SODIUM

TABLET;ORAL					
PRAVACHOL					
+	BRISTOL MYERS SQUIBB	10MG **	N019898	002	Oct 31, 1991
+		20MG **	N019898	003	Oct 31, 1991
+		40MG **	N019898	004	Mar 22, 1993
+		80MG **	N019898	008	Dec 18, 2001
PRAVASTATIN SODIUM					
	HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018
		40MG	A206061	002	Nov 23, 2018
		80MG	A206061	003	Nov 23, 2018
	MYLAN	10MG	A077013	001	Oct 23, 2006
		20MG	A077013	002	Oct 23, 2006
		40MG	A077013	003	Oct 23, 2006
		80MG	A077013	004	Dec 28, 2007
	MYLAN PHARMS INC	10MG	A079187	001	May 27, 2010
		20MG	A079187	002	May 27, 2010
		40MG	A079187	003	May 27, 2010
		80MG	A079187	004	May 27, 2010
	PLIVA HRVATSKA DOO	10MG	A077730	001	Nov 21, 2006
		20MG	A077730	002	Nov 21, 2006
		30MG	A077730	003	Nov 21, 2006
		40MG	A077730	005	Nov 21, 2006
	RANBAXY LABS LTD	10MG	A076445	001	Apr 23, 2007
		20MG	A076445	002	Apr 23, 2007
		40MG	A076445	003	Apr 23, 2007
		80MG	A076445	004	Apr 23, 2007
	ZYDUS PHARMS USA	10MG	A077751	001	Apr 30, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PRAZEPAM				
CAPSULE;ORAL				
CENTRAX				
PARKE DAVIS	5MG	N018144	001	
	10MG	N018144	002	
	20MG	N018144	003	May 10, 1982
PRAZEPAM				
USL PHARMA	5MG	A070427	001	Nov 06, 1987
	10MG	A070428	001	Nov 06, 1987
TABLET;ORAL				
CENTRAX				
PARKE DAVIS	10MG	N017415	001	
PRAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
PRAZOSIN HYDROCHLORIDE				
AM THERAP	EQ 1MG BASE	A072782	001	May 16, 1989
	EQ 2MG BASE	A072783	001	May 16, 1989
	EQ 5MG BASE	A072784	001	May 16, 1989
ANI PHARMS	EQ 1MG BASE	A072577	002	May 16, 1989
	EQ 2MG BASE	A072577	001	May 16, 1989
	EQ 5MG BASE	A072577	003	May 16, 1989
DAVA PHARMS INC	EQ 1MG BASE	A072705	001	May 16, 1989
	EQ 2MG BASE	A072706	001	May 16, 1989
	EQ 5MG BASE	A072707	001	May 16, 1989
PUREPAC PHARM	EQ 1MG BASE	A072991	001	May 16, 1989
	EQ 2MG BASE	A072921	001	May 16, 1989
	EQ 5MG BASE	A072992	001	May 16, 1989
WATSON LABS	EQ 1MG BASE	A072352	001	May 16, 1989
	EQ 2MG BASE	A072333	001	May 16, 1989
	EQ 5MG BASE	A072609	001	May 16, 1989
TABLET, EXTENDED RELEASE;ORAL				
MINIPRESS XL				
PFIZER	2.5MG	N019775	001	Jan 29, 1992
	5MG	N019775	002	Jan 29, 1992
PREDNICARBATE				
CREAM;TOPICAL				
DERMATOP E EMOLLIENT				
+ VALEANT BERMUDA	0.1% **	N020279	001	Oct 29, 1993
PREDNICARBATE				
FOUGERA PHARMS	0.1%	A077287	001	Sep 19, 2006
OINTMENT;TOPICAL				
DERMATOP				
+ VALEANT PHARMS NORTH	0.1% **	N019568	001	Sep 23, 1991
PREDNISOLONE				
CREAM;TOPICAL				
METI-DERM				
SCHERING	0.5%	N010209	002	
SYRUP;ORAL				
PREDNISOLONE				
IVAX SUB TEVA PHARMS	15MG/5ML	A040287	001	May 28, 1999
NESHER PHARMS	5MG/5ML	A040423	001	Oct 22, 2001
	15MG/5ML	A040364	001	Apr 10, 2002
PHARM ASSOC	5MG/5ML	A040570	001	Aug 25, 2005
PHARMOBEDIENT CNSLTG	15MG/5ML	A040313	001	Sep 10, 2003
TEVA PHARMS	15MG/5ML	A040322	001	Jan 19, 2000
WE PHARMS	15MG/5ML	A040192	001	May 28, 1998
PRELONE				
MURO	5MG/5ML	A089654	001	Jan 17, 1989
TABLET;ORAL				
CORTALONE				
HALSEY	1MG	A080304	003	
	2.5MG	A080304	002	
	5MG	A080304	001	
DELTA-CORTEF				
PHARMACIA AND UPJOHN	5MG	N009987	004	
FERNISOLONE-P				
FERNDALE LABS	5MG	A083941	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISOLONE

TABLET;ORAL			
PREDNISOLONE			
BARR	5MG	A084426 002	
BUNDY	5MG	A083675 001	
CHARTWELL RX	5MG	A084542 001	
ELKINS SINN	5MG	A080625 001	
EVERYLIFE	1MG	A084439 001	
	2.5MG	A084439 002	
	5MG	A084439 003	
FERRANTE	2.5MG	A080562 001	
	5MG	A080562 002	
FOSUN PHARMA	5MG	A080339 001	
HEATHER	5MG	A080326 001	
IMPAX LABS	5MG	A080780 001	
INWOOD LABS	5MG	A080748 001	
IVAX SUB TEVA PHARMS	5MG	A080378 001	
MARSHALL PHARMA	5MG	A080307 001	
PANRAY	1MG	A080351 001	
	5MG	A080351 002	
PHOENIX LABS NY	5MG	A080322 001	
PUREPAC PHARM	5MG	A080325 001	
PVT FORM	5MG	A080211 001	
RISING	5MG	A084773 001	
ROXANE	5MG	A080327 002	
SPERTI	1MG	A080358 001	
	2.5MG	A080358 002	
	5MG	A080358 003	
SUPERPHARM	5MG	A088892 001	Feb 26, 1985
TABLICAPS	5MG	A085170 001	
TEVA	5MG	A080398 001	
UDL	5MG	A087987 001	Jan 18, 1983
VALEANT PHARM INTL	5MG	A080236 001	
VITARINE	5MG	A080534 001	
WATSON LABS	5MG	A085085 002	
	5MG	A085415 001	
	5MG	A085416 001	
WEST WARD	5MG	A080324 001	
WHITEWORTH TOWN PLSN	5MG	A080342 001	
STERANE			
PFIZER	5MG	N009996 001	

PREDNISOLONE ACETATE

INJECTABLE;INJECTION			
METICORTELONE			
SCHERING	25MG/ML	N010255 002	
PREDNISOLONE ACETATE			
AKORN	25MG/ML	A083032 001	
	50MG/ML	A084492 001	
BEL MAR	25MG/ML	A083738 001	
	50MG/ML	A083738 002	
CENT PHARMS	25MG/ML	A084717 001	
	50MG/ML	A084717 002	
WATSON LABS	25MG/ML	A083398 001	
	25MG/ML	A083654 001	
	40MG/ML	A083767 001	
	50MG/ML	A083764 001	
	50MG/ML	A085781 001	
STERANE			
PFIZER	25MG/ML	N011446 001	
SUSPENSION;ORAL			
FLO-PRED			
TARO	EQ 5MG BASE/5ML	N022067 001	Jan 17, 2008
	EQ 15MG BASE/5ML	N022067 002	Jan 17, 2008
SUSPENSION/DROPS;OPHTHALMIC			
ECONOPRED			
HARROW EYE	0.125%	N017468 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC				
BLEPHAMIDE S.O.P.				
ALLERGAN	0.2%;10%	A087748	001	Dec 03, 1986
CETAPRED				
ALCON	0.25%;10%	A087771	001	Aug 06, 1993
METIMYD				
SCHERING	0.5%;10%	N010210	002	Sep 09, 1984
PREDSULFAIR				
PHARMAFAIR	0.5%;10%	A088032	001	Apr 15, 1983
VASOCIDIN				
NOVARTIS	0.5%;10%	A088791	001	Oct 05, 1984
SUSPENSION;OPHTHALMIC				
BLEPHAMIDE				
+ ALLERGAN	0.2%;10%	N012813	002	
ISOPTO CETAPRED				
ALCON	0.25%;10%	A087547	001	
SUSPENSION/DROPS;OPHTHALMIC				
METIMYD				
SCHERING	0.5%;10%	N010210	001	
PREDAMIDE				
AKORN	0.5%;10%	A088059	001	Jul 29, 1983
PREDSULFAIR				
PHARMAFAIR	0.5%;10%	A088007	001	Apr 19, 1983
PREDSULFAIR II				
PHARMAFAIR	0.2%;10%	A088837	001	Dec 24, 1985
SULPHRIN				
BAUSCH AND LOMB	0.5%;10%	A088089	001	Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE;INJECTION				
HYDELTRASOL				
MERCK	EQ 20MG PHOSPHATE/ML	N011583	002	
PREDNISOLONE SODIUM PHOSPHATE				
WATSON LABS	EQ 20MG PHOSPHATE/ML	A080517	001	
OINTMENT;OPHTHALMIC, OTIC				
HYDELTRASOL				
MERCK	EQ 0.25% PHOSPHATE	N011028	001	
SOLUTION;ORAL				
ORAPRED				
CONCORDIA PHARMS INC	EQ 15MG BASE/5ML **	A075117	001	Dec 14, 2000
PREDNISOLONE SODIUM PHOSPHATE				
AMNEAL PHARMS	EQ 15MG BASE/5ML	A078345	001	Mar 10, 2009
BAUSCH	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002
NESHER PHARMS	EQ 5MG BASE/5ML	A076982	001	May 24, 2005
	EQ 15MG BASE/5ML	A076988	001	May 24, 2005
PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002
PHARMOBEDIENT CNSLTG	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002
VINTAGE	EQ 15MG BASE/5ML	A079010	001	May 26, 2009
VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416	001	Oct 31, 2007
WE PHARMS	EQ 5MG BASE/5ML	A075181	001	Dec 23, 2002
XTTRIUM LABS INC	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004
SOLUTION/DROPS;OPHTHALMIC				
INFLAMASE FORTE				
+ NOVARTIS	EQ 0.9% PHOSPHATE	A080751	002	
INFLAMASE MILD				
+ NOVARTIS	EQ 0.11% PHOSPHATE	A080751	001	
METRETON				
SCHERING	EQ 0.5% PHOSPHATE	A083834	001	
PREDAIR				
PHARMAFAIR	EQ 0.11% PHOSPHATE	A088415	001	Feb 29, 1984
PREDAIR FORTE				
PHARMAFAIR	EQ 0.9% PHOSPHATE	A088165	001	Mar 28, 1983
PREDNISOLONE SODIUM PHOSPHATE				
AKORN	EQ 0.11% PHOSPHATE	A083358	001	
	EQ 0.9% PHOSPHATE	A083358	002	
ALCON PHARMS LTD	EQ 0.11% PHOSPHATE	A081043	001	Oct 24, 1991
	EQ 0.9% PHOSPHATE	A081044	001	Oct 24, 1991
BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065	001	Jul 29, 1994
SOLA BARNES HIND	EQ 0.11% PHOSPHATE	A084171	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISOLONE SODIUM PHOSPHATE				
SOLUTION/DROPS;OPHTHALMIC				
PREDNISOLONE SODIUM PHOSPHATE				
		EQ 0.9% PHOSPHATE	A084168 001	
		EQ 0.9% PHOSPHATE	A084169 001	
		EQ 0.9% PHOSPHATE	A084172 001	
TABLET, ORALLY DISINTEGRATING;ORAL				
PREDNISOLONE SODIUM PHOSPHATE				
	RISING	EQ 10MG BASE	A202179 001	Apr 10, 2013
		EQ 15MG BASE	A202179 002	Apr 10, 2013
		EQ 30MG BASE	A202179 003	Apr 10, 2013
PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE				
	SANDOZ	EQ 0.23% PHOSPHATE;10%	A073630 001	May 27, 1993
SULSTER				
	AKORN	EQ 0.23% PHOSPHATE;10%	A074511 001	Jul 30, 1996
VASOCIDIN				
+	NOVARTIS	EQ 0.23% PHOSPHATE;10% **	N018988 001	Aug 26, 1988
PREDNISOLONE TEBUTATE				
INJECTABLE;INJECTION				
HYDELTRA-TBA				
	MERCK	20MG/ML	N010562 001	
PREDNISOLONE TEBUTATE				
	WATSON LABS	20MG/ML	A083362 001	Feb 17, 1984
PREDNISONE				
SOLUTION;ORAL				
PREDNISONE				
	XTTRIUM LABS INC	5MG/5ML	A089726 001	Aug 02, 1988
SYRUP;ORAL				
LIQUID PRED				
	MURO	5MG/5ML	A087611 002	Sep 07, 1982
TABLET;ORAL				
CORTAN				
	HALSEY	20MG	A087480 001	
DELTA-DOME				
	BAYER PHARMS	5MG	A080293 001	
DELTASONE				
+	PHARMACIA AND UPJOHN	2.5MG **	N009986 005	
+		5MG **	N009986 002	
+		10MG **	N009986 006	
+		20MG **	N009986 007	
+		50MG **	N009986 008	
FERNISONE				
	FERNDALE LABS	5MG	A083364 001	
METICORTEN				
+	SCHERING	1MG **	N009766 002	
+		5MG **	N009766 001	
ORASONE				
	SOLVAY	1MG	A083009 001	
		5MG	A083009 002	
		10MG	A083009 003	
		20MG	A083009 004	
		50MG	A085999 001	
PARACORT				
	PARKE DAVIS	5MG	N010962 002	
PREDNICEN-M				
	SCHWARZ PHARMA	5MG	A084655 001	
PREDNISONE				
	AM THERAP	5MG	A089387 001	Nov 06, 1986
		10MG	A089388 001	Nov 06, 1986
		20MG	A089389 001	Nov 06, 1986
	AMNEAL PHARMS NY	5MG	A089597 001	Oct 05, 1987
		10MG	A089598 001	Oct 05, 1987
		20MG	A089599 001	Oct 05, 1987
	BUNDY	5MG	A083676 001	
	CHARTWELL MOLECULAR	5MG	A080514 001	
		20MG	A084275 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISONE

TABLET;ORAL

PREDNISONE

CHARTWELL RX	5MG	A083059	001	
CONTRACT PHARMACAL	5MG	A080209	001	
DURAMED PHARMS BARR	5MG	A088394	001	Oct 04, 1983
	10MG	A088395	001	Oct 04, 1983
	20MG	A088396	001	Oct 04, 1983
ELKINS SINN	5MG	A080491	001	
	20MG	A085811	001	
EVERYLIFE	1MG	A084440	001	
	2.5MG	A084440	002	
	5MG	A084440	003	
FERRANTE	2.5MG	A080563	001	
	5MG	A080563	002	
HALSEY	5MG	A080300	001	
HEATHER	5MG	A080320	001	
	10MG	A084341	001	
	20MG	A084417	001	
	20MG	A085543	001	
	50MG	A086946	001	
HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010
	2.5MG	A040538	001	Jan 08, 2004
	50MG	A088465	001	Jun 01, 1984
IMPAX LABS	5MG	A080782	001	
INWOOD LABS	1MG	A080328	001	
	2.5MG	A080306	001	
	5MG	A080279	001	
IVAX SUB TEVA PHARMS	5MG	A080283	001	
	10MG	A084133	001	
	20MG	A084134	001	
KV PHARM	5MG	A084236	001	
LEDERLE	5MG	A086968	001	
MARSHALL PHARMA	5MG	A080301	001	
MUTUAL PHARM	5MG	A080701	001	
	10MG	A086595	001	
	20MG	A084634	001	
NYLOS	5MG	A085115	001	
PANRAY	1MG	A080350	001	
	2.5MG	A080350	002	
	5MG	A080350	003	
PHARMAVITE	5MG	A084662	002	
PHOENIX LABS NY	5MG	A080321	001	
	20MG	A083807	001	
PUREPAC PHARM	5MG	A080353	001	
	10MG	A086062	001	
	20MG	A086061	001	
PVT FORM	20MG	A085151	001	
REXALL	5MG	A080232	001	
RISING	5MG	A084774	001	
	10MG	A089983	001	Jan 12, 1989
	20MG	A085813	001	
	50MG	A089984	001	Jan 12, 1989
ROXANE	20MG	N017109	001	
+	25MG	A087833	001	May 04, 1982
SANDOZ	5MG	A080336	002	
SCHERER LABS	5MG	A080371	001	
SPERTI	1MG	A080359	001	
	2.5MG	A080359	002	
	5MG	A080359	003	
SUN PHARM INDUSTRIES	50MG	A086596	001	
SUPERPHARM	5MG	A088865	001	Oct 25, 1984
	10MG	A088866	001	Oct 25, 1984
	20MG	A088867	001	Oct 25, 1984
TEVA	5MG	A080397	001	
UDL	5MG	A087984	001	Jan 18, 1983
	10MG	A087985	001	Jan 18, 1983
	20MG	A087986	001	Jan 18, 1983
UPSHER SMITH	5MG	A087471	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISONE

TABLET;ORAL

PREDNISONE

	20MG	A087470	001	
VALEANT PHARM INTL	5MG	A080237	001	
VANGARD	5MG	A087682	001	Jan 15, 1982
	20MG	A087701	001	Jan 15, 1982
VITARINE	5MG	A080334	001	
	5MG	A080506	001	
WATSON LABS	5MG	A085084	002	
	10MG	A087773	001	Jul 13, 1982
	20MG	A086813	001	
	50MG	A086867	001	
	50MG	A087772	001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG	A084913	001	
	5MG	A080343	001	
	10MG	A089028	001	Jul 24, 1986
	20MG	A084913	002	

SERVISONE

LEDERLE	5MG	A080223	001	

PREGABALIN

CAPSULE;ORAL

PREGABALIN

ACI	25MG	A215755	001	Apr 26, 2023
	50MG	A215755	002	Apr 26, 2023
	75MG	A215755	003	Apr 26, 2023
	100MG	A215755	004	Apr 26, 2023
	150MG	A215755	005	Apr 26, 2023
	200MG	A215755	006	Apr 26, 2023
	225MG	A215755	007	Apr 26, 2023
	300MG	A215755	008	Apr 26, 2023
LUPIN LTD	25MG	A091040	001	May 03, 2022
	50MG	A091040	002	May 03, 2022
	75MG	A091040	003	May 03, 2022
	100MG	A091040	004	May 03, 2022
	150MG	A091040	005	May 03, 2022
	200MG	A091040	006	May 03, 2022
	225MG	A091040	007	May 03, 2022
	300MG	A091040	008	May 03, 2022
MYLAN	25MG	A091228	001	Sep 20, 2019
	50MG	A091228	002	Sep 20, 2019
	75MG	A091228	003	Sep 20, 2019
	100MG	A091228	004	Sep 20, 2019
	150MG	A091228	005	Sep 20, 2019
	200MG	A091228	006	Sep 20, 2019
	225MG	A091228	007	Sep 20, 2019
	300MG	A091228	008	Sep 20, 2019
ZYDUS PHARMS	25MG	A206752	001	Dec 09, 2022
	50MG	A206752	002	Dec 09, 2022
	75MG	A206752	003	Dec 09, 2022
	100MG	A206752	004	Dec 09, 2022
	150MG	A206752	005	Dec 09, 2022
	200MG	A206752	006	Dec 09, 2022
	225MG	A206752	007	Dec 09, 2022
	300MG	A206752	008	Dec 09, 2022

TABLET, EXTENDED RELEASE;ORAL

PREGABALIN

ALVOGEN	82.5MG	A211687	001	Jul 06, 2021
	165MG	A211687	002	Jul 06, 2021
	330MG	A211687	003	Jul 06, 2021
MYLAN	82.5MG	A211948	001	Apr 13, 2021
	165MG	A211967	001	Nov 04, 2021
	330MG	A211431	001	Jul 02, 2021
SCIEGEN PHARMS INC	82.5MG	A215675	001	Sep 14, 2022
	165MG	A215675	002	Sep 14, 2022
	330MG	A215675	003	Sep 14, 2022
ZYDUS PHARMS	82.5MG	A215577	001	Aug 26, 2022
	165MG	A215577	002	Aug 26, 2022
	330MG	A215577	003	Aug 26, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PRILOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CITANEST				
+ ASTRAZENECA	1% **	N014763	004	
+	2% **	N014763	005	
+	3% **	N014763	003	
CITANEST PLAIN				
+ ASTRAZENECA	4% **	N014763	007	
CITANEST PLAIN DENTAL				
+ DENTSPLY PHARM	4%	N021382	001	
PRIMAQUINE PHOSPHATE				
TABLET;ORAL				
PRIMAQUINE PHOSPHATE				
ALVOGEN	EQ 15MG BASE	A203924	001	Feb 03, 2014
PRIMIDONE				
SUSPENSION;ORAL				
MYSOLINE				
+ NURO PHARMA	250MG/5ML	N010401	001	
TABLET;ORAL				
PRIMIDONE				
DR REDDYS LABS LTD	50MG	A040862	001	Oct 03, 2008
	250MG	A040862	002	Oct 03, 2008
HIKMA INTL PHARMS	50MG	A040667	001	Jul 27, 2006
	250MG	A040667	002	Jul 27, 2006
IMPAX LABS	50MG	A040717	001	Feb 12, 2008
	250MG	A040717	002	Feb 12, 2008
WATSON LABS	250MG	A085052	001	
PROBENECID				
TABLET;ORAL				
BENEMID				
+ MERCK	500MG **	N007898	004	
PROBENECID				
AUROBINDO PHARMA USA	500MG	A084211	002	
IVAX SUB TEVA PHARMS	500MG	A083740	001	May 09, 1984
LEDERLE	500MG	A086917	001	
WATSON LABS	500MG	A086150	002	Apr 23, 1982
PROBUCOL				
TABLET;ORAL				
LORELCO				
SANOFI AVENTIS US	250MG	N017535	001	
	500MG	N017535	002	Jul 06, 1988
PROCAINAMIDE HYDROCHLORIDE				
CAPSULE;ORAL				
PROCAINAMIDE HYDROCHLORIDE				
ANI PHARMS	250MG	A089219	001	Jul 01, 1986
	375MG	A089219	002	Jul 01, 1986
	500MG	A089219	003	Jul 01, 1986
ASCOT	250MG	A087542	001	Jan 08, 1982
	375MG	A087697	001	Mar 01, 1983
	500MG	A087543	001	Jan 08, 1982
IVAX SUB TEVA PHARMS	250MG	A084604	001	
	375MG	A084595	001	
	500MG	A084606	001	
LANNETT	250MG	A083693	001	
	500MG	A084696	001	
LEDERLE	250MG	A086942	001	
	375MG	A086952	001	
	500MG	A086943	001	
ROXANE	250MG	A088989	001	Apr 26, 1985
	500MG	A088990	001	Apr 26, 1985
VANGARD	250MG	A087643	001	Jun 01, 1982
	500MG	A087875	001	Jun 01, 1982
WATSON LABS	250MG	A083287	001	
	250MG	A083795	001	
	250MG	A085167	001	
	375MG	A084403	001	
	375MG	A087020	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL				
PROCAINAMIDE HYDROCHLORIDE				
	500MG		A084280 001	
	500MG		A084357 001	
	500MG		A087021 001	
PROCAN				
PARKE DAVIS	250MG		A085804 001	
	375MG		A087502 001	
	500MG		A085079 001	
PROCAPAN				
PANRAY	250MG		A083553 002	
PRONESTYL				
+ APOTHECON	250MG	**	N007335 001	
+	375MG	**	N007335 004	
+	500MG	**	N007335 003	
INJECTABLE;INJECTION				
PROCAINAMIDE HYDROCHLORIDE				
ABRAXIS PHARM	100MG/ML		A089415 001	Nov 17, 1986
	500MG/ML		A089416 001	Nov 17, 1986
HOSPIRA	500MG/ML		A089537 001	Aug 25, 1987
INTL MEDICATION	500MG/ML		A088637 001	Jul 31, 1984
PHARMAFAIR	100MG/ML		A088824 001	Nov 20, 1985
	500MG/ML		A088830 001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML		A088530 001	Mar 04, 1985
	500MG/ML		A088531 001	Mar 04, 1985
SOLOPAK	500MG/ML		A088532 001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML		A089528 001	May 03, 1988
	500MG/ML		A089529 001	May 03, 1988
WATSON LABS	100MG/ML		A087079 001	
	500MG/ML		A087080 001	
WEST-WARD PHARMS INT	100MG/ML		A089029 001	Apr 17, 1986
	500MG/ML		A089030 001	Apr 17, 1986
PRONESTYL				
+ APOTHECON	100MG/ML	**	N007335 002	
+	500MG/ML	**	N007335 005	
TABLET;ORAL				
PRONESTYL				
APOTHECON	250MG		N017371 001	
	375MG		N017371 002	
	500MG		N017371 003	
TABLET, EXTENDED RELEASE;ORAL				
PROCAINAMIDE HYDROCHLORIDE				
ANI PHARMS	250MG		A088958 001	Dec 02, 1985
	250MG		A089369 001	Aug 14, 1987
	500MG		A088959 001	Dec 02, 1985
	500MG		A088974 001	Jul 22, 1985
	500MG		A089369 002	Jan 09, 1987
	750MG		A089369 003	Aug 14, 1987
	750MG		A089438 001	Mar 23, 1987
	1GM		A040111 001	Dec 13, 1996
INWOOD LABS	500MG		A089840 001	Mar 06, 1989
SANDOZ	500MG		A089284 001	Jun 23, 1986
WATSON LABS	250MG		A088533 001	Dec 03, 1984
	250MG		A089026 001	Oct 22, 1985
	500MG		A088534 001	Dec 03, 1984
	500MG		A089027 001	Oct 22, 1985
	750MG		A088535 001	Nov 03, 1984
	750MG		A089042 001	Oct 22, 1985
	1GM		A089520 001	Jan 15, 1987
PROCAN SR				
+ PARKE DAVIS	250MG		A086468 001	
+ PARKEDALE	500MG		A086065 001	
+	750MG		A087510 001	Apr 01, 1982
	1GM		A088489 001	Jan 16, 1985
PROCANBID				
KING PHARMS	500MG		N020545 001	Jan 31, 1996
	1GM		N020545 002	Jan 31, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
PRONESTYL-SR				
	APOTHECON	500MG	A087361 001	

PROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
NOVOCAIN				
	HOSPIRA	1%	A085362 003	
		2%	A085362 004	
		10%	A086797 001	
PROCAINE HYDROCHLORIDE				
	ABRAXIS PHARM	1%	A080384 002	
		1%	A080421 001	
		2%	A080384 003	
		2%	A080421 002	
	BEL MAR	1%	A080711 001	
		2%	A080756 001	
	ELKINS SINN	1%	A083315 001	
		2%	A083315 002	
	GD SEARLE LLC	1%	A086202 001	
		2%	A086202 002	
	HOSPIRA	1%	A080416 001	
		2%	A080416 002	
	MILES	1%	A080415 001	
		2%	A080415 002	
	WATSON LABS	1%	A080658 001	
		1%	A083535 001	
		2%	A080658 002	
		2%	A083535 002	

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE;INJECTION				
ACHROMYCIN				
	LEDERLE	40MG/VIAL;100MG/VIAL	N050276 001	
		40MG/VIAL;250MG/VIAL	N050276 003	
TETRACYN				
	PFIZER	40MG/VIAL;100MG/VIAL	A060285 002	
		40MG/VIAL;250MG/VIAL	A060285 003	

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE;INJECTION				
DICURIN PROCAINE				
	LILLY	100MG/ML;50MG/ML	N008869 001	

PROCHLORPERAZINE

SUPPOSITORY;RECTAL				
COMPAZINE				
	GLAXOSMITHKLINE	2.5MG **	N011127 003	
		5MG **	N011127 001	
		25MG **	N011127 002	
PROCHLORPERAZINE				
	ABLE	2.5MG	A040407 001	Jul 11, 2001
		5MG	A040407 002	Jul 11, 2001
		25MG	A040407 003	Jul 11, 2001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE;ORAL				
COMPAZINE				
+	GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276 001	
PROCHLORPERAZINE				
	ALPHARMA US PHARMS	EQ 10MG BASE/ML	A087153 001	Jun 08, 1982
PROCHLORPERAZINE EDISYLATE				
	MORTON GROVE	EQ 10MG BASE/ML	A088598 001	Oct 25, 1984
INJECTABLE;INJECTION				
COMPAZINE				
+	GLAXOSMITHKLINE	EQ 5MG BASE/ML **	N010742 002	
PROCHLORPERAZINE				
	BAXTER HLTHCARE	EQ 5MG BASE/ML	A087759 001	Oct 01, 1982
PROCHLORPERAZINE EDISYLATE				
	HIKMA	EQ 5MG BASE/ML	A089523 001	May 03, 1988
	HOSPIRA	EQ 5MG BASE/ML	A089703 001	Apr 07, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION				
PROCHLORPERAZINE EDISYLATE				
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A089675	001	Dec 05, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A089251	001	Dec 04, 1986
TEVA PARENTERAL	EQ 5MG BASE/ML	A040505	001	May 30, 2003
WATSON LABS	EQ 5MG BASE/ML	A089530	001	Jul 08, 1987
	EQ 5MG BASE/ML	A089605	001	Jul 08, 1987
	EQ 5MG BASE/ML	A089606	001	Jul 08, 1987
WYETH AYERST	EQ 5MG BASE/ML	A086348	001	
SYRUP;ORAL				
COMPAZINE				
GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N011188	001	
PROCHLORPERAZINE EDISYLATE				
ALPHARMA US PHARMS	EQ 5MG BASE/5ML	A087154	001	Sep 01, 1982
MORTON GROVE	EQ 5MG BASE/5ML	A088597	001	Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL				
COMPAZINE				
GLAXOSMITHKLINE	EQ 10MG BASE	N011000	001	
	EQ 10MG BASE	N021019	001	Oct 06, 1999
	EQ 15MG BASE	N011000	002	
	EQ 15MG BASE	N021019	002	Oct 06, 1999
	EQ 30MG BASE	N011000	003	
	EQ 75MG BASE	N011000	004	
TABLET;ORAL				
COMPAZINE				
+ GLAXOSMITHKLINE	EQ 5MG BASE **	N010571	001	
+	EQ 10MG BASE **	N010571	002	
+	EQ 25MG BASE **	N010571	003	
PROCHLORPERAZINE				
WATSON LABS	EQ 5MG BASE	A085580	001	
	EQ 10MG BASE	A085178	001	
	EQ 25MG BASE	A085579	001	
PROCHLORPERAZINE MALEATE				
CHARTWELL RX	EQ 5MG BASE	A040101	001	Jul 19, 1996
	EQ 10MG BASE	A040101	002	Jul 19, 1996
	EQ 25MG BASE	A040101	003	Jul 19, 1996
DURAMED PHARMS BARR	EQ 5MG BASE	A040207	001	May 01, 1997
	EQ 5MG BASE	A089484	001	Jan 20, 1987
	EQ 10MG BASE	A040207	002	May 01, 1997
	EQ 10MG BASE	A089485	001	Jan 20, 1987
	EQ 25MG BASE	A089486	001	Jan 20, 1987
IVAX SUB TEVA PHARMS	EQ 5MG BASE	A040162	001	Jan 20, 1998
	EQ 10MG BASE	A040162	002	Jan 20, 1998
MYLAN	EQ 5MG BASE	A040185	002	Oct 28, 1996
	EQ 10MG BASE	A040185	001	Oct 28, 1996
TEVA PHARMS	EQ 5MG BASE	A040120	001	Jul 11, 1996
	EQ 10MG BASE	A040120	002	Jul 11, 1996

PROCYCLIDINE HYDROCHLORIDE

TABLET;ORAL				
KEMADRIN				
MONARCH PHARMS	2MG	N009818	005	
	5MG	N009818	003	

PROGESTERONE

CAPSULE;ORAL				
PROGESTERONE				
TEVA PHARMS	100MG	A202121	001	Feb 29, 2012
	200MG	A202121	002	Feb 29, 2012
PROMETRIUM				
VIRTUS	300MG	N019781	003	Oct 15, 1999
INJECTABLE;INJECTION				
PROGESTERONE				
+ ACTAVIS LABS UT INC	50MG/ML **	N017362	002	
AM REGENT	50MG/ML	A090845	001	Jun 22, 2009
LILLY	25MG/ML	N009238	002	
	50MG/ML	N009238	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROGESTERONE

INSERT, EXTENDED RELEASE;INTRAUTERINE				
PROGESTASERT				
	ALZA	38MG	N017553 001	
SYSTEM;VAGINAL				
MILPROSA				
+	FERRING PHARMS INC	1.78GM	N201110 001	Apr 29, 2020

PROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL				
SPARINE				
	WYETH AYERST	30MG/ML	N010942 001	
		100MG/ML	N010942 004	
INJECTABLE;INJECTION				
PROMAZINE HYDROCHLORIDE				
	WATSON LABS	25MG/ML	A084510 001	
		50MG/ML	A084517 001	
SPARINE				
	HIKMA	25MG/ML	N010349 008	
		50MG/ML	N010349 006	
SYRUP;ORAL				
SPARINE				
	WYETH AYERST	10MG/5ML	N010942 003	
TABLET;ORAL				
SPARINE				
	WYETH AYERST	10MG	N010348 006	
		25MG	N010348 001	
		50MG	N010348 002	
		100MG	N010348 003	
		200MG	N010348 004	

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION				
PHENERGAN				
	WYETH AYERST	25MG/ML	N008857 002	
		50MG/ML	N008857 003	
PROMETHAZINE HYDROCHLORIDE				
	ABBOTT	25MG/ML	A084223 001	
		50MG/ML	A084222 001	
	AKORN	25MG/ML	A083955 002	
		50MG/ML	A083955 001	
	AM REGENT	25MG/ML	A040515 001	Mar 19, 2003
	BEDFORD LABS	25MG/ML	A040524 001	Mar 17, 2004
		50MG/ML	A040524 002	Mar 17, 2004
	HOSPIRA	25MG/ML	A040372 001	Jun 08, 2000
		50MG/ML	A040372 002	Jun 08, 2000
		50MG/ML	A083838 002	
	MARSAM PHARMS LLC	25MG/ML	A089463 001	May 02, 1988
		50MG/ML	A089477 001	May 02, 1988
	MYLAN INSTITUTIONAL	25MG/ML	A040471 001	Nov 21, 2002
	SANDOZ	25MG/ML	A040593 001	Nov 08, 2006
		50MG/ML	A040593 002	Nov 08, 2006
	TEVA PHARMS USA	25MG/ML **	A040454 001	Aug 22, 2002
		50MG/ML **	A040454 002	Aug 22, 2002
	WATSON LABS	25MG/ML	A083532 001	
		25MG/ML	A084591 001	
		50MG/ML	A080629 002	
		50MG/ML	A083532 002	
	WOCKHARDT	25MG/ML	A040785 001	Sep 26, 2008
		50MG/ML	A040785 002	Sep 26, 2008
ZIPAN-25				
	ALTANA	25MG/ML	A083997 001	
ZIPAN-50				
	ALTANA	50MG/ML	A083997 002	
SUPPOSITORY;RECTAL				
PHENERGAN				
+	MYLAN	12.5MG **	N010926 002	
+		25MG **	N010926 001	
+		50MG **	N011689 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL				
PROMETHACON				
POLYMEDICA	25MG	A084901	001	
	50MG	A084902	001	
PROMETHAZINE HYDROCHLORIDE				
ABLE	12.5MG	A040504	001	Apr 11, 2003
	25MG	A040504	002	Apr 11, 2003
	50MG	A040449	001	Feb 27, 2003
WATSON LABS INC	12.5MG	A040479	001	Jun 24, 2003
	25MG	A040479	002	Jun 24, 2003
SYRUP;ORAL				
MYMETHAZINE FORTIS				
USL PHARMA	25MG/5ML	A087996	001	Jan 18, 1983
PROMETH FORTIS				
ALPHARMA US PHARMS	25MG/5ML	A084772	001	
PROMETH PLAIN				
ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953	001	
PROMETHAZINE				
CENCI	6.25MG/5ML	A089013	001	Sep 20, 1985
PROMETHAZINE HYDROCHLORIDE				
AMNEAL PHARMS	6.25MG/5ML	A040882	001	Dec 30, 2009
KV PHARM	6.25MG/5ML	A085388	001	
	25MG/5ML	A085385	001	
PHARM ASSOC	6.25MG/5ML	A040643	001	Apr 26, 2006
	6.25MG/5ML	A087518	001	
WHITEWORTH TOWN PLSN	6.25MG/5ML	A086395	001	
PROMETHAZINE HYDROCHLORIDE PLAIN				
+ ANI PHARMS	6.25MG/5ML **	N008381	004	Apr 18, 1984
+	25MG/5ML **	N008381	003	
TABLET;ORAL				
PHENERGAN				
+ DELCOR ASSET CORP	12.5MG **	N007935	002	
+	25MG **	N007935	003	
+	50MG **	N007935	004	
PROMETHAZINE HYDROCHLORIDE				
ABBOTT	12.5MG	A084160	001	
	25MG	A084166	001	
	50MG	A084539	001	
ABLE	12.5MG	A040558	001	Jul 01, 2004
	25MG	A040558	002	Jul 01, 2004
	50MG	A040558	003	Jul 01, 2004
AUROBINDO PHARMA USA	12.5MG	A091054	001	Aug 30, 2011
	25MG	A091054	002	Aug 30, 2011
	50MG	A091054	003	Aug 30, 2011
CHARTWELL MOLECULAR	12.5MG	A080949	001	
	25MG	A080949	002	
	50MG	A080949	003	
IMPAX LABS	12.5MG	A040791	002	Feb 12, 2008
	25MG	A040791	003	Feb 12, 2008
	25MG	A084214	002	Jul 07, 1982
	50MG	A040791	001	May 20, 2008
INVATECH	12.5MG	A084233	001	
	25MG	A085146	001	
	50MG	A085146	002	
IVAX SUB TEVA PHARMS	12.5MG	A083604	001	
	25MG	A083603	001	
	50MG	A083613	001	
PVT FORM	12.5MG	A083214	001	
	25MG	A083658	001	
SANDOZ	12.5MG	A084176	002	May 22, 2009
SUN PHARM INDS INC	12.5MG	A040863	001	Dec 30, 2008
	25MG	A040863	002	Dec 30, 2008
	50MG	A040863	003	Dec 30, 2008
SUN PHARM INDUSTRIES	12.5MG	A084555	001	
	25MG	A084554	001	
	50MG	A084557	001	
TABLICAPS	12.5MG	A084080	001	
	25MG	A084027	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROMETHAZINE HYDROCHLORIDE

TABLET;ORAL				
PROMETHAZINE HYDROCHLORIDE				
	TEVA	25MG	A089109 001	Sep 10, 1985
	WATSON LABS	12.5MG	A083401 001	
		12.5MG	A083712 001	
		12.5MG	A085986 001	
		25MG	A083204 001	
		25MG	A085684 001	
		50MG	A083403 001	
		50MG	A085664 001	
REMSED				
	BRISTOL MYERS SQUIBB	25MG	A083176 002	
		50MG	A083176 001	

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
PROPAFENONE HYDROCHLORIDE				
	MYLAN	225MG	A203803 001	Apr 29, 2016
		325MG	A203803 002	Apr 29, 2016
		425MG	A203803 003	Apr 29, 2016
RYTHMOL SR				
+	GLAXOSMITHKLINE LLC	225MG	N021416 001	Sep 04, 2003
+		325MG	N021416 002	Sep 04, 2003
+		425MG	N021416 003	Sep 04, 2003
TABLET;ORAL				
PROPAFENONE HYDROCHLORIDE				
	NESHER PHARMS	150MG	A076193 001	Feb 07, 2002
		225MG	A076193 002	Feb 07, 2002
		300MG	A076193 003	Feb 07, 2002
RYTHMOL				
+	GLAXOSMITHKLINE LLC	150MG **	N019151 001	Nov 27, 1989
+		225MG **	N019151 003	Nov 20, 1992
+		300MG **	N019151 002	Nov 27, 1989

PROPANTHELINE BROMIDE

INJECTABLE;INJECTION				
PRO-BANTHINE				
	GD SEARLE LLC	30MG/VIAL	N008843 001	
TABLET;ORAL				
PRO-BANTHINE				
+	SHIRE	7.5MG **	N008732 003	
+		15MG **	N008732 002	
PROPANTHELINE BROMIDE				
	ASCOT	15MG	A087663 001	Oct 25, 1982
	HEATHER	15MG	A085780 001	
	HIKMA	7.5MG	A080927 001	
		15MG	A080927 002	
	IMPAX LABS	15MG	A084541 002	
	MYLAN	15MG	A083706 001	
	PAR PHARM	15MG	A088377 001	Dec 08, 1983
	PVT FORM	15MG	A080977 001	
	SANDOZ	15MG	A080928 001	
	TABLICAPS	15MG	A084428 001	
	WATSON LABS	15MG	A083029 002	
		15MG	A083151 001	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
KAINAIR				
	PHARMAFAIR	0.5%	A088087 001	Jun 07, 1983
OPHTHAINE				
+	APOTHECON	0.5% **	N008883 001	
OPHTHETIC				
+	ALLERGAN	0.5% **	N012583 001	
PARACAINE				
	OPTOPICS	0.5%	A087681 001	Aug 05, 1982
PROPARACAINE HYDROCHLORIDE				
	SOLA BARNES HIND	0.5%	A084144 001	
		0.5%	A084151 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROPIOLACTONE
SOLUTION;IRRIGATION
BETAPRONE

FOREST LABS	N/A	N011657 001	

PROPIOMAZINE HYDROCHLORIDE
INJECTABLE;INJECTION
LARGON

HIKMA	20MG/ML	N012382 002	

PROPOFOL
INJECTABLE;INJECTION
DIPRIVAN

FRESENIUS KABI USA	10MG/ML	N019627 001	Oct 02, 1989

PROPOFOL

TEVA PARENTERAL	10MG/ML	A075392 001	Sep 19, 2000
WATSON LABS INC	10MG/ML	A205307 001	Dec 22, 2015

PROPOXYPHENE HYDROCHLORIDE
CAPSULE;ORAL
DARVON

XANODYNE PHARM	32MG	N010997 001	
	65MG	N010997 003	

DOLENE

HERITAGE PHARMS INC	65MG	A080530 001	

KESSO-GESIC

MK LABS	65MG	A083544 001	

PROPHENE 65

HALSEY	65MG	A083538 002	

PROPOXYPHENE HYDROCHLORIDE

ALRA	65MG	A083184 001	
IMPAX LABS	65MG	A083317 001	
IVAX SUB TEVA PHARMS	32MG	A083597 001	
MUTUAL PHARM	65MG	A083186 001	
MYLAN	32MG	A083528 001	
	65MG	A040569 001	Dec 16, 2004
	65MG	A083299 001	
NEXGEN PHARMA INC	65MG	A083185 001	
PAR PHARM	65MG	A080269 001	
PUREPAC PHARM	65MG	A083278 001	
PVT FORM	32MG	A083464 001	
	65MG	A083113 001	
ROXANE	32MG	A083089 001	
	65MG	A083089 002	
SANDOZ	32MG	A084014 001	
	65MG	A083125 002	
	65MG	A083688 001	
	65MG	A083870 002	
	65MG	A086495 001	
TEVA	65MG	A088615 001	Oct 22, 1984
VALEANT PHARM INTL	65MG	A080783 001	
VINTAGE PHARMS	65MG	A040908 001	Jul 17, 2009
WATSON LABS	65MG	A080908 002	
	65MG	A085190 001	
WEST WARD	65MG	A083501 001	
WHITEWORTH TOWN PLSN	65MG	A084551 001	

PROPOXYPHENE HYDROCHLORIDE 65

WARNER CHILCOTT	65MG	A083786 001	

PROPOXYPHENE NAPSYLATE
SUSPENSION;ORAL
DARVON-N

AAIPHARMA LLC	50MG/5ML	N016861 001	

TABLET;ORAL
DARVON-N

XANODYNE PHARM	100MG	N016862 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
PROPRANOLOL HYDROCHLORIDE					
	INWOOD LABS	60MG	A072499	001	Apr 11, 1989
		80MG	A072500	001	Apr 11, 1989
		120MG	A072501	001	Apr 11, 1989
		160MG	A072502	001	Apr 11, 1989
	MYLAN	60MG	A078022	001	Feb 15, 2007
		80MG	A078022	002	Feb 15, 2007
		120MG	A078022	003	Feb 15, 2007
		160MG	A078022	004	Feb 15, 2007
	UPSHER SMITH LABS	60MG	A078311	001	Mar 06, 2009
		80MG	A078311	002	Mar 06, 2009
		120MG	A078311	003	Mar 06, 2009
		160MG	A078311	004	Mar 06, 2009
CONCENTRATE;ORAL					
PROPRANOLOL HYDROCHLORIDE INTENSOL					
	ROXANE	80MG/ML	A071388	001	May 15, 1987
INJECTABLE;INJECTION					
PROPRANOLOL HYDROCHLORIDE					
+	BAXTER HLTHCARE CORP	1MG/ML **	N016419	001	
	CHARTWELL INJECTABLE	1MG/ML	A075792	001	Aug 29, 2000
	FOSUN PHARMA	1MG/ML	A076400	001	Feb 26, 2003
	SMITH AND NEPHEW	1MG/ML	A070135	001	Apr 15, 1986
		1MG/ML	A070137	001	Apr 15, 1986
	SOLOPAK	1MG/ML	A070136	001	Apr 15, 1986
SOLUTION;ORAL					
PROPRANOLOL HYDROCHLORIDE					
	PAI HOLDINGS PHARM	20MG/5ML	A071984	001	Mar 03, 1989
		40MG/5ML	A071985	001	Mar 03, 1989
SUSPENSION;ORAL					
INDERAL					
	WYETH AYERST	10MG/ML	N019536	001	Dec 12, 1986
TABLET;ORAL					
INDERAL					
+	WYETH PHARMS	10MG **	N016418	001	
+		20MG **	N016418	003	
+		40MG **	N016418	002	
+		60MG **	N016418	009	Oct 18, 1982
+		80MG **	N016418	004	
+		90MG **	N016418	010	Oct 18, 1982
PROPRANOLOL HYDROCHLORIDE					
	ANI PHARMS	60MG	A071791	001	Jul 15, 1987
		90MG	A071977	001	Apr 06, 1988
	CHARTWELL RX	10MG	A070663	001	Jun 13, 1986
		20MG	A070664	001	Jun 13, 1986
		40MG	A070665	001	Jun 13, 1986
		60MG	A070666	001	Oct 10, 1986
		80MG	A070667	001	Jun 13, 1986
	DAVA PHARMS INC	10MG	A070125	001	Jul 30, 1985
		20MG	A070126	001	Jul 30, 1985
		40MG	A070127	001	Jul 30, 1985
		60MG	A071495	001	Dec 31, 1987
		80MG	A070128	001	Jul 30, 1985
		90MG	A071496	001	Dec 31, 1987
	DURAMED PHARMS BARR	10MG	A070306	001	Sep 09, 1985
		20MG	A070307	001	Sep 09, 1985
		40MG	A070308	001	Sep 09, 1985
		60MG	A070309	001	Oct 01, 1986
		80MG	A070310	001	Sep 09, 1985
		90MG	A071327	001	Oct 01, 1986
	INTERPHARM	10MG	A071368	001	May 05, 1987
		20MG	A071369	001	May 05, 1987
		40MG	A071370	001	May 05, 1987
		80MG	A071371	001	May 05, 1987
	IVAX SUB TEVA PHARMS	10MG	A072063	001	Jul 29, 1988
		20MG	A072066	001	Jul 29, 1988
		40MG	A072067	001	Jul 29, 1988
		60MG	A072068	001	Jul 29, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

	80MG	A072069	001	Jul 29, 1988
LEDERLE	10MG	A072117	001	Jun 23, 1988
	20MG	A072118	001	Jun 23, 1988
	40MG	A072119	001	Jun 23, 1988
	80MG	A072120	001	Jun 23, 1988
MYLAN	60MG	A072275	001	Jun 09, 1989
PUREPAC PHARM	10MG	A070814	001	Nov 03, 1986
	20MG	A070815	001	Nov 03, 1986
	40MG	A070816	001	Nov 03, 1986
	60MG	A070817	001	Nov 03, 1986
	80MG	A070757	001	Nov 03, 1986
ROXANE	10MG	A070516	001	Jul 07, 1986
	20MG	A070517	001	Jul 07, 1986
	40MG	A070518	001	Jul 07, 1986
	60MG	A070519	001	Sep 24, 1986
	80MG	A070520	001	Jul 07, 1986
	90MG	A070521	001	Sep 24, 1986
SANDOZ	10MG	A071658	001	Jul 05, 1988
	20MG	A071687	001	Jul 05, 1988
	40MG	A071688	001	Jul 05, 1988
	60MG	A072197	001	Jul 05, 1988
	80MG	A071689	001	Jul 05, 1988
	90MG	A072198	001	Jul 05, 1988
SCHERING	10MG	A070120	001	Aug 06, 1985
	20MG	A070121	001	Aug 06, 1985
	40MG	A070122	001	Aug 06, 1985
	60MG	A070123	001	Oct 29, 1986
	80MG	A070124	001	Aug 06, 1985
STRIDES PHARMA	90MG	A071288	001	Oct 22, 1986
SUPERPHARM	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
	80MG	A071518	001	Jun 08, 1988
TEVA	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986
	80MG	A070442	001	Sep 15, 1986
WATSON LABS	10MG	A070140	001	Jul 30, 1985
	10MG	A070378	001	Mar 19, 1987
	20MG	A070141	001	Jul 30, 1985
	20MG	A070379	001	Mar 19, 1987
	40MG	A070142	001	Jul 30, 1985
	40MG	A070380	001	Mar 19, 1987
	60MG	A070143	001	Jan 15, 1987
	60MG	A070178	002	Apr 23, 2018
	60MG	A070381	001	Mar 19, 1987
	60MG	A071098	001	Oct 06, 1986
	80MG	A070144	001	Jul 30, 1985
	80MG	A070382	001	Mar 19, 1987
	80MG	A070551	001	Jul 10, 1986
	90MG	A071183	001	Oct 06, 1986
	90MG	A071792	001	Jul 15, 1987
WATSON LABS TEVA	10MG	A070548	001	Jul 10, 1986
	20MG	A070549	001	Apr 11, 1986
	40MG	A070550	001	Apr 11, 1986

PROPYLIODONE

SUSPENSION;INTRATRACHEAL

DIONOSIL AQUEOUS

GLAXOSMITHKLINE	50%	N009309	001	

DIONOSIL OILY

GLAXOSMITHKLINE	60%	N009309	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROPYLTHIOURACIL

TABLET;ORAL				
PROPYLTHIOURACIL				
	ABBOTT	50MG	A084075 001	
	ANABOLIC	50MG	A080285 001	
	ANI PHARMS	50MG	A080215 001	
	CHARTWELL MOLECULAR	50MG	A080016 001	
	CHARTWELL RX	50MG	A084543 001	
	HALSEY	50MG	A080015 001	
	IMPAX LABS	50MG	A080159 001	
	LILLY	50MG	N006213 001	
	SUN PHARM INDUSTRIES	50MG	A083982 001	
	TABLICAPS	50MG	A080840 001	
	WATSON LABS	50MG	A080932 001	
		50MG	A085201 001	

PROTAMINE SULFATE

INJECTABLE;INJECTION				
PROTAMINE SULFATE				
	HIKMA	10MG/ML	A089474 001	Nov 05, 1986
		10MG/ML	A089475 001	Nov 05, 1986
+	LILLY	10MG/ML **	N006460 002	
	PHARMACIA AND UPJOHN	50MG/VIAL	N007413 001	
		250MG/VIAL	N007413 002	Aug 02, 1984

PROTEIN HYDROLYSATE

INJECTABLE;INJECTION				
AMINOSOL 5%				
	ABBVIE	5%	N005932 012	Jan 31, 1985
HYPROTIGEN 5%				
	B BRAUN	5%	N006170 003	Jan 10, 1984

PROTIRELIN

INJECTABLE;INJECTION				
THYPINONE				
	ABBOTT	0.5MG/ML	N017638 001	
THYREL TRH				
	FERRING	0.5MG/ML	N018087 001	

PROTOKYLOL HYDROCHLORIDE

TABLET;ORAL				
VENTAIRE				
	SANOFI AVENTIS US	2MG	A083459 001	

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL				
VIVACTIL				
	CHARTWELL RX	5MG	A073644 001	Aug 24, 1995
		10MG	A073645 001	Aug 24, 1995
	TEVA WOMENS	5MG **	N016012 001	
		10MG **	N016012 002	

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
NOVAFED				
	SANOFI AVENTIS US	120MG	N017603 001	
SUDAFED 12 HOUR				
+	GLAXOSMITHKLINE	120MG **	N017941 002	
TABLET, EXTENDED RELEASE;ORAL				
SUDAFED 12 HOUR				
	MCNEIL CONS	120MG	A073585 001	Oct 31, 1991

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
ACTIFED				
	GLAXOSMITHKLINE	120MG;5MG	N018996 001	Jun 17, 1985
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES				
	KV PHARM	120MG;5MG	A071798 001	Mar 16, 1989
SYRUP;ORAL				
ACTAHIST				
	CENCI	30MG/5ML;1.25MG/5ML	A088344 001	Feb 09, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL				
HISTAFED				
	CENCI	30MG/5ML;1.25MG/5ML	A088283 001	Apr 20, 1984
MYFED				
	USL PHARMA	30MG/5ML;1.25MG/5ML	A088116 001	Mar 04, 1983
TRILITRON				
	NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	A088474 001	Feb 12, 1985
TABLET;ORAL				
ALLERFED				
	PVT FORM	60MG;2.5MG	A088860 001	Jan 31, 1985
CORPHED				
	FOSUN PHARMA	60MG;2.5MG	A088602 001	Apr 11, 1985
PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE				
	SANDOZ	60MG;2.5MG	A088193 001	May 17, 1983
TRILITRON				
	NEWTRON PHARMS	60MG;2.5MG	A088515 001	Jan 09, 1985
TRIPHED				
	TEVA	60MG;2.5MG	A088630 001	May 17, 1984
TRIPROLIDINE AND PSEUDOEPHEDRINE				
	WATSON LABS	60MG;2.5MG	A088318 002	Jan 13, 1984
	WEST WARD	60MG;2.5MG	A088117 001	Apr 19, 1983
TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
	IVAX SUB TEVA PHARMS	60MG;2.5MG	A085273 001	Dec 12, 1984
	SUPERPHARM	60MG;2.5MG	A088578 001	Feb 21, 1985
TABLET, EXTENDED RELEASE;ORAL				
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES				
	KV PHARM	120MG;5MG	A072758 001	Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL				
PSEUDO-12				
	UCB INC	EQ 60MG HYDROCHLORIDE/5ML	N019401 001	Jun 19, 1987

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
AFRINOL				
+	SCHERING PLOUGH	120MG	N018191 001	

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL				
PYRIDOSTIGMINE BROMIDE				
	ANI PHARMS	30MG	A040512 002	Jul 20, 2005
		60MG	A040512 001	Oct 08, 2003
	IMPAX LABS INC	60MG	A040457 001	Dec 26, 2002
	SOLVAY	30MG	A089572 001	Nov 27, 1990
	US ARMY	30MG	N020414 001	Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION				
HEXA-BETALIN				
	LILLY	100MG/ML	A080854 001	
PYRIDOXINE HYDROCHLORIDE				
	AKORN	100MG/ML	A087967 001	Oct 01, 1982
	BEL MAR	100MG/ML	A080761 001	
	DELL LABS	50MG/ML	A083771 001	
		100MG/ML	A083772 001	
	DR REDDYS	100MG/ML	A080572 001	
	ELKINS SINN	100MG/ML	A080581 001	
	LUITPOLD	100MG/ML	A080669 001	
	MYLAN INSTITUTIONAL	100MG/ML	A204879 001	Jul 14, 2016
	WATSON LABS	100MG/ML	A083760 001	

PYRILAMINE MALEATE

TABLET;ORAL				
PYRILAMINE MALEATE				
	IMPAX LABS	25MG	A080808 001	
	WATSON LABS	25MG	A085231 001	

PYRIMETHAMINE; SULFADOXINE
TABLET;ORAL
FANSIDAR
ROCHE 25MG;500MG N018557 001

PYRITHIONE ZINC
LOTION;TOPICAL
HEAD & SHOULDERS CONDITIONER
WARNER CHILCOTT 0.3% N019412 002 Mar 10, 1986

PYRVINIUM PAMOATE
SUSPENSION;ORAL
POVAN
PARKE DAVIS EQ 50MG BASE/5ML N011964 001
TABLET;ORAL
POVAN
PARKE DAVIS EQ 50MG BASE N012485 002

QUAZEPAM
TABLET;ORAL
DORAL
GALT PHARMS 7.5MG N018708 003 Feb 26, 1987

QUETIAPINE FUMARATE
TABLET;ORAL
QUETIAPINE FUMARATE
ACTAVIS GRP PTC EQ 25MG BASE A201762 001 Feb 27, 2013
EQ 50MG BASE A201762 002 Feb 27, 2013
EQ 100MG BASE A201762 003 Feb 27, 2013
EQ 150MG BASE A201762 004 Feb 27, 2013
EQ 200MG BASE A201762 005 Feb 27, 2013
EQ 300MG BASE A201762 006 Feb 27, 2013
EQ 400MG BASE A201762 007 Feb 27, 2013
ALEMBIC EQ 25MG BASE A203390 001 Oct 28, 2014
EQ 50MG BASE A203390 002 Oct 28, 2014
EQ 100MG BASE A203390 003 Oct 28, 2014
EQ 200MG BASE A203390 004 Oct 28, 2014
EQ 300MG BASE A203390 005 Oct 28, 2014
EQ 400MG BASE A203390 006 Oct 28, 2014
JUBILANT GENERICS EQ 25MG BASE A203150 001 Nov 26, 2013
MYLAN PHARMS INC EQ 25MG BASE A090323 001 Mar 27, 2012
TORRENT PHARMS LTD EQ 25MG BASE A200363 001 Mar 27, 2012
EQ 50MG BASE A200363 002 Mar 27, 2012
EQ 100MG BASE A200363 003 Mar 27, 2012
EQ 200MG BASE A200363 004 Mar 27, 2012
EQ 300MG BASE A200363 005 Mar 27, 2012
EQ 400MG BASE A200363 006 Mar 27, 2012
SEROQUEL
\+ ASTRAZENECA EQ 150MG BASE ** N020639 004 Dec 20, 1998
TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE
AMNEAL PHARMS EQ 400MG BASE A211405 001 Oct 26, 2018
ANCHEN PHARMS EQ 150MG BASE A090757 001 Dec 01, 2017
EQ 200MG BASE A090757 002 Dec 01, 2017
EQ 300MG BASE A090757 003 Dec 01, 2017
EQ 400MG BASE A090757 004 Dec 01, 2017
RISING EQ 50MG BASE A202228 001 Feb 02, 2021
EQ 150MG BASE A202228 002 Feb 02, 2021
EQ 200MG BASE A202228 003 Feb 02, 2021
EQ 300MG BASE A202228 004 Feb 02, 2021
EQ 400MG BASE A202228 005 Feb 02, 2021

QUINAPRIL HYDROCHLORIDE
TABLET;ORAL
ACCUPRIL
\+ PFIZER PHARMS EQ 5MG BASE N019885 001 Nov 19, 1991
\+ EQ 10MG BASE N019885 002 Nov 19, 1991
\+ EQ 20MG BASE N019885 003 Nov 19, 1991
\+ EQ 40MG BASE N019885 004 Nov 19, 1991
QUINAPRIL HYDROCHLORIDE
ACTAVIS ELIZABETH EQ 5MG BASE A076459 001 Dec 22, 2004
EQ 10MG BASE A076459 002 Dec 22, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL				
QUINAPRIL HYDROCHLORIDE				
	EQ 20MG BASE	A076459	003	Dec 22, 2004
	EQ 40MG BASE	A076459	004	Dec 22, 2004
ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005
	EQ 10MG BASE	A076049	002	Jan 14, 2005
	EQ 20MG BASE	A076049	003	Jan 14, 2005
	EQ 40MG BASE	A076049	004	Jan 14, 2005
ANI PHARMS	EQ 5MG BASE	A075504	001	Aug 24, 2007
	EQ 10MG BASE	A075504	002	Aug 24, 2007
	EQ 20MG BASE	A075504	003	Aug 24, 2007
	EQ 40MG BASE	A075504	004	Aug 24, 2007
APOTEX INC	EQ 5MG BASE	A076240	001	Jan 26, 2006
	EQ 10MG BASE	A076240	002	Jan 26, 2006
	EQ 20MG BASE	A076240	003	Jan 26, 2006
	EQ 40MG BASE	A076240	004	Jan 26, 2006
CHARTWELL RX	EQ 5MG BASE	A076803	001	Mar 02, 2005
	EQ 10MG BASE	A076803	002	Mar 02, 2005
	EQ 20MG BASE	A076803	003	Mar 02, 2005
	EQ 40MG BASE	A076803	004	Mar 02, 2005
MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005
	EQ 5MG BASE	A076694	001	Dec 23, 2004
	EQ 10MG BASE	A076036	002	Jan 28, 2005
	EQ 10MG BASE	A076694	002	Dec 23, 2004
	EQ 20MG BASE	A076036	003	Jan 28, 2005
	EQ 20MG BASE	A076694	003	Dec 23, 2004
	EQ 40MG BASE	A076036	004	Jan 28, 2005
	EQ 40MG BASE	A076694	004	Dec 23, 2004
SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004
	EQ 5MG BASE	A090800	001	Jun 18, 2009
	EQ 10MG BASE	A076607	002	Dec 15, 2004
	EQ 10MG BASE	A090800	002	Jun 18, 2009
	EQ 20MG BASE	A076607	003	Dec 15, 2004
	EQ 20MG BASE	A090800	003	Jun 18, 2009
	EQ 40MG BASE	A076607	004	Dec 15, 2004
	EQ 40MG BASE	A090800	004	Jun 18, 2009

QUINESTROL

TABLET;ORAL				
ESTROVIS				
PARKE DAVIS	0.1MG	N016768	002	
	0.2MG	N016768	003	

QUINETHAZONE

TABLET;ORAL				
HYDROMOX				
LEDERLE	50MG	N013264	001	

QUINETHAZONE; RESERPINE

TABLET;ORAL				
HYDROMOX R				
LEDERLE	50MG;0.125MG	N013927	001	

QUINIDINE GLUCONATE

INJECTABLE;INJECTION				
QUINIDINE GLUCONATE				
+ LILLY	80MG/ML	N007529	002	Feb 10, 1989
TABLET;ORAL				
QUINACT				
BAYER HLTHCARE	266MG	A085978	001	
	400MG	A086099	001	
TABLET, EXTENDED RELEASE;ORAL				
DURAQUIN				
WARNER CHILCOTT	330MG	N017917	001	
QUINAGLUTE				
+ BAYER HLTHCARE	324MG **	N016647	001	
QUINALAN				
CHARTWELL MOLECULAR	324MG	A088081	001	Feb 10, 1986
QUINATIME				
WATSON LABS	324MG	A087448	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

QUINIDINE GLUCONATE				
TABLET, EXTENDED RELEASE;ORAL				
QUINIDINE GLUCONATE				
ANI PHARMS	324MG		A087810 001	Sep 29, 1982
ASCOT	324MG		A088582 001	Jun 17, 1985
CYCLE	324MG		A088431 001	Jan 06, 1984
HALSEY	324MG		A089476 001	Apr 10, 1987
RISING	324MG		A089894 001	Dec 15, 1988
SUPERPHARM	324MG		A089164 001	Nov 21, 1985
WATSON LABS	324MG		A087785 001	Jan 24, 1983
QUINIDINE POLYGALACTURONATE				
TABLET;ORAL				
CARDIOQUIN				
PHARM RES ASSOC	275MG		N011642 002	
QUINIDINE SULFATE				
CAPSULE;ORAL				
CIN-QUIN				
SOLVAY	200MG		A085296 001	
	300MG		A085297 001	
QUINIDINE SULFATE				
LILLY	200MG		A085103 001	
TABLET;ORAL				
CIN-QUIN				
+ SOLVAY	100MG		A085299 001	
+	200MG		A084932 001	
	300MG		A085298 001	
QUINIDINE SULFATE				
BARR	200MG		A084177 001	
CHARTWELL MOLECULAR	200MG		A083743 001	
CONTRACT PHARMACAL	200MG		A083808 001	
CYCLE	200MG		A083640 001	
	300MG		A085632 001	
DAVA PHARMS INC	200MG		A087011 001	
ELKINS SINN	200MG		A083622 001	
EVERYLIFE	200MG		A083439 001	
HALSEY	200MG		A083583 001	
HIKMA	200MG		A083862 001	
IMPAX LABS	200MG		A083347 001	
IVAX SUB TEVA PHARMS	200MG		A084549 001	
KING PHARMS	200MG		A085175 001	
KV PHARM	200MG		A085276 001	
LEDERLE	200MG		A086176 001	
LILLY	200MG		A085038 001	
PERRIGO	200MG		A085322 001	
PHARMAVITE	200MG		A084627 001	
PUREPAC PHARM	200MG		A084003 001	
SANDOZ	200MG		A084631 001	
	200MG		A084914 001	
	300MG		A089839 001	Sep 29, 1988
SCHERER LABS	200MG		A085068 001	
SUN PHARM INDUSTRIES	100MG		A081029 001	Apr 14, 1989
	200MG		A081030 001	Apr 14, 1989
	300MG		A081031 001	Apr 14, 1989
SUPERPHARM	200MG		A088973 001	Apr 10, 1985
USL PHARMA	200MG		A087837 001	Apr 14, 1982
VALEANT PHARM INTL	200MG		A083393 001	
VANGARD	200MG		A087909 001	Jul 13, 1982
VINTAGE PHARMS	200MG		A083963 001	
WARNER CHILCOTT	200MG		A083879 001	
WATSON LABS	100MG		A085584 001	
	200MG		A083288 001	
	200MG		A085140 002	
	300MG		A085583 001	
WHITEWORTH TOWN PLSN	200MG		A085444 001	
QUINORA				
KEY PHARMS	200MG		A083576 001	
+ SCHERING	300MG		A085222 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

QUINIDINE SULFATE				
TABLET, EXTENDED RELEASE;ORAL				
QUINIDEX				
	WYETH PHARMS INC	300MG	N012796 002	
QUINIDINE SULFATE				
	COSETTE	300MG	A040045 001	Jun 30, 1994
QUININE SULFATE				
CAPSULE;ORAL				
QUININE SULFATE				
	AURORBINDO PHARMA USA	324MG	A202581 001	Dec 14, 2012
RABEPRAZOLE SODIUM				
CAPSULE, DELAYED RELEASE;ORAL				
ACIPHEX SPRINKLE				
+	AYTU	5MG	N204736 001	Mar 26, 2013
+		10MG	N204736 002	Mar 26, 2013
TABLET, DELAYED RELEASE;ORAL				
ACIPHEX				
+	WOODWARD	10MG **	N020973 001	May 29, 2002
RABEPRAZOLE SODIUM				
	MYLAN	20MG	A076885 001	Nov 08, 2013
	TEVA PHARMS USA	20MG	A076822 001	Nov 08, 2013
RAMIPRIL				
CAPSULE;ORAL				
RAMIPRIL				
	ACTAVIS ELIZABETH	1.25MG	A077513 001	Jun 18, 2008
		2.5MG	A077513 002	Jun 18, 2008
		5MG	A077513 003	Jun 18, 2008
		10MG	A077513 004	Jun 18, 2008
	CHARTWELL RX	1.25MG	A077514 001	Jun 18, 2008
		2.5MG	A077514 002	Jun 18, 2008
		5MG	A077514 003	Jun 18, 2008
		10MG	A077514 004	Jun 18, 2008
	CIPLA	1.25MG	A077004 001	Aug 07, 2008
		2.5MG	A077004 002	Aug 07, 2008
		5MG	A077004 003	Aug 07, 2008
		10MG	A077004 004	Aug 07, 2008
	RANBAXY LABS LTD	5MG	A078849 001	Mar 06, 2009
		10MG	A078849 002	Mar 06, 2009
	TEVA PHARMS	1.25MG	A077470 001	Jun 18, 2008
		2.5MG	A077470 002	Jun 18, 2008
		5MG	A077470 003	Jun 18, 2008
		10MG	A077470 004	Jun 18, 2008
	WATSON LABS	5MG	A076549 003	Oct 24, 2005
TABLET;ORAL				
ALTACE				
+	KING PFIZER	1.25MG **	N022021 001	Feb 27, 2007
+		2.5MG **	N022021 002	Feb 27, 2007
+		5MG **	N022021 003	Feb 27, 2007
+		10MG **	N022021 004	Feb 27, 2007
RAMIPRIL				
	APOTEX	1.25MG	A091069 001	Dec 02, 2015
		2.5MG	A091069 002	Dec 02, 2015
		5MG	A091069 003	Dec 02, 2015
		10MG	A091069 004	Dec 02, 2015
	MYLAN PHARMS INC	1.25MG	A090650 001	Jun 30, 2011
		2.5MG	A090650 002	Jun 30, 2011
		5MG	A090650 003	Jun 30, 2011
		10MG	A090650 004	Jun 30, 2011
	ZYDUS PHARMS USA INC	1.25MG	A090697 001	Sep 24, 2009
		2.5MG	A090697 002	Sep 24, 2009
		5MG	A090697 003	Sep 24, 2009
		10MG	A090697 004	Sep 24, 2009

RANITIDINE BISMUTH CITRATE

TABLET;ORAL

TRITEC

GLAXOSMITHKLINE	400MG	N020559	001	Aug 08, 1996

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

AJANTA PHARMA LTD	EQ 150MG BASE	A209859	001	Sep 27, 2018
	EQ 300MG BASE	A209859	002	Sep 27, 2018
APPCO	EQ 150MG BASE	A211893	001	Apr 05, 2019
	EQ 300MG BASE	A211893	002	Apr 05, 2019
AUROBINDO PHARMA	EQ 150MG BASE	A211058	001	Jul 16, 2018
	EQ 300MG BASE	A211058	002	Jul 16, 2018
MYLAN	EQ 150MG BASE	A075564	001	Oct 27, 2000
	EQ 300MG BASE	A075564	002	Oct 27, 2000
NOVITIUM PHARMA	EQ 150MG BASE	A210681	001	Nov 23, 2018
	EQ 300MG BASE	A210681	002	Nov 23, 2018
TEVA	EQ 150MG BASE	A075557	001	Oct 31, 2003
	EQ 300MG BASE	A075557	002	Oct 31, 2003

ZANTAC 150

+ GLAXOSMITHKLINE	EQ 150MG BASE **	N020095	001	Mar 08, 1994

ZANTAC 300

+ GLAXOSMITHKLINE	EQ 300MG BASE **	N020095	002	Mar 08, 1994

GRANULE, EFFERVESCENT;ORAL

ZANTAC 150

GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251	002	Mar 31, 1994

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

BEDFORD	EQ 25MG BASE/ML	A074764	001	Nov 19, 2004
HIKMA	EQ 25MG BASE/ML	A074777	001	Mar 02, 2005
	EQ 25MG BASE/ML	A077458	001	Feb 16, 2006
MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016
ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013

ZANTAC

+ PAI HOLDINGS PHARM	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984

ZANTAC IN PLASTIC CONTAINER

PAI HOLDINGS PHARM	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991
	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 15MG BASE/ML	A076124	001	Feb 21, 2007
AMNEAL PHARMS	EQ 15MG BASE/ML	A078312	001	Sep 02, 2008
APOTEX INC	EQ 15MG BASE/ML	A077602	001	Sep 17, 2007
AUROBINDO PHARMA	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010
EPIC PHARMA LLC	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011
LANNETT CO INC	EQ 15MG BASE/ML	A078890	001	Jul 01, 2010
NOSTRUM LABS INC	EQ 15MG BASE/ML	A078684	001	Aug 27, 2009
	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011
RANBAXY	EQ 15MG BASE/ML	A078448	001	Dec 13, 2007
TARO	EQ 15MG BASE/ML	A077476	001	Jun 13, 2011
TOLMAR	EQ 15MG BASE/ML	A090054	001	Nov 15, 2010
TORRENT	EQ 15MG BASE/ML	A090102	001	May 26, 2009
WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009
	EQ 15MG BASE/ML	A079212	001	Feb 23, 2009

ZANTAC

+ GLAXO GRP LTD	EQ 15MG BASE/ML	N019675	001	Dec 30, 1988

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AMNEAL PHARMS NY	EQ 150MG BASE	A077824	001	Oct 13, 2006
	EQ 300MG BASE	A077824	002	Oct 13, 2006
ANI PHARMS	EQ 75MG BASE	A075212	001	Jan 14, 2000
	EQ 75MG BASE	A075296	001	Jan 14, 2000
	EQ 150MG BASE	A074488	001	Jul 31, 1997
	EQ 150MG BASE	A077426	001	Dec 19, 2005
	EQ 300MG BASE	A074488	002	Jul 31, 1997
	EQ 300MG BASE	A077426	002	Dec 19, 2005
APOTEX	EQ 75MG BASE	A075167	001	May 04, 2000
APOTEX INC	EQ 150MG BASE	A200172	001	May 31, 2012
AUROBINDO PHARMA	EQ 75MG BASE	A207579	001	Nov 13, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RANITIDINE HYDROCHLORIDE

TABLET;ORAL					
RANITIDINE HYDROCHLORIDE					
		EQ 150MG BASE	A207578	001	Nov 13, 2017
	BOEHRINGER INGELHEIM	EQ 150MG BASE	A074662	001	Aug 29, 1997
		EQ 300MG BASE	A074662	002	Aug 29, 1997
	CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999
	GRANULES	EQ 150MG BASE	A210243	001	Aug 20, 2018
		EQ 150MG BASE	A210243	002	Aug 20, 2018
	HERITAGE PHARMA AVET	EQ 150MG BASE	A075165	001	Sep 30, 1998
		EQ 300MG BASE	A075165	002	Sep 30, 1998
	MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000
		EQ 150MG BASE	A074023	001	Aug 22, 1997
		EQ 150MG BASE	A074552	001	Jul 30, 1998
		EQ 300MG BASE	A074023	002	Aug 22, 1997
		EQ 300MG BASE	A074552	002	Jul 30, 1998
	NOSTRUM LABS INC	EQ 150MG BASE	A203694	001	Nov 30, 2017
		EQ 300MG BASE	A203694	002	Nov 30, 2017
	PERRIGO	EQ 75MG BASE	A076195	001	Aug 30, 2002
	PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011
		EQ 150MG BASE	A091429	002	May 11, 2011
	RANBAXY	EQ 75MG BASE	A075254	001	Jan 14, 2000
		EQ 150MG BASE	A075000	001	Jan 30, 1998
		EQ 300MG BASE	A075000	002	Jan 30, 1998
	SANDOZ	EQ 75MG BASE	A075519	001	Sep 26, 2002
	STRIDES PHARMA	EQ 75MG BASE	A201745	001	Feb 29, 2012
		EQ 75MG BASE	A209160	001	Mar 05, 2018
		EQ 150MG BASE	A200536	001	Jun 28, 2011
		EQ 150MG BASE	A205512	001	Aug 22, 2016
		EQ 150MG BASE	A209161	001	Feb 22, 2018
		EQ 150MG BASE	A210010	001	Aug 01, 2018
		EQ 300MG BASE	A205512	002	Aug 22, 2016
		EQ 300MG BASE	A210010	002	Aug 01, 2018
	SUN PHARM INDS LTD	EQ 75MG BASE	A075132	001	Jan 14, 2000
		EQ 150MG BASE	A075439	001	Apr 19, 2000
		EQ 300MG BASE	A075439	002	Apr 19, 2000
	THINQ PHARM-CRO PVT	EQ 150MG BASE	A210228	001	Aug 30, 2019
	WATSON LABS	EQ 150MG BASE	A074864	001	Oct 20, 1997
		EQ 300MG BASE	A074864	002	Oct 20, 1997
	WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006
		EQ 75MG BASE	A078884	001	Jul 31, 2008
		EQ 150MG BASE	A078653	001	Nov 26, 2007
		EQ 150MG BASE	A078701	001	Nov 12, 2009
		EQ 300MG BASE	A078701	002	Dec 11, 2009
	WOCKHARDT LTD	EQ 150MG BASE	A075208	001	Dec 17, 1998
		EQ 300MG BASE	A075208	002	Dec 17, 1998
ZANTAC 150					
+	CHATTEM SANOFI	EQ 150MG BASE	N021698	001	Aug 31, 2004
+		EQ 150MG BASE	N021698	002	Mar 13, 2007
+	GLAXO GRP LTD	EQ 150MG BASE **	N018703	001	Jun 09, 1983
ZANTAC 300					
+	GLAXO GRP LTD	EQ 300MG BASE **	N018703	002	Dec 09, 1985
ZANTAC 75					
+	CHATTEM SANOFI	EQ 75MG BASE	N020520	001	Dec 19, 1995
TABLET, EFFERVESCENT;ORAL					
ZANTAC 150					
	GLAXO GRP LTD	EQ 150MG BASE	N020251	001	Mar 31, 1994
ZANTAC 25					
	GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004
ZANTAC 75					
+	CHATTEM SANOFI	EQ 75MG BASE **	N020745	001	Feb 26, 1998

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL					
RANEXA					
+	MENARINI INTL	500MG	N021526	002	Jan 27, 2006
+		1GM	N021526	001	Feb 12, 2007
RANOLAZINE					
	ACCORD HLTHCARE	500MG	A212930	001	May 18, 2021
		1GM	A212930	002	May 18, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RANOLAZINE
TABLET, EXTENDED RELEASE;ORAL
RANOLAZINE

AMNEAL	500MG	A207690	001	Mar 11, 2021
	1GM	A207690	002	Mar 11, 2021
ANI PHARMS	500MG	A210482	001	Oct 29, 2019
	1GM	A210482	002	Oct 29, 2019
CIPLA	500MG	A211291	001	May 28, 2019
	1GM	A211291	002	May 28, 2019

RAPACURONIUM BROMIDE
INJECTABLE;INJECTION
RAPLON

ORGANON USA INC	100MG/VIAL	N020984	001	Aug 18, 1999
	200MG/VIAL	N020984	002	Aug 18, 1999

RASAGILINE MESYLATE
TABLET;ORAL
RASAGILINE MESYLATE

APOTEX INC	EQ 0.5MG BASE	A201950	001	Sep 12, 2013
	EQ 1MG BASE	A201950	002	Sep 12, 2013
CARNEGIE	EQ 0.5MG BASE	A201942	001	Nov 18, 2021
	EQ 1MG BASE	A201942	002	Nov 18, 2021
WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013
	EQ 1MG BASE	A201823	002	Jul 01, 2013

RAUWOLFIA SERPENTINA ROOT
TABLET;ORAL
HIWOLFIA

BOWMAN PHARMS	50MG	N009276	003
	50MG	N009276	005
	100MG	N009276	004

HYSERPIN

PHYS PRODS VA	50MG	N010581	001

KOGLUCOID

PANRAY	50MG	N009278	001
	100MG	N009278	002

RAUDIXIN

APOTHECON	50MG	N008842	001
	100MG	N008842	002

RAUSERPIN

FERNDALE LABS	50MG	N009926	002
	100MG	N009926	004

RAUVAL

PAL PAK	50MG	N009108	002
	100MG	N009108	004

RAUWOLFIA SERPENTINA

BUNDY	50MG	N009477	001
	100MG	N009477	002
HALSEY	50MG	A080498	001
	100MG	A080498	002
IMPAX LABS	50MG	N009273	001
	100MG	N009273	002
IVAX SUB TEVA PHARMS	50MG	N011521	001
	100MG	N011521	002
PUREPAC PHARM	50MG	A080842	001
	100MG	A080842	002
PVT FORM	50MG	A080583	001
	100MG	A080583	002
SOLVAY	50MG	A080500	001
	100MG	A080500	002
TABLICAPS	50MG	A083867	001
	100MG	A083444	001
VALEANT PHARM INTL	50MG	N009668	001
	100MG	N009668	002
WATSON LABS	50MG	A080907	001
	100MG	A080914	001

WOLFINA

FOREST PHARMS	50MG	N009255	008
	100MG	N009255	006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

REPAGLINIDE				
TABLET;ORAL				
PRANDIN				
+	GEMINI LABS LLC	0.5MG **	N020741 001	Dec 22, 1997
+		1MG **	N020741 002	Dec 22, 1997
+		2MG **	N020741 003	Dec 22, 1997
REPAGLINIDE				
	ACTAVIS TOTOWA	0.5MG	A090008 001	Jan 22, 2014
		1MG	A090008 002	Jan 22, 2014
		2MG	A090008 003	Jan 22, 2014
	KENTON	0.5MG	A091517 001	Apr 24, 2015
		1MG	A091517 002	Apr 24, 2015
		2MG	A091517 003	Apr 24, 2015
	MYLAN	0.5MG	A090252 001	Aug 23, 2013
		1MG	A090252 002	Jan 22, 2014
		2MG	A090252 003	Jan 22, 2014
RESCINNAMINE				
CAPSULE;ORAL				
CINNASIL				
	PANRAY	0.5MG	A084736 001	
TABLET;ORAL				
MODERIL				
	PFIZER	0.25MG	N010686 003	
		0.5MG	N010686 006	
RESERPINE				
ELIXIR;ORAL				
SERPASIL				
	NOVARTIS	0.2MG/4ML	N009115 005	
INJECTABLE;INJECTION				
SANDRIL				
	LILLY	2.5MG/ML	N010012 001	
SERPASIL				
	NOVARTIS	2.5MG/ML	N009434 002	
TABLET;ORAL				
HISERPIA				
	BOWMAN PHARMS	0.1MG	N009631 002	
		0.25MG	N009631 004	
RAU-SED				
	BRISTOL MYERS SQUIBB	0.1MG	N009357 001	
		0.25MG	N009357 004	
		0.5MG	N009357 006	
		1MG	N009357 008	
RESERPINE				
	BARR	0.25MG	A080721 002	
	BELL PHARMA	0.1MG	A083058 001	
		0.25MG	A083058 002	
	BUNDY	0.1MG	N009663 001	
		0.25MG	N009663 003	
	CYCLE	0.1MG	N009859 001	
		0.25MG	N009859 002	
	ELKINS SINN	0.1MG	A083145 001	
		0.25MG	A083145 002	
	EVERYLIFE	0.1MG	N010441 001	
		0.25MG	N010441 002	
		0.5MG	N010441 003	
		1MG	N010441 004	
	HALSEY	0.1MG	A080457 002	
		0.25MG	A080457 001	
		1MG	A080457 003	
	HIKMA INTL PHARMS	0.1MG	A080975 001	
		0.25MG	A080975 002	
		1MG	A080975 003	
	IMPAX LABS	0.1MG	N009627 001	
		0.25MG	N009627 002	
	IVAX SUB TEVA PHARMS	0.1MG	N011185 001	
		0.25MG	N011185 002	
	MARSHALL PHARMA	0.1MG	A080492 001	
		0.25MG	A080492 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RESERPINE

TABLET;ORAL

RESERPINE					
	MK LABS	0.1MG	A080525	002	
		0.25MG	A080525	001	
	MYLAN	1MG	A084974	001	
	PHARMAVITE	0.25MG	A084663	001	
	PUREPAC PHARM	0.1MG	A080753	002	
		0.25MG	A080753	001	
	PVT FORM	0.1MG	A086117	001	
		0.25MG	A080582	001	
		0.25MG	A085775	001	
		1MG	A080582	002	
	REXALL	0.25MG	A080637	001	
+	SANDOZ	0.1MG	N009838	001	
+		0.25MG	N009838	002	
	SOLVAY	0.25MG	A080446	001	
	TABLICAPS	0.25MG	A085207	001	
	TEVA	0.1MG	A089020	001	Mar 07, 1985
		0.25MG	A089019	001	Mar 07, 1985
	VALEANT PHARM INTL	0.1MG	N009667	001	
		0.25MG	N009667	002	
	WATSON LABS	0.1MG	A080679	001	
		0.25MG	A080393	001	
		0.25MG	A085401	001	
		1MG	A080749	001	
	WHITEWORTH TOWN PLSN	0.1MG	A080723	001	
		0.25MG	A080723	002	
		1MG	A080723	003	
SANDRIL					
	LILLY	0.1MG	N009376	004	
		0.25MG	N009376	001	
SERPALAN					
	LANNETT	0.1MG	N010124	001	
		0.25MG	N010124	002	
SERPANRAY					
	PANRAY	0.1MG	N009391	001	
		0.25MG	N009391	002	
		1MG	N009391	004	
SERPASIL					
	NOVARTIS	0.1MG	N009115	001	
		0.25MG	N009115	003	
		1MG	N009115	004	
SERPATE					
	VALE	0.1MG	N009453	001	
		0.25MG	N009453	002	
SERPIVITE					
	VITARINE	0.25MG	N009645	002	

RESERPINE; TRICHLORMETHIAZIDE

TABLET;ORAL

METATENSIN #2					
	SANOFI AVENTIS US	0.1MG;2MG	N012972	001	
METATENSIN #4					
	SANOFI AVENTIS US	0.1MG;4MG	N012972	002	
NAQUIVAL					
	SCHERING	0.1MG;4MG	N012265	003	
TRICHLORMETHIAZIDE W/ RESERPINE					
	WATSON LABS	0.1MG;4MG	A085248	001	

RIBAVIRIN

CAPSULE;ORAL

REBETOL					
	MERCK SHARP DOHME	200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy**	N020903	001	Jun 03, 1998
+		200MG **	N020903	002	Jul 25, 2001
RIBASPHERE					
	CHARTWELL RX	200MG	A076203	001	Apr 06, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RIBAVIRIN

CAPSULE;ORAL				
RIBAVIRIN				
	CHARTWELL RX	200MG	A076192 001	Apr 06, 2004
	TEVA	200MG	A076277 001	Oct 04, 2004
SOLUTION;ORAL				
REBETOL				
+	SCHERING	40MG/ML	N021546 001	Jul 29, 2003
TABLET;ORAL				
COPEGUS				
+	ROCHE	200MG **	N021511 001	Dec 03, 2002
+		400MG **	N021511 002	Jun 21, 2005
RIBAVIRIN				
	BEXIMCO PHARMS USA	200MG	A202546 001	Aug 12, 2014
		400MG	A202546 002	Aug 12, 2014
		500MG	A202546 003	Aug 12, 2014
		600MG	A202546 004	Aug 12, 2014
	CHARTWELL RX	200MG	A077456 001	Dec 05, 2005
		400MG	A077456 002	Dec 05, 2005
		600MG	A077456 003	Dec 05, 2005
	HERITAGE PHARMA AVET	200MG	A077053 001	Dec 05, 2005
	ZYDUS PHARMS USA	400MG	A077094 002	Mar 16, 2007
		500MG	A077094 004	Apr 18, 2008
		600MG	A077094 003	Mar 16, 2007

RIFAMPIN

CAPSULE;ORAL				
RIFADIN				
	SANOFI AVENTIS US	150MG	A062303 001	
+		300MG	N050420 001	
INJECTABLE;INJECTION				
RIFAMPIN				
	AVET LIFESCIENCES	600MG/VIAL	A204101 001	Aug 18, 2014
	WATSON PHARMS TEVA	600MG/VIAL	A206736 001	Jan 19, 2016

RILUZOLE

TABLET;ORAL				
RILUZOLE				
	APOTEX CORP	50MG	A091300 001	Jun 18, 2013
	DAITO PHARMS CO LTD	50MG	A204430 001	Oct 16, 2018

RIMANTADINE HYDROCHLORIDE

SYRUP;ORAL				
FLUMADINE				
	FOREST LABS	50MG/5ML	N019650 001	Sep 17, 1993
TABLET;ORAL				
FLUMADINE				
+	SUN PHARM INDS INC	100MG	N019649 001	Sep 17, 1993
RIMANTADINE HYDROCHLORIDE				
	CHARTWELL RX	100MG	A076375 001	Jan 14, 2003
	IMPAX LABS INC	100MG	A075916 001	Nov 02, 2001

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC				
VEXOL				
	HARROW EYE	1%	N020474 001	Dec 30, 1994

RISEDRONATE SODIUM

TABLET;ORAL				
ACTONEL				
+	APIL	5MG	N020835 002	Apr 14, 2000
+		30MG	N020835 001	Mar 27, 1998
+		75MG **	N020835 004	Apr 16, 2007
RISEDRONATE SODIUM				
	HANGZHOU BINJIANG	35MG	A207516 001	Feb 15, 2019
	MYLAN	5MG	A200477 001	Nov 30, 2015
		30MG	A200477 002	Nov 30, 2015
		35MG	A200477 003	Nov 30, 2015
		75MG	A200477 004	Jun 10, 2014
		150MG	A200477 005	Jun 10, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RISEDRONATE SODIUM				
TABLET, DELAYED RELEASE;ORAL				
RISEDRONATE SODIUM				
IMPAX LABS INC	35MG	A205066	001	Jun 29, 2018
ZYDUS PHARMS	35MG	A203822	001	Sep 11, 2018
RISPERIDONE				
SOLUTION;ORAL				
RISPERIDONE				
ANI PHARMS	1MG/ML	A076440	001	Jan 30, 2009
APOZEAL PHARMS	1MG/ML	A078909	001	Jul 29, 2009
PRECISION DOSE	1MG/ML	A076797	001	Jun 28, 2010
WOCKHARDT	1MG/ML	A078744	001	Oct 08, 2009
TABLET;ORAL				
RISPERDAL				
JANSSEN PHARMS	5MG	N020272	005	Dec 29, 1993
RISPERIDONE				
DASH PHARMS	0.25MG	A076288	001	Sep 15, 2008
	0.5MG	A076288	002	Sep 15, 2008
	1MG	A076288	003	Sep 15, 2008
	2MG	A076288	004	Sep 15, 2008
	3MG	A076288	005	Sep 15, 2008
	4MG	A076288	006	Sep 15, 2008
HERITAGE PHARMA AVET	0.25MG	A076228	001	Jun 30, 2008
	0.25MG	A077769	001	Oct 16, 2008
	0.5MG	A076228	002	Jun 30, 2008
	0.5MG	A077769	002	Oct 16, 2008
	1MG	A076228	003	Jun 30, 2008
	1MG	A077769	003	Oct 16, 2008
	2MG	A076228	004	Jun 30, 2008
	2MG	A077769	004	Oct 16, 2008
	3MG	A076228	005	Jun 30, 2008
	3MG	A077769	005	Oct 16, 2008
	4MG	A076228	006	Jun 30, 2008
	4MG	A077769	006	Oct 16, 2008
JUBILANT CADISTA	0.25MG	A078828	001	Mar 23, 2009
	0.5MG	A078828	002	Mar 23, 2009
	1MG	A078828	003	Mar 23, 2009
	2MG	A078828	004	Mar 23, 2009
	3MG	A078828	005	Mar 23, 2009
	4MG	A078828	006	Mar 23, 2009
RATIOPHARM	0.25MG	A077784	001	Jun 08, 2010
	0.5MG	A077784	002	Jun 08, 2010
	1MG	A077784	003	Jun 08, 2010
	2MG	A077784	004	Jun 08, 2010
	3MG	A077784	005	Jun 08, 2010
	4MG	A077784	006	Jun 08, 2010
SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014
	0.5MG	A078036	002	Mar 10, 2014
	1MG	A078036	003	Mar 10, 2014
	2MG	A078036	004	Mar 10, 2014
	3MG	A078036	005	Mar 10, 2014
	4MG	A078036	006	Mar 10, 2014
SYNTHON PHARMS	0.25MG	A078187	001	Oct 22, 2009
	0.5MG	A078187	002	Oct 22, 2009
	1MG	A078187	003	Oct 22, 2009
	2MG	A078187	004	Oct 22, 2009
	3MG	A078187	005	Oct 22, 2009
	4MG	A078187	006	Oct 22, 2009
WATSON LABS	0.25MG	A077860	001	Dec 05, 2008
	0.5MG	A077860	002	Dec 05, 2008
	1MG	A077860	003	Dec 05, 2008
	2MG	A077860	004	Dec 05, 2008
	3MG	A077860	005	Dec 05, 2008
	4MG	A077860	006	Dec 05, 2008
WEST WARD PHARMS	0.25MG	A078740	001	May 29, 2009
	0.5MG	A078740	002	May 29, 2009
	1MG	A078740	003	May 29, 2009
	2MG	A078740	004	May 29, 2009
	3MG	A078740	005	May 29, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RISPERIDONE

TABLET;ORAL					
RISPERIDONE					
		4MG	A078740	006	May 29, 2009
TABLET, ORALLY DISINTEGRATING;ORAL					
RISPERDAL					
+	JANSSEN PHARMS	0.5MG **	N021444	001	Apr 02, 2003
+		1MG **	N021444	002	Apr 02, 2003
+		2MG **	N021444	003	Apr 02, 2003
+		3MG **	N021444	004	Dec 23, 2004
+		4MG **	N021444	005	Dec 23, 2004
RISPERIDONE					
	ACTAVIS LABS FL INC	0.5MG	A076996	001	Apr 19, 2011
		1MG	A076996	002	Apr 19, 2011
		2MG	A076996	003	Apr 19, 2011
		3MG	A076996	004	Apr 19, 2011
		4MG	A076996	005	Apr 19, 2011
	CHARTWELL RX	0.5MG	A076908	001	Mar 12, 2012
		1MG	A076908	002	Mar 12, 2012
		2MG	A076908	003	Mar 12, 2012
	DASH PHARMS	0.25MG	A091537	006	Feb 12, 2013
		0.5MG	A091537	001	Mar 30, 2011
		1MG	A091537	002	Mar 30, 2011
		2MG	A091537	003	Mar 30, 2011
		3MG	A091537	004	Mar 30, 2011
		4MG	A091537	005	Mar 30, 2011

RITODRINE HYDROCHLORIDE

INJECTABLE;INJECTION					
RITODRINE HYDROCHLORIDE					
	ABRAXIS PHARM	10MG/ML	A071188	001	Jul 23, 1987
		15MG/ML	A071189	001	Jul 23, 1987
	HOSPIRA	10MG/ML	A071618	001	Feb 28, 1991
		15MG/ML	A071619	001	Feb 28, 1991
RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	HOSPIRA	30MG/100ML	A071438	001	Jan 22, 1991
YUTOPAR					
	ASTRAZENECA	10MG/ML	N018580	001	
		15MG/ML	N018580	002	Sep 27, 1984
TABLET;ORAL					
YUTOPAR					
	ASTRAZENECA	10MG	N018555	001	

RITONAVIR

CAPSULE;ORAL					
NORVIR					
	ABBOTT	100MG	N020680	001	Mar 01, 1996
+	ABBVIE	100MG **	N020945	001	Jun 29, 1999
RITONAVIR					
	HIKMA	100MG	A205801	001	Dec 03, 2020
SOLUTION;ORAL					
NORVIR					
+	ABBVIE	80MG/ML	N020659	001	Mar 01, 1996

RIVASTIGMINE TARTRATE

CAPSULE;ORAL					
EXELON					
+	NOVARTIS	EQ 1.5MG BASE **	N020823	003	Apr 21, 2000
+		EQ 3MG BASE **	N020823	004	Apr 21, 2000
+		EQ 4.5MG BASE **	N020823	005	Apr 21, 2000
+		EQ 6MG BASE **	N020823	006	Apr 21, 2000
RIVASTIGMINE TARTRATE					
	APOTEX INC	EQ 1.5MG BASE	A091072	001	May 16, 2013
		EQ 3MG BASE	A091072	002	May 16, 2013
		EQ 4.5MG BASE	A091072	003	May 16, 2013
		EQ 6MG BASE	A091072	004	May 16, 2013
SOLUTION;ORAL					
EXELON					
	NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RIZATRIPTAN BENZOATE

TABLET;ORAL				
MAXALT				
+	ORGANON LLC	EQ 5MG BASE **	N020864 001	Jun 29, 1998
RIZATRIPTAN BENZOATE				
	APOTEX INC	EQ 5MG BASE	A202244 001	Dec 31, 2012
		EQ 10MG BASE	A202244 002	Dec 31, 2012
	AVET LIFESCIENCES	EQ 5MG BASE	A204090 001	Nov 26, 2013
		EQ 10MG BASE	A204090 002	Nov 26, 2013
	JUBILANT GENERICS	EQ 5MG BASE	A203252 001	Dec 31, 2014
		EQ 10MG BASE	A203252 002	Dec 31, 2014
	SANDOZ	EQ 5MG BASE	A079230 001	Dec 31, 2012
		EQ 10MG BASE	A079230 002	Dec 31, 2012
	UNICHEM	EQ 5MG BASE	A207836 001	Mar 07, 2017
		EQ 10MG BASE	A207836 002	Mar 07, 2017
TABLET, ORALLY DISINTEGRATING;ORAL				
MAXALT-MLT				
+	ORGANON	EQ 5MG BASE **	N020865 001	Jun 29, 1998
RIZATRIPTAN BENZOATE				
	APOTEX INC	EQ 5MG BASE	A202477 001	Jul 01, 2013
		EQ 10MG BASE	A202477 002	Jul 01, 2013
	JUBILANT GENERICS	EQ 5MG BASE	A203334 001	Oct 16, 2015
		EQ 10MG BASE	A203334 002	Oct 16, 2015
	MYLAN PHARMS INC	EQ 5MG BASE	A078173 001	Dec 31, 2012
		EQ 10MG BASE	A078173 002	Dec 31, 2012
	SANDOZ	EQ 5MG BASE	A078739 001	Jul 01, 2013
		EQ 10MG BASE	A078739 002	Jul 01, 2013
	UNICHEM	EQ 5MG BASE	A207835 001	Mar 07, 2017
		EQ 10MG BASE	A207835 002	Mar 07, 2017

ROCURONIUM BROMIDE

INJECTABLE;INJECTION				
ROCURONIUM BROMIDE				
	TEVA PHARMS	50MG/5ML (10MG/ML)	A078717 001	Nov 26, 2008
		100MG/10ML (10MG/ML)	A078717 002	Nov 26, 2008
ZEMURON				
+	ORGANON USA INC	50MG/5ML (10MG/ML) **	N020214 001	Mar 17, 1994
+		10MG/ML (10MG/ML) **	N020214 002	Mar 17, 1994
+		100MG/10ML (10MG/ML) **	N020214 003	Mar 17, 1994

ROFECOXIB

SUSPENSION;ORAL				
VIOXX				
	MERCK	12.5MG/5ML	N021052 001	May 20, 1999
		25MG/5ML	N021052 002	May 20, 1999
TABLET;ORAL				
VIOXX				
	MERCK	12.5MG	N021042 001	May 20, 1999
		25MG	N021042 002	May 20, 1999
		50MG	N021042 003	Feb 25, 2000

ROFLUMILAST

TABLET;ORAL				
ROFLUMILAST				
	BRECKENRIDGE	500MCG	A208236 001	Oct 03, 2018
	TORRENT	500MCG	A208272 001	Aug 06, 2018

ROLAPITANT HYDROCHLORIDE

EMULSION;INTRAVENOUS				
VARUBI				
+	TERSERA	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399 001	Oct 25, 2017

ROMIDEPSIN

SOLUTION;INTRAVENOUS				
ROMIDEPSIN				
+	TEVA PHARMS USA INC	10MG/2ML (5MG/ML)	N208574 001	Mar 13, 2020
+		27.5MG/5.5ML (5MG/ML)	N208574 002	Mar 13, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL					
REQUIP					
+	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE **	N020658	001	Sep 19, 1997
+		EQ 0.5MG BASE **	N020658	002	Sep 19, 1997
+		EQ 1MG BASE **	N020658	003	Sep 19, 1997
+		EQ 2MG BASE **	N020658	004	Sep 19, 1997
+		EQ 3MG BASE **	N020658	006	Jan 27, 1999
+		EQ 4MG BASE **	N020658	007	Jan 27, 1999
+		EQ 5MG BASE **	N020658	005	Sep 19, 1997
ROPINIROLE HYDROCHLORIDE					
	COSETTE	EQ 0.25MG BASE	A077460	001	May 05, 2008
		EQ 0.5MG BASE	A077460	002	May 05, 2008
		EQ 1MG BASE	A077460	003	May 05, 2008
		EQ 2MG BASE	A077460	004	May 05, 2008
		EQ 3MG BASE	A077460	005	May 05, 2008
		EQ 4MG BASE	A077460	006	May 05, 2008
		EQ 5MG BASE	A077460	007	May 19, 2008
	EPIC PHARMA LLC	EQ 0.25MG BASE	A078230	001	May 20, 2008
		EQ 0.5MG BASE	A078230	002	May 20, 2008
		EQ 1MG BASE	A078230	003	May 20, 2008
		EQ 2MG BASE	A078230	004	May 20, 2008
		EQ 3MG BASE	A078230	005	May 20, 2008
		EQ 4MG BASE	A078230	006	May 20, 2008
		EQ 5MG BASE	A078230	007	May 20, 2008
	HIKMA	EQ 0.25MG BASE	A077852	001	May 05, 2008
		EQ 0.5MG BASE	A077852	002	May 05, 2008
		EQ 1MG BASE	A077852	003	May 05, 2008
		EQ 2MG BASE	A077852	004	May 05, 2008
		EQ 3MG BASE	A077852	005	May 05, 2008
		EQ 4MG BASE	A077852	006	May 05, 2008
		EQ 5MG BASE	A077852	007	May 19, 2008
	MYLAN	EQ 0.25MG BASE	A078881	001	May 05, 2008
		EQ 0.5MG BASE	A078881	002	May 05, 2008
		EQ 1MG BASE	A078881	003	May 05, 2008
		EQ 2MG BASE	A078881	004	May 05, 2008
		EQ 3MG BASE	A078881	005	May 05, 2008
		EQ 4MG BASE	A078881	006	May 05, 2008
		EQ 5MG BASE	A078881	007	May 19, 2008
TABLET, EXTENDED RELEASE;ORAL					
REQUIP XL					
+	GLAXOSMITHKLINE LLC	EQ 2MG BASE **	N022008	001	Jun 13, 2008
+		EQ 3MG BASE **	N022008	002	Jun 13, 2008
+		EQ 4MG BASE **	N022008	003	Jun 13, 2008
+		EQ 6MG BASE **	N022008	006	Apr 10, 2009
+		EQ 8MG BASE **	N022008	004	Jun 13, 2008
+		EQ 12MG BASE **	N022008	005	Oct 31, 2008
ROPINIROLE HYDROCHLORIDE					
	MYLAN PHARMS INC	EQ 2MG BASE	A200462	001	Oct 15, 2012
		EQ 3MG BASE	A200462	002	Oct 15, 2012
		EQ 4MG BASE	A200462	003	Oct 15, 2012
		EQ 6MG BASE	A200462	004	Oct 15, 2012
		EQ 8MG BASE	A200462	005	Oct 15, 2012
		EQ 12MG BASE	A200462	006	Oct 15, 2012
	WATSON LABS INC	EQ 2MG BASE	A200431	001	Jun 06, 2012
		EQ 4MG BASE	A200431	002	Jun 06, 2012
		EQ 6MG BASE	A200431	003	Jun 06, 2012
		EQ 8MG BASE	A200431	004	Jun 06, 2012
		EQ 12MG BASE	A200431	005	Jun 06, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION					
NAROPIN					
+	FRESENIUS KABI USA	50MG/10ML (5MG/ML) **	N020533	013	May 01, 1998
+		75MG/10ML (7.5MG/ML) **	N020533	012	Sep 24, 1996
ROPIVACAINE HYDROCHLORIDE					
	RISING	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014
		150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014
		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014
		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ROSE BENGAL SODIUM I-131				
INJECTABLE;INJECTION				
ROBENGATOPE				
BRACCO	0.5mCi/VIAL	N016224	001	
	1mCi/VIAL	N016224	002	
	2mCi/VIAL	N016224	003	
SODIUM ROSE BENGAL I 131				
SORIN	0.5mCi/ML	N017318	001	
ROSIGLITAZONE MALEATE				
TABLET;ORAL				
AVANDIA				
+ WOODWARD	EQ 2MG BASE	N021071	002	May 25, 1999
+	EQ 4MG BASE	N021071	003	May 25, 1999
+	EQ 8MG BASE **	N021071	004	May 25, 1999
ROSIGLITAZONE MALEATE				
ANI PHARMS	EQ 2MG BASE	A076747	001	Jan 25, 2013
	EQ 4MG BASE	A076747	002	Jan 25, 2013
	EQ 8MG BASE	A076747	003	Jan 25, 2013
ROSUVASTATIN CALCIUM				
CAPSULE;ORAL				
EZALLOR SPRINKLE				
+ SUN PHARM	EQ 5MG BASE	N208647	001	Dec 18, 2018
+	EQ 10MG BASE	N208647	002	Dec 18, 2018
+	EQ 20MG BASE	N208647	003	Dec 18, 2018
+	EQ 40MG BASE	N208647	004	Dec 18, 2018
TABLET;ORAL				
ROSUVASTATIN CALCIUM				
AMNEAL PHARMS CO	EQ 5MG BASE	A208850	001	Oct 16, 2018
	EQ 10MG BASE	A208850	002	Oct 16, 2018
	EQ 20MG BASE	A208850	003	Oct 16, 2018
	EQ 40MG BASE	A208850	004	Oct 16, 2018
APOTEX	EQ 5MG BASE	A079145	001	Jul 19, 2016
	EQ 10MG BASE	A079145	002	Jul 19, 2016
	EQ 20MG BASE	A079145	003	Jul 19, 2016
	EQ 40MG BASE	A079145	004	Jul 19, 2016
INVENTIA	EQ 5MG BASE	A207653	001	Feb 05, 2021
	EQ 10MG BASE	A207653	002	Feb 05, 2021
	EQ 20MG BASE	A207653	003	Feb 05, 2021
	EQ 40MG BASE	A207653	004	Feb 05, 2021
STRIDES PHARMA	EQ 5MG BASE	A079161	001	Jul 19, 2016
	EQ 10MG BASE	A079161	002	Jul 19, 2016
	EQ 20MG BASE	A079161	003	Jul 19, 2016
	EQ 40MG BASE	A079161	004	Jul 19, 2016
SUNSHINE	EQ 5MG BASE	A210667	001	Apr 01, 2020
	EQ 10MG BASE	A210667	002	Apr 01, 2020
	EQ 20MG BASE	A210667	003	Apr 01, 2020
	EQ 40MG BASE	A210667	004	Apr 01, 2020
TEVA PHARMS USA	EQ 5MG BASE	A079166	001	Jul 19, 2016
	EQ 10MG BASE	A079166	002	Jul 19, 2016
	EQ 20MG BASE	A079166	003	Jul 19, 2016
	EQ 40MG BASE	A079166	004	Jul 19, 2016
ZHEJIANG JINGXIN	EQ 5MG BASE	A206513	001	Mar 01, 2019
	EQ 10MG BASE	A206513	002	Mar 01, 2019
	EQ 20MG BASE	A206513	003	Mar 01, 2019
	EQ 40MG BASE	A206513	004	Mar 01, 2019
RUFINAMIDE				
TABLET;ORAL				
BANZEL				
+ EISAI INC	100MG **	N021911	001	Nov 14, 2008
SAFFLOWER OIL				
INJECTABLE;INJECTION				
LIPOSYN 10%				
ABBOTT	10% (10GM/100ML)	N018203	001	
LIPOSYN 20%				
ABBOTT	20% (20GM/100ML)	N018614	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SAFFLOWER OIL; SOYBEAN OIL				
INJECTABLE;INJECTION				
LIPOSYN II 10%				
HOSPIRA	5%;5% (5GM/100ML)	N018997	001	Aug 27, 1984
LIPOSYN II 20%				
HOSPIRA	10%;10% (10GM/100ML)	N018991	001	Aug 27, 1984
SAFINAMIDE MESYLATE				
TABLET;ORAL				
SAFINAMIDE MESYLATE				
AUROBINDO PHARMA	EQ 50MG BASE	A215902	001	Jun 14, 2023
	EQ 100MG BASE	A215902	002	Jun 14, 2023
SALMETEROL XINAFOATE				
AEROSOL, METERED;INHALATION				
SEREVENT				
GLAXOSMITHKLINE	EQ 0.021MG BASE/INH	N020236	001	Feb 04, 1994
SAMARIUM SM-153 LEXIDRONAM PENTASODIUM				
INJECTABLE;INJECTION				
QUADRAMET				
+ LANTHEUS MEDICAL	50mCi/ML	N020570	001	Mar 28, 1997
SAQUINAVIR				
CAPSULE;ORAL				
FORTOVASE				
+ HOFFMANN LA ROCHE	200MG **	N020828	001	Nov 07, 1997
SAQUINAVIR MESYLATE				
CAPSULE;ORAL				
INVIRASE				
+ HOFFMANN LA ROCHE	EQ 200MG BASE	N020628	001	Dec 06, 1995
TABLET;ORAL				
INVIRASE				
+ HOFFMANN-LA ROCHE	EQ 500MG BASE	N021785	001	Dec 17, 2004
SARALASIN ACETATE				
INJECTABLE;INJECTION				
SARENIN				
PROCTER AND GAMBLE	EQ 0.6MG BASE/ML	N018009	001	
SAXAGLIPTIN HYDROCHLORIDE				
TABLET;ORAL				
ONGLYZA				
+ ASTRAZENECA AB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009
+	EQ 5MG BASE	N022350	002	Jul 31, 2009
SECOBARBITAL SODIUM				
CAPSULE;ORAL				
SECOBARBITAL SODIUM				
ANABOLIC	100MG	A084422	001	
BARR	100MG	A084225	001	
EVERYLIFE	100MG	A085895	001	
HALSEY	100MG	A084676	001	
IVAX PHARMS	100MG	A085869	001	
KV PHARM	100MG	A085285	001	
LANNETT	50MG	A085909	001	
	100MG	A085903	001	
PARKE DAVIS	100MG	A084762	001	
PERRIGO	100MG	A084561	001	
PUREPAC PHARM	100MG	A085867	001	
VALEANT PHARM INTL	100MG	A085477	001	
VITARINE	100MG	A085898	001	
	100MG	A086273	001	
WATSON LABS	100MG	A085792	001	
WEST WARD	100MG	A084926	001	
WHITEWORTH TOWN PLSN	100MG	A085798	001	
WYETH AYERST	100MG	A086390	001	
SECONAL SODIUM				
VALEANT PHARMS NORTH	50MG	A086101	001	Oct 03, 1983
	100MG	A086101	002	Oct 03, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SECOBARBITAL SODIUM				
INJECTABLE;INJECTION				
SECOBARBITAL SODIUM				
ELKINS SINN	100MG/VIAL		A083281 001	
WYETH AYERST	50MG/ML		A083262 001	
SECONAL SODIUM				
LILLY	50MG/ML **		N007392 002	
SUPPOSITORY;RECTAL				
SECONAL SODIUM				
LILLY	30MG		A086530 001	
	60MG		A086530 002	
	120MG		A086530 003	
	200MG		A086530 004	
SECRETIN				
INJECTABLE;INJECTION				
SECRETIN-FERRING				
FERRING	75CU/VIAL		N018290 001	
SECRETIN SYNTHETIC PORCINE				
FOR SOLUTION;INTRAVENOUS				
SECREFLO				
CHIRHOCLIN	16MCG/VIAL		N021136 001	Apr 04, 2002
SELEGILINE HYDROCHLORIDE				
CAPSULE;ORAL				
ELDEPRYL				
+ SOMERSET	5MG **		N020647 001	May 15, 1996
SELEGILINE HYDROCHLORIDE				
LANNETT CO INC	5MG		A075145 001	Sep 15, 2003
TABLET;ORAL				
SELEGILINE HYDROCHLORIDE				
BAYSHORE PHARMS LLC	5MG		A074912 001	Apr 30, 1998
CHARTWELL MOLECULES	5MG		A074565 001	Aug 02, 1996
	5MG		A074641 001	Aug 02, 1996
COSETTE	5MG		A074744 001	Jan 27, 1997
	5MG		A074756 001	Nov 25, 1998
DASH PHARMS NATCO	5MG		A074866 001	Nov 26, 1997
G AND W LABS INC	5MG		A074537 001	Aug 02, 1996
+ SOMERSET	5MG **		N019334 001	Jun 05, 1989
SELENIUM SULFIDE				
LOTION/SHAMPOO;TOPICAL				
EXSEL				
ALLERGAN HERBERT	2.5%		A083892 001	
SELENIUM SULFIDE				
ACTAVIS MID ATLANTIC	2.5%		A084394 001	
COSETTE	2.5%		A086209 001	
IVAX PHARMS	2.5%		A085777 001	
PHARMOBEDIENT CNSLTG	2.5%		A088228 001	Sep 01, 1983
SELSUN				
+ CHATTEM	2.5% **		N007936 001	
SELENOMETHIONINE SE-75				
INJECTABLE;INJECTION				
SELENOMETHIONINE SE 75				
GE HEALTHCARE	250uCi/ML		N017257 001	
MALLINCKRODT	100uCi/ML		N017098 001	
PHARMALUCENCE	500uCi/ML		N017322 001	
SETHOTOPE				
BRACCO	85-550uCi/ML		N017047 001	
SELEXIPAG				
TABLET;ORAL				
SELEXIPAG				
ZYDUS	0.2MG		A214302 001	Dec 21, 2022
	0.4MG		A214302 002	Dec 21, 2022
	0.6MG		A214302 003	Dec 21, 2022
	0.8MG		A214302 004	Dec 21, 2022
	1MG		A214302 005	Dec 21, 2022
	1.2MG		A214302 006	Dec 21, 2022
	1.4MG		A214302 007	Dec 21, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SELEXIPAG					
TABLET;ORAL					
SELEXIPAG					
		1.6MG	A214302	008	Dec 21, 2022
SERMORELIN ACETATE					
INJECTABLE;INJECTION					
GEREF					
+	EMD SERONO	EQ 0.05MG BASE/AMP **	N019863	001	Dec 28, 1990
+	EMD SERONO INC	EQ 0.5MG BASE/VIAL **	N020443	001	Sep 26, 1997
+		EQ 1MG BASE/VIAL **	N020443	002	Sep 26, 1997
SERTRALINE HYDROCHLORIDE					
CONCENTRATE;ORAL					
SERTRALINE HYDROCHLORIDE					
	RANBAXY LABS LTD	EQ 20MG BASE/ML	A078053	001	Feb 05, 2007
TABLET;ORAL					
SERTRALINE HYDROCHLORIDE					
	ANDA REPOSITORY	EQ 25MG BASE	A077818	001	Feb 06, 2007
		EQ 50MG BASE	A077818	002	Feb 06, 2007
		EQ 100MG BASE	A077818	003	Feb 06, 2007
	CHARTWELL MOLECULAR	EQ 25MG BASE	A077162	001	Feb 06, 2007
		EQ 50MG BASE	A077162	002	Feb 06, 2007
		EQ 100MG BASE	A077162	003	Feb 06, 2007
	FOSUN PHARMA	EQ 25MG BASE	A077713	001	Feb 06, 2007
		EQ 50MG BASE	A077713	002	Feb 06, 2007
		EQ 100MG BASE	A077713	003	Feb 06, 2007
	HERITAGE PHARMA AVET	EQ 25MG BASE	A077299	001	Feb 06, 2007
		EQ 25MG BASE	A077345	001	Feb 06, 2007
		EQ 25MG BASE	A077663	001	Feb 06, 2007
		EQ 50MG BASE	A077299	002	Feb 06, 2007
		EQ 50MG BASE	A077345	002	Feb 06, 2007
		EQ 50MG BASE	A077663	002	Feb 06, 2007
		EQ 100MG BASE	A077299	003	Feb 06, 2007
		EQ 100MG BASE	A077345	003	Feb 06, 2007
		EQ 100MG BASE	A077663	003	Feb 06, 2007
	HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009
		EQ 50MG BASE	A077864	002	Aug 10, 2009
		EQ 100MG BASE	A077864	003	Aug 10, 2009
	IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719	003	Jun 30, 2006
		EQ 50MG BASE	A075719	001	Jun 30, 2006
		EQ 100MG BASE	A075719	002	Jun 30, 2006
	MYLAN	EQ 25MG BASE	A076671	001	Feb 06, 2007
		EQ 50MG BASE	A076671	002	Feb 06, 2007
		EQ 100MG BASE	A076671	003	Feb 06, 2007
	MYLAN PHARMS INC	EQ 25MG BASE	A076540	001	Mar 20, 2007
		EQ 25MG BASE	A078626	001	Jan 31, 2008
		EQ 50MG BASE	A076540	002	Mar 20, 2007
		EQ 50MG BASE	A078626	002	Jan 31, 2008
		EQ 100MG BASE	A076540	003	Mar 20, 2007
		EQ 100MG BASE	A078626	003	Jan 31, 2008
	SUN PHARM INDS (IN)	EQ 25MG BASE	A078108	001	Feb 06, 2007
		EQ 50MG BASE	A078108	002	Feb 06, 2007
		EQ 100MG BASE	A078108	003	Feb 06, 2007
	SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007
		EQ 50MG BASE	A077977	002	Feb 06, 2007
		EQ 100MG BASE	A077977	003	Feb 06, 2007
		EQ 150MG BASE	A077977	004	Feb 06, 2007
		EQ 200MG BASE	A077977	005	Feb 06, 2007
	TORRENT PHARMS	EQ 25MG BASE	A077765	001	Feb 06, 2007
		EQ 50MG BASE	A077765	002	Feb 06, 2007
		EQ 100MG BASE	A077765	003	Feb 06, 2007
	ZYDUS	EQ 25MG BASE	A077106	001	Feb 06, 2007
		EQ 50MG BASE	A077106	002	Feb 06, 2007
		EQ 100MG BASE	A077106	003	Feb 06, 2007
ZOLOFT					
+	VIATRIS	EQ 150MG BASE **	N019839	003	Dec 30, 1991
+		EQ 200MG BASE **	N019839	004	Dec 30, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SEVELAMER CARBONATE				
FOR SUSPENSION;ORAL				
SEVELAMER CARBONATE				
LUPIN LTD	800MG/PACKET	A201513	001	Dec 23, 2021
	2.4GM/PACKET	A201513	002	Dec 23, 2021
TABLET;ORAL				
SEVELAMER CARBONATE				
IMPAX LABS INC	800MG	A090975	001	Oct 23, 2017
LUPIN LTD	800MG	A204600	001	Jan 14, 2021
STRIDES PHARMA	800MG	A201069	001	Aug 05, 2020
SEVELAMER HYDROCHLORIDE				
CAPSULE;ORAL				
RENAGEL				
GENZYME	403MG	N020926	001	Oct 30, 1998
TABLET;ORAL				
SEVELAMER HYDROCHLORIDE				
RISING	400MG	A201068	001	Dec 14, 2020
	800MG	A201068	002	Dec 14, 2020
SIBUTRAMINE HYDROCHLORIDE				
CAPSULE;ORAL				
MERIDIA				
ABBOTT	5MG	N020632	001	Nov 22, 1997
	10MG	N020632	002	Nov 22, 1997
	15MG	N020632	003	Nov 22, 1997
SILDENAFIL CITRATE				
FOR SUSPENSION;ORAL				
SILDENAFIL CITRATE				
TRIS PHARMA INC	EQ 10MG BASE/ML	A212312	001	Nov 17, 2021
TABLET;ORAL				
SILDENAFIL CITRATE				
ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013
APOTEX CORP	EQ 20MG BASE	A091379	001	Nov 06, 2012
PERRIGO R AND D	EQ 25MG BASE	A205791	001	Apr 23, 2020
	EQ 50MG BASE	A205791	002	Apr 23, 2020
WATSON LABS INC	EQ 25MG BASE	A202506	001	Nov 25, 2020
	EQ 50MG BASE	A202506	002	Nov 25, 2020
	EQ 100MG BASE	A202506	003	Nov 25, 2020
SILODOSIN				
CAPSULE;ORAL				
SILODOSIN				
ALEMBIC	4MG	A211731	001	Nov 22, 2019
	8MG	A211731	002	Nov 22, 2019
ZYDUS PHARMS	4MG	A204816	001	Dec 08, 2022
	8MG	A204816	002	Dec 08, 2022
SILVER SULFADIAZINE				
CREAM;TOPICAL				
SSD AF				
DR REDDYS LA	1%	N018578	003	Jul 11, 1990
DRESSING;TOPICAL				
SILDAFLO				
FRANKLIN PHARMS	1%	N019608	001	Nov 30, 1989
SIMEPREVIR SODIUM				
CAPSULE;ORAL				
OLYSIO				
+ JANSSEN PRODS	EQ 150MG BASE	N205123	001	Nov 22, 2013
SIMETHICONE-CELLULOSE				
SUSPENSION;ORAL				
SONORX				
BRACCO	7.5MG/ML	N020773	001	Oct 29, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SIMVASTATIN					
TABLET;ORAL					
SIMVASTATIN					
	CHARTWELL RX	5MG	A077766	001	Dec 20, 2006
		10MG	A077766	002	Dec 20, 2006
		20MG	A077766	003	Dec 20, 2006
		40MG	A077766	004	Dec 20, 2006
		80MG	A077766	005	Dec 20, 2006
	IVAX SUB TEVA PHARMS	5MG	A076052	001	Jun 23, 2006
		10MG	A076052	002	Jun 23, 2006
		20MG	A076052	003	Jun 23, 2006
		40MG	A076052	004	Jun 23, 2006
		80MG	A076052	005	Dec 20, 2006
	MYLAN PHARMS INC	5MG	A090868	001	Jun 08, 2010
		10MG	A090868	002	Jun 08, 2010
		20MG	A090868	003	Jun 08, 2010
		40MG	A090868	004	Jun 08, 2010
		80MG	A090868	005	Jun 08, 2010
	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006
		10MG	A076285	002	Dec 20, 2006
		20MG	A076285	003	Dec 20, 2006
		40MG	A076285	004	Dec 20, 2006
		80MG	A076285	005	Jun 23, 2006
	WATSON LABS TEVA	5MG	A076685	001	Dec 20, 2006
		10MG	A076685	002	Dec 20, 2006
		20MG	A076685	003	Dec 20, 2006
		40MG	A076685	004	Dec 20, 2006
		80MG	A076685	005	Dec 20, 2006
ZOCOR					
+	ORGANON	80MG **	N019766	005	Jul 10, 1998
TABLET, ORALLY DISINTEGRATING;ORAL					
SIMVASTATIN					
+	SYNTHON PHARMS	10MG	N021961	001	Oct 09, 2007
+		20MG	N021961	002	Oct 09, 2007
+		40MG	N021961	003	Oct 09, 2007
+		80MG	N021961	004	Oct 09, 2007
SIMVASTATIN; SITAGLIPTIN PHOSPHATE					
TABLET;ORAL					
JUVISYNC					
+	MERCK SHARP DOHME	10MG;EQ 50MG BASE **	N202343	004	Sep 18, 2012
+		10MG;EQ 100MG BASE **	N202343	001	Oct 07, 2011
+		20MG;EQ 50MG BASE **	N202343	005	Sep 18, 2012
+		20MG;EQ 100MG BASE **	N202343	002	Oct 07, 2011
+		40MG;EQ 50MG BASE **	N202343	006	Sep 18, 2012
+		40MG;EQ 100MG BASE **	N202343	003	Oct 07, 2011
SIROLIMUS					
SOLUTION;ORAL					
SIROLIMUS					
	TORRENT	1MG/ML	A215016	001	Dec 27, 2021
TABLET;ORAL					
RAPAMUNE					
+	PF PRISM CV	5MG **	N021110	003	Feb 23, 2004
SODIUM BENZOATE; SODIUM PHENYLACETATE					
SOLUTION;ORAL					
UCEPHAN					
	B BRAUN	100MG/ML;100MG/ML	N019530	001	Dec 23, 1987
SODIUM BICARBONATE					
INJECTABLE;INJECTION					
SODIUM BICARBONATE					
	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005
		1MEQ/ML	A077394	002	Nov 09, 2005
SODIUM BICARBONATE IN PLASTIC CONTAINER					
+	ABBOTT	0.9MEQ/ML **	N019443	001	Jun 03, 1986
+		1MEQ/ML **	N019443	002	Jun 03, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SODIUM BICARBONATE; TARTARIC ACID				
GRANULE, EFFERVESCENT;ORAL				
BAROS				
	MALLINCKRODT INC	460MG/GM;420MG/GM	N018509 001	Aug 07, 1985
SODIUM CHLORIDE				
AEROSOL, METERED;INHALATION				
BRONCHO SALINE				
+	BLAIREX	0.9%	N019912 001	Sep 03, 1992
INJECTABLE;INJECTION				
SODIUM CHLORIDE				
	ABBOTT	20GM/100ML	N017013 001	
	B BRAUN	20GM/100ML	N017038 001	
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	450MG/100ML	N018184 001	
	MILES	450MG/100ML	N018503 001	
SODIUM CHLORIDE 0.9%				
+	MEDEFIL INC	9MG/ML (9MG/ML)	N202832 001	Jan 06, 2012
+		18MG/2ML (9MG/ML)	N202832 002	Jan 06, 2012
+		22.5MG/2.5ML (9MG/ML)	N202832 003	Jan 06, 2012
+		27MG/3ML (9MG/ML)	N202832 004	Jan 06, 2012
+		45MG/5ML (9MG/ML)	N202832 005	Jan 06, 2012
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+	LIEBEL-FLARSHEIM	450MG/50ML (9MG/ML)	N021569 001	Jul 27, 2006
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER				
+	ABRAXIS PHARM	234MG/ML **	N019329 001	Apr 22, 1987
SOLUTION;INJECTION				
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	ABRAXIS PHARM	90MG/10ML (9MG/ML)	A088909 002	May 15, 1985
		270MG/30ML (9MG/ML)	A088909 001	Feb 07, 1985
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	ABBOTT	90MG/10ML (9MG/ML)	N019218 001	Jul 13, 1984
		180MG/20ML (9MG/ML)	N019218 002	Apr 30, 1985
+	HOSPIRA	18MG/2ML (9MG/ML)	N018803 004	Jan 22, 2015
+		27MG/3ML (9MG/ML)	N018803 005	Jan 22, 2015
+		45MG/5ML (9MG/ML)	N018803 006	Jan 22, 2015
+	ICU MEDICAL INC	45MG/5ML (9MG/ML)	N019217 002	Nov 18, 1998
+		90MG/10ML (9MG/ML)	N019217 003	Nov 18, 1998
+		360MG/40ML (9MG/ML)	N019217 004	Apr 01, 1999
	JUBILANT CADISTA	27MG/3ML (9MG/ML)	A203352 002	May 18, 2016
		90MG/10ML (9MG/ML)	A203352 001	May 18, 2016
	MILES	450MG/50ML (9MG/ML)	N018502 002	
		900MG/100ML	N018502 001	
SODIUM CHLORIDE 0.9% IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE				
+	ICU MEDICAL INC	90MG/10ML (9MG/ML)	N019217 001	Jul 13, 1984
SOLUTION;INTRAVENOUS				
SODIUM CHLORIDE 14.6%				
+	HOSPIRA	50MEQ/20ML (2.5MEQ/ML) **	N018897 001	Jul 20, 1984
SOLUTION;IRRIGATION				
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	450MG/100ML	N017864 001	
		450MG/100ML	N018497 001	Feb 19, 1982
	HOSPIRA	450MG/100ML	N017670 001	
		450MG/100ML	N018380 001	
SODIUM CHLORIDE IN PLASTIC CONTAINER				
	MILES	900MG/100ML	N018247 001	
SODIUM CHROMATE CR-51				
INJECTABLE;INJECTION				
CHROMITOPE SODIUM				
	BRACCO	2mCi/VIAL	N013993 002	
		200uCi/ML	N013993 001	
SODIUM CHROMATE CR 51				
	CURIUM	100uCi/ML	N016708 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS				
FLUORINE F-18				
+	GE HEALTHCARE	2mCi/ML **	N017042 001	
SODIUM FLUORIDE F 18				
+	NIH NCI DCTD	10-200mCi/ML **	N022494 001	Jan 26, 2011
SODIUM FLUORIDE F-18				
	DECATUR	10-200mCi/ML	A204464 001	Oct 21, 2014
	SHERTECH LABS LLC	10-200mCi/ML	A204315 001	Sep 22, 2014
	UCSF RODIOPHARM	10-200mCi/ML	A204437 001	Mar 13, 2014
	UIHC PET IMAGING	10-200mCi/ML	A204462 001	Nov 17, 2015
	UNIV TX MD ANDERSON	10-200mCi/ML	A203247 001	Dec 23, 2013

SODIUM FLUORIDE; TRICLOSAN

PASTE;DENTAL				
COLGATE TOTAL				
+	COLGATE PALMOLIVE	0.24%;0.3%	N020231 001	Jul 11, 1997

SODIUM IODIDE I-123

CAPSULE;ORAL				
SODIUM IODIDE I 123				
	CARDINAL HEALTH 418	400uCi	N018671 003	May 27, 1982
	GE HEALTHCARE	100uCi	N017630 001	
		200uCi	N017630 003	Jan 08, 1993
SOLUTION;ORAL				
SODIUM IODIDE I 123				
	GE HEALTHCARE	2mCi/ML **	N017630 002	

SODIUM IODIDE I-131

CAPSULE;ORAL				
IODOTOPE				
	BRACCO	1-130mCi	N010929 001	
		1-150mCi	N010929 003	
SODIUM IODIDE I 131				
	CIS	50uCi	N017316 001	
		100uCi	N017316 002	
	CURIUM	0.8-100mCi	N016515 002	
+		0.8-100mCi	N016517 001	
		15-100uCi	N016517 002	
	JUBILANT	2-200mCi	N021305 004	Nov 18, 2004
SOLUTION;ORAL				
HICON				
	JUBILANT	1-250mCi/0.25ML	N021305 002	Jan 24, 2003
		1-500mCi/0.5ML	N021305 003	Jan 24, 2003
		1-1000mCi/ML	N021305 005	Apr 04, 2006
IODOTOPE				
	BRACCO	7-106mCi/BOT	N010929 002	
SODIUM IODIDE I 131				
	CIS	50mCi/ML	N017315 001	
+	CURIUM	3.5-150mCi/VIAL	N016515 001	

SODIUM LACTATE

INJECTABLE;INJECTION				
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER				
	B BRAUN	1.87GM/100ML	N018186 001	
	BAXTER HLTHCARE	1.87GM/100ML	N016692 001	
	HOSPIRA	1.87GM/100ML	N018249 001	
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER				
	B BRAUN	1.87GM/100ML	N020004 001	Apr 21, 1992
SODIUM LACTATE IN PLASTIC CONTAINER				
+	HOSPIRA	5MEQ/ML	N018947 001	Sep 05, 1984

SODIUM MONOFLUOROPHOSPHATE

GEL;DENTAL				
EXTRA-STRENGTH AIM				
	CHESEBROUGH PONDS	1.2%	N019518 002	Aug 06, 1986
PASTE;DENTAL				
EXTRA-STRENGTH AIM				
	CHESEBROUGH PONDS	1.2%	N019518 001	Jun 03, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION				
NIPRIDE				
	ROCHE	50MG/VIAL	N017546 001	
NITROPRESS				
	ABBOTT	50MG/VIAL	A071555 001	Nov 16, 1987
+	ABBVIE	50MG/VIAL **	N018450 001	
	HOSPIRA	50MG/VIAL	A070566 001	Jun 09, 1986
	VPNA	25MG/ML	A071961 001	Aug 01, 1988
SODIUM NITROPRUSSIDE				
	ABRAXIS PHARM	50MG/VIAL	A070031 001	Jan 17, 1985
	AKORN	25MG/ML	A208635 001	May 04, 2017
	AMPHASTAR PHARMS INC	25MG/ML	A209832 001	Dec 18, 2017
	AVET LIFESCIENCES	25MG/ML	A208923 001	Nov 08, 2022
+	BAXTER HLTHCARE	50MG/VIAL **	N018581 001	Jul 28, 1982
	CHARTWELL RX	25MG/ML	A209834 001	Jun 26, 2018
	CIPLA	25MG/ML	A210855 001	Jul 16, 2018
	EUGIA PHARMA	25MG/ML	A211934 001	Dec 10, 2020
	SUN PHARM	25MG/ML	A210467 001	Nov 26, 2018
	TEVA PARENTERAL	25MG/ML	A073465 001	Mar 30, 1992
SOLUTION;INTRAVENOUS				
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%				
+	EXELA PHARMA	10MG/50ML (0.2MG/ML) **	N209387 002	Dec 07, 2017

SODIUM OXYBATE

SOLUTION;ORAL				
SODIUM OXYBATE				
	HIKMA	0.5GM/ML	A202090 001	Jan 17, 2017

SODIUM PHENYLBUTYRATE

TABLET;ORAL				
SODIUM PHENYLBUTYRATE				
	ALVOGEN	500MG	A090910 001	Nov 18, 2011

SODIUM PHOSPHATE P-32

SOLUTION;INJECTION, ORAL				
PHOSPHOTOPE				
	BRACCO	1-8mCi/VIAL	N010927 001	
SODIUM PHOSPHATE P 32				
	MALLINCKRODT	0.67mCi/ML	N011777 001	
		1.5mCi/VIAL	N011777 002	

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL				
OSMOPREP				
+	SALIX PHARMS	0.398GM;1.102GM	N021892 001	Mar 16, 2006
VISICOL				
	SALIX PHARMS	0.398GM;1.102GM	N021097 001	Sep 21, 2000

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL				
KAYEXALATE				
+	CONCORDIA	453.6GM/BOT **	N011287 001	
SODIUM POLYSTYRENE SULFONATE				
	CITRUSPHRMA	454GM/BOT	A040909 001	Dec 03, 2008
+	PAI HOLDINGS PHARM	453.6GM/BOT	A088786 001	Sep 11, 1984
SUSPENSION;ORAL, RECTAL				
SODIUM POLYSTYRENE SULFONATE				
	ANI PHARMS	15GM/60ML	A090590 001	May 13, 2011
	HIKMA	15GM/60ML	A089049 001	Nov 17, 1986
	MORTON GROVE	15GM/60ML	A088717 001	Sep 11, 1984
	ROXANE	15GM/60ML	A088453 001	Nov 17, 1983

SODIUM SUCCINATE

INJECTABLE;INJECTION				
SODIUM SUCCINATE				
	ELKINS SINN	30%	A080516 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SODIUM TETRADECYL SULFATE				
INJECTABLE;INJECTION				
SOTRADECOL				
+ ELKINS SINN	1% **	N005970	004	
+	3% **	N005970	005	
SODIUM THIOSULFATE				
INJECTABLE;INJECTION				
SODIUM THIOSULFATE				
+ US ARMY	250MG/ML	N020166	001	Feb 14, 1992
SOFOSBUVIR				
TABLET;ORAL				
SOFOSBUVIR				
TEVA PHARMS USA INC	400MG	A211353	001	Jan 27, 2022
SOLIFENACIN SUCCINATE				
TABLET;ORAL				
SOLIFENACIN SUCCINATE				
ACCORD HLTHCARE	5MG	A207477	001	Jan 04, 2022
	10MG	A207477	002	Jan 04, 2022
AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019
	10MG	A205483	002	May 20, 2019
AMNEAL PHARMS CO	5MG	A209719	001	May 20, 2019
	10MG	A209719	002	May 20, 2019
BRECKENRIDGE	5MG	A209818	001	May 20, 2019
	10MG	A209818	002	May 20, 2019
CIPLA	5MG	A209839	001	May 20, 2019
	10MG	A209839	002	May 20, 2019
LANNETT CO INC	5MG	A211622	001	Jun 06, 2023
	10MG	A211622	002	Jun 06, 2023
SUNSHINE	5MG	A213346	001	Apr 13, 2020
	10MG	A213346	002	Apr 13, 2020
ZYDUS PHARMS	5MG	A207721	001	Oct 19, 2020
	10MG	A207721	002	Oct 19, 2020
SORBITOL				
SOLUTION;IRRIGATION				
SORBITOL 3% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	3GM/100ML	N018512	001	May 27, 1982
SOTALOL HYDROCHLORIDE				
TABLET;ORAL				
BETAPACE				
LEGACY PHARMA	320MG	N019865	004	Oct 30, 1992
BETAPACE AF				
LEGACY PHARMA	40MG	N021151	006	Apr 02, 2003
	60MG	N021151	007	Apr 02, 2003
	100MG	N021151	005	Mar 14, 2003
SOTALOL HYDROCHLORIDE				
IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000
	120MG	A075663	002	Nov 07, 2000
	160MG	A075663	003	Nov 07, 2000
	240MG	A075663	004	Nov 07, 2000
MYLAN	80MG	A075725	001	Dec 19, 2000
	120MG	A075725	002	Dec 19, 2000
	160MG	A075725	003	Dec 19, 2000
	240MG	A075725	004	Dec 19, 2000
NATCO PHARMA USA	80MG	A075237	001	May 01, 2000
	120MG	A075237	002	May 01, 2000
	160MG	A075237	003	May 01, 2000
	240MG	A075237	004	May 01, 2000
SUN PHARM INDUSTRIES	80MG	A075515	001	Oct 15, 2001
	80MG	A076576	001	Apr 08, 2004
	120MG	A075515	004	Oct 15, 2001
	120MG	A076576	002	Apr 08, 2004
	160MG	A075515	002	Oct 15, 2001
	160MG	A076576	003	Apr 08, 2004
	240MG	A075515	003	Oct 15, 2001
TEVA	80MG	A076883	001	Jul 26, 2004
	120MG	A076883	002	Jul 26, 2004
	160MG	A076883	003	Jul 26, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOTALOL HYDROCHLORIDE				
TABLET;ORAL				
SOTALOL HYDROCHLORIDE				
UPSHER SMITH LABS	80MG	A075366	001	May 01, 2000
	120MG	A075366	002	May 01, 2000
	160MG	A075366	003	May 01, 2000
	240MG	A075366	004	May 01, 2000
WATSON LABS	80MG	A075238	001	Jul 13, 2000
	120MG	A075238	002	Jul 13, 2000
	160MG	A075238	003	Jul 13, 2000
	240MG	A075238	004	Jul 13, 2000
SOYBEAN OIL				
INJECTABLE;INJECTION				
INTRALIPID 10%				
+ FRESENIUS	10%	N017643	001	
LIPOSYN III 10%				
HOSPIRA	10%	N018969	001	Sep 24, 1984
LIPOSYN III 20%				
HOSPIRA	20%	N018970	001	Sep 25, 1984
LIPOSYN III 30%				
HOSPIRA	30%	N020181	001	Jan 13, 1998
SOYACAL 10%				
ALPHA THERA	10%	N018465	001	Jun 29, 1983
SOYACAL 20%				
ALPHA THERA	20%	N018786	001	Jun 29, 1983
TRAVAMULSION 10%				
BAXTER HLTHCARE	10%	N018660	001	Feb 26, 1982
TRAVAMULSION 20%				
BAXTER HLTHCARE	20%	N018758	001	Feb 15, 1983
SPARFLOXACIN				
TABLET;ORAL				
ZAGAM				
MYLAN	200MG	N020677	001	Dec 19, 1996
SPECTINOMYCIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
TROBICIN				
PFIZER	EQ 2GM BASE/VIAL	N050347	001	
	EQ 4GM BASE/VIAL	N050347	002	
SPIRAPRIL HYDROCHLORIDE				
TABLET;ORAL				
RENORMAX				
SCHERING	3MG	N020240	001	Dec 29, 1994
	6MG	N020240	002	Dec 29, 1994
	12MG	N020240	003	Dec 29, 1994
	24MG	N020240	004	Dec 29, 1994
SPIRONOLACTONE				
TABLET;ORAL				
SPIRONOLACTONE				
ACTAVIS ELIZABETH	25MG	A040353	003	Mar 15, 2006
	50MG	A040353	001	Jul 29, 1999
	100MG	A040353	002	Jul 29, 1999
ASCOT	25MG	A087687	001	Oct 20, 1982
CHARTWELL RX	25MG	A086809	001	
IVAX PHARMS	25MG	A087108	001	
LEDERLE	25MG	A087634	001	
MUTUAL PHARM	25MG	A087265	001	
MYLAN	25MG	A087086	001	
PUREPAC PHARM	25MG	A087998	001	Oct 14, 1983
	25MG	A088053	001	Aug 25, 1983
SUPERPHARM	25MG	A089364	001	Nov 07, 1986
UPSHER SMITH	25MG	A087554	001	
VANGARD	25MG	A087648	001	Feb 01, 1982
WARNER CHILCOTT	25MG	A087952	001	Nov 18, 1982
WATSON LABS	25MG	A086898	002	Mar 02, 1982
	25MG	A087078	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

STANOZOLOL

TABLET;ORAL					
WINSTROL					
+	LUNDBECK INC	2MG	N012885	001	May 14, 1984

STAVUDINE

CAPSULE;ORAL					
STAVUDINE					
	AUROBINDO PHARMA	15MG	A077672	003	Dec 29, 2008
		20MG	A077672	004	Dec 29, 2008
		30MG	A077672	001	Dec 29, 2008
		40MG	A077672	002	Dec 29, 2008
	HETERO LABS LTD III	15MG	A078957	001	Dec 29, 2008
		20MG	A078957	002	Dec 29, 2008
		30MG	A078957	003	Dec 29, 2008
		40MG	A078957	004	Dec 29, 2008
	MYLAN	15MG	A079069	001	Dec 29, 2008
		20MG	A079069	002	Dec 29, 2008
		30MG	A079069	003	Dec 29, 2008
		40MG	A079069	004	Dec 29, 2008
	MYLAN LABS LTD	30MG	A078775	001	Jan 05, 2009
		40MG	A078775	002	Jan 05, 2009
ZERIT					
	BRISTOL	5MG	N020412	001	Jun 24, 1994
+		15MG **	N020412	002	Jun 24, 1994
+		20MG **	N020412	003	Jun 24, 1994
+		30MG **	N020412	004	Jun 24, 1994
+		40MG **	N020412	005	Jun 24, 1994
CAPSULE, EXTENDED RELEASE;ORAL					
ZERIT XR					
	BRISTOL MYERS SQUIBB	37.5MG	N021453	001	Dec 31, 2002
		50MG	N021453	002	Dec 31, 2002
		75MG	N021453	003	Dec 31, 2002
		100MG	N021453	004	Dec 31, 2002
FOR SOLUTION;ORAL					
STAVUDINE					
	AUROBINDO PHARMA	1MG/ML	A077774	001	Dec 29, 2008
	CIPLA LTD	1MG/ML	A078030	001	Mar 20, 2009
ZERIT					
+	BRISTOL	1MG/ML **	N020413	001	Sep 06, 1996

STERILE WATER FOR INJECTION

LIQUID;N/A					
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER					
	ABRAXIS PHARM	100%	A089099	001	Dec 29, 1987
		100%	A089100	001	Dec 29, 1987
STERILE WATER FOR INJECTION					
	HIKMA	100% (20ML)	A206369	002	Sep 02, 2015
+	HOSPIRA	100% (1ML)	N018801	001	Oct 27, 1982
+		100% (5.2ML)	N018801	006	May 02, 2023
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER					
	B BRAUN	100%	N019077	001	Mar 02, 1984

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION					
STERILE WATER IN PLASTIC CONTAINER					
	MILES	100%	N018246	001	

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION					
STREPTOMYCIN SULFATE					
	COPANOS	EQ 500MG BASE/ML	A060684	001	
	LILLY	EQ 1GM BASE/VIAL	A060107	001	
		EQ 1GM BASE/2ML	A060404	001	
		EQ 5GM BASE/VIAL	A060107	002	
	PFIZER	EQ 1GM BASE/VIAL **	A060076	001	
		EQ 1GM BASE/2.5ML	A060111	001	
		EQ 5GM BASE/VIAL **	A060076	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SUCCINYLCHOLINE CHLORIDE				
INJECTABLE;INJECTION				
ANECTINE				
SANDOZ	50MG/ML	N008453	003	
	500MG/VIAL	N008453	001	
	1GM/VIAL	N008453	004	
QUELICIN PRESERVATIVE FREE				
+ HOSPIRA	20MG/ML **	N008845	001	
+	50MG/ML **	N008845	002	
+	100MG/ML **	N008845	004	
SUCCINYLCHOLINE CHLORIDE				
AMPHASTAR PHARMS INC	20MG/ML	A213432	001	Jun 08, 2020
BRECKENRIDGE	20MG/ML	A212638	001	Oct 09, 2019
INTL MEDICATION	100MG/VIAL	A085400	001	Feb 04, 1982
MANKIND PHARMA	20MG/ML	A216127	001	Feb 02, 2023
ORGANON USA INC	20MG/ML	A080997	001	
SUCOSTRIN				
+ APOTHECON	20MG/ML	N008847	001	
+	100MG/ML	N008847	003	
SUFENTANIL CITRATE				
INJECTABLE;INJECTION				
SUFENTANIL CITRATE				
WATSON LABS	EQ 0.05MG BASE/ML	A074406	001	Dec 15, 1995
SULFACETAMIDE SODIUM				
OINTMENT;OPHTHALMIC				
BLEPH-10				
ALLERGAN	10%	A084015	001	
CETAMIDE				
ALCON	10%	A080021	001	
SODIUM SULAMYD				
+ SCHERING	10% **	N005963	002	
SULFAIR 10				
PHARMAFAIR	10%	A088000	001	Dec 22, 1982
SOLUTION/DROPS;OPHTHALMIC				
BLEPH-10				
+ ALLERGAN	10%	A080028	001	
BLEPH-30				
ALLERGAN	30%	A080028	002	
ISOPTO CETAMIDE				
ALCON	15%	A080020	002	
OCUSULF-10				
MIZA PHARMS USA	10%	A080660	001	
OCUSULF-30				
MIZA PHARMS USA	30%	A080660	002	
SODIUM SULAMYD				
+ SCHERING	10% **	N005963	001	
+	30% **	N005963	003	
SODIUM SULFACETAMIDE				
AKORN	10%	A083021	001	
	15%	A083021	002	
	30%	A083021	003	
SOLA BARNES HIND	10%	A084143	001	
	10%	A084145	001	
	30%	A084146	001	
	30%	A084147	001	
SULF-10				
NOVARTIS	10%	A080025	001	
SULF-15				
NOVARTIS	15%	A089047	001	Oct 31, 1995
SULFACEL-15				
OPTOPICS	15%	A080024	001	
SULFACETAMIDE SODIUM				
AKORN	10%	A040215	001	May 25, 1999
ALCON PHARMS LTD	30%	A089068	001	May 05, 1987
EPIC PHARMA LLC	30%	A040216	001	May 25, 1999
PHARMAFAIR	10%	A088947	001	May 17, 1985
SULFAIR 10				
PHARMAFAIR	10%	A087949	001	Dec 13, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULFACETAMIDE SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
SULFAIR FORTE				
PHARMAFAIR	30%	A088385	001	Oct 13, 1983
SULFAIR-15				
PHARMAFAIR	15%	A088186	001	May 25, 1983
SULTEN-10				
BAUSCH AND LOMB	10%	A087818	001	Feb 03, 1983
SULFACYTINE				
TABLET;ORAL				
RENOQUID				
GLENWOOD	250MG	N017569	001	
SULFADIAZINE				
TABLET;ORAL				
SULFADIAZINE				
ABBVIE	300MG	N004125	005	
CHARTWELL MOLECULAR	500MG	A080084	001	
EVERYLIFE	500MG	A080088	001	
+ IMPAX LABS	500MG	A080081	001	
LEDERLE	500MG	N004054	001	
+ LILLY	500MG	N004122	002	
SULFADIAZINE SODIUM				
INJECTABLE;INJECTION				
SULFADIAZINE SODIUM				
LEDERLE	250MG/ML	N004054	002	
SULFADIAZINE; SULFAMERAZINE				
SUSPENSION;ORAL				
SULFONAMIDES DUPLEX				
LILLY	250MG/5ML;250MG/5ML	N006317	007	
SULFAMETER				
TABLET;ORAL				
SULLA				
BAYER HLTHCARE	500MG	N016000	002	
SULFAMETHIZOLE				
TABLET;ORAL				
MICROSUL				
FOREST PHARMS	1GM	A086012	001	
PROKLAR				
FOREST PHARMS	500MG	A080273	001	
THIOSULFIL				
WYETH AYERST	250MG	N008565	001	
	500MG	N008565	004	
SULFAMETHOXAZOLE				
SUSPENSION;ORAL				
GANTANOL				
ROCHE	500MG/5ML	N013664	002	
TABLET;ORAL				
GANTANOL				
ROCHE	500MG	N012715	002	
GANTANOL-DS				
ROCHE	1GM	N012715	003	
SULFAMETHOXAZOLE				
ASCOT	500MG	A087662	001	Oct 20, 1982
BARR	500MG	A087189	001	Jul 25, 1983
HEATHER	500MG	A086163	001	
RISING	500MG	A085844	001	
WATSON LABS	500MG	A085053	001	
	1GM	A086000	001	
UROBAK				
SHIONOGI	500MG	A087307	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE;INJECTION					
BACTRIM					
+	SUN PHARM INDS INC	80MG/ML;16MG/ML **	N018374	001	
SEPTRA					
	MONARCH PHARMS	80MG/ML;16MG/ML **	N018452	001	
SULFAMETHOXAZOLE AND TRIMETHOPRIM					
	ABRAXIS PHARM	80MG/ML;16MG/ML	A070223	001	Dec 29, 1987
	BEDFORD	80MG/ML;16MG/ML	A072383	001	Apr 29, 1992
	HIKMA	80MG/ML;16MG/ML	A070627	001	Dec 29, 1987
		80MG/ML;16MG/ML	A070628	001	Dec 29, 1987
	HOSPIRA	80MG/ML;16MG/ML	A073199	001	Sep 11, 1992
	WATSON LABS	80MG/ML;16MG/ML	A071556	001	Dec 29, 1987
SUSPENSION;ORAL					
BACTRIM					
+	SUN PHARM INDUSTRIES	200MG/5ML;40MG/5ML **	N017560	001	
BACTRIM PEDIATRIC					
	SUN PHARM INDUSTRIES	200MG/5ML;40MG/5ML **	N017560	002	
SEPTRA					
	MONARCH PHARMS	200MG/5ML;40MG/5ML **	N017598	001	
SEPTRA GRAPE					
	MONARCH PHARMS	200MG/5ML;40MG/5ML **	N017598	002	Feb 12, 1986
SULFAMETHOXAZOLE AND TRIMETHOPRIM					
	ANI PHARMS	200MG/5ML;40MG/5ML	A070028	001	Jun 02, 1987
	LUPIN LTD	200MG/5ML;40MG/5ML	A212699	001	Jan 05, 2021
	TEVA	200MG/5ML;40MG/5ML	N018812	001	Jan 28, 1983
		200MG/5ML;40MG/5ML	N018812	002	Jun 10, 1983
SULFATRIM					
	PHARM ASSOC	200MG/5ML;40MG/5ML	N018615	002	Jan 07, 1983
SULMEPRIM					
	USL PHARMA	200MG/5ML;40MG/5ML	A070063	001	Aug 01, 1986
SULMEPRIM PEDIATRIC					
	USL PHARMA	200MG/5ML;40MG/5ML	A070064	001	Aug 01, 1986
TRIMETH/SULFA					
	ALPHARMA US PHARMS	200MG/5ML;40MG/5ML	A072289	001	May 23, 1988
		200MG/5ML;40MG/5ML	A072398	001	May 23, 1988
	NASKA	200MG/5ML;40MG/5ML	A072399	001	May 23, 1988
TABLET;ORAL					
COTRIM					
	TEVA	400MG;80MG	A070034	001	May 16, 1985
COTRIM D.S.					
	TEVA	800MG;160MG	A070048	001	Mar 18, 1985
SULFAMETHOPRIM					
	NOVEL LABS INC	400MG;80MG	A070022	001	Feb 15, 1985
SULFAMETHOPRIM-DS					
	NOVEL LABS INC	800MG;160MG	A070032	001	Feb 15, 1985
SULFAMETHOXAZOLE AND TRIMETHOPRIM					
	FOSUN PHARMA	400MG;80MG	A070889	001	Nov 13, 1986
		400MG;80MG	N018598	003	May 19, 1982
		800MG;160MG	A070890	001	Nov 13, 1986
	HEATHER	400MG;80MG	N018946	001	Aug 10, 1984
		800MG;160MG	N018946	002	Aug 10, 1984
	INTERPHARM	400MG;80MG	A071299	001	Oct 27, 1987
		800MG;160MG	A071300	001	Oct 27, 1987
	MARTEC USA LLC	400MG;80MG	A072408	001	Dec 07, 1988
	MUTUAL PHARM	400MG;80MG	A070006	001	Nov 14, 1984
	PLIVA	400MG;80MG	A070215	001	Sep 10, 1985
		800MG;160MG	A070216	001	Sep 10, 1985
	ROXANE	400MG;80MG	A072768	001	Aug 30, 1991
	TEVA	400MG;80MG	N018242	001	
		800MG;160MG	N018242	002	
	USL PHARMA	400MG;80MG	A070203	001	Nov 08, 1985
		800MG;160MG	A070204	001	Nov 08, 1985
	WATSON LABS	400MG;80MG	A070002	001	Nov 07, 1984
		400MG;80MG	N018852	001	May 09, 1983
		800MG;160MG	A070000	001	Nov 07, 1984
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH					
	FOSUN PHARMA	800MG;160MG	N018598	004	May 19, 1982
	HERITAGE PHARMA AVET	800MG;160MG	A070037	001	Jun 02, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL				
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH				
MARTEC USA LLC	800MG;160MG	A072417	001	Dec 07, 1988
MUTUAL PHARM	800MG;160MG	A070007	001	Nov 14, 1984
ROXANE	800MG;160MG	A072769	001	Aug 30, 1991
WATSON LABS	800MG;160MG	N018854	001	May 09, 1983
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH				
HERITAGE PHARMA AVET	400MG;80MG	A070030	001	Jun 02, 1987
SULFATRIM-DS				
SUPERPHARM	800MG;160MG	A070066	001	Jun 24, 1985
SULFATRIM-SS				
SUPERPHARM	400MG;80MG	A070065	002	Jun 24, 1985
UROPLUS DS				
SHIONOGI	800MG;160MG	A071816	001	Sep 28, 1987
UROPLUS SS				
SHIONOGI	400MG;80MG	A071815	001	Sep 28, 1987

SULFANILAMIDE

CREAM;VAGINAL				
AVC				
+ MYLAN SPECIALITY LP	15% **	N006530	003	Jan 27, 1987
SULFANILAMIDE				
COSETTE	15%	A088718	001	Sep 19, 1985
SUPPOSITORY;VAGINAL				
AVC				
MYLAN SPECIALITY LP	1.05GM	N006530	004	Jan 27, 1987

SULFAPHENAZOLE

SUSPENSION;ORAL				
SULFABID				
PHARM RES ASSOC	500MG/5ML	N013093	001	
TABLET;ORAL				
SULFABID				
PURDUE FREDERICK	500MG	N013092	002	

SULFAPYRIDINE

TABLET;ORAL				
SULFAPYRIDINE				
LILLY	500MG	N000159	001	

SULFASALAZINE

SUSPENSION;ORAL				
AZULFIDINE				
PHARMACIA AND UPJOHN	250MG/5ML	N018605	001	
TABLET;ORAL				
S.A.S.-500				
SOLVAY	500MG	A083450	001	
SULFASALAZINE				
EPIC PHARMA LLC	500MG	A086184	001	
SUN PHARM INDUSTRIES	500MG	A089590	001	Oct 19, 1987
SUPERPHARM	500MG	A089339	001	Oct 26, 1987
WATSON LABS	500MG	A084964	001	
	500MG	A087197	001	
TABLET, DELAYED RELEASE;ORAL				
SULFASALAZINE				
WATSON LABS	500MG	A088052	001	May 24, 1983

SULFINPYRAZONE

CAPSULE;ORAL				
ANTURANE				
+ NOVARTIS	200MG **	N011556	004	
SULFINPYRAZONE				
BARR	200MG	A087666	001	Sep 17, 1982
IVAX PHARMS	200MG	A087770	001	Nov 19, 1982
PAR PHARM	200MG	A088934	001	Sep 06, 1985
VANGARD	200MG	A088666	001	Feb 17, 1984
TABLET;ORAL				
ANTURANE				
NOVARTIS	100MG **	N011556	003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULFINPYRAZONE
TABLET;ORAL
SULFINPYRAZONE

BARR	100MG	A087665 001	Sep 17, 1982
IVAX PHARMS	100MG	A087769 001	Jun 01, 1982
PAR PHARM	100MG	A088933 001	Sep 06, 1985
WATSON LABS	100MG	A087667 001	May 26, 1982

SULFISOXAZOLE
TABLET;ORAL

GANTRISIN		
ROCHE	500MG	N006525 001
SOSOL		
MK LABS	500MG	A080036 001
SOXAZOLE		
ALRA	500MG	A080366 001
SULFALAR		
PARKE DAVIS	500MG	A084955 001
SULFISOXAZOLE		
ANI PHARMS	500MG	A080142 001
BARR	500MG	A084031 001
HEATHER	500MG	A080189 001
IMPAX LABS	500MG	A080109 001
LANNETT	500MG	A080085 001
LEDERLE	500MG	A087649 001
PHARMERAL	500MG	A084385 001
PUREPAC PHARM	500MG	A080087 001
RISING	500MG	A085628 001
ROXANE	500MG	A080082 001
VALEANT PHARM INTL	500MG	A080268 002
VITARINE	500MG	A087332 001
WATSON LABS	500MG	A085534 001
WEST WARD	500MG	A080379 001
SULSOXIN		
SOLVAY	500MG	A080040 001

SULFISOXAZOLE ACETYL
EMULSION;ORAL
LIPO GANTRISIN

ROCHE	EQ 1GM BASE/5ML	N009182 009

SUSPENSION;ORAL
GANTRISIN PEDIATRIC

ROCHE	EQ 500MG BASE/5ML	N009182 004

SYRUP;ORAL
GANTRISIN

ROCHE	EQ 500MG BASE/5ML	N009182 002

SULFISOXAZOLE DIOLAMINE
INJECTABLE;INJECTION
GANTRISIN

ROCHE	EQ 400MG BASE/ML	N006917 001

OINTMENT;OPHTHALMIC
GANTRISIN

ROCHE	EQ 4% BASE	N008414 002

SOLUTION/DROPS;OPHTHALMIC
GANTRISIN

ROCHE	EQ 4% BASE	N007757 002

SULFISOXAZOLE DIOLAMINE

SOLA BARNES HIND	EQ 4% BASE	A084148 001

SULFOXONE SODIUM
TABLET, DELAYED RELEASE;ORAL
DIASONE SODIUM

ABBVIE	165MG	N006044 003

SULFUR
POWDER;TOPICAL
BENSULFOID

POYTHRESS	33.32%	N002918 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULINDAC				
TABLET;ORAL				
CLINORIL				
+ MERCK	150MG **		N017911 001	
+	200MG **		N017911 002	
SULINDAC				
ANI PHARMS	150MG		A072973 002	Feb 28, 1992
	200MG		A072973 001	Feb 28, 1992
CHARTWELL RX	150MG		A072712 001	Aug 30, 1991
	200MG		A072713 001	Aug 30, 1991
EPIC PHARMA LLC	150MG		A073262 002	Sep 06, 1991
	200MG		A073262 001	Sep 06, 1991
RISING	150MG		A073039 002	Jun 22, 1993
	200MG		A073039 001	Jun 22, 1993
SUMATRIPTAN				
SPRAY;NASAL				
IMITREX				
GLAXOSMITHKLINE	10MG/SPRAY		N020626 002	Aug 26, 1997
SUMATRIPTAN SUCCINATE				
INJECTABLE;SUBCUTANEOUS				
ALSUMA				
MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		N022377 001	Jun 29, 2010
SUMATRIPTAN SUCCINATE				
ANTARES PHARMA INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		A078319 001	Dec 10, 2015
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A078319 002	Dec 10, 2015
BAXTER HLTHCARE CORP	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A207101 001	Jan 19, 2023
FRESENIUS KABI USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A079240 002	Sep 18, 2009
	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		A079240 001	Sep 18, 2009
MYLAN LABS LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A203322 001	Apr 14, 2014
PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A077871 001	Jul 09, 2009
SANDOZ	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		A078067 002	Feb 06, 2009
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A078067 001	Feb 06, 2009
STERISCIENCE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A090314 001	Jun 10, 2010
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A090641 001	Jul 28, 2010
TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		A078318 001	Feb 06, 2009
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A078318 002	Feb 06, 2009
TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A077907 001	Feb 06, 2009
ZYDUS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A090310 001	Aug 11, 2010
SUMAVEL DOSEPRO				
+ ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N022239 002	Nov 26, 2013
+	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		N022239 001	Jul 15, 2009
SYSTEM;IONTOPHORESIS				
ZECUITY				
+ TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR		N202278 001	Jan 17, 2013
TABLET;ORAL				
SUMATRIPTAN SUCCINATE				
FOSUN PHARMA	EQ 25MG BASE		A076976 001	Aug 10, 2009
	EQ 50MG BASE		A076976 002	Aug 10, 2009
	EQ 100MG BASE		A076976 003	Aug 10, 2009
HIKMA PHARMS	EQ 25MG BASE		A078298 001	May 21, 2013
	EQ 50MG BASE		A078298 002	May 21, 2013
	EQ 100MG BASE		A078298 003	May 21, 2013
MYLAN	EQ 25MG BASE		A077163 001	Nov 02, 2009
	EQ 50MG BASE		A077163 002	Nov 02, 2009
	EQ 100MG BASE		A077163 003	Nov 02, 2009
ROXANE	EQ 25MG BASE		A078241 001	Aug 10, 2009
	EQ 50MG BASE		A078241 002	Aug 10, 2009
	EQ 100MG BASE		A078241 003	Aug 10, 2009
SUN PHARM INDS LTD	EQ 25MG BASE		A076554 001	Aug 10, 2009
	EQ 50MG BASE		A076554 002	Aug 10, 2009
	EQ 100MG BASE		A076572 001	Feb 09, 2009
TEVA	EQ 25MG BASE		A076840 001	Feb 09, 2009
	EQ 50MG BASE		A076840 002	Feb 09, 2009
	EQ 100MG BASE		A076840 003	Feb 09, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SUPROFEN				
SOLUTION/DROPS;OPHTHALMIC				
PROFENAL				
ALCON	1%	N019387	001	Dec 23, 1988
TACRINE HYDROCHLORIDE				
CAPSULE;ORAL				
COGNEX				
SHIONOGI INC	EQ 10MG BASE	N020070	001	Sep 09, 1993
	EQ 20MG BASE	N020070	002	Sep 09, 1993
	EQ 30MG BASE	N020070	003	Sep 09, 1993
	EQ 40MG BASE	N020070	004	Sep 09, 1993
TACROLIMUS				
CAPSULE;ORAL				
TACROLIMUS				
CONCORD BIOTECH LTD	EQ 0.5MG BASE	A213112	001	Nov 10, 2020
HERITAGE PHARMA AVET	EQ 5MG BASE	A090402	001	Jul 01, 2010
INJECTABLE;INJECTION				
TACROLIMUS				
HOSPIRA	EQ 5MG BASE/ML	A203900	001	Aug 25, 2017
TADALAFIL				
TABLET;ORAL				
TADALAFIL				
CHARTWELL RX	2.5MG	A210716	001	Dec 29, 2020
	5MG	A210716	002	Dec 29, 2020
	10MG	A210716	003	Dec 29, 2020
	20MG	A210716	004	Dec 29, 2020
MYLAN	5MG	A206957	001	Apr 29, 2019
	20MG	A200630	001	Aug 03, 2018
RISING	2.5MG	A206956	001	Apr 29, 2019
	10MG	A206956	002	Apr 29, 2019
	20MG	A206956	003	Apr 29, 2019
ZYDUS PHARMS	20MG	A212515	001	Jun 06, 2023
TALBUTAL				
TABLET;ORAL				
LOTUSATE				
SANOFI AVENTIS US	120MG	N009410	005	
TAMOXIFEN CITRATE				
TABLET;ORAL				
NOLVADEX				
+ ASTRAZENECA	EQ 10MG BASE **	N017970	001	
+	EQ 20MG BASE **	N017970	002	Mar 21, 1994
TAMOXIFEN CITRATE				
ACTAVIS LABS FL INC	EQ 10MG BASE	A076179	001	Feb 20, 2003
	EQ 20MG BASE	A076179	002	Feb 20, 2003
AEGIS PHARMS	EQ 10MG BASE	A076398	001	Mar 31, 2003
	EQ 20MG BASE	A076398	002	Mar 31, 2003
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075740	001	Feb 20, 2003
	EQ 20MG BASE	A075740	002	Feb 20, 2003
PHARMACHEMIE	EQ 10MG BASE	A074539	001	Mar 31, 2003
ROXANE	EQ 10MG BASE	A076027	001	Feb 20, 2003
	EQ 20MG BASE	A076027	002	Feb 20, 2003
TEVA	EQ 10MG BASE	A074504	001	Apr 28, 2003
	EQ 20MG BASE	A074504	002	Apr 28, 2003
TAMSULOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
TAMSULOSIN HYDROCHLORIDE				
ANCHEN PHARMS	0.4MG	A202010	001	Jan 04, 2013
ASCENT PHARMS INC	0.4MG	A214730	001	May 04, 2022
MYLAN	0.4MG	A090408	001	Apr 27, 2010
TAPENTADOL HYDROCHLORIDE				
SOLUTION;ORAL				
NUCYNTA				
+ COLLEGIUM PHARM INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TAZAROTENE
CREAM;TOPICAL
TAZAROTENE
FOUGERA PHARMS INC 0.1% A211175 001 Jan 28, 2019

TECHNETIUM TC-99M APCITIDE
INJECTABLE;INJECTION
ACUTECT
CIS BIO INTL SA N/A N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE
INJECTABLE;INJECTION
NEO TECT KIT
CIS BIO INTL SA N/A ** N021012 001 Aug 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT
INJECTABLE;INJECTION
HEPATOLITE
SUN PHARM INDS INC N/A N018467 001 Mar 16, 1982

TECHNETIUM TC-99M ETIDRONATE KIT
INJECTABLE;INJECTION
CINTICHEM TECHNETIUM 99M HEDSPA
GE HEALTHCARE N/A N017653 001
MPI STANNOUS DIPHOSPHONATE
GE HEALTHCARE N/A N017667 001
OSTEOSCAN
MALLINCKRODT N/A N017454 001
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
GE HEALTHCARE N/A N017562 001

TECHNETIUM TC-99M FERPENTETATE KIT
INJECTABLE;INJECTION
RENOTEC
BRACCO N/A N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT
INJECTABLE;INJECTION
GLUCOSCAN
BRISTOL MYERS SQUIBB N/A N017907 001
TECHNESCAN GLUCEPTATE
DRAXIMAGE N/A N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT
INJECTABLE;INJECTION
TECHNESCAN HIDA
DRAXIMAGE N/A N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE
INJECTABLE;INJECTION
DRAXIMAGE MDP-10
JUBILANT N/A N018035 001

TECHNETIUM TC-99M MEDRONATE KIT
INJECTABLE;INJECTION
AMERSCAN MDP KIT
GE HEALTHCARE N/A N018335 001 Aug 05, 1982
OSTEOLITE
PHARMALUCENCE N/A N017972 001
TECHNETIUM TC 99M MPI MDP
GE HEALTHCARE N/A N018141 001
N/A N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT
INJECTABLE;INJECTION
AN-DTPA
JUBILANT DRAXIMAGE N/A N017714 001
MPI DTPA KIT - CHELATE
GE HEALTHCARE N/A N017255 001
TECHNETIUM TC-99M PENTETATE KIT
GE HEALTHCARE N/A N017264 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TECHNETIUM TC-99M POLYPHOSPHATE KIT
INJECTABLE;INJECTION
SODIUM POLYPHOSPHATE-TIN KIT

	GE HEALTHCARE	N/A	N017664	001	

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT
INJECTABLE;INJECTION
PYROLITE

	PHARMALUCENCE	N/A	N017684	001	

TECHNETIUM TC-99M PYROPHOSPHATE KIT
INJECTABLE;INJECTION
PHOSPHOTEC

	BRACCO	N/A	N017680	001	

TECHNETIUM TC-99M RED BLOOD CELL KIT
INJECTABLE;INJECTION
RBC-SCAN

	CADEMA	N/A	N020063	001	Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT
INJECTABLE;INJECTION
MIRALUMA

	LANTHEUS MEDCL	N/A	N019785	003	May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE
SOLUTION;INJECTION, ORAL
SODIUM PERTECHNETATE TC 99M

+	GE HEALTHCARE	2-100mCi/ML **	N017471	001	
+	MALLINCKRODT	10-60mCi/ML **	N017725	001	
	PHARMALUCENCE	12mCi/ML	N017321	001	
		24mCi/ML	N017321	002	
		48mCi/ML	N017321	003	

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
SOLUTION;INJECTION, ORAL
MINITEC

	BRACCO	0.22-2.22 CI/GENERATOR	N017339	001	

SOLUTION;INTRAVENOUS
TECHNELITE

	LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771	001	

ULTRA-TECHNEKOW FM

	CURIUM	0.25-3 CI/GENERATOR	N017243	002	

SOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC
RADIOGENIX SYSTEM

+	NORTHSTAR MEDICAL	30-1153mCi/GENERATOR	N202158	001	Feb 08, 2018

SOLUTION;INTRAVENOUS, ORAL
TECHNETIUM TC 99M GENERATOR

+	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013
		830-16600mCi/GENERATOR	N017693	001	

TECHNETIUM TC-99M SUCCIMER KIT
INJECTABLE;INJECTION
MPI DMSA KIDNEY REAGENT

+	GE HEALTHCARE	N/A **	N017944	001	May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID
SOLUTION;INJECTION, ORAL
TECHNETIUM TC 99M SULFUR COLLOID

	GE HEALTHCARE	4mCi/ML	N017456	001	

SOLUTION;ORAL
TECHNETIUM TC 99M SULFUR COLLOID

	MALLINCKRODT	3mCi/ML	N017724	001	

TECHNETIUM TC-99M SULFUR COLLOID KIT
SOLUTION;INJECTION, ORAL
TECHNECOLL

	MALLINCKRODT	N/A	N017059	001	

TECHNETIUM TC 99M TSC

	GE HEALTHCARE	N/A	N017784	001	

TESULOID

	BRACCO	N/A	N016923	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TECHNETIUM TC-99M TEBOROXIME KIT					
INJECTABLE;INJECTION					
CARDIOTEC					
	BRACCO	N/A	N019928	001	Dec 19, 1990
TEGASEROD MALEATE					
TABLET;ORAL					
ZELNORM					
+	ALFASIGMA	EQ 2MG BASE	N021200	001	Jul 24, 2002
+		EQ 6MG BASE	N021200	002	Jul 24, 2002
TELAPREVIR					
TABLET;ORAL					
INCIVEK					
	VERTEX PHARMS	375MG	N201917	001	May 23, 2011
TELAVANCIN HYDROCHLORIDE					
POWDER;INTRAVENOUS					
VIBATIV					
+	CUMBERLAND	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009
TELBIVUDINE					
SOLUTION;ORAL					
TYZEKA					
	NOVARTIS	100MG/5ML	N022154	001	Apr 28, 2009
TABLET;ORAL					
TYZEKA					
+	NOVARTIS	600MG	N022011	001	Oct 25, 2006
TELITHROMYCIN					
TABLET;ORAL					
KETEK					
	SANOFI AVENTIS US	300MG	N021144	002	Feb 09, 2005
		400MG	N021144	001	Apr 01, 2004
TELMISARTAN					
TABLET;ORAL					
TELMISARTAN					
	HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019
		40MG	A207843	002	Feb 19, 2019
		80MG	A207843	003	Feb 19, 2019
	JUBILANT GENERICS	20MG	A204164	001	Aug 22, 2016
		40MG	A204164	002	Aug 22, 2016
		80MG	A204164	003	Aug 22, 2016
	TORRENT	20MG	A203171	001	Jul 07, 2014
		40MG	A203171	002	Jul 07, 2014
		80MG	A203171	003	Jul 07, 2014
TEMAZEPAM					
CAPSULE;ORAL					
TEMAZ					
	QUANTUM PHARMICS	15MG	A070564	001	Oct 15, 1985
		30MG	A070547	001	Oct 15, 1985
TEMAZEPAM					
	AUROBINDO PHARMA USA	7.5MG	A070920	002	May 21, 2010
		15MG	A070920	004	Jul 07, 1986
		22.5MG	A070920	003	Jun 12, 2009
		30MG	A070920	001	Jul 10, 1986
	DURAMED PHARMS BARR	15MG	A071708	001	Sep 29, 1988
		30MG	A071709	001	Sep 29, 1988
	SUN PHARM INDUSTRIES	15MG	A071174	001	Jul 10, 1986
		22.5MG	A071175	002	Sep 14, 2009
		30MG	A071175	001	Jul 10, 1986
	USL PHARMA	15MG	A070489	001	Jul 07, 1986
		30MG	A070490	001	Jul 07, 1986
	WATSON LABS	15MG	A070383	001	Mar 23, 1987
		15MG	A071446	001	May 21, 1993
		30MG	A070384	001	Mar 23, 1987
		30MG	A071447	001	May 21, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TEMOZOLOMIDE

CAPSULE;ORAL					
TEMODAR					
+	MERCK SHARP DOHME	5MG	N021029	001	Aug 11, 1999
+		20MG	N021029	002	Aug 11, 1999
+		100MG	N021029	003	Aug 11, 1999
+		140MG	N021029	005	Oct 19, 2006
+		180MG	N021029	006	Oct 19, 2006
+		250MG	N021029	004	Aug 11, 1999
TEMOZOLOMIDE					
	ANI PHARMS	5MG	A203490	001	Jul 13, 2016
		20MG	A203490	002	Jul 13, 2016
		100MG	A203490	003	Jul 13, 2016
		140MG	A203490	004	Jul 13, 2016
		180MG	A203490	005	Jul 13, 2016
		250MG	A203490	006	Jul 13, 2016
	APOTEX	5MG	A204159	001	Jul 05, 2018
		20MG	A204159	002	Jul 05, 2018
		100MG	A204159	003	Jul 05, 2018
		140MG	A204159	004	Jul 05, 2018
		180MG	A204159	005	Jul 05, 2018
		250MG	A204159	006	Jul 05, 2018
	CHARTWELL MOLECULAR	5MG	A203898	001	Feb 10, 2016
		20MG	A203898	002	Feb 10, 2016
		100MG	A203898	003	Feb 10, 2016
		140MG	A203898	004	Feb 10, 2016
		180MG	A203898	005	Feb 10, 2016
		250MG	A203898	006	Feb 10, 2016
	HERITAGE	5MG	A078879	001	Mar 01, 2010
		20MG	A078879	002	Mar 01, 2010
		100MG	A078879	003	Mar 01, 2010
		140MG	A078879	005	Mar 01, 2010
		180MG	A078879	006	Mar 01, 2010
		250MG	A078879	004	Mar 01, 2010
	MYLAN	5MG	A205227	001	Jun 29, 2016
		20MG	A205227	002	Jun 29, 2016
		100MG	A205227	003	Jun 29, 2016
		140MG	A205227	004	Jun 29, 2016
		180MG	A205227	005	Jun 29, 2016
		250MG	A205227	006	Jun 29, 2016
	WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017
		20MG	A203959	002	Apr 18, 2017
		100MG	A203959	003	Apr 18, 2017
		140MG	A203959	004	Apr 18, 2017
		250MG	A203959	005	Apr 18, 2017

TENIPOSIDE

INJECTABLE;INJECTION					
VUMON					
+	HQ SPECLT PHARMA	10MG/ML	N020119	001	Jul 14, 1992

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL					
TENOFOVIR DISOPROXIL FUMARATE					
	CASI PHARMS INC	300MG	A209550	001	Feb 26, 2018
	MYLAN	150MG	A206569	001	Nov 27, 2018
		200MG	A206569	002	Nov 27, 2018
		250MG	A206569	003	Nov 27, 2018
		300MG	A206569	004	Nov 27, 2018

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL					
HYTRIN					
+	ABBOTT	EQ 1MG BASE **	N020347	001	Dec 14, 1994
+		EQ 2MG BASE **	N020347	002	Dec 14, 1994
+		EQ 5MG BASE **	N020347	003	Dec 14, 1994
+		EQ 10MG BASE **	N020347	004	Dec 14, 1994
TERAZOSIN HYDROCHLORIDE					
	BIONPHARMA	EQ 1MG BASE	A075667	001	Jul 28, 2000
		EQ 2MG BASE	A075667	002	Jul 28, 2000
		EQ 5MG BASE	A075667	003	Jul 28, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TERAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
TERAZOSIN HYDROCHLORIDE				
	EQ 10MG BASE	A075667	004	Jul 28, 2000
HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001
	EQ 2MG BASE	A075498	002	Apr 12, 2001
	EQ 5MG BASE	A075498	003	Apr 12, 2001
	EQ 10MG BASE	A075498	004	Apr 12, 2001
MYLAN	EQ 1MG BASE	A075140	002	Feb 11, 2000
	EQ 2MG BASE	A075140	003	Feb 11, 2000
	EQ 5MG BASE	A075140	001	Feb 11, 2000
	EQ 10MG BASE	A075140	004	Feb 11, 2000
MYLAN TECHNOLOGIES	EQ 1MG BASE	A075384	001	Dec 01, 2000
	EQ 2MG BASE	A075384	002	Dec 01, 2000
	EQ 5MG BASE	A075384	003	Dec 01, 2000
	EQ 10MG BASE	A075384	004	Dec 01, 2000
RANBAXY LABS LTD	EQ 1MG BASE	A076021	001	Aug 22, 2002
	EQ 2MG BASE	A076021	002	Aug 22, 2002
	EQ 5MG BASE	A076021	003	Aug 22, 2002
	EQ 10MG BASE	A076021	004	Aug 22, 2002
TABLET;ORAL				
HYTRIN				
ABBOTT	EQ 1MG BASE	N019057	001	Aug 07, 1987
	EQ 2MG BASE	N019057	002	Aug 07, 1987
	EQ 5MG BASE	N019057	003	Aug 07, 1987
	EQ 10MG BASE	N019057	004	Aug 07, 1987
TERAZOSIN HYDROCHLORIDE				
CHARTWELL RX	EQ 1MG BASE	A074657	001	Apr 28, 2000
	EQ 2MG BASE	A074657	002	Apr 28, 2000
	EQ 5MG BASE	A074657	003	Apr 28, 2000
	EQ 10MG BASE	A074657	004	Apr 28, 2000
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A074530	001	Apr 21, 2000
	EQ 2MG BASE	A074530	002	Apr 21, 2000
	EQ 5MG BASE	A074530	003	Apr 21, 2000
	EQ 10MG BASE	A074530	004	Apr 21, 2000
SANDOZ	EQ 1MG BASE	A074315	001	Dec 31, 1998
	EQ 2MG BASE	A074315	002	Dec 31, 1998
	EQ 5MG BASE	A074315	003	Dec 31, 1998
	EQ 10MG BASE	A074315	004	Dec 31, 1998
TEVA	EQ 1MG BASE	A074446	001	May 18, 2000
	EQ 2MG BASE	A074446	002	May 18, 2000
	EQ 5MG BASE	A074446	003	May 18, 2000
	EQ 10MG BASE	A074446	004	May 18, 2000
TERBINAFINE				
GEL;TOPICAL				
LAMISIL				
GLAXOSMITHKLINE CONS	1%	N020846	001	Apr 29, 1998
TERBINAFINE HYDROCHLORIDE				
CREAM;TOPICAL				
LAMISIL				
NOVARTIS	1% **	N020192	001	Dec 30, 1992
GRANULE;ORAL				
LAMISIL				
+ NOVARTIS	EQ 125MG BASE/PACKET	N022071	001	Sep 28, 2007
+	EQ 187.5MG BASE/PACKET	N022071	002	Sep 28, 2007
SOLUTION;TOPICAL				
LAMISIL				
GLAXOSMITHKLINE CONS	1%	N020749	001	Oct 17, 1997
TABLET;ORAL				
LAMISIL				
+ NOVARTIS	EQ 250MG BASE **	N020539	001	May 10, 1996
TERBINAFINE HYDROCHLORIDE				
GEDEON RICHTER USA	EQ 250MG BASE	A077065	001	Jul 02, 2007
HERITAGE PHARMA AVET	EQ 250MG BASE	A076377	001	Jul 02, 2007
MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007
	EQ 250MG BASE	A077195	001	Jul 02, 2007
ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007
WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TERBUTALINE SULFATE				
AEROSOL, METERED;INHALATION				
BRETHAIRE				
NOVARTIS	0.2MG/INH	N018762	001	Aug 17, 1984
BRICANYL				
SANOFI AVENTIS US	0.2MG/INH	N018000	001	Mar 19, 1985
INJECTABLE;INJECTION				
BRETHINE				
+ PHARMACARE	1MG/ML **	N018571	001	
BRICANYL				
SANOFI AVENTIS US	1MG/ML	N017466	001	
TERBUTALINE SULFATE				
AKORN	1MG/ML	A078151	001	Jan 07, 2008
DR REDDYS	1MG/ML	A076853	001	Jul 20, 2004
TABLET;ORAL				
BRICANYL				
SANOFI AVENTIS US	2.5MG	N017618	001	
	5MG	N017618	002	
TERCONAZOLE				
CREAM;VAGINAL				
TERAZOL 3				
+ JANSSEN PHARMS	0.8% **	N019964	001	Feb 21, 1991
TERAZOL 7				
+ JANSSEN PHARMS	0.4% **	N019579	001	Dec 31, 1987
SUPPOSITORY;VAGINAL				
TERAZOL 3				
+ JANSSEN PHARMS	80MG **	N019641	001	May 24, 1988
TERCONAZOLE				
FOUGERA PHARMS	80MG	A076850	001	Jul 12, 2006
TERIFLUNOMIDE				
TABLET;ORAL				
TERIFLUNOMIDE				
BRECKENRIDGE	7MG	A209583	001	Sep 24, 2021
	14MG	A209583	002	Sep 24, 2021
WATSON LABS TEVA	7MG	A209549	001	Jul 27, 2018
	14MG	A209549	002	Jul 27, 2018
TERIPARATIDE				
SOLUTION;SUBCUTANEOUS				
FORTEO				
LILLY	0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002
TERIPARATIDE ACETATE				
INJECTABLE;INJECTION				
PARATHAR				
SANOFI AVENTIS US	200 UNITS/VIAL	N019498	001	Dec 23, 1987
TESTOLACTONE				
INJECTABLE;INJECTION				
TESLAC				
BRISTOL MYERS SQUIBB	100MG/ML	N016119	001	
TABLET;ORAL				
TESLAC				
BRISTOL MYERS SQUIBB	50MG	N016118	001	
	250MG	N016118	002	
TESTOSTERONE				
FILM, EXTENDED RELEASE;TRANSDERMAL				
ANDRODERM				
+ ABBVIE	2MG/24HR **	N020489	003	Oct 20, 2011
	2.5MG/24HR	N020489	001	Sep 29, 1995
+	4MG/24HR **	N020489	004	Oct 20, 2011
	5MG/24HR	N020489	002	May 02, 1997
TESTODERM				
ALZA	4MG/24HR	N019762	001	Oct 12, 1993
	6MG/24HR	N019762	002	Oct 12, 1993
TESTODERM TTS				
ALZA	5MG/24HR	N020791	001	Dec 18, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TESTOSTERONE				
GEL;TRANSDERMAL				
ANDROGEL				
+	BESINS HLTHCARE	1.62% (20.25MG/1.25GM PACKET) **	N022309 002	Sep 07, 2012
+		1.62% (40.5MG/2.5GM PACKET) **	N022309 003	Sep 07, 2012
+		25MG/2.5GM PACKET **	N021015 001	Feb 28, 2000
+		50MG/5GM PACKET **	N021015 002	Feb 28, 2000
TESTOSTERONE				
	ANI PHARMS	25MG/2.5GM PACKET	N202763 001	Feb 14, 2012
		50MG/5GM PACKET	N202763 002	Feb 14, 2012
	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098 002	Jan 31, 2013
		50MG/5GM PACKET	N203098 003	Jan 31, 2013
GEL, METERED;TRANSDERMAL				
ANDROGEL				
+	BESINS HLTHCARE	12.5MG/1.25GM ACTUATION **	N021015 003	Sep 26, 2003
TESTOSTERONE				
	ALEMBIC	1.62% (20.25MG/1.25GM ACTUATION)	A213922 001	Mar 03, 2021
	PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098 001	Jan 31, 2013
INJECTABLE;INJECTION				
TESTOSTERONE				
	DR REDDYS	100MG/ML	A086417 001	Jul 07, 1983
	WATSON LABS	25MG/ML	A086420 001	May 10, 1983
		50MG/ML	A086419 001	Aug 23, 1983
SOLUTION, METERED;TRANSDERMAL				
AXIRON				
+	ELI LILLY AND CO	30MG/1.5ML ACTUATION **	N022504 001	Nov 23, 2010
TESTOSTERONE				
	ALEMBIC	30MG/1.5ML ACTUATION	A212882 001	Jun 14, 2021
	APOTEX	30MG/1.5ML ACTUATION	A209181 001	Nov 25, 2020
TABLET, EXTENDED RELEASE;BUCCAL				
STRIANT				
+	AUXILIUM PHARMS LLC	30MG	N021543 001	Jun 19, 2003
TESTOSTERONE CYPIONATE				
INJECTABLE;INJECTION				
DEPO-TESTOSTERONE				
	PFIZER	50MG/ML	A085635 001	
TESTOSTERONE CYPIONATE				
	RISING	200MG/ML	A040652 001	Dec 11, 2006
	WATSON LABS	100MG/ML	A084401 001	
		100MG/ML	A086029 001	
		200MG/ML	A084401 002	
SOLUTION;INTRAMUSCULAR				
TESTOSTERONE CYPIONATE				
+	SLAYBACK PHARMA LLC	200MG/ML (200MG/ML)	N216318 001	Jun 02, 2022
TESTOSTERONE ENANTHATE				
INJECTABLE;INJECTION				
DELATESTRYL				
	ENDO PHARMS	200MG/ML	N009165 001	
+		200MG/ML	N009165 003	
TESTOSTERONE ENANTHATE				
	RISING	200MG/ML	A040647 001	Oct 05, 2009
	WATSON LABS	100MG/ML	A083667 001	
		100MG/ML	A085599 001	
		200MG/ML	A083667 002	
TESTOSTERONE PROPIONATE				
INJECTABLE;INJECTION				
TESTOSTERONE PROPIONATE				
	BEL MAR	25MG/ML	A080741 001	
		50MG/ML	A080742 001	
		100MG/ML	A080743 001	
	ELKINS SINN	25MG/ML	A080276 001	
	LILLY	50MG/ML	A080254 002	
	WATSON LABS	25MG/ML	A080188 001	
		25MG/ML	A085490 001	
		50MG/ML	A080188 002	
		50MG/ML	A085490 002	
		100MG/ML	A080188 003	
		100MG/ML	A083595 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TETRABENAZINE

TABLET;ORAL				
TETRABENAZINE				
AJANTA PHARMA LTD	12.5MG	A213621	001	Dec 04, 2020
	25MG	A213621	002	Dec 04, 2020
HIKMA	12.5MG	A209739	001	Apr 08, 2019
	25MG	A209739	002	Apr 08, 2019
SUN PHARM	12.5MG	A206129	001	Aug 17, 2015
	25MG	A206129	002	Aug 17, 2015

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL				
ACHROMYCIN V				
+ AVET	250MG	N050278	003	
+	500MG	N050278	001	
BRISTACYCLINE				
BRISTOL	250MG	A061658	001	
	250MG	A061888	001	
	500MG	A061658	002	
	500MG	A061888	002	
CYCLOPAR				
WARNER CHILCOTT	250MG	A061725	001	
	250MG	A062175	001	
	250MG	A062332	001	
	500MG	A061725	002	
	500MG	A062332	002	
PANMYCIN				
PHARMACIA AND UPJOHN	250MG	A060347	001	
RETET				
SOLVAY	250MG	A061443	001	
	500MG	A061443	002	
ROBITET				
WYETH AYERST	250MG	A061734	001	
	500MG	A061734	002	
SUMYCIN				
APOTHECON	100MG	A060429	002	
	125MG	A060429	004	
	250MG	A060429	001	
	500MG	A060429	003	
TETRACHEL				
ANGUS	250MG	A060343	001	
	500MG	A060343	003	
TETRACYCLINE HYDROCHLORIDE				
ABBOTT	250MG	A061802	001	
	500MG	A061802	002	
ANI PHARMS	250MG	A061471	001	
AUROBINDO PHARMA USA	250MG	A060783	001	
	500MG	A060783	002	
ELKINS SINN	250MG	A060059	001	
FERRANTE	125MG	A060173	001	
	250MG	A060173	002	
HEATHER	250MG	A061148	001	
	500MG	A061148	002	
HIKMA	250MG	A060768	001	
	500MG	A060768	002	
IMPAX LABS	100MG	A060469	002	
	250MG	A060469	001	
	500MG	A060469	003	
IVAX SUB TEVA PHARMS	250MG	A060704	001	
	500MG	A060704	002	
MAST MM	250MG	A062085	001	
PUREPAC PHARM	250MG	A060290	001	
	500MG	A060290	002	
PVT FORM	250MG	A062686	001	Jul 24, 1986
	500MG	A062686	002	Jul 24, 1986
ROXANE	500MG	A061214	002	
SUN PHARM INDUSTRIES	250MG	A060736	001	
	500MG	A060736	002	
SUPERPHARM	250MG	A062540	001	Mar 21, 1985
	500MG	A062540	002	Mar 21, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL				
TETRACYCLINE HYDROCHLORIDE				
	VALEANT PHARM INTL	250MG	A060471 001	
		500MG	A060471 002	
	WARNER CHILCOTT	250MG	A062300 001	
		500MG	A062300 002	
	WATSON LABS	250MG	A062103 001	
		250MG	A062343 001	
		500MG	A062103 002	
		500MG	A062343 002	
	WYETH AYERST	250MG	A061685 001	
		500MG	A061685 002	
TETRACYN				
	PFIPHARMECS	250MG	A060082 003	
		500MG	A060082 004	
FIBER, EXTENDED RELEASE;PERIODONTAL				
ACTISITE				
	SCHIFF AND CO	12.7MG/FIBER	N050653 001	Mar 25, 1994
FOR SOLUTION;TOPICAL				
TOPICYCLINE				
	SHIRE	2.2MG/ML	N050493 001	
INJECTABLE;INJECTION				
ACHROMYCIN				
	LEDERLE	250MG/VIAL	N050273 002	
		500MG/VIAL	N050273 003	
TETRACYN				
	PFIZER	250MG/VIAL	A060096 001	
		500MG/VIAL	A060096 002	
OINTMENT;OPHTHALMIC				
ACHROMYCIN				
	STORZ	10MG/GM	N050266 001	
SUSPENSION;ORAL				
ACHROMYCIN V				
	LEDERLE	125MG/5ML	N050263 002	
SUMYCIN				
	PAR PHARM	125MG/5ML	A060400 001	
TETRACYCLINE HYDROCHLORIDE				
	ALPHARMA US PHARMS	125MG/5ML	A060633 001	
	FERRANTE	125MG/5ML	A060174 001	
	PROTER	125MG/5ML	A060446 001	
	PUREPAC PHARM	125MG/5ML	A060291 001	
TETRACYN				
	PFIPHARMECS	125MG/5ML	A060095 001	
TETRAMED				
	IVAX SUB TEVA PHARMS	125MG/5ML	A061468 001	
SUSPENSION/DROPS;OPHTHALMIC				
ACHROMYCIN				
	STORZ	1%	N050268 001	
TABLET;ORAL				
PANMYCIN				
	PHARMACIA AND UPJOHN	250MG	A061705 001	
		500MG	A061705 002	
SUMYCIN				
	STRIDES PHARMA	50MG	A061147 003	
		100MG	A061147 002	
		250MG	A061147 001	
		500MG	A061147 004	

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE;ORAL				
TETREX				
	BRISTOL	EQ 100MG HYDROCHLORIDE	A061653 001	
		EQ 250MG HYDROCHLORIDE	A061653 002	
		EQ 250MG HYDROCHLORIDE	A061889 002	
		EQ 250MG HYDROCHLORIDE	N050212 002	
		EQ 500MG HYDROCHLORIDE	A061653 003	
		EQ 500MG HYDROCHLORIDE	A061889 001	
		EQ 500MG HYDROCHLORIDE	N050212 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THALIDOMIDE				
CAPSULE;ORAL				
THALIDOMIDE				
NATCO	150MG	A213267	001	Apr 27, 2023
THALLOUS CHLORIDE TL-201				
INJECTABLE;INJECTION				
THALLOUS CHLORIDE TL 201				
BRACCO	1mCi/ML	N018548	001	Dec 30, 1982
+ GE HEALTHCARE	1mCi/ML	N018110	002	Feb 27, 1996
+ LANTHEUS MEDCL	1mCi/ML	N017806	001	
TRACE LIFE	1mCi/ML	A075569	001	Nov 21, 2001
INJECTABLE;INTRAVENOUS				
THALLOUS CHLORIDE TL 201				
CURIUM	2mCi/ML	A077698	001	Nov 09, 2006
+ LANTHEUS MEDCL	2mCi/ML	N017806	002	Oct 09, 1998
THEOPHYLLINE				
CAPSULE;ORAL				
BRONKODYL				
SANOFI AVENTIS US	100MG	A085264	001	
	200MG	A085264	002	
ELIXOPHYLLIN				
FOREST LABS	100MG	A085545	001	Jul 31, 1984
	200MG	A083921	001	Jul 31, 1984
SOMOPHYLLIN-T				
FISONS	100MG	A087155	001	Feb 25, 1985
	200MG	A087155	002	Feb 25, 1985
	250MG	A087155	003	Feb 25, 1985
THEOPHYLLINE				
KV PHARM	100MG	A085263	001	
	200MG	A085263	002	
SCHERER RP	100MG	A084731	002	Nov 07, 1986
	200MG	A084731	001	Nov 07, 1986
	250MG	A084731	003	Nov 07, 1986
CAPSULE, EXTENDED RELEASE;ORAL				
AEROLATE III				
FLEMING PHARMS	65MG	A085075	003	Nov 24, 1986
AEROLATE JR				
FLEMING PHARMS	130MG	A085075	002	Nov 24, 1986
AEROLATE SR				
FLEMING PHARMS	260MG	A085075	001	Nov 24, 1986
ELIXOPHYLLIN SR				
FOREST LABS	125MG	A086826	001	Jan 29, 1985
	250MG	A086826	002	Jan 29, 1985
SLO-BID				
SANOFI AVENTIS US	50MG	A088269	001	Jan 31, 1985
	75MG	A089539	001	May 10, 1989
	100MG	A087892	001	Jan 31, 1985
	125MG	A089540	001	May 10, 1989
	200MG	A087893	001	Jan 31, 1985
	300MG	A087894	001	Jan 31, 1985
SLO-PHYLLIN				
SANOFI AVENTIS US	60MG	A085206	001	May 24, 1982
+	125MG	A085203	001	May 24, 1982
	250MG	A085205	001	May 24, 1982
SOMOPHYLLIN-CRT				
GRAHAM DM	50MG	A087763	001	Feb 27, 1985
	100MG	A087194	001	
	200MG	A088382	001	Feb 27, 1985
+	250MG	A087193	001	
	300MG	A088383	001	Feb 27, 1985
THEO-DUR				
SCHERING	50MG	A088022	001	Sep 10, 1985
	75MG	A088015	001	Sep 10, 1985
	125MG	A088016	001	Sep 10, 1985
	200MG	A087995	001	Sep 10, 1985
THEOBID				
WHITBY	260MG	A085983	001	Mar 20, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL					
THEOBID JR.					
WHITBY	130MG		A087854	001	Mar 20, 1985
THEOCLEAR L.A.-130					
SCHWARZ PHARMA	130MG		A086569	001	May 27, 1982
THEOCLEAR L.A.-260					
SCHWARZ PHARMA	260MG		A086569	002	May 27, 1982
THEOPHYL-SR					
ORTHO MCNEIL PHARM	125MG		A086480	001	Feb 08, 1985
	250MG		A086471	001	Feb 08, 1985
THEOPHYLLINE					
CENT PHARMS	125MG		A088654	001	Feb 12, 1985
	250MG		A088689	001	Feb 12, 1985
HOSPIRA	100MG		A089976	001	Jan 04, 1995
	200MG		A089977	001	Jan 04, 1995
	300MG		A089932	001	Jan 04, 1995
INWOOD LABS	100MG		A040052	001	Feb 14, 1994
	125MG		A040052	002	Feb 14, 1994
	200MG		A040052	003	Feb 14, 1994
	300MG		A040052	004	Feb 14, 1994
SANDOZ	260MG		A087462	001	May 11, 1982
THEOPHYLLINE-SR					
SCHERER RP	300MG		A088255	001	Jun 12, 1986
THEOVENT					
SCHERING	125MG		A087010	001	Jan 31, 1985
	250MG		A087910	001	Jan 31, 1985
ELIXIR;ORAL					
ELIXOMIN					
CENCI	80MG/15ML		A088303	001	Jan 25, 1984
LANOPHYLLIN					
LANNETT	80MG/15ML		A084578	001	
THEOLIXIR					
PANRAY	80MG/15ML		A084559	001	
THEOPHYL-225					
ORTHO MCNEIL PHARM	112.5MG/15ML		A086485	001	
THEOPHYLLINE					
ALPHARMA US PHARMS	80MG/15ML		A089223	001	May 27, 1988
CENCI	80MG/15ML		A087679	001	Apr 15, 1982
CHARTWELL RX	80MG/15ML		A085952	001	
HALSEY	80MG/15ML		A085169	001	
PHARM ASSOC	80MG/15ML		A086720	001	
+ PRECISION DOSE	80MG/15ML		A085863	001	
ROXANE	80MG/15ML		A084739	001	
TARO	80MG/15ML		A089626	001	Oct 28, 1988
WOCKHARDT	80MG/15ML		A086748	001	
INJECTABLE;INJECTION					
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	40MG/100ML		N019083	001	Nov 07, 1984
+	40MG/100ML		N019826	001	Aug 14, 1992
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	80MG/100ML		N019083	002	Nov 07, 1984
+	80MG/100ML		N019826	002	Aug 14, 1992
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	160MG/100ML		N019083	003	Nov 07, 1984
+	160MG/100ML		N019826	003	Aug 14, 1992
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	200MG/100ML		N019212	001	Nov 07, 1984
	200MG/100ML		N019826	004	Aug 14, 1992
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER					
+ B BRAUN	320MG/100ML		N019826	006	Aug 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	4MG/ML		N019212	003	Nov 07, 1984
	400MG/100ML		N019212	002	Nov 07, 1984
	400MG/100ML		N019826	005	Aug 14, 1992
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER					
BAXTER HLTHCARE	4MG/ML		N018649	007	Jul 26, 1982
	40MG/100ML		N018649	001	Jul 26, 1982
	80MG/100ML		N018649	002	Jul 26, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THEOPHYLLINE

INJECTABLE;INJECTION					
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER					
		160MG/100ML	N018649	003	Jul 26, 1982
		200MG/100ML	N018649	004	Jul 26, 1982
		320MG/100ML	N018649	006	Nov 13, 1985
		400MG/100ML	N018649	005	Jul 26, 1982
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	HOSPIRA INC	4MG/ML	N019211	007	Dec 14, 1984
+		40MG/100ML	N019211	001	Dec 14, 1984
		80MG/100ML	N019211	002	Dec 14, 1984
+		160MG/100ML	N019211	003	Dec 14, 1984
		200MG/100ML	N019211	004	Dec 14, 1984
+		320MG/100ML	N019211	006	Jan 20, 1988
		400MG/100ML	N019211	005	Dec 14, 1984
SOLUTION;ORAL					
AEROLATE					
	FLEMING PHARMS	150MG/15ML	A089141	001	Dec 03, 1986
THEOLAIR					
	3M	80MG/15ML	A086107	001	
THEOPHYLLINE					
+	ROXANE	80MG/15ML	A087449	001	Sep 15, 1983
SUSPENSION;ORAL					
ELIXICON					
	FOREST LABS	100MG/5ML	A085502	001	
SYRUP;ORAL					
ACCURBRON					
	SANOFI AVENTIS US	150MG/15ML	A088746	001	Nov 22, 1985
AQUAPHYLLIN					
	FERNDALE LABS	80MG/15ML	A087917	001	Jan 18, 1983
SLO-PHYLLIN					
	SANOFI AVENTIS US	80MG/15ML	A085187	001	
THEOCLEAR-80					
	CENT PHARMS	80MG/15ML	A087095	001	Mar 01, 1982
THEOPHYLLINE					
	ALPHARMA US PHARMS	80MG/15ML	A086001	001	
+		150MG/15ML	A086545	001	
TABLET;ORAL					
QUIBRON-T					
	MONARCH PHARMS	300MG	A088656	001	Aug 22, 1985
SLO-PHYLLIN					
	SANOFI AVENTIS US	100MG	A085202	001	
		200MG	A085204	001	
THEOCLEAR-100					
	CENT PHARMS	100MG	A085353	002	
THEOCLEAR-200					
	CENT PHARMS	200MG	A085353	001	
THEOLAIR					
	MEDICIS	125MG	A086399	001	
		250MG	A086399	002	
THEOPHYL-225					
	ORTHO MCNEIL PHARM	225MG	A084726	001	
TABLET, CHEWABLE;ORAL					
THEOPHYL					
	ORTHO MCNEIL PHARM	100MG	A086506	001	Sep 12, 1985
TABLET, EXTENDED RELEASE;ORAL					
DURAPHYL					
	FOREST LABS	100MG	A088503	001	Apr 03, 1985
		200MG	A088504	001	Apr 03, 1985
		300MG	A088505	001	Apr 03, 1985
LABID					
	WARNER CHILCOTT	250MG	A087225	001	
QUIBRON-T/SR					
	MONARCH PHARMS	300MG	A087563	001	Jun 21, 1983
SUSTAIRE					
	ROERIG	100MG	A085665	001	
		300MG	A085665	002	
T-PHYL					
	PHARM RES ASSOC	200MG	A088253	001	Aug 17, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THEOPHYLLINE				
TABLET, EXTENDED RELEASE;ORAL				
THEO-DUR				
+ SCHERING	100MG **		A085328 001	
+	200MG		A086998 001	
+	300MG **		A085328 002	
	450MG		A089131 001	Jun 25, 1986
THEOLAIR-SR				
3M	200MG		A088369 001	Jul 16, 1987
	250MG		A086363 002	Jul 16, 1987
	300MG		A088364 001	Jul 16, 1987
	500MG		A089132 001	Jul 16, 1987
THEOPHYLLINE				
ABLE	300MG		A040548 001	Apr 30, 2004
	400MG		A040543 001	Apr 27, 2004
	450MG		A040546 001	Apr 30, 2004
	600MG		A040539 001	Apr 27, 2004
HERITAGE PHARMA AVET	100MG		A089807 001	Apr 30, 1990
	200MG		A089808 001	Apr 30, 1990
INWOOD LABS	450MG		A040034 001	Apr 28, 1995
UNI-DUR				
SCHERING	400MG		A089822 001	Jan 04, 1995
	600MG		A089823 001	Jan 04, 1995
THEOPHYLLINE SODIUM GLYCINATE				
ELIXIR;ORAL				
SYNOPHYLATE				
CENT PHARMS	EQ 165MG BASE/15ML		N006333 008	
TABLET;ORAL				
ASBRON				
NOVARTIS	EQ 150MG BASE		A085148 001	
THIABENDAZOLE				
SUSPENSION;ORAL				
MINTEZOL				
MERCK SHARP DOHME	500MG/5ML		N016097 001	
TABLET, CHEWABLE;ORAL				
MINTEZOL				
MERCK SHARP DOHME	500MG		N016096 001	
THIAMINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
BETALIN S				
+ LILLY	100MG/ML		A080853 001	
THIAMINE HYDROCHLORIDE				
ABRAXIS PHARM	100MG/ML		A080509 001	
AKORN	100MG/ML		A087968 001	Oct 01, 1982
BEL MAR	100MG/ML		A080718 001	
	200MG/ML		A080712 001	
DELL LABS	100MG/ML		A083775 001	
HOSPIRA	100MG/ML		A040079 001	May 03, 1996
LUITPOLD	100MG/ML		A080667 001	
PARKE DAVIS	100MG/ML		A080770 001	
WATSON LABS	100MG/ML		A083534 001	
	200MG/ML		A083534 002	
WYETH AYERST	100MG/ML		A080553 001	
THIAMYLAL SODIUM				
INJECTABLE;INJECTION				
SURITAL				
PARKEDALE	1GM/VIAL		N007600 003	
	5GM/VIAL		N007600 005	
	10GM/VIAL		N007600 009	
THIETHYLPERAZINE MALATE				
INJECTABLE;INJECTION				
TORECAN				
NOVARTIS	5MG/ML		N012754 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THIETHYLPERAZINE MALEATE				
SUPPOSITORY;RECTAL				
TORECAN				
NOVARTIS	10MG	N013247	001	
TABLET;ORAL				
TORECAN				
NOVARTIS	10MG	N012753	001	
THIOPENTAL SODIUM				
SUSPENSION;RECTAL				
PENTOTHAL				
ABBOTT	400MG/GM	N011679	001	
THIORIDAZINE				
SUSPENSION;ORAL				
MELLARIL-S				
NOVARTIS	EQ 25MG HYDROCHLORIDE/5ML **	N017923	001	
	EQ 100MG HYDROCHLORIDE/5ML **	N017923	002	
THIORIDAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
MELLARIL				
NOVARTIS	30MG/ML **	N011808	012	
	100MG/ML **	N011808	018	
THIORIDAZINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	100MG/ML	A088229	001	Aug 23, 1983
ALPHARMA US PHARMS	30MG/ML	A087766	001	Apr 26, 1983
ANI PHARMS	30MG/ML	A089602	001	Nov 09, 1987
	100MG/ML	A089603	001	Nov 09, 1987
EPIC PHARMA LLC	30MG/ML	A040125	001	Aug 16, 1996
	100MG/ML	A040126	001	Aug 16, 1996
PHARM ASSOC	30MG/ML	A040187	001	Aug 28, 1997
	100MG/ML	A040213	001	May 29, 1998
SANDOZ	30MG/ML	A088307	001	Nov 23, 1983
	100MG/ML	A088308	001	Nov 23, 1983
WOCKHARDT	30MG/ML	A088258	001	Jul 25, 1983
	100MG/ML	A088227	001	Jul 05, 1983
THIORIDAZINE HYDROCHLORIDE INTENSOL				
ROXANE	30MG/ML	A088941	001	Dec 16, 1985
	100MG/ML	A088942	001	Dec 16, 1985
TABLET;ORAL				
MELLARIL				
+ NOVARTIS	10MG **	N011808	003	
+	15MG **	N011808	016	
+	25MG **	N011808	006	
+	50MG **	N011808	011	
+	100MG **	N011808	009	
+	150MG **	N011808	017	
+	200MG **	N011808	015	
THIORIDAZINE HYDROCHLORIDE				
ANI PHARMS	10MG	A088270	001	Apr 14, 1983
	10MG	A088493	001	May 17, 1985
	15MG	A088271	001	Apr 14, 1983
	25MG	A088272	001	Apr 14, 1983
	50MG	A088194	001	Apr 14, 1983
	100MG	A088273	001	Oct 03, 1983
	100MG	A088456	001	May 17, 1985
CHARTWELL RX	10MG	A088131	001	Aug 30, 1983
	15MG	A088132	001	Aug 30, 1983
	25MG	A088133	001	Aug 30, 1983
	50MG	A088134	001	Aug 30, 1983
	100MG	A088135	001	Nov 20, 1984
	150MG	A088136	001	Sep 17, 1986
	200MG	A088137	001	Sep 17, 1986
HERITAGE PHARMA AVET	10MG	A088476	001	Nov 08, 1983
	25MG	A088478	001	Nov 08, 1983
	50MG	A088479	001	Nov 08, 1983
	100MG	A088736	001	Jul 24, 1984
MUTUAL PHARM	10MG	A088375	001	Nov 18, 1983
	25MG	A087264	001	Nov 18, 1983
	50MG	A088370	001	Nov 18, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL					
THIORIDAZINE HYDROCHLORIDE					
	100MG		A088379	001	Nov 16, 1983
MYLAN	10MG		A088332	001	Jun 27, 1983
	25MG		A088333	001	Jun 27, 1983
	50MG		A088334	001	Jun 27, 1983
	100MG		A088335	001	Nov 18, 1983
PAR PHARM	10MG		A088351	001	Dec 05, 1983
	15MG		A088352	001	Dec 05, 1983
	25MG		A088336	001	Dec 05, 1983
	50MG		A088322	001	Dec 05, 1983
	100MG		A088480	001	Dec 29, 1983
	150MG		A089764	001	Feb 09, 1988
	200MG		A089765	001	Feb 09, 1988
ROXANE	10MG		A088663	001	Mar 15, 1984
	25MG		A088664	001	Mar 15, 1984
	50MG		A088665	001	Mar 15, 1984
	100MG		A089048	001	Feb 26, 1985
SUN PHARM INDUSTRIES	10MG		A089953	004	Aug 01, 1986
	15MG		A088461	001	Nov 18, 1983
	25MG		A089953	003	Aug 01, 1986
	50MG		A089953	002	Aug 01, 1986
	100MG		A089953	001	Oct 07, 1988
	150MG		A088737	001	Sep 26, 1984
	200MG		A088738	001	Oct 16, 1984
SUPERPHARM	10MG		A089103	001	Jul 02, 1985
	25MG		A089104	001	Jul 02, 1985
	50MG		A089105	001	Jul 02, 1985
WATSON LABS	10MG		A088412	001	Sep 12, 1983
	10MG		A088561	001	May 11, 1984
	15MG		A088345	001	Jul 28, 1983
	15MG		A088562	001	May 11, 1984
	25MG		A088296	001	Jul 28, 1983
	25MG		A088755	001	Jul 24, 1984
	50MG		A088323	001	Jul 28, 1983
	50MG		A088563	001	May 11, 1984
	100MG		A088284	001	Aug 25, 1983
	100MG		A088564	001	May 11, 1984
	150MG		A088410	001	Mar 05, 1984
	150MG		A088869	001	Jun 28, 1985
	200MG		A088381	001	Mar 14, 1984
WATSON LABS TEVA	15MG		A088477	001	Nov 08, 1983
	25MG		A088567	001	May 11, 1984
	200MG		A088872	001	Apr 26, 1985
WEST WARD	10MG		A088658	001	Mar 26, 1984
	15MG		A088659	001	Mar 26, 1984
	25MG		A088660	001	Mar 26, 1984
	50MG		A088661	001	Mar 26, 1984

THIOTEPA

INJECTABLE;INJECTION					
THIOPLEX					
+ IMMUNEX	15MG/VIAL **		N020058	001	Dec 22, 1994
THIOTEPA					
FRESENIUS KABI USA	15MG/VIAL		A075698	001	Sep 20, 2001
IMMUNEX	15MG/VIAL		N011683	001	
TEVA PARENTERAL	15MG/VIAL **		A075730	001	Apr 20, 2001
	30MG/VIAL **		A075730	002	Apr 20, 2001

THIOTHIXENE

CAPSULE;ORAL					
NAVANE					
+ PFIZER	1MG **		N016584	001	
+	2MG **		N016584	002	
+	5MG **		N016584	003	
+	10MG **		N016584	004	
+	20MG **		N016584	005	
THIOTHIXENE					
AM THERAP	1MG		A071884	001	Aug 12, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THIOTHIXENE				
CAPSULE;ORAL				
THIOTHIXENE				
	2MG		A071885 001	Aug 12, 1987
	5MG		A071886 001	Aug 12, 1987
	10MG		A071887 001	Aug 12, 1987
	20MG		A072200 001	Dec 17, 1987
CHARTWELL RX	1MG		A070600 001	Jun 05, 1987
	2MG		A070601 001	Jun 05, 1987
	5MG		A070602 001	Jun 05, 1987
	10MG		A070603 001	Jun 05, 1987
EPIC PHARMA LLC	1MG		A071529 002	Jun 24, 1987
	2MG		A071529 003	Jun 24, 1987
	5MG		A071529 001	Jun 24, 1987
	10MG		A071529 004	Jun 24, 1987
WATSON LABS	2MG		A071626 001	Jun 25, 1987
	5MG		A071627 001	Jun 25, 1987
	10MG		A071628 001	Jun 25, 1987
THIOTHIXENE HYDROCHLORIDE				
CONCENTRATE;ORAL				
NAVANE				
+ PFIZER	EQ 5MG BASE/ML		N016758 001	
THIOTHIXENE HYDROCHLORIDE				
ALPHARMA US PHARMS	EQ 5MG BASE/ML		A070969 001	Oct 16, 1987
PACO	EQ 1MG BASE/ML		A071917 001	Sep 20, 1989
	EQ 5MG BASE/ML		A071939 001	Dec 16, 1988
TEVA	EQ 5MG BASE/ML		A071184 001	Jun 22, 1987
TEVA PHARMS	EQ 5MG BASE/ML		A071554 001	Oct 16, 1987
THIOTHIXENE HYDROCHLORIDE INTENSOL				
HIKMA	EQ 5MG BASE/ML		A073494 001	Jun 30, 1992
INJECTABLE;INJECTION				
NAVANE				
PFIZER	EQ 2MG BASE/ML		N016904 001	
	EQ 10MG BASE/VIAL		N016904 002	
TIAGABINE HYDROCHLORIDE				
TABLET;ORAL				
GABITRIL				
CEPHALON	6MG		N020646 006	Nov 29, 2005
	8MG		N020646 007	Nov 29, 2005
	10MG		N020646 008	Nov 29, 2005
	20MG		N020646 004	Sep 30, 1997
TIAGABINE HYDROCHLORIDE				
AMNEAL PHARMS CO	2MG		A208181 001	Dec 08, 2017
	4MG		A208181 002	Dec 08, 2017
	12MG		A208181 003	Dec 08, 2017
	16MG		A208181 004	Dec 08, 2017
WILSHIRE PHARMS INC	2MG		A206857 001	Oct 13, 2017
	4MG		A206857 002	Oct 13, 2017
	12MG		A206857 003	Oct 13, 2017
	16MG		A206857 004	Oct 13, 2017
TICAGRELOR				
TABLET;ORAL				
TICAGRELOR				
AMNEAL	90MG		A208531 001	Jan 23, 2019
MYLAN	60MG		A208597 001	Jul 09, 2021
	90MG		A208597 002	Jul 09, 2021
SIGMAPHARM LABS LLC	90MG		A208596 001	Apr 07, 2020
SUNSHINE	90MG		A208508 001	Apr 06, 2020
WATSON LABS INC	60MG		A208390 001	Sep 04, 2018
	90MG		A208390 002	Sep 04, 2018
TICARCILLIN DISODIUM				
INJECTABLE;INJECTION				
TICAR				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL		N050497 001	
	EQ 3GM BASE/VIAL		A062690 001	Dec 19, 1986
	EQ 3GM BASE/VIAL		N050497 002	
	EQ 6GM BASE/VIAL		N050497 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TICARCILLIN DISODIUM				
INJECTABLE;INJECTION				
TICAR				
	EQ 20GM BASE/VIAL	N050497	004	
	EQ 30GM BASE/VIAL	N050497	005	Apr 04, 1984
TICLOPIDINE HYDROCHLORIDE				
TABLET;ORAL				
TICLID				
ROCHE PALO	125MG	N019979	001	Mar 24, 1993
	250MG	N019979	002	Oct 31, 1991
TICLOPIDINE HYDROCHLORIDE				
ACTAVIS ELIZABETH	250MG	A075253	001	Aug 20, 1999
CHARTWELL RX	250MG	A075318	001	Aug 20, 1999
	250MG	A075326	001	Aug 20, 1999
MYLAN	250MG	A075161	001	Sep 13, 1999
	250MG	A075316	001	Nov 02, 1999
SUN PHARM INDS INC	250MG	A075526	001	Sep 26, 2002
TEVA	250MG	A075149	001	Aug 20, 1999
WATSON LABS	250MG	A075309	001	Apr 26, 2000
TIGECYCLINE				
POWDER;INTRAVENOUS				
TIGECYCLINE				
XELLIA PHARMS APS	50MG/VIAL	A205722	001	Oct 18, 2019
TILUDRONATE DISODIUM				
TABLET;ORAL				
SKELID				
+ SANOFI AVENTIS US	EQ 200MG BASE **	N020707	001	Mar 07, 1997
TIMOLOL				
SOLUTION/DROPS;OPHTHALMIC				
TIMOLOL				
EPIC PHARMA LLC	EQ 0.25% BASE	A205309	001	Sep 30, 2016
	EQ 0.5% BASE	A205309	002	Sep 30, 2016
TIMOLOL MALEATE				
SOLUTION/DROPS;OPHTHALMIC				
TIMOLOL MALEATE				
AKORN	EQ 0.25% BASE	A074465	001	Mar 25, 1997
	EQ 0.25% BASE	A074515	001	Mar 25, 1997
	EQ 0.5% BASE	A074466	001	Mar 25, 1997
	EQ 0.5% BASE	A074516	001	Mar 25, 1997
APOTEX INC	EQ 0.25% BASE	A075411	001	Sep 08, 2000
	EQ 0.5% BASE	A075412	001	Sep 08, 2000
FOUGERA	EQ 0.25% BASE	A074667	001	Mar 25, 1997
	EQ 0.5% BASE	A074668	001	Mar 25, 1997
HIKMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002
TABLET;ORAL				
BLOCADREN				
+ MERCK	5MG **	N018017	001	
+	10MG **	N018017	002	
+	20MG **	N018017	004	
TIMOLOL MALEATE				
ANI PHARMS	5MG	A072917	001	Jul 31, 1991
	10MG	A072918	001	Jul 31, 1991
	20MG	A072919	001	Jul 31, 1991
CHARTWELL RX	5MG	A072550	001	Apr 13, 1989
	10MG	A072551	001	Apr 13, 1989
	20MG	A072552	001	Apr 13, 1989
QUANTUM PHARMICS	5MG	A072466	001	May 19, 1989
	10MG	A072467	001	May 19, 1989
	20MG	A072468	001	May 19, 1989
TEVA	5MG	A072648	001	Jun 16, 1993
	10MG	A072649	001	Jun 16, 1993
	20MG	A072650	001	Jun 16, 1993
USL PHARMA	5MG	A072001	001	Apr 11, 1989
	10MG	A072002	001	Apr 11, 1989
	20MG	A072003	001	Apr 11, 1989
WATSON LABS	5MG	A072269	001	Apr 11, 1989
	10MG	A072270	001	Apr 11, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TIMOLOL MALEATE				
TABLET;ORAL				
TIMOLOL MALEATE				
	20MG		A072271 001	Apr 11, 1989
TINIDAZOLE				
TABLET;ORAL				
TINIDAZOLE				
HIKMA	250MG		A201172 001	Apr 30, 2012
	500MG		A201172 002	Apr 30, 2012
TINZAPARIN SODIUM				
INJECTABLE;INJECTION				
INNOHEP				
LEO PHARMA AS	20,000 IU/ML		N020484 001	Jul 14, 2000
TIOCONAZOLE				
CREAM;TOPICAL				
TZ-3				
PFIZER	1%		N018682 001	Feb 18, 1983
TIOPRONIN				
TABLET, DELAYED RELEASE;ORAL				
TIOPRONIN				
PAR PHARM	100MG		A217219 001	Feb 24, 2023
	300MG		A217219 002	Feb 24, 2023
TIPRANAVIR				
SOLUTION;ORAL				
APTIVUS				
+ BOEHRINGER INGELHEIM	100MG/ML		N022292 001	Jun 23, 2008
TIROFIBAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
AGGRASTAT				
MEDICURE	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)		N020912 001	May 14, 1998
SOLUTION;INTRAVENOUS				
AGGRASTAT				
MEDICURE	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)		N020913 001	May 14, 1998
TIZANIDINE HYDROCHLORIDE				
CAPSULE;ORAL				
TIZANIDINE HYDROCHLORIDE				
MYLAN PHARMS INC	EQ 2MG BASE		A091502 001	Nov 09, 2012
	EQ 4MG BASE		A091502 002	Nov 09, 2012
	EQ 6MG BASE		A091502 003	Nov 09, 2012
PAR PHARM INC	EQ 2MG BASE		A207199 001	Mar 14, 2017
	EQ 4MG BASE		A207199 002	Mar 14, 2017
	EQ 6MG BASE		A207199 003	Mar 14, 2017
TABLET;ORAL				
TIZANIDINE HYDROCHLORIDE				
ANI PHARMS	EQ 2MG BASE		A076283 001	Jul 12, 2002
	EQ 2MG BASE		A076284 001	Jul 03, 2002
	EQ 2MG BASE		A076321 001	Sep 30, 2004
	EQ 2MG BASE		A076371 001	Apr 09, 2003
	EQ 4MG BASE		A076283 002	Jul 12, 2002
	EQ 4MG BASE		A076284 002	Jul 03, 2002
	EQ 4MG BASE		A076321 002	Sep 30, 2004
	EQ 4MG BASE		A076371 002	Apr 09, 2003
AUROBINDO PHARMA USA	EQ 2MG BASE		A076282 001	Dec 16, 2003
	EQ 4MG BASE		A076282 002	Dec 16, 2003
PAR PHARM INC	EQ 2MG BASE		A207170 001	Jan 26, 2017
	EQ 4MG BASE		A207170 002	Jan 26, 2017
RISING	EQ 2MG BASE		A076354 001	Mar 28, 2003
	EQ 4MG BASE		A076354 002	Mar 28, 2003
ZANAFLEX				
+ LEGACY PHARMA USA	EQ 2MG BASE **		N020397 002	Feb 04, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TOBRAMYCIN				
SOLUTION;INHALATION				
TOBRAMYCIN				
LUOXIN AUROVITAS	300MG/5ML	A210871	001	Jan 22, 2021
MYLAN	300MG/5ML	A209554	001	Oct 13, 2017
SOLUTION/DROPS;OPHTHALMIC				
AKTOB				
EPIC PHARMA LLC	0.3%	A064096	001	Jan 31, 1996
TOBRAMYCIN				
ALCON PHARMS LTD	0.3%	A063176	001	May 25, 1994
APOTEX INC	0.3%	A065087	001	Feb 25, 2002
TOBRAMYCIN SULFATE				
INJECTABLE;INJECTION				
NEBCIN				
LILLY	EQ 10MG BASE/ML	A062008	004	
	EQ 10MG BASE/ML	A062707	001	Apr 29, 1987
+	EQ 10MG BASE/ML **	N050477	005	
	EQ 40MG BASE/ML	A062008	001	
+	EQ 1.2GM BASE/VIAL **	N050519	001	
TOBRAMYCIN SULFATE				
APOTHECON	EQ 10MG BASE/ML	A064021	001	May 31, 1994
	EQ 40MG BASE/ML	A064021	002	May 31, 1994
	EQ 40MG BASE/ML	A064026	001	May 31, 1994
EPIC PHARMA LLC	EQ 40MG BASE/ML	A205179	001	Sep 16, 2014
HIKMA	EQ 10MG BASE/ML	A063113	001	Apr 26, 1991
	EQ 10MG BASE/ML	A063128	001	Nov 27, 1991
	EQ 40MG BASE/ML	A063118	001	Jul 29, 1991
	EQ 40MG BASE/ML	A063127	001	Nov 27, 1991
HOSPIRA	EQ 10MG BASE/ML	A063080	001	Apr 30, 1991
	EQ 10MG BASE/ML	A063112	001	Apr 30, 1991
	EQ 40MG BASE/ML	A063161	001	May 29, 1991
IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994
TEVA PHARMS USA	EQ 40MG BASE/ML	A063100	001	Jan 30, 1992
WATSON LABS INC	EQ 10MG BASE/ML	A062945	001	Aug 09, 1989
	EQ 40MG BASE/ML	A062945	002	Aug 09, 1989
TOBRAMYCIN SULFATE (PHARMACY BULK)				
HOSPIRA	EQ 40MG BASE/ML **	A063116	001	May 18, 1992
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
HOSPIRA	EQ 1.2MG BASE/ML	A063081	003	Jul 31, 1990
	EQ 1.6MG BASE/ML	A063081	006	Jun 02, 1993
	EQ 80MG BASE/100ML	A063081	001	Jul 31, 1990
TOCAINIDE HYDROCHLORIDE				
TABLET;ORAL				
TONOCARD				
ASTRAZENECA	400MG	N018257	001	Nov 09, 1984
	600MG	N018257	002	Nov 09, 1984
TOFACITINIB CITRATE				
TABLET;ORAL				
TOFACITINIB CITRATE				
AJANTA PHARMA LTD	EQ 10MG BASE	A212943	001	Jun 01, 2021
MICRO LABS	EQ 5MG BASE	A209738	001	Mar 13, 2023
ZYDUS PHARMS	EQ 5MG BASE	A209829	001	Mar 13, 2023
TABLET, EXTENDED RELEASE;ORAL				
TOFACITINIB				
ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021
	EQ 22MG BASE	A214264	002	Aug 19, 2021
TOLAZAMIDE				
TABLET;ORAL				
TOLAZAMIDE				
BARR	100MG	A070162	001	Jan 14, 1986
	250MG	A070163	001	Jan 14, 1986
	500MG	A070164	001	Jan 14, 1986
CHARTWELL RX	100MG	A071633	001	Dec 09, 1987
	250MG	A070289	001	Mar 13, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

	500MG		A070290 001	Mar 13, 1986
COSETTE	100MG		N018894 001	Nov 02, 1984
	250MG		N018894 002	Nov 02, 1984
	500MG		N018894 003	Nov 02, 1984
DURAMED PHARMS BARR	100MG		A070165 001	Jan 10, 1986
	250MG		A070166 001	Jan 10, 1986
	500MG		A070167 001	Jan 10, 1986
INTERPHARM	250MG		A071270 001	Sep 23, 1986
	500MG		A071271 001	Sep 23, 1986
MYLAN PHARMS INC	250MG		A070259 001	Jan 02, 1986
	500MG		A070259 003	Mar 17, 1986
PAR PHARM	100MG		A070159 001	Jan 06, 1986
	250MG		A070160 001	Jan 06, 1986
	500MG		A070161 001	Jan 06, 1986
SUN PHARM INDUSTRIES	100MG		A071357 001	Jul 16, 1987
	250MG		A071358 001	Jul 16, 1987
	500MG		A071359 001	Jul 16, 1987
SUPERPHARM	250MG		A070763 001	Jun 16, 1986
	500MG		A070764 001	Jun 16, 1986
USL PHARMA	100MG		A071355 001	Jan 11, 1988
	250MG		A070168 001	Apr 02, 1986
	500MG		A070169 001	Apr 02, 1986
WATSON LABS	100MG		A070242 001	Aug 01, 1986
	100MG		A070513 001	Jan 09, 1986
	250MG		A070243 001	Aug 01, 1986
	250MG		A070514 001	Jan 09, 1986
	500MG		A070244 001	Aug 01, 1986
	500MG		A070515 001	Jan 09, 1986

TOLINASE

+ PHARMACIA AND UPJOHN	100MG	**	N015500 002	
+	250MG	**	N015500 004	
+	500MG	**	N015500 005	

TOLAZOLINE HYDROCHLORIDE

INJECTABLE;INJECTION

PRISCOLINE

NOVARTIS	25MG/ML		N006403 005	Feb 22, 1985

TOLBUTAMIDE

TABLET;ORAL

ORINASE

PHARMACIA AND UPJOHN	250MG	**	N010670 002	
	500MG	**	N010670 001	

TOLBUTAMIDE

ALRA	500MG		A086141 001	
ANI PHARMS	500MG		A087093 001	
ASCOT	500MG		A087541 001	Mar 01, 1983
BARR	500MG		A087121 001	
CHARTWELL RX	500MG		A086574 001	
DAVA PHARMS INC	500MG		A086926 001	
MYLAN PHARMS INC	500MG		A086445 001	
PARKE DAVIS	500MG		A086047 001	
PUREPAC PHARM	500MG		A088950 001	Jun 17, 1985
SANDOZ	500MG		N012678 001	
SUPERPHARM	500MG		A088893 001	Nov 19, 1984
VANGARD	500MG		A087876 001	Apr 20, 1982
WATSON LABS	250MG		A089110 001	May 29, 1987
	500MG		A086109 001	
	500MG		A087318 001	
	500MG		A089111 001	May 29, 1987

TOLBUTAMIDE SODIUM

INJECTABLE;INJECTION

ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL		N012095 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TOLCAPONE				
TABLET;ORAL				
TASMAR				
BAUSCH	200MG	N020697	002	Jan 29, 1998
TOLCAPONE				
ALVOGEN	100MG	A207729	001	Jul 29, 2020
DR REDDYS LABS SA	100MG	A210095	001	Aug 01, 2019
TOLMETIN SODIUM				
CAPSULE;ORAL				
TOLECTIN DS				
+ ORTHO MCNEIL JANSSEN	EQ 400MG BASE	N018084	001	
TOLMETIN SODIUM				
ANI PHARMS	EQ 400MG BASE	A073308	001	Jan 24, 1992
	EQ 400MG BASE	A073392	001	Jan 24, 1992
	EQ 400MG BASE	A073519	001	May 29, 1992
FOSUN PHARMA	EQ 400MG BASE	A073462	001	Apr 30, 1992
SUN PHARM INDUSTRIES	EQ 400MG BASE	A073311	001	Nov 27, 1991
TEVA	EQ 400MG BASE	A073290	001	Nov 27, 1991
TABLET;ORAL				
TOLECTIN				
+ ORTHO MCNEIL JANSSEN	EQ 200MG BASE	N017628	001	
TOLECTIN 600				
+ ORTHO MCNEIL JANSSEN	EQ 600MG BASE	N017628	002	Mar 08, 1989
TOLMETIN SODIUM				
ANI PHARMS	EQ 600MG BASE	A073527	001	Jun 30, 1992
COSETTE	EQ 600MG BASE	A074399	001	Mar 28, 1996
	EQ 600MG BASE	A074729	001	Feb 27, 1997
FOSUN PHARMA	EQ 200MG BASE	A073588	001	Jul 31, 1992
	EQ 600MG BASE	A074002	001	Sep 27, 1993
SUN PHARM INDUSTRIES	EQ 200MG BASE	A073310	001	Nov 27, 1991
TOLTERODINE TARTRATE				
CAPSULE, EXTENDED RELEASE;ORAL				
TOLTERODINE TARTRATE				
AUROBINDO PHARMA USA	2MG	A201486	001	Oct 31, 2013
	4MG	A201486	002	Oct 31, 2013
TABLET;ORAL				
TOLTERODINE TARTRATE				
APOTEX CORP	1MG	A200164	001	Sep 25, 2012
	2MG	A200164	002	Sep 25, 2012
MYLAN PHARMS INC	1MG	A202641	001	Nov 27, 2012
	2MG	A202641	002	Nov 27, 2012
TOLVAPTAN				
TABLET;ORAL				
SAMSCA				
+ OTSUKA	60MG **	N022275	003	May 19, 2009
TOPIRAMATE				
CAPSULE;ORAL				
TOPAMAX SPRINKLE				
+ JANSSEN PHARMS	50MG **	N020844	003	Oct 26, 1998
TOPIRAMATE				
BARR	15MG	A076448	001	Apr 15, 2009
	25MG	A076448	002	Apr 15, 2009
FOSUN PHARMA	15MG	A079206	001	Oct 14, 2009
	25MG	A079206	002	Oct 14, 2009
STRIDES PHARMA	15MG	A078418	001	Oct 14, 2009
	25MG	A078418	002	Oct 14, 2009
WATSON LABS	15MG	A077868	001	Apr 15, 2009
	25MG	A077868	002	Apr 15, 2009
CAPSULE, EXTENDED RELEASE;ORAL				
TOPIRAMATE				
ZYDUS PHARMS	200MG	A216167	001	Feb 09, 2023
TABLET;ORAL				
TOPAMAX				
JANSSEN PHARMS	300MG	N020505	003	Dec 24, 1996
	400MG	N020505	006	Dec 24, 1996
TOPIRAMATE				
ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TOPIRAMATE

TABLET;ORAL

TOPIRAMATE

	50MG	A078637	002	Feb 27, 2013
	100MG	A078637	003	Feb 27, 2013
	200MG	A078637	004	Feb 27, 2013
BARR	25MG	A076315	001	Mar 27, 2009
	100MG	A076315	002	Mar 27, 2009
	200MG	A076315	003	Mar 27, 2009
CHARTWELL	25MG	A078410	001	Sep 11, 2013
	50MG	A078410	002	Sep 11, 2013
	100MG	A078410	003	Sep 11, 2013
	200MG	A078410	004	Sep 11, 2013
HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013
	50MG	A091185	002	Nov 25, 2013
	100MG	A091185	003	Nov 25, 2013
	200MG	A091185	004	Nov 25, 2013
MYLAN	25MG	A076314	001	Mar 27, 2009
	50MG	A076314	002	Mar 27, 2009
	100MG	A076314	003	Mar 27, 2009
	200MG	A076314	004	Mar 27, 2009
PLIVA HRVATSKA DOO	25MG	A077905	001	Mar 30, 2009
	50MG	A077905	002	Mar 30, 2009
	100MG	A077905	003	Mar 30, 2009
	200MG	A077905	004	Mar 30, 2009
ROXANE	25MG	A076306	001	Mar 27, 2009
	50MG	A076306	002	Mar 27, 2009
	100MG	A076306	003	Mar 27, 2009
	200MG	A076306	004	Mar 27, 2009
TEVA	25MG	A076317	001	Mar 27, 2009
	50MG	A076317	002	Mar 27, 2009
	100MG	A076317	003	Mar 27, 2009
	200MG	A076317	004	Mar 27, 2009
TORRENT PHARMS	25MG	A079153	001	Mar 27, 2009
	50MG	A079153	002	Mar 27, 2009
	100MG	A079153	003	Mar 27, 2009
	200MG	A079153	004	Mar 27, 2009
UPSHER SMITH LABS	25MG	A078499	001	Jan 07, 2010
	50MG	A078499	002	Jan 07, 2010
	100MG	A078499	003	Jan 07, 2010
	200MG	A078499	004	Jan 07, 2010
WATSON LABS	25MG	A077643	001	Mar 27, 2009
	50MG	A077643	002	Mar 27, 2009
	100MG	A077643	003	Mar 27, 2009
	200MG	A077643	004	Mar 27, 2009
WOCKHARDT	25MG	A090353	001	Sep 01, 2010
	50MG	A090353	002	Sep 01, 2010
	100MG	A090353	003	Sep 01, 2010
	200MG	A090353	004	Sep 01, 2010

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

FRESENIUS KABI USA	EQ 4MG BASE/VIAL	A091376	001	Nov 29, 2010
MEITHEAL	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012
MYLAN LABS LTD	EQ 4MG BASE/VIAL	A091542	001	Aug 28, 2012
SUN PHARM INDS LTD	EQ 4MG BASE/VIAL	A202203	001	Aug 29, 2013

SOLUTION;INTRAVENOUS

TOPOTECAN

+	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N200199	001	Feb 25, 2011
+		EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **	N200199	002	Feb 25, 2011
+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N200199	003	Feb 25, 2011

TOPOTECAN HYDROCHLORIDE

DASH PHARMS	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TORSEMIDE

INJECTABLE;INJECTION					
DEMADEX					
+	ROCHE	50MG/5ML (10MG/ML) **	N020137	002	Aug 23, 1993
+		20MG/2ML (10MG/ML) **	N020137	001	Aug 23, 1993
TORSEMIDE					
	AM REGENT	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010
		50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010
	WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008
		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008
TABLET;ORAL					
DEMADEX					
+	MYLAN SPECIALITY LP	5MG **	N020136	001	Aug 23, 1993
+		10MG **	N020136	002	Aug 23, 1993
+		20MG **	N020136	003	Aug 23, 1993
+		100MG **	N020136	004	Aug 23, 1993
SOAANZ					
+	SARFE PHARMS	20MG	N213218	001	Jun 14, 2021
+		60MG	N213218	002	Jun 14, 2021
TORSEMIDE					
	SUN PHARM INDS	5MG	A078478	001	Feb 26, 2008
		10MG	A078478	002	Feb 26, 2008
		20MG	A078478	003	Feb 26, 2008
		100MG	A078478	004	Feb 26, 2008
	TEVA	5MG	A076110	001	May 14, 2002
		10MG	A076110	002	May 14, 2002
		20MG	A076110	003	May 14, 2002
		100MG	A076110	004	May 14, 2002

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
CONZIP					
+	CIPHER PHARMS INC	150MG	N022370	004	Aug 01, 2011
TABLET;ORAL					
TRAMADOL HYDROCHLORIDE					
	ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013
	ACTAVIS ELIZABETH	50MG	A075960	001	Jun 19, 2002
	ASTA	50MG	A075974	001	Jul 12, 2002
	GRAVITI PHARMS	50MG	A075968	001	Jun 25, 2002
	IVAX SUB TEVA PHARMS	50MG	A075963	001	Jul 03, 2002
	MACLEODS PHARMS LTD	50MG	A205702	001	Sep 25, 2015
	MYLAN	50MG	A075986	001	Jun 21, 2002
	MYLAN PHARMS INC	50MG	A075980	001	Nov 21, 2002
	NORTHSTAR HLTHCARE	50MG	A078935	001	May 26, 2010
	PLIVA	50MG	A075982	001	Jul 01, 2002
	SPECGX LLC	50MG	A075983	001	Jun 25, 2002
	SUN PHARM INDUSTRIES	50MG	A076100	001	Jun 20, 2002
	WATSON LABS	50MG	A075962	001	Jun 24, 2002
ULTRAM					
+	JANSSEN PHARMS	50MG **	N020281	002	Mar 03, 1995
+		100MG **	N020281	001	Mar 03, 1995
TABLET, EXTENDED RELEASE;ORAL					
RYZOLT					
+	PURDUE PHARMA	100MG **	N021745	001	Dec 30, 2008
+		200MG **	N021745	002	Dec 30, 2008
+		300MG **	N021745	003	Dec 30, 2008
TRAMADOL HYDROCHLORIDE					
	ACTAVIS ELIZABETH	100MG	A091609	001	Jun 27, 2012
		200MG	A091609	002	Jun 27, 2012
		300MG	A091609	003	Jun 27, 2012
	ANCHEN PHARMS	100MG	A200491	001	Jun 27, 2012
		200MG	A200491	002	Jun 27, 2012
		300MG	A200491	003	Jun 27, 2012
	AUROBINDO PHARMA LTD	100MG	A204421	001	Oct 20, 2015
		200MG	A204421	002	Oct 20, 2015
		300MG	A204421	003	Oct 20, 2015
	MYLAN	100MG	A205257	001	Dec 22, 2015
		200MG	A205257	002	Dec 22, 2015
		300MG	A205257	003	Dec 22, 2015
	STRIDES PHARMA	100MG	A078783	001	Nov 13, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRAMADOL HYDROCHLORIDE					
TABLET, EXTENDED RELEASE;ORAL					
TRAMADOL HYDROCHLORIDE					
		200MG	A078783	002	Nov 13, 2009
		300MG	A078783	003	Sep 20, 2011
	SUN PHARM	200MG	A091607	002	Dec 30, 2011
ULTRAM ER					
+	VALEANT PHARMS	100MG **	N021692	001	Sep 08, 2005
+		200MG **	N021692	002	Sep 08, 2005
+		300MG **	N021692	003	Sep 08, 2005
TABLET, ORALLY DISINTEGRATING;ORAL					
RYBIX ODT					
	SHIONOGI INC	50MG	N021693	001	May 05, 2005
TRAMETINIB DIMETHYL SULFOXIDE					
TABLET;ORAL					
MEKINIST					
+	NOVARTIS	EQ 1MG	N204114	002	May 29, 2013
TRANDOLAPRIL					
TABLET;ORAL					
MAVIK					
+	ABBVIE	1MG **	N020528	001	Apr 26, 1996
+		2MG **	N020528	002	Apr 26, 1996
+		4MG **	N020528	003	Apr 26, 1996
TRANDOLAPRIL					
	CHARTWELL MOLECULAR	1MG	A077307	002	Jun 12, 2007
		2MG	A077307	001	Jun 12, 2007
		4MG	A077307	003	Jun 12, 2007
	DR REDDYS LABS LTD	1MG	A078493	001	Aug 25, 2008
		2MG	A078493	002	Aug 25, 2008
		4MG	A078493	003	Aug 25, 2008
	EPIC PHARMA LLC	1MG	A077256	001	Jun 12, 2007
		2MG	A077256	002	Jun 12, 2007
		4MG	A077256	003	Jun 12, 2007
	INVAGEN PHARMS	1MG	A078320	001	Jun 12, 2007
		2MG	A078320	002	Jun 12, 2007
		4MG	A078320	003	Jun 12, 2007
	MYLAN	1MG	A078346	001	Apr 28, 2008
		2MG	A078346	002	Apr 28, 2008
		4MG	A078346	003	Apr 28, 2008
	TEVA PHARMS	1MG	A077489	001	Dec 12, 2006
		2MG	A077489	002	Dec 12, 2006
		4MG	A077489	003	Dec 12, 2006
	WATSON LABS	1MG	A077805	001	Jun 12, 2007
		2MG	A077805	002	Jun 12, 2007
		4MG	A077805	003	Jun 12, 2007
TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE					
TABLET, EXTENDED RELEASE;ORAL					
TARKA					
+	ABBVIE	1MG;240MG **	N020591	003	Oct 22, 1996
+		2MG;180MG	N020591	001	Oct 22, 1996
+		2MG;240MG	N020591	004	Oct 22, 1996
+		4MG;240MG	N020591	002	Oct 22, 1996
TRANEXAMIC ACID					
INJECTABLE;INJECTION					
TRANEXAMIC ACID					
	AKORN	100MG/ML	A206594	001	Sep 28, 2017
	CHARTWELL RX	100MG/ML	A202755	001	Feb 25, 2016
	RISING	100MG/ML	A206634	001	Jun 09, 2016
	ZYDUS PHARMS	100MG/ML	A205228	001	Jul 17, 2017
TABLET;ORAL					
CYKLOKAPRON					
	PHARMACIA AND UPJOHN	500MG	N019280	001	Dec 30, 1986
TRANEXAMIC ACID					
	APOTEX	650MG	A202286	001	Jan 27, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRAVOPROST				
SOLUTION/DROPS;OPHTHALMIC				
IZBA				
+ NOVARTIS	0.003% **	N204822 001	May 15, 2014	
TRAVATAN				
+ ALCON PHARMS LTD	0.004% **	N021257 001	Mar 16, 2001	
TRAZODONE HYDROCHLORIDE				
TABLET;ORAL				
DESYREL				
+ PRAGMA	50MG **	N018207 001		
+	100MG **	N018207 002		
+	150MG **	N018207 003	Mar 25, 1985	
+	300MG **	N018207 004	Nov 07, 1988	
TRAZODONE HYDROCHLORIDE				
ALVOGEN	50MG	A071636 001	Apr 18, 1988	
	100MG	A071514 001	Apr 18, 1988	
AM THERAP	50MG	A071139 001	Oct 29, 1986	
	100MG	A071140 001	Oct 29, 1986	
FOSUN PHARMA	100MG	A072483 001	Apr 30, 1990	
MYLAN	50MG	A071405 001	Feb 27, 1991	
	100MG	A071406 001	Feb 27, 1991	
MYLAN PHARMS INC	50MG	A090514 001	Jun 02, 2009	
	100MG	A090514 002	Jun 02, 2009	
	150MG	A090514 003	Jun 02, 2009	
	300MG	A090514 004	Jun 02, 2009	
QUANTUM PHARMICS	100MG	A070921 001	Dec 01, 1986	
RISING	50MG	A072484 001	Apr 30, 1990	
TEVA	150MG	A074357 001	Apr 30, 1997	
USL PHARMA	50MG	A070491 001	Apr 29, 1987	
	100MG	A070492 001	Apr 29, 1987	
WATSON LABS	50MG	A070857 001	Oct 10, 1986	
	50MG	A071112 001	Nov 17, 1986	
	100MG	A070858 001	Oct 10, 1986	
	100MG	A071113 001	Nov 17, 1986	
TRIALODINE				
QUANTUM PHARMICS	50MG	A070942 001	Dec 01, 1986	
TABLET, EXTENDED RELEASE;ORAL				
OLEPTRO				
+ ANGELINI PHARMA	150MG **	N022411 001	Feb 02, 2010	
+	300MG **	N022411 002	Feb 02, 2010	
TREPROSTINIL				
SOLUTION;INTRAVENOUS, SUBCUTANEOUS				
REMODULIN				
UNITED THERAP	20MG/20ML (1MG/ML)	N208276 001	Jul 30, 2018	
	50MG/20ML (2.5MG/ML)	N208276 002	Jul 30, 2018	
	100MG/20ML (5MG/ML)	N208276 003	Jul 30, 2018	
	200MG/20ML (10MG/ML)	N208276 004	Jul 30, 2018	
TRETINOIN				
CAPSULE;ORAL				
VESANOID				
+ CHEPLAPHARM	10MG **	N020438 001	Nov 22, 1995	
CREAM;TOPICAL				
RENOVA				
+ VALEANT PHARMS NORTH	0.05% **	N019963 001	Dec 29, 1995	
TRETINOIN				
ALLERGAN	0.0375%	A090098 001	Mar 22, 2010	
	0.075%	A202209 001	Oct 11, 2012	
ZO SKIN HEALTH	0.05%	A076498 001	Sep 15, 2005	
GEL;TOPICAL				
AVITA				
MYLAN	0.025%	N020400 001	Jan 29, 1998	
TRETINOIN				
MYLAN	0.04%	A202567 001	Jul 17, 2013	
	0.1%	A202026 001	Jul 17, 2013	
SOLUTION;TOPICAL				
RETIN-A				
+ VALEANT INTL	0.05%	N016921 001		

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRETINOIN				
SOLUTION;TOPICAL				
TRETINOIN				
TEVA PHARMS	0.05%	A074873	001	Jun 19, 1998
WOCKHARDT	0.05%	A075260	001	Jan 25, 1999
SWAB;TOPICAL				
RETIN-A				
VALEANT INTL	0.05%	N016921	002	
TRIAMCINOLONE				
TABLET;ORAL				
ARISTOCORT				
ASTELLAS	1MG	N011161	009	
	2MG	N011161	004	
	4MG	N011161	007	
	8MG	N011161	011	
	16MG	N011161	010	
KENACORT				
DELCOR ASSET CORP	1MG	N011283	003	
	2MG	N011283	008	
	4MG	N011283	006	
	8MG	N011283	010	
TRIAMCINOLONE				
BARR	2MG	A084286	001	
	2MG	A084318	001	
	4MG	A084267	001	
	4MG	A084319	001	
	8MG	A084268	001	
	8MG	A084320	001	
IMPAX LABS	4MG	A084340	001	
IVAX SUB TEVA PHARMS	4MG	A083750	001	
MYLAN	2MG	A084406	001	
PUREPAC PHARM	2MG	A084020	002	
	4MG	A084020	003	
ROXANE	2MG	A084708	001	
	4MG	A084709	001	
	8MG	A084707	001	
SANDOZ	4MG	A085601	001	
TEVA	4MG	A084775	001	
WATSON LABS	4MG	A084270	001	
	4MG	A085834	001	
TRIAMCINOLONE ACETONIDE				
AEROSOL, METERED;INHALATION				
AZMACORT				
ABBVIE	0.1MG/INH	N018117	001	Apr 23, 1982
AEROSOL, METERED;NASAL				
NASACORT				
CHATTEM SANOFI	0.055MG/INH	N019798	001	Jul 11, 1991
CREAM;TOPICAL				
ARISTOCORT				
ASTELLAS	0.025%	A083017	003	
	0.1%	A083016	004	
+	0.5%	A083015	002	
ARISTOCORT A				
ASTELLAS	0.025%	A083017	004	
	0.025%	A088818	001	Oct 16, 1984
	0.1%	A083016	005	
	0.1%	A088819	001	Oct 16, 1984
	0.5%	A083015	003	
	0.5%	A088820	001	Oct 16, 1984
FLUTEX				
IVAX PHARMS	0.025%	A085539	001	
	0.1%	A085539	002	
	0.5%	A085539	003	
KENALOG				
+ DELCOR ASSET CORP	0.5%	A083943	001	
KENALOG-H				
DELCOR ASSET CORP	0.1%	A086240	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL					
TRIACET					
	TEVA	0.025%	A084908	001	
		0.1%	A084908	002	
		0.5%	A084908	003	
TRIACORT					
	SOLVAY	0.1%	A087113	001	
TRIAMCINOLONE ACETONIDE					
	ACTAVIS MID ATLANTIC	0.1%	A087798	001	Jun 04, 1982
	ALPHARMA US PHARMS	0.025%	A087797	001	Jun 07, 1982
	AMBIX	0.025%	A087932	001	May 09, 1983
	MORTON GROVE	0.025%	A088094	001	Sep 01, 1983
		0.1%	A088095	001	Sep 01, 1983
		0.5%	A088096	001	Sep 01, 1983
+	MYLAN	0.025% **	N011601	003	
+		0.1% **	N011601	006	
	PHARMADERM	0.025%	A087990	001	Jul 07, 1983
		0.1%	A087991	001	Jul 07, 1983
		0.5%	A087992	001	Jul 07, 1983
	PHARMAFAIR	0.025%	A087921	001	Aug 10, 1982
		0.1%	A087912	001	Aug 10, 1982
		0.5%	A087922	001	Aug 10, 1982
	TARO	0.025%	A040038	001	Oct 26, 1994
		0.025%	A086277	001	
		0.1%	A086276	001	
		0.5%	A086275	001	
	TOPIDERM	0.025%	A089274	001	Feb 21, 1989
		0.1%	A089275	001	Feb 21, 1989
		0.5%	A089276	001	Feb 21, 1989
TRIATEX					
	IVAX PHARMS	0.025%	A087430	001	Nov 01, 1988
		0.1%	A087429	001	Nov 01, 1988
		0.5%	A087428	001	Nov 01, 1988
TRYMEX					
	SAVAGE LABS	0.025%	A088196	001	Mar 25, 1983
		0.1%	A088197	001	Mar 25, 1983
		0.5%	A088198	001	Mar 25, 1983
GEL;TOPICAL					
ARISTOGEL					
	ASTELLAS	0.1%	A083380	001	
INJECTABLE;INJECTION					
TRIAMCINOLONE ACETONIDE					
	PARNELL	3MG/ML	N019503	001	Oct 16, 1987
	SANDOZ	10MG/ML	A090166	001	May 27, 2009
		40MG/ML	A090164	001	Jun 01, 2009
	WATSON LABS	40MG/ML	A085825	001	
INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL					
TRIVARIS					
+	ALLERGAN	8MG/0.1ML (8MG/0.1ML) **	N022220	001	Jun 16, 2008
LOTION;TOPICAL					
KENALOG					
	DELCOR ASSET CORP	0.025% **	A084343	001	
+		0.025% **	N011602	003	
		0.1% **	A084343	002	
+		0.1% **	N011602	001	
TRIAMCINOLONE ACETONIDE					
	ALPHARMA US PHARMS	0.025%	A087191	001	Sep 08, 1982
		0.1%	A087192	001	Sep 08, 1982
	PAI HOLDINGS PHARM	0.025%	A204608	001	Jul 07, 2016
		0.1%	A204606	001	Jul 07, 2016
OINTMENT;TOPICAL					
ARISTOCORT					
	ASTELLAS	0.1%	A080750	004	
+		0.5% **	A080745	002	
ARISTOCORT A					
	ASTELLAS	0.1%	A080750	003	
		0.1%	A088780	001	Oct 01, 1984
+		0.5% **	A080745	003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL				
ARISTOCORT A				
	0.5%	A088781	001	Oct 05, 1984
FLUTEX				
IVAX PHARMS	0.025%	A087375	001	Nov 01, 1988
	0.1%	A087377	001	Nov 01, 1988
	0.5%	A087376	001	Nov 01, 1988
KENALOG				
+ DELCOR ASSET CORP	0.5% **	A083944	001	
TRIAMCINOLONE ACETONIDE				
ACTAVIS MID ATLANTIC	0.1%	A087799	001	Jun 07, 1982
ALPHARMA US PHARMS	0.5%	A089913	001	Dec 23, 1988
MORTON GROVE	0.025%	A088090	001	Sep 01, 1983
	0.1%	A088091	001	Sep 01, 1983
	0.5%	A088092	001	Sep 01, 1983
+ MYLAN	0.025% **	N011600	003	
+	0.1% **	N011600	001	
PAI HOLDINGS PHARM	0.5%	A208590	001	Mar 03, 2017
PHARMADERM	0.025%	A088692	001	Aug 02, 1984
	0.1%	A088690	001	Aug 02, 1984
STRIDES PHARMA	0.1%	A211315	001	Mar 18, 2020
	0.5%	A211315	002	Mar 18, 2020
TARO	0.025%	A040040	001	Sep 30, 1994
	0.025%	A040374	001	Jun 05, 2001
	0.1%	A087902	001	Dec 27, 1982
	0.5%	A040386	001	Jun 05, 2001
TRIANEX				
CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995
TRYMEX				
SAVAGE LABS	0.025%	A088693	001	Aug 02, 1984
	0.1%	A088691	001	Aug 02, 1984
PASTE;DENTAL				
KENALOG IN ORABASE				
+ DELCOR ASSET CORP	0.1% **	N012097	001	
ORALONE				
TARO	0.1%	A071383	001	Jul 06, 1987
SPRAY;TOPICAL				
KENALOG				
+ SUN PHARM INDS INC	0.147MG/GM	N012104	001	
SPRAY, METERED;NASAL				
ALLERNAZE				
LUPIN ATLANTIS	0.05MG/SPRAY	N020120	001	Feb 04, 2000
NASACORT HFA				
SANOFI AVENTIS US	0.055MG/SPRAY	N020784	001	Apr 07, 2004
TRIAMCINOLONE ACETONIDE				
PERRIGO PHARMA INTL	0.055MG/SPRAY	A078104	001	Jul 30, 2009

TRIAMCINOLONE DIACETATE

INJECTABLE;INJECTION				
ARISTOCORT				
FOSUN PHARMA	25MG/ML	N011685	003	
+	40MG/ML **	N012802	001	
TRIAMCINOLONE DIACETATE				
AKORN	25MG/ML	A085122	001	
	40MG/ML	A086394	001	
WATSON LABS	40MG/ML	A084072	001	
	40MG/ML	A085529	001	
SYRUP;ORAL				
ARISTOCORT				
ASTELLAS	2MG/5ML	N011960	004	
KENACORT				
DELCOR ASSET CORP	EQ 4MG BASE/5ML	N012515	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIAMCINOLONE HEXACETONIDE				
INJECTABLE;INJECTION				
ARISTOSPAN				
+ SANDOZ	5MG/ML **	N016466	001	
+	20MG/ML **	N016466	002	
TRIAMTERENE				
CAPSULE;ORAL				
TRIAMTERENE				
EYWA	50MG	A214768	001	Jul 06, 2022
	100MG	A214768	002	Jul 06, 2022
TRIAZOLAM				
TABLET;ORAL				
HALCION				
PFIZER	0.5MG	N017892	002	Nov 15, 1982
TRIAZOLAM				
MYLAN PHARMS INC	0.125MG	A074031	001	Mar 25, 1994
	0.25MG	A074031	002	Mar 25, 1994
WATSON LABS	0.125MG	A074445	001	Oct 20, 1995
	0.25MG	A074445	002	Oct 20, 1995
TRICHLORMETHIAZIDE				
TABLET;ORAL				
METAHYDRIN				
SANOFI AVENTIS US	2MG	N012594	001	Jun 16, 1988
	4MG	N012594	002	Jun 16, 1988
NAQUA				
SCHERING	2MG	N012265	001	
	4MG	N012265	002	
TRICHLOREX				
LANNETT	4MG	A083436	001	
	4MG	A085630	001	
TRICHLORMAS				
MAST MM	4MG	A086259	001	
TRICHLORMETHIAZIDE				
CHARTWELL RX	4MG	A085568	001	
IMPAX LABS	4MG	A083967	001	
PAR PHARM	2MG	A087007	001	
	4MG	A087005	001	
SANDOZ	4MG	A086171	001	
WATSON LABS	2MG	A083847	001	
	2MG	A086458	001	
	4MG	A083462	001	
	4MG	A083855	001	
	4MG	A085962	001	
TRICLOFOS SODIUM				
SOLUTION;ORAL				
TRICLOS				
SANOFI AVENTIS US	1.5GM/15ML	N016830	001	
TABLET;ORAL				
TRICLOS				
SANOFI AVENTIS US	750MG	N016809	002	
TRIDIHEXETHYL CHLORIDE				
INJECTABLE;INJECTION				
PATHILON				
LEDERLE	10MG/ML	N009729	001	
TABLET;ORAL				
PATHILON				
LEDERLE	25MG	N009489	005	
TRIENTINE HYDROCHLORIDE				
CAPSULE;ORAL				
CLOVIQUE				
CHARTWELL RX	250MG	A209731	001	Oct 21, 2019
TRIENTINE HYDROCHLORIDE				
ACCORD HLTHCARE	250MG	A212929	001	Aug 30, 2021
AMNEAL	250MG	A210619	001	Feb 08, 2019
CHARTWELL RX	250MG	A209415	001	Sep 16, 2019
LUPIN LTD	250MG	A211637	001	May 21, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIFLUOPERAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
STELAZINE				
+	GLAXOSMITHKLINE	EQ 10MG BASE/ML **	N011552 006	
TRIFLUOPERAZINE HYDROCHLORIDE				
	FOSUN PHARMA	EQ 10MG BASE/ML	A085787 001	Apr 15, 1982
	WOCKHARDT	EQ 10MG BASE/ML	A088143 001	Jul 26, 1983
INJECTABLE;INJECTION				
STELAZINE				
+	GLAXOSMITHKLINE	EQ 2MG BASE/ML **	N011552 005	
TABLET;ORAL				
STELAZINE				
+	GLAXOSMITHKLINE	EQ 1MG BASE **	N011552 001	
+		EQ 2MG BASE **	N011552 002	
+		EQ 5MG BASE **	N011552 003	
+		EQ 10MG BASE **	N011552 004	
TRIFLUOPERAZINE HYDROCHLORIDE				
	ATHEM	EQ 1MG BASE	A040153 001	Oct 25, 1996
		EQ 2MG BASE	A040153 002	Oct 25, 1996
		EQ 5MG BASE	A040153 003	Oct 25, 1996
		EQ 10MG BASE	A040153 004	Oct 25, 1996
	DURAMED PHARMS BARR	EQ 1MG BASE	A088967 001	Apr 23, 1985
		EQ 2MG BASE	A088968 001	Apr 23, 1985
		EQ 5MG BASE	A088969 001	Apr 23, 1985
		EQ 10MG BASE	A088970 001	Apr 23, 1985
	IVAX PHARMS	EQ 1MG BASE	A087612 001	Nov 19, 1982
		EQ 2MG BASE	A087613 001	Nov 19, 1982
		EQ 5MG BASE	A087328 001	Nov 19, 1982
		EQ 10MG BASE	A087614 001	Nov 19, 1982
	WATSON LABS	EQ 1MG BASE	A085975 001	Jun 23, 1988
		EQ 2MG BASE	A085976 001	Jun 23, 1988
		EQ 5MG BASE	A085973 001	Jun 23, 1988
		EQ 10MG BASE	A088710 001	Jun 23, 1988
TRIFLUPROMAZINE				
SUSPENSION;ORAL				
VESPRIN				
	APOTHECON	EQ 50MG HYDROCHLORIDE/5ML	N011491 004	
TRIFLUPROMAZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
VESPRIN				
	APOTHECON	3MG/ML	N011325 005	
		10MG/ML	N011325 004	
		20MG/ML	N011325 001	
TABLET;ORAL				
VESPRIN				
	BRISTOL MYERS SQUIBB	10MG	N011123 001	
		25MG	N011123 002	
		50MG	N011123 003	
TRIFLURIDINE				
SOLUTION/DROPS;OPHTHALMIC				
TRIFLURIDINE				
	HIKMA	1%	A205438 001	Jul 28, 2017
TRIHEXYPHENIDYL HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
ARTANE				
	LEDERLE	5MG	N006773 010	
		5MG	N012947 001	
ELIXIR;ORAL				
ARTANE				
	LEDERLE	2MG/5ML	N006773 009	
TRIHEXYPHENIDYL HYDROCHLORIDE				
	PHARM VENTURES	2MG/5ML	A089514 001	Apr 07, 1989
TABLET;ORAL				
ARTANE				
+	LEDERLE	2MG **	N006773 005	
+		5MG **	N006773 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIHEXYPHENIDYL HYDROCHLORIDE				
TABLET;ORAL				
TREMIN				
SCHERING	2MG	A080381	001	
	5MG	A080381	003	
TRIHEXYPHENIDYL HYDROCHLORIDE				
HIKMA	2MG	A040337	002	Feb 16, 2000
	5MG	A040337	001	Feb 16, 2000
NYLOS	5MG	A085622	001	
VANGARD	2MG	A088035	001	Jul 30, 1982
WATSON LABS	2MG	A040184	001	Feb 06, 1998
	2MG	A085117	001	
	5MG	A040184	002	Feb 06, 1998
	5MG	A085105	001	
TRILOSTANE				
CAPSULE;ORAL				
MODRASTANE				
BIOENVISION	30MG	N018719	002	Dec 31, 1984
	60MG	N018719	001	Dec 31, 1984
TRIMEPRAZINE TARTRATE				
CAPSULE, EXTENDED RELEASE;ORAL				
TEMARIL				
ALLERGAN HERBERT	EQ 5MG BASE	N011316	004	
SYRUP;ORAL				
TEMARIL				
ALLERGAN HERBERT	EQ 2.5MG BASE/5ML	N011316	003	
TRIMEPRAZINE TARTRATE				
ALPHARMA US PHARMS	EQ 2.5MG BASE/5ML	A085015	001	Feb 18, 1982
MORTON GROVE	EQ 2.5MG BASE/5ML	A088285	001	Apr 11, 1985
TABLET;ORAL				
TEMARIL				
ALLERGAN HERBERT	EQ 2.5MG BASE	N011316	001	
TRIMETHADIONE				
CAPSULE;ORAL				
TRIDIONE				
ABBVIE	300MG	N005856	005	
SOLUTION;ORAL				
TRIDIONE				
ABBVIE	200MG/5ML	N005856	002	
TABLET;ORAL				
TRIDIONE				
+ ABBVIE	150MG	N005856	009	
TRIMETHAPHAN CAMSYLATE				
INJECTABLE;INJECTION				
ARFONAD				
ROCHE	50MG/ML	N008983	001	
TRIMETHOBENZAMIDE HYDROCHLORIDE				
CAPSULE;ORAL				
TIGAN				
+ KING PHARMS LLC	300MG **	N017531	006	Dec 13, 2001
INJECTABLE;INJECTION				
TRIMETHOBENZAMIDE HYDROCHLORIDE				
AM REGENT	100MG/ML	A091330	001	Mar 08, 2011
HOSPIRA	100MG/ML	A088804	001	Apr 03, 1987
SMITH AND NEPHEW	100MG/ML	A088960	001	Apr 04, 1986
	100MG/ML	A089043	001	Apr 04, 1986
SOLOPAK	100MG/ML	A089094	001	Apr 04, 1986
WATSON LABS	100MG/ML	A086577	001	Oct 19, 1982
	100MG/ML	A087939	001	Dec 28, 1982
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE				
AM REGENT	100MG/ML	A091329	001	Mar 08, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIMETHOPRIM				
TABLET;ORAL				
PROLOPRIM				
MONARCH PHARMS	100MG	N017943	001	
	200MG	N017943	003	Jul 14, 1982
TRIMETHOPRIM				
SUN PHARM INDUSTRIES	100MG	A070494	001	Jan 22, 1986
	200MG	A070495	001	Sep 24, 1986
TEVA	200MG **	A071259	001	Jun 18, 1987
TRIMPEX				
ROCHE	100MG	N017952	001	
TRIMPEX 200				
ROCHE	200MG	N017952	002	Nov 09, 1982
TRIMETHOPRIM HYDROCHLORIDE				
SOLUTION;ORAL				
PRIMSOL				
ALLEGIS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995
+	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000
TRIMETREXATE GLUCURONATE				
INJECTABLE;INJECTION				
NEUTREXIN				
MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N020326	001	Dec 17, 1993
	EQ 200MG BASE/VIAL	N020326	002	Jul 31, 1998
TRIMIPRAMINE MALEATE				
CAPSULE;ORAL				
SURMONTIL				
+ ODYSSEY PHARMS	EQ 25MG BASE **	N016792	001	
+	EQ 50MG BASE **	N016792	002	
+	EQ 100MG BASE **	N016792	003	Sep 15, 1982
TRIMIPRAMINE MALEATE				
USL PHARMA	EQ 25MG BASE	A071283	001	Dec 08, 1987
	EQ 50MG BASE	A071284	001	Dec 08, 1987
	EQ 100MG BASE	A071285	001	Dec 08, 1987
TRIOXSALEN				
TABLET;ORAL				
TRISORALEN				
VALEANT PHARM INTL	5MG	N012697	001	
TRIPELENNAMINE CITRATE				
ELIXIR;ORAL				
PBZ				
NOVARTIS	EQ 25MG HYDROCHLORIDE/5ML	N005914	004	
TRIPELENNAMINE HYDROCHLORIDE				
TABLET;ORAL				
PBZ				
NOVARTIS	25MG	A083149	001	
	50MG	N005914	002	
TRIPELENNAMINE HYDROCHLORIDE				
ANABOLIC	50MG	A083037	001	
BARR	50MG	A080744	001	
HEATHER	50MG	A083989	001	
IMPAX LABS	50MG	A080785	001	
LANNETT	50MG	A083557	001	
NYLOS	50MG	A085412	001	
PARKE DAVIS	25MG	A083625	001	
	50MG	A083626	001	
WATSON LABS	50MG	A080713	001	
	50MG	A080790	001	
	50MG	A085188	001	
TABLET, EXTENDED RELEASE;ORAL				
PBZ-SR				
NOVARTIS	50MG	N010533	002	
	100MG	N010533	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM;VAGINAL				
GYNE-SULF				
	COSETTE	3.7%;2.86%;3.42%	A088607 001	Jun 09, 1986
SULTRIN				
	ORTHO MCNEIL PHARM	3.7%;2.86%;3.42%	N005794 001	
TRIPLE SULFA				
	ALPHARMA US PHARMS	3.7%;2.86%;3.42%	A087864 001	Sep 01, 1982
	FOUGERA	3.7%;2.86%;3.42%	A086424 001	
	PADAGIS US	3.7%;2.86%;3.42%	A087285 001	Nov 15, 1982
TRYSUL				
	SAVAGE LABS	3.7%;2.86%;3.42%	A087887 001	Jul 23, 1982
VAGILIA				
	COSETTE	3.7%;2.86%;3.42%	A088821 001	Nov 09, 1987
TABLET;VAGINAL				
SULTRIN				
	ORTHO MCNEIL PHARM	184MG;143.75MG;172.5MG	N005794 002	
TRIPLE SULFA				
	FOUGERA	184MG;143.75MG;172.5MG	A088463 001	Jan 03, 1985
	PHARMADERM	184MG;143.75MG;172.5MG	A088462 001	Jan 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL				
ACTIDIL				
	GLAXOSMITHKLINE	1.25MG/5ML	N011496 002	Jul 01, 1983
MYIDYL				
	USL PHARMA	1.25MG/5ML	A087963 001	Jan 18, 1983
TRIPROLIDINE HYDROCHLORIDE				
	ALPHARMA US PHARMS	1.25MG/5ML	A085940 001	
	HALSEY	1.25MG/5ML	A088735 001	Jan 17, 1985
	PHARM ASSOC	1.25MG/5ML	A087514 001	Feb 10, 1982
TABLET;ORAL				
ACTIDIL				
	GLAXOSMITHKLINE	2.5MG	N011110 002	Jul 01, 1983
TRIPROLIDINE HYDROCHLORIDE				
	VITARINE	2.5MG	A085610 001	
	WATSON LABS	2.5MG	A085094 001	

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION;ORAL				
LANTRISUL				
	LANNETT	167MG/5ML;167MG/5ML;167MG/5ML	A080123 002	
NEOTRIZINE				
	LILLY	167MG/5ML;167MG/5ML;167MG/5ML	N006317 012	
SULFALOID				
	FOREST PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080100 001	
SULFOSE				
	WYETH AYERST	167MG/5ML;167MG/5ML;167MG/5ML	A080013 002	
TERFONYL				
	BRISTOL MYERS SQUIBB	167MG/5ML;167MG/5ML;167MG/5ML	N006904 002	
TRIPLE SULFA				
	ALPHARMA US PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080280 001	
TRIPLE SULFAS				
	LEDERLE	167MG/5ML;167MG/5ML;167MG/5ML	N006920 003	
TABLET;ORAL				
NEOTRIZINE				
	LILLY	167MG;167MG;167MG	N006317 011	
SULFA-TRIPLE #2				
	IMPAX LABS	167MG;167MG;167MG	A080079 001	
SULFALOID				
	FOREST PHARMS	167MG;167MG;167MG	A080099 001	
SULFOSE				
	WYETH AYERST	167MG;167MG;167MG	A080013 001	
TERFONYL				
	BRISTOL MYERS SQUIBB	167MG;167MG;167MG	N006904 001	
TRIPLE SULFA				
	PUREPAC PHARM	167MG;167MG;167MG	A080086 001	
TRIPLE SULFAS				
	LEDERLE	167MG;167MG;167MG	N006920 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)				
TABLET;ORAL				
TRIPLE SULFOID				
PAL PAK	167MG;167MG;167MG	A080094	001	
TROGLITAZONE				
TABLET;ORAL				
PRELAY				
SANKYO	200MG	N020719	001	Jan 29, 1997
	300MG	N020719	003	Aug 04, 1997
	400MG	N020719	002	Jan 29, 1997
REZULIN				
PFIZER PHARMS	200MG	N020720	001	Jan 29, 1997
	300MG	N020720	003	Aug 04, 1997
	400MG	N020720	002	Jan 29, 1997
TROLAMINE POLYPEPTIDE OLEATE CONDENSATE				
SOLUTION/DROPS;OTIC				
CERUMENEX				
PHARM RES ASSOC	10%	N011340	002	
TROLEANDOMYCIN				
CAPSULE;ORAL				
TAO				
PFIZER	EQ 250MG BASE	N050336	002	
SUSPENSION;ORAL				
TAO				
PFIZER	EQ 125MG BASE/5ML	N050332	001	
TROPICAMIDE				
SOLUTION/DROPS;OPHTHALMIC				
MYDRIACYL				
ALCON	0.5% **	N012111	002	
	1% **	N012111	004	
MYDRIAFAIR				
PHARMAFAIR	0.5%	A088274	001	Sep 16, 1983
	1%	A088230	001	Sep 16, 1983
TROPICAMIDE				
AKORN	1%	A088447	001	Aug 28, 1985
ALCON PHARMS LTD	1%	A089172	001	Dec 28, 1990
MIZA PHARMS USA	0.5%	A087636	001	Jul 30, 1982
	1%	A087637	001	Aug 09, 1982
WATSON LABS	0.5%	A089171	001	Dec 28, 1990
TROSPIUM CHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
SANCTURA XR				
+ ALLERGAN	60MG **	N022103	001	Aug 03, 2007
TROSPIUM CHLORIDE				
UPSHER SMITH LABS	60MG	A091635	001	Apr 29, 2015
TABLET;ORAL				
SANCTURA				
+ ALLERGAN	20MG **	N021595	001	May 28, 2004
TROVAFLOXACIN MESYLATE				
TABLET;ORAL				
TROVAN				
PFIZER	EQ 100MG BASE	N020759	001	Dec 18, 1997
	EQ 200MG BASE	N020759	002	Dec 18, 1997
TRYPAN BLUE				
SOLUTION;OPHTHALMIC				
MEMBRANEBLUE				
+ DORC	0.15%	N022278	001	Feb 20, 2009
TUBOCURARINE CHLORIDE				
INJECTABLE;INJECTION				
TUBOCURARINE CHLORIDE				
BRISTOL MYERS SQUIBB	3MG/ML	N005657	001	
HOSPIRA	3MG/ML	N006095	001	
LILLY	3MG/ML	N006325	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TYROPANOATE SODIUM				
CAPSULE;ORAL				
BILOPAQUE				
	GE HEALTHCARE	750MG	N013731 001	
UMBRALISIB TOSYLATE				
TABLET;ORAL				
UKONIQ				
+	TG THERAPS	EQ 200MG BASE	N213176 001	Feb 05, 2021
UNOPROSTONE ISOPROPYL				
SOLUTION/DROPS;OPHTHALMIC				
RESCULA				
+	SUCAMPO PHARMA LLC	0.15% **	N021214 001	Aug 03, 2000
URACIL MUSTARD				
CAPSULE;ORAL				
URACIL MUSTARD				
	SHIRE	1MG	N012892 001	
UREA				
INJECTABLE;INJECTION				
STERILE UREA				
	HOSPIRA	40GM/VIAL	N017698 001	
UREAPHIL				
	HOSPIRA	40GM/VIAL	N012154 001	
UREA C-13				
FOR SOLUTION;ORAL				
BREATHTEK UBT FOR H-PYLORI				
	OTSUKA AMERICA	EQ 75MG/POUCH	N020586 002	May 10, 2001
HELICOSOL				
	METABOLIC SOLUTIONS	125MG/VIAL	N021092 001	Dec 17, 1999
MERETEK UBT KIT (W/ PRANACTIN)				
	OTSUKA AMERICA	125MG/VIAL	N020586 001	Sep 17, 1996
PYLORI-CHEK BREATH TEST				
	DXS DEVICES	100MG/VIAL	N020900 001	Feb 04, 1999
UREA, C-14				
CAPSULE;ORAL				
PYTEST KIT				
+	AVENT	1uCi	N020617 002	May 09, 1997
URSODIOL				
CAPSULE;ORAL				
ACTIGALL				
	TEVA BRANDED PHARM	150MG	N019594 001	Dec 31, 1987
URSODIOL				
	IMPAX LABS INC	300MG	A077895 001	Jul 27, 2006
	MYLAN	300MG	A090530 001	Feb 17, 2010
	TEVA PHARMS	300MG	A075592 001	May 25, 2000
TABLET;ORAL				
URSODIOL				
	IMPAX LABS INC	250MG	A200826 001	Dec 23, 2011
		500MG	A200826 002	Dec 23, 2011
	TEVA PHARMS USA	250MG	A079184 001	May 13, 2009
		500MG	A079184 002	May 13, 2009
VALACYCLOVIR HYDROCHLORIDE				
TABLET;ORAL				
VALACYCLOVIR HYDROCHLORIDE				
	HIKMA	EQ 500MG BASE	A078656 001	May 24, 2010
		EQ 1GM BASE	A078656 002	May 24, 2010
	MYLAN	EQ 500MG BASE	A078070 001	May 24, 2010
		EQ 1GM BASE	A078070 002	May 24, 2010
	TEVA PHARMS	EQ 500MG BASE	A077655 001	May 24, 2010
		EQ 1GM BASE	A077655 002	May 24, 2010
	WATSON LABS INC	EQ 500MG BASE	A090370 001	Mar 16, 2011
		EQ 1GM BASE	A090370 002	Mar 16, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VALDECOXIB				
TABLET;ORAL				
BEXTRA				
GD SEARLE	10MG	N021341	002	Nov 16, 2001
	20MG	N021341	003	Nov 16, 2001
VALGANCICLOVIR HYDROCHLORIDE				
TABLET;ORAL				
VALGANCICLOVIR HYDROCHLORIDE				
CIPLA	EQ 450MG BASE	A209672	001	Nov 09, 2018
MYLAN	EQ 450MG BASE	A205151	001	Mar 03, 2021
VALPROATE SODIUM				
INJECTABLE;INJECTION				
DEPACON				
+ ABBVIE	EQ 100MG BASE/ML **	N020593	001	Dec 30, 1996
VALPROATE SODIUM				
MYLAN	EQ 100MG BASE/ML	A208120	001	Dec 22, 2021
VALPROIC ACID				
CAPSULE;ORAL				
DEPAKENE				
+ ABBVIE	250MG **	N018081	001	
VALPROIC ACID				
PAR PHARM	250MG	A070431	001	Feb 28, 1986
SCHERER RP	250MG	A070195	001	Jul 02, 1987
UPSHER SMITH LABS	250MG	A070631	001	Jun 11, 1987
CAPSULE, DELAYED RELEASE;ORAL				
STAVZOR				
+ BIONPHARMA	125MG **	N022152	001	Jul 29, 2008
+	250MG **	N022152	002	Jul 29, 2008
+	500MG **	N022152	003	Jul 29, 2008
SYRUP;ORAL				
DEPAKENE				
+ ABBVIE	250MG/5ML **	N018082	001	
VALPROIC ACID				
LANNETT CO INC	250MG/5ML	A077960	001	Oct 13, 2006
NOSTRUM LABS INC	250MG/5ML	A077105	001	Jul 29, 2005
PHARMOBEDIENT CNSLTG	250MG/5ML	A070868	001	Jul 01, 1986
VALSARTAN				
CAPSULE;ORAL				
DIOVAN				
NOVARTIS	80MG	N020665	001	Dec 23, 1996
	160MG	N020665	002	Dec 23, 1996
SOLUTION;ORAL				
PREXXARTAN				
+ CARMEL BIOSCIENCES	20MG/5ML **	N209139	001	Dec 19, 2017
+	80MG/20ML **	N209139	002	Dec 19, 2017
TABLET;ORAL				
VALSARTAN				
IVAX PHARMS	40MG	A077530	001	Jan 04, 2016
	80MG	A077530	002	Jan 04, 2016
	160MG	A077530	003	Jan 04, 2016
	320MG	A077530	004	Jan 04, 2016
TORRENT	40MG	A202728	001	Jan 05, 2015
	80MG	A202728	002	Jan 05, 2015
	160MG	A202728	003	Jan 05, 2015
	320MG	A202728	004	Jan 05, 2015
UNICHEM	40MG	A209261	001	May 04, 2018
	80MG	A209261	002	May 04, 2018
	160MG	A209261	003	May 04, 2018
	320MG	A209261	004	May 04, 2018
WATSON LABS INC	40MG	A090642	001	Jan 05, 2015
	80MG	A090642	002	Jan 05, 2015
	160MG	A090642	003	Jan 05, 2015
	320MG	A090642	004	Jan 05, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VANCOMYCIN				
SOLUTION;INTRAVENOUS, ORAL				
VANCOMYCIN				
+ XELLIA PHARMS APS	5GM/100ML (50MG/ML)	N213895	001	Aug 26, 2021
VANCOMYCIN HYDROCHLORIDE				
CAPSULE;ORAL				
VANCOMYCIN HYDROCHLORIDE				
FRESENIUS KABI USA	EQ 125MG BASE	A065453	001	Jun 18, 2012
	EQ 250MG BASE	A065453	002	Jun 18, 2012
WATSON LABS	EQ 125MG BASE	A065510	001	Apr 09, 2012
	EQ 250MG BASE	A065510	002	Apr 09, 2012
FOR SOLUTION;ORAL				
VANCOCIN HYDROCHLORIDE				
ANI PHARMS	EQ 500MG BASE/6ML	A061667	001	
VANCOLED				
LEDERLE	EQ 250MG BASE/5ML	A063321	002	Oct 15, 1993
	EQ 500MG BASE/6ML	A063321	003	Oct 15, 1993
INJECTABLE;INJECTION				
VANCOCIN HYDROCHLORIDE				
STERISCIENCE	EQ 500MG BASE/VIAL **	A060180	001	
	EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984
	EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987
	EQ 500MG BASE/VIAL **	A062812	001	Nov 17, 1987
	EQ 1GM BASE/VIAL **	A060180	002	Mar 21, 1986
	EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986
	EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987
	EQ 1GM BASE/VIAL **	A062812	002	Nov 17, 1987
	EQ 10GM BASE/VIAL **	A062812	003	Nov 17, 1987
VANCOLED				
HIKMA	EQ 500MG BASE/VIAL **	A062682	001	Jul 22, 1986
	EQ 1GM BASE/VIAL **	A062682	002	Mar 30, 1988
	EQ 2GM BASE/VIAL **	A062682	003	May 11, 1988
	EQ 5GM BASE/VIAL **	A062682	004	May 11, 1988
	EQ 10GM BASE/VIAL **	A062682	005	May 11, 1988
VANCOMYCIN HYDROCHLORIDE				
AVET LIFESCIENCES	EQ 500MG BASE/VIAL	A202275	001	Oct 31, 2013
	EQ 1GM BASE/VIAL	A202275	002	Oct 31, 2013
	EQ 10GM BASE/VIAL	A202464	001	Oct 09, 2013
	EQ 5GM BASE/VIAL	A202274	001	Oct 31, 2013
HIKMA	EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988
	EQ 500MG BASE/VIAL	A203300	001	Aug 11, 2020
	EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988
KNACK	EQ 500MG BASE/VIAL	A213059	001	Feb 15, 2022
	EQ 750MG BASE/VIAL	A213059	002	Feb 15, 2022
	EQ 1GM BASE/VIAL	A213059	003	Feb 15, 2022
MYLAN LABS LTD	EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011
SANDOZ	EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010
	EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010
TEVA PHARMS USA	EQ 500MG BASE/VIAL	A201251	001	Dec 23, 2015
	EQ 1GM BASE/VIAL	A201251	002	Dec 23, 2015
	EQ 5GM BASE/VIAL	A201250	001	Dec 23, 2015
	EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015
XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015
	EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015
	EQ 5GM BASE/VIAL	A206243	001	Dec 23, 2015
	EQ 10GM BASE/VIAL	A206243	002	Dec 23, 2015
VANCOR				
PHARMACIA AND UPJOHN	EQ 500MG BASE/VIAL	A062956	001	Aug 01, 1988
	EQ 1GM BASE/VIAL	A062956	002	Aug 01, 1988
POWDER;INTRAVENOUS				
VANCOMYCIN HYDROCHLORIDE				
+ MYLAN LABS LTD	EQ 250MG BASE/VIAL **	N209481	001	Jul 10, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VARDENAFIL HYDROCHLORIDE				
TABLET;ORAL				
LEVITRA				
+ BAYER HLTHCARE	EQ 2.5MG BASE **	N021400	003	Aug 19, 2003
+	EQ 5MG BASE **	N021400	001	Aug 19, 2003
+	EQ 10MG BASE **	N021400	002	Aug 19, 2003
+	EQ 20MG BASE **	N021400	004	Aug 19, 2003
VARDENAFIL HYDROCHLORIDE				
STEVENS J	EQ 5MG BASE	A210738	001	Oct 31, 2018
	EQ 10MG BASE	A210738	002	Oct 31, 2018
	EQ 20MG BASE	A210738	003	Oct 31, 2018
TABLET, ORALLY DISINTEGRATING;ORAL				
STAXYN				
+ BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010
VARENICLINE TARTRATE				
TABLET;ORAL				
CHANTIX				
+ PF PRISM CV	EQ 0.5MG BASE **	N021928	001	May 10, 2006
+	EQ 1MG BASE **	N021928	002	May 10, 2006
VASOPRESSIN				
SOLUTION;INTRAVENOUS				
VASOSTRICT				
+ PAR STERILE PRODUCTS	50UNITS/50ML (1UNITS/ML)	N204485	006	Apr 12, 2023
+	60UNITS/100ML (0.6UNITS/ML)	N204485	004	Apr 15, 2020
VASOPRESSIN TANNATE				
INJECTABLE;INJECTION				
PITRESSIN TANNATE				
+ PARKE DAVIS	5PRESSOR UNITS/ML **	N003402	001	
VECURONIUM BROMIDE				
INJECTABLE;INJECTION				
NORCURON				
+ ORGANON USA INC	10MG/VIAL **	N018776	002	Apr 30, 1984
+	20MG/VIAL **	N018776	003	Jan 03, 1992
VECURONIUM BROMIDE				
HIKMA	10MG/VIAL	A075218	001	Aug 23, 1999
	20MG/VIAL	A075218	002	Aug 23, 1999
HOSPIRA	4MG/VIAL	A075558	001	Sep 11, 2001
WATSON LABS	10MG/VIAL	A074334	001	Aug 31, 1995
	20MG/VIAL	A074334	002	Aug 31, 1995
VENLAFAXINE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
EFFEXOR XR				
UPJOHN	EQ 100MG BASE	N020699	003	Oct 20, 1997
VENLAFAXINE HYDROCHLORIDE				
ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012
	EQ 75MG BASE	A078087	002	Mar 16, 2012
	EQ 150MG BASE	A078087	003	Mar 16, 2012
MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011
	EQ 75MG BASE	A078789	002	Jun 01, 2011
	EQ 150MG BASE	A078789	003	Jun 01, 2011
TORRENT	EQ 37.5MG BASE	A090899	001	Jun 01, 2011
	EQ 75MG BASE	A090899	002	Jun 01, 2011
	EQ 150MG BASE	A090899	003	Jun 01, 2011
TABLET;ORAL				
EFFEXOR				
+ WYETH PHARMS INC	EQ 12.5MG BASE **	N020151	001	Dec 28, 1993
+	EQ 25MG BASE **	N020151	002	Dec 28, 1993
+	EQ 37.5MG BASE **	N020151	006	Dec 28, 1993
+	EQ 50MG BASE **	N020151	003	Dec 28, 1993
+	EQ 75MG BASE **	N020151	004	Dec 28, 1993
+	EQ 100MG BASE **	N020151	005	Dec 28, 1993
VENLAFAXINE HYDROCHLORIDE				
CHARTWELL RX	EQ 25MG BASE	A077515	001	Jun 13, 2008
	EQ 37.5MG BASE	A077515	002	Jun 13, 2008
	EQ 50MG BASE	A077515	003	Jun 13, 2008
	EQ 75MG BASE	A077515	004	Jun 13, 2008
	EQ 100MG BASE	A077515	005	Jun 13, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL				
VENLAFAXINE HYDROCHLORIDE				
MYLAN	EQ 25MG BASE	A077166	001	Jun 13, 2008
	EQ 37.5MG BASE	A077166	002	Jun 13, 2008
	EQ 50MG BASE	A077166	003	Jun 13, 2008
	EQ 75MG BASE	A077166	004	Jun 13, 2008
	EQ 100MG BASE	A077166	005	Jun 13, 2008
PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517	001	Jun 13, 2008
	EQ 37.5MG BASE	A078517	002	Jun 13, 2008
	EQ 50MG BASE	A078517	003	Jun 13, 2008
	EQ 75MG BASE	A078517	004	Jun 13, 2008
	EQ 100MG BASE	A078517	005	Jun 13, 2008
PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010
	EQ 37.5MG BASE	A090027	002	Aug 04, 2010
	EQ 50MG BASE	A090027	003	Aug 04, 2010
	EQ 75MG BASE	A090027	004	Aug 04, 2010
	EQ 100MG BASE	A090027	005	Aug 04, 2010
TABLET, EXTENDED RELEASE;ORAL				
VENLAFAXINE HYDROCHLORIDE				
SUNNY	EQ 75MG BASE	A214423	001	Jan 04, 2022
	EQ 150MG BASE	A214423	002	Jan 04, 2022

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
VERAPAMIL HYDROCHLORIDE				
RISING	100MG	A078306	001	Aug 09, 2007
	200MG	A078306	002	Aug 09, 2007
	300MG	A078306	003	Aug 09, 2007
INJECTABLE;INJECTION				
CALAN				
GD SEARLE LLC	2.5MG/ML	N019038	001	Mar 30, 1984
ISOPTIN				
+ MT ADAMS	2.5MG/ML **	N018485	001	
VERAPAMIL HYDROCHLORIDE				
ABRAXIS PHARM	2.5MG/ML	A070348	001	May 01, 1986
BEDFORD	2.5MG/ML	A072888	001	Jul 28, 1995
HOSPIRA	2.5MG/ML	A070577	001	Feb 02, 1987
	2.5MG/ML	A070739	001	May 06, 1987
	2.5MG/ML	A070740	001	May 06, 1987
INTL MEDICATION	2.5MG/ML	A070451	001	Dec 16, 1985
LUITPOLD	2.5MG/ML	A070225	001	Nov 12, 1985
	2.5MG/ML	A070617	001	Nov 12, 1985
MARSAM PHARMS LLC	2.5MG/ML	A072233	001	Feb 26, 1993
	2.5MG/ML	A073485	001	Sep 27, 1993
SMITH AND NEPHEW	2.5MG/ML	A070696	001	Jul 31, 1987
	2.5MG/ML	A070697	001	Jul 31, 1987
SOLOPAK	2.5MG/ML	A070695	001	Jul 31, 1987
SOLUTION;INTRAVENOUS				
VERAPAMIL HYDROCHLORIDE				
EXELA PHARMA	10MG/4ML (2.5MG/ML)	N018925	002	Apr 05, 2018
TABLET;ORAL				
CALAN				
PFIZER	40MG **	N018817	003	Feb 23, 1988
+	80MG **	N018817	001	Sep 10, 1984
+	120MG **	N018817	002	Sep 10, 1984
	160MG **	N018817	004	Feb 23, 1988
ISOPTIN				
+ MT ADAMS	40MG **	N018593	003	Nov 23, 1987
+	80MG **	N018593	001	Mar 08, 1982
+	120MG **	N018593	002	Mar 08, 1982
VERAPAMIL HYDROCHLORIDE				
ACTAVIS ELIZABETH	80MG	A071019	001	Sep 24, 1986
	120MG	A070468	001	Sep 24, 1986
CHARTWELL RX	40MG	A073168	001	Jul 31, 1992
	80MG	A071423	001	May 24, 1988
	120MG	A071424	001	May 25, 1988
MUTUAL PHARM	80MG	A070482	001	Sep 24, 1986
	120MG	A070483	001	Sep 24, 1986
PLIVA	40MG	A072751	001	Feb 23, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VERAPAMIL HYDROCHLORIDE

TABLET;ORAL					
VERAPAMIL HYDROCHLORIDE					
	80MG		A072124	001	Jan 26, 1989
	120MG		A072125	001	Jan 26, 1989
RISING	80MG		A071483	002	Feb 15, 1989
	120MG		A071483	001	Feb 15, 1989
SUN PHARM INDUSTRIES	80MG		A071489	002	Jan 13, 1988
	120MG		A071489	001	Jan 13, 1988
WARNER CHILCOTT	80MG		A070340	001	Sep 24, 1986
	120MG		A070341	001	Sep 24, 1986
WATSON LABS	40MG		A072799	001	Apr 28, 1989
	40MG		A072923	001	Jun 29, 1993
	80MG		A070855	001	Sep 24, 1986
	80MG		A071366	001	Oct 01, 1986
	120MG		A070856	001	Sep 24, 1986
	120MG		A071367	001	Oct 01, 1986
TABLET, EXTENDED RELEASE;ORAL					
CALAN SR					
+ PFIZER	120MG		N019152	003	Mar 06, 1991
+	180MG	**	N019152	002	Dec 15, 1989
+	240MG		N019152	001	Dec 16, 1986
COVERA-HS					
PFIZER	180MG		N020552	001	Feb 26, 1996
	240MG		N020552	002	Feb 26, 1996
VERAPAMIL HYDROCHLORIDE					
APOTEX CORP	120MG		A200878	001	Apr 20, 2012
	180MG		A200878	002	Apr 20, 2012
	240MG		A200878	003	Apr 20, 2012
IVAX SUB TEVA PHARMS	120MG		A073568	002	Oct 10, 1997
	180MG		A074330	001	Jan 31, 1994
	240MG		A073568	001	Jul 31, 1992
PLIVA	240MG		A072922	001	Mar 01, 1996
RISING	120MG		A074587	002	Feb 21, 1997
	180MG		A074587	003	Sep 09, 1997
	240MG		A074587	001	Mar 23, 1996
SUN PHARM INDS INC	120MG		A090529	001	Dec 30, 2011
	180MG		A090529	002	Dec 30, 2011
	240MG		A090529	003	Dec 30, 2011

VERATRUM VIRIDE ROOT

TABLET;ORAL					
VERTAVIS					
MEDPOINTE PHARM HLC	130CSR UNIT		N005691	002	

VIDARABINE

INJECTABLE;INJECTION					
VIRA-A					
PARKEDALE	EQ 187.4MG BASE/ML		N050523	001	
OINTMENT;OPHTHALMIC					
VIRA-A					
PARKEDALE	3%		N050486	001	

VIGABATRIN

FOR SOLUTION;ORAL					
VIGABATRIN					
ACCORD HLTHCARE	500MG/PACKET		A214425	001	Nov 13, 2020
CHARTWELL RX	500MG/PACKET		A211790	001	Mar 10, 2022
GRANULES	500MG/PACKET		A213469	001	Apr 24, 2020
SPECGX LLC	500MG/PACKET		A212626	001	Jul 28, 2021
ZYDUS	500MG/PACKET		A214671	001	Mar 02, 2023

VINBLASTINE SULFATE

INJECTABLE;INJECTION					
VELBAN					
+ LILLY	10MG/VIAL	**	N012665	001	
VINBLASTINE SULFATE					
ABRAXIS PHARM	10MG/VIAL		A089011	001	Nov 18, 1985
HOSPIRA	10MG/VIAL		A089565	001	Aug 18, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VINCRISTINE SULFATE

INJECTABLE;INJECTION				
ONCOVIN				
+	LILLY	1MG/VIAL **	N014103 001	
+		1MG/ML **	N014103 003	Mar 07, 1984
+		5MG/VIAL **	N014103 002	
VINCASAR PFS				
	TEVA PARENTERAL	1MG/ML	A071426 001	Jul 17, 1987
VINCREX				
	BRISTOL MYERS SQUIBB	5MG/VIAL	A070867 001	Jul 12, 1988
VINCRISTINE SULFATE				
	ABIC	1MG/ML	A070873 001	Feb 19, 1987
	ABRAXIS PHARM	1MG/ML	A070411 001	Sep 10, 1986
	FRESENIUS KABI USA	1MG/ML	A076296 001	Dec 20, 2002
		1MG/ML	A076401 001	Oct 28, 2003
	HOSPIRA	1MG/VIAL	A071559 001	Apr 11, 1988
		2MG/VIAL	A071560 001	Apr 11, 1988
		5MG/VIAL	A071561 001	Apr 11, 1988
VINCRISTINE SULFATE PFS				
	TEVA PHARMS USA	1MG/ML	A075493 001	Sep 01, 1999
INJECTABLE, LIPOSOMAL;INTRAVENOUS				
MARQIBO KIT				
+	ACROTECH	5MG/5ML (1MG/ML)	N202497 001	Aug 09, 2012

VINORELBINE TARTRATE

INJECTABLE;INJECTION				
NAVELBINE				
+	PIERRE FABRE	EQ 10MG BASE/ML **	N020388 001	Dec 23, 1994
VINORELBINE TARTRATE				
	EBEWE PHARMA	EQ 10MG BASE/ML	A078408 001	Feb 13, 2008
	FRESENIUS KABI USA	EQ 10MG BASE/ML	A076849 001	Apr 18, 2005
	HOSPIRA	EQ 10MG BASE/ML	A076827 001	Jun 02, 2005
	MYLAN LABS LTD	EQ 10MG BASE/ML	A200148 001	Aug 31, 2012
	NOVAST LABS	EQ 10MG BASE/ML	A208997 001	Aug 05, 2019
	TEVA PHARMS USA	EQ 10MG BASE/ML	A076028 001	Feb 03, 2003

VIOMYCIN SULFATE

INJECTABLE;INJECTION				
VIOCIN SULFATE				
	PFIZER	EQ 1GM BASE/VIAL	A061086 001	
		EQ 5GM BASE/VIAL	A061086 002	

VITAMIN A

CAPSULE;ORAL				
AQUASOL A				
	ASTRAZENECA	25,000USP UNITS	A083080 002	
		50,000USP UNITS	A083080 001	
VITAMIN A				
	BANNER PHARMACAPS	50,000USP UNITS	A083973 001	
	CHASE CHEM	50,000 IU	A083351 001	
	EVERYLIFE	50,000 IU	A083134 001	
	IMPAX LABS	50,000USP UNITS	A080952 001	
	WEST WARD	50,000USP UNITS	A080985 001	

VITAMIN A PALMITATE

CAPSULE;ORAL				
AFAXIN				
	STERLING WINTHROP	EQ 50,000 UNITS BASE	A083187 001	
ALPHALIN				
	LILLY	EQ 50,000 UNITS BASE	A080883 001	
DEL-VI-A				
	DEL RAY LABS	EQ 50,000 UNITS BASE	A080830 001	
VI-DOM-A				
	BAYER PHARMS	EQ 50,000 UNITS BASE	A080972 001	
VITAMIN A				
	BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702 001	
	BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860 001	
	CHASE CHEM	EQ 50,000 UNITS BASE	A080746 001	
		EQ 50,000 UNITS BASE	A083207 001	
	ELKINS SINN	EQ 50,000 UNITS BASE	A085479 001	
	EVERYLIFE	EQ 50,000 UNITS BASE	A080943 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VITAMIN A PALMITATE				
CAPSULE;ORAL				
VITAMIN A				
	EQ 50,000 UNITS BASE	A083114 001		
IMPAX LABS	EQ 50,000 UNITS BASE	A080953 001		
	EQ 50,000 UNITS BASE	A080955 001		
IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035 001		
	EQ 50,000 UNITS BASE	A083190 001		
MK LABS	EQ 25,000 UNITS BASE	A083457 002		
	EQ 50,000 UNITS BASE	A083457 001		
WEST WARD	EQ 50,000 UNITS BASE	A080967 001		
WHARTON LABS	EQ 50,000 UNITS BASE	A083665 001		
VITAMIN A PALMITATE				
ARCUM	EQ 50,000 UNITS BASE	A083311 001		
	EQ 50,000 UNITS BASE	A083321 001		
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948 001		
	EQ 50,000 UNITS BASE	A083981 001		
VITAMIN A SOLUBILIZED				
TEVA	EQ 50,000 UNITS BASE	A080921 001		
INJECTABLE;INJECTION				
VITAMIN A PALMITATE				
BEL MAR	EQ 50,000 UNITS BASE/ML	A080819 001		
VORICONAZOLE				
FOR SUSPENSION;ORAL				
VORICONAZOLE				
RISING	200MG/5ML	A202361 001	May 28, 2013	
INJECTABLE;INTRAVENOUS				
VORICONAZOLE				
EUGIA PHARMA	200MG/VIAL	A212162 001	Feb 02, 2023	
MYLAN LABS LTD	200MG/VIAL	A210849 001	Oct 11, 2022	
TABLET;ORAL				
VORICONAZOLE				
TEVA PHARMS	50MG	A091658 001	Apr 06, 2012	
	200MG	A091658 002	Apr 06, 2012	
VORTIOXETINE HYDROBROMIDE				
TABLET;ORAL				
TRINTELLIX				
+ TAKEDA PHARMS USA	EQ 15MG BASE **	N204447 003	Sep 30, 2013	
VORTIOXETINE HYDROBROMIDE				
ZYDUS PHARMS	EQ 5MG BASE	A211146 001	Sep 17, 2021	
	EQ 10MG BASE	A211146 002	Sep 17, 2021	
	EQ 20MG BASE	A211146 003	Sep 17, 2021	
WARFARIN POTASSIUM				
TABLET;ORAL				
ATHROMBIN-K				
PHARM RES ASSOC	2MG	N011771 007		
	5MG	N011771 004		
	10MG	N011771 005		
	25MG	N011771 006		
WARFARIN SODIUM				
INJECTABLE;INJECTION				
COUMADIN				
BRISTOL MYERS SQUIBB	5MG/VIAL	N009218 024	Feb 07, 1995	
	50MG/VIAL	N009218 020		
	75MG/VIAL	N009218 012		
TABLET;ORAL				
ATHROMBIN				
PHARM RES ASSOC	5MG	N011771 003		
	10MG	N011771 002		
	25MG	N011771 001		
COUMADIN				
+ BRISTOL MYERS SQUIBB	1MG **	N009218 022	Mar 01, 1990	
+	2MG	N009218 013		
+	2.5MG	N009218 018		
+	3MG	N009218 025	Nov 18, 1996	
+	4MG	N009218 023	Aug 24, 1993	
+	5MG	N009218 007		

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

WARFARIN SODIUM				
TABLET;ORAL				
COUMADIN				
+	6MG	N009218	026	Nov 18, 1996
+	7.5MG	N009218	016	
+	10MG	N009218	005	
PANWARFIN				
ABBOTT	2MG	N017020	001	
	2.5MG	N017020	002	
	5MG	N017020	003	
	7.5MG	N017020	004	
	10MG	N017020	005	
WARFARIN SODIUM				
AUROBINDO PHARMA USA	1MG	A040415	001	Sep 27, 2004
	2MG	A040415	002	Sep 27, 2004
	2.5MG	A040415	003	Sep 29, 2004
	3MG	A040415	004	Sep 27, 2004
	4MG	A040415	005	Sep 27, 2004
	5MG	A040415	006	Sep 27, 2004
	6MG	A040415	007	Sep 27, 2004
	7.5MG	A040415	008	Sep 27, 2004
	10MG	A040415	009	Sep 27, 2004
CHARTWELL RX	1MG	A040196	001	Sep 30, 1997
	2MG	A040196	002	Sep 30, 1997
	2.5MG	A040196	003	Sep 30, 1997
	3MG	A040196	008	Jul 26, 2000
	4MG	A040196	004	Sep 30, 1997
	5MG	A040196	005	Sep 30, 1997
	6MG	A040196	009	Jul 26, 2000
	7.5MG	A040196	006	Sep 30, 1997
	10MG	A040196	007	Sep 30, 1997
USL PHARMA	2MG	A088719	001	Jun 27, 1985
	2.5MG	A088720	001	Aug 06, 1985
	5MG	A088721	001	Jul 02, 1985
WATSON LABS	2MG	A086123	001	Aug 17, 1982
	2.5MG	A086120	001	Aug 17, 1982
	5MG	A086119	001	Aug 17, 1982
	7.5MG	A086118	001	Aug 17, 1982
	10MG	A086122	001	Aug 17, 1982
XENON XE-127				
GAS;INHALATION				
XENON XE 127				
MALLINCKRODT	5mCi/VIAL	N018536	001	Oct 01, 1982
	10mCi/VIAL	N018536	002	Oct 01, 1982
XENON XE-133				
GAS;INHALATION				
XENON XE 133				
GE HEALTHCARE	1 CI/AMP	N017256	002	
	10mCi/VIAL	N017687	002	
	20mCi/VIAL	N017687	003	
GEN ELECTRIC	5-100 CI/CYLINDER	N017550	001	
	0.25-5 CI/AMP	N017550	003	
XENON XE 133-V.S.S.				
GE HEALTHCARE	10mCi/VIAL	N017687	001	
INJECTABLE;INJECTION				
XENON XE 133				
GE HEALTHCARE	1.3-1.7 CI/AMP	N017256	001	
LANTHEUS MEDCL	6.3mCi/ML	N017283	001	
SOLUTION;INHALATION, INJECTION				
XENEISOL				
MALLINCKRODT	18-25mCi/AMP	N017262	002	
XYLOSE				
POWDER;ORAL				
XYLO-PFAN				
SAVAGE LABS	25GM/BOT	N017605	001	
XYLOSE				
LYNE	25GM/BOT	N018856	001	Mar 26, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ZALCITABINE
TABLET;ORAL
HIVID

ROCHE	0.375MG	N020199	001	Jun 19, 1992
	0.75MG	N020199	002	Jun 19, 1992

ZALEPLON
CAPSULE;ORAL
ZALEPLON

HIKMA PHARMS	5MG	A078147	001	Nov 25, 2008
	10MG	A078147	002	Nov 25, 2008
MYLAN	5MG	A077238	001	Jun 06, 2008
	10MG	A077238	002	Jun 06, 2008
TEVA PHARMS	5MG	A077239	001	Jun 06, 2008
	10MG	A077239	002	Jun 06, 2008
UPSHER SMITH LABS	5MG	A078095	001	Jun 06, 2008
	5MG	A078706	001	Jun 06, 2008
	10MG	A078095	002	Jun 06, 2008
	10MG	A078706	002	Jun 06, 2008

ZICONOTIDE ACETATE
INJECTABLE;INTRATHECAL
PRIALT

TERSERA	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004

ZIDOVUDINE
INJECTABLE;INJECTION
ZIDOVUDINE

AM REGENT	10MG/ML	A091457	001	May 06, 2010
LIAONING CHENGDA	10MG/ML	A204538	001	Nov 26, 2013

TABLET;ORAL
RETROVIR

VIIV HLTHCARE	200MG	N020518	001	Dec 19, 1995
+	300MG **	N020518	002	Oct 04, 1996

ZIDOVUDINE

AUROBINDO PHARMA	60MG	N022294	001	Jul 23, 2009
HEC PHARM	300MG	A202058	001	Oct 07, 2011
HIKMA	300MG	A076844	001	Sep 19, 2005
MYLAN LABS LTD	100MG	N200732	001	Feb 23, 2011
RANBAXY LABS LTD	300MG	A077327	001	Sep 19, 2005

ZILEUTON
TABLET;ORAL
ZYFLO

CHIESI	300MG	N020471	001	Dec 09, 1996

TABLET, EXTENDED RELEASE;ORAL
ZILEUTON

LUPIN LTD	600MG	A211972	001	Nov 05, 2019
TEVA PHARMS USA	600MG	A211043	001	May 03, 2022

ZYFLO CR

+	CHIESI	600MG **	N022052	001	May 30, 2007

ZINC SULFATE
INJECTABLE;INJECTION
ZINC SULFATE

ABRAXIS PHARM	EQ 1MG ZINC/ML	N019229	002	May 05, 1987

ZIPRASIDONE HYDROCHLORIDE
CAPSULE;ORAL
ZIPRASIDONE HYDROCHLORIDE

MYLAN	EQ 20MG BASE	A202395	001	Oct 10, 2013
	EQ 40MG BASE	A202395	002	Oct 10, 2013
	EQ 60MG BASE	A202395	003	Oct 10, 2013
	EQ 80MG BASE	A202395	004	Oct 10, 2013

SUSPENSION;ORAL
GEODON

PFIZER INC	EQ 10MG BASE/ML	N021483	001	Mar 29, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

ZOLEDRONIC ACID

	ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013
	AVET LIFESCIENCES	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013
	BRECKENRIDGE	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013
	DR REDDYS	EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018
	EUGIA PHARMA	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016
		EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017
	NOVAST LABS	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020
	SHILPA	EQ 4MG BASE/5ML	A208513	001	May 15, 2019
	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013
		EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013

ZOMETA

+	NOVARTIS	EQ 4MG BASE/VIAL **	N021223	001	Aug 20, 2001
+		EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003
+		EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

	ANI PHARMS	2.5MG	A090861	001	Mar 04, 2014
		5MG	A090861	002	Mar 04, 2014
	APOTEX INC	2.5MG	A202078	001	May 14, 2013
		5MG	A202078	002	May 14, 2013
	MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015
		5MG	A203772	002	Sep 30, 2015
	NATCO PHARMA USA	2.5MG	A203186	001	May 14, 2013
		5MG	A203186	002	May 14, 2013
	SUN PHARMA GLOBAL	2.5MG	A203476	001	Nov 13, 2014
		5MG	A203476	002	Nov 13, 2014

ZOMIG

+	IPR	2.5MG	N020768	001	Nov 25, 1997
+		5MG	N020768	002	Nov 25, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

	APOTEX INC	2.5MG	A202476	001	May 14, 2013
		5MG	A202476	002	May 14, 2013
	MACLEODS PHARMS LTD	2.5MG	A204336	001	Oct 22, 2015
		5MG	A204336	002	Oct 22, 2015
	RISING	2.5MG	A202855	001	Sep 20, 2019
		5MG	A202855	002	Sep 20, 2019

ZOMIG-ZMT

+	ASTRAZENECA	2.5MG	N021231	001	Feb 13, 2001
+		5MG	N021231	002	Sep 17, 2001

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

+	AYTU	5MG/SPRAY	N022196	001	Dec 19, 2008

TABLET;ORAL

ZOLPIDEM TARTRATE

	DR REDDYS LABS LTD	5MG	A077985	001	Apr 23, 2007
		10MG	A077985	002	Apr 23, 2007
	HIKMA	5MG	A078129	001	Apr 30, 2008
		10MG	A078129	002	Apr 30, 2008
	MYLAN PHARMS INC	5MG	A078016	001	Apr 23, 2007
		10MG	A078016	002	Apr 23, 2007
	RISING	5MG	A076578	001	Apr 23, 2007
		10MG	A076578	002	Apr 23, 2007
	STRIDES PHARMA	5MG	A076062	001	Apr 23, 2007
		5MG	A078616	001	Nov 21, 2008
		10MG	A076062	002	Apr 23, 2007
		10MG	A078616	002	Nov 21, 2008
	SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007
		10MG	A077359	002	Apr 23, 2007
	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007
		10MG	A078055	002	Apr 23, 2007
	SUN PHARM INDUSTRIES	5MG	A077288	001	Apr 23, 2007
		10MG	A077288	002	Apr 23, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ZOLPIDEM TARTRATE

TABLET;ORAL					
ZOLPIDEM TARTRATE					
	SYNTHON PHARMS	5MG	A077540	001	Apr 23, 2007
		10MG	A077540	002	Apr 23, 2007
	WATSON LABS	5MG	A077773	001	Apr 23, 2007
		10MG	A077773	002	Apr 23, 2007
	WOCKHARDT	5MG	A078426	001	May 15, 2007
		10MG	A078426	002	May 15, 2007
	YUNG SHIN PHARM	5MG	A077990	001	Apr 23, 2007
		10MG	A077990	002	Apr 23, 2007
TABLET;SUBLINGUAL					
INTERMEZZO					
+	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011
+		3.5MG	N022328	002	Nov 23, 2011
ZOLPIDEM TARTRATE					
	MYLAN	5MG	A202657	001	Aug 08, 2016
		10MG	A202657	002	Aug 08, 2016
TABLET, EXTENDED RELEASE;ORAL					
ZOLPIDEM TARTRATE					
	ACTAVIS ELIZABETH	6.25MG	A078179	002	Oct 13, 2010
		12.5MG	A078179	001	Jun 06, 2011
	ACTAVIS LABS FL INC	6.25MG	A090153	001	Mar 25, 2013
		12.5MG	A090153	002	Mar 25, 2013
	ANCHEN PHARMS	6.25MG	A078148	002	Apr 14, 2011
		12.5MG	A078148	001	Dec 03, 2010
	BRECKENRIDGE	6.25MG	A213592	001	Jun 04, 2020
		12.5MG	A213592	002	Jun 04, 2020
	SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011
		12.5MG	A078483	002	Jun 06, 2011
TABLET, ORALLY DISINTEGRATING;ORAL					
TOVALT ODT					
+	BIOVAIL LABS INTL	5MG	N021412	001	Apr 25, 2007
+		10MG	N021412	002	Apr 25, 2007

ZONISAMIDE

CAPSULE;ORAL					
ZONEGRAN					
+	CONCORDIA	50MG **	N020789	002	Aug 22, 2003
ZONISAMIDE					
	ANI PHARMS	25MG	A077639	001	Dec 22, 2005
		25MG	A077641	003	Dec 22, 2005
		50MG	A077639	002	Dec 22, 2005
		50MG	A077641	002	Dec 22, 2005
		100MG	A077639	003	Dec 22, 2005
		100MG	A077641	001	Dec 22, 2005
	EPIC PHARMA LLC	25MG	A077876	001	Feb 21, 2007
		50MG	A077876	002	Feb 21, 2007
		100MG	A077876	003	Feb 21, 2007
	HERITAGE PHARMA AVET	25MG	A077650	001	Apr 20, 2006
		50MG	A077650	002	Apr 20, 2006
		100MG	A077650	003	Apr 20, 2006
	MYLAN PHARMS INC	25MG	A077647	001	Dec 22, 2005
		50MG	A077647	002	Dec 22, 2005
		100MG	A077647	003	Dec 22, 2005
	RISING	25MG	A077637	001	Dec 22, 2005
		50MG	A077637	002	Dec 22, 2005
		100MG	A077637	003	Dec 22, 2005
	ROXANE	25MG	A077648	001	Dec 22, 2005
		50MG	A077648	002	Dec 22, 2005
		100MG	A077648	003	Dec 22, 2005
	SUN PHARM INDUSTRIES	25MG	A077635	001	Dec 22, 2005
		50MG	A077635	002	Dec 22, 2005
		100MG	A077635	003	Dec 22, 2005
	UPSHER SMITH LABS	25MG	A077644	001	Dec 22, 2005
		50MG	A077644	002	Dec 22, 2005
		100MG	A077644	003	Dec 22, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG
325MG;325MG;50MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG;40MG
325MG;325MG;50MG;40MG

ACETAMINOPHEN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG

AMINOPHYLLINE
TABLET; ORAL
100MG;200MG

ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG
650MG;50MG

ASPIRIN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG
650MG;50MG;40MG

ASPIRIN;CAFFEINE;CARISOPRODOL
TABLET; ORAL
160MG;32MG;200MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
160MG;32MG;200MG;16MG

ASPIRIN;CARISOPRODOL
TABLET; ORAL
325MG;200MG

ASPIRIN;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
325MG;200MG;16MG

ASPIRIN;MEPROBAMATE
TABLET; ORAL
325MG;200MG

ASPIRIN;METHOCARBAMOL
TABLET; ORAL
325MG;400MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG;25MG;
50MG;100MG

PREDNISONE
TABLET; ORAL
1MG;2.5MG;5MG;10MG;
20MG;25MG;50MG

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ABACAVIR SULFATE, ABACAVIR SULFATE
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIPRAZOLE
ABILIFY ASIMTUFII, ARIPIPRAZOLE
ABILIFY MAINTENA KIT, ARIPIPRAZOLE
ABILIFY MYCITE KIT, ARIPIPRAZOLE
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ABLYSINOL, ALCOHOL
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ABSORICA, ISOTRETINOIN
ABSORICA LD, ISOTRETINOIN
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCRUFER, FERRIC MALTOL
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETIC ACID, ACETIC ACID, GLACIAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ACIPHEX, RABEPRAZOLE SODIUM
ACITRETIN, ACITRETIN
ACTHAR GEL, CORTICOTROPIN
ACTICLATE, DOXYCYCLINE HYCLATE
ACTIGALL, URSODIOL
ACTIQ, FENTANYL CITRATE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR, KETOROLAC TROMETHAMINE
ACULAR LS, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACZONE, DAPSONE
ADAPALENE, ADAPALENE (OTC)
ADAPALENE, ADAPALENE
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADASUVE, LOXAPINE
ADCIRCA, TADALAFIL
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADDYI, FLIBANSERIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ADEMPAS, RIOCIGUAT
ADENOSINE, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADLARITY, DONEPEZIL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ADRENACLICK, EPINEPHRINE
ADRENALIN, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL DUAL ACTION WITH ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADZENYS XR-ODT, AMPHETAMINE
AEMCOLO, RIFAMYCIN SODIUM
AFINITOR, EVEROLIMUS
AFINITOR DISPERZ, EVEROLIMUS
AFIRMELLE, ETHINYL ESTRADIOL
AGAMREE, VAMOROLONE
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AIRDUO DIGIHALER, FLUTICASONE PROPIONATE
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
AIRSUPRA, ALBUTEROL SULFATE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKEEGA, ABIRATERONE ACETATE
AKLIEF, TRIFAROTENE
AKOVAZ, EPHEDRINE SULFATE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBENDAZOLE, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALECENSA, ALECTINIB HYDROCHLORIDE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALIMTA, PEMETREXED DISODIUM
ALINIA, NITAZOXANIDE
ALISKIREN HEMIFUMARATE, ALISKIREN HEMIFUMARATE
ALKINDI SPRINKLE, HYDROCORTISONE
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ALLI, ORLISTAT (OTC)
ALLOPURINOL, ALLOPURINOL
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALLZITAL, ACETAMINOPHEN
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALTABAX, RETAPAMULIN
ALTACE, RAMIPRIL
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
ALTAVERA, ETHINYL ESTRADIOL
ALTOPREV, LOVASTATIN
ALTRENO, TRETINOIN
ALUNBRIG, BRIGATINIB
ALVAIZ, ELTROMBOPAG CHOLINE
ALVESCO, CICLESONIDE
ALVIMOPAN, ALVIMOPAN
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
ALYQ, TADALAFIL
AMABELZ, ESTRADIOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBIEN, ZOLPIDEM TARTRATE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMBRISENTAN, AMBRISENTAN
AMCINONIDE, AMCINONIDE
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINO ACIDS, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITIZA, LUBIPROSTONE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMMONIA N 13, AMMONIA N-13
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMMONUL, SODIUM BENZOATE
AMNESTEEM, ISOTRETINOIN
AMONDYS 45, CASIMERSEN
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN

APPENDIX A - PRODUCT NAME INDEX

**** A ****

AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMVUTTRA, VUTRISIRAN SODIUM
AMYVID, FLORBETAPIR F-18
AMZEEQ, MINOCYCLINE HYDROCHLORIDE
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCOBON, FLUCYTOSINE
ANDROGEL, TESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANGIOMAX RTU, BIVALIRUDIN
ANNOVERA, ETHINYL ESTRADIOL
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ANTARA (MICRONIZED), FENOFIBRATE
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
ANTIVERT, MECLIZINE HYDROCHLORIDE
ANUSOL HC, HYDROCORTISONE
ANZEMET, DOLASETRON MESYLATE
APHEXDA, MOTIXAFORTIDE ACETATE
APIXABAN, APIXABAN
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APOMORPHINE HYDROCHLORIDE, APOMORPHINE HYDROCHLORIDE
APONVIE, APREPITANT
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APREMILAST, APREMILAST
APREPITANT, APREPITANT
APRETUDE, CABOTEGRAVIR
APRISO, MESALAMINE
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
APTIOM, ESLICARBAZEPINE ACETATE
APTIVUS, TIPRANAVIR
AQUASOL A, VITAMIN A PALMITATE
ARAKODA, TAFENOQUINE SUCCINATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
ARAZLO, TAZAROTENE
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ARGATROBAN, ARGATROBAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIDOL KIT, MANNITOL
ARIKAYCE KIT, AMIKACIN SULFATE
ARIMIDEX, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE

APPENDIX A - PRODUCT NAME INDEX

**** A ****

APPENDIX A - PRODUCT NAME INDEX

**** A ****

AXID AR, NIZATIDINE (OTC)
AXUMIN, FLUCICLOVINE F-18
AYUNA, ETHINYL ESTRADIOL
AYVAKIT, AVAPRITINIB
AZACITIDINE, AZACITIDINE
AZACTAM, AZTREONAM
AZASAN, AZATHIOPRINE
AZASITE, AZITHROMYCIN
AZATHIOPRINE, AZATHIOPRINE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZEDRA, IOBENGUANE I-131
AZELAIC ACID, AZELAIC ACID
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
AZELEX, AZELAIC ACID
AZILECT, RASAGILINE MESYLATE
AZITHROMYCIN, AZITHROMYCIN
AZOPT, BRINZOLAMIDE
AZOR, AMLODIPINE BESYLATE
AZSTARYS, DEXMETHYLPHENIDATE HYDROCHLORIDE
AZTREONAM, AZTREONAM
AZULFIDINE, SULFASALAZINE
AZULFIDINE EN-TABS, SULFASALAZINE

**** B ****

BACITRACIN, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTRIM, SULFAMETHOXAZOLE
BACTRIM DS, SULFAMETHOXAZOLE
BAFIERTAM, MONOMETHYL FUMARATE
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BALCOLTRA, ETHINYL ESTRADIOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BALVERSA, ERDAFITINIB
BALZIVA-28, ETHINYL ESTRADIOL
BANZEL, RUFINAMIDE
BAQSIMI, GLUCAGON
BARACLUDE, ENTECAVIR
BARHEMSYS, AMISULPRIDE
BAXDELA, DELAFLOXACIN MEGLUMINE
BEKYREE, DESOGESTREL
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BELEODAQ, BELINOSTAT
BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
BELSOMRA, SUVOREXANT
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZNIDAZOLE, BENZNIDAZOLE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE

APPENDIX A - PRODUCT NAME INDEX

**** B ****

BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAINE, BETAINE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BEXAROTENE, BEXAROTENE
BEYAZ, DROSPIRENONE
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BIJUVA, ESTRADIOL
BIKTARVY, BICTEGRAVIR SODIUM
BILTRICIDE, PRAZIQUANTEL
BIMATOPROST, BIMATOPROST
BINOSTO, ALENDRONATE SODIUM
BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH SUBSALICYLATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
BLUDIGO, INDIGOTINDISULFONATE SODIUM
BONJESTA, DOXYLAMINE SUCCINATE
BONSITY, TERIPARATIDE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BORTEZOMIB, BORTEZOMIB
BOSENTAN, BOSENTAN
BOSULIF, BOSUTINIB MONOHYDRATE
BRAFTOVI, ENCORAFENIB
BRENZAVVY, BEXAGLIFLOZIN
BREO ELLIPTA, FLUTICASONE FUROATE
BRETHINE, TERBUTALINE SULFATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVITAL SODIUM, METHOHEXITAL SODIUM
BREXAFEMME, IBREXAFUNGERP CITRATE
BREXPIPRAZOLE, BREXPIPRAZOLE
BREYNA, BUDESONIDE
BREZTRI AEROSPHERE, BUDESONIDE
BRIDION, SUGAMMADEX SODIUM
BRIELLYN, ETHINYL ESTRADIOL
BRILINTA, TICAGRELOR

APPENDIX A - PRODUCT NAME INDEX

**** B ****

BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BRINZOLAMIDE, BRINZOLAMIDE
BRISDELLE, PAROXETINE MESYLATE
BRIVIACT, BRIVARACETAM
BRIXADI, BUPRENORPHINE
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,
BROMSITE, BROMFENAC SODIUM
BRONCHITOL, MANNITOL
BROVANA, ARFORMOTEROL TARTRATE
BRUKINSA, ZANUBRUTINIB
BRYHALI, HALOBETASOL PROPIONATE
BSS, CALCIUM CHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUMEX, BUMETANIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE, BUPRENORPHINE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUSULFAN, BUSULFAN
BUSULFEX, BUSULFAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTAPAP, ACETAMINOPHEN
BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTRANS, BUPRENORPHINE
BYDUREON BCISE, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
BYFAVO, REMIMAZOLAM BESYLATE
BYLVAY, ODEVIXIBAT
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

**** C ****

CABAZITAXEL, CABAZITAXEL
CABENUVA KIT, CABOTEGRAVIR
CABERGOLINE, CABERGOLINE
CABOMETYX, CABOZANTINIB S-MALATE
CABTREO, ADAPALENE
CADUET, AMLODIPINE BESYLATE
CAFCIT, CAFFEINE CITRATE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCIPOTRIENE, CALCIPOTRIENE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CALCIUM GLUCONATE, CALCIUM GLUCONATE
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CALDOLOR, IBUPROFEN
CALQUENCE, ACALABRUTINIB
CALQUENCE, ACALABRUTINIB MALEATE
CAMBIA, DICLOFENAC POTASSIUM
CAMCEVI KIT, LEUPROLIDE MESYLATE
CAMILA, NORETHINDRONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CAMZYOS, MAVACAMTEN
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CAPECITABINE, CAPECITABINE
CAPEX, FLUOCINOLONE ACETONIDE
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPLYTA, LUMATEPERONE TOSYLATE
CAPRELSA, VANDETANIB
CAPTOPRIL, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARFILZOMIB, CARFILZOMIB
CARGLUMIC ACID, CARGLUMIC ACID
CARISOPRODOL, CARISOPRODOL
CARMUSTINE, CARMUSTINE
CARNITOR, LEVOCARNITINE
CARNITOR SF, LEVOCARNITINE
CAROSPIR, SPIRONOLACTONE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CASODEX, BICALUTAMIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CASPORYN HC, HYDROCORTISONE
CATAFLAM, DICLOFENAC POTASSIUM
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT, ALPROSTADIL
CAVERJECT IMPULSE, ALPROSTADIL
CAYSTON, AZTREONAM

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFIXIME, CEFIXIME
CEFOTETAN, CEFOTETAN DISODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CELEBREX, CELECOXIB
CELECOXIB, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTANY, MUPIROCIN
CEPHALEXIN, CEPHALEXIN
CEQUA, CYCLOSPORINE
CERDELGA, ELIGLUSTAT TARTRATE
CEREBYX, FOSPHENYTOIN SODIUM
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CERIANNA, FLUOROESTRADIOL F-18
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
CETRORELIX ACETATE, CETRORELIX ACETATE
CETROTIDE, CETRORELIX ACETATE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHABELINA FE, ETHINYL ESTRADIOL
CHEMET, SUCCIMER
CHENODIOL, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S ALAWAY, KETOTIFEN FUMARATE (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLBAM, CHOLIC ACID
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLINE C-11, CHOLINE C-11
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIALIS, TADALAFIL
CIBINQO, ABROCITINIB
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CIDOFOVIR, CIDOFOVIR
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMDUO, LAMIVUDINE
CIMETIDINE, CIMETIDINE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CINVANTI, APREPITANT
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CLADRIBINE, CLADRIBINE
CLARAVIS, ISOTRETINOIN
CLARINEX, DESLORATADINE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CLARINEX-D 12 HOUR, DESLORATADINE
CLARISCAN, GADOTERATE MEGLUMINE
CLARITHROMYCIN, CLARITHROMYCIN
CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLENPIQ, CITRIC ACID
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEVIPREX, CLEVIDIPINE
CLIMARA, ESTRADIOL
CLIMARA PRO, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINOLIPID 20%, OLIVE OIL
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLOCORTOLONE PIVALATE, CLOCORTOLONE PIVALATE
CLODERM, CLOCORTOLONE PIVALATE
CLOFARABINE, CLOFARABINE
CLOLAR, CLOFARABINE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE, CLONIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
CODEINE SULFATE, CODEINE SULFATE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLCHICINE, COLCHICINE
COLCRYS, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMBOGESIC IV, ACETAMINOPHEN
COMETRIQ, CABOZANTINIB S-MALATE
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONRAY, IOTHALAMATE MEGLUMINE
CONTRAVE, BUPROPION HYDROCHLORIDE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPIKTRA, DUVELISIB
CORDRAN, FLURANDRENOLIDE
COREG, CARVEDILOL
COREG CR, CARVEDILOL PHOSPHATE
CORGARD, NADOLOL
CORLANOR, IVABRADINE
CORLANOR, IVABRADINE HYDROCHLORIDE
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORPHEDRA, EPHEDRINE SULFATE
CORTEF, HYDROCORTISONE
CORTENEMA, HYDROCORTISONE
CORTIFOAM, HYDROCORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
COSELA, TRILACICLIB DIHYDROCHLORIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN
COTELLIC, COBIMETINIB FUMARATE
COTEMPLA XR-ODT, METHYLPHENIDATE
COXANTO, OXAPROZIN
COZAAR, LOSARTAN POTASSIUM

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CRESEMBA, ISAVUCONAZONIUM SULFATE
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CUPRIC CHLORIDE, CUPRIC CHLORIDE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIC SULFATE, CUPRIC SULFATE
CUPRIMINE, PENICILLAMINE
CUVPOSA, GLYCOPYRROLATE
CUVRIOR, TRIENTINE TETRAHYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSET, BROMOCRIPTINE MESYLATE
CYCLOSPORINE, CYCLOSPORINE
CYKLOKAPRON, TRANEXAMIC ACID
CYMBALTA, DULOXETINE HYDROCHLORIDE
CYONANZ, ETHINYL ESTRADIOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE
CYSTADROPS, CYSTEAMINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
CYTALUX, PAFOLACIANINE SODIUM
CYTARABINE, CYTARABINE
CYTOMEL, LIOTHYRONINE SODIUM
CYTOTEC, MISOPROSTOL
CYTOXAN, CYCLOPHOSPHAMIDE

**** D ****

DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DACARBAZINE, DACARBAZINE
DACTINOMYCIN, DACTINOMYCIN
DALFAMPRIDINE, DALFAMPRIDINE
DALIRESP, ROFLUMILAST
DALVANCE, DALBAVANCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DANTROLENE SODIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DAPTOMYCIN, DAPTOMYCIN
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE, DAPTOMYCIN
DARAPRIM, PYRIMETHAMINE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DARUNAVIR, DARUNAVIR
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DATSCAN, IOFLUPANE I-123
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DAURISMO, GLASDEGIB MALEATE
DAYBUE, TROFINETIDE
DAYPRO, OXAPROZIN
DAYSEE, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DAYTRANA, METHYLPHENIDATE
DAYVIGO, LEMBOREXANT
DDAVP, DESMOPRESSIN ACETATE
DECITABINE, DECITABINE
DEFENCATH, HEPARIN SODIUM
DEFERASIROX, DEFERASIROX
DEFERIPRONE, DEFERIPRONE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEFINITY, PERFLUTREN
DEFINITY RT, PERFLUTREN
DEFITELIO, DEFIBROTIDE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSTRIGO, DORAVIRINE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DELZICOL, MESALAMINE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMSER, METYROSINE
DENAVIR, PENCICLOVIR
DEOXYCHOLIC ACID, DEOXYCHOLIC ACID
DEPAKOTE, DIVALPROEX SODIUM
DEPAKOTE ER, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMOTIC, FLUOCINOLONE ACETONIDE
DESCOVY, EMTRICITABINE
DESFERAL, DEFEROXAMINE MESYLATE
DESFLURANE, DESFLURANE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DESVENLAFAXINE, DESVENLAFAXINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DETECTNET, COPPER CU-64 DOTATATE
DETROL, TOLTERODINE TARTRATE
DETROL LA, TOLTERODINE TARTRATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DEXILANT, DEXLANSOPRAZOLE
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DEXTENZA, DEXAMETHASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
DEXTROSE 50%, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DEXYCU KIT, DEXAMETHASONE
DHIVY, CARBIDOPA
DIABETA, GLYBURIDE
DIACOMIT, STIRIPENTOL
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIASTAT, DIAZEPAM
DIASTAT ACUDIAL, DIAZEPAM
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM, DIATRIZOATE MEGLUMINE
DIAZEPAM, DIAZEPAM
DIAZEPAM INTENSOL, DIAZEPAM
DIAZOXIDE, DIAZOXIDE
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DICHLORPHENAMIDE, DICHLORPHENAMIDE
DICLEGIS, DOXYLAMINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DIFFERIN, ADAPALENE (OTC)
DIFFERIN, ADAPALENE
DIFICID, FIDAXOMICIN
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIFLUPREDNATE, DIFLUPREDNATE
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DIOVAN, VALSARTAN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPRIVAN, PROPOFOL
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DIURIL, CHLOROTHIAZIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

**** D ****

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DYANAVEL XR, AMPHETAMINE
DYANAVEL XR 10, AMPHETAMINE
DYANAVEL XR 15, AMPHETAMINE
DYANAVEL XR 20, AMPHETAMINE
DYANAVEL XR 5, AMPHETAMINE
DYCLOPRO, DYCLONINE HYDROCHLORIDE
DYMISTA, AZELASTINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE

**** E ****

E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECOZA, ECONAZOLE NITRATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDETATE CALCIUM DISODIUM, EDETATE CALCIUM DISODIUM
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE
EDURANT, RILPIVIRINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFINACONAZOLE, EFINACONAZOLE
EFUDEX, FLUOROURACIL
EGATEN, TRICLABENDAZOLE
ELCYS, CYSTEINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELIDEL, PIMECROLIMUS
ELIGARD KIT, LEUPROLIDE ACETATE
ELIGLUSTAT TARTRATE, ELIGLUSTAT TARTRATE
ELIMITE, PERMETHRIN
ELINEST, ETHINYL ESTRADIOL
ELIQUIS, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE
ELLA, ULIPRISTAL ACETATE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOXATIN, OXALIPLATIN
ELUCIREM, GADOPICLENOL
ELURYNG, ETHINYL ESTRADIOL
ELYXYB, CELECOXIB
EMBELINE, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMERPHED, EPHEDRINE SULFATE
EMFLAZA, DEFLAZACORT
EMPAVELI, PEGCETACOPLAN
EMSAM, SELEGILINE
EMTRICITABINE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE

APPENDIX A - PRODUCT NAME INDEX

**** E ****

EMTRIVA, EMTRICITABINE
EMVERM, MEBENDAZOLE
EMZAHH, NORETHINDRONE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDARI, L-GLUTAMINE
ENDOMETRIN, PROGESTERONE
ENILLORING, ETHINYL ESTRADIOL
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
ENSKYCE, DESOGESTREL
ENSTILAR, BETAMETHASONE DIPROPIONATE
ENTACAPONE, ENTACAPONE
ENTADFI, FINASTERIDE
ENTECAVIR, ENTECAVIR
ENTERO VU 24%, BARIUM SULFATE
ENTOCORT EC, BUDESONIDE
ENTRESTO, SACUBITRIL
ENVARSUS XR, TACROLIMUS
EOVIST, GADOXETATE DISODIUM
EPANED, ENALAPRIL MALEATE
EPCLUSA, SOFOSBUVIR
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIDIOLEX, CANNABIDIOL
EPIDUO, ADAPALENE
EPIDUO FORTE, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPINEPHRINE, EPINEPHRINE
EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
EPIPEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPRONTIA, TOPIRAMATE
EPSOLAY, BENZOYL PEROXIDE
EPTIFIBATIDE, EPTIFIBATIDE
EPZICOM, ABACAVIR SULFATE
EQUETRO, CARBAMAZEPINE
ERAXIS, ANIDULAFUNGIN
ERGOCALCIFEROL, ERGOCALCIFEROL
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERIVEDGE, VISMODEGIB
ERLEADA, APALUTAMIDE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERMEZA, LEVOTHYROXINE SODIUM
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ERY-TAB, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN

APPENDIX A - PRODUCT NAME INDEX

**** E ****

ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ESBRIET, PIRFENIDONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESTARYLLA, ETHINYL ESTRADIOL
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADIOL, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESZOPICLONE, ESZOPICLONE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETHACRYNIC ACID, ETHACRYNIC ACID
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHINYL ESTRADIOL AND NORELGESTROMIN, ETHINYL ESTRADIOL
ETHINYL ESTRADIOL; ETONOGESTREL, ETHINYL ESTRADIOL
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETHYOL, AMIFOSTINE
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
ETRAVIRINE, ETRAVIRINE
EUCRISA, CRISABOROLE
EURAX, CROTAMITON
EUTHYROX, LEVOTHYROXINE SODIUM **
EVAMIST, ESTRADIOL
EVEKEO, AMPHETAMINE SULFATE
EVEKEO ODT, AMPHETAMINE SULFATE
EVEROLIMUS, EVEROLIMUS
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOMELA, MELPHALAN HYDROCHLORIDE
EVOTAZ, ATAZANAVIR SULFATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EVRYSDI, RISDIPLAM
EXCEDRIN (MIGRAINE RELIEF), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE
EXEM FOAM KIT, AIR POLYMER-TYPE A
EXEMESTANE, EXEMESTANE
EXFORGE, AMLODIPINE BESYLATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXJADE, DEFERASIROX
EXKIVITY, MOBOCERTINIB SUCCINATE
EXONDYS 51, ETEPLIRSEN
EXPAREL, BUPIVACAINE
EXSERVAN, RILUZOLE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
EXTRANEAL, ICODEXTRIN
EXXUA, GEPIRONE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** E ****

EYSUVIS, LOTEPREDNOL ETABONATE
EZETIMIBE, EZETIMIBE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE

**** F ****

FABHALTA, IPTACOPAN HYDROCHLORIDE
FABIOR, TAZAROTENE
FALLBACK SOLO, LEVONORGESTREL (OTC)
FALMINA, ETHINYL ESTRADIOL
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FANAPT, ILOPERIDONE
FARESTON, TOREMIFENE CITRATE
FARXIGA, DAPAGLIFLOZIN
FASLODEX, FULVESTRANT
FEBUXOSTAT, FEBUXOSTAT
FELBAMATE, FELBAMATE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FELODIPINE, FELODIPINE
FEMARA, LETROZOLE
FEMRING, ESTRADIOL ACETATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FENOGLIDE, FENOFIBRATE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENSOLVI KIT, LEUPROLIDE ACETATE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
FENTORA, FENTANYL CITRATE
FERAHEME, FERUMOXYTOL
FERRIPROX, DEFERIPRONE
FERRLECIT, FERRIC OXYHYDROXIDE
FERUMOXYTOL, FERUMOXYTOL
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FETROJA, CEFIDEROCOL SULFATE TOSYLATE
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FEXINIDAZOLE, FEXINIDAZOLE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FILSPARI, SPARSENTAN
FILSUVEZ, BIRCH TRITERPENES
FINACEA, AZELAIC ACID
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FINTEPLA, FENFLURAMINE HYDROCHLORIDE
FINZALA, ETHINYL ESTRADIOL
FIORICET W/ CODEINE, ACETAMINOPHEN

APPENDIX A - PRODUCT NAME INDEX

**** F ****

FIRAZYR, ICATIBANT ACETATE
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE
FIRMAGON, DEGARELIX ACETATE
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE
FLAC, FLUOCINOLONE ACETONIDE
FLAGYL, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLECTOR, DICLOFENAC EPOLAMINE
FLEQSUVY, BACLOFEN
FLOLAN, EPOPROSTENOL SODIUM
FLOLIPID, SIMVASTATIN
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT HFA, FLUTICASONE PROPIONATE
FLOXURIDINE, FLOXURIDINE
FLUCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUCONAZOLE, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOCINONIDE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUORESCEIN SODIUM, FLUORESCEIN SODIUM
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE, BENOXINATE HYDROCHLORIDE
FLUORESCITE, FLUORESCEIN SODIUM
FLUORODOPA F18, FLUORODOPA F-18
FLUOROMETHOLONE, FLUOROMETHOLONE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLUTAMIDE, FLUTAMIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML, FLUOROMETHOLONE
FML FORTE, FLUOROMETHOLONE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCINVEZ, FOSAPREPITANT DIMEGLUMINE
FOLIC ACID, FOLIC ACID
FOLOTYN, PRALATREXATE
FOMEPIZOLE, FOMEPIZOLE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM

APPENDIX A - PRODUCT NAME INDEX

**** F ****

FORANE, ISOFLURANE
FORFIVO XL, BUPROPION HYDROCHLORIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
FORTAMET, METFORMIN HYDROCHLORIDE
FORTEO, TERIPARATIDE
FORTESTA, TESTOSTERONE
FOSAMAX, ALENDRONATE SODIUM
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSCAVIR, FOSCARNET SODIUM
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FOSRENOL, LANTHANUM CARBONATE
FOTIVDA, TIVOZANIB HYDROCHLORIDE
FRAGMIN, DALTEPARIN SODIUM
FROVA, FROVATRIPTAN SUCCINATE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FRUZAQLA, FRUQUINTINIB
FULVESTRANT, FULVESTRANT
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
FURADANTIN, NITROFURANTOIN
FUROSCIX, FUROSEMIDE
FUROSEMIDE, FUROSEMIDE
FUSILEV, LEVOLEUCOVORIN CALCIUM
FUZEON, ENFUVIRTIDE
FYARRO, SIROLIMUS
FYAVOLV, ETHINYL ESTRADIOL
FYCOMPA, PERAMPANEL
FYREMADEL, GANIRELIX ACETATE

**** G ****

GABAPENTIN, GABAPENTIN
GABITRIL, TIAGABINE HYDROCHLORIDE
GABLOFEN, BACLOFEN
GADAVIST, GADOBUTROL
GADOBUTROL, GADOBUTROL
GADOTERATE MEGLUMINE, GADOTERATE MEGLUMINE
GALAFOLD, MIGALASTAT HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
GALLIUM GA 68 EDOTREOTIDE, GALLIUM GA-68 EDOTREOTIDE
GALLIUM GA 68 GOZETOTIDE, GALLIUM GA-68 GOZETOTIDE
GALZIN, ZINC ACETATE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE
GANZYK-RTU, GANCICLOVIR
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GATIFLOXACIN, GATIFLOXACIN
GATTEX KIT, TEDUGLUTIDE RECOMBINANT
GAVRETO, PRALSETINIB
GEFITINIB, GEFITINIB
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GEMMILY, ETHINYL ESTRADIOL
GEMTESA, VIBEGRON
GENERLAC, LACTULOSE
GENGRAF, CYCLOSPORINE

APPENDIX A - PRODUCT NAME INDEX

**** G ****

GENOSYL, NITRIC OXIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENVOYA, COBICISTAT
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GIAPREZA, ANGIOTENSIN II ACETATE
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GILENYA, FINGOLIMOD HYDROCHLORIDE
GILOTRIF, AFATINIB DIMALEATE
GIMOTI, METOCLOPRAMIDE HYDROCHLORIDE
GIVLAARI, GIVOSIRAN SODIUM
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLATOPA, GLATIRAMER ACETATE
GLEEVEC, IMATINIB MESYLATE
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE
GLEOSTINE, LOMUSTINE
GLIADEL, CARMUSTINE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM I-125
GLOPERBA, COLCHICINE
GLUCAGEN, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCOTROL XL, GLIPIZIDE
GLUMETZA, METFORMIN HYDROCHLORIDE
GLYBURIDE, GLYBURIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYDO, LIDOCAINE HYDROCHLORIDE
GLYNASE, GLYBURIDE
GLYRX-PF, GLYCOPYRROLATE
GLYSET, MIGLITOL
GLYXAMBI, EMPAGLIFLOZIN
GOCOVRI, AMANTADINE HYDROCHLORIDE
GOLYTELY, POLYETHYLENE GLYCOL 3350
GOPRELTO, COCAINE HYDROCHLORIDE
GRALISE, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GUAIFENESIN, GUAIFENESIN (OTC)
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
GVOKE HYPOPEN, GLUCAGON
GVOKE KIT, GLUCAGON
GVOKE PFS, GLUCAGON
GYNAZOLE-1, BUTOCONAZOLE NITRATE

**** H ****

HABITROL, NICOTINE (OTC)
HAILEY 1.5/30, ETHINYL ESTRADIOL
HAILEY 24 FE, ETHINYL ESTRADIOL
HAILEY FE 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1/20, ETHINYL ESTRADIOL
HALAVEN, ERIBULIN MESYLATE

APPENDIX A - PRODUCT NAME INDEX

**** H ****

HALCINONIDE, HALCINONIDE
HALCION, TRIAZOLAM
HALDOL, HALOPERIDOL DECANOATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HALOETTE, ETHINYL ESTRADIOL
HALOG, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HARVONI, LEDIPASVIR
HEATHER, NORETHINDRONE
HECTOROL, DOXERCALCIFEROL
HEMABATE, CARBOPROST TROMETHAMINE
HEMADY, DEXAMETHASONE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPSERA, ADEFOVIR DIPIVOXIL
HEPZATO, MELPHALAN HYDROCHLORIDE
HER STYLE, LEVONORGESTREL (OTC)
HETLIOZ, TASIMELTEON
HETLIOZ LQ, TASIMELTEON
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
HICON, SODIUM IODIDE I-131
HIPREX, METHENAMINE HIPPURATE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HORIZANT, GABAPENTIN ENACARBIL
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDREA, HYDROXYUREA
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ASPIRIN, ASPIRIN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
HYDROCORTISONE, HYDROCORTISONE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
HYFTOR, SIROLIMUS

APPENDIX A - PRODUCT NAME INDEX

**** H ****

HYSINGLA ER, HYDROCODONE BITARTRATE
HYZAAR, HYDROCHLOROTHIAZIDE

**** I ****

IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBRANCE, PALBOCICLIB
IBSRELA, TENAPANOR HYDROCHLORIDE
IBUPROFEN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN LYSINE, IBUPROFEN LYSINE
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
ICATIBANT ACETATE, ICATIBANT ACETATE
ICLEVIA, ETHINYL ESTRADIOL
ICLUSIG, PONATINIB HYDROCHLORIDE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IDHIFA, ENASIDENIB MESYLATE
IDKIT:HP, CITRIC ACID
IDOSE TR, TRAVOPROST
IFEX, IFOSFAMIDE
IFOSFAMIDE, IFOSFAMIDE
IGALMI, DEXMEDETOMIDINE HYDROCHLORIDE
IHEEZO, CHLOROPROCAINE HYDROCHLORIDE
ILEVRO, NEPAFENAC
ILLUCCIX, GALLIUM GA-68 GOZETOTIDE
ILUVIEN, FLUOCINOLONE ACETONIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IMBRUVICA, IBRUTINIB
IMCIVREE, SETMELANOTIDE ACETATE
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMIQUIMOD, IMIQUIMOD
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMMPHENTIV, PHENYLEPHRINE HYDROCHLORIDE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMPAVIDO, MILTEFOSINE
IMPOYZ, CLOBETASOL PROPIONATE
IMURAN, AZATHIOPRINE
IMVEXXY, ESTRADIOL
INBRIJA, LEVODOPA
INCASSIA, NORETHINDRONE
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN, INDOMETHACIN
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN, INDOMETHACIN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFANT'S ADVIL, IBUPROFEN (OTC)
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFED, FERRIC OXYHYDROXIDE
INFUMORPH, MORPHINE SULFATE

APPENDIX A - PRODUCT NAME INDEX

**** I ****

INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INGREZZA, VALBENAZINE TOSYLATE
INJECTAFER, FERRIC CARBOXYMALTOSE
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INPEFA, SOTAGLIFLOZIN
INQOVI, CEDAZURIDINE
INREBIC, FEDRATINIB HYDROCHLORIDE
INSPRA, EPLERENONE
INTELENCE, ETRAVIRINE
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTRAROSA, PRASTERONE
INTROVALE, ETHINYL ESTRADIOL
INTUNIV, GUANFACINE HYDROCHLORIDE
INVANZ, ERTAPENEM SODIUM
INVEGA, PALIPERIDONE
INVEGA HAFYERA, PALIPERIDONE PALMITATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVELTYS, LOTEPREDNOL ETABONATE
INVOKAMET, CANAGLIFLOZIN
INVOKAMET XR, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
IODIXANOL, IODIXANOL
IOFLUPANE I-123, IOFLUPANE I-123
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IOPAMIDOL, IOPAMIDOL
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN, IRBESARTAN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRESSA, GEFITINIB
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISENTRESS, RALTEGRAVIR POTASSIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISIBLOOM, DESOGESTREL
ISOFLURANE, ISOFLURANE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISONIAZID, ISONIAZID
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
ISOPTO ATROPINE, ATROPINE SULFATE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOSULFAN BLUE, ISOSULFAN BLUE
ISOTRETINOIN, ISOTRETINOIN
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISRADIPINE, ISRADIPINE
ISTALOL, TIMOLOL MALEATE
ISTODAX, ROMIDEPSIN
ISTURISA, OSILODROSTAT PHOSPHATE

APPENDIX A - PRODUCT NAME INDEX

**** I ****

ITRACONAZOLE, ITRACONAZOLE
IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE
IVERMECTIN, IVERMECTIN (OTC)
IVERMECTIN, IVERMECTIN
IVY BLOCK, BENTOQUATAM (OTC)
IWILFIN, EFLORNITHINE HYDROCHLORIDE
IXEMPRA KIT, IXABEPILONE
IYUZEH, LATANOPROST
IZERVAY, AVACINCAPTAD PEGOL SODIUM

**** J ****

JADENU, DEFERASIROX
JADENU SPRINKLE, DEFERASIROX
JAIMIESS, ETHINYL ESTRADIOL
JAKAFI, RUXOLITINIB PHOSPHATE
JALYN, DUTASTERIDE
JANTOVEN, WARFARIN SODIUM
JANUMET, METFORMIN HYDROCHLORIDE
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
JARDIANCE, EMPAGLIFLOZIN
JATENZO, TESTOSTERONE UNDECANOATE
JAYPIRCA, PIRTOBRUTINIB
JELMYTO, MITOMYCIN
JENCYCLA, NORETHINDRONE
JENTADUETO, LINAGLIPTIN
JENTADUETO XR, LINAGLIPTIN
JESDUVROQ, DAPRODUSTAT
JEVTANA KIT, CABAZITAXEL
JOENJA, LENIOLISIB PHOSPHATE
JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE
JUBLIA, EFINACONAZOLE
JULUCA, DOLUTEGRAVIR SODIUM
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
JUXTAPID, LOMITAPIDE MESYLATE
JYLAMVO, METHOTREXATE
JYNARQUE, TOLVAPTAN

**** K ****

KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KAITLIB FE, ETHINYL ESTRADIOL
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KALLIGA, DESOGESTREL
KALYDECO, IVACAFTOR
KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
KARBINAL ER, CARBINOXAMINE MALEATE
KARIVA, DESOGESTREL
KATERZIA, AMLODIPINE BENZOATE
KAZANO, ALOGLIPTIN BENZOATE
KELNOR, ETHINYL ESTRADIOL
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-80, TRIAMCINOLONE ACETONIDE
KENGREAL, CANGRELOR
KEPPRA, LEVETIRACETAM
KEPPRA XR, LEVETIRACETAM
KERENDIA, FINERENONE
KERYDIN, TAVABOROLE
KETALAR, KETAMINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** K ****

KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KEVEYIS, DICHLORPHENAMIDE
KHAPZORY, LEVOLEUCOVORIN
KIMIDESS, DESOGESTREL
KIMYRSA, ORITAVANCIN DIPHOSPHATE
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KISQALI, RIBOCICLIB SUCCINATE
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KITABIS PAK, TOBRAMYCIN
KLARON, SULFACETAMIDE SODIUM
KLISYRI, TIRBANIBULIN
KLONOPIN, CLONAZEPAM
KLOR-CON, POTASSIUM CHLORIDE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOXXADO, NALOXONE HYDROCHLORIDE
KONVOMEP, OMEPRAZOLE
KORLYM, MIFEPRISTONE
KORSUVA, DIFELIKEFALIN ACETATE
KOSELUGO, SELUMETINIB SULFATE
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE
KRAZATI, ADAGRASIB
KRINTAFEL, TAFENOQUINE SUCCINATE
KURVELO, ETHINYL ESTRADIOL
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
KYBELLA, DEOXYCHOLIC ACID
KYLEENA, LEVONORGESTREL
KYPROLIS, CARFILZOMIB
KYZATREX, TESTOSTERONE UNDECANOATE

**** L ****

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN DEXTROSE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE, LABETALOL HYDROCHLORIDE
LACOSAMIDE, LACOSAMIDE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL, LAMOTRIGINE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMIVUDINE, LAMIVUDINE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LAMPIT, NIFURTIMOX
LANORINAL, ASPIRIN
LANOXIN, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANREOTIDE ACETATE, LANREOTIDE ACETATE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), AMOXICILLIN

APPENDIX A - PRODUCT NAME INDEX

**** L ****

LANTHANUM CARBONATE, LANTHANUM CARBONATE
LAPATINIB DITOSYLATE, LAPATINIB DITOSYLATE
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LASTACAFT, ALCAFTADINE (OTC)
LATANOPROST, LATANOPROST
LATISSE, BIMATOPROST
LATUDA, LURASIDONE HYDROCHLORIDE
LEFLUNOMIDE, LEFLUNOMIDE
LENALIDOMIDE, LENALIDOMIDE
LENVIMA, LENVATINIB MESYLATE
LEQVIO, INCLISIRAN SODIUM
LERIBANE, ETHINYL ESTRADIOL
LESCOL XL, FLUVASTATIN SODIUM
LESSINA-28, ETHINYL ESTRADIOL
LETAIRIS, AMBRISENTAN
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEUPROLIDE ACETATE FOR DEPOT SUSPENSION, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVO-T, LEVOTHYROXINE SODIUM **
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVOCARNITINE SF, LEVOCARNITINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOCETIRIZINE HYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOLET, LEVOTHYROXINE SODIUM **
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LEVOMILNACIPRAN HYDROCHLORIDE, LEVOMILNACIPRAN HYDROCHLORIDE
LEVONEST, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LEVOXYL, LEVOTHYROXINE SODIUM **
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXETTE, HALOBETASOL PROPIONATE
LEXISCAN, REGADENOSON
LEXIVA, FOSAMPRENAVIR CALCIUM
LIALDA, MESALAMINE
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LICART, DICLOFENAC EPOLAMINE
LIDEX, FLUOCINONIDE
LIDOCAINE, LIDOCAINE

APPENDIX A - PRODUCT NAME INDEX

**** L ****

APPENDIX A - PRODUCT NAME INDEX

** L **

LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORATADINE, LORATADINE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORBRENA, LORLATINIB
LOREEV XR, LORAZEPAM
LORYNA, DROSPIRENONE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSEASONIQUE, ETHINYL ESTRADIOL
LOTEMAX, LOTEPREDNOL ETABONATE
LOTEMAX SM, LOTEPREDNOL ETABONATE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
LOVENOX, ENOXAPARIN SODIUM
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LUBIPROSTONE, LUBIPROSTONE
LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
LUMAKRAS, SOTORASIB
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
LUMI-SPORYN, BACITRACIN ZINC
LUMIFY, BRIMONIDINE TARTRATE (OTC)
LUMIGAN, BIMATOPROST
LUMRYZ, SODIUM OXYBATE
LUNESTA, ESZOPICLONE
LUPKYNIS, VOCLOSPORIN
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
LUTATHERA, LUTETIUM LU 177 DOTATATE
LUVOX, FLUVOXAMINE MALEATE
LUZU, LULICONAZOLE
LYBALVI, OLANZAPINE
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
LYNPARZA, OLAPARIB
LYPQOZET, ATORVASTATIN CALCIUM
LYRICA, PREGABALIN
LYRICA CR, PREGABALIN
LYSODREN, MITOTANE
LYSTEDA, TRANEXAMIC ACID
LYTGOBI, FUTIBATINIB
LYVISPAH, BACLOFEN

** M **

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MACITENTAN, MACITENTAN
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MALARONE, ATOVAQUONE
MALARONE PEDIATRIC, ATOVAQUONE

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MALATHION, MALATHION
MALMOREDE, ETHINYL ESTRADIOL
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MARAVIROC, MARAVIROC
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARLISSA, ETHINYL ESTRADIOL
MARPLAN, ISOCARBOXAZID
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVENCLAD, CLADRIBINE
MAVYRET, GLECAPREVIR
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MAYZENT, SIPONIMOD
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGACE ES, MEGESTROL ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MEKTOVI, BINIMETINIB
MELAMISA, DROSPIRENONE
MELOXICAM, MELOXICAM
MELPHALAN, MELPHALAN
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENEST, ESTROGENS, ESTERIFIED
MENOSTAR, ESTRADIOL
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPURINE, MERCAPTOPURINE
MEROPENEM, MEROPENEM
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM
MERREM, MEROPENEM
MERZEE, ETHINYL ESTRADIOL
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE SR-89

APPENDIX A - PRODUCT NAME INDEX

**** M ****

METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHSUXIMIDE, METHSUXIMIDE
METHYLENE BLUE, METHYLENE BLUE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE, METHYLPHENIDATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPIRONE, METYRAPONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METYROSINE, METYROSINE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIACALCIN, CALCITONIN SALMON
MIBELAS 24 FE, ETHINYL ESTRADIOL
MICAFUNGIN, MICAFUNGIN SODIUM
MICAFUNGIN IN SODIUM CHLORIDE 0.9%, MICAFUNGIN SODIUM
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MICARDIS, TELMISARTAN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM IN 0.8% SODIUM CHLORIDE, MIDAZOLAM
MIDAZOLAM IN 0.9% SODIUM CHLORIDE, MIDAZOLAM
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MIDOL LIQUID GELS, IBUPROFEN (OTC)
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIEBO, PERFLUOROHEXYLOCTANE
MIFEPREX, MIFEPRISTONE
MIFEPRISTONE, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGLITOL, MIGLITOL
MIGLUSTAT, MIGLUSTAT
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILI, ETHINYL ESTRADIOL
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIVELLE, ESTRADIOL
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRABEGRON, MIRABEGRON
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MIRVASO, BRIMONIDINE TARTRATE
MISOPROSTOL, MISOPROSTOL
MITIGARE, COLCHICINE
MITIGO, MORPHINE SULFATE
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MIVACURIUM CHLORIDE, MIVACURIUM CHLORIDE
MOBIC, MELOXICAM
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONO-LINYAH, ETHINYL ESTRADIOL
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE, SODIUM PHOSPHATE, DIBASIC,
MONODOX, DOXYCYCLINE
MONOFERRIC, FERRIC DERISOMALTOSE
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHINE SULFATE, MORPHINE SULFATE
MOTEGRITY, PRUCALOPRIDE SUCCINATE
MOTOFEN, ATROPINE SULFATE
MOTPOLY XR, LACOSAMIDE
MOTRIN IB, IBUPROFEN (OTC)
MOUNJARO, TIRZEPATIDE

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MOVANTIK, NALOXEGOL OXALATE
MOVIPREP, ASCORBIC ACID
MOXIDECTIN, MOXIDECTIN
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
MOZOBIL, PLERIXAFOR
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MULPLETA, LUSUTROMBOPAG
MULTAQ, DRONEDARONE HYDROCHLORIDE
MULTIHANCE, GADOBENATE DIMEGLUMINE
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5, MAGNESIUM CHLORIDE
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4, MAGNESIUM CHLORIDE
MULTRYS, CUPRIC SULFATE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
MUSE, ALPROSTADIL
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYCAMINE, MICAFUNGIN SODIUM
MYCAPSSA, OCTREOTIDE ACETATE
MYCOBUTIN, RIFABUTIN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
MYDAYIS, AMPHETAMINE ASPARTATE
MYDCOMBI, PHENYLEPHRINE HYDROCHLORIDE
MYDRIACYL, TROPICAMIDE
MYFEMBREE, ESTRADIOL
MYFORTIC, MYCOPHENOLIC SODIUM
MYKACET, NYSTATIN
MYLERAN, BUSULFAN
MYORISAN, ISOTRETINOIN
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYRBETRIQ, MIRABEGRON
MYRBETRIQ GRANULES, MIRABEGRON
MYSOLINE, PRIMIDONE
MYTESI, CROFELEMER
MYZILRA, ETHINYL ESTRADIOL

**** N ****

NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALFON, FENOPROFEN CALCIUM
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NALMEFENE HYDROCHLORIDE, NALMEFENE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE (OTC)
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALTREXONE, NALTREXONE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN, NAPROXEN
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NARCAN, NALOXONE HYDROCHLORIDE (OTC)
NARDIL, PHENELZINE SULFATE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NASCOBAL, CYANOCOBALAMIN
NASONEX 24HR ALLERGY, MOMETASONE FUROATE (OTC)
NATACYN, NATAMYCIN
NATAZIA, DIENOGEST
NATEGLINIDE, NATEGLINIDE
NATESTO, TESTOSTERONE
NATROBA, SPINOSAD
NAYZILAM, MIDAZOLAM
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NELARABINE, NELARABINE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOPROFEN, IBUPROFEN LYSINE
NEORAL, CYCLOSPORINE
NEOSPORIN, GRAMICIDIN
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NEOSTIGMINE METHYSULFATE, NEOSTIGMINE METHYLSULFATE
NEPHROSCAN, TECHNETIUM TC-99M SUCCIMER
NERLYNX, NERATINIB MALEATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NESINA, ALOGLIPTIN BENZOATE
NETSPOT, GALLIUM DOTATATE GA-68
NEUPRO, ROTIGOTINE
NEURACEQ, FLORBETABEN F-18
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEVANAC, NEPAFENAC
NEVIRAPINE, NEVIRAPINE
NEXAVAR, SORAFENIB TOSYLATE
NEXESTA FE, ETHINYL ESTRADIOL
NEXICLON XR, CLONIDINE
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXLETOL, BEMPEDOIC ACID
NEXLIZET, BEMPEDOIC ACID
NEXPLANON, ETONOGESTREL
NEXTERONE, AMIODARONE HYDROCHLORIDE
NEXTSTELLIS, DROSPIRENONE
NIACIN, NIACIN
NIACOR, NIACIN

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NICODERM CQ, NICOTINE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTROL, NICOTINE
NIFEDIPINE, NIFEDIPINE
NIKKI, DROSPIRENONE
NILANDRON, NILUTAMIDE
NILOTINIB HYDROCHLORIDE, NILOTINIB HYDROCHLORIDE
NILUTAMIDE, NILUTAMIDE
NIMBEX, CISATRACURIUM BESYLATE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMODIPINE, NIMODIPINE
NINLARO, IXAZOMIB CITRATE
NIPENT, PENTOSTATIN
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
NISOLDIPINE, NISOLDIPINE
NITAZOXANIDE, NITAZOXANIDE
NITHIODOTE, SODIUM NITRITE
NITISINONE, NITISINONE
NITRO-DUR, NITROGLYCERIN
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROSTAT, NITROGLYCERIN
NITYR, NITISINONE
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL ANTI-DANDRUFF, KETOCONAZOLE (OTC)
NOR-QD, NORETHINDRONE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE, NOREPINEPHRINE BITARTRATE
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE, NORETHINDRONE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORITATE, METRONIDAZOLE
NORLIQVA, AMLODIPINE BESYLATE
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NORTHERA, DROXIDOPA
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NORVIR, RITONAVIR
NOURIANZ, ISTRADEFYLLINE
NOXAFIL, POSACONAZOLE
NOXAFIL POWDERMIX KIT, POSACONAZOLE
NOXIVENT, NITRIC OXIDE
NUBEQA, DAROLUTAMIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE
NULIBRY, FOSDENOPTERIN HYDROBROMIDE
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
NUMBRINO, COCAINE HYDROCHLORIDE
NUPLAZID, PIMAVANSERIN TARTRATE
NURTEC ODT, RIMEGEPANT SULFATE
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
NUVARING, ETHINYL ESTRADIOL
NUVESSA, METRONIDAZOLE
NUVIGIL, ARMODAFINIL
NUZYRA, OMADACYCLINE TOSYLATE
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
NYMALIZE, NIMODIPINE
NYSTATIN, NYSTATIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTOP, NYSTATIN

**** O ****

OCALIVA, OBETICHOLIC ACID
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCUFLOX, OFLOXACIN
ODEFSEY, EMTRICITABINE
ODOMZO, SONIDEGIB PHOSPHATE
OFEV, NINTEDANIB ESYLATE
OFLOXACIN, OFLOXACIN
OGEN 5, ESTROPIPATE
OGSIVEO, NIROGACESTAT HYDROBROMIDE
OJJAARA, MOMELOTINIB DIHYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLINVYK, OLICERIDINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLPRUVA, SODIUM PHENYLBUTYRATE
OLUMIANT, BARICITINIB
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEGAVEN, FISH OIL TRIGLYCERIDES
OMEPRAZOLE, OMEPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMIDRIA, KETOROLAC TROMETHAMINE
OMNARIS, CICLESONIDE
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL

APPENDIX A - PRODUCT NAME INDEX

**** O ****

OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNIPRED, PREDNISOLONE ACETATE
OMNISCAN, GADODIAMIDE
ONDANSETRON, ONDANSETRON
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONEXTON, BENZOYL PEROXIDE
ONFI, CLOBAZAM
ONGENTYS, OPICAPONE
ONIVYDE, IRINOTECAN HYDROCHLORIDE
ONPATTRO, PATISIRAN SODIUM
ONSURA, ETHINYL ESTRADIOL
ONUREG, AZACITIDINE
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPFOLDA, MIGLUSTAT
OPSUMIT, MACITENTAN
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
OPVEE, NALMEFENE HYDROCHLORIDE
OPZELURA, RUXOLITINIB PHOSPHATE
ORABLOC, ARTICAINE HYDROCHLORIDE
ORACEA, DOXYCYCLINE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVERSE, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORBACTIV, ORITAVANCIN DIPHOSPHATE
ORENITRAM, TREPROSTINIL DIOLAMINE
ORFADIN, NITISINONE
ORGOVYX, RELUGOLIX
ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
ORILISSA, ELAGOLIX SODIUM
ORKAMBI, IVACAFTOR
ORLADEYO, BEROTRALSTAT HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORPHENGESIC, ASPIRIN
ORPHENGESIC FORTE, ASPIRIN
ORSERDU, ELACESTRANT DIHYDROCHLORIDE
ORVATEN, MIDODRINE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OSENI, ALOGLIPTIN BENZOATE
OSHIH, ETHINYL ESTRADIOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMOLEX ER, AMANTADINE HYDROCHLORIDE
OSPHENA, OSPEMIFENE
OTEZLA, APREMILAST
OTICAIR, HYDROCORTISONE
OTOVEL, CIPROFLOXACIN HYDROCHLORIDE
OTREXUP, METHOTREXATE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM

APPENDIX A - PRODUCT NAME INDEX

**** O ****

OXBRYTA, VOXELOTOR
OXCARBAZEPINE, OXCARBAZEPINE
OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
OXISTAT, OXICONAZOLE NITRATE
OXLUMO, LUMASIRAN SODIUM
OXSORALEN-ULTRA, METHOXSALEN
OXTELLAR XR, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYCONTIN, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
OXYTROL, OXYBUTYNIN
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
OZEMPIC, SEMAGLUTIDE
OZOBAX DS, BACLOFEN
OZURDEX, DEXAMETHASONE

**** P ****

PACERONE, AMIODARONE HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PALBOCICLIB, PALBOCICLIB
PALIPERIDONE, PALIPERIDONE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANDEL, HYDROCORTISONE PROBUTATE
PANRETIN, ALITRETINOIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARAGARD T 380A, COPPER
PARICALCITOL, PARICALCITOL
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCYPROMINE SULFATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PARSABIV, ETELCALCETIDE
PASER, AMINOSALICYLIC ACID
PATADAY ONCE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
PATADAY TWICE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXLOVID (COPACKAGED), NIRMATRELVIR
PAZOPANIB HYDROCHLORIDE, PAZOPANIB HYDROCHLORIDE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDMARK, SODIUM THIOSULFATE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
PEMAZYRE, PEMIGATINIB
PEMETREXED, PEMETREXED
PEMETREXED, PEMETREXED DISODIUM
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PEMETREXED DITROMETHAMINE, PEMETREXED DITROMETHAMINE
PEMFEXY, PEMETREXED
PENCICLOVIR, PENCICLOVIR
PENICILLAMINE, PENICILLAMINE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENNSAID, DICLOFENAC SODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOSTATIN, PENTOSTATIN
PENTOXIFYLLINE, PENTOXIFYLLINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERMETHRIN, PERMETHRIN (OTC)
PERMETHRIN, PERMETHRIN
PERPHENAZINE, PERPHENAZINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERSANTINE, DIPYRIDAMOLE
PERSERIS KIT, RISPERIDONE
PFIZERPEN, PENICILLIN G POTASSIUM
PHEBURANE, SODIUM PHENYLBUTYRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENELZINE SULFATE, PHENELZINE SULFATE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PHENYTOIN, PHENYTOIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHEXXI, CITRIC ACID
PHILITH, ETHINYL ESTRADIOL
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOTOFRIN, PORFIMER SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHYRAGO, DASATINIB
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PIFELTRO, DORAVIRINE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIMECROLIMUS, PIMECROLIMUS
PIMOZIDE, PIMOZIDE
PIMTREA, DESOGESTREL
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIPERACILLIN, PIPERACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIQRAY, ALPELISIB
PIRFENIDONE, PIRFENIDONE
PIROXICAM, PIROXICAM

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
PITOCIN, OXYTOCIN
PLAN B ONE-STEP, LEVONORGESTREL (OTC)
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLAVIX, CLOPIDOGREL BISULFATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLENVU, ASCORBIC ACID
PLERIXAFOR, PLERIXAFOR
PLUVICTO, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
PODOFILOX, PODOFILOX
POKONZA, POTASSIUM CHLORIDE
POLMON, DEXCHLORPHENIRAMINE MALEATE
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POMALYST, POMALIDOMIDE
PONSTEL, MEFENAMIC ACID
PONVORY, PONESIMOD
PORTIA-28, ETHINYL ESTRADIOL
POSACONAZOLE, POSACONAZOLE
POSIMIR, BUPIVACAINE
POSLUMA, FLOTUFOLASTAT F-18 GALLIUM
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PRASUGREL, PRASUGREL HYDROCHLORIDE
PRASUGREL HYDROCHLORIDE, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZIQUANTEL, PRAZIQUANTEL
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PRE-OP, HEXACHLOROPHENE
PRE-OP II, HEXACHLOROPHENE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PREDNICARBATE, PREDNICARBATE
PREDNISOLONE, PREDNISOLONE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISONE, PREDNISONE
PREDNISONE INTENSOL, PREDNISONE
PREGABALIN, PREGABALIN
PRELONE, PREDNISOLONE
PREMARIN, ESTROGENS, CONJUGATED
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PRESTALIA, AMLODIPINE BESYLATE
PRETOMANID, PRETOMANID
PREVACID, LANSOPRAZOLE
PREVACID 24 HR, LANSOPRAZOLE (OTC)
PREVALITE, CHOLESTYRAMINE
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVDUO, GLYCOPYRROLATE
PREVIFEM, ETHINYL ESTRADIOL
PREVYMIS, LETERMOVIR
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR
PRIALT, ZICONOTIDE ACETATE
PRIFTIN, RIFAPENTINE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PRIMATENE MIST, EPINEPHRINE (OTC)
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROAIR DIGIHALER, ALBUTEROL SULFATE
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROBALAN, PROBENECID
PROBENECID, PROBENECID
PROBENECID AND COLCHICINE, COLCHICINE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCARDIA, NIFEDIPINE
PROCARDIA XL, NIFEDIPINE
PROCHLORPERAZINE, PROCHLORPERAZINE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCOMP, PROCHLORPERAZINE MALEATE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROCYSBI, CYSTEAMINE BITARTRATE
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROHANCE MULTIPACK, GADOTERIDOL
PROLENSA, BROMFENAC SODIUM
PROMACTA, ELTROMBOPAG OLAMINE
PROMACTA KIT, ELTROMBOPAG OLAMINE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPOFOL, PROPOFOL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTONIX, PANTOPRAZOLE SODIUM
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
PROVAYBLUE, METHYLENE BLUE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PULMICORT FLEXHALER, BUDESONIDE
PULMICORT RESPULES, BUDESONIDE
PUR-WASH, PURIFIED WATER (OTC)
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
PURINETHOL, MERCAPTOPURINE
PURIXAN, MERCAPTOPURINE
PYLARIFY, PIFLUFOLASTAT F-18
PYLERA, BISMUTH SUBCITRATE POTASSIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
PYRIMETHAMINE, PYRIMETHAMINE
PYRUKYND, MITAPIVAT SULFATE
PYTEST, UREA, C-14

**** Q ****

QALSODY, TOFERSEN

APPENDIX A - PRODUCT NAME INDEX

**** Q ****

QBRELIS, LISINOPRIL
QBREXZA, GLYCOPYRRONIUM TOSYLATE
QDOLO, TRAMADOL HYDROCHLORIDE
QELBREE, VILOXAZINE HYDROCHLORIDE
QINLOCK, RIPRETINIB
QLOSI, PILOCARPINE HYDROCHLORIDE
QNASL, BECLOMETHASONE DIPROPIONATE
QOLIANA, BRIMONIDINE TARTRATE
QSYMIA, PHENTERMINE HYDROCHLORIDE
QTERN, DAPAGLIFLOZIN
QUALAQUIN, QUININE SULFATE
QUARTETTE, ETHINYL ESTRADIOL
QUASENSE, ETHINYL ESTRADIOL
QUDEXY XR, TOPIRAMATE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUININE SULFATE, QUININE SULFATE
QULIPTA, ATOGEPANT
QUTENZA, CAPSAICIN
QUVIVIQ, DARIDOREXANT HYDROCHLORIDE
QUZYTTIR, CETIRIZINE HYDROCHLORIDE
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

**** R ****

R-GENE 10, ARGININE HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RADICAVA, EDARAVONE
RADICAVA ORS, EDARAVONE
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMELTEON, RAMELTEON
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RAPAFLO, SILODOSIN
RAPAMUNE, SIROLIMUS
RAPIVAB, PERAMIVIR
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RASUVO, METHOTREXATE
RAVICTI, GLYCEROL PHENYLBUTYRATE
RAYALDEE, CALCIFEDIOL
RAYOS, PREDNISONE
READI-CAT 2, BARIUM SULFATE
READI-CAT 2 SMOOTHIE, BARIUM SULFATE
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)
RECARBRIO, CILASTATIN SODIUM
RECLAST, ZOLEDRONIC ACID
RECORLEV, LEVOKETOCONAZOLE
RECTIV, NITROGLYCERIN
REGADENOSON, REGADENOSON
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELEXXII, METHYLPHENIDATE HYDROCHLORIDE
RELISTOR, METHYLNALTREXONE BROMIDE
RELPAX, ELETRIPTAN HYDROBROMIDE
RELYVRIO, SODIUM PHENYLBUTYRATE
REMERON, MIRTAZAPINE

APPENDIX A - PRODUCT NAME INDEX

**** R ****

REMERON SOLTAB, MIRTAZAPINE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
REMODULIN, TREPROSTINIL
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENOVA, TRETINOIN
RENVELA, SEVELAMER CARBONATE
REPAGLINIDE, REPAGLINIDE
RESTASIS, CYCLOSPORINE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETEVMO, SELPERCATINIB
RETIN-A, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A-MICRO, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE
REVLIMID, LENALIDOMIDE
REVONTO, DANTROLENE SODIUM
REXULTI, BREXPIPRAZOLE
REYATAZ, ATAZANAVIR SULFATE
REYVOW, LASMIDITAN SUCCINATE
REZIPRES, EPHEDRINE HYDROCHLORIDE
REZLIDHIA, OLUTASIDENIB
REZUROCK, BELUMOSUDIL MESYLATE
REZZAYO, REZAFUNGIN ACETATE
RHINOCORT ALLERGY, BUDESONIDE (OTC)
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE
RHOPRESSA, NETARSUDIL MESYLATE
RIBAVIRIN, RIBAVIRIN
RIDAURA, AURANOFIN
RIFABUTIN, RIFABUTIN
RIFADIN, RIFAMPIN
RIFAMPIN, RIFAMPIN
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RINVOQ, UPADACITINIB
RIOCIGUAT, RIOCIGUAT
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERDAL, RISPERIDONE
RISPERDAL CONSTA, RISPERIDONE
RISPERIDONE, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITONAVIR, RITONAVIR
RIVASTIGMINE, RIVASTIGMINE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIVFLOZA, NEDOSIRAN SODIUM
RIVIVE, NALOXONE HYDROCHLORIDE (OTC)
RIZAFILM, RIZATRIPTAN BENZOATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROBAXIN, METHOCARBAMOL
ROBINUL, GLYCOPYRROLATE
ROBINUL FORTE, GLYCOPYRROLATE
ROCALTROL, CALCITRIOL
ROCKLATAN, LATANOPROST
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROFLUMILAST, ROFLUMILAST
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** R ****

ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROMIDEPSIN, ROMIDEPSIN
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
ROWASA, MESALAMINE
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXYBOND, OXYCODONE HYDROCHLORIDE
ROZEREM, RAMELTEON
ROZLYTREK, ENTRECTINIB
RUBRACA, RUCAPARIB CAMSYLATE
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
RUFINAMIDE, RUFINAMIDE
RUKOBIA, FOSTEMSAVIR TROMETHAMINE
RYALTRIS, MOMETASONE FUROATE
RYANODEX, DANTROLENE SODIUM
RYBELSUS, SEMAGLUTIDE
RYDAPT, MIDOSTAURIN
RYKINDO, RISPERIDONE
RYTARY, CARBIDOPA
RYZUMVI, PHENTOLAMINE MESYLATE

**** S ****

SABRIL, VIGABATRIN
SAFYRAL, DROSPIRENONE
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALONPAS, MENTHOL (OTC)
SAMSCA, TOLVAPTAN
SANCUSO, GRANISETRON
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SAPHRIS, ASENAPINE MALEATE
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SAVAYSA, EDOXABAN TOSYLATE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SAXAGLIPTIN, SAXAGLIPTIN HYDROCHLORIDE
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
SAXENDA, LIRAGLUTIDE RECOMBINANT
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCEMBLIX, ASCIMINIB HYDROCHLORIDE
SCENESSE, AFAMELANOTIDE
SCLEROSOL, TALC
SCOPOLAMINE, SCOPOLAMINE
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
SECUADO, ASENAPINE
SEGLENTIS, CELECOXIB
SEGLUROMET, ERTUGLIFLOZIN
SEIZALAM, MIDAZOLAM HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SELENIOUS ACID, SELENIOUS ACID
SELENIUM SULFIDE, SELENIUM SULFIDE
SELEXIPAG, SELEXIPAG
SELZENTRY, MARAVIROC
SENSIPAR, CINACALCET HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEPTRA, SULFAMETHOXAZOLE
SEPTRA DS, SULFAMETHOXAZOLE
SEREVENT, SALMETEROL XINAFOATE
SERNIVO, BETAMETHASONE DIPROPIONATE
SEROMYCIN, CYCLOSERINE
SEROQUEL, QUETIAPINE FUMARATE
SEROQUEL XR, QUETIAPINE FUMARATE

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SETLAKIN, ETHINYL ESTRADIOL
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SEVOFLURANE, SEVOFLURANE
SEYSARA, SARECYCLINE HYDROCHLORIDE
SEZABY, PHENOBARBITAL SODIUM
SFROWASA, MESALAMINE
SIGNIFOR, PASIREOTIDE DIASPARTATE
SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
SIKLOS, HYDROXYUREA
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILENOR, DOXEPIN HYDROCHLORIDE
SILODOSIN, SILODOSIN
SILVADENE, SILVER SULFADIAZINE
SIMBRINZA, BRIMONIDINE TARTRATE
SIMLIYA, DESOGESTREL
SIMPESSE, ETHINYL ESTRADIOL
SIMVASTATIN, SIMVASTATIN
SINCALIDE, SINCALIDE
SINE-AID IB, IBUPROFEN (OTC)
SINEMET, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
SINUVA, MOMETASONE FUROATE
SIROLIMUS, SIROLIMUS
SIRTURO, BEDAQUILINE FUMARATE
SITAVIG, ACYCLOVIR
SIVEXTRO, TEDIZOLID PHOSPHATE
SKLICE, IVERMECTIN (OTC)
SKYCLARYS, OMAVELOXOLONE
SKYLA, LEVONORGESTREL
SLYND, DROSPIRENONE
SMOFLIPID 20%, FISH OIL
SOAANZ, TORSEMIDE
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, FERRIC OXYHYDROXIDE
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM NITRITE, SODIUM NITRITE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID, CITRIC ACID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SOHONOS, PALOVAROTENE
SOJOURN, SEVOFLURANE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLOSEC, SECNIDAZOLE
SOLTAMOX, TAMOXIFEN CITRATE

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOLUPREP S, CHLORHEXIDINE GLUCONATE (OTC)
SOMA, CARISOPRODOL
SOMATULINE DEPOT, LANREOTIDE ACETATE
SONATA, ZALEPLON
SOOLANTRA, IVERMECTIN
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTYKTU, DEUCRAVACITINIB
SOTYLIZE, SOTALOL HYDROCHLORIDE
SOVALDI, SOFOSBUVIR
SOVUNA, HYDROXYCHLOROQUINE SULFATE
SPINRAZA, NUSINERSEN SODIUM
SPIRIVA, TIOTROPIUM BROMIDE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRAVATO, ESKETAMINE HYDROCHLORIDE
SPRINTEC, ETHINYL ESTRADIOL
SPRITAM, LEVETIRACETAM
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SPY AGENT GREEN KIT, INDOCYANINE GREEN
SSD, SILVER SULFADIAZINE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN
STENDRA, AVANAFIL
STERILE WATER, STERILE WATER FOR IRRIGATION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERITALC, TALC
STIE-CORT, HYDROCORTISONE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STIVARGA, REGORAFENIB
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIBILD, COBICISTAT
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
STROMECTOL, IVERMECTIN
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUCRALFATE, SUCRALFATE
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SUFLAVE, MAGNESIUM SULFATE

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SUGAMMADEX SODIUM, SUGAMMADEX SODIUM
SULAR, NISOLDIPINE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFADIAZINE, SULFADIAZINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SUMATRIPTAN, SUMATRIPTAN
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUNITINIB MALATE, SUNITINIB MALATE
SUNLENCA, LENACAPAVIR SODIUM
SUNOSI, SOLRIAMFETOL HYDROCHLORIDE
SUPPRELIN LA, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
SUSTOL, GRANISETRON
SUTAB, MAGNESIUM SULFATE
SUTENT, SUNITINIB MALATE
SYEDA, DROSPIRENONE
SYFOVRE, PEGCETACOPLAN
SYMBICORT, BUDESONIDE
SYMBICORT AEROSPHERE, BUDESONIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
SYMDEKO (COPACKAGED), IVACAFTOR
SYMFI, EFAVIRENZ
SYMFI LO, EFAVIRENZ
SYMJEPI, EPINEPHRINE
SYMLIN, PRAMLINTIDE ACETATE
SYMPAZAN, CLOBAZAM
SYMPROIC, NALDEMEDINE TOSYLATE
SYMTUZA, COBICISTAT
SYNALAR, FLUOCINOLONE ACETONIDE
SYNAREL, NAFARELIN ACETATE
SYNDROS, DRONABINOL
SYNERCID, DALFOPRISTIN
SYNJARDY, EMPAGLIFLOZIN
SYNJARDY XR, EMPAGLIFLOZIN
SYNRIBO, OMACETAXINE MEPESUCCINATE
SYNTHROID, LEVOTHYROXINE SODIUM **
SYPRINE, TRIENTINE HYDROCHLORIDE

**** T ****

TABRECTA, CAPMATINIB HYDROCHLORIDE
TACLONEX, BETAMETHASONE DIPROPIONATE
TACROLIMUS, TACROLIMUS
TADALAFIL, TADALAFIL
TADLIQ, TADALAFIL
TAFINLAR, DABRAFENIB MESYLATE
TAFLUPROST, TAFLUPROST
TAGAMET HB, CIMETIDINE (OTC)
TAGITOL V, BARIUM SULFATE
TAGRISSO, OSIMERTINIB MESYLATE
TALC, TALC
TALICIA, AMOXICILLIN
TALZENNA, TALAZOPARIB TOSYLATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TARGRETIN, BEXAROTENE
TARPEYO, BUDESONIDE

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TASCENSO ODT, FINGOLIMOD LAURYL SULFATE
TASIGNA, NILOTINIB HYDROCHLORIDE
TASIMELTEON, TASIMELTEON
TASMAR, TOLCAPONE
TAUVID, FLORTAUCIPIR F-18
TAVABOROLE, TAVABOROLE
TAVALISSE, FOSTAMATINIB DISODIUM
TAVNEOS, AVACOPAN
TAXOTERE, DOCETAXEL
TAYTULLA, ETHINYL ESTRADIOL
TAZAROTENE, TAZAROTENE
TAZICEF, CEFTAZIDIME
TAZORAC, TAZAROTENE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TAZVERIK, TAZEMETOSTAT HYDROBROMIDE
TECFIDERA, DIMETHYL FUMARATE
TECHNEGAS KIT, TECHNETIUM TC-99M LABELED CARBON
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TECHNETIUM TC-99M MEDRONATE KIT, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC-99M SULFUR COLLOID KIT, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
TEFLARO, CEFTAROLINE FOSAMIL
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEGSEDI, INOTERSEN SODIUM
TEKTURNA, ALISKIREN HEMIFUMARATE
TELMISARTAN, TELMISARTAN
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TEMAZEPAM, TEMAZEPAM
TEMBEXA, BRINCIDOFOVIR
TEMODAR, TEMOZOLOMIDE
TEMOZOLOMIDE, TEMOZOLOMIDE
TEMSIROLIMUS, TEMSIROLIMUS
TENOFOVIR ALAFENAMIDE, TENOFOVIR ALAFENAMIDE FUMARATE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TEPADINA, THIOTEPA
TEPMETKO, TEPOTINIB HYDROCHLORIDE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERCONAZOLE, TERCONAZOLE
TERIFLUNOMIDE, TERIFLUNOMIDE
TERIL, CARBAMAZEPINE
TERIPARATIDE, TERIPARATIDE
TERLIVAZ, TERLIPRESSIN ACETATE
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTOPEL, TESTOSTERONE
TESTOSTERONE, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TETRABENAZINE, TETRABENAZINE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** T ****

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TOLVAPTAN, TOLVAPTAN
TOPAMAX, TOPIRAMATE
TOPICORT, DESOXIMETASONE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TOPROL-XL, METOPROLOL SUCCINATE
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TORISEL, TEMSIROLIMUS
TORSEMIDE, TORSEMIDE
TOSYMRA, SUMATRIPTAN
TOVIAZ, FESOTERODINE FUMARATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TPOXX, TECOVIRIMAT
TRACLEER, BOSENTAN
TRADJENTA, LINAGLIPTIN
TRALEMENT, CUPRIC SULFATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANDOLAPRIL, TRANDOLAPRIL
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANEXAMIC ACID, TRANEXAMIC ACID
TRANSDERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVATAN Z, TRAVOPROST
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRECATOR, ETHIONAMIDE
TRELEGY ELLIPTA, FLUTICASONE FUROATE
TRELSTAR, TRIPTORELIN PAMOATE
TREPROSTINIL, TREPROSTINIL
TRETINOIN, TRETINOIN
TRETINOIN MICROSPHERE, TRETINOIN
TREXALL, METHOTREXATE SODIUM
TREXIMET, NAPROXEN SODIUM
TREZIX, ACETAMINOPHEN
TRI LO SPRINTEC, ETHINYL ESTRADIOL
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-LINYAH, ETHINYL ESTRADIOL
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRI-MILI, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE, TRIAMTERENE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIBENZOR, AMLODIPINE BESYLATE
TRICOR, FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
TRIESENCE, TRIAMCINOLONE ACETONIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIGLIDE, FENOFIBRATE

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIJARDY XR, EMPAGLIFLOZIN
TRIKAFTA (COPACKAGED), ELEXACAFTOR, IVACAFTOR, TEZACAFTOR
TRILEPTAL, OXCARBAZEPINE
TRILIPIX, CHOLINE FENOFIBRATE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
TRIPTODUR KIT, TRIPTORELIN PAMOATE
TRISENOX, ARSENIC TRIOXIDE
TRIUMEQ, ABACAVIR SULFATE
TRIUMEQ PD, ABACAVIR SULFATE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVORA-28, ETHINYL ESTRADIOL
TROKENDI XR, TOPIRAMATE
TROPHAMINE, AMINO ACIDS
TROPHAMINE 10%, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
TRUDHESA, DIHYDROERGOTAMINE MESYLATE
TRULANCE, PLECANATIDE
TRUQAP, CAPIVASERTIB
TRUVADA, EMTRICITABINE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
TUKYSA, TUCATINIB
TURALIO, PEXIDARTINIB HYDROCHLORIDE
TURQOZ, ETHINYL ESTRADIOL
TUXARIN ER, CHLORPHENIRAMINE MALEATE
TWIRLA, ETHINYL ESTRADIOL
TWYNEO, BENZOYL PEROXIDE
TYBLUME, ETHINYL ESTRADIOL
TYBOST, COBICISTAT
TYDEMY, DROSPIRENONE
TYGACIL, TIGECYCLINE
TYKERB, LAPATINIB DITOSYLATE
TYLENOL, ACETAMINOPHEN (OTC)
TYMLOS, ABALOPARATIDE
TYRVAYA, VARENICLINE TARTRATE
TYVASO, TREPROSTINIL
TYVASO DPI, TREPROSTINIL
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

**** U ****

UBRELVY, UBROGEPANT
UCERIS, BUDESONIDE
ULORIC, FEBUXOSTAT
ULSPIRA, NITRIC OXIDE
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
UNASYN, AMPICILLIN SODIUM
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITHROID, LEVOTHYROXINE SODIUM **
UPNEEQ, OXYMETAZOLINE HYDROCHLORIDE
UPTRAVI, SELEXIPAG
UREX, METHENAMINE HIPPURATE
UROCIT-K, POTASSIUM CITRATE

APPENDIX A - PRODUCT NAME INDEX

**** U ****

UROXATRAL, ALFUZOSIN HYDROCHLORIDE
URSO 250, URSODIOL
URSO FORTE, URSODIOL
URSODIOL, URSODIOL
UVADEX, METHOXSALEN
UZEDY, RISPERIDONE

**** V ****

VABOMERE, MEROPENEM
VAGIFEM, ESTRADIOL
VAGISTAT-1, TIOCONAZOLE (OTC)
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALIUM, DIAZEPAM
VALNAC, BETAMETHASONE VALERATE
VALPROATE SODIUM, VALPROATE SODIUM
VALPROIC ACID, VALPROIC ACID
VALRUBICIN, VALRUBICIN
VALSARTAN, VALSARTAN
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTOCO, DIAZEPAM
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VANFLYTA, QUIZARTINIB DIHYDROCHLORIDE
VANOS, FLUOCINONIDE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VARIBAR HONEY, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARIBAR PUDDING, BARIUM SULFATE
VARIBAR THIN HONEY, BARIUM SULFATE
VARIBAR THIN LIQUID, BARIUM SULFATE
VARITHENA, POLIDOCANOL
VARUBI, ROLAPITANT HYDROCHLORIDE
VASCEPA, ICOSAPENT ETHYL
VASERETIC, ENALAPRIL MALEATE
VASOPRESSIN, VASOPRESSIN
VASOPRESSIN IN SODIUM CHLORIDE 0.9%, VASOPRESSIN
VASOSTRICT, VASOPRESSIN
VASOTEC, ENALAPRIL MALEATE
VAZALORE, ASPIRIN (OTC)
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VEKLURY, REMDESIVIR
VELCADE, BORTEZOMIB
VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELPHORO, FERRIC OXYHYDROXIDE
VELSIPITY, ETRASIMOD ARGININE
VELTASSA, PATIROMER SORBITEX CALCIUM
VELTIN, CLINDAMYCIN PHOSPHATE
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VENCLEXTA, VENETOCLAX
VENLAFAXINE BESYLATE, VENLAFAXINE BESYLATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, FERRIC OXYHYDROXIDE

APPENDIX A - PRODUCT NAME INDEX

** V **

VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VEOZAH, FEZOLINETANT
VERAMYST, FLUTICASONE FUROATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VEREGEN, SINECATECHINS
VERELAN, VERAPAMIL HYDROCHLORIDE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERKAZIA, CYCLOSPORINE
VERQUVO, VERICIGUAT
VERSACLOZ, CLOZAPINE
VERZENIO, ABEMACICLIB
VESICARE, SOLIFENACIN SUCCINATE
VESICARE LS, SOLIFENACIN SUCCINATE
VEVYE, CYCLOSPORINE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBERZI, ELUXADOLINE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICTOZA, LIRAGLUTIDE RECOMBINANT
VIDAZA, AZACITIDINE
VIENVA, ETHINYL ESTRADIOL
VIGABATRIN, VIGABATRIN
VIGADRONE, VIGABATRIN
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIGPODER, VIGABATRIN
VIIBRYD, VILAZODONE HYDROCHLORIDE
VIJOICE, ALPELISIB
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
VILTEPSO, VILTOLARSEN
VIMPAT, LACOSAMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VIORELE, DESOGESTREL
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAMUNE XR, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIROPTIC, TRIFLURIDINE
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISIONBLUE, TRYPAN BLUE
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISTARIL, HYDROXYZINE PAMOATE
VISTOGARD, URIDINE TRIACETATE
VISUDYNE, VERTEPORFIN
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITRAKVI, LAROTRECTINIB SULFATE
VIVELLE-DOT, ESTRADIOL
VIVIMUSTA, BENDAMUSTINE HYDROCHLORIDE
VIVITROL, NALTREXONE
VIVJOA, OTESECONAZOLE
VIZAMYL, FLUTEMETAMOL F-18
VIZIMPRO, DACOMITINIB
VOCABRIA, CABOTEGRAVIR SODIUM
VOGELXO, TESTOSTERONE
VOLNEA, DESOGESTREL

APPENDIX A - PRODUCT NAME INDEX

**** V ****

VOLTAREN ARTHRITIS PAIN, DICLOFENAC SODIUM (OTC)
VONJO, PACRITINIB CITRATE
VOQUEZNA, VONOPRAZAN FUMARATE
VOQUEZNA DUAL PAK, AMOXICILLIN
VOQUEZNA TRIPLE PAK, AMOXICILLIN
VORICONAZOLE, VORICONAZOLE
VOSEVI, SOFOSBUVIR
VOSOL, ACETIC ACID, GLACIAL
VOSOL HC, ACETIC ACID, GLACIAL
VOTRIENT, PAZOPANIB HYDROCHLORIDE
VOXZOGO, VOSORITIDE
VRAYLAR, CARIPRAZINE HYDROCHLORIDE
VTAMA, TAPINAROF
VUITY, PILOCARPINE HYDROCHLORIDE
VUMERITY, DIROXIMEL FUMARATE
VUSION, MICONAZOLE NITRATE
VYDUO, NEBIVOLOL HYDROCHLORIDE
VYFEMLA, ETHINYL ESTRADIOL
VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE
VYNDAMAX, TAFAMIDIS
VYNDAQEL, TAFAMIDIS MEGLUMINE
VYONDYS 53, GOLODIRSEN
VYTORIN, EZETIMIBE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE
VYXEOS, CYTARABINE
VYZULTA, LATANOPROSTENE BUNOD

**** W ****

WAINUA, EPLONTERSEN SODIUM
WAKIX, PITOLISANT HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
WEGOVY, SEMAGLUTIDE
WELCHOL, COLESEVELAM HYDROCHLORIDE
WELIREG, BELZUTIFAN
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
WERA, ETHINYL ESTRADIOL
WINLEVI, CLASCOTERONE
WIXELA INHUB, FLUTICASONE PROPIONATE
WOMEN'S ROGAINE, MINOXIDIL (OTC)
WYNZORA, BETAMETHASONE DIPROPIONATE

**** X ****

XACDURO (COPACKAGED), DURLOBACTAM SODIUM
XACIATO, CLINDAMYCIN PHOSPHATE
XADAGO, SAFINAMIDE MESYLATE
XALATAN, LATANOPROST
XALKORI, CRIZOTINIB
XANAX, ALPRAZOLAM
XANAX XR, ALPRAZOLAM
XARACOLL, BUPIVACAINE HYDROCHLORIDE
XARELTO, RIVAROXABAN
XATMEP, METHOTREXATE SODIUM
XCOPRI, CENOBAMATE
XDEMVY, LOTILANER
XELJANZ, TOFACITINIB CITRATE
XELJANZ XR, TOFACITINIB CITRATE
XELODA, CAPECITABINE
XELPROS, LATANOPROST
XELSTRYM, DEXTROAMPHETAMINE
XENAZINE, TETRABENAZINE
XENICAL, ORLISTAT
XENLETA, LEFAMULIN ACETATE
XENON XE 133, XENON XE-133
XENOVIEW, XENON XE-129 HYPERPOLARIZED

APPENDIX A - PRODUCT NAME INDEX

** X **

XEPI, OZENOXACIN
XERAVA, ERAVACYCLINE DIHYDROCHLORIDE
XERESE, ACYCLOVIR
XERMELO, TELOTRISTAT ETIPRATE
XHANCE, FLUTICASONE PROPIONATE
XIFAXAN, RIFAXIMIN
XIGDUO XR, DAPAGLIFLOZIN
XIIDRA, LIFITEGRAST
XIPERE, TRIAMCINOLONE ACETONIDE
XOFIGO, RADIUM RA-223 DICHLORIDE
XOFLUZA, BALOXAVIR MARBOXIL
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
XOPENEX HFA, LEVALBUTEROL TARTRATE
XOSPATA, GILTERITINIB FUMARATE
XPHOZAH, TENAPANOR HYDROCHLORIDE
XPOVIO, SELINEXOR
XTAMPZA ER, OXYCODONE
XTANDI, ENZALUTAMIDE
XULANE, ETHINYL ESTRADIOL
XURIDEN, URIDINE TRIACETATE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE
XYREM, SODIUM OXYBATE
XYWAV, CALCIUM OXYBATE
XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)

** Y **

YAELA, DROSPIRENONE
YARGESA, MIGLUSTAT
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE
YCANTH, CANTHARIDIN
YONDELIS, TRABECTEDIN
YONSA, ABIRATERONE ACETATE
YUPELRI, REVEFENACIN
YUTIQ, FLUOCINOLONE ACETONIDE

** Z **

ZADITOR, KETOTIFEN FUMARATE (OTC)
ZAFIRLUKAST, ZAFIRLUKAST
ZALEPLON, ZALEPLON
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN
ZARONTIN, ETHOSUXIMIDE
ZAVESCA, MIGLUSTAT
ZAVZPRET, ZAVEGEPANT HYDROCHLORIDE
ZEGALOGUE, DASIGLUCAGON HYDROCHLORIDE
ZEGALOGUE (AUTOINJECTOR), DASIGLUCAGON HYDROCHLORIDE
ZEGERID, OMEPRAZOLE
ZEGERID OTC, OMEPRAZOLE (OTC)
ZEJULA, NIRAPARIB TOSYLATE
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZELBORAF, VEMURAFENIB
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
ZEMDRI, PLAZOMICIN SULFATE
ZEMPLAR, PARICALCITOL
ZENATANE, ISOTRETINOIN
ZEPATIER, ELBASVIR
ZEPBOUND, TIRZEPATIDE
ZEPOSIA, OZANIMOD HYDROCHLORIDE
ZEPZELCA, LURBINECTEDIN
ZERBAXA, CEFTOLOZANE SULFATE
ZERVIATE, CETIRIZINE HYDROCHLORIDE
ZESTORETIC, HYDROCHLOROTHIAZIDE

APPENDIX A - PRODUCT NAME INDEX

** Z **

ZESTRIL, LISINOPRIL
ZETIA, EZETIMIBE
ZETONNA, CICLESONIDE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZILBRYSQ, ZILUCOPLAN SODIUM
ZILEUTON, ZILEUTON
ZILRETTA, TRIAMCINOLONE ACETONIDE
ZILXI, MINOCYCLINE HYDROCHLORIDE
ZIMHI, NALOXONE HYDROCHLORIDE
ZINC CHLORIDE, ZINC CHLORIDE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINC SULFATE, ZINC SULFATE
ZINGO, LIDOCAINE HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZITUVIMET, METFORMIN HYDROCHLORIDE
ZITUVIO, SITAGLIPTIN
ZOCOR, SIMVASTATIN
ZOKINVY, LONAFARNIB
ZOLADEX, GOSERELIN ACETATE
ZOLEDRONIC, ZOLEDRONIC ACID
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLINZA, VORINOSTAT
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOMIG, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISADE, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZONTIVITY, VORAPAXAR SULFATE
ZORTRESS, EVEROLIMUS
ZORYVE, ROFLUMILAST
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZTALMY, GANAXOLONE
ZTLIDO, LIDOCAINE
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
ZULRESSO, BREXANOLONE
ZUMANDIMINE, DROSPIRENONE
ZURAGARD, ISOPROPYL ALCOHOL (OTC)
ZURZUVAE, ZURANOLONE
ZYCLARA, IMIQUIMOD
ZYDELIG, IDELALISIB
ZYFLO, ZILEUTON
ZYKADIA, CERITINIB
ZYLET, LOTEPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAXID, GATIFLOXACIN
ZYNRELEF KIT, BUPIVACAINE
ZYPITAMAG, PITAVASTATIN MAGNESIUM
ZYPREXA, OLANZAPINE
ZYPREXA RELPREVV, OLANZAPINE PAMOATE
ZYPREXA ZYDIS, OLANZAPINE
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** Z ****

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** 3 ****

3D IMAGING DRUG
* 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

3M
* 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
* 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)

3M HEALTH CARE
* 3M HEALTH CARE INFECTION PREVENTION DIV
SOLUPREP S, CHLORHEXIDINE GLUCONATE (OTC)

**** 6 ****

60 DEGREES PHARMS
* 60 DEGREES PHARMACEUTICALS INC
ARAKODA, TAFENOQUINE SUCCINATE

**** A ****

AAA USA INC
* ADVANCED ACCELERATOR APPLICATIONS USA INC
LUTATHERA, LUTETIUM LU 177 DOTATATE
NETSPOT, GALLIUM DOTATATE GA-68

AADI
* AADI BIOSCIENCE INC
FYARRO, SIROLIMUS

AAIPHARMA LLC
* AAIPHARMA LLC
AZASAN, AZATHIOPRINE

ABBVIE
* ABBVIE
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
* ABBVIE INC
ACULAR LS, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACZONE, DAPSONE
ALPHAGAN P, BRIMONIDINE TARTRATE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
CANASA, MESALAMINE
CARAFATE, SUCRALFATE
CELEXA, CITALOPRAM HYDROBROMIDE
COMBIGAN, BRIMONIDINE TARTRATE
CYCLOSPORINE, CYCLOSPORINE
DALVANCE, DALBAVANCIN HYDROCHLORIDE
DELZICOL, MESALAMINE
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DUOPA, CARBIDOPA
DURYSTA, BIMATOPROST
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
GENGRAF, CYCLOSPORINE
KALETRA, LOPINAVIR
LASTACAFT, ALCAFTADINE (OTC)
LATISSE, BIMATOPROST
LEXAPRO, ESCITALOPRAM OXALATE
LINZESS, LINACLOTIDE
LUMIGAN, BIMATOPROST
MAVYRET, GLECAPREVIR
NAMENDA XR, MEMANTINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ABBVIE INC
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
ORILISSA, ELAGOLIX SODIUM
OZURDEX, DEXAMETHASONE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
QULIPTA, ATOGEPANT
RECTIV, NITROGLYCERIN
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTASIS, CYCLOSPORINE
RINVOQ, UPADACITINIB
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SYNTHROID, LEVOTHYROXINE SODIUM **
TEFLARO, CEFTAROLINE FOSAMIL
TRICOR, FENOFIBRATE
TRILIPIX, CHOLINE FENOFIBRATE
UBRELVY, UBROGEPANT
ULTANE, SEVOFLURANE
VENCLEXTA, VENETOCLAX
VIBERZI, ELUXADOLINE
VIIBRYD, VILAZODONE HYDROCHLORIDE
VRAYLAR, CARIPRAZINE HYDROCHLORIDE
VUITY, PILOCARPINE HYDROCHLORIDE
ZEMPLAR, PARICALCITOL
ZYMAXID, GATIFLOXACIN

ABBVIE ENDOCRINE INC
* ABBVIE ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE

ABHAI INC
* ABHAI INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ABHAI LLC
* ABHAI LLC
ATOVAQUONE, ATOVAQUONE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
LEFLUNOMIDE, LEFLUNOMIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
URSODIOL, URSODIOL

ABON PHARMS LLC
* ABON PHARMACEUTICALS LLC
ATOVAQUONE, ATOVAQUONE
CLOFARABINE, CLOFARABINE

ABRAXIS PHARM
* ABRAXIS PHARMACEUTICAL PRODUCTS
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACACIA
* ACACIA PHARMA LTD
BARHEMSYS, AMISULPRIDE
BYFAVO, REMIMAZOLAM BESYLATE

ACADIA PHARMS INC
* ACADIA PHARMACEUTICALS INC
DAYBUE, TROFINETIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACADIA PHARMACEUTICALS INC
NUPLAZID, PIMAVANSERIN TARTRATE

ACCELRX LABS

* ACCELRX LABS LLC
CARISOPRODOL, CARISOPRODOL

ACCORD

* ACCORD BIOPHARMA INC
CAMCEVI KIT, LEUPROLIDE MESYLATE

ACCORD HLTHCARE

* ACCORD HEALTHCARE INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
APIXABAN, APIXABAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATROPINE SULFATE, ATROPINE SULFATE
AZACITIDINE, AZACITIDINE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BIVALIRUDIN, BIVALIRUDIN
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CABAZITAXEL, CABAZITAXEL
CAPECITABINE, CAPECITABINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBOPLATIN, CARBOPLATIN
CARMUSTINE, CARMUSTINE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLOFARABINE, CLOFARABINE
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE
DALFAMPRIDINE, DALFAMPRIDINE
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DOCETAXEL, DOCETAXEL
DODEX, CYANOCOBALAMIN
DOFETILIDE, DOFETILIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
EPLERENONE, EPLERENONE
EPTIFIBATIDE, EPTIFIBATIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ETOPOSIDE, ETOPOSIDE
EZETIMIBE, EZETIMIBE
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUOROURACIL, FLUOROURACIL
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT
FUROSEMIDE, FUROSEMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACCORD HEALTHCARE INC
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LISINOPRIL, LISINOPRIL
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MITOMYCIN, MITOMYCIN
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PACLITAXEL, PACLITAXEL
PARICALCITOL, PARICALCITOL
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIRFENIDONE, PIRFENIDONE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROGESTERONE, PROGESTERONE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
REGADENOSON, REGADENOSON
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SPIRONOLACTONE, SPIRONOLACTONE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TACROLIMUS, TACROLIMUS
TADALAFIL, TADALAFIL
TEMOZOLOMIDE, TEMOZOLOMIDE
TEMSIROLIMUS, TEMSIROLIMUS
TERIFLUNOMIDE, TERIFLUNOMIDE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACCORD HLTHCARE INC

* ACCORD HEALTHCARE INC USA
BUSULFAN, BUSULFAN
TIGECYCLINE, TIGECYCLINE

ACELLA

* ACELLA PHARMACEUTICALS LLC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BENZONATATE, BENZONATATE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CICLOPIROX, CICLOPIROX
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DUTASTERIDE, DUTASTERIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACELLA PHARMACEUTICALS LLC
NIFEDIPINE, NIFEDIPINE
PHENYTOIN SODIUM, PHENYTOIN SODIUM

ACELLA PHARMS LLC

* ACELLA PHARMACEUTICALS LLC
GABAPENTIN, GABAPENTIN

ACER

* ACER THERAPEUTICS INC
OLPRUVA, SODIUM PHENYLBUTYRATE

ACERUS

* ACERUS PHARMACEUTICALS CORP
NATESTO, TESTOSTERONE

ACI

* ACI HEALTHCARE LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZITHROMYCIN, AZITHROMYCIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
LEVETIRACETAM, LEVETIRACETAM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ACIC PHARMS

* ACIC PHARMACEUTICALS INC
BACLOFEN, BACLOFEN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
TRANEXAMIC ACID, TRANEXAMIC ACID
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

ACORDA

* ACORDA THERAPEUTICS INC
AMPYRA, DALFAMPRIDINE
INBRIJA, LEVODOPA

ACROTECH BIOPHARMA

* ACROTECH BIOPHARMA INC
BELEODAQ, BELINOSTAT
EVOMELA, MELPHALAN HYDROCHLORIDE
FOLOTYN, PRALATREXATE
FUSILEV, LEVOLEUCOVORIN CALCIUM
KHAPZORY, LEVOLEUCOVORIN

ACS DOBFAR

* ACS DOBFAR SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOXITIN SODIUM
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
MEROPENEM, MEROPENEM

ACS DOBFAR SPA

* ACS DOBFAR SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
ERTAPENEM SODIUM, ERTAPENEM SODIUM
MEROPENEM, MEROPENEM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

ACTAVIS

* ACTAVIS LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
DOCETAXEL, DOCETAXEL
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
OXALIPLATIN, OXALIPLATIN
PEMETREXED, PEMETREXED

ACTAVIS ELIZABETH

* ACTAVIS ELIZABETH LLC
ALBENDAZOLE, ALBENDAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS ELIZABETH LLC
ALPRAZOLAM, ALPRAZOLAM
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LOVASTATIN, LOVASTATIN
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NIFEDIPINE, NIFEDIPINE
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
RANOLAZINE, RANOLAZINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM

* ACTAVIS ELIZABETH LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
ALPRAZOLAM, ALPRAZOLAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

ACTAVIS INC

* ACTAVIS INC
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE

ACTAVIS LABS

* ACTAVIS LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
PERMETHRIN, PERMETHRIN

ACTAVIS LABS FL

* ACTAVIS LABORATORIES FL INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
ISOTRETINOIN, ISOTRETINOIN
MESALAMINE, MESALAMINE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

ACTAVIS LABS FL INC

* ACTAVIS LABORATORIES FL INC
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS LABORATORIES FL INC
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CLARITHROMYCIN, CLARITHROMYCIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DALFAMPRIDINE, DALFAMPRIDINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
GEFITINIB, GEFITINIB
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
LEVETIRACETAM, LEVETIRACETAM
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NAPROXEN SODIUM, NAPROXEN SODIUM
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OMEPRAZOLE, OMEPRAZOLE
PALIPERIDONE, PALIPERIDONE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISONE, PREDNISONE
RAMELTEON, RAMELTEON
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TETRABENAZINE, TETRABENAZINE
TRANEXAMIC ACID, TRANEXAMIC ACID
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

ACTAVIS LABS UT INC

* ACTAVIS LABORATORIES UT INC
AZELAIC ACID, AZELAIC ACID
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLONIDINE, CLONIDINE
FIORICET W/ CODEINE, ACETAMINOPHEN
LIDOCAINE, LIDOCAINE
SCOPOLAMINE, SCOPOLAMINE
TESTOSTERONE, TESTOSTERONE
* ACTAVIS LABORATORIES UT INC INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
PIMECROLIMUS, PIMECROLIMUS
TESTOSTERONE, TESTOSTERONE

ACTAVIS LLC

* ACTAVIS LLC
AZACITIDINE, AZACITIDINE
DAPSONE, DAPSONE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE

ACTAVIS MID ATLANTIC

* ACTAVIS MID ATLANTIC LLC
ACYCLOVIR, ACYCLOVIR
ADAPALENE, ADAPALENE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ACTAVIS MID ATLANTIC LLC
  HYDROCORTISONE, HYDROCORTISONE
  LEVETIRACETAM, LEVETIRACETAM
  MESALAMINE, MESALAMINE
  NITROFURANTOIN, NITROFURANTOIN
  NYSTATIN, NYSTATIN
  VALNAC, BETAMETHASONE VALERATE
* ACTAVIS MID ATLANTIC LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
  IBUPROFEN, IBUPROFEN
  PERMETHRIN, PERMETHRIN (OTC)

ACTAVIS PHARMA

* ACTAVIS PHARMA INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
  MICONAZOLE NITRATE, MICONAZOLE NITRATE

ACTAVIS TOTOWA

* ACTAVIS TOTOWA LLC
  DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
  FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
  IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
  OXALIPLATIN, OXALIPLATIN
  PACLITAXEL, PACLITAXEL
  PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
  TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
  VINORELBINE TARTRATE, VINORELBINE TARTRATE

ACTELION

* ACTELION PHARMACEUTICALS US INC
  OPSUMIT, MACITENTAN
  TRACLEER, BOSENTAN
  UPTRAVI, SELEXIPAG
  VELETRI, EPOPROSTENOL SODIUM
  VENTAVIS, ILOPROST
  ZAVESCA, MIGLUSTAT

ADAMAS OPERATIONS

* ADAMAS OPERATIONS LLC
  GOCOVRI, AMANTADINE HYDROCHLORIDE
  OSMOLEX ER, AMANTADINE HYDROCHLORIDE

ADAMIS PHARMS CORP

* ADAMIS PHARMACEUTICALS CORP
  SYMJEPI, EPINEPHRINE
  ZIMHI, NALOXONE HYDROCHLORIDE

ADAPTIS

* ADAPTIS PHARMA PRIVATE LTD
  BICALUTAMIDE, BICALUTAMIDE
  DUTASTERIDE, DUTASTERIDE
  PREGABALIN, PREGABALIN
  VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

ADARE PHARMS INC

* ADARE PHARMACEUTICALS INC
  DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
  POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
  PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

ADHERA

* ADHERA THERAPEUTICS INC
  PRESTALIA, AMLODIPINE BESYLATE

ADIENNE SA

* ADIENNE SA
  TEPADINA, THIOTEPA

AET PHARMA

* AET PHARMA US INC
  LEFLUNOMIDE, LEFLUNOMIDE
  POSACONAZOLE, POSACONAZOLE

AFAXYS

* AFAXYS PHARMA LLC
  LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

AGEPHA PHARMA FZ

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AGEPHA PHARMA FZ LLC
LODOCO, COLCHICINE

AGILE

* AGILE THERAPEUTICS INC
TWIRLA, ETHINYL ESTRADIOL

AGIOS PHARMS INC

* AGIOS PHARMACEUTICALS INC
PYRUKYND, MITAPIVAT SULFATE

AGNITIO

* AGNITIO INC
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ETHACRYNIC ACID, ETHACRYNIC ACID
PHYTONADIONE, PHYTONADIONE
TRIAMTERENE, TRIAMTERENE

AGOURON PHARMS

* AGOURON PHARMACEUTICALS LLC
VIRACEPT, NELFINAVIR MESYLATE

AILEX PHARMS LLC

* AILEX PHARMACEUTICALS LLC
CROMOLYN SODIUM, CROMOLYN SODIUM
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

AIPING PHARM INC

* AIPING PHARMACEUTICAL INC
LEVETIRACETAM, LEVETIRACETAM
SORINE, SOTALOL HYDROCHLORIDE

AIRGAS THERAP

* AIRGAS THERAPEUTICS LLC
ULSPIRA, NITRIC OXIDE

AIRIS PHARMA PVT LTD

* AIRIS PHARMA PRIVATE LTD
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM

AIZANT

* AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LTD
ALBUTEROL SULFATE, ALBUTEROL SULFATE
PIRFENIDONE, PIRFENIDONE
ZILEUTON, ZILEUTON
* AIZANT DRUG RESEARCH SOLUTIONS PVT LTD
ELIGLUSTAT TARTRATE, ELIGLUSTAT TARTRATE

AJANTA PHARMA LTD

* AJANTA PHARMA LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CAPTOPRIL, CAPTOPRIL
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ENTACAPONE, ENTACAPONE
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AJANTA PHARMA LTD
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RANOLAZINE, RANOLAZINE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
TADALAFIL, TADALAFIL
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPIRAMATE, TOPIRAMATE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN

AJENAT PHARMS
* AJENAT PHARMACEUTICALS LLC
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
TRANXENE, CLORAZEPATE DIPOTASSIUM

AKARX INC
* AKARX INC
DOPTELET, AVATROMBOPAG MALEATE

AKCEA THERAPS
* AKCEA THERAPEUTICS INC
TEGSEDI, INOTERSEN SODIUM

AKORN
* AKORN OPERATING CO LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
CEFTRIAXONE, CEFTRIAXONE SODIUM
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FAMOTIDINE, FAMOTIDINE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

ALBIREO
* ALBIREO AB
BYLVAY, ODEVIXIBAT

ALCON
* ALCON LABORATORIES INC
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
MIOSTAT, CARBACHOL
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
* ALCON RESEARCH LLC
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

ALCON LABS
* ALCON LABORATORIES LTD
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE

ALCON LABS INC
* ALCON LABORATORIES INC
ALCAINE, PROPARACAINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
EYSUVIS, LOTEPREDNOL ETABONATE
FLUORESCITE, FLUORESCEIN SODIUM
INVELTYS, LOTEPREDNOL ETABONATE
ISOPTO ATROPINE, ATROPINE SULFATE
MYDRIACYL, TROPICAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALCON LABORATORIES INC
PATADAY ONCE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
PATADAY TWICE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
RHOPRESSA, NETARSUDIL MESYLATE
ROCKLATAN, LATANOPROST
SIMBRINZA, BRIMONIDINE TARTRATE

ALCON PHARMS LTD

* ALCON PHARMACEUTICALS LTD
BETADINE, POVIDONE-IODINE
ZADITOR, KETOTIFEN FUMARATE (OTC)

ALEMBIC

* ALEMBIC PHARMACEUTICALS LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADAPALENE, ADAPALENE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ASENAPINE MALEATE, ASENAPINE MALEATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
BIMATOPROST, BIMATOPROST
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARMUSTINE, CARMUSTINE
CELECOXIB, CELECOXIB
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLARITHROMYCIN, CLARITHROMYCIN
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DAPSONE, DAPSONE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DEFERASIROX, DEFERASIROX
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESONIDE, DESONIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOCETAXEL, DOCETAXEL
DOCOSANOL, DOCOSANOL (OTC)
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE (MICRONIZED), FENOFIBRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ALEMBIC PHARMACEUTICALS LTD
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
FULVESTRANT, FULVESTRANT
GLYCOPYRROLATE, GLYCOPYRROLATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ITRACONAZOLE, ITRACONAZOLE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METRONIDAZOLE, METRONIDAZOLE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MODAFINIL, MODAFINIL
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MUPIROCIN, MUPIROCIN CALCIUM
NADOLOL, NADOLOL
NIFEDIPINE, NIFEDIPINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PACLITAXEL, PACLITAXEL
PIRFENIDONE, PIRFENIDONE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREGABALIN, PREGABALIN
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SELEXIPAG, SELEXIPAG
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TAVABOROLE, TAVABOROLE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TERIFLUNOMIDE, TERIFLUNOMIDE
THEOPHYLLINE, THEOPHYLLINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TRAVOPROST, TRAVOPROST
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

ALEMBIC GLOBAL

* ALEMBIC GLOBAL HOLDING SA
TREPROSTINIL, TREPROSTINIL

ALEMBIC LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALEMBIC LTD
LITHIUM CARBONATE, LITHIUM CARBONATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

ALEMBIC PHARMS LTD

* ALEMBIC PHARMACEUTICALS LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DESVENLAFAXINE, DESVENLAFAXINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEFLUNOMIDE, LEFLUNOMIDE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEPROBAMATE, MEPROBAMATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ALEXZA PHARMS

* ALEXZA PHARMACEUTICALS INC
ADASUVE, LOXAPINE

ALIGNSCIENCE PHARMA

* ALIGNSCIENCE PHARMA INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ALIMERA SCIENCES INC

* ALIMERA SCIENCES INC
ILUVIEN, FLUOCINOLONE ACETONIDE
YUTIQ, FLUOCINOLONE ACETONIDE

ALKALOIDA ZRT

* ALKALOIDA CHEMICAL CO ZRT
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE

ALKEM

* ALKEM LABORATORIES LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
GABAPENTIN, GABAPENTIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD

* ALKEM LABORATORIES LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
APREMILAST, APREMILAST
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZATHIOPRINE, AZATHIOPRINE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BREXPIPRAZOLE, BREXPIPRAZOLE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CEFDINIR, CEFDINIR
CEFIXIME, CEFIXIME
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
COLCHICINE, COLCHICINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALKEM LABORATORIES LTD
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DALFAMPRIDINE, DALFAMPRIDINE
DEFERASIROX, DEFERASIROX
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERYTHROMYCIN, ERYTHROMYCIN
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
EVEROLIMUS, EVEROLIMUS
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
IBUPROFEN, IBUPROFEN
ITRACONAZOLE, ITRACONAZOLE
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MARINOL, DRONABINOL
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
NIFEDIPINE, NIFEDIPINE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANOLAZINE, RANOLAZINE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROFLUMILAST, ROFLUMILAST
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
RUFINAMIDE, RUFINAMIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SIROLIMUS, SIROLIMUS
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TACROLIMUS, TACROLIMUS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALKEM LABORATORIES LTD
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
TICAGRELOR, TICAGRELOR
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TOLVAPTAN, TOLVAPTAN
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALSARTAN, VALSARTAN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN

ALKERMES
* ALKERMES INC
VIVITROL, NALTREXONE

ALKERMES INC
* ALKERMES INC
ARISTADA INITIO KIT, ARIPIPRAZOLE LAUROXIL
ARISTADA, ARIPIPRAZOLE LAUROXIL
LYBALVI, OLANZAPINE

ALLEGIANCE HLTHCARE
* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLERGAN
* ALLERGAN INC
AVAGE, TAZAROTENE
OCUFLOX, OFLOXACIN
TAZORAC, TAZAROTENE
* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
* ALLERGAN SALES LLC
AVYCAZ, AVIBACTAM SODIUM
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
CONDYLOX, PODOFILOX
CRINONE, PROGESTERONE
ESTRACE, ESTRADIOL
INFED, FERRIC OXYHYDROXIDE
OXYTROL, OXYBUTYNIN
RAPAFLO, SILODOSIN
SAPHRIS, ASENAPINE MALEATE
URSO 250, URSODIOL
URSO FORTE, URSODIOL

ALMAJECT
* ALMAJECT INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

ALMATICA
* ALMATICA PHARMA INC
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
GRALISE, GABAPENTIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* ALMATICA PHARMA LLC
LOREEV XR, LORAZEPAM
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
VENLAFAXINE BESYLATE, VENLAFAXINE BESYLATE
ZESTORETIC, HYDROCHLOROTHIAZIDE

ALMIRALL
* ALMIRALL LLC
ACTICLATE, DOXYCYCLINE HYCLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALMIRALL LLC
ACZONE, DAPSONE
ALTABAX, RETAPAMULIN
AZELEX, AZELAIC ACID
CORDRAN, FLURANDRENOLIDE
KLISYRI, TIRBANIBULIN
SEYSARA, SARECYCLINE HYDROCHLORIDE
VELTIN, CLINDAMYCIN PHOSPHATE

ALNYLAM PHARMS INC
* ALNYLAM PHARMACEUTICALS INC
AMVUTTRA, VUTRISIRAN SODIUM
GIVLAARI, GIVOSIRAN SODIUM
ONPATTRO, PATISIRAN SODIUM
OXLUMO, LUMASIRAN SODIUM

ALTAIRE PHARMS INC
* ALTAIRE PHARMACEUTICALS INC
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
OFLOXACIN, OFLOXACIN

ALTATHERA PHARMS LLC
* ALTATHERA PHARMACEUTICALS LLC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ALTHERA PHARMS
* ALTHERA PHARMACEUTICALS LLC
LYPQOZET, ATORVASTATIN CALCIUM

ALVOGEN
* ALVOGEN INC
ACETYLCYSTEINE, ACETYLCYSTEINE
BONSITY, TERIPARATIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE, BUPRENORPHINE
CARBIDOPA, CARBIDOPA
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DISULFIRAM, DISULFIRAM
ESTRADIOL, ESTRADIOL
FELBAMATE, FELBAMATE
FLUOCINONIDE, FLUOCINONIDE
HYDROCODONE BITARTRATE, HYDROCODONE BITARTRATE
LIDEX, FLUOCINONIDE
MELPHALAN, MELPHALAN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PREGABALIN, PREGABALIN
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIMETHAMINE, PYRIMETHAMINE
RIVASTIGMINE, RIVASTIGMINE
THYRO-TABS, LEVOTHYROXINE SODIUM **
UREX, METHENAMINE HIPPURATE

AM REGENT
* AMERICAN REGENT INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ATROPINE SULFATE, ATROPINE SULFATE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CUPRIC SULFATE, CUPRIC SULFATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMERICAN REGENT INC
ESTRADIOL VALERATE, ESTRADIOL VALERATE
FOMEPIZOLE, FOMEPIZOLE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INJECTAFER, FERRIC CARBOXYMALTOSE
ISOSULFAN BLUE, ISOSULFAN BLUE
LEVOCARNITINE, LEVOCARNITINE
METHOCARBAMOL, METHOCARBAMOL
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
MULTRYS, CUPRIC SULFATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
OLANZAPINE, OLANZAPINE
PACLITAXEL, PACLITAXEL
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
SELENIOUS ACID, SELENIOUS ACID
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TRALEMENT, CUPRIC SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VASOPRESSIN, VASOPRESSIN
VENOFER, FERRIC OXYHYDROXIDE
ZINC SULFATE, ZINC SULFATE

AMARIN PHARMS

* AMARIN PHARMACEUTICALS IRELAND LTD
VASCEPA, ICOSAPENT ETHYL

AMGEN

* AMGEN INC
SENSIPAR, CINACALCET HYDROCHLORIDE

AMGEN INC

* AMGEN INC
CORLANOR, IVABRADINE
CORLANOR, IVABRADINE HYDROCHLORIDE
LUMAKRAS, SOTORASIB
OTEZLA, APREMILAST

AMICI

* AMICI PHARMACEUTICALS LLC
CATAFLAM, DICLOFENAC POTASSIUM
DIGOXIN, DIGOXIN

AMICUS THERAP US

* AMICUS THERAPEUTICS US LLC
GALAFOLD, MIGALASTAT HYDROCHLORIDE
OPFOLDA, MIGLUSTAT

AMIVAS

* AMIVAS INC
ARTESUNATE, ARTESUNATE

AMNEAL

* AMNEAL EU LTD
AMINOCAPROIC ACID, AMINOCAPROIC ACID
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATROPINE SULFATE, ATROPINE SULFATE
AZACITIDINE, AZACITIDINE
BUSULFAN, BUSULFAN
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARMUSTINE, CARMUSTINE
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CLOFARABINE, CLOFARABINE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DARUNAVIR, DARUNAVIR
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL EU LTD
DEXAMETHASONE, DEXAMETHASONE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIFLUPREDNATE, DIFLUPREDNATE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DOCETAXEL, DOCETAXEL
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETRAVIRINE, ETRAVIRINE
FLUOROMETHOLONE, FLUOROMETHOLONE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FULVESTRANT, FULVESTRANT
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METYROSINE, METYROSINE
NELARABINE, NELARABINE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OFLOXACIN, OFLOXACIN
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIRFENIDONE, PIRFENIDONE
PLERIXAFOR, PLERIXAFOR
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
PREDNISONE, PREDNISONE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIOTHIXENE, THIOTHIXENE
TIOPRONIN, TIOPRONIN
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VASOPRESSIN, VASOPRESSIN
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

* AMNEAL PHARMACEUTICALS LLC
ACTIVELLA, ESTRADIOL
ACYCLOVIR, ACYCLOVIR
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AZATHIOPRINE, AZATHIOPRINE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
BEXAROTENE, BEXAROTENE
BUPRENORPHINE, BUPRENORPHINE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DAPSONE, DAPSONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS LLC
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ELURYNG, ETHINYL ESTRADIOL
ESTRADIOL, ESTRADIOL
ETHINYL ESTRADIOL AND NORELGESTROMIN, ETHINYL ESTRADIOL
FENOFIBRATE, FENOFIBRATE
FLUOCINONIDE, FLUOCINONIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LIDOCAINE, LIDOCAINE
LIORESAL, BACLOFEN
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LUBIPROSTONE, LUBIPROSTONE
LYVISPAH, BACLOFEN
MUPIROCIN, MUPIROCIN CALCIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NAPROXEN, NAPROXEN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
POSACONAZOLE, POSACONAZOLE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
SAXAGLIPTIN, SAXAGLIPTIN HYDROCHLORIDE
SIROLIMUS, SIROLIMUS
SPIRONOLACTONE, SPIRONOLACTONE
SUCRALFATE, SUCRALFATE
TAVABOROLE, TAVABOROLE
TESTOSTERONE, TESTOSTERONE
TIGECYCLINE, TIGECYCLINE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOMIG, ZOLMITRIPTAN

AMNEAL PHARM

* AMNEAL PHARMACEUTICAL
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FOLIC ACID, FOLIC ACID
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE

AMNEAL PHARMS

* AMNEAL PHARMACEUTICALS
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATOVAQUONE, ATOVAQUONE
CALCITRIOL, CALCITRIOL
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
COLCHICINE, COLCHICINE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ENTECAVIR, ENTECAVIR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESTRADIOL, ESTRADIOL
FELBAMATE, FELBAMATE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
INDOMETHACIN, INDOMETHACIN
ITRACONAZOLE, ITRACONAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
LORAZEPAM, LORAZEPAM
MEROPENEM, MEROPENEM
METAXALONE, METAXALONE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NIACIN, NIACIN
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TEMOZOLOMIDE, TEMOZOLOMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
WARFARIN SODIUM, WARFARIN SODIUM

* AMNEAL PHARMACEUTICALS HOLDINGS GMBH
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CELECOXIB, CELECOXIB
DUTASTERIDE, DUTASTERIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IRBESARTAN, IRBESARTAN
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PALIPERIDONE, PALIPERIDONE
PARICALCITOL, PARICALCITOL
PRASUGREL, PRASUGREL HYDROCHLORIDE
RIVASTIGMINE, RIVASTIGMINE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SPIRONOLACTONE, SPIRONOLACTONE
SUCRALFATE, SUCRALFATE
TOBRAMYCIN, TOBRAMYCIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VIGABATRIN, VIGABATRIN

AMNEAL PHARMS CO

* AMNEAL PHARMACEUTICALS CO GMBH
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARGATROBAN, ARGATROBAN
BUMETANIDE, BUMETANIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLOBAZAM, CLOBAZAM
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ERYTHROMYCIN, ERYTHROMYCIN
ETHACRYNIC ACID, ETHACRYNIC ACID
ETODOLAC, ETODOLAC
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FUROSEMIDE, FUROSEMIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
NADOLOL, NADOLOL
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PARICALCITOL, PARICALCITOL
PHYTONADIONE, PHYTONADIONE
PREGABALIN, PREGABALIN
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SILODOSIN, SILODOSIN
TADALAFIL, TADALAFIL
TERIFLUNOMIDE, TERIFLUNOMIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
URSODIOL, URSODIOL

AMNEAL PHARMS NY

* AMNEAL PHARMACEUTICALS NY LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
GABAPENTIN, GABAPENTIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* AMNEAL PHARMACEUTICALS NY LLC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
* AMNEAL PHARMACEUTICALS OF NY LLC
BEXAROTENE, BEXAROTENE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISOTRETINOIN, ISOTRETINOIN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PROGESTERONE, PROGESTERONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

AMNEALS PHARMS
* AMNEALS PHARMACEUTICALS LLC
FAMOTIDINE, FAMOTIDINE

AMPHASTAR PHARM
* AMPHASTAR PHARMACEUTICAL INC
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM

AMPHASTAR PHARMS INC
* AMPHASTAR PHARMACEUTICALS INC
BAQSIMI, GLUCAGON
CORTROSYN, COSYNTROPIN
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE
GLUCAGON, GLUCAGON
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
VASOPRESSIN, VASOPRESSIN

AMRING PHARMS
* AMRING PHARMACEUTICALS INC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LATANOPROST, LATANOPROST
LYSTEDA, TRANEXAMIC ACID
MESALAMINE, MESALAMINE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE

AMRYT
* AMRYT PHARMACEUTICALS DAC
FILSUVEZ, BIRCH TRITERPENES
JUXTAPID, LOMITAPIDE MESYLATE

AMTA
* AMTA LABS LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
MESALAMINE, MESALAMINE
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

AMYLYX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMYLYX PHARMACEUTICALS INC
RELYVRIO, SODIUM PHENYLBUTYRATE

ANACOR PHARMS INC
* ANACOR PHARMACEUTICALS INC
EUCRISA, CRISABOROLE
KERYDIN, TAVABOROLE

ANBEX
* ANBEX INC
IOSAT, POTASSIUM IODIDE (OTC)

ANBISON LAB
* ANBISON LABORATORY CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
MONTELUKAST SODIUM, MONTELUKAST SODIUM

ANCHEN PHARMS
* ANCHEN PHARMACEUTICALS INC
ALISKIREN HEMIFUMARATE, ALISKIREN HEMIFUMARATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
TRETINOIN, TRETINOIN
* ANCHEN PHARMACEUTICALS, INC
ALPRAZOLAM, ALPRAZOLAM
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN

ANDA REPOSITORY
* ANDA REPOSITORY LLC
AMCINONIDE, AMCINONIDE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM, DIATRIZOATE MEGLUMINE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRIMIDONE, PRIMIDONE

ANDOR PHARMS
* ANDOR PHARMACEUTICALS LLC
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ANDRX LABS LLC
* ANDRX LABS LLC
FORTAMET, METFORMIN HYDROCHLORIDE

ANI PHARMS
* ANI PHARMACEUTICALS INC
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
ARIMIDEX, ANASTROZOLE
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
BACLOFEN, BACLOFEN
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BEXAROTENE, BEXAROTENE
BRETHINE, TERBUTALINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ANI PHARMACEUTICALS INC
CASODEX, BICALUTAMIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
CORTENEMA, HYDROCORTISONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ETODOLAC, ETODOLAC
FELBAMATE, FELBAMATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
GLIPIZIDE, GLIPIZIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
LITHOBID, LITHIUM CARBONATE
LUVOX, FLUVOXAMINE MALEATE
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIGLUSTAT, MIGLUSTAT
MISOPROSTOL, MISOPROSTOL
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NILUTAMIDE, NILUTAMIDE
OXISTAT, OXICONAZOLE NITRATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PANDEL, HYDROCORTISONE PROBUTATE
PENICILLAMINE, PENICILLAMINE
PINDOLOL, PINDOLOL
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CITRATE, POTASSIUM CITRATE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
VALPROIC ACID, VALPROIC ACID
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VEREGEN, SINECATECHINS

ANIMA

* ANIMA PHARMACEUTICALS PVT LTD
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXAMETHASONE, DEXAMETHASONE
TRIACIN-C, CODEINE PHOSPHATE

ANNORA

* ANNORA PHARMA PRIVATE LTD
APREMILAST, APREMILAST
DROXIDOPA, DROXIDOPA
LAMIVUDINE, LAMIVUDINE

ANNORA PHARMA

* ANNORA PHARMA PRIVATE LTD
AMINOCAPROIC ACID, AMINOCAPROIC ACID
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM, DIATRIZOATE MEGLUMINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPLERENONE, EPLERENONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ANNORA PHARMA PRIVATE LTD
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
GLYCOPYRROLATE, GLYCOPYRROLATE
ITRACONAZOLE, ITRACONAZOLE
IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
NABUMETONE, NABUMETONE
OXCARBAZEPINE, OXCARBAZEPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
THEOPHYLLINE, THEOPHYLLINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
ZAFIRLUKAST, ZAFIRLUKAST
ZILEUTON, ZILEUTON

ANTARES PHARMA INC
* ANTARES PHARMA INC
TLANDO, TESTOSTERONE UNDECANOATE
XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE

ANTIBIOTICE
* ANTIBIOTICE SA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM

ANXIN
* ANXIN PHARMA INC
SEVELAMER CARBONATE, SEVELAMER CARBONATE

APELLIS PHARMS
* APELLIS PHARMACEUTICALS INC
EMPAVELI, PEGCETACOPLAN
SYFOVRE, PEGCETACOPLAN

APGDI
* ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
MYRBETRIQ GRANULES, MIRABEGRON
MYRBETRIQ, MIRABEGRON

APIL
* ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD
ACTONEL, RISEDRONATE SODIUM
ATELVIA, RISEDRONATE SODIUM
LO LOESTRIN FE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
TAYTULLA, ETHINYL ESTRADIOL

APNAR PHARMA LP
* APNAR PHARMA LP
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

APOTEX
* APOTEX INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACYCLOVIR, ACYCLOVIR
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC

ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATOVAQUONE, ATOVAQUONE
ATROPINE SULFATE, ATROPINE SULFATE
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
BICALUTAMIDE, BICALUTAMIDE
BIMATOPROST, BIMATOPROST
BORTEZOMIB, BORTEZOMIB
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BUSULFAN, BUSULFAN
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CELECOXIB, CELECOXIB
CIMETIDINE, CIMETIDINE (OTC)
CYCLOSPORINE, CYCLOSPORINE
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DEXAMETHASONE, DEXAMETHASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ETODOLAC, ETODOLAC
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GEFITINIB, GEFITINIB
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
ICOSAPENT ETHYL, ICOSAPENT ETHYL
IMATINIB MESYLATE, IMATINIB MESYLATE
LACOSAMIDE, LACOSAMIDE
LAMIVUDINE, LAMIVUDINE
LENALIDOMIDE, LENALIDOMIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
MACITENTAN, MACITENTAN
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MODAFINIL, MODAFINIL
MOMETASONE FUROATE, MOMETASONE FUROATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NILOTINIB HYDROCHLORIDE, NILOTINIB HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE, OMEPRAZOLE (OTC)
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAZOPANIB HYDROCHLORIDE, PAZOPANIB HYDROCHLORIDE
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PENICILLAMINE, PENICILLAMINE
PENTOXIFYLLINE, PENTOXIFYLLINE
PIRFENIDONE, PIRFENIDONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREGABALIN, PREGABALIN
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
REGADENOSON, REGADENOSON
RISEDRONATE SODIUM, RISEDRONATE SODIUM
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SIROLIMUS, SIROLIMUS
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TASIMELTEON, TASIMELTEON
TERIFLUNOMIDE, TERIFLUNOMIDE
TERIPARATIDE, TERIPARATIDE
TETRABENAZINE, TETRABENAZINE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLVAPTAN, TOLVAPTAN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

APOTEX INC

* APOTEX INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
CALCITONIN-SALMON, CALCITONIN SALMON
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFPROZIL, CEFPROZIL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMIQUIMOD, IMIQUIMOD
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* APOTEX INC
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* APOTEX INC ETOBICOKE SITE
ACYCLOVIR, ACYCLOVIR
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
ETODOLAC, ETODOLAC
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
LEFLUNOMIDE, LEFLUNOMIDE
LORATADINE, LORATADINE (OTC)
MIRTAZAPINE, MIRTAZAPINE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

* APOTEX INC RICHMOND HILL
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

APOTHECON

* APOTHECON INC DIV BRISTOL MYERS SQUIBB
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-80, TRIAMCINOLONE ACETONIDE

APP PHARMS

* APP PHARMACEUTICALS LLC
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPCO

* APPCO PHARMA LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METAXALONE, METAXALONE
MODAFINIL, MODAFINIL
PERPHENAZINE, PERPHENAZINE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

APRECIA PHARMS

* APRECIA PHARMACEUTICALS LLC
SPRITAM, LEVETIRACETAM

APTAPHARMA INC

* APTAPHARMA INC
CHLORZOXAZONE, CHLORZOXAZONE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN (OTC)
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

AQUESTIVE
* AQUESTIVE THERAPEUTICS INC
EXSERVAN, RILUZOLE

ARBOR PHARMS LLC
* ARBOR PHARMACEUTICALS LLC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
ERY-TAB, ERYTHROMYCIN
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
EVEKEO, AMPHETAMINE SULFATE
SKLICE, IVERMECTIN (OTC)

ARCUTIS
* ARCUTIS BIOTHERAPEUTICS INC
ZORYVE, ROFLUMILAST

ARDELYX INC
* ARDELYX INC
IBSRELA, TENAPANOR HYDROCHLORIDE
XPHOZAH, TENAPANOR HYDROCHLORIDE

AREVA PHARMS
* AREVA PHARMACEUTICALS INC
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FUROSEMIDE, FUROSEMIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

ARMSTRONG PHARMS
* ARMSTRONG PHARMACEUTICALS INC
PRIMATENE MIST, EPINEPHRINE (OTC)

ARNA PHARMA
* ARNA PHARMA PTY LTD
ARIDOL KIT, MANNITOL

ARRAY BIOPHARMA INC
* ARRAY BIOPHARMA INC
BRAFTOVI, ENCORAFENIB
MEKTOVI, BINIMETINIB

ARROW INTL
* ARROW INTERNATIONAL LTD
LENALIDOMIDE, LENALIDOMIDE

ARTHUR GRP
* ARTHUR GROUP LLC
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE

ASCEND THERAPS US
* ASCEND THERAPEUTICS US LLC
ESTROGEL, ESTRADIOL

ASCENT PHARMS INC
* ASCENT PHARMACEUTICALS INC
BENZONATATE, BENZONATATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DRONABINOL, DRONABINOL
DUTASTERIDE, DUTASTERIDE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
IBUPROFEN, IBUPROFEN (OTC)
ICOSAPENT ETHYL, ICOSAPENT ETHYL
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ASCENT PHARMACEUTICALS INC
LISINOPRIL, LISINOPRIL
MELOXICAM, MELOXICAM
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PALIPERIDONE, PALIPERIDONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ASPEN
* ASPEN PHARMA USA INC
ACETYLCYSTEINE, ACETYLCYSTEINE
GLYCOPYRROLATE, GLYCOPYRROLATE

ASPEN GLOBAL INC
* ASPEN GLOBAL INC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CYCLESSA, DESOGESTREL

ASPIRO
* ASPIRO PHARMA LTD
ACETAMINOPHEN, ACETAMINOPHEN
DAPTOMYCIN, DAPTOMYCIN
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACOSAMIDE, LACOSAMIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUGAMMADEX SODIUM, SUGAMMADEX SODIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ASSERTIO
* ASSERTIO THERAPEUTICS INC
CAMBIA, DICLOFENAC POTASSIUM
ZIPSOR, DICLOFENAC POTASSIUM

ASTELLAS
* ASTELLAS PHARMA US INC
AMBISOME, AMPHOTERICIN B
ASTAGRAF XL, TACROLIMUS
CRESEMBA, ISAVUCONAZONIUM SULFATE
LEXISCAN, REGADENOSON
MYCAMINE, MICAFUNGIN SODIUM
PROGRAF, TACROLIMUS
VEOZAH, FEZOLINETANT
VESICARE LS, SOLIFENACIN SUCCINATE
VESICARE, SOLIFENACIN SUCCINATE
XOSPATA, GILTERITINIB FUMARATE
XTANDI, ENZALUTAMIDE

ASTRAL
* ASTRAL STERITECH PVT LTD
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

ASTRAZENECA
* ASTRAZENECA LP
PULMICORT FLEXHALER, BUDESONIDE
SYMBICORT, BUDESONIDE
* ASTRAZENECA PHARMACEUTICALS LP
AIRSUPRA, ALBUTEROL SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ASTRAZENECA PHARMACEUTICALS LP
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BRILINTA, TICAGRELOR
DALIRESP, ROFLUMILAST
FASLODEX, FULVESTRANT
IRESSA, GEFITINIB
KOSELUGO, SELUMETINIB SULFATE
LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
LYNPARZA, OLAPARIB
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXIUM, ESOMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PULMICORT RESPULES, BUDESONIDE
SEROQUEL, QUETIAPINE FUMARATE
SYMBICORT AEROSPHERE, BUDESONIDE
TAGRISSO, OSIMERTINIB MESYLATE
TRUQAP, CAPIVASERTIB
* ASTRAZENECA UK LTD
CALQUENCE, ACALABRUTINIB
CALQUENCE, ACALABRUTINIB MALEATE
SEROQUEL XR, QUETIAPINE FUMARATE

ASTRAZENECA AB
* ASTRAZENECA AB
BREZTRI AEROSPHERE, BUDESONIDE
BYDUREON BCISE, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
FARXIGA, DAPAGLIFLOZIN
QTERN, DAPAGLIFLOZIN
SYMLIN, PRAMLINTIDE ACETATE
XIGDUO XR, DAPAGLIFLOZIN

ASTRAZENECA LP
* ASTRAZENECA LP
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

ATHEM
* ATHEM HOLDINGS LLC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID

ATHENA
* ATHENA BIOSCIENCE LLC
NEXICLON XR, CLONIDINE
QDOLO, TRAMADOL HYDROCHLORIDE

ATLAS PHARMS LLC
* ATLAS PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ATNAHS PHARMA US
* ATNAHS PHARMA US LTD
ANAPROX DS, NAPROXEN SODIUM
EC-NAPROSYN, NAPROXEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
NAPROSYN, NAPROXEN

ATON
* ATON PHARMA INC
LODOSYN, CARBIDOPA

AUCTA
* AUCTA PHARMACEUTICALS INC
DEFERASIROX, DEFERASIROX
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
MOTPOLY XR, LACOSAMIDE
OXCARBAZEPINE, OXCARBAZEPINE
VIGADRONE, VIGABATRIN

AURINIA
* AURINIA PHARMACEUTICALS INC
LUPKYNIS, VOCLOSPORIN

AUROBINDO

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NEVIRAPINE, NEVIRAPINE
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA

* AUROBINDO PHARMA LTD
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACYCLOVIR, ACYCLOVIR
AFIRMELLE, ETHINYL ESTRADIOL
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALPRAZOLAM, ALPRAZOLAM
AMBRISENTAN, AMBRISENTAN
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATENOLOL, ATENOLOL
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AYUNA, ETHINYL ESTRADIOL
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARBIDOPA, CARBIDOPA
CARISOPRODOL, CARISOPRODOL
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOZAPINE, CLOZAPINE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYONANZ, ETHINYL ESTRADIOL
DALFAMPRIDINE, DALFAMPRIDINE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIMETHYL FUMARATE, DIMETHYL FUMARATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMZAHH, NORETHINDRONE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENTECAVIR, ENTECAVIR
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESZOPICLONE, ESZOPICLONE
EZETIMIBE, EZETIMIBE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOFIBRATE, FENOFIBRATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
INCASSIA, NORETHINDRONE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KALLIGA, DESOGESTREL
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LEFLUNOMIDE, LEFLUNOMIDE
LEVETIRACETAM, LEVETIRACETAM
LO SIMPESSE, ETHINYL ESTRADIOL
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MELOXICAM, MELOXICAM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN
NEXESTA FE, ETHINYL ESTRADIOL
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NIFEDIPINE, NIFEDIPINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
OSHIH, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREGABALIN, PREGABALIN
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RIBAVIRIN, RIBAVIRIN
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RUFINAMIDE, RUFINAMIDE
SAXAGLIPTIN, SAXAGLIPTIN HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIMLIYA, DESOGESTREL
SIMPESSE, ETHINYL ESTRADIOL
SIMVASTATIN, SIMVASTATIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERIFLUNOMIDE, TERIFLUNOMIDE
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANDOLAPRIL, TRANDOLAPRIL
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRI-LO-MILI, ETHINYL ESTRADIOL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZAFIRLUKAST, ZAFIRLUKAST
ZALEPLON, ZALEPLON
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

AUROBINDO PHARMA LTD

* AUROBINDO PHARMA LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
LEVOFLOXACIN, LEVOFLOXACIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
* AUROBINDO PHARMA LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ARIPIPRAZOLE, ARIPIPRAZOLE
ARMODAFINIL, ARMODAFINIL
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFIXIME, CEFIXIME
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
COLCHICINE, COLCHICINE
DARUNAVIR, DARUNAVIR
DEFERASIROX, DEFERASIROX
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DIGOXIN, DIGOXIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOFETILDE, DOFETILIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
EFAVIRENZ, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRICITABINE, EMTRICITABINE
ENTACAPONE, ENTACAPONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FELODIPINE, FELODIPINE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE (OTC)
FINASTERIDE, FINASTERIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCYTOSINE, FLUCYTOSINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ICLEVIA, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LACOSAMIDE, LACOSAMIDE
LACTULOSE, LACTULOSE
LANSOPRAZOLE, LANSOPRAZOLE
LO-ZUMANDIMINE, DROSPIRENONE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHOCARBAMOL, METHOCARBAMOL
METRONIDAZOLE, METRONIDAZOLE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MILI, ETHINYL ESTRADIOL
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NIACIN, NIACIN
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PYRIMETHAMINE, PYRIMETHAMINE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMELTEON, RAMELTEON
RAMIPRIL, RAMIPRIL
REPAGLINIDE, REPAGLINIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROFLUMILAST, ROFLUMILAST
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
TADALAFIL, TADALAFIL
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRI-MILI, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
URSODIOL, URSODIOL
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VIGABATRIN, VIGABATRIN
VORICONAZOLE, VORICONAZOLE
ZONISAMIDE, ZONISAMIDE
ZUMANDIMINE, DROSPIRENONE
* AUROBINDO PHARMA LTD INC
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA USA
* AUROBINDO PHARMA USA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BUDESONIDE, BUDESONIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLONAZEPAM, CLONAZEPAM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
ELIMITE, PERMETHRIN
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
RASAGILINE MESYLATE, RASAGILINE MESYLATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID

AUROLIFE PHARMA LLC
* AUROLIFE PHARMA LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

AUSTARPHARMA
* AUSTARPHARMA LLC
FENOFIBRATE, FENOFIBRATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL

AUSTARPHARMA LLC
* AUSTARPHARMA LLC
METHOCARBAMOL, METHOCARBAMOL

AUXILIUM PHARMS INC
* AUXILIUM PHARMACEUTICALS INC
TESTOPEL, TESTOSTERONE

AUXILIUM PHARMS LLC
* AUXILIUM PHARMACEUTICALS LLC
EDEX, ALPROSTADIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUXILIUM PHARMACEUTICALS LLC
TESTIM, TESTOSTERONE
THEO-24, THEOPHYLLINE

AVADEL CNS
* AVADEL CNS PHARMACEUTICALS LLC
LUMRYZ, SODIUM OXYBATE

AVANIR PHARMS
* AVANIR PHARMACEUTICALS INC
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC
* AVANTHI INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
INDOMETHACIN, INDOMETHACIN
LOMAIRA, PHENTERMINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEMA PHARMA
* AVEMA PHARMA SOLUTIONS
IBUPROFEN, IBUPROFEN (OTC)

AVENT
* AVENT INC
PYTEST, UREA, C-14

AVEO PHARMS
* AVEO PHARMACEUTICALS INC
FOTIVDA, TIVOZANIB HYDROCHLORIDE

AVERITAS
* AVERITAS PHARMA INC
QUTENZA, CAPSAICIN

AVET
* AVET PHARMACEUTICALS INC
DOXERCALCIFEROL, DOXERCALCIFEROL

AVET LIFESCIENCES
* AVET LIFESCIENCES LTD
ACARBOSE, ACARBOSE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
BICNU, CARMUSTINE
CIDOFOVIR, CIDOFOVIR
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
FUROSEMIDE, FUROSEMIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPOFOL, PROPOFOL
TRANEXAMIC ACID, TRANEXAMIC ACID
ZOLEDRONIC ACID, ZOLEDRONIC ACID
* AVET LIFESCIENCES PRIVATE LTD
FOSCARNET SODIUM, FOSCARNET SODIUM
NEOSTIGMINE METHYSULFATE, NEOSTIGMINE METHYLSULFATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

AVEVA
* AVEVA DRUG DELIVERY SYSTEMS INC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE, BUPRENORPHINE
CLONIDINE, CLONIDINE
FENTANYL-100, FENTANYL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* AVEVA DRUG DELIVERY SYSTEMS INC
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
NICOTINE, NICOTINE (OTC)

AVID RADIOPHARMS INC
* AVID RADIOPHARMACEUTICALS INC
AMYVID, FLORBETAPIR F-18
TAUVID, FLORTAUCIPIR F-18

AVION PHARMS
* AVION PHARMACEUTICALS LLC
BALCOLTRA, ETHINYL ESTRADIOL
DHIVY, CARBIDOPA
PONSTEL, MEFENAMIC ACID

AVONDALE PHARMS
* AVONDALE PHARMACEUTICALS LLC
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
MELOXICAM, MELOXICAM
NIACOR, NIACIN

AXSOME
* AXSOME THERAPEUTICS INC
AUVELITY, BUPROPION HYDROCHLORIDE

AXSOME MALTA
* AXSOME MALTA LTD
SUNOSI, SOLRIAMFETOL HYDROCHLORIDE

AYANA PHARMA LTD
* AYANA PHARMA LTD
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE

AYTU
* AYTU BIOSCIENCE INC
KARBINAL ER, CARBINOXAMINE MALEATE

AYTU BIOPHARMA
* AYTU BIOPHARMA INC
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE

AZURITY
* AZURITY PHARMACEUTICALS INC
BIDIL, HYDRALAZINE HYDROCHLORIDE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EPANED, ENALAPRIL MALEATE
EPRONTIA, TOPIRAMATE
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
EVEKEO ODT, AMPHETAMINE SULFATE
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE
FLEQSUVY, BACLOFEN
GLIADEL, CARMUSTINE
HORIZANT, GABAPENTIN ENACARBIL
KATERZIA, AMLODIPINE BENZOATE
KONVOMEP, OMEPRAZOLE
NYMALIZE, NIMODIPINE
QBRELIS, LISINOPRIL
SOTYLIZE, SOTALOL HYDROCHLORIDE
THYQUIDITY, LEVOTHYROXINE SODIUM
TRIPTODUR KIT, TRIPTORELIN PAMOATE
XATMEP, METHOTREXATE SODIUM
ZONISADE, ZONISAMIDE

** B **

B BRAUN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC

ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINO ACIDS, AMINO ACIDS
BALANCED SALT, CALCIUM CHLORIDE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS

B BRAUN MEDICAL INC

* B BRAUN MEDICAL INC
ACETAMINOPHEN, ACETAMINOPHEN
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CALCIUM GLUCONATE, CALCIUM GLUCONATE
HEPARIN SODIUM, HEPARIN SODIUM
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM

BAJAJ

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAJAJ MEDICAL
  CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
  LACTULOSE, LACTULOSE
* BAJAJ MEDICAL LLC
  CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
  CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

BAMF

* BAMF HEALTH INC
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BANNER LIFE SCIENCES

* BANNER LIFE SCIENCES LLC
  BAFIERTAM, MONOMETHYL FUMARATE

BARR

* BARR LABORATORIES INC
  AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
  ARANELLE, ETHINYL ESTRADIOL
  ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
  BALZIVA-28, ETHINYL ESTRADIOL
  CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
  CLONAZEPAM, CLONAZEPAM
  DANAZOL, DANAZOL
  DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
  DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
  DIPYRIDAMOLE, DIPYRIDAMOLE
  DUTASTERIDE, DUTASTERIDE
  ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
  ESTRADIOL AND NORGESTIMATE, ESTRADIOL
  FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
  GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
  HYDROXYUREA, HYDROXYUREA
  HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
  ISONIAZID, ISONIAZID
  JUNEL 1.5/30, ETHINYL ESTRADIOL
  JUNEL 1/20, ETHINYL ESTRADIOL
  JUNEL FE 1.5/30, ETHINYL ESTRADIOL
  JUNEL FE 1/20, ETHINYL ESTRADIOL
  KARIVA, DESOGESTREL
  KELNOR, ETHINYL ESTRADIOL
  LESSINA-28, ETHINYL ESTRADIOL
  MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
  MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
  MEGESTROL ACETATE, MEGESTROL ACETATE
  METHOTREXATE SODIUM, METHOTREXATE SODIUM
  NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
  NIACIN, NIACIN
  NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
  NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
  NORTREL 0.5/35-28, ETHINYL ESTRADIOL
  NORTREL 1/35-21, ETHINYL ESTRADIOL
  NORTREL 1/35-28, ETHINYL ESTRADIOL
  NORTREL 7/7/7, ETHINYL ESTRADIOL
  PORTIA-28, ETHINYL ESTRADIOL
  SPRINTEC, ETHINYL ESTRADIOL
  TREXALL, METHOTREXATE SODIUM
  TRI-LEGEST FE, ETHINYL ESTRADIOL
  TRI-SPRINTEC, ETHINYL ESTRADIOL
  WARFARIN SODIUM, WARFARIN SODIUM
* BARR LABORATORIES INC A WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
  LANTHANUM CARBONATE, LANTHANUM CARBONATE
* BARR PHARMACEUTICALS
  LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BARR LABS INC

* BARR LABORATORIES INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BARR LABORATORIES INC
ACITRETIN, ACITRETIN
CLOZAPINE, CLOZAPINE
ESTRADIOL, ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
TRETINOIN, TRETINOIN
TRI LO SPRINTEC, ETHINYL ESTRADIOL

BAUSCH

* BAUSCH HEALTH AMERICAS INC
ACANYA, BENZOYL PEROXIDE
BRYHALI, HALOBETASOL PROPIONATE
DUOBRII, HALOBETASOL PROPIONATE
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EFUDEX, FLUOROURACIL
JUBLIA, EFINACONAZOLE
LOCOID, HYDROCORTISONE BUTYRATE
ONEXTON, BENZOYL PEROXIDE
OXSORALEN-ULTRA, METHOXSALEN
SYPRINE, TRIENTINE HYDROCHLORIDE
* BAUSCH HEALTH IRELAND LTD
TARGRETIN, BEXAROTENE
* BAUSCH HEALTH US LLC
AMMONUL, SODIUM BENZOATE
ANCOBON, FLUCYTOSINE
APLENZIN, BUPROPION HYDROBROMIDE
ARAZLO, TAZAROTENE
ATIVAN, LORAZEPAM
CABTREO, ADAPALENE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CESAMET, NABILONE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
DEMSER, METYROSINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
ELIDEL, PIMECROLIMUS
FLUNISOLIDE, FLUNISOLIDE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISORDIL, ISOSORBIDE DINITRATE
KLARON, SULFACETAMIDE SODIUM
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LOCOID, HYDROCORTISONE BUTYRATE
LOPROX, CICLOPIROX
LUZU, LULICONAZOLE
MESTINON, PYRIDOSTIGMINE BROMIDE
METROGEL-VAGINAL, METRONIDAZOLE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
NORITATE, METRONIDAZOLE
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETIN-A-MICRO, TRETINOIN
SOLODYN, MINOCYCLINE HYDROCHLORIDE
TASMAR, TOLCAPONE
TIAZAC, DILTIAZEM HYDROCHLORIDE
VANOS, FLUOCINONIDE
VASERETIC, ENALAPRIL MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAUSCH HEALTH US LLC
VASOTEC, ENALAPRIL MALEATE
VIRAZOLE, RIBAVIRIN
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
XENAZINE, TETRABENAZINE
XERESE, ACYCLOVIR
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZIANA, CLINDAMYCIN PHOSPHATE
ZOVIRAX, ACYCLOVIR
ZYCLARA, IMIQUIMOD

BAUSCH AND LOMB

* BAUSCH AND LOMB INC
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALREX, LOTEPREDNOL ETABONATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BRINZOLAMIDE, BRINZOLAMIDE
CHILDREN'S ALAWAY, KETOTIFEN FUMARATE (OTC)
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
ISTALOL, TIMOLOL MALEATE
LATANOPROST, LATANOPROST
LOTEMAX, LOTEPREDNOL ETABONATE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
OFLOXACIN, OFLOXACIN
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
PROLENSA, BROMFENAC SODIUM
RETISERT, FLUOCINOLONE ACETONIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TROPICAMIDE, TROPICAMIDE
VYZULTA, LATANOPROSTENE BUNOD
ZIRGAN, GANCICLOVIR
ZYLET, LOTEPREDNOL ETABONATE

* BAUSCH AND LOMB PHARMACEUTICALS INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN, ERYTHROMYCIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE

BAUSCH AND LOMB INC

* BAUSCH AND LOMB INC
ALAWAY, KETOTIFEN FUMARATE (OTC)
ATROPINE SULFATE, ATROPINE SULFATE
BEPREVE, BEPOTASTINE BESILATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAUSCH AND LOMB INC
LACRISERT, HYDROXYPROPYL CELLULOSE
LOTEMAX SM, LOTEPREDNOL ETABONATE
LOTEMAX, LOTEPREDNOL ETABONATE
LUMIFY, BRIMONIDINE TARTRATE (OTC)
METHAZOLAMIDE, METHAZOLAMIDE
MIEBO, PERFLUOROHEXYLOCTANE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
XIPERE, TRIAMCINOLONE ACETONIDE

BAUSCH LOMB IRELAND

* BAUSCH AND LOMB IRELAND LTD
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE, BENOXINATE HYDROCHLORIDE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE

BAXTER HLTHCARE

* BAXTER HEALTHCARE CORP
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYTOXAN, CYCLOPHOSPHAMIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
EXTRANEAL, ICODEXTRIN
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FORANE, ISOFLURANE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
IFEX, IFOSFAMIDE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MESNEX, MESNA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NEXTERONE, AMIODARONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SEVOFLURANE, SEVOFLURANE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERILE WATER, STERILE WATER FOR IRRIGATION
SUPRANE, DESFLURANE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
* BAXTER HEALTHCARE INTERNATI0NAL SPECIALTY THERAPIES DIV
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

* BAXTER HEALTHCARE CORP
ACETAMINOPHEN, ACETAMINOPHEN
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BORTEZOMIB, BORTEZOMIB
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINOLIPID 20%, OLIVE OIL
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE, DAPTOMYCIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
EPTIFIBATIDE, EPTIFIBATIDE
FLUMAZENIL, FLUMAZENIL
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FUROSEMIDE, FUROSEMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MICAFUNGIN IN SODIUM CHLORIDE 0.9%, MICAFUNGIN SODIUM
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE, NOREPINEPHRINE BITARTRATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
REGADENOSON, REGADENOSON
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRANSDERM SCOP, SCOPOLAMINE
VASOPRESSIN IN SODIUM CHLORIDE 0.9%, VASOPRESSIN
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
* BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE

BAYER

* BAYER HEALTHCARE LLC
ALEVE, NAPROXEN SODIUM (OTC)

BAYER HEALTHCARE

* BAYER HEALTHCARE PHARMACEUTICALS INC
LAMPIT, NIFURTIMOX
NUBEQA, DAROLUTAMIDE
VITRAKVI, LAROTRECTINIB SULFATE

BAYER HEALTHCARE LLC

* BAYER HEALTHCARE LLC
CHILDREN'S CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)

BAYER HLTHCARE

* BAYER HEALTHCARE CONSUMER CARE
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
CHILDREN'S ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
* BAYER HEALTHCARE PHARMACEUTICALS INC
ADEMPAS, RIOCIGUAT
ANGELIQ, DROSPIRENONE
BEYAZ, DROSPIRENONE
BILTRICIDE, PRAZIQUANTEL
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CLIMARA PRO, ESTRADIOL
CLIMARA, ESTRADIOL
EOVIST, GADOXETATE DISODIUM
GADAVIST, GADOBUTROL
KERENDIA, FINERENONE
KYLEENA, LEVONORGESTREL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAYER HEALTHCARE PHARMACEUTICALS INC
MENOSTAR, ESTRADIOL
MIRENA, LEVONORGESTREL
NATAZIA, DIENOGEST
NEXAVAR, SORAFENIB TOSYLATE
SAFYRAL, DROSPIRENONE
SKYLA, LEVONORGESTREL
STIVARGA, REGORAFENIB
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
VITRAKVI, LAROTRECTINIB SULFATE
XOFIGO, RADIUM RA-223 DICHLORIDE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE

BAYSHORE PHARMS LLC

* BAYSHORE PHARMACEUTICALS LLC
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
ETODOLAC, ETODOLAC
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METOLAZONE, METOLAZONE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PINDOLOL, PINDOLOL
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

BDSI

* BIODELIVERY SCIENCES INTERNATIONAL INC
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
SYMPROIC, NALDEMEDINE TOSYLATE

BE PHARMS

* BE PHARMACEUTICALS AG
DAPTOMYCIN, DAPTOMYCIN
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
HEPARIN SODIUM, HEPARIN SODIUM
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

BECTON DICKINSON

* BECTON DICKINSON AND CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BECTON DICKINSON CO

* BECTON DICKINSON AND CO
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

BEIGENE

* BEIGENE USA INC
BRUKINSA, ZANUBRUTINIB

BEIJING

* BEIJING SCIECURE PHARMACEUTICAL CO LTD
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FOSCARNET SODIUM, FOSCARNET SODIUM

BEIJING TIDE PHARM

* BEIJING TIDE PHARMACEUTICAL CO LTD
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE

BEIJING YILING

* BEIJING YILING BIO-ENGEERING AND TECHNOLOGY CO LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BEIJING YILING BIO-ENGEERING AND TECHNOLOGY CO LTD
ANASTROZOLE, ANASTROZOLE
LETROZOLE, LETROZOLE

BELCHER

* BELCHER PHARMACEUTICALS LLC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
CEFIXIME, CEFIXIME
CHLORZOXAZONE, CHLORZOXAZONE
GABAPENTIN, GABAPENTIN
LEVETIRACETAM, LEVETIRACETAM
MEFENAMIC ACID, MEFENAMIC ACID
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TACROLIMUS, TACROLIMUS

BELCHER PHARMS

* BELCHER PHARMACEUTICALS LLC
CEPHALEXIN, CEPHALEXIN
DESLORATADINE, DESLORATADINE

BELOTECA

* BELOTECA INC
DAPSONE, DAPSONE
DIAZEPAM, DIAZEPAM
THIOTEPA, THIOTEPA

BENUVIA OPERATIONS

* BENUVIA OPERATIONS LLC
SYNDROS, DRONABINOL

BEOWULF ASSET

* BEOWULF ASSET MANAGEMENT LP
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
NYSTATIN, NYSTATIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

BESINS HLTHCARE

* BESINS HEALTHCARE IRELAND LTD
ANDROGEL, TESTOSTERONE

BEXIMCO PHARMS USA

* BEXIMCO PHARMACEUTICALS USA INC
BACLOFEN, BACLOFEN
CARBIDOPA, CARBIDOPA
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NADOLOL, NADOLOL
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

BEXIMCO USA

* BEXIMCO PHARMACEUTICALS USA INC
CARVEDILOL, CARVEDILOL

BIOCODEX SA

* BIOCODEX SA
DIACOMIT, STIRIPENTOL

BIOCON PHARMA

* BIOCON PHARMA INC
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
* BIOCON PHARMA LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
EVEROLIMUS, EVEROLIMUS
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
POSACONAZOLE, POSACONAZOLE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BIOCON PHARMA LTD
SIMVASTATIN, SIMVASTATIN
TACROLIMUS, TACROLIMUS
TERIFLUNOMIDE, TERIFLUNOMIDE

BIOCRYST
* BIOCRYST PHARMACEUTICALS INC
ORLADEYO, BEROTRALSTAT HYDROCHLORIDE
RAPIVAB, PERAMIVIR

BIOFRONTERA
* BIOFRONTERA BIOSCIENCE GMBH
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE

BIOGEN IDEC
* BIOGEN IDEC INC
SPINRAZA, NUSINERSEN SODIUM

BIOGEN INC
* BIOGEN INC
TECFIDERA, DIMETHYL FUMARATE
VUMERITY, DIROXIMEL FUMARATE
ZURZUVAE, ZURANOLONE

BIOGEN MA
* BIOGEN MA INC
QALSODY, TOFERSEN

BIOLINERX LTD
* BIOLINERX LTD
APHEXDA, MOTIXAFORTIDE ACETATE

BIOMARIN PHARM
* BIOMARIN PHARMACEUTICAL INC
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
VOXZOGO, VOSORITIDE

BIOMEDCL RES FDN
* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISANA
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BIONPHARMA
* BIONPHARMA INC
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ATOVAQUONE, ATOVAQUONE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BENZONATATE, BENZONATATE
BEXAROTENE, BEXAROTENE
CALCITRIOL, CALCITRIOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DEXAMETHASONE, DEXAMETHASONE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DOFETILIDE, DOFETILIDE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DROXIDOPA, DROXIDOPA
DUTASTERIDE, DUTASTERIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BIONPHARMA INC
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVETIRACETAM, LEVETIRACETAM
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
METHIMAZOLE, METHIMAZOLE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PARICALCITOL, PARICALCITOL
POTASSIUM CITRATE, POTASSIUM CITRATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROGESTERONE, PROGESTERONE
RUFINAMIDE, RUFINAMIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
TETRABENAZINE, TETRABENAZINE
THEOPHYLLINE, THEOPHYLLINE
VALPROIC ACID, VALPROIC ACID
VITAMIN D, ERGOCALCIFEROL
ZONISAMIDE, ZONISAMIDE

BIOXCEL
* BIOXCEL THERAPEUTICS INC
IGALMI, DEXMEDETOMIDINE HYDROCHLORIDE

BLUE EARTH
* BLUE EARTH DIAGNOSTICS LTD
AXUMIN, FLUCICLOVINE F-18
POSLUMA, FLOTUFOLASTAT F-18 GALLIUM

BLUE WATER BIOTECH
* BLUE WATER BIOTECH INC
ENTADFI, FINASTERIDE

BLUEPHARMA INDUSTRIA
* BLUEPHARMA INDUSTRIA FARMACEUTICA SA
DROXIDOPA, DROXIDOPA

BLUEPRINT MEDICINES
* BLUEPRINT MEDICINES CORP
AYVAKIT, AVAPRITINIB

BOEHRINGER INGELHEIM
* BOEHRINGER INGELHEIM
GILOTRIF, AFATINIB DIMALEATE
GLYXAMBI, EMPAGLIFLOZIN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
APTIVUS, TIPRANAVIR
ATROVENT HFA, IPRATROPIUM BROMIDE
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
JARDIANCE, EMPAGLIFLOZIN
JENTADUETO XR, LINAGLIPTIN
JENTADUETO, LINAGLIPTIN
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MOBIC, MELOXICAM
OFEV, NINTEDANIB ESYLATE
PERSANTINE, DIPYRIDAMOLE
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRIVA, TIOTROPIUM BROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
SYNJARDY XR, EMPAGLIFLOZIN
SYNJARDY, EMPAGLIFLOZIN
TRADJENTA, LINAGLIPTIN
TRIJARDY XR, EMPAGLIFLOZIN
VIRAMUNE XR, NEVIRAPINE
VIRAMUNE, NEVIRAPINE

BPI LABS

* BPI LABS LLC
ABLYSINOL, ALCOHOL
EPINEPHRINE, EPINEPHRINE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
ZOLEDRONIC ACID, ZOLEDRONIC ACID

BRACCO

* BRACCO DIAGNOSTICS INC
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
ENTERO VU 24%, BARIUM SULFATE
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
KINEVAC, SINCALIDE
LIQUID E-Z-PAQUE, BARIUM SULFATE
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MULTIHANCE, GADOBENATE DIMEGLUMINE
PROHANCE MULTIPACK, GADOTERIDOL
PROHANCE, GADOTERIDOL
READI-CAT 2 SMOOTHIE, BARIUM SULFATE
READI-CAT 2, BARIUM SULFATE
TAGITOL V, BARIUM SULFATE
VARIBAR HONEY, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARIBAR PUDDING, BARIUM SULFATE
VARIBAR THIN HONEY, BARIUM SULFATE
VARIBAR THIN LIQUID, BARIUM SULFATE

BRAEBURN

* BRAEBURN INC
BRIXADI, BUPRENORPHINE

BRAINTREE

* BRAINTREE LABORATORIES INC
GOLYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

* BRAINTREE LABORATORIES INC
SUFLAVE, MAGNESIUM SULFATE
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
SUTAB, MAGNESIUM SULFATE

BRECKENRIDGE

* BRECKENRIDGE PHARMACEUTICAL INC
ALPRAZOLAM, ALPRAZOLAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BRECKENRIDGE PHARMACEUTICAL INC
ARIPIPRAZOLE, ARIPIPRAZOLE
ASENAPINE MALEATE, ASENAPINE MALEATE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
CLOBAZAM, CLOBAZAM
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPLERENONE, EPLERENONE
EVEROLIMUS, EVEROLIMUS
EXEMESTANE, EXEMESTANE
LAMIVUDINE, LAMIVUDINE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MIGLUSTAT, MIGLUSTAT
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OMEPRAZOLE, OMEPRAZOLE
PENICILLAMINE, PENICILLAMINE
RIVASTIGMINE, RIVASTIGMINE
ROFLUMILAST, ROFLUMILAST
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

BRECKENRIDGE PHARM

* BRECKENRIDGE PHARMACEUTICAL INC
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
OXCARBAZEPINE, OXCARBAZEPINE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

BRIGHAM WOMENS

* BRIGHAM AND WOMENS HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

BRIGHAM WOMENS HOSP

* BRIGHAM AND WOMENS HOSP INC
AMMONIA N 13, AMMONIA N-13

BRIGHTGENE

* BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD
ENTECAVIR, ENTECAVIR

BRISTOL

* BRISTOL MYERS SQUIBB CO
AUGTYRO, REPOTRECTINIB
CAMZYOS, MAVACAMTEN
EVOTAZ, ATAZANAVIR SULFATE
ONUREG, AZACITIDINE
POMALYST, POMALIDOMIDE
SOTYKTU, DEUCRAVACITINIB

BRISTOL MYERS SQUIBB

* BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
BARACLUDE, ENTECAVIR
IDHIFA, ENASIDENIB MESYLATE
REVLIMID, LENALIDOMIDE
* BRISTOL MYERS SQUIBB CO
REYATAZ, ATAZANAVIR SULFATE
SPRYCEL, DASATINIB
* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
ELIQUIS, APIXABAN

BRISTOL-MYERS

* BRISTOL-MYERS SQUIBB CO
ABRAXANE, PACLITAXEL
ISTODAX, ROMIDEPSIN
THALOMID, THALIDOMIDE
VIDAZA, AZACITIDINE

BROOKS STERISCIENCE

* BROOKS STERISCIENCE LTD
MEROPENEM, MEROPENEM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

BTG INTL

* BTG INTERNATIONAL INC
CYANOKIT, HYDROXOCOBALAMIN
THYROSAFE, POTASSIUM IODIDE (OTC)
VISTOGARD, URIDINE TRIACETATE
XURIDEN, URIDINE TRIACETATE

BWXT ITG

* BWXT ITG CANADA INC
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE

**** C ****

CADILA

* CADILA HEALTHCARE LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DUTASTERIDE, DUTASTERIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELBAMATE, FELBAMATE
FLUOCINONIDE, FLUOCINONIDE
INDOMETHACIN, INDOMETHACIN
LEVOFLOXACIN, LEVOFLOXACIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PIROXICAM, PIROXICAM
RANOLAZINE, RANOLAZINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

CADILA PHARMS LTD

* CADILA PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GEMFIBROZIL, GEMFIBROZIL
GLYBURIDE, GLYBURIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NATEGLINIDE, NATEGLINIDE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CADILA PHARMACEUTICALS LTD
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PREGABALIN, PREGABALIN
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN, TELMISARTAN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

CALL INC

* CALL INC DBA ROCHESTER PHARMACEUTICALS
ADAPALENE, ADAPALENE

CALLIDITAS

* CALLIDITAS THERAPEUTICS AB
TARPEYO, BUDESONIDE

CAPELLON PHARMS LLC

* CAPELLON PHARMACEUTICALS LLC
POLMON, DEXCHLORPHENIRAMINE MALEATE

CAPLIN

* CAPLIN STERILES LTD
ARGATROBAN, ARGATROBAN
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
ETOMIDATE, ETOMIDATE
GLYCOPYRROLATE, GLYCOPYRROLATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OFLOXACIN, OFLOXACIN
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

CARA THERAP

* CARA THERAPEUTICS INC
KORSUVA, DIFELIKEFALIN ACETATE

CARDINAL HEALTH 414

* CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEDRONATE KIT, TECHNETIUM TC-99M MEDRONATE KIT

CARDINAL HEALTH 418

* CARDINAL HEALTH 418 INC
SODIUM IODIDE I 123, SODIUM IODIDE I-123

CARDINAL HLTH 414

* CARDINAL HEALTH 414 LLC
AMMONIA N 13, AMMONIA N-13

CARIBE HOLDINGS

* CARIBE HOLDINGS CAYMAN CO LTD DBA PURACAP CARIBE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
GEMFIBROZIL, GEMFIBROZIL

CARLSBAD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
GLIMEPIRIDE, GLIMEPIRIDE
LOVASTATIN, LOVASTATIN

CARLSBAD TECHNOLOGY
* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR

CARNEGIE
* CARNEGIE PHARMACEUTICALS LLC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
ETRAVIRINE, ETRAVIRINE
FAMOTIDINE, FAMOTIDINE
LATANOPROST, LATANOPROST
LETROZOLE, LETROZOLE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE

CASI PHARMS INC
* CASI PHARMACEUTICALS INC
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

CASPER PHARMA LLC
* CASPER PHARMA LLC
ANTIVERT, MECLIZINE HYDROCHLORIDE
AQUASOL A, VITAMIN A PALMITATE
CASPORYN HC, HYDROCORTISONE
EDETATE CALCIUM DISODIUM, EDETATE CALCIUM DISODIUM
FURADANTIN, NITROFURANTOIN
LUMI-SPORYN, BACITRACIN ZINC
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
THALITONE, CHLORTHALIDONE
ZYLOPRIM, ALLOPURINOL

CATALENT
* CATALENT PHARMA SOLUTIONS LLC
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
VALPROIC ACID, VALPROIC ACID

CATALYST PHARMS
* CATALYST PHARMACEUTICALS INC
AGAMREE, VAMOROLONE
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE
FYCOMPA, PERAMPANEL

CEDIPROF INC
* CEDIPROF INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
LEVO-T, LEVOTHYROXINE SODIUM **

CELATOR PHARMS
* CELATOR PHARMACEUTICALS INC
VYXEOS, CYTARABINE

CELGENE INTL
* CELGENE INTERNATIONAL II SARL
ZEPOSIA, OZANIMOD HYDROCHLORIDE

CELLTRION
* CELLTRION INC
LEVOFLOXACIN, LEVOFLOXACIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE

CEPHALON
* CEPHALON INC
GABITRIL, TIAGABINE HYDROCHLORIDE
NUVIGIL, ARMODAFINIL
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CEPHALON LLC
ACTIQ, FENTANYL CITRATE
FENTORA, FENTANYL CITRATE
PROVIGIL, MODAFINIL

CEROVENE INC

* CEROVENE INC
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
PYRIMETHAMINE, PYRIMETHAMINE
SEROMYCIN, CYCLOSERINE

CHANGZHOU PHARM

* CHANGZHOU PHARMACEUTICAL FACTORY
CAPTOPRIL, CAPTOPRIL
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
PREGABALIN, PREGABALIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

CHARTWELL

* CHARTWELL LIFE MOLECULES LLC
ALLOPURINOL, ALLOPURINOL
AMOXICILLIN, AMOXICILLIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN, CIPROFLOXACIN
CLARITHROMYCIN, CLARITHROMYCIN
COLOCORT, HYDROCORTISONE
FLUCONAZOLE, FLUCONAZOLE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
TEMOZOLOMIDE, TEMOZOLOMIDE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
* CHARTWELL PHARMA SCIENCE LLC
SULFASALAZINE, SULFASALAZINE
* CHARTWELL SCHEDULED LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

CHARTWELL INJECTABLE

* CHARTWELL INJECTABLES LLC
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
TERBUTALINE SULFATE, TERBUTALINE SULFATE

CHARTWELL MOLECULAR

* CHARTWELL MOLECULAR HOLDINGS LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CALCIUM ACETATE, CALCIUM ACETATE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FOLIC ACID, FOLIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CHARTWELL MOLECULAR HOLDINGS LLC
GLIMEPIRIDE, GLIMEPIRIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRBESARTAN, IRBESARTAN
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMIVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
RAMIPRIL, RAMIPRIL
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THEOPHYLLINE, THEOPHYLLINE
ZALEPLON, ZALEPLON
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CHARTWELL MOLECULES

* CHARTWELL MOLECULES LLC
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DISULFIRAM, DISULFIRAM
GEMFIBROZIL, GEMFIBROZIL
INDOMETHACIN, INDOMETHACIN
NABUMETONE, NABUMETONE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

CHARTWELL RX

* CHARTWELL RX SCIENCES LLC
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATOVAQUONE, ATOVAQUONE
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CALCIUM ACETATE, CALCIUM ACETATE
CARBAMAZEPINE, CARBAMAZEPINE
CARISOPRODOL, CARISOPRODOL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CICLOPIROX, CICLOPIROX
CILOSTAZOL, CILOSTAZOL
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CHARTWELL RX SCIENCES LLC
DEFERASIROX, DEFERASIROX
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DUVOID, BETHANECHOL CHLORIDE
EPLERENONE, EPLERENONE
ERGOCALCIFEROL, ERGOCALCIFEROL
ETHACRYNIC ACID, ETHACRYNIC ACID
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE, FENOFIBRATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HALCINONIDE, HALCINONIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
INDOMETHACIN, INDOMETHACIN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
LINEZOLID, LINEZOLID
LISINOPRIL, LISINOPRIL
LOCHOLEST LIGHT, CHOLESTYRAMINE
LOCHOLEST, CHOLESTYRAMINE
LOVASTATIN, LOVASTATIN
METHIMAZOLE, METHIMAZOLE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METRONIDAZOLE, METRONIDAZOLE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MONODOX, DOXYCYCLINE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PREGABALIN, PREGABALIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
REPAGLINIDE, REPAGLINIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
RUFINAMIDE, RUFINAMIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CHARTWELL RX SCIENCES LLC
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TAVABOROLE, TAVABOROLE
TELMISARTAN, TELMISARTAN
TETRABENAZINE, TETRABENAZINE
TINIDAZOLE, TINIDAZOLE
TOBRAMYCIN, TOBRAMYCIN
TRAVOPROST, TRAVOPROST
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
URSODIOL, URSODIOL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

CHARTWELL TETRA
* CHARTWELL TETRA LLC
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

CHATTEM
* CHATTEM INC
UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHATTEM SANOFI
* CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NICODERM CQ, NICOTINE (OTC)
XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)

CHEMI SPA
* CHEMI SPA
DECITABINE, DECITABINE
TEMOZOLOMIDE, TEMOZOLOMIDE

CHEMISCH FBRK KRSSLR
* CHEMISCHE FABRIK KREUSSLER & CO. GMBH
ASCLERA, POLIDOCANOL

CHEMISTRY HLTH
* CHEMISTRY AND HEALTH FZ LLC
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE

CHEMO RESEARCH SL
* CHEMO RESEARCH SL
BENZNIDAZOLE, BENZNIDAZOLE
ESTRADIOL, ESTRADIOL
NUVESSA, METRONIDAZOLE

CHEMOCENTRYX
* CHEMOCENTRYX INC
TAVNEOS, AVACOPAN

CHENGDU SHUODE
* CHENGDU SHUODE PHARMACEUTICAL CO LTD
NALMEFENE HYDROCHLORIDE, NALMEFENE HYDROCHLORIDE

CHEPLAPHARM
* CHEPLAPHARM ARZNEIMITTEL GMBH
DROXIA, HYDROXYUREA
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
HYDREA, HYDROXYUREA
KLONOPIN, CLONAZEPAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CHEPLAPHARM ARZNEIMITTEL GMBH
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
XELODA, CAPECITABINE
XENICAL, ORLISTAT
* CHEPLAPHARM REGISTRATION GMBH
ZYPREXA RELPREVV, OLANZAPINE PAMOATE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE

CHIA TAI TIANQING
* CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT

CHIESI
* CHIESI FARMACEUTICI SPA
MYCAPSSA, OCTREOTIDE ACETATE
* CHIESI USA INC
BETHKIS, TOBRAMYCIN
BRONCHITOL, MANNITOL
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CLEVIPREX, CLEVIDIPINE
FERRIPROX, DEFERIPRONE
KENGREAL, CANGRELOR
ZYFLO, ZILEUTON

CHILDRENS HOSP MI
* CHILDRENS HOSP MICHIGAN
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CHINA RESOURCES
* CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

CHIRHOCLIN
* CHIRHOCLIN INC
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CIDARA THERAPS
* CIDARA THERAPEUTICS INC
REZZAYO, REZAFUNGIN ACETATE

CINTEX SVCS
* CINTEX SERVICES LLC
DESONIDE, DESONIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

CIPHER PHARMS INC
* CIPHER PHARMACEUTICALS INC
CONZIP, TRAMADOL HYDROCHLORIDE
LIPOFEN, FENOFIBRATE

CIPLA
* CIPLA LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
AZACITIDINE, AZACITIDINE
BUDESONIDE, BUDESONIDE
CELECOXIB, CELECOXIB
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DARUNAVIR, DARUNAVIR
DEFERASIROX, DEFERASIROX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

* CIPLA LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUPREDNATE, DIFLUPREDNATE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EMTRICITABINE, EMTRICITABINE
ENTECAVIR, ENTECAVIR
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
EXEMESTANE, EXEMESTANE
FENOFIBRATE, FENOFIBRATE
FINASTERIDE, FINASTERIDE
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
ICATIBANT ACETATE, ICATIBANT ACETATE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LENALIDOMIDE, LENALIDOMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
MELOXICAM, MELOXICAM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEVIRAPINE, NEVIRAPINE
PHYTONADIONE, PHYTONADIONE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREGABALIN, PREGABALIN
RITONAVIR, RITONAVIR
SUMATRIPTAN, SUMATRIPTAN
TADALAFIL, TADALAFIL
TAVABOROLE, TAVABOROLE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE, TESTOSTERONE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VASOPRESSIN, VASOPRESSIN
ZIDOVUDINE, ZIDOVUDINE

CIPLA LTD
* CIPLA LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
ZIDOVUDINE, ZIDOVUDINE

CIPLA USA
* CIPLA USA INC
ZEMDRI, PLAZOMICIN SULFATE

CISEN
* CISEN PHARMACEUTICAL CO LTD
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM

CLINIGEN
* CLINIGEN INC
ETHYOL, AMIFOSTINE

CLINIGEN HLTHCARE
* CLINIGEN HEALTHCARE LTD
FOSCAVIR, FOSCARNET SODIUM

CLIVUNEL INC
* CLINUVEL INC
SCENESSE, AFAMELANOTIDE

CMP DEV LLC
* CMP DEVELOPMENT LLC
ATORVALIQ, ATORVASTATIN CALCIUM
CAROSPIR, SPIRONOLACTONE
LIQREV, SILDENAFIL CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CMP DEVELOPMENT LLC
NORLIQVA, AMLODIPINE BESYLATE
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
TADLIQ, TADALAFIL

CMP PHARMA INC

* CMP PHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE

COLGATE-PALMOLIVE CO

* COLGATE-PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLLEGIUM PHARM INC

* COLLEGIUM PHARMACEUTICAL INC
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
XTAMPZA ER, OXYCODONE

COMBE

* COMBE INC
VAGISTAT-1, TIOCONAZOLE (OTC)

COMMAVE THERAP

* COMMAVE THERAPEUTICS SA
AZSTARYS, DEXMETHYLPHENIDATE HYDROCHLORIDE

CONCORD BIOTECH LTD

* CONCORD BIOTECH LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
TACROLIMUS, TACROLIMUS

CONCORDIA

* CONCORDIA PHARMACEUTICALS INC
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE
LANOXIN, DIGOXIN
NILANDRON, NILUTAMIDE
PANRETIN, ALITRETINOIN
PARNATE, TRANYLCYPROMINE SULFATE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
SALAGEN, PILOCARPINE HYDROCHLORIDE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE

CONCORDIA PHARMS INC

* CONCORDIA PHARMACEUTICALS INC
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE

CONTRACT PHARMACAL

* CONTRACT PHARMACAL CORP
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

COOPERSURGICAL

* COOPERSURGICAL INC
PARAGARD T 380A, COPPER

CORCEPT THERAP

* CORCEPT THERAPEUTICS INC
KORLYM, MIFEPRISTONE

CORDEN PHARMA

* CORDEN PHARMA LATINA SPA
GLEOSTINE, LOMUSTINE

COREPHARMA

* COREPHARMA LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* COREPHARMA LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
LISINOPRIL, LISINOPRIL
LOVASTATIN, LOVASTATIN
MELOXICAM, MELOXICAM
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TORSEMIDE, TORSEMIDE

CORIUM
* CORIUM INC
ADLARITY, DONEPEZIL HYDROCHLORIDE

CORMEDIX
* CORMEDIX INC
DEFENCATH, HEPARIN SODIUM

COSETTE
* COSETTE PHARMACEUTICALS INC
ACEPHEN, ACETAMINOPHEN (OTC)
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AZOR, AMLODIPINE BESYLATE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
BETA-VAL, BETAMETHASONE VALERATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
DAPSONE, DAPSONE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DOXYCYCLINE, DOXYCYCLINE
EFFIENT, PRASUGREL HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
INDOMETHACIN, INDOMETHACIN
LIDOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MIGERGOT, CAFFEINE
MOMETASONE FUROATE, MOMETASONE FUROATE
MYKACET, NYSTATIN
NYSTATIN, NYSTATIN
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

* COSETTE PHARMACEUTICALS INC
TAZAROTENE, TAZAROTENE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIBENZOR, AMLODIPINE BESYLATE
WELCHOL, COLESEVELAM HYDROCHLORIDE

COVIS

* COVIS PHARMA GMBH
ALTOPREV, LOVASTATIN
ALVESCO, CICLESONIDE
DUAKLIR PRESSAIR, ACLIDINIUM BROMIDE
FERAHEME, FERUMOXYTOL
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
OMNARIS, CICLESONIDE
PRILOSEC, OMEPRAZOLE MAGNESIUM
RILUTEK, RILUZOLE
SULAR, NISOLDIPINE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
ZETONNA, CICLESONIDE

CPPI CV

* CP PHARMACEUTICALS INTERNATIONAL CV
SUTENT, SUNITINIB MALATE

CREEKWOOD PHARMS

* CREEKWOOD PHARMACEUTICALS LLC
FENOFIBRATE, FENOFIBRATE
PREGABALIN, PREGABALIN
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SILODOSIN, SILODOSIN

CROSSMEDIKA SA

* CROSSMEDIKA SA
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

CROWN LABS

* CROWN LABORATORIES INC
ALA-CORT, HYDROCORTISONE
TRIDERM, TRIAMCINOLONE ACETONIDE

CROWN LABS INC

* CROWN LABORATORIES INC
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN

CSPC OUYI

* CSPC OUYI PHARMACEUTICAL CO LTD
AZITHROMYCIN, AZITHROMYCIN
CARBAMAZEPINE, CARBAMAZEPINE
CELECOXIB, CELECOXIB
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
GABAPENTIN, GABAPENTIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PALIPERIDONE, PALIPERIDONE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE

CSPC OUYI PHARM CO

* CSPC OUYI PHARMACEUTICAL CO LTD
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

CSPC-NBP PHARM

* CSPC-NBP PHARMACEUTICAL CO LTD
BENZONATATE, BENZONATATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS

CTI BIOPHARMA CORP

* CTI BIOPHARMA CORP
VONJO, PACRITINIB CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

CUBIST PHARMS LLC
* CUBIST PHARMACEUTICALS LLC
DIFICID, FIDAXOMICIN
SIVEXTRO, TEDIZOLID PHOSPHATE
ZERBAXA, CEFTOLOZANE SULFATE

CUMBERLAND
* CUMBERLAND PHARMACEUTICALS INC
SANCUSO, GRANISETRON
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VIBATIV, TELAVANCIN HYDROCHLORIDE

CUMBERLAND PHARMS
* CUMBERLAND PHARMACEUTICALS INC
ACETADOTE, ACETYLCYSTEINE
CALDOLOR, IBUPROFEN
LACTULOSE, LACTULOSE

CURIUM
* CURIUM US LLC
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
IOFLUPANE I-123, IOFLUPANE I-123
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
SODIUM IODIDE I 123, SODIUM IODIDE I-123
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
XENON XE 133, XENON XE-133

CURRAX
* CURRAX PHARMACEUTICALS LLC
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
SILENOR, DOXEPIN HYDROCHLORIDE
TREXIMET, NAPROXEN SODIUM

CUSTOPHARM INC
* CUSTOPHARM INC
CALCITONIN-SALMON, CALCITONIN SALMON

CYCLE
* CYCLE PHARMACEUTICALS LTD
NITYR, NITISINONE
TASCENSO ODT, FINGOLIMOD LAURYL SULFATE

CYCLOMEDICA
* CYCLOMEDICA AUSTRALIA PTY LTD
TECHNEGAS KIT, TECHNETIUM TC-99M LABELED CARBON

** D **

DAEWOONG PHARM CO
* DAEWOONG PHARMACEUTICAL CO LTD
MEROPENEM, MEROPENEM

DAIICHI SANKYO INC
* DAIICHI SANKYO INC
SAVAYSA, EDOXABAN TOSYLATE
TURALIO, PEXIDARTINIB HYDROCHLORIDE
VANFLYTA, QUIZARTINIB DIHYDROCHLORIDE

DAITO
* DAITO PHARMACEUTICAL CO LTD
METHOTREXATE SODIUM, METHOTREXATE SODIUM

DANCO LABS LLC
* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

DARE
* DARE BIOSCIENCE INC
XACIATO, CLINDAMYCIN PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

DASH PHARMS
* DASH PHARMACEUTICALS LLC
TESTOSTERONE, TESTOSTERONE

DASH PHARMS NATCO
* DASH PHARMACEUTICALS LLC A FULLY OWNED SUB OF NATCO PHARMA LTD
ALBUTEROL SULFATE, ALBUTEROL SULFATE

DAVA PHARMS INC
* DAVA PHARMACEUTICALS INC
AMOXICILLIN, AMOXICILLIN
MORPHINE SULFATE, MORPHINE SULFATE
PROPYLTHIOURACIL, PROPYLTHIOURACIL

DAVIS AND GECK
* DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DECATUR
* DECATUR MEMORIAL HOSP
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

DECIPHERA PHARMS
* DECIPHERA PHARMACEUTICALS LLC
QINLOCK, RIPRETINIB

DELCATH SYSTEMS INC
* DELCATH SYSTEMS INC
HEPZATO, MELPHALAN HYDROCHLORIDE

DENTSPLY PHARM
* DENTSPLY PHARMACEUTICAL INC
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE

DEPROCO
* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DERMAVANT SCI
* DERMAVANT SCIENCES INC
VTAMA, TAPINAROF

DEVA HOLDING AS
* DEVA HOLDING AS
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TEMOZOLOMIDE, TEMOZOLOMIDE

DEXCEL
* DEXCEL PHARMA TECHNOLOGIES LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
HEMADY, DEXAMETHASONE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE (OTC)
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN

DEXCEL LTD
* DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA
* DEXCEL PHARMA TECHNOLOGIES LTD
OMEPRAZOLE, OMEPRAZOLE (OTC)

DIALYSIS SUPS
* DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DIALYSIS SUPPLIES INC
NORMOCARB HF 35, MAGNESIUM CHLORIDE

DORC

* DORC INTERNATIONAL BV
VISIONBLUE, TRYPAN BLUE

DOW PHARM

* DOW PHARMACEUTICAL SCIENCES
ALTRENO, TRETINOIN
ATRALIN, TRETINOIN

DR REDDYS

* DR REDDYS LABORATORIES INC
FENOFIBRATE, FENOFIBRATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
PROGESTERONE, PROGESTERONE
PROPOFOL, PROPOFOL
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* DR REDDYS LABORATORIES LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ALBENDAZOLE, ALBENDAZOLE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZACITIDINE, AZACITIDINE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BIVALIRUDIN, BIVALIRUDIN
BORTEZOMIB, BORTEZOMIB
CABAZITAXEL, CABAZITAXEL
CAPECITABINE, CAPECITABINE
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARFILZOMIB, CARFILZOMIB
CARMUSTINE, CARMUSTINE
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
CLOFARABINE, CLOFARABINE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
COLCHICINE, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DAPTOMYCIN, DAPTOMYCIN
DARUNAVIR, DARUNAVIR
DECITABINE, DECITABINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIFLUPREDNATE, DIFLUPREDNATE
DOCETAXEL, DOCETAXEL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
EPHEDRINE SULFATE, EPHEDRINE SULFATE
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESZOPICLONE, ESZOPICLONE
FEBUXOSTAT, FEBUXOSTAT
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IMATINIB MESYLATE, IMATINIB MESYLATE
LANSOPRAZOLE, LANSOPRAZOLE
LENALIDOMIDE, LENALIDOMIDE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LIDOCAINE, LIDOCAINE
LUBIPROSTONE, LUBIPROSTONE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NELARABINE, NELARABINE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE, OMEPRAZOLE (OTC)
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PARICALCITOL, PARICALCITOL
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PENICILLAMINE, PENICILLAMINE
PHYTONADIONE, PHYTONADIONE
PLERIXAFOR, PLERIXAFOR
POSACONAZOLE, POSACONAZOLE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
REGADENOSON, REGADENOSON
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIROLIMUS, SIROLIMUS
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUNITINIB MALATE, SUNITINIB MALATE
TADALAFIL, TADALAFIL
TETRABENAZINE, TETRABENAZINE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
TIMOLOL MALEATE, TIMOLOL MALEATE
TOPIRAMATE, TOPIRAMATE
TREPROSTINIL, TREPROSTINIL
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
VIGABATRIN, VIGABATRIN
VINORELBINE TARTRATE, VINORELBINE TARTRATE

DR REDDYS LA

* DR REDDYS LABORATORIES LOUISIANA LLC
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPURIN, ALLOPURINOL
SSD, SILVER SULFADIAZINE

DR REDDYS LABS EU

* DR REDDYS LABORATORIES EU LTD
PERMETHRIN, PERMETHRIN

DR REDDYS LABS INC

* DR REDDYS LABORATORIES INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES INC
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LEVOFLOXACIN, LEVOFLOXACIN
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SIMVASTATIN, SIMVASTATIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

DR REDDYS LABS LTD

* DR REDDYS LABORATORIES LIMITED
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
* DR REDDYS LABORATORIES LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVETIRACETAM, LEVETIRACETAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LTD
NATEGLINIDE, NATEGLINIDE
NIZATIDINE, NIZATIDINE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TACROLIMUS, TACROLIMUS
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZAFIRLUKAST, ZAFIRLUKAST
ZENATANE, ISOTRETINOIN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

DR REDDYS LABS SA

* DR REDDYS LABORATORIES SA
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CAMILA, NORETHINDRONE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHLORZOXAZONE, CHLORZOXAZONE
CLARITHROMYCIN, CLARITHROMYCIN
CLONIDINE, CLONIDINE
CYCLOSPORINE, CYCLOSPORINE
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOFETILIDE, DOFETILIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ERRIN, NORETHINDRONE
ERYC, ERYTHROMYCIN
ESTAZOLAM, ESTAZOLAM
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUOROURACIL, FLUOROURACIL
HABITROL, NICOTINE (OTC)
HALOETTE, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LOW-OGESTREL-28, ETHINYL ESTRADIOL
MERCAPTOPURINE, MERCAPTOPURINE
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
RAMELTEON, RAMELTEON

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES SA
REZIPRES, EPHEDRINE HYDROCHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TOBRAMYCIN, TOBRAMYCIN
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIMETHOPRIM, TRIMETHOPRIM
TRIVORA-28, ETHINYL ESTRADIOL

DUCHESNAY

* DUCHESNAY INC
BONJESTA, DOXYLAMINE SUCCINATE
DICLEGIS, DOXYLAMINE SUCCINATE
OSPHENA, OSPEMIFENE

DURAMED PHARMS BARR

* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
AVIANE-28, ETHINYL ESTRADIOL
CRYSELLE, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
ENPRESSE-28, ETHINYL ESTRADIOL
VELIVET, DESOGESTREL

DUSA

* DUSA PHARMACEUTICALS INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

DUTCH OPHTHALMIC

* DUTCH OPHTHALMIC RESEARCH CENTER INTERNATIONAL BV
TISSUEBLUE, BRILLIANT BLUE G

REDDYS

* DOCTOR REDDYS LABORATORIES LTD
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**** E ****

E5 PHARMA INC

* E5 PHARMA INC
DIAZOXIDE, DIAZOXIDE

EAGLE PHARMS

* EAGLE PHARMACEUTICALS INC
BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
PEMFEXY, PEMETREXED
RYANODEX, DANTROLENE SODIUM
VASOPRESSIN, VASOPRESSIN

ECI PHARMS LLC

* ECI PHARMACEUTICALS LLC
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

ECOLAB

* ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

EDENBRIDGE PHARMS

* EDENBRIDGE PHARMACEUTICALS LLC
ALBENDAZOLE, ALBENDAZOLE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CARBIDOPA, CARBIDOPA
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ETHACRYNIC ACID, ETHACRYNIC ACID
IVERMECTIN, IVERMECTIN
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TINIDAZOLE, TINIDAZOLE
YARGESA, MIGLUSTAT

EDISON THERAPS LLC

* EDISON THERAPEUTICS LLC
METHERGINE, METHYLERGONOVINE MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** E **

EIGER BIOPHARMS
* EIGER BIOPHARMACEUTICALS INC
ZOKINVY, LONAFARNIB

EIRGEN
* EIRGEN PHARMA LTD
RAYALDEE, CALCIFEDIOL

EISAI INC
* EISAI INC
ARICEPT, DONEPEZIL HYDROCHLORIDE
BANZEL, RUFINAMIDE
DAYVIGO, LEMBOREXANT
HALAVEN, ERIBULIN MESYLATE
LENVIMA, LENVATINIB MESYLATE

ELI LILLY AND CO
* ELI LILLY AND CO
MOUNJARO, TIRZEPATIDE
OLUMIANT, BARICITINIB
PROZAC, FLUOXETINE HYDROCHLORIDE
REYVOW, LASMIDITAN SUCCINATE
VERZENIO, ABEMACICLIB
ZEPBOUND, TIRZEPATIDE

ELI LILLY CO
* ELI LILLY CO
ADCIRCA, TADALAFIL

ELITE LABS
* ELITE LABORATORIES INC
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

ELITE LABS INC
* ELITE LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
DANTROLENE SODIUM, DANTROLENE SODIUM
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
ISRADIPINE, ISRADIPINE
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

ELITE PHARM SOLUTION
* ELITE PHARMACEUTICAL SOLUTION INC
NIFEDIPINE, NIFEDIPINE

ELYSIUM
* ELYSIUM PHARMACEUTICALS LTD
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE

EMD SERONO INC
* EMD SERONO INC
CETROTIDE, CETRORELIX ACETATE
MAVENCLAD, CLADRIBINE
TEPMETKO, TEPOTINIB HYDROCHLORIDE

EMED MEDCL
* EMED MEDICAL CO LLC
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

EMERGENT
* EMERGENT OPERATIONS IRELAND LTD
NARCAN, NALOXONE HYDROCHLORIDE (OTC)

EMERGENT BIODEFENSE
* EMERGENT BIODEFENSE OPERATIONS LANSING INC
TEMBEXA, BRINCIDOFOVIR
* EMERGENT BIODEFENSE OPERATIONS LANSING LLC
TEMBEXA, BRINCIDOFOVIR

EMMAUS MEDCL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EMMAUS MEDICAL INC
ENDARI, L-GLUTAMINE

ENCUBE

* ENCUBE ETHICALS PRIVATE LTD
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
AZELAIC ACID, AZELAIC ACID
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DAPSONE, DAPSONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
DOCOSANOL, DOCOSANOL (OTC)
FLUOROURACIL, FLUOROURACIL
KETOCONAZOLE, KETOCONAZOLE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
MESALAMINE, MESALAMINE
METRONIDAZOLE, METRONIDAZOLE
MUPIROCIN, MUPIROCIN CALCIUM
TACROLIMUS, TACROLIMUS
TAVABOROLE, TAVABOROLE
TESTOSTERONE, TESTOSTERONE
TRETINOIN MICROSPHERE, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

ENCUBE ETHICALS

* ENCUBE ETHICALS PVT LTD
ADAPALENE, ADAPALENE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESONIDE, DESONIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
PERMETHRIN, PERMETHRIN

ENDO PHARM

* ENDO PHARMACEUTICAL SOLUTIONS INC
SUPPRELIN LA, HISTRELIN ACETATE
VALSTAR PRESERVATIVE FREE, VALRUBICIN

ENDO PHARMS

* ENDO PHARMACEUTICALS INC
FORTESTA, TESTOSTERONE
FROVA, FROVATRIPTAN SUCCINATE
PERCODAN, ASPIRIN

ENDO PHARMS INC

* ENDO PHARMACEUTICALS INC
AVEED, TESTOSTERONE UNDECANOATE
COLY-MYCIN S, COLISTIN SULFATE
MEGACE ES, MEGESTROL ACETATE
NASCOBAL, CYANOCOBALAMIN

ENTASIS THERAP

* ENTASIS THERAPEUTICS INC
XACDURO (COPACKAGED), DURLOBACTAM SODIUM

EPI HLTH

* EPI HEALTH LLC
CLODERM, CLOCORTOLONE PIVALATE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE

EPIC PHARMA

* EPIC PHARMA LLC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
SULINDAC, SULINDAC
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL

EPIC PHARMA LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EPIC PHARMA LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CILOSTAZOL, CILOSTAZOL
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DESOXIMETASONE, DESOXIMETASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERYTHROMYCIN, ERYTHROMYCIN
ESTRADIOL, ESTRADIOL
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LOVASTATIN, LOVASTATIN
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NIZATIDINE, NIZATIDINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREGABALIN, PREGABALIN
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RIFAMPIN, RIFAMPIN
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SULFADIAZINE, SULFADIAZINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TROPICACYL, TROPICAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EPIC PHARMA LLC
VORICONAZOLE, VORICONAZOLE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

EPIZYME INC

* EPIZYME INC
TAZVERIK, TAZEMETOSTAT HYDROBROMIDE

ESKAYEF

* ESKAYEF PHARMACEUTICALS LTD
PREGABALIN, PREGABALIN

ESPERION THERAPS INC

* ESPERION THERAPEUTICS INC
NEXLETOL, BEMPEDOIC ACID
NEXLIZET, BEMPEDOIC ACID

ESSENTIAL ISOTOPES

* ESSENTIAL ISOTOPES LLC
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ETHYPHARM

* ETHYPHARM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
* ETHYPHARM SA
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM

ETHYPHARM USA CORP

* ETHYPHARM USA CORP
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

ETON

* ETON PHARMACEUTICALS INC
ALKINDI SPRINKLE, HYDROCORTISONE
BETAINE, BETAINE
NITISINONE, NITISINONE

EUGIA PHARMA

* EUGIA PHARMA SPECIALITIES LTD
ACETAMINOPHEN, ACETAMINOPHEN
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
AMPHOTERICIN B, AMPHOTERICIN B
ANASTROZOLE, ANASTROZOLE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZACITIDINE, AZACITIDINE
AZITHROMYCIN, AZITHROMYCIN
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BIVALIRUDIN, BIVALIRUDIN
BORTEZOMIB, BORTEZOMIB
BROMFENAC SODIUM, BROMFENAC SODIUM
BUDESONIDE, BUDESONIDE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CAPECITABINE, CAPECITABINE
CARBOPLATIN, CARBOPLATIN
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DACTINOMYCIN, DACTINOMYCIN
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EUGIA PHARMA SPECIALITIES LTD
DOCETAXEL, DOCETAXEL
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPTIFIBATIDE, EPTIFIBATIDE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ETOMIDATE, ETOMIDATE
EXEMESTANE, EXEMESTANE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
ICATIBANT ACETATE, ICATIBANT ACETATE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
LENALIDOMIDE, LENALIDOMIDE
LETROZOLE, LETROZOLE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIFITEGRAST, LIFITEGRAST
LINEZOLID, LINEZOLID
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEROPENEM, MEROPENEM
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
OXALIPLATIN, OXALIPLATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PLERIXAFOR, PLERIXAFOR
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POSACONAZOLE, POSACONAZOLE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROGESTERONE, PROGESTERONE
REGADENOSON, REGADENOSON
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EUGIA PHARMA SPECIALITIES LTD
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIROFIBAN HYDROCHLORIDE, TIROFIBAN HYDROCHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VASOPRESSIN, VASOPRESSIN
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

EUGIA PHARMA SPECLTS

* EUGIA PHARMA SPECIALITIES LTD
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
OXACILLIN SODIUM, OXACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

EUROCEPT PHARMS

* EUROCEPT PHARMACEUTICALS
PASER, AMINOSALICYLIC ACID

EUROHLTH INTL SARL

* EUROHEALTH INTERNATIONAL SARL
AZACITIDINE, AZACITIDINE

EVEREST LIFE SCI

* EVEREST LIFE SCIENCES LLC
DAPSONE, DAPSONE

EVOFEM INC

* EVOFEM INC
PHEXXI, CITRIC ACID

EVOKE PHARMA INC

* EVOKE PHARMA INC
GIMOTI, METOCLOPRAMIDE HYDROCHLORIDE

EVUS

* EVUS HEALTH SOLUTIONS LLC
NITROMIST, NITROGLYCERIN

EXELA PHARMA

* EXELA PHARMA SCIENCES LLC
ACETYLCYSTEINE, ACETYLCYSTEINE
AKOVAZ, EPHEDRINE SULFATE
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
CAFFEINE CITRATE, CAFFEINE CITRATE
CUPRIC CHLORIDE, CUPRIC CHLORIDE
ELCYS, CYSTEINE HYDROCHLORIDE
GANZYK-RTU, GANCICLOVIR
GLYRX-PF, GLYCOPYRROLATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MIDAZOLAM IN 0.8% SODIUM CHLORIDE, MIDAZOLAM
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
POTASSIUM ACETATE, POTASSIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZINC CHLORIDE, ZINC CHLORIDE

EXELA PHARMA SCIENCE

* EXELA PHARMA SCIENCES
CAFFEINE CITRATE, CAFFEINE CITRATE

EXELIXIS

* EXELIXIS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EXELIXIS INC
COMETRIQ, CABOZANTINIB S-MALATE

EXELIXIS INC
* EXELIXIS INC
CABOMETYX, CABOZANTINIB S-MALATE

EXELTIS USA INC
* EXELTIS USA INC
SLYND, DROSPIRENONE
TYBLUME, ETHINYL ESTRADIOL

EYENOVIA
* EYENOVIA INC
MYDCOMBI, PHENYLEPHRINE HYDROCHLORIDE

EYEPOINT PHARMS
* EYEPOINT PHARMACEUTICALS INC
DEXYCU KIT, DEXAMETHASONE

EYWA
* EYWA PHARMA INC
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
NIACIN, NIACIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
VALPROIC ACID, VALPROIC ACID

EYWA PHARMA
* EYWA PHARMA PTE LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
BACLOFEN, BACLOFEN
URSODIOL, URSODIOL

EZRA VENTURES
* EZRA VENTURES LLC
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE

LILLY
* ELI LILLY AND CO
ALIMTA, PEMETREXED DISODIUM
CIALIS, TADALAFIL
CYMBALTA, DULOXETINE HYDROCHLORIDE
EVISTA, RALOXIFENE HYDROCHLORIDE
FORTEO, TERIPARATIDE
STRATTERA, ATOMOXETINE HYDROCHLORIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE

**** F ****

FABRE KRAMER
* FABRE KRAMER PHARMACEUTICALS INC
EXXUA, GEPIRONE HYDROCHLORIDE

FDC LTD
* FDC LTD
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
LATANOPROST, LATANOPROST
OFLOXACIN, OFLOXACIN
TIMOLOL MALEATE, TIMOLOL MALEATE

FDN CONSUMER
* FOUNDATION CONSUMER BRANDS LLC
ALAVERT, LORATADINE (OTC)
* FOUNDATION CONSUMER HEALTHCARE LLC
PLAN B ONE-STEP, LEVONORGESTREL (OTC)

FEINSTEIN
* FEINSTEIN INSTITUTE MEDICAL RESEARCH
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUORODOPA F18, FLUORODOPA F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

FENNEC PHARMS INC
* FENNEC PHARMACEUTICALS INC
PEDMARK, SODIUM THIOSULFATE

FERA PHARMS LLC
* FERA PHARMACEUTICALS LLC
GENTAMICIN SULFATE, GENTAMICIN SULFATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE

FERRER INTERNACIONAL
* FERRER INTERNACIONAL SA
XEPI, OZENOXACIN

FERRING
* FERRING PHARMACEUTICALS INC
ENDOMETRIN, PROGESTERONE
FIRMAGON, DEGARELIX ACETATE

FERRING PHARMS INC
* FERRING PHARMACEUTICALS INC
CERVIDIL, DINOPROSTONE
CLENPIQ, CITRIC ACID
DDAVP, DESMOPRESSIN ACETATE

FLAMINGO PHARMS
* FLAMINGO PHARMACEUTICALS LTD
METRONIDAZOLE, METRONIDAZOLE
PIROXICAM, PIROXICAM

FLORIDA
* FLORIDA PHARMACEUTICAL PRODUCTS LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
SUMATRIPTAN, SUMATRIPTAN

FOLDRX PHARMS
* FOLDRX PHARMACEUTICALS LLC A WHOLLY OWNED SUB OF PFIZER INC
VYNDAMAX, TAFAMIDIS
VYNDAQEL, TAFAMIDIS MEGLUMINE

FOSUN PHARMA
* FOSUN PHARMA USA INC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

FOUGERA PHARMS
* FOUGERA PHARMACEUTICALS INC
ADAPALENE, ADAPALENE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE, HYDROCORTISONE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN, NYSTATIN
OXISTAT, OXICONAZOLE NITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FOUGERA PHARMACEUTICALS INC
PREDNICARBATE, PREDNICARBATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

FOUGERA PHARMS INC

* FOUGERA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
TACROLIMUS, TACROLIMUS
TERCONAZOLE, TERCONAZOLE

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
* FRESENIUS KABI IPSUM SRL
NAFCILLIN SODIUM, NAFCILLIN SODIUM

FRESENIUS KABI

* FRESENIUS KABI ANTI INFECTIVES SRL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
* FRESENIUS KABI AUSTRIA GMBH
LACTULOSE, LACTULOSE

FRESENIUS KABI USA

* FRESENIUS KABI USA LLC
ACETAMINOPHEN, ACETAMINOPHEN
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
AZTREONAM, AZTREONAM
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BORTEZOMIB, BORTEZOMIB
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CARBOPLATIN, CARBOPLATIN
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CEFOTETAN, CEFOTETAN DISODIUM
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FRESENIUS KABI USA LLC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAPTOMYCIN, DAPTOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPRIVAN, PROPOFOL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FULVESTRANT, FULVESTRANT
FUROSEMIDE, FUROSEMIDE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
ICATIBANT ACETATE, ICATIBANT ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FRESENIUS KABI USA LLC
IFOSFAMIDE, IFOSFAMIDE
INDOMETHACIN, INDOMETHACIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACOSAMIDE, LACOSAMIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANNITOL 25%, MANNITOL
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5, MAGNESIUM CHLORIDE
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4, MAGNESIUM CHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OMEGAVEN, FISH OIL TRIGLYCERIDES
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POSACONAZOLE, POSACONAZOLE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FRESENIUS KABI USA LLC
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
POTASSIUM CHLORIDE 10MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
POTASSIUM CHLORIDE 20MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
POTASSIUM CHLORIDE 40MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROMIDEPSIN, ROMIDEPSIN
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SMOFLIPID 20%, FISH OIL
SODIUM ACETATE, SODIUM ACETATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM PHOSPHATES, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
VALPROATE SODIUM, VALPROATE SODIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VASOPRESSIN, VASOPRESSIN
VIBISONE, CYANOCOBALAMIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
ZINC SULFATE, ZINC SULFATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

FRESENIUS MEDCL

* FRESENIUS MEDICAL CARE NORTH AMERICA
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FRESENIUS MEDICAL CARE NORTH AMERICA
PHOSLO GELCAPS, CALCIUM ACETATE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

** G **

G1 THERAP
* G1 THERAPEUTICS INC
COSELA, TRILACICLIB DIHYDROCHLORIDE

GALDERMA LABS
* GALDERMA LABORATORIES INC
CLOBEX, CLOBETASOL PROPIONATE
EPIDUO FORTE, ADAPALENE

GALDERMA LABS LP
* GALDERMA LABORATORIES L P
CLOBEX, CLOBETASOL PROPIONATE
* GALDERMA LABORATORIES LP
AKLIEF, TRIFAROTENE
CAPEX, FLUOCINOLONE ACETONIDE
CLOBEX, CLOBETASOL PROPIONATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
DIFFERIN, ADAPALENE (OTC)
EPIDUO, ADAPALENE
EPSOLAY, BENZOYL PEROXIDE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
MIRVASO, BRIMONIDINE TARTRATE
ORACEA, DOXYCYCLINE
SOOLANTRA, IVERMECTIN
TRI-LUMA, FLUOCINOLONE ACETONIDE
TWYNEO, BENZOYL PEROXIDE
VECTICAL, CALCITRIOL

GALT PHARMS
* GALT PHARMACEUTICALS LLC
DORAL, QUAZEPAM
ORAVIG, MICONAZOLE
ORPHENGESIC FORTE, ASPIRIN
ORPHENGESIC, ASPIRIN

GE HEALTHCARE
* GE HEALTHCARE
ADREVIEW, IOBENGUANE SULFATE I-123
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CERIANNA, FLUOROESTRADIOL F-18
CLARISCAN, GADOTERATE MEGLUMINE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VIZAMYL, FLUTEMETAMOL F-18

GE HLTHCARE INC
* GE HEALTHCARE INC
DATSCAN, IOFLUPANE I-123

GENBIOPRO

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

* GENBIOPRO INC
MIFEPRISTONE, MIFEPRISTONE

GENENTECH

* GENENTECH INC
ERIVEDGE, VISMODEGIB

GENENTECH INC

* GENENTECH INC
COTELLIC, COBIMETINIB FUMARATE
ESBRIET, PIRFENIDONE
EVRYSDI, RISDIPLAM
GAVRETO, PRALSETINIB
ROZLYTREK, ENTRECTINIB
XOFLUZA, BALOXAVIR MARBOXIL

GENERICS

* GENERICS INTERNATIONAL VENTURES ENTERPRISES LLC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

GENEYORK PHARMS

* GENEYORK PHARMACEUTICALS GROUP LLC
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
PREDNISONE, PREDNISONE

GENSCO

* GENSCO LABORATORIES LLC DBA GENSCO PHARMA
RIZAFILM, RIZATRIPTAN BENZOATE

GENUS

* GENUS LIFESCIENCES INC
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
NYSTATIN, NYSTATIN

GENUS LIFESCIENCES

* GENUS LIFE SCIENCES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMCINONIDE, AMCINONIDE
GOPRELTO, COCAINE HYDROCHLORIDE
LEVOLET, LEVOTHYROXINE SODIUM **
MONOKET, ISOSORBIDE MONONITRATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

GENZYME

* GENZYME CORP
CLOLAR, CLOFARABINE
MOZOBIL, PLERIXAFOR
RENAGEL, SEVELAMER HYDROCHLORIDE
RENVELA, SEVELAMER CARBONATE

GENZYME CORP

* GENZYME CORP
CAPRELSA, VANDETANIB
CERDELGA, ELIGLUSTAT TARTRATE

GILEAD

* GILEAD SCIENCES INC
CAYSTON, AZTREONAM
EMTRIVA, EMTRICITABINE
HEPSERA, ADEFOVIR DIPIVOXIL
LETAIRIS, AMBRISENTAN
TRUVADA, EMTRICITABINE

GILEAD SCIENCES

* GILEAD SCIENCES LLC
ATRIPLA, EFAVIRENZ

GILEAD SCIENCES INC

* GILEAD SCIENCES INC
BIKTARVY, BICTEGRAVIR SODIUM
COMPLERA, EMTRICITABINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GILEAD SCIENCES INC
DESCOVY, EMTRICITABINE
EPCLUSA, SOFOSBUVIR
GENVOYA, COBICISTAT
HARVONI, LEDIPASVIR
ODEFSEY, EMTRICITABINE
SOVALDI, SOFOSBUVIR
STRIBILD, COBICISTAT
SUNLENCA, LENACAPAVIR SODIUM
TYBOST, COBICISTAT
VEKLURY, REMDESIVIR
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VOSEVI, SOFOSBUVIR
ZYDELIG, IDELALISIB

GISKIT

* GISKIT PHARMA BV
EXEM FOAM KIT, AIR POLYMER-TYPE A

GLAND

* GLAND PHARMA LTD
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
DECITABINE, DECITABINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
MEROPENEM, MEROPENEM
MESNA, MESNA
OXALIPLATIN, OXALIPLATIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

GLAND PHARMA LTD

* GLAND PHARMA LTD
ADENOSINE, ADENOSINE
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARGATROBAN, ARGATROBAN
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
BUMETANIDE, BUMETANIDE
CALCITRIOL, CALCITRIOL
CARBOPLATIN, CARBOPLATIN
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CISPLATIN, CISPLATIN
CLOFARABINE, CLOFARABINE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYTARABINE, CYTARABINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DOCETAXEL, DOCETAXEL
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAND PHARMA LTD
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ETOMIDATE, ETOMIDATE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FOMEPIZOLE, FOMEPIZOLE
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GANIRELIX ACETATE, GANIRELIX ACETATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACOSAMIDE, LACOSAMIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LINCOMYCIN HYDROCHLORIDE, LINCOMYCIN HYDROCHLORIDE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NELARABINE, NELARABINE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
POSACONAZOLE, POSACONAZOLE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
REGADENOSON, REGADENOSON
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TEMSIROLIMUS, TEMSIROLIMUS
THIOTEPA, THIOTEPA
TIMOLOL MALEATE, TIMOLOL MALEATE
TIROFIBAN HYDROCHLORIDE, TIROFIBAN HYDROCHLORIDE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZINC SULFATE, ZINC SULFATE
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAND PHARMA LTD
ZOLEDRONIC, ZOLEDRONIC ACID

GLAUKOS

* GLAUKOS CORP
IDOSE TR, TRAVOPROST
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE

GLAXO GRP ENGLAND

* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE

GLAXO GRP LTD

* GLAXO GROUP LTD DBA GLAXOSMITHKLINE
FLOVENT HFA, FLUTICASONE PROPIONATE
* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
BREO ELLIPTA, FLUTICASONE FUROATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE

GLAXOSMITHKLINE

* GLAXOSMITHKLINE
ABREVA, DOCOSANOL (OTC)
EPIVIR-HBV, LAMIVUDINE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
RELENZA, ZANAMIVIR
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VERAMYST, FLUTICASONE FUROATE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
* GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL DUAL ACTION WITH ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
AXID AR, NIZATIDINE (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
INFANT'S ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
* GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ARNUITY ELLIPTA, FLUTICASONE FUROATE
KRINTAFEL, TAFENOQUINE SUCCINATE
TRELEGY ELLIPTA, FLUTICASONE FUROATE
* GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
SEREVENT, SALMETEROL XINAFOATE
VENTOLIN HFA, ALBUTEROL SULFATE
* GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
JESDUVROQ, DAPRODUSTAT
* GLAXOSMITHKLINE LLC
OJJAARA, MOMELOTINIB DIHYDROCHLORIDE
ZEJULA, NIRAPARIB TOSYLATE

GLAXOSMITHKLINE CONS

* GLAXOSMITHKLINE CONSUMER HEALTHCARE
ALLI, ORLISTAT (OTC)
EXCEDRIN (MIGRAINE RELIEF), ACETAMINOPHEN (OTC)
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
VOLTAREN ARTHRITIS PAIN, DICLOFENAC SODIUM (OTC)

GLAXOSMITHKLINE LLC

* GLAXOSMITHKLINE LLC
FLOLAN, EPOPROSTENOL SODIUM
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
MEPRON, ATOVAQUONE

GLENMARK GENERICS

* GLENMARK GENERICS INC USA
ADAPALENE, ADAPALENE (OTC)
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
IMIQUIMOD, IMIQUIMOD
MOMETASONE FUROATE, MOMETASONE FUROATE
NIZATIDINE, NIZATIDINE
ZONISAMIDE, ZONISAMIDE
* GLENMARK GENERICS LIMITED
BRIELLYN, ETHINYL ESTRADIOL
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
* GLENMARK GENERICS LTD
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
ASHLYNA, ETHINYL ESTRADIOL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
CARVEDILOL, CARVEDILOL
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESOXIMETASONE, DESOXIMETASONE
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
HEATHER, NORETHINDRONE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LITHIUM CARBONATE, LITHIUM CARBONATE
MARLISSA, ETHINYL ESTRADIOL
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK GENERICS LTD
NAPROXEN, NAPROXEN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
URSODIOL, URSODIOL
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VIORELE, DESOGESTREL
ZOLMITRIPTAN, ZOLMITRIPTAN
* GLENMARK GENERICS LTD INDIA
INDOMETHACIN, INDOMETHACIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

GLENMARK PHARMS

* GLENMARK PHARMACEUTICALS INC
TERIFLUNOMIDE, TERIFLUNOMIDE
* GLENMARK PHARMACEUTICALS INC USA
CICLOPIROX, CICLOPIROX
CLOTRIMAZOLE, CLOTRIMAZOLE
MUPIROCIN, MUPIROCIN
* GLENMARK PHARMACEUTICALS LTD
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
* GLENMARK PHARMACEUTICALS SA
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ATOVAQUONE, ATOVAQUONE
AZELAIC ACID, AZELAIC ACID
CALCIPOTRIENE, CALCIPOTRIENE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESONIDE, DESONIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
HAILEY 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1.5/30, ETHINYL ESTRADIOL
LINEZOLID, LINEZOLID
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

GLENMARK PHARMS INC

* GLENMARK PHARMACEUTICALS INC USA
CALCIPOTRIENE, CALCIPOTRIENE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
FULVESTRANT, FULVESTRANT
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LITHIUM CARBONATE, LITHIUM CARBONATE
MUPIROCIN, MUPIROCIN CALCIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

GLENMARK PHARMS LTD

* GLENMARK PHARMACEUTICALS LTD
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK PHARMACEUTICALS LTD
APREMILAST, APREMILAST
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTRADIOL, ESTRADIOL
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
GABAPENTIN, GABAPENTIN
HAILEY 24 FE, ETHINYL ESTRADIOL
HAILEY FE 1/20, ETHINYL ESTRADIOL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
INDOMETHACIN, INDOMETHACIN
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LIDOCAINE, LIDOCAINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN SODIUM, NAPROXEN SODIUM
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OXCARBAZEPINE, OXCARBAZEPINE
PIMECROLIMUS, PIMECROLIMUS
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
RUFINAMIDE, RUFINAMIDE
SAXAGLIPTIN, SAXAGLIPTIN HYDROCHLORIDE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SIROLIMUS, SIROLIMUS
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
TACROLIMUS, TACROLIMUS
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
THEOPHYLLINE, THEOPHYLLINE
TOPIRAMATE, TOPIRAMATE
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK PHARMACEUTICALS LTD
VORICONAZOLE, VORICONAZOLE

GLENMARK PHARMS SA

* GLENMARK PHARMACEUTICALS SA SWITZERLAND
ACYCLOVIR, ACYCLOVIR
APREPITANT, APREPITANT
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
NITROGLYCERIN, NITROGLYCERIN

GLENMARK SPECIALTY

* GLENMARK SPECIALTY SA
RYALTRIS, MOMETASONE FUROATE

GLOBAL BLOOD THERAPS

* GLOBAL BLOOD THERAPEUTICS INC
OXBRYTA, VOXELOTOR

GLW

* GLW PHARMA GMBH
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS

GRANULATION TECH

* GRANULATION TECHNOLOGY INC
PREDNISONE, PREDNISONE

GRANULES

* GRANULES INDIA LTD
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GABAPENTIN, GABAPENTIN
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
NAPROXEN, NAPROXEN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

* GRANULES PHARMACEUTICALS INC
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
COLCHICINE, COLCHICINE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOFETILIDE, DOFETILIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
PENICILLAMINE, PENICILLAMINE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
RAMELTEON, RAMELTEON
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

GRANULES INDIA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

* GRANULES INDIA LTD
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GRAVITI PHARMS

* GRAVITI PHARMACEUTICALS INC
GABAPENTIN, GABAPENTIN
MONTELUKAST SODIUM, MONTELUKAST SODIUM
* GRAVITI PHARMACEUTICALS PRIVATE LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BACLOFEN, BACLOFEN
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FUROSEMIDE, FUROSEMIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE

GUANGZHOU NOVAKEN

* GUANGZHOU NOVAKEN PHARMACEUTICAL CO LTD
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

GUARDIAN DRUG

* GUARDIAN DRUG CO
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)

GUERBET

* GUERBET
ELUCIREM, GADOPICLENOL
* GUERBET LLC
DOTAREM, GADOTERATE MEGLUMINE
LIPIODOL, ETHIODIZED OIL

** H **

HAEMONETICS

* HAEMONETICS CORP
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

HAINAN POLY

* HAINAN POLY PHARM CO LTD
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AZITHROMYCIN, AZITHROMYCIN
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
FLUCONAZOLE, FLUCONAZOLE
IOPAMIDOL, IOPAMIDOL
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

HAINAN POLY PHARM

* HAINAN POLY PHARMACEUTICAL CO LTD
DAPTOMYCIN, DAPTOMYCIN
GADOBUTROL, GADOBUTROL
LEVETIRACETAM, LEVETIRACETAM
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

HALOCARBON PRODS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE
SEVOFLURANE, SEVOFLURANE

HANGZHOU BINJIANG
* HANGZHOU MINSHENG BINJIANG PHARMACEUTICAL CO LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM

HANGZHOU ZHONGMEI
* HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD
DAPTOMYCIN, DAPTOMYCIN
TACROLIMUS, TACROLIMUS

HARM REDUCTION THERP
* HARM REDUCTION THERAPEUTICS INC
RIVIVE, NALOXONE HYDROCHLORIDE (OTC)

HARMAN FINOCHEM
* HARMAN FINOCHEM LTD
ALLOPURINOL, ALLOPURINOL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

HARMONY
* HARMONY BIOSCIENCES LLC
WAKIX, PITOLISANT HYDROCHLORIDE

HARROW EYE
* HARROW EYE LLC
FLAREX, FLUOROMETHOLONE ACETATE
IHEEZO, CHLOROPROCAINE HYDROCHLORIDE
ILEVRO, NEPAFENAC
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
NATACYN, NATAMYCIN
NEVANAC, NEPAFENAC
TOBRADEX ST, DEXAMETHASONE
TRIESENCE, TRIAMCINOLONE ACETONIDE
VERKAZIA, CYCLOSPORINE
VEVYE, CYCLOSPORINE
ZERVIATE, CETIRIZINE HYDROCHLORIDE

HBT LABS INC
* HBT LABS INC
FULVESTRANT, FULVESTRANT

HEC PHARM
* HEC PHARM USA INC
CLARITHROMYCIN, CLARITHROMYCIN
LEVOFLOXACIN, LEVOFLOXACIN
OLANZAPINE, OLANZAPINE
PRASUGREL, PRASUGREL HYDROCHLORIDE

HEC PHARM CO LTD
* HEC PHARM CO LTD
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE

HELSINN
* HELSINN BIREX PHARMACEUTICALS LTD
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE

HELSINN HLTHCARE
* HELSINN HEALTHCARE SA
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT

HERITAGE LIFE
* HERITAGE LIFE SCIENCES BARBADOS INC
CLOZARIL, CLOZAPINE

HERITAGE PHARMA
* HERITAGE PHARMA LABS INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAZOLAMIDE, ACETAZOLAMIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HERITAGE PHARMA LABS INC
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIFLUNISAL, DIFLUNISAL
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHIMAZOLE, METHIMAZOLE
NIFEDIPINE, NIFEDIPINE

HERITAGE PHARMA AVET

* HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INC
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

HERITAGE PHARMS

* HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
FELODIPINE, FELODIPINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE, GLYBURIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LEFLUNOMIDE, LEFLUNOMIDE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
NYSTATIN, NYSTATIN
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

HERITAGE PHARMS INC

* HERITAGE PHARMACEUTICALS INC
CALCIUM ACETATE, CALCIUM ACETATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

HERITAGE PHARMS LABS

* HERITAGE PHARMACEUTICALS LABS INC DBA AVET PHARMACEUTICALS LABS INC
BENZONATATE, BENZONATATE

HERON THERAPS INC

* HERON THERAPEUTICS INC
APONVIE, APREPITANT
CINVANTI, APREPITANT
SUSTOL, GRANISETRON
ZYNRELEF KIT, BUPIVACAINE

HETERO LABS

* HETERO LABS LTD
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LINEZOLID, LINEZOLID

HETERO LABS LTD III

* HETERO LABS LTD UNIT III

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HETERO LABS LTD UNIT III
ABACAVIR SULFATE, ABACAVIR SULFATE
ACYCLOVIR, ACYCLOVIR
ARIPIPRAZOLE, ARIPIPRAZOLE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATOVAQUONE, ATOVAQUONE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOBAZAM, CLOBAZAM
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DARUNAVIR, DARUNAVIR
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
EZETIMIBE, EZETIMIBE
FENOFIBRATE, FENOFIBRATE
FINASTERIDE, FINASTERIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACOSAMIDE, LACOSAMIDE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LEVOCETIRIZINE HYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LOPINAVIR AND RITONAVIR, LOPINAVIR
LORATADINE, LORATADINE (OTC)
MARAVIROC, MARAVIROC
METHOCARBAMOL, METHOCARBAMOL
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NAPROXEN, NAPROXEN
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXCARBAZEPINE, OXCARBAZEPINE
POSACONAZOLE, POSACONAZOLE
PREGABALIN, PREGABALIN
RANOLAZINE, RANOLAZINE
RITONAVIR, RITONAVIR
ROFLUMILAST, ROFLUMILAST
RUFINAMIDE, RUFINAMIDE
SIMVASTATIN, SIMVASTATIN
TADALAFIL, TADALAFIL
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TORSEMIDE, TORSEMIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD V

* HETERO LABS LTD UNIT V
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
APIXABAN, APIXABAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HETERO LABS LTD UNIT V
ARIPIPRAZOLE, ARIPIPRAZOLE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BREXPIPRAZOLE, BREXPIPRAZOLE
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
COLCHICINE, COLCHICINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
ENTECAVIR, ENTECAVIR
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ESZOPICLONE, ESZOPICLONE
FAMCICLOVIR, FAMCICLOVIR
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
IRBESARTAN, IRBESARTAN
LACOSAMIDE, LACOSAMIDE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LENALIDOMIDE, LENALIDOMIDE
LEVOFLOXACIN, LEVOFLOXACIN
LINEZOLID, LINEZOLID
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIRFENIDONE, PIRFENIDONE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID, CITRIC ACID
TELMISARTAN, TELMISARTAN
TERIFLUNOMIDE, TERIFLUNOMIDE
TETRABENAZINE, TETRABENAZINE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOLVAPTAN, TOLVAPTAN
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN

HEYL CHEMISCH

* HEYL CHEMISCH PHARMAZEUTISHE FABRIK
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HIKMA

* HIKMA FARMACEUTICA PORTUGAL SA
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
DOCETAXEL, DOCETAXEL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ETOMIDATE, ETOMIDATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HIKMA FARMACEUTICA PORTUGAL SA
  VECURONIUM BROMIDE, VECURONIUM BROMIDE
* HIKMA PHARMACEUTICALS
  AMOXICILLIN, AMOXICILLIN
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
* HIKMA PHARMACEUTICALS INTERNATIONAL LTD
  CODEINE SULFATE, CODEINE SULFATE
  DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
  DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
  DIGOXIN, DIGOXIN
  FUROSEMIDE, FUROSEMIDE
  GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
  MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
  MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
  MORPHINE SULFATE, MORPHINE SULFATE
  RUFINAMIDE, RUFINAMIDE
  STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
  SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
* HIKMA PHARMACEUTICALS LLC
  ABIRATERONE ACETATE, ABIRATERONE ACETATE
  DANTROLENE SODIUM, DANTROLENE SODIUM
  DOXERCALCIFEROL, DOXERCALCIFEROL
  PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
* HIKMA PHARMACEUTICALS USA INC
  ACARBOSE, ACARBOSE
  ACETAMINOPHEN, ACETAMINOPHEN
  ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
  ACYCLOVIR, ACYCLOVIR
  ADENOSINE, ADENOSINE
  ALBUTEROL SULFATE, ALBUTEROL SULFATE
  ALENDRONATE SODIUM, ALENDRONATE SODIUM
  ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
  ALPRAZOLAM, ALPRAZOLAM
  ALPROSTADIL, ALPROSTADIL
  ALVIMOPAN, ALVIMOPAN
  AMICAR, AMINOCAPROIC ACID
  AMIKACIN SULFATE, AMIKACIN SULFATE
  AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
  AMRINONE LACTATE, INAMRINONE LACTATE
  ATIVAN, LORAZEPAM
  ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
  ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
  ATROPINE SULFATE, ATROPINE SULFATE
  AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
  AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
  BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
  BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  BEXAROTENE, BEXAROTENE
  BIMATOPROST, BIMATOPROST
  BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
  BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
  BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
  BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
  BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
  BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
  CAFCIT, CAFFEINE CITRATE
  CALCIPOTRIENE, CALCIPOTRIENE
  CALCITRIOL, CALCITRIOL
  CALCIUM ACETATE, CALCIUM ACETATE
  CAPECITABINE, CAPECITABINE
  CARBOPLATIN, CARBOPLATIN
  CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
  CEFOXITIN, CEFOXITIN SODIUM
  CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
  CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HIKMA PHARMACEUTICALS USA INC
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CICLOPIROX, CICLOPIROX
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COMBOGESIC IV, ACETAMINOPHEN
CORMAX, CLOBETASOL PROPIONATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFERIPRONE, DEFERIPRONE
DESONIDE, DESONIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DRONABINOL, DRONABINOL
DURAMORPH PF, MORPHINE SULFATE
EMBELINE, CLOBETASOL PROPIONATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
EVEROLIMUS, EVEROLIMUS
EXEMESTANE, EXEMESTANE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENTANYL CITRATE, FENTANYL CITRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HIKMA PHARMACEUTICALS USA INC
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GATIFLOXACIN, GATIFLOXACIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMMPHENTIV, PHENYLEPHRINE HYDROCHLORIDE
INFUMORPH, MORPHINE SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KLOXXADO, NALOXONE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN DEXTROSE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACTULOSE, LACTULOSE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOCARNITINE, LEVOCARNITINE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LITHIUM CARBONATE, LITHIUM CARBONATE
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM, LORAZEPAM
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MERCAPTOPURINE, MERCAPTOPURINE
MESNA, MESNA
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM IN 0.9% SODIUM CHLORIDE, MIDAZOLAM
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA PHARMACEUTICALS USA INC
OFLOXACIN, OFLOXACIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
POSACONAZOLE, POSACONAZOLE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROPOFOL, PROPOFOL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
PYRAZINAMIDE, PYRAZINAMIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
REGADENOSON, REGADENOSON
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
ROBAXIN, METHOCARBAMOL
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
RUFINAMIDE, RUFINAMIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
THIOTEPA, THIOTEPA
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TORSEMIDE, TORSEMIDE
TRIAZOLAM, TRIAZOLAM
VALPROIC ACID, VALPROIC ACID
VALRUBICIN, VALRUBICIN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VIGABATRIN, VIGABATRIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VOSOL, ACETIC ACID, GLACIAL
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
ZALEPLON, ZALEPLON

HIKMA FARMACEUTICA

* HIKMA FARMACEUTICA (PORTUGAL) SA
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CEFOXITIN, CEFOXITIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HIKMA FARMACEUTICA (PORTUGAL) SA
CEFTRIAXONE, CEFTRIAXONE SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUMAZENIL, FLUMAZENIL
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
VALPROATE SODIUM, VALPROATE SODIUM
* HIKMA FARMACEUTICA PORTUGAL LDA
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
* HIKMA FARMACEUTICA PORTUGAL SA
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
* HIKMA FARMACEUTICA SA
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HIKMA INTL PHARMS

* HIKMA INTERNATIONAL PHARMACEUTICALS LLC
CAPTOPRIL, CAPTOPRIL
DIGOXIN, DIGOXIN
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
MITIGARE, COLCHICINE
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

HIKMA PHARM CO LTD

* HIKMA PHARM CO LTD
ARGATROBAN, ARGATROBAN

HIKMA PHARMS

* HIKMA PHARMACEUTICALS
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
RIFAMPIN, RIFAMPIN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
* HIKMA PHARMACEUTICALS CO LTD
PARICALCITOL, PARICALCITOL

HILL DERMAC

* HILL DERMACEUTICALS INC
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMOTIC, FLUOCINOLONE ACETONIDE

HILL DERMACEUTICALS

* HILL DERMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HILL DERMACEUTICALS INC
TOLAK, FLUOROURACIL

HISAMITSU

* HISAMITSU PHARMACEUTICAL CO INC
SECUADO, ASENAPINE

HISAMITSU PHARM CO

* HISAMITSU PHARMACEUTICAL CO INC
SALONPAS, MENTHOL (OTC)

HISUN PHARM HANGZHOU

* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
CLADRIBINE, CLADRIBINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
OLANZAPINE, OLANZAPINE
* HISUN PHARMACEUTICAL HANGZHOU CO LTD
DACTINOMYCIN, DACTINOMYCIN
DAPTOMYCIN, DAPTOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
TICAGRELOR, TICAGRELOR

HLTHCARE

* HEALTHCARE PHARMACEUTICALS LTD
ATENOLOL, ATENOLOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE

HOFFMANN LA ROCHE

* HOFFMANN LA ROCHE INC
ZELBORAF, VEMURAFENIB

HOFFMANN-LA ROCHE

* HOFFMANN-LA ROCHE INC
ALECENSA, ALECTINIB HYDROCHLORIDE

HONG KONG

* HONG KONG KING FRIEND INDUSTRIAL CO LTD
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM

HOPE PHARMS

* HOPE PHARMACEUTICALS
NITHIODOTE, SODIUM NITRITE
SODIUM NITRITE, SODIUM NITRITE
SODIUM THIOSULFATE, SODIUM THIOSULFATE

HORIZON

* HORIZON MEDICINES LLC
DUEXIS, FAMOTIDINE
* HORIZON THERAPEUTICS IRELAND DAC
PENNSAID, DICLOFENAC SODIUM
* HORIZON THERAPEUTICS USA INC
PROCYSBI, CYSTEAMINE BITARTRATE
RAYOS, PREDNISONE

HORIZON THERAP US

* HORIZON THERAPEUTICS US HOLDING LLC
BUPHENYL, SODIUM PHENYLBUTYRATE
RAVICTI, GLYCEROL PHENYLBUTYRATE

HOSPIRA

* HOSPIRA INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ADENOSINE, ADENOSINE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
AMIDATE, ETOMIDATE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
ARGATROBAN, ARGATROBAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC
ATROPINE SULFATE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
AZTREONAM, AZTREONAM
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BORTEZOMIB, BORTEZOMIB
BUMETANIDE, BUMETANIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUSULFAN, BUSULFAN
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CORLOPAM, FENOLDOPAM MESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAPTOMYCIN, DAPTOMYCIN
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEXTROSE 25%, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50%, DEXTROSE
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
ENALAPRILAT, ENALAPRILAT
EPINEPHRINE, EPINEPHRINE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOPHED, NOREPINEPHRINE BITARTRATE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA INC

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LORAZEPAM, LORAZEPAM
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 25%, MANNITOL
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PARICALCITOL, PARICALCITOL
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PEMETREXED DITROMETHAMINE, PEMETREXED DITROMETHAMINE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROPOFOL, PROPOFOL
QUELICIN, SUCCINYLCHOLINE CHLORIDE
REGADENOSON, REGADENOSON
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUFENTANIL CITRATE, SUFENTANIL CITRATE
TAZICEF, CEFTAZIDIME
THAM, TROMETHAMINE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VITAMIN K1, PHYTONADIONE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC
ZOLEDRONIC ACID, ZOLEDRONIC ACID
* HOSPIRA WORLDWIDE, INC
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

HOSPIRA INC

* HOSPIRA INC
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
DOCETAXEL, DOCETAXEL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
MORPHINE SULFATE, MORPHINE SULFATE
NIPENT, PENTOSTATIN
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HOSPIRA WORLDWIDE

* HOSPIRA WORLDWIDE PTY
OXALIPLATIN, OXALIPLATIN

HOT SHOTS NM LLC

* HOT SHOTS NUCLEAR MEDICINE LLC
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HQ SPCLT PHARMA

* HQ SPECIALTY PHARMA CORP
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CISPLATIN, CISPLATIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MEROPENEM, MEROPENEM

HQ SPECLT PHARMA

* HQ SPECIALTY PHARMA CORP
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

HRA PHARMA

* HRA PHARMA RARE DISEASES
LYSODREN, MITOTANE
METOPIRONE, METYRAPONE

HUMANWELL PURACAP

* HUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTD
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
IBUPROFEN, IBUPROFEN (OTC)
ICOSAPENT ETHYL, ICOSAPENT ETHYL

HUONS

* HUONS CO LTD
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

ROCHE

* HOFFMANN LA ROCHE INC
FUZEON, ENFUVIRTIDE
TAMIFLU, OSELTAMIVIR PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

SHUANGCHENG
* HAINAN SHUANGCHENG PHARMACEUTICALS CO LTD
BIVALIRUDIN, BIVALIRUDIN
EPTIFIBATIDE, EPTIFIBATIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

** I **

I 3 PHARMS
* I 3 PHARMACEUTICALS LLC
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
MARAVIROC, MARAVIROC
POSACONAZOLE, POSACONAZOLE

I3 PHARMS
* I3 PHARMACEUTICALS LLC
RAMELTEON, RAMELTEON
RANOLAZINE, RANOLAZINE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

IBSA
* IBSA INSTITUT BIOCHIMIQUE SA
FLECTOR, DICLOFENAC EPOLAMINE
LIDOCAINE, LIDOCAINE
TIROSINT, LEVOTHYROXINE SODIUM
TIROSINT-SOL, LEVOTHYROXINE SODIUM

IBSA INST BIO
* IBSA INSTITUT BIOCHIMIQUE SA
LICART, DICLOFENAC EPOLAMINE

ICHNOS
* ICHNOS SCIENCES SA
DEFERASIROX, DEFERASIROX

ICU MEDICAL INC
* ICU MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* ICU MEDICAL INC
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION

IDORSIA
* IDORSIA PHARMACEUTICALS LTD
QUVIVIQ, DARIDOREXANT HYDROCHLORIDE

IMPACT
* IMPACT BIOMEDICINES INC A WHOLLY OWNED SUB OF CELGENE CORP
INREBIC, FEDRATINIB HYDROCHLORIDE

IMPAX
* IMPAX LABORATORIES LLC
ADRENACLICK, EPINEPHRINE
BACLOFEN, BACLOFEN
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE

IMPAX LABS
* IMPAX LABORATORIES INC
ACARBOSE, ACARBOSE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
DANTROLENE SODIUM, DANTROLENE SODIUM
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIGOXIN, DIGOXIN
DIPYRIDAMOLE, DIPYRIDAMOLE
FENOFIBRATE, FENOFIBRATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
OMEPRAZOLE, OMEPRAZOLE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RILUZOLE, RILUZOLE
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE

IMPAX LABS INC
* IMPAX LABORATORIES INC
ACITRETIN, ACITRETIN
BUDESONIDE, BUDESONIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
EMVERM, MEBENDAZOLE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCORTISONE, HYDROCORTISONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

* IMPAX LABORATORIES INC
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RYTARY, CARBIDOPA

IMPAX PHARMS
* IMPAX PHARMACEUTICALS
GEMFIBROZIL, GEMFIBROZIL
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE

IMPEL PHARMS
* IMPEL PHARMACEUTICALS INC
TRUDHESA, DIHYDROERGOTAMINE MESYLATE

IMS LTD
* INTERNATIONAL MEDICATION SYSTEMS LTD
REGADENOSON, REGADENOSON

INCYTE CORP
* INCYTE CORP
JAKAFI, RUXOLITINIB PHOSPHATE
OPZELURA, RUXOLITINIB PHOSPHATE
PEMAZYRE, PEMIGATINIB

INDCHEMIE HEALTH
* INDCHEMIE HEALTH SPECIALTIES PVT LTD
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE

INDICUS PHARMA
* INDICUS PHARMA LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

INDIVIOR
* INDIVIOR INC
OPVEE, NALMEFENE HYDROCHLORIDE
PERSERIS KIT, RISPERIDONE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

INDOCO
* INDOCO REMEDIES LTD
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
APIXABAN, APIXABAN
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FEBUXOSTAT, FEBUXOSTAT
GLYCOPYRROLATE, GLYCOPYRROLATE
LACOSAMIDE, LACOSAMIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
OLANZAPINE, OLANZAPINE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

INDOCO REMEDIES
* INDOCO REMEDIES LTD
GLIMEPIRIDE, GLIMEPIRIDE

INFORLIFE
* INFORLIFE SA
ACETAMINOPHEN, ACETAMINOPHEN
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

* INFORLIFE SA
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM IN 0.9% SODIUM CHLORIDE, MIDAZOLAM
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE, NOREPINEPHRINE BITARTRATE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

INGENUS PHARMS LLC
* INGENUS PHARMACEUTICALS LLC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
CABERGOLINE, CABERGOLINE
CARMUSTINE, CARMUSTINE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE

INNOCOLL
* INNOCOLL PHARMACEUTICALS LTD
POSIMIR, BUPIVACAINE

INNOCOLL PHARMS
* INNOCOLL PHARMACEUTICALS
XARACOLL, BUPIVACAINE HYDROCHLORIDE

INNOGENIX
* INNOGENIX LLC
BACLOFEN, BACLOFEN
HALOPERIDOL, HALOPERIDOL
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METOLAZONE, METOLAZONE
METRONIDAZOLE, METRONIDAZOLE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
RAMELTEON, RAMELTEON

INNOPHARMA
* INNOPHARMA LICENSING LLC A SUB OF PFIZER INC
PROPOFOL, PROPOFOL

INSMED INC
* INSMED INC
ARIKAYCE KIT, AMIKACIN SULFATE

INTAS PHARMS USA
* INTAS PHARMACEUTICALS USA
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

INTELLIPHARMACEUTICS
* INTELLIPHARMACEUTICS CORP
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

INTERCEPT PHARMS INC
* INTERCEPT PHARMACEUTICALS INC
OCALIVA, OBETICHOLIC ACID

INTERSECT ENT INC
* INTERSECT ENT INC
SINUVA, MOMETASONE FUROATE

INTL ISOTOPES
* INTERNATIONAL ISOTOPES INC
SODIUM IODIDE I 131, SODIUM IODIDE I-131

INTL MEDICATION
* INTERNATIONAL MEDICATION SYSTEM
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* INTERNATIONAL MEDICATION SYSTEM
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE

INTL MEDICATION SYS

* INTERNATIONAL MEDICATION SYSTEMS LTD
ATROPINE SULFATE, ATROPINE SULFATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
DEXTROSE 50%, DEXTROSE
EPINEPHRINE, EPINEPHRINE
LORAZEPAM, LORAZEPAM
MORPHINE SULFATE, MORPHINE SULFATE
SODIUM BICARBONATE, SODIUM BICARBONATE

INTRA-CELLULAR

* INTRA-CELLULAR THERAPIES INC
CAPLYTA, LUMATEPERONE TOSYLATE

INVAGEN PHARMS

* INVAGEN PHARMACEUTICALS INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LANREOTIDE ACETATE, LANREOTIDE ACETATE
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LEUPROLIDE ACETATE FOR DEPOT SUSPENSION, LEUPROLIDE ACETATE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PENICILLAMINE, PENICILLAMINE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PREGABALIN, PREGABALIN
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIMVASTATIN, SIMVASTATIN
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VIGABATRIN, VIGABATRIN
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

INVATECH
* INVATECH PHARMA SOLUTIONS LLC
DIVALPROEX SODIUM, DIVALPROEX SODIUM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE

INVENTIA
* INVENTIA HEALTHCARE LTD
CHLORTHALIDONE, CHLORTHALIDONE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
PALIPERIDONE, PALIPERIDONE
TELMISARTAN, TELMISARTAN

INVENTIA HLTHCARE
* INVENTIA HEALTHCARE PRIVATE LTD
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

IONETIX
* IONETIX CORP
AMMONIA N 13, AMMONIA N-13

IONIS PHARMS INC
* IONIS PHARMACEUTICALS INC
WAINUA, EPLONTERSEN SODIUM

IPCA LABS LTD
* IPCA LABORATORIES LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
ESZOPICLONE, ESZOPICLONE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

IPR
* IPR PHARMACEUTICALS INC
CRESTOR, ROSUVASTATIN CALCIUM

IPSEN
* IPSEN BIOPHARMACEUTICALS INC
ONIVYDE, IRINOTECAN HYDROCHLORIDE
SOHONOS, PALOVAROTENE

IPSEN PHARMA
* IPSEN PHARMA BIOTECH SAS
SOMATULINE DEPOT, LANREOTIDE ACETATE

IRONSHORE PHARMS
* IRONSHORE PHARMACEUTICALS AND DEVELOPMENT INC
JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE

ISOLOGIC INNOVATIVE
* ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

ISOTEX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* ISOTEX DIAGNOSTICS
GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTITUTO BIO ITA SPA

* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIPERACILLIN, PIPERACILLIN SODIUM

ITALFARMACO SA

* ITALFARMACO SA
TIGLUTIK KIT, RILUZOLE

IVAX SUB TEVA PHARMS

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
CABERGOLINE, CABERGOLINE
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
DIAZEPAM, DIAZEPAM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FAMOTIDINE, FAMOTIDINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE

IVERIC BIO

* IVERIC BIO INC
IZERVAY, AVACINCAPTAD PEGOL SODIUM

**** J ****

HENGRUI PHARMA

* JIANGSU HENGRUI PHARMACEUTICALS CO LTD
CARMUSTINE, CARMUSTINE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DAPTOMYCIN, DAPTOMYCIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GADOBUTROL, GADOBUTROL
GADOTERATE MEGLUMINE, GADOTERATE MEGLUMINE
IODIXANOL, IODIXANOL
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
THIOTEPA, THIOTEPA

J AND J CONSUMER INC

* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIV
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
MOTRIN IB, IBUPROFEN (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
RHINOCORT ALLERGY, BUDESONIDE (OTC)
SINE-AID IB, IBUPROFEN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIV
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TYLENOL, ACETAMINOPHEN (OTC)
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

JANSSEN BIOTECH

* JANSSEN BIOTECH INC
AKEEGA, ABIRATERONE ACETATE
BALVERSA, ERDAFITINIB
ERLEADA, APALUTAMIDE
ZYTIGA, ABIRATERONE ACETATE

JANSSEN PHARMS

* JANSSEN PHARMACEUTICALS INC
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
HALDOL, HALOPERIDOL DECANOATE
INVEGA HAFYERA, PALIPERIDONE PALMITATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVEGA, PALIPERIDONE
INVOKAMET XR, CANAGLIFLOZIN
INVOKAMET, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
PONVORY, PONESIMOD
RISPERDAL CONSTA, RISPERIDONE
RISPERDAL, RISPERIDONE
SPORANOX, ITRACONAZOLE
SPRAVATO, ESKETAMINE HYDROCHLORIDE
TOPAMAX, TOPIRAMATE
XARELTO, RIVAROXABAN

JANSSEN PRODS

* JANSSEN PRODUCTS LP
EDURANT, RILPIVIRINE HYDROCHLORIDE
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR
SYMTUZA, COBICISTAT
YONDELIS, TRABECTEDIN

JANSSEN R AND D

* JANSSEN RESEARCH AND DEVELOPMENT LLC
INTELENCE, ETRAVIRINE

JANSSEN THERAP

* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
SIRTURO, BEDAQUILINE FUMARATE

JAZZ

* JAZZ PHARMACEUTICALS IRELAND LTD
XYWAV, CALCIUM OXYBATE
ZEPZELCA, LURBINECTEDIN

JAZZ PHARMS

* JAZZ PHARMACEUTICALS INC
XYREM, SODIUM OXYBATE

JAZZ PHARMS INC

* JAZZ PHARMACEUTICALS INC
DEFITELIO, DEFIBROTIDE SODIUM

JAZZ PHARMS RES

* JAZZ PHARMACEUTICALS RESEARCH UK LTD
EPIDIOLEX, CANNABIDIOL

JDP

* JDP THERAPEUTICS LLC
QUZYTTIR, CETIRIZINE HYDROCHLORIDE

JIANGSU HANSOH PHARM

* JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
AZACITIDINE, AZACITIDINE
BORTEZOMIB, BORTEZOMIB
DECITABINE, DECITABINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
FULVESTRANT, FULVESTRANT
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
ICATIBANT ACETATE, ICATIBANT ACETATE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
PEMETREXED DISODIUM, PEMETREXED DISODIUM
VINORELBINE TARTRATE, VINORELBINE TARTRATE

JOHNS HOPKINS UNIV

* JOHNS HOPKINS UNIV
AMMONIA N 13, AMMONIA N-13

JOHNSON AND JOHNSON

* JOHNSON AND JOHNSON CONSUMER INC
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
* JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
WOMEN'S ROGAINE, MINOXIDIL (OTC)

JOURNEY

* JOURNEY MEDICAL CORP
AMZEEQ, MINOCYCLINE HYDROCHLORIDE
EURAX, CROTAMITON
EXELDERM, SULCONAZOLE NITRATE
QBREXZA, GLYCOPYRRONIUM TOSYLATE
ZILXI, MINOCYCLINE HYDROCHLORIDE

JUBILANT

* JUBILANT DRAXIMAGE INC DBA JUBILANT RADIOPHARMA
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE DTPA, TECHNETIUM TC-99M PENTETATE KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
HICON, SODIUM IODIDE I-131
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
SODIUM IODIDE I 131, SODIUM IODIDE I-131
TECHNETIUM TC-99M SULFUR COLLOID KIT, TECHNETIUM TC-99M SULFUR COLLOID KIT

JUBILANT CADISTA

* JUBILANT CADISTA PHARMACEUTICALS INC
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCOMP, PROCHLORPERAZINE MALEATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

* JUBILANT DRAXIMAGE INC
TECHNETIUM TC 99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
* JUBILANT DRAXIMAGE RADIOPHARMACIES INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
* JUBILANT DRAXIMAGE USA INC
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

JUBILANT GENERICS

* JUBILANT GENERICS LTD
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JUBILANT GENERICS LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
IRBESARTAN, IRBESARTAN
OLANZAPINE, OLANZAPINE
RISPERIDONE, RISPERIDONE
SPIRONOLACTONE, SPIRONOLACTONE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
ZOLMITRIPTAN, ZOLMITRIPTAN

STEVENS J

* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
DIGOXIN, DIGOXIN
UNITHROID, LEVOTHYROXINE SODIUM **

**** K ****

GRIFFEN

* KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

KADMON PHARMS LLC

* KADMON PHARMACEUTICALS LLC
REZUROCK, BELUMOSUDIL MESYLATE

KAI PHARMS INC

* KAI PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF AMGEN INC
PARSABIV, ETELCALCETIDE

KALEO INC

* KALEO INC
AUVI-Q, EPINEPHRINE

KARYOPHARM THERAPS

* KARYOPHARM THERAPEUTICS INC
XPOVIO, SELINEXOR

KENTON

* KENTON CHEMICALS AND PHARMACEUTICALS CORP
ANASTROZOLE, ANASTROZOLE
CAPTOPRIL, CAPTOPRIL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
RILUZOLE, RILUZOLE

KERYX BIOPHARMS

* KERYX BIOPHARMACEUTICALS INC
AURYXIA, FERRIC CITRATE

KETTERING MEDCTR

* KETTERING MEDCTR
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

KINDEVA

* KINDEVA DRUG DELIVERY LP
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
PROVENTIL-HFA, ALBUTEROL SULFATE

KINDOS

* KINDOS PHARMACEUTICALS CO LTD
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
NELARABINE, NELARABINE
PLERIXAFOR, PLERIXAFOR
THIOTEPA, THIOTEPA

KING PHARMS

* KING PHARMACEUTICALS INC
SYNERCID, DALFOPRISTIN
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** K ****

* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC
CYTOMEL, LIOTHYRONINE SODIUM
LEVOXYL, LEVOTHYROXINE SODIUM **

KING PHARMS LLC

* KING PHARMACEUTICALS LLC
ALTACE, RAMIPRIL
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
SILVADENE, SILVER SULFADIAZINE

KNACK

* KNACK PHARMACEUTICALS INC
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

KNIGHT THERAPS

* KNIGHT THERAPEUTICS USA INC
IMPAVIDO, MILTEFOSINE

KOWA CO

* KOWA CO LTD
LIVALO, PITAVASTATIN CALCIUM

KOWA PHARMS

* KOWA PHARMACEUTICALS AMERICA INC
SEGLENTIS, CELECOXIB

KRAMER

* KRAMER LABORATORIES INC
NIZORAL ANTI-DANDRUFF, KETOCONAZOLE (OTC)

KREITCHMAN PET CTR

* KREITCHMAN PET CENTER
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

KVK TECH

* KVK TECH INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KALEXATE, SODIUM POLYSTYRENE SULFONATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

KVK TECH INC

* KVK TECH INC
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

KYOWA KIRIN

* KYOWA KIRIN INC
FARESTON, TOREMIFENE CITRATE
NOURIANZ, ISTRADEFYLLINE

KYTHERA BIOPHARMS

* KYTHERA BIOPHARMACEUTICALS INC
KYBELLA, DEOXYCHOLIC ACID

**** L ****

L PERRIGO CO

* L PERRIGO CO
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
CIMETIDINE, CIMETIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* L PERRIGO CO
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

LA JOLLA PHARMA
* LA JOLLA PHARMA LLC
GIAPREZA, ANGIOTENSIN II ACETATE

LAB HRA PHARMA
* LABORATOIRE HRA PHARMA
ELLA, ULIPRISTAL ACETATE

LABORATOIRE HRA
* LABORATOIRE HRA PHARMA
LEVONORGESTREL, LEVONORGESTREL (OTC)

LABORATORIOS GRIFOLS
* LABORATORIOS GRIFOLS SA
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LABORATORIOS SALVAT
* LABORATORIOS SALVAT SA
OTOVEL, CIPROFLOXACIN HYDROCHLORIDE

LABS JUVISE
* LABORATOIRES JUVISE PHARMACEUTICALS
PYLERA, BISMUTH SUBCITRATE POTASSIUM

LACER PHARMA
* LACER PHARMA LLC
ERTACZO, SERTACONAZOLE NITRATE

LANDELA PHARM
* LANDELA PHARMACEUTICAL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

LANNETT
* LANNETT CO INC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
LANORINAL, ASPIRIN
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID

LANNETT CO INC
* LANNETT CO INC
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BACLOFEN, BACLOFEN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CODEINE SULFATE, CODEINE SULFATE
DANAZOL, DANAZOL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LOPINAVIR AND RITONAVIR, LOPINAVIR
LORATADINE, LORATADINE (OTC)
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METAXALONE, METAXALONE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LANNETT CO INC
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NIACIN, NIACIN
OMEPRAZOLE, OMEPRAZOLE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SUMATRIPTAN, SUMATRIPTAN
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
URSODIOL, URSODIOL

LANTHEUS MEDCL
* LANTHEUS MEDICAL IMAGING INC
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
DEFINITY RT, PERFLUTREN
DEFINITY, PERFLUTREN
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
XENON XE 133, XENON XE-133

LARKEN LABS
* LARKEN LABORATORIES INC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
OFLOXACIN, OFLOXACIN

LARKEN LABS INC
* LARKEN LABORATORIES INC
ALLZITAL, ACETAMINOPHEN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
DEXAMETHASONE, DEXAMETHASONE

LAURUS
* LAURUS LABS LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
GABAPENTIN, GABAPENTIN
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LOPINAVIR AND RITONAVIR, LOPINAVIR
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIRFENIDONE, PIRFENIDONE

LAVIPHARM
* LAVIPHARM SA
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE

LEADIANT BIOSCI INC
* LEADIANT BIOSCIENCES INC
ABELCET, AMPHOTERICIN B
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
MATULANE, PROCARBAZINE HYDROCHLORIDE

LEADING
* LEADING PHARMA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
FOLIC ACID, FOLIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LEADING PHARMA LLC
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYUREA, HYDROXYUREA
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LORAZEPAM, LORAZEPAM
NIFEDIPINE, NIFEDIPINE
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
THEOPHYLLINE, THEOPHYLLINE

LEADING PHARMA
* LEADING PHARMA LLC
LACOSAMIDE, LACOSAMIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE

LEGACY PHARMA
* LEGACY PHARMA INC
ALA-SCALP, HYDROCORTISONE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
CROTAN, CROTAMITON

LEGACY PHARMA USA
* LEGACY PHARMA USA INC
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

LEO PHARMA AS
* LEO PHARMA AS
DOVONEX, CALCIPOTRIENE
ENSTILAR, BETAMETHASONE DIPROPIONATE
FINACEA, AZELAIC ACID
PROTOPIC, TACROLIMUS
TACLONEX, BETAMETHASONE DIPROPIONATE

LEXICON PHARMS INC
* LEXICON PHARMACEUTICALS INC
INPEFA, SOTAGLIFLOZIN

LGM PHARMA
* LGM PHARMA SOLUTIONS LLC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CHENODIOL, CHENODIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCODONE BITARTRATE AND ASPIRIN, ASPIRIN
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
NABUMETONE, NABUMETONE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
URSODIOL, URSODIOL

LIEBEL-FLARSHEIM
* LIEBEL-FLARSHEIM CO LLC
CONRAY, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LIFE MOLECULAR
* LIFE MOLECULAR IMAGING LTD
NEURACEQ, FLORBETABEN F-18

LINDE GAS EQUIP
* LINDE GAS AND EQUIPMENT INC
NOXIVENT, NITRIC OXIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

LNHC
* LNHC INC
SITAVIG, ACYCLOVIR

LNK
* LNK INTERNATIONAL INC
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LNK INTL INC
* LNK INTERNATIONAL INC
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

LONG GROVE PHARMS
* LONG GROVE PHARMACEUTICALS LLC
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
CALCITRIOL, CALCITRIOL
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

LOREAL USA
* LOREAL USA PRODUCTS INC
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD
* LOTUS PHARMACEUTICAL CO LTD NANTOU PLANT
LENALIDOMIDE, LENALIDOMIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM

LOXO ONCOL
* LOXO ONCOLOGY INC
JAYPIRCA, PIRTOBRUTINIB

LOXO ONCOL ELI LILLY
* LOXO ONCOLOGY INC A WHOLLY OWNED SUB OF ELI LILLY AND CO
RETEVMO, SELPERCATINIB

LUITPOLD
* LUITPOLD PHARMACEUTICALS INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID

LUKARE MEDICAL LLC
* LUKARE MEDICAL LLC
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

LUNDBECK NA LTD
* LUNDBECK NA LTD
NORTHERA, DROXIDOPA

LUNDBECK PHARMS LLC
* LUNDBECK PHARMACEUTICALS LLC
ONFI, CLOBAZAM
SABRIL, VIGABATRIN

LUOXIN AUROVITAS
* LUOXIN AUROVITAS PHARMA CHENGDU CO LTD
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

LUPIN
* LUPIN INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ANTARA (MICRONIZED), FENOFIBRATE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
BROVANA, ARFORMOTEROL TARTRATE
BUDESONIDE, BUDESONIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
DESOXIMETASONE, DESOXIMETASONE
DIMETHYL FUMARATE, DIMETHYL FUMARATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUPIN INC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
MIBELAS 24 FE, ETHINYL ESTRADIOL
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SOLOSEC, SECNIDAZOLE
TESTOSTERONE, TESTOSTERONE
TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
XOPENEX HFA, LEVALBUTEROL TARTRATE

* LUPIN LTD
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOVASTATIN, LOVASTATIN
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TRANDOLAPRIL, TRANDOLAPRIL

LUPIN LTD

* LUPIN LIMITED
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

* LUPIN LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
ALLOPURINOL, ALLOPURINOL
AMABELZ, ESTRADIOL
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ARMODAFINIL, ARMODAFINIL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
AZITHROMYCIN, AZITHROMYCIN
BEKYREE, DESOGESTREL
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BIMATOPROST, BIMATOPROST
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
BROMFENAC SODIUM, BROMFENAC SODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CELECOXIB, CELECOXIB
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUPIN LTD
DARUNAVIR, DARUNAVIR
DAYSEE, ETHINYL ESTRADIOL
DECITABINE, DECITABINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENSKYCE, DESOGESTREL
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
ETHACRYNIC ACID, ETHACRYNIC ACID
FALLBACK SOLO, LEVONORGESTREL (OTC)
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FYAVOLV, ETHINYL ESTRADIOL
GANIRELIX ACETATE, GANIRELIX ACETATE
GATIFLOXACIN, GATIFLOXACIN
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
JENCYCLA, NORETHINDRONE
KAITLIB FE, ETHINYL ESTRADIOL
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
KURVELO, ETHINYL ESTRADIOL
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LEFLUNOMIDE, LEFLUNOMIDE
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEFENAMIC ACID, MEFENAMIC ACID
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRABEGRON, MIRABEGRON
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NIACIN, NIACIN
NIKKI, DROSPIRENONE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
PALIPERIDONE, PALIPERIDONE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LUPIN LTD
PENICILLAMINE, PENICILLAMINE
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANOLAZINE, RANOLAZINE
RIFABUTIN, RIFABUTIN
RUFINAMIDE, RUFINAMIDE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SUPRAX, CEFIXIME
TADALAFIL, TADALAFIL
TAVABOROLE, TAVABOROLE
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TENOFOVIR ALAFENAMIDE, TENOFOVIR ALAFENAMIDE FUMARATE
TESTOSTERONE, TESTOSTERONE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TURQOZ, ETHINYL ESTRADIOL
TYDEMY, DROSPIRENONE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VYFEMLA, ETHINYL ESTRADIOL
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LUPIN PHARMS

* LUPIN PHARMACEUTICALS INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
DESLORATADINE, DESLORATADINE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DROXIDOPA, DROXIDOPA
MELOXICAM, MELOXICAM
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
RIFAMPIN, RIFAMPIN
SUPRAX, CEFIXIME
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

LYNE

* LYNE LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
LEVOCARNITINE, LEVOCARNITINE
NYSTATIN, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

LYRUS LIFE SCIENCES

* LYRUS LIFE SCIENCES PRIVATE LTD
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE

PERRIGO

* L PERRIGO CO
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* L PERRIGO CO
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
TIOCONAZOLE, TIOCONAZOLE (OTC)

**** M ****

MA GENERAL HOSP
* MASSACHUSETTS GENERAL HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MACLEODS PHARMS LTD
* MACLEODS PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CELECOXIB, CELECOXIB
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENTACAPONE, ENTACAPONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
FAMCICLOVIR, FAMCICLOVIR
FEBUXOSTAT, FEBUXOSTAT
FLUOCINONIDE, FLUOCINONIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LIDOCAINE, LIDOCAINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEVIRAPINE, NEVIRAPINE
NIACIN, NIACIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRAZINAMIDE, PYRAZINAMIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
REPAGLINIDE, REPAGLINIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MACLEODS PHARMACEUTICALS LTD
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
TADALAFIL, TADALAFIL
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

MAIA PHARMS INC

* MAIA PHARMACEUTICALS INC
ANGIOMAX RTU, BIVALIRUDIN
BACLOFEN, BACLOFEN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
SINCALIDE, SINCALIDE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

MAINPOINTE

* MAINPOINTE PHARMACEUTICALS LLC
TUXARIN ER, CHLORPHENIRAMINE MALEATE

MALLINCKRODT ARD

* MALLINCKRODT ARD INC
ACTHAR GEL, CORTICOTROPIN

MALLINCKRODT HOSP

* MALLINCKRODT HOSP PRODUCTS IP LTD
INOMAX, NITRIC OXIDE
UVADEX, METHOXSALEN

MALLINCKRODT IRELAND

* MALLINCKRODT PHARMACEUTICALS IRELAND LTD
TERLIVAZ, TERLIPRESSIN ACETATE

MANKIND PHARMA

* MANKIND PHARMA LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATROPINE SULFATE, ATROPINE SULFATE
BACLOFEN, BACLOFEN
CHLORTHALIDONE, CHLORTHALIDONE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE, FENOFIBRATE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROGLYCERIN, NITROGLYCERIN
OFLOXACIN, OFLOXACIN
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
RANOLAZINE, RANOLAZINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MANKIND PHARMA LTD
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN, TOBRAMYCIN
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

MARINUS
* MARINUS PHARMACEUTICALS INC
ZTALMY, GANAXOLONE

MARIUS PHARMS LLC
* MARIUS PHARMACEUTICALS LLC
KYZATREX, TESTOSTERONE UNDECANOATE

MARKSANS PHARMA
* MARKSANS PHARMA LTD
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
PARICALCITOL, PARICALCITOL

MAYNE PHARMA
* MAYNE PHARMA INTERNATIONAL PTY LTD
DORYX MPC, DOXYCYCLINE HYCLATE
DORYX, DOXYCYCLINE HYCLATE
TOLSURA, ITRACONAZOLE
* MAYNE PHARMA LLC
ANNOVERA, ETHINYL ESTRADIOL
BIJUVA, ESTRADIOL
FABIOR, TAZAROTENE
IMVEXXY, ESTRADIOL
LEXETTE, HALOBETASOL PROPIONATE
NEXTSTELLIS, DROSPIRENONE
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE
SORILUX, CALCIPOTRIENE

MAYNE PHARMA COMMRCL
* MAYNE PHARMA COMMERCIAL LLC
SOLTAMOX, TAMOXIFEN CITRATE

MC2
* MC2 THERAPEUTICS LTD
WYNZORA, BETAMETHASONE DIPROPIONATE

MCGUFF
* MCGUFF PHARMACEUTICALS INC
ASCOR, ASCORBIC ACID

MCNEIL
* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
IBUPROFEN, IBUPROFEN (OTC)

MCPRF
* MAYO CLINIC PET RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MDD US
* MDD US OPERATIONS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MDD US OPERATIONS LLC
APOKYN, APOMORPHINE HYDROCHLORIDE
XADAGO, SAFINAMIDE MESYLATE

MDGH
* MEDICINES DEVELOPMENT FOR GLOBAL HEALTH
MOXIDECTIN, MOXIDECTIN

MEDEFIL INC
* MEDEFIL INC
ATROPINE SULFATE, ATROPINE SULFATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION

MEDEXUS
* MEDEXUS PHARMA INC
RASUVO, METHOTREXATE

MEDI-RADIOPHARMA
* MEDI-RADIOPHARMA LTD
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT

MEDICINES360
* MEDICINES360
LILETTA, LEVONORGESTREL

MEDICURE
* MEDICURE INTERNATIONAL INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
ZYPITAMAG, PITAVASTATIN MAGNESIUM

MEDIMETRIKS PHARMS
* MEDIMETRIKS PHARMACEUTICALS INC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
LOPROX, CICLOPIROX
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR, FLUOCINOLONE ACETONIDE

MEDLINE INDUSTRIES
* MEDLINE INDUSTRIES INC
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)

MEDTECH PRODUCTS
* MEDTECH PRODUCTS INC
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
NIX, PERMETHRIN (OTC)
TAGAMET HB, CIMETIDINE (OTC)

MEDUNIK
* MEDUNIK CANADA INC
NITISINONE, NITISINONE
PHEBURANE, SODIUM PHENYLBUTYRATE

MEITHEAL
* MEITHEAL PHARMACEUTICALS INC
ADENOSINE, ADENOSINE
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZACITIDINE, AZACITIDINE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BORTEZOMIB, BORTEZOMIB
BUSULFAN, BUSULFAN
CARMUSTINE, CARMUSTINE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLOFARABINE, CLOFARABINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MEITHEAL PHARMACEUTICALS INC
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DACTINOMYCIN, DACTINOMYCIN
DAPTOMYCIN, DAPTOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DECITABINE, DECITABINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOXERCALCIFEROL, DOXERCALCIFEROL
ETOPOSIDE, ETOPOSIDE
FUROSEMIDE, FUROSEMIDE
GANIRELIX ACETATE, GANIRELIX ACETATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
ISOSULFAN BLUE, ISOSULFAN BLUE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
REGADENOSON, REGADENOSON
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TIGECYCLINE, TIGECYCLINE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VORICONAZOLE, VORICONAZOLE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

MELINTA
* MELINTA SUBSIDIARY CORP
BAXDELA, DELAFLOXACIN MEGLUMINE

MELINTA THERAP
* MELINTA THERAPEUTICS LLC
KIMYRSA, ORITAVANCIN DIPHOSPHATE
ORBACTIV, ORITAVANCIN DIPHOSPHATE

MEM SLOAN-KETTERING
* MEMORIAL SLOAN-KETTERING CANCER CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MERCK
* MERCK AND CO INC
CANCIDAS, CASPOFUNGIN ACETATE
EMEND, APREPITANT
PRIMAXIN, CILASTATIN SODIUM

MERCK AND CO INC
* MERCK AND CO INC
EMEND, FOSAPREPITANT DIMEGLUMINE

MERCK SHARP DOHME
* MERCK SHARP AND DOHME CORP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MERCK SHARP AND DOHME CORP
BELSOMRA, SUVOREXANT
JANUVIA, SITAGLIPTIN PHOSPHATE
NOXAFIL, POSACONAZOLE
PREVYMIS, LETERMOVIR
STROMECTOL, IVERMECTIN
TEMODAR, TEMOZOLOMIDE
VERQUVO, VERICIGUAT
* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
WELIREG, BELZUTIFAN

MERIDIAN BIOSCIENCE

* MERIDIAN BIOSCIENCE ISRAEL LTD
IDKIT:HP, CITRIC ACID

MERRO PHARM USA

* MERRO PHARMACEUTICAL USA INC
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

MERZ PHARMS

* MERZ PHARMACEUTICALS LLC
CUVPOSA, GLYCOPYRROLATE

METACEL PHARMS LLC

* METACEL PHARMACEUTICALS LLC
OZOBAX DS, BACLOFEN

METHAPHARM

* METHAPHARM INC
PROVOCHOLINE, METHACHOLINE CHLORIDE

METUCHEN PHARMS

* METUCHEN PHARMACEUTICALS LLC
STENDRA, AVANAFIL

MICRO LABS

* MICRO LABS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BACLOFEN, BACLOFEN
BIMATOPROST, BIMATOPROST
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CELECOXIB, CELECOXIB
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM
DALFAMPRIDINE, DALFAMPRIDINE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ERYTHRA-DERM, ERYTHROMYCIN
FAMOTIDINE, FAMOTIDINE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LIFITEGRAST, LIFITEGRAST
LINCOMYCIN HYDROCHLORIDE, LINCOMYCIN HYDROCHLORIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFENAMIC ACID, MEFENAMIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MICRO LABS LTD
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MISOPROSTOL, MISOPROSTOL
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PIRFENIDONE, PIRFENIDONE
PIROXICAM, PIROXICAM
RAMELTEON, RAMELTEON
RANOLAZINE, RANOLAZINE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
ROFLUMILAST, ROFLUMILAST
RUFINAMIDE, RUFINAMIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIMVASTATIN, SIMVASTATIN
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TAFLUPROST, TAFLUPROST
TELMISARTAN, TELMISARTAN
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN, TOBRAMYCIN
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAVOPROST, TRAVOPROST
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

MICRO LABS LTD
* MICRO LABS LTD
NEVIRAPINE, NEVIRAPINE

MICRO LABS LTD INDIA
* MICRO LABS LTD INDIA
ACETAZOLAMIDE, ACETAZOLAMIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MIDWEST MEDCL
* MIDWEST MEDICAL ISOTOPES LLC CYCLOTRON DIV
AMMONIA N 13, AMMONIA N-13
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIKART
* MIKART LLC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORZOXAZONE, CHLORZOXAZONE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ETHOSUXIMIDE, ETHOSUXIMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
METHAZOLAMIDE, METHAZOLAMIDE
METHOCARBAMOL, METHOCARBAMOL
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

MILLA PHARMS
* MILLA PHARMACEUTICALS INC
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
SODIUM ACETATE, SODIUM ACETATE

MILLICENT
* MILLICENT HOLDINGS LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MILLICENT HOLDINGS LTD
FEMRING, ESTRADIOL ACETATE
* MILLICENT PHARMA LTD
INTRAROSA, PRASTERONE

MIPS CRF
* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIRATI THERAPS
* MIRATI THERAPEUTICS INC
KRAZATI, ADAGRASIB

MIRUM
* MIRUM PHARMACEUTICALS INC
CHOLBAM, CHOLIC ACID
LIVMARLI, MARALIXIBAT CHLORIDE

MISEMER
* MISEMER PHARMACEUTICALS INC
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
KETOPROFEN, KETOPROFEN

MISSION PHARMA
* MISSION PHARMACAL CO
LITHOSTAT, ACETOHYDROXAMIC ACID
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TEXACORT, HYDROCORTISONE
THIOLA, TIOPRONIN
TINDAMAX, TINIDAZOLE
UROCIT-K, POTASSIUM CITRATE

MISSION PHARMACAL
* MISSION PHARMACAL CO
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
THIOLA EC, TIOPRONIN

MITSUBISHI TANABE
* MITSUBISHI TANABE PHARMA CORP
RADICAVA ORS, EDARAVONE
RADICAVA, EDARAVONE

MLV
* MLV PHARMA LLC
CARISOPRODOL, CARISOPRODOL
METHOCARBAMOL, METHOCARBAMOL
NYSTATIN, NYSTATIN
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

MMT
* MERIDIAN MEDICAL TECHNOLOGIES LLC
DUODOTE, ATROPINE
SEIZALAM, MIDAZOLAM HYDROCHLORIDE

MOBIUS THERAP
* MOBIUS THERAPEUTICS LLC
MITOSOL, MITOMYCIN

MOLNLYCKE HLTH
* MOLNLYCKE HEALTH CARE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

MONARCH PHARMS
* MONARCH PHARMACEUTICALS LLC
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
VIROPTIC, TRIFLURIDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

MONTEREY PHARMS LLC

* MONTEREY PHARMACEUTICALS LLC
METHOCARBAMOL, METHOCARBAMOL

MOUNTAIN

* MOUNTAIN LLC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
METAXALONE, METAXALONE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

MSD MERCK CO

* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
DELSTRIGO, DORAVIRINE
EMEND, APREPITANT
NOXAFIL POWDERMIX KIT, POSACONAZOLE
PIFELTRO, DORAVIRINE
RECARBRIO, CILASTATIN SODIUM

MSD SUB MERCK

* MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC
BRIDION, SUGAMMADEX SODIUM
INVANZ, ERTAPENEM SODIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISENTRESS, RALTEGRAVIR POTASSIUM
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUMET, METFORMIN HYDROCHLORIDE
SEGLUROMET, ERTUGLIFLOZIN
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN
ZEPATIER, ELBASVIR
ZOLINZA, VORINOSTAT

MSN

* MSN LABORATORIES PRIVATE LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACYCLOVIR, ACYCLOVIR
ALBENDAZOLE, ALBENDAZOLE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BORTEZOMIB, BORTEZOMIB
BUMETANIDE, BUMETANIDE
CAPECITABINE, CAPECITABINE
CARMUSTINE, CARMUSTINE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLOFARABINE, CLOFARABINE
DARUNAVIR, DARUNAVIR
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DOFETILIDE, DOFETILIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
FEBUXOSTAT, FEBUXOSTAT
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
HALOPERIDOL, HALOPERIDOL
ISOSULFAN BLUE, ISOSULFAN BLUE
LACOSAMIDE, LACOSAMIDE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PACLITAXEL, PACLITAXEL
PIRFENIDONE, PIRFENIDONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MSN LABORATORIES PRIVATE LTD
PLERIXAFOR, PLERIXAFOR
PREGABALIN, PREGABALIN
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIOCIGUAT, RIOCIGUAT
ROFLUMILAST, ROFLUMILAST
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SIROLIMUS, SIROLIMUS
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TASIMELTEON, TASIMELTEON
TERIFLUNOMIDE, TERIFLUNOMIDE
THIOTEPA, THIOTEPA
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TOLVAPTAN, TOLVAPTAN
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE

MSN LABS PVT LTD

* MSN LABORATORIES PRIVATE LTD
LACOSAMIDE, LACOSAMIDE

MSN PHARMS INC

* MSN PHARMACEUTICALS INC
DROXIDOPA, DROXIDOPA

MYCOVIA PHARMS

* MYCOVIA PHARMACEUTICALS INC
VIVJOA, OTESECONAZOLE

MYLAN

* MYLAN INSTITUTIONAL LLC A VIATRIS CO
ALOPRIM, ALLOPURINOL SODIUM
* MYLAN LABORATORIES LTD A VIATRIS CO
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
* MYLAN PHARMACEUTICALS
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
* MYLAN PHARMACEUTICALS INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACETAMINOPHEN, ACETAMINOPHEN
ACITRETIN, ACITRETIN
ALLOPURINOL, ALLOPURINOL
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BREYNA, BUDESONIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
CLOZAPINE, CLOZAPINE
COLCHICINE, COLCHICINE
CYCLOSPORINE, CYCLOSPORINE
CYSTAGON, CYSTEAMINE BITARTRATE
DAPSONE, DAPSONE
DENAVIR, PENCICLOVIR
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ERMEZA, LEVOTHYROXINE SODIUM
ERYGEL, ERYTHROMYCIN
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESTRADIOL, ESTRADIOL
ETOPOSIDE, ETOPOSIDE
EVEROLIMUS, EVEROLIMUS
EXTINA, KETOCONAZOLE
FENOFIBRATE, FENOFIBRATE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FUROSEMIDE, FUROSEMIDE
GLATIRAMER ACETATE, GLATIRAMER ACETATE
HALCINONIDE, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
IMATINIB MESYLATE, IMATINIB MESYLATE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LANSOPRAZOLE, LANSOPRAZOLE
LENALIDOMIDE, LENALIDOMIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MERCAPTOPURINE, MERCAPTOPURINE
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIRTAZAPINE, MIRTAZAPINE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NEVIRAPINE, NEVIRAPINE
NISOLDIPINE, NISOLDIPINE
OLANZAPINE, OLANZAPINE
ONDANSETRON, ONDANSETRON
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
REGADENOSON, REGADENOSON
ROFLUMILAST, ROFLUMILAST
RUFINAMIDE, RUFINAMIDE
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
SAXAGLIPTIN, SAXAGLIPTIN HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SUCRALFATE, SUCRALFATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUNITINIB MALATE, SUNITINIB MALATE
SYMFI LO, EFAVIRENZ
TACROLIMUS, TACROLIMUS
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN, TELMISARTAN
TERIFLUNOMIDE, TERIFLUNOMIDE
TETRABENAZINE, TETRABENAZINE
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TRAVOPROST, TRAVOPROST
TRETINOIN, TRETINOIN
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
VALSARTAN, VALSARTAN
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VUSION, MICONAZOLE NITRATE
WIXELA INHUB, FLUTICASONE PROPIONATE
ZONALON, DOXEPIN HYDROCHLORIDE
* MYLAN PHARMACEUTICALS INC A VIATRIS CO
DAPTOMYCIN, DAPTOMYCIN

MYLAN ASI

* MYLAN ASI LLC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

MYLAN INSTITUTIONAL

* MYLAN INSTITUTIONAL INC
BUSULFAN, BUSULFAN
* MYLAN INSTITUTIONAL LLC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
BIVALIRUDIN, BIVALIRUDIN
CIDOFOVIR, CIDOFOVIR
COSYNTROPIN, COSYNTROPIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DURACLON, CLONIDINE HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
FOMEPIZOLE, FOMEPIZOLE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
ISOSULFAN BLUE, ISOSULFAN BLUE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN INSTITUTIONAL LLC
ULTIVA, REMIFENTANIL HYDROCHLORIDE

MYLAN IRELAND LTD

* MYLAN IRELAND LTD
ARIXTRA, FONDAPARINUX SODIUM
MIACALCIN, CALCITONIN SALMON
PRETOMANID, PRETOMANID
YUPELRI, REVEFENACIN

MYLAN LABS LTD

* MYLAN LABORATORIES LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ADENOSINE, ADENOSINE
BACLOFEN, BACLOFEN
CIMDUO, LAMIVUDINE
CLOFARABINE, CLOFARABINE
CYANOCOBALAMIN, CYANOCOBALAMIN
DAPTOMYCIN, DAPTOMYCIN
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
EPTIFIBATIDE, EPTIFIBATIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETOMIDATE, ETOMIDATE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
IBANDRONATE SODIUM, IBANDRONATE SODIUM
LAMIVUDINE, LAMIVUDINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
OXALIPLATIN, OXALIPLATIN
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
POSACONAZOLE, POSACONAZOLE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
RIFAMPIN, RIFAMPIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SYMFI, EFAVIRENZ

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN LABORATORIES LTD
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

MYLAN PHARMS INC

* MYLAN PHARMACEUTICALS INC
ABACAVIR SULFATE, ABACAVIR SULFATE
ACYCLOVIR, ACYCLOVIR
AMNESTEEM, ISOTRETINOIN
ARMODAFINIL, ARMODAFINIL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AVITA, TRETINOIN
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
ESZOPICLONE, ESZOPICLONE
FENOFIBRATE, FENOFIBRATE
LANSOPRAZOLE, LANSOPRAZOLE
LITHIUM CARBONATE, LITHIUM CARBONATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VORICONAZOLE, VORICONAZOLE
ZIDOVUDINE, ZIDOVUDINE

* MYLAN PHARMACEUTICALS INC.
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM

MYLAN SPCLT VIATRIS

* MYLAN SPECIALTY LP A VIATRIS CO
DIPENTUM, OLSALAZINE SODIUM

MYLAN SPECIALITY LP

* MYLAN SPECIALTY LP
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
CORTIFOAM, HYDROCORTISONE ACETATE
DEPEN, PENICILLAMINE
DYMISTA, AZELASTINE HYDROCHLORIDE
EDLUAR, ZOLPIDEM TARTRATE
ELESTRIN, ESTRADIOL
EPIFOAM, HYDROCORTISONE ACETATE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
FELBATOL, FELBAMATE
GASTROCROM, CROMOLYN SODIUM
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
MUSE, ALPROSTADIL
PROCTOFOAM HC, HYDROCORTISONE ACETATE
ROWASA, MESALAMINE
SFROWASA, MESALAMINE
SOMA, CARISOPRODOL
TOBI PODHALER, TOBRAMYCIN
TOBI, TOBRAMYCIN

MYLAN SPECLT

* MYLAN SPECIALTY LP
PERFOROMIST, FORMOTEROL FUMARATE

MYLAN TECH VIATRIS

* MYLAN TECHNOLOGIES INC A VIATRIS CO

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN TECHNOLOGIES INC A VIATRIS CO
METHYLPHENIDATE, METHYLPHENIDATE

MYLAN TECHNOLOGIES

* MYLAN TECHNOLOGIES INC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CLONIDINE, CLONIDINE
ESTRADIOL, ESTRADIOL
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
RIVASTIGMINE, RIVASTIGMINE
SCOPOLAMINE, SCOPOLAMINE
XULANE, ETHINYL ESTRADIOL

MYOVANT SCIENCES

* MYOVANT SCIENCES GMBH
MYFEMBREE, ESTRADIOL

**** N ****

NAARI PTE LTD

* NAARI PTE LTD
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

NABRIVA

* NABRIVA THERAPEUTICS IRELAND DAC
XENLETA, LEFAMULIN ACETATE

NAL PHARM

* NAL PHARMACEUTICAL GROUP LTD
LIDOCAINE, LIDOCAINE

NALPROPION

* NALPROPION PHARMACEUTICALS LLC
CONTRAVE, BUPROPION HYDROCHLORIDE

NANG KUANG PHARM CO

* NANG KUANG PHARMACEUTICAL CO LTD
ICATIBANT ACETATE, ICATIBANT ACETATE
LINEZOLID, LINEZOLID
PEMETREXED DISODIUM, PEMETREXED DISODIUM

NANJING

* NANJING SIMCERE DONGYUAN PHARMACEUTICAL CO LTD
CELECOXIB, CELECOXIB

NANJING KING-FRIEND

* NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE

NANOCOPOEIA

* NANOCOPOEIA LLC
PHYRAGO, DASATINIB

NAPO PHARMS INC

* NAPO PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NAPO PHARMACEUTICALS INC
MYTESI, CROFELEMER

NATCO

* NATCO PHARMA LTD
ALPRAZOLAM, ALPRAZOLAM
CARISOPRODOL, CARISOPRODOL
GEFITINIB, GEFITINIB
GLYCOPYRROLATE, GLYCOPYRROLATE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
NITROGLYCERIN, NITROGLYCERIN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
TERIFLUNOMIDE, TERIFLUNOMIDE
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE

NATCO PHARMA

* NATCO PHARMA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
SUNITINIB MALATE, SUNITINIB MALATE

NATCO PHARMA LTD

* NATCO PHARMA LIMITED
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
* NATCO PHARMA LTD
ANASTROZOLE, ANASTROZOLE
ARMODAFINIL, ARMODAFINIL
AZACITIDINE, AZACITIDINE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
LANSOPRAZOLE, LANSOPRAZOLE
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LAPATINIB DITOSYLATE, LAPATINIB DITOSYLATE
LETROZOLE, LETROZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

NAVINTA LLC

* NAVINTA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARGLUMIC ACID, CARGLUMIC ACID
CARMUSTINE, CARMUSTINE
FAMOTIDINE, FAMOTIDINE
FOMEPIZOLE, FOMEPIZOLE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
METHOCARBAMOL, METHOCARBAMOL
PENICILLAMINE, PENICILLAMINE
RIBAVIRIN, RIBAVIRIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

NCM USA BRONX LLC

* NCM USA BRONX LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NE RX PHARMA

* NE RX PHARMA LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
METOLAZONE, METOLAZONE

NEOS THERAPS

* NEOS THERAPEUTICS
ADZENYS XR-ODT, AMPHETAMINE

NEOS THERAPS INC

* NEOS THERAPEUTICS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

* NEOS THERAPEUTICS INC
COTEMPLA XR-ODT, METHYLPHENIDATE

NEPHRON

* NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
* NEPHRON PHARMACEUTICALS CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BUDESONIDE, BUDESONIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION

NEURELIS INC

* NEURELIS INC
VALTOCO, DIAZEPAM

NEUROCRINE

* NEUROCRINE BIOSCIENCES INC
INGREZZA, VALBENAZINE TOSYLATE
ONGENTYS, OPICAPONE

NEXTWAVE

* NEXTWAVE PHARMACEUTICALS INC A SUB OF TRIS PHARMA INC
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NEXTWAVE PHARMS

* NEXTWAVE PHARMACEUTICALS INC
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE

NEXUS

* NEXUS PHARMACEUTICALS LLC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
BUSULFAN, BUSULFAN
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
EMERPHED, EPHEDRINE SULFATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
NELARABINE, NELARABINE
POTASSIUM CHLORIDE 10MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ, POTASSIUM CHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TIROFIBAN HYDROCHLORIDE, TIROFIBAN HYDROCHLORIDE

NEXUS PHARMS

* NEXUS PHARMACEUTICALS INC
FLUORESCEIN SODIUM, FLUORESCEIN SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

NIAGARA PHARMS

* NIAGARA PHARMACEUTICALS INC
PUR-WASH, PURIFIED WATER (OTC)

NIPPON SHINYAKU

* NIPPON SHINYAKU CO LTD
VILTEPSO, VILTOLARSEN

NIVAGEN PHARMS INC

* NIVAGEN PHARMACEUTICALS INC
CALCIUM GLUCONATE, CALCIUM GLUCONATE
DECITABINE, DECITABINE
EFINACONAZOLE, EFINACONAZOLE
TEMOZOLOMIDE, TEMOZOLOMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

NOBELPHARMA
* NOBELPHARMA CO LTD
HYFTOR, SIROLIMUS

NODEN PHARMA
* NODEN PHARMA DAC
TEKTURNA, ALISKIREN HEMIFUMARATE

NORTEC DEV ASSOC
* NORTEC DEVELOPMENT ASSOC INC
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHLAND
* NORTHLAND NUCLEAR MEDICINE LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

NORTHSTAR HLTHCARE
* NORTHSTAR HEALTHCARE HOLDINGS LTD
ALLOPURINOL, ALLOPURINOL
BACLOFEN, BACLOFEN
GEMFIBROZIL, GEMFIBROZIL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTON WATERFORD
* NORTON WATERFORD LTD
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

NORWICH
* NORWICH PHARMACEUTICALS INC
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE

NOSTRUM LABS INC
* NOSTRUM LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CALCIUM ACETATE, CALCIUM ACETATE
CARBAMAZEPINE, CARBAMAZEPINE
CARISOPRODOL, CARISOPRODOL
CLARITHROMYCIN, CLARITHROMYCIN
DAPSONE, DAPSONE
ELIXOPHYLLIN, THEOPHYLLINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCODONE, HYDROCODONE BITARTRATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SUCRALFATE, SUCRALFATE
THEOPHYLLINE, THEOPHYLLINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

NOSTRUM PHARMS LLC
* NOSTRUM PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
THEOCHRON, THEOPHYLLINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

NOVA LABS LTD
* NOVA LABORATORIES LTD
PURIXAN, MERCAPTOPURINE

NOVADAQ TECH
* NOVADAQ TECHNOLOGIES ULC
SPY AGENT GREEN KIT, INDOCYANINE GREEN

NOVARTIS
* NOVARTIS PHARMACEUTICALS CORP
AFINITOR, EVEROLIMUS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

* NOVARTIS PHARMACEUTICALS CORP
ALOMIDE, LODOXAMIDE TROMETHAMINE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
COARTEM, ARTEMETHER
DESFERAL, DEFEROXAMINE MESYLATE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
EGATEN, TRICLABENDAZOLE
EXFORGE HCT, AMLODIPINE BESYLATE
EXFORGE, AMLODIPINE BESYLATE
EXJADE, DEFERASIROX
FABHALTA, IPTACOPAN HYDROCHLORIDE
GILENYA, FINGOLIMOD HYDROCHLORIDE
GLEEVEC, IMATINIB MESYLATE
JADENU SPRINKLE, DEFERASIROX
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KISQALI, RIBOCICLIB SUCCINATE
LEQVIO, INCLISIRAN SODIUM
LOCAMETZ, GALLIUM GA-68 GOZETOTIDE
MAYZENT, SIPONIMOD
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MYFORTIC, MYCOPHENOLIC SODIUM
NEORAL, CYCLOSPORINE
PIQRAY, ALPELISIB
PLUVICTO, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
PROMACTA KIT, ELTROMBOPAG OLAMINE
PROMACTA, ELTROMBOPAG OLAMINE
RYDAPT, MIDOSTAURIN
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SCEMBLIX, ASCIMINIB HYDROCHLORIDE
TAFINLAR, DABRAFENIB MESYLATE
TASIGNA, NILOTINIB HYDROCHLORIDE
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TOBRADEX, DEXAMETHASONE
TOBREX, TOBRAMYCIN
TRILEPTAL, OXCARBAZEPINE
TYKERB, LAPATINIB DITOSYLATE
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIJOICE, ALPELISIB
VOTRIENT, PAZOPANIB HYDROCHLORIDE
XIIDRA, LIFITEGRAST
ZORTRESS, EVEROLIMUS
ZYKADIA, CERITINIB

NOVARTIS PHARM

* NOVARTIS PHARMACEUTICAL CORP
AFINITOR DISPERZ, EVEROLIMUS
TABRECTA, CAPMATINIB HYDROCHLORIDE

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
FEMARA, LETROZOLE

NOVARTIS PHARMS CORP

* NOVARTIS PHARMACEUTICALS CORP
ENTRESTO, SACUBITRIL
JADENU, DEFERASIROX

NOVAST LABS

* NOVAST LABORATORIES CHINA LTD
NORETHINDRONE, NORETHINDRONE
* NOVAST LABORATORIES INC
DOCETAXEL, DOCETAXEL
* NOVAST LABORATORIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVAST LABORATORIES LTD
CARBOPLATIN, CARBOPLATIN
CARISOPRODOL, CARISOPRODOL
CHABELINA FE, ETHINYL ESTRADIOL
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DECITABINE, DECITABINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOLISHALE, ETHINYL ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HER STYLE, LEVONORGESTREL (OTC)
INDOMETHACIN, INDOMETHACIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LERIBANE, ETHINYL ESTRADIOL
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LO-MALMOREDE, ETHINYL ESTRADIOL
MALMOREDE, ETHINYL ESTRADIOL
MELAMISA, DROSPIRENONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE, NORETHINDRONE
OXALIPLATIN, OXALIPLATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PIMTREA, DESOGESTREL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PROBENECID AND COLCHICINE, COLCHICINE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RANOLAZINE, RANOLAZINE
SETLAKIN, ETHINYL ESTRADIOL
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLCAPONE, TOLCAPONE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRI-LO-LINYAH, ETHINYL ESTRADIOL
TRIAZOLAM, TRIAZOLAM
YAELA, DROSPIRENONE

NOVAST LABS LTD

* NOVAST LABORATORIES LTD
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
ELINEST, ETHINYL ESTRADIOL
FALMINA, ETHINYL ESTRADIOL
LEVONEST, ETHINYL ESTRADIOL
MONO-LINYAH, ETHINYL ESTRADIOL
PHILITH, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
WERA, ETHINYL ESTRADIOL

NOVATECH SA

* NOVATECH SA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

* NOVATECH SA
STERITALC, TALC

NOVEL LABS INC

* NOVEL LABORATORIES INC
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
CARBIDOPA, CARBIDOPA
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FAMOTIDINE, FAMOTIDINE
FLUCYTOSINE, FLUCYTOSINE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
LEVONORGESTREL, LEVONORGESTREL (OTC)
LINEZOLID, LINEZOLID
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE, SODIUM PHOSPHATE, DIBASIC,
MORPHINE SULFATE, MORPHINE SULFATE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
PHENELZINE SULFATE, PHENELZINE SULFATE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
TEMAZEPAM, TEMAZEPAM
TRIMETHOPRIM, TRIMETHOPRIM
VORICONAZOLE, VORICONAZOLE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

NOVELGENIX THERAPS

* NOVELGENIX THERAPEUTICS PVT LTD
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

NOVEN

* NOVEN PHARMACEUTICALS INC
MINIVELLE, ESTRADIOL

NOVEN PHARMS INC

* NOVEN PHARMACEUTICALS INC
COMBIPATCH, ESTRADIOL
DAYTRANA, METHYLPHENIDATE
XELSTRYM, DEXTROAMPHETAMINE

NOVITIUM PHARMA

* NOVITIUM PHARMA LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALPRAZOLAM, ALPRAZOLAM
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
BETAINE, BETAINE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARBAMAZEPINE, CARBAMAZEPINE
CARGLUMIC ACID, CARGLUMIC ACID
CHLORZOXAZONE, CHLORZOXAZONE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

* NOVITIUM PHARMA LLC
CLOTRIMAZOLE, CLOTRIMAZOLE
DAPSONE, DAPSONE
DEXAMETHASONE, DEXAMETHASONE
DIAZOXIDE, DIAZOXIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
ESTAZOLAM, ESTAZOLAM
ESTRADIOL, ESTRADIOL
FAMOTIDINE, FAMOTIDINE
FELBAMATE, FELBAMATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
LACOSAMIDE, LACOSAMIDE
LEVOCARNITINE SF, LEVOCARNITINE
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MELOXICAM, MELOXICAM
METHSUXIMIDE, METHSUXIMIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NAPROXEN, NAPROXEN
NITISINONE, NITISINONE
NITROFURANTOIN, NITROFURANTOIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIFABUTIN, RIFABUTIN
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SIROLIMUS, SIROLIMUS
SOVUNA, HYDROXYCHLOROQUINE SULFATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TADALAFIL, TADALAFIL
THIOTHIXENE, THIOTHIXENE
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
VALSARTAN, VALSARTAN

NOVO
* NOVO NORDISK INC
OZEMPIC, SEMAGLUTIDE
RIVFLOZA, NEDOSIRAN SODIUM
RYBELSUS, SEMAGLUTIDE
SAXENDA, LIRAGLUTIDE RECOMBINANT
WEGOVY, SEMAGLUTIDE

NOVO NORDISK
* NOVO NORDISK PHARMACEUTICALS INC
GLUCAGEN, GLUCAGON HYDROCHLORIDE

NOVO NORDISK INC
* NOVO NORDISK INC
VAGIFEM, ESTRADIOL
VICTOZA, LIRAGLUTIDE RECOMBINANT

NOVUGEN
* NOVUGEN ONCOLOGY SDN BHD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
SUNITINIB MALATE, SUNITINIB MALATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVUGEN PHARMA MALAYSIA SDN BHD
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE

NUKEMED

* NUKEMED INC DBA SPECTRONRX
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NUVO PHARM

* NUVO PHARMACEUTICAL INC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

NUVO PHARMS INC

* NUVO PHAMACEUTICALS INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
NAPROXEN, NAPROXEN
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SULFASALAZINE, SULFASALAZINE

NXDC

* NX DEVELOPMENT CORP
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE

**** O ****

OCULAR THERAPEUTIX

* OCULAR THERAPEUTIX INC
DEXTENZA, DEXAMETHASONE

OCUPHIRE

* OCUPHIRE PHARMA INC
RYZUMVI, PHENTOLAMINE MESYLATE

OHM LABS

* OHM LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

OHM LABS INC

* OHM LABORATORIES INC
EZETIMIBE, EZETIMIBE
GUAIFENESIN, GUAIFENESIN (OTC)
VALSARTAN, VALSARTAN

OMNIVIUM PHARMS

* OMNIVIUM PHARMACEUTICALS LLC
ISONIAZID, ISONIAZID
NUMBRINO, COCAINE HYDROCHLORIDE
SODIUM BICARBONATE, SODIUM BICARBONATE

OMSAV PHARMA

* OMSAV PHARMA RESEARCH PRIVATE LTD
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

ON TARGET LABS

* ON TARGET LABORATORIES INC
CYTALUX, PAFOLACIANINE SODIUM

ONYX PHARMS AMGEN

* ONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC
KYPROLIS, CARFILZOMIB

OPERAND PHARMS

* OPERAND PHARMACEUTICALS III LTD
EPHEDRINE SULFATE, EPHEDRINE SULFATE

OPTIMUS

* OPTIMUS PHARMA PRIVATE LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* OPTIMUS PHARMA PRIVATE LTD
AMINOCAPROIC ACID, AMINOCAPROIC ACID
BREXPIPRAZOLE, BREXPIPRAZOLE

OPTINOSE US INC

* OPTINOSE US INC
XHANCE, FLUTICASONE PROPIONATE

ORAPHARMA

* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORASIS PHARMS

* ORASIS PHARMACEUTICALS LTD
QLOSI, PILOCARPINE HYDROCHLORIDE

ORBICULAR

* ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LTD
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE

ORBION PHARMS

* ORBION PHARMACEUTICALS PRIVATE LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MODAFINIL, MODAFINIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZOLMITRIPTAN, ZOLMITRIPTAN

OREXO US INC

* OREXO US INC
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

ORGANON

* ORGANON LLC A SUB OF ORGANON AND CO
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CLARINEX, DESLORATADINE
COZAAR, LOSARTAN POTASSIUM
DIPROLENE, BETAMETHASONE DIPROPIONATE
FOSAMAX, ALENDRONATE SODIUM
HYZAAR, HYDROCHLOROTHIAZIDE
MAXALT-MLT, RIZATRIPTAN BENZOATE
PROPECIA, FINASTERIDE
PROSCAR, FINASTERIDE
SINEMET, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
VYTORIN, EZETIMIBE
ZETIA, EZETIMIBE
ZOCOR, SIMVASTATIN

* ORGANON USA LLC
NEXPLANON, ETONOGESTREL
REMERON, MIRTAZAPINE

ORGANON LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* ORGANON LLC
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
CLARINEX-D 12 HOUR, DESLORATADINE
DULERA, FORMOTEROL FUMARATE
FOSAMAX PLUS D, ALENDRONATE SODIUM
MAXALT, RIZATRIPTAN BENZOATE

ORGANON USA ORGANON
* ORGANON USA LLC A SUB OF ORGANON AND CO
GANIRELIX ACETATE, GANIRELIX ACETATE
NUVARING, ETHINYL ESTRADIOL
REMERON SOLTAB, MIRTAZAPINE

ORIENT PHARMA
* ORIENT PHARMA CO LTD
EZETIMIBE, EZETIMIBE

ORIENT PHARMA CO LTD
* ORIENT PHARMA CO LTD
CARISOPRODOL, CARISOPRODOL
GLYBURIDE, GLYBURIDE
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ORION PHARMA
* ORION PHARMA
COMTAN, ENTACAPONE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA

ORPHALAN
* ORPHALAN SA
CUVRIOR, TRIENTINE TETRAHYDROCHLORIDE

OSMOTICA PHARM US
* OSMOTICA PHARMACEUTICAL US LLC
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RELEXXII, METHYLPHENIDATE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OTSUKA
* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY ASIMTUFII, ARIPIPRAZOLE
ABILIFY MYCITE KIT, ARIPIPRAZOLE
ABILIFY, ARIPIPRAZOLE
INQOVI, CEDAZURIDINE
JYNARQUE, TOLVAPTAN
REXULTI, BREXPIPRAZOLE
SAMSCA, TOLVAPTAN

OTSUKA PHARM
* OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OTSUKA PHARM CO LTD
* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MAINTENA KIT, ARIPIPRAZOLE

OTTER PHARMS
* OTTER PHARMACEUTICALS LLC
OTREXUP, METHOTREXATE
SYMPAZAN, CLOBAZAM

OVERSEAS
* OVERSEAS PHARMACEUTICALS LTD
LEVETIRACETAM, LEVETIRACETAM

OXFORD PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* OXFORD PHARMACEUTICALS LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BACLOFEN, BACLOFEN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LORAZEPAM, LORAZEPAM
METHOCARBAMOL, METHOCARBAMOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
RIMACTANE, RIFAMPIN
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

OYSTER POINT PHARMA

* OYSTER POINT PHARMA INC
TYRVAYA, VARENICLINE TARTRATE

**** P ****

P AND L

* P AND L DEVELOPMENT LLC
ADAPALENE, ADAPALENE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DOCOSANOL, DOCOSANOL (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)

P AND L DEV LLC

* P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC
IBUPROFEN, IBUPROFEN (OTC)

PACIFIC PHARMA

* PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
* PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

PACIRA PHARMS INC

* PACIRA PHARMACEUTICALS INC
EXPAREL, BUPIVACAINE
ZILRETTA, TRIAMCINOLONE ACETONIDE

PADAGIS ISRAEL

* PADAGIS ISRAEL PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
AMMONIUM LACTATE, AMMONIUM LACTATE
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PADAGIS ISRAEL PHARMACEUTICALS LTD
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BUDESONIDE, BUDESONIDE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DAPSONE, DAPSONE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ESTRADIOL, ESTRADIOL
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GYNAZOLE-1, BUTOCONAZOLE NITRATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
IMIQUIMOD, IMIQUIMOD
IVERMECTIN, IVERMECTIN
KETOCONAZOLE, KETOCONAZOLE
MESALAMINE, MESALAMINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE (OTC)
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PERMETHRIN, PERMETHRIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SUMATRIPTAN, SUMATRIPTAN
TAZAROTENE, TAZAROTENE
TERCONAZOLE, TERCONAZOLE
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

PADAGIS US

* PADAGIS US LLC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BRINZOLAMIDE, BRINZOLAMIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CALCIUM ACETATE, CALCIUM ACETATE
CENTANY, MUPIROCIN
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CICLOPIROX, CICLOPIROX
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COMPRO, PROCHLORPERAZINE
CYCLOSPORINE, CYCLOSPORINE
DESONIDE, DESONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PADAGIS US LLC
DESOXIMETASONE, DESOXIMETASONE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ENTOCORT EC, BUDESONIDE
ERYTHROMYCIN, ERYTHROMYCIN
EVAMIST, ESTRADIOL
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROCORTISONE, HYDROCORTISONE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MORPHINE SULFATE, MORPHINE SULFATE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NYSTATIN, NYSTATIN
NYSTOP, NYSTATIN
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PODOFILOX, PODOFILOX
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
REPAGLINIDE, REPAGLINIDE
SCOPOLAMINE, SCOPOLAMINE
SELENIUM SULFIDE, SELENIUM SULFIDE
STIE-CORT, HYDROCORTISONE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TAVABOROLE, TAVABOROLE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

PAI HOLDINGS PHARM

* PAI HOLDINGS LLC DBA PHARMACEUTICAL ASSOCIATES INC
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
LACTULOSE, LACTULOSE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LITHIUM CITRATE, LITHIUM CITRATE
PHENYTOIN, PHENYTOIN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

PALATIN TECHNOLOGIES

* PALATIN TECHNOLOGIES INC
VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE

PANACEA

* PANACEA BIOTEC PHARMA LTD
PRASUGREL, PRASUGREL HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TACROLIMUS, TACROLIMUS

PAR FORM

* PAR FORMULATIONS PRIVATE LTD
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR PHARM

* PAR PHARMACEUTICAL
EVEROLIMUS, EVEROLIMUS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PAR PHARMACEUTICAL INC
ALPRAZOLAM, ALPRAZOLAM
ALVIMOPAN, ALVIMOPAN
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLONAZEPAM, CLONAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROXYUREA, HYDROXYUREA
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LAMOTRIGINE, LAMOTRIGINE
MINOXIDIL, MINOXIDIL
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
PIMOZIDE, PIMOZIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TOPIRAMATE, TOPIRAMATE
URSODIOL, URSODIOL

PAR PHARM INC

* PAR PHARMACEUTICAL INC
AMBRISENTAN, AMBRISENTAN
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
CHLORZOXAZONE, CHLORZOXAZONE
COLCHICINE, COLCHICINE
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
ETHACRYNIC ACID, ETHACRYNIC ACID
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
PENICILLAMINE, PENICILLAMINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PRAZIQUANTEL, PRAZIQUANTEL
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
TIOPRONIN, TIOPRONIN
TOLCAPONE, TOLCAPONE
TOLVAPTAN, TOLVAPTAN
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VIGABATRIN, VIGABATRIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR STERILE PRODUCTS

* PAR STERILE PRODUCTS LLC
ADRENALIN, EPINEPHRINE
ARGATROBAN, ARGATROBAN
BREVITAL SODIUM, METHOHEXITAL SODIUM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CALCITONIN-SALMON, CALCITONIN SALMON
COLY-MYCIN M, COLISTIMETHATE SODIUM
CORPHEDRA, EPHEDRINE SULFATE
DANTRIUM, DANTROLENE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PAR STERILE PRODUCTS LLC
KETALAR, KETAMINE HYDROCHLORIDE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
MICAFUNGIN, MICAFUNGIN SODIUM
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PITOCIN, OXYTOCIN
POSACONAZOLE, POSACONAZOLE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TREPROSTINIL, TREPROSTINIL
VASOSTRICT, VASOPRESSIN

PARAGON BIOTECK
* PARAGON BIOTECK INC
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

PARAPRO LLC
* PARAPRO LLC
NATROBA, SPINOSAD

PARATEK PHARMS INC
* PARATEK PHARMACEUTICALS INC
NUZYRA, OMADACYCLINE TOSYLATE

PARKE DAVIS
* PARKE DAVIS DIV WARNER LAMBERT CO
CELONTIN, METHSUXIMIDE
CEREBYX, FOSPHENYTOIN SODIUM
NARDIL, PHENELZINE SULFATE
ZARONTIN, ETHOSUXIMIDE

PARKE-DAVIS
* PARKE-DAVIS DIVISION OF PFIZER INC
ZARONTIN, ETHOSUXIMIDE

PATHEON SOFTGELS
* PATHEON SOFTGELS BV
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

PATRIN
* PATRIN PHARMA INC
CALCITRIOL, CALCITRIOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
FLAC, FLUOCINOLONE ACETONIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
PREGABALIN, PREGABALIN

PENN LIFE
* PENN LIFE SCIENCES LLC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
CARMUSTINE, CARMUSTINE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
THIOTEPA, THIOTEPA

PERRIGO NEW YORK
* PERRIGO NEW YORK INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
PERMETHRIN, PERMETHRIN (OTC)

PERRIGO PHARMA INTL
* PERRIGO PHARMA INTERNATIONAL DAC
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
MINOXIDIL, MINOXIDIL (OTC)
NASONEX 24HR ALLERGY, MOMETASONE FUROATE (OTC)
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
* PERRIGO PHARMA INTERNATIONAL DESIGNATED ACTIVITY CO
LORATADINE, LORATADINE (OTC)
PREVACID 24 HR, LANSOPRAZOLE (OTC)

PERRIGO R AND D
* PERRIGO R AND D CO
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PERRIGO R AND D CO
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LEVONORGESTREL, LEVONORGESTREL (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

PETNET

* PETNET SOLUTIONS INC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PF PRISM CV

* PF PRISM CV
BOSULIF, BOSUTINIB MONOHYDRATE
INLYTA, AXITINIB
PRISTIQ, DESVENLAFAXINE SUCCINATE
RAPAMUNE, SIROLIMUS
TORISEL, TEMSIROLIMUS
TYGACIL, TIGECYCLINE
VFEND, VORICONAZOLE
XALKORI, CRIZOTINIB
XELJANZ, TOFACITINIB CITRATE

PFIZER

* PFIZER CENTRAL RESEARCH
DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN
* PFIZER CHEMICALS DIV PFIZER INC
DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN
* PFIZER INC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
AROMASIN, EXEMESTANE
ARTHROTEC, DICLOFENAC SODIUM
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
CAVERJECT IMPULSE, ALPROSTADIL
CAVERJECT, ALPROSTADIL
CIBINQO, ABROCITINIB
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
COLESTID, COLESTIPOL HYDROCHLORIDE
CORVERT, IBUTILIDE FUMARATE
CYKLOKAPRON, TRANEXAMIC ACID
CYTOTEC, MISOPROSTOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PFIZER INC
DAURISMO, GLASDEGIB MALEATE
DAYPRO, OXAPROZIN
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ESTRING, ESTRADIOL
FLAGYL, METRONIDAZOLE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FRAGMIN, DALTEPARIN SODIUM
GLUCOTROL XL, GLIPIZIDE
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
HALCION, TRIAZOLAM
HEMABATE, CARBOPROST TROMETHAMINE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
IBRANCE, PALBOCICLIB
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LITFULO, RITLECITINIB TOSYLATE
LOMOTIL, ATROPINE SULFATE
LORBRENA, LORLATINIB
MEDROL, METHYLPREDNISOLONE
MERREM, MEROPENEM
MYCOBUTIN, RIFABUTIN
NICOTROL, NICOTINE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
NURTEC ODT, RIMEGEPANT SULFATE
OGEN 5, ESTROPIPATE
PAXLOVID (COPACKAGED), NIRMATRELVIR
PREPIDIL, DINOPROSTONE
PROCARDIA, NIFEDIPINE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROVERA, MEDROXYPROGESTERONE ACETATE
SONATA, ZALEPLON
SYNAREL, NAFARELIN ACETATE
TALZENNA, TALAZOPARIB TOSYLATE
TESSALON, BENZONATATE
TOVIAZ, FESOTERODINE FUMARATE
UNASYN, AMPICILLIN SODIUM
VELSIPITY, ETRASIMOD ARGININE
VIZIMPRO, DACOMITINIB
XELJANZ XR, TOFACITINIB CITRATE
XELJANZ, TOFACITINIB CITRATE
ZAVZPRET, ZAVEGEPANT HYDROCHLORIDE
ZITHROMAX, AZITHROMYCIN
ZYVOX, LINEZOLID
* PFIZER LABORATORIES DIV PFIZER INC
FELDENE, PIROXICAM
MINIPRESS, PRAZOSIN HYDROCHLORIDE
PFIZERPEN, PENICILLIN G POTASSIUM
PROCARDIA XL, NIFEDIPINE
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VISTARIL, HYDROXYZINE PAMOATE
* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

PFIZER INC

* PFIZER INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PFIZER INC
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
NICOTROL, NICOTINE

PFIZER PHARMS

* PFIZER PHARMACEUTICALS LTD
LOPID, GEMFIBROZIL

PHARM ASSOC

* PHARMACEUTICAL ASSOC INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORAZEPAM, LORAZEPAM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
* PHARMACEUTICAL ASSOCIATES INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
THEOPHYLLINE, THEOPHYLLINE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

PHARM SOURCING

* PHARMACEUTICAL SOURCING PARTNERS INC
MESALAMINE, MESALAMINE

PHARMA RES SOFTWARE

* PHARMA RESEARCH SOFTWARE SOLUTION LLC
POKONZA, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMACHEMIE BV

* PHARMACHEMIE BV
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA

* PHARMACIA AND UPJOHN CO LLC
CADUET, AMLODIPINE BESYLATE
DILANTIN, PHENYTOIN

PHARMACIA AND UPJOHN

* PHARMACIA AND UPJOHN CO

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PHARMACIA AND UPJOHN CO
CORTEF, HYDROCORTISONE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
R-GENE 10, ARGININE HYDROCHLORIDE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE

PHARMACOSMOS AS
* PHARMACOSMOS AS
MONOFERRIC, FERRIC DERISOMALTOSE

PHARMACYCLICS LLC
* PHARMACYCLICS LLC
IMBRUVICA, IBRUTINIB

PHARMADAX INC
* PHARMADAX INC
LEVETIRACETAM, LEVETIRACETAM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

PHARMALOGIC
* PHARMALOGIC SOUTH CAROLINA LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

PHARMALOGIC HLDGS
* PHARMALOGIC HOLDINGS CORP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

PHARMASCIENCE INC
* PHARMASCIENCE INC
BORTEZOMIB, BORTEZOMIB
BUSULFAN, BUSULFAN
DECITABINE, DECITABINE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM

PHARMING
* PHARMING TECHNOLOGIES BV
JOENJA, LENIOLISIB PHOSPHATE

PHATHOM
* PHATHOM PHARMACEUTICALS INC
VOQUEZNA DUAL PAK, AMOXICILLIN
VOQUEZNA TRIPLE PAK, AMOXICILLIN
VOQUEZNA, VONOPRAZAN FUMARATE

PHOTOCURE ASA
* PHOTOCURE ASA
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE FABRE DERMA
* PIERRE FABRE DERMATOLOGIE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

PIERREL
* PIERREL S.P.A.
ORABLOC, ARTICAINE HYDROCHLORIDE

PINNACLE BIOLGS
* PINNACLE BIOLOGICS INC
PHOTOFRIN, PORFIMER SODIUM

PIRAMAL CRITICAL
* PIRAMAL CRITICAL CARE INC
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
GABLOFEN, BACLOFEN
GLYCOPYRROLATE, GLYCOPYRROLATE
ISOFLURANE, ISOFLURANE
MITIGO, MORPHINE SULFATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SOJOURN, SEVOFLURANE
* PIRAMAL CRITICAL CARE LTD
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM

PIRAMAL HLTHCARE UK
* PIRAMAL HEALTHCARE UK LTD
CLOBAZAM, CLOBAZAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PIRAMAL HEALTHCARE UK LTD
DEFERASIROX, DEFERASIROX
EPLERENONE, EPLERENONE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
TETRABENAZINE, TETRABENAZINE

PIRAMAL PHARMA
* PIRAMAL PHARMA LTD
ISOFLURANE, ISOFLURANE

PLD ACQUISITIONS
* PLD ACQUISITIONS LLC DBA AVEMA PHARMA SOLUTIONS
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

PLD ACQUISITIONS LLC
* PLD ACQUISITIONS LLC
LORATADINE, LORATADINE (OTC)
ZOLMITRIPTAN, ZOLMITRIPTAN

PLIVA
* PLIVA INC
AZITHROMYCIN, AZITHROMYCIN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

PLIVA PHARM IND
* PLIVA PHARMACEUTICAL INDUSTRY INC
TORSEMIDE, TORSEMIDE

PLX PHARMA
* PLX PHARMA INC
VAZALORE, ASPIRIN (OTC)

POHL BOSKAMP
* POHL BOSKAMP
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLAREAN
* POLAREAN INC
XENOVIEW, XENON XE-129 HYPERPOLARIZED

POLYGEN PHARMS
* POLYGEN PHARMACEUTICALS INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

POWDER PHARMS
* POWDER PHARMACEUTICALS INC
ZINGO, LIDOCAINE HYDROCHLORIDE

PRASCO
* PRASCO LLC DBA PRASCO LABORATORIES
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
EPLERENONE, EPLERENONE
ESTRADIOL, ESTRADIOL
MIRTAZAPINE, MIRTAZAPINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

PRAXGEN
* PRAXGEN PHARMACEUTICALS LLC
METHYLPREDNISOLONE, METHYLPREDNISOLONE
RANOLAZINE, RANOLAZINE

PRECISION DERMAT
* PRECISION DERMATOLOGY INC
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

PRECISION DOSE INC

* PRECISION DOSE INC
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE

PRECISION NUCLEAR

* PRECISION NUCLEAR LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PRIMUS PHARMS

* PRIMUS PHARMACEUTICALS INC
IMPOYZ, CLOBETASOL PROPIONATE
SERNIVO, BETAMETHASONE DIPROPIONATE

PRINSTON INC

* PRINSTON PHARMACEUTICAL INC
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CAPTOPRIL, CAPTOPRIL
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENTECAVIR, ENTECAVIR
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE, FENOFIBRATE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LEVETIRACETAM, LEVETIRACETAM
LEVOMILNACIPRAN HYDROCHLORIDE, LEVOMILNACIPRAN HYDROCHLORIDE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PEMETREXED DISODIUM, PEMETREXED DISODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PRINSTON PHARMACEUTICAL INC
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREGABALIN, PREGABALIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROFLUMILAST, ROFLUMILAST
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SILODOSIN, SILODOSIN
TADALAFIL, TADALAFIL
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VORICONAZOLE, VORICONAZOLE
VYDUO, NEBIVOLOL HYDROCHLORIDE

PROF DSPLS

* PROFESSIONAL DISPOSABLES INC
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

PROGENICS PHARMS INC

* PROGENICS PHARMACEUTICALS INC
AZEDRA, IOBENGUANE I-131
PYLARIFY, PIFLUFOLASTAT F-18

PROPEL PHARMA

* PROPEL PHARMA CORP
VIGABATRIN, VIGABATRIN

PROTEGA PHARMS

* PROTEGA PHARMACEUTICALS INC
ROXYBOND, OXYCODONE HYDROCHLORIDE

PROVELL

* PROVELL PHARMACEUTICALS LLC
EUTHYROX, LEVOTHYROXINE SODIUM **

PROVENSIS

* PROVENSIS LTD
VARITHENA, POLIDOCANOL

PROVEPHARM SAS

* PROVEPHARM SAS
BAL, DIMERCAPROL
BLUDIGO, INDIGOTINDISULFONATE SODIUM
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PROVAYBLUE, METHYLENE BLUE
TRANEXAMIC ACID, TRANEXAMIC ACID

PTC THERAP

* PTC THERAPEUTICS INC
EMFLAZA, DEFLAZACORT

PULMOFLOW INC

* PULMOFLOW INC
KITABIS PAK, TOBRAMYCIN

PUMA BIOTECH

* PUMA BIOTECHNOLOGY INC
NERLYNX, NERATINIB MALEATE

PURACAP PHARM

* PURACAP PHARMACEUTICAL LLC
MELOXICAM, MELOXICAM

PURACAP PHARM LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PURACAP PHARMACEUTICAL LLC
BENZONATATE, BENZONATATE
ERGOCALCIFEROL, ERGOCALCIFEROL
ETHOSUXIMIDE, ETHOSUXIMIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

PURDUE PHARMA LP
* PURDUE PHARMA LP
BUTRANS, BUPRENORPHINE
HYSINGLA ER, HYDROCODONE BITARTRATE
MS CONTIN, MORPHINE SULFATE
NALMEFENE HYDROCHLORIDE, NALMEFENE HYDROCHLORIDE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

PURE SOURCE
* PURE SOURCE LLC
THEROXIDIL, MINOXIDIL (OTC)

PYROS PHARMS
* PYROS PHARMACEUTICALS INC
VIGPODER, VIGABATRIN

**** Q ****

Q BIOMED
* Q BIOMED INC
METASTRON, STRONTIUM CHLORIDE SR-89
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

QILU
* QILU PHARMACEUTICAL CO LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM
EXEMESTANE, EXEMESTANE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE

QILU PHARM HAINAN
* QILU PHARMACEUTICAL HAINAN CO LTD
BORTEZOMIB, BORTEZOMIB
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
GEFITINIB, GEFITINIB
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PEMETREXED DISODIUM, PEMETREXED DISODIUM
TADALAFIL, TADALAFIL

QINGDAO BAHEAL PHARM
* QINGDAO BAHEAL PHARMACEUTICAL CO LTD
CELECOXIB, CELECOXIB
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE

QOL MEDCL
* QOL MEDICAL LLC
ETHAMOLIN, ETHANOLAMINE OLEATE

QUAGEN
* QUAGEN PHARMACEUTICALS LLC
ALBUTEROL SULFATE, ALBUTEROL SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** Q **

* QUAGEN PHARMACEUTICALS LLC
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

QUEEN HAMAMATSU PET
* QUEEN HAMAMATSU PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

** R **

R-PHARM US LLC
* R-PHARM US LLC
IXEMPRA KIT, IXABEPILONE

RADIOMEDIX
* RADIOMEDIX INC
DETECTNET, COPPER CU-64 DOTATATE

RADIUS
* RADIUS HEALTH INC
BINOSTO, ALENDRONATE SODIUM
TYMLOS, ABALOPARATIDE

RAYNER SURGICAL
* RAYNER SURGICAL INC
OMIDRIA, KETOROLAC TROMETHAMINE

RB HLTH
* RB HEALTH US LLC
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX, GUAIFENESIN (OTC)

REATA PHARMS
* REATA PHARMACEUTICALS INC
SKYCLARYS, OMAVELOXOLONE

RECORDATI RARE
* RECORDATI RARE DISEASES INC
CARBAGLU, CARGLUMIC ACID
CHEMET, SUCCIMER
COSMEGEN, DACTINOMYCIN
CYSTADANE, BETAINE
CYSTADROPS, CYSTEAMINE HYDROCHLORIDE
ISTURISA, OSILODROSTAT PHOSPHATE
NEOPROFEN, IBUPROFEN LYSINE
SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
SIGNIFOR, PASIREOTIDE DIASPARTATE

REDHILL
* REDHILL BIOPHARMA INC
AEMCOLO, RIFAMYCIN SODIUM
* REDHILL BIOPHARMA LTD
TALICIA, AMOXICILLIN

RELIANCE LIFE
* RELIANCE LIFE SCIENCES PVT LTD
CAPECITABINE, CAPECITABINE

REMPEX
* REMPEX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF MELINTA THERAPEUTICS LLC
MINOCIN, MINOCYCLINE HYDROCHLORIDE
VABOMERE, MEROPENEM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

RENATA
* RENATA LTD
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
PREGABALIN, PREGABALIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

RENEW PHARMS
* RENEW PHARMACEUTICALS LTD
INDOCYANINE GREEN, INDOCYANINE GREEN

RESILIA PHARMS
* RESILIA PHARMACEUTICALS INC
ECOZA, ECONAZOLE NITRATE

REYOUNG
* REYOUNG CORPORATION
FENOFIBRATE (MICRONIZED), FENOFIBRATE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE

RHODES PHARMS
* RHODES PHARMACEUTICALS LP
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

RHYTHM
* RHYTHM PHARMACEUTICALS INC
IMCIVREE, SETMELANOTIDE ACETATE

RICONPHARMA LLC
* RICONPHARMA LLC
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH
CARBAMAZEPINE, CARBAMAZEPINE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FLUNISOLIDE, FLUNISOLIDE
ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
SCOPOLAMINE, SCOPOLAMINE

RIGEL PHARMS INC
* RIGEL PHARMACEUTICALS INC
REZLIDHIA, OLUTASIDENIB
TAVALISSE, FOSTAMATINIB DISODIUM

RILEY CONSUMER
* RILEY CONSUMER CARE LLC DBA CARLIN CONSUMER HEALTH
ZEGERID OTC, OMEPRAZOLE (OTC)

RISE PHARMA
* RISE PHARMA LLC
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLORZOXAZONE, CHLORZOXAZONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
KETOCONAZOLE, KETOCONAZOLE

RISING

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* RISING PHARMA HOLDING INC
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAPECITABINE, CAPECITABINE
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CYTARABINE, CYTARABINE
DIGOXIN, DIGOXIN
DIPYRIDAMOLE, DIPYRIDAMOLE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
* RISING PHARMA HOLDINGS INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACETIC ACID, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ADENOSINE, ADENOSINE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZATHIOPRINE, AZATHIOPRINE
BACLOFEN, BACLOFEN
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
CALCITRIOL, CALCITRIOL
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CICLOPIROX, CICLOPIROX
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DAPSONE, DAPSONE
DESOXIMETASONE, DESOXIMETASONE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXERCALCIFEROL, DOXERCALCIFEROL
EPLERENONE, EPLERENONE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
EXEMESTANE, EXEMESTANE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCORTISONE, HYDROCORTISONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* RISING PHARMA HOLDINGS INC
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), AMOXICILLIN
LEVETIRACETAM, LEVETIRACETAM
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN
LINEZOLID, LINEZOLID
LORAZEPAM, LORAZEPAM
METHIMAZOLE, METHIMAZOLE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NADOLOL, NADOLOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NATEGLINIDE, NATEGLINIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NITAZOXANIDE, NITAZOXANIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PARICALCITOL, PARICALCITOL
PERPHENAZINE, PERPHENAZINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PREGABALIN, PREGABALIN
PROBENECID AND COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RANOLAZINE, RANOLAZINE
RISPERIDONE, RISPERIDONE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SULFAMYLON, MAFENIDE ACETATE
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
TEMOZOLOMIDE, TEMOZOLOMIDE
THIOTHIXENE, THIOTHIXENE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
TROPICACYL, TROPICAMIDE
VORICONAZOLE, VORICONAZOLE
ZILEUTON, ZILEUTON
* RISING PHARMACEUTICALS
URSODIOL, URSODIOL

RISING PHARMS

* RISING PHARMACEUTICALS INC
ZAFIRLUKAST, ZAFIRLUKAST

RK PHARMA

* RK PHARMA INC
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** R ****

* RK PHARMA INC
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MITOMYCIN, MITOMYCIN
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
NADOLOL, NADOLOL
PALIPERIDONE, PALIPERIDONE
URSODIOL, URSODIOL

ROCHE PALO
* ROCHE PALO ALTO LLC
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

ROMARK
* ROMARK LABORATORIES
ALINIA, NITAZOXANIDE

ROXANE
* ROXANE LABORATORIES INC
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

RUBICON
* RUBICON RESEARCH PRIVATE LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
ARIPIPRAZOLE, ARIPIPRAZOLE
BACLOFEN, BACLOFEN
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARVEDILOL, CARVEDILOL
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* RUBICON RESEARCH PRIVATE LTD
PREGABALIN, PREGABALIN
PRIMIDONE, PRIMIDONE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

RVL PHARMS

* RVL PHARMACEUTICALS INC
UPNEEQ, OXYMETAZOLINE HYDROCHLORIDE

** S **

SAGE CHEMS

* SAGE CHEMICALS INC
APOMORPHINE HYDROCHLORIDE, APOMORPHINE HYDROCHLORIDE

SAGE PRODS

* SAGE PRODUCTS INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGE THERAP

* SAGE THERAPEUTICS INC
ZULRESSO, BREXANOLONE

SAGENT

* SAGENT PHARMACEUTICALS
BUMETANIDE, BUMETANIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
VALPROATE SODIUM, VALPROATE SODIUM

SAGENT PHARMS

* SAGENT PHARMACEUTICALS INC
CAFFEINE CITRATE, CAFFEINE CITRATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXACILLIN SODIUM, OXACILLIN SODIUM
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

SAGENT PHARMS INC

* SAGENT PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPTIFIBATIDE, EPTIFIBATIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SAGENT PHARMACEUTICALS INC
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOROURACIL, FLUOROURACIL
FULVESTRANT, FULVESTRANT
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYDO, LIDOCAINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LINEZOLID, LINEZOLID
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OXYTOCIN, OXYTOCIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PROPOFOL, PROPOFOL
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

SALIX

* SALIX PHARMACEUTICALS INC
APRISO, MESALAMINE
FENOGLIDE, FENOFIBRATE
PLENVU, ASCORBIC ACID
RELISTOR, METHYLNALTREXONE BROMIDE
TRULANCE, PLECANATIDE
UCERIS, BUDESONIDE
ZEGERID, OMEPRAZOLE

SALIX PHARMS

* SALIX PHARMACEUTICALS INC
ANUSOL HC, HYDROCORTISONE
DIURIL, CHLOROTHIAZIDE
MOVIPREP, ASCORBIC ACID
RELISTOR, METHYLNALTREXONE BROMIDE
XIFAXAN, RIFAXIMIN

SAMSON MEDCL

* SAMSON MEDICAL TECHNOLOGIES LLC
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

SANDOZ

* SANDOZ
DOCETAXEL, DOCETAXEL

* SANDOZ INC
ACETAMINOPHEN, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANDOZ INC
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANGIOMAX, BIVALIRUDIN
APREPITANT, APREPITANT
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARRANON, NELARABINE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
AZOPT, BRINZOLAMIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BIMATOPROST, BIMATOPROST
BORTEZOMIB, BORTEZOMIB
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CLARITHROMYCIN, CLARITHROMYCIN
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COSYNTROPIN, COSYNTROPIN
CROMOLYN SODIUM, CROMOLYN SODIUM
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSPORINE, CYCLOSPORINE
DECITABINE, DECITABINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIGOXIN, DIGOXIN
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DUREZOL, DIFLUPREDNATE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPLERENONE, EPLERENONE
ETODOLAC, ETODOLAC
EXELON, RIVASTIGMINE
EZETIMIBE, EZETIMIBE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC

FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FERUMOXYTOL, FERUMOXYTOL
FLUMAZENIL, FLUMAZENIL
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FULVESTRANT, FULVESTRANT
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GATIFLOXACIN, GATIFLOXACIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLATOPA, GLATIRAMER ACETATE
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HEPARIN SODIUM, HEPARIN SODIUM
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISONIAZID, ISONIAZID
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ITRACONAZOLE, ITRACONAZOLE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), AMOXICILLIN
LANSOPRAZOLE, LANSOPRAZOLE
LATANOPROST, LATANOPROST
LESCOL XL, FLUVASTATIN SODIUM
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOFLOXACIN, LEVOFLOXACIN
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LINEZOLID, LINEZOLID
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOTREL, AMLODIPINE BESYLATE
MAXITROL, DEXAMETHASONE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYDRIACYL, TROPICAMIDE
NADOLOL, NADOLOL
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEVIRAPINE, NEVIRAPINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OMEPRAZOLE, OMEPRAZOLE
OMNIPRED, PREDNISOLONE ACETATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXALIPLATIN, OXALIPLATIN
OXAPROZIN, OXAPROZIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERPHENAZINE, PERPHENAZINE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIRFENIDONE, PIRFENIDONE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QOLIANA, BRIMONIDINE TARTRATE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RECLAST, ZOLEDRONIC ACID
REGONOL, PYRIDOSTIGMINE BROMIDE
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILODOSIN, SILODOSIN
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TACROLIMUS, TACROLIMUS
TAFLUPROST, TAFLUPROST
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TERIFLUNOMIDE, TERIFLUNOMIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TIGECYCLINE, TIGECYCLINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRADEX, DEXAMETHASONE
TOBREX, TOBRAMYCIN
TRAVATAN Z, TRAVOPROST
TREPROSTINIL, TREPROSTINIL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VIVELLE-DOT, ESTRADIOL
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANDOZ CANADA INC

* SANDOZ CANADA INC
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INFUVITE PEDIATRIC, ASCORBIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SANDOZ INC

* SANDOZ INC
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

SANOFI

* SANOFI AVENTIS US LLC
FEXINIDAZOLE, FEXINIDAZOLE
FLOMAX, TAMSULOSIN HYDROCHLORIDE
* SANOFI GENZYME
HECTOROL, DOXERCALCIFEROL
RENVELA, SEVELAMER CARBONATE

SANOFI AVENTIS US

* SANOFI AVENTIS US INC
JEVTANA KIT, CABAZITAXEL
* SANOFI AVENTIS US LLC
AMARYL, GLIMEPIRIDE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBIEN, ZOLPIDEM TARTRATE
ARAVA, LEFLUNOMIDE
AUBAGIO, TERIFLUNOMIDE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
DIABETA, GLYBURIDE
ELOXATIN, OXALIPLATIN
FERRLECIT, FERRIC OXYHYDROXIDE
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOVENOX, ENOXAPARIN SODIUM
MULTAQ, DRONEDARONE HYDROCHLORIDE
PLAVIX, CLOPIDOGREL BISULFATE
PRIFTIN, RIFAPENTINE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
RIFADIN, RIFAMPIN
TAXOTERE, DOCETAXEL

SANTARUS INC

* SANTARUS INC
GLUMETZA, METFORMIN HYDROCHLORIDE

SAPTALIS PHARMS

* SAPTALIS PHARMACEUTICALS LLC
ACETIC ACID, ACETIC ACID, GLACIAL
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
LEVOCARNITINE, LEVOCARNITINE
LIKMEZ, METRONIDAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
VOSOL HC, ACETIC ACID, GLACIAL

SAREPTA THERAPS INC

* SAREPTA THERAPEUTICS INC
AMONDYS 45, CASIMERSEN
EXONDYS 51, ETEPLIRSEN
VYONDYS 53, GOLODIRSEN

SARFE PHARMS

* SARFEZ PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SARFEZ PHARMACEUTICALS INC
SOAANZ, TORSEMIDE

SAVIOR LIFETEC CORP

* SAVIOR LIFETEC CORP
ERTAPENEM SODIUM, ERTAPENEM SODIUM
MEROPENEM, MEROPENEM

SAWAI USA

* SAWAI USA INC
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM

SCHERING

* SCHERING CORP
NOXAFIL, POSACONAZOLE

SCIARRA LABS

* SCIARRA LABORATORIES INC
SCLEROSOL, TALC
TALC, TALC

SCIECURE PHARMA INC

* SCIECURE PHARMA INC
CARBAMAZEPINE, CARBAMAZEPINE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE

SCIEGEN PHARMS INC

* SCIEGEN PHARMACEUTICALS INC
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARISOPRODOL, CARISOPRODOL
CELECOXIB, CELECOXIB
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
ETHACRYNIC ACID, ETHACRYNIC ACID
EZETIMIBE, EZETIMIBE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LISINOPRIL, LISINOPRIL
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NABUMETONE, NABUMETONE
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
PHYTONADIONE, PHYTONADIONE
PIRFENIDONE, PIRFENIDONE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SCIEGEN PHARMACEUTICALS INC
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
VALPROIC ACID, VALPROIC ACID
VALSARTAN, VALSARTAN

SCILEX HLDG
* SCILEX HOLDING CO
ELYXYB, CELECOXIB

SCILEX PHARMS
* SCILEX PHARMACEUTICALS INC
GLOPERBA, COLCHICINE
ZTLIDO, LIDOCAINE

SCINOPHARM TAIWAN
* SCINOPHARM TAIWAN LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

SCPHARMACEUTICALS
* SCPHARMACEUTICALS INC
FUROSCIX, FUROSEMIDE

SCYNEXIS
* SCYNEXIS INC
BREXAFEMME, IBREXAFUNGERP CITRATE

SEAGEN
* SEAGEN INC
TUKYSA, TUCATINIB

SEBELA IRELAND LTD
* SEBELA IRELAND LTD
BRISDELLE, PAROXETINE MESYLATE
IMURAN, AZATHIOPRINE
LOTRONEX, ALOSETRON HYDROCHLORIDE
MICORT-HC, HYDROCORTISONE ACETATE
MOTOFEN, ATROPINE SULFATE
NAFTIN, NAFTIFINE HYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
RIDAURA, AURANOFIN

SECURA
* SECURA BIO INC
COPIKTRA, DUVELISIB

SENORES PHARMS
* SENORES PHARMACEUTICALS INC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

SENTISS
* SENTISS AG
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BROMFENAC SODIUM, BROMFENAC SODIUM
CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
ERYTHROMYCIN, ERYTHROMYCIN
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
OFLOXACIN, OFLOXACIN

SENTISS PHARMA
* SENTISS PHARMA PRIVATE LTD
TIMOLOL MALEATE, TIMOLOL MALEATE

SENTYNL THERAPS INC
* SENTYNL THERAPEUTICS INC
NULIBRY, FOSDENOPTERIN HYDROBROMIDE

SEPTODONT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SEPTODONT INC
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
DYCLOPRO, DYCLONINE HYDROCHLORIDE

SEPTODONT HOLDING
* SEPTODONT HOLDING SAS
ORAVERSE, PHENTOLAMINE MESYLATE

SEPTODONT INC
* SEPTODONT INC
LIDOCAINE, LIDOCAINE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

SERVIER
* SERVIER PHARMACEUTICALS LLC
TIBSOVO, IVOSIDENIB

SETON PHARM
* SETON PHARMACEUTICAL LLC
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

SETON PHARMS
* SETON PHARMACEUTICALS LLC
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE

SHANDONG
* SHANDONG ANXIN PHARMACEUTICAL CO LTD
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
* SHANDONG NEW TIME PHARMACEUTICAL CO LTD
MILRINONE LACTATE, MILRINONE LACTATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SEVOFLURANE, SEVOFLURANE

SHANDONG LUYE
* SHANDONG LUYE PHARMACEUTICAL CO LTD
RYKINDO, RISPERIDONE

SHANDONG XINHUA
* SHANDONG XINHUA PHARMACEUTICAL CO LTD
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)

SHANGHAI HENGRUI
* SHANGHAI HENGRUI PHARMACEUTICAL CO LTD
DESFLURANE, DESFLURANE
SEVOFLURANE, SEVOFLURANE

SHENZHEN TECHDOW
* SHENZHEN TECHDOW PHARMACEUTICAL CO LTD
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

SHIELD TX
* SHIELD TX UK LTD
ACCRUFER, FERRIC MALTOL

SHILPA
* SHILPA MEDICARE LTD
APREMILAST, APREMILAST
BUSULFAN, BUSULFAN
CAPECITABINE, CAPECITABINE
DOCETAXEL, DOCETAXEL
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PEMETREXED, PEMETREXED DISODIUM

SHILPA MEDICARE
* SHILPA MEDICARE LTD
AZACITIDINE, AZACITIDINE

SHIONOGI INC
* SHIONOGI INC
FETROJA, CEFIDEROCOL SULFATE TOSYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SHORLA
* SHORLA PHARMA LTD
JYLAMVO, METHOTREXATE
NELARABINE, NELARABINE

SIDMAK LABS INDIA
* SIDMAK LABORATORIES INDIA PVT LTD
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

SIGA TECHNOLOGIES
* SIGA TECHNOLOGIES INC
TPOXX, TECOVIRIMAT

SIGMAPHARM LABS LLC
* SIGMAPHARM LABORATORIES LLC
ACITRETIN, ACITRETIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMBRISENTAN, AMBRISENTAN
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
ASENAPINE MALEATE, ASENAPINE MALEATE
DISULFIRAM, DISULFIRAM
DOFETILIDE, DOFETILIDE
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

SINOTHERAPEUTICS INC
* SINOTHERAPEUTICS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
MESALAMINE, MESALAMINE
POSACONAZOLE, POSACONAZOLE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

SINTETICA US
* SINTETICA US LLC
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

SK LIFE
* SK LIFE SCIENCE INC
XCOPRI, CENOBAMATE

SKYEPHARMA AG
* SKYEPHARMA AG
TRIGLIDE, FENOFIBRATE

SLATE RUN PHARMA
* SLATE RUN PHARMACEUTICALS LLC
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
AZITHROMYCIN, AZITHROMYCIN
BIVALIRUDIN, BIVALIRUDIN
CILOSTAZOL, CILOSTAZOL
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
EPTIFIBATIDE, EPTIFIBATIDE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
METHOCARBAMOL, METHOCARBAMOL
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
VORICONAZOLE, VORICONAZOLE

SLAYBACK PHARMA LLC
* SLAYBACK PHARMA LLC
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
DEOXYCHOLIC ACID, DEOXYCHOLIC ACID
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
ICATIBANT ACETATE, ICATIBANT ACETATE
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
MERZEE, ETHINYL ESTRADIOL
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SLAYBACK PHARMA LLC
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PREVDUO, GLYCOPYRROLATE
TOFACITINIB CITRATE, TOFACITINIB CITRATE
VIVIMUSTA, BENDAMUSTINE HYDROCHLORIDE

SOCIETAL CDMO
* SOCIETAL CDMO GAINESVILLE LLC
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE

SOFGEN PHARMS
* SOFGEN PHARMACEUTICALS LLC
IBUPROFEN, IBUPROFEN (OTC)
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PROGESTERONE, PROGESTERONE

SOFIE
* SOFIE CO DBA SOFIE
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
* SOFIE CO DBA SOFIE (FKA ZEVACOR PHARMA INC)
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SOLA PHARMS
* SOLA PHARMACEUTICALS
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CYANOCOBALAMIN, CYANOCOBALAMIN
DIMETHYL FUMARATE, DIMETHYL FUMARATE
TERIFLUNOMIDE, TERIFLUNOMIDE

SOLARIS PHARMA CORP
* SOLARIS PHARMA CORP
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
METRONIDAZOLE, METRONIDAZOLE
TAZAROTENE, TAZAROTENE

SOLUBIOMIX
* SOLUBIOMIX LLC
COXANTO, OXAPROZIN

SOMERSET
* SOMERSET PHARMACEUTICALS INC
EMSAM, SELEGILINE
* SOMERSET THERAPEUTICS LLC
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
LATANOPROST, LATANOPROST
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SOMERSET THERAPS LLC
* SOMERSET THERAPEUTICS LLC
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
METHOCARBAMOL, METHOCARBAMOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SOMERSET THERAPEUTICS LLC
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TROPICAMIDE, TROPICAMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SPECGX LLC

* SPECGX LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
POSACONAZOLE, POSACONAZOLE
RESTORIL, TEMAZEPAM
ROXICODONE, OXYCODONE HYDROCHLORIDE
TOFRANIL, IMIPRAMINE HYDROCHLORIDE

SPECTRA MDCL DEVICES

* SPECTRA MEDICAL DEVICES INC
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

SPIL

* SUN PHARMA INDUSTRIES LTD
AMPHOTERICIN B, AMPHOTERICIN B
ASPRUZYO SPRINKLE, RANOLAZINE
KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
NIFEDIPINE, NIFEDIPINE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)

SPRINGWORKS

* SPRINGWORKS THERAPEUTICS INC
OGSIVEO, NIROGACESTAT HYDROBROMIDE

SPROUT PHARMS

* SPROUT PHARMACEUTICALS INC
ADDYI, FLIBANSERIN

SQUARE PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SQUARE PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
ARIPIPRAZOLE, ARIPIPRAZOLE
CALCIUM ACETATE, CALCIUM ACETATE
MIRTAZAPINE, MIRTAZAPINE
VALSARTAN, VALSARTAN

SS PHARMA
* SS PHARMA LLC
DRISDOL, ERGOCALCIFEROL
HIPREX, METHENAMINE HIPPURATE
PARLODEL, BROMOCRIPTINE MESYLATE
ROCALTROL, CALCITRIOL

ST RENATUS
* ST RENATUS LLC
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE

STALLION LABS
* STALLION LABORATORIES PRIVATE LTD
LEVETIRACETAM, LEVETIRACETAM

STAND HOMEOPATH
* STANDARD HOMEOPATHIC CO
IVY BLOCK, BENTOQUATAM (OTC)

STASON PHARMS
* STASON PHARMACEUTICALS INC
PURINETHOL, MERCAPTOPURINE

STEMLINE THERAP
* STEMLINE THERAPEUTICS INC
ORSERDU, ELACESTRANT DIHYDROCHLORIDE

STERISCIENCE
* STERISCIENCE PTE LTD
ACETYLCYSTEINE, ACETYLCYSTEINE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
FOCINVEZ, FOSAPREPITANT DIMEGLUMINE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
OXACILLIN SODIUM, OXACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
SODIUM BICARBONATE, SODIUM BICARBONATE

STI PHARMA LLC
* STI PHARMA LLC
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE

STIEFEL
* STIEFEL LABORATORIES INC
DUAC, BENZOYL PEROXIDE

STRIDES PHARMA
* STRIDES PHARMA GLOBAL PTE LTD
ABACAVIR SULFATE, ABACAVIR SULFATE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
ALBENDAZOLE, ALBENDAZOLE
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
BENZONATATE, BENZONATATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* STRIDES PHARMA GLOBAL PTE LTD
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CABERGOLINE, CABERGOLINE
CALCITRIOL, CALCITRIOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLARITHROMYCIN, CLARITHROMYCIN
COLCHICINE, COLCHICINE
CYCLOSPORINE, CYCLOSPORINE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DOFETILIDE, DOFETILIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
DUTASTERIDE, DUTASTERIDE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ERGOCALCIFEROL, ERGOCALCIFEROL
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUCYTOSINE, FLUCYTOSINE
GABAPENTIN, GABAPENTIN
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ICOSAPENT ETHYL, ICOSAPENT ETHYL
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHOXSALEN, METHOXSALEN
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NATEGLINIDE, NATEGLINIDE
NEVIRAPINE, NEVIRAPINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLANZAPINE, OLANZAPINE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PIROXICAM, PIROXICAM
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* STRIDES PHARMA GLOBAL PTE LTD
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREDNISONE, PREDNISONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
ROFLUMILAST, ROFLUMILAST
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TACROLIMUS, TACROLIMUS
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TESTOSTERONE, TESTOSTERONE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TORSEMIDE, TORSEMIDE
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
URSODIOL, URSODIOL
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZILEUTON, ZILEUTON

STRONGBRIDGE

* STRONGBRIDGE DUBLIN LTD
RECORLEV, LEVOKETOCONAZOLE

SUCAMPO PHARMA LLC

* SUCAMPO PHARMA AMERICAS LLC
AMITIZA, LUBIPROSTONE

SUMITOMO PHARMA

* SUMITOMO PHARMA SWITZERLAND GMBH
ORGOVYX, RELUGOLIX

SUMITOMO PHARMA AM

* SUMITOMO PHARMA AMERICA INC
APTIOM, ESLICARBAZEPINE ACETATE

SUN PHARM

* SUN PHARMACEUTICAL INDUSTRIES LTD
ABSORICA LD, ISOTRETINOIN
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AMBRISENTAN, AMBRISENTAN
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BOSENTAN, BOSENTAN
BROMSITE, BROMFENAC SODIUM
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
CAPECITABINE, CAPECITABINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBOPLATIN, CARBOPLATIN
CEQUA, CYCLOSPORINE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
DALFAMPRIDINE, DALFAMPRIDINE
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOFETILIDE, DOFETILIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESZOPICLONE, ESZOPICLONE
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE, FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FYREMADEL, GANIRELIX ACETATE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMATINIB MESYLATE, IMATINIB MESYLATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACOSAMIDE, LACOSAMIDE
LANSOPRAZOLE, LANSOPRAZOLE
LENALIDOMIDE, LENALIDOMIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LORATADINE, LORATADINE (OTC)
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NIACIN, NIACIN
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
ODOMZO, SONIDEGIB PHOSPHATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE (OTC)
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
PALIPERIDONE, PALIPERIDONE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAZOPANIB HYDROCHLORIDE, PAZOPANIB HYDROCHLORIDE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANOLAZINE, RANOLAZINE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
SAXAGLIPTIN, SAXAGLIPTIN HYDROCHLORIDE
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUNITINIB MALATE, SUNITINIB MALATE
TADALAFIL, TADALAFIL
TEMOZOLOMIDE, TEMOZOLOMIDE
TOBRAMYCIN, TOBRAMYCIN
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WINLEVI, CLASCOTERONE
XELPROS, LATANOPROST
YONSA, ABIRATERONE ACETATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SUN PHARM INDS

* SUN PHARMACEUTICAL INDUSTRIES LTD
CARBIDOPA AND LEVODOPA, CARBIDOPA
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLANZAPINE, OLANZAPINE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

SUN PHARM INDS (IN)

* SUN PHARMACEUTICAL INDUSTRIES LTD
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC

* SUN PHARMACEUTICAL INDUSTRIES INC
ABSORICA, ISOTRETINOIN
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CLONAZEPAM, CLONAZEPAM
CLOZAPINE, CLOZAPINE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIGOXIN, DIGOXIN
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
HALOG, HALCINONIDE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
REPAGLINIDE, REPAGLINIDE
SEZABY, PHENOBARBITAL SODIUM
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SUN PHARMACEUTICAL INDUSTRIES INC
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

SUN PHARM INDS LTD

* SUN PHARMACEUTICAL INDUSTRIES LTD
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DOXYCYCLINE, DOXYCYCLINE
FAMOTIDINE, FAMOTIDINE (OTC)
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GLYCOPYRROLATE, GLYCOPYRROLATE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
RILUZOLE, RILUZOLE
RISPERIDONE, RISPERIDONE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TOPIRAMATE, TOPIRAMATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

SUN PHARM INDUSTRIES

* SUN PHARMACEUTICAL INDUSTRIES INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CHLORTHALIDONE, CHLORTHALIDONE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SUN PHARMACEUTICAL INDUSTRIES INC
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NYSTATIN, NYSTATIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PREDNISONE, PREDNISONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUALAQUIN, QUININE SULFATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
ULTRAVATE, HALOBETASOL PROPIONATE

SUNNY

* SUNNY PHARMTECH INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

SUNOVION PHARMS INC

* SUNOVION PHARMACEUTICALS INC
LATUDA, LURASIDONE HYDROCHLORIDE

SUNSHINE

* SUNSHINE LAKE PHARMA CO LTD
ARIPIPRAZOLE, ARIPIPRAZOLE
AZITHROMYCIN, AZITHROMYCIN
CLARITHROMYCIN, CLARITHROMYCIN
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
FEBUXOSTAT, FEBUXOSTAT
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, LINAGLIPTIN
LINAGLIPTIN, LINAGLIPTIN
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
RANOLAZINE, RANOLAZINE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TADALAFIL, TADALAFIL

SUPERNUS PHARMS

* SUPERNUS PHARMACEUTICALS INC
OXTELLAR XR, OXCARBAZEPINE
QELBREE, VILOXAZINE HYDROCHLORIDE
TROKENDI XR, TOPIRAMATE

SUVEN PHARMS

* SUVEN PHARMACEUTICALS LTD
CALCIUM ACETATE, CALCIUM ACETATE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
GLYCOPYRROLATE, GLYCOPYRROLATE
MALATHION, MALATHION

SVC PHARMA

* SVC PHARMA LP
DRONABINOL, DRONABINOL

SWEDISH ORPHAN

* SWEDISH ORPHAN BIOVITRUM AB PUBL
ORFADIN, NITISINONE

SYNTHON PHARMS

* SYNTHON PHARMACEUTICALS INC
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

SYNTHON PHARMS INC

* SYNTHON PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SYNTHON PHARMACEUTICALS INC
PALBOCICLIB, PALBOCICLIB

** T **

ACME LABS
* THE ACME LABORATORIES LTD
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
METHOCARBAMOL, METHOCARBAMOL
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

GEN HOSP
* THE GENERAL HOSPITAL CORP
AMMONIA N 13, AMMONIA N-13

METHODIST
* THE METHODIST HOSP RESEARCH INSTITUTE
AMMONIA N 13, AMMONIA N-13

METHODIST HOSP RES
* THE METHODIST HOSP RESEARCH INSTITUTE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

RITEDOSE CORP
* THE RITEDOSE CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TAGI
* TAGI PHARMA INC
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE

TAIHO ONCOLOGY
* TAIHO ONCOLOGY INC
LONSURF, TIPIRACIL HYDROCHLORIDE
LYTGOBI, FUTIBATINIB

TAKEDA PHARMS USA
* TAKEDA PHARMACEUTICALS USA INC
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
ALUNBRIG, BRIGATINIB
CARBATROL, CARBAMAZEPINE
COLCRYS, COLCHICINE
DEXILANT, DEXLANSOPRAZOLE
DUETACT, GLIMEPIRIDE
EXKIVITY, MOBOCERTINIB SUCCINATE
FIRAZYR, ICATIBANT ACETATE
FOSRENOL, LANTHANUM CARBONATE
FRUZAQLA, FRUQUINTINIB
GATTEX KIT, TEDUGLUTIDE RECOMBINANT
ICLUSIG, PONATINIB HYDROCHLORIDE
INTUNIV, GUANFACINE HYDROCHLORIDE
KAZANO, ALOGLIPTIN BENZOATE
LIALDA, MESALAMINE
LIVTENCITY, MARIBAVIR
MOTEGRITY, PRUCALOPRIDE SUCCINATE
MYDAYIS, AMPHETAMINE ASPARTATE
NESINA, ALOGLIPTIN BENZOATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TAKEDA PHARMACEUTICALS USA INC
NINLARO, IXAZOMIB CITRATE
OSENI, ALOGLIPTIN BENZOATE
PENTASA, MESALAMINE
PREVACID, LANSOPRAZOLE
ROZEREM, RAMELTEON
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
ULORIC, FEBUXOSTAT
VELCADE, BORTEZOMIB
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

TAMARANG

* TAMARANG SA
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TARO

* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAZOLAMIDE, ACETAZOLAMIDE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
BUMETANIDE, BUMETANIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOCORTOLONE PIVALATE, CLOCORTOLONE PIVALATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DEFERIPRONE, DEFERIPRONE
DESONIDE, DESONIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FELBAMATE, FELBAMATE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE, HYDROCORTISONE
IMIQUIMOD, IMIQUIMOD
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
IVERMECTIN, IVERMECTIN (OTC)
KETOCONAZOLE, KETOCONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
METRONIDAZOLE, METRONIDAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TARO PHARMACEUTICAL INDUSTRIES LTD
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
PHENYTOIN, PHENYTOIN
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TERIL, CARBAMAZEPINE
TOPICORT, DESOXIMETASONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
WARFARIN SODIUM, WARFARIN SODIUM

* TARO PHARMACEUTICALS INC
ACETIC ACID, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADAPALENE, ADAPALENE
ADAPALENE, ADAPALENE (OTC)
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMMONIUM LACTATE, AMMONIUM LACTATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DAPSONE, DAPSONE
DERMABET, BETAMETHASONE VALERATE
DOCOSANOL, DOCOSANOL (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
TAVABOROLE, TAVABOROLE
TAZAROTENE, TAZAROTENE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERCONAZOLE, TERCONAZOLE
TOPICORT, DESOXIMETASONE
TRETINOIN, TRETINOIN

* TARO PHARMACEUTICALS USA INC
AZELAIC ACID, AZELAIC ACID
CICLOPIROX, CICLOPIROX
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DAPSONE, DAPSONE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
KETOZOLE, KETOCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TARO PHARMACEUTICALS USA INC
LIDOCAINE, LIDOCAINE
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PHENYTOIN, PHENYTOIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)

TARO PHARM INDS
* TARO PHARMACEUTICAL INDUSTRIES LTD
AMCINONIDE, AMCINONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE

TARSUS
* TARSUS PHARMACEUTICALS INC
XDEMVY, LOTILANER

TASMAN PHARMA
* TASMAN PHARMA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
KETOCONAZOLE, KETOCONAZOLE
VERSACLOZ, CLOZAPINE

TCG FLUENT PHARMA
* TCG FLUENT PHARMA INVESTORS LP
FLOLIPID, SIMVASTATIN

TEIKOKU PHARMA USA
* TEIKOKU PHARMA USA INC
LIDODERM, LIDOCAINE

TELIGENT
* TELIGENT PHARMA INC
FLURANDRENOLIDE, FLURANDRENOLIDE

TELIX
* TELIX PHARMACEUTICALS US INC
ILLUCCIX, GALLIUM GA-68 GOZETOTIDE

TENSHI
* TENSHI KAIZEN PVT LTD
LORATADINE, LORATADINE (OTC)

TERSERA
* TERSERA THERAPEUTICS LLC
ERGOMAR, ERGOTAMINE TARTRATE
PRIALT, ZICONOTIDE ACETATE
VARUBI, ROLAPITANT HYDROCHLORIDE
XERMELO, TELOTRISTAT ETIPRATE
ZOLADEX, GOSERELIN ACETATE

TETRAPHASE PHARMS
* TETRAPHASE PHARMACEUTICALS INC
XERAVA, ERAVACYCLINE DIHYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

TEVA

* TEVA NEUROSCIENCE INC
AUSTEDO XR, DEUTETRABENAZINE
AZILECT, RASAGILINE MESYLATE
UZEDY, RISPERIDONE

* TEVA PHARMACEUTICALS USA INC
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CARVEDILOL, CARVEDILOL
CEFACLOR, CEFACLOR
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CILOSTAZOL, CILOSTAZOL
CIMETIDINE, CIMETIDINE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
EPITOL, CARBAMAZEPINE
ESZOPICLONE, ESZOPICLONE
ETODOLAC, ETODOLAC
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALZIN, ZINC ACETATE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOFLOXACIN, LEVOFLOXACIN
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA INC
MUPIROCIN, MUPIROCIN
NAPROXEN, NAPROXEN
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
OXAPROZIN, OXAPROZIN
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PENICILLIN-VK, PENICILLIN V POTASSIUM
PIROXICAM, PIROXICAM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRELONE, PREDNISOLONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SUCRALFATE, SUCRALFATE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
ACTIGALL, URSODIOL
AUSTEDO, DEUTETRABENAZINE
CONDYLOX, PODOFILOX
LOSEASONIQUE, ETHINYL ESTRADIOL
MICROZIDE, HYDROCHLOROTHIAZIDE
NOR-QD, NORETHINDRONE
PROAIR DIGIHALER, ALBUTEROL SULFATE
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROGLYCEM, DIAZOXIDE
QNASL, BECLOMETHASONE DIPROPIONATE
QUARTETTE, ETHINYL ESTRADIOL
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
ZIAC, BISOPROLOL FUMARATE

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TEVA PHARM

* TEVA PHARMACEUTICAL INDUSTRIES LTD
AIRDUO DIGIHALER, FLUTICASONE PROPIONATE
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
ARMONAIR DIGIHALER, FLUTICASONE PROPIONATE

TEVA PHARMS

* TEVA PHARMACEUTICALS DEVELOPMENT INC
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
PYRIMETHAMINE, PYRIMETHAMINE

* TEVA PHARMACEUTICALS USA
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
BUDESONIDE, BUDESONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM
FAMCICLOVIR, FAMCICLOVIR
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
IRBESARTAN, IRBESARTAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA
LANSOPRAZOLE, LANSOPRAZOLE
LETROZOLE, LETROZOLE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

TEVA PHARMS INC

* TEVA PHARMACEUTICALS INC
ALVAIZ, ELTROMBOPAG CHOLINE
ALYQ, TADALAFIL
CETRORELIX ACETATE, CETRORELIX ACETATE
PAZOPANIB HYDROCHLORIDE, PAZOPANIB HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

TEVA PHARMS INTL

* TEVA PHARMACEUTICALS INTERNATIONAL GMBH
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
SYNRIBO, OMACETAXINE MEPESUCCINATE

TEVA PHARMS USA

* TEVA PHARMACEUTICALS USA
ACITRETIN, ACITRETIN
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BEXAROTENE, BEXAROTENE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUDESONIDE, BUDESONIDE
CLARAVIS, ISOTRETINOIN
CLOZAPINE, CLOZAPINE
COPAXONE, GLATIRAMER ACETATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EPTIFIBATIDE, EPTIFIBATIDE
ESTRADIOL, ESTRADIOL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LOGILIA, ULIPRISTAL ACETATE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OMEPRAZOLE, OMEPRAZOLE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUNITINIB MALATE, SUNITINIB MALATE
TADALAFIL, TADALAFIL
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOBRAMYCIN, TOBRAMYCIN
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TREPROSTINIL, TREPROSTINIL
VIGABATRIN, VIGABATRIN
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN

* TEVA PHARMACEUTICALS USA INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ALYQ, TADALAFIL
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
CAPECITABINE, CAPECITABINE
DAPTOMYCIN, DAPTOMYCIN
DARUNAVIR, DARUNAVIR
DEFERASIROX, DEFERASIROX
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
EFINACONAZOLE, EFINACONAZOLE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
ESTRADIOL, ESTRADIOL
EVEROLIMUS, EVEROLIMUS
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
ICATIBANT ACETATE, ICATIBANT ACETATE
IVERMECTIN, IVERMECTIN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
MESALAMINE, MESALAMINE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METRONIDAZOLE, METRONIDAZOLE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ONSURA, ETHINYL ESTRADIOL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PENCICLOVIR, PENCICLOVIR
PIRFENIDONE, PIRFENIDONE
TERIFLUNOMIDE, TERIFLUNOMIDE
TERIPARATIDE, TERIPARATIDE
TOBRAMYCIN, TOBRAMYCIN
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TEVA PHARMS USA INC

* TEVA PHARMACEUTICALS USA INC
CHLORZOXAZONE, CHLORZOXAZONE
CYCLOSPORINE, CYCLOSPORINE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
ETHINYL ESTRADIOL; ETONOGESTREL, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA PHARMACEUTICALS USA INC
FINZALA, ETHINYL ESTRADIOL
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
FULVESTRANT, FULVESTRANT
LUBIPROSTONE, LUBIPROSTONE
MIFEPRISTONE, MIFEPRISTONE
NALTREXONE, NALTREXONE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
PLERIXAFOR, PLERIXAFOR
POTASSIUM CITRATE, POTASSIUM CITRATE
RISPERIDONE, RISPERIDONE
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
TASIMELTEON, TASIMELTEON
TIOPRONIN, TIOPRONIN

TEYRO LABS
* TEYRO LABS PRIVATE LTD
CAPECITABINE, CAPECITABINE
CARBOPLATIN, CARBOPLATIN
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

THE FEINSTEIN INST
* THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

THE J MOLNER
* THE J MOLNER CO OU
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE

THEA PHARMA
* THEA PHARMA INC
AKTEN, LIDOCAINE HYDROCHLORIDE
AZASITE, AZITHROMYCIN
BETIMOL, TIMOLOL
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSOPT, DORZOLAMIDE HYDROCHLORIDE
IYUZEH, LATANOPROST
ZIOPTAN, TAFLUPROST

THEPHARMANETWORK LLC
* THEPHARMANETWORK LLC
ISONIAZID, ISONIAZID
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
THERMAZENE, SILVER SULFADIAZINE

THERACOSBIO
* THERACOSBIO LLC
BRENZAVVY, BEXAGLIFLOZIN

THERAGNOSTICS
* THERAGNOSTICS INC
NEPHROSCAN, TECHNETIUM TC-99M SUCCIMER

THERAVIA
* THERAVIA PHARMA
SIKLOS, HYDROXYUREA

THINQ PHARM-CRO PVT
* THINQ PHARMA-CRO PRIVATE LTD
FLUCONAZOLE, FLUCONAZOLE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TINIDAZOLE, TINIDAZOLE

TIANJIN KINGYORK
* TIANJIN KINGYORK PHARMACEUTICALS CO LTD
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE

TIANJIN TIANYAO
* TIANJIN TIANYAO PHARMACEUTICALS CO LTD
CELECOXIB, CELECOXIB

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TIANJIN TIANYAO PHARMACEUTICALS CO LTD
METHYLPREDNISOLONE, METHYLPREDNISOLONE

TILDE SCIENCES

* TILDE SCIENCES LLC
DARAPRIM, PYRIMETHAMINE

TOLMAR

* TOLMAR INC
ELIGARD KIT, LEUPROLIDE ACETATE
JATENZO, TESTOSTERONE UNDECANOATE
KETOCONAZOLE, KETOCONAZOLE
* TOLMAR INTERNATIONAL LTD
FENSOLVI KIT, LEUPROLIDE ACETATE

TONIX MEDS

* TONIX MEDICINES INC
TOSYMRA, SUMATRIPTAN
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE

TOPROL

* TOPROL ACQUISITION LLC
TOPROL-XL, METOPROLOL SUCCINATE

TORPHARM

* TORPHARM INC
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

TORRENT

* TORRENT PHARMA INC
APREPITANT, APREPITANT
DICHLORPHENAMIDE, DICHLORPHENAMIDE
ERYTHROMYCIN, ERYTHROMYCIN
NITISINONE, NITISINONE
* TORRENT PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ARIPIPRAZOLE, ARIPIPRAZOLE
CELECOXIB, CELECOXIB
DAPSONE, DAPSONE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NYSTATIN, NYSTATIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
PENCICLOVIR, PENCICLOVIR
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
TADALAFIL, TADALAFIL
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

TORRENT PHARMS

* TORRENT PHARMACEUTICALS LTD
CARBAMAZEPINE, CARBAMAZEPINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TORRENT PHARMACEUTICALS LTD
RISPERIDONE, RISPERIDONE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TORRENT PHARMS LTD

* TORRENT PHARMACEUTICALS LTD
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELODIPINE, FELODIPINE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE

TRAVERE

* TRAVERE THERAPEUTICS INC
FILSPARI, SPARSENTAN

TREVENA

* TREVENA INC
OLINVYK, OLICERIDINE

TRIS PHARMA INC

* TRIS PHARMA INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DYANAVEL XR 10, AMPHETAMINE
DYANAVEL XR 15, AMPHETAMINE
DYANAVEL XR 20, AMPHETAMINE
DYANAVEL XR 5, AMPHETAMINE
DYANAVEL XR, AMPHETAMINE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
IBUPROFEN, IBUPROFEN (OTC)
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
THEOPHYLLINE, THEOPHYLLINE

TRUSTEES UNIV PA

* TRUSTEES OF THE UNIV OF PENNSYLVANIA
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

TULEX PHARMS INC

* TULEX PHARMACEUTICALS INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
NAPROXEN, NAPROXEN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

TWI PHARMS

* TWI PHARMACEUTICALS INC
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FORFIVO XL, BUPROPION HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
NAPRELAN, NAPROXEN SODIUM
NIFEDIPINE, NIFEDIPINE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TWI PHARMACEUTICALS INC
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TESTOSTERONE, TESTOSTERONE
TOPIRAMATE, TOPIRAMATE
ZESTRIL, LISINOPRIL

TWI PHARMS INC

* TWI PHARMACEUTICALS INC
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

** U **

UBI

* UBI PHARMA INC
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
VORICONAZOLE, VORICONAZOLE

UCB INC

* UCB INC
BRIVIACT, BRIVARACETAM
FINTEPLA, FENFLURAMINE HYDROCHLORIDE
KEPPRA XR, LEVETIRACETAM
KEPPRA, LEVETIRACETAM
NAYZILAM, MIDAZOLAM
NEUPRO, ROTIGOTINE
VIMPAT, LACOSAMIDE
ZILBRYSQ, ZILUCOPLAN SODIUM

UCLA BIOMEDICAL

* UCLA BIOMEDICAL CYCLOTRON
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UCSF RODIOPHARM

* UCSF RADIOPHARMACEUTICAL FACILITY
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UIHC PET IMAGING

* UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
GALLIUM GA 68 EDOTREOTIDE, GALLIUM GA-68 EDOTREOTIDE

ULTRAGENYX PHARM INC

* ULTRAGENYX PHARMACEUTICAL INC
DOJOLVI, TRIHEPTANOIN

UMEDICA

* UMEDICA LABORATORIES PRIVATE LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CARBAMAZEPINE, CARBAMAZEPINE
CELECOXIB, CELECOXIB
CHLORTHALIDONE, CHLORTHALIDONE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
GLYCOPYRROLATE, GLYCOPYRROLATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TADALAFIL, TADALAFIL

UNICHEM

* UNICHEM LABORATORIES LTD
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UNICHEM LABORATORIES LTD
ARIPIPRAZOLE, ARIPIPRAZOLE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PIROXICAM, PIROXICAM
PRASUGREL HYDROCHLORIDE, PRASUGREL HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANOLAZINE, RANOLAZINE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZONISAMIDE, ZONISAMIDE

UNICHEM LABS LTD

* UNICHEM LABORATORIES LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM

* UNICHEM LABORATORIES LTD
LAMOTRIGINE, LAMOTRIGINE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

UNIMARK REMEDIES LTD

* UNIMARK REMEDIES LTD
MONTELUKAST SODIUM, MONTELUKAST SODIUM

UNIQUE

* UNIQUE PHARMACEUTICAL LABORATORIES A DIV OF JB CHEMICALS AND PHARMACEUTICALS LTD
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GLIPIZIDE, GLIPIZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

UNIQUE PHARM

* UNIQUE PHARMACEUTICAL LABORATORIES
CARBAMAZEPINE, CARBAMAZEPINE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)

UNITED BIOMEDCL

* UNITED BIOMEDICAL INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UNITED BIOMEDICAL INC
TERBUTALINE SULFATE, TERBUTALINE SULFATE

UNITED GUARDIAN

* UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

UNITED RES LABS

* UNITED RESEARCH LABORATORIES LLC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
OXAZEPAM, OXAZEPAM

UNITED THERAP

* UNITED THERAPEUTICS CORP
ORENITRAM, TREPROSTINIL DIOLAMINE
REMODULIN, TREPROSTINIL
TYVASO DPI, TREPROSTINIL
TYVASO, TREPROSTINIL

UNIV ALAHAMA BIRM

* UNIV ALABAMA AT BIRMINGHAM
AMMONIA N 13, AMMONIA N-13

UNIV CA LOS ANGELES

* UNIV CALIFORNIA LOS ANGELES
GALLIUM GA 68 GOZETOTIDE, GALLIUM GA-68 GOZETOTIDE

UNIV MICHIGAN

* UNIV MICHIGAN PET RADIOPHARMACEUTICAL PRODUCTION PROGRAM
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV OF CA SAN FRAN

* UNIV OF CALIFORNIA SAN FRANCISCO
GALLIUM GA 68 GOZETOTIDE, GALLIUM GA-68 GOZETOTIDE

UNIV SOUTHERN CA

* UNIV SOUTHERN CALIFORNIA DBA USC MOLECULAR IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX MD ANDERSON

* UNIV TEXAS MD ANDERSON CANCER CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX SW MEDCTR

* UNIV TEXAS SOUTHWESTERN MEDCTR
AMMONIA N 13, AMMONIA N-13

UNIV UTAH CYCLOTRON

* UNIV UTAH CYCLOTRON RADIOCHEMISTRY LAB
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UNIV WISCONSIN

* UNIV WISCONSIN SYSTEM
AMMONIA N 13, AMMONIA N-13

UPJOHN

* UPJOHN MANUFACTURING IRELAND UNLTD
LIPITOR, ATORVASTATIN CALCIUM
RELPAX, ELETRIPTAN HYDROBROMIDE

* UPJOHN US 2 LLC
CELEBREX, CELECOXIB
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
INSPRA, EPLERENONE
LYRICA CR, PREGABALIN
LYRICA, PREGABALIN
XALATAN, LATANOPROST
XANAX XR, ALPRAZOLAM
XANAX, ALPRAZOLAM

UPSHER SMITH LABS

* UPSHER SMITH LABORATORIES LLC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UPSHER SMITH LABORATORIES LLC
BEXAROTENE, BEXAROTENE
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BUMETANIDE, BUMETANIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CLOBAZAM, CLOBAZAM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DROXIDOPA, DROXIDOPA
ELIGLUSTAT TARTRATE, ELIGLUSTAT TARTRATE
ETHACRYNIC ACID, ETHACRYNIC ACID
EXEMESTANE, EXEMESTANE
FAMOTIDINE, FAMOTIDINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
HALOPERIDOL, HALOPERIDOL
ISOTRETINOIN, ISOTRETINOIN
JANTOVEN, WARFARIN SODIUM
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
LAMIVUDINE, LAMIVUDINE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYORISAN, ISOTRETINOIN
NYSTATIN, NYSTATIN
ORVATEN, MIDODRINE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PACERONE, AMIODARONE HYDROCHLORIDE
PREVALITE, CHOLESTYRAMINE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUDEXY XR, TOPIRAMATE
RAMELTEON, RAMELTEON
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
VIGABATRIN, VIGABATRIN
VOGELXO, TESTOSTERONE

URL LABS
* URL LABORATORIES LLC
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

UROGEN PHARMA
* UROGEN PHARMA LTD
JELMYTO, MITOMYCIN

UROVANT
* UROVANT SCIENCES GMBH
GEMTESA, VIBEGRON

US ANTIBIOTICS
* US ANTIBIOTICS LLC
AMOXIL, AMOXICILLIN
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
LAROTID, AMOXICILLIN

USPHARMA
* USPHARMA LTD
NITRO-DUR, NITROGLYCERIN

USPHARMA WINDLAS
* USPHARMA WINDLAS LLC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE

USV

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** U **

* USV PRIVATE LTD
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
ZOLEDRONIC ACID, ZOLEDRONIC ACID

USWM

* USWM LLC
CORGARD, NADOLOL
IWILFIN, EFLORNITHINE HYDROCHLORIDE
LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
REVONTO, DANTROLENE SODIUM

** V **

VALEANT

* VALEANT PHARMACEUTICALS INTERNATIONAL
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
MYSOLINE, PRIMIDONE

VALEANT BERMUDA

* VALEANT INTERNATIONAL BERMUDA
RETIN-A, TRETINOIN

VALEANT INTL

* VALEANT INTERNATIONAL BARBADOS SRL
RETIN-A, TRETINOIN
* VALEANT INTERNATIONAL SRL
BENZAMYCIN, BENZOYL PEROXIDE

VALEANT LUXEMBOURG

* VALEANT PHARMACEUTICALS LUXEMBOURG SARL
TARGRETIN, BEXAROTENE
VISUDYNE, VERTEPORFIN

VALEANT PHARM INTL

* VALEANT PHARMACEUTICALS INTERNATIONAL
ANDROID 25, METHYLTESTOSTERONE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE

VALEANT PHARMS

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
PENTOXIFYLLINE, PENTOXIFYLLINE

VALEANT PHARMS INTL

* VALEANT PHARMACEUTICALS INTERNATIONAL
COLAZAL, BALSALAZIDE DISODIUM
CUPRIMINE, PENICILLAMINE

VALEANT PHARMS NORTH

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
CARAC, FLUOROURACIL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FENOFIBRATE, FENOFIBRATE
NIFEDIPINE, NIFEDIPINE
RENOVA, TRETINOIN
RETIN-A, TRETINOIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

VALIDUS PHARMS

* VALIDUS PHARMACEUTICALS LLC
ANZEMET, DOLASETRON MESYLATE
BUMEX, BUMETANIDE
EQUETRO, CARBAMAZEPINE
LASIX, FUROSEMIDE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE

VALIDUS PHARMS INC

* VALIDUS PHARMACEUTICALS INC
MARPLAN, ISOCARBOXAZID

VALINOR

* VALINOR PHARMA LLC
MOVANTIK, NALOXEGOL OXALATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

VANCOCIN ITALIA
* VANCOCIN ITALIA SRL
MULPLETA, LUSUTROMBOPAG

VANDA PHARMS INC
* VANDA PHARMACEUTICALS INC
FANAPT, ILOPERIDONE
HETLIOZ LQ, TASIMELTEON
HETLIOZ, TASIMELTEON

VELOXIS PHARMS INC
* VELOXIS PHARMACEUTICALS INC
ENVARSUS XR, TACROLIMUS

VERITY
* VERITY PHARMACEUTICALS INC
TRELSTAR, TRIPTORELIN PAMOATE

VERO BIOTECH INC
* VERO BIOTECH INC
GENOSYL, NITRIC OXIDE

VEROSCIENCE
* VEROSCIENCE LLC
CYCLOSET, BROMOCRIPTINE MESYLATE

VERRICA PHARMS
* VERRICA PHARMACEUTICALS INC
YCANTH, CANTHARIDIN

VERTEX PHARMS
* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR

VERTEX PHARMS INC
* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR
ORKAMBI, IVACAFTOR
SYMDEKO (COPACKAGED), IVACAFTOR
TRIKAFTA (COPACKAGED), ELEXACAFTOR, IVACAFTOR, TEZACAFTOR

VERTICAL PHARMS
* VERTICAL PHARMACEUTICALS LLC
DIVIGEL, ESTRADIOL
DSUVIA, SUFENTANIL CITRATE

VIATRIS
* VIATRIS SPECIALTY LLC
CARDURA XL, DOXAZOSIN MESYLATE
CARDURA, DOXAZOSIN MESYLATE
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN
NORVASC, AMLODIPINE BESYLATE
REVATIO, SILDENAFIL CITRATE
VIAGRA, SILDENAFIL CITRATE
ZOLOFT, SERTRALINE HYDROCHLORIDE

VICURON HOLDINGS
* VICURON HOLDINGS LLC
ERAXIS, ANIDULAFUNGIN

VIFOR FRESENIUS
* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
VELPHORO, FERRIC OXYHYDROXIDE

VIFOR PHARMA
* VIFOR PHARMA INC
VELTASSA, PATIROMER SORBITEX CALCIUM

VIIV HLTHCARE
* VIIV HEALTHCARE CO
APRETUDE, CABOTEGRAVIR
CABENUVA KIT, CABOTEGRAVIR
COMBIVIR, LAMIVUDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VIIV HEALTHCARE CO
DOVATO, DOLUTEGRAVIR SODIUM
EPIVIR, LAMIVUDINE
EPZICOM, ABACAVIR SULFATE
JULUCA, DOLUTEGRAVIR SODIUM
LEXIVA, FOSAMPRENAVIR CALCIUM
RETROVIR, ZIDOVUDINE
RUKOBIA, FOSTEMSAVIR TROMETHAMINE
SELZENTRY, MARAVIROC
TIVICAY PD, DOLUTEGRAVIR SODIUM
TIVICAY, DOLUTEGRAVIR SODIUM
TRIUMEQ PD, ABACAVIR SULFATE
TRIUMEQ, ABACAVIR SULFATE
VOCABRIA, CABOTEGRAVIR SODIUM
ZIAGEN, ABACAVIR SULFATE

VINTAGE
* VINTAGE PHARMACEUTICALS LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
DUTASTERIDE, DUTASTERIDE

VINTAGE PHARMS
* VINTAGE PHARMACEUTICALS
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
KIMIDESS, DESOGESTREL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
* VINTAGE PHARMACEUTICALS INC
ALLOPURINOL, ALLOPURINOL
BACLOFEN, BACLOFEN
IBUPROFEN, IBUPROFEN (OTC)
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PERPHENAZINE, PERPHENAZINE
PREDNISONE, PREDNISONE

VINTAGE PHARMS LLC
* VINTAGE PHARMACEUTICALS LLC
FELODIPINE, FELODIPINE
MYZILRA, ETHINYL ESTRADIOL
PERCOCET, ACETAMINOPHEN
PREVIFEM, ETHINYL ESTRADIOL

VIRTUS
* VIRTUS PHARMACEUTICALS LLC
CROMOLYN SODIUM, CROMOLYN SODIUM
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PROMETRIUM, PROGESTERONE

VIRTUS PHARM
* VIRTUS PHARMACEUTICAL INC
ACARBOSE, ACARBOSE
ALBUTEROL SULFATE, ALBUTEROL SULFATE

VISTA PHARMS
* VISTA PHARMACEUTICALS INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM
* VISTAPHARM INC
ARIPIPRAZOLE, ARIPIPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
PHENYTOIN, PHENYTOIN
SUCRALFATE, SUCRALFATE

VISUM PHARM
* VISUM PHARMACEUTICAL CO LTD
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

VITRUVIAS
* VITRUVIAS THERAPEUTICS INC
ENTECAVIR, ENTECAVIR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

VITRUVIAS THERAP
* VITRUVIAS THERAPEUTICS LLC
CYANOCOBALAMIN, CYANOCOBALAMIN

VIVUS
* VIVUS INC
QSYMIA, PHENTERMINE HYDROCHLORIDE

VIWIT PHARM
* VIWIT PHARMACEUTICAL CO LTD
LEVETIRACETAM, LEVETIRACETAM
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

VKT PHARMA
* VKT PHARMA PRIVATE LTD
FAMOTIDINE, FAMOTIDINE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
TADALAFIL, TADALAFIL

VPI PHARMS INC
* VPI PHARMACEUTICALS INC
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM

VPNA
* VALEANT PHARMACEUTICALS NORTH AMERICA
DICLOFENAC SODIUM, DICLOFENAC SODIUM

** W **

WA UNIV SCH MED
* WASHINGTON UNIV SCHOOL MEDICINE
AMMONIA N 13, AMMONIA N-13

WANBANG BIOPHARMS
* WANBANG BIOPHARMACEUTICALS
CARISOPRODOL, CARISOPRODOL
LEFLUNOMIDE, LEFLUNOMIDE

WATSON LABS
* WATSON LABORATORIES
FOLIC ACID, FOLIC ACID
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
* WATSON LABORATORIES INC
ACARBOSE, ACARBOSE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMOXAPINE, AMOXAPINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
COL-PROBENECID, COLCHICINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTAZOLAM, ESTAZOLAM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METRONIDAZOLE, METRONIDAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WATSON LABORATORIES INC
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NABUMETONE, NABUMETONE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NATEGLINIDE, NATEGLINIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NIZATIDINE, NIZATIDINE
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUASENSE, ETHINYL ESTRADIOL
RAMIPRIL, RAMIPRIL
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
* WATSON LABS INC
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS INC

* WATSON LABORATORIES INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
BOSENTAN, BOSENTAN
BRINZOLAMIDE, BRINZOLAMIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
COLCHICINE, COLCHICINE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
PENICILLAMINE, PENICILLAMINE
PERPHENAZINE, PERPHENAZINE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL

WATSON LABS TEVA

* WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
ALVIMOPAN, ALVIMOPAN
BICALUTAMIDE, BICALUTAMIDE
BUPRENORPHINE, BUPRENORPHINE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
GLIPIZIDE, GLIPIZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
ISRADIPINE, ISRADIPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
PROBENECID, PROBENECID
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

WATSON PHARMS INC

* WATSON PHARMACEUTICALS INC
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

WAVERLEY PHARMA INC

* WAVERLEY PHARMA INC
BORTEZOMIB, BORTEZOMIB
PEMETREXED DISODIUM, PEMETREXED DISODIUM

WAYLIS THERAP

* WAYLIS THERAPEUTICS LLC
FLUTAMIDE, FLUTAMIDE
LEUKERAN, CHLORAMBUCIL
MYLERAN, BUSULFAN
THIOGUANINE, THIOGUANINE
VALIUM, DIAZEPAM

WES PHARMA INC

* WES PHARMA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

WEST WARD

* WEST WARD PHARMACEUTICAL CORP
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

WEST WARD PHARM CORP

* WEST WARD PHARMACEUTICAL CORP
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

WEST-WARD PHARMS INT

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
BUMETANIDE, BUMETANIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYTARABINE, CYTARABINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIGOXIN, DIGOXIN
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
PENTOSTATIN, PENTOSTATIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, FERRIC OXYHYDROXIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOTEPA, THIOTEPA

WESTMINSTER PHARMS

* WESTMINSTER PHARMACEUTICALS LLC
EPLERENONE, EPLERENONE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MIGLITOL, MIGLITOL
POSACONAZOLE, POSACONAZOLE
RISPERIDONE, RISPERIDONE

WILSHIRE PHARMS INC

* WILSHIRE PHARMACEUTICALS INC
CARISOPRODOL, CARISOPRODOL
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

WINDER LABS LLC

* WINDER LABORATOIRIES LLC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE

WISCONSIN

* WISCONSIN MEDICAL RADIOPHARMACY LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WOCKHARDT

* WOCKHARDT LTD
CAPTOPRIL, CAPTOPRIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LANSOPRAZOLE, LANSOPRAZOLE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

WOCKHARDT BIO AG

* WOCKHARDT BIO AG
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACETAMINOPHEN, ACETAMINOPHEN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
BROMFED-DM, BROMPHENIRAMINE MALEATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DECITABINE, DECITABINE
ENTACAPONE, ENTACAPONE
GENERLAC, LACTULOSE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
LAMOTRIGINE, LAMOTRIGINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
NYSTATIN, NYSTATIN
OXACILLIN SODIUM, OXACILLIN SODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WOCKHARDT BIO AG
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

WOCKHARDT LTD

* WOCKHARDT LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE

WOODWARD

* WOODWARD PHARMA SERVICES LLC
ACIPHEX, RABEPRAZOLE SODIUM
AVODART, DUTASTERIDE
COREG CR, CARVEDILOL PHOSPHATE
COREG, CARVEDILOL
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
JALYN, DUTASTERIDE
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
LUNESTA, ESZOPICLONE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MIVACURIUM CHLORIDE, MIVACURIUM CHLORIDE

WRASER PHARMS

* WRASER PHARMACEUTICALS LLC
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WUSM CYCLOTRON

* WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WYETH PHARMS

* WYETH PHARMACEUTICALS LLC
DUAVEE, BAZEDOXIFENE ACETATE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
TRECATOR, ETHIONAMIDE

** X **

X-GEN PHARMS INC

* X-GEN PHARMACEUTICALS INC
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE

XELLIA PHARMS APS

* XELLIA PHARMACEUTICALS APS
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DAPTOMYCIN, DAPTOMYCIN
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

XERIS

* XERIS PHARMACEUTICALS INC
GVOKE HYPOPEN, GLUCAGON
GVOKE KIT, GLUCAGON
GVOKE PFS, GLUCAGON
KEVEYIS, DICHLORPHENAMIDE

XGEN PHARMS

* XGEN PHARMACEUTICALS DJB INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
AMPHOTERICIN B, AMPHOTERICIN B
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DACTINOMYCIN, DACTINOMYCIN
FOLIC ACID, FOLIC ACID
IBUPROFEN LYSINE, IBUPROFEN LYSINE
LINCOMYCIN HYDROCHLORIDE, LINCOMYCIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** X **

* XGEN PHARMACEUTICALS DJB INC
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID

XIAMEN LP PHARM CO

* XIAMEN LP PHARMACUETICAL CO LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

XIROMED

* XIROMED PHARMA ESPANA SL
ACYCLOVIR, ACYCLOVIR
ALTAVERA, ETHINYL ESTRADIOL
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ENILLORING, ETHINYL ESTRADIOL
EPHEDRINE SULFATE, EPHEDRINE SULFATE
ESTARYLLA, ETHINYL ESTRADIOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
FLUOCINONIDE, FLUOCINONIDE
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
FULVESTRANT, FULVESTRANT
GEMMILY, ETHINYL ESTRADIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
INTROVALE, ETHINYL ESTRADIOL
ISIBLOOM, DESOGESTREL
JAIMIESS, ETHINYL ESTRADIOL
KETOCONAZOLE, KETOCONAZOLE
LANSOPRAZOLE, LANSOPRAZOLE
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LORYNA, DROSPIRENONE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
OMEPRAZOLE, OMEPRAZOLE
PROGESTERONE, PROGESTERONE
RAMELTEON, RAMELTEON
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SYEDA, DROSPIRENONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE, TESTOSTERONE
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
VIENVA, ETHINYL ESTRADIOL
VOLNEA, DESOGESTREL

XSPIRE PHARMA

* XSPIRE PHARMA
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
NALFON, FENOPROFEN CALCIUM
TREZIX, ACETAMINOPHEN
ZONTIVITY, VORAPAXAR SULFATE

* XSPIRE PHARMA LLC
DEXAMETHASONE, DEXAMETHASONE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM

XTTRIUM

* XTTRIUM LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** X **

XTTRIUM LABS INC
* XTTRIUM LABORATORIES INC
LACTULOSE, LACTULOSE

** Y **

YABAO PHARM
* YABAO PHARMACEUTICAL CO LTD BEIJING
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE

YAOPHARMA CO LTD
* YAOPHARMA CO LTD
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YICHANG HUMANWELL
* YICHANG HUMANWELL PHARMACEUTICAL CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YILING
* YILING PHARMACEUTICAL LTD
ACYCLOVIR, ACYCLOVIR
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CELECOXIB, CELECOXIB
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
FELODIPINE, FELODIPINE
LAMOTRIGINE, LAMOTRIGINE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PREGABALIN, PREGABALIN
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

YOUNGTECH PHARMS INC
* YOUNGTECH PHARMACEUTICALS INC
METOPROLOL TARTRATE, METOPROLOL TARTRATE

YUNG SHIN PHARM
* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
AZITHROMYCIN, AZITHROMYCIN
CEFACLOR, CEFACLOR
CEPHALEXIN, CEPHALEXIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
FELODIPINE, FELODIPINE
MELOXICAM, MELOXICAM

** Z **

ZAMBON SPA
* ZAMBON SPA ITALY
MONUROL, FOSFOMYCIN TROMETHAMINE

ZEALAND PHARMA
* ZEALAND PHARMA US INC
ZEGALOGUE (AUTOINJECTOR), DASIGLUCAGON HYDROCHLORIDE
ZEGALOGUE, DASIGLUCAGON HYDROCHLORIDE

ZENNOVA
* ZENNOVA PHARMACEUTICALS CHENGDU CO LTD
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ZHEJIANG HISUN PHARM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZHEJIANG HISUN PHARMACEUTICAL CO LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

ZHEJIANG JINGXIN

* ZHEJIANG JINGXIN PHARMACEUTICAL CO LTD
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM

ZHEJIANG JIUZHOU

* ZHEJIANG JIUZHOU BIOPHARMA CO LTD
CARBAMAZEPINE, CARBAMAZEPINE

ZHEJIANG JUTAI PHARM

* ZHEJIANG JUTAI PHARMACEUTICAL CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

ZHEJIANG NOVUS PHARM

* ZHEJIANG NOVUS PHARMACEUTICALS CO LTD
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ZHEJIANG YONGTAI

* ZHEJIANG YONGTAI PHARMACEUTICAL CO LTD
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
GABAPENTIN, GABAPENTIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

ZR PHARMA

* ZR PHARMA AND GMBH
RUBRACA, RUCAPARIB CAMSYLATE

ZUREX PHARMA

* ZUREX PHARMA
ZURAGARD, ISOPROPYL ALCOHOL (OTC)

ZYDUS

* ZYDUS WORLDWIDE DMCC
ACETAZOLAMIDE, ACETAZOLAMIDE
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
IVERMECTIN, IVERMECTIN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEFLUNOMIDE, LEFLUNOMIDE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLENE BLUE, METHYLENE BLUE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXCARBAZEPINE, OXCARBAZEPINE
PHYTONADIONE, PHYTONADIONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TOPIRAMATE, TOPIRAMATE
URSODIOL, URSODIOL
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VIGABATRIN, VIGABATRIN
ZITUVIMET, METFORMIN HYDROCHLORIDE
ZITUVIO, SITAGLIPTIN

ZYDUS HLTHCARE

* ZYDUS HEALTHCARE USA LLC
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** Z **

ZYDUS LIFESCIENCES

* ZYDUS LIFESCIENCES LTD
ACYCLOVIR, ACYCLOVIR
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
FEBUXOSTAT, FEBUXOSTAT
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
SUCRALFATE, SUCRALFATE
TAVABOROLE, TAVABOROLE

ZYDUS NOVELTECH INC

* ZYDUS NOVELTECH INC
ETHINYL ESTRADIOL AND NORELGESTROMIN, ETHINYL ESTRADIOL

ZYDUS PHARMS

* ZYDUS PHARMACEUTICALS USA INC
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ALBENDAZOLE, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMBRISENTAN, AMBRISENTAN
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BORTEZOMIB, BORTEZOMIB
BOSENTAN, BOSENTAN
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLCHICINE, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DARUNAVIR, DARUNAVIR
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC

DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENTECAVIR, ENTECAVIR
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESTRADIOL, ESTRADIOL
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
EXEMESTANE, EXEMESTANE
EZETIMIBE, EZETIMIBE
FAMOTIDINE, FAMOTIDINE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
FULVESTRANT, FULVESTRANT
GLIPIZIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
IMATINIB MESYLATE, IMATINIB MESYLATE
INDOMETHACIN, INDOMETHACIN
ISOTRETINOIN, ISOTRETINOIN
ITRACONAZOLE, ITRACONAZOLE
IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LENALIDOMIDE, LENALIDOMIDE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LINEZOLID, LINEZOLID
LUBIPROSTONE, LUBIPROSTONE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NADOLOL, NADOLOL
NATEGLINIDE, NATEGLINIDE
NELARABINE, NELARABINE
NIFEDIPINE, NIFEDIPINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN, NYSTATIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PERPHENAZINE, PERPHENAZINE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
PLERIXAFOR, PLERIXAFOR
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RAMELTEON, RAMELTEON
RIVASTIGMINE, RIVASTIGMINE
ROFLUMILAST, ROFLUMILAST
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIROLIMUS, SIROLIMUS
SPIRONOLACTONE, SPIRONOLACTONE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUGAMMADEX SODIUM, SUGAMMADEX SODIUM
TADALAFIL, TADALAFIL
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMOZOLOMIDE, TEMOZOLOMIDE
TERIFLUNOMIDE, TERIFLUNOMIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZINC SULFATE, ZINC SULFATE
ZOLMITRIPTAN, ZOLMITRIPTAN

ZYDUS PHARMS USA

* ZYDUS PHARMACEUTICALS USA INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
AZATHIOPRINE, AZATHIOPRINE
BENZONATATE, BENZONATATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
LAMOTRIGINE, LAMOTRIGINE
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN, NAPROXEN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SIMVASTATIN, SIMVASTATIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

ZYDUS PHARMS USA INC

* ZYDUS PHARMACEUTICALS USA INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
CARVEDILOL, CARVEDILOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FINASTERIDE, FINASTERIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
OMEPRAZOLE, OMEPRAZOLE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

ZYLA

* ZYLA LIFE SCIENCES US INC
INDOCIN, INDOMETHACIN
SPRIX, KETOROLAC TROMETHAMINE

APPENDIX C

UNIFORM TERMS

DOSAGE FORMS

AEROSOL, FOAM
AEROSOL, METERED
CAPSULE
CAPSULE, DELAYED REL PELLETS
CAPSULE, DELAYED RELEASE
CAPSULE, EXTENDED RELEASE
CAPSULE, PELLETS
CAPSULE, TABLET
CAPSULE, TABLET, TABLET
CLOTH
CONCENTRATE
CREAM
CREAM, AUGMENTED
CREAM, INSERT
ELIXIR
EMULSION
ENEMA
FILM
FILM, EXTENDED RELEASE
FOAM
FOR SOLUTION
FOR SUSPENSION
FOR SUSPENSION, DELAYED RELEASE
FOR SUSPENSION, EXTENDED RELEASE
GAS
GEL
GEL, AUGMENTED
GEL, METERED
GRANULE
GRANULE, DELAYED RELEASE
GRANULES
GRANULES, EXTENDED RELEASE
GUM, CHEWING
IMPLANT
INHALANT
INJECTABLE
INJECTABLE, LIPID COMPLEX
INJECTABLE, LIPOSOMAL
INJECTION, EXTENDED RELEASE
INSERT
INSERT, EXTENDED RELEASE
INTRAUTERINE DEVICE
JELLY
LIQUID
LOTION
LOTION, AUGMENTED
LOTION/SHAMPOO
OIL
OIL/DROPS
OINTMENT
OINTMENT, AUGMENTED
PASTE
PATCH
PELLET
PELLETS
POWDER
POWDER, EXTENDED RELEASE
POWDER, METERED
RING
SHAMPOO
SOLUTION
SOLUTION FOR SLUSH
SOLUTION, EXTENDED RELEASE
SOLUTION, GEL FORMING/DROPS
SOLUTION, METERED
SOLUTION/DROPS
SPONGE
SPRAY
SPRAY, METERED
SUPPOSITORY
SUSPENSION
SUSPENSION, EXTENDED RELEASE
SUSPENSION, LIPOSOMAL
SUSPENSION/DROPS
SWAB
SYRUP
SYSTEM
TABLET
TABLET, CHEWABLE
TABLET, DELAYED RELEASE
TABLET, EFFERVESCENT
TABLET, EXTENDED RELEASE
TABLET, EXTENDED RELEASE, CHEWABLE
TABLET, FOR SUSPENSION
TABLET, ORALLY DISINTEGRATING
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
TAPE
TROCHE/LOZENGE

Note: Terms comprise currently marketed products

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL
CARDIAC
DENTAL
ENDOCERVICAL
ENDOTRACHEAL
ENTERAL
IMPLANTATION
INFILTRATION
INHALATION
INJECTION
INTERSTITIAL
INTRA-ANAL
INTRA-ARTERIAL
INTRA-ARTICULAR
INTRACAMERAL
INTRACAVITARY
INTRACRANIAL
INTRADERMAL
INTRAMUSCULAR
INTRAOCULAR
INTRAOSSEOUS
INTRAPERITONEAL
INTRAPLEURAL
INTRATHECAL
INTRAUTERINE
INTRAVENOUS
INTRAVESICAL
INTRAVITREAL
IRRIGATION
IV (INFUSION)
N/A
NASAL
OPHTHALMIC
ORAL
ORAL-21
ORAL-28
OTIC
PERFUSION
PERIARTICULAR
PERIODONTAL
PYELOCALYCEAL
RECTAL
SPINAL
SUBCUTANEOUS
SUBLINGUAL
TOPICAL
TRANSDERMAL
TRANSMUCOSAL
URETHRAL
VAGINAL

Note: Terms comprise currently marketed products

APPENDIX C

UNIFORM TERMS

ABBREVIATIONS

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
MCI	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SC	SUBCUTANEOUS
SQ CM	SQUARE CENTIMETER
U	UNITS
UCI	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) for periods of exclusivity and provides patent information that has been submitted to the Food and Drug Administration (FDA) concerning the listed drug products.

Exclusivity

This *Addendum* identifies:

- Drugs approved under section 505(c) of the FD&C Act that have qualified under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) for five-year and three-year periods of exclusivity pursuant to Section 505(c)(3)(E) and Section 505(j)(5)(F) of the FD&C Act
- Drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the FD&C Act
- Drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the FD&C Act
- Drugs that have qualified for Generating Antibiotic Incentives Now (GAIN) exclusivity pursuant to Section 505E of the FD&C Act
- Generic drugs approved under section 505(j) of the FD&C Act that have qualified for 180-day exclusivity pursuant to Section 505(j)(5)(B)(iv) of the FD&C Act
- Generic drugs approved under section 505(j) of the FD&C Act that have qualified for Competitive Generic Therapy (CGT) exclusivity pursuant to Section 505(j)(5)(B)(v) of the FD&C Act

This section is arranged in alphabetical order by established name of the active ingredient, followed by the proprietary name (brand name or trade name) of the drug product. Active ingredient headings for multiple active ingredient, fixed-combination drug products are arranged alphabetically.

Individual descriptions of the protected use have been added to each Orphan Drug Exclusivity entry listed in the Orange Book. Such descriptions of Orphan Drug Exclusivity were included beginning with the 38th edition of the Orange Book. The ODE* code means that the timing of approval of certain follow-on applications may be subject to delay due to ODE for another drug that has the same active moiety.

For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. The exclusivity codes are general shorthand descriptions and do not necessarily identify, with specificity, the actual scope of exclusivity.

Patent Information

The FD&C Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. In addition, patent information must be filed on Form FDA 3542 within 30 days of the date of approval of a Section 505(b) drug application.[1] FDA publishes certain information from Form FDA 3542 in the Orange Book after approval of the new drug application (NDA) or supplement.

The Orange Book includes the patent submission date (i.e., the date on which the FDA receives patent information from the NDA holder on Form FDA 3542) for each newly listed patent to facilitate assessments of whether patent information is untimely filed with respect to a pending 505(b)(2) application or abbreviated new drug application (ANDA) and whether patent information was submitted before the date on which a 505(b)(2) application or ANDA (excluding an amendment or supplement to the 505(b)(2) application or ANDA) was submitted.[2]

The patents that FDA regards as covered by the statutory provisions for submission of patent information for listing in the Orange Book are:

- Patents that claim the drug for which the applicant submitted the application and are drug substance (active ingredient) patents or drug product (formulation or composition) patents; or
- Patents that claim a method of using such drug for which approval has been granted in the application.

This information, as provided by the NDA holder on Form FDA 3542, will be published as described above. An NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that the patent claims either the drug substance or the drug product.

The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the Annual Edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Orange Book, updated regularly, should be consulted for the most recent patent and exclusivity information.

[1] Please note that the date of approval for an NDA for a drug for which FDA intends to recommend controls under the Controlled Substances Act is the later of the date on the approval letter for the NDA or the date of issuance of the interim final rule controlling the drug (see Section 505(x)(1) and (2) of the FD&C Act).

[2] See 21 CFR 314.50(i)(4) and 314.94(a)(12)(vi); see 21 CFR 314.107(b)(3)(i). The submission date for patent information is determined in accordance with 21 CFR 314.53(d)(5).

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ						
N 205551 001	8129385	Oct 05, 2027	DS DP		M-294	Jun 15, 2026
	8129385*PED	Apr 05, 2028			PED	Dec 15, 2026
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ PD						
N 215413 001	8129385	Oct 05, 2027	DS DP		NPP	Jun 15, 2026
	8129385*PED	Apr 05, 2028			PED	Dec 15, 2026
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
ABALOPARATIDE - TYMLOS						
N 208743 001	10996208	Apr 30, 2038	DP		I-907	Dec 19, 2025
	11255842	Jan 10, 2040	U-3322		M-270	Sep 20, 2024
	11680942	Jan 10, 2040	U-3322			
	11782041	Apr 30, 2038	DP U-2009			
	11782041	Apr 30, 2038	DP U-3543			
	7803770	Apr 28, 2031	U-2009			
	8148333	Nov 08, 2027	DP			
	8748382	Oct 03, 2027	U-2009			
	8748382	Oct 03, 2027	U-3543			
	RE49444	Apr 28, 2031	U-2009			
	RE49444	Apr 28, 2031	U-3543			
ABAMETAPIR - XEGLYZE						
N 206966 001	10292389	Dec 17, 2034	DP U-2863		NCE	Jul 24, 2025
	7812163	Oct 28, 2026	DP U-2863			
	8212038	Jul 16, 2024	DP U-2863			
	9357783	Jul 16, 2024	DP			
	9839631	Jul 16, 2024	DS DP U-2863			
ABEMACICLIB - VERZENIO						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132		I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135		NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
ABEMACICLIB - VERZENIO						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132		I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135		NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABEMACICLIB - VERZENIO						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132		I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135		NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
ABEMACICLIB - VERZENIO						
N 208716 004	7855211	Dec 15, 2029	DS DP U-1981		I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2132		NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
ABIRATERONE ACETATE - YONSA						
N 210308 001	10292990	May 20, 2034	U-2535			
	9889144	Mar 17, 2034	DP			
ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA						
N 216793 001	11091459	Mar 27, 2038	DS DP		NP	Aug 11, 2026
	11207311	Jul 28, 2037	U-2830			
	11673877	Mar 27, 2038	DS DP			
	8071579	Aug 12, 2027	U-2830			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2830			
	8436185	Apr 24, 2029	DS DP			
	8859562	Aug 04, 2031	U-2830			
ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA						
N 216793 002	11091459	Mar 27, 2038	DS DP		NP	Aug 11, 2026
	11207311	Jul 28, 2037	U-2830			
	11673877	Mar 27, 2038	DS DP			
	8071579	Aug 12, 2027	U-2830			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2830			
	8436185	Apr 24, 2029	DS DP			
	8859562	Aug 04, 2031	U-2830			
ABROCITINIB - CIBINQO						
N 213871 001	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP		NPP	Feb 09, 2026
	9549929	Feb 19, 2034	U-3195			
ABROCITINIB - CIBINQO						
N 213871 002	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP		NPP	Feb 09, 2026
	9549929	Feb 19, 2034	U-3195			
ABROCITINIB - CIBINQO						
N 213871 003	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP		NPP	Feb 09, 2026
	9549929	Feb 19, 2034	U-3195			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACALABRUTINIB - CALQUENCE						
N 210259 001	10167291	Jul 01, 2036	DP U-2145		ODE-175	Oct 31, 2024
	10167291	Jul 01, 2036	DP U-2666		ODE-274	Nov 21, 2026
	10167291	Jul 01, 2036	DP U-2667			
	10167291	Jul 01, 2036	DP U-2668			
	10167291	Jul 01, 2036	DP U-2669			
	10167291	Jul 01, 2036	DP U-2670			
	10167291	Jul 01, 2036	DP U-2671			
	10239883	Jul 11, 2032	U-2666			
	10239883	Jul 11, 2032	U-2668			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	11771696	Jan 21, 2035	U-3710			
	7459554	Nov 24, 2026	DS			
	9290504	Jul 11, 2032	DS DP			
	9758524	Jul 11, 2032	U-2145			
	9796721	Jul 01, 2036	DS DP U-2145			
	9796721	Jul 01, 2036	DS DP U-2666			
	9796721	Jul 01, 2036	DS DP U-2667			
	9796721	Jul 01, 2036	DS DP U-2668			
	9796721	Jul 01, 2036	DS DP U-2669			
	9796721	Jul 01, 2036	DS DP U-2670			
	9796721	Jul 01, 2036	DS DP U-2671			
ACALABRUTINIB MALEATE - CALQUENCE						
N 216387 001	10239883	Jul 11, 2032	U-2666			
	10239883	Jul 11, 2032	U-2668			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	11059829	Jul 01, 2036	DS DP U-2145			
	11059829	Jul 01, 2036	DS DP U-2666			
	11059829	Jul 01, 2036	DS DP U-2667			
	11059829	Jul 01, 2036	DS DP U-2668			
	11059829	Jul 01, 2036	DS DP U-2669			
	11059829	Jul 01, 2036	DS DP U-2670			
	11059829	Jul 01, 2036	DS DP U-2671			
	11771696	Jan 21, 2035	U-3710			
	7459554	Nov 24, 2026	DS			
	9290504	Jul 11, 2032	DS DP			
	9758524	Jul 11, 2032	U-2145			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETAMINOPHEN - OFIRMEV						
N 022450 001	10383834	Nov 13, 2028	U-2262			
	10383834	Nov 13, 2028	U-2621			
	9399012	Sep 11, 2031	U-2261			
	9399012	Sep 11, 2031	U-2262			
	9399012*PED	Mar 11, 2032				
	9610265	Nov 13, 2028	U-2263			
	9610265*PED	May 13, 2029				
	9987238	Nov 13, 2028	U-2261			
	9987238*PED	May 13, 2029				
ACETAMINOPHEN - ACETAMINOPHEN						
N 204767 001	8741959	Apr 19, 2030	DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ						
N 208653 001	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ						
N 208653 002	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ						
N 208653 003	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
ACETAMINOPHEN; IBUPROFEN - COMBOGESIC						
N 209471 001	10532036	Sep 22, 2025	U-3553		NP	Mar 01, 2026
	11197830	Feb 27, 2039	DP U-3553			
	11534407	Feb 27, 2039	DP U-3553			
ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV						
N 215320 001	11213498	Jan 14, 2036	DP		NP	Oct 17, 2026
	11389416	Jul 17, 2035	DP			
	11446266	Oct 26, 2031	U-3744			
	11446266	Oct 26, 2031	U-3745			
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR						
N 204031 001	7976870	Jun 01, 2027	U-1498			
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029	U-1499			
	8741885	May 16, 2032	DP U-1499			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR						
N 204031 001	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
	9468636	May 16, 2032	U-1499			
ACETYLCYSTEINE - ACETADOTE						
N 021539 001	8148356	May 21, 2026	DP			
	8399445	Aug 24, 2025	U-1373			
	8653061	Aug 24, 2025	U-1373			
	8722738	Apr 06, 2032	U-1373			
	9327028	Jul 21, 2031	U-1839			
ACETYLCYSTEINE - CETYLEV						
N 207916 001	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
	9561204	May 08, 2032	U-1373			
ACETYLCYSTEINE - CETYLEV						
N 207916 002	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
	9561204	May 08, 2032	U-1373			
ACLIDINIUM BROMIDE - TUDORZA PRESSAIR						
N 202450 001	10085974	Mar 13, 2029	DP U-2513			
	11000517	Mar 13, 2029	DP U-2513			
	8051851	Apr 22, 2027	DP			
	RE46417	Feb 10, 2025	DS DP U-2513			
ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR						
N 210595 001	10085974	Mar 13, 2029	DP U-2513			
	11000517	Mar 13, 2029	DP U-2513			
	8051851	Apr 22, 2027	DP			
	RE46417	Feb 10, 2025	DS DP U-2513			
ACYCLOVIR - AVACLYR						
N 202408 001					ODE-235	Mar 29, 2026
ACYCLOVIR - SITAVIG						
N 203791 001	8592434	Jun 16, 2030	DP U-1460			
	8747896	Jun 03, 2027	DP U-1460			
	8791127	Mar 23, 2027	DP U-1460			
ADAGRASIB - KRAZATI						
N 216340 001	10689377	May 17, 2037	DS DP U-3490		NCE	Dec 12, 2027
					ODE-352	Dec 12, 2029
ADAPALENE - DIFFERIN						
N 021753 001	7579377	Feb 23, 2025	U-818			
	7737181	Aug 29, 2024	DP			
ADAPALENE - DIFFERIN						
N 022502 001	7998467	May 31, 2028	DP U-1078			
	8435502	Sep 15, 2026	DP U-1078			
	8709392	Sep 15, 2026	DP U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ADAPALENE; BENZOYL PEROXIDE - EPIDUO								
N	022320	001	7820186	Nov 23, 2025	DP			
			7964202	Sep 01, 2024	DP U-1078			
			8071644	Jul 18, 2027	DP U-1078			
			8080537	Jul 18, 2027	U-1078			
			8129362	Jul 18, 2027	U-1078			
ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CABTREO								
N	216632	001	10220049	Jun 03, 2029	DP U-3713		NP	Oct 20, 2026
			10624918	Jun 03, 2029	U-3713			
			11389467	Dec 28, 2040	DP U-3713			
			8288434	Aug 05, 2029	DP U-3713			
			9561208	Jun 03, 2029	DP U-3713			
AFAMELANOTIDE - SCENESSE								
N	210797	001	10076555	Feb 11, 2025	U-2638		NCE	Oct 08, 2024
			8334265	Mar 11, 2029	U-2638		ODE-270	Oct 08, 2026
AFATINIB DIMALEATE - GILOTRIF								
N	201292	001	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
			10004743*PED	Jan 05, 2031			ODE-230	Jan 12, 2025
			8426586	Oct 10, 2029	DS		PED	Jul 12, 2025
			8426586*PED	Apr 10, 2030			PED	Oct 07, 2025
			8545884	Dec 19, 2029	DP			
			8545884*PED	Jun 19, 2030				
			9539258	Nov 09, 2026	U-1950			
			9539258*PED	May 09, 2027				
			RE43431	Jan 13, 2026	DS			
			RE43431*PED	Jul 13, 2026				
AFATINIB DIMALEATE - GILOTRIF								
N	201292	002	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
			10004743*PED	Jan 05, 2031			ODE-230	Jan 12, 2025
			8426586	Oct 10, 2029	DS		PED	Jul 12, 2025
			8426586*PED	Apr 10, 2030			PED	Oct 07, 2025
			8545884	Dec 19, 2029	DP			
			8545884*PED	Jun 19, 2030				
			9539258	Nov 09, 2026	U-1950			
			9539258*PED	May 09, 2027				
			RE43431	Jan 13, 2026	DS			
			RE43431*PED	Jul 13, 2026				
AFATINIB DIMALEATE - GILOTRIF								
N	201292	003	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
			10004743*PED	Jan 05, 2031			ODE-230	Jan 12, 2025
			8426586	Oct 10, 2029	DS		PED	Jul 12, 2025
			8426586*PED	Apr 10, 2030			PED	Oct 07, 2025
			8545884	Dec 19, 2029	DP			
			8545884*PED	Jun 19, 2030				
			9539258	Nov 09, 2026	U-1950			
			9539258*PED	May 09, 2027				
			RE43431	Jan 13, 2026	DS			
			RE43431*PED	Jul 13, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AIR POLYMER-TYPE A - EXEM FOAM KIT						
N 212279 001	9034300	Oct 15, 2030	DP U-2663		NCE	Nov 07, 2024
	9259494	May 04, 2035	DP U-2663			
	9849199	Feb 11, 2036	DP			
ALBUTEROL SULFATE - PROAIR HFA						
N 021457 001	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
	11395889	May 18, 2031	DP			
	8132712	Sep 07, 2028	DP			
	9463289	May 18, 2031	DP			
	9808587	May 18, 2031	DP			
ALBUTEROL SULFATE - PROAIR RESPICLICK						
N 205636 001	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10765820	May 19, 2025	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
ALBUTEROL SULFATE - PROAIR DIGIHALER						
N 205636 002	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	10765820	May 19, 2025	DP			
	10918816	Dec 14, 2035	DP			
	11000653	Dec 18, 2038	DP			
	11173259	Jul 06, 2040	DP			
	11266796	Feb 22, 2041	DP			
	11344685	Sep 26, 2039	DP			
	11351317	Feb 10, 2038	DP			
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
ALBUTEROL SULFATE; BUDESONIDE - AIRSUPRA						
N 214070 001	9415009	May 28, 2030	U-3509		NP	Jan 10, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT						
N 021747 001	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
ALCAFTADINE - LASTACAFT						
N 022134 001	10617695	Mar 19, 2027	DP U-3267			
	8664215	Dec 23, 2027	U-3267			
ALCOHOL - ABLYSINOL						
N 207987 001					ODE-192	Jun 21, 2025
ALCOHOL - ABLYSINOL						
N 207987 002					ODE-192	Jun 21, 2025
ALECTINIB HYDROCHLORIDE - ALECENSA						
N 208434 001	10350214	Apr 24, 2035	DP		ODE-159	Nov 06, 2024
	11433076	Apr 24, 2035	DP			
	9126931	May 29, 2031	DS			
	9365514	Mar 04, 2032	DP			
	9440922	Jun 09, 2030	DP			
ALENDRONATE SODIUM - BINOSTO						
N 202344 001	9592195	Dec 05, 2031	DP			
ALISKIREN HEMIFUMARATE - TEKTURNA						
N 021985 001	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
ALISKIREN HEMIFUMARATE - TEKTURNA						
N 021985 002	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N 022545 001	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N 022545 002	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N 022545 003	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N 022545 004	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT						
N 022107 001	8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT						
N 022107 002	8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT						
N 022107 003	8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT						
N 022107 004	8618172	Jul 13, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA								
N	022217	001	8168616	Jul 03, 2026	DP			
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA								
N	022217	002	8168616	Jul 03, 2026	DP			
ALLOPURINOL; LESINURAD - DUZALLO								
N	209203	001	10183012	Nov 26, 2028	U-2104			
			8003681	Aug 25, 2025	DS			
			8084483	Aug 17, 2029	U-2104			
			8283369	Nov 26, 2028	U-2104			
			8357713	Dec 22, 2029	DP U-2104			
			8546436	Feb 29, 2032	DS			
			8546437	Apr 29, 2029	U-2104			
			9216179	Aug 01, 2031	U-2104			
			9956205	Dec 28, 2031	U-2104			
ALLOPURINOL; LESINURAD - DUZALLO								
N	209203	002	10183012	Nov 26, 2028	U-2104			
			8003681	Aug 25, 2025	DS			
			8084483	Aug 17, 2029	U-2104			
			8283369	Nov 26, 2028	U-2104			
			8357713	Dec 22, 2029	DP U-2104			
			8546436	Feb 29, 2032	DS			
			8546437	Apr 29, 2029	U-2104			
			9216179	Aug 01, 2031	U-2104			
			9956205	Dec 28, 2031	U-2104			
ALOGLIPTIN BENZOATE - NESINA								
N	022271	001	7807689	Jun 27, 2028	DS DP U-1337		M-300	Jul 27, 2026
			8173663	Dec 02, 2025	U-1338			
			8288539	Mar 15, 2025	DS			
			8697125	Jun 16, 2029	DP			
ALOGLIPTIN BENZOATE - NESINA								
N	022271	002	7807689	Jun 27, 2028	DS DP U-1337		M-300	Jul 27, 2026
			8173663	Dec 02, 2025	U-1338			
			8288539	Mar 15, 2025	DS			
			8697125	Jun 16, 2029	DP			
ALOGLIPTIN BENZOATE - NESINA								
N	022271	003	7807689	Jun 27, 2028	DS DP U-1337		M-300	Jul 27, 2026
			8173663	Dec 02, 2025	U-1338			
			8288539	Mar 15, 2025	DS			
			8697125	Jun 16, 2029	DP			
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO								
N	203414	001	7807689	Jun 27, 2028	DS DP U-1337		M-300	Jul 27, 2026
			8173663	Mar 15, 2025	U-1338			
			8288539	Jun 24, 2025	DS			
			8900638	May 24, 2029	DP			
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO								
N	203414	002	7807689	Jun 27, 2028	DS DP U-1337		M-300	Jul 27, 2026
			8173663	Mar 15, 2025	U-1338			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES			PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO										
N 203414	002		8288539	Jun 24, 2025	DS					
			8900638	May 24, 2029		DP				
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI										
N 022426	001		7807689	Jun 27, 2028	DS	DP	U-1337			
			8173663	Mar 15, 2025			U-1338			
			8288539	Mar 15, 2025	DS					
			8637079	Jun 04, 2029		DP				
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI										
N 022426	002		7807689	Jun 27, 2028	DS	DP	U-1337			
			8173663	Mar 15, 2025			U-1338			
			8288539	Mar 15, 2025	DS					
			8637079	Jun 04, 2029		DP				
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI										
N 022426	003		7807689	Jun 27, 2028	DS	DP	U-1337			
			8173663	Mar 15, 2025			U-1338			
			8288539	Mar 15, 2025	DS					
			8637079	Jun 04, 2029		DP				
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI										
N 022426	004		7807689	Jun 27, 2028	DS	DP	U-1337			
			8173663	Mar 15, 2025			U-1338			
			8288539	Mar 15, 2025	DS					
			8637079	Jun 04, 2029		DP				
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI										
N 022426	005		7807689	Jun 27, 2028	DS	DP	U-1337			
			8173663	Mar 15, 2025			U-1338			
			8288539	Mar 15, 2025	DS					
			8637079	Jun 04, 2029		DP				
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI										
N 022426	006		7807689	Jun 27, 2028	DS	DP	U-1337			
			8173663	Mar 15, 2025			U-1338			
			8288539	Mar 15, 2025	DS					
			8637079	Jun 04, 2029		DP				
ALPELISIB - PIQRAY										
N 212526	001		8227462	Apr 29, 2033	DS	DP	U-2539		NCE	May 24, 2024
			8476268	Sep 10, 2029	DS	DP				
ALPELISIB - PIQRAY										
N 212526	002		8227462	Apr 29, 2033	DS	DP	U-2539		NCE	May 24, 2024
			8476268	Sep 10, 2029	DS	DP				
ALPELISIB - PIQRAY										
N 212526	003		8227462	Apr 29, 2033	DS	DP	U-2539		NCE	May 24, 2024
			8476268	Sep 10, 2029	DS	DP				
ALPELISIB - VIJOICE										
N 215039	001		8227462	Apr 29, 2033	DS	DP			NCE	May 24, 2024
			8476268	Sep 10, 2029	DS	DP			ODE-396	Apr 05, 2029

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALPELISIB - VIJOICE						
N 215039 002	8227462	Apr 29, 2033	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP		ODE-396	Apr 05, 2029
ALPELISIB - VIJOICE						
N 215039 003	8227462	Apr 29, 2033	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP		ODE-396	Apr 05, 2029
ALVIMOPAN - ENTEREG						
N 021775 001	8946262	Feb 12, 2030	U-1655			
AMANTADINE HYDROCHLORIDE - GOCOVRI						
N 208944 001	10154971	Dec 04, 2034	U-2459		ODE-153	Aug 24, 2024
	10646456	Jun 17, 2034	U-2808			
	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
	11197835	Dec 02, 2030	U-2106			
	8389578	Jan 22, 2028	U-2105			
	8741343	Dec 02, 2030	U-2106			
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			
	9867791	Dec 02, 2030	U-2106			
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
AMANTADINE HYDROCHLORIDE - GOCOVRI						
N 208944 002	10154971	Dec 04, 2034	U-2459		ODE-153	Aug 24, 2024
	10646456	Jun 17, 2034	U-2808			
	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
	11197835	Dec 02, 2030	U-2106			
	8389578	Jan 22, 2028	U-2105			
	8741343	Dec 02, 2030	U-2106			
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			
	9867791	Dec 02, 2030	U-2106			
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMANTADINE HYDROCHLORIDE - GOCOVRI						
N 208944 002	9877933	Dec 02, 2030	U-2224			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 001	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	10500170	Feb 15, 2038	U-20			
	10500171	Feb 15, 2038	U-2497			
	10500172	Feb 15, 2038	U-2497			
	10512617	Feb 15, 2038	U-2497			
	8252331	Mar 13, 2030	DP			
	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8574626	Nov 28, 2025	DP U-20			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 002	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	10500170	Feb 15, 2038	U-20			
	10500171	Feb 15, 2038	U-2497			
	10500172	Feb 15, 2038	U-2497			
	10512617	Feb 15, 2038	U-2497			
	8252331	Mar 13, 2030	DP			
	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8574626	Nov 28, 2025	DP U-20			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 002	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025			U-219	
	9072697	Nov 23, 2025			U-3054	
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 003	10213393	Feb 15, 2038			U-20	
	10213394	Feb 15, 2038			U-2497	
	10500170	Feb 15, 2038			U-20	
	10500171	Feb 15, 2038			U-2497	
	10500172	Feb 15, 2038			U-2497	
	10512617	Feb 15, 2038			U-2497	
	8252331	Mar 13, 2030	DP			
	8389578	Jan 22, 2028			U-219	
	8389578	Jan 22, 2028			U-3054	
	8574626	Nov 28, 2025	DP		U-20	
	8796337	Nov 23, 2025			U-219	
	8796337	Nov 23, 2025			U-2497	
	8796337	Nov 23, 2025			U-3054	
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025			U-219	
	8895615	Nov 23, 2025			U-3054	
	8895616	Nov 23, 2025			U-219	
	8895616	Nov 23, 2025			U-3054	
	8895617	Nov 23, 2025			U-219	
	8895617	Nov 23, 2025			U-3054	
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025			U-219	
	9072697	Nov 23, 2025			U-3054	
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 004	10213393	Feb 15, 2038			U-20	
	10213394	Feb 15, 2038			U-2497	
	10500170	Feb 15, 2038			U-20	
	10500171	Feb 15, 2038			U-2497	
	10500172	Feb 15, 2038			U-2497	
	10512617	Feb 15, 2038			U-2497	
	8252331	Mar 13, 2030	DP			
	8389578	Jan 22, 2028			U-219	
	8389578	Jan 22, 2028			U-3054	
	8574626	Nov 28, 2025	DP		U-20	
	8796337	Nov 23, 2025			U-219	
	8796337	Nov 23, 2025			U-2497	
	8796337	Nov 23, 2025			U-3054	
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025			U-219	
	8895615	Nov 23, 2025			U-3054	
	8895616	Nov 23, 2025			U-219	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 004	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
AMBRISENTAN - LETAIRIS						
N 022081 001	8377933	Dec 11, 2027	U-1754			
	9474752	Dec 11, 2027	U-1754			
	9549926	Oct 14, 2031	U-1965			
AMBRISENTAN - LETAIRIS						
N 022081 002	8377933	Dec 11, 2027	U-1754			
	9474752	Dec 11, 2027	U-1754			
	9549926	Oct 14, 2031	U-1965			
AMIFAMPRIDINE PHOSPHATE - FIRDAPSE						
N 208078 001	10626088	Feb 25, 2037	DP		NPP	Sep 29, 2025
	10793893	May 26, 2034	U-2956		ODE-223	Nov 28, 2025
	11060128	Jun 29, 2032	U-2956			
	11268128	Jun 29, 2032	U-2956			
	11274331	Jun 29, 2032	U-2956			
	11274332	Jun 29, 2032	U-2956			
AMIKACIN SULFATE - ARIKAYCE KIT						
N 207356 001	10251900	May 15, 2035	U-2414		ODE-214	Sep 28, 2025
	10751355	May 15, 2035	U-2414		GAIN	Sep 28, 2030
	11446318	May 15, 2035	U-2414			
	7718189	Jun 06, 2025	DP U-2415			
	8226975	Aug 15, 2028	DP			
	8632804	Dec 05, 2026	U-2416			
	8642075	Dec 05, 2026	DP			
	8679532	Dec 05, 2026	U-2415			
	8802137	Apr 08, 2024	DP U-2414			
	9566234	Jan 18, 2034	DP U-2415			
	9827317	Apr 08, 2024	DP U-2415			
	9895385	May 15, 2035	U-2417			
AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN						
N 020965 001	10357567	Jan 12, 2038	U-3163			
	11077192	Jan 12, 2038	U-3163			
	11135293	Jan 12, 2038	U-3163			
	11571478	Jan 12, 2038	U-3163			
	11690914	Jan 12, 2038	U-3163			
AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ						
N 208081 001	11235169	Oct 15, 2040	U-3303			
	11540981	Feb 07, 2028	DP			
AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN						
N 208630 001					ODE-146	Jun 06, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMIODARONE HYDROCHLORIDE - NEXTERONE						
N 022325 001	7635773	Mar 13, 2029	DP			
AMIODARONE HYDROCHLORIDE - NEXTERONE						
N 022325 002	7635773	Mar 13, 2029	DP			
AMIODARONE HYDROCHLORIDE - NEXTERONE						
N 022325 003	7635773	Mar 13, 2029	DP			
AMISULPRIDE - BARHEMSYS						
N 209510 001	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	11357753	Feb 09, 2038	U-2754			
	9084765	Feb 26, 2034	U-1744			
	9084765	Feb 26, 2034	U-2754			
	9084765	Feb 26, 2034	U-3467			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			
AMISULPRIDE - BARHEMSYS						
N 209510 002	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	11357753	Feb 09, 2038	U-2754			
	9084765	Feb 26, 2034	U-1744			
	9084765	Feb 26, 2034	U-2754			
	9084765	Feb 26, 2034	U-3467			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			
AMLODIPINE BENZOATE - KATERZIA						
N 211340 001	10695329	Oct 16, 2037	DP			
	10799453	Apr 11, 2039	DP			
	10894039	Oct 06, 2037	U-185			
	10894039	Oct 06, 2037	U-3			
	10952998	Oct 06, 2037	DP			
	10959991	Oct 06, 2037	U-158			
	10959991	Oct 06, 2037	U-39			
	11364230	Oct 06, 2037	DP			
	11471409	Oct 06, 2037	U-3447			
	11471409	Oct 06, 2037	U-3448			
	11484498	Oct 06, 2037	DP			
	11701326	Oct 06, 2037	DP			
AMLODIPINE BESYLATE - NORLIQVA						
N 214439 001	11253474	Feb 24, 2041	DP U-3309			
	11253474	Feb 24, 2041	DP U-3310			
	11253474	Feb 24, 2041	DP U-3311			
	11458095	Feb 24, 2041	DP U-3309			
	11458095	Feb 24, 2041	DP U-3310			
	11458095	Feb 24, 2041	DP U-3311			
	11723866	Feb 24, 2041	DP U-3309			
	11723866	Feb 24, 2041	DP U-3310			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMLODIPINE BESYLATE - NORLIQVA							
N 214439	001	11723866	Feb 24, 2041	DP U-3311			
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI							
N 210045	001	10350171	Jun 14, 2038	DP			
		10925835	Jun 14, 2038	U-2410			
		10945960	Jun 14, 2038	DP			
		9408837	Feb 28, 2030	U-2410			
		9662315	May 22, 2029	DP U-2410			
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI							
N 210045	002	10350171	Jun 14, 2038	DP			
		10925835	Jun 14, 2038	U-2410			
		10945960	Jun 14, 2038	DP			
		9408837	Feb 28, 2030	U-2410			
		9662315	May 22, 2029	DP U-2410			
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI							
N 210045	003	10350171	Jun 14, 2038	DP			
		10925835	Jun 14, 2038	U-2410			
		10945960	Jun 14, 2038	DP			
		9408837	Feb 28, 2030	U-2410			
		9662315	May 22, 2029	DP U-2410			
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA							
N 205003	001	7846961	Oct 05, 2029	DS DP U-3			
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA							
N 205003	002	7846961	Oct 05, 2029	DS DP U-3			
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA							
N 205003	003	7846961	Oct 05, 2029	DS DP U-3			
AMOXICILLIN - MOXATAG							
N 050813	001	8299052	May 07, 2027	U-1304			
		8357394	Dec 08, 2026	DP			
		8778924	Dec 08, 2026	DS DP U-897			
AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK							
N 215152	001	7977488	Aug 11, 2028	DS		NCE	May 03, 2027
		9186411	Aug 11, 2030	DP		GAIN	May 03, 2032
AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA							
N 213004	001	10238606	Feb 12, 2034	DP		NP	Nov 01, 2022
		11135172	Feb 12, 2034	DP U-2660		GAIN	Nov 01, 2027
		9050263	Feb 12, 2034	DP U-2660			
		9498445	Feb 12, 2034	DP U-2660			
		9603806	Feb 12, 2034	DP U-2660			
AMOXICILLIN; VONOPRAZAN FUMARATE - VOQUEZNA DUAL PAK							
N 215153	001	7977488	Aug 11, 2028	DS		NCE	May 03, 2027
		9186411	Aug 11, 2030	DP		GAIN	May 03, 2032
AMPHETAMINE - ADZENYS ER							
N 204325	001	8709491	Jun 28, 2032	DP			
		9017731	Jun 28, 2032	DP			
		9265737	Jun 28, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE - ADZENYS XR-ODT								
N	204326	001	8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N	204326	002	8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N	204326	003	8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N	204326	004	8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N	204326	005	8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N	204326	006	8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N	022063	001	8846100	Aug 24, 2029	DP			
			9173857	May 12, 2026			U-2025	
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N	022063	002	8846100	Aug 24, 2029	DP			
			9173857	May 12, 2026			U-2025	
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N	022063	003	8846100	Aug 24, 2029	DP			
			9173857	May 12, 2026			U-2025	
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N	022063	004	8846100	Aug 24, 2029	DP			
			9173857	May 12, 2026			U-2025	
AMPHETAMINE SULFATE - EVEKEO ODT								
N	209905	001	10130580	Apr 19, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE SULFATE - EVEKEO ODT								
N	209905	001	10441554	Mar 10, 2037	DP			
			11160772	Mar 10, 2037	DP			
AMPHETAMINE SULFATE - EVEKEO ODT								
N	209905	002	10130580	Apr 19, 2024	DP			
			10441554	Mar 10, 2037	DP			
			11160772	Mar 10, 2037	DP			
AMPHETAMINE SULFATE - EVEKEO ODT								
N	209905	003	10130580	Apr 19, 2024	DP			
			10441554	Mar 10, 2037	DP			
			11160772	Mar 10, 2037	DP			
AMPHETAMINE SULFATE - EVEKEO ODT								
N	209905	004	10130580	Apr 19, 2024	DP			
			10441554	Mar 10, 2037	DP			
			11160772	Mar 10, 2037	DP			
AMPHETAMINE SULFATE - EVEKEO ODT								
N	209905	005	10130580	Apr 19, 2024	DP			
			10441554	Mar 10, 2037	DP			
			11160772	Mar 10, 2037	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR								
N	208147	001	10086087	Mar 15, 2027	DP			
			11590228	Sep 07, 2036	DP U-3538			
			8062667	Mar 29, 2029	DP			
			8597684	Mar 15, 2027	DP			
			8747902	Mar 15, 2027	DP			
			8883217	Mar 15, 2027	DP			
			9675703	Mar 15, 2027	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 5								
N	210526	001	11590081	Sep 24, 2038	DP U-3538			
			8337890	Mar 15, 2027	DP			
			8747902	Mar 15, 2027	DP			
			9675704	Mar 15, 2027	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 10								
N	210526	002	11590081	Sep 24, 2038	DP U-3538			
			8337890	Mar 15, 2027	DP			
			8747902	Mar 15, 2027	DP			
			9675704	Mar 15, 2027	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 15								
N	210526	003	11590081	Sep 24, 2038	DP U-3538			
			8337890	Mar 15, 2027	DP			
			8747902	Mar 15, 2027	DP			
			9675704	Mar 15, 2027	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 20								
N	210526	004	11590081	Sep 24, 2038	DP U-3538			
			8337890	Mar 15, 2027	DP			
			8747902	Mar 15, 2027	DP			
			9675704	Mar 15, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPICILLIN/AMPICILLIN TRIHYDRATE - AMPICILLIN TRIHYDRATE						
A 216554 001					CGT	Jun 03, 2024
AMPICILLIN/AMPICILLIN TRIHYDRATE - AMPICILLIN TRIHYDRATE						
A 216554 002					CGT	Jun 03, 2024
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 001	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	11219662	Jan 06, 2037	U-3262			
	11559559	Dec 18, 2034	U-3514			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 002	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	11219662	Jan 06, 2037	U-3262			
	11559559	Dec 18, 2034	U-3514			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Nov 20, 2030	U-2221			
	9867863	Dec 16, 2029	U-2231			
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 003	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	11219662	Jan 06, 2037	U-3262			
	11559559	Dec 18, 2034	U-3514			
	9220745	Dec 18, 2034	U-2217			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 003	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			
APALUTAMIDE - ERLEADA						
N 210951 001	10052314	Sep 23, 2033	U-2381	Y		
	10052314	Sep 23, 2033	U-2382	Y		
	10702508	Apr 30, 2038	U-3012			
	10849888	Sep 23, 2033	U-3013			
	8445507	Sep 15, 2030	DS DP U-2237			
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	9884054	Sep 23, 2033	U-2237			
	9987261	Mar 27, 2027	DP			
	RE49353	Sep 23, 2033	U-2381			
APALUTAMIDE - ERLEADA						
N 210951 002	10702508	Apr 30, 2038	U-3012			
	10849888	Sep 23, 2033	U-3013			
	8445507	Sep 15, 2030	DS DP U-2237			
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	9884054	Sep 23, 2033	U-2237			
	9987261	Mar 27, 2027	DP			
	RE49353	Sep 23, 2033	U-2381			
APIXABAN - ELIQUIS						
N 202155 001	6967208	Nov 21, 2026	DS DP U-1167			
	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-1501			
	6967208	Nov 21, 2026	DS DP U-1502			
	6967208	Nov 21, 2026	DS DP U-1729			
	6967208	Nov 21, 2026	DS DP U-1730			
	9326945	Feb 24, 2031	DP			
APIXABAN - ELIQUIS						
N 202155 002	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	9326945	Feb 24, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APIXABAN - ELIQUIS						
N 202155 002	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	9326945	Feb 24, 2031	DP			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 001	10420763	Jun 11, 2030	DP U-2825			
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			
	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 002	10420763	Jun 11, 2030	DP U-2825			
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			
	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 003	10420763	Jun 11, 2030	DP U-2825			
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			
	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 003	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 004	10420763	Jun 11, 2030	DP U-2825			
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			
	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 005	10420763	Jun 11, 2030	DP U-2825			
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			
	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
APREMILAST - OTEZLA						
N 205437 001	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
APREMILAST - OTEZLA						
N 205437 002	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
APREMILAST - OTEZLA						
N 205437 003	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APREMILAST - OTEZLA								
N 205437	003		9872854	May 29, 2034	U-2232			
			9872854	May 29, 2034	U-2233			
APREPITANT - EMEND								
N 021549	001		8258132	Sep 26, 2027	DP U-1743			
			8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND								
N 021549	002		8258132	Sep 26, 2027	DP U-1743			
			8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND								
N 021549	003		8258132	Sep 26, 2027	DP U-1743			
			8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND								
N 207865	001		8258132	Sep 26, 2027	DP U-1916			
APREPITANT - CINVANTI								
N 209296	001		10500208	Sep 18, 2035	DP			
			10624850	Sep 18, 2035	U-2161			
			10953018	Sep 18, 2035	U-2161			
			11173118	Sep 18, 2035	DP			
			11744800	Sep 18, 2035	DP			
			9561229	Sep 18, 2035	DP U-2161			
			9808465	Sep 18, 2035	U-2161			
			9974742	Sep 18, 2035	DP			
			9974793	Sep 18, 2035	DP			
			9974794	Sep 18, 2035	DP U-2161			
APREPITANT - APONVIE								
N 216457	001		10500208	Sep 18, 2035	DP			
			10624850	Sep 18, 2035	U-3440			
			10953018	Sep 18, 2035	U-3440			
			11173118	Sep 18, 2035	DP			
			11744800	Sep 18, 2035	DP U-3690			
			9561229	Sep 18, 2035	DP U-3440			
			9808465	Sep 18, 2035	U-3440			
			9974742	Sep 18, 2035	DP			
			9974793	Sep 18, 2035	DP			
			9974794	Sep 18, 2035	DP U-3440			
ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE								
N 022434	001		7589106	Sep 26, 2027	DP U-1163			
			7687516	Sep 26, 2027	DP U-1164			
ARIPIPRAZOLE - ABILIFY								
N 021436	001		8017615	Jun 16, 2024	DP			
			8017615*PED	Dec 16, 2024				
			8759350	Mar 02, 2027	U-1529			
			9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY								
N 021436	002		8017615	Jun 16, 2024	DP			
			8017615*PED	Dec 16, 2024				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021436 002	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY						
N 021436 003	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY						
N 021436 004	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY						
N 021436 005	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY						
N 021436 006	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY						
N 021713 001	8759350	Mar 02, 2027	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 002	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY						
N 021729 003	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY						
N 021729 004	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
ARIPIPRAZOLE - ABILIFY						
N 021729 005	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
ARIPIPRAZOLE - ABILIFY						
N 021866 001	7115587	Jul 21, 2024	DP		U-764	
	7115587*PED	Jan 21, 2025				
	7550445	Jul 21, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 001	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
	11648347	Apr 06, 2034	DP			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
	11648347	Apr 06, 2034	DP			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 003	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 003	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
	11648347	Apr 06, 2034	DP			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 004	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
	11648347	Apr 06, 2034	DP			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 001	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 001	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 002	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9433371	Sep 15, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 002	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 003	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 004	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 004	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 005	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 006	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 006	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY ASIMTUFII						
N 217006 001	10517951	Apr 23, 2033	DP		U-3245	
	10517951	Apr 23, 2033	DP		U-814	
	11097007	Apr 23, 2033	DP		U-3245	
	11097007	Apr 23, 2033	DP		U-814	
	11638757	Apr 23, 2033	DP		U-3245	
	11638757	Apr 23, 2033	DP		U-814	
	8338427	Mar 15, 2025	DP		U-1530	
	8399469	Jun 29, 2025	DS			
ARIPIPRAZOLE - ABILIFY ASIMTUFII						
N 217006 002	10517951	Apr 23, 2033	DP		U-3245	
	10517951	Apr 23, 2033	DP		U-814	
	11097007	Apr 23, 2033	DP		U-3245	
	11097007	Apr 23, 2033	DP		U-814	
	11638757	Apr 23, 2033	DP		U-3245	
	11638757	Apr 23, 2033	DP		U-814	
	8338427	Mar 15, 2025	DP		U-1530	
	8399469	Jun 29, 2025	DS			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 001	10112903	Jun 24, 2030	DS		U-543	
	10226458	Mar 19, 2032			U-543	
	10238651	Mar 19, 2035			U-2402	
	10813928	Mar 19, 2035			U-2983	
	11097006	Oct 24, 2033	DP		U-764	
	11273158	Apr 06, 2039			U-543	
	11406632	Mar 19, 2035			U-2402	
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030			U-543	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 001	9034867	Nov 07, 2032	DP		U-543	
	9193685	Oct 24, 2033	DP		U-543	
	9452131	Mar 19, 2035			U-2402	
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 002	10112903	Jun 24, 2030	DS		U-543	
	10226458	Mar 19, 2032			U-543	
	10238651	Mar 19, 2035			U-2402	
	10813928	Mar 19, 2035			U-2983	
	11097006	Oct 24, 2033	DP		U-764	
	11273158	Apr 06, 2039			U-543	
	11406632	Mar 19, 2035			U-2402	
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030			U-543	
	9034867	Nov 07, 2032	DP		U-543	
	9193685	Oct 24, 2033	DP		U-543	
	9452131	Mar 19, 2035			U-2402	
	9526726	Mar 19, 2035	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 003	10112903	Jun 24, 2030	DS		U-543	
	10226458	Mar 19, 2032			U-543	
	10238651	Mar 19, 2035			U-2402	
	10813928	Mar 19, 2035			U-2402	
	11097006	Oct 24, 2033	DP		U-764	
	11273158	Apr 06, 2039			U-543	
	11406632	Mar 19, 2035			U-2402	
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030			U-543	
	9034867	Nov 07, 2032	DP		U-543	
	9193685	Oct 24, 2033	DP		U-543	
	9452131	Mar 19, 2035			U-2402	
	9526726	Mar 19, 2035	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 004	10112903	Jun 24, 2030	DS		U-543	
	10226458	Mar 19, 2032			U-543	
	10238651	Mar 19, 2035			U-2402	
	10813928	Mar 19, 2035			U-2983	
	11097006	Oct 24, 2033	DP		U-764	
	11273158	Apr 06, 2039			U-543	
	11406632	Mar 19, 2035			U-2402	
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030			U-543	
	9034867	Nov 07, 2032	DP		U-543	
	9193685	Oct 24, 2033	DP		U-543	
	9452131	Mar 19, 2035			U-2402	
ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT						
N 209830 001	10016415	Sep 08, 2035	DP			
	10112903	Jun 24, 2030	DS		U-543	
	10688091	Aug 17, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT								
N 209830	001	10849894	Aug 17, 2035		U-543			
		11154552	Aug 17, 2035	DP				
		11273158	Apr 06, 2039		U-543			
		8431576	Oct 26, 2030	DS				
		8796276	Jun 24, 2030		U-543			
ARSENIC TRIOXIDE - TRISENOX								
N 021248	001						ODE-167	Jan 12, 2025
ARSENIC TRIOXIDE - TRISENOX								
N 021248	002						ODE-167	Jan 12, 2025
ARTESUNATE - ARTESUNATE								
N 213036	001						NCE	May 26, 2025
							ODE-290	May 26, 2027
ASCIMINIB HYDROCHLORIDE - SCEMBLIX								
N 215358	001	11407735	May 14, 2040	DS			NCE	Oct 29, 2026
		8829195	May 13, 2033	DS	U-1374		ODE-381	Oct 29, 2028
							ODE-382	Oct 29, 2028
ASCIMINIB HYDROCHLORIDE - SCEMBLIX								
N 215358	002	11407735	May 14, 2040	DS			NCE	Oct 29, 2026
		8829195	May 13, 2033	DS	U-1374		ODE-381	Oct 29, 2028
							ODE-382	Oct 29, 2028
ASCORBIC ACID - ASCOR								
N 209112	001						ODE-160	Oct 02, 2024
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP								
N 021881	001	7169381	Sep 01, 2024	DS	DP			
		7658914	Sep 01, 2024	DS	DP			
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU								
N 209381	001	10016504	Sep 10, 2033		DP			
		10646512	Mar 25, 2032		DP			
		10780112	Mar 09, 2032		DP			
		10792306	Mar 09, 2032		DP	U-2310		
		10918723	Sep 10, 2033			U-2310		
		11529368	Mar 09, 2032		DP	U-2310		
		8999313	Sep 10, 2033		DP			
		9326969	Sep 10, 2033			U-2310		
		9592252	Aug 11, 2032		DP	U-2310		
		9707297	Sep 10, 2033		DP			
ASENAPINE - SECUADO								
N 212268	001	10022445	Jul 25, 2033		DP			
		10583121	Jul 25, 2033		DP	U-2763		
		10814002	Jul 25, 2033		DP	U-2763		
		11123305	Jul 25, 2033		DP			
		11813364	Sep 22, 2033		DP			
		9687474	Jul 25, 2033		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ASENAPINE - SECUADO						
N 212268 002	10022445	Jul 25, 2033	DP			
	10583121	Jul 25, 2033	DP U-2763			
	10814002	Jul 25, 2033	DP U-2763			
	11123305	Jul 25, 2033	DP			
	11813364	Sep 22, 2033	DP			
	9687474	Jul 25, 2033	DP			
ASENAPINE - SECUADO						
N 212268 003	10022445	Jul 25, 2033	DP			
	10583121	Jul 25, 2033	DP U-2763			
	10814002	Jul 25, 2033	DP U-2763			
	11123305	Jul 25, 2033	DP			
	11813364	Sep 22, 2033	DP			
	9687474	Jul 25, 2033	DP			
ASENAPINE MALEATE - SAPHRIS						
N 022117 001	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS						
N 022117 002	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS						
N 022117 003	7741358	Apr 06, 2026	DS DP U-1893			
	7741358	Apr 06, 2026	DS DP U-1966			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
ASPIRIN - VAZALORE						
N 203697 001	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032	U-3559			
	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032	U-1731			
	9226892	Sep 29, 2032	U-1732			
	9226892	Sep 29, 2032	U-1733			
ASPIRIN - VAZALORE						
N 203697 002	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032	U-3559			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ASPIRIN; OMEPRAZOLE - YOSPRALA								
N 205103	001		9539214	Mar 13, 2033	U-1902			
			9987231	Jan 02, 2033	U-2324			
ASPIRIN; OMEPRAZOLE - YOSPRALA								
N 205103	002		9539214	Mar 13, 2033	U-1902			
			9987231	Jan 02, 2033	U-2324			
ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ								
N 206353	001		10039718	Oct 06, 2032	DP			
			8148374	Sep 03, 2029	DS DP U-1279			
ATOGEPANT - QULIPTA								
N 215206	001		10117836	Jan 30, 2035	DP		I-909	Apr 17, 2026
			8754096	Jul 19, 2032	DS DP U-3534		NCE	Sep 28, 2026
			9499545	Nov 10, 2031	DS DP U-3534			
			9850246	Mar 13, 2033	DS			
ATOGEPANT - QULIPTA								
N 215206	002		10117836	Jan 30, 2035	DP		I-909	Apr 17, 2026
			8754096	Jul 19, 2032	DS DP U-3534		NCE	Sep 28, 2026
			9499545	Nov 10, 2031	DS DP U-3534			
			9850246	Mar 13, 2033	DS			
ATOGEPANT - QULIPTA								
N 215206	003		10117836	Jan 30, 2035	DP		I-909	Apr 17, 2026
			8754096	Jul 19, 2032	DS DP U-3534		NCE	Sep 28, 2026
			9499545	Nov 10, 2031	DS DP U-3534			
			9850246	Mar 13, 2033	DS			
ATORVASTATIN CALCIUM - ATORVALIQ								
N 213260	001		11369567	Jun 07, 2037	DP			
			11654106	Jun 07, 2037	DP U-3612			
			11654106	Jun 07, 2037	DP U-3613			
AVACINCAPTAD PEGOL SODIUM - IZERVAY								
N 217225	001		10947544	Feb 14, 2025	DS U-3673			
			11273171	Jul 11, 2034	U-3673			
			11491176	Jul 11, 2034	U-3673			
			7538211	Feb 14, 2025	DS			
			7579456	Feb 14, 2025	DS			
			7803931	Feb 14, 2025	DS			
			8236773	Nov 11, 2026	U-3673			
			9617546	Feb 14, 2025	DS U-3673			
AVACOPAN - TAVNEOS								
N 214487	001		11603356	May 29, 2041	DS DP U-3558		NCE	Oct 07, 2026
			8445515	Feb 03, 2031	DS DP		ODE-377	Oct 07, 2028
			8906938	Dec 21, 2029	DS DP			
AVANAFIL - STENDRA								
N 202276	001		6656935	Apr 27, 2025	DS DP U-155		M-282	Oct 18, 2025
AVANAFIL - STENDRA								
N 202276	002		6656935	Apr 27, 2025	DS DP U-155		M-282	Oct 18, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AVANAFIL - STENDRA						
N 202276 003	6656935	Apr 27, 2025	DS DP U-155		M-282	Oct 18, 2025
AVAPRITINIB - AYVAKIT						
N 212608 001	9200002	Oct 15, 2034	DS DP U-2726		I-863	Jun 16, 2024
	9200002	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-3168		ODE-356	Jun 16, 2028
	9994575	Oct 15, 2034	DS DP U-2726		ODE-366	Jan 09, 2027
	9994575	Oct 15, 2034	DS DP U-3168		ODE-434	May 22, 2030
AVAPRITINIB - AYVAKIT						
N 212608 002	9200002	Oct 15, 2034	DS DP U-2726		I-863	Jun 16, 2024
	9200002	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-3168		ODE-356	Jun 16, 2028
	9994575	Oct 15, 2034	DS DP U-2726		ODE-366	Jan 09, 2027
	9994575	Oct 15, 2034	DS DP U-3168		ODE-434	May 22, 2030
AVAPRITINIB - AYVAKIT						
N 212608 003	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726		ODE-356	Jun 16, 2028
	9994575	Oct 15, 2034	DS DP U-2726		ODE-366	Jan 09, 2027
					ODE-434	May 22, 2030
AVAPRITINIB - AYVAKIT						
N 212608 004	11827642	Oct 15, 2034	DS DP U-3506		I-863	Jun 16, 2024
	9200002	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9200002	Oct 15, 2034	DS DP U-3506		I-912	May 22, 2026
	9944651	Oct 15, 2034	DS DP U-3168		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-3506		ODE-356	Jun 16, 2028
	9994575	Oct 15, 2034	DS DP U-3168		ODE-366	Jan 09, 2027
	9994575	Oct 15, 2034	DS DP U-3506		ODE-434	May 22, 2030
AVAPRITINIB - AYVAKIT						
N 212608 005	9200002	Oct 15, 2034	DS DP U-3168		I-863	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9994575	Oct 15, 2034	DS DP U-3168		NCE	Jan 09, 2025
					ODE-356	Jun 16, 2028
					ODE-366	Jan 09, 2027
					ODE-434	May 22, 2030
AVATROMBOPAG MALEATE - DOPTELET						
N 210238 001	7638536	May 05, 2025	DS DP		ODE-246	Jun 26, 2026
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244		NCE	Feb 25, 2020
	7112592	Jan 07, 2026	DS DP U-2508		NPP	Dec 20, 2025
	7112592	Jan 07, 2026	DS DP U-282		GAIN	Feb 25, 2025
	7612087	Nov 12, 2026	DP			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ							
N 206494	001	7112592	Jan 07, 2026	DS DP U-2244		NCE	Feb 25, 2020
		7112592	Jan 07, 2026	DS DP U-2508		NPP	Dec 20, 2025
		7112592	Jan 07, 2026	DS DP U-282		GAIN	Feb 25, 2025
		7612087	Nov 12, 2026	DP			
		8471025	Aug 12, 2031	DS			
		8835455	Oct 08, 2030	DP			
		8969566	Jun 15, 2032	DS			
		9284314	Jun 15, 2032	DS			
		9695122	Jun 15, 2032	DS			
AXITINIB - INLYTA							
N 202324	001	10570202	Feb 03, 2035	U-2844			
		10869924	Jan 12, 2037	U-3044			
		6534524	Apr 29, 2025	DS DP			
		8791140	Dec 14, 2030	DS			
AXITINIB - INLYTA							
N 202324	002	10570202	Feb 03, 2035	U-2844			
		10869924	Jan 12, 2037	U-3044			
		6534524	Apr 29, 2025	DS DP			
		8791140	Dec 14, 2030	DS			
AZACITIDINE - VIDAZA							
N 050794	001					I-889	May 20, 2025
						ODE-399	May 20, 2029
AZACITIDINE - ONUREG							
N 214120	001	11571436	May 14, 2029	DP		ODE-320	Sep 01, 2027
		8846628	Jun 03, 2030	DP U-2950			
AZACITIDINE - ONUREG							
N 214120	002	11571436	May 14, 2029	DP		ODE-320	Sep 01, 2027
		8846628	Jun 03, 2030	DP U-2950			
AZELAIC ACID - FINACEA							
N 207071	001	10117812	Oct 18, 2027	DP U-1796			
		7700076	Sep 18, 2027	DP			
		8435498	Mar 01, 2024	U-1727			
		9211259	Feb 28, 2029	U-1796			
		9265725	Dec 08, 2027	DP			
AZELASTINE HYDROCHLORIDE - ASTEPRO							
N 022203	001	8071073	Jun 04, 2028	DP			
		8518919	Nov 22, 2025	U-1430			
AZELASTINE HYDROCHLORIDE - ASTEPRO							
N 022203	002	8071073	Jun 04, 2028	DP			
		8518919	Nov 22, 2025	U-1430			
		9919050	Nov 22, 2025	DP			
AZELASTINE HYDROCHLORIDE - ASTEPRO ALLERGY							
N 213872	001	8071073	Jun 04, 2028	DP			
		8518919	Nov 22, 2025	U-3166			
		9919050	Nov 22, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZELASTINE HYDROCHLORIDE - CHILDREN'S ASTEPRO ALLERGY								
N 213872	002		8071073	Jun 04, 2028	DP			
			8518919	Nov 22, 2025			U-3166	
			9919050	Nov 22, 2025	DP			
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA								
N 202236	001		8163723*PED	Feb 29, 2024				
			8168620	Feb 24, 2026	DP			
AZILSARTAN KAMEDOXOMIL - EDARBI								
N 200796	001		7157584	May 22, 2025	DS			
			7572920	Jan 07, 2025	DP		U-3	
			9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL - EDARBI								
N 200796	002		7157584	May 22, 2025	DS			
			7572920	Jan 07, 2025	DP		U-3	
			9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR								
N 202331	001		7157584	May 22, 2025	DS			
			7572920	Jan 07, 2025	DP		U-3	
			9066936	Mar 26, 2028	DP			
			9169238	Feb 04, 2030	DP			
			9387249	Jul 01, 2031			U-3	
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR								
N 202331	002		7157584	May 22, 2025	DS			
			7572920	Jan 07, 2025	DP		U-3	
			9066936	Mar 26, 2028	DP			
			9169238	Feb 04, 2030	DP			
			9387249	Jul 01, 2031			U-3	
AZITHROMYCIN - ZMAX								
N 050797	001		6984403	Feb 14, 2024	DP		U-282	
			7887844	Feb 14, 2024	DP			
BACLOFEN - OZOBAX								
N 208193	001		10610502	Aug 30, 2039			U-2779	
BACLOFEN - LYVISPAH								
N 215422	001		10792262	Jul 29, 2039	DP		U-3263	
			11491125	Sep 29, 2041	DP		U-3488	
			11491125	Sep 29, 2041	DP		U-3489	
			11654124	Jul 29, 2039	DP			
BACLOFEN - LYVISPAH								
N 215422	002		10792262	Jul 29, 2039	DP		U-3263	
			11491125	Sep 29, 2041	DP		U-3488	
			11491125	Sep 29, 2041	DP		U-3489	
			11654124	Jul 29, 2039	DP			
BACLOFEN - LYVISPAH								
N 215422	003		10792262	Jul 29, 2039	DP		U-3263	
			11491125	Sep 29, 2041	DP		U-3488	
			11491125	Sep 29, 2041	DP		U-3489	
			11654124	Jul 29, 2039	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BACLOFEN - LYVISPAH						
N 215422 003	10792262	Jul 29, 2039	DP U-3263			
	11491125	Sep 29, 2041	DP U-3488			
	11491125	Sep 29, 2041	DP U-3489			
	11654124	Jul 29, 2039	DP			
BACLOFEN - FLEQSUVY						
N 215602 001	11324696	Sep 29, 2037	DP			
	11446246	Sep 08, 2037	U-3433			
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 001	10392406	Apr 27, 2036	DS			
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 002	10392406	Apr 27, 2036	DS			
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 003	10392406	Apr 27, 2036	DS			
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA						
N 214410 001	10392406	Apr 27, 2036	DS			
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BALOXAVIR MARBOXIL - XOFLUZA						
N 214410 001	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
BALSALAZIDE DISODIUM - COLAZAL						
N 020610 001	7452872	Aug 24, 2026	U-141			
	7625884	Aug 24, 2026	U-141			
BALSALAZIDE DISODIUM - GIAZO						
N 022205 001	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
	8497256	Jun 23, 2031	U-1229			
	9192616	Aug 02, 2026	U-1229			
BARICITINIB - OLUMIANT						
N 207924 001	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	11806555	Nov 02, 2031	U-3500		I-891	May 10, 2025
	8158616	Jun 08, 2030	DS DP			
	8420629	Mar 10, 2029	U-247			
	9089574	Nov 30, 2032	U-3372			
	9737469	Nov 02, 2031	U-3500			
BARICITINIB - OLUMIANT						
N 207924 002	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	11806555	Nov 02, 2031	U-3500		I-891	May 10, 2025
	8158616	Jun 08, 2030	DS DP			
	8420629	Mar 10, 2029	U-247			
	9089574	Nov 30, 2032	U-3372			
	9737469	Nov 02, 2031	U-3500			
BARICITINIB - OLUMIANT						
N 207924 003	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	11806555	Nov 02, 2031	U-3500		I-891	May 10, 2025
	8158616	Jun 08, 2030	DS DP			
	9089574	Nov 30, 2032	U-3372			
	9737469	Nov 02, 2031	U-3500			
BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE						
N 022247 001	6479535	May 06, 2024	DP U-594			
	6479535	May 06, 2024	DP U-904			
	7683051	Mar 10, 2027	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-904			
BECLOMETHASONE DIPROPIONATE - QVAR 80						
N 020911 001	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
	11395889	May 18, 2031	DP			
	9463289	May 18, 2031	DP			
	9808587	May 18, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BECLOMETHASONE DIPROPIONATE - QVAR 40						
N 020911 002	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
	11395889	May 18, 2031	DP			
	9463289	May 18, 2031	DP			
	9808587	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QNASL						
N 202813 001	10188811	Oct 21, 2031	DP			
	7780038	Jan 24, 2027	DP			
BECLOMETHASONE DIPROPIONATE - QNASL						
N 202813 002	10188811	Oct 21, 2031	DP			
	7780038	Jan 24, 2027	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER						
N 207921 001	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
	10792447	Jan 25, 2039	DP			
	11395888	Jan 26, 2038	DP			
	11395889	May 18, 2031	DP			
	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
	11793953	Jan 26, 2038	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER						
N 207921 002	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
	10792447	Jan 25, 2039	DP			
	11395888	Jan 26, 2038	DP			
	11395889	May 18, 2031	DP			
	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
	11793953	Jan 26, 2038	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
BEDAQUILINE FUMARATE - SIRTURO						
N 204384 001	7498343	Dec 01, 2026	DS DP U-1321		ODE-251	Aug 09, 2026
	8546428	Mar 19, 2029	DS DP U-1321		ODE-307	May 27, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BEDAQUILINE FUMARATE - SIRTURO						
N 204384 002	7498343	Dec 01, 2026	DS DP U-1321		ODE-307	May 27, 2027
	8546428	Mar 19, 2029	DS DP U-1321			
BELINOSTAT - BELEODAQ						
N 206256 001	6888027	Aug 10, 2026	DS DP U-1544			
	8835501	Oct 27, 2027	DP			
BELUMOSUDIL MESYLATE - REZUROCK						
N 214783 001	10183931	Oct 07, 2033	U-3246		NCE	Jul 16, 2026
	10696660	Oct 07, 2033	U-3246		ODE-362	Jul 16, 2028
	11311541	Apr 09, 2035	U-3369			
	8357693	Oct 30, 2029	DS DP U-3247			
	9815820	Oct 07, 2033	U-3247			
BELZUTIFAN - WELIREG						
N 215383 001	9908845	Sep 05, 2034	DS DP U-3201		NCE	Aug 13, 2026
	9908845	Sep 05, 2034	DS DP U-3780		ODE-364	Aug 13, 2028
	9969689	Sep 05, 2034	DS DP U-3201			
	9969689	Sep 05, 2034	DS DP U-3780			
BEMPEDOIC ACID - NEXLETOL						
N 211616 001	11613511	Jun 19, 2040	DS		NCE	Feb 21, 2025
	11760714	Jun 19, 2040	DP			
	7335799	Dec 03, 2025	DS			
BEMPEDOIC ACID; EZETIMIBE - NEXLIZET						
N 211617 001	10912751	Mar 14, 2036	U-3224		NCE	Feb 21, 2025
	11613511	Jun 19, 2040	DS			
	11744816	Mar 14, 2036	U-3692			
	11760714	Jun 19, 2040	DP			
	7335799	Dec 03, 2025	DS			
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 001	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 002	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 002	8445524	Mar 26, 2029	DS DP		U-1402	
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP		U-1402	
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP		U-1542	
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP		U-1402	
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
	9533955	Mar 26, 2029	DP		U-1949	
	9533955	Mar 26, 2029	DP		U-1952	
	9533955*PED	Sep 26, 2029				
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 003	8344006	Sep 23, 2029	DP		U-1402	
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP		U-1542	
	8791270*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 004	8344006	Sep 23, 2029	DP		U-1402	
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP		U-1542	
	8791270*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - BELRAPZO						
N 205580 001	10010533	Jan 28, 2031	DP			
	11103483	Jan 28, 2031	DP		U-1971	
	11103483	Jan 28, 2031	DP		U-1972	
	11844783	Jan 28, 2031			U-1542	
	11844783	Jan 28, 2031			U-1971	
	11844783	Jan 28, 2031			U-1972	
	8609707	Aug 11, 2031	DP		U-1971	
	8609707	Aug 11, 2031	DP		U-1972	
	8791270	Jan 12, 2026	DP		U-1971	
	8791270	Jan 12, 2026	DP		U-1972	
	9265831	Jan 28, 2031	DP			
	9572796	Jan 28, 2031	DP		U-1971	
	9572796	Jan 28, 2031	DP		U-1972	
	9572797	Jan 28, 2031			U-1971	
	9572797	Jan 28, 2031			U-1972	
BENDAMUSTINE HYDROCHLORIDE - BENDEKA						
N 208194 001	10010533	Jan 28, 2031	DP			
	10052385	Mar 15, 2033			U-1971	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENDAMUSTINE HYDROCHLORIDE - BENDEKA						
N 208194 001	10052385	Mar 15, 2033	U-1972			
	11103483	Jan 28, 2031	DP U-1971			
	11103483	Jan 28, 2031	DP U-1972			
	11844783	Jan 28, 2031	U-1542			
	11844783	Jan 28, 2031	U-1971			
	11844783	Jan 28, 2031	U-1972			
	8609707	Aug 11, 2031	DP U-1542			
	8791270	Jan 12, 2026	DP U-1790			
	9000021	Mar 15, 2033	U-1542			
	9034908	Mar 15, 2033	U-1542			
	9144568	Mar 15, 2033	U-1542			
	9265831	Jan 28, 2031	DP			
	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			
BENDAMUSTINE HYDROCHLORIDE - VIVIMUSTA						
N 212209 001	11844784	Jul 29, 2042	DP			
BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM - FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE						
N 211039 001	10293047	Nov 15, 2037	DP U-2755			
	10632197	Nov 15, 2037	DP U-2755			
	10842872	Nov 15, 2037	U-3001			
BENZNIDAZOLE - BENZNIDAZOLE						
N 209570 001					ODE-154	Aug 29, 2024
BENZNIDAZOLE - BENZNIDAZOLE						
N 209570 002					ODE-154	Aug 29, 2024
BENZOYL PEROXIDE - EPSOLAY						
N 214510 001	10933046	Feb 19, 2040	DP U-3357		NP	Apr 22, 2025
	10945987	Feb 19, 2040	U-3356			
	11426378	Aug 18, 2040	U-3356			
	11541026	Feb 19, 2040	U-3356			
	11628155	Dec 27, 2040	U-3356			
	9687465	Nov 27, 2032	DP U-3356			
	9868103	Aug 08, 2028	DP U-3356			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE						
A 208683 001					PC	Mar 30, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA						
N 050819 001	10220049	Jun 03, 2029	DP U-916			
	10624918	Jun 03, 2029	U-916			
	8288434	Aug 05, 2029	DP U-124			
	8663699	Jun 03, 2029	U-124			
	8895070	Jun 03, 2029	U-124			
	9078870	Jun 03, 2029	DP			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON						
N 050819 002	10137142	Jun 03, 2029	DP U-916			
	10220049	Jun 03, 2029	DP U-916			
	8288434	Aug 05, 2029	DP U-1033			
	8288434	Aug 05, 2029	DP U-124			
	8288434	Aug 05, 2029	DP U-134			
	8288434	Aug 05, 2029	DP U-818			
	8288434	Aug 05, 2029	DP U-916			
	8288434	Aug 05, 2029	DP U-921			
	9504704	Jun 03, 2029	DP U-124			
	9504704	Jun 03, 2029	DP U-134			
	9504704	Jun 03, 2029	DP U-818			
	9504704	Jun 03, 2029	DP U-916			
	9561208	Jun 03, 2029	DP U-916			
BENZOYL PEROXIDE; TRETINOIN - TWYNEO						
N 214902 001	10420743	Jul 12, 2038	U-3194		NC	Jul 26, 2024
	10653899	Dec 30, 2030	DP U-3194			
	11071878	Dec 30, 2030	DP			
	8617580	Feb 03, 2028	DP			
	9868103	Aug 08, 2028	DP U-3194			
BENZYL ALCOHOL - ULESFIA						
N 022129 001	7294342	May 19, 2024	U-970			
BEPOTASTINE BESILATE - BEPREVE						
N 022288 001	8784789	Jan 13, 2025	DP			
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO						
N 214094 001	10125102	Apr 07, 2035	DS U-3010		NCE	Dec 03, 2025
	10329260	Mar 09, 2035	DS		ODE-333	Dec 03, 2027
	10662160	Nov 01, 2039	DS U-3010			
	10689346	Mar 09, 2035	U-3010			
	11117867	Nov 01, 2039	DP U-3010			
	11230530	Mar 09, 2035	U-3300			
	11618733	Nov 01, 2039	U-3300			
	11708333	Mar 09, 2035	U-3300			
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO						
N 214094 002	10125102	Apr 07, 2035	DS U-3010		NCE	Dec 03, 2025
	10329260	Mar 09, 2035	DS		ODE-333	Dec 03, 2027
	10662160	Nov 01, 2039	DS U-3010			
	10689346	Mar 09, 2035	U-3010			
	11117867	Nov 01, 2039	DP U-3010			
	11230530	Mar 09, 2035	U-3300			
	11618733	Nov 01, 2039	U-3300			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO						
N 214094 002	11708333	Mar 09, 2035	U-3300			
BESIFLOXACIN HYDROCHLORIDE - BESIVANCE						
N 022308 001	8415342	Nov 07, 2030	U-80			
	8481526	Jan 09, 2031	DS			
	8604020	Mar 12, 2030	DP			
	8937062	Nov 13, 2029	U-80			
BETAMETHASONE DIPROPIONATE - SERNIVO						
N 208079 001	10179137	Aug 31, 2030	DP U-1858			
	9364485	Aug 31, 2030	DP U-1858			
	9433630	Aug 31, 2030	DP U-1858			
	9439911	Aug 31, 2030	DP U-1858			
	9655907	Aug 31, 2030	DP U-1858			
	9775851	Aug 31, 2030	DP U-1858			
	9877974	Aug 31, 2030	DP U-1858			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR						
N 207589 001	10130640	Jun 10, 2031	DP			
	10130640*PED	Dec 10, 2031				
	10617698	Jun 10, 2031	DP			
	10660908	Jun 10, 2031	DP U-2627			
	10682364	Jun 10, 2031	DP			
	10688108	Jun 10, 2031	U-2627			
	10716799	Jun 10, 2031	DP			
	9119781	Jun 10, 2031	DP U-1761			
	9119781	Jun 10, 2031	DP U-2627			
	9119781*PED	Dec 10, 2031				
	9566286	Jun 10, 2031	DP			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - WYNZORA						
N 213422 001	10265265	Sep 27, 2027	DP			
	11696919	Mar 18, 2039	DP			
BETRIXABAN - BEVYXXA						
N 208383 001	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP U-2034			
	8557852	Sep 08, 2028	U-1167			
	8557852	Sep 08, 2028	U-2030			
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026	U-1502			
BETRIXABAN - BEVYXXA						
N 208383 002	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP U-2034			
	8557852	Sep 08, 2028	U-1167			
	8557852	Sep 08, 2028	U-2030			
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026	U-1502			
BEXAGLIFLOZIN - BRENZAVVY						
N 214373 001	10533032	Jul 03, 2031	U-2214		NCE	Jan 20, 2028
	10981942	Jun 13, 2031	DS DP			
	7838499	Jan 30, 2029	DS DP U-2214			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BEXAGLIFLOZIN - BRENZAVVY						
N 214373 001	8106021	Aug 22, 2028	U-2214			
	8802637	Aug 22, 2028	DS DP U-2214			
	8987323	May 14, 2032	DS DP			
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY						
N 210251 001	10385067	Jun 19, 2035	U-257		M-82	Feb 24, 2024
	10548846	Nov 08, 2036	DP		ODE-256	Jun 18, 2026
	11744802	Nov 08, 2036	DP			
	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9216996	Dec 19, 2033	DS DP			
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
	9708342	Jun 19, 2035	DS DP			
	9732092	Dec 19, 2033	DS DP			
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY						
N 210251 002	10385067	Jun 19, 2035	U-257		ODE-378	Oct 07, 2028
	7390791	Apr 17, 2025	DS DP			
	8754065	Aug 15, 2032	DS DP U-257			
	9216996	Dec 19, 2033	DS DP			
	9296769	Aug 15, 2032	DS DP U-257			
	9708342	Jun 19, 2035	DS DP			
	9732092	Dec 19, 2033	DS DP			
BIMATOPROST - LUMIGAN						
N 022184 001	7851504	Jun 13, 2027	DS DP			
	8278353	Mar 16, 2025	DP			
	8299118	Mar 16, 2025	U-1295			
	8309605	Mar 16, 2025	U-1293			
	8309605	Mar 16, 2025	U-1294			
	8338479	Mar 16, 2025	DP U-1295			
	8524777	Mar 16, 2025	U-1235			
	8586630	Mar 16, 2025	U-1458			
	8772338	Mar 16, 2025	DP U-1528			
	8933120	Mar 16, 2025	DP			
	8933127	Mar 16, 2025	DP			
	9155716	Mar 16, 2025	DP U-1528			
	9241918	Mar 16, 2025	DP U-1814			
BIMATOPROST - LATISSE						
N 022369 001	8101161	May 25, 2024	U-1217			
	8101161	May 25, 2024	U-1218			
BIMATOPROST - DURYSTA						
N 211911 001	10398707	Apr 30, 2024	U-2759			
	10441543	Dec 19, 2026	DP			
	7799336	Apr 24, 2029	DP			
	8206737	Apr 07, 2027	U-2759			
	8629185	Jul 15, 2031	DS DP			
	8673341	Feb 19, 2025	U-2759			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BIMATOPROST - DURYSTA						
N 211911 001	9149428	Dec 19, 2026	DP			
	9492316	Oct 31, 2034	DP			
	9980974	Oct 31, 2034	U-2759			
BINIMETINIB - MEKTOVI						
N 210498 001	10005761	Aug 27, 2030	U-2331		I-928	Oct 11, 2026
	10005761	Aug 27, 2030	U-3737		ODE-194	Jun 27, 2025
	7777050	Mar 13, 2024	DS DP			
	9314464	Jul 04, 2031	U-2332			
	9314464	Jul 04, 2031	U-3737			
	9562016	Oct 18, 2033	DS DP			
	9598376	Oct 18, 2033	U-2330			
	9850229	Aug 27, 2030	U-2333			
	9980944	Oct 18, 2033	U-2334			
BIVALIRUDIN - ANGIOMAX						
N 020873 001	7582727	Jul 27, 2028	DP			
	7598343	Jul 27, 2028	DP			
BOCEPREVIR - VICTRELIS						
N 202258 001	7772178	Nov 11, 2027	DP U-1128			
	8119602	Mar 17, 2027	U-1233			
	RE43298	Dec 22, 2024	DS DP U-1128			
BORTEZOMIB - BORTEZOMIB						
N 205004 001	8962572	Nov 03, 2032	DP			
BORTEZOMIB - BORTEZOMIB						
N 215331 001	11679119	Sep 23, 2042	U-3632			
	11679119	Sep 23, 2042	U-3633			
	11752164	Sep 23, 2042	U-3632			
	11752164	Sep 23, 2042	U-3633			
BORTEZOMIB - BORTEZOMIB						
N 215331 002	11679119	Sep 23, 2042	U-3632			
	11679119	Sep 23, 2042	U-3633			
	11752164	Sep 23, 2042	U-3632			
	11752164	Sep 23, 2042	U-3633			
BOSENTAN - TRACLEER						
N 021290 001					ODE*	Sep 05, 2024
BOSENTAN - TRACLEER						
N 021290 002					ODE*	Sep 05, 2024
BOSENTAN - TRACLEER						
N 209279 001	7959945	Dec 28, 2027	DP		ODE-161	Sep 05, 2024
	8309126	May 15, 2026	DP			
BOSUTINIB MONOHYDRATE - BOSULIF						
N 203341 001	11103497	Feb 28, 2034	U-3216		I-923	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-163	Dec 19, 2024
	11103497*PED	Aug 28, 2034			ODE-444	Sep 26, 2030
	7417148	Dec 11, 2025	U-1283		PED	Jun 19, 2025
	7417148	Dec 11, 2025	U-3707		PED	Mar 26, 2027
	7417148	Dec 11, 2025	U-3708		PED	Mar 26, 2031

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BOSUTINIB MONOHYDRATE - BOSULIF						
N 203341 001	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
	RE42376	Apr 13, 2024	DS			
	RE42376*PED	Oct 13, 2024				
BOSUTINIB MONOHYDRATE - BOSULIF						
N 203341 002	11103497	Feb 28, 2034	U-3216		I-923	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-163	Dec 19, 2024
	11103497*PED	Aug 28, 2034			ODE-444	Sep 26, 2030
	7417148	Dec 11, 2025	U-1283		PED	Jun 19, 2025
	7417148	Dec 11, 2025	U-3707		PED	Mar 26, 2027
	7417148	Dec 11, 2025	U-3708		PED	Mar 26, 2031
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
	RE42376	Apr 13, 2024	DS			
	RE42376*PED	Oct 13, 2024				
BOSUTINIB MONOHYDRATE - BOSULIF						
N 203341 003	11103497	Feb 28, 2034	U-3216		I-923	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-163	Dec 19, 2024
	11103497*PED	Aug 28, 2034			ODE-444	Sep 26, 2030
	7417148	Dec 11, 2025	U-1283		PED	Jun 19, 2025
	7417148	Dec 11, 2025	U-3707		PED	Mar 26, 2027
	7417148	Dec 11, 2025	U-3708		PED	Mar 26, 2031
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
	RE42376	Apr 13, 2024	DS			
	RE42376*PED	Oct 13, 2024				
BOSUTINIB MONOHYDRATE - BOSULIF						
N 217729 001	11103497	Feb 28, 2034	U-3216		NP	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-444	Sep 26, 2030
	11103497*PED	Aug 28, 2034			PED	Mar 26, 2027
	7417148	Dec 11, 2025	U-3707		PED	Mar 26, 2031
	7417148	Dec 11, 2025	U-3708			
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
	RE42376	Apr 13, 2024	DS DP			
	RE42376*PED	Oct 13, 2024				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BOSUTINIB MONOHYDRATE - BOSULIF						
N 217729 002	11103497	Feb 28, 2034	U-3216		NP	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-444	Sep 26, 2030
	11103497*PED	Aug 28, 2034			PED	Mar 26, 2027
	7417148	Dec 11, 2025	U-3707		PED	Mar 26, 2031
	7417148	Dec 11, 2025	U-3708			
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
	RE42376	Apr 13, 2024	DS DP			
	RE42376*PED	Oct 13, 2024				
BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)						
N 210557 001	10286034	Nov 05, 2033	U-2568		NCE	Jun 21, 2024
	11590209	Apr 29, 2041	U-3539			
	6794489	Jun 28, 2025	DS DP			
	9352013	Nov 05, 2033	U-2568			
	9700592	Nov 05, 2033	U-2568			
BREXANOLONE - ZULRESSO						
N 211371 001	10117951	Mar 13, 2029	DP		NCE	Jun 17, 2024
	10251894	Nov 27, 2033	U-2552		NPP	Jun 16, 2025
	10322139	Jan 23, 2033	DP			
	10940156	Mar 08, 2037	U-2552			
	7635773	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9750822	Mar 13, 2029	DP			
BREXPIPRAZOLE - REXULTI						
N 205422 001	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	7888362	Apr 12, 2026	DS	Y	NPP	Dec 27, 2024
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			
BREXPIPRAZOLE - REXULTI						
N 205422 002	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	7888362	Apr 12, 2026	DS	Y	NPP	Dec 27, 2024
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BREXPIPRAZOLE - REXULTI						
N 205422 003	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	7888362	Apr 12, 2026	DS	Y	NPP	Dec 27, 2024
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			
BREXPIPRAZOLE - REXULTI						
N 205422 004	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	7888362	Apr 12, 2026	DS	Y	NPP	Dec 27, 2024
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			
BREXPIPRAZOLE - REXULTI						
N 205422 005	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	7888362	Apr 12, 2026	DS	Y	NPP	Dec 27, 2024
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			
BREXPIPRAZOLE - REXULTI						
N 205422 006	7888362	Apr 12, 2026	DS	Y	I-913	May 10, 2026
	8349840	Apr 12, 2026	DP U-1529		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			
BRIGATINIB - ALUNBRIG						
N 208772 001	10385078	Nov 10, 2035	DS DP U-2837		ODE-142	Apr 28, 2024
	9012462	Apr 28, 2031	DS		ODE-300	May 22, 2027
	9273077	May 21, 2029	U-2837			
	9611283	Apr 10, 2034	U-2837			
BRIGATINIB - ALUNBRIG						
N 208772 002	10385078	Nov 10, 2035	DS DP U-2837		ODE-142	Apr 28, 2024
	9012462	Apr 28, 2031	DS		ODE-300	May 22, 2027
	9273077	May 21, 2029	U-2837			
	9611283	Apr 10, 2034	U-2837			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BRIGATINIB - ALUNBRIG						
N 208772 002	10385078	Nov 10, 2035	DS DP U-2837		ODE-142	Apr 28, 2024
	9012462	Apr 28, 2031	DS		ODE-300	May 22, 2027
	9273077	May 21, 2029	U-2837			
	9611283	Apr 10, 2034	U-2837			
BRIGATINIB - ALUNBRIG						
N 208772 003	10385078	Nov 10, 2035	DS DP U-2837		ODE-142	Apr 28, 2024
	9012462	Apr 28, 2031	DS		ODE-300	May 22, 2027
	9273077	May 21, 2029	U-2837			
	9611283	Apr 10, 2034	U-2837			
BRILLIANT BLUE G - TISSUEBLUE						
N 209569 001					NCE	Dec 20, 2024
					ODE-282	Dec 20, 2026
BRIMONIDINE TARTRATE - QOLIANA						
N 021764 001	7265117	Aug 19, 2025	DP			
BRIMONIDINE TARTRATE - ALPHAGAN P						
N 021770 001	8858961*PED	Mar 02, 2024				
BRIMONIDINE TARTRATE - MIRVASO						
N 204708 001	10201517	Jun 13, 2031	DP			
	7439241	Aug 25, 2025	U-1428			
	8053427	Jun 13, 2031	DP U-1428			
	8163725	Jun 13, 2031	DP			
	8231885	May 24, 2025	DP			
	8410102	May 24, 2025	U-1428			
	8426410	May 24, 2025	U-1428			
	8513247	Mar 25, 2031	DP U-1428			
	8513249	Mar 25, 2031	DP U-1428			
	8859551	May 25, 2024	U-1428			
	9861631	Mar 25, 2031	U-1428			
	9861632	Mar 25, 2031	U-1428			
BRIMONIDINE TARTRATE - LUMIFY						
N 208144 001	11596600	Jul 27, 2029	U-2222			
	11833245	Jul 27, 2029	U-2222			
	8293742	Jul 14, 2030	U-2222			
	9259425	Jul 14, 2030	U-2222			
BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA						
N 204251 001	9044484	Oct 30, 2030	DP			
	9421265	Jun 17, 2030	DP			
BRINCIDOFOVIR - TEMBEXA						
N 214460 001	9303051	Aug 31, 2031	DS DP U-3165		NP	Jun 04, 2024
					ODE-354	Jun 04, 2028
BRINCIDOFOVIR - TEMBEXA						
N 214461 001	10112909	Oct 10, 2034	U-3165		NP	Jun 04, 2024
	10487061	Oct 10, 2034	DP U-3165		ODE-354	Jun 04, 2028
	8962829	Oct 10, 2034	DS DP			
	9303051	Aug 31, 2031	DS DP U-3165			
	9371344	Oct 10, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BRINZOLAMIDE - BRINZOLAMIDE						
A 211914 001					CGT	Apr 07, 2024
BRIVARACETAM - BRIVIACT						
N 205836 001	10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
BRIVARACETAM - BRIVIACT						
N 205836 002	10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
BRIVARACETAM - BRIVIACT						
N 205836 003	10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
BRIVARACETAM - BRIVIACT						
N 205836 004	10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
BRIVARACETAM - BRIVIACT						
N 205836 005	10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
BRIVARACETAM - BRIVIACT						
N 205837 001	6911461	Feb 21, 2026	DS DP U-1815		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2130			
BRIVARACETAM - BRIVIACT						
N 205838 001	6911461	Feb 21, 2026	DS DP U-2295		NPP	Aug 27, 2024
BROMFENAC SODIUM - PROLENSA						
N 203168 001	10085958	Nov 19, 2032	DP			
	8129431	Sep 11, 2025	DS DP			
	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
	8871813	Jan 16, 2024	DP			
	8927606	Jan 16, 2024	U-100			
	8927606	Jan 16, 2024	U-1095			
	8927606	Jan 16, 2024	U-810			
	9144609	Jan 16, 2024	DP			
	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
BROMFENAC SODIUM - BROMSITE						
N 206911 001	8778999	Aug 07, 2029	DP U-1834			
BROMOCRIPTINE MESYLATE - CYCLOSET						
N 020866 001	10688094	Apr 30, 2032	U-2870			
	10688094	Apr 30, 2032	U-2871			
	10688094	Apr 30, 2032	U-2872			
	10688094	Apr 30, 2032	U-2873			
	10688094	Apr 30, 2032	U-2874			
	10688094	Apr 30, 2032	U-2875			
	10688094	Apr 30, 2032	U-2876			
	10688094	Apr 30, 2032	U-2877			
	10688094	Apr 30, 2032	U-2878			
	10688094	Apr 30, 2032	U-2879			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BROMOCRIPTINE MESYLATE - CYCLOSET						
N 020866 001	10688094	Apr 30, 2032	U-2880			
	10688094	Apr 30, 2032	U-2881			
	10688094	Apr 30, 2032	U-2882			
	10688094	Apr 30, 2032	U-2883			
	10688094	Apr 30, 2032	U-2884			
	10688094	Apr 30, 2032	U-2885			
	10688094	Apr 30, 2032	U-2886			
	10688094	Apr 30, 2032	U-2887			
	10688094	Apr 30, 2032	U-2888			
	10688155	Jun 07, 2030	U-2281			
	10688155	Jun 07, 2030	U-2890			
	10688155	Jun 07, 2030	U-2891			
	10688155	Jun 07, 2030	U-2892			
	10688155	Jun 07, 2030	U-2893			
	10688155	Jun 07, 2030	U-2894			
	10688155	Jun 07, 2030	U-2895			
	10688155	Jun 07, 2030	U-2896			
	10688155	Jun 07, 2030	U-2897			
	10688155	Jun 07, 2030	U-2898			
	10688155	Jun 07, 2030	U-2899			
	10688155	Jun 07, 2030	U-2900			
	10688155	Jun 07, 2030	U-2901			
	10688155	Jun 07, 2030	U-2902			
	10688155	Jun 07, 2030	U-2903			
	10688155	Jun 07, 2030	U-2904			
	10688155	Jun 07, 2030	U-2905			
	10688155	Jun 07, 2030	U-2906			
	10688155	Jun 07, 2030	U-2907			
	10688155	Jun 07, 2030	U-2908			
	10688155	Jun 07, 2030	U-2909			
	10688155	Jun 07, 2030	U-2910			
	10688155	Jun 07, 2030	U-2911			
	10688155	Jun 07, 2030	U-2912			
	10688155	Jun 07, 2030	U-2913			
	10688155	Jun 07, 2030	U-2914			
	10688155	Jun 07, 2030	U-2915			
	10688155	Jun 07, 2030	U-2916			
	10688155	Jun 07, 2030	U-2917			
	10688155	Jun 07, 2030	U-2918			
	10688155	Jun 07, 2030	U-2919			
	10688155	Jun 07, 2030	U-2920			
	10688155	Jun 07, 2030	U-2921			
	10688155	Jun 07, 2030	U-2922			
	10688155	Jun 07, 2030	U-2923			
	10688155	Jun 07, 2030	U-2924			
	10688155	Jun 07, 2030	U-2925			
	10688155	Jun 07, 2030	U-2926			
	10688155	Jun 07, 2030	U-2927			
	10688155	Jun 07, 2030	U-2928			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BROMOCRIPTINE MESYLATE - CYCLOSET						
N 020866 001	10688155	Jun 07, 2030	U-2929			
	10688155	Jun 07, 2030	U-2930			
	10688155	Jun 07, 2030	U-2931			
	10688155	Jun 07, 2030	U-2932			
	10688155	Jun 07, 2030	U-2933			
	10688155	Jun 07, 2030	U-2934			
	10688155	Jun 07, 2030	U-2935			
	10688155	Jun 07, 2030	U-2936			
	10688155	Jun 07, 2030	U-2937			
	11000522	Apr 30, 2032	U-3119			
	11000522	Apr 30, 2032	U-3120			
	11000522	Apr 30, 2032	U-3121			
	11000522	Apr 30, 2032	U-3122			
	8431155	Apr 30, 2032	DP U-976			
	8613947	Apr 30, 2032	DP U-976			
	8877708	Jun 07, 2030	DP U-1706			
	9192576	Apr 30, 2032	DP U-976			
	9352025	Jun 07, 2030	U-2111			
	9352025	Jun 07, 2030	U-2112			
	9352025	Jun 07, 2030	U-2113			
	9352025	Jun 07, 2030	U-2114			
	9352025	Jun 07, 2030	U-2115			
	9352025	Jun 07, 2030	U-2116			
	9352025	Jun 07, 2030	U-2117			
	9352025	Jun 07, 2030	U-2118			
	9352025	Jun 07, 2030	U-2119			
	9522117	Apr 30, 2032	DP U-1939			
	9522117	Apr 30, 2032	DP U-976			
	9700555	Apr 30, 2032	DP U-2183			
	9700555	Apr 30, 2032	DP U-2184			
	9700555	Apr 30, 2032	DP U-2185			
	9700555	Apr 30, 2032	DP U-2186			
	9700555	Apr 30, 2032	DP U-2187			
	9700555	Apr 30, 2032	DP U-2188			
	9700555	Apr 30, 2032	DP U-2189			
	9700555	Apr 30, 2032	DP U-2190			
	9700555	Apr 30, 2032	DP U-2191			
	9700555	Apr 30, 2032	DP U-2192			
	9700555	Apr 30, 2032	DP U-2193			
	9700555	Apr 30, 2032	DP U-2194			
	9700555	Apr 30, 2032	DP U-2195			
	9700555	Apr 30, 2032	DP U-2196			
	9700555	Apr 30, 2032	DP U-2197			
	9700555	Apr 30, 2032	DP U-2198			
	9895422	Jun 07, 2030	U-2114			
	9895422	Jun 07, 2030	U-2116			
	9895422	Jun 07, 2030	U-2281			
	9895422	Jun 07, 2030	U-2282			
	9895422	Jun 07, 2030	U-2283			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BROMOCRIPTINE MESYLATE - CYCLOSET							
N 020866	001	9895422	Jun 07, 2030	U-2284			
		9895422	Jun 07, 2030	U-2285			
		9895422	Jun 07, 2030	U-2286			
		9895422	Jun 07, 2030	U-2287			
		9993474	Apr 30, 2032	U-2384			
		9993474	Apr 30, 2032	U-2385			
		9993474	Apr 30, 2032	U-2386			
		9993474	Apr 30, 2032	U-2387			
		9993474	Apr 30, 2032	U-2388			
		9993474	Apr 30, 2032	U-2389			
		9993474	Apr 30, 2032	U-2390			
		9993474	Apr 30, 2032	U-2391			
		9993474	Apr 30, 2032	U-2392			
		9993474	Apr 30, 2032	U-2393			
BUDESONIDE - UCERIS							
N 203634	001	10307375	Sep 07, 2031	DP			
		10660858	Sep 07, 2031	DP			
		8895064	Sep 07, 2031	DP			
		9132093	Sep 07, 2031	DP			
		9192581	Sep 07, 2031	DP U-1325			
BUDESONIDE - ORTIKOS							
N 211929	001	10172802	Sep 09, 2036	U-2554			
		9707182	Sep 09, 2036	DP U-2554			
BUDESONIDE - ORTIKOS							
N 211929	002	10172802	Sep 09, 2036	U-2554			
		9707182	Sep 09, 2036	DP U-2554			
BUDESONIDE - TARPEYO							
N 215935	001	8491932	May 07, 2029	DP U-3269		NP	Dec 15, 2024
						ODE-389	Dec 15, 2028
BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE							
N 216579	001	10716753	May 28, 2030	DP U-3203			
		9415009	May 28, 2030	U-3203			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N 021929	001	7587988	Apr 10, 2026	DP			
		7587988*PED	Oct 10, 2026				
		8387615	Mar 26, 2027	DP			
		8387615*PED	Sep 26, 2027				
		8528545	Oct 16, 2028	DP			
		8528545*PED	Apr 16, 2029				
		8616196	Apr 07, 2029	DP			
		8616196*PED	Oct 07, 2029				
		8875699	Nov 10, 2024	DP			
		8875699*PED	May 10, 2025				
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N 021929	002	7587988	Apr 10, 2026	DP			
		7587988*PED	Oct 10, 2026				
		8387615	Mar 26, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N 021929	002	8387615*PED	Sep 26, 2027				
		8528545	Oct 16, 2028	DP			
		8528545*PED	Apr 16, 2029				
		8616196	Apr 07, 2029	DP			
		8616196*PED	Oct 07, 2029				
		8875699	Nov 10, 2024	DP			
		8875699*PED	May 10, 2025				
BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE							
N 212122	001	10716753	May 28, 2030	DP U-2889			
		11331442	Oct 05, 2038	DP			
		11833292	Oct 05, 2038	DP			
		8324266	May 28, 2030	U-2889			
		8703806	May 28, 2030	U-2889			
		8808713	May 28, 2030	DP U-2889			
		8815258	Mar 17, 2031	U-2889			
		9415009	May 28, 2030	U-2889			
		9463161	May 28, 2030	DP U-2889			
BUPIVACAINE - EXPAREL							
N 022496	001	11033495	Jan 22, 2041	DP U-3182		NPP	Mar 22, 2024
		11179336	Jan 22, 2041	DP U-3250			
		11278494	Jan 22, 2041	DP U-3250			
		11304904	Jan 22, 2041	DP U-3346			
		11311486	Jan 22, 2041	DP U-3250			
		11357727	Jan 22, 2041	DP U-3380			
		11426348	Jan 22, 2041	DP U-3380			
		11452691	Jan 22, 2041	DP U-3439			
		11819574	Jan 22, 2041	DP U-3250			
		11819575	Jan 22, 2041	DP U-3250			
BUPIVACAINE - EXPAREL							
N 022496	002	11033495	Jan 22, 2041	DP U-3182		NPP	Mar 22, 2024
		11179336	Jan 22, 2041	DP U-3250			
		11278494	Jan 22, 2041	DP U-3250			
		11304904	Jan 22, 2041	DP U-3346			
		11311486	Jan 22, 2041	DP U-3250			
		11357727	Jan 22, 2041	DP U-3380			
		11426348	Jan 22, 2041	DP U-3380			
		11452691	Jan 22, 2041	DP U-3439			
		11819574	Jan 22, 2041	DP U-3250			
		11819575	Jan 22, 2041	DP U-3250			
BUPIVACAINE - POSIMIR							
N 204803	001	11400019	Jan 12, 2041	DP		NP	Feb 01, 2024
		11771624	Jan 12, 2041	U-3724			
		8153149	Sep 15, 2025	DP			
		8153661	Sep 15, 2025	U-3074			
		8753665	Sep 15, 2025	DP U-3074			
		8846072	Sep 15, 2025	DP U-3074			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPIVACAINE HYDROCHLORIDE - XARACOLL						
N 209511 001	11746141	Jan 09, 2033	DP			
	RE47826	May 20, 2029	U-2949			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 001	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
	11844837	Apr 21, 2036	U-3417			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 002	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
	11844837	Apr 21, 2036	U-3417			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 003	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
	11844837	Apr 21, 2036	U-3417			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 003	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 004	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
	11844837	Apr 21, 2036	U-3417			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
BUPRENORPHINE - SUBLOCADE						
N 209819 001	10198218	Jun 06, 2031	U-2489			
	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
	11000520	Nov 06, 2035	U-3111			
	11839611	Nov 06, 2035	U-3111			
	8921387	Jan 06, 2032	DP U-2173			
	8921387	Jan 06, 2032	DP U-2174			
	8975270	Sep 05, 2031	DP U-2175			
	8975270	Sep 05, 2031	DP U-2206			
	9272044	Jun 06, 2031	U-2176			
	9272044	Jun 06, 2031	U-2177			
	9272044	Jun 06, 2031	U-2178			
	9272044	Jun 06, 2031	U-2209			
	9498432	Jun 06, 2031	DP U-2179			
	9782402	Jun 06, 2031	DP U-2176			
	9782402	Jun 06, 2031	DP U-2180			
	9782402	Jun 06, 2031	DP U-2207			
	9782402	Jun 06, 2031	DP U-2208			
	9827241	Jun 06, 2031	DP U-2174			
	9827241	Jun 06, 2031	DP U-2181			
	9827241	Jun 06, 2031	DP U-2206			
	9827241	Jun 06, 2031	DP U-2210			
	9827241	Jun 06, 2031	DP U-2211			
BUPRENORPHINE - SUBLOCADE						
N 209819 002	10198218	Jun 06, 2031	U-2489			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE - SUBLOCADE						
N 209819 002	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
	10646484	Jun 22, 2038	U-2489			
	11000520	Nov 06, 2035	U-3111			
	11839611	Nov 06, 2035	U-3111			
	8921387	Jan 06, 2032	DP U-2173			
	8921387	Jan 06, 2032	DP U-2174			
	8975270	Sep 05, 2031	DP U-2175			
	8975270	Sep 05, 2031	DP U-2206			
	9272044	Jun 06, 2031	U-2176			
	9272044	Jun 06, 2031	U-2177			
	9272044	Jun 06, 2031	U-2178			
	9272044	Jun 06, 2031	U-2209			
	9498432	Jun 06, 2031	DP U-2179			
	9782402	Jun 06, 2031	DP U-2176			
	9782402	Jun 06, 2031	DP U-2180			
	9782402	Jun 06, 2031	DP U-2207			
	9782402	Jun 06, 2031	DP U-2208			
	9827241	Jun 06, 2031	DP U-2174			
	9827241	Jun 06, 2031	DP U-2181			
	9827241	Jun 06, 2031	DP U-2206			
	9827241	Jun 06, 2031	DP U-2210			
	9827241	Jun 06, 2031	DP U-2211			
BUPRENORPHINE - BRIXADI						
N 210136 001	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 002	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 003	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE - BRIXADI						
N 210136 004	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 005	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 006	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 007	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE						
N 204442 001	7736665	Apr 25, 2024	U-1878			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 001	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 002	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 003	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 004	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 005	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 006	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 007	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE						
N 022410 001	11135216	Aug 07, 2029	DP U-3111			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
	9687454	Aug 07, 2029	DP U-1464			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE						
N 022410 002	11135216	Aug 07, 2029	DP U-3111			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
	9687454	Aug 07, 2029	DP U-1464			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE						
N 022410 003	11135216	Aug 07, 2029	DP U-3111			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
	9687454	Aug 07, 2029	DP U-1464			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE						
N 022410 004	11135216	Aug 07, 2029	DP U-3111			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
	9687454	Aug 07, 2029	DP U-1464			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 001	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
	11433066	Sep 18, 2032	U-3131			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 002	10874661	Sep 18, 2032	DP			
	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP		U-3131	
	11020388	Sep 18, 2032	DP		U-3131	
	11433066	Sep 18, 2032			U-3131	
	8470361	May 22, 2030	DP		U-1425	
	8658198	Dec 03, 2027	DP		U-1494	
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 003	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP		U-3131	
	11020388	Sep 18, 2032	DP		U-3131	
	11433066	Sep 18, 2032			U-3131	
	8470361	May 22, 2030	DP		U-1425	
	8658198	Dec 03, 2027	DP		U-1494	
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 004	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP		U-3131	
	11020388	Sep 18, 2032	DP		U-3131	
	11433066	Sep 18, 2032			U-3131	
	8470361	May 22, 2030	DP		U-1425	
	8658198	Dec 03, 2027	DP		U-1494	
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 005	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP		U-3131	
	11020388	Sep 18, 2032	DP		U-3131	
	11433066	Sep 18, 2032			U-3131	
	8470361	May 22, 2030	DP		U-1425	
	8658198	Dec 03, 2027	DP		U-1494	
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 006	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP		U-3131	
	8470361	May 22, 2030	DP		U-1425	
	8658198	Dec 03, 2027	DP		U-1494	
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP	Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 006	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP	Y		
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL						
N 205637 001	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
	9655843	Jul 23, 2027	DP U-2017			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL						
N 205637 002	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
	9655843	Jul 23, 2027	DP U-2017			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL						
N 205637 003	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
	9655843	Jul 23, 2027	DP U-2017			
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 001	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 003	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 003	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROCHLORIDE - FORFIVO XL						
N 022497 001	7674479	Jun 25, 2027	DP			
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	10058518	Nov 05, 2034	U-3419		NP	Aug 18, 2025
	10064857	Nov 05, 2034	U-3419			
	10080727	Nov 05, 2034	U-3419			
	10092560	Nov 05, 2034	U-3419			
	10092561	Nov 05, 2034	U-3419			
	10105327	Nov 05, 2034	U-3419			
	10105361	Nov 05, 2034	U-3419			
	10251879	Nov 05, 2034	U-3419			
	10463634	Nov 05, 2034	U-3419			
	10512643	Nov 05, 2034	U-3419			
	10548857	Nov 05, 2034	U-3419			
	10596167	Nov 05, 2034	U-3419			
	10772850	Nov 05, 2034	U-3419			
	10780064	Jan 07, 2040	U-3419			
	10780066	Nov 09, 2034	U-3419			
	10786469	Nov 05, 2034	U-3419			
	10786496	Nov 05, 2034	U-3419			
	10799497	Nov 05, 2034	U-3419			
	10806710	Nov 05, 2034	U-3419			
	10864209	Nov 05, 2034	U-3419			
	10874663	Nov 05, 2034	U-3419			
	10874664	Nov 05, 2034	U-3419			
	10874665	Nov 05, 2034	U-3419			
	10881624	Nov 05, 2034	U-3419			
	10881657	Nov 05, 2034	U-3419			
	10894046	Nov 05, 2034	U-3419			
	10894047	Nov 05, 2034	U-3419			
	10898453	Nov 05, 2034	U-3419			
	10925842	Jan 07, 2040	U-3419			
	10933034	Nov 05, 2034	U-3419			
	10940124	Jan 07, 2040	U-3419			
	10945973	Nov 05, 2034	U-3419			
	10966941	Nov 05, 2034	U-3419			
	10966942	Jan 07, 2040	U-3419			
	10966974	Nov 05, 2034	U-3419			
	11020389	Nov 05, 2034	U-3419			
	11058648	Nov 05, 2034	U-3419			
	11090300	Nov 05, 2034	U-3419			
	11096937	Nov 05, 2034	U-3419			
	11123343	Nov 05, 2034	U-3419			
	11129826	Nov 05, 2034	U-3419			
	11141388	Nov 05, 2034	U-3419			
	11141416	Nov 05, 2034	U-3419			
	11147808	Nov 05, 2034	U-3419			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	11185515	Nov 05, 2034			U-3419	
	11191739	Nov 05, 2034	DP		U-3419	
	11197839	Nov 05, 2034	DP		U-3419	
	11207281	Nov 05, 2034			U-3419	
	11213521	Nov 05, 2034			U-3419	
	11229640	Nov 05, 2034			U-3419	
	11234946	Nov 05, 2034			U-3419	
	11253491	Nov 05, 2034			U-3419	
	11253492	Nov 05, 2034			U-3419	
	11273133	Nov 05, 2034			U-3419	
	11273134	Nov 05, 2034			U-3419	
	11285118	Nov 05, 2034			U-3419	
	11285146	Nov 05, 2034			U-3419	
	11291638	Nov 05, 2034			U-3419	
	11291665	Nov 05, 2034			U-3419	
	11298351	Nov 05, 2034			U-3419	
	11298352	Nov 05, 2034			U-3419	
	11311534	Nov 05, 2034			U-3419	
	11344544	Nov 05, 2034			U-3419	
	11357744	Nov 05, 2034			U-3419	
	11364233	Nov 05, 2034			U-3419	
	11382874	Nov 05, 2034			U-3419	
	11419867	Nov 05, 2034			U-3419	
	11426370	Nov 05, 2034			U-3419	
	11426401	Nov 05, 2034			U-3419	
	11433067	Nov 05, 2034	DP		U-3419	
	11439636	Nov 05, 2034			U-3419	
	11478468	Nov 05, 2034			U-3419	
	11497721	Nov 05, 2034			U-3419	
	11510918	Nov 05, 2034			U-3419	
	11517542	Nov 05, 2034			U-3419	
	11517543	Nov 05, 2034			U-3419	
	11524007	Nov 05, 2034			U-3419	
	11524008	Nov 05, 2034			U-3419	
	11534414	Nov 05, 2034	DP		U-3419	
	11541021	Nov 05, 2034			U-3419	
	11541048	Nov 05, 2034			U-3419	
	11596627	Nov 05, 2034			U-3419	
	11617728	Nov 05, 2034			U-3419	
	11617747	Nov 05, 2034			U-3563	
	11717518	Jan 20, 2043			U-3419	
	11730706	Jan 23, 2043			U-3419	
	11752144	Feb 23, 2043			U-3419	
	11779579	Nov 05, 2034			U-3419	
	11839612	Mar 02, 2043			U-3419	
	11844797	Apr 20, 2043			U-3778	
	8569328	Oct 29, 2033	DP		U-3419	
	9168234	Nov 05, 2034			U-3419	
	9198905	Nov 05, 2034			U-3419	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	9205083	Nov 05, 2034			U-3419	
	9238032	Nov 05, 2034			U-3419	
	9278095	Nov 05, 2034			U-3419	
	9314462	Nov 05, 2034			U-3419	
	9370513	Nov 05, 2034			U-3419	
	9375429	Nov 05, 2034			U-3419	
	9408815	Nov 05, 2034			U-3419	
	9421176	Nov 05, 2034			U-3419	
	9457023	Nov 05, 2034			U-3419	
	9457025	Nov 05, 2034			U-3419	
	9474731	Nov 05, 2034			U-3419	
	9486450	Nov 05, 2034			U-3419	
	9700528	Nov 05, 2034			U-3419	
	9700553	Nov 05, 2034			U-3419	
	9707191	Nov 05, 2034			U-3419	
	9763932	Nov 05, 2034			U-3419	
	9861595	Nov 05, 2034			U-3419	
	9867819	Nov 05, 2034			U-3419	
	9968568	Nov 05, 2034			U-3419	
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE						
N 200063 001	10231964	Jul 02, 2034			U-1583	
	10307376	Nov 08, 2027			U-1585	
	10403170	Jun 05, 2033			U-1583	
	10828294	Jul 02, 2034			U-1583	
	10835527	Jul 02, 2034			U-1583	
	11033543	Jan 10, 2031			U-1583	
	11139056	Jun 05, 2033			U-1583	
	11278544	Apr 21, 2024			U-1583	
	11324741	May 29, 2029			U-1583	
	7375111	Mar 26, 2025	DP			
	7462626	Jul 20, 2024			U-1583	
	8088786	Feb 03, 2029	DP			
	8318788	Nov 08, 2027			U-1584	
	8722085	Nov 08, 2027			U-1585	
	8815889	Jul 20, 2024			U-1586	
	8916195	Feb 02, 2030			U-1639	
	9107837	Jun 04, 2027			U-1639	
	9125868	Nov 08, 2027			U-1585	
	9248123	Jan 13, 2032			U-1808	
	9633575	Jun 25, 2033			U-1583	
CABAZITAXEL - JEVTANA KIT						
N 201023 001	10583110	Oct 27, 2030			U-2753	
	10716777	Oct 27, 2030			U-2856	
	7241907	Dec 10, 2025	DS			
	7241907*PED	Jun 10, 2026				
	8927592	Oct 27, 2030			U-3200	
	8927592*PED	Apr 27, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CABOTEGRAVIR - APRETUDE						
N 215499 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	11224597	Sep 15, 2031	DP			
	8410103	Apr 28, 2026	DS DP			
CABOTEGRAVIR SODIUM - VOCABRIA						
N 212887 001	10927129	Apr 28, 2026	DS DP		M-273	Jan 31, 2025
	8410103	Apr 28, 2026	DS DP U-3061		NCE	Jan 21, 2026
	8410103	Apr 28, 2026	DS DP U-3348		NPP	Mar 29, 2025
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT						
N 212888 001	10927129	Apr 28, 2026	DS DP		D-184	Jan 31, 2025
	11224597	Sep 15, 2031	DP U-3348		NCE	Jan 21, 2026
	11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
	7125879	Apr 21, 2025	DS DP U-3348			
	8410103	Apr 28, 2026	DS DP U-3348			
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT						
N 212888 002	10927129	Apr 28, 2026	DS DP		D-184	Jan 31, 2025
	11224597	Sep 15, 2031	DP U-3348		NCE	Jan 21, 2026
	11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
	7125879	Apr 21, 2025	DS DP U-3348			
	8410103	Apr 28, 2026	DS DP U-3348			
CABOZANTINIB S-MALATE - COMETRIQ						
N 203756 001	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
	11298349	Feb 10, 2032	DP			
	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP U-1617			
	9717720	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - COMETRIQ						
N 203756 002	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
	11298349	Feb 10, 2032	DP			
	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP U-1617			
	9717720	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 001	10034873	Jul 18, 2031	U-2488		I-854	Jan 22, 2024
	10039757	Jul 18, 2031	U-1480		I-873	Sep 17, 2024
	11091439	Jan 15, 2030	DS		ODE-227	Jan 14, 2026
	11091440	Jan 15, 2030	DP		ODE-375	Sep 17, 2028
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11298349	Feb 10, 2032	DP			
	7579473	Aug 14, 2026	DS DP			
	8497284	Sep 24, 2024	U-1220			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 001	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
	8877776	Oct 08, 2030	DS DP U-3225			
	9724342	Jul 09, 2033	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 002	10034873	Jul 18, 2031	U-2488		I-854	Jan 22, 2024
	10039757	Jul 18, 2031	U-1480		I-873	Sep 17, 2024
	11091439	Jan 15, 2030	DS		ODE-227	Jan 14, 2026
	11091440	Jan 15, 2030	DP		ODE-375	Sep 17, 2028
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11298349	Feb 10, 2032	DP			
	7579473	Aug 14, 2026	DS DP			
	8497284	Sep 24, 2024	U-1220			
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
	8877776	Oct 08, 2030	DS DP U-3225			
	9724342	Jul 09, 2033	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 003	10034873	Jul 18, 2031	U-2488		I-854	Jan 22, 2024
	10039757	Jul 18, 2031	U-1480		I-873	Sep 17, 2024
	11091439	Jan 15, 2030	DS		ODE-227	Jan 14, 2026
	11091440	Jan 15, 2030	DP		ODE-375	Sep 17, 2028
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11298349	Feb 10, 2032	DP			
	7579473	Aug 14, 2026	DS DP			
	8497284	Sep 24, 2024	U-1220			
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
	8877776	Oct 08, 2030	DS DP U-3225			
	9724342	Jul 09, 2033	DP			
CALCIFEDIOL - RAYALDEE						
N 208010 001	10213442	Feb 02, 2027	DP			
	10300078	Mar 14, 2034	DP			
	10357502	Mar 14, 2034	DP			
	11154509	Apr 25, 2028	U-3248			
	11253528	Mar 14, 2034	DP			
	11801253	Sep 07, 2030	DP U-3721			
	11801253	Sep 07, 2030	DP U-3722			
	11801253	Sep 07, 2030	DP U-3723			
	8207149	Apr 25, 2028	U-1871			
	8361488	Jul 19, 2028	DP			
	8426391	Aug 27, 2028	U-1872			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CALCIFEDIOL - RAYALDEE						
N 208010 001	8778373	Apr 25, 2028	U-1873			
	8906410	Feb 02, 2027	DP			
	9408858	Apr 25, 2028	U-1888			
	9498486	Apr 25, 2028	U-1920			
	9861644	Mar 14, 2034	DP			
	9925147	Apr 25, 2028	DP U-2255			
	9925147	Apr 25, 2028	DP U-2256			
	9925147	Apr 25, 2028	DP U-2257			
	9925147	Apr 25, 2028	DP U-2258			
	9925147	Apr 25, 2028	DP U-2259			
	9943530	Feb 02, 2027	U-2274			
CALCIPOTRIENE - SORILUX						
N 022563 001	8263580	May 07, 2028	DP U-1280			
	8263580	May 07, 2028	DP U-2662			
	8629128	May 26, 2026	DP U-1280			
	8629128	May 26, 2026	DP U-1767			
	8629128	May 26, 2026	DP U-2662			
CALCIUM ACETATE - PHOSLYRA						
N 022581 001	8591938	Feb 23, 2030	DP U-1469			
	8592480	Jul 20, 2027	U-1469			
	9089528	Jul 20, 2027	U-1469			
CALCIUM GLUCONATE - CALCIUM GLUCONATE						
A 216541 001					CGT	Apr 30, 2024
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
A 217174 001					CGT	Mar 10, 2024
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
A 217174 002					CGT	Mar 10, 2024
CALCIUM GLUCONATE - CALCIUM GLUCONATE						
A 217689 001					CGT	Apr 17, 2024
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
N 210906 001	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
N 210906 002	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
N 210906 003	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV						
N 212690 001	10195168	Jan 11, 2033	DP		I-870	Aug 12, 2024
	10213400	Mar 15, 2033	U-2499		ODE-361	Jul 21, 2027
	10213400*PED	Sep 15, 2033			ODE-369	Aug 12, 2028
	10675258	Jan 11, 2033	U-2938			
	10864181	Mar 15, 2033	U-3017			
	10864181*PED	Sep 15, 2033				
	11253494	Mar 15, 2033	U-3323			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV						
N 212690 001	11253494	Mar 15, 2033			U-3324	
	11253494*PED	Sep 15, 2033				
	11426373	Sep 19, 2037			U-3432	
	11554102	Jan 11, 2033	DP			
	8591922	Jan 11, 2033	DP			
	8772306	Mar 15, 2033			U-1532	
	8772306	Mar 15, 2033			U-3198	
	8772306*PED	Sep 15, 2033				
	8901173	Jan 11, 2033	DP			
	9050302	Mar 15, 2033			U-1532	
	9050302*PED	Sep 15, 2033				
	9132107	Jan 11, 2033	DP			
	9486426	Mar 15, 2033			U-1532	
	9486426*PED	Sep 15, 2033				
CANAGLIFLOZIN - INVOKANA						
N 204042 001	10617668	May 11, 2031	DP		U-2441	
	10617668	May 11, 2031	DP		U-2632	
	10617668	May 11, 2031	DP		U-2794	
	10617668	May 11, 2031	DP		U-2795	
	10617668	May 11, 2031	DP		U-2796	
	10617668	May 11, 2031	DP		U-2797	
	10617668	May 11, 2031	DP		U-2798	
	10617668	May 11, 2031	DP		U-2799	
	10617668	May 11, 2031	DP		U-493	
	7943582	Feb 26, 2029	DS DP		U-2441	
	7943582	Feb 26, 2029	DS DP		U-2632	
	7943582	Feb 26, 2029	DS DP		U-493	
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	
	8222219	Apr 11, 2025			U-2632	
	8222219	Apr 11, 2025			U-493	
	8513202	Dec 03, 2027	DS DP		U-2441	
	8513202	Dec 03, 2027	DS DP		U-2632	
	8513202	Dec 03, 2027	DS DP		U-493	
CANAGLIFLOZIN - INVOKANA						
N 204042 002	10617668	May 11, 2031	DP		U-2441	
	10617668	May 11, 2031	DP		U-2632	
	10617668	May 11, 2031	DP		U-2794	
	10617668	May 11, 2031	DP		U-2795	
	10617668	May 11, 2031	DP		U-2796	
	10617668	May 11, 2031	DP		U-2797	
	10617668	May 11, 2031	DP		U-2798	
	10617668	May 11, 2031	DP		U-2799	
	10617668	May 11, 2031	DP		U-493	
	7943582	Feb 26, 2029	DS DP		U-2441	
	7943582	Feb 26, 2029	DS DP		U-2632	
	7943582	Feb 26, 2029	DS DP		U-493	
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN - INVOKANA						
N 204042 002	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 001	11576894	Jul 06, 2030	DP			
	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 002	11576894	Jul 06, 2030	DP			
	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 003	11576894	Jul 06, 2030	DP			
	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 004	11576894	Jul 06, 2030	DP			
	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 004	7943582	Feb 26, 2029	DS DP		U-493	
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	
	8222219	Apr 11, 2025			U-2632	
	8222219	Apr 11, 2025			U-493	
	8513202	Dec 03, 2027	DS DP		U-2441	
	8513202	Dec 03, 2027	DS DP		U-2632	
	8513202	Dec 03, 2027	DS DP		U-493	
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 001	7943582	Feb 26, 2029	DS DP		U-2441	
	7943582	Feb 26, 2029	DS DP		U-2632	
	7943582	Feb 26, 2029	DS DP		U-493	
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	
	8222219	Apr 11, 2025			U-2632	
	8222219	Apr 11, 2025			U-493	
	8513202	Dec 03, 2027	DS DP		U-2441	
	8513202	Dec 03, 2027	DS DP		U-2632	
	8513202	Dec 03, 2027	DS DP		U-493	
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 002	7943582	Feb 26, 2029	DS DP		U-2441	
	7943582	Feb 26, 2029	DS DP		U-2632	
	7943582	Feb 26, 2029	DS DP		U-493	
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	
	8222219	Apr 11, 2025			U-2632	
	8222219	Apr 11, 2025			U-493	
	8513202	Dec 03, 2027	DS DP		U-2441	
	8513202	Dec 03, 2027	DS DP		U-2632	
	8513202	Dec 03, 2027	DS DP		U-493	
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 003	7943582	Feb 26, 2029	DS DP		U-2441	
	7943582	Feb 26, 2029	DS DP		U-2632	
	7943582	Feb 26, 2029	DS DP		U-493	
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	
	8222219	Apr 11, 2025			U-2632	
	8222219	Apr 11, 2025			U-493	
	8513202	Dec 03, 2027	DS DP		U-2441	
	8513202	Dec 03, 2027	DS DP		U-2632	
	8513202	Dec 03, 2027	DS DP		U-493	
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 004	7943582	Feb 26, 2029	DS DP		U-2441	
	7943582	Feb 26, 2029	DS DP		U-2632	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 004	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANGRELOR - KENGREAL						
N 204958 001	10039780	Jul 10, 2035	U-2260			
	8680052	Mar 09, 2033	U-2979			
	9295687	Jul 10, 2035	DP			
	9427448	Nov 10, 2030	U-1926			
	9439921	Jul 10, 2035	DP			
	9700575	Jul 10, 2035	DP			
	9925265	May 13, 2029	U-2260			
CANNABIDIOL - EPIDIOLEX						
N 210365 001	10092525	Jun 17, 2035	U-2427		M-270	Oct 20, 2026
	10111840	Jun 17, 2035	U-2442		ODE-216	Sep 28, 2025
	10111840	Jun 17, 2035	U-2443		ODE-326	Jul 31, 2027
	10137095	Jun 17, 2035	U-2454		ODE-332	Jul 31, 2027
	10137095	Jun 17, 2035	U-2455			
	10603288	Jun 17, 2035	U-2780			
	10603288	Jun 17, 2035	U-2781			
	10603288	Jun 17, 2035	U-2782			
	10603288	Jun 17, 2035	U-2783			
	10709671	Jun 17, 2035	U-2862			
	10709673	Jun 17, 2035	DP			
	10709674	Jun 17, 2035	U-2780			
	10709674	Jun 17, 2035	U-2781			
	10849860	Jun 17, 2035	U-2427			
	10849860	Jun 17, 2035	U-2454			
	10918608	Oct 13, 2035	U-3071			
	10918608	Oct 13, 2035	U-3072			
	10918608	Oct 13, 2035	U-3073			
	10966939	Jun 17, 2035	DP U-2780			
	10966939	Jun 17, 2035	DP U-2781			
	11065209	Oct 13, 2035	U-3071			
	11096905	Oct 13, 2035	DS DP U-2780			
	11096905	Oct 13, 2035	DS DP U-2781			
	11154516	Jun 17, 2035	U-3235			
	11154516	Jun 17, 2035	U-3236			
	11160795	Mar 01, 2041	U-3233			
	11207292	Apr 26, 2039	DS U-3235			
	11207292	Apr 26, 2039	DS U-3236			
	11207292	Apr 26, 2039	DS U-3277			
	11311498	Jun 17, 2035	U-3375			
	11311498	Jun 17, 2035	U-3376			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANNABIDIOL - EPIDIOLEX						
N 210365 001	11357741	Jun 17, 2035	U-2862			
	11400055	Oct 13, 2035	U-3071			
	11406623	Mar 01, 2041	U-3233			
	11446258	Jun 17, 2035	U-2780			
	11446258	Jun 17, 2035	U-2781			
	11446258	Jun 17, 2035	U-3071			
	11633369	Jun 17, 2035	DP U-2780			
	11633369	Jun 17, 2035	DP U-2781			
	11633369	Jun 17, 2035	DP U-3071			
	11701330	Jun 17, 2035	U-2780			
	11701330	Jun 17, 2035	U-2781			
	11766411	Jun 17, 2035	U-2781			
	9949937	Jun 17, 2035	U-2421			
	9956183	Jun 17, 2035	U-2422			
	9956183	Jun 17, 2035	U-2423			
	9956184	Jun 17, 2035	U-2424			
	9956185	Jun 17, 2035	U-2425			
	9956186	Jun 17, 2035	U-2426			
CANTHARIDIN - YCANTH						
N 212905 001	11052064	May 28, 2035	DP U-3663			
	11052064	May 28, 2035	DP U-3665			
	11147790	Aug 22, 2038	DP U-3663			
	11147790	Aug 22, 2038	DP U-3664			
CAPIVASERTIB - TRUQAP						
N 218197 001	10039766	Apr 16, 2033	U-3762		NCE	Nov 16, 2028
	10059714	Oct 10, 2028	DS DP			
	10654855	Oct 10, 2028	U-3762			
	11760760	Oct 10, 2028	U-3762			
	8101623	Mar 10, 2030	DS DP U-3762			
	8809336	Oct 25, 2025	U-3762			
	9006430	Oct 25, 2025	DP			
	9487525	Apr 16, 2033	DS DP			
CAPIVASERTIB - TRUQAP						
N 218197 002	10039766	Apr 16, 2033	U-3762		NCE	Nov 16, 2028
	10059714	Oct 10, 2028	DS DP			
	10654855	Oct 10, 2028	U-3762			
	11760760	Oct 10, 2028	U-3762			
	8101623	Mar 10, 2030	DS DP U-3762			
	8809336	Oct 25, 2025	U-3762			
	9006430	Oct 25, 2025	DP			
	9487525	Apr 16, 2033	DS DP			
CAPMATINIB HYDROCHLORIDE - TABRECTA						
N 213591 001	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CAPMATINIB HYDROCHLORIDE - TABRECTA								
N 213591	002		10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
			7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
			8420645	Jun 05, 2031	DS DP			
			8461330	Nov 19, 2027	DS DP			
			8901123	May 20, 2029	U-2813			
CAPSAICIN - QUTENZA								
N 022395	001		10034841	Sep 06, 2025	DP			
			8821920	Mar 26, 2030	DP			
			9226903	Dec 15, 2028	DP			
CARBAMAZEPINE - EQUETRO								
N 021710	001		6977253	May 19, 2024	U-693			
CARBAMAZEPINE - EQUETRO								
N 021710	002		6977253	May 19, 2024	U-693			
CARBAMAZEPINE - EQUETRO								
N 021710	003		6977253	May 19, 2024	U-693			
CARBAMAZEPINE - CARNEXIV								
N 206030	001		11529357	Jan 31, 2040	DP			
			7635773	Mar 13, 2029	DP			
			8410077	Mar 13, 2029	DP			
			9493582	Feb 27, 2033	DP			
			9629797	Nov 10, 2028	U-2004			
			9629797	Nov 10, 2028	U-2005			
			9629797	Nov 10, 2028	U-2006			
			9750822	Mar 13, 2029	DP			
			9770407	Nov 10, 2028	DP			
CARBIDOPA; LEVODOPA - RYTARY								
N 203312	001		8377474	Dec 26, 2028	DP U-1645			
			8377474	Dec 26, 2028	DP U-219			
			8454998	Dec 26, 2028	DP U-1645			
			8454998	Dec 26, 2028	DP U-1646			
			8454998	Dec 26, 2028	DP U-1647			
			8454998	Dec 26, 2028	DP U-1649			
			8454998	Dec 26, 2028	DP U-219			
			8557283	Dec 26, 2028	DP U-1645			
			8557283	Dec 26, 2028	DP U-219			
			9089607	Dec 26, 2028	DP U-1645			
			9089607	Dec 26, 2028	DP U-1720			
			9089608	Dec 26, 2028	DP			
			9463246	Dec 26, 2028	DP U-219			
			9533046	Dec 26, 2028	DP U-219			
			9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY								
N 203312	002		8377474	Dec 26, 2028	DP U-1645			
			8377474	Dec 26, 2028	DP U-219			
			8454998	Dec 26, 2028	DP U-1645			
			8454998	Dec 26, 2028	DP U-1646			
			8454998	Dec 26, 2028	DP U-1647			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 002	8454998	Dec 26, 2028	DP U-1649			
	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
	9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 003	8377474	Dec 26, 2028	DP U-1645			
	8377474	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
	9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 004	8377474	Dec 26, 2028	DP U-1645			
	8377474	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
	9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - DHIVY						
N 214869 001	11033521	Mar 28, 2039	DP U-219			
	11033521	Mar 28, 2039	DP U-3304			
	11033521	Mar 28, 2039	DP U-3305			
	11439613	Mar 28, 2039	U-3557			
	11819485	Mar 28, 2039	U-3557			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBINOXAMINE MALEATE - KARBINAL ER						
N 022556 001	8062667	Mar 29, 2029	DP			
	9522191	Jun 15, 2027	DP			
CARFILZOMIB - KYPROLIS						
N 202714 001	7232818	Apr 14, 2025	DS DP			
	7417042	Jul 20, 2026	DS DP			
	7491704	Apr 14, 2025			U-1260	
	7491704	Apr 14, 2025			U-2319	
	7491704	Apr 14, 2025			U-2320	
	7491704	Apr 14, 2025			U-2947	
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025			U-1260	
	8129346	Apr 14, 2025			U-2319	
	8129346	Apr 14, 2025			U-2320	
	8129346	Apr 14, 2025			U-2947	
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025			U-1260	
	8207127	Apr 14, 2025			U-2319	
	8207127	Apr 14, 2025			U-2320	
	8207127	Apr 14, 2025			U-2947	
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	RE47954	Oct 21, 2029			U-3449	
CARFILZOMIB - KYPROLIS						
N 202714 002	7232818	Apr 14, 2025	DS DP			
	7417042	Jul 20, 2026	DS DP			
	7491704	Apr 14, 2025			U-1260	
	7491704	Apr 14, 2025			U-2319	
	7491704	Apr 14, 2025			U-2320	
	7491704	Apr 14, 2025			U-2947	
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025			U-1260	
	8129346	Apr 14, 2025			U-2319	
	8129346	Apr 14, 2025			U-2320	
	8129346	Apr 14, 2025			U-2947	
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025			U-1260	
	8207127	Apr 14, 2025			U-2319	
	8207127	Apr 14, 2025			U-2320	
	8207127	Apr 14, 2025			U-2947	
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	RE47954	Oct 21, 2029			U-3449	
CARFILZOMIB - KYPROLIS						
N 202714 003	7232818	Apr 14, 2025	DS DP			
	7417042	Jul 20, 2026	DS DP			
	7491704	Apr 14, 2025			U-2319	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARFILZOMIB - KYPROLIS						
N 202714 003	7491704	Apr 14, 2025	U-2320			
	7491704	Apr 14, 2025	U-2947			
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025	U-2319			
	8129346	Apr 14, 2025	U-2320			
	8129346	Apr 14, 2025	U-2947			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-2319			
	8207127	Apr 14, 2025	U-2320			
	8207127	Apr 14, 2025	U-2947			
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	RE47954	Oct 21, 2029	U-3449			
CARGLUMIC ACID - CARBAGLU						
N 022562 001					ODE-345	Jan 22, 2028
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	7943621	Dec 16, 2028	DS DP			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	7943621	Dec 16, 2028	DS DP			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 002	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 003	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7943621	Dec 16, 2028	DS DP			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 004	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7943621	Dec 16, 2028	DS DP			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
CARVEDILOL PHOSPHATE - COREG CR						
N 022012 001	8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR						
N 022012 002	8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR						
N 022012 003	8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR						
N 022012 004	8101209	Sep 11, 2025	DP			
CASIMERSEN - AMONDYS 45						
N 213026 001	10287586	Nov 12, 2030	DS DP		NCE	Feb 25, 2026
	10781450	Nov 12, 2030	U-3089		ODE-347	Feb 25, 2028
	9228187	Nov 12, 2030	DS DP			
	9447415	Jun 28, 2025	DS DP			
	9758783	Nov 12, 2030	U-3088			
	9758783	Nov 12, 2030	U-3089			
	RE48960	Jun 28, 2025	DS DP U-3087			
	RE48960	Jun 28, 2025	DS DP U-3088			
CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE						
N 206110 001	9636407	Dec 21, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE						
N 206110 002	9636407	Dec 21, 2032	DP			
CEDAZURIDINE; DECITABINE - INQOVI						
N 212576 001	8268800	Aug 22, 2030	DS U-2864		NCE	Jul 07, 2025
	8268800	Aug 22, 2030	DS U-2865		ODE-316	Jul 07, 2027
	8268800	Aug 22, 2030	DS U-2866			
	8268800	Aug 22, 2030	DS U-2867			
	8618075	Oct 16, 2028	U-2864			
	8618075	Oct 16, 2028	U-2867			
	9567363	Oct 16, 2028	DS			
CEFIDEROCOL SULFATE TOSYLATE - FETROJA						
N 209445 001	10004750	Sep 03, 2035	DS DP		NCE	Nov 14, 2024
	9238657	Nov 14, 2033	DS DP U-282		GAIN	Nov 14, 2029
	9238657	Nov 14, 2033	DS DP U-3470			
	9238657	Nov 14, 2033	DS DP U-3471			
	9949982	Sep 03, 2035	DP			
CEFIXIME - SUPRAX						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			
CEFTAROLINE FOSAMIL - TEFLARO						
N 200327 001	8247400	Feb 10, 2031	DP U-282			
	9629861	Sep 21, 2030	DP			
CEFTAROLINE FOSAMIL - TEFLARO						
N 200327 002	8247400	Feb 10, 2031	DP U-282			
	9629861	Sep 21, 2030	DP			
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA						
N 206829 001	10028963	Sep 07, 2032	U-2565		NCE	Dec 19, 2019
	10028963	Sep 07, 2032	U-2566		NPP	Apr 21, 2025
	10125149	Aug 14, 2035	DP		GAIN	Dec 19, 2024
	10376496	Sep 09, 2034	U-2610			
	10376496	Sep 09, 2034	U-2611			
	10420841	Mar 14, 2034	U-1672			
	10420841	Mar 14, 2034	U-2631			
	10420841	Mar 14, 2034	U-3360			
	10420841	Mar 14, 2034	U-3361			
	10933053	Sep 09, 2034	U-3090			
	10933053	Sep 09, 2034	U-3091			
	11278622	Mar 14, 2034	U-3335			
	11278622	Mar 14, 2034	U-3336			
	7129232	May 15, 2028	DS DP U-1676			
	7129232	May 15, 2028	DS DP U-3360			
	7129232	May 15, 2028	DS DP U-3361			
	7129232	May 15, 2028	DS DP U-36			
	8476425	Sep 27, 2032	DS			
	8685957	Sep 27, 2032	DS U-36			
	8906898	May 28, 2034	DS DP			
	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
	8968753	Mar 14, 2034	U-3360			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA							
N 206829	001	8968753	Mar 14, 2034	U-3361			
		9320740	Mar 14, 2034	DP			
		9724353	Sep 07, 2032	U-2565			
		9724353	Sep 07, 2032	U-2566			
		9872906	Mar 14, 2034	DP			
CELECOXIB - ELYXYB							
N 212157	001	10376527	May 27, 2036	DP U-2718			
		10722456	May 27, 2036	DP U-2718			
		10799517	May 27, 2036	DP U-2718			
		9572819	May 27, 2036	DP U-2718			
		9795620	May 27, 2036	DP U-2718			
		9949990	May 27, 2036	DP U-2718			
CELECOXIB; TRAMADOL HYDROCHLORIDE - SEGLENTIS							
N 213426	001	10238668	Apr 19, 2030	DS DP U-3244		NP	Oct 15, 2024
		10245276	Apr 19, 2030	DS DP			
		10548909	Apr 19, 2030	U-3244			
		11478488	Apr 19, 2030	U-3244			
		8598152	Apr 19, 2030	DS DP			
		8846744	Jun 03, 2031	DP			
		9012440	Apr 19, 2030	DS DP			
CENOBAMATE - XCOPRI							
N 212839	001	11654133	Jun 16, 2039	U-3610		NCE	Mar 10, 2025
		7598279	Oct 30, 2032	DS			
CENOBAMATE - XCOPRI							
N 212839	002	11654133	Jun 16, 2039	U-3610		NCE	Mar 10, 2025
		7598279	Oct 30, 2032	DS			
CENOBAMATE - XCOPRI							
N 212839	003	11654133	Jun 16, 2039	U-3610		NCE	Mar 10, 2025
		7598279	Oct 30, 2032	DS			
CENOBAMATE - XCOPRI							
N 212839	004	11654133	Jun 16, 2039	U-3610		NCE	Mar 10, 2025
		7598279	Oct 30, 2032	DS			
CENOBAMATE - XCOPRI							
N 212839	005	11654133	Jun 16, 2039	U-3610		NCE	Mar 10, 2025
		7598279	Oct 30, 2032	DS			
CENOBAMATE - XCOPRI							
N 212839	006	11654133	Jun 16, 2039	U-3610		NCE	Mar 10, 2025
		7598279	Oct 30, 2032	DS			
CERITINIB - ZYKADIA							
N 205755	001	7893074	Apr 25, 2026	DS DP		ODE-145	May 26, 2024
		7964592	Apr 29, 2028	DS DP			
		8039479	Jun 29, 2030	DS DP			
		8377921	Nov 20, 2027	U-1179			
		8399450	Nov 20, 2027	DS DP			
		8703787	Feb 02, 2032	U-1179			
		9309229	Jan 18, 2032	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CERITINIB - ZYKADIA								
N 211225	001		7893074	Apr 25, 2026	DS DP		ODE*	May 26, 2024
			7964592	Apr 29, 2028	DS DP			
			8039479	Jun 29, 2030	DS DP			
			8377921	Nov 20, 2027	U-1179			
			8399450	Nov 20, 2027	DS DP			
			8703787	Feb 02, 2032	U-1179			
			9309229	Jan 18, 2032	DS DP			
CETIRIZINE HYDROCHLORIDE - ZERVIATE								
N 208694	001		8829005	Mar 15, 2030	U-1680			
			8829005*PED	Sep 15, 2030				
			9254286	Jul 09, 2032	DP			
			9254286*PED	Jan 09, 2033				
			9750684	Mar 15, 2030	DP			
			9993471	Mar 15, 2030	U-1680			
CETIRIZINE HYDROCHLORIDE - QUZYTTIR								
N 211415	001		8263581	Feb 28, 2030	U-2635			
			8314083	Feb 28, 2030	U-2634			
			8513259	Feb 11, 2030	U-2636			
			9119771	Feb 11, 2030	U-2635			
			9180090	Feb 11, 2030	U-2635			
CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE								
N 021669	001		7066916	Feb 17, 2024	U-737			
			7427574	Apr 25, 2026	DP			
			7717889	Feb 27, 2025	DP U-1022			
			7935093	Oct 02, 2027	DP U-1022			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
N 020832	002		6991394	Jan 31, 2024	DP			
			7422388	Apr 25, 2027	DP U-1397			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
N 020832	005		7422388	Apr 25, 2027	DP U-1397			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP								
N 020832	006		6991394	Jan 31, 2024	DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
N 020832	007		7422388	Apr 25, 2027	DP U-1397			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP S								
N 208288	001						M-292	Jan 20, 2026
CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL								
N 208791	001		8969412	Sep 05, 2026	DP U-2609			
			9504666	Dec 11, 2033	DP			
CHLOROPROCAINE HYDROCHLORIDE - IHEEZO								
N 216227	001		10792271	Sep 15, 2038	DP U-3457		NP	Sep 27, 2025
CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - TUXARIN ER								
N 206323	001		9066942	Jan 03, 2032	U-1716			
			9107921	Jan 03, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS								
N 021441	001		7863287	Feb 28, 2027	DP			
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS								
N 021587	001		10238640	May 25, 2024	DP			
CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR								
N 207768	001		8062667	Mar 29, 2029	DP			
			8790700	Mar 15, 2027	DP			
CHOLINE FENOFIBRATE - TRILIPIX								
N 022224	001		7259186	Jan 07, 2025	DS			
CHOLINE FENOFIBRATE - TRILIPIX								
N 022224	002		7259186	Jan 07, 2025	DS			
CICLESONIDE - ALVESCO								
N 021658	002		8371292	Feb 01, 2028	U-1355			
CICLESONIDE - ALVESCO								
N 021658	003		8371292	Feb 01, 2028	U-1355			
CICLESONIDE - OMNARIS								
N 022004	001		8371292	Feb 01, 2028	U-1356			
CICLESONIDE - ZETONNA								
N 202129	001		8371292	Feb 01, 2028	U-1357			
CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO								
N 212819	001		8487093	Nov 19, 2029	DS DP U-2586		NCE	Jul 16, 2024
			8487093	Nov 19, 2029	DS DP U-2587		GAIN	Jul 16, 2029
			8487093	Nov 19, 2029	DS DP U-2840			
CINACALCET HYDROCHLORIDE - SENSIPAR								
N 021688	001		7829595	Sep 22, 2026	DP U-1098			
			9375405	Sep 22, 2026	DP			
CINACALCET HYDROCHLORIDE - SENSIPAR								
N 021688	002		7829595	Sep 22, 2026	DP U-1098			
			9375405	Sep 22, 2026	DP			
CINACALCET HYDROCHLORIDE - SENSIPAR								
N 021688	003		7829595	Sep 22, 2026	DP U-1098			
			9375405	Sep 22, 2026	DP			
CIPROFLOXACIN - OTIPRIO								
N 207986	001		11040004	Nov 12, 2037	U-2252			
			11246863	Nov 27, 2038	DP			
			11369566	Apr 21, 2029	DP			
			8318817	Apr 27, 2030	U-1792			
			9205048	Apr 21, 2029	U-1793			
			9220796	Jul 01, 2035	DP			
			9233068	Dec 11, 2029	DP			
			9603796	Apr 21, 2029	DS DP U-2252			
CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL								
N 208251	001		8932610	Mar 24, 2030	DP U-1578			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX						
N 021537 001	8846650	Jun 04, 2025	DP U-1578			
CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI						
N 208352 001	10568855	Mar 15, 2033	U-1			
	11337989	Mar 15, 2033	U-1			
	11439610	Mar 15, 2033	DS DP			
	6706276	Mar 06, 2024	DP			
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK						
N 202535 001	8450338	Oct 10, 2028	DP			
	8481083	Oct 10, 2028	DP			
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIQ						
N 209589 001	10624879	Jun 23, 2034	DP			
	11191753	Jun 23, 2034	U-3261			
	9827231	Jun 26, 2034	DP U-2162			
CLADRIBINE - MAVENCLAD						
N 022561 001	10849919	Nov 23, 2038	U-3411			
	7713947	Oct 16, 2026	U-2520			
	7888328	Apr 11, 2024	DP U-2521			
	8377903	May 31, 2026	U-2522			
	8785415	Apr 11, 2024	DP U-2523			
CLASCOTERONE - WINLEVI						
N 213433 001	10159682	Aug 14, 2028	U-2942		NCE	Aug 26, 2025
	11207332	Nov 20, 2028	DP U-3280			
	8143240	Jan 12, 2025	U-2942			
	8785427	Jul 25, 2030	DP			
	8865690	Jul 24, 2024	U-2942			
	9211295	Jul 24, 2024	DP			
	9433628	Feb 28, 2029	DP			
	9486458	Jul 24, 2028	U-2942			
CLEVIDIPINE - CLEVIPREX						
N 022156 001	10010537	Oct 10, 2031	DP			
	11103490	Oct 10, 2031	DP			
	8658676	Oct 10, 2031	DP			
CLEVIDIPINE - CLEVIPREX						
N 022156 002	10010537	Oct 10, 2031	DP			
	11103490	Oct 10, 2031	DP			
	8658676	Oct 10, 2031	DP			
CLEVIDIPINE - CLEVIPREX						
N 022156 003	10010537	Oct 10, 2031	DP			
	11103490	Oct 10, 2031	DP			
	8658676	Oct 10, 2031	DP			
CLINDAMYCIN PHOSPHATE - CLINDESSE						
N 050793 001	9789057	Dec 02, 2026	DP U-137			
CLINDAMYCIN PHOSPHATE - EVOCLIN						
N 050801 001	7141237	Feb 03, 2024	DP			
	7374747	Jan 23, 2024	DP U-921			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CLINDAMYCIN PHOSPHATE - XACIATO						
N 215650 001	11129896	Sep 22, 2036	U-3293		NP	Dec 07, 2024
					GAIN	Dec 07, 2029
CLOBAZAM - SYMPAZAN						
N 210833 001	11541002	Jan 31, 2040	DP U-724			
	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
CLOBAZAM - SYMPAZAN						
N 210833 002	11541002	Jan 31, 2040	DP U-724			
	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
CLOBAZAM - SYMPAZAN						
N 210833 003	11541002	Jan 31, 2040	DP U-724			
	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
CLOBETASOL PROPIONATE - OLUX E						
N 022013 001	8460641	Nov 05, 2028	DP U-1410			
	8962000	Aug 31, 2025	DP U-1410			
CLOBETASOL PROPIONATE - IMPOYZ						
N 209483 001	10064875	Aug 31, 2030	DP U-1408			
	10064875	Aug 31, 2030	DP U-1858			
	10064875	Aug 31, 2030	DP U-193			
	10064875	Aug 31, 2030	DP U-742			
	10064875	Aug 31, 2030	DP U-88			
	10588914	Aug 31, 2030	DP U-2771			
	9855334	Mar 11, 2035	DP			
	9956231	Aug 31, 2030	DP U-1408			
	9956231	Aug 31, 2030	DP U-1761			
	9956231	Aug 31, 2030	DP U-1858			
	9956231	Aug 31, 2030	DP U-193			
	9956231	Aug 31, 2030	DP U-742			
	9956231	Aug 31, 2030	DP U-88			
CLONIDINE - NEXICLON XR						
N 022500 001	8337890	Apr 17, 2027	DP			
	8623409	Sep 08, 2031	DP			
CLONIDINE - NEXICLON XR						
N 022500 002	8337890	Apr 17, 2027	DP			
	8623409	Sep 08, 2031	DP			
CLOZAPINE - VERSACLOZ						
N 203479 001	8057811	May 01, 2028	DP			
COBICISTAT - TYBOST						
N 203094 001	10039718	Oct 06, 2032	DP		ODE-260	Aug 22, 2026
	10039718*PED	Apr 06, 2033				
	8148374	Sep 03, 2029	DS DP U-1279			
	8148374*PED	Mar 03, 2030				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COBICISTAT; DARUNAVIR - PREZCOBIX						
N 205395 001	10039718	Oct 06, 2032	DP			
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP		U-1279	
	8148374	Sep 03, 2029	DS DP		U-2939	
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA						
N 210455 001	10039718	Oct 06, 2032	DP			
	10786518	Jul 19, 2038			U-2978	
	7390791	Apr 17, 2025	DS DP			
	7700645	Dec 26, 2026	DS DP			
	8148374	Sep 03, 2029	DS DP		U-2353	
	8148374	Sep 03, 2029	DS DP		U-2364	
	8148374	Sep 03, 2029	DS DP		U-2365	
	8148374	Sep 03, 2029	DS DP		U-2766	
	8148374	Sep 03, 2029	DS DP		U-2767	
	8148374	Sep 03, 2029	DS DP		U-2768	
	8518987	Feb 16, 2024	DS DP			
	8754065	Aug 15, 2032	DS DP		U-2352	
	8754065	Aug 15, 2032	DS DP		U-2765	
	9296769	Aug 15, 2032	DS DP		U-2352	
	9296769	Aug 15, 2032	DS DP		U-2765	
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA						
N 207561 001	10039718	Oct 06, 2032	DP			
	10039718*PED	Apr 06, 2033				
	7176220	Aug 27, 2026	DS DP		U-257	
	7176220*PED	Feb 27, 2027				
	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	7635704	Oct 26, 2026	DS DP		U-257	
	7635704*PED	Apr 26, 2027				
	8148374	Sep 03, 2029	DS DP		U-1279	
	8148374*PED	Mar 03, 2030				
	8633219	Apr 30, 2030	DP		U-257	
	8633219*PED	Oct 30, 2030				
	8754065	Aug 15, 2032	DS DP		U-257	
	8754065*PED	Feb 15, 2033				
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				
	9296769	Aug 15, 2032	DS DP		U-257	
	9296769*PED	Feb 15, 2033				
	9891239	Sep 03, 2029	DP		U-257	
	9891239*PED	Mar 03, 2030				
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD						
N 203100 001	10039718	Oct 06, 2032	DP			
	10039718*PED	Apr 06, 2033				
	7176220	Aug 27, 2026	DS DP		U-257	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD						
N 203100 001	7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1279			
	8592397	Jan 13, 2024	DP U-257			
	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
	8716264	Jan 13, 2024	DP U-257			
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				
	9457036	Jan 13, 2024	DP U-257			
	9744181	Jan 13, 2024	DP U-257			
	9891239	Sep 03, 2029	DP U-257			
	9891239*PED	Mar 03, 2030				
COBIMETINIB FUMARATE - COTELLIC						
N 206192 001	10478400	Jun 29, 2036	DS DP U-1776		I-902	Oct 28, 2025
	10478400*PED	Dec 29, 2036			M-278	Jul 28, 2025
	10590102	Jun 30, 2036	DS DP U-1776		ODE-416	Oct 28, 2029
	10590102*PED	Dec 30, 2036			PED	Jan 28, 2026
	11087354	Jun 22, 2034	U-1776			
	11087354*PED	Dec 22, 2034				
	11254649	Jun 30, 2036	DS DP U-1776			
	11254649*PED	Dec 30, 2036				
	11597699	Oct 05, 2026	U-3554			
	7803839	Nov 10, 2029	DS DP			
	7803839*PED	May 10, 2030				
	8362002	Oct 05, 2026	U-1776			
	8362002*PED	Apr 05, 2027				
COCAINE HYDROCHLORIDE - NUMBRINO						
N 209575 001	10016407	Feb 07, 2037	U-2225			
	10016407	Feb 07, 2037	U-2226			
	10016407	Feb 07, 2037	U-2329			
	10149843	Feb 07, 2037	U-2478			
	10149843	Feb 07, 2037	U-2479			
	10231961	Feb 07, 2037	DP			
	10413505	Feb 07, 2037	U-3014			
	10420760	Feb 07, 2037	U-2478			
	10857095	Feb 07, 2037	U-3014			
	10894012	Feb 07, 2037	U-3014			
	10933060	Feb 07, 2037	U-2478			
	10933060	Feb 07, 2037	U-3014			
	10973811	Feb 07, 2037	U-3680			
	11040032	Feb 07, 2037	DP			
	9867815	Feb 07, 2037	U-2225			
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
	9867815	Feb 07, 2037	U-2329			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COCAINE HYDROCHLORIDE - GOPRELTO						
N 209963 001	10016407	Feb 07, 2037	U-2329			
	10149843	Feb 07, 2037	U-2478			
	10149843	Feb 07, 2037	U-2479			
	10231961	Feb 07, 2037	DP			
	10413505	Feb 07, 2037	U-2479			
	10420760	Feb 07, 2037	U-2478			
	10857095	Feb 07, 2037	U-3014			
	10894012	Feb 07, 2037	U-3014			
	10933060	Feb 07, 2037	U-3014			
	10973811	Feb 07, 2037	U-2226			
	10987347	Feb 07, 2037	U-2225			
	11040032	Feb 07, 2037	DP			
	9867815	Feb 07, 2037	U-2225			
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
COLCHICINE - COLCHICINE						
A 208678 001					PC	Apr 29, 2024
COLCHICINE - COLCRYS						
N 022352 001	7601758	Feb 10, 2029	U-1007			
	7619004	Dec 03, 2028	U-1020			
	7820681	Feb 17, 2029	U-1020			
	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
	7935731	Dec 03, 2028	U-1116			
	7964647	Oct 06, 2028	U-1007			
	7964648	Oct 06, 2028	U-1161			
	7981938	Oct 06, 2028	U-1166			
	8093296	Oct 06, 2028	U-1007			
	8093297	Oct 06, 2028	U-1161			
	8093298	Oct 06, 2028	U-1116			
	8097655	Oct 06, 2028	U-1020			
	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			
COLCHICINE - MITIGARE						
N 204820 001	8927607	Aug 22, 2033	U-1020			
	9399036	Aug 22, 2033	U-1020			
	9555029	Aug 22, 2033	U-1020			
	9675613	Aug 22, 2033	U-1020			
	9789108	Aug 22, 2033	U-1020			
COLCHICINE - GLOPERBA						
N 210942 001	10226423	Dec 20, 2037	DP			
	10383820	Nov 22, 2036	DP U-2814			
	10383821	Nov 22, 2036	DP			
	9907751	Nov 22, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COLCHICINE - LODOCO						
N 215727 001	10130585	Dec 31, 2034	U-3642			
	10206891	Jan 22, 2035	U-3641			
	10265281	Jan 22, 2035	U-3639			
	10842762	Jan 22, 2035	U-3640			
	11026899	Jan 22, 2035	U-3639			
	11026900	Jan 22, 2035	U-3639			
	11026901	Jan 22, 2035	U-3638			
	9744144	Jan 22, 2035	U-3643			
COLESEVELAM HYDROCHLORIDE - WELCHOL						
N 022362 001					M-232	Oct 20, 2024
COLESEVELAM HYDROCHLORIDE - WELCHOL						
N 022362 002					M-232	Oct 20, 2024
COPANLISIB DIHYDROCHLORIDE - ALIQOPA						
N 209936 001	10383876	Mar 29, 2032	DS DP		ODE-155	Sep 14, 2024
	7511041	May 13, 2024	DS DP			
	9636344	Mar 29, 2032	U-2124			
	RE46856	Oct 22, 2029	DS DP U-2124			
COPPER CU-64 DOTATATE - DETECTNET						
N 213227 001	10159759	Aug 23, 2032	U-2951		NCE	Sep 03, 2025
	10383961	Aug 23, 2032	U-2951		ODE-317	Sep 03, 2027
	11160888	Aug 23, 2032	U-2951			
CORTICOTROPIN - ACTHAR GEL						
N 008372 008	11752199	Feb 25, 2041	U-3686			
	11752199	Feb 25, 2041	U-3687			
	11752199	Feb 25, 2041	U-3688			
CRISABOROLE - EUCRISA						
N 207695 001	8039451	Jun 29, 2029	DS DP		D-191	Apr 03, 2026
	8039451*PED	Dec 29, 2029				
	8168614	Jan 20, 2030	U-1932			
	8168614*PED	Jul 20, 2030				
	8501712	Feb 16, 2027	U-1932			
	8501712*PED	Aug 16, 2027				
	9682092	Feb 16, 2027	U-1932			
	9682092*PED	Aug 16, 2027				
CRIZOTINIB - XALKORI						
N 202570 001	7230098	Aug 26, 2025	DS		I-852	Jan 14, 2024
	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058		ODE-328	Jan 14, 2028
	7825137	May 12, 2027	U-3403		ODE-407	Jul 14, 2029
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
	8785632	Mar 01, 2025	DS			
CRIZOTINIB - XALKORI						
N 202570 002	7230098	Aug 26, 2025	DS		I-852	Jan 14, 2024
	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058		ODE-328	Jan 14, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CRIZOTINIB - XALKORI						
N 202570 002	7825137	May 12, 2027	U-3403		ODE-407	Jul 14, 2029
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
	8785632	Mar 01, 2025	DS			
CRIZOTINIB - XALKORI						
N 217581 001	7230098	Aug 26, 2025	DS		I-852	Jan 14, 2024
	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS			
	8785632	Mar 01, 2025	DS DP			
CRIZOTINIB - XALKORI						
N 217581 002	7230098	Aug 26, 2025	DS		I-852	Jan 14, 2024
	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS			
	8785632	Mar 01, 2025	DS DP			
CRIZOTINIB - XALKORI						
N 217581 003	7230098	Aug 26, 2025	DS		I-852	Jan 14, 2024
	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS			
	8785632	Mar 01, 2025	DS DP			
CROFELEMER - MYTESI						
N 202292 001	8962680	Oct 31, 2031	U-1319			
	9585868	Oct 31, 2031	U-1319			
CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT						
N 209376 001	11786548	Jul 01, 2041	DP		NCE	Apr 30, 2024
CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT						
N 209376 002	11786548	Jul 01, 2041	DP		NCE	Apr 30, 2024
CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS						
N 209376 003	11786548	Jul 01, 2041	DP		NCE	Apr 30, 2024
CYANOCOBALAMIN - NASCOBAL						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7404489	Mar 12, 2024	DP			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
	9415007	Jul 28, 2024	U-1896			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 210735 001	9662342	Jun 26, 2035	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 210735 002	9662342	Jun 26, 2035	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 210735 003	9662342	Jun 26, 2035	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 210852 001	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 210852 002	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 210852 003	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 212501 001	10993952	Feb 15, 2036	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 212501 002	10993952	Feb 15, 2036	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 212501 003	10993952	Feb 15, 2036	DP			
CYCLOSPORINE - RESTASIS MULTIDOSE						
N 050790 002	8292129	Feb 25, 2031	DP			
	8561859	Apr 16, 2032	DP			
	8629111	Aug 27, 2024	DP			
	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
	9248191	Aug 27, 2024	U-1479			
	9669974	May 11, 2034	DP			
	9676525	Feb 07, 2034	DP			
CYCLOSPORINE - CEQUA						
N 210913 001	10441630	Aug 23, 2033	DP			
	10918694	Feb 28, 2037	DP			
	8980839	Aug 23, 2033	DP U-1483			
	9937225	Aug 23, 2033	DP U-1483			
CYCLOSPORINE - VERKAZIA						
N 214965 001	11612658	Jan 27, 2026	U-3560		NP	Jun 23, 2024
	7973081	Jan 27, 2026	DP		ODE-358	Jun 23, 2028
	8298568	Nov 03, 2027	DP			
	8524779	Jan 27, 2026	DP			
	9132071	Jun 02, 2029	DP			
	9220694	Jan 27, 2026	DP			
	9956289	Jan 27, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYCLOSPORINE - VEVYE						
N 217469 001	10813976	Sep 22, 2037	DP		NP	May 30, 2026
	11154513	Nov 20, 2038	DP U-1900			
	11413323	Oct 11, 2039	U-3627			
	8614178	Dec 13, 2030	DP			
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 001	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
	10328037	Aug 16, 2036	U-1399			
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	8026284	Sep 22, 2027	U-1399			
	8026284*PED	Mar 22, 2028				
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
	9925156	Jan 26, 2027	DS DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DS DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DS DP U-1399			
	9925158*PED	Jul 26, 2027				
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 002	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
	10328037	Aug 16, 2036	U-1399			
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	8026284	Sep 22, 2027	U-1399			
	8026284*PED	Mar 22, 2028				
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
	9925156	Jan 26, 2027	DS DP U-1399			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYSTEAMINE BITARTRATE - PROCYSBI							
N 203389	002	9925156*PED	Jul 26, 2027				
		9925157	Jan 26, 2027	DS DP U-1399			
		9925157*PED	Jul 26, 2027				
		9925158	Jan 26, 2027	DS DP U-1399			
		9925158*PED	Jul 26, 2027				
CYSTEAMINE BITARTRATE - PROCYSBI							
N 213491	001	10143665	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
		10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
		10328037	Aug 16, 2036	U-1399			
		10328037*PED	Feb 16, 2037				
		10548859	Aug 16, 2036	U-1399			
		10548859*PED	Feb 16, 2037				
		10905662	Aug 16, 2036	U-1399			
		10905662*PED	Feb 16, 2037				
		8026284	Sep 22, 2027	U-1399			
		8026284*PED	Mar 22, 2028				
		9173851	Jun 17, 2034	DP			
		9173851*PED	Dec 17, 2034				
		9192590	Jan 26, 2027	U-1399			
		9192590*PED	Jul 26, 2027				
		9198882	Jan 26, 2027	U-1399			
		9198882*PED	Jul 26, 2027				
		9233077	Jun 17, 2034	DP			
		9233077*PED	Dec 17, 2034				
		9925156	Jan 26, 2027	DP U-1399			
		9925156*PED	Jul 26, 2027				
		9925157	Jan 26, 2027	DP U-1399			
		9925157*PED	Jul 26, 2027				
		9925158	Jan 26, 2027	DP U-1399			
		9925158*PED	Jul 26, 2027				
CYSTEAMINE BITARTRATE - PROCYSBI							
N 213491	002	10143665	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
		10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
		10328037	Aug 16, 2036	U-1399			
		10328037*PED	Feb 16, 2037				
		10548859	Aug 16, 2036	U-1399			
		10548859*PED	Feb 16, 2037				
		10905662	Aug 16, 2036	U-1399			
		10905662*PED	Feb 16, 2037				
		8026284	Sep 22, 2027	U-1399			
		8026284*PED	Mar 22, 2028				
		9173851	Jun 17, 2034	DP			
		9173851*PED	Dec 17, 2034				
		9192590	Jan 26, 2027	U-1399			
		9192590*PED	Jul 26, 2027				
		9198882	Jan 26, 2027	U-1399			
		9198882*PED	Jul 26, 2027				
		9233077	Jun 17, 2034	DP			
		9233077*PED	Dec 17, 2034				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYSTEAMINE BITARTRATE - PROCYSBI						
N 213491 002	9925156	Jan 26, 2027	DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DP U-1399			
	9925158*PED	Jul 26, 2027				
CYSTEINE HYDROCHLORIDE - ELCYS						
N 210660 001	10478453	Jan 15, 2039	DP U-2752			
	10583155	Jan 15, 2039	DP U-2752			
	10653719	Jan 15, 2039	DP			
	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
	11510941	Jan 15, 2039	DP			
	11510942	Jan 15, 2039	DP U-2752			
	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
	11826383	Jan 15, 2039	DP			
CYSTEINE HYDROCHLORIDE - NOURESS						
N 212535 001	10478453	Jan 15, 2039	DP U-2752			
	10493051	Mar 15, 2039	DP			
	10543186	Mar 15, 2039	U-2722			
	10583155	Jan 15, 2039	DP U-2752			
	10653719	Jan 15, 2039	DP			
	10702490	Mar 15, 2039	DP			
	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
	11045438	Mar 15, 2039	DP			
	11510941	Mar 02, 2039	DP			
	11510942	Jan 15, 2039	DP U-2752			
CYTARABINE; DAUNORUBICIN - VYXEOS						
N 209401 001	10028912	Oct 15, 2032	DP U-3149		NPP	Mar 30, 2024
	10028912	Oct 15, 2032	DP U-3150		ODE-287	Aug 03, 2024
	10166184	Oct 15, 2032	DP U-3149		ODE-350	Mar 30, 2028
	10835492	Oct 15, 2032	U-3150			
	7850990	Jan 23, 2027	DP U-3147			
	8022279	Sep 14, 2027	DP U-3147			
	8092828	Apr 01, 2029	U-3147			
	8431806	Apr 22, 2025	DP U-3147			
	8518437	Jun 07, 2026	DP			
	9271931	Jan 23, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 022512 001	7932273	Sep 07, 2025	DS DP		I-862	Jun 21, 2024
	9034822	Jan 20, 2031	U-1759		PED	Dec 21, 2024
	9034822*PED	Jul 20, 2031				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 022512 002	7932273	Sep 07, 2025	DS DP		I-862	Jun 21, 2024
	9034822	Jan 20, 2031	U-1759		PED	Dec 21, 2024
	9034822*PED	Jul 20, 2031				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 022512 003	7866474	Aug 31, 2027	DP	Y	I-862	Jun 21, 2024
	7866474*PED	Mar 02, 2028			PED	Dec 21, 2024
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 001	7932273	Sep 07, 2025	DS DP		NP	Jun 21, 2024
	7932273*PED	Mar 07, 2026			PED	Dec 21, 2024
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 002	7932273	Sep 07, 2025	DS DP		NP	Jun 21, 2024
	7932273*PED	Mar 07, 2026			PED	Dec 21, 2024
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 003	7932273	Sep 07, 2025	DS DP		NP	Jun 21, 2024
	7932273*PED	Mar 07, 2026			PED	Dec 21, 2024
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 004	7932273	Sep 07, 2025	DS DP		NP	Jun 21, 2024
	7932273*PED	Mar 07, 2026			PED	Dec 21, 2024
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 005	7932273	Sep 07, 2025	DS DP		NP	Jun 21, 2024
	7932273*PED	Mar 07, 2026			PED	Dec 21, 2024
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 006	7932273	Sep 07, 2025	DS DP		NP	Jun 21, 2024
	7932273*PED	Mar 07, 2026			PED	Dec 21, 2024
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
DABRAFENIB MESYLATE - TAFINLAR						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP		ODE-428	Mar 16, 2030

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DABRAFENIB MESYLATE - TAFINLAR						
N 217514 001	8415345	Jan 20, 2030	DS DP			
	8703781	Oct 15, 2030	DS DP U-3565			
	8835443	Jun 10, 2025	U-3565			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 001	8329159	Jul 24, 2029	DS			
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 002	8329159	Jul 24, 2029	DS			
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 003	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
DACOMITINIB - VIZIMPRO						
N 211288 001	10596162	Feb 02, 2026	U-3338		ODE-206	Sep 27, 2025
	10603314	Feb 02, 2026	U-3337		ODE-213	Sep 27, 2025
	7772243	Aug 26, 2028	DS DP			
	8623883	May 05, 2025	U-1403			
DACOMITINIB - VIZIMPRO						
N 211288 002	10596162	Feb 02, 2026	U-3338		ODE-206	Sep 27, 2025
	10603314	Feb 02, 2026	U-3337		ODE-213	Sep 27, 2025
	7772243	Aug 26, 2028	DS DP			
	8623883	May 05, 2025	U-1403			
DACOMITINIB - VIZIMPRO						
N 211288 003	10596162	Feb 02, 2026	U-3338		ODE-206	Sep 27, 2025
	10603314	Feb 02, 2026	U-3337		ODE-213	Sep 27, 2025
	7772243	Aug 26, 2028	DS DP			
	8623883	May 05, 2025	U-1403			
DALBAVANCIN HYDROCHLORIDE - DALVANCE						
N 021883 001	6900175	May 23, 2028	U-3499		NCE	May 23, 2019
					NPP	Jul 22, 2024
					GAIN	May 23, 2024
DANTROLENE SODIUM - RYANODEX						
N 205579 001	7758890	Jun 30, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN - FARXIGA						
N 202293 001	6515117	Oct 04, 2025	DS DP U-2139		I-857	Apr 30, 2024
	6515117	Oct 04, 2025	DS DP U-493		M-298	May 08, 2026
	7456254	Jun 30, 2025	DP U-2139			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
DAPAGLIFLOZIN - FARXIGA						
N 202293 002	10973836	Mar 09, 2040	U-3127		I-857	Apr 30, 2024
	11826376	Jul 18, 2039	U-3766		M-298	May 08, 2026
	6515117	Oct 04, 2025	DS DP U-2139			
	6515117	Oct 04, 2025	DS DP U-493			
	7456254	Jun 30, 2025	DP U-2139			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 001	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9616028	Nov 12, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR								
N	205649	002	6515117	Oct 04, 2025	DS DP		U-493	
			7919598	Dec 16, 2029	DS			
			8501698	Jun 20, 2027	DP		U-493	
			8685934	May 26, 2030			U-1522	
			9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR								
N	205649	003	6515117	Oct 04, 2025	DS DP		U-493	
			7919598	Dec 16, 2029	DS			
			8501698	Jun 20, 2027	DP		U-493	
			8685934	May 26, 2030			U-1522	
			9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR								
N	205649	004	6515117	Oct 04, 2025	DS DP		U-493	
			7919598	Dec 16, 2029	DS			
			8501698	Jun 20, 2027	DP		U-493	
			8685934	May 26, 2030			U-1522	
			9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR								
N	205649	005	6515117	Oct 04, 2025	DS DP		U-493	
			7919598	Dec 16, 2029	DS			
			8501698	Jun 20, 2027	DP		U-493	
			8685934	May 26, 2030			U-1522	
			9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR								
N	210874	001	6515117	Oct 04, 2025	DS DP		U-493	
			7919598	Dec 16, 2029	DS			
			8501698	Jun 20, 2027	DP		U-493	
			8628799	Jul 13, 2025	DP			
			8716251	Mar 21, 2028	DP			
			9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR								
N	210874	002	6515117	Oct 04, 2025	DS DP		U-493	
			7919598	Dec 16, 2029	DS			
			8501698	Jun 20, 2027	DP		U-493	
			8628799	Jul 13, 2025	DP			
			8716251	Mar 21, 2028	DP			
			9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR								
N	210874	003	6515117	Oct 04, 2025	DS DP		U-493	
			7919598	Dec 16, 2029	DS			
			8501698	Jun 20, 2027	DP		U-493	
			8628799	Jul 13, 2025	DP			
			8716251	Mar 21, 2028	DP			
			9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR								
N	210874	004	6515117	Oct 04, 2025	DS DP		U-493	
			7919598	Dec 16, 2029	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR						
N 210874 004	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN						
N 209091 001	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN						
N 209091 002	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
DAPRODUSTAT - JESDUVROQ						
N 216951 001	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
DAPRODUSTAT - JESDUVROQ						
N 216951 002	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
DAPRODUSTAT - JESDUVROQ						
N 216951 003	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPRODUSTAT - JESDUVROQ						
N 216951 004	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
DAPRODUSTAT - JESDUVROQ						
N 216951 005	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
DAPSONE - ACZONE						
N 207154 001	11273132	Nov 18, 2033	DP			
	9161926	Nov 18, 2033	DP			
	9517219	Nov 18, 2033	U-1033			
DAPTOMYCIN - CUBICIN						
N 021572 002	8003673	Sep 04, 2028	U-1180			
DAPTOMYCIN - CUBICIN RF						
N 021572 003	9138456	Nov 23, 2030	DP			
DAPTOMYCIN - DAPTOMYCIN						
N 210282 001	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
DAPTOMYCIN - DAPTOMYCIN						
N 210282 002	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
DAPTOMYCIN - DAPZURA RT						
N 213645 001	11173189	Mar 11, 2041	DP U-3294			
DAPTOMYCIN - DAPTOMYCIN						
N 217415 001	11759497	Aug 28, 2038	DP			
DAPTOMYCIN - DAPTOMYCIN						
N 217415 002	11759497	Aug 28, 2038	DP			
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ						
N 214985 001	10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ						
N 214985 002	10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
DAROLUTAMIDE - NUBEQA						
N 212099 001	10010530	Jan 28, 2036	DS		I-900	Aug 05, 2025
	10383853	Jan 28, 2036	DS		NCE	Jul 30, 2024
	10711013	Oct 27, 2030	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAROLUTAMIDE - NUBEQA						
N 212099 001	10835515	Jan 28, 2036	DP U-2605			
	11046713	Oct 27, 2030	DS			
	11168058	Feb 27, 2038	DS DP			
	8975254	Mar 25, 2033	DS DP U-2605			
	9657003	Oct 27, 2030	DS DP U-2605			
DARUNAVIR - PREZISTA						
N 021976 001	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA						
N 021976 002	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA						
N 021976 003	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA						
N 021976 004	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA						
N 021976 005	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA						
N 021976 006	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA						
N 202895 001	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR - VIEKIRA PAK (COPACKAGED)						
N 206619 001	10201542	Oct 18, 2033	DP U-1753			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Dec 19, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR - VIEKIRA PAK (COPACKAGED)						
N 206619 001	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9629841	Oct 18, 2033	DP U-1753			
DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR						
N 208624 001	10105365	Jan 02, 2035	DP U-1889			
	10201541	May 17, 2032	DP			
	10201584	May 17, 2032	U-1889			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9333204	Jan 02, 2035	DP U-1889			
	9744170	Jan 02, 2035	DP U-1889			
DASATINIB - SPRYCEL						
N 021986 001	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
DASATINIB - SPRYCEL						
N 021986 002	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
DASATINIB - SPRYCEL						
N 021986 003	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
DASATINIB - SPRYCEL						
N 021986 004	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASATINIB - SPRYCEL						
N 021986 005	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
DASATINIB - SPRYCEL						
N 021986 006	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
DASATINIB - PHYRAGO						
N 216099 001	11202778	Jan 22, 2041	U-3770			
	11202778	Jan 22, 2041	U-3771			
	11202778	Jan 22, 2041	U-3772			
	11298356	Jan 22, 2041	DP			
	11324745	Jan 22, 2041	U-3767			
	11324745	Jan 22, 2041	U-3768			
	11324745	Jan 22, 2041	U-3769			
DASATINIB - PHYRAGO						
N 216099 002	11202778	Jan 22, 2041	U-3770			
	11202778	Jan 22, 2041	U-3771			
	11202778	Jan 22, 2041	U-3772			
	11298356	Jan 22, 2041	DP			
	11324745	Jan 22, 2041	U-3767			
	11324745	Jan 22, 2041	U-3768			
	11324745	Jan 22, 2041	U-3769			
DASATINIB - PHYRAGO						
N 216099 003	11202778	Jan 22, 2041	U-3770			
	11202778	Jan 22, 2041	U-3771			
	11202778	Jan 22, 2041	U-3772			
	11298356	Jan 22, 2041	DP			
	11324745	Jan 22, 2041	U-3767			
	11324745	Jan 22, 2041	U-3768			
	11324745	Jan 22, 2041	U-3769			
DASATINIB - PHYRAGO						
N 216099 004	11202778	Jan 22, 2041	U-3770			
	11202778	Jan 22, 2041	U-3771			
	11202778	Jan 22, 2041	U-3772			
	11298356	Jan 22, 2041	DP			
	11324745	Jan 22, 2041	U-3767			
	11324745	Jan 22, 2041	U-3768			
	11324745	Jan 22, 2041	U-3769			
DASATINIB - PHYRAGO						
N 216099 005	11202778	Jan 22, 2041	U-3770			
	11202778	Jan 22, 2041	U-3771			
	11202778	Jan 22, 2041	U-3772			
	11298356	Jan 22, 2041	DP			
	11324745	Jan 22, 2041	U-3767			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASATINIB - PHYRAGO						
N 216099 005	11324745	Jan 22, 2041	U-3768			
	11324745	Jan 22, 2041	U-3769			
DASATINIB - PHYRAGO						
N 216099 006	11202778	Jan 22, 2041	U-3770			
	11202778	Jan 22, 2041	U-3771			
	11202778	Jan 22, 2041	U-3772			
	11298356	Jan 22, 2041	DP			
	11324745	Jan 22, 2041	U-3767			
	11324745	Jan 22, 2041	U-3768			
	11324745	Jan 22, 2041	U-3769			
DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE						
N 214231 001	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
	11795204	Jan 06, 2034	U-3752			
DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)						
N 214231 002	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
	11795204	Jan 06, 2034	U-3752			
DEFERASIROX - JADENU						
N 206910 001	9283209	Nov 21, 2034	DS DP			
DEFERASIROX - JADENU						
N 206910 002	9283209	Nov 21, 2034	DS DP			
DEFERASIROX - JADENU						
N 206910 003	9283209	Nov 21, 2034	DS DP			
DEFERIPRONE - FERRIPROX						
N 021825 001					I-859	Apr 30, 2024
					ODE-417	Apr 30, 2028
					ODE-420	Apr 30, 2028
					ODE-421	Apr 30, 2028
DEFERIPRONE - FERRIPROX						
N 021825 002					I-859	Apr 30, 2024
					ODE-417	Apr 30, 2028
					ODE-420	Apr 30, 2028
					ODE-421	Apr 30, 2028
DEFERIPRONE - FERRIPROX						
N 208030 001	8703156	Oct 26, 2029	DP U-3083		I-859	Apr 30, 2024
					ODE-417	Apr 30, 2028
					ODE-418	Apr 30, 2028
					ODE-419	Apr 30, 2028
DEFERIPRONE - FERRIPROX						
N 208030 002	8703156	Oct 26, 2029	DP U-3083		I-859	Apr 30, 2024
					ODE-417	Apr 30, 2028
					ODE-418	Apr 30, 2028
					ODE-419	Apr 30, 2028
DEFERIPRONE - FERRIPROX						
N 212269 001	10780055	Oct 25, 2038	DP U-3083		I-859	Apr 30, 2024
	10940115	Oct 25, 2038	DP U-3083		ODE-417	Apr 30, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEFERIPRONE - FERRIPROX						
N 212269 001	10940116	Oct 25, 2038	DP		ODE-420	Apr 30, 2028
	11357731	Oct 25, 2038	U-3083		ODE-421	Apr 30, 2028
	11458103	Oct 25, 2038	DP			
	11723874	Oct 25, 2038	U-3083			
DEFIBROTIDE SODIUM - DEFITELIO						
N 208114 001	11085043	Jun 22, 2032	DP			
	11236328	Jun 22, 2032	U-3301			
	11746348	Jun 22, 2032	DP			
DEFLAZACORT - EMFLAZA						
N 208684 001					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA						
N 208684 002					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA						
N 208684 003					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA						
N 208684 004					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA						
N 208685 001					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
DEGARELIX ACETATE - FIRMAGON						
N 022201 001	10695398	Apr 27, 2032	U-1895			
	10729739	Feb 10, 2029	U-1978			
	10973870	Feb 10, 2029	U-1978			
	11766468	Apr 27, 2032	U-1978			
	11826397	Apr 27, 2032	U-1978			
	9415085	Apr 27, 2032	U-1895			
	9579359	Feb 10, 2029	U-1978			
DEGARELIX ACETATE - FIRMAGON						
N 022201 002	10695398	Apr 27, 2032	U-1895			
	10729739	Feb 10, 2029	U-1978			
	10973870	Feb 10, 2029	U-1978			
	11766468	Apr 27, 2032	U-1978			
	11826397	Apr 27, 2032	U-1978			
	9415085	Apr 27, 2032	U-1895			
	9579359	Feb 10, 2029	U-1978			
DELAFLOXACIN MEGLUMINE - BAXDELA						
N 208610 001	7728143	Jun 19, 2031	DS		NCE	Jun 19, 2022
	8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	8273892	Aug 06, 2026	DS			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	8969569	Oct 07, 2025	DP U-2028			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DELAFLOXACIN MEGLUMINE - BAXDELA						
N 208610 001	9539250	Oct 07, 2025	DS DP U-2028			
	RE46617	Dec 28, 2029	DS			
DELAFLOXACIN MEGLUMINE - BAXDELA						
N 208611 001	7635773	Mar 13, 2029	DP		NCE	Jun 19, 2022
	7728143	Jun 19, 2031	DS		GAIN	Jun 19, 2027
	8252813	Oct 02, 2026	DP U-2028			
	8273892	Aug 06, 2026	DS			
	8410077	Mar 13, 2029	DP			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9539250	Oct 07, 2025	DS DP U-2028			
	9750822	Mar 13, 2029	DP			
	RE46617	Dec 28, 2029	DS			
DEOXYCHOLIC ACID - KYBELLA						
N 206333 001	10500214	Mar 02, 2030	DP			
	7622130	Dec 10, 2027	U-1690			
	7754230	Dec 10, 2027	U-1690			
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025	U-1690			
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025	U-1690			
	8883770	Feb 21, 2028	DP			
	9522155	Feb 21, 2028	DP U-1940			
	9636349	Feb 21, 2028	U-1940			
	9949986	Feb 21, 2028	U-1940			
DESMOPRESSIN ACETATE - NOCDURNA						
N 022517 001	11020448	May 21, 2029	U-2327			
	7560429	Feb 02, 2024	DP U-2326			
	9974826	Apr 13, 2030	U-2326			
DESMOPRESSIN ACETATE - NOCDURNA						
N 022517 002	10137167	May 21, 2029	U-2327			
	7560429	Feb 02, 2024	DP U-2326			
	9974826	Apr 13, 2030	U-2327			
DESMOPRESSIN ACETATE - NOCTIVA						
N 201656 001	11419914	Jun 15, 2030	U-3431			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
DESMOPRESSIN ACETATE - NOCTIVA						
N 201656 002	11419914	Jun 15, 2030	U-3431			
	9539302	Jun 15, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DESONIDE - VERDESO						
N 021978 001	8460641	Aug 13, 2027	DP U-1412			
	8962000	Aug 31, 2025	DP U-1412			
	9492384	Aug 31, 2025	DP U-1412			
DESOXIMETASONE - TOPICORT						
N 204141 001	8277780	Sep 01, 2028	DP U-1408			
	8715624	May 26, 2026	DP U-1408			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 001	8269040	Jul 05, 2027	DS			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 002	8269040	Jul 05, 2027	DS			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 003	8269040	Jul 05, 2027	DS			
DEUCRAVACITINIB - SOTYKTU						
N 214958 001	10000480	Nov 07, 2033	DS DP		NCE	Sep 09, 2027
	11021475	Nov 07, 2033	U-3434			
	RE47929	Nov 07, 2033	DS DP U-3434			
DEUTETRABENAZINE - AUSTEDO						
N 208082 001	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			ODE-134	Apr 03, 2024
	11179386	Mar 15, 2038	DP U-1995		PED	Oct 03, 2024
	11179386	Mar 15, 2038	DP U-3055		PED	Dec 24, 2024
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11666566	Sep 18, 2033	DP			
	11666566*PED	Mar 18, 2034				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO						
N 208082 002	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			ODE-134	Apr 03, 2024
	11179386	Mar 15, 2038	DP U-1995		PED	Oct 03, 2024
	11179386	Mar 15, 2038	DP U-3055		PED	Dec 24, 2024
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11666566	Sep 18, 2033	DP			
	11666566*PED	Mar 18, 2034				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO						
N 208082 003	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			ODE-134	Apr 03, 2024
	11179386	Mar 15, 2038	DP U-1995		PED	Oct 03, 2024
	11179386	Mar 15, 2038	DP U-3055		PED	Dec 24, 2024
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11666566	Sep 18, 2033	DP			
	11666566*PED	Mar 18, 2034				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	8524733	Apr 03, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO						
N 208082 003	8524733*PED	Oct 03, 2031				
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP		U-1995	
	9550780	Sep 18, 2033	DS DP		U-3055	
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 001	10959996	Mar 07, 2036			U-3055	
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP		U-1995	
	11179386	Mar 15, 2038	DP		U-3055	
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP		U-1995	
	11311488	Jun 10, 2041	DP		U-3055	
	11357772	Mar 07, 2036			U-1995	
	11357772	Mar 07, 2036			U-3055	
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036			U-1995	
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036			U-1995	
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036			U-1995	
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP		U-1995	
	9550780	Sep 18, 2033	DS DP		U-3055	
	9550780*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 002	10959996	Mar 07, 2036			U-3055	
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP		U-1995	
	11179386	Mar 15, 2038	DP		U-3055	
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP		U-1995	
	11311488	Jun 10, 2041	DP		U-3055	
	11357772	Mar 07, 2036			U-1995	
	11357772	Mar 07, 2036			U-3055	
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036			U-1995	
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036			U-1995	
	11564917*PED	Sep 07, 2036				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 002	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 003	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
DEXAMETHASONE - DEXAMETHASONE						
A 217695 003					CGT	Apr 29, 2024
DEXAMETHASONE - DEXTENZA						
N 208742 001	11458041	Nov 16, 2037	U-1680		I-876	Oct 07, 2024
	11458041	Nov 16, 2037	U-3455			
	8409606	May 14, 2030	DP			
	8563027	Feb 12, 2030	U-2487			
	9254267	Sep 11, 2024	DP			
DEXAMETHASONE - DEXYCU KIT						
N 208912 001	10022502	Jun 22, 2034	U-2340			
	10028965	May 23, 2034	U-2340			
	10159683	May 23, 2034	DP			
	10799642	May 11, 2032	DP			
	11097061	Jun 23, 2039	DP U-3418			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXAMETHASONE - HEMADY						
N 211379 001	10537585	Dec 18, 2037	DP		ODE-271	Oct 03, 2026
	11304961	Dec 18, 2037	DP U-3344			
DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST						
N 050818 001	7795316	Aug 03, 2028	DP U-1082			
	8101582	Dec 19, 2027	DP U-1082			
	8450287	Dec 19, 2027	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 001	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084*PED	Apr 15, 2024				
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 002	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084*PED	Apr 15, 2024				
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT SOLUTAB						
N 208056 001	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 001					NPP	Dec 16, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 002	10016396	Jan 04, 2032	DP		NPP	Dec 16, 2025
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 003	10016396	Jan 04, 2032	DP		NPP	Dec 16, 2025
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 004	8242158	Jan 04, 2032	DP		NPP	Dec 16, 2025
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 005					NPP	Dec 16, 2025
DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE						
N 206628 003	9649296	Apr 20, 2036	DP			
	9717796	Apr 20, 2036	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE						
N 206628 004	9649296	Apr 20, 2036	DP			
	9717796	Apr 20, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE								
N 206628	004	9649296	Apr 20, 2036		DP			
		9717796	Apr 20, 2036		DP			
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI								
N 215390	001	10792246	Jun 26, 2039		DP U-3350		NP	Apr 05, 2025
		11478422	Jun 26, 2039		DP			
		11497711	Jun 26, 2039		DP U-3645			
		11517524	Jun 26, 2039		DP U-3645			
		11786508	Dec 29, 2037		U-3698			
		11806334	Jan 12, 2043		U-3725			
		11839604	Dec 29, 2037		U-3756			
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI								
N 215390	002	10792246	Jun 26, 2039		DP U-3350		NP	Apr 05, 2025
		11478422	Jun 26, 2039		DP			
		11497711	Jun 26, 2039		DP U-3645			
		11517524	Jun 26, 2039		DP U-3645			
		11786508	Dec 29, 2037		U-3698			
		11806334	Jan 12, 2043		U-3725			
		11839604	Dec 29, 2037		U-3756			
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS								
N 212994	001	10584112	Dec 09, 2037	DS	DP		NCE	May 07, 2026
		10584113	Dec 09, 2037		DP			
		10759778	Dec 09, 2037		DP			
		10858341	Dec 09, 2037		U-3094			
		10954213	Dec 09, 2037		U-3094			
		9079928	Jul 27, 2032		DP			
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS								
N 212994	002	10584112	Dec 09, 2037	DS	DP		NCE	May 07, 2026
		10584113	Dec 09, 2037		DP			
		10759778	Dec 09, 2037		DP			
		10858341	Dec 09, 2037		U-3094			
		10954213	Dec 09, 2037		U-3094			
		9079928	Jul 27, 2032		DP			
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS								
N 212994	003	10584112	Dec 09, 2037	DS	DP		NCE	May 07, 2026
		10584113	Dec 09, 2037		DP			
		10759778	Dec 09, 2037		DP			
		10858341	Dec 09, 2037		U-3094			
		10954213	Dec 09, 2037		U-3094			
		9079928	Jul 27, 2032		DP			
DEXTROAMPHETAMINE - XELSTRYM								
N 215401	001	11559501	Jan 06, 2042		DP		NP	Mar 22, 2025
		8591941	Oct 07, 2025		DP			
		8632802	Oct 07, 2025		DP			
		9034370	Oct 07, 2025		DP			
		9456993	Oct 24, 2033		DP U-3340			
		9474722	Oct 24, 2033		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 002	11559501	Jan 06, 2042	DP		NP	Mar 22, 2025
	8591941	Oct 07, 2025	DP			
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 003	11559501	Jan 06, 2042	DP		NP	Mar 22, 2025
	8591941	Oct 07, 2025	DP			
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 004	11559501	Jan 06, 2042	DP		NP	Mar 22, 2025
	8591941	Oct 07, 2025	DP			
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA						
N 021879 001	7659282	Aug 13, 2026	U-1093			
DIAZEPAM - VALTOCO						
N 211635 001	10265402	May 11, 2025	DP		ODE-279	Jan 10, 2027
	11241414	Mar 27, 2029	DP			
	11793786	Mar 27, 2029	DP			
	8895546	Mar 27, 2029	DP			
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
DIAZEPAM - VALTOCO						
N 211635 002	10265402	May 11, 2025	DP		ODE-279	Jan 10, 2027
	11241414	Mar 27, 2029	DP			
	11793786	Mar 27, 2029	DP			
	8895546	Mar 27, 2029	DP			
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
DIAZEPAM - VALTOCO						
N 211635 003	10265402	May 11, 2025	DP		ODE-279	Jan 10, 2027
	11241414	Mar 27, 2029	DP			
	11793786	Mar 27, 2029	DP			
	8895546	Mar 27, 2029	DP			
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
DICLOFENAC - ZORVOLEX						
N 204592 001	8679544	Apr 23, 2030	DP			
	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DICLOFENAC - ZORVOLEX							
N 204592	001	9173854	Apr 23, 2030	DP			
		9180095	Apr 23, 2030	U-55			
		9180096	Apr 23, 2030	DP			
		9186328	Apr 23, 2030	U-55			
DICLOFENAC - ZORVOLEX							
N 204592	002	8679544	Apr 23, 2030	DP			
		8999387	Apr 23, 2030	U-55			
		9017721	Apr 23, 2030	DP			
		9173854	Apr 23, 2030	DP			
		9180095	Apr 23, 2030	U-55			
		9180096	Apr 23, 2030	DP			
		9186328	Apr 23, 2030	U-55			
DICLOFENAC EPOLAMINE - LICART							
N 206976	001	11344520	Feb 20, 2035	U-3393			
		11351133	Feb 20, 2035	U-3393			
DICLOFENAC POTASSIUM - CAMBIA							
N 022165	001	7759394	Jun 16, 2026	DS DP U-436			
		8097651	Jun 16, 2026	DS DP U-436			
		8927604	Jun 16, 2026	U-436			
		9827197	Jun 16, 2026	DP			
DICLOFENAC POTASSIUM - ZIPSOR							
N 022202	001	7662858	Feb 24, 2029	U-1035		NPP	May 25, 2024
		7884095	Feb 24, 2029	U-1111			
		7939518	Feb 24, 2029	U-980			
		8110606	Feb 24, 2029	U-980			
		8623920	Feb 24, 2029	U-1482			
		9561200	Feb 24, 2029	U-1482			
DICLOFENAC SODIUM - PENNSAID							
N 020947	001	8217078	Jul 10, 2029	U-1248			
		8546450	Aug 09, 2030	U-1435			
		8546450	Aug 09, 2030	U-1436			
		8618164	Jul 10, 2029	U-1477			
		8741956	Jul 10, 2029	U-1435			
DICLOFENAC SODIUM - DYLOJECT							
N 022396	001	8946292	Mar 22, 2027	U-1659			
DICLOFENAC SODIUM - PENNSAID							
N 204623	001	8217078	Jul 10, 2029	U-1477			
		8252838	Apr 21, 2028	DP U-1489			
		8546450	Aug 09, 2030	U-1435			
		8546450	Aug 09, 2030	U-1436			
		8563613	Oct 17, 2027	DP U-1488			
		8618164	Jul 10, 2029	U-1477			
		8741956	Jul 10, 2029	U-1435			
		8871809	Oct 17, 2027	U-1614			
		9066913	Oct 17, 2027	DP U-1488			
		9101591	Oct 17, 2027	DP U-1488			
		9132110	Oct 17, 2027	U-1488			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DICLOFENAC SODIUM - PENNSAID						
N 204623 001	9168304	Oct 17, 2027	DP			
	9168305	Oct 17, 2027	U-1488			
	9220784	Oct 17, 2027	U-1488			
	9339551	Oct 17, 2027	U-1488			
	9339552	Oct 17, 2027	DP U-1488			
	9370501	Jul 10, 2029	U-1614			
	9375412	Jul 10, 2029	U-1614			
	9415029	Jul 10, 2029	U-1614			
	9539335	Oct 17, 2027	U-1614			
DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA						
N 022252 001	8071577	May 13, 2026	DP U-1			
	8153616	Jan 30, 2028	U-1240			
DIFELIKEFALIN ACETATE - KORSUVA						
N 214916 001	10017536	Nov 12, 2027	DS U-3204		NCE	Aug 23, 2026
	10138270	Nov 12, 2027	U-3204			
	10793596	Nov 12, 2027	DS DP U-3204			
	7402564	Nov 12, 2027	DS DP U-3204			
	7713937	Nov 12, 2027	DS DP U-3204			
	7727963	Nov 12, 2027	DS DP U-3204			
	8217007	Nov 12, 2027	U-3204			
	8236766	Nov 12, 2027	U-3204			
	8486894	Nov 12, 2027	U-3204			
	8536131	Nov 12, 2027	DS DP U-3204			
	9334305	Nov 12, 2027	U-3204			
	9359399	Nov 12, 2027	U-3204			
DIHYDROERGOTAMINE MESYLATE - TRUDHESA						
N 213436 001	10507295	Dec 25, 2032	DP		NP	Sep 02, 2024
	10940278	Jan 23, 2033	DP			
	11185497	Jan 04, 2039	U-3218			
	11266799	Nov 05, 2036	DP			
	9550036	Sep 05, 2032	DP			
	9919117	Mar 17, 2033	DP U-3218			
DIMETHYL FUMARATE - TECFIDERA						
N 204063 001	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
	11129806	Nov 16, 2035	U-1384			
	11246850	Nov 16, 2035	U-1384			
	8399514	Feb 07, 2028	U-1384			
DIMETHYL FUMARATE - TECFIDERA						
N 204063 002	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DIMETHYL FUMARATE - TECFIDERA						
N 204063 002	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
	11129806	Nov 16, 2035	U-1384			
	11246850	Nov 16, 2035	U-1384			
	8399514	Feb 07, 2028	U-1384			
DIROXIMEL FUMARATE - VUMERITY						
N 211855 001	10080733	Sep 20, 2033	DS DP U-1384			
	8669281	Sep 20, 2033	DS DP			
	9090558	Sep 20, 2033	U-1384			
DOCETAXEL - DOCETAXEL						
N 205934 001	10842770	Aug 07, 2031	DP U-2998			
	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			
	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
DOCETAXEL - DOCETAXEL						
N 205934 002	10842770	Aug 07, 2031	DP U-2998			
	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			
	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
DOCETAXEL - DOCETAXEL						
N 205934 003	10842770	Aug 07, 2031	DP U-2998			
	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			
	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
DOCETAXEL - DOCETAXEL						
N 215813 001	10398785	Mar 14, 2036	DP			
DOCETAXEL - DOCETAXEL						
N 215813 002	10398785	Mar 14, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOCETAXEL - DOCETAXEL						
N 215813 003	10398785	Mar 14, 2036	DP			
DOLUTEGRAVIR SODIUM - TIVICAY						
N 204790 001	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
DOLUTEGRAVIR SODIUM - TIVICAY						
N 204790 002	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
DOLUTEGRAVIR SODIUM - TIVICAY						
N 204790 003	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
DOLUTEGRAVIR SODIUM - TIVICAY PD						
N 213983 001	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO						
N 211994 001	11234985	Jan 24, 2031	DP U-257			
	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA						
N 210192 001	10426780	Jan 24, 2031	DS DP U-257			
	7125879	Apr 21, 2025	DS DP U-257			
	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
DONEPEZIL HYDROCHLORIDE - ARICEPT						
N 022568 001	8481565	Oct 04, 2026	DP			
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 001	10016372	Jul 26, 2037	U-3334		NP	Mar 11, 2025
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	11648214	Sep 23, 2037	DP U-3334			
	11679086	May 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 002	10016372	Jul 26, 2037	U-3334		NP	Mar 11, 2025
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	11648214	Sep 23, 2037	DP U-3334			
	11679086	May 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 001	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 002	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 002	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 003	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 004	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 004	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
DORAVIRINE - PIFELTRO						
N 210806 001	8486975	Oct 07, 2031	DS DP U-2394		NPP	Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2630			
	8486975	Oct 07, 2031	DS DP U-3308			
DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO						
N 210807 001	10603282	Nov 29, 2036	DP		NPP	Jan 27, 2025
	10842751	Nov 29, 2036	DP			
	8486975	Oct 07, 2031	DS DP U-2395			
	8486975	Oct 07, 2031	DS DP U-2629			
	8486975	Oct 07, 2031	DS DP U-3307			
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 001	10238620	May 18, 2027	U-620			
	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
	11096920	Apr 11, 2028	U-620			
	11110074	Jul 20, 2027	U-620			
	11234954	Jan 18, 2028	U-620			
	7915307	Aug 24, 2027	U-620			
	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	9486437	May 18, 2027	U-620			
	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 002	10238620	May 18, 2027	U-620			
	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
	11096920	Apr 11, 2028	U-620			
	11110074	Jul 20, 2027	U-620			
	11234954	Jan 18, 2028	U-620			
	7915307	Aug 24, 2027	U-620			
	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	9486437	May 18, 2027	U-620			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOXEPIN HYDROCHLORIDE - SILENOR								
N 022036	002		9532971	Jun 01, 2029	DP			
			9572814	Jul 20, 2027			U-620	
			9861607	May 18, 2027			U-620	
			9907780	Apr 11, 2028	DP			
DOXYCYCLINE - ORACEA								
N 050805	001		7749532	Dec 19, 2027	DP		U-1063	
			8206740	Dec 24, 2025	DP		U-925	
			8394405	Apr 07, 2024	DP		U-925	
			8394406	Apr 07, 2024	DP		U-925	
			8470364	Apr 07, 2024	DP		U-925	
			8709478	Apr 07, 2024			U-1063	
DOXYCYCLINE HYCLATE - DORYX								
N 050795	001		8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	002		8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	003		8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	004		8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	005		8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	006		8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX MPC								
N 050795	007		8715724	Feb 03, 2028	DP			
			9295652	Oct 23, 2034	DP		U-918	
			9446057	Dec 23, 2034	DP		U-918	
			9511031	Oct 23, 2034	DP			
DOXYCYCLINE HYCLATE - DORYX MPC								
N 050795	008		8715724	Feb 03, 2028	DP			
			9295652	Oct 23, 2034	DP		U-918	
			9446057	Dec 23, 2034	DP		U-918	
			9511031	Oct 23, 2034	DP			
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA								
N 209661	001		9089489	Feb 18, 2033	DP		U-1382	
			9375404	Feb 18, 2033	DP		U-1382	
			9526703	Feb 18, 2033	DP		U-1382	
			9937132	Feb 18, 2033	DP		U-1382	
DRONABINOL - SYNDROS								
N 205525	001		10265293	Aug 06, 2028	DS	DP		
			11253472	Aug 06, 2028	DS	DP		
			8222292	Aug 06, 2028	DS	DP		
			9345771	Aug 06, 2028	DS	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DRONEDARONE HYDROCHLORIDE - MULTAQ								
N 022425	001		8410167	Apr 16, 2029	U-1387			
			8410167	Apr 16, 2029	U-1388			
			8602215	Jun 30, 2031	U-1473			
			9107900	Apr 16, 2029	U-1726			
			9107900	Apr 16, 2029	U-1728			
DROSPIRENONE - SLYND								
N 211367	001		10179140	Jun 28, 2031	U-2553			
			10603281	Jun 28, 2031	U-2553			
			10849857	Jun 28, 2031	DP U-2553			
			10987364	Jun 28, 2031	DP			
			11123299	Jun 28, 2031	DP			
			11291632	Jun 28, 2031	DP			
			11291633	Jun 28, 2031	DP			
			11351122	Jun 28, 2031	DP			
			11413249	Jun 28, 2031	U-2553			
			11439598	Jun 28, 2031	DP			
			11478487	Jun 28, 2031	DP			
			11504334	Jun 28, 2031	DP			
			9603860	Jun 28, 2031	U-2553			
DROSPIRENONE - DROSPIRENONE								
N 216285	001		10179140	Jun 28, 2031	U-2553		NP	Jun 29, 2025
			10603281	Jun 28, 2031	U-2553			
			10849857	Jun 28, 2031	DP U-2553			
			10987364	Jun 28, 2031	DP			
			11123299	Jun 28, 2031	DP			
			11291632	Jun 28, 2031	DP			
			11291633	Jun 28, 2031	DP			
			11351122	Jun 28, 2031	DP			
			11413249	Jun 28, 2031	U-2553			
			11439598	Jun 28, 2031	DP			
			11478487	Jun 28, 2031	DP			
			11504334	Jun 28, 2031	DP			
			9603860	Jun 28, 2031	U-2553			
DROSPIRENONE; ESTETROL - NEXTSTELLIS								
N 214154	001		11793760	Jun 17, 2036	DP		NCE	Apr 15, 2026
			7732430	Mar 02, 2025	DP U-3152			
DROSPIRENONE; ESTRADIOL - ANGELIQ								
N 021355	001		8906890	Oct 22, 2031	DP			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ								
N 022532	001		11617751	Jul 17, 2030	DP U-1			
			11617751	Jul 17, 2030	DP U-3572			
			11617751	Jul 17, 2030	DP U-3573			
			11617751	Jul 17, 2030	DP U-3574			
			8617597	Feb 08, 2030	DP			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL								
N 022574	001		11617751	Jul 17, 2030	DP U-1			
			11617751	Jul 17, 2030	DP U-3572			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL								
N 022574	001		8617597	Feb 08, 2030	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE								
N 212516	001		10413525	Apr 13, 2037	DP			
			10959982	Apr 13, 2037	DP			
			11202772	Apr 13, 2037	DP			
			9839626	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE								
N 212516	002		10413525	Apr 13, 2037	DP			
			10959982	Apr 13, 2037	DP			
			11202772	Apr 13, 2037	DP			
			9839626	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE								
N 212516	003		10413525	Apr 13, 2037	DP			
			10959982	Apr 13, 2037	DP			
			11202772	Apr 13, 2037	DP			
			9839626	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE								
N 212516	004		10413525	Apr 13, 2037	DP			
			10959982	Apr 13, 2037	DP			
			11202772	Apr 13, 2037	DP			
			9839626	Apr 13, 2037	DP			
DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM - XACDURO (COPACKAGED)								
N 216974	001		10376499	Nov 17, 2035	DP U-2840		NCE	May 23, 2028
			9309245	Apr 02, 2033	DS		GAIN	May 23, 2033
			9623014	Apr 02, 2033	U-2840			
			9968593	Nov 17, 2035	DP U-2840			
DUVELISIB - COPIKTRA								
N 211155	001		11312718	Jan 10, 2032	DP		ODE-208	Sep 24, 2025
			8193182	Feb 13, 2030	DS			
			9216982	Jan 05, 2029	U-2412			
			9216982	Jan 05, 2029	U-2413			
			9840505	Jan 10, 2032	U-2412			
			9840505	Jan 10, 2032	U-2413			
			RE46621	May 17, 2032	DS DP			
DUVELISIB - COPIKTRA								
N 211155	002		11312718	Jan 10, 2032	DP		ODE-208	Sep 24, 2025
			8193182	Feb 13, 2030	DS			
			9216982	Jan 05, 2029	U-2412			
			9216982	Jan 05, 2029	U-2413			
			9840505	Jan 10, 2032	U-2412			
			9840505	Jan 10, 2032	U-2413			
			RE46621	May 17, 2032	DS DP			
ECONAZOLE NITRATE - ECOZA								
N 205175	001		10071054	Aug 08, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EDARAVONE - RADICAVA						
N 209176 001					ODE-144	May 05, 2024
EDARAVONE - RADICAVA						
N 209176 002					ODE*	May 05, 2024
EDARAVONE - RADICAVA ORS						
N 215446 001	10987341	Nov 01, 2039	DP		NP	May 12, 2025
	11241416	Nov 01, 2039	DP			
	11478450	Nov 01, 2039	U-3468			
	11826352	Nov 01, 2039	DP			
EDETATE CALCIUM DISODIUM - EDETATE CALCIUM DISODIUM						
A 216435 001					CGT	Jan 08, 2024
EDOXABAN TOSYLATE - SAVAYSA						
N 206316 001	7365205	Apr 18, 2027	DS			
	9149532	Mar 28, 2028	DP			
EDOXABAN TOSYLATE - SAVAYSA						
N 206316 002	7365205	Apr 18, 2027	DS			
	9149532	Mar 28, 2028	DP			
EDOXABAN TOSYLATE - SAVAYSA						
N 206316 003	7365205	Apr 18, 2027	DS			
	9149532	Mar 28, 2028	DP			
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA						
N 021937 001	8592397	Jan 13, 2024	DP	U-1170		
	8592397	Jan 13, 2024	DP	U-750		
	8598185	Apr 28, 2029	DP			
	8716264	Jan 13, 2024	DP	U-257		
	9018192	Jun 13, 2026	U-1170			
	9018192	Jun 13, 2026	U-750			
	9457036	Jan 13, 2024	DP	U-257		
	9545414	Jun 13, 2026	DP	U-1170		
	9545414	Jun 13, 2026	DP	U-750		
	9744181	Jan 13, 2024	DP	U-257		
EFINACONAZOLE - JUBLIA						
N 203567 001	10105444	Jul 08, 2030	DP			
	10342875	Oct 02, 2034	DP	U-2720		
	10478601	Apr 25, 2035	DP	U-2721		
	10512640	Jan 03, 2028	U-1969			
	10828293	Oct 02, 2034	U-2720			
	10828369	Jan 03, 2028	DP			
	10864274	Oct 02, 2034	U-2720			
	11213519	Jan 03, 2028	U-2720			
	11654139	Oct 02, 2034	U-1969			
	7214506	Feb 22, 2026	U-281			
	8039494	Jul 08, 2030	U-281			
	8486978	Oct 24, 2030	DP			
	9302009	Oct 24, 2030	DP			
	9566272	Jan 03, 2028	U-1969			
	9662394	Oct 02, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EFINACONAZOLE - JUBLIA						
N 203567 001	9861698	Jul 08, 2030	DP			
	9877955	Jan 03, 2028	U-1969			
ELACESTRANT DIHYDROCHLORIDE - ORSERDU						
N 217639 001	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			
	11779552	Oct 10, 2034	U-3524			
	11819480	Nov 29, 2036	U-3523			
	7612114	Aug 18, 2026	DS DP U-3523			
	8399520	Dec 25, 2024	DS DP U-3523			
ELACESTRANT DIHYDROCHLORIDE - ORSERDU						
N 217639 002	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			
	11779552	Oct 10, 2034	U-3524			
	11819480	Nov 29, 2036	U-3523			
	7612114	Aug 18, 2026	DS DP U-3523			
	8399520	Dec 25, 2024	DS DP U-3523			
ELAGOLIX SODIUM - ORILISSA						
N 210450 001	10537572	Sep 01, 2036	U-2735			
	10682351	Sep 01, 2036	U-2850			
	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040	U-3654			
	11690854	Apr 19, 2038	U-3653			
	11707464	Mar 14, 2034	U-3672			
	7056927	Sep 10, 2024	DS DP			
	7176211	Jul 06, 2024	U-2360			
	7419983	Jul 06, 2024	DS DP U-2360			
ELAGOLIX SODIUM - ORILISSA						
N 210450 002	11344551	Mar 14, 2034	U-3388			
	11344551	Mar 14, 2034	U-3389			
	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040	U-3654			
	7056927	Sep 10, 2024	DS DP			
	7176211	Jul 06, 2024	U-2360			
	7419983	Jul 06, 2024	DS DP U-2360			
ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)						
N 213388 001	10881659	Mar 14, 2034	U-2842			
	11045470	Mar 14, 2034	U-2842			
	11459305	Nov 07, 2028	DP U-2842			
	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040	U-3655			
	7056927	Sep 10, 2024	DS DP			
	7419983	Jul 06, 2024	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELBASVIR; GRAZOPREVIR - ZEPATIER						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813		NPP	Dec 09, 2024
	8871759	May 04, 2031	DS DP U-1813			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 001	10022352	Apr 09, 2027	DP U-2651		NCE	Oct 21, 2024
	10022352	Apr 09, 2027	DP U-3156		NPP	Jun 08, 2024
	10081621	Mar 25, 2031	DP U-2652		ODE-275	Oct 21, 2026
	10081621	Mar 25, 2031	DP U-3032		ODE-323	Dec 21, 2027
	10081621	Mar 25, 2031	DP U-3157		ODE-357	Jun 08, 2028
	10239867	Apr 09, 2027	DS DP U-2653			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-2645			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-2645			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	11179367	Dec 08, 2037	DP U-3253			
	11426407	Oct 06, 2035	DS DP U-3425			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3498			
	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
	11639347	Apr 09, 2027	DS DP U-3587			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2645			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-2646			
	8354427	Jul 06, 2026	U-3029			
	8354427	Jul 06, 2026	U-3145			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2645			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-2645			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2648			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2649			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-2650			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 001	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-2645			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 002	10022352	Apr 09, 2027	DP U-3156		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-3157		NPP	Jun 08, 2024
	10239867	Apr 09, 2027	DS DP U-3158		ODE-357	Jun 08, 2028
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-3144			
	11179367	Dec 08, 2037	DP U-3253			
	11426407	Oct 06, 2035	DS DP U-3425			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3498			
	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
	11639347	Apr 09, 2027	DS DP U-3587			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-3145			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-3144			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3146			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-3144			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 001	10022352	Apr 09, 2027	DP U-3596		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-3600		NP	Apr 26, 2026
	10239867	Apr 09, 2027	DS DP U-3590		ODE-433	Apr 26, 2030
	10272046	Feb 27, 2033	DP U-3599			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10793547	Dec 08, 2037	DS DP U-3588			
	11147770	Feb 27, 2033	DP U-3598			
	11179367	Dec 08, 2037	DP U-3597			
	11426407	Oct 06, 2035	DS DP U-3595			
	11453655	Dec 08, 2037	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 001	11517564	Dec 08, 2037	DP U-3586			
	11564916	Aug 13, 2029	U-3585			
	11578062	Mar 25, 2031	DP U-3584			
	11639347	Apr 09, 2027	DS DP U-3583			
	11752106	Feb 27, 2033	DP U-3696			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			
	8598181	May 01, 2027	U-3589			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3592			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-3591			
	9974781	Apr 09, 2027	DP U-3589			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 002	10022352	Apr 09, 2027	DP U-3596		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-3600		NP	Apr 26, 2026
	10239867	Apr 09, 2027	DS DP U-3590		ODE-433	Apr 26, 2030
	10272046	Feb 27, 2033	DP U-3599			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10793547	Dec 08, 2037	DS DP U-3588			
	11147770	Feb 27, 2033	DP U-3598			
	11179367	Dec 08, 2037	DP U-3597			
	11426407	Oct 06, 2035	DS DP U-3595			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3586			
	11564916	Aug 13, 2029	U-3585			
	11578062	Mar 25, 2031	DP U-3584			
	11639347	Apr 09, 2027	DS DP U-3583			
	11752106	Feb 27, 2033	DP U-3696			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			
	8598181	May 01, 2027	U-3589			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3592			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 002	9670163	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-3591			
	9974781	Apr 09, 2027	DP U-3589			
ELIGLUSTAT TARTRATE - CERDELGA						
N 205494 001	10888544	Dec 13, 2038	U-3040			
	10888544	Dec 13, 2038	U-3041			
	10888547	Jan 31, 2031	U-3042			
	10888547	Jan 31, 2031	U-3043			
	11458119	Nov 24, 2030	DS DP			
	7196205	Jun 26, 2026	DS			
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 001	7547719	Jul 13, 2025	DS DP U-1306		ODE-210	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 002	7547719	Jul 13, 2025	DS DP U-1306		ODE-210	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 002	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 003	7547719	Jul 13, 2025	DS DP U-1306		ODE-210	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 004	7547719	Jul 13, 2025	DS DP U-1306		ODE-210	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 005	7547719	Jul 13, 2025	DS DP U-1306		ODE-210	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA KIT						
N 207027 001	7547719	Jul 13, 2025	DS DP U-1306		ODE*	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
ELTROMBOPAG OLAMINE - PROMACTA KIT						
N 207027 002	7547719	Jul 13, 2025	DS DP U-1306		ODE*	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
ELUXADOLINE - VIBERZI						
N 206940 001	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			
	11160792	Mar 14, 2033	DP			
	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
	7741356	May 27, 2029	DS DP			
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	8772325	Mar 14, 2025	U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
ELUXADOLINE - VIBERZI						
N 206940 002	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			
	11160792	Mar 14, 2033	DP			
	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
	11484527	Mar 14, 2033	U-3475			
	7741356	May 27, 2029	DS DP			
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	8772325	Mar 14, 2025	U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELUXADOLINE - VIBERZI						
N 206940 002	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
ELVITEGRAVIR - VITEKTA						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257			
	7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				
ELVITEGRAVIR - VITEKTA						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257			
	7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				
EMPAGLIFLOZIN - JARDIANCE						
N 204629 001	10258637	Apr 03, 2034	U-2290		I-869	Aug 18, 2024
	10258637*PED	Oct 03, 2034			I-922	Sep 21, 2026
	11090323	Apr 03, 2034	U-3191		M-82	Feb 24, 2025
	11090323*PED	Oct 03, 2034			NPP	Jun 20, 2026
	11666590	Apr 03, 2034	U-3691		PED	Aug 24, 2025
	11813275	Apr 03, 2034	U-3759		PED	Dec 20, 2026
	11813275	Apr 03, 2034	U-3760			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	U-1651			
	8551957*PED	Apr 14, 2030				
	9949997	May 17, 2034	U-2292			
	9949997	May 17, 2034	U-3199			
	9949997	May 17, 2034	U-3325			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN - JARDIANCE						
N 204629 002	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN - JARDIANCE						
N 204629 002	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	U-1651			
	8551957*PED	Apr 14, 2030				
	9949997	May 17, 2034	U-2292			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 001	10258637	Apr 03, 2034	U-2290			
	10258637*PED	Oct 03, 2034				
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-1651			
	8551957*PED	Apr 14, 2030				
	8673927	May 04, 2027	U-1652	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9173859	May 04, 2027	DP U-1772	Y		
	9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 002	10258637	Apr 03, 2034	U-2290			
	10258637*PED	Oct 03, 2034				
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 002	8551957	Oct 14, 2029	DP		U-1651	
	8551957*PED	Apr 14, 2030				
	8673927	May 04, 2027		Y	U-1652	
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9173859	May 04, 2027	DP	Y	U-1772	
	9949998	Jun 11, 2034			U-2290	
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 001	10022379	Apr 02, 2029	DP		U-2732	
	10258637	Apr 03, 2034			U-2731	
	10258637*PED	Oct 03, 2034				
	10406172	Jun 15, 2030	DP		U-2733	
	10596120	Mar 07, 2032	DP		U-2776	
	10596120	Mar 07, 2032	DP		U-2790	
	11090323	Apr 03, 2034			U-3192	
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP		U-3531	
	11833166	Apr 03, 2034			U-3776	
	11833166	Apr 03, 2034			U-3777	
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP		U-2730	
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 002	10022379	Apr 02, 2029	DP		U-2732	
	10258637	Apr 03, 2034			U-2731	
	10258637*PED	Oct 03, 2034				
	10406172	Jun 15, 2030	DP		U-2733	
	10596120	Mar 07, 2032	DP		U-2776	
	10596120	Mar 07, 2032	DP		U-2790	
	11090323	Apr 03, 2034			U-3192	
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP		U-3531	
	11833166	Apr 03, 2034			U-3776	
	11833166	Apr 03, 2034			U-3777	
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 002	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP		U-2730	
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 003	10022379	Apr 02, 2029	DP		U-2732	
	10258637	Apr 03, 2034			U-2731	
	10258637*PED	Oct 03, 2034				
	10406172	Jun 15, 2030	DP		U-2733	
	10596120	Mar 07, 2032	DP		U-2776	
	10596120	Mar 07, 2032	DP		U-2790	
	11090323	Apr 03, 2034			U-3192	
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP		U-3531	
	11833166	Apr 03, 2034			U-3776	
	11833166	Apr 03, 2034			U-3777	
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP		U-2730	
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 004	10022379	Apr 02, 2029	DP		U-2732	
	10258637	Apr 03, 2034			U-2731	
	10258637*PED	Oct 03, 2034				
	10406172	Jun 15, 2030	DP		U-2733	
	10596120	Mar 07, 2032	DP		U-2776	
	10596120	Mar 07, 2032	DP		U-2790	
	11090323	Apr 03, 2034			U-3192	
	11090323*PED	Oct 03, 2034				
	11833166	Apr 03, 2034			U-3776	
	11833166	Apr 03, 2034			U-3777	
	7407955	May 02, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 004	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-2730			
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 001	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11813275	Apr 03, 2034	U-3759			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 002	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11813275	Apr 03, 2034	U-3759			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 003	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 004	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 001	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11813275	Apr 03, 2034	U-3759			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 001	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 002	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11813275	Apr 03, 2034	U-3759			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 003	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 004	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 004	11090323*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY						
N 208351 001	7125879	Apr 21, 2025	DS DP U-257			
	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA						
N 202123 001	10857102	Jan 14, 2033	DP			
	7125879	Apr 21, 2025	DS DP U-257			
	8592397	Jan 13, 2024	DP U-257			
	8716264	Jan 13, 2024	DP U-257			
	8841310	Dec 09, 2025	DP U-257			
	9457036	Jan 13, 2024	DP U-257			
	9744181	Jan 13, 2024	DP U-257			
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY						
N 208215 001	7390791	Apr 17, 2025	DS DP		ODE-284	Sep 28, 2024
	7390791*PED	Oct 17, 2025			ODE-285	Sep 28, 2024
	8754065	Aug 15, 2032	DS DP U-1259			
	8754065	Aug 15, 2032	DS DP U-1663			
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1259			
	9296769	Aug 15, 2032	DS DP U-1663			
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY						
N 208215 002	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-1663			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1663			
	9296769*PED	Feb 15, 2033				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA						
N 021752 001	8592397	Jan 13, 2024	DP U-1170			
	8592397	Jan 13, 2024	DP U-248			
	8592397	Jan 13, 2024	DP U-541			
	8716264	Jan 13, 2024	DP U-257			
	9457036	Jan 13, 2024	DP U-257			
	9744181	Jan 13, 2024	DP U-257			
ENALAPRIL MALEATE - EPANED KIT						
N 204308 001	8568747	Nov 06, 2032	DP			
	8778366	Nov 06, 2032	U-1723			
	8778366	Nov 06, 2032	U-185			
	8778366	Nov 06, 2032	U-1892			
	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-71			
	9855214	Nov 06, 2032	DP			
	9968553	Nov 06, 2032	U-1723			
	9968553	Nov 06, 2032	U-185			
	9968553	Nov 06, 2032	U-1892			
	9968553	Nov 06, 2032	U-3			
	9968553	Nov 06, 2032	U-71			
ENALAPRIL MALEATE - EPANED						
N 208686 001	10039745	Mar 25, 2036	DP			
	10154987	Mar 25, 2036	U-1723			
	10154987	Mar 25, 2036	U-185			
	10154987	Mar 25, 2036	U-1892			
	10154987	Mar 25, 2036	U-3			
	10154987	Mar 25, 2036	U-71			
	10772868	Mar 25, 2036	DP			
	10786482	Mar 25, 2036	DP			
	11040023	Mar 25, 2036	DP			
	11141405	Mar 25, 2036	DP			
	11173141	Mar 25, 2036	DP			
	9669008	Mar 25, 2036	DP			
	9808442	Mar 25, 2036	U-1723			
	9808442	Mar 25, 2036	U-185			
	9808442	Mar 25, 2036	U-1892			
	9808442	Mar 25, 2036	U-3			
	9808442	Mar 25, 2036	U-71			
ENASIDENIB MESYLATE - IDHIFA						
N 209606 001	10093654	Aug 01, 2034	DS DP U-2087		ODE-151	Aug 01, 2024
	10294215	Jan 07, 2033	DP U-2087			
	10610125	Jun 21, 2030	U-2087			
	9512107	Jan 07, 2033	DS DP U-2087			
	9732062	Sep 16, 2034	DS			
	9738625	Aug 01, 2034	DS			
ENASIDENIB MESYLATE - IDHIFA						
N 209606 002	10093654	Aug 01, 2034	DS DP U-2087		ODE-151	Aug 01, 2024
	10294215	Jan 07, 2033	DP U-2087			
	10610125	Jun 21, 2030	U-2087			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENASIDENIB MESYLATE - IDHIFA						
N 209606 002	9512107	Jan 07, 2033	DS DP U-2087			
	9732062	Sep 16, 2034	DS			
	9738625	Aug 01, 2034	DS			
ENCORAFENIB - BRAFTOVI						
N 210496 001	10005761	Aug 27, 2030	U-2335		I-928	Oct 11, 2026
	8501758	Mar 04, 2031	DS DP		ODE-194	Jun 27, 2025
	8541575	Feb 26, 2030	DS DP U-2335		ODE-445	Oct 11, 2030
	8946250	Jul 23, 2029	DS DP			
	9314464	Jul 04, 2031	U-2336			
	9387208	Nov 21, 2032	DP			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			
	9763941	Nov 21, 2032	U-2335			
	9850229	Aug 27, 2030	U-2337			
	9850230	Aug 27, 2030	U-2334			
ENCORAFENIB - BRAFTOVI						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-928	Oct 11, 2026
	10005761	Aug 27, 2030	U-2802		ODE-194	Jun 27, 2025
	10005761	Aug 27, 2030	U-2803		ODE-445	Oct 11, 2030
	10005761	Aug 27, 2030	U-3738			
	10258622	Nov 21, 2032	U-2802			
	8501758	Aug 27, 2030	DS DP			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8541575	Feb 26, 2030	DS DP U-3738			
	8946250	Jul 23, 2029	DS DP			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9314464	Jul 04, 2031	U-3738			
	9387208	Nov 21, 2032	DP			
	9474754	Aug 05, 2033	U-2802			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			
	9763941	Nov 21, 2032	U-2335			
	9850229	Aug 27, 2030	U-2337			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
	9850230	Aug 27, 2030	U-3738			
	RE49556	Feb 27, 2030	DS DP			
ENTRECTINIB - ROZLYTREK						
N 212725 001	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	10231965	Feb 17, 2035	U-2618		NPP	Oct 20, 2026
	10398693	Jul 18, 2038	DP		ODE-265	Aug 15, 2026
	10561651	Feb 19, 2035	U-2745		ODE-313	Aug 15, 2026
	10738037	May 18, 2037	DS DP U-2946		ODE-448	Oct 20, 2030

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENTRECTINIB - ROZLYTREK						
N 212725 001	11091469	May 18, 2037	U-2617			
	11091469	May 18, 2037	U-2618			
	11253515	Jul 18, 2038	DP			
	8299057	Mar 01, 2029	DS DP			
	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
ENTRECTINIB - ROZLYTREK						
N 212725 002	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	10231965	Feb 17, 2035	U-2618		NPP	Oct 20, 2026
	10398693	Jul 18, 2038	DP		ODE-265	Aug 15, 2026
	10561651	Feb 19, 2035	U-2745		ODE-313	Aug 15, 2026
	10738037	May 18, 2037	DS DP U-2946		ODE-448	Oct 20, 2030
	11091469	May 18, 2037	U-2617			
	11091469	May 18, 2037	U-2618			
	11253515	Jul 18, 2038	DP			
	8299057	Mar 01, 2029	DS DP			
	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
ENTRECTINIB - ROZLYTREK						
N 218550 001					NCE	Aug 15, 2024
					NP	Oct 20, 2026
					ODE-448	Oct 20, 2030
ENZALUTAMIDE - XTANDI						
N 203415 001	7709517	Aug 13, 2027	DS DP		I-926	Nov 17, 2026
	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	8183274	Aug 24, 2026	U-3763			
	9126941	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENZALUTAMIDE - XTANDI						
N 203415 001	9126941	May 15, 2026	U-3763			
ENZALUTAMIDE - XTANDI						
N 213674 001	11839689	Sep 11, 2033	DP		I-926	Nov 17, 2026
	7709517	Aug 13, 2027	DS DP			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	8183274	Aug 24, 2026	U-3763			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
	9126941	May 15, 2026	U-3763			
ENZALUTAMIDE - XTANDI						
N 213674 002	11839689	Sep 11, 2033	DP		I-926	Nov 17, 2026
	7709517	Aug 13, 2027	DS DP			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	8183274	Aug 24, 2026	U-3763			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
	9126941	May 15, 2026	U-3763			
EPHEDRINE SULFATE - EMERPHED						
N 213407 001	11090278	May 16, 2040	U-3183			
	11241400	May 16, 2040	U-3183			
	11464752	May 16, 2040	DP			
	11478436	May 16, 2040	U-3183			
	11571398	May 16, 2040	U-3183			
EPHEDRINE SULFATE - EMERPHED						
N 213407 002	11464752	May 16, 2040	DP			
	11571398	May 16, 2040	U-3183			
EPHEDRINE SULFATE - EPHEDRINE SULFATE						
N 213994 001	10869845	Jan 22, 2040	DP			
EPHEDRINE SULFATE - EPHEDRINE SULFATE						
N 213994 002	10869845	Jan 22, 2040	DP			
EPINEPHRINE - EPIPEN						
N 019430 001	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
	9586010	Sep 11, 2025	DP			
EPINEPHRINE - EPIPEN JR.						
N 019430 002	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
	9586010	Sep 11, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - AUVI-Q						
N 201739 001	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	11590286	Dec 12, 2026	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025			U-1758	
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
	9724471	May 23, 2027	DP		U-2092	
	9737669	Nov 23, 2024	DP			
EPINEPHRINE - AUVI-Q						
N 201739 002	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
	10688244	Dec 21, 2037	DP		U-2980	
	10737028	Nov 23, 2024	DP			
	10842938	Dec 21, 2037	DP		U-2980	
	11590286	Dec 12, 2026	DP			
	11771830	Dec 21, 2037	DP		U-2980	
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025			U-1758	
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
	9724471	May 23, 2027	DP		U-2092	
	9737669	Nov 23, 2024	DP			
EPINEPHRINE - AUVI-Q						
N 201739 003	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
	10688244	Dec 21, 2037	DP		U-2980	
	10737028	Nov 23, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - AUVI-Q						
N 201739 003	10842938	Dec 21, 2037	DP U-2980			
	11590286	Dec 12, 2026	DP			
	11771830	Dec 21, 2037	DP U-2980			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025	U-1758			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
	9833573	Nov 23, 2024	U-2172			
EPINEPHRINE - ADRENALIN						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
EPINEPHRINE - ADRENALIN						
N 204640 001	10130592	Mar 13, 2035	DP			
	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
EPINEPHRINE - EPINEPHRINE						
N 205029 001	10004700	Aug 14, 2034	DP U-2325		Y	
	10039728	Aug 14, 2034	U-1828		Y	
	9283197	Aug 15, 2034	DP U-1828		Y	
	9283197	Aug 15, 2034	DP U-1829		Y	
	9283197	Aug 15, 2034	DP U-1830		Y	
EPINEPHRINE - PRIMATENE MIST						
N 205920 001	8367734	Jan 26, 2026	DP			
EPINEPHRINE - SYMJEPI						
N 207534 001	11141540	Oct 20, 2036	DP U-3379			
EPINEPHRINE - SYMJEPI						
N 207534 002	11141540	Oct 20, 2036	DP U-3379			
EPINEPHRINE - ADRENALIN						
N 215875 001	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
EPINEPHRINE - ADRENALIN						
N 215875 002	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - ADRENALIN						
N 215875 002	11207280	Mar 21, 2039	DP			
EPINEPHRINE - ADRENALIN						
N 215875 003	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
EPINEPHRINE - ADRENALIN						
N 215875 004	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
EPINEPHRINE - ADRENALIN						
N 215875 005	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
EPOPROSTENOL SODIUM - VELETRI						
N 022260 001	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
EPOPROSTENOL SODIUM - VELETRI						
N 022260 002	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA						
N 211109 001	10961190	Oct 19, 2037	DS		NCE	Aug 27, 2023
	11578044	Oct 19, 2037	DS		GAIN	Aug 27, 2028
	8796245	Aug 07, 2029	U-2380			
	8906887	Dec 28, 2030	DP			
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA						
N 211109 002	10961190	Oct 19, 2037	DS		NCE	Aug 27, 2023
	11578044	Oct 19, 2037	DS		GAIN	Aug 27, 2028
	8796245	Aug 07, 2029	U-2380			
	8906887	Dec 28, 2030	DP			
ERDAFITINIB - BALVERSA						
N 212018 001	10898482	Feb 09, 2036	DP U-2518		NCE	Apr 12, 2024
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	11077106	Feb 02, 2038	U-3196			
	11684620	Feb 09, 2036	U-2518			
	11684620	Feb 09, 2036	U-3065			
	11684620	Feb 09, 2036	U-3066			
	11684620	Feb 09, 2036	U-3067			
	8895601	Apr 12, 2033	DS DP			
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
ERDAFITINIB - BALVERSA						
N 212018 002	10898482	Feb 09, 2036	DP U-2518		NCE	Apr 12, 2024
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERDAFITINIB - BALVERSA						
N 212018 002	10898482	Feb 09, 2036	DP U-3067			
	11077106	Feb 02, 2038	U-3196			
	11684620	Feb 09, 2036	U-2518			
	11684620	Feb 09, 2036	U-3065			
	11684620	Feb 09, 2036	U-3066			
	11684620	Feb 09, 2036	U-3067			
	8895601	Apr 12, 2033	DS DP			
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
ERDAFITINIB - BALVERSA						
N 212018 003	10898482	Feb 09, 2036	DP U-2518		NCE	Apr 12, 2024
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	11077106	Feb 02, 2038	U-3196			
	11684620	Feb 09, 2036	U-2518			
	11684620	Feb 09, 2036	U-3065			
	11684620	Feb 09, 2036	U-3066			
	11684620	Feb 09, 2036	U-3067			
	8895601	Apr 12, 2033	DS DP			
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
ERIBULIN MESYLATE - HALAVEN						
N 201532 001	6214865*PED	Jan 20, 2024			M-280	Sep 13, 2025
	RE46965	Jan 08, 2027	DP		PED	Mar 13, 2026
	RE46965*PED	Jul 08, 2027				
ERTUGLIFLOZIN - STEGLATRO						
N 209803 001	8080580	Jul 13, 2030	DS DP U-2214		M-275	Sep 17, 2024
ERTUGLIFLOZIN - STEGLATRO						
N 209803 002	8080580	Jul 13, 2030	DS DP U-2214		M-275	Sep 17, 2024
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 001	8080580	Jul 13, 2030	DS DP U-2214		M-275	Sep 17, 2024
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 002	8080580	Jul 13, 2030	DS DP U-2214		M-275	Sep 17, 2024
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 003	8080580	Jul 13, 2030	DS DP U-2214		M-275	Sep 17, 2024
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 004	8080580	Jul 13, 2030	DS DP U-2214		M-275	Sep 17, 2024
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN						
N 209805 001	7326708	Nov 24, 2026	DS DP U-2214		M-275	Sep 17, 2024
	7326708*PED	May 24, 2027				
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN						
N 209805 002	7326708	Nov 24, 2026	DS DP U-2214		M-275	Sep 17, 2024
	7326708*PED	May 24, 2027				
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 001					NPP	May 12, 2026
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 002					NPP	May 12, 2026
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 003					NPP	May 12, 2026
ESCITALOPRAM OXALATE - LEXAPRO						
N 021365 001					NPP	May 12, 2026
ESKETAMINE HYDROCHLORIDE - SPRAVATO						
N 211243 001	10869844	Sep 10, 2035	U-3034		NCE*	Mar 05, 2024
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	11446260	Mar 14, 2034	U-3444			
	11446260	Mar 14, 2034	U-3445			
	11446260	Mar 14, 2034	U-3446			
	8785500	Mar 05, 2033	U-2502			
	9592207	Mar 20, 2027	U-2502			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 001	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
	10912781	Oct 23, 2028	DP			
	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 001	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 002	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
	10912781	Oct 23, 2028	DP			
	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 003	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
	10912781	Oct 23, 2028	DP			
	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 004	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
	10912781	Oct 23, 2028	DP			
	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESLICARBAZEPINE ACETATE - APTIOM							
N 022416	004	9750747	Aug 24, 2032			U-2121	
		9763954	Sep 13, 2028			U-2123	
ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER							
N 205703	001	8829054	Mar 15, 2033	DP			
		8835505	Mar 15, 2033	DP			
ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER							
N 205703	002	8829054	Mar 15, 2033	DP			
		8835505	Mar 15, 2033	DP			
ESOMEPRAZOLE MAGNESIUM - ESOMEPRAZOLE MAGNESIUM							
N 214278	001	10076494	Dec 08, 2036	DP			
		10835488	Dec 08, 2036	DP			
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N 022511	001	8945621	Oct 17, 2031			U-1661	
		9220698	Mar 10, 2031			U-1781	
		9393208	Sep 03, 2029			U-1781	
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N 022511	002	8945621	Oct 17, 2031			U-1661	
		9393208	Sep 03, 2029			U-1781	
ESTRADIOL - MINIVELLE							
N 203752	001	8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028			U-2086	
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	002	8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028			U-2086	
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	003	8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028			U-2086	
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	004	8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028			U-2086	
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	005	8231906	Jul 04, 2030	DS DP			
		9724310	Jul 10, 2028	DS DP			
		9730900	Jul 10, 2028	DP		U-2086	
		9833419	Jul 10, 2028	DP			
ESTRADIOL - IMVEXXY							
N 208564	001	10258630	Dec 20, 2033			U-2316	
		10258630	Dec 20, 2033			U-2317	
		10398708	Dec 20, 2033			U-2317	
		10398708	Dec 20, 2033			U-2614	
		10471072	Jun 18, 2033			U-2316	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTRADIOL - IMVEXXY						
N 208564 001	10471072	Jun 18, 2033	U-2317			
	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
	10668082	Jun 18, 2033	U-2316			
	10668082	Jun 18, 2033	U-2317			
	10806697	Nov 21, 2032	DP			
	10835487	Nov 21, 2032	U-2316			
	10835487	Nov 21, 2032	U-2317			
	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
	11116717	Jun 18, 2033	DP			
	11123283	Jun 18, 2033	DP			
	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
	11497709	Nov 21, 2032	U-2316			
	11497709	Nov 21, 2032	U-2317			
	9180091	Dec 20, 2033	DP U-2316			
	9180091	Dec 20, 2033	DP U-2317			
	9289382	Nov 21, 2032	DP			
ESTRADIOL - IMVEXXY						
N 208564 002	10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2614			
	10471072	Jun 18, 2033	U-2316			
	10471072	Jun 18, 2033	U-2317			
	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
	10668082	Jun 18, 2033	U-2316			
	10668082	Jun 18, 2033	U-2317			
	10806697	Nov 21, 2032	DP			
	10835487	Nov 21, 2032	U-2316			
	10835487	Nov 21, 2032	U-2317			
	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
	11116717	Jun 18, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTRADIOL - IMVEXXY						
N 208564 002	11123283	Jun 18, 2033	DP			
	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
	11497709	Nov 21, 2032	U-2316			
	11497709	Nov 21, 2032	U-2317			
	9180091	Dec 20, 2033	DP U-2316			
	9180091	Dec 20, 2033	DP U-2317			
	9289382	Nov 21, 2032	DP			
ESTRADIOL ACETATE - FEMTRACE						
N 021633 001	7572779	Oct 02, 2025	U-904			
ESTRADIOL ACETATE - FEMTRACE						
N 021633 002	7572779	Oct 02, 2025	U-904			
ESTRADIOL ACETATE - FEMTRACE						
N 021633 003	7572779	Oct 02, 2025	U-904			
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE						
N 214846 001	11033551	Sep 29, 2037	U-3129		I-898	Aug 05, 2025
	11793812	May 03, 2038	U-2360		M-289	Jan 27, 2026
	11795178	Sep 27, 2033	DS DP		NCE	Dec 18, 2025
	7300935	Jan 28, 2025	DS		NP	May 26, 2024
	8058280	Jan 28, 2025	DS			
	9346822	Feb 17, 2024	U-3129			
ESTRADIOL; PROGESTERONE - BIJUVA						
N 210132 001	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10639375	Nov 21, 2032	DP			
	10675288	Nov 21, 2032	U-2439			
	10806740	Nov 21, 2032	DP U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11103513	Nov 21, 2032	U-2439			
	11103516	Nov 21, 2032	DP			
	11110099	Nov 21, 2032	DP			
	11529360	Nov 21, 2032	DP			
	11793819	Nov 21, 2032	U-2439			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			
	8846649	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			
	9006222	Nov 21, 2032	DP U-2439			
	9114145	Nov 21, 2032	U-2439			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTRADIOL; PROGESTERONE - BIJUVA						
N 210132 001	9114146	Nov 21, 2032	DP		U-2439	
	9301920	Nov 21, 2032	DP		U-2439	
ESTRADIOL; PROGESTERONE - BIJUVA						
N 210132 002	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032			U-2439	
	10675288	Nov 21, 2032			U-2439	
	11033626	Nov 21, 2032	DP		U-2439	
	11166963	Nov 21, 2032	DP			
	11793819	Nov 21, 2032			U-2439	
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032			U-2439	
	8846649	Nov 21, 2032	DP		U-2439	
	8933059	Nov 21, 2032	DP		U-2439	
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			
	9114145	Nov 21, 2032			U-2439	
	9114146	Nov 21, 2032	DP		U-2439	
	9301920	Nov 21, 2032	DP		U-2439	
ETELCALCETIDE - PARSABIV						
N 208325 001	10344765	Jun 27, 2034	DP			
	11162500	Jun 27, 2034	DP			
	8377880	Jul 29, 2030	DS	DP		
	8999932	Feb 07, 2031	DS	DP	U-2014	
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS	DP	U-2014	
	9820938	Jun 27, 2034	DP			
ETELCALCETIDE - PARSABIV						
N 208325 002	10344765	Jun 27, 2034	DP			
	11162500	Jun 27, 2034	DP			
	8377880	Jul 29, 2030	DS	DP		
	8999932	Feb 07, 2031	DS	DP	U-2014	
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS	DP	U-2014	
	9820938	Jun 27, 2034	DP			
ETELCALCETIDE - PARSABIV						
N 208325 003	10344765	Jun 27, 2034	DP			
	11162500	Jun 27, 2034	DP			
	8377880	Jul 29, 2030	DS	DP		
	8999932	Feb 07, 2031	DS	DP	U-2014	
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS	DP	U-2014	
	9820938	Jun 27, 2034	DP			
ETEPLIRSEN - EXONDYS 51						
N 206488 001	10337003	Mar 14, 2034			U-1918	
	10364431	Mar 14, 2034			U-1918	
	10364431	Mar 14, 2034			U-1919	
	10781451	Jun 28, 2025	DS	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETEPLIRSEN - EXONDYS 51						
N 206488 001	9018368	Jun 28, 2025	DS DP			
	9243245	Oct 27, 2028	DS		U-2097	
	9243245	Oct 27, 2028	DS		U-2098	
	9506058	Mar 14, 2034			U-1918	
	9506058	Mar 14, 2034			U-1919	
	RE47751	Jun 28, 2025			U-1918	
	RE47751	Jun 28, 2025			U-2664	
	RE47751	Jun 28, 2025			U-2673	
	RE47751	Jun 28, 2025			U-2674	
	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028			U-2097	
ETEPLIRSEN - EXONDYS 51						
N 206488 002	10337003	Mar 14, 2034			U-1918	
	10364431	Mar 14, 2034			U-1918	
	10364431	Mar 14, 2034			U-1919	
	10781451	Jun 28, 2025	DS DP			
	9018368	Jun 28, 2025	DS DP			
	9243245	Oct 27, 2028	DS		U-2097	
	9243245	Oct 27, 2028	DS		U-2098	
	9506058	Mar 14, 2034			U-1918	
	9506058	Mar 14, 2034			U-1919	
	RE47751	Jun 28, 2025			U-1918	
	RE47751	Jun 28, 2025			U-2664	
	RE47751	Jun 28, 2025			U-2673	
	RE47751	Jun 28, 2025			U-2674	
	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028			U-2097	
ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE						
N 021840 001	7320969	Jan 30, 2024			U-828	
	7855190	Dec 05, 2028			U-1	
ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE						
N 022262 001	7855190	Dec 05, 2028			U-1	
ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA						
N 204017 001	8246978	Aug 26, 2028	DP			
	8747888	Jul 10, 2028	DP			
	9050348	Jul 10, 2028	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE						
N 204061 001	8415332	Mar 11, 2029	DP			
	8450299	Oct 07, 2025			U-1	
ETHINYL ESTRADIOL; LEVONORGESTREL - BALCOLTRA						
N 208612 001	7838042	Jun 01, 2027	DS		U-3251	
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE						
N 022501 001	7704984	Feb 02, 2029			U-1090	
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE						
N 204654 001	7704984	Feb 02, 2029			U-1	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA								
N 209627	001		10632066	Feb 01, 2039	U-2786			
			10632066	Feb 01, 2039	U-2787			
			10765628	Feb 01, 2039	U-2786			
			10765628	Feb 01, 2039	U-2787			
			10780047	Feb 01, 2039	U-2786			
			10780047	Feb 01, 2039	U-2787			
			10918649	Jun 21, 2039	DP			
			10925882	Jun 21, 2039	DP			
			10940157	Jun 21, 2039	DP			
			11529308	Jun 21, 2039	DP			
ETONOGESTREL - IMPLANON								
N 021529	001		9757552	Jul 28, 2030	DP U-1			
ETONOGESTREL - NEXPLANON								
N 021529	002		10821277	May 31, 2027	DP			
			8722037	Sep 28, 2027	DP			
			8888745	Aug 28, 2026	DP			
			9757552	Jul 28, 2030	DP U-1			
ETRASIMOD ARGININE - VELSIPITY								
N 216956	001		10301262	Jun 21, 2036	DS DP		NCE	Oct 12, 2028
			10676435	Jun 21, 2036	U-3731			
			11007175	Jan 06, 2036	U-3730			
			11091435	Jun 21, 2036	DS DP			
			8580841	Mar 05, 2030	DS DP			
			9126932	Jul 22, 2029	U-3732			
EVEROLIMUS - AFINITOR								
N 022334	001		8410131	Nov 01, 2025	U-1368			
			8410131*PED	May 01, 2026				
			9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR								
N 022334	002		8410131	Nov 01, 2025	U-1368			
			8410131*PED	May 01, 2026				
			9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR								
N 022334	003		8410131	Nov 01, 2025	U-1368			
			8410131*PED	May 01, 2026				
			9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR								
N 022334	004		8410131	Nov 01, 2025	U-1368			
			8410131*PED	May 01, 2026				
			9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR DISPERZ								
N 203985	001						ODE-169	Apr 10, 2025
EVEROLIMUS - AFINITOR DISPERZ								
N 203985	002						ODE-169	Apr 10, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EVEROLIMUS - AFINITOR DISPERZ						
N 203985 003					ODE-169	Apr 10, 2025
EXENATIDE SYNTHETIC - BYETTA						
N 021773 001					M-232	Nov 04, 2024
EXENATIDE SYNTHETIC - BYETTA						
N 021773 002					M-232	Nov 04, 2024
EXENATIDE SYNTHETIC - BYDUREON						
N 022200 001	6515117	Oct 04, 2025	DS DP U-2588		NPP	Jul 22, 2024
	6515117*PED	Apr 04, 2026			PED	Jan 22, 2025
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON						
N 022200 001	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
EXENATIDE SYNTHETIC - BYDUREON PEN						
N 022200 002	6515117	Oct 04, 2025	DS DP U-2588		NPP	Jul 22, 2024
	6515117*PED	Apr 04, 2026			PED	Jan 22, 2025
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON PEN						
N 022200 002	7612176*PED	Oct 13, 2025				
	8216180	Jan 12, 2028	DP			
	8216180*PED	Jul 12, 2028				
	8329648	Aug 18, 2026			U-2588	
	8329648	Aug 18, 2026			U-2589	
	8329648	Aug 18, 2026			U-2590	
	8329648	Aug 18, 2026			U-2593	
	8329648	Aug 18, 2026			U-2594	
	8329648	Aug 18, 2026			U-2595	
	8329648	Aug 18, 2026			U-2596	
	8329648	Aug 18, 2026			U-3188	
	8329648	Aug 18, 2026			U-3189	
	8329648	Aug 18, 2026			U-3190	
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028			U-2588	
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP		U-2588	
	8431685	Apr 13, 2025	DP		U-2589	
	8431685	Apr 13, 2025	DP		U-2590	
	8431685	Apr 13, 2025	DP		U-3188	
	8431685	Apr 13, 2025	DP		U-3189	
	8431685	Apr 13, 2025	DP		U-3190	
	8431685*PED	Oct 13, 2025				
	8439864	Mar 25, 2028	DP			
	8439864*PED	Sep 25, 2028				
	8461105	Apr 13, 2025	DP		U-2588	
	8461105	Apr 13, 2025	DP		U-2589	
	8461105	Apr 13, 2025	DP		U-2590	
	8461105	Apr 13, 2025	DP		U-3188	
	8461105	Apr 13, 2025	DP		U-3189	
	8461105	Apr 13, 2025	DP		U-3190	
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP		U-2588	
	8501698*PED	Dec 20, 2027				
	8690837	May 19, 2029	DP			
	8690837*PED	Nov 19, 2029				
	8721615	Jan 18, 2030	DP			
	8721615*PED	Jul 18, 2030				
	8758292	Nov 12, 2027	DP			
	8758292*PED	May 12, 2028				
	8827963	Feb 04, 2029	DP			
	8827963*PED	Aug 04, 2029				
	8906851	Aug 18, 2026			U-2588	
	8906851	Aug 18, 2026			U-2589	
	8906851	Aug 18, 2026			U-2590	
	8906851	Aug 18, 2026			U-2593	
	8906851	Aug 18, 2026			U-3188	
	8906851	Aug 18, 2026			U-3189	
	8906851	Aug 18, 2026			U-3190	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON PEN						
N 022200 002	8906851*PED	Feb 18, 2027				
	8998876	Jan 07, 2030	DP			
	8998876*PED	Jul 07, 2030				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9320853	Mar 25, 2028	DP			
	9320853*PED	Sep 25, 2028				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
EXENATIDE SYNTHETIC - BYDUREON BCISE						
N 209210 001	6515117	Oct 04, 2025	DS DP U-2588		NPP	Jul 22, 2024
	6515117*PED	Apr 04, 2026			PED	Jan 22, 2025
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON BCISE						
N 209210 001	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2597			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2597			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	U-2588			
	8501698*PED	Dec 20, 2027				
	8895033	Oct 04, 2030	DP U-2589			
	8895033	Oct 04, 2030	DP U-2590			
	8895033	Oct 04, 2030	DP U-2597			
	8895033	Oct 04, 2030	DP U-2601			
	8895033	Oct 04, 2030	DP U-2602			
	8895033	Oct 04, 2030	DP U-3188			
	8895033	Oct 04, 2030	DP U-3189			
	8895033	Oct 04, 2030	DP U-3190			
	8895033*PED	Apr 04, 2031				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-2597			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2597			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON BCISE						
N 209210 001	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-2597			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
EZETIMIBE - ZETIA						
N 021445 001	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			
	7612058*PED	Apr 30, 2026				
EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET						
N 213072 001	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET						
N 213072 002	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET						
N 213072 003	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET						
N 213072 004	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
FAMOTIDINE; IBUPROFEN - DUEXIS						
N 022519 001	8067451	Jul 18, 2026	DP U-1196			
	8309127	Jul 18, 2026	DP			
	8318202	Jul 18, 2026	DP			
	8449910	Jul 18, 2026	DP			
	8501228	Jul 18, 2026	U-1196			
FEBUXOSTAT - ULORIC						
N 021856 001	7361676	Mar 08, 2024	DP			
	8372872	Sep 08, 2031	U-1346			
	9107912	Sep 08, 2031	U-1346			
FEBUXOSTAT - ULORIC						
N 021856 002	7361676	Mar 08, 2024	DP			
	8372872	Sep 08, 2031	U-1346			
	9107912	Sep 08, 2031	U-1346			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEDRATINIB HYDROCHLORIDE - INREBIC						
N 212327 001	10391094	Jun 04, 2032	DP U-2607		NCE	Aug 16, 2024
	11400092	Sep 24, 2039	U-3409		ODE-259	Aug 16, 2026
	7528143	Nov 16, 2031	DS DP			
	7825246	Dec 16, 2026	DS			
	8138199	Jun 30, 2028	U-2607			
FENFLURAMINE HYDROCHLORIDE - FINTEPLA						
N 212102 001	10452815	Jun 29, 2038	U-2859	Y	I-887	Mar 25, 2025
	10452815*PED	Dec 29, 2038			ODE-312	Jun 25, 2027
	10478441	May 03, 2033	U-2860		ODE-393	Mar 25, 2029
	10478441*PED	Nov 03, 2033			PED	Sep 25, 2025
	10478442	May 03, 2033	U-2860		PED	Dec 25, 2027
	10478442*PED	Nov 03, 2033			PED	Sep 25, 2029
	10603290	Aug 02, 2037	U-2861			
	10603290	Aug 02, 2037	U-3347			
	10603290*PED	Feb 02, 2038				
	10947183	Dec 20, 2036	DS DP			
	10947183*PED	Jun 20, 2037				
	11040018	Aug 02, 2037	U-2861			
	11040018	Aug 02, 2037	U-3347			
	11040018*PED	Feb 02, 2038				
	11406606	Aug 02, 2037	U-3406			
	11406606	Aug 02, 2037	U-3407			
	11406606*PED	Feb 02, 2038				
	11759440	Aug 02, 2037	U-3694			
	11759440*PED	Feb 02, 2038				
	11786487	Aug 02, 2037	U-3733			
	11786487*PED	Feb 02, 2038				
	9549909	May 03, 2033	U-2858			
	9549909*PED	Nov 03, 2033				
	9603814	May 03, 2033	U-2858			
	9603814*PED	Nov 03, 2033				
	9603815	May 03, 2033	U-2858			
	9603815*PED	Nov 03, 2033				
	9610260	May 03, 2033	U-2858			
	9610260*PED	Nov 03, 2033				
FENOFIBRATE - ANTARA (MICRONIZED)						
N 021695 004	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
FENOFIBRATE - ANTARA (MICRONIZED)						
N 021695 005	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
FENOFIBRATE - FENOGLIDE						
N 022118 001	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
	9173847	Oct 01, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENOFIBRATE - FENOGLIDE						
N 022118 001	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
	9173847	Oct 01, 2024	DP			
FENOFIBRATE - FENOGLIDE						
N 022118 002	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
	9173847	Oct 01, 2024	DP			
FENOFIBRIC ACID - FIBRICOR						
N 022418 001	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
FENOFIBRIC ACID - FIBRICOR						
N 022418 002	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
FENTANYL - SUBSYS						
N 202788 001	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 002	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL - SUBSYS						
N 202788 003	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 004	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 005	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 006	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 007	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL - SUBSYS						
N 202788 007	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL CITRATE - FENTORA						
N 021947 001	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N 021947 002	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N 021947 003	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N 021947 004	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N 021947 005	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - ONSOLIS						
N 022266 001	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 002	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 003	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 004	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 005	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - LAZANDA						
N 022569 001	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
	9731869	Jan 26, 2032	DP			
	9814705	Jan 08, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL CITRATE - LAZANDA						
N 022569 002	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
	9731869	Jan 26, 2032	DP			
	9814705	Jan 08, 2024	DP			
FENTANYL CITRATE - LAZANDA						
N 022569 003	9731869	Jan 26, 2032	DP			
	9814705	Jan 08, 2024	DP			
FENTANYL HYDROCHLORIDE - IONSYS						
N 021338 001	6975902	Apr 01, 2024	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Feb 03, 2033	DP			
	9364656	Sep 30, 2031	U-736			
	9731121	Oct 17, 2031	DP			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 001	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435		NPP	Nov 19, 2024
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 002	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435		NPP	Nov 19, 2024
	11433091	Jan 08, 2027	U-3436			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 002	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 003	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435		NPP	Nov 19, 2024
	11433091	Jan 08, 2027	U-3436		NS	Apr 28, 2024
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 004	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
FERRIC CITRATE - AURYXIA						
N 205874 001	10300039	Jul 21, 2030	U-2549			
	7767851	Feb 18, 2024	DS DP			
	8093423	Apr 21, 2026	U-1577			
	8299298	Feb 18, 2024	DP			
	8338642	Feb 18, 2024	DS DP U-1577			
	8609896	Feb 18, 2024	DP			
	8754257	Feb 18, 2024	DP			
	8754258	Feb 18, 2024	DP			
	8846976	Feb 18, 2024	U-1577			
	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
	9328133	Feb 18, 2024	DS DP U-1577			
	9387191	Jul 21, 2030	DP			
	9757416	Feb 18, 2024	DS DP U-1577			
FERRIC DERISOMALTOSE - MONOFERRIC						
N 208171 001	10414831	Mar 25, 2029	DS DP			
	11633489	Jun 22, 2036	U-3594			
	8815301	Aug 14, 2029	DS DP U-2734			
FERRIC DERISOMALTOSE - MONOFERRIC						
N 208171 002	10414831	Mar 25, 2029	DS DP			
	11633489	Jun 22, 2036	U-3594			
	8815301	Aug 14, 2029	DS DP U-2734			
FERRIC DERISOMALTOSE - MONOFERRIC						
N 208171 003	10414831	Mar 25, 2029	DS DP			
	11633489	Jun 22, 2036	U-3594			
	8815301	Aug 14, 2029	DS DP U-2734			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC MALTOL - ACCRUFER						
N 212320 001	10179120	Jan 06, 2035	U-2603		NCE	Jul 25, 2024
	9248148	Mar 29, 2031	U-2603			
	9802973	Oct 23, 2035	DS DP U-2603			
FERRIC OXYHYDROXIDE - VELPHORO						
N 205109 001	10624855	Nov 26, 2034	DP			
	10624855*PED	May 26, 2035				
	10682376	Nov 13, 2028	DP			
	10682376*PED	May 13, 2029				
	10695367	Nov 13, 2028	DP			
	10695367*PED	May 13, 2029				
	10925896	Nov 13, 2028	DP			
	10925896*PED	May 13, 2029				
	10925897	Nov 13, 2028	DP			
	10925897*PED	May 13, 2029				
	10933090	Nov 13, 2028	DP			
	10933090*PED	May 13, 2029				
	11013761	Nov 13, 2028	DP			
	11013761*PED	May 13, 2029				
	11013762	Nov 13, 2028	DP			
	11013762*PED	May 13, 2029				
	11234938	Nov 26, 2034	DP			
	11234938*PED	May 26, 2035				
	11446252	Nov 26, 2034	DP			
	11446252*PED	May 26, 2035				
	9561251	Jan 23, 2030	DP U-1468			
	9561251*PED	Jul 23, 2030				
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC						
N 206317 001	7816404	Apr 17, 2029	DP U-1656			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC						
N 208551 001	7816404	Apr 17, 2029	U-1656			
	7857977	Sep 08, 2027	U-1656			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC AVNU						
N 212860 001	7816404	Apr 17, 2029	DS U-2801			
FESOTERODINE FUMARATE - TOVIAZ						
N 022030 001	7807715	Jun 07, 2027	DP U-913		I-861	Jun 17, 2024
	8088398	Jun 07, 2027	DP U-913		PED	Dec 17, 2024
	8501723	Jun 07, 2027	DP			
	8501723*PED	Dec 07, 2027				
FESOTERODINE FUMARATE - TOVIAZ						
N 022030 002	7807715	Jun 07, 2027	DP U-913		I-861	Jun 17, 2024
	8088398	Jun 07, 2027	DP U-913		PED	Dec 17, 2024
	8501723	Jun 07, 2027	DP			
	8501723*PED	Dec 07, 2027				
FEXINIDAZOLE - FEXINIDAZOLE						
N 214429 001					NCE	Jul 16, 2026
					ODE-359	Jul 16, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY								
N 201373	001		8933097	Aug 02, 2030	DP			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES								
N 201373	002		8933097	Aug 02, 2030	DP			
FEZOLINETANT - VEOZAH								
N 216578	001		10836768	Mar 28, 2034	U-3621		NCE	May 12, 2028
			8871761	Apr 04, 2031	DS			
			9422299	Mar 28, 2034	DS DP U-3622			
			9987274	Mar 28, 2034	U-3622			
FIDAXOMICIN - DIFICID								
N 201699	001		7378508	Jul 31, 2027	DS DP		ODE-367	Jan 24, 2027
			7863249	Jul 31, 2027	DS DP			
			7906489	Mar 04, 2027	U-2741			
			7906489	Mar 04, 2027	U-319			
			7906489*PED	Sep 04, 2027				
			8586551*PED	Jan 15, 2024				
			8859510	Jul 31, 2027	U-2741			
			8859510	Jul 31, 2027	U-319			
			8859510*PED	Jan 31, 2028				
FIDAXOMICIN - DIFICID								
N 213138	001		7378508	Jul 31, 2027	DS DP		ODE-367	Jan 24, 2027
			7378508*PED	Jan 31, 2028				
			7863249	Jul 31, 2027	DP			
			7863249*PED	Jan 31, 2028				
			7906489	Mar 04, 2027	U-2741			
			7906489*PED	Sep 04, 2027				
			8586551*PED	Jan 23, 2024				
			8859510	Jul 31, 2027	U-2741			
			8859510*PED	Jan 31, 2028				
			9808530	May 28, 2034	DP			
			9808530*PED	Nov 28, 2034				
FINAFLOXACIN - XTORO								
N 206307	001		8536167	Aug 08, 2031	U-1679			
			9119859	Jul 02, 2030	U-1679			
			9504691	Nov 21, 2033	DP U-1679			
			9993483	Jul 02, 2030	DP			
FINERENONE - KERENDIA								
N 215341	001		8436180	Apr 12, 2029	DS DP		M-279	Sep 01, 2025
							NCE	Jul 09, 2026
FINERENONE - KERENDIA								
N 215341	002		8436180	Apr 12, 2029	DS DP		M-279	Sep 01, 2025
							NCE	Jul 09, 2026
FINGOLIMOD HYDROCHLORIDE - GILENYA								
N 022527	001		10543179	Dec 25, 2027	U-2719			
			8324283	Mar 29, 2026	DP			
			8324283*PED	Sep 29, 2026				
			9187405	Jun 25, 2027	U-2613			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FINGOLIMOD HYDROCHLORIDE - GILENYA						
N 022527 001	9187405*PED	Dec 25, 2027				
FINGOLIMOD HYDROCHLORIDE - GILENYA						
N 022527 002	9592208	Mar 30, 2032	DP U-2315			
	9592208*PED	Sep 30, 2032				
FINGOLIMOD LAURYL SULFATE - TASCENSO ODT						
N 214962 001	10555902	Jan 19, 2036	U-3268			
	10925829	Jan 19, 2036	DP			
	9925138	Jan 19, 2036	DP			
FINGOLIMOD LAURYL SULFATE - TASCENSO ODT						
N 214962 002	10555902	Jan 19, 2036	U-3493			
	10925829	Jan 19, 2036	DP			
	9925138	Jan 19, 2036	DP			
FISH OIL TRIGLYCERIDES - OMEGAVEN						
N 210589 001	10350186	Nov 05, 2024	U-2585		ODE-202	Jul 27, 2025
	9566260	Jul 11, 2025	DP U-2366			
	9629821	Jul 11, 2025	DP U-2367			
FISH OIL TRIGLYCERIDES - OMEGAVEN						
N 210589 002	10350186	Nov 05, 2024	U-2585		ODE-202	Jul 27, 2025
	9566260	Jul 11, 2025	DP U-2366			
	9629821	Jul 11, 2025	DP U-2367			
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%						
N 207648 001					NPP	Mar 22, 2025
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%						
N 207648 002					NPP	Mar 22, 2025
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%						
N 207648 003					NPP	Mar 22, 2025
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%						
N 207648 004					NPP	Mar 22, 2025
FLIBANSERIN - ADDYI						
N 022526 001	7151103	May 09, 2028	U-1734			
FLORBETABEN F-18 - NEURACEQ						
N 204677 001	7807135	Mar 18, 2029	DS DP U-1497			
FLORBETAPIR F-18 - AMYVID						
N 202008 001	7687052	Apr 30, 2027	DS DP			
	8506929	Apr 30, 2027	DS DP U-1423			
FLORBETAPIR F-18 - AMYVID						
N 202008 002	7687052	Apr 30, 2027	DS DP			
	8506929	Apr 30, 2027	DS DP U-1423			
FLORBETAPIR F-18 - AMYVID						
N 202008 003	7687052	Apr 30, 2027	DS DP			
	8506929	Apr 30, 2027	DS DP U-1423			
FLORTAUCIPIR F-18 - TAUVID						
N 212123 001	8932557	May 26, 2032	DS		NCE	May 28, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLORTAUCIPIR F-18 - TAUVID						
N 212123 002	8932557	May 26, 2032	DS		NCE	May 28, 2025
FLORTAUCIPIR F-18 - TAUVID						
N 212123 003	8932557	May 26, 2032	DS			
FLORTAUCIPIR F-18 - TAUVID						
N 212123 004	8932557	May 26, 2032	DS			
FLOTUFOLASTAT F-18 GALLIUM - POSLUMA						
N 216023 001	11413360	Nov 22, 2038	DS U-3614		NCE	May 25, 2028
	11413360	Nov 22, 2038	DS U-3615			
FLUCICLOVINE F-18 - AXUMIN						
N 208054 001	10010632	Nov 28, 2026	DP			
	10124079	Dec 30, 2035	U-2450			
	10716868	Dec 30, 2035	U-2450			
	10933147	Dec 30, 2035	U-2450			
	10953112	Nov 28, 2026	U-1879			
	10967077	Dec 30, 2035	U-2450			
	9387266	Nov 28, 2026	U-1879			
FLUOCINOLONE ACETONIDE - ILUVIEN						
N 201923 001	8871241	Aug 12, 2027	DP			
FLUOCINOLONE ACETONIDE - YUTIQ						
N 210331 001	7998108	Jan 12, 2028	DP U-3410			
	8871241	Aug 12, 2027	DP			
FLUORESCEIN SODIUM - FLUORESCEIN SODIUM						
A 215709 001					CGT	Apr 21, 2024
FLUORODOPA F-18 - FLUORODOPA F18						
N 200655 001					NCE	Oct 10, 2024
					W	Oct 10, 2024
FLUOROESTRADIOL F-18 - CERIANNA						
N 212155 001					NCE	May 20, 2025
FLUTEMETAMOL F-18 - VIZAMYL						
N 203137 001	7270800	Sep 03, 2025	DS DP U-336			
	8236282	May 21, 2024	DS DP			
	8916131	Sep 16, 2028	DP			
FLUTEMETAMOL F-18 - VIZAMYL						
N 203137 002	7270800	Sep 03, 2025	DS DP U-336			
	8236282	May 21, 2024	DS DP			
	8916131	Sep 16, 2028	DP			
FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF						
N 022051 002	8062264	Apr 05, 2026	DP			
	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			
	9320862	Nov 06, 2024	DP			
FLUTICASONE FUROATE - ARNUITY ELLIPTA						
N 205625 001	8201556	Feb 05, 2029	DP			
	8746242	Oct 11, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE - ARNUITY ELLIPTA						
N 205625 001	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
FLUTICASONE FUROATE - ARNUITY ELLIPTA						
N 205625 002	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8201556	Feb 05, 2029	DP			
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
FLUTICASONE FUROATE - ARNUITY ELLIPTA						
N 205625 003	8113199	Oct 23, 2027	DP		M-290	Mar 01, 2026
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8201556	Feb 05, 2029	DP			
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA						
N 209482 001	11090294	Nov 29, 2030			U-3202	
	7439393	May 21, 2025	DS DP		U-2127	
	7439393	May 21, 2025	DS DP		U-2957	
	7439393*PED	Nov 21, 2025				
	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8183257	Jul 27, 2025			U-2128	
	8183257	Jul 27, 2025			U-2129	
	8309572	Apr 27, 2025			U-2129	
	8511304	Jun 14, 2027	DP		U-2954	
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA							
N 209482	001	9333310*PED	Apr 02, 2028				
		9750726	Nov 29, 2030	DP			
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA							
N 209482	002	7439393	May 21, 2025	DS DP U-2957			
		7439393*PED	Nov 21, 2025				
		7488827	Dec 18, 2027	DS DP			
		7498440	Apr 27, 2025	DS DP			
		8113199	Oct 23, 2027	DP			
		8113199*PED	Apr 23, 2028				
		8161968	Feb 05, 2028	DP			
		8161968*PED	Aug 05, 2028				
		8183257	Jul 27, 2025	U-2129			
		8309572	Apr 27, 2025	U-2129			
		8511304	Jun 14, 2027	DP U-2954			
		8511304*PED	Dec 14, 2027				
		8534281	Mar 08, 2030	DP			
		8534281*PED	Sep 08, 2030				
		8746242	Oct 11, 2030	DP			
		8746242*PED	Apr 11, 2031				
		9333310	Oct 02, 2027	DP			
		9333310*PED	Apr 02, 2028				
		9750726	Nov 29, 2030	DP			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA							
N 204275	001	11116721	Feb 26, 2029	DP U-1401		NPP	May 13, 2026
		11116721	Feb 26, 2029	DP U-1691		PED	Nov 13, 2026
		11116721	Feb 26, 2029	DP U-3623			
		11116721*PED	Aug 26, 2029				
		7439393	May 21, 2025	DS DP U-1401			
		7439393	May 21, 2025	DS DP U-1691			
		7439393	May 21, 2025	DS DP U-2099			
		7439393	May 21, 2025	DS DP U-2100			
		7439393	May 21, 2025	DS DP U-3623			
		7439393*PED	Nov 21, 2025				
		8113199	Oct 23, 2027	DP			
		8113199*PED	Apr 23, 2028				
		8161968	Feb 05, 2028	DP			
		8161968*PED	Aug 05, 2028				
		8511304	Jun 14, 2027	DP U-1424			
		8511304	Jun 14, 2027	DP U-1691			
		8511304	Jun 14, 2027	DP U-3623			
		8511304*PED	Dec 14, 2027				
		8534281	Mar 08, 2030	DP			
		8534281*PED	Sep 08, 2030				
		8746242	Oct 11, 2030	DP			
		8746242*PED	Apr 11, 2031				
		9333310	Oct 02, 2027	DP			
		9333310*PED	Apr 02, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA						
N 204275 002	11116721	Feb 26, 2029	DP U-1691			
	11116721	Feb 26, 2029	DP U-3623			
	11116721*PED	Aug 26, 2029				
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	7439393	May 21, 2025	DS DP U-3623			
	7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8511304	Jun 14, 2027	DP U-1691			
	8511304	Jun 14, 2027	DP U-3623			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA						
N 204275 003	11116721	Feb 26, 2029	DP U-3623		NS	May 13, 2026
	11116721*PED	Aug 26, 2029			PED	Nov 13, 2026
	7439393	May 21, 2025	DS DP U-3623			
	7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8511304	Jun 14, 2027	DP U-3623			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
FLUTICASONE PROPIONATE - FLOVENT HFA						
N 021433 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
FLUTICASONE PROPIONATE - FLOVENT HFA						
N 021433 002	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 001	10022510	May 18, 2031	DP		NPP	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 001	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 003	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 004	10022510	May 18, 2031	DP		NPP	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 004	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 005	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 006	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 007	10022510	May 18, 2031	DP		NS	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 008	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Nov 08, 2030	DP			
	8714149*PED	May 08, 2031				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - XHANCE						
N 209022 001	10076614	Oct 20, 2034	DP			
	10076615	Jul 30, 2029	U-2133			
	10124132	Mar 06, 2027	DP U-2133			
	10179216	Jul 08, 2033	DP U-2133			
	10252010	Feb 07, 2031	DP			
	10300229	Jul 07, 2035	DP U-2133			
	10478574	Nov 04, 2033	U-2133			
	11033696	May 20, 2033	DP			
	11554229	Feb 23, 2036	U-2133			
	11602603	Oct 27, 2028	DP U-2133			
	7975690	Dec 29, 2025	U-2133			
	8522778	Apr 20, 2024	DP			
	8550073	Oct 22, 2029	DP			
	8978647	Dec 06, 2030	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
N 021254 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
N 021254 003	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK						
N 208799 001	10022510	May 18, 2031	DP		M-61	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK						
N 208799 001	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK						
N 208799 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK						
N 208799 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK						
N 208799 003	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 004	10022510	May 18, 2031	DP		M-61	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 004	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 005	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 006	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
FOMEPIZOLE - ANTIZOL						
N 020696 001	7553863	Jun 30, 2027	DS DP			
FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE						
N 208294 001	10716753	May 28, 2030	DP U-2889			
	8324266	May 28, 2030	U-2889			
	8703806	May 28, 2030	U-2889			
	8808713	May 28, 2030	DP U-2889			
	8815258	Mar 17, 2031	U-2889			
	9415009	May 28, 2030	U-2889			
	9463161	May 28, 2030	DP U-2889			
FOSAPREPITANT DIMEGLUMINE - EMEND						
N 022023 001					D-186	May 02, 2025
FOSAPREPITANT DIMEGLUMINE - EMEND						
N 022023 002					D-186	May 02, 2025
FOSAPREPITANT DIMEGLUMINE - FOCINVEZ						
N 216686 001	11065265	Jan 11, 2039	DP			
FOSDENOPTERIN HYDROBROMIDE - NULIBRY						
N 214018 001	7504095	Jan 31, 2025	DP U-3092		M-286	Oct 27, 2025
					NCE	Feb 26, 2026
					ODE-342	Feb 26, 2028
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO						
N 210493 001	10208073	May 23, 2032	U-2301			
	10624911	Jun 02, 2037	DP			
	10717721	May 23, 2032	DS			
	10828297	Dec 17, 2030	U-2301			
	11312698	May 23, 2032	DS DP			
	11529362	Jun 02, 2037	DP			
	8426450	May 23, 2032	DS DP			
	8895586	May 23, 2032	U-2301			
	9186357	Nov 18, 2030	U-2301			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO							
N 210493	001	9403772	May 23, 2032	DS	U-2301		
		9908907	May 23, 2032	DS DP			
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO							
N 210493	002	10208073	May 23, 2032		U-2301		
		10624911	Jun 02, 2037	DP			
		10717721	May 23, 2032	DS			
		10828297	Dec 17, 2030		U-2301		
		11312698	May 23, 2032	DS DP			
		11529362	Jun 02, 2037	DP			
		8426450	May 23, 2032	DS DP			
		8895586	May 23, 2032		U-2301		
		9186357	Nov 18, 2030		U-2301		
		9403772	May 23, 2032	DS	U-2301		
		9908907	May 23, 2032	DS DP			
FOSPHENYTOIN SODIUM - SESQUIENT							
N 210864	001	7635773	Mar 13, 2029	DP			
		8410077	Mar 13, 2029	DP			
		9200088	Mar 13, 2029	DP			
		9493582	Feb 27, 2033	DP			
		9750822	Mar 13, 2029	DP			
FOSPHENYTOIN SODIUM - SESQUIENT							
N 210864	002	7635773	Mar 13, 2029	DP			
		8410077	Mar 13, 2029	DP			
		9200088	Mar 13, 2029	DP			
		9493582	Feb 27, 2033	DP			
		9750822	Mar 13, 2029	DP			
FOSTAMATINIB DISODIUM - TAVALISSE							
N 209299	001	7449458	Sep 04, 2031	DS		ODE-174	Apr 17, 2025
		7538108	Mar 28, 2026	DS	U-2294		
		7989448	Jun 12, 2026	DS	U-2294		
		8163902	Jun 17, 2026	DS	U-2294		
		8211889	Jan 19, 2026	DS			
		8263122	Nov 24, 2030	DP			
		8445485	Jun 17, 2026	DP			
		8652492	Nov 06, 2028	DP			
		8771648	Jul 27, 2032	DP			
		8912170	Jun 17, 2026		U-2294		
		8951504	Jul 27, 2032		U-2294		
		9266912	Jan 19, 2026		U-2294		
		9283238	Jun 17, 2026		U-2294		
		RE48898	Jan 19, 2026	DP			
FOSTAMATINIB DISODIUM - TAVALISSE							
N 209299	002	7449458	Sep 04, 2031	DS		ODE-174	Apr 17, 2025
		7538108	Mar 28, 2026	DS	U-2294		
		7989448	Jun 12, 2026	DS	U-2294		
		8163902	Jun 17, 2026	DS	U-2294		
		8211889	Jan 19, 2026	DS			
		8263122	Nov 24, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FOSTAMATINIB DISODIUM - TAVALISSE							
N 209299	002	8445485	Jun 17, 2026	DP			
		8652492	Nov 06, 2028	DP			
		8771648	Jul 27, 2032	DP			
		8912170	Jun 17, 2026	U-2294			
		8951504	Jul 27, 2032	U-2294			
		9266912	Jan 19, 2026	U-2294			
		9283238	Jun 17, 2026	U-2294			
		RE48898	Jan 19, 2026	DP			
FOSTEMSAVIR TROMETHAMINE - RUKOBIA							
N 212950	001	7745625	Nov 19, 2027	DS		NCE	Jul 02, 2025
		8168615	Feb 25, 2025	DP			
		8461333	Feb 25, 2025	DS			
FRUQUINTINIB - FRUZAQLA							
N 217564	001	10519142	Sep 07, 2035	DS DP U-3753			
		11046674	Sep 07, 2035	U-3753			
		7829574	May 09, 2028	DS DP			
		8212033	May 09, 2028	U-3753			
FRUQUINTINIB - FRUZAQLA							
N 217564	002	10519142	Sep 07, 2035	DS DP U-3753			
		11046674	Sep 07, 2035	U-3753			
		7829574	May 09, 2028	DS DP			
		8212033	May 09, 2028	U-3753			
FULVESTRANT - FULVESTRANT							
N 210326	001	10188663	Feb 14, 2034	DP U-2540			
		9271990	May 17, 2034	DP U-2540			
		9833459	Feb 14, 2034	DP U-2540			
FUROSEMIDE - FUROSCIX							
N 209988	001	10272064	Apr 03, 2034	DP			
		11433044	Apr 03, 2034	U-3462			
		9884039	Apr 03, 2034	U-3462			
FUTIBATINIB - LYTGOBI							
N 214801	001	10434103	Mar 31, 2036	DS DP		NCE	Sep 30, 2027
		11833151	Nov 05, 2039	DP		ODE-410	Sep 30, 2029
		9108973	Feb 23, 2033	DS DP U-3456			
GABAPENTIN - GRALISE							
N 022544	001	7438927	Feb 26, 2024	U-1114			
GABAPENTIN - GRALISE							
N 022544	002	7438927	Feb 26, 2024	U-1114			
GABAPENTIN ENACARBIL - HORIZANT							
N 022399	001	6818787	Apr 06, 2025	DS DP			
		8026279	Nov 10, 2026	DS DP			
		8114909	Apr 11, 2026	U-1231			
		8686034	Jan 24, 2025	U-1231			
		8686034	Jan 24, 2025	U-1247			
		8795725	Jun 10, 2029	DP U-1231			
		8795725	Jun 10, 2029	DP U-1247			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GABAPENTIN ENACARBIL - HORIZANT						
N 022399 002	6818787	Apr 06, 2025	DS DP			
	8026279	Nov 10, 2026	DS DP			
	8114909	Apr 11, 2026	U-1231			
	8686034	Jan 24, 2025	U-1231			
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
GADOBUTROL - GADOBUTROL						
A 216081 001					CGT	Apr 29, 2024
GADOBUTROL - GADOBUTROL						
A 216081 002					CGT	Apr 29, 2024
GADOPICLENOL - ELUCIREM						
N 216986 001	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM						
N 216986 002	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM						
N 216986 003	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM						
N 216986 004	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM						
N 216986 005	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM						
N 216986 006	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM						
N 216986 007	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			
GALLIUM DOTATATE GA-68 - NETSPOT						
N 208547 001	9375498	Aug 10, 2032	DP			
GALLIUM GA-68 EDOTREOTIDE - GALLIUM GA 68 EDOTREOTIDE						
N 210828 001					NCE	Aug 21, 2024
					ODE-383	Aug 21, 2026
					W	Aug 21, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GALLIUM GA-68 EDOTREOTIDE - GALLIUM GA 68 EDOTREOTIDE						
N 210828 001					W	Aug 21, 2026
GALLIUM GA-68 GOZETOTIDE - GALLIUM GA 68 GOZETOTIDE						
N 212642 001					NCE	Dec 01, 2025
					W	Dec 01, 2025
GALLIUM GA-68 GOZETOTIDE - GALLIUM GA 68 GOZETOTIDE						
N 212643 001					NCE	Dec 01, 2025
					W	Dec 01, 2025
GALLIUM GA-68 GOZETOTIDE - ILLUCCIX						
N 214032 001	11027031	Jul 28, 2035	U-3317			
GALLIUM GA-68 GOZETOTIDE - LOCAMETZ						
N 215841 001	11369590	Aug 15, 2028	DS DP U-3400		NP	Mar 23, 2025
GANAXOLONE - ZTALMY						
N 215904 001	10603308	Aug 10, 2037	U-3374		NCE	Jun 01, 2027
	7858609	Nov 28, 2026	DP		ODE-395	Jun 01, 2029
	8022054	Nov 28, 2026	DP			
	8318714	Nov 28, 2026	DP			
	8367651	Nov 28, 2026	DP			
	8618087	Nov 28, 2026	U-3374			
	9029355	Nov 28, 2026	DP			
	9056116	Nov 28, 2026	U-3374			
GANCICLOVIR - GANZYK-RTU						
N 209347 001	9486530	Sep 02, 2034	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 001	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 002	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 003	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 004	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 005	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 006	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 007	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 008	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 009	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 010	9241948	Jul 01, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GEPIRONE HYDROCHLORIDE - EXXUA						
N 021164 001	7538116	Sep 02, 2025	U-3699		NCE	Sep 22, 2028
GEPIRONE HYDROCHLORIDE - EXXUA						
N 021164 002	7538116	Sep 02, 2025	U-3699		NCE	Sep 22, 2028
GEPIRONE HYDROCHLORIDE - EXXUA						
N 021164 003	7538116	Sep 02, 2025	U-3699		NCE	Sep 22, 2028
GEPIRONE HYDROCHLORIDE - EXXUA						
N 021164 004	7538116	Sep 02, 2025	U-3699		NCE	Sep 22, 2028
GILTERITINIB FUMARATE - XOSPATA						
N 211349 001	10786500	Jul 01, 2036	DP		ODE-222	Nov 28, 2025
	8969336	Jan 27, 2031	DS DP			
	9487491	Jul 28, 2030	U-2456			
GIVOSIRAN SODIUM - GIVLAARI						
N 212194 001	10119143	Oct 03, 2034	DS DP U-2672		NCE	Nov 20, 2024
	10125364	Mar 15, 2033	DS DP U-2672		ODE-273	Nov 20, 2026
	10131907	Aug 24, 2028	DS DP U-2672			
	10273477	Mar 08, 2024	DS			
	11028392	Oct 03, 2034	DS DP U-2672			
	11530408	May 18, 2024	DS DP			
	8106022	Dec 12, 2029	DS DP U-2672			
	8828956	Dec 04, 2028	DS DP U-2672			
	9133461	Nov 30, 2033	DS DP U-2672			
	9150605	Aug 28, 2025	DS DP			
	9631193	Mar 15, 2033	U-2672			
	9708615	Mar 08, 2024	DS			
GLASDEGIB MALEATE - DAURISMO						
N 210656 001	10414748	Apr 13, 2036	DS DP		ODE-224	Nov 21, 2025
	11168066	Apr 13, 2036	U-3254			
	8148401	Jan 30, 2031	DS DP			
	8431597	Jun 29, 2028	DP			
GLASDEGIB MALEATE - DAURISMO						
N 210656 002	10414748	Apr 13, 2036	DS DP		ODE-224	Nov 21, 2025
	11168066	Apr 13, 2036	U-3254			
	8148401	Jan 30, 2031	DS DP			
	8431597	Jun 29, 2028	DP			
GLECAPREVIR; PIBRENTASVIR - MAVYRET						
N 209394 001	10028937	Jun 10, 2030	U-2141		ODE-232	Apr 30, 2026
	10028937	Jun 10, 2030	U-3237		ODE-233	Apr 30, 2026
	10028937*PED	Dec 10, 2030			ODE-372	Jun 10, 2028
	10039754	Jun 10, 2030	U-2141		PED	Oct 30, 2026
	10039754	Jun 10, 2030	U-3237		PED	Oct 30, 2026
	10039754*PED	Dec 10, 2030			PED	Dec 10, 2028
	10286029	Mar 14, 2034	U-3237			
	10286029*PED	Sep 14, 2034				
	11246866	Jun 24, 2036	DP			
	11246866*PED	Dec 24, 2036				
	11484534	Mar 14, 2034	U-3237			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLECAPREVIR; PIBRENTASVIR - MAVYRET								
N 209394	001		11484534*PED	Sep 14, 2034				
			8648037	Jan 19, 2032	DS DP U-2141			
			8648037	Jan 19, 2032	DS DP U-3237			
			8648037*PED	Jul 19, 2032				
			8937150	May 18, 2032	DS DP			
			8937150*PED	Nov 18, 2032				
			9321807	Jun 05, 2035	DS			
			9321807*PED	Dec 05, 2035				
			9586978	Nov 06, 2030	U-2141			
			9586978	Nov 06, 2030	U-3237			
			9586978*PED	May 06, 2031				
			RE48923	May 08, 2035	DS			
			RE48923*PED	Nov 08, 2035				
GLECAPREVIR; PIBRENTASVIR - MAVYRET								
N 215110	001		10028937	Jun 10, 2030	U-3238		ODE-372	Jun 10, 2028
			10028937*PED	Dec 10, 2030			PED	Dec 10, 2028
			10039754	Jun 10, 2030	U-3238			
			10039754*PED	Dec 10, 2030				
			10286029	Mar 14, 2034	U-3238			
			10286029*PED	Sep 14, 2034				
			8648037	Jan 19, 2032	DS DP U-3238			
			8648037*PED	Jul 19, 2032				
			8937150	May 18, 2032	DS DP			
			8937150*PED	Nov 18, 2032				
			9321807	Jun 05, 2035	DS DP			
			9321807*PED	Dec 05, 2035				
			9586978	Nov 06, 2030	U-3238			
			9586978*PED	May 06, 2031				
			RE48923	May 08, 2035	DS			
			RE48923*PED	Nov 08, 2035				
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT								
N 021925	001		7700128	Jan 30, 2027	DP			
			8071130	Jun 08, 2028	DP			
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT								
N 021925	002		7700128	Jan 30, 2027	DP			
			8071130	Jun 08, 2028	DP			
GLIPIZIDE - GLIPIZIDE								
A 214874	001						CGT	Apr 15, 2024
GLUCAGON - BAQSIMI								
N 210134	001		10213487	Feb 16, 2036	DP U-2604			
			10765602	Sep 23, 2039	DP			
			10894133	Jan 03, 2038	DP			
GLUCAGON - GVOKE PFS								
N 212097	001		11590205	Apr 22, 2036	DP U-2742			
			9649364	Apr 22, 2036	DP U-2742			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLUCAGON - GVOKE PFS								
N 212097	002		11590205	Apr 22, 2036	DP U-2742			
			9649364	Apr 22, 2036	DP U-2742			
GLUCAGON - GVOKE HYPOPEN								
N 212097	003		11590205	Apr 22, 2036	DP U-2742			
			9649364	Apr 22, 2036	DP U-2742			
GLUCAGON - GVOKE HYPOPEN								
N 212097	004		11590205	Apr 22, 2036	DP U-2742			
			9649364	Apr 22, 2036	DP U-2742			
GLUCAGON - GVOKE KIT								
N 212097	005		11590205	Apr 22, 2036	DP U-2742			
GLYCEROL PHENYLBUTYRATE - RAVICTI								
N 203284	001		10045958	Sep 22, 2030	U-1816		ODE-157	Apr 28, 2024
			10045959	Sep 22, 2030	U-1816			
			10183002	Sep 22, 2030	U-1816			
			10183003	Sep 22, 2030	U-1816			
			10183004	Sep 22, 2030	U-1816			
			10183005	Sep 22, 2030	U-1816			
			10183006	Sep 22, 2030	U-1816			
			10668040	Sep 22, 2030	U-1816			
			8404215	Mar 09, 2032	U-1383			
			8642012	Sep 22, 2030	U-1383			
			9095559	Mar 09, 2032	U-1383			
			9254278	Mar 09, 2032	U-1816			
			9326966	Mar 09, 2032	U-1816			
			9561197	Sep 22, 2030	U-1383			
			9962359	Sep 22, 2030	U-1816			
			9999608	Sep 22, 2030	U-1816			
GLYCOPYRROLATE - SEEBRI								
N 207923	001		8182838	Oct 20, 2028	DP			
			8479730	Oct 11, 2028	DP			
GLYCOPYRROLATE - LONHALA MAGNAIR KIT								
N 208437	001		10376661	Sep 14, 2035	DP			
			10688518	Nov 12, 2036	DP			
			10744277	Dec 07, 2036	DP U-2941			
			10940110	Feb 26, 2029	DP U-1773			
			11278683	Aug 16, 2026	DP			
			7458372	Nov 18, 2024	DP			
			7931212	Nov 25, 2025	DP			
			9168556	Sep 01, 2032	DP			
			9265900	Dec 07, 2028	DP			
			9604018	May 16, 2033	DP			
			9789270	Oct 30, 2030	DP			
GLYCOPYRROLATE; INDACATEROL MALEATE - UTIBRON								
N 207930	001		6878721	Feb 25, 2025	DS DP U-1773			
			8182838	Oct 20, 2028	DP			
			8479730	Oct 11, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO						
N 216903 001	10456354	Oct 25, 2038	DP			
	11110054	Oct 25, 2038	DP			
GLYCOPYRRONIUM TOSYLATE - QBREXZA						
N 210361 001	10004717	Feb 28, 2033	DP U-2398			
	10052267	Oct 17, 2028	DP U-2398			
	10543192	Feb 28, 2033	DP			
	10548875	Feb 28, 2033	DS DP U-2398			
	8618160	Dec 10, 2029	DP U-2398			
	8859610	Feb 28, 2033	DP U-2398			
	9259414	Feb 28, 2033	U-2398			
	9744105	Jul 18, 2030	DP U-2398			
GOLODIRSEN - VYONDYS 53						
N 211970 001	10227590	Jun 28, 2025	DS DP		NCE	Dec 12, 2024
	10266827	Jun 28, 2025	U-2675		ODE-280	Dec 12, 2026
	10421966	Jun 28, 2025	DS DP			
	10968450	Jun 28, 2025	DS DP			
	10995337	Jun 28, 2025	DP U-2675			
	9024007	Jun 28, 2025	DS DP			
	9994851	Jun 28, 2025	DS DP			
	RE47691	Jun 28, 2025	DP			
GRANISETRON - SANCUSO						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
GRANISETRON - SUSTOL						
N 022445 001	10357570	Sep 28, 2024	U-2253			
	8252304	Sep 28, 2024	DP			
	8252305	Sep 28, 2024	U-1891			
	8715710	Sep 28, 2024	DP			
	9913910	Sep 28, 2024	U-2253			
GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON						
N 205474 001	10105324	Nov 13, 2035	DS DP U-2023			
	9549907	Nov 13, 2035	DS DP U-2023			
	9808431	Nov 13, 2035	DS DP U-2023			
HALOBETASOL PROPIONATE - ULTRAVATE						
N 208183 001	8962028	Jun 19, 2033	DP U-1775			
HALOBETASOL PROPIONATE - BRYHALI						
N 209355 001	10478502	Nov 02, 2031	DP U-2625			
	11839656	Nov 02, 2031	U-2625			
	8809307	Nov 02, 2031	DP			
HALOBETASOL PROPIONATE - LEXETTE						
N 210566 001	10857159	Nov 30, 2036	DP		NPP	Aug 18, 2024
	10857159*PED	May 30, 2037				
	11020407	Nov 30, 2036	DP U-3143			
HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII						
N 209354 001	10251895	Jun 06, 2036	DP			
	10426787	Jun 06, 2036	U-2625			
	10478502	Nov 02, 2031	DP U-2625			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII						
N 209354 001	11648256	Jun 06, 2036	DP		U-2625	
	11679115	Jun 06, 2036	DP		U-2625	
	11839656	Nov 02, 2031			U-2625	
	8809307	Nov 02, 2031	DP			
HEPARIN SODIUM; TAUROLIDINE - DEFENCATH						
N 214520 001	11738120	Apr 15, 2042	DS DP			
	7696182	May 16, 2025	DS DP		U-3774	
	8541393	Nov 02, 2024	DS DP		U-3774	
	9339036	Nov 02, 2024	DS DP			
HEPARIN SODIUM; TAUROLIDINE - DEFENCATH						
N 214520 002	11738120	Apr 15, 2042	DS DP			
	7696182	May 16, 2025	DS DP		U-3774	
	8541393	Nov 02, 2024	DS DP		U-3774	
	9339036	Nov 02, 2024	DS DP			
HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT						
N 022555 001	10556010	Dec 19, 2036			U-2250	
	11235168	Jan 04, 2038			U-2250	
	11311620	Dec 19, 2036			U-2250	
HISTRELIN ACETATE - SUPPRELIN LA						
N 022058 001	8062652	Jun 16, 2026			U-1197	
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 001	10028946	Jul 25, 2033			U-1810	
	10092559	Sep 12, 2034			U-55	
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033			U-1810	
	10722511	Jul 25, 2033			U-1810	
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033			U-1810	
	9326982	Jul 25, 2033			U-1810	
	9333201	Jul 25, 2033			U-1810	
	9339499	Jul 25, 2033			U-1810	
	9421200	Jul 25, 2033			U-1810	
	9433619	Jul 25, 2033			U-1810	
	9452163	Sep 12, 2034			U-55	
	9486451	Sep 12, 2034			U-55	
	9610286	Jul 25, 2033			U-1810	
	9713611	Sep 12, 2034	DP		U-55	
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 002	10028946	Jul 25, 2033			U-1810	
	10092559	Sep 12, 2034			U-55	
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033			U-1810	
	10722511	Jul 25, 2033			U-1810	
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033			U-1810	
	9326982	Jul 25, 2033			U-1810	
	9333201	Jul 25, 2033			U-1810	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 002	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 003	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 004	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 005	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 005	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 006	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	11844865	Feb 13, 2025	DP U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 002	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	11844865	Feb 13, 2025	DP U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	11844865	Feb 13, 2025	DP U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	11844865	Feb 13, 2025	DP U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 004	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027			U-1556	
	9492391	Aug 24, 2027			U-1556	
	9545380	Aug 24, 2027			U-1556	
	9572779	Dec 21, 2031	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027			U-1556	
	11844865	Feb 13, 2025	DP		U-1556	
	8808740	Dec 21, 2031	DP		U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027			U-1556	
	9492391	Aug 24, 2027			U-1556	
	9545380	Aug 24, 2027			U-1556	
	9572779	Dec 21, 2031	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027			U-1556	
	11844865	Feb 13, 2025	DP		U-1556	
	8808740	Dec 21, 2031	DP		U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027			U-1556	
	9492391	Aug 24, 2027			U-1556	
	9545380	Aug 24, 2027			U-1556	
	9572779	Dec 21, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 006	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027			U-1556	
	11844865	Feb 13, 2025	DP		U-1556	
	8808740	Dec 21, 2031	DP		U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027			U-1556	
	9492391	Aug 24, 2027			U-1556	
	9545380	Aug 24, 2027			U-1556	
	9572779	Dec 21, 2031	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCORTISONE - ALKINDI SPRINKLE						
N 213876 001	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
HYDROCORTISONE - ALKINDI SPRINKLE						
N 213876 002	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
HYDROCORTISONE - ALKINDI SPRINKLE						
N 213876 003	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
HYDROCORTISONE - ALKINDI SPRINKLE						
N 213876 004	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
HYDROCORTISONE BUTYRATE - LOCOID						
N 022076 001	7378405	Dec 19, 2026	DP			
	7981877	Jan 23, 2025	DP			
HYDROGEN PEROXIDE - ESKATA						
N 209305 001	10098910	Apr 21, 2035	DP U-2205			
	10493103	Apr 21, 2035	DP			
	10729720	Apr 21, 2035	DP			
	9675639	Jul 04, 2035	DP U-2205			
	9980983	Apr 21, 2035	U-2205			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP						
N 019034 001	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP						
N 019034 002	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 003	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 004	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 005	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 006	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 007	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 007	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROXYUREA - SIKLOS						
N 208843 001					ODE-177	Dec 21, 2024
HYDROXYUREA - SIKLOS						
N 208843 002					ODE-177	Dec 21, 2024
IBREXAFUNGERP CITRATE - BREXAFEMME						
N 214900 001	10174074	Jan 19, 2035	DS DP		I-903	Nov 30, 2025
	10370406	Jan 19, 2035	U-3159		NCE	Jun 01, 2026
	10927142	Jan 19, 2035	DS		GAIN	Jun 01, 2031
	11534433	Jun 10, 2039	U-3159			
	11534433	Jun 10, 2039	U-3508			
	8188085	Aug 28, 2030	DS DP U-3159			
IBRUTINIB - IMBRUVICA						
N 205552 001	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		ODE-152	Aug 02, 2024
	10004746	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10004746	Jun 03, 2031	U-2242		PED	Feb 02, 2025
	10004746*PED	Dec 03, 2031			PED	Feb 24, 2026
	10016435	Jun 03, 2031	U-1650		PED	Feb 24, 2030
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10294231	Jun 03, 2033	DP			
	10294231*PED	Dec 03, 2033				
	10294232	Jun 03, 2033	DP			
	10294232*PED	Dec 03, 2033				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 001	10752634	Jun 03, 2033	DP			
	10752634*PED	Dec 03, 2033				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	11672803	Jun 03, 2031			U-1684	
	11672803	Jun 03, 2031			U-1946	
	11672803	Jun 03, 2031			U-2241	
	11672803	Jun 03, 2031			U-2242	
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026			U-1456	
	8476284	Dec 28, 2026			U-1650	
	8476284	Dec 28, 2026			U-1946	
	8476284	Dec 28, 2026			U-1947	
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026			U-1456	
	8497277	Dec 28, 2026			U-1491	
	8497277	Dec 28, 2026			U-1650	
	8497277	Dec 28, 2026			U-1946	
	8497277	Dec 28, 2026			U-1947	
	8497277	Dec 28, 2026			U-2241	
	8497277	Dec 28, 2026			U-2242	
	8497277	Dec 28, 2026			U-3422	
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027			U-1491	
	8563563	Apr 26, 2027			U-1650	
	8563563	Apr 26, 2027			U-1946	
	8563563	Apr 26, 2027			U-2219	
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026			U-1491	
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031			U-1456	
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026			U-1456	
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	
	8952015	Dec 28, 2026			U-1947	
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 001	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1745			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS DP			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS DP			
	9296753*PED	Apr 30, 2034				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9540382*PED	Feb 18, 2034				
	9713617	Jun 03, 2033	DP			
	9713617*PED	Dec 03, 2033				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2150			
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 205552 002	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10004746	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10004746	Jun 03, 2031	U-2242		PED	Feb 24, 2026
	10004746*PED	Dec 03, 2031			PED	Feb 24, 2030
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10294231	Jun 03, 2033	DP			
	10294231*PED	Dec 03, 2033				
	10294232	Jun 03, 2033	DP			
	10294232*PED	Dec 03, 2033				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1650			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 002	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 002	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
	9713617	Jun 03, 2033	DP			
	9713617*PED	Dec 03, 2033				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 001	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10004746	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10004746	Jun 03, 2031	U-2242		PED	Feb 24, 2026
	10004746*PED	Dec 03, 2031			PED	Feb 24, 2030
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 001	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034			U-2654	
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031			U-1650	
	10478439	Jun 03, 2031			U-1684	
	10478439	Jun 03, 2031			U-1946	
	10478439	Jun 03, 2031			U-2241	
	10478439	Jun 03, 2031			U-2242	
	10478439	Jun 03, 2031			U-2665	
	10478439	Jun 03, 2031			U-3422	
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031			U-1456	
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034			U-2846	
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031			U-1491	
	10751342	Jun 03, 2031			U-1946	
	10751342	Jun 03, 2031			U-2943	
	10751342	Jun 03, 2031			U-2944	
	10751342*PED	Dec 03, 2031				
	10752634	Jun 03, 2033	DP			
	10752634*PED	Dec 03, 2033				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	11672803	Jun 03, 2031			U-1684	
	11672803	Jun 03, 2031			U-1946	
	11672803	Jun 03, 2031			U-2241	
	11672803	Jun 03, 2031			U-2242	
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026			U-1456	
	8476284	Dec 28, 2026			U-1650	
	8476284	Dec 28, 2026			U-1946	
	8476284	Dec 28, 2026			U-2241	
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026			U-1456	
	8497277	Dec 28, 2026			U-1491	
	8497277	Dec 28, 2026			U-1650	
	8497277	Dec 28, 2026			U-1946	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 001	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 001	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 002	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10004746	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10004746	Jun 03, 2031	U-2242		PED	Feb 24, 2026
	10004746*PED	Dec 03, 2031			PED	Feb 24, 2030
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 002	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 002	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 003	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10004746	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10004746	Jun 03, 2031	U-2242		PED	Feb 24, 2026
	10004746*PED	Dec 03, 2031			PED	Feb 24, 2030
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 003	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 003	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 004	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10004746	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10004746	Jun 03, 2031	U-2242		PED	Feb 24, 2026
	10004746*PED	Dec 03, 2031			PED	Feb 24, 2030
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 004	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034			U-2654	
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031			U-1456	
	10478439	Jun 03, 2031			U-1650	
	10478439	Jun 03, 2031			U-1684	
	10478439	Jun 03, 2031			U-1946	
	10478439	Jun 03, 2031			U-1947	
	10478439	Jun 03, 2031			U-2241	
	10478439	Jun 03, 2031			U-2242	
	10478439	Jun 03, 2031			U-2665	
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031			U-1456	
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034			U-2846	
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031			U-1491	
	10751342	Jun 03, 2031			U-1946	
	10751342	Jun 03, 2031			U-2943	
	10751342	Jun 03, 2031			U-2944	
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026			U-1456	
	8476284	Dec 28, 2026			U-1650	
	8476284	Dec 28, 2026			U-1946	
	8476284	Dec 28, 2026			U-1947	
	8476284	Dec 28, 2026			U-2241	
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026			U-1456	
	8497277	Dec 28, 2026			U-1491	
	8497277	Dec 28, 2026			U-1650	
	8497277	Dec 28, 2026			U-1946	
	8497277	Dec 28, 2026			U-1947	
	8497277	Dec 28, 2026			U-2241	
	8497277	Dec 28, 2026			U-2242	
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027			U-1491	
	8563563	Apr 26, 2027			U-1650	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 004	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 004	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 217003 001	10106548	Jun 03, 2033	DS DP		NP	Aug 24, 2025
	10106548*PED	Dec 03, 2033			ODE-405	Aug 24, 2029
	10125140	Jun 03, 2033	DS DP		PED	Feb 24, 2026
	10125140*PED	Dec 03, 2033			PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
IBUPROFEN - CHILDREN'S ADVIL-FLAVORED						
N 020589 002	10238640	May 25, 2024	DP			
IBUPROFEN - CALDOLOR						
N 022348 001					M-128	Nov 19, 2024
IBUPROFEN - CALDOLOR						
N 022348 002	11806400	Mar 16, 2032	U-3746		M-128	Nov 19, 2024
	8735452	Sep 30, 2029	U-981			
	8871810	Sep 30, 2029	U-981			
	9012508	Sep 14, 2030	U-981			
	9114068	Sep 30, 2029	U-1735			
	9138404	Sep 30, 2029	U-1756			
	9295639	Sep 30, 2029	U-1756			
	9649284	Sep 30, 2029	U-2018			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBUPROFEN - CALDOLOR						
N 022348 003	11806400	Mar 16, 2032	U-3746		M-128	Nov 19, 2024
	8735452	Sep 30, 2029	U-981			
	8871810	Sep 30, 2029	U-981			
	9012508	Sep 14, 2030	U-981			
	9072661	Mar 16, 2032	U-2264			
	9072710	Mar 16, 2032	U-2266			
IBUPROFEN LYSINE - NEOPROFEN						
N 021903 001	8415337	Mar 02, 2032	DS DP			
ICOSAPENT ETHYL - VASCEPA						
N 202057 001	10010517	Apr 29, 2030	U-2690			
	10265287	Apr 29, 2030	U-2700			
	10278935	Jun 28, 2033	U-2701			
	10278936	Jun 28, 2033	U-2702			
	10278937	Jun 28, 2033	U-2703			
	10383840	Jun 28, 2033	U-2704			
	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	10786478	Jun 28, 2033	U-2959			
	10786478	Jun 28, 2033	U-2960			
	10792267	Apr 29, 2030	U-2961			
	10792270	Jun 28, 2033	U-2962			
	10842766	Apr 29, 2030	U-2997			
	10842768	Jun 15, 2030	U-2688			
	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
	11103477	Apr 29, 2030	U-3209			
	11116742	Jun 28, 2033	U-3221			
	11154526	Apr 29, 2030	U-3240			
	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
	11369582	Jun 28, 2033	U-2841			
	11717504	Apr 29, 2030	U-3669			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8410086	Jun 15, 2030	U-2688			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ICOSAPENT ETHYL - VASCEPA						
N 202057 001	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8454994	Apr 29, 2030	U-2689			
	8455472	Jun 15, 2030	U-2690			
	8501225	Apr 29, 2030	U-1287			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1478			
	8617593	Apr 29, 2030	U-2691			
	8617594	Apr 29, 2030	U-1287			
	8618166	Apr 29, 2030	U-2689			
	8623406	Apr 29, 2030	U-1478			
	8623406	Apr 29, 2030	U-2692			
	8642077	Apr 29, 2030	U-2693			
	8669245	Jun 15, 2030	U-2694			
	8680144	Feb 09, 2030	U-2695			
	8691871	Apr 29, 2030	U-2689			
	8703185	Apr 29, 2030	U-2691			
	8709475	Apr 29, 2030	U-2689			
	8710041	Jun 15, 2030	U-2690			
	9198892	Sep 25, 2027	U-2706			
	9603826	Jun 28, 2033	U-2696			
	9610272	Jun 28, 2033	U-2697			
	9623001	Jun 28, 2033	U-2698			
	9693984	Jun 28, 2033	U-2697			
	9693985	Jun 28, 2033	U-2696			
	9693986	Jun 28, 2033	U-2698			
	9700537	May 31, 2027	U-2707			
	9918954	Jun 28, 2033	U-2699			
ICOSAPENT ETHYL - VASCEPA						
N 202057 002	10010517	Apr 29, 2030	U-2690			
	10265287	Apr 29, 2030	U-2700			
	10278935	Jun 28, 2033	U-2701			
	10278936	Jun 28, 2033	U-2702			
	10278937	Jun 28, 2033	U-2703			
	10383840	Jun 28, 2033	U-2704			
	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	10786478	Jun 28, 2033	U-2959			
	10786478	Jun 28, 2033	U-2960			
	10792267	Apr 29, 2030	U-2961			
	10792270	Jun 28, 2033	U-2962			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ICOSAPENT ETHYL - VASCEPA						
N 202057 002	10842766	Apr 29, 2030	U-2997			
	10842768	Jun 15, 2030	U-2688			
	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
	11103477	Apr 29, 2030	U-3209			
	11116742	Jun 28, 2033	U-3221			
	11154526	Apr 29, 2030	U-3240			
	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
	11369582	Jun 28, 2033	U-2841			
	11717504	Apr 29, 2030	U-3669			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8410086	Jun 15, 2030	U-2688			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8454994	Apr 29, 2030	U-2689			
	8501225	Apr 29, 2030	U-1287			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-2691			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-2692			
	8642077	Apr 29, 2030	U-2693			
	8669245	Jun 15, 2030	U-2694			
	8680144	Feb 09, 2030	U-2695			
	8691871	Apr 29, 2030	U-2689			
	8703185	Apr 29, 2030	U-2691			
	8709475	Apr 29, 2030	U-2689			
	8710041	Jun 15, 2030	U-2690			
	9198892	Sep 25, 2027	U-2706			
	9603826	Jun 28, 2033	U-2696			
	9610272	Jun 28, 2033	U-2697			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ICOSAPENT ETHYL - VASCEPA						
N 202057 002	9623001	Jun 28, 2033	U-2698			
	9693984	Jun 28, 2033	U-2697			
	9693985	Jun 28, 2033	U-2696			
	9693986	Jun 28, 2033	U-2698			
	9700537	May 31, 2027	U-2707			
	9918954	Jun 28, 2033	U-2699			
IDELALISIB - ZYDELIG						
N 205858 001	10730879	Mar 05, 2033	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
	RE44638	Aug 05, 2025	DS DP			
IDELALISIB - ZYDELIG						
N 205858 002	10730879	Mar 05, 2033	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
	RE44638	Aug 05, 2025	DS DP			
ILOPERIDONE - FANAPT						
N 022192 001	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 002	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT						
N 022192 003	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 004	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 005	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 006	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 007	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT							
N 022192	007	9157121	Apr 05, 2030	U-1674			
IMIQUIMOD - ALDARA							
N 020723	001	7696159	Apr 01, 2024	DS U-1047			
		7696159	Apr 01, 2024	DS U-1048			
IMIQUIMOD - ZYCLARA							
N 022483	001	10238644	Dec 11, 2029	U-68			
		10238645	Aug 18, 2029	U-1455			
		10238645	Aug 18, 2029	U-172			
		10918635	Apr 30, 2030	U-1455			
		10918635	Apr 30, 2030	U-172			
		11202752	Apr 30, 2030	U-1455			
		11202752	Apr 30, 2030	U-172			
		8236816	Dec 11, 2029	U-68			
		8299109	Dec 11, 2029	U-68			
		8598196	Aug 18, 2029	U-1455			
		8598196	Aug 18, 2029	U-172			
IMIQUIMOD - ZYCLARA							
N 022483	002	11318130	Dec 11, 2029	U-68			
		8222270	Dec 11, 2029	U-68			
INCLISIRAN SODIUM - LEQVIO							
N 214012	001	10125369	Aug 18, 2034	DS DP U-3652		NCE	Dec 22, 2026
		10131907	Aug 24, 2028	DS DP U-3652			
		10273477	Mar 08, 2024	DS			
		10669544	Mar 08, 2024	DS			
		10806791	Dec 04, 2028	DS			
		10851377	Aug 25, 2036	U-3652			
		11530408	May 18, 2024	DS			
		8106022	Dec 12, 2029	DS DP U-3652			
		8222222	Dec 29, 2027	U-3652			
		8809292	May 10, 2027	DS DP U-3652			
		8828956	Dec 04, 2028	DS DP U-3652			
		9370582	Dec 04, 2028	DS DP U-3652			
		9708615	Mar 08, 2024	DS			
INDACATEROL MALEATE - ARCAPTA NEOHALER							
N 022383	001	6878721	Feb 25, 2025	DS DP U-1168			
		8479730	Oct 11, 2028	DP			
INDIGOTINDISULFONATE SODIUM - BLUDIGO							
N 216264	001	10927258	Dec 23, 2037	DS		NCE	Jul 08, 2027
		11499050	Dec 23, 2037	DS			
		11845867	Nov 25, 2036	DS			
INDOCYANINE GREEN - SPY AGENT GREEN KIT							
N 211580	001	10631746	Aug 04, 2035	DP U-2815		I-911	Jun 05, 2026
		11712320	Jul 14, 2039	DP			
		8185176	Jun 04, 2028	U-2462			
		8406860	Apr 09, 2029	U-2463			
		8647605	Feb 11, 2029	U-2464			
		8647605	Feb 11, 2029	U-2468			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INDOCYANINE GREEN - SPY AGENT GREEN KIT						
N 211580 001	9421280	Nov 24, 2025	U-2466			
	9421280	Nov 24, 2025	U-2467			
INDOMETHACIN - INDOMETHACIN						
A 216184 001					CGT	Jan 30, 2024
INDOMETHACIN - TIVORBEX						
N 204768 001	8734847	Apr 23, 2030	DP			
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
INDOMETHACIN - TIVORBEX						
N 204768 002	8734847	Apr 23, 2030	DP			
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
INFIGRATINIB PHOSPHATE - TRUSELTIQ						
N 214622 001	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	11160804	Dec 11, 2034	DP		ODE-353	May 28, 2028
	8552002	Aug 25, 2029	DS DP			
	9067896	Aug 06, 2028	DS			
INFIGRATINIB PHOSPHATE - TRUSELTIQ						
N 214622 002	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	11160804	Dec 11, 2034	DP		ODE-353	May 28, 2028
	8552002	Aug 25, 2029	DS DP			
	9067896	Aug 06, 2028	DS			
INGENOL MEBUTATE - PICATO						
N 202833 001	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
	9789078	May 15, 2033	U-2138			
	9820959	Dec 18, 2026	DP U-1440			
	9833428	Dec 18, 2026	DP			
	9833429	Dec 18, 2026	DP			
	9861603	Dec 18, 2026	U-1440			
INGENOL MEBUTATE - PICATO						
N 202833 002	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
	9820959	Dec 18, 2026	DP U-1440			
	9833428	Dec 18, 2026	DP			
	9833429	Dec 18, 2026	DP			
	9861603	Dec 18, 2026	U-1440			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INGENOL MEBUTATE - PICATO						
N 202833 002	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
	9820959	Dec 18, 2026	DP U-1440			
	9833428	Dec 18, 2026	DP			
	9833429	Dec 18, 2026	DP			
	9861603	Dec 18, 2026	U-1440			
INOTERSEN SODIUM - TEGSEDI						
N 211172 001	8101743	Apr 01, 2025	DS DP		ODE-212	Oct 05, 2025
	8697860	Apr 29, 2031	DP			
	9061044	Apr 29, 2031	DS			
	9399774	Apr 29, 2031	U-2430			
IOBENGUANE I-131 - AZEDRA						
N 209607 001					ODE-204	Jul 30, 2025
IPRATROPIUM BROMIDE - ATROVENT HFA						
N 021527 001	8474447	Jan 17, 2030	DP			
IPTACOPAN HYDROCHLORIDE - FABHALTA						
N 218276 001	11603363	May 25, 2041	DS DP			
	9682968	Jul 14, 2034	DS DP			
IRINOTECAN HYDROCHLORIDE - ONIVYDE						
N 207793 001	10456360	Oct 15, 2036	DP			
	10722508	May 02, 2025	DS DP			
	10980795	Jun 12, 2033	U-1848			
	10993914	Oct 15, 2036	DP			
	11369597	Jun 12, 2033	U-1848			
	8147867	Aug 29, 2028	DS DP			
	8329213	Jan 06, 2027	DS DP			
	8703181	May 02, 2025	U-1434			
	8992970	May 02, 2025	DS DP			
	9339497	Jun 12, 2033	U-1848			
	9364473	Jun 12, 2033	U-1856			
	9452162	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1848			
	9492442	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1917			
	9717724	Jun 12, 2033	U-1848			
	9717724	Jun 12, 2033	U-2091			
	9724303	May 02, 2025	DS DP			
	9730891	May 02, 2025	U-1848			
	9782349	May 02, 2025	DS DP			
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207500 001	10206879	Sep 14, 2027	DP		NCE	Mar 06, 2020
	10206879*PED	Mar 14, 2028			ODE-305	Mar 06, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207500 001	10603280	Sep 14, 2027	DP		ODE-90	Mar 06, 2022
	10603280*PED	Mar 14, 2028			PED	Sep 06, 2020
	6812238	Oct 31, 2025	DS		PED	Sep 06, 2022
	6812238*PED	May 01, 2026			PED	Sep 06, 2022
					GAIN	Sep 06, 2025
					GAIN	Sep 06, 2027
					GAIN	Sep 06, 2027
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207500 002	10206879	Sep 14, 2027	DP		NCE	Mar 06, 2020
	10206879*PED	Mar 14, 2028			ODE*	Mar 06, 2022
	10603280	Sep 14, 2027	DP		PED	Sep 06, 2020
	10603280*PED	Mar 14, 2028			PED	Sep 06, 2022
	6812238	Oct 31, 2025	DS		GAIN	Sep 06, 2025
	6812238*PED	May 01, 2026			GAIN	Sep 06, 2027
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207501 001	6812238	Oct 31, 2025	DS		NCE	Mar 06, 2020
	6812238*PED	May 01, 2026			ODE-305	Mar 06, 2022
					ODE-90	Mar 06, 2022
					PED	Sep 06, 2020
					PED	Sep 06, 2022
					PED	Sep 06, 2022
					GAIN	Sep 06, 2025
					GAIN	Sep 06, 2027
					GAIN	Sep 06, 2027
ISOPROPYL ALCOHOL - ZURAGARD						
N 210872 001	10688291	Dec 20, 2034	DP U-1397		M-268	Jun 24, 2024
	8226971	May 06, 2025	DP			
	8389583	Aug 09, 2029	U-1397			
	8703828	May 23, 2028	DP			
	9011897	Feb 08, 2025	DP			
	9629368	May 23, 2028	U-1397			
	9844654	Apr 24, 2036	DP U-1397			
ISOTRETINOIN - ABSORICA LD						
N 211913 001	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 002	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 003	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 004	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 005	9700535	Aug 04, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ISOTRETINOIN - ABSORICA LD						
N 211913 005	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 006	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISTRADEFYLLINE - NOURIANZ						
N 022075 001	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2028	DP U-2623			
	8318201	Sep 05, 2027	DP			
ISTRADEFYLLINE - NOURIANZ						
N 022075 002	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2028	DP U-2623			
	8318201	Sep 05, 2027	DP			
ITRACONAZOLE - ONMEL						
N 022484 001	8486456	Oct 03, 2028	DP U-1054			
ITRACONAZOLE - TOLSURA						
N 208901 001	10463740	Jun 21, 2033	DP U-2453			
	10806792	Jun 21, 2033	DP			
	8921374	Jun 21, 2033	DP			
	9272046	Jun 21, 2033	DP			
	9713642	Jun 21, 2033	U-2453			
IVABRADINE - CORLANOR						
N 209964 001	7361649	Feb 22, 2026	DS DP U-1694		ODE-234	Apr 22, 2026
	7361650	Feb 22, 2026	DS DP U-1694		PED	Oct 22, 2026
	7867996	Dec 12, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 001	7361649	Feb 22, 2026	DS DP U-1694			
	7361649*PED	Aug 22, 2026				
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Dec 12, 2026	DS DP U-1694			
	7867996*PED	Jun 12, 2027				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 002	7361649	Feb 22, 2026	DS DP U-1694			
	7361649*PED	Aug 22, 2026				
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Dec 12, 2026	DS DP U-1694			
	7867996*PED	Jun 12, 2027				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
IVACAFTOR - KALYDECO						
N 203188 001	10646481	Aug 13, 2029	DP		ODE-189	Jul 31, 2024
	11564916	Aug 13, 2029	U-3530		ODE-190	May 17, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 203188 001	7495103	May 20, 2027	DS DP		ODE-199	Aug 15, 2025
	8324242	Aug 05, 2027	U-1311		ODE-338	Dec 21, 2027
	8324242	Aug 05, 2027	U-1906			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8754224	Dec 28, 2026	DS DP			
	9670163	Dec 28, 2026	DP U-1311			
IVACAFTOR - KALYDECO						
N 207925 001	10272046	Feb 27, 2033	DP U-2531		ODE-189	Jul 31, 2024
	10646481	Aug 13, 2029	DP		ODE-190	May 17, 2024
	11147770	Feb 27, 2033	DP U-3339		ODE-199	Aug 15, 2025
	11564916	Aug 13, 2029	U-3528		ODE-236	Apr 29, 2026
	11752106	Feb 27, 2033	DP U-3697		ODE-338	Dec 21, 2027
	7495103	May 20, 2027	DS DP		ODE-435	May 03, 2030
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
IVACAFTOR - KALYDECO						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		ODE-189	Jul 31, 2024
	10646481	Aug 13, 2029	DP		ODE-190	May 17, 2024
	11147770	Feb 27, 2033	DP U-3339		ODE-199	Aug 15, 2025
	11564916	Aug 13, 2029	U-3528		ODE-236	Apr 29, 2026
	11752106	Feb 27, 2033	DP U-3697		ODE-338	Dec 21, 2027
	7495103	May 20, 2027	DS DP		ODE-435	May 03, 2030
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		ODE-189	Jul 31, 2024
	10646481	Aug 13, 2029	DP		ODE-190	May 17, 2024
	11147770	Feb 27, 2033	DP U-3339		ODE-199	Aug 15, 2025
	11564916	Aug 13, 2029	U-3528		ODE-236	Apr 29, 2026
	11752106	Feb 27, 2033	DP U-3697		ODE-338	Dec 21, 2027
	7495103	May 20, 2027	DS DP		ODE-435	May 03, 2030
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
IVACAFTOR - KALYDECO						
N 207925 003	10272046	Feb 27, 2033	DP U-2967		ODE-189	Jul 31, 2024
	10646481	Aug 13, 2029	DP		ODE-190	May 17, 2024
	11147770	Feb 27, 2033	DP U-3339		ODE-199	Aug 15, 2025
	11564916	Aug 13, 2029	U-3528		ODE-236	Apr 29, 2026
	11752106	Feb 27, 2033	DP U-3697		ODE-338	Dec 21, 2027
	7495103	May 20, 2027	DS DP		ODE-435	May 03, 2030
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2963			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2964			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2965			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2966			
IVACAFTOR - KALYDECO						
N 207925 004	10272046	Feb 27, 2033	DP U-3605		NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	11147770	Feb 27, 2033	DP U-3604			
	11564916	Aug 13, 2029	U-3603			
	11752106	Feb 27, 2033	DP U-3697			
	7495103	May 20, 2027	DS DP			
	8324242	Aug 05, 2027	U-3609			
	8354427	Jul 06, 2026	U-3608			
	8410274	Dec 28, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 004	8629162	Jun 24, 2025	U-3607			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3606			
IVACAFTOR - KALYDECO						
N 207925 005	10272046	Feb 27, 2033	DP U-3605		NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	11147770	Feb 27, 2033	DP U-3604			
	11564916	Aug 13, 2029	U-3603			
	11752106	Feb 27, 2033	DP U-3697			
	7495103	May 20, 2027	DS DP			
	8324242	Aug 05, 2027	U-3609			
	8354427	Jul 06, 2026	U-3608			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-3607			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3606			
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		ODE-173	Feb 12, 2025
	10022352	Apr 09, 2027	DP U-2573		ODE-247	Jun 21, 2026
	10058546	Jul 15, 2033	U-2399		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	10646481	Aug 13, 2029	DP			
	11564916	Aug 13, 2029	U-3527			
	11578062	Mar 25, 2031	DP U-3545			
	11639347	Apr 09, 2027	DS DP U-2569			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			
	8354427	Jul 06, 2026	U-3021			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2246			
	8598181	May 01, 2027	U-2246			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2247			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	001	8754224	Dec 28, 2026	DS DP			
		9012496	Jul 15, 2033	U-2248			
		9670163	Dec 28, 2026	DP U-2246			
		9931334	Dec 28, 2026	DP U-2275			
		9931334	Dec 28, 2026	DP U-2575			
		9974781	Apr 09, 2027	DP U-2318			
		9974781	Apr 09, 2027	DP U-2574			
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	002	10022352	Apr 09, 2027	DP U-2343		ODE-173	Feb 12, 2025
		10022352	Apr 09, 2027	DP U-2573		ODE-247	Jun 21, 2026
		10058546	Jul 15, 2033	U-2399		ODE-335	Dec 21, 2027
		10058546	Jul 15, 2033	U-2572			
		10058546	Jul 15, 2033	U-3022			
		10058546	Jul 15, 2033	U-3023			
		10081621	Mar 25, 2031	DP U-2420			
		10081621	Mar 25, 2031	DP U-2571			
		10081621	Mar 25, 2031	DP U-3024			
		10081621	Mar 25, 2031	DP U-3025			
		10206877	Apr 14, 2035	DP U-2498			
		10206877	Apr 14, 2035	DP U-2570			
		10206877	Apr 14, 2035	DP U-3026			
		10206877	Apr 14, 2035	DP U-3027			
		10239867	Apr 09, 2027	DS DP U-2512			
		10239867	Apr 09, 2027	DS DP U-2569			
		10646481	Aug 13, 2029	DP			
		11564916	Aug 13, 2029	U-3527			
		11578062	Mar 25, 2031	DP U-3545			
		11639347	Apr 09, 2027	DS DP U-2569			
		7495103	May 20, 2027	DS DP			
		7645789	May 01, 2027	DS DP			
		7776905	Jun 03, 2027	DS DP			
		8324242	Aug 05, 2027	U-2246			
		8354427	Jul 06, 2026	U-3021			
		8410274	Dec 28, 2026	DP			
		8415387	Nov 12, 2027	U-2246			
		8598181	May 01, 2027	U-2246			
		8623905	May 01, 2027	DS DP			
		8629162	Jun 24, 2025	U-2247			
		8754224	Dec 28, 2026	DS DP			
		9012496	Jul 15, 2033	U-2248			
		9670163	Dec 28, 2026	DP U-2246			
		9931334	Dec 28, 2026	DP U-2275			
		9931334	Dec 28, 2026	DP U-2575			
		9974781	Apr 09, 2027	DP U-2318			
		9974781	Apr 09, 2027	DP U-2574			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	001	10076513	Dec 04, 2028	DP U-2411			
		10597384	Dec 04, 2028	DS DP U-2777			
		10646481	Aug 13, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 001	11052075	Dec 04, 2028	DP U-3181			
	11564916	Aug 13, 2029	U-3529			
	7495103	May 20, 2027	DS DP			
	7973038	Nov 08, 2026	U-1973			
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1911			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8754224	Dec 28, 2026	DS DP			
	8846718	Jul 02, 2029	U-1717			
	8846718	Jul 02, 2029	U-1908			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DS DP			
	9670163	Dec 28, 2026	DP U-1911			
	9931334	Dec 28, 2026	DP U-2276			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 002	10597384	Dec 04, 2028	DS DP U-2777			
	10646481	Aug 13, 2029	DP			
	11052075	Dec 04, 2028	DP U-3181			
	11564916	Aug 13, 2029	U-3529			
	7495103	May 20, 2027	DS DP			
	7973038	Nov 08, 2026	U-1973			
	8324242	Aug 05, 2027	U-1911			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1909			
	8754224	Dec 28, 2026	DS DP			
	8846718	Jul 02, 2029	U-1908			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP U-1911			
	9931334	Dec 28, 2026	DP U-2276			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778		NPP	Sep 02, 2025
	10646481	Aug 13, 2029	DP		ODE-195	Aug 07, 2025
	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
	7495103	May 20, 2027	DS DP			
	7973038	Nov 08, 2026	U-2374			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 001	8324242	Aug 05, 2027	U-2374			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-2396			
	8741933	Nov 08, 2026	U-2374			
	8754224	Dec 28, 2026	DS DP			
	8846718	Jul 02, 2029	U-2375			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-2375			
	9192606	Sep 29, 2029	DP U-2397			
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP U-2376			
	9931334	Dec 28, 2026	DP U-2376			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778		NPP	Sep 02, 2025
	10646481	Aug 13, 2029	DP		ODE-195	Aug 07, 2025
	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
	7495103	May 20, 2027	DS DP			
	7973038	Nov 08, 2026	U-2374			
	8324242	Aug 05, 2027	U-2374			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-2396			
	8741933	Nov 08, 2026	U-2374			
	8754224	Dec 28, 2026	DS DP			
	8846718	Jul 02, 2029	U-2375			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-2375			
	9192606	Sep 29, 2029	DP U-2397			
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP U-2376			
	9931334	Dec 28, 2026	DP U-2376			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 003	10597384	Dec 04, 2028	DS DP U-3430		NS	Sep 02, 2025
	10646481	Aug 13, 2029	DP		ODE-408	Sep 02, 2029
	11564916	Aug 13, 2029	U-3526			
	7495103	May 20, 2027	DS DP			
	7973038	Nov 08, 2026	U-3424			
	8324242	Aug 05, 2027	U-3424			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-3426			
	8741933	Nov 08, 2026	U-3424			
	8754224	Dec 28, 2026	DS DP			
	8846718	Jul 02, 2029	U-3427			
	8993600	Dec 11, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 003	9150552	Dec 04, 2028	U-3427			
	9192606	Sep 29, 2029	DP U-3428			
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP U-3429			
	9931334	Dec 28, 2026	DP U-3429			
IVERMECTIN - SOOLANTRA						
N 206255 001	10206939	Mar 13, 2034	U-1631			
	11033565	Apr 22, 2024	DP			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
	9089587	Mar 13, 2034	U-1631			
	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
	9782425	Mar 13, 2034	U-1631			
IVOSIDENIB - TIBSOVO						
N 211192 001	10449184	Mar 13, 2035	DP		I-875	Aug 25, 2024
	10610125	Jun 21, 2030	U-2784		I-893	May 25, 2025
	10610125	Jun 21, 2030	U-2785		I-924	Oct 24, 2026
	10610125	Jun 21, 2030	U-3385		ODE-203	Jul 20, 2025
	10653710	Oct 18, 2036	U-3387		ODE-242	May 02, 2026
	10717764	Jan 18, 2033	U-3215		ODE-368	Aug 25, 2028
	10799490	Mar 13, 2035	DP U-2981		ODE-447	Oct 24, 2030
	10799490	Mar 13, 2035	DP U-2982			
	10799490	Mar 13, 2035	DP U-3384			
	10980788	Jun 07, 2039	U-3112			
	10980788	Jun 07, 2039	U-3113			
	10980788	Jun 07, 2039	U-3214			
	10980788	Jun 07, 2039	U-3383			
	10980788	Jun 07, 2039	U-3743			
	11667673	Jan 18, 2033	U-3742			
	9474779	Aug 19, 2033	DS DP U-2350			
	9474779	Aug 19, 2033	DS DP U-2533			
	9474779	Aug 19, 2033	DS DP U-2534			
	9474779	Aug 19, 2033	DS DP U-3213			
	9474779	Aug 19, 2033	DS DP U-3386			
	9474779	Aug 19, 2033	DS DP U-3742			
	9850277	Jan 18, 2033	DS DP U-2350			
	9850277	Jan 18, 2033	DS DP U-2533			
	9850277	Jan 18, 2033	DS DP U-2534			
	9850277	Jan 18, 2033	DS DP U-3213			
	9850277	Jan 18, 2033	DS DP U-3386			
	9850277	Jan 18, 2033	DS DP U-3742			
	9968595	Mar 13, 2035	DP U-2351			
	9968595	Mar 13, 2035	DP U-2533			
	9968595	Mar 13, 2035	DP U-2534			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVOSIDENIB - TIBSOVO						
N 211192 001	9968595	Mar 13, 2035	DP U-3384			
IXABEPILONE - IXEMPRA KIT						
N 022065 001	7312237	Aug 21, 2024	U-965			
IXABEPILONE - IXEMPRA KIT						
N 022065 002	7312237	Aug 21, 2024	U-965			
IXAZOMIB CITRATE - NINLARO						
N 208462 001	7442830	Nov 20, 2029	DS DP U-2434			
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-2434			
	8530694	Aug 06, 2027	DS DP U-2434			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-2434			
	9175017	Jun 16, 2029	U-2434			
	9233115	Aug 12, 2024	U-2434			
IXAZOMIB CITRATE - NINLARO						
N 208462 002	7442830	Nov 20, 2029	DS DP U-2434			
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-2434			
	8530694	Aug 06, 2027	DS DP U-2434			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-2434			
	9175017	Jun 16, 2029	U-2434			
	9233115	Aug 12, 2024	U-2434			
IXAZOMIB CITRATE - NINLARO						
N 208462 003	7442830	Nov 20, 2029	DS DP U-2434			
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-2434			
	8530694	Aug 06, 2027	DS DP U-2434			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-2434			
	9175017	Jun 16, 2029	U-2434			
	9233115	Aug 12, 2024	U-2434			
KETOROLAC TROMETHAMINE - ACULAR LS						
N 021528 001	8008338	May 24, 2027	DS DP U-1181			
	8207215	May 28, 2024	U-1251			
	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
	8541463	May 28, 2024	U-1441			
	8541463*PED	Nov 28, 2024				
	8648107	May 28, 2024	DP			
	8906950	May 28, 2024	U-1626			
	8946281	May 28, 2024	U-1662			
	9216167	May 28, 2024	U-1800			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
KETOROLAC TROMETHAMINE - ACUVAIL						
N 022427 001	7842714	Aug 15, 2029	DS DP			
	8512717	Mar 07, 2028	DP			
	8992952	Aug 05, 2024	DP			
	9192571	Mar 07, 2028	DP			
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA						
N 205388 001	8173707*PED	Jan 30, 2024				
	8586633*PED	Jan 30, 2024				
	9066856	Oct 23, 2033	DP			
	9066856*PED	Apr 23, 2034				
	9278101*PED	Jan 30, 2024				
	9399040*PED	Jan 30, 2024				
	9486406	Oct 23, 2033	DP			
	9486406*PED	Apr 23, 2034				
	9855246	Oct 23, 2033	DP			
KETOTIFEN FUMARATE - ACUVUE THERAVISION WITH KETOTIFEN						
N 022388 001	9474746	Mar 27, 2028	DP		NP	Feb 25, 2025
	9962376	Jun 27, 2030	DP			
L-GLUTAMINE - ENDARI						
N 208587 001					ODE-150	Jul 07, 2024
LACOSAMIDE - VIMPAT						
N 022253 001					D-188	Apr 28, 2026
					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022253 002					D-188	Apr 28, 2026
					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022253 003					D-188	Apr 28, 2026
					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022253 004					D-188	Apr 28, 2026
					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022254 001					D-188	Apr 28, 2026
					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022255 001					D-188	Apr 28, 2026
					NPP	Oct 14, 2024
LACOSAMIDE - MOTPOLY XR						
N 216185 001	11337943	Jun 05, 2040	DP U-3660			
LACOSAMIDE - MOTPOLY XR						
N 216185 002	11337943	Jun 05, 2040	DP U-3660			
LACOSAMIDE - MOTPOLY XR						
N 216185 003	11337943	Jun 05, 2040	DP U-3660			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LACTITOL - PIZENSY								
N 211281	001		10806743	May 12, 2037	U-1516		NCE	Feb 12, 2025
LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS								
N 206510	001		7169780*PED	Apr 03, 2024				
			7754731	Mar 11, 2029	DS DP U-1663			
			7754731*PED	Sep 11, 2029				
LAMOTRIGINE - LAMICTAL XR								
N 022115	001		8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR								
N 022115	002		8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR								
N 022115	003		8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR								
N 022115	004		8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR								
N 022115	005		8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR								
N 022115	006		8637512	Jun 14, 2028	DP			
LANREOTIDE ACETATE - SOMATULINE DEPOT								
N 022074	001						ODE-156	Sep 15, 2024
LANREOTIDE ACETATE - SOMATULINE DEPOT								
N 022074	002						ODE-156	Sep 15, 2024
LANREOTIDE ACETATE - SOMATULINE DEPOT								
N 022074	003						ODE-156	Sep 15, 2024
LANSOPRAZOLE - LANSOPRAZOLE								
N 208025	001		11077055	Apr 21, 2036	DP			
LANTHANUM CARBONATE - FOSRENOL								
N 021468	001		7381428	Aug 26, 2024	U-890			
			7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL								
N 021468	002		7381428	Aug 26, 2024	U-890			
			7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL								
N 021468	003		7381428	Aug 26, 2024	U-890			
			7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL								
N 021468	004		7381428	Aug 26, 2024	U-890			
			7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL								
N 204734	001		7465465	Aug 26, 2024	DP			
			8980327	Dec 01, 2030	DP			
			9023397	Dec 01, 2030	DP			
LANTHANUM CARBONATE - FOSRENOL								
N 204734	002		7465465	Aug 26, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LANTHANUM CARBONATE - FOSRENOL						
N 204734 002	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
LAPATINIB DITOSYLATE - TYKERB						
N 022059 001	8821927	Sep 18, 2029	DS DP			
LAROTRECTINIB SULFATE - VITRAKVI						
N 210861 001	10005783	Oct 21, 2029	U-2472		ODE-215	Nov 26, 2025
	10047097	Oct 21, 2029	U-2474		ODE-220	Nov 26, 2025
	10172861	Nov 16, 2035	DS DP		ODE-221	Nov 26, 2025
	10285993	Nov 16, 2035	U-2470			
	10774085	Oct 21, 2029	U-2470			
	10799505	Aug 15, 2036	DS DP			
	10813936	Nov 16, 2035	U-2987			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2475			
LAROTRECTINIB SULFATE - VITRAKVI						
N 210861 002	10005783	Oct 21, 2029	U-2472		ODE-215	Nov 26, 2025
	10047097	Oct 21, 2029	U-2474		ODE-220	Nov 26, 2025
	10172861	Nov 16, 2035	DS DP		ODE-221	Nov 26, 2025
	10285993	Nov 16, 2035	U-2470			
	10774085	Oct 21, 2029	U-2470			
	10799505	Aug 15, 2036	DS DP			
	10813936	Nov 16, 2035	U-2987			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2475			
LAROTRECTINIB SULFATE - VITRAKVI						
N 211710 001	10005783	Oct 21, 2029	U-2472		ODE-215	Nov 26, 2025
	10045991	Apr 04, 2037	U-2473		ODE-220	Nov 26, 2025
	10047097	Oct 21, 2029	U-2474		ODE-221	Nov 26, 2025
	10137127	Apr 04, 2037	DP			
	10172861	Nov 16, 2035	DS			
	10668072	Apr 04, 2037	DP			
	10774085	Oct 21, 2029	U-2470			
	10799505	Aug 15, 2036	DS			
	11191766	Apr 04, 2037	U-2471			
	11484535	Apr 04, 2037	U-2470			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAROTRECTINIB SULFATE - VITRAKVI						
N 211710 001	9782414	Nov 16, 2035	U-2471			
LASMIDITAN SUCCINATE - REYVOW						
N 211280 001	11053214	Dec 05, 2037	DS DP U-1719		NCE	Jan 31, 2025
	7423050	Feb 17, 2028	DS DP U-1719			
LASMIDITAN SUCCINATE - REYVOW						
N 211280 002	11053214	Dec 05, 2037	DS DP U-1719		NCE	Jan 31, 2025
	7423050	Feb 17, 2028	DS DP U-1719			
LASMIDITAN SUCCINATE - REYVOW						
N 211280 003	11053214	Dec 05, 2037	DS DP U-1719		NCE	Jan 31, 2025
	7423050	Feb 17, 2028	DS DP U-1719			
LATANOPROST - XELPROS						
N 206185 001	9539262	Oct 15, 2028	U-2400			
	9629852	Sep 12, 2029	DP			
LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN						
N 208259 001	10174017	Jan 27, 2030	DS DP U-1524			
	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Jan 27, 2030	DS DP U-1524			
	10882840	Jul 11, 2026	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
	11185538	Mar 14, 2034	DP			
	11197853	Mar 14, 2034	DP			
	11618748	Jan 27, 2030	U-1524			
	8394826	Nov 10, 2030	DS DP U-1524			
	8450344	Jul 11, 2026	DS DP U-1524			
	9096569	Jul 11, 2026	DS DP U-1524			
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP U-1524			
	9993470	Mar 14, 2034	DS DP U-1524			
LATANOPROSTENE BUNOD - VYZULTA						
N 207795 001	7273946	Oct 03, 2025	DS DP U-2144			
	7629345	Jan 05, 2025	DP U-2144			
	7910767	Jan 05, 2025	DS DP U-2144			
	8058467	Jan 05, 2025	DS U-2144			
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 001	10039779	Jan 30, 2034	DS DP U-2369		ODE*	Aug 28, 2026
	10039779	Jan 30, 2034	DS DP U-2370		ODE-136	Apr 07, 2024
	10039779*PED	Jul 30, 2034			PED	Oct 07, 2024
	10456414	Sep 14, 2032	DP			
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 001	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	DP U-1470			
	9511056*PED	Nov 12, 2030				
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 002	10039779	Jan 30, 2034	DS DP U-1470		ODE*	Apr 07, 2024
	10039779*PED	Jul 30, 2034			ODE*	Aug 28, 2026
	10456414	Sep 14, 2032	DP		PED	Oct 07, 2024
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 002	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 212477 001	10456414	Sep 14, 2032	DP		ODE-262	Aug 28, 2026
	7964580	Mar 26, 2029	DS DP U-1470		ODE-263	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-264	Aug 28, 2026
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 212477 002	10456414	Sep 14, 2032	DP		ODE-262	Aug 28, 2026
	7964580	Mar 26, 2029	DS DP U-1470		ODE-263	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-264	Aug 28, 2026
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 212477 002	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
LEFAMULIN ACETATE - XENLETA						
N 211672 001	8071643	Jan 16, 2029	DS DP		NCE	Aug 19, 2024
	8153689	Mar 19, 2028	DS DP		GAIN	Aug 19, 2029
	9120727	May 23, 2031	DS DP			
LEFAMULIN ACETATE - XENLETA						
N 211673 001	8071643	Jan 16, 2029	DS DP		NCE	Aug 19, 2024
	8153689	Mar 19, 2028	DS DP		GAIN	Aug 19, 2029
LEMBOREXANT - DAYVIGO						
N 212028 001	10188652	Oct 21, 2035	DP U-2791		M-293	Apr 20, 2026
	8268848	Sep 20, 2031	DS DP U-2791		NCE	Apr 07, 2025
LEMBOREXANT - DAYVIGO						
N 212028 002	10188652	Oct 21, 2035	DP U-2791		M-293	Apr 20, 2026
	8268848	Sep 20, 2031	DS DP U-2791		NCE	Apr 07, 2025
LENACAPAVIR SODIUM - SUNLENCA						
N 215973 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP U-3507			
LENACAPAVIR SODIUM - SUNLENCA						
N 215974 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP U-3507			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N 021880 001	7465800	Apr 27, 2027	DS DP		ODE-131	Feb 22, 2024
	7855217	Nov 24, 2024	DS DP		ODE-241	May 28, 2026
	8741929	Mar 08, 2028	U-1983		ODE-245	May 28, 2026
LENALIDOMIDE - REVLIMID						
N 021880 002	7465800	Apr 27, 2027	DS DP		ODE-131	Feb 22, 2024
	7855217	Nov 24, 2024	DS DP		ODE-241	May 28, 2026
	8741929	Mar 08, 2028	U-1983		ODE-245	May 28, 2026
LENALIDOMIDE - REVLIMID						
N 021880 003	7465800	Apr 27, 2027	DS DP		ODE-131	Feb 22, 2024
	7855217	Nov 24, 2024	DS DP		ODE-241	May 28, 2026
	8741929	Mar 08, 2028	U-1983		ODE-245	May 28, 2026
LENALIDOMIDE - REVLIMID						
N 021880 004	7465800	Apr 27, 2027	DS DP		ODE-131	Feb 22, 2024
	7855217	Nov 24, 2024	DS DP		ODE-241	May 28, 2026
	8741929	Mar 08, 2028	U-1983		ODE-245	May 28, 2026
LENALIDOMIDE - REVLIMID						
N 021880 005	7465800	Apr 27, 2027	DS DP		ODE-131	Feb 22, 2024
	7855217	Nov 24, 2024	DS DP		ODE-241	May 28, 2026
	8741929	Mar 08, 2028	U-1983		ODE-245	May 28, 2026
LENALIDOMIDE - REVLIMID						
N 021880 006	7465800	Apr 27, 2027	DS DP		ODE-131	Feb 22, 2024
	7855217	Nov 24, 2024	DS DP		ODE-241	May 28, 2026
	8741929	Mar 08, 2028	U-1983		ODE-245	May 28, 2026
LENIOLISIB PHOSPHATE - JOENJA						
N 217759 001	8653092	Feb 19, 2032	DS DP		NCE	Mar 24, 2028
					ODE-430	Mar 24, 2030
LENVATINIB MESYLATE - LENVIMA						
N 206947 001	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	11090386	Feb 23, 2036	U-3519		M-272	Dec 19, 2024
	11186547	Aug 26, 2035	DS		ODE-196	Aug 15, 2025
	7253286	Oct 24, 2025	DS DP			
	7612208	Sep 19, 2026	DS DP			
	9006256	Jul 27, 2027	U-1695			
LENVATINIB MESYLATE - LENVIMA						
N 206947 002	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	11090386	Feb 23, 2036	U-3519		M-272	Dec 19, 2024
	11186547	Aug 26, 2035	DS		ODE-196	Aug 15, 2025
	7253286	Oct 24, 2025	DS DP			
	7612208	Sep 19, 2026	DS DP			
	9006256	Jul 27, 2027	U-1695			
LESINURAD - ZURAMPIC						
N 207988 001	10183012	Nov 26, 2028	U-2311			
	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029	U-1801			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LESINURAD - ZURAMPIC						
N 207988 001	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			
	8357713	Dec 22, 2029	DP U-1801			
	8357713	Dec 22, 2029	DP U-1802			
	8357713	Dec 22, 2029	DP U-1803			
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029	U-1803			
	9216179	Aug 01, 2031	U-1806			
	9956205	Dec 28, 2031	U-2311			
LETERMOVIR - PREVYMIS						
N 209939 001	8513255	May 22, 2024	DS DP		D-189	Aug 02, 2026
	RE46791	May 22, 2024	DS DP		I-916	Jun 05, 2026
					ODE-165	Nov 08, 2024
					ODE-423	Jun 05, 2030
LETERMOVIR - PREVYMIS						
N 209939 002	8513255	May 22, 2024	DS DP		D-189	Aug 02, 2026
	RE46791	May 22, 2024	DS DP		I-916	Jun 05, 2026
					ODE-165	Nov 08, 2024
					ODE-423	Jun 05, 2030
LETERMOVIR - PREVYMIS						
N 209940 001	10603384	Feb 28, 2033	DP		D-189	Aug 02, 2026
	8513255	May 22, 2024	DS DP		I-916	Jun 05, 2026
	RE46791	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
					ODE-423	Jun 05, 2030
LETERMOVIR - PREVYMIS						
N 209940 002	10603384	Feb 28, 2033	DP		D-189	Aug 02, 2026
	8513255	May 22, 2024	DS DP		I-916	Jun 05, 2026
	RE46791	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
					ODE-423	Jun 05, 2030
LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)						
N 209935 001	10799506	Apr 14, 2036	DP		NPP	Dec 10, 2024
	8324225	Jun 17, 2028	DS DP			
	8415355	Mar 13, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-2505			
	8962630	Dec 09, 2029	U-3264			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-2505			
	9416136	Aug 20, 2029	U-3264			
	9868739	Nov 09, 2031	U-2505			
	9868739	Nov 09, 2031	U-3264			
LEUPROLIDE ACETATE - LUPRON DEPOT-PED KIT						
N 020263 009	8921326	Feb 05, 2031	DP		NS	Apr 14, 2026
	9617303	Mar 22, 2028	U-3611			
LEUPROLIDE ACETATE - LUPRON DEPOT						
N 020517 003	8921326	Feb 05, 2031	DP U-1666			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEUPROLIDE ACETATE - ELIGARD KIT								
N	021343	001	11771841	Dec 22, 2041	DS DP			
LEUPROLIDE ACETATE - ELIGARD KIT								
N	021379	001	11771841	Dec 22, 2041	DS DP			
LEUPROLIDE ACETATE - ELIGARD KIT								
N	021488	001	11771841	Dec 22, 2041	DS DP			
LEUPROLIDE ACETATE - ELIGARD KIT								
N	021731	001	11771841	Dec 22, 2041	DS DP			
LEUPROLIDE ACETATE - FENSOLVI KIT								
N	213150	001	11771841	Dec 22, 2041	DS DP			
LEUPROLIDE MESYLATE - CAMCEVI KIT								
N	211488	001	10646572	Jan 16, 2027	DP		NP	May 25, 2024
			11717555	Jan 01, 2039	DP			
			9572857	Jan 16, 2027	DP			
			9744207	Jan 16, 2027	DP			
LEVALBUTEROL TARTRATE - XOPENEX HFA								
N	021730	001	7256310	Oct 08, 2024	DS DP U-636			
LEVETIRACETAM - KEPPRA								
N	021035	001	8802142	Jun 07, 2031	DP			
			8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA								
N	021035	002	8802142	Jun 07, 2031	DP			
			8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA								
N	021035	003	8802142	Jun 07, 2031	DP			
			8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA								
N	021035	004	8802142	Jun 07, 2031	DP			
			8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA XR								
N	022285	001	7858122	Sep 17, 2028	DP			
LEVETIRACETAM - KEPPRA XR								
N	022285	002	7858122	Sep 17, 2028	DP			
LEVETIRACETAM - ELEPSIA XR								
N	204417	001	8163306	Sep 03, 2027	DP			
			8425938	Feb 22, 2026	DP			
			8431156	Oct 31, 2027	DP			
			8470367	Oct 31, 2027	DP			
			8535717	Feb 22, 2026	DP			
LEVETIRACETAM - ELEPSIA XR								
N	204417	002	8163306	Sep 03, 2027	DP			
			8425938	Feb 22, 2026	DP			
			8431156	Oct 31, 2027	DP			
			8470367	Oct 31, 2027	DP			
			8535717	Feb 22, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVETIRACETAM - SPRITAM						
N 207958 001	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
LEVETIRACETAM - SPRITAM						
N 207958 002	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
LEVETIRACETAM - SPRITAM						
N 207958 003	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
LEVETIRACETAM - SPRITAM						
N 207958 004	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR						
N 209090 001	8633194	Oct 16, 2027	DP			
LEVODOPA - INBRIJA						
N 209184 001	7182961	Feb 22, 2024	DP			
	8545878	Nov 16, 2032	DP			
	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
LEVOKETOCONAZOLE - RECORLEV						
N 214133 001	10098877	Jan 10, 2026	U-3283		ODE-385	Dec 30, 2028
	10517868	Jan 10, 2026	U-3283			
	10835530	Jan 10, 2026	U-3283			
	11020393	Mar 02, 2040	U-3282			
	11278547	Mar 02, 2040	U-3282			
	11478471	Jan 10, 2026	U-3283			
	9918984	Jan 10, 2026	U-3283			
LEVOLEUCOVORIN - KHAPZORY						
N 211226 001	11541012	Mar 25, 2039	DP			
LEVOLEUCOVORIN - KHAPZORY						
N 211226 002	11541012	Mar 25, 2039	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 001	8481598	Mar 02, 2031	U-839			
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 002	8481598	Mar 02, 2031	U-839			
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 003	8481598	Mar 02, 2031	U-839			
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 004	8481598	Mar 02, 2031	U-839			
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
LEVONORGESTREL - MIRENA						
N 021225 001	10561524	Sep 16, 2029	U-2948			
	10987244	Apr 01, 2031	DP			
	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
LEVONORGESTREL - SKYLA						
N 203159 001	10561524	Sep 16, 2029	U-2948			
	10987244	Apr 01, 2031	DP			
	11628088	Feb 07, 2027	DP			
	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
LEVONORGESTREL - LILETTA						
N 206229 001	10028858	Mar 22, 2034	DP U-2348		I-917	Jun 29, 2026
	11090186	Oct 24, 2033	U-2348			
	11571328	Sep 07, 2040	DP			
LEVONORGESTREL - KYLEENA						
N 208224 001	10561524	Sep 16, 2029	U-2948			
	10987244	Apr 01, 2031	DP			
	11628088	Feb 07, 2027	DP			
	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 003	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 004	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 005	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 006	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 007	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 008	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 009	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 010	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 011	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 012	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 002	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 003	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 004	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 005	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 006	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 007	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 008	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 009	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 010	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 011	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 012	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 013	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 001	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 002	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 003	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 001	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 002	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 003	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 004	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 005	10537538	Feb 28, 2037	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 005	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 006	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 007	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 008	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 009	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 010	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 011	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 012	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 013	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 014	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 014	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 015	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 210632 001	10398669	Dec 01, 2036	DP			
	11135190	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 210632 002	10398669	Dec 01, 2036	DP			
	11135190	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 210632 003	10398669	Dec 01, 2036	DP			
	11135190	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
LEVOTHYROXINE SODIUM - THYQUIDITY						
N 214047 001	9050307	Aug 06, 2031	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 214253 001	11154498	Jul 20, 2036	DP			
LEVOTHYROXINE SODIUM - ERMEZA						
N 215809 001	9345772	Feb 27, 2035	DP			
LIDOCAINE - ZTLIDO						
N 207962 001	10765640	May 10, 2031	DP			
	10765749	May 10, 2031	DP			
	11278623	May 10, 2031	DP			
	11786455	May 10, 2031	DP		U-2267	
	11793766	May 10, 2031			U-2267	
	9283174	May 10, 2031	DP			
	9925264	May 10, 2031	DP		U-2267	
	9931403	May 10, 2031	DP			
LIDOCAINE HYDROCHLORIDE - ZINGO						
N 022114 001	8540665	Oct 22, 2029			U-1438	
	9358338	Apr 27, 2035			U-1870	
	9370622	Sep 28, 2035			U-1870	
LIDOCAINE HYDROCHLORIDE - AKTEN						
N 022221 001	8759401	Jul 24, 2026	DP		U-1523	
LIDOCAINE; TETRACAINE - PLIAGLIS						
N 021717 001	10350180	Jan 14, 2031	DP			
	10603293	Jan 14, 2031	DP			
	10751305	Jan 14, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LIFITEGRAST - XIIDRA						
N 208073 001	10124000	Nov 05, 2024	U-1900			
	11058677	Dec 18, 2033	DP			
	7314938	Mar 10, 2025	DS DP			
	7745460	Nov 05, 2024	DS DP U-1880			
	7790743	Nov 05, 2024	U-1880			
	7928122	Nov 05, 2024	DS DP			
	8084047	May 17, 2026	DS DP			
	8168655	May 09, 2029	U-1880			
	8367701	Apr 15, 2029	DP U-1880			
	8592450	May 17, 2026	U-1880			
	8927574	Nov 12, 2030	DP			
	9085553	Jul 25, 2033	DP			
	9216174	Nov 05, 2024	DP			
	9353088	Oct 21, 2030	DP			
	9447077	Apr 15, 2029	U-1900			
	9890141	Oct 21, 2030	DS			
LINACLOTIDE - LINZESS						
N 202811 001	7304036	Aug 30, 2026	DS DP U-1278		I-921	Jun 12, 2026
	7304036	Aug 30, 2026	DS DP U-1516			
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
	8748573	Oct 30, 2031	U-1515			
	8748573	Oct 30, 2031	U-1516			
	8802628	Oct 30, 2031	DP			
	8933030	Feb 17, 2031	DP			
	9708371	Aug 16, 2033	DP U-1515			
	9708371	Aug 16, 2033	DP U-1516			
LINACLOTIDE - LINZESS						
N 202811 002	7304036	Aug 30, 2026	DS DP U-1278			
	7304036	Aug 30, 2026	DS DP U-1516			
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
	8748573	Oct 30, 2031	U-1515			
	8748573	Oct 30, 2031	U-1516			
	8802628	Oct 30, 2031	DP			
	8933030	Feb 17, 2031	DP			
	9708371	Aug 16, 2033	DP U-1515			
LINACLOTIDE - LINZESS						
N 202811 003	10675325	Aug 11, 2031	DP		I-921	Jun 12, 2026
	10702576	Aug 11, 2031	U-1516			
	10702576	Aug 11, 2031	U-3644			
	7304036	Aug 30, 2026	DS DP U-1516			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINACLOTIDE - LINZESS						
N 202811 003	7304036	Aug 30, 2026	DS DP U-3644			
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1516			
	8110553	Jan 28, 2024	U-3644			
	8933030	Feb 17, 2031	DP U-1516			
	8933030	Feb 17, 2031	DP U-3644			
	9708371	Aug 16, 2033	DP U-1516			
	9708371	Aug 16, 2033	DP U-3644			
LINAGLIPTIN - TRADJENTA						
N 201280 001	10034877	Aug 05, 2029	U-2347		M-295	Jun 20, 2026
	10034877*PED	Feb 05, 2030			PED	Dec 20, 2026
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503	Y		
	8846695*PED	Dec 04, 2030				
	8853156	Mar 05, 2031	DP U-1642			
	8853156*PED	Sep 05, 2031				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9486526	Aug 05, 2029	U-1915			
	9486526*PED	Feb 05, 2030				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 001	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	10973827	Apr 02, 2029	DP			
	10973827*PED	Oct 02, 2029				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503			
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 002	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 002	10973827	Apr 02, 2029	DP			
	10973827*PED	Oct 02, 2029				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503			
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 003	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	10973827	Apr 02, 2029	DP			
	10973827*PED	Oct 02, 2029				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503	Y		
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 001	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9173859	May 04, 2027	DP U-1503	Y		
	9173859*PED	Nov 04, 2027				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
	9555001*PED	Sep 06, 2033				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 001	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9173859	May 04, 2027	DP U-1503	Y		
	9173859*PED	Nov 04, 2027				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
	9555001*PED	Sep 06, 2033				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 002	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9173859	May 04, 2027	DP U-1503	Y		
	9173859*PED	Nov 04, 2027				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
	9555001*PED	Sep 06, 2033				
LIRAGLUTIDE RECOMBINANT - VICTOZA						
N 022341 001	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DS DP			
	8114833*PED	Feb 13, 2026				
	9265893	Sep 23, 2032	DP			
	9265893*PED	Mar 23, 2033				
	9968659	Jan 09, 2037	U-2313			
	9968659*PED	Jul 09, 2037				
LIRAGLUTIDE RECOMBINANT - SAXENDA						
N 206321 001	10220155	Jul 17, 2026	DP			
	10220155*PED	Jan 17, 2027				
	10357616	Jan 20, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LIRAGLUTIDE RECOMBINANT - SAXENDA						
N 206321 001	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DP			
	8114833*PED	Feb 13, 2026				
	8684969	Oct 20, 2025	DP			
	8684969*PED	Apr 20, 2026				
	8920383	Jul 17, 2026	DP			
	8920383*PED	Jan 17, 2027				
	9108002	Jan 26, 2026	DP			
	9108002*PED	Jul 26, 2026				
	9132239	Feb 01, 2032	DP			
	9132239*PED	Aug 01, 2032				
	9457154	Sep 27, 2027	DP			
	9457154*PED	Mar 27, 2028				
	9616180	Jan 20, 2026	DP			
	9616180*PED	Jul 20, 2026				
	9687611	Feb 27, 2027	DP			
	9687611*PED	Aug 27, 2027				
	9775953	Jul 17, 2026	DP			
	9775953*PED	Jan 17, 2027				
	9861757	Jan 20, 2026	DP			
	9861757*PED	Jul 20, 2026				
	9968659	Jan 09, 2037			U-2438	
	9968659*PED	Jul 09, 2037				
	RE46363	Aug 03, 2026	DP			
	RE46363*PED	Feb 03, 2027				
LISINOPRIL - QBRELIS						
N 208401 001	10039800	Nov 06, 2035			U-1723	
	10039800	Nov 06, 2035			U-185	
	10039800	Nov 06, 2035			U-1864	
	10039800	Nov 06, 2035			U-1991	
	10039800	Nov 06, 2035			U-3	
	10039800	Nov 06, 2035			U-71	
	10039800	Nov 06, 2035			U-8	
	10265370	Nov 06, 2035	DP			
	10406199	Nov 06, 2035			U-1723	
	10406199	Nov 06, 2035			U-185	
	10406199	Nov 06, 2035			U-1864	
	10406199	Nov 06, 2035			U-1991	
	10406199	Nov 06, 2035			U-3	
	10406199	Nov 06, 2035			U-71	
	10406199	Nov 06, 2035			U-8	
	10940177	Nov 06, 2035	DP			
	11179434	Nov 06, 2035	DP			
	11771733	Nov 06, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISINOPRIL - QBRELIS						
N 208401 001	9463183	Nov 06, 2035	DP			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-8			
	9814751	Nov 06, 2035	DP			
LITHIUM CITRATE - LITHIUM CITRATE						
A 218036 001					CGT	Mar 18, 2024
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 001	10016404	Mar 07, 2025	U-1316			
	10555938	Mar 07, 2025	U-1316			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 002	10016404	Mar 07, 2025	U-1316			
	10555938	Mar 07, 2025	U-1316			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 003	10016404	Mar 07, 2025	U-1316			
	10555938	Mar 07, 2025	U-1316			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 004	10016404	Mar 07, 2025	U-1316			
	10555938	Mar 07, 2025	U-1316			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 005	10016404	Mar 07, 2025	U-1316			
	10555938	Mar 07, 2025	U-1316			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 006	10016404	Mar 07, 2025	U-1316			
	10555938	Mar 07, 2025	U-1316			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
LONAFARNIB - ZOKINVY						
N 213969 001	7838531	Jul 26, 2024	U-3070		NCE	Nov 20, 2025
	8828356	Oct 17, 2024	U-3070		ODE-324	Nov 20, 2027
LONAFARNIB - ZOKINVY						
N 213969 002	7838531	Jul 26, 2024	U-3070		NCE	Nov 20, 2025
	8828356	Oct 17, 2024	U-3070		ODE-324	Nov 20, 2027
LORAZEPAM - LOREEV XR						
N 214826 001	8999393	Jan 08, 2034	DP U-3210			
LORAZEPAM - LOREEV XR						
N 214826 002	8999393	Jan 08, 2034	DP U-3210			
LORAZEPAM - LOREEV XR						
N 214826 003	8999393	Jan 08, 2034	DP U-3210			
LORAZEPAM - LOREEV XR						
N 214826 004	8999393	Jan 08, 2034	DP U-3210			
LORLATINIB - LORBRENA						
N 210868 001	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		ODE-217	Nov 02, 2025
	11020376	Jul 27, 2036	DP		ODE-218	Nov 02, 2025
	11299500	Oct 04, 2038	DS		ODE-219	Nov 02, 2025
	8680111	Mar 05, 2033	DS DP		ODE-349	Mar 03, 2028
LORLATINIB - LORBRENA						
N 210868 002	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		ODE-217	Nov 02, 2025
	11020376	Jul 27, 2036	DP		ODE-218	Nov 02, 2025
	11299500	Oct 04, 2038	DS		ODE-219	Nov 02, 2025
	8680111	Mar 05, 2033	DS DP		ODE-349	Mar 03, 2028
LOTEPREDNOL ETABONATE - LOTEMAX SM						
N 208219 001	10596107	Dec 23, 2036	DP U-2764			
	11534395	Jan 26, 2036	DP U-2764			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOTEPREDNOL ETABONATE - LOTEMAX SM								
N 208219	001		10596107	Dec 23, 2036	DP U-2764			
			11534395	Jan 26, 2036	DP U-2764			
LOTEPREDNOL ETABONATE - INVELTYS								
N 210565	001		10058511	May 03, 2033	DP U-2492			
			10646437	May 03, 2033	DP			
			10688045	May 03, 2033	DP			
			10864219	May 03, 2033	U-3011			
			11219597	May 03, 2033	U-3278			
			11219597	May 03, 2033	U-3279			
			11642317	May 03, 2033	DP			
			9056057	May 03, 2033	DP U-2491			
			9393213	May 03, 2033	DP			
			9532955	May 03, 2033	U-2491			
			9737491	May 03, 2033	U-2492			
			9827191	May 03, 2033	DP U-2493			
LOTEPREDNOL ETABONATE - EYSUVIS								
N 210933	001		10058511	May 03, 2033	DP U-2492			
			10646436	May 03, 2033	DP			
			10688045	May 03, 2033	DP			
			10857096	May 03, 2033	U-2985			
			10940108	May 03, 2033	U-2985			
			10945948	May 03, 2033	U-2985			
			10993908	May 03, 2033	U-3117			
			11219596	May 03, 2033	U-2985			
			11596599	May 03, 2033	U-2985			
			11642317	May 03, 2033	DP			
			9056057	May 03, 2033	DP U-2491			
			9393213	May 03, 2033	DP			
			9532955	May 03, 2033	U-2491			
			9737491	May 03, 2033	U-2492			
			9827191	May 03, 2033	DP U-2985			
LOTILANER - XDEMVY								
N 217603	001		10835517	Dec 14, 2038	U-3674		NCE	Jul 24, 2028
			11197847	Dec 14, 2038	U-3674			
			11690826	Dec 14, 2038	U-3674			
			11690827	Dec 14, 2038	U-3674			
			11752137	Dec 14, 2038	DP			
			8383659	Jan 17, 2030	DS DP			
LOXAPINE - ADASUVE								
N 022549	001		7458374	Aug 18, 2024	DP			
			7537009	Oct 28, 2024	DP			
			8387612	Oct 23, 2026	DP			
			8991387	May 21, 2024	DP			
			9370629	May 20, 2024	DP			
LUBIPROSTONE - AMITIZA								
N 021908	001		8026393	Oct 25, 2027	DP			
			8338639	Jan 23, 2027	DP			
			8748481	Sep 01, 2025	U-1520			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LUBIPROSTONE - AMITIZA						
N 021908 001	8779187	Jan 23, 2027	DP			
LUBIPROSTONE - AMITIZA						
N 021908 002	7795312	Sep 17, 2024	U-1085			
	8026393	Oct 25, 2027	DP			
	8338639	Jan 23, 2027	DP			
	8748481	Sep 01, 2025	U-1519			
	8779187	Jan 23, 2027	DP			
LULICONAZOLE - LUZU						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
	9453006	Sep 06, 2033	DS			
LUMASIRAN SODIUM - OXLUMO						
N 214103 001	10131907	Aug 24, 2028	DS DP U-2995		I-901	Oct 06, 2025
	10435692	Dec 26, 2034	U-2995		NCE	Nov 23, 2025
	10465195	Dec 26, 2034	DS DP U-2995		ODE-339	Nov 23, 2027
	10478500	Oct 09, 2035	DS DP U-2995		ODE-415	Oct 06, 2029
	10487330	Dec 26, 2034	DS DP U-2995			
	10612024	Aug 14, 2035	DS DP U-2995			
	10612027	Aug 14, 2035	DS DP U-2995			
	11060093	Dec 26, 2034	DS DP U-2995			
	11261447	Nov 20, 2038	DS DP U-2995			
	11401517	Aug 14, 2035	DS DP U-2995			
	11446380	Oct 09, 2035	DS DP			
	8106022	Dec 12, 2029	DS DP U-2995			
	8828956	Dec 04, 2028	DS DP U-2995			
	9828606	Dec 26, 2034	DS DP			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 001	10117867	May 27, 2029	U-3271		I-882	Dec 17, 2024
	10464938	Mar 12, 2028	DP		NCE	Dec 20, 2024
	10695345	Aug 30, 2039	DP U-543			
	10960009	Dec 03, 2034	U-814			
	11026951	Dec 03, 2034	U-3274			
	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11753419	Dec 10, 2040	DP			
	11806348	Aug 30, 2039	DP U-3362			
	11806348	Aug 30, 2039	DP U-3363			
	8598119	Dec 28, 2029	U-543			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9586960	Mar 12, 2029	DS DP			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Mar 12, 2029	DS DP			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-814			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 002	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11753419	Dec 10, 2040	DP			
	11806348	Aug 30, 2039	DP U-3362			
	11806348	Aug 30, 2039	DP U-3363			
	8648077	Dec 01, 2029	DS DP			
	9168258	May 27, 2029	DP			
	9199995	Mar 12, 2029	U-2713			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Feb 12, 2029	DS			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-814			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 003	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11753419	Dec 10, 2040	DP			
	11806348	Aug 30, 2039	DP U-3362			
	11806348	Aug 30, 2039	DP U-3363			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Feb 12, 2029	DS			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-814			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 001	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP U-543			
	9815827	Feb 20, 2024	U-2166			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LURASIDONE HYDROCHLORIDE - LATUDA								
N 200603	001		9815827	Feb 20, 2024			U-543	
			9827242	May 23, 2031			U-2199	
			9827242	May 23, 2031			U-2201	
			9907794	May 26, 2026	DP			
			9907794*PED	Nov 26, 2026				
			RE45573	Jun 23, 2025	DS			
			RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA								
N 200603	002		8729085	May 26, 2026	DP			
			8729085*PED	Nov 26, 2026				
			8883794	May 26, 2026	DP			
			8883794*PED	Nov 26, 2026				
			9174975	Feb 20, 2024			U-1770	
			9174975*PED	Aug 20, 2024				
			9259423	May 23, 2031			U-1822	
			9259423*PED	Nov 23, 2031				
			9555027	May 26, 2026	DP		U-543	
			9815827	Feb 20, 2024			U-2166	
			9815827	Feb 20, 2024			U-543	
			9827242	May 23, 2031			U-2199	
			9827242	May 23, 2031			U-2201	
			9907794	May 26, 2026	DP			
			9907794*PED	Nov 26, 2026				
			RE45573	Jun 23, 2025	DS			
			RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA								
N 200603	003		8729085	May 26, 2026	DP			
			8729085*PED	Nov 26, 2026				
			8883794	May 26, 2026	DP			
			8883794*PED	Nov 26, 2026				
			9174975	Feb 20, 2024			U-1770	
			9174975*PED	Aug 20, 2024				
			9259423	May 23, 2031			U-1822	
			9259423*PED	Nov 23, 2031				
			9555027	May 26, 2026	DP		U-543	
			9815827	Feb 20, 2024			U-2166	
			9815827	Feb 20, 2024			U-543	
			9827242	May 23, 2031			U-2199	
			9827242	May 23, 2031			U-2201	
			9907794	May 26, 2026	DP			
			9907794*PED	Nov 26, 2026				
			RE45573	Jun 23, 2025	DS			
			RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA								
N 200603	004		8729085	May 26, 2026	DP			
			8729085*PED	Nov 26, 2026				
			8883794	May 26, 2026	DP			
			8883794*PED	Nov 26, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 004	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP U-543			
	9815827	Feb 20, 2024	U-2166			
	9815827	Feb 20, 2024	U-543			
	9827242	May 23, 2031	U-2199			
	9827242	May 23, 2031	U-2201			
	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 005	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP U-543			
	9815827	Feb 20, 2024	U-2166			
	9815827	Feb 20, 2024	U-543			
	9827242	May 23, 2031	U-2199			
	9827242	May 23, 2031	U-2201			
	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
LURBINECTEDIN - ZEPZELCA						
N 213702 001	7763615	Dec 13, 2029	DS DP U-2836		NCE	Jun 15, 2025
					ODE-304	Jun 15, 2027
LUSUTROMBOPAG - MULPLETA						
N 210923 001	7601746	Sep 05, 2024	DS DP U-2344			
	8530668	Jan 21, 2030	DS DP			
	8889722	Jul 29, 2028	DS DP			
	9427402	Sep 29, 2031	DP			
LUTETIUM LU 177 DOTATATE - LUTATHERA						
N 208700 001	10596276	Jul 25, 2038	DP		ODE-166	Jan 26, 2025
	10596278	Jul 25, 2038	DP			
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO						
N 215833 001	10398791	Oct 17, 2034	DS DP		NCE	Mar 23, 2027
	10406240	Aug 15, 2028	DS DP U-3345			
	11318121	Aug 15, 2028	DS DP U-3345			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MACIMORELIN ACETATE - MACRILEN						
N 205598 001	8192719	Oct 12, 2027	U-2220		ODE-170	Dec 20, 2024
MACITENTAN - OPSUMIT						
N 204410 001	10946015	Sep 11, 2026	DP U-1445			
	7094781	Dec 05, 2025	DS DP			
	8268847	Apr 18, 2029	U-1446			
	8367685	Oct 04, 2028	DP U-1445			
	9265762	May 29, 2027	DP U-1820			
MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE						
N 215344 001					NP	Jun 15, 2026
MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB						
N 213135 001	10143656	Aug 04, 2037	DP			
	11033498	Aug 04, 2037	U-3164			
	11382864	Aug 04, 2037	U-3164			
	11638697	Aug 04, 2037	DP			
MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT						
N 022372 001					ODE-315	Aug 05, 2027
MALATHION - OVIDE						
N 018613 001	7560445	Feb 01, 2027	DS DP U-986			
	7977324	Aug 14, 2026	DP			
MANNITOL - BRONCHITOL						
N 202049 001					ODE-327	Oct 30, 2027
MARALIXIBAT CHLORIDE - LIVMARLI						
N 214662 001	11229647	Feb 12, 2040	U-3290		NCE	Sep 29, 2026
	11260053	May 26, 2031	U-3290		NPP	Mar 13, 2026
	11376251	Oct 26, 2032	U-3290		ODE-379	Sep 29, 2028
	11497745	Feb 12, 2040	U-3290		ODE-429	Mar 13, 2030
MARAVIROC - SELZENTRY						
N 208984 001					NPP	Oct 30, 2023
					PED	Apr 30, 2024
MARIBAVIR - LIVTENCITY						
N 215596 001	11684632	Jan 04, 2032	U-3650		NCE	Nov 23, 2026
					ODE-388	Nov 23, 2028
MAVACAMTEN - CAMZYOS						
N 214998 001	9181200	Jun 19, 2034	DS DP		M-297	Jun 15, 2026
	9585883	Jun 19, 2034	U-3373		NCE	Apr 28, 2027
					ODE-398	Apr 28, 2029
MAVACAMTEN - CAMZYOS						
N 214998 002	9181200	Jun 19, 2034	DS DP		M-297	Jun 15, 2026
	9585883	Jun 19, 2034	U-3373		NCE	Apr 28, 2027
					ODE-398	Apr 28, 2029
MAVACAMTEN - CAMZYOS						
N 214998 003	9181200	Jun 19, 2034	DS DP		M-297	Jun 15, 2026
	9585883	Jun 19, 2034	U-3373		NCE	Apr 28, 2027
					ODE-398	Apr 28, 2029

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MAVACAMTEN - CAMZYOS						
N 214998 004	9181200	Jun 19, 2034	DS DP		M-297	Jun 15, 2026
	9585883	Jun 19, 2034	U-3373		NCE	Apr 28, 2027
					ODE-398	Apr 28, 2029
MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR						
N 202317 001	7838564	Mar 07, 2026	DP			
	7872050	Jul 08, 2029	U-1427			
	8450375	Mar 07, 2026	DP			
	8501818	Mar 07, 2026	DP			
	8501819	Mar 07, 2026	U-1427			
	9382191	Mar 07, 2026	DP			
MEGESTROL ACETATE - MEGACE ES						
N 021778 001	7101576	Apr 22, 2024	U-755			
	9040088	Apr 22, 2024	U-755			
	9101540	Apr 22, 2024	DP U-755			
	9101549	Apr 22, 2024	U-755			
	9107827	Apr 22, 2024	U-755			
MELOXICAM - VIVLODEX						
N 207233 001	9526734	Mar 31, 2033	DP			
	9649318	Mar 31, 2035	DP			
	9808468	Mar 31, 2035	U-2160			
	9808468	Mar 31, 2035	U-2165			
MELOXICAM - VIVLODEX						
N 207233 002	9526734	Mar 31, 2033	DP			
	9649318	Mar 31, 2035	DP			
	9808468	Mar 31, 2035	U-2160			
	9808468	Mar 31, 2035	U-2165			
MELOXICAM - ANJESO						
N 210583 001	10463673	Feb 24, 2024	DP U-2750			
	10471067	Feb 24, 2024	DP U-2750			
	10709713	May 26, 2030	U-2750			
	10881663	Mar 08, 2039	U-3038			
	11253478	May 26, 2030	DP U-3318			
	11458145	Mar 08, 2039	U-3318			
	9974746	May 26, 2030	DP			
MELOXICAM - QMIIZ ODT						
N 211210 001	8545879	Aug 31, 2030	DP			
MELOXICAM - QMIIZ ODT						
N 211210 002	8545879	Aug 31, 2030	DP			
MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO						
N 214383 001	10285946	Apr 25, 2032	DP		NCE	Feb 26, 2026
	10322182	Apr 25, 2032	DP		ODE-348	Feb 26, 2028
	10543274	Apr 25, 2032	U-3093			
	10869928	Apr 25, 2032	DP			
	11344622	Apr 25, 2032	U-3093			
	6992207	Jun 25, 2024	DS DP U-3093			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MELPHALAN HYDROCHLORIDE - HEPZATO						
N 201848 001	10098997	Nov 07, 2032	DP		NP	Aug 14, 2026
	10195334	Jan 16, 2033	DP		ODE-438	Aug 14, 2030
	10369264	Nov 07, 2032	DP			
	10569004	Nov 07, 2032	U-3680			
	10569004	Nov 07, 2032	U-3683			
	11083831	Dec 30, 2032	DP			
	11241522	Nov 07, 2032	DP			
	11633528	Nov 07, 2032	U-3675			
	11833286	Dec 30, 2032	DP			
	9314561	Feb 07, 2034	DP			
	9707331	Sep 17, 2034	DP			
MELPHALAN HYDROCHLORIDE - EVOMELA						
N 207155 001	10040872	Jan 30, 2034	DP			
	10864183	May 28, 2030	DP			
	10940128	Jun 14, 2030	DP U-3086			
	11020363	May 28, 2030	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
MELPHALAN HYDROCHLORIDE - MELPHALAN HYDROCHLORIDE						
N 217110 001	10537520	Jun 29, 2036	DP			
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 001	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 002	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 003	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 004	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
MENTHOL; METHYL SALICYLATE - SALONPAS						
N 022029 001	8809615	Jan 03, 2030	DP			
	9233184	Aug 01, 2027	DP			
MENTHOL; METHYL SALICYLATE - SALONPAS						
N 022029 002	8809615	Jan 03, 2030	DP			
	9233184	Aug 01, 2027	DP			
MEROPENEM; VABORBACTAM - VABOMERE						
N 209776 001	10172874	Aug 08, 2031	DP		NCE	Aug 29, 2022
	10183034	Aug 08, 2031	U-2490		GAIN	Aug 29, 2027
	10561675	Aug 08, 2031	U-2490			
	11007206	Aug 08, 2031	U-3128			
	11376237	Apr 06, 2039	U-3421			
	8680136	Aug 29, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MEROPENEM; VABORBACTAM - VABOMERE						
N 209776 001	9694025	Aug 08, 2031	U-2120			
MESALAMINE - SFROWASA						
N 019618 002	7645801	Jul 24, 2027	DS DP			
MESALAMINE - CANASA						
N 021252 002	8217083	Jun 06, 2028	DP			
	8436051	Jun 06, 2028	DP			
MESALAMINE - APRISO						
N 022301 001	8865688	May 01, 2030	U-1310			
METAXALONE - SKELAXIN						
N 013217 003	7122566	Feb 06, 2026	U-915			
METFORMIN HYDROCHLORIDE - GLUMETZA						
N 021748 002	7780987	Mar 23, 2025	DS DP			
METFORMIN HYDROCHLORIDE - RIOMET ER						
N 212595 001	9962336	May 01, 2035	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET						
N 021842 001	9101660	Jan 22, 2027	DP			
	9320714	Feb 03, 2029	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET						
N 021842 002	9101660	Jan 22, 2027	DP			
	9320714	Feb 03, 2029	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR						
N 022024 001	7785627	Jul 31, 2026	DP			
	7959946	Jul 31, 2026	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR						
N 022024 002	7785627	Jul 31, 2026	DP			
	7959946	Jul 31, 2026	DP			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR						
N 200678 001	8628799	Jul 13, 2025	DP			
	9339472	Jul 13, 2025	DP			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR						
N 200678 002	8628799	Jul 13, 2025	DP			
	9339472	Jul 13, 2025	DP			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR						
N 200678 003	8628799	Jul 13, 2025	DP			
	9339472	Jul 13, 2025	DP			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET						
N 022044 001	7326708	Nov 24, 2026	DS DP U-802		M-187	Dec 04, 2023
	7326708*PED	May 24, 2027			PED	Jun 04, 2024
	8414921	Jul 21, 2028	DP U-1036			
	8414921*PED	Jan 21, 2029				
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET						
N 022044 002	7326708	Nov 24, 2026	DS DP U-802		M-187	Dec 04, 2023
	7326708*PED	May 24, 2027			PED	Jun 04, 2024
	8414921	Jul 21, 2028	DP U-1036			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET						
N 022044 002	8414921*PED	Jan 21, 2029				
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N 202270 001	7326708	Nov 24, 2026	DS DP U-1227		M-187	Dec 04, 2023
	7326708*PED	May 24, 2027			PED	Jun 04, 2024
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N 202270 002	7326708	Nov 24, 2026	DS DP U-1227		M-187	Dec 04, 2023
	7326708*PED	May 24, 2027			PED	Jun 04, 2024
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N 202270 003	7326708	Nov 24, 2026	DS DP U-1227			
	7326708*PED	May 24, 2027				
METHOTREXATE - OTREXUP						
N 204824 001	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 002	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 003	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - OTREXUP						
N 204824 003	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 004	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 005	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 006	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - OTREXUP						
N 204824 006	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 007	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 008	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - RASUVO						
N 205776 001	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 002	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 003	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 004	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 005	8664231	Jun 01, 2029	U-1442			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - RASUVO						
N 205776 006	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 007	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 008	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 009	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 010	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - JYLAMVO						
N 212479 001	11129833	Oct 28, 2035	DP			
	11771701	Oct 29, 2034	DP U-3700			
	11771701	Oct 29, 2034	DP U-3701			
	11771701	Oct 29, 2034	DP U-3702			
	11771701	Oct 29, 2034	DP U-3703			
	11771701	Oct 29, 2034	DP U-3704			
METHOTREXATE SODIUM - XATMEP						
N 208400 001	10231927	Jan 02, 2033	U-1349		ODE-137	Apr 25, 2024
	10231927	Jan 02, 2033	U-1699		ODE-138	Apr 25, 2024
	10610485	Jan 02, 2033	DP			
	11116724	Jan 02, 2033	U-1349			
	11116724	Jan 02, 2033	U-1699			
	9259427	Jan 02, 2033	DP			
	9855215	Jan 02, 2033	DP			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 001	10376584	Apr 08, 2024	DP U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			
	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 002	10376584	Apr 08, 2024	DP U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			
	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 003	10376584	Apr 08, 2024	DP U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 003	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP		U-1185	
	9180125	Sep 30, 2029	DP		U-1185	
	9492445	Sep 30, 2029	DP		U-1185	
	9669096	Apr 08, 2024	DP			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 208271 001	10307417	Mar 10, 2031	DP			
	10376505	Mar 10, 2031	DP			
	8420663	Sep 30, 2029			U-1185	
	8524276	Mar 10, 2031	DP			
	8956651	Mar 10, 2031	DP			
	9180125	Sep 30, 2029	DP		U-1185	
	9314461	Mar 10, 2031	DP			
	9492445	Sep 30, 2029	DP		U-1185	
	9724343	Sep 30, 2029	DP		U-1185	
METHYLPHENIDATE - DAYTRANA						
N 021514 001	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025			U-2024	
METHYLPHENIDATE - DAYTRANA						
N 021514 002	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025			U-2024	
METHYLPHENIDATE - DAYTRANA						
N 021514 003	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025			U-2024	
METHYLPHENIDATE - DAYTRANA						
N 021514 004	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025			U-2024	
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 001	11166947	Jan 25, 2038			U-3299	
	8840924	Jun 05, 2026	DP			
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 002	11166947	Jan 25, 2038			U-3299	
	8840924	Jun 05, 2026	DP			
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 003	11166947	Jan 25, 2038			U-3299	
	8840924	Jun 05, 2026	DP			
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - METHYLIN						
N 021419 001	7691880	Oct 07, 2024	DP			
METHYLPHENIDATE HYDROCHLORIDE - METHYLIN						
N 021419 002	7691880	Oct 07, 2024	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR						
N 202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP		U-1415	
	8563033	Feb 15, 2031	DP		U-1415	
	8778390	Feb 15, 2031	DP		U-1543	
	8956649	Feb 15, 2031	DP		U-1665	
	9040083	Feb 15, 2031	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 001	10857143	Aug 14, 2033	DP		U-2993	
	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP		U-2993	
	11633389	Aug 14, 2033	DP			
	8202537	Mar 15, 2027	DP			
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP		U-1827	
	9545399	Aug 14, 2033	DP		U-1827	
	9844544	Aug 14, 2033	DP		U-2203	
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 002	10857143	Aug 14, 2033	DP		U-2993	
	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP		U-2993	
	11633389	Aug 14, 2033	DP			
	8202537	Mar 15, 2027	DP			
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP		U-1827	
	9545399	Aug 14, 2033	DP		U-1827	
	9844544	Aug 14, 2033	DP		U-2203	
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 003	10857143	Aug 14, 2033	DP		U-2993	
	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP		U-2993	
	11633389	Aug 14, 2033	DP			
	8202537	Mar 15, 2027	DP			
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP		U-1827	
	9545399	Aug 14, 2033	DP		U-1827	
	9844544	Aug 14, 2033	DP		U-2203	
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 001	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032			U-2357	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 001	10617651	Mar 23, 2032	U-2357			
	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 002	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
	10617651	Mar 23, 2032	U-2357			
	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 003	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
	10617651	Mar 23, 2032	U-2357			
	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 004	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 004	10617651	Mar 23, 2032	U-2357			
	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 005	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
	10617651	Mar 23, 2032	U-2357			
	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 001	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 002	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 002	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 003	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 004	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 005	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 006	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI						
N 209388 001	11020361	Dec 22, 2029	U-2843			
	11628150	Dec 22, 2029	DP U-2843			
	11813231	Dec 22, 2029	DP U-2843			
	8334281	May 16, 2030	DP U-2843			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE						
N 210428 001	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE						
N 210428 002	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE						
N 210428 003	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE						
N 210428 004	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
METRONIDAZOLE - VANDAZOLE						
N 021806 001	7456207	Sep 22, 2024	DP			
METRONIDAZOLE - NUVESSA						
N 205223 001	10238634	Jun 28, 2032	DP			
	10596155	Jun 28, 2032	DP			
	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028	U-1682			
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032	U-1664			
	9198858	Jun 28, 2032	U-1664			
METRONIDAZOLE - LIKMEZ						
N 216755 001	11541035	Oct 04, 2039	DP			
MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE - VUSION						
N 021026 001	8147852	Mar 30, 2028	U-1426			
MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE						
A 216159 001					PC	Jan 02, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE						
A 216159 002					PC	Jan 02, 2024
MIDAZOLAM - NAYZILAM						
N 211321 001	8217033	Jan 18, 2028	DP U-2526		ODE-243	May 17, 2026
	8809322	Jan 18, 2028	DP			
	9289432	Jan 18, 2028	DP U-2526			
	9687495	Jan 18, 2028	DP U-2526			
MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE						
N 211844 001	10966990	Jun 20, 2038	DP			
MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE						
N 211844 002	10966990	Jun 20, 2038	DP			
MIDAZOLAM HYDROCHLORIDE - SEIZALAM						
N 209566 001					ODE-207	Sep 14, 2025
MIDOSTAURIN - RYDAPT						
N 207997 001	7973031	Oct 09, 2028	U-2007		ODE-140	Apr 28, 2024
	8575146	Dec 02, 2030	U-2008		ODE-141	Apr 28, 2024
MIFEPRISTONE - KORLYM						
N 202107 001	10006924	Aug 12, 2036	U-1643			
	10151763	Jan 18, 2037	U-1643			
	10166242	Apr 20, 2036	U-1643			
	10166243	Apr 20, 2036	U-1643			
	10195214	Jun 19, 2037	U-1643			
	10231983	Aug 22, 2038	U-1643			
	10314850	Aug 22, 2038	U-1643			
	10495650	Aug 12, 2036	U-1643			
	10500216	Mar 05, 2033	U-1643			
	10660904	Apr 20, 2036	U-1643			
	10780097	Aug 22, 2038	U-1643			
	10842800	Jun 19, 2037	U-1643			
	10842801	Nov 15, 2032	U-1643			
	8921348	Aug 27, 2028	U-1643			
	9829495	Aug 15, 2036	U-1643			
	9943526	Apr 20, 2036	U-1643			
MIGALASTAT HYDROCHLORIDE - GALAFOLD						
N 208623 001	10076514	Mar 15, 2037	U-2371		ODE-205	Aug 10, 2025
	10251873	May 30, 2038	U-2371			
	10383864	May 16, 2027	U-2371			
	10406143	May 16, 2027	U-2371			
	10471053	May 30, 2038	U-2371			
	10525045	Apr 28, 2028	U-2371			
	10792278	May 30, 2038	U-2371			
	10792279	May 30, 2038	U-2371			
	10799491	May 30, 2038	U-2371			
	10806727	May 30, 2038	U-2371			
	10813921	Feb 12, 2029	U-2371			
	10849889	May 30, 2038	U-2371			
	10849890	May 30, 2038	U-2371			
	10857141	May 30, 2038	U-2371			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIGALASTAT HYDROCHLORIDE - GALAFOLD						
N 208623 001	10857142	May 30, 2038	U-2371			
	10874655	May 30, 2038	U-2371			
	10874656	May 30, 2038	U-2371			
	10874657	May 30, 2038	U-2371			
	10925866	Apr 28, 2028	U-2371			
	11033538	Apr 28, 2028	U-2371			
	11234972	Mar 15, 2037	U-2371			
	11241422	May 16, 2027	U-2371			
	11278536	May 30, 2038	U-2371			
	11278537	May 30, 2038	U-2371			
	11278538	May 30, 2038	U-2371			
	11278539	May 30, 2038	U-2371			
	11278540	May 30, 2038	U-2371			
	11304940	May 30, 2038	DS			
	11357761	May 30, 2038	U-2371			
	11357762	May 30, 2038	U-2371			
	11357763	May 30, 2038	U-2371			
	11357764	May 30, 2038	DS			
	11357765	May 30, 2038	DS			
	11357784	Feb 06, 2039	U-2371			
	11376244	May 30, 2038	DS			
	11389436	May 30, 2038	U-2371			
	11389437	May 30, 2038	U-2371			
	11426396	May 30, 2038	DS			
	11458128	May 30, 2038	U-2371			
	11612593	May 30, 2038	DS			
	11612594	May 30, 2038	DS			
	11622962	Mar 17, 2039	DS			
	11633387	May 30, 2038	DS			
	11633388	Mar 25, 2039	U-2371			
	11642334	Feb 20, 2039	U-2371			
	11666564	May 30, 2038	U-2371			
	11786516	May 30, 2038	DS			
	11813255	May 30, 2038	U-2371			
	11826360	Feb 16, 2039	DS			
	11833164	Jan 11, 2042	U-2371			
	8592362	Feb 12, 2029	U-2371	Y		
	9000011	May 16, 2027	U-2371			
	9095584	Feb 12, 2029	U-2371			
	9480682	May 16, 2027	U-2371			
	9987263	May 16, 2027	U-2371			
	9999618	Apr 28, 2028	U-2372			
	9999618	Apr 28, 2028	U-2373			
	RE48608	Feb 12, 2029	U-2371			
MIGLUSTAT - OPFOLDA						
N 215211 001	10208299	Sep 30, 2035	DS DP U-3726		NP	Sep 28, 2026
	10512677	Mar 07, 2033	U-3726			
	10857212	Aug 12, 2037	U-3726			
	10961522	Sep 30, 2035	U-3726			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIGLUSTAT - OPFOLDA						
N 215211 001	11278599	Mar 07, 2033	U-3726			
	11278601	Dec 29, 2036	DP U-3726			
	11753632	Sep 30, 2035	U-3726			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N 022256 001	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N 022256 002	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N 022256 003	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N 022256 004	7994220	Sep 19, 2029	U-819			
MINOCYCLINE HYDROCHLORIDE - MINOCIN						
N 050444 001	9084802	May 12, 2031	U-282			
	9278105	May 12, 2031	U-282			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 001	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 002	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 003	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 004	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	9192615	Nov 17, 2031	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 005	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	9192615	Nov 17, 2031	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 006	7790705	Jun 24, 2025	U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 006	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 007	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 008	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - XIMINO						
N 201922 001	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
MINOCYCLINE HYDROCHLORIDE - XIMINO						
N 201922 003	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
MINOCYCLINE HYDROCHLORIDE - XIMINO						
N 201922 005	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
MINOCYCLINE HYDROCHLORIDE - MINOLIRA						
N 209269 001	11103517	Apr 07, 2036	DP			
MINOCYCLINE HYDROCHLORIDE - MINOLIRA						
N 209269 002	11103517	Apr 07, 2036	DP			
MINOCYCLINE HYDROCHLORIDE - AMZEEQ						
N 212379 001	10086080	Oct 01, 2030	U-2647			
	10137200	Oct 01, 2030	U-2647			
	10213512	Oct 01, 2030	DP U-2647			
	10265404	Oct 01, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MINOCYCLINE HYDROCHLORIDE - AMZEEQ								
N 212379	001		10398641	Sep 08, 2037	U-2647			
			10517882	Oct 01, 2030	U-2647			
			10821187	Oct 01, 2030	U-2647			
			10849847	Sep 08, 2037	U-2647			
			8865139	Oct 01, 2030	DP U-2647			
			8945516	Oct 01, 2030	DP			
			8992896	Oct 01, 2030	DP U-2647			
			9675700	Oct 01, 2030	DP U-2647			
MINOCYCLINE HYDROCHLORIDE - ZILXI								
N 213690	001		10213512	Oct 01, 2030	DP U-1631			
			10265404	Oct 01, 2030	DP			
			10322186	Oct 01, 2030	U-1631			
			10946101	Oct 01, 2030	U-1631			
			8865139	Oct 01, 2030	DP U-1631			
			8945516	Oct 01, 2030	DP			
			8992896	Oct 01, 2030	DP U-1631			
			9675700	Oct 01, 2030	DP U-1631			
MIPOMERSEN SODIUM - KYNAMRO								
N 203568	001		7511131	Jan 29, 2027	DS			
MIRABEGRON - MYRBETRIQ								
N 202611	001		10842780	Sep 28, 2029	DP U-2996		I-855	Mar 25, 2024
			10842780	Sep 28, 2029	DP U-3670		PED	Sep 25, 2024
			10842780*PED	Mar 28, 2030				
			11707451	Sep 28, 2029	U-2996			
			11707451	Sep 28, 2029	U-3670			
			11707451*PED	Mar 28, 2030				
			8772315	Oct 30, 2028	U-2300			
			8772315*PED	Apr 30, 2029				
			8835474*PED	May 04, 2024				
			RE44872*PED	May 04, 2024				
MIRABEGRON - MYRBETRIQ								
N 202611	002		10842780	Sep 28, 2029	DP U-2996		I-855	Mar 25, 2024
			10842780	Sep 28, 2029	DP U-3670		PED	Sep 25, 2024
			10842780*PED	Mar 28, 2030				
			11707451	Sep 28, 2029	U-2996			
			11707451	Sep 28, 2029	U-3670			
			11707451*PED	Mar 28, 2030				
			8772315	Oct 30, 2028	U-2300			
			8772315*PED	Apr 30, 2029				
			8835474*PED	May 04, 2024				
			RE44872*PED	May 04, 2024				
MIRABEGRON - MYRBETRIQ GRANULES								
N 213801	001		10058536	Mar 31, 2036	DP U-3108		NP	Mar 25, 2024
			10058536*PED	Oct 01, 2036			PED	Sep 25, 2024
			7342117*PED	May 04, 2024				
			7982049*PED	May 04, 2024				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MITAPIVAT SULFATE - PYRUKYND						
N 216196 001	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321		ODE-392	Feb 17, 2029
	11254652	Nov 21, 2038	DS DP			
	11793806	Apr 12, 2033	U-3320			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
	RE49582	Feb 24, 2031	DS DP			
MITAPIVAT SULFATE - PYRUKYND						
N 216196 002	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321		ODE-392	Feb 17, 2029
	11254652	Nov 21, 2038	DS DP			
	11793806	Apr 12, 2033	U-3320			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
	RE49582	Feb 24, 2031	DS DP			
MITAPIVAT SULFATE - PYRUKYND						
N 216196 003	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321		ODE-392	Feb 17, 2029
	11254652	Nov 21, 2038	DS DP			
	11793806	Apr 12, 2033	U-3320			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
	RE49582	Feb 24, 2031	DS DP			
MITOMYCIN - MITOSOL						
N 022572 001	7806265	Feb 01, 2029	DP			
	8186511	Jul 19, 2026	DP			
	9205075	Jul 19, 2026	DP			
	9539241	Jan 02, 2028	DS DP U-2095			
	9649428	May 21, 2029	U-2095			
MITOMYCIN - JELMYTO						
N 211728 001	9040074	Jan 20, 2031	DP		ODE-289	Apr 15, 2027
	9950069	Jan 20, 2031	DP			
MOBOCERTINIB SUCCINATE - EXKIVITY						
N 215310 001	10227342	May 13, 2035	DS DP U-3220		NCE	Sep 15, 2026
	9796712	May 13, 2035	DS DP		ODE-374	Sep 15, 2028
MOMELOTINIB DIHYDROCHLORIDE - OJJAARA						
N 216873 001	8486941	Jan 03, 2030	DS DP U-1201		NCE	Sep 15, 2028
	9809559	Jun 11, 2035	U-1201		ODE-441	Sep 15, 2030
	RE48285	Jun 11, 2035	DS DP U-1201			
MOMELOTINIB DIHYDROCHLORIDE - OJJAARA						
N 216873 002	8486941	Jan 03, 2030	DS DP U-1201		NCE	Sep 15, 2028
	9809559	Jun 11, 2035	U-1201		ODE-441	Sep 15, 2030
	RE48285	Jun 11, 2035	DS DP U-1201			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MOMELOTINIB DIHYDROCHLORIDE - OJJAARA						
N 216873 003	8486941	Jan 03, 2030	DS DP U-1201		NCE	Sep 15, 2028
	9809559	Jun 11, 2035	U-1201		ODE-441	Sep 15, 2030
	RE48285	Jun 11, 2035	DS DP U-1201			
MOMETASONE FUROATE - SINUVA						
N 209310 001	10232152	Nov 24, 2034	DP U-2272			
	10357640	Oct 03, 2031	U-2272			
	10406332	Mar 13, 2034	DP			
	7544192	Nov 29, 2026	U-2272			
	7662141	Mar 12, 2024	U-2272			
	7713255	Mar 12, 2024	U-2272			
	7951130	Mar 12, 2024	U-2272			
	7951131	Mar 12, 2024	U-2272			
	7951133	Mar 12, 2024	U-2272			
	8025635	Jun 12, 2027	DP U-2272			
	8109918	Mar 12, 2024	U-2272			
	8763222	Feb 08, 2032	DP			
	9585681	Apr 04, 2026	U-2272			
MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS						
N 211746 001	10016443	Sep 04, 2034	U-3297		NP	Jan 13, 2025
	10376526	Sep 04, 2034	DP			
	10517880	Sep 04, 2034	DP U-3297			
	10548907	Sep 04, 2034	U-3297			
	10561672	Sep 04, 2034	DP			
	10646500	Sep 04, 2034	U-3297			
	10758550	Sep 04, 2034	U-3296			
	10765686	Sep 04, 2034	U-3295			
	11400101	Sep 04, 2034	U-3297			
	11679210	Sep 03, 2038	DP			
	9078923	Sep 04, 2034	DP U-3297			
	9370483	Sep 04, 2034	DP			
	9750754	Sep 04, 2034	DP U-3297			
	9937189	Sep 04, 2034	DP			
MONOMETHYL FUMARATE - BAFIERTAM						
N 210296 001	10098863	Feb 27, 2035	DP U-1384			
	10105335	Feb 27, 2035	DP			
	10105336	Feb 27, 2035	DP U-1384			
	10105337	Feb 27, 2035	DP			
	10918615	Aug 12, 2035	DP U-1384			
	10918616	Jun 03, 2035	U-1384			
	10918617	Aug 10, 2035	DP			
	10945985	Aug 14, 2035	DP			
	11590095	Mar 18, 2036	U-1384			
	9326947	Feb 27, 2035	DP			
	9326965	Feb 27, 2035	U-1384			
	9511043	Feb 27, 2035	U-1384			
	9517209	Feb 27, 2035	DP			
	9566259	Feb 27, 2035	DP			
	9636318	Feb 27, 2035	U-1384			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MONOMETHYL FUMARATE - BAFIERTAM						
N 210296 001	9636319	Feb 27, 2035	DP			
	9814691	Feb 27, 2035	U-1384			
	9814692	Feb 27, 2035	U-1384			
	9820960	Feb 27, 2035	DP			
	9820961	Feb 27, 2035	DP U-1384			
MORPHINE SULFATE - MORPHINE SULFATE						
N 022195 001					NPP	Jun 02, 2024
MORPHINE SULFATE - MORPHINE SULFATE						
N 022195 002					NPP	Jun 02, 2024
MORPHINE SULFATE - MORPHINE SULFATE						
N 022207 001					NPP	Jun 02, 2024
MORPHINE SULFATE - MORPHINE SULFATE						
N 022207 002					NPP	Jun 02, 2024
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 001	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 002	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 003	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 004	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 005	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHABOND ER						
N 206544 001	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER						
N 206544 002	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE - MORPHABOND ER								
N 206544	003		10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER								
N 206544	004		10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - ARYMO ER								
N 208603	001		9044402	Jul 01, 2033	DP		U-1556	
			9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE - ARYMO ER								
N 208603	002		9044402	Jul 01, 2033	DP		U-1556	
			9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE - ARYMO ER								
N 208603	003		9044402	Jul 01, 2033	DP		U-1556	
			9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N 022321	001		7682633	Jun 19, 2027			U-1510	
			7682634	Jun 19, 2027	DP			
			7815934	Dec 12, 2027	DP			
			8158156	Jun 19, 2027			U-1510	
			8623418	Nov 07, 2029			U-1640	
			8685443	Jul 03, 2025			U-1508	
			8685444	Jul 03, 2025	DP			
			8846104	Jun 19, 2027	DP			
			8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N 022321	002		7682633	Jun 19, 2027			U-1510	
			7682634	Jun 19, 2027	DP			
			7815934	Dec 12, 2027	DP			
			8158156	Jun 19, 2027			U-1510	
			8623418	Nov 07, 2029			U-1640	
			8685443	Jul 03, 2025			U-1508	
			8685444	Jul 03, 2025	DP			
			8846104	Jun 19, 2027	DP			
			8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N 022321	003		7682633	Jun 19, 2027			U-1510	
			7682634	Jun 19, 2027	DP			
			7815934	Dec 12, 2027	DP			
			8158156	Jun 19, 2027			U-1510	
			8623418	Nov 07, 2029			U-1640	
			8685443	Jul 03, 2025			U-1508	
			8685444	Jul 03, 2025	DP			
			8846104	Jun 19, 2027	DP			
			8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N 022321	004		7682633	Jun 19, 2027			U-1510	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 004	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MOTIXAFORTIDE ACETATE - APHEXDA						
N 217159 001					NCE	Sep 08, 2028
					ODE-442	Sep 08, 2030
MOXIDECTIN - MOXIDECTIN						
N 210867 001					ODE-193	Jun 13, 2025
MOXIFLOXACIN HYDROCHLORIDE - MOXEZA						
N 022428 001	8450311	May 29, 2029	DP			
	9114168	May 29, 2029	DP			
NAFTIFINE HYDROCHLORIDE - NAFTIN						
N 204286 001	10166205	Jan 31, 2033	DP			
	10166206	Jan 31, 2033	DP			
	10695303	Jan 31, 2033	DP			
	10729667	Jan 31, 2033	DP			
	8778365	Jan 31, 2033	DP			
	9161914	Jan 31, 2033	U-540			
NALDEMEDINE TOSYLATE - SYMPROIC						
N 208854 001	10952968	May 13, 2033	DS DP			
	9108975	Nov 11, 2031	DS DP			
	RE46365	Jan 11, 2028	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALDEMEDINE TOSYLATE - SYMPROIC						
N 208854 001	RE46375	Oct 05, 2026	DS DP U-1185			
NALMEFENE HYDROCHLORIDE - OPVEE						
N 217470 001	11458091	Jul 10, 2038	DP U-3630		NP	May 22, 2026
NALOXEGOL OXALATE - MOVANTIK						
N 204760 001	7056500	Jun 29, 2024	DP U-1185			
	7786133	Sep 16, 2028	DS DP			
	8067431	Dec 16, 2024	U-1185			
	9012469	Apr 02, 2032	DS DP			
NALOXEGOL OXALATE - MOVANTIK						
N 204760 002	7056500	Jun 29, 2024	DP U-1185			
	7786133	Sep 16, 2028	DS DP			
	8067431	Dec 16, 2024	U-1185			
	9012469	Apr 02, 2032	DS DP			
NALOXONE HYDROCHLORIDE - EVZIO						
N 205787 001	10143972	May 24, 2031	U-2476			
	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	10960155	Jun 25, 2026	DP			
	11590286	Dec 12, 2026	DP			
	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9517307	Jul 18, 2034	DP U-1925			
	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXONE HYDROCHLORIDE - NARCAN								
N 208411	002		9480644	Mar 16, 2035	DP U-1903	Y		
			9707226	Mar 16, 2035	DP U-1903	Y		
NALOXONE HYDROCHLORIDE - REXTOVY								
N 208969	001						NP	Mar 07, 2026
NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)								
N 209862	001		10143792	May 24, 2031	U-2476			
			10220158	Mar 20, 2035	DP U-2500			
			10314977	Nov 23, 2024	DP			
			10322239	Feb 28, 2031	U-1907			
			10335549	Apr 30, 2025	DP			
			10737028	Nov 23, 2024	DP			
			10960155	Jun 25, 2026	DP			
			11590286	Dec 12, 2026	DP			
			7731686	Jun 01, 2026	DP			
			7731690	Jan 15, 2025	DP			
			7749194	Oct 30, 2028	DP			
			7918823	Nov 23, 2024	DP			
			7947017	Mar 12, 2028	DP			
			8016788	Mar 21, 2025	DP			
			8021344	Nov 02, 2029	DP			
			8206360	Feb 27, 2027	DP			
			8226610	Apr 10, 2029	DP			
			8231573	Nov 25, 2028	DP			
			8313466	Nov 23, 2024	DP			
			8361029	Nov 23, 2024	DP			
			8425462	Nov 23, 2024	DP			
			8608698	Nov 23, 2024	DP			
			8627816	Feb 04, 2032	DP			
			8926594	Mar 31, 2026	DP			
			8939943	Feb 28, 2031	DP			
			9022022	Feb 28, 2031	DP			
			9056170	Nov 23, 2024	DP			
			9238108	Feb 20, 2027	DP			
			9278182	Feb 01, 2026	DP			
			9474869	Feb 28, 2031	DP U-1907			
			9517307	Jul 18, 2034	DP U-1925			
			9724471	May 23, 2027	DP U-2092			
			9737669	Nov 23, 2024	DP			
NALOXONE HYDROCHLORIDE - KLOXXADO								
N 212045	001		10722510	Aug 26, 2034	DP U-3110			
			10973814	Aug 26, 2034	DP U-3110			
			11135155	Aug 26, 2034	DP			
			11617713	Aug 26, 2034	DP U-3110			
			11628139	Aug 26, 2034	DP U-3110			
NALOXONE HYDROCHLORIDE - ZIMHI								
N 212854	001		11027072	May 24, 2039	DP			
			11571518	Jun 14, 2041	DP U-3515			
			11571518	Jun 14, 2041	DP U-3516			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXONE HYDROCHLORIDE - ZIMHI						
N 212854 001	11571518	Jun 14, 2041	DP		U-3517	
NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)						
N 215457 001	10143792	May 24, 2031			U-2476	
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031			U-1907	
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	11590286	Dec 12, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9474869	Feb 28, 2031	DP		U-1907	
	9737669	Nov 23, 2024	DP			
	9814838	Feb 28, 2031	DP			
NALOXONE HYDROCHLORIDE - RIVIVE						
N 217722 001	11020343	May 11, 2032			U-3671	
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ						
N 205777 001	9073933	Mar 30, 2025	DS			
	9522919	Mar 30, 2025	DS DP			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ						
N 205777 002	9073933	Mar 30, 2025	DS			
	9522919	Mar 30, 2025	DS DP			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ						
N 205777 003	9073933	Mar 30, 2025	DS			
	9522919	Mar 30, 2025	DS DP			
NALTREXONE - VIVITROL						
N 021897 001	7919499	Oct 15, 2029			U-1123	
	7919499	Oct 15, 2029			U-1124	
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER						
N 207621 001	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025			U-1508	
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER						
N 207621 002	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025			U-1508	
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER						
N 207621 003	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025			U-1508	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER						
N 207621 004	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER						
N 207621 005	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER						
N 207621 006	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
NAPROXEN SODIUM - NAPROXEN SODIUM						
N 021920 001	10022344	Mar 03, 2026	DP U-1731			
	10022344	Mar 03, 2026	DP U-1732			
	10028925	Mar 03, 2026	DP U-1731			
	10028925	Mar 03, 2026	DP U-1732			
	11090280	Mar 03, 2026	DP U-1731			
	11090280	Mar 03, 2026	DP U-1732			
	9693978	Mar 03, 2026	DP			
	9693979	Mar 03, 2026	DP			
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET						
N 021926 001	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET						
N 021926 002	7332183	Oct 02, 2025	DP U-1719			
	7332183*PED	Apr 02, 2026				
NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON						
N 206302 001	7803838	Aug 29, 2026	DP			
	7838552	Oct 04, 2027	U-185			
NEDOSIRAN SODIUM - RIVFLOZA						
N 215842 001	10351854	Oct 09, 2035	DS DP		NCE	Sep 29, 2028
	10738311	Oct 09, 2035	DS DP U-3709		ODE-443	Sep 29, 2030
	11053502	Oct 29, 2035	DS DP			
	11286488	Oct 12, 2038	DS DP U-3709			
	11359203	Oct 09, 2035	DS DP U-3709			
	11661604	Oct 12, 2038	DS DP U-3709			
NEDOSIRAN SODIUM - RIVFLOZA						
N 215842 002	10351854	Oct 09, 2035	DS DP		NCE	Sep 29, 2028
	10738311	Oct 09, 2035	DS DP U-3709		ODE-443	Sep 29, 2030
	11053502	Oct 29, 2035	DS DP			
	11286488	Oct 12, 2038	DS DP U-3709			
	11359203	Oct 09, 2035	DS DP U-3709			
	11661604	Oct 12, 2038	DS DP U-3709			
NEDOSIRAN SODIUM - RIVFLOZA						
N 215842 003	10351854	Oct 09, 2035	DS DP		NCE	Sep 29, 2028
	10738311	Oct 09, 2035	DS DP U-3709		ODE-443	Sep 29, 2030
	11053502	Oct 29, 2035	DS DP			
	11286488	Oct 12, 2038	DS DP U-3709			
	11359203	Oct 09, 2035	DS DP U-3709			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NEDOSIRAN SODIUM - RIVFLOZA						
N 215842 003	11661604	Oct 12, 2038	DS DP U-3709			
NEPAFENAC - NEVANAC						
N 021862 001	7834059	Jan 31, 2027	U-1095			
	8071648	Dec 02, 2025	DP			
	8324281	Dec 02, 2025	DP			
NEPAFENAC - ILEVRO						
N 203491 001	7947295	Jun 08, 2024	DP			
	8921337	Mar 31, 2032	DP			
	9662398	Dec 01, 2030	DP			
NERATINIB MALEATE - NERLYNX						
N 208051 001	10035788	Oct 15, 2028	U-2043		D-182	Jun 28, 2024
	10035788	Oct 15, 2028	U-3047			
	10035788	Oct 15, 2028	U-3097			
	7399865	Dec 29, 2030	DS DP			
	7982043	Oct 08, 2025	U-2043			
	7982043	Oct 08, 2025	U-3047			
	7982043	Oct 08, 2025	U-3097			
	8518446	Nov 20, 2030	DP U-2043			
	8518446	Nov 20, 2030	DP U-3047			
	8518446	Nov 20, 2030	DP U-3097			
	8669273	Jul 18, 2031	U-3047			
	8790708	Nov 05, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-3047			
	8790708	Nov 05, 2030	DP U-3097			
	9139558	Oct 15, 2028	U-2043			
	9139558	Oct 15, 2028	U-3047			
	9139558	Oct 15, 2028	U-3097			
	9211291	Mar 24, 2030	U-2043			
	9211291	Mar 24, 2030	U-3097			
	9265784	Aug 04, 2029	U-3047			
	9630946	Oct 15, 2028	U-2043			
	9630946	Oct 15, 2028	U-3047			
	9630946	Oct 15, 2028	U-3097			
NETARSUDIL MESYLATE - RHOPRESSA						
N 208254 001	10174017	Jan 27, 2030	DS DP U-1524			
	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Jan 27, 2030	DS DP U-1524			
	10882840	Jul 11, 2026	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
	11185538	Mar 14, 2034	DP			
	11618748	Jan 27, 2030	U-1524			
	8394826	Nov 10, 2030	DS DP U-1524			
	8450344	Jul 11, 2026	DS DP U-1524			
	9096569	Jul 11, 2026	DS DP U-1524			
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP U-1524			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NETARSUDIL MESYLATE - RHOPRESSA						
N 208254 001	10174017	Jan 27, 2030	DS DP U-1524			
	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Jan 27, 2030	DS DP U-1524			
	10882840	Jul 11, 2026	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
	11185538	Mar 14, 2034	DP			
	11618748	Jan 27, 2030	U-1524			
	8394826	Nov 10, 2030	DS DP U-1524			
	8450344	Jul 11, 2026	DS DP U-1524			
	9096569	Jul 11, 2026	DS DP U-1524			
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP U-1524			
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO						
N 205718 001	10233154	Sep 25, 2035	DS			
	10676440	Sep 25, 2035	DS DP			
	10828297	Dec 17, 2030	U-2293			
	10961195	Sep 25, 2035	DS DP			
	11559523	Nov 18, 2030	DP U-3522			
	8623826	Nov 18, 2030	U-2293			
	8951969	Nov 18, 2030	DP			
	9186357	Nov 18, 2030	U-2293			
	9271975	Sep 09, 2031	U-2293			
	9943515	Nov 18, 2030	U-2293			
	9951016	Sep 25, 2035	DS DP			
NEVIRAPINE - VIRAMUNE XR						
N 201152 001	8460704	Mar 12, 2029	U-1409			
NICARDIPINE HYDROCHLORIDE - NICARDIPINE HYDROCHLORIDE						
A 215377 001					CGT	Mar 20, 2024
NICARDIPINE HYDROCHLORIDE - NICARDIPINE HYDROCHLORIDE						
A 215377 002					CGT	Mar 20, 2024
NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER						
N 019734 002	10758616	Apr 18, 2027	DP			
	11547758	Apr 18, 2027	U-1029			
	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER						
N 019734 003	10758616	Apr 18, 2027	DP			
	11547758	Apr 18, 2027	U-1029			
	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER						
N 019734 004	10758616	Apr 18, 2027	DP			
	11547758	Apr 18, 2027	U-1029			
	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER						
N 019734 005	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
NICOTINE POLACRILEX - NICORETTE						
N 018612 002	8323683	Apr 30, 2028				
NICOTINE POLACRILEX - NICORETTE						
N 020066 002	8323683	Apr 30, 2028	DP			
NICOTINE POLACRILEX - NICORETTE						
N 022360 001	8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
NICOTINE POLACRILEX - NICORETTE						
N 022360 002	8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
NIFURTIMOX - LAMPIT						
N 213464 001					NCE	Aug 06, 2025
					ODE-319	Aug 06, 2027
NIFURTIMOX - LAMPIT						
N 213464 002					NCE	Aug 06, 2025
					ODE-319	Aug 06, 2027
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 001	7169791*PED	Jan 04, 2024			ODE-171	Mar 22, 2025
	8163904	Aug 23, 2028	DS DP		ODE-172	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-380	Sep 23, 2028
	8293756	Sep 25, 2027	DP		PED	Sep 22, 2025
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2025
	8389537	Jul 18, 2026	U-1374		PED	Mar 23, 2029
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS U-1374			
	9061029	Apr 07, 2032	DS U-3231			
	9061029*PED	Oct 07, 2032				
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 002	7169791*PED	Jan 04, 2024			ODE-171	Mar 22, 2025
	8163904	Aug 23, 2028	DS DP		ODE-172	Mar 22, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 002	8163904*PED	Feb 23, 2029			ODE-380	Sep 23, 2028
	8293756	Sep 25, 2027	DP		PED	Sep 22, 2025
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2025
	8389537	Jul 18, 2026	U-1374		PED	Mar 23, 2029
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS U-1374			
	9061029	Apr 07, 2032	DS U-3231			
	9061029*PED	Oct 07, 2032				
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 003	7169791*PED	Jan 04, 2024			ODE-171	Mar 22, 2025
	8163904	Aug 23, 2028	DS DP		ODE-172	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-380	Sep 23, 2028
	8293756	Sep 25, 2027	DP		PED	Sep 22, 2025
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2025
	8389537	Jul 18, 2026	U-1374		PED	Mar 23, 2029
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS U-1374			
	9061029	Apr 07, 2032	DS U-3231			
	9061029*PED	Oct 07, 2032				
NIMODIPINE - NYMALIZE						
N 203340 002	10342787	Apr 16, 2038	DP U-2804			
	10576070	Apr 16, 2038	DP U-2804			
	11207306	Apr 16, 2038	U-2804			
	11413277	Apr 16, 2038	DP U-2804			
	11806338	Apr 16, 2038	DP			
	8517997	May 14, 2024	DP			
NINTEDANIB ESYLATE - OFEV						
N 205832 001	10105323	Jun 04, 2029	DP		ODE-261	Sep 06, 2026
	10105323*PED	Dec 04, 2029			PED	Mar 06, 2027
	10154990	Jan 08, 2026	U-2620			
	10154990*PED	Jul 08, 2026				
	6762180	Oct 01, 2025	DS DP			
	6762180*PED	Apr 01, 2026				
	7119093	Feb 21, 2024	DS DP			
	9907756	Jun 07, 2029	DP			
	9907756*PED	Dec 07, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NINTEDANIB ESYLATE - OFEV						
N 205832 002	10105323	Jun 04, 2029	DP		ODE-261	Sep 06, 2026
	10105323*PED	Dec 04, 2029			PED	Mar 06, 2027
	10154990	Jan 08, 2026	U-2620			
	10154990*PED	Jul 08, 2026				
	6762180	Oct 01, 2025	DS DP			
	6762180*PED	Apr 01, 2026				
	7119093	Feb 21, 2024	DS DP			
	9907756	Jun 07, 2029	DP			
	9907756*PED	Dec 07, 2029				
NIRAPARIB TOSYLATE - ZEJULA						
N 208447 001	11091459	Mar 27, 2038	DP		ODE-133	Mar 27, 2024
	11673877	Mar 27, 2038	DP U-3646		ODE-277	Oct 23, 2026
	11673877	Mar 27, 2038	DP U-3647		ODE-295	Apr 29, 2027
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
NIRAPARIB TOSYLATE - ZEJULA						
N 214876 001	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
	11730725	Jan 04, 2039	DP			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
NIRAPARIB TOSYLATE - ZEJULA						
N 214876 002	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
	11730725	Jan 04, 2039	DP			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
NIRAPARIB TOSYLATE - ZEJULA						
N 214876 003	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
	11730725	Jan 04, 2039	DP			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIRAPARIB TOSYLATE - ZEJULA						
N 214876 003	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
	11730725	Jan 04, 2039	DP			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)						
N 217188 001	11351149	Aug 05, 2041	DS DP U-3629		NCE	May 25, 2028
	11541034	Oct 31, 2041	U-3629			
NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)						
N 217188 002					NCE	May 25, 2028
NIROGACESTAT HYDROBROMIDE - OGSIVEO						
N 217677 001	10590087	Aug 09, 2039	DS			
	10710966	Aug 09, 2039	DS U-3754			
	10941118	Aug 09, 2039	DS U-3754			
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP U-3754			
	11807611	Sep 08, 2042	DP U-3754			
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP U-3754			
	11845732	Aug 09, 2039	DS U-3754			
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
NITISINONE - ORFADIN						
N 206356 001	9301932	Feb 28, 2033	DP U-1836			
NITISINONE - NITYR						
N 209449 001	10328029	Jan 05, 2035	DP U-1836			
NITISINONE - NITYR						
N 209449 002	10328029	Jan 05, 2035	DP U-1836			
NITISINONE - NITYR						
N 209449 003	10328029	Jan 05, 2035	DP U-1836			
NITRIC OXIDE - INOMAX						
N 020845 002	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NITRIC OXIDE - INOMAX						
N 020845 002	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
NITRIC OXIDE - INOMAX						
N 020845 003	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
	9408993	Jan 06, 2031	DP U-1824			
	9408993*PED	Jul 06, 2031				
	9770570	May 03, 2036	U-2148			
	9770570*PED	Nov 03, 2036				
NITRIC OXIDE - GENOSYL						
N 202860 001	10124142	Aug 18, 2025	U-3037			
	10213572	Feb 12, 2036	DP			
	10737051	Oct 20, 2035	DP			
	10814092	Oct 17, 2025	U-3037			
	10926054	Aug 13, 2029	DP			
	11103669	Jun 21, 2030	DP			
	11291793	Aug 18, 2025	DP			
	11383059	Aug 18, 2025	U-3037			
	11511252	Sep 21, 2029	DP			
	11554241	Aug 18, 2025	U-3037			
	11672938	Jul 22, 2040	U-3037			
	7560076	Apr 21, 2027	DP			
	7618594	Oct 17, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NITRIC OXIDE - GENOSYL								
N 202860	001		7947227	Oct 17, 2026	U-3037			
			8057742	Jan 18, 2026	U-3037			
			8226916	Aug 18, 2025	U-3037			
			8607785	Jul 14, 2030	DP			
			8609028	Aug 18, 2025	U-3037			
			8821801	Aug 18, 2025	DP			
			8944049	Aug 13, 2029	DP			
			9522249	Aug 18, 2025	DP			
			9604028	Aug 13, 2029	U-2793			
			9701538	Jan 28, 2029	DP			
			9956373	Aug 18, 2025	U-3037			
NITROGLYCERIN - NITROLINGUAL PUMPSPRAY								
N 018705	002		7872049	Mar 12, 2029	DP U-2223			
NITROGLYCERIN - GONITRO								
N 208424	001		9101592	Mar 11, 2032	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N 214628	001		10159657	Jan 30, 2038	DP			
			10226436	Jan 30, 2038	DP U-3461			
			10420735	Jan 30, 2038	DP U-3461			
			10568850	Jan 30, 2038	DP			
			11413259	Jan 30, 2038	DP U-3461			
			11602508	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N 214628	002		10159657	Jan 30, 2038	DP			
			10226436	Jan 30, 2038	DP U-3461			
			10420735	Jan 30, 2038	DP U-3461			
			10568850	Jan 30, 2038	DP			
			11413259	Jan 30, 2038	DP U-3461			
			11602508	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N 214628	003		10159657	Jan 30, 2038	DP			
			10226436	Jan 30, 2038	DP U-3461			
			10420735	Jan 30, 2038	DP U-3461			
			10568850	Jan 30, 2038	DP			
			11413259	Jan 30, 2038	DP U-3461			
			11602508	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N 215700	001		10888534	Apr 26, 2039	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N 215700	002		10888534	Apr 26, 2039	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N 215700	003		10888534	Apr 26, 2039	DP			
NORGESTREL - OPILL								
N 017031	001						RTO	Jul 13, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NUSINERSEN SODIUM - SPINRAZA						
N 209531 001	10266822	Dec 05, 2025	U-1942			
	10266822	Dec 05, 2025	U-1943			
	10266822	Dec 05, 2025	U-1944			
	10436802	Sep 11, 2035	U-1941			
	10436802	Sep 11, 2035	U-1942			
	10436802	Sep 11, 2035	U-1943			
	10436802	Sep 11, 2035	U-1944			
	10436802	Sep 11, 2035	U-2093			
	10436802	Sep 11, 2035	U-2094			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025	U-1942			
	8110560	Dec 05, 2025	U-1943			
	8110560	Dec 05, 2025	U-1944			
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030	U-1941			
	9717750	Jun 17, 2030	U-1942			
	9717750	Jun 17, 2030	U-1943			
	9717750	Jun 17, 2030	U-2093			
	9717750	Jun 17, 2030	U-2094			
	9926559	Jan 09, 2034	U-1943			
OBETICHOLIC ACID - OCALIVA						
N 207999 001	10047117	Sep 06, 2033	U-1854			
	10052337	Apr 26, 2036	DP			
	10174073	Jun 17, 2033	DS			
	10751349	Apr 26, 2036	DP			
	10758549	Apr 26, 2036	U-2945			
	9238673	Jun 17, 2033	DP			
	RE48286	Feb 21, 2027	DS DP			
OBETICHOLIC ACID - OCALIVA						
N 207999 002	10047117	Sep 06, 2033	U-1854			
	10052337	Apr 26, 2036	DP			
	10174073	Jun 17, 2033	DS			
	10751349	Apr 26, 2036	DP			
	10758549	Apr 26, 2036	U-2945			
	9238673	Jun 17, 2033	DP			
	RE48286	Feb 21, 2027	DS DP			
OCTREOTIDE ACETATE - MYCAPSSA						
N 208232 001	10238709	Feb 03, 2036	U-2857			
	10695397	Feb 03, 2036	U-2857			
	11052126	Feb 03, 2036	U-2857			
	11141457	Dec 28, 2040	U-3232			
	11338011	Feb 03, 2036	U-2857			
	11510963	Feb 03, 2036	U-2857			
	8329198	Sep 17, 2029	DP			
	8535695	Sep 17, 2029	U-2857			
	9265812	Sep 17, 2029	DP			
	9566246	Sep 17, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ODEVIXIBAT - BYLVAY						
N 215498 001	10011633	Nov 08, 2031	U-3186		I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3187		NCE	Jul 20, 2026
	10011633	Nov 08, 2031	U-3648		ODE-363	Jul 20, 2028
	10011633	Nov 08, 2031	U-3649		ODE-436	Jun 13, 2030
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3187			
	11732006	Nov 08, 2031	U-3648			
	11732006	Nov 08, 2031	U-3649			
	11801226	Jun 20, 2039	DP			
	11802115	Jun 20, 2039	DP			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
ODEVIXIBAT - BYLVAY						
N 215498 002	10011633	Nov 08, 2031	U-3186		I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3187		NCE	Jul 20, 2026
	10011633	Nov 08, 2031	U-3648		ODE-363	Jul 20, 2028
	10011633	Nov 08, 2031	U-3649		ODE-436	Jun 13, 2030
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ODEVIXIBAT - BYLVAY						
N 215498 002	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3187			
	11732006	Nov 08, 2031	U-3648			
	11732006	Nov 08, 2031	U-3649			
	11801226	Jun 20, 2039	DP			
	11802115	Jun 20, 2039	DP			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
ODEVIXIBAT - BYLVAY						
N 215498 003	10011633	Nov 08, 2031	U-3186		I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3187		NCE	Jul 20, 2026
	10011633	Nov 08, 2031	U-3648		ODE-363	Jul 20, 2028
	10011633	Nov 08, 2031	U-3649		ODE-436	Jun 13, 2030
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3187			
	11732006	Nov 08, 2031	U-3648			
	11732006	Nov 08, 2031	U-3649			
	11801226	Jun 20, 2039	DP			
	11802115	Jun 20, 2039	DP			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ODEVIXIBAT - BYLVAY						
N 215498 003	10011633	Nov 08, 2031	U-3186		I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3187		NCE	Jul 20, 2026
	10011633	Nov 08, 2031	U-3648		ODE-363	Jul 20, 2028
	10011633	Nov 08, 2031	U-3649		ODE-436	Jun 13, 2030
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3187			
	11732006	Nov 08, 2031	U-3648			
	11732006	Nov 08, 2031	U-3649			
	11801226	Jun 20, 2039	DP			
	11802115	Jun 20, 2039	DP			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
ODEVIXIBAT - BYLVAY						
N 215498 004	10011633	Nov 08, 2031	U-3186		I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3187		NCE	Jul 20, 2026
	10011633	Nov 08, 2031	U-3648		ODE-363	Jul 20, 2028
	10011633	Nov 08, 2031	U-3649		ODE-436	Jun 13, 2030
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ODEVIXIBAT - BYLVAY						
N 215498 004	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3187			
	11732006	Nov 08, 2031	U-3648			
	11732006	Nov 08, 2031	U-3649			
	11801226	Jun 20, 2039	DP			
	11802115	Jun 20, 2039	DP			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 001	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
	11707466	Nov 12, 2041	DP			
	11793805	Aug 23, 2031	U-3734			
	7262298	Nov 23, 2025	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 002	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
	11707466	Nov 12, 2041	DP			
	11793805	Aug 23, 2031	U-3734			
	7262298	Nov 23, 2025	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 002	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 003	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
	11707466	Nov 12, 2041	DP			
	11793805	Aug 23, 2031	U-3734			
	7262298	Nov 23, 2025	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 004	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
	11707466	Nov 12, 2041	DP			
	11793805	Aug 23, 2031	U-3734			
	7262298	Nov 23, 2025	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLAPARIB - LYNPARZA						
N 206162 001	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027	U-1634			
	8247416	Sep 24, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA						
N 206162 001	8859562	Aug 04, 2031	U-1634			
	8912187	Mar 12, 2024	U-1634			
OLAPARIB - LYNPARZA						
N 208558 001	11633396	Oct 07, 2029	DP		I-885	Mar 11, 2025
	7449464	Oct 11, 2024	DS DP		I-914	May 31, 2026
	7981889	Oct 11, 2024	DS DP		ODE-180	Aug 17, 2024
	8071579	Aug 12, 2027	U-2480		ODE-181	Aug 17, 2024
	8071579	Aug 12, 2027	U-2482		ODE-226	Dec 19, 2025
	8071579	Aug 12, 2027	U-2483		ODE-283	Dec 27, 2026
	8071579	Aug 12, 2027	U-2716		ODE-306	May 08, 2027
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8071579	Aug 12, 2027	U-3631			
	8071579	Aug 12, 2027	U-3695			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-3631			
	8143241	Aug 12, 2027	U-3695			
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA						
N 208558 001	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8859562	Aug 04, 2031	U-3631			
	8859562	Aug 04, 2031	U-3695			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
	8912187	Mar 12, 2024	U-3695			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9169235	Mar 12, 2024	U-3631			
	9566276	Mar 12, 2024	U-2716			
OLAPARIB - LYNPARZA						
N 208558 002	11633396	Oct 07, 2029	DP		I-885	Mar 11, 2025
	7449464	Oct 11, 2024	DS DP		I-914	May 31, 2026
	7981889	Oct 11, 2024	DS DP		ODE-180	Aug 17, 2024
	8071579	Aug 12, 2027	U-2480		ODE-181	Aug 17, 2024
	8071579	Aug 12, 2027	U-2482		ODE-226	Dec 19, 2025
	8071579	Aug 12, 2027	U-2483		ODE-283	Dec 27, 2026
	8071579	Aug 12, 2027	U-2716		ODE-306	May 08, 2027
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8071579	Aug 12, 2027	U-3631			
	8071579	Aug 12, 2027	U-3695			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA						
N 208558 002	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-3631			
	8143241	Aug 12, 2027	U-3695			
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8859562	Aug 04, 2031	U-3631			
	8859562	Aug 04, 2031	U-3695			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
	8912187	Mar 12, 2024	U-3695			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9169235	Mar 12, 2024	U-3631			
	9566276	Mar 12, 2024	U-2716			
OLICERIDINE - OLINVYK						
N 210730 001	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
	8835488	Mar 23, 2032	DS DP U-2986			
	9309234	Mar 23, 2032	DS DP U-2986			
	9642842	Mar 23, 2032	DP U-2986			
OLICERIDINE - OLINVYK						
N 210730 002	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
	8835488	Mar 23, 2032	DS DP U-2986			
	9309234	Mar 23, 2032	DS DP U-2986			
	9642842	Mar 23, 2032	DP U-2986			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLICERIDINE - OLINVYK						
N 210730 003	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
	8835488	Mar 23, 2032	DS DP U-2986			
	9309234	Mar 23, 2032	DS DP U-2986			
	9642842	Mar 23, 2032	DP U-2986			
OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT						
N 203108 001	7220742	May 12, 2025	DS DP U-1547			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP U-1547			
	7727984	Jan 19, 2027	DS			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	8034809	May 12, 2025	U-1547			
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT						
N 206756 001	7220742	May 12, 2025	DS DP U-1703			
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7727984	Jan 19, 2027	DS			
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	8034809	May 12, 2025	U-1702			
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
OLOPATADINE HYDROCHLORIDE - PATADAY ONCE DAILY RELIEF						
N 206276 001	8791154	May 19, 2032	DP U-1680			
	9533053	May 19, 2032	DP			
OLUTASIDENIB - REZLIDHIA						
N 215814 001	10414752	Sep 18, 2035	DP		NCE	Dec 01, 2027
	10532047	May 16, 2039	DS		ODE-413	Dec 01, 2029
	10550098	Sep 18, 2035	DP			
	10959994	May 16, 2039	DP			
	11013733	May 16, 2039	U-3496			
	11013734	May 16, 2039	U-3495			
	11376246	May 16, 2039	U-3495			
	11497743	May 16, 2039	U-3495			
	11498913	Sep 18, 2035	DP			
	11723905	Nov 12, 2039	DP			
	11738018	Jul 17, 2039	U-3684			
	9834539	Sep 18, 2035	DS DP U-3497			
OMACETAXINE MEPESUCCINATE - SYNRIBO						
N 203585 001	6987103	Oct 26, 2026	U-1300			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OMADACYCLINE TOSYLATE - NUZYRA						
N 209816 001	10111890	Aug 03, 2037	U-2444		NCE	Oct 02, 2023
	10124014	Mar 05, 2029	U-2449		GAIN	Oct 02, 2028
	10383884	Oct 31, 2037	U-2576			
	10835542	Oct 31, 2037	U-2576			
	7553828	Jun 02, 2024	DS			
	8383610	Sep 23, 2030	DS			
	9265740	Mar 05, 2029	U-1569			
	9314475	Mar 18, 2031	DP			
	9724358	Mar 05, 2029	U-1569			
OMADACYCLINE TOSYLATE - NUZYRA						
N 209817 001	10124014	Mar 05, 2029	U-2449		NCE	Oct 02, 2023
	10383884	Oct 31, 2037	U-2576		GAIN	Oct 02, 2028
	10835542	Oct 31, 2037	U-2576			
	7553828	Jun 02, 2024	DS			
	9265740	Mar 05, 2029	DP			
	9724358	Mar 05, 2029	U-1569			
OMAVELOXOLONE - SKYCLARYS						
N 216718 001	11091430	Apr 20, 2029	U-3552		NCE	Feb 28, 2028
	8124799	Dec 03, 2029	DS		ODE-427	Feb 28, 2030
	8440854	Apr 20, 2029	DP			
	8993640	Apr 24, 2033	DS DP			
	9670147	Apr 20, 2029	DS			
	9701709	Apr 24, 2033	DS DP			
OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE						
N 207931 001	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8420596	Apr 10, 2031	DS DP			
	8420596*PED	Oct 10, 2031				
	8642538	Sep 10, 2029	DS DP	U-1638		
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
OMEGA-3-CARBOXYLIC ACIDS - EPANOVA						
N 205060 001	10117844	Jan 04, 2033	U-2447			
	7960370	Dec 20, 2026	DP			
	8383678	Feb 07, 2025	DP	U-1511		
	9012501	Feb 07, 2025	DP	U-1511		
	9050308	Jan 04, 2033	U-1511			
	9050309	Jan 04, 2033	DS			
	9132112	Feb 07, 2025	DP	U-1511		
OMEPRAZOLE - OMEPRAZOLE						
N 022032 001	9023391	Aug 16, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OMEPRAZOLE - OMEPRAZOLE						
N 209400 001	10076494	Dec 08, 2036	DP			
	10835488	Dec 08, 2036	DP			
OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEP						
N 213593 001	10751333	Jul 16, 2039	DP			
	11103492	Jul 16, 2039	DP			
	11633478	Jul 16, 2039	DP			
	11771686	Mar 01, 2040	U-623			
OMIDENEPAG ISOPROPYL - OMLONTI						
N 215092 001	10179127	Jan 08, 2035	DP U-3454		NCE	Sep 22, 2027
	10702511	Jan 08, 2035	DP U-3454			
	10765750	Jan 08, 2035	DP			
	10774072	Jun 10, 2035	DS			
	11197849	Jan 08, 2035	DP U-3454			
	11666563	Jul 16, 2039	U-3454			
	11793798	Jan 08, 2035	DP U-3454			
	8648097	Oct 13, 2029	DS DP			
	8685986	Oct 13, 2029	DP			
	9415038	Jan 08, 2035	DP U-3454			
	RE48183	Jan 08, 2035	DP U-3454			
ONDANSETRON - ZUPLENZ						
N 022524 001	8580830	Nov 23, 2029	DP			
	9095577	Jul 13, 2030	DP			
ONDANSETRON - ZUPLENZ						
N 022524 002	8580830	Nov 23, 2029	DP			
	9095577	Jul 13, 2030	DP			
OPICAPONE - ONGENTYS						
N 212489 001	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029	U-2811			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-2811			
	9550759	Jul 26, 2026	U-2817			
	9550759	Jul 26, 2026	U-2818			
	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP U-2811			
OPICAPONE - ONGENTYS						
N 212489 002	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029	U-2811			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-2811			
	9550759	Jul 26, 2026	U-2817			
	9550759	Jul 26, 2026	U-2818			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OPICAPONE - ONGENTYS						
N 212489 002	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP U-2811			
ORITAVANCIN DIPHOSPHATE - ORBACTIV						
N 206334 001	8420592	Aug 29, 2029	U-1570		NCE	Aug 06, 2019
	9649352	Jul 16, 2035	DP		GAIN	Aug 06, 2024
	9682061	Apr 26, 2030	U-1569			
ORITAVANCIN DIPHOSPHATE - KIMYRSA						
N 214155 001	8420592	Aug 29, 2029	U-3101		NCE	Aug 06, 2019
	9649352	Jul 16, 2035	DS DP		NP	Mar 12, 2024
	9682061	Apr 26, 2030	U-3101		GAIN	Aug 06, 2024
OSILODROSTAT PHOSPHATE - ISTURISA						
N 212801 001	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
OSILODROSTAT PHOSPHATE - ISTURISA						
N 212801 002	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
OSILODROSTAT PHOSPHATE - ISTURISA						
N 212801 003	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
OSIMERTINIB MESYLATE - TAGRISSO						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		ODE-176	Apr 18, 2025
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	11524951	Jul 25, 2032	DS DP			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
OSIMERTINIB MESYLATE - TAGRISSO						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		ODE-176	Apr 18, 2025
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	11524951	Jul 25, 2032	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OSIMERTINIB MESYLATE - TAGRISSO						
N 208065 002	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
OSPEMIFENE - OSPHENA						
N 203505 001	6245819	Jul 21, 2025	U-1370			
	6245819	Jul 21, 2025	U-905			
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8470890	Feb 13, 2024	U-905			
	8642079	Jul 09, 2028	DP			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	8772353	Feb 13, 2024	U-905			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-905			
	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
	9855224	Feb 13, 2024	U-905			
OTESECONAZOLE - VIVJOA						
N 215888 001	10414751	Mar 17, 2036	DS DP		NCE	Apr 26, 2027
	11247981	May 09, 2033	U-3366		GAIN	Apr 26, 2032
	8236962	Apr 22, 2031	DS DP			
	8754227	Apr 22, 2031	U-3366			
	9840492	Mar 17, 2036	DS DP			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 001	10220042	Apr 13, 2027	U-2501			
	11166960	Apr 13, 2027	DP			
	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027	U-2041			
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027	U-2041			
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
	9855278	Apr 13, 2027	DP			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 002	10220042	Apr 13, 2027	U-2501			
	11166960	Apr 13, 2027	DP			
	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027	U-2041			
	8617600	Apr 13, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXCARBAZEPINE - OXTELLAR XR						
N 202810 002	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027	U-2041			
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
	9855278	Apr 13, 2027	DP			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 003	10220042	Apr 13, 2027	U-2501			
	11166960	Apr 13, 2027	DP			
	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027	U-2041			
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027	U-2041			
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
	9855278	Apr 13, 2027	DP			
OXYBUTYNIN CHLORIDE - GELNIQUE						
N 022204 001	10449173	Nov 06, 2029	DP		U-2637	
	8920392	Mar 26, 2031	U-1644			
	9259388	Nov 06, 2029	U-1644			
OXYCODONE - XTAMPZA ER						
N 208090 001	10004729	Dec 10, 2030	DP		U-1556	
	10188644	Sep 02, 2036	DP		U-1556	
	10646485	Sep 02, 2036	DP		U-1556	
	10668060	Dec 10, 2030	DP		U-1556	
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	9682075	Dec 10, 2030	DP		U-1556	
	9737530	Sep 02, 2036	DP		U-1556	
	9968598	Sep 02, 2036	DP		U-1556	
OXYCODONE - XTAMPZA ER						
N 208090 002	10004729	Dec 10, 2030	DP		U-1556	
	10188644	Sep 02, 2036	DP		U-1556	
	10646485	Sep 02, 2036	DP		U-1556	
	10668060	Dec 10, 2030	DP		U-1556	
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	9682075	Dec 10, 2030	DP		U-1556	
	9737530	Sep 02, 2036	DP		U-1556	
	9968598	Sep 02, 2036	DP		U-1556	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE - XTAMPZA ER						
N 208090 003	10004729	Dec 10, 2030	DP U-1556			
	10188644	Sep 02, 2036	DP U-1556			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER						
N 208090 004	10004729	Dec 10, 2030	DP U-1556			
	10188644	Sep 02, 2036	DP U-1556			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER						
N 208090 005	10004729	Dec 10, 2030	DP U-1556			
	10188644	Sep 02, 2036	DP U-1556			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 001	10407434	Mar 30, 2025	DS			
	10696684	Mar 30, 2025	DS			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 001	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 002	10407434	Mar 30, 2025	DS			
	10696684	Mar 30, 2025	DS			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 003	10407434	Mar 30, 2025	DS			
	10696684	Mar 30, 2025	DS			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 004	10407434	Mar 30, 2025	DS			
	10696684	Mar 30, 2025	DS			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 004	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 005	10407434	Mar 30, 2025	DS			
	10696684	Mar 30, 2025	DS			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 006	10407434	Mar 30, 2025	DS			
	10696684	Mar 30, 2025	DS			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 007	10407434	Mar 30, 2025	DS			
	10696684	Mar 30, 2025	DS			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808741	Aug 24, 2027	U-1556			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN								
N	022272	007	8894988	Aug 24, 2027	DP			
			9073933	Mar 30, 2025	DS			
			9492389	Aug 24, 2027	DP			
			9492391	Aug 24, 2027			U-1556	
			9492392	Aug 24, 2027	DP			
			9492393	Aug 24, 2027			U-1556	
			9522919	Mar 30, 2025	DS DP			
			9763933	Aug 24, 2027	DP			
			9770416	Aug 24, 2027	DP			
			9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXAYDO								
N	202080	001	7201920	Mar 16, 2025	DP			
			9492443	May 26, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXAYDO								
N	202080	002	7201920	Mar 16, 2025	DP			
			9492443	May 26, 2024	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND								
N	209777	001	10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND								
N	209777	002	10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND								
N	209777	003	10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
OXYMETAZOLINE HYDROCHLORIDE - RHOFADE								
N	208552	001	10335391	Jun 11, 2035			U-2567	
			10751325	Jun 11, 2035			U-2921	
			11517560	Jun 11, 2035			U-3494	
			7812049	May 02, 2028			U-1959	
			8420688	Aug 02, 2024			U-1959	
			8815929	Jan 22, 2024			U-1959	
			8883838	Dec 01, 2031	DP			
			9974773	Jun 11, 2035			U-2306	
OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ								
N	212520	001	10799481	Dec 16, 2039			U-2849	
			10814001	Dec 16, 2039	DP			
			10898573	Dec 16, 2039	DP			
			10912765	Aug 26, 2031			U-2849	
			10940138	Dec 16, 2039			U-2849	
			11103482	Dec 16, 2039	DP			
			11311515	Dec 16, 2039	DP			
			11324722	Dec 16, 2039			U-2849	
			11541036	Dec 16, 2039	DP			
			11701343	Dec 16, 2039			U-2849	
			8357714	Aug 26, 2031			U-2849	
			9867808	Aug 26, 2031			U-2849	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ						
N 212520 001	10799481	Dec 16, 2039			U-2849	
	10814001	Dec 16, 2039	DP			
	10898573	Dec 16, 2039	DP			
	10912765	Aug 26, 2031			U-2849	
	10940138	Dec 16, 2039			U-2849	
	11103482	Dec 16, 2039	DP			
	11311515	Dec 16, 2039	DP			
	11324722	Dec 16, 2039			U-2849	
	11541036	Dec 16, 2039	DP			
	11701343	Dec 16, 2039			U-2849	
	8357714	Aug 26, 2031			U-2849	
	9867808	Aug 26, 2031			U-2849	
OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE						
N 208032 001	8580282	Apr 02, 2030	DP		U-1876	
	9308191	Apr 02, 2030	DP		U-1876	
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 001	8808737	Jun 21, 2027			U-3085	
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 002	8808737	Jun 21, 2027			U-3085	
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 003	8808737	Jun 21, 2027			U-3085	
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 004	8808737	Jun 21, 2027			U-3085	
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 005	8808737	Jun 21, 2027			U-3085	
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 006	8808737	Jun 21, 2027			U-3085	
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 007	8808737	Jun 21, 2027			U-3085	
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 001	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8808737	Jun 21, 2027			U-1598	
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 002	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 002	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 003	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 004	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 005	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 006	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 007	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OZANIMOD HYDROCHLORIDE - ZEPOSIA						
N 209899 001	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
	11680050	Sep 30, 2038	DS DP U-2774		NCE	Mar 25, 2025
	11680050	Sep 30, 2038	DS DP U-3740			
	8481573	May 14, 2029	DS DP U-2774			
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
OZANIMOD HYDROCHLORIDE - ZEPOSIA						
N 209899 002	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
	11680050	Sep 30, 2038	DS DP U-2774		NCE	Mar 25, 2025
	11680050	Sep 30, 2038	DS DP U-3740			
	8481573	May 14, 2029	DS DP U-2774			
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OZANIMOD HYDROCHLORIDE - ZEPOSIA						
N 209899 003	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
	11680050	Sep 30, 2038	DS DP U-2774		NCE	Mar 25, 2025
	11680050	Sep 30, 2038	DS DP U-3740			
	8481573	May 14, 2029	DS DP U-2774			
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
OZENOXACIN - XEPI						
N 208945 001	9180200	Jan 29, 2032	DP U-805			
	9399014	Dec 15, 2029	U-805			
PACLITAXEL - ABRAXANE						
N 021660 001	7758891	Feb 21, 2026	U-1434			
	7758891*PED	Aug 21, 2026				
	7820788	Oct 27, 2024	DP U-1092			
	7820788	Oct 27, 2024	DP U-1290			
	7820788	Oct 27, 2024	DP U-1434			
	7820788*PED	Apr 27, 2025				
	7923536*PED	Jun 09, 2024				
	8034375	Aug 13, 2026	U-1290			
	8138229*PED	Jun 09, 2024				
	8268348	Feb 21, 2026	U-1290			
	8314156*PED	Jun 09, 2024				
	9101543	Feb 21, 2026	U-1434			
	9101543*PED	Aug 21, 2026				
	9393318	Mar 04, 2032	U-1290			
	9393318*PED	Sep 04, 2032				
	9511046	Jan 12, 2034	U-1434			
	9511046*PED	Jul 12, 2034				
	9597409	Mar 04, 2032	U-1290			
	9597409*PED	Sep 04, 2032				
PACRITINIB CITRATE - VONJO						
N 208712 001	8153632	Jan 17, 2029	DS DP U-3331		NCE	Feb 28, 2027
	8153632	Jan 17, 2029	DS DP U-3332		ODE-397	Feb 28, 2029
	8980873	Mar 25, 2030	DS DP U-3331			
	8980873	Mar 25, 2030	DS DP U-3332			
	9573964	May 05, 2028	U-3331			
	9573964	May 05, 2028	U-3332			
PAFOLACIANINE SODIUM - CYTALUX						
N 214907 001	10881747	Aug 26, 2033	DS DP U-3291		I-905	Dec 16, 2025
	9061057	Aug 26, 2033	DS DP U-3291		NCE	Nov 29, 2026
	9254341	Oct 04, 2033	DS DP		ODE-390	Nov 29, 2028
	9333270	Aug 26, 2033	DS DP U-3291			
	9341629	Aug 26, 2033	DS DP			
	9789208	Aug 26, 2033	DS DP U-3291			
PALBOCICLIB - IBRANCE						
N 207103 001	10723730	Feb 08, 2034	DS DP			
	RE47739	Mar 05, 2027	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALBOCICLIB - IBRANCE						
N 207103 002	10723730	Feb 08, 2034	DS DP			
	RE47739	Mar 05, 2027	DS DP			
PALBOCICLIB - IBRANCE						
N 207103 003	10723730	Feb 08, 2034	DS DP			
	RE47739	Mar 05, 2027	DS DP			
PALBOCICLIB - IBRANCE						
N 212436 001	10723730	Feb 08, 2034	DS DP			
	11065250	Aug 19, 2036	DP			
	RE47739	Mar 05, 2027	DS DP			
PALBOCICLIB - IBRANCE						
N 212436 002	10723730	Feb 08, 2034	DS DP			
	11065250	Aug 19, 2036	DP			
	RE47739	Mar 05, 2027	DS DP			
PALBOCICLIB - IBRANCE						
N 212436 003	10723730	Feb 08, 2034	DS DP			
	11065250	Aug 19, 2036	DP			
	RE47739	Mar 05, 2027	DS DP			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 001	9439906	Jan 26, 2031			U-1901	
	9439906	Jan 26, 2031			U-2757	
	9439906	Jan 26, 2031			U-2758	
	9439906	Jan 26, 2031			U-543	
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 002	9439906	Jan 26, 2031			U-1901	
	9439906	Jan 26, 2031			U-2757	
	9439906	Jan 26, 2031			U-2758	
	9439906	Jan 26, 2031			U-543	
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 003	9439906	Jan 26, 2031			U-1901	
	9439906	Jan 26, 2031			U-2757	
	9439906	Jan 26, 2031			U-2758	
	9439906	Jan 26, 2031			U-543	
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 004	9439906	Jan 26, 2031			U-1901	
	9439906	Jan 26, 2031			U-2757	
	9439906	Jan 26, 2031			U-2758	
	9439906	Jan 26, 2031			U-543	
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 005	9439906	Jan 26, 2031			U-1901	
	9439906	Jan 26, 2031			U-2757	
	9439906	Jan 26, 2031			U-2758	
	9439906	Jan 26, 2031			U-543	
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 001	10143693	Apr 05, 2036			U-2457	
	10143693	Apr 05, 2036			U-2458	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 002	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 003	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 004	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
PALIPERIDONE PALMITATE - INVEGA HAFYERA						
N 207946 005	11304951	May 07, 2041	U-3349		NS	Aug 30, 2024
	11324751	May 07, 2041	U-3359			
	11666697	Nov 24, 2041	U-3626			
PALIPERIDONE PALMITATE - INVEGA HAFYERA						
N 207946 006	11304951	May 07, 2041	U-3349		NS	Aug 30, 2024
	11324751	May 07, 2041	U-3359			
	11666697	Nov 24, 2041	U-3626			
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 001	7947724	Jan 30, 2024	DP			
	7947724*PED	Jul 30, 2024				
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				
	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457020*PED	Jul 30, 2024				
	9457021	Jan 30, 2024	DP			
	9457021*PED	Jul 30, 2024				
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 002	7947724	Jan 30, 2024	DP			
	7947724*PED	Jul 30, 2024				
	7947725	Jan 30, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 002	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457020*PED	Jul 30, 2024				
PALOVAROTENE - SOHONOS						
N 215559 001	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
PALOVAROTENE - SOHONOS						
N 215559 002	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
PALOVAROTENE - SOHONOS						
N 215559 003	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
PALOVAROTENE - SOHONOS						
N 215559 004	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
PALOVAROTENE - SOHONOS						
N 215559 005	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 001	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PANOBINOSTAT LACTATE - FARYDAK							
N 205353	002	7989494	Jan 17, 2028	DS DP			
		8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK							
N 205353	003	7989494	Jan 17, 2028	DS DP			
		8883842	Jun 13, 2028	U-1669			
PANTOPRAZOLE SODIUM - PROTONIX							
N 022020	001	7544370	Jun 07, 2026	DP			
		7550153	Sep 30, 2024	U-859			
		7553498	Sep 30, 2024	U-859			
		7838027	Sep 30, 2024	DP U-859			
PAROXETINE MESYLATE - PEXEVA							
N 021299	001	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA							
N 021299	002	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA							
N 021299	003	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA							
N 021299	004	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - BRISDELLE							
N 204516	001	7598271	May 04, 2025	DS			
		8658663	Apr 06, 2029	DS DP U-904			
		8946251	Aug 04, 2026	DS DP U-904			
		9393237	Aug 04, 2026	U-904			
PASIREOTIDE DIASPARTATE - SIGNIFOR							
N 200677	001	7473761	Dec 14, 2026	DS DP			
		8299209	Dec 27, 2025	DS DP			
PASIREOTIDE DIASPARTATE - SIGNIFOR							
N 200677	002	7473761	Dec 14, 2026	DS DP			
		8299209	Dec 27, 2025	DS DP			
PASIREOTIDE DIASPARTATE - SIGNIFOR							
N 200677	003	7473761	Dec 14, 2026	DS DP			
		8299209	Dec 27, 2025	DS DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT							
N 203255	001	7473761	Dec 14, 2026	DS DP		ODE-268	Jun 29, 2025
		7759308	Oct 25, 2026	DP			
		9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT							
N 203255	002	7473761	Dec 14, 2026	DS DP		ODE-268	Jun 29, 2025
		7759308	Oct 25, 2026	DP			
		9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT							
N 203255	003	7473761	Dec 14, 2026	DS DP		ODE-268	Jun 29, 2025
		7759308	Oct 25, 2026	DP			
		9351923	May 23, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT						
N 203255 004	7473761	Dec 14, 2026	DS DP		ODE-268	Jun 29, 2025
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT						
N 203255 005	7473761	Dec 14, 2026	DS DP		ODE-268	Jun 29, 2025
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 001	10485821	Mar 30, 2024	U-1766		NPP	Oct 02, 2026
	11123363	Oct 08, 2033	U-1766			
	7556799	Feb 27, 2025	U-1766			
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	May 29, 2027	DP			
	8287847	Mar 30, 2024	U-1766			
	8337824	May 29, 2030	DS U-1766			
	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
	9492476	Oct 08, 2033	U-1766			
	9925212	Oct 08, 2033	U-1766			
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 002	10485821	Mar 30, 2024	U-1766		NPP	Oct 02, 2026
	11123363	Oct 08, 2033	U-1766			
	7556799	Feb 27, 2025	U-1766			
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	May 29, 2027	DP			
	8287847	Mar 30, 2024	U-1766			
	8337824	May 29, 2030	DS U-1766			
	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
	9492476	Oct 08, 2033	U-1766			
	9925212	Oct 08, 2033	U-1766			
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 003	10485821	Mar 30, 2024	U-1766		NPP	Oct 02, 2026
	11123363	Oct 08, 2033	U-1766			
	7556799	Feb 27, 2025	U-1766			
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	May 29, 2027	DP			
	8287847	Mar 30, 2024	U-1766			
	8337824	May 29, 2030	DS U-1766			
	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
	9492476	Oct 08, 2033	U-1766			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 003	9925212	Oct 08, 2033	U-1766			
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 004	10485821	Mar 30, 2024	U-1766		NS	Oct 02, 2026
	11123363	Oct 08, 2033	U-1766			
	7556799	Feb 27, 2025	U-1766			
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	May 29, 2027	DP			
	8287847	Mar 30, 2024	U-1766			
	8337824	May 29, 2030	DS U-1766			
	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
	9492476	Oct 08, 2033	U-1766			
	9925212	Oct 08, 2033	U-1766			
PATISIRAN SODIUM - ONPATTRO						
N 210922 001	10240152	Oct 20, 2029	DS DP U-2378		ODE-197	Aug 10, 2025
	11079379	Aug 27, 2035	DS DP U-2378			
	11141378	Apr 15, 2029	DP			
	8058069	Apr 15, 2029	DP			
	8158601	Nov 10, 2030	DP U-2378			
	8168775	Oct 20, 2029	DS DP U-2378			
	8334373	May 27, 2025	DS DP			
	8492359	Apr 15, 2029	DP			
	8642076	Oct 03, 2027	DP			
	8741866	Oct 20, 2029	U-2378			
	8802644	Oct 21, 2030	DP U-2378			
	8822668	Apr 15, 2029	DP U-2378			
	9234196	Oct 20, 2029	DP U-2378			
	9364435	Apr 15, 2029	DP U-2378			
PEGCETACOPLAN - EMPAVELI						
N 215014 001	10035822	Nov 15, 2033	DS		M-288	Feb 08, 2026
	10125171	Aug 02, 2033	DS		NCE	May 14, 2026
	10875893	Nov 15, 2033	DS U-3124		ODE-351	May 14, 2028
	11040107	Apr 09, 2038	DP U-3172			
	11040107	Apr 09, 2038	DP U-3173			
	11040107	Apr 09, 2038	DP U-3174			
	11292815	Nov 15, 2033	DS DP U-3124			
	11292815	Nov 15, 2033	DS DP U-3354			
	11661441	Jan 13, 2033	DS U-3124			
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	9169307	Nov 18, 2027	DS U-3123			
PEGCETACOPLAN - SYFOVRE						
N 217171 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		NP	Feb 22, 2026
	10875893	Nov 15, 2033	DS U-3540			
	11292815	Nov 15, 2033	DS DP U-3540			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGCETACOPLAN - SYFOVRE						
N 217171 001	11661441	Jan 13, 2033	DS		U-3540	
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	8168584	Apr 07, 2027			U-3540	
	8168584	Apr 07, 2027			U-3542	
	9056076	Oct 25, 2026			U-3540	
	9169307	Nov 18, 2027	DS		U-3541	
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 001	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 002	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 003	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 004	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 005	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 006	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 006	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS						
N 202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS						
N 202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEMETREXED - PEMFEXY						
N 209472 001	11793813	Feb 19, 2036	DP			
	9604990	Oct 28, 2035	DS			
PEMETREXED DISODIUM - PEMETREXED						
N 215179 001	11147817	Mar 26, 2035	DP			
PEMETREXED DISODIUM - PEMETREXED						
N 215179 002	11147817	Mar 26, 2035	DP			
PEMETREXED DISODIUM - PEMETREXED						
N 215179 003	11147817	Mar 26, 2035	DP			
PEMIGATINIB - PEMAZYRE						
N 213736 001	10131667	Jun 12, 2033	U-2809		I-899	Aug 26, 2025
	11466004	May 03, 2039	U-3464		NCE	Apr 17, 2025
	11466004	May 03, 2039	U-3465		ODE-292	Apr 17, 2027
	11466004	May 03, 2039	U-3466		ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040	U-3568			
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
	9611267	Jan 30, 2035	DS DP			
PEMIGATINIB - PEMAZYRE						
N 213736 002	10131667	Jun 12, 2033	U-2809		I-899	Aug 26, 2025
	11466004	May 03, 2039	U-3464		NCE	Apr 17, 2025
	11466004	May 03, 2039	U-3465		ODE-292	Apr 17, 2027
	11466004	May 03, 2039	U-3466		ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040	U-3568			
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
	9611267	Jan 30, 2035	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEMIGATINIB - PEMAZYRE						
N 213736 003	10131667	Jun 12, 2033	U-2809		I-899	Aug 26, 2025
	11466004	May 03, 2039	U-3464		NCE	Apr 17, 2025
	11466004	May 03, 2039	U-3465		ODE-292	Apr 17, 2027
	11466004	May 03, 2039	U-3466		ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040	U-3568			
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
	9611267	Jan 30, 2035	DS DP			
PENCICLOVIR - PENCICLOVIR						
A 216981 001					CGT	Feb 28, 2024
PERAMIVIR - RAPIVAB						
N 206426 001	10391075	Feb 12, 2027	U-2622			
	10391075	Feb 12, 2027	U-3069			
	8778997	May 07, 2027	U-1627			
	8778997	May 07, 2027	U-2622			
	8778997	May 07, 2027	U-3069			
PERAMPANEL - FYCOMPA						
N 202834 001	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
	8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA						
N 202834 002	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
	8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA						
N 202834 003	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
	8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA						
N 202834 004	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
	8772497	Jul 01, 2026	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERAMPANEL - FYCOMPA						
N 202834 005	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
	8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA						
N 202834 006	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
	8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA						
N 208277 001	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
	8772497	Jul 01, 2026	DS			
PERFLUOROHEXYLOCTANE - MIEBO						
N 216675 001	10058615	Sep 12, 2033	U-1900		NCE	May 18, 2028
	10369117	Sep 12, 2033	U-1900			
	10449164	Sep 12, 2033	U-1900			
	10507132	Jun 21, 2037	U-1900			
	10576154	Sep 12, 2033	U-1900			
	11357738	Sep 29, 2036	DP			
PERFLUTREN - DEFINITY						
N 021064 001	10583207	Dec 28, 2035	U-665			
	10583208	Mar 16, 2037	U-665			
	10588988	May 04, 2037	U-665			
	11266750	Mar 16, 2037	U-665			
	11529431	Mar 16, 2037	U-665			
	9789210	Mar 16, 2037	U-665			
PERFLUTREN - DEFINITY RT						
N 021064 002	10022460	Dec 28, 2035	DS DP			
	10583207	Dec 28, 2035	U-665			
	10583208	Mar 16, 2037	U-665			
	10588988	May 04, 2037	U-665			
	11266750	Mar 16, 2037	U-665			
	11395856	Dec 28, 2035	DS DP U-665			
	11529431	Mar 16, 2037	U-665			
	9789210	Mar 16, 2037	U-665			
PEXIDARTINIB HYDROCHLORIDE - TURALIO						
N 211810 001	10189833	May 05, 2036	U-2606		NCE	Aug 02, 2024
	10435404	Jul 24, 2038	DP		ODE-250	Aug 02, 2026
	10730876	May 05, 2036	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEXIDARTINIB HYDROCHLORIDE - TURALIO						
N 211810 001	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038	U-2606			
	7893075	May 04, 2033	DS			
	8404700	Nov 21, 2027	DS			
	8461169	Apr 19, 2028	U-2606			
	8722702	Nov 21, 2027	DS			
	9169250	Nov 21, 2027	DS			
	9358235	Jun 08, 2033	U-2606			
	9802932	May 05, 2036	DS			
PEXIDARTINIB HYDROCHLORIDE - TURALIO						
N 211810 002	10189833	May 05, 2036	U-2606		NCE	Aug 02, 2024
	10435404	Jul 24, 2038	DP		ODE*	Aug 02, 2026
	10730876	May 05, 2036	DS			
	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038	U-2606			
	7893075	May 04, 2033	DS			
	8404700	Nov 21, 2027	DS			
	8461169	Apr 19, 2028	U-2606			
	8722702	Nov 21, 2027	DS			
	9169250	Nov 21, 2027	DS			
	9358235	Jun 08, 2033	U-2606			
	9802932	May 05, 2036	DS			
PHENOBARBITAL SODIUM - SEZABY						
N 215910 001	11857683	Apr 07, 2042	DP U-3779		ODE-414	Nov 17, 2029
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N 202088 001	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N 202088 002	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N 202088 003	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 001	8580298	May 15, 2029	DP		NPP	Jun 24, 2025
	8580299	Jun 14, 2029	U-3399			
	8895057	Jun 09, 2028	U-3398			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-3398			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 002	8580298	May 15, 2029	DP		NPP	Jun 24, 2025
	8580299	Jun 14, 2029	U-3399			
	8895057	Jun 09, 2028	U-3398			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-3398			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 003	8580298	May 15, 2029	DP		NPP	Jun 24, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 003	8580299	Jun 14, 2029	U-3399			
	8895057	Jun 09, 2028	U-3398			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-3398			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 004	8580298	May 15, 2029	DP		NPP	Jun 24, 2025
	8580299	Jun 14, 2029	U-3399			
	8895057	Jun 09, 2028	U-3398			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-3398			
PHENTOLAMINE MESYLATE - RYZUMVI						
N 217064 001					NP	Sep 25, 2026
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE						
N 203510 001	8859623	Nov 14, 2033	U-1594			
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE						
N 203510 002	8859623	Nov 14, 2033	U-1594			
PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV						
N 203826 004	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV						
N 203826 005	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI						
N 215352 001	10839960	Jul 15, 2031	U-3685		NP	May 05, 2026
	11398306	Jul 15, 2031	U-3685			
PIFLUFOLASTAT F-18 - PYLARIFY						
N 214793 001	10947197	Jun 09, 2037	DS DP U-3130		NCE	May 26, 2026
	8487129	Nov 07, 2027	DS DP			
	8778305	Sep 21, 2030	DS DP U-3130			
	9861713	Jul 31, 2029	DS DP U-3130			
PILOCARPINE HYDROCHLORIDE - VUITY						
N 214028 001	10610518	Apr 24, 2039	U-3252		D-187	Mar 28, 2026
	10610518	Apr 24, 2039	U-3561		NP	Oct 28, 2024
	10610518	Apr 24, 2039	U-3562			
	11285134	Apr 24, 2039	U-3252			
	11285134	Apr 24, 2039	U-3561			
	11285134	Apr 24, 2039	U-3562			
PILOCARPINE HYDROCHLORIDE - QLOSI						
N 217836 001	10639297	Aug 18, 2037	DP U-3741		NP	Oct 17, 2026
	11129812	Aug 18, 2037	U-3741			
	9867810	Aug 18, 2037	DP U-3741			
PIMAVANSERIN TARTRATE - NUPLAZID						
N 207318 001	10028944	Jan 15, 2024	U-1974			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIMAVANSERIN TARTRATE - NUPLAZID						
N 207318 001	7601740	Apr 29, 2030	DS DP			
	7659285	Aug 24, 2026			U-1844	
	7732615	Jun 03, 2028	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8618130	Jan 15, 2024			U-1845	
	8921393	Jan 15, 2024			U-1846	
	9566271	Jan 15, 2024			U-1974	
PIMAVANSERIN TARTRATE - NUPLAZID						
N 207318 002	10028944	Jan 15, 2024			U-1974	
	10517860	Mar 23, 2037			U-1974	
	10953000	Mar 23, 2037			U-1974	
	7601740	Apr 29, 2030	DS DP			
	7659285	Aug 24, 2026			U-1844	
	7732615	Jun 03, 2028	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8618130	Jan 15, 2024			U-1845	
	8921393	Jan 15, 2024			U-1846	
	9566271	Jan 15, 2024			U-1974	
PIMAVANSERIN TARTRATE - NUPLAZID						
N 210793 001	10028944	Jan 15, 2024			U-1974	
	10449185	Aug 27, 2038	DP			
	10646480	Aug 27, 2038	DP			
	10849891	Aug 27, 2038	DP		U-1974	
	11452721	Aug 27, 2038	DP			
	7601740	Apr 29, 2030	DS DP			
	7659285	Aug 24, 2026			U-1844	
	7732615	Jun 03, 2028	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8618130	Jan 15, 2024			U-1845	
	8921393	Jan 15, 2024			U-1846	
	9566271	Jan 15, 2024			U-1974	
PIRFENIDONE - ESBRIET						
N 022535 001	7566729	Apr 22, 2029			U-1600	
	7635707	Apr 22, 2029			U-1609	
	7696236	Dec 18, 2027			U-1601	
	7767225	Sep 22, 2026	DP		U-1602	
	7767700	Dec 18, 2027			U-1601	
	7816383	Jan 08, 2030			U-1603	
	7910610	Jan 08, 2030			U-1604	
	7988994	Sep 22, 2026	DP		U-1602	
	8013002	Jan 08, 2030			U-1603	
	8084475	Jan 08, 2030			U-1605	
	8318780	Jan 08, 2030			U-1606	
	8383150	May 10, 2028	DP		U-2361	
	8420674	Dec 18, 2027	DP		U-1608	
	8592462	Apr 22, 2029			U-1609	
	8609701	Apr 22, 2029			U-1610	
	8648098	Jan 08, 2030			U-1611	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRFENIDONE - ESBRIET						
N 022535 001	8753679	Sep 22, 2026	DP U-1602			
	8754109	Jan 08, 2030	U-1612			
	8778947	Aug 30, 2033	U-1613			
PIRFENIDONE - ESBRIET						
N 208780 001	10188637	Mar 28, 2037	DP			
	7566729	Apr 22, 2029	U-2077			
	7566729	Apr 22, 2029	U-2078			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	May 10, 2028	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRFENIDONE - ESBRIET						
N 208780 002	10188637	Mar 28, 2037	DP			
	7566729	Apr 22, 2029			U-2269	
	7566729	Apr 22, 2029			U-2270	
	7635707	Apr 22, 2029			U-2072	
	7635707	Apr 22, 2029			U-2073	
	7635707	Apr 22, 2029			U-2074	
	7635707	Apr 22, 2029			U-2075	
	7635707	Apr 22, 2029			U-2076	
	7635707	Apr 22, 2029			U-2083	
	7767700	Dec 18, 2027			U-2080	
	7816383	Jan 08, 2030			U-2042	
	7816383	Jan 08, 2030			U-2050	
	7910610	Jan 08, 2030			U-2048	
	7910610	Jan 08, 2030			U-2049	
	8013002	Jan 08, 2030			U-2047	
	8013002	Jan 08, 2030			U-2082	
	8084475	Jan 08, 2030			U-2054	
	8084475	Jan 08, 2030			U-2268	
	8318780	Jan 08, 2030			U-2046	
	8318780	Jan 08, 2030			U-2081	
	8383150	May 10, 2028	DP		U-2361	
	8420674	Dec 18, 2027			U-2079	
	8592462	Apr 22, 2029			U-2055	
	8592462	Apr 22, 2029			U-2056	
	8592462	Apr 22, 2029			U-2057	
	8592462	Apr 22, 2029			U-2058	
	8592462	Apr 22, 2029			U-2059	
	8592462	Apr 22, 2029			U-2060	
	8592462	Apr 22, 2029			U-2061	
	8592462	Apr 22, 2029			U-2062	
	8592462	Apr 22, 2029			U-2063	
	8609701	Apr 22, 2029			U-2064	
	8609701	Apr 22, 2029			U-2065	
	8609701	Apr 22, 2029			U-2066	
	8609701	Apr 22, 2029			U-2067	
	8609701	Apr 22, 2029			U-2068	
	8609701	Apr 22, 2029			U-2069	
	8609701	Apr 22, 2029			U-2070	
	8648098	Jan 08, 2030			U-2051	
	8648098	Jan 08, 2030			U-2052	
	8754109	Jan 08, 2030			U-2053	
	8778947	Aug 30, 2033			U-2044	
	8778947	Aug 30, 2033			U-2045	
PIRFENIDONE - ESBRIET						
N 208780 003	10188637	Mar 28, 2037	DP			
	7566729	Apr 22, 2029			U-2077	
	7566729	Apr 22, 2029			U-2078	
	7635707	Apr 22, 2029			U-2072	
	7635707	Apr 22, 2029			U-2073	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRFENIDONE - ESBRIET						
N 208780 003	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	May 10, 2028	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
PIRTOBRUTINIB - JAYPIRCA						
N 216059 001	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10464905	Dec 16, 2036	U-3761			
	10695323	Dec 16, 2036	DS DP U-3518			
	10695323	Dec 16, 2036	DS DP U-3761			
	10918622	Dec 16, 2036	U-3518			
	10918622	Dec 16, 2036	U-3761			
PIRTOBRUTINIB - JAYPIRCA						
N 216059 002	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRTOBRUTINIB - JAYPIRCA						
N 216059 002	10464905	Dec 16, 2036	U-3761			
	10695323	Dec 16, 2036	DS DP U-3518			
	10695323	Dec 16, 2036	DS DP U-3761			
	10918622	Dec 16, 2036	U-3518			
	10918622	Dec 16, 2036	U-3761			
PITAVASTATIN CALCIUM - PITAVASTATIN CALCIUM						
A 206015 001					PC	Feb 19, 2024
PITAVASTATIN CALCIUM - PITAVASTATIN CALCIUM						
A 206015 002					PC	Feb 19, 2024
PITAVASTATIN CALCIUM - PITAVASTATIN CALCIUM						
A 206015 003					PC	Feb 19, 2024
PITAVASTATIN CALCIUM - LIVALO						
N 022363 001	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
PITAVASTATIN CALCIUM - LIVALO						
N 022363 002	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
PITAVASTATIN CALCIUM - LIVALO						
N 022363 003	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
PITAVASTATIN MAGNESIUM - ZYPITAMAG						
N 208379 001	8829186	Jan 19, 2031	DS DP			
PITAVASTATIN MAGNESIUM - ZYPITAMAG						
N 208379 002	8829186	Jan 19, 2031	DS DP			
PITAVASTATIN MAGNESIUM - ZYPITAMAG						
N 208379 003	8829186	Jan 19, 2031	DS DP			
PITOLISANT HYDROCHLORIDE - WAKIX						
N 211150 001	8207197	Mar 07, 2030	DS DP		NCE	Aug 14, 2024
	8354430	Feb 06, 2026	U-1101		ODE-255	Aug 14, 2026
	8354430	Feb 06, 2026	U-1102		ODE-331	Oct 13, 2027
	8486947	Sep 26, 2029	U-1101			
	8486947	Sep 26, 2029	U-1102			
PITOLISANT HYDROCHLORIDE - WAKIX						
N 211150 002	8207197	Mar 07, 2030	DS DP		NCE	Aug 14, 2024
	8354430	Feb 06, 2026	U-1101		ODE-255	Aug 14, 2026
	8354430	Feb 06, 2026	U-1102		ODE-331	Oct 13, 2027
	8486947	Sep 26, 2029	U-1101			
	8486947	Sep 26, 2029	U-1102			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PLAZOMICIN SULFATE - ZEMDRI						
N 210303 001	8383596	Jun 02, 2031	DS U-2328		NCE	Jun 25, 2023
	8822424	Nov 21, 2028	DP		GAIN	Jun 25, 2028
	9266919	Nov 21, 2028	U-2328			
	9688711	Nov 21, 2028	DS U-2328			
PLECANATIDE - TRULANCE						
N 208745 001	10011637	Jun 05, 2034	DS			
	11142549	Jun 05, 2034	DP			
	11319346	Mar 01, 2032	DP			
	11834521	Jun 05, 2034	DP			
	7041786	Jan 30, 2028	DS			
	9610321	Sep 15, 2031	U-1999			
	9610321	Sep 15, 2031	U-2230			
	9616097	Aug 20, 2032	DP			
	9919024	Sep 15, 2031	U-1999			
	9919024	Sep 15, 2031	U-2230			
	9925231	Sep 15, 2031	DP			
PODOFILOX - PODOFILOX						
A 211871 001					CGT	Jun 10, 2024
POLIDOCANOL - VARITHENA						
N 205098 001	7731986	Nov 17, 2024	DS DP U-1463			
	7814943	Nov 19, 2027	DP U-1461			
	8122917	Sep 09, 2024	DP			
	9480652	May 12, 2032	DP			
POMALIDOMIDE - POMALYST						
N 204026 001	10555939	May 19, 2030	DP		M-14	Nov 20, 2023
	10555939*PED	Nov 19, 2030			ODE-296	May 14, 2027
	8198262	Jun 17, 2025	U-1360		ODE-297	May 14, 2027
	8198262	Jun 17, 2025	U-2254		PED	May 20, 2024
	8198262*PED	Dec 17, 2025			PED	Nov 14, 2027
	8828427	Jun 21, 2031	DS DP		PED	Nov 14, 2027
	8828427*PED	Dec 21, 2031				
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
POMALIDOMIDE - POMALYST						
N 204026 002	10555939	May 19, 2030	DP		M-14	Nov 20, 2023
	10555939*PED	Nov 19, 2030			ODE-296	May 14, 2027
	8198262	Jun 17, 2025	U-1360		ODE-297	May 14, 2027
	8198262	Jun 17, 2025	U-2254		PED	May 20, 2024
	8198262*PED	Dec 17, 2025			PED	Nov 14, 2027
	8828427	Jun 21, 2031	DS DP		PED	Nov 14, 2027
	8828427*PED	Dec 21, 2031				
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
POMALIDOMIDE - POMALYST						
N 204026 003	10555939	May 19, 2030	DP		M-14	Nov 20, 2023
	10555939*PED	Nov 19, 2030			ODE-296	May 14, 2027
	8198262	Jun 17, 2025	U-1360		ODE-297	May 14, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
POMALIDOMIDE - POMALYST						
N 204026 003	8198262	Jun 17, 2025	U-2254		PED	May 20, 2024
	8198262*PED	Dec 17, 2025			PED	Nov 14, 2027
	8828427	Jun 21, 2031	DS DP		PED	Nov 14, 2027
	8828427*PED	Dec 21, 2031				
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
POMALIDOMIDE - POMALYST						
N 204026 004	10555939	May 19, 2030	DP		M-14	Nov 20, 2023
	10555939*PED	Nov 19, 2030			ODE-296	May 14, 2027
	8198262	Jun 17, 2025	U-1360		ODE-297	May 14, 2027
	8198262	Jun 17, 2025	U-2254		PED	May 20, 2024
	8198262*PED	Dec 17, 2025			PED	Nov 14, 2027
	8828427	Jun 21, 2031	DS DP		PED	Nov 14, 2027
	8828427*PED	Dec 21, 2031				
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 001	11192895	Dec 12, 2033	U-1700			
	11192895	Dec 12, 2033	U-1701			
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 002	11192895	Dec 12, 2033	U-1700			
	11192895	Dec 12, 2033	U-1701			
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 002	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 003	11192895	Dec 12, 2033	U-1700			
	11192895	Dec 12, 2033	U-1701			
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 004	11192895	Dec 12, 2033	U-1700			
	11192895	Dec 12, 2033	U-1701			
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
PONESIMOD - PONVORY						
N 213498 001	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PONESIMOD - PONVORY						
N 213498 002	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 003	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 004	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 005	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 006	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 007	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 008	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 009	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PONESIMOD - PONVORY						
N 213498 009	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 010	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
POSACONAZOLE - NOXAFIL						
N 205053 001					I-881	Jun 17, 2024
					NPP	May 31, 2024
					ODE-355	Jun 17, 2028
POSACONAZOLE - NOXAFIL						
N 205596 001	10117951	Mar 13, 2029	DP		I-881	Jun 17, 2024
	8410077	Mar 13, 2029	DP		NPP	May 31, 2024
	9023790	Jul 04, 2031	DP U-1698		ODE-355	Jun 17, 2028
	9023790	Jul 04, 2031	DP U-3160			
	9023790	Jul 04, 2031	DP U-3171			
	9358297	Jun 24, 2031	DP U-3160			
	9358297	Jun 24, 2031	DP U-3171			
	9493582	Feb 27, 2033	DP			
	9750822	Mar 13, 2029	DP			
POSACONAZOLE - NOXAFIL POWDERMIX KIT						
N 214770 001					NP	May 31, 2024
POTASSIUM CHLORIDE - POTASSIUM CHLORIDE						
A 217704 001					CGT	Mar 11, 2024
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES						
A 216274 001					CGT	Apr 13, 2024
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES						
A 216274 002					CGT	Apr 10, 2024
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES						
A 216274 003					CGT	Apr 10, 2024
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES						
N 212121 001	10632150	Apr 19, 2039	DP U-2789			
PRALATREXATE - FOLOTYN						
N 022468 001	7622470	May 31, 2025	U-1015			
	8299078	May 31, 2025	U-1004			
PRALATREXATE - FOLOTYN						
N 022468 002	7622470	May 31, 2025	U-1015			
	8299078	May 31, 2025	U-1004			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PRALSETINIB - GAVRETO						
N 213721 001	10030005	Nov 01, 2036	DS DP U-2952		NCE	Sep 04, 2025
	10030005	Nov 01, 2036	DS DP U-3002		ODE-318	Sep 04, 2027
	11273160	Apr 03, 2039	U-2952		ODE-340	Dec 01, 2027
					ODE-341	Dec 01, 2027
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 001	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 002	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 003	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 004	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 005	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 006	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 007	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRASTERONE - INTRAROSA						
N 208470 001	8268806	Mar 19, 2031	DP			
	8629129	Aug 07, 2028	DP			
	8957054	Jan 08, 2030	U-1922			
PREDNISOLONE ACETATE - FLO-PRED						
N 022067 001	7799331	Oct 11, 2028	DP U-1068			
	7799331	Oct 11, 2028	DP U-139			
PREDNISOLONE ACETATE - FLO-PRED						
N 022067 002	7799331	Oct 11, 2028	DP U-1068			
	7799331	Oct 11, 2028	DP U-139			
PREDNISONE - RAYOS						
N 202020 001	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
PREDNISONE - RAYOS						
N 202020 002	8309124	Apr 23, 2024				
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PREDNISONE - RAYOS						
N 202020 002	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
PREDNISONE - RAYOS						
N 202020 003	8168218	Jan 07, 2028	DP U-1269			
	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
PREGABALIN - LYRICA CR						
N 209501 001	10022447	Nov 02, 2026	U-2136			
	10022447	Nov 02, 2026	U-2137			
	10022447*PED	May 02, 2027				
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	8945620*PED	May 02, 2027				
	9144559	Nov 02, 2026	DP			
	9144559*PED	May 02, 2027				
PREGABALIN - LYRICA CR						
N 209501 002	10022447	Nov 02, 2026	U-2136			
	10022447	Nov 02, 2026	U-2137			
	10022447*PED	May 02, 2027				
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	8945620*PED	May 02, 2027				
	9144559	Nov 02, 2026	DP			
	9144559*PED	May 02, 2027				
PREGABALIN - LYRICA CR						
N 209501 003	10022447	Nov 02, 2026	U-2136			
	10022447	Nov 02, 2026	U-2137			
	10022447*PED	May 02, 2027				
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	8945620*PED	May 02, 2027				
	9144559	Nov 02, 2026	DP			
	9144559*PED	May 02, 2027				
PRETOMANID - PRETOMANID						
N 212862 001					NCE	Aug 14, 2024
					ODE-253	Aug 14, 2026
					GAIN	Aug 14, 2029
PROGESTERONE - MILPROSA						
N 201110 001	10537584	Feb 03, 2029	DP			
	10548904	Feb 03, 2029	U-2810			
	8580293	Jan 21, 2030	U-2810			
PROPOFOL - DIPRIVAN						
N 019627 002	8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PROPOFOL - DIPRIVAN							
N 019627	002	8476010	Dec 01, 2024	DS DP			
		8476010*PED	Jun 01, 2025				
PROPRANOLOL HYDROCHLORIDE - HEMANGEOL							
N 205410	001	8338489	Oct 16, 2028	U-1496			
		8987262	Oct 16, 2028	U-1988			
QUAZEPAM - DORAL							
N 018708	001	7608616	Jun 03, 2028	U-1012			
QUAZEPAM - DORAL							
N 018708	003	7608616	Jun 03, 2028	U-1012			
QUIZARTINIB DIHYDROCHLORIDE - VANFLYTA							
N 216993	001	7820657	Sep 26, 2028	DS		NCE	Jul 20, 2028
		7968543	Aug 15, 2029	DP U-3661		ODE-437	Jul 20, 2030
		8129374	Mar 16, 2027	U-3661			
		8357690	Feb 26, 2031	U-3661			
		8557810	Mar 16, 2027	DP			
		8836218	Mar 23, 2030	U-3661			
		8865710	Aug 15, 2029	DP			
		8883783	Mar 16, 2027	DS			
		9555040	May 14, 2030	U-3661			
		9585892	Mar 16, 2027	U-3661			
		9675549	Sep 30, 2033	DP			
QUIZARTINIB DIHYDROCHLORIDE - VANFLYTA							
N 216993	002	7820657	Sep 26, 2028	DS		NCE	Jul 20, 2028
		7968543	Aug 15, 2029	DP U-3661		ODE-437	Jul 20, 2030
		8129374	Mar 16, 2027	U-3661			
		8357690	Feb 26, 2031	U-3661			
		8557810	Mar 16, 2027	DP			
		8836218	Mar 23, 2030	U-3661			
		8865710	Aug 15, 2029	DP			
		8883783	Mar 16, 2027	DS			
		9555040	May 14, 2030	U-3661			
		9585892	Mar 16, 2027	U-3661			
		9675549	Sep 30, 2033	DP			
RALTEGRAVIR POTASSIUM - ISENTRESS							
N 022145	001	7169780*PED	Apr 03, 2024				
		7754731	Mar 11, 2029	DS DP U-257			
		7754731*PED	Sep 11, 2029				
		8771733	Jun 02, 2030	DS DP U-257			
		8852632	Jan 28, 2028	DS DP U-257			
RALTEGRAVIR POTASSIUM - ISENTRESS HD							
N 022145	002	10772888	Mar 30, 2032	U-1663			
		7169780*PED	Apr 03, 2024				
		7754731	Mar 11, 2029	DS DP U-257			
		7754731*PED	Sep 11, 2029				
		8771733	Jun 02, 2030	DS DP U-257			
		9649311	Oct 21, 2030	DP			
		9649311*PED	Apr 21, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RALTEGRAVIR POTASSIUM - ISENTRESS HD							
N 022145	002	10772888	Mar 30, 2032	U-1663			
		7169780*PED	Apr 03, 2024				
		7754731	Mar 11, 2029	DS DP U-257			
		7754731*PED	Sep 11, 2029				
		8771733	Jun 02, 2030	DS DP U-257			
		9649311	Oct 21, 2030	DP			
		9649311*PED	Apr 21, 2031				
RALTEGRAVIR POTASSIUM - ISENTRESS							
N 203045	001	7169780*PED	Apr 03, 2024				
		7754731	Mar 11, 2029	DS DP U-257			
		7754731*PED	Sep 11, 2029				
RALTEGRAVIR POTASSIUM - ISENTRESS							
N 203045	002	7169780*PED	Apr 03, 2024				
		7754731	Mar 11, 2029	DS DP U-257			
		7754731*PED	Sep 11, 2029				
		8771733	Jun 02, 2030	DS DP U-257			
RALTEGRAVIR POTASSIUM - ISENTRESS							
N 205786	001	7169780*PED	Apr 03, 2024				
		7754731	Mar 11, 2029	DS DP U-257			
		7754731*PED	Sep 11, 2029				
RANOLAZINE - ASPRUZYO SPRINKLE							
N 216018	001	11510878	Jan 24, 2038	DP			
RANOLAZINE - ASPRUZYO SPRINKLE							
N 216018	002	10898444	Jan 24, 2038	DP			
		11510878	Jan 24, 2038	DP			
RASAGILINE MESYLATE - AZILECT							
N 021641	001	7572834	Dec 05, 2026	DP			
		7815942	Aug 27, 2027	DS DP U-219			
RASAGILINE MESYLATE - AZILECT							
N 021641	002	7572834	Dec 05, 2026	DP			
		7815942	Aug 27, 2027	DS DP U-219			
REGADENOSON - LEXISCAN							
N 022161	001	8106183	Feb 02, 2027	DS			
		RE47301	Feb 02, 2027	DP			
REGORAFENIB - STIVARGA							
N 203085	001	8637553	Feb 16, 2031	DS DP		ODE-139	Apr 27, 2024
		8680124	Jun 02, 2030	U-1506			
		9458107	Apr 08, 2031	DP			
		9957232	Jul 09, 2032	DS			
RELUGOLIX - ORGOVYX							
N 214621	001	10350170	Feb 25, 2036	DP		NCE	Dec 18, 2025
		10449191	Sep 29, 2037	U-3020			
		10786501	Sep 29, 2037	U-3020			
		11583526	Sep 29, 2037	U-3020			
		11795178	Sep 27, 2033	DS DP			
		7300935	Jan 28, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RELUGOLIX - ORGOVYX							
N 214621	001	8058280	Jan 28, 2025	DS DP			
		8735401	Feb 04, 2024	U-3019			
REMDESIVIR - VEKLURY							
N 214787	001	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
		10675296	Jul 10, 2038	DP		M-301	Jul 13, 2026
		10695361	Sep 16, 2036	U-2984		NCE	Oct 22, 2025
		10695361	Sep 16, 2036	U-3249		NPP	Apr 25, 2025
		10695361	Sep 16, 2036	U-3367			
		10695361	Sep 16, 2036	U-3368			
		11007208	Sep 16, 2036	U-2984			
		11007208	Sep 16, 2036	U-3249			
		11007208	Sep 16, 2036	U-3367			
		11007208	Sep 16, 2036	U-3368			
		11266681	Jul 10, 2038	U-2984			
		11266681	Jul 10, 2038	U-3249			
		11266681	Jul 10, 2038	U-3367			
		11266681	Jul 10, 2038	U-3368			
		11382926	Sep 16, 2036	U-3367			
		11382926	Sep 16, 2036	U-3368			
		11491169	May 28, 2041	U-3484			
		11491169	May 28, 2041	U-3485			
		11492353	Dec 08, 2031	DS			
		8008264	Sep 06, 2029	DS DP			
		8318682	Apr 22, 2029	DS DP			
		9724360	Oct 29, 2035	DS DP			
		9949994	Oct 29, 2035	DS			
		RE46762	Apr 22, 2029	DS DP			
REMDESIVIR - VEKLURY							
N 214787	002	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
		10675296	Jul 10, 2038	DP		M-301	Jul 13, 2026
		10695361	Sep 16, 2036	U-2984		NCE	Oct 22, 2025
		10695361	Sep 16, 2036	U-3249		NPP	Apr 25, 2025
		10695361	Sep 16, 2036	U-3367			
		10695361	Sep 16, 2036	U-3368			
		11007208	Sep 16, 2036	U-2984			
		11007208	Sep 16, 2036	U-3249			
		11007208	Sep 16, 2036	U-3367			
		11007208	Sep 16, 2036	U-3368			
		11266681	Jul 10, 2038	U-2984			
		11266681	Jul 10, 2038	U-3249			
		11266681	Jul 10, 2038	U-3367			
		11266681	Jul 10, 2038	U-3368			
		11382926	Sep 16, 2036	U-3367			
		11382926	Sep 16, 2036	U-3368			
		11491169	May 28, 2041	U-3484			
		11491169	May 28, 2041	U-3485			
		11492353	Dec 08, 2031	DS			
		8008264	Sep 06, 2029	DS DP			
		8318682	Apr 22, 2029	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
REMDESIVIR - VEKLURY						
N 214787 002	9724360	Oct 29, 2035	DS DP			
	9949994	Oct 29, 2035	DS			
	RE46762	Apr 22, 2029	DS DP			
REMIMAZOLAM BESYLATE - BYFAVO						
N 212295 001	10052334	Nov 07, 2031	U-2968		NCE	Oct 06, 2025
	10195210	Nov 07, 2031	U-2968			
	10342800	Nov 07, 2031	U-2968			
	10472365	Jul 10, 2027	U-2968			
	10722522	Nov 07, 2031	U-2968			
	10961250	Jul 10, 2027	DP U-2968			
	9561236	Apr 30, 2033	U-2968			
	9737547	Nov 07, 2031	U-2968			
	9777007	Jul 10, 2027	DP			
	9827251	Nov 07, 2031	U-2968			
	9914738	Jul 10, 2027	DP			
REPOTRECTINIB - AUGTYRO						
N 218213 001	10294242	Jul 05, 2036	DS			
	11452725	Jul 24, 2036	U-3755			
	9714258	Jan 23, 2035	DS DP			
RETAPAMULIN - ALTABAX						
N 022055 001	7875630	Feb 14, 2027	DS			
	8207191	Aug 30, 2024	U-805			
REVEFENACIN - YUPELRI						
N 210598 001	10106503	Mar 10, 2025	U-2440			
	10343995	Mar 10, 2025	U-2440			
	10550081	Jul 14, 2030	DS			
	11008289	Jul 14, 2030	U-2440			
	11247969	Mar 10, 2025	DP			
	11484531	Oct 23, 2039	U-2440			
	11691948	Jul 14, 2030	DP			
	11858898	Jul 14, 2030	DS DP U-2440			
	7288657	Dec 23, 2025	DS			
	7491736	Mar 10, 2025	U-2440			
	7521041	Mar 10, 2025	U-2440			
	7550595	Mar 10, 2025	DP			
	7585879	Mar 10, 2025	DS DP U-2440			
	7910608	Mar 10, 2025	DS DP			
	8034946	Mar 10, 2025	DP			
	8053448	Mar 10, 2025	U-2440			
	8273894	Mar 10, 2025	DP			
	8541451	Aug 25, 2031	DS			
	9765028	Jul 14, 2030	DS			
REZAFUNGIN ACETATE - REZZAYO						
N 217417 001	10702573	Mar 14, 2033	DS DP U-3566		NCE	Mar 22, 2028
	11197909	Jul 14, 2038	DS DP U-3566		ODE-426	Mar 22, 2030
	11654196	Mar 02, 2032	DS DP U-3566		GAIN	Mar 22, 2033
	11712459	Mar 15, 2037	DP U-3566		GAIN	Mar 22, 2035
	11819533	Jul 11, 2038	DS DP U-3566			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
REZAFUNGIN ACETATE - REZZAYO						
N 217417 001	8722619	Mar 02, 2032	DS DP U-3566			
	9526835	Mar 14, 2033	DS DP U-3566			
RIBOCICLIB SUCCINATE - KISQALI						
N 209092 001	10799506	Apr 14, 2036	DP		NPP	Dec 10, 2024
	8324225	Jun 17, 2028	DS DP			
	8415355	Mar 13, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-1981			
	8962630	Dec 09, 2029	U-2355			
	8962630	Dec 09, 2029	U-2356			
	8962630	Dec 09, 2029	U-3265			
	8962630	Dec 09, 2029	U-3266			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-1981			
	9416136	Aug 20, 2029	U-2355			
	9416136	Aug 20, 2029	U-2356			
	9416136	Aug 20, 2029	U-3265			
	9416136	Aug 20, 2029	U-3266			
	9868739	Nov 09, 2031	U-1981			
	9868739	Nov 09, 2031	U-2355			
	9868739	Nov 09, 2031	U-2356			
	9868739	Nov 09, 2031	U-3265			
	9868739	Nov 09, 2031	U-3266			
RIFAMYCIN SODIUM - AEMCOLO						
N 210910 001	8263120	May 03, 2025	DP		NCE	Nov 16, 2023
	8486446	May 03, 2025	DP		GAIN	Nov 16, 2028
	8529945	May 03, 2025	DP			
	8741948	May 03, 2025	DP U-2448			
RIFAXIMIN - XIFAXAN						
N 021361 001	10703763	Feb 27, 2026	U-1708			
	10703763	Feb 27, 2026	U-2847			
	10703763	Feb 27, 2026	U-2848			
	7045620	Jun 19, 2024	DS DP			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029	U-1121			
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS U-1526			
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	9271968	Feb 27, 2026	DP			
RIFAXIMIN - XIFAXAN						
N 021361 002	10314828	Jul 24, 2029	U-1481			
	10335397	Jul 24, 2029	U-2579			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIFAXIMIN - XIFAXAN						
N 021361 002	10456384	Feb 26, 2029	U-2643			
	10456384	Feb 26, 2029	U-2644			
	10703763	Feb 27, 2026	U-1708			
	10703763	Feb 27, 2026	U-2847			
	10703763	Feb 27, 2026	U-2848			
	10709694	Jul 24, 2029	U-2579			
	10765667	Feb 26, 2029	U-2643			
	10765667	Feb 26, 2029	U-2644			
	11564912	Feb 26, 2029	U-3511			
	11564912	Feb 26, 2029	U-3512			
	11779571	Feb 26, 2029	U-3706			
	7045620	Jun 19, 2024	DS			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7915275	Feb 23, 2025	U-1707			
	7915275	Feb 23, 2025	U-1708			
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP U-1707			
	8193196	Sep 02, 2027	DS DP U-1708			
	8309569	Jul 18, 2029	U-1707			
	8309569	Jul 18, 2029	U-1708			
	8518949	Feb 27, 2026	DP			
	8642573	Oct 02, 2029	U-1481			
	8741904	Feb 27, 2026	DS U-1526			
	8741904	Feb 27, 2026	DS U-1707			
	8741904	Feb 27, 2026	DS U-1708			
	8829017	Jul 24, 2029	U-1562			
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			
	9271968	Feb 27, 2026	DP			
	9421195	Jul 24, 2029	U-1481			
	9629828	Jul 24, 2029	U-1994			
RILPIVIRINE HYDROCHLORIDE - EDURANT						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
RILUZOLE - TIGLUTIK KIT						
N 209080 001	8765150	Mar 12, 2029	DP U-2401			
RILUZOLE - EXSERVAN						
N 212640 001	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIMEGEPANT SULFATE - NURTEC ODT						
N 212728 001	11083724	Mar 25, 2039	DP U-2718		I-865	May 27, 2024
	11083724	Mar 25, 2039	DP U-3142		NCE	Feb 27, 2025
	8314117	Mar 09, 2030	DS DP U-2718			
	8314117	Mar 09, 2030	DS DP U-3142			
	8759372	Feb 25, 2033	DS DP			
RIOCIGUAT - ADEMPAS						
N 204819 001	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS						
N 204819 002	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS						
N 204819 003	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS						
N 204819 004	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS						
N 204819 005	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
RIPRETINIB - QINLOCK						
N 213973 001	10966966	Aug 12, 2040	U-3153		NCE	May 15, 2025
	11185535	Dec 30, 2040	DP		ODE-298	May 15, 2027
	11266635	Aug 12, 2040	U-3330			
	11344536	Aug 12, 2040	U-3381			
	11395818	Dec 30, 2040	DP			
	11426390	Aug 12, 2040	U-3416			
	11433056	Aug 12, 2040	U-3423			
	11529336	Aug 12, 2040	U-3382			
	11534432	Aug 12, 2040	U-3442			
	11576903	Dec 30, 2040	DP			
	11576904	Aug 12, 2040	U-3537			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIPRETINIB - QINLOCK						
N 213973 001	11612591	Dec 30, 2040	DP			
	11779572	Oct 06, 2042	U-3714			
	11793795	Dec 30, 2040	DP			
	11801237	Dec 30, 2040	DP U-3219			
	11813251	Aug 12, 2040	U-3750			
	11844788	Dec 30, 2040	DP			
	11850240	Dec 30, 2040	DP			
	11850241	Dec 30, 2040	DP			
	8188113	Jul 27, 2030	DS DP			
	8461179	May 15, 2034	DS DP			
	RE48731	Jun 07, 2032	U-3219			
RISDIPLAM - EVRYSDI						
N 213535 001	11534444	Oct 04, 2038	U-1943		M-270	Oct 03, 2026
	11827646	Jan 25, 2036	U-1943		NCE	Aug 07, 2025
	9586955	Feb 08, 2033	DS DP		NPP	May 27, 2025
	9969754	May 11, 2035	DS DP U-1943		ODE-334	Aug 07, 2027
					ODE-400	May 27, 2029
RISEDRONATE SODIUM - ATELVIA						
N 022560 001	7645459	Jan 09, 2028	DP U-662			
	7645460	Jan 09, 2028	DP U-662			
	8246989	Jan 16, 2026	DP			
RISPERIDONE - PERSERIS KIT						
N 210655 001	10010612	Feb 13, 2028	DP			
	10058554	Sep 26, 2026	U-2363			
	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			
	11013809	Feb 13, 2028	DP U-3135			
	11110093	Nov 05, 2026	DP U-3135			
	11712475	Feb 13, 2028	U-3135			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028	U-543			
	9597402	Sep 26, 2026	DP			
RISPERIDONE - PERSERIS KIT						
N 210655 002	10010612	Feb 13, 2028	DP			
	10058554	Sep 26, 2026	U-2363			
	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			
	11013809	Feb 13, 2028	DP U-3135			
	11110093	Nov 05, 2026	DP U-3135			
	11712475	Feb 13, 2028	U-3135			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028	U-543			
	9597402	Sep 26, 2026	DP			
RISPERIDONE - RYKINDO						
N 212849 001	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - RYKINDO						
N 212849 001	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - RYKINDO						
N 212849 002	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - RYKINDO						
N 212849 003	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - RYKINDO						
N 212849 004	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - UZEDY						
N 213586 001	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 002	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 003	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - UZEDY						
N 213586 003	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 004	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 005	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 006	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 007	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RITLECITINIB TOSYLATE - LITFULO						
N 215830 001	9617258	Dec 03, 2034	DS DP		NCE	Jun 23, 2028
RIVAROXABAN - XARELTO						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301		I-867	Aug 23, 2024
	7157456	Aug 28, 2024	DS DP U-1302		PED	Feb 23, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIVAROXABAN - XARELTO						
N 022406 001	7157456*PED	Feb 28, 2025				
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9415053	Nov 13, 2024	DP U-3284			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
	9539218	Feb 17, 2034	U-3288			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301		I-867	Aug 23, 2024
	7157456	Aug 28, 2024	DS DP U-1302		PED	Feb 23, 2025
	7157456*PED	Feb 28, 2025				
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3286			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-3289			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301		I-867	Aug 23, 2024
	7157456	Aug 28, 2024	DS DP U-1302		PED	Feb 23, 2025
	7157456*PED	Feb 28, 2025				
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3287			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-3285			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 022406 004	10828310	Jan 31, 2039	U-3207		I-867	Aug 23, 2024
	10828310	Jan 31, 2039	U-3208		PED	Feb 23, 2025
	10828310*PED	Jul 31, 2039				
	7157456	Aug 28, 2024	DS DP			
	7157456*PED	Feb 28, 2025				
	9415053	Nov 13, 2024	DP U-2435			
	9415053	Nov 13, 2024	DP U-3205			
	9415053	Nov 13, 2024	DP U-3206			
	9415053*PED	May 13, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIVAROXABAN - XARELTO						
N 215859 001	7157456	Aug 28, 2024	DS DP		NP	Dec 20, 2024
					PED	Jun 20, 2025
RIZATRIPTAN BENZOATE - RIZAFILM						
N 205394 001	9301948	Jul 30, 2034	DS DP			
ROFLUMILAST - DALIRESP						
N 022522 001	8536206	Mar 08, 2024	U-1115			
	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			
ROFLUMILAST - DALIRESP						
N 022522 002	8536206	Mar 08, 2024	U-1115			
	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			
ROFLUMILAST - ZORYVE						
N 215985 001	10940142	Jun 07, 2037	DP		NP	Jul 29, 2025
	11129818	Aug 25, 2037	U-3408		NPP	Oct 05, 2026
	11129818	Aug 25, 2037	U-3712			
	11793796	Jun 07, 2037	DP			
	11819496	Jun 07, 2037	U-3748			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	U-3408			
	9907788	Jun 07, 2037	U-3712			
ROFLUMILAST - ZORYVE						
N 217242 001	10940142	Jun 07, 2037	DP			
	11129818	Aug 25, 2037	U-3773			
	11707454	Dec 03, 2041	U-3773			
	11793796	Jun 07, 2037	DP			
	11819496	Jun 07, 2037	U-3773			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	U-3773			
ROLAPITANT HYDROCHLORIDE - VARUBI						
N 206500 001	7049320	Aug 19, 2028	DS DP U-1741			
	7563801	Apr 04, 2027	DP			
	7981905	Apr 04, 2027	U-1741			
	8178550	Apr 04, 2027	DS DP			
	8361500	Oct 09, 2029	DP			
	8404702	Apr 04, 2027	U-1741			
	8470842	Jan 18, 2029	U-1741			
ROLAPITANT HYDROCHLORIDE - VARUBI						
N 208399 001	7049320	Aug 19, 2028	DS DP U-1741			
	7981905	Apr 04, 2027	U-1741			
	8178550	Apr 04, 2027	DS DP			
	8404702	Apr 04, 2027	U-1741			
	8470842	Jan 18, 2029	U-1741			
	9101615	Jul 14, 2032	U-1741			
ROPIVACAINE HYDROCHLORIDE - NAROPIN						
N 020533 006	7828787	Oct 18, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROPIVACAINE HYDROCHLORIDE - NAROPIN						
N 020533 006	7857802	Nov 28, 2026	DP			
	8162915	May 23, 2024	DP			
ROPIVACAINE HYDROCHLORIDE - NAROPIN						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8162915	May 23, 2024	DP			
ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE						
N 208647 001	10413543	Feb 12, 2036	DP			
ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE						
N 208647 002	10413543	Feb 12, 2036	DP			
ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE						
N 208647 003	10413543	Feb 12, 2036	DP			
ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE						
N 208647 004	10413543	Feb 12, 2036	DP			
ROTIGOTINE - NEUPRO						
N 021829 001	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP		U-1272	
	8246979	Sep 01, 2027	DP		U-1273	
	8246980	Nov 27, 2025	DP			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 002	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP		U-1272	
	8246979	Sep 01, 2027	DP		U-1273	
	8246980	Nov 27, 2025	DP			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 003	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP		U-1272	
	8246979	Sep 01, 2027	DP		U-1273	
	8246980	Nov 27, 2025	DP			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 004	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP		U-1272	
	8246979	Sep 01, 2027	DP		U-1273	
	8246980	Nov 27, 2025	DP			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 005	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP		U-1272	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROTIGOTINE - NEUPRO						
N 021829 005	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 006	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	9925150	Mar 01, 2032	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 001	10130636	Aug 17, 2035	U-2012		ODE-168	Apr 06, 2025
	10130636	Aug 17, 2035	U-2101			
	10130636	Aug 17, 2035	U-2273			
	10130636	Aug 17, 2035	U-2830			
	10278974	Feb 10, 2031	DP			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 002	10130636	Aug 17, 2035	U-2012		ODE-168	Apr 06, 2025
	10130636	Aug 17, 2035	U-2101			
	10130636	Aug 17, 2035	U-2273			
	10130636	Aug 17, 2035	U-2830			
	10278974	Feb 10, 2031	DP			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 002	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 003	10130636	Aug 17, 2035	U-2012		ODE-168	Apr 06, 2025
	10130636	Aug 17, 2035	U-2101			
	10130636	Aug 17, 2035	U-2273			
	10130636	Aug 17, 2035	U-2830			
	10278974	Feb 10, 2031	DP			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 001	10016429	Jun 12, 2028	U-3226		I-872	Sep 22, 2024
	10016429	Jun 12, 2028	U-3230		M-285	Dec 19, 2025
	10016429*PED	Dec 12, 2028			ODE-238	May 24, 2026
	7598257	Dec 24, 2027	DS DP U-3227		ODE-373	Sep 22, 2028
	7598257	Dec 24, 2027	DS DP U-3228		PED	Mar 22, 2025
	7598257*PED	Jun 24, 2028			PED	Jun 19, 2026
	8415362	Dec 24, 2027	DS DP		PED	Nov 24, 2026
	8415362*PED	Jun 24, 2028			PED	Mar 22, 2029

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 001	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 002	10016429	Jun 12, 2028	U-3226		I-872	Sep 22, 2024
	10016429	Jun 12, 2028	U-3230		M-285	Dec 19, 2025
	10016429*PED	Dec 12, 2028			ODE-238	May 24, 2026
	7598257	Dec 24, 2027	DS DP U-3227		ODE-373	Sep 22, 2028
	7598257	Dec 24, 2027	DS DP U-3228		PED	Mar 22, 2025
	7598257*PED	Jun 24, 2028			PED	Jun 19, 2026
	8415362	Dec 24, 2027	DS DP		PED	Nov 24, 2026
	8415362*PED	Jun 24, 2028			PED	Mar 22, 2029
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 002	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 003	10016429	Jun 12, 2028	U-3226		M-285	Dec 19, 2025
	10016429	Jun 12, 2028	U-3230		ODE-238	May 24, 2026
	10016429*PED	Dec 12, 2028			ODE-373	Sep 22, 2028
	7598257	Dec 24, 2027	DS DP U-3227		PED	Jun 19, 2026
	7598257	Dec 24, 2027	DS DP U-3228		PED	Nov 24, 2026
	7598257*PED	Jun 24, 2028			PED	Mar 22, 2029
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 004	10016429	Jun 12, 2028	U-3226		M-285	Dec 19, 2025
	10016429	Jun 12, 2028	U-3230		ODE-238	May 24, 2026
	10016429*PED	Dec 12, 2028			ODE-373	Sep 22, 2028
	7598257	Dec 24, 2027	DS DP U-3227		PED	Jun 19, 2026
	7598257	Dec 24, 2027	DS DP U-3228		PED	Nov 24, 2026
	7598257*PED	Jun 24, 2028			PED	Mar 22, 2029
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 004	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 005	10016429	Jun 12, 2028	U-3226		M-285	Dec 19, 2025
	10016429	Jun 12, 2028	U-3230		ODE-238	May 24, 2026
	10016429*PED	Dec 12, 2028			ODE-373	Sep 22, 2028
	7598257	Dec 24, 2027	DS DP U-3227		PED	Jun 19, 2026
	7598257	Dec 24, 2027	DS DP U-3228		PED	Nov 24, 2026
	7598257*PED	Jun 24, 2028			PED	Mar 22, 2029
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
RUXOLITINIB PHOSPHATE - OPZELURA						
N 215309 001	10610530	Jun 12, 2028	U-3229		I-896	Jul 18, 2025
	10610530	Jun 12, 2028	U-3404		NP	Sep 21, 2024
	10610530*PED	Dec 12, 2028			PED	Mar 21, 2025
	10639310	Dec 12, 2026	U-3229		PED	Jan 18, 2026
	10639310*PED	Jun 12, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - OPZELURA						
N 215309 001	10758543	May 20, 2031	DP			
	10758543*PED	Nov 20, 2031				
	10869870	May 20, 2031	U-3229			
	10869870	May 20, 2031	U-3404			
	10869870*PED	Nov 20, 2031				
	11219624	May 20, 2031	DP U-3229			
	11219624*PED	Nov 20, 2031				
	11510923	Sep 04, 2040	U-3505			
	11571425	May 20, 2031	DP			
	11590136	May 20, 2031	U-3229			
	11590136	May 20, 2031	U-3404			
	11590137	Sep 04, 2040	U-3505			
	11590138	Jun 10, 2040	U-3551			
	11602536	May 05, 2041	U-3550			
	7598257	Dec 24, 2027	DS DP			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-3229			
	8822481	Jun 12, 2028	U-3404			
	8822481*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3229			
	9079912	Dec 12, 2026	U-3404			
	9079912*PED	Jun 12, 2027				
	9974790	Dec 12, 2026	U-3229			
	9974790	Dec 12, 2026	U-3404			
	9974790*PED	Jun 12, 2027				
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 001	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	11135192	Aug 22, 2033	U-3084			
	7468390*PED	May 27, 2024				
	8101659	Jan 15, 2025	DP			
	8101659*PED	Jul 15, 2025				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 002	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	11135192	Aug 22, 2033	U-3084			
	7468390*PED	May 27, 2024				
	8101659	Jan 15, 2025	DP			
	8101659*PED	Jul 15, 2025				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 002	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 003	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	11135192	Aug 22, 2033	U-3084			
	7468390*PED	May 27, 2024				
	8101659	Jan 15, 2025	DP			
	8101659*PED	Jul 15, 2025				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
SAFINAMIDE MESYLATE - XADAGO						
N 207145 001	8076515	Dec 10, 2028	DS DP	U-1993		
	8278485	Jun 08, 2027	DS	U-1993		
	8283380	Mar 21, 2031		U-1993		
SAFINAMIDE MESYLATE - XADAGO						
N 207145 002	8076515	Dec 10, 2028	DS DP	U-1993		
	8278485	Jun 08, 2027	DS	U-1993		
	8283380	Mar 21, 2031		U-1993		
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N 022181 001	7566462	Nov 16, 2025	DP			
	7566462*PED	May 16, 2026				
	7566714	Nov 17, 2024	U-989			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 16, 2026				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	9433624	Nov 17, 2024	U-1589			
	9433624*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1156			
	RE43797*PED	May 17, 2025				
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N 205065 001	7566714	Nov 17, 2024	U-1589			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N 205065 001	8067416	Nov 17, 2024	U-1589			
	8067416*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	9216178*PED	May 01, 2033				
	9433624	Nov 17, 2024	U-1589			
	9433624*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N 205065 002	7566714	Nov 17, 2024	U-1589			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	8067416	Nov 17, 2024	U-1589			
	8067416*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	9216178*PED	May 01, 2033				
	9433624	Nov 17, 2024	U-1589			
	9433624*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
SARECYCLINE HYDROCHLORIDE - SEYSARA						
N 209521 001	8318706	May 01, 2031	DS DP U-2405			
	8513223	Dec 07, 2029	U-2406			
	9255068	Feb 09, 2033	DS DP U-2407			
	9255068	Feb 09, 2033	DS DP U-2408			
	9481639	Aug 10, 2028	U-2409			
SARECYCLINE HYDROCHLORIDE - SEYSARA						
N 209521 002	8318706	May 01, 2031	DS DP U-2405			
	8513223	Dec 07, 2029	U-2406			
	9255068	Feb 09, 2033	DS DP U-2407			
	9255068	Feb 09, 2033	DS DP U-2408			
	9481639	Aug 10, 2028	U-2409			
SARECYCLINE HYDROCHLORIDE - SEYSARA						
N 209521 003	8318706	May 01, 2031	DS DP U-2405			
	8513223	Dec 07, 2029	U-2406			
	9255068	Feb 09, 2033	DS DP U-2407			
	9255068	Feb 09, 2033	DS DP U-2408			
	9481639	Aug 10, 2028	U-2409			
SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN						
A 205941 001					PC	Jan 27, 2024
SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN						
A 205941 002					PC	Jan 27, 2024
SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN						
A 205972 001					PC	Jan 27, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN						
A 205972 002					PC	Jan 27, 2024
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N 022350 001	7951400	Nov 30, 2028	DP			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N 022350 002	7951400	Nov 30, 2028	DP			
SECNIDAZOLE - SOLOSEC						
N 209363 001	10335390	Sep 04, 2035	DP U-2583		I-866	Jun 30, 2024
	10335390	Sep 04, 2035	DP U-3270		NCE	Sep 15, 2022
	10682338	Sep 04, 2035	DP U-2583		NPP	Jan 26, 2025
	10682338	Sep 04, 2035	DP U-3270		GAIN	Sep 15, 2027
	10849884	Sep 04, 2035	DP U-2583			
	10849884	Sep 04, 2035	DP U-3169			
	10849884	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-3302			
	10857133	Sep 04, 2035	DP U-2583			
	10857133	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000507	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-3302			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-3270			
	11000508	Sep 04, 2035	DP U-3302			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-3270			
	11020377	Sep 04, 2035	DP U-3302			
	11324721	Sep 04, 2035	DP U-2583			
	11324721	Sep 04, 2035	DP U-3169			
	11324721	Sep 04, 2035	DP U-3270			
	11324721	Sep 04, 2035	DP U-3302			
	11602522	Sep 04, 2035	DP U-3169			
	11602522	Sep 04, 2035	DP U-3302			
	11684607	Sep 16, 2035	DP U-2583			
	11684607	Sep 16, 2035	DP U-3169			
	11684607	Sep 16, 2035	DP U-3270			
	11684607	Sep 16, 2035	DP U-3302			
SELENIOUS ACID - SELENIOUS ACID						
N 209379 001					NCE	Apr 30, 2024
SELENIOUS ACID - SELENIOUS ACID						
N 209379 002					NCE	Apr 30, 2024
SELENIOUS ACID - SELENIOUS ACID						
N 209379 003					NCE	Apr 30, 2024
SELEXIPAG - UPTRAVI						
N 207947 001	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELEXIPAG - UPTRAVI						
N 207947 001	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 002	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 003	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 004	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 005	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 006	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 007	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELEXIPAG - UPTRAVI						
N 207947 008	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 214275 001	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELINEXOR - XPOVIO						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584		NCE	Jul 03, 2024
	10519139	Aug 14, 2035	DS DP U-2855		ODE-257	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-3018		ODE-310	Jun 22, 2027
	10544108	Jul 26, 2032	U-2584		ODE-346	Dec 18, 2027
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS DP			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELINEXOR - XPOVIO						
N 212306 002	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELINEXOR - XPOVIO						
N 212306 002	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS DP			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELINEXOR - XPOVIO						
N 212306 003	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS DP			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELINEXOR - XPOVIO						
N 212306 004	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELINEXOR - XPOVIO						
N 212306 004	11807629	Aug 14, 2035	DS DP			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELPERCATINIB - RETEVMO						
N 213246 001	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-2828		ODE-303	May 08, 2027
	10137124	Oct 10, 2037	U-3450		ODE-409	Sep 21, 2029
	10137124	Oct 10, 2037	U-3451		ODE-412	Sep 21, 2029
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3451			
	10172851	Oct 10, 2037	U-3452			
	10172851	Oct 10, 2037	U-3453			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3451			
	10584124	Oct 10, 2038	DS U-3452			
	10584124	Oct 10, 2038	DS U-3453			
	10786489	Oct 10, 2038	DP U-2971			
	10786489	Oct 10, 2038	DP U-2972			
	10786489	Oct 10, 2038	DP U-2973			
	10786489	Oct 10, 2038	DP U-2974			
	10786489	Oct 10, 2038	DP U-2975			
	10786489	Oct 10, 2038	DP U-2976			
	10786489	Oct 10, 2038	DP U-2977			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3451			
	10786489	Oct 10, 2038	DP U-3452			
	10786489	Oct 10, 2038	DP U-3453			
SELPERCATINIB - RETEVMO						
N 213246 002	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-2828		ODE-303	May 08, 2027
	10137124	Oct 10, 2037	U-3450		ODE-409	Sep 21, 2029
	10137124	Oct 10, 2037	U-3451		ODE-412	Sep 21, 2029
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELPERCATINIB - RETEVMO						
N 213246 002	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3451			
	10584124	Oct 10, 2038	DS U-3452			
	10584124	Oct 10, 2038	DS U-3453			
	10786489	Oct 10, 2038	DP U-2971			
	10786489	Oct 10, 2038	DP U-2972			
	10786489	Oct 10, 2038	DP U-2973			
	10786489	Oct 10, 2038	DP U-2974			
	10786489	Oct 10, 2038	DP U-2975			
	10786489	Oct 10, 2038	DP U-2976			
	10786489	Oct 10, 2038	DP U-2977			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3451			
	10786489	Oct 10, 2038	DP U-3452			
	10786489	Oct 10, 2038	DP U-3453			
SELUMETINIB SULFATE - KOSELUGO						
N 213756 001	11813246	Mar 26, 2029	DP		NCE	Apr 10, 2025
	7425637	Mar 13, 2024	DS		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
SELUMETINIB SULFATE - KOSELUGO						
N 213756 002	11813246	Mar 26, 2029	DP		NCE	Apr 10, 2025
	7425637	Mar 13, 2024	DS		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
SEMAGLUTIDE - OZEMPIC						
N 209637 001	10220155	Jul 17, 2026	DP			
	10335462	Jun 21, 2033	U-2580			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-2202			
	8536122	Mar 20, 2026	DS DP U-2202			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - OZEMPIC						
N 209637 001	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
SEMAGLUTIDE - OZEMPIC						
N 209637 002	10220155	Jul 17, 2026	DP			
	10335462	Jun 21, 2033	U-2580			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-2202			
	8536122	Mar 20, 2026	DS DP U-2202			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
SEMAGLUTIDE - OZEMPIC						
N 209637 003	10220155	Jul 17, 2026	DP		D-185	Mar 28, 2025
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-3355			
	8536122	Mar 20, 2026	DS DP U-3355			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - OZEMPIC						
N 209637 004	10220155	Jul 17, 2026	DP			
	10335462	Jun 21, 2033	DP		U-2580	
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP		U-3469	
	8536122	Mar 20, 2026	DS DP		U-3469	
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
SEMAGLUTIDE - RYBELSUS						
N 213051 001	10086047	Dec 16, 2031	DP			
	10278923	May 02, 2034			U-2628	
	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
	11382957	Dec 16, 2031	DP			
	11759501	Mar 15, 2033	DP			
	11759502	Mar 15, 2033	DP			
	11759503	Mar 15, 2033	DP			
	8129343	Dec 05, 2031	DS DP		U-2628	
	8536122	Mar 20, 2026	DS DP		U-2628	
	9278123	Dec 16, 2031	DP		U-2628	
SEMAGLUTIDE - RYBELSUS						
N 213051 002	10086047	Dec 16, 2031	DP			
	10278923	May 02, 2034			U-2628	
	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
	11382957	Dec 16, 2031	DP			
	11759501	Mar 15, 2033	DP			
	11759502	Mar 15, 2033	DP			
	11759503	Mar 15, 2033	DP			
	8129343	Dec 05, 2031	DS DP		U-2628	
	8536122	Mar 20, 2026	DS DP		U-2628	
	9278123	Dec 16, 2031	DP		U-2628	
SEMAGLUTIDE - RYBELSUS						
N 213051 003	10086047	Dec 16, 2031	DP			
	10278923	May 02, 2034			U-2628	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - RYBELSUS						
N 213051 003	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
	11382957	Dec 16, 2031	DP			
	11759501	Mar 15, 2033	DP			
	11759502	Mar 15, 2033	DP			
	11759503	Mar 15, 2033	DP			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - WEGOVY						
N 215256 001	10888605	Aug 24, 2038	DP U-3162		NP	Jun 04, 2024
	11318191	Feb 17, 2041	DP U-3162		NPP	Dec 23, 2025
	11752198	Aug 24, 2038	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY						
N 215256 002	10888605	Aug 24, 2038	DP U-3162		NP	Jun 04, 2024
	11318191	Feb 17, 2041	DP U-3162		NPP	Dec 23, 2025
	11752198	Aug 24, 2038	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY						
N 215256 003	10888605	Aug 24, 2038	DP U-3162		NP	Jun 04, 2024
	11318191	Feb 17, 2041	DP U-3162		NPP	Dec 23, 2025
	11752198	Aug 24, 2038	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY						
N 215256 004	10888605	Aug 24, 2038	DP U-3162		D-190	Jul 21, 2026
	11318191	Feb 17, 2041	DP U-3162		NP	Jun 04, 2024
	11752198	Aug 24, 2038	DP U-3162		NPP	Dec 23, 2025
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY						
N 215256 005	10888605	Aug 24, 2038	DP U-3162		NP	Jun 04, 2024
	11318191	Feb 17, 2041	DP U-3162		NPP	Dec 23, 2025
	11752198	Aug 24, 2038	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SETMELANOTIDE ACETATE - IMCIVREE						
N 213793 001	11129869	Jul 04, 2034	DP		I-892	Jun 16, 2025
	8039435	Oct 13, 2027	DS DP		NCE	Nov 25, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SETMELANOTIDE ACETATE - IMCIVREE						
N 213793 001	9458195	Oct 13, 2027	DS DP		ODE-336	Nov 25, 2027
					ODE-402	Jun 16, 2029
SEVELAMER CARBONATE - RENVELA						
N 022127 001	7985418	Oct 27, 2025	DP			
SEVELAMER CARBONATE - RENVELA						
N 022318 001	9095509	Dec 06, 2030	DP			
SEVELAMER CARBONATE - RENVELA						
N 022318 002	9095509	Dec 06, 2030	DP			
SILDENAFIL CITRATE - REVATIO						
N 021845 001					M-287	Jan 31, 2026
SILDENAFIL CITRATE - REVATIO						
N 022473 001					M-287	Jan 31, 2026
SILDENAFIL CITRATE - REVATIO						
N 203109 001					M-287	Jan 31, 2026
SILDENAFIL CITRATE - LIQREV						
N 214952 001	11337979	Dec 24, 2038	DP U-3582			
	11464778	Dec 24, 2038	DP U-3582			
	11759468	Dec 24, 2038	DP U-3582			
SIMEPREVIR SODIUM - OLYSIO						
N 205123 001	7671032	May 19, 2025	DS DP			
	8148399	Sep 05, 2029	DS DP U-1467			
	8349869	Jul 28, 2026	DS DP U-1467			
	8741926	Jul 28, 2026	DS U-1467			
	8754106	Jul 28, 2026	DS U-1467			
	9040562	Jul 28, 2026	DS DP U-1467			
	9353103	Jul 28, 2026	U-1467			
	9623022	Jul 28, 2026	U-1467			
	9856265	Jul 28, 2026	DS DP U-1467			
SIMVASTATIN - FLOLIPID						
N 206679 001	10300041	Apr 26, 2027	DP			
	9597289	Feb 23, 2030	DP			
SIMVASTATIN - FLOLIPID						
N 206679 002	10300041	Apr 26, 2027	DP			
	9597289	Feb 23, 2030	DP			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 001	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 002	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 003	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 004	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 005	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 006	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
SINCALIDE - SINCALIDE						
N 210850 001	11110063	Apr 20, 2038	DP U-3481			
	11110063	Apr 20, 2038	DP U-3482			
	11110063	Apr 20, 2038	DP U-3483			
	11318100	Apr 20, 2038	DP U-3477			
	11318100	Apr 20, 2038	DP U-3478			
	11318100	Apr 20, 2038	DP U-3479			
	11318100	Apr 20, 2038	DP U-3480			
	11737983	Apr 20, 2038	DP U-3482			
	11737983	Apr 20, 2038	DP U-3689			
SINECATECHINS - VEREGEN						
N 021902 001	7858662	Oct 02, 2026	DP U-172			
	9770406	Jul 12, 2025	DP U-172			
SIPONIMOD - MAYZENT						
N 209884 001	7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
	8492441	Nov 30, 2030	U-2511		NCE	Mar 26, 2024
SIPONIMOD - MAYZENT						
N 209884 002	7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
	8492441	Nov 30, 2030	U-2511		NCE	Mar 26, 2024
SIPONIMOD - MAYZENT						
N 209884 003	7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
	8492441	Nov 30, 2030	U-2511		NCE	Mar 26, 2024
SIROLIMUS - FYARRO						
N 213312 001	10206887	Apr 15, 2030	DP		NP	Nov 22, 2024
	10705070	Mar 05, 2036	DP		ODE-386	Nov 22, 2028
	10973806	Jun 29, 2036	U-3258			
	11497737	Oct 28, 2040	DP			
	8911786	Feb 14, 2029	DP U-3259			
SIROLIMUS - HYFTOR						
N 213478 001					NP	Mar 22, 2025
					ODE-391	Mar 22, 2029
SITAGLIPTIN - ZITUVIO						
N 211566 001	10925871	Feb 25, 2035	DP			
SITAGLIPTIN - ZITUVIO						
N 211566 002	10925871	Feb 25, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SITAGLIPTIN - ZITUVIO						
N 211566 003	10925871	Feb 25, 2035	DP			
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802		M-187	Dec 04, 2023
	7326708*PED	May 24, 2027			PED	Jun 04, 2024
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802		M-187	Dec 04, 2023
	7326708*PED	May 24, 2027			PED	Jun 04, 2024
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802		M-187	Dec 04, 2023
	7326708*PED	May 24, 2027			PED	Jun 04, 2024
SODIUM BENZOATE; SODIUM PHENYLACETATE - SODIUM PHENYLACETATE AND SODIUM BENZOATE						
A 217526 001					CGT	Mar 17, 2024
SODIUM CHLORIDE - SODIUM CHLORIDE 23.4%						
A 217796 001					CGT	Jan 23, 2024
SODIUM NITRITE - SODIUM NITRITE						
N 203922 001	8568793	Dec 24, 2031	DS DP			
	9687506	Feb 10, 2030	DP U-3394			
	9687506	Feb 10, 2030	DP U-3395			
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE						
N 201444 001	10479686	Jul 07, 2030	DP U-3390			
	11753301	Feb 10, 2030	DS DP U-3681			
	8496973	Mar 29, 2031	DS DP U-1419			
	8568793	Dec 24, 2031	DS DP			
	9345724	Jul 07, 2030	DS DP U-2015			
	9585912	Jul 07, 2030	DS DP			
	9687506	Feb 10, 2030	DP U-3394			
	9687506	Feb 10, 2030	DP U-3395			
SODIUM OXYBATE - XYREM						
N 021196 001	10213400	Mar 15, 2033	U-2499		ODE-231	Oct 26, 2025
	10213400*PED	Sep 15, 2033			PED	Apr 26, 2026
	10864181	Mar 15, 2033	U-1532			
	10864181*PED	Sep 15, 2033				
	11253494	Mar 15, 2033	U-3323			
	11253494	Mar 15, 2033	U-3324			
	11253494*PED	Sep 15, 2033				
	7668730	Jun 16, 2024	U-1110	Y		
	7668730*PED	Dec 16, 2024				
	8772306	Mar 15, 2033	U-1532			
	8772306*PED	Sep 15, 2033				
	9050302	Mar 15, 2033	U-1532			
	9050302*PED	Sep 15, 2033				
	9486426	Mar 15, 2033	U-1532			
	9486426*PED	Sep 15, 2033				
SODIUM OXYBATE - LUMRYZ						
N 214755 001	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM OXYBATE - LUMRYZ						
N 214755 001	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
	11766418	Jul 21, 2037	DP			
	11779557	Mar 16, 2042	U-3705			
	11839597	Jul 21, 2037	DP			
SODIUM OXYBATE - LUMRYZ						
N 214755 002	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
	11766418	Jul 21, 2037	DP			
	11779557	Mar 16, 2042	U-3705			
	11826335	Jul 21, 2037	U-3751			
	11839597	Jul 21, 2037	DP			
SODIUM OXYBATE - LUMRYZ						
N 214755 003	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
	11766418	Jul 21, 2037	DP			
	11779557	Mar 16, 2042	U-3705			
	11839597	Jul 21, 2037	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM OXYBATE - LUMRYZ						
N 214755 003	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
	11766418	Jul 21, 2037	DP			
	11779557	Mar 16, 2042	U-3705			
	11839597	Jul 21, 2037	DP			
SODIUM OXYBATE - LUMRYZ						
N 214755 004	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
	11766418	Jul 21, 2037	DP			
	11779557	Mar 16, 2042	U-3705			
	11839597	Jul 21, 2037	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 001	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 002	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 003	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 004	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 004	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 005	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 006	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE; TAURURSODIOL - RELYVRIO						
N 216660 001	10251896	Dec 24, 2033	U-3460		NCE	Sep 29, 2027
	10857162	Dec 24, 2033	U-3460		ODE-411	Sep 29, 2029
	11071742	Dec 24, 2033	DP			
	11583542	Jul 27, 2040	DP			
	9872865	Dec 24, 2033	U-3460			
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP						
N 021892 001	7687075	Jun 22, 2028	DS DP			
SODIUM THIOSULFATE - SODIUM THIOSULFATE						
N 203923 001	10479686	Jul 07, 2030	DP U-3390			
	11753301	Feb 10, 2030	DS DP U-3682			
	8496973	Mar 29, 2031	DS DP U-1419			
	9345724	Jul 07, 2030	DS DP U-2015			
	9585912	Jul 07, 2030	DS DP			
SODIUM THIOSULFATE - PEDMARK						
N 212937 001	10596190	Jan 05, 2038	U-3443	Y	NP	Sep 20, 2025
	11291728	Jul 01, 2039	DP		ODE-384	Sep 20, 2029
	11510984	Jul 01, 2039	DP			
	11617793	Jul 01, 2039	DP			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA						
N 207078 001	10300087	Oct 14, 2035	DS U-2312			
	10335432	Feb 10, 2032	U-2312			
	10398730	Feb 10, 2032	U-2312			
	10413569	Feb 10, 2032	DS			
	10695365	Oct 22, 2033	DS			
	11406662	Feb 10, 2032	DS			
	11738044	Oct 14, 2035	U-2312			
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS U-2312			
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
	9913860	Oct 22, 2033	DS U-2312			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA						
N 207078 002	10300087	Oct 14, 2035	DS U-2312			
	10398730	Feb 10, 2032	U-2312			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA						
N 207078 002	10413569	Feb 10, 2032	DS			
	10695365	Oct 22, 2033	DS			
	11406662	Feb 10, 2032	DS			
	11738044	Oct 14, 2035	U-2312			
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS U-2312			
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
	9913860	Oct 22, 2033	DS U-2312			
SOFOSBUVIR - SOVALDI						
N 204671 001	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-135	Apr 07, 2024
	8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9549941	Mar 26, 2029	U-1958			
	9549941*PED	Sep 26, 2029				
SOFOSBUVIR - SOVALDI						
N 204671 002	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Apr 07, 2024
	7964580*PED	Sep 26, 2029			ODE*	Aug 28, 2026
	8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR - SOVALDI						
N 212480 001	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Apr 07, 2024
	7964580*PED	Sep 26, 2029			ODE-258	Aug 28, 2026
	8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
SOFOSBUVIR - SOVALDI						
N 212480 002	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Apr 07, 2024
	7964580*PED	Sep 26, 2029			ODE-258	Aug 28, 2026
	8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 208341 001	10086011	Jan 30, 2034	U-1470		M-264	Jul 14, 2023
	10086011*PED	Jul 30, 2034			M-277	Apr 27, 2025
	11116783	Jan 30, 2034	DP U-1470		ODE-293	Mar 19, 2027
	11116783*PED	Jul 30, 2034			ODE-376	Jun 10, 2028
	7964580	Mar 26, 2029	DS DP U-1470		PED	Jan 14, 2024
	7964580*PED	Sep 26, 2029			PED	Sep 19, 2027
	8334270	Mar 21, 2028	DS DP U-1470		PED	Dec 10, 2028
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR - EPCLUSA							
N 208341	001	8633309*PED	Sep 26, 2029				
		8735372	Mar 21, 2028	U-1470			
		8735372*PED	Sep 21, 2028				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		8921341	Nov 16, 2032	DS DP U-1470			
		8921341*PED	May 16, 2033				
		8940718	Nov 16, 2032	DS DP U-1470			
		8940718*PED	May 16, 2033				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
		9757406	Jan 30, 2034	DP			
		9757406*PED	Jul 30, 2034				
SOFOSBUVIR; VELPATASVIR - EPCLUSA							
N 208341	002	10086011	Jan 30, 2034	U-1470		M-264	Jul 14, 2023
		10086011*PED	Jul 30, 2034			M-277	Apr 27, 2025
		11116783	Jan 30, 2034	DP U-1470		ODE-293	Mar 19, 2027
		11116783*PED	Jul 30, 2034			ODE-376	Jun 10, 2028
		7964580	Mar 26, 2029	DS DP U-1470		PED	Jan 14, 2024
		7964580*PED	Sep 26, 2029			PED	Sep 19, 2027
		8334270	Mar 21, 2028	DS DP U-1470		PED	Dec 10, 2028
		8334270*PED	Sep 21, 2028				
		8575135	Nov 16, 2032	DS DP U-1470			
		8575135*PED	May 16, 2033				
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8735372	Mar 21, 2028	U-1470			
		8735372*PED	Sep 21, 2028				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		8921341	Nov 16, 2032	DS DP U-1470			
		8921341*PED	May 16, 2033				
		8940718	Nov 16, 2032	DS DP U-1470			
		8940718*PED	May 16, 2033				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
		9757406	Jan 30, 2034	DP			
		9757406*PED	Jul 30, 2034				
SOFOSBUVIR; VELPATASVIR - EPCLUSA							
N 214187	001	11116783	Jan 30, 2034	DP U-1470		M-277	Apr 27, 2025
		11116783*PED	Jul 30, 2034			ODE-376	Jun 10, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 001	11707479	Jan 30, 2034	DP U-1470		PED	Dec 10, 2028
	11707479*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 002	11116783	Jan 30, 2034	DP U-1470		M-277	Apr 27, 2025
	11116783*PED	Jul 30, 2034			ODE-376	Jun 10, 2028
	11707479	Jan 30, 2034	DP U-1470		PED	Dec 10, 2028
	11707479*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 002	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI						
N 209195 001	10912814	Jun 01, 2037	DP			
	11116783	Jan 30, 2034	DP U-2039			
	11116783	Jan 30, 2034	DP U-2040			
	11116783*PED	Jul 30, 2034				
	11338007	Jun 01, 2037	DP U-2039			
	11338007	Jun 01, 2037	DP U-2040			
	11338007*PED	Dec 01, 2037				
	7964580	Mar 26, 2029	DS DP U-2039			
	7964580	Mar 26, 2029	DS DP U-2040			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-2039			
	8334270	Mar 21, 2028	DS DP U-2040			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-2039			
	8575135	Nov 16, 2032	DS DP U-2040			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	8940718*PED	May 16, 2033				
	8957046	Mar 21, 2028	U-2039			
	8957046	Mar 21, 2028	U-2040			
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9085573*PED	Sep 21, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI						
N 209195 001	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9284342*PED	Mar 13, 2031				
	9296782	Jul 17, 2034	DS DP			
	9585906	Mar 21, 2028	DS DP U-2039			
	9585906	Mar 21, 2028	DS DP U-2040			
	9868745	Nov 16, 2032	DS DP			
SOLIFENACIN SUCCINATE - VESICARE LS						
N 209529 001	9918970	May 18, 2031	DP			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 001	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	10512609	Sep 05, 2037	U-2548			
	10912754	Jun 01, 2038	U-3082			
	10940133	Mar 19, 2040	U-3099			
	10959976	Jun 01, 2038	U-3151			
	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
	11648232	Jun 01, 2038	U-3602			
	11753368	Jun 07, 2026	U-2548			
	11771666	Dec 30, 2042	U-3693			
	11771667	Dec 30, 2042	U-3693			
	11779554	Dec 30, 2042	U-3693			
	11793776	Dec 30, 2042	U-3693			
	11839598	Mar 19, 2040	U-3765			
	11839599	Mar 19, 2040	U-3764			
	11850226	Mar 19, 2040	U-3775			
	11850227	Mar 19, 2040	U-3775			
	11850228	Mar 19, 2040	U-3775			
	8440715	Jun 11, 2031	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 002	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	10512609	Sep 05, 2037	U-2548			
	10912754	Jun 01, 2038	U-3082			
	10959976	Jun 01, 2038	U-3151			
	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
	11648232	Jun 01, 2038	U-3602			
	11753368	Jun 07, 2026	U-2548			
	11771666	Dec 30, 2042	U-3693			
	11771667	Dec 30, 2042	U-3693			
	11779554	Dec 30, 2042	U-3693			
	11793776	Dec 30, 2042	U-3693			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 002	11839598	Mar 19, 2040	U-3765			
	11839599	Mar 19, 2040	U-3764			
	11850226	Mar 19, 2040	U-3775			
	11850227	Mar 19, 2040	U-3775			
	11850228	Mar 19, 2040	U-3775			
	8440715	Jun 11, 2031	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
SONIDEGIB PHOSPHATE - ODOMZO						
N 205266 001	10266523	Mar 30, 2036	DS DP			
	8063043	Sep 15, 2029	DS DP			
	8178563	Jul 24, 2029	DS U-1722			
SORAFENIB TOSYLATE - NEXAVAR						
N 021923 001	8877933	Dec 24, 2027	DS DP U-1624			
	9737488	Sep 10, 2028	DP U-1480			
	9737488	Sep 10, 2028	DP U-1696			
	9737488	Sep 10, 2028	DP U-2107			
SOTAGLIFLOZIN - INPEFA						
N 216203 001	7781577	May 04, 2028	DS DP U-3628		NCE	May 26, 2028
	8217156	Oct 07, 2030	DS DP			
	8476413	May 29, 2028	DS DP U-3628			
SOTAGLIFLOZIN - INPEFA						
N 216203 002	7781577	May 04, 2028	DS DP U-3628		NCE	May 26, 2028
	8217156	Oct 07, 2030	DS DP			
	8476413	May 29, 2028	DS DP U-3628			
SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE						
N 022306 001	10512620	Aug 14, 2038	U-2769			
	10512620	Aug 14, 2038	U-3547			
	10799138	Apr 05, 2039	U-3125			
	10799138	Apr 05, 2039	U-3549			
	11583216	Aug 21, 2039	U-3549			
	11696902	Aug 14, 2038	U-2769			
SOTALOL HYDROCHLORIDE - SOTYLIZE						
N 205108 001	10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			
	11013703	Apr 01, 2034	DP			
	11850222	Nov 19, 2034	U-2096			
	11850222	Nov 19, 2034	U-2494			
	9724297	Aug 31, 2035	DP U-2096			
SOTORASIB - LUMAKRAS						
N 214665 001	10519146	May 21, 2038	DS DP		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP U-3306		ODE-352	May 28, 2028
	11426404	Sep 15, 2040	U-3306			
	11827635	May 20, 2040	DS DP U-3306			
SOTORASIB - LUMAKRAS						
N 214665 002	10519146	May 21, 2038	DS DP		NCE	May 28, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOTORASIB - LUMAKRAS						
N 214665 002	11236091	May 20, 2040	DS DP U-3306		ODE-352	May 28, 2028
	11426404	Sep 15, 2040	U-3306			
	11827635	May 20, 2040	DS DP U-3306			
SPARSENTAN - FILSPARI						
N 216403 001	9993461	Mar 29, 2030	U-3269		NCE	Feb 17, 2028
					ODE-389	Feb 17, 2030
SPARSENTAN - FILSPARI						
N 216403 002	9993461	Mar 29, 2030	U-3269		NCE	Feb 17, 2028
					ODE-389	Feb 17, 2030
SPINOSAD - NATROBA						
N 022408 001	9895388	Nov 25, 2033	U-3365		I-858	Apr 28, 2024
SPIRONOLACTONE - CAROSPIR						
N 209478 001	10493083	Oct 28, 2036	DP			
	10624906	Oct 28, 2036	DP			
	10660907	Oct 28, 2036	DP			
	10888570	Oct 28, 2036	DP			
	11389461	Oct 28, 2036	DP			
	11395828	Oct 28, 2036	U-2109			
	11395828	Oct 28, 2036	U-3401			
	11395828	Oct 28, 2036	U-3402			
	11491166	Oct 28, 2036	DP			
	9757394	Oct 28, 2036	DP U-2109			
STIRIPENTOL - DIACOMIT						
N 206709 001					M-281	Jul 14, 2025
					ODE-198	Aug 20, 2025
					ODE-403	Jul 14, 2029
STIRIPENTOL - DIACOMIT						
N 206709 002					M-281	Jul 14, 2025
					ODE-198	Aug 20, 2025
					ODE-403	Jul 14, 2029
STIRIPENTOL - DIACOMIT						
N 207223 001					NPP	Jul 14, 2025
					ODE-198	Aug 20, 2025
					ODE-403	Jul 14, 2029
STIRIPENTOL - DIACOMIT						
N 207223 002					NPP	Jul 14, 2025
					ODE-198	Aug 20, 2025
					ODE-403	Jul 14, 2029
SUFENTANIL CITRATE - DSUVIA						
N 209128 001	10245228	Jan 05, 2027	DP U-1351			
	10342762	Jan 05, 2027	DP			
	10507180	Jan 05, 2027	DP U-1351			
	10896751	Mar 16, 2030	DP			
	11672738	Feb 02, 2038	DP			
	11676691	Mar 16, 2030	DP			
	8202535	Oct 22, 2030	U-1351			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUFENTANIL CITRATE - DSUVIA						
N 209128 001	8226978	Jan 05, 2027	DP U-1351			
	8231900	Jan 05, 2027	DP			
	8252328	Jan 05, 2027	DP			
	8252329	Jan 05, 2027	DP			
	8535714	Jan 05, 2027	DP U-1351			
	8574189	Mar 16, 2030	DP			
	8778393	Jan 05, 2027	U-1351			
	8778394	Jan 05, 2027	U-1351			
	8865211	Jan 05, 2027	U-1351			
	8865743	Oct 22, 2030	U-1351			
	8945592	Jul 29, 2031	DP			
	9320710	Jan 05, 2027	U-1351			
	9744129	Jan 05, 2027	DP			
SUGAMMADEX SODIUM - BRIDION						
N 022225 001	RE44733	Jan 27, 2026	DS DP U-1794		M-291	Jan 22, 2024
					NPP	Jun 25, 2024
SUGAMMADEX SODIUM - BRIDION						
N 022225 002	RE44733	Jan 27, 2026	DS DP U-1794		M-291	Jan 22, 2024
					NPP	Jun 25, 2024
SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON						
N 203684 001	10232061	Jul 06, 2038	DP			
	10335502	Jul 06, 2038	DP			
	11723869	May 15, 2039	DP U-3666			
	11723869	May 15, 2039	DP U-3667			
	11723869	May 15, 2039	DP U-3668			
SUMATRIPTAN - TOSYMRA						
N 210884 001	10603305	Jun 16, 2030	DP U-1719			
	11337962	Jun 16, 2030	DP U-1719			
	8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
	9283280	May 09, 2026	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO						
N 022239 001	7776007	Nov 22, 2026	DP			
	7901385	Jul 31, 2026	DP			
	8287489	Dec 06, 2024	DP			
SUMATRIPTAN SUCCINATE - ALSUMA						
N 022377 001	7811254	Aug 26, 2027	DP U-1083			
SUMATRIPTAN SUCCINATE - ZECUITY						
N 202278 001	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
	8597272	Apr 12, 2027	DP			
	8983594	Nov 19, 2030	DP U-1328			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUMATRIPTAN SUCCINATE - ZECUITY						
N 202278 001	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
	9427578	Apr 12, 2027	DP U-1328			
SUMATRIPTAN SUCCINATE - ONZETRA XSAIL						
N 206099 001	10076614	Oct 20, 2034	DP			
	10076615	Jul 30, 2029	U-2010			
	10076615	Jul 30, 2029	U-2011			
	10076615	Jul 30, 2029	U-2404			
	10124132	Mar 06, 2027	DP U-1719			
	10124132	Mar 06, 2027	DP U-2010			
	10124132	Mar 06, 2027	DP U-2011			
	10398859	Dec 19, 2027	DP			
	10478574	Nov 04, 2033	U-2404			
	10722667	Dec 30, 2028	DP			
	11571531	Feb 23, 2026	U-1809			
	7975690	Aug 18, 2025	DP U-1809			
	8550073	Oct 22, 2029	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
	9649456	Oct 21, 2030	DP U-1719			
	9649456	Oct 21, 2030	DP U-2010			
	9649456	Oct 21, 2030	DP U-2011			
SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH						
N 208223 001	10537554	Jan 29, 2036	U-72			
	11364224	Jan 29, 2036	U-72			
SUVOREXANT - BELSOMRA						
N 204569 001	10098892	May 29, 2033	DP			
	7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA						
N 204569 002	10098892	May 29, 2033	DP			
	7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA						
N 204569 003	10098892	May 29, 2033	DP			
	7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA						
N 204569 004	10098892	May 29, 2033	DP			
	7951797	Nov 20, 2029	DS DP U-620			
TACROLIMUS - PROGRAF						
N 050708 001					ODE-294	May 24, 2025
					ODE-360	Jul 16, 2028
TACROLIMUS - PROGRAF						
N 050708 002					ODE-294	May 24, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TACROLIMUS - PROGRAF						
N 050708 002					ODE-360	Jul 16, 2028
TACROLIMUS - PROGRAF						
N 050708 003					ODE-294	May 24, 2025
					ODE-360	Jul 16, 2028
TACROLIMUS - PROGRAF						
N 050709 001					ODE-294	May 24, 2025
					ODE-360	Jul 16, 2028
TACROLIMUS - ASTAGRAF XL						
N 204096 001					ODE*	May 24, 2025
TACROLIMUS - ASTAGRAF XL						
N 204096 002					ODE*	May 24, 2025
TACROLIMUS - ASTAGRAF XL						
N 204096 003					ODE*	May 24, 2025
TACROLIMUS - ENVARSUS XR						
N 206406 001	10166190	May 30, 2028	DP			
	10548880	Aug 30, 2024		U-2677		
	10548880	Aug 30, 2024		U-2678		
	10864199	May 30, 2028		U-2677		
	10864199	May 30, 2028		U-2678		
	11077096	Aug 30, 2024	DP			
	11110081	May 30, 2028		U-2678		
	11123331	May 30, 2028		U-2677		
	11419823	May 30, 2028	DP			
	7994214	Aug 30, 2024	DP			
	8486993	Aug 30, 2024	DP	U-1752		
	8586084	Aug 30, 2024		U-1752		
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024		U-1752		
	8664239	Aug 30, 2028		U-1752		
	8664239	Aug 30, 2028		U-2677		
	8664239	Aug 30, 2028		U-2678		
	8685998	Aug 30, 2028	DP	U-1752		
	8685998	Aug 30, 2028	DP	U-2677		
	8685998	Aug 30, 2028	DP	U-2678		
	8889185	Aug 30, 2024		U-1752		
	8889186	Aug 30, 2024		U-1752		
	9161907	Aug 30, 2024	DP	U-1752		
	9549918	May 30, 2028	DP			
	9757362	Aug 30, 2024	DP			
	9763920	Aug 30, 2024	DP			
TACROLIMUS - ENVARSUS XR						
N 206406 002	10166190	May 30, 2028	DP			
	10548880	Aug 30, 2024		U-2677		
	10548880	Aug 30, 2024		U-2678		
	10864199	May 30, 2028		U-2677		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TACROLIMUS - ENVARSUS XR						
N 206406 002	10864199	May 30, 2028	U-2678			
	11077096	Aug 30, 2024	DP			
	11110081	May 30, 2028	U-2678			
	11123331	May 30, 2028	U-2677			
	11419823	May 30, 2028	DP			
	7994214	Aug 30, 2024	DP			
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
	8685998	Aug 30, 2028	DP U-1752			
	8685998	Aug 30, 2028	DP U-2677			
	8685998	Aug 30, 2028	DP U-2678			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
	9161907	Aug 30, 2024	DP U-1752			
	9549918	May 30, 2028	DP			
	9757362	Aug 30, 2024	DP			
	9763920	Aug 30, 2024	DP			
TACROLIMUS - ENVARSUS XR						
N 206406 003	10166190	May 30, 2028	DP			
	10548880	Aug 30, 2024	U-2677			
	10548880	Aug 30, 2024	U-2678			
	10864199	May 30, 2028	U-2677			
	10864199	May 30, 2028	U-2678			
	11077096	Aug 30, 2024	DP			
	11110081	May 30, 2028	U-2678			
	11123331	May 30, 2028	U-2677			
	11419823	May 30, 2028	DP			
	7994214	Aug 30, 2024	DP			
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
	8685998	Aug 30, 2028	DP U-1752			
	8685998	Aug 30, 2028	DP U-2677			
	8685998	Aug 30, 2028	DP U-2678			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TACROLIMUS - ENVARSUS XR							
N 206406	003	9161907	Aug 30, 2024	DP U-1752			
		9549918	May 30, 2028	DP			
		9757362	Aug 30, 2024	DP			
		9763920	Aug 30, 2024	DP			
TACROLIMUS - PROGRAF							
N 210115	001					ODE-269	May 24, 2025
						ODE-360	Jul 16, 2028
TACROLIMUS - PROGRAF							
N 210115	002					ODE-269	May 24, 2025
						ODE-360	Jul 16, 2028
TADALAFIL - TADLIQ							
N 214522	001	11382917	Dec 24, 2038	DP U-3397			
		11666576	Dec 24, 2038	DP U-3397			
TAFAMIDIS - VYNDAMAX							
N 212161	001	7214695	Dec 19, 2024	DS DP		NCE	May 03, 2024
		7214696	Dec 19, 2024	U-2524		ODE-237	May 03, 2026
		9770441	Aug 31, 2035	DS DP U-2524			
TAFAMIDIS MEGLUMINE - VYNDAQEL							
N 211996	001	7214695	Dec 19, 2024	DS DP		NCE	May 03, 2024
		7214696	Dec 19, 2024	U-2524		ODE-237	May 03, 2026
TAFENOQUINE SUCCINATE - ARAKODA							
N 210607	001	10342791	Dec 02, 2035	U-2582			
		10888558	Dec 02, 2035	U-2582			
		11744828	Dec 02, 2035	U-2582			
TAFENOQUINE SUCCINATE - KRINTAFEL							
N 210795	001					ODE-201	Jul 20, 2025
TAFLUPROST - ZIOPTAN							
N 202514	001	10864159	May 28, 2029	DP U-778			
		9999593	May 28, 2029	DP			
TALAZOPARIB TOSYLATE - TALZENNA							
N 211651	001	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
		10780088	Jul 27, 2029	U-3651			
		8012976	Oct 19, 2029	DS DP			
		8420650	Jul 27, 2029	DS DP			
		8735392	Oct 20, 2031	DS DP			
		9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA							
N 211651	002	10189837	Oct 20, 2031	DS DP			
		8012976	Oct 19, 2029	DS DP			
		8420650	Jul 27, 2029	DS DP			
		8735392	Oct 20, 2031	DS DP			
		9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA							
N 211651	003	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
		10780088	Jul 27, 2029	U-3651			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 003	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 004	10189837	Oct 20, 2031	DS DP			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 005	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 006	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALC - STERITALC						
N 205555 001					ODE-143	May 01, 2024
					ODE-191	May 01, 2024
TALC - STERITALC						
N 205555 002					ODE-143	May 01, 2024
					ODE-191	May 01, 2024
TALC - STERITALC						
N 205555 003					ODE-143	May 01, 2024
					ODE-191	May 01, 2024
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 001	7994364	Jun 27, 2025	DS DP U-931		NPP	Jul 03, 2026
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 002	7994364	Jun 27, 2025	DS DP U-931		NPP	Jul 03, 2026
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 003	7994364	Jun 27, 2025	DS DP U-931		NPP	Jul 03, 2026
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 001	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8114383	Oct 10, 2024	DP	Y		
	8536130	Sep 22, 2028	U-1276			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 001	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8114383	Oct 10, 2024	DP	Y		
	8536130	Sep 22, 2028	U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 002	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8114383	Oct 10, 2024	DP	Y		
	8536130	Sep 22, 2028	U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 003	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8114383	Oct 10, 2024	DP	Y		
	8536130	Sep 22, 2028	U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 004	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8114383	Oct 10, 2024	DP	Y		
	8536130	Sep 22, 2028	U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 005	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8114383	Oct 10, 2024	DP	Y		
	8536130	Sep 22, 2028	U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 203794 001	7994364	Jun 27, 2025	DS DP U-1289		NPP	Jul 03, 2026
TAPINAROF - VTAMA						
N 215272 001	10195160	May 19, 2036	DP		NCE	May 23, 2027
	10426743	May 19, 2036	U-2625			
	10647649	Nov 13, 2038	DS			
	11458108	May 19, 2036	DP			
	11590088	Nov 13, 2039	U-2625			
	11597692	Nov 13, 2038	DS DP			
	11612573	May 19, 2036	U-2625			
	11617724	May 19, 2036	DP			
	11622945	May 19, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TASIMELTEON - HETLIOZ						
N 205677 001	10071977	Feb 12, 2035	DS DP		ODE-330	Dec 01, 2027
	10149829	Jan 25, 2033	U-2477			
	10149829	Jan 25, 2033	U-3006			
	10179119	Aug 29, 2035	U-3003			
	10376487	Jul 27, 2035	U-2615			
	10376487	Jul 27, 2035	U-3007			
	10449176	Jan 25, 2033	U-2149			
	10610510	Jan 25, 2033	U-2805			
	10610510	Jan 25, 2033	U-3009			
	10610511	Oct 10, 2034	U-2615			
	10610511	Oct 10, 2034	U-3007			
	10829465	Feb 12, 2035	DS DP			
	10945988	Jan 25, 2033	U-2149			
	10980770	Jan 25, 2033	U-3106			
	10980770	Jan 25, 2033	U-3107			
	11141400	Oct 10, 2034	U-2615			
	11141400	Oct 10, 2034	U-3007			
	11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			
	11285129	Jan 25, 2033	U-3343			
	11566011	Feb 12, 2035	DS DP			
	11633377	Jan 25, 2033	U-2149			
	11633377	Jan 25, 2033	U-3003			
	11759446	Feb 21, 2041	U-3003			
	11760740	Feb 12, 2035	DS DP			
	11786502	Oct 10, 2034	U-3007			
	11786502	Oct 10, 2034	U-3739			
	11833130	Jan 25, 2033	U-2149			
	11833130	Jan 25, 2033	U-3003			
	11850229	Jan 25, 2033	U-3342			
	11850229	Jan 25, 2033	U-3343			
	9060995	Jan 25, 2033	U-1710			
	9539234	Jan 25, 2033	U-1934			
	9539234	Jan 25, 2033	U-3004			
	9549913	Jan 25, 2033	U-1486			
	9730910	May 17, 2034	U-2085			
	9730910	May 17, 2034	U-3005			
	9855241	Jan 25, 2033	U-2149			
	RE46604	Jan 25, 2033	U-2147			
TASIMELTEON - HETLIOZ LQ						
N 214517 001	10071977	Feb 12, 2035	DS DP		ODE-329	Dec 01, 2027
	10149829	Jan 25, 2033	U-3006			
	10179119	Aug 29, 2035	U-3003			
	10376487	Jul 27, 2035	U-3007			
	10610510	Jan 25, 2033	U-3009			
	10610511	Oct 10, 2034	U-3007			
	10829465	Feb 12, 2035	DS DP			
	10980770	Jan 25, 2033	U-3106			
	11141400	Oct 10, 2034	U-3007			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TASIMELTEON - HETLIOZ LQ						
N 214517 001	11202770	Dec 11, 2040	DP			
	11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			
	11566011	Feb 12, 2035	DS DP			
	11633377	Jan 25, 2033	U-3003			
	11759446	Feb 21, 2041	U-3003			
	11760740	Feb 12, 2035	DS DP			
	11786502	Oct 10, 2034	U-3007			
	11833130	Jan 25, 2033	U-3003			
	11850229	Jan 25, 2033	U-3342			
	9539234	Jan 25, 2033	U-3004			
	9730910	May 17, 2034	U-3005			
TAZAROTENE - FABIOR						
N 202428 001	10568859	Feb 24, 2030	DP U-2760			
	10688071	Feb 24, 2030	DP U-2760			
	8808716	Feb 24, 2030	DP			
TAZAROTENE - ARAZLO						
N 211882 001	11311482	May 11, 2038	U-2368			
	11679116	Jun 06, 2036	DP			
TAZEMETOSTAT HYDROBROMIDE - TAZVERIK						
N 211723 001	10155002	Apr 13, 2032	U-2736		NCE	Jan 23, 2025
	10245269	Apr 11, 2033	U-2737		ODE-299	Jan 23, 2027
	10245269	Apr 11, 2033	U-2851		ODE-314	Jun 18, 2027
	10245269	Apr 11, 2033	U-2854			
	10369155	Oct 16, 2035	U-2736			
	10369155	Oct 16, 2035	U-2852			
	10369155	Oct 16, 2035	U-2853			
	10420775	Apr 13, 2032	U-2736			
	10420775	Apr 13, 2032	U-2852			
	10420775	Apr 13, 2032	U-2853			
	10786511	Dec 19, 2035	DP			
	10821113	Apr 11, 2033	DS DP			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-3179			
	11491163	Apr 11, 2033	U-3491			
	11491163	Apr 11, 2033	U-3492			
	8410088	Jan 23, 2034	DS DP			
	8691507	Sep 12, 2031	U-2852			
	8765732	Apr 13, 2032	U-2852			
	8765732	Apr 13, 2032	U-2853			
	8895245	Sep 12, 2031	U-2852			
	9090562	Apr 13, 2032	DS DP			
	9175331	Sep 12, 2031	U-2852			
	9333217	Sep 12, 2031	U-2852			
	9334527	Sep 12, 2031	U-2852			
	9394283	Apr 11, 2033	DS DP U-2852			
	9394283	Apr 11, 2033	DS DP U-2853			
	9522152	Apr 13, 2032	U-2738			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAZEMETOSTAT HYDROBROMIDE - TAZVERIK						
N 211723 001	9549931	Apr 13, 2032	U-2736			
	9549931	Apr 13, 2032	U-2852			
	9549931	Apr 13, 2032	U-2853			
	9688665	Aug 22, 2034	U-2736			
	9855275	Apr 13, 2032	U-2736			
	9872862	Apr 11, 2033	U-2738			
	9889138	Oct 16, 2035	U-2736			
	9889138	Oct 16, 2035	U-2852			
	9889138	Oct 16, 2035	U-2853			
	9949999	Sep 12, 2031	U-2851			
TECHNETIUM TC-99M LABELED CARBON - TECHNEGAS KIT						
N 022335 001					NP	Sep 29, 2026
TECHNETIUM TC-99M SULFUR COLLOID KIT - TECHNETIUM TC-99M SULFUR COLLOID KIT						
A 213516 001					CGT	Jun 01, 2024
TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVIEW 30ML						
N 020372 002	9549999	Mar 10, 2030	DP			
TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT						
N 202207 001	6409990	May 12, 2025	DS		NPP	May 19, 2024
	9439985	Jan 30, 2029	DP			
TECOVIRIMAT - TPOXX						
N 208627 001	7737168	Sep 04, 2031	U-2346		ODE-200	Jul 13, 2025
	8039504	Jul 23, 2027	DP			
	8124643	Jun 18, 2024	DS DP			
	9339466	Mar 23, 2031	DS DP			
TECOVIRIMAT - TPOXX						
N 214518 001	10576165	Aug 02, 2031	DP			
	7737168	Sep 04, 2031	U-3377			
	8039504	Jul 23, 2027	DP			
	8124643	Jun 18, 2024	DS DP			
	8530509	Jun 18, 2024	DP			
	8802714	Jun 18, 2024	U-3377			
	9233097	Aug 02, 2031	DP			
	9907859	Aug 02, 2031	U-3377			
TEDIZOLID PHOSPHATE - SIVEXTRO						
N 205435 001	10065947	Feb 03, 2030	DP		NCE	Jun 20, 2019
	10442829	Feb 03, 2030	DS		GAIN	Jun 20, 2024
	7816379	Jun 20, 2028	DS DP U-2507			
	8420676	Feb 23, 2028	DS DP U-282			
	8426389	Dec 31, 2030	DS DP U-282			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
TEDIZOLID PHOSPHATE - SIVEXTRO						
N 205436 001	10065947	Feb 03, 2030	DP		NCE	Jun 20, 2019
	10442829	Feb 03, 2030	DS		GAIN	Jun 20, 2024
	7816379	Jun 20, 2028	DS DP U-2507			
	8420676	Feb 23, 2028	DS DP U-282			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES			PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TEDIZOLID PHOSPHATE - SIVEXTRO										
N 205436	001		8426389	Dec 31, 2030	DS	DP	U-282			
			9624250	Feb 03, 2030	DS	DP	U-2507			
			9988406	Feb 03, 2030		DP				
TEDUGLUTIDE RECOMBINANT - GATTEX KIT										
N 203441	001		7847061	Nov 01, 2025			U-1320	Y	ODE-240	May 16, 2026
			7847061*PED	May 01, 2026						
			9060992	Nov 01, 2025			U-1320	Y		
			9060992*PED	May 01, 2026						
TELAPREVIR - INCIVEK										
N 201917	001		7820671	Feb 25, 2025	DS	DP				
			8431615	May 30, 2028			U-1398			
TELAVANCIN HYDROCHLORIDE - VIBATIV										
N 022110	001		7531623	Jan 01, 2027	DS					
TELAVANCIN HYDROCHLORIDE - VIBATIV										
N 022110	002		7531623	Jan 01, 2027	DS					
TELOTRISTAT ETIPRATE - XERMELO										
N 208794	001		7553840	Dec 11, 2027	DS				ODE-132	Feb 28, 2024
			7709493	Feb 28, 2031	DS		U-1979			
			7968559	Dec 11, 2027			U-1979			
			8193204	Feb 27, 2031	DS					
			8653094	Dec 19, 2028			U-1979			
TEMSIROLIMUS - TORISEL										
N 022088	001		8026276	Jan 20, 2026		DP				
			8455539*PED	Jan 25, 2024						
			8722700*PED	Jan 25, 2024						
			8791097	May 10, 2032			U-1550			
			8791097	May 10, 2032			U-1551			
			8791097*PED	Nov 10, 2032						
TENAPANOR HYDROCHLORIDE - IBSRELA										
N 211801	001		8541448	Aug 01, 2033	DS	DP			NCE	Sep 12, 2024
			8969377	Dec 30, 2029	DS	DP				
			9006281	May 02, 2030			U-2626			
			9408840	Dec 30, 2029			U-2626			
TENAPANOR HYDROCHLORIDE - XPHOZAH										
N 213931	001		10272079	Apr 10, 2034			U-3736		NCE	Sep 12, 2024
			10272079	Apr 10, 2034			U-381		NP	Oct 17, 2026
			10940146	Apr 10, 2034			U-3736			
			10940146	Apr 10, 2034			U-381			
			8541448	Aug 01, 2033	DS	DP				
			8969377	Dec 30, 2029	DS	DP				
TENAPANOR HYDROCHLORIDE - XPHOZAH										
N 213931	002		10272079	Apr 10, 2034			U-3736		NCE	Sep 12, 2024
			10272079	Apr 10, 2034			U-381		NP	Oct 17, 2026
			10940146	Apr 10, 2034			U-3736			
			10940146	Apr 10, 2034			U-381			
			8541448	Aug 01, 2033	DS	DP				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENAPANOR HYDROCHLORIDE - XPHOZAH						
N 213931 002	8969377	Dec 30, 2029	DS DP			
TENAPANOR HYDROCHLORIDE - XPHOZAH						
N 213931 003	10272079	Apr 10, 2034	U-3736		NCE	Sep 12, 2024
	10272079	Apr 10, 2034	U-381		NP	Oct 17, 2026
	10940146	Apr 10, 2034	U-3736			
	10940146	Apr 10, 2034	U-381			
	8541448	Aug 01, 2033	DS DP			
	8969377	Dec 30, 2029	DS DP			
TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY						
N 208464 001	7390791	Apr 17, 2025	DS DP		NPP	Oct 17, 2025
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-1275			
	8754065	Aug 15, 2032	DS DP U-999			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1275			
	9296769	Aug 15, 2032	DS DP U-999			
	9296769*PED	Feb 15, 2033				
TEPOTINIB HYDROCHLORIDE - TEPMETKO						
N 214096 001	8329692	Oct 30, 2029	DS DP		NCE	Feb 03, 2026
	8580781	Mar 19, 2030	DS DP		ODE-325	Feb 03, 2028
	8658643	Jul 04, 2028	U-3077			
	8921357	May 30, 2028	DS DP			
	8927540	Jul 21, 2028	U-3078			
	9062029	Jul 04, 2028	DP			
	9284300	Apr 29, 2028	DP			
	9403799	Jul 04, 2028	U-3077			
TERIFLUNOMIDE - AUBAGIO						
N 202992 001	6794410	Sep 12, 2026	U-1285		M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034	U-1786			
	9186346*PED	Aug 04, 2034				
TERIFLUNOMIDE - AUBAGIO						
N 202992 002	6794410	Sep 12, 2026	U-1285		M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034	U-1786			
	9186346*PED	Aug 04, 2034				
TERIPARATIDE - FORTEO						
N 021318 001	7517334	Mar 25, 2025	DP			
TERIPARATIDE - FORTEO						
N 021318 002	7517334	Mar 25, 2025	DP			
TERLIPRESSIN ACETATE - TERLIVAZ						
N 022231 001	10335452	Apr 05, 2037	U-3711		NCE	Sep 14, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TERLIPRESSIN ACETATE - TERLIVAZ						
N 022231 001					ODE-406	Sep 14, 2029
TESTOSTERONE - TESTIM						
N 021454 001	7320968	Jan 18, 2025	U-843			
TESTOSTERONE - ANDROGEL						
N 022309 001	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
TESTOSTERONE - ANDROGEL						
N 022309 002	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
TESTOSTERONE - ANDROGEL						
N 022309 003	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
TESTOSTERONE - AXIRON						
N 022504 001	8419307	Feb 26, 2027	U-1386			
	8435944	Sep 27, 2027	U-1390			
	8807861	Feb 26, 2027	DP U-1563			
	8993520	Jun 02, 2026	U-1390			
	9180194	Jun 02, 2026	U-1390			
	9289586	Feb 26, 2027	U-1390			
TESTOSTERONE - VOGELXO						
N 204399 002	8785426	Feb 11, 2034	DP U-1531			
	9295675	Feb 11, 2034	DP U-1531			
	9662340	Feb 11, 2034	DP U-1531			
TESTOSTERONE - VOGELXO						
N 204399 003	8785426	Feb 11, 2034	DP U-1531			
	9295675	Feb 11, 2034	DP U-1531			
	9662340	Feb 11, 2034	DP U-1531			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE - NATESTO						
N 205488 001	11090312	Mar 17, 2034	U-1616			
	8574622	Feb 04, 2024	DP			
	8784869	Feb 04, 2024	DP			
	8784882	Feb 04, 2024	DP U-1557			
	8877230	Feb 04, 2024	U-1616			
TESTOSTERONE CYPIONATE - TESTOSTERONE CYPIONATE						
N 216318 001	11311554	Mar 25, 2039	DP			
	11642355	Mar 25, 2039	DP			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 001	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
	10821072	Jun 04, 2033	DP U-2418			
	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
	11160751	Oct 07, 2034	DP U-2418			
	11191908	Oct 18, 2035	DP			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11771646	Apr 10, 2034	DP			
	11813435	Feb 25, 2035	DP			
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 002	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
	10821072	Jun 04, 2033	DP U-2418			
	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
	11160751	Oct 07, 2034	DP U-2418			
	11191908	Oct 18, 2035	DP			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11771646	Apr 10, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 002	11813435	Feb 25, 2035	DP			
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP		U-2418	
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 003	10238662	Feb 19, 2035	DP		U-2418	
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
	10821072	Jun 04, 2033	DP		U-2418	
	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP		U-2418	
	11160751	Oct 07, 2034	DP		U-2418	
	11191908	Oct 18, 2035	DP			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11771646	Apr 10, 2034	DP			
	11813435	Feb 25, 2035	DP			
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP		U-2418	
TESTOSTERONE UNDECANOATE - AVEED						
N 022219 001	7718640	Mar 14, 2027	DP			
	8338395	May 08, 2027			U-1500	
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 001	10543219	Apr 12, 2030			U-2506	
	10617696	Apr 12, 2030	DS	DP		
	11179402	Apr 14, 2026	DS	DP		
	11179403	Apr 12, 2030			U-2506	
	11331325	Jan 06, 2027			U-2506	
	11426416	Apr 12, 2030			U-3420	
	11564933	Apr 12, 2039			U-1103	
	8241664	Mar 29, 2029	DP		U-2506	
	8492369	Dec 20, 2030	DP		U-2506	
	8778916	Apr 12, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 002	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
	11179402	Apr 14, 2026	DS DP			
	11179403	Apr 12, 2030	U-2506			
	11331325	Jan 06, 2027	U-2506			
	11426416	Apr 12, 2030	U-3420			
	11564933	Apr 12, 2039	U-1103			
	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 003	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
	11179402	Apr 14, 2026	DS DP			
	11179403	Apr 12, 2030	U-2506			
	11331325	Jan 06, 2027	U-2506			
	11426416	Apr 12, 2030	U-3420			
	11564933	Apr 12, 2039	U-1103			
	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
TESTOSTERONE UNDECANOATE - TLANDO						
N 208088 001	10226473	Nov 30, 2030	U-1500		NP	Mar 28, 2025
	10716794	Nov 30, 2030	U-1500			
	11304960	Jan 08, 2029	DP U-1500			
	11311555	Nov 30, 2030	U-1500			
	11364249	Nov 30, 2030	U-1500			
	11433083	Nov 30, 2030	U-1500			
	11464735	Apr 28, 2041	DP U-1500			
	11559530	Nov 28, 2037	U-1500			
	8778922	Jan 08, 2029	DP U-1500			
	8865695	Jan 08, 2029	U-1500			
	9943527	Nov 30, 2030	U-1500			
	9949985	Nov 30, 2030	U-1500			
TESTOSTERONE UNDECANOATE - KYZATREX						
N 213953 001	10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
	10576090	Dec 31, 2030	DP			
	11590146	Dec 31, 2030	DP			
	11617758	Mar 15, 2033	DP U-2506			
TESTOSTERONE UNDECANOATE - KYZATREX						
N 213953 002	10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
	10576090	Dec 31, 2030	DP			
	11590146	Dec 31, 2030	DP			
	11617758	Mar 15, 2033	DP U-2506			
TESTOSTERONE UNDECANOATE - KYZATREX						
N 213953 003	10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
	10576090	Dec 31, 2030	DP			
	11590146	Dec 31, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE UNDECANOATE - KYZATREX							
N 213953	003	11617758	Mar 15, 2033	DP U-2506			
THIOTEPA - TEPADINA							
N 208264	001					ODE-129	Jan 26, 2024
THIOTEPA - TEPADINA							
N 208264	002					ODE-129	Jan 26, 2024
TICAGRELOR - BRILINTA							
N 022433	001	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
		10300065	Jan 27, 2036	U-2542		M-283	May 09, 2025
		10300065*PED	Jul 27, 2036			PED	May 05, 2024
		8425934	Apr 17, 2030	DP		PED	Nov 09, 2025
		8425934*PED	Oct 17, 2030				
		RE46276	Oct 30, 2024	DS DP U-1935			
		RE46276	Oct 30, 2024	DS DP U-1936			
		RE46276	Oct 30, 2024	DS DP U-1937			
		RE46276	Oct 30, 2024	DS DP U-1938			
		RE46276	Oct 30, 2024	DS DP U-2838			
		RE46276	Oct 30, 2024	DS DP U-2839			
		RE46276	Oct 30, 2024	DS DP U-2988			
		RE46276*PED	Apr 30, 2025				
TICAGRELOR - BRILINTA							
N 022433	002	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
		10300065	Jan 27, 2036	U-2542		M-283	May 09, 2025
		10300065*PED	Jul 27, 2036			PED	May 05, 2024
		8425934	Apr 17, 2030	DP		PED	Nov 09, 2025
		8425934*PED	Oct 17, 2030				
		RE46276	Oct 30, 2024	DS DP U-1935			
		RE46276	Oct 30, 2024	DS DP U-1936			
		RE46276	Oct 30, 2024	DS DP U-1937			
		RE46276	Oct 30, 2024	DS DP U-1938			
		RE46276	Oct 30, 2024	DS DP U-2838			
		RE46276	Oct 30, 2024	DS DP U-2839			
		RE46276	Oct 30, 2024	DS DP U-2988			
		RE46276*PED	Apr 30, 2025				
TIGECYCLINE - TYGACIL							
N 021821	001	10588975	Mar 13, 2026	DP			
		7879828	Feb 05, 2029	DP			
		8372995	Oct 08, 2030	DP			
		8975242	Oct 24, 2028	DP			
		9254328	Mar 13, 2026	DP			
		9694078	Mar 13, 2026	DP			
TIGECYCLINE - TIGECYCLINE							
N 211158	001	9855335	Apr 07, 2033	DP			
TIOPRONIN - THIOLA							
N 019569	001					ODE-267	Jun 28, 2026
TIOPRONIN - THIOLA EC							
N 211843	001	11458104	Nov 14, 2038	U-3441		ODE*	Jun 28, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIOPRONIN - THIOLA EC						
N 211843 002	11458104	Nov 14, 2038	U-3441		ODE*	Jun 28, 2026
TIOTROPIUM BROMIDE - SPIRIVA						
N 021395 001	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
	9010323	Apr 19, 2030	DP			
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT						
N 021936 001	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP			
	9027967*PED	Oct 01, 2027				
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT						
N 021936 002	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP			
	9027967*PED	Oct 01, 2027				
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF						
N 207981 001	10456399	Feb 03, 2037	U-3657		ODE-229	Feb 22, 2026
	10456399	Feb 03, 2037	U-3658			
	10457666	Jun 17, 2034	DS DP			
	10960004	Feb 03, 2037	U-3657			
	10960004	Feb 03, 2037	U-3658			
	9527833	Jun 17, 2034	DS DP			
	9943537	Sep 05, 2034	U-3659			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
	RE46284	Sep 22, 2029	U-3656			
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF						
N 207981 002	10456399	Feb 03, 2037	U-3657		ODE-229	Feb 22, 2026
	10456399	Feb 03, 2037	U-3658			
	10457666	Jun 17, 2034	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF						
N 207981 002	10960004	Feb 03, 2037	U-3657			
	10960004	Feb 03, 2037	U-3658			
	9527833	Jun 17, 2034	DS DP			
	9943537	Sep 05, 2034	U-3659			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
	RE46284	Sep 22, 2029	U-3656			
TIRBANIBULIN - KLISYRI						
N 213189 001	10323001	Dec 28, 2027	DP		NCE	Dec 14, 2025
	10617693	Mar 12, 2038	U-3015			
	10669236	Sep 07, 2038	DS DP			
	11497750	Mar 12, 2038	U-3015			
	7300931	Feb 06, 2026	DS DP			
	7851470	Feb 02, 2029	DS DP U-3015			
	8236799	Dec 28, 2025	DS DP			
	8980890	Dec 28, 2025	DS DP			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 001	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 002	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 003	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 004	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 005	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 006	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - ZEPBOUND						
N 217806 001	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP		NP	Nov 08, 2026
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 002	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP		NP	Nov 08, 2026
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 003	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP		NP	Nov 08, 2026
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 004	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP		NP	Nov 08, 2026
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 005	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP		NP	Nov 08, 2026
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 006	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP		NP	Nov 08, 2026
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 001	11504365	Nov 05, 2039	U-3476		NCE	Mar 10, 2026
	6821987	Apr 26, 2024	DS DP U-3100			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 002	11504365	Nov 05, 2039	U-3476		NCE	Mar 10, 2026
	6821987	Apr 26, 2024	DS DP U-3100			
TOBRAMYCIN - TOBI PODHALER						
N 201688 001	10207066	Nov 04, 2030	DP U-909			
	11484671	Nov 07, 2024	DP U-909			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8664187	Jun 20, 2025	U-909			
	8869794	Sep 12, 2028	DP U-909			
	RE47526	Apr 09, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOFACITINIB CITRATE - XELJANZ						
N 203214 001	RE41783	Dec 08, 2025	DS		I-879	Dec 14, 2024
TOFACITINIB CITRATE - XELJANZ						
N 203214 002	RE41783	Dec 08, 2025	DS		I-879	Dec 14, 2024
TOFACITINIB CITRATE - XELJANZ XR						
N 208246 001	11253523	Mar 14, 2034	U-3326		I-879	Dec 14, 2024
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
	9937181	Mar 14, 2034	DP			
	RE41783	Dec 08, 2025	DS			
TOFACITINIB CITRATE - XELJANZ XR						
N 208246 002	10639309	Mar 14, 2034	DP			
	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
	RE41783	Dec 08, 2025	DS			
TOFACITINIB CITRATE - XELJANZ						
N 213082 001	RE41783	Dec 08, 2025	DS			
TOFERSEN - QALSODY						
N 215887 001	10385341	Apr 01, 2035	DS DP		NCE	Apr 25, 2028
	10669546	Apr 01, 2035	U-3575		ODE-432	Apr 25, 2030
	10968453	Apr 01, 2035	U-3575			
TOLVAPTAN - SAMSCA						
N 022275 001	10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - SAMSCA						
N 022275 002	10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - SAMSCA						
N 022275 003	10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE						
N 204441 001	10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE						
N 204441 002	10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE						
N 204441 003	10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE						
N 204441 004	10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOLVAPTAN - JYNARQUE						
N 204441 005	10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
TOPIRAMATE - TROKENDI XR						
N 201635 001	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 002	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 003	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TROKENDI XR						
N 201635 003	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 004	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - QUDEXY XR						
N 205122 001	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 002	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - QUDEXY XR						
N 205122 002	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 003	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 004	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 005	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - EPRONTIA						
N 214679 001	11433046	Aug 21, 2040	U-3413			
	11433046	Aug 21, 2040	U-3414			
	11433046	Aug 21, 2040	U-3415			
	11633374	Aug 21, 2040	DP			
	11826343	Aug 21, 2040	DP			
TOPOTECAN HYDROCHLORIDE - HYCAMTIN						
N 020981 001	8158645	Dec 10, 2024	DP			
TOPOTECAN HYDROCHLORIDE - HYCAMTIN						
N 020981 002	8158645	Dec 10, 2024	DP			
TORSEMIDE - SOAANZ						
N 213218 001	10154963	Oct 06, 2033	DP			
TORSEMIDE - SOAANZ						
N 213218 002	10154963	Oct 06, 2033	DP			
TRABECTEDIN - YONDELIS						
N 207953 001	8895557	Jan 07, 2028	DP			
	8895557*PED	Jul 07, 2028				
TRAMADOL HYDROCHLORIDE - QDOLO						
N 214044 001	11103452	Sep 01, 2040	DP U-3197			
	11752103	Sep 01, 2040	DP U-3197			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 001	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 001	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 002	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 002	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 003	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 217513 001	7378423	May 29, 2027	DS DP		NP	Mar 16, 2026
	8703781	Oct 15, 2030	DS DP U-3564		ODE-428	Mar 16, 2030
	8835443	Jun 10, 2025	U-3564			
TRANEXAMIC ACID - TRANEXAMIC ACID						
A 217155 001					CGT	Apr 16, 2024
TRANEXAMIC ACID - LYSTEDA						
N 022430 001	7947739	Mar 04, 2025	DP			
	8022106	Mar 04, 2025	U-1182			
	8273795	Mar 04, 2025	U-1182			
	8487005	Mar 04, 2025	DP U-1182			
	8791160	Mar 04, 2025	DP U-1182			
	8809394	Mar 04, 2025	DP U-1182			
	8957113	Mar 04, 2025	DP U-1182			
	9060939	Mar 04, 2025	DP			
TRAVOPROST - TRAVATAN Z						
N 021994 001	8268299	Oct 13, 2029	DP			
	8323630	Sep 20, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAVOPROST - TRAVATAN Z						
N 021994 001	8388941	Sep 20, 2027	DP			
TRAVOPROST - IZBA						
N 204822 001	8178582	Oct 10, 2029	DP			
	8722735	Oct 10, 2029	DP			
	8754123	May 19, 2029	DP			
	9144561	Mar 13, 2029	DP			
TRAVOPROST - IDOSE TR						
N 218010 001	10206813	Oct 17, 2030	DP			
	11426306	Oct 17, 2030	DP			
TRAZODONE HYDROCHLORIDE - DESYREL						
N 018207 001	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL						
N 018207 002	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL						
N 018207 003	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL						
N 018207 004	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - OLEPTRO						
N 022411 001	7829120	Mar 27, 2027	DP		U-796	
	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - OLEPTRO						
N 022411 002	7829120	Mar 27, 2027	DP		U-796	
	8133893	Mar 13, 2029	DS DP			
TREPROSTINIL - REMODULIN						
N 021272 001	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024			U-2845	
	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP		U-1437	
	8653137	Sep 05, 2028			U-1437	
	8658694	Sep 05, 2028			U-1437	
	9199908	May 24, 2024			U-1771	
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024			U-2036	
TREPROSTINIL - REMODULIN						
N 021272 002	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024			U-2845	
	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP		U-1437	
	8653137	Sep 05, 2028			U-1437	
	8658694	Sep 05, 2028			U-1437	
	9199908	May 24, 2024			U-1771	
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024			U-2036	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL - REMODULIN						
N 021272 003	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024	U-2845			
	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN						
N 021272 004	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024	U-2845			
	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN						
N 021272 005	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024	U-2845			
	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN						
N 021272 006	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 021272 007	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL - REMODULIN						
N 021272 007	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 021272 008	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO						
N 022387 001	10376525	May 14, 2027	U-1849		I-856	Mar 31, 2024
	10716793	May 14, 2027	U-1849			
	11723887	Dec 15, 2028	DS			
	11826327	Jan 04, 2042	U-3749			
	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 208276 001	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN						
N 208276 002	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN						
N 208276 003	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN						
N 208276 004	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - TYVASO DPI						
N 214324 001	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL - TYVASO DPI						
N 214324 001	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	11723887	Dec 15, 2028	DS			
	11826327	Jan 04, 2042	U-3749			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO DPI						
N 214324 002	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	11723887	Dec 15, 2028	DS			
	11826327	Jan 04, 2042	U-3749			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO DPI						
N 214324 003	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	11723887	Dec 15, 2028	DS			
	11826327	Jan 04, 2042	U-3749			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO DPI						
N 214324 004	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	11723887	Dec 15, 2028	DS			
	11826327	Jan 04, 2042	U-3749			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 001	11723887	Dec 15, 2028	DS		ODE-272	Oct 18, 2026
	7417070	Jul 30, 2026	DS			
	7544713	Jul 14, 2024	U-1475			
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 001	11723887	Dec 15, 2028	DS		ODE-272	Oct 18, 2026
	7417070	Jul 30, 2026	DS			
	7544713	Jul 14, 2024	U-1475			
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 002	11723887	Dec 15, 2028	DS		ODE-272	Oct 18, 2026
	7417070	Jul 30, 2026	DS			
	7544713	Jul 14, 2024	U-1475			
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 003	11723887	Dec 15, 2028	DS		ODE-272	Oct 18, 2026
	7417070	Jul 30, 2026	DS			
	7544713	Jul 14, 2024	U-1475			
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 004	11723887	Dec 15, 2028	DS		ODE-272	Oct 18, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 004	7417070	Jul 30, 2026	DS			
	7544713	Jul 14, 2024	U-1475			
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 005	11723887	Dec 15, 2028	DS		ODE-272	Oct 18, 2026
	7417070	Jul 30, 2026	DS			
	7544713	Jul 14, 2024	U-1475			
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TRETINOIN - TRETINOIN MICROSPHERE						
A 215609 001					CGT	Mar 06, 2024
TRETINOIN - ALTRENO						
N 209353 001	10653656	Aug 22, 2038	DP U-2368			
	11324710	Aug 22, 2038	U-2368			
TRIAMCINOLONE ACETONIDE - TRIESENCE						
N 022048 001	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029	U-1257			
	8211880	Mar 10, 2029	U-1258			
TRIAMCINOLONE ACETONIDE - ZILRETTA						
N 208845 001	8828440	Aug 04, 2031	DP			
	9555048	Aug 04, 2031	U-2151			
TRIAMCINOLONE ACETONIDE - XIPERE						
N 211950 001	8636713	May 02, 2027	U-3234		NP	Oct 22, 2024
	9636332	Nov 08, 2033	U-3234			
	9937075	May 02, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRICLABENDAZOLE - EGATEN						
N 208711 001					NCE	Feb 13, 2024
					ODE-228	Feb 13, 2026
TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR						
N 215760 001	10988436	May 03, 2039	DS		NP	Apr 28, 2025
	11072577	May 03, 2039	U-3370		ODE-401	Apr 28, 2029
TRIFAROTENE - AKLIEF						
N 211527 001	7807708	Jul 19, 2031	DS DP		NCE	Oct 04, 2024
	8227507	Dec 21, 2025	U-818			
	8470871	Dec 21, 2025	U-2639			
	9084778	May 30, 2033	DP U-134			
	9498465	May 30, 2033	DP U-1033			
TRIHEPTANOIN - DOJOLVI						
N 213687 001	8697748	Apr 28, 2029	DP		NCE	Jun 30, 2025
	9186344	Jul 01, 2025	DP		ODE-311	Jun 30, 2027
TRILACICLIB DIHYDROCHLORIDE - COSELA						
N 214200 001	10085992	Mar 14, 2034	U-3081		NCE	Feb 12, 2026
	10189849	Oct 25, 2031	DS			
	10189850	Oct 25, 2031	DP			
	10927120	Oct 25, 2031	DP			
	10966984	Mar 14, 2034	U-3079			
	10966984	Mar 14, 2034	U-3080			
	11040042	Mar 14, 2034	DP			
	11529352	Jul 23, 2039	U-3504			
	11717523	Mar 14, 2034	U-3678			
	11717523	Mar 14, 2034	U-3679			
	8598186	Oct 25, 2031	DS DP			
	8598197	Oct 25, 2031	DS DP			
	9487530	Mar 14, 2034	U-3079			
	9487530	Mar 14, 2034	U-3080			
	9957276	Oct 25, 2031	DS			
TRIPTORELIN PAMOATE - TRELSTAR						
N 022437 001	10166181	Jun 30, 2029	DP			
TRIPTORELIN PAMOATE - TRIPTODUR KIT						
N 208956 001	10166181	Jun 30, 2029	DP		ODE-149	Jun 29, 2024
TROFINETIDE - DAYBUE						
N 217026 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	9212204	Jan 27, 2032	U-3556		ODE-425	Mar 10, 2030
TUCATINIB - TUKYSA						
N 213411 001	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
	11504370	Mar 25, 2033	U-2788		NCE	Apr 17, 2025
	7452895	Nov 16, 2024	DS DP U-2788		ODE-309	Apr 17, 2027
	8648087	Apr 12, 2031	DS DP		ODE-422	Jan 19, 2030
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TUCATINIB - TUKYSA						
N 213411 002	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
	11504370	Mar 25, 2033	U-2788		NCE	Apr 17, 2025
	7452895	Nov 16, 2024	DS DP U-2788		ODE-309	Apr 17, 2027
	8648087	Apr 12, 2031	DS DP		ODE-422	Jan 19, 2030
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
UBROGEPANT - UBRELVY						
N 211765 001	10117836	Jan 30, 2035	DP		NCE	Dec 23, 2024
	11717515	Dec 22, 2041	U-3677			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Dec 23, 2033	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
UBROGEPANT - UBRELVY						
N 211765 002	10117836	Jan 30, 2035	DP		NCE	Dec 23, 2024
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Dec 23, 2033	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
ULIPRISTAL ACETATE - ELLA						
N 022474 001	10159681	Apr 13, 2030	U-2510		M-271	Jun 24, 2024
	10772897	Apr 13, 2030	U-2958			
	8426392	Jun 12, 2030	U-1389			
	8512745	Jun 02, 2030	DP			
	8735380	Feb 20, 2029	DP			
	8962603	Jun 12, 2030	U-1657			
	9283233	Apr 13, 2030	U-1821			
	9844510	Dec 08, 2028	DP			
UMBRALISIB TOSYLATE - UKONIQ						
N 213176 001	10072013	Jul 02, 2033	U-3063		NCE	Feb 05, 2026
	10072013	Jul 02, 2033	U-3064			
	10414773	May 26, 2035	DS DP U-3063			
	10414773	May 26, 2035	DS DP U-3064			
	10570142	Jul 02, 2033	DS DP U-3063			
	10570142	Jul 02, 2033	DS DP U-3064			
	10947244	May 26, 2035	U-3063			
	10947244	May 26, 2035	U-3064			
	10981919	Jul 02, 2033	U-3063			
	10981919	Jul 02, 2033	U-3064			
	9150579	Jul 02, 2033	DS DP			
	9669033	Jul 02, 2033	U-3063			
	9669033	Jul 02, 2033	U-3064			
	9969740	May 26, 2035	DS DP U-3063			
	9969740	May 26, 2035	DS DP U-3064			
UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA						
N 205382 001	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA						
N 205382 001	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA						
N 203975 001	11090294	Nov 29, 2030	U-3203			
	7439393	May 21, 2025	DS DP U-1476			
	7439393*PED	Nov 21, 2025				
	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8183257	Jul 27, 2025	U-1476			
	8309572	Apr 27, 2025	U-1476			
	8511304	Jun 14, 2027	DP U-1476			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
	9750726	Nov 29, 2030	DP			
UPADACITINIB - RINVOQ						
N 211675 001	10519164	Oct 17, 2036	DP		I-880	Dec 14, 2024
	10597400	Oct 17, 2036	U-3255		I-883	Jan 14, 2025
	10981923	Oct 17, 2036	DS		I-886	Mar 16, 2025
	10981924	Oct 17, 2036	DP		I-888	Apr 29, 2025
	10995095	Oct 17, 2036	U-3298		I-919	May 18, 2026
	11186584	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11198697	Oct 17, 2036	DP			
	11365198	Oct 17, 2036	U-3275			
	11512092	Oct 17, 2036	U-3275			
	11512092	Oct 17, 2036	U-3371			
	11512092	Oct 17, 2036	U-3487			
	11524964	Oct 17, 2036	U-3371			
	11535624	Oct 17, 2036	U-3255			
	11535625	Oct 17, 2036	U-3298			
	11564922	Mar 09, 2038	U-3624			
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
	11718627	Oct 17, 2036	DS DP			
	11767326	Oct 17, 2036	U-3298			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
UPADACITINIB - RINVOQ						
N 211675 001	11773105	Oct 17, 2036	DS DP			
	11773106	Oct 17, 2036	U-3275			
	11773106	Oct 17, 2036	U-3371			
	11773106	Oct 17, 2036	U-3487			
	11780847	Oct 17, 2036	DP			
	11780848	Oct 17, 2036	U-3371			
	11787815	Oct 17, 2036	DP			
	11795175	Oct 17, 2036	U-3255			
	8962629	Jan 15, 2031	DS U-3255			
	8962629	Jan 15, 2031	DS U-3275			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
	8962629	Jan 15, 2031	DS U-3624			
	9951080	Oct 17, 2036	DS DP			
	9963459	Oct 17, 2036	DP			
	RE47221	Dec 01, 2030	DS			
UPADACITINIB - RINVOQ						
N 211675 002	10344036	Oct 17, 2036	DP		I-883	Jan 14, 2025
	10550126	Oct 17, 2036	U-3298		I-886	Mar 16, 2025
	10730883	Oct 17, 2036	DP		I-919	May 18, 2026
	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	10981924	Oct 17, 2036	DP			
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	11535626	Oct 17, 2036	U-3298			
	11564922	Mar 09, 2038	U-3624			
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
	11718627	Oct 17, 2036	DS DP			
	11767326	Oct 17, 2036	U-3298			
	11773105	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3624			
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
UPADACITINIB - RINVOQ						
N 211675 003	10202393	Oct 17, 2036	DP		I-886	Mar 16, 2025
	10981923	Oct 17, 2036	DS		I-919	May 18, 2026
	11186584	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11198697	Oct 17, 2036	DP			
	11564922	Mar 09, 2038	U-3624			
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
	11718627	Oct 17, 2036	DS DP			
	11773105	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3624			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
UPADACITINIB - RINVOQ						
N 211675 003	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
URIDINE TRIACETATE - VISTOGARD						
N 208159 001	7776838	Aug 17, 2027	U-1791			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 001	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055		ODE-440	Aug 18, 2030
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 002	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055		ODE-440	Aug 18, 2030
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 002	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 003	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055		ODE-440	Aug 18, 2030
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 003	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N 022257 001	8889109	Dec 11, 2027	DP			
	9642911	Dec 11, 2027	DP			
VALSARTAN - DIOVAN						
N 021283 001					NPP	Apr 19, 2024
VALSARTAN - DIOVAN						
N 021283 002					NPP	Apr 19, 2024
VALSARTAN - DIOVAN						
N 021283 004					NPP	Apr 19, 2024
VAMOROLONE - AGAMREE						
N 215239 001	10857161	May 28, 2029	DP U-3747		NCE	Oct 26, 2028
	11382922	Jul 16, 2040	DS DP		ODE-450	Oct 26, 2030
	11471471	Mar 17, 2040	U-3747			
	11690853	Jun 29, 2036	U-3747			
	11833159	May 28, 2029	DP			
	8334279	May 28, 2029	U-3747			
VANCOMYCIN - VANCOMYCIN						
N 213895 001	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11000567	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
A 214913 001					PC	Feb 25, 2024
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
A 214913 002					PC	Feb 25, 2024
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
A 217489 001					CGT	Feb 12, 2024
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
A 217489 002					CGT	Feb 12, 2024
VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT						
N 208910 001	10493028	Mar 13, 2035	DP			
	10688046	Mar 13, 2035	DP			
	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT						
N 208910 001	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
	11638692	Mar 13, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT						
N 208910 002	10493028	Mar 13, 2035	DP			
	10688046	Mar 13, 2035	DP			
	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
	11638692	Mar 13, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
N 211962 001	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
	11628200	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
N 211962 002	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
	11628200	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
N 211962 003	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
	11628200	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
N 211962 004	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
	11628200	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
N 211962 005	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
	11628200	Nov 06, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE								
N 211962	006		10039804	Nov 06, 2035	DP U-282			
			10188697	Nov 06, 2035	DP U-282			
			10849956	Nov 06, 2035	DP			
			11517609	Nov 06, 2035	U-282			
			11628200	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE								
N 211962	007		10039804	Nov 06, 2035	DP U-282			
			10188697	Nov 06, 2035	DP U-282			
			10849956	Nov 06, 2035	DP			
			11517609	Nov 06, 2035	U-282			
			11628200	Nov 06, 2035	DP			
VANDETANIB - CAPRELSA								
N 022405	001		8067427	Aug 08, 2028	DP			
VANDETANIB - CAPRELSA								
N 022405	002		8067427	Aug 08, 2028	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA								
N 021400	001		8273876	Jul 23, 2027	U-1288			
VARDENAFIL HYDROCHLORIDE - LEVITRA								
N 021400	002		8273876	Jul 23, 2027	U-1288			
VARDENAFIL HYDROCHLORIDE - LEVITRA								
N 021400	003		8273876	Jul 23, 2027	U-1288			
VARDENAFIL HYDROCHLORIDE - LEVITRA								
N 021400	004		8273876	Jul 23, 2027	U-1288			
VARDENAFIL HYDROCHLORIDE - STAXYN								
N 200179	001		8613950	Dec 23, 2028	DP			
VARENICLINE TARTRATE - TYRVAYA								
N 213978	001		10456396	Oct 19, 2035	DP U-1900		NP	Oct 15, 2024
			11224598	Oct 19, 2035	U-1900			
			9504644	Oct 19, 2035	U-1900			
			9504645	Oct 19, 2035	DP			
			9532944	Oct 19, 2035	U-1900			
			9597284	Oct 19, 2035	U-1900			
VASOPRESSIN - VASOSTRICT								
N 204485	001		9375478	Jan 30, 2035	U-1857			
			9687526	Jan 30, 2035	U-1857			
			9744209	Jan 30, 2035	U-1857			
			9744239	Jan 30, 2035	U-1857			
			9750785	Jan 30, 2035	DP			
VASOPRESSIN - VASOSTRICT								
N 204485	002		9375478	Jan 30, 2035	U-1857			
			9687526	Jan 30, 2035	U-1857			
			9744209	Jan 30, 2035	U-1857			
			9744239	Jan 30, 2035	U-1857			
			9750785	Jan 30, 2035	DP			
			9937223	Jan 30, 2035	U-1857			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VASOPRESSIN - VASOSTRICT						
N 204485 003	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
VASOPRESSIN - VASOSTRICT						
N 204485 004	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
VASOPRESSIN - VASOSTRICT						
N 204485 005	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
VASOPRESSIN - VASOSTRICT						
N 204485 006	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
VEMURAFENIB - ZELBORAF						
N 202429 001	7504509	Oct 22, 2026	DS DP		ODE-158	Nov 06, 2024
	7863288	Jun 20, 2029	DS DP			
	8143271	Jun 21, 2026	DS DP			
	8470818	Aug 02, 2026	U-1418			
	8470818	Aug 02, 2026	U-2164			
	8741920	Jul 27, 2030	DS DP			
	9447089	Jun 06, 2032	DP			
VENETOCLAX - VENCLEXTA						
N 208573 001	10730873	Nov 21, 2031	DS		ODE-185	Jun 08, 2025
	10993942	Sep 06, 2033	U-3114		ODE-211	Nov 21, 2025
	11110087	Sep 06, 2033	U-3222		ODE-239	May 15, 2026
	11110087	Sep 06, 2033	U-3223			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VENETOCLAX - VENCLEXTA						
N 208573 001	11369599	May 23, 2032	DP			
	11413282	Sep 06, 2033	U-3412			
	11590128	Sep 06, 2033	U-3548			
	8546399	Jun 27, 2031	DS DP			
	8722657	Jan 29, 2032	DS			
	9174982	May 26, 2030	U-2323			
	9174982	May 26, 2030	U-2445			
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
VENETOCLAX - VENCLEXTA						
N 208573 002	10730873	Nov 21, 2031	DS		ODE-185	Jun 08, 2025
	10993942	Sep 06, 2033	U-3114		ODE-211	Nov 21, 2025
	11110087	Sep 06, 2033	U-3222		ODE-239	May 15, 2026
	11110087	Sep 06, 2033	U-3223			
	11369599	May 23, 2032	DP			
	11413282	Sep 06, 2033	U-3412			
	11590128	Sep 06, 2033	U-3548			
	8546399	Jun 27, 2031	DS DP			
	8722657	Jan 29, 2032	DS			
	9174982	May 26, 2030	U-2323			
	9174982	May 26, 2030	U-2445			
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
VENETOCLAX - VENCLEXTA						
N 208573 003	10730873	Nov 21, 2031	DS		ODE-185	Jun 08, 2025
	10993942	Sep 06, 2033	U-3114		ODE-211	Nov 21, 2025
	11110087	Sep 06, 2033	U-3222		ODE-239	May 15, 2026
	11110087	Sep 06, 2033	U-3223			
	11369599	May 23, 2032	DP			
	11413282	Sep 06, 2033	U-3412			
	11590128	Sep 06, 2033	U-3548			
	8546399	Jun 27, 2031	DS DP			
	8722657	Jan 29, 2032	DS			
	9174982	May 26, 2030	U-2323			
	9174982	May 26, 2030	U-2445			
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
VENLAFAXINE BESYLATE - VENLAFAXINE BESYLATE						
N 215429 001	7776358	May 16, 2028	DP			
VERICIGUAT - VERQUVO						
N 214377 001	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	11439642	May 19, 2031	U-3062			
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VERICIGUAT - VERQUVO						
N 214377 001	9993476	May 19, 2031	U-3062			
VERICIGUAT - VERQUVO						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	11439642	May 19, 2031	U-3062			
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
VERICIGUAT - VERQUVO						
N 214377 003	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	11439642	May 19, 2031	U-3062			
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
VIBEGRON - GEMTESA						
N 213006 001	8247415	Dec 01, 2030	DS DP U-3045		NCE	Dec 23, 2025
	8653260	Apr 02, 2029	DS			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 001	11324753	Sep 04, 2029	U-727		NCE	Apr 02, 2026
	11458143	Sep 04, 2029	U-727		NPP	Apr 29, 2025
	9358204	Feb 07, 2033	DP			
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 002	11324753	Sep 04, 2029	U-727		NCE	Apr 02, 2026
	11458143	Sep 04, 2029	U-727		NPP	Apr 29, 2025
	9358204	Feb 07, 2033	DP			
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 003	11324753	Sep 04, 2029	U-727		NCE	Apr 02, 2026
	11458143	Sep 04, 2029	U-727		NPP	Apr 29, 2025
	9358204	Feb 07, 2033	DP			
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
VILTOLARSEN - VILTEPSO						
N 212154 001	10870676	Aug 31, 2031	DS DP U-3039		NCE	Aug 12, 2025
	9079934	Aug 31, 2031	DS DP		ODE-280	Aug 12, 2027
VISMODEGIB - ERIVEDGE						
N 203388 001	7888364	Nov 11, 2028	DS DP			
	9278961	Dec 15, 2028	U-1825			
	9790183	Sep 02, 2025	U-3109			
VOCLOSPORIN - LUPKYNIS						
N 213716 001	10286036	Dec 07, 2037	U-3056		NCE	Jan 22, 2026
	11622991	Dec 07, 2037	U-3056			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VOCLOSPORIN - LUPKYNIS						
N 213716 001	7332472	Oct 17, 2024	DS DP U-3056			
VONOPRAZAN FUMARATE - VOQUEZNA						
N 215151 001	7977488	Aug 11, 2028	DS		NCE	May 03, 2027
	9186411	Aug 11, 2030	DP		NP	Nov 01, 2026
VONOPRAZAN FUMARATE - VOQUEZNA						
N 215151 002	7977488	Aug 11, 2028	DS		NCE	May 03, 2027
	9186411	Aug 11, 2030	DP		NP	Nov 01, 2026
VORAPAXAR SULFATE - ZONTIVITY						
N 204886 001	7304078	Dec 23, 2027	DS DP U-1512			
	7713999	May 30, 2024	DS DP U-2291			
VORINOSTAT - ZOLINZA						
N 021991 001	7399787	Feb 09, 2025	U-892			
	7456219	Mar 11, 2027	DS			
	7851509	Feb 21, 2024	DP U-892			
	8093295	May 16, 2026	DP			
	8450372	Mar 18, 2028	U-892			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 001	11458134	Jun 15, 2027	DP U-3463		M-187	Jan 22, 2024
	11458134*PED	Dec 15, 2027			M-232	Aug 23, 2026
	7144884	Jun 17, 2026	DS DP U-1439		PED	Feb 23, 2027
	7144884*PED	Dec 17, 2026				
	8722684	Jun 30, 2031	DS DP			
	8722684*PED	Dec 30, 2031				
	8969355	Jun 15, 2027	U-1668			
	8969355*PED	Dec 15, 2027				
	9125908	Jun 15, 2027	U-2309			
	9125908*PED	Dec 15, 2027				
	9125909	Jun 15, 2027	U-2309			
	9125909*PED	Dec 15, 2027				
	9125910	Jun 15, 2027	U-2309			
	9125910*PED	Dec 15, 2027				
	9227946	Jun 15, 2027	U-1668			
	9227946*PED	Dec 15, 2027				
	9278096	Mar 21, 2032	U-2436			
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027	U-1668			
	9861630*PED	Dec 15, 2027				
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 002	11458134	Jun 15, 2027	DP U-3463		M-187	Jan 22, 2024
	11458134*PED	Dec 15, 2027			M-232	Aug 23, 2026
	7144884	Jun 17, 2026	DS DP U-1439		PED	Feb 23, 2027
	7144884*PED	Dec 17, 2026				
	8722684	Jun 30, 2031	DS DP			
	8722684*PED	Dec 30, 2031				
	8969355	Jun 15, 2027	U-1668			
	8969355*PED	Dec 15, 2027				
	9125908	Jun 15, 2027	U-2309			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 002	9125908*PED	Dec 15, 2027				
	9125909	Jun 15, 2027	U-2309			
	9125909*PED	Dec 15, 2027				
	9125910	Jun 15, 2027	U-2309			
	9125910*PED	Dec 15, 2027				
	9227946	Jun 15, 2027	U-1668			
	9227946*PED	Dec 15, 2027				
	9278096	Mar 21, 2032	U-2436			
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027	U-1668			
	9861630*PED	Dec 15, 2027				
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 003	11458134	Jun 15, 2027	DP U-3463		M-187	Jan 22, 2024
	11458134*PED	Dec 15, 2027			M-232	Aug 23, 2026
	7144884	Jun 17, 2026	DS DP U-1439		PED	Feb 23, 2027
	7144884*PED	Dec 17, 2026				
	8722684	Jun 30, 2031	DS DP			
	8722684*PED	Dec 30, 2031				
	8969355	Jun 15, 2027	U-1668			
	8969355*PED	Dec 15, 2027				
	9125908	Jun 15, 2027	U-2309			
	9125908*PED	Dec 15, 2027				
	9125909	Jun 15, 2027	U-2309			
	9125909*PED	Dec 15, 2027				
	9125910	Jun 15, 2027	U-2309			
	9125910*PED	Dec 15, 2027				
	9227946	Jun 15, 2027	U-1668			
	9227946*PED	Dec 15, 2027				
	9278096	Mar 21, 2032	U-2436			
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027	U-1668			
	9861630*PED	Dec 15, 2027				
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 004	11458134	Jun 15, 2027	DP U-3463		M-187	Jan 22, 2024
	11458134*PED	Dec 15, 2027			M-232	Aug 23, 2026
	7144884	Jun 17, 2026	DS DP U-1439		PED	Feb 23, 2027
	7144884*PED	Dec 17, 2026				
	8722684	Jun 30, 2031	DS DP			
	8722684*PED	Dec 30, 2031				
	8969355	Jun 15, 2027	U-1668			
	8969355*PED	Dec 15, 2027				
	9125908	Jun 15, 2027	U-2309			
	9125908*PED	Dec 15, 2027				
	9125909	Jun 15, 2027	U-2309			
	9125909*PED	Dec 15, 2027				
	9125910	Jun 15, 2027	U-2309			
	9125910*PED	Dec 15, 2027				
	9227946	Jun 15, 2027	U-1668			
	9227946*PED	Dec 15, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 004	9278096	Mar 21, 2032	U-2436			
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027	U-1668			
	9861630*PED	Dec 15, 2027				
VOSORITIDE - VOXZOGO						
N 214938 001	10646550	Aug 01, 2036	DP U-3256		NCE	Nov 19, 2026
	8198242	Jun 11, 2030	DS DP U-3256		NPP	Oct 20, 2026
	9907834	Aug 01, 2036	DP		ODE-387	Nov 19, 2028
	RE48267	May 20, 2030	U-3256		ODE-449	Oct 20, 2030
VOSORITIDE - VOXZOGO						
N 214938 002	10646550	Aug 01, 2036	DP U-3256		NCE	Nov 19, 2026
	8198242	Jun 11, 2030	DS DP U-3256		NPP	Oct 20, 2026
	9907834	Aug 01, 2036	DP		ODE-387	Nov 19, 2028
	RE48267	May 20, 2030	U-3256		ODE-449	Oct 20, 2030
VOSORITIDE - VOXZOGO						
N 214938 003	10646550	Aug 01, 2036	DP U-3256		NCE	Nov 19, 2026
	8198242	Jun 11, 2030	DS DP U-3256		NPP	Oct 20, 2026
	9907834	Aug 01, 2036	DP		ODE-387	Nov 19, 2028
	RE48267	May 20, 2030	U-3256		ODE-449	Oct 20, 2030
VOXELOTOR - OXBRYTA						
N 213137 001	10017491	Dec 28, 2032	DP		NCE	Nov 25, 2024
	10034879	Dec 28, 2032	DS DP		ODE-281	Nov 25, 2026
	10493035	Oct 12, 2037	DP		ODE-394	Dec 17, 2028
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	11452720	Feb 06, 2035	U-3459			
	9018210	Nov 25, 2033	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			
VOXELOTOR - OXBRYTA						
N 213137 002	10017491	Dec 28, 2032	DP		NCE	Nov 25, 2024
	10034879	Dec 28, 2032	DS DP		ODE-394	Dec 17, 2028
	10493035	Oct 12, 2037	DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	11452720	Feb 06, 2035	U-3459			
	9018210	Nov 25, 2033	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VOXELOTOR - OXBRYTA						
N 216157 001	10017491	Dec 28, 2032	DP		NCE	Nov 25, 2024
	10034879	Dec 28, 2032	DS DP		ODE-394	Dec 17, 2028
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	11452720	Feb 06, 2035	U-3459			
	9018210	Nov 25, 2033	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			
VUTRISIRAN SODIUM - AMVUTTRA						
N 215515 001	10131907	Aug 24, 2028	DS DP U-3396		NCE	Jun 13, 2027
	10208307	Jul 28, 2036	DS DP U-3396		ODE-212	Jun 13, 2029
	10570391	Nov 16, 2032	DS DP U-3396			
	10612024	Aug 14, 2035	DS DP U-3396			
	10683501	Jul 28, 2036	DS DP U-3396			
	10806791	Dec 04, 2028	DS			
	11286486	Jul 28, 2036	DS DP U-3396			
	11401517	Aug 14, 2035	DS DP U-3396			
	8106022	Dec 12, 2029	DS DP U-3396			
	8828956	Dec 04, 2028	DS DP U-3396			
	9370581	Dec 04, 2028	DS DP U-3396			
	9399775	Nov 16, 2032	DS DP U-3396			
XENON XE-129 HYPERPOLARIZED - XENOVIEW						
N 214375 001	10583205	Feb 20, 2035	DP		NCE	Dec 23, 2027
	11052161	Dec 29, 2035	DP			
ZANUBRUTINIB - BRUKINSA						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		I-871	Aug 31, 2024
	10570139	Apr 22, 2034	U-2537		I-874	Sep 14, 2024
	10570139	Apr 22, 2034	U-2666		NCE	Nov 14, 2024
	10570139	Apr 22, 2034	U-3063		ODE-274	Jan 19, 2030
	10570139	Apr 22, 2034	U-3486		ODE-276	Nov 14, 2026
	10927117	Aug 15, 2037	DS DP		ODE-370	Sep 14, 2028
	11142528	Apr 22, 2034	DP U-1745		ODE-371	Aug 31, 2028
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	11786531	Jan 19, 2043	U-3715			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZANUBRUTINIB - BRUKINSA						
N 213217 001	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET						
N 216386 001	7220862	Jan 21, 2024	DS DP		NCE	Mar 09, 2028
	8481546	Oct 07, 2031	DS DP U-3555			
ZICONOTIDE ACETATE - PRIALT						
N 021060 001	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
	9707270	Oct 01, 2024	U-2084			
ZICONOTIDE ACETATE - PRIALT						
N 021060 002	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
	9707270	Oct 01, 2024	U-2084			
ZICONOTIDE ACETATE - PRIALT						
N 021060 003	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
	9707270	Oct 01, 2024	U-2084			
ZICONOTIDE ACETATE - PRIALT						
N 021060 004	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
	9707270	Oct 01, 2024	U-2084			
ZILUCOPLAN SODIUM - ZILBRYSQ						
N 216834 001	10106579	Jun 12, 2035	DS DP U-3735		NCE	Oct 17, 2028
	10208089	Jun 12, 2035	DS U-3735		ODE-446	Oct 17, 2030
	10435438	Jun 12, 2035	DS U-3735			
	10562934	Jun 12, 2035	DS			
	10835574	Jun 12, 2035	DP			
	11014965	Jun 12, 2035	DS U-3735			
	11535650	Jun 12, 2035	DP			
	11752190	Jun 12, 2035	DP U-3735			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZILUCOPLAN SODIUM - ZILBRYSQ								
N	216834	002	10106579	Jun 12, 2035	DS DP U-3735		NCE	Oct 17, 2028
			10208089	Jun 12, 2035	DS U-3735		ODE-446	Oct 17, 2030
			10435438	Jun 12, 2035	DS U-3735			
			10562934	Jun 12, 2035	DS			
			10835574	Jun 12, 2035	DP			
			11014965	Jun 12, 2035	DS U-3735			
			11535650	Jun 12, 2035	DP			
			11752190	Jun 12, 2035	DP U-3735			
ZILUCOPLAN SODIUM - ZILBRYSQ								
N	216834	003	10106579	Jun 12, 2035	DS DP U-3735		NCE	Oct 17, 2028
			10208089	Jun 12, 2035	DS U-3735		ODE-446	Oct 17, 2030
			10435438	Jun 12, 2035	DS U-3735			
			10562934	Jun 12, 2035	DS			
			10835574	Jun 12, 2035	DP			
			11014965	Jun 12, 2035	DS U-3735			
			11535650	Jun 12, 2035	DP			
			11752190	Jun 12, 2035	DP U-3735			
ZIPRASIDONE HYDROCHLORIDE - GEODON								
N	020825	001					M-232	Jan 28, 2025
ZIPRASIDONE HYDROCHLORIDE - GEODON								
N	020825	002					M-232	Jan 28, 2025
ZIPRASIDONE HYDROCHLORIDE - GEODON								
N	020825	003					M-232	Jan 28, 2025
ZIPRASIDONE HYDROCHLORIDE - GEODON								
N	020825	004					M-232	Jan 28, 2025
ZOLEDRONIC ACID - ZOMETA								
N	021223	002	8324189	May 29, 2025	U-1308			
			8324189	May 29, 2025	U-1309			
			8324189	May 29, 2025	U-53			
ZOLEDRONIC ACID - ZOMETA								
N	021223	003	7932241	Feb 05, 2028	DP			
			8324189	May 29, 2025	U-1308			
			8324189	May 29, 2025	U-1309			
			8324189	May 29, 2025	U-53			
ZOLEDRONIC ACID - RECLAST								
N	021817	001	7932241	Feb 05, 2028	DP			
ZOLPIDEM TARTRATE - EDLUAR								
N	021997	001	9265720	Feb 25, 2031	U-674			
			9597281	Apr 06, 2027	U-674			
ZOLPIDEM TARTRATE - EDLUAR								
N	021997	002	9265720	Feb 25, 2031	U-674			
			9597281	Apr 06, 2027	U-674			
ZOLPIDEM TARTRATE - ZOLPIMIST								
N	022196	001	8236285	Aug 07, 2032	DS DP U-70			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZOLPIDEM TARTRATE - INTERMEZZO							
N 022328	001	7658945	Apr 15, 2027	DP U-1194			
		7682628	Feb 16, 2025	U-1194			
		8242131	Aug 20, 2029	U-1266			
		8252809	Feb 16, 2025	DP			
ZOLPIDEM TARTRATE - INTERMEZZO							
N 022328	002	7658945	Apr 15, 2027	DP U-1194			
		7682628	Feb 16, 2025	U-1194			
		8242131	Aug 20, 2029	U-1266			
		8252809	Feb 16, 2025	DP			
ZONISAMIDE - ZONISADE							
N 214273	001	11478456	Aug 18, 2038	U-3458			
		11529333	Aug 18, 2038	DP			
ZURANOLONE - ZURZUVAE							
N 217369	001	10172871	Apr 17, 2034	U-2552		NCE	Oct 31, 2028
		10342810	Apr 17, 2034	U-2552			
		11236121	Aug 23, 2037	DS			
		9512165	Apr 17, 2034	DS DP			
ZURANOLONE - ZURZUVAE							
N 217369	002	10172871	Apr 17, 2034	U-2552		NCE	Oct 31, 2028
		10342810	Apr 17, 2034	U-2552			
		11236121	Aug 23, 2037	DS			
		9512165	Apr 17, 2034	DS DP			
ZURANOLONE - ZURZUVAE							
N 217369	003	10172871	Apr 17, 2034	U-2552		NCE	Oct 31, 2028
		10342810	Apr 17, 2034	U-2552			
		11236121	Aug 23, 2037	DS			
		9512165	Apr 17, 2034	DS DP			

PATENT AND EXCLUSIVITY TERMS

PATENT & EXCLUSIVITY ABBREVIATIONS

CGT	COMPETITIVE GENERIC THERAPY
D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
GAIN	GAIN EXCLUSIVITY
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY (SEE INDIVIDUAL REFERENCES)
ODE*	FDA has not recognized Orphan-Drug Exclusivity (ODE) for this drug, but it contains the same active moiety or moieties as another drug(s) that was eligible for ODE, and also shares ODE-protected use(s) or indication(s) with that drug(s). An application seeking approval for the same active moiety or moieties, including an ANDA that cites this NDA as its basis of submission, may not be approved for such ODE-protected use(s) and indication(s)
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL

EXCLUSIVITY DOSING SCHEDULE

D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN
D-35	FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
D-36	FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
D-37	DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "..1/2 TO 1 HOUR BEFORE EATING" TO ".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43	INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44	IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45	ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46	NEW DOSING REGIMEN OF 80MG DAILY
D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-48	ADMINISTRATION OF CISATRACURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRACURIUM FOLLOWING INDUCTION WITH THIOPENTAL
D-49	PEDIATRIC DOSING GUIDELINES
D-50	INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
D-51	OPTIONAL STARTING DOSE OF 40MG/DAY
D-52	ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
D-53	USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
D-54	USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
D-55	ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
D-56	ADDITION OF POSTPRANDIAL DOSING

EXCLUSIVITY DOSING SCHEDULE

D-57	3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
D-58	CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
D-59	REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
D-60	ADDITION OF A POST-OPERATIVE DOSING REGIMEN
D-61	ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-62	ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-63	TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
D-64	INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
D-70	80MG ONCE DAILY DOSING REGIMEN
D-71	EIGHT WEEK DOSING REGIMEN
D-72	INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
D-73	ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-74	ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-75	INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
D-76	FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
D-77	ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
D-78	USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
D-79	NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
D-80	CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
D-81	NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS
D-82	USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-83	750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
D-84	ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
D-85	LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
D-86	FOR USE IN SELECT EXTERNAL INSULIN PUMPS
D-87	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

EXCLUSIVITY DOSING SCHEDULE

D-88	NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
D-89	USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
D-90	ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
D-91	ALTERNATE INTERMITTENT DOSING REGIMEN
D-92	ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
D-93	ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
D-94	NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
D-95	BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
D-96	ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
D-97	PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFORE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
D-98	DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
D-99	ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
D-100	750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
D-101	ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
D-102	NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
D-103	NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
D-104	0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
D-105	USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-106	FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
D-107	PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-108	TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
D-109	PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE
D-110	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
D-111	PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
D-112	PROVIDES FOR PEDIATRIC PUMP USE
D-113	ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
D-114	NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
D-115	STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
D-116	ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS

EXCLUSIVITY DOSING SCHEDULE

D-117	50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
D-118	TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
D-119	DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
D-120	DOSING REGIMEN ADJUSTMENTS
D-121	CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION
D-122	USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
D-123	ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
D-124	ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
D-125	EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
D-126	CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
D-127	DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE
D-128	SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
D-129	800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
D-130	DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
D-131	EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
D-132	45MG FOR 6 MONTH ADMINISTRATION
D-133	NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
D-134	INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY
D-135	UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE
D-136	ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS
D-137	NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS
D-138	80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
D-139	ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE
D-140	REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY
D-141	DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
D-142	DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE
D-143	INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
D-144	LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
D-145	UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.

EXCLUSIVITY DOSING SCHEDULE

D-146	CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY
D-147	ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION
D-148	EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT
D-149	DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP
D-150	1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE
D-151	DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1
D-152	DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS.
D-153	IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY
D-154	ADDITION OF A 1500MG-SINGLE-DOSE REGIMEN FOR THE TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSI)
D-155	SINGLE IV DOSE OF FOSAPREPITANT 150MG DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID FOR PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
D-156	DOSING INFORMATION ADDED TO THE LABELING PROVIDING INFORMATION ON TRANSITIONING FROM SUBCUTANEOUS OR INTRAVENOUS ROUTES OF ADMINISTRATION OF TREPROSTINIL
D-157	UPDATED INFORMATION ADDED TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING PROVIDING DOSAGE RECOMMENDATIONS FOR INTERRUPTIONS AND DISCONTINUATION OF THERAPY
D-158	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 1 HCV INFECTION
D-159	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 4 HCV INFECTION
D-160	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE PATIENTS WITH DECOMPENSATED CIRRHOSIS WITH GENOTYPE 1 HCV INFECTION
D-161	DOSAGE RECOMMENDATIONS ADDED TO INCLUDE TREATMENT OF HCV GENOTYPE 3 SUBJECTS CO-INFECTED WITH HIV-1
D-162	DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH COMPENSATED (CHILD-PUGH A) OR DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS AND TREATMENT OF CHRONIC HCV GENOTYPE 3 INFECTION IN SUBJECTS WITH DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS
D-163	DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS
D-164	UPDATES TO THE DOSAGE AND ADMINISTRATION, DOSE MODIFICATIONS SECTION OF THE LABELING
D-165	DOSING RECOMMENDATION ADDED TO THE LABELING FOR IMBRUVICA USE IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL)
D-166	BROADEN INITIAL STARTING DOSE FOR BIPOLAR I DISORDER TO 5-10MG TWICE DAILY
D-167	ADDITION OF 1200 MG ONCE DAILY DOSING FOR TREATMENT-NAIVE PATIENTS OR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED ON AN INITIAL REGIMEN OF RALTEGRAVIR FILM-COATED TABLETS 400 MG TWICE DAILY
D-168	NEW DOSING REGIMEN OF 10 MG ONCE DAILY FOR THE REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR DVT AND/OR PE AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
D-169	ONCE-DAILY DOSING FOR PATIENTS 5 YEARS OF AGE AND OLDER WHO HAVE UNDETECTABLE SERUM AND URINE SUCCINYLACETONE CONCENTRATIONS AFTER A MINIMUM OF 4 WEEKS ON A STABLE DOSAGE OF NITISINONE

EXCLUSIVITY DOSING SCHEDULE

D-170	TO ALLOW WITHDRAWAL THERAPY OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE WHO HAVE ACHIEVED A SUSTAINED MOLECULAR RESPONSE ON NILOTINIB THERAPY FOR A MINIMUM OF ONE YEAR PRIOR TO DISCONTINUATION
D-171	REVISED DOSING TO INCLUDE UP-TITRATION AS A STRATEGY TO IMPROVE TOLERABILITY AND THEREBY REDUCE TREATMENT DISCONTINUATION FOR ROFLUMILAST MAINTENANCE DOSAGE OF 500 MCG DAILY
D-172	ADDITION OF A ONCE WEEKLY DOSING REGIMEN FOR CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
D-173	DOSING RECOMMENDATION FOR THE USE OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE FIXED DOSE COMBINATION IN HIV-1 INFECTED ADULT PATIENTS WITH END-STAGE-RENAL DISEASE WHO ARE RECEIVING CHRONIC HEMODIALYSIS
D-174	MODIFICATIONS TO THE EXISTING DOSING REGIMEN TO ALLOW FOR TREATMENT INTERRUPTIONS OF UP TO 8 WEEKS FOR INTOLERABLE ADVERSE REACTIONS
D-175	EIGHT-WEEK DOSING REGIMEN FOR THE TREATMENT OF GENOTYPES 1, 2, 3, 4, 5, AND 6, CHRONIC HEPATITIS C VIRUS INFECTION IN TREATMENT-NAIVE SUBJECTS WITH COMPENSATED CIRRHOSIS BASED ON THE RESULTS FROM THE EXPEDITION-8 STUDY
D-176	IBRUTINIB IN COMBINATION WITH RITUXIMAB
D-177	INFORMATION ADDED TO THE DOSING SECTION IN REGARD TO THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT INCLUDING PATIENTS WITH END STAGE RENAL DISEASE ON DIALYSIS
D-181	DOSING REGIMEN EXTENDING THE CONTRACEPTION USE FROM 5 YEARS TO UP TO 6 YEARS
D-182	NEW DOSING REGIMEN FOR THE PREVENTION AND MANAGEMENT OF NERATINIBASSOCIATED DIARRHEA
D-183	3-DAY DOSING REGIMEN FOR THE TREATMENT OF COVID-19 IN ADULTS AND PEDIATRIC PATIENTS (>12 YEARS AND WEIGHING AT LEAST 40 KG) WITH POSITIVE RESULTS OF DIRECT SARS-COV-2 VIRAL TESTING, WHO ARE NOT HOSPITALIZED AND HAVE MILD-TO-MODERATE COVID-19, AND ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH
D-184	NEW DOSING SCHEDULE FOR CABOTEGRAVIR/RILPIVRINE INJECTION EVERY 2 MONTHS
D-185	ADDITION OF A 3RD MAINTENANCE DOSE OF SEMAGLUTIDE
D-186	ADDITION OF A 3-DAY FOSAPREPITANT FOR INJECTION INTRAVENOUS DOSING REGIMEN IN PEDIATRIC PATIENTS FOR THE CURRENTLY APPROVED PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
D-187	ADDITION OF SECOND DOSE FOR TREATMENT OF PRESBYOPIA IN ADULTS
D-188	USE OF ALTERNATE INITIAL DOSING REGIMEN FOR INITIATION OF LACOSAMIDE TREATMENT IN PARTIAL ONSET SEIZURE PATIENTS ≥1 MONTH TO <17 YEARS OF AGE AND IN PRIMARY GENERALIZED TONIC-CLONIC SEIZURE PATIENTS ≥4 TO <17 YEARS
D-189	EXTENSION OF LETERMOVIR DOSING REGIMEN FROM 100 TO 200 DAYS POST-TRANSPLANT FOR THE PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN ADULT CMV SEROPOSITIVE RECIPIENTS (R+) OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT WHO ARE AT RISK FOR LATE CMV INFECTION AND DISEASE
D-190	USE OF SEMAGLUTIDE 1.7 MG SUBCUTANEOUS WEEKLY AS AN ADDITIONAL MAINTENANCE DOSE
D-191	ADDITION OF A ONCE DAILY DOSING REGIMEN

EXCLUSIVITY INDICATION

I-1	DYSMENORRHEA
I-2	CHOLANGIOPANCREATOGRAPHY
I-3	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4	PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5	HYSTEROSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN

EXCLUSIVITY INDICATION

I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14	SEBORRHEIC DERMATITIS
I-15	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16	STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26	TREATMENT OF LIVER FLUKES
I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS

EXCLUSIVITY INDICATION

I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54	RENAL CONCENTRATION CAPACITY TEST
I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66	UNCOMPLICATED GONORRHEA
I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD

	EXCLUSIVITY INDICATION
	AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS

EXCLUSIVITY INDICATION

I-121	EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUKOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY
I-132	TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
I-133	MANAGEMENT OF CHRONIC STABLE ANGINA
I-134	HEART FAILURE POST MYOCARDIAL INFARCTION
I-135	BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136	IDIOPATHIC CHRONIC URTICARIA
I-137	PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
I-138	TREATMENT OF ACUTE RECURRENT GENITAL HERPES
I-139	PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
I-140	PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
I-141	TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142	LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143	EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144	ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145	0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146	CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147	PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148	TREATMENT OF ACUTE PNEUMOCYSTIS CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2) IS LESS THAN OR EQUAL TO 55 TORR
I-149	TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151	PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152	SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153	MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
I-154	PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155	TREATMENT OF ONYCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT

	EXCLUSIVITY INDICATION
I-156	ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157	TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158	TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159	FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160	TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161	TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162	FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163	TREATMENT OF PHOTOPHOBIA
I-164	CHRONIC BACTERIAL PROSTATITIS
I-165	MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166	TREATMENT OF BULIMIA
I-167	COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168	MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169	USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170	PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171	RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172	TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONYCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS

EXCLUSIVITY INDICATION

I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREA IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY

EXCLUSIVITY INDICATION

I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
I-235	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
I-236	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-237	MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-238	ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
I-239	TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-240	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
I-241	USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
I-242	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
I-243	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
I-244	REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
I-245	TREATMENT OF ACUTE SINUSITIS
I-246	TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
I-247	USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
I-248	INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
I-249	TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY

EXCLUSIVITY INDICATION

I-250	PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
I-251	TREATMENT OF GENERALIZED ANXIETY DISORDER
I-252	NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
I-253	COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
I-254	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
I-255	PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
I-256	USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
I-257	TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION
I-258	FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
I-259	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-260	EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
I-261	TREATMENT OF SOCIAL ANXIETY DISORDER
I-262	TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
I-263	TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
I-264	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
I-265	TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
I-266	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
I-267	USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
I-268	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-277	TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
I-278	TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
I-279	TREATMENT OF POST-TRAUMATIC STRESS DISORDER
I-280	USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

	EXCLUSIVITY INDICATION
I-281	INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-282	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
I-283	TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
I-284	TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
I-285	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
I-286	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
I-287	USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
I-288	CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
I-289	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
I-290	PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-291	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
I-307	NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
I-308	TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
I-309	USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-310	REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
I-311	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS

EXCLUSIVITY INDICATION

I-312	FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-313	EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
I-314	TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
I-315	THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-316	TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
I-317	PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
I-318	FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-319	USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
I-320	TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYMPTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS

EXCLUSIVITY INDICATION

I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER
I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME
I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-358	TREATMENT OF PANIC DISORDER
I-359	TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-360	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
I-361	TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
I-362	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-363	ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-364	TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
I-365	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
I-366	PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-367	COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
I-368	USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
I-369	PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
I-370	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
I-371	HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
I-372	NOSOCOMIAL PNEUMONIA
I-373	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-374	SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
I-375	FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
I-376	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
I-377	USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN

	EXCLUSIVITY INDICATION
	STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
I-378	RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-379	USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
I-380	TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
I-381	TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
I-382	FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
I-383	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-384	USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
I-385	MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
I-386	RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
I-387	ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE
I-388	TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-389	SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
I-390	USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
I-391	ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
I-392	TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECURRENCE AFTER STEM CELL TRANSPLANT OR RESISTANCE TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVEMENT IN DISEASE RELATED SX OR INCREASED SURVIVAL
I-393	CHRONIC BACTERIAL PROSTATITIS
I-394	USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
I-395	TO IMPROVE PHYSICAL FUNCTION
I-396	EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
I-397	EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
I-398	IDIOPATHIC SHORT STATURE
I-399	TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS
I-400	USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-401	LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
I-402	DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
I-403	USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
I-404	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED

EXCLUSIVITY INDICATION

	FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
I-405	TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
I-406	PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
I-407	IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
I-408	STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
I-409	ESOPHAGEAL CANDIDIASIS
I-410	USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
I-411	EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
I-412	MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-413	ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-414	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-415	SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
I-416	THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
I-417	USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
I-418	ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
I-419	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-420	TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
I-421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
I-422	INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
I-423	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
I-424	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
I-425	ELOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
I-426	TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-427	TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-428	FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
I-429	FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
I-430	FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
I-431	NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS

EXCLUSIVITY INDICATION

	PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
I-432	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
I-433	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
I-434	PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
I-435	CHRONIC IDIOPATHIC CONSTIPATION
I-436	FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
I-437	TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-438	EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
I-439	USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
I-440	FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
I-441	USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
I-442	USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
I-443	TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
I-444	USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS
I-445	TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
I-446	EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
I-447	USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
I-448	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
I-449	TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
I-450	TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
I-451	MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
I-452	EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
I-453	USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
I-454	MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
I-455	MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)
I-456	TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS.

	EXCLUSIVITY INDICATION
	INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
I-457	TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
I-458	USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
I-459	NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
I-460	TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
I-461	USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
I-462	LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
I-463	TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
I-464	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
I-465	PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
I-466	FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
I-467	USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
I-468	USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION
I-469	RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
I-470	DIABETIC PERIPHERAL NEUROPATHIC PAIN
I-471	INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
I-472	USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
I-473	USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
I-474	TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN
I-475	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
I-476	TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
I-477	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
I-478	FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
I-479	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
I-480	PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
I-481	INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-482	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
I-483	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-484	FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
I-485	TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION

EXCLUSIVITY INDICATION

I-486	ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
I-487	INDICATED FOR THE RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
I-488	MAINTENANCE THERAPY IN BIPOLAR I DISORDER
I-489	FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
I-490	FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
I-491	INFLUENZA PROPHYLAXIS
I-492	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
I-493	ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
I-494	CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
I-495	ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
I-496	LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
I-497	PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
I-498	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-499	USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY
I-500	FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETENT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
I-502	FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
I-503	TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-504	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
I-505	TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
I-506	ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
I-507	ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-508	PREMENSTRUAL DYSPHONIC DISORDER
I-509	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
I-510	ADULT DERMATOFIBROSARCOMA PROTUBERANS (DFSP)
I-511	ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
I-512	ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
I-513	ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
I-514	ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)

EXCLUSIVITY INDICATION

I-515	PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
I-516	PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-517	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
I-518	TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
I-519	USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
I-520	USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL
I-521	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
I-522	TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.
I-523	USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
I-524	GENERALIZED ANXIETY DISORDER (GAD)
I-525	USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
I-526	TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
I-527	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-528	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-529	TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE
I-530	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER
I-531	MAINTENANCE TREATMENT OF SCHIZOPHRENIA
I-532	TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES
I-533	ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)
I-534	EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECURRENCE OF VTE IN PATIENTS WITH CANCER
I-535	MANAGEMENT OF FIBROMYALGIA
I-536	FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME
I-537	LONG TERM TREATMENT OF PANIC DISORDER
I-538	SHORT TERM TREATMENT OF PANIC DISORDER
I-539	REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER
I-540	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17
I-541	TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17
I-542	EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS
I-543	USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
I-544	ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
I-545	ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER

	EXCLUSIVITY INDICATION
I-546	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
I-547	ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
I-548	SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE
I-549	USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-550	TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE
I-551	TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME
I-552	ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER
I-553	FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
I-554	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
I-555	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
I-556	PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
I-557	USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD
I-558	MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-559	ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
I-560	MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX
I-561	LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
I-562	MAINTENANCE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
I-563	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-564	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-565	USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
I-566	MANAGEMENT OF FIBROMYALGIA
I-567	INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-568	USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
I-569	TREATMENT OF CHRONIC HEPATITIS B
I-570	TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
I-571	NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER
I-572	TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
I-573	TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
I-574	MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
I-575	MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA

EXCLUSIVITY INDICATION

I-576	ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-577	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
I-578	EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
I-579	TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
I-580	INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
I-581	TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-582	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
I-583	ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST)
I-584	TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS
I-585	TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
I-586	COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
I-587	ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
I-588	ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
I-589	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
I-590	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
I-591	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
I-592	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)
I-593	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
I-594	INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
I-595	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-596	USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-597	MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-598	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
I-599	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
I-600	FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-601	MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
I-602	TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
I-603	GOUT FLARES
I-604	PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK
I-605	ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
I-606	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
I-607	INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS
I-608	REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH

	EXCLUSIVITY INDICATION
	HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
I-610	TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
I-611	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
I-612	MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
I-613	MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
I-614	SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
I-615	MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-616	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
I-617	MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
I-618	ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
I-619	INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
I-620	FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
I-621	PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
I-622	ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER
I-623	TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
I-624	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
I-625	PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
I-626	RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-627	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
I-628	MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
I-629	ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-630	TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
I-631	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
I-632	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
I-633	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-634	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
I-635	ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
I-636	TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
I-637	USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER

	EXCLUSIVITY INDICATION
I-638	FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
I-639	TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
I-640	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-641	TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-642	TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-643	REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
I-644	MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)
I-645	MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
I-646	SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)
I-647	SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
I-648	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
I-649	TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
I-650	TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY
I-651	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY
I-652	MANAGEMENT OF POSTHERPETIC NEURALGIA
I-653	TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
I-654	MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE
I-655	TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
I-656	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
I-657	PLAQUE PSORIASIS OF THE SCALP
I-658	FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
I-659	PLAQUE PSORIASIS OF THE BODY
I-660	TREATMENT OF DEEP VEIN THROMBOSIS
I-661	TREATMENT OF PULMONARY EMBOLISM
I-662	REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM
I-663	IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
I-664	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
I-665	TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L
I-666	TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY
I-667	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE
I-668	PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT

EXCLUSIVITY INDICATION

I-669 SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%

I-670 TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN

I-671 FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

I-672 USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB

I-673 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCLUDING METHICILLIN-SUSCEPTIBLE AND RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE

I-674 TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE

I-675 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER

I-676 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE

I-677 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT

I-678 TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

I-679 RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS

I-680 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

I-681 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT

I-682 TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS

I-683 TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED

I-684 PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS

I-685 EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE

I-686 INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY

I-687 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY

I-688 GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE

I-689 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION

I-690 INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)

I-691 INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY

I-692 INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.

I-693 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

I-694 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY

EXCLUSIVITY INDICATION

I-695 REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA

I-696 USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER

I-697 FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION

I-698 SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS

I-699 FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA

I-700 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)

I-701 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSION FREE SURVIVAL

I-702 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA

I-703 MODERATE TO SEVERE BINGE EATING DISORDER (BED)

I-704 EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN

I-705 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE

I-706 EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

I-707 POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY

I-708 DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER

I-709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS

I-710 ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.

I-711 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.

I-712 EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY

I-713 REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL ("INDUCTION") TREATMENT OF OPIOID DEPENDENCE

I-714 EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFARCTION

I-715 FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.

I-716 REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY

I-717 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4

I-718 EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY

I-719 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.

I-720 EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.

I-721 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.

I-722 REVISED INDICATION FOR USE IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR

	EXCLUSIVITY INDICATION
	REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY.
I-723	AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
I-724	TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL DIFFERENTIATED, NON-FUNCTIONAL NEUROENDOCRINE TUMORS (NET) OF GI OR LUNG ORIGIN WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
I-725	TREATMENT OF HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION THERAPY WITH PALBOCICLIB AND FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY.
I-726	EXPANSION OF THE PATIENT POPULATION TO INCLUDE PATIENTS WITH RECURRENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE 1 OR 3 AFTER LIVER TRANSPLANTATION
I-727	EXPANSION OF THE INDICATION TO INCLUDE TREATMENT OF SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C VIRUS INFECTION, INCLUDING SUBJECTS WHO ARE CO-INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) BASED ON THE RESULTS FROM THE ALLY-2 CLINICAL TRIAL
I-728	EXPANDED INDICATION FOR USE IN ULTRASONOGRAPHY OF THE LIVER FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN ADULT AND PEDIATRIC PATIENTS
I-729	PROVIDES FOR THE FRONTLINE INDICATION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
I-730	NEW INDICATION FOR THE TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
I-731	FOR USE IN MAGNETIC RESONANCE ANGIOGRAPHY IN ADULT AND PEDIATRIC PATIENTS (INCLUDING TERM NEONATES) TO EVALUATE KNOWN OR SUSPECTED SUPRA-AORTIC OR RENAL ARTERY DISEASE
I-732	TREATMENT OF PEDIATRIC PATIENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TO REDUCE LDL-C, TOTAL C, NONHDL-C AND APOB AS AN ADJUNCT TO DIET, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS
I-733	USE OF CANAGLIFLOZIN FOR INITIAL THERAPY IN COMBINATION WITH METFORMIN
I-734	EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC THERAPY.
I-735	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH CANAGLIFLOZIN AND METFORMIN IS APPROPRIATE
I-736	REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL)
I-737	REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL) WITH 17P DELETION
I-738	REVISIONS TO THE INDICATIONS AND USAGE SECTION WITH RESPECT TO COMPLICATED INTRA-ABDOMINAL INFECTIONS
I-739	TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
I-740	EXPANDED INDICATION FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER TO INCLUDE THE G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R MUTATION IN THE CFTR GENE
I-741	TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
I-742	TREATMENT OF NODAL MARGINAL ZONE LYMPHOMA
I-743	INFORMATION ADDED TO THE LABELING FOR THE ADDITION OF THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 4 (GT4) INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS BASED ON RESULTS FROM STUDY M11-665
I-744	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
I-745	MEKINIST, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
I-746	NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS

EXCLUSIVITY INDICATION

I-747	FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED WITH HIGH-DOSE BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH CLASS 3 BETA-THALASSEMIA
I-748	TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS FIVE YEARS OF AGE AND OLDER
I-749	MONOTHERAPY FOR THE TREATMENT OF HORMONE RECEPTOR (HR) POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY
I-750	REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
I-751	TREATMENT OF TARDIVE DYSKINESIA
I-752	CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY (CCTA) TO ASSIST DIAGNOSTIC EVALUATION OF PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE
I-753	TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
I-754	TO REDUCE THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY WHEN USED FOR THE TREATMENT OF ADULTS WITH CARCINOID SYNDROME
I-755	ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
I-756	EXPANDED THE APPROVED INDICATION BY REMOVING THE RESTRICTION FOR USE ONLY IN PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
I-757	TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
I-758	FOR USE WITH RILPIVIRINE AS A COMPLETE REGIMEN TO REPLACE THE CURRENT ARV REGIMEN IN VIROLOGICALLY SUPPRESSED PATIENTS ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TX FAILURE OR KNOWN SUBSTITUTIONS ASSOC. WITH RESISTANCE TO EITHER ARV
I-759	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+CML)
I-760	FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
I-761	TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE OR OTHER NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
I-762	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE METASTATIC BREAST CANCER WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT OR METASTATIC SETTING
I-763	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
I-764	TREATMENT IN ADULT PATIENTS FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)
I-765	ABIRATERONE ACETATE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
I-766	TREATMENT OF MINIMALLY TO MODERATELY THICK ACTINIC KERATOSIS OF THE UPPER EXTREMITIES IN CONJUNCTION WITH A BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATOR
I-767	TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON
I-768	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
I-769	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
I-770	TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
I-771	REVISION OF THE INDICATION SECTION OF THE PACKAGE INSERT REGARDING AN INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA

EXCLUSIVITY INDICATION

I-772 FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY

I-773 FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGE 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES

I-774 TO ALLOW FOR FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS, AS DETECTED BY AN FDA APPROVED TEST

I-775 REVISED INDICATION FOR FIXED-DOSE COMBINATION OF FLUTICASONE FUROATE, UMECLIDINIUM, AND VILANTEROL TO TREAT AIRFLOW OBSTRUCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND TO REDUCE COPD EXACERBATIONS IN PTS WITH HISTORY OF EXACERBATIONS

I-776 FIRSTLINE MAINTENANCE TX IN PTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE, SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA WHO ARE IN COMPLETE OR PARTIAL RESPONSE TO FIRSTLINE PLATINUM-BASED CHEMOTHERAPY

I-777 CO-ADMINISTRATION THERAPY OF MIRABEGRON WITH SOLIFENACIN SUCCINATE FOR TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY

I-778 DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION

I-779 USE OF TOLVAPTAN TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

I-780 TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)

I-781 DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS

I-782 REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

I-783 EXPANDED INDICATION TO INCLUDE RIBOCICLIB WITH AN AROMATASE INHIBITOR IN PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY

I-784 RIBOCICLIB WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY

I-785 TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE

I-786 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

I-787 FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

I-788 NEW INDICATION FOR CANAGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)

I-789 VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY

I-790 USE OF FERRIC CITRATE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WITH CKD NOT ON DIALYSIS

I-791 TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY

I-792 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB

EXCLUSIVITY INDICATION

I-793	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
I-794	TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
I-795	VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
I-796	USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
I-797	USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
I-798	TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION)
I-799	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
I-800	TREATMENT OF OCULAR INFLAMMATION FOLLOWING OPHTHALMIC SURGERY
I-801	USE IN CARDIAC MRI TO ASSESS MYOCARDIAL PERFUSION (STRESS, REST) AND LATE GADOLINIUM ENHANCEMENT IN ADULT PATIENTS WITH KNOWN OR SUSPECTED CORONARY ARTERY DISEASE (CAD)
I-802	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
I-803	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE
I-804	EXPANDED INDICATION FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
I-805	SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
I-806	EXPANDED INDICATION FOR PTS WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML) ON A STABLE ARV REGIMEN WITH NO HX OF TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W RESISTANCE TO DORAVIRINE, LAMIVUDINE OR TENOFOVIR DISOPROXIL FUMARATE
I-807	TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
I-808	TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
I-809	TO REDUCE THE RISK OF END-STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND DIABETIC NEPHROPATHY WITH ALBUMINURIA > 300 MG/DAY
I-810	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING
I-811	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 12 YEARS OF AGE OR OLDER, WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 48 HOURS AND ARE AT HIGH RISK OF DEVELOPING INFLUENZA-RELATED COMPLICATIONS
I-812	FOR USE IN AT RISK ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF HIV-1 INFECTION FROM SEXUAL ACQUISITION, EXCLUDING INDIVIDUALS AT RISK FROM RECEPTIVE VAGINAL SEX
I-813	TX OF ADULT PTS W/ ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY POSITIVE STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
I-814	TX OF ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY DEFINED BY POSITIVE STATUS GENOMIC INSTABILITY & WHO HAVE PROGRESSED >6MO AFTER RESPONSE TO LAST PLATINUM-BASED CHEMO
I-815	TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA (CABP) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
I-816	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE >= 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY

EXCLUSIVITY INDICATION

I-817	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
I-818	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN
I-819	ADJUNCT TO MAX TOLERATED STATIN TX TO REDUCE RISK OF MI, STROKE, CORONARY REVASCULARIZATION, & UNSTABLE ANGINA REQUIRING HOSPITALIZATION IN ADULTS W/ ELEVATED TG LEVELS & ESTABLISHED CV DISEASE OR DIABETES MELLITUS & 2+ RISK FACTORS FOR CV DISEASE
I-820	INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION
I-821	TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE
I-822	REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
I-823	USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
I-824	RIVAROXABAN IN COMBINATION WITH ASPIRIN, IS INDICATED TO REDUCE THE RISK OF MAJOR CV EVENTS (CV DEATH, MI, AND STROKE) IN PATIENTS WITH CHRONIC CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD)
I-825	TREATMENT FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES WITH A PROGRESSIVE PHENOTYPE
I-826	ENCORAFENIB, IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY
I-827	EXPANDED INDICATION FOR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML) ON A STABLE ARV REGIMEN WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO DORAVIRINE
I-828	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CUSHING’S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
I-829	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY (CPP)
I-830	TREATMENT OF ADULT PATIENTS WITH A DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC)-ASSOCIATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY
I-831	W/BEVACIZUMAB FOR MAINTENANCE TX OF ADULTS W/ADV. EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMO & CA ASSOCIATED W/ HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE STATUS
I-832	TX OF ADULT PTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
I-833	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
I-834	TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE (NYHA CLASS II-IV) WITH REDUCED EJECTION FRACTION
I-835	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
I-836	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
I-837	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY

EXCLUSIVITY INDICATION

I-838 TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) OF THE FEET

I-839 TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE

I-840 TREATMENT OF SYMPTOMS IN ADULTS WITH MAJOR DEPRESSIVE DISORDER (MDD) WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR.

I-841 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS

I-842 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY IN COMBINATION WITH DARATUMUMAB AND DEXAMETHASONE

I-843 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER

I-844 INDICATED IN PATIENTS 18 YEARS OF AGE AND OLDER FOR THE TREATMENT OF HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY THE FOLLOWING SUSCEPTIBLE GRAM-NEGATIVE MICROORGANISMS: ACINETOBACTER BAUMANNII COMPLEX, ESCHERICHIA COLI, ENTEROBACTER CLOACAE COMPLEX, KLEBSIELLA PNEUMONIAE, PSEUDOMONAS AERUGINOSA, AND SERRATIA MARCESCENS

I-845 TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST

I-846 TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NARCOLEPSY

I-847 EXPANDED INDICATION OF THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST

I-848 REDUCE THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE (NIH STROKE SCALE SCORE <=5) OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK (TIA)

I-849 CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO AT LEAST TWO PRIOR KINASE INHIBITORS

I-850 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PATIENTS 16 YEARS OF AGE AND OLDER

I-851 TO REDUCE THE RISK OF A FIRST MYOCARDIAL INFARCTION (MI) OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD) AT HIGH RISK FOR SUCH EVENTS

I-852 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE

I-853 INDICATION OF OSIMERTINIB AS ADJUVANT THERAPY AFTER TUMOR RESECTION IN ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST

I-854 FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA, AS A FIRST-LINE TREATMENT IN COMBINATION WITH NIVOLUMAB

I-855 TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 3 YEARS AND OLDER AND WEIGHING 35 KILOGRAMS OR MORE

I-856 INDICATION FOR THE TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE TO IMPROVE EXERCISE ABILITY

I-857 TO REDUCE THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION

I-858 FOR THE TOPICAL TREATMENT OF SCABIES INFESTATIONS IN ADULT AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER

I-859 TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS

I-860 FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN ADULT PATIENTS

I-861 TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING GREATER THAN 25 KG

EXCLUSIVITY INDICATION

I-862	TREATMENT OF VENOUS THROMBOEMBOLIC EVENTS (VTE) IN PEDIATRIC PATIENTS 8 TO LESS THAN 18 YEARS OF AGE WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR AT LEAST 5 DAYS AND TO REDUCE THE RISK OF RECURRENCE OF VTE IN PEDIATRIC PATIENTS 8 TO LESS THAN 18 YEARS OF AGE WHO HAVE BEEN PREVIOUSLY TREATED
I-863	TREATMENT OF ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM), INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) AND SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN)
I-864	TREATMENT OF ADULT PATIENTS WITH MAST CELL LEUKEMIA (MCL)
I-865	FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
I-866	FOR THE TREATMENT OF TRICHOMONIASIS CAUSED BY TRICHOMONAS VAGINALIS IN ADULTS
I-867	INDICATED TO REDUCE THE RISK OF MAJOR THROMBOTIC VASCULAR EVENTS (MYOCARDIAL INFARCTION, ISCHEMIC STROKE, ACUTE LIMB ISCHEMIA, AND MAJOR AMPUTATION OF VASCULAR ETIOLOGY) IN PATIENTS WITH PAD, INCLUDING PATIENTS WHO HAVE RECENTLY UNDERGONE A LOWER EXTREMITY REVASCULARIZATION PROCEDURE DUE TO SYMPTOMATIC PAD
I-868	LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
I-869	REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
I-870	INDICATED FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) IN ADULTS
I-871	TREATMENT OF ADULT PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM)
I-872	ADDITION OF THE INDICATION OF TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
I-873	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
I-874	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE ANTI-CD20-BASED REGIMEN
I-875	FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST
I-876	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
I-877	INDICATION FOR THE USE OF ABEMACICLIB IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, NODE-POSITIVE, EARLY CANCER (EBC) AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE>20% AS DETERMINED BY AN FDA APPROVED TEST
I-878	ADDITION OF A NEW INDICATION FOR ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
I-879	TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS, TO THE PRESCRIBING INFORMATION
I-880	TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
I-881	FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS 13 YEARS OF AGE AND OLDER
I-882	INDICATED FOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I OR II DISORDER (BIPOLAR DEPRESSION) IN ADULTS, AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
I-883	TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, INCLUDING BIOLOGICS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
I-884	REVISIONS TO THE LABELING TO INCLUDE DATA FOR SUBJECTS WITH MILD TO MODERATE PLAQUE PSORIASIS, AND TO ALLOW FOR AN EXPANSION OF THE INDICATION
I-885	FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH NEOADJUVANT OR ADJUVANT CHEMOTHERAPY

EXCLUSIVITY INDICATION

I-886	TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
I-887	INDICATION FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) IN PATIENTS WHO ARE 2 YEARS OF AGE AND OLDER
I-888	TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
I-889	TREATMENT OF PEDIATRIC PATIENTS AGED ONE MONTH AND OLDER WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)
I-890	TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
I-891	TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NONINVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
I-892	CHRONIC WEIGHT MANAGEMENT IN ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH BARDET-BIEDL SYNDROME (BBS)
I-893	IN COMBINATION WITH AZACITIDINE OR AS MONOTHERAPY FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST IN ADULTS 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
I-894	DABRAFENIB IS INDICATED IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH UNRESECTABLE OR METASTATIC SOLID TUMORS WITH BRAF V600E MUTATION WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT AND HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
I-895	TRAMETINIB IS INDICATED IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH UNRESECTABLE OR METASTATIC SOLID TUMORS WITH BRAF V600E MUTATION WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT AND HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
I-896	INDICATED FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
I-897	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH UNRESECTABLE, RECURRENT OR REFRACTORY INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE
I-898	FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
I-899	TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT
I-900	TREATMENT OF ADULT PATIENTS WITH METASTATIC HORMONESENSITIVE PROSTATE CANCER (MHSPC) IN COMBINATION WITH DOCETAXEL
I-901	EXPANDED INDICATION TO INCLUDE LOWERING OF PLASMA OXALATE LEVELS IN ADULT AND PEDIATRIC PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)
I-902	TREATMENT OF ADULT PATIENTS WITH HISTIOCYTIC NEOPLASMS
I-903	REDUCTION IN THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN ADULT AND POST-MENARCHAL PEDIATRIC FEMALES
I-904	ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADULTS
I-905	ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT AND NONMALIGNANT PULMONARY LESIONS IN ADULT PATIENTS WITH KNOWN OR SUSPECTED CANCER IN THE LUNG
I-906	TUCATINIB IN COMBINATION WITH TRASTUZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH RAS WILD-TYPE, HER2-POSITIVE, UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY
I-907	TO INCREASE BONE DENSITY IN MEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE (DEFINED AS A HISTORY OF OSTEOPOROTIC FRACTURE OR MULTIPLE RISK FACTORS FOR FRACTURE), OR PATIENTS WHO HAVE FAILED OR ARE INTOLERANT TO OTHER AVAILABLE OSTEOPOROSIS THERAPY
I-908	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA WITH A BRAF V600 MUTATION WHO REQUIRE SYSTEMIC THERAPY
I-909	PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS

EXCLUSIVITY INDICATION

I-910	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY
I-911	FOR FLUORESCENCE IMAGING OF LYMPH NODES AND DELINEATION OF LYMPHATIC VESSELS DURING LYMPHATIC MAPPING IN ADULTS WITH BREAST CANCER FOR WHICH THIS PROCEDURE IS A COMPONENT OF INTRAOPERATIVE MANAGEMENT
I-912	TREATMENT OF ADULT PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS (ISM)
I-913	TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
I-914	IN COMBINATION WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE FOR THE TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS BRCA-MUTATED (BRCAM) METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
I-915	TREATMENT OF IRON DEFICIENCY IN ADULT PATIENTS WITH HEART FAILURE AND NEW YORK HEART ASSOCIATION CLASS II/III TO IMPROVE EXERCISE CAPACITY
I-916	PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT RECIPIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE [D+/R-])
I-917	TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR UP TO 5 YEARS IN PATIENTS WHO CHOOSE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
I-918	TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS)
I-919	TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
I-920	USE OF TALAZOPARIB IN COMBINATION WITH ENZALUTAMIDE FOR THE TREATMENT OF ADULT PATIENTS WITH HOMOLOGOUS RECOMBINATION REPAIR (HRR) GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).
I-921	TREATMENT OF FUNCTIONAL CONSTIPATION IN PEDIATRIC PATIENTS 6 TO 17 YEARS OF AGE
I-922	USE OF EMPAGLIFLOZIN TO REDUCE THE RISK OF SUSTAINED DECLINE IN EGFR, END-STAGE KIDNEY DISEASE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
I-923	FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
I-924	FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES (MDS) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
I-925	TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON’S DISEASE
I-926	TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS
I-928	ENCORAFENIB IN COMBINATION WITH BINIMETINIB, IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST

EXCLUSIVITY MISCELLANEOUS

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
M-2	APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
M-4	CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
M-5	INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION

EXCLUSIVITY MISCELLANEOUS

M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
M-12	NEW LANGUAGE FOR PEDIATRIC USE
M-13	INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
M-14	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
M-15	LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
M-16	CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
M-17	INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
M-18	INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
M-19	INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
M-20	LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
M-21	COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
M-22	CHANGE IN TIME TO ONSET OF ACTION
M-23	INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
M-24	INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
M-25	ADDITIONAL SAFETY AND PHARMACOKINETICS INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PACKAGE INSERT
M-26	INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
M-27	INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
M-28	INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
M-29	LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
M-30	CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
M-31	INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
M-32	ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
M-33	INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
M-34	EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
M-35	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY

EXCLUSIVITY MISCELLANEOUS

M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE

M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS

M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL

M-39 FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST

M-40 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS

M-41 REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"

M-42 ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION

M-43 INCLUSION OF RESULTS OF STUDY "PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION"

M-44 CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18

M-45 INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING, "EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY"

M-46 PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY

M-47 PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS

M-48 CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES

M-49 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN

M-50 NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION

M-51 INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY

M-52 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

M-53 FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT

M-54 INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL

M-55 INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.

M-56 INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL

M-57 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS

M-58 CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS

M-59 RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS

M-60 CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA

M-61 REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN

EXCLUSIVITY MISCELLANEOUS

	REQUEST
M-62	CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES
M-63	DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
M-64	CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS
M-65	ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
M-66	USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
M-67	INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
M-68	DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
M-69	RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
M-70	PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
M-71	REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
M-72	INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
M-73	NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
M-74	REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLESCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
M-75	PROVISION FOR USE OF ARGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)
M-76	REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
M-77	USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
M-78	CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
M-79	LABELING REVISIONS RELATED TO SMOKING AND ERLOTINIB EXPOSURE
M-80	ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
M-81	ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOTOXICOSIS)
M-82	LABELING REVISIONS RELATED TO CLINICAL STUDIES
M-83	ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
M-84	STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
M-85	INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
M-86	LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
M-87	INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
M-88	ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE

EXCLUSIVITY MISCELLANEOUS

M-89	PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
M-90	LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
M-91	UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
M-92	UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION"
M-93	EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
M-94	INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
M-95	INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
M-96	UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
M-97	LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
M-98	NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
M-99	ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATIENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
M-100	INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
M-101	INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
M-102	INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
M-103	SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
M-104	INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
M-105	NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
M-106	ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT
M-107	INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED 1-MONTH BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516 ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
M-108	CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
M-110	CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
M-111	LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
M-112	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS

EXCLUSIVITY MISCELLANEOUS

M-113	LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS
M-114	CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)
M-115	REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES
M-116	LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008
M-117	ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL
M-118	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36
M-119	LABELING CHANGES REGARDING MISSED DOSES
M-120	CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS
M-121	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43
M-122	LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL
M-123	UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY
M-124	LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS
M-125	LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE
M-126	UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086
M-127	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004
M-128	CLINICAL TRIAL STUDY RESULTS
M-129	RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE
M-130	ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT
M-131	INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS
M-132	REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS
M-133	INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY
M-134	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING
M-135	ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT
M-136	ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS
M-137	LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
M-138	INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER
M-139	INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA
M-140	INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION
M-141	REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)
M-142	ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY

EXCLUSIVITY MISCELLANEOUS

M-143	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER
M-144	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE
M-145	ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING
M-146	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS
M-147	OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES
M-148	LABELING CHANGES BASED ON STUDY H80-EW-GWDM
M-149	INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD
M-150	ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE
M-151	REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF AGE
M-152	INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION
M-153	ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN
M-154	UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.
M-155	ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT
M-156	UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.
M-157	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND SULFONYLUREA
M-158	UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS
M-159	ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
M-160	UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT
M-161	UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN ALONE OR WITH METFORMIN
M-162	INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE
M-163	INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
M-164	REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED "PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA"
M-165	PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, "A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LYMPHOMA (LL)"

EXCLUSIVITY MISCELLANEOUS

M-166 UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) - EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) - RESISTANT SUBJECTS

M-167 APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED "BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH".

M-168 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY)

M-169 UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.

M-170 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION REGARDING USE FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

M-171 UPDATES TO LABELING WITH RESULTS TO THE TIGER CLINICAL TRIAL

M-172 UPDATES TO THE CLINICAL TRIALS SECTION OF THE LABELING TO INCLUDE RESULTS OF STUDIES PERFORMED TO EVALUATE THE BENEFIT OF ADDING INCRUSE ELLIPTA TO PATIENTS WHO ARE ON BACKGROUND THERAPY WITH BREO ELLIPTA AND ADVAIR DISKUS

M-173 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING DESCRIBING THE EFFECTS OF STIOLTO RESPIMAT ON COPD PATIENTS

M-174 INFORMATION ADDED TO CLINICAL STUDIES SECTION OF THE LABELING REGARDING INITIAL COMBINATION THERAPY OF EMPAGLIFLOZIN WITH METFORMIN

M-175 INFORMATION ADDED TO THE LABELING DESCRIBING SAVOR, A PHASE IV TRIAL EVALUATING THE EFFECT OF SAXAGLIPTIN ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHAEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES

M-176 INFORMATION ADDED TO THE LABELING DESCRIBING TRIAL NN2211-3916, A TRIAL EVALUATING THE SAFETY AND EFFICACY OF LIRAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT

M-177 INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE

M-178 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE OF REMISSION IN CROHN'S DISEASE IN PEDIATRIC PATIENTS

M-179 UPDATES TO THE PRODUCT LABELING WITH STUDY REPORTS FROM THE OPTIMIST-1 AND OPTIMIST-2 CLINICAL TRIALS

M-180 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA

M-181 UPDATE TO THE DOSAGE AND ADMINISTRATION, PATIENT SELECTION (2.1), SECTION OF THE PACKAGE INSERT TO INCLUDE THE USE OF AN FDA-APPROVED PLASMA TEST FOR THE IDENTIFICATION OF EGFR EXON 19 DELETION OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

M-182 UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, "A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE"

M-183 CHANGES TO THE DOSAGE AND ADMINISTRATION AND CLINICAL STUDIES SECTIONS OF THE LABELING TO SUPPORT THE REDUCE-TO-QUIT PARADIGM

M-184 UPDATES MADE TO THE LABELING TO INCLUDE INFORMATION FROM STUDY MO25743 ON THE ANTI-TUMOR ACTIVITY OF VEMURAFENIB IN THE TREATMENT OF PATIENTS WITH BRAF V600E MUTATION-POSITIVE MELANOMA WITH BRAIN METASTASES

M-185 UPDATES TO THE LABELING TO INCLUDE RESULTS OF A TRIAL TO EVALUATE THE SAFETY OF MOXIFLOXACIN IN PEDIATRIC PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS

M-186 UPDATES TO THE PRODUCT INFORMATION REGARDING MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS BASED UPON THE RESULTS FROM STUDY 331-10-232

M-187 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING

M-188 PROVIDES FOR DATA SUPPORTING THE SAFETY AND EFFECTIVENESS FOR THE MAINTENANCE TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER (BED)

EXCLUSIVITY MISCELLANEOUS

M-189 LABELING DESCRIBING THE EXPECTED REDUCTION OF ABUSE OF SINGLE-ENTITY MORPHINE BY THE INTRANASAL ROUTE OF ADMINISTRATION DUE TO PHYSICOCHEMICAL PROPERTIES

M-190 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE LACK OF EFFICACY OF TARCEVA IN MAINTENANCE TREATMENT OF PATIENTS WITHOUT EGFR MUTATIONS

M-191 ADDITION OF DATA BASED ON PEDIATRIC STUDIES TO FULFILL THE POSTMARKETING REQUIREMENT 1857-2

M-192 PROVIDES FOR DATA EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS

M-193 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA

M-194 INFORMATION ADDED TO THE LABELING REGARDING USE OF REGADENOSON ADMINISTRATION FOLLOWING AN INADEQUATE EXERCISE STRESS TEST AS COMPARED TO REGADENOSON ALONE

M-195 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING REFLECTING LACK OF EFFICACY FOR IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17

M-196 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM A RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY OF INTRAVENOUS ACETAMINOPHEN FOR THE TREATMENT OF ACUTE PAIN IN PEDIATRIC PATIENTS TO FULFILL THE POST-MARKETING REQUIREMENT 1704-1

M-197 NEW CLINICAL DATA ADDED TO THE PRESCRIBING INFORMATION REGARDING CANAGLIFLOZIN ADD-ON COMBINATION THERAPY WITH METFORMIN AND A DIPEPTIDYL-PEPTIDASE-4 INHIBITOR

M-198 PACKAGE INSERT UPDATED WITH RESULTS FROM STUDY CV181168, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN ADDED TO DAPAGLIFLOZIN AND METFORMIN

M-199 INFORMATION ADDED TO LABELING REGARDING THE TREATMENT OF PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD NOT RECEIVED PRIOR SYSTEMIC THERAPY FOR METASTATIC DISEASE.

M-200 CLINICAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING.

M-201 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM AN OPEN LABEL, MULTI-CENTER STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS INCLUDING TUMORS OF THE CENTRAL NERVOUS SYSTEM.

M-202 INCLUSION OF DATA FROM THE SUMMIT STUDY FOR BREO ELLIPTA (FLUTICASONE FUROATE/VILANTEROL TRIFENATATE) INHALATION POWDER IN THE PACKAGE INSERT.

M-203 PROVIDES FOR REVISIONS TO THE PACKAGE INSERT TO REFLECT RESULTS OF TWO POSTMARKETING REQUIREMENT STUDIES ROP111662 AND ROP111569

M-204 CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

M-205 INFORMATION ADDED TO THE LABELING REGARDING RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ON PATIENTS WITH SEVERE RENAL IMPAIRMENT

M-206 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM COMPLERA TO ODEFSEY

M-207 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM ATRIPLA TO ODEFSEY

M-208 INFORMATION ADDED TO THE LABELING TO INCLUDE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

M-209 INFORMATION ADDED TO THE LABELING REGARDING CABAZITAXEL AT 20 MG/M2 BASED ON THE RESULTS OF THE PROSELICA STUDY

M-210 INFORMATION ADDED TO LABELING TO SUPPORT THE USE OF SYMBICORT TO REDUCE EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

M-211 PROVIDES FOR LABELING CHANGES REGARDING THE USE OF DAPTOMYCIN IN THE PEDIATRIC POPULATION FOR STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) BASED ON RESULTS OF A

EXCLUSIVITY MISCELLANEOUS

TRIAL IN PEDIATRIC PATIENTS 1 TO 17 YEARS OF AGE

M-212 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND EXENATIDE EXTENDED RELEASE

M-213 INFORMATION ADDED TO THE LABELING TO INCLUDE THE EFFICACY AND SAFETY OF CARIPRAZINE RELATIVE TO PLACEBO IN THE PREVENTION OF RELAPSE OF SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA

M-214 INFORMATION ADDED TO THE CLINICAL TRIALS SECTION OF THE LABELING REGARDING A POSTMARKETING SAFETY AND EFFICACY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS

M-215 INFORMATION ADDED TO THE LABELING REGARDING THE COMPARISON OF PALIPERIDONE PALMITATE COMPARED WITH ORAL ANTIPSYCHOTIC TREATMENT IN DELAYING TIME TO TREATMENT FAILURE IN ADULTS WITH SCHIZOPHRENIA WHO HAVE BEEN INCARCERATED

M-216 UPDATE THE PRESCRIBING INFORMATION AND PATIENT LABELING WITH FINDINGS FROM STUDY RP103-08 CONDUCTED IN TREATMENT-NAIVE NEPHROPATHIC CYSTINOSIS PATIENTS TO EXPAND THE INDICATED POPULATION TO PATIENTS 1 YEAR AND OLDER

M-217 INCORPORATION OF THE LABELING REVISIONS PROVIDED FOR IN NDA 022253/S-039 AND NDA 022255/S-022 INTO THE LACOSAMIDE INJECTION LABELING

M-218 ADDITIONAL INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS AGED 6 THROUGH 11 YEARS (TRIAL 4)

M-219 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS 7 TO 14 YEARS OF AGE WITH DUCHENNE MUSCULAR DYSTROPHY

M-220 ADDITIONAL INFORMATION ADDED TO THE LABELING FROM STUDY PC B308/13 REGARDING THE USE OF BLUE LIGHT CYSTOSCOPY WITH CYSVIEW AS AN ADJUNCT TO WHITE LIGHT CYSTOSCOPY

M-221 DRUG FACTS LABELING CHANGES UNDER THE DIRECTIONS HEADING TO REVISE THE STATED PREPARATION TIME OF A DRY SITE FROM 120 SECONDS SCRUBBING AND 90 SECONDS DRYING TO 30 SECONDS SCRUBBING AND 30 SECONDS DRYING

M-222 ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1

M-223 INFORMATION ADDED TO SECTION 8.1 OF THE LABELING REGARDING PREGNANT PATIENTS WHO ARE ALREADY ON A STABLE RILPIVIRINE REGIMEN PRIOR TO PREGNANCY AND WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML)

M-224 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF EXENATIDE EXTENDED RELEASE AS ADD-ON IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN GLARGINE WITH OR WITHOUT METFORMIN

M-225 REVISIONS TO SECTION 8.4 OF THE PRESCRIBING INFORMATION TO INCLUDE A SAFETY AND EFFICACY STUDY IN PEDIATRIC PATIENTS AGES >=6 YEARS TO <18 YEARS WITH CHRONIC IDIOPATHIC CONSTIPATION

M-226 CHANGES TO THE LABELING BASED ON RESULTS FROM A CONTROLLED CLINICAL TRIAL IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY

M-227 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER

M-228 INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX

M-229 REVISED LABELING TO INCORPORATE THE PEDIATRIC USE OF LOTEPREDNOL ETABONATE GEL IN PATIENTS FOR THE TREATMENT OF POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY

M-230 REVISIONS TO THE GLECAPREVIR/PIBRENTASVIR COMBINATION PRODUCT PRESCRIBING INFORMATION TO INCLUDE SAFETY AND EFFICACY DATA FROM THE HCV/HIV-1 COINFECTION STUDY M14-730 AND FROM THE LIVER AND RENAL TRANSPLANT STUDY M13-596

M-231 REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION (SECTION 8.3) OF THE PACKAGE INSERT WITH THE RESULTS OF CLINICAL TRIAL WV25651, CONDUCTED TO EVALUATE THE EFFECT OF VALGANCICLOVIR ON SPERMATOGENESIS AND TO FULFILL PMR 1670-3

M-232 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES

M-233 INFORMATION ADDED TO THE LABELING TO DESCRIBE FIXED-DOSE COMBINATION OF TIOTROPIUM BROMIDE AND OLODATEROL TO INCLUDE REDUCTION OF COPD EXACERBATIONS

EXCLUSIVITY MISCELLANEOUS

M-234 UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS

M-235 INFORMATION ADDED TO SECTION 14 OF THE LABELING TO DESCRIBE STUDY LAP016A2307 TO FULFILL POSTMARKETING STUDY REQUIREMENT 1586-1

M-236 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO INCLUDE EFFICACY AND SAFETY DATA FROM A STUDY IN PATIENTS WITH TREATMENT NAIVE CLL/SLL TREATED WITH IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB OR CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB

M-237 INFORMATION ADDED TO LABELING TO DESCRIBE A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN ADOLESCENT SMOKERS

M-238 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF 45 ML/MIN/1.73 M2 OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT

M-239 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A TRIAL CONDUCTED IN TREATMENT NAIVE PEDIATRIC PATIENTS, AGES 2 YEARS TO < 18 YEARS WITH TRANSFUSIONAL IRON OVERLOAD

M-240 INFORMATION ADDED TO LABELING REGARDING A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITES

M-241 INFORMATION ADDED TO THE LABELING FOR SAFETY & EFFICACY STUDY ENTITLED, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (LOW/INT-1 RISK) & TRANSFUSIONAL IRON OVERLOAD

M-242 INFORMATION ADDED TO THE LABELING REGARDING THE EFFICACY AND SAFETY OF INSULIN DEGLUDEC/LIRAGLUTIDE VS INSULIN GLARGINE IN PTS W/ TYPE 2 DIABETES INADEQUATELY CONTROLLED ON SGLT2I WITH OR WITHOUT ORAL ANTIDIABETIC THERAPIES

M-243 INFORMATION ADDED TO LABELING FROM PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH CANCER

M-244 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS

M-245 ADDITIONAL INFORMATION ADDED TO THE LABELING BASED ON SAFETY AND EFFICACY DATA FROM THE IMPACT TRIAL

M-246 ADDITION OF STUDY BRF117277, A NON-RANDOMIZED, OPEN-LABEL, MULTI-CENTER, MULTI-COHORT TRIAL OF DABRAFENIB PLUS TRAMETINIB IN SUBJECTS WITH BRAF MUTATION-POSITIVE MELANOMA THAT HAS METASTASIZED TO THE BRAIN

M-247 REVISIONS TO THE LABELING REGARDING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION AS A CONDITION OF USE FOR INSULIN ASPART

M-248 INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE

M-249 INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY LVM-MD-15 TO FULFILL POSTMARKETING COMMITMENT 1943-4

M-250 REVISIONS TO THE PEDIATRIC USE SECTION TO INCLUDE AN OPEN-LABEL CLINICAL TRIAL TO FULFILL PMR 1655-1

M-251 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING INFLUENZA VIRUS RESISTANCE TO OSELTAMIVIR IN IMMUNOCOMPROMISED PATIENTS

M-252 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME

M-253 INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY P061, A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-SITE, DOUBLE-BLIND STUDY TO EVALUATE SAFETY AND EFFICACY OF SUVOREXANT FOR THE TREATMENT OF INSOMNIA IN SUBJECTS WITH ALZHEIMERS DISEASE

M-254 INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER

M-255 INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY GS-US-320-4018 IN VIROLOGICALLY SUPPRESSED ADULTS W/ CHRONIC HEP B INFECTION WHO SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALAFENAMIDE

EXCLUSIVITY MISCELLANEOUS

M-256 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION TO FULFILL A POST-MARKETING REQUIREMENT

M-257 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE USE OF PLAQUE PSORIASIS OF THE SCALP

M-258 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4

M-259 INFORMATION ADDED TO THE LABELING REGARDING SAFETY AND EFFICACY IN SUBJECTS WITH HCV SUBTYPE 3B INFECTION

M-260 INFORMATION ADDED TO THE LABELING DESCRIBING A RANDOMIZED, OPEN-LABEL STUDY THAT EXAMINED THE CONCOMITANT USE OF DIMETHYL FUMARATE AND SEVERAL NON-LIVE VACCINES IN ADULTS 27-55 YEARS OF AGE WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS

M-261 ADDITIONAL INFORMATION ADDED TO THE LABELING REGARDING THE USE IN PATIENTS ON CHRONIC HEMODIALYSIS

M-262 REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE PACKAGE INSERT TO INCLUDE THE RESULT OF STUDY P146 TO FULFILL THE REQUIREMENTS OF PMR 3003-4

M-263 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY ICL670E2419 (THETIS TRIAL) TO SUPPORT PMR 3342-2 AND 3342-3

M-264 INFORMATION ADDED TO THE LABELING DESCRIBING A PHASE 2, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY/EFFICACY OF SOFOSBUVIR/VELPATASVIR IN SUBJECTS WITH CHRONIC HCV INFECTION WHO HAVE RECEIVED A LIVER TRANSPLANT

M-265 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2

M-266 INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY GS-US-320-4035 IN VIROLOGICALLY SUPPRESSED ADULTS W/ CHRONIC HEP B INFECTION WHO SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALFAENAMIDE

M-267 INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY LUAA21004-402

M-268 ADDITION OF INFORMATION TO THE LABEL REGARDING A CLEAR PRODUCT PRESENTATION AND 26 ML VOLUME PRODUCTS

M-269 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1

M-270 INFORMATION ADDED TO CLINICAL PHARMACOLOGY SECTION

M-271 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY HRA2914-5016

M-272 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1

M-273 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 207966 ATLAS-2M

M-274 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY CBAF312A2130

M-275 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV

M-276 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1200.120, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST

M-277 UPDATES THE US PRESCRIBING INFORMATION WITH CLINICAL DATA REGARDING THE USE OF SOFOSBUVIR AND VELPATASVIR FOR THE TREATMENT OF CHRONIC HCV GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION IN PEOPLE WHO INJECT DRUGS (PWID), INCLUDING THOSE ON MEDICATION-ASSISTED TREATMENT (MAT) FOR OPIOID USE DISORDER

M-278 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULT OF STUDY GO29665

M-279 INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF FIGARO-DKD STUDY

M-280 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDIES E7389-G000-223 AND E7389-G000-213, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST

M-281 REVISIONS TO THE LABELING TO PROVIDE FOR THE EXPANSION OF THE USE OF STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME IN PATIENTS TAKING CLOBAZAM TO INCLUDE PEDIATRIC PATIENTS WHO ARE 6 MONTHS TO LESS THAN 2 YEARS OF AGE AND WEIGHING 7 KG OR MORE

M-282 REVISIONS TO THE LABELING TO ADD THE RESULTS OF A CLINICAL STUDY (TA-303) IN PATIENTS WITH ED FOLLOWING BILATERAL NERVE-SPARING RADICAL PROSTATECTOMY

M-283 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULT OF STUDY

EXCLUSIVITY MISCELLANEOUS

	HESTIA3
M-284	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM GALILEO TRIAL
M-285	REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
M-286	INFORMATION ADDED TO CLINICAL PHARMACOLOGY SECTION TO INCLUDE RESULTS FROM STUDY ORGN001-102
M-287	LABELING REGARDING NEW DOSING REGIMEN IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND TREATMENT OF PAH IN PEDIATRIC PATIENTS (AGES 1-17)
M-288	INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF STUDY APL2-308
M-289	INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF MVT-601-035
M-290	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULT OF STUDY HZA114971
M-291	REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE PACKAGE INSERT TO INCLUDE THE RESULT OF STUDY P145
M-292	REVISIONS TO THE LABELING TO DESCRIBE MODIFIED FORMULATION BASED ON RESULTS OF STUDIES EM-05-014624 AND EM-05-014815
M-293	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E2006-A001-113
M-294	INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY 205860
M-295	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
M-296	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
M-297	LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY MYK-461-017
M-298	LABELING REVISIONS RELATED TO STUDY D1699CC00001
M-299	CLINICAL STUDY INFORMATION ADDED TO THE LABEL ABOUT THE TREATMENT OF MODERATE TO SEVERE GENITAL PSORIASIS
M-300	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST
M-301	CLINICAL STUDY INFORMATION ADDED TO LABEL ABOUT THE TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN PATIENTS WITH SEVERELY REDUCED RENAL FUNCTION (ESTIMATED GLOMERULAR FILTRATION RATE, EGFR < 30 ML/MIN)
M-302	INFORMATION ADDED TO LABELING REGARDING OSTEOSARCOMA

ORPHAN DRUG EXCLUSIVITY

ODE-1	TO REDUCE CHRONIC DROOLING IN PATIENTS AGED 3 - 16 WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING (E.G. CEREBRAL PALSY)
ODE-2	FOR TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
ODE-3	TO TREAT INFANTILE SPASMS
ODE-4	TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION
ODE-5	FOR SEQUENTIAL USE FOR THE TREATMENT OF CYANIDE POISONING THAT IS JUDGED TO BE LIFE-THREATENING
ODE-6	FOR THE MANAGEMENT OF POSTHERPETIC NEURALGIA
ODE-7	TO REDUCE THE RISK OF PRETERM BIRTH IN WOMEN WITH SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
ODE-8	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
ODE-9	TREATMENT OF ASYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-10	FOR USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER

ORPHAN DRUG EXCLUSIVITY

ODE-11	TREATMENT OF PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-12	TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-13	TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA WITH THE BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-14	TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA IN ADULTS 18 YEARS OF AGE AND OLDER
ODE-15	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA APPROVED TEST
ODE-16	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY IS INADEQUATE
ODE-17	ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE OR OLDER
ODE-19	TREATMENT OF PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS, INCLUDING PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
ODE-20	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A G551D MUTATION IN THE CFTR GENE.
ODE-21	AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY
ODE-22	FOR THE CONTROL OF HYPERGLYCEMIA SECONDARY TO HYPERCORTISOLISM IN ADULT PATIENTS WITH ENDOGENOUS CUSHING'S SYNDROME WHO HAVE TYPE 2 DIABETES MELLITUS OR GLUCOSE INTOLERANCE AND HAVE FAILED SURGERY OR ARE NOT CANDIDATES FOR SURGERY
ODE-23	ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
ODE-24	TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) NOT REQUIRING IMMEDIATE SURGERY
ODE-25	MANAGEMENT OF POSTHERPETIC NEURALGIA IN ADULTS.
ODE-26	TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
ODE-27	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
ODE-28	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
ODE-29	LOCALIZATION OF LYMPH NODES DRAINING A PRIMARY TUMOR IN PATIENTS WITH MELANOMA WHEN USED WITH A HAND-HELD GAMMA COUNTER
ODE-30	TREATMENT OF ADULT PATIENTS WITH CHRONIC, ACCELERATED OR BLAST PHASE PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH RESISTANCE, OR INTOLERANCE TO PRIOR THERAPY
ODE-31	TREATMENT OF CORNEAL CYSTINE CRYSTAL ACCUMULATION IN PATIENTS WITH CYSTINOSIS
ODE-32	TREATMENT OF ADULT PATIENTS WITH CHRONIC OR ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE AND/OR INTOLERANCE TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKI)
ODE-33	TREATMENT OF PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER (MTC)
ODE-34	TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-35	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) THAT IS RESISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY.
ODE-36	ADJUNCT TO A LOW-FAT DIET AND OTHER LIPID-LOWERING TREATMENTS, INCLUDING LDL APHERESIS WHERE AVAILABLE, TO REDUCE LDL-C, TC, APOLIPOPROTEIN B, & NON-HDL-C IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
ODE-37	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
ODE-38	PART OF COMBINATION THERAPY IN ADULTS (GREATER THAN OR EQUAL TO 18 YEARS) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)

ORPHAN DRUG EXCLUSIVITY

ODE-39	TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L.
ODE-40	TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN COMBINATION WITH CHEMOTHERAPY, APPROVED UNDER NDA #21588/S-037
ODE-41	ADJUNCT TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LDL-C, APOLIPOPROTEIN B (APO B), TOTAL CHOLESTEROL (TC), AND NON-HIGH DENSITY LIPOPROTEIN-CHOLESTEROL (NON-HDL-C) IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
ODE-42	USE AS A NITROGEN-BINDING ADJUNCTIVE THERAPY FOR CHRONIC MGMT OF ADULT AND PEDIATRIC PATIENTS AT LEAST 2 YRS WITH UREA CYCLE DISORDERS THAT CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
ODE-43	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND BORTEZOMIB AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY.
ODE-44	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE.
ODE-45	MANAGEMENT OF NEPHROPATHIC CYSTINOSIS IN ADULTS AND CHILDREN AGES 6 YEARS AND OLDER.
ODE-46	IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS REGARDLESS OF THEIR POST-ICTUS NEUROLOGICAL CONDITION
ODE-47	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA APPROVED TEST.
ODE-48	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA APPROVED TEST
ODE-49	TREATMENT OF MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
ODE-50	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST.
ODE-51	TOPICAL TREATMENT OF STAGE 1A AND 1B MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN-DIRECTED THERAPY
ODE-52	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS AS FIRST-LINE TREATMENT, IN COMBINATION WITH GEMCITABINE.
ODE-53	TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) WHO GROUP 1, TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING.
ODE-54	TX OF PAH TO DELAY DISEASE PROGRESSION. DISEASE PROGRESSION INCLUDED: DEATH, INITIATION OF IV OR SC PROSTANOIDS, OR CLINICAL WORSENING OF PAH (DECREASED 6-MINUTE WALK DISTANCE, WORSENED PAH SYMPTOMS AND NEED FOR ADDITIONAL PAH TREATMENT).
ODE-55	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-56	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DCT) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT.
ODE-57	TRAMETINIB IN COMBO WITH DABRAFENIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
ODE-58	DABRAFENIB IN COMBO WITH TRAMETINIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
ODE-59	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
ODE-60	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED

ORPHAN DRUG EXCLUSIVITY

	AT LEAST ONE PRIOR THERAPY
ODE-61	TREATMENT OF NEUROGENIC SYMPTOMATIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE-BETA-HYDROXYLASE DEFICIENCY, AND NONDIABETIC AUTONOMIC NEUROPATHY
ODE-62	TREATMENT OF PROLIFERATING INFANTILE HEMANGIOMA REQUIRING SYSTEMIC THERAPY.
ODE-63	TREATMENT OF VISCERAL LEISHMANIASIS DUE TO LEISHMANIA DONOVANI; CUTANEOUS LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS, LEISHMANIA GUYANENSIS, AND LEISHMANIA PANAMENSIS; AND MUCOSAL LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS.
ODE-64	SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC)
ODE-65	TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS PART OF A COMBINATION REGIMEN.
ODE-66	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB.
ODE-67	GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
ODE-68	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
ODE-69	TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK
ODE-70	RELAPSED CLL, IN COMBO. WITH RITUXIMAB, IN PATIENTS FOR WHOM RITUXIMAB ALONE WOULD BE CONSIDERED APPROPRIATE THERAPY DUE TO OTHER CO-MORBIDITIES; AND RELAPSED SLL IN PATIENTS WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
ODE-71	RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA (FL) IN PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-72	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-73	LONG-TERM TREATMENT OF ADULT PATIENTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS (EMS), INTERMEDIATE METABOLIZERS (IMS), OR POOR METABOLIZERS (PMS) AS DETECTED BY AN FDA-CLEARED TEST.
ODE-74	TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
ODE-75	TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
ODE-76	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE NOT RECEIVED AT LEAST 1 PRIOR THERAPY
ODE-77	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
ODE-78	TREATMENT OF HYPERCALCEMIA IN ADULT PATIENTS WITH PRIMARY HYPERPARATHYROIDISM FOR WHOM PARATHYROIDECTOMY WOULD BE INDICATED ON THE BASIS OF SERUM CALCIUM LEVELS, BUT WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY.
ODE-79	TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
ODE-80	TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
ODE-81	TREATMENT OF PATIENTS WITH ACROMEGALY WHO HAVE HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
ODE-82	TREATMENT OF PATIENTS WITH UNRESECTABLE,WELL- OR MODERATELY-DIFFERENTIATED LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO IMPROVE PROGRESSION-FREE SURVIVAL
ODE-83	USE OF AS MONOTHERAPY FOR PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA MUTATED (AS DETECTED BY AN FDA-APPROVED TEST) ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
ODE-84	TREATMENT OF MOTOR FLUCTUATIONS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE
ODE-85	AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES
ODE-86	TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
ODE-87	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE,

ORPHAN DRUG EXCLUSIVITY

	RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
ODE-88	FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
ODE-89	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR REGIMENS, INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT
ODE-90	TREATMENT OF INVASIVE MUCORMYCOSIS IN PATIENTS 18 YEARS OF AGE AND OLDER
ODE-91	TREATMENT OF BILE ACID SYNTHESIS DISORDERS DUE TO SINGLE ENZYME DEFECTS
ODE-92	TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
ODE-93	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR F508DEL MUTATION IN THE CFTR GENE
ODE-94	PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY TRANSPLANT PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-95	FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-96	TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS
ODE-97	TO EXPAND THE INDICATION TO PEDIATRIC PATIENTS 2-6 YEARS OF AGE WITH NEPHROPATHIC CYSTINOSIS
ODE-98	TREATMENT OF HEREDITARY OROTIC ACIDURIA
ODE-99	FOR USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, FOR THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED FOLLOWING GEMCITABINE-BASED THERAPY
ODE-100	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA OR LEIOMYOSARCOMA WHO RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
ODE-101	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATION, IN COMBINATION WITH VEMURAFENIB. COTELLIC IS NOT INDICATED FOR TREATMENT OF PATIENTS WITH WILD-TYPE BRAF MELANOMA
ODE-102	FOR TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), AS DETECTED BY AN FDA-APPROVED TEST, WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
ODE-103	USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-104	EMERGENCY TX OF PTS FOLLOWING A FU OR CAPECITABINE OD, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING TOXICITY AFFECTING THE CARDIAC SYSTEM OR CNS, AND/OR EARLY-ONSET, UNUSUALLY SEVERE AR W/IN 96 HRS FOLLOWING THE END OF FU OR CAPECITABINE ADMIN.
ODE-105	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-106	FOR USE OF UPTRAVI (SELEXIPAG) TABLETS, 200, 400, 600, 800, 1000, 1200, 1400, AND 1600 MCG FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH, WHO GROUP I) TO REDUCE THE RISKS OF DISEASE PROGRESSION AND HOSPITALIZATION FOR PAH
ODE-107	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
ODE-108	TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-109	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE THERAPY)
ODE-110	FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
ODE-111	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE.

ORPHAN DRUG EXCLUSIVITY

ODE-112	FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).
ODE-113	FOR TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH ACQUIRED METHEMOGLOBINEMIA.
ODE-114	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-115	TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
ODE-116	TREATMENT OF PROGRESSIVE KERATOCONUS
ODE-117	FOR TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-118	AN ADJUNCT TO DIET TO REDUCE LDL-C, TOTAL-C, NONHDL-C AND APOB IN CHILDREN AND ADOLESCENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS (E.G., LDL APHERESIS)
ODE-119	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
ODE-120	FOR USE AFTER RADIOLABELING WITH GA 68, WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS.
ODE-121	TREATMENT OF CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY
ODE-122	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
ODE-123	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6-11 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-124	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE FORMULATIONS, WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE, IN ADULTS WITH THE FOLLOWING SEIZURE TYPES: PARTIAL WITH COMPLEX SYMPTOMOLOGY, GENERALIZED CLONIC-TONIC, AND MIXED
ODE-125	INDICATED IN PEDIATRIC PATIENTS 10 YEARS AND OLDER FOR THE PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4 AND CKD STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
ODE-126	AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES
ODE-127	TREATMENT OF SPINAL MUSCULAR ATROPHY IN PEDIATRIC AND ADULT PATIENTS
ODE-128	TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
ODE-129	INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDS. PATIENTS WITH CLASS 3 BETA-THALASSEMIA
ODE-130	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER
ODE-131	TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
ODE-132	TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
ODE-133	INDICATED FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-134	TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
ODE-135	TREATMENT OF CHRONIC HCV GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-136	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS

ORPHAN DRUG EXCLUSIVITY

ODE-137	TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS
ODE-138	TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS A COMPONENT OF A COMBINATION CHEMOTHERAPY MAINTENANCE REGIMEN
ODE-139	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC OR LIVER CANCER) WHO HAVE BEEN PREVIOUSLY TREATED WITH THE DRUG SORAFENIB.
ODE-140	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
ODE-141	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 MUTATION-POSITIVE AS DETECTED BY AN FDA APPROVED TEST, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION
ODE-142	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-143	TO DECREASE THE RECURRENCE OF PNEUMOTHORAX IN ADULTS
ODE-144	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
ODE-145	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
ODE-146	OPTICAL IMAGING AGENT INDICATED IN PATIENTS WITH GLIOMA (SUSPECTED WORLD HEALTH ORGANIZATION GRADES III OR IV ON PREOPERATIVE IMAGING) AS AN ADJUNCT FOR THE VISUALIZATION OF MALIGNANT TISSUE DURING SURGERY
ODE-147	DABRAFENIB IN COMBINATION WITH TRAMETINIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-148	TRAMETINIB IN COMBINATION WITH DABRAFENIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-149	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
ODE-150	TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.
ODE-151	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-152	TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
ODE-153	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
ODE-154	FOR USE IN CHILDREN AGES 2 TO 12 YEARS OLD WITH CHAGAS DISEASE
ODE-155	TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-156	TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY
ODE-157	FOR USE AS A NITROGEN-BINDING AGENT FOR CHRONIC MANAGEMENT OF PEDIATRIC PATIENTS >=2 MONTHS AND < 2 YEARS OF AGE WITH UREA CYCLE DISORDERS (UCDS) WHO CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
ODE-158	TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
ODE-159	FOR TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE, METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST, EXCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-160	FOR TREATMENT OF SCURVY IN ADULT AND PEDIATRIC PATIENTS AGE 5 MONTHS AND OLDER FOR WHOM ORAL ADMINISTRATION IS NOT POSSIBLE, INSUFFICIENT OR CONTRAINDICATED
ODE-161	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) IN PEDIATRIC PATIENTS AGED 3 YRS AND OLDER WITH IDIOPATHIC OR CONGENITAL PAH TO IMPROVE PULMONARY VASCULAR RESISTANCE (PVR), WHICH IS EXPECTED TO RESULT IN AN

ORPHAN DRUG EXCLUSIVITY

	IMPROVEMENT IN EXERCISE ABILITY
ODE-162	TREATMENT OF NEPHROPATHIC CYSTINOSIS IN PEDIATRIC PATIENTS 1 YEAR OF AGE TO LESS THAN 2 YEARS OF AGE
ODE-163	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)
ODE-164	TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
ODE-165	PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN ADULT CMV-SEROPOSITIVE RECIPIENTS [R+] OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
ODE-166	TREATMENT OF SOMATOSTATIN RECEPTOR-POSITIVE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) INCLUDING FOREGUT, MIDGUT, AND HINDGUT NEUROENDOCRINE TUMORS IN ADULTS
ODE-167	ARSENIC TRIOXIDE FOR USE IN COMBINATION WITH TRETINOIN FOR TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
ODE-168	FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-169	FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
ODE-170	FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY (AGHD)
ODE-171	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) IN CHRONIC PHASE
ODE-172	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR THERAPY
ODE-173	TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS AGED 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR
ODE-174	FOR THE TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
ODE-175	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-176	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
ODE-177	TO REDUCE THE FREQUENCY OF PAINFUL CRISES AND TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS IN PEDIATRIC PATIENTS, 2 YEARS OF AGE AND OLDER, WITH SICKLE CELL ANEMIA WITH RECURRENT MODERATE TO SEVERE PAINFUL CRISIS
ODE-178	INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
ODE-179	TREATMENT OF PATIENTS WITH CLL AND TREATMENT OF PATIENTS WITH INDOLENT B-CELL NHL THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
ODE-180	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-181	TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
ODE-182	TRAMETINIB IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION

ORPHAN DRUG EXCLUSIVITY

ODE-183	TRAMETINIB AND DABRAFENIB IN COMBINATION, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
ODE-184	INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH HIV-1 INFECTION
ODE-185	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-186	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R
ODE-187	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
ODE-188	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGES 2 TO LESS THAN 6 YEARS WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, AND R117H
ODE-189	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: 711+3A-G, E831X, 2789+5G-A, 3272-26A-G, AND 3849+10KBC-T
ODE-190	TX OF CF IN PTS 2 YRS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, D1270N
ODE-191	TO DECREASE THE RECURRENCE OF MALIGNANT PLEURAL EFFUSIONS IN SYMPTOMATIC PATIENTS FOLLOWING MAXIMAL DRAINAGE OF THE PLEURAL EFFUSION
ODE-192	INDICATED TO INDUCE CONTROLLED CARDIAC SEPTAL INFRACTION TO IMPROVE EXERCISE CAPACITY IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY WHO ARE NOT CANDIDATES FOR SURGICAL MYECTOMY
ODE-193	INDICATED FOR THE TREATMENT OF ONCHOCERCIASIS DUE TO ONCHOCERCA VOLVULUS IN PATIENTS AGED 12 YEARS AND OLDER
ODE-194	ENCORAFENIB IS INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
ODE-195	FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 THROUGH 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-196	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
ODE-197	INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
ODE-198	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM
ODE-199	THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 12 MONTHS AND OLDER WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-200	INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
ODE-201	INDICATED FOR THE RADICAL CURE (PREVENTION OF RELAPSE) OF PLASMODIUM VIVAX MALARIA IN PATIENTS AGED 16 YEARS AND OLDER WHO ARE RECEIVING APPROPRIATE ANTIMALARIAL THERAPY FOR ACUTE P. VIVAX INFECTION
ODE-202	INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS IN PEDIATRIC PATIENTS WITH PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS (PNAC)
ODE-203	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-204	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY
ODE-205	INDICATED FOR THE TREATMENT OF ADULTS WITH A CONFIRMED DIAGNOSIS OF FABRY DISEASE AND AN AMENABLE GALACTOSIDASE ALPHA GENE (GLA) VARIANT BASED ON IN VITRO ASSAY DATA

ORPHAN DRUG EXCLUSIVITY

ODE-206	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-207	TREATMENT OF STATUS EPILEPTICUS IN ADULTS
ODE-208	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) AFTER AT LEAST TWO PRIOR THERAPIES
ODE-209	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) AFTER AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-210	INDICATED IN COMBINATION WITH STANDARD IMMUNOSUPPRESSIVE THERAPY FOR THE FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
ODE-211	INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-212	INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
ODE-213	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-214	TX OF MAC LUNG DISEASE IN ADULTS WITH LIMITED OR NO ALTERNATIVE TX OPTIONS AS PART OF A COMBO ANTIBACTERIAL DRUG REGIMEN WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER A MINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMEN THERAPY
ODE-215	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION
ODE-216	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-217	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DIESASE
ODE-218	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON ALECTINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
ODE-219	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
ODE-220	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY
ODE-221	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE NO SATISFACTORY ALTERNATIVE TREATMENTS OR THAT HAVE PROGRESSED FOLLOWING TREATMENT
ODE-222	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WHO HAVE RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-223	TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS)
ODE-224	INDICATED, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE >=75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-225	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
ODE-226	MAINTENANCE TREATMENT OF ADULTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR

ORPHAN DRUG EXCLUSIVITY

	PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
ODE-227	INDICATED FOR TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
ODE-228	INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER
ODE-229	TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
ODE-230	FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR (EGFR) MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-231	INDICATED FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEDIATRIC PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY
ODE-232	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1,2,3,4,5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A)
ODE-233	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH
ODE-234	INDICATED FOR THE TREATMENT OF STABLE SYMPTOMATIC HEART FAILURE DUE TO DILATED CARDIOMYOPATHY (DCM) IN PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER, WHO ARE IN SINUS RHYTHM WITH AN ELEVATED HEART RATE
ODE-235	INDICATED FOR THE TREATMENT OF ACUTE HERPETIC KERATITIS (DENDRITIC ULCERS) IN PATIENTS WITH HERPES SIMPLEX (HSV-1 AND HSV-2) VIRUS
ODE-236	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 MONTHS TO LESS THAN 12 MONTHS WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-237	TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) IN ADULTS TO REDUCE CARDIOVASCULAR MORTALITY AND CARDIOVASCULAR-RELATED HOSPITALIZATION
ODE-238	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
ODE-239	TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-240	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
ODE-241	INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
ODE-242	TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST IN ADULT PTS WHO ARE >=75 YRS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-243	ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
ODE-244	TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) IN PATIENTS 6 TO LESS THAN 17 YEARS OF AGE
ODE-245	INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
ODE-246	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
ODE-247	TX OF PTS W/ CYSTIC FIBROSIS (CF) AGE 6 TO <12 YRS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR W/ AT LEAST 1 MUTATION IN CF TRANSMEMBRANE CONDUCTANCE REGULATORY GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
ODE-248	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE

ORPHAN DRUG EXCLUSIVITY

ODE-249	TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGE 6 YEARS TO LESS THAN 12 YEARS WHO ARE HOMOZYGOUS FOR F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR GENE THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
ODE-250	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
ODE-251	INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS (12 TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 30 KG) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
ODE-252	TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
ODE-253	INDICATED AS PART OF A COMBINATION REGIMEN WITH BEDAQUILINE AND LINEZOLID FOR THE TREATMENT OF ADULTS WITH PULMONARY EXTENSIVELY DRUG RESISTANT (XDR) OR TREATMENT-INTOLERANT OR NONRESPONSIVE MULTIDRUG-RESISTANT (MDR) TUBERCULOSIS (TB)
ODE-254	INDICATED TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
ODE-255	INDICATED FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN ADULT PATIENTS WITH NARCOLEPSY
ODE-256	FOR HIV-1 INFECTION IN PEDIATRIC PTS AT LEAST 25 KG W/ NO ANTIRETROVIRAL (ARV) TX HX OR TO REPLACE CURRENT ARV REGIMEN FOR VIROLOGICALLY-SUPPRESSED ON STABLE ARV W/ NO HX TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W/ RESISTANCE TO BIC, FTC, OR TAF
ODE-257	IN COMBO W/ DEXAMETHASONE FOR ADULTS W/ RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO RECEIVED AT LEAST 4 PRIOR THERAPIES AND REFRACTORY TO AT LEAST 2 PROTEASOME INHIBITORS, AT LEAST 2 IMMUNOMODULATORY AGENTS, AND AN ANTI-CD38 MONOCLONAL ANTIBODY
ODE-258	FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-259	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF)
ODE-260	INDICATED TO INCREASE SYSTEMIC EXPOSURE OF ATAZANAVIR IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35 KG
ODE-261	INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
ODE-262	TREATMENT OF PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
ODE-263	TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH DECOMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-264	TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION WHO ARE LIVER TRANSPLANT RECIPIENTS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-265	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ROS1-POSITIVE
ODE-266	ADULT & PED >=12YRS OLD W/ SOLID TUMORS THAT HAVE NTRK W/O KNOWN ACQUIRED RESISTANCE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY & HAVE EITHER PROGRESSED FOLLOWING TX OR HAVE NO SATISFACTORY ALTERNATIVE TX
ODE-267	INDICATED IN COMBINATION WITH HIGH FLUID INTAKE, ALKALI, AND DIET MODIFICATION, FOR THE PREVENTION OF CYSTINE STONE FORMATION IN PEDIATRIC PATIENTS 20KG TO 9 YEARS OF AGE W/SEVERE HOMOZYGOUS CYSTINURIA, WHO ARE NOT RESPONSIVE TO THESE MEASURES ALONE
ODE-268	INDICATED FOR TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE

ORPHAN DRUG EXCLUSIVITY

ODE-269	PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY TRANSPLANT, LIVER TRANSPLANTS, AND HEART TRANSPLANT, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-270	INDICATED TO INCREASE PAIN FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
ODE-271	INDICATED IN COMBINATION WITH OTHER ANTI-MYELOMA PRODUCTS FOR THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA (MM)
ODE-272	INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION
ODE-273	INDICATED FOR THE TREATMENT OF ADULTS WITH ACUTE HEPATIC PORPHYRIA (AHP)
ODE-274	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-275	INDICATED FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
ODE-276	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-277	TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
ODE-278	TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED BY GENOMIC INSTABILITY & PROGRESSED >6 MONTHS AFTER RESPONSE TO THE LAST PLATINUM-BASED CHEMOTHERAPY
ODE-279	INDICATED FOR THE ACUTE TX OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E. SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT’S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 6 YEARS OF AGE AND OLDER
ODE-280	INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
ODE-281	INDICATED FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
ODE-282	INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM)
ODE-283	MAINTENANCE TX OF ADULTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DZ HAS NOT PROGRESSED ON >=16WKS OF 1ST LINE PLATINUM BASED CHEMO REGIMEN. SELECT PTS FOR THERAPY BASED ON APPROVED COMPANION DIAGNOSTIC
ODE-284	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 35KG
ODE-285	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS OTHER THAN PROTEASE INHIBITORS THAT REQUIRE A CYP3A INHIBITOR, FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 25KG AND LESS THAN 35KG
ODE-286	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CUSHING’S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-287	TREATMENT OF ADULTS WITH NEWLY DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
ODE-288	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
ODE-289	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)
ODE-290	INDICATED FOR THE INITIAL TREATMENT OF SEVERE MALARIA IN ADULT AND PEDIATRIC PATIENTS TO ALWAYS BE FOLLOWED BY A COMPLETE TREATMENT COURSE OF AN APPROPRIATE ORAL ANTIMALARIAL REGIMEN
ODE-291	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE A MUTATION THAT LEADS TO MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING AS DETECTED BY AN FDA-APPROVED TEST
ODE-292	INDICATED FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE

ORPHAN DRUG EXCLUSIVITY

	LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST
ODE-293	TX OF PED PTS 6 YRS OF AGE & OLDER OR WEIGHING AT LEAST 17 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-294	PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY OR HEART TRANSPLANTS, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-295	INDICATED FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
ODE-296	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
ODE-297	FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE
ODE-298	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE RECEIVED PRIOR TREATMENT WITH 3 OR MORE KINASE INHIBITORS, INCLUDING IMATINIB
ODE-299	INDICATED FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS AND OLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOID SARCOMA NOT ELIGIBLE FOR COMPLETE RESECTION
ODE-300	FOR THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST, NOT INCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-301	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
ODE-302	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
ODE-303	ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
ODE-304	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
ODE-305	TREATMENT OF INVASIVE ASPERGILLOSIS
ODE-306	W/ BEVACIZUMAB FOR MAINT TX OF ADULTS W/ ADV EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CA IN COMPLETE OR PARTIAL RESPONSE TO 1ST LINE PT BASED CHEMO & WHOSE CA IS ASSOC W/ HOMOLOGOUS RECOMB DEF + STATUS DEFINED BY GENOMIC INSTABILITY
ODE-307	INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS 5 YEARS AND OLDER TO LESS THAN 12 YEARS OF AGE AND WEIGHING AT LEAST 15 KG WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)
ODE-308	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE CAPACITY
ODE-309	INDICATED FOR USE IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE FOR TREATMENT OF ADULT PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER AND BRAIN METASTASES, WHO HAVE RECEIVED ONE OR MORE PRIOR ANTI-HER2-BASED REGIMENS IN THE METASTATIC SETTING
ODE-310	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
ODE-311	INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS FOR THE TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH MOLECULARLY CONFIRMED LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD)
ODE-312	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-313	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION, ARE METASTATIC OR

ORPHAN DRUG EXCLUSIVITY

	WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY, AND HAVE EITHER PROGRESSED FOLLOWING TREATMENT OR HAVE NO SATISFACTORY ALTERNATIVE THERAPY
ODE-314	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES, AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
ODE-315	FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
ODE-316	TREATMENT OF ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), INCLUDING PREVIOUSLY TREATED AND UNTREATED, DE NOVO AND SECONDARY MDS WITH THE FOLLOWING FRENCH-AMERICAN-BRITISH SUBTYPES (REFRACTORY ANEMIA, REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS, REFRACTORY ANEMIA WITH EXCESS BLASTS, AND CHRONIC MYELOMONOCYTIC LEUKEMIA [CMML]) AND INTERMEDIATE-1, INTERMEDIATE-2, AND HIGH-RISK INTERNATIONAL PROGNOSTIC SCORING SYSTEM GROUPS.
ODE-317	FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
ODE-318	TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST
ODE-319	INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI
ODE-320	INDICATED FOR CONTINUED TREATMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR COMPLETE REMISSION WITH INCOMPLETE BLOOD COUNT RECOVERY (CRI) FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY
ODE-321	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 4 MONTHS TO LESS THAN 6 MONTHS WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-322	TREATMENT OF NARCOLEPSY
ODE-323	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE A MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA
ODE-324	TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES
ODE-325	TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING ALTERATIONS
ODE-326	TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS BETWEEN 1 AND 2 YEARS OF AGE
ODE-327	ADD-ON MAINTENANCE THERAPY TO IMPROVE PULMONARY FUNCTION IN ADULT PATIENTS 18 YEARS OF AGE AND OLDER WITH CYSTIC FIBROSIS AND WHO HAVE PASSED THE BRONCHITOL TOLERANCE TEST
ODE-328	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE
ODE-329	FOR THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PEDIATRIC PATIENTS 3 TO 15 YEARS OF AGE
ODE-330	THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PATIENTS 16 YEARS OF AGE AND OLDER
ODE-331	TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NACROLEPSY
ODE-332	TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (TSC) IN PATIENTS 1 YEAR OF AGE AND OLDER
ODE-333	PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
ODE-334	TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) IN PATIENTS 2 MONTHS OF AGE AND OLDER
ODE-335	FOR TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE AT LEAST ONE OF THE ADDITIONAL MUTATIONS IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT HAVE BEEN IDENTIFIED AS RESPONSIVE TO

ORPHAN DRUG EXCLUSIVITY

	TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND IDENTIFIED IN THE APPROVAL ON DECEMBER 21, 2020
ODE-336	INDICATED FOR CHRONIC WEIGHT MANAGEMENT IN ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH OBESITY DUE TO PROOPIOMELANOCORTIN (POMC), PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 1 (PCSK1), OR LEPTIN RECEPTOR (LEPR) DEFICIENCY CONFIRMED BY GENETIC TESTING DEMONSTRATING VARIANTS IN POMC, PCSK1, OR LEPR GENES THAT ARE INTERPRETED AS PATHOGENIC, LIKELY PATHOGENIC, OR OF UNCERTAIN SIGNIFICANCE (VUS)
ODE-337	FOR ADJUVANT THERAPY AFTER TUMOR RESECTION IN ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
ODE-338	FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 4 MONTHS AND OLDER WHO HAVE ONE OF THE ADDITIONAL MUTATIONS IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT HAVE BEEN IDENTIFIED AS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON IN VITRO DATA AND IDENTIFIED IN THE APPROVAL ON DECEMBER 21, 2020
ODE-339	TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) TO LOWER URINARY OXALATE LEVELS IN PEDIATRIC AND ADULT PATIENTS
ODE-340	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
ODE-341	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
ODE-342	INDICATED TO REDUCE THE RISK OF MORTALITY IN PATIENTS WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A
ODE-343	FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
ODE-344	FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
ODE-345	IN PEDIATRIC AND ADULT PATIENTS AS ADJUNCTIVE THERAPY TO STANDARD OF CARE FOR THE TREATMENT OF ACUTE HYPERAMMONEMIA DUE TO PROPIONIC ACIDEMIA (PA) OR METHYLMALONIC ACIDEMIA (MMA)
ODE-346	FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY, EXCLUDING ADULT PATIENTS COVERED BY XPOVIO'S PREVIOUS INDICATION FOR MULTIPLE MYELOMA APPROVED ON JULY 3, 2019
ODE-347	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING
ODE-348	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST FOUR PRIOR LINES OF THERAPY AND WHOSE DISEASE IS REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT, AND ONE CD-38 DIRECTED MONOCLONAL ANTIBODY
ODE-349	TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST, EXCLUDING PATIENTS WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DISEASE; OR ALECTINIB OR CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
ODE-350	TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER
ODE-351	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
ODE-352	TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY
ODE-353	FOR TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST
ODE-354	TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULT AND PEDIATRIC PATIENTS, INCLUDING NEONATES

ORPHAN DRUG EXCLUSIVITY

ODE-355 FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER

ODE-356 FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM). ADVSM INCLUDES PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), AND MAST CELL LEUKEMIA (MCL)

ODE-357 FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 6 THROUGH 11 YEARS OLD WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA

ODE-358 FOR THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS (VKC) IN CHILDREN AND ADULTS

ODE-359 FOR THE TREATMENT OF BOTH THE FIRST-STAGE (HEMOLYMPHATIC) AND SECOND-STAGE (MENINGOENCEPHALITIC) HUMAN AFRICAN TRYPANOSOMIASIS (HAT) DUE TO TRYPANOSOMA BRUCEI GAMBIENSE IN PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 20 KG

ODE-360 FOR PROPHYLAXIS OF ORGAN REJECTION IN ADULT AND PEDIATRIC PATIENTS RECEIVING ALLOGENEIC LUNG TRANSPLANT

ODE-361 INDICATED FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY

ODE-362 TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY

ODE-363 TREATMENT OF PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

ODE-364 TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU (VHL) DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA (RCC), CENTRAL NERVOUS SYSTEM (CNS) HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS (PNET), NOT REQUIRING IMMEDIATE SURGERY

ODE-366 INDICATED FOR THE TREATMENT OF ADULTS WITH UNRESECTABLE OR METASTATIC GIST HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION, INCLUDING PDGFRA D842V MUTATIONS

ODE-367 PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER FOR THE TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA (CDAD)

ODE-368 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST

ODE-369 THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) IN ADULTS

ODE-370 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE ANTI-CD20-BASED REGIMEN

ODE-371 TREATMENT OF ADULT PATIENTS WITH WALDENSTRM'S MACROGLOBULINEMIA (WM)

ODE-372 FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A); AND TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH

ODE-373 TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER

ODE-374 TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 INSERTION MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY

ODE-375 THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE

ODE-376 FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 6 YEARS OF AGE WEIGHING LESS THAN 17 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH

ORPHAN DRUG EXCLUSIVITY

	DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-377	AS AN ADJUNCTIVE TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS (GRANULOMATOSIS WITH POLYANGIITIS [GPA] AND MICROSCOPIC POLYANGIITIS [MPA])
ODE-378	A COMPLETE REGIMEN FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN PEDIATRIC PATIENTS WEIGHING 14 KG TO LESS THAN 25 KG WHO HAVE NO ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF BIKTARVY
ODE-379	FOR TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH ALAGILLE SYNDROME (ALGS) 1 YEAR OF AGE AND OLDER
ODE-380	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH ACCELERATED PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR (TKI) THERAPY
ODE-381	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP) WITH THE T315I MUTATION
ODE-382	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP), PREVIOUSLY TREATED WITH TWO OR MORE TYROSINE KINASE INHIBITORS (TKIS)
ODE-383	FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR THE LOCALIZATION OF KNOWN SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS
ODE-384	TO REDUCE THE RISK OF OTOTOXICITY ASSOCIATED WITH CISPLATIN IN PEDIATRIC PATIENTS 1 MONTH OF AGE AND OLDER WITH LOCALIZED, NON-METASTATIC SOLID TUMORS
ODE-385	FOR TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-386	FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA)
ODE-387	TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES
ODE-388	FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG) WITH POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTION/DISEASE THAT IS REFRACTORY TO TREATMENT (WITH OR WITHOUT GENOTYPIC RESISTANCE) WITH GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET
ODE-389	TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) AT RISK OF RAPID DISEASE PROGRESSION, GENERALLY A URINE PROTEIN-TO-CREATININE RATIO (UPCR) > OR = 1.5 G/G
ODE-390	AS AN ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT LESIONS IN ADULT PATIENTS WITH OVARIAN CANCER
ODE-391	TREATMENT OF FACIAL ANGIOFIBROMA ASSOCIATED WITH TUBEROUS SCLEROSIS IN ADULTS AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER
ODE-392	TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY
ODE-393	TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-394	FOR TREATMENT OF SICKLE CELL DISEASE (SCD) IN PEDIATRIC PATIENTS 4 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE
ODE-395	TREATMENT OF SEIZURES ASSOCIATED WITH CYCLIN-DEPENDENT KINASE-LIKE 5 (CDKL5) DEFICIENCY DISORDER (CDD) IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-396	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH SEVERE MANIFESTATIONS OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) WHO REQUIRE SYSTEMIC THERAPY
ODE-397	TREATMENT OF ADULTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF) WITH A PLATELET COUNT BELOW 50 X 10^9/L
ODE-398	TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS

ORPHAN DRUG EXCLUSIVITY

ODE-399	TREATMENT OF PEDIATRIC PATIENTS AGED ONE MONTH AND OLDER WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)
ODE-400	TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) IN PEDIATRIC PATIENTS BETWEEN BIRTH AND 2 MONTHS OF AGE
ODE-401	TREATMENT OF ADULT PATIENTS WITH STABLE WILSON'S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE
ODE-402	FOR CHRONIC WEIGHT MANAGEMENT IN ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH MONOGENIC OR SYNDROMIC OBESITY DUE TO BARDET-BIEDL SYNDROME (BBS)
ODE-403	TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS TAKING CLOBAZAM WHO ARE 6 MONTHS TO LESS THAN 2 YEARS OF AGE AND WEIGHING 7 KG OR MORE
ODE-404	TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT
ODE-405	TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
ODE-406	TO IMPROVE KIDNEY FUNCTION IN ADULTS WITH HEPATORENAL SYNDROME WITH RAPID REDUCTION IN KIDNEY FUNCTION
ODE-407	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH UNRESECTABLE, RECURRENT, OR REFRACTORY INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) THAT IS ALK-POSITIVE
ODE-408	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 1 YEAR TO LESS THAN 2 YEARS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-409	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
ODE-410	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA HARBORING FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) GENE FUSIONS OR OTHER REARRANGEMENTS
ODE-411	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS
ODE-412	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST
ODE-413	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-414	TREATMENT OF NEONATAL SEIZURES IN TERM AND PRETERM INFANTS
ODE-415	TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) TO LOWER PLASMA OXALATE LEVELS IN PEDIATRIC AND ADULT PATIENTS
ODE-416	TREATMENT OF ADULT PATIENTS WITH HISTIOCYTIC NEOPLASMS
ODE-417	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT PATIENTS WITH THALASSEMIA SYNDROMES EXCLUDING ADULT PATIENTS COVERED BY THE INDICATION FOR THALASSEMIA SYNDROMES APPROVED ON OCTOBER 14, 2011
ODE-418	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
ODE-419	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT AND PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
ODE-420	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
ODE-421	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT AND PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
ODE-422	TREATMENT OF ADULT PATIENTS WITH RAS WILD-TYPE, HER2-POSITIVE UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY
ODE-423	FOR PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT RECIPIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE [D+/R-])
ODE-424	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR
ODE-425	TREATMENT OF RETT SYNDROME IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND

ORPHAN DRUG EXCLUSIVITY

OLDER

ODE-426 FOR USE IN PATIENTS 18 YEARS OF AGE OR OLDER WHO HAVE LIMITED OR NO ALTERNATIVE OPTIONS FOR THE TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS

ODE-427 TREATMENT OF FRIEDREICH'S ATAXIA IN ADULTS AND ADOLESCENTS AGED 16 YEARS AND OLDER

ODE-428 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY

ODE-429 TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 1 YEAR OF AGE WITH ALAGILLE SYNDROME (ALGS)

ODE-430 TREATMENT OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA (PI3K DELTA) SYNDROME (APDS) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

ODE-431 TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN ADULTS WITH NARCOLEPSY

ODE-432 TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE

ODE-433 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 2 YEARS TO LESS THAN 6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA

ODE-434 TREATMENT OF ADULT PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS (ISM)

ODE-435 THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS 1 MONTH TO LESS THAN 4 MONTHS OF AGE WHO HAVE AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA

ODE-436 TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS)

ODE-437 FOR USE IN COMBINATION WITH STANDARD INDUCTION AND CONSOLIDATION, AND AS MAINTENANCE THERAPY FOLLOWING CONSOLIDATION CHEMOTHERAPY, FOR THE TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 INTERNAL TANDEM DUPLICATION (ITD)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST

ODE-438 AS A LIVER-DIRECTED TREATMENT FOR ADULT PATIENTS WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES AFFECTING LESS THAN 50% OF THE LIVER AND NO EXTRAHEPATIC DISEASE OR EXTRAHEPATIC DISEASE LIMITED TO THE BONE, LYMPH NODES, SUBCUTANEOUS TISSUES, OR LUNG THAT IS AMENABLE TO RESECTION OR RADIATION

ODE-439 FOR THE REDUCTION IN VOLUME OF NEW HETEROTOPIC OSSIFICATION IN ADULTS AND PEDIATRIC PATIENTS AGED 8 YEARS AND OLDER FOR FEMALES AND 10 YEARS AND OLDER FOR MALES WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)

ODE-440 FOR TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE

ODE-441 TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF OR SECONDARY MF [POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL THROMBOCYTHEMIA (ET)], IN ADULTS WITH ANEMIA

ODE-442 TO MOBILIZE HEMATOPOIETIC STEM CELLS TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

ODE-443 TO LOWER URINARY OXALATE LEVELS IN CHILDREN 9 YEARS OF AGE AND OLDER AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1) AND RELATIVELY PRESERVED KIDNEY FUNCTION, E.G., EGFR GREATER THAN OR EQUAL TO 30 ML/MIN/1.73 M^2

ODE-444 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY

ODE-445 TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST

ODE-446 TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN ADULT PATIENTS WHO ARE ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE

ODE-447 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES (MDS) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST

ODE-448 TREATMENT OF PEDIATRIC PATIENTS OLDER THAN 1 MONTH UP TO 12 YEARS OF AGE WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN

ORPHAN DRUG EXCLUSIVITY

	SEVERE MORBIDITY, AND HAVE PROGRESSED FOLLOWING TREATMENT OR HAVE NO SATISFACTORY ALTERNATIVE THERAPY
ODE-449	TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS LESS THAN 5 YEARS OF AGE WITH ACHONDROPLASIA WITH OPEN EPIPHYSES
ODE-450	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-451	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR
ODE-452	FOR ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS WHO REQUIRE SYSTEMIC TREATMENT
ODE-453	TREATMENT OF INVASIVE MUCORMYCOSIS IN PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER
ODE-454	TREATMENT OF INVASIVE MUCORMYCOSIS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WHO WEIGH 16 KG AND GREATER
ODE-455	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WITH ADENOCARCINOMA HISTOLOGY
ODE-456	TREATMENT OF ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
ODE-457	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 14 KG TO LESS THAN 25 KG
ODE-458	TREATMENT OF INVASIVE ASPERGILLOSIS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WHO WEIGH 16 KILOGRAMS (KG) AND GREATER
ODE-459	TREATMENT OF INVASIVE ASPERGILLOSIS IN PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER

PATENT USE

U-1	PREVENTION OF PREGNANCY
U-2	TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
U-3	TREATMENT OF HYPERTENSION
U-4	PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
U-5	METHOD OF PRODUCING BRONCHODILATION
U-6	METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
U-7	INCREASING CARDIAC CONTRACTILITY
U-8	ACUTE MYOCARDIAL INFARCTION
U-9	CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
U-10	DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS
U-11	TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
U-12	METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
U-13	A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
U-14	ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
U-15	METHOD OF LOWERING INTRAOCULAR PRESSURE
U-16	USE IN LUNG SCANNING PROCEDURES
U-17	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-18	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-19	TREATMENT OF INFLAMMATION
U-20	A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
U-21	TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
U-22	METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND

PATENT USE

	METABOLISM IN WARM-BLOODED ANIMALS
U-23	METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
U-24	METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
U-25	REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
U-26	REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27	DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28	CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29	CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
U-30	CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31	INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32	PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33	TREATING VIRAL INFECTIONS IN A MAMMAL
U-34	TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35	TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36	METHODS OF TREATING BACTERIAL ILLNESSES
U-37	METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38	TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39	ANGINA PECTORIS
U-40	METHOD OF TREATMENT OF BURNS
U-41	METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42	ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43	MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA
U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48	ANALGESIA
U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY
U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55	TREATMENT OF PAIN
U-56	AID TO SMOKING CESSATION
U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY

PATENT USE

U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS
U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA
U-71	METHOD OF TREATMENT OF HEART FAILURE
U-72	TREATMENT OF MIGRAINE
U-73	METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES
U-84	A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-85	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-86	METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
U-87	METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
U-88	TREATMENT OF MODERATE PLAQUE PSORIASIS
U-89	TREATMENT OR PROPHYLAXIS OF EMESIS
U-90	TREATMENT OF PSYCHOTIC DISORDERS
U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY
U-93	USE AS AN ANTIHISTAMINE/DECONGESTANT
U-94	TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED
U-95	SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
U-96	METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
U-97	A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
U-98	A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
U-99	METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
U-100	METHOD OF TREATING OCULAR INFLAMMATION
U-101	ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE

PATENT USE

U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS
U-109	ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PESSARY
U-111	DIABETES
U-112	CONTRACEPTION
U-113	METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
U-114	USE FOR INHIBITING BONE RESORPTION
U-115	USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
U-116	METHOD OF MYOCARDIAL IMAGING
U-117	TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
U-118	METHOD OF LOWERING BLOOD SUGAR LEVEL
U-119	TREATMENT OF NASAL HYPERSECRETION
U-120	CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
U-121	METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122	A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123	METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124	TREATMENT OF ACNE
U-125	TREATMENT NEUROGENERATIVE DISEASES
U-126	TREATMENT OF GASTRITIS
U-127	METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128	METHOD FOR TREATMENT OF TUMORS
U-129	METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130	MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131	PHOTODAMAGED SKIN
U-132	INHIBITING HIV PROTEASE
U-133	MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134	TREATMENT OF ACNE VULGARIS
U-135	ANTITUMOR AGENT
U-136	PROCESS FOR WASTE NITROGEN REMOVAL
U-137	METHOD OF TREATING BACTERIAL VAGINOSIS
U-138	TREATMENT OF ALLERGIC RHINITIS
U-139	TREATMENT OF ALLERGIC REACTIONS
U-140	USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141	TREATMENT OF ULCERATIVE COLITIS
U-142	METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143	BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING

PATENT USE

U-144	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146	METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147	DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2
U-148	DEVICE FOR COLLECTING A BREATH SAMPLE
U-149	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150	METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151	RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152	METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
U-153	TREATMENT OF INITIAL EPISODE GENITAL HERPES
U-154	METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-155	TREATMENT OF ERECTILE DYSFUNCTION
U-156	METHOD OF PROVIDING ANESTHESIA
U-157	TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
U-158	ANGINA
U-159	TREATMENT OF INTERSTITIAL CYSTITIS
U-160	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED

PATENT USE

	HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOPE OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197	USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198	TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
U-199	METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
U-200	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202	METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203	TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204	USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205	METHOD FOR TREATING HEARTBURN
U-206	METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
U-207	USE AS NASAL SPRAY
U-208	VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209	VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
U-210	METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211	USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212	METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214	USE AS A BLOOD GLUCOSE-LOWERING AGENT

PATENT USE

U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKINSON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS
U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS
U-248	TREATMENT OF HIV
U-249	METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
U-250	TREATMENT OF HEPATITIS B INFECTION

PATENT USE

U-251	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
U-252	METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
U-253	ORAL TRANSMUCOSAL USE
U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
U-265	USE AS LAXATIVE
U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION

PATENT USE

U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA
U-289	TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
U-290	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294	TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296	TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
U-297	PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298	METHOD OF COMBATING BACTERIA IN A PATIENT
U-299	TREATMENT OF ADENOMATOUS POLYPS
U-300	INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
U-302	TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303	METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
U-304	A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
U-305	METHODS FOR USING THE DRUG PRODUCT
U-306	TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307	CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308	CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS

PATENT USE

U-322	TREATMENT OF ALZHEIMER'S DEMENTIA
U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITIONS EMPLOYING OLANZAPINE
U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
U-344	METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
U-345	RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
U-346	METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMACOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
U-347	METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
U-348	METHOD OF USE FOR INHIBITING HIV INFECTION
U-349	METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
U-350	PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-351	INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR
U-352	INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-353	PREVENTION AND TREATMENT OF OSTEOPOROSIS
U-354	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-355	METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING

PATENT USE

U-356	DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
U-357	USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
U-358	DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
U-359	METHOD OF USE OF VISICOL
U-360	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-361	MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
U-362	USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
U-363	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
U-364	TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-365	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
U-366	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
U-367	TREATMENT OF CARDIOVASCULAR DISORDERS
U-368	HEARTBURN
U-369	METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
U-370	INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
U-371	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHOMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABILIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA

PATENT USE

U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P
U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
U-406	METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407	METHOD OF TREATING OTOPATHY
U-408	FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409	METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
U-410	METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-411	METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
U-412	TREATMENT OF TYPE 2 DIABETES
U-413	USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
U-414	A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-415	A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-416	A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-417	COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

PATENT USE

U-419	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420	METHOD OF TREATMENT OF TYPE II DIABETES
U-421	USE FOR SEDATION
U-422	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424	FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
U-425	METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-426	PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
U-427	METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
U-428	METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
U-429	METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
U-430	METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
U-431	POSTTRAUMATIC STRESS DISORDER
U-432	REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
U-433	USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
U-434	CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
U-435	A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
U-436	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
U-437	METHOD OF USE EQUAL TO PROCESS OF PREPARATION
U-438	TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
U-439	TREATMENT OF OBESITY
U-440	METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
U-441	METHOD OF TREATING MS BY ADMINISTERING COPAXONE
U-442	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
U-443	MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
U-444	TREATMENT OF MIGRAINE
U-445	USE AS AN ANTIMYCOTIC AGENT
U-446	TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-447	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-448	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-449	USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER

PATENT USE

U-450	INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
U-451	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-452	USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
U-453	TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
U-454	METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
U-455	TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
U-456	METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
U-457	METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
U-458	METHOD OF USE OF IMAGENT
U-459	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-460	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
U-461	METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
U-462	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
U-463	VENOGRAPHY
U-464	PERIPHERAL ARTERIOGRAPHY
U-465	CT IMAGING OF THE HEAD
U-466	TREATMENT OF IRRITABLE BOWEL SYNDROME
U-467	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
U-468	METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
U-469	TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
U-470	THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
U-471	METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
U-472	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
U-473	TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
U-474	TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
U-475	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-476	METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-477	METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
U-478	METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
U-479	METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
U-480	CONTRAST AGENT FOR MRI

PATENT USE

U-481	DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
U-482	METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
U-483	METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
U-484	METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
U-485	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-486	EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
U-487	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-488	METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
U-489	EXPECTORANT
U-490	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-491	METHOD OF DELIVERING A DRUG TO THE LUNG
U-492	METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
U-493	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-494	TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
U-495	PERITONEAL DIALYSIS SOLUTION
U-496	METHOD FOR TREATING CHRONIC RENAL FAILURE
U-497	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
U-498	INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
U-499	METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
U-500	USE AS AN ANTIHYPERTENSIVE AGENT
U-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
U-502	PITYRIASIS VERSICOLOR
U-503	GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
U-504	TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
U-505	ULTRASOUND CONTRAST AGENT
U-506	PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
U-507	ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
U-508	METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
U-509	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-510	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
U-511	USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
U-512	USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA

PATENT USE

U-513	METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA
U-514	PREVENTION OF OVULATION IN A WOMAN
U-515	TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
U-516	METHOD OF TREATING A PSYCHOTIC DISEASE
U-517	STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
U-518	OBSESSIVE COMPULSIVE DISORDER
U-519	POST OPERATIVE NAUSEA AND VOMITING
U-520	PREMENOPAUSAL OSTEOPOROSIS
U-521	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-522	TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
U-523	METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
U-524	METHOD OF TREATING DIARRHEA
U-525	METHOD OF TREATING PARASITIC INFECTIONS
U-526	METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
U-527	METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
U-528	PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
U-529	ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
U-530	TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOMPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
U-531	TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
U-532	TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
U-533	ERECTILE DYSFUNCTION
U-534	HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
U-535	TREATMENT OF SOCIAL ANXIETY DISORDER
U-536	CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
U-537	TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
U-538	FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
U-539	TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-540	TREATMENT OF FUNGAL INFECTIONS
U-541	METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
U-542	METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
U-543	TREATMENT OF SCHIZOPHRENIA
U-544	TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
U-545	METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
U-546	USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
U-547	MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER

PATENT USE

U-548	A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
U-549	USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
U-550	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-551	METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
U-552	TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
U-553	MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS
U-554	TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
U-555	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
U-556	USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
U-557	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-558	INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
U-559	METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
U-560	METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
U-561	COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
U-562	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-563	MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
U-564	TREATMENT OF HIV IN CONCOMITANT THERAPY
U-565	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
U-566	FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-567	METHOD OF TREATING INFERTILITY
U-568	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
U-569	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
U-570	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
U-571	TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
U-572	INTENSIVE CARE UNIT SEDATION
U-573	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-574	PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-575	LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.
U-576	ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
U-577	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN

PATENT USE

U-578	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
U-579	TREATMENT OF EPILEPSY AND/OR MIGRAINE.
U-580	TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
U-581	METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
U-582	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
U-583	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
U-584	SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
U-585	TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
U-586	AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
U-587	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
U-588	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
U-589	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
U-590	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955
U-591	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
U-592	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
U-593	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
U-594	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
U-595	35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-596	TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-597	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
U-598	PROPHYLACTIC TREATMENT OF MIGRAINE
U-599	METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
U-600	A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
U-601	TREATMENT OF BIPOLAR DISORDER
U-602	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
U-603	METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
U-604	METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION

PATENT USE

U-605	TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
U-606	USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
U-607	CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
U-608	USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
U-609	USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
U-610	ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
U-611	METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
U-612	TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
U-613	REDUCTION OF SERUM PHOSPHATE
U-614	TREATMENT OF SEXUAL DYSFUNCTION
U-615	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-616	MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
U-617	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-618	USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
U-619	TREATMENT OF MALIGNANT NEOPLASM
U-620	TREATMENT OF INSOMNIA
U-621	METHOD OF TREATING CANCER
U-622	TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
U-623	SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
U-624	REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
U-625	ALLERGIC RHINITIS OR NASAL POLYPS
U-626	CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
U-627	TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
U-628	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-629	METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
U-630	TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
U-631	TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN
U-632	METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING
U-633	METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR

PATENT USE

U-634	METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL
U-635	TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS
U-636	TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
U-637	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
U-638	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
U-639	TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
U-640	USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGLYCEMIA
U-641	USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION
U-642	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-643	THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE
U-644	TREATMENT OF SEASONAL ALLERGIC RHINITIS
U-645	TREATMENT OF ASTHMA
U-646	METHOD OF TREATING OTITIS
U-647	TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-648	THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN
U-649	A METHOD FOR TREATING A TUMOR DISEASE
U-650	TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
U-651	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
U-652	TREATMENT OF CARDIAC ARRHYTHMIA
U-653	STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
U-654	LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4
U-655	TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS
U-656	REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-657	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-658	TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER
U-659	TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
U-660	TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE
U-661	TREATMENT OF SEIZURE DISORDER
U-662	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-663	THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
U-664	TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION
U-665	METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
U-666	METHOD OF TREATING ADHD
U-667	MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE
U-668	LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT

PATENT USE

	OF PATIENTS WITH DIABETES MELLITUS
U-669	INDICATION OF TYPE II DIABETES
U-670	TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
U-671	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4
U-672	TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
U-673	METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML
U-674	METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
U-675	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
U-676	METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION
U-677	A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
U-678	METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-679	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-680	A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
U-681	TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-682	NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
U-683	PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE
U-684	TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-685	EXPECTORANT AND COUGH SUPPRESSANT
U-686	EXPECTORANT AND NASAL DECONGESTANT
U-687	REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-688	TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-689	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-690	TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-691	USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-692	USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
U-693	THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
U-694	LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
U-695	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-696	TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

PATENT USE

U-697	A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-698	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA
U-699	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-700	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-701	TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
U-702	TOPICAL AEROSOL HAIR REGROWTH TREATMENT
U-703	TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
U-704	METHOD OF ADMINISTERING INSULIN VIA INHALATION
U-705	TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
U-706	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
U-707	ALLERGIC RHINITIS
U-708	TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
U-709	METHOD OF COMBATING BACTERIA IN A PATIENT
U-710	A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549
U-711	ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
U-712	A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA
U-713	TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
U-714	TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM
U-715	FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER
U-716	THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
U-717	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-718	TREATMENT OF FUNGAL INFECTIONS
U-719	TREATMENT OF PSYCHOSIS
U-720	TREATMENT OF NEUROLEPTIC DISEASES
U-721	TREATMENT OF INFLUENZA
U-722	PROPHYLAXIS OF INFLUENZA
U-723	PROPHYLACTIC TREATMENT OF MIGRAINE
U-724	METHOD OF TREATING SEIZURES
U-725	ALLERGIC RHINITIS AND URTICARIA
U-726	ALLERGIC RHINITIS
U-727	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
U-728	METHOD FOR TREATING BACTERIAL INFECTION
U-729	TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-730	USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS
U-731	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-732	ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)

PATENT USE

U-733	MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
U-734	FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS
U-735	METHOD OF TREATING CHRONIC IRON OVERLOAD
U-736	METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
U-737	DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE
U-738	INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
U-739	METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT
U-740	FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
U-741	COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER
U-742	TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
U-743	ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
U-744	TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS
U-745	TREATMENT OR PREVENTION OF EMESIS
U-746	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-747	PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-748	A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
U-749	METHOD OF CONTRACEPTION
U-750	TREATMENT OF HIV-1 INFECTION IN ADULTS
U-751	ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA
U-752	SUNSCREEN
U-753	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
U-754	USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA
U-755	TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
U-756	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-757	USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
U-758	TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER
U-759	METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
U-760	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS
U-761	TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
U-762	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-763	ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
U-764	TREATMENT OF SCHIZOPHRENIA
U-765	METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
U-766	TREATMENT OF SEIZURES
U-767	MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
U-768	A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID
U-769	REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

PATENT USE

U-770	LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-771	METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELLITUS, IN A HUMAN PATIENT
U-772	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
U-773	PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-774	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
U-775	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
U-776	TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.
U-777	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-778	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-779	A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
U-780	A METHOD FOR THE TREATMENT OF CANCER
U-781	FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
U-782	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTENT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
U-783	DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER
U-784	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
U-785	USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
U-786	PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS
U-787	MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
U-788	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE
U-789	TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
U-790	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
U-791	GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
U-792	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-793	FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-794	CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
U-795	METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE
U-796	METHOD OF TREATING DEPRESSION
U-797	METHOD OF TREATING ANXIETY
U-798	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID

PATENT USE

U-799	METHOD FOR INHIBITING SEROTONIN UPTAKE
U-800	TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
U-801	METHOD OF TREATING CANCER
U-802	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
U-803	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
U-804	TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
U-805	TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
U-806	INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS
U-807	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION
U-808	THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
U-809	TREATMENT OF CHRONIC IDIOPATHIC URTICARIA
U-810	METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE
U-811	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA
U-812	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-813	MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-814	TREATMENT OF SCHIZOPHRENIA
U-815	TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING
U-816	DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER
U-817	NASAL ADMINISTRATION OF CYANOCOBALAMIN
U-818	TOPICAL TREATMENT OF ACNE VULGARIS
U-819	MANAGEMENT OF FIBROMYALGIA
U-820	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER
U-821	METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.
U-822	USE IN LIPID MANAGEMENT
U-823	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE
U-824	METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
U-825	USE FOR PREVENTION OF BREAST CANCER
U-826	RELIEF OF MODERATE TO SEVERE PAIN
U-827	USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
U-828	PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
U-829	TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY
U-830	TREATMENT OF RELAPSED SMALL CELL LUNG CANCER
U-831	METHOD OF ADMINISTERING LANREOTIDE ACETATE
U-832	ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.
U-833	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE

PATENT USE

U-834	INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION
U-835	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER
U-836	A METHOD FOR THE TREATMENT OF LEUKEMIAS
U-837	GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS
U-838	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE
U-839	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-840	TREATMENT FOR TYPE 2 DIABETES MELLITUS
U-841	INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER
U-842	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
U-843	METHOD FOR ADMINISTRATION OF TESTOSTERONE
U-844	PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
U-845	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
U-846	USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE
U-847	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-848	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-849	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
U-850	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-851	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-852	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-853	TREATMENT OR PREVENTION OF EMESIS
U-854	PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
U-855	METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION
U-856	SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-857	INHIBITION OF TRANSPLANT REJECTION
U-858	PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-859	EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD
U-860	FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
U-861	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-862	ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
U-863	TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY

PATENT USE

U-864	PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-865	TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
U-866	THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
U-867	TREATMENT OF MIGRAINE
U-868	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA
U-869	METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
U-870	METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
U-871	METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
U-872	TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-873	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
U-874	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-875	FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE
U-876	TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-877	FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
U-878	A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
U-879	A METHOD OF TREATING OR PREVENTING ILEUS
U-880	ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-881	TREATMENT OF NON-SMALL CELL LUNG CANCER
U-882	MANAGEMENT OF FIBROMYALGIA (FM)
U-883	TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
U-884	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
U-885	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
U-886	ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA
U-887	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-888	FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
U-889	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)
U-890	REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-891	USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE
U-892	TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
U-893	CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
U-894	TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER
U-895	TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-896	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER
U-897	METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
U-898	USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH

PATENT USE

	SHORT BOWEL SYNDROME
U-899	USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-900	INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION
U-901	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
U-902	USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
U-903	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS
U-904	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
U-905	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
U-906	PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS
U-907	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER
U-908	PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS
U-909	TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-910	TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY
U-911	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
U-912	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-913	TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
U-914	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-915	TREATMENT OF MUSCULOSKELETAL CONDITIONS
U-916	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
U-917	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-918	TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
U-919	FOR THE TREATMENT OF DERMATITIS
U-920	STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
U-921	TREATMENT OF ACNE VULGARIS
U-922	FOR THE TREATMENT OF FUNGAL INFECTIONS
U-923	METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
U-924	TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS
U-925	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
U-926	MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
U-927	METHOD FOR INCREASING TEAR PRODUCTION
U-928	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-929	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
U-930	TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
U-931	RELIEF OF MODERATE TO SEVERE ACUTE PAIN

PATENT USE

U-932	PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI
U-933	FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-934	IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA
U-935	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER
U-936	USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
U-937	TREATMENT OF PROSTATE CANCER
U-938	TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-939	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-940	METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA
U-941	METHOD TO TREAT OVARIAN CANCER
U-942	METHOD TO TREAT MULTIPLE MYELOMA
U-943	GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
U-944	TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-945	SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION
U-946	TREATMENT OF BREAST CANCER
U-947	WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS
U-948	TREATMENT OF DIABETES MELLITUS
U-949	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
U-950	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
U-951	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
U-952	USE AS AN ANALGESIC
U-953	METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
U-954	CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
U-955	PROPHYLACTIC TREATMENT OF MIGRAINE
U-956	TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE
U-957	A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
U-958	METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
U-959	METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
U-960	METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
U-961	METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING

PATENT USE

	IXABEPILONE
U-962	SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-963	PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-964	ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-965	USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
U-966	TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
U-967	A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
U-968	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-969	TREATMENT OF MIGRAINE
U-970	TOPICAL TREATMENT OF LICE INFESTATIONS
U-971	INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
U-972	MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
U-973	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
U-974	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-975	TREATMENT OF PULMONARY HYPERTENSION
U-976	IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
U-977	TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
U-978	METHOD OF TREATING HYPONATREMIA
U-979	RELIEF OF MUSCLE SPASM
U-980	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-981	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-982	A METHOD OF TREATING OSTEOPOROSIS
U-983	METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
U-984	METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
U-985	TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-986	TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR
U-987	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
U-988	TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350
U-989	FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-990	TREATMENT OF PROTOZOAL INFECTION
U-991	TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS
U-992	REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION
U-993	METHOD OF TREATING INFERTILITY

PATENT USE

U-994	METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
U-995	METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN
U-996	AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA
U-997	TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
U-998	ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
U-999	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
U-1000	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS
U-1001	METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION
U-1002	METHOD OF TREATING INFLAMMATORY CONDITIONS
U-1003	A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW
U-1004	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1005	METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
U-1006	NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
U-1007	METHOD OF TREATING GOUT FLARES
U-1008	APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION
U-1009	METHOD FOR ADMINISTRATION OF TESTOSTERONE
U-1010	TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION
U-1011	USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
U-1012	METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION
U-1013	METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-1014	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-1015	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1016	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS
U-1017	A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-1018	TREATMENT OF PULMONARY HYPERTENSION BY INHALATION
U-1019	TREATMENT OF PULMONARY HYPERTENSION
U-1020	METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
U-1021	SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER
U-1022	FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION
U-1023	TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
U-1024	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP
U-1025	TREATING FREQUENT HEARTBURN

PATENT USE

U-1026	A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.
U-1027	REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL
U-1028	A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY
U-1029	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
U-1030	IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
U-1031	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1032	USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS
U-1033	TOPICAL TREATMENT OF ACNE VULGARIS
U-1034	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
U-1035	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1036	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
U-1037	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST
U-1038	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
U-1039	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN
U-1040	INHIBITION OF THROMBIN IN A PATIENT
U-1041	TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE
U-1042	METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
U-1043	MANAGEMENT OF MODERATE TO SEVERE PAIN
U-1044	TOPICAL TREATMENT OF SCALP PSORIASIS
U-1045	MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY
U-1046	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY
U-1047	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
U-1048	WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES
U-1049	PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
U-1050	USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS
U-1051	TREATMENT OF OROPHARYNGEAL CANDIDIASIS
U-1052	RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
U-1053	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
U-1054	ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS
U-1055	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
U-1056	TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
U-1057	TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
U-1058	USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-1059	ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA
U-1060	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS

PATENT USE

U-1061	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
U-1062	ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE
U-1063	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
U-1064	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-1065	METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-1066	METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
U-1067	TREATMENT OF CANCER
U-1068	TREATMENT OF ASTHMA
U-1069	A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
U-1070	A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE
U-1071	METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION
U-1072	THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
U-1073	USE FOR THE TREATMENT OF ASTHMA AND COPD
U-1074	USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT
U-1075	USE FOR THE TREATMENT OF ASTHMA
U-1076	REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
U-1077	PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION
U-1078	TREATMENT OF ACNE
U-1079	REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1080	METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT
U-1081	LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1082	USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS
U-1083	ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
U-1084	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-1085	METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME
U-1086	TREATMENT OF AUTOIMMUNE DISEASE
U-1087	DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
U-1088	RELIEF OF MUSCLE SPASM
U-1089	INHIBITION OF THROMBIN
U-1090	LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
U-1091	ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA
U-1092	TREATMENT OF BREAST CANCER
U-1093	TREATMENT OF PSEUDOBULBAR AFFECT
U-1094	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN

PATENT USE

U-1095	METHOD OF TREATING OCULAR INFLAMMATION
U-1096	TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
U-1097	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
U-1098	METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
U-1099	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1100	REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
U-1101	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
U-1102	METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
U-1103	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-1104	USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN
U-1105	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
U-1106	TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT
U-1107	TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT
U-1108	TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE
U-1109	TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-1110	METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
U-1111	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1112	METHOD OF MR IMAGING OF A MAMMAL
U-1113	TREATMENT AND PROPHYLAXIS OF INFLUENZA
U-1114	TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA
U-1115	TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
U-1116	METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
U-1117	TREATMENT OF BREAST CANCER
U-1118	USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-1119	CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
U-1120	TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL
U-1121	METHOD OF TREATING TRAVELERS' DIARRHEA
U-1122	TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES
U-1123	TREATMENT OF ALCOHOL DEPENDENCE
U-1124	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION
U-1125	METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS
U-1126	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL
U-1127	TREATMENT OF PATENT DUCTUS ARTERIOSUS
U-1128	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
U-1129	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT

PATENT USE

	NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1130	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1131	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1132	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1133	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1134	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1135	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C
U-1136	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1137	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1138	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1139	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1140	REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1141	REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1142	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1143	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1144	REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1145	REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1146	REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1147	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1148	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1149	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1150	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C
U-1151	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
U-1152	CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
U-1153	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
U-1154	TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB

PATENT USE

U-1155	USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
U-1156	TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA (HPA)
U-1157	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1158	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1159	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
U-1160	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER
U-1161	FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
U-1162	TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP
U-1163	METHOD OF TREATING THROMBOSIS
U-1164	METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION
U-1165	USE FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1166	A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
U-1167	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
U-1168	THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-1169	MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN
U-1170	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1171	REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
U-1172	TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
U-1173	TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
U-1174	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
U-1175	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1176	TREATMENT OR PREVENTION OF STROKE
U-1177	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1178	RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
U-1179	TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
U-1180	TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
U-1181	A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT
U-1182	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
U-1183	A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN
U-1184	TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA

PATENT USE

U-1185	TREATMENT OF OPIOID-INDUCED CONSTIPATION
U-1186	ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
U-1187	TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)
U-1188	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
U-1189	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
U-1190	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
U-1191	METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFONYLUREA(INCL GLIPIZIDE, GLIMEPIRIDE & GLYBURIDE)
U-1192	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
U-1193	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)
U-1194	METHOD FOR TREATING INSOMNIA
U-1195	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA
U-1196	RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS
U-1197	METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
U-1198	RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE
U-1199	TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-1200	REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
U-1201	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
U-1202	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-1203	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-1204	TREATMENT OF UVEITIS
U-1205	TREATMENT OF MACULAR EDEMA
U-1206	DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX
U-1207	INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIVE ESOPHAGITIS
U-1208	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-1209	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER
U-1210	USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
U-1211	USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
U-1212	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1213	TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER
U-1214	METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES

PATENT USE

	ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1215	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1216	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1217	METHOD OF INCREASING HAIR GROWTH
U-1218	METHOD OF STIMULATING HAIR GROWTH
U-1219	METHOD OF INCREASING THE NUMBER OF HAIRS
U-1220	TREATMENT OF RENAL CELL CARCINOMA
U-1221	TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION
U-1222	TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS
U-1223	METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE
U-1224	REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE
U-1225	ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS
U-1226	A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
U-1227	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
U-1228	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN
U-1229	TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS
U-1230	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT
U-1231	TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
U-1232	USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENDED FOR USE W/ASPIRIN
U-1233	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD
U-1234	FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
U-1235	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1236	USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1237	COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS
U-1238	TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
U-1239	MAGNETIC RESONANCE IMAGING OF THE LIVER
U-1240	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
U-1241	MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1242	PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS
U-1243	WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
U-1244	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYLUREA
U-1245	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE

PATENT USE

U-1246	SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA
U-1247	MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
U-1248	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE
U-1249	TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
U-1250	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1251	A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
U-1252	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
U-1253	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
U-1254	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
U-1255	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
U-1256	TREATMENT OF SEBORRHEIC DERMATITIS
U-1257	TREATMENT OF OPHTHALMIC DISORDERS
U-1258	VISUALIZATION DURING VITRECTOMY PROCEDURES
U-1259	PROPHYLAXIS OF HIV-1 INFECTION
U-1260	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
U-1261	REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
U-1262	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
U-1263	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
U-1264	TREATMENT OF A RESPIRATORY DISEASE
U-1265	PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1266	METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
U-1267	TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
U-1268	TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
U-1269	TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
U-1270	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
U-1271	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
U-1272	TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
U-1273	TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
U-1274	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
U-1275	TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1276	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY

PATENT USE

U-1277	METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
U-1278	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS
U-1279	TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
U-1280	USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
U-1281	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
U-1282	PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
U-1283	A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
U-1284	A METHOD OF TREATING A NEOPLASM
U-1285	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
U-1286	A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
U-1287	METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1288	TREATMENT OF ERECTILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET
U-1289	MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
U-1290	TREATMENT OF LUNG CANCER
U-1291	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
U-1292	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
U-1293	A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1294	METHOD OF TREATING GLAUCOMA IN A PATIENT
U-1295	A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1296	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION
U-1297	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS
U-1298	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES
U-1299	TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1300	TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1301	TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
U-1302	TREATMENT OF PULMONARY EMBOLISM (PE)
U-1303	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
U-1304	USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES
U-1305	TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS
U-1306	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
U-1307	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
U-1308	MULTIPLE MYELOMA
U-1309	BONE METASTASES
U-1310	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

PATENT USE

U-1311	METHOD OF TREATING CYSTIC FIBROSIS
U-1312	USE FOR THE TREATMENT OF HYPERGLYCEMIA
U-1313	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1314	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1315	THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-1316	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1317	TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1318	TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1319	SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
U-1320	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
U-1321	TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
U-1322	METHOD OF REDUCING OCULAR HYPERTENSION
U-1323	REDUCING THE RISK OF STROKE
U-1324	MANAGEMENT OF CYSTIC FIBROSIS PATIENTS
U-1325	INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
U-1326	METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE
U-1327	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
U-1328	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
U-1329	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER
U-1330	METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1331	METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1332	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1333	METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
U-1334	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1335	METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN
U-1336	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN
U-1337	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
U-1338	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
U-1339	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN

PATENT USE

U-1340	METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1341	METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1342	METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1343	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1344	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION
U-1345	USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1346	USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE
U-1347	TREATMENT OF A SKIN DISORDER
U-1348	TREATMENT OF OSTEOARTHRITIS
U-1349	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
U-1350	TREATMENT OF ANKYLOSING SPONDYLITIS
U-1351	TREATMENT OF ACUTE PAIN
U-1352	TREATMENT OF PRIMARY DYSMENORRHEA
U-1353	ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1354	INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH
U-1355	MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
U-1356	TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
U-1357	TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD
U-1358	TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS
U-1359	USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
U-1360	USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1361	USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
U-1362	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
U-1363	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
U-1364	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1365	PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
U-1366	TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO

PATENT USE

	ANOVULATORY INFERTILE WOMEN
U-1367	METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN
U-1368	TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB
U-1369	TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
U-1370	TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
U-1371	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA
U-1372	ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION
U-1373	METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS
U-1374	TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
U-1375	ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS
U-1376	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-1377	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1378	TREATMENT OF A NITROGEN METABOLISM DISORDER
U-1379	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1380	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE
U-1381	USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1382	TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
U-1383	DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER
U-1384	METHOD OF TREATING MULTIPLE SCLEROSIS
U-1385	METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS
U-1386	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF
U-1387	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1388	TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1389	ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD
U-1390	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF
U-1391	METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION
U-1392	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1393	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1394	METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING(I)24MICROG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1395	USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED

PATENT USE

	CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1396	TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
U-1397	USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY
U-1398	METHOD OF TREATING CHRONIC HEPATITIS C
U-1399	MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES
U-1400	FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1401	INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
U-1402	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
U-1403	FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
U-1404	METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS
U-1405	THERAPEUTIC TREATMENT OF BONE METASTASES
U-1406	TREATMENT OF MELANOMA
U-1407	TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)
U-1408	TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
U-1409	TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION
U-1410	TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES
U-1411	THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
U-1412	TREATMENT OF ATOPIC DERMATITIS
U-1413	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION
U-1414	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
U-1415	TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2
U-1416	USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES
U-1417	USE FOR TREATMENT OF HELICOBACTER INFECTIONS
U-1418	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST
U-1419	TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING
U-1420	METHOD OF ONCE A DAY ADMINISTRATION
U-1421	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE
U-1422	METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT
U-1423	AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
U-1424	LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-1425	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE

PATENT USE

U-1426	USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS
U-1427	ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY
U-1428	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
U-1429	TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
U-1430	TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-1431	METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE
U-1432	METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX
U-1433	IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1434	TREATMENT OF PANCREATIC CANCER
U-1435	COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.
U-1436	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT
U-1437	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
U-1438	ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1439	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
U-1440	USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
U-1441	A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
U-1442	SUBCUTANEOUS INJECTION OF METHOTREXATE
U-1443	ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
U-1444	A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
U-1445	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
U-1446	METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES
U-1447	TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
U-1448	TREATING SEVERE HYPERTRIGLYCERIDEMIA
U-1449	METHOD OF ALLEVIATING A SKIN CONDITION
U-1450	TREATMENT OF ALLERGIC RHINITIS SYMPTOMS
U-1451	APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY
U-1452	METHOD FOR CHRONIC WEIGHT MANAGEMENT
U-1453	A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1454	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS

PATENT USE

U-1455	TREATMENT OF PERIANAL WARTS
U-1456	TREATMENT OF MANTLE CELL LYMPHOMA
U-1457	A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM
U-1458	A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1459	TREATMENT OF CARCINOMA OF THE THYROID
U-1460	TREATMENT OF HERPES LABIALIS
U-1461	A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE
U-1462	A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE
U-1463	A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES
U-1464	TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION
U-1465	USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
U-1466	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1467	METHOD OF TREATING HEPATITIS C
U-1468	CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS
U-1469	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
U-1470	FOR THE TREATMENT OF HEPATITIS C
U-1471	A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.
U-1472	INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-1473	MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RHYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF
U-1474	A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT
U-1475	USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).
U-1476	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.
U-1477	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE
U-1478	METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1479	INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
U-1480	TREATMENT OF ADVANCED RENAL CELL CARCINOMA
U-1481	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
U-1482	DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1483	INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
U-1484	COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)
U-1485	TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS

PATENT USE

U-1486	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
U-1487	METHOD OF INCREASING EYELASH GROWTH
U-1488	USE OF TOPICAL DICLOFENAC FOR TREATING PAIN
U-1489	USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS
U-1490	FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
U-1491	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1492	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1493	METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1494	SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
U-1495	RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.
U-1496	METHOD TO TREAT HEMANGIOMA.
U-1497	NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
U-1498	METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM
U-1499	MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-1500	TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).
U-1501	PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
U-1502	PROPHYLAXIS OF PULMONARY EMBOLISM
U-1503	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1504	USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4
U-1505	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
U-1506	TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR
U-1507	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1508	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED
U-1509	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER
U-1510	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.
U-1511	TREATMENT OF HYPERTRIGLYCERIDEMIA
U-1512	REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1513	TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-1514	MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL
U-1515	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.
U-1516	METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.
U-1517	TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.
U-1518	MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
U-1519	METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME
U-1520	METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT

PATENT USE

U-1521	MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
U-1522	TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
U-1523	METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE
U-1524	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
U-1525	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
U-1526	THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
U-1527	FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-1528	A METHOD OF LOWERING INTRAOCULAR PRESSURE
U-1529	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1530	USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
U-1531	METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
U-1532	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.
U-1533	PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.
U-1534	ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.
U-1535	ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.
U-1536	ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.
U-1537	TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.
U-1538	ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.
U-1539	PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
U-1540	BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1541	TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.
U-1542	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
U-1543	TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23
U-1544	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).
U-1545	A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE
U-1546	FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.
U-1547	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
U-1548	FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-1549	FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
U-1550	METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.
U-1551	METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.

PATENT USE

U-1552	FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE)
U-1553	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1554	FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
U-1555	MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1556	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-1557	A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.
U-1558	FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA
U-1559	INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER
U-1560	A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE
U-1561	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
U-1562	TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)
U-1563	A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.
U-1564	A METHOD OF TREATING GAUCHER'S DISEASE
U-1565	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
U-1566	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-1567	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
U-1568	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
U-1569	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
U-1570	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE
U-1571	TREATMENT OF GAUCHER DISEASE TYPE 1
U-1572	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.
U-1573	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
U-1574	A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.
U-1575	PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
U-1576	TREATMENT OF LEUKEMIA
U-1577	CONTROL OF SERUM PHOSPHOROUS LEVELS
U-1578	TREATMENT OF ACUTE OTITIS MEDIA
U-1579	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1580	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY
U-1581	IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.
U-1582	TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA

PATENT USE

U-1583	FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1584	USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
U-1585	USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
U-1586	FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
U-1587	SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.
U-1588	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
U-1589	METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-1590	KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA
U-1591	TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER
U-1592	TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-1593	MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.
U-1594	DILATION OF THE PUPIL
U-1595	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS
U-1596	LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
U-1597	TREATMENT OF DIABETIC MACULAR EDEMA
U-1598	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
U-1599	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-1600	DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1601	DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1602	METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION
U-1603	METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-1604	METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2
U-1605	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER
U-1606	METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM
U-1607	METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION
U-1608	DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION
U-1609	CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1610	CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN USE OF PIRFENIDONE
U-1611	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER
U-1612	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER
U-1613	DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN
U-1614	USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN

PATENT USE

U-1615	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
U-1616	NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-1617	METHOD OF TREATING MEDULLARY THYROID CANCER
U-1618	A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FORMULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT
U-1619	TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1620	METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.
U-1621	PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.
U-1622	FOR THE TREATMENT OF POLYCYTHEMIA VERA
U-1623	USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.
U-1624	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
U-1625	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
U-1626	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING
U-1627	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS
U-1628	METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION
U-1629	METHOD OF TREATING ACROMEGALY
U-1630	TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL
U-1631	TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
U-1632	TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
U-1633	USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
U-1634	TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR
U-1635	USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION
U-1636	USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
U-1637	TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
U-1638	TREATMENT OF HCV INFECTION USING PARITAPREVIR
U-1639	USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1640	TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1641	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-1642	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN
U-1643	TREATING CUSHING'S SYNDROME
U-1644	TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN
U-1645	TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

PATENT USE

U-1646	TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1647	TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1648	TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1649	TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
U-1650	TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA
U-1651	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
U-1652	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
U-1653	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)
U-1654	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)
U-1655	A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY
U-1656	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
U-1657	METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99
U-1658	TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN
U-1659	MANAGEMENT OF PAIN
U-1660	TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
U-1661	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN
U-1662	A METHOD OF TREATING OCULAR PAIN
U-1663	TREATMENT OF HIV-1 INFECTION
U-1664	TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL
U-1665	METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1
U-1666	PALLIATIVE TREATMENT OF PROSTATE CANCER
U-1667	TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS
U-1668	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
U-1669	TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE
U-1670	NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.
U-1671	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS
U-1672	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
U-1673	TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
U-1674	DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1675	USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
U-1676	METHODS FOR TREATING BACTERIAL INFECTIONS
U-1677	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)
U-1678	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
U-1679	TREATMENT OF ACUTE OTITIS EXTERNA

PATENT USE

U-1680	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1681	TREATMENT OF PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
U-1682	TREATMENT OF BACTERIAL VAGINOSIS
U-1683	TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-1684	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1685	DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1686	A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION
U-1687	TREATMENT OF HCV INFECTION USING OMBITASVIR
U-1688	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1689	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1690	METHOD FOR REDUCTION OF SUBMENTAL FAT
U-1691	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
U-1692	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1693	METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1694	A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
U-1695	METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER
U-1696	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
U-1697	PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE.
U-1698	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
U-1699	A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
U-1700	A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
U-1701	A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN
U-1702	TREATMENT OF COPD
U-1703	TREATMENT OF RESPIRATORY COMPLAINTS
U-1704	USE FOR TREATMENT IN PATIENTS WITH DIABETES
U-1705	USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA
U-1706	TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE
U-1707	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.
U-1708	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.
U-1709	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
U-1710	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE
U-1711	FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL
U-1712	MEKINIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1713	TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1714	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER

PATENT USE

	WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1715	P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR
U-1716	TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS
U-1717	METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
U-1718	METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE.
U-1719	ACUTE TREATMENT OF MIGRAINE
U-1720	METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
U-1721	USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
U-1722	TREATMENT OF BASAL CELL CARCINOMA
U-1723	TREATMENT OF HEART FAILURE
U-1724	METHOD OF INHIBITING HEPATITIS C VIRUS
U-1725	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
U-1726	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1727	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
U-1728	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1729	REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)
U-1730	REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM
U-1731	TEMPORARY RELIEF OF MINOR ACHES AND PAINS
U-1732	TEMPORARY REDUCTION OF FEVER
U-1733	TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE
U-1734	USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
U-1735	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL
U-1736	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1737	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE
U-1738	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
U-1739	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1740	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
U-1741	PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
U-1742	ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY

PATENT USE

U-1743	FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
U-1744	PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
U-1745	FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
U-1746	MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY
U-1747	FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD
U-1748	FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1749	ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
U-1750	TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
U-1751	TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY
U-1752	PROPHYLAXIS OF ORGAN REJECTION
U-1753	TREATMENT OF HCV INFECTION USING DASABUVIR
U-1754	FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL
U-1755	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
U-1756	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-1757	INHIBITION ON PI3K KINASE
U-1758	METHOD OF TREATING ALLERGIC REACTION VIA INJECTION
U-1759	METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB
U-1760	RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT
U-1761	PLAQUE PSORIASIS
U-1762	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1763	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1764	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1765	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1766	TREATMENT OF HYPERKALEMIA
U-1767	USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER
U-1768	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN
U-1769	TREATMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE
U-1770	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA
U-1771	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION
U-1772	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
U-1773	LONG-TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1774	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE

PATENT USE

U-1775	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS
U-1776	METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA
U-1777	TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
U-1778	METHOD FOR TREATING MULTIPLE MYELOMA
U-1779	METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS
U-1780	METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA
U-1781	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT
U-1782	FOR HEAD LICE INFESTATIONS
U-1783	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM AS CLAIMED
U-1784	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM TRIHYDRATE AS CLAIMED
U-1785	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM FORMULATION AS CLAIMED
U-1786	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE
U-1787	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY
U-1788	TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN
U-1789	METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION
U-1790	FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA
U-1791	EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS
U-1792	TREATMENT OF OTIC INFECTION OR INFLAMMATION
U-1793	TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1794	REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK
U-1795	REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE
U-1796	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
U-1797	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
U-1798	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN
U-1799	METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES
U-1800	A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT
U-1801	REDUCTION OF SERUM URIC ACID LEVELS
U-1802	TREATMENT OF GOUT
U-1803	TREATMENT OF HYPERURICEMIA
U-1804	ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT
U-1805	USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
U-1806	COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA

PATENT USE

	INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
U-1807	TREATMENT OF PEDIATRIC PATIENTS 8 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
U-1808	USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
U-1809	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
U-1810	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
U-1811	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATIONS AFTER CONFIRMING THE PRESENCE OF BRAF V600E MUTATION
U-1812	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA
U-1813	TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS
U-1814	METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
U-1815	TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
U-1816	TREATMENT OF A UREA CYCLE DISORDER
U-1817	PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-1818	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH LETROZOLE AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN, OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1819	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-1820	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
U-1821	METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
U-1822	TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER
U-1823	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT
U-1824	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1825	METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL
U-1826	TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1827	A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1
U-1828	INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
U-1829	EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
U-1830	INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY
U-1831	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG
U-1832	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1833	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1834	TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN PATIENTS UNDERGOING CATARACT SURGERY
U-1835	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION,

PATENT USE

	AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-1836	TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE
U-1837	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA
U-1838	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
U-1839	COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY
U-1840	TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
U-1841	USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1842	METHOD OF TREATING EPILEPSY
U-1843	TREATMENT OF PSYCHOSIS
U-1844	TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS
U-1845	TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF
U-1846	TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF
U-1847	METHOD OF TREATING A BACTERIAL INFECTION
U-1848	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1849	METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE
U-1850	METHOD OF ADMINISTERING LEVETIRACETAM
U-1851	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1852	METHOD OF TREATING TYPE 2 DIABETES
U-1853	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
U-1854	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
U-1855	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS
U-1856	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
U-1857	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
U-1858	TREATMENT OF PLAQUE PSORIASIS
U-1859	TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1860	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1861	USE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT
U-1862	TREATMENT OF POST-MYOCARDIAL INFARCTION
U-1863	TREATMENT OF STROKE
U-1864	TREATMENT OF MYOCARDIAL INFARCTION
U-1865	TREATMENT OF THROMBOTIC STROKE
U-1866	TREATMENT OF STABLE AND UNSTABLE ANGINA
U-1867	METHOD OF INHIBITING PLATELET AGGREGATION

PATENT USE

U-1868	TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION
U-1869	TREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE
U-1870	ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1871	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D
U-1872	USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY
U-1873	ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE
U-1874	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING OMEPRAZOLE ACCORDING TO CLAIMS 1-8
U-1875	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING S-OMEPRAZOLE TRIHYDRATE ACCORDING TO CLAIMS 1-3
U-1876	METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH
U-1877	METHOD OF TREATING PULMONARY HYPERTENSION BY ORALLY ADMINISTERING A FORMULATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF TREPROSTINIL
U-1878	FOR OPIOID DEPENDENCE
U-1879	METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY
U-1880	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1881	IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR
U-1882	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANALGESIC AND ANTIPYRETIC ACTIVITY
U-1883	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)
U-1884	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1885	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1886	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1887	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1888	USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE
U-1889	TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
U-1890	OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP))
U-1891	TREATMENT OR PREVENTION OF NAUSEA AND VOMITING
U-1892	METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION
U-1893	METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS
U-1894	COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-1895	METHOD OF TREATING PROSTATE CANCER
U-1896	SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES
U-1897	METHOD OF TREATING ACS USING ANGIOPLASTY WITH AGGRASTAT (TIROFIBAN

PATENT USE

	HYDROCHLORIDE)
U-1898	METHOD OF INHIBITING PLATELET AGGREGATION WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1899	TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1900	TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1901	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
U-1902	TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-1903	USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.
U-1904	(I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1905	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1906	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1907	USE OF A DELIVERY DEVICE TO ADMINISTER A DOSE OF NALOXONE
U-1908	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND FORM I LUMACAFTOR
U-1909	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND LUMACAFTOR
U-1910	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338
U-1911	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR
U-1912	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING A DOSAGE UNIT AS DEFINED IN CLAIM 1 OF U.S. PATENT NO. 9,192,606
U-1913	TREATMENT OF PEDIATRIC PATIENTS WITH BILATERAL OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1914	IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-1915	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN
U-1916	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV)
U-1917	TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1918	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1919	RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1920	USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4
U-1921	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT
U-1922	INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE

PATENT USE

U-1923 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN OR LIXISENATIDE BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE

U-1924 KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY

U-1925 USE OF AN AUTO INJECTOR TO ADMINISTER NALOXONE HCL

U-1926 METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS INFUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI

U-1927 TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB

U-1928 RUBRACA IS INDICATED AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES.

U-1929 TREATMENT OF DIABETES MELLITUS WITH AN INHALED INSULIN TO IMPROVE GLYCEMIC CONTROL USING A DRY POWDER INHALATION SYSTEM COMPRISING AN INHALER, A CARTRIDGE AND A DRY POWDER MEDICAMENT COMPRISING INSULIN IN A SINGLE INHALATION

U-1930 METHOD OF AEROSOLIZING/DEAGGLOMERATING AN INSULIN DRY POWDER FOR USE IN TREATING DIABETES MELLITUS VIA ORAL INHALATION USING AN INHALER WITH A CARTRIDGE CONTAINING THE INSULIN DRY POWDER.

U-1931 PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE

U-1932 METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.

U-1933 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY

U-1934 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR

U-1935 REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION

U-1936 TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION

U-1937 TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION

U-1938 TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION

U-1939 ADMINISTRATION ONCE DAILY WITHIN TWO HOURS AFTER WAKING IN THE MORNING FOR IMPROVEMENT OF GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT

U-1940 IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING

U-1941 TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY

U-1942 TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA

U-1943 TREATMENT OF SPINAL MUSCULAR ATROPHY

U-1944 TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE

U-1945 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN.

U-1946 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA

U-1947 TREATMENT OF MARGINAL ZONE LYMPHOMA

U-1948 A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA

U-1949 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

U-1950 TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY

U-1951 TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL

PATENT USE

U-1952	FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
U-1953	REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1954	TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1955	TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1956	FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1957	PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1958	FOR THE TREATMENT OF GENOTYPE 1, 2, 3 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AS A COMPONENT OF A COMBINATION ANTIVIRAL TREATMENT REGIMEN WITH RIBAVIRIN
U-1959	TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
U-1960	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
U-1961	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
U-1962	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
U-1963	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
U-1964	ELEVATION OF INTRACELLULAR CGMP RESULTING IN INCREASED INTESTINAL FLUID AND ACCELERATED TRANSIT
U-1965	FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL, WHEREIN THE WEIGHT RATIO OF AMBRISENTAN TO TADALAFIL IS ABOUT 1:2 TO ABOUT 1:3
U-1966	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17
U-1967	METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1968	METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1969	TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
U-1970	TREATMENT OF ONYCHOMYCHOSIS OF A TOENAIL CAUSED BY TRICHOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES
U-1971	FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
U-1972	FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
U-1973	METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
U-1974	TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS
U-1975	METHOD OF INCREASING EYELASH GROWTH WITH BIMATOPROST
U-1976	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN
U-1977	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY

PATENT USE

	TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN
U-1978	TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
U-1979	THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
U-1980	A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-1981	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-1982	USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
U-1983	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
U-1984	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
U-1985	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
U-1986	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
U-1987	METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL
U-1988	METHOD TO TREAT INFANTILE HEMANGIOMA
U-1989	INTRAVITREAL TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-1990	INTRAVITREAL TREATMENT OF DIABETIC MACULAR EDEMA
U-1991	REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
U-1992	USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
U-1993	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING "OFF" EPISODES
U-1994	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS
U-1995	TREATMENT OF TARDIVE DYSKINESIA
U-1996	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1997	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR A PPAR-GAMMA AGONIST AND/OR SULFONYLUREA AND/OR INSULIN
U-1998	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1999	CHRONIC IDIOPATHIC CONSTIPATION
U-2000	MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2001	USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
U-2002	USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2003	A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM BY HOLDING AN INSERTER HANDLE WITH ONE HAND, ADVANCING THE INSERTER THROUGH THE CERVIX AND INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE INTRAUTERINE SYSTEM
U-2004	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY

PATENT USE

U-2005	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH GENERALIZED TONIC-CLONIC SEIZURES
U-2006	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH MIXED SEIZURE PATTERNS THAT INCLUDE PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY, GENERALIZED TONIC-CLONIC SEIZURES, OR OTHER PARTIAL OR GENERALIZED SEIZURES
U-2007	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE FLT3 MUTATION-POSITIVE, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION CHEMOTHERAPY
U-2008	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
U-2009	METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE.
U-2010	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
U-2011	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
U-2012	A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
U-2013	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
U-2014	A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT)
U-2015	SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING
U-2016	TREATMENT FOR ONYCHOMYCOSIS THAT IS TINEA UNGUIUM
U-2017	TREATMENT OF OPIOID DEPENDENCE
U-2018	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-2019	METHOD OF DELIVERING TO A PATIENT WITH DIABETES MELLITUS IN A SINGLE INHALATION, GREATER THAN 75% OF A DRY POWDER DOSE COMPRISING INSULIN AND FUMARYL DIKETOPIPERAZINE USING A HIGH RESISTANCE TO FLOW DRY POWDER INHALER.
U-2020	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2021	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS
U-2022	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS
U-2023	A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
U-2024	METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF
U-2025	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-2026	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
U-2027	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
U-2028	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
U-2029	PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS
U-2030	PROPHYLAXIS OF VENOUS THROMBOSIS
U-2031	TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2032	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.

PATENT USE

U-2033	MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS
U-2034	INHIBITING COAGULATION
U-2035	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
U-2036	A METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING PARENTERALLY ADMINISTERING A FORMULATION COMPRISING A) 0.1 TO 5% W/V OF TREPROSTINIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND B) A CITRATE BUFFER
U-2037	MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
U-2038	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2039	TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
U-2040	TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
U-2041	TREATMENT OF PARTIAL-ONSET SEIZURES
U-2042	DISCONTINUING ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
U-2043	EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
U-2044	DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
U-2045	ADMINISTRATION OF PIRFENIDONE AND AVOIDING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
U-2046	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6
U-2047	ADMINISTERING PIRFENIDONE CONCURRENTLY WITH FLUVOXAMINE, THE PIRFENIDONE AT A DOSE OF ABOUT 801 MG/DAY TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-2048	ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
U-2049	DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
U-2050	ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
U-2051	DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2052	DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2053	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY
U-2054	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2 TO AVOID REDUCED PIRFENIDONE EFFICACY
U-2055	DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 LIVER ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2056	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY, FOLLOWING BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
U-2057	DOSING 2403 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

PATENT USE

U-2058 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE, FOLLOWED BY ADMINISTERING 2403MG/DAY IN TREATMENT OF IPF

U-2059 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE IN TREATMENT OF IPF

U-2060 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN AT LEAST 1600MG/DAY IN TREATMENT OF IPF

U-2061 DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

U-2062 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY DOSE IN TREATMENT OF IPF

U-2063 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF

U-2064 DOSING AT LEAST 1602 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION

U-2065 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION

U-2066 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE, FOLLOWED BY FULL DAILY DOSE

U-2067 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY

U-2068 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE

U-2069 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING A SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY

U-2070 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN SUB-1600 MG/DAY, THEN AT LEAST 1602 MG/DAY

U-2071 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

U-2072 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

U-2073 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING FULL DAILY DOSE IN TREATMENT OF IPF

U-2074 DOSING 1602 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

U-2075 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF

U-2076 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING 801 MG/DAY FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF

U-2077 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE THEN FULL DAY DAILY DOSE IN TREATMENT OF IPF

PATENT USE

U-2078	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2079	PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF FIBROSIS AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
U-2080	PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF IPF AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
U-2081	DISCONTINUING USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6 AND THEN ADMINISTERING PIRFENIDONE
U-2082	MODIFYING PIRFENIDONE ADMINISTRATION FROM A DOSE OF ABOUT 2400 MG/DAY DOWNWARD BY ABOUT 1600 MG/DAY WHILE CO-ADMINISTERING FLUVOXAMINE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-2083	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY 801 MG/DAY, DOSE, THEN 1602 MG/DAY IN TREATMENT OF IPF
U-2084	TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE
U-2085	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH RIFAMPIN
U-2086	A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
U-2087	TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
U-2088	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
U-2089	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
U-2090	FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
U-2091	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT NOT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
U-2092	METHOD FOR CONFIRMING DOSE DELIVERY
U-2093	TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY
U-2094	TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY
U-2095	MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY
U-2096	SOTYLIZE IS INDICATED FOR THE MAINTENANCE OF NORMAL SINUS RHYTHM [DELAY IN TIME TO RECURRENCE OF ATRIAL FIBRILLATION/ATRIAL FLUTTER (AFIB/AFL)] IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM
U-2097	TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-2098	INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-2099	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
U-2100	INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER
U-2101	MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY

PATENT USE

U-2102 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA

U-2103 MAINTENANCE TREATMENT OF BRCA-MUTATED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY

U-2104 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE

U-2105 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

U-2106 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

U-2107 TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT

U-2108 TREATMENT OF HORMONE RECEPTOR POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY

U-2109 CAROSPIR IS INDICATED FOR TREATMENT OF NYHA CLASS III-IV HEART FAILURE AND REDUCED EJECTION FRACTION TO INCREASE SURVIVAL, MANAGE EDEMA, AND TO REDUCE THE NEED FOR HOSPITALIZATION FOR HEART FAILURE

U-2110 METHOD FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH MODERATE RENAL IMPAIRMENT WHO ARE OBESE, OR OVERWEIGHT AND HAVE AT LEAST ONE WEIGHT RELATED COMORBID CONDITION

U-2111 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1-5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1-5

U-2112 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 6

U-2113 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 7

U-2114 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9

U-2115 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 10 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 10

U-2116 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12

U-2117 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 14-15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 14-15

U-2118 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-18

U-2119 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19

U-2120 TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT

PATENT USE

	INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS
U-2121	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
U-2122	USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2123	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
U-2124	TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
U-2125	THE TREATMENT OF AN INFLAMMATORY DISORDER OF THE RESPIRATORY TRACT BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR AGONIST
U-2126	USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2127	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-2128	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION
U-2129	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
U-2130	TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
U-2131	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY, AND A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
U-2132	IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY
U-2133	METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY
U-2134	THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR
U-2135	AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING
U-2136	TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-2137	TREATMENT OF POSTHERPETIC NEURALGIA
U-2138	TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP USING MORE THAN ONE TREATMENT COURSE OF INGENOL MEBUTATE
U-2139	TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
U-2140	METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2141	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
U-2142	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
U-2143	AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS, TO REDUCE THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS AND/OR PULMONARY EMBOLISM IN CERTAIN PATIENTS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
U-2144	REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-2145	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2146	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A ROTATING DRIVE SLEEVE

PATENT USE

U-2147	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME
U-2148	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE
U-2149	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
U-2150	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
U-2151	METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE
U-2152	TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
U-2153	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2154	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2155	REDUCING BODY WEIGHT IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2156	REDUCING HBA1C IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2157	TREATING TYPE 2 DIABETES MELLITUS BY STIMULATING INSULIN RELEASE
U-2158	DECREASING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY USING A SUSTAINED-RELEASE COMPOSITION
U-2159	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
U-2160	MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM
U-2161	TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
U-2162	FOR CLEANSING THE LARGE INTESTINE AS A PREPARATION FOR COLONOSCOPY
U-2163	TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB OR ABEMACICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-2164	ZELBORAF IS INDICATED FOR THE TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
U-2165	MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM
U-2166	TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
U-2167	METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
U-2168	METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
U-2169	METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
U-2170	METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
U-2171	ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
U-2172	METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS)
U-2173	TREATING OPIOID DEPENDENCE BY ADMINISTERING BUPRENORPHINE
U-2174	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
U-2175	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE MONTHLY
U-2176	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE
U-2177	TREATING OPIOID ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
U-2178	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE COMPOSITION WITH 28 DAY DOSE DURATION

PATENT USE

U-2179 IN SITU FORMATION OF SOLID BUPRENORPHINE COMPOSITION

U-2180 TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE

U-2181 TREATING OPIOID DEPENDENCY BY SUBCUTANEOUSLY ADMINISTERING BUPRENORPHINE

U-2182 IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

U-2183 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13

U-2184 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 13, AND 14

U-2185 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27

U-2186 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15, 27, AND 28

U-2187 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29 AND 39

U-2188 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29, 39, AND 40

U-2189 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41 AND 52

U-2190 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41, 52, AND 53

U-2191 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54 AND 64

U-2192 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54, 64, AND 65

U-2193 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66 AND 75

U-2194 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66, 75, AND 76

U-2195 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77 AND 87

U-2196 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77, 87, AND 88

U-2197 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89 AND 99

U-2198 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89, 99, AND 100

U-2199 TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA

U-2200 COMBINATION TREATMENT WITH INSULIN GLARGINE WITH OR WITHOUT METFORMIN FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

U-2201 TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER

U-2202 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC

PATENT USE

	CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2203	A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED
U-2204	TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
U-2205	TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
U-2206	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE
U-2207	TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
U-2208	TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE
U-2209	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
U-2210	TREATING OPIOID ADDICTION BY 100 MG OR 300 MG DOSE BUPRENORPHINE
U-2211	TREATING OPIOID ADDICTION BY ADMINISTRATION OF BUPRENORPHINE
U-2212	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2213	REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2214	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
U-2215	ERTUGLIFLOZIN IN COMBINATION WITH SITAGLIPTIN AND IN FURTHER COMBINATION WITH METFORMIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2216	ERTUGLIFLOZIN AND SITAGLIPTIN IN COMBINATION AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2217	TREATING HIGH OUTPUT SHOCK WITH ANGIOTENSIN II BY INCREASING MEAN ARTERIAL PRESSURE IN PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
U-2218	MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR HIGHER WITH ANGIOTENSIN II IN SHOCK PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
U-2219	TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA
U-2220	A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIMORELIN
U-2221	TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
U-2222	RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
U-2223	METHOD OF TREATING ANGINA PECTORIS
U-2224	TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2225	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH HEPATIC IMPAIRMENT
U-2226	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH RENAL IMPAIRMENT
U-2227	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN GERIATRIC PATIENTS
U-2228	TREATMENT OF SMALL LYMPHOCYTIC LEUKEMIA
U-2229	IN COMBINATION WITH TRETINOIN, TREATING ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-A GENE EXPRESSION
U-2230	IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
U-2231	TREATING REFRACTORY HYPOTENSION WITH ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
U-2232	TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE

PATENT USE

U-2233	TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT
U-2234	USE OF IVACAFTOR FOR TREATING CYSTIC FIBROSIS IN A PATIENT WITH A MILD TO MODERATE CF PHENOTYPE WITH AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2235	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
U-2236	REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
U-2237	TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2238	METHOD OF IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH DIABETES MELLITUS BY ADMINISTERING A MIXTURE OF INSULIN DEGLUDEC AND INSULIN ASPART DURING OR AROUND THE TIME OF THE LARGEST MEAL OF THE DAY
U-2239	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
U-2240	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY TO BRIMONIDINE 0.2% TID
U-2241	TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
U-2242	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-2243	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
U-2244	A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2245	A METHOD OF TREATING A BACTERIAL INFECTION IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2246	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
U-2247	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF PATIENTS WITH A MILD TO MODERATE CLINICAL PHENOTYPE OF CYSTIC FIBROSIS HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
U-2248	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR THE F508DEL MUTATION AND A SECOND MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
U-2249	MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
U-2250	DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
U-2251	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-2252	THE TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
U-2253	PROPHYLACTIC TREATMENT OF NAUSEA AND VOMITING, INCLUDING PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED CHEMOTHERAPY
U-2254	USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY
U-2255	TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND THE SUSTAINED RELEASE IS OVER AT LEAST 10 HOURS
U-2256	TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE

PATENT USE

	LEVEL AND CMAX IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2257	TREATING SHPT IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE SERUM PARATHYROID HORMONE LEVEL AND CHANGE IN SERUM CONCENTRATION OF CALCIFEDIOL IN DOSE INTERVAL IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2258	TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX24HR/C24HR IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2259	TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND TMAX IS INCREASED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2260	METHOD OF REDUCING THE RISK OF PERIPROCEDURAL MYOCARDIAL INFARCTION, AND STENT THROMBOSIS IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND THEN A CONTINUOUS INFUSION
U-2261	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN OR MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2262	MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER
U-2263	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN WITH ADJUNCTIVE OPIOID ANALGESICS
U-2264	METHODS OF TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
U-2265	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HEC AND MEC IN ADULT AND PEDIATRIC PATIENTS
U-2266	METHODS OF MAKING AQUEOUS COMPOSITION AND TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
U-2267	METHOD FOR RELIEVING THE PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA
U-2268	DISCONTINUING A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2269	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2270	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2271	THERAPEUTIC TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER, SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
U-2272	TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT
U-2273	A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
U-2274	MAINTAINING SERUM 25-HYDROXYVITAMIN D AT A LEVEL OF AT LEAST 30 NG/ML WITH ORAL, SUSTAINED RELEASE 25-HYDROXYVITAMIN D
U-2275	TREATING CYSTIC FIBROSIS PATIENTS AGES 12 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR
U-2276	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT AGE 6 OR OLDER HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
U-2277	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE
U-2278	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN
U-2279	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN AND A SECOND ORAL ANTIDIABETIC DRUG

PATENT USE

U-2280	ADJUNCTIVE TREATMENT OF PATIENTS WITH TSC-ASSOCIATED PARTIAL-ONSET SEIZURES
U-2281	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2282	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 2
U-2283	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 3-7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 3-7
U-2284	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 8
U-2285	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 11 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 11
U-2286	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 14 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 14
U-2287	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-19
U-2288	TREATMENT OF TYPE 2 DIABETES MELLITUS WITH EXENATIDE AS AN ADD-ON TO BASIL INSULIN OR BASAL INSULIN PLUS METFORMIN THERAPY
U-2289	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS
U-2290	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-2291	REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)
U-2292	METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-2293	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY
U-2294	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
U-2295	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2296	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-2297	IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES PATIENTS BY ADMINISTERING A STARTING DOSE OF 10 MCG FOR 14 DAYS AND INCREASING TO A MAINTENANCE DOSE OF 20 MCG ON DAY 15
U-2298	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
U-2299	TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION

PATENT USE

U-2300	USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-2301	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY
U-2302	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-2303	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-2304	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION
U-2305	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
U-2306	ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
U-2307	TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
U-2308	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
U-2309	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
U-2310	FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS
U-2311	TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE
U-2312	TREATMENT OF HYPERKALEMIA IN ADULTS
U-2313	METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE
U-2314	TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE USING DOPTELET
U-2315	TREATMENT OF MULTIPLE SCLEROSIS IN THE PEDIATRIC PATIENT POPULATION WITH 0.25 MG FINGOLIMOD
U-2316	TREATMENT OF DYSPAREUNIA
U-2317	TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
U-2318	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2319	KYPROLIS IS INDICATED IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-2320	KYPROLIS IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
U-2321	A METHOD OF APPLYING TRYPAN BLUE ONTO AN OUTER SURFACE OF THE ANTERIOR LENS CAPSULE TO FACILITATE REMOVAL OF THE LENS SUBSTANCE
U-2322	TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
U-2323	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2324	FOR SECONDARY PREVENTION OF CARDIOVASCULAR AND CEREBROVASCULAR EVENTS IN PATIENTS AT RISK OF DEVELOPING ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-2325	EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE 1), INCLUDING ANAPHYLAXIS; A

PATENT USE

	METHOD OF TREATING ALLERGIC REACTION, ANAPHYLAXIS, ANAPHYLACTIC SHOCK, OR COMBINATION THEREOF BY AN INJECTION OF AT LEAST ONE DOSAGE OF THE INJECTABLE LIQUID PHARMACEUTICAL
U-2326	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-2327	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
U-2328	METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS
U-2329	METHOD OF ADMINISTERING A LOCAL ANESTHETIC PRIOR TO PERFORMING A DIAGNOSTIC OR SURGICAL PROCEDURE ON A SUBJECT WITH HEPATIC OR RENAL IMPAIRMENT
U-2330	METHOD OF TREATING MELANOMA
U-2331	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA
U-2332	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
U-2333	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2334	TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2335	TREATMENT OF MELANOMA
U-2336	TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
U-2337	INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2338	MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR ABOVE WITH ABOUT 1 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN HYPOTENSIVE PATIENTS TREATED WITH VASOPRESSIN OR A VASOPRESSIN ANALOGUE AND REDUCING VASOPRESSIN OR VASOPRESSIN ANALOGUE USE
U-2339	USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
U-2340	TREATMENT OF POSTOPERATIVE INFLAMMATION
U-2341	METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
U-2342	METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
U-2343	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2344	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE
U-2345	TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
U-2346	TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
U-2347	TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT
U-2348	A METHOD FOR PREVENTION OF PREGNANCY
U-2349	FOR ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 5 YEARS AND OLDER
U-2350	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML)
U-2351	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION
U-2352	TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS

PATENT USE

U-2353 TX OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENATES IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS

U-2354 COMBINATION WITH OTHER ANTIRETROVIRALS (ATV) FOR TREATMENT OF HIV-1 IN ATV TREATMENT-EXPERIENCED PATIENTS 2 YEARS AND OLDER WITH EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ATV

U-2355 IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE TREATMENT OF PRE/PERIMENOPAUSAL OR POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY

U-2356 IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY

U-2357 METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

U-2358 TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-NEGATIVE BREAST CANCER WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM, HER2-NEGATIVE METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING

U-2359 TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER WHO SHOULD HAVE BEEN TREATED WITH PRIOR ENDOCRINE THERAPY OR BE CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY

U-2360 MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS

U-2361 METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS

U-2362 TREATMENT OF HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6

U-2363 ADMINISTRATION OF RISPERIDONE

U-2364 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY

U-2365 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS

U-2366 TREATMENT OF LIVER DISEASE THROUGH NUTRITION FOR PATIENTS UNDER THE AGE OF 12

U-2367 USE FOR PATIENTS WITH PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS OR PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE

U-2368 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER

U-2369 FOR THE TREATMENT OF GENOTYPE 1, 4, 5 OR 6 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION

U-2370 FOR TREATMENT-NAIVE GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION FOR A DURATION OF 8-WEEKS

U-2371 THE TREATMENT OF FABRY PATIENTS

U-2372 A METHOD OF REDUCING LEFT VENTRICULAR MASS INDEX (LVMI) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT

U-2373 A METHOD OF REDUCING PODOCYTE GLOBOTRIAOSYLCERAMIDE (GL-3) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT

U-2374 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR

U-2375 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR FORM I AND IVACAFTOR

U-2376 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR

U-2377 USE OF VITAL DYE FOR FACILITATING SURGICAL PROCEDURES FOR VITREO-RETINAL SURGERY

U-2378 TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS

U-2379 USE IN IDENTIFICATION OF INTRAOCULAR MEMBRANES TO FACILITATE REMOVAL DURING

PATENT USE

OPHTHALMIC SURGERY

U-2380 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER

U-2381 TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)

U-2382 TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)

U-2383 METHOD OF CONTROLLING GLYCEMIA IN A DIABETIC PATIENT WITH DELAYED OR PROLONGED FOOD ABSORPTION BY ADMINISTERING 50 TO 75% OF A PREDETERMINED DOSE OF INSULIN-FDKP AT MEALTIME, AND ADMINISTERING REMAINDER OF DOSE 30-120 MINUTES AFTER BEGINNING OF MEAL

U-2384 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10

U-2385 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1,10 AND 11

U-2386 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 19

U-2387 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 19 AND 20

U-2388 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21 AND 28

U-2389 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21, 28, AND 29

U-2390 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30 AND 41

U-2391 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30, 41, AND 42

U-2392 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43 AND 50

U-2393 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43, 50 AND 51

U-2394 FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY

U-2395 FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY

U-2396 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFTOR

U-2397 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AND IVACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 9192606

U-2398 TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER

U-2399 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 12 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->A, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S PATENT 10058546

U-2400 REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

PATENT USE

U-2401	A METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS IN A PATIENT IN NEED OF SUCH TREATMENT, SAID METHOD COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A SUSPENSION ACCORDING TO CLAIM 1
U-2402	TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION
U-2403	TREATMENT OF PSORIASIS USING A DOSAGE TITRATION SCHEDULE
U-2404	METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
U-2405	A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
U-2406	A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
U-2407	A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
U-2408	A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
U-2409	A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES
U-2410	TREATMENT OF ADULT PATIENTS FOR WHOM TREATMENT WITH BOTH AMLODIPINE FOR HYPERTENSION AND CELECOXIB FOR OSTEOARTHRITIS ARE APPROPRIATE
U-2411	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 12 YEARS OR OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1, 19, OR 21 OF U.S. PATENT NO. 10,076,513 AND IVACAFTOR
U-2412	FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)
U-2413	FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)
U-2414	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION DRUG REGIMEN
U-2415	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
U-2416	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS WITH CYSTIC FIBROSIS AS PART OF A COMBINATION DRUG REGIMEN
U-2417	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN NON-CYSTIC FIBROSIS ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
U-2418	METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY
U-2419	METHOD OF OPERATING AN INJECTION DEVICE
U-2420	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-2421	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2422	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
U-2423	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
U-2424	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2425	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2426	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2427	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME

PATENT USE

U-2428	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
U-2429	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
U-2430	TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS
U-2431	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS
U-2432	LONG-TERM, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2433	METHOD OF TREATING A BIOLOGICAL RHYTHM DISORDER, SUCH AS INSOMNIA
U-2434	USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2435	REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CV DEATH, MI, AND STROKE) IN CHRONIC CAD OR PAD
U-2436	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT
U-2437	TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
U-2438	CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE
U-2439	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
U-2440	FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2441	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
U-2442	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2443	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2444	TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION
U-2445	TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
U-2446	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2447	TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET
U-2448	TREATMENT OF TRAVELERS' DIARRHEA CAUSED BY NON-INVASIVE STRAINS OF ESCHERICHIA COLI IN ADULTS
U-2449	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION
U-2450	POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT
U-2451	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-2452	COMBINATION WITH IMMUNOSUPPRESSIVE THERAPY FOR FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
U-2453	TREATMENT OF FUNGAL INFECTIONS, INCLUDING BLASTOMYCOSIS, HISTOPLASMOSIS, AND ASPERGILLOSIS
U-2454	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2455	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2456	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)

PATENT USE

U-2457	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO
U-2458	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO
U-2459	TREATMENT OF DYSKINESIA AND DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2460	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CORONARY ARTERY BYPASS GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2461	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CARDIOVASCULAR BYPASS GRAFT AND VASCULATURE IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2462	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL WITH ARTERIOVENOUS MALFORMATION IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2463	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION IN SURGICAL FLAPS IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2464	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF TRANSPLANTED ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2465	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2466	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF DONOR ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2467	VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO DONOR ORGAN IN PATIENTS 12 YEARS AND OLDER
U-2468	VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO TRANSPLANTED ORGAN IN PATIENTS 12 YEARS AND OLDER
U-2469	METHOD OF TREATING CANCEROUS SOLID TUMORS
U-2470	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
U-2471	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT
U-2472	METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
U-2473	METHOD OF TREATING CMN, IFS, HGG, DIPGS, PTC, SOFT TISSUE SARCOMA, AND SPINDLE CELL SARCOMA SOLID TUMORS EXHIBITING AN NTRK GENE FUSION IN A PEDIATRIC PATIENT WITH AN ORAL SOLUTION
U-2474	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION
U-2475	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION IN A PEDIATRIC PATIENT
U-2476	USE OF A DELIVERY DEVICE TO DELIVER A DOSE OF NALOXONE
U-2477	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
U-2478	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES
U-2479	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES
U-2480	MAINTENANCE TREATMENT OF GBRCA- OR SBRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
U-2481	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
U-2482	TREATMENT OF HR-NEGATIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR

PATENT USE

	METASTATIC SETTING
U-2483	TREATMENT OF HR-POSITIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND WITH ENDOCRINE THERAPY OR ARE INAPPROPRIATE FOR ENDOCRINE THERAPY
U-2484	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
U-2485	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES THROUGH A SINGLE BREATH ACTIVATED STEP
U-2486	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE WITH A POWDER INHALER
U-2487	DEXTENZA IS APPROVED FOR THE TREATMENT OF OCULAR PAIN FOLLOWING OPHTHALMIC SURGERY
U-2488	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
U-2489	TREATMENT OF MODERATE TO SEVERE OPIOID USE DISORDER
U-2490	TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
U-2491	A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
U-2492	A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
U-2493	A METHOD FOR TREATING INFLAMMATION AND/OR OTHER DISORDERS IN AN EYE OF A PATIENT
U-2494	INDICATED FOR THE TREATMENT OF VENTRICULAR ARRHYTHMIAS, SUCH AS SUSTAINED VENTRICULAR TACHYCARDIA, THAT IN THE JUDGEMENT OF THE PHYSICIAN ARE LIFE-THREATENING
U-2495	VENTRICULAR FIBRILLATION
U-2496	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-2497	TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTION IN ADULT PATIENTS
U-2498	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-2499	METHOD OF REDUCING ADVERSE EFFECTS IN PATIENTS SUFFERING FROM EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY WHO ARE CONCOMITANTLY ADMINISTERED SODIUM OXYBATE AND DIVALPROEX SODIUM
U-2500	USE OF A DELIVERY DEVICE TO DELIVER A BIOEQUIVALENT DOSE OF A NALOXONE COMPOSITION VIA A NEEDLE
U-2501	TREATMENT OF PARTIAL-ONSET SEIZURES
U-2502	TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULT IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-2503	TREATMENT OF ADULTS WITH METASTATIC GASTRIC OR GJA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, EITHER A TAXANE OR IRINOTECAN, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
U-2504	TREATMENT OF HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN IN COMBINATION WITH RIBOCICLIB AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
U-2505	TREATMENT OF PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-2506	METHOD OF TREATING TESTOSTERONE DEFICIENCY
U-2507	METHOD OF TREATING ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA
U-2508	A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS,

PATENT USE

	PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2509	A METHOD OF TREATING A BACTERIAL INFECTION IN COMPLICATED INTRA-ABDOMINAL INFECTION (CIAI) AND COMPLICATED URINARY TRACT INFECTION (CUTI), INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2510	A METHOD FOR CONTRACEPTION COMPRISING THE STEP OF ORAL ADMINISTRATION A DOSAGE OF 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
U-2511	A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE
U-2512	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR
U-2513	MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2514	MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2515	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-2516	A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2517	A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2518	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-2519	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
U-2520	TREATING MS WITH ORAL CLADRIBINE ACC. TO THE STEPS (I) INDUCTION PERIOD WITH ABOUT 1.7 MG/KG-3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) MAINTENANCE PERIOD WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
U-2521	TREATMENT OF MS WITH A TABLET WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE AND HYDROXYPROPYL-B-CYCLODEXTRIN AND (B) AMORPHOUS FREE CLADRIBINE AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, CLADRIBINE/CYCLODEXTRIN 1:10-1:16 W/W
U-2522	TREATING RRMS OR SPMS WITH ORAL CLADRIBINE: (I) 2-4 MONTHS INDUCTION WITH 1.7 MG/KG - 3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) 2-4 MONTHS MAINTENANCE WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
U-2523	TREATMENT OF MS WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE (2CDA) AND CYCLODEXTRIN AND (B) AMORPHOUS FREE 2CDA AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, FORMULATED AS A SOLID ORAL FORM, W/O SIGN. AMOUNTS OF CRYST. 2CDA
U-2524	TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
U-2525	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY OR URGE INCONTINENCE
U-2526	ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
U-2527	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2528	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE

PATENT USE

U-2529 TREATMENT OF A MODERATE MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA

U-2530 TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO < 6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR

U-2531 TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046

U-2532 TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG

U-2533 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

U-2534 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)

U-2535 USE IN COMBINATION WITH METHYLPREDNISOLONE FOR THE TREATMENT OF PATIENTS WITH PROSTATE CANCER

U-2536 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE

U-2537 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

U-2538 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER

U-2539 IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN, WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER

U-2540 TREATMENT OF HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN

U-2541 REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION (MI), AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY WITH A HISTORY OF MI BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY

U-2542 REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY AND HAVING OR WHO HAD ACUTE CORONARY SYNDROME BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY

U-2543 TREATMENT OF SCHIZOPHRENIA WITH CARIPRAZINE

U-2544 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE

U-2545 TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE

U-2546 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA

U-2547 METHOD OF PROVIDING CONTRACEPTION IN A WOMAN HAVING A BMI OF 25 KG/M2 OR MORE WITH RESULTANT LIMITED BLEEDING EVENTS PER TREATMENT CYCLE

U-2548 TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)

U-2549 CONTROL OF SERUM PHOSPHORUS LEVELS

U-2550 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT

U-2551 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT

U-2552 METHOD OF TREATING POSTPARTUM DEPRESSION

U-2553 PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

U-2554 TREATMENT OF MILD TO MODERATE ACTIVE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON

U-2555 A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY

PATENT USE

	INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
U-2556	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULTS WHO HAVE INTOLERANCE TO OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR A GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-2557	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON
U-2558	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
U-2559	USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
U-2560	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
U-2561	USE IN COMBINATION WITH CISPLATIN FOR TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT PRIOR CHEMOTHERAPY TREATMENT
U-2562	TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER IN COMBINATION WITH PREDNISONE
U-2563	TREATMENT OF ADVANCED GASTRIC ADENOCARCINOMA IN COMBINATION WITH CISPLATIN AND FLUOROURACIL IN PATIENTS THAT HAVE NOT RECEIVED PRIOR CHEMOTHERAPY
U-2564	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN COMBINATION WITH CISPLATIN AND FLUOROURACIL
U-2565	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
U-2566	TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
U-2567	ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM, WHERE THE PATIENT EXPERIENCES NO REBOUND OR WORSENING OF FACIAL ERYTHEMA POST-TREATMENT
U-2568	TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
U-2569	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR
U-2570	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-2571	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-2572	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S. PATENT 10058546
U-2573	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2574	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2575	TREATING CYSTIC FIBROSIS PATIENTS AGES 6 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR
U-2576	TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
U-2577	TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC IMMUNE

PATENT USE

	THROMBOCYTOPENIA WHO HAS HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
U-2578	TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE
U-2579	REDUCTION IN A SUBJECT'S RISK OF EXPERIENCING A BREAKTHROUGH OVERT HEPATIC ENCEPHALOPATHY (HE) EPISODE
U-2580	A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
U-2581	TREATING HYPOTENSION WITH ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK
U-2582	FOR THE ORAL PREVENTION/PROPHYLAXIS OF MALARIA IN ADULTS, COMPRISING A THREE-PHASE DOSING REGIMEN CONSISTING OF A LOADING/INITIAL DOSE, A MAINTENANCE/EXPOSURE DOSE, AND A TERMINAL/POST-EXPOSURE DOSE
U-2583	TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN
U-2584	XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES
U-2585	TREATMENT OF PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS IN PATIENTS UNDER THE AGE OF 12
U-2586	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI)
U-2587	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)
U-2588	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
U-2589	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
U-2590	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
U-2591	LOWERING PLASMA GLUCAGON IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE
U-2592	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2593	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2594	REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2595	REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2596	REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2597	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
U-2598	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN INJECTABLE SUSTAINED RELEASE FORMULATION OF EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE
U-2599	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS
U-2600	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY

PATENT USE

	ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2601	STIMULATING INSULIN RELEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2602	DELAYING GASTRIC EMPTYING IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2603	METHOD OF TREATING IRON DEFICIENCY
U-2604	TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES
U-2605	TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER
U-2606	TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
U-2607	TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS
U-2608	METHOD OF TREATING SCHIZOPHRENIA
U-2609	A METHOD FOR INDUCING A REGIONAL ANAESTHESIA VIA INTRATHECAL ADMINISTRATION OF A PATENTED PRESERVATIVE FREE SOLUTION FOR INJECTION (WITH A SPECIFIC COMPOSITION, PH, OSMOLALITY AND DENSITY) CONTAINING 9-11 MG/ML CHLOROPROCAINE HCL
U-2610	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-2611	TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-2612	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN PATIENTS 10 YEARS OF AGE AND OLDER
U-2613	TREATMENT OF RELAPSING-REMITTING SCLEROSIS (MS)
U-2614	TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA
U-2615	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
U-2616	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE
U-2617	TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER
U-2618	TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
U-2619	TREATMENT OF ADULTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA CAUSED BY SUSCEPTIBLE MICROORGANISMS
U-2620	USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
U-2621	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN
U-2622	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER
U-2623	A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSON'S DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY
U-2624	TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
U-2625	TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
U-2626	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION BY ADMINISTERING TENAPANOR
U-2627	TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER
U-2628	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
U-2629	TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF DELSTRIGO

PATENT USE

U-2630	FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO DORAVIRINE
U-2631	TREATMENT OF COMPLICATED URINARY TRACT INFECTION
U-2632	REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
U-2633	TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER, PROGRESSED ON: CRIZOTINIB + AT LEAST 1 OTHER ALK INHIBITOR FOR METASTATIC DISEASE; OR ALECTINIB, OR CERITINIB AS FIRST ALK INHIBITOR FOR METASTATIC DISEASE.
U-2634	METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA
U-2635	TREATMENT OF ACUTE URTICARIA
U-2636	METHOD OF INCREASING PEAK PLASMA OR ONSET OF PLASMA CONCENTRATION BY INTRAVENOUS INJECTION IN INDIVIDUALS IN NEED OF TREATMENT FOR ACUTE URTICARIA
U-2637	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL
U-2638	INCREASE PAIN-FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
U-2639	METHOD OF ACTIVATING RARGAMMA RECEPTOR
U-2640	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING
U-2641	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
U-2642	METHOD OF TREATING CANCER BY DETECTING A CREATININE CLEARANCE OF A PATIENT AND ADMINISTERING LONSURF
U-2643	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER AND SYMPTOMS THEREOF
U-2644	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER
U-2645	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2646	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE ONE F508DEL MUTATION AND ONE R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2647	TREATMENT OF NON-NODULAR ACNE VULGARIS
U-2648	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2649	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR; AND ANOTHER COMPOSITION COMPRISING IVACAFTOR
U-2650	TREATMENT OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE USING A SOLID COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AMORPHOUS IVACAFTOR, AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR
U-2651	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2652	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
U-2653	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF

PATENT USE

	ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2654	TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
U-2655	A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS
U-2656	TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
U-2657	TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
U-2658	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE
U-2659	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE USING A DOSAGE TITRATION SCHEDULE
U-2660	TREATMENT OF H. PYLORI INFECTION IN ADULTS
U-2661	CHRONIC WEIGHT MANAGEMENT IN ADULT PATIENTS USING AN EXTENDED RELEASE TABLET CONTAINING LORCARSERIN HYDROCHLORIDE HEMIHYDRATE
U-2662	USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER
U-2663	USE IN SONOHYSTEROSALPINOGRAPHY TO ASSESS FALLOPIAN TUBE PATENCY
U-2664	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY INDUCING SKIPPING OF EXON 51
U-2665	TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
U-2666	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
U-2667	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA
U-2668	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
U-2669	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
U-2670	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA
U-2671	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
U-2672	TREATMENT OF ACUTE HEPATIC PORPHYRIA
U-2673	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY CORRECTING A DEFECTIVE GENE FOR DYSTROPHIN
U-2674	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY RESTORING OR INCREASING FUNCTIONAL DYSTROPHIN PROTEIN PRODUCTION
U-2675	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
U-2676	TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 1
U-2677	PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS
U-2678	PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT
U-2679	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II AT AN INITIAL RATE OF ABOUT 20 NG/KG/MIN AND TITRATING DOWN TO ACHIEVE AND/OR MAINTAIN A MAP OF ABOUT 65 MM HG OR ABOVE
U-2680	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION
U-2681	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION, AND TITRATING THE RATE UP
U-2682	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY

PATENT USE

U-2683 TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY

U-2684 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB

U-2685 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB

U-2686 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY

U-2687 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY

U-2688 USE OF VASCEPA TO LOWER TRIGLYCERIDES AND LDL-C IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY

U-2689 USE OF VASCEPA TO TREAT MIXED DYSLIPIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>=150 MG/DL) AND ON STATIN THERAPY

U-2690 USE OF VASCEPA TO LOWER TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY

U-2691 USE OF VASCEPA TO TREAT HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY

U-2692 USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY

U-2693 USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY

U-2694 USE OF VASCEPA TO LOWER TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY

U-2695 USE OF VASCEPA TO TREAT MIXED HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY

U-2696 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION, AND UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)

U-2697 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)

U-2698 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)

U-2699 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS

U-2700 USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON ROSUVASTATIN THERAPY

U-2701 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)

U-2702 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS

U-2703 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT (CV DEATH, CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND DIABETES MELLITUS

U-2704 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND

PATENT USE

	AT LEAST ONE RISK FACTOR FOR CARDIOVASCULAR DISEASE
U-2705	METHOD OF USING CAPSAICIN IN COMBINATION WITH A GEL COMPOSITION FOR REMOVAL OF CAPSAICIN FROM A TREATMENT AREA OR UNINTENDED AREA
U-2706	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF ONSET AND/OR RECURRENCE OF CARDIOVASCULAR EVENTS IN A PATIENT WHO HAS ESCAPED THE UNSTABLE PERIOD AFTER CARDIOVASCULAR ANGIOPLASTY
U-2707	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE OCCURRENCE OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH HYPERCHOLESTEROLEMIA
U-2708	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
U-2709	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-2710	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-2711	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 750 MG OF ELEMENTAL IRON
U-2712	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 750 MG OF ELEMENTAL IRON
U-2713	MODULATION OF 5-HYDROXYTRYPTAMINE 2 RECEPTOR ACTIVITY IN SCHIZOPHRENIA
U-2714	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN RESIDUAL SYMPTOMS OF SCHIZOPHRENIA
U-2715	TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 2
U-2716	MAINTENANCE TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN
U-2717	ACUTE TREATMENT OF MIGRAINE WITH HEADACHE, WITH OR WITHOUT AURA IN ADULTS
U-2718	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
U-2719	TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS BY DETERMINING VARICELLA ZOSTER VIRUS (VZV) STATUS AND VACCINATING PRIOR TO COMMENCING TREATMENT
U-2720	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
U-2721	TOPICAL TREATMENT OF TINEA UNGUIUM BY USING AN APPLICATOR FOR APPLYING A SOLUTION FOR TREATING TINEA UNGUIUM TO AN AFFECTED PART OF A PATIENT
U-2722	METHOD OF INTRAVENOUSLY ADMINISTERING A DILUTED CYSTEINE HYDROCHLORIDE SOLUTION TO A NEONATE IN NEED THEREOF
U-2723	MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
U-2724	A METHOD OF ORAL DELIVERY OF TREPROSTINIL COMPRISING ADMINISTERING AN ORAL OSMOTIC PHARMACEUTICAL DOSAGE FORM
U-2725	A METHOD OF TREATING PULMONARY HYPERTENSION AND PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING AN ORAL OSMOTIC PHARMACEUTICAL DOSAGE FORM
U-2726	TREATMENT OF UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION
U-2727	NASAL ADMINISTRATION OF DIAZEPAM FOR TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY IN PATIENTS 6 YEARS OF AGE AND OLDER
U-2728	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
U-2729	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH MESOTHELIOMA
U-2730	METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
U-2731	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT

PATENT USE

	(45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
U-2732	METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
U-2733	METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
U-2734	METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE
U-2735	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150MG ELAGOLIX WHILE CO-ADMINISTERING RIFAMPIN
U-2736	METHOD OF TREATING EPITHELIOID SARCOMA
U-2737	METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)
U-2738	METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA
U-2739	INCREASING BLOOD PRESSURE WITH AN INITIAL RATE OF ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK, AND TITRATING THE RATE UP.
U-2740	INCREASING BLOOD PRESSURE WITH A RATE OF ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK
U-2741	TREATMENT OF CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER
U-2742	TREATMENT OF SEVERE HYPOGLYCEMIA
U-2743	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF UNSTABLE ANGINA IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-2744	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF STROKE IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-2745	TREATMENT OF NEUROBLASTOMAS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
U-2746	USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2747	USE OF NEXLETOL AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2748	USE OF NEXLETOL AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR INHIBITING CHOLESTEROL SYNTHESIS TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2749	USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR INHIBITING CHOLESTEROL SYNTHESIS TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2750	MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
U-2751	A TRANSDERMAL METHOD OF CONTRACEPTION
U-2752	METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION
U-2753	INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING AS A 3 WEEK CYCLE CABAZITAXEL AFTER 5 MG DEXCHLORPHENIRAMINE, 8 MG DEXAMETHASONE, AND AN H2-AGONIST
U-2754	TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-2755	OCULAR EXAMINATION, INTRAOCULAR PRESSURE MEASUREMENT, OR REMOVAL OF FOREIGN BODIES OR SUTURES, IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC
U-2756	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE

PATENT USE

U-2757	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
U-2758	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
U-2759	REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
U-2760	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OF AGE OR OLDER
U-2761	INTRAVENOUS SOTALOL DOSING REGIMEN FOR ACHIEVING STEADY STATE CONCENTRATION (EXPOSURE) FASTER COMPARED TO THE CONVENTIONAL ORAL DOSING IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING
U-2762	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A MAJOR CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CARDIOVASCULAR DISEASE
U-2763	METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
U-2764	TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY
U-2765	TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40 KG WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2766	TX OF HIV1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS & PEDIATRIC PATIENTS AT LEAST 40KG HAVING NO PRIOR ARV TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MO
U-2767	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO HAVE NO PRIOR ARV TREATMENT HISTORY
U-2768	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS
U-2769	DOSING REGIMEN FOR INTRAVENOUS SOTALOL FOR ADMINISTRATION IN A FACILITY THAT CAN PROVIDE CONTINUOUS ELECTROCARDIOGRAPHIC MONITORING AND CARDIAC RESUSCITATION.
U-2770	CUSHING'S DISEASE
U-2771	TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
U-2772	MAINTENANCE TREATMENT OF CHRONIC PULMONARY DISEASE (COPD)
U-2774	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
U-2775	TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
U-2776	TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
U-2777	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR
U-2778	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 2 TO 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR
U-2779	TREATMENT OF SPASTICITY
U-2780	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2781	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME

PATENT USE

U-2782	USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2783	USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH DRAVET SYNDROME
U-2784	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)
U-2785	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)
U-2786	METHOD OF PREVENTING PREGNANCY BY INSERTING A VAGINAL SYSTEM CONTAINING 103 MG OF SEGESTERONE ACETATE AND 17.4 MG ETHINYL ESTRADIOL INTO A VAGINA FOR UP TO THIRTEEN 21/7-DAY (IN/OUT) CYCLES
U-2787	METHOD OF CONTRACEPTION BY INSERTING A VAGINAL SYSTEM FOR UP TO 13 21/7-DAY (IN/OUT) CYCLES, WHEREIN EFFICACY REQUIRES THE SYSTEM CANNOT BE OUT OF THE VAGINA FOR MORE THAN 2 CUMULATIVE HOURS IN ANY SUCH CYCLE WITHOUT USING ALTERNATIVE CONTRACEPTION
U-2788	TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER
U-2789	POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-2790	TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
U-2791	TREATMENT OF ADULT PATIENTS WITH INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
U-2792	TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
U-2793	A METHOD FOR DELIVERING NITRIC OXIDE TO A PATIENT WITH PULMONARY HYPERTENSION OR HYPOXIA
U-2794	TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 100 MG CANAGLIFLOZIN PER DAY
U-2795	TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 300 MG CANAGLIFLOZIN PER DAY
U-2796	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY
U-2797	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY
U-2798	REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY
U-2799	REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY
U-2800	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
U-2801	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT THERAPY
U-2802	BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY
U-2803	BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST
U-2804	A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS
U-2805	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY

PATENT USE

U-2806	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF FOOD
U-2807	TREATMENT OF MODERATE TO SEVERE MIGRAINE PAIN WITH PAIN FREE AT 2 HOURS POST ADMINISTRATION
U-2808	TREATMENT OF DYSKINESIA, DECREASING OFF TIME, AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2809	FOR THE TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT
U-2810	METHOD OF SUPPORTING EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-2811	METHOD OF TREATING PARKINSON'S DISEASE
U-2812	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE
U-2813	USE FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING MUTATION
U-2814	A METHOD OF PROPHYLACTIC TREATMENT OF GOUT FLARES IN ADULTS COMPRISES ADMINISTERING TO A PATIENT A LIQUID COLCHICINE ORAL SOLUTION
U-2815	MEASURING TIME-VARYING CHANGE IN BLOOD IN A TISSUE VOLUME USING MODIFIED BEER-LAMBERT LAW IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2816	METHOD FOR TREATING INFLUENZA
U-2817	METHOD OF INHIBITING COMT IN THE PERIPHERY
U-2818	METHOD OF REDUCING O-METHYLATION OF L-DOPA
U-2819	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
U-2820	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY
U-2821	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
U-2822	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY
U-2823	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
U-2824	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY
U-2825	TREATMENT OF "OFF" EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
U-2826	TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
U-2827	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
U-2828	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
U-2829	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS
U-2830	A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC),

PATENT USE

	WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION
U-2831	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
U-2832	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
U-2833	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
U-2834	TREATMENT OF ADULTS WITH PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH), (WHO GROUP 4) AFTER SURGICAL TREATMENT, OR INOPERABLE CTEPH, TO IMPROVE EXERCISE CAPACITY AND WHO FUNCTIONAL CLASS
U-2835	TREATMENT OF ADULTS WITH PULMONARY HYPERTENSION (PAH), (WHO GROUP 1), TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING
U-2836	TREATMENT OF ADULT PATIENTS WITH SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY.
U-2837	TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
U-2838	REDUCTION OF THE RATE OF A FIRST MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
U-2839	TREATMENT OF MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
U-2840	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP)
U-2841	USE OF VASCEPA WITH HIGH INTENSITY STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND (1) ESTABLISHED CV DISEASE, OR (2) DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE
U-2842	MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS)
U-2843	NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS
U-2844	IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
U-2845	A METHOD OF TREATING A HUMAN PATIENT SUFFERING FROM PULMONARY HYPERTENSION
U-2846	TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE REFRACTORY TO SYSTEMIC THERAPY
U-2847	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE IN ADULTS
U-2848	TREATMENT OF TRAVELERS' DIARRHEA (TD) CAUSED BY NONINVASIVE STRAINS OF ESCHERIA COLI IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-2849	METHOD OF TREATING BLEPHAROPTOSIS
U-2850	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG ELAGOLIX WHILE CO-ADMINISTERING KETOCONAZOLE
U-2851	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
U-2852	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
U-2853	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
U-2854	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2
U-2855	XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
U-2856	INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING 20 TO 25 MG/M2 CABAZITAXEL AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN H2-ANTAGONIST
U-2857	USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR

PATENT USE

LANREOTIDE

U-2858 USE IN COMBINATION WITH STIRIPENTOL, VALPROATE, AND CLOBAZAM FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME

U-2859 USE OF CARDIAC MONITORING AND RESTRICTED DISTRIBUTION OF FENFLURAMINE TO MITIGATE RISK OF CARDIOVASCULAR TOXICITY IN THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME

U-2860 USE IN COMBINATION WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME

U-2861 USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME

U-2862 USE FOR THE TREATMENT OF FOCAL SEIZURES IN PATIENTS WITH DRAVET SYNDROME

U-2863 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER

U-2864 METHOD FOR INHIBITING CYTIDINE DEAMINASE BY ADMINISTERING CEDAZURIDINE

U-2865 TREATMENT OF MYELODYSPLASTIC SYNDROME

U-2866 TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA

U-2867 METHOD FOR INHIBITING DEGRADATION OF A CDA SUBSTRATE BY ADMINISTERING CEDAZURIDINE

U-2868 TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE

U-2869 IV ADMINISTRATION OF CANGRELOR BEFORE PCI AND CONTINUOUS INFUSION FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI AND, DURING OR AFTER THE CONTINUOUS INFUSION, ADMINISTRATION OF A LOADING DOSE OF TICAGRELOR OR AN EQUIVALENT THERAPY (PER LABELING)

U-2870 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2

U-2871 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2 AND 3

U-2872 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4 AND 5

U-2873 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4, 5, AND 6

U-2874 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7 AND 8

U-2875 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7, 8, AND 9

U-2876 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10 AND 11

U-2877 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10, 11, AND 12

U-2878 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 14

U-2879 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 14, AND 15

U-2880 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16 AND 17

U-2881 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16, 17, AND 18

PATENT USE

U-2882 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19 AND 20

U-2883 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19, 20, AND 21

U-2884 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 22, 23, AND 24

U-2885 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25 AND 26

U-2886 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25, 26, AND 27

U-2887 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28 AND 29

U-2888 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28, 29, AND 30

U-2889 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-2890 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2891 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 3 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2892 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 4 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2893 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2894 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2895 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2896 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2897 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 9

U-2898 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 10

U-2899 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN

PATENT USE

CLAIMS 1 AND 11

U-2900 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 13

U-2901 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2902 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 16 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2903 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 17 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2904 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1, 17 AND 18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2905 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2906 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 22 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22

U-2907 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 23 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22

U-2908 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 24 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22

U-2909 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 25 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22

U-2910 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 26 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2911 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 27 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2912 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 28 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2913 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 29 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2914 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 30 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2915 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2

PATENT USE

DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 31 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2916 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 32 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2917 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 33 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS

U-2918 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 34 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2919 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 36 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2920 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 38 AND WHEREIN THE EFFECTS ARE AS RECITED CLAIM 26

U-2921 ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS

U-2922 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 39 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2923 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 40 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2924 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 42 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42

U-2925 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 42 AND 43 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42

U-2926 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2927 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 45 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2928 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 46 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2929 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 47 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2930 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 48 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2931 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2

PATENT USE

	DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 49 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
U-2932	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 50 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
U-2933	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 51 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
U-2934	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 52 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
U-2935	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 44 AND 54
U-2936	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 56 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
U-2937	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 57 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
U-2938	TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY WITH A MIXTURE OF SODIUM, POTASSIUM, MAGNESIUM, AND CALCIUM SALTS OF GHB
U-2939	TREATMENT OF HIV INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
U-2940	METHOD OF TREATING PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
U-2941	A METHOD OF USING AN AEROSOL DELIVERY DEVICE TO AEROSOLIZE GLYCOPYRROLATE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2942	METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17A-PROPIONATE
U-2943	TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
U-2944	TREATMENT OF RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
U-2945	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
U-2946	TREATMENT OF COLORECTAL CANCER THAT HAS A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
U-2947	KYPROLIS IS INDICATED IN COMBINATION WITH DARATUMUMAB PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-2948	A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM (IUS) BY DETERMINING A DEPTH OF THE UTERUS, HOLDING AN INSERTER HANDLE WITH ONE HAND, INSERTING THE IUS INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE IUS INTO THE UTERUS
U-2949	A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION
U-2950	CONTINUED TREATMENT OF ADULTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR CR WITH INCOMPLETE BLOOD COUNT RECOVERY FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY
U-2951	USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION

PATENT USE

	OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
U-2952	TREATMENT OF ADULT PATIENTS WITH METASTATIC REARRANGED DURING TRANSFECTION (RET) FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST
U-2953	USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ASTHMA
U-2954	METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD
U-2955	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA
U-2956	METHOD OF TREATING LAMBERT-EATON MYASTHENIC SYNDROME WITH AMIFAMPRIDINE
U-2957	MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-2958	A METHOD FOR CONTRACEPTION, THE METHOD COMPRISING ADMINISTERING A TABLET COMPRISING 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
U-2959	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A THIRD AND FURTHER CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TG LEVELS (>=150 MG/DL) AND ESTABLISHED CARDIOVASCULAR DISEASE
U-2960	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A SECOND OR FURTHER CARDIOVASCULAR (CV) EVENT IN AN ADULT PATIENT WITH ELEVATED TG LEVELS (>= 150 MG/DL) AND DIABETES MELLITUS AND 2 OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE
U-2961	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF MYOCARDIAL INFARCTION, STROKE, BOTH IN AN ADULT PATIENT WITH TYPE 2 DIABETES MELLITUS
U-2962	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-2963	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2964	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE
U-2965	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2966	TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
U-2967	TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046
U-2968	USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
U-2969	TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
U-2970	TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
U-2971	THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
U-2972	THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
U-2973	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS PAPILLARY THYROID CANCER

PATENT USE

U-2974 TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS MEDULLARY THYROID CANCER

U-2975 TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS DIFFERENTIATED THYROID CANCER

U-2976 TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS RECURRENT THYROID CANCER

U-2977 TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE REFRACTORY DIFFERENTIATED THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND ARE RADIOACTIVE IODINE-REFRACTORY

U-2978 TREATMENT OF HIV-1 INFECTION IN ADULT OR PEDIATRIC PATIENTS (>=40 KG) WITH <50 COPIES/ML HIV-1 RNA AFTER >= 6 MONTHS ON PRIOR ANTIRETROVIRAL REGIMEN AND NO KNOWN DARUNAVIR OR TENOFOVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS

U-2979 METHOD COMPRISING IV ADMINISTRATION OF CANGRELOR BEFORE PCI THEN CONTINUOUS INFUSION FOR AT LEAST 2 HOURS OR THE DURATION OF PCI AND, DURING OR AFTER CONTINUOUS INFUSION, ADMINISTRATION OF A LOADING DOSE OF TICAGRELOR, OR AN EQUIVALENT METHOD

U-2980 METHOD OF TREATING AN ALLERGIC REACTION USING AN AUTO-INJECTOR

U-2981 A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND THE AML IS NEWLY DIAGNOSED

U-2982 A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND WHERE THE AML IS RELAPSED/REFRACTORY

U-2983 TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INJECTION

U-2984 TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION

U-2985 A METHOD FOR TREATING DRY EYE IN A PATIENT

U-2986 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

U-2987 METHOD OF TREATING LUNG CANCER, UNDIFFERENTIATED SARCOMA, OR COLORECTAL CANCER THAT EXHIBITS AN NTRK GENE FUSION

U-2988 REDUCTION OF THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK

U-2989 METHOD OF USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER

U-2990 METHOD OF USE FOR TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER

U-2991 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG

U-2992 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG

U-2993 A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED

U-2994 REDUCTION OF RISK OF MYOCARDIAL INFARCTION, STROKE OR CARDIOVASCULAR DEATH IN A PATIENT WITH CHRONIC CAD OR PAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY

U-2995 TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)

U-2996 ADMINISTRATION OF AN EXTENDED RELEASE TABLET FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY

U-2997 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF STROKE IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDES AND ATRIAL FIBRILLATION

PATENT USE

U-2998	METHOD OF ADMINISTERING DOCETAXEL TO A SUBJECT COMBINING THE DOCETAXEL PRO-EMULSION FORMULATION WITH AN AQUEOUS MEDIUM TO PRODUCE DOCETAXEL EMULSION
U-2999	METHOD OF USE OF TREATING, AS AN INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY IN PARTIAL ONSET SEIZURE PATIENTS WITH EPILEPSY AGED 17 YEARS OR OLDER
U-3000	METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA
U-3001	PROCEDURES IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC.
U-3002	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
U-3003	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON
U-3004	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
U-3005	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE USE OF TASIMELTEON WITH RIFAMPIN
U-3006	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
U-3007	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
U-3008	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
U-3009	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
U-3010	PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-3011	A METHOD FOR TREATING OCULAR INFLAMMATION
U-3012	TREATMENT IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) THAT IMPROVES METASTASIS FREE SURVIVAL
U-3013	TREATMENT IN COMBINATION WITH ORCHIECTOMY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)
U-3014	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES
U-3015	TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP
U-3016	ADJUVANT THERAPY AFTER TUMOR RESECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER(NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
U-3017	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH A SALT OF GAMMA-HYDROXYBUTYRATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED
U-3018	XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-3019	TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER THAT IS SEX-HORMONE-DEPENDENT
U-3020	TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER
U-3021	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE
U-3022	TREATMENT OF CF IN PATIENTS 12 YEARS AND OLDER WHO HAVE A F508DEL OR G551D CFTR MUTATION AND A 2ND MUTATION SELECTED FROM R117H, A455E, 2789+5G->A, & 3849+10KBC->T, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546
U-3023	TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE A F508DEL OR G551D CFTR MUTATION AND A 2ND MUTATION SELECTED FROM R117H, A455E, 2789+5G->A, AND

PATENT USE

	3849+10KBC->T, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546
U-3024	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-3025	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-3026	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-3027	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-3028	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3029	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3030	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA
U-3031	TREATMENT OF CF IN PATIENTS 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA
U-3032	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
U-3033	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-3034	TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3035	TREATMENT OF DEPRESSIVE SYMPTOMS IN ADULTS WITH MDD WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR BY NASALLY ADMINISTERING 56MG OR 84 MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3036	TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE FOLLOWED BY A MAINTENANCE PHASE OF 56MG OR 84 MG WEEKLY OR 1X EVERY TWO WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3037	A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
U-3038	MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION IN PATIENTS WITH MILD RENAL IMPAIRMENT
U-3039	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
U-3040	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MILD HEPATIC IMPAIRMENT AND ARE CONCURRENTLY TAKING A STRONG OR MODERATE CYP3A INHIBITOR
U-3041	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MODERATE TO SEVERE RENAL IMPAIRMENT
U-3042	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 POOR METABOLIZERS WITH 84 MG ONCE DAILY OF ELIGLUSTAT (EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE)
U-3043	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE OR INTERMEDIATE METABOLIZERS WITH 84 MG TWICE PER DAY OF ELIGLUSTAT

PATENT USE

	(EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE TWICE PER DAY)
U-3044	AXITINIB IN COMBINATION WITH AVELUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
U-3045	TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-3046	METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER
U-3047	USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
U-3048	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 500 TO 750 MG OF ELEMENTAL IRON
U-3049	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 500 TO 750 MG OF ELEMENTAL IRON
U-3050	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS
U-3051	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS
U-3052	USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT ON STATIN THERAPY AND HAVING ATRIAL FIBRILLATION AND TRIGLYCERIDE LEVELS OF GREATER THAN 500 MG/DL
U-3053	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF MYOCARDIAL INFARCTION IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND ESTABLISHED CV DISEASE OR DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE
U-3054	TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS IN ADULT PATIENTS WITH PARKINSON'S DISEASE
U-3055	A METHOD OF TREATING HUNTINGTON'S CHOREA
U-3056	TREATMENT OF PATIENTS WITH ACTIVE LUPUS NEPHRITIS
U-3057	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE
U-3058	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE
U-3059	TREATMENT OF HIV-1 INFECTION IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
U-3060	TREATMENT OF HIV INFECTION IN ADULTS
U-3061	TREATMENT OF HIV-1 IN AN ADULT IN COMBINATION WITH RILPIVIRINE
U-3062	REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
U-3063	RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
U-3064	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
U-3065	TREATMENT OF ADULTS WITH METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-3066	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC, SURGICALLY UNRESECTABLE UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY

PATENT USE

U-3067	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-3068	TREATMENT IN COMBINATION WITH CABOTEGRAVIR OF HIV-1 INFECTION IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
U-3069	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER
U-3070	REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)
U-3071	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
U-3072	USE FOR THE TREATMENT OF GENERALIZED SEIZURES OR FOCAL SEIZURES WITH IMPAIRMENT IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
U-3073	USE FOR REDUCING SEIZURE FREQUENCY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
U-3074	METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS
U-3075	TREATMENT OF ADRENAL INSUFFICIENCY
U-3076	METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER
U-3077	TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), OR STABILIZING OR IMPROVING SYMPTOMS ASSOCIATED WITH HAVING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB
U-3078	TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, HAVING A MET KINASE ALTERATION(S) BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB
U-3079	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
U-3080	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER
U-3081	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A CARBOPLATIN AND ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
U-3082	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA (OSA) IN AN ADULT THROUGH A DOSING REGIMEN THAT INCLUDES ORAL ADMINISTRATION OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY
U-3083	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
U-3084	TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION
U-3085	DOSE MODIFICATION FOR RENAL IMPAIRMENT
U-3086	FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
U-3087	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY INDUCING EXON-SKIPPING OF EXON 45
U-3088	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING
U-3089	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION
U-3090	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-3091	TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-3092	METHOD OF TREATING MOLYBDENUM COFACTOR DEFICIENCY TYPE A
U-3093	IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFACTORY TO AT LEAST 1 PROTEASOME INHIBITOR, 1 IMMUNOMODULATORY AGENT, AND 1 ANTI-CD38 MAB) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR LINES OF THERAPY

PATENT USE

U-3094	TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE
U-3095	TREATMENT OF HYPERLIPIDEMIA
U-3096	TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
U-3097	EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY
U-3098	TREATMENT OF REFRACTORY EPILEPSY PATIENTS WITH FENFLURAMINE THAT REDUCES THE RISK OF CARDIOVASCULAR TOXICITY BY USING CARDIAC MONITORING AND RESTRICTED DISTRIBUTION
U-3099	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA (OSA) IN A PATIENT WITH MODERATE RENAL IMPAIRMENT
U-3100	A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR
U-3101	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS WITH A SINGLE DOSE OF 1200MG ORITAVANCIN OR ITS SINGLE DOSE EQUIVALENT
U-3102	REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
U-3103	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
U-3104	TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA
U-3105	TREATMENT OF STAPHYLOCOCCAL ENTEROCOLITIS
U-3106	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
U-3107	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
U-3108	TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS AGED 3 YEARS AND OLDER BY ADMINISTRATION OF AN EXTENDED-RELEASE SUSPENSION FORMULATION OF MIRABEGRON
U-3109	METHOD OF USING VISMODEGIB TO TREAT BASAL CELL CARCINOMA
U-3110	USE OF NALOXONE FOR THE EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION, FOR ADULT AND PEDIATRIC PATIENTS
U-3111	TREATING OPIOID USE DISORDER
U-3112	TREATING NEWLY DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
U-3113	TREATING RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
U-3114	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP THAT INCLUDES A DOSE OF 50 MG PER DAY FOR 1 WEEK FOLLOWED BY 100 MG PER DAY FOR 1 WEEK
U-3115	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING ABOUT 1 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS
U-3116	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING ABOUT 1 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS

PATENT USE

U-3117	ADMINISTRATION TO THE EYE OF A PATIENT FOR TREATMENT OF DRY EYE CONDITION
U-3118	TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
U-3119	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 11
U-3120	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 11, AND 12
U-3121	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 23
U-3122	ADJUNCT TO DIET EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 23, AND 24
U-3123	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF COMPLEMENT INHIBITOR PEGCETACOPLAN
U-3124	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN
U-3125	USE FOR LOADING DOSE IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM OR FOR THE TREATMENT OF LIFE-THREATENING VENTRICULAR TACHYCARDIA
U-3126	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A SECOND AND FURTHER CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-3127	REDUCTION OF THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND WITHOUT TYPE II DIABETES
U-3128	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED
U-3129	MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN
U-3130	METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) IN MEN WITH PROSTATE CANCER
U-3131	USE OF ZUBSOLV FOR TREATMENT OF OPIOID DEPENDENCE
U-3132	INDICATED FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
U-3133	TREATING SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY
U-3134	INCREASING HEMOGLOBIN TO TREAT SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY
U-3135	TREATING SCHIZOPHRENIA
U-3136	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN
U-3137	METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN
U-3138	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE
U-3139	METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE
U-3140	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN
U-3141	METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN
U-3142	PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
U-3143	FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE AND OLDER

PATENT USE

U-3144	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3145	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3146	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA
U-3147	FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
U-3148	METHOD OF TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS BEFORE AND AFTER ADMINISTERING AN INACTIVE VACCINE
U-3149	METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
U-3150	METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
U-3151	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA) WITH A DOSING REGIMEN THAT INCLUDES A DOSE OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY
U-3152	USE BY FEMALES OF REPRODUCTIVE POTENTIAL TO PREVENT PREGNANCY
U-3153	TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS HAVING PROGRESSED FROM A FIRST LINE ADMINISTRATION OF IMATINIB, A SECOND LINE ADMINISTRATION OF SUNITINIB, AND A THIRD LINE ADMINISTRATION OF REGORAFENIB
U-3154	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR; AND ANOTHER COMPOSITION COMPRISING IVACAFTOR
U-3155	TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA
U-3156	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3157	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
U-3158	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-3159	TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC)
U-3160	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WHO ARE SEVERELY IMMUNOCOMPROMISED
U-3161	METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
U-3162	METHOD FOR WEIGHT MANAGEMENT
U-3163	TREATMENT OF ACTINIC KERATOSES OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY
U-3164	GASTROINTESTINAL TABLETS INDICATED FOR CLEANSING THE COLON IN PREPARATION FOR COLONOSCOPY
U-3165	METHOD OF TREATING HUMAN SMALLPOX DISEASE

PATENT USE

U-3166	OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARY RELIEF OF THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES: NASAL CONGESTION, RUNNY NOSE, SNEEZING AND ITCHY NOSE
U-3167	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG
U-3168	TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS, INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), AND MAST CELL LEUKEMIA (MCL)
U-3169	TREATMENT OF TRICHOMONIASIS IN ADULTS
U-3170	TREATING CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PATIENTS NOT TAKING AN ACE INHIBITOR OR AN ARB OR PREVIOUSLY TAKING LOW DOSES OF THESE AGENTS, BY TITRATING UP FROM HALF THE USUALLY RECOMMENDED STARTING DOSE
U-3171	TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER
U-3172	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN
U-3173	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN TWICE WEEKLY
U-3174	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN EVERY THREE DAYS
U-3175	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY ADMINISTERING THE FORMULATION OF DAPTOMYCIN AS RECITED IN CLAIM 18
U-3176	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND S. AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY RECONSTITUTING AND ADMINISTERING THE FORMULATION AS RECITED IN CLAIM 12
U-3177	TREATMENT OF VENOUS THROMBOTIC DISEASE
U-3178	REDUCE THE RISK OF RECURRENCE OF VENOUS THROMBOTIC DISEASE
U-3179	METHOD OF TREATING FOLLICULAR LYMPHOMA
U-3180	DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-3181	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET ACCORDING TO CLAIM 1 OF U.S. PATENT NO. 11,052,075, WHERE THE TABLET FURTHER COMPRISES IVACAFTOR
U-3182	METHOD OF PROVIDING POSTSURGICAL PAIN MANAGEMENT, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
U-3183	USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION
U-3184	MEKINIST(R) IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-3185	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-3186	METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
U-3187	METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
U-3188	IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-3189	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION

PATENT USE

U-3190	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
U-3191	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-3192	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
U-3193	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
U-3194	TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
U-3195	TREATMENT OF ADULTS WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS OR WHEN USE OF THOSE THERAPIES IS INADVISABLE
U-3196	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS, AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS
U-3197	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
U-3198	METHOD OF TREATING PATIENTS WITH IDIOPATHIC HYPERSOMNIA WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED
U-3199	METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH PLUS HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS, HEART FAILURE AND REDUCED EJECTION FRACTION BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
U-3200	INCREASING SURVIVAL IN MCRPC PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN ANTIHISTAMINE, A CORTICOSTEROID, AND AN H2-ANTAGONIST
U-3201	TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA, CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS, NOT REQUIRING IMMEDIATE SURGERY
U-3202	MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) COMPRISING THE ONCE PER DAY ADMINISTRATION OF TRELEGY ELLIPTA, 100 MCG FLUTICASONE FUROATE/62.5 MCG UMECLIDINIUM/25 MCG VILANTEROL
U-3203	MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-3204	TREATMENT OF MODERATE-TO-SEVERE PRURITUS ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD-AP) IN ADULTS UNDERGOING HEMODIALYSIS (HD)
U-3205	REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION AND STROKE) IN PATIENTS WITH CAD
U-3206	REDUCTION OF RISK OF MAJOR THROMBOTIC VASCULAR EVENTS (MYOCARDIAL INFARCTION, ISCHEMIC STROKE, ACUTE LIMB ISCHEMIA, AND MAJOR AMPUTATION OF VASCULAR ETIOLOGY) IN PATIENTS WITH PAD
U-3207	REDUCTION OF RISK OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH CAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY
U-3208	REDUCTION OF RISK OF MYOCARDIAL INFARCTION AND ISCHEMIC STROKE IN PATIENTS WITH PAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY
U-3209	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK MYOCARDIAL INFARCTION IN AN ADULT PATIENT HAVING ATRIAL FIBRILLATION OR ATRIAL FLUTTER AND ELEVATED TRIGLYCERIDE LEVELS
U-3210	ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS
U-3211	TREATING DISTRIBUTIVE SHOCK WITH ANGIOTENSIN II

PATENT USE

U-3212 TREATING SEPTIC SHOCK WITH ANGIOTENSIN II

U-3213 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA

U-3214 A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL

U-3215 A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY AN IDH1 MUTATION

U-3216 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C

U-3217 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT F317L

U-3218 NASAL ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE BY METERED SPRAY FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

U-3219 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR

U-3220 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 EXON INSERTION MUTATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY

U-3221 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT IN A PATIENT WITH PRIOR PERCUTANEOUS CORONARY INTERVENTION

U-3222 TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE

U-3223 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE

U-3224 A METHOD OF TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY DECREASING THE LEVEL OF LDL-C USING A FIXED DOSE COMBINATION OF 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE

U-3225 TREATMENT OF DIFFERENTIATED THYROID CANCER THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY

U-3226 FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY

U-3227 FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF

U-3228 FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA

U-3229 FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE

U-3230 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)

U-3231 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) BY ADMINISTERING NILOTINIB DISPERSED IN A FRUIT PREPARATION

U-3232 USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHILE AVOIDING CONCOMITANT ADMINISTRATION OF LEVONORGESTREL

U-3233 USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX IN PATIENTS TAKING EVEROLIMUS

U-3234 TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS

U-3235 USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME

U-3236 USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME

U-3237 TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN

PATENT USE

	ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
U-3238	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG
U-3239	TREATMENT OF ADVANCED RENAL CELL CARCINOMA (RCC) IN PATIENTS WHO HAVE RECEIVED PRIOR ANTI-ANGIOGENIC THERAPY
U-3240	USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT HAVING TRIGLYCERIDE LEVELS OF AT LEAST ABOUT 500 MG/DL, ON ANTICOAGULANT/ANTIPLATELET/THROMBOLYTIC THERAPY, AND HAVING ATRIAL FIBRILLATION AND/OR ATRIAL FLUTTER
U-3241	IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE-POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE >=20%
U-3242	IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY
U-3243	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3244	A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB
U-3245	MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
U-3246	FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
U-3247	FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOLD DISEASE
U-3248	TREATING SECONDARY HYPERPARATHYROIDISM IN STAGE 3/4 CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL WHILE AVOIDING PTH OVERSUPPRESSION
U-3249	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)
U-3250	METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
U-3251	ADMINISTRATION OF FERROUS BISGLYCINATE TABLETS
U-3252	USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS
U-3253	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO AT LEAST ONE OF CLAIMS 1-9 OF US11179367
U-3254	USE, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE >= 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
U-3255	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3256	USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES
U-3257	TREATMENT OF TRD IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE IN A MAINTENANCE PHASE WEEKLY OR 1X EVERY TWO WEEKS TO ADULTS WHO HAVE BEEN ADMINISTERED ESKETAMINE IN A INDUCTION PHASE FOR ABOUT 4 WEEKS
U-3258	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE BETWEEN ABOUT 56 MG/M2 AND ABOUT 100 MG/M2 ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE
U-3259	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA)
U-3260	METHOD OF TREATING SPASTICITY
U-3261	FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY
U-3262	TREATING HYPOTENSION WITH ANGIOTENSIN II IN A PATIENT RECEIVING AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR

PATENT USE

U-3263	METHOD FOR TREATING SPASTICITY
U-3264	AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3265	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3266	IN COMBINATION WITH FULVESTRANT AS INITIAL ENDOCRINE-BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN OR IN MEN, FOR THE TREATMENT OF HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3267	USE OF LASTACAFT TO TEMPORARY RELIEVE ITCHY EYES DUE TO POLLEN, RAGWEED, GRASS, ANIMAL HAIR AND DANDER
U-3268	TREATMENT OF MULTIPLE SCLEROSIS IN PEDIATRIC PATIENTS 10 YEARS OF AGE AND OLDER AND WEIGHING LESS THAN OR EQUAL TO 40 KG
U-3269	TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK OF RAPID DISEASE PROGRESSION
U-3270	TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER
U-3271	TREATMENT OF BIPOLAR DEPRESSION
U-3272	AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR THE TREATMENT OF ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) OR CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD), BY INHIBITING EXPRESSION OF THE PCSK9 GENE
U-3274	TREATMENT OF BIPOLAR I DISORDER, BIPOLAR II DISORDER, OR BIPOLAR DEPRESSION
U-3275	TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3276	TREATMENT OF PATIENTS WITH PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
U-3277	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX
U-3278	A METHOD OF REDUCING POST-SURGICAL PAIN FOLLOWING OCULAR SURGERY
U-3279	A METHOD OF TREATING POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY
U-3280	METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17ALPHA-PROPIONATE
U-3281	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
U-3282	DURING LEVOKETOCONAZOLE DOSAGE TITRATION FOR THE TREATMENT OF CUSHING'S SYNDROME IN PATIENTS WHO CONCOMITANTLY USE METFORMIN, MONITORING GLYCEMIA, KIDNEY FUNCTION AND VITAMIN B-12 AND ADJUSTING DOSAGE OF METFORMIN AS NEEDED
U-3283	TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME FOR WHOM SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
U-3284	PROPHYLAXIS OF THROMBOEMBOLIC DISEASES IN PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH CONGENITAL HEART DISEASE WHO HAVE UNDERGONE THE FONTAN PROCEDURE AND A BODY WEIGHT OF >=50 KG
U-3285	TREATMENT OF DVT AND/OR PE AND REDUCTION IN THE RISK OF RECURRENT DVT AND/OR PE IN PEDIATRIC PATIENTS (>=50 KG) ONCE DAILY WITH RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS AFTER AT LEAST 5 DAYS PARENTERAL ANTICOAGULANT TREATMENT
U-3286	TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND THE REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 18 YEARS WITH A BODY WEIGHT OF 30 KG TO 49.9 KG AFTER AT LEAST 5 DAYS OF INITIAL PARENTERAL ANTICOAGULANT TREATMENT
U-3287	TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND THE REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 18 YEARS WITH A BODY WEIGHT OF >=50 KG AFTER AT LEAST 5 DAYS OF INITIAL PARENTERAL ANTICOAGULANT TREATMENT
U-3288	PROPHYLAXIS OF PE, DVT AND/OR STROKE IN PEDIATRIC PATIENTS (>=50 KG) AGED 2 YEARS AND OLDER WITH CONGENITAL HEART DISEASE AFTER FONTAN PROCEDURE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS

PATENT USE

U-3289 TREATMENT OF DVT AND/OR PE AND REDUCTION IN RISK OF RECURRENT DVT AND/OR PE IN PEDIATRIC PATIENTS (30-49.9 KG) ONCE DAILY WITH RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS AFTER AT LEAST 5 DAYS PARENTERAL ANTICOAGULANT TREATMENT

U-3290 TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH ALAGILLE SYNDROME (ALGS)

U-3291 CYTALUX IS AN OPTICAL IMAGING AGENT INDICATED IN ADULT PATIENTS WITH OVARIAN CANCER AS AN ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT LESIONS

U-3292 USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT ON STATIN THERAPY AND HAVING ATRIAL FIBRILLATION OR ATRIAL FLUTTER AND TRIGLYCERIDE LEVELS OF ABOUT 500 MG/DL TO ABOUT 2,000 MG/DL

U-3293 METHOD OF TREATING BACTERIAL VAGINOSIS BY SINGLE DOSE ADMINISTRATION OF A CLINDAMYCIN PHARMACEUTICAL GEL FORMULATION

U-3294 METHOD OF TREATING A BACTERIAL INFECTION BY ADMINISTERING A RECONSTITUTED SOLID FORMULATION OF DAPTOMYCIN CONTAINING 31.0 TO 59.4% WT TOTAL MANNITOL AND SORBITOL

U-3295 METHOD OF DELIVERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A NASAL AIRWAY

U-3296 TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A PEDIATRIC PATIENT

U-3297 TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE

U-3298 TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE

U-3299 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS

U-3300 PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-3301 TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT)

U-3302 TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER

U-3303 TOPICAL LESION-DIRECTED AND FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS OF THE FACE AND SCALP WITH PHOTODYNAMIC THERAPY BY POSITIONING AN ILLUMINATION DEVICE IN AN APPROPRIATE DISTANCE AND ILLUMINATING THE TREATMENT AREA WITH NARROWBAND RED LIGHT

U-3304 METHOD OF TREATING PARKINSON'S DISEASE BY ORALLY ADMINISTERING SEGMENTS OF A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA—25 MG/LEVODOPA—100 MG, EACH SEGMENT HAVING CARBIDOPA—6.25 MG/LEVODOPA—25 MG

U-3305 METHOD OF TREATING PARKINSON'S DISEASE BY ORALLY ADMINISTERING A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA—25 MG/LEVODOPA—100 MG

U-3306 TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY

U-3307 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35KG WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED

U-3308 FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS TO TREAT HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35KG WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IF VIROLOGICALLY SUPPRESSED

U-3309 NORLIQVA IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-3310 NORLIQVA IS INDICATED FOR THE SYMPTOMATIC TREATMENT OF CHRONIC STABLE ANGINA

U-3311 NORLIQVA IS INDICATED FOR THE TREATMENT OF CONFIRMED OR SUSPECTED VASOSPASTIC ANGINA

U-3312 METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY

PATENT USE

	INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
U-3313	METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON
U-3314	METHOD OF TREATING IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER HAVING INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-3315	METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY ADMINISTERING IV AT LEAST ABOUT 0.6 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS
U-3316	METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6 GRAMS OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS
U-3317	POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
U-3318	MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INJECTION
U-3319	METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY
U-3320	METHOD FOR INCREASING THE LIFETIME OF RED BLOOD CELLS (RBCS) FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY
U-3321	METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY BY ADMINISTERING A DAILY DOSE OF 10MG TO 100MG
U-3322	USE FOR DETECTING NEUTRALIZING ANTIBODIES
U-3323	METHOD OF REDUCING ADVERSE EFFECTS IN PATIENTS WHO ARE CONCOMITANTLY ADMINISTERED A SALT OF GAMMA-HYDROXYBUTYRATE AND DIVALPROEX SODIUM
U-3324	METHOD OF TREATING PATIENTS WITH A SALT OF GAMMA-HYDROXYBUTYRATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED
U-3325	METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND HEART FAILURE BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
U-3326	A METHOD OF TREATING ANKYLOSING SPONDYLITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, AND 87-98
U-3327	A METHOD OF TREATING PSORIATIC ARTHRITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 8, 15-20, 27-31, 34-44, 46, 48, 50, 53, 59, 62, 68-71, 73, 76, 82-84, AND 87-98
U-3328	A METHOD OF TREATING RHEUMATOID ARTHRITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 2, 8, 9, 15-21, 27-31, 34-43, 50, 51, 59, 60, 68-71, 73, 74, 82-84 AND 87-98
U-3329	A METHOD OF TREATING ULCERATIVE COLITIS, BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 AND 87-98
U-3330	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM PALMER-PLANTER ERYTHRODYSESTHESIA SYNDROME
U-3331	TREATMENT OF MYELOFIBROSIS WITH PACRITINIB
U-3332	USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)
U-3333	ADJUVANT TREATMENT OF PATIENTS WITH GBRCA-MUTATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE HIGH RISK EARLY BREAST CANCER WHO HAVE BEEN TREATED WITH NEOADJUVANT OR ADJUVANT CHEMOTHERAPY
U-3334	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-3335	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
U-3336	TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP)
U-3337	ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY

PATENT USE

	BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OF ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION
U-3338	ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OR ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION WITH T790M MUTATION
U-3339	TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11147770
U-3340	A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE
U-3341	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3342	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
U-3343	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
U-3344	A METHOD OF TREATING ADULTS WITH MULTIPLE MYELOMA USING DEXAMETHASONE IN COMBINATION WITH AN ANTI-MYELOMA PRODUCT
U-3345	FOR TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR (AR) PATHWAY INHIBITION AND TAXANE-BASED CHEMOTHERAPY
U-3346	METHOD OF PROVIDING LOCAL OR REGIONAL ANALGESIA VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK OR FEMORAL NERVE BLOCK FOR REGIONAL ANALGESIA
U-3347	USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
U-3348	TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG
U-3349	REINITIATION OF SCHIZOPHRENIA TREATMENT WHEREIN MORE THAN 6 MONTHS 3 WEEKS BUT LESS THAN 8 MONTHS HAVE ELAPSED SINCE THE LAST DOSE
U-3350	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL ADMINISTRATION
U-3351	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-3352	METHOD TO TREAT IRON DEFICIENCY ANEMIA IN ADULTS & PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-3353	TREATMENT IN COMBINATION WITH CABOTEGRAVIR OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 AND OLDER TO REPLACE CURRENT REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
U-3354	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN SO AS TO REDUCE THE SENSITIVITY OF CELLS TO COMPLEMENT-DEPENDENT DAMAGE
U-3355	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-3356	TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER
U-3357	TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 65 YEARS OF AGE AND OLDER
U-3358	USE OF VASCEPA TO REDUCE THE INCIDENCE OF MI IN AN ADULT PATIENT ON STATIN THERAPY AND WITH ELEVATED TRIGLYCERIDE LEVELS (>150 MG/DL), WHEREIN THE PATIENT EXPERIENCES ATRIAL FIBRILLATION AND/OR FLUTTER INSTEAD OF AN INCIDENCE OF MI
U-3359	TREATMENT OF SCHIZOPHRENIA BY ADMINISTERING A DOSE UP TO TWO WEEKS BEFORE OR THREE WEEKS AFTER THE SCHEDULED SIX-MONTH DOSE
U-3360	COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH

PATENT USE

	METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
U-3361	COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
U-3362	TREATMENT OF BIPOLAR DEPRESSION MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D1/D2 SIGNALING PATHWAYS
U-3363	TREATMENT OF SCHIZOPHRENIA MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D1/D2 SIGNALING PATHWAYS
U-3364	TREATMENT OF BIPOLAR DISORDER I, BIPOLAR DISORDER II, OR BIPOLAR DEPRESSION
U-3365	THE PRODUCT COMPOSITION (NATROBA) IS FOR THE TOPICAL TREATMENT OF HUMAN SCABIES MITE INFESTATIONS BY MELTING AND DELIVERING THE ACTIVE INGREDIENT, SPINOSAD, TO THE STRATUM CORNEUM WHERE SCABIES MITES LIVE AND BREED
U-3366	VIVJOA IS INDICATED TO REDUCE THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN FEMALES WITH A HISTORY OF RVVC WHO ARE NOT OF REPRODUCTIVE POTENTIAL
U-3367	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION
U-3368	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG)
U-3369	TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 AND OLDER WITH SCLERODERMATOUS FORM OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY
U-3370	A METHOD FOR THE TREATMENT OF ADULT PATIENTS WITH STABLE WILSON’S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE
U-3371	TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3372	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
U-3373	TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
U-3374	TREATMENT OF SEIZURES ASSOCIATED WITH CYCLIN-DEPENDENT KINASE-LIKE 5 (CDKL5) DEFICIENCY DISORDER (CDD) IN PATIENTS 2 YEARS OF AGE AND OLDER
U-3375	USE FOR THE TREATMENT OF ABSENCE SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-3376	USE FOR THE TREATMENT OF ABSENCE SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-3377	TPOXX IS INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 3 KG
U-3378	MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-3379	A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF EPINEPHRINE
U-3380	METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
U-3381	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM HYPERTENSION
U-3382	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM A GRADE 3 ADVERSE REACTION WHILE BEING ADMINISTERED RIPRETINIB DAILY
U-3383	TREATING NEWLY DIAGNOSED AML CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE OF IVOSIDENIB TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL, IN COMBINATION WITH AZACITIDINE
U-3384	A METHOD FOR TREATING AML BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING IVOSIDENIB WHEREIN THE AML IS NEWLY DIAGNOSED AND CHARACTERIZED BY A MUTANT IDH1 AND THE COMPOSITION IS ADMINISTERED IN COMBINATION WITH AZACITIDINE
U-3385	A METHOD FOR TREATING NEWLY DIAGNOSED AML WITH IVOSIDENIB AND AZACITIDINE WHEREIN THE AML HAS AN IDH1 MUTATION CAPABLE OF CONVERTING ALPHA-KETOGLUTARATE TO 2-HYDROXYGLUTARATE (2HG)
U-3386	A METHOD FOR TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WITH IVOSIDENIB

PATENT USE

	IN COMBINATION WITH AZACITIDINE WHEREIN THE CANCER IS NEWLY DIAGNOSED AML
U-3387	A METHOD FOR TREATING NEWLY DIAGNOSED AML CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 SELECTED FROM R132H, R132C, R132L, R132V, R132S AND R132GF BY ADMINISTERING IVOSIDENIB AND AZACITIDINE
U-3388	USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN TO REDUCE DYSMENORRHEA AND NON-MENSTRUAL PELVIC PAIN
U-3389	USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN HAVING DYSPAREUNIA ASSOCIATED WITH ENDOMETRIOSIS
U-3390	SODIUM THIOSULFATE INJECTION IS ADMINISTERED BY INTRAVENOUS INJECTION
U-3391	A METHOD OF TITRATING AN OPIOID TO MANAGE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
U-3392	A METHOD OF TITRATING AN OPIOID TO MANAGE NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-3393	METHOD OF TREATING ACUTE PAIN DUE TO MINOR STRAINS, SPRAINS, AND CONTUSIONS USING A DICLOFENAC PATCH CONTAINING HEPARIN FOR ONCE DAILY ADMINISTRATION WHERE HEPARIN IS NOT RELEASED
U-3394	SODIUM NITRITE INJECTION IS ADMINISTERED BY INTRAVENOUS INJECTION
U-3395	SODIUM NITRITE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM THIOSULFATE FOR THE TREATMENT OF ACUTE CYANIDE POISONING
U-3396	AMVUTTRA IS INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
U-3397	TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY
U-3398	FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
U-3399	FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY
U-3400	FOR USE AFTER RADIOLABELING WITH GALLIUM-68, FOR POSITRON EMISSION TOMOGRAPHY OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
U-3401	CAROSPIR IS INDICATED AS AN ADD-ON THERAPY FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULT PATIENTS WHO ARE NOT ADEQUATELY CONTROLLED ON OTHER AGENTS
U-3402	CAROSPIR IS INDICATED FOR THE MANAGEMENT OF EDEMA IN ADULT CIRRHOTIC PATIENTS WHEN EDEMA IS NOT RESPONSIVE TO FLUID AND SODIUM RESTRICTION
U-3403	METHOD OF REVERSING OR INHIBITING THE PROGRESS OF UNRESECTABLE, RECURRENT, OR REFRACTORY INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) THAT IS ALK-POSITIVE IN ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER
U-3404	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-3405	TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG BY MONTHLY ADMINISTRATION OF RILPIVIRINE SUSPENSION AS PART OF COMBINATION THERAPY
U-3406	USE OF FENFLURAMINE AT REDUCED AMOUNTS WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-3407	USE OF FENFLURAMINE AT REDUCED AMOUNTS WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX GASTAUT SYNDROME
U-3408	TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 12 YEARS OF AGE AND OLDER. (1)
U-3409	TREATING ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS, MONITORING THIAMINE LEVELS AND ADMINISTERING THIAMINE OR A THIAMINE EQUIVALENT

PATENT USE

U-3410	A METHOD OF INJECTING AN IMPLANT
U-3411	TREATING NON-EARLY SPMS BY ADMINISTERING ORAL CLADRIBINE AT A FIXED DOSE PER PATIENT, PER BODY WEIGHT AND PER TREATMENT YEAR, WHICH FIXED DOSE IS 1.75 +/- 0.2 MG/KG, TO BE ADMINISTERED WITHIN MONTHS 1 AND 2 IN EACH OF 2 ADJACENT TREATMENT YEARS
U-3412	TREATMENT OF ADULTS WITH RELAPSED, REFRACTORY OR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA INCLUDING A DOSE RAMP-UP AND IN COMBINATION WITH OBINUTUZUMAB IN MULTIPLE 28-DAY DOSING CYCLES FOLLOWED BY ADMINISTRATION IN ABSENCE OF OBINUTUZUMAB
U-3413	INDICATED AS ADJUNCTIVE THERAPY FOR THE TREATMENT OF PARTIAL-ONSET SEIZURES, PRIMARY GENERALIZED TONIC-CLONIC SEIZURES, AND SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE AND OLDER
U-3414	INDICATED AS INITIAL MONOTHERAPY FOR THE TREATMENT OF PARTIAL-ONSET OR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 2 YEARS OF AGE AND OLDER
U-3415	INDICATED FOR THE PREVENTIVE TREATMENT OF MIGRAINE IN PATIENTS 12 YEARS AND OLDER
U-3416	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS BEING TREATED CONCURRENTLY WITH A CYP3A4 INHIBITOR
U-3417	TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
U-3418	A METHOD OF LOADING MEDICATION INTO A SYRINGE AND DELIVERING THE MEDICATION TO A TREATMENT SITE
U-3419	DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
U-3420	A METHOD OF TREATING TESTOSTERONE DEFICIENCY IN MEN
U-3421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI,KLEBSIELLA PNEUMONIA,ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED
U-3422	TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
U-3423	METHOD OF TREATING GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM GRADE 2 OR GRADE 3 MYALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY
U-3424	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR
U-3425	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOUND OF CLAIM 1 OR COMPOSITION OF CLAIM 29 OF US11426407
U-3426	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFTOR
U-3427	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR FORM I AND IVACAFTOR
U-3428	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AND IVACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 9192606
U-3429	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR
U-3430	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR
U-3431	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INDUCING AN ANTIDIURETIC EFFECT BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF ABOUT 0.05-5 MCG DESMOPRESSIN
U-3432	TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY WITH A MIXTURE OF SODIUM, POTASSIUM, MAGNESIUM, AND CALCIUM SALTS OF GHB ADMINISTERED BETWEEN 2 AND 4 HOURS AFTER EATING

PATENT USE

U-3433	INDICATED FOR THE TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS
U-3434	TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ADULTS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY
U-3435	METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 46.7 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN 15 MINUTES
U-3436	METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 46.7 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN LESS THAN 15 MINUTES
U-3437	METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YEAR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & HEAVY UTERINE BLEEDING OR GI DISORDER BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO GIVE AT LEAST 0.7 G OF IRON IN 15 MINUTES
U-3438	METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 46.7 KG BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN < 15 MINUTES
U-3439	METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA NERVE BLOCK, FOR EXAMPLE, NTERSCALENE BRACHIAL PLEXUS FOR REGIONAL ANALGESIA
U-3440	A METHOD OF ADMINISTERING APREPITANT FOR PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
U-3441	A METHOD OF TREATING CYSTINURIA BY ORALLY ADMINISTERING TIOPRONIN WITH FOOD TO PREVENT CYSTINE STONE FORMATION IN ADULTS AND PEDIATRIC PATIENTS WITH SEVERE HOMOZYGOUS CYSTINURIA
U-3442	TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS PREVIOUSLY ADMINISTERED AT LEAST THREE TYROSINE KINASE INHIBITORS, WHERE ONE OF THE KINASE INHIBITORS IS IMATINIB
U-3443	A METHOD OF REDUCING OTOTOXICITY IN A HUMAN PEDIATRIC PATIENT ABOUT 5 YEARS OF AGE OR UNDER WITH LOCALIZED MEDULLOBLASTOMA COMPRISING ADMINISTERING SODIUM THIOSULFATE ABOUT SIX HOURS AFTER ADMINISTRATION OF CISPLATIN
U-3444	TREATMENT OF DEPRESSIVE SYMPTOMS IN ADULTS WITH MDD WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE AS A PHARMACEUTICAL COMPOSITION TWICE PER WEEK IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3445	TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE TWICE PER WEEK AS A PHARMACEUTICAL COMPOSITION IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3446	TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE AS A PHARMACEUTICAL COMPOSITION IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3447	A METHOD OF TREATING CORONARY ARTERY DISEASE
U-3448	A METHOD OF TREATING HYPERTENSION
U-3449	USE IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-3450	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST
U-3451	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
U-3452	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY
U-3453	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
U-3454	METHOD OF TREATING OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN PATIENTS

PATENT USE

U-3455	TREATMENT OF OCULAR INFLAMMATION AND PAIN FOLLOWING OPHTHALMIC SURGERY
U-3456	METHOD OF TREATING INTRAHEPATIC CHOLANGIOCARCINOMA
U-3457	METHOD OF INDUCING OCULAR ANESTHESIA
U-3458	A METHOD OF TREATING SEIZURES
U-3459	TREATING SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR AND ANOTHER ACTIVE AGENT
U-3460	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS
U-3461	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
U-3462	USE OF A LIQUID FORMULATION COMPRISING FUROSEMIDE TO TREAT CONGESTION DUE TO FLUID OVERLOAD (EDEMA) IN ADULTS WITH NYHA CLASS II/III CHRONIC HEART FAILURE
U-3463	USE OF TRINTELLIX FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN ADULTS
U-3464	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING ONCE DAILY A TABLET CONTAINING ABOUT 0.5 MG TO ABOUT 10 MG OF PEMIGATINIB
U-3465	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB QD FOR 14 DAYS THEN NOT ADMINISTERING PEMIGATINIB FOR 7 DAYS IN A 21-DAY CYCLE
U-3466	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB IN A DAILY DOSE OF ABOUT 5 MG TO ABOUT 20 MG
U-3467	PREVENTION AND TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-3468	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
U-3469	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-3470	METHOD OF TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, COMPRISING ADMINISTERING CEFIDEROCOL SULFATE TOSYLATE
U-3471	METHOD OF TREATING HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) COMPRISING ADMINISTERING CEFIDEROCOL SULFATE TOSYLATE
U-3472	METHOD TO TREAT IDA IN ADULTS WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & HEAVY UTERINE BLEEDING OR GI DISORDER WEIGHING AT LEAST 40 KG BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO GIVE AT LEAST 0.6 G OF IRON IN 15 MINUTES OR LESS
U-3473	METHOD TO TREAT IRON DEFICIENCY ANEMIA IN ADULTS WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.6 G OF ELEMENTAL IRON IN 15 MINUTES OR LESS
U-3474	METHOD TO TREAT IRON DEFICIENCY ANEMIA IN ADULTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.6 G OF ELEMENTAL IRON IN 15 MINUTES OR LESS
U-3475	REDUCTION OF THE FREQUENCY OF ABDOMINAL PAIN AND DIARRHEA, IN AN INFLAMMATORY BOWEL DISEASE WITH DIARRHEA (IBS-D) PATIENT, WITH ELUXADOLINE TWICE DAILY WITH FOOD
U-3476	TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS
U-3477	ACCELERATE THE TRANSIT OF A BARIUM MEAL THROUGH THE SMALL BOWEL, THEREBY DECREASING THE TIME AND EXTENT OF RADIATION ASSOCIATED WITH FLUOROSCOPY AND X-RAY EXAMINATION OF THE INTESTINAL TRACT
U-3478	STIMULATE GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
U-3479	STIMULATE PANCREATIC SECRETION IN COMBINATION WITH SECRETIN PRIOR TO OBTAINING A DUODENAL ASPIRATE FOR ANALYSIS

PATENT USE

U-3480	STIMULATE GALLBLADDER CONTRACTION. AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
U-3481	DIAGNOSIS OF GALL BLADDER DISORDERS OR OTHER DIAGNOSTIC IMAGING BY STIMULATING GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
U-3482	DIAGNOSIS OF PANCREATIC DISORDERS BY STIMULATING PANCREATIC SECRETION IN COMBINATION WITH SECRETIN PRIOR TO OBTAINING A DUODENAL ASPIRATE FOR ANALYSIS
U-3483	DIAGNOSTIC IMAGING BY ACCELERATING THE TRAN IT OFA BARIUM MEAL THROUGH THE SMALL BOWEL, THEREBY DECREASING THE TIME AND EXTENT OF RADIATION ASSOCIATED WITH FLUOROSCOPY AND X-RAY EXAMINATION OF THE INTESTINAL TRACT
U-3484	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALE THEREOF, IS NOT RECOMMENDED
U-3485	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED
U-3486	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA
U-3487	TREATMENT OF ADULTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH OBJECTIVE SIGNS OF INFLAMMATION WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3488	TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS, PARTICULARLY FOR THE RELIEF OF FLEXOR SPASMS AND CONCOMITANT PAIN, CLONUS, AND MUSCULAR RIGIDITY
U-3489	TREATMENT OF SPASTICITY RESULTING FROM SPINAL CORD INJURIES AND OTHER SPINAL CORD DISEASES
U-3490	TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-3491	METHOD OF TREATING LYMPHOMA
U-3492	METHOD OF TREATING SARCOMA
U-3493	THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS) IN PATIENTS 10 YEARS OF AGE AND OLDER
U-3494	ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN FEMALE ADULTS
U-3495	A METHOD OF TREATING ACUTE MYELOID LEUKEMIA (AML) IN PATIENTS WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION
U-3496	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOID LEUKEMIA (AML)
U-3497	A METHOD OF TREATING A CANCER WHERE THE CANCER IS ACUTE MYELOID LEUKEMIA (AML)
U-3498	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA BY ADMINISTERING DAILY ELX (200 MG OR 100 MG); TEZ; AND IVA
U-3499	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) IN ADULT AND PEDIATRIC PATIENTS USING A TWO-DOSE REGIMEN OF DALBAVANCIN
U-3500	TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
U-3501	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-3502	TREATMENT OF A UREA CYCLE DISORDER INVOLVING DEFICIENCIES OF CARBAMYLPHOSPHATE SYNTHETASE, ORNITHINE TRANSCARBAMYLASE, OR ARGININOSUCCINIC ACID SYNTHETASE
U-3503	ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
U-3504	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN THAT INCLUDES AN IMMUNE CHECKPOINT INHIBITOR FOR EXTENSIVE-STAGE SMALL CELL CANCER

PATENT USE

U-3505	FOR TOPICAL TREATMENT OF MODERATE AD IN NON-IMMUNOCOMPROMISED PATIENTS, WITH BASELINE BSA OF 3-20% AND ITCH NRS SCORE OF ≥4, WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
U-3506	TREATMENT OF INDOLENT SYSTEMIC MASTOCYTOSIS (ISM)
U-3507	IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION
U-3508	REDUCTION IN THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN ADULT AND POST-MENARCHAL PEDIATRIC FEMALES
U-3509	AS-NEEDED TREATMENT OR PREVENTION OF BRONCHOCONSTRICTION AND REDUCTION OF THE RISK OF EXACERBATIONS IN PATIENTS WITH ASTHMA 18 YEARS OF AGE AND OLDER
U-3510	COMBINATION TREATMENT OF COLORECTAL CANCER INCLUDING RAS WILD-TYPE HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING UNRESECTABLE OR METASTATIC COLORECTAL CANCER
U-3511	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULT FEMALE SUBJECTS AND SYMPTOMS THEREOF
U-3512	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULT FEMALE SUBJECTS
U-3513	TREATMENT OF SCHIZOPHRENIA IN ADULTS
U-3514	INCREASING BLOOD PRESSURE IN A PATIENT HAVING DISTRIBUTIVE SHOCK
U-3515	A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF AN OPIOID ANTAGONIST COMPRISING AN EMERGENCY SYRINGE DEVICE
U-3516	A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF AN OPIOID ANTAGONIST COMPRISING AN EMERGENCY SYRINGE DEVICE INCLUDING A NEEDLE GUARD
U-3517	A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF AN OPIOID ANTAGONIST COMPRISING AN EMERGENCY SYRINGE DEVICE INCLUDING A WINDOW CONFIGURED TO ALLOW THE USER TO VIEW THE OPIOID ANTAGONIST IN THE SYRINGE
U-3518	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR
U-3519	TREATMENT WITH LENVIMA BY ADMINISTERING LENVIMA AS A SUSPENSION
U-3520	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING A COMPOSITION COMPRISING SOLRIAMFETOL HYDROCHLORIDE AND 2-CHLOROPROPANE, WHEREIN THE COMPOSITION COMPRISES LESS THAN ABOUT 5 PPM 2CHLOROPROPANE
U-3521	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT
U-3522	METHOD OF TREATING EMESIS
U-3523	TREATMENT OF AN ER-POSITIVE BREAST CANCER
U-3524	TREATMENT OF AN ER-POSITIVE BREAST CANCER FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
U-3525	TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA BY ADMINISTERING THE COMPOSITION RECITED IN US 11564916 CLAIM 1
U-3526	TREATMENT OF CF IN A PATIENT AGE 1 TO <6 YEARS AND WEIGHING 7 KG OR MORE WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916
U-3527	TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO IS HOMOZYGOUS FOR F508DEL OR HAS AT LEAST ONE CFTR GENE MUTATION RESPONSIVE TO TEZ/IVA BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE USING THE COMPOSITION RECITED IN US 11564916 CLAIM 1
U-3528	TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916
U-3529	TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916
U-3530	TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916

PATENT USE

U-3531 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN

U-3532 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN

U-3533 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN

U-3534 PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS

U-3535 A METHOD OF TREATING ANEMIA

U-3536 TREATMENT OF DEPRESSION IN ADULTS WITH MOD AND ACUTE SUICIDAL IDEATION OR BEHAVIOR IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE IN A MAINTENANCE PHASE WEEKLY OR LX EVERY 2 WEEKS AFTER INDUCTION PHASE

U-3537 TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM GRADE 2 OR GRADE 3 ARTHRALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY

U-3538 METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER

U-3539 TREATING ACQUIRED, GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN A PREMENOPAUSAL FEMALE PATIENT WITH CONTROLLED HYPERTENSION BY INJECTING BREMELANOTIDE MORE THAN ONCE WITH AT LEAST 24 HOURS BETWEEN DOSES AND NO MORE THAN 8 DOSES PER MONTH

U-3540 TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF PEGCETACOPLAN

U-3541 TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERING COMPLEMENT INHIBITOR PEGCETACOPLAN

U-3542 TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF PEGCETACOPLAN AND ALSO ADMINISTERING AN ANTI-VEGF AGENT

U-3543 TREATMENT TO INCREASE BONE DENSITY IN MEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE

U-3544 TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON IN VITRO DATA BY ADMINISTERING ELEXACAFTOR, IVACAFTOR, AND A SOLID DISPERSION OF TEZACAFTOR AND A POLYMER

U-3545 TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO IS HOMOZYGOUS FOR F508DEL OR HAS AT LEAST ONE CFTR GENE MUTATION RESPONSIVE TO TEZ/IVA BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE USING THE COMPOSITION RECITED IN US 11578062 CLAIM 6 OR 13

U-3546 IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE

U-3547 INTRAVENOUS SOTALOL DOSING REGIMEN FOR ACHIEVING STEADY STATE EXPOSURE IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING

U-3548 TREATMENT OF AML BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE TO ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES PER A DOSE RAMP-UP INCLUDING AN INITIAL 100 MG OR A FINAL 400 MG PER DAY DOSE

U-3549 INTRAVENOUS SOTALOL DOSING REGIMEN FOR USE IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING

U-3550 FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, IN THE ABSENCE OF LASER OR PHOTOTHERAPY, WHEREIN THE VITILIGO AFFECTS AT LEAST ONE OF THE LOWER EXTREMITIES, TRUNK, AND FEET OF THE PATIENT

U-3551 FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, IN THE ABSENCE OF PHOTOTHERAPY, WHEREIN THE VITILIGO AFFECTS AT LEAST ONE OF THE LOWER EXTREMITIES, TRUNK, AND FEET OF THE PATIENT

U-3552 TREATMENT OF FRIEDREICH'S ATAXIA IN ADULTS AND ADOLESCENTS AGED 16 YEARS AND

PATENT USE

	OLDER
U-3553	A METHOD OF TREATING MILD TO MODERATE ACUTE PAIN IN ADULTS BY ADMINISTERING 975-1000 MG OF ACETAMINOPHEN AND 292.5-300 MG OF IBUPROFEN IN A SINGLE ADMINISTRATION
U-3554	AS A SINGLE AGENT FOR THE TREATMENT OF ADULT PATIENTS WITH HISTIOCYTIC NEOPLASMS
U-3555	ADMINISTRATION OF ZAVEGEPANT FOR ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-3556	TREATMENT OF RETT SYNDROME OR A SYMPTOM THEREOF
U-3557	TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND SYMPTOMATIC PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-3558	AN ADJUNCTIVE TREATMENT OF ADULT PATIENTS WITH TAVNEOS (AVACOPAN) WITH SEVERE ACTIVE ANCA-ASSOCIATED VASCULITIS (GPA AND MPA) IN COMBINATION WITH STANDARD THERAPY INCLUDING GLUCOCORTICOIDS
U-3559	A METHOD OF TARGETING RELEASE OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) TO THE SMALL INTESTINE OF THE SUBJECT WHEN ADMINISTERED ORALLY
U-3560	FOR THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS IN CHILDREN AND ADULTS
U-3561	TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY
U-3562	TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY
U-3563	DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO INCREASE DEXTROMETHORPHAN PLASMA LEVELS
U-3564	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY
U-3565	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY
U-3566	TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
U-3567	TO INCREASE MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
U-3568	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INHIBITORS
U-3569	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INDUCERS
U-3570	TREATMENT OF RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INDUCERS
U-3571	TREATMENT OF RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INHIBITORS
U-3572	RAISE FOLATE LEVELS IN WOMEN WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION FOR THE PURPOSE OF REDUCING THE RISK OF A NEURAL TUBE DEFECT IN A PREGNANCY
U-3573	TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YEARS OF AGE IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL
U-3574	TREATMENT OF MOOD CHANGES AND/OR ANXIETY AS SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) IN WOMEN WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
U-3575	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE
U-3576	TREATMENT OF NARCOLEPSY-RELATED CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS USING A ONCE-DAILY PHARMACEUTICAL FORMULATION COMPRISING AN OXYBATE

PATENT USE

U-3577 TREATMENT OF NARCOLEPSY-RELATED CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS USING A SINGLE DAILY, BEDTIME DOSE OF A GAMMA-HYDROXYBUTYRATE FORMULATION

U-3578 TREATMENT OF NARCOLEPSY, CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS USING A ONCE-NIGHTLY GAMMA-HYDROXYBUTYRATE FORMULATION

U-3579 TREATMENT OF NARCOLEPSY AND ASSOCIATED DISORDERS AND SYMPTOMS USING A COMPOSITION COMPRISING GAMMA-HYDROXYBUTYRATE ONCE DAILY

U-3580 TREATMENT OF NARCOLEPSY USING A DOSE PROPORTIONAL, ORAL PHARMACEUTICAL COMPOSITION COMPRISING GAMMA-HYDROXYBUTYRATE ONCE DAILY

U-3581 TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN ADULTS WITH NARCOLEPSY

U-3582 LIQREV IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS TO IMPROVE EXERCISE ABILITY AND DELAY CLINICAL WORSENING

U-3583 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA

U-3584 TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON IN VITRO DATA BY ADMINISTERING ELEXACAFTOR, IVACAFTOR, AND A SOLID DISPERSION OF TEZACAFTOR AND A POLYMER

U-3585 TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA COMPRISING ADMINISTERING THE COMPOSITION RECITED IN US 11564916 CLAIM 1

U-3586 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA BY ADMINISTERING DAILY ELX (100 MG OR 80 MG); TEZ; AND IVA

U-3587 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA

U-3588 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR

U-3589 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR

U-3590 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA

U-3591 TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA

U-3592 TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA

U-3593 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR

U-3594 TREATMENT OF IRON DEFICIENCY ANEMIA (DIA) IN ADULTS PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE

U-3595 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOUND OF CLAIM 1 OR COMPOSITION OF CLAIM 29 OF US 11426407

U-3596 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR

U-3597 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO ANY ONE OF CLAIMS 1-3 AND 7-9 OF

PATENT USE

US11179367

U-3598 TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 11147770

U-3599 TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 10272046

U-3600 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621

U-3601 TREATMENT OF A DISORDER TREATABLE WITH GAMMA-HYDROXYBUTYRATE USING A SINGLE, DAILY DOSE OF A GAMMA-HYDROXYBUTYRATE FORMULATION

U-3602 TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS WITH A DOSING REGIMEN THAT INCLUDES ORAL ADMINISTRATION OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY

U-3603 TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916

U-3604 TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11147770

U-3605 TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046

U-3606 TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR

U-3607 TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA

U-3608 TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS A R117H MUTATION IN THE CFTR GENE

U-3609 TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA

U-3610 CO-ADMINISTRATION OF CENOBAMATE WITH PHENOBARBITAL AND/OR PHENYTOIN FOR THE TREATMENT OF PARTIAL ONSET SEIZURES

U-3611 TREATMENT OF PEDIATRIC PATIENTS WITH CENTRAL PRECOCIOUS PUBERTY

U-3612 AS AN ADJUNCT TO DIET TO REDUCE LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN ADULTS AND PEDIATRIC PATIENTS AGED 10 YEARS AND OLDER WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-3613 AS AN ADJUNCT TO OTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LOWERING THERAPIES, OR ALONE IF SUCH TREATMENTS ARE UNAVAILABLE, TO REDUCE LDL-C IN ADULTS AND PEDIATRIC PATIENTS AGED 10 YEARS AND OLDER WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-3614 POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED METASTASIS WHO ARE CANDIDATES FOR INITIAL DEFINITIVE THERAPY

U-3615 POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED RECURRENCE BASED ON ELEVATED SERUM PROSTATE-SPECIFIC ANTIGEN (PSA) LEVEL

U-3616 A METHOD OF ADMINISTERING AN OPIOID MAINTENANCE TREATMENT COMPRISING BUPRENORPHINE

U-3617 A METHOD OF ADMINISTERING AN OPIOID MAINTENANCE TREATMENT COMPRISING BUPRENORPHINE. A METHOD OF TREATING OPIOID WITHDRAWAL USING AN OPIOID

PATENT USE

	MAINTENANCE TREATMENT COMPRISING BUPRENORPHINE
U-3618	A METHOD OF SUSTAINED DELIVERY OF BUPRENORPHINE TO A HUMAN OR NON-HUMAN ANIMAL BODY. A METHOD FOR TREATMENT FOR OPIOID MAINTENANCE THERAPY
U-3619	A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION
U-3620	A METHOD OF DELIVERY OF AN OPIOID BIOACTIVE AGENT. A METHOD OF TREATMENT OR PROPHYLAXIS OF A HUMAN OR NON-HUMAN ANIMAL FOR THE TREATMENT OF OPIOID ADDICTION AND/OR THE SYMPTOMS OF OPIOID WITHDRAWAL
U-3621	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE WITH MENOPAUSE
U-3622	TREATMENT OF MODERATE TO SEVERE VASOMETER SYMPTOMS DUE TO MENOPAUSE
U-3623	MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 5 YEARS AND OLDER. RECOMMENDED DOSAGES: BREO 100/25 OR 200/25 AGES 18 YEARS AND OLDER; BREO 100/25 AGES 12-17 YEARS, AND BREO 50/25, AGES 5-11 YEARS
U-3624	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3626	TREATMENT OF SCHIZOPHRENIA BY ADMINISTRATION OF A SIX-MONTH PALIPERIDONE PALMITATE INJECTABLE SUSPENSION FILLED SYRINGE THAT HAS BEEN SHIPPED AND STORED IN A HORIZONAL POSITION
U-3627	TREATMENT OF DRY EYE DISEASE (DED)
U-3628	REDUCTION OF RISK OF CARDIOVASCULAR DEATH, HOSPITALIZATION FOR HEART FAILURE, AND URGENT HEART FAILURE IN ADULTS WITH HEART FAILURE OR TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY DISEASE, AND OTHER CARDIOVASCULAR RISK FACTORS
U-3629	TREATMENT OF MILD-TO-MODERATE CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS WHO ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH
U-3630	TREATING OPIOID OVERDOSE
U-3631	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS BRCA-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN COMBINATION WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE
U-3632	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA
U-3633	TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA
U-3634	METHOD OF TREATING IDA IN ADULT PATIENTS WEIGHING AT LEAST 46.7 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II/III TO IMPROVE EXERCISE CAPACITY BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN 15 MINUTES
U-3635	METHOD TO TREAT IDA IN ADULTS WEIGHING AT LEAST 40 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II/III TO IMPROVE EXERCISE CAPACITY BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON IN ABOUT ≤ 15 MIN
U-3636	METHOD TO TREAT IDA IN ADULTS WEIGHING AT LEAST 40 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II/III TO IMPROVE EXERCISE CAPACITY BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
U-3637	METHOD TO TREAT IRON DEFICIENCY IN ADULTS WEIGHING AT LEAST 40 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II/III TO IMPROVE EXERCISE CAPACITY BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
U-3638	A METHOD FOR TREATING AND/OR REDUCING THE RISK OF ACUTE MYOCARDIAL INFARCTION
U-3639	A METHOD FOR TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT
U-3640	A METHOD OF TREATING AND/OR REDUCING THE RISK OF INFLAMMATION, ATHEROSCLEROTIC VASCULAR DISEASE, AND CHOLESTEROL CRYSTAL INDUCED INFLAMMATION WITHIN ATHEROSCLEROTIC PLAQUES
U-3641	A METHOD OF TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT; ACUTE CORONARY SYNDROME, OUT-OF-HOSPITAL CARDIAC ARREST, AND/OR NONCARDIOEMBOLIC ISCHEMIC STROKE
U-3642	A METHOD OF TREATING CARDIOVASCULAR DISEASE
U-3643	METHOD OF TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT

PATENT USE

U-3644	TREATMENT OF FUNCTIONAL CONSTIPATION IN PEDIATRIC PATIENTS 6 TO 17 YEARS OF AGE
U-3645	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION
U-3646	A METHOD OF TREATMENT OF OVARIAN CANCER OR FALLOPIAN TUBE CANCER
U-3647	A METHOD OF TREATMENT OF RECURRENT OVARIAN CANCER OR FALLOPIAN TUBE CANCER ASSOCIATED WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATION
U-3648	METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)
U-3649	METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)
U-3650	TREATMENT OF PATIENTS WITH POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTION/DISEASE REFRACTORY TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR, OR FOSCARNET, WHERE THE PATIENT IS A STEM CELL, KIDNEY, OR LIVER TRANSPLANT RECIPIENT
U-3651	TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE
U-3652	AS AN ADJUNCT TO DIET AND STATIN THERAPY FOR THE TREATMENT OF ADULTS WITH PRIMARY HYPERLIPIDEMIA, INCLUDING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH), BY INHIBITING EXPRESSION OF THE PCSK9 GENE
U-3653	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN A PATIENT WITH MODERATE HEPATIC IMPAIRMENT
U-3654	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG OR 200 MG ELAGOLIX WHILE CO-ADMINISTERING OMEPRAZOLE
U-3655	MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) USING 300 MG ELAGOLIX WHILE CO-ADMINISTERING OMEPRAZOLE
U-3656	TREATMENT OF METASTATIC COLORECTAL CANCER ALONE OR WITH BEVACIZUMAB IN PATIENTS PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY
U-3657	TREATMENT OF METASTATIC COLORECTAL CANCER ALONE OR WITH BEVACIZUMAB IN SEVERELY RENALLY IMPAIRED PATIENTS PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN THERAPY, AN ANTI-VEGF BIOLOGIC, AND IF RAS WILD-TYPE, ANTI-EGFR THERAPY
U-3658	TREATMENT OF METASTATIC GASTRIC OR GJA IN SEVERELY RENALLY IMPAIRED PATIENTS TREATED WITH AT LEAST TWO LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, A TAXANE OR IRINOTECAN, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
U-3659	TREATMENT OF METASTATIC COLORECTAL CANCER WITH BEVACIZUMAB IN PATIENTS PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY
U-3660	TREATMENT OF PARTIAL-ONSET SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG
U-3661	COMBINATION WITH STANDARD CYTARABINE AND ANTHRACYCLINE INDUCTION AND CYTARABINE CONSOLIDATION, AND AS MAINTENANCE MONOTHERAPY FOLLOWING CONSOLIDATION CHEMOTHERAPY, FOR ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA
U-3662	DEXTROMETHORPHAN AND BUPROPRION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
U-3663	TOPICAL TREATMENT OF MOLLUSCUM CONTAGIOSUM IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
U-3664	TOPICAL TREATMENT OF SKIN LESIONS CAUSED BY AN INFECTION WITH MOLLUSCUM CONTAGIOSUM IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
U-3665	TOPICAL DELIVERY OF A CANTHARIDIN FORMULATION TO ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER FOR TREATING MOLLUSCUM CONTAGIOSUM
U-3666	USE IN ADULT AND PEDIATRIC PATIENTS WITH SUBOPTIMAL ECHOCARDIOGRAMS TO OPACIFY THE LEFT VENTRICULAR CHAMBER AND TO IMPROVE THE DELINEATION OF THE LEFT VENTRICULAR ENDOCARDIAL BORDER
U-3667	USE IN ULTRASONOGRAPHY OF THE URINARY TRACT IN PEDIATRIC PATIENTS FOR THE

PATENT USE

	EVALUATION OF SUSPECTED OR KNOWN VESICOURETERAL REFLUX
U-3668	USE WITH ULTRASOUND OF THE LIVER IN ADULT AND PEDIATRIC PATIENTS TO CHARACTERIZE FOCAL LIVER LESIONS
U-3669	USE OF VASCEPA TO REDUCE THE INCIDENCE OF STROKE IN AN ADULT PATIENT ON STATIN THERAPY AND WITH ELEVATED TRIGLYCERIDE LEVELS (>150 MG/DL), WHEREIN THE PATIENT EXPERIENCES ATRIAL FIBRILLATION AND/OR FLUTTER INSTEAD OF AN INCIDENCE OF STROKE
U-3670	ADMINISTRATION OF AN EXTENDED RELEASE TABLET FOR THE TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS AGED 3 YEARS AND OLDER AND WEIGHING 35 KG OR MORE
U-3671	USE OF INTRANASAL NALOXONE FOR THE TREATMENT OF OPIOID OVERDOSE
U-3672	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG ELAGOLIX FOR UP TO 24 MONTHS
U-3673	TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
U-3674	TREATMENT OF DEMODEX BLEPHARITIS VIA TOPICAL ADMINISTRATION TO AN OCULAR SURFACE
U-3675	A PERCUTANEOUS HEPATIC PERFUSION PROCEDURE FOR TREATING A PATIENT WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES
U-3676	REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
U-3677	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT WITH SEVERE HEPATIC IMPAIRMENT
U-3678	A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
U-3679	A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
U-3680	A METHOD FOR TREATING A SUBJECT WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES
U-3681	TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE SERIOUS OR LIFE-THREATENING
U-3682	SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE SERIOUS OR LIFE-THREATENING
U-3683	A METHOD OF TREATING A PATIENT WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES
U-3684	A METHOD OF TREATING AN ADULT PATIENT WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA HAVING A SUSCEPTIBLE IDH1 MUTATION
U-3685	METHOD OF ADMINISTERING AN EFFECTIVE DOSE OF TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE TO AN EYE
U-3686	TREATMENT OF EXACERBATIONS OF MULTIPLE SCLEROSIS IN ADULTS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
U-3687	TREATMENT OF INFANTILE SPASMS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
U-3688	TREATMENT OF OPHTHALMIC DISEASES WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
U-3689	DIAGNOSIS OF GALL BLADDER DISORDERS BY STIMULATING GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
U-3690	A METHOD FOR PREVENTING OF POST-OPERATIVE NAUSEA AND VOMITING
U-3691	TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
U-3692	A METHOD OF TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY DECREASING THE LEVEL OF LDL-C USING 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE

PATENT USE

U-3693	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL
U-3694	METHOD OF REDUCING OR AMELIORATING SEIZURES IN A PATIENT BY ADMINISTERING A LIQUID FORMULATION OF FENFLURAMINE WITH STIRIPENTOL THEREBY MODULATING DOWN THE FORMATION OF NORFENFLURAMINE AND RESULTING IN HIGHER LEVELS OF FENFLURAMINE
U-3695	MAINTENANCE TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
U-3696	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 11752106
U-3697	TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <6 YEARS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11752106
U-3698	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA BY SUBLINGUAL OR BUCCAL ADMINISTRATION
U-3699	TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITH SEXUAL DYSFUNCTION CAUSED BY EITHER MAJOR DEPRESSION OR PRIOR TREATMENTS, OR TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITHOUT THE RISK OF SEXUAL DYSFUNCTION ADVERSE REACTIONS
U-3700	TREATMENT OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH AN ORAL SOLUTION OF METHOTREXATE
U-3701	TREATMENT OF ADULTS WITH MYCOSIS FUNGOIDES WITH AN ORAL SOLUTION OF METHOTREXATE
U-3702	TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS WITH AN ORAL SOLUTION OF METHOTREXATE
U-3703	TREATMENT OF ADULTS WITH RHEUMATOID ARTHRITIS WITH AN ORAL SOLUTION OF METHOTREXATE
U-3704	TREATMENT OF ADULTS WITH SEVERE PSORIASIS WITH AN ORAL SOLUTION OF METHOTREXATE
U-3705	TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY WHO HAVE AN APNEA/HYPOPNEA INDEX ≤15 WITH A ONCE-NIGHTLY FORMULATION OF GAMMA-HYDROXYBUTYRATE
U-3706	TREATMENT OF BLOATING ASSOCIATED WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D) IN ADULT FEMALE SUBJECTS
U-3707	A METHOD OF TREATING PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE PH+ CML, NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
U-3708	A METHOD OF TREATING PATIENTS WITH ACCELERATED, OR BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY
U-3709	METHOD OF TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1)
U-3710	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA BY ORALLY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH INTRAVENOUS ADMINISTRATION OF OBINUTUZUMAB
U-3711	A METHOD TO IMPROVE KIDNEY FUNCTION IN ADULTS WITH HEPATORENAL SYNDROME WITH RAPID REDUCTION IN KIDNEY FUNCTION
U-3712	TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 6 YEARS OF AGE OR OLDER
U-3713	TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-3714	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS HAVING PRE-EXISTING SEVERE HEPATIC IMPAIRMENT AND SUFFERING FROM AN ADVERSE EVENT WHILE BEING ADMINISTERED RIPRETINIB DAILY
U-3715	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) RECEIVING A MODERATE CYP3A INDUCER
U-3716	TREATMENT OF ADULT PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM) RECEIVING A MODERATE CYP3A INDUCER
U-3717	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) RECEIVING A MODERATE CYP3A INDUCER
U-3718	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA

PATENT USE

	(MZL) RECEIVING A MODERATE CYP3A INDUCER, WHO HAVE RECEIVED AT LEAST ONE ANTI-CD20-BASED REGIMEN
U-3719	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) RECEIVING A MODERATE CYP3A INDUCER, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-3720	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING A MODERATE CYP3A INDUCER
U-3721	TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN CHRONIC KIDNEY DISEASE PATIENTS RECEIVING CHOLESTYRAMINE
U-3722	TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN CHRONIC KIDNEY DISEASE PATIENTS RECEIVING PHENOBARBITAL OR OTHER ANTICONVULSANTS
U-3723	TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN CHRONIC KIDNEY DISEASE PATIENTS RECEIVING CYP3A INHIBITORS
U-3724	TO PRODUCE POST-SURGICAL ANALGESIA
U-3725	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION IN PATIENTS WITH SEVERE HEPATIC IMPAIRMENT
U-3726	THE TREATMENT OF POMPE PATIENTS
U-3727	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-3728	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-3729	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-3730	A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING ESTRASIMOD ARGININE IN AN AMOUNT EQUIVALENT TO ABOUT 2.0 MG OF ESTRASIMOD
U-3731	A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF THE FORM OF ESTRASIMOD ARGININE AS CLAIMED
U-3732	A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF ESTRASIMOD ARGININE
U-3733	METHOD OF TREATING SEIZURES IN A PATIENT BY ADMINISTERING A LIQUID FORMULATION OF FENFLURAMINE OR ITS SALTS PLUS STIRIPENTOL THEREBY REDUCING NORFENFLURAMINE FORMATION WHILE INCREASING THE FENFLURAMINE LEVEL. PATIENTS CAN HAVE E.G. DRAVET OR LGS
U-3734	METHOD OF TREATING SCHIZOPHRENIA IN A PATIENT WHO HAS PREVIOUSLY EXPERIENCED SIGNIFICANT WEIGHT GAIN INDUCED BY OLANZAPINE ALONE BY ADMINISTERING A COMPOSITION COMPRISING OLANZAPINE AND SAMIDORPHAN
U-3735	TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN
U-3736	REDUCTION OF SERUM PHOSPHORUS IN ADULTS
U-3737	MEKTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH ENCORAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
U-3738	BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
U-3739	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
U-3740	TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) IN ADULTS
U-3741	TREATMENT OF PRESBYOPIA
U-3742	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES
U-3743	A METHOD OF TREATING RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
U-3744	METHOD OF TREATING MILD TO MODERATE PAIN IN ADULTS

PATENT USE

U-3745	METHOD OF TREATING MODERATE TO SEVERE PAIN IN ADULTS AS AN ADJUNCT TO OPIOID ANALGESICS
U-3746	METHODS OF MAKING AQUEOUS COMPOSITION AND TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ATERIOSIS WITH AQUEOUS COMPOSITION
U-3747	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
U-3748	TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 6 YEARS OF AGE AND OLDER
U-3749	METHOD OF TREATING PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE
U-3750	TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH A WILD TYPE KIT MUTATION IN PATIENTS PREVIOUSLY ADMINISTERED THREE OR MORE KINASE INHIBITORS, WHERE ONE OF THE KINASE INHIBITORS IS IMATINIB
U-3751	TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY WITH A ONCE-NIGHTLY GAMMA-HYDROXYBUTYRATE FORMULATION
U-3752	METHOD OF TREATING DIABETIC HYPOGLYCEMIA
U-3753	TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY, ANTI-VEGF THERAPY, AND, IF RAS WILD-TYPE AND MEDICALLY APPROPRIATE, ANTI-EGFR THERAPY
U-3754	TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS
U-3755	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
U-3756	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION
U-3757	TREATMENT OF HYPOTHYROIDISM BY ORAL ADMINISTRATION OF L-THYROXINE TO A PATIENT ON AN EMPTY STOMACH 15 MINUTES BEFORE BREAKFAST
U-3758	TREATMENT OF PITUITARY THYROTROPIN SUPPRESSION BY ORAL ADMINISTRATION OF L-THYROXINE TO A PATIENT ON AN EMPTY STOMACH 15 MINUTES BEFORE BREAKFAST
U-3759	METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH HEART FAILURE AND TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN
U-3760	METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION IN PATIENTS WITH HEART FAILURE BY ADMINISTRATION OF EMPAGLIFLOZIN
U-3761	ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR
U-3762	TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY
U-3763	TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE (BCR) AT HIGH RISK FOR METASTASIS
U-3764	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING OBSTRUCTIVE SLEEP APNEA (OSA) AND NO, MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT
U-3765	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING MODERATE OR SEVERE RENAL IMPAIRMENT
U-3766	REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE AND URGENT HEART FAILURE VISITS IN ADULTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND WITHOUT TYPE II DIABETES
U-3767	USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
U-3768	USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
U-3769	USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH

PATENT USE

U-3770	USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
U-3771	USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
U-3772	USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
U-3773	TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN PATIENTS 9 YEARS OF AGE AND OLDER
U-3774	A CATHETER LOCK SOLUTION TO REDUCE CATHETER-RELATED BLOODSTREAM INFECTIONS IN ADULT PATIENTS RECEIVING HEMODIALYSIS THROUGH A CENTRAL VENOUS CATHETER
U-3775	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING NO, MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT
U-3776	TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
U-3777	TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
U-3778	TREATMENT OF MAJOR DEPRESSIVE DISORDER BY ADMINISTERING DEXTROMETHORPHAN AND BUPROPION TO A SUBJECT HAVING MODERATE HEPATIC IMPAIRMENT
U-3779	METHOD OF TREATING NEONATAL SEIZURES
U-3780	TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FOLLOWING A PROGRAMMED DEATH RECEPTOR-1 OR PROGRAMMED DEATH-LIGAND INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR
U-3781	REDUCTION IN LOSS OF KIDNEY FUNCTION IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK OF DISEASE PROGRESSION